cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
THCA	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-38.15	4.94e-146	6.75e-140	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-38.15	4.94e-146	6.75e-140	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-38.15	4.94e-146	6.75e-140	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-38.15	4.94e-146	6.75e-140	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-38.15	4.94e-146	6.75e-140	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-38.13	5.9e-146	7.79e-140	-1.05	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-37.99	2.36e-145	2.06e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-37.95	3.32e-145	2.59e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-37.95	3.32e-145	2.59e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-37.95	3.32e-145	2.59e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-37.95	3.32e-145	2.59e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-37.91	4.62e-145	3.49e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-37.91	4.92e-145	3.49e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-37.91	4.92e-145	3.49e-139	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	37.91	4.92e-145	3.49e-139	1.04	0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-37.85	8.54e-145	5.84e-139	-1.05	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-37.78	1.54e-144	1.02e-138	-1.05	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-37.75	2.21e-144	1.41e-138	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-37.75	2.21e-144	1.41e-138	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-37.68	4.03e-144	2.53e-138	-1.04	-0.87	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-37.21	3.42e-142	2.02e-136	-1.05	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-37.21	3.42e-142	2.02e-136	-1.05	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	37.19	4.25e-142	2.47e-136	1.04	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-37.1	9.34e-142	5.19e-136	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-37.06	1.37e-141	7.49e-136	-1.05	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-36.83	1.27e-140	6.18e-135	-1.05	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-36.78	1.94e-140	9.28e-135	-1.05	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-36.44	5.16e-139	2.2e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-36.44	5.16e-139	2.2e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-36.44	5.16e-139	2.2e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-36.44	5.16e-139	2.2e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	36.41	7.07e-139	2.91e-133	1.03	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	36.41	7.07e-139	2.91e-133	1.03	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	36.41	7.07e-139	2.91e-133	1.03	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-36.28	2.23e-138	8.64e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-36.28	2.23e-138	8.64e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-36.28	2.23e-138	8.64e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-36.28	2.23e-138	8.64e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-36.28	2.23e-138	8.64e-133	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-36.26	2.88e-138	1.07e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-36.26	2.88e-138	1.07e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-36.26	2.88e-138	1.07e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-36.23	3.61e-138	1.23e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-36.23	3.61e-138	1.23e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-36.23	3.61e-138	1.23e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-36.23	3.61e-138	1.23e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-36.23	3.61e-138	1.23e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-36.23	3.61e-138	1.23e-132	-1.04	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	36.23	3.61e-138	1.23e-132	1.04	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	36.23	3.61e-138	1.23e-132	1.04	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	36.23	3.61e-138	1.23e-132	1.04	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	36.17	6.65e-138	2.18e-132	1.03	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-36.09	1.48e-137	4.76e-132	-1.05	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	35.97	4.59e-137	1.44e-131	1.04	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-35.95	5.59e-137	1.74e-131	-1.02	-0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	35.93	6.55e-137	2.02e-131	1.05	0.86	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-35.74	4.13e-136	1.24e-130	-1.04	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-35.68	7.11e-136	2.09e-130	-1.03	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	35.57	2.08e-135	5.94e-130	1.03	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
THCA	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	35.52	3.4e-135	9.64e-130	1.06	0.85	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-35.3	2.85e-134	7.79e-129	-1.04	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	34.87	1.95e-132	4.85e-127	1.03	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	34.87	1.95e-132	4.85e-127	1.03	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	34.87	1.95e-132	4.85e-127	1.03	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-34.82	3.11e-132	7.68e-127	-1.02	-0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	34.67	1.36e-131	3.33e-126	1.02	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	34.39	2e-130	4.7e-125	1.08	0.85	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	34.29	5.58e-130	1.3e-124	1.03	0.85	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
THCA	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-34.09	3.77e-129	8.75e-124	-1.05	-0.84	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-34.07	4.78e-129	1.1e-123	-1.01	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	34.06	5.37e-129	1.23e-123	1.03	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
THCA	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	33.98	1.14e-128	2.58e-123	1.05	0.84	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-33.79	7.18e-128	1.55e-122	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-33.76	9.62e-128	2.05e-122	-1.02	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-33.76	1.04e-127	2.2e-122	-1	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	33.57	6.33e-127	1.3e-121	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
THCA	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-33.57	6.59e-127	1.33e-121	-1.14	-0.84	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
THCA	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	33.51	1.23e-126	2.45e-121	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	33.49	1.42e-126	2.82e-121	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
THCA	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	33.41	3.25e-126	6.34e-121	1.14	0.84	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
THCA	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	33.38	4.29e-126	8.26e-121	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-33.37	4.56e-126	8.74e-121	-1.04	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	33.32	7.67e-126	1.43e-120	1.06	0.84	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	33.3	8.94e-126	1.65e-120	1.06	0.84	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
THCA	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-33.3	9.75e-126	1.79e-120	-1.14	-0.84	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	33.3	9.84e-126	1.8e-120	1.01	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	33.15	4.24e-125	7.63e-120	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	33.12	5.41e-125	9.68e-120	1.05	0.84	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	33.1	6.74e-125	1.2e-119	1.06	0.84	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	33.1	7.02e-125	1.21e-119	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	33.1	7.02e-125	1.21e-119	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	33.1	7.02e-125	1.21e-119	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	33.1	7.02e-125	1.21e-119	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	33.1	7.02e-125	1.21e-119	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	33.1	7.02e-125	1.21e-119	1.03	0.84	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-32.97	2.46e-124	4.12e-119	-0.99	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-32.97	2.56e-124	4.27e-119	-0.99	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-32.96	2.78e-124	4.53e-119	-0.99	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-32.96	2.78e-124	4.53e-119	-0.99	-0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	32.95	3.09e-124	5.02e-119	1.03	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	32.94	3.37e-124	5.45e-119	0.98	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
THCA	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	32.92	4.2e-124	6.7e-119	1	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	32.92	4.2e-124	6.7e-119	1	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	32.91	4.73e-124	7.51e-119	1.02	0.84	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-32.84	9.21e-124	1.43e-118	-0.99	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-32.84	9.21e-124	1.43e-118	-0.99	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-32.82	1.14e-123	1.76e-118	-0.99	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	32.82	1.16e-123	1.79e-118	1.06	0.83	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
THCA	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-32.81	1.22e-123	1.88e-118	-1.05	-0.83	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	32.73	2.64e-123	4e-118	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	32.71	3.34e-123	4.97e-118	1.03	0.83	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	32.71	3.34e-123	4.97e-118	1.03	0.83	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	32.71	3.34e-123	4.97e-118	1.03	0.83	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-32.69	4.08e-123	5.96e-118	-0.99	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-32.69	4.08e-123	5.96e-118	-0.99	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-32.66	5.31e-123	7.74e-118	-0.97	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	32.65	6.07e-123	8.81e-118	1.02	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	32.62	7.81e-123	1.13e-117	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	32.58	1.22e-122	1.74e-117	1.05	0.83	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	32.58	1.22e-122	1.74e-117	1.05	0.83	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
THCA	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-32.56	1.52e-122	2.16e-117	-1.12	-0.83	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-32.55	1.58e-122	2.23e-117	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	32.52	2.25e-122	3.15e-117	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
THCA	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	32.52	2.33e-122	3.26e-117	1.04	0.83	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-32.51	2.43e-122	3.39e-117	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	32.5	2.75e-122	3.82e-117	0.99	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	32.48	3.36e-122	4.65e-117	1.02	0.83	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	32.45	4.7e-122	6.44e-117	1.02	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-32.43	5.59e-122	7.52e-117	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	32.31	1.91e-121	2.53e-116	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
THCA	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	32.31	1.91e-121	2.53e-116	1.04	0.83	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-32.27	2.68e-121	3.45e-116	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	32.25	3.28e-121	4.02e-116	1.02	0.83	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
THCA	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-32.23	4.03e-121	4.92e-116	-1.12	-0.83	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	32.2	5.33e-121	6.42e-116	1	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
THCA	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-32.2	5.6e-121	6.66e-116	-1.12	-0.83	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-32.2	5.6e-121	6.66e-116	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
THCA	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-32.17	7.36e-121	8.73e-116	-1.11	-0.83	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	32.13	1.16e-120	1.36e-115	1	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	32.1	1.52e-120	1.76e-115	1.02	0.83	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
THCA	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-32.04	2.64e-120	3e-115	-1.03	-0.83	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
THCA	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-31.98	5.01e-120	5.15e-115	-1.12	-0.83	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	31.91	9.77e-120	9.93e-115	0.98	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
THCA	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	31.91	1.03e-119	1.03e-114	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	31.91	1.03e-119	1.03e-114	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	31.91	1.03e-119	1.03e-114	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	31.91	1.03e-119	1.03e-114	0.98	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	31.91	1.04e-119	1.04e-114	0.97	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	31.9	1.19e-119	1.16e-114	1.01	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	31.88	1.38e-119	1.33e-114	0.95	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
THCA	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-31.87	1.61e-119	1.54e-114	-1.03	-0.83	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	31.82	2.52e-119	2.41e-114	1	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	31.78	4.01e-119	3.79e-114	0.97	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
THCA	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	31.72	6.87e-119	6.42e-114	1.02	0.83	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-31.72	7.18e-119	6.69e-114	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-31.71	7.81e-119	7.24e-114	-0.98	-0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	31.65	1.37e-118	1.27e-113	1	0.83	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
THCA	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	31.6	2.47e-118	2.23e-113	1.11	0.82	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-31.59	2.62e-118	2.37e-113	-1.01	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
THCA	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-31.58	2.91e-118	2.62e-113	-1.11	-0.82	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
THCA	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-31.58	2.91e-118	2.62e-113	-1.11	-0.82	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	31.58	3.02e-118	2.71e-113	0.96	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
THCA	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-31.57	3.07e-118	2.75e-113	-1.11	-0.82	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
THCA	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	31.55	3.83e-118	3.42e-113	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	31.52	5.26e-118	4.69e-113	1.01	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	31.51	5.78e-118	5.14e-113	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	31.51	6.06e-118	5.35e-113	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	31.51	6.06e-118	5.35e-113	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	31.51	6.06e-118	5.35e-113	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
THCA	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	31.5	6.34e-118	5.56e-113	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	31.5	6.34e-118	5.56e-113	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
THCA	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	31.5	6.34e-118	5.56e-113	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-31.49	7.19e-118	6.29e-113	-1.01	-0.82	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-31.45	1.03e-117	8.96e-113	-1	-0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
THCA	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-31.45	1.13e-117	9.8e-113	-1.1	-0.82	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	31.42	1.4e-117	1.21e-112	1.1	0.82	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-31.42	1.52e-117	1.31e-112	-1.11	-0.82	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
THCA	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-31.4	1.73e-117	1.49e-112	-1.11	-0.82	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	31.38	2.12e-117	1.82e-112	0.99	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	31.38	2.19e-117	1.88e-112	1.01	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	31.34	3.34e-117	2.85e-112	0.95	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	31.32	3.99e-117	3.39e-112	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
THCA	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	31.32	4.15e-117	3.52e-112	1.1	0.82	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	31.31	4.52e-117	3.79e-112	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	31.31	4.52e-117	3.79e-112	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	31.31	4.52e-117	3.79e-112	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	31.29	5.24e-117	4.38e-112	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	31.16	1.98e-116	1.63e-111	1.01	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	31.13	2.71e-116	2.21e-111	1.09	0.82	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	31.13	2.71e-116	2.21e-111	1.09	0.82	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	31.13	2.71e-116	2.21e-111	1.09	0.82	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-31.12	3.24e-116	2.55e-111	-1.09	-0.82	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	31.12	3.24e-116	2.55e-111	1.09	0.82	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
THCA	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-31.11	3.39e-116	2.65e-111	-1.02	-0.82	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	31.11	3.46e-116	2.7e-111	1.09	0.82	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	31.1	3.61e-116	2.81e-111	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
THCA	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	31.07	5.33e-116	4.13e-111	1.1	0.82	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
THCA	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-31.06	5.41e-116	4.19e-111	-1.12	-0.82	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
THCA	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	31.02	8.93e-116	6.88e-111	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
THCA	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	30.99	1.19e-115	9.14e-111	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
THCA	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	30.98	1.27e-115	9.78e-111	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	30.98	1.29e-115	9.87e-111	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
THCA	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-30.96	1.55e-115	1.18e-110	-1.03	-0.82	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	30.96	1.64e-115	1.25e-110	0.97	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
THCA	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	30.95	1.68e-115	1.28e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	30.94	2.03e-115	1.53e-110	1.09	0.82	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	30.93	2.05e-115	1.55e-110	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	30.93	2.15e-115	1.61e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	30.93	2.15e-115	1.61e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	30.93	2.15e-115	1.61e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	30.93	2.15e-115	1.61e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	30.93	2.16e-115	1.61e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	30.92	2.27e-115	1.69e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	30.91	2.58e-115	1.87e-110	1.09	0.82	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
THCA	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	30.91	2.7e-115	1.94e-110	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
THCA	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	30.91	2.7e-115	1.94e-110	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-30.91	2.74e-115	1.97e-110	-1.01	-0.82	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	30.9	2.87e-115	2.02e-110	1.09	0.82	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	30.9	2.87e-115	2.02e-110	1.09	0.82	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	30.9	2.87e-115	2.02e-110	1.09	0.82	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	30.9	2.87e-115	2.02e-110	1.09	0.82	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	30.9	2.87e-115	2.02e-110	1.09	0.82	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	30.9	2.87e-115	2.02e-110	1.09	0.82	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	30.89	3.05e-115	2.14e-110	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
THCA	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	30.87	3.82e-115	2.67e-110	1.01	0.82	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	30.86	4.29e-115	3e-110	1.03	0.82	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	30.85	4.88e-115	3.4e-110	1.09	0.82	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	30.85	4.88e-115	3.4e-110	1.09	0.82	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
THCA	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-30.84	5.55e-115	3.85e-110	-0.96	-0.82	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
THCA	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	30.82	6.58e-115	4.53e-110	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	30.82	6.58e-115	4.53e-110	1	0.82	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-30.8	8.26e-115	5.66e-110	-1.01	-0.82	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-30.78	9.45e-115	6.45e-110	-1.01	-0.82	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	30.77	1.09e-114	7.37e-110	1.02	0.82	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	30.76	1.24e-114	8.32e-110	1.08	0.82	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	30.76	1.24e-114	8.32e-110	1.08	0.82	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	30.74	1.43e-114	9.57e-110	0.99	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	30.73	1.65e-114	1.1e-109	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
THCA	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-30.72	1.82e-114	1.21e-109	-1.01	-0.82	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
THCA	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	30.71	1.96e-114	1.3e-109	1.08	0.82	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	30.71	1.96e-114	1.3e-109	1.08	0.82	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
THCA	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-30.71	2.05e-114	1.35e-109	-0.96	-0.82	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
THCA	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
THCA	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	30.7	2.29e-114	1.47e-109	1.02	0.82	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
THCA	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-30.7	2.29e-114	1.47e-109	-1.02	-0.82	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-30.7	2.29e-114	1.47e-109	-1.02	-0.82	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
THCA	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-30.7	2.29e-114	1.47e-109	-1.02	-0.82	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
THCA	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	30.69	2.52e-114	1.62e-109	0.95	0.82	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
THCA	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	30.67	3e-114	1.93e-109	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	30.67	3.1e-114	1.99e-109	1.08	0.82	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	30.63	4.36e-114	2.79e-109	1.08	0.82	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	30.63	4.36e-114	2.79e-109	0.98	0.82	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	30.63	4.43e-114	2.82e-109	1.08	0.82	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	30.63	4.43e-114	2.82e-109	1.08	0.82	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	30.63	4.43e-114	2.82e-109	1.08	0.82	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	30.61	5.67e-114	3.61e-109	1.03	0.82	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
THCA	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	30.59	6.95e-114	4.4e-109	1.02	0.82	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	30.59	6.95e-114	4.4e-109	1.02	0.82	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
THCA	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	30.58	7.56e-114	4.78e-109	1.03	0.82	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	30.57	8.66e-114	5.45e-109	1.08	0.82	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	30.57	8.73e-114	5.46e-109	1.08	0.82	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	30.57	8.73e-114	5.46e-109	1.08	0.82	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	30.57	8.73e-114	5.46e-109	1.08	0.82	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	30.52	1.4e-113	8.75e-109	1.07	0.82	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
THCA	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	30.49	1.99e-113	1.23e-108	1.03	0.81	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	30.46	2.71e-113	1.67e-108	1.08	0.81	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	30.4	4.61e-113	2.82e-108	1.03	0.81	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	30.4	4.61e-113	2.82e-108	1.03	0.81	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-30.39	5.19e-113	3.17e-108	-0.97	-0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
THCA	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	30.32	1.04e-112	6.28e-108	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
THCA	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	30.32	1.08e-112	6.5e-108	0.95	0.81	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
THCA	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	30.32	1.1e-112	6.57e-108	1	0.81	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	30.26	1.95e-112	1.15e-107	1.08	0.81	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	30.26	1.95e-112	1.15e-107	1.08	0.81	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	30.24	2.58e-112	1.5e-107	1.08	0.81	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	30.24	2.58e-112	1.5e-107	0.98	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	30.23	2.76e-112	1.61e-107	1.02	0.81	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	30.21	3.26e-112	1.89e-107	1.02	0.81	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	30.2	3.75e-112	2.16e-107	1.08	0.81	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
THCA	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-30.2	3.78e-112	2.17e-107	-1.02	-0.81	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
THCA	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-30.2	3.78e-112	2.17e-107	-1.02	-0.81	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
THCA	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	30.2	3.9e-112	2.2e-107	1.08	0.81	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	30.18	4.42e-112	2.48e-107	1.08	0.81	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
THCA	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	30.18	4.87e-112	2.72e-107	1.03	0.81	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	30.12	8.9e-112	4.94e-107	1.07	0.81	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	30.11	9.4e-112	5.21e-107	1.08	0.81	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
THCA	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-30.1	1.05e-111	5.81e-107	-1.01	-0.81	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	30.1	1.07e-111	5.93e-107	0.98	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
THCA	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-30.1	1.09e-111	5.99e-107	-1.12	-0.81	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
THCA	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	30.1	1.09e-111	6.02e-107	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-30.08	1.28e-111	7.03e-107	-0.97	-0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	30.07	1.4e-111	7.7e-107	1.08	0.81	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	30.07	1.4e-111	7.7e-107	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	30.07	1.43e-111	7.84e-107	0.98	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
THCA	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	30.05	1.79e-111	9.74e-107	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	30.05	1.79e-111	9.74e-107	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
THCA	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-30.04	1.93e-111	1.05e-106	-0.95	-0.81	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
THCA	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	30.02	2.42e-111	1.32e-106	1.08	0.81	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
THCA	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	30.02	2.46e-111	1.34e-106	1.02	0.81	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	30	2.88e-111	1.55e-106	1.01	0.81	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
THCA	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-30	2.88e-111	1.55e-106	-1.01	-0.81	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
THCA	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	29.98	3.51e-111	1.88e-106	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	29.98	3.51e-111	1.88e-106	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	29.98	3.51e-111	1.88e-106	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
THCA	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	29.98	3.51e-111	1.88e-106	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
THCA	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	29.97	4.03e-111	2.15e-106	0.94	0.81	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	29.96	4.39e-111	2.34e-106	0.95	0.81	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
THCA	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	29.88	1.04e-110	5.51e-106	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	29.86	1.22e-110	6.41e-106	1.08	0.81	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	29.86	1.24e-110	6.55e-106	1.08	0.81	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
THCA	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-29.85	1.39e-110	7.28e-106	-1.01	-0.81	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	29.85	1.41e-110	7.38e-106	1.08	0.81	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	29.85	1.44e-110	7.56e-106	1.08	0.81	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
THCA	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	29.85	1.45e-110	7.56e-106	0.94	0.81	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
THCA	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	29.83	1.63e-110	8.51e-106	1.08	0.81	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	29.81	2.16e-110	1.12e-105	0.98	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
THCA	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-29.79	2.62e-110	1.36e-105	-1.01	-0.81	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	29.79	2.66e-110	1.37e-105	0.97	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	29.78	2.74e-110	1.41e-105	1.08	0.81	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	29.78	2.87e-110	1.47e-105	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	29.78	2.87e-110	1.47e-105	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
THCA	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	29.78	2.87e-110	1.47e-105	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	29.77	3.08e-110	1.56e-105	1.02	0.81	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
THCA	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	29.72	5.2e-110	2.63e-105	0.99	0.81	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	29.7	6.28e-110	3.16e-105	1.07	0.81	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
THCA	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-29.69	7.07e-110	3.55e-105	-1.09	-0.81	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
THCA	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	29.68	7.89e-110	3.95e-105	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
THCA	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-29.68	7.99e-110	3.99e-105	-1.01	-0.81	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
THCA	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-29.68	7.99e-110	3.99e-105	-1.01	-0.81	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-29.68	7.99e-110	3.99e-105	-1.01	-0.81	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	29.61	1.65e-109	8.18e-105	1.07	0.81	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	29.61	1.69e-109	8.38e-105	0.96	0.81	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
THCA	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	29.6	1.85e-109	9.13e-105	1.01	0.81	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
THCA	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-29.58	2.27e-109	1.12e-104	-1.01	-0.81	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
THCA	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
THCA	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-29.56	2.76e-109	1.32e-104	-1.01	-0.81	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-29.56	2.9e-109	1.38e-104	-1.01	-0.81	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
THCA	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-29.46	7.51e-109	3.53e-104	-1.01	-0.81	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-29.46	7.51e-109	3.53e-104	-1.01	-0.81	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
THCA	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-29.46	7.51e-109	3.53e-104	-1.01	-0.81	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-29.46	7.51e-109	3.53e-104	-1.01	-0.81	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-29.46	7.9e-109	3.71e-104	-1.01	-0.81	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	29.45	8.76e-109	4.11e-104	1.07	0.81	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
THCA	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	29.4	1.45e-108	6.77e-104	1.07	0.8	Shingles;	chr7:38346957	chr7:38343894~38350022:-
THCA	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-29.36	2.19e-108	1.02e-103	-1.02	-0.8	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
THCA	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	29.35	2.5e-108	1.15e-103	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	29.34	2.58e-108	1.19e-103	1.06	0.8	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	29.34	2.58e-108	1.19e-103	1.06	0.8	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	29.34	2.64e-108	1.21e-103	0.98	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
THCA	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-29.25	6.6e-108	3.01e-103	-1.01	-0.8	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
THCA	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	29.25	6.7e-108	3.06e-103	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
THCA	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-29.24	8.03e-108	3.66e-103	-1	-0.8	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	29.21	1.01e-107	4.57e-103	0.93	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
THCA	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-29.21	1.01e-107	4.57e-103	-1.01	-0.8	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	29.14	2.23e-107	1.01e-102	1.08	0.8	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-29.1	3.24e-107	1.46e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-29.07	4.42e-107	1.96e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-29.07	4.42e-107	1.96e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-29.07	4.42e-107	1.96e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-29.07	4.42e-107	1.96e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-29.07	4.42e-107	1.96e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-29.07	4.58e-107	2.01e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-29.07	4.58e-107	2.01e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-29.07	4.58e-107	2.01e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-29.07	4.58e-107	2.01e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-29.07	4.58e-107	2.01e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-29.07	4.58e-107	2.01e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-29.02	7.32e-107	3.18e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-29.02	7.32e-107	3.18e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-29.02	7.32e-107	3.18e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-29.02	7.32e-107	3.18e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	29.02	7.32e-107	3.18e-102	0.99	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	29.02	7.32e-107	3.18e-102	0.99	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	29.02	7.32e-107	3.18e-102	0.99	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	29.02	7.32e-107	3.18e-102	0.99	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	29.02	7.32e-107	3.18e-102	0.99	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-29.02	7.45e-107	3.23e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-28.99	9.81e-107	4.24e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-28.96	1.36e-106	5.84e-102	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
THCA	cis	rs858239	0.669	rs12539467	ENSG00000230658.1	KLHL7-AS1	28.96	1.39e-106	5.96e-102	1.03	0.8	Cerebrospinal fluid biomarker levels;	chr7:23076240	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	28.93	2.02e-106	8.62e-102	1.06	0.8	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
THCA	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	28.9	2.77e-106	1.17e-101	1.06	0.8	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
THCA	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-28.86	3.98e-106	1.68e-101	-1	-0.8	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	28.86	4.1e-106	1.71e-101	1	0.8	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	28.86	4.1e-106	1.71e-101	1	0.8	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	28.86	4.1e-106	1.71e-101	1	0.8	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
THCA	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	28.86	4.1e-106	1.71e-101	1	0.8	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	28.86	4.1e-106	1.71e-101	1	0.8	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-28.85	4.24e-106	1.77e-101	-1	-0.8	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
THCA	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	28.84	5.05e-106	2.1e-101	0.93	0.8	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
THCA	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	28.83	5.24e-106	2.17e-101	1.06	0.8	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	28.81	6.53e-106	2.69e-101	1.06	0.8	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-28.8	7.81e-106	3.22e-101	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-28.79	8.05e-106	3.31e-101	-0.98	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-28.79	8.05e-106	3.31e-101	-0.98	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-28.79	8.05e-106	3.31e-101	-0.98	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
THCA	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-28.79	8.33e-106	3.42e-101	-1	-0.8	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-28.77	1.03e-105	4.21e-101	-1	-0.8	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
THCA	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
THCA	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
THCA	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
THCA	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	28.77	1.05e-105	4.25e-101	1	0.8	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-28.76	1.09e-105	4.37e-101	-1	-0.8	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-28.76	1.09e-105	4.37e-101	-1	-0.8	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	28.76	1.09e-105	4.37e-101	1	0.8	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
THCA	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	28.76	1.09e-105	4.37e-101	1	0.8	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	28.76	1.09e-105	4.37e-101	1	0.8	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	28.7	2.04e-105	8.13e-101	1.07	0.8	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
THCA	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	28.7	2.21e-105	8.81e-101	1.01	0.8	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
THCA	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-28.69	2.34e-105	9.3e-101	-0.87	-0.8	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
THCA	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	28.67	2.94e-105	1.17e-100	1.05	0.8	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
THCA	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-28.6	5.9e-105	2.33e-100	-0.87	-0.8	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
THCA	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	28.6	6.14e-105	2.42e-100	1.06	0.8	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
THCA	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	28.59	6.77e-105	2.66e-100	1.03	0.8	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
THCA	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-28.58	7.67e-105	3.01e-100	-0.87	-0.8	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
THCA	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-28.57	8.4e-105	3.29e-100	-1.06	-0.8	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	28.57	8.59e-105	3.36e-100	0.97	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-28.56	9.57e-105	3.73e-100	-1.01	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
THCA	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-28.55	1.05e-104	4.07e-100	-1.02	-0.8	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	28.54	1.14e-104	4.42e-100	1.07	0.8	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	28.53	1.2e-104	4.65e-100	1.06	0.8	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
THCA	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	28.53	1.2e-104	4.65e-100	1.06	0.8	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-28.52	1.46e-104	5.66e-100	-0.99	-0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
THCA	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	28.51	1.62e-104	6.27e-100	1	0.8	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	28.49	1.93e-104	7.42e-100	0.98	0.8	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
THCA	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	28.4	4.89e-104	1.86e-99	1.01	0.79	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	28.4	4.93e-104	1.87e-99	1.06	0.79	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
THCA	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	28.4	5.02e-104	1.9e-99	1.17	0.79	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
THCA	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	28.37	6.68e-104	2.52e-99	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	28.37	6.68e-104	2.52e-99	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	28.37	6.68e-104	2.52e-99	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	28.37	6.68e-104	2.52e-99	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	28.37	6.68e-104	2.52e-99	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
THCA	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	28.36	7.41e-104	2.79e-99	1	0.79	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
THCA	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	28.36	7.51e-104	2.82e-99	1.17	0.79	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
THCA	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-28.36	7.7e-104	2.88e-99	-0.87	-0.79	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
THCA	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-28.34	9.17e-104	3.42e-99	-0.87	-0.79	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
THCA	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	28.34	9.26e-104	3.45e-99	1	0.79	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	28.33	9.96e-104	3.7e-99	1.04	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
THCA	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	28.31	1.21e-103	4.48e-99	0.95	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
THCA	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	28.29	1.57e-103	5.79e-99	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
THCA	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	28.29	1.57e-103	5.79e-99	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
THCA	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	28.25	2.39e-103	8.69e-99	1.16	0.79	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
THCA	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	28.22	3.36e-103	1.21e-98	1.05	0.79	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	28.22	3.36e-103	1.21e-98	1.05	0.79	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
THCA	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	28.21	3.52e-103	1.27e-98	1.16	0.79	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
THCA	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-28.21	3.53e-103	1.27e-98	-0.92	-0.79	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
THCA	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	28.19	4.4e-103	1.58e-98	1	0.79	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
THCA	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	28.19	4.59e-103	1.65e-98	1	0.79	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
THCA	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	28.17	5.44e-103	1.95e-98	1.16	0.79	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	28.16	5.92e-103	2.12e-98	1.01	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
THCA	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	28.13	8.04e-103	2.86e-98	1	0.79	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	28.11	9.73e-103	3.42e-98	0.97	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	28.08	1.41e-102	4.93e-98	0.99	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
THCA	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	28.07	1.6e-102	5.6e-98	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
THCA	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	28.06	1.78e-102	6.2e-98	0.99	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	28.05	1.97e-102	6.83e-98	1	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
THCA	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-28.03	2.27e-102	7.84e-98	-0.99	-0.79	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	28.01	2.92e-102	1.01e-97	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	28	3.23e-102	1.11e-97	0.98	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	27.98	3.95e-102	1.36e-97	1.04	0.79	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	27.96	4.77e-102	1.63e-97	1.04	0.79	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	27.95	5.59e-102	1.91e-97	1.05	0.79	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
THCA	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	27.93	6.57e-102	2.24e-97	1.15	0.79	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
THCA	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-27.93	6.78e-102	2.27e-97	-0.94	-0.79	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
THCA	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	27.93	7.01e-102	2.35e-97	0.99	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
THCA	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	27.92	7.25e-102	2.42e-97	0.99	0.79	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.69	rs311608	ENSG00000253404.1	AC034243.1	27.9	9.18e-102	3.05e-97	0.96	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138708000	chr5:138744434~138753309:-
THCA	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	27.89	9.8e-102	3.25e-97	0.94	0.79	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
THCA	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	27.88	1.13e-101	3.74e-97	0.99	0.79	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
THCA	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	27.87	1.23e-101	4.04e-97	1.15	0.79	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
THCA	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	27.87	1.23e-101	4.04e-97	1.15	0.79	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
THCA	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	27.85	1.55e-101	5.1e-97	0.99	0.79	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
THCA	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	27.85	1.61e-101	5.3e-97	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
THCA	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	27.85	1.61e-101	5.3e-97	1.2	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
THCA	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	27.84	1.77e-101	5.79e-97	0.99	0.79	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	27.84	1.77e-101	5.79e-97	0.99	0.79	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
THCA	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	27.84	1.77e-101	5.79e-97	0.99	0.79	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	27.82	2.06e-101	6.73e-97	1.03	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
THCA	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	27.8	2.7e-101	8.78e-97	0.99	0.79	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-27.79	2.81e-101	9.08e-97	-0.93	-0.79	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-27.79	2.81e-101	9.08e-97	-0.93	-0.79	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-27.79	2.81e-101	9.08e-97	-0.93	-0.79	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-27.79	2.81e-101	9.08e-97	-0.93	-0.79	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
THCA	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	27.78	3.36e-101	1.08e-96	1.19	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
THCA	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	27.76	3.85e-101	1.24e-96	1.19	0.79	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
THCA	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	27.76	4.17e-101	1.34e-96	0.99	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	27.74	4.87e-101	1.56e-96	1.04	0.79	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
THCA	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	27.72	5.92e-101	1.9e-96	1.01	0.79	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
THCA	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-27.71	6.88e-101	2.2e-96	-0.87	-0.79	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
THCA	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	27.67	1.01e-100	3.23e-96	1.18	0.79	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
THCA	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	27.66	1.22e-100	3.86e-96	1	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
THCA	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-27.62	1.74e-100	5.49e-96	-0.99	-0.79	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-27.62	1.85e-100	5.83e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	27.61	1.96e-100	6.16e-96	0.92	0.79	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-27.6	2.25e-100	6.99e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-27.6	2.25e-100	6.99e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-27.6	2.25e-100	6.99e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-27.6	2.25e-100	6.99e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-27.6	2.25e-100	6.99e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-27.6	2.25e-100	6.99e-96	-0.93	-0.79	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	27.6	2.25e-100	7e-96	0.93	0.79	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
THCA	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-27.58	2.58e-100	8e-96	-0.99	-0.79	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	27.57	3.13e-100	9.68e-96	0.99	0.79	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	27.57	3.13e-100	9.68e-96	0.99	0.79	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
THCA	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	27.56	3.16e-100	9.77e-96	0.99	0.79	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	27.56	3.34e-100	1.03e-95	1.05	0.79	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
THCA	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	27.55	3.78e-100	1.16e-95	1.16	0.79	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
THCA	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	27.55	3.78e-100	1.16e-95	1.16	0.79	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
THCA	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-27.55	3.8e-100	1.17e-95	-1	-0.79	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
THCA	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	27.54	4.07e-100	1.25e-95	1.19	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	27.54	4.27e-100	1.31e-95	1.03	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
THCA	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-27.53	4.71e-100	1.44e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-27.53	4.71e-100	1.44e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-27.53	4.71e-100	1.44e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-27.52	5.23e-100	1.59e-95	-0.92	-0.79	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
THCA	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	27.5	6.17e-100	1.88e-95	0.99	0.79	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
THCA	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-27.5	6.48e-100	1.97e-95	-0.87	-0.79	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
THCA	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-27.49	6.67e-100	2.03e-95	-1	-0.79	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
THCA	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-27.49	6.83e-100	2.07e-95	-0.92	-0.79	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-27.49	6.83e-100	2.07e-95	-0.92	-0.79	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
THCA	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	27.48	7.44e-100	2.25e-95	0.99	0.79	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-27.48	7.68e-100	2.32e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-27.48	7.68e-100	2.32e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-27.48	7.68e-100	2.32e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-27.48	7.68e-100	2.32e-95	-0.93	-0.79	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-27.47	8.24e-100	2.48e-95	-0.92	-0.79	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	27.46	9.25e-100	2.78e-95	0.94	0.78	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
THCA	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-27.42	1.4e-99	4.2e-95	-0.93	-0.78	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-27.42	1.43e-99	4.29e-95	-0.92	-0.78	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-27.41	1.61e-99	4.8e-95	-0.92	-0.78	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-27.41	1.61e-99	4.8e-95	-0.92	-0.78	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
THCA	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	27.4	1.8e-99	5.38e-95	0.96	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
THCA	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-27.39	2.07e-99	6.14e-95	-0.93	-0.78	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
THCA	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	27.38	2.16e-99	6.42e-95	1.14	0.78	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
THCA	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	27.36	2.78e-99	8.23e-95	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-27.34	3.39e-99	1e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-27.34	3.39e-99	1e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	27.32	4.37e-99	1.28e-94	0.94	0.78	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	27.32	4.37e-99	1.28e-94	0.94	0.78	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	27.31	4.77e-99	1.4e-94	0.94	0.78	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
THCA	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-27.26	8e-99	2.33e-94	-0.93	-0.78	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-27.24	9.34e-99	2.7e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-27.24	9.34e-99	2.7e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-27.24	9.34e-99	2.7e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-27.24	9.34e-99	2.7e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-27.24	9.34e-99	2.7e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-27.24	9.34e-99	2.7e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-27.22	1.23e-98	3.54e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-27.21	1.35e-98	3.87e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-27.21	1.35e-98	3.87e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-27.21	1.35e-98	3.87e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	27.19	1.66e-98	4.75e-94	0.94	0.78	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
THCA	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-27.16	2.3e-98	6.52e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-27.16	2.3e-98	6.52e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
THCA	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	27.16	2.34e-98	6.61e-94	0.98	0.78	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
THCA	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-27.15	2.48e-98	6.99e-94	-0.86	-0.78	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
THCA	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-27.13	3.07e-98	8.51e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-27.13	3.07e-98	8.51e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-27.13	3.07e-98	8.51e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-27.13	3.1e-98	8.56e-94	-0.92	-0.78	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	27.13	3.1e-98	8.56e-94	0.98	0.78	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	27.13	3.1e-98	8.56e-94	0.98	0.78	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
THCA	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	27.13	3.26e-98	9e-94	0.94	0.78	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
THCA	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-27.13	3.26e-98	9.01e-94	-1.07	-0.78	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
THCA	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	27.12	3.6e-98	9.91e-94	0.97	0.78	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
THCA	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-27.1	4.16e-98	1.14e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	27.1	4.18e-98	1.15e-93	0.94	0.78	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
THCA	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-27.1	4.48e-98	1.23e-93	-1.06	-0.78	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
THCA	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-27.08	5.1e-98	1.39e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-27.08	5.1e-98	1.39e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-27.08	5.1e-98	1.39e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-27.08	5.1e-98	1.39e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
THCA	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	27.08	5.31e-98	1.45e-93	1.15	0.78	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
THCA	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-27.07	5.82e-98	1.58e-93	-0.87	-0.78	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
THCA	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-27.04	7.73e-98	2.07e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
THCA	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-27.04	8.17e-98	2.18e-93	-1.06	-0.78	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
THCA	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	27.03	9.02e-98	2.41e-93	0.93	0.78	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	27.03	9.02e-98	2.41e-93	0.93	0.78	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
THCA	cis	rs4853012	0.793	rs6723185	ENSG00000217702.2	RP11-287D1.4	27.01	1.07e-97	2.82e-93	1.15	0.78	Gestational age at birth (maternal effect);	chr2:74117757	chr2:74130583~74135395:+
THCA	cis	rs8013143	0.961	rs7147308	ENSG00000279656.1	RP11-298I3.6	-27.01	1.12e-97	2.96e-93	-1.07	-0.78	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23028420	chr14:23023083~23024217:-
THCA	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	27	1.21e-97	3.19e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-26.99	1.33e-97	3.48e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	26.98	1.57e-97	4.11e-93	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	26.97	1.62e-97	4.23e-93	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	26.97	1.62e-97	4.23e-93	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	26.97	1.62e-97	4.23e-93	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
THCA	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	26.97	1.62e-97	4.23e-93	0.97	0.78	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	26.97	1.62e-97	4.23e-93	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	26.97	1.62e-97	4.23e-93	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-26.97	1.77e-97	4.61e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
THCA	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	26.96	1.82e-97	4.73e-93	1	0.78	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-26.96	1.93e-97	4.99e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
THCA	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	26.95	2.08e-97	5.36e-93	0.99	0.78	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	26.95	2.17e-97	5.59e-93	0.95	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
THCA	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	26.94	2.24e-97	5.77e-93	0.99	0.78	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-26.94	2.38e-97	6.1e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-26.94	2.38e-97	6.1e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-26.94	2.38e-97	6.1e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-26.94	2.38e-97	6.1e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-26.93	2.56e-97	6.51e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-26.92	3.02e-97	7.67e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-26.91	3.15e-97	8e-93	-0.92	-0.78	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-26.91	3.29e-97	8.35e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-26.91	3.29e-97	8.35e-93	-0.93	-0.78	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	26.9	3.73e-97	9.44e-93	0.93	0.78	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
THCA	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-26.89	4.15e-97	1.05e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-26.89	4.15e-97	1.05e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
THCA	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	26.87	4.86e-97	1.22e-92	0.94	0.78	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
THCA	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-26.86	5.19e-97	1.31e-92	-0.92	-0.78	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-26.86	5.58e-97	1.38e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
THCA	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-26.86	5.63e-97	1.38e-92	-0.84	-0.78	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
THCA	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-26.83	7.36e-97	1.79e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-26.83	7.36e-97	1.79e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-26.83	7.36e-97	1.79e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-26.83	7.36e-97	1.79e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-26.83	7.36e-97	1.79e-92	-0.93	-0.78	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
THCA	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-26.82	8.6e-97	2.09e-92	-0.99	-0.78	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
THCA	cis	rs113525195	1	rs113525195	ENSG00000279656.1	RP11-298I3.6	-26.82	8.69e-97	2.11e-92	-1.07	-0.78	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;	chr14:23030112	chr14:23023083~23024217:-
THCA	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-26.81	9.14e-97	2.21e-92	-0.92	-0.78	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-26.8	9.88e-97	2.39e-92	-0.92	-0.78	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	26.79	1.16e-96	2.8e-92	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	26.79	1.16e-96	2.8e-92	0.96	0.78	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
THCA	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	26.78	1.32e-96	3.17e-92	1.12	0.78	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
THCA	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-26.78	1.35e-96	3.23e-92	-0.92	-0.78	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	26.75	1.79e-96	4.27e-92	0.93	0.78	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
THCA	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-26.73	2.16e-96	5.14e-92	-0.92	-0.78	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
THCA	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-26.73	2.28e-96	5.41e-92	-0.86	-0.78	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
THCA	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-26.73	2.28e-96	5.41e-92	-0.86	-0.78	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
THCA	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-26.72	2.54e-96	6.02e-92	-0.92	-0.78	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
THCA	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	26.69	3.34e-96	7.86e-92	1.17	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
THCA	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	26.69	3.34e-96	7.86e-92	1.17	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
THCA	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-26.65	4.92e-96	1.15e-91	-0.96	-0.78	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
THCA	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-26.65	4.98e-96	1.16e-91	-0.92	-0.78	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-26.65	4.98e-96	1.16e-91	-0.92	-0.78	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
THCA	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	26.65	5.29e-96	1.23e-91	1.22	0.78	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
THCA	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-26.64	5.74e-96	1.33e-91	-0.93	-0.78	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-26.64	5.74e-96	1.33e-91	-0.93	-0.78	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-26.63	6.46e-96	1.49e-91	-0.92	-0.78	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-26.62	6.8e-96	1.57e-91	-0.92	-0.78	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-26.59	9.17e-96	2.11e-91	-0.93	-0.78	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-26.57	1.17e-95	2.69e-91	-0.93	-0.77	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	26.56	1.32e-95	3.02e-91	0.9	0.77	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	26.56	1.36e-95	3.11e-91	0.95	0.77	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
THCA	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-26.55	1.42e-95	3.24e-91	-0.93	-0.77	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	26.54	1.56e-95	3.56e-91	0.92	0.77	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
THCA	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-26.53	1.82e-95	4.15e-91	-0.93	-0.77	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
THCA	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-26.53	1.89e-95	4.3e-91	-0.87	-0.77	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
THCA	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	26.52	2.04e-95	4.63e-91	0.98	0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
THCA	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-26.52	2.09e-95	4.73e-91	-0.93	-0.77	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-26.52	2.09e-95	4.73e-91	-0.93	-0.77	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-26.5	2.51e-95	5.68e-91	-0.92	-0.77	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	26.48	3.15e-95	7.1e-91	0.98	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-26.46	3.85e-95	8.65e-91	-0.93	-0.77	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
THCA	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	26.46	3.92e-95	8.8e-91	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
THCA	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	26.45	4.16e-95	9.33e-91	1.05	0.77	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
THCA	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-26.45	4.2e-95	9.41e-91	-0.92	-0.77	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
THCA	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-26.45	4.33e-95	9.69e-91	-0.85	-0.77	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
THCA	cis	rs7188445	0.556	rs7194711	ENSG00000261390.4	RP11-345M22.2	-26.45	4.47e-95	1e-90	-0.86	-0.77	Urate levels;	chr16:79715134	chr16:79715232~79770563:-
THCA	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-26.43	5.32e-95	1.19e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-26.43	5.32e-95	1.19e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	26.39	7.9e-95	1.75e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
THCA	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-26.39	8.05e-95	1.79e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-26.37	9.62e-95	2.13e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	26.37	9.63e-95	2.13e-90	0.97	0.77	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-26.36	1.08e-94	2.39e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-26.36	1.16e-94	2.56e-90	-0.93	-0.77	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	26.34	1.35e-94	2.95e-90	0.93	0.77	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
THCA	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	26.34	1.35e-94	2.95e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	26.34	1.35e-94	2.95e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
THCA	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	26.34	1.35e-94	2.95e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	26.34	1.35e-94	2.95e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	26.34	1.35e-94	2.95e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	26.34	1.35e-94	2.95e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	26.34	1.37e-94	2.99e-90	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	26.34	1.37e-94	2.99e-90	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
THCA	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	26.34	1.37e-94	2.99e-90	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
THCA	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	26.34	1.37e-94	2.99e-90	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	26.33	1.52e-94	3.32e-90	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
THCA	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	26.33	1.52e-94	3.32e-90	0.99	0.77	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-26.33	1.54e-94	3.33e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-26.33	1.54e-94	3.33e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-26.33	1.54e-94	3.33e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-26.33	1.54e-94	3.33e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-26.33	1.54e-94	3.33e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-26.33	1.54e-94	3.33e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
THCA	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	26.32	1.65e-94	3.56e-90	1.19	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
THCA	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-26.32	1.71e-94	3.7e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-26.32	1.71e-94	3.7e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-26.32	1.71e-94	3.7e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
THCA	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	26.32	1.74e-94	3.75e-90	0.95	0.77	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
THCA	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	26.32	1.74e-94	3.75e-90	0.95	0.77	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
THCA	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	26.32	1.74e-94	3.75e-90	0.95	0.77	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
THCA	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-26.32	1.74e-94	3.75e-90	-0.95	-0.77	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-26.31	1.9e-94	4.07e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-26.31	1.9e-94	4.07e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-26.31	1.9e-94	4.07e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
THCA	cis	rs10256972	0.514	rs2140578	ENSG00000229043.2	AC091729.9	-26.31	1.96e-94	4.2e-90	-0.87	-0.77	Endometriosis;Longevity;	chr7:1174367	chr7:1160374~1165267:+
THCA	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-26.3	2.2e-94	4.73e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
THCA	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-26.29	2.47e-94	5.3e-90	-0.94	-0.77	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
THCA	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	26.27	2.92e-94	6.24e-90	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
THCA	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-26.27	2.97e-94	6.35e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-26.24	3.92e-94	8.34e-90	-0.91	-0.77	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
THCA	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	26.23	4.4e-94	9.33e-90	0.94	0.77	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
THCA	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	26.23	4.4e-94	9.33e-90	0.94	0.77	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-26.23	4.66e-94	9.89e-90	-0.92	-0.77	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-26.22	4.77e-94	1.01e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-26.15	1.01e-93	2.12e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-26.15	1.01e-93	2.12e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-26.15	1.01e-93	2.12e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-26.15	1.01e-93	2.12e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-26.14	1.13e-93	2.36e-89	-0.91	-0.77	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-26.11	1.53e-93	3.19e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-26.1	1.74e-93	3.62e-89	-0.91	-0.77	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-26.08	2.15e-93	4.45e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
THCA	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	26.06	2.86e-93	5.92e-89	0.94	0.77	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
THCA	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	26.04	3.27e-93	6.75e-89	1.2	0.77	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
THCA	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	26.01	4.62e-93	9.53e-89	1.18	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
THCA	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-26.01	4.8e-93	9.88e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-26.01	4.8e-93	9.88e-89	-0.92	-0.77	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
THCA	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	25.91	1.43e-92	2.91e-88	0.97	0.77	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	25.89	1.59e-92	3.24e-88	0.85	0.77	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
THCA	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	25.89	1.73e-92	3.53e-88	0.96	0.77	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
THCA	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-25.87	2.01e-92	4.09e-88	-0.92	-0.77	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
THCA	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-25.86	2.32e-92	4.72e-88	-0.93	-0.77	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
THCA	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	25.85	2.57e-92	5.21e-88	0.96	0.77	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
THCA	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	25.82	3.4e-92	6.88e-88	0.96	0.77	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
THCA	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	25.81	4e-92	8.08e-88	0.97	0.77	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-25.74	8.18e-92	1.65e-87	-0.92	-0.76	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
THCA	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-25.74	8.61e-92	1.73e-87	-0.97	-0.76	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
THCA	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	25.74	8.72e-92	1.75e-87	0.98	0.76	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
THCA	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	25.72	1.05e-91	2.1e-87	0.91	0.76	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
THCA	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	25.72	1.08e-91	2.16e-87	1.13	0.76	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
THCA	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	25.71	1.19e-91	2.38e-87	1.02	0.76	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
THCA	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	25.68	1.57e-91	3.13e-87	0.96	0.76	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-25.67	1.85e-91	3.69e-87	-0.92	-0.76	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-25.65	2.1e-91	4.18e-87	-0.91	-0.76	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-25.65	2.1e-91	4.18e-87	-0.91	-0.76	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
THCA	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	25.63	2.83e-91	5.64e-87	0.98	0.76	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	25.61	3.23e-91	6.41e-87	1.02	0.76	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	25.56	5.66e-91	1.12e-86	1.02	0.76	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
THCA	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	25.56	5.75e-91	1.14e-86	0.97	0.76	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-25.55	6.52e-91	1.29e-86	-0.96	-0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
THCA	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-25.54	6.84e-91	1.35e-86	-0.91	-0.76	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
THCA	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-25.53	8.23e-91	1.62e-86	-0.92	-0.76	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-25.53	8.23e-91	1.62e-86	-0.92	-0.76	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
THCA	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	25.51	9.68e-91	1.9e-86	0.96	0.76	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
THCA	cis	rs1799949	0.827	rs74252763	ENSG00000198496.9	NBR2	-25.5	1.13e-90	2.22e-86	-0.93	-0.76	Menopause (age at onset);	chr17:43324652	chr17:43125610~43153671:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	25.49	1.16e-90	2.28e-86	0.98	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
THCA	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-25.48	1.37e-90	2.68e-86	-0.92	-0.76	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	25.41	2.73e-90	5.34e-86	1.02	0.76	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
THCA	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	25.4	3.32e-90	6.45e-86	0.93	0.76	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
THCA	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	25.4	3.32e-90	6.45e-86	0.93	0.76	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
THCA	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	25.4	3.32e-90	6.45e-86	0.93	0.76	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
THCA	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	25.39	3.38e-90	6.57e-86	0.93	0.76	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	25.39	3.44e-90	6.69e-86	1.01	0.76	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	25.39	3.44e-90	6.69e-86	1.01	0.76	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
THCA	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-25.38	3.93e-90	7.61e-86	-0.92	-0.76	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	25.38	4.07e-90	7.87e-86	0.93	0.76	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
THCA	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	25.37	4.32e-90	8.37e-86	1.19	0.76	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
THCA	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	25.35	5.59e-90	1.08e-85	0.92	0.76	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	25.35	5.62e-90	1.09e-85	1.01	0.76	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-25.35	5.66e-90	1.09e-85	-0.92	-0.76	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
THCA	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-25.33	6.43e-90	1.24e-85	-0.9	-0.76	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	25.32	7.28e-90	1.4e-85	1.01	0.76	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	25.3	8.83e-90	1.69e-85	1.01	0.76	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	25.3	9.15e-90	1.75e-85	1.01	0.76	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	25.3	9.15e-90	1.75e-85	1.01	0.76	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	25.3	9.15e-90	1.75e-85	1.01	0.76	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	25.3	9.15e-90	1.75e-85	1.01	0.76	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	25.3	9.75e-90	1.86e-85	1.02	0.76	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	25.3	9.75e-90	1.86e-85	1.02	0.76	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	25.3	9.75e-90	1.86e-85	1.02	0.76	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	25.3	9.75e-90	1.86e-85	1.02	0.76	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
THCA	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-25.26	1.39e-89	2.64e-85	-0.86	-0.76	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
THCA	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	25.26	1.45e-89	2.75e-85	1.02	0.76	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	25.25	1.55e-89	2.95e-85	0.9	0.76	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	25.25	1.65e-89	3.12e-85	0.92	0.76	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
THCA	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	25.24	1.71e-89	3.22e-85	0.92	0.76	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	25.24	1.81e-89	3.42e-85	1.02	0.76	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	25.23	2.06e-89	3.89e-85	1.02	0.76	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-25.22	2.15e-89	4.05e-85	-0.89	-0.76	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-25.22	2.23e-89	4.21e-85	-0.9	-0.76	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	25.22	2.24e-89	4.22e-85	1.02	0.76	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	25.22	2.24e-89	4.22e-85	1.02	0.76	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-25.21	2.39e-89	4.49e-85	-0.89	-0.76	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	25.2	2.71e-89	5.07e-85	1.02	0.76	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	25.2	2.72e-89	5.1e-85	1.13	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
THCA	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	25.2	2.72e-89	5.1e-85	1.13	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	25.2	2.75e-89	5.14e-85	0.9	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
THCA	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	25.2	2.85e-89	5.34e-85	1.19	0.76	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
THCA	cis	rs7188445	0.592	rs7196490	ENSG00000261390.4	RP11-345M22.2	-25.19	3.1e-89	5.79e-85	-0.85	-0.76	Urate levels;	chr16:79718572	chr16:79715232~79770563:-
THCA	cis	rs10256972	0.567	rs2960850	ENSG00000229043.2	AC091729.9	-25.18	3.43e-89	6.41e-85	-0.86	-0.76	Endometriosis;Longevity;	chr7:1172013	chr7:1160374~1165267:+
THCA	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	25.18	3.54e-89	6.6e-85	1.01	0.76	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	25.18	3.54e-89	6.6e-85	1.01	0.76	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	25.17	3.6e-89	6.72e-85	1.02	0.76	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	25.17	3.63e-89	6.76e-85	1.02	0.76	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	25.17	3.71e-89	6.9e-85	1.01	0.76	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	25.16	4.02e-89	7.46e-85	1.01	0.76	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	25.16	4.03e-89	7.48e-85	1.02	0.76	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	25.16	4.03e-89	7.48e-85	1.02	0.76	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
THCA	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	25.16	4.21e-89	7.81e-85	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	25.15	4.42e-89	8.17e-85	0.9	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	25.15	4.53e-89	8.36e-85	1.01	0.76	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	25.14	4.94e-89	9.1e-85	1.01	0.76	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	25.14	4.94e-89	9.1e-85	1.01	0.76	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	25.13	5.59e-89	1.03e-84	1.01	0.76	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	25.13	5.87e-89	1.08e-84	1.01	0.76	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	25.13	5.87e-89	1.08e-84	1.01	0.76	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	25.13	5.9e-89	1.08e-84	1.01	0.76	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
THCA	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	25.13	6.03e-89	1.11e-84	1.13	0.76	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
THCA	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	25.11	6.79e-89	1.24e-84	1.01	0.76	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
THCA	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	25.09	8.77e-89	1.6e-84	0.96	0.76	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	25.09	9.24e-89	1.68e-84	1.01	0.76	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	25.08	9.55e-89	1.74e-84	1.01	0.76	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-25.08	1.01e-88	1.82e-84	-0.89	-0.76	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	25.06	1.2e-88	2.16e-84	1.01	0.76	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	25.06	1.26e-88	2.26e-84	0.91	0.76	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	25.06	1.28e-88	2.3e-84	1.01	0.76	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	25.05	1.31e-88	2.35e-84	1.01	0.76	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	25.05	1.34e-88	2.41e-84	1.01	0.76	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	25.05	1.34e-88	2.41e-84	1.01	0.76	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	25.05	1.35e-88	2.42e-84	1.01	0.76	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	25.05	1.35e-88	2.42e-84	1.01	0.76	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	25.05	1.4e-88	2.51e-84	1.01	0.76	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	25.05	1.4e-88	2.51e-84	1.01	0.76	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	25.05	1.4e-88	2.51e-84	1.01	0.76	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	25.04	1.55e-88	2.76e-84	1.01	0.76	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	25.04	1.55e-88	2.76e-84	1.01	0.76	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	25.02	1.79e-88	3.18e-84	1.02	0.76	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-25.02	1.82e-88	3.24e-84	-0.89	-0.76	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
THCA	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	25.02	1.91e-88	3.4e-84	1.11	0.76	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
THCA	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	25.02	1.93e-88	3.42e-84	1.01	0.76	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
THCA	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	25.01	2.04e-88	3.61e-84	0.95	0.76	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	25.01	2.09e-88	3.7e-84	1.01	0.76	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	25.01	2.19e-88	3.87e-84	1.01	0.76	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	25.01	2.2e-88	3.89e-84	0.88	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	25	2.43e-88	4.3e-84	0.88	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
THCA	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	24.99	2.67e-88	4.71e-84	0.9	0.76	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	24.98	2.9e-88	5.1e-84	1.02	0.76	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
THCA	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	24.98	2.9e-88	5.11e-84	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
THCA	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	24.98	2.9e-88	5.11e-84	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	24.97	3.11e-88	5.46e-84	1.01	0.76	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	24.97	3.12e-88	5.48e-84	1.01	0.76	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	24.97	3.28e-88	5.75e-84	1.02	0.76	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	24.97	3.32e-88	5.83e-84	0.91	0.76	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	24.95	3.95e-88	6.92e-84	1.01	0.75	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	24.95	4.09e-88	7.16e-84	0.89	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	24.95	4.2e-88	7.34e-84	1.01	0.75	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	24.95	4.2e-88	7.34e-84	1.01	0.75	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	24.94	4.23e-88	7.38e-84	1.01	0.75	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	24.94	4.23e-88	7.39e-84	0.91	0.75	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	24.94	4.33e-88	7.55e-84	1.01	0.75	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	24.94	4.33e-88	7.55e-84	1.01	0.75	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	24.93	4.79e-88	8.33e-84	1.11	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
THCA	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-24.93	5.05e-88	8.77e-84	-1.01	-0.75	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	24.91	6.11e-88	1.05e-83	1	0.75	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	24.91	6.11e-88	1.05e-83	1	0.75	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	24.91	6.11e-88	1.05e-83	1	0.75	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	24.91	6.11e-88	1.05e-83	1	0.75	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	24.91	6.11e-88	1.05e-83	1	0.75	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	24.91	6.24e-88	1.08e-83	1	0.75	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	24.9	6.93e-88	1.19e-83	1	0.75	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	24.89	7.7e-88	1.33e-83	1	0.75	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	24.89	7.94e-88	1.37e-83	1	0.75	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	24.88	8.57e-88	1.47e-83	1.01	0.75	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	24.87	9.35e-88	1.61e-83	1	0.75	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	24.87	9.9e-88	1.7e-83	0.88	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	24.87	9.93e-88	1.7e-83	1.01	0.75	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	24.86	9.97e-88	1.71e-83	0.88	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
THCA	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	24.85	1.16e-87	1.98e-83	0.89	0.75	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
THCA	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	24.85	1.16e-87	1.98e-83	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
THCA	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	24.85	1.16e-87	1.98e-83	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	24.85	1.19e-87	2.03e-83	1.01	0.75	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	24.85	1.23e-87	2.09e-83	1.01	0.75	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	24.84	1.27e-87	2.18e-83	0.9	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
THCA	cis	rs7188445	0.556	rs7203910	ENSG00000261390.4	RP11-345M22.2	-24.84	1.29e-87	2.21e-83	-0.84	-0.75	Urate levels;	chr16:79711722	chr16:79715232~79770563:-
THCA	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	24.84	1.29e-87	2.21e-83	1	0.75	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	24.83	1.39e-87	2.37e-83	1.02	0.75	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-24.83	1.42e-87	2.42e-83	-1.02	-0.75	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	24.83	1.44e-87	2.45e-83	1.01	0.75	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	24.82	1.67e-87	2.83e-83	0.88	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	24.81	1.72e-87	2.92e-83	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
THCA	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-24.8	1.92e-87	3.25e-83	-0.89	-0.75	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
THCA	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	24.79	2.14e-87	3.62e-83	0.98	0.75	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
THCA	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	24.78	2.39e-87	4.04e-83	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
THCA	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	24.78	2.53e-87	4.27e-83	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
THCA	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	24.78	2.53e-87	4.27e-83	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
THCA	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	24.77	2.67e-87	4.51e-83	0.91	0.75	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	24.77	2.9e-87	4.89e-83	1.01	0.75	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	24.75	3.33e-87	5.61e-83	1.32	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	24.73	4.08e-87	6.87e-83	1.02	0.75	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	24.72	4.64e-87	7.8e-83	1.01	0.75	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	24.72	4.69e-87	7.88e-83	1	0.75	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	24.72	4.69e-87	7.88e-83	1	0.75	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	24.72	4.69e-87	7.88e-83	1	0.75	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-24.71	5.1e-87	8.57e-83	-0.9	-0.75	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	24.71	5.31e-87	8.91e-83	1	0.75	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	24.71	5.32e-87	8.91e-83	1.01	0.75	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	24.7	5.86e-87	9.81e-83	1.13	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
THCA	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	24.68	6.92e-87	1.16e-82	0.89	0.75	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	24.67	8.14e-87	1.36e-82	1.03	0.75	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	24.67	8.32e-87	1.39e-82	0.91	0.75	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	24.65	9.61e-87	1.6e-82	0.89	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
THCA	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-24.62	1.35e-86	2.25e-82	-0.89	-0.75	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.832	rs2070835	ENSG00000198496.9	NBR2	-24.6	1.67e-86	2.78e-82	-0.9	-0.75	Menopause (age at onset);	chr17:43022008	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	24.6	1.74e-86	2.89e-82	1	0.75	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-24.59	2.03e-86	3.36e-82	-0.89	-0.75	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	24.58	2.16e-86	3.58e-82	1.03	0.75	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	24.58	2.16e-86	3.58e-82	1.03	0.75	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	24.57	2.39e-86	3.96e-82	0.99	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
THCA	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	24.56	2.61e-86	4.32e-82	1	0.75	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	24.56	2.64e-86	4.36e-82	0.9	0.75	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	24.55	2.81e-86	4.64e-82	1.02	0.75	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	24.55	2.81e-86	4.64e-82	1.02	0.75	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	24.55	2.81e-86	4.64e-82	1.02	0.75	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-24.5	4.98e-86	8.17e-82	-0.89	-0.75	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-24.5	4.98e-86	8.17e-82	-0.89	-0.75	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
THCA	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	24.5	4.98e-86	8.17e-82	1.3	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	24.5	5.21e-86	8.56e-82	1.02	0.75	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	24.49	5.74e-86	9.4e-82	1.01	0.75	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	24.49	5.74e-86	9.4e-82	1.01	0.75	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	24.44	9.36e-86	1.52e-81	0.89	0.75	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	24.44	9.68e-86	1.58e-81	1	0.75	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-24.43	1.11e-85	1.81e-81	-0.9	-0.75	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
THCA	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	24.43	1.13e-85	1.84e-81	1.12	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
THCA	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	24.4	1.46e-85	2.37e-81	1.02	0.75	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	24.4	1.46e-85	2.37e-81	1.02	0.75	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	24.38	1.94e-85	3.14e-81	1.03	0.75	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-24.37	2.05e-85	3.31e-81	-0.87	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
THCA	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	24.37	2.13e-85	3.45e-81	1.16	0.75	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
THCA	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	24.37	2.13e-85	3.45e-81	1.16	0.75	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
THCA	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	24.35	2.62e-85	4.24e-81	1.03	0.75	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-24.34	2.9e-85	4.68e-81	-0.89	-0.75	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	24.33	3.22e-85	5.19e-81	0.88	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
THCA	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-24.32	3.58e-85	5.77e-81	-0.84	-0.75	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
THCA	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	24.31	3.78e-85	6.1e-81	0.89	0.75	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
THCA	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	24.3	4.4e-85	7.06e-81	0.95	0.75	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
THCA	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-24.3	4.41e-85	7.06e-81	-0.89	-0.75	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
THCA	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	24.3	4.41e-85	7.06e-81	1.1	0.75	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
THCA	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	24.3	4.57e-85	7.31e-81	0.99	0.75	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	24.28	5.62e-85	8.98e-81	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	24.27	6.26e-85	9.99e-81	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	24.27	6.26e-85	9.99e-81	0.87	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	24.23	9.55e-85	1.52e-80	1.02	0.75	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	24.22	1.07e-84	1.71e-80	1.03	0.75	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	24.22	1.07e-84	1.71e-80	1.03	0.75	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	24.21	1.19e-84	1.89e-80	0.87	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	24.21	1.19e-84	1.89e-80	0.87	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	24.21	1.2e-84	1.9e-80	1	0.74	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-24.2	1.26e-84	2e-80	-0.92	-0.74	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
THCA	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	24.2	1.31e-84	2.08e-80	0.94	0.74	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
THCA	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	24.2	1.35e-84	2.14e-80	0.82	0.74	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
THCA	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-24.19	1.41e-84	2.23e-80	-0.89	-0.74	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	24.19	1.44e-84	2.28e-80	1.02	0.74	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	24.18	1.52e-84	2.4e-80	1.02	0.74	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	24.18	1.67e-84	2.64e-80	1.02	0.74	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	24.17	1.85e-84	2.92e-80	1.12	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
THCA	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	24.17	1.88e-84	2.96e-80	1.02	0.74	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	24.16	2.02e-84	3.19e-80	1.02	0.74	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	24.16	2.02e-84	3.19e-80	1.02	0.74	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	24.15	2.16e-84	3.4e-80	1.03	0.74	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	24.14	2.34e-84	3.68e-80	0.9	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
THCA	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	24.14	2.44e-84	3.83e-80	0.79	0.74	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
THCA	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	24.11	3.4e-84	5.31e-80	1	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	24.11	3.4e-84	5.31e-80	1	0.74	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
THCA	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	24.1	3.66e-84	5.72e-80	0.89	0.74	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	24.07	5.16e-84	8.01e-80	0.89	0.74	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	24.07	5.33e-84	8.27e-80	0.89	0.74	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	24.07	5.41e-84	8.39e-80	0.89	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
THCA	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	24.04	7.22e-84	1.12e-79	0.86	0.74	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	24.04	7.29e-84	1.13e-79	0.88	0.74	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	24.03	8.17e-84	1.25e-79	0.89	0.74	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	24.02	9.36e-84	1.43e-79	0.89	0.74	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	24.02	9.39e-84	1.44e-79	0.87	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	24.01	9.51e-84	1.46e-79	0.98	0.74	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-24	1.13e-83	1.73e-79	-0.88	-0.74	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-23.99	1.29e-83	1.98e-79	-0.88	-0.74	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
THCA	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	23.98	1.43e-83	2.19e-79	0.93	0.74	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-23.96	1.68e-83	2.56e-79	-0.87	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
THCA	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-23.96	1.7e-83	2.58e-79	-0.89	-0.74	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	23.95	1.89e-83	2.87e-79	0.89	0.74	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	23.94	2.05e-83	3.11e-79	1	0.74	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
THCA	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-23.94	2.07e-83	3.14e-79	-0.88	-0.74	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	23.92	2.57e-83	3.87e-79	0.87	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
THCA	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	23.9	3.13e-83	4.65e-79	0.98	0.74	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
THCA	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	23.9	3.17e-83	4.7e-79	0.94	0.74	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
THCA	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	23.9	3.17e-83	4.7e-79	0.94	0.74	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
THCA	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-23.89	3.76e-83	5.56e-79	-1.04	-0.74	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
THCA	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	23.87	4.79e-83	7.06e-79	1.02	0.74	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
THCA	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	23.86	5.24e-83	7.72e-79	0.94	0.74	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
THCA	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	23.86	5.32e-83	7.82e-79	0.94	0.74	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
THCA	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-23.85	5.58e-83	8.19e-79	-0.88	-0.74	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	23.85	5.64e-83	8.27e-79	0.88	0.74	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	23.85	5.64e-83	8.27e-79	0.88	0.74	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	23.85	5.64e-83	8.27e-79	0.88	0.74	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
THCA	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-23.85	5.82e-83	8.53e-79	-0.88	-0.74	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-23.84	6.28e-83	9.2e-79	-0.88	-0.74	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
THCA	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-23.84	6.45e-83	9.44e-79	-0.83	-0.74	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
THCA	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	23.84	6.51e-83	9.53e-79	1.01	0.74	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
THCA	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	23.82	7.41e-83	1.08e-78	0.8	0.74	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
THCA	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	23.82	7.62e-83	1.11e-78	0.94	0.74	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
THCA	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-23.81	8.96e-83	1.3e-78	-0.87	-0.74	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
THCA	cis	rs875971	0.597	rs11771318	ENSG00000226824.5	RP4-756H11.3	23.8	9.32e-83	1.35e-78	0.97	0.74	Aortic root size;	chr7:66597493	chr7:66654538~66669855:+
THCA	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-23.8	9.77e-83	1.42e-78	-0.83	-0.74	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	23.79	1.05e-82	1.52e-78	0.87	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
THCA	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	23.79	1.08e-82	1.57e-78	0.98	0.74	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-23.79	1.08e-82	1.57e-78	-0.87	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
THCA	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	23.77	1.31e-82	1.9e-78	0.98	0.74	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	23.76	1.52e-82	2.2e-78	1	0.74	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
THCA	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	23.75	1.74e-82	2.5e-78	0.94	0.74	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
THCA	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	23.73	2.04e-82	2.91e-78	1.28	0.74	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	23.73	2.04e-82	2.91e-78	1.28	0.74	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	23.73	2.04e-82	2.91e-78	1.28	0.74	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	23.73	2.04e-82	2.91e-78	1.28	0.74	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	23.73	2.15e-82	3.08e-78	0.87	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
THCA	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-23.72	2.26e-82	3.23e-78	-0.88	-0.74	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	23.68	3.52e-82	5e-78	0.88	0.74	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	23.67	3.84e-82	5.44e-78	0.88	0.74	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	23.67	3.84e-82	5.44e-78	0.88	0.74	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
THCA	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	23.66	4.33e-82	6.11e-78	0.93	0.74	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
THCA	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-23.66	4.45e-82	6.27e-78	-0.95	-0.74	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.886	rs9718079	ENSG00000231760.4	RP11-350J20.5	23.64	5.66e-82	7.95e-78	0.99	0.74	Lung cancer;	chr6:149645947	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	23.6	8.44e-82	1.18e-77	0.85	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
THCA	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	23.52	1.97e-81	2.72e-77	0.94	0.74	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.923	rs9688452	ENSG00000231760.4	RP11-350J20.5	23.52	2.04e-81	2.81e-77	1	0.74	Lung cancer;	chr6:149658764	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-23.5	2.55e-81	3.5e-77	-0.87	-0.73	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-23.49	2.88e-81	3.94e-77	-0.87	-0.73	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
THCA	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	23.48	3.03e-81	4.14e-77	0.94	0.73	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
THCA	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	23.43	5.24e-81	7.09e-77	1.28	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
THCA	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	23.43	5.24e-81	7.09e-77	1.28	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	23.43	5.33e-81	7.2e-77	1.02	0.73	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-23.43	5.51e-81	7.45e-77	-0.99	-0.73	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-23.41	6.64e-81	8.97e-77	-0.86	-0.73	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
THCA	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	23.41	6.8e-81	9.17e-77	0.79	0.73	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	23.41	6.8e-81	9.17e-77	0.79	0.73	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	23.41	6.8e-81	9.17e-77	0.79	0.73	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
THCA	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-23.39	7.89e-81	1.06e-76	-0.86	-0.73	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
THCA	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	23.39	8.53e-81	1.15e-76	0.8	0.73	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	23.39	8.53e-81	1.15e-76	0.8	0.73	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	23.39	8.53e-81	1.15e-76	0.8	0.73	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	23.39	8.53e-81	1.15e-76	0.8	0.73	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
THCA	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	23.38	9e-81	1.21e-76	0.86	0.73	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
THCA	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	23.38	9.08e-81	1.22e-76	0.98	0.73	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	23.37	1.03e-80	1.38e-76	1.3	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
THCA	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-23.36	1.09e-80	1.46e-76	-0.94	-0.73	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	23.3	2.11e-80	2.8e-76	1.01	0.73	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
THCA	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-23.29	2.54e-80	3.35e-76	-1.09	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
THCA	cis	rs7188445	0.614	rs62043313	ENSG00000261390.4	RP11-345M22.2	-23.26	3.22e-80	4.25e-76	-0.82	-0.73	Urate levels;	chr16:79710237	chr16:79715232~79770563:-
THCA	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	23.25	3.71e-80	4.88e-76	0.98	0.73	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
THCA	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	23.24	4.09e-80	5.39e-76	0.88	0.73	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
THCA	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	23.24	4.24e-80	5.58e-76	0.87	0.73	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
THCA	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	23.23	4.42e-80	5.8e-76	1.3	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	23.21	5.54e-80	7.26e-76	1.01	0.73	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	23.21	5.54e-80	7.26e-76	1.01	0.73	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
THCA	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	23.18	8.22e-80	1.07e-75	0.79	0.73	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	23.18	8.22e-80	1.07e-75	0.79	0.73	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	23.18	8.22e-80	1.07e-75	0.79	0.73	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
THCA	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-23.15	1.04e-79	1.36e-75	-1.06	-0.73	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
THCA	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	23.14	1.27e-79	1.65e-75	0.79	0.73	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
THCA	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-23.13	1.41e-79	1.83e-75	-0.87	-0.73	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
THCA	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-23.1	1.92e-79	2.47e-75	-0.87	-0.73	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
THCA	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	23.04	3.58e-79	4.56e-75	0.79	0.73	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
THCA	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-23.02	4.57e-79	5.8e-75	-0.86	-0.73	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
THCA	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	22.97	7.79e-79	9.82e-75	1.05	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
THCA	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	22.96	8.57e-79	1.08e-74	0.98	0.73	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
THCA	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	22.94	1.11e-78	1.39e-74	0.88	0.73	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
THCA	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-22.94	1.13e-78	1.41e-74	-0.86	-0.73	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
THCA	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	22.85	2.7e-78	3.34e-74	0.92	0.73	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	22.85	2.77e-78	3.42e-74	1	0.73	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	22.85	2.97e-78	3.65e-74	1.25	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
THCA	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	22.85	2.97e-78	3.65e-74	1.25	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
THCA	cis	rs10256972	0.527	rs2949170	ENSG00000229043.2	AC091729.9	-22.83	3.54e-78	4.33e-74	-0.83	-0.73	Endometriosis;Longevity;	chr7:1176802	chr7:1160374~1165267:+
THCA	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-22.83	3.58e-78	4.37e-74	-1.06	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
THCA	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-22.81	4.22e-78	5.14e-74	-0.88	-0.72	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
THCA	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	22.81	4.46e-78	5.44e-74	1.3	0.72	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
THCA	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	22.8	4.85e-78	5.87e-74	0.99	0.72	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
THCA	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-22.8	4.86e-78	5.88e-74	-1.07	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
THCA	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-22.8	4.86e-78	5.88e-74	-1.07	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
THCA	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	22.8	5.05e-78	6.11e-74	0.81	0.72	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
THCA	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	22.75	8.12e-78	9.72e-74	1.1	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
THCA	cis	rs2283792	0.812	rs5995269	ENSG00000224086.5	LL22NC03-86G7.1	-22.73	1.05e-77	1.24e-73	-0.86	-0.72	Multiple sclerosis;	chr22:21935025	chr22:21938293~21977632:+
THCA	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-22.68	1.86e-77	2.15e-73	-0.92	-0.72	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-22.66	2.33e-77	2.69e-73	-0.92	-0.72	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
THCA	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-22.66	2.35e-77	2.71e-73	-0.86	-0.72	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
THCA	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	22.65	2.62e-77	3.02e-73	0.78	0.72	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
THCA	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-22.63	3.05e-77	3.49e-73	-1.07	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
THCA	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	22.63	3.13e-77	3.59e-73	1	0.72	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-22.63	3.18e-77	3.64e-73	-0.92	-0.72	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.812	rs94194	ENSG00000224086.5	LL22NC03-86G7.1	-22.62	3.37e-77	3.84e-73	-0.85	-0.72	Multiple sclerosis;	chr22:21933937	chr22:21938293~21977632:+
THCA	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	22.62	3.55e-77	4.04e-73	1.26	0.72	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
THCA	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-22.6	4.24e-77	4.81e-73	-0.92	-0.72	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
THCA	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	22.59	4.57e-77	5.18e-73	0.78	0.72	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
THCA	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-22.59	4.75e-77	5.39e-73	-0.9	-0.72	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-22.56	6.41e-77	7.14e-73	-0.92	-0.72	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-22.56	6.55e-77	7.3e-73	-0.92	-0.72	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-22.56	6.55e-77	7.3e-73	-0.92	-0.72	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
THCA	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-22.55	7.55e-77	8.39e-73	-1.05	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
THCA	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-22.55	7.55e-77	8.39e-73	-0.92	-0.72	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
THCA	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	22.54	7.97e-77	8.85e-73	0.92	0.72	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
THCA	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-22.52	1.06e-76	1.17e-72	-0.84	-0.72	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
THCA	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-22.51	1.16e-76	1.28e-72	-0.92	-0.72	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-22.51	1.16e-76	1.28e-72	-0.92	-0.72	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-22.51	1.16e-76	1.28e-72	-0.92	-0.72	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
THCA	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	22.5	1.22e-76	1.34e-72	0.92	0.72	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
THCA	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-22.5	1.23e-76	1.35e-72	-0.92	-0.72	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
THCA	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	22.5	1.27e-76	1.4e-72	0.92	0.72	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	22.5	1.27e-76	1.4e-72	0.92	0.72	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
THCA	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-22.49	1.41e-76	1.54e-72	-0.96	-0.72	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
THCA	cis	rs9322193	0.923	rs4870052	ENSG00000231760.4	RP11-350J20.5	22.48	1.51e-76	1.65e-72	0.99	0.72	Lung cancer;	chr6:149839978	chr6:149796151~149826294:-
THCA	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-22.47	1.8e-76	1.97e-72	-0.92	-0.72	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
THCA	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-22.47	1.81e-76	1.98e-72	-1.06	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
THCA	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-22.47	1.81e-76	1.98e-72	-1.06	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
THCA	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-22.46	1.94e-76	2.11e-72	-1.05	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	22.45	2.21e-76	2.41e-72	0.93	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
THCA	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	22.44	2.39e-76	2.61e-72	0.97	0.72	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
THCA	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	22.44	2.49e-76	2.71e-72	1.22	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-22.43	2.71e-76	2.94e-72	-0.91	-0.72	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
THCA	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-22.43	2.71e-76	2.94e-72	-0.91	-0.72	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-22.43	2.79e-76	3.02e-72	-0.91	-0.72	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-22.42	2.87e-76	3.11e-72	-0.91	-0.72	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	22.42	3.04e-76	3.29e-72	0.92	0.72	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs2275045	ENSG00000231760.4	RP11-350J20.5	22.41	3.43e-76	3.71e-72	0.99	0.72	Lung cancer;	chr6:149842775	chr6:149796151~149826294:-
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-22.4	3.58e-76	3.87e-72	-0.91	-0.72	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
THCA	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-22.36	6.07e-76	6.52e-72	-1.05	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
THCA	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-22.36	6.07e-76	6.52e-72	-1.05	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
THCA	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-22.36	6.07e-76	6.52e-72	-1.05	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
THCA	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-22.33	7.74e-76	8.29e-72	-0.92	-0.72	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
THCA	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	22.33	7.81e-76	8.36e-72	1.25	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
THCA	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-22.32	8.54e-76	9.12e-72	-0.92	-0.72	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
THCA	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-22.32	9.29e-76	9.91e-72	-0.91	-0.72	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
THCA	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	22.29	1.26e-75	1.35e-71	0.89	0.72	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
THCA	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	22.29	1.27e-75	1.35e-71	0.91	0.72	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
THCA	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-22.28	1.37e-75	1.46e-71	-0.92	-0.72	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
THCA	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-22.28	1.37e-75	1.46e-71	-0.92	-0.72	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
THCA	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	22.27	1.59e-75	1.69e-71	0.78	0.72	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
THCA	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	22.26	1.67e-75	1.77e-71	0.77	0.72	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
THCA	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-22.26	1.73e-75	1.83e-71	-0.82	-0.72	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
THCA	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	22.24	2.03e-75	2.15e-71	1.28	0.72	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
THCA	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-22.22	2.69e-75	2.85e-71	-0.82	-0.72	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-22.22	2.69e-75	2.85e-71	-0.82	-0.72	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-22.21	3.05e-75	3.22e-71	-0.85	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
THCA	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	22.2	3.38e-75	3.56e-71	1.23	0.72	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
THCA	cis	rs9322193	0.923	rs2184370	ENSG00000231760.4	RP11-350J20.5	22.18	3.99e-75	4.2e-71	0.98	0.72	Lung cancer;	chr6:149843242	chr6:149796151~149826294:-
THCA	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	22.18	4.01e-75	4.22e-71	1.23	0.72	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	22.16	5.06e-75	5.32e-71	1.26	0.71	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
THCA	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	22.16	5.37e-75	5.64e-71	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-22.15	5.64e-75	5.92e-71	-0.91	-0.71	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	22.09	1.04e-74	1.09e-70	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	22.09	1.15e-74	1.2e-70	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	22.04	1.93e-74	2.01e-70	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	22.03	1.99e-74	2.07e-70	0.93	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	22.03	1.99e-74	2.07e-70	0.93	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	22.03	2.05e-74	2.13e-70	0.86	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
THCA	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	22.03	2.05e-74	2.13e-70	0.76	0.71	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	22.03	2.11e-74	2.19e-70	0.94	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
THCA	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	22	2.88e-74	2.98e-70	0.88	0.71	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
THCA	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	22	2.94e-74	3.04e-70	0.77	0.71	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	21.99	3.34e-74	3.44e-70	0.77	0.71	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	21.99	3.34e-74	3.44e-70	0.77	0.71	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	21.99	3.34e-74	3.44e-70	0.77	0.71	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
THCA	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	21.97	3.84e-74	3.94e-70	1.26	0.71	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
THCA	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-21.97	4.1e-74	4.2e-70	-1.04	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
THCA	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	21.95	5.13e-74	5.23e-70	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
THCA	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-21.94	5.28e-74	5.39e-70	-0.87	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
THCA	cis	rs2283792	0.687	rs381849	ENSG00000224086.5	LL22NC03-86G7.1	-21.94	5.36e-74	5.46e-70	-0.83	-0.71	Multiple sclerosis;	chr22:21951341	chr22:21938293~21977632:+
THCA	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	21.92	6.88e-74	7e-70	0.76	0.71	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
THCA	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	21.91	7.4e-74	7.53e-70	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
THCA	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	21.91	7.82e-74	7.95e-70	0.93	0.71	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
THCA	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	21.91	7.97e-74	8.08e-70	0.76	0.71	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
THCA	cis	rs2283792	0.718	rs239918	ENSG00000224086.5	LL22NC03-86G7.1	-21.88	1.05e-73	1.06e-69	-0.82	-0.71	Multiple sclerosis;	chr22:21959457	chr22:21938293~21977632:+
THCA	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	21.87	1.16e-73	1.17e-69	0.83	0.71	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
THCA	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-21.86	1.32e-73	1.32e-69	-0.88	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	21.86	1.34e-73	1.34e-69	0.93	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
THCA	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	21.86	1.35e-73	1.35e-69	0.9	0.71	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
THCA	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	21.85	1.41e-73	1.41e-69	0.81	0.71	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	21.85	1.5e-73	1.5e-69	0.86	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
THCA	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-21.84	1.56e-73	1.56e-69	-0.76	-0.71	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-21.84	1.56e-73	1.56e-69	-0.76	-0.71	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	21.83	1.91e-73	1.91e-69	0.76	0.71	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
THCA	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	21.83	1.92e-73	1.91e-69	0.82	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	21.83	1.92e-73	1.91e-69	0.82	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
THCA	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-21.83	1.93e-73	1.93e-69	-0.76	-0.71	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	21.82	2.05e-73	2.04e-69	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
THCA	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	21.81	2.21e-73	2.19e-69	0.92	0.71	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
THCA	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-21.8	2.61e-73	2.59e-69	-0.81	-0.71	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-21.8	2.61e-73	2.59e-69	-0.81	-0.71	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.566	rs7254009	ENSG00000226686.6	LINC01535	-21.8	2.61e-73	2.59e-69	-0.81	-0.71	Obesity-related traits;	chr19:37427707	chr19:37251912~37265535:+
THCA	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-21.79	2.71e-73	2.68e-69	-0.76	-0.71	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
THCA	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-21.78	3.09e-73	3.05e-69	-1.06	-0.71	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-21.78	3.09e-73	3.05e-69	-1.06	-0.71	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
THCA	cis	rs11673344	0.566	rs2385180	ENSG00000226686.6	LINC01535	-21.78	3.22e-73	3.18e-69	-0.81	-0.71	Obesity-related traits;	chr19:37431454	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	21.77	3.67e-73	3.62e-69	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
THCA	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	21.75	4.16e-73	4.1e-69	0.76	0.71	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	21.75	4.33e-73	4.26e-69	0.93	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
THCA	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-21.75	4.5e-73	4.42e-69	-0.75	-0.71	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
THCA	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	21.74	4.91e-73	4.82e-69	1.2	0.71	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
THCA	cis	rs11673344	0.566	rs10419281	ENSG00000226686.6	LINC01535	-21.74	4.92e-73	4.83e-69	-0.81	-0.71	Obesity-related traits;	chr19:37459351	chr19:37251912~37265535:+
THCA	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	21.71	6.46e-73	6.31e-69	0.86	0.71	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
THCA	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-21.71	6.71e-73	6.55e-69	-1.22	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	21.71	6.79e-73	6.63e-69	0.93	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
THCA	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	21.7	7.36e-73	7.18e-69	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
THCA	cis	rs858239	0.601	rs6966776	ENSG00000230658.1	KLHL7-AS1	21.7	7.45e-73	7.26e-69	0.83	0.71	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23101228~23105703:-
THCA	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-21.68	9.43e-73	9.17e-69	-0.91	-0.71	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
THCA	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	21.67	1.06e-72	1.03e-68	0.77	0.71	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
THCA	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-21.66	1.22e-72	1.19e-68	-0.92	-0.71	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
THCA	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	21.65	1.25e-72	1.21e-68	0.76	0.71	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	21.62	1.71e-72	1.66e-68	0.76	0.71	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-21.62	1.83e-72	1.77e-68	-0.75	-0.71	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
THCA	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-21.62	1.88e-72	1.81e-68	-0.75	-0.71	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
THCA	cis	rs11673344	0.566	rs1968251	ENSG00000226686.6	LINC01535	-21.61	1.96e-72	1.89e-68	-0.81	-0.71	Obesity-related traits;	chr19:37457005	chr19:37251912~37265535:+
THCA	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	21.61	1.98e-72	1.92e-68	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	21.6	2.16e-72	2.08e-68	0.91	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
THCA	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-21.6	2.28e-72	2.19e-68	-0.86	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
THCA	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-21.59	2.5e-72	2.41e-68	-0.75	-0.71	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-21.59	2.5e-72	2.41e-68	-0.75	-0.71	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
THCA	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	21.59	2.53e-72	2.43e-68	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	21.59	2.53e-72	2.43e-68	0.81	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
THCA	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-21.59	2.53e-72	2.44e-68	-0.78	-0.71	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
THCA	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	21.58	2.67e-72	2.57e-68	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
THCA	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-21.58	2.81e-72	2.71e-68	-0.78	-0.71	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
THCA	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-21.58	2.92e-72	2.8e-68	-1.04	-0.71	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
THCA	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	21.57	2.97e-72	2.85e-68	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
THCA	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-21.57	2.97e-72	2.86e-68	-0.91	-0.71	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.887	rs11155662	ENSG00000231760.4	RP11-350J20.5	21.57	3.03e-72	2.91e-68	0.98	0.71	Lung cancer;	chr6:149592731	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	21.55	3.77e-72	3.62e-68	0.86	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
THCA	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-21.55	3.92e-72	3.75e-68	-1.05	-0.7	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-21.55	3.92e-72	3.75e-68	-1.05	-0.7	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-21.55	3.92e-72	3.75e-68	-1.05	-0.7	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-21.55	3.92e-72	3.75e-68	-1.05	-0.7	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
THCA	cis	rs7569084	0.687	rs1344891	ENSG00000204929.10	AC074391.1	21.54	4.42e-72	4.23e-68	0.89	0.7	Sum eosinophil basophil counts;	chr2:65458890	chr2:65436711~66084639:+
THCA	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-21.53	4.83e-72	4.62e-68	-0.92	-0.7	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
THCA	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-21.53	4.92e-72	4.7e-68	-0.82	-0.7	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	21.53	4.96e-72	4.73e-68	0.84	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
THCA	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	21.52	5.5e-72	5.25e-68	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
THCA	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-21.5	6.47e-72	6.17e-68	-0.78	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
THCA	cis	rs7188445	0.736	rs11642757	ENSG00000261390.4	RP11-345M22.2	-21.49	6.98e-72	6.65e-68	-0.82	-0.7	Urate levels;	chr16:79719570	chr16:79715232~79770563:-
THCA	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-21.49	7.22e-72	6.87e-68	-1.05	-0.7	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
THCA	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	21.49	7.5e-72	7.14e-68	0.92	0.7	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
THCA	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	21.48	7.97e-72	7.58e-68	0.9	0.7	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
THCA	cis	rs7569084	0.687	rs12614851	ENSG00000204929.10	AC074391.1	21.48	8.04e-72	7.64e-68	0.89	0.7	Sum eosinophil basophil counts;	chr2:65458050	chr2:65436711~66084639:+
THCA	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-21.48	8.31e-72	7.89e-68	-1.06	-0.7	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
THCA	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-21.48	8.4e-72	7.94e-68	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
THCA	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-21.46	9.84e-72	9.28e-68	-1.05	-0.7	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
THCA	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	21.46	1.04e-71	9.81e-68	0.76	0.7	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
THCA	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-21.45	1.13e-71	1.06e-67	-1.05	-0.7	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
THCA	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	21.43	1.36e-71	1.28e-67	0.81	0.7	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-21.43	1.37e-71	1.29e-67	-0.92	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
THCA	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	21.43	1.46e-71	1.37e-67	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
THCA	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-21.42	1.59e-71	1.49e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-21.42	1.59e-71	1.49e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-21.42	1.59e-71	1.49e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-21.42	1.59e-71	1.49e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
THCA	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	21.41	1.71e-71	1.6e-67	0.95	0.7	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
THCA	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-21.41	1.75e-71	1.65e-67	-0.86	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
THCA	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	21.39	2.17e-71	2.03e-67	0.77	0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
THCA	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-21.39	2.28e-71	2.14e-67	-0.92	-0.7	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
THCA	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-21.38	2.33e-71	2.18e-67	-1.05	-0.7	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-21.38	2.36e-71	2.21e-67	-1.05	-0.7	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
THCA	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-21.35	3.3e-71	3.08e-67	-0.78	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
THCA	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	21.35	3.39e-71	3.16e-67	0.82	0.7	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
THCA	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	21.35	3.47e-71	3.23e-67	0.81	0.7	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
THCA	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-21.34	3.73e-71	3.47e-67	-0.79	-0.7	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
THCA	cis	rs7569084	0.663	rs1437461	ENSG00000204929.10	AC074391.1	21.34	3.96e-71	3.68e-67	0.88	0.7	Sum eosinophil basophil counts;	chr2:65452578	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.687	rs7562559	ENSG00000204929.10	AC074391.1	21.34	3.96e-71	3.68e-67	0.88	0.7	Sum eosinophil basophil counts;	chr2:65452719	chr2:65436711~66084639:+
THCA	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	21.33	4.09e-71	3.8e-67	0.8	0.7	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
THCA	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	21.33	4.31e-71	4.01e-67	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	21.31	5.27e-71	4.9e-67	0.94	0.7	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
THCA	cis	rs7569084	0.687	rs1437462	ENSG00000204929.10	AC074391.1	21.31	5.31e-71	4.93e-67	0.88	0.7	Sum eosinophil basophil counts;	chr2:65449559	chr2:65436711~66084639:+
THCA	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	21.3	5.75e-71	5.34e-67	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
THCA	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-21.3	5.82e-71	5.4e-67	-1.19	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	21.3	5.83e-71	5.4e-67	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	21.3	5.83e-71	5.4e-67	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
THCA	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	21.3	5.91e-71	5.48e-67	0.75	0.7	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
THCA	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	21.3	6.12e-71	5.68e-67	0.9	0.7	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	21.29	6.32e-71	5.86e-67	0.95	0.7	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
THCA	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-21.29	6.35e-71	5.89e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
THCA	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	21.29	6.54e-71	6.06e-67	0.9	0.7	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-21.29	6.57e-71	6.08e-67	-0.95	-0.7	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
THCA	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-21.28	7.56e-71	7e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
THCA	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-21.27	7.82e-71	7.23e-67	-1.05	-0.7	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
THCA	cis	rs7195287	0.826	rs9925824	ENSG00000276791.1	CTD-2270P14.5	-21.26	8.78e-71	8.12e-67	-0.8	-0.7	Eosinophil counts;	chr16:2777972	chr16:2777319~2780568:+
THCA	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-21.26	9.09e-71	8.4e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-21.26	9.09e-71	8.4e-67	-0.77	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
THCA	cis	rs11673344	0.566	rs11666708	ENSG00000226686.6	LINC01535	-21.25	1.02e-70	9.42e-67	-0.81	-0.7	Obesity-related traits;	chr19:37396208	chr19:37251912~37265535:+
THCA	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	21.23	1.23e-70	1.13e-66	1.21	0.7	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
THCA	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	21.22	1.44e-70	1.32e-66	0.88	0.7	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
THCA	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	21.21	1.58e-70	1.45e-66	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	21.2	1.71e-70	1.57e-66	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
THCA	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	21.2	1.71e-70	1.58e-66	0.86	0.7	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
THCA	cis	rs7569084	0.687	rs1370394	ENSG00000204929.10	AC074391.1	21.2	1.75e-70	1.61e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65453176	chr2:65436711~66084639:+
THCA	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	21.19	1.97e-70	1.81e-66	0.86	0.7	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	21.18	2.11e-70	1.94e-66	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
THCA	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	21.16	2.72e-70	2.49e-66	0.93	0.7	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	21.14	3.18e-70	2.91e-66	0.96	0.7	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-21.13	3.57e-70	3.26e-66	-0.91	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
THCA	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	21.1	4.96e-70	4.52e-66	0.82	0.7	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
THCA	cis	rs7569084	0.687	rs4671663	ENSG00000204929.10	AC074391.1	21.1	5.14e-70	4.68e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65434400	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.687	rs11692813	ENSG00000204929.10	AC074391.1	21.1	5.14e-70	4.68e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65435172	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.663	rs11126037	ENSG00000204929.10	AC074391.1	21.1	5.14e-70	4.68e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65436024	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.687	rs11126038	ENSG00000204929.10	AC074391.1	21.1	5.14e-70	4.68e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65436100	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.663	rs11694714	ENSG00000204929.10	AC074391.1	21.1	5.14e-70	4.68e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65436802	chr2:65436711~66084639:+
THCA	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-21.09	5.45e-70	4.96e-66	-1.03	-0.7	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
THCA	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	21.09	5.72e-70	5.2e-66	0.83	0.7	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
THCA	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	21.08	6.28e-70	5.71e-66	0.8	0.7	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
THCA	cis	rs7569084	0.687	rs12993075	ENSG00000204929.10	AC074391.1	21.05	8.31e-70	7.54e-66	0.88	0.7	Sum eosinophil basophil counts;	chr2:65431010	chr2:65436711~66084639:+
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	21.05	8.35e-70	7.58e-66	0.91	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
THCA	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-21.04	9.32e-70	8.45e-66	-1.18	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
THCA	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	21.03	1.04e-69	9.45e-66	0.8	0.7	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
THCA	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-21.02	1.19e-69	1.08e-65	-1.18	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
THCA	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-21	1.43e-69	1.29e-65	-1.19	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
THCA	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-21	1.43e-69	1.29e-65	-1.19	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
THCA	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-20.99	1.69e-69	1.52e-65	-0.78	-0.7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
THCA	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	20.99	1.7e-69	1.53e-65	0.89	0.7	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	20.97	2.03e-69	1.82e-65	0.8	0.7	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	20.97	2.04e-69	1.83e-65	0.9	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
THCA	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-20.96	2.27e-69	2.04e-65	-0.87	-0.7	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
THCA	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-20.95	2.54e-69	2.28e-65	-0.76	-0.69	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
THCA	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-20.95	2.6e-69	2.33e-65	-1.18	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
THCA	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-20.95	2.6e-69	2.33e-65	-1.18	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	20.94	2.78e-69	2.49e-65	0.92	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
THCA	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	20.94	2.92e-69	2.62e-65	0.8	0.69	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-20.94	3.02e-69	2.71e-65	-0.9	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
THCA	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-20.94	3.05e-69	2.73e-65	-1.18	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
THCA	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-20.94	3.05e-69	2.73e-65	-1.18	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
THCA	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-20.94	3.05e-69	2.73e-65	-1.18	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-20.93	3.39e-69	3.04e-65	-0.95	-0.69	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
THCA	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	20.92	3.53e-69	3.16e-65	0.8	0.69	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
THCA	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-20.92	3.6e-69	3.22e-65	-0.75	-0.69	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
THCA	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	20.89	4.79e-69	4.28e-65	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
THCA	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	20.87	5.99e-69	5.34e-65	0.74	0.69	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	20.85	7.96e-69	7.07e-65	0.91	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
THCA	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-20.83	9.6e-69	8.5e-65	-0.77	-0.69	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
THCA	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	20.81	1.18e-68	1.04e-64	0.78	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
THCA	cis	rs7569084	0.663	rs4671128	ENSG00000204929.10	AC074391.1	20.81	1.2e-68	1.06e-64	0.87	0.69	Sum eosinophil basophil counts;	chr2:65438130	chr2:65436711~66084639:+
THCA	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	20.81	1.22e-68	1.08e-64	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	20.79	1.43e-68	1.26e-64	0.78	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
THCA	cis	rs2283792	0.745	rs5756306	ENSG00000224086.5	LL22NC03-86G7.1	20.78	1.64e-68	1.44e-64	0.79	0.69	Multiple sclerosis;	chr22:21978846	chr22:21938293~21977632:+
THCA	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	20.77	1.76e-68	1.55e-64	1.27	0.69	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
THCA	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-20.77	1.81e-68	1.58e-64	-0.85	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
THCA	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	20.77	1.84e-68	1.61e-64	0.82	0.69	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	20.76	2.14e-68	1.87e-64	0.91	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	20.75	2.35e-68	2.05e-64	0.92	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
THCA	cis	rs7569084	0.687	rs6755006	ENSG00000204929.10	AC074391.1	-20.74	2.5e-68	2.18e-64	-0.87	-0.69	Sum eosinophil basophil counts;	chr2:65426008	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.687	rs6755128	ENSG00000204929.10	AC074391.1	-20.74	2.5e-68	2.18e-64	-0.87	-0.69	Sum eosinophil basophil counts;	chr2:65426065	chr2:65436711~66084639:+
THCA	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-20.73	2.88e-68	2.51e-64	-0.77	-0.69	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000273295.1	AP000350.5	20.73	2.92e-68	2.54e-64	0.81	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23901432~23907068:-
THCA	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-20.73	2.96e-68	2.58e-64	-0.89	-0.69	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
THCA	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-20.7	3.94e-68	3.42e-64	-1.18	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
THCA	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	20.69	4.21e-68	3.65e-64	0.84	0.69	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
THCA	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	20.68	4.7e-68	4.07e-64	0.89	0.69	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
THCA	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-20.68	4.99e-68	4.32e-64	-0.73	-0.69	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
THCA	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	20.67	5.56e-68	4.81e-64	0.89	0.69	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
THCA	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	20.66	5.96e-68	5.15e-64	0.85	0.69	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
THCA	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	20.66	5.99e-68	5.18e-64	0.75	0.69	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
THCA	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-20.65	6.81e-68	5.88e-64	-0.77	-0.69	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	20.65	7.02e-68	6.06e-64	0.9	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	20.63	8.47e-68	7.31e-64	0.79	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
THCA	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-20.61	1.03e-67	8.86e-64	-0.88	-0.69	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
THCA	cis	rs2486288	0.656	rs12908581	ENSG00000259520.4	CTD-2651B20.3	20.59	1.3e-67	1.12e-63	0.84	0.69	Glomerular filtration rate;	chr15:45256437	chr15:45251580~45279251:-
THCA	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-20.58	1.43e-67	1.22e-63	-0.89	-0.69	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	20.58	1.49e-67	1.28e-63	0.8	0.69	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
THCA	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-20.57	1.56e-67	1.34e-63	-0.76	-0.69	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	20.54	2.2e-67	1.88e-63	0.9	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
THCA	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	20.53	2.45e-67	2.09e-63	0.74	0.69	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
THCA	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	20.53	2.45e-67	2.09e-63	0.74	0.69	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
THCA	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	20.53	2.45e-67	2.09e-63	0.74	0.69	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.923	rs9371486	ENSG00000231760.4	RP11-350J20.5	20.5	3.35e-67	2.85e-63	0.93	0.69	Lung cancer;	chr6:149832090	chr6:149796151~149826294:-
THCA	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	20.49	3.76e-67	3.19e-63	0.75	0.69	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
THCA	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	20.48	4.18e-67	3.54e-63	0.74	0.69	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
THCA	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	20.48	4.18e-67	3.54e-63	0.74	0.69	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-20.46	5.12e-67	4.33e-63	-0.73	-0.69	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-20.46	5.49e-67	4.63e-63	-0.73	-0.69	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-20.46	5.54e-67	4.67e-63	-0.74	-0.69	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
THCA	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-20.45	5.63e-67	4.75e-63	-1.04	-0.69	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
THCA	cis	rs7569084	0.687	rs11675538	ENSG00000204929.10	AC074391.1	20.43	7e-67	5.89e-63	0.86	0.69	Sum eosinophil basophil counts;	chr2:65459327	chr2:65436711~66084639:+
THCA	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-20.43	7.69e-67	6.46e-63	-0.74	-0.69	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	20.43	7.71e-67	6.48e-63	0.83	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
THCA	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-20.42	8.18e-67	6.86e-63	-0.73	-0.69	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
THCA	cis	rs7569084	0.64	rs11126039	ENSG00000204929.10	AC074391.1	20.41	9.26e-67	7.75e-63	0.86	0.69	Sum eosinophil basophil counts;	chr2:65457953	chr2:65436711~66084639:+
THCA	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-20.4	1.02e-66	8.57e-63	-1.04	-0.69	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
THCA	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	20.4	1.03e-66	8.61e-63	0.73	0.69	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-20.4	1.05e-66	8.75e-63	-0.73	-0.69	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
THCA	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	20.4	1.05e-66	8.81e-63	0.88	0.69	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
THCA	cis	rs2283792	0.812	rs240064	ENSG00000224086.5	LL22NC03-86G7.1	20.4	1.06e-66	8.84e-63	0.79	0.69	Multiple sclerosis;	chr22:21927265	chr22:21938293~21977632:+
THCA	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	20.39	1.12e-66	9.35e-63	1.14	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
THCA	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	20.39	1.12e-66	9.36e-63	0.73	0.69	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
THCA	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	20.39	1.17e-66	9.76e-63	0.74	0.69	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-20.38	1.3e-66	1.08e-62	-0.89	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
THCA	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-20.38	1.31e-66	1.09e-62	-0.77	-0.68	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
THCA	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-20.37	1.34e-66	1.11e-62	-0.73	-0.68	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
THCA	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	20.37	1.37e-66	1.13e-62	0.74	0.68	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
THCA	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	20.37	1.45e-66	1.2e-62	0.91	0.68	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
THCA	cis	rs992157	0.775	rs1877714	ENSG00000261338.2	RP11-378A13.1	-20.37	1.46e-66	1.21e-62	-0.73	-0.68	Colorectal cancer;	chr2:218270205	chr2:218255319~218257366:+
THCA	cis	rs7569084	0.687	rs934731	ENSG00000204929.10	AC074391.1	20.36	1.51e-66	1.25e-62	0.86	0.68	Sum eosinophil basophil counts;	chr2:65456353	chr2:65436711~66084639:+
THCA	cis	rs7569084	0.687	rs7577452	ENSG00000204929.10	AC074391.1	20.36	1.51e-66	1.25e-62	0.86	0.68	Sum eosinophil basophil counts;	chr2:65456694	chr2:65436711~66084639:+
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	20.36	1.54e-66	1.28e-62	0.88	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
THCA	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	20.36	1.58e-66	1.31e-62	0.81	0.68	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	20.36	1.62e-66	1.34e-62	0.83	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
THCA	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	20.36	1.65e-66	1.36e-62	0.77	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
THCA	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-20.35	1.72e-66	1.42e-62	-0.76	-0.68	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
THCA	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-20.35	1.84e-66	1.52e-62	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
THCA	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-20.34	1.98e-66	1.64e-62	-0.73	-0.68	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-20.34	1.98e-66	1.64e-62	-0.73	-0.68	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-20.32	2.41e-66	1.98e-62	-0.73	-0.68	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	20.3	3.08e-66	2.53e-62	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
THCA	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	20.27	4.03e-66	3.3e-62	0.88	0.68	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
THCA	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	20.27	4.14e-66	3.38e-62	0.76	0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
THCA	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-20.27	4.27e-66	3.49e-62	-0.73	-0.68	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-20.27	4.27e-66	3.49e-62	-0.73	-0.68	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	20.27	4.35e-66	3.55e-62	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
THCA	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-20.26	4.52e-66	3.69e-62	-0.73	-0.68	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
THCA	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-20.26	4.6e-66	3.75e-62	-0.73	-0.68	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-20.26	4.6e-66	3.75e-62	-0.73	-0.68	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
THCA	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	20.26	4.64e-66	3.78e-62	0.74	0.68	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.884	rs9371201	ENSG00000231760.4	RP11-350J20.5	20.26	4.83e-66	3.94e-62	0.92	0.68	Lung cancer;	chr6:149823865	chr6:149796151~149826294:-
THCA	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	20.25	5.12e-66	4.17e-62	0.73	0.68	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	20.24	6.04e-66	4.92e-62	0.83	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
THCA	cis	rs9322193	0.884	rs10872647	ENSG00000231760.4	RP11-350J20.5	20.23	6.2e-66	5.04e-62	0.93	0.68	Lung cancer;	chr6:149758687	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs10872648	ENSG00000231760.4	RP11-350J20.5	20.23	6.2e-66	5.04e-62	0.93	0.68	Lung cancer;	chr6:149758699	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs11155679	ENSG00000231760.4	RP11-350J20.5	20.23	6.2e-66	5.04e-62	0.93	0.68	Lung cancer;	chr6:149758881	chr6:149796151~149826294:-
THCA	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	20.23	6.23e-66	5.07e-62	0.73	0.68	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
THCA	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-20.22	7.1e-66	5.65e-62	-0.75	-0.68	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
THCA	cis	rs7569084	0.687	rs35839762	ENSG00000204929.10	AC074391.1	20.21	7.88e-66	6.26e-62	0.86	0.68	Sum eosinophil basophil counts;	chr2:65441318	chr2:65436711~66084639:+
THCA	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
THCA	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
THCA	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
THCA	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
THCA	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
THCA	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	20.2	8.85e-66	7e-62	0.91	0.68	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
THCA	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-20.19	9.48e-66	7.49e-62	-0.76	-0.68	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-20.19	9.51e-66	7.51e-62	-0.76	-0.68	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
THCA	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	20.19	9.71e-66	7.67e-62	0.73	0.68	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
THCA	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	20.19	1.03e-65	8.1e-62	0.74	0.68	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
THCA	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	20.18	1.12e-65	8.84e-62	0.87	0.68	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-20.16	1.32e-65	1.04e-61	-0.9	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
THCA	cis	rs9326248	0.53	rs11216171	ENSG00000254851.1	RP11-109L13.1	-20.16	1.41e-65	1.1e-61	-0.96	-0.68	Blood protein levels;	chr11:116878397	chr11:117135528~117138582:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	20.16	1.43e-65	1.12e-61	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
THCA	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	20.14	1.67e-65	1.31e-61	0.91	0.68	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
THCA	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	20.13	1.86e-65	1.45e-61	0.87	0.68	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
THCA	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	20.11	2.32e-65	1.81e-61	0.86	0.68	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
THCA	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	20.1	2.59e-65	2.01e-61	0.73	0.68	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
THCA	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9889968	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs61348930	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.614	rs28758251	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9899943	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11080138	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73265612	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11658435	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73265624	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs2269915	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs2269916	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11649765	ENSG00000263531.1	RP13-753N3.1	20.1	2.62e-65	2.01e-61	1.33	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30863921~30864940:-
THCA	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-20.09	2.9e-65	2.22e-61	-0.87	-0.68	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
THCA	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-20.09	2.93e-65	2.25e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-20.09	2.93e-65	2.25e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-20.09	2.93e-65	2.25e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
THCA	cis	rs9326248	0.769	rs499910	ENSG00000254851.1	RP11-109L13.1	-20.09	2.98e-65	2.28e-61	-0.95	-0.68	Blood protein levels;	chr11:116892318	chr11:117135528~117138582:+
THCA	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-20.07	3.59e-65	2.75e-61	-0.73	-0.68	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
THCA	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	20.07	3.75e-65	2.87e-61	0.82	0.68	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
THCA	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-20.07	3.77e-65	2.89e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
THCA	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	20.06	4.11e-65	3.14e-61	0.82	0.68	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
THCA	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-20.06	4.23e-65	3.23e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-20.06	4.23e-65	3.23e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-20.06	4.23e-65	3.23e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
THCA	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-20.04	5.02e-65	3.82e-61	-0.75	-0.68	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
THCA	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-20.04	5.23e-65	3.98e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
THCA	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	20.04	5.3e-65	4.03e-61	0.82	0.68	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
THCA	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	20.03	5.33e-65	4.05e-61	0.87	0.68	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	20.03	5.33e-65	4.05e-61	0.87	0.68	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
THCA	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	20.03	5.64e-65	4.29e-61	0.82	0.68	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	20.03	5.89e-65	4.47e-61	0.82	0.68	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	20.02	6.21e-65	4.72e-61	1.32	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
THCA	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-20.02	6.52e-65	4.95e-61	-0.72	-0.68	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
THCA	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	20.01	6.68e-65	5.07e-61	0.86	0.68	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
THCA	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-20.01	7.33e-65	5.56e-61	-1.15	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
THCA	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	20	7.36e-65	5.58e-61	0.92	0.68	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
THCA	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	20	7.53e-65	5.71e-61	0.82	0.68	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	20	7.57e-65	5.73e-61	0.82	0.68	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	20	7.57e-65	5.73e-61	0.82	0.68	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
THCA	cis	rs507080	0.922	rs478296	ENSG00000255239.1	AP002954.6	20	8.01e-65	6.06e-61	0.92	0.68	Serum metabolite levels;	chr11:118696666	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs493834	ENSG00000255239.1	AP002954.6	20	8.01e-65	6.06e-61	0.92	0.68	Serum metabolite levels;	chr11:118696735	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs644498	ENSG00000255239.1	AP002954.6	20	8.01e-65	6.06e-61	0.92	0.68	Serum metabolite levels;	chr11:118696777	chr11:118688039~118690600:-
THCA	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-19.99	8.98e-65	6.78e-61	-0.76	-0.68	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
THCA	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	19.98	9.24e-65	6.98e-61	0.81	0.68	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
THCA	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-19.98	9.84e-65	7.42e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
THCA	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-19.98	9.84e-65	7.42e-61	-0.76	-0.68	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-19.98	9.84e-65	7.42e-61	-0.76	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
THCA	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	19.98	1.01e-64	7.59e-61	0.82	0.68	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	19.98	1.01e-64	7.59e-61	0.82	0.68	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	19.98	1.01e-64	7.59e-61	0.82	0.68	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	19.98	1.01e-64	7.59e-61	0.82	0.68	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	19.98	1.01e-64	7.64e-61	0.82	0.68	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	19.98	1.01e-64	7.64e-61	0.82	0.68	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	19.97	1.07e-64	8.09e-61	0.82	0.68	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
THCA	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-19.97	1.08e-64	8.11e-61	-0.9	-0.68	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
THCA	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	19.96	1.14e-64	8.55e-61	0.91	0.68	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
THCA	cis	rs7174755	1	rs7174755	ENSG00000260657.2	RP11-315D16.4	-19.96	1.18e-64	8.9e-61	-0.85	-0.68	Major depressive disorder;	chr15:68304789	chr15:68267792~68277994:-
THCA	cis	rs9322193	0.884	rs1125	ENSG00000231760.4	RP11-350J20.5	19.96	1.25e-64	9.37e-61	0.9	0.68	Lung cancer;	chr6:149658280	chr6:149796151~149826294:-
THCA	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	19.95	1.29e-64	9.71e-61	0.82	0.68	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
THCA	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-19.95	1.3e-64	9.73e-61	-0.76	-0.68	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
THCA	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	19.95	1.34e-64	1.01e-60	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
THCA	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	19.95	1.35e-64	1.01e-60	0.91	0.68	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
THCA	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	19.94	1.41e-64	1.06e-60	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	19.94	1.46e-64	1.1e-60	0.84	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
THCA	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	19.93	1.63e-64	1.22e-60	0.91	0.68	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
THCA	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	19.93	1.66e-64	1.24e-60	0.91	0.68	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	19.92	1.8e-64	1.35e-60	0.91	0.68	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
THCA	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	19.92	1.8e-64	1.35e-60	0.91	0.68	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
THCA	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	19.92	1.86e-64	1.39e-60	0.84	0.68	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
THCA	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-19.91	1.97e-64	1.47e-60	-0.75	-0.68	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
THCA	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	19.91	2.03e-64	1.52e-60	0.82	0.68	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-19.89	2.66e-64	1.98e-60	-0.81	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	19.88	2.86e-64	2.13e-60	0.81	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
THCA	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	19.88	2.9e-64	2.16e-60	1.32	0.68	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-19.88	3e-64	2.23e-60	-0.78	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
THCA	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	19.87	3.1e-64	2.3e-60	0.81	0.68	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
THCA	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-19.87	3.15e-64	2.34e-60	-0.75	-0.68	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
THCA	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	19.87	3.21e-64	2.38e-60	0.9	0.68	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
THCA	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-19.86	3.41e-64	2.53e-60	-0.87	-0.68	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
THCA	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	19.86	3.67e-64	2.72e-60	1.13	0.68	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
THCA	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-19.85	3.88e-64	2.87e-60	-0.82	-0.68	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
THCA	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	19.85	3.99e-64	2.95e-60	0.91	0.68	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
THCA	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	19.84	4.45e-64	3.28e-60	0.81	0.68	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	19.84	4.45e-64	3.28e-60	0.81	0.68	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
THCA	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	19.83	4.67e-64	3.44e-60	0.9	0.68	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	19.83	4.67e-64	3.44e-60	0.9	0.68	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
THCA	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	19.83	4.97e-64	3.66e-60	0.78	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
THCA	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-19.82	5.44e-64	4e-60	-0.73	-0.67	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
THCA	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-19.82	5.73e-64	4.22e-60	-0.73	-0.67	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
THCA	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	19.81	5.88e-64	4.33e-60	0.81	0.67	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	19.81	5.88e-64	4.33e-60	0.81	0.67	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
THCA	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-19.81	6.13e-64	4.51e-60	-0.72	-0.67	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
THCA	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	19.81	6.18e-64	4.54e-60	0.9	0.67	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	19.81	6.18e-64	4.54e-60	0.9	0.67	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	19.81	6.18e-64	4.54e-60	0.9	0.67	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
THCA	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-19.79	7.33e-64	5.38e-60	-0.75	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
THCA	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	19.79	7.53e-64	5.52e-60	0.78	0.67	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	19.78	8e-64	5.86e-60	0.81	0.67	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
THCA	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	19.78	8.08e-64	5.91e-60	0.84	0.67	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
THCA	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	19.78	8.18e-64	5.99e-60	0.9	0.67	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	19.78	8.42e-64	6.16e-60	0.91	0.67	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	19.78	8.76e-64	6.41e-60	0.9	0.67	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
THCA	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	19.77	9.84e-64	7.19e-60	0.9	0.67	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
THCA	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-19.76	1.01e-63	7.39e-60	-0.73	-0.67	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
THCA	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	19.75	1.16e-63	8.43e-60	0.91	0.67	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
THCA	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	19.75	1.17e-63	8.53e-60	0.9	0.67	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
THCA	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	19.75	1.17e-63	8.53e-60	0.9	0.67	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
THCA	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-19.74	1.27e-63	9.25e-60	-0.73	-0.67	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	19.74	1.28e-63	9.31e-60	0.8	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
THCA	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	19.74	1.3e-63	9.42e-60	0.77	0.67	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
THCA	cis	rs7195287	0.779	rs2335454	ENSG00000276791.1	CTD-2270P14.5	19.74	1.3e-63	9.44e-60	0.78	0.67	Eosinophil counts;	chr16:2778156	chr16:2777319~2780568:+
THCA	cis	rs858239	0.669	rs56400441	ENSG00000230658.1	KLHL7-AS1	19.73	1.4e-63	1.02e-59	0.83	0.67	Cerebrospinal fluid biomarker levels;	chr7:23103945	chr7:23101228~23105703:-
THCA	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-19.73	1.43e-63	1.04e-59	-0.72	-0.67	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
THCA	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-19.73	1.43e-63	1.04e-59	-0.72	-0.67	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
THCA	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	19.73	1.45e-63	1.05e-59	0.81	0.67	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
THCA	cis	rs858239	0.614	rs2014816	ENSG00000230658.1	KLHL7-AS1	19.72	1.67e-63	1.21e-59	0.82	0.67	Cerebrospinal fluid biomarker levels;	chr7:23083417	chr7:23101228~23105703:-
THCA	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	19.71	1.77e-63	1.28e-59	0.81	0.67	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
THCA	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	19.71	1.78e-63	1.28e-59	0.91	0.67	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
THCA	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	19.71	1.79e-63	1.29e-59	0.86	0.67	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
THCA	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	19.71	1.81e-63	1.31e-59	0.91	0.67	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	19.71	1.81e-63	1.31e-59	0.91	0.67	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
THCA	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	19.7	1.94e-63	1.4e-59	1.12	0.67	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
THCA	cis	rs9322193	0.884	rs11155675	ENSG00000231760.4	RP11-350J20.5	19.68	2.45e-63	1.76e-59	0.92	0.67	Lung cancer;	chr6:149742883	chr6:149796151~149826294:-
THCA	cis	rs1153858	0.723	rs11855527	ENSG00000259520.4	CTD-2651B20.3	19.68	2.52e-63	1.81e-59	0.85	0.67	Homoarginine levels;	chr15:45314487	chr15:45251580~45279251:-
THCA	cis	rs7208859	0.673	rs12103759	ENSG00000263531.1	RP13-753N3.1	19.68	2.55e-63	1.83e-59	1.31	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs59029591	ENSG00000263531.1	RP13-753N3.1	19.68	2.55e-63	1.83e-59	1.31	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73265633	ENSG00000263531.1	RP13-753N3.1	19.68	2.55e-63	1.83e-59	1.31	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9913782	ENSG00000263531.1	RP13-753N3.1	19.68	2.55e-63	1.83e-59	1.31	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9911989	ENSG00000263531.1	RP13-753N3.1	-19.68	2.55e-63	1.83e-59	-1.31	-0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	19.68	2.59e-63	1.86e-59	1.3	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
THCA	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-19.67	2.78e-63	2e-59	-0.72	-0.67	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
THCA	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	19.67	2.8e-63	2.01e-59	1.32	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
THCA	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	19.67	2.88e-63	2.07e-59	0.92	0.67	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
THCA	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-19.66	2.94e-63	2.11e-59	-0.74	-0.67	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
THCA	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	19.66	3.03e-63	2.17e-59	1.31	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
THCA	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-19.64	3.68e-63	2.63e-59	-0.75	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
THCA	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	19.64	3.79e-63	2.71e-59	0.91	0.67	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	19.64	3.79e-63	2.71e-59	0.91	0.67	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
THCA	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	19.62	4.55e-63	3.25e-59	1.32	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
THCA	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	19.61	5.46e-63	3.9e-59	0.91	0.67	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	19.61	5.48e-63	3.91e-59	0.89	0.67	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
THCA	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	19.61	5.48e-63	3.91e-59	0.89	0.67	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	19.61	5.48e-63	3.91e-59	0.89	0.67	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
THCA	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs56085216	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11650305	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs11654914	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9914271	ENSG00000263531.1	RP13-753N3.1	19.6	5.83e-63	4.13e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30863921~30864940:-
THCA	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	19.6	5.84e-63	4.13e-59	0.77	0.67	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	19.59	6.22e-63	4.39e-59	1.29	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
THCA	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	19.59	6.78e-63	4.78e-59	0.9	0.67	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	19.59	6.78e-63	4.78e-59	0.9	0.67	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	19.59	6.78e-63	4.78e-59	0.9	0.67	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	19.59	6.78e-63	4.78e-59	0.9	0.67	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
THCA	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	19.59	6.78e-63	4.78e-59	0.9	0.67	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	19.59	6.78e-63	4.78e-59	0.9	0.67	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
THCA	cis	rs7569084	0.687	rs963539	ENSG00000204929.10	AC074391.1	-19.58	7.57e-63	5.33e-59	-0.84	-0.67	Sum eosinophil basophil counts;	chr2:65421413	chr2:65436711~66084639:+
THCA	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-19.57	7.77e-63	5.47e-59	-0.73	-0.67	Breast cancer;	chr11:743813	chr11:779617~780755:+
THCA	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	19.57	7.79e-63	5.48e-59	0.91	0.67	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	19.57	7.82e-63	5.5e-59	0.91	0.67	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	19.56	9.12e-63	6.4e-59	0.9	0.67	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
THCA	cis	rs7174755	1	rs68069953	ENSG00000260657.2	RP11-315D16.4	19.56	9.31e-63	6.54e-59	0.85	0.67	Major depressive disorder;	chr15:68304235	chr15:68267792~68277994:-
THCA	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	19.55	9.88e-63	6.94e-59	1.17	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
THCA	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	19.53	1.25e-62	8.68e-59	0.73	0.67	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
THCA	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	19.53	1.27e-62	8.82e-59	0.9	0.67	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
THCA	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	19.53	1.29e-62	8.91e-59	0.91	0.67	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	19.52	1.41e-62	9.76e-59	0.93	0.67	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	19.51	1.59e-62	1.1e-58	0.85	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	19.5	1.75e-62	1.2e-58	0.82	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
THCA	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	19.47	2.29e-62	1.57e-58	0.89	0.67	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	19.47	2.29e-62	1.57e-58	0.89	0.67	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	19.47	2.29e-62	1.57e-58	0.89	0.67	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	19.47	2.29e-62	1.57e-58	0.89	0.67	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	19.47	2.29e-62	1.57e-58	0.89	0.67	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
THCA	cis	rs950027	0.62	rs872192	ENSG00000259520.4	CTD-2651B20.3	-19.46	2.56e-62	1.75e-58	-0.78	-0.67	Response to fenofibrate (adiponectin levels);	chr15:45322304	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1617634	ENSG00000259520.4	CTD-2651B20.3	-19.46	2.56e-62	1.75e-58	-0.78	-0.67	Response to fenofibrate (adiponectin levels);	chr15:45323380	chr15:45251580~45279251:-
THCA	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	19.46	2.73e-62	1.87e-58	0.9	0.67	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	19.46	2.74e-62	1.87e-58	0.9	0.67	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	19.46	2.74e-62	1.87e-58	0.9	0.67	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
THCA	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	19.46	2.74e-62	1.87e-58	0.9	0.67	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
THCA	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	19.46	2.76e-62	1.88e-58	0.89	0.67	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
THCA	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-19.46	2.79e-62	1.91e-58	-0.84	-0.67	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
THCA	cis	rs7569084	0.663	rs6546150	ENSG00000204929.10	AC074391.1	-19.45	2.94e-62	2e-58	-0.83	-0.67	Sum eosinophil basophil counts;	chr2:65415066	chr2:65436711~66084639:+
THCA	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	19.45	3.01e-62	2.05e-58	1.12	0.67	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	19.45	3.01e-62	2.05e-58	1.12	0.67	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	19.45	3.01e-62	2.05e-58	1.12	0.67	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	19.45	3.01e-62	2.05e-58	1.12	0.67	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	19.45	3.01e-62	2.05e-58	1.12	0.67	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
THCA	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	19.45	3.03e-62	2.07e-58	0.91	0.67	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
THCA	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	19.43	3.89e-62	2.64e-58	0.79	0.67	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	19.43	3.89e-62	2.64e-58	0.79	0.67	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
THCA	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	19.42	4e-62	2.72e-58	0.71	0.67	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
THCA	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	19.41	4.81e-62	3.23e-58	0.8	0.67	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	19.41	4.81e-62	3.23e-58	0.8	0.67	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	19.39	5.41e-62	3.62e-58	0.8	0.67	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	19.39	5.41e-62	3.62e-58	0.8	0.67	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	19.39	5.41e-62	3.62e-58	0.8	0.67	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	19.39	5.41e-62	3.62e-58	0.8	0.67	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
THCA	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	19.39	5.5e-62	3.69e-58	0.84	0.67	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
THCA	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	19.39	5.82e-62	3.9e-58	1.11	0.67	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
THCA	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	19.38	6.17e-62	4.13e-58	0.8	0.67	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	19.38	6.17e-62	4.13e-58	0.8	0.67	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
THCA	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	19.37	6.88e-62	4.6e-58	0.71	0.67	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	19.37	7.29e-62	4.87e-58	0.8	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
THCA	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-19.35	8.36e-62	5.58e-58	-0.7	-0.67	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
THCA	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	19.35	8.46e-62	5.65e-58	0.89	0.67	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
THCA	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-19.35	8.49e-62	5.67e-58	-0.79	-0.67	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
THCA	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-19.35	8.55e-62	5.7e-58	-0.82	-0.67	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-19.35	8.81e-62	5.88e-58	-0.84	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
THCA	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	19.35	9.19e-62	6.12e-58	0.79	0.67	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
THCA	cis	rs507080	0.922	rs644867	ENSG00000255239.1	AP002954.6	19.35	9.24e-62	6.16e-58	0.9	0.67	Serum metabolite levels;	chr11:118696836	chr11:118688039~118690600:-
THCA	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-19.34	1.01e-61	6.69e-58	-0.83	-0.67	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
THCA	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	19.33	1.07e-61	7.13e-58	0.85	0.67	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	19.33	1.07e-61	7.13e-58	0.85	0.67	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	19.33	1.13e-61	7.48e-58	0.85	0.67	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	19.33	1.13e-61	7.48e-58	0.85	0.67	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	19.33	1.13e-61	7.48e-58	0.85	0.67	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-19.33	1.13e-61	7.48e-58	-0.85	-0.67	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	19.33	1.14e-61	7.57e-58	0.8	0.67	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
THCA	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-19.32	1.19e-61	7.9e-58	-0.89	-0.67	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
THCA	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	19.32	1.2e-61	7.99e-58	0.85	0.67	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	19.32	1.2e-61	7.99e-58	0.85	0.67	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
THCA	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	19.32	1.24e-61	8.25e-58	1.27	0.67	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
THCA	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-19.32	1.25e-61	8.28e-58	-0.85	-0.67	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-19.31	1.33e-61	8.79e-58	-0.85	-0.67	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-19.31	1.33e-61	8.79e-58	-0.85	-0.67	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
THCA	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-19.3	1.44e-61	9.49e-58	-0.74	-0.67	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
THCA	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	19.3	1.46e-61	9.67e-58	1.3	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
THCA	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-19.3	1.5e-61	9.92e-58	-0.73	-0.66	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
THCA	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	19.3	1.51e-61	9.99e-58	0.8	0.66	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
THCA	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-19.29	1.6e-61	1.06e-57	-0.84	-0.66	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
THCA	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	19.29	1.62e-61	1.07e-57	0.9	0.66	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
THCA	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-19.29	1.67e-61	1.1e-57	-0.85	-0.66	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
THCA	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-19.28	1.78e-61	1.17e-57	-0.72	-0.66	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
THCA	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-19.28	1.79e-61	1.18e-57	-0.85	-0.66	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
THCA	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-19.28	1.83e-61	1.2e-57	-0.75	-0.66	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
THCA	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	19.28	1.84e-61	1.21e-57	0.84	0.66	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
THCA	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	19.28	1.87e-61	1.23e-57	1.27	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73263788	ENSG00000263531.1	RP13-753N3.1	19.28	1.87e-61	1.23e-57	1.27	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs12949860	ENSG00000263531.1	RP13-753N3.1	19.28	1.87e-61	1.23e-57	1.27	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30863921~30864940:-
THCA	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-19.28	1.95e-61	1.28e-57	-0.73	-0.66	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
THCA	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	19.27	2.05e-61	1.35e-57	0.85	0.66	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	19.27	2.05e-61	1.35e-57	0.85	0.66	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	19.27	2.05e-61	1.35e-57	0.85	0.66	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	19.27	2.09e-61	1.37e-57	0.79	0.66	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	19.27	2.09e-61	1.37e-57	0.79	0.66	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	19.27	2.09e-61	1.37e-57	0.79	0.66	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
THCA	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-19.27	2.13e-61	1.39e-57	-0.85	-0.66	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-19.27	2.13e-61	1.39e-57	-0.85	-0.66	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-19.27	2.18e-61	1.43e-57	-0.85	-0.66	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
THCA	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-19.27	2.18e-61	1.43e-57	-0.85	-0.66	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	19.26	2.24e-61	1.46e-57	0.79	0.66	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
THCA	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	19.25	2.5e-61	1.62e-57	0.85	0.66	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-19.25	2.5e-61	1.62e-57	-0.85	-0.66	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-19.25	2.5e-61	1.62e-57	-0.85	-0.66	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
THCA	cis	rs7195287	0.591	rs63744561	ENSG00000276791.1	CTD-2270P14.5	19.25	2.5e-61	1.62e-57	0.79	0.66	Eosinophil counts;	chr16:2778171	chr16:2777319~2780568:+
THCA	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-19.25	2.56e-61	1.66e-57	-0.85	-0.66	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
THCA	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-19.25	2.56e-61	1.66e-57	-0.85	-0.66	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-19.25	2.56e-61	1.66e-57	-0.85	-0.66	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-19.25	2.56e-61	1.66e-57	-0.85	-0.66	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
THCA	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-19.25	2.56e-61	1.66e-57	-0.85	-0.66	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-19.25	2.62e-61	1.7e-57	-0.85	-0.66	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-19.24	2.72e-61	1.77e-57	-0.84	-0.66	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-19.24	2.83e-61	1.83e-57	-0.84	-0.66	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-19.24	2.83e-61	1.84e-57	-0.85	-0.66	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	19.24	2.86e-61	1.85e-57	0.81	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
THCA	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	19.24	2.87e-61	1.86e-57	0.79	0.66	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	19.24	2.87e-61	1.86e-57	0.79	0.66	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	19.24	2.87e-61	1.86e-57	0.79	0.66	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	19.24	2.87e-61	1.86e-57	0.79	0.66	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
THCA	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-19.24	2.99e-61	1.93e-57	-0.84	-0.66	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
THCA	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	19.23	3.05e-61	1.97e-57	0.88	0.66	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	19.23	3.09e-61	1.99e-57	0.79	0.66	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	19.23	3.09e-61	1.99e-57	0.79	0.66	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	19.23	3.09e-61	1.99e-57	0.79	0.66	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	19.23	3.09e-61	1.99e-57	0.79	0.66	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	19.23	3.09e-61	1.99e-57	0.79	0.66	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
THCA	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	19.23	3.16e-61	2.04e-57	0.85	0.66	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
THCA	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
THCA	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
THCA	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-19.23	3.19e-61	2.05e-57	-0.84	-0.66	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.846	rs240051	ENSG00000224086.5	LL22NC03-86G7.1	-19.23	3.27e-61	2.1e-57	-0.78	-0.66	Multiple sclerosis;	chr22:21909763	chr22:21938293~21977632:+
THCA	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
THCA	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
THCA	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-19.23	3.31e-61	2.12e-57	-0.85	-0.66	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.846	rs240053	ENSG00000224086.5	LL22NC03-86G7.1	-19.23	3.31e-61	2.12e-57	-0.78	-0.66	Multiple sclerosis;	chr22:21911000	chr22:21938293~21977632:+
THCA	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-19.22	3.4e-61	2.18e-57	-0.85	-0.66	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-19.22	3.43e-61	2.2e-57	-0.84	-0.66	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	19.22	3.47e-61	2.22e-57	0.79	0.66	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	19.21	3.79e-61	2.43e-57	0.85	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
THCA	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
THCA	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-19.21	3.91e-61	2.5e-57	-0.84	-0.66	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
THCA	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	19.21	4.01e-61	2.56e-57	1.27	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
THCA	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-19.21	4.11e-61	2.62e-57	-0.84	-0.66	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-19.21	4.11e-61	2.62e-57	-0.84	-0.66	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-19.21	4.11e-61	2.62e-57	-0.84	-0.66	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
THCA	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-19.21	4.11e-61	2.62e-57	-0.84	-0.66	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-19.21	4.11e-61	2.62e-57	-0.84	-0.66	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-19.2	4.53e-61	2.88e-57	-0.84	-0.66	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	19.19	4.73e-61	3.01e-57	0.79	0.66	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	19.19	4.78e-61	3.04e-57	0.8	0.66	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	19.19	4.78e-61	3.04e-57	0.8	0.66	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	19.19	4.78e-61	3.04e-57	0.8	0.66	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	19.19	4.78e-61	3.04e-57	0.8	0.66	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	19.19	4.78e-61	3.04e-57	0.8	0.66	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	19.18	5.23e-61	3.32e-57	0.79	0.66	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
THCA	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-19.18	5.61e-61	3.56e-57	-0.75	-0.66	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
THCA	cis	rs433852	0.718	rs550455	ENSG00000232871.7	SEC1P	-19.18	5.65e-61	3.58e-57	-0.8	-0.66	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48633258	chr19:48638071~48682245:+
THCA	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-19.17	5.85e-61	3.7e-57	-0.83	-0.66	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
THCA	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	19.17	6.12e-61	3.87e-57	0.8	0.66	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-19.16	6.88e-61	4.35e-57	-0.8	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
THCA	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	19.15	7.2e-61	4.55e-57	0.79	0.66	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
THCA	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-19.15	7.22e-61	4.56e-57	-0.84	-0.66	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-19.15	7.7e-61	4.86e-57	-0.8	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
THCA	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	19.15	7.72e-61	4.87e-57	0.8	0.66	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
THCA	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-19.15	7.85e-61	4.95e-57	-0.73	-0.66	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
THCA	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	19.14	8.35e-61	5.26e-57	0.7	0.66	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
THCA	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	19.14	8.35e-61	5.26e-57	0.7	0.66	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
THCA	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-19.14	8.58e-61	5.41e-57	-0.85	-0.66	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
THCA	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-19.14	8.77e-61	5.52e-57	-0.71	-0.66	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
THCA	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	19.14	8.78e-61	5.53e-57	1.32	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
THCA	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	19.13	9.64e-61	6.07e-57	0.78	0.66	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
THCA	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-19.12	1.08e-60	6.82e-57	-0.7	-0.66	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
THCA	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	19.11	1.12e-60	7.02e-57	1.27	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
THCA	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	19.11	1.16e-60	7.32e-57	1.11	0.66	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
THCA	cis	rs7174755	0.924	rs8035431	ENSG00000260657.2	RP11-315D16.4	19.1	1.26e-60	7.9e-57	0.84	0.66	Major depressive disorder;	chr15:68305012	chr15:68267792~68277994:-
THCA	cis	rs6597981	0.592	rs28625355	ENSG00000279672.1	CMB9-55F22.1	19.1	1.27e-60	7.98e-57	0.72	0.66	Breast cancer;	chr11:736334	chr11:779617~780755:+
THCA	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-19.08	1.61e-60	1.01e-56	-0.74	-0.66	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
THCA	cis	rs433852	0.718	rs386551	ENSG00000232871.7	SEC1P	-19.07	1.84e-60	1.16e-56	-0.8	-0.66	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48635029	chr19:48638071~48682245:+
THCA	cis	rs11428934	1	rs11428934	ENSG00000232871.7	SEC1P	19.07	1.89e-60	1.19e-56	0.81	0.66	Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;	chr19:48640988	chr19:48638071~48682245:+
THCA	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	19.06	1.98e-60	1.24e-56	0.83	0.66	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.673	rs3816780	ENSG00000263531.1	RP13-753N3.1	19.06	1.99e-60	1.24e-56	1.26	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30863921~30864940:-
THCA	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	19.06	2.08e-60	1.3e-56	0.69	0.66	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
THCA	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-19.05	2.29e-60	1.43e-56	-0.7	-0.66	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
THCA	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	19.04	2.43e-60	1.52e-56	0.84	0.66	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	19.04	2.47e-60	1.55e-56	0.76	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
THCA	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	19.04	2.58e-60	1.61e-56	0.84	0.66	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
THCA	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-19.04	2.6e-60	1.63e-56	-0.69	-0.66	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
THCA	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-19.04	2.62e-60	1.64e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
THCA	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-19.02	2.94e-60	1.83e-56	-0.84	-0.66	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-19.02	2.94e-60	1.83e-56	-0.84	-0.66	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
THCA	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
THCA	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
THCA	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-19.02	2.94e-60	1.84e-56	-0.7	-0.66	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
THCA	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-19.02	3.19e-60	1.99e-56	-0.7	-0.66	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
THCA	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-19.02	3.19e-60	1.99e-56	-0.7	-0.66	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
THCA	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
THCA	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
THCA	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-19.01	3.34e-60	2.07e-56	-0.7	-0.66	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
THCA	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	19.01	3.56e-60	2.21e-56	0.79	0.66	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	19	3.72e-60	2.31e-56	0.8	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
THCA	cis	rs7174755	0.923	rs11634149	ENSG00000260657.2	RP11-315D16.4	19	3.85e-60	2.39e-56	0.84	0.66	Major depressive disorder;	chr15:68306072	chr15:68267792~68277994:-
THCA	cis	rs7569084	0.663	rs10190233	ENSG00000204929.10	AC074391.1	-19	3.94e-60	2.44e-56	-0.82	-0.66	Sum eosinophil basophil counts;	chr2:65413095	chr2:65436711~66084639:+
THCA	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	18.99	4.36e-60	2.7e-56	0.84	0.66	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	18.99	4.36e-60	2.7e-56	0.84	0.66	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	18.99	4.36e-60	2.7e-56	0.84	0.66	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
THCA	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	18.98	4.59e-60	2.84e-56	0.84	0.66	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
THCA	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	18.98	4.86e-60	3e-56	0.84	0.66	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
THCA	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	18.97	5.06e-60	3.13e-56	1.09	0.66	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
THCA	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-18.97	5.25e-60	3.24e-56	-0.7	-0.66	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
THCA	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	18.97	5.54e-60	3.42e-56	0.84	0.66	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	18.97	5.54e-60	3.42e-56	0.84	0.66	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	18.97	5.54e-60	3.42e-56	0.84	0.66	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	18.97	5.54e-60	3.42e-56	0.84	0.66	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	18.97	5.54e-60	3.42e-56	0.84	0.66	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
THCA	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	18.96	5.59e-60	3.44e-56	1.1	0.66	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
THCA	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-18.95	6.23e-60	3.83e-56	-0.7	-0.66	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
THCA	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-18.95	6.23e-60	3.83e-56	-0.7	-0.66	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-18.95	6.23e-60	3.83e-56	-0.7	-0.66	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
THCA	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-18.95	6.32e-60	3.89e-56	-0.84	-0.66	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	18.95	6.61e-60	4.06e-56	0.78	0.66	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	18.94	7.2e-60	4.42e-56	0.78	0.66	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	18.94	7.2e-60	4.42e-56	0.78	0.66	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	18.94	7.2e-60	4.42e-56	0.78	0.66	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
THCA	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	18.94	7.48e-60	4.59e-56	0.84	0.66	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	18.94	7.48e-60	4.59e-56	0.84	0.66	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	18.93	8.03e-60	4.92e-56	0.78	0.66	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
THCA	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	18.93	8.16e-60	5e-56	0.78	0.66	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
THCA	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	18.92	8.82e-60	5.41e-56	0.7	0.66	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
THCA	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	18.92	9.43e-60	5.78e-56	0.84	0.66	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
THCA	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	18.92	9.53e-60	5.84e-56	0.7	0.66	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
THCA	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-18.91	9.91e-60	6.07e-56	-0.84	-0.66	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
THCA	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-18.91	9.93e-60	6.08e-56	-0.68	-0.66	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
THCA	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-18.91	9.95e-60	6.09e-56	-0.84	-0.66	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
THCA	cis	rs7174755	0.923	rs9672310	ENSG00000260657.2	RP11-315D16.4	18.91	1.03e-59	6.31e-56	0.83	0.66	Major depressive disorder;	chr15:68306578	chr15:68267792~68277994:-
THCA	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	18.9	1.14e-59	7e-56	0.78	0.66	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
THCA	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-18.89	1.25e-59	7.65e-56	-0.84	-0.66	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	18.89	1.27e-59	7.78e-56	0.83	0.66	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	18.89	1.28e-59	7.83e-56	0.76	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
THCA	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	18.89	1.31e-59	8e-56	0.78	0.66	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
THCA	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-18.88	1.32e-59	8.06e-56	-0.91	-0.66	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
THCA	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	18.88	1.37e-59	8.35e-56	0.84	0.66	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
THCA	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	18.88	1.37e-59	8.35e-56	0.84	0.66	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	18.88	1.37e-59	8.35e-56	0.84	0.66	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	18.88	1.37e-59	8.35e-56	0.84	0.66	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	18.88	1.37e-59	8.35e-56	0.84	0.66	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	18.88	1.37e-59	8.35e-56	0.84	0.66	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	18.88	1.44e-59	8.74e-56	0.84	0.66	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
THCA	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-18.88	1.45e-59	8.8e-56	-0.7	-0.66	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
THCA	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	18.88	1.45e-59	8.82e-56	1.09	0.66	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
THCA	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	18.88	1.46e-59	8.87e-56	0.84	0.66	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
THCA	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	18.88	1.46e-59	8.87e-56	0.84	0.66	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	18.88	1.46e-59	8.87e-56	0.84	0.66	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	18.88	1.46e-59	8.87e-56	0.84	0.66	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	18.88	1.46e-59	8.87e-56	0.84	0.66	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-18.88	1.46e-59	8.87e-56	-0.84	-0.66	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	18.87	1.47e-59	8.93e-56	0.76	0.66	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	18.87	1.49e-59	9.08e-56	0.78	0.66	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
THCA	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	18.87	1.5e-59	9.09e-56	0.84	0.66	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-18.86	1.64e-59	9.95e-56	-0.78	-0.66	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
THCA	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-18.86	1.74e-59	1.06e-55	-0.7	-0.66	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
THCA	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	18.86	1.82e-59	1.1e-55	0.84	0.66	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
THCA	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	18.85	1.97e-59	1.19e-55	1.09	0.66	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
THCA	cis	rs7208859	0.623	rs9914242	ENSG00000263531.1	RP13-753N3.1	18.83	2.33e-59	1.41e-55	1.25	0.66	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30863921~30864940:-
THCA	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-18.83	2.34e-59	1.41e-55	-1.06	-0.66	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
THCA	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	18.83	2.38e-59	1.43e-55	0.85	0.66	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
THCA	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	18.83	2.39e-59	1.44e-55	0.83	0.66	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
THCA	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	18.82	2.65e-59	1.6e-55	0.82	0.66	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
THCA	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-18.81	2.98e-59	1.79e-55	-0.84	-0.66	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-18.8	3.18e-59	1.91e-55	-0.87	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
THCA	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-18.8	3.37e-59	2.02e-55	-0.71	-0.66	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
THCA	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-18.8	3.37e-59	2.02e-55	-0.71	-0.66	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
THCA	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-18.8	3.44e-59	2.06e-55	-0.84	-0.66	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-18.8	3.44e-59	2.06e-55	-0.84	-0.66	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-18.79	3.54e-59	2.12e-55	-0.84	-0.66	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	18.79	3.57e-59	2.14e-55	0.78	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
THCA	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	18.79	3.6e-59	2.16e-55	1.08	0.65	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
THCA	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	18.78	3.99e-59	2.39e-55	0.83	0.65	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	18.78	4.23e-59	2.54e-55	0.83	0.65	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-18.77	4.35e-59	2.6e-55	-0.84	-0.65	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	18.77	4.35e-59	2.6e-55	0.89	0.65	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
THCA	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-18.77	4.43e-59	2.64e-55	-0.84	-0.65	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
THCA	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-18.77	4.43e-59	2.64e-55	-0.84	-0.65	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
THCA	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-18.77	4.43e-59	2.64e-55	-0.84	-0.65	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	18.77	4.55e-59	2.71e-55	0.8	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
THCA	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	18.77	4.68e-59	2.79e-55	0.83	0.65	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
THCA	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-18.76	5.08e-59	3.02e-55	-0.83	-0.65	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-18.76	5.08e-59	3.02e-55	-0.83	-0.65	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	18.76	5.22e-59	3.11e-55	0.78	0.65	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	18.75	5.79e-59	3.44e-55	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
THCA	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-18.75	5.83e-59	3.47e-55	-0.91	-0.65	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
THCA	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-18.74	5.97e-59	3.55e-55	-0.69	-0.65	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
THCA	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	18.74	5.99e-59	3.56e-55	0.84	0.65	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	18.74	6.08e-59	3.61e-55	0.89	0.65	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
THCA	cis	rs7174755	0.961	rs12148843	ENSG00000260657.2	RP11-315D16.4	18.73	6.65e-59	3.9e-55	0.84	0.65	Major depressive disorder;	chr15:68302184	chr15:68267792~68277994:-
THCA	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	18.72	7.4e-59	4.33e-55	0.89	0.65	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	18.72	7.4e-59	4.33e-55	0.89	0.65	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
THCA	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	18.7	9.55e-59	5.58e-55	1.08	0.65	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
THCA	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-18.69	1.02e-58	5.96e-55	-0.84	-0.65	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	18.69	1.06e-58	6.18e-55	0.83	0.65	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
THCA	cis	rs7174755	0.961	rs1122247	ENSG00000260657.2	RP11-315D16.4	18.69	1.07e-58	6.26e-55	0.85	0.65	Major depressive disorder;	chr15:68302523	chr15:68267792~68277994:-
THCA	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	18.69	1.08e-58	6.28e-55	0.89	0.65	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
THCA	cis	rs7174755	0.961	rs11631030	ENSG00000260657.2	RP11-315D16.4	18.69	1.11e-58	6.48e-55	0.84	0.65	Major depressive disorder;	chr15:68303463	chr15:68267792~68277994:-
THCA	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-18.68	1.21e-58	7.03e-55	-0.83	-0.65	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	18.68	1.24e-58	7.24e-55	0.91	0.65	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
THCA	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	18.67	1.28e-58	7.48e-55	0.83	0.65	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
THCA	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	18.66	1.47e-58	8.54e-55	0.69	0.65	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
THCA	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	18.66	1.47e-58	8.54e-55	0.69	0.65	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
THCA	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	18.66	1.47e-58	8.54e-55	0.69	0.65	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	18.65	1.57e-58	9.13e-55	0.77	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
THCA	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-18.65	1.59e-58	9.25e-55	-0.83	-0.65	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
THCA	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-18.65	1.65e-58	9.57e-55	-0.88	-0.65	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-18.64	1.76e-58	1.02e-54	-0.74	-0.65	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-18.64	1.76e-58	1.02e-54	-0.74	-0.65	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-18.64	1.76e-58	1.02e-54	-0.74	-0.65	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-18.64	1.76e-58	1.02e-54	-0.74	-0.65	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-18.64	1.76e-58	1.02e-54	-0.74	-0.65	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
THCA	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-18.63	2.02e-58	1.17e-54	-0.72	-0.65	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
THCA	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-18.63	2.03e-58	1.17e-54	-0.69	-0.65	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
THCA	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-18.63	2.03e-58	1.17e-54	-0.69	-0.65	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-18.62	2.21e-58	1.28e-54	-0.7	-0.65	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
THCA	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	18.62	2.24e-58	1.29e-54	0.78	0.65	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
THCA	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-18.62	2.27e-58	1.31e-54	-0.71	-0.65	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
THCA	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	18.62	2.36e-58	1.36e-54	0.79	0.65	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	18.62	2.36e-58	1.36e-54	0.79	0.65	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
THCA	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	18.61	2.59e-58	1.49e-54	0.85	0.65	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
THCA	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-18.61	2.67e-58	1.53e-54	-0.82	-0.65	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
THCA	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	18.59	3.08e-58	1.77e-54	0.85	0.65	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
THCA	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	18.59	3.18e-58	1.82e-54	0.69	0.65	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
THCA	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-18.59	3.28e-58	1.89e-54	-0.84	-0.65	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
THCA	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	18.58	3.35e-58	1.92e-54	0.77	0.65	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
THCA	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	18.58	3.43e-58	1.97e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	18.58	3.43e-58	1.97e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	18.58	3.43e-58	1.97e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	18.58	3.43e-58	1.97e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
THCA	cis	rs67180937	0.844	rs4846384	ENSG00000272750.1	RP11-378J18.8	-18.58	3.51e-58	2.01e-54	-0.73	-0.65	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222624272	chr1:222658867~222661512:-
THCA	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	18.58	3.56e-58	2.04e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	18.58	3.56e-58	2.04e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	18.58	3.56e-58	2.04e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
THCA	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	18.58	3.56e-58	2.04e-54	0.84	0.65	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
THCA	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	18.57	3.9e-58	2.23e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	18.57	3.9e-58	2.23e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	18.57	3.9e-58	2.23e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	18.57	3.9e-58	2.23e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
THCA	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	18.57	3.98e-58	2.28e-54	0.83	0.65	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
THCA	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	18.56	4.15e-58	2.37e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	18.56	4.31e-58	2.46e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
THCA	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	18.54	5.14e-58	2.93e-54	0.79	0.65	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
THCA	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	18.54	5.24e-58	2.99e-54	0.81	0.65	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
THCA	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	18.54	5.55e-58	3.16e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
THCA	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	18.54	5.65e-58	3.22e-54	0.83	0.65	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
THCA	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-18.53	6.01e-58	3.42e-54	-0.71	-0.65	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
THCA	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	18.53	6.17e-58	3.51e-54	0.82	0.65	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	18.53	6.17e-58	3.51e-54	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	18.53	6.23e-58	3.54e-54	0.78	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
THCA	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	18.53	6.28e-58	3.57e-54	1.26	0.65	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
THCA	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-18.53	6.29e-58	3.58e-54	-0.74	-0.65	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
THCA	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	18.52	6.33e-58	3.6e-54	0.84	0.65	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	18.52	6.48e-58	3.69e-54	0.83	0.65	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	18.52	6.48e-58	3.69e-54	0.83	0.65	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
THCA	cis	rs67180937	0.844	rs4846770	ENSG00000272750.1	RP11-378J18.8	-18.52	6.55e-58	3.72e-54	-0.72	-0.65	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222622227	chr1:222658867~222661512:-
THCA	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	18.51	7.11e-58	4.04e-54	0.74	0.65	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
THCA	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	18.51	7.12e-58	4.04e-54	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
THCA	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	18.51	7.13e-58	4.04e-54	0.83	0.65	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
THCA	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	18.51	7.14e-58	4.05e-54	0.83	0.65	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
THCA	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	18.51	7.21e-58	4.09e-54	0.69	0.65	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
THCA	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	18.51	7.26e-58	4.12e-54	0.77	0.65	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
THCA	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	18.51	7.27e-58	4.12e-54	0.72	0.65	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
THCA	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	18.5	8.16e-58	4.62e-54	0.79	0.65	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
THCA	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	18.5	8.45e-58	4.79e-54	0.84	0.65	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
THCA	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	18.49	8.8e-58	4.98e-54	0.83	0.65	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
THCA	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	18.49	9.01e-58	5.1e-54	0.86	0.65	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
THCA	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	18.49	9.07e-58	5.13e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	18.49	9.07e-58	5.13e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	18.49	9.07e-58	5.13e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	18.49	9.07e-58	5.13e-54	1.07	0.65	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
THCA	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-18.49	9.1e-58	5.14e-54	-0.82	-0.65	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
THCA	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-18.49	9.43e-58	5.32e-54	-0.7	-0.65	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
THCA	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-18.49	9.65e-58	5.44e-54	-0.7	-0.65	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
THCA	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-18.49	9.65e-58	5.44e-54	-0.7	-0.65	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
THCA	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-18.49	9.65e-58	5.44e-54	-0.7	-0.65	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
THCA	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-18.48	9.75e-58	5.5e-54	-0.74	-0.65	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
THCA	cis	rs17023223	0.581	rs61808932	ENSG00000231365.4	RP11-418J17.1	-18.48	9.8e-58	5.52e-54	-0.75	-0.65	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119101197	chr1:119140396~119275973:+
THCA	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-18.48	1.07e-57	6.04e-54	-0.74	-0.65	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-18.47	1.19e-57	6.68e-54	-0.74	-0.65	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
THCA	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-18.46	1.21e-57	6.82e-54	-0.85	-0.65	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
THCA	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-18.46	1.21e-57	6.82e-54	-0.85	-0.65	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-18.46	1.3e-57	7.3e-54	-0.74	-0.65	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
THCA	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	18.45	1.35e-57	7.58e-54	0.78	0.65	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
THCA	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	18.45	1.36e-57	7.65e-54	0.89	0.65	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-18.45	1.38e-57	7.75e-54	-0.76	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
THCA	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	18.45	1.42e-57	7.97e-54	0.81	0.65	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
THCA	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-18.45	1.42e-57	7.99e-54	-0.74	-0.65	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
THCA	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	18.45	1.46e-57	8.17e-54	0.89	0.65	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
THCA	cis	rs7188445	0.899	rs57652769	ENSG00000261390.4	RP11-345M22.2	-18.44	1.62e-57	9.06e-54	-0.79	-0.65	Urate levels;	chr16:79720079	chr16:79715232~79770563:-
THCA	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	18.43	1.68e-57	9.44e-54	0.81	0.65	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
THCA	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-18.43	1.76e-57	9.84e-54	-0.74	-0.65	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	18.42	1.87e-57	1.05e-53	0.77	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
THCA	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-18.42	1.89e-57	1.06e-53	-0.79	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
THCA	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	18.42	1.93e-57	1.08e-53	0.67	0.65	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
THCA	cis	rs7174755	0.961	rs58175526	ENSG00000260657.2	RP11-315D16.4	18.42	1.93e-57	1.08e-53	0.85	0.65	Major depressive disorder;	chr15:68300789	chr15:68267792~68277994:-
THCA	cis	rs7174755	0.923	rs9672383	ENSG00000260657.2	RP11-315D16.4	18.41	2.07e-57	1.15e-53	0.82	0.65	Major depressive disorder;	chr15:68306731	chr15:68267792~68277994:-
THCA	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	18.41	2.09e-57	1.16e-53	0.84	0.65	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
THCA	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	18.41	2.13e-57	1.19e-53	0.78	0.65	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	18.41	2.13e-57	1.19e-53	0.78	0.65	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
THCA	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	18.41	2.28e-57	1.27e-53	0.83	0.65	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	18.4	2.45e-57	1.36e-53	0.79	0.65	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	18.4	2.49e-57	1.39e-53	0.78	0.65	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	18.4	2.49e-57	1.39e-53	0.78	0.65	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
THCA	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-18.38	2.87e-57	1.6e-53	-0.74	-0.65	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-18.38	2.87e-57	1.6e-53	-0.74	-0.65	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-18.38	2.93e-57	1.63e-53	-0.74	-0.65	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
THCA	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	18.38	2.96e-57	1.65e-53	0.83	0.65	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
THCA	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	18.37	3.21e-57	1.78e-53	0.84	0.65	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
THCA	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	18.37	3.32e-57	1.84e-53	0.83	0.65	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	18.37	3.32e-57	1.84e-53	0.83	0.65	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000218537.1	MIF-AS1	18.36	3.58e-57	1.99e-53	0.84	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23894426~23898930:-
THCA	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	18.36	3.64e-57	2.02e-53	0.67	0.65	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
THCA	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	18.36	3.69e-57	2.04e-53	0.83	0.65	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
THCA	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	18.36	3.71e-57	2.05e-53	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
THCA	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-18.36	3.75e-57	2.08e-53	-0.82	-0.65	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
THCA	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-18.36	3.87e-57	2.14e-53	-0.82	-0.65	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
THCA	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	18.36	3.91e-57	2.16e-53	0.74	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
THCA	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-18.35	4e-57	2.21e-53	-0.73	-0.65	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-18.35	4.03e-57	2.23e-53	-0.73	-0.65	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
THCA	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-18.35	4.03e-57	2.23e-53	-0.73	-0.65	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-18.35	4.03e-57	2.23e-53	-0.73	-0.65	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-18.35	4.03e-57	2.23e-53	-0.73	-0.65	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-18.35	4.06e-57	2.24e-53	-0.74	-0.65	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
THCA	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	18.35	4.13e-57	2.28e-53	0.75	0.65	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
THCA	cis	rs1153858	0.895	rs12593402	ENSG00000259520.4	CTD-2651B20.3	-18.34	4.61e-57	2.53e-53	-0.82	-0.65	Homoarginine levels;	chr15:45325194	chr15:45251580~45279251:-
THCA	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-18.34	4.8e-57	2.63e-53	-0.76	-0.65	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
THCA	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	18.34	4.84e-57	2.66e-53	0.74	0.65	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-18.33	5.09e-57	2.79e-53	-0.74	-0.65	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
THCA	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	18.33	5.13e-57	2.81e-53	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	18.33	5.13e-57	2.81e-53	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	18.33	5.13e-57	2.81e-53	0.82	0.65	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
THCA	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	18.33	5.31e-57	2.91e-53	0.87	0.65	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
THCA	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	18.33	5.38e-57	2.95e-53	0.83	0.65	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	18.33	5.38e-57	2.95e-53	0.83	0.65	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	18.33	5.38e-57	2.95e-53	0.83	0.65	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
THCA	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-18.32	5.96e-57	3.26e-53	-0.74	-0.65	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-18.32	5.97e-57	3.27e-53	-0.74	-0.65	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-18.32	5.97e-57	3.27e-53	-0.74	-0.65	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-18.32	5.97e-57	3.27e-53	-0.74	-0.65	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-18.32	5.99e-57	3.27e-53	-0.74	-0.65	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-18.32	5.99e-57	3.27e-53	-0.74	-0.65	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
THCA	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	18.32	6e-57	3.28e-53	0.83	0.65	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	18.32	6e-57	3.28e-53	0.83	0.65	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	18.32	6e-57	3.28e-53	0.83	0.65	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	18.31	6.38e-57	3.48e-53	0.84	0.65	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
THCA	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-18.31	6.43e-57	3.51e-53	-0.82	-0.65	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
THCA	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-18.31	6.65e-57	3.63e-53	-0.82	-0.65	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
THCA	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-18.31	6.65e-57	3.63e-53	-0.82	-0.65	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
THCA	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	18.3	6.91e-57	3.76e-53	0.67	0.65	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
THCA	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	18.3	7.03e-57	3.83e-53	0.79	0.65	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
THCA	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-18.3	7.46e-57	4.06e-53	-0.82	-0.64	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
THCA	cis	rs1153858	1	rs59889118	ENSG00000259520.4	CTD-2651B20.3	-18.29	7.47e-57	4.07e-53	-0.82	-0.64	Homoarginine levels;	chr15:45326532	chr15:45251580~45279251:-
THCA	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	18.29	7.56e-57	4.12e-53	0.84	0.64	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	18.29	7.56e-57	4.12e-53	0.84	0.64	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
THCA	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	18.28	8.99e-57	4.88e-53	0.82	0.64	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
THCA	cis	rs67180937	0.882	rs17163313	ENSG00000272750.1	RP11-378J18.8	-18.28	9.17e-57	4.99e-53	-0.72	-0.64	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222626283	chr1:222658867~222661512:-
THCA	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	18.27	9.28e-57	5.04e-53	0.78	0.64	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
THCA	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-18.27	9.39e-57	5.1e-53	-0.74	-0.64	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-18.27	9.39e-57	5.1e-53	-0.74	-0.64	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
THCA	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	18.27	9.78e-57	5.31e-53	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
THCA	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-18.27	9.81e-57	5.33e-53	-0.73	-0.64	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
THCA	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	18.27	9.98e-57	5.42e-53	0.83	0.64	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
THCA	cis	rs1153858	1	rs28679834	ENSG00000259520.4	CTD-2651B20.3	-18.27	1e-56	5.45e-53	-0.83	-0.64	Homoarginine levels;	chr15:45324008	chr15:45251580~45279251:-
THCA	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-18.27	1.02e-56	5.54e-53	-0.72	-0.64	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
THCA	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	18.26	1.03e-56	5.6e-53	0.83	0.64	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	18.26	1.07e-56	5.81e-53	0.85	0.64	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
THCA	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-18.26	1.09e-56	5.89e-53	-0.73	-0.64	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-18.26	1.09e-56	5.89e-53	-0.73	-0.64	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
THCA	cis	rs7174755	0.884	rs11634026	ENSG00000260657.2	RP11-315D16.4	18.26	1.09e-56	5.9e-53	0.85	0.64	Major depressive disorder;	chr15:68305668	chr15:68267792~68277994:-
THCA	cis	rs1153858	1	rs12593370	ENSG00000259520.4	CTD-2651B20.3	-18.26	1.13e-56	6.09e-53	-0.82	-0.64	Homoarginine levels;	chr15:45325219	chr15:45251580~45279251:-
THCA	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-18.25	1.24e-56	6.7e-53	-0.74	-0.64	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	18.24	1.33e-56	7.16e-53	0.79	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
THCA	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	18.24	1.34e-56	7.22e-53	0.75	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
THCA	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-18.24	1.37e-56	7.39e-53	-0.73	-0.64	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
THCA	cis	rs71335811	1	rs71335811	ENSG00000232871.7	SEC1P	-18.23	1.56e-56	8.43e-53	-0.78	-0.64	Myeloid white cell count;	chr19:48626814	chr19:48638071~48682245:+
THCA	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-18.22	1.61e-56	8.71e-53	-0.82	-0.64	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
THCA	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	18.22	1.63e-56	8.8e-53	1.23	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
THCA	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-18.22	1.68e-56	9.05e-53	-0.73	-0.64	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-18.22	1.68e-56	9.05e-53	-0.73	-0.64	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-18.22	1.68e-56	9.05e-53	-0.73	-0.64	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-18.22	1.68e-56	9.05e-53	-0.73	-0.64	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-18.22	1.69e-56	9.07e-53	-0.74	-0.64	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-18.22	1.72e-56	9.24e-53	-0.77	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
THCA	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-18.22	1.72e-56	9.25e-53	-0.74	-0.64	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-18.22	1.72e-56	9.25e-53	-0.74	-0.64	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-18.22	1.72e-56	9.25e-53	-0.74	-0.64	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-18.22	1.72e-56	9.25e-53	-0.74	-0.64	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-18.22	1.72e-56	9.25e-53	-0.74	-0.64	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-18.22	1.73e-56	9.29e-53	-0.73	-0.64	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
THCA	cis	rs7208859	0.673	rs9915139	ENSG00000263531.1	RP13-753N3.1	18.22	1.74e-56	9.34e-53	1.21	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30863921~30864940:-
THCA	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	18.22	1.76e-56	9.43e-53	1.05	0.64	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
THCA	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-18.21	1.87e-56	1e-52	-0.73	-0.64	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	18.21	1.88e-56	1.01e-52	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
THCA	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-18.21	1.93e-56	1.04e-52	-0.73	-0.64	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
THCA	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	18.21	1.93e-56	1.04e-52	0.81	0.64	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
THCA	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-18.21	1.96e-56	1.05e-52	-0.73	-0.64	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
THCA	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-18.2	1.98e-56	1.06e-52	-0.85	-0.64	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
THCA	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-18.2	1.99e-56	1.07e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
THCA	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-18.2	1.99e-56	1.07e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-18.2	2.06e-56	1.1e-52	-0.73	-0.64	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-18.2	2.09e-56	1.12e-52	-0.73	-0.64	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-18.2	2.09e-56	1.12e-52	-0.73	-0.64	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
THCA	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	18.2	2.12e-56	1.13e-52	1.22	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	18.2	2.12e-56	1.13e-52	1.22	0.64	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	18.2	2.12e-56	1.13e-52	1.22	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	18.2	2.12e-56	1.13e-52	1.22	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
THCA	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	18.19	2.23e-56	1.19e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	18.19	2.23e-56	1.19e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	18.19	2.23e-56	1.19e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	18.19	2.23e-56	1.19e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	18.19	2.25e-56	1.2e-52	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	18.19	2.25e-56	1.2e-52	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	18.19	2.37e-56	1.26e-52	0.86	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
THCA	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	18.18	2.44e-56	1.31e-52	0.78	0.64	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
THCA	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-18.18	2.53e-56	1.35e-52	-0.74	-0.64	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-18.18	2.53e-56	1.35e-52	-0.74	-0.64	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
THCA	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-18.18	2.54e-56	1.36e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
THCA	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-18.18	2.54e-56	1.36e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
THCA	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	18.18	2.65e-56	1.41e-52	1.07	0.64	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
THCA	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	18.18	2.69e-56	1.44e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	18.18	2.69e-56	1.44e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	18.18	2.69e-56	1.44e-52	0.81	0.64	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
THCA	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-18.18	2.7e-56	1.44e-52	-0.74	-0.64	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
THCA	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	18.17	2.73e-56	1.45e-52	1.06	0.64	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
THCA	cis	rs1153858	1	rs1980288	ENSG00000259520.4	CTD-2651B20.3	-18.17	2.9e-56	1.54e-52	-0.82	-0.64	Homoarginine levels;	chr15:45328414	chr15:45251580~45279251:-
THCA	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-18.17	2.92e-56	1.56e-52	-0.82	-0.64	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
THCA	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-18.16	3.01e-56	1.6e-52	-0.82	-0.64	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.633	rs240068	ENSG00000224086.5	LL22NC03-86G7.1	-18.16	3.16e-56	1.68e-52	-0.75	-0.64	Multiple sclerosis;	chr22:21936031	chr22:21938293~21977632:+
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	18.15	3.35e-56	1.78e-52	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	18.15	3.35e-56	1.78e-52	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
THCA	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-18.15	3.36e-56	1.78e-52	-0.82	-0.64	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	18.14	4.01e-56	2.13e-52	0.82	0.64	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.638	rs7644414	ENSG00000229759.1	MRPS18AP1	18.14	4.03e-56	2.14e-52	0.78	0.64	Coronary artery disease;	chr3:48257589	chr3:48256350~48256938:-
THCA	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-18.13	4.17e-56	2.22e-52	-0.74	-0.64	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
THCA	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	18.13	4.22e-56	2.24e-52	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
THCA	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-18.13	4.27e-56	2.27e-52	-0.73	-0.64	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
THCA	cis	rs7188445	0.932	rs17689455	ENSG00000261390.4	RP11-345M22.2	-18.13	4.28e-56	2.27e-52	-0.77	-0.64	Urate levels;	chr16:79712438	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs73575083	ENSG00000261390.4	RP11-345M22.2	-18.13	4.28e-56	2.27e-52	-0.77	-0.64	Urate levels;	chr16:79713958	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs73575085	ENSG00000261390.4	RP11-345M22.2	-18.13	4.28e-56	2.27e-52	-0.77	-0.64	Urate levels;	chr16:79714179	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs73575086	ENSG00000261390.4	RP11-345M22.2	-18.13	4.28e-56	2.27e-52	-0.77	-0.64	Urate levels;	chr16:79714588	chr16:79715232~79770563:-
THCA	cis	rs7617773	0.962	rs6797587	ENSG00000229759.1	MRPS18AP1	-18.13	4.28e-56	2.27e-52	-0.76	-0.64	Coronary artery disease;	chr3:48156124	chr3:48256350~48256938:-
THCA	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	18.13	4.39e-56	2.33e-52	1.05	0.64	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
THCA	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-18.13	4.4e-56	2.33e-52	-0.74	-0.64	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-18.13	4.4e-56	2.33e-52	-0.74	-0.64	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-18.13	4.4e-56	2.33e-52	-0.74	-0.64	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-18.13	4.4e-56	2.33e-52	-0.74	-0.64	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
THCA	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	18.13	4.41e-56	2.34e-52	0.85	0.64	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
THCA	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	18.13	4.46e-56	2.36e-52	0.82	0.64	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
THCA	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-18.13	4.53e-56	2.4e-52	-0.73	-0.64	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
THCA	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-18.12	4.72e-56	2.5e-52	-0.74	-0.64	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
THCA	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	18.12	4.8e-56	2.54e-52	1.15	0.64	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	18.12	4.86e-56	2.57e-52	0.82	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
THCA	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-18.12	4.87e-56	2.57e-52	-0.73	-0.64	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-18.12	4.87e-56	2.57e-52	-0.73	-0.64	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-18.12	4.87e-56	2.57e-52	-0.73	-0.64	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
THCA	cis	rs55720021	1	rs55720021	ENSG00000232871.7	SEC1P	18.12	4.89e-56	2.58e-52	0.79	0.64	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;	chr19:48640984	chr19:48638071~48682245:+
THCA	cis	rs7174755	0.923	rs4777033	ENSG00000260657.2	RP11-315D16.4	-18.12	5.08e-56	2.68e-52	-0.81	-0.64	Major depressive disorder;	chr15:68308010	chr15:68267792~68277994:-
THCA	cis	rs9595066	0.564	rs12869383	ENSG00000227258.4	SMIM2-AS1	-18.11	5.18e-56	2.73e-52	-0.71	-0.64	Schizophrenia;	chr13:44131305	chr13:44110451~44240517:+
THCA	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	18.11	5.27e-56	2.78e-52	0.78	0.64	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
THCA	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	18.11	5.27e-56	2.78e-52	0.84	0.64	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
THCA	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-18.11	5.36e-56	2.83e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	18.11	5.42e-56	2.86e-52	0.78	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
THCA	cis	rs7174755	0.962	rs1020842	ENSG00000260657.2	RP11-315D16.4	-18.11	5.51e-56	2.91e-52	-0.8	-0.64	Major depressive disorder;	chr15:68309840	chr15:68267792~68277994:-
THCA	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-18.1	5.79e-56	3.04e-52	-0.73	-0.64	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
THCA	cis	rs17023223	0.581	rs12064109	ENSG00000231365.4	RP11-418J17.1	-18.1	6.01e-56	3.16e-52	-0.75	-0.64	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119099673	chr1:119140396~119275973:+
THCA	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	18.1	6.22e-56	3.27e-52	0.78	0.64	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
THCA	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-18.09	6.38e-56	3.35e-52	-0.73	-0.64	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
THCA	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	18.09	6.41e-56	3.36e-52	0.69	0.64	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
THCA	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-18.09	6.57e-56	3.45e-52	-0.82	-0.64	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
THCA	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-18.09	6.8e-56	3.57e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
THCA	cis	rs1153858	1	rs12909158	ENSG00000259520.4	CTD-2651B20.3	-18.08	7.38e-56	3.87e-52	-0.81	-0.64	Homoarginine levels;	chr15:45328976	chr15:45251580~45279251:-
THCA	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-18.08	7.4e-56	3.88e-52	-0.73	-0.64	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-18.08	7.72e-56	4.04e-52	-0.74	-0.64	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-18.08	7.72e-56	4.04e-52	-0.74	-0.64	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
THCA	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-18.08	7.72e-56	4.04e-52	-0.74	-0.64	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-18.08	7.72e-56	4.04e-52	-0.74	-0.64	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-18.08	7.72e-56	4.04e-52	-0.74	-0.64	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-18.08	7.72e-56	4.04e-52	-0.74	-0.64	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-18.08	7.75e-56	4.05e-52	-0.74	-0.64	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
THCA	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-18.08	7.83e-56	4.1e-52	-0.71	-0.64	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
THCA	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-18.07	8.02e-56	4.19e-52	-0.74	-0.64	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
THCA	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	18.07	8.16e-56	4.27e-52	1.03	0.64	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
THCA	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-18.07	8.27e-56	4.32e-52	-0.71	-0.64	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
THCA	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-18.07	8.45e-56	4.42e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
THCA	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-18.07	8.45e-56	4.42e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
THCA	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	18.07	8.45e-56	4.42e-52	0.82	0.64	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.622	rs2266979	ENSG00000224086.5	LL22NC03-86G7.1	-18.07	8.74e-56	4.57e-52	-0.73	-0.64	Multiple sclerosis;	chr22:21977447	chr22:21938293~21977632:+
THCA	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-18.06	8.88e-56	4.64e-52	-0.74	-0.64	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-18.06	8.88e-56	4.64e-52	-0.74	-0.64	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-18.06	8.94e-56	4.66e-52	-0.73	-0.64	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
THCA	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-18.06	9.36e-56	4.89e-52	-0.83	-0.64	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-18.06	9.37e-56	4.89e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-18.06	9.42e-56	4.91e-52	-0.73	-0.64	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
THCA	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	18.06	9.67e-56	5.04e-52	0.94	0.64	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
THCA	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-18.05	9.78e-56	5.1e-52	-0.74	-0.64	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-18.05	9.83e-56	5.12e-52	-0.73	-0.64	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-18.05	9.83e-56	5.12e-52	-0.73	-0.64	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
THCA	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-18.05	1.02e-55	5.31e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-18.05	1.02e-55	5.31e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
THCA	cis	rs7174755	0.962	rs4777034	ENSG00000260657.2	RP11-315D16.4	-18.05	1.04e-55	5.43e-52	-0.8	-0.64	Major depressive disorder;	chr15:68309546	chr15:68267792~68277994:-
THCA	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-18.05	1.06e-55	5.52e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
THCA	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-18.05	1.06e-55	5.52e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-18.05	1.06e-55	5.52e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-18.05	1.06e-55	5.52e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
THCA	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	18.04	1.12e-55	5.8e-52	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
THCA	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	18.04	1.17e-55	6.08e-52	0.8	0.64	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
THCA	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-18.04	1.17e-55	6.08e-52	-0.73	-0.64	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-18.04	1.2e-55	6.22e-52	-0.73	-0.64	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
THCA	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-18.03	1.21e-55	6.28e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
THCA	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-18.03	1.24e-55	6.44e-52	-0.83	-0.64	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-18.03	1.27e-55	6.56e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
THCA	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-18.03	1.27e-55	6.6e-52	-0.84	-0.64	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-18.03	1.28e-55	6.61e-52	-0.74	-0.64	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
THCA	cis	rs7188445	0.836	rs3813580	ENSG00000261390.4	RP11-345M22.2	-18.03	1.3e-55	6.71e-52	-0.77	-0.64	Urate levels;	chr16:79715383	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs73575079	ENSG00000261390.4	RP11-345M22.2	-18.03	1.32e-55	6.83e-52	-0.77	-0.64	Urate levels;	chr16:79711344	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs7203756	ENSG00000261390.4	RP11-345M22.2	18.03	1.32e-55	6.83e-52	0.77	0.64	Urate levels;	chr16:79711709	chr16:79715232~79770563:-
THCA	cis	rs2283792	0.622	rs381523	ENSG00000224086.5	LL22NC03-86G7.1	-18.02	1.37e-55	7.1e-52	-0.73	-0.64	Multiple sclerosis;	chr22:21951257	chr22:21938293~21977632:+
THCA	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	18.02	1.43e-55	7.38e-52	1.06	0.64	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
THCA	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	18.02	1.43e-55	7.38e-52	1.06	0.64	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
THCA	cis	rs2283792	0.622	rs239917	ENSG00000224086.5	LL22NC03-86G7.1	-18.02	1.43e-55	7.41e-52	-0.74	-0.64	Multiple sclerosis;	chr22:21960091	chr22:21938293~21977632:+
THCA	cis	rs1153858	1	rs4775895	ENSG00000259520.4	CTD-2651B20.3	-18.02	1.44e-55	7.43e-52	-0.82	-0.64	Homoarginine levels;	chr15:45325759	chr15:45251580~45279251:-
THCA	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-18.02	1.45e-55	7.51e-52	-0.73	-0.64	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
THCA	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-18.01	1.52e-55	7.84e-52	-0.81	-0.64	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-18.01	1.58e-55	8.15e-52	-0.73	-0.64	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
THCA	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	18.01	1.62e-55	8.38e-52	0.83	0.64	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
THCA	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	18	1.69e-55	8.71e-52	0.81	0.64	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
THCA	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-17.99	1.99e-55	1.02e-51	-0.82	-0.64	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	17.99	1.99e-55	1.02e-51	0.82	0.64	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	17.99	1.99e-55	1.02e-51	0.82	0.64	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	17.99	1.99e-55	1.02e-51	0.82	0.64	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	17.99	1.99e-55	1.02e-51	0.82	0.64	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-17.98	2.12e-55	1.08e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
THCA	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-17.98	2.12e-55	1.08e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
THCA	cis	rs7188445	0.932	rs4575545	ENSG00000261390.4	RP11-345M22.2	-17.98	2.18e-55	1.12e-51	-0.79	-0.64	Urate levels;	chr16:79721549	chr16:79715232~79770563:-
THCA	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-17.98	2.24e-55	1.15e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
THCA	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	17.98	2.25e-55	1.15e-51	1.04	0.64	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
THCA	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	17.98	2.27e-55	1.16e-51	0.83	0.64	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.932	rs17689159	ENSG00000261390.4	RP11-345M22.2	-17.98	2.27e-55	1.16e-51	-0.77	-0.64	Urate levels;	chr16:79708493	chr16:79715232~79770563:-
THCA	cis	rs950027	0.62	rs1617984	ENSG00000259520.4	CTD-2651B20.3	-17.97	2.38e-55	1.22e-51	-0.75	-0.64	Response to fenofibrate (adiponectin levels);	chr15:45330464	chr15:45251580~45279251:-
THCA	cis	rs7188445	0.932	rs17767419	ENSG00000261390.4	RP11-345M22.2	-17.97	2.52e-55	1.29e-51	-0.77	-0.64	Urate levels;	chr16:79710651	chr16:79715232~79770563:-
THCA	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	17.96	2.72e-55	1.39e-51	0.81	0.64	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
THCA	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-17.95	2.85e-55	1.46e-51	-0.81	-0.64	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
THCA	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	17.95	2.9e-55	1.48e-51	0.67	0.64	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
THCA	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-17.95	2.91e-55	1.49e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-17.95	2.95e-55	1.5e-51	-0.73	-0.64	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	17.95	2.96e-55	1.51e-51	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
THCA	cis	rs7617773	1	rs7617773	ENSG00000229759.1	MRPS18AP1	-17.95	2.99e-55	1.52e-51	-0.76	-0.64	Coronary artery disease;	chr3:48152025	chr3:48256350~48256938:-
THCA	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-17.95	3.03e-55	1.55e-51	-0.67	-0.64	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
THCA	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	17.95	3.12e-55	1.59e-51	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
THCA	cis	rs7188445	0.932	rs17767491	ENSG00000261390.4	RP11-345M22.2	-17.95	3.14e-55	1.6e-51	-0.77	-0.64	Urate levels;	chr16:79711590	chr16:79715232~79770563:-
THCA	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	17.94	3.26e-55	1.66e-51	0.85	0.64	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
THCA	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	17.94	3.26e-55	1.66e-51	0.85	0.64	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
THCA	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	17.94	3.26e-55	1.66e-51	0.85	0.64	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
THCA	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	17.94	3.26e-55	1.66e-51	0.85	0.64	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
THCA	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	17.94	3.26e-55	1.66e-51	0.85	0.64	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	17.94	3.45e-55	1.75e-51	0.77	0.64	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
THCA	cis	rs17023223	0.553	rs72691108	ENSG00000231365.4	RP11-418J17.1	-17.93	3.52e-55	1.79e-51	-0.75	-0.64	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119219552	chr1:119140396~119275973:+
THCA	cis	rs9481169	0.557	rs33980500	ENSG00000255389.1	C6orf3	-17.93	3.88e-55	1.97e-51	-1.05	-0.64	Inflammatory skin disease;	chr6:111592059	chr6:111599875~111602295:+
THCA	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-17.92	4.04e-55	2.05e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-17.92	4.04e-55	2.05e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
THCA	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-17.92	4.23e-55	2.14e-51	-0.82	-0.64	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-17.92	4.23e-55	2.14e-51	-0.82	-0.64	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-17.92	4.23e-55	2.14e-51	-0.82	-0.64	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-17.92	4.23e-55	2.14e-51	-0.82	-0.64	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-17.92	4.25e-55	2.15e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-17.92	4.25e-55	2.15e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	17.91	4.39e-55	2.22e-51	0.74	0.64	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
THCA	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-17.91	4.46e-55	2.25e-51	-0.73	-0.64	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
THCA	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-17.91	4.47e-55	2.26e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-17.91	4.65e-55	2.35e-51	-0.73	-0.64	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-17.91	4.65e-55	2.35e-51	-0.73	-0.64	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
THCA	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-17.91	4.72e-55	2.38e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-17.9	4.84e-55	2.44e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	17.9	4.84e-55	2.44e-51	0.8	0.64	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
THCA	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	17.9	4.9e-55	2.47e-51	0.81	0.64	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
THCA	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	17.9	4.96e-55	2.5e-51	0.8	0.64	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	17.9	5.01e-55	2.53e-51	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
THCA	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	17.9	5.16e-55	2.6e-51	0.77	0.64	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
THCA	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-17.9	5.2e-55	2.62e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
THCA	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	17.9	5.21e-55	2.62e-51	0.82	0.64	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	17.9	5.21e-55	2.62e-51	0.82	0.64	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.932	rs17767742	ENSG00000261390.4	RP11-345M22.2	-17.9	5.26e-55	2.65e-51	-0.77	-0.64	Urate levels;	chr16:79715108	chr16:79715232~79770563:-
THCA	cis	rs7617773	0.823	rs9839446	ENSG00000229759.1	MRPS18AP1	-17.89	5.52e-55	2.78e-51	-0.75	-0.64	Coronary artery disease;	chr3:48153176	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.823	rs9839447	ENSG00000229759.1	MRPS18AP1	-17.89	5.52e-55	2.78e-51	-0.75	-0.64	Coronary artery disease;	chr3:48153177	chr3:48256350~48256938:-
THCA	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	17.89	5.6e-55	2.81e-51	1.04	0.64	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
THCA	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	17.89	5.73e-55	2.88e-51	0.84	0.64	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
THCA	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-17.89	5.85e-55	2.94e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
THCA	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
THCA	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-17.89	5.89e-55	2.95e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
THCA	cis	rs7188445	0.932	rs17767904	ENSG00000261390.4	RP11-345M22.2	-17.88	6.07e-55	3.04e-51	-0.77	-0.64	Urate levels;	chr16:79716078	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs73575095	ENSG00000261390.4	RP11-345M22.2	-17.88	6.07e-55	3.04e-51	-0.77	-0.64	Urate levels;	chr16:79716435	chr16:79715232~79770563:-
THCA	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-17.88	6.24e-55	3.13e-51	-0.73	-0.64	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
THCA	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-17.88	6.31e-55	3.16e-51	-0.73	-0.64	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
THCA	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-17.88	6.36e-55	3.18e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-17.88	6.36e-55	3.18e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.963	rs6771787	ENSG00000229759.1	MRPS18AP1	-17.88	6.39e-55	3.2e-51	-0.75	-0.64	Coronary artery disease;	chr3:48152752	chr3:48256350~48256938:-
THCA	cis	rs7617773	1	rs6771889	ENSG00000229759.1	MRPS18AP1	-17.88	6.39e-55	3.2e-51	-0.75	-0.64	Coronary artery disease;	chr3:48152836	chr3:48256350~48256938:-
THCA	cis	rs507080	0.733	rs497678	ENSG00000255239.1	AP002954.6	17.88	6.39e-55	3.2e-51	0.87	0.64	Serum metabolite levels;	chr11:118697172	chr11:118688039~118690600:-
THCA	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	17.88	6.48e-55	3.24e-51	0.84	0.64	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
THCA	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-17.88	6.53e-55	3.27e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
THCA	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-17.88	6.53e-55	3.27e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-17.88	6.54e-55	3.27e-51	-0.72	-0.64	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
THCA	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	17.88	6.56e-55	3.28e-51	0.82	0.64	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	17.88	6.56e-55	3.28e-51	0.82	0.64	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
THCA	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-17.87	6.67e-55	3.33e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	17.87	6.75e-55	3.37e-51	0.77	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
THCA	cis	rs7174755	0.923	rs898590	ENSG00000260657.2	RP11-315D16.4	-17.87	6.78e-55	3.39e-51	-0.8	-0.64	Major depressive disorder;	chr15:68311837	chr15:68267792~68277994:-
THCA	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-17.87	6.93e-55	3.45e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
THCA	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-17.87	7.15e-55	3.55e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
THCA	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-17.87	7.18e-55	3.57e-51	-0.82	-0.64	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
THCA	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-17.87	7.18e-55	3.57e-51	-0.82	-0.64	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
THCA	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	17.87	7.34e-55	3.64e-51	1.22	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	17.87	7.34e-55	3.64e-51	1.22	0.64	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
THCA	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-17.86	7.42e-55	3.69e-51	-0.82	-0.64	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-17.86	7.42e-55	3.69e-51	-0.82	-0.64	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
THCA	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	17.86	7.55e-55	3.75e-51	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
THCA	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-17.86	7.71e-55	3.82e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-17.86	7.71e-55	3.82e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-17.86	7.71e-55	3.82e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-17.86	7.71e-55	3.82e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	17.86	7.82e-55	3.88e-51	0.84	0.64	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
THCA	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-17.85	8.36e-55	4.15e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-17.85	8.36e-55	4.15e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	17.85	8.42e-55	4.17e-51	0.84	0.64	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	17.85	8.42e-55	4.17e-51	0.84	0.64	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	17.85	8.42e-55	4.17e-51	0.84	0.64	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	17.85	8.42e-55	4.17e-51	0.84	0.64	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
THCA	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-17.85	8.47e-55	4.19e-51	-0.81	-0.64	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
THCA	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-17.85	8.59e-55	4.25e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
THCA	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-17.85	8.62e-55	4.27e-51	-0.8	-0.64	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
THCA	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	17.85	8.67e-55	4.29e-51	1.06	0.64	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
THCA	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-17.85	8.78e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-17.85	8.78e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-17.85	8.78e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	17.85	8.78e-55	4.34e-51	0.8	0.64	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-17.85	8.79e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-17.85	8.79e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-17.85	8.79e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-17.85	8.79e-55	4.34e-51	-0.8	-0.64	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-17.85	8.81e-55	4.35e-51	-0.8	-0.64	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-17.85	8.81e-55	4.35e-51	-0.8	-0.64	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-17.85	8.81e-55	4.35e-51	-0.8	-0.64	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
THCA	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	17.85	9.05e-55	4.46e-51	1.05	0.64	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
THCA	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	17.84	9.37e-55	4.61e-51	0.84	0.64	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	17.84	9.37e-55	4.61e-51	0.84	0.64	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	17.84	9.37e-55	4.61e-51	0.84	0.64	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	17.84	9.39e-55	4.62e-51	0.75	0.64	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	17.84	9.51e-55	4.68e-51	0.84	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
THCA	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-17.84	9.69e-55	4.76e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-17.84	1e-54	4.91e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
THCA	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-17.83	1.04e-54	5.11e-51	-0.8	-0.64	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-17.83	1.04e-54	5.11e-51	-0.8	-0.64	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-17.83	1.04e-54	5.11e-51	-0.8	-0.64	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
THCA	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-17.83	1.04e-54	5.11e-51	-0.8	-0.64	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
THCA	cis	rs7617773	1	rs6442108	ENSG00000229759.1	MRPS18AP1	-17.83	1.06e-54	5.2e-51	-0.75	-0.64	Coronary artery disease;	chr3:48151469	chr3:48256350~48256938:-
THCA	cis	rs7617773	1	rs6442109	ENSG00000229759.1	MRPS18AP1	-17.83	1.06e-54	5.2e-51	-0.75	-0.64	Coronary artery disease;	chr3:48151491	chr3:48256350~48256938:-
THCA	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	17.83	1.07e-54	5.25e-51	0.83	0.64	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-17.83	1.07e-54	5.25e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-17.83	1.08e-54	5.27e-51	-0.81	-0.64	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-17.83	1.09e-54	5.33e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-17.83	1.09e-54	5.33e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-17.83	1.09e-54	5.33e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
THCA	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-17.83	1.11e-54	5.4e-51	-0.81	-0.64	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-17.83	1.11e-54	5.4e-51	-0.81	-0.64	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
THCA	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-17.83	1.11e-54	5.4e-51	-0.81	-0.64	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
THCA	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	17.83	1.11e-54	5.4e-51	0.81	0.64	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
THCA	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	17.82	1.15e-54	5.62e-51	0.8	0.64	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
THCA	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-17.82	1.16e-54	5.67e-51	-0.8	-0.64	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
THCA	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-17.82	1.22e-54	5.94e-51	-0.81	-0.63	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-17.82	1.22e-54	5.94e-51	-0.81	-0.63	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
THCA	cis	rs7617773	1	rs11711766	ENSG00000229759.1	MRPS18AP1	-17.82	1.22e-54	5.94e-51	-0.75	-0.63	Coronary artery disease;	chr3:48151680	chr3:48256350~48256938:-
THCA	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-17.82	1.22e-54	5.95e-51	-0.81	-0.63	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-17.82	1.22e-54	5.95e-51	-0.81	-0.63	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
THCA	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	17.82	1.26e-54	6.13e-51	0.84	0.63	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.932	rs17689625	ENSG00000261390.4	RP11-345M22.2	-17.81	1.32e-54	6.42e-51	-0.76	-0.63	Urate levels;	chr16:79715065	chr16:79715232~79770563:-
THCA	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-17.81	1.33e-54	6.48e-51	-0.82	-0.63	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	17.81	1.35e-54	6.58e-51	0.81	0.63	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
THCA	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-17.81	1.38e-54	6.73e-51	-0.75	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
THCA	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-17.8	1.51e-54	7.34e-51	-0.81	-0.63	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
THCA	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	17.8	1.53e-54	7.43e-51	0.82	0.63	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
THCA	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	17.8	1.56e-54	7.6e-51	0.81	0.63	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
THCA	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	17.79	1.57e-54	7.64e-51	1.05	0.63	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
THCA	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	17.79	1.71e-54	8.3e-51	0.82	0.63	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
THCA	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-17.79	1.73e-54	8.37e-51	-0.83	-0.63	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-17.78	1.79e-54	8.69e-51	-0.8	-0.63	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	17.78	1.81e-54	8.78e-51	0.74	0.63	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
THCA	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-17.78	1.83e-54	8.85e-51	-0.85	-0.63	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
THCA	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-17.77	1.97e-54	9.53e-51	-0.83	-0.63	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
THCA	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-17.77	2.11e-54	1.02e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	17.77	2.15e-54	1.04e-50	0.82	0.63	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
THCA	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	17.76	2.21e-54	1.07e-50	1.11	0.63	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
THCA	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	17.76	2.23e-54	1.08e-50	0.8	0.63	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
THCA	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-17.76	2.28e-54	1.1e-50	-0.81	-0.63	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
THCA	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-17.76	2.28e-54	1.1e-50	-0.81	-0.63	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
THCA	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-17.76	2.28e-54	1.1e-50	-0.81	-0.63	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
THCA	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-17.76	2.28e-54	1.1e-50	-0.81	-0.63	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs2467862	ENSG00000259520.4	CTD-2651B20.3	-17.76	2.34e-54	1.13e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45351645	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1145084	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.41e-54	1.16e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45383242	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1145093	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.43e-54	1.17e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45357615	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1049518	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.43e-54	1.17e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45361169	chr15:45251580~45279251:-
THCA	cis	rs950027	0.584	rs1145086	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.43e-54	1.17e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45362129	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1153857	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.43e-54	1.17e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45366897	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1153855	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.43e-54	1.17e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45368560	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1145080	ENSG00000259520.4	CTD-2651B20.3	-17.75	2.43e-54	1.17e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45389140	chr15:45251580~45279251:-
THCA	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-17.75	2.44e-54	1.18e-50	-0.74	-0.63	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
THCA	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-17.75	2.54e-54	1.23e-50	-0.73	-0.63	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
THCA	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	17.75	2.55e-54	1.23e-50	0.81	0.63	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
THCA	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-17.74	2.69e-54	1.29e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
THCA	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	17.73	3.06e-54	1.47e-50	0.81	0.63	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
THCA	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-17.73	3.06e-54	1.47e-50	-0.85	-0.63	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-17.73	3.09e-54	1.49e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-17.73	3.26e-54	1.56e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
THCA	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	17.72	3.43e-54	1.65e-50	0.68	0.63	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
THCA	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-17.72	3.64e-54	1.75e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
THCA	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-17.71	3.69e-54	1.77e-50	-0.78	-0.63	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
THCA	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	17.71	3.71e-54	1.78e-50	0.67	0.63	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
THCA	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-17.71	3.81e-54	1.83e-50	-0.75	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
THCA	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	17.71	3.84e-54	1.84e-50	0.68	0.63	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
THCA	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	17.71	3.87e-54	1.86e-50	0.82	0.63	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
THCA	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	17.71	3.87e-54	1.86e-50	0.82	0.63	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	17.71	3.87e-54	1.86e-50	0.82	0.63	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
THCA	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
THCA	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	17.71	4.07e-54	1.95e-50	0.82	0.63	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-17.71	4.07e-54	1.95e-50	-0.82	-0.63	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
THCA	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	17.7	4.27e-54	2.04e-50	0.82	0.63	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.899	rs17689024	ENSG00000261390.4	RP11-345M22.2	-17.69	4.83e-54	2.31e-50	-0.77	-0.63	Urate levels;	chr16:79706081	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.932	rs56738967	ENSG00000261390.4	RP11-345M22.2	-17.69	4.83e-54	2.31e-50	-0.77	-0.63	Urate levels;	chr16:79706644	chr16:79715232~79770563:-
THCA	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-17.69	4.89e-54	2.34e-50	-0.83	-0.63	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-17.69	4.9e-54	2.34e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
THCA	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-17.69	4.9e-54	2.34e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
THCA	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-17.68	5.06e-54	2.41e-50	-0.81	-0.63	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs1719246	ENSG00000259520.4	CTD-2651B20.3	-17.68	5.23e-54	2.49e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45333281	chr15:45251580~45279251:-
THCA	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	17.68	5.38e-54	2.57e-50	0.73	0.63	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
THCA	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-17.68	5.46e-54	2.6e-50	-0.84	-0.63	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
THCA	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	17.67	5.89e-54	2.8e-50	0.84	0.63	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
THCA	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-17.67	5.95e-54	2.83e-50	-0.82	-0.63	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
THCA	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-17.67	6.25e-54	2.97e-50	-0.84	-0.63	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
THCA	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	17.66	6.4e-54	3.04e-50	0.78	0.63	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
THCA	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	17.66	6.45e-54	3.06e-50	0.82	0.63	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
THCA	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-17.66	6.54e-54	3.1e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	17.65	7.19e-54	3.41e-50	0.74	0.63	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
THCA	cis	rs17023223	0.537	rs3936018	ENSG00000231365.4	RP11-418J17.1	-17.65	7.63e-54	3.62e-50	-0.75	-0.63	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119139747	chr1:119140396~119275973:+
THCA	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	17.64	7.95e-54	3.76e-50	0.82	0.63	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	17.64	7.95e-54	3.76e-50	0.82	0.63	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
THCA	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	17.64	7.95e-54	3.76e-50	0.82	0.63	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	17.64	7.95e-54	3.76e-50	0.82	0.63	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	17.64	7.95e-54	3.76e-50	0.82	0.63	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
THCA	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	17.64	8.27e-54	3.91e-50	0.81	0.63	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
THCA	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-17.64	8.32e-54	3.93e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-17.63	8.96e-54	4.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
THCA	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-17.63	8.96e-54	4.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
THCA	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-17.63	8.96e-54	4.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
THCA	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-17.63	8.96e-54	4.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
THCA	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-17.63	9.13e-54	4.31e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
THCA	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-17.63	9.36e-54	4.41e-50	-0.81	-0.63	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
THCA	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-17.63	9.48e-54	4.46e-50	-0.82	-0.63	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.932	rs73575076	ENSG00000261390.4	RP11-345M22.2	-17.62	9.58e-54	4.51e-50	-0.77	-0.63	Urate levels;	chr16:79710251	chr16:79715232~79770563:-
THCA	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-17.62	1.06e-53	4.97e-50	-0.73	-0.63	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
THCA	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	17.61	1.17e-53	5.5e-50	0.79	0.63	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
THCA	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-17.6	1.2e-53	5.63e-50	-0.74	-0.63	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
THCA	cis	rs950027	0.62	rs2486274	ENSG00000259520.4	CTD-2651B20.3	-17.6	1.23e-53	5.77e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45374030	chr15:45251580~45279251:-
THCA	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-17.6	1.27e-53	5.95e-50	-0.82	-0.63	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
THCA	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-17.6	1.27e-53	5.96e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-17.6	1.27e-53	5.96e-50	-0.74	-0.63	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
THCA	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-17.59	1.39e-53	6.51e-50	-1	-0.63	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-17.59	1.39e-53	6.52e-50	-0.82	-0.63	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
THCA	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-17.59	1.44e-53	6.74e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-17.59	1.45e-53	6.76e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-17.59	1.46e-53	6.84e-50	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
THCA	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-17.58	1.49e-53	6.98e-50	-0.82	-0.63	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
THCA	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	17.58	1.54e-53	7.18e-50	0.79	0.63	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
THCA	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-17.58	1.55e-53	7.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-17.58	1.55e-53	7.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-17.58	1.55e-53	7.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-17.58	1.55e-53	7.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-17.58	1.55e-53	7.23e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
THCA	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	17.58	1.55e-53	7.25e-50	0.81	0.63	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
THCA	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-17.58	1.56e-53	7.3e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
THCA	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-17.58	1.56e-53	7.3e-50	-0.8	-0.63	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
THCA	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-17.58	1.57e-53	7.34e-50	-0.85	-0.63	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
THCA	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-17.56	1.84e-53	8.54e-50	-0.82	-0.63	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
THCA	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	17.56	1.84e-53	8.56e-50	0.67	0.63	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
THCA	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	17.56	1.98e-53	9.2e-50	0.8	0.63	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
THCA	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	17.55	2.17e-53	1.01e-49	0.8	0.63	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
THCA	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	17.55	2.2e-53	1.02e-49	0.82	0.63	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
THCA	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	17.54	2.27e-53	1.05e-49	0.8	0.63	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
THCA	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-17.54	2.29e-53	1.06e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-17.54	2.38e-53	1.1e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-17.54	2.38e-53	1.1e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-17.54	2.38e-53	1.1e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
THCA	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	17.54	2.48e-53	1.15e-49	0.78	0.63	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
THCA	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-17.53	2.51e-53	1.16e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
THCA	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-17.53	2.55e-53	1.18e-49	-0.84	-0.63	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
THCA	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	17.53	2.58e-53	1.19e-49	0.79	0.63	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
THCA	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-17.53	2.76e-53	1.27e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
THCA	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-17.53	2.76e-53	1.27e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
THCA	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-17.53	2.76e-53	1.27e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	17.52	2.84e-53	1.31e-49	0.81	0.63	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
THCA	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	17.52	2.84e-53	1.31e-49	0.81	0.63	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
THCA	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	17.52	2.84e-53	1.31e-49	0.81	0.63	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	17.52	2.84e-53	1.31e-49	0.81	0.63	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
THCA	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	17.52	2.84e-53	1.31e-49	0.81	0.63	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
THCA	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	17.52	2.91e-53	1.34e-49	0.67	0.63	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
THCA	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	17.52	2.91e-53	1.34e-49	0.67	0.63	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
THCA	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-17.51	3.12e-53	1.43e-49	-0.74	-0.63	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	17.51	3.19e-53	1.46e-49	1.18	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
THCA	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-17.51	3.22e-53	1.48e-49	-0.72	-0.63	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
THCA	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-17.51	3.3e-53	1.52e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
THCA	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-17.51	3.32e-53	1.52e-49	-0.7	-0.63	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
THCA	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	17.51	3.38e-53	1.55e-49	0.79	0.63	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
THCA	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	17.51	3.4e-53	1.56e-49	0.79	0.63	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
THCA	cis	rs7174755	0.923	rs4777036	ENSG00000260657.2	RP11-315D16.4	-17.49	4.12e-53	1.89e-49	-0.79	-0.63	Major depressive disorder;	chr15:68313230	chr15:68267792~68277994:-
THCA	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-17.49	4.21e-53	1.93e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
THCA	cis	rs7188445	0.932	rs3813582	ENSG00000261390.4	RP11-345M22.2	-17.48	4.3e-53	1.97e-49	-0.76	-0.63	Urate levels;	chr16:79715456	chr16:79715232~79770563:-
THCA	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-17.48	4.32e-53	1.98e-49	-0.8	-0.63	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
THCA	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	17.48	4.33e-53	1.98e-49	0.72	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
THCA	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	17.48	4.47e-53	2.04e-49	0.71	0.63	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
THCA	cis	rs977987	1	rs977987	ENSG00000261783.1	RP11-252K23.2	-17.47	4.93e-53	2.25e-49	-0.85	-0.63	Dupuytren's disease;	chr16:75472695	chr16:75379818~75381260:-
THCA	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-17.47	4.99e-53	2.28e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs35861938	ENSG00000259520.4	CTD-2651B20.3	-17.47	5.08e-53	2.32e-49	-0.73	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45345145	chr15:45251580~45279251:-
THCA	cis	rs950027	0.596	rs2467865	ENSG00000259520.4	CTD-2651B20.3	-17.47	5.08e-53	2.32e-49	-0.73	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45346109	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs2461700	ENSG00000259520.4	CTD-2651B20.3	-17.47	5.08e-53	2.32e-49	-0.73	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45348429	chr15:45251580~45279251:-
THCA	cis	rs950027	0.62	rs2453533	ENSG00000259520.4	CTD-2651B20.3	-17.47	5.08e-53	2.32e-49	-0.73	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45349027	chr15:45251580~45279251:-
THCA	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-17.46	5.59e-53	2.55e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
THCA	cis	rs2283792	0.622	rs5756323	ENSG00000224086.5	LL22NC03-86G7.1	17.46	5.71e-53	2.6e-49	0.71	0.63	Multiple sclerosis;	chr22:21980398	chr22:21938293~21977632:+
THCA	cis	rs17023223	0.553	rs55696509	ENSG00000231365.4	RP11-418J17.1	-17.46	5.79e-53	2.64e-49	-0.75	-0.63	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119144033	chr1:119140396~119275973:+
THCA	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	17.45	6.18e-53	2.81e-49	0.8	0.63	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
THCA	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	17.45	6.21e-53	2.82e-49	1.16	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	17.45	6.21e-53	2.82e-49	1.16	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
THCA	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-17.45	6.22e-53	2.82e-49	-0.71	-0.63	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
THCA	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	17.45	6.39e-53	2.9e-49	1.13	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	17.45	6.39e-53	2.9e-49	1.13	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	17.45	6.39e-53	2.9e-49	1.13	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	17.45	6.39e-53	2.9e-49	1.13	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	17.45	6.39e-53	2.9e-49	1.13	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
THCA	cis	rs7188445	0.932	rs17767383	ENSG00000261390.4	RP11-345M22.2	-17.45	6.42e-53	2.91e-49	-0.76	-0.63	Urate levels;	chr16:79710504	chr16:79715232~79770563:-
THCA	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-17.44	6.64e-53	3.01e-49	-1	-0.63	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
THCA	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-17.44	6.7e-53	3.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-17.44	6.7e-53	3.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
THCA	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-17.44	6.7e-53	3.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-17.44	6.7e-53	3.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
THCA	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-17.44	6.71e-53	3.04e-49	-0.74	-0.63	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
THCA	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-17.44	6.74e-53	3.05e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
THCA	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-17.44	6.91e-53	3.13e-49	-0.79	-0.63	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-17.44	6.91e-53	3.13e-49	-0.79	-0.63	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
THCA	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
THCA	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
THCA	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
THCA	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
THCA	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
THCA	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	17.44	7.04e-53	3.18e-49	0.83	0.63	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
THCA	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-17.44	7.11e-53	3.21e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-17.43	7.29e-53	3.29e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
THCA	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-17.43	7.56e-53	3.41e-49	-0.8	-0.63	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	17.42	8.06e-53	3.64e-49	0.79	0.63	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
THCA	cis	rs950027	0.62	rs1145089	ENSG00000259520.4	CTD-2651B20.3	-17.42	8.07e-53	3.64e-49	-0.74	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45359856	chr15:45251580~45279251:-
THCA	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	17.42	8.08e-53	3.64e-49	0.73	0.63	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
THCA	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	17.42	8.24e-53	3.71e-49	0.82	0.63	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.899	rs58722186	ENSG00000261390.4	RP11-345M22.2	-17.42	8.41e-53	3.79e-49	-0.77	-0.63	Urate levels;	chr16:79717694	chr16:79715232~79770563:-
THCA	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-17.42	8.45e-53	3.81e-49	-0.74	-0.63	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-17.42	8.85e-53	3.98e-49	-0.73	-0.63	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	17.41	9.07e-53	4.08e-49	1.17	0.63	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
THCA	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	17.41	9.33e-53	4.2e-49	0.72	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
THCA	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	17.41	9.4e-53	4.23e-49	1	0.63	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
THCA	cis	rs2283792	0.73	rs2027790	ENSG00000224086.5	LL22NC03-86G7.1	-17.4	9.95e-53	4.47e-49	-0.74	-0.63	Multiple sclerosis;	chr22:21933592	chr22:21938293~21977632:+
THCA	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-17.4	9.96e-53	4.48e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-17.4	1.01e-52	4.55e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
THCA	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	17.4	1.1e-52	4.93e-49	0.67	0.63	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
THCA	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-17.4	1.1e-52	4.95e-49	-0.81	-0.63	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-17.39	1.13e-52	5.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-17.39	1.13e-52	5.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-17.39	1.13e-52	5.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-17.39	1.13e-52	5.04e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
THCA	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-17.39	1.14e-52	5.11e-49	-0.82	-0.63	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
THCA	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-17.39	1.15e-52	5.16e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
THCA	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-17.39	1.16e-52	5.19e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
THCA	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	17.39	1.17e-52	5.22e-49	0.72	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
THCA	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-17.38	1.25e-52	5.57e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
THCA	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	17.38	1.26e-52	5.62e-49	0.78	0.63	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
THCA	cis	rs524281	0.773	rs7951079	ENSG00000255320.1	RP11-755F10.1	17.38	1.27e-52	5.67e-49	0.96	0.63	Electroencephalogram traits;	chr11:66213079	chr11:66244840~66246239:-
THCA	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-17.38	1.28e-52	5.72e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-17.38	1.28e-52	5.72e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-17.38	1.28e-52	5.72e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-17.38	1.28e-52	5.72e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-17.38	1.28e-52	5.72e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
THCA	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	17.38	1.32e-52	5.85e-49	0.81	0.63	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	17.38	1.32e-52	5.85e-49	0.81	0.63	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
THCA	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	17.37	1.37e-52	6.1e-49	0.81	0.63	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	17.37	1.38e-52	6.15e-49	0.81	0.63	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
THCA	cis	rs1153858	1	rs2668747	ENSG00000259520.4	CTD-2651B20.3	-17.37	1.4e-52	6.2e-49	-0.78	-0.63	Homoarginine levels;	chr15:45325018	chr15:45251580~45279251:-
THCA	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	17.37	1.4e-52	6.2e-49	0.83	0.63	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	17.37	1.4e-52	6.2e-49	0.83	0.63	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
THCA	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	17.37	1.4e-52	6.2e-49	0.83	0.63	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
THCA	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-17.37	1.4e-52	6.22e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
THCA	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	17.37	1.51e-52	6.68e-49	0.8	0.63	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	17.37	1.51e-52	6.68e-49	0.8	0.63	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
THCA	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-17.36	1.56e-52	6.92e-49	-0.81	-0.63	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
THCA	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-17.36	1.56e-52	6.92e-49	-0.72	-0.63	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
THCA	cis	rs950027	0.62	rs1153862	ENSG00000259520.4	CTD-2651B20.3	-17.36	1.58e-52	6.99e-49	-0.73	-0.63	Response to fenofibrate (adiponectin levels);	chr15:45339670	chr15:45251580~45279251:-
THCA	cis	rs2283792	0.566	rs1005579	ENSG00000224086.5	LL22NC03-86G7.1	-17.36	1.58e-52	6.99e-49	-0.73	-0.63	Multiple sclerosis;	chr22:21946569	chr22:21938293~21977632:+
THCA	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-17.36	1.63e-52	7.21e-49	-0.79	-0.63	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
THCA	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-17.36	1.63e-52	7.21e-49	-0.79	-0.63	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-17.35	1.81e-52	8.03e-49	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
THCA	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-17.35	1.82e-52	8.03e-49	-0.79	-0.62	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	17.35	1.85e-52	8.2e-49	0.81	0.62	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	17.35	1.85e-52	8.2e-49	0.81	0.62	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	17.35	1.85e-52	8.2e-49	0.81	0.62	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
THCA	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-17.34	1.88e-52	8.31e-49	-0.72	-0.62	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-17.34	1.88e-52	8.31e-49	-0.72	-0.62	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
THCA	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-17.34	1.95e-52	8.61e-49	-0.78	-0.62	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
THCA	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-17.34	1.98e-52	8.74e-49	-0.79	-0.62	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-17.34	1.98e-52	8.74e-49	-0.79	-0.62	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-17.34	1.98e-52	8.74e-49	-0.79	-0.62	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-17.34	1.98e-52	8.74e-49	-0.79	-0.62	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-17.33	2.19e-52	9.64e-49	-0.79	-0.62	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
THCA	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-17.33	2.2e-52	9.72e-49	-0.7	-0.62	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
THCA	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	17.33	2.24e-52	9.87e-49	0.96	0.62	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
THCA	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	17.32	2.44e-52	1.07e-48	1	0.62	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
THCA	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	17.32	2.44e-52	1.07e-48	0.79	0.62	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
THCA	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-17.32	2.46e-52	1.08e-48	-0.73	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
THCA	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-17.32	2.46e-52	1.08e-48	-0.73	-0.62	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
THCA	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-17.32	2.46e-52	1.08e-48	-0.73	-0.62	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
THCA	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-17.31	2.84e-52	1.25e-48	-0.8	-0.62	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
THCA	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-17.3	2.88e-52	1.27e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-17.3	2.89e-52	1.27e-48	-0.8	-0.62	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-17.3	2.97e-52	1.3e-48	-0.72	-0.62	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
THCA	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-17.3	2.97e-52	1.3e-48	-0.72	-0.62	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
THCA	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-17.29	3.27e-52	1.43e-48	-0.83	-0.62	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-17.29	3.27e-52	1.43e-48	-0.83	-0.62	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
THCA	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-17.29	3.4e-52	1.49e-48	-0.8	-0.62	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-17.28	3.56e-52	1.56e-48	-0.67	-0.62	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
THCA	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	17.28	3.57e-52	1.56e-48	0.82	0.62	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
THCA	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-17.28	3.6e-52	1.58e-48	-0.8	-0.62	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
THCA	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-17.28	3.64e-52	1.59e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-17.28	3.69e-52	1.62e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-17.28	3.71e-52	1.62e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
THCA	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	17.28	3.81e-52	1.67e-48	0.66	0.62	Breast cancer;	chr11:750849	chr11:779617~780755:+
THCA	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-17.28	3.84e-52	1.68e-48	-0.78	-0.62	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
THCA	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	17.28	3.92e-52	1.72e-48	0.81	0.62	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
THCA	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-17.28	3.94e-52	1.72e-48	-0.82	-0.62	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.73	rs2329884	ENSG00000224086.5	LL22NC03-86G7.1	-17.27	4e-52	1.75e-48	-0.74	-0.62	Multiple sclerosis;	chr22:21927890	chr22:21938293~21977632:+
THCA	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-17.27	4.17e-52	1.82e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
THCA	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	17.27	4.19e-52	1.83e-48	0.81	0.62	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	17.27	4.19e-52	1.83e-48	0.81	0.62	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	17.27	4.19e-52	1.83e-48	0.81	0.62	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
THCA	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-17.27	4.26e-52	1.86e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
THCA	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-17.26	4.4e-52	1.92e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
THCA	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-17.26	4.54e-52	1.98e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
THCA	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	17.26	4.77e-52	2.07e-48	0.81	0.62	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-17.26	4.77e-52	2.07e-48	-0.81	-0.62	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-17.26	4.77e-52	2.07e-48	-0.81	-0.62	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-17.26	4.77e-52	2.07e-48	-0.81	-0.62	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
THCA	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-17.26	4.77e-52	2.07e-48	-0.81	-0.62	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
THCA	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-17.26	4.79e-52	2.08e-48	-0.82	-0.62	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
THCA	cis	rs17023223	0.537	rs2794310	ENSG00000231365.4	RP11-418J17.1	-17.26	4.84e-52	2.11e-48	-0.72	-0.62	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119019307	chr1:119140396~119275973:+
THCA	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-17.25	5.09e-52	2.21e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
THCA	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-17.25	5.09e-52	2.21e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
THCA	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	17.25	5.28e-52	2.29e-48	0.76	0.62	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
THCA	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-17.25	5.34e-52	2.32e-48	-0.5	-0.62	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
THCA	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-17.24	5.49e-52	2.39e-48	-0.81	-0.62	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
THCA	cis	rs67180937	0.733	rs17532708	ENSG00000272750.1	RP11-378J18.8	-17.24	5.56e-52	2.41e-48	-0.69	-0.62	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222726085	chr1:222658867~222661512:-
THCA	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-17.24	5.61e-52	2.43e-48	-0.83	-0.62	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
THCA	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-17.24	5.76e-52	2.5e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
THCA	cis	rs524281	0.682	rs4483592	ENSG00000255320.1	RP11-755F10.1	17.24	5.82e-52	2.53e-48	0.94	0.62	Electroencephalogram traits;	chr11:66222968	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs2155201	ENSG00000255320.1	RP11-755F10.1	17.24	5.82e-52	2.53e-48	0.94	0.62	Electroencephalogram traits;	chr11:66224873	chr11:66244840~66246239:-
THCA	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-17.24	5.83e-52	2.53e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
THCA	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	17.23	6.13e-52	2.66e-48	1	0.62	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
THCA	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-17.23	6.35e-52	2.75e-48	-0.83	-0.62	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
THCA	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-17.22	6.75e-52	2.93e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
THCA	cis	rs17023223	0.537	rs2765542	ENSG00000231365.4	RP11-418J17.1	-17.22	7.16e-52	3.09e-48	-0.72	-0.62	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119017703	chr1:119140396~119275973:+
THCA	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	17.22	7.22e-52	3.11e-48	0.78	0.62	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
THCA	cis	rs2283792	0.73	rs2083565	ENSG00000224086.5	LL22NC03-86G7.1	-17.21	7.56e-52	3.26e-48	-0.74	-0.62	Multiple sclerosis;	chr22:21929985	chr22:21938293~21977632:+
THCA	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-17.21	7.81e-52	3.37e-48	-0.71	-0.62	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
THCA	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	17.21	7.93e-52	3.42e-48	0.67	0.62	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
THCA	cis	rs524281	0.731	rs11227433	ENSG00000255320.1	RP11-755F10.1	17.2	8.53e-52	3.67e-48	0.94	0.62	Electroencephalogram traits;	chr11:66237222	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs10791861	ENSG00000255320.1	RP11-755F10.1	17.2	8.53e-52	3.67e-48	0.94	0.62	Electroencephalogram traits;	chr11:66240999	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs10791862	ENSG00000255320.1	RP11-755F10.1	17.2	8.53e-52	3.67e-48	0.94	0.62	Electroencephalogram traits;	chr11:66246193	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs2155198	ENSG00000255320.1	RP11-755F10.1	17.2	8.53e-52	3.67e-48	0.94	0.62	Electroencephalogram traits;	chr11:66246829	chr11:66244840~66246239:-
THCA	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	17.2	9.1e-52	3.91e-48	0.69	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
THCA	cis	rs17023223	0.537	rs2645305	ENSG00000231365.4	RP11-418J17.1	-17.19	9.5e-52	4.09e-48	-0.72	-0.62	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119018742	chr1:119140396~119275973:+
THCA	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	17.19	9.8e-52	4.21e-48	0.66	0.62	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
THCA	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-17.18	1.06e-51	4.53e-48	-0.8	-0.62	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-17.18	1.06e-51	4.53e-48	-0.8	-0.62	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
THCA	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-17.18	1.09e-51	4.66e-48	-0.98	-0.62	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
THCA	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	17.17	1.19e-51	5.08e-48	0.7	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
THCA	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-17.17	1.2e-51	5.14e-48	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-17.17	1.2e-51	5.14e-48	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
THCA	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-17.17	1.23e-51	5.28e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
THCA	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-17.17	1.24e-51	5.32e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
THCA	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	17.16	1.38e-51	5.88e-48	0.8	0.62	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
THCA	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-17.15	1.42e-51	6.09e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
THCA	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	17.15	1.45e-51	6.18e-48	0.67	0.62	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
THCA	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	17.15	1.45e-51	6.18e-48	0.67	0.62	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
THCA	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-17.15	1.48e-51	6.33e-48	-0.82	-0.62	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
THCA	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-17.15	1.54e-51	6.57e-48	-0.7	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
THCA	cis	rs524281	0.773	rs7925123	ENSG00000255320.1	RP11-755F10.1	17.14	1.64e-51	6.98e-48	0.94	0.62	Electroencephalogram traits;	chr11:66225742	chr11:66244840~66246239:-
THCA	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-17.14	1.69e-51	7.22e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-17.13	1.78e-51	7.6e-48	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
THCA	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-17.13	1.81e-51	7.72e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
THCA	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-17.13	1.92e-51	8.16e-48	-0.8	-0.62	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
THCA	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	17.12	1.95e-51	8.29e-48	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
THCA	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-17.12	2.08e-51	8.86e-48	-0.76	-0.62	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
THCA	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-17.12	2.09e-51	8.9e-48	-0.8	-0.62	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
THCA	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-17.12	2.1e-51	8.91e-48	-0.78	-0.62	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
THCA	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-17.12	2.1e-51	8.91e-48	-0.79	-0.62	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-17.12	2.14e-51	9.09e-48	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	17.1	2.54e-51	1.08e-47	0.67	0.62	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-17.1	2.57e-51	1.09e-47	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
THCA	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-17.1	2.58e-51	1.09e-47	-0.79	-0.62	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
THCA	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	17.09	2.68e-51	1.14e-47	0.77	0.62	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
THCA	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	17.09	2.73e-51	1.16e-47	0.82	0.62	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
THCA	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	17.08	2.97e-51	1.26e-47	0.7	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
THCA	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-17.08	2.99e-51	1.26e-47	-0.8	-0.62	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
THCA	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-17.08	2.99e-51	1.26e-47	-0.8	-0.62	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-17.08	2.99e-51	1.26e-47	-0.8	-0.62	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
THCA	cis	rs2283792	0.73	rs738858	ENSG00000224086.5	LL22NC03-86G7.1	-17.08	3.08e-51	1.3e-47	-0.73	-0.62	Multiple sclerosis;	chr22:21926544	chr22:21938293~21977632:+
THCA	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-17.08	3.15e-51	1.33e-47	-0.79	-0.62	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
THCA	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-17.07	3.29e-51	1.39e-47	-0.82	-0.62	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-17.07	3.35e-51	1.41e-47	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
THCA	cis	rs2882667	1	rs2882667	ENSG00000253404.1	AC034243.1	17.07	3.44e-51	1.45e-47	0.72	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138978417	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	17.07	3.5e-51	1.47e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
THCA	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-17.07	3.51e-51	1.48e-47	-0.82	-0.62	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
THCA	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-17.07	3.51e-51	1.48e-47	-0.82	-0.62	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-17.07	3.51e-51	1.48e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
THCA	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-17.06	3.71e-51	1.56e-47	-0.79	-0.62	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	17.06	3.76e-51	1.58e-47	0.7	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-17.06	4.05e-51	1.7e-47	-0.76	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
THCA	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	17.05	4.5e-51	1.89e-47	0.66	0.62	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
THCA	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	17.04	4.5e-51	1.89e-47	0.76	0.62	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
THCA	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	17.04	4.66e-51	1.96e-47	0.82	0.62	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
THCA	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	17.04	4.66e-51	1.96e-47	1.13	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	17.04	4.66e-51	1.96e-47	1.13	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.954	rs12499324	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119472631	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs9998585	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119475647	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs6842762	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119477081	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.908	rs11098527	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119478751	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10518328	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119480624	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs6848389	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119481467	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs6822679	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119481547	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs4577559	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119482888	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs7656252	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119483113	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs28845498	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119484031	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs28753180	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119484212	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs56270433	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119484875	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10006706	ENSG00000245958.5	RP11-33B1.1	-17.04	4.69e-51	1.97e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119487997	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs12508173	ENSG00000245958.5	RP11-33B1.1	-17.04	4.8e-51	2.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119397371	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.908	rs12504149	ENSG00000245958.5	RP11-33B1.1	-17.04	4.8e-51	2.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119397422	chr4:119454791~119552025:+
THCA	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	17.04	4.97e-51	2.08e-47	0.82	0.62	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
THCA	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	17.04	4.97e-51	2.08e-47	0.82	0.62	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
THCA	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-17.03	5.03e-51	2.11e-47	-0.81	-0.62	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
THCA	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	17.03	5.03e-51	2.11e-47	0.81	0.62	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
THCA	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-17.03	5.3e-51	2.22e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-17.03	5.3e-51	2.22e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
THCA	cis	rs507080	0.769	rs12290522	ENSG00000255239.1	AP002954.6	17.03	5.43e-51	2.27e-47	0.83	0.62	Serum metabolite levels;	chr11:118615610	chr11:118688039~118690600:-
THCA	cis	rs1155848	0.892	rs953005	ENSG00000227354.5	RBM26-AS1	17.03	5.49e-51	2.29e-47	0.98	0.62	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480544	chr13:79406309~79424328:+
THCA	cis	rs11098499	0.779	rs80242894	ENSG00000245958.5	RP11-33B1.1	-17.02	5.75e-51	2.4e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119454597	chr4:119454791~119552025:+
THCA	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-17.02	5.79e-51	2.42e-47	-0.82	-0.62	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
THCA	cis	rs11098499	0.909	rs28571712	ENSG00000245958.5	RP11-33B1.1	-17.02	5.95e-51	2.48e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119454825	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs9994730	ENSG00000245958.5	RP11-33B1.1	-17.02	5.95e-51	2.48e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119460409	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs11098526	ENSG00000245958.5	RP11-33B1.1	-17.02	5.95e-51	2.48e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119469204	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.779	rs7699346	ENSG00000245958.5	RP11-33B1.1	-17.02	5.96e-51	2.49e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119389387	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs12510138	ENSG00000245958.5	RP11-33B1.1	-17.02	6.01e-51	2.51e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119502780	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	17.01	6.24e-51	2.6e-47	1.13	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.909	rs11723839	ENSG00000245958.5	RP11-33B1.1	-17.01	6.25e-51	2.6e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119378518	chr4:119454791~119552025:+
THCA	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	17.01	6.45e-51	2.69e-47	1	0.62	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
THCA	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	17.01	6.74e-51	2.81e-47	0.65	0.62	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.954	rs7681544	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119490100	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs11940028	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119490752	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs11935596	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119491302	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs12507964	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119491906	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs11098530	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119491999	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs6834796	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119493538	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs11734241	ENSG00000245958.5	RP11-33B1.1	-17	6.99e-51	2.91e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119495717	chr4:119454791~119552025:+
THCA	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-17	7.01e-51	2.91e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-17	7.03e-51	2.92e-47	-0.66	-0.62	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
THCA	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-17	7.05e-51	2.93e-47	-0.79	-0.62	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
THCA	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-17	7.05e-51	2.93e-47	-0.79	-0.62	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
THCA	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	17	7.62e-51	3.16e-47	0.66	0.62	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	17	7.62e-51	3.16e-47	0.66	0.62	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.954	rs28685688	ENSG00000245958.5	RP11-33B1.1	-16.99	7.73e-51	3.2e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119499179	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs7687843	ENSG00000245958.5	RP11-33B1.1	-16.99	7.73e-51	3.2e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119500056	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs2306455	ENSG00000245958.5	RP11-33B1.1	-16.99	7.73e-51	3.2e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119500814	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10031483	ENSG00000245958.5	RP11-33B1.1	-16.99	7.73e-51	3.2e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119501481	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10031665	ENSG00000245958.5	RP11-33B1.1	-16.99	7.73e-51	3.2e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119501697	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs3733523	ENSG00000245958.5	RP11-33B1.1	-16.99	7.73e-51	3.2e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119502564	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.58	rs12509234	ENSG00000245958.5	RP11-33B1.1	-16.99	7.91e-51	3.28e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119398279	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs10014719	ENSG00000245958.5	RP11-33B1.1	-16.99	7.91e-51	3.28e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119399560	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	16.99	8.02e-51	3.32e-47	0.69	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
THCA	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-16.98	8.75e-51	3.61e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
THCA	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	16.98	8.82e-51	3.64e-47	1.14	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.779	rs28495013	ENSG00000245958.5	RP11-33B1.1	-16.98	9.15e-51	3.78e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119454676	chr4:119454791~119552025:+
THCA	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	16.98	9.19e-51	3.78e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
THCA	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-16.98	9.21e-51	3.79e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
THCA	cis	rs11098499	0.908	rs7695996	ENSG00000245958.5	RP11-33B1.1	-16.98	9.29e-51	3.82e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119400878	chr4:119454791~119552025:+
THCA	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-16.97	9.7e-51	3.98e-47	-0.71	-0.62	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
THCA	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-16.97	9.76e-51	4.01e-47	-0.8	-0.62	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-16.97	9.76e-51	4.01e-47	-0.8	-0.62	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-16.97	9.76e-51	4.01e-47	-0.8	-0.62	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
THCA	cis	rs11098499	0.908	rs7696649	ENSG00000245958.5	RP11-33B1.1	-16.97	9.79e-51	4.02e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119401022	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs12502423	ENSG00000245958.5	RP11-33B1.1	-16.97	9.89e-51	4.06e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119503017	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.623	rs11657662	ENSG00000263531.1	RP13-753N3.1	-16.97	1e-50	4.11e-47	-1.14	-0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9912440	ENSG00000263531.1	RP13-753N3.1	16.97	1e-50	4.11e-47	1.15	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.954	rs67265404	ENSG00000245958.5	RP11-33B1.1	-16.97	1.01e-50	4.13e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119438115	chr4:119454791~119552025:+
THCA	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	16.97	1.02e-50	4.18e-47	1.12	0.62	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	16.97	1.02e-50	4.18e-47	1.12	0.62	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	16.97	1.02e-50	4.18e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.954	rs3890049	ENSG00000245958.5	RP11-33B1.1	-16.96	1.09e-50	4.45e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119405128	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs71629403	ENSG00000245958.5	RP11-33B1.1	-16.96	1.09e-50	4.45e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119451412	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs28634456	ENSG00000245958.5	RP11-33B1.1	-16.96	1.12e-50	4.59e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119454623	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.821	rs10032151	ENSG00000245958.5	RP11-33B1.1	-16.96	1.15e-50	4.7e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119470473	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs10032158	ENSG00000245958.5	RP11-33B1.1	-16.96	1.15e-50	4.7e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119470477	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	16.95	1.18e-50	4.79e-47	0.69	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	16.95	1.19e-50	4.85e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9898084	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	16.95	1.23e-50	4.98e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
THCA	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-16.95	1.25e-50	5.07e-47	-0.8	-0.62	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
THCA	cis	rs977987	0.872	rs3743609	ENSG00000261783.1	RP11-252K23.2	-16.95	1.25e-50	5.08e-47	-0.79	-0.62	Dupuytren's disease;	chr16:75433123	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-16.95	1.27e-50	5.15e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
THCA	cis	rs524281	0.773	rs2236651	ENSG00000255320.1	RP11-755F10.1	16.94	1.33e-50	5.39e-47	0.93	0.62	Electroencephalogram traits;	chr11:66233947	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs4393319	ENSG00000255320.1	RP11-755F10.1	16.94	1.33e-50	5.39e-47	0.93	0.62	Electroencephalogram traits;	chr11:66234407	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs10896105	ENSG00000255320.1	RP11-755F10.1	16.94	1.33e-50	5.39e-47	0.93	0.62	Electroencephalogram traits;	chr11:66234789	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs2236652	ENSG00000255320.1	RP11-755F10.1	16.94	1.33e-50	5.39e-47	0.93	0.62	Electroencephalogram traits;	chr11:66235210	chr11:66244840~66246239:-
THCA	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-16.94	1.34e-50	5.42e-47	-0.71	-0.62	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
THCA	cis	rs977987	0.872	rs1542864	ENSG00000261783.1	RP11-252K23.2	-16.94	1.39e-50	5.63e-47	-0.79	-0.62	Dupuytren's disease;	chr16:75437480	chr16:75379818~75381260:-
THCA	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	16.94	1.41e-50	5.71e-47	0.77	0.62	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
THCA	cis	rs11098499	0.909	rs78332141	ENSG00000245958.5	RP11-33B1.1	-16.94	1.42e-50	5.76e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119454627	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs28655325	ENSG00000245958.5	RP11-33B1.1	-16.93	1.45e-50	5.87e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119451844	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs7436506	ENSG00000245958.5	RP11-33B1.1	-16.93	1.49e-50	6.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119472614	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10008459	ENSG00000245958.5	RP11-33B1.1	-16.93	1.49e-50	6.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119473076	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs2127821	ENSG00000245958.5	RP11-33B1.1	-16.93	1.49e-50	6.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119473380	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10006525	ENSG00000245958.5	RP11-33B1.1	-16.93	1.49e-50	6.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119487776	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs12508504	ENSG00000245958.5	RP11-33B1.1	-16.93	1.49e-50	6.01e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119489452	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	16.93	1.55e-50	6.27e-47	0.69	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.908	rs71614449	ENSG00000245958.5	RP11-33B1.1	-16.93	1.56e-50	6.3e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119465900	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs35063680	ENSG00000245958.5	RP11-33B1.1	-16.93	1.56e-50	6.3e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119465947	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs34858317	ENSG00000245958.5	RP11-33B1.1	-16.93	1.56e-50	6.3e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119465955	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	16.93	1.57e-50	6.36e-47	1.15	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
THCA	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	16.93	1.58e-50	6.39e-47	0.63	0.62	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
THCA	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	16.92	1.61e-50	6.5e-47	0.82	0.62	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
THCA	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	16.92	1.61e-50	6.51e-47	0.76	0.62	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
THCA	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-16.92	1.62e-50	6.55e-47	-0.82	-0.62	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
THCA	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-16.92	1.67e-50	6.72e-47	-0.71	-0.62	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
THCA	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-16.92	1.7e-50	6.87e-47	-0.81	-0.62	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
THCA	cis	rs11098499	0.909	rs71614422	ENSG00000245958.5	RP11-33B1.1	-16.92	1.71e-50	6.89e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119438185	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.738	rs34566984	ENSG00000245958.5	RP11-33B1.1	-16.92	1.71e-50	6.89e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119440115	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs17009122	ENSG00000245958.5	RP11-33B1.1	-16.92	1.71e-50	6.89e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119441248	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.505	rs75122014	ENSG00000245958.5	RP11-33B1.1	-16.92	1.71e-50	6.89e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119441271	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs9685777	ENSG00000245958.5	RP11-33B1.1	-16.92	1.71e-50	6.89e-47	-0.62	-0.62	Corneal astigmatism;	chr4:119444810	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	16.92	1.71e-50	6.9e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
THCA	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-16.92	1.72e-50	6.91e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
THCA	cis	rs17023223	0.537	rs7525871	ENSG00000231365.4	RP11-418J17.1	-16.92	1.75e-50	7.04e-47	-0.71	-0.62	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119079271	chr1:119140396~119275973:+
THCA	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	16.92	1.75e-50	7.05e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
THCA	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	16.92	1.76e-50	7.06e-47	0.83	0.62	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
THCA	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	16.91	1.8e-50	7.24e-47	0.76	0.62	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
THCA	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	16.91	1.82e-50	7.34e-47	1.12	0.62	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
THCA	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	16.91	1.86e-50	7.46e-47	0.69	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
THCA	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-16.91	1.87e-50	7.51e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
THCA	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-16.91	1.87e-50	7.51e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
THCA	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-16.91	1.89e-50	7.58e-47	-0.78	-0.62	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
THCA	cis	rs11098499	0.954	rs13133522	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119403269	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs35091806	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119404374	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs6846442	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119405168	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.738	rs34965784	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119440431	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs71614438	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119450097	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs66506550	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119450290	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs7659501	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119450397	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.657	rs71614442	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119458191	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs2892848	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119460186	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs11941899	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119461603	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs7681978	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119462620	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.821	rs28665282	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119463031	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.738	rs10026493	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119463039	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs7681214	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119464165	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.908	rs28559989	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119465472	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs28632018	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119465575	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs17046116	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119466104	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs17046118	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119466341	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs7654587	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119467251	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs11098525	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119468997	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs6838814	ENSG00000245958.5	RP11-33B1.1	-16.91	1.91e-50	7.61e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119471288	chr4:119454791~119552025:+
THCA	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	16.91	1.93e-50	7.69e-47	0.99	0.61	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
THCA	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	16.91	1.94e-50	7.75e-47	0.99	0.61	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
THCA	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-16.9	2.05e-50	8.15e-47	-0.78	-0.61	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
THCA	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	16.9	2.09e-50	8.32e-47	0.81	0.61	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	16.9	2.09e-50	8.32e-47	0.81	0.61	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
THCA	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	16.9	2.1e-50	8.35e-47	1.15	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	16.9	2.1e-50	8.35e-47	1.15	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	16.9	2.12e-50	8.41e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
THCA	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	16.9	2.13e-50	8.43e-47	0.57	0.61	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
THCA	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	16.9	2.13e-50	8.44e-47	0.66	0.61	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
THCA	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-16.9	2.16e-50	8.55e-47	-0.88	-0.61	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
THCA	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-16.89	2.25e-50	8.88e-47	-0.78	-0.61	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
THCA	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	16.89	2.25e-50	8.89e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	16.89	2.31e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	16.89	2.32e-50	9.12e-47	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.954	rs11729521	ENSG00000245958.5	RP11-33B1.1	-16.89	2.36e-50	9.29e-47	-0.62	-0.61	Corneal astigmatism;	chr4:119495633	chr4:119454791~119552025:+
THCA	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	16.89	2.37e-50	9.34e-47	0.79	0.61	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
THCA	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	16.89	2.44e-50	9.6e-47	0.65	0.61	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
THCA	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	16.88	2.51e-50	9.88e-47	0.76	0.61	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
THCA	cis	rs11098499	0.909	rs9759478	ENSG00000245958.5	RP11-33B1.1	-16.88	2.55e-50	1e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119446843	chr4:119454791~119552025:+
THCA	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	16.88	2.64e-50	1.04e-46	0.79	0.61	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
THCA	cis	rs11098499	0.954	rs12506546	ENSG00000245958.5	RP11-33B1.1	-16.88	2.69e-50	1.06e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119380463	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10017543	ENSG00000245958.5	RP11-33B1.1	-16.87	2.78e-50	1.09e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119400265	chr4:119454791~119552025:+
THCA	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.568	rs11658027	ENSG00000263531.1	RP13-753N3.1	-16.87	2.84e-50	1.11e-46	-1.12	-0.61	Body mass index;	chr17:30767864	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	16.87	2.84e-50	1.11e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
THCA	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	16.87	2.88e-50	1.12e-46	0.72	0.61	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
THCA	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	16.87	2.95e-50	1.15e-46	0.7	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	16.87	2.95e-50	1.15e-46	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
THCA	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-16.87	2.96e-50	1.15e-46	-0.77	-0.61	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
THCA	cis	rs11098499	0.954	rs17006190	ENSG00000245958.5	RP11-33B1.1	-16.86	3.04e-50	1.18e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119497683	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs3733519	ENSG00000245958.5	RP11-33B1.1	-16.86	3.04e-50	1.18e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119502293	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-16.86	3.08e-50	1.2e-46	-0.78	-0.61	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
THCA	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-16.86	3.12e-50	1.21e-46	-0.81	-0.61	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
THCA	cis	rs524281	0.773	rs10750781	ENSG00000255320.1	RP11-755F10.1	16.86	3.18e-50	1.24e-46	0.95	0.61	Electroencephalogram traits;	chr11:66269799	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs2017969	ENSG00000255320.1	RP11-755F10.1	16.86	3.18e-50	1.24e-46	0.95	0.61	Electroencephalogram traits;	chr11:66271561	chr11:66244840~66246239:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-16.86	3.21e-50	1.25e-46	-0.79	-0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
THCA	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-16.86	3.26e-50	1.27e-46	-0.81	-0.61	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
THCA	cis	rs11098499	0.954	rs10008392	ENSG00000245958.5	RP11-33B1.1	-16.86	3.34e-50	1.3e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119397684	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs17005535	ENSG00000245958.5	RP11-33B1.1	-16.85	3.5e-50	1.36e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119490407	chr4:119454791~119552025:+
THCA	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	16.85	3.51e-50	1.36e-46	0.77	0.61	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
THCA	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	16.85	3.55e-50	1.38e-46	0.72	0.61	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
THCA	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-16.84	3.84e-50	1.49e-46	-0.65	-0.61	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
THCA	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-16.84	3.84e-50	1.49e-46	-0.81	-0.61	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
THCA	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	16.84	3.86e-50	1.49e-46	0.65	0.61	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
THCA	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	16.84	3.99e-50	1.54e-46	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
THCA	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-16.84	3.99e-50	1.54e-46	-0.81	-0.61	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
THCA	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	16.84	4.02e-50	1.56e-46	1.12	0.61	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
THCA	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-16.83	4.16e-50	1.61e-46	-0.8	-0.61	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
THCA	cis	rs524281	0.731	rs11227439	ENSG00000255320.1	RP11-755F10.1	16.83	4.18e-50	1.62e-46	0.94	0.61	Electroencephalogram traits;	chr11:66258208	chr11:66244840~66246239:-
THCA	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	16.83	4.29e-50	1.66e-46	0.65	0.61	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
THCA	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	16.82	4.76e-50	1.83e-46	0.82	0.61	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
THCA	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	16.82	4.76e-50	1.83e-46	0.82	0.61	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
THCA	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	16.82	4.76e-50	1.83e-46	0.82	0.61	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
THCA	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	16.82	4.76e-50	1.83e-46	0.82	0.61	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
THCA	cis	rs7208859	0.623	rs7214570	ENSG00000263531.1	RP13-753N3.1	16.82	5.04e-50	1.94e-46	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	16.81	5.27e-50	2.03e-46	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
THCA	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-16.81	5.28e-50	2.03e-46	-0.79	-0.61	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
THCA	cis	rs11098499	0.954	rs9993199	ENSG00000245958.5	RP11-33B1.1	16.81	5.48e-50	2.11e-46	0.62	0.61	Corneal astigmatism;	chr4:119471718	chr4:119454791~119552025:+
THCA	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-16.8	5.72e-50	2.2e-46	-0.78	-0.61	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
THCA	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-16.8	5.91e-50	2.27e-46	-0.78	-0.61	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
THCA	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-16.8	5.91e-50	2.27e-46	-0.8	-0.61	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	16.8	5.99e-50	2.3e-46	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
THCA	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-16.8	6.03e-50	2.31e-46	-0.81	-0.61	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
THCA	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	16.8	6.19e-50	2.38e-46	0.71	0.61	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
THCA	cis	rs11098499	0.954	rs2389802	ENSG00000245958.5	RP11-33B1.1	-16.79	6.38e-50	2.45e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119404577	chr4:119454791~119552025:+
THCA	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	16.79	6.39e-50	2.45e-46	1.13	0.61	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
THCA	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	16.79	6.68e-50	2.56e-46	0.75	0.61	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
THCA	cis	rs1153858	1	rs10519021	ENSG00000259520.4	CTD-2651B20.3	-16.78	7.32e-50	2.8e-46	-0.77	-0.61	Homoarginine levels;	chr15:45339597	chr15:45251580~45279251:-
THCA	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	16.78	7.47e-50	2.86e-46	0.81	0.61	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
THCA	cis	rs11098499	0.908	rs2017057	ENSG00000245958.5	RP11-33B1.1	-16.78	7.55e-50	2.89e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119336556	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10518331	ENSG00000245958.5	RP11-33B1.1	-16.78	7.76e-50	2.97e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119402440	chr4:119454791~119552025:+
THCA	cis	rs17023223	0.509	rs10923740	ENSG00000231365.4	RP11-418J17.1	-16.77	7.9e-50	3.02e-46	-0.72	-0.61	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119057664	chr1:119140396~119275973:+
THCA	cis	rs11098499	0.909	rs11723757	ENSG00000245958.5	RP11-33B1.1	-16.77	7.9e-50	3.02e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119378514	chr4:119454791~119552025:+
THCA	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	16.77	8.22e-50	3.14e-46	0.98	0.61	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
THCA	cis	rs11098499	0.954	rs878373	ENSG00000245958.5	RP11-33B1.1	-16.76	8.96e-50	3.42e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119316329	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10006877	ENSG00000245958.5	RP11-33B1.1	-16.76	8.96e-50	3.42e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119321638	chr4:119454791~119552025:+
THCA	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-16.76	9.21e-50	3.51e-46	-0.78	-0.61	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
THCA	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-16.76	9.4e-50	3.58e-46	-0.78	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
THCA	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	16.76	9.4e-50	3.59e-46	0.78	0.61	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
THCA	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-16.76	9.41e-50	3.59e-46	-0.79	-0.61	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-16.76	9.41e-50	3.59e-46	-0.79	-0.61	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
THCA	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-16.76	9.55e-50	3.64e-46	-0.77	-0.61	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
THCA	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	16.75	9.6e-50	3.66e-46	0.8	0.61	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
THCA	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	16.75	9.75e-50	3.71e-46	0.65	0.61	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
THCA	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	16.75	9.82e-50	3.74e-46	0.64	0.61	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
THCA	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	16.75	1e-49	3.81e-46	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
THCA	cis	rs17023223	0.537	rs12086549	ENSG00000231365.4	RP11-418J17.1	16.75	1.01e-49	3.85e-46	0.71	0.61	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071714	chr1:119140396~119275973:+
THCA	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	16.75	1.03e-49	3.91e-46	0.71	0.61	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
THCA	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-16.75	1.04e-49	3.98e-46	-0.79	-0.61	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
THCA	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	16.74	1.1e-49	4.18e-46	1.1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.909	rs35165976	ENSG00000245958.5	RP11-33B1.1	-16.74	1.1e-49	4.2e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119404475	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	16.74	1.12e-49	4.25e-46	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
THCA	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	16.74	1.14e-49	4.33e-46	0.76	0.61	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
THCA	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-16.74	1.17e-49	4.43e-46	-0.79	-0.61	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
THCA	cis	rs11098499	0.954	rs12505469	ENSG00000245958.5	RP11-33B1.1	-16.73	1.27e-49	4.83e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119328430	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs1480931	ENSG00000245958.5	RP11-33B1.1	-16.73	1.31e-49	4.98e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119474654	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-16.72	1.35e-49	5.13e-46	-0.78	-0.61	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
THCA	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-16.72	1.36e-49	5.15e-46	-0.78	-0.61	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
THCA	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	16.72	1.37e-49	5.18e-46	0.81	0.61	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
THCA	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	16.72	1.38e-49	5.23e-46	1.12	0.61	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	16.72	1.38e-49	5.23e-46	1.12	0.61	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	16.72	1.38e-49	5.23e-46	1.12	0.61	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
THCA	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	16.72	1.38e-49	5.24e-46	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
THCA	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-16.72	1.39e-49	5.27e-46	-0.7	-0.61	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
THCA	cis	rs11098499	0.954	rs59394118	ENSG00000245958.5	RP11-33B1.1	-16.72	1.39e-49	5.28e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119374396	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs9996417	ENSG00000245958.5	RP11-33B1.1	-16.72	1.39e-49	5.28e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119374707	chr4:119454791~119552025:+
THCA	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-16.72	1.42e-49	5.37e-46	-0.81	-0.61	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
THCA	cis	rs7188445	1	rs7190187	ENSG00000261390.4	RP11-345M22.2	-16.72	1.42e-49	5.37e-46	-0.74	-0.61	Urate levels;	chr16:79701281	chr16:79715232~79770563:-
THCA	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	16.72	1.42e-49	5.38e-46	1.13	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
THCA	cis	rs1153858	1	rs56850226	ENSG00000259520.4	CTD-2651B20.3	-16.72	1.43e-49	5.39e-46	-0.78	-0.61	Homoarginine levels;	chr15:45340920	chr15:45251580~45279251:-
THCA	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-16.72	1.43e-49	5.42e-46	-0.79	-0.61	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
THCA	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	16.72	1.46e-49	5.52e-46	0.82	0.61	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
THCA	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-16.71	1.48e-49	5.6e-46	-0.81	-0.61	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	16.71	1.57e-49	5.94e-46	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	16.7	1.71e-49	6.45e-46	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.954	rs59866101	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119375436	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.618	rs6858383	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119375617	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs6832410	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119375645	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs1112817	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119376645	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.779	rs10016060	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119377257	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10005644	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119377322	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs10016448	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119377690	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.657	rs9996569	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119377849	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.908	rs11729050	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119378911	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs28429722	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119378938	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10014845	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119379922	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.779	rs7674500	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119382438	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs28884220	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119386056	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs28793658	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119386059	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs4507344	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119386330	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs4373140	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119386543	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs13113483	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119387884	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.542	rs10440343	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119388632	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs28668716	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119388720	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.542	rs7677836	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119389483	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs10002083	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119389997	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10024844	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119390373	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs7437420	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119391748	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs4345162	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119391804	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.657	rs4463052	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119392103	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs13151285	ENSG00000245958.5	RP11-33B1.1	-16.7	1.74e-49	6.52e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119393586	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs10034623	ENSG00000245958.5	RP11-33B1.1	-16.69	1.82e-49	6.83e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119476674	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.618	rs28491261	ENSG00000245958.5	RP11-33B1.1	-16.69	1.86e-49	6.96e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119373745	chr4:119454791~119552025:+
THCA	cis	rs1153858	1	rs7171577	ENSG00000259520.4	CTD-2651B20.3	-16.69	1.88e-49	7.05e-46	-0.77	-0.61	Homoarginine levels;	chr15:45335781	chr15:45251580~45279251:-
THCA	cis	rs11098499	0.909	rs1546504	ENSG00000245958.5	RP11-33B1.1	-16.69	1.93e-49	7.22e-46	-0.61	-0.61	Corneal astigmatism;	chr4:119320024	chr4:119454791~119552025:+
THCA	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-16.69	1.97e-49	7.35e-46	-0.79	-0.61	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-16.69	1.97e-49	7.35e-46	-0.79	-0.61	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-16.69	1.97e-49	7.35e-46	-0.79	-0.61	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-16.69	1.97e-49	7.36e-46	-0.79	-0.61	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
THCA	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	16.68	2.07e-49	7.75e-46	0.72	0.61	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
THCA	cis	rs11098499	0.954	rs3733524	ENSG00000245958.5	RP11-33B1.1	-16.68	2.12e-49	7.94e-46	-0.62	-0.61	Corneal astigmatism;	chr4:119502574	chr4:119454791~119552025:+
THCA	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	16.68	2.14e-49	8.01e-46	0.77	0.61	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
THCA	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	16.68	2.15e-49	8.02e-46	0.68	0.61	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
THCA	cis	rs9402673	0.58	rs2297339	ENSG00000232876.1	CTA-212D2.2	-16.68	2.23e-49	8.31e-46	-0.71	-0.61	High light scatter reticulocyte count;Reticulocyte count;	chr6:135054853	chr6:135055033~135060550:+
THCA	cis	rs1153858	1	rs11070453	ENSG00000259520.4	CTD-2651B20.3	-16.67	2.24e-49	8.35e-46	-0.77	-0.61	Homoarginine levels;	chr15:45352956	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs12593230	ENSG00000259520.4	CTD-2651B20.3	-16.67	2.24e-49	8.35e-46	-0.77	-0.61	Homoarginine levels;	chr15:45354770	chr15:45251580~45279251:-
THCA	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	16.67	2.24e-49	8.37e-46	0.63	0.61	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
THCA	cis	rs875971	0.83	rs12673450	ENSG00000226824.5	RP4-756H11.3	-16.67	2.33e-49	8.71e-46	-0.81	-0.61	Aortic root size;	chr7:66544233	chr7:66654538~66669855:+
THCA	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-16.67	2.35e-49	8.75e-46	-0.72	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
THCA	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	16.67	2.38e-49	8.89e-46	1.11	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
THCA	cis	rs524281	0.731	rs476551	ENSG00000255320.1	RP11-755F10.1	16.67	2.43e-49	9.07e-46	0.91	0.61	Electroencephalogram traits;	chr11:66238852	chr11:66244840~66246239:-
THCA	cis	rs1153858	1	rs67831559	ENSG00000259520.4	CTD-2651B20.3	-16.66	2.51e-49	9.34e-46	-0.78	-0.61	Homoarginine levels;	chr15:45357109	chr15:45251580~45279251:-
THCA	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	16.66	2.66e-49	9.93e-46	0.72	0.61	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
THCA	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	16.66	2.74e-49	1.02e-45	0.72	0.61	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
THCA	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	16.65	2.81e-49	1.05e-45	0.65	0.61	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.954	rs13107475	ENSG00000245958.5	RP11-33B1.1	-16.65	2.9e-49	1.08e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119471856	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs6849171	ENSG00000245958.5	RP11-33B1.1	-16.65	2.9e-49	1.08e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119488394	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs28572238	ENSG00000245958.5	RP11-33B1.1	-16.65	2.99e-49	1.11e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119395531	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs28714195	ENSG00000245958.5	RP11-33B1.1	-16.65	2.99e-49	1.11e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119395795	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.623	rs9895785	ENSG00000263531.1	RP13-753N3.1	-16.65	3.02e-49	1.12e-45	-1.13	-0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30863921~30864940:-
THCA	cis	rs524281	0.773	rs11227448	ENSG00000255320.1	RP11-755F10.1	16.64	3.24e-49	1.2e-45	0.94	0.61	Electroencephalogram traits;	chr11:66281020	chr11:66244840~66246239:-
THCA	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	16.64	3.26e-49	1.21e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
THCA	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-16.63	3.56e-49	1.32e-45	-1.08	-0.61	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
THCA	cis	rs11098499	0.909	rs1546502	ENSG00000245958.5	RP11-33B1.1	-16.63	3.59e-49	1.33e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119314743	chr4:119454791~119552025:+
THCA	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	16.63	3.6e-49	1.33e-45	1.11	0.61	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	16.63	3.62e-49	1.34e-45	0.62	0.61	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	16.63	3.64e-49	1.35e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
THCA	cis	rs1153858	1	rs1618874	ENSG00000259520.4	CTD-2651B20.3	-16.63	3.65e-49	1.35e-45	-0.77	-0.61	Homoarginine levels;	chr15:45330588	chr15:45251580~45279251:-
THCA	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	16.63	3.66e-49	1.35e-45	0.79	0.61	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	16.63	3.66e-49	1.35e-45	0.79	0.61	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
THCA	cis	rs11098499	0.738	rs28408407	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119454875	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs1809406	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119455967	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs2389809	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119456244	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs9994810	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119460435	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs10020027	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119460724	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.779	rs7356491	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119460819	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.908	rs28499576	ENSG00000245958.5	RP11-33B1.1	-16.63	3.71e-49	1.37e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119465522	chr4:119454791~119552025:+
THCA	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	16.62	3.87e-49	1.43e-45	0.79	0.61	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
THCA	cis	rs17023223	0.537	rs7532510	ENSG00000231365.4	RP11-418J17.1	-16.62	3.92e-49	1.45e-45	-0.7	-0.61	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051613	chr1:119140396~119275973:+
THCA	cis	rs11098499	0.865	rs4001305	ENSG00000245958.5	RP11-33B1.1	-16.62	3.96e-49	1.46e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119438081	chr4:119454791~119552025:+
THCA	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-16.62	3.97e-49	1.47e-45	-0.79	-0.61	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
THCA	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	16.61	4.37e-49	1.61e-45	0.81	0.61	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
THCA	cis	rs524281	0.773	rs10791863	ENSG00000255320.1	RP11-755F10.1	16.61	4.4e-49	1.62e-45	0.94	0.61	Electroencephalogram traits;	chr11:66259887	chr11:66244840~66246239:-
THCA	cis	rs1153858	1	rs4774577	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Homoarginine levels;	chr15:45352487	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4774578	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Homoarginine levels;	chr15:45353853	chr15:45251580~45279251:-
THCA	cis	rs61524473	1	rs61524473	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Metabolite levels (small molecules and protein measures);	chr15:45354085	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs10444821	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Homoarginine levels;	chr15:45355038	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs72623915	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Homoarginine levels;	chr15:45355235	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs66714503	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Homoarginine levels;	chr15:45355840	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs2066090	ENSG00000259520.4	CTD-2651B20.3	-16.61	4.48e-49	1.65e-45	-0.77	-0.61	Homoarginine levels;	chr15:45357820	chr15:45251580~45279251:-
THCA	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	16.61	4.57e-49	1.68e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.954	rs4309825	ENSG00000245958.5	RP11-33B1.1	16.61	4.59e-49	1.69e-45	0.61	0.61	Corneal astigmatism;	chr4:119393726	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs2389803	ENSG00000245958.5	RP11-33B1.1	16.6	4.67e-49	1.72e-45	0.62	0.61	Corneal astigmatism;	chr4:119472356	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	16.6	4.71e-49	1.73e-45	1.12	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
THCA	cis	rs2283792	0.73	rs894095	ENSG00000224086.5	LL22NC03-86G7.1	-16.6	4.77e-49	1.75e-45	-0.73	-0.61	Multiple sclerosis;	chr22:21928404	chr22:21938293~21977632:+
THCA	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	16.6	5.01e-49	1.84e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	16.6	5.04e-49	1.85e-45	1.1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
THCA	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	16.59	5.22e-49	1.91e-45	0.76	0.61	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
THCA	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-16.59	5.45e-49	2e-45	-0.8	-0.61	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
THCA	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	16.59	5.47e-49	2.01e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.738	rs72918577	ENSG00000245958.5	RP11-33B1.1	-16.59	5.63e-49	2.06e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119405546	chr4:119454791~119552025:+
THCA	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	16.58	6.08e-49	2.23e-45	1.06	0.61	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
THCA	cis	rs67180937	0.7	rs12043288	ENSG00000272750.1	RP11-378J18.8	-16.58	6.09e-49	2.23e-45	-0.67	-0.61	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222732952	chr1:222658867~222661512:-
THCA	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	16.58	6.12e-49	2.24e-45	0.64	0.61	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.908	rs1002152	ENSG00000245958.5	RP11-33B1.1	-16.58	6.29e-49	2.3e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119352232	chr4:119454791~119552025:+
THCA	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-16.57	6.48e-49	2.37e-45	-0.81	-0.61	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
THCA	cis	rs11098499	0.954	rs3733520	ENSG00000245958.5	RP11-33B1.1	-16.57	6.61e-49	2.41e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119502325	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.779	rs10011097	ENSG00000245958.5	RP11-33B1.1	-16.57	6.83e-49	2.5e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119389204	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs10026736	ENSG00000245958.5	RP11-33B1.1	-16.56	7.09e-49	2.59e-45	-0.62	-0.61	Corneal astigmatism;	chr4:119463167	chr4:119454791~119552025:+
THCA	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	16.56	7.27e-49	2.65e-45	0.71	0.61	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
THCA	cis	rs1153858	1	rs4775911	ENSG00000259520.4	CTD-2651B20.3	16.56	7.38e-49	2.69e-45	0.78	0.61	Homoarginine levels;	chr15:45357589	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs16952714	ENSG00000259520.4	CTD-2651B20.3	-16.56	7.47e-49	2.73e-45	-0.77	-0.61	Homoarginine levels;	chr15:45358160	chr15:45251580~45279251:-
THCA	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	16.56	7.68e-49	2.8e-45	1.1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	16.55	8.29e-49	3.02e-45	1.1	0.61	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
THCA	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	16.54	9.01e-49	3.27e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	16.54	9.01e-49	3.27e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	16.54	9.01e-49	3.27e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
THCA	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	16.54	9.02e-49	3.27e-45	0.71	0.61	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
THCA	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	16.54	9.04e-49	3.28e-45	0.79	0.61	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
THCA	cis	rs977987	0.8	rs11149815	ENSG00000261783.1	RP11-252K23.2	-16.54	9.44e-49	3.42e-45	-0.78	-0.61	Dupuytren's disease;	chr16:75302275	chr16:75379818~75381260:-
THCA	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-16.53	1.01e-48	3.67e-45	-0.99	-0.61	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
THCA	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	16.53	1.01e-48	3.68e-45	1.1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	16.53	1.01e-48	3.68e-45	1.1	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
THCA	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	16.53	1.03e-48	3.72e-45	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
THCA	cis	rs1153858	1	rs1613559	ENSG00000259520.4	CTD-2651B20.3	-16.53	1.07e-48	3.88e-45	-0.77	-0.61	Homoarginine levels;	chr15:45329918	chr15:45251580~45279251:-
THCA	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	16.52	1.11e-48	4.01e-45	0.79	0.61	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	16.52	1.11e-48	4.01e-45	0.79	0.61	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	16.52	1.11e-48	4.01e-45	0.79	0.61	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
THCA	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-16.52	1.14e-48	4.11e-45	-0.68	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
THCA	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-16.52	1.15e-48	4.14e-45	-0.65	-0.61	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
THCA	cis	rs7240205	0.853	rs34288695	ENSG00000275805.1	RP11-349H17.2	16.52	1.16e-48	4.2e-45	0.7	0.61	Breast cancer;	chr18:26563122	chr18:26565723~26575626:-
THCA	cis	rs7727544	0.735	rs274559	ENSG00000233006.5	AC034220.3	-16.51	1.2e-48	4.32e-45	-0.46	-0.61	Blood metabolite levels;	chr5:132384378	chr5:132311285~132369916:-
THCA	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	16.51	1.25e-48	4.5e-45	0.98	0.61	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
THCA	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-16.51	1.3e-48	4.67e-45	-0.71	-0.61	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
THCA	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-16.5	1.39e-48	5.02e-45	-0.76	-0.61	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
THCA	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	16.5	1.41e-48	5.08e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.618	rs35265692	ENSG00000245958.5	RP11-33B1.1	-16.5	1.42e-48	5.11e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119403980	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	16.5	1.43e-48	5.16e-45	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	16.5	1.43e-48	5.16e-45	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	16.5	1.43e-48	5.16e-45	0.69	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.623	rs60890550	ENSG00000263531.1	RP13-753N3.1	16.5	1.46e-48	5.24e-45	1.14	0.61	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30863921~30864940:-
THCA	cis	rs1153858	1	rs61365925	ENSG00000259520.4	CTD-2651B20.3	-16.49	1.48e-48	5.33e-45	-0.77	-0.61	Homoarginine levels;	chr15:45358113	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs12101539	ENSG00000259520.4	CTD-2651B20.3	-16.49	1.48e-48	5.33e-45	-0.77	-0.61	Homoarginine levels;	chr15:45358468	chr15:45251580~45279251:-
THCA	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	16.49	1.51e-48	5.45e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
THCA	cis	rs1930961	1	rs5996946	ENSG00000272977.1	CTA-390C10.10	-16.49	1.55e-48	5.59e-45	-0.98	-0.61	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25476218~25479971:+
THCA	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	16.48	1.73e-48	6.22e-45	0.68	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
THCA	cis	rs7188445	1	rs11150190	ENSG00000261390.4	RP11-345M22.2	-16.47	1.82e-48	6.53e-45	-0.73	-0.61	Urate levels;	chr16:79700352	chr16:79715232~79770563:-
THCA	cis	rs11098499	0.954	rs10017371	ENSG00000245958.5	RP11-33B1.1	-16.47	1.85e-48	6.65e-45	-0.61	-0.61	Corneal astigmatism;	chr4:119372621	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs1022145	ENSG00000245958.5	RP11-33B1.1	-16.47	1.87e-48	6.72e-45	-0.61	-0.6	Corneal astigmatism;	chr4:119309824	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.908	rs9995234	ENSG00000245958.5	RP11-33B1.1	-16.47	1.89e-48	6.77e-45	-0.61	-0.6	Corneal astigmatism;	chr4:119400672	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	16.47	1.93e-48	6.91e-45	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
THCA	cis	rs7240205	0.853	rs10853666	ENSG00000275805.1	RP11-349H17.2	16.47	1.93e-48	6.91e-45	0.7	0.6	Breast cancer;	chr18:26564147	chr18:26565723~26575626:-
THCA	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	16.47	1.95e-48	7e-45	0.69	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
THCA	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	16.47	1.98e-48	7.09e-45	0.71	0.6	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
THCA	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	16.46	2.1e-48	7.52e-45	0.63	0.6	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	16.46	2.1e-48	7.52e-45	0.63	0.6	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
THCA	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	16.46	2.16e-48	7.75e-45	0.71	0.6	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
THCA	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-16.46	2.19e-48	7.82e-45	-0.77	-0.6	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-16.46	2.19e-48	7.82e-45	-0.77	-0.6	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
THCA	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-16.46	2.21e-48	7.92e-45	-0.77	-0.6	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
THCA	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-16.45	2.26e-48	8.1e-45	-0.78	-0.6	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
THCA	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-16.45	2.32e-48	8.28e-45	-0.76	-0.6	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
THCA	cis	rs11098499	0.697	rs4560394	ENSG00000245958.5	RP11-33B1.1	-16.45	2.35e-48	8.41e-45	-0.61	-0.6	Corneal astigmatism;	chr4:119392280	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.954	rs1546505	ENSG00000245958.5	RP11-33B1.1	-16.45	2.44e-48	8.72e-45	-0.61	-0.6	Corneal astigmatism;	chr4:119320069	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-16.45	2.45e-48	8.73e-45	-0.78	-0.6	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
THCA	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-16.45	2.48e-48	8.85e-45	-0.61	-0.6	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
THCA	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	16.44	2.49e-48	8.88e-45	1.15	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
THCA	cis	rs1153858	1	rs12439274	ENSG00000259520.4	CTD-2651B20.3	-16.44	2.51e-48	8.96e-45	-0.77	-0.6	Homoarginine levels;	chr15:45344469	chr15:45251580~45279251:-
THCA	cis	rs524281	0.773	rs11227447	ENSG00000255320.1	RP11-755F10.1	16.44	2.52e-48	9e-45	0.93	0.6	Electroencephalogram traits;	chr11:66280809	chr11:66244840~66246239:-
THCA	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	16.44	2.64e-48	9.4e-45	0.68	0.6	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	16.44	2.64e-48	9.4e-45	0.68	0.6	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
THCA	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	16.44	2.72e-48	9.7e-45	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.909	rs10020034	ENSG00000245958.5	RP11-33B1.1	-16.43	2.79e-48	9.95e-45	-0.61	-0.6	Corneal astigmatism;	chr4:119373176	chr4:119454791~119552025:+
THCA	cis	rs17023223	0.537	rs17023171	ENSG00000231365.4	RP11-418J17.1	-16.43	2.79e-48	9.95e-45	-0.69	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050645	chr1:119140396~119275973:+
THCA	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-16.43	2.87e-48	1.02e-44	-0.64	-0.6	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
THCA	cis	rs7727544	0.735	rs274558	ENSG00000233006.5	AC034220.3	-16.42	3.12e-48	1.11e-44	-0.46	-0.6	Blood metabolite levels;	chr5:132385482	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.735	rs274557	ENSG00000233006.5	AC034220.3	-16.42	3.12e-48	1.11e-44	-0.46	-0.6	Blood metabolite levels;	chr5:132385512	chr5:132311285~132369916:-
THCA	cis	rs7104764	0.701	rs3782115	ENSG00000277290.1	RP11-326C3.16	-16.42	3.14e-48	1.12e-44	-0.63	-0.6	Menarche (age at onset);	chr11:223272	chr11:243099~243483:-
THCA	cis	rs17023223	0.537	rs2361271	ENSG00000231365.4	RP11-418J17.1	-16.42	3.21e-48	1.14e-44	-0.69	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060782	chr1:119140396~119275973:+
THCA	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	16.42	3.26e-48	1.16e-44	1.01	0.6	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
THCA	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	16.42	3.26e-48	1.16e-44	1.01	0.6	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
THCA	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	16.42	3.26e-48	1.16e-44	1.01	0.6	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
THCA	cis	rs17111396	1	rs10873333	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81034469	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs726627	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81034540	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs726626	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81034770	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs726625	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81034805	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs726628	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81034855	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs11159483	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81034967	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs61978725	ENSG00000259167.2	NMNAT1P1	16.42	3.36e-48	1.19e-44	0.8	0.6	Uric acid levels;	chr14:81035378	chr14:81032529~81033404:+
THCA	cis	rs524281	0.773	rs2155030	ENSG00000255320.1	RP11-755F10.1	16.41	3.43e-48	1.22e-44	0.92	0.6	Electroencephalogram traits;	chr11:66263216	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs2155031	ENSG00000255320.1	RP11-755F10.1	16.41	3.43e-48	1.22e-44	0.92	0.6	Electroencephalogram traits;	chr11:66263456	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs2298468	ENSG00000255320.1	RP11-755F10.1	16.41	3.43e-48	1.22e-44	0.92	0.6	Electroencephalogram traits;	chr11:66275491	chr11:66244840~66246239:-
THCA	cis	rs524281	0.773	rs79770412	ENSG00000255320.1	RP11-755F10.1	16.41	3.43e-48	1.22e-44	0.92	0.6	Electroencephalogram traits;	chr11:66277873	chr11:66244840~66246239:-
THCA	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-16.41	3.44e-48	1.22e-44	-0.49	-0.6	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
THCA	cis	rs17023223	0.537	rs1325940	ENSG00000231365.4	RP11-418J17.1	-16.41	3.55e-48	1.26e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044064	chr1:119140396~119275973:+
THCA	cis	rs11098499	0.865	rs11098513	ENSG00000245958.5	RP11-33B1.1	-16.41	3.67e-48	1.3e-44	-0.61	-0.6	Corneal astigmatism;	chr4:119394920	chr4:119454791~119552025:+
THCA	cis	rs1153858	0.725	rs74572151	ENSG00000259520.4	CTD-2651B20.3	-16.41	3.7e-48	1.31e-44	-0.77	-0.6	Homoarginine levels;	chr15:45355328	chr15:45251580~45279251:-
THCA	cis	rs17111396	1	rs12323481	ENSG00000259167.2	NMNAT1P1	16.4	3.8e-48	1.34e-44	0.8	0.6	Uric acid levels;	chr14:81035702	chr14:81032529~81033404:+
THCA	cis	rs11098499	0.909	rs73842633	ENSG00000245958.5	RP11-33B1.1	-16.4	3.96e-48	1.4e-44	-0.62	-0.6	Corneal astigmatism;	chr4:119454309	chr4:119454791~119552025:+
THCA	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	16.4	4.08e-48	1.44e-44	0.8	0.6	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
THCA	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	16.4	4.08e-48	1.44e-44	0.8	0.6	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
THCA	cis	rs17111396	1	rs12323693	ENSG00000259167.2	NMNAT1P1	16.4	4.12e-48	1.46e-44	0.8	0.6	Uric acid levels;	chr14:81038613	chr14:81032529~81033404:+
THCA	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-16.4	4.16e-48	1.47e-44	-0.7	-0.6	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
THCA	cis	rs1153858	1	rs11852800	ENSG00000259520.4	CTD-2651B20.3	16.39	4.22e-48	1.49e-44	0.76	0.6	Homoarginine levels;	chr15:45346933	chr15:45251580~45279251:-
THCA	cis	rs7240205	0.853	rs58806199	ENSG00000275805.1	RP11-349H17.2	-16.39	4.3e-48	1.52e-44	-0.7	-0.6	Breast cancer;	chr18:26562683	chr18:26565723~26575626:-
THCA	cis	rs17111396	1	rs12323785	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81035726	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs11159484	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81037209	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs12323893	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81037309	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs11159487	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81037812	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs11159488	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81037815	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.95	rs13353103	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81038031	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs13353125	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81038079	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs13353104	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81038207	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.95	rs12323355	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81038516	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs12323350	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81038588	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs12323762	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81038745	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.95	rs12184961	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81039207	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs12185035	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81039335	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs12184963	ENSG00000259167.2	NMNAT1P1	16.39	4.35e-48	1.53e-44	0.8	0.6	Uric acid levels;	chr14:81039393	chr14:81032529~81033404:+
THCA	cis	rs524281	0.731	rs2276036	ENSG00000255320.1	RP11-755F10.1	16.39	4.37e-48	1.54e-44	0.92	0.6	Electroencephalogram traits;	chr11:66265959	chr11:66244840~66246239:-
THCA	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	16.39	4.53e-48	1.59e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
THCA	cis	rs7188445	1	rs11864901	ENSG00000261390.4	RP11-345M22.2	-16.39	4.53e-48	1.59e-44	-0.73	-0.6	Urate levels;	chr16:79697908	chr16:79715232~79770563:-
THCA	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-16.38	4.76e-48	1.67e-44	-0.85	-0.6	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
THCA	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	16.38	4.77e-48	1.68e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	16.38	4.77e-48	1.68e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	16.38	4.77e-48	1.68e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
THCA	cis	rs17023223	0.537	rs2361272	ENSG00000231365.4	RP11-418J17.1	-16.38	4.99e-48	1.75e-44	-0.69	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060794	chr1:119140396~119275973:+
THCA	cis	rs3779195	0.697	rs1688606	ENSG00000272950.1	RP11-307C18.1	16.38	5.09e-48	1.79e-44	0.87	0.6	Sex hormone-binding globulin levels;	chr7:98345539	chr7:98322853~98323430:+
THCA	cis	rs11155671	0.53	rs9968871	ENSG00000223701.3	RAET1E-AS1	16.37	5.29e-48	1.86e-44	0.8	0.6	Testicular germ cell tumor;	chr6:149888060	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs9969044	ENSG00000223701.3	RAET1E-AS1	16.37	5.29e-48	1.86e-44	0.8	0.6	Testicular germ cell tumor;	chr6:149888068	chr6:149884431~149919508:+
THCA	cis	rs17023223	0.537	rs12081585	ENSG00000231365.4	RP11-418J17.1	-16.37	5.47e-48	1.92e-44	-0.71	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119073333	chr1:119140396~119275973:+
THCA	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-16.37	5.52e-48	1.93e-44	-0.78	-0.6	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
THCA	cis	rs17111396	1	rs12323790	ENSG00000259167.2	NMNAT1P1	16.37	5.71e-48	2e-44	0.8	0.6	Uric acid levels;	chr14:81035933	chr14:81032529~81033404:+
THCA	cis	rs11155671	0.53	rs7758033	ENSG00000223701.3	RAET1E-AS1	16.36	5.98e-48	2.09e-44	0.79	0.6	Testicular germ cell tumor;	chr6:149886999	chr6:149884431~149919508:+
THCA	cis	rs3779195	0.627	rs6950023	ENSG00000272950.1	RP11-307C18.1	16.36	6.31e-48	2.21e-44	0.89	0.6	Sex hormone-binding globulin levels;	chr7:98286323	chr7:98322853~98323430:+
THCA	cis	rs3779195	0.627	rs6967728	ENSG00000272950.1	RP11-307C18.1	16.36	6.31e-48	2.21e-44	0.89	0.6	Sex hormone-binding globulin levels;	chr7:98286325	chr7:98322853~98323430:+
THCA	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-16.36	6.37e-48	2.23e-44	-0.6	-0.6	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
THCA	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	16.35	6.41e-48	2.24e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
THCA	cis	rs17023223	0.581	rs2765529	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039277	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs1325938	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119040019	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2765530	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119041773	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2765531	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119042874	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2794313	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119044817	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2794312	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048423	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2765532	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119048923	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs56708249	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050582	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs17023174	ENSG00000231365.4	RP11-418J17.1	-16.35	6.42e-48	2.24e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119050678	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs17023185	ENSG00000231365.4	RP11-418J17.1	-16.35	6.5e-48	2.27e-44	-0.71	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119068164	chr1:119140396~119275973:+
THCA	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-16.35	6.8e-48	2.37e-44	-0.78	-0.6	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
THCA	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-16.35	7.01e-48	2.45e-44	-0.68	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
THCA	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	16.34	7.11e-48	2.48e-44	0.71	0.6	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
THCA	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	16.34	7.11e-48	2.48e-44	0.71	0.6	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
THCA	cis	rs1431005	0.793	rs7695310	ENSG00000250620.1	RP11-91J3.3	16.34	7.31e-48	2.55e-44	0.76	0.6	Response to statin therapy;	chr4:187415987	chr4:187413564~187415697:+
THCA	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	16.34	7.32e-48	2.55e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
THCA	cis	rs17111396	0.95	rs2192727	ENSG00000259167.2	NMNAT1P1	16.34	7.4e-48	2.58e-44	0.8	0.6	Uric acid levels;	chr14:81032811	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs11159485	ENSG00000259167.2	NMNAT1P1	16.34	7.67e-48	2.67e-44	0.8	0.6	Uric acid levels;	chr14:81037775	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.95	rs11159486	ENSG00000259167.2	NMNAT1P1	16.34	7.67e-48	2.67e-44	0.8	0.6	Uric acid levels;	chr14:81037780	chr14:81032529~81033404:+
THCA	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-16.34	7.78e-48	2.71e-44	-0.7	-0.6	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
THCA	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	16.33	7.94e-48	2.76e-44	0.67	0.6	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
THCA	cis	rs11098499	0.954	rs11722872	ENSG00000245958.5	RP11-33B1.1	-16.33	8.14e-48	2.83e-44	-0.6	-0.6	Corneal astigmatism;	chr4:119311875	chr4:119454791~119552025:+
THCA	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-16.33	8.56e-48	2.98e-44	-0.48	-0.6	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
THCA	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	16.33	8.63e-48	3e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
THCA	cis	rs17111396	1	rs61978742	ENSG00000259167.2	NMNAT1P1	16.32	8.76e-48	3.04e-44	0.8	0.6	Uric acid levels;	chr14:81039023	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.951	rs61978743	ENSG00000259167.2	NMNAT1P1	16.32	8.76e-48	3.04e-44	0.8	0.6	Uric acid levels;	chr14:81039047	chr14:81032529~81033404:+
THCA	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	16.32	8.85e-48	3.08e-44	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
THCA	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	-16.32	8.9e-48	3.09e-44	-1.01	-0.6	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
THCA	cis	rs7743045	0.652	rs9387621	ENSG00000253194.1	RP11-351A11.1	16.32	9.31e-48	3.23e-44	0.85	0.6	Mean platelet volume;	chr6:118973412	chr6:118934785~119031541:+
THCA	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	16.32	9.37e-48	3.25e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.863	rs3736115	ENSG00000245958.5	RP11-33B1.1	16.32	9.61e-48	3.33e-44	0.62	0.6	Corneal astigmatism;	chr4:119567548	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	16.32	9.64e-48	3.35e-44	0.8	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
THCA	cis	rs17023223	0.537	rs12072768	ENSG00000231365.4	RP11-418J17.1	-16.32	9.66e-48	3.35e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119051295	chr1:119140396~119275973:+
THCA	cis	rs7727544	0.735	rs2569266	ENSG00000233006.5	AC034220.3	-16.32	9.67e-48	3.35e-44	-0.46	-0.6	Blood metabolite levels;	chr5:132371099	chr5:132311285~132369916:-
THCA	cis	rs7188445	1	rs61221126	ENSG00000261390.4	RP11-345M22.2	-16.31	9.7e-48	3.36e-44	-0.73	-0.6	Urate levels;	chr16:79699377	chr16:79715232~79770563:-
THCA	cis	rs17023223	0.509	rs6668960	ENSG00000231365.4	RP11-418J17.1	-16.31	9.75e-48	3.38e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119058189	chr1:119140396~119275973:+
THCA	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	16.31	9.77e-48	3.39e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
THCA	cis	rs17023223	0.537	rs61808892	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119056584	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2361269	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119059592	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2645300	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060444	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2361270	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119060699	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2361273	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061077	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs10923741	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119061850	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs10802073	ENSG00000231365.4	RP11-418J17.1	-16.31	1.01e-47	3.5e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062032	chr1:119140396~119275973:+
THCA	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	16.31	1.02e-47	3.53e-44	0.67	0.6	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
THCA	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	16.31	1.02e-47	3.54e-44	0.61	0.6	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
THCA	cis	rs3779195	0.858	rs3779196	ENSG00000272950.1	RP11-307C18.1	16.31	1.02e-47	3.55e-44	0.87	0.6	Sex hormone-binding globulin levels;	chr7:98360794	chr7:98322853~98323430:+
THCA	cis	rs3779195	0.789	rs6965424	ENSG00000272950.1	RP11-307C18.1	16.31	1.02e-47	3.55e-44	0.87	0.6	Sex hormone-binding globulin levels;	chr7:98361813	chr7:98322853~98323430:+
THCA	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	16.31	1.07e-47	3.71e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
THCA	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-16.3	1.1e-47	3.79e-44	-0.49	-0.6	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
THCA	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	16.3	1.1e-47	3.81e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
THCA	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	16.3	1.12e-47	3.86e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
THCA	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	16.3	1.13e-47	3.9e-44	0.7	0.6	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
THCA	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-16.3	1.17e-47	4.03e-44	-0.76	-0.6	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
THCA	cis	rs17111396	0.95	rs28478356	ENSG00000259167.2	NMNAT1P1	16.3	1.19e-47	4.09e-44	0.79	0.6	Uric acid levels;	chr14:81034034	chr14:81032529~81033404:+
THCA	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	16.29	1.2e-47	4.14e-44	0.63	0.6	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
THCA	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-16.29	1.21e-47	4.17e-44	-0.76	-0.6	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
THCA	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-16.29	1.21e-47	4.17e-44	-0.76	-0.6	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
THCA	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-16.29	1.21e-47	4.17e-44	-0.76	-0.6	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
THCA	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-16.29	1.21e-47	4.17e-44	-0.76	-0.6	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
THCA	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-16.29	1.23e-47	4.23e-44	-0.78	-0.6	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
THCA	cis	rs1431005	0.893	rs7663709	ENSG00000250620.1	RP11-91J3.3	16.29	1.23e-47	4.24e-44	0.76	0.6	Response to statin therapy;	chr4:187414777	chr4:187413564~187415697:+
THCA	cis	rs1431005	0.784	rs67451289	ENSG00000250620.1	RP11-91J3.3	16.29	1.23e-47	4.24e-44	0.76	0.6	Response to statin therapy;	chr4:187415295	chr4:187413564~187415697:+
THCA	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	16.29	1.24e-47	4.26e-44	0.67	0.6	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
THCA	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-16.29	1.24e-47	4.28e-44	-0.64	-0.6	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
THCA	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	16.29	1.25e-47	4.31e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
THCA	cis	rs1153858	1	rs16942000	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45340805	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.945	rs7182300	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45342730	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.887	rs7171163	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45344197	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs56669689	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45345531	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs56806728	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45345616	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4775906	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45346096	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs7179743	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45346133	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4775907	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45346449	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs7163720	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45347176	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs7167900	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45347273	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs12591058	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45347974	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs7169587	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45348181	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.943	rs28605551	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45349522	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4775909	ENSG00000259520.4	CTD-2651B20.3	-16.29	1.26e-47	4.34e-44	-0.76	-0.6	Homoarginine levels;	chr15:45350844	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs9783731	ENSG00000259520.4	CTD-2651B20.3	16.29	1.26e-47	4.34e-44	0.76	0.6	Homoarginine levels;	chr15:45350686	chr15:45251580~45279251:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-16.29	1.27e-47	4.35e-44	-0.79	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
THCA	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-16.29	1.28e-47	4.41e-44	-0.76	-0.6	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
THCA	cis	rs7727544	0.735	rs274566	ENSG00000233006.5	AC034220.3	-16.29	1.29e-47	4.44e-44	-0.46	-0.6	Blood metabolite levels;	chr5:132379319	chr5:132311285~132369916:-
THCA	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-16.29	1.31e-47	4.49e-44	-0.77	-0.6	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
THCA	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	16.29	1.31e-47	4.5e-44	1.09	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
THCA	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	16.28	1.4e-47	4.8e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
THCA	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	16.28	1.41e-47	4.84e-44	1.13	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	16.28	1.41e-47	4.84e-44	0.79	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
THCA	cis	rs7727544	0.735	rs274568	ENSG00000233006.5	AC034220.3	-16.28	1.42e-47	4.85e-44	-0.46	-0.6	Blood metabolite levels;	chr5:132377886	chr5:132311285~132369916:-
THCA	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-16.28	1.45e-47	4.96e-44	-0.79	-0.6	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
THCA	cis	rs10170846	1	rs10170846	ENSG00000261428.2	RP11-16P6.1	-16.28	1.45e-47	4.98e-44	-0.62	-0.6	Schizophrenia (inflammation and infection response interaction);	chr2:222652986	chr2:222566899~222569719:-
THCA	cis	rs7743045	0.652	rs12527291	ENSG00000253194.1	RP11-351A11.1	16.27	1.47e-47	5.05e-44	0.84	0.6	Mean platelet volume;	chr6:118977672	chr6:118934785~119031541:+
THCA	cis	rs17023223	0.537	rs2765534	ENSG00000231365.4	RP11-418J17.1	-16.27	1.5e-47	5.14e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119055169	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs1343723	ENSG00000231365.4	RP11-418J17.1	-16.27	1.5e-47	5.14e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119062431	chr1:119140396~119275973:+
THCA	cis	rs17111396	1	rs12323799	ENSG00000259167.2	NMNAT1P1	16.27	1.52e-47	5.2e-44	0.79	0.6	Uric acid levels;	chr14:81036183	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs12323491	ENSG00000259167.2	NMNAT1P1	16.27	1.52e-47	5.2e-44	0.79	0.6	Uric acid levels;	chr14:81036333	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.95	rs112548722	ENSG00000259167.2	NMNAT1P1	16.27	1.52e-47	5.2e-44	0.79	0.6	Uric acid levels;	chr14:81044512	chr14:81032529~81033404:+
THCA	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	16.27	1.54e-47	5.26e-44	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	16.27	1.54e-47	5.26e-44	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	16.27	1.54e-47	5.26e-44	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
THCA	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-16.27	1.54e-47	5.27e-44	-0.67	-0.6	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
THCA	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-16.27	1.58e-47	5.39e-44	-0.76	-0.6	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
THCA	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	16.27	1.61e-47	5.49e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
THCA	cis	rs17111396	1	rs28416942	ENSG00000259167.2	NMNAT1P1	16.26	1.66e-47	5.66e-44	0.79	0.6	Uric acid levels;	chr14:81033965	chr14:81032529~81033404:+
THCA	cis	rs17023223	0.537	rs2645301	ENSG00000231365.4	RP11-418J17.1	-16.26	1.72e-47	5.86e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047797	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs6662165	ENSG00000231365.4	RP11-418J17.1	-16.26	1.72e-47	5.86e-44	-0.7	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119071448	chr1:119140396~119275973:+
THCA	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	16.26	1.81e-47	6.19e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
THCA	cis	rs17111396	1	rs61978724	ENSG00000259167.2	NMNAT1P1	16.25	1.86e-47	6.36e-44	0.79	0.6	Uric acid levels;	chr14:81031959	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs2268470	ENSG00000259167.2	NMNAT1P1	16.25	1.86e-47	6.36e-44	0.79	0.6	Uric acid levels;	chr14:81033151	chr14:81032529~81033404:+
THCA	cis	rs11098499	0.82	rs11737395	ENSG00000245958.5	RP11-33B1.1	-16.24	2.02e-47	6.87e-44	-0.61	-0.6	Corneal astigmatism;	chr4:119599549	chr4:119454791~119552025:+
THCA	cis	rs17023223	0.537	rs1057991	ENSG00000231365.4	RP11-418J17.1	-16.24	2.04e-47	6.93e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032547	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs1057990	ENSG00000231365.4	RP11-418J17.1	-16.24	2.04e-47	6.93e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119032609	chr1:119140396~119275973:+
THCA	cis	rs17023223	0.537	rs2645302	ENSG00000231365.4	RP11-418J17.1	-16.24	2.09e-47	7.09e-44	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119047775	chr1:119140396~119275973:+
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	16.24	2.15e-47	7.3e-44	0.69	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
THCA	cis	rs11098499	0.865	rs11722183	ENSG00000245958.5	RP11-33B1.1	-16.24	2.16e-47	7.33e-44	-0.6	-0.6	Corneal astigmatism;	chr4:119359442	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	16.24	2.19e-47	7.44e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
THCA	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-16.24	2.21e-47	7.49e-44	-0.89	-0.6	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
THCA	cis	rs11673344	0.683	rs11668615	ENSG00000226686.6	LINC01535	16.23	2.38e-47	8.08e-44	0.77	0.6	Obesity-related traits;	chr19:37063632	chr19:37251912~37265535:+
THCA	cis	rs17111396	1	rs2268472	ENSG00000259167.2	NMNAT1P1	16.23	2.39e-47	8.1e-44	0.79	0.6	Uric acid levels;	chr14:81033802	chr14:81032529~81033404:+
THCA	cis	rs524281	0.773	rs2282568	ENSG00000255320.1	RP11-755F10.1	16.23	2.4e-47	8.13e-44	0.92	0.6	Electroencephalogram traits;	chr11:66285361	chr11:66244840~66246239:-
THCA	cis	rs977987	0.732	rs999675	ENSG00000261783.1	RP11-252K23.2	-16.23	2.46e-47	8.33e-44	-0.82	-0.6	Dupuytren's disease;	chr16:75272504	chr16:75379818~75381260:-
THCA	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	16.22	2.49e-47	8.43e-44	0.63	0.6	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
THCA	cis	rs11155671	0.53	rs7756850	ENSG00000223701.3	RAET1E-AS1	16.22	2.52e-47	8.53e-44	0.78	0.6	Testicular germ cell tumor;	chr6:149891460	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs9371542	ENSG00000223701.3	RAET1E-AS1	16.22	2.52e-47	8.53e-44	0.78	0.6	Testicular germ cell tumor;	chr6:149891949	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.567	rs7747457	ENSG00000223701.3	RAET1E-AS1	16.22	2.52e-47	8.53e-44	0.78	0.6	Lung cancer;	chr6:149892366	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs9371223	ENSG00000223701.3	RAET1E-AS1	16.22	2.52e-47	8.53e-44	0.78	0.6	Testicular germ cell tumor;	chr6:149893670	chr6:149884431~149919508:+
THCA	cis	rs17111396	1	rs2268471	ENSG00000259167.2	NMNAT1P1	16.22	2.59e-47	8.78e-44	0.79	0.6	Uric acid levels;	chr14:81033195	chr14:81032529~81033404:+
THCA	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-16.22	2.6e-47	8.81e-44	-0.77	-0.6	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
THCA	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-16.22	2.61e-47	8.83e-44	-0.79	-0.6	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
THCA	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	16.22	2.62e-47	8.86e-44	1	0.6	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
THCA	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	16.22	2.65e-47	8.98e-44	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
THCA	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-16.22	2.75e-47	9.3e-44	-0.67	-0.6	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
THCA	cis	rs7188445	0.899	rs7195321	ENSG00000261390.4	RP11-345M22.2	-16.22	2.76e-47	9.32e-44	-0.72	-0.6	Urate levels;	chr16:79701065	chr16:79715232~79770563:-
THCA	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-16.22	2.76e-47	9.32e-44	-0.79	-0.6	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
THCA	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-16.21	2.86e-47	9.67e-44	-0.89	-0.6	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
THCA	cis	rs3779195	0.86	rs12704986	ENSG00000272950.1	RP11-307C18.1	16.21	2.87e-47	9.71e-44	0.87	0.6	Sex hormone-binding globulin levels;	chr7:98357118	chr7:98322853~98323430:+
THCA	cis	rs7240205	0.853	rs4555225	ENSG00000275805.1	RP11-349H17.2	-16.21	2.91e-47	9.83e-44	-0.69	-0.6	Breast cancer;	chr18:26561892	chr18:26565723~26575626:-
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	16.21	2.95e-47	9.93e-44	0.74	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
THCA	cis	rs7727544	0.636	rs2631365	ENSG00000233006.5	AC034220.3	-16.21	3.03e-47	1.02e-43	-0.46	-0.6	Blood metabolite levels;	chr5:132370257	chr5:132311285~132369916:-
THCA	cis	rs11098499	0.866	rs72676074	ENSG00000245958.5	RP11-33B1.1	-16.2	3.06e-47	1.03e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119438686	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	16.2	3.08e-47	1.04e-43	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
THCA	cis	rs17111396	1	rs2300525	ENSG00000259167.2	NMNAT1P1	-16.2	3.16e-47	1.06e-43	-0.79	-0.6	Uric acid levels;	chr14:81031049	chr14:81032529~81033404:+
THCA	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-16.2	3.29e-47	1.11e-43	-0.6	-0.6	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
THCA	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-16.2	3.29e-47	1.11e-43	-0.6	-0.6	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
THCA	cis	rs11155671	0.53	rs9383577	ENSG00000223701.3	RAET1E-AS1	16.2	3.31e-47	1.11e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149886059	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs9383914	ENSG00000223701.3	RAET1E-AS1	16.2	3.31e-47	1.11e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149886098	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.517	rs9397058	ENSG00000223701.3	RAET1E-AS1	16.2	3.31e-47	1.11e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149886113	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs7768626	ENSG00000223701.3	RAET1E-AS1	16.2	3.31e-47	1.11e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149886826	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs7768665	ENSG00000223701.3	RAET1E-AS1	16.2	3.31e-47	1.11e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149886888	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs7758020	ENSG00000223701.3	RAET1E-AS1	16.2	3.31e-47	1.11e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149886975	chr6:149884431~149919508:+
THCA	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	16.2	3.35e-47	1.12e-43	0.67	0.6	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
THCA	cis	rs7743045	0.652	rs72970476	ENSG00000253194.1	RP11-351A11.1	16.2	3.39e-47	1.14e-43	0.85	0.6	Mean platelet volume;	chr6:118997887	chr6:118934785~119031541:+
THCA	cis	rs17111396	1	rs72689918	ENSG00000259167.2	NMNAT1P1	16.19	3.47e-47	1.16e-43	0.79	0.6	Uric acid levels;	chr14:81035599	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs72689919	ENSG00000259167.2	NMNAT1P1	16.19	3.47e-47	1.16e-43	0.79	0.6	Uric acid levels;	chr14:81035600	chr14:81032529~81033404:+
THCA	cis	rs7104764	0.719	rs3782116	ENSG00000277290.1	RP11-326C3.16	-16.19	3.61e-47	1.21e-43	-0.62	-0.6	Menarche (age at onset);	chr11:223119	chr11:243099~243483:-
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	16.19	3.65e-47	1.22e-43	0.78	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
THCA	cis	rs916888	0.779	rs199526	ENSG00000214401.4	KANSL1-AS1	-16.19	3.76e-47	1.26e-43	-0.8	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46193576~46196723:+
THCA	cis	rs9326248	0.569	rs11216161	ENSG00000254851.1	RP11-109L13.1	-16.18	3.84e-47	1.29e-43	-0.87	-0.6	Blood protein levels;	chr11:116850485	chr11:117135528~117138582:+
THCA	cis	rs11155671	0.53	rs9383912	ENSG00000223701.3	RAET1E-AS1	16.18	3.86e-47	1.29e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149885479	chr6:149884431~149919508:+
THCA	cis	rs11098499	0.818	rs55825515	ENSG00000245958.5	RP11-33B1.1	-16.18	3.92e-47	1.31e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119565247	chr4:119454791~119552025:+
THCA	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-16.18	3.99e-47	1.33e-43	-0.49	-0.6	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
THCA	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-16.18	4.13e-47	1.38e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-16.18	4.13e-47	1.38e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-16.18	4.13e-47	1.38e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-16.18	4.13e-47	1.38e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-16.18	4.13e-47	1.38e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-16.18	4.13e-47	1.38e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
THCA	cis	rs1153858	1	rs9788780	ENSG00000259520.4	CTD-2651B20.3	-16.18	4.13e-47	1.38e-43	-0.75	-0.6	Homoarginine levels;	chr15:45393289	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs11070457	ENSG00000259520.4	CTD-2651B20.3	-16.18	4.13e-47	1.38e-43	-0.75	-0.6	Homoarginine levels;	chr15:45394745	chr15:45251580~45279251:-
THCA	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-16.18	4.14e-47	1.38e-43	-0.65	-0.6	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.567	rs7742692	ENSG00000223701.3	RAET1E-AS1	16.18	4.15e-47	1.38e-43	0.79	0.6	Lung cancer;	chr6:149892363	chr6:149884431~149919508:+
THCA	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	16.17	4.23e-47	1.41e-43	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	16.17	4.55e-47	1.52e-43	0.73	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
THCA	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	16.17	4.63e-47	1.54e-43	0.67	0.6	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
THCA	cis	rs11098499	0.863	rs7664986	ENSG00000245958.5	RP11-33B1.1	-16.16	4.72e-47	1.57e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119508797	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.818	rs10008791	ENSG00000245958.5	RP11-33B1.1	-16.16	4.72e-47	1.57e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119510314	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs11736416	ENSG00000245958.5	RP11-33B1.1	-16.16	4.72e-47	1.57e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119510506	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775845	ENSG00000245958.5	RP11-33B1.1	-16.16	4.72e-47	1.57e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119511292	chr4:119454791~119552025:+
THCA	cis	rs7727544	0.735	rs270605	ENSG00000233006.5	AC034220.3	16.16	4.83e-47	1.6e-43	0.46	0.6	Blood metabolite levels;	chr5:132316118	chr5:132311285~132369916:-
THCA	cis	rs1153858	1	rs1365610	ENSG00000259520.4	CTD-2651B20.3	-16.16	4.9e-47	1.63e-43	-0.75	-0.6	Homoarginine levels;	chr15:45402412	chr15:45251580~45279251:-
THCA	cis	rs17111396	1	rs17628249	ENSG00000259167.2	NMNAT1P1	16.16	4.93e-47	1.64e-43	0.8	0.6	Uric acid levels;	chr14:81031636	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs17545722	ENSG00000259167.2	NMNAT1P1	16.16	5.07e-47	1.68e-43	0.79	0.6	Uric acid levels;	chr14:81031658	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.95	rs61978723	ENSG00000259167.2	NMNAT1P1	16.16	5.07e-47	1.68e-43	0.79	0.6	Uric acid levels;	chr14:81031781	chr14:81032529~81033404:+
THCA	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	16.16	5.09e-47	1.69e-43	0.67	0.6	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	16.16	5.09e-47	1.69e-43	0.67	0.6	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
THCA	cis	rs3779195	0.929	rs10953259	ENSG00000272950.1	RP11-307C18.1	-16.15	5.17e-47	1.71e-43	-0.87	-0.6	Sex hormone-binding globulin levels;	chr7:98383795	chr7:98322853~98323430:+
THCA	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-16.15	5.21e-47	1.73e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
THCA	cis	rs7188445	1	rs7188445	ENSG00000261390.4	RP11-345M22.2	-16.15	5.25e-47	1.74e-43	-0.71	-0.6	Urate levels;	chr16:79701090	chr16:79715232~79770563:-
THCA	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-16.15	5.3e-47	1.76e-43	-0.63	-0.6	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
THCA	cis	rs7743045	0.643	rs114000233	ENSG00000253194.1	RP11-351A11.1	16.15	5.36e-47	1.78e-43	0.84	0.6	Mean platelet volume;	chr6:118935167	chr6:118934785~119031541:+
THCA	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-16.15	5.46e-47	1.81e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
THCA	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	16.15	5.61e-47	1.86e-43	0.7	0.6	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
THCA	cis	rs11155671	0.53	rs7757984	ENSG00000223701.3	RAET1E-AS1	16.15	5.69e-47	1.89e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149887515	chr6:149884431~149919508:+
THCA	cis	rs916888	0.779	rs199526	ENSG00000262539.1	RP11-259G18.3	-16.15	5.69e-47	1.89e-43	-0.92	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770341	chr17:46259551~46260606:-
THCA	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	16.14	6.03e-47	2e-43	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
THCA	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	16.14	6.03e-47	2e-43	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
THCA	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	16.14	6.03e-47	2e-43	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000250470.1	AP000351.3	16.14	6.11e-47	2.02e-43	0.77	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23976904~23977585:-
THCA	cis	rs11098499	0.82	rs6829903	ENSG00000245958.5	RP11-33B1.1	-16.14	6.22e-47	2.06e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119585729	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs7669520	ENSG00000245958.5	RP11-33B1.1	-16.14	6.22e-47	2.06e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119594123	chr4:119454791~119552025:+
THCA	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-16.14	6.23e-47	2.06e-43	-0.78	-0.6	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-16.14	6.23e-47	2.06e-43	-0.78	-0.6	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-16.14	6.25e-47	2.07e-43	-0.78	-0.6	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	16.14	6.29e-47	2.08e-43	0.78	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
THCA	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	16.14	6.29e-47	2.08e-43	0.78	0.6	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
THCA	cis	rs17023223	0.537	rs2765533	ENSG00000231365.4	RP11-418J17.1	-16.13	6.37e-47	2.11e-43	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119054772	chr1:119140396~119275973:+
THCA	cis	rs11155671	0.53	rs7742993	ENSG00000223701.3	RAET1E-AS1	16.13	6.38e-47	2.11e-43	0.78	0.6	Testicular germ cell tumor;	chr6:149883959	chr6:149884431~149919508:+
THCA	cis	rs11098499	0.954	rs6857105	ENSG00000245958.5	RP11-33B1.1	-16.13	6.39e-47	2.11e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119301143	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	16.13	6.64e-47	2.19e-43	0.67	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.863	rs6835635	ENSG00000245958.5	RP11-33B1.1	-16.13	6.82e-47	2.25e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119537712	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.524	rs8069400	ENSG00000263531.1	RP13-753N3.1	16.13	6.88e-47	2.27e-43	1.17	0.6	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30863921~30864940:-
THCA	cis	rs11155671	0.53	rs9322228	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149888173	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs7774787	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149888296	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs2342767	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149888581	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs7764376	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149889208	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs6933882	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149889666	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs6939761	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149889858	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs3823021	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149889863	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs4869763	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149890548	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs4869764	ENSG00000223701.3	RAET1E-AS1	16.13	6.97e-47	2.3e-43	0.79	0.6	Testicular germ cell tumor;	chr6:149890692	chr6:149884431~149919508:+
THCA	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	16.13	6.97e-47	2.3e-43	0.99	0.6	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
THCA	cis	rs17023223	0.537	rs10802075	ENSG00000231365.4	RP11-418J17.1	-16.12	7.21e-47	2.38e-43	-0.69	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119084604	chr1:119140396~119275973:+
THCA	cis	rs7188445	0.932	rs11150191	ENSG00000261390.4	RP11-345M22.2	-16.12	7.23e-47	2.38e-43	-0.71	-0.6	Urate levels;	chr16:79700390	chr16:79715232~79770563:-
THCA	cis	rs11098499	0.863	rs9884402	ENSG00000245958.5	RP11-33B1.1	-16.12	7.29e-47	2.4e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119568827	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.731	rs9995026	ENSG00000245958.5	RP11-33B1.1	-16.12	7.29e-47	2.4e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119569344	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs11098532	ENSG00000245958.5	RP11-33B1.1	-16.12	7.29e-47	2.4e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119569571	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs13140391	ENSG00000245958.5	RP11-33B1.1	-16.12	7.29e-47	2.4e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119582282	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs13140409	ENSG00000245958.5	RP11-33B1.1	-16.12	7.29e-47	2.4e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119582305	chr4:119454791~119552025:+
THCA	cis	rs1153858	1	rs7181167	ENSG00000259520.4	CTD-2651B20.3	-16.12	7.41e-47	2.44e-43	-0.75	-0.6	Homoarginine levels;	chr15:45394038	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs11070456	ENSG00000259520.4	CTD-2651B20.3	-16.12	7.41e-47	2.44e-43	-0.75	-0.6	Homoarginine levels;	chr15:45394637	chr15:45251580~45279251:-
THCA	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-16.12	7.81e-47	2.57e-43	-0.9	-0.6	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
THCA	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	16.11	8e-47	2.63e-43	0.6	0.6	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.82	rs13128602	ENSG00000245958.5	RP11-33B1.1	16.11	8e-47	2.63e-43	0.6	0.6	Corneal astigmatism;	chr4:119538211	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs1383533	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119513421	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs2291185	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119513678	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs10030660	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119515549	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs13149407	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119516670	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs34868248	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119521275	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3733525	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119525893	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775847	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119526487	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775848	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119526569	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs10013305	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119529269	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775849	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119529753	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.818	rs7688802	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119530513	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs7695620	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119531621	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs12502389	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119533036	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.821	rs3775852	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119533401	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.82	rs6534140	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119534156	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs7657849	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119534339	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs10034450	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119534494	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs1480939	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119535772	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs1480940	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119536527	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs58452170	ENSG00000245958.5	RP11-33B1.1	-16.11	8e-47	2.63e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119538519	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	16.11	8.23e-47	2.7e-43	0.68	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
THCA	cis	rs17111396	0.951	rs2300522	ENSG00000259167.2	NMNAT1P1	16.11	8.25e-47	2.71e-43	0.79	0.6	Uric acid levels;	chr14:81030296	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs2300523	ENSG00000259167.2	NMNAT1P1	16.11	8.25e-47	2.71e-43	0.79	0.6	Uric acid levels;	chr14:81030476	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs2300524	ENSG00000259167.2	NMNAT1P1	16.11	8.25e-47	2.71e-43	0.79	0.6	Uric acid levels;	chr14:81030592	chr14:81032529~81033404:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000231271.1	AP000350.8	16.11	8.29e-47	2.72e-43	0.75	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23949918~23954042:+
THCA	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	16.11	8.56e-47	2.81e-43	0.68	0.6	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
THCA	cis	rs67180937	0.677	rs17011666	ENSG00000272750.1	RP11-378J18.8	-16.1	8.72e-47	2.86e-43	-0.68	-0.6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222625623	chr1:222658867~222661512:-
THCA	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-16.1	8.75e-47	2.87e-43	-0.75	-0.6	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
THCA	cis	rs17111396	1	rs12147797	ENSG00000259167.2	NMNAT1P1	16.1	8.93e-47	2.92e-43	0.79	0.6	Uric acid levels;	chr14:81031290	chr14:81032529~81033404:+
THCA	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	16.1	8.94e-47	2.93e-43	0.48	0.6	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
THCA	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-16.1	9.08e-47	2.97e-43	-0.77	-0.6	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
THCA	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	16.1	9.19e-47	3.01e-43	0.7	0.6	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
THCA	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	16.1	9.44e-47	3.09e-43	0.46	0.6	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
THCA	cis	rs11098499	0.909	rs79026312	ENSG00000245958.5	RP11-33B1.1	-16.1	9.5e-47	3.11e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119519522	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs35111518	ENSG00000245958.5	RP11-33B1.1	-16.1	9.5e-47	3.11e-43	-0.61	-0.6	Corneal astigmatism;	chr4:119519527	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs1552095	ENSG00000245958.5	RP11-33B1.1	-16.1	9.52e-47	3.11e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119539151	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775843	ENSG00000245958.5	RP11-33B1.1	-16.1	9.54e-47	3.12e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119506689	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775844	ENSG00000245958.5	RP11-33B1.1	-16.1	9.54e-47	3.12e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119506878	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs7678400	ENSG00000245958.5	RP11-33B1.1	-16.1	9.54e-47	3.12e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119540802	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs1480936	ENSG00000245958.5	RP11-33B1.1	-16.1	9.54e-47	3.12e-43	-0.6	-0.6	Corneal astigmatism;	chr4:119541706	chr4:119454791~119552025:+
THCA	cis	rs7188445	0.966	rs8053589	ENSG00000261390.4	RP11-345M22.2	-16.09	9.81e-47	3.21e-43	-0.72	-0.6	Urate levels;	chr16:79693093	chr16:79715232~79770563:-
THCA	cis	rs9660180	0.967	rs61422524	ENSG00000231050.1	RP1-140A9.1	16.09	9.92e-47	3.24e-43	0.7	0.6	Body mass index;	chr1:1836126	chr1:1891471~1892658:+
THCA	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-16.08	1.07e-46	3.5e-43	-0.64	-0.6	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-16.08	1.08e-46	3.54e-43	-0.72	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
THCA	cis	rs17023223	0.537	rs2645292	ENSG00000231365.4	RP11-418J17.1	-16.08	1.12e-46	3.66e-43	-0.68	-0.6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119030571	chr1:119140396~119275973:+
THCA	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	16.08	1.13e-46	3.67e-43	0.73	0.6	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
THCA	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-16.08	1.13e-46	3.69e-43	-0.48	-0.6	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
THCA	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	16.07	1.24e-46	4.03e-43	0.75	0.6	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
THCA	cis	rs7188445	1	rs11150189	ENSG00000261390.4	RP11-345M22.2	-16.07	1.26e-46	4.1e-43	-0.71	-0.6	Urate levels;	chr16:79700330	chr16:79715232~79770563:-
THCA	cis	rs7727544	0.66	rs272886	ENSG00000233006.5	AC034220.3	16.07	1.28e-46	4.16e-43	0.46	0.6	Blood metabolite levels;	chr5:132330147	chr5:132311285~132369916:-
THCA	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	16.06	1.35e-46	4.39e-43	1.11	0.6	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
THCA	cis	rs7727544	0.735	rs272884	ENSG00000233006.5	AC034220.3	16.06	1.36e-46	4.43e-43	0.46	0.6	Blood metabolite levels;	chr5:132332961	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.735	rs272881	ENSG00000233006.5	AC034220.3	16.06	1.36e-46	4.43e-43	0.46	0.6	Blood metabolite levels;	chr5:132333571	chr5:132311285~132369916:-
THCA	cis	rs3779195	0.929	rs2906184	ENSG00000272950.1	RP11-307C18.1	-16.06	1.41e-46	4.57e-43	-0.86	-0.6	Sex hormone-binding globulin levels;	chr7:98310675	chr7:98322853~98323430:+
THCA	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-16.06	1.44e-46	4.68e-43	-0.69	-0.6	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
THCA	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-16.05	1.5e-46	4.85e-43	-0.75	-0.6	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
THCA	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-16.05	1.59e-46	5.17e-43	-0.48	-0.59	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
THCA	cis	rs7240205	0.853	rs10432165	ENSG00000275805.1	RP11-349H17.2	-16.04	1.66e-46	5.37e-43	-0.69	-0.59	Breast cancer;	chr18:26555361	chr18:26565723~26575626:-
THCA	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-16.04	1.67e-46	5.4e-43	-0.59	-0.59	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
THCA	cis	rs3779195	0.697	rs13232861	ENSG00000272950.1	RP11-307C18.1	16.04	1.67e-46	5.41e-43	0.87	0.59	Sex hormone-binding globulin levels;	chr7:98299769	chr7:98322853~98323430:+
THCA	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-16.04	1.69e-46	5.46e-43	-0.59	-0.59	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
THCA	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-16.04	1.69e-46	5.46e-43	-0.59	-0.59	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
THCA	cis	rs11098499	0.863	rs11098531	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119543846	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs28718422	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119545149	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs12498539	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119547215	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.818	rs12498599	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119547348	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs10009626	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119548850	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3822194	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119550493	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3822195	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119550505	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775854	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119550816	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs2306456	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119551267	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs11947234	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119553704	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs6853998	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119554705	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs6858777	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119554811	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs11933966	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119555560	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs36040693	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119556461	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs11731756	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119557541	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs34308924	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119560276	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs2170276	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119564669	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs1552092	ENSG00000245958.5	RP11-33B1.1	-16.04	1.71e-46	5.52e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119567341	chr4:119454791~119552025:+
THCA	cis	rs17111396	0.95	rs12323422	ENSG00000259167.2	NMNAT1P1	16.04	1.71e-46	5.53e-43	0.79	0.59	Uric acid levels;	chr14:81038629	chr14:81032529~81033404:+
THCA	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-16.04	1.78e-46	5.76e-43	-0.75	-0.59	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
THCA	cis	rs11098499	0.863	rs13134665	ENSG00000245958.5	RP11-33B1.1	-16.04	1.79e-46	5.78e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119505275	chr4:119454791~119552025:+
THCA	cis	rs7569084	1	rs13385171	ENSG00000204929.10	AC074391.1	-16.04	1.79e-46	5.79e-43	-0.73	-0.59	Sum eosinophil basophil counts;	chr2:65434709	chr2:65436711~66084639:+
THCA	cis	rs17111396	1	rs13353102	ENSG00000259167.2	NMNAT1P1	16.03	1.82e-46	5.89e-43	0.79	0.59	Uric acid levels;	chr14:81037923	chr14:81032529~81033404:+
THCA	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	16.03	1.98e-46	6.38e-43	0.67	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
THCA	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-16.02	2.01e-46	6.47e-43	-0.75	-0.59	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
THCA	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	16.02	2.07e-46	6.66e-43	0.8	0.59	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
THCA	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-16.02	2.11e-46	6.8e-43	-0.82	-0.59	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
THCA	cis	rs1153858	0.943	rs12439575	ENSG00000259520.4	CTD-2651B20.3	-16.02	2.14e-46	6.91e-43	-0.75	-0.59	Homoarginine levels;	chr15:45392618	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4534782	ENSG00000259520.4	CTD-2651B20.3	-16.02	2.19e-46	7.05e-43	-0.75	-0.59	Homoarginine levels;	chr15:45360735	chr15:45251580~45279251:-
THCA	cis	rs11155671	0.53	rs9397420	ENSG00000223701.3	RAET1E-AS1	-16.02	2.19e-46	7.06e-43	-0.78	-0.59	Testicular germ cell tumor;	chr6:149885645	chr6:149884431~149919508:+
THCA	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	16.02	2.21e-46	7.12e-43	1.04	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
THCA	cis	rs1930961	1	rs6004669	ENSG00000272977.1	CTA-390C10.10	-16.01	2.27e-46	7.3e-43	-0.97	-0.59	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25476218~25479971:+
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-16.01	2.31e-46	7.44e-43	-0.73	-0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
THCA	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-16.01	2.31e-46	7.44e-43	-0.76	-0.59	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
THCA	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	16.01	2.38e-46	7.64e-43	0.67	0.59	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
THCA	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	16	2.5e-46	8.02e-43	1.04	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
THCA	cis	rs1431005	0.893	rs7676864	ENSG00000250620.1	RP11-91J3.3	16	2.58e-46	8.28e-43	0.75	0.59	Response to statin therapy;	chr4:187400331	chr4:187413564~187415697:+
THCA	cis	rs1153858	1	rs2467864	ENSG00000259520.4	CTD-2651B20.3	15.99	2.78e-46	8.91e-43	0.74	0.59	Homoarginine levels;	chr15:45348900	chr15:45251580~45279251:-
THCA	cis	rs977987	0.835	rs3851734	ENSG00000261783.1	RP11-252K23.2	-15.99	2.81e-46	9.03e-43	-0.76	-0.59	Dupuytren's disease;	chr16:75338022	chr16:75379818~75381260:-
THCA	cis	rs11098499	0.863	rs59732491	ENSG00000245958.5	RP11-33B1.1	-15.99	2.89e-46	9.27e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119568433	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs11723090	ENSG00000245958.5	RP11-33B1.1	-15.99	2.89e-46	9.27e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119569437	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs6833334	ENSG00000245958.5	RP11-33B1.1	-15.99	2.89e-46	9.27e-43	-0.6	-0.59	Corneal astigmatism;	chr4:119583072	chr4:119454791~119552025:+
THCA	cis	rs11155671	0.53	rs9371544	ENSG00000223701.3	RAET1E-AS1	15.99	2.93e-46	9.4e-43	0.77	0.59	Testicular germ cell tumor;	chr6:149896224	chr6:149884431~149919508:+
THCA	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	15.99	3.01e-46	9.63e-43	0.69	0.59	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
THCA	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	15.98	3.18e-46	1.02e-42	1.06	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
THCA	cis	rs7569084	0.687	rs12614851	ENSG00000281920.1	RP11-418H16.1	15.98	3.21e-46	1.03e-42	0.75	0.59	Sum eosinophil basophil counts;	chr2:65458050	chr2:65623272~65628424:+
THCA	cis	rs1153858	1	rs12437840	ENSG00000259520.4	CTD-2651B20.3	-15.98	3.23e-46	1.03e-42	-0.75	-0.59	Homoarginine levels;	chr15:45376857	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4775937	ENSG00000259520.4	CTD-2651B20.3	-15.98	3.23e-46	1.03e-42	-0.75	-0.59	Homoarginine levels;	chr15:45386416	chr15:45251580~45279251:-
THCA	cis	rs7743045	0.652	rs3756940	ENSG00000253194.1	RP11-351A11.1	15.98	3.35e-46	1.07e-42	0.84	0.59	Mean platelet volume;	chr6:119002822	chr6:118934785~119031541:+
THCA	cis	rs1431005	0.893	rs998344	ENSG00000250620.1	RP11-91J3.3	15.97	3.53e-46	1.13e-42	0.76	0.59	Response to statin therapy;	chr4:187413335	chr4:187413564~187415697:+
THCA	cis	rs1153858	1	rs12437887	ENSG00000259520.4	CTD-2651B20.3	-15.97	3.58e-46	1.14e-42	-0.75	-0.59	Homoarginine levels;	chr15:45376896	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs8032904	ENSG00000259520.4	CTD-2651B20.3	-15.97	3.69e-46	1.17e-42	-0.75	-0.59	Homoarginine levels;	chr15:45359111	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.943	rs8038342	ENSG00000259520.4	CTD-2651B20.3	-15.97	3.69e-46	1.17e-42	-0.75	-0.59	Homoarginine levels;	chr15:45359339	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4774579	ENSG00000259520.4	CTD-2651B20.3	-15.97	3.69e-46	1.17e-42	-0.75	-0.59	Homoarginine levels;	chr15:45359605	chr15:45251580~45279251:-
THCA	cis	rs7569084	0.663	rs1437461	ENSG00000281920.1	RP11-418H16.1	15.96	3.81e-46	1.21e-42	0.75	0.59	Sum eosinophil basophil counts;	chr2:65452578	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs7562559	ENSG00000281920.1	RP11-418H16.1	15.96	3.81e-46	1.21e-42	0.75	0.59	Sum eosinophil basophil counts;	chr2:65452719	chr2:65623272~65628424:+
THCA	cis	rs9322193	0.504	rs7771014	ENSG00000223701.3	RAET1E-AS1	15.96	3.85e-46	1.23e-42	0.79	0.59	Lung cancer;	chr6:149884310	chr6:149884431~149919508:+
THCA	cis	rs7727544	0.735	rs273914	ENSG00000233006.5	AC034220.3	15.96	3.93e-46	1.25e-42	0.45	0.59	Blood metabolite levels;	chr5:132324738	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.735	rs272894	ENSG00000233006.5	AC034220.3	15.96	3.93e-46	1.25e-42	0.45	0.59	Blood metabolite levels;	chr5:132326767	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.684	rs2631363	ENSG00000233006.5	AC034220.3	-15.96	3.96e-46	1.26e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132371403	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.66	rs2631361	ENSG00000233006.5	AC034220.3	-15.96	3.96e-46	1.26e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132371688	chr5:132311285~132369916:-
THCA	cis	rs1153858	1	rs4625670	ENSG00000259520.4	CTD-2651B20.3	-15.96	3.96e-46	1.26e-42	-0.74	-0.59	Homoarginine levels;	chr15:45360728	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs12595087	ENSG00000259520.4	CTD-2651B20.3	-15.95	4.31e-46	1.37e-42	-0.74	-0.59	Homoarginine levels;	chr15:45363034	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1890565	ENSG00000259520.4	CTD-2651B20.3	-15.95	4.31e-46	1.37e-42	-0.74	-0.59	Homoarginine levels;	chr15:45371101	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs12594857	ENSG00000259520.4	CTD-2651B20.3	-15.95	4.31e-46	1.37e-42	-0.74	-0.59	Homoarginine levels;	chr15:45374980	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs16942568	ENSG00000259520.4	CTD-2651B20.3	-15.95	4.31e-46	1.37e-42	-0.74	-0.59	Homoarginine levels;	chr15:45385192	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.943	rs11070454	ENSG00000259520.4	CTD-2651B20.3	-15.95	4.31e-46	1.37e-42	-0.74	-0.59	Homoarginine levels;	chr15:45388054	chr15:45251580~45279251:-
THCA	cis	rs7188445	0.966	rs79193369	ENSG00000261390.4	RP11-345M22.2	-15.95	4.38e-46	1.39e-42	-0.73	-0.59	Urate levels;	chr16:79691119	chr16:79715232~79770563:-
THCA	cis	rs1153858	1	rs1554521	ENSG00000259520.4	CTD-2651B20.3	15.95	4.48e-46	1.42e-42	0.75	0.59	Homoarginine levels;	chr15:45371991	chr15:45251580~45279251:-
THCA	cis	rs977987	0.669	rs1001861	ENSG00000261783.1	RP11-252K23.2	-15.94	4.67e-46	1.48e-42	-0.8	-0.59	Dupuytren's disease;	chr16:75272557	chr16:75379818~75381260:-
THCA	cis	rs17111396	1	rs2268473	ENSG00000259167.2	NMNAT1P1	15.94	4.73e-46	1.5e-42	0.79	0.59	Uric acid levels;	chr14:81034052	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs28448639	ENSG00000259167.2	NMNAT1P1	15.94	4.73e-46	1.5e-42	0.79	0.59	Uric acid levels;	chr14:81034053	chr14:81032529~81033404:+
THCA	cis	rs11155671	0.53	rs4870080	ENSG00000223701.3	RAET1E-AS1	15.94	4.74e-46	1.5e-42	0.79	0.59	Testicular germ cell tumor;	chr6:149881508	chr6:149884431~149919508:+
THCA	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	15.94	4.92e-46	1.56e-42	1.03	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
THCA	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	15.94	4.96e-46	1.57e-42	0.73	0.59	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
THCA	cis	rs7727544	0.684	rs274560	ENSG00000233006.5	AC034220.3	-15.94	5.03e-46	1.59e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132383758	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.684	rs611084	ENSG00000233006.5	AC034220.3	-15.93	5.1e-46	1.61e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132374047	chr5:132311285~132369916:-
THCA	cis	rs1799949	0.602	rs8176199	ENSG00000198496.9	NBR2	-15.93	5.11e-46	1.62e-42	-0.8	-0.59	Menopause (age at onset);	chr17:43078507	chr17:43125610~43153671:+
THCA	cis	rs1153858	1	rs1153858	ENSG00000259520.4	CTD-2651B20.3	15.93	5.14e-46	1.63e-42	0.74	0.59	Homoarginine levels;	chr15:45360505	chr15:45251580~45279251:-
THCA	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-15.93	5.17e-46	1.64e-42	-0.66	-0.59	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
THCA	cis	rs1153858	1	rs66528868	ENSG00000259520.4	CTD-2651B20.3	-15.92	5.81e-46	1.84e-42	-0.74	-0.59	Homoarginine levels;	chr15:45376349	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs7494956	ENSG00000259520.4	CTD-2651B20.3	-15.92	5.81e-46	1.84e-42	-0.74	-0.59	Homoarginine levels;	chr15:45376367	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs2114501	ENSG00000259520.4	CTD-2651B20.3	-15.92	5.81e-46	1.84e-42	-0.74	-0.59	Homoarginine levels;	chr15:45378118	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs67461176	ENSG00000259520.4	CTD-2651B20.3	-15.92	5.81e-46	1.84e-42	-0.74	-0.59	Homoarginine levels;	chr15:45384621	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs66939267	ENSG00000259520.4	CTD-2651B20.3	-15.92	5.81e-46	1.84e-42	-0.74	-0.59	Homoarginine levels;	chr15:45384704	chr15:45251580~45279251:-
THCA	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	15.92	5.97e-46	1.88e-42	0.67	0.59	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
THCA	cis	rs1153858	1	rs1346266	ENSG00000259520.4	CTD-2651B20.3	-15.92	6.14e-46	1.94e-42	-0.74	-0.59	Homoarginine levels;	chr15:45402318	chr15:45251580~45279251:-
THCA	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-15.92	6.16e-46	1.94e-42	-0.48	-0.59	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
THCA	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-15.91	6.27e-46	1.98e-42	-0.63	-0.59	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
THCA	cis	rs7240205	0.818	rs4264473	ENSG00000275805.1	RP11-349H17.2	15.91	6.32e-46	2e-42	0.68	0.59	Breast cancer;	chr18:26565915	chr18:26565723~26575626:-
THCA	cis	rs7727544	0.735	rs272860	ENSG00000233006.5	AC034220.3	15.91	6.34e-46	2e-42	0.46	0.59	Blood metabolite levels;	chr5:132348482	chr5:132311285~132369916:-
THCA	cis	rs11098499	0.82	rs28394116	ENSG00000245958.5	RP11-33B1.1	-15.91	6.75e-46	2.13e-42	-0.6	-0.59	Corneal astigmatism;	chr4:119603128	chr4:119454791~119552025:+
THCA	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	15.91	6.91e-46	2.18e-42	0.67	0.59	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
THCA	cis	rs7727544	0.684	rs270602	ENSG00000233006.5	AC034220.3	15.9	6.99e-46	2.2e-42	0.46	0.59	Blood metabolite levels;	chr5:132321007	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.684	rs272893	ENSG00000233006.5	AC034220.3	15.9	6.99e-46	2.2e-42	0.46	0.59	Blood metabolite levels;	chr5:132327369	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-15.9	7.1e-46	2.23e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
THCA	cis	rs17111396	1	rs2268469	ENSG00000259167.2	NMNAT1P1	15.9	7.16e-46	2.25e-42	0.79	0.59	Uric acid levels;	chr14:81032435	chr14:81032529~81033404:+
THCA	cis	rs1153858	1	rs1049503	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45361509	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs3759899	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45363705	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs7164602	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45379127	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs12441971	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45379759	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1346268	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45380831	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.943	rs67045941	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45384813	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs67744121	ENSG00000259520.4	CTD-2651B20.3	-15.89	7.74e-46	2.43e-42	-0.74	-0.59	Homoarginine levels;	chr15:45385039	chr15:45251580~45279251:-
THCA	cis	rs11155671	0.53	rs2342769	ENSG00000223701.3	RAET1E-AS1	15.89	7.81e-46	2.46e-42	0.77	0.59	Testicular germ cell tumor;	chr6:149895371	chr6:149884431~149919508:+
THCA	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	15.89	7.87e-46	2.47e-42	0.67	0.59	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
THCA	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	15.89	7.94e-46	2.5e-42	0.7	0.59	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
THCA	cis	rs7727544	0.735	rs2631370	ENSG00000233006.5	AC034220.3	-15.89	8.07e-46	2.53e-42	-0.46	-0.59	Blood metabolite levels;	chr5:132368084	chr5:132311285~132369916:-
THCA	cis	rs1153858	1	rs3809472	ENSG00000259520.4	CTD-2651B20.3	-15.89	8.16e-46	2.56e-42	-0.74	-0.59	Homoarginine levels;	chr15:45402120	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1820518	ENSG00000259520.4	CTD-2651B20.3	-15.89	8.16e-46	2.56e-42	-0.74	-0.59	Homoarginine levels;	chr15:45402381	chr15:45251580~45279251:-
THCA	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	15.89	8.27e-46	2.6e-42	0.62	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	15.89	8.27e-46	2.6e-42	0.62	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	15.89	8.27e-46	2.6e-42	0.62	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	15.89	8.27e-46	2.6e-42	0.62	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
THCA	cis	rs7727544	0.735	rs272875	ENSG00000233006.5	AC034220.3	15.89	8.35e-46	2.62e-42	0.46	0.59	Blood metabolite levels;	chr5:132339195	chr5:132311285~132369916:-
THCA	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	15.88	9.43e-46	2.95e-42	1.03	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
THCA	cis	rs11155671	0.53	rs9383940	ENSG00000223701.3	RAET1E-AS1	15.87	9.61e-46	3.01e-42	0.79	0.59	Testicular germ cell tumor;	chr6:149904923	chr6:149884431~149919508:+
THCA	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	15.87	9.66e-46	3.02e-42	0.6	0.59	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
THCA	cis	rs7174755	0.743	rs4777035	ENSG00000260657.2	RP11-315D16.4	-15.87	9.96e-46	3.12e-42	-0.72	-0.59	Major depressive disorder;	chr15:68312831	chr15:68267792~68277994:-
THCA	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	15.86	1.07e-45	3.36e-42	0.75	0.59	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
THCA	cis	rs7240205	0.853	rs6508448	ENSG00000275805.1	RP11-349H17.2	15.86	1.08e-45	3.37e-42	0.68	0.59	Breast cancer;	chr18:26556863	chr18:26565723~26575626:-
THCA	cis	rs7182621	0.846	rs12915935	ENSG00000259363.4	CTD-2054N24.2	-15.86	1.09e-45	3.39e-42	-0.75	-0.59	Colonoscopy-negative controls vs population controls;	chr15:99871875	chr15:99807023~99877148:+
THCA	cis	rs7240205	0.853	rs1941160	ENSG00000275805.1	RP11-349H17.2	15.86	1.13e-45	3.53e-42	0.68	0.59	Breast cancer;	chr18:26553529	chr18:26565723~26575626:-
THCA	cis	rs1431005	0.893	rs67136716	ENSG00000250620.1	RP11-91J3.3	15.86	1.14e-45	3.56e-42	0.76	0.59	Response to statin therapy;	chr4:187414928	chr4:187413564~187415697:+
THCA	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	15.86	1.15e-45	3.59e-42	0.67	0.59	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
THCA	cis	rs11098499	0.954	rs6847248	ENSG00000245958.5	RP11-33B1.1	-15.85	1.17e-45	3.66e-42	-0.6	-0.59	Corneal astigmatism;	chr4:119304800	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	15.85	1.23e-45	3.82e-42	0.78	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
THCA	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	15.85	1.23e-45	3.84e-42	0.66	0.59	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
THCA	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	15.85	1.28e-45	3.99e-42	1.03	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
THCA	cis	rs11155671	0.53	rs6935829	ENSG00000223701.3	RAET1E-AS1	15.84	1.3e-45	4.05e-42	0.77	0.59	Testicular germ cell tumor;	chr6:149896675	chr6:149884431~149919508:+
THCA	cis	rs7743045	0.711	rs4946371	ENSG00000253194.1	RP11-351A11.1	15.84	1.33e-45	4.14e-42	0.84	0.59	Mean platelet volume;	chr6:118935483	chr6:118934785~119031541:+
THCA	cis	rs7727544	0.735	rs272879	ENSG00000233006.5	AC034220.3	15.84	1.33e-45	4.15e-42	0.45	0.59	Blood metabolite levels;	chr5:132334853	chr5:132311285~132369916:-
THCA	cis	rs7240205	0.853	rs2000649	ENSG00000275805.1	RP11-349H17.2	15.84	1.36e-45	4.22e-42	0.68	0.59	Breast cancer;	chr18:26552897	chr18:26565723~26575626:-
THCA	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	15.84	1.36e-45	4.25e-42	0.73	0.59	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
THCA	cis	rs7240205	0.853	rs4404156	ENSG00000275805.1	RP11-349H17.2	15.84	1.42e-45	4.42e-42	0.68	0.59	Breast cancer;	chr18:26563490	chr18:26565723~26575626:-
THCA	cis	rs7727544	0.684	rs2516788	ENSG00000233006.5	AC034220.3	-15.84	1.42e-45	4.43e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132379873	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.66	rs274563	ENSG00000233006.5	AC034220.3	-15.84	1.42e-45	4.43e-42	-0.45	-0.59	Blood metabolite levels;	chr5:132382167	chr5:132311285~132369916:-
THCA	cis	rs10853057	0.541	rs77675516	ENSG00000214174.7	AMZ2P1	15.84	1.44e-45	4.46e-42	0.98	0.59	White matter microstructure (global fractional anisotropy);	chr17:65050690	chr17:64966550~64975576:-
THCA	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	15.83	1.44e-45	4.48e-42	0.62	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	15.83	1.5e-45	4.66e-42	0.62	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
THCA	cis	rs7743045	0.624	rs12527363	ENSG00000253194.1	RP11-351A11.1	15.83	1.51e-45	4.7e-42	0.84	0.59	Mean platelet volume;	chr6:119008222	chr6:118934785~119031541:+
THCA	cis	rs11098499	0.863	rs3822192	ENSG00000245958.5	RP11-33B1.1	-15.83	1.56e-45	4.84e-42	-0.6	-0.59	Corneal astigmatism;	chr4:119524565	chr4:119454791~119552025:+
THCA	cis	rs7569084	0.687	rs1437462	ENSG00000281920.1	RP11-418H16.1	15.82	1.63e-45	5.07e-42	0.74	0.59	Sum eosinophil basophil counts;	chr2:65449559	chr2:65623272~65628424:+
THCA	cis	rs1153858	1	rs4271549	ENSG00000259520.4	CTD-2651B20.3	-15.82	1.64e-45	5.08e-42	-0.74	-0.59	Homoarginine levels;	chr15:45360532	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs4627277	ENSG00000259520.4	CTD-2651B20.3	-15.82	1.64e-45	5.08e-42	-0.74	-0.59	Homoarginine levels;	chr15:45360570	chr15:45251580~45279251:-
THCA	cis	rs11098499	0.863	rs3822190	ENSG00000245958.5	RP11-33B1.1	-15.82	1.65e-45	5.13e-42	-0.6	-0.59	Corneal astigmatism;	chr4:119506943	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3822191	ENSG00000245958.5	RP11-33B1.1	-15.82	1.65e-45	5.13e-42	-0.6	-0.59	Corneal astigmatism;	chr4:119506946	chr4:119454791~119552025:+
THCA	cis	rs7240205	0.818	rs12964926	ENSG00000275805.1	RP11-349H17.2	15.81	1.84e-45	5.7e-42	0.68	0.59	Breast cancer;	chr18:26567363	chr18:26565723~26575626:-
THCA	cis	rs1153858	1	rs7169818	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45347993	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs2453541	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45353180	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs2461702	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45355229	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1145091	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45357798	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1049508	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45361394	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1145085	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45365606	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1288775	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45369480	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs1145081	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45387469	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.943	rs1145079	ENSG00000259520.4	CTD-2651B20.3	-15.81	1.88e-45	5.83e-42	-0.74	-0.59	Homoarginine levels;	chr15:45389563	chr15:45251580~45279251:-
THCA	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	15.81	1.91e-45	5.91e-42	0.69	0.59	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
THCA	cis	rs7240205	0.816	rs2019480	ENSG00000275805.1	RP11-349H17.2	15.8	2.04e-45	6.3e-42	0.68	0.59	Breast cancer;	chr18:26545720	chr18:26565723~26575626:-
THCA	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	15.8	2.12e-45	6.54e-42	1.01	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	15.8	2.12e-45	6.54e-42	1.01	0.59	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
THCA	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-15.8	2.17e-45	6.72e-42	-0.59	-0.59	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
THCA	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-15.8	2.17e-45	6.72e-42	-0.59	-0.59	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
THCA	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-15.79	2.23e-45	6.9e-42	-0.68	-0.59	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
THCA	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	15.79	2.24e-45	6.92e-42	0.69	0.59	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
THCA	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	15.79	2.24e-45	6.92e-42	0.69	0.59	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
THCA	cis	rs67311347	0.955	rs2123999	ENSG00000223797.4	ENTPD3-AS1	15.79	2.41e-45	7.44e-42	0.47	0.59	Renal cell carcinoma;	chr3:40337247	chr3:40313802~40453329:-
THCA	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	15.78	2.51e-45	7.74e-42	0.98	0.59	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
THCA	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-15.78	2.56e-45	7.89e-42	-0.58	-0.59	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
THCA	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-15.78	2.6e-45	8e-42	-0.58	-0.59	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
THCA	cis	rs7569084	0.905	rs13417564	ENSG00000204929.10	AC074391.1	-15.78	2.62e-45	8.06e-42	-0.73	-0.59	Sum eosinophil basophil counts;	chr2:65438139	chr2:65436711~66084639:+
THCA	cis	rs7240205	0.853	rs10454719	ENSG00000275805.1	RP11-349H17.2	-15.77	2.76e-45	8.51e-42	-0.68	-0.59	Breast cancer;	chr18:26559666	chr18:26565723~26575626:-
THCA	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-15.77	2.78e-45	8.57e-42	-0.58	-0.59	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
THCA	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-15.77	2.87e-45	8.85e-42	-0.68	-0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
THCA	cis	rs1153858	0.943	rs4774580	ENSG00000259520.4	CTD-2651B20.3	-15.77	2.88e-45	8.87e-42	-0.74	-0.59	Homoarginine levels;	chr15:45359888	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	15.76	3e-45	9.24e-42	0.74	0.59	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
THCA	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	15.76	3.01e-45	9.25e-42	0.69	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
THCA	cis	rs67311347	0.91	rs13089215	ENSG00000223797.4	ENTPD3-AS1	-15.76	3.09e-45	9.51e-42	-0.48	-0.59	Renal cell carcinoma;	chr3:40454403	chr3:40313802~40453329:-
THCA	cis	rs17111396	0.95	rs10143800	ENSG00000259167.2	NMNAT1P1	15.76	3.12e-45	9.59e-42	0.79	0.59	Uric acid levels;	chr14:81029998	chr14:81032529~81033404:+
THCA	cis	rs3779195	0.929	rs1635612	ENSG00000272950.1	RP11-307C18.1	15.76	3.15e-45	9.69e-42	0.83	0.59	Sex hormone-binding globulin levels;	chr7:98385737	chr7:98322853~98323430:+
THCA	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-15.76	3.16e-45	9.73e-42	-0.63	-0.59	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
THCA	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	15.76	3.16e-45	9.73e-42	0.99	0.59	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
THCA	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	15.75	3.32e-45	1.02e-41	0.74	0.59	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
THCA	cis	rs147858478	1	rs147858478	ENSG00000233006.5	AC034220.3	15.75	3.5e-45	1.08e-41	0.45	0.59	High light scatter reticulocyte percentage of red cells;	chr5:132347099	chr5:132311285~132369916:-
THCA	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-15.74	3.73e-45	1.15e-41	-0.58	-0.59	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
THCA	cis	rs7727544	0.709	rs272852	ENSG00000233006.5	AC034220.3	15.74	3.83e-45	1.17e-41	0.45	0.59	Blood metabolite levels;	chr5:132353074	chr5:132311285~132369916:-
THCA	cis	rs7569084	0.663	rs4671128	ENSG00000281920.1	RP11-418H16.1	15.73	4.19e-45	1.29e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65438130	chr2:65623272~65628424:+
THCA	cis	rs11155671	0.53	rs1334510	ENSG00000223701.3	RAET1E-AS1	15.73	4.25e-45	1.3e-41	0.77	0.59	Testicular germ cell tumor;	chr6:149880043	chr6:149884431~149919508:+
THCA	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-15.73	4.37e-45	1.34e-41	-0.58	-0.59	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
THCA	cis	rs7727544	0.735	rs4705933	ENSG00000233006.5	AC034220.3	15.73	4.41e-45	1.35e-41	0.45	0.59	Blood metabolite levels;	chr5:132342719	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.735	rs272867	ENSG00000233006.5	AC034220.3	15.73	4.41e-45	1.35e-41	0.45	0.59	Blood metabolite levels;	chr5:132345364	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.661	rs273900	ENSG00000233006.5	AC034220.3	15.72	4.49e-45	1.38e-41	0.45	0.59	Blood metabolite levels;	chr5:132358913	chr5:132311285~132369916:-
THCA	cis	rs5769707	0.967	rs5770585	ENSG00000188511.11	C22orf34	15.72	4.51e-45	1.38e-41	0.67	0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49414524~49657542:-
THCA	cis	rs7569084	0.687	rs4671663	ENSG00000281920.1	RP11-418H16.1	15.72	4.62e-45	1.41e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65434400	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs11692813	ENSG00000281920.1	RP11-418H16.1	15.72	4.62e-45	1.41e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65435172	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.663	rs11126037	ENSG00000281920.1	RP11-418H16.1	15.72	4.62e-45	1.41e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65436024	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs11126038	ENSG00000281920.1	RP11-418H16.1	15.72	4.62e-45	1.41e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65436100	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.663	rs11694714	ENSG00000281920.1	RP11-418H16.1	15.72	4.62e-45	1.41e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65436802	chr2:65623272~65628424:+
THCA	cis	rs11098499	0.863	rs2306457	ENSG00000245958.5	RP11-33B1.1	-15.72	4.8e-45	1.47e-41	-0.6	-0.59	Corneal astigmatism;	chr4:119551684	chr4:119454791~119552025:+
THCA	cis	rs7569084	0.687	rs1344891	ENSG00000281920.1	RP11-418H16.1	15.72	4.95e-45	1.51e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65458890	chr2:65623272~65628424:+
THCA	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	15.71	5.31e-45	1.62e-41	1.02	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
THCA	cis	rs1153858	0.887	rs7164139	ENSG00000259520.4	CTD-2651B20.3	-15.71	5.5e-45	1.68e-41	-0.74	-0.59	Homoarginine levels;	chr15:45378653	chr15:45251580~45279251:-
THCA	cis	rs17023223	0.537	rs2794311	ENSG00000231365.4	RP11-418J17.1	15.7	5.56e-45	1.7e-41	0.66	0.59	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119053326	chr1:119140396~119275973:+
THCA	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	15.7	5.71e-45	1.74e-41	0.61	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
THCA	cis	rs1153858	1	rs2467863	ENSG00000259520.4	CTD-2651B20.3	-15.7	5.72e-45	1.75e-41	-0.74	-0.59	Homoarginine levels;	chr15:45349682	chr15:45251580~45279251:-
THCA	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-15.7	5.93e-45	1.81e-41	-0.47	-0.59	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
THCA	cis	rs7569084	0.64	rs11126039	ENSG00000281920.1	RP11-418H16.1	15.7	5.94e-45	1.82e-41	0.74	0.59	Sum eosinophil basophil counts;	chr2:65457953	chr2:65623272~65628424:+
THCA	cis	rs11098499	0.863	rs3775841	ENSG00000245958.5	RP11-33B1.1	-15.7	5.95e-45	1.82e-41	-0.59	-0.59	Corneal astigmatism;	chr4:119504622	chr4:119454791~119552025:+
THCA	cis	rs1153858	1	rs12440038	ENSG00000259520.4	CTD-2651B20.3	-15.69	6.12e-45	1.87e-41	-0.74	-0.59	Homoarginine levels;	chr15:45414541	chr15:45251580~45279251:-
THCA	cis	rs1153858	0.943	rs7402632	ENSG00000259520.4	CTD-2651B20.3	-15.69	6.2e-45	1.89e-41	-0.74	-0.59	Homoarginine levels;	chr15:45409715	chr15:45251580~45279251:-
THCA	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	15.69	6.38e-45	1.95e-41	0.77	0.59	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
THCA	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	15.69	6.63e-45	2.02e-41	0.45	0.59	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	15.69	6.67e-45	2.03e-41	0.45	0.59	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
THCA	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-15.68	6.86e-45	2.09e-41	-0.58	-0.59	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
THCA	cis	rs17111396	1	rs2300526	ENSG00000259167.2	NMNAT1P1	15.68	7.34e-45	2.24e-41	0.79	0.59	Uric acid levels;	chr14:81031123	chr14:81032529~81033404:+
THCA	cis	rs1153858	1	rs8042786	ENSG00000259520.4	CTD-2651B20.3	-15.67	7.69e-45	2.34e-41	-0.74	-0.59	Homoarginine levels;	chr15:45411341	chr15:45251580~45279251:-
THCA	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	15.67	8.14e-45	2.48e-41	0.61	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	15.67	8.14e-45	2.48e-41	0.61	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	15.67	8.14e-45	2.48e-41	0.61	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	15.67	8.14e-45	2.48e-41	0.61	0.59	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
THCA	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	15.66	8.7e-45	2.65e-41	1.02	0.59	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
THCA	cis	rs1153858	0.832	rs1145078	ENSG00000259520.4	CTD-2651B20.3	-15.66	9.02e-45	2.74e-41	-0.73	-0.59	Homoarginine levels;	chr15:45390079	chr15:45251580~45279251:-
THCA	cis	rs7569084	0.687	rs11675538	ENSG00000281920.1	RP11-418H16.1	15.65	9.35e-45	2.84e-41	0.73	0.59	Sum eosinophil basophil counts;	chr2:65459327	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs934731	ENSG00000281920.1	RP11-418H16.1	15.65	1.02e-44	3.08e-41	0.73	0.59	Sum eosinophil basophil counts;	chr2:65456353	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs7577452	ENSG00000281920.1	RP11-418H16.1	15.65	1.02e-44	3.08e-41	0.73	0.59	Sum eosinophil basophil counts;	chr2:65456694	chr2:65623272~65628424:+
THCA	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-15.63	1.16e-44	3.53e-41	-0.78	-0.58	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
THCA	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-15.63	1.16e-44	3.53e-41	-0.58	-0.58	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
THCA	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-15.63	1.17e-44	3.57e-41	-0.98	-0.58	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
THCA	cis	rs1431005	0.893	rs12501227	ENSG00000250620.1	RP11-91J3.3	15.63	1.19e-44	3.62e-41	0.76	0.58	Response to statin therapy;	chr4:187401223	chr4:187413564~187415697:+
THCA	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	15.63	1.21e-44	3.67e-41	0.63	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	15.63	1.21e-44	3.67e-41	0.63	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
THCA	cis	rs1431005	0.893	rs68010462	ENSG00000250620.1	RP11-91J3.3	15.63	1.24e-44	3.77e-41	0.76	0.58	Response to statin therapy;	chr4:187418181	chr4:187413564~187415697:+
THCA	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	15.63	1.25e-44	3.78e-41	0.66	0.58	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
THCA	cis	rs7569084	0.687	rs1370394	ENSG00000281920.1	RP11-418H16.1	15.62	1.31e-44	3.96e-41	0.74	0.58	Sum eosinophil basophil counts;	chr2:65453176	chr2:65623272~65628424:+
THCA	cis	rs11155671	0.53	rs4458704	ENSG00000223701.3	RAET1E-AS1	15.62	1.39e-44	4.22e-41	0.79	0.58	Testicular germ cell tumor;	chr6:149911743	chr6:149884431~149919508:+
THCA	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	15.61	1.4e-44	4.25e-41	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	15.61	1.4e-44	4.25e-41	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
THCA	cis	rs7569084	1	rs7569084	ENSG00000204929.10	AC074391.1	-15.61	1.44e-44	4.38e-41	-0.72	-0.58	Sum eosinophil basophil counts;	chr2:65429835	chr2:65436711~66084639:+
THCA	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-15.6	1.58e-44	4.79e-41	-0.81	-0.58	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
THCA	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	15.6	1.6e-44	4.83e-41	0.63	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
THCA	cis	rs11098499	0.863	rs10004484	ENSG00000245958.5	RP11-33B1.1	-15.6	1.67e-44	5.05e-41	-0.58	-0.58	Corneal astigmatism;	chr4:119521273	chr4:119454791~119552025:+
THCA	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	15.59	1.8e-44	5.44e-41	0.61	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	15.59	1.8e-44	5.44e-41	0.61	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
THCA	cis	rs12022452	0.591	rs16827359	ENSG00000238287.1	RP11-656D10.3	15.58	1.94e-44	5.86e-41	0.83	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr1:40535766	chr1:40493157~40508661:-
THCA	cis	rs7569084	0.687	rs12993075	ENSG00000281920.1	RP11-418H16.1	15.58	2.11e-44	6.36e-41	0.74	0.58	Sum eosinophil basophil counts;	chr2:65431010	chr2:65623272~65628424:+
THCA	cis	rs67383717	0.643	rs10759883	ENSG00000175611.10	LINC00476	-15.57	2.15e-44	6.47e-41	-0.62	-0.58	Parkinson's disease (pesticide exposure interaction);	chr9:95790481	chr9:95759231~95875977:-
THCA	cis	rs2455601	0.882	rs11042105	ENSG00000254860.4	TMEM9B-AS1	15.57	2.23e-44	6.72e-41	0.81	0.58	Schizophrenia;	chr11:8872963	chr11:8964675~8977527:+
THCA	cis	rs2455601	0.882	rs10840139	ENSG00000254860.4	TMEM9B-AS1	15.57	2.23e-44	6.72e-41	0.81	0.58	Schizophrenia;	chr11:8873291	chr11:8964675~8977527:+
THCA	cis	rs7743045	0.614	rs4946386	ENSG00000253194.1	RP11-351A11.1	15.57	2.25e-44	6.78e-41	0.83	0.58	Mean platelet volume;	chr6:119001827	chr6:118934785~119031541:+
THCA	cis	rs5769707	0.846	rs5770610	ENSG00000188511.11	C22orf34	15.57	2.28e-44	6.86e-41	0.68	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49414524~49657542:-
THCA	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	15.56	2.49e-44	7.48e-41	0.58	0.58	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
THCA	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-15.56	2.54e-44	7.63e-41	-0.66	-0.58	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
THCA	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-15.56	2.54e-44	7.63e-41	-0.66	-0.58	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
THCA	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-15.56	2.54e-44	7.63e-41	-0.66	-0.58	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
THCA	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-15.55	2.7e-44	8.12e-41	-0.75	-0.58	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
THCA	cis	rs1431005	0.893	rs9684748	ENSG00000250620.1	RP11-91J3.3	15.55	2.72e-44	8.19e-41	0.74	0.58	Response to statin therapy;	chr4:187398070	chr4:187413564~187415697:+
THCA	cis	rs7727544	0.684	rs272869	ENSG00000233006.5	AC034220.3	15.55	2.86e-44	8.6e-41	0.45	0.58	Blood metabolite levels;	chr5:132342304	chr5:132311285~132369916:-
THCA	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	15.54	2.91e-44	8.74e-41	0.57	0.58	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
THCA	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-15.54	2.94e-44	8.83e-41	-0.57	-0.58	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
THCA	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-15.54	3.01e-44	9.04e-41	-0.96	-0.58	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
THCA	cis	rs2455601	0.882	rs11042106	ENSG00000254860.4	TMEM9B-AS1	-15.53	3.26e-44	9.79e-41	-0.81	-0.58	Schizophrenia;	chr11:8874536	chr11:8964675~8977527:+
THCA	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-15.53	3.38e-44	1.01e-40	-0.6	-0.58	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
THCA	cis	rs5769707	0.967	rs739248	ENSG00000188511.11	C22orf34	15.52	3.61e-44	1.08e-40	0.68	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49414524~49657542:-
THCA	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	15.52	3.7e-44	1.11e-40	0.62	0.58	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
THCA	cis	rs1153858	1	rs1153849	ENSG00000259520.4	CTD-2651B20.3	-15.52	3.79e-44	1.13e-40	-0.74	-0.58	Homoarginine levels;	chr15:45403497	chr15:45251580~45279251:-
THCA	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-15.52	3.83e-44	1.14e-40	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-15.52	3.83e-44	1.14e-40	-0.63	-0.58	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
THCA	cis	rs7727544	0.645	rs272857	ENSG00000233006.5	AC034220.3	15.52	3.86e-44	1.15e-40	0.45	0.58	Blood metabolite levels;	chr5:132349604	chr5:132311285~132369916:-
THCA	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-15.51	3.97e-44	1.19e-40	-0.62	-0.58	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
THCA	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-15.51	3.97e-44	1.19e-40	-0.75	-0.58	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
THCA	cis	rs11098499	0.863	rs6858592	ENSG00000245958.5	RP11-33B1.1	-15.51	4.02e-44	1.2e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119537537	chr4:119454791~119552025:+
THCA	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-15.51	4.09e-44	1.22e-40	-0.58	-0.58	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
THCA	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-15.51	4.29e-44	1.28e-40	-0.77	-0.58	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
THCA	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	15.5	4.41e-44	1.31e-40	0.61	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	15.5	4.41e-44	1.31e-40	0.61	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	15.5	4.41e-44	1.31e-40	0.61	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	15.5	4.41e-44	1.31e-40	0.61	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
THCA	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-15.5	4.45e-44	1.33e-40	-0.77	-0.58	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
THCA	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	15.5	4.55e-44	1.35e-40	0.62	0.58	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
THCA	cis	rs7182621	0.774	rs12101368	ENSG00000259363.4	CTD-2054N24.2	-15.5	4.72e-44	1.41e-40	-0.75	-0.58	Colonoscopy-negative controls vs population controls;	chr15:99872475	chr15:99807023~99877148:+
THCA	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-15.49	5.04e-44	1.5e-40	-0.65	-0.58	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
THCA	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-15.49	5.04e-44	1.5e-40	-0.65	-0.58	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
THCA	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-15.48	5.65e-44	1.68e-40	-0.47	-0.58	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
THCA	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	15.48	5.67e-44	1.68e-40	0.74	0.58	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
THCA	cis	rs1153858	1	rs60476496	ENSG00000259520.4	CTD-2651B20.3	-15.47	5.93e-44	1.76e-40	-0.73	-0.58	Homoarginine levels;	chr15:45421603	chr15:45251580~45279251:-
THCA	cis	rs11673344	0.573	rs73039109	ENSG00000226686.6	LINC01535	15.47	6.2e-44	1.84e-40	0.73	0.58	Obesity-related traits;	chr19:36891073	chr19:37251912~37265535:+
THCA	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-15.47	6.4e-44	1.9e-40	-0.75	-0.58	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
THCA	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	15.47	6.53e-44	1.94e-40	0.94	0.58	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
THCA	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-15.46	6.58e-44	1.95e-40	-0.74	-0.58	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
THCA	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	15.46	6.62e-44	1.97e-40	0.68	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	15.46	6.85e-44	2.03e-40	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
THCA	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-15.46	6.88e-44	2.04e-40	-0.47	-0.58	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
THCA	cis	rs11098499	0.69	rs34818745	ENSG00000245958.5	RP11-33B1.1	-15.46	6.9e-44	2.05e-40	-0.6	-0.58	Corneal astigmatism;	chr4:119335900	chr4:119454791~119552025:+
THCA	cis	rs17023223	0.537	rs2645295	ENSG00000231365.4	RP11-418J17.1	-15.46	6.93e-44	2.06e-40	-0.65	-0.58	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119039825	chr1:119140396~119275973:+
THCA	cis	rs10853057	0.541	rs8076716	ENSG00000214174.7	AMZ2P1	15.45	7.54e-44	2.23e-40	0.98	0.58	White matter microstructure (global fractional anisotropy);	chr17:65051891	chr17:64966550~64975576:-
THCA	cis	rs5769707	0.967	rs763127	ENSG00000188511.11	C22orf34	15.45	7.74e-44	2.29e-40	0.65	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49414524~49657542:-
THCA	cis	rs11098499	0.863	rs9997631	ENSG00000245958.5	RP11-33B1.1	-15.44	8.06e-44	2.39e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119548840	chr4:119454791~119552025:+
THCA	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	15.44	8.08e-44	2.39e-40	0.73	0.58	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
THCA	cis	rs7569084	0.687	rs35839762	ENSG00000281920.1	RP11-418H16.1	15.44	8.16e-44	2.41e-40	0.73	0.58	Sum eosinophil basophil counts;	chr2:65441318	chr2:65623272~65628424:+
THCA	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	15.44	8.19e-44	2.42e-40	0.59	0.58	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
THCA	cis	rs5769707	0.967	rs2071904	ENSG00000188511.11	C22orf34	15.44	8.25e-44	2.44e-40	0.68	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49414524~49657542:-
THCA	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	15.44	8.37e-44	2.47e-40	0.59	0.58	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
THCA	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-15.44	8.48e-44	2.51e-40	-0.57	-0.58	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
THCA	cis	rs17111396	1	rs17111398	ENSG00000259167.2	NMNAT1P1	15.44	8.73e-44	2.58e-40	0.77	0.58	Uric acid levels;	chr14:81057911	chr14:81032529~81033404:+
THCA	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-15.43	9.1e-44	2.69e-40	-0.75	-0.58	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
THCA	cis	rs7727544	0.684	rs272849	ENSG00000233006.5	AC034220.3	15.43	9.49e-44	2.8e-40	0.45	0.58	Blood metabolite levels;	chr5:132354548	chr5:132311285~132369916:-
THCA	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	15.43	9.63e-44	2.84e-40	0.76	0.58	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
THCA	cis	rs17111396	1	rs2268474	ENSG00000259167.2	NMNAT1P1	-15.43	9.83e-44	2.9e-40	-0.76	-0.58	Uric acid levels;	chr14:81058063	chr14:81032529~81033404:+
THCA	cis	rs11098499	0.866	rs3756156	ENSG00000245958.5	RP11-33B1.1	-15.43	9.9e-44	2.92e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119603686	chr4:119454791~119552025:+
THCA	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-15.42	1.01e-43	2.98e-40	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
THCA	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	15.42	1.09e-43	3.22e-40	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	15.42	1.1e-43	3.23e-40	0.66	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
THCA	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-15.41	1.11e-43	3.26e-40	-0.75	-0.58	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
THCA	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-15.41	1.11e-43	3.27e-40	-0.57	-0.58	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
THCA	cis	rs11098499	0.863	rs1155576	ENSG00000245958.5	RP11-33B1.1	-15.41	1.11e-43	3.28e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119529004	chr4:119454791~119552025:+
THCA	cis	rs992157	0.932	rs1870125	ENSG00000261338.2	RP11-378A13.1	15.41	1.12e-43	3.29e-40	0.63	0.58	Colorectal cancer;	chr2:218323178	chr2:218255319~218257366:+
THCA	cis	rs7727544	0.684	rs274546	ENSG00000233006.5	AC034220.3	15.41	1.12e-43	3.3e-40	0.45	0.58	Blood metabolite levels;	chr5:132364175	chr5:132311285~132369916:-
THCA	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-15.41	1.13e-43	3.33e-40	-0.68	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000225282.1	AP000350.6	15.41	1.16e-43	3.41e-40	0.7	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23926900~23929574:+
THCA	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	15.41	1.18e-43	3.47e-40	0.61	0.58	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
THCA	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-15.41	1.2e-43	3.54e-40	-0.65	-0.58	Height;	chr3:53074760	chr3:53064283~53065091:-
THCA	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	15.41	1.21e-43	3.57e-40	0.62	0.58	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
THCA	cis	rs524281	0.773	rs7945723	ENSG00000255320.1	RP11-755F10.1	15.41	1.22e-43	3.57e-40	0.88	0.58	Electroencephalogram traits;	chr11:66288986	chr11:66244840~66246239:-
THCA	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-15.4	1.33e-43	3.9e-40	-0.63	-0.58	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
THCA	cis	rs7208859	0.673	rs9889755	ENSG00000263531.1	RP13-753N3.1	-15.39	1.38e-43	4.06e-40	-1.03	-0.58	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30863921~30864940:-
THCA	cis	rs5769707	0.935	rs5770594	ENSG00000188511.11	C22orf34	15.39	1.4e-43	4.11e-40	0.68	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49414524~49657542:-
THCA	cis	rs5769707	0.967	rs4524218	ENSG00000188511.11	C22orf34	15.39	1.4e-43	4.11e-40	0.68	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49414524~49657542:-
THCA	cis	rs11098499	0.863	rs10018280	ENSG00000245958.5	RP11-33B1.1	-15.39	1.42e-43	4.14e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119556984	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs6534141	ENSG00000245958.5	RP11-33B1.1	-15.39	1.42e-43	4.14e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119564068	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs2127823	ENSG00000245958.5	RP11-33B1.1	-15.39	1.42e-43	4.14e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119564515	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.863	rs3775858	ENSG00000245958.5	RP11-33B1.1	-15.39	1.42e-43	4.14e-40	-0.58	-0.58	Corneal astigmatism;	chr4:119564873	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	15.38	1.52e-43	4.45e-40	0.72	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
THCA	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-15.37	1.69e-43	4.94e-40	-0.75	-0.58	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-15.37	1.69e-43	4.94e-40	-0.75	-0.58	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
THCA	cis	rs992157	0.932	rs10203039	ENSG00000261338.2	RP11-378A13.1	15.37	1.72e-43	5.03e-40	0.62	0.58	Colorectal cancer;	chr2:218322644	chr2:218255319~218257366:+
THCA	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	15.37	1.78e-43	5.19e-40	0.62	0.58	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
THCA	cis	rs80028505	0.908	rs56056710	ENSG00000271304.1	DPRXP2	15.36	1.85e-43	5.4e-40	1.01	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36068575	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs58237753	ENSG00000271304.1	DPRXP2	15.36	1.85e-43	5.4e-40	1.01	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36068578	chr6:35989515~35990436:-
THCA	cis	rs7188445	1	rs76819459	ENSG00000261390.4	RP11-345M22.2	-15.36	1.86e-43	5.43e-40	-0.7	-0.58	Urate levels;	chr16:79685020	chr16:79715232~79770563:-
THCA	cis	rs7569084	0.687	rs6755006	ENSG00000281920.1	RP11-418H16.1	-15.36	1.89e-43	5.51e-40	-0.73	-0.58	Sum eosinophil basophil counts;	chr2:65426008	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs6755128	ENSG00000281920.1	RP11-418H16.1	-15.36	1.89e-43	5.51e-40	-0.73	-0.58	Sum eosinophil basophil counts;	chr2:65426065	chr2:65623272~65628424:+
THCA	cis	rs1431005	0.892	rs72725289	ENSG00000250620.1	RP11-91J3.3	15.36	1.96e-43	5.71e-40	0.71	0.58	Response to statin therapy;	chr4:187477579	chr4:187413564~187415697:+
THCA	cis	rs992157	0.932	rs10194082	ENSG00000261338.2	RP11-378A13.1	15.36	1.96e-43	5.72e-40	0.62	0.58	Colorectal cancer;	chr2:218323854	chr2:218255319~218257366:+
THCA	cis	rs992157	0.932	rs1473901	ENSG00000261338.2	RP11-378A13.1	15.36	1.96e-43	5.72e-40	0.62	0.58	Colorectal cancer;	chr2:218324115	chr2:218255319~218257366:+
THCA	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	15.36	1.99e-43	5.79e-40	0.65	0.58	Height;	chr3:53073764	chr3:53064283~53065091:-
THCA	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-15.36	2e-43	5.82e-40	-0.76	-0.58	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
THCA	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-15.35	2.2e-43	6.4e-40	-0.73	-0.58	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
THCA	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	15.35	2.21e-43	6.43e-40	0.64	0.58	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
THCA	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-15.35	2.24e-43	6.51e-40	-0.46	-0.58	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
THCA	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-15.35	2.24e-43	6.51e-40	-0.46	-0.58	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
THCA	cis	rs80028505	0.908	rs56413204	ENSG00000271304.1	DPRXP2	15.34	2.26e-43	6.58e-40	0.98	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36037125	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs58390233	ENSG00000271304.1	DPRXP2	15.34	2.26e-43	6.58e-40	0.98	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36037323	chr6:35989515~35990436:-
THCA	cis	rs80028505	1	rs2237096	ENSG00000271304.1	DPRXP2	15.34	2.26e-43	6.58e-40	0.98	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36040225	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.808	rs61195139	ENSG00000271304.1	DPRXP2	15.34	2.26e-43	6.58e-40	0.98	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36078449	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs7748078	ENSG00000271304.1	DPRXP2	15.34	2.26e-43	6.58e-40	0.98	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36080233	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.71	rs80032177	ENSG00000271304.1	DPRXP2	15.34	2.26e-43	6.58e-40	0.98	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36081939	chr6:35989515~35990436:-
THCA	cis	rs7188445	1	rs11644836	ENSG00000261390.4	RP11-345M22.2	-15.34	2.3e-43	6.68e-40	-0.7	-0.58	Urate levels;	chr16:79678758	chr16:79715232~79770563:-
THCA	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	15.34	2.37e-43	6.9e-40	0.63	0.58	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
THCA	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	15.34	2.41e-43	7e-40	0.68	0.58	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
THCA	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	15.34	2.41e-43	7e-40	0.68	0.58	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
THCA	cis	rs1431005	0.892	rs72725288	ENSG00000250620.1	RP11-91J3.3	15.33	2.53e-43	7.33e-40	0.71	0.58	Response to statin therapy;	chr4:187477411	chr4:187413564~187415697:+
THCA	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	15.33	2.67e-43	7.73e-40	0.61	0.58	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
THCA	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	15.33	2.75e-43	7.97e-40	0.68	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
THCA	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	15.32	2.86e-43	8.29e-40	0.75	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
THCA	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-15.32	2.9e-43	8.42e-40	-0.57	-0.58	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
THCA	cis	rs80028505	0.908	rs7759175	ENSG00000271304.1	DPRXP2	15.32	2.93e-43	8.5e-40	0.97	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36045247	chr6:35989515~35990436:-
THCA	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	15.32	3.02e-43	8.76e-40	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	15.32	3.02e-43	8.76e-40	0.69	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
THCA	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	15.32	3.04e-43	8.79e-40	0.47	0.58	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
THCA	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-15.31	3.11e-43	8.99e-40	-0.57	-0.58	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
THCA	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	15.31	3.12e-43	9.02e-40	0.68	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
THCA	cis	rs9326248	0.539	rs660443	ENSG00000254851.1	RP11-109L13.1	-15.31	3.14e-43	9.08e-40	-0.76	-0.58	Blood protein levels;	chr11:116889977	chr11:117135528~117138582:+
THCA	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-15.31	3.16e-43	9.15e-40	-0.57	-0.58	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
THCA	cis	rs3779195	0.929	rs4268041	ENSG00000272950.1	RP11-307C18.1	-15.31	3.18e-43	9.19e-40	-0.84	-0.58	Sex hormone-binding globulin levels;	chr7:98376226	chr7:98322853~98323430:+
THCA	cis	rs11098499	0.863	rs1010740	ENSG00000245958.5	RP11-33B1.1	15.31	3.19e-43	9.23e-40	0.6	0.58	Corneal astigmatism;	chr4:119542254	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-15.3	3.42e-43	9.9e-40	-0.75	-0.58	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
THCA	cis	rs62388641	0.636	rs35412353	ENSG00000272279.1	RP11-157J24.2	15.3	3.51e-43	1.01e-39	0.99	0.58	Daytime sleep phenotypes;	chr6:1529209	chr6:1528364~1528911:-
THCA	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-15.3	3.52e-43	1.02e-39	-0.62	-0.58	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-15.3	3.52e-43	1.02e-39	-0.62	-0.58	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
THCA	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	15.3	3.73e-43	1.08e-39	0.75	0.58	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
THCA	cis	rs7182621	0.622	rs12904160	ENSG00000259363.4	CTD-2054N24.2	-15.3	3.73e-43	1.08e-39	-0.72	-0.58	Colonoscopy-negative controls vs population controls;	chr15:99869471	chr15:99807023~99877148:+
THCA	cis	rs1431005	0.964	rs978629	ENSG00000250620.1	RP11-91J3.3	15.29	3.88e-43	1.12e-39	0.74	0.58	Response to statin therapy;	chr4:187426241	chr4:187413564~187415697:+
THCA	cis	rs7569084	0.663	rs10190233	ENSG00000281920.1	RP11-418H16.1	-15.29	4.08e-43	1.18e-39	-0.72	-0.58	Sum eosinophil basophil counts;	chr2:65413095	chr2:65623272~65628424:+
THCA	cis	rs11098499	0.78	rs12504773	ENSG00000245958.5	RP11-33B1.1	-15.29	4.08e-43	1.18e-39	-0.58	-0.58	Corneal astigmatism;	chr4:119640994	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.78	rs7680914	ENSG00000245958.5	RP11-33B1.1	-15.29	4.08e-43	1.18e-39	-0.58	-0.58	Corneal astigmatism;	chr4:119641898	chr4:119454791~119552025:+
THCA	cis	rs7182621	0.793	rs12904168	ENSG00000259363.4	CTD-2054N24.2	-15.28	4.18e-43	1.21e-39	-0.73	-0.58	Colonoscopy-negative controls vs population controls;	chr15:99869495	chr15:99807023~99877148:+
THCA	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	15.28	4.24e-43	1.22e-39	0.67	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
THCA	cis	rs1153858	0.945	rs2467854	ENSG00000259520.4	CTD-2651B20.3	-15.28	4.25e-43	1.23e-39	-0.73	-0.58	Homoarginine levels;	chr15:45409399	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs2461701	ENSG00000259520.4	CTD-2651B20.3	-15.28	4.25e-43	1.23e-39	-0.73	-0.58	Homoarginine levels;	chr15:45411193	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs2467858	ENSG00000259520.4	CTD-2651B20.3	-15.28	4.25e-43	1.23e-39	-0.73	-0.58	Homoarginine levels;	chr15:45419294	chr15:45251580~45279251:-
THCA	cis	rs1153858	1	rs10519022	ENSG00000259520.4	CTD-2651B20.3	15.28	4.25e-43	1.23e-39	0.73	0.58	Homoarginine levels;	chr15:45371486	chr15:45251580~45279251:-
THCA	cis	rs80028505	0.808	rs73729685	ENSG00000271304.1	DPRXP2	15.28	4.28e-43	1.23e-39	0.97	0.58	Foot ulcer in diabetes and neuropathy;	chr6:36043296	chr6:35989515~35990436:-
THCA	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-15.28	4.3e-43	1.24e-39	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
THCA	cis	rs9326248	0.52	rs10892060	ENSG00000254851.1	RP11-109L13.1	-15.28	4.39e-43	1.26e-39	-0.76	-0.58	Blood protein levels;	chr11:117010946	chr11:117135528~117138582:+
THCA	cis	rs6860806	0.507	rs635620	ENSG00000233006.5	AC034220.3	-15.28	4.55e-43	1.31e-39	-0.47	-0.58	Breast cancer;	chr5:132384571	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.507	rs635619	ENSG00000233006.5	AC034220.3	-15.28	4.55e-43	1.31e-39	-0.47	-0.58	Breast cancer;	chr5:132384573	chr5:132311285~132369916:-
THCA	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-15.28	4.57e-43	1.32e-39	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-15.28	4.57e-43	1.32e-39	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-15.28	4.57e-43	1.32e-39	-0.61	-0.58	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
THCA	cis	rs5769707	0.967	rs2051626	ENSG00000188511.11	C22orf34	15.27	4.64e-43	1.34e-39	0.67	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49414524~49657542:-
THCA	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	15.27	4.72e-43	1.36e-39	0.67	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	15.27	4.72e-43	1.36e-39	0.67	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
THCA	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	15.27	4.76e-43	1.37e-39	0.46	0.58	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
THCA	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	15.27	4.86e-43	1.4e-39	0.75	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
THCA	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	15.27	4.86e-43	1.4e-39	0.75	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
THCA	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	15.27	4.92e-43	1.41e-39	0.46	0.58	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	15.27	4.92e-43	1.41e-39	0.46	0.58	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
THCA	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-15.27	4.97e-43	1.43e-39	-0.62	-0.58	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
THCA	cis	rs11155671	0.53	rs9397398	ENSG00000223701.3	RAET1E-AS1	15.26	5.25e-43	1.51e-39	0.76	0.58	Testicular germ cell tumor;	chr6:149872467	chr6:149884431~149919508:+
THCA	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-15.26	5.31e-43	1.53e-39	-0.46	-0.58	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
THCA	cis	rs11098499	0.909	rs10017335	ENSG00000245958.5	RP11-33B1.1	15.26	5.44e-43	1.56e-39	0.58	0.58	Corneal astigmatism;	chr4:119460368	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	15.26	5.49e-43	1.58e-39	0.73	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
THCA	cis	rs1431005	0.963	rs6553064	ENSG00000250620.1	RP11-91J3.3	15.26	5.49e-43	1.58e-39	0.73	0.58	Response to statin therapy;	chr4:187423507	chr4:187413564~187415697:+
THCA	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-15.26	5.6e-43	1.61e-39	-0.78	-0.58	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
THCA	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	15.26	5.67e-43	1.63e-39	0.61	0.58	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
THCA	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-15.25	5.7e-43	1.64e-39	-0.64	-0.58	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
THCA	cis	rs638893	0.636	rs6421569	ENSG00000278376.1	RP11-158I9.8	-15.25	5.74e-43	1.65e-39	-0.7	-0.58	Vitiligo;	chr11:118785066	chr11:118791254~118793137:+
THCA	cis	rs638893	0.578	rs1790188	ENSG00000278376.1	RP11-158I9.8	-15.25	5.74e-43	1.65e-39	-0.7	-0.58	Vitiligo;	chr11:118790346	chr11:118791254~118793137:+
THCA	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	15.25	6.26e-43	1.79e-39	0.74	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
THCA	cis	rs5769707	0.967	rs9616701	ENSG00000188511.11	C22orf34	15.24	6.49e-43	1.86e-39	0.67	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49414524~49657542:-
THCA	cis	rs1153858	1	rs7402650	ENSG00000259520.4	CTD-2651B20.3	-15.24	6.59e-43	1.89e-39	-0.73	-0.58	Homoarginine levels;	chr15:45409697	chr15:45251580~45279251:-
THCA	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-15.24	6.73e-43	1.92e-39	-0.47	-0.58	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
THCA	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-15.24	6.73e-43	1.92e-39	-0.47	-0.58	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-15.24	6.73e-43	1.92e-39	-0.47	-0.58	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
THCA	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-15.24	6.73e-43	1.92e-39	-0.47	-0.58	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	15.24	6.77e-43	1.94e-39	0.75	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
THCA	cis	rs638893	0.527	rs7933859	ENSG00000278376.1	RP11-158I9.8	-15.24	6.79e-43	1.94e-39	-0.69	-0.58	Vitiligo;	chr11:118791336	chr11:118791254~118793137:+
THCA	cis	rs638893	0.578	rs4508234	ENSG00000278376.1	RP11-158I9.8	-15.24	6.79e-43	1.94e-39	-0.69	-0.58	Vitiligo;	chr11:118791494	chr11:118791254~118793137:+
THCA	cis	rs638893	0.578	rs5006102	ENSG00000278376.1	RP11-158I9.8	-15.24	6.79e-43	1.94e-39	-0.69	-0.58	Vitiligo;	chr11:118791631	chr11:118791254~118793137:+
THCA	cis	rs6860806	0.507	rs2631364	ENSG00000233006.5	AC034220.3	-15.23	7.38e-43	2.11e-39	-0.47	-0.57	Breast cancer;	chr5:132371222	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-15.23	7.38e-43	2.11e-39	-0.47	-0.57	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
THCA	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-15.23	7.63e-43	2.18e-39	-0.74	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
THCA	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-15.23	7.66e-43	2.19e-39	-0.61	-0.57	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
THCA	cis	rs1431005	0.963	rs72725286	ENSG00000250620.1	RP11-91J3.3	15.23	7.69e-43	2.2e-39	0.72	0.57	Response to statin therapy;	chr4:187475655	chr4:187413564~187415697:+
THCA	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	15.22	7.99e-43	2.28e-39	0.72	0.57	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	15.22	8.1e-43	2.31e-39	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
THCA	cis	rs17111396	0.95	rs12323621	ENSG00000259167.2	NMNAT1P1	15.22	8.2e-43	2.34e-39	0.75	0.57	Uric acid levels;	chr14:81034254	chr14:81032529~81033404:+
THCA	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	15.22	8.28e-43	2.36e-39	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
THCA	cis	rs62388641	0.636	rs62388638	ENSG00000272279.1	RP11-157J24.2	15.22	8.38e-43	2.39e-39	0.99	0.57	Daytime sleep phenotypes;	chr6:1529224	chr6:1528364~1528911:-
THCA	cis	rs17111396	1	rs2024422	ENSG00000259167.2	NMNAT1P1	15.21	9.24e-43	2.63e-39	0.77	0.57	Uric acid levels;	chr14:81050593	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs10131847	ENSG00000259167.2	NMNAT1P1	15.21	9.24e-43	2.63e-39	0.77	0.57	Uric acid levels;	chr14:81051134	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs72689928	ENSG00000259167.2	NMNAT1P1	15.21	9.24e-43	2.63e-39	0.77	0.57	Uric acid levels;	chr14:81051689	chr14:81032529~81033404:+
THCA	cis	rs524281	0.725	rs3132851	ENSG00000255320.1	RP11-755F10.1	-15.21	9.25e-43	2.63e-39	-0.86	-0.57	Electroencephalogram traits;	chr11:66288671	chr11:66244840~66246239:-
THCA	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	15.21	9.4e-43	2.68e-39	0.47	0.57	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
THCA	cis	rs80028505	0.908	rs7760578	ENSG00000271304.1	DPRXP2	15.2	9.58e-43	2.73e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36040286	chr6:35989515~35990436:-
THCA	cis	rs10170846	0.8	rs10194743	ENSG00000261428.2	RP11-16P6.1	15.2	9.61e-43	2.74e-39	0.58	0.57	Schizophrenia (inflammation and infection response interaction);	chr2:222653432	chr2:222566899~222569719:-
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	15.2	9.69e-43	2.76e-39	0.73	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
THCA	cis	rs2455601	0.935	rs12049908	ENSG00000254860.4	TMEM9B-AS1	15.2	9.69e-43	2.76e-39	0.81	0.57	Schizophrenia;	chr11:8897762	chr11:8964675~8977527:+
THCA	cis	rs1431005	0.928	rs4623072	ENSG00000250620.1	RP11-91J3.3	15.2	9.92e-43	2.82e-39	0.73	0.57	Response to statin therapy;	chr4:187459164	chr4:187413564~187415697:+
THCA	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	15.2	9.96e-43	2.83e-39	0.61	0.57	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
THCA	cis	rs80028505	0.908	rs6910685	ENSG00000271304.1	DPRXP2	15.2	1.01e-42	2.88e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36080640	chr6:35989515~35990436:-
THCA	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	15.2	1.02e-42	2.89e-39	0.45	0.57	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
THCA	cis	rs17023223	0.537	rs12086	ENSG00000231365.4	RP11-418J17.1	-15.2	1.02e-42	2.9e-39	-0.71	-0.57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119031237	chr1:119140396~119275973:+
THCA	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	15.2	1.03e-42	2.92e-39	0.71	0.57	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
THCA	cis	rs638893	0.636	rs493720	ENSG00000278376.1	RP11-158I9.8	-15.2	1.04e-42	2.95e-39	-0.71	-0.57	Vitiligo;	chr11:118733969	chr11:118791254~118793137:+
THCA	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	15.2	1.04e-42	2.96e-39	0.73	0.57	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
THCA	cis	rs992157	0.764	rs2015863	ENSG00000261338.2	RP11-378A13.1	-15.2	1.04e-42	2.96e-39	-0.61	-0.57	Colorectal cancer;	chr2:218320438	chr2:218255319~218257366:+
THCA	cis	rs1431005	0.927	rs12651176	ENSG00000250620.1	RP11-91J3.3	15.19	1.05e-42	2.99e-39	0.73	0.57	Response to statin therapy;	chr4:187439724	chr4:187413564~187415697:+
THCA	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-15.19	1.07e-42	3.04e-39	-0.76	-0.57	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-15.19	1.07e-42	3.04e-39	-0.76	-0.57	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
THCA	cis	rs9660180	0.967	rs12040325	ENSG00000231050.1	RP1-140A9.1	15.19	1.09e-42	3.09e-39	0.68	0.57	Body mass index;	chr1:1770997	chr1:1891471~1892658:+
THCA	cis	rs1431005	0.927	rs72725278	ENSG00000250620.1	RP11-91J3.3	15.19	1.11e-42	3.14e-39	0.72	0.57	Response to statin therapy;	chr4:187465625	chr4:187413564~187415697:+
THCA	cis	rs6907340	0.517	rs9465531	ENSG00000228412.5	RP4-625H18.2	15.19	1.14e-42	3.24e-39	0.79	0.57	Endometriosis;	chr6:19798418	chr6:19802164~19804752:-
THCA	cis	rs80028505	0.908	rs73730440	ENSG00000271304.1	DPRXP2	15.18	1.2e-42	3.38e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36069449	chr6:35989515~35990436:-
THCA	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	15.18	1.22e-42	3.45e-39	0.6	0.57	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
THCA	cis	rs7188445	1	rs12444166	ENSG00000261390.4	RP11-345M22.2	-15.18	1.22e-42	3.46e-39	-0.7	-0.57	Urate levels;	chr16:79676053	chr16:79715232~79770563:-
THCA	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-15.18	1.25e-42	3.54e-39	-0.74	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
THCA	cis	rs80028505	0.908	rs56362075	ENSG00000271304.1	DPRXP2	15.18	1.26e-42	3.57e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36073360	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs3730366	ENSG00000271304.1	DPRXP2	15.18	1.26e-42	3.57e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36076448	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs76703794	ENSG00000271304.1	DPRXP2	15.18	1.26e-42	3.57e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36083422	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs76171341	ENSG00000271304.1	DPRXP2	15.18	1.26e-42	3.57e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36083423	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs73409842	ENSG00000271304.1	DPRXP2	15.18	1.26e-42	3.57e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36083636	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs6908622	ENSG00000271304.1	DPRXP2	15.18	1.26e-42	3.57e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36085370	chr6:35989515~35990436:-
THCA	cis	rs6860806	0.531	rs274556	ENSG00000233006.5	AC034220.3	-15.17	1.33e-42	3.77e-39	-0.47	-0.57	Breast cancer;	chr5:132386383	chr5:132311285~132369916:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-15.17	1.34e-42	3.79e-39	-0.68	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
THCA	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	15.17	1.38e-42	3.88e-39	0.46	0.57	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
THCA	cis	rs2455601	1	rs72632952	ENSG00000254860.4	TMEM9B-AS1	15.17	1.4e-42	3.94e-39	0.81	0.57	Schizophrenia;	chr11:8896429	chr11:8964675~8977527:+
THCA	cis	rs2455601	1	rs11042114	ENSG00000254860.4	TMEM9B-AS1	15.17	1.4e-42	3.94e-39	0.81	0.57	Schizophrenia;	chr11:8898342	chr11:8964675~8977527:+
THCA	cis	rs6860806	0.507	rs183898	ENSG00000233006.5	AC034220.3	-15.16	1.46e-42	4.11e-39	-0.47	-0.57	Breast cancer;	chr5:132381210	chr5:132311285~132369916:-
THCA	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-15.16	1.55e-42	4.36e-39	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
THCA	cis	rs17111396	1	rs4619328	ENSG00000259167.2	NMNAT1P1	15.16	1.55e-42	4.38e-39	0.77	0.57	Uric acid levels;	chr14:81053576	chr14:81032529~81033404:+
THCA	cis	rs17111396	1	rs2024424	ENSG00000259167.2	NMNAT1P1	15.16	1.55e-42	4.38e-39	0.77	0.57	Uric acid levels;	chr14:81054035	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.951	rs28855991	ENSG00000259167.2	NMNAT1P1	15.16	1.55e-42	4.38e-39	0.77	0.57	Uric acid levels;	chr14:81054218	chr14:81032529~81033404:+
THCA	cis	rs1153858	1	rs1145074	ENSG00000259520.4	CTD-2651B20.3	-15.16	1.57e-42	4.42e-39	-0.72	-0.57	Homoarginine levels;	chr15:45411626	chr15:45251580~45279251:-
THCA	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	15.15	1.58e-42	4.45e-39	0.58	0.57	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
THCA	cis	rs1431005	1	rs72723291	ENSG00000250620.1	RP11-91J3.3	15.15	1.61e-42	4.53e-39	0.73	0.57	Response to statin therapy;	chr4:187425714	chr4:187413564~187415697:+
THCA	cis	rs5769707	0.967	rs1018812	ENSG00000188511.11	C22orf34	15.15	1.61e-42	4.53e-39	0.66	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49414524~49657542:-
THCA	cis	rs7208859	0.623	rs609063	ENSG00000263531.1	RP13-753N3.1	15.15	1.71e-42	4.81e-39	1.07	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs383436	ENSG00000263531.1	RP13-753N3.1	15.15	1.71e-42	4.81e-39	1.07	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30863921~30864940:-
THCA	cis	rs17826219	0.714	rs11650821	ENSG00000263531.1	RP13-753N3.1	15.15	1.71e-42	4.81e-39	1.07	0.57	Body mass index;	chr17:30641132	chr17:30863921~30864940:-
THCA	cis	rs11098499	0.82	rs13122709	ENSG00000245958.5	RP11-33B1.1	-15.14	1.78e-42	4.99e-39	-0.57	-0.57	Corneal astigmatism;	chr4:119634201	chr4:119454791~119552025:+
THCA	cis	rs638893	0.636	rs2186781	ENSG00000278376.1	RP11-158I9.8	-15.14	1.8e-42	5.06e-39	-0.71	-0.57	Vitiligo;	chr11:118734738	chr11:118791254~118793137:+
THCA	cis	rs638893	0.636	rs7119702	ENSG00000278376.1	RP11-158I9.8	-15.14	1.8e-42	5.06e-39	-0.71	-0.57	Vitiligo;	chr11:118736985	chr11:118791254~118793137:+
THCA	cis	rs12468226	1	rs3731696	ENSG00000273456.1	RP11-686O6.2	15.14	1.84e-42	5.16e-39	0.76	0.57	Urate levels;	chr2:202567081	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.81	rs115255999	ENSG00000273456.1	RP11-686O6.2	15.14	1.84e-42	5.16e-39	0.76	0.57	Urate levels;	chr2:202572326	chr2:202374932~202375604:-
THCA	cis	rs9595066	1	rs4942282	ENSG00000227258.4	SMIM2-AS1	15.14	1.85e-42	5.2e-39	0.81	0.57	Schizophrenia;	chr13:44134280	chr13:44110451~44240517:+
THCA	cis	rs992157	0.932	rs4672884	ENSG00000261338.2	RP11-378A13.1	-15.14	1.9e-42	5.33e-39	-0.61	-0.57	Colorectal cancer;	chr2:218317758	chr2:218255319~218257366:+
THCA	cis	rs11098499	0.954	rs6820115	ENSG00000245958.5	RP11-33B1.1	-15.14	1.91e-42	5.35e-39	-0.54	-0.57	Corneal astigmatism;	chr4:119477027	chr4:119454791~119552025:+
THCA	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	15.14	1.91e-42	5.37e-39	0.6	0.57	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
THCA	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-15.13	1.99e-42	5.57e-39	-0.69	-0.57	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
THCA	cis	rs1431005	1	rs12650667	ENSG00000250620.1	RP11-91J3.3	15.13	2.01e-42	5.63e-39	0.73	0.57	Response to statin therapy;	chr4:187424873	chr4:187413564~187415697:+
THCA	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-15.13	2.03e-42	5.69e-39	-0.69	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
THCA	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	15.13	2.08e-42	5.82e-39	0.46	0.57	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
THCA	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	15.13	2.09e-42	5.85e-39	0.6	0.57	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
THCA	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	15.13	2.14e-42	5.98e-39	0.96	0.57	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
THCA	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	15.12	2.15e-42	6.02e-39	0.68	0.57	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
THCA	cis	rs732716	0.819	rs12459919	ENSG00000267769.1	CTB-50L17.9	-15.12	2.26e-42	6.32e-39	-0.73	-0.57	Mean corpuscular volume;	chr19:4434506	chr19:4454014~4455286:+
THCA	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-15.12	2.32e-42	6.47e-39	-0.61	-0.57	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
THCA	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-15.12	2.36e-42	6.6e-39	-0.59	-0.57	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000235689.1	AP000351.13	15.11	2.41e-42	6.72e-39	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:24006305~24008258:-
THCA	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-15.11	2.41e-42	6.73e-39	-0.86	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
THCA	cis	rs9595066	1	rs4942281	ENSG00000227258.4	SMIM2-AS1	15.11	2.46e-42	6.86e-39	0.82	0.57	Schizophrenia;	chr13:44133990	chr13:44110451~44240517:+
THCA	cis	rs6860806	0.507	rs270608	ENSG00000233006.5	AC034220.3	15.11	2.53e-42	7.06e-39	0.46	0.57	Breast cancer;	chr5:132312713	chr5:132311285~132369916:-
THCA	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	15.11	2.54e-42	7.1e-39	0.73	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
THCA	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	15.11	2.55e-42	7.12e-39	0.46	0.57	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
THCA	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	15.11	2.62e-42	7.31e-39	0.69	0.57	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
THCA	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-15.1	2.67e-42	7.44e-39	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	15.1	2.72e-42	7.6e-39	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
THCA	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	15.1	2.75e-42	7.65e-39	0.46	0.57	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
THCA	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	15.1	2.78e-42	7.76e-39	0.68	0.57	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	15.1	2.78e-42	7.76e-39	0.68	0.57	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
THCA	cis	rs80028505	1	rs16883989	ENSG00000271304.1	DPRXP2	15.1	2.78e-42	7.76e-39	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36043181	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs6930333	ENSG00000271304.1	DPRXP2	15.1	2.78e-42	7.76e-39	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36046811	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs6921999	ENSG00000271304.1	DPRXP2	15.1	2.78e-42	7.76e-39	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36052151	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.71	rs6934216	ENSG00000271304.1	DPRXP2	15.1	2.78e-42	7.76e-39	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36059856	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.731	rs61364424	ENSG00000271304.1	DPRXP2	15.1	2.78e-42	7.76e-39	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36064129	chr6:35989515~35990436:-
THCA	cis	rs2945232	1	rs2945232	ENSG00000253893.2	FAM85B	-15.1	2.79e-42	7.79e-39	-0.71	-0.57	Schizophrenia;	chr8:8240516	chr8:8167819~8226614:-
THCA	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	15.1	2.87e-42	7.98e-39	0.63	0.57	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	15.1	2.87e-42	7.98e-39	0.63	0.57	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	15.1	2.87e-42	7.98e-39	0.63	0.57	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	15.1	2.87e-42	7.98e-39	0.63	0.57	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
THCA	cis	rs7727544	0.709	rs441969	ENSG00000233006.5	AC034220.3	15.1	2.9e-42	8.08e-39	0.45	0.57	Blood metabolite levels;	chr5:132366428	chr5:132311285~132369916:-
THCA	cis	rs80028505	0.908	rs56059109	ENSG00000271304.1	DPRXP2	15.09	2.93e-42	8.16e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36057530	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs73407870	ENSG00000271304.1	DPRXP2	15.09	2.93e-42	8.16e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36060470	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs73407871	ENSG00000271304.1	DPRXP2	15.09	2.93e-42	8.16e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36060866	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs60100837	ENSG00000271304.1	DPRXP2	15.09	2.93e-42	8.16e-39	0.96	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36064311	chr6:35989515~35990436:-
THCA	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	15.09	3e-42	8.34e-39	0.68	0.57	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	15.09	3e-42	8.34e-39	0.68	0.57	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
THCA	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-15.09	3.03e-42	8.42e-39	-0.46	-0.57	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
THCA	cis	rs638893	0.636	rs526850	ENSG00000278376.1	RP11-158I9.8	-15.09	3.03e-42	8.43e-39	-0.71	-0.57	Vitiligo;	chr11:118734418	chr11:118791254~118793137:+
THCA	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-15.09	3.04e-42	8.46e-39	-0.69	-0.57	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
THCA	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-15.09	3.16e-42	8.77e-39	-0.79	-0.57	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
THCA	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	15.08	3.28e-42	9.11e-39	0.46	0.57	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	15.08	3.28e-42	9.11e-39	0.46	0.57	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	15.08	3.28e-42	9.11e-39	0.46	0.57	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	15.08	3.28e-42	9.11e-39	0.46	0.57	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
THCA	cis	rs7208859	0.573	rs216442	ENSG00000263531.1	RP13-753N3.1	15.08	3.36e-42	9.32e-39	1.07	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216445	ENSG00000263531.1	RP13-753N3.1	15.08	3.36e-42	9.32e-39	1.07	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216446	ENSG00000263531.1	RP13-753N3.1	15.08	3.36e-42	9.32e-39	1.07	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30863921~30864940:-
THCA	cis	rs11155671	0.53	rs2342770	ENSG00000223701.3	RAET1E-AS1	15.08	3.41e-42	9.45e-39	0.75	0.57	Testicular germ cell tumor;	chr6:149895549	chr6:149884431~149919508:+
THCA	cis	rs992157	0.644	rs6741757	ENSG00000261338.2	RP11-378A13.1	15.08	3.47e-42	9.61e-39	0.61	0.57	Colorectal cancer;	chr2:218318025	chr2:218255319~218257366:+
THCA	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-15.08	3.48e-42	9.66e-39	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	15.07	3.6e-42	9.98e-39	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.623	rs122898	ENSG00000263531.1	RP13-753N3.1	-15.07	3.61e-42	1e-38	-1.07	-0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30863921~30864940:-
THCA	cis	rs80028505	1	rs61212706	ENSG00000271304.1	DPRXP2	15.07	3.75e-42	1.04e-38	0.94	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36071654	chr6:35989515~35990436:-
THCA	cis	rs732716	0.785	rs62130978	ENSG00000267769.1	CTB-50L17.9	-15.07	3.82e-42	1.06e-38	-0.74	-0.57	Mean corpuscular volume;	chr19:4429010	chr19:4454014~4455286:+
THCA	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-15.07	3.87e-42	1.07e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
THCA	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	15.07	3.95e-42	1.09e-38	0.64	0.57	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
THCA	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	15.06	4.23e-42	1.17e-38	0.55	0.57	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
THCA	cis	rs732716	0.785	rs56272533	ENSG00000267769.1	CTB-50L17.9	-15.06	4.24e-42	1.17e-38	-0.74	-0.57	Mean corpuscular volume;	chr19:4420045	chr19:4454014~4455286:+
THCA	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-15.06	4.26e-42	1.18e-38	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
THCA	cis	rs1431005	1	rs60320548	ENSG00000250620.1	RP11-91J3.3	15.06	4.33e-42	1.2e-38	0.72	0.57	Response to statin therapy;	chr4:187436265	chr4:187413564~187415697:+
THCA	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	15.05	4.39e-42	1.21e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
THCA	cis	rs11098499	0.863	rs13136462	ENSG00000245958.5	RP11-33B1.1	-15.05	4.43e-42	1.22e-38	-0.57	-0.57	Corneal astigmatism;	chr4:119622018	chr4:119454791~119552025:+
THCA	cis	rs6907340	0.517	rs6939160	ENSG00000228412.5	RP4-625H18.2	15.05	4.45e-42	1.23e-38	0.78	0.57	Endometriosis;	chr6:19802086	chr6:19802164~19804752:-
THCA	cis	rs7188445	0.933	rs74037509	ENSG00000261390.4	RP11-345M22.2	-15.05	4.49e-42	1.24e-38	-0.7	-0.57	Urate levels;	chr16:79679107	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.933	rs76390413	ENSG00000261390.4	RP11-345M22.2	-15.05	4.49e-42	1.24e-38	-0.7	-0.57	Urate levels;	chr16:79680019	chr16:79715232~79770563:-
THCA	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-15.05	4.6e-42	1.27e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
THCA	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-15.05	4.82e-42	1.33e-38	-0.73	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
THCA	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-15.04	4.88e-42	1.34e-38	-0.73	-0.57	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
THCA	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-15.04	4.9e-42	1.35e-38	-0.56	-0.57	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
THCA	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-15.04	4.97e-42	1.37e-38	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-15.04	5.02e-42	1.38e-38	-0.74	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
THCA	cis	rs7188445	0.933	rs28773265	ENSG00000261390.4	RP11-345M22.2	-15.04	5.18e-42	1.43e-38	-0.7	-0.57	Urate levels;	chr16:79678864	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.898	rs74247468	ENSG00000261390.4	RP11-345M22.2	-15.04	5.18e-42	1.43e-38	-0.7	-0.57	Urate levels;	chr16:79679188	chr16:79715232~79770563:-
THCA	cis	rs11098499	0.82	rs28535956	ENSG00000245958.5	RP11-33B1.1	15.04	5.36e-42	1.48e-38	0.57	0.57	Corneal astigmatism;	chr4:119615703	chr4:119454791~119552025:+
THCA	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	15.04	5.37e-42	1.48e-38	0.91	0.57	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
THCA	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	15.03	5.43e-42	1.49e-38	0.6	0.57	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
THCA	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	15.03	5.64e-42	1.55e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
THCA	cis	rs1431005	0.964	rs59345911	ENSG00000250620.1	RP11-91J3.3	15.03	5.66e-42	1.56e-38	0.72	0.57	Response to statin therapy;	chr4:187436078	chr4:187413564~187415697:+
THCA	cis	rs7188445	0.966	rs11150188	ENSG00000261390.4	RP11-345M22.2	-15.03	5.8e-42	1.6e-38	-0.69	-0.57	Urate levels;	chr16:79673401	chr16:79715232~79770563:-
THCA	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-15.03	5.82e-42	1.6e-38	-0.65	-0.57	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	15.03	5.89e-42	1.62e-38	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
THCA	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	15.02	5.97e-42	1.64e-38	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
THCA	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	15.02	6.09e-42	1.67e-38	0.68	0.57	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
THCA	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-15.02	6.27e-42	1.72e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-15.02	6.27e-42	1.72e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-15.02	6.27e-42	1.72e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-15.02	6.27e-42	1.72e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
THCA	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-15.02	6.29e-42	1.73e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-15.02	6.29e-42	1.73e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-15.02	6.29e-42	1.73e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-15.02	6.29e-42	1.73e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-15.02	6.29e-42	1.73e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
THCA	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-15.02	6.29e-42	1.73e-38	-0.74	-0.57	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
THCA	cis	rs6860806	0.507	rs273917	ENSG00000233006.5	AC034220.3	15.02	6.32e-42	1.73e-38	0.46	0.57	Breast cancer;	chr5:132323925	chr5:132311285~132369916:-
THCA	cis	rs270601	0.955	rs273911	ENSG00000233006.5	AC034220.3	15.02	6.32e-42	1.73e-38	0.46	0.57	Acylcarnitine levels;	chr5:132325833	chr5:132311285~132369916:-
THCA	cis	rs6860806	0.507	rs272891	ENSG00000233006.5	AC034220.3	15.02	6.32e-42	1.73e-38	0.46	0.57	Breast cancer;	chr5:132328701	chr5:132311285~132369916:-
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000235689.1	AP000351.13	15.02	6.4e-42	1.75e-38	0.71	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:24006305~24008258:-
THCA	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-15.02	6.42e-42	1.76e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
THCA	cis	rs992157	0.672	rs2382829	ENSG00000261338.2	RP11-378A13.1	15.02	6.53e-42	1.79e-38	0.6	0.57	Colorectal cancer;	chr2:218319894	chr2:218255319~218257366:+
THCA	cis	rs992157	0.764	rs2891079	ENSG00000261338.2	RP11-378A13.1	15.02	6.53e-42	1.79e-38	0.6	0.57	Colorectal cancer;	chr2:218319968	chr2:218255319~218257366:+
THCA	cis	rs992157	0.764	rs4552182	ENSG00000261338.2	RP11-378A13.1	15.02	6.53e-42	1.79e-38	0.6	0.57	Colorectal cancer;	chr2:218320149	chr2:218255319~218257366:+
THCA	cis	rs992157	0.764	rs4423579	ENSG00000261338.2	RP11-378A13.1	15.02	6.53e-42	1.79e-38	0.6	0.57	Colorectal cancer;	chr2:218320310	chr2:218255319~218257366:+
THCA	cis	rs992157	0.764	rs62183964	ENSG00000261338.2	RP11-378A13.1	15.02	6.53e-42	1.79e-38	0.6	0.57	Colorectal cancer;	chr2:218321869	chr2:218255319~218257366:+
THCA	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	15.01	6.65e-42	1.82e-38	0.68	0.57	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	15.01	6.65e-42	1.82e-38	0.68	0.57	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	15.01	6.65e-42	1.82e-38	0.68	0.57	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	15.01	6.65e-42	1.82e-38	0.68	0.57	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	15.01	6.65e-42	1.82e-38	0.68	0.57	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
THCA	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	15.01	6.65e-42	1.82e-38	0.68	0.57	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
THCA	cis	rs992157	0.764	rs3731861	ENSG00000261338.2	RP11-378A13.1	-15.01	6.81e-42	1.86e-38	-0.61	-0.57	Colorectal cancer;	chr2:218326533	chr2:218255319~218257366:+
THCA	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	15.01	6.84e-42	1.87e-38	0.64	0.57	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
THCA	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-15.01	6.93e-42	1.9e-38	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
THCA	cis	rs732716	0.785	rs62130979	ENSG00000267769.1	CTB-50L17.9	-15.01	6.94e-42	1.9e-38	-0.74	-0.57	Mean corpuscular volume;	chr19:4432447	chr19:4454014~4455286:+
THCA	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-15.01	6.95e-42	1.9e-38	-0.85	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
THCA	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	15.01	7.01e-42	1.92e-38	1	0.57	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
THCA	cis	rs80028505	0.908	rs73407868	ENSG00000271304.1	DPRXP2	15.01	7.13e-42	1.95e-38	0.94	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36054534	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs3730327	ENSG00000271304.1	DPRXP2	15.01	7.13e-42	1.95e-38	0.94	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36059365	chr6:35989515~35990436:-
THCA	cis	rs80028505	1	rs73407876	ENSG00000271304.1	DPRXP2	15.01	7.13e-42	1.95e-38	0.94	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36066143	chr6:35989515~35990436:-
THCA	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-15.01	7.25e-42	1.98e-38	-0.55	-0.57	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
THCA	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-15	7.33e-42	2e-38	-0.46	-0.57	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
THCA	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	15	7.34e-42	2e-38	0.68	0.57	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
THCA	cis	rs3779195	1	rs3779195	ENSG00000272950.1	RP11-307C18.1	-15	7.49e-42	2.05e-38	-0.84	-0.57	Sex hormone-binding globulin levels;	chr7:98364050	chr7:98322853~98323430:+
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	15	7.61e-42	2.08e-38	0.73	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
THCA	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-15	7.81e-42	2.13e-38	-0.46	-0.57	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
THCA	cis	rs9326248	0.509	rs533556	ENSG00000254851.1	RP11-109L13.1	-15	7.86e-42	2.15e-38	-0.74	-0.57	Blood protein levels;	chr11:116870856	chr11:117135528~117138582:+
THCA	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	15	7.88e-42	2.15e-38	0.69	0.57	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
THCA	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-15	8.04e-42	2.19e-38	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
THCA	cis	rs1431005	0.964	rs112852905	ENSG00000250620.1	RP11-91J3.3	15	8.05e-42	2.2e-38	0.72	0.57	Response to statin therapy;	chr4:187427031	chr4:187413564~187415697:+
THCA	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	14.99	8.19e-42	2.23e-38	0.73	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
THCA	cis	rs12468226	1	rs11899836	ENSG00000273456.1	RP11-686O6.2	14.99	8.22e-42	2.24e-38	0.74	0.57	Urate levels;	chr2:202371316	chr2:202374932~202375604:-
THCA	cis	rs2283792	0.967	rs743409	ENSG00000224086.5	LL22NC03-86G7.1	-14.99	8.31e-42	2.26e-38	-0.68	-0.57	Multiple sclerosis;	chr22:21774926	chr22:21938293~21977632:+
THCA	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	14.99	8.51e-42	2.32e-38	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
THCA	cis	rs80028505	0.908	rs73730437	ENSG00000271304.1	DPRXP2	14.99	8.6e-42	2.34e-38	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36068735	chr6:35989515~35990436:-
THCA	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	14.99	8.61e-42	2.35e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
THCA	cis	rs7208859	0.562	rs11650923	ENSG00000263531.1	RP13-753N3.1	14.99	8.65e-42	2.35e-38	1.08	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30863921~30864940:-
THCA	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-14.99	8.65e-42	2.35e-38	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
THCA	cis	rs992157	0.764	rs1870124	ENSG00000261338.2	RP11-378A13.1	14.99	8.66e-42	2.36e-38	0.6	0.57	Colorectal cancer;	chr2:218323017	chr2:218255319~218257366:+
THCA	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-14.99	8.73e-42	2.38e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
THCA	cis	rs6907340	0.517	rs9465533	ENSG00000228412.5	RP4-625H18.2	14.99	8.94e-42	2.43e-38	0.78	0.57	Endometriosis;	chr6:19801477	chr6:19802164~19804752:-
THCA	cis	rs1930961	1	rs5996946	ENSG00000100058.11	CRYBB2P1	14.98	8.95e-42	2.43e-38	0.95	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25448105~25520854:+
THCA	cis	rs80028505	0.803	rs7745927	ENSG00000271304.1	DPRXP2	14.98	8.95e-42	2.43e-38	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36037898	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs7745536	ENSG00000271304.1	DPRXP2	14.98	8.95e-42	2.43e-38	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36037914	chr6:35989515~35990436:-
THCA	cis	rs7208859	0.623	rs56378576	ENSG00000263531.1	RP13-753N3.1	14.98	9.02e-42	2.45e-38	1.08	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs35916850	ENSG00000263531.1	RP13-753N3.1	14.98	9.02e-42	2.45e-38	1.08	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30863921~30864940:-
THCA	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	14.98	9.24e-42	2.51e-38	0.64	0.57	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	14.98	9.24e-42	2.51e-38	0.64	0.57	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
THCA	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-14.98	9.4e-42	2.55e-38	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
THCA	cis	rs5769707	0.967	rs5769698	ENSG00000188511.11	C22orf34	14.98	9.41e-42	2.56e-38	0.66	0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49414524~49657542:-
THCA	cis	rs80028505	0.908	rs7775290	ENSG00000271304.1	DPRXP2	14.98	9.46e-42	2.57e-38	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36069132	chr6:35989515~35990436:-
THCA	cis	rs11098499	0.82	rs28578366	ENSG00000245958.5	RP11-33B1.1	14.98	9.61e-42	2.61e-38	0.57	0.57	Corneal astigmatism;	chr4:119615750	chr4:119454791~119552025:+
THCA	cis	rs7569084	0.663	rs6546150	ENSG00000281920.1	RP11-418H16.1	-14.98	9.76e-42	2.65e-38	-0.71	-0.57	Sum eosinophil basophil counts;	chr2:65415066	chr2:65623272~65628424:+
THCA	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-14.98	9.81e-42	2.67e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-14.98	9.81e-42	2.67e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
THCA	cis	rs11098499	0.73	rs12505735	ENSG00000245958.5	RP11-33B1.1	-14.98	9.88e-42	2.68e-38	-0.57	-0.57	Corneal astigmatism;	chr4:119611801	chr4:119454791~119552025:+
THCA	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-14.97	9.95e-42	2.7e-38	-0.74	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
THCA	cis	rs992157	0.73	rs2382828	ENSG00000261338.2	RP11-378A13.1	14.97	9.97e-42	2.71e-38	0.6	0.57	Colorectal cancer;	chr2:218319769	chr2:218255319~218257366:+
THCA	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	14.97	1e-41	2.72e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	14.97	1e-41	2.72e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
THCA	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-14.97	1e-41	2.73e-38	-0.61	-0.57	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
THCA	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	14.97	1.03e-41	2.79e-38	0.63	0.57	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
THCA	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-14.97	1.06e-41	2.86e-38	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
THCA	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-14.97	1.07e-41	2.89e-38	-0.64	-0.57	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
THCA	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	14.97	1.07e-41	2.9e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	14.97	1.07e-41	2.9e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	14.97	1.07e-41	2.9e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	14.96	1.1e-41	2.98e-38	0.67	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
THCA	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	14.96	1.12e-41	3.03e-38	0.54	0.57	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000228039.3	KB-1125A3.10	14.96	1.13e-41	3.05e-38	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23963780~23964374:+
THCA	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-14.96	1.15e-41	3.11e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
THCA	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-14.96	1.15e-41	3.11e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
THCA	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	14.96	1.2e-41	3.23e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-14.96	1.2e-41	3.23e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-14.96	1.2e-41	3.23e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-14.96	1.2e-41	3.23e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
THCA	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	14.95	1.22e-41	3.28e-38	1.01	0.57	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
THCA	cis	rs7208859	0.573	rs73267829	ENSG00000263531.1	RP13-753N3.1	14.95	1.23e-41	3.31e-38	1.08	0.57	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30863921~30864940:-
THCA	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-14.95	1.25e-41	3.36e-38	-0.72	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
THCA	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	14.95	1.26e-41	3.39e-38	0.66	0.57	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
THCA	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-14.95	1.27e-41	3.41e-38	-0.64	-0.57	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
THCA	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	14.95	1.31e-41	3.52e-38	0.68	0.57	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
THCA	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-14.95	1.31e-41	3.53e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
THCA	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-14.95	1.31e-41	3.53e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
THCA	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-14.95	1.31e-41	3.53e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
THCA	cis	rs2658782	1	rs2605585	ENSG00000279684.1	RP11-755E23.2	-14.94	1.41e-41	3.8e-38	-0.97	-0.57	Pulmonary function decline;	chr11:93438696	chr11:93286629~93288903:-
THCA	cis	rs1431005	1	rs72499925	ENSG00000250620.1	RP11-91J3.3	14.94	1.42e-41	3.81e-38	0.72	0.57	Response to statin therapy;	chr4:187432596	chr4:187413564~187415697:+
THCA	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-14.94	1.44e-41	3.88e-38	-0.73	-0.57	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
THCA	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-14.94	1.46e-41	3.93e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-14.94	1.46e-41	3.93e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
THCA	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-14.93	1.53e-41	4.12e-38	-0.45	-0.57	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
THCA	cis	rs12220777	1	rs11201312	ENSG00000230091.5	TMEM254-AS1	14.93	1.57e-41	4.2e-38	1.07	0.57	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036022	chr10:80046860~80078912:-
THCA	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	14.93	1.57e-41	4.22e-38	0.54	0.57	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
THCA	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-14.93	1.59e-41	4.26e-38	-0.65	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
THCA	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	14.93	1.61e-41	4.31e-38	0.66	0.57	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
THCA	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-14.92	1.66e-41	4.43e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-14.92	1.66e-41	4.43e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-14.92	1.66e-41	4.43e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-14.92	1.66e-41	4.43e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
THCA	cis	rs17111396	1	rs17111396	ENSG00000259167.2	NMNAT1P1	14.92	1.71e-41	4.57e-38	0.76	0.57	Uric acid levels;	chr14:81057710	chr14:81032529~81033404:+
THCA	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-14.91	1.83e-41	4.88e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
THCA	cis	rs7188445	0.933	rs12449109	ENSG00000261390.4	RP11-345M22.2	-14.91	1.87e-41	4.98e-38	-0.68	-0.57	Urate levels;	chr16:79682146	chr16:79715232~79770563:-
THCA	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	14.91	1.87e-41	5e-38	0.72	0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
THCA	cis	rs7188445	0.933	rs12449161	ENSG00000261390.4	RP11-345M22.2	-14.91	1.89e-41	5.03e-38	-0.68	-0.57	Urate levels;	chr16:79682409	chr16:79715232~79770563:-
THCA	cis	rs992157	0.764	rs1870123	ENSG00000261338.2	RP11-378A13.1	14.91	1.9e-41	5.07e-38	0.6	0.57	Colorectal cancer;	chr2:218322975	chr2:218255319~218257366:+
THCA	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	14.91	1.9e-41	5.07e-38	0.55	0.57	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
THCA	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	14.91	1.93e-41	5.15e-38	0.62	0.57	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
THCA	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	14.91	1.94e-41	5.18e-38	0.54	0.57	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
THCA	cis	rs11155671	0.53	rs9371215	ENSG00000223701.3	RAET1E-AS1	14.91	1.96e-41	5.21e-38	0.75	0.57	Testicular germ cell tumor;	chr6:149873162	chr6:149884431~149919508:+
THCA	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	14.91	1.97e-41	5.24e-38	0.46	0.57	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
THCA	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-14.91	1.99e-41	5.3e-38	-1	-0.57	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
THCA	cis	rs80028505	0.908	rs60909394	ENSG00000271304.1	DPRXP2	14.91	1.99e-41	5.3e-38	0.95	0.57	Foot ulcer in diabetes and neuropathy;	chr6:36087155	chr6:35989515~35990436:-
THCA	cis	rs638893	0.636	rs6589687	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118744951	chr11:118791254~118793137:+
THCA	cis	rs638893	0.53	rs1961138	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118748714	chr11:118791254~118793137:+
THCA	cis	rs638893	0.578	rs485901	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118751536	chr11:118791254~118793137:+
THCA	cis	rs638893	0.578	rs580079	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118754900	chr11:118791254~118793137:+
THCA	cis	rs638893	0.588	rs2508929	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118770742	chr11:118791254~118793137:+
THCA	cis	rs638893	0.636	rs548167	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118777687	chr11:118791254~118793137:+
THCA	cis	rs638893	0.685	rs486651	ENSG00000278376.1	RP11-158I9.8	-14.91	2.01e-41	5.33e-38	-0.68	-0.57	Vitiligo;	chr11:118779150	chr11:118791254~118793137:+
THCA	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-14.9	2.02e-41	5.37e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
THCA	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-14.9	2.02e-41	5.37e-38	-0.8	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
THCA	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-14.9	2.06e-41	5.47e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-14.9	2.09e-41	5.55e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-14.9	2.09e-41	5.55e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
THCA	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	14.9	2.1e-41	5.57e-38	0.6	0.57	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
THCA	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	14.9	2.19e-41	5.81e-38	0.68	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
THCA	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-14.9	2.21e-41	5.85e-38	-0.64	-0.57	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
THCA	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	14.9	2.23e-41	5.9e-38	1.07	0.57	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
THCA	cis	rs11155671	0.53	rs7763849	ENSG00000223701.3	RAET1E-AS1	14.89	2.27e-41	6e-38	0.74	0.57	Testicular germ cell tumor;	chr6:149885244	chr6:149884431~149919508:+
THCA	cis	rs7240205	0.816	rs7233016	ENSG00000275805.1	RP11-349H17.2	-14.89	2.32e-41	6.13e-38	-0.65	-0.57	Breast cancer;	chr18:26541387	chr18:26565723~26575626:-
THCA	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	14.89	2.36e-41	6.25e-38	0.75	0.57	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
THCA	cis	rs2487048	0.761	rs2980083	ENSG00000226334.1	RP11-217B7.2	-14.89	2.45e-41	6.48e-38	-0.76	-0.57	Intraocular pressure;	chr9:104929081	chr9:104927553~104928892:+
THCA	cis	rs7188445	0.933	rs11644082	ENSG00000261390.4	RP11-345M22.2	-14.89	2.46e-41	6.5e-38	-0.69	-0.57	Urate levels;	chr16:79680519	chr16:79715232~79770563:-
THCA	cis	rs732716	0.785	rs62129354	ENSG00000267769.1	CTB-50L17.9	-14.89	2.47e-41	6.54e-38	-0.74	-0.57	Mean corpuscular volume;	chr19:4396508	chr19:4454014~4455286:+
THCA	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-14.88	2.5e-41	6.61e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
THCA	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	14.88	2.55e-41	6.74e-38	0.59	0.57	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
THCA	cis	rs11098499	0.78	rs10013652	ENSG00000245958.5	RP11-33B1.1	-14.88	2.56e-41	6.77e-38	-0.53	-0.57	Corneal astigmatism;	chr4:119371101	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-14.88	2.59e-41	6.85e-38	-0.72	-0.57	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
THCA	cis	rs10256972	0.721	rs6975972	ENSG00000229043.2	AC091729.9	-14.88	2.6e-41	6.86e-38	-0.59	-0.57	Endometriosis;Longevity;	chr7:1030832	chr7:1160374~1165267:+
THCA	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-14.88	2.62e-41	6.91e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
THCA	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	14.88	2.62e-41	6.92e-38	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
THCA	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	14.88	2.62e-41	6.92e-38	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
THCA	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-14.88	2.66e-41	7.03e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-14.88	2.66e-41	7.03e-38	-0.72	-0.57	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
THCA	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-14.88	2.71e-41	7.14e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-14.88	2.71e-41	7.14e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-14.88	2.71e-41	7.14e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
THCA	cis	rs7569084	0.687	rs963539	ENSG00000281920.1	RP11-418H16.1	-14.88	2.72e-41	7.18e-38	-0.71	-0.57	Sum eosinophil basophil counts;	chr2:65421413	chr2:65623272~65628424:+
THCA	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	14.88	2.73e-41	7.21e-38	0.85	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
THCA	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-14.87	2.81e-41	7.42e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
THCA	cis	rs6860806	0.507	rs274570	ENSG00000233006.5	AC034220.3	-14.87	2.88e-41	7.59e-38	-0.46	-0.57	Breast cancer;	chr5:132377534	chr5:132311285~132369916:-
THCA	cis	rs1930961	1	rs6004669	ENSG00000100058.11	CRYBB2P1	14.87	2.91e-41	7.67e-38	0.95	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25448105~25520854:+
THCA	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	14.87	3.02e-41	7.94e-38	0.85	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
THCA	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	14.87	3.02e-41	7.94e-38	0.85	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
THCA	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-14.86	3.05e-41	8.03e-38	-0.73	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
THCA	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-14.86	3.07e-41	8.07e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
THCA	cis	rs3096299	0.503	rs9925045	ENSG00000274627.1	RP11-104N10.2	14.86	3.13e-41	8.24e-38	0.55	0.57	Multiple myeloma (IgH translocation);	chr16:89490068	chr16:89516797~89522217:+
THCA	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	14.86	3.24e-41	8.53e-38	0.74	0.57	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
THCA	cis	rs11098499	0.657	rs10434028	ENSG00000245958.5	RP11-33B1.1	-14.86	3.28e-41	8.62e-38	-0.54	-0.57	Corneal astigmatism;	chr4:119373309	chr4:119454791~119552025:+
THCA	cis	rs7188445	0.583	rs80170002	ENSG00000261390.4	RP11-345M22.2	-14.86	3.3e-41	8.67e-38	-0.69	-0.57	Urate levels;	chr16:79677817	chr16:79715232~79770563:-
THCA	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	14.86	3.31e-41	8.69e-38	0.74	0.57	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
THCA	cis	rs528808	1	rs528808	ENSG00000219755.1	RP1-199J3.5	14.86	3.31e-41	8.69e-38	0.87	0.57	Age-related hearing impairment;	chr6:99656413	chr6:99575712~99576456:+
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	14.86	3.32e-41	8.72e-38	0.73	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
THCA	cis	rs6860806	0.531	rs270607	ENSG00000233006.5	AC034220.3	14.85	3.44e-41	9.01e-38	0.45	0.57	Breast cancer;	chr5:132313493	chr5:132311285~132369916:-
THCA	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	14.85	3.44e-41	9.02e-38	0.59	0.57	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
THCA	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	14.85	3.46e-41	9.06e-38	0.71	0.57	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
THCA	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	14.85	3.48e-41	9.11e-38	0.66	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
THCA	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-14.85	3.52e-41	9.21e-38	-0.59	-0.57	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
THCA	cis	rs7188445	1	rs16950982	ENSG00000261390.4	RP11-345M22.2	-14.85	3.56e-41	9.32e-38	-0.67	-0.57	Urate levels;	chr16:79668474	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.871	rs8048928	ENSG00000261390.4	RP11-345M22.2	-14.85	3.58e-41	9.38e-38	-0.67	-0.57	Urate levels;	chr16:79671039	chr16:79715232~79770563:-
THCA	cis	rs6504950	0.83	rs72831295	ENSG00000275710.1	RP11-257O5.4	14.85	3.64e-41	9.52e-38	0.76	0.57	Breast cancer;	chr17:54966443	chr17:54964474~54964679:+
THCA	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-14.85	3.64e-41	9.53e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-14.85	3.64e-41	9.53e-38	-0.54	-0.57	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
THCA	cis	rs2283792	0.935	rs5750113	ENSG00000224086.5	LL22NC03-86G7.1	-14.84	3.9e-41	1.02e-37	-0.67	-0.56	Multiple sclerosis;	chr22:21865784	chr22:21938293~21977632:+
THCA	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-14.84	3.99e-41	1.04e-37	-0.72	-0.56	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-14.84	3.99e-41	1.04e-37	-0.72	-0.56	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-14.84	4.05e-41	1.06e-37	-0.72	-0.56	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-14.84	4.05e-41	1.06e-37	-0.72	-0.56	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-14.84	4.05e-41	1.06e-37	-0.72	-0.56	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
THCA	cis	rs7188445	0.871	rs8047723	ENSG00000261390.4	RP11-345M22.2	14.83	4.21e-41	1.1e-37	0.67	0.56	Urate levels;	chr16:79671018	chr16:79715232~79770563:-
THCA	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-14.83	4.29e-41	1.12e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
THCA	cis	rs638893	0.636	rs583213	ENSG00000278376.1	RP11-158I9.8	-14.83	4.36e-41	1.14e-37	-0.68	-0.56	Vitiligo;	chr11:118798469	chr11:118791254~118793137:+
THCA	cis	rs7208859	0.623	rs170051	ENSG00000263531.1	RP13-753N3.1	14.83	4.43e-41	1.16e-37	1.06	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.51	rs216402	ENSG00000263531.1	RP13-753N3.1	14.83	4.43e-41	1.16e-37	1.06	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216434	ENSG00000263531.1	RP13-753N3.1	14.83	4.43e-41	1.16e-37	1.06	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216436	ENSG00000263531.1	RP13-753N3.1	14.83	4.43e-41	1.16e-37	1.06	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs11651857	ENSG00000263531.1	RP13-753N3.1	14.83	4.43e-41	1.16e-37	1.06	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216439	ENSG00000263531.1	RP13-753N3.1	14.83	4.43e-41	1.16e-37	1.06	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30863921~30864940:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-14.83	4.45e-41	1.16e-37	-0.71	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
THCA	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	14.83	4.46e-41	1.16e-37	0.66	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
THCA	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	14.83	4.52e-41	1.18e-37	0.59	0.56	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
THCA	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	14.82	4.58e-41	1.19e-37	0.54	0.56	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
THCA	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-14.82	4.61e-41	1.2e-37	-0.54	-0.56	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
THCA	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	14.82	4.81e-41	1.25e-37	0.46	0.56	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
THCA	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-14.82	4.87e-41	1.27e-37	-0.97	-0.56	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
THCA	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	14.81	5.07e-41	1.32e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	14.81	5.15e-41	1.34e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	14.81	5.15e-41	1.34e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	14.81	5.15e-41	1.34e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	14.81	5.15e-41	1.34e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	14.81	5.15e-41	1.34e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	14.81	5.15e-41	1.34e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
THCA	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-14.81	5.3e-41	1.38e-37	-0.67	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
THCA	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	14.81	5.54e-41	1.43e-37	0.96	0.56	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
THCA	cis	rs2283792	0.967	rs11704205	ENSG00000224086.5	LL22NC03-86G7.1	-14.81	5.55e-41	1.44e-37	-0.66	-0.56	Multiple sclerosis;	chr22:21790964	chr22:21938293~21977632:+
THCA	cis	rs7188445	0.933	rs7187128	ENSG00000261390.4	RP11-345M22.2	-14.8	5.59e-41	1.45e-37	-0.69	-0.56	Urate levels;	chr16:79675606	chr16:79715232~79770563:-
THCA	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	14.8	5.65e-41	1.46e-37	0.45	0.56	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	14.8	5.65e-41	1.46e-37	0.45	0.56	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
THCA	cis	rs7188445	1	rs11646791	ENSG00000261390.4	RP11-345M22.2	-14.8	5.77e-41	1.49e-37	-0.67	-0.56	Urate levels;	chr16:79667641	chr16:79715232~79770563:-
THCA	cis	rs17111396	1	rs10150860	ENSG00000259167.2	NMNAT1P1	14.8	5.83e-41	1.51e-37	0.77	0.56	Uric acid levels;	chr14:81055208	chr14:81032529~81033404:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-14.8	6.12e-41	1.58e-37	-0.73	-0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
THCA	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	14.79	6.19e-41	1.6e-37	0.59	0.56	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
THCA	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	14.79	6.21e-41	1.61e-37	0.84	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
THCA	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-14.79	6.32e-41	1.63e-37	-0.54	-0.56	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
THCA	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	14.79	6.32e-41	1.63e-37	0.67	0.56	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
THCA	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	14.79	6.42e-41	1.66e-37	0.8	0.56	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
THCA	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	14.79	6.42e-41	1.66e-37	0.8	0.56	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
THCA	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-14.79	6.45e-41	1.67e-37	-0.45	-0.56	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-14.79	6.45e-41	1.67e-37	-0.45	-0.56	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
THCA	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-14.79	6.62e-41	1.71e-37	-0.65	-0.56	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-14.79	6.63e-41	1.71e-37	-0.72	-0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
THCA	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	14.79	6.78e-41	1.75e-37	0.55	0.56	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
THCA	cis	rs6504950	0.83	rs12949538	ENSG00000275710.1	RP11-257O5.4	-14.78	6.87e-41	1.77e-37	-0.76	-0.56	Breast cancer;	chr17:54933309	chr17:54964474~54964679:+
THCA	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	14.78	6.94e-41	1.79e-37	0.66	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
THCA	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	14.78	7.22e-41	1.86e-37	0.46	0.56	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
THCA	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	14.78	7.22e-41	1.86e-37	0.46	0.56	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
THCA	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	14.78	7.31e-41	1.88e-37	0.54	0.56	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
THCA	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-14.78	7.45e-41	1.92e-37	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
THCA	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	14.78	7.46e-41	1.92e-37	0.46	0.56	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
THCA	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-14.77	7.62e-41	1.96e-37	-0.63	-0.56	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
THCA	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	14.77	7.62e-41	1.96e-37	0.98	0.56	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
THCA	cis	rs6504950	0.79	rs8076984	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54958067	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs17745231	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54959168	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs12938118	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54959998	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs1802212	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54961293	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs17817901	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54961384	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs12150038	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54964159	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs12951542	ENSG00000275710.1	RP11-257O5.4	14.77	7.72e-41	1.99e-37	0.76	0.56	Breast cancer;	chr17:54964604	chr17:54964474~54964679:+
THCA	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	14.77	7.76e-41	2e-37	0.71	0.56	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
THCA	cis	rs80028505	0.908	rs56156688	ENSG00000271304.1	DPRXP2	14.77	7.93e-41	2.04e-37	0.95	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36027856	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs61763101	ENSG00000271304.1	DPRXP2	14.77	7.93e-41	2.04e-37	0.95	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36028636	chr6:35989515~35990436:-
THCA	cis	rs80028505	1	rs80028505	ENSG00000271304.1	DPRXP2	14.77	7.93e-41	2.04e-37	0.95	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36030611	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs6932598	ENSG00000271304.1	DPRXP2	14.77	7.93e-41	2.04e-37	0.95	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36031303	chr6:35989515~35990436:-
THCA	cis	rs732716	0.785	rs55660045	ENSG00000267769.1	CTB-50L17.9	-14.77	8.22e-41	2.11e-37	-0.72	-0.56	Mean corpuscular volume;	chr19:4425308	chr19:4454014~4455286:+
THCA	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	14.76	8.51e-41	2.19e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
THCA	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	14.76	8.65e-41	2.22e-37	0.68	0.56	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
THCA	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	14.76	8.81e-41	2.26e-37	0.45	0.56	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
THCA	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	14.76	8.96e-41	2.3e-37	0.75	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
THCA	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	14.76	8.99e-41	2.31e-37	0.8	0.56	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
THCA	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-14.76	9.21e-41	2.36e-37	-0.95	-0.56	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
THCA	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-14.75	9.26e-41	2.37e-37	-0.64	-0.56	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
THCA	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	14.75	9.35e-41	2.4e-37	0.46	0.56	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
THCA	cis	rs270601	0.837	rs367805	ENSG00000233006.5	AC034220.3	14.75	9.58e-41	2.45e-37	0.45	0.56	Acylcarnitine levels;	chr5:132365587	chr5:132311285~132369916:-
THCA	cis	rs11098499	0.866	rs7665125	ENSG00000245958.5	RP11-33B1.1	-14.75	9.64e-41	2.47e-37	-0.52	-0.56	Corneal astigmatism;	chr4:119480924	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	14.75	9.67e-41	2.48e-37	0.69	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
THCA	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-14.75	9.68e-41	2.48e-37	-0.64	-0.56	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-14.75	9.68e-41	2.48e-37	-0.64	-0.56	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-14.75	9.68e-41	2.48e-37	-0.64	-0.56	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
THCA	cis	rs6504950	0.72	rs9914836	ENSG00000275710.1	RP11-257O5.4	14.75	9.88e-41	2.53e-37	0.74	0.56	Breast cancer;	chr17:54920514	chr17:54964474~54964679:+
THCA	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-14.75	1.01e-40	2.58e-37	-0.72	-0.56	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-14.75	1.01e-40	2.58e-37	-0.72	-0.56	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
THCA	cis	rs7208859	0.623	rs79607958	ENSG00000263531.1	RP13-753N3.1	14.75	1.01e-40	2.59e-37	1.07	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs75136574	ENSG00000263531.1	RP13-753N3.1	14.75	1.01e-40	2.59e-37	1.07	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs77544470	ENSG00000263531.1	RP13-753N3.1	14.75	1.01e-40	2.59e-37	1.07	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30863921~30864940:-
THCA	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-14.75	1.01e-40	2.59e-37	-0.73	-0.56	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
THCA	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	14.74	1.02e-40	2.62e-37	0.46	0.56	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
THCA	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	14.74	1.03e-40	2.62e-37	0.54	0.56	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
THCA	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	14.74	1.05e-40	2.67e-37	0.54	0.56	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
THCA	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	14.74	1.06e-40	2.71e-37	0.45	0.56	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
THCA	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-14.74	1.07e-40	2.74e-37	-0.55	-0.56	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
THCA	cis	rs11098499	0.738	rs28687057	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119359657	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.775	rs67281037	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119360002	chr4:119454791~119552025:+
THCA	cis	rs10028773	0.506	rs12374346	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Educational attainment;	chr4:119360550	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs12374244	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119360817	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs12374352	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119360822	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.775	rs10021601	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119361408	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs6857892	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119361541	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.909	rs28581362	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119362393	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.82	rs12503082	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119363162	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs12499602	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119363232	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.774	rs11098505	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119363472	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs13105020	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119364533	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs6824111	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119364813	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.775	rs10029303	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119365600	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs9995136	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119365690	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs13125526	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119366864	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs12513310	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119366884	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs12510451	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119367988	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.774	rs73842616	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119369528	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.645	rs72676059	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119369673	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.569	rs55845118	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119369758	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs7677068	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119370549	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.866	rs9991221	ENSG00000245958.5	RP11-33B1.1	-14.74	1.09e-40	2.78e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119370952	chr4:119454791~119552025:+
THCA	cis	rs7188445	0.933	rs56892402	ENSG00000261390.4	RP11-345M22.2	-14.74	1.11e-40	2.83e-37	-0.68	-0.56	Urate levels;	chr16:79682728	chr16:79715232~79770563:-
THCA	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-14.74	1.12e-40	2.85e-37	-0.54	-0.56	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
THCA	cis	rs2283792	1	rs2266967	ENSG00000224086.5	LL22NC03-86G7.1	-14.73	1.13e-40	2.89e-37	-0.66	-0.56	Multiple sclerosis;	chr22:21802500	chr22:21938293~21977632:+
THCA	cis	rs7188445	0.871	rs16950997	ENSG00000261390.4	RP11-345M22.2	-14.73	1.14e-40	2.89e-37	-0.67	-0.56	Urate levels;	chr16:79673733	chr16:79715232~79770563:-
THCA	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	14.73	1.17e-40	2.97e-37	0.66	0.56	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	14.73	1.17e-40	2.97e-37	0.66	0.56	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000235689.1	AP000351.13	-14.73	1.17e-40	2.98e-37	-0.7	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:24006305~24008258:-
THCA	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	14.73	1.18e-40	3e-37	0.64	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
THCA	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-14.73	1.2e-40	3.05e-37	-0.64	-0.56	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-14.73	1.2e-40	3.05e-37	-0.64	-0.56	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
THCA	cis	rs80028505	0.908	rs56133220	ENSG00000271304.1	DPRXP2	14.73	1.21e-40	3.07e-37	0.94	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36064891	chr6:35989515~35990436:-
THCA	cis	rs1431005	1	rs56063429	ENSG00000250620.1	RP11-91J3.3	14.73	1.21e-40	3.07e-37	0.71	0.56	Response to statin therapy;	chr4:187450476	chr4:187413564~187415697:+
THCA	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-14.73	1.22e-40	3.09e-37	-0.6	-0.56	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
THCA	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-14.73	1.24e-40	3.14e-37	-0.6	-0.56	Breast cancer;	chr11:825777	chr11:779617~780755:+
THCA	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	14.73	1.25e-40	3.18e-37	0.62	0.56	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	14.72	1.26e-40	3.21e-37	0.62	0.56	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
THCA	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	14.72	1.26e-40	3.21e-37	0.45	0.56	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
THCA	cis	rs12429206	0.587	rs17589481	ENSG00000233672.5	RNASEH2B-AS1	-14.72	1.27e-40	3.21e-37	-0.85	-0.56	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50892028	chr13:50862172~50910764:-
THCA	cis	rs1153858	1	rs4395020	ENSG00000259520.4	CTD-2651B20.3	-14.72	1.28e-40	3.26e-37	-0.72	-0.56	Homoarginine levels;	chr15:45360691	chr15:45251580~45279251:-
THCA	cis	rs11098499	0.731	rs6846966	ENSG00000245958.5	RP11-33B1.1	-14.72	1.32e-40	3.35e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119372053	chr4:119454791~119552025:+
THCA	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-14.72	1.34e-40	3.38e-37	-0.73	-0.56	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
THCA	cis	rs2283792	0.967	rs5999823	ENSG00000224086.5	LL22NC03-86G7.1	-14.72	1.35e-40	3.41e-37	-0.66	-0.56	Multiple sclerosis;	chr22:21856587	chr22:21938293~21977632:+
THCA	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	14.72	1.35e-40	3.42e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
THCA	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	14.72	1.37e-40	3.46e-37	0.6	0.56	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
THCA	cis	rs2283792	1	rs5999515	ENSG00000224086.5	LL22NC03-86G7.1	14.72	1.37e-40	3.47e-37	0.65	0.56	Multiple sclerosis;	chr22:21790812	chr22:21938293~21977632:+
THCA	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-14.72	1.38e-40	3.5e-37	-0.98	-0.56	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
THCA	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	14.72	1.38e-40	3.5e-37	0.59	0.56	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
THCA	cis	rs11098499	0.564	rs11098507	ENSG00000245958.5	RP11-33B1.1	-14.71	1.39e-40	3.52e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119367131	chr4:119454791~119552025:+
THCA	cis	rs7188445	0.871	rs11150187	ENSG00000261390.4	RP11-345M22.2	14.71	1.47e-40	3.72e-37	0.67	0.56	Urate levels;	chr16:79670515	chr16:79715232~79770563:-
THCA	cis	rs2882667	0.515	rs13161286	ENSG00000253404.1	AC034243.1	14.71	1.51e-40	3.81e-37	0.68	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139148416	chr5:138744434~138753309:-
THCA	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-14.71	1.52e-40	3.82e-37	-0.7	-0.56	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
THCA	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-14.71	1.53e-40	3.85e-37	-0.63	-0.56	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
THCA	cis	rs2658782	1	rs2658779	ENSG00000279684.1	RP11-755E23.2	14.7	1.55e-40	3.92e-37	0.99	0.56	Pulmonary function decline;	chr11:93429971	chr11:93286629~93288903:-
THCA	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-14.7	1.58e-40	3.99e-37	-0.64	-0.56	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
THCA	cis	rs17111396	0.951	rs12323890	ENSG00000259167.2	NMNAT1P1	14.7	1.59e-40	4e-37	0.78	0.56	Uric acid levels;	chr14:81037408	chr14:81032529~81033404:+
THCA	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-14.7	1.63e-40	4.1e-37	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
THCA	cis	rs10793273	1	rs10793273	ENSG00000254675.1	RP11-7I15.4	-14.7	1.64e-40	4.14e-37	-0.61	-0.56	Pelvic organ prolapse;	chr11:78031549	chr11:78022933~78023721:+
THCA	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	14.7	1.66e-40	4.18e-37	0.71	0.56	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
THCA	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	14.69	1.74e-40	4.38e-37	0.61	0.56	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
THCA	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	14.69	1.8e-40	4.53e-37	0.45	0.56	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	14.69	1.8e-40	4.53e-37	0.45	0.56	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
THCA	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	14.69	1.82e-40	4.57e-37	0.65	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
THCA	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	14.69	1.83e-40	4.59e-37	0.63	0.56	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
THCA	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	14.68	1.9e-40	4.77e-37	0.54	0.56	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	14.68	1.9e-40	4.77e-37	0.53	0.56	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
THCA	cis	rs992157	0.764	rs10932774	ENSG00000261338.2	RP11-378A13.1	14.68	1.91e-40	4.79e-37	0.6	0.56	Colorectal cancer;	chr2:218326846	chr2:218255319~218257366:+
THCA	cis	rs11098499	0.687	rs71610270	ENSG00000245958.5	RP11-33B1.1	-14.68	1.94e-40	4.86e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119366281	chr4:119454791~119552025:+
THCA	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	14.68	1.95e-40	4.89e-37	0.62	0.56	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
THCA	cis	rs638893	0.588	rs529717	ENSG00000278376.1	RP11-158I9.8	-14.68	1.96e-40	4.93e-37	-0.67	-0.56	Vitiligo;	chr11:118769372	chr11:118791254~118793137:+
THCA	cis	rs2283792	0.967	rs5999550	ENSG00000224086.5	LL22NC03-86G7.1	-14.68	2e-40	5.01e-37	-0.65	-0.56	Multiple sclerosis;	chr22:21796997	chr22:21938293~21977632:+
THCA	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	14.68	2e-40	5.02e-37	0.59	0.56	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
THCA	cis	rs10256972	0.721	rs4720249	ENSG00000229043.2	AC091729.9	-14.68	2.02e-40	5.07e-37	-0.59	-0.56	Endometriosis;Longevity;	chr7:1032927	chr7:1160374~1165267:+
THCA	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	14.68	2.05e-40	5.13e-37	0.89	0.56	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
THCA	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-14.68	2.05e-40	5.14e-37	-0.64	-0.56	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-14.67	2.08e-40	5.22e-37	-0.63	-0.56	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
THCA	cis	rs2283792	0.567	rs2027789	ENSG00000224086.5	LL22NC03-86G7.1	-14.67	2.14e-40	5.37e-37	-0.67	-0.56	Multiple sclerosis;	chr22:21933490	chr22:21938293~21977632:+
THCA	cis	rs7743045	0.777	rs6916491	ENSG00000253194.1	RP11-351A11.1	14.67	2.17e-40	5.42e-37	0.8	0.56	Mean platelet volume;	chr6:118926569	chr6:118934785~119031541:+
THCA	cis	rs7188445	0.871	rs7202770	ENSG00000261390.4	RP11-345M22.2	-14.67	2.18e-40	5.46e-37	-0.67	-0.56	Urate levels;	chr16:79672643	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.835	rs1424231	ENSG00000261390.4	RP11-345M22.2	-14.67	2.18e-40	5.46e-37	-0.67	-0.56	Urate levels;	chr16:79672854	chr16:79715232~79770563:-
THCA	cis	rs6504950	0.8	rs35647022	ENSG00000275710.1	RP11-257O5.4	14.67	2.21e-40	5.53e-37	0.76	0.56	Breast cancer;	chr17:54930710	chr17:54964474~54964679:+
THCA	cis	rs10256972	0.758	rs11979275	ENSG00000229043.2	AC091729.9	-14.67	2.22e-40	5.55e-37	-0.59	-0.56	Endometriosis;Longevity;	chr7:1029699	chr7:1160374~1165267:+
THCA	cis	rs10256972	0.758	rs11980081	ENSG00000229043.2	AC091729.9	-14.67	2.22e-40	5.55e-37	-0.59	-0.56	Endometriosis;Longevity;	chr7:1029736	chr7:1160374~1165267:+
THCA	cis	rs2283792	1	rs5999521	ENSG00000224086.5	LL22NC03-86G7.1	-14.67	2.23e-40	5.58e-37	-0.65	-0.56	Multiple sclerosis;	chr22:21792110	chr22:21938293~21977632:+
THCA	cis	rs5769707	0.837	rs1573726	ENSG00000188511.11	C22orf34	14.67	2.26e-40	5.66e-37	0.66	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49414524~49657542:-
THCA	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-14.67	2.26e-40	5.67e-37	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
THCA	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-14.67	2.28e-40	5.7e-37	-0.5	-0.56	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
THCA	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-14.67	2.28e-40	5.7e-37	-0.73	-0.56	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
THCA	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	14.66	2.3e-40	5.76e-37	0.65	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
THCA	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-14.66	2.34e-40	5.84e-37	-0.5	-0.56	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-14.66	2.34e-40	5.84e-37	-0.5	-0.56	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
THCA	cis	rs1431005	0.964	rs79181778	ENSG00000250620.1	RP11-91J3.3	14.66	2.44e-40	6.09e-37	0.71	0.56	Response to statin therapy;	chr4:187425756	chr4:187413564~187415697:+
THCA	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-14.66	2.51e-40	6.27e-37	-0.5	-0.56	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
THCA	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	14.65	2.55e-40	6.38e-37	0.78	0.56	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
THCA	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-14.65	2.59e-40	6.47e-37	-0.7	-0.56	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
THCA	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	14.65	2.62e-40	6.55e-37	0.64	0.56	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
THCA	cis	rs11098499	0.779	rs10857066	ENSG00000245958.5	RP11-33B1.1	-14.65	2.63e-40	6.56e-37	-0.53	-0.56	Corneal astigmatism;	chr4:119365441	chr4:119454791~119552025:+
THCA	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	14.65	2.65e-40	6.61e-37	0.74	0.56	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
THCA	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-14.65	2.67e-40	6.66e-37	-0.63	-0.56	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-14.65	2.67e-40	6.66e-37	-0.63	-0.56	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-14.65	2.67e-40	6.66e-37	-0.63	-0.56	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
THCA	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	14.65	2.73e-40	6.81e-37	0.99	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
THCA	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-14.65	2.75e-40	6.85e-37	-0.73	-0.56	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
THCA	cis	rs950027	0.787	rs2433616	ENSG00000259520.4	CTD-2651B20.3	-14.65	2.77e-40	6.91e-37	-0.67	-0.56	Response to fenofibrate (adiponectin levels);	chr15:45436401	chr15:45251580~45279251:-
THCA	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-14.65	2.77e-40	6.91e-37	-0.73	-0.56	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-14.65	2.81e-40	7.01e-37	-0.81	-0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
THCA	cis	rs6504950	0.76	rs7214573	ENSG00000275710.1	RP11-257O5.4	14.65	2.81e-40	7.01e-37	0.76	0.56	Breast cancer;	chr17:54929293	chr17:54964474~54964679:+
THCA	cis	rs10256972	0.758	rs4723649	ENSG00000229043.2	AC091729.9	-14.64	2.91e-40	7.24e-37	-0.59	-0.56	Endometriosis;Longevity;	chr7:1032269	chr7:1160374~1165267:+
THCA	cis	rs1431005	0.963	rs58289169	ENSG00000250620.1	RP11-91J3.3	14.64	2.91e-40	7.25e-37	0.7	0.56	Response to statin therapy;	chr4:187476388	chr4:187413564~187415697:+
THCA	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	14.64	2.97e-40	7.39e-37	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	14.64	2.97e-40	7.39e-37	0.98	0.56	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
THCA	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	14.64	3.02e-40	7.5e-37	0.88	0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
THCA	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-14.64	3.02e-40	7.51e-37	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
THCA	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-14.64	3.08e-40	7.65e-37	-0.98	-0.56	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
THCA	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	14.63	3.12e-40	7.77e-37	0.66	0.56	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
THCA	cis	rs992157	0.764	rs13020391	ENSG00000261338.2	RP11-378A13.1	-14.63	3.18e-40	7.9e-37	-0.6	-0.56	Colorectal cancer;	chr2:218319713	chr2:218255319~218257366:+
THCA	cis	rs732716	0.74	rs62129356	ENSG00000267769.1	CTB-50L17.9	-14.63	3.2e-40	7.95e-37	-0.73	-0.56	Mean corpuscular volume;	chr19:4400317	chr19:4454014~4455286:+
THCA	cis	rs6504950	0.83	rs17817877	ENSG00000275710.1	RP11-257O5.4	14.63	3.23e-40	8.03e-37	0.76	0.56	Breast cancer;	chr17:54957267	chr17:54964474~54964679:+
THCA	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	14.63	3.28e-40	8.15e-37	0.74	0.56	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
THCA	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	14.63	3.3e-40	8.2e-37	0.55	0.56	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
THCA	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	14.62	3.47e-40	8.62e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	14.62	3.47e-40	8.62e-37	0.65	0.56	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
THCA	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	14.62	3.55e-40	8.8e-37	0.97	0.56	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
THCA	cis	rs10740039	0.548	rs9415607	ENSG00000254271.1	RP11-131N11.4	-14.62	3.55e-40	8.81e-37	-0.71	-0.56	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737616	chr10:60734342~60741828:+
THCA	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	14.62	3.57e-40	8.85e-37	0.74	0.56	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
THCA	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-14.62	3.63e-40	9e-37	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
THCA	cis	rs12468226	1	rs16824599	ENSG00000273456.1	RP11-686O6.2	14.62	3.69e-40	9.14e-37	0.74	0.56	Urate levels;	chr2:202358243	chr2:202374932~202375604:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	14.62	3.7e-40	9.16e-37	0.72	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
THCA	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-14.62	3.75e-40	9.28e-37	-0.7	-0.56	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
THCA	cis	rs2283792	0.935	rs2283794	ENSG00000224086.5	LL22NC03-86G7.1	-14.61	3.87e-40	9.58e-37	-0.66	-0.56	Multiple sclerosis;	chr22:21858180	chr22:21938293~21977632:+
THCA	cis	rs9595066	0.941	rs9533777	ENSG00000227258.4	SMIM2-AS1	-14.61	3.91e-40	9.67e-37	-0.73	-0.56	Schizophrenia;	chr13:44134584	chr13:44110451~44240517:+
THCA	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-14.61	4.03e-40	9.97e-37	-0.82	-0.56	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
THCA	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	14.61	4.1e-40	1.01e-36	0.67	0.56	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
THCA	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-14.61	4.22e-40	1.04e-36	-0.64	-0.56	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-14.61	4.22e-40	1.04e-36	-0.64	-0.56	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-14.61	4.22e-40	1.04e-36	-0.64	-0.56	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
THCA	cis	rs2658782	1	rs2605583	ENSG00000279684.1	RP11-755E23.2	-14.6	4.23e-40	1.05e-36	-0.98	-0.56	Pulmonary function decline;	chr11:93431791	chr11:93286629~93288903:-
THCA	cis	rs6504950	0.83	rs12936860	ENSG00000275710.1	RP11-257O5.4	14.6	4.31e-40	1.06e-36	0.76	0.56	Breast cancer;	chr17:54952865	chr17:54964474~54964679:+
THCA	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-14.6	4.5e-40	1.11e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-14.6	4.5e-40	1.11e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
THCA	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	14.6	4.59e-40	1.13e-36	0.86	0.56	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
THCA	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	14.59	4.67e-40	1.15e-36	0.65	0.56	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
THCA	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	14.59	4.74e-40	1.17e-36	0.86	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
THCA	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	14.59	4.75e-40	1.17e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
THCA	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	14.59	4.81e-40	1.19e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
THCA	cis	rs732716	0.719	rs56088814	ENSG00000267769.1	CTB-50L17.9	-14.59	4.92e-40	1.21e-36	-0.71	-0.56	Mean corpuscular volume;	chr19:4422181	chr19:4454014~4455286:+
THCA	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	14.59	4.95e-40	1.22e-36	0.88	0.56	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
THCA	cis	rs9660180	0.819	rs4648629	ENSG00000231050.1	RP1-140A9.1	-14.59	4.98e-40	1.23e-36	-0.7	-0.56	Body mass index;	chr1:1764023	chr1:1891471~1892658:+
THCA	cis	rs9308062	1	rs9308062	ENSG00000273449.1	RP11-218F10.3	-14.59	5.09e-40	1.25e-36	-0.5	-0.56	Small cell lung carcinoma;	chr4:163517048	chr4:163529771~163530697:+
THCA	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	14.59	5.1e-40	1.26e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
THCA	cis	rs760794	0.577	rs7752808	ENSG00000228412.5	RP4-625H18.2	14.58	5.19e-40	1.28e-36	0.74	0.56	Endometriosis;	chr6:19792665	chr6:19802164~19804752:-
THCA	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	14.58	5.23e-40	1.29e-36	0.66	0.56	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
THCA	cis	rs732716	0.785	rs9973266	ENSG00000267769.1	CTB-50L17.9	-14.58	5.33e-40	1.31e-36	-0.74	-0.56	Mean corpuscular volume;	chr19:4392718	chr19:4454014~4455286:+
THCA	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	14.58	5.33e-40	1.31e-36	0.54	0.56	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
THCA	cis	rs5769707	0.837	rs5769709	ENSG00000188511.11	C22orf34	14.58	5.34e-40	1.31e-36	0.66	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49414524~49657542:-
THCA	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	14.58	5.38e-40	1.32e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	14.58	5.38e-40	1.32e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	14.58	5.38e-40	1.32e-36	0.64	0.56	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
THCA	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	14.58	5.38e-40	1.32e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
THCA	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-14.58	5.44e-40	1.34e-36	-0.8	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
THCA	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	14.58	5.47e-40	1.34e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	14.58	5.47e-40	1.34e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	14.58	5.47e-40	1.34e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	14.58	5.47e-40	1.34e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	14.58	5.47e-40	1.34e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	14.58	5.47e-40	1.34e-36	0.73	0.56	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	14.58	5.51e-40	1.35e-36	0.74	0.56	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
THCA	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	14.58	5.61e-40	1.38e-36	1.06	0.56	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
THCA	cis	rs6142102	0.602	rs11696338	ENSG00000276073.1	RP5-1125A11.7	-14.57	5.89e-40	1.45e-36	-0.5	-0.56	Skin pigmentation;	chr20:34099805	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.58	rs6142101	ENSG00000276073.1	RP5-1125A11.7	-14.57	5.89e-40	1.45e-36	-0.5	-0.56	Skin pigmentation;	chr20:34110039	chr20:33985617~33988989:-
THCA	cis	rs5769707	0.872	rs5770604	ENSG00000188511.11	C22orf34	14.57	5.95e-40	1.46e-36	0.65	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49414524~49657542:-
THCA	cis	rs11098499	0.866	rs6847778	ENSG00000245958.5	RP11-33B1.1	-14.57	6.01e-40	1.48e-36	-0.53	-0.56	Corneal astigmatism;	chr4:119372427	chr4:119454791~119552025:+
THCA	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	14.57	6.11e-40	1.5e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	14.57	6.11e-40	1.5e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	14.57	6.11e-40	1.5e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
THCA	cis	rs638893	0.636	rs61901410	ENSG00000278376.1	RP11-158I9.8	14.57	6.15e-40	1.51e-36	0.7	0.56	Vitiligo;	chr11:118790488	chr11:118791254~118793137:+
THCA	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-14.56	6.33e-40	1.55e-36	-0.99	-0.56	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-14.56	6.33e-40	1.55e-36	-0.99	-0.56	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
THCA	cis	rs2283792	1	rs6518986	ENSG00000224086.5	LL22NC03-86G7.1	-14.56	6.34e-40	1.55e-36	-0.65	-0.56	Multiple sclerosis;	chr22:21831058	chr22:21938293~21977632:+
THCA	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-14.56	6.38e-40	1.56e-36	-0.73	-0.56	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
THCA	cis	rs11098499	0.866	rs12501602	ENSG00000245958.5	RP11-33B1.1	-14.56	6.43e-40	1.57e-36	-0.53	-0.56	Corneal astigmatism;	chr4:119366780	chr4:119454791~119552025:+
THCA	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	14.56	6.51e-40	1.59e-36	0.82	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
THCA	cis	rs6504950	0.76	rs17745189	ENSG00000275710.1	RP11-257O5.4	14.56	6.55e-40	1.6e-36	0.76	0.56	Breast cancer;	chr17:54936619	chr17:54964474~54964679:+
THCA	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-14.56	6.59e-40	1.61e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-14.56	6.59e-40	1.61e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
THCA	cis	rs992157	0.764	rs2382827	ENSG00000261338.2	RP11-378A13.1	14.56	6.8e-40	1.66e-36	0.59	0.56	Colorectal cancer;	chr2:218319664	chr2:218255319~218257366:+
THCA	cis	rs992157	0.764	rs2891076	ENSG00000261338.2	RP11-378A13.1	14.56	6.8e-40	1.66e-36	0.59	0.56	Colorectal cancer;	chr2:218319675	chr2:218255319~218257366:+
THCA	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-14.56	6.81e-40	1.67e-36	-0.73	-0.56	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
THCA	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-14.56	6.93e-40	1.7e-36	-0.49	-0.56	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
THCA	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	14.56	6.96e-40	1.7e-36	0.65	0.56	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
THCA	cis	rs2283792	1	rs5749986	ENSG00000224086.5	LL22NC03-86G7.1	14.55	7.07e-40	1.73e-36	0.65	0.56	Multiple sclerosis;	chr22:21803372	chr22:21938293~21977632:+
THCA	cis	rs992157	0.764	rs2891077	ENSG00000261338.2	RP11-378A13.1	14.55	7.08e-40	1.73e-36	0.59	0.56	Colorectal cancer;	chr2:218319707	chr2:218255319~218257366:+
THCA	cis	rs992157	0.73	rs2891078	ENSG00000261338.2	RP11-378A13.1	14.55	7.08e-40	1.73e-36	0.59	0.56	Colorectal cancer;	chr2:218319709	chr2:218255319~218257366:+
THCA	cis	rs2283792	0.935	rs8141851	ENSG00000224086.5	LL22NC03-86G7.1	-14.55	7.1e-40	1.73e-36	-0.65	-0.56	Multiple sclerosis;	chr22:21812161	chr22:21938293~21977632:+
THCA	cis	rs2658782	0.951	rs117384439	ENSG00000279684.1	RP11-755E23.2	14.55	7.11e-40	1.74e-36	0.98	0.56	Pulmonary function decline;	chr11:93378312	chr11:93286629~93288903:-
THCA	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	14.55	7.3e-40	1.78e-36	0.71	0.56	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
THCA	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	14.55	7.34e-40	1.79e-36	0.72	0.56	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	14.55	7.36e-40	1.8e-36	0.72	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
THCA	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	14.55	7.39e-40	1.8e-36	1.07	0.56	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
THCA	cis	rs732716	0.785	rs56033249	ENSG00000267769.1	CTB-50L17.9	-14.55	7.51e-40	1.83e-36	-0.74	-0.56	Mean corpuscular volume;	chr19:4369450	chr19:4454014~4455286:+
THCA	cis	rs5769707	0.837	rs5770599	ENSG00000188511.11	C22orf34	14.55	7.54e-40	1.84e-36	0.66	0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49414524~49657542:-
THCA	cis	rs732716	0.785	rs11667543	ENSG00000267769.1	CTB-50L17.9	-14.55	7.6e-40	1.85e-36	-0.74	-0.56	Mean corpuscular volume;	chr19:4374853	chr19:4454014~4455286:+
THCA	cis	rs732716	0.785	rs34080966	ENSG00000267769.1	CTB-50L17.9	14.55	7.67e-40	1.87e-36	0.71	0.56	Mean corpuscular volume;	chr19:4417848	chr19:4454014~4455286:+
THCA	cis	rs9660180	0.819	rs4648629	ENSG00000268575.1	RP1-283E3.8	14.54	7.85e-40	1.92e-36	0.59	0.56	Body mass index;	chr1:1764023	chr1:1702736~1737688:-
THCA	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-14.54	8.22e-40	2e-36	-0.59	-0.56	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
THCA	cis	rs6142102	0.602	rs4911145	ENSG00000276073.1	RP5-1125A11.7	14.54	8.23e-40	2e-36	0.49	0.56	Skin pigmentation;	chr20:34027417	chr20:33985617~33988989:-
THCA	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-14.54	8.24e-40	2.01e-36	-0.7	-0.56	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
THCA	cis	rs6519955	0.866	rs9626920	ENSG00000231711.2	LINC00899	-14.54	8.3e-40	2.02e-36	-0.46	-0.56	Dupuytren's disease;	chr22:46033113	chr22:46039907~46044853:-
THCA	cis	rs2283792	1	rs5999750	ENSG00000224086.5	LL22NC03-86G7.1	-14.54	8.31e-40	2.02e-36	-0.65	-0.56	Multiple sclerosis;	chr22:21833720	chr22:21938293~21977632:+
THCA	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-14.53	8.85e-40	2.15e-36	-0.68	-0.56	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
THCA	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-14.53	9.17e-40	2.23e-36	-0.63	-0.56	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-14.53	9.17e-40	2.23e-36	-0.63	-0.56	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-14.53	9.17e-40	2.23e-36	-0.63	-0.56	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-14.53	9.17e-40	2.23e-36	-0.63	-0.56	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-14.53	9.17e-40	2.23e-36	-0.63	-0.56	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
THCA	cis	rs6504950	0.83	rs56175787	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54940386	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs17817847	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54940920	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs35097996	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54944562	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.79	rs8066833	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54948114	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.821	rs8066588	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54948328	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs3087650	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54951967	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.83	rs12937006	ENSG00000275710.1	RP11-257O5.4	14.53	9.36e-40	2.27e-36	0.75	0.56	Breast cancer;	chr17:54953100	chr17:54964474~54964679:+
THCA	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	14.52	9.47e-40	2.3e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
THCA	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-14.52	9.48e-40	2.3e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
THCA	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	14.52	9.53e-40	2.31e-36	0.64	0.56	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
THCA	cis	rs7188445	0.898	rs11644758	ENSG00000261390.4	RP11-345M22.2	-14.52	9.53e-40	2.31e-36	-0.67	-0.56	Urate levels;	chr16:79675094	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.866	rs11644799	ENSG00000261390.4	RP11-345M22.2	-14.52	9.53e-40	2.31e-36	-0.67	-0.56	Urate levels;	chr16:79675212	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.933	rs74637523	ENSG00000261390.4	RP11-345M22.2	-14.52	9.53e-40	2.31e-36	-0.67	-0.56	Urate levels;	chr16:79677400	chr16:79715232~79770563:-
THCA	cis	rs7188445	0.898	rs74037508	ENSG00000261390.4	RP11-345M22.2	-14.52	9.53e-40	2.31e-36	-0.67	-0.56	Urate levels;	chr16:79677439	chr16:79715232~79770563:-
THCA	cis	rs6504950	0.72	rs9914596	ENSG00000275710.1	RP11-257O5.4	14.52	9.54e-40	2.32e-36	0.72	0.56	Breast cancer;	chr17:54919190	chr17:54964474~54964679:+
THCA	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-14.52	9.72e-40	2.36e-36	-0.82	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-14.52	1.03e-39	2.49e-36	-0.79	-0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
THCA	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-14.52	1.04e-39	2.51e-36	-0.81	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
THCA	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-14.51	1.05e-39	2.53e-36	-0.98	-0.56	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
THCA	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	14.51	1.05e-39	2.55e-36	0.71	0.56	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
THCA	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	14.51	1.06e-39	2.57e-36	0.77	0.56	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
THCA	cis	rs2581828	0.931	rs2336722	ENSG00000242142.1	SERBP1P3	14.51	1.07e-39	2.59e-36	0.62	0.56	Crohn's disease;	chr3:53105961	chr3:53064283~53065091:-
THCA	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	14.51	1.09e-39	2.63e-36	0.68	0.56	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
THCA	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-14.51	1.13e-39	2.74e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
THCA	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-14.5	1.19e-39	2.88e-36	-0.7	-0.56	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
THCA	cis	rs2658782	1	rs2019814	ENSG00000279684.1	RP11-755E23.2	-14.5	1.2e-39	2.89e-36	-0.98	-0.56	Pulmonary function decline;	chr11:93435719	chr11:93286629~93288903:-
THCA	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	14.5	1.2e-39	2.9e-36	0.68	0.56	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
THCA	cis	rs638893	0.636	rs61901411	ENSG00000278376.1	RP11-158I9.8	14.5	1.21e-39	2.92e-36	0.7	0.56	Vitiligo;	chr11:118794615	chr11:118791254~118793137:+
THCA	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-14.5	1.21e-39	2.93e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
THCA	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	14.5	1.21e-39	2.93e-36	0.56	0.56	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
THCA	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-14.5	1.22e-39	2.93e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-14.5	1.22e-39	2.93e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
THCA	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-14.5	1.25e-39	3.02e-36	-0.89	-0.56	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
THCA	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	14.49	1.28e-39	3.09e-36	0.71	0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
THCA	cis	rs2658782	0.951	rs72972357	ENSG00000279684.1	RP11-755E23.2	14.49	1.3e-39	3.12e-36	0.98	0.56	Pulmonary function decline;	chr11:93385674	chr11:93286629~93288903:-
THCA	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-14.49	1.3e-39	3.13e-36	-0.7	-0.56	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-14.49	1.32e-39	3.18e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
THCA	cis	rs80028505	0.908	rs79062678	ENSG00000271304.1	DPRXP2	14.49	1.33e-39	3.2e-36	0.94	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36090426	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs7766032	ENSG00000271304.1	DPRXP2	14.49	1.33e-39	3.2e-36	0.94	0.56	Foot ulcer in diabetes and neuropathy;	chr6:36101212	chr6:35989515~35990436:-
THCA	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	14.49	1.36e-39	3.27e-36	0.87	0.56	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
THCA	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-14.49	1.36e-39	3.28e-36	-0.73	-0.56	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
THCA	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	14.49	1.36e-39	3.29e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	14.49	1.37e-39	3.31e-36	0.7	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
THCA	cis	rs11098499	0.722	rs1814814	ENSG00000245958.5	RP11-33B1.1	-14.49	1.41e-39	3.39e-36	-0.53	-0.56	Corneal astigmatism;	chr4:119336969	chr4:119454791~119552025:+
THCA	cis	rs6142102	0.602	rs4911402	ENSG00000276073.1	RP5-1125A11.7	-14.49	1.41e-39	3.4e-36	-0.5	-0.56	Skin pigmentation;	chr20:34079839	chr20:33985617~33988989:-
THCA	cis	rs9322193	0.543	rs9371533	ENSG00000223701.3	RAET1E-AS1	14.48	1.43e-39	3.43e-36	0.74	0.56	Lung cancer;	chr6:149889545	chr6:149884431~149919508:+
THCA	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	14.48	1.47e-39	3.54e-36	0.63	0.56	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
THCA	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	14.48	1.49e-39	3.59e-36	0.64	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
THCA	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-14.48	1.51e-39	3.62e-36	-0.65	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
THCA	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	14.48	1.56e-39	3.73e-36	0.67	0.56	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
THCA	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-14.47	1.58e-39	3.78e-36	-0.97	-0.56	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-14.47	1.58e-39	3.78e-36	-0.97	-0.56	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
THCA	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-14.47	1.58e-39	3.78e-36	-0.97	-0.56	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
THCA	cis	rs2658782	1	rs2658781	ENSG00000279684.1	RP11-755E23.2	14.47	1.58e-39	3.78e-36	0.97	0.56	Pulmonary function decline;	chr11:93433202	chr11:93286629~93288903:-
THCA	cis	rs2283792	1	rs1892846	ENSG00000224086.5	LL22NC03-86G7.1	-14.47	1.59e-39	3.8e-36	-0.65	-0.56	Multiple sclerosis;	chr22:21832190	chr22:21938293~21977632:+
THCA	cis	rs2283792	1	rs1892848	ENSG00000224086.5	LL22NC03-86G7.1	-14.47	1.59e-39	3.8e-36	-0.65	-0.56	Multiple sclerosis;	chr22:21832273	chr22:21938293~21977632:+
THCA	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	14.47	1.6e-39	3.84e-36	0.61	0.56	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
THCA	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-14.47	1.62e-39	3.89e-36	-0.97	-0.56	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
THCA	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-14.47	1.68e-39	4.03e-36	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
THCA	cis	rs6538678	0.857	rs4762626	ENSG00000258343.1	RP11-536G4.2	-14.46	1.74e-39	4.15e-36	-0.89	-0.56	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95795345~95858839:-
THCA	cis	rs6142102	0.581	rs4911148	ENSG00000276073.1	RP5-1125A11.7	-14.46	1.75e-39	4.19e-36	-0.5	-0.55	Skin pigmentation;	chr20:34080438	chr20:33985617~33988989:-
THCA	cis	rs6504950	0.745	rs35079296	ENSG00000275710.1	RP11-257O5.4	14.46	1.86e-39	4.45e-36	0.72	0.55	Breast cancer;	chr17:54916849	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.745	rs1962045	ENSG00000275710.1	RP11-257O5.4	14.46	1.86e-39	4.45e-36	0.72	0.55	Breast cancer;	chr17:54918789	chr17:54964474~54964679:+
THCA	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	14.45	1.92e-39	4.59e-36	0.83	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
THCA	cis	rs1431005	1	rs55849435	ENSG00000250620.1	RP11-91J3.3	14.45	1.98e-39	4.72e-36	0.7	0.55	Response to statin therapy;	chr4:187455185	chr4:187413564~187415697:+
THCA	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-14.45	2.01e-39	4.78e-36	-0.68	-0.55	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
THCA	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-14.45	2.03e-39	4.85e-36	-0.68	-0.55	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
THCA	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	14.45	2.04e-39	4.87e-36	0.72	0.55	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
THCA	cis	rs2980439	0.729	rs2955585	ENSG00000253893.2	FAM85B	-14.45	2.05e-39	4.88e-36	-0.68	-0.55	Neuroticism;	chr8:8235989	chr8:8167819~8226614:-
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	14.45	2.05e-39	4.89e-36	0.71	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
THCA	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-14.45	2.1e-39	5e-36	-0.67	-0.55	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
THCA	cis	rs11098499	0.82	rs2389885	ENSG00000245958.5	RP11-33B1.1	-14.44	2.17e-39	5.17e-36	-0.56	-0.55	Corneal astigmatism;	chr4:119612776	chr4:119454791~119552025:+
THCA	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	14.44	2.18e-39	5.18e-36	0.64	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
THCA	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-14.44	2.19e-39	5.19e-36	-0.7	-0.55	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
THCA	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	14.44	2.19e-39	5.19e-36	0.87	0.55	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
THCA	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	14.44	2.19e-39	5.19e-36	0.87	0.55	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
THCA	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	14.44	2.23e-39	5.27e-36	0.96	0.55	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
THCA	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-14.44	2.23e-39	5.28e-36	-0.68	-0.55	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-14.44	2.25e-39	5.31e-36	-0.68	-0.55	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-14.44	2.25e-39	5.31e-36	-0.68	-0.55	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	14.44	2.3e-39	5.42e-36	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
THCA	cis	rs80028505	0.908	rs16883860	ENSG00000271304.1	DPRXP2	-14.43	2.41e-39	5.69e-36	-0.92	-0.55	Foot ulcer in diabetes and neuropathy;	chr6:36034685	chr6:35989515~35990436:-
THCA	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	14.43	2.55e-39	6.02e-36	0.72	0.55	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
THCA	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	14.42	2.7e-39	6.36e-36	0.67	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
THCA	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	14.42	2.7e-39	6.36e-36	0.53	0.55	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
THCA	cis	rs6504950	0.83	rs8073158	ENSG00000275710.1	RP11-257O5.4	14.42	2.73e-39	6.43e-36	0.75	0.55	Breast cancer;	chr17:54951254	chr17:54964474~54964679:+
THCA	cis	rs3096299	0.685	rs4785568	ENSG00000274627.1	RP11-104N10.2	14.42	2.75e-39	6.47e-36	0.54	0.55	Multiple myeloma (IgH translocation);	chr16:89487299	chr16:89516797~89522217:+
THCA	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-14.42	2.76e-39	6.49e-36	-0.97	-0.55	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
THCA	cis	rs732716	0.785	rs7769	ENSG00000267769.1	CTB-50L17.9	-14.41	2.87e-39	6.75e-36	-0.74	-0.55	Mean corpuscular volume;	chr19:4360546	chr19:4454014~4455286:+
THCA	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	14.41	2.96e-39	6.97e-36	0.53	0.55	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
THCA	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-14.41	3.01e-39	7.08e-36	-0.7	-0.55	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
THCA	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-14.41	3.11e-39	7.31e-36	-0.68	-0.55	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
THCA	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-14.41	3.15e-39	7.4e-36	-0.57	-0.55	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
THCA	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	14.4	3.17e-39	7.45e-36	0.91	0.55	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
THCA	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-14.4	3.34e-39	7.85e-36	-0.96	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
THCA	cis	rs6142102	0.602	rs4911399	ENSG00000276073.1	RP5-1125A11.7	-14.4	3.37e-39	7.92e-36	-0.49	-0.55	Skin pigmentation;	chr20:34035612	chr20:33985617~33988989:-
THCA	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-14.39	3.5e-39	8.21e-36	-0.77	-0.55	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
THCA	cis	rs6142102	0.602	rs932388	ENSG00000276073.1	RP5-1125A11.7	-14.39	3.61e-39	8.46e-36	-0.49	-0.55	Skin pigmentation;	chr20:34069572	chr20:33985617~33988989:-
THCA	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-14.39	3.61e-39	8.46e-36	-0.67	-0.55	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
THCA	cis	rs80028505	0.614	rs3761980	ENSG00000271304.1	DPRXP2	-14.39	3.78e-39	8.86e-36	-0.92	-0.55	Foot ulcer in diabetes and neuropathy;	chr6:36026129	chr6:35989515~35990436:-
THCA	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	14.39	3.8e-39	8.88e-36	0.72	0.55	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	14.39	3.8e-39	8.88e-36	0.72	0.55	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	14.39	3.8e-39	8.88e-36	0.72	0.55	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	14.39	3.8e-39	8.88e-36	0.72	0.55	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
THCA	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-14.39	3.81e-39	8.91e-36	-0.67	-0.55	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
THCA	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	14.39	3.81e-39	8.91e-36	0.67	0.55	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
THCA	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	14.39	3.81e-39	8.91e-36	0.67	0.55	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
THCA	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	14.39	3.81e-39	8.91e-36	0.67	0.55	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
THCA	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-14.38	3.87e-39	9.04e-36	-0.7	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
THCA	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-14.38	3.87e-39	9.05e-36	-0.73	-0.55	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-14.38	3.87e-39	9.05e-36	-0.73	-0.55	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-14.38	3.87e-39	9.05e-36	-0.73	-0.55	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-14.38	3.87e-39	9.05e-36	-0.73	-0.55	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
THCA	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	14.38	3.98e-39	9.31e-36	0.96	0.55	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
THCA	cis	rs1155848	0.571	rs7983556	ENSG00000227354.5	RBM26-AS1	14.38	4.12e-39	9.63e-36	0.88	0.55	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79608777	chr13:79406309~79424328:+
THCA	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	14.38	4.13e-39	9.64e-36	0.54	0.55	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
THCA	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-14.37	4.27e-39	9.98e-36	-0.67	-0.55	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
THCA	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-14.37	4.35e-39	1.02e-35	-0.64	-0.55	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
THCA	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-14.37	4.36e-39	1.02e-35	-0.72	-0.55	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
THCA	cis	rs12134133	1	rs7526831	ENSG00000274245.1	RP11-357P18.2	14.37	4.38e-39	1.02e-35	0.59	0.55	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207372559~207373252:+
THCA	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-14.37	4.39e-39	1.03e-35	-0.68	-0.55	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
THCA	cis	rs9481169	0.85	rs60962769	ENSG00000255389.1	C6orf3	-14.37	4.51e-39	1.05e-35	-1	-0.55	Inflammatory skin disease;	chr6:111598221	chr6:111599875~111602295:+
THCA	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	14.37	4.54e-39	1.06e-35	0.53	0.55	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
THCA	cis	rs11098499	0.754	rs1814813	ENSG00000245958.5	RP11-33B1.1	14.37	4.54e-39	1.06e-35	0.52	0.55	Corneal astigmatism;	chr4:119337052	chr4:119454791~119552025:+
THCA	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-14.37	4.57e-39	1.07e-35	-0.67	-0.55	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
THCA	cis	rs2283792	1	rs2283792	ENSG00000224086.5	LL22NC03-86G7.1	-14.37	4.58e-39	1.07e-35	-0.65	-0.55	Multiple sclerosis;	chr22:21776836	chr22:21938293~21977632:+
THCA	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	14.37	4.58e-39	1.07e-35	0.67	0.55	Height;	chr11:118703185	chr11:118688039~118690600:-
THCA	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	14.37	4.58e-39	1.07e-35	0.67	0.55	Height;	chr11:118703207	chr11:118688039~118690600:-
THCA	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	14.37	4.6e-39	1.07e-35	0.45	0.55	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	14.37	4.6e-39	1.07e-35	0.45	0.55	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
THCA	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-14.37	4.61e-39	1.07e-35	-0.49	-0.55	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
THCA	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-14.37	4.64e-39	1.08e-35	-0.68	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
THCA	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	14.36	4.74e-39	1.1e-35	0.94	0.55	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
THCA	cis	rs992157	0.764	rs4672886	ENSG00000261338.2	RP11-378A13.1	-14.36	4.76e-39	1.11e-35	-0.58	-0.55	Colorectal cancer;	chr2:218320822	chr2:218255319~218257366:+
THCA	cis	rs12468226	1	rs76284304	ENSG00000273456.1	RP11-686O6.2	14.36	4.76e-39	1.11e-35	0.7	0.55	Urate levels;	chr2:202427116	chr2:202374932~202375604:-
THCA	cis	rs950027	0.787	rs1547487	ENSG00000259520.4	CTD-2651B20.3	-14.36	4.77e-39	1.11e-35	-0.67	-0.55	Response to fenofibrate (adiponectin levels);	chr15:45431785	chr15:45251580~45279251:-
THCA	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-14.36	4.84e-39	1.13e-35	-0.61	-0.55	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
THCA	cis	rs80028505	1	rs7770183	ENSG00000271304.1	DPRXP2	14.36	4.94e-39	1.15e-35	0.94	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36114796	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs56044978	ENSG00000271304.1	DPRXP2	14.36	4.94e-39	1.15e-35	0.94	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36115327	chr6:35989515~35990436:-
THCA	cis	rs638893	0.528	rs521910	ENSG00000278376.1	RP11-158I9.8	14.36	4.95e-39	1.15e-35	0.65	0.55	Vitiligo;	chr11:118739920	chr11:118791254~118793137:+
THCA	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	14.36	5.04e-39	1.17e-35	0.53	0.55	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
THCA	cis	rs80028505	0.908	rs16884628	ENSG00000271304.1	DPRXP2	14.36	5.12e-39	1.19e-35	0.92	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36090191	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs16884660	ENSG00000271304.1	DPRXP2	14.36	5.12e-39	1.19e-35	0.92	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36092434	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs7745082	ENSG00000271304.1	DPRXP2	14.36	5.12e-39	1.19e-35	0.92	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36097845	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs16884906	ENSG00000271304.1	DPRXP2	14.36	5.12e-39	1.19e-35	0.92	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36102922	chr6:35989515~35990436:-
THCA	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-14.35	5.35e-39	1.24e-35	-0.66	-0.55	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
THCA	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-14.35	5.38e-39	1.25e-35	-0.45	-0.55	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
THCA	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	14.35	5.38e-39	1.25e-35	0.7	0.55	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	14.35	5.42e-39	1.26e-35	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
THCA	cis	rs6504950	0.751	rs12937760	ENSG00000275710.1	RP11-257O5.4	14.35	5.52e-39	1.28e-35	0.75	0.55	Breast cancer;	chr17:54938769	chr17:54964474~54964679:+
THCA	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-14.35	5.52e-39	1.28e-35	-0.67	-0.55	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
THCA	cis	rs7208859	0.573	rs216443	ENSG00000263531.1	RP13-753N3.1	14.35	5.52e-39	1.28e-35	1.05	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30863921~30864940:-
THCA	cis	rs6504950	0.705	rs17745123	ENSG00000275710.1	RP11-257O5.4	14.35	5.58e-39	1.29e-35	0.73	0.55	Breast cancer;	chr17:54910871	chr17:54964474~54964679:+
THCA	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	14.35	5.58e-39	1.29e-35	0.65	0.55	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
THCA	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-14.34	5.83e-39	1.35e-35	-0.67	-0.55	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
THCA	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-14.34	5.89e-39	1.36e-35	-0.81	-0.55	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
THCA	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	14.34	5.9e-39	1.36e-35	0.65	0.55	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
THCA	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-14.34	6.17e-39	1.42e-35	-0.71	-0.55	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
THCA	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	14.33	6.43e-39	1.48e-35	0.64	0.55	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
THCA	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-14.33	6.49e-39	1.5e-35	-0.61	-0.55	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-14.33	6.49e-39	1.5e-35	-0.61	-0.55	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
THCA	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	14.33	6.51e-39	1.5e-35	1.04	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
THCA	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	14.33	6.62e-39	1.53e-35	1.04	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
THCA	cis	rs2283792	1	rs3810610	ENSG00000224086.5	LL22NC03-86G7.1	-14.33	6.71e-39	1.55e-35	-0.65	-0.55	Multiple sclerosis;	chr22:21761209	chr22:21938293~21977632:+
THCA	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-14.33	6.99e-39	1.61e-35	-0.54	-0.55	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
THCA	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-14.32	7.13e-39	1.64e-35	-0.61	-0.55	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-14.32	7.13e-39	1.64e-35	-0.61	-0.55	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
THCA	cis	rs11098499	0.821	rs56155624	ENSG00000245958.5	RP11-33B1.1	-14.32	7.17e-39	1.65e-35	-0.53	-0.55	Corneal astigmatism;	chr4:119369871	chr4:119454791~119552025:+
THCA	cis	rs12468226	1	rs16839149	ENSG00000273456.1	RP11-686O6.2	14.32	7.28e-39	1.68e-35	0.7	0.55	Urate levels;	chr2:202427621	chr2:202374932~202375604:-
THCA	cis	rs2980439	0.729	rs2955586	ENSG00000253893.2	FAM85B	-14.32	7.33e-39	1.69e-35	-0.68	-0.55	Neuroticism;	chr8:8236445	chr8:8167819~8226614:-
THCA	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	14.32	7.34e-39	1.69e-35	1.04	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
THCA	cis	rs1061377	0.861	rs35739603	ENSG00000249207.1	RP11-360F5.1	-14.31	7.82e-39	1.8e-35	-0.68	-0.55	Uric acid levels;	chr4:39107938	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-14.31	7.86e-39	1.81e-35	-0.67	-0.55	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
THCA	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	14.31	7.91e-39	1.82e-35	0.55	0.55	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
THCA	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	14.31	8e-39	1.84e-35	0.44	0.55	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
THCA	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	14.31	8.2e-39	1.88e-35	0.72	0.55	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
THCA	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	14.31	8.36e-39	1.92e-35	0.44	0.55	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	14.31	8.36e-39	1.92e-35	0.44	0.55	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
THCA	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	14.31	8.45e-39	1.94e-35	0.61	0.55	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
THCA	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-14.31	8.49e-39	1.95e-35	-0.82	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
THCA	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-14.3	8.88e-39	2.03e-35	-0.7	-0.55	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
THCA	cis	rs12468226	1	rs74766638	ENSG00000273456.1	RP11-686O6.2	14.3	8.98e-39	2.05e-35	0.7	0.55	Urate levels;	chr2:202445168	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs76528043	ENSG00000273456.1	RP11-686O6.2	14.3	8.98e-39	2.05e-35	0.7	0.55	Urate levels;	chr2:202466116	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs12468226	ENSG00000273456.1	RP11-686O6.2	14.3	8.98e-39	2.05e-35	0.7	0.55	Urate levels;	chr2:202472278	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs74508472	ENSG00000273456.1	RP11-686O6.2	14.3	8.98e-39	2.05e-35	0.7	0.55	Urate levels;	chr2:202517290	chr2:202374932~202375604:-
THCA	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	14.3	9.17e-39	2.1e-35	0.9	0.55	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
THCA	cis	rs12468226	0.746	rs75987655	ENSG00000273456.1	RP11-686O6.2	14.3	9.18e-39	2.1e-35	0.74	0.55	Urate levels;	chr2:202581913	chr2:202374932~202375604:-
THCA	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	14.3	9.46e-39	2.16e-35	0.71	0.55	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
THCA	cis	rs2283792	0.871	rs8136867	ENSG00000224086.5	LL22NC03-86G7.1	-14.3	9.47e-39	2.16e-35	-0.65	-0.55	Multiple sclerosis;	chr22:21850504	chr22:21938293~21977632:+
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	14.29	9.58e-39	2.19e-35	0.66	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
THCA	cis	rs1431005	0.963	rs72725287	ENSG00000250620.1	RP11-91J3.3	14.29	9.8e-39	2.24e-35	0.67	0.55	Response to statin therapy;	chr4:187477151	chr4:187413564~187415697:+
THCA	cis	rs11098499	0.78	rs7692994	ENSG00000245958.5	RP11-33B1.1	-14.29	9.84e-39	2.25e-35	-0.52	-0.55	Corneal astigmatism;	chr4:119506334	chr4:119454791~119552025:+
THCA	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-14.29	9.88e-39	2.25e-35	-0.61	-0.55	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
THCA	cis	rs80028505	0.908	rs73729698	ENSG00000271304.1	DPRXP2	14.29	1e-38	2.28e-35	0.97	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36054864	chr6:35989515~35990436:-
THCA	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-14.29	1.01e-38	2.31e-35	-0.7	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
THCA	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-14.28	1.06e-38	2.42e-35	-0.67	-0.55	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
THCA	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	14.28	1.07e-38	2.45e-35	0.72	0.55	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	14.28	1.08e-38	2.47e-35	0.7	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
THCA	cis	rs12468226	1	rs116635509	ENSG00000273456.1	RP11-686O6.2	14.28	1.11e-38	2.54e-35	0.7	0.55	Urate levels;	chr2:202460027	chr2:202374932~202375604:-
THCA	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	14.28	1.12e-38	2.55e-35	0.6	0.55	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
THCA	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	14.28	1.14e-38	2.6e-35	0.63	0.55	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
THCA	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-14.28	1.15e-38	2.61e-35	-0.67	-0.55	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
THCA	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-14.27	1.17e-38	2.65e-35	-0.49	-0.55	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
THCA	cis	rs80028505	0.908	rs58583792	ENSG00000271304.1	DPRXP2	14.27	1.21e-38	2.76e-35	0.9	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36032925	chr6:35989515~35990436:-
THCA	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-14.27	1.22e-38	2.78e-35	-0.7	-0.55	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
THCA	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	14.27	1.23e-38	2.79e-35	0.64	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	14.27	1.23e-38	2.79e-35	0.64	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	14.27	1.23e-38	2.79e-35	0.64	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
THCA	cis	rs7743045	0.504	rs4946385	ENSG00000253194.1	RP11-351A11.1	14.26	1.31e-38	2.96e-35	0.76	0.55	Mean platelet volume;	chr6:118985247	chr6:118934785~119031541:+
THCA	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	14.26	1.32e-38	3e-35	0.45	0.55	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
THCA	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	14.26	1.35e-38	3.06e-35	0.77	0.55	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
THCA	cis	rs67311347	0.955	rs6773383	ENSG00000223797.4	ENTPD3-AS1	14.26	1.41e-38	3.19e-35	0.44	0.55	Renal cell carcinoma;	chr3:40335921	chr3:40313802~40453329:-
THCA	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-14.26	1.42e-38	3.21e-35	-0.58	-0.55	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
THCA	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	14.25	1.44e-38	3.25e-35	0.67	0.55	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-14.25	1.45e-38	3.28e-35	-0.69	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
THCA	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	14.25	1.45e-38	3.29e-35	0.64	0.55	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
THCA	cis	rs80028505	0.908	rs16883819	ENSG00000271304.1	DPRXP2	14.25	1.45e-38	3.29e-35	0.89	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36029991	chr6:35989515~35990436:-
THCA	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	14.25	1.5e-38	3.4e-35	0.44	0.55	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
THCA	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-14.25	1.51e-38	3.42e-35	-0.92	-0.55	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
THCA	cis	rs7208859	0.673	rs1347360	ENSG00000263531.1	RP13-753N3.1	14.25	1.51e-38	3.42e-35	0.96	0.55	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30863921~30864940:-
THCA	cis	rs6504950	0.615	rs66898273	ENSG00000275710.1	RP11-257O5.4	14.25	1.52e-38	3.44e-35	0.71	0.55	Breast cancer;	chr17:54916595	chr17:54964474~54964679:+
THCA	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	14.25	1.56e-38	3.52e-35	0.53	0.55	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
THCA	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	14.25	1.56e-38	3.53e-35	0.64	0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
THCA	cis	rs732716	0.785	rs11666453	ENSG00000267769.1	CTB-50L17.9	-14.25	1.56e-38	3.53e-35	-0.73	-0.55	Mean corpuscular volume;	chr19:4368800	chr19:4454014~4455286:+
THCA	cis	rs524281	0.861	rs10791855	ENSG00000255320.1	RP11-755F10.1	14.24	1.62e-38	3.66e-35	0.79	0.55	Electroencephalogram traits;	chr11:66196266	chr11:66244840~66246239:-
THCA	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	14.24	1.66e-38	3.74e-35	0.73	0.55	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
THCA	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-14.24	1.72e-38	3.87e-35	-0.44	-0.55	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
THCA	cis	rs7743045	0.504	rs10499090	ENSG00000253194.1	RP11-351A11.1	14.23	1.75e-38	3.93e-35	0.75	0.55	Mean platelet volume;	chr6:119000386	chr6:118934785~119031541:+
THCA	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-14.23	1.75e-38	3.95e-35	-0.7	-0.55	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
THCA	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	14.23	1.88e-38	4.24e-35	0.53	0.55	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
THCA	cis	rs80028505	0.908	rs16884919	ENSG00000271304.1	DPRXP2	-14.23	1.89e-38	4.26e-35	-0.92	-0.55	Foot ulcer in diabetes and neuropathy;	chr6:36103740	chr6:35989515~35990436:-
THCA	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-14.23	1.9e-38	4.28e-35	-0.6	-0.55	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-14.23	1.9e-38	4.28e-35	-0.6	-0.55	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
THCA	cis	rs2658782	0.951	rs2608215	ENSG00000279684.1	RP11-755E23.2	-14.22	1.94e-38	4.36e-35	-0.96	-0.55	Pulmonary function decline;	chr11:93415651	chr11:93286629~93288903:-
THCA	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	14.22	1.96e-38	4.42e-35	0.62	0.55	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
THCA	cis	rs80028505	0.908	rs3804451	ENSG00000271304.1	DPRXP2	14.22	1.99e-38	4.48e-35	0.92	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36110184	chr6:35989515~35990436:-
THCA	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	14.22	2.05e-38	4.61e-35	0.52	0.55	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
THCA	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-14.22	2.08e-38	4.67e-35	-0.43	-0.55	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
THCA	cis	rs12468226	1	rs7587234	ENSG00000273456.1	RP11-686O6.2	14.22	2.11e-38	4.75e-35	0.72	0.55	Urate levels;	chr2:202351699	chr2:202374932~202375604:-
THCA	cis	rs12220777	1	rs11201298	ENSG00000230091.5	TMEM254-AS1	14.21	2.15e-38	4.82e-35	1.02	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033995	chr10:80046860~80078912:-
THCA	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	14.21	2.15e-38	4.83e-35	0.63	0.55	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
THCA	cis	rs2283792	1	rs13943	ENSG00000224086.5	LL22NC03-86G7.1	-14.2	2.35e-38	5.26e-35	-0.65	-0.55	Multiple sclerosis;	chr22:21761913	chr22:21938293~21977632:+
THCA	cis	rs12468226	0.935	rs75597391	ENSG00000273456.1	RP11-686O6.2	14.2	2.4e-38	5.38e-35	0.7	0.55	Urate levels;	chr2:202398850	chr2:202374932~202375604:-
THCA	cis	rs2980439	0.558	rs2955584	ENSG00000253893.2	FAM85B	-14.2	2.42e-38	5.42e-35	-0.68	-0.55	Neuroticism;	chr8:8234652	chr8:8167819~8226614:-
THCA	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	14.2	2.48e-38	5.54e-35	0.6	0.55	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
THCA	cis	rs7743045	0.504	rs4946382	ENSG00000253194.1	RP11-351A11.1	14.2	2.49e-38	5.56e-35	0.75	0.55	Mean platelet volume;	chr6:118979312	chr6:118934785~119031541:+
THCA	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	14.2	2.5e-38	5.59e-35	0.64	0.55	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
THCA	cis	rs1062177	1	rs2016409	ENSG00000213433.5	RPLP1P6	14.2	2.52e-38	5.64e-35	0.58	0.55	Preschool internalizing problems;	chr5:151746763	chr5:151765859~151766378:-
THCA	cis	rs2658782	0.789	rs1456238	ENSG00000279684.1	RP11-755E23.2	-14.19	2.81e-38	6.26e-35	-0.95	-0.55	Pulmonary function decline;	chr11:93384204	chr11:93286629~93288903:-
THCA	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-14.19	2.81e-38	6.27e-35	-0.6	-0.55	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
THCA	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-14.19	2.82e-38	6.3e-35	-0.7	-0.55	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
THCA	cis	rs12468226	1	rs115170232	ENSG00000273456.1	RP11-686O6.2	14.19	2.83e-38	6.3e-35	0.7	0.55	Urate levels;	chr2:202416790	chr2:202374932~202375604:-
THCA	cis	rs80028505	0.908	rs6457878	ENSG00000271304.1	DPRXP2	14.19	2.84e-38	6.32e-35	0.92	0.55	Foot ulcer in diabetes and neuropathy;	chr6:36108503	chr6:35989515~35990436:-
THCA	cis	rs7174755	0.772	rs8025474	ENSG00000260657.2	RP11-315D16.4	14.18	2.96e-38	6.59e-35	0.76	0.55	Major depressive disorder;	chr15:68094185	chr15:68267792~68277994:-
THCA	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	14.18	2.97e-38	6.62e-35	0.73	0.55	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
THCA	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	14.18	2.97e-38	6.62e-35	0.73	0.55	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
THCA	cis	rs10256972	0.721	rs10435145	ENSG00000229043.2	AC091729.9	-14.18	3.06e-38	6.8e-35	-0.58	-0.55	Endometriosis;Longevity;	chr7:1026352	chr7:1160374~1165267:+
THCA	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	14.17	3.16e-38	7.03e-35	0.44	0.55	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
THCA	cis	rs12468226	1	rs75040639	ENSG00000273456.1	RP11-686O6.2	14.17	3.23e-38	7.18e-35	0.7	0.55	Urate levels;	chr2:202486973	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.872	rs115187557	ENSG00000273456.1	RP11-686O6.2	14.17	3.23e-38	7.18e-35	0.7	0.55	Urate levels;	chr2:202495351	chr2:202374932~202375604:-
THCA	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-14.17	3.35e-38	7.44e-35	-0.58	-0.55	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
THCA	cis	rs1153858	0.945	rs16943246	ENSG00000259520.4	CTD-2651B20.3	-14.17	3.41e-38	7.56e-35	-0.71	-0.55	Homoarginine levels;	chr15:45428399	chr15:45251580~45279251:-
THCA	cis	rs2980439	0.783	rs2948305	ENSG00000253893.2	FAM85B	-14.16	3.53e-38	7.83e-35	-0.69	-0.55	Neuroticism;	chr8:8241055	chr8:8167819~8226614:-
THCA	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-14.16	3.58e-38	7.95e-35	-0.58	-0.55	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
THCA	cis	rs2658782	0.756	rs3019205	ENSG00000279684.1	RP11-755E23.2	-14.16	3.59e-38	7.96e-35	-0.93	-0.55	Pulmonary function decline;	chr11:93376387	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.789	rs2658775	ENSG00000279684.1	RP11-755E23.2	-14.16	3.71e-38	8.23e-35	-0.93	-0.55	Pulmonary function decline;	chr11:93393633	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.789	rs2658773	ENSG00000279684.1	RP11-755E23.2	-14.16	3.71e-38	8.23e-35	-0.93	-0.55	Pulmonary function decline;	chr11:93393748	chr11:93286629~93288903:-
THCA	cis	rs8037818	1	rs11071856	ENSG00000276724.1	RP11-1000B6.7	-14.16	3.76e-38	8.32e-35	-0.78	-0.55	Obesity-related traits;	chr15:32633591	chr15:32583612~32584312:+
THCA	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-14.16	3.79e-38	8.4e-35	-0.64	-0.55	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
THCA	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-14.16	3.81e-38	8.43e-35	-0.69	-0.55	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
THCA	cis	rs6860806	0.507	rs272872	ENSG00000233006.5	AC034220.3	-14.16	3.84e-38	8.51e-35	-0.45	-0.55	Breast cancer;	chr5:132340171	chr5:132311285~132369916:-
THCA	cis	rs2658782	0.906	rs2658791	ENSG00000279684.1	RP11-755E23.2	-14.15	3.85e-38	8.53e-35	-0.95	-0.55	Pulmonary function decline;	chr11:93465817	chr11:93286629~93288903:-
THCA	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	14.15	3.86e-38	8.54e-35	0.6	0.55	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
THCA	cis	rs11098499	0.866	rs11098506	ENSG00000245958.5	RP11-33B1.1	-14.15	3.88e-38	8.58e-35	-0.52	-0.55	Corneal astigmatism;	chr4:119363816	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	14.15	3.92e-38	8.68e-35	0.69	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
THCA	cis	rs12220777	1	rs72644212	ENSG00000230091.5	TMEM254-AS1	14.15	4.03e-38	8.91e-35	1.04	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80022758	chr10:80046860~80078912:-
THCA	cis	rs12468226	1	rs79919139	ENSG00000273456.1	RP11-686O6.2	14.15	4.17e-38	9.21e-35	0.7	0.55	Urate levels;	chr2:202382786	chr2:202374932~202375604:-
THCA	cis	rs12134133	1	rs6673333	ENSG00000274245.1	RP11-357P18.2	14.15	4.22e-38	9.33e-35	0.58	0.55	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285802	chr1:207372559~207373252:+
THCA	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-14.14	4.28e-38	9.46e-35	-0.71	-0.55	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
THCA	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	14.14	4.32e-38	9.54e-35	0.6	0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
THCA	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-14.14	4.6e-38	1.01e-34	-0.69	-0.55	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
THCA	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-14.14	4.66e-38	1.03e-34	-0.58	-0.55	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
THCA	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-14.13	4.78e-38	1.05e-34	-0.72	-0.55	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
THCA	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	14.13	4.79e-38	1.06e-34	0.54	0.55	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
THCA	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-14.13	4.85e-38	1.07e-34	-0.67	-0.55	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
THCA	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	14.13	5.01e-38	1.1e-34	0.61	0.55	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
THCA	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-14.13	5.03e-38	1.11e-34	-0.6	-0.55	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
THCA	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	14.13	5.04e-38	1.11e-34	0.52	0.55	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
THCA	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	14.13	5.05e-38	1.11e-34	0.73	0.55	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
THCA	cis	rs2658782	0.789	rs3020057	ENSG00000279684.1	RP11-755E23.2	-14.13	5.19e-38	1.14e-34	-0.93	-0.55	Pulmonary function decline;	chr11:93385349	chr11:93286629~93288903:-
THCA	cis	rs7772486	0.754	rs13214277	ENSG00000235652.6	RP11-545I5.3	14.12	5.27e-38	1.16e-34	0.51	0.55	Lobe attachment (rater-scored or self-reported);	chr6:145814989	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs9386132	ENSG00000235652.6	RP11-545I5.3	14.12	5.27e-38	1.16e-34	0.51	0.55	Lobe attachment (rater-scored or self-reported);	chr6:145819615	chr6:145799409~145886585:+
THCA	cis	rs5769707	0.935	rs1109320	ENSG00000188511.11	C22orf34	14.12	5.45e-38	1.2e-34	0.65	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49414524~49657542:-
THCA	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-14.12	5.47e-38	1.2e-34	-0.67	-0.55	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
THCA	cis	rs5769707	0.967	rs17182154	ENSG00000188511.11	C22orf34	14.12	5.48e-38	1.2e-34	0.65	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49414524~49657542:-
THCA	cis	rs9481169	0.85	rs13210247	ENSG00000255389.1	C6orf3	-14.12	5.57e-38	1.22e-34	-0.9	-0.55	Inflammatory skin disease;	chr6:111601517	chr6:111599875~111602295:+
THCA	cis	rs12220777	1	rs11201297	ENSG00000230091.5	TMEM254-AS1	14.11	5.76e-38	1.26e-34	1.01	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033993	chr10:80046860~80078912:-
THCA	cis	rs6504950	0.745	rs9915913	ENSG00000275710.1	RP11-257O5.4	14.11	5.76e-38	1.26e-34	0.7	0.55	Breast cancer;	chr17:54920807	chr17:54964474~54964679:+
THCA	cis	rs12468226	1	rs76021735	ENSG00000273456.1	RP11-686O6.2	14.11	5.84e-38	1.28e-34	0.7	0.55	Urate levels;	chr2:202511476	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs57080353	ENSG00000273456.1	RP11-686O6.2	14.11	5.84e-38	1.28e-34	0.7	0.55	Urate levels;	chr2:202511824	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.81	rs3736578	ENSG00000273456.1	RP11-686O6.2	14.11	5.84e-38	1.28e-34	0.7	0.55	Urate levels;	chr2:202519989	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs116439150	ENSG00000273456.1	RP11-686O6.2	14.11	5.84e-38	1.28e-34	0.7	0.55	Urate levels;	chr2:202523814	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs12467409	ENSG00000273456.1	RP11-686O6.2	14.11	5.84e-38	1.28e-34	0.7	0.55	Urate levels;	chr2:202529625	chr2:202374932~202375604:-
THCA	cis	rs2980439	0.818	rs2948300	ENSG00000253893.2	FAM85B	-14.11	5.9e-38	1.29e-34	-0.7	-0.55	Neuroticism;	chr8:8248986	chr8:8167819~8226614:-
THCA	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-14.11	5.93e-38	1.3e-34	-0.67	-0.55	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
THCA	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-14.11	6.03e-38	1.32e-34	-0.69	-0.55	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
THCA	cis	rs5769707	0.839	rs73176988	ENSG00000188511.11	C22orf34	14.11	6.09e-38	1.34e-34	0.65	0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49414524~49657542:-
THCA	cis	rs7772486	0.754	rs12199362	ENSG00000235652.6	RP11-545I5.3	14.11	6.12e-38	1.34e-34	0.51	0.55	Lobe attachment (rater-scored or self-reported);	chr6:145797089	chr6:145799409~145886585:+
THCA	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	14.11	6.24e-38	1.37e-34	0.44	0.55	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
THCA	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-14.11	6.33e-38	1.39e-34	-0.71	-0.55	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
THCA	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-14.1	6.38e-38	1.4e-34	-0.7	-0.55	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
THCA	cis	rs2658782	0.666	rs2925361	ENSG00000279684.1	RP11-755E23.2	-14.1	6.54e-38	1.43e-34	-0.93	-0.55	Pulmonary function decline;	chr11:93365657	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.789	rs3020073	ENSG00000279684.1	RP11-755E23.2	-14.1	6.54e-38	1.43e-34	-0.93	-0.55	Pulmonary function decline;	chr11:93370664	chr11:93286629~93288903:-
THCA	cis	rs524281	0.861	rs10896094	ENSG00000255320.1	RP11-755F10.1	14.1	6.99e-38	1.53e-34	0.78	0.55	Electroencephalogram traits;	chr11:66191735	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs2293121	ENSG00000255320.1	RP11-755F10.1	14.1	6.99e-38	1.53e-34	0.78	0.55	Electroencephalogram traits;	chr11:66193876	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs10791854	ENSG00000255320.1	RP11-755F10.1	14.1	6.99e-38	1.53e-34	0.78	0.55	Electroencephalogram traits;	chr11:66196072	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs2177053	ENSG00000255320.1	RP11-755F10.1	14.1	6.99e-38	1.53e-34	0.78	0.55	Electroencephalogram traits;	chr11:66198674	chr11:66244840~66246239:-
THCA	cis	rs524281	0.814	rs10896098	ENSG00000255320.1	RP11-755F10.1	14.1	6.99e-38	1.53e-34	0.78	0.55	Electroencephalogram traits;	chr11:66200945	chr11:66244840~66246239:-
THCA	cis	rs1062177	1	rs2915882	ENSG00000213433.5	RPLP1P6	-14.09	7.21e-38	1.58e-34	-0.58	-0.54	Preschool internalizing problems;	chr5:151765875	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs2915880	ENSG00000213433.5	RPLP1P6	-14.09	7.21e-38	1.58e-34	-0.58	-0.54	Preschool internalizing problems;	chr5:151767773	chr5:151765859~151766378:-
THCA	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-14.09	7.48e-38	1.63e-34	-0.7	-0.54	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
THCA	cis	rs7772486	0.754	rs9386134	ENSG00000235652.6	RP11-545I5.3	14.09	7.52e-38	1.64e-34	0.51	0.54	Lobe attachment (rater-scored or self-reported);	chr6:145824372	chr6:145799409~145886585:+
THCA	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-14.09	7.61e-38	1.66e-34	-0.71	-0.54	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-14.09	7.61e-38	1.66e-34	-0.71	-0.54	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-14.09	7.61e-38	1.66e-34	-0.71	-0.54	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-14.08	7.75e-38	1.69e-34	-0.71	-0.54	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
THCA	cis	rs2283792	0.967	rs3810609	ENSG00000224086.5	LL22NC03-86G7.1	-14.08	7.75e-38	1.69e-34	-0.64	-0.54	Multiple sclerosis;	chr22:21758513	chr22:21938293~21977632:+
THCA	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-14.08	7.81e-38	1.7e-34	-0.69	-0.54	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	14.08	8e-38	1.74e-34	0.59	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
THCA	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	14.08	8.21e-38	1.78e-34	0.44	0.54	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	14.08	8.24e-38	1.79e-34	0.44	0.54	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
THCA	cis	rs9890032	0.57	rs8068504	ENSG00000266490.1	CTD-2349P21.9	14.08	8.52e-38	1.85e-34	0.54	0.54	Hip circumference adjusted for BMI;	chr17:30785052	chr17:30792372~30792833:+
THCA	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	14.07	8.79e-38	1.91e-34	0.82	0.54	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
THCA	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-14.07	8.82e-38	1.91e-34	-0.66	-0.54	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-14.07	8.82e-38	1.91e-34	-0.66	-0.54	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
THCA	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	14.07	9.04e-38	1.96e-34	0.73	0.54	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
THCA	cis	rs10740039	0.583	rs9415608	ENSG00000254271.1	RP11-131N11.4	-14.07	9.15e-38	1.99e-34	-0.69	-0.54	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737680	chr10:60734342~60741828:+
THCA	cis	rs12468226	1	rs12472408	ENSG00000273456.1	RP11-686O6.2	14.07	9.25e-38	2.01e-34	0.7	0.54	Urate levels;	chr2:202413973	chr2:202374932~202375604:-
THCA	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	14.06	9.56e-38	2.07e-34	0.64	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	14.06	9.56e-38	2.07e-34	0.64	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
THCA	cis	rs1431005	0.858	rs77580406	ENSG00000250620.1	RP11-91J3.3	14.06	9.83e-38	2.13e-34	0.69	0.54	Response to statin therapy;	chr4:187493654	chr4:187413564~187415697:+
THCA	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-14.06	1.01e-37	2.18e-34	-0.48	-0.54	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
THCA	cis	rs7208859	0.623	rs426434	ENSG00000263531.1	RP13-753N3.1	14.06	1.01e-37	2.18e-34	0.95	0.54	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30863921~30864940:-
THCA	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-14.06	1.01e-37	2.2e-34	-0.66	-0.54	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
THCA	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	14.06	1.02e-37	2.21e-34	0.61	0.54	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	14.06	1.02e-37	2.21e-34	0.61	0.54	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	14.06	1.02e-37	2.21e-34	0.61	0.54	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	14.06	1.02e-37	2.21e-34	0.61	0.54	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	14.06	1.02e-37	2.21e-34	0.61	0.54	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
THCA	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-14.06	1.03e-37	2.22e-34	-0.71	-0.54	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
THCA	cis	rs1062177	1	rs17741826	ENSG00000213433.5	RPLP1P6	14.06	1.03e-37	2.23e-34	0.57	0.54	Preschool internalizing problems;	chr5:151769701	chr5:151765859~151766378:-
THCA	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	14.05	1.05e-37	2.28e-34	0.61	0.54	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
THCA	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-14.05	1.06e-37	2.29e-34	-0.6	-0.54	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
THCA	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-14.05	1.07e-37	2.31e-34	-0.66	-0.54	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-14.05	1.07e-37	2.31e-34	-0.66	-0.54	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-14.05	1.07e-37	2.31e-34	-0.66	-0.54	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
THCA	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-14.05	1.07e-37	2.31e-34	-0.69	-0.54	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-14.05	1.07e-37	2.31e-34	-0.69	-0.54	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
THCA	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-14.05	1.07e-37	2.31e-34	-0.69	-0.54	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
THCA	cis	rs12468226	0.873	rs12470401	ENSG00000273456.1	RP11-686O6.2	14.05	1.08e-37	2.33e-34	0.7	0.54	Urate levels;	chr2:202236436	chr2:202374932~202375604:-
THCA	cis	rs524281	0.861	rs7946917	ENSG00000255320.1	RP11-755F10.1	14.05	1.09e-37	2.34e-34	0.78	0.54	Electroencephalogram traits;	chr11:66189106	chr11:66244840~66246239:-
THCA	cis	rs12468226	0.81	rs77090459	ENSG00000273456.1	RP11-686O6.2	14.05	1.09e-37	2.35e-34	0.69	0.54	Urate levels;	chr2:202542132	chr2:202374932~202375604:-
THCA	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-14.05	1.12e-37	2.41e-34	-0.66	-0.54	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
THCA	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	14.05	1.13e-37	2.43e-34	0.81	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
THCA	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-14.05	1.13e-37	2.44e-34	-0.66	-0.54	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-14.05	1.13e-37	2.44e-34	-0.66	-0.54	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
THCA	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-14.05	1.13e-37	2.44e-34	-0.66	-0.54	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
THCA	cis	rs11155671	0.53	rs6557133	ENSG00000223701.3	RAET1E-AS1	14.04	1.18e-37	2.55e-34	0.73	0.54	Testicular germ cell tumor;	chr6:149874248	chr6:149884431~149919508:+
THCA	cis	rs1062177	1	rs2915878	ENSG00000213433.5	RPLP1P6	-14.04	1.19e-37	2.56e-34	-0.57	-0.54	Preschool internalizing problems;	chr5:151770101	chr5:151765859~151766378:-
THCA	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-14.04	1.21e-37	2.61e-34	-0.74	-0.54	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
THCA	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-14.02	1.42e-37	3.05e-34	-0.64	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
THCA	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	14.02	1.43e-37	3.07e-34	0.44	0.54	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	14.02	1.43e-37	3.08e-34	0.44	0.54	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
THCA	cis	rs11098499	0.73	rs78971550	ENSG00000245958.5	RP11-33B1.1	-14.02	1.44e-37	3.1e-34	-0.52	-0.54	Corneal astigmatism;	chr4:119359886	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.645	rs78422072	ENSG00000245958.5	RP11-33B1.1	-14.02	1.44e-37	3.1e-34	-0.52	-0.54	Corneal astigmatism;	chr4:119359887	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-14.02	1.53e-37	3.28e-34	-0.69	-0.54	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
THCA	cis	rs6538678	0.824	rs1436120	ENSG00000258343.1	RP11-536G4.2	14.01	1.57e-37	3.36e-34	0.86	0.54	Lupus nephritis in systemic lupus erythematosus;	chr12:95826872	chr12:95795345~95858839:-
THCA	cis	rs9890032	0.618	rs1979507	ENSG00000266490.1	CTD-2349P21.9	14.01	1.59e-37	3.4e-34	0.54	0.54	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30792372~30792833:+
THCA	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-14.01	1.61e-37	3.45e-34	-0.57	-0.54	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
THCA	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	14.01	1.63e-37	3.49e-34	0.83	0.54	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
THCA	cis	rs12468226	1	rs16839077	ENSG00000273456.1	RP11-686O6.2	14.01	1.66e-37	3.54e-34	0.7	0.54	Urate levels;	chr2:202343970	chr2:202374932~202375604:-
THCA	cis	rs10256972	0.616	rs6957733	ENSG00000229043.2	AC091729.9	-14	1.82e-37	3.89e-34	-0.57	-0.54	Endometriosis;Longevity;	chr7:1066691	chr7:1160374~1165267:+
THCA	cis	rs1062177	1	rs2964584	ENSG00000213433.5	RPLP1P6	-14	1.89e-37	4.04e-34	-0.57	-0.54	Preschool internalizing problems;	chr5:151763317	chr5:151765859~151766378:-
THCA	cis	rs638893	0.578	rs500254	ENSG00000278376.1	RP11-158I9.8	13.99	1.92e-37	4.1e-34	0.62	0.54	Vitiligo;	chr11:118808071	chr11:118791254~118793137:+
THCA	cis	rs1062177	1	rs2964585	ENSG00000213433.5	RPLP1P6	-13.99	1.93e-37	4.11e-34	-0.58	-0.54	Preschool internalizing problems;	chr5:151762334	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs2964578	ENSG00000213433.5	RPLP1P6	-13.99	1.93e-37	4.11e-34	-0.58	-0.54	Preschool internalizing problems;	chr5:151767637	chr5:151765859~151766378:-
THCA	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-13.99	1.98e-37	4.22e-34	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-13.99	1.98e-37	4.22e-34	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
THCA	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-13.99	2.04e-37	4.35e-34	-0.69	-0.54	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
THCA	cis	rs7174755	0.772	rs80187654	ENSG00000260657.2	RP11-315D16.4	13.99	2.07e-37	4.41e-34	0.75	0.54	Major depressive disorder;	chr15:68082833	chr15:68267792~68277994:-
THCA	cis	rs2658782	0.756	rs3019222	ENSG00000279684.1	RP11-755E23.2	-13.98	2.12e-37	4.51e-34	-0.96	-0.54	Pulmonary function decline;	chr11:93346552	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.826	rs1975820	ENSG00000279684.1	RP11-755E23.2	-13.98	2.12e-37	4.51e-34	-0.96	-0.54	Pulmonary function decline;	chr11:93348649	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.756	rs3019223	ENSG00000279684.1	RP11-755E23.2	-13.98	2.12e-37	4.51e-34	-0.96	-0.54	Pulmonary function decline;	chr11:93351016	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.826	rs2925355	ENSG00000279684.1	RP11-755E23.2	-13.98	2.12e-37	4.51e-34	-0.96	-0.54	Pulmonary function decline;	chr11:93357721	chr11:93286629~93288903:-
THCA	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-13.98	2.14e-37	4.56e-34	-0.72	-0.54	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
THCA	cis	rs80028505	0.808	rs41271263	ENSG00000271304.1	DPRXP2	13.98	2.16e-37	4.59e-34	0.94	0.54	Foot ulcer in diabetes and neuropathy;	chr6:36052382	chr6:35989515~35990436:-
THCA	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-13.98	2.22e-37	4.73e-34	-1.01	-0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
THCA	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	13.98	2.25e-37	4.78e-34	0.71	0.54	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
THCA	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-13.98	2.3e-37	4.89e-34	-0.8	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
THCA	cis	rs7772486	0.754	rs6570718	ENSG00000235652.6	RP11-545I5.3	-13.97	2.37e-37	5.03e-34	-0.5	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145767307	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.654	rs6906402	ENSG00000235652.6	RP11-545I5.3	-13.97	2.37e-37	5.03e-34	-0.5	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145768171	chr6:145799409~145886585:+
THCA	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-13.97	2.43e-37	5.15e-34	-0.71	-0.54	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
THCA	cis	rs11098499	0.604	rs12642411	ENSG00000245958.5	RP11-33B1.1	-13.97	2.46e-37	5.22e-34	-0.55	-0.54	Corneal astigmatism;	chr4:119659370	chr4:119454791~119552025:+
THCA	cis	rs12468226	0.873	rs78798541	ENSG00000273456.1	RP11-686O6.2	13.97	2.49e-37	5.28e-34	0.7	0.54	Urate levels;	chr2:202194708	chr2:202374932~202375604:-
THCA	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	13.97	2.5e-37	5.31e-34	0.71	0.54	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
THCA	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-13.97	2.54e-37	5.39e-34	-0.7	-0.54	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
THCA	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	13.96	2.57e-37	5.44e-34	0.82	0.54	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
THCA	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	13.96	2.59e-37	5.48e-34	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
THCA	cis	rs710216	0.536	rs710222	ENSG00000227533.4	SLC2A1-AS1	13.96	2.67e-37	5.65e-34	0.67	0.54	Red cell distribution width;	chr1:42947982	chr1:42959049~42983358:+
THCA	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	13.96	2.68e-37	5.68e-34	0.81	0.54	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
THCA	cis	rs5769707	0.967	rs2187891	ENSG00000188511.11	C22orf34	13.96	2.76e-37	5.83e-34	0.63	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49414524~49657542:-
THCA	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-13.95	2.83e-37	5.98e-34	-0.78	-0.54	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
THCA	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-13.95	2.85e-37	6.03e-34	-0.67	-0.54	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
THCA	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-13.95	2.9e-37	6.11e-34	-0.44	-0.54	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
THCA	cis	rs524281	0.861	rs10791858	ENSG00000255320.1	RP11-755F10.1	13.95	2.99e-37	6.32e-34	0.78	0.54	Electroencephalogram traits;	chr11:66210925	chr11:66244840~66246239:-
THCA	cis	rs524281	0.817	rs10791859	ENSG00000255320.1	RP11-755F10.1	13.95	2.99e-37	6.32e-34	0.78	0.54	Electroencephalogram traits;	chr11:66210982	chr11:66244840~66246239:-
THCA	cis	rs5769707	0.933	rs2157444	ENSG00000188511.11	C22orf34	13.95	3.04e-37	6.41e-34	0.63	0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49414524~49657542:-
THCA	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-13.95	3.05e-37	6.43e-34	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
THCA	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-13.95	3.05e-37	6.44e-34	-0.8	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
THCA	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	13.95	3.08e-37	6.5e-34	0.81	0.54	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
THCA	cis	rs1062177	1	rs2915877	ENSG00000213433.5	RPLP1P6	-13.94	3.12e-37	6.58e-34	-0.58	-0.54	Preschool internalizing problems;	chr5:151771040	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs2964576	ENSG00000213433.5	RPLP1P6	-13.94	3.12e-37	6.58e-34	-0.58	-0.54	Preschool internalizing problems;	chr5:151771041	chr5:151765859~151766378:-
THCA	cis	rs2658782	0.724	rs1869914	ENSG00000279684.1	RP11-755E23.2	-13.94	3.16e-37	6.66e-34	-0.92	-0.54	Pulmonary function decline;	chr11:93379326	chr11:93286629~93288903:-
THCA	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	13.94	3.19e-37	6.73e-34	0.68	0.54	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
THCA	cis	rs12220777	1	rs74372131	ENSG00000230091.5	TMEM254-AS1	13.94	3.41e-37	7.18e-34	1.03	0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80027458	chr10:80046860~80078912:-
THCA	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	13.94	3.42e-37	7.19e-34	0.64	0.54	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
THCA	cis	rs6538678	0.824	rs7299632	ENSG00000258343.1	RP11-536G4.2	-13.94	3.42e-37	7.19e-34	-0.86	-0.54	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95795345~95858839:-
THCA	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	13.93	3.48e-37	7.33e-34	0.52	0.54	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	13.93	3.48e-37	7.33e-34	0.52	0.54	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
THCA	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-13.93	3.5e-37	7.36e-34	-0.69	-0.54	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
THCA	cis	rs2658782	0.789	rs3019206	ENSG00000279684.1	RP11-755E23.2	-13.93	3.6e-37	7.56e-34	-0.92	-0.54	Pulmonary function decline;	chr11:93377907	chr11:93286629~93288903:-
THCA	cis	rs11098499	0.604	rs2389886	ENSG00000245958.5	RP11-33B1.1	-13.93	3.7e-37	7.77e-34	-0.54	-0.54	Corneal astigmatism;	chr4:119649267	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.604	rs2389887	ENSG00000245958.5	RP11-33B1.1	-13.93	3.7e-37	7.77e-34	-0.54	-0.54	Corneal astigmatism;	chr4:119649489	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.604	rs34278750	ENSG00000245958.5	RP11-33B1.1	-13.93	3.7e-37	7.77e-34	-0.54	-0.54	Corneal astigmatism;	chr4:119649981	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.604	rs10022185	ENSG00000245958.5	RP11-33B1.1	-13.93	3.7e-37	7.77e-34	-0.54	-0.54	Corneal astigmatism;	chr4:119650610	chr4:119454791~119552025:+
THCA	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-13.92	3.86e-37	8.1e-34	-0.69	-0.54	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
THCA	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-13.92	3.89e-37	8.15e-34	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
THCA	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	13.92	3.96e-37	8.3e-34	0.6	0.54	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
THCA	cis	rs2283792	0.967	rs5755099	ENSG00000224086.5	LL22NC03-86G7.1	-13.92	4.08e-37	8.55e-34	-0.64	-0.54	Multiple sclerosis;	chr22:21770751	chr22:21938293~21977632:+
THCA	cis	rs62158211	0.955	rs1823125	ENSG00000234997.1	AC016745.3	13.92	4.16e-37	8.7e-34	0.63	0.54	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113332835	chr2:113424495~113425324:+
THCA	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	13.92	4.17e-37	8.74e-34	0.63	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
THCA	cis	rs2658782	0.756	rs2658777	ENSG00000279684.1	RP11-755E23.2	-13.91	4.2e-37	8.8e-34	-0.93	-0.54	Pulmonary function decline;	chr11:93415257	chr11:93286629~93288903:-
THCA	cis	rs6504950	0.705	rs9899545	ENSG00000275710.1	RP11-257O5.4	13.91	4.3e-37	8.99e-34	0.7	0.54	Breast cancer;	chr17:54909484	chr17:54964474~54964679:+
THCA	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	13.91	4.34e-37	9.07e-34	0.9	0.54	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
THCA	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-13.91	4.4e-37	9.19e-34	-0.69	-0.54	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
THCA	cis	rs11155671	0.53	rs4870080	ENSG00000268592.3	RAET1E-AS1	13.91	4.44e-37	9.28e-34	0.73	0.54	Testicular germ cell tumor;	chr6:149881508	chr6:149863494~149919507:+
THCA	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	13.91	4.44e-37	9.29e-34	0.81	0.54	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
THCA	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	13.91	4.59e-37	9.59e-34	0.44	0.54	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
THCA	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-13.9	4.84e-37	1.01e-33	-0.57	-0.54	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
THCA	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-13.9	4.9e-37	1.02e-33	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
THCA	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	13.9	4.96e-37	1.03e-33	0.6	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
THCA	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	13.89	5.26e-37	1.09e-33	0.56	0.54	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	13.89	5.26e-37	1.09e-33	0.56	0.54	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
THCA	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-13.89	5.53e-37	1.15e-33	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-13.88	5.65e-37	1.17e-33	-0.69	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	13.88	5.7e-37	1.18e-33	0.67	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
THCA	cis	rs2658782	0.951	rs72972364	ENSG00000279684.1	RP11-755E23.2	13.88	5.77e-37	1.2e-33	0.98	0.54	Pulmonary function decline;	chr11:93388962	chr11:93286629~93288903:-
THCA	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	13.88	5.9e-37	1.23e-33	0.61	0.54	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	13.88	6.01e-37	1.25e-33	0.67	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
THCA	cis	rs9309473	0.95	rs10206899	ENSG00000163016.8	ALMS1P	13.88	6.08e-37	1.26e-33	0.83	0.54	Metabolite levels;	chr2:73673773	chr2:73644919~73685576:+
THCA	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	13.88	6.13e-37	1.27e-33	0.6	0.54	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
THCA	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-13.87	6.28e-37	1.3e-33	-0.94	-0.54	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
THCA	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	13.87	6.31e-37	1.31e-33	0.81	0.54	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	13.87	6.33e-37	1.31e-33	0.69	0.54	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
THCA	cis	rs7569084	1	rs7583469	ENSG00000204929.10	AC074391.1	13.87	6.46e-37	1.34e-33	0.66	0.54	Sum eosinophil basophil counts;	chr2:65424222	chr2:65436711~66084639:+
THCA	cis	rs2658782	0.789	rs2658776	ENSG00000279684.1	RP11-755E23.2	-13.87	6.49e-37	1.34e-33	-0.92	-0.54	Pulmonary function decline;	chr11:93414761	chr11:93286629~93288903:-
THCA	cis	rs524281	0.861	rs3953856	ENSG00000255320.1	RP11-755F10.1	13.87	6.62e-37	1.37e-33	0.78	0.54	Electroencephalogram traits;	chr11:66198437	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs2889313	ENSG00000255320.1	RP11-755F10.1	13.87	6.62e-37	1.37e-33	0.78	0.54	Electroencephalogram traits;	chr11:66198595	chr11:66244840~66246239:-
THCA	cis	rs2283792	1	rs9607287	ENSG00000224086.5	LL22NC03-86G7.1	-13.87	6.65e-37	1.38e-33	-0.63	-0.54	Multiple sclerosis;	chr22:21809136	chr22:21938293~21977632:+
THCA	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-13.87	6.84e-37	1.42e-33	-0.61	-0.54	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	13.87	6.86e-37	1.42e-33	0.6	0.54	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
THCA	cis	rs2658782	0.789	rs2259633	ENSG00000279684.1	RP11-755E23.2	-13.86	7.04e-37	1.46e-33	-0.92	-0.54	Pulmonary function decline;	chr11:93408414	chr11:93286629~93288903:-
THCA	cis	rs2283792	0.967	rs5749998	ENSG00000224086.5	LL22NC03-86G7.1	-13.86	7.1e-37	1.47e-33	-0.63	-0.54	Multiple sclerosis;	chr22:21808085	chr22:21938293~21977632:+
THCA	cis	rs7772486	0.719	rs2206141	ENSG00000235652.6	RP11-545I5.3	-13.86	7.11e-37	1.47e-33	-0.5	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145765056	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs73207564	ENSG00000275759.1	RP11-131L12.3	-13.86	7.13e-37	1.47e-33	-0.78	-0.54	Glucose homeostasis traits;	chr12:118429566	chr12:118428281~118428870:+
THCA	cis	rs2658782	0.789	rs3020076	ENSG00000279684.1	RP11-755E23.2	-13.86	7.29e-37	1.51e-33	-0.92	-0.54	Pulmonary function decline;	chr11:93407892	chr11:93286629~93288903:-
THCA	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	13.86	7.39e-37	1.53e-33	0.82	0.54	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
THCA	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-13.86	7.5e-37	1.55e-33	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
THCA	cis	rs524281	0.861	rs10750779	ENSG00000255320.1	RP11-755F10.1	13.85	7.7e-37	1.59e-33	0.77	0.54	Electroencephalogram traits;	chr11:66207120	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs10750780	ENSG00000255320.1	RP11-755F10.1	13.85	7.7e-37	1.59e-33	0.77	0.54	Electroencephalogram traits;	chr11:66207121	chr11:66244840~66246239:-
THCA	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	13.85	7.93e-37	1.64e-33	0.6	0.54	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	13.85	7.93e-37	1.64e-33	0.6	0.54	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
THCA	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-13.85	7.99e-37	1.65e-33	-0.78	-0.54	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
THCA	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-13.85	7.99e-37	1.65e-33	-0.78	-0.54	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-13.85	7.99e-37	1.65e-33	-0.78	-0.54	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943447	ENSG00000275759.1	RP11-131L12.3	-13.85	8.03e-37	1.66e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118430598	chr12:118428281~118428870:+
THCA	cis	rs6504950	0.705	rs9899602	ENSG00000275710.1	RP11-257O5.4	-13.85	8.12e-37	1.67e-33	-0.7	-0.54	Breast cancer;	chr17:54909547	chr17:54964474~54964679:+
THCA	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-13.84	8.41e-37	1.73e-33	-0.8	-0.54	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
THCA	cis	rs12134133	1	rs11584921	ENSG00000274245.1	RP11-357P18.2	13.84	8.55e-37	1.76e-33	0.57	0.54	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207372559~207373252:+
THCA	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-13.84	8.66e-37	1.78e-33	-0.7	-0.54	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
THCA	cis	rs7772486	0.79	rs2265474	ENSG00000235652.6	RP11-545I5.3	13.84	8.67e-37	1.78e-33	0.5	0.54	Lobe attachment (rater-scored or self-reported);	chr6:145860956	chr6:145799409~145886585:+
THCA	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	13.83	9.31e-37	1.91e-33	0.94	0.54	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
THCA	cis	rs7772486	0.72	rs6931553	ENSG00000235652.6	RP11-545I5.3	-13.83	9.36e-37	1.92e-33	-0.49	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145791212	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs6937661	ENSG00000235652.6	RP11-545I5.3	-13.83	9.36e-37	1.92e-33	-0.49	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145792163	chr6:145799409~145886585:+
THCA	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	13.83	9.5e-37	1.95e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
THCA	cis	rs6142102	0.625	rs6142068	ENSG00000276073.1	RP5-1125A11.7	13.83	9.91e-37	2.03e-33	0.47	0.54	Skin pigmentation;	chr20:33969366	chr20:33985617~33988989:-
THCA	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	13.83	1e-36	2.06e-33	0.6	0.54	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
THCA	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	13.82	1.04e-36	2.13e-33	0.88	0.54	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
THCA	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-13.82	1.08e-36	2.21e-33	-0.57	-0.54	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
THCA	cis	rs1431005	1	rs1431005	ENSG00000250620.1	RP11-91J3.3	-13.82	1.1e-36	2.26e-33	-0.67	-0.54	Response to statin therapy;	chr4:187424214	chr4:187413564~187415697:+
THCA	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-13.82	1.12e-36	2.29e-33	-0.71	-0.54	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
THCA	cis	rs6538678	0.784	rs7297403	ENSG00000258343.1	RP11-536G4.2	-13.81	1.16e-36	2.37e-33	-0.85	-0.54	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95795345~95858839:-
THCA	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-13.81	1.17e-36	2.39e-33	-0.59	-0.54	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
THCA	cis	rs11098499	0.566	rs7664440	ENSG00000245958.5	RP11-33B1.1	-13.81	1.18e-36	2.41e-33	-0.53	-0.54	Corneal astigmatism;	chr4:119657385	chr4:119454791~119552025:+
THCA	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	13.81	1.18e-36	2.41e-33	0.71	0.54	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
THCA	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	13.81	1.2e-36	2.44e-33	0.51	0.54	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
THCA	cis	rs7772486	0.754	rs2328709	ENSG00000235652.6	RP11-545I5.3	-13.81	1.2e-36	2.45e-33	-0.5	-0.54	Lobe attachment (rater-scored or self-reported);	chr6:145785683	chr6:145799409~145886585:+
THCA	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-13.81	1.2e-36	2.45e-33	-0.7	-0.54	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
THCA	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	13.81	1.21e-36	2.48e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	13.81	1.21e-36	2.48e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
THCA	cis	rs12220777	1	rs72644211	ENSG00000230091.5	TMEM254-AS1	13.81	1.22e-36	2.48e-33	1.02	0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80021939	chr10:80046860~80078912:-
THCA	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	13.81	1.24e-36	2.52e-33	0.52	0.54	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
THCA	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	13.8	1.26e-36	2.57e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
THCA	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-13.8	1.26e-36	2.57e-33	-0.68	-0.54	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
THCA	cis	rs7772486	0.754	rs9373475	ENSG00000235652.6	RP11-545I5.3	13.8	1.28e-36	2.61e-33	0.49	0.54	Lobe attachment (rater-scored or self-reported);	chr6:145805283	chr6:145799409~145886585:+
THCA	cis	rs2658782	0.789	rs56091149	ENSG00000279684.1	RP11-755E23.2	13.8	1.32e-36	2.68e-33	0.96	0.54	Pulmonary function decline;	chr11:93340474	chr11:93286629~93288903:-
THCA	cis	rs12468226	1	rs13389798	ENSG00000273456.1	RP11-686O6.2	13.8	1.33e-36	2.72e-33	0.68	0.54	Urate levels;	chr2:202348370	chr2:202374932~202375604:-
THCA	cis	rs1062177	1	rs6890099	ENSG00000213433.5	RPLP1P6	-13.8	1.34e-36	2.73e-33	-0.57	-0.54	Preschool internalizing problems;	chr5:151772401	chr5:151765859~151766378:-
THCA	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	13.8	1.35e-36	2.75e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	13.8	1.35e-36	2.75e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
THCA	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	13.79	1.38e-36	2.8e-33	0.81	0.54	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
THCA	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-13.79	1.39e-36	2.82e-33	-0.67	-0.54	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
THCA	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-13.79	1.42e-36	2.88e-33	-0.58	-0.54	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
THCA	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-13.79	1.42e-36	2.89e-33	-0.63	-0.54	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
THCA	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	13.79	1.42e-36	2.89e-33	0.8	0.54	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
THCA	cis	rs12468226	1	rs58288071	ENSG00000273456.1	RP11-686O6.2	13.79	1.43e-36	2.91e-33	0.7	0.54	Urate levels;	chr2:202350016	chr2:202374932~202375604:-
THCA	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	13.79	1.43e-36	2.91e-33	0.6	0.54	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	13.79	1.43e-36	2.91e-33	0.6	0.54	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	13.79	1.43e-36	2.91e-33	0.6	0.54	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
THCA	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-13.79	1.44e-36	2.93e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
THCA	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	13.79	1.47e-36	2.98e-33	0.8	0.54	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
THCA	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
THCA	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-13.79	1.47e-36	2.98e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	13.79	1.48e-36	3.01e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
THCA	cis	rs732716	0.752	rs11085072	ENSG00000267769.1	CTB-50L17.9	-13.78	1.51e-36	3.07e-33	-0.73	-0.54	Mean corpuscular volume;	chr19:4368145	chr19:4454014~4455286:+
THCA	cis	rs2283792	1	rs3788332	ENSG00000224086.5	LL22NC03-86G7.1	-13.78	1.53e-36	3.11e-33	-0.63	-0.54	Multiple sclerosis;	chr22:21817278	chr22:21938293~21977632:+
THCA	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	13.78	1.54e-36	3.13e-33	0.51	0.54	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
THCA	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-13.78	1.56e-36	3.15e-33	-0.51	-0.54	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
THCA	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	13.78	1.57e-36	3.19e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
THCA	cis	rs7174755	0.772	rs75395345	ENSG00000260657.2	RP11-315D16.4	13.78	1.57e-36	3.19e-33	0.73	0.54	Major depressive disorder;	chr15:68081380	chr15:68267792~68277994:-
THCA	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	13.78	1.57e-36	3.19e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	13.78	1.57e-36	3.19e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	13.78	1.57e-36	3.19e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	13.78	1.57e-36	3.19e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	13.78	1.57e-36	3.19e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	13.77	1.69e-36	3.42e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
THCA	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-13.77	1.78e-36	3.61e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	13.77	1.79e-36	3.61e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	13.77	1.79e-36	3.61e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
THCA	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	13.77	1.84e-36	3.72e-33	0.81	0.54	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
THCA	cis	rs524281	0.861	rs9645684	ENSG00000255320.1	RP11-755F10.1	13.77	1.84e-36	3.72e-33	0.77	0.54	Electroencephalogram traits;	chr11:66140493	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.604	rs2389882	ENSG00000245958.5	RP11-33B1.1	-13.76	1.86e-36	3.76e-33	-0.54	-0.54	Corneal astigmatism;	chr4:119645578	chr4:119454791~119552025:+
THCA	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	13.76	1.87e-36	3.78e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
THCA	cis	rs4814920	0.756	rs1543472	ENSG00000275142.1	RP5-999L4.2	13.76	1.92e-36	3.87e-33	0.92	0.54	Bipolar disorder (body mass index interaction);	chr20:19867383	chr20:19871891~19872284:+
THCA	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	13.76	1.94e-36	3.91e-33	0.8	0.54	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	13.76	1.97e-36	3.98e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
THCA	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-13.76	2.02e-36	4.08e-33	-0.77	-0.54	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
THCA	cis	rs524281	0.861	rs7941431	ENSG00000255320.1	RP11-755F10.1	13.75	2.08e-36	4.18e-33	0.77	0.54	Electroencephalogram traits;	chr11:66192686	chr11:66244840~66246239:-
THCA	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-13.75	2.16e-36	4.35e-33	-0.78	-0.54	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7295288	ENSG00000275759.1	RP11-131L12.3	-13.75	2.16e-36	4.35e-33	-0.74	-0.54	Glucose homeostasis traits;	chr12:118418008	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	13.74	2.26e-36	4.56e-33	0.68	0.54	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
THCA	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-13.74	2.3e-36	4.63e-33	-0.64	-0.54	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
THCA	cis	rs7772486	0.754	rs9399567	ENSG00000235652.6	RP11-545I5.3	13.74	2.34e-36	4.71e-33	0.5	0.54	Lobe attachment (rater-scored or self-reported);	chr6:145826159	chr6:145799409~145886585:+
THCA	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	13.74	2.38e-36	4.78e-33	0.53	0.54	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
THCA	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-13.74	2.43e-36	4.88e-33	-0.95	-0.54	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
THCA	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	13.74	2.45e-36	4.91e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	13.74	2.45e-36	4.91e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
THCA	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	13.74	2.45e-36	4.91e-33	0.55	0.54	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
THCA	cis	rs1062177	1	rs12518722	ENSG00000213433.5	RPLP1P6	-13.74	2.45e-36	4.92e-33	-0.57	-0.54	Preschool internalizing problems;	chr5:151851899	chr5:151765859~151766378:-
THCA	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	13.74	2.46e-36	4.94e-33	0.81	0.54	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	13.74	2.46e-36	4.94e-33	0.81	0.54	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	13.74	2.46e-36	4.94e-33	0.81	0.54	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	13.74	2.46e-36	4.94e-33	0.81	0.54	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
THCA	cis	rs10740039	0.583	rs2127353	ENSG00000254271.1	RP11-131N11.4	-13.73	2.49e-36	4.99e-33	-0.68	-0.54	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60750206	chr10:60734342~60741828:+
THCA	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-13.73	2.57e-36	5.15e-33	-0.78	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
THCA	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-13.73	2.57e-36	5.15e-33	-0.78	-0.54	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
THCA	cis	rs1062177	1	rs12653926	ENSG00000213433.5	RPLP1P6	-13.73	2.58e-36	5.17e-33	-0.57	-0.54	Preschool internalizing problems;	chr5:151870687	chr5:151765859~151766378:-
THCA	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	13.73	2.65e-36	5.3e-33	0.51	0.53	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
THCA	cis	rs2283792	1	rs6928	ENSG00000224086.5	LL22NC03-86G7.1	-13.73	2.73e-36	5.46e-33	-0.63	-0.53	Multiple sclerosis;	chr22:21760715	chr22:21938293~21977632:+
THCA	cis	rs9481169	0.85	rs4947128	ENSG00000255389.1	C6orf3	-13.72	2.78e-36	5.57e-33	-0.95	-0.53	Inflammatory skin disease;	chr6:111597665	chr6:111599875~111602295:+
THCA	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-13.72	2.82e-36	5.64e-33	-0.78	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
THCA	cis	rs1062177	1	rs2964571	ENSG00000213433.5	RPLP1P6	-13.72	2.86e-36	5.73e-33	-0.57	-0.53	Preschool internalizing problems;	chr5:151791695	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs2915869	ENSG00000213433.5	RPLP1P6	-13.72	2.86e-36	5.73e-33	-0.57	-0.53	Preschool internalizing problems;	chr5:151791948	chr5:151765859~151766378:-
THCA	cis	rs524281	0.861	rs580891	ENSG00000255320.1	RP11-755F10.1	13.72	2.88e-36	5.75e-33	0.75	0.53	Electroencephalogram traits;	chr11:66187210	chr11:66244840~66246239:-
THCA	cis	rs7772486	0.754	rs6915718	ENSG00000235652.6	RP11-545I5.3	-13.72	2.88e-36	5.77e-33	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145779540	chr6:145799409~145886585:+
THCA	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-13.72	2.89e-36	5.79e-33	-0.81	-0.53	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
THCA	cis	rs524281	0.861	rs10896081	ENSG00000255320.1	RP11-755F10.1	13.72	2.94e-36	5.88e-33	0.78	0.53	Electroencephalogram traits;	chr11:66112883	chr11:66244840~66246239:-
THCA	cis	rs7772486	0.754	rs857881	ENSG00000235652.6	RP11-545I5.3	-13.71	3.04e-36	6.07e-33	-0.5	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145649657	chr6:145799409~145886585:+
THCA	cis	rs1062177	0.951	rs2915876	ENSG00000213433.5	RPLP1P6	-13.71	3.06e-36	6.11e-33	-0.57	-0.53	Preschool internalizing problems;	chr5:151771184	chr5:151765859~151766378:-
THCA	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	13.71	3.06e-36	6.11e-33	0.64	0.53	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
THCA	cis	rs524281	0.814	rs10896093	ENSG00000255320.1	RP11-755F10.1	13.71	3.08e-36	6.15e-33	0.76	0.53	Electroencephalogram traits;	chr11:66190940	chr11:66244840~66246239:-
THCA	cis	rs6142102	0.602	rs68051854	ENSG00000276073.1	RP5-1125A11.7	-13.71	3.08e-36	6.15e-33	-0.48	-0.53	Skin pigmentation;	chr20:34114150	chr20:33985617~33988989:-
THCA	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	13.71	3.12e-36	6.23e-33	0.8	0.53	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
THCA	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	13.71	3.13e-36	6.26e-33	0.6	0.53	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
THCA	cis	rs1062177	0.826	rs1549920	ENSG00000213433.5	RPLP1P6	-13.71	3.19e-36	6.37e-33	-0.56	-0.53	Preschool internalizing problems;	chr5:151761283	chr5:151765859~151766378:-
THCA	cis	rs6538678	0.824	rs2367583	ENSG00000258343.1	RP11-536G4.2	-13.71	3.2e-36	6.39e-33	-0.85	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95856582	chr12:95795345~95858839:-
THCA	cis	rs17111396	0.773	rs10147243	ENSG00000259167.2	NMNAT1P1	13.71	3.22e-36	6.43e-33	0.67	0.53	Uric acid levels;	chr14:81044834	chr14:81032529~81033404:+
THCA	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	13.71	3.25e-36	6.49e-33	0.51	0.53	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
THCA	cis	rs7772486	0.754	rs697053	ENSG00000235652.6	RP11-545I5.3	-13.7	3.37e-36	6.72e-33	-0.5	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145668671	chr6:145799409~145886585:+
THCA	cis	rs9481169	0.717	rs13191781	ENSG00000255389.1	C6orf3	-13.7	3.44e-36	6.85e-33	-1.03	-0.53	Inflammatory skin disease;	chr6:111620083	chr6:111599875~111602295:+
THCA	cis	rs9595066	1	rs9595066	ENSG00000227258.4	SMIM2-AS1	13.7	3.61e-36	7.19e-33	0.7	0.53	Schizophrenia;	chr13:44132132	chr13:44110451~44240517:+
THCA	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-13.7	3.65e-36	7.27e-33	-0.68	-0.53	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
THCA	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	13.7	3.67e-36	7.3e-33	0.52	0.53	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
THCA	cis	rs9890032	0.618	rs55872374	ENSG00000266490.1	CTD-2349P21.9	13.69	3.71e-36	7.38e-33	0.53	0.53	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30792372~30792833:+
THCA	cis	rs62388641	0.813	rs34779492	ENSG00000272279.1	RP11-157J24.2	13.69	3.72e-36	7.4e-33	0.91	0.53	Daytime sleep phenotypes;	chr6:1547737	chr6:1528364~1528911:-
THCA	cis	rs62388641	0.774	rs13212794	ENSG00000272279.1	RP11-157J24.2	13.69	3.72e-36	7.4e-33	0.91	0.53	Daytime sleep phenotypes;	chr6:1548349	chr6:1528364~1528911:-
THCA	cis	rs524281	0.861	rs10896085	ENSG00000255320.1	RP11-755F10.1	13.69	3.72e-36	7.41e-33	0.77	0.53	Electroencephalogram traits;	chr11:66146361	chr11:66244840~66246239:-
THCA	cis	rs7772486	0.754	rs6906258	ENSG00000235652.6	RP11-545I5.3	-13.69	3.77e-36	7.51e-33	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145768220	chr6:145799409~145886585:+
THCA	cis	rs1062177	1	rs62394155	ENSG00000213433.5	RPLP1P6	-13.69	3.82e-36	7.6e-33	-0.57	-0.53	Preschool internalizing problems;	chr5:151868508	chr5:151765859~151766378:-
THCA	cis	rs6538678	0.746	rs1865736	ENSG00000258343.1	RP11-536G4.2	-13.69	3.82e-36	7.61e-33	-0.85	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95854051	chr12:95795345~95858839:-
THCA	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-13.69	3.85e-36	7.66e-33	-0.6	-0.53	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
THCA	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-13.69	3.85e-36	7.66e-33	-0.6	-0.53	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
THCA	cis	rs6504950	0.72	rs28564882	ENSG00000275710.1	RP11-257O5.4	13.69	3.87e-36	7.7e-33	0.69	0.53	Breast cancer;	chr17:54912237	chr17:54964474~54964679:+
THCA	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-13.69	3.91e-36	7.77e-33	-0.56	-0.53	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
THCA	cis	rs6504950	0.679	rs9897646	ENSG00000275710.1	RP11-257O5.4	13.69	3.95e-36	7.86e-33	0.71	0.53	Breast cancer;	chr17:54907990	chr17:54964474~54964679:+
THCA	cis	rs5769707	0.749	rs8137251	ENSG00000188511.11	C22orf34	13.69	3.96e-36	7.87e-33	0.65	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49414524~49657542:-
THCA	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	13.68	4.06e-36	8.07e-33	0.68	0.53	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
THCA	cis	rs710216	0.536	rs710221	ENSG00000227533.4	SLC2A1-AS1	13.68	4.23e-36	8.39e-33	0.67	0.53	Red cell distribution width;	chr1:42948529	chr1:42959049~42983358:+
THCA	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	13.68	4.31e-36	8.55e-33	0.8	0.53	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	13.68	4.31e-36	8.55e-33	0.8	0.53	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
THCA	cis	rs6538678	0.746	rs4762630	ENSG00000258343.1	RP11-536G4.2	-13.68	4.45e-36	8.83e-33	-0.84	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95795345~95858839:-
THCA	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	13.68	4.46e-36	8.84e-33	0.82	0.53	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	13.68	4.46e-36	8.84e-33	0.82	0.53	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
THCA	cis	rs7772486	0.738	rs2246334	ENSG00000235652.6	RP11-545I5.3	13.67	4.48e-36	8.89e-33	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145862499	chr6:145799409~145886585:+
THCA	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-13.67	4.53e-36	8.98e-33	-0.66	-0.53	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
THCA	cis	rs62388641	0.813	rs55821127	ENSG00000272279.1	RP11-157J24.2	13.67	4.59e-36	9.11e-33	0.91	0.53	Daytime sleep phenotypes;	chr6:1550635	chr6:1528364~1528911:-
THCA	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	13.67	4.61e-36	9.13e-33	0.7	0.53	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
THCA	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-13.67	4.68e-36	9.28e-33	-0.53	-0.53	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
THCA	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-13.67	4.77e-36	9.44e-33	-0.76	-0.53	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
THCA	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-13.67	4.8e-36	9.5e-33	-0.91	-0.53	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
THCA	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	13.66	4.98e-36	9.86e-33	0.59	0.53	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
THCA	cis	rs8062405	1	rs12325113	ENSG00000251417.2	RP11-1348G14.4	-13.66	5.08e-36	1.01e-32	-0.52	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28802743~28817828:+
THCA	cis	rs56163509	1	rs56163509	ENSG00000251417.2	RP11-1348G14.4	-13.66	5.08e-36	1.01e-32	-0.52	-0.53	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62037369	ENSG00000251417.2	RP11-1348G14.4	-13.66	5.08e-36	1.01e-32	-0.52	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.965	rs7359397	ENSG00000251417.2	RP11-1348G14.4	-13.66	5.08e-36	1.01e-32	-0.52	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28802743~28817828:+
THCA	cis	rs9890032	0.52	rs2321926	ENSG00000266490.1	CTD-2349P21.9	13.66	5.12e-36	1.01e-32	0.53	0.53	Hip circumference adjusted for BMI;	chr17:30714534	chr17:30792372~30792833:+
THCA	cis	rs1062177	0.906	rs2964573	ENSG00000213433.5	RPLP1P6	-13.66	5.36e-36	1.06e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151780561	chr5:151765859~151766378:-
THCA	cis	rs7772486	0.692	rs2265915	ENSG00000235652.6	RP11-545I5.3	13.65	5.64e-36	1.11e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145873196	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.713	rs1986729	ENSG00000235652.6	RP11-545I5.3	13.65	5.64e-36	1.11e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145873695	chr6:145799409~145886585:+
THCA	cis	rs1062177	1	rs2347596	ENSG00000213433.5	RPLP1P6	-13.65	5.78e-36	1.14e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151799638	chr5:151765859~151766378:-
THCA	cis	rs1062177	0.95	rs892005	ENSG00000213433.5	RPLP1P6	-13.65	5.78e-36	1.14e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151801060	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs72802204	ENSG00000213433.5	RPLP1P6	-13.65	5.78e-36	1.14e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151803622	chr5:151765859~151766378:-
THCA	cis	rs80028505	0.908	rs73730459	ENSG00000271304.1	DPRXP2	13.65	5.88e-36	1.16e-32	0.9	0.53	Foot ulcer in diabetes and neuropathy;	chr6:36117226	chr6:35989515~35990436:-
THCA	cis	rs1062177	1	rs1062177	ENSG00000213433.5	RPLP1P6	-13.64	6.01e-36	1.19e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151805140	chr5:151765859~151766378:-
THCA	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	13.64	6.05e-36	1.19e-32	0.82	0.53	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	13.64	6.26e-36	1.23e-32	0.79	0.53	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000206090.4	AP000350.7	13.64	6.29e-36	1.24e-32	0.66	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23939998~23942798:+
THCA	cis	rs12134133	1	rs1583090	ENSG00000274245.1	RP11-357P18.2	13.64	6.41e-36	1.26e-32	0.57	0.53	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207372559~207373252:+
THCA	cis	rs67180937	0.621	rs2378607	ENSG00000272750.1	RP11-378J18.8	-13.64	6.52e-36	1.28e-32	-0.58	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222746553	chr1:222658867~222661512:-
THCA	cis	rs1062177	1	rs892006	ENSG00000213433.5	RPLP1P6	-13.64	6.54e-36	1.29e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151801329	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs17804178	ENSG00000213433.5	RPLP1P6	-13.64	6.62e-36	1.3e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151818168	chr5:151765859~151766378:-
THCA	cis	rs1062177	1	rs2964612	ENSG00000213433.5	RPLP1P6	-13.64	6.62e-36	1.3e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151819189	chr5:151765859~151766378:-
THCA	cis	rs12134133	1	rs61822669	ENSG00000274245.1	RP11-357P18.2	13.63	6.79e-36	1.34e-32	0.57	0.53	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207247869	chr1:207372559~207373252:+
THCA	cis	rs1577917	0.559	rs2223788	ENSG00000203875.9	SNHG5	-13.63	6.88e-36	1.35e-32	-0.58	-0.53	Response to antipsychotic treatment;	chr6:86102202	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.523	rs1413724	ENSG00000203875.9	SNHG5	-13.63	6.88e-36	1.35e-32	-0.58	-0.53	Response to antipsychotic treatment;	chr6:86104831	chr6:85660950~85678736:-
THCA	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	13.63	6.93e-36	1.36e-32	0.64	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
THCA	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	13.63	7.06e-36	1.39e-32	0.79	0.53	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
THCA	cis	rs11155671	0.53	rs1334510	ENSG00000268592.3	RAET1E-AS1	13.63	7.2e-36	1.41e-32	0.71	0.53	Testicular germ cell tumor;	chr6:149880043	chr6:149863494~149919507:+
THCA	cis	rs1062177	1	rs973529	ENSG00000213433.5	RPLP1P6	-13.62	7.37e-36	1.45e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151808597	chr5:151765859~151766378:-
THCA	cis	rs8040855	0.756	rs2342118	ENSG00000259295.5	CSPG4P12	-13.62	7.44e-36	1.46e-32	-0.78	-0.53	Bulimia nervosa;	chr15:85149785	chr15:85191438~85213905:+
THCA	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	13.62	7.46e-36	1.46e-32	0.61	0.53	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
THCA	cis	rs2284378	0.515	rs6059579	ENSG00000276073.1	RP5-1125A11.7	-13.62	7.61e-36	1.49e-32	-0.47	-0.53	Breast cancer;	chr20:33940059	chr20:33985617~33988989:-
THCA	cis	rs62388641	0.813	rs34114087	ENSG00000272279.1	RP11-157J24.2	13.62	7.74e-36	1.52e-32	0.9	0.53	Daytime sleep phenotypes;	chr6:1553203	chr6:1528364~1528911:-
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000206090.4	AP000350.7	13.61	8.18e-36	1.6e-32	0.67	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23939998~23942798:+
THCA	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	13.61	8.29e-36	1.62e-32	0.52	0.53	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
THCA	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	13.61	8.32e-36	1.63e-32	0.49	0.53	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
THCA	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	13.61	8.41e-36	1.65e-32	0.51	0.53	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
THCA	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	13.61	8.45e-36	1.65e-32	0.64	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
THCA	cis	rs7240205	0.724	rs6508447	ENSG00000275805.1	RP11-349H17.2	13.61	8.56e-36	1.68e-32	0.61	0.53	Breast cancer;	chr18:26552657	chr18:26565723~26575626:-
THCA	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	13.61	8.61e-36	1.68e-32	0.8	0.53	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
THCA	cis	rs1062177	1	rs2915887	ENSG00000213433.5	RPLP1P6	-13.61	8.64e-36	1.69e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151825943	chr5:151765859~151766378:-
THCA	cis	rs524281	0.861	rs10750778	ENSG00000255320.1	RP11-755F10.1	13.61	8.67e-36	1.69e-32	0.76	0.53	Electroencephalogram traits;	chr11:66181177	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs6591208	ENSG00000255320.1	RP11-755F10.1	13.61	8.67e-36	1.69e-32	0.76	0.53	Electroencephalogram traits;	chr11:66182218	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs10896091	ENSG00000255320.1	RP11-755F10.1	13.61	8.67e-36	1.69e-32	0.76	0.53	Electroencephalogram traits;	chr11:66183354	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs7929909	ENSG00000255320.1	RP11-755F10.1	13.61	8.67e-36	1.69e-32	0.76	0.53	Electroencephalogram traits;	chr11:66184227	chr11:66244840~66246239:-
THCA	cis	rs2283792	0.776	rs9610458	ENSG00000224086.5	LL22NC03-86G7.1	-13.61	8.77e-36	1.71e-32	-0.63	-0.53	Multiple sclerosis;	chr22:21851064	chr22:21938293~21977632:+
THCA	cis	rs8062405	0.964	rs7187333	ENSG00000251417.2	RP11-1348G14.4	-13.6	8.98e-36	1.76e-32	-0.51	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs12446589	ENSG00000251417.2	RP11-1348G14.4	-13.6	8.98e-36	1.76e-32	-0.51	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28802743~28817828:+
THCA	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	13.6	9.35e-36	1.83e-32	0.82	0.53	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
THCA	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	13.6	9.65e-36	1.88e-32	0.54	0.53	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
THCA	cis	rs7945705	0.747	rs2568020	ENSG00000254860.4	TMEM9B-AS1	13.6	9.66e-36	1.89e-32	0.58	0.53	Hemoglobin concentration;	chr11:8973168	chr11:8964675~8977527:+
THCA	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-13.6	9.72e-36	1.9e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	13.59	9.82e-36	1.91e-32	0.76	0.53	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
THCA	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-13.59	9.82e-36	1.91e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
THCA	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-13.59	9.84e-36	1.92e-32	-0.61	-0.53	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
THCA	cis	rs5769707	0.592	rs6009783	ENSG00000188511.11	C22orf34	13.59	9.85e-36	1.92e-32	0.67	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49414524~49657542:-
THCA	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-13.59	1.01e-35	1.96e-32	-0.73	-0.53	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
THCA	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	13.59	1.02e-35	1.98e-32	0.8	0.53	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
THCA	cis	rs62388641	0.813	rs62390562	ENSG00000272279.1	RP11-157J24.2	13.59	1.05e-35	2.05e-32	0.9	0.53	Daytime sleep phenotypes;	chr6:1551467	chr6:1528364~1528911:-
THCA	cis	rs5769707	0.609	rs135861	ENSG00000188511.11	C22orf34	13.59	1.06e-35	2.05e-32	0.68	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49414524~49657542:-
THCA	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	13.59	1.06e-35	2.06e-32	0.63	0.53	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
THCA	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	13.59	1.07e-35	2.07e-32	0.57	0.53	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
THCA	cis	rs7772486	0.79	rs9403749	ENSG00000235652.6	RP11-545I5.3	13.59	1.07e-35	2.09e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145841103	chr6:145799409~145886585:+
THCA	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	13.59	1.07e-35	2.09e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	13.59	1.07e-35	2.09e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
THCA	cis	rs1062177	0.855	rs62395861	ENSG00000213433.5	RPLP1P6	-13.59	1.08e-35	2.09e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151889709	chr5:151765859~151766378:-
THCA	cis	rs1062177	0.95	rs59580263	ENSG00000213433.5	RPLP1P6	-13.59	1.08e-35	2.09e-32	-0.57	-0.53	Preschool internalizing problems;	chr5:151890016	chr5:151765859~151766378:-
THCA	cis	rs2658782	1	rs2605582	ENSG00000279684.1	RP11-755E23.2	-13.58	1.08e-35	2.11e-32	-0.91	-0.53	Pulmonary function decline;	chr11:93430633	chr11:93286629~93288903:-
THCA	cis	rs11155671	0.53	rs9383912	ENSG00000268592.3	RAET1E-AS1	13.58	1.09e-35	2.12e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149885479	chr6:149863494~149919507:+
THCA	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	13.58	1.11e-35	2.15e-32	0.7	0.53	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
THCA	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	13.58	1.11e-35	2.16e-32	0.63	0.53	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
THCA	cis	rs7772486	0.79	rs2249386	ENSG00000235652.6	RP11-545I5.3	13.58	1.13e-35	2.2e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145865475	chr6:145799409~145886585:+
THCA	cis	rs1062177	0.826	rs2915879	ENSG00000213433.5	RPLP1P6	-13.58	1.16e-35	2.25e-32	-0.55	-0.53	Preschool internalizing problems;	chr5:151767881	chr5:151765859~151766378:-
THCA	cis	rs17111396	0.865	rs7158224	ENSG00000259167.2	NMNAT1P1	13.58	1.16e-35	2.25e-32	0.67	0.53	Uric acid levels;	chr14:81052863	chr14:81032529~81033404:+
THCA	cis	rs1062177	1	rs41494545	ENSG00000213433.5	RPLP1P6	13.58	1.17e-35	2.26e-32	0.56	0.53	Preschool internalizing problems;	chr5:151855533	chr5:151765859~151766378:-
THCA	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-13.58	1.18e-35	2.28e-32	-0.96	-0.53	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
THCA	cis	rs5769707	0.632	rs6009782	ENSG00000188511.11	C22orf34	13.58	1.19e-35	2.3e-32	0.67	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49414524~49657542:-
THCA	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	13.58	1.19e-35	2.31e-32	0.62	0.53	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
THCA	cis	rs1062177	1	rs62377945	ENSG00000213433.5	RPLP1P6	-13.57	1.2e-35	2.32e-32	-0.56	-0.53	Preschool internalizing problems;	chr5:151828443	chr5:151765859~151766378:-
THCA	cis	rs11155671	0.53	rs9383577	ENSG00000268592.3	RAET1E-AS1	13.57	1.24e-35	2.4e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149886059	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs9383914	ENSG00000268592.3	RAET1E-AS1	13.57	1.24e-35	2.4e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149886098	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.517	rs9397058	ENSG00000268592.3	RAET1E-AS1	13.57	1.24e-35	2.4e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149886113	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs7768626	ENSG00000268592.3	RAET1E-AS1	13.57	1.24e-35	2.4e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149886826	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs7768665	ENSG00000268592.3	RAET1E-AS1	13.57	1.24e-35	2.4e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149886888	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs7758020	ENSG00000268592.3	RAET1E-AS1	13.57	1.24e-35	2.4e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149886975	chr6:149863494~149919507:+
THCA	cis	rs1263173	0.91	rs1263170	ENSG00000254851.1	RP11-109L13.1	-13.57	1.28e-35	2.47e-32	-0.74	-0.53	HDL cholesterol;	chr11:116807697	chr11:117135528~117138582:+
THCA	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	13.57	1.28e-35	2.48e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	13.57	1.28e-35	2.48e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
THCA	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	13.57	1.3e-35	2.5e-32	0.72	0.53	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
THCA	cis	rs7772486	0.79	rs2253654	ENSG00000235652.6	RP11-545I5.3	13.57	1.31e-35	2.53e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145878309	chr6:145799409~145886585:+
THCA	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	13.57	1.31e-35	2.54e-32	0.43	0.53	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
THCA	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-13.56	1.32e-35	2.55e-32	-0.61	-0.53	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
THCA	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-13.56	1.33e-35	2.56e-32	-0.6	-0.53	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
THCA	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-13.56	1.33e-35	2.56e-32	-0.59	-0.53	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
THCA	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	13.56	1.34e-35	2.59e-32	0.54	0.53	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
THCA	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-13.56	1.36e-35	2.63e-32	-0.78	-0.53	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
THCA	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	13.56	1.36e-35	2.63e-32	0.43	0.53	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000206090.4	AP000350.7	-13.56	1.43e-35	2.76e-32	-0.66	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23939998~23942798:+
THCA	cis	rs7786410	1	rs7786410	ENSG00000226278.1	PSPHP1	13.55	1.51e-35	2.9e-32	0.8	0.53	Age-related hearing impairment;	chr7:55854630	chr7:55764797~55773288:+
THCA	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-13.55	1.55e-35	2.99e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-13.55	1.55e-35	2.99e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
THCA	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	13.55	1.56e-35	3.01e-32	0.66	0.53	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
THCA	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-13.55	1.58e-35	3.03e-32	-0.83	-0.53	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
THCA	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-13.55	1.58e-35	3.05e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-13.55	1.58e-35	3.05e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	13.54	1.61e-35	3.1e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
THCA	cis	rs5769707	0.609	rs739247	ENSG00000188511.11	C22orf34	13.54	1.62e-35	3.11e-32	0.67	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49414524~49657542:-
THCA	cis	rs1062177	1	rs12515762	ENSG00000213433.5	RPLP1P6	-13.54	1.63e-35	3.13e-32	-0.56	-0.53	Preschool internalizing problems;	chr5:151830361	chr5:151765859~151766378:-
THCA	cis	rs6142102	0.625	rs6142067	ENSG00000276073.1	RP5-1125A11.7	-13.54	1.65e-35	3.17e-32	-0.47	-0.53	Skin pigmentation;	chr20:33968766	chr20:33985617~33988989:-
THCA	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-13.54	1.67e-35	3.21e-32	-0.64	-0.53	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
THCA	cis	rs7945705	0.719	rs2012680	ENSG00000254860.4	TMEM9B-AS1	13.54	1.67e-35	3.21e-32	0.58	0.53	Hemoglobin concentration;	chr11:8974512	chr11:8964675~8977527:+
THCA	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-13.54	1.69e-35	3.25e-32	-0.79	-0.53	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
THCA	cis	rs7772486	0.754	rs697054	ENSG00000235652.6	RP11-545I5.3	13.54	1.7e-35	3.27e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145682634	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	13.54	1.71e-35	3.29e-32	0.68	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
THCA	cis	rs12468226	0.873	rs79071680	ENSG00000273456.1	RP11-686O6.2	13.54	1.73e-35	3.31e-32	0.69	0.53	Urate levels;	chr2:202191520	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.873	rs79860867	ENSG00000273456.1	RP11-686O6.2	13.54	1.73e-35	3.31e-32	0.69	0.53	Urate levels;	chr2:202192397	chr2:202374932~202375604:-
THCA	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	13.54	1.74e-35	3.33e-32	0.69	0.53	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
THCA	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-13.54	1.74e-35	3.34e-32	-0.6	-0.53	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
THCA	cis	rs992157	0.735	rs12990082	ENSG00000261338.2	RP11-378A13.1	13.54	1.75e-35	3.35e-32	0.55	0.53	Colorectal cancer;	chr2:218237609	chr2:218255319~218257366:+
THCA	cis	rs12468226	0.873	rs59293950	ENSG00000273456.1	RP11-686O6.2	13.54	1.75e-35	3.35e-32	0.68	0.53	Urate levels;	chr2:202214069	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.873	rs12472035	ENSG00000273456.1	RP11-686O6.2	13.54	1.75e-35	3.35e-32	0.68	0.53	Urate levels;	chr2:202221970	chr2:202374932~202375604:-
THCA	cis	rs80028505	0.908	rs7762483	ENSG00000271304.1	DPRXP2	13.54	1.75e-35	3.36e-32	0.85	0.53	Foot ulcer in diabetes and neuropathy;	chr6:36088164	chr6:35989515~35990436:-
THCA	cis	rs11098499	0.754	rs878376	ENSG00000245958.5	RP11-33B1.1	-13.54	1.76e-35	3.38e-32	-0.52	-0.53	Corneal astigmatism;	chr4:119316547	chr4:119454791~119552025:+
THCA	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-13.53	1.8e-35	3.45e-32	-0.67	-0.53	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
THCA	cis	rs992157	0.71	rs10169718	ENSG00000261338.2	RP11-378A13.1	-13.53	1.8e-35	3.46e-32	-0.55	-0.53	Colorectal cancer;	chr2:218238857	chr2:218255319~218257366:+
THCA	cis	rs9309473	0.948	rs7607892	ENSG00000163016.8	ALMS1P	13.53	1.81e-35	3.47e-32	0.78	0.53	Metabolite levels;	chr2:73591580	chr2:73644919~73685576:+
THCA	cis	rs8062405	1	rs80275162	ENSG00000251417.2	RP11-1348G14.4	-13.53	1.83e-35	3.5e-32	-0.5	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28802743~28817828:+
THCA	cis	rs17826219	0.706	rs609472	ENSG00000263531.1	RP13-753N3.1	13.53	1.83e-35	3.51e-32	0.9	0.53	Body mass index;	chr17:30624409	chr17:30863921~30864940:-
THCA	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	13.53	1.86e-35	3.57e-32	0.79	0.53	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	13.53	1.87e-35	3.58e-32	0.8	0.53	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
THCA	cis	rs6142102	0.646	rs2223553	ENSG00000276073.1	RP5-1125A11.7	-13.53	1.88e-35	3.6e-32	-0.47	-0.53	Skin pigmentation;	chr20:34121638	chr20:33985617~33988989:-
THCA	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	13.53	1.88e-35	3.6e-32	0.81	0.53	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
THCA	cis	rs5769707	0.732	rs135865	ENSG00000188511.11	C22orf34	13.53	1.89e-35	3.62e-32	0.64	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49414524~49657542:-
THCA	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	13.53	1.94e-35	3.72e-32	0.68	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
THCA	cis	rs9890032	0.532	rs1808257	ENSG00000266490.1	CTD-2349P21.9	13.52	1.95e-35	3.74e-32	0.53	0.53	Hip circumference adjusted for BMI;	chr17:30712948	chr17:30792372~30792833:+
THCA	cis	rs9595066	1	rs66786230	ENSG00000227258.4	SMIM2-AS1	13.52	1.97e-35	3.77e-32	0.77	0.53	Schizophrenia;	chr13:44137489	chr13:44110451~44240517:+
THCA	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	13.52	1.97e-35	3.77e-32	0.68	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.567	rs7742692	ENSG00000268592.3	RAET1E-AS1	13.52	2.05e-35	3.92e-32	0.7	0.53	Lung cancer;	chr6:149892363	chr6:149863494~149919507:+
THCA	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	13.52	2.06e-35	3.93e-32	0.6	0.53	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
THCA	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	13.52	2.07e-35	3.96e-32	0.82	0.53	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
THCA	cis	rs7772486	0.72	rs991507	ENSG00000235652.6	RP11-545I5.3	-13.52	2.11e-35	4.02e-32	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145702473	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-13.52	2.12e-35	4.05e-32	-0.6	-0.53	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.754	rs9373476	ENSG00000235652.6	RP11-545I5.3	13.52	2.14e-35	4.08e-32	0.48	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145818605	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.727	rs11155442	ENSG00000235652.6	RP11-545I5.3	13.52	2.14e-35	4.08e-32	0.48	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145819589	chr6:145799409~145886585:+
THCA	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	13.51	2.19e-35	4.19e-32	0.5	0.53	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
THCA	cis	rs11098499	0.604	rs17051352	ENSG00000245958.5	RP11-33B1.1	-13.51	2.21e-35	4.22e-32	-0.54	-0.53	Corneal astigmatism;	chr4:119660272	chr4:119454791~119552025:+
THCA	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	13.51	2.22e-35	4.24e-32	0.68	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
THCA	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	13.51	2.27e-35	4.33e-32	0.79	0.53	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	13.51	2.27e-35	4.33e-32	0.79	0.53	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
THCA	cis	rs673078	0.607	rs61943451	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118438929	chr12:118428281~118428870:+
THCA	cis	rs673078	0.518	rs61943452	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118438990	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943454	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118439140	chr12:118428281~118428870:+
THCA	cis	rs673078	0.517	rs61943455	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118439414	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs73207566	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118439471	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs2393416	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118439968	chr12:118428281~118428870:+
THCA	cis	rs673078	0.56	rs4406856	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118440094	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs4457791	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118440144	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943456	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118440326	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17513006	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118440383	chr12:118428281~118428870:+
THCA	cis	rs673078	0.56	rs61943457	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118440487	chr12:118428281~118428870:+
THCA	cis	rs673078	0.562	rs55883417	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118440801	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs55842338	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118441259	chr12:118428281~118428870:+
THCA	cis	rs673078	0.518	rs17441251	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118441361	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17513013	ENSG00000275759.1	RP11-131L12.3	-13.51	2.27e-35	4.33e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118442070	chr12:118428281~118428870:+
THCA	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	13.51	2.28e-35	4.33e-32	0.43	0.53	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
THCA	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-13.51	2.29e-35	4.36e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
THCA	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	13.51	2.35e-35	4.47e-32	0.82	0.53	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
THCA	cis	rs11155671	0.53	rs9397398	ENSG00000268592.3	RAET1E-AS1	13.51	2.36e-35	4.5e-32	0.71	0.53	Testicular germ cell tumor;	chr6:149872467	chr6:149863494~149919507:+
THCA	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	13.5	2.38e-35	4.53e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
THCA	cis	rs992157	0.661	rs17653757	ENSG00000261338.2	RP11-378A13.1	13.5	2.42e-35	4.6e-32	0.55	0.53	Colorectal cancer;	chr2:218244641	chr2:218255319~218257366:+
THCA	cis	rs1153858	0.887	rs28569043	ENSG00000259520.4	CTD-2651B20.3	-13.5	2.43e-35	4.61e-32	-0.69	-0.53	Homoarginine levels;	chr15:45438728	chr15:45251580~45279251:-
THCA	cis	rs7772486	0.727	rs6941429	ENSG00000235652.6	RP11-545I5.3	13.5	2.47e-35	4.7e-32	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145631147	chr6:145799409~145886585:+
THCA	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	13.5	2.48e-35	4.71e-32	0.42	0.53	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
THCA	cis	rs524281	0.861	rs10896086	ENSG00000255320.1	RP11-755F10.1	13.5	2.57e-35	4.88e-32	0.77	0.53	Electroencephalogram traits;	chr11:66147293	chr11:66244840~66246239:-
THCA	cis	rs10256972	0.621	rs10951594	ENSG00000229043.2	AC091729.9	-13.5	2.59e-35	4.92e-32	-0.56	-0.53	Endometriosis;Longevity;	chr7:1048971	chr7:1160374~1165267:+
THCA	cis	rs80028505	0.908	rs7764494	ENSG00000271304.1	DPRXP2	13.49	2.64e-35	5.02e-32	0.86	0.53	Foot ulcer in diabetes and neuropathy;	chr6:36113563	chr6:35989515~35990436:-
THCA	cis	rs7772486	0.754	rs10872580	ENSG00000235652.6	RP11-545I5.3	-13.49	2.67e-35	5.06e-32	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145819145	chr6:145799409~145886585:+
THCA	cis	rs5769707	0.632	rs135871	ENSG00000188511.11	C22orf34	13.49	2.71e-35	5.14e-32	0.68	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49414524~49657542:-
THCA	cis	rs11155671	0.53	rs9397420	ENSG00000268592.3	RAET1E-AS1	-13.49	2.73e-35	5.18e-32	-0.7	-0.53	Testicular germ cell tumor;	chr6:149885645	chr6:149863494~149919507:+
THCA	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	13.49	2.75e-35	5.21e-32	0.48	0.53	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
THCA	cis	rs1061377	0.965	rs12511857	ENSG00000249207.1	RP11-360F5.1	-13.49	2.76e-35	5.23e-32	-0.66	-0.53	Uric acid levels;	chr4:39143252	chr4:39112677~39126818:-
THCA	cis	rs11155671	0.53	rs9322228	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149888173	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs7774787	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149888296	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs2342767	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149888581	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs7764376	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149889208	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs6933882	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149889666	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs6939761	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149889858	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs3823021	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149889863	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs4869763	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149890548	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs4869764	ENSG00000268592.3	RAET1E-AS1	13.49	2.76e-35	5.23e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149890692	chr6:149863494~149919507:+
THCA	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	13.49	2.76e-35	5.23e-32	0.64	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
THCA	cis	rs7772486	0.754	rs702306	ENSG00000235652.6	RP11-545I5.3	-13.49	2.79e-35	5.29e-32	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145669893	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs17441172	ENSG00000275759.1	RP11-131L12.3	13.49	2.85e-35	5.4e-32	0.75	0.53	Glucose homeostasis traits;	chr12:118430456	chr12:118428281~118428870:+
THCA	cis	rs2111504	0.583	rs1008425	ENSG00000267213.4	AC007773.2	13.49	2.88e-35	5.46e-32	0.49	0.53	Bipolar disorder;	chr19:32361239	chr19:32390050~32405560:-
THCA	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	13.48	2.97e-35	5.62e-32	0.64	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
THCA	cis	rs8040855	0.86	rs7172266	ENSG00000259295.5	CSPG4P12	-13.48	3.02e-35	5.71e-32	-0.77	-0.53	Bulimia nervosa;	chr15:85172982	chr15:85191438~85213905:+
THCA	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-13.48	3.04e-35	5.75e-32	-0.75	-0.53	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-13.48	3.04e-35	5.75e-32	-0.75	-0.53	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
THCA	cis	rs12468226	1	rs2350809	ENSG00000273456.1	RP11-686O6.2	13.48	3.04e-35	5.75e-32	0.65	0.53	Urate levels;	chr2:202464210	chr2:202374932~202375604:-
THCA	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-13.48	3.05e-35	5.77e-32	-0.77	-0.53	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
THCA	cis	rs11098499	1	rs11098500	ENSG00000245958.5	RP11-33B1.1	-13.48	3.07e-35	5.8e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119298084	chr4:119454791~119552025:+
THCA	cis	rs524281	0.861	rs10896080	ENSG00000255320.1	RP11-755F10.1	13.48	3.08e-35	5.82e-32	0.76	0.53	Electroencephalogram traits;	chr11:66109325	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs3825067	ENSG00000255320.1	RP11-755F10.1	-13.48	3.08e-35	5.82e-32	-0.76	-0.53	Electroencephalogram traits;	chr11:66110948	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs11227415	ENSG00000255320.1	RP11-755F10.1	-13.48	3.08e-35	5.82e-32	-0.76	-0.53	Electroencephalogram traits;	chr11:66117988	chr11:66244840~66246239:-
THCA	cis	rs9322193	0.504	rs7771014	ENSG00000268592.3	RAET1E-AS1	13.48	3.11e-35	5.89e-32	0.71	0.53	Lung cancer;	chr6:149884310	chr6:149863494~149919507:+
THCA	cis	rs524281	0.861	rs11607393	ENSG00000255320.1	RP11-755F10.1	13.48	3.13e-35	5.92e-32	0.76	0.53	Electroencephalogram traits;	chr11:66107678	chr11:66244840~66246239:-
THCA	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	13.48	3.13e-35	5.92e-32	0.79	0.53	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
THCA	cis	rs12468226	1	rs112306637	ENSG00000273456.1	RP11-686O6.2	13.48	3.18e-35	6e-32	0.68	0.53	Urate levels;	chr2:202334195	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs111252524	ENSG00000273456.1	RP11-686O6.2	13.48	3.18e-35	6e-32	0.68	0.53	Urate levels;	chr2:202334465	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs112753638	ENSG00000273456.1	RP11-686O6.2	13.48	3.18e-35	6e-32	0.68	0.53	Urate levels;	chr2:202334496	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.935	rs113188021	ENSG00000273456.1	RP11-686O6.2	13.48	3.18e-35	6e-32	0.68	0.53	Urate levels;	chr2:202336237	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs6731027	ENSG00000273456.1	RP11-686O6.2	13.48	3.18e-35	6e-32	0.68	0.53	Urate levels;	chr2:202337443	chr2:202374932~202375604:-
THCA	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-13.47	3.2e-35	6.06e-32	-0.56	-0.53	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
THCA	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	13.47	3.23e-35	6.1e-32	0.8	0.53	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	13.47	3.23e-35	6.11e-32	0.67	0.53	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
THCA	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-13.47	3.32e-35	6.26e-32	-0.69	-0.53	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
THCA	cis	rs11155671	0.53	rs7742993	ENSG00000268592.3	RAET1E-AS1	13.47	3.33e-35	6.28e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149883959	chr6:149863494~149919507:+
THCA	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-13.47	3.36e-35	6.34e-32	-0.59	-0.53	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
THCA	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-13.47	3.43e-35	6.46e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
THCA	cis	rs7617773	0.502	rs6804828	ENSG00000229759.1	MRPS18AP1	13.47	3.43e-35	6.48e-32	0.63	0.53	Coronary artery disease;	chr3:48352066	chr3:48256350~48256938:-
THCA	cis	rs524281	0.861	rs7943911	ENSG00000255320.1	RP11-755F10.1	13.47	3.45e-35	6.51e-32	0.76	0.53	Electroencephalogram traits;	chr11:66175583	chr11:66244840~66246239:-
THCA	cis	rs7208859	0.673	rs450585	ENSG00000263531.1	RP13-753N3.1	13.47	3.48e-35	6.57e-32	0.92	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30863921~30864940:-
THCA	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	13.47	3.49e-35	6.58e-32	0.59	0.53	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
THCA	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	13.47	3.5e-35	6.59e-32	0.75	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
THCA	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-13.47	3.5e-35	6.6e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
THCA	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-13.46	3.51e-35	6.62e-32	-0.66	-0.53	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
THCA	cis	rs1062177	0.826	rs2915822	ENSG00000213433.5	RPLP1P6	13.46	3.52e-35	6.63e-32	0.55	0.53	Preschool internalizing problems;	chr5:151751340	chr5:151765859~151766378:-
THCA	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	13.46	3.69e-35	6.96e-32	0.79	0.53	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	13.46	3.69e-35	6.96e-32	0.79	0.53	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	13.46	3.69e-35	6.96e-32	0.79	0.53	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	13.46	3.69e-35	6.96e-32	0.79	0.53	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
THCA	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-13.46	3.7e-35	6.98e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
THCA	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-13.46	3.71e-35	6.99e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
THCA	cis	rs8040855	0.756	rs12909477	ENSG00000259295.5	CSPG4P12	-13.46	3.77e-35	7.08e-32	-0.8	-0.53	Bulimia nervosa;	chr15:85146644	chr15:85191438~85213905:+
THCA	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-13.46	3.78e-35	7.11e-32	-0.42	-0.53	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
THCA	cis	rs673078	0.607	rs8467	ENSG00000275759.1	RP11-131L12.3	-13.46	3.79e-35	7.12e-32	-0.74	-0.53	Glucose homeostasis traits;	chr12:118417479	chr12:118428281~118428870:+
THCA	cis	rs7945705	0.714	rs2653570	ENSG00000254860.4	TMEM9B-AS1	13.46	3.81e-35	7.16e-32	0.58	0.53	Hemoglobin concentration;	chr11:8966276	chr11:8964675~8977527:+
THCA	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	13.46	3.84e-35	7.21e-32	0.53	0.53	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
THCA	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	13.45	3.88e-35	7.29e-32	0.79	0.53	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
THCA	cis	rs11155671	0.53	rs7757984	ENSG00000268592.3	RAET1E-AS1	13.45	3.97e-35	7.45e-32	0.7	0.53	Testicular germ cell tumor;	chr6:149887515	chr6:149863494~149919507:+
THCA	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-13.45	3.98e-35	7.47e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
THCA	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	13.45	3.99e-35	7.48e-32	0.81	0.53	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
THCA	cis	rs6142102	0.517	rs6059580	ENSG00000276073.1	RP5-1125A11.7	-13.45	4.07e-35	7.64e-32	-0.46	-0.53	Skin pigmentation;	chr20:33940067	chr20:33985617~33988989:-
THCA	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	13.45	4.09e-35	7.68e-32	0.8	0.53	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
THCA	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-13.45	4.14e-35	7.77e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
THCA	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-13.45	4.16e-35	7.79e-32	-0.6	-0.53	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
THCA	cis	rs7772486	0.754	rs9390358	ENSG00000235652.6	RP11-545I5.3	13.45	4.19e-35	7.84e-32	0.48	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145824542	chr6:145799409~145886585:+
THCA	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	13.45	4.19e-35	7.85e-32	0.54	0.53	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
THCA	cis	rs11098499	0.909	rs28555550	ENSG00000245958.5	RP11-33B1.1	-13.45	4.22e-35	7.9e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119289885	chr4:119454791~119552025:+
THCA	cis	rs11098499	1	rs28419773	ENSG00000245958.5	RP11-33B1.1	-13.45	4.22e-35	7.9e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119289906	chr4:119454791~119552025:+
THCA	cis	rs11098499	1	rs11726229	ENSG00000245958.5	RP11-33B1.1	-13.45	4.22e-35	7.9e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119290425	chr4:119454791~119552025:+
THCA	cis	rs7945705	0.747	rs10840158	ENSG00000254860.4	TMEM9B-AS1	13.44	4.31e-35	8.07e-32	0.58	0.53	Hemoglobin concentration;	chr11:8999350	chr11:8964675~8977527:+
THCA	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-13.44	4.36e-35	8.16e-32	-0.66	-0.53	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
THCA	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	13.44	4.4e-35	8.24e-32	0.79	0.53	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
THCA	cis	rs7208859	0.673	rs216410	ENSG00000263531.1	RP13-753N3.1	-13.44	4.44e-35	8.32e-32	-0.93	-0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576813	chr17:30863921~30864940:-
THCA	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	13.44	4.5e-35	8.42e-32	0.79	0.53	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
THCA	cis	rs11098499	0.955	rs56386062	ENSG00000245958.5	RP11-33B1.1	-13.44	4.51e-35	8.44e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119233980	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs4145951	ENSG00000245958.5	RP11-33B1.1	-13.44	4.51e-35	8.44e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119234662	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs35916640	ENSG00000245958.5	RP11-33B1.1	-13.44	4.51e-35	8.44e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119234697	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs13114751	ENSG00000245958.5	RP11-33B1.1	-13.44	4.51e-35	8.44e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119235462	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.913	rs35271032	ENSG00000245958.5	RP11-33B1.1	-13.44	4.51e-35	8.44e-32	-0.51	-0.53	Corneal astigmatism;	chr4:119235504	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.754	rs864148	ENSG00000235652.6	RP11-545I5.3	-13.44	4.6e-35	8.6e-32	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145655539	chr6:145799409~145886585:+
THCA	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-13.44	4.6e-35	8.61e-32	-0.69	-0.53	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-13.44	4.6e-35	8.61e-32	-0.69	-0.53	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
THCA	cis	rs673078	0.562	rs56347775	ENSG00000275759.1	RP11-131L12.3	-13.44	4.63e-35	8.66e-32	-0.76	-0.53	Glucose homeostasis traits;	chr12:118438002	chr12:118428281~118428870:+
THCA	cis	rs8062405	1	rs7498555	ENSG00000251417.2	RP11-1348G14.4	-13.44	4.64e-35	8.67e-32	-0.51	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28802743~28817828:+
THCA	cis	rs9481169	0.85	rs35815577	ENSG00000255389.1	C6orf3	-13.44	4.69e-35	8.77e-32	-1.01	-0.53	Inflammatory skin disease;	chr6:111603527	chr6:111599875~111602295:+
THCA	cis	rs524281	0.861	rs11227411	ENSG00000255320.1	RP11-755F10.1	13.43	4.7e-35	8.79e-32	0.76	0.53	Electroencephalogram traits;	chr11:66112007	chr11:66244840~66246239:-
THCA	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	13.43	4.75e-35	8.88e-32	0.92	0.53	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
THCA	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-13.43	4.78e-35	8.93e-32	-0.65	-0.53	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
THCA	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	13.43	4.8e-35	8.96e-32	0.42	0.53	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
THCA	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-13.43	4.8e-35	8.97e-32	-0.55	-0.53	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
THCA	cis	rs8062405	0.895	rs62036658	ENSG00000251417.2	RP11-1348G14.4	-13.43	4.87e-35	9.09e-32	-0.51	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28802743~28817828:+
THCA	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	13.43	4.89e-35	9.12e-32	0.59	0.53	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
THCA	cis	rs8062405	0.789	rs151174	ENSG00000259982.1	CDC37P1	13.43	4.94e-35	9.22e-32	0.64	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28496748	chr16:28700294~28701540:-
THCA	cis	rs524281	0.861	rs7124165	ENSG00000255320.1	RP11-755F10.1	13.43	5e-35	9.33e-32	0.77	0.53	Electroencephalogram traits;	chr11:66133747	chr11:66244840~66246239:-
THCA	cis	rs732716	0.853	rs12459922	ENSG00000267769.1	CTB-50L17.9	-13.43	5.04e-35	9.41e-32	-0.66	-0.53	Mean corpuscular volume;	chr19:4455865	chr19:4454014~4455286:+
THCA	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-13.43	5.06e-35	9.43e-32	-0.64	-0.53	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
THCA	cis	rs6538678	0.824	rs4762631	ENSG00000258343.1	RP11-536G4.2	-13.43	5.11e-35	9.52e-32	-0.83	-0.53	Lupus nephritis in systemic lupus erythematosus;	chr12:95855698	chr12:95795345~95858839:-
THCA	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-13.43	5.12e-35	9.53e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-13.43	5.12e-35	9.53e-32	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
THCA	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-13.43	5.12e-35	9.53e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-13.43	5.12e-35	9.53e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-13.43	5.12e-35	9.53e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-13.43	5.12e-35	9.53e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-13.43	5.12e-35	9.53e-32	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
THCA	cis	rs2658782	0.694	rs3019221	ENSG00000279684.1	RP11-755E23.2	-13.43	5.13e-35	9.55e-32	-0.9	-0.53	Pulmonary function decline;	chr11:93346534	chr11:93286629~93288903:-
THCA	cis	rs5769707	0.706	rs763128	ENSG00000188511.11	C22orf34	13.43	5.15e-35	9.58e-32	0.67	0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49414524~49657542:-
THCA	cis	rs80028505	1	rs6936327	ENSG00000271304.1	DPRXP2	13.42	5.21e-35	9.7e-32	0.85	0.53	Foot ulcer in diabetes and neuropathy;	chr6:36102098	chr6:35989515~35990436:-
THCA	cis	rs80028505	0.908	rs16884857	ENSG00000271304.1	DPRXP2	13.42	5.21e-35	9.7e-32	0.85	0.53	Foot ulcer in diabetes and neuropathy;	chr6:36102450	chr6:35989515~35990436:-
THCA	cis	rs992157	0.735	rs13392177	ENSG00000261338.2	RP11-378A13.1	-13.42	5.3e-35	9.85e-32	-0.55	-0.53	Colorectal cancer;	chr2:218248233	chr2:218255319~218257366:+
THCA	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	13.42	5.35e-35	9.95e-32	0.61	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
THCA	cis	rs524281	0.861	rs7120326	ENSG00000255320.1	RP11-755F10.1	13.42	5.35e-35	9.96e-32	0.76	0.53	Electroencephalogram traits;	chr11:66081785	chr11:66244840~66246239:-
THCA	cis	rs11155671	0.53	rs7758033	ENSG00000268592.3	RAET1E-AS1	13.42	5.44e-35	1.01e-31	0.7	0.53	Testicular germ cell tumor;	chr6:149886999	chr6:149863494~149919507:+
THCA	cis	rs6683071	0.501	rs3002146	ENSG00000272750.1	RP11-378J18.8	13.42	5.47e-35	1.02e-31	0.63	0.53	Cognitive performance;	chr1:222636066	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.553	rs1391557	ENSG00000272750.1	RP11-378J18.8	13.42	5.47e-35	1.02e-31	0.63	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222658867~222661512:-
THCA	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-13.42	5.52e-35	1.03e-31	-0.64	-0.53	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
THCA	cis	rs524281	0.861	rs3862386	ENSG00000255320.1	RP11-755F10.1	13.42	5.6e-35	1.04e-31	0.77	0.53	Electroencephalogram traits;	chr11:66126953	chr11:66244840~66246239:-
THCA	cis	rs17111396	0.826	rs10138781	ENSG00000259167.2	NMNAT1P1	13.42	5.66e-35	1.05e-31	0.67	0.53	Uric acid levels;	chr14:81053518	chr14:81032529~81033404:+
THCA	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-13.41	5.72e-35	1.06e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.764	rs7762562	ENSG00000235652.6	RP11-545I5.3	13.41	5.72e-35	1.06e-31	0.48	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145837858	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-13.41	5.77e-35	1.07e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.789	rs9991166	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119316696	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.708	rs10005237	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119316742	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs878372	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119317625	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs10213267	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119317919	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs10212775	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119318089	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs11732087	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119318676	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs2964	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119318976	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs1511025	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119319083	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12510269	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119320491	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12506610	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119320504	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.743	rs10003567	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119320519	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs10006259	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119320990	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs28652763	ENSG00000245958.5	RP11-33B1.1	-13.41	5.78e-35	1.07e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119321157	chr4:119454791~119552025:+
THCA	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	13.41	5.83e-35	1.08e-31	0.48	0.53	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
THCA	cis	rs11098499	0.955	rs7685268	ENSG00000245958.5	RP11-33B1.1	-13.41	5.83e-35	1.08e-31	-0.5	-0.53	Corneal astigmatism;	chr4:119241033	chr4:119454791~119552025:+
THCA	cis	rs12468226	1	rs6739198	ENSG00000273456.1	RP11-686O6.2	13.41	5.84e-35	1.08e-31	0.62	0.53	Urate levels;	chr2:202492273	chr2:202374932~202375604:-
THCA	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-13.41	5.85e-35	1.08e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
THCA	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-13.41	5.87e-35	1.09e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
THCA	cis	rs6142102	0.625	rs6141436	ENSG00000276073.1	RP5-1125A11.7	-13.41	5.89e-35	1.09e-31	-0.47	-0.53	Skin pigmentation;	chr20:33966765	chr20:33985617~33988989:-
THCA	cis	rs7772486	0.754	rs4896839	ENSG00000235652.6	RP11-545I5.3	-13.41	5.89e-35	1.09e-31	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145698553	chr6:145799409~145886585:+
THCA	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-13.41	5.99e-35	1.11e-31	-0.66	-0.53	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
THCA	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	13.41	6e-35	1.11e-31	0.63	0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
THCA	cis	rs1153858	0.945	rs1974981	ENSG00000259520.4	CTD-2651B20.3	13.41	6.07e-35	1.12e-31	0.69	0.53	Homoarginine levels;	chr15:45436925	chr15:45251580~45279251:-
THCA	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	13.41	6.08e-35	1.13e-31	0.82	0.53	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
THCA	cis	rs11155671	0.53	rs9968871	ENSG00000268592.3	RAET1E-AS1	13.41	6.11e-35	1.13e-31	0.71	0.53	Testicular germ cell tumor;	chr6:149888060	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs9969044	ENSG00000268592.3	RAET1E-AS1	13.41	6.11e-35	1.13e-31	0.71	0.53	Testicular germ cell tumor;	chr6:149888068	chr6:149863494~149919507:+
THCA	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-13.41	6.22e-35	1.15e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
THCA	cis	rs7772486	0.719	rs702307	ENSG00000235652.6	RP11-545I5.3	-13.41	6.23e-35	1.15e-31	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145672318	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-13.41	6.23e-35	1.15e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-13.41	6.29e-35	1.16e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	13.4	6.32e-35	1.17e-31	0.5	0.53	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.79	rs2485632	ENSG00000235652.6	RP11-545I5.3	13.4	6.33e-35	1.17e-31	0.48	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145872092	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2253307	ENSG00000235652.6	RP11-545I5.3	13.4	6.33e-35	1.17e-31	0.48	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145875045	chr6:145799409~145886585:+
THCA	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-13.4	6.34e-35	1.17e-31	-0.65	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
THCA	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-13.4	6.4e-35	1.18e-31	-0.58	-0.53	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
THCA	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	13.4	6.41e-35	1.18e-31	0.48	0.53	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
THCA	cis	rs8062405	1	rs12443881	ENSG00000251417.2	RP11-1348G14.4	-13.4	6.49e-35	1.2e-31	-0.51	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28802743~28817828:+
THCA	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-13.4	6.5e-35	1.2e-31	-0.42	-0.53	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
THCA	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-13.4	6.55e-35	1.21e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-13.4	6.55e-35	1.21e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-13.4	6.55e-35	1.21e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
THCA	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	13.4	6.56e-35	1.21e-31	0.68	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
THCA	cis	rs732716	0.853	rs1127888	ENSG00000267769.1	CTB-50L17.9	-13.4	6.63e-35	1.23e-31	-0.66	-0.53	Mean corpuscular volume;	chr19:4454086	chr19:4454014~4455286:+
THCA	cis	rs6142102	0.625	rs4911384	ENSG00000276073.1	RP5-1125A11.7	-13.4	6.66e-35	1.23e-31	-0.47	-0.53	Skin pigmentation;	chr20:33968001	chr20:33985617~33988989:-
THCA	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-13.4	6.7e-35	1.24e-31	-0.79	-0.53	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
THCA	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	13.4	6.77e-35	1.25e-31	0.79	0.53	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
THCA	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-13.4	6.79e-35	1.25e-31	-0.64	-0.53	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
THCA	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	13.4	6.8e-35	1.26e-31	0.49	0.53	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
THCA	cis	rs638893	0.578	rs582200	ENSG00000278376.1	RP11-158I9.8	13.4	6.82e-35	1.26e-31	0.63	0.53	Vitiligo;	chr11:118798199	chr11:118791254~118793137:+
THCA	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	13.4	6.83e-35	1.26e-31	0.6	0.53	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
THCA	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	13.4	6.86e-35	1.27e-31	0.67	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
THCA	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	13.4	6.88e-35	1.27e-31	0.8	0.53	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
THCA	cis	rs3002131	0.688	rs2936040	ENSG00000225265.1	TAF1A-AS1	-13.4	6.91e-35	1.28e-31	-0.73	-0.53	Interleukin-10 levels;	chr1:222590319	chr1:222589825~222593032:+
THCA	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	13.4	6.92e-35	1.28e-31	0.49	0.53	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
THCA	cis	rs524281	0.648	rs10896089	ENSG00000255320.1	RP11-755F10.1	13.39	6.94e-35	1.28e-31	0.75	0.53	Electroencephalogram traits;	chr11:66168821	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs10896087	ENSG00000255320.1	RP11-755F10.1	13.39	6.95e-35	1.28e-31	0.75	0.53	Electroencephalogram traits;	chr11:66157078	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs4013917	ENSG00000255320.1	RP11-755F10.1	13.39	6.95e-35	1.28e-31	0.75	0.53	Electroencephalogram traits;	chr11:66158714	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.754	rs938056	ENSG00000245958.5	RP11-33B1.1	-13.39	7.05e-35	1.3e-31	-0.52	-0.53	Corneal astigmatism;	chr4:119316298	chr4:119454791~119552025:+
THCA	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-13.39	7.11e-35	1.31e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-13.39	7.11e-35	1.31e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-13.39	7.11e-35	1.31e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-13.39	7.11e-35	1.31e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-13.39	7.11e-35	1.31e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
THCA	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-13.39	7.22e-35	1.33e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
THCA	cis	rs6142102	0.625	rs1883707	ENSG00000276073.1	RP5-1125A11.7	13.39	7.27e-35	1.34e-31	0.47	0.53	Skin pigmentation;	chr20:33964781	chr20:33985617~33988989:-
THCA	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-13.39	7.3e-35	1.34e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-13.39	7.3e-35	1.34e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
THCA	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-13.39	7.32e-35	1.35e-31	-0.9	-0.53	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
THCA	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-13.39	7.33e-35	1.35e-31	-0.63	-0.53	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
THCA	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	13.39	7.39e-35	1.36e-31	0.68	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
THCA	cis	rs6504950	0.72	rs9910653	ENSG00000275710.1	RP11-257O5.4	13.39	7.41e-35	1.36e-31	0.65	0.53	Breast cancer;	chr17:54914907	chr17:54964474~54964679:+
THCA	cis	rs9525916	1	rs9525916	ENSG00000227258.4	SMIM2-AS1	13.39	7.48e-35	1.38e-31	0.54	0.53	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44128733	chr13:44110451~44240517:+
THCA	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-13.39	7.57e-35	1.39e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-13.38	7.68e-35	1.41e-31	-0.59	-0.53	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
THCA	cis	rs524281	0.773	rs11227413	ENSG00000255320.1	RP11-755F10.1	13.38	7.74e-35	1.42e-31	0.76	0.53	Electroencephalogram traits;	chr11:66116225	chr11:66244840~66246239:-
THCA	cis	rs7772486	0.754	rs2064185	ENSG00000235652.6	RP11-545I5.3	-13.38	7.77e-35	1.43e-31	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145745678	chr6:145799409~145886585:+
THCA	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	13.38	7.77e-35	1.43e-31	0.78	0.53	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
THCA	cis	rs11098499	0.955	rs6815725	ENSG00000245958.5	RP11-33B1.1	-13.38	7.79e-35	1.43e-31	-0.5	-0.53	Corneal astigmatism;	chr4:119237255	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs1551	ENSG00000245958.5	RP11-33B1.1	-13.38	7.79e-35	1.43e-31	-0.5	-0.53	Corneal astigmatism;	chr4:119237345	chr4:119454791~119552025:+
THCA	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	13.38	7.8e-35	1.43e-31	0.54	0.53	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
THCA	cis	rs6519955	0.897	rs4073601	ENSG00000231711.2	LINC00899	13.38	7.82e-35	1.44e-31	0.44	0.53	Dupuytren's disease;	chr22:46038806	chr22:46039907~46044853:-
THCA	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	13.38	7.84e-35	1.44e-31	0.59	0.53	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
THCA	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-13.38	7.85e-35	1.44e-31	-0.68	-0.53	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
THCA	cis	rs524281	0.817	rs10791849	ENSG00000255320.1	RP11-755F10.1	13.38	7.99e-35	1.47e-31	0.77	0.53	Electroencephalogram traits;	chr11:66123126	chr11:66244840~66246239:-
THCA	cis	rs673078	0.607	rs73207578	ENSG00000275759.1	RP11-131L12.3	-13.38	8.03e-35	1.48e-31	-0.75	-0.53	Glucose homeostasis traits;	chr12:118447080	chr12:118428281~118428870:+
THCA	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	13.38	8.07e-35	1.48e-31	0.86	0.53	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
THCA	cis	rs7772486	0.72	rs6901888	ENSG00000235652.6	RP11-545I5.3	-13.38	8.12e-35	1.49e-31	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145702008	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs4896841	ENSG00000235652.6	RP11-545I5.3	-13.38	8.12e-35	1.49e-31	-0.49	-0.53	Lobe attachment (rater-scored or self-reported);	chr6:145720386	chr6:145799409~145886585:+
THCA	cis	rs992157	0.687	rs35271699	ENSG00000261338.2	RP11-378A13.1	13.38	8.13e-35	1.49e-31	0.55	0.53	Colorectal cancer;	chr2:218252759	chr2:218255319~218257366:+
THCA	cis	rs1062177	1	rs12654573	ENSG00000213433.5	RPLP1P6	-13.38	8.17e-35	1.5e-31	-0.54	-0.53	Preschool internalizing problems;	chr5:151827912	chr5:151765859~151766378:-
THCA	cis	rs524281	0.861	rs10896077	ENSG00000255320.1	RP11-755F10.1	13.38	8.37e-35	1.54e-31	0.75	0.53	Electroencephalogram traits;	chr11:66084262	chr11:66244840~66246239:-
THCA	cis	rs524281	0.817	rs7115081	ENSG00000255320.1	RP11-755F10.1	13.38	8.37e-35	1.54e-31	0.75	0.53	Electroencephalogram traits;	chr11:66086070	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs11227403	ENSG00000255320.1	RP11-755F10.1	13.38	8.37e-35	1.54e-31	0.75	0.53	Electroencephalogram traits;	chr11:66090957	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs7935336	ENSG00000255320.1	RP11-755F10.1	13.38	8.37e-35	1.54e-31	0.75	0.53	Electroencephalogram traits;	chr11:66097854	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs11227409	ENSG00000255320.1	RP11-755F10.1	13.38	8.37e-35	1.54e-31	0.75	0.53	Electroencephalogram traits;	chr11:66103467	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs11227410	ENSG00000255320.1	RP11-755F10.1	13.38	8.37e-35	1.54e-31	0.75	0.53	Electroencephalogram traits;	chr11:66105925	chr11:66244840~66246239:-
THCA	cis	rs7772486	0.754	rs1415747	ENSG00000235652.6	RP11-545I5.3	13.38	8.37e-35	1.54e-31	0.49	0.53	Lobe attachment (rater-scored or self-reported);	chr6:145756113	chr6:145799409~145886585:+
THCA	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-13.38	8.41e-35	1.54e-31	-0.68	-0.53	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
THCA	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	13.38	8.42e-35	1.55e-31	0.79	0.53	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
THCA	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	13.37	8.44e-35	1.55e-31	0.51	0.53	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
THCA	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-13.37	8.47e-35	1.55e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-13.37	8.47e-35	1.55e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-13.37	8.47e-35	1.55e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-13.37	8.47e-35	1.55e-31	-0.6	-0.53	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
THCA	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	13.37	8.5e-35	1.56e-31	0.63	0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
THCA	cis	rs1062177	0.724	rs2964590	ENSG00000213433.5	RPLP1P6	13.37	8.5e-35	1.56e-31	0.55	0.53	Preschool internalizing problems;	chr5:151738585	chr5:151765859~151766378:-
THCA	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-13.37	8.5e-35	1.56e-31	-0.75	-0.53	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-13.37	8.5e-35	1.56e-31	-0.75	-0.53	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-13.37	8.5e-35	1.56e-31	-0.75	-0.53	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
THCA	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-13.37	8.5e-35	1.56e-31	-0.75	-0.53	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
THCA	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-13.37	8.71e-35	1.59e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
THCA	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-13.37	8.74e-35	1.6e-31	-0.67	-0.52	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
THCA	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-13.37	8.75e-35	1.6e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
THCA	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	13.37	8.87e-35	1.62e-31	0.42	0.52	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
THCA	cis	rs8062405	1	rs72793811	ENSG00000251417.2	RP11-1348G14.4	-13.37	9e-35	1.65e-31	-0.51	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs72793812	ENSG00000251417.2	RP11-1348G14.4	-13.37	9e-35	1.65e-31	-0.51	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28802743~28817828:+
THCA	cis	rs11098499	0.754	rs9991959	ENSG00000245958.5	RP11-33B1.1	13.37	9.04e-35	1.65e-31	0.51	0.52	Corneal astigmatism;	chr4:119332618	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12711071	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119319779	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs1546503	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119320012	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.708	rs1546506	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119320085	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs28643450	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119324087	chr4:119454791~119552025:+
THCA	cis	rs10028773	0.7	rs7671797	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Educational attainment;	chr4:119327002	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs7672372	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119327251	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs7672594	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119327388	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs7672778	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119327430	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs2036860	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119327779	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs2036857	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119328085	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs2036856	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119328133	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs4443261	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119328146	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12513083	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119328457	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12509621	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119328505	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs1511017	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119329650	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.789	rs12498994	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119329663	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12507565	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119329966	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.826	rs12511640	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119330093	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs1980026	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119330488	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.722	rs28713555	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119330840	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.743	rs11098501	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119330862	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs11098502	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119330908	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.708	rs11732686	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119331175	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs11724409	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119331206	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.789	rs1980024	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119331892	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs34425882	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119332022	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs4107728	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119332755	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs17049949	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119334135	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs7689729	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119335037	chr4:119454791~119552025:+
THCA	cis	rs10028773	0.7	rs7690338	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Educational attainment;	chr4:119335313	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.865	rs3956464	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119335609	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.619	rs28502463	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119335868	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.648	rs2002047	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119336073	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.775	rs2002049	ENSG00000245958.5	RP11-33B1.1	-13.37	9.04e-35	1.65e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119336262	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.754	rs4896838	ENSG00000235652.6	RP11-545I5.3	-13.37	9.11e-35	1.66e-31	-0.49	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145694315	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-13.37	9.28e-35	1.69e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-13.37	9.28e-35	1.69e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
THCA	cis	rs11098499	1	rs3749591	ENSG00000245958.5	RP11-33B1.1	-13.36	9.29e-35	1.69e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119292875	chr4:119454791~119552025:+
THCA	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	13.36	9.36e-35	1.71e-31	0.79	0.52	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
THCA	cis	rs7945705	0.747	rs2742480	ENSG00000254860.4	TMEM9B-AS1	13.36	9.43e-35	1.72e-31	0.58	0.52	Hemoglobin concentration;	chr11:8971583	chr11:8964675~8977527:+
THCA	cis	rs8040855	0.659	rs8037886	ENSG00000259295.5	CSPG4P12	-13.36	9.45e-35	1.72e-31	-0.79	-0.52	Bulimia nervosa;	chr15:85143533	chr15:85191438~85213905:+
THCA	cis	rs992157	0.735	rs13388024	ENSG00000261338.2	RP11-378A13.1	13.36	9.45e-35	1.72e-31	0.54	0.52	Colorectal cancer;	chr2:218233050	chr2:218255319~218257366:+
THCA	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-13.36	9.49e-35	1.73e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
THCA	cis	rs8062405	1	rs62036616	ENSG00000251417.2	RP11-1348G14.4	-13.36	9.51e-35	1.73e-31	-0.51	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28802743~28817828:+
THCA	cis	rs7772486	0.754	rs9390356	ENSG00000235652.6	RP11-545I5.3	-13.36	9.56e-35	1.74e-31	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145797847	chr6:145799409~145886585:+
THCA	cis	rs6538678	0.824	rs2887026	ENSG00000258343.1	RP11-536G4.2	-13.36	9.57e-35	1.74e-31	-0.83	-0.52	Lupus nephritis in systemic lupus erythematosus;	chr12:95854713	chr12:95795345~95858839:-
THCA	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-13.36	9.6e-35	1.75e-31	-0.6	-0.52	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-13.36	9.61e-35	1.75e-31	-0.59	-0.52	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
THCA	cis	rs7772486	0.79	rs2253768	ENSG00000235652.6	RP11-545I5.3	13.36	9.62e-35	1.75e-31	0.48	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145878786	chr6:145799409~145886585:+
THCA	cis	rs2455601	1	rs11042108	ENSG00000254860.4	TMEM9B-AS1	13.36	9.66e-35	1.76e-31	0.81	0.52	Schizophrenia;	chr11:8884474	chr11:8964675~8977527:+
THCA	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-13.36	9.66e-35	1.76e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-13.36	9.66e-35	1.76e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-13.36	9.66e-35	1.76e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
THCA	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	13.36	9.76e-35	1.78e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
THCA	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	13.36	1e-34	1.82e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
THCA	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	13.36	1e-34	1.82e-31	0.67	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
THCA	cis	rs7429990	0.896	rs7427648	ENSG00000229759.1	MRPS18AP1	-13.36	1.01e-34	1.84e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48116749	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	13.36	1.02e-34	1.85e-31	0.91	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
THCA	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-13.35	1.02e-34	1.86e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
THCA	cis	rs11155671	0.53	rs7756850	ENSG00000268592.3	RAET1E-AS1	13.35	1.03e-34	1.87e-31	0.69	0.52	Testicular germ cell tumor;	chr6:149891460	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs9371542	ENSG00000268592.3	RAET1E-AS1	13.35	1.03e-34	1.87e-31	0.69	0.52	Testicular germ cell tumor;	chr6:149891949	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.567	rs7747457	ENSG00000268592.3	RAET1E-AS1	13.35	1.03e-34	1.87e-31	0.69	0.52	Lung cancer;	chr6:149892366	chr6:149863494~149919507:+
THCA	cis	rs11155671	0.53	rs9371223	ENSG00000268592.3	RAET1E-AS1	13.35	1.03e-34	1.87e-31	0.69	0.52	Testicular germ cell tumor;	chr6:149893670	chr6:149863494~149919507:+
THCA	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-13.35	1.04e-34	1.89e-31	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-13.35	1.04e-34	1.89e-31	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-13.35	1.04e-34	1.89e-31	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
THCA	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-13.35	1.09e-34	1.98e-31	-0.6	-0.52	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
THCA	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	13.35	1.09e-34	1.98e-31	0.63	0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
THCA	cis	rs9309473	0.95	rs73947808	ENSG00000163016.8	ALMS1P	13.35	1.11e-34	2.01e-31	0.8	0.52	Metabolite levels;	chr2:73494123	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	13.35	1.11e-34	2.01e-31	0.78	0.52	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
THCA	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-13.35	1.11e-34	2.02e-31	-0.68	-0.52	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
THCA	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-13.35	1.12e-34	2.03e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
THCA	cis	rs6142102	0.517	rs6142046	ENSG00000276073.1	RP5-1125A11.7	-13.35	1.12e-34	2.04e-31	-0.46	-0.52	Skin pigmentation;	chr20:33926255	chr20:33985617~33988989:-
THCA	cis	rs673078	0.607	rs2393418	ENSG00000275759.1	RP11-131L12.3	-13.34	1.13e-34	2.05e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118445995	chr12:118428281~118428870:+
THCA	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-13.34	1.14e-34	2.07e-31	-0.59	-0.52	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
THCA	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	13.34	1.15e-34	2.09e-31	0.57	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
THCA	cis	rs7772486	0.701	rs7772717	ENSG00000235652.6	RP11-545I5.3	13.34	1.15e-34	2.09e-31	0.49	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145633718	chr6:145799409~145886585:+
THCA	cis	rs11098499	1	rs12506395	ENSG00000245958.5	RP11-33B1.1	-13.34	1.16e-34	2.11e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119263939	chr4:119454791~119552025:+
THCA	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	13.34	1.18e-34	2.14e-31	0.91	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	13.34	1.18e-34	2.14e-31	0.91	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
THCA	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-13.34	1.2e-34	2.18e-31	-0.69	-0.52	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
THCA	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	13.34	1.22e-34	2.21e-31	0.68	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
THCA	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-13.34	1.22e-34	2.21e-31	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
THCA	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-13.34	1.23e-34	2.22e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
THCA	cis	rs524281	0.861	rs7931544	ENSG00000255320.1	RP11-755F10.1	13.34	1.24e-34	2.25e-31	0.75	0.52	Electroencephalogram traits;	chr11:66149563	chr11:66244840~66246239:-
THCA	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	13.33	1.25e-34	2.27e-31	0.59	0.52	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
THCA	cis	rs7945705	0.747	rs2653605	ENSG00000254860.4	TMEM9B-AS1	13.33	1.27e-34	2.3e-31	0.58	0.52	Hemoglobin concentration;	chr11:8971762	chr11:8964675~8977527:+
THCA	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	13.33	1.28e-34	2.31e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
THCA	cis	rs524281	0.861	rs1862005	ENSG00000255320.1	RP11-755F10.1	13.33	1.28e-34	2.32e-31	0.75	0.52	Electroencephalogram traits;	chr11:66095931	chr11:66244840~66246239:-
THCA	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-13.33	1.29e-34	2.33e-31	-0.58	-0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
THCA	cis	rs11098499	0.789	rs10212719	ENSG00000245958.5	RP11-33B1.1	-13.33	1.31e-34	2.37e-31	-0.52	-0.52	Corneal astigmatism;	chr4:119333282	chr4:119454791~119552025:+
THCA	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-13.33	1.31e-34	2.37e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
THCA	cis	rs732716	0.889	rs62129355	ENSG00000267769.1	CTB-50L17.9	-13.33	1.33e-34	2.4e-31	-0.68	-0.52	Mean corpuscular volume;	chr19:4397037	chr19:4454014~4455286:+
THCA	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-13.33	1.33e-34	2.4e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
THCA	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-13.33	1.35e-34	2.43e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-13.33	1.35e-34	2.43e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-13.33	1.35e-34	2.43e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-13.33	1.35e-34	2.43e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
THCA	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-13.33	1.35e-34	2.44e-31	-0.6	-0.52	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
THCA	cis	rs11098499	0.955	rs1511018	ENSG00000245958.5	RP11-33B1.1	-13.33	1.35e-34	2.44e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119240425	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs1511019	ENSG00000245958.5	RP11-33B1.1	-13.33	1.35e-34	2.44e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119244852	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs35434465	ENSG00000245958.5	RP11-33B1.1	-13.33	1.35e-34	2.44e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119248223	chr4:119454791~119552025:+
THCA	cis	rs11098499	1	rs6837898	ENSG00000245958.5	RP11-33B1.1	-13.33	1.35e-34	2.44e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119257999	chr4:119454791~119552025:+
THCA	cis	rs5769707	0.616	rs135869	ENSG00000188511.11	C22orf34	13.33	1.35e-34	2.44e-31	0.68	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49414524~49657542:-
THCA	cis	rs6504950	0.72	rs7216138	ENSG00000275710.1	RP11-257O5.4	13.33	1.36e-34	2.45e-31	0.65	0.52	Breast cancer;	chr17:54918303	chr17:54964474~54964679:+
THCA	cis	rs12134133	1	rs6660254	ENSG00000274245.1	RP11-357P18.2	13.32	1.39e-34	2.51e-31	0.56	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207272746	chr1:207372559~207373252:+
THCA	cis	rs7429990	0.87	rs13089844	ENSG00000229759.1	MRPS18AP1	-13.32	1.4e-34	2.52e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48098741	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs12493348	ENSG00000229759.1	MRPS18AP1	-13.32	1.4e-34	2.52e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48102048	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs12486714	ENSG00000229759.1	MRPS18AP1	-13.32	1.4e-34	2.52e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48107210	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs2361684	ENSG00000229759.1	MRPS18AP1	-13.32	1.4e-34	2.52e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48111128	chr3:48256350~48256938:-
THCA	cis	rs673078	0.607	rs7958551	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118442585	chr12:118428281~118428870:+
THCA	cis	rs11098499	1	rs35643470	ENSG00000245958.5	RP11-33B1.1	-13.32	1.4e-34	2.52e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119263793	chr4:119454791~119552025:+
THCA	cis	rs673078	0.607	rs7958652	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118442630	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs111607725	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118442957	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs76809232	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118444979	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61944660	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118445326	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61944662	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118445520	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs4254101	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118445877	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs4622305	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118445912	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs73207575	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118446711	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61944663	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118446886	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs73207577	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118447012	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs73207579	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118447123	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61944664	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118447145	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7969871	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118447331	chr12:118428281~118428870:+
THCA	cis	rs673078	0.56	rs7970361	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118447723	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61944669	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118448530	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61944670	ENSG00000275759.1	RP11-131L12.3	-13.32	1.4e-34	2.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118448697	chr12:118428281~118428870:+
THCA	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	13.32	1.42e-34	2.55e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
THCA	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	13.32	1.42e-34	2.56e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	13.32	1.42e-34	2.56e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
THCA	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	13.32	1.43e-34	2.57e-31	0.61	0.52	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
THCA	cis	rs7429990	0.932	rs13085054	ENSG00000229759.1	MRPS18AP1	-13.32	1.45e-34	2.6e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48092647	chr3:48256350~48256938:-
THCA	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-13.32	1.47e-34	2.65e-31	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
THCA	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-13.32	1.48e-34	2.65e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-13.32	1.48e-34	2.65e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-13.32	1.48e-34	2.65e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-13.32	1.48e-34	2.65e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-13.32	1.48e-34	2.65e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
THCA	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	13.32	1.48e-34	2.65e-31	0.61	0.52	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
THCA	cis	rs1062177	0.756	rs2964588	ENSG00000213433.5	RPLP1P6	13.32	1.48e-34	2.67e-31	0.55	0.52	Preschool internalizing problems;	chr5:151738825	chr5:151765859~151766378:-
THCA	cis	rs2111504	0.583	rs8104714	ENSG00000267213.4	AC007773.2	13.32	1.49e-34	2.68e-31	0.49	0.52	Bipolar disorder;	chr19:32381203	chr19:32390050~32405560:-
THCA	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	13.32	1.51e-34	2.71e-31	0.95	0.52	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
THCA	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	13.32	1.51e-34	2.71e-31	0.95	0.52	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
THCA	cis	rs2455601	1	rs56336128	ENSG00000254860.4	TMEM9B-AS1	13.31	1.52e-34	2.73e-31	0.81	0.52	Schizophrenia;	chr11:8886752	chr11:8964675~8977527:+
THCA	cis	rs8062405	1	rs62036622	ENSG00000251417.2	RP11-1348G14.4	-13.31	1.52e-34	2.73e-31	-0.51	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28802743~28817828:+
THCA	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	13.31	1.53e-34	2.74e-31	0.62	0.52	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
THCA	cis	rs6142102	0.502	rs58393429	ENSG00000276073.1	RP5-1125A11.7	-13.31	1.55e-34	2.78e-31	-0.47	-0.52	Skin pigmentation;	chr20:33957996	chr20:33985617~33988989:-
THCA	cis	rs11098499	0.955	rs11931312	ENSG00000245958.5	RP11-33B1.1	-13.31	1.55e-34	2.79e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119237868	chr4:119454791~119552025:+
THCA	cis	rs673078	0.607	rs10850967	ENSG00000275759.1	RP11-131L12.3	-13.31	1.56e-34	2.81e-31	-0.63	-0.52	Glucose homeostasis traits;	chr12:118380072	chr12:118428281~118428870:+
THCA	cis	rs6504950	0.72	rs12602751	ENSG00000275710.1	RP11-257O5.4	13.31	1.57e-34	2.81e-31	0.65	0.52	Breast cancer;	chr17:54916813	chr17:54964474~54964679:+
THCA	cis	rs11098499	0.575	rs907204	ENSG00000245958.5	RP11-33B1.1	-13.31	1.57e-34	2.81e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119317499	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.575	rs907205	ENSG00000245958.5	RP11-33B1.1	-13.31	1.57e-34	2.81e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119317509	chr4:119454791~119552025:+
THCA	cis	rs992157	0.71	rs12996912	ENSG00000261338.2	RP11-378A13.1	13.31	1.59e-34	2.86e-31	0.55	0.52	Colorectal cancer;	chr2:218245832	chr2:218255319~218257366:+
THCA	cis	rs11098499	0.955	rs1397608	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119240589	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs7684942	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119241046	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.913	rs10010696	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119243148	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.913	rs11098496	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119246311	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs35197422	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119248159	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.955	rs1511015	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119249318	chr4:119454791~119552025:+
THCA	cis	rs11098499	1	rs28374891	ENSG00000245958.5	RP11-33B1.1	-13.31	1.59e-34	2.86e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119262395	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.754	rs4895682	ENSG00000235652.6	RP11-545I5.3	-13.31	1.64e-34	2.94e-31	-0.49	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145741725	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.754	rs9999724	ENSG00000245958.5	RP11-33B1.1	-13.31	1.65e-34	2.96e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119318789	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs714899	ENSG00000245958.5	RP11-33B1.1	-13.31	1.65e-34	2.96e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119321880	chr4:119454791~119552025:+
THCA	cis	rs1062177	0.826	rs2053063	ENSG00000213433.5	RPLP1P6	-13.31	1.66e-34	2.97e-31	-0.55	-0.52	Preschool internalizing problems;	chr5:151787203	chr5:151765859~151766378:-
THCA	cis	rs9890032	0.581	rs62070592	ENSG00000266490.1	CTD-2349P21.9	13.3	1.68e-34	3e-31	0.52	0.52	Hip circumference adjusted for BMI;	chr17:30695531	chr17:30792372~30792833:+
THCA	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	13.3	1.7e-34	3.05e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	13.3	1.7e-34	3.05e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	13.3	1.7e-34	3.05e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	13.3	1.7e-34	3.05e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
THCA	cis	rs6142102	0.625	rs6142056	ENSG00000276073.1	RP5-1125A11.7	-13.3	1.72e-34	3.08e-31	-0.46	-0.52	Skin pigmentation;	chr20:33953349	chr20:33985617~33988989:-
THCA	cis	rs80028505	0.908	rs7752459	ENSG00000271304.1	DPRXP2	13.3	1.79e-34	3.21e-31	0.87	0.52	Foot ulcer in diabetes and neuropathy;	chr6:36116895	chr6:35989515~35990436:-
THCA	cis	rs62158211	0.955	rs7556815	ENSG00000234997.1	AC016745.3	-13.3	1.83e-34	3.28e-31	-0.63	-0.52	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113328208	chr2:113424495~113425324:+
THCA	cis	rs6142102	0.58	rs4911139	ENSG00000276073.1	RP5-1125A11.7	-13.29	1.86e-34	3.34e-31	-0.47	-0.52	Skin pigmentation;	chr20:33963729	chr20:33985617~33988989:-
THCA	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	13.29	1.87e-34	3.35e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
THCA	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	13.29	1.89e-34	3.38e-31	0.49	0.52	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
THCA	cis	rs673078	0.607	rs73207573	ENSG00000275759.1	RP11-131L12.3	-13.29	1.9e-34	3.39e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118444664	chr12:118428281~118428870:+
THCA	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	13.29	1.91e-34	3.41e-31	0.42	0.52	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
THCA	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-13.29	1.91e-34	3.42e-31	-0.74	-0.52	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
THCA	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	13.29	1.99e-34	3.56e-31	0.78	0.52	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
THCA	cis	rs6142102	0.625	rs4911381	ENSG00000276073.1	RP5-1125A11.7	13.29	2e-34	3.57e-31	0.46	0.52	Skin pigmentation;	chr20:33962539	chr20:33985617~33988989:-
THCA	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	13.29	2.01e-34	3.58e-31	0.55	0.52	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
THCA	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	13.29	2.02e-34	3.61e-31	0.67	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
THCA	cis	rs7772486	0.72	rs702320	ENSG00000235652.6	RP11-545I5.3	-13.28	2.03e-34	3.62e-31	-0.49	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145685518	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.865	rs10213221	ENSG00000245958.5	RP11-33B1.1	-13.28	2.03e-34	3.62e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119334771	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	13.28	2.03e-34	3.63e-31	0.66	0.52	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
THCA	cis	rs11155671	0.53	rs2342769	ENSG00000268592.3	RAET1E-AS1	13.28	2.07e-34	3.69e-31	0.68	0.52	Testicular germ cell tumor;	chr6:149895371	chr6:149863494~149919507:+
THCA	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-13.28	2.08e-34	3.72e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
THCA	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	13.28	2.09e-34	3.73e-31	0.81	0.52	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
THCA	cis	rs524281	0.637	rs7126075	ENSG00000255320.1	RP11-755F10.1	13.28	2.1e-34	3.74e-31	0.76	0.52	Electroencephalogram traits;	chr11:66173092	chr11:66244840~66246239:-
THCA	cis	rs524281	0.861	rs2177054	ENSG00000255320.1	RP11-755F10.1	13.28	2.1e-34	3.74e-31	0.76	0.52	Electroencephalogram traits;	chr11:66177141	chr11:66244840~66246239:-
THCA	cis	rs8062405	0.728	rs9931989	ENSG00000259982.1	CDC37P1	-13.28	2.1e-34	3.74e-31	-0.65	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28700294~28701540:-
THCA	cis	rs17111396	0.826	rs10134487	ENSG00000259167.2	NMNAT1P1	13.28	2.11e-34	3.77e-31	0.66	0.52	Uric acid levels;	chr14:81057542	chr14:81032529~81033404:+
THCA	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-13.28	2.11e-34	3.77e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-13.28	2.14e-34	3.81e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
THCA	cis	rs1062177	0.724	rs2915828	ENSG00000213433.5	RPLP1P6	13.28	2.16e-34	3.85e-31	0.55	0.52	Preschool internalizing problems;	chr5:151738560	chr5:151765859~151766378:-
THCA	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	13.28	2.17e-34	3.86e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	13.28	2.17e-34	3.86e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
THCA	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-13.28	2.21e-34	3.93e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-13.28	2.21e-34	3.93e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
THCA	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	13.28	2.22e-34	3.96e-31	0.42	0.52	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
THCA	cis	rs7208859	0.673	rs423151	ENSG00000263531.1	RP13-753N3.1	13.28	2.23e-34	3.96e-31	0.91	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30625268	chr17:30863921~30864940:-
THCA	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-13.27	2.25e-34	4e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
THCA	cis	rs5769707	0.681	rs135879	ENSG00000188511.11	C22orf34	13.27	2.26e-34	4.02e-31	0.65	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49414524~49657542:-
THCA	cis	rs5769707	0.642	rs135880	ENSG00000188511.11	C22orf34	13.27	2.26e-34	4.02e-31	0.65	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49414524~49657542:-
THCA	cis	rs11098499	0.955	rs13113112	ENSG00000245958.5	RP11-33B1.1	-13.27	2.27e-34	4.03e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119234885	chr4:119454791~119552025:+
THCA	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	13.27	2.3e-34	4.09e-31	0.48	0.52	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
THCA	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	13.27	2.3e-34	4.1e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
THCA	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-13.27	2.31e-34	4.1e-31	-0.62	-0.52	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
THCA	cis	rs7208859	0.673	rs216420	ENSG00000263531.1	RP13-753N3.1	13.27	2.31e-34	4.11e-31	0.9	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30863921~30864940:-
THCA	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	13.27	2.32e-34	4.12e-31	0.78	0.52	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
THCA	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-13.27	2.34e-34	4.16e-31	-0.59	-0.52	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
THCA	cis	rs11098499	1	rs10029750	ENSG00000245958.5	RP11-33B1.1	-13.27	2.35e-34	4.17e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119251388	chr4:119454791~119552025:+
THCA	cis	rs1075265	0.584	rs2357954	ENSG00000233266.1	HMGB1P31	13.27	2.37e-34	4.21e-31	0.69	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54135300	chr2:54051334~54051760:+
THCA	cis	rs8062405	1	rs7187776	ENSG00000251417.2	RP11-1348G14.4	-13.27	2.39e-34	4.24e-31	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	13.27	2.39e-34	4.24e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
THCA	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	13.27	2.39e-34	4.25e-31	0.55	0.52	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
THCA	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	13.27	2.42e-34	4.29e-31	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
THCA	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	13.27	2.46e-34	4.35e-31	0.48	0.52	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
THCA	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	13.26	2.46e-34	4.36e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
THCA	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-13.26	2.49e-34	4.41e-31	-0.6	-0.52	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-13.26	2.49e-34	4.41e-31	-0.6	-0.52	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-13.26	2.49e-34	4.41e-31	-0.6	-0.52	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	13.26	2.49e-34	4.41e-31	0.6	0.52	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
THCA	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-13.26	2.5e-34	4.43e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
THCA	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	13.26	2.52e-34	4.45e-31	0.57	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	13.26	2.52e-34	4.45e-31	0.57	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
THCA	cis	rs7208859	0.673	rs216409	ENSG00000263531.1	RP13-753N3.1	-13.26	2.52e-34	4.45e-31	-0.91	-0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30863921~30864940:-
THCA	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-13.26	2.52e-34	4.45e-31	-0.62	-0.52	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
THCA	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	13.26	2.52e-34	4.46e-31	0.82	0.52	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
THCA	cis	rs673078	0.607	rs61944661	ENSG00000275759.1	RP11-131L12.3	-13.26	2.56e-34	4.52e-31	-0.75	-0.52	Glucose homeostasis traits;	chr12:118445514	chr12:118428281~118428870:+
THCA	cis	rs1155848	0.571	rs6563125	ENSG00000227354.5	RBM26-AS1	13.26	2.58e-34	4.56e-31	0.81	0.52	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79630618	chr13:79406309~79424328:+
THCA	cis	rs1155848	0.571	rs58739959	ENSG00000227354.5	RBM26-AS1	13.26	2.58e-34	4.56e-31	0.81	0.52	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79633468	chr13:79406309~79424328:+
THCA	cis	rs11098499	0.754	rs66900435	ENSG00000245958.5	RP11-33B1.1	-13.26	2.59e-34	4.58e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119328270	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs1980027	ENSG00000245958.5	RP11-33B1.1	-13.26	2.59e-34	4.58e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119330422	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs10213554	ENSG00000245958.5	RP11-33B1.1	13.26	2.59e-34	4.58e-31	0.51	0.52	Corneal astigmatism;	chr4:119339630	chr4:119454791~119552025:+
THCA	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-13.26	2.64e-34	4.66e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-13.26	2.64e-34	4.66e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
THCA	cis	rs80028505	0.908	rs7771484	ENSG00000271304.1	DPRXP2	-13.26	2.68e-34	4.73e-31	-0.83	-0.52	Foot ulcer in diabetes and neuropathy;	chr6:36095214	chr6:35989515~35990436:-
THCA	cis	rs7772486	0.754	rs6932863	ENSG00000235652.6	RP11-545I5.3	-13.26	2.7e-34	4.76e-31	-0.49	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145700119	chr6:145799409~145886585:+
THCA	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	13.25	2.75e-34	4.85e-31	1.08	0.52	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
THCA	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-13.25	2.77e-34	4.89e-31	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
THCA	cis	rs1185460	0.804	rs13929	ENSG00000271751.1	RP11-110I1.14	-13.25	2.81e-34	4.97e-31	-0.64	-0.52	Coronary artery disease;	chr11:119045044	chr11:119065263~119065677:-
THCA	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	13.25	2.82e-34	4.97e-31	0.61	0.52	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
THCA	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	13.25	2.84e-34	5e-31	0.93	0.52	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
THCA	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	13.25	2.91e-34	5.13e-31	0.59	0.52	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
THCA	cis	rs80028505	1	rs16884694	ENSG00000271304.1	DPRXP2	13.25	2.97e-34	5.23e-31	0.83	0.52	Foot ulcer in diabetes and neuropathy;	chr6:36095385	chr6:35989515~35990436:-
THCA	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	13.25	2.98e-34	5.25e-31	0.79	0.52	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
THCA	cis	rs5769707	0.681	rs9616329	ENSG00000188511.11	C22orf34	13.24	3e-34	5.28e-31	0.64	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49414524~49657542:-
THCA	cis	rs11155671	0.53	rs9371544	ENSG00000268592.3	RAET1E-AS1	13.24	3.03e-34	5.34e-31	0.68	0.52	Testicular germ cell tumor;	chr6:149896224	chr6:149863494~149919507:+
THCA	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	13.24	3.06e-34	5.39e-31	0.67	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
THCA	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	13.24	3.13e-34	5.51e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
THCA	cis	rs6142102	0.538	rs6142058	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33954995	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs2050208	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33955767	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.602	rs4911380	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33958418	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs4911138	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33959893	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs4243974	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33960062	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs6142061	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33960529	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs6142062	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33960706	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs6141432	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33960791	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.602	rs6141433	ENSG00000276073.1	RP5-1125A11.7	-13.24	3.15e-34	5.55e-31	-0.46	-0.52	Skin pigmentation;	chr20:33961056	chr20:33985617~33988989:-
THCA	cis	rs7772486	0.754	rs2328707	ENSG00000235652.6	RP11-545I5.3	-13.24	3.15e-34	5.55e-31	-0.49	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145732362	chr6:145799409~145886585:+
THCA	cis	rs12022452	0.822	rs6600343	ENSG00000238287.1	RP11-656D10.3	-13.24	3.19e-34	5.61e-31	-0.77	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562538	chr1:40493157~40508661:-
THCA	cis	rs67311347	0.956	rs7640228	ENSG00000223797.4	ENTPD3-AS1	-13.24	3.22e-34	5.67e-31	-0.42	-0.52	Renal cell carcinoma;	chr3:40474699	chr3:40313802~40453329:-
THCA	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	13.24	3.23e-34	5.68e-31	0.66	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
THCA	cis	rs992157	0.735	rs2271541	ENSG00000261338.2	RP11-378A13.1	13.24	3.25e-34	5.72e-31	0.54	0.52	Colorectal cancer;	chr2:218217396	chr2:218255319~218257366:+
THCA	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	13.24	3.26e-34	5.73e-31	0.48	0.52	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
THCA	cis	rs6142102	0.625	rs7263727	ENSG00000276073.1	RP5-1125A11.7	-13.23	3.33e-34	5.86e-31	-0.46	-0.52	Skin pigmentation;	chr20:33953133	chr20:33985617~33988989:-
THCA	cis	rs10170846	0.893	rs1447108	ENSG00000261428.2	RP11-16P6.1	13.23	3.4e-34	5.98e-31	0.53	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222677512	chr2:222566899~222569719:-
THCA	cis	rs10170846	0.893	rs12614976	ENSG00000261428.2	RP11-16P6.1	13.23	3.4e-34	5.98e-31	0.53	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222678177	chr2:222566899~222569719:-
THCA	cis	rs7208859	0.673	rs216440	ENSG00000263531.1	RP13-753N3.1	13.23	3.44e-34	6.04e-31	0.9	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30863921~30864940:-
THCA	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	13.23	3.45e-34	6.05e-31	0.6	0.52	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
THCA	cis	rs2882667	0.652	rs6596463	ENSG00000253404.1	AC034243.1	13.23	3.5e-34	6.14e-31	0.6	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139109237	chr5:138744434~138753309:-
THCA	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-13.23	3.6e-34	6.31e-31	-0.66	-0.52	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
THCA	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-13.22	3.63e-34	6.37e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
THCA	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	13.22	3.65e-34	6.4e-31	0.42	0.52	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	13.22	3.65e-34	6.4e-31	0.42	0.52	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	13.22	3.65e-34	6.4e-31	0.42	0.52	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
THCA	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-13.22	3.8e-34	6.66e-31	-0.49	-0.52	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
THCA	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-13.22	3.87e-34	6.78e-31	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
THCA	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-13.22	3.89e-34	6.81e-31	-0.64	-0.52	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-13.22	3.89e-34	6.81e-31	-0.64	-0.52	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
THCA	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	13.22	3.89e-34	6.82e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
THCA	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	13.22	3.92e-34	6.86e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
THCA	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	13.22	3.92e-34	6.86e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
THCA	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-13.22	3.92e-34	6.87e-31	-0.5	-0.52	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
THCA	cis	rs8062405	0.964	rs62036614	ENSG00000251417.2	RP11-1348G14.4	-13.22	3.98e-34	6.97e-31	-0.51	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28802743~28817828:+
THCA	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	13.21	4.02e-34	7.03e-31	0.79	0.52	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
THCA	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-13.21	4.09e-34	7.15e-31	-0.51	-0.52	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
THCA	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	13.21	4.11e-34	7.18e-31	0.42	0.52	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
THCA	cis	rs524281	0.773	rs7127808	ENSG00000255320.1	RP11-755F10.1	13.21	4.11e-34	7.19e-31	0.76	0.52	Electroencephalogram traits;	chr11:66164448	chr11:66244840~66246239:-
THCA	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-13.21	4.12e-34	7.21e-31	-0.59	-0.52	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
THCA	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-13.21	4.16e-34	7.28e-31	-0.66	-0.52	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
THCA	cis	rs7772486	0.754	rs702318	ENSG00000235652.6	RP11-545I5.3	-13.21	4.18e-34	7.3e-31	-0.49	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145684737	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.754	rs10518300	ENSG00000245958.5	RP11-33B1.1	13.21	4.2e-34	7.34e-31	0.52	0.52	Corneal astigmatism;	chr4:119328344	chr4:119454791~119552025:+
THCA	cis	rs992157	0.56	rs12987130	ENSG00000261338.2	RP11-378A13.1	-13.21	4.21e-34	7.36e-31	-0.53	-0.52	Colorectal cancer;	chr2:218240267	chr2:218255319~218257366:+
THCA	cis	rs7208859	0.614	rs216412	ENSG00000263531.1	RP13-753N3.1	-13.21	4.27e-34	7.47e-31	-0.89	-0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576376	chr17:30863921~30864940:-
THCA	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-13.21	4.3e-34	7.51e-31	-0.59	-0.52	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-13.21	4.3e-34	7.51e-31	-0.59	-0.52	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
THCA	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	13.21	4.3e-34	7.51e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	13.21	4.3e-34	7.51e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	13.21	4.3e-34	7.51e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	13.21	4.3e-34	7.51e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	13.21	4.3e-34	7.51e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
THCA	cis	rs9309473	1	rs7576245	ENSG00000163016.8	ALMS1P	13.21	4.34e-34	7.57e-31	0.75	0.52	Metabolite levels;	chr2:73602551	chr2:73644919~73685576:+
THCA	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	13.21	4.34e-34	7.58e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
THCA	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	13.2	4.4e-34	7.67e-31	0.54	0.52	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
THCA	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	13.2	4.4e-34	7.67e-31	0.54	0.52	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
THCA	cis	rs8062405	0.656	rs7189927	ENSG00000259982.1	CDC37P1	-13.2	4.47e-34	7.79e-31	-0.65	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28700294~28701540:-
THCA	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	13.2	4.55e-34	7.93e-31	0.55	0.52	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
THCA	cis	rs992157	0.56	rs7605980	ENSG00000261338.2	RP11-378A13.1	13.2	4.55e-34	7.93e-31	0.53	0.52	Colorectal cancer;	chr2:218236146	chr2:218255319~218257366:+
THCA	cis	rs992157	0.56	rs6738394	ENSG00000261338.2	RP11-378A13.1	-13.2	4.57e-34	7.97e-31	-0.53	-0.52	Colorectal cancer;	chr2:218245902	chr2:218255319~218257366:+
THCA	cis	rs7772486	0.701	rs11155438	ENSG00000235652.6	RP11-545I5.3	13.2	4.76e-34	8.3e-31	0.48	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145628976	chr6:145799409~145886585:+
THCA	cis	rs2283792	1	rs2006893	ENSG00000224086.5	LL22NC03-86G7.1	-13.2	4.77e-34	8.31e-31	-0.62	-0.52	Multiple sclerosis;	chr22:21774389	chr22:21938293~21977632:+
THCA	cis	rs6142102	0.625	rs4012234	ENSG00000276073.1	RP5-1125A11.7	-13.2	4.77e-34	8.31e-31	-0.46	-0.52	Skin pigmentation;	chr20:33965241	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.649	rs4911382	ENSG00000276073.1	RP5-1125A11.7	-13.2	4.77e-34	8.31e-31	-0.46	-0.52	Skin pigmentation;	chr20:33965289	chr20:33985617~33988989:-
THCA	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-13.2	4.84e-34	8.43e-31	-0.65	-0.52	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
THCA	cis	rs524281	0.861	rs12226649	ENSG00000255320.1	RP11-755F10.1	13.19	4.87e-34	8.49e-31	0.75	0.52	Electroencephalogram traits;	chr11:66074576	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.691	rs9996644	ENSG00000245958.5	RP11-33B1.1	-13.19	4.88e-34	8.49e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119317722	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.691	rs9996494	ENSG00000245958.5	RP11-33B1.1	-13.19	4.88e-34	8.49e-31	-0.51	-0.52	Corneal astigmatism;	chr4:119317725	chr4:119454791~119552025:+
THCA	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	13.19	4.9e-34	8.53e-31	0.51	0.52	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
THCA	cis	rs5769707	0.554	rs10854876	ENSG00000188511.11	C22orf34	13.19	5.02e-34	8.73e-31	0.67	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49414524~49657542:-
THCA	cis	rs524281	0.684	rs7946447	ENSG00000255320.1	RP11-755F10.1	13.19	5.04e-34	8.77e-31	0.74	0.52	Electroencephalogram traits;	chr11:66096867	chr11:66244840~66246239:-
THCA	cis	rs2283792	0.905	rs5755694	ENSG00000224086.5	LL22NC03-86G7.1	-13.19	5.07e-34	8.82e-31	-0.61	-0.52	Multiple sclerosis;	chr22:21846241	chr22:21938293~21977632:+
THCA	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-13.19	5.12e-34	8.9e-31	-0.56	-0.52	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
THCA	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	13.19	5.13e-34	8.93e-31	0.6	0.52	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
THCA	cis	rs7174755	0.608	rs10162905	ENSG00000260657.2	RP11-315D16.4	13.19	5.17e-34	9e-31	0.68	0.52	Major depressive disorder;	chr15:68103709	chr15:68267792~68277994:-
THCA	cis	rs11155671	0.53	rs6935829	ENSG00000268592.3	RAET1E-AS1	13.19	5.18e-34	9.01e-31	0.68	0.52	Testicular germ cell tumor;	chr6:149896675	chr6:149863494~149919507:+
THCA	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-13.19	5.21e-34	9.05e-31	-0.59	-0.52	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
THCA	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	13.19	5.21e-34	9.05e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
THCA	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	13.19	5.21e-34	9.05e-31	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
THCA	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	13.19	5.3e-34	9.21e-31	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
THCA	cis	rs1062177	0.855	rs919262	ENSG00000213433.5	RPLP1P6	13.18	5.45e-34	9.47e-31	0.53	0.52	Preschool internalizing problems;	chr5:151886523	chr5:151765859~151766378:-
THCA	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	13.18	5.47e-34	9.51e-31	0.63	0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
THCA	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-13.18	5.47e-34	9.51e-31	-0.6	-0.52	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
THCA	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-13.18	5.49e-34	9.53e-31	-0.63	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
THCA	cis	rs7772486	0.72	rs1890171	ENSG00000235652.6	RP11-545I5.3	-13.18	5.54e-34	9.62e-31	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145750978	chr6:145799409~145886585:+
THCA	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	13.18	5.55e-34	9.63e-31	0.61	0.52	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
THCA	cis	rs6504950	0.8	rs9916547	ENSG00000275710.1	RP11-257O5.4	13.18	5.59e-34	9.7e-31	0.64	0.52	Breast cancer;	chr17:54929529	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.8	rs8065361	ENSG00000275710.1	RP11-257O5.4	13.18	5.59e-34	9.7e-31	0.64	0.52	Breast cancer;	chr17:54931492	chr17:54964474~54964679:+
THCA	cis	rs7429990	0.803	rs11714518	ENSG00000229759.1	MRPS18AP1	-13.18	5.63e-34	9.76e-31	-0.61	-0.52	Educational attainment (years of education);	chr3:48115145	chr3:48256350~48256938:-
THCA	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-13.18	5.63e-34	9.78e-31	-0.68	-0.52	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
THCA	cis	rs6142102	0.602	rs6141435	ENSG00000276073.1	RP5-1125A11.7	-13.18	5.64e-34	9.79e-31	-0.46	-0.52	Skin pigmentation;	chr20:33963473	chr20:33985617~33988989:-
THCA	cis	rs67180937	0.583	rs61827168	ENSG00000272750.1	RP11-378J18.8	13.18	5.75e-34	9.97e-31	0.61	0.52	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222634138	chr1:222658867~222661512:-
THCA	cis	rs732716	0.853	rs72990643	ENSG00000267769.1	CTB-50L17.9	-13.18	5.76e-34	9.99e-31	-0.66	-0.52	Mean corpuscular volume;	chr19:4454739	chr19:4454014~4455286:+
THCA	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	13.17	5.93e-34	1.03e-30	0.59	0.52	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
THCA	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-13.17	6e-34	1.04e-30	-0.79	-0.52	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
THCA	cis	rs2288884	0.537	rs7254131	ENSG00000275055.1	CTC-471J1.11	-13.17	6e-34	1.04e-30	-0.4	-0.52	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035774	chr19:52049007~52049754:+
THCA	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	13.17	6.02e-34	1.04e-30	0.9	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
THCA	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-13.17	6.15e-34	1.07e-30	-0.76	-0.52	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
THCA	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-13.17	6.2e-34	1.07e-30	-0.62	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
THCA	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	13.17	6.24e-34	1.08e-30	0.67	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
THCA	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	13.17	6.29e-34	1.09e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	13.17	6.29e-34	1.09e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
THCA	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	13.17	6.31e-34	1.09e-30	0.66	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	13.17	6.31e-34	1.09e-30	0.66	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
THCA	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-13.17	6.33e-34	1.1e-30	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
THCA	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	13.17	6.38e-34	1.1e-30	0.55	0.52	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
THCA	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	13.17	6.38e-34	1.1e-30	0.55	0.52	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
THCA	cis	rs992157	0.71	rs12694432	ENSG00000261338.2	RP11-378A13.1	13.17	6.46e-34	1.12e-30	0.54	0.52	Colorectal cancer;	chr2:218217607	chr2:218255319~218257366:+
THCA	cis	rs7044106	0.512	rs7873848	ENSG00000226752.6	PSMD5-AS1	-13.16	6.57e-34	1.14e-30	-0.66	-0.52	Hip circumference adjusted for BMI;	chr9:120591944	chr9:120824828~120854385:+
THCA	cis	rs944289	0.616	rs1742867	ENSG00000257826.1	RP11-116N8.4	13.16	6.57e-34	1.14e-30	0.54	0.52	Thyroid cancer;	chr14:36067937	chr14:36061026~36067190:-
THCA	cis	rs6504950	0.745	rs12603899	ENSG00000275710.1	RP11-257O5.4	13.16	6.6e-34	1.14e-30	0.64	0.52	Breast cancer;	chr17:54932737	chr17:54964474~54964679:+
THCA	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	13.16	6.64e-34	1.15e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
THCA	cis	rs5769707	0.605	rs9616702	ENSG00000188511.11	C22orf34	13.16	6.74e-34	1.16e-30	0.68	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49414524~49657542:-
THCA	cis	rs11098499	0.662	rs13108589	ENSG00000245958.5	RP11-33B1.1	-13.16	6.74e-34	1.16e-30	-0.5	-0.52	Corneal astigmatism;	chr4:119346947	chr4:119454791~119552025:+
THCA	cis	rs1062177	0.774	rs2964574	ENSG00000213433.5	RPLP1P6	-13.16	6.77e-34	1.17e-30	-0.55	-0.52	Preschool internalizing problems;	chr5:151776150	chr5:151765859~151766378:-
THCA	cis	rs1062177	0.855	rs6896664	ENSG00000213433.5	RPLP1P6	-13.16	6.82e-34	1.18e-30	-0.52	-0.52	Preschool internalizing problems;	chr5:151885713	chr5:151765859~151766378:-
THCA	cis	rs2288884	0.515	rs17779341	ENSG00000275055.1	CTC-471J1.11	-13.16	6.85e-34	1.18e-30	-0.4	-0.52	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047148	chr19:52049007~52049754:+
THCA	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-13.16	6.85e-34	1.18e-30	-0.59	-0.52	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
THCA	cis	rs7772486	0.754	rs6570708	ENSG00000235652.6	RP11-545I5.3	-13.16	6.86e-34	1.18e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145668292	chr6:145799409~145886585:+
THCA	cis	rs638893	0.947	rs515707	ENSG00000278376.1	RP11-158I9.8	-13.16	6.89e-34	1.19e-30	-0.57	-0.52	Vitiligo;	chr11:118814772	chr11:118791254~118793137:+
THCA	cis	rs7772486	0.754	rs697055	ENSG00000235652.6	RP11-545I5.3	13.16	6.91e-34	1.19e-30	0.49	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145682654	chr6:145799409~145886585:+
THCA	cis	rs12134133	1	rs6540893	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262382	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs61822674	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207263378	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs10442696	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264783	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7535532	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264991	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7543117	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265351	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs6684804	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265670	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs11582249	ENSG00000274245.1	RP11-357P18.2	13.16	6.93e-34	1.19e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268263	chr1:207372559~207373252:+
THCA	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	13.16	6.96e-34	1.2e-30	0.74	0.52	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	13.16	6.97e-34	1.2e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
THCA	cis	rs11098499	0.955	rs13129661	ENSG00000245958.5	RP11-33B1.1	-13.16	6.97e-34	1.2e-30	-0.5	-0.52	Corneal astigmatism;	chr4:119231754	chr4:119454791~119552025:+
THCA	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	13.16	7.03e-34	1.21e-30	0.42	0.52	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
THCA	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	13.16	7.06e-34	1.22e-30	0.61	0.52	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
THCA	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-13.16	7.08e-34	1.22e-30	-0.63	-0.52	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
THCA	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-13.16	7.09e-34	1.22e-30	-0.65	-0.52	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
THCA	cis	rs7772486	0.719	rs702317	ENSG00000235652.6	RP11-545I5.3	-13.15	7.28e-34	1.25e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145683874	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.72	rs4896837	ENSG00000235652.6	RP11-545I5.3	-13.15	7.28e-34	1.25e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145693032	chr6:145799409~145886585:+
THCA	cis	rs7208859	0.673	rs1347359	ENSG00000263531.1	RP13-753N3.1	13.15	7.33e-34	1.26e-30	0.9	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30863921~30864940:-
THCA	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	13.15	7.38e-34	1.27e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	13.15	7.38e-34	1.27e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	13.15	7.38e-34	1.27e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	13.15	7.38e-34	1.27e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	13.15	7.38e-34	1.27e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
THCA	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-13.15	7.51e-34	1.29e-30	-0.65	-0.52	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
THCA	cis	rs673078	0.607	rs6490177	ENSG00000275759.1	RP11-131L12.3	-13.15	7.53e-34	1.3e-30	-0.65	-0.52	Glucose homeostasis traits;	chr12:118358280	chr12:118428281~118428870:+
THCA	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	13.15	7.64e-34	1.31e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
THCA	cis	rs1061377	0.965	rs1137714	ENSG00000249207.1	RP11-360F5.1	-13.15	7.7e-34	1.32e-30	-0.64	-0.52	Uric acid levels;	chr4:39143105	chr4:39112677~39126818:-
THCA	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-13.15	7.7e-34	1.32e-30	-0.72	-0.52	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
THCA	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	13.15	7.77e-34	1.34e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
THCA	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-13.15	7.77e-34	1.34e-30	-0.61	-0.52	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-13.15	7.77e-34	1.34e-30	-0.61	-0.52	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
THCA	cis	rs992157	0.56	rs6436047	ENSG00000261338.2	RP11-378A13.1	13.15	7.83e-34	1.35e-30	0.52	0.52	Colorectal cancer;	chr2:218244190	chr2:218255319~218257366:+
THCA	cis	rs11098499	0.754	rs17595608	ENSG00000245958.5	RP11-33B1.1	-13.14	7.86e-34	1.35e-30	-0.5	-0.52	Corneal astigmatism;	chr4:119329351	chr4:119454791~119552025:+
THCA	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	13.14	7.88e-34	1.36e-30	0.57	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
THCA	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	13.14	7.96e-34	1.37e-30	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
THCA	cis	rs7829975	0.511	rs2955578	ENSG00000253893.2	FAM85B	-13.14	7.96e-34	1.37e-30	-0.65	-0.52	Mood instability;	chr8:8279561	chr8:8167819~8226614:-
THCA	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	13.14	7.99e-34	1.37e-30	0.62	0.52	Depression;	chr6:28240757	chr6:28176188~28176674:+
THCA	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-13.14	8.17e-34	1.4e-30	-0.61	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
THCA	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	13.14	8.19e-34	1.41e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-13.14	8.21e-34	1.41e-30	-0.65	-0.52	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
THCA	cis	rs2455601	1	rs12223690	ENSG00000254860.4	TMEM9B-AS1	13.14	8.23e-34	1.41e-30	0.8	0.52	Schizophrenia;	chr11:8880277	chr11:8964675~8977527:+
THCA	cis	rs2455601	1	rs7104661	ENSG00000254860.4	TMEM9B-AS1	13.14	8.23e-34	1.41e-30	0.8	0.52	Schizophrenia;	chr11:8880954	chr11:8964675~8977527:+
THCA	cis	rs524281	0.861	rs918299	ENSG00000255320.1	RP11-755F10.1	13.14	8.27e-34	1.42e-30	0.74	0.52	Electroencephalogram traits;	chr11:66160136	chr11:66244840~66246239:-
THCA	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	13.14	8.4e-34	1.44e-30	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
THCA	cis	rs11098499	0.754	rs1849457	ENSG00000245958.5	RP11-33B1.1	-13.14	8.42e-34	1.45e-30	-0.51	-0.52	Corneal astigmatism;	chr4:119333200	chr4:119454791~119552025:+
THCA	cis	rs228614	0.51	rs150893	ENSG00000246560.2	RP11-10L12.4	-13.14	8.47e-34	1.45e-30	-0.66	-0.52	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102817075	chr4:102828055~102844075:+
THCA	cis	rs17826219	0.561	rs562840	ENSG00000263531.1	RP13-753N3.1	13.14	8.49e-34	1.46e-30	0.89	0.52	Body mass index;	chr17:30622372	chr17:30863921~30864940:-
THCA	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	13.14	8.59e-34	1.47e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	13.14	8.59e-34	1.47e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	13.14	8.59e-34	1.47e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
THCA	cis	rs11098499	1	rs11098499	ENSG00000245958.5	RP11-33B1.1	-13.13	8.69e-34	1.49e-30	-0.51	-0.52	Corneal astigmatism;	chr4:119266456	chr4:119454791~119552025:+
THCA	cis	rs2455601	1	rs12418190	ENSG00000254860.4	TMEM9B-AS1	13.13	8.72e-34	1.49e-30	0.8	0.52	Schizophrenia;	chr11:8878271	chr11:8964675~8977527:+
THCA	cis	rs7772486	0.754	rs1055212	ENSG00000235652.6	RP11-545I5.3	-13.13	8.73e-34	1.5e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145737179	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.754	rs1980025	ENSG00000245958.5	RP11-33B1.1	13.13	8.85e-34	1.52e-30	0.51	0.52	Corneal astigmatism;	chr4:119331651	chr4:119454791~119552025:+
THCA	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-13.13	8.86e-34	1.52e-30	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
THCA	cis	rs1062177	0.855	rs6884630	ENSG00000213433.5	RPLP1P6	-13.13	8.96e-34	1.54e-30	-0.52	-0.52	Preschool internalizing problems;	chr5:151889436	chr5:151765859~151766378:-
THCA	cis	rs7772486	0.692	rs1577916	ENSG00000235652.6	RP11-545I5.3	-13.13	9.09e-34	1.56e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145748653	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.72	rs7752286	ENSG00000235652.6	RP11-545I5.3	-13.13	9.09e-34	1.56e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145751526	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.559	rs7763210	ENSG00000203875.9	SNHG5	-13.13	9.13e-34	1.56e-30	-0.57	-0.52	Response to antipsychotic treatment;	chr6:86098900	chr6:85660950~85678736:-
THCA	cis	rs5769707	0.681	rs8137111	ENSG00000188511.11	C22orf34	13.13	9.21e-34	1.58e-30	0.69	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49414524~49657542:-
THCA	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-13.13	9.27e-34	1.59e-30	-0.63	-0.52	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
THCA	cis	rs9309473	0.95	rs6756885	ENSG00000163016.8	ALMS1P	13.13	9.31e-34	1.59e-30	0.77	0.52	Metabolite levels;	chr2:73578045	chr2:73644919~73685576:+
THCA	cis	rs11098499	0.754	rs10212714	ENSG00000245958.5	RP11-33B1.1	-13.13	9.34e-34	1.6e-30	-0.51	-0.52	Corneal astigmatism;	chr4:119333147	chr4:119454791~119552025:+
THCA	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	13.13	9.41e-34	1.61e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
THCA	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	13.13	9.47e-34	1.62e-30	0.66	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
THCA	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-13.13	9.47e-34	1.62e-30	-0.74	-0.52	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
THCA	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-13.12	9.58e-34	1.64e-30	-0.67	-0.52	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
THCA	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-13.12	9.69e-34	1.66e-30	-0.63	-0.52	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
THCA	cis	rs12468226	0.872	rs1061157	ENSG00000273456.1	RP11-686O6.2	13.12	9.71e-34	1.66e-30	0.68	0.52	Urate levels;	chr2:202556476	chr2:202374932~202375604:-
THCA	cis	rs7772486	0.701	rs697056	ENSG00000235652.6	RP11-545I5.3	-13.12	9.73e-34	1.67e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145682761	chr6:145799409~145886585:+
THCA	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	13.12	9.75e-34	1.67e-30	0.62	0.52	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
THCA	cis	rs748404	0.518	rs2927085	ENSG00000249839.1	AC011330.5	-13.12	9.92e-34	1.7e-30	-0.61	-0.52	Lung cancer;	chr15:43697332	chr15:43663654~43684339:-
THCA	cis	rs6504950	0.8	rs9891704	ENSG00000275710.1	RP11-257O5.4	13.12	1.02e-33	1.74e-30	0.64	0.52	Breast cancer;	chr17:54933394	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.8	rs9900816	ENSG00000275710.1	RP11-257O5.4	13.12	1.02e-33	1.74e-30	0.64	0.52	Breast cancer;	chr17:54934696	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.8	rs9907961	ENSG00000275710.1	RP11-257O5.4	13.12	1.02e-33	1.74e-30	0.64	0.52	Breast cancer;	chr17:54935566	chr17:54964474~54964679:+
THCA	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	13.12	1.02e-33	1.74e-30	0.59	0.52	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
THCA	cis	rs8062405	1	rs3088215	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs28403629	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs61737565	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs4788099	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs9972693	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.964	rs9972768	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.965	rs62037363	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs7205323	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs4788101	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62037364	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62037365	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.929	rs11150609	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.737	rs11861132	ENSG00000251417.2	RP11-1348G14.4	-13.12	1.02e-33	1.74e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28802743~28817828:+
THCA	cis	rs7772486	0.719	rs7753770	ENSG00000235652.6	RP11-545I5.3	-13.12	1.03e-33	1.75e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145745025	chr6:145799409~145886585:+
THCA	cis	rs11155671	0.53	rs7763849	ENSG00000268592.3	RAET1E-AS1	13.12	1.03e-33	1.76e-30	0.68	0.52	Testicular germ cell tumor;	chr6:149885244	chr6:149863494~149919507:+
THCA	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-13.12	1.04e-33	1.78e-30	-0.58	-0.52	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
THCA	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-13.11	1.06e-33	1.81e-30	-0.67	-0.52	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
THCA	cis	rs12134133	0.688	rs6540875	ENSG00000274245.1	RP11-357P18.2	13.11	1.07e-33	1.82e-30	0.57	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.719	rs6696142	ENSG00000274245.1	RP11-357P18.2	13.11	1.07e-33	1.82e-30	0.57	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.752	rs57003024	ENSG00000274245.1	RP11-357P18.2	13.11	1.07e-33	1.82e-30	0.57	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207372559~207373252:+
THCA	cis	rs1062177	0.756	rs2915827	ENSG00000213433.5	RPLP1P6	13.11	1.07e-33	1.83e-30	0.54	0.52	Preschool internalizing problems;	chr5:151740144	chr5:151765859~151766378:-
THCA	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	13.11	1.07e-33	1.83e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	13.11	1.07e-33	1.83e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
THCA	cis	rs10853057	0.541	rs11656396	ENSG00000214174.7	AMZ2P1	13.11	1.08e-33	1.84e-30	0.81	0.52	White matter microstructure (global fractional anisotropy);	chr17:65049958	chr17:64966550~64975576:-
THCA	cis	rs11098499	0.826	rs4472123	ENSG00000245958.5	RP11-33B1.1	-13.11	1.08e-33	1.84e-30	-0.5	-0.52	Corneal astigmatism;	chr4:119315475	chr4:119454791~119552025:+
THCA	cis	rs9309473	0.95	rs6546858	ENSG00000163016.8	ALMS1P	13.11	1.08e-33	1.84e-30	0.75	0.52	Metabolite levels;	chr2:73611486	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	13.11	1.08e-33	1.84e-30	0.75	0.52	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	13.11	1.08e-33	1.85e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
THCA	cis	rs1061377	0.748	rs12506723	ENSG00000249207.1	RP11-360F5.1	-13.11	1.09e-33	1.87e-30	-0.64	-0.52	Uric acid levels;	chr4:39103152	chr4:39112677~39126818:-
THCA	cis	rs4853012	0.793	rs6723185	ENSG00000257800.1	FNBP1P1	13.11	1.12e-33	1.91e-30	0.47	0.52	Gestational age at birth (maternal effect);	chr2:74117757	chr2:74120680~74123218:+
THCA	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	13.11	1.13e-33	1.92e-30	0.75	0.52	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
THCA	cis	rs1062177	0.756	rs2915826	ENSG00000213433.5	RPLP1P6	13.11	1.14e-33	1.95e-30	0.54	0.52	Preschool internalizing problems;	chr5:151740402	chr5:151765859~151766378:-
THCA	cis	rs1062177	0.756	rs2964587	ENSG00000213433.5	RPLP1P6	13.11	1.14e-33	1.95e-30	0.54	0.52	Preschool internalizing problems;	chr5:151740411	chr5:151765859~151766378:-
THCA	cis	rs1062177	0.855	rs1346489	ENSG00000213433.5	RPLP1P6	-13.11	1.14e-33	1.95e-30	-0.52	-0.52	Preschool internalizing problems;	chr5:151886973	chr5:151765859~151766378:-
THCA	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-13.11	1.15e-33	1.95e-30	-0.67	-0.52	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
THCA	cis	rs1061377	0.748	rs6816202	ENSG00000249207.1	RP11-360F5.1	-13.11	1.15e-33	1.95e-30	-0.64	-0.52	Uric acid levels;	chr4:39106868	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs6842561	ENSG00000249207.1	RP11-360F5.1	-13.11	1.15e-33	1.95e-30	-0.64	-0.52	Uric acid levels;	chr4:39106873	chr4:39112677~39126818:-
THCA	cis	rs524281	0.861	rs9736673	ENSG00000255320.1	RP11-755F10.1	13.11	1.15e-33	1.96e-30	0.74	0.52	Electroencephalogram traits;	chr11:66156553	chr11:66244840~66246239:-
THCA	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	13.1	1.17e-33	1.99e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	13.1	1.17e-33	1.99e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	13.1	1.17e-33	1.99e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	13.1	1.17e-33	1.99e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
THCA	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-13.1	1.17e-33	2e-30	-0.64	-0.52	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
THCA	cis	rs5769707	0.681	rs4824068	ENSG00000188511.11	C22orf34	13.1	1.18e-33	2e-30	0.67	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49414524~49657542:-
THCA	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	13.1	1.18e-33	2e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	13.1	1.18e-33	2e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
THCA	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-13.1	1.19e-33	2.02e-30	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
THCA	cis	rs1062177	0.756	rs2964591	ENSG00000213433.5	RPLP1P6	13.1	1.19e-33	2.02e-30	0.54	0.52	Preschool internalizing problems;	chr5:151737836	chr5:151765859~151766378:-
THCA	cis	rs7772486	0.754	rs9497401	ENSG00000235652.6	RP11-545I5.3	-13.1	1.19e-33	2.02e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145730135	chr6:145799409~145886585:+
THCA	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-13.1	1.19e-33	2.03e-30	-0.57	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
THCA	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	13.1	1.2e-33	2.04e-30	0.63	0.52	Height;	chr11:118781100	chr11:118688039~118690600:-
THCA	cis	rs6504950	0.8	rs7209926	ENSG00000275710.1	RP11-257O5.4	-13.1	1.2e-33	2.04e-30	-0.65	-0.52	Breast cancer;	chr17:54928963	chr17:54964474~54964679:+
THCA	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	13.1	1.22e-33	2.07e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
THCA	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	13.1	1.24e-33	2.11e-30	0.65	0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	13.1	1.25e-33	2.13e-30	0.65	0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
THCA	cis	rs7772486	0.655	rs2142981	ENSG00000235652.6	RP11-545I5.3	-13.1	1.26e-33	2.14e-30	-0.47	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145750559	chr6:145799409~145886585:+
THCA	cis	rs6452524	0.901	rs1039786	ENSG00000249664.1	CTD-2227C6.2	13.1	1.27e-33	2.15e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83204222	chr5:83012285~83013109:-
THCA	cis	rs732716	0.889	rs11666856	ENSG00000267769.1	CTB-50L17.9	-13.1	1.27e-33	2.15e-30	-0.65	-0.52	Mean corpuscular volume;	chr19:4437453	chr19:4454014~4455286:+
THCA	cis	rs9928842	0.823	rs2870472	ENSG00000280152.1	RP11-331F4.5	13.1	1.27e-33	2.16e-30	0.73	0.52	Alcoholic chronic pancreatitis;	chr16:75244943	chr16:75245994~75250077:-
THCA	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	13.09	1.28e-33	2.17e-30	0.62	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
THCA	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-13.09	1.3e-33	2.2e-30	-0.61	-0.52	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
THCA	cis	rs10170846	0.893	rs11692810	ENSG00000261428.2	RP11-16P6.1	-13.09	1.31e-33	2.22e-30	-0.52	-0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222679377	chr2:222566899~222569719:-
THCA	cis	rs10170846	0.893	rs10932967	ENSG00000261428.2	RP11-16P6.1	13.09	1.31e-33	2.22e-30	0.52	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222679392	chr2:222566899~222569719:-
THCA	cis	rs11159086	1	rs4899516	ENSG00000259005.1	RP3-449M8.6	13.09	1.31e-33	2.22e-30	0.54	0.52	Advanced glycation end-product levels;	chr14:74492825	chr14:74474007~74474864:-
THCA	cis	rs7208859	0.673	rs216418	ENSG00000263531.1	RP13-753N3.1	13.09	1.31e-33	2.22e-30	0.89	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30863921~30864940:-
THCA	cis	rs7208859	0.623	rs216423	ENSG00000263531.1	RP13-753N3.1	13.09	1.31e-33	2.22e-30	0.89	0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30863921~30864940:-
THCA	cis	rs5769707	0.568	rs2011097	ENSG00000188511.11	C22orf34	13.09	1.32e-33	2.23e-30	0.66	0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49414524~49657542:-
THCA	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	13.09	1.32e-33	2.24e-30	0.42	0.52	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
THCA	cis	rs9309473	0.95	rs7566364	ENSG00000163016.8	ALMS1P	13.09	1.33e-33	2.25e-30	0.75	0.52	Metabolite levels;	chr2:73615762	chr2:73644919~73685576:+
THCA	cis	rs1062177	0.855	rs6892117	ENSG00000213433.5	RPLP1P6	13.09	1.33e-33	2.25e-30	0.51	0.52	Preschool internalizing problems;	chr5:151885424	chr5:151765859~151766378:-
THCA	cis	rs9309473	0.95	rs6546860	ENSG00000163016.8	ALMS1P	13.09	1.34e-33	2.27e-30	0.76	0.52	Metabolite levels;	chr2:73617122	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	13.09	1.34e-33	2.28e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	13.09	1.34e-33	2.28e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	13.09	1.36e-33	2.3e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
THCA	cis	rs1061377	0.965	rs7690465	ENSG00000249207.1	RP11-360F5.1	-13.09	1.36e-33	2.3e-30	-0.64	-0.52	Uric acid levels;	chr4:39147015	chr4:39112677~39126818:-
THCA	cis	rs7772486	0.754	rs9399561	ENSG00000235652.6	RP11-545I5.3	13.09	1.37e-33	2.33e-30	0.48	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145634551	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs4766899	ENSG00000275759.1	RP11-131L12.3	-13.09	1.39e-33	2.36e-30	-0.62	-0.52	Glucose homeostasis traits;	chr12:118374888	chr12:118428281~118428870:+
THCA	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	13.08	1.42e-33	2.4e-30	0.8	0.52	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-13.08	1.44e-33	2.44e-30	-0.67	-0.52	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
THCA	cis	rs673078	0.607	rs2036489	ENSG00000275759.1	RP11-131L12.3	-13.08	1.45e-33	2.45e-30	-0.62	-0.52	Glucose homeostasis traits;	chr12:118364643	chr12:118428281~118428870:+
THCA	cis	rs10170846	0.861	rs7571732	ENSG00000261428.2	RP11-16P6.1	-13.08	1.45e-33	2.46e-30	-0.51	-0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222673597	chr2:222566899~222569719:-
THCA	cis	rs7772486	0.754	rs702319	ENSG00000235652.6	RP11-545I5.3	-13.08	1.5e-33	2.53e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145684981	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs10082823	ENSG00000275759.1	RP11-131L12.3	-13.08	1.51e-33	2.54e-30	-0.62	-0.52	Glucose homeostasis traits;	chr12:118365386	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs2062519	ENSG00000275759.1	RP11-131L12.3	-13.08	1.51e-33	2.54e-30	-0.62	-0.52	Glucose homeostasis traits;	chr12:118367577	chr12:118428281~118428870:+
THCA	cis	rs7772486	0.72	rs4896844	ENSG00000235652.6	RP11-545I5.3	-13.08	1.51e-33	2.56e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145754088	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.764	rs7745696	ENSG00000235652.6	RP11-545I5.3	13.08	1.52e-33	2.56e-30	0.47	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145841693	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9403750	ENSG00000235652.6	RP11-545I5.3	13.08	1.52e-33	2.56e-30	0.47	0.52	Lobe attachment (rater-scored or self-reported);	chr6:145846626	chr6:145799409~145886585:+
THCA	cis	rs12468226	1	rs7565875	ENSG00000273456.1	RP11-686O6.2	13.08	1.52e-33	2.56e-30	0.61	0.52	Urate levels;	chr2:202516412	chr2:202374932~202375604:-
THCA	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	13.08	1.52e-33	2.58e-30	0.42	0.52	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
THCA	cis	rs992157	0.56	rs4674275	ENSG00000261338.2	RP11-378A13.1	-13.08	1.53e-33	2.58e-30	-0.52	-0.52	Colorectal cancer;	chr2:218233015	chr2:218255319~218257366:+
THCA	cis	rs992157	0.585	rs62182795	ENSG00000261338.2	RP11-378A13.1	-13.08	1.53e-33	2.58e-30	-0.52	-0.52	Colorectal cancer;	chr2:218235479	chr2:218255319~218257366:+
THCA	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-13.07	1.55e-33	2.61e-30	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-13.07	1.55e-33	2.61e-30	-0.65	-0.52	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
THCA	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	13.07	1.56e-33	2.64e-30	0.61	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
THCA	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-13.07	1.56e-33	2.64e-30	-0.65	-0.52	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
THCA	cis	rs1062177	0.826	rs2915873	ENSG00000213433.5	RPLP1P6	-13.07	1.59e-33	2.68e-30	-0.54	-0.52	Preschool internalizing problems;	chr5:151777097	chr5:151765859~151766378:-
THCA	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	13.07	1.59e-33	2.68e-30	0.63	0.52	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
THCA	cis	rs8040855	0.791	rs8042888	ENSG00000259295.5	CSPG4P12	-13.07	1.59e-33	2.69e-30	-0.78	-0.52	Bulimia nervosa;	chr15:85152360	chr15:85191438~85213905:+
THCA	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	13.07	1.63e-33	2.75e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	13.07	1.63e-33	2.75e-30	0.67	0.52	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
THCA	cis	rs9309473	0.95	rs13427832	ENSG00000163016.8	ALMS1P	13.07	1.65e-33	2.78e-30	0.76	0.52	Metabolite levels;	chr2:73617691	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-13.07	1.65e-33	2.79e-30	-0.65	-0.52	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
THCA	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	13.07	1.66e-33	2.81e-30	0.65	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
THCA	cis	rs2882667	0.627	rs1549203	ENSG00000253404.1	AC034243.1	-13.07	1.67e-33	2.82e-30	-0.59	-0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139132655	chr5:138744434~138753309:-
THCA	cis	rs9525916	0.967	rs9533775	ENSG00000227258.4	SMIM2-AS1	-13.07	1.68e-33	2.83e-30	-0.53	-0.52	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);	chr13:44123820	chr13:44110451~44240517:+
THCA	cis	rs227275	0.554	rs223333	ENSG00000246560.2	RP11-10L12.4	13.07	1.69e-33	2.84e-30	0.64	0.52	Allergic disease (asthma, hay fever or eczema);	chr4:102868653	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223328	ENSG00000246560.2	RP11-10L12.4	13.07	1.69e-33	2.84e-30	0.64	0.52	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873379	chr4:102828055~102844075:+
THCA	cis	rs950027	0.787	rs1153845	ENSG00000259520.4	CTD-2651B20.3	13.06	1.7e-33	2.87e-30	0.62	0.52	Response to fenofibrate (adiponectin levels);	chr15:45432531	chr15:45251580~45279251:-
THCA	cis	rs6142102	0.625	rs1883706	ENSG00000276073.1	RP5-1125A11.7	-13.06	1.74e-33	2.93e-30	-0.46	-0.52	Skin pigmentation;	chr20:33965071	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs1883705	ENSG00000276073.1	RP5-1125A11.7	-13.06	1.74e-33	2.93e-30	-0.46	-0.52	Skin pigmentation;	chr20:33965072	chr20:33985617~33988989:-
THCA	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-13.06	1.75e-33	2.95e-30	-0.61	-0.52	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
THCA	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-13.06	1.75e-33	2.95e-30	-0.57	-0.52	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
THCA	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-13.06	1.77e-33	2.99e-30	-0.63	-0.52	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
THCA	cis	rs9309473	0.948	rs2421577	ENSG00000163016.8	ALMS1P	13.06	1.78e-33	3e-30	0.75	0.52	Metabolite levels;	chr2:73613871	chr2:73644919~73685576:+
THCA	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	13.06	1.78e-33	3e-30	0.93	0.52	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
THCA	cis	rs9309473	0.851	rs6546850	ENSG00000163016.8	ALMS1P	13.06	1.79e-33	3.02e-30	0.74	0.52	Metabolite levels;	chr2:73604020	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.898	rs6546852	ENSG00000163016.8	ALMS1P	13.06	1.79e-33	3.02e-30	0.74	0.52	Metabolite levels;	chr2:73606304	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.95	rs6546853	ENSG00000163016.8	ALMS1P	13.06	1.79e-33	3.02e-30	0.74	0.52	Metabolite levels;	chr2:73606612	chr2:73644919~73685576:+
THCA	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	13.06	1.8e-33	3.04e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
THCA	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	13.06	1.81e-33	3.05e-30	0.58	0.52	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
THCA	cis	rs8040855	0.69	rs8041189	ENSG00000259295.5	CSPG4P12	-13.06	1.85e-33	3.11e-30	-0.78	-0.52	Bulimia nervosa;	chr15:85143096	chr15:85191438~85213905:+
THCA	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	13.06	1.85e-33	3.12e-30	0.8	0.52	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
THCA	cis	rs8062405	0.965	rs56040780	ENSG00000251417.2	RP11-1348G14.4	-13.06	1.86e-33	3.13e-30	-0.49	-0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28802743~28817828:+
THCA	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	13.06	1.87e-33	3.14e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	13.06	1.87e-33	3.14e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	13.06	1.87e-33	3.14e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	13.06	1.87e-33	3.14e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
THCA	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	13.06	1.87e-33	3.14e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	13.06	1.87e-33	3.14e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
THCA	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-13.06	1.87e-33	3.15e-30	-0.66	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
THCA	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	13.05	1.89e-33	3.17e-30	0.61	0.52	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
THCA	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-13.05	1.89e-33	3.17e-30	-0.74	-0.52	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
THCA	cis	rs8062405	0.728	rs11642449	ENSG00000259982.1	CDC37P1	13.05	1.89e-33	3.18e-30	0.64	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28700294~28701540:-
THCA	cis	rs7772486	0.727	rs4896843	ENSG00000235652.6	RP11-545I5.3	-13.05	1.89e-33	3.18e-30	-0.48	-0.52	Lobe attachment (rater-scored or self-reported);	chr6:145742315	chr6:145799409~145886585:+
THCA	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-13.05	1.9e-33	3.19e-30	-0.61	-0.52	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
THCA	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	13.05	1.9e-33	3.2e-30	0.42	0.52	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	13.05	1.9e-33	3.2e-30	0.42	0.52	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	13.05	1.9e-33	3.2e-30	0.42	0.52	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
THCA	cis	rs10170846	0.861	rs6740452	ENSG00000261428.2	RP11-16P6.1	13.05	1.9e-33	3.2e-30	0.51	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222653733	chr2:222566899~222569719:-
THCA	cis	rs10170846	0.789	rs972650	ENSG00000261428.2	RP11-16P6.1	13.05	1.9e-33	3.2e-30	0.51	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222655568	chr2:222566899~222569719:-
THCA	cis	rs10170846	0.861	rs12694582	ENSG00000261428.2	RP11-16P6.1	13.05	1.9e-33	3.2e-30	0.51	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222657236	chr2:222566899~222569719:-
THCA	cis	rs10170846	0.731	rs10180632	ENSG00000261428.2	RP11-16P6.1	13.05	1.9e-33	3.2e-30	0.51	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222661665	chr2:222566899~222569719:-
THCA	cis	rs10170846	0.8	rs10180462	ENSG00000261428.2	RP11-16P6.1	13.05	1.9e-33	3.2e-30	0.51	0.52	Schizophrenia (inflammation and infection response interaction);	chr2:222661666	chr2:222566899~222569719:-
THCA	cis	rs673078	0.66	rs76842574	ENSG00000275759.1	RP11-131L12.3	-13.05	1.91e-33	3.22e-30	-0.62	-0.52	Glucose homeostasis traits;	chr12:118371789	chr12:118428281~118428870:+
THCA	cis	rs673078	0.615	rs56324376	ENSG00000275759.1	RP11-131L12.3	-13.05	1.91e-33	3.22e-30	-0.62	-0.52	Glucose homeostasis traits;	chr12:118372134	chr12:118428281~118428870:+
THCA	cis	rs228614	0.536	rs223325	ENSG00000246560.2	RP11-10L12.4	13.05	1.92e-33	3.22e-30	0.64	0.52	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102875751	chr4:102828055~102844075:+
THCA	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	13.05	1.93e-33	3.24e-30	0.53	0.52	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
THCA	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-13.05	1.98e-33	3.32e-30	-0.97	-0.52	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
THCA	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	13.05	2e-33	3.35e-30	0.58	0.52	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
THCA	cis	rs6519955	0.86	rs8136098	ENSG00000231711.2	LINC00899	13.05	2.01e-33	3.37e-30	0.44	0.52	Dupuytren's disease;	chr22:46029766	chr22:46039907~46044853:-
THCA	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	13.05	2.04e-33	3.42e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
THCA	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-13.04	2.07e-33	3.47e-30	-0.62	-0.52	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
THCA	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	13.04	2.08e-33	3.48e-30	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	13.04	2.08e-33	3.48e-30	0.66	0.52	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
THCA	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-13.04	2.08e-33	3.49e-30	-0.75	-0.52	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	13.04	2.09e-33	3.51e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	13.04	2.09e-33	3.51e-30	0.65	0.52	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
THCA	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	13.04	2.1e-33	3.52e-30	0.57	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
THCA	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	13.04	2.11e-33	3.53e-30	0.62	0.52	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
THCA	cis	rs992157	0.735	rs13430006	ENSG00000261338.2	RP11-378A13.1	-13.04	2.22e-33	3.71e-30	-0.55	-0.52	Colorectal cancer;	chr2:218248366	chr2:218255319~218257366:+
THCA	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	13.04	2.23e-33	3.74e-30	0.54	0.52	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
THCA	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	13.04	2.24e-33	3.74e-30	0.6	0.52	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
THCA	cis	rs228614	0.51	rs65671	ENSG00000246560.2	RP11-10L12.4	13.04	2.24e-33	3.75e-30	0.65	0.52	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102801081	chr4:102828055~102844075:+
THCA	cis	rs11098499	1	rs7659194	ENSG00000245958.5	RP11-33B1.1	-13.03	2.29e-33	3.82e-30	-0.5	-0.52	Corneal astigmatism;	chr4:119285992	chr4:119454791~119552025:+
THCA	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-13.03	2.31e-33	3.87e-30	-0.62	-0.52	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
THCA	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	13.03	2.32e-33	3.88e-30	0.6	0.52	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
THCA	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	13.03	2.33e-33	3.9e-30	0.53	0.52	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
THCA	cis	rs9928842	0.722	rs1035540	ENSG00000280152.1	RP11-331F4.5	13.03	2.35e-33	3.92e-30	0.72	0.52	Alcoholic chronic pancreatitis;	chr16:75244897	chr16:75245994~75250077:-
THCA	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	13.03	2.4e-33	4.02e-30	0.62	0.52	Height;	chr11:118764443	chr11:118688039~118690600:-
THCA	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-13.03	2.4e-33	4.02e-30	-0.64	-0.52	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
THCA	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	13.03	2.42e-33	4.04e-30	0.62	0.52	Height;	chr3:53073584	chr3:53064283~53065091:-
THCA	cis	rs1062177	0.756	rs2964592	ENSG00000213433.5	RPLP1P6	13.03	2.44e-33	4.07e-30	0.53	0.52	Preschool internalizing problems;	chr5:151736127	chr5:151765859~151766378:-
THCA	cis	rs1061377	0.748	rs1036034	ENSG00000249207.1	RP11-360F5.1	-13.03	2.44e-33	4.08e-30	-0.64	-0.52	Uric acid levels;	chr4:39105299	chr4:39112677~39126818:-
THCA	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	13.03	2.45e-33	4.08e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	13.03	2.45e-33	4.08e-30	0.55	0.52	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
THCA	cis	rs673078	0.607	rs11068919	ENSG00000275759.1	RP11-131L12.3	-13.03	2.46e-33	4.11e-30	-0.65	-0.52	Glucose homeostasis traits;	chr12:118354925	chr12:118428281~118428870:+
THCA	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	13.03	2.47e-33	4.13e-30	0.61	0.52	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
THCA	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	13.03	2.49e-33	4.16e-30	0.93	0.52	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
THCA	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	13.02	2.52e-33	4.21e-30	0.62	0.51	Height;	chr11:118773873	chr11:118688039~118690600:-
THCA	cis	rs10170846	0.861	rs4674677	ENSG00000261428.2	RP11-16P6.1	13.02	2.53e-33	4.22e-30	0.51	0.51	Schizophrenia (inflammation and infection response interaction);	chr2:222664939	chr2:222566899~222569719:-
THCA	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-13.02	2.53e-33	4.23e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
THCA	cis	rs992157	0.735	rs10932765	ENSG00000261338.2	RP11-378A13.1	13.02	2.55e-33	4.25e-30	0.54	0.51	Colorectal cancer;	chr2:218234761	chr2:218255319~218257366:+
THCA	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-13.02	2.55e-33	4.25e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
THCA	cis	rs228614	0.51	rs223453	ENSG00000246560.2	RP11-10L12.4	13.02	2.58e-33	4.3e-30	0.65	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789895	chr4:102828055~102844075:+
THCA	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	13.02	2.6e-33	4.34e-30	0.54	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
THCA	cis	rs228614	0.51	rs223412	ENSG00000246560.2	RP11-10L12.4	13.02	2.6e-33	4.34e-30	0.65	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102812443	chr4:102828055~102844075:+
THCA	cis	rs11098499	1	rs13116504	ENSG00000245958.5	RP11-33B1.1	-13.02	2.69e-33	4.48e-30	-0.5	-0.51	Corneal astigmatism;	chr4:119288257	chr4:119454791~119552025:+
THCA	cis	rs5769707	0.681	rs2319346	ENSG00000188511.11	C22orf34	13.02	2.73e-33	4.55e-30	0.67	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49414524~49657542:-
THCA	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-13.02	2.74e-33	4.57e-30	-0.69	-0.51	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
THCA	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	13.02	2.74e-33	4.57e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
THCA	cis	rs7772486	0.79	rs7742333	ENSG00000235652.6	RP11-545I5.3	-13.01	2.76e-33	4.6e-30	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145837893	chr6:145799409~145886585:+
THCA	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	13.01	2.85e-33	4.75e-30	0.54	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
THCA	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-13.01	2.87e-33	4.78e-30	-0.41	-0.51	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-13.01	2.87e-33	4.78e-30	-0.41	-0.51	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
THCA	cis	rs2980439	0.807	rs2980438	ENSG00000253893.2	FAM85B	-13.01	2.91e-33	4.83e-30	-0.64	-0.51	Neuroticism;	chr8:8237303	chr8:8167819~8226614:-
THCA	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	13.01	2.92e-33	4.86e-30	0.61	0.51	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
THCA	cis	rs8062405	0.965	rs8049439	ENSG00000251417.2	RP11-1348G14.4	-13.01	2.95e-33	4.9e-30	-0.48	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28802743~28817828:+
THCA	cis	rs228614	0.51	rs223362	ENSG00000246560.2	RP11-10L12.4	13.01	2.97e-33	4.94e-30	0.65	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102848077	chr4:102828055~102844075:+
THCA	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-13.01	2.99e-33	4.97e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
THCA	cis	rs1062177	0.756	rs2915815	ENSG00000213433.5	RPLP1P6	13.01	3.03e-33	5.03e-30	0.54	0.51	Preschool internalizing problems;	chr5:151736322	chr5:151765859~151766378:-
THCA	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-13	3.03e-33	5.04e-30	-0.88	-0.51	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
THCA	cis	rs6504950	0.8	rs12952253	ENSG00000275710.1	RP11-257O5.4	13	3.05e-33	5.08e-30	0.67	0.51	Breast cancer;	chr17:54928355	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.8	rs7208123	ENSG00000275710.1	RP11-257O5.4	13	3.05e-33	5.08e-30	0.67	0.51	Breast cancer;	chr17:54928978	chr17:54964474~54964679:+
THCA	cis	rs9309473	0.95	rs6546849	ENSG00000163016.8	ALMS1P	13	3.09e-33	5.14e-30	0.74	0.51	Metabolite levels;	chr2:73603910	chr2:73644919~73685576:+
THCA	cis	rs12458462	0.509	rs3786241	ENSG00000274828.1	RP11-567M16.6	13	3.13e-33	5.2e-30	0.4	0.51	Monocyte count;	chr18:79734328	chr18:79677287~79679358:-
THCA	cis	rs227275	0.554	rs223371	ENSG00000246560.2	RP11-10L12.4	13	3.15e-33	5.23e-30	0.65	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102838032	chr4:102828055~102844075:+
THCA	cis	rs228614	0.534	rs223387	ENSG00000246560.2	RP11-10L12.4	13	3.25e-33	5.4e-30	0.65	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102828359	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223381	ENSG00000246560.2	RP11-10L12.4	13	3.25e-33	5.4e-30	0.65	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102832578	chr4:102828055~102844075:+
THCA	cis	rs6142102	0.625	rs6141431	ENSG00000276073.1	RP5-1125A11.7	-13	3.32e-33	5.5e-30	-0.46	-0.51	Skin pigmentation;	chr20:33952508	chr20:33985617~33988989:-
THCA	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	13	3.32e-33	5.51e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
THCA	cis	rs673078	0.607	rs11068926	ENSG00000275759.1	RP11-131L12.3	-12.99	3.36e-33	5.57e-30	-0.65	-0.51	Glucose homeostasis traits;	chr12:118367320	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs4442583	ENSG00000275759.1	RP11-131L12.3	-12.99	3.36e-33	5.57e-30	-0.65	-0.51	Glucose homeostasis traits;	chr12:118367914	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943370	ENSG00000275759.1	RP11-131L12.3	-12.99	3.36e-33	5.57e-30	-0.65	-0.51	Glucose homeostasis traits;	chr12:118369469	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943371	ENSG00000275759.1	RP11-131L12.3	-12.99	3.36e-33	5.57e-30	-0.65	-0.51	Glucose homeostasis traits;	chr12:118369600	chr12:118428281~118428870:+
THCA	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	12.99	3.37e-33	5.58e-30	0.55	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	12.99	3.37e-33	5.58e-30	0.55	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
THCA	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	12.99	3.41e-33	5.66e-30	0.62	0.51	Height;	chr11:118760944	chr11:118688039~118690600:-
THCA	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	12.99	3.42e-33	5.68e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
THCA	cis	rs7772486	0.72	rs6570713	ENSG00000235652.6	RP11-545I5.3	-12.99	3.43e-33	5.69e-30	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145753949	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs59594854	ENSG00000275759.1	RP11-131L12.3	-12.99	3.46e-33	5.73e-30	-0.61	-0.51	Glucose homeostasis traits;	chr12:118374000	chr12:118428281~118428870:+
THCA	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	12.99	3.47e-33	5.76e-30	0.67	0.51	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
THCA	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	12.99	3.49e-33	5.79e-30	0.49	0.51	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
THCA	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	12.99	3.54e-33	5.86e-30	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
THCA	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	12.99	3.54e-33	5.87e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
THCA	cis	rs6142102	0.517	rs6142050	ENSG00000276073.1	RP5-1125A11.7	-12.99	3.55e-33	5.88e-30	-0.45	-0.51	Skin pigmentation;	chr20:33939322	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.625	rs9753690	ENSG00000276073.1	RP5-1125A11.7	-12.99	3.56e-33	5.89e-30	-0.46	-0.51	Skin pigmentation;	chr20:33952995	chr20:33985617~33988989:-
THCA	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	12.99	3.56e-33	5.9e-30	0.93	0.51	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
THCA	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	12.99	3.59e-33	5.95e-30	0.41	0.51	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
THCA	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	12.99	3.63e-33	6.01e-30	0.77	0.51	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
THCA	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	12.99	3.66e-33	6.06e-30	0.66	0.51	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
THCA	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	12.98	3.69e-33	6.11e-30	0.46	0.51	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
THCA	cis	rs6504950	0.8	rs72829484	ENSG00000275710.1	RP11-257O5.4	12.98	3.74e-33	6.19e-30	0.66	0.51	Breast cancer;	chr17:54931919	chr17:54964474~54964679:+
THCA	cis	rs6570726	0.791	rs10457788	ENSG00000235652.6	RP11-545I5.3	12.98	3.76e-33	6.22e-30	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145600000	chr6:145799409~145886585:+
THCA	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	12.98	3.77e-33	6.25e-30	0.8	0.51	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
THCA	cis	rs7174755	0.608	rs62004789	ENSG00000260657.2	RP11-315D16.4	12.98	3.8e-33	6.29e-30	0.67	0.51	Major depressive disorder;	chr15:68148268	chr15:68267792~68277994:-
THCA	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	12.98	3.82e-33	6.32e-30	0.6	0.51	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
THCA	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-12.98	3.82e-33	6.33e-30	-0.64	-0.51	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
THCA	cis	rs6142102	0.517	rs8119076	ENSG00000276073.1	RP5-1125A11.7	-12.98	3.84e-33	6.35e-30	-0.46	-0.51	Skin pigmentation;	chr20:33937909	chr20:33985617~33988989:-
THCA	cis	rs2288884	0.515	rs73053909	ENSG00000275055.1	CTC-471J1.11	-12.98	3.84e-33	6.36e-30	-0.4	-0.51	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032864	chr19:52049007~52049754:+
THCA	cis	rs227275	0.554	rs223457	ENSG00000246560.2	RP11-10L12.4	12.98	3.97e-33	6.56e-30	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102788506	chr4:102828055~102844075:+
THCA	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	12.97	4.05e-33	6.69e-30	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
THCA	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	12.97	4.08e-33	6.75e-30	0.92	0.51	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
THCA	cis	rs992157	0.56	rs4674274	ENSG00000261338.2	RP11-378A13.1	-12.97	4.1e-33	6.78e-30	-0.52	-0.51	Colorectal cancer;	chr2:218224408	chr2:218255319~218257366:+
THCA	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	12.97	4.12e-33	6.81e-30	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
THCA	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	12.97	4.18e-33	6.9e-30	0.85	0.51	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
THCA	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	12.97	4.18e-33	6.9e-30	0.85	0.51	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
THCA	cis	rs934734	0.532	rs6752053	ENSG00000204929.10	AC074391.1	-12.97	4.22e-33	6.96e-30	-0.61	-0.51	Rheumatoid arthritis;	chr2:65439540	chr2:65436711~66084639:+
THCA	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	12.97	4.23e-33	6.99e-30	0.6	0.51	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
THCA	cis	rs6570726	0.643	rs9403735	ENSG00000235652.6	RP11-545I5.3	12.97	4.24e-33	7.01e-30	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145615455	chr6:145799409~145886585:+
THCA	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	12.97	4.35e-33	7.18e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	12.97	4.35e-33	7.18e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
THCA	cis	rs6570726	0.791	rs9403729	ENSG00000235652.6	RP11-545I5.3	12.96	4.46e-33	7.36e-30	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145585871	chr6:145799409~145886585:+
THCA	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	12.96	4.53e-33	7.46e-30	0.58	0.51	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
THCA	cis	rs9928842	0.823	rs4888365	ENSG00000280152.1	RP11-331F4.5	12.96	4.56e-33	7.52e-30	0.73	0.51	Alcoholic chronic pancreatitis;	chr16:75248349	chr16:75245994~75250077:-
THCA	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	12.96	4.6e-33	7.58e-30	0.54	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
THCA	cis	rs9309473	0.898	rs6546851	ENSG00000163016.8	ALMS1P	12.96	4.6e-33	7.58e-30	0.74	0.51	Metabolite levels;	chr2:73606156	chr2:73644919~73685576:+
THCA	cis	rs12468226	0.938	rs12463937	ENSG00000273456.1	RP11-686O6.2	12.96	4.65e-33	7.66e-30	0.65	0.51	Urate levels;	chr2:202246543	chr2:202374932~202375604:-
THCA	cis	rs9309473	0.606	rs77962988	ENSG00000163016.8	ALMS1P	12.96	4.66e-33	7.68e-30	0.94	0.51	Metabolite levels;	chr2:73658963	chr2:73644919~73685576:+
THCA	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	12.96	4.67e-33	7.7e-30	0.78	0.51	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
THCA	cis	rs732716	0.74	rs78869060	ENSG00000267769.1	CTB-50L17.9	-12.96	4.69e-33	7.73e-30	-0.65	-0.51	Mean corpuscular volume;	chr19:4444745	chr19:4454014~4455286:+
THCA	cis	rs9890032	0.509	rs11656986	ENSG00000266490.1	CTD-2349P21.9	12.96	4.78e-33	7.87e-30	0.51	0.51	Hip circumference adjusted for BMI;	chr17:30694324	chr17:30792372~30792833:+
THCA	cis	rs12468226	1	rs13426118	ENSG00000273456.1	RP11-686O6.2	12.96	4.79e-33	7.89e-30	0.59	0.51	Urate levels;	chr2:202390762	chr2:202374932~202375604:-
THCA	cis	rs992157	0.697	rs13384682	ENSG00000261338.2	RP11-378A13.1	12.96	4.8e-33	7.91e-30	0.53	0.51	Colorectal cancer;	chr2:218204414	chr2:218255319~218257366:+
THCA	cis	rs992157	0.71	rs7569907	ENSG00000261338.2	RP11-378A13.1	12.96	4.8e-33	7.91e-30	0.53	0.51	Colorectal cancer;	chr2:218205828	chr2:218255319~218257366:+
THCA	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	12.96	4.87e-33	8.02e-30	0.64	0.51	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
THCA	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-12.96	4.89e-33	8.05e-30	-0.64	-0.51	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
THCA	cis	rs227275	0.554	rs223454	ENSG00000246560.2	RP11-10L12.4	12.95	4.93e-33	8.11e-30	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102789773	chr4:102828055~102844075:+
THCA	cis	rs9309473	1	rs60844734	ENSG00000163016.8	ALMS1P	12.95	4.97e-33	8.18e-30	0.75	0.51	Metabolite levels;	chr2:73396077	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs11899902	ENSG00000163016.8	ALMS1P	12.95	4.97e-33	8.18e-30	0.75	0.51	Metabolite levels;	chr2:73404436	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	12.95	4.97e-33	8.18e-30	0.75	0.51	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
THCA	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-12.95	5.02e-33	8.26e-30	-0.62	-0.51	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
THCA	cis	rs227275	0.586	rs223448	ENSG00000246560.2	RP11-10L12.4	12.95	5.05e-33	8.31e-30	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102792189	chr4:102828055~102844075:+
THCA	cis	rs992157	0.56	rs1514132	ENSG00000261338.2	RP11-378A13.1	-12.95	5.07e-33	8.34e-30	-0.52	-0.51	Colorectal cancer;	chr2:218219359	chr2:218255319~218257366:+
THCA	cis	rs227275	0.554	rs223363	ENSG00000246560.2	RP11-10L12.4	12.95	5.08e-33	8.35e-30	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102846182	chr4:102828055~102844075:+
THCA	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	12.95	5.14e-33	8.45e-30	0.54	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
THCA	cis	rs227275	0.554	rs149576	ENSG00000246560.2	RP11-10L12.4	12.95	5.15e-33	8.46e-30	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102811411	chr4:102828055~102844075:+
THCA	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	12.95	5.17e-33	8.5e-30	0.63	0.51	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
THCA	cis	rs934734	0.532	rs7569113	ENSG00000204929.10	AC074391.1	12.95	5.18e-33	8.52e-30	0.62	0.51	Rheumatoid arthritis;	chr2:65429907	chr2:65436711~66084639:+
THCA	cis	rs2382817	0.58	rs6756265	ENSG00000261338.2	RP11-378A13.1	-12.95	5.22e-33	8.57e-30	-0.52	-0.51	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease;	chr2:218230831	chr2:218255319~218257366:+
THCA	cis	rs992157	0.56	rs12992937	ENSG00000261338.2	RP11-378A13.1	-12.95	5.23e-33	8.59e-30	-0.52	-0.51	Colorectal cancer;	chr2:218222349	chr2:218255319~218257366:+
THCA	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-12.95	5.26e-33	8.63e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-12.95	5.26e-33	8.63e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-12.95	5.26e-33	8.63e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-12.95	5.26e-33	8.63e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-12.95	5.26e-33	8.63e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-12.95	5.26e-33	8.63e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
THCA	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	12.95	5.32e-33	8.73e-30	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
THCA	cis	rs5769707	0.681	rs4622843	ENSG00000188511.11	C22orf34	12.95	5.38e-33	8.83e-30	0.63	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49643268	chr22:49414524~49657542:-
THCA	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-12.94	5.43e-33	8.91e-30	-0.63	-0.51	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
THCA	cis	rs6683071	0.688	rs3811465	ENSG00000272750.1	RP11-378J18.8	-12.94	5.43e-33	8.91e-30	-0.63	-0.51	Cognitive performance;	chr1:222712777	chr1:222658867~222661512:-
THCA	cis	rs433852	0.904	rs8102492	ENSG00000232871.7	SEC1P	12.94	5.5e-33	9.02e-30	0.68	0.51	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48637552	chr19:48638071~48682245:+
THCA	cis	rs9309473	1	rs6546836	ENSG00000163016.8	ALMS1P	12.94	5.73e-33	9.39e-30	0.74	0.51	Metabolite levels;	chr2:73450706	chr2:73644919~73685576:+
THCA	cis	rs7174755	0.637	rs113002386	ENSG00000260657.2	RP11-315D16.4	12.94	5.74e-33	9.41e-30	0.68	0.51	Major depressive disorder;	chr15:68172375	chr15:68267792~68277994:-
THCA	cis	rs6504950	0.8	rs17745183	ENSG00000275710.1	RP11-257O5.4	12.94	5.76e-33	9.44e-30	0.66	0.51	Breast cancer;	chr17:54936234	chr17:54964474~54964679:+
THCA	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	12.94	5.79e-33	9.49e-30	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
THCA	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	12.94	5.81e-33	9.52e-30	0.59	0.51	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
THCA	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-12.94	5.81e-33	9.52e-30	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
THCA	cis	rs6683071	0.688	rs3008637	ENSG00000272750.1	RP11-378J18.8	12.94	5.84e-33	9.58e-30	0.63	0.51	Cognitive performance;	chr1:222684427	chr1:222658867~222661512:-
THCA	cis	rs6683071	0.688	rs2936049	ENSG00000272750.1	RP11-378J18.8	12.94	5.84e-33	9.58e-30	0.63	0.51	Cognitive performance;	chr1:222684825	chr1:222658867~222661512:-
THCA	cis	rs6142102	0.58	rs9753679	ENSG00000276073.1	RP5-1125A11.7	-12.94	5.87e-33	9.62e-30	-0.45	-0.51	Skin pigmentation;	chr20:33953054	chr20:33985617~33988989:-
THCA	cis	rs11098499	1	rs13435802	ENSG00000245958.5	RP11-33B1.1	12.93	5.96e-33	9.76e-30	0.49	0.51	Corneal astigmatism;	chr4:119256805	chr4:119454791~119552025:+
THCA	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-12.93	6.04e-33	9.9e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-12.93	6.04e-33	9.9e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-12.93	6.04e-33	9.9e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-12.93	6.04e-33	9.9e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
THCA	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-12.93	6.04e-33	9.9e-30	-0.65	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
THCA	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-12.93	6.07e-33	9.95e-30	-0.7	-0.51	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
THCA	cis	rs587080	0.624	rs674485	ENSG00000245532.5	NEAT1	-12.93	6.08e-33	9.95e-30	-0.38	-0.51	Plateletcrit;	chr11:65429922	chr11:65422774~65445540:+
THCA	cis	rs5769707	0.681	rs8140095	ENSG00000188511.11	C22orf34	12.93	6.18e-33	1.01e-29	0.68	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49414524~49657542:-
THCA	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-12.93	6.21e-33	1.02e-29	-0.63	-0.51	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
THCA	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-12.93	6.21e-33	1.02e-29	-0.63	-0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
THCA	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-12.93	6.22e-33	1.02e-29	-0.6	-0.51	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
THCA	cis	rs6570726	0.791	rs12208019	ENSG00000235652.6	RP11-545I5.3	12.93	6.23e-33	1.02e-29	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145614436	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs11155435	ENSG00000235652.6	RP11-545I5.3	12.93	6.23e-33	1.02e-29	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145617409	chr6:145799409~145886585:+
THCA	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-12.93	6.23e-33	1.02e-29	-0.68	-0.51	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
THCA	cis	rs9309473	0.797	rs6723247	ENSG00000163016.8	ALMS1P	12.93	6.33e-33	1.03e-29	0.75	0.51	Metabolite levels;	chr2:73619622	chr2:73644919~73685576:+
THCA	cis	rs9595066	1	rs7981575	ENSG00000227258.4	SMIM2-AS1	12.93	6.43e-33	1.05e-29	0.72	0.51	Schizophrenia;	chr13:44136811	chr13:44110451~44240517:+
THCA	cis	rs10853057	0.541	rs8082708	ENSG00000214174.7	AMZ2P1	-12.92	6.69e-33	1.09e-29	-0.78	-0.51	White matter microstructure (global fractional anisotropy);	chr17:65046182	chr17:64966550~64975576:-
THCA	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	12.92	6.72e-33	1.1e-29	0.78	0.51	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
THCA	cis	rs7829975	0.511	rs2980512	ENSG00000253893.2	FAM85B	-12.92	6.77e-33	1.11e-29	-0.65	-0.51	Mood instability;	chr8:8283379	chr8:8167819~8226614:-
THCA	cis	rs227275	0.554	rs223421	ENSG00000246560.2	RP11-10L12.4	12.92	6.87e-33	1.12e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102805861	chr4:102828055~102844075:+
THCA	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-12.92	6.87e-33	1.12e-29	-0.7	-0.51	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
THCA	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	12.92	6.99e-33	1.14e-29	0.58	0.51	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
THCA	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	12.92	7.03e-33	1.15e-29	0.62	0.51	Height;	chr11:118749988	chr11:118688039~118690600:-
THCA	cis	rs9309473	1	rs2901438	ENSG00000163016.8	ALMS1P	12.92	7.06e-33	1.15e-29	0.74	0.51	Metabolite levels;	chr2:73438528	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.861	rs6546856	ENSG00000163016.8	ALMS1P	12.92	7.17e-33	1.17e-29	0.74	0.51	Metabolite levels;	chr2:73610624	chr2:73644919~73685576:+
THCA	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-12.91	7.22e-33	1.18e-29	-0.54	-0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
THCA	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	12.91	7.22e-33	1.18e-29	0.58	0.51	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
THCA	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	12.91	7.23e-33	1.18e-29	0.59	0.51	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
THCA	cis	rs11155671	0.53	rs9371215	ENSG00000268592.3	RAET1E-AS1	12.91	7.25e-33	1.18e-29	0.68	0.51	Testicular germ cell tumor;	chr6:149873162	chr6:149863494~149919507:+
THCA	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	12.91	7.43e-33	1.21e-29	0.79	0.51	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
THCA	cis	rs1062177	0.756	rs2915817	ENSG00000213433.5	RPLP1P6	12.91	7.56e-33	1.23e-29	0.54	0.51	Preschool internalizing problems;	chr5:151735956	chr5:151765859~151766378:-
THCA	cis	rs5769707	0.605	rs6009791	ENSG00000188511.11	C22orf34	12.91	7.64e-33	1.24e-29	0.67	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49414524~49657542:-
THCA	cis	rs6142102	0.517	rs6059577	ENSG00000276073.1	RP5-1125A11.7	-12.91	7.64e-33	1.24e-29	-0.45	-0.51	Skin pigmentation;	chr20:33939880	chr20:33985617~33988989:-
THCA	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-12.91	7.65e-33	1.25e-29	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
THCA	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-12.91	7.67e-33	1.25e-29	-0.63	-0.51	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-12.91	7.67e-33	1.25e-29	-0.63	-0.51	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-12.91	7.67e-33	1.25e-29	-0.63	-0.51	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
THCA	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	12.91	7.7e-33	1.25e-29	0.6	0.51	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
THCA	cis	rs2658782	0.789	rs2605574	ENSG00000279684.1	RP11-755E23.2	-12.91	7.71e-33	1.25e-29	-0.83	-0.51	Pulmonary function decline;	chr11:93403278	chr11:93286629~93288903:-
THCA	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-12.91	7.75e-33	1.26e-29	-0.64	-0.51	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
THCA	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-12.91	7.75e-33	1.26e-29	-0.64	-0.51	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
THCA	cis	rs7208859	0.562	rs216408	ENSG00000263531.1	RP13-753N3.1	-12.91	7.81e-33	1.27e-29	-0.89	-0.51	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30863921~30864940:-
THCA	cis	rs6683071	0.894	rs12073392	ENSG00000272750.1	RP11-378J18.8	-12.91	7.88e-33	1.28e-29	-0.63	-0.51	Cognitive performance;	chr1:222753336	chr1:222658867~222661512:-
THCA	cis	rs9309473	1	rs56672945	ENSG00000163016.8	ALMS1P	12.91	7.9e-33	1.28e-29	0.75	0.51	Metabolite levels;	chr2:73395535	chr2:73644919~73685576:+
THCA	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	12.9	7.97e-33	1.3e-29	0.47	0.51	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
THCA	cis	rs3096299	0.738	rs9929606	ENSG00000274627.1	RP11-104N10.2	12.9	8.16e-33	1.33e-29	0.49	0.51	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89516797~89522217:+
THCA	cis	rs673078	0.607	rs2036314	ENSG00000275759.1	RP11-131L12.3	-12.9	8.22e-33	1.34e-29	-0.65	-0.51	Glucose homeostasis traits;	chr12:118367132	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61943369	ENSG00000275759.1	RP11-131L12.3	-12.9	8.22e-33	1.34e-29	-0.65	-0.51	Glucose homeostasis traits;	chr12:118368145	chr12:118428281~118428870:+
THCA	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	12.9	8.33e-33	1.35e-29	0.61	0.51	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
THCA	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	12.9	8.34e-33	1.36e-29	0.76	0.51	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
THCA	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	12.9	8.36e-33	1.36e-29	0.93	0.51	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
THCA	cis	rs1061377	0.748	rs1964345	ENSG00000249207.1	RP11-360F5.1	-12.9	8.56e-33	1.39e-29	-0.63	-0.51	Uric acid levels;	chr4:39104793	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs1964347	ENSG00000249207.1	RP11-360F5.1	-12.9	8.56e-33	1.39e-29	-0.63	-0.51	Uric acid levels;	chr4:39104956	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs1036033	ENSG00000249207.1	RP11-360F5.1	-12.9	8.56e-33	1.39e-29	-0.63	-0.51	Uric acid levels;	chr4:39105295	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.748	rs4974933	ENSG00000249207.1	RP11-360F5.1	-12.9	8.56e-33	1.39e-29	-0.63	-0.51	Uric acid levels;	chr4:39105636	chr4:39112677~39126818:-
THCA	cis	rs227275	0.554	rs223388	ENSG00000246560.2	RP11-10L12.4	12.9	8.58e-33	1.39e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102828287	chr4:102828055~102844075:+
THCA	cis	rs3096299	0.586	rs4572400	ENSG00000274627.1	RP11-104N10.2	12.9	8.58e-33	1.39e-29	0.49	0.51	Multiple myeloma (IgH translocation);	chr16:89467108	chr16:89516797~89522217:+
THCA	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	12.9	8.58e-33	1.39e-29	0.61	0.51	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
THCA	cis	rs5769707	0.609	rs2071890	ENSG00000188511.11	C22orf34	12.9	8.61e-33	1.4e-29	0.64	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49414524~49657542:-
THCA	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-12.9	8.64e-33	1.4e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
THCA	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	12.89	9.01e-33	1.46e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
THCA	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	12.89	9.38e-33	1.52e-29	0.48	0.51	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
THCA	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-12.89	9.39e-33	1.52e-29	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
THCA	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-12.89	9.4e-33	1.52e-29	-0.61	-0.51	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
THCA	cis	rs992157	0.56	rs10932763	ENSG00000261338.2	RP11-378A13.1	-12.89	9.41e-33	1.52e-29	-0.51	-0.51	Colorectal cancer;	chr2:218221140	chr2:218255319~218257366:+
THCA	cis	rs227275	0.554	rs223436	ENSG00000246560.2	RP11-10L12.4	12.89	9.44e-33	1.53e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102798749	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223424	ENSG00000246560.2	RP11-10L12.4	12.89	9.44e-33	1.53e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102804177	chr4:102828055~102844075:+
THCA	cis	rs227275	0.524	rs223423	ENSG00000246560.2	RP11-10L12.4	12.89	9.44e-33	1.53e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102804737	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223422	ENSG00000246560.2	RP11-10L12.4	12.89	9.44e-33	1.53e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102805616	chr4:102828055~102844075:+
THCA	cis	rs9928842	0.823	rs6564243	ENSG00000280152.1	RP11-331F4.5	12.89	9.53e-33	1.54e-29	0.72	0.51	Alcoholic chronic pancreatitis;	chr16:75262103	chr16:75245994~75250077:-
THCA	cis	rs8062405	0.756	rs151301	ENSG00000259982.1	CDC37P1	12.89	9.54e-33	1.54e-29	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28700294~28701540:-
THCA	cis	rs992157	0.56	rs6436048	ENSG00000261338.2	RP11-378A13.1	12.88	9.62e-33	1.56e-29	0.52	0.51	Colorectal cancer;	chr2:218244310	chr2:218255319~218257366:+
THCA	cis	rs6142102	0.625	rs6142051	ENSG00000276073.1	RP5-1125A11.7	-12.88	9.64e-33	1.56e-29	-0.45	-0.51	Skin pigmentation;	chr20:33945212	chr20:33985617~33988989:-
THCA	cis	rs227275	0.554	rs223439	ENSG00000246560.2	RP11-10L12.4	12.88	9.75e-33	1.58e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102798377	chr4:102828055~102844075:+
THCA	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	12.88	9.76e-33	1.58e-29	0.48	0.51	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
THCA	cis	rs934734	0.532	rs2028150	ENSG00000204929.10	AC074391.1	-12.88	9.78e-33	1.58e-29	-0.62	-0.51	Rheumatoid arthritis;	chr2:65427878	chr2:65436711~66084639:+
THCA	cis	rs934734	0.532	rs2028151	ENSG00000204929.10	AC074391.1	-12.88	9.78e-33	1.58e-29	-0.62	-0.51	Rheumatoid arthritis;	chr2:65428479	chr2:65436711~66084639:+
THCA	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	12.88	9.83e-33	1.59e-29	0.47	0.51	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
THCA	cis	rs227275	0.554	rs223442	ENSG00000246560.2	RP11-10L12.4	12.88	9.92e-33	1.61e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102793960	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223441	ENSG00000246560.2	RP11-10L12.4	12.88	9.92e-33	1.61e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102794228	chr4:102828055~102844075:+
THCA	cis	rs227275	0.524	rs150894	ENSG00000246560.2	RP11-10L12.4	12.88	9.94e-33	1.61e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102811541	chr4:102828055~102844075:+
THCA	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	12.88	1e-32	1.62e-29	0.48	0.51	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
THCA	cis	rs587080	0.654	rs595366	ENSG00000245532.5	NEAT1	-12.88	1e-32	1.62e-29	-0.38	-0.51	Plateletcrit;	chr11:65429460	chr11:65422774~65445540:+
THCA	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-12.88	1.01e-32	1.63e-29	-0.4	-0.51	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-12.88	1.01e-32	1.63e-29	-0.4	-0.51	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-12.88	1.03e-32	1.66e-29	-0.38	-0.51	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	12.88	1.03e-32	1.66e-29	0.41	0.51	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
THCA	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-12.88	1.03e-32	1.67e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
THCA	cis	rs227275	0.554	rs223409	ENSG00000246560.2	RP11-10L12.4	12.88	1.04e-32	1.67e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102815023	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223404	ENSG00000246560.2	RP11-10L12.4	12.88	1.04e-32	1.67e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102816951	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs150895	ENSG00000246560.2	RP11-10L12.4	12.88	1.04e-32	1.69e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102791432	chr4:102828055~102844075:+
THCA	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-12.88	1.05e-32	1.69e-29	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-12.88	1.05e-32	1.69e-29	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
THCA	cis	rs9309473	1	rs6715819	ENSG00000163016.8	ALMS1P	12.88	1.05e-32	1.7e-29	0.76	0.51	Metabolite levels;	chr2:73545182	chr2:73644919~73685576:+
THCA	cis	rs8062405	1	rs11861174	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62037367	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs7198606	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.929	rs11864750	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.964	rs7193733	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs8055982	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs7498665	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.964	rs11864107	ENSG00000251417.2	RP11-1348G14.4	-12.88	1.05e-32	1.7e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28802743~28817828:+
THCA	cis	rs9309473	1	rs6546835	ENSG00000163016.8	ALMS1P	12.87	1.06e-32	1.71e-29	0.73	0.51	Metabolite levels;	chr2:73437587	chr2:73644919~73685576:+
THCA	cis	rs992157	0.735	rs13393821	ENSG00000261338.2	RP11-378A13.1	12.87	1.06e-32	1.71e-29	0.53	0.51	Colorectal cancer;	chr2:218212019	chr2:218255319~218257366:+
THCA	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	12.87	1.06e-32	1.71e-29	0.38	0.51	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	12.87	1.06e-32	1.71e-29	0.38	0.51	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	12.87	1.06e-32	1.71e-29	0.38	0.51	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
THCA	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	12.87	1.06e-32	1.72e-29	0.48	0.51	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
THCA	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	12.87	1.07e-32	1.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
THCA	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	12.87	1.08e-32	1.74e-29	0.54	0.51	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
THCA	cis	rs7772486	0.79	rs6570723	ENSG00000235652.6	RP11-545I5.3	12.87	1.08e-32	1.74e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145830094	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs6570724	ENSG00000235652.6	RP11-545I5.3	12.87	1.08e-32	1.74e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145830147	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs6917135	ENSG00000235652.6	RP11-545I5.3	12.87	1.08e-32	1.74e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145831290	chr6:145799409~145886585:+
THCA	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	12.87	1.09e-32	1.76e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	12.87	1.09e-32	1.76e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	12.87	1.09e-32	1.76e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	12.87	1.09e-32	1.76e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	12.87	1.09e-32	1.76e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
THCA	cis	rs8062405	1	rs62037371	ENSG00000251417.2	RP11-1348G14.4	-12.87	1.12e-32	1.8e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28802743~28817828:+
THCA	cis	rs9309473	0.898	rs10209517	ENSG00000163016.8	ALMS1P	12.87	1.12e-32	1.8e-29	0.74	0.51	Metabolite levels;	chr2:73618265	chr2:73644919~73685576:+
THCA	cis	rs227275	0.554	rs223367	ENSG00000246560.2	RP11-10L12.4	12.87	1.13e-32	1.82e-29	0.64	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102843836	chr4:102828055~102844075:+
THCA	cis	rs7772486	0.686	rs857880	ENSG00000235652.6	RP11-545I5.3	-12.87	1.15e-32	1.85e-29	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145649979	chr6:145799409~145886585:+
THCA	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	12.87	1.15e-32	1.85e-29	0.62	0.51	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
THCA	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	12.86	1.17e-32	1.88e-29	0.62	0.51	Height;	chr11:118761813	chr11:118688039~118690600:-
THCA	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	12.86	1.17e-32	1.88e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
THCA	cis	rs5769707	0.667	rs4824069	ENSG00000188511.11	C22orf34	12.86	1.18e-32	1.9e-29	0.67	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49414524~49657542:-
THCA	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	12.86	1.18e-32	1.9e-29	0.52	0.51	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
THCA	cis	rs8062405	1	rs3888190	ENSG00000251417.2	RP11-1348G14.4	-12.86	1.19e-32	1.92e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28802743~28817828:+
THCA	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	12.86	1.19e-32	1.92e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
THCA	cis	rs7576126	1	rs7576126	ENSG00000204929.10	AC074391.1	-12.86	1.2e-32	1.92e-29	-0.61	-0.51	Severe influenza A (H1N1) infection;	chr2:65431235	chr2:65436711~66084639:+
THCA	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	12.86	1.2e-32	1.93e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
THCA	cis	rs11722779	0.692	rs223414	ENSG00000246560.2	RP11-10L12.4	12.86	1.22e-32	1.95e-29	0.63	0.51	Schizophrenia;	chr4:102811688	chr4:102828055~102844075:+
THCA	cis	rs7772486	0.79	rs1832362	ENSG00000235652.6	RP11-545I5.3	12.86	1.22e-32	1.96e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145858819	chr6:145799409~145886585:+
THCA	cis	rs227275	0.554	rs223395	ENSG00000246560.2	RP11-10L12.4	12.86	1.23e-32	1.97e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102823801	chr4:102828055~102844075:+
THCA	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-12.86	1.23e-32	1.98e-29	-0.65	-0.51	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
THCA	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	12.86	1.24e-32	1.99e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	12.86	1.24e-32	1.99e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
THCA	cis	rs934734	0.673	rs754110	ENSG00000204929.10	AC074391.1	12.86	1.25e-32	2e-29	0.61	0.51	Rheumatoid arthritis;	chr2:65464626	chr2:65436711~66084639:+
THCA	cis	rs6142102	0.625	rs4911137	ENSG00000276073.1	RP5-1125A11.7	-12.86	1.26e-32	2.03e-29	-0.45	-0.51	Skin pigmentation;	chr20:33947657	chr20:33985617~33988989:-
THCA	cis	rs227275	0.554	rs223399	ENSG00000246560.2	RP11-10L12.4	12.86	1.27e-32	2.03e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102820800	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223386	ENSG00000246560.2	RP11-10L12.4	12.86	1.27e-32	2.03e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102829111	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223385	ENSG00000246560.2	RP11-10L12.4	12.86	1.27e-32	2.03e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102829159	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.873	rs223384	ENSG00000246560.2	RP11-10L12.4	12.86	1.27e-32	2.03e-29	0.63	0.51	Schizophrenia;	chr4:102829976	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223383	ENSG00000246560.2	RP11-10L12.4	12.86	1.27e-32	2.03e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102830094	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223382	ENSG00000246560.2	RP11-10L12.4	12.86	1.27e-32	2.03e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102831145	chr4:102828055~102844075:+
THCA	cis	rs7772486	0.79	rs2249147	ENSG00000235652.6	RP11-545I5.3	12.85	1.3e-32	2.09e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145863863	chr6:145799409~145886585:+
THCA	cis	rs228614	0.51	rs223377	ENSG00000246560.2	RP11-10L12.4	12.85	1.3e-32	2.09e-29	0.63	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102834919	chr4:102828055~102844075:+
THCA	cis	rs494459	0.838	rs567680	ENSG00000255239.1	AP002954.6	12.85	1.33e-32	2.13e-29	0.62	0.51	Height;	chr11:118737823	chr11:118688039~118690600:-
THCA	cis	rs9309473	1	rs3738848	ENSG00000163016.8	ALMS1P	12.85	1.34e-32	2.15e-29	0.74	0.51	Metabolite levels;	chr2:73534754	chr2:73644919~73685576:+
THCA	cis	rs934734	0.532	rs7569257	ENSG00000204929.10	AC074391.1	-12.85	1.34e-32	2.15e-29	-0.62	-0.51	Rheumatoid arthritis;	chr2:65429842	chr2:65436711~66084639:+
THCA	cis	rs2288884	0.515	rs9676397	ENSG00000275055.1	CTC-471J1.11	-12.85	1.35e-32	2.16e-29	-0.39	-0.51	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52076750	chr19:52049007~52049754:+
THCA	cis	rs8062405	1	rs8061590	ENSG00000251417.2	RP11-1348G14.4	-12.85	1.35e-32	2.16e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28802743~28817828:+
THCA	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	12.85	1.37e-32	2.2e-29	0.52	0.51	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
THCA	cis	rs227275	0.554	rs223357	ENSG00000246560.2	RP11-10L12.4	12.85	1.4e-32	2.24e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102851095	chr4:102828055~102844075:+
THCA	cis	rs732716	0.889	rs11085074	ENSG00000267769.1	CTB-50L17.9	-12.84	1.42e-32	2.27e-29	-0.67	-0.51	Mean corpuscular volume;	chr19:4386355	chr19:4454014~4455286:+
THCA	cis	rs732716	0.889	rs55637375	ENSG00000267769.1	CTB-50L17.9	-12.84	1.42e-32	2.27e-29	-0.67	-0.51	Mean corpuscular volume;	chr19:4386848	chr19:4454014~4455286:+
THCA	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-12.84	1.44e-32	2.3e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-12.84	1.44e-32	2.3e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.754	rs702304	ENSG00000235652.6	RP11-545I5.3	-12.84	1.47e-32	2.35e-29	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145669661	chr6:145799409~145886585:+
THCA	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	12.84	1.48e-32	2.37e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
THCA	cis	rs934734	0.532	rs10184881	ENSG00000204929.10	AC074391.1	-12.84	1.48e-32	2.37e-29	-0.61	-0.51	Rheumatoid arthritis;	chr2:65457018	chr2:65436711~66084639:+
THCA	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	12.84	1.5e-32	2.4e-29	0.6	0.51	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
THCA	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-12.84	1.52e-32	2.43e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
THCA	cis	rs9309473	0.66	rs56131703	ENSG00000163016.8	ALMS1P	12.84	1.53e-32	2.45e-29	0.9	0.51	Metabolite levels;	chr2:73620133	chr2:73644919~73685576:+
THCA	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	12.84	1.53e-32	2.45e-29	0.62	0.51	Height;	chr11:118737916	chr11:118688039~118690600:-
THCA	cis	rs6496932	0.802	rs6497006	ENSG00000218052.5	ADAMTS7P4	12.84	1.55e-32	2.47e-29	0.66	0.51	Central corneal thickness;Corneal structure;	chr15:85330306	chr15:85255369~85330334:-
THCA	cis	rs732716	0.853	rs62129349	ENSG00000267769.1	CTB-50L17.9	-12.83	1.56e-32	2.49e-29	-0.67	-0.51	Mean corpuscular volume;	chr19:4385662	chr19:4454014~4455286:+
THCA	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-12.83	1.56e-32	2.5e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-12.83	1.56e-32	2.5e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-12.83	1.56e-32	2.5e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.79	rs7753833	ENSG00000235652.6	RP11-545I5.3	12.83	1.57e-32	2.5e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145840296	chr6:145799409~145886585:+
THCA	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	12.83	1.58e-32	2.51e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	12.83	1.58e-32	2.51e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	12.83	1.58e-32	2.51e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	12.83	1.58e-32	2.51e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
THCA	cis	rs9309473	0.606	rs79234109	ENSG00000163016.8	ALMS1P	12.83	1.59e-32	2.53e-29	0.94	0.51	Metabolite levels;	chr2:73621227	chr2:73644919~73685576:+
THCA	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	12.83	1.59e-32	2.53e-29	0.77	0.51	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
THCA	cis	rs2658782	0.901	rs7116173	ENSG00000279684.1	RP11-755E23.2	12.83	1.59e-32	2.54e-29	0.85	0.51	Pulmonary function decline;	chr11:93489145	chr11:93286629~93288903:-
THCA	cis	rs7772486	0.686	rs857883	ENSG00000235652.6	RP11-545I5.3	-12.83	1.6e-32	2.56e-29	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145648078	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs857882	ENSG00000235652.6	RP11-545I5.3	-12.83	1.6e-32	2.56e-29	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145648580	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs857877	ENSG00000235652.6	RP11-545I5.3	-12.83	1.6e-32	2.56e-29	-0.47	-0.51	Lobe attachment (rater-scored or self-reported);	chr6:145655094	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-12.83	1.64e-32	2.62e-29	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
THCA	cis	rs587080	0.624	rs512715	ENSG00000245532.5	NEAT1	-12.83	1.65e-32	2.64e-29	-0.37	-0.51	Plateletcrit;	chr11:65423737	chr11:65422774~65445540:+
THCA	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-12.83	1.66e-32	2.64e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
THCA	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	12.83	1.66e-32	2.64e-29	0.6	0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
THCA	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-12.83	1.66e-32	2.64e-29	-0.62	-0.51	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
THCA	cis	rs6570726	0.764	rs9403733	ENSG00000235652.6	RP11-545I5.3	12.83	1.67e-32	2.67e-29	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145591175	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.738	rs6917199	ENSG00000235652.6	RP11-545I5.3	12.83	1.67e-32	2.67e-29	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145597184	chr6:145799409~145886585:+
THCA	cis	rs8062405	1	rs8055138	ENSG00000251417.2	RP11-1348G14.4	-12.83	1.69e-32	2.69e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28802743~28817828:+
THCA	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	12.82	1.73e-32	2.75e-29	0.62	0.51	Height;	chr11:118746590	chr11:118688039~118690600:-
THCA	cis	rs8062405	0.728	rs8056890	ENSG00000259982.1	CDC37P1	12.82	1.73e-32	2.75e-29	0.64	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28700294~28701540:-
THCA	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-12.82	1.75e-32	2.79e-29	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
THCA	cis	rs9309473	0.95	rs13391258	ENSG00000163016.8	ALMS1P	12.82	1.76e-32	2.8e-29	0.76	0.51	Metabolite levels;	chr2:73621806	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.898	rs6546861	ENSG00000163016.8	ALMS1P	12.82	1.76e-32	2.8e-29	0.76	0.51	Metabolite levels;	chr2:73622734	chr2:73644919~73685576:+
THCA	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-12.82	1.78e-32	2.84e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
THCA	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-12.82	1.8e-32	2.87e-29	-0.72	-0.51	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
THCA	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
THCA	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
THCA	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
THCA	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
THCA	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
THCA	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-12.82	1.81e-32	2.87e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
THCA	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	12.82	1.83e-32	2.91e-29	0.59	0.51	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
THCA	cis	rs2288884	0.537	rs9636140	ENSG00000275055.1	CTC-471J1.11	-12.82	1.85e-32	2.93e-29	-0.39	-0.51	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056610	chr19:52049007~52049754:+
THCA	cis	rs1062177	0.855	rs919263	ENSG00000213433.5	RPLP1P6	-12.82	1.85e-32	2.94e-29	-0.52	-0.51	Preschool internalizing problems;	chr5:151886292	chr5:151765859~151766378:-
THCA	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	12.82	1.86e-32	2.95e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	12.82	1.86e-32	2.95e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	12.82	1.86e-32	2.95e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	12.82	1.86e-32	2.95e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
THCA	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	12.81	1.88e-32	2.99e-29	0.46	0.51	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
THCA	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	12.81	1.89e-32	3e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	12.81	1.89e-32	3e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	12.81	1.89e-32	3e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
THCA	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	12.81	1.92e-32	3.05e-29	0.56	0.51	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
THCA	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-12.81	1.92e-32	3.05e-29	-0.64	-0.51	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
THCA	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	12.81	1.93e-32	3.07e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.569	rs7720588	ENSG00000249664.1	CTD-2227C6.2	12.81	1.96e-32	3.1e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83081107	chr5:83012285~83013109:-
THCA	cis	rs11159086	1	rs4899514	ENSG00000259005.1	RP3-449M8.6	-12.81	1.99e-32	3.16e-29	-0.54	-0.51	Advanced glycation end-product levels;	chr14:74473467	chr14:74474007~74474864:-
THCA	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	12.81	2e-32	3.18e-29	0.49	0.51	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
THCA	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	12.81	2.01e-32	3.18e-29	0.61	0.51	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
THCA	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	12.8	2.07e-32	3.28e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	12.8	2.07e-32	3.28e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
THCA	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	12.8	2.08e-32	3.3e-29	0.62	0.51	Height;	chr11:118747911	chr11:118688039~118690600:-
THCA	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-12.8	2.08e-32	3.3e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-12.8	2.08e-32	3.3e-29	-0.59	-0.51	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.663	rs9996501	ENSG00000245958.5	RP11-33B1.1	-12.8	2.1e-32	3.33e-29	-0.5	-0.51	Corneal astigmatism;	chr4:119317763	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.697	rs28458294	ENSG00000245958.5	RP11-33B1.1	-12.8	2.1e-32	3.33e-29	-0.5	-0.51	Corneal astigmatism;	chr4:119317769	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.663	rs28369503	ENSG00000245958.5	RP11-33B1.1	-12.8	2.1e-32	3.33e-29	-0.5	-0.51	Corneal astigmatism;	chr4:119317770	chr4:119454791~119552025:+
THCA	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-12.8	2.1e-32	3.33e-29	-0.75	-0.51	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
THCA	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-12.8	2.1e-32	3.33e-29	-0.62	-0.51	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
THCA	cis	rs5769707	0.706	rs2071903	ENSG00000188511.11	C22orf34	12.8	2.13e-32	3.37e-29	0.66	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49414524~49657542:-
THCA	cis	rs8062405	1	rs4788102	ENSG00000251417.2	RP11-1348G14.4	-12.8	2.19e-32	3.47e-29	-0.49	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28802743~28817828:+
THCA	cis	rs9309473	0.95	rs6711001	ENSG00000163016.8	ALMS1P	12.8	2.22e-32	3.51e-29	0.76	0.51	Metabolite levels;	chr2:73623693	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs10175180	ENSG00000163016.8	ALMS1P	12.8	2.24e-32	3.54e-29	0.73	0.51	Metabolite levels;	chr2:73445995	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs10496191	ENSG00000163016.8	ALMS1P	12.8	2.24e-32	3.54e-29	0.73	0.51	Metabolite levels;	chr2:73446670	chr2:73644919~73685576:+
THCA	cis	rs7772486	0.727	rs10447449	ENSG00000235652.6	RP11-545I5.3	12.8	2.25e-32	3.55e-29	0.46	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145817571	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs9386133	ENSG00000235652.6	RP11-545I5.3	12.8	2.25e-32	3.55e-29	0.46	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145820077	chr6:145799409~145886585:+
THCA	cis	rs5769707	0.604	rs1018814	ENSG00000188511.11	C22orf34	12.8	2.25e-32	3.56e-29	0.67	0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49414524~49657542:-
THCA	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-12.79	2.27e-32	3.59e-29	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
THCA	cis	rs9928842	0.77	rs8048371	ENSG00000280152.1	RP11-331F4.5	12.79	2.28e-32	3.61e-29	0.73	0.51	Alcoholic chronic pancreatitis;	chr16:75241649	chr16:75245994~75250077:-
THCA	cis	rs7429990	0.965	rs7651237	ENSG00000229759.1	MRPS18AP1	-12.79	2.31e-32	3.65e-29	-0.64	-0.51	Educational attainment (years of education);	chr3:48064038	chr3:48256350~48256938:-
THCA	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-12.79	2.32e-32	3.66e-29	-0.64	-0.51	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
THCA	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	12.79	2.32e-32	3.67e-29	0.46	0.51	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
THCA	cis	rs7829975	0.539	rs35571782	ENSG00000253893.2	FAM85B	-12.79	2.33e-32	3.68e-29	-0.65	-0.51	Mood instability;	chr8:8284301	chr8:8167819~8226614:-
THCA	cis	rs9322193	0.923	rs2880436	ENSG00000223701.3	RAET1E-AS1	12.79	2.33e-32	3.68e-29	0.7	0.51	Lung cancer;	chr6:149859123	chr6:149884431~149919508:+
THCA	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	12.79	2.34e-32	3.7e-29	0.67	0.51	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
THCA	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	12.79	2.35e-32	3.72e-29	0.73	0.51	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	12.79	2.35e-32	3.72e-29	0.73	0.51	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
THCA	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	12.79	2.36e-32	3.73e-29	0.61	0.51	Height;	chr11:118742526	chr11:118688039~118690600:-
THCA	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-12.79	2.37e-32	3.74e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
THCA	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-12.79	2.37e-32	3.74e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
THCA	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	12.79	2.37e-32	3.74e-29	0.6	0.51	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
THCA	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	12.79	2.37e-32	3.74e-29	0.6	0.51	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
THCA	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	12.79	2.38e-32	3.76e-29	0.61	0.51	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
THCA	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	12.79	2.38e-32	3.77e-29	0.65	0.51	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
THCA	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-12.79	2.4e-32	3.79e-29	-0.64	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
THCA	cis	rs9309473	1	rs1403284	ENSG00000163016.8	ALMS1P	-12.79	2.4e-32	3.8e-29	-0.77	-0.51	Metabolite levels;	chr2:73499535	chr2:73644919~73685576:+
THCA	cis	rs1823874	0.581	rs12905599	ENSG00000182397.13	DNM1P46	-12.79	2.45e-32	3.87e-29	-0.62	-0.51	IgG glycosylation;	chr15:99799733	chr15:99790156~99806927:-
THCA	cis	rs6570726	0.791	rs11759979	ENSG00000235652.6	RP11-545I5.3	12.79	2.46e-32	3.89e-29	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145597745	chr6:145799409~145886585:+
THCA	cis	rs934734	0.673	rs7575614	ENSG00000204929.10	AC074391.1	12.79	2.46e-32	3.89e-29	0.6	0.51	Rheumatoid arthritis;	chr2:65462666	chr2:65436711~66084639:+
THCA	cis	rs934734	0.673	rs6742215	ENSG00000204929.10	AC074391.1	12.79	2.46e-32	3.89e-29	0.6	0.51	Rheumatoid arthritis;	chr2:65463362	chr2:65436711~66084639:+
THCA	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	12.78	2.51e-32	3.96e-29	0.74	0.51	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
THCA	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	12.78	2.51e-32	3.97e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
THCA	cis	rs7772486	0.754	rs9497419	ENSG00000235652.6	RP11-545I5.3	12.78	2.54e-32	4e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145821473	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs6921073	ENSG00000235652.6	RP11-545I5.3	12.78	2.54e-32	4e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145823241	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.727	rs12190966	ENSG00000235652.6	RP11-545I5.3	12.78	2.54e-32	4e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145825684	chr6:145799409~145886585:+
THCA	cis	rs934734	0.532	rs6546151	ENSG00000204929.10	AC074391.1	-12.78	2.54e-32	4.01e-29	-0.61	-0.51	Rheumatoid arthritis;	chr2:65449449	chr2:65436711~66084639:+
THCA	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	12.78	2.61e-32	4.12e-29	0.59	0.51	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
THCA	cis	rs6504950	0.72	rs9895901	ENSG00000275710.1	RP11-257O5.4	12.78	2.63e-32	4.15e-29	0.66	0.51	Breast cancer;	chr17:54907524	chr17:54964474~54964679:+
THCA	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	12.78	2.63e-32	4.15e-29	0.61	0.51	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
THCA	cis	rs227275	0.554	rs223319	ENSG00000246560.2	RP11-10L12.4	12.78	2.63e-32	4.15e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102881157	chr4:102828055~102844075:+
THCA	cis	rs228614	0.509	rs223318	ENSG00000246560.2	RP11-10L12.4	12.78	2.63e-32	4.15e-29	0.63	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102881422	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223315	ENSG00000246560.2	RP11-10L12.4	12.78	2.63e-32	4.15e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102884286	chr4:102828055~102844075:+
THCA	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	12.78	2.64e-32	4.16e-29	0.58	0.51	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
THCA	cis	rs6570726	0.791	rs2096201	ENSG00000235652.6	RP11-545I5.3	12.78	2.64e-32	4.17e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145613137	chr6:145799409~145886585:+
THCA	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	12.78	2.64e-32	4.17e-29	0.62	0.51	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
THCA	cis	rs9322193	0.923	rs9371207	ENSG00000223701.3	RAET1E-AS1	12.78	2.68e-32	4.23e-29	0.7	0.51	Lung cancer;	chr6:149858087	chr6:149884431~149919508:+
THCA	cis	rs9309473	0.898	rs10170786	ENSG00000163016.8	ALMS1P	12.78	2.7e-32	4.25e-29	0.73	0.51	Metabolite levels;	chr2:73585861	chr2:73644919~73685576:+
THCA	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	12.78	2.73e-32	4.3e-29	0.56	0.51	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
THCA	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	12.78	2.73e-32	4.31e-29	0.6	0.51	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
THCA	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	12.78	2.74e-32	4.31e-29	0.38	0.51	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
THCA	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-12.77	2.79e-32	4.39e-29	-0.62	-0.51	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
THCA	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	12.77	2.81e-32	4.43e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
THCA	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-12.77	2.86e-32	4.51e-29	-0.72	-0.51	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
THCA	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-12.77	2.86e-32	4.51e-29	-0.62	-0.51	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-12.77	2.86e-32	4.51e-29	-0.62	-0.51	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-12.77	2.86e-32	4.51e-29	-0.62	-0.51	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-12.77	2.86e-32	4.51e-29	-0.62	-0.51	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
THCA	cis	rs9309473	0.606	rs6759452	ENSG00000163016.8	ALMS1P	12.77	2.87e-32	4.51e-29	0.93	0.51	Metabolite levels;	chr2:73651225	chr2:73644919~73685576:+
THCA	cis	rs11098499	0.566	rs17051356	ENSG00000245958.5	RP11-33B1.1	-12.77	2.87e-32	4.52e-29	-0.51	-0.51	Corneal astigmatism;	chr4:119664153	chr4:119454791~119552025:+
THCA	cis	rs11673344	0.808	rs57916401	ENSG00000226686.6	LINC01535	12.77	2.89e-32	4.55e-29	0.59	0.51	Obesity-related traits;	chr19:37153149	chr19:37251912~37265535:+
THCA	cis	rs7188445	0.688	rs4889015	ENSG00000261390.4	RP11-345M22.2	12.77	2.9e-32	4.56e-29	0.6	0.51	Urate levels;	chr16:79684833	chr16:79715232~79770563:-
THCA	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-12.77	2.91e-32	4.57e-29	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
THCA	cis	rs227275	0.554	rs223359	ENSG00000246560.2	RP11-10L12.4	12.77	2.91e-32	4.58e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102849422	chr4:102828055~102844075:+
THCA	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	12.77	3e-32	4.72e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
THCA	cis	rs228614	0.51	rs170565	ENSG00000246560.2	RP11-10L12.4	12.77	3.01e-32	4.74e-29	0.66	0.51	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798277	chr4:102828055~102844075:+
THCA	cis	rs6683071	0.601	rs3002129	ENSG00000272750.1	RP11-378J18.8	12.76	3.05e-32	4.79e-29	0.62	0.51	Cognitive performance;	chr1:222681993	chr1:222658867~222661512:-
THCA	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	12.76	3.05e-32	4.79e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	12.76	3.05e-32	4.79e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	12.76	3.05e-32	4.79e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
THCA	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-12.76	3.05e-32	4.8e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
THCA	cis	rs1823874	0.581	rs12910401	ENSG00000182397.13	DNM1P46	-12.76	3.07e-32	4.82e-29	-0.62	-0.51	IgG glycosylation;	chr15:99799692	chr15:99790156~99806927:-
THCA	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	12.76	3.07e-32	4.83e-29	0.62	0.51	Height;	chr3:53085313	chr3:53064283~53065091:-
THCA	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	12.76	3.08e-32	4.84e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	12.76	3.08e-32	4.84e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	12.76	3.08e-32	4.84e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
THCA	cis	rs227275	0.554	rs223339	ENSG00000246560.2	RP11-10L12.4	12.76	3.08e-32	4.84e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102864700	chr4:102828055~102844075:+
THCA	cis	rs7772486	0.79	rs2253880	ENSG00000235652.6	RP11-545I5.3	12.76	3.1e-32	4.87e-29	0.46	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145879638	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2814879	ENSG00000235652.6	RP11-545I5.3	12.76	3.1e-32	4.87e-29	0.46	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145880607	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs61944671	ENSG00000275759.1	RP11-131L12.3	-12.76	3.1e-32	4.87e-29	-0.74	-0.51	Glucose homeostasis traits;	chr12:118450046	chr12:118428281~118428870:+
THCA	cis	rs6570726	0.791	rs9399558	ENSG00000235652.6	RP11-545I5.3	12.76	3.12e-32	4.9e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145590594	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs9376953	ENSG00000235652.6	RP11-545I5.3	12.76	3.12e-32	4.9e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145591090	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs13202312	ENSG00000235652.6	RP11-545I5.3	12.76	3.12e-32	4.9e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145591957	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs7765675	ENSG00000235652.6	RP11-545I5.3	12.76	3.12e-32	4.9e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145593941	chr6:145799409~145886585:+
THCA	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-12.76	3.2e-32	5.02e-29	-0.37	-0.51	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
THCA	cis	rs2288884	0.515	rs11882053	ENSG00000275055.1	CTC-471J1.11	-12.76	3.23e-32	5.06e-29	-0.39	-0.51	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047687	chr19:52049007~52049754:+
THCA	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	12.76	3.3e-32	5.17e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	12.76	3.3e-32	5.17e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	12.76	3.3e-32	5.17e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	12.76	3.3e-32	5.17e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
THCA	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-12.75	3.38e-32	5.3e-29	-0.63	-0.51	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
THCA	cis	rs992157	0.687	rs10206984	ENSG00000261338.2	RP11-378A13.1	12.75	3.39e-32	5.31e-29	0.53	0.51	Colorectal cancer;	chr2:218202257	chr2:218255319~218257366:+
THCA	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	12.75	3.45e-32	5.4e-29	0.59	0.51	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
THCA	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-12.75	3.49e-32	5.47e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-12.75	3.49e-32	5.47e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
THCA	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	12.75	3.51e-32	5.5e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
THCA	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	12.75	3.54e-32	5.54e-29	0.53	0.51	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
THCA	cis	rs11098499	1	rs58601355	ENSG00000245958.5	RP11-33B1.1	-12.75	3.55e-32	5.55e-29	-0.5	-0.51	Corneal astigmatism;	chr4:119265212	chr4:119454791~119552025:+
THCA	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-12.75	3.6e-32	5.64e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-12.75	3.6e-32	5.64e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-12.75	3.6e-32	5.64e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
THCA	cis	rs6570726	0.791	rs6912079	ENSG00000235652.6	RP11-545I5.3	12.74	3.72e-32	5.82e-29	0.48	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145573813	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9376968	ENSG00000235652.6	RP11-545I5.3	12.74	3.76e-32	5.88e-29	0.46	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145859228	chr6:145799409~145886585:+
THCA	cis	rs6504950	1	rs17745344	ENSG00000275710.1	RP11-257O5.4	12.74	3.76e-32	5.89e-29	0.68	0.51	Breast cancer;	chr17:54970958	chr17:54964474~54964679:+
THCA	cis	rs9309473	0.95	rs6705977	ENSG00000163016.8	ALMS1P	12.74	3.79e-32	5.93e-29	0.76	0.51	Metabolite levels;	chr2:73622043	chr2:73644919~73685576:+
THCA	cis	rs11155671	0.53	rs9383940	ENSG00000268592.3	RAET1E-AS1	12.74	3.81e-32	5.96e-29	0.68	0.51	Testicular germ cell tumor;	chr6:149904923	chr6:149863494~149919507:+
THCA	cis	rs11098499	1	rs6849889	ENSG00000245958.5	RP11-33B1.1	-12.74	3.82e-32	5.97e-29	-0.49	-0.51	Corneal astigmatism;	chr4:119265193	chr4:119454791~119552025:+
THCA	cis	rs62158211	1	rs62158211	ENSG00000234997.1	AC016745.3	-12.74	3.85e-32	6.01e-29	-0.62	-0.51	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113348562	chr2:113424495~113425324:+
THCA	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	12.74	3.89e-32	6.08e-29	0.56	0.51	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
THCA	cis	rs9309473	0.606	rs1589576	ENSG00000163016.8	ALMS1P	12.74	3.89e-32	6.09e-29	0.84	0.51	Metabolite levels;	chr2:73511677	chr2:73644919~73685576:+
THCA	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	12.74	3.95e-32	6.17e-29	0.76	0.51	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
THCA	cis	rs638893	0.898	rs587816	ENSG00000278376.1	RP11-158I9.8	-12.74	3.96e-32	6.2e-29	-0.56	-0.51	Vitiligo;	chr11:118819162	chr11:118791254~118793137:+
THCA	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-12.74	4e-32	6.25e-29	-0.61	-0.51	Height;	chr11:118758322	chr11:118688039~118690600:-
THCA	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-12.74	4.01e-32	6.26e-29	-0.64	-0.51	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
THCA	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	12.73	4.04e-32	6.31e-29	0.59	0.51	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
THCA	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	12.73	4.05e-32	6.33e-29	0.76	0.51	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
THCA	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	12.73	4.08e-32	6.37e-29	0.59	0.51	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
THCA	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	12.73	4.11e-32	6.41e-29	0.6	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
THCA	cis	rs7301826	0.651	rs4759794	ENSG00000256250.1	RP11-989F5.1	-12.73	4.12e-32	6.43e-29	-0.61	-0.51	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs10773824	ENSG00000256250.1	RP11-989F5.1	-12.73	4.12e-32	6.43e-29	-0.61	-0.51	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810606~130812438:+
THCA	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-12.73	4.27e-32	6.66e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
THCA	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	12.73	4.29e-32	6.68e-29	0.49	0.51	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
THCA	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	12.73	4.32e-32	6.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	12.73	4.32e-32	6.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	12.73	4.32e-32	6.73e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
THCA	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	12.73	4.33e-32	6.75e-29	0.38	0.51	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
THCA	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	12.73	4.35e-32	6.79e-29	0.41	0.51	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	12.73	4.35e-32	6.79e-29	0.41	0.51	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
THCA	cis	rs11722779	0.81	rs223417	ENSG00000246560.2	RP11-10L12.4	12.73	4.39e-32	6.84e-29	0.63	0.51	Schizophrenia;	chr4:102810568	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.805	rs223416	ENSG00000246560.2	RP11-10L12.4	12.73	4.39e-32	6.84e-29	0.63	0.51	Schizophrenia;	chr4:102810580	chr4:102828055~102844075:+
THCA	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	12.72	4.59e-32	7.15e-29	0.37	0.51	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	12.72	4.59e-32	7.15e-29	0.37	0.51	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
THCA	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-12.72	4.59e-32	7.15e-29	-0.61	-0.51	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
THCA	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	12.72	4.63e-32	7.2e-29	0.61	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
THCA	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	12.72	4.67e-32	7.28e-29	0.53	0.51	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
THCA	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-12.72	4.69e-32	7.3e-29	-0.64	-0.51	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
THCA	cis	rs6504950	0.679	rs9908752	ENSG00000275710.1	RP11-257O5.4	12.72	4.81e-32	7.48e-29	0.66	0.51	Breast cancer;	chr17:54905855	chr17:54964474~54964679:+
THCA	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-12.72	4.81e-32	7.49e-29	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-12.72	4.81e-32	7.49e-29	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-12.72	4.81e-32	7.49e-29	-0.56	-0.51	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.806	rs7740785	ENSG00000235652.6	RP11-545I5.3	12.72	4.82e-32	7.5e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145850163	chr6:145799409~145886585:+
THCA	cis	rs6504950	0.695	rs9904377	ENSG00000275710.1	RP11-257O5.4	12.72	4.82e-32	7.5e-29	0.64	0.51	Breast cancer;	chr17:54908621	chr17:54964474~54964679:+
THCA	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-12.72	4.84e-32	7.53e-29	-0.57	-0.51	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
THCA	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	12.72	4.84e-32	7.53e-29	0.37	0.51	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	12.72	4.84e-32	7.53e-29	0.37	0.51	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
THCA	cis	rs944289	0.616	rs408783	ENSG00000257826.1	RP11-116N8.4	12.72	4.84e-32	7.53e-29	0.53	0.51	Thyroid cancer;	chr14:36065667	chr14:36061026~36067190:-
THCA	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-12.71	5.02e-32	7.81e-29	-0.88	-0.51	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
THCA	cis	rs6452524	0.901	rs2662238	ENSG00000249664.1	CTD-2227C6.2	12.71	5.14e-32	7.98e-29	0.66	0.51	Hypertension (SNP x SNP interaction);	chr5:83203488	chr5:83012285~83013109:-
THCA	cis	rs9309473	1	rs11903916	ENSG00000163016.8	ALMS1P	12.71	5.25e-32	8.15e-29	0.72	0.51	Metabolite levels;	chr2:73588201	chr2:73644919~73685576:+
THCA	cis	rs6570726	0.791	rs9403734	ENSG00000235652.6	RP11-545I5.3	12.71	5.27e-32	8.18e-29	0.47	0.51	Lobe attachment (rater-scored or self-reported);	chr6:145610323	chr6:145799409~145886585:+
THCA	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	12.71	5.28e-32	8.19e-29	0.59	0.51	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
THCA	cis	rs227275	0.527	rs223308	ENSG00000246560.2	RP11-10L12.4	12.71	5.29e-32	8.21e-29	0.63	0.51	Allergic disease (asthma, hay fever or eczema);	chr4:102891342	chr4:102828055~102844075:+
THCA	cis	rs8062405	0.679	rs72793818	ENSG00000251417.2	RP11-1348G14.4	-12.71	5.32e-32	8.25e-29	-0.48	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28802743~28817828:+
THCA	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	12.71	5.33e-32	8.27e-29	0.64	0.51	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
THCA	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-12.7	5.38e-32	8.34e-29	-0.58	-0.51	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
THCA	cis	rs12220777	0.585	rs75995665	ENSG00000230091.5	TMEM254-AS1	12.7	5.41e-32	8.39e-29	0.9	0.51	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80017462	chr10:80046860~80078912:-
THCA	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-12.7	5.42e-32	8.41e-29	-0.62	-0.51	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
THCA	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	12.7	5.43e-32	8.42e-29	0.65	0.51	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
THCA	cis	rs4500972	1	rs4500972	ENSG00000163016.8	ALMS1P	12.7	5.45e-32	8.45e-29	0.73	0.51	Glomerular filtration rate (creatinine);	chr2:73540770	chr2:73644919~73685576:+
THCA	cis	rs9928842	0.77	rs4888364	ENSG00000280152.1	RP11-331F4.5	12.7	5.47e-32	8.48e-29	0.71	0.51	Alcoholic chronic pancreatitis;	chr16:75245612	chr16:75245994~75250077:-
THCA	cis	rs4964805	0.626	rs4964827	ENSG00000257681.1	RP11-341G23.4	12.7	5.47e-32	8.48e-29	0.61	0.51	Attention deficit hyperactivity disorder;	chr12:103783303	chr12:103746315~103768858:-
THCA	cis	rs9309473	1	rs6546838	ENSG00000163016.8	ALMS1P	12.7	5.51e-32	8.54e-29	0.73	0.51	Metabolite levels;	chr2:73452153	chr2:73644919~73685576:+
THCA	cis	rs9481169	0.557	rs13190932	ENSG00000255389.1	C6orf3	-12.7	5.7e-32	8.83e-29	-1	-0.51	Inflammatory skin disease;	chr6:111591867	chr6:111599875~111602295:+
THCA	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	12.7	5.71e-32	8.85e-29	0.46	0.51	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
THCA	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-12.7	5.75e-32	8.91e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-12.7	5.75e-32	8.91e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
THCA	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-12.7	5.75e-32	8.91e-29	-0.57	-0.51	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
THCA	cis	rs62158211	0.908	rs62158169	ENSG00000234997.1	AC016745.3	-12.7	5.82e-32	9.01e-29	-0.61	-0.51	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113324250	chr2:113424495~113425324:+
THCA	cis	rs3091242	0.933	rs9645452	ENSG00000224183.1	SDHDP6	12.69	6.02e-32	9.31e-29	0.62	0.51	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25294164~25294643:-
THCA	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	12.69	6.05e-32	9.36e-29	0.59	0.51	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
THCA	cis	rs8062405	1	rs4451951	ENSG00000251417.2	RP11-1348G14.4	-12.69	6.12e-32	9.46e-29	-0.48	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28802743~28817828:+
THCA	cis	rs853679	0.517	rs868987	ENSG00000280107.1	AL022393.9	12.69	6.14e-32	9.49e-29	0.62	0.51	Depression;	chr6:28142370	chr6:28170845~28172521:+
THCA	cis	rs67180937	0.583	rs2936052	ENSG00000272750.1	RP11-378J18.8	12.69	6.28e-32	9.69e-29	0.6	0.51	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629034	chr1:222658867~222661512:-
THCA	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-12.69	6.42e-32	9.91e-29	-0.61	-0.51	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
THCA	cis	rs9309473	0.653	rs6718843	ENSG00000163016.8	ALMS1P	12.68	6.47e-32	9.98e-29	0.76	0.51	Metabolite levels;	chr2:73625378	chr2:73644919~73685576:+
THCA	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-12.68	6.49e-32	1e-28	-0.86	-0.51	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
THCA	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	12.68	6.62e-32	1.02e-28	0.6	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
THCA	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-12.68	6.63e-32	1.02e-28	-0.61	-0.5	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
THCA	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-12.68	6.65e-32	1.02e-28	-0.37	-0.5	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
THCA	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-12.68	6.74e-32	1.04e-28	-0.86	-0.5	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
THCA	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-12.68	6.78e-32	1.04e-28	-0.84	-0.5	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-12.68	6.78e-32	1.04e-28	-0.84	-0.5	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
THCA	cis	rs992157	0.56	rs7578940	ENSG00000261338.2	RP11-378A13.1	-12.68	6.8e-32	1.05e-28	-0.51	-0.5	Colorectal cancer;	chr2:218218595	chr2:218255319~218257366:+
THCA	cis	rs9309473	0.948	rs6719753	ENSG00000163016.8	ALMS1P	12.68	6.81e-32	1.05e-28	0.73	0.5	Metabolite levels;	chr2:73521927	chr2:73644919~73685576:+
THCA	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	12.68	6.83e-32	1.05e-28	0.56	0.5	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.79	rs2253764	ENSG00000235652.6	RP11-545I5.3	12.68	6.85e-32	1.05e-28	0.46	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145878745	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.535	rs7671759	ENSG00000245958.5	RP11-33B1.1	-12.68	6.92e-32	1.06e-28	-0.5	-0.5	Corneal astigmatism;	chr4:119326939	chr4:119454791~119552025:+
THCA	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-12.68	7e-32	1.08e-28	-0.69	-0.5	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
THCA	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	12.67	7.16e-32	1.1e-28	0.45	0.5	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
THCA	cis	rs9309473	1	rs10496193	ENSG00000163016.8	ALMS1P	12.67	7.25e-32	1.11e-28	0.74	0.5	Metabolite levels;	chr2:73546376	chr2:73644919~73685576:+
THCA	cis	rs7301826	0.571	rs4759788	ENSG00000256250.1	RP11-989F5.1	-12.67	7.36e-32	1.13e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810606~130812438:+
THCA	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	12.67	7.42e-32	1.14e-28	0.42	0.5	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
THCA	cis	rs638893	0.898	rs577121	ENSG00000278376.1	RP11-158I9.8	-12.67	7.44e-32	1.14e-28	-0.55	-0.5	Vitiligo;	chr11:118819841	chr11:118791254~118793137:+
THCA	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-12.67	7.47e-32	1.15e-28	-0.63	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
THCA	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	12.67	7.48e-32	1.15e-28	0.37	0.5	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	12.67	7.48e-32	1.15e-28	0.37	0.5	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	12.67	7.48e-32	1.15e-28	0.37	0.5	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
THCA	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	12.67	7.48e-32	1.15e-28	0.37	0.5	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
THCA	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-12.67	7.48e-32	1.15e-28	-0.37	-0.5	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
THCA	cis	rs6504950	0.72	rs9913784	ENSG00000275710.1	RP11-257O5.4	12.67	7.57e-32	1.16e-28	0.64	0.5	Breast cancer;	chr17:54911710	chr17:54964474~54964679:+
THCA	cis	rs934734	0.532	rs10153675	ENSG00000204929.10	AC074391.1	-12.67	7.6e-32	1.17e-28	-0.62	-0.5	Rheumatoid arthritis;	chr2:65422446	chr2:65436711~66084639:+
THCA	cis	rs9326248	0.516	rs6589577	ENSG00000254851.1	RP11-109L13.1	-12.67	7.65e-32	1.17e-28	-0.88	-0.5	Blood protein levels;	chr11:116879261	chr11:117135528~117138582:+
THCA	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	12.67	7.66e-32	1.17e-28	0.48	0.5	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
THCA	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	12.67	7.76e-32	1.19e-28	0.59	0.5	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
THCA	cis	rs6570726	0.818	rs437147	ENSG00000235652.6	RP11-545I5.3	12.66	7.99e-32	1.22e-28	0.48	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145554287	chr6:145799409~145886585:+
THCA	cis	rs62158211	1	rs1807282	ENSG00000234997.1	AC016745.3	-12.66	8e-32	1.23e-28	-0.61	-0.5	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113352459	chr2:113424495~113425324:+
THCA	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-12.66	8e-32	1.23e-28	-0.69	-0.5	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
THCA	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	12.66	8.02e-32	1.23e-28	0.66	0.5	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
THCA	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	12.66	8.09e-32	1.24e-28	0.61	0.5	Height;	chr11:118786602	chr11:118688039~118690600:-
THCA	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-12.66	8.15e-32	1.25e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.61	rs9668291	ENSG00000256250.1	RP11-989F5.1	-12.66	8.2e-32	1.26e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810606~130812438:+
THCA	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	12.66	8.24e-32	1.26e-28	0.4	0.5	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
THCA	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-12.66	8.27e-32	1.27e-28	-0.37	-0.5	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
THCA	cis	rs8062405	1	rs55991577	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs56358680	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62036626	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62036657	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs12444171	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs56404918	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs55719896	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs55830740	ENSG00000251417.2	RP11-1348G14.4	-12.66	8.28e-32	1.27e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28802743~28817828:+
THCA	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	12.66	8.39e-32	1.28e-28	0.65	0.5	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
THCA	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-12.66	8.47e-32	1.3e-28	-0.37	-0.5	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-12.66	8.47e-32	1.3e-28	-0.37	-0.5	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
THCA	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	12.66	8.5e-32	1.3e-28	0.59	0.5	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
THCA	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-12.66	8.53e-32	1.3e-28	-0.84	-0.5	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
THCA	cis	rs8062405	1	rs62036617	ENSG00000251417.2	RP11-1348G14.4	-12.65	8.62e-32	1.32e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs4788095	ENSG00000251417.2	RP11-1348G14.4	-12.65	8.62e-32	1.32e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.964	rs72793809	ENSG00000251417.2	RP11-1348G14.4	-12.65	8.62e-32	1.32e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62036620	ENSG00000251417.2	RP11-1348G14.4	-12.65	8.62e-32	1.32e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62036621	ENSG00000251417.2	RP11-1348G14.4	-12.65	8.62e-32	1.32e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28802743~28817828:+
THCA	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-12.65	8.79e-32	1.34e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
THCA	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-12.65	8.88e-32	1.36e-28	-0.58	-0.5	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
THCA	cis	rs11155671	0.53	rs2342770	ENSG00000268592.3	RAET1E-AS1	12.65	9.02e-32	1.38e-28	0.67	0.5	Testicular germ cell tumor;	chr6:149895549	chr6:149863494~149919507:+
THCA	cis	rs227275	0.525	rs223332	ENSG00000246560.2	RP11-10L12.4	12.65	9.05e-32	1.38e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102869029	chr4:102828055~102844075:+
THCA	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-12.65	9.07e-32	1.38e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
THCA	cis	rs11722779	0.869	rs223350	ENSG00000246560.2	RP11-10L12.4	12.65	9.17e-32	1.4e-28	0.63	0.5	Schizophrenia;	chr4:102856899	chr4:102828055~102844075:+
THCA	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	12.65	9.17e-32	1.4e-28	0.59	0.5	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
THCA	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-12.65	9.32e-32	1.42e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-12.65	9.32e-32	1.42e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
THCA	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-12.65	9.36e-32	1.43e-28	-0.56	-0.5	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
THCA	cis	rs227275	0.525	rs1383733	ENSG00000246560.2	RP11-10L12.4	12.65	9.39e-32	1.43e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102995297	chr4:102828055~102844075:+
THCA	cis	rs9309473	0.606	rs78941213	ENSG00000163016.8	ALMS1P	12.65	9.39e-32	1.43e-28	0.93	0.5	Metabolite levels;	chr2:73658010	chr2:73644919~73685576:+
THCA	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-12.65	9.41e-32	1.43e-28	-0.72	-0.5	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-12.64	9.47e-32	1.44e-28	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
THCA	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-12.64	9.49e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-12.64	9.5e-32	1.45e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
THCA	cis	rs7829975	0.511	rs2980423	ENSG00000253893.2	FAM85B	-12.64	9.6e-32	1.46e-28	-0.65	-0.5	Mood instability;	chr8:8285053	chr8:8167819~8226614:-
THCA	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-12.64	9.67e-32	1.47e-28	-0.7	-0.5	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
THCA	cis	rs227275	0.525	rs7685399	ENSG00000246560.2	RP11-10L12.4	12.64	9.73e-32	1.48e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102991926	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs7688940	ENSG00000246560.2	RP11-10L12.4	12.64	9.73e-32	1.48e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102994153	chr4:102828055~102844075:+
THCA	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-12.64	9.76e-32	1.49e-28	-0.63	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
THCA	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-12.64	9.76e-32	1.49e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
THCA	cis	rs8062405	0.895	rs56186137	ENSG00000251417.2	RP11-1348G14.4	-12.64	9.77e-32	1.49e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28802743~28817828:+
THCA	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-12.64	9.95e-32	1.51e-28	-0.37	-0.5	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
THCA	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-12.64	9.95e-32	1.51e-28	-0.37	-0.5	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-12.64	9.95e-32	1.51e-28	-0.37	-0.5	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-12.64	9.95e-32	1.51e-28	-0.37	-0.5	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-12.64	9.95e-32	1.51e-28	-0.37	-0.5	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-12.64	9.95e-32	1.51e-28	-0.37	-0.5	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
THCA	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-12.64	9.95e-32	1.51e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-12.64	1e-31	1.52e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
THCA	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-12.64	1e-31	1.53e-28	-0.56	-0.5	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
THCA	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	12.64	1.01e-31	1.53e-28	0.42	0.5	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
THCA	cis	rs11098499	0.532	rs4504231	ENSG00000245958.5	RP11-33B1.1	-12.64	1.01e-31	1.54e-28	-0.49	-0.5	Corneal astigmatism;	chr4:119665736	chr4:119454791~119552025:+
THCA	cis	rs2288884	0.537	rs12151270	ENSG00000275055.1	CTC-471J1.11	-12.64	1.02e-31	1.55e-28	-0.39	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058984	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.537	rs12151130	ENSG00000275055.1	CTC-471J1.11	-12.64	1.02e-31	1.55e-28	-0.39	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060531	chr19:52049007~52049754:+
THCA	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-12.64	1.02e-31	1.55e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-12.64	1.02e-31	1.56e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
THCA	cis	rs2288884	0.515	rs2869602	ENSG00000275055.1	CTC-471J1.11	-12.64	1.03e-31	1.57e-28	-0.39	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52072324	chr19:52049007~52049754:+
THCA	cis	rs11722779	0.935	rs7676736	ENSG00000246560.2	RP11-10L12.4	12.64	1.03e-31	1.57e-28	0.62	0.5	Schizophrenia;	chr4:103016729	chr4:102828055~102844075:+
THCA	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	12.64	1.03e-31	1.57e-28	0.77	0.5	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
THCA	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	12.63	1.04e-31	1.58e-28	0.59	0.5	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
THCA	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-12.63	1.05e-31	1.6e-28	-0.84	-0.5	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
THCA	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-12.63	1.05e-31	1.6e-28	-0.62	-0.5	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
THCA	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-12.63	1.06e-31	1.61e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	12.63	1.06e-31	1.61e-28	0.61	0.5	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
THCA	cis	rs934734	0.532	rs13383320	ENSG00000204929.10	AC074391.1	-12.63	1.06e-31	1.62e-28	-0.61	-0.5	Rheumatoid arthritis;	chr2:65418003	chr2:65436711~66084639:+
THCA	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	12.63	1.08e-31	1.64e-28	0.58	0.5	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	12.63	1.08e-31	1.64e-28	0.58	0.5	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	12.63	1.08e-31	1.64e-28	0.58	0.5	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
THCA	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-12.63	1.08e-31	1.64e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
THCA	cis	rs977987	0.528	rs9926933	ENSG00000261783.1	RP11-252K23.2	12.63	1.09e-31	1.65e-28	0.8	0.5	Dupuytren's disease;	chr16:75467669	chr16:75379818~75381260:-
THCA	cis	rs227275	0.525	rs28845922	ENSG00000246560.2	RP11-10L12.4	12.63	1.09e-31	1.65e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102981959	chr4:102828055~102844075:+
THCA	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	12.63	1.09e-31	1.65e-28	0.61	0.5	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
THCA	cis	rs9309473	1	rs2056486	ENSG00000163016.8	ALMS1P	12.63	1.09e-31	1.65e-28	0.73	0.5	Metabolite levels;	chr2:73490440	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs10193972	ENSG00000163016.8	ALMS1P	12.63	1.09e-31	1.65e-28	0.73	0.5	Metabolite levels;	chr2:73490529	chr2:73644919~73685576:+
THCA	cis	rs1062177	0.694	rs2915816	ENSG00000213433.5	RPLP1P6	12.63	1.09e-31	1.66e-28	0.51	0.5	Preschool internalizing problems;	chr5:151736296	chr5:151765859~151766378:-
THCA	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-12.63	1.09e-31	1.66e-28	-0.63	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
THCA	cis	rs8062405	1	rs1987472	ENSG00000251417.2	RP11-1348G14.4	-12.63	1.1e-31	1.66e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28802743~28817828:+
THCA	cis	rs3002131	0.562	rs2173401	ENSG00000225265.1	TAF1A-AS1	-12.63	1.1e-31	1.66e-28	-0.7	-0.5	Interleukin-10 levels;	chr1:222575992	chr1:222589825~222593032:+
THCA	cis	rs3002131	0.604	rs3008644	ENSG00000225265.1	TAF1A-AS1	-12.63	1.1e-31	1.66e-28	-0.7	-0.5	Interleukin-10 levels;	chr1:222577402	chr1:222589825~222593032:+
THCA	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-12.63	1.1e-31	1.67e-28	-0.62	-0.5	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
THCA	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	12.63	1.12e-31	1.7e-28	0.46	0.5	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
THCA	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-12.63	1.13e-31	1.71e-28	-0.63	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
THCA	cis	rs67180937	0.583	rs2936054	ENSG00000272750.1	RP11-378J18.8	12.63	1.13e-31	1.71e-28	0.6	0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222627290	chr1:222658867~222661512:-
THCA	cis	rs6570726	0.791	rs370112	ENSG00000235652.6	RP11-545I5.3	12.63	1.14e-31	1.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145538717	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs427128	ENSG00000235652.6	RP11-545I5.3	12.63	1.14e-31	1.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145544781	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.658	rs9403737	ENSG00000235652.6	RP11-545I5.3	12.62	1.16e-31	1.76e-28	0.46	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145641057	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs4896832	ENSG00000235652.6	RP11-545I5.3	12.62	1.16e-31	1.76e-28	0.46	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145643015	chr6:145799409~145886585:+
THCA	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-12.62	1.18e-31	1.78e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
THCA	cis	rs9399137	0.507	rs7768278	ENSG00000232876.1	CTA-212D2.2	-12.62	1.21e-31	1.83e-28	-0.63	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134953819	chr6:135055033~135060550:+
THCA	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-12.62	1.21e-31	1.83e-28	-0.61	-0.5	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
THCA	cis	rs6504950	1	rs17818028	ENSG00000275710.1	RP11-257O5.4	-12.62	1.22e-31	1.84e-28	-0.67	-0.5	Breast cancer;	chr17:54985394	chr17:54964474~54964679:+
THCA	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	12.62	1.22e-31	1.84e-28	0.67	0.5	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
THCA	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-12.62	1.23e-31	1.86e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-12.62	1.23e-31	1.86e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-12.62	1.23e-31	1.86e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-12.62	1.23e-31	1.86e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-12.62	1.23e-31	1.86e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-12.62	1.23e-31	1.86e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
THCA	cis	rs9389248	0.728	rs1022491	ENSG00000232876.1	CTA-212D2.2	12.61	1.26e-31	1.9e-28	0.63	0.5	High light scatter reticulocyte percentage of red cells;	chr6:134938228	chr6:135055033~135060550:+
THCA	cis	rs7945705	0.712	rs61876274	ENSG00000254860.4	TMEM9B-AS1	-12.61	1.26e-31	1.91e-28	-0.56	-0.5	Hemoglobin concentration;	chr11:8997643	chr11:8964675~8977527:+
THCA	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-12.61	1.27e-31	1.92e-28	-0.72	-0.5	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
THCA	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	12.61	1.27e-31	1.92e-28	0.62	0.5	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.933	rs3093584	ENSG00000224183.1	SDHDP6	12.61	1.27e-31	1.93e-28	0.62	0.5	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25294164~25294643:-
THCA	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-12.61	1.27e-31	1.93e-28	-0.57	-0.5	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
THCA	cis	rs227275	0.525	rs4623004	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103000141	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs11097796	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103002401	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs11097797	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103002507	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4699046	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103004514	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4699047	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103005385	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs28778380	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103006416	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs10029073	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103006991	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4698874	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103009354	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs724446	ENSG00000246560.2	RP11-10L12.4	12.61	1.29e-31	1.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103010206	chr4:102828055~102844075:+
THCA	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-12.61	1.31e-31	1.98e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
THCA	cis	rs227275	0.525	rs13150426	ENSG00000246560.2	RP11-10L12.4	12.61	1.33e-31	2.01e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103013743	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs28445579	ENSG00000246560.2	RP11-10L12.4	12.61	1.33e-31	2.01e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103016438	chr4:102828055~102844075:+
THCA	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	12.61	1.33e-31	2.01e-28	0.9	0.5	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
THCA	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-12.61	1.34e-31	2.03e-28	-0.63	-0.5	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
THCA	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-12.61	1.35e-31	2.03e-28	-0.64	-0.5	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
THCA	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	12.61	1.35e-31	2.03e-28	0.75	0.5	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
THCA	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	12.61	1.35e-31	2.04e-28	0.61	0.5	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
THCA	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	12.61	1.36e-31	2.05e-28	0.42	0.5	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
THCA	cis	rs875971	0.862	rs10282433	ENSG00000237310.1	GS1-124K5.4	-12.61	1.38e-31	2.08e-28	-0.37	-0.5	Aortic root size;	chr7:66256452	chr7:66493706~66495474:+
THCA	cis	rs5769707	0.681	rs2071902	ENSG00000188511.11	C22orf34	12.6	1.38e-31	2.09e-28	0.66	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49414524~49657542:-
THCA	cis	rs56080343	0.688	rs10083190	ENSG00000275759.1	RP11-131L12.3	-12.6	1.39e-31	2.1e-28	-0.61	-0.5	Neuroticism;	chr12:118365385	chr12:118428281~118428870:+
THCA	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	12.6	1.39e-31	2.1e-28	0.64	0.5	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
THCA	cis	rs6504950	1	rs12940106	ENSG00000275710.1	RP11-257O5.4	12.6	1.42e-31	2.13e-28	0.68	0.5	Breast cancer;	chr17:54990322	chr17:54964474~54964679:+
THCA	cis	rs4819052	0.851	rs2838865	ENSG00000223768.1	LINC00205	-12.6	1.45e-31	2.19e-28	-0.47	-0.5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45293285~45297354:+
THCA	cis	rs8040855	0.657	rs6496733	ENSG00000259295.5	CSPG4P12	-12.6	1.45e-31	2.19e-28	-0.73	-0.5	Bulimia nervosa;	chr15:85129945	chr15:85191438~85213905:+
THCA	cis	rs524281	0.692	rs10896076	ENSG00000255320.1	RP11-755F10.1	12.6	1.45e-31	2.19e-28	0.7	0.5	Electroencephalogram traits;	chr11:66073197	chr11:66244840~66246239:-
THCA	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	12.6	1.47e-31	2.21e-28	0.41	0.5	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
THCA	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-12.6	1.47e-31	2.21e-28	-0.58	-0.5	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
THCA	cis	rs4888378	0.535	rs9319483	ENSG00000261783.1	RP11-252K23.2	12.6	1.47e-31	2.21e-28	0.73	0.5	Coronary artery disease;	chr16:75311893	chr16:75379818~75381260:-
THCA	cis	rs524281	0.861	rs10896095	ENSG00000255320.1	RP11-755F10.1	12.6	1.48e-31	2.23e-28	0.71	0.5	Electroencephalogram traits;	chr11:66195089	chr11:66244840~66246239:-
THCA	cis	rs9928842	0.882	rs11641896	ENSG00000280152.1	RP11-331F4.5	12.6	1.49e-31	2.25e-28	0.73	0.5	Alcoholic chronic pancreatitis;	chr16:75266281	chr16:75245994~75250077:-
THCA	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	12.6	1.51e-31	2.27e-28	0.58	0.5	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
THCA	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-12.6	1.51e-31	2.27e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-12.6	1.51e-31	2.27e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
THCA	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-12.59	1.52e-31	2.29e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-12.59	1.52e-31	2.29e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-12.59	1.52e-31	2.29e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-12.59	1.52e-31	2.29e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
THCA	cis	rs2658782	0.901	rs11601056	ENSG00000279684.1	RP11-755E23.2	12.59	1.53e-31	2.31e-28	0.87	0.5	Pulmonary function decline;	chr11:93495995	chr11:93286629~93288903:-
THCA	cis	rs875971	0.862	rs12537823	ENSG00000237310.1	GS1-124K5.4	12.59	1.54e-31	2.32e-28	0.37	0.5	Aortic root size;	chr7:66255897	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-12.59	1.54e-31	2.32e-28	-0.37	-0.5	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
THCA	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-12.59	1.54e-31	2.32e-28	-0.37	-0.5	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-12.59	1.54e-31	2.32e-28	-0.37	-0.5	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-12.59	1.54e-31	2.32e-28	-0.37	-0.5	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-12.59	1.54e-31	2.32e-28	-0.37	-0.5	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
THCA	cis	rs9309473	0.948	rs10170849	ENSG00000163016.8	ALMS1P	12.59	1.54e-31	2.32e-28	0.73	0.5	Metabolite levels;	chr2:73520805	chr2:73644919~73685576:+
THCA	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-12.59	1.54e-31	2.32e-28	-0.66	-0.5	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
THCA	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	12.59	1.56e-31	2.35e-28	0.58	0.5	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
THCA	cis	rs944289	0.616	rs395212	ENSG00000257826.1	RP11-116N8.4	-12.59	1.57e-31	2.36e-28	-0.53	-0.5	Thyroid cancer;	chr14:36065759	chr14:36061026~36067190:-
THCA	cis	rs8062405	0.964	rs78613234	ENSG00000251417.2	RP11-1348G14.4	-12.59	1.57e-31	2.36e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28802743~28817828:+
THCA	cis	rs8062405	1	rs62036624	ENSG00000251417.2	RP11-1348G14.4	-12.59	1.57e-31	2.36e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28802743~28817828:+
THCA	cis	rs80028505	0.764	rs1967966	ENSG00000271304.1	DPRXP2	12.59	1.58e-31	2.37e-28	0.84	0.5	Foot ulcer in diabetes and neuropathy;	chr6:36104395	chr6:35989515~35990436:-
THCA	cis	rs6570726	0.791	rs1280276	ENSG00000235652.6	RP11-545I5.3	12.59	1.58e-31	2.38e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145571214	chr6:145799409~145886585:+
THCA	cis	rs228614	0.543	rs223330	ENSG00000246560.2	RP11-10L12.4	12.59	1.59e-31	2.39e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102872502	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223329	ENSG00000246560.2	RP11-10L12.4	12.59	1.59e-31	2.39e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873031	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223327	ENSG00000246560.2	RP11-10L12.4	12.59	1.59e-31	2.39e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873560	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223326	ENSG00000246560.2	RP11-10L12.4	12.59	1.59e-31	2.39e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102873770	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223324	ENSG00000246560.2	RP11-10L12.4	12.59	1.59e-31	2.39e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102876177	chr4:102828055~102844075:+
THCA	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	12.59	1.6e-31	2.4e-28	0.6	0.5	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
THCA	cis	rs227275	0.527	rs223338	ENSG00000246560.2	RP11-10L12.4	12.59	1.6e-31	2.4e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102864959	chr4:102828055~102844075:+
THCA	cis	rs8040855	0.658	rs12909111	ENSG00000259295.5	CSPG4P12	12.59	1.6e-31	2.4e-28	0.71	0.5	Bulimia nervosa;	chr15:85061095	chr15:85191438~85213905:+
THCA	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-12.59	1.6e-31	2.4e-28	-0.85	-0.5	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
THCA	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	12.59	1.61e-31	2.42e-28	0.63	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	12.59	1.62e-31	2.42e-28	0.65	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
THCA	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	12.59	1.62e-31	2.43e-28	0.58	0.5	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	12.59	1.62e-31	2.43e-28	0.58	0.5	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	12.59	1.62e-31	2.43e-28	0.58	0.5	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
THCA	cis	rs524281	0.861	rs10791856	ENSG00000255320.1	RP11-755F10.1	12.58	1.68e-31	2.52e-28	0.71	0.5	Electroencephalogram traits;	chr11:66197179	chr11:66244840~66246239:-
THCA	cis	rs934734	0.532	rs7557569	ENSG00000204929.10	AC074391.1	-12.58	1.69e-31	2.54e-28	-0.61	-0.5	Rheumatoid arthritis;	chr2:65417427	chr2:65436711~66084639:+
THCA	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-12.58	1.71e-31	2.57e-28	-0.52	-0.5	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
THCA	cis	rs1155848	0.571	rs6563127	ENSG00000227354.5	RBM26-AS1	12.58	1.75e-31	2.62e-28	0.77	0.5	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79642012	chr13:79406309~79424328:+
THCA	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-12.58	1.75e-31	2.62e-28	-0.56	-0.5	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
THCA	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-12.58	1.75e-31	2.63e-28	-0.64	-0.5	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
THCA	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	12.58	1.76e-31	2.63e-28	0.88	0.5	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
THCA	cis	rs9309473	0.95	rs7567585	ENSG00000163016.8	ALMS1P	12.58	1.77e-31	2.65e-28	0.73	0.5	Metabolite levels;	chr2:73524839	chr2:73644919~73685576:+
THCA	cis	rs11098499	0.615	rs28551750	ENSG00000245958.5	RP11-33B1.1	-12.58	1.77e-31	2.66e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119343746	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.691	rs9995716	ENSG00000245958.5	RP11-33B1.1	-12.58	1.77e-31	2.66e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119343841	chr4:119454791~119552025:+
THCA	cis	rs11722779	0.873	rs6533041	ENSG00000246560.2	RP11-10L12.4	12.58	1.78e-31	2.67e-28	0.62	0.5	Schizophrenia;	chr4:102951615	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4699037	ENSG00000246560.2	RP11-10L12.4	12.58	1.78e-31	2.67e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102957010	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs3857198	ENSG00000246560.2	RP11-10L12.4	12.58	1.78e-31	2.67e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102957720	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.935	rs3857199	ENSG00000246560.2	RP11-10L12.4	12.58	1.78e-31	2.67e-28	0.62	0.5	Schizophrenia;	chr4:102957991	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4699039	ENSG00000246560.2	RP11-10L12.4	12.58	1.78e-31	2.67e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102958354	chr4:102828055~102844075:+
THCA	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-12.58	1.79e-31	2.69e-28	-0.68	-0.5	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
THCA	cis	rs9309473	1	rs6546837	ENSG00000163016.8	ALMS1P	12.58	1.8e-31	2.69e-28	0.72	0.5	Metabolite levels;	chr2:73450771	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs6756987	ENSG00000163016.8	ALMS1P	12.58	1.8e-31	2.69e-28	0.72	0.5	Metabolite levels;	chr2:73459950	chr2:73644919~73685576:+
THCA	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	12.58	1.8e-31	2.7e-28	0.88	0.5	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
THCA	cis	rs9309473	0.95	rs6745480	ENSG00000163016.8	ALMS1P	12.58	1.8e-31	2.7e-28	0.73	0.5	Metabolite levels;	chr2:73612928	chr2:73644919~73685576:+
THCA	cis	rs7743045	0.625	rs12664251	ENSG00000253194.1	RP11-351A11.1	12.58	1.81e-31	2.71e-28	0.72	0.5	Mean platelet volume;	chr6:119023381	chr6:118934785~119031541:+
THCA	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	12.58	1.81e-31	2.71e-28	0.58	0.5	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
THCA	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-12.58	1.83e-31	2.74e-28	-0.83	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
THCA	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	12.57	1.84e-31	2.76e-28	0.59	0.5	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
THCA	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-12.57	1.85e-31	2.76e-28	-0.85	-0.5	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-12.57	1.85e-31	2.76e-28	-0.85	-0.5	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
THCA	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	12.57	1.86e-31	2.78e-28	0.6	0.5	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	12.57	1.86e-31	2.78e-28	0.6	0.5	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	12.57	1.86e-31	2.78e-28	0.6	0.5	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	12.57	1.86e-31	2.78e-28	0.6	0.5	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	12.57	1.86e-31	2.78e-28	0.6	0.5	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-12.57	1.86e-31	2.78e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
THCA	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-12.57	1.86e-31	2.78e-28	-0.85	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
THCA	cis	rs67311347	0.876	rs13068097	ENSG00000223797.4	ENTPD3-AS1	-12.57	1.88e-31	2.81e-28	-0.4	-0.5	Renal cell carcinoma;	chr3:40462933	chr3:40313802~40453329:-
THCA	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-12.57	1.92e-31	2.87e-28	-0.84	-0.5	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
THCA	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	12.57	1.92e-31	2.87e-28	0.7	0.5	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
THCA	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	12.57	1.94e-31	2.9e-28	0.58	0.5	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
THCA	cis	rs9309473	1	rs10186501	ENSG00000163016.8	ALMS1P	12.57	1.96e-31	2.92e-28	0.72	0.5	Metabolite levels;	chr2:73470717	chr2:73644919~73685576:+
THCA	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	12.57	1.97e-31	2.95e-28	0.65	0.5	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
THCA	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	12.57	1.99e-31	2.97e-28	0.83	0.5	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
THCA	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	12.57	2e-31	2.99e-28	0.37	0.5	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	12.57	2e-31	2.99e-28	0.37	0.5	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
THCA	cis	rs934734	0.532	rs1437466	ENSG00000204929.10	AC074391.1	-12.57	2e-31	2.99e-28	-0.6	-0.5	Rheumatoid arthritis;	chr2:65437216	chr2:65436711~66084639:+
THCA	cis	rs9928842	0.823	rs11149811	ENSG00000280152.1	RP11-331F4.5	12.57	2.01e-31	3e-28	0.73	0.5	Alcoholic chronic pancreatitis;	chr16:75266810	chr16:75245994~75250077:-
THCA	cis	rs4964805	0.58	rs1866292	ENSG00000257681.1	RP11-341G23.4	12.56	2.03e-31	3.03e-28	0.61	0.5	Attention deficit hyperactivity disorder;	chr12:103780414	chr12:103746315~103768858:-
THCA	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-12.56	2.04e-31	3.05e-28	-0.62	-0.5	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
THCA	cis	rs9309473	0.95	rs6726694	ENSG00000163016.8	ALMS1P	12.56	2.05e-31	3.06e-28	0.74	0.5	Metabolite levels;	chr2:73620103	chr2:73644919~73685576:+
THCA	cis	rs228614	0.51	rs3774987	ENSG00000246560.2	RP11-10L12.4	12.56	2.08e-31	3.1e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799709	chr4:102828055~102844075:+
THCA	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	12.56	2.09e-31	3.11e-28	0.42	0.5	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
THCA	cis	rs12468226	0.873	rs6435138	ENSG00000273456.1	RP11-686O6.2	-12.56	2.09e-31	3.12e-28	-0.63	-0.5	Urate levels;	chr2:202234310	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.873	rs6761131	ENSG00000273456.1	RP11-686O6.2	-12.56	2.09e-31	3.12e-28	-0.63	-0.5	Urate levels;	chr2:202237675	chr2:202374932~202375604:-
THCA	cis	rs67180937	0.583	rs3008616	ENSG00000272750.1	RP11-378J18.8	12.56	2.11e-31	3.15e-28	0.6	0.5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222623831	chr1:222658867~222661512:-
THCA	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	12.56	2.12e-31	3.15e-28	0.41	0.5	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
THCA	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	12.56	2.12e-31	3.16e-28	0.62	0.5	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
THCA	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	12.56	2.13e-31	3.17e-28	0.37	0.5	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
THCA	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-12.56	2.14e-31	3.18e-28	-0.4	-0.5	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
THCA	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-12.56	2.15e-31	3.2e-28	-0.37	-0.5	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
THCA	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	12.56	2.16e-31	3.22e-28	0.89	0.5	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
THCA	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	12.56	2.16e-31	3.22e-28	0.89	0.5	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
THCA	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	12.56	2.16e-31	3.22e-28	0.89	0.5	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
THCA	cis	rs228614	0.51	rs223447	ENSG00000246560.2	RP11-10L12.4	12.56	2.17e-31	3.23e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102792202	chr4:102828055~102844075:+
THCA	cis	rs8062405	0.964	rs11860513	ENSG00000251417.2	RP11-1348G14.4	-12.56	2.18e-31	3.24e-28	-0.48	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28802743~28817828:+
THCA	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	12.56	2.18e-31	3.24e-28	0.37	0.5	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
THCA	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	12.56	2.18e-31	3.24e-28	0.37	0.5	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
THCA	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	12.56	2.18e-31	3.24e-28	0.37	0.5	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
THCA	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-12.56	2.21e-31	3.29e-28	-0.55	-0.5	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
THCA	cis	rs7772486	0.754	rs1415746	ENSG00000235652.6	RP11-545I5.3	-12.55	2.23e-31	3.31e-28	-0.47	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145755971	chr6:145799409~145886585:+
THCA	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	12.55	2.23e-31	3.31e-28	0.63	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
THCA	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	12.55	2.24e-31	3.34e-28	0.37	0.5	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
THCA	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	12.55	2.27e-31	3.38e-28	0.61	0.5	Height;	chr11:118791319	chr11:118688039~118690600:-
THCA	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	12.55	2.27e-31	3.38e-28	0.58	0.5	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
THCA	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-12.55	2.29e-31	3.4e-28	-0.53	-0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
THCA	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-12.55	2.32e-31	3.44e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-12.55	2.32e-31	3.44e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-12.55	2.34e-31	3.48e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-12.55	2.34e-31	3.48e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
THCA	cis	rs2288884	0.515	rs11084133	ENSG00000275055.1	CTC-471J1.11	-12.55	2.34e-31	3.48e-28	-0.38	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52041125	chr19:52049007~52049754:+
THCA	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	12.55	2.35e-31	3.49e-28	0.61	0.5	Height;	chr11:118808920	chr11:118688039~118690600:-
THCA	cis	rs2288884	0.537	rs7254254	ENSG00000275055.1	CTC-471J1.11	-12.55	2.36e-31	3.51e-28	-0.38	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52035824	chr19:52049007~52049754:+
THCA	cis	rs227275	0.525	rs3974485	ENSG00000246560.2	RP11-10L12.4	12.55	2.36e-31	3.51e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102993283	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs2866417	ENSG00000246560.2	RP11-10L12.4	12.55	2.36e-31	3.51e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102993481	chr4:102828055~102844075:+
THCA	cis	rs524281	0.817	rs10896092	ENSG00000255320.1	RP11-755F10.1	12.55	2.37e-31	3.51e-28	0.71	0.5	Electroencephalogram traits;	chr11:66190575	chr11:66244840~66246239:-
THCA	cis	rs11722779	0.844	rs223345	ENSG00000246560.2	RP11-10L12.4	12.55	2.38e-31	3.53e-28	0.62	0.5	Schizophrenia;	chr4:102859366	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.873	rs223344	ENSG00000246560.2	RP11-10L12.4	12.55	2.38e-31	3.53e-28	0.62	0.5	Schizophrenia;	chr4:102859765	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.775	rs223341	ENSG00000246560.2	RP11-10L12.4	12.55	2.38e-31	3.53e-28	0.62	0.5	Schizophrenia;	chr4:102862343	chr4:102828055~102844075:+
THCA	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	12.55	2.41e-31	3.58e-28	0.58	0.5	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
THCA	cis	rs2288884	0.515	rs3752118	ENSG00000275055.1	CTC-471J1.11	-12.55	2.43e-31	3.6e-28	-0.38	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048233	chr19:52049007~52049754:+
THCA	cis	rs6570726	0.791	rs4335004	ENSG00000235652.6	RP11-545I5.3	12.55	2.43e-31	3.61e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145583628	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000228039.3	KB-1125A3.10	12.54	2.44e-31	3.62e-28	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23963780~23964374:+
THCA	cis	rs9928842	0.882	rs9927264	ENSG00000280152.1	RP11-331F4.5	12.54	2.45e-31	3.64e-28	0.72	0.5	Alcoholic chronic pancreatitis;	chr16:75226343	chr16:75245994~75250077:-
THCA	cis	rs8040855	0.658	rs4842864	ENSG00000259295.5	CSPG4P12	12.54	2.46e-31	3.65e-28	0.7	0.5	Bulimia nervosa;	chr15:85101315	chr15:85191438~85213905:+
THCA	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-12.54	2.46e-31	3.65e-28	-0.58	-0.5	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
THCA	cis	rs2658782	0.901	rs2605611	ENSG00000279684.1	RP11-755E23.2	-12.54	2.52e-31	3.73e-28	-0.85	-0.5	Pulmonary function decline;	chr11:93496153	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.901	rs10466368	ENSG00000279684.1	RP11-755E23.2	-12.54	2.52e-31	3.73e-28	-0.85	-0.5	Pulmonary function decline;	chr11:93496590	chr11:93286629~93288903:-
THCA	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	12.54	2.53e-31	3.75e-28	0.59	0.5	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
THCA	cis	rs12468226	0.817	rs6722588	ENSG00000273456.1	RP11-686O6.2	-12.54	2.59e-31	3.83e-28	-0.64	-0.5	Urate levels;	chr2:202187163	chr2:202374932~202375604:-
THCA	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	12.54	2.6e-31	3.86e-28	0.58	0.5	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
THCA	cis	rs6570726	0.791	rs383841	ENSG00000235652.6	RP11-545I5.3	-12.54	2.64e-31	3.91e-28	-0.47	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145567193	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	12.54	2.65e-31	3.93e-28	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
THCA	cis	rs227275	0.525	rs10032234	ENSG00000246560.2	RP11-10L12.4	12.54	2.65e-31	3.93e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102980538	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs3886723	ENSG00000246560.2	RP11-10L12.4	12.54	2.65e-31	3.93e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102983013	chr4:102828055~102844075:+
THCA	cis	rs228614	0.517	rs3886722	ENSG00000246560.2	RP11-10L12.4	12.54	2.65e-31	3.93e-28	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102983084	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs11737544	ENSG00000246560.2	RP11-10L12.4	12.54	2.65e-31	3.93e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102983877	chr4:102828055~102844075:+
THCA	cis	rs11098499	0.569	rs10023641	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119337255	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.644	rs3986377	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119339115	chr4:119454791~119552025:+
THCA	cis	rs10028773	0.556	rs4473640	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Educational attainment;	chr4:119339282	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.691	rs10010355	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119339888	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.691	rs9307471	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119340107	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.644	rs17517414	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119340946	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.722	rs10006192	ENSG00000245958.5	RP11-33B1.1	-12.53	2.69e-31	3.98e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119341867	chr4:119454791~119552025:+
THCA	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	12.53	2.72e-31	4.02e-28	0.59	0.5	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
THCA	cis	rs2283792	0.819	rs2266965	ENSG00000224086.5	LL22NC03-86G7.1	-12.53	2.73e-31	4.04e-28	-0.58	-0.5	Multiple sclerosis;	chr22:21766866	chr22:21938293~21977632:+
THCA	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	12.53	2.75e-31	4.06e-28	0.57	0.5	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
THCA	cis	rs6496932	0.802	rs56306166	ENSG00000218052.5	ADAMTS7P4	12.53	2.75e-31	4.07e-28	0.64	0.5	Central corneal thickness;Corneal structure;	chr15:85326848	chr15:85255369~85330334:-
THCA	cis	rs638893	1	rs113641235	ENSG00000278376.1	RP11-158I9.8	12.53	2.79e-31	4.13e-28	0.59	0.5	Vitiligo;	chr11:118829555	chr11:118791254~118793137:+
THCA	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-12.53	2.81e-31	4.15e-28	-0.62	-0.5	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-12.53	2.81e-31	4.15e-28	-0.62	-0.5	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
THCA	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	12.53	2.81e-31	4.15e-28	0.41	0.5	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	12.53	2.81e-31	4.15e-28	0.41	0.5	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
THCA	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	12.53	2.82e-31	4.16e-28	0.57	0.5	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	12.53	2.82e-31	4.16e-28	0.57	0.5	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
THCA	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	12.53	2.82e-31	4.16e-28	0.41	0.5	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	12.53	2.82e-31	4.16e-28	0.41	0.5	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	12.53	2.87e-31	4.24e-28	0.41	0.5	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
THCA	cis	rs9309473	0.606	rs62149804	ENSG00000163016.8	ALMS1P	12.53	2.87e-31	4.24e-28	0.87	0.5	Metabolite levels;	chr2:73609879	chr2:73644919~73685576:+
THCA	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	12.53	2.88e-31	4.26e-28	0.62	0.5	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
THCA	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	12.53	2.89e-31	4.27e-28	0.63	0.5	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
THCA	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	12.53	2.93e-31	4.33e-28	0.58	0.5	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
THCA	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	12.53	2.93e-31	4.33e-28	0.57	0.5	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	12.53	2.93e-31	4.33e-28	0.57	0.5	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
THCA	cis	rs6570726	0.764	rs9399553	ENSG00000235652.6	RP11-545I5.3	12.53	2.94e-31	4.34e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145552528	chr6:145799409~145886585:+
THCA	cis	rs6504950	1	rs9896044	ENSG00000275710.1	RP11-257O5.4	12.53	2.95e-31	4.35e-28	0.63	0.5	Breast cancer;	chr17:54971181	chr17:54964474~54964679:+
THCA	cis	rs227275	0.525	rs9917919	ENSG00000246560.2	RP11-10L12.4	12.52	2.98e-31	4.4e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102918497	chr4:102828055~102844075:+
THCA	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	12.52	2.99e-31	4.41e-28	0.57	0.5	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
THCA	cis	rs12022452	1	rs2184877	ENSG00000238287.1	RP11-656D10.3	-12.52	3e-31	4.43e-28	-0.74	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40531260	chr1:40493157~40508661:-
THCA	cis	rs1150668	0.965	rs1654774	ENSG00000216901.1	AL022393.7	12.52	3.01e-31	4.44e-28	0.59	0.5	Pubertal anthropometrics;	chr6:28128502	chr6:28176188~28176674:+
THCA	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	12.52	3.03e-31	4.47e-28	0.37	0.5	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
THCA	cis	rs11098499	0.722	rs17595727	ENSG00000245958.5	RP11-33B1.1	12.52	3.07e-31	4.53e-28	0.47	0.5	Corneal astigmatism;	chr4:119340919	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.698	rs4422403	ENSG00000245958.5	RP11-33B1.1	-12.52	3.08e-31	4.55e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119337039	chr4:119454791~119552025:+
THCA	cis	rs2283792	0.765	rs34550586	ENSG00000224086.5	LL22NC03-86G7.1	-12.52	3.11e-31	4.59e-28	-0.59	-0.5	Multiple sclerosis;	chr22:21791345	chr22:21938293~21977632:+
THCA	cis	rs227275	0.525	rs6533052	ENSG00000246560.2	RP11-10L12.4	12.52	3.13e-31	4.62e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102990624	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs13117110	ENSG00000246560.2	RP11-10L12.4	12.52	3.13e-31	4.62e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103003981	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs13144033	ENSG00000246560.2	RP11-10L12.4	12.52	3.13e-31	4.62e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103004032	chr4:102828055~102844075:+
THCA	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	12.52	3.14e-31	4.62e-28	0.6	0.5	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
THCA	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	12.52	3.14e-31	4.63e-28	0.37	0.5	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
THCA	cis	rs2288884	0.559	rs8111873	ENSG00000275055.1	CTC-471J1.11	-12.52	3.15e-31	4.64e-28	-0.4	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014267	chr19:52049007~52049754:+
THCA	cis	rs227275	0.554	rs223334	ENSG00000246560.2	RP11-10L12.4	-12.52	3.15e-31	4.65e-28	-0.61	-0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102867054	chr4:102828055~102844075:+
THCA	cis	rs6504950	1	rs9894529	ENSG00000275710.1	RP11-257O5.4	12.52	3.19e-31	4.7e-28	0.63	0.5	Breast cancer;	chr17:54977885	chr17:54964474~54964679:+
THCA	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	12.52	3.19e-31	4.71e-28	0.36	0.5	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
THCA	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-12.52	3.22e-31	4.75e-28	-0.6	-0.5	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
THCA	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	12.52	3.23e-31	4.75e-28	0.61	0.5	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
THCA	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-12.51	3.24e-31	4.78e-28	-0.84	-0.5	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
THCA	cis	rs944289	0.589	rs847514	ENSG00000257826.1	RP11-116N8.4	12.51	3.24e-31	4.78e-28	0.52	0.5	Thyroid cancer;	chr14:36060904	chr14:36061026~36067190:-
THCA	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	12.51	3.25e-31	4.79e-28	0.41	0.5	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
THCA	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	12.51	3.29e-31	4.84e-28	0.57	0.5	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
THCA	cis	rs6570726	0.791	rs408443	ENSG00000235652.6	RP11-545I5.3	12.51	3.29e-31	4.85e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145553507	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs436156	ENSG00000235652.6	RP11-545I5.3	12.51	3.29e-31	4.85e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145553737	chr6:145799409~145886585:+
THCA	cis	rs6504950	0.72	rs2877634	ENSG00000275710.1	RP11-257O5.4	12.51	3.31e-31	4.87e-28	0.62	0.5	Breast cancer;	chr17:54910184	chr17:54964474~54964679:+
THCA	cis	rs9309473	1	rs2421555	ENSG00000163016.8	ALMS1P	12.51	3.32e-31	4.88e-28	0.72	0.5	Metabolite levels;	chr2:73589828	chr2:73644919~73685576:+
THCA	cis	rs11098499	0.874	rs13139045	ENSG00000245958.5	RP11-33B1.1	-12.51	3.39e-31	4.99e-28	-0.45	-0.5	Corneal astigmatism;	chr4:119247433	chr4:119454791~119552025:+
THCA	cis	rs228614	0.51	rs223435	ENSG00000246560.2	RP11-10L12.4	12.51	3.39e-31	4.99e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799826	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223434	ENSG00000246560.2	RP11-10L12.4	12.51	3.39e-31	4.99e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102799902	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223420	ENSG00000246560.2	RP11-10L12.4	12.51	3.39e-31	4.99e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102806853	chr4:102828055~102844075:+
THCA	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-12.51	3.42e-31	5.04e-28	-0.61	-0.5	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
THCA	cis	rs227275	0.525	rs7672319	ENSG00000246560.2	RP11-10L12.4	12.51	3.43e-31	5.04e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102990002	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs6533051	ENSG00000246560.2	RP11-10L12.4	12.51	3.43e-31	5.04e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102990065	chr4:102828055~102844075:+
THCA	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-12.51	3.45e-31	5.08e-28	-0.37	-0.5	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
THCA	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-12.51	3.48e-31	5.12e-28	-0.56	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
THCA	cis	rs227275	0.525	rs6533050	ENSG00000246560.2	RP11-10L12.4	12.51	3.5e-31	5.15e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102979044	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs5028609	ENSG00000246560.2	RP11-10L12.4	12.51	3.52e-31	5.18e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102959294	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs6815540	ENSG00000246560.2	RP11-10L12.4	12.51	3.52e-31	5.18e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102959922	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4698867	ENSG00000246560.2	RP11-10L12.4	12.51	3.52e-31	5.18e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102961049	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs7663876	ENSG00000246560.2	RP11-10L12.4	12.51	3.52e-31	5.18e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102966174	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs6821173	ENSG00000246560.2	RP11-10L12.4	12.51	3.52e-31	5.18e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102966404	chr4:102828055~102844075:+
THCA	cis	rs12022452	0.822	rs7545012	ENSG00000238287.1	RP11-656D10.3	12.51	3.55e-31	5.21e-28	0.75	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40562178	chr1:40493157~40508661:-
THCA	cis	rs9399137	0.507	rs7771310	ENSG00000232876.1	CTA-212D2.2	-12.5	3.59e-31	5.28e-28	-0.62	-0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134951397	chr6:135055033~135060550:+
THCA	cis	rs6570726	0.791	rs436498	ENSG00000235652.6	RP11-545I5.3	12.5	3.63e-31	5.34e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145555211	chr6:145799409~145886585:+
THCA	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	12.5	3.64e-31	5.34e-28	0.57	0.5	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
THCA	cis	rs9309473	1	rs7604682	ENSG00000163016.8	ALMS1P	12.5	3.64e-31	5.35e-28	0.72	0.5	Metabolite levels;	chr2:73560899	chr2:73644919~73685576:+
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	12.5	3.71e-31	5.45e-28	0.64	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
THCA	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-12.5	3.73e-31	5.47e-28	-0.64	-0.5	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
THCA	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	12.5	3.75e-31	5.51e-28	0.58	0.5	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	12.5	3.75e-31	5.51e-28	0.58	0.5	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
THCA	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	12.5	3.76e-31	5.52e-28	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
THCA	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-12.5	3.8e-31	5.58e-28	-0.53	-0.5	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
THCA	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	12.5	3.88e-31	5.69e-28	0.65	0.5	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
THCA	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-12.5	3.89e-31	5.7e-28	-0.53	-0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
THCA	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	12.5	3.89e-31	5.7e-28	0.63	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
THCA	cis	rs12468226	1	rs77435512	ENSG00000273456.1	RP11-686O6.2	12.49	3.97e-31	5.83e-28	0.58	0.5	Urate levels;	chr2:202334165	chr2:202374932~202375604:-
THCA	cis	rs6570726	0.738	rs4495284	ENSG00000235652.6	RP11-545I5.3	12.49	4.01e-31	5.88e-28	0.46	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145595481	chr6:145799409~145886585:+
THCA	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	12.49	4.11e-31	6.02e-28	0.88	0.5	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
THCA	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-12.49	4.11e-31	6.03e-28	-0.37	-0.5	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-12.49	4.11e-31	6.03e-28	-0.37	-0.5	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-12.49	4.11e-31	6.03e-28	-0.37	-0.5	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
THCA	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-12.49	4.11e-31	6.03e-28	-0.83	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
THCA	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	12.49	4.16e-31	6.09e-28	0.57	0.5	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
THCA	cis	rs1150668	0.965	rs1150690	ENSG00000216901.1	AL022393.7	12.49	4.29e-31	6.27e-28	0.59	0.5	Pubertal anthropometrics;	chr6:28197520	chr6:28176188~28176674:+
THCA	cis	rs12458462	0.892	rs12456692	ENSG00000274828.1	RP11-567M16.6	12.48	4.33e-31	6.34e-28	0.41	0.5	Monocyte count;	chr18:79722189	chr18:79677287~79679358:-
THCA	cis	rs227275	0.556	rs223449	ENSG00000246560.2	RP11-10L12.4	12.48	4.33e-31	6.34e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102791180	chr4:102828055~102844075:+
THCA	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-12.48	4.35e-31	6.37e-28	-0.52	-0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
THCA	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-12.48	4.35e-31	6.37e-28	-0.36	-0.5	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
THCA	cis	rs9309473	1	rs6724782	ENSG00000163016.8	ALMS1P	12.48	4.35e-31	6.37e-28	0.72	0.5	Metabolite levels;	chr2:73452863	chr2:73644919~73685576:+
THCA	cis	rs9309473	1	rs6546839	ENSG00000163016.8	ALMS1P	12.48	4.35e-31	6.37e-28	0.72	0.5	Metabolite levels;	chr2:73453381	chr2:73644919~73685576:+
THCA	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-12.48	4.39e-31	6.42e-28	-0.52	-0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
THCA	cis	rs228614	0.51	rs223446	ENSG00000246560.2	RP11-10L12.4	12.48	4.39e-31	6.43e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793025	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223437	ENSG00000246560.2	RP11-10L12.4	12.48	4.39e-31	6.43e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798736	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223419	ENSG00000246560.2	RP11-10L12.4	12.48	4.39e-31	6.43e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102808586	chr4:102828055~102844075:+
THCA	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	12.48	4.43e-31	6.48e-28	0.57	0.5	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
THCA	cis	rs9309473	1	rs58603761	ENSG00000163016.8	ALMS1P	12.48	4.44e-31	6.49e-28	0.72	0.5	Metabolite levels;	chr2:73499478	chr2:73644919~73685576:+
THCA	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	12.48	4.45e-31	6.51e-28	0.53	0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
THCA	cis	rs227275	0.525	rs10028116	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102931421	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs9307281	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102934971	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.903	rs6533037	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Schizophrenia;	chr4:102935865	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.903	rs4530634	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Schizophrenia;	chr4:102937924	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs7676943	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102938135	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs6419160	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102938648	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.901	rs28674656	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Schizophrenia;	chr4:102944396	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.838	rs3974494	ENSG00000246560.2	RP11-10L12.4	12.48	4.54e-31	6.64e-28	0.62	0.5	Schizophrenia;	chr4:102945323	chr4:102828055~102844075:+
THCA	cis	rs67311347	1	rs67311347	ENSG00000223797.4	ENTPD3-AS1	12.48	4.54e-31	6.64e-28	0.41	0.5	Renal cell carcinoma;	chr3:40491752	chr3:40313802~40453329:-
THCA	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	12.48	4.55e-31	6.64e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
THCA	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-12.48	4.61e-31	6.73e-28	-0.54	-0.5	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
THCA	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-12.48	4.61e-31	6.73e-28	-0.54	-0.5	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
THCA	cis	rs6570726	0.791	rs440477	ENSG00000235652.6	RP11-545I5.3	12.48	4.61e-31	6.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145533052	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs385729	ENSG00000235652.6	RP11-545I5.3	12.48	4.61e-31	6.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145534329	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs7755253	ENSG00000235652.6	RP11-545I5.3	12.48	4.61e-31	6.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145537757	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs376257	ENSG00000235652.6	RP11-545I5.3	12.48	4.61e-31	6.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145541813	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.693	rs450921	ENSG00000235652.6	RP11-545I5.3	12.48	4.61e-31	6.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145543124	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs365747	ENSG00000235652.6	RP11-545I5.3	12.48	4.61e-31	6.73e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145545648	chr6:145799409~145886585:+
THCA	cis	rs6496932	0.802	rs12441698	ENSG00000218052.5	ADAMTS7P4	12.48	4.64e-31	6.77e-28	0.65	0.5	Central corneal thickness;Corneal structure;	chr15:85310470	chr15:85255369~85330334:-
THCA	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	12.48	4.69e-31	6.85e-28	0.63	0.5	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
THCA	cis	rs228614	0.51	rs223410	ENSG00000246560.2	RP11-10L12.4	12.47	4.75e-31	6.92e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102813568	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223400	ENSG00000246560.2	RP11-10L12.4	12.47	4.75e-31	6.92e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102820439	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223445	ENSG00000246560.2	RP11-10L12.4	12.47	4.77e-31	6.96e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793337	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223443	ENSG00000246560.2	RP11-10L12.4	12.47	4.77e-31	6.96e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102793629	chr4:102828055~102844075:+
THCA	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-12.47	4.78e-31	6.98e-28	-0.62	-0.5	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
THCA	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-12.47	4.8e-31	7.01e-28	-0.59	-0.5	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
THCA	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	12.47	4.85e-31	7.07e-28	0.62	0.5	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
THCA	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	12.47	4.86e-31	7.09e-28	0.63	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
THCA	cis	rs9399137	0.507	rs4896118	ENSG00000232876.1	CTA-212D2.2	12.47	4.89e-31	7.12e-28	0.63	0.5	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954927	chr6:135055033~135060550:+
THCA	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	12.47	4.89e-31	7.13e-28	0.6	0.5	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
THCA	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	12.47	4.89e-31	7.13e-28	0.57	0.5	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
THCA	cis	rs324126	0.78	rs60935857	ENSG00000277977.1	CTD-3018O17.5	12.47	4.94e-31	7.21e-28	0.47	0.5	Colonoscopy-negative controls vs population controls;	chr19:52382606	chr19:52392659~52392755:+
THCA	cis	rs934734	0.532	rs10166100	ENSG00000204929.10	AC074391.1	-12.47	4.98e-31	7.25e-28	-0.61	-0.5	Rheumatoid arthritis;	chr2:65418616	chr2:65436711~66084639:+
THCA	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	12.47	4.99e-31	7.27e-28	0.4	0.5	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	12.47	4.99e-31	7.27e-28	0.4	0.5	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	12.47	5.03e-31	7.32e-28	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
THCA	cis	rs6570726	0.689	rs411785	ENSG00000235652.6	RP11-545I5.3	12.47	5.04e-31	7.34e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145567262	chr6:145799409~145886585:+
THCA	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-12.47	5.08e-31	7.4e-28	-0.84	-0.5	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
THCA	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-12.47	5.08e-31	7.4e-28	-0.84	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-12.47	5.08e-31	7.4e-28	-0.84	-0.5	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
THCA	cis	rs12468226	1	rs16839090	ENSG00000273456.1	RP11-686O6.2	12.47	5.13e-31	7.47e-28	0.63	0.5	Urate levels;	chr2:202348338	chr2:202374932~202375604:-
THCA	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	12.46	5.21e-31	7.58e-28	0.65	0.5	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
THCA	cis	rs944289	0.589	rs63360860	ENSG00000257826.1	RP11-116N8.4	12.46	5.21e-31	7.58e-28	0.53	0.5	Thyroid cancer;	chr14:36068846	chr14:36061026~36067190:-
THCA	cis	rs11098499	0.697	rs35280960	ENSG00000245958.5	RP11-33B1.1	-12.46	5.22e-31	7.59e-28	-0.5	-0.5	Corneal astigmatism;	chr4:119335904	chr4:119454791~119552025:+
THCA	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-12.46	5.24e-31	7.62e-28	-0.59	-0.5	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
THCA	cis	rs6504950	1	rs7221223	ENSG00000275710.1	RP11-257O5.4	12.46	5.25e-31	7.63e-28	0.66	0.5	Breast cancer;	chr17:54981646	chr17:54964474~54964679:+
THCA	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	12.46	5.38e-31	7.83e-28	0.62	0.5	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
THCA	cis	rs12468226	0.873	rs3181153	ENSG00000273456.1	RP11-686O6.2	-12.46	5.39e-31	7.83e-28	-0.62	-0.5	Urate levels;	chr2:202205155	chr2:202374932~202375604:-
THCA	cis	rs8040855	0.597	rs994989	ENSG00000259295.5	CSPG4P12	12.46	5.39e-31	7.84e-28	0.75	0.5	Bulimia nervosa;	chr15:85117485	chr15:85191438~85213905:+
THCA	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	12.46	5.42e-31	7.87e-28	0.41	0.5	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
THCA	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	12.46	5.42e-31	7.88e-28	0.59	0.5	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
THCA	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	12.46	5.42e-31	7.88e-28	0.59	0.5	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
THCA	cis	rs6570726	0.791	rs446362	ENSG00000235652.6	RP11-545I5.3	12.46	5.43e-31	7.9e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145557580	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs414600	ENSG00000235652.6	RP11-545I5.3	12.46	5.43e-31	7.9e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145558470	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6915094	ENSG00000235652.6	RP11-545I5.3	12.46	5.43e-31	7.9e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145562404	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs365869	ENSG00000235652.6	RP11-545I5.3	12.46	5.43e-31	7.9e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145563615	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9403746	ENSG00000235652.6	RP11-545I5.3	-12.46	5.44e-31	7.91e-28	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145782632	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.625	rs9390355	ENSG00000235652.6	RP11-545I5.3	-12.46	5.44e-31	7.91e-28	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145791806	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.658	rs4895683	ENSG00000235652.6	RP11-545I5.3	-12.46	5.44e-31	7.91e-28	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145792518	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.625	rs2050027	ENSG00000235652.6	RP11-545I5.3	-12.46	5.44e-31	7.91e-28	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145794977	chr6:145799409~145886585:+
THCA	cis	rs11722779	0.658	rs6533044	ENSG00000246560.2	RP11-10L12.4	12.46	5.46e-31	7.93e-28	0.62	0.5	Schizophrenia;	chr4:102965261	chr4:102828055~102844075:+
THCA	cis	rs7301826	0.651	rs10744485	ENSG00000256250.1	RP11-989F5.1	-12.46	5.49e-31	7.97e-28	-0.6	-0.5	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810606~130812438:+
THCA	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	12.46	5.49e-31	7.97e-28	0.41	0.5	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
THCA	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	12.46	5.5e-31	7.98e-28	0.57	0.5	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
THCA	cis	rs9309473	0.95	rs6546847	ENSG00000163016.8	ALMS1P	12.46	5.55e-31	8.05e-28	0.72	0.5	Metabolite levels;	chr2:73558231	chr2:73644919~73685576:+
THCA	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-12.46	5.61e-31	8.14e-28	-0.52	-0.5	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
THCA	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	12.46	5.61e-31	8.14e-28	0.41	0.5	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
THCA	cis	rs228614	0.51	rs223464	ENSG00000246560.2	RP11-10L12.4	12.46	5.68e-31	8.25e-28	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780603	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223463	ENSG00000246560.2	RP11-10L12.4	12.46	5.68e-31	8.25e-28	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780620	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs223462	ENSG00000246560.2	RP11-10L12.4	12.46	5.68e-31	8.25e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102780661	chr4:102828055~102844075:+
THCA	cis	rs227275	0.531	rs223460	ENSG00000246560.2	RP11-10L12.4	12.46	5.68e-31	8.25e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102782903	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs223398	ENSG00000246560.2	RP11-10L12.4	12.45	5.77e-31	8.37e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102821256	chr4:102828055~102844075:+
THCA	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	12.45	5.78e-31	8.39e-28	0.41	0.5	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	12.45	5.81e-31	8.43e-28	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
THCA	cis	rs11722779	0.935	rs3974481	ENSG00000246560.2	RP11-10L12.4	12.45	5.83e-31	8.46e-28	0.62	0.5	Schizophrenia;	chr4:102956834	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.838	rs4533776	ENSG00000246560.2	RP11-10L12.4	12.45	5.87e-31	8.5e-28	0.61	0.5	Schizophrenia;	chr4:102912732	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.838	rs6821247	ENSG00000246560.2	RP11-10L12.4	12.45	5.87e-31	8.5e-28	0.61	0.5	Schizophrenia;	chr4:102913483	chr4:102828055~102844075:+
THCA	cis	rs11098499	0.629	rs28369518	ENSG00000245958.5	RP11-33B1.1	-12.45	5.88e-31	8.52e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119350475	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.722	rs10025925	ENSG00000245958.5	RP11-33B1.1	-12.45	5.88e-31	8.52e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119350589	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.731	rs10015579	ENSG00000245958.5	RP11-33B1.1	-12.45	5.88e-31	8.52e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119350647	chr4:119454791~119552025:+
THCA	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-12.45	5.94e-31	8.61e-28	-0.59	-0.5	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
THCA	cis	rs7174755	0.637	rs10152713	ENSG00000260657.2	RP11-315D16.4	-12.45	5.95e-31	8.62e-28	-0.65	-0.5	Major depressive disorder;	chr15:68179553	chr15:68267792~68277994:-
THCA	cis	rs6683071	0.688	rs2378604	ENSG00000272750.1	RP11-378J18.8	-12.45	5.97e-31	8.64e-28	-0.62	-0.5	Cognitive performance;	chr1:222730968	chr1:222658867~222661512:-
THCA	cis	rs228614	0.51	rs223455	ENSG00000246560.2	RP11-10L12.4	12.45	5.97e-31	8.65e-28	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102789026	chr4:102828055~102844075:+
THCA	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	12.45	6e-31	8.68e-28	0.62	0.5	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	12.45	6e-31	8.68e-28	0.62	0.5	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	12.45	6e-31	8.68e-28	0.62	0.5	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	12.45	6e-31	8.68e-28	0.62	0.5	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
THCA	cis	rs228614	0.51	rs223459	ENSG00000246560.2	RP11-10L12.4	12.45	6.02e-31	8.72e-28	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102788229	chr4:102828055~102844075:+
THCA	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-12.45	6.04e-31	8.74e-28	-0.55	-0.5	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
THCA	cis	rs8062405	1	rs2008514	ENSG00000251417.2	RP11-1348G14.4	12.45	6.07e-31	8.79e-28	0.48	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28802743~28817828:+
THCA	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	12.45	6.09e-31	8.81e-28	0.57	0.5	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	12.45	6.09e-31	8.81e-28	0.57	0.5	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
THCA	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-12.45	6.09e-31	8.82e-28	-0.62	-0.5	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
THCA	cis	rs6570726	0.791	rs12208812	ENSG00000235652.6	RP11-545I5.3	12.45	6.14e-31	8.89e-28	0.46	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145579788	chr6:145799409~145886585:+
THCA	cis	rs227275	0.588	rs223458	ENSG00000246560.2	RP11-10L12.4	12.45	6.18e-31	8.95e-28	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102788414	chr4:102828055~102844075:+
THCA	cis	rs11098499	0.691	rs28396837	ENSG00000245958.5	RP11-33B1.1	-12.45	6.2e-31	8.97e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119350386	chr4:119454791~119552025:+
THCA	cis	rs9309473	0.898	rs7580750	ENSG00000163016.8	ALMS1P	12.45	6.2e-31	8.98e-28	0.72	0.5	Metabolite levels;	chr2:73560999	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.898	rs11126403	ENSG00000163016.8	ALMS1P	12.45	6.2e-31	8.98e-28	0.72	0.5	Metabolite levels;	chr2:73569796	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.898	rs11126404	ENSG00000163016.8	ALMS1P	12.45	6.2e-31	8.98e-28	0.72	0.5	Metabolite levels;	chr2:73569797	chr2:73644919~73685576:+
THCA	cis	rs524281	0.861	rs7942894	ENSG00000255320.1	RP11-755F10.1	12.45	6.25e-31	9.04e-28	0.71	0.5	Electroencephalogram traits;	chr11:66209054	chr11:66244840~66246239:-
THCA	cis	rs3002131	0.736	rs2936027	ENSG00000225265.1	TAF1A-AS1	-12.45	6.25e-31	9.04e-28	-0.7	-0.5	Interleukin-10 levels;	chr1:222588974	chr1:222589825~222593032:+
THCA	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	12.45	6.25e-31	9.05e-28	0.61	0.5	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
THCA	cis	rs227275	0.525	rs3974608	ENSG00000246560.2	RP11-10L12.4	12.44	6.3e-31	9.11e-28	0.61	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102925641	chr4:102828055~102844075:+
THCA	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-12.44	6.32e-31	9.14e-28	-0.61	-0.5	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
THCA	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-12.44	6.33e-31	9.15e-28	-0.65	-0.5	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
THCA	cis	rs526231	0.511	rs1011453	ENSG00000175749.11	EIF3KP1	12.44	6.33e-31	9.15e-28	0.66	0.5	Primary biliary cholangitis;	chr5:103032323	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs62362558	ENSG00000175749.11	EIF3KP1	12.44	6.33e-31	9.15e-28	0.66	0.5	Primary biliary cholangitis;	chr5:103032789	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs4421079	ENSG00000175749.11	EIF3KP1	12.44	6.33e-31	9.15e-28	0.66	0.5	Primary biliary cholangitis;	chr5:103033372	chr5:103032376~103033031:+
THCA	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-12.44	6.37e-31	9.2e-28	-0.59	-0.5	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
THCA	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-12.44	6.37e-31	9.2e-28	-0.37	-0.5	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	12.44	6.4e-31	9.25e-28	0.36	0.5	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
THCA	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-12.44	6.41e-31	9.26e-28	-0.47	-0.5	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-12.44	6.41e-31	9.26e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-12.44	6.41e-31	9.26e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
THCA	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-12.44	6.41e-31	9.26e-28	-0.47	-0.5	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-12.44	6.41e-31	9.26e-28	-0.47	-0.5	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
THCA	cis	rs227275	0.556	rs6842179	ENSG00000246560.2	RP11-10L12.4	12.44	6.41e-31	9.26e-28	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103018363	chr4:102828055~102844075:+
THCA	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-12.44	6.44e-31	9.3e-28	-0.36	-0.5	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
THCA	cis	rs6570726	0.738	rs7746330	ENSG00000235652.6	RP11-545I5.3	12.44	6.45e-31	9.32e-28	0.46	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145578121	chr6:145799409~145886585:+
THCA	cis	rs228614	0.514	rs59550147	ENSG00000246560.2	RP11-10L12.4	12.44	6.49e-31	9.38e-28	0.61	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102914239	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223356	ENSG00000246560.2	RP11-10L12.4	12.44	6.58e-31	9.51e-28	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102852344	chr4:102828055~102844075:+
THCA	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-12.44	6.77e-31	9.77e-28	-0.61	-0.5	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
THCA	cis	rs7772486	0.686	rs702305	ENSG00000235652.6	RP11-545I5.3	-12.44	6.82e-31	9.84e-28	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145652704	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs857875	ENSG00000235652.6	RP11-545I5.3	-12.44	6.82e-31	9.84e-28	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145658897	chr6:145799409~145886585:+
THCA	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	12.44	6.83e-31	9.86e-28	0.4	0.5	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
THCA	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	12.44	6.86e-31	9.9e-28	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
THCA	cis	rs6570726	0.791	rs400329	ENSG00000235652.6	RP11-545I5.3	12.44	6.87e-31	9.92e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145558306	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs435671	ENSG00000235652.6	RP11-545I5.3	12.44	6.87e-31	9.92e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145560079	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs367065	ENSG00000235652.6	RP11-545I5.3	12.44	6.87e-31	9.92e-28	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145561173	chr6:145799409~145886585:+
THCA	cis	rs9309473	0.898	rs9807961	ENSG00000163016.8	ALMS1P	12.43	6.98e-31	1.01e-27	0.72	0.5	Metabolite levels;	chr2:73466916	chr2:73644919~73685576:+
THCA	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	12.43	7.05e-31	1.02e-27	0.59	0.5	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-12.43	7.05e-31	1.02e-27	-0.59	-0.5	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-12.43	7.05e-31	1.02e-27	-0.59	-0.5	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
THCA	cis	rs524281	0.817	rs10896097	ENSG00000255320.1	RP11-755F10.1	12.43	7.06e-31	1.02e-27	0.7	0.5	Electroencephalogram traits;	chr11:66200482	chr11:66244840~66246239:-
THCA	cis	rs12022452	0.818	rs11810978	ENSG00000238287.1	RP11-656D10.3	-12.43	7.07e-31	1.02e-27	-0.76	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554175	chr1:40493157~40508661:-
THCA	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-12.43	7.18e-31	1.03e-27	-0.76	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
THCA	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-12.43	7.25e-31	1.04e-27	-0.84	-0.5	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
THCA	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	12.43	7.37e-31	1.06e-27	0.59	0.5	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
THCA	cis	rs8062405	1	rs8062405	ENSG00000251417.2	RP11-1348G14.4	12.43	7.45e-31	1.07e-27	0.47	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28802743~28817828:+
THCA	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	12.43	7.46e-31	1.07e-27	0.62	0.5	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
THCA	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	12.43	7.51e-31	1.08e-27	0.58	0.5	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
THCA	cis	rs12022452	0.822	rs11208390	ENSG00000238287.1	RP11-656D10.3	-12.43	7.53e-31	1.08e-27	-0.75	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40556342	chr1:40493157~40508661:-
THCA	cis	rs227275	0.554	rs223467	ENSG00000246560.2	RP11-10L12.4	12.43	7.54e-31	1.09e-27	0.61	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102779721	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223405	ENSG00000246560.2	RP11-10L12.4	12.43	7.55e-31	1.09e-27	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102815894	chr4:102828055~102844075:+
THCA	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	12.42	7.75e-31	1.11e-27	0.59	0.5	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-12.42	7.75e-31	1.11e-27	-0.59	-0.5	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
THCA	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	12.42	7.83e-31	1.13e-27	0.57	0.5	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
THCA	cis	rs11098499	0.913	rs67073020	ENSG00000245958.5	RP11-33B1.1	-12.42	7.87e-31	1.13e-27	-0.48	-0.5	Corneal astigmatism;	chr4:119231402	chr4:119454791~119552025:+
THCA	cis	rs227275	0.556	rs223426	ENSG00000246560.2	RP11-10L12.4	12.42	7.88e-31	1.13e-27	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102801330	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223425	ENSG00000246560.2	RP11-10L12.4	12.42	7.88e-31	1.13e-27	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102802836	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223418	ENSG00000246560.2	RP11-10L12.4	12.42	7.88e-31	1.13e-27	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102809336	chr4:102828055~102844075:+
THCA	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	12.42	7.98e-31	1.15e-27	0.87	0.5	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
THCA	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	12.42	8.05e-31	1.16e-27	0.57	0.5	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
THCA	cis	rs6496932	0.755	rs56909106	ENSG00000218052.5	ADAMTS7P4	12.42	8.12e-31	1.17e-27	0.64	0.5	Central corneal thickness;Corneal structure;	chr15:85320817	chr15:85255369~85330334:-
THCA	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-12.42	8.22e-31	1.18e-27	-0.83	-0.5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
THCA	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	12.41	8.4e-31	1.21e-27	0.57	0.5	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	12.41	8.4e-31	1.21e-27	0.57	0.5	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
THCA	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	12.41	8.44e-31	1.21e-27	0.41	0.5	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
THCA	cis	rs944289	0.561	rs371191	ENSG00000257826.1	RP11-116N8.4	12.41	8.48e-31	1.22e-27	0.52	0.5	Thyroid cancer;	chr14:36064000	chr14:36061026~36067190:-
THCA	cis	rs228614	0.51	rs223415	ENSG00000246560.2	RP11-10L12.4	12.41	8.51e-31	1.22e-27	0.63	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102811016	chr4:102828055~102844075:+
THCA	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-12.41	8.53e-31	1.23e-27	-0.53	-0.5	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
THCA	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	12.41	8.62e-31	1.24e-27	0.47	0.5	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
THCA	cis	rs9309473	0.95	rs10207264	ENSG00000163016.8	ALMS1P	12.41	8.67e-31	1.24e-27	0.72	0.5	Metabolite levels;	chr2:73486970	chr2:73644919~73685576:+
THCA	cis	rs228614	0.51	rs223397	ENSG00000246560.2	RP11-10L12.4	12.41	8.68e-31	1.25e-27	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102821494	chr4:102828055~102844075:+
THCA	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-12.41	8.73e-31	1.25e-27	-0.37	-0.5	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-12.41	8.73e-31	1.25e-27	-0.37	-0.5	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
THCA	cis	rs9309473	1	rs11901272	ENSG00000163016.8	ALMS1P	12.41	8.75e-31	1.26e-27	0.72	0.5	Metabolite levels;	chr2:73493317	chr2:73644919~73685576:+
THCA	cis	rs6496932	0.755	rs12905673	ENSG00000218052.5	ADAMTS7P4	-12.41	8.84e-31	1.27e-27	-0.64	-0.5	Central corneal thickness;Corneal structure;	chr15:85346540	chr15:85255369~85330334:-
THCA	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-12.41	8.87e-31	1.27e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-12.41	8.87e-31	1.27e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-12.41	8.87e-31	1.27e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
THCA	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	12.41	8.88e-31	1.27e-27	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
THCA	cis	rs524281	0.861	rs11227426	ENSG00000255320.1	RP11-755F10.1	12.41	8.93e-31	1.28e-27	0.71	0.5	Electroencephalogram traits;	chr11:66204480	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.691	rs17009144	ENSG00000245958.5	RP11-33B1.1	12.41	8.95e-31	1.28e-27	0.47	0.5	Corneal astigmatism;	chr4:119349640	chr4:119454791~119552025:+
THCA	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	12.41	8.97e-31	1.29e-27	0.62	0.5	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
THCA	cis	rs227275	0.555	rs223403	ENSG00000246560.2	RP11-10L12.4	12.41	9.11e-31	1.31e-27	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102817086	chr4:102828055~102844075:+
THCA	cis	rs227275	0.555	rs223402	ENSG00000246560.2	RP11-10L12.4	12.41	9.11e-31	1.31e-27	0.63	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102817198	chr4:102828055~102844075:+
THCA	cis	rs2288884	0.515	rs8112458	ENSG00000275055.1	CTC-471J1.11	-12.4	9.18e-31	1.32e-27	-0.38	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52030052	chr19:52049007~52049754:+
THCA	cis	rs934734	0.532	rs2860773	ENSG00000204929.10	AC074391.1	-12.4	9.31e-31	1.33e-27	-0.59	-0.5	Rheumatoid arthritis;	chr2:65438507	chr2:65436711~66084639:+
THCA	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	12.4	9.34e-31	1.34e-27	0.57	0.5	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
THCA	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-12.4	9.35e-31	1.34e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
THCA	cis	rs12468226	0.817	rs2350360	ENSG00000273456.1	RP11-686O6.2	-12.4	9.39e-31	1.35e-27	-0.62	-0.5	Urate levels;	chr2:202222980	chr2:202374932~202375604:-
THCA	cis	rs9322193	0.607	rs6925151	ENSG00000231760.4	RP11-350J20.5	12.4	9.53e-31	1.36e-27	0.7	0.5	Lung cancer;	chr6:149889587	chr6:149796151~149826294:-
THCA	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	12.4	9.64e-31	1.38e-27	0.4	0.5	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
THCA	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	12.4	9.7e-31	1.39e-27	0.59	0.5	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
THCA	cis	rs12458462	0.892	rs35928863	ENSG00000274828.1	RP11-567M16.6	12.4	9.71e-31	1.39e-27	0.41	0.5	Monocyte count;	chr18:79678956	chr18:79677287~79679358:-
THCA	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	12.4	9.73e-31	1.39e-27	0.57	0.5	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
THCA	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	12.4	9.75e-31	1.4e-27	0.61	0.5	Height;	chr3:53072864	chr3:53064283~53065091:-
THCA	cis	rs11722779	0.933	rs7695096	ENSG00000246560.2	RP11-10L12.4	12.4	9.78e-31	1.4e-27	0.62	0.5	Schizophrenia;	chr4:103011399	chr4:102828055~102844075:+
THCA	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	12.4	9.83e-31	1.41e-27	0.57	0.5	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
THCA	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	12.4	9.86e-31	1.41e-27	0.59	0.5	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	12.4	9.86e-31	1.41e-27	0.59	0.5	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
THCA	cis	rs6570726	0.791	rs9497357	ENSG00000235652.6	RP11-545I5.3	12.4	9.87e-31	1.41e-27	0.45	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145591752	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs4263604	ENSG00000235652.6	RP11-545I5.3	12.4	9.87e-31	1.41e-27	0.45	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145595561	chr6:145799409~145886585:+
THCA	cis	rs227275	0.524	rs223337	ENSG00000246560.2	RP11-10L12.4	12.4	9.88e-31	1.41e-27	0.61	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102865214	chr4:102828055~102844075:+
THCA	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	12.4	9.97e-31	1.43e-27	0.72	0.5	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
THCA	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	12.4	9.98e-31	1.43e-27	0.65	0.5	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	12.4	9.98e-31	1.43e-27	0.65	0.5	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
THCA	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	12.4	1e-30	1.43e-27	0.57	0.5	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	12.4	1e-30	1.43e-27	0.57	0.5	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	12.4	1e-30	1.43e-27	0.57	0.5	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	12.39	1.01e-30	1.44e-27	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
THCA	cis	rs6570726	0.818	rs412350	ENSG00000235652.6	RP11-545I5.3	12.39	1.01e-30	1.45e-27	0.47	0.5	Lobe attachment (rater-scored or self-reported);	chr6:145531273	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.691	rs12510133	ENSG00000245958.5	RP11-33B1.1	-12.39	1.02e-30	1.45e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119350189	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.754	rs12506487	ENSG00000245958.5	RP11-33B1.1	-12.39	1.02e-30	1.45e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119350206	chr4:119454791~119552025:+
THCA	cis	rs4964805	0.626	rs11111771	ENSG00000257681.1	RP11-341G23.4	-12.39	1.02e-30	1.45e-27	-0.6	-0.5	Attention deficit hyperactivity disorder;	chr12:103785493	chr12:103746315~103768858:-
THCA	cis	rs7188445	0.712	rs6564688	ENSG00000261390.4	RP11-345M22.2	12.39	1.02e-30	1.45e-27	0.59	0.5	Urate levels;	chr16:79680061	chr16:79715232~79770563:-
THCA	cis	rs5769707	0.632	rs1476037	ENSG00000188511.11	C22orf34	12.39	1.03e-30	1.47e-27	0.64	0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49414524~49657542:-
THCA	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	12.39	1.03e-30	1.47e-27	0.59	0.5	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
THCA	cis	rs6496932	0.802	rs4843047	ENSG00000218052.5	ADAMTS7P4	12.39	1.04e-30	1.48e-27	0.64	0.5	Central corneal thickness;Corneal structure;	chr15:85316545	chr15:85255369~85330334:-
THCA	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	12.39	1.05e-30	1.5e-27	0.65	0.5	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
THCA	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	12.39	1.05e-30	1.5e-27	0.63	0.5	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
THCA	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	12.39	1.05e-30	1.5e-27	0.36	0.5	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
THCA	cis	rs6504950	1	rs9902718	ENSG00000275710.1	RP11-257O5.4	12.39	1.05e-30	1.5e-27	0.64	0.5	Breast cancer;	chr17:54984261	chr17:54964474~54964679:+
THCA	cis	rs853679	0.517	rs9393891	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28111382	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9468286	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28111650	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.516	rs7739216	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Parkinson's disease;	chr6:28112168	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs35512245	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28112175	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380055	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28113851	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368553	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28114487	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368554	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28114933	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs4713137	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28115743	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9348793	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Depression;	chr6:28116411	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.586	rs6905516	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Parkinson's disease;	chr6:28118700	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.586	rs6905522	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Parkinson's disease;	chr6:28118701	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.586	rs9468290	ENSG00000280107.1	AL022393.9	-12.39	1.06e-30	1.51e-27	-0.6	-0.5	Parkinson's disease;	chr6:28119896	chr6:28170845~28172521:+
THCA	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-12.39	1.06e-30	1.52e-27	-0.68	-0.5	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
THCA	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-12.39	1.06e-30	1.52e-27	-0.68	-0.5	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
THCA	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	12.39	1.07e-30	1.52e-27	0.6	0.5	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	12.39	1.07e-30	1.52e-27	0.6	0.5	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	12.39	1.07e-30	1.52e-27	0.6	0.5	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
THCA	cis	rs6496932	0.802	rs2063442	ENSG00000218052.5	ADAMTS7P4	12.39	1.07e-30	1.53e-27	0.64	0.5	Central corneal thickness;Corneal structure;	chr15:85314813	chr15:85255369~85330334:-
THCA	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	12.39	1.07e-30	1.53e-27	0.59	0.5	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
THCA	cis	rs228614	0.536	rs223375	ENSG00000246560.2	RP11-10L12.4	12.39	1.08e-30	1.53e-27	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102836484	chr4:102828055~102844075:+
THCA	cis	rs2658782	0.789	rs2605580	ENSG00000279684.1	RP11-755E23.2	-12.39	1.08e-30	1.54e-27	-0.81	-0.5	Pulmonary function decline;	chr11:93413888	chr11:93286629~93288903:-
THCA	cis	rs227275	0.525	rs223461	ENSG00000246560.2	RP11-10L12.4	12.39	1.08e-30	1.54e-27	0.61	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102782372	chr4:102828055~102844075:+
THCA	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	12.39	1.09e-30	1.55e-27	0.87	0.5	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
THCA	cis	rs6570726	0.791	rs392612	ENSG00000235652.6	RP11-545I5.3	-12.39	1.09e-30	1.55e-27	-0.47	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145560450	chr6:145799409~145886585:+
THCA	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-12.39	1.1e-30	1.57e-27	-0.55	-0.5	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
THCA	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	12.38	1.1e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
THCA	cis	rs944289	0.561	rs395660	ENSG00000257826.1	RP11-116N8.4	12.38	1.11e-30	1.57e-27	0.52	0.5	Thyroid cancer;	chr14:36063593	chr14:36061026~36067190:-
THCA	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	12.38	1.11e-30	1.57e-27	0.59	0.5	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
THCA	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-12.38	1.11e-30	1.58e-27	-0.37	-0.5	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
THCA	cis	rs228614	0.51	rs223392	ENSG00000246560.2	RP11-10L12.4	12.38	1.11e-30	1.58e-27	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102824599	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223390	ENSG00000246560.2	RP11-10L12.4	12.38	1.11e-30	1.58e-27	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102827640	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs50034	ENSG00000246560.2	RP11-10L12.4	12.38	1.11e-30	1.58e-27	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102832214	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs223380	ENSG00000246560.2	RP11-10L12.4	12.38	1.11e-30	1.58e-27	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102833343	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs223379	ENSG00000246560.2	RP11-10L12.4	12.38	1.11e-30	1.58e-27	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:102833434	chr4:102828055~102844075:+
THCA	cis	rs12022452	0.822	rs11811369	ENSG00000238287.1	RP11-656D10.3	-12.38	1.12e-30	1.59e-27	-0.74	-0.5	Age-related hearing impairment (SNP x SNP interaction);	chr1:40560611	chr1:40493157~40508661:-
THCA	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-12.38	1.12e-30	1.59e-27	-0.84	-0.5	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
THCA	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-12.38	1.12e-30	1.6e-27	-0.37	-0.5	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-12.38	1.12e-30	1.6e-27	-0.37	-0.5	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-12.38	1.12e-30	1.6e-27	-0.37	-0.5	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
THCA	cis	rs6496932	0.802	rs12442399	ENSG00000218052.5	ADAMTS7P4	12.38	1.13e-30	1.6e-27	0.64	0.5	Central corneal thickness;Corneal structure;	chr15:85311619	chr15:85255369~85330334:-
THCA	cis	rs6496932	0.802	rs8038403	ENSG00000218052.5	ADAMTS7P4	12.38	1.13e-30	1.6e-27	0.64	0.5	Central corneal thickness;Corneal structure;	chr15:85313364	chr15:85255369~85330334:-
THCA	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	12.38	1.15e-30	1.63e-27	0.35	0.5	Height;	chr11:118758322	chr11:118791254~118793137:+
THCA	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	12.38	1.15e-30	1.63e-27	0.53	0.5	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
THCA	cis	rs6504950	1	rs28558726	ENSG00000275710.1	RP11-257O5.4	12.38	1.16e-30	1.65e-27	0.63	0.5	Breast cancer;	chr17:54981315	chr17:54964474~54964679:+
THCA	cis	rs6570726	0.791	rs11155433	ENSG00000235652.6	RP11-545I5.3	-12.38	1.16e-30	1.65e-27	-0.45	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145586695	chr6:145799409~145886585:+
THCA	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-12.38	1.18e-30	1.67e-27	-0.63	-0.5	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
THCA	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	12.38	1.18e-30	1.68e-27	0.56	0.5	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
THCA	cis	rs228614	0.51	rs223353	ENSG00000246560.2	RP11-10L12.4	12.38	1.19e-30	1.68e-27	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102854547	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223352	ENSG00000246560.2	RP11-10L12.4	12.38	1.19e-30	1.68e-27	0.62	0.5	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102855710	chr4:102828055~102844075:+
THCA	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	12.38	1.2e-30	1.69e-27	0.58	0.5	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
THCA	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	12.38	1.2e-30	1.69e-27	0.58	0.5	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
THCA	cis	rs944289	0.616	rs448145	ENSG00000257826.1	RP11-116N8.4	12.38	1.2e-30	1.7e-27	0.52	0.5	Thyroid cancer;	chr14:36069722	chr14:36061026~36067190:-
THCA	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-12.37	1.21e-30	1.72e-27	-0.37	-0.5	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
THCA	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-12.37	1.21e-30	1.72e-27	-0.37	-0.5	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-12.37	1.21e-30	1.72e-27	-0.37	-0.5	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	12.37	1.21e-30	1.72e-27	0.56	0.5	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
THCA	cis	rs12458462	0.859	rs2242177	ENSG00000274828.1	RP11-567M16.6	12.37	1.21e-30	1.72e-27	0.41	0.5	Monocyte count;	chr18:79717379	chr18:79677287~79679358:-
THCA	cis	rs2288884	0.559	rs61287503	ENSG00000275055.1	CTC-471J1.11	-12.37	1.22e-30	1.72e-27	-0.4	-0.5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017939	chr19:52049007~52049754:+
THCA	cis	rs1062177	0.756	rs2964589	ENSG00000213433.5	RPLP1P6	12.37	1.22e-30	1.73e-27	0.53	0.5	Preschool internalizing problems;	chr5:151738628	chr5:151765859~151766378:-
THCA	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	12.37	1.25e-30	1.77e-27	0.65	0.5	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	12.37	1.25e-30	1.77e-27	0.65	0.5	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
THCA	cis	rs11098499	0.691	rs12502524	ENSG00000245958.5	RP11-33B1.1	-12.37	1.25e-30	1.77e-27	-0.47	-0.5	Corneal astigmatism;	chr4:119350259	chr4:119454791~119552025:+
THCA	cis	rs11673344	0.966	rs111927298	ENSG00000226686.6	LINC01535	12.37	1.25e-30	1.78e-27	0.59	0.5	Obesity-related traits;	chr19:37193034	chr19:37251912~37265535:+
THCA	cis	rs4718428	0.705	rs4717331	ENSG00000226824.5	RP4-756H11.3	-12.37	1.25e-30	1.78e-27	-0.72	-0.5	Corneal structure;	chr7:66913899	chr7:66654538~66669855:+
THCA	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-12.37	1.28e-30	1.81e-27	-0.58	-0.5	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
THCA	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-12.37	1.28e-30	1.81e-27	-0.63	-0.5	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
THCA	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	12.37	1.29e-30	1.83e-27	0.57	0.5	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
THCA	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	12.37	1.31e-30	1.85e-27	0.62	0.5	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
THCA	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	12.37	1.31e-30	1.86e-27	0.57	0.5	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
THCA	cis	rs6860806	0.507	rs2631372	ENSG00000233006.5	AC034220.3	12.37	1.32e-30	1.87e-27	0.39	0.5	Breast cancer;	chr5:132367886	chr5:132311285~132369916:-
THCA	cis	rs11722779	0.869	rs223323	ENSG00000246560.2	RP11-10L12.4	12.37	1.32e-30	1.87e-27	0.63	0.5	Schizophrenia;	chr4:102878412	chr4:102828055~102844075:+
THCA	cis	rs7772486	0.622	rs1292333	ENSG00000235652.6	RP11-545I5.3	-12.37	1.33e-30	1.88e-27	-0.46	-0.5	Lobe attachment (rater-scored or self-reported);	chr6:145661208	chr6:145799409~145886585:+
THCA	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	12.36	1.33e-30	1.88e-27	0.71	0.5	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
THCA	cis	rs227275	0.525	rs2086499	ENSG00000246560.2	RP11-10L12.4	12.36	1.33e-30	1.89e-27	0.62	0.5	Allergic disease (asthma, hay fever or eczema);	chr4:103008672	chr4:102828055~102844075:+
THCA	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	12.36	1.35e-30	1.9e-27	0.41	0.5	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
THCA	cis	rs9322193	0.884	rs880245	ENSG00000223701.3	RAET1E-AS1	-12.36	1.37e-30	1.93e-27	-0.69	-0.5	Lung cancer;	chr6:149846262	chr6:149884431~149919508:+
THCA	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	12.36	1.38e-30	1.94e-27	0.62	0.5	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
THCA	cis	rs526231	0.543	rs34791	ENSG00000175749.11	EIF3KP1	12.36	1.38e-30	1.95e-27	0.66	0.5	Primary biliary cholangitis;	chr5:103126400	chr5:103032376~103033031:+
THCA	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-12.36	1.39e-30	1.96e-27	-0.37	-0.5	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-12.36	1.39e-30	1.96e-27	-0.37	-0.5	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
THCA	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-12.36	1.39e-30	1.96e-27	-0.37	-0.5	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-12.36	1.39e-30	1.96e-27	-0.37	-0.5	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-12.36	1.39e-30	1.96e-27	-0.37	-0.5	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
THCA	cis	rs324126	0.78	rs2059817	ENSG00000277977.1	CTD-3018O17.5	12.36	1.4e-30	1.97e-27	0.47	0.5	Colonoscopy-negative controls vs population controls;	chr19:52379032	chr19:52392659~52392755:+
THCA	cis	rs1150668	1	rs1150668	ENSG00000216901.1	AL022393.7	12.36	1.4e-30	1.98e-27	0.59	0.5	Pubertal anthropometrics;	chr6:28162011	chr6:28176188~28176674:+
THCA	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	12.36	1.4e-30	1.98e-27	0.55	0.5	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
THCA	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-12.36	1.42e-30	2e-27	-0.58	-0.5	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
THCA	cis	rs6504950	1	rs9915183	ENSG00000275710.1	RP11-257O5.4	12.36	1.42e-30	2.01e-27	0.63	0.5	Breast cancer;	chr17:54969776	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9895808	ENSG00000275710.1	RP11-257O5.4	12.36	1.42e-30	2.01e-27	0.63	0.5	Breast cancer;	chr17:54971081	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9897447	ENSG00000275710.1	RP11-257O5.4	12.36	1.42e-30	2.01e-27	0.63	0.5	Breast cancer;	chr17:54971108	chr17:54964474~54964679:+
THCA	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-12.36	1.43e-30	2.02e-27	-0.56	-0.5	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
THCA	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-12.36	1.44e-30	2.03e-27	-0.37	-0.5	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
THCA	cis	rs77505915	0.512	rs12921808	ENSG00000261783.1	RP11-252K23.2	12.36	1.46e-30	2.06e-27	0.72	0.5	Migraine;	chr16:75350086	chr16:75379818~75381260:-
THCA	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	12.35	1.46e-30	2.06e-27	0.56	0.5	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
THCA	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	12.35	1.48e-30	2.08e-27	0.62	0.5	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
THCA	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-12.35	1.48e-30	2.09e-27	-0.6	-0.5	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
THCA	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	12.35	1.5e-30	2.11e-27	0.37	0.5	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
THCA	cis	rs6504950	1	rs9892976	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54982968	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9902687	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54971563	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs8080491	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54972508	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs6504948	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54972626	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs6504949	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54972772	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs8078550	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54976018	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9914732	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54977006	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9916642	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54977136	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9915832	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54977336	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9893306	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54977388	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs6504950	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54979110	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs6504951	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54979614	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9903146	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54980386	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.962	rs9902950	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54980403	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9903220	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54980504	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9903825	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54980553	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs16955471	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54981446	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9891865	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54982672	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs9892173	ENSG00000275710.1	RP11-257O5.4	12.35	1.5e-30	2.12e-27	0.63	0.5	Breast cancer;	chr17:54982853	chr17:54964474~54964679:+
THCA	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	12.35	1.51e-30	2.13e-27	0.84	0.5	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
THCA	cis	rs11673344	0.864	rs7260386	ENSG00000226686.6	LINC01535	12.35	1.51e-30	2.13e-27	0.58	0.5	Obesity-related traits;	chr19:37158656	chr19:37251912~37265535:+
THCA	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	12.35	1.51e-30	2.13e-27	0.57	0.5	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
THCA	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	12.35	1.52e-30	2.14e-27	0.59	0.5	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
THCA	cis	rs934734	0.509	rs12185577	ENSG00000204929.10	AC074391.1	-12.35	1.52e-30	2.14e-27	-0.6	-0.5	Rheumatoid arthritis;	chr2:65432354	chr2:65436711~66084639:+
THCA	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	12.35	1.53e-30	2.16e-27	0.59	0.49	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
THCA	cis	rs6504950	1	rs9903444	ENSG00000275710.1	RP11-257O5.4	12.35	1.53e-30	2.16e-27	0.63	0.49	Breast cancer;	chr17:54980532	chr17:54964474~54964679:+
THCA	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-12.35	1.54e-30	2.17e-27	-0.65	-0.49	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
THCA	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	12.35	1.55e-30	2.18e-27	0.66	0.49	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
THCA	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	12.35	1.55e-30	2.18e-27	0.66	0.49	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
THCA	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-12.35	1.55e-30	2.18e-27	-0.61	-0.49	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	12.35	1.55e-30	2.19e-27	0.64	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
THCA	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-12.35	1.55e-30	2.19e-27	-0.65	-0.49	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
THCA	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	12.35	1.56e-30	2.19e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
THCA	cis	rs228614	0.51	rs223468	ENSG00000246560.2	RP11-10L12.4	12.35	1.56e-30	2.19e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102779265	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223465	ENSG00000246560.2	RP11-10L12.4	12.35	1.56e-30	2.19e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102780174	chr4:102828055~102844075:+
THCA	cis	rs638893	1	rs73005500	ENSG00000278376.1	RP11-158I9.8	12.35	1.56e-30	2.19e-27	0.58	0.49	Vitiligo;	chr11:118826666	chr11:118791254~118793137:+
THCA	cis	rs62158211	1	rs4618068	ENSG00000234997.1	AC016745.3	-12.35	1.56e-30	2.19e-27	-0.6	-0.49	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113351778	chr2:113424495~113425324:+
THCA	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	12.35	1.56e-30	2.2e-27	0.59	0.49	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
THCA	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-12.35	1.59e-30	2.23e-27	-0.61	-0.49	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
THCA	cis	rs11105298	0.891	rs11105313	ENSG00000258302.2	RP11-981P6.1	-12.34	1.61e-30	2.26e-27	-0.47	-0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89529599	chr12:89561129~89594878:+
THCA	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-12.34	1.63e-30	2.29e-27	-0.36	-0.49	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
THCA	cis	rs4927850	0.958	rs2044599	ENSG00000231464.1	AC024937.4	12.34	1.65e-30	2.31e-27	0.62	0.49	Pancreatic cancer;	chr3:196009869	chr3:195996738~195998233:+
THCA	cis	rs4927850	1	rs4927704	ENSG00000231464.1	AC024937.4	12.34	1.65e-30	2.31e-27	0.62	0.49	Pancreatic cancer;	chr3:196011357	chr3:195996738~195998233:+
THCA	cis	rs4927850	1	rs4927848	ENSG00000231464.1	AC024937.4	12.34	1.65e-30	2.31e-27	0.62	0.49	Pancreatic cancer;	chr3:196011535	chr3:195996738~195998233:+
THCA	cis	rs228614	0.536	rs223477	ENSG00000246560.2	RP11-10L12.4	12.34	1.65e-30	2.32e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769099	chr4:102828055~102844075:+
THCA	cis	rs26232	0.583	rs154258	ENSG00000175749.11	EIF3KP1	-12.34	1.65e-30	2.32e-27	-0.64	-0.49	Rheumatoid arthritis;	chr5:103027919	chr5:103032376~103033031:+
THCA	cis	rs26232	0.551	rs26431	ENSG00000175749.11	EIF3KP1	-12.34	1.65e-30	2.32e-27	-0.64	-0.49	Rheumatoid arthritis;	chr5:103030090	chr5:103032376~103033031:+
THCA	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-12.34	1.66e-30	2.33e-27	-0.6	-0.49	Height;	chr3:53085518	chr3:53064283~53065091:-
THCA	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-12.34	1.66e-30	2.33e-27	-0.36	-0.49	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs12673450	ENSG00000237310.1	GS1-124K5.4	12.34	1.66e-30	2.34e-27	0.37	0.49	Aortic root size;	chr7:66544233	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	12.34	1.66e-30	2.34e-27	0.56	0.49	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	12.34	1.66e-30	2.34e-27	0.56	0.49	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
THCA	cis	rs853679	0.517	rs9380047	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28070115	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs7755442	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28071237	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs12174753	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28074687	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs55747925	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28076559	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs56310871	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28076704	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs34716816	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28078391	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380049	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28080757	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380050	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28080760	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393885	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28082231	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393886	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28082261	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.515	rs9368549	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Parkinson's disease;	chr6:28082269	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs56364346	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28082984	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9357061	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28083994	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368550	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28084025	chr6:28170845~28172521:+
THCA	cis	rs853679	0.542	rs2295594	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28085319	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9366715	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28096855	chr6:28170845~28172521:+
THCA	cis	rs853679	0.598	rs9380054	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28099759	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.547	rs2116981	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Parkinson's disease;	chr6:28100173	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368552	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28100648	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs2281588	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28104824	chr6:28170845~28172521:+
THCA	cis	rs853679	0.542	rs34131763	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28107222	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs35193936	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28108492	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs36078605	ENSG00000280107.1	AL022393.9	-12.34	1.7e-30	2.38e-27	-0.6	-0.49	Depression;	chr6:28110254	chr6:28170845~28172521:+
THCA	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	12.34	1.71e-30	2.4e-27	0.36	0.49	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
THCA	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-12.34	1.72e-30	2.41e-27	-0.6	-0.49	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
THCA	cis	rs673078	0.66	rs17619932	ENSG00000275759.1	RP11-131L12.3	-12.34	1.73e-30	2.42e-27	-0.62	-0.49	Glucose homeostasis traits;	chr12:118352228	chr12:118428281~118428870:+
THCA	cis	rs4927850	1	rs6799572	ENSG00000231464.1	AC024937.4	12.34	1.75e-30	2.45e-27	0.61	0.49	Pancreatic cancer;	chr3:196013537	chr3:195996738~195998233:+
THCA	cis	rs9309473	0.615	rs62153183	ENSG00000163016.8	ALMS1P	12.34	1.75e-30	2.45e-27	0.86	0.49	Metabolite levels;	chr2:73536239	chr2:73644919~73685576:+
THCA	cis	rs324126	0.78	rs4802926	ENSG00000277977.1	CTD-3018O17.5	-12.34	1.76e-30	2.47e-27	-0.46	-0.49	Colonoscopy-negative controls vs population controls;	chr19:52377012	chr19:52392659~52392755:+
THCA	cis	rs4718428	0.672	rs12530806	ENSG00000226824.5	RP4-756H11.3	-12.33	1.77e-30	2.47e-27	-0.72	-0.49	Corneal structure;	chr7:66925737	chr7:66654538~66669855:+
THCA	cis	rs6496932	0.802	rs12439958	ENSG00000218052.5	ADAMTS7P4	12.33	1.77e-30	2.49e-27	0.64	0.49	Central corneal thickness;Corneal structure;	chr15:85310499	chr15:85255369~85330334:-
THCA	cis	rs228614	0.51	rs223470	ENSG00000246560.2	RP11-10L12.4	12.33	1.78e-30	2.49e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102778004	chr4:102828055~102844075:+
THCA	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-12.33	1.78e-30	2.5e-27	-0.63	-0.49	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
THCA	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	12.33	1.79e-30	2.51e-27	0.57	0.49	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
THCA	cis	rs17111396	0.627	rs61978744	ENSG00000259167.2	NMNAT1P1	12.33	1.79e-30	2.51e-27	0.76	0.49	Uric acid levels;	chr14:81045140	chr14:81032529~81033404:+
THCA	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-12.33	1.79e-30	2.51e-27	-0.55	-0.49	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
THCA	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	12.33	1.8e-30	2.52e-27	0.36	0.49	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.686	rs2328708	ENSG00000235652.6	RP11-545I5.3	-12.33	1.81e-30	2.54e-27	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145774603	chr6:145799409~145886585:+
THCA	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	12.33	1.82e-30	2.54e-27	0.57	0.49	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
THCA	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	12.33	1.83e-30	2.56e-27	0.41	0.49	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
THCA	cis	rs1930961	0.702	rs1930966	ENSG00000272977.1	CTA-390C10.10	-12.33	1.86e-30	2.6e-27	-0.94	-0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25476218~25479971:+
THCA	cis	rs11105298	0.891	rs10858879	ENSG00000258302.2	RP11-981P6.1	-12.33	1.86e-30	2.61e-27	-0.47	-0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:89561129~89594878:+
THCA	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	12.33	1.88e-30	2.63e-27	0.57	0.49	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
THCA	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-12.33	1.89e-30	2.64e-27	-0.62	-0.49	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
THCA	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	12.33	1.91e-30	2.66e-27	0.4	0.49	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	12.33	1.91e-30	2.66e-27	0.4	0.49	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
THCA	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	12.33	1.93e-30	2.7e-27	0.6	0.49	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
THCA	cis	rs6504950	1	rs7222197	ENSG00000275710.1	RP11-257O5.4	-12.32	1.95e-30	2.72e-27	-0.63	-0.49	Breast cancer;	chr17:54970138	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs1990674	ENSG00000275710.1	RP11-257O5.4	12.32	1.95e-30	2.72e-27	0.63	0.49	Breast cancer;	chr17:54983714	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs10468513	ENSG00000275710.1	RP11-257O5.4	12.32	1.95e-30	2.72e-27	0.63	0.49	Breast cancer;	chr17:54985542	chr17:54964474~54964679:+
THCA	cis	rs6504950	1	rs56348638	ENSG00000275710.1	RP11-257O5.4	12.32	1.95e-30	2.72e-27	0.63	0.49	Breast cancer;	chr17:54987189	chr17:54964474~54964679:+
THCA	cis	rs227275	0.554	rs223316	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102881949	chr4:102828055~102844075:+
THCA	cis	rs227275	0.554	rs223314	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102884642	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs7254	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888488	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.566	rs6822658	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Schizophrenia;	chr4:102891964	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs6823625	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892437	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs6846762	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892577	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs4699032	ENSG00000246560.2	RP11-10L12.4	12.32	1.95e-30	2.72e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102892724	chr4:102828055~102844075:+
THCA	cis	rs5769707	0.542	rs739242	ENSG00000188511.11	C22orf34	12.32	1.95e-30	2.73e-27	0.63	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49414524~49657542:-
THCA	cis	rs228614	0.51	rs223311	ENSG00000246560.2	RP11-10L12.4	12.32	1.96e-30	2.74e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102888757	chr4:102828055~102844075:+
THCA	cis	rs853679	0.542	rs9393892	ENSG00000280107.1	AL022393.9	-12.32	1.96e-30	2.74e-27	-0.6	-0.49	Depression;	chr6:28113616	chr6:28170845~28172521:+
THCA	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
THCA	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-12.32	1.97e-30	2.75e-27	-0.37	-0.49	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	12.32	1.97e-30	2.75e-27	0.37	0.49	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
THCA	cis	rs324126	0.78	rs11084150	ENSG00000277977.1	CTD-3018O17.5	-12.32	1.97e-30	2.75e-27	-0.46	-0.49	Colonoscopy-negative controls vs population controls;	chr19:52381851	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs1993531	ENSG00000277977.1	CTD-3018O17.5	12.32	1.97e-30	2.75e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52381633	chr19:52392659~52392755:+
THCA	cis	rs12022452	0.908	rs11811487	ENSG00000238287.1	RP11-656D10.3	-12.32	1.98e-30	2.76e-27	-0.76	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40555398	chr1:40493157~40508661:-
THCA	cis	rs7772486	0.558	rs9376965	ENSG00000235652.6	RP11-545I5.3	12.32	1.99e-30	2.77e-27	0.49	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145808919	chr6:145799409~145886585:+
THCA	cis	rs228614	0.51	rs223451	ENSG00000246560.2	RP11-10L12.4	12.32	2.01e-30	2.8e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791032	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223450	ENSG00000246560.2	RP11-10L12.4	12.32	2.01e-30	2.8e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102791052	chr4:102828055~102844075:+
THCA	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-12.32	2.03e-30	2.84e-27	-0.36	-0.49	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
THCA	cis	rs7945705	0.747	rs1123936	ENSG00000254860.4	TMEM9B-AS1	12.32	2.03e-30	2.84e-27	0.53	0.49	Hemoglobin concentration;	chr11:8981759	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	12.32	2.03e-30	2.84e-27	0.53	0.49	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
THCA	cis	rs853679	0.517	rs9393895	ENSG00000280107.1	AL022393.9	-12.32	2.04e-30	2.84e-27	-0.6	-0.49	Depression;	chr6:28159843	chr6:28170845~28172521:+
THCA	cis	rs9309473	1	rs10189574	ENSG00000163016.8	ALMS1P	12.32	2.06e-30	2.88e-27	0.71	0.49	Metabolite levels;	chr2:73471391	chr2:73644919~73685576:+
THCA	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-12.32	2.06e-30	2.88e-27	-0.37	-0.49	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
THCA	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	12.32	2.09e-30	2.91e-27	0.58	0.49	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
THCA	cis	rs12458462	0.892	rs58675823	ENSG00000274828.1	RP11-567M16.6	12.32	2.11e-30	2.94e-27	0.4	0.49	Monocyte count;	chr18:79703672	chr18:79677287~79679358:-
THCA	cis	rs9322193	0.884	rs1108889	ENSG00000223701.3	RAET1E-AS1	12.32	2.11e-30	2.95e-27	0.69	0.49	Lung cancer;	chr6:149845433	chr6:149884431~149919508:+
THCA	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	12.32	2.12e-30	2.96e-27	0.42	0.49	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
THCA	cis	rs9309473	0.615	rs11680965	ENSG00000163016.8	ALMS1P	12.31	2.13e-30	2.97e-27	0.86	0.49	Metabolite levels;	chr2:73498789	chr2:73644919~73685576:+
THCA	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	12.31	2.14e-30	2.97e-27	0.58	0.49	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
THCA	cis	rs4718428	0.705	rs11028	ENSG00000226824.5	RP4-756H11.3	-12.31	2.14e-30	2.99e-27	-0.71	-0.49	Corneal structure;	chr7:66811230	chr7:66654538~66669855:+
THCA	cis	rs228614	0.536	rs223484	ENSG00000246560.2	RP11-10L12.4	12.31	2.15e-30	2.99e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102764314	chr4:102828055~102844075:+
THCA	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	12.31	2.15e-30	2.99e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
THCA	cis	rs3931020	0.705	rs28482086	ENSG00000272864.1	RP11-17E13.2	-12.31	2.15e-30	2.99e-27	-0.54	-0.49	Resistin levels;	chr1:74760568	chr1:74698769~74699333:-
THCA	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-12.31	2.16e-30	3e-27	-0.61	-0.49	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
THCA	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-12.31	2.16e-30	3.01e-27	-0.65	-0.49	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
THCA	cis	rs228614	0.51	rs223313	ENSG00000246560.2	RP11-10L12.4	12.31	2.17e-30	3.02e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102886563	chr4:102828055~102844075:+
THCA	cis	rs524281	0.861	rs485857	ENSG00000255320.1	RP11-755F10.1	12.31	2.17e-30	3.02e-27	0.69	0.49	Electroencephalogram traits;	chr11:66192048	chr11:66244840~66246239:-
THCA	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
THCA	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	12.31	2.17e-30	3.02e-27	0.59	0.49	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
THCA	cis	rs324126	0.78	rs11084153	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52382142	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs11084154	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52382168	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs11084155	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52383613	chr19:52392659~52392755:+
THCA	cis	rs324126	0.752	rs11084156	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52383634	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs11084157	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52383652	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs8104808	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52384174	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs8104812	ENSG00000277977.1	CTD-3018O17.5	12.31	2.19e-30	3.05e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52384184	chr19:52392659~52392755:+
THCA	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-12.31	2.21e-30	3.07e-27	-0.36	-0.49	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
THCA	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-12.31	2.21e-30	3.08e-27	-0.53	-0.49	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
THCA	cis	rs9309473	0.948	rs7566385	ENSG00000163016.8	ALMS1P	12.31	2.25e-30	3.12e-27	0.72	0.49	Metabolite levels;	chr2:73529690	chr2:73644919~73685576:+
THCA	cis	rs11105306	1	rs11105306	ENSG00000258302.2	RP11-981P6.1	12.31	2.29e-30	3.18e-27	0.47	0.49	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858889	ENSG00000258302.2	RP11-981P6.1	12.31	2.29e-30	3.18e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs11105309	ENSG00000258302.2	RP11-981P6.1	12.31	2.29e-30	3.18e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:89561129~89594878:+
THCA	cis	rs5769707	0.521	rs6009810	ENSG00000188511.11	C22orf34	12.31	2.31e-30	3.21e-27	0.62	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49414524~49657542:-
THCA	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	12.3	2.33e-30	3.24e-27	0.65	0.49	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
THCA	cis	rs9309473	1	rs10187416	ENSG00000163016.8	ALMS1P	12.3	2.34e-30	3.25e-27	0.72	0.49	Metabolite levels;	chr2:73486614	chr2:73644919~73685576:+
THCA	cis	rs853679	0.517	rs6932109	ENSG00000280107.1	AL022393.9	12.3	2.35e-30	3.26e-27	0.6	0.49	Depression;	chr6:28110525	chr6:28170845~28172521:+
THCA	cis	rs9309473	1	rs7585004	ENSG00000163016.8	ALMS1P	12.3	2.36e-30	3.28e-27	0.73	0.49	Metabolite levels;	chr2:73439517	chr2:73644919~73685576:+
THCA	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	12.3	2.36e-30	3.28e-27	0.6	0.49	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	12.3	2.36e-30	3.28e-27	0.6	0.49	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	12.3	2.36e-30	3.28e-27	0.6	0.49	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	12.3	2.36e-30	3.28e-27	0.6	0.49	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
THCA	cis	rs228614	0.51	rs223349	ENSG00000246560.2	RP11-10L12.4	12.3	2.36e-30	3.28e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102857277	chr4:102828055~102844075:+
THCA	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	12.3	2.38e-30	3.3e-27	0.56	0.49	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
THCA	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	12.3	2.39e-30	3.31e-27	0.58	0.49	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
THCA	cis	rs10028773	0.666	rs12498657	ENSG00000245958.5	RP11-33B1.1	-12.3	2.39e-30	3.31e-27	-0.47	-0.49	Educational attainment;	chr4:119341711	chr4:119454791~119552025:+
THCA	cis	rs12458462	0.859	rs35493271	ENSG00000274828.1	RP11-567M16.6	12.3	2.4e-30	3.33e-27	0.4	0.49	Monocyte count;	chr18:79688793	chr18:79677287~79679358:-
THCA	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-12.3	2.41e-30	3.35e-27	-0.36	-0.49	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
THCA	cis	rs11155671	0.53	rs6557133	ENSG00000268592.3	RAET1E-AS1	12.3	2.42e-30	3.35e-27	0.66	0.49	Testicular germ cell tumor;	chr6:149874248	chr6:149863494~149919507:+
THCA	cis	rs7772486	0.806	rs2253648	ENSG00000235652.6	RP11-545I5.3	12.3	2.42e-30	3.35e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145878160	chr6:145799409~145886585:+
THCA	cis	rs853679	0.517	rs16893666	ENSG00000280107.1	AL022393.9	12.3	2.44e-30	3.39e-27	0.6	0.49	Depression;	chr6:28086929	chr6:28170845~28172521:+
THCA	cis	rs227275	0.554	rs223466	ENSG00000246560.2	RP11-10L12.4	12.3	2.45e-30	3.39e-27	0.6	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102780039	chr4:102828055~102844075:+
THCA	cis	rs853679	0.517	rs9393884	ENSG00000280107.1	AL022393.9	-12.3	2.45e-30	3.4e-27	-0.6	-0.49	Depression;	chr6:28079011	chr6:28170845~28172521:+
THCA	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-12.3	2.46e-30	3.41e-27	-0.53	-0.49	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
THCA	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	12.3	2.47e-30	3.42e-27	0.6	0.49	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
THCA	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-12.3	2.47e-30	3.42e-27	-0.65	-0.49	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-12.3	2.47e-30	3.42e-27	-0.65	-0.49	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	12.3	2.47e-30	3.42e-27	0.65	0.49	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	12.3	2.47e-30	3.42e-27	0.65	0.49	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	12.3	2.47e-30	3.42e-27	0.65	0.49	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	12.3	2.47e-30	3.42e-27	0.65	0.49	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
THCA	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	12.3	2.48e-30	3.43e-27	0.56	0.49	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
THCA	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-12.3	2.48e-30	3.43e-27	-0.36	-0.49	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
THCA	cis	rs526231	0.543	rs4386712	ENSG00000175749.11	EIF3KP1	12.3	2.49e-30	3.45e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103033530	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs56235607	ENSG00000175749.11	EIF3KP1	12.3	2.49e-30	3.45e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103036902	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs55741939	ENSG00000175749.11	EIF3KP1	12.3	2.49e-30	3.45e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103036984	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs158395	ENSG00000175749.11	EIF3KP1	12.3	2.49e-30	3.45e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103075685	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs158400	ENSG00000175749.11	EIF3KP1	12.3	2.49e-30	3.45e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103077628	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs257302	ENSG00000175749.11	EIF3KP1	12.3	2.49e-30	3.45e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103080426	chr5:103032376~103033031:+
THCA	cis	rs944289	0.616	rs410546	ENSG00000257826.1	RP11-116N8.4	12.3	2.49e-30	3.45e-27	0.51	0.49	Thyroid cancer;	chr14:36071858	chr14:36061026~36067190:-
THCA	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	12.3	2.5e-30	3.47e-27	0.57	0.49	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
THCA	cis	rs673078	0.562	rs61944668	ENSG00000275759.1	RP11-131L12.3	-12.3	2.51e-30	3.47e-27	-0.73	-0.49	Glucose homeostasis traits;	chr12:118448446	chr12:118428281~118428870:+
THCA	cis	rs9309473	0.615	rs74523560	ENSG00000163016.8	ALMS1P	12.3	2.51e-30	3.47e-27	0.86	0.49	Metabolite levels;	chr2:73537058	chr2:73644919~73685576:+
THCA	cis	rs12134133	1	rs10494890	ENSG00000274245.1	RP11-357P18.2	-12.3	2.51e-30	3.48e-27	-0.53	-0.49	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207251041	chr1:207372559~207373252:+
THCA	cis	rs4718428	0.705	rs28648401	ENSG00000226824.5	RP4-756H11.3	-12.3	2.53e-30	3.5e-27	-0.71	-0.49	Corneal structure;	chr7:66902145	chr7:66654538~66669855:+
THCA	cis	rs4718428	0.607	rs66954441	ENSG00000226824.5	RP4-756H11.3	-12.3	2.53e-30	3.5e-27	-0.71	-0.49	Corneal structure;	chr7:66904222	chr7:66654538~66669855:+
THCA	cis	rs12022452	0.822	rs7514623	ENSG00000238287.1	RP11-656D10.3	-12.3	2.53e-30	3.5e-27	-0.74	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr1:40559330	chr1:40493157~40508661:-
THCA	cis	rs228614	0.51	rs223438	ENSG00000246560.2	RP11-10L12.4	-12.3	2.54e-30	3.51e-27	-0.61	-0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102798584	chr4:102828055~102844075:+
THCA	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-12.3	2.54e-30	3.52e-27	-0.84	-0.49	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
THCA	cis	rs3002131	0.522	rs2378583	ENSG00000225265.1	TAF1A-AS1	-12.3	2.55e-30	3.52e-27	-0.71	-0.49	Interleukin-10 levels;	chr1:222565958	chr1:222589825~222593032:+
THCA	cis	rs324126	0.78	rs1993530	ENSG00000277977.1	CTD-3018O17.5	-12.29	2.58e-30	3.57e-27	-0.47	-0.49	Colonoscopy-negative controls vs population controls;	chr19:52381756	chr19:52392659~52392755:+
THCA	cis	rs11673344	0.801	rs112263309	ENSG00000226686.6	LINC01535	12.29	2.6e-30	3.6e-27	0.58	0.49	Obesity-related traits;	chr19:37160333	chr19:37251912~37265535:+
THCA	cis	rs6504950	0.745	rs9914088	ENSG00000275710.1	RP11-257O5.4	12.29	2.61e-30	3.6e-27	0.63	0.49	Breast cancer;	chr17:54902624	chr17:54964474~54964679:+
THCA	cis	rs67311347	1	rs4128740	ENSG00000223797.4	ENTPD3-AS1	12.29	2.61e-30	3.61e-27	0.41	0.49	Renal cell carcinoma;	chr3:40478041	chr3:40313802~40453329:-
THCA	cis	rs853679	0.517	rs9468297	ENSG00000280107.1	AL022393.9	-12.29	2.62e-30	3.62e-27	-0.6	-0.49	Depression;	chr6:28151096	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9295758	ENSG00000280107.1	AL022393.9	-12.29	2.62e-30	3.62e-27	-0.6	-0.49	Depression;	chr6:28152885	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs17774663	ENSG00000280107.1	AL022393.9	-12.29	2.62e-30	3.62e-27	-0.6	-0.49	Depression;	chr6:28153120	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9357065	ENSG00000280107.1	AL022393.9	-12.29	2.62e-30	3.62e-27	-0.6	-0.49	Depression;	chr6:28161802	chr6:28170845~28172521:+
THCA	cis	rs7772486	0.558	rs62435775	ENSG00000235652.6	RP11-545I5.3	12.29	2.63e-30	3.64e-27	0.49	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145815279	chr6:145799409~145886585:+
THCA	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-12.29	2.64e-30	3.65e-27	-0.73	-0.49	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
THCA	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-12.29	2.64e-30	3.65e-27	-0.73	-0.49	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-12.29	2.64e-30	3.65e-27	-0.73	-0.49	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
THCA	cis	rs12458462	1	rs12458462	ENSG00000274828.1	RP11-567M16.6	12.29	2.65e-30	3.66e-27	0.41	0.49	Monocyte count;	chr18:79712436	chr18:79677287~79679358:-
THCA	cis	rs673078	0.607	rs4767671	ENSG00000275759.1	RP11-131L12.3	-12.29	2.66e-30	3.67e-27	-0.73	-0.49	Glucose homeostasis traits;	chr12:118396038	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7312555	ENSG00000275759.1	RP11-131L12.3	-12.29	2.66e-30	3.67e-27	-0.73	-0.49	Glucose homeostasis traits;	chr12:118414120	chr12:118428281~118428870:+
THCA	cis	rs9309473	1	rs11689392	ENSG00000163016.8	ALMS1P	12.29	2.67e-30	3.69e-27	0.71	0.49	Metabolite levels;	chr2:73394898	chr2:73644919~73685576:+
THCA	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-12.29	2.67e-30	3.69e-27	-0.64	-0.49	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-12.29	2.67e-30	3.69e-27	-0.64	-0.49	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-12.29	2.67e-30	3.69e-27	-0.64	-0.49	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
THCA	cis	rs934734	0.532	rs12185610	ENSG00000204929.10	AC074391.1	-12.29	2.68e-30	3.7e-27	-0.59	-0.49	Rheumatoid arthritis;	chr2:65434334	chr2:65436711~66084639:+
THCA	cis	rs875971	0.83	rs4718358	ENSG00000237310.1	GS1-124K5.4	12.29	2.71e-30	3.74e-27	0.36	0.49	Aortic root size;	chr7:66508681	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
THCA	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	12.29	2.72e-30	3.76e-27	0.37	0.49	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	12.29	2.73e-30	3.77e-27	0.56	0.49	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
THCA	cis	rs526231	0.511	rs55810112	ENSG00000175749.11	EIF3KP1	12.29	2.75e-30	3.79e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103026645	chr5:103032376~103033031:+
THCA	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	12.29	2.75e-30	3.79e-27	0.63	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
THCA	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-12.29	2.78e-30	3.83e-27	-0.61	-0.49	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
THCA	cis	rs8040855	0.627	rs11632899	ENSG00000259295.5	CSPG4P12	12.29	2.81e-30	3.87e-27	0.7	0.49	Bulimia nervosa;	chr15:85057609	chr15:85191438~85213905:+
THCA	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	12.29	2.81e-30	3.88e-27	0.58	0.49	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
THCA	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-12.28	2.81e-30	3.88e-27	-0.37	-0.49	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-12.28	2.81e-30	3.88e-27	-0.37	-0.49	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-12.28	2.81e-30	3.88e-27	-0.37	-0.49	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
THCA	cis	rs7743045	0.573	rs6929403	ENSG00000253194.1	RP11-351A11.1	12.28	2.83e-30	3.9e-27	0.71	0.49	Mean platelet volume;	chr6:119025747	chr6:118934785~119031541:+
THCA	cis	rs8040855	0.627	rs12913859	ENSG00000259295.5	CSPG4P12	12.28	2.83e-30	3.9e-27	0.74	0.49	Bulimia nervosa;	chr15:85095187	chr15:85191438~85213905:+
THCA	cis	rs7576126	0.563	rs1807337	ENSG00000204929.10	AC074391.1	-12.28	2.84e-30	3.91e-27	-0.6	-0.49	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65436711~66084639:+
THCA	cis	rs12458462	0.851	rs3859317	ENSG00000274828.1	RP11-567M16.6	12.28	2.84e-30	3.91e-27	0.4	0.49	Monocyte count;	chr18:79683093	chr18:79677287~79679358:-
THCA	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-12.28	2.84e-30	3.92e-27	-0.61	-0.49	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
THCA	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	12.28	2.85e-30	3.93e-27	0.57	0.49	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
THCA	cis	rs9309473	0.66	rs17349321	ENSG00000163016.8	ALMS1P	12.28	2.87e-30	3.95e-27	0.85	0.49	Metabolite levels;	chr2:73416625	chr2:73644919~73685576:+
THCA	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-12.28	2.88e-30	3.96e-27	-0.65	-0.49	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
THCA	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-12.28	2.89e-30	3.98e-27	-0.61	-0.49	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
THCA	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-12.28	2.91e-30	4.01e-27	-0.62	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
THCA	cis	rs2455601	0.608	rs1368017	ENSG00000254860.4	TMEM9B-AS1	12.28	2.92e-30	4.02e-27	0.6	0.49	Schizophrenia;	chr11:8845523	chr11:8964675~8977527:+
THCA	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-12.28	2.92e-30	4.02e-27	-0.37	-0.49	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	12.28	2.93e-30	4.03e-27	0.56	0.49	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
THCA	cis	rs12458462	0.892	rs2242175	ENSG00000274828.1	RP11-567M16.6	12.28	2.95e-30	4.06e-27	0.41	0.49	Monocyte count;	chr18:79704406	chr18:79677287~79679358:-
THCA	cis	rs6570726	0.764	rs448258	ENSG00000235652.6	RP11-545I5.3	12.28	2.97e-30	4.09e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145548009	chr6:145799409~145886585:+
THCA	cis	rs2455601	0.608	rs59025804	ENSG00000254860.4	TMEM9B-AS1	12.28	2.98e-30	4.1e-27	0.61	0.49	Schizophrenia;	chr11:8848754	chr11:8964675~8977527:+
THCA	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-12.28	2.98e-30	4.1e-27	-0.59	-0.49	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
THCA	cis	rs7772486	0.686	rs4895684	ENSG00000235652.6	RP11-545I5.3	-12.28	3e-30	4.12e-27	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145792887	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9386131	ENSG00000235652.6	RP11-545I5.3	12.28	3e-30	4.12e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145800472	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs7739735	ENSG00000235652.6	RP11-545I5.3	12.28	3e-30	4.12e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145802400	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs7744014	ENSG00000235652.6	RP11-545I5.3	12.28	3e-30	4.12e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145802682	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.597	rs1970306	ENSG00000235652.6	RP11-545I5.3	12.28	3.01e-30	4.14e-27	0.49	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145833407	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.597	rs9386136	ENSG00000235652.6	RP11-545I5.3	12.28	3.01e-30	4.14e-27	0.49	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145837164	chr6:145799409~145886585:+
THCA	cis	rs228614	0.51	rs223358	ENSG00000246560.2	RP11-10L12.4	12.28	3.04e-30	4.17e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102849637	chr4:102828055~102844075:+
THCA	cis	rs1858037	0.836	rs2576923	ENSG00000204929.10	AC074391.1	-12.28	3.04e-30	4.18e-27	-0.64	-0.49	Rheumatoid arthritis;	chr2:65406750	chr2:65436711~66084639:+
THCA	cis	rs9309473	0.66	rs79370894	ENSG00000163016.8	ALMS1P	12.28	3.04e-30	4.18e-27	0.85	0.49	Metabolite levels;	chr2:73456388	chr2:73644919~73685576:+
THCA	cis	rs8040855	0.627	rs17540307	ENSG00000259295.5	CSPG4P12	12.28	3.04e-30	4.18e-27	0.74	0.49	Bulimia nervosa;	chr15:85090614	chr15:85191438~85213905:+
THCA	cis	rs853679	0.517	rs4713150	ENSG00000280107.1	AL022393.9	-12.28	3.05e-30	4.19e-27	-0.6	-0.49	Depression;	chr6:28168434	chr6:28170845~28172521:+
THCA	cis	rs10463554	0.526	rs114525197	ENSG00000175749.11	EIF3KP1	12.28	3.07e-30	4.22e-27	0.65	0.49	Parkinson's disease;	chr5:103107341	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.759	rs461609	ENSG00000175749.11	EIF3KP1	12.28	3.07e-30	4.22e-27	0.65	0.49	Parkinson's disease;	chr5:103111601	chr5:103032376~103033031:+
THCA	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	12.27	3.1e-30	4.26e-27	0.56	0.49	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
THCA	cis	rs12458462	0.892	rs2007483	ENSG00000274828.1	RP11-567M16.6	12.27	3.1e-30	4.27e-27	0.4	0.49	Monocyte count;	chr18:79716131	chr18:79677287~79679358:-
THCA	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	12.27	3.11e-30	4.27e-27	0.41	0.49	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
THCA	cis	rs526231	0.511	rs12109860	ENSG00000175749.11	EIF3KP1	12.27	3.11e-30	4.27e-27	0.66	0.49	Primary biliary cholangitis;	chr5:103057408	chr5:103032376~103033031:+
THCA	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	12.27	3.12e-30	4.29e-27	0.41	0.49	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	12.27	3.12e-30	4.29e-27	0.41	0.49	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
THCA	cis	rs12458462	0.787	rs56006341	ENSG00000274828.1	RP11-567M16.6	12.27	3.13e-30	4.3e-27	0.4	0.49	Monocyte count;	chr18:79679844	chr18:79677287~79679358:-
THCA	cis	rs673078	0.607	rs56080343	ENSG00000275759.1	RP11-131L12.3	-12.27	3.14e-30	4.32e-27	-0.61	-0.49	Glucose homeostasis traits;	chr12:118439113	chr12:118428281~118428870:+
THCA	cis	rs228614	0.509	rs223480	ENSG00000246560.2	RP11-10L12.4	12.27	3.18e-30	4.37e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766881	chr4:102828055~102844075:+
THCA	cis	rs526231	0.511	rs55896090	ENSG00000175749.11	EIF3KP1	12.27	3.19e-30	4.38e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103026300	chr5:103032376~103033031:+
THCA	cis	rs1061377	0.585	rs1367296	ENSG00000249207.1	RP11-360F5.1	-12.27	3.25e-30	4.46e-27	-0.6	-0.49	Uric acid levels;	chr4:39066895	chr4:39112677~39126818:-
THCA	cis	rs4718428	0.705	rs4718422	ENSG00000226824.5	RP4-756H11.3	-12.27	3.25e-30	4.46e-27	-0.72	-0.49	Corneal structure;	chr7:66894282	chr7:66654538~66669855:+
THCA	cis	rs4718428	0.705	rs13231140	ENSG00000226824.5	RP4-756H11.3	-12.27	3.25e-30	4.46e-27	-0.72	-0.49	Corneal structure;	chr7:66896631	chr7:66654538~66669855:+
THCA	cis	rs228614	0.536	rs150897	ENSG00000246560.2	RP11-10L12.4	12.27	3.28e-30	4.5e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769309	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223472	ENSG00000246560.2	RP11-10L12.4	12.27	3.28e-30	4.5e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102774327	chr4:102828055~102844075:+
THCA	cis	rs8040855	0.627	rs12905036	ENSG00000259295.5	CSPG4P12	12.27	3.29e-30	4.52e-27	0.74	0.49	Bulimia nervosa;	chr15:85094557	chr15:85191438~85213905:+
THCA	cis	rs10463554	0.963	rs72785733	ENSG00000175749.11	EIF3KP1	12.27	3.34e-30	4.57e-27	0.65	0.49	Parkinson's disease;	chr5:103038488	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs6881612	ENSG00000175749.11	EIF3KP1	12.27	3.34e-30	4.57e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103041309	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs58344084	ENSG00000175749.11	EIF3KP1	12.27	3.34e-30	4.57e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103042508	chr5:103032376~103033031:+
THCA	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-12.27	3.34e-30	4.58e-27	-0.83	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
THCA	cis	rs5769707	0.521	rs6009807	ENSG00000188511.11	C22orf34	12.27	3.35e-30	4.59e-27	0.62	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49414524~49657542:-
THCA	cis	rs9309473	1	rs2140195	ENSG00000163016.8	ALMS1P	12.27	3.38e-30	4.63e-27	0.72	0.49	Metabolite levels;	chr2:73475217	chr2:73644919~73685576:+
THCA	cis	rs853679	0.513	rs9468296	ENSG00000280107.1	AL022393.9	-12.27	3.38e-30	4.63e-27	-0.6	-0.49	Depression;	chr6:28145952	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs4711164	ENSG00000280107.1	AL022393.9	-12.27	3.38e-30	4.63e-27	-0.6	-0.49	Depression;	chr6:28147378	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs4711165	ENSG00000280107.1	AL022393.9	-12.27	3.38e-30	4.63e-27	-0.6	-0.49	Depression;	chr6:28147406	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs4713148	ENSG00000280107.1	AL022393.9	-12.27	3.38e-30	4.63e-27	-0.6	-0.49	Depression;	chr6:28148143	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs2273564	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28089816	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs1853097	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28090857	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393888	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28091439	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9357063	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28092227	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs3823180	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28093966	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368551	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28094014	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393890	ENSG00000280107.1	AL022393.9	-12.26	3.41e-30	4.67e-27	-0.6	-0.49	Depression;	chr6:28096077	chr6:28170845~28172521:+
THCA	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	12.26	3.43e-30	4.7e-27	0.65	0.49	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
THCA	cis	rs9322193	0.607	rs9371228	ENSG00000231760.4	RP11-350J20.5	-12.26	3.45e-30	4.72e-27	-0.7	-0.49	Lung cancer;	chr6:149921977	chr6:149796151~149826294:-
THCA	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-12.26	3.46e-30	4.73e-27	-0.55	-0.49	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
THCA	cis	rs8040855	0.627	rs62019482	ENSG00000259295.5	CSPG4P12	12.26	3.5e-30	4.79e-27	0.74	0.49	Bulimia nervosa;	chr15:85071796	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs11631548	ENSG00000259295.5	CSPG4P12	12.26	3.5e-30	4.79e-27	0.74	0.49	Bulimia nervosa;	chr15:85076017	chr15:85191438~85213905:+
THCA	cis	rs9928842	1	rs9928842	ENSG00000280152.1	RP11-331F4.5	12.26	3.54e-30	4.85e-27	0.69	0.49	Alcoholic chronic pancreatitis;	chr16:75208969	chr16:75245994~75250077:-
THCA	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	12.26	3.56e-30	4.88e-27	0.36	0.49	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	12.26	3.56e-30	4.88e-27	0.36	0.49	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	12.26	3.57e-30	4.89e-27	0.56	0.49	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
THCA	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	12.26	3.61e-30	4.93e-27	0.39	0.49	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
THCA	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	12.26	3.61e-30	4.94e-27	0.55	0.49	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
THCA	cis	rs526231	0.543	rs27361	ENSG00000175749.11	EIF3KP1	12.26	3.65e-30	5e-27	0.66	0.49	Primary biliary cholangitis;	chr5:103213266	chr5:103032376~103033031:+
THCA	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-12.26	3.66e-30	5.01e-27	-0.6	-0.49	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
THCA	cis	rs2274273	0.84	rs943590	ENSG00000258413.1	RP11-665C16.6	-12.26	3.68e-30	5.03e-27	-0.62	-0.49	Protein biomarker;	chr14:55271878	chr14:55262767~55272075:-
THCA	cis	rs2288884	0.559	rs73052102	ENSG00000275055.1	CTC-471J1.11	-12.26	3.68e-30	5.04e-27	-0.4	-0.49	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52021748	chr19:52049007~52049754:+
THCA	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	12.26	3.7e-30	5.05e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	12.26	3.7e-30	5.05e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
THCA	cis	rs9309473	0.606	rs62149777	ENSG00000163016.8	ALMS1P	12.25	3.75e-30	5.12e-27	0.85	0.49	Metabolite levels;	chr2:73568237	chr2:73644919~73685576:+
THCA	cis	rs2274273	0.774	rs17128440	ENSG00000258413.1	RP11-665C16.6	-12.25	3.75e-30	5.13e-27	-0.62	-0.49	Protein biomarker;	chr14:55395194	chr14:55262767~55272075:-
THCA	cis	rs526231	0.543	rs158244	ENSG00000175749.11	EIF3KP1	12.25	3.75e-30	5.13e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103075062	chr5:103032376~103033031:+
THCA	cis	rs6570726	0.791	rs370654	ENSG00000235652.6	RP11-545I5.3	12.25	3.76e-30	5.13e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145557869	chr6:145799409~145886585:+
THCA	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-12.25	3.76e-30	5.14e-27	-0.57	-0.49	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
THCA	cis	rs12468226	1	rs7597469	ENSG00000273456.1	RP11-686O6.2	12.25	3.76e-30	5.14e-27	0.62	0.49	Urate levels;	chr2:202329547	chr2:202374932~202375604:-
THCA	cis	rs12468226	1	rs113877751	ENSG00000273456.1	RP11-686O6.2	12.25	3.76e-30	5.14e-27	0.62	0.49	Urate levels;	chr2:202329998	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.935	rs113021930	ENSG00000273456.1	RP11-686O6.2	12.25	3.76e-30	5.14e-27	0.62	0.49	Urate levels;	chr2:202330448	chr2:202374932~202375604:-
THCA	cis	rs732716	0.813	rs760369	ENSG00000267769.1	CTB-50L17.9	12.25	3.79e-30	5.18e-27	0.61	0.49	Mean corpuscular volume;	chr19:4449290	chr19:4454014~4455286:+
THCA	cis	rs11098499	0.722	rs7673476	ENSG00000245958.5	RP11-33B1.1	-12.25	3.8e-30	5.19e-27	-0.47	-0.49	Corneal astigmatism;	chr4:119327528	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000228039.3	KB-1125A3.10	12.25	3.81e-30	5.2e-27	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23963780~23964374:+
THCA	cis	rs7772486	0.686	rs9390357	ENSG00000235652.6	RP11-545I5.3	12.25	3.81e-30	5.2e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145808211	chr6:145799409~145886585:+
THCA	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	12.25	3.82e-30	5.21e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
THCA	cis	rs6504950	1	rs7219874	ENSG00000275710.1	RP11-257O5.4	12.25	3.86e-30	5.27e-27	0.62	0.49	Breast cancer;	chr17:54988446	chr17:54964474~54964679:+
THCA	cis	rs934734	0.511	rs62141115	ENSG00000204929.10	AC074391.1	-12.25	3.86e-30	5.27e-27	-0.59	-0.49	Rheumatoid arthritis;	chr2:65445058	chr2:65436711~66084639:+
THCA	cis	rs2284219	0.565	rs2284217	ENSG00000196295.10	AC005154.6	-12.25	3.87e-30	5.28e-27	-0.41	-0.49	Type 2 diabetes;	chr7:30673992	chr7:30516309~30594809:-
THCA	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-12.25	3.87e-30	5.28e-27	-0.61	-0.49	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
THCA	cis	rs26232	0.521	rs40508	ENSG00000175749.11	EIF3KP1	12.25	3.88e-30	5.29e-27	0.65	0.49	Rheumatoid arthritis;	chr5:103108234	chr5:103032376~103033031:+
THCA	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-12.25	3.88e-30	5.29e-27	-0.56	-0.49	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	12.25	3.89e-30	5.31e-27	0.56	0.49	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-12.25	3.91e-30	5.33e-27	-0.56	-0.49	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
THCA	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	12.25	3.92e-30	5.35e-27	0.41	0.49	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	12.25	3.92e-30	5.35e-27	0.41	0.49	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	12.25	3.92e-30	5.35e-27	0.41	0.49	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
THCA	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	12.25	3.93e-30	5.36e-27	0.56	0.49	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	12.25	3.93e-30	5.36e-27	0.56	0.49	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
THCA	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	12.25	3.94e-30	5.37e-27	0.4	0.49	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
THCA	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-12.25	4e-30	5.46e-27	-0.61	-0.49	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
THCA	cis	rs11105298	0.891	rs10858869	ENSG00000258302.2	RP11-981P6.1	12.25	4e-30	5.46e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858871	ENSG00000258302.2	RP11-981P6.1	12.25	4e-30	5.46e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:89561129~89594878:+
THCA	cis	rs4718428	0.672	rs13241598	ENSG00000273142.1	RP11-458F8.4	-12.25	4.01e-30	5.46e-27	-0.46	-0.49	Corneal structure;	chr7:66835665	chr7:66902857~66906297:+
THCA	cis	rs9481169	0.85	rs4947129	ENSG00000255389.1	C6orf3	-12.25	4.04e-30	5.51e-27	-0.9	-0.49	Inflammatory skin disease;	chr6:111609703	chr6:111599875~111602295:+
THCA	cis	rs4718428	0.705	rs4718424	ENSG00000226824.5	RP4-756H11.3	-12.25	4.05e-30	5.51e-27	-0.71	-0.49	Corneal structure;	chr7:66911108	chr7:66654538~66669855:+
THCA	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	12.25	4.05e-30	5.52e-27	0.63	0.49	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
THCA	cis	rs7772486	0.686	rs9399564	ENSG00000235652.6	RP11-545I5.3	-12.25	4.05e-30	5.52e-27	-0.46	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145757771	chr6:145799409~145886585:+
THCA	cis	rs526231	0.511	rs10434792	ENSG00000175749.11	EIF3KP1	12.24	4.09e-30	5.58e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103053898	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs10434793	ENSG00000175749.11	EIF3KP1	12.24	4.09e-30	5.58e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103054111	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34377	ENSG00000175749.11	EIF3KP1	12.24	4.09e-30	5.58e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103064852	chr5:103032376~103033031:+
THCA	cis	rs11105298	0.891	rs10858890	ENSG00000258302.2	RP11-981P6.1	12.24	4.1e-30	5.58e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:89561129~89594878:+
THCA	cis	rs853679	0.517	rs9468298	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28154567	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9295759	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28156691	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9348796	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28158424	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs11552219	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28159056	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393896	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28159925	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393897	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28159932	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9357066	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28162053	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368556	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28163375	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368557	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28163759	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380059	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28164580	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380060	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28164825	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs35227624	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28164948	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380061	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28165025	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368558	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28165528	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.587	rs9393899	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Parkinson's disease;	chr6:28165750	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.527	rs4713151	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Parkinson's disease;	chr6:28168578	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393901	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28169019	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs3173443	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28169249	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9348797	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28169755	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380062	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28169791	chr6:28170845~28172521:+
THCA	cis	rs853679	0.542	rs9380063	ENSG00000280107.1	AL022393.9	-12.24	4.12e-30	5.61e-27	-0.6	-0.49	Depression;	chr6:28170075	chr6:28170845~28172521:+
THCA	cis	rs4964805	0.549	rs1976256	ENSG00000257681.1	RP11-341G23.4	12.24	4.13e-30	5.62e-27	0.58	0.49	Attention deficit hyperactivity disorder;	chr12:103763121	chr12:103746315~103768858:-
THCA	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-12.24	4.17e-30	5.67e-27	-0.57	-0.49	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
THCA	cis	rs853679	0.517	rs4713152	ENSG00000280107.1	AL022393.9	-12.24	4.18e-30	5.68e-27	-0.6	-0.49	Depression;	chr6:28169676	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9348794	ENSG00000280107.1	AL022393.9	-12.24	4.18e-30	5.68e-27	-0.6	-0.49	Depression;	chr6:28149979	chr6:28170845~28172521:+
THCA	cis	rs10463554	0.759	rs34815	ENSG00000175749.11	EIF3KP1	12.24	4.19e-30	5.7e-27	0.65	0.49	Parkinson's disease;	chr5:103098561	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	12.24	4.2e-30	5.71e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	12.24	4.2e-30	5.71e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
THCA	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	12.24	4.2e-30	5.71e-27	0.4	0.49	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
THCA	cis	rs228614	0.51	rs6830407	ENSG00000246560.2	RP11-10L12.4	12.24	4.2e-30	5.72e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102895366	chr4:102828055~102844075:+
THCA	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	12.24	4.21e-30	5.72e-27	0.62	0.49	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	12.24	4.21e-30	5.72e-27	0.62	0.49	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
THCA	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	12.24	4.26e-30	5.79e-27	0.59	0.49	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	12.24	4.26e-30	5.79e-27	0.59	0.49	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	12.24	4.26e-30	5.79e-27	0.59	0.49	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
THCA	cis	rs1061377	0.621	rs11096974	ENSG00000249207.1	RP11-360F5.1	-12.24	4.28e-30	5.81e-27	-0.59	-0.49	Uric acid levels;	chr4:39062039	chr4:39112677~39126818:-
THCA	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	12.24	4.29e-30	5.84e-27	0.62	0.49	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
THCA	cis	rs26232	0.521	rs67019105	ENSG00000175749.11	EIF3KP1	12.24	4.3e-30	5.84e-27	0.65	0.49	Rheumatoid arthritis;	chr5:103038459	chr5:103032376~103033031:+
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	12.24	4.31e-30	5.86e-27	0.61	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
THCA	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	12.24	4.44e-30	6.03e-27	0.56	0.49	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-12.24	4.45e-30	6.04e-27	-0.56	-0.49	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
THCA	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-12.24	4.45e-30	6.05e-27	-0.51	-0.49	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
THCA	cis	rs324126	0.78	rs55748277	ENSG00000277977.1	CTD-3018O17.5	12.23	4.5e-30	6.11e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52384992	chr19:52392659~52392755:+
THCA	cis	rs875971	1	rs6979382	ENSG00000237310.1	GS1-124K5.4	12.23	4.53e-30	6.15e-27	0.36	0.49	Aortic root size;	chr7:66421388	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6961990	ENSG00000237310.1	GS1-124K5.4	12.23	4.53e-30	6.15e-27	0.36	0.49	Aortic root size;	chr7:66423583	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	12.23	4.53e-30	6.15e-27	0.36	0.49	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
THCA	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	12.23	4.53e-30	6.16e-27	0.41	0.49	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
THCA	cis	rs11098499	0.675	rs11098534	ENSG00000245958.5	RP11-33B1.1	-12.23	4.56e-30	6.19e-27	-0.48	-0.49	Corneal astigmatism;	chr4:119635617	chr4:119454791~119552025:+
THCA	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	12.23	4.59e-30	6.23e-27	0.41	0.49	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	12.23	4.59e-30	6.23e-27	0.41	0.49	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	12.23	4.59e-30	6.23e-27	0.41	0.49	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
THCA	cis	rs853679	0.517	rs9380058	ENSG00000280107.1	AL022393.9	-12.23	4.67e-30	6.33e-27	-0.6	-0.49	Depression;	chr6:28159666	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393898	ENSG00000280107.1	AL022393.9	-12.23	4.67e-30	6.33e-27	-0.6	-0.49	Depression;	chr6:28162598	chr6:28170845~28172521:+
THCA	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	12.23	4.67e-30	6.33e-27	0.41	0.49	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
THCA	cis	rs526231	0.543	rs32849	ENSG00000175749.11	EIF3KP1	12.23	4.67e-30	6.33e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103134339	chr5:103032376~103033031:+
THCA	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	12.23	4.68e-30	6.35e-27	0.71	0.49	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
THCA	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-12.23	4.71e-30	6.39e-27	-0.67	-0.49	Depression;	chr6:28091659	chr6:28115628~28116551:+
THCA	cis	rs526231	0.543	rs257303	ENSG00000175749.11	EIF3KP1	12.23	4.73e-30	6.41e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103081023	chr5:103032376~103033031:+
THCA	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	12.23	4.73e-30	6.42e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	12.23	4.73e-30	6.42e-27	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
THCA	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	12.23	4.74e-30	6.42e-27	0.41	0.49	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs28707772	ENSG00000223797.4	ENTPD3-AS1	12.23	4.74e-30	6.42e-27	0.41	0.49	Renal cell carcinoma;	chr3:40463175	chr3:40313802~40453329:-
THCA	cis	rs6538678	0.895	rs7137751	ENSG00000258343.1	RP11-536G4.2	-12.23	4.75e-30	6.44e-27	-0.7	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95795345~95858839:-
THCA	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-12.23	4.76e-30	6.46e-27	-0.65	-0.49	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
THCA	cis	rs12468226	1	rs113491584	ENSG00000273456.1	RP11-686O6.2	12.23	4.79e-30	6.49e-27	0.62	0.49	Urate levels;	chr2:202331724	chr2:202374932~202375604:-
THCA	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	12.23	4.8e-30	6.5e-27	0.4	0.49	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
THCA	cis	rs853679	0.517	rs3734573	ENSG00000280107.1	AL022393.9	-12.23	4.81e-30	6.52e-27	-0.6	-0.49	Depression;	chr6:28091659	chr6:28170845~28172521:+
THCA	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	12.23	4.85e-30	6.57e-27	0.56	0.49	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
THCA	cis	rs853679	0.517	rs9393887	ENSG00000280107.1	AL022393.9	-12.23	4.85e-30	6.57e-27	-0.6	-0.49	Depression;	chr6:28091242	chr6:28170845~28172521:+
THCA	cis	rs6570726	0.791	rs443628	ENSG00000235652.6	RP11-545I5.3	12.23	4.92e-30	6.66e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145562348	chr6:145799409~145886585:+
THCA	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-12.22	4.94e-30	6.68e-27	-0.53	-0.49	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
THCA	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-12.22	4.94e-30	6.68e-27	-0.53	-0.49	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
THCA	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	12.22	4.94e-30	6.68e-27	0.58	0.49	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
THCA	cis	rs9309473	0.66	rs11679594	ENSG00000163016.8	ALMS1P	12.22	4.94e-30	6.69e-27	0.85	0.49	Metabolite levels;	chr2:73552380	chr2:73644919~73685576:+
THCA	cis	rs62158211	0.826	rs62158168	ENSG00000234997.1	AC016745.3	-12.22	4.98e-30	6.74e-27	-0.58	-0.49	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113320804	chr2:113424495~113425324:+
THCA	cis	rs227275	0.525	rs6853193	ENSG00000246560.2	RP11-10L12.4	12.22	4.99e-30	6.75e-27	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102994888	chr4:102828055~102844075:+
THCA	cis	rs228614	0.51	rs223378	ENSG00000246560.2	RP11-10L12.4	12.22	5e-30	6.76e-27	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102833488	chr4:102828055~102844075:+
THCA	cis	rs324126	0.78	rs3170100	ENSG00000277977.1	CTD-3018O17.5	12.22	5.01e-30	6.78e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52385367	chr19:52392659~52392755:+
THCA	cis	rs324126	0.743	rs34221182	ENSG00000277977.1	CTD-3018O17.5	12.22	5.06e-30	6.85e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52378107	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs10445583	ENSG00000277977.1	CTD-3018O17.5	12.22	5.06e-30	6.85e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52379480	chr19:52392659~52392755:+
THCA	cis	rs324126	0.752	rs10445584	ENSG00000277977.1	CTD-3018O17.5	12.22	5.06e-30	6.85e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52379552	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs10445585	ENSG00000277977.1	CTD-3018O17.5	12.22	5.06e-30	6.85e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52379571	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs10445586	ENSG00000277977.1	CTD-3018O17.5	12.22	5.06e-30	6.85e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52379870	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs62108317	ENSG00000277977.1	CTD-3018O17.5	12.22	5.06e-30	6.85e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52380230	chr19:52392659~52392755:+
THCA	cis	rs8040855	0.627	rs3816105	ENSG00000259295.5	CSPG4P12	12.22	5.09e-30	6.89e-27	0.74	0.49	Bulimia nervosa;	chr15:85097680	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs2304418	ENSG00000259295.5	CSPG4P12	12.22	5.09e-30	6.89e-27	0.74	0.49	Bulimia nervosa;	chr15:85097752	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs1532776	ENSG00000259295.5	CSPG4P12	12.22	5.1e-30	6.9e-27	0.73	0.49	Bulimia nervosa;	chr15:85081383	chr15:85191438~85213905:+
THCA	cis	rs4713118	0.516	rs6931858	ENSG00000280107.1	AL022393.9	-12.22	5.11e-30	6.91e-27	-0.59	-0.49	Parkinson's disease;	chr6:28110633	chr6:28170845~28172521:+
THCA	cis	rs6504950	1	rs8082471	ENSG00000275710.1	RP11-257O5.4	12.22	5.11e-30	6.91e-27	0.62	0.49	Breast cancer;	chr17:54990632	chr17:54964474~54964679:+
THCA	cis	rs526231	0.543	rs34779	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103117064	chr5:103032376~103033031:+
THCA	cis	rs526231	0.547	rs34780	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103117853	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.759	rs34781	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Parkinson's disease;	chr5:103118735	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34784	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103121626	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34785	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103122399	chr5:103032376~103033031:+
THCA	cis	rs526231	0.578	rs34786	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103122409	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34787	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103123199	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34789	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103125035	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs26525	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103129219	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs32851	ENSG00000175749.11	EIF3KP1	12.22	5.18e-30	6.99e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103132967	chr5:103032376~103033031:+
THCA	cis	rs227275	0.556	rs724447	ENSG00000246560.2	RP11-10L12.4	-12.22	5.18e-30	7e-27	-0.62	-0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103010149	chr4:102828055~102844075:+
THCA	cis	rs5769707	0.521	rs7285764	ENSG00000188511.11	C22orf34	12.22	5.19e-30	7.01e-27	0.62	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49414524~49657542:-
THCA	cis	rs5769707	0.521	rs9616715	ENSG00000188511.11	C22orf34	12.22	5.19e-30	7.01e-27	0.62	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49414524~49657542:-
THCA	cis	rs5769707	0.521	rs6009805	ENSG00000188511.11	C22orf34	12.22	5.19e-30	7.01e-27	0.62	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49414524~49657542:-
THCA	cis	rs524281	0.861	rs10896090	ENSG00000255320.1	RP11-755F10.1	12.22	5.2e-30	7.03e-27	0.73	0.49	Electroencephalogram traits;	chr11:66177715	chr11:66244840~66246239:-
THCA	cis	rs7772486	0.686	rs4896827	ENSG00000235652.6	RP11-545I5.3	12.22	5.21e-30	7.03e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145632202	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs4896828	ENSG00000235652.6	RP11-545I5.3	12.22	5.21e-30	7.03e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145632203	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs6570701	ENSG00000235652.6	RP11-545I5.3	12.22	5.21e-30	7.03e-27	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145632954	chr6:145799409~145886585:+
THCA	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	12.22	5.28e-30	7.13e-27	0.4	0.49	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	12.22	5.28e-30	7.13e-27	0.4	0.49	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
THCA	cis	rs11148252	0.512	rs9526950	ENSG00000235660.1	LINC00345	-12.22	5.29e-30	7.13e-27	-0.63	-0.49	Lewy body disease;	chr13:52600328	chr13:52484161~52484680:-
THCA	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	12.22	5.33e-30	7.19e-27	0.61	0.49	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
THCA	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	12.22	5.33e-30	7.19e-27	0.61	0.49	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
THCA	cis	rs2739330	0.731	rs5751792	ENSG00000224205.1	AP000351.4	12.22	5.37e-30	7.23e-27	0.59	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23987320~23991421:-
THCA	cis	rs526231	0.511	rs158402	ENSG00000175749.11	EIF3KP1	12.22	5.38e-30	7.25e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103079821	chr5:103032376~103033031:+
THCA	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	12.21	5.42e-30	7.31e-27	0.56	0.49	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	12.21	5.42e-30	7.31e-27	0.56	0.49	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	12.21	5.42e-30	7.31e-27	0.56	0.49	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
THCA	cis	rs465969	0.744	rs34659678	ENSG00000255389.1	C6orf3	-12.21	5.45e-30	7.34e-27	-0.95	-0.49	Psoriasis;	chr6:111567337	chr6:111599875~111602295:+
THCA	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-12.21	5.48e-30	7.38e-27	-0.62	-0.49	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
THCA	cis	rs7772486	0.623	rs735535	ENSG00000235652.6	RP11-545I5.3	-12.21	5.51e-30	7.42e-27	-0.46	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145715693	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.566	rs735536	ENSG00000235652.6	RP11-545I5.3	-12.21	5.51e-30	7.42e-27	-0.46	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145715696	chr6:145799409~145886585:+
THCA	cis	rs11105298	0.891	rs10858881	ENSG00000258302.2	RP11-981P6.1	12.21	5.58e-30	7.51e-27	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:89561129~89594878:+
THCA	cis	rs227275	0.525	rs1080081	ENSG00000246560.2	RP11-10L12.4	12.21	5.6e-30	7.54e-27	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103029268	chr4:102828055~102844075:+
THCA	cis	rs227275	0.525	rs4699049	ENSG00000246560.2	RP11-10L12.4	12.21	5.6e-30	7.54e-27	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103030467	chr4:102828055~102844075:+
THCA	cis	rs853679	0.517	rs4713135	ENSG00000280107.1	AL022393.9	-12.21	5.6e-30	7.54e-27	-0.6	-0.49	Depression;	chr6:28071808	chr6:28170845~28172521:+
THCA	cis	rs7772486	0.686	rs2179323	ENSG00000235652.6	RP11-545I5.3	-12.21	5.62e-30	7.56e-27	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145661650	chr6:145799409~145886585:+
THCA	cis	rs7773456	0.533	rs9350190	ENSG00000228412.5	RP4-625H18.2	-12.21	5.64e-30	7.6e-27	-0.74	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr6:19811429	chr6:19802164~19804752:-
THCA	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	12.21	5.65e-30	7.6e-27	0.62	0.49	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
THCA	cis	rs8040855	0.627	rs11632175	ENSG00000259295.5	CSPG4P12	12.21	5.65e-30	7.61e-27	0.73	0.49	Bulimia nervosa;	chr15:85068449	chr15:85191438~85213905:+
THCA	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	12.21	5.66e-30	7.62e-27	0.41	0.49	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
THCA	cis	rs2455601	0.608	rs10840137	ENSG00000254860.4	TMEM9B-AS1	12.21	5.67e-30	7.64e-27	0.6	0.49	Schizophrenia;	chr11:8868532	chr11:8964675~8977527:+
THCA	cis	rs8040855	0.627	rs12904238	ENSG00000259295.5	CSPG4P12	12.21	5.69e-30	7.65e-27	0.74	0.49	Bulimia nervosa;	chr15:85096610	chr15:85191438~85213905:+
THCA	cis	rs80028505	0.908	rs7760405	ENSG00000271304.1	DPRXP2	12.21	5.69e-30	7.66e-27	0.81	0.49	Foot ulcer in diabetes and neuropathy;	chr6:36106054	chr6:35989515~35990436:-
THCA	cis	rs9309473	0.66	rs10496192	ENSG00000163016.8	ALMS1P	12.21	5.74e-30	7.72e-27	0.85	0.49	Metabolite levels;	chr2:73452739	chr2:73644919~73685576:+
THCA	cis	rs11105298	0.891	rs11105299	ENSG00000258302.2	RP11-981P6.1	12.21	5.75e-30	7.73e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs1008764	ENSG00000258302.2	RP11-981P6.1	12.21	5.75e-30	7.73e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:89561129~89594878:+
THCA	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-12.21	5.75e-30	7.73e-27	-0.63	-0.49	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
THCA	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	12.21	5.75e-30	7.74e-27	0.57	0.49	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
THCA	cis	rs992157	0.71	rs12612347	ENSG00000261338.2	RP11-378A13.1	-12.21	5.79e-30	7.79e-27	-0.51	-0.49	Colorectal cancer;	chr2:218192615	chr2:218255319~218257366:+
THCA	cis	rs2455601	0.671	rs10840135	ENSG00000254860.4	TMEM9B-AS1	12.21	5.8e-30	7.8e-27	0.61	0.49	Schizophrenia;	chr11:8858247	chr11:8964675~8977527:+
THCA	cis	rs8040855	0.627	rs35668291	ENSG00000259295.5	CSPG4P12	12.21	5.91e-30	7.94e-27	0.73	0.49	Bulimia nervosa;	chr15:85109582	chr15:85191438~85213905:+
THCA	cis	rs67311347	1	rs73080126	ENSG00000223797.4	ENTPD3-AS1	12.21	5.93e-30	7.97e-27	0.41	0.49	Renal cell carcinoma;	chr3:40467662	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs28871903	ENSG00000223797.4	ENTPD3-AS1	12.21	5.93e-30	7.97e-27	0.41	0.49	Renal cell carcinoma;	chr3:40469603	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs56291770	ENSG00000223797.4	ENTPD3-AS1	12.21	5.93e-30	7.97e-27	0.41	0.49	Renal cell carcinoma;	chr3:40473879	chr3:40313802~40453329:-
THCA	cis	rs11722779	0.935	rs11938650	ENSG00000246560.2	RP11-10L12.4	12.21	5.94e-30	7.98e-27	0.62	0.49	Schizophrenia;	chr4:103021639	chr4:102828055~102844075:+
THCA	cis	rs875971	0.825	rs1129531	ENSG00000237310.1	GS1-124K5.4	-12.2	5.95e-30	8e-27	-0.36	-0.49	Aortic root size;	chr7:66154117	chr7:66493706~66495474:+
THCA	cis	rs2455601	0.608	rs16906256	ENSG00000254860.4	TMEM9B-AS1	12.2	5.99e-30	8.05e-27	0.6	0.49	Schizophrenia;	chr11:8865550	chr11:8964675~8977527:+
THCA	cis	rs7772486	0.875	rs863820	ENSG00000235652.6	RP11-545I5.3	-12.2	6e-30	8.06e-27	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:146026266	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	12.2	6.01e-30	8.07e-27	0.56	0.49	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
THCA	cis	rs1858037	0.867	rs72621551	ENSG00000204929.10	AC074391.1	12.2	6.03e-30	8.09e-27	0.64	0.49	Rheumatoid arthritis;	chr2:65388087	chr2:65436711~66084639:+
THCA	cis	rs4718428	0.705	rs12536410	ENSG00000273142.1	RP11-458F8.4	-12.2	6.1e-30	8.19e-27	-0.46	-0.49	Corneal structure;	chr7:66789303	chr7:66902857~66906297:+
THCA	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	12.2	6.16e-30	8.27e-27	0.39	0.49	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	12.2	6.16e-30	8.27e-27	0.39	0.49	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	12.2	6.16e-30	8.27e-27	0.39	0.49	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	12.2	6.16e-30	8.27e-27	0.39	0.49	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	12.2	6.16e-30	8.27e-27	0.39	0.49	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
THCA	cis	rs7569084	1	rs13385171	ENSG00000281920.1	RP11-418H16.1	-12.2	6.24e-30	8.36e-27	-0.6	-0.49	Sum eosinophil basophil counts;	chr2:65434709	chr2:65623272~65628424:+
THCA	cis	rs6570726	0.791	rs378937	ENSG00000235652.6	RP11-545I5.3	12.2	6.24e-30	8.36e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145513609	chr6:145799409~145886585:+
THCA	cis	rs11722779	0.935	rs3857200	ENSG00000246560.2	RP11-10L12.4	12.2	6.27e-30	8.41e-27	0.61	0.49	Schizophrenia;	chr4:103001864	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs11731885	ENSG00000246560.2	RP11-10L12.4	12.2	6.27e-30	8.41e-27	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103010913	chr4:102828055~102844075:+
THCA	cis	rs4718428	0.705	rs4717331	ENSG00000273142.1	RP11-458F8.4	-12.2	6.28e-30	8.42e-27	-0.45	-0.49	Corneal structure;	chr7:66913899	chr7:66902857~66906297:+
THCA	cis	rs875971	0.862	rs10256544	ENSG00000237310.1	GS1-124K5.4	12.2	6.3e-30	8.44e-27	0.36	0.49	Aortic root size;	chr7:66210141	chr7:66493706~66495474:+
THCA	cis	rs227275	0.525	rs17215211	ENSG00000246560.2	RP11-10L12.4	12.2	6.3e-30	8.44e-27	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:103025961	chr4:102828055~102844075:+
THCA	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-12.2	6.3e-30	8.45e-27	-0.36	-0.49	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
THCA	cis	rs11098499	0.532	rs4833624	ENSG00000245958.5	RP11-33B1.1	-12.2	6.33e-30	8.48e-27	-0.48	-0.49	Corneal astigmatism;	chr4:119664342	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.532	rs12512646	ENSG00000245958.5	RP11-33B1.1	-12.2	6.33e-30	8.48e-27	-0.48	-0.49	Corneal astigmatism;	chr4:119664578	chr4:119454791~119552025:+
THCA	cis	rs324126	0.78	rs62108319	ENSG00000277977.1	CTD-3018O17.5	12.2	6.34e-30	8.49e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52380577	chr19:52392659~52392755:+
THCA	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-12.2	6.34e-30	8.49e-27	-0.56	-0.49	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
THCA	cis	rs875971	0.929	rs6970860	ENSG00000237310.1	GS1-124K5.4	12.2	6.39e-30	8.56e-27	0.36	0.49	Aortic root size;	chr7:66511647	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6957199	ENSG00000237310.1	GS1-124K5.4	12.2	6.39e-30	8.56e-27	0.36	0.49	Aortic root size;	chr7:66513532	chr7:66493706~66495474:+
THCA	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	12.2	6.42e-30	8.6e-27	0.59	0.49	Height;	chr3:53091453	chr3:53064283~53065091:-
THCA	cis	rs875971	0.964	rs6978429	ENSG00000237310.1	GS1-124K5.4	12.2	6.44e-30	8.62e-27	0.36	0.49	Aortic root size;	chr7:66494889	chr7:66493706~66495474:+
THCA	cis	rs875971	0.929	rs12535036	ENSG00000237310.1	GS1-124K5.4	12.2	6.44e-30	8.62e-27	0.36	0.49	Aortic root size;	chr7:66499076	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs12698523	ENSG00000237310.1	GS1-124K5.4	12.2	6.44e-30	8.62e-27	0.36	0.49	Aortic root size;	chr7:66503126	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6970030	ENSG00000237310.1	GS1-124K5.4	12.2	6.44e-30	8.62e-27	0.36	0.49	Aortic root size;	chr7:66503692	chr7:66493706~66495474:+
THCA	cis	rs875971	0.928	rs6970357	ENSG00000237310.1	GS1-124K5.4	12.2	6.44e-30	8.62e-27	0.36	0.49	Aortic root size;	chr7:66503891	chr7:66493706~66495474:+
THCA	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-12.2	6.48e-30	8.68e-27	-0.51	-0.49	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
THCA	cis	rs4819052	0.808	rs2246697	ENSG00000223768.1	LINC00205	-12.2	6.5e-30	8.69e-27	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.819	rs7279136	ENSG00000223768.1	LINC00205	-12.2	6.5e-30	8.69e-27	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.788	rs4819051	ENSG00000223768.1	LINC00205	-12.2	6.5e-30	8.69e-27	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.819	rs8134084	ENSG00000223768.1	LINC00205	-12.2	6.5e-30	8.69e-27	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs7276828	ENSG00000223768.1	LINC00205	-12.2	6.5e-30	8.69e-27	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45293285~45297354:+
THCA	cis	rs324126	0.78	rs62108320	ENSG00000277977.1	CTD-3018O17.5	12.2	6.5e-30	8.7e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52380770	chr19:52392659~52392755:+
THCA	cis	rs324126	0.752	rs62108321	ENSG00000277977.1	CTD-3018O17.5	12.2	6.5e-30	8.7e-27	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52380825	chr19:52392659~52392755:+
THCA	cis	rs4853012	1	rs2280643	ENSG00000257800.1	FNBP1P1	12.2	6.5e-30	8.7e-27	0.47	0.49	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74120680~74123218:+
THCA	cis	rs4853012	0.887	rs2280644	ENSG00000257800.1	FNBP1P1	12.2	6.5e-30	8.7e-27	0.47	0.49	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74120680~74123218:+
THCA	cis	rs7182621	1	rs7182621	ENSG00000259363.4	CTD-2054N24.2	12.2	6.52e-30	8.72e-27	0.58	0.49	Colonoscopy-negative controls vs population controls;	chr15:99884400	chr15:99807023~99877148:+
THCA	cis	rs7772486	0.875	rs2748501	ENSG00000235652.6	RP11-545I5.3	12.19	6.56e-30	8.78e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145991122	chr6:145799409~145886585:+
THCA	cis	rs526231	0.578	rs34794	ENSG00000175749.11	EIF3KP1	12.19	6.6e-30	8.83e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103087664	chr5:103032376~103033031:+
THCA	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	12.19	6.6e-30	8.83e-27	0.36	0.49	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
THCA	cis	rs2455601	0.608	rs11042104	ENSG00000254860.4	TMEM9B-AS1	-12.19	6.62e-30	8.85e-27	-0.59	-0.49	Schizophrenia;	chr11:8869377	chr11:8964675~8977527:+
THCA	cis	rs875971	1	rs3735148	ENSG00000237310.1	GS1-124K5.4	12.19	6.63e-30	8.87e-27	0.36	0.49	Aortic root size;	chr7:66506022	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.566	rs4870118	ENSG00000231760.4	RP11-350J20.5	-12.19	6.76e-30	9.04e-27	-0.71	-0.49	Lung cancer;	chr6:149923877	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.566	rs4869767	ENSG00000231760.4	RP11-350J20.5	-12.19	6.76e-30	9.04e-27	-0.71	-0.49	Lung cancer;	chr6:149923974	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.566	rs4869768	ENSG00000231760.4	RP11-350J20.5	-12.19	6.76e-30	9.04e-27	-0.71	-0.49	Lung cancer;	chr6:149924067	chr6:149796151~149826294:-
THCA	cis	rs7773456	0.576	rs4140624	ENSG00000228412.5	RP4-625H18.2	-12.19	6.79e-30	9.08e-27	-0.75	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19802164~19804752:-
THCA	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	12.19	6.84e-30	9.14e-27	0.36	0.49	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
THCA	cis	rs17111396	0.627	rs59741121	ENSG00000259167.2	NMNAT1P1	12.19	6.87e-30	9.18e-27	0.75	0.49	Uric acid levels;	chr14:81036434	chr14:81032529~81033404:+
THCA	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
THCA	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	12.19	6.9e-30	9.21e-27	0.36	0.49	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
THCA	cis	rs228614	0.536	rs223475	ENSG00000246560.2	RP11-10L12.4	12.19	6.91e-30	9.23e-27	0.61	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771986	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223474	ENSG00000246560.2	RP11-10L12.4	12.19	6.91e-30	9.23e-27	0.61	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102772007	chr4:102828055~102844075:+
THCA	cis	rs8040855	0.658	rs11634877	ENSG00000259295.5	CSPG4P12	12.19	6.94e-30	9.27e-27	0.73	0.49	Bulimia nervosa;	chr15:85068246	chr15:85191438~85213905:+
THCA	cis	rs9309473	0.528	rs79799178	ENSG00000163016.8	ALMS1P	12.19	7.02e-30	9.37e-27	0.85	0.49	Metabolite levels;	chr2:73564108	chr2:73644919~73685576:+
THCA	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-12.19	7.03e-30	9.39e-27	-0.37	-0.49	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
THCA	cis	rs6570726	0.791	rs4332001	ENSG00000235652.6	RP11-545I5.3	12.19	7.06e-30	9.42e-27	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145613705	chr6:145799409~145886585:+
THCA	cis	rs4718428	0.705	rs10267335	ENSG00000226824.5	RP4-756H11.3	-12.19	7.06e-30	9.43e-27	-0.71	-0.49	Corneal structure;	chr7:66938233	chr7:66654538~66669855:+
THCA	cis	rs526231	0.543	rs34832	ENSG00000175749.11	EIF3KP1	12.19	7.1e-30	9.47e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103108891	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34770	ENSG00000175749.11	EIF3KP1	12.19	7.1e-30	9.47e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103111942	chr5:103032376~103033031:+
THCA	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	12.19	7.14e-30	9.52e-27	0.4	0.49	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
THCA	cis	rs526231	0.543	rs257310	ENSG00000175749.11	EIF3KP1	12.19	7.16e-30	9.55e-27	0.65	0.49	Primary biliary cholangitis;	chr5:103083149	chr5:103032376~103033031:+
THCA	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-12.18	7.17e-30	9.56e-27	-0.61	-0.49	Height;	chr3:53080524	chr3:53064283~53065091:-
THCA	cis	rs2739330	0.761	rs5760176	ENSG00000224205.1	AP000351.4	-12.18	7.2e-30	9.6e-27	-0.59	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23987320~23991421:-
THCA	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	12.18	7.23e-30	9.64e-27	0.39	0.49	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
THCA	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	12.18	7.24e-30	9.65e-27	0.61	0.49	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
THCA	cis	rs11105298	0.891	rs10777184	ENSG00000258302.2	RP11-981P6.1	12.18	7.25e-30	9.66e-27	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:89561129~89594878:+
THCA	cis	rs4718428	0.705	rs12698547	ENSG00000226824.5	RP4-756H11.3	-12.18	7.26e-30	9.68e-27	-0.72	-0.49	Corneal structure;	chr7:66813271	chr7:66654538~66669855:+
THCA	cis	rs9399137	0.507	rs7772031	ENSG00000232876.1	CTA-212D2.2	12.18	7.35e-30	9.79e-27	0.61	0.49	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134938596	chr6:135055033~135060550:+
THCA	cis	rs6496932	0.802	rs67928464	ENSG00000218052.5	ADAMTS7P4	12.18	7.41e-30	9.87e-27	0.63	0.49	Central corneal thickness;Corneal structure;	chr15:85338535	chr15:85255369~85330334:-
THCA	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-12.18	7.43e-30	9.89e-27	-0.51	-0.49	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
THCA	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	12.18	7.46e-30	9.93e-27	0.4	0.49	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
THCA	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	12.18	7.5e-30	9.99e-27	0.59	0.49	Height;	chr11:118809363	chr11:118688039~118690600:-
THCA	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	12.18	7.52e-30	1e-26	0.56	0.49	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
THCA	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	12.18	7.57e-30	1.01e-26	0.57	0.49	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	12.18	7.57e-30	1.01e-26	0.57	0.49	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
THCA	cis	rs26232	0.521	rs3776856	ENSG00000175749.11	EIF3KP1	12.18	7.6e-30	1.01e-26	0.65	0.49	Rheumatoid arthritis;	chr5:103023102	chr5:103032376~103033031:+
THCA	cis	rs4718428	0.705	rs62465692	ENSG00000273142.1	RP11-458F8.4	-12.18	7.68e-30	1.02e-26	-0.45	-0.49	Corneal structure;	chr7:66830758	chr7:66902857~66906297:+
THCA	cis	rs4718428	0.662	rs34577323	ENSG00000273142.1	RP11-458F8.4	-12.18	7.68e-30	1.02e-26	-0.45	-0.49	Corneal structure;	chr7:66845054	chr7:66902857~66906297:+
THCA	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-12.18	7.68e-30	1.02e-26	-0.41	-0.49	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
THCA	cis	rs4819052	0.851	rs7281263	ENSG00000223768.1	LINC00205	-12.18	7.69e-30	1.02e-26	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45293285~45297354:+
THCA	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-12.18	7.69e-30	1.02e-26	-0.36	-0.49	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
THCA	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-12.18	7.69e-30	1.02e-26	-0.36	-0.49	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
THCA	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-12.18	7.69e-30	1.02e-26	-0.36	-0.49	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-12.18	7.69e-30	1.02e-26	-0.36	-0.49	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
THCA	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-12.18	7.69e-30	1.02e-26	-0.36	-0.49	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
THCA	cis	rs853679	0.517	rs3757187	ENSG00000280107.1	AL022393.9	-12.18	7.7e-30	1.02e-26	-0.6	-0.49	Depression;	chr6:28139876	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs3757185	ENSG00000280107.1	AL022393.9	-12.18	7.7e-30	1.02e-26	-0.6	-0.49	Depression;	chr6:28139998	chr6:28170845~28172521:+
THCA	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	12.18	7.8e-30	1.04e-26	0.36	0.49	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
THCA	cis	rs9928842	0.824	rs889515	ENSG00000280152.1	RP11-331F4.5	12.18	7.82e-30	1.04e-26	0.69	0.49	Alcoholic chronic pancreatitis;	chr16:75217401	chr16:75245994~75250077:-
THCA	cis	rs853679	0.517	rs1904840	ENSG00000280107.1	AL022393.9	-12.18	7.86e-30	1.05e-26	-0.6	-0.49	Depression;	chr6:28140454	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9368555	ENSG00000280107.1	AL022393.9	-12.18	7.86e-30	1.05e-26	-0.6	-0.49	Depression;	chr6:28141189	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393893	ENSG00000280107.1	AL022393.9	-12.18	7.86e-30	1.05e-26	-0.6	-0.49	Depression;	chr6:28141484	chr6:28170845~28172521:+
THCA	cis	rs6570726	0.818	rs9390338	ENSG00000235652.6	RP11-545I5.3	12.17	7.87e-30	1.05e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145587129	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6570693	ENSG00000235652.6	RP11-545I5.3	12.17	7.87e-30	1.05e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145589705	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6570694	ENSG00000235652.6	RP11-545I5.3	12.17	7.87e-30	1.05e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145590068	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6570695	ENSG00000235652.6	RP11-545I5.3	12.17	7.87e-30	1.05e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145590150	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs9386125	ENSG00000235652.6	RP11-545I5.3	12.17	7.87e-30	1.05e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145590541	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs9373466	ENSG00000235652.6	RP11-545I5.3	12.17	7.87e-30	1.05e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145590880	chr6:145799409~145886585:+
THCA	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28089816	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28090857	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28091439	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28092227	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28093966	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28094014	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-12.17	7.88e-30	1.05e-26	-0.67	-0.49	Depression;	chr6:28096077	chr6:28115628~28116551:+
THCA	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	12.17	7.89e-30	1.05e-26	0.64	0.49	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
THCA	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-12.17	7.92e-30	1.05e-26	-0.36	-0.49	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-12.17	7.92e-30	1.05e-26	-0.36	-0.49	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
THCA	cis	rs7743045	0.625	rs9387624	ENSG00000253194.1	RP11-351A11.1	12.17	8e-30	1.06e-26	0.71	0.49	Mean platelet volume;	chr6:119010723	chr6:118934785~119031541:+
THCA	cis	rs2274273	0.837	rs11625968	ENSG00000258413.1	RP11-665C16.6	-12.17	8e-30	1.06e-26	-0.63	-0.49	Protein biomarker;	chr14:55334286	chr14:55262767~55272075:-
THCA	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	12.17	8.03e-30	1.07e-26	0.36	0.49	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
THCA	cis	rs7240205	0.657	rs1111207	ENSG00000275805.1	RP11-349H17.2	-12.17	8.06e-30	1.07e-26	-0.56	-0.49	Breast cancer;	chr18:26545893	chr18:26565723~26575626:-
THCA	cis	rs7240205	0.657	rs1111208	ENSG00000275805.1	RP11-349H17.2	-12.17	8.06e-30	1.07e-26	-0.56	-0.49	Breast cancer;	chr18:26545901	chr18:26565723~26575626:-
THCA	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	12.17	8.08e-30	1.07e-26	0.36	0.49	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
THCA	cis	rs11105298	0.786	rs10858867	ENSG00000258302.2	RP11-981P6.1	12.17	8.09e-30	1.07e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.786	rs3803128	ENSG00000258302.2	RP11-981P6.1	12.17	8.09e-30	1.07e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10506972	ENSG00000258302.2	RP11-981P6.1	12.17	8.09e-30	1.07e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs12228177	ENSG00000258302.2	RP11-981P6.1	12.17	8.09e-30	1.07e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858872	ENSG00000258302.2	RP11-981P6.1	12.17	8.09e-30	1.07e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:89561129~89594878:+
THCA	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	12.17	8.11e-30	1.08e-26	0.4	0.49	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
THCA	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	12.17	8.14e-30	1.08e-26	0.56	0.49	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	12.17	8.14e-30	1.08e-26	0.56	0.49	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	12.17	8.14e-30	1.08e-26	0.56	0.49	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
THCA	cis	rs7773456	0.576	rs6924929	ENSG00000228412.5	RP4-625H18.2	-12.17	8.14e-30	1.08e-26	-0.74	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr6:19812381	chr6:19802164~19804752:-
THCA	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	12.17	8.24e-30	1.09e-26	0.61	0.49	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
THCA	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	12.17	8.29e-30	1.1e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
THCA	cis	rs12468226	0.938	rs80282360	ENSG00000273456.1	RP11-686O6.2	12.17	8.33e-30	1.1e-26	0.61	0.49	Urate levels;	chr2:202275121	chr2:202374932~202375604:-
THCA	cis	rs9322193	0.566	rs3922947	ENSG00000231760.4	RP11-350J20.5	-12.17	8.36e-30	1.11e-26	-0.7	-0.49	Lung cancer;	chr6:149924856	chr6:149796151~149826294:-
THCA	cis	rs6570726	0.846	rs6570700	ENSG00000235652.6	RP11-545I5.3	12.17	8.38e-30	1.11e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145610416	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs870491	ENSG00000235652.6	RP11-545I5.3	12.17	8.38e-30	1.11e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145612254	chr6:145799409~145886585:+
THCA	cis	rs11148252	0.532	rs9536185	ENSG00000235660.1	LINC00345	-12.17	8.39e-30	1.11e-26	-0.63	-0.49	Lewy body disease;	chr13:52605666	chr13:52484161~52484680:-
THCA	cis	rs526231	0.511	rs17155009	ENSG00000175749.11	EIF3KP1	12.17	8.46e-30	1.12e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103038440	chr5:103032376~103033031:+
THCA	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-12.17	8.46e-30	1.12e-26	-0.6	-0.49	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
THCA	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	12.17	8.47e-30	1.12e-26	0.56	0.49	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
THCA	cis	rs875971	1	rs778726	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66363744	chr7:66493706~66495474:+
THCA	cis	rs875971	0.767	rs1695815	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66366357	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778685	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66371189	chr7:66493706~66495474:+
THCA	cis	rs875971	0.929	rs778682	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66372947	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs11765965	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66377234	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs1643388	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66379575	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778722	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66379841	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs778721	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66380410	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778706	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66395437	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs778700	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66401463	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778699	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66403303	chr7:66493706~66495474:+
THCA	cis	rs875971	0.929	rs778692	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66407462	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs4718343	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66409301	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs1968225	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66409786	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6460295	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66417741	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs6978721	ENSG00000237310.1	GS1-124K5.4	12.17	8.49e-30	1.12e-26	0.36	0.49	Aortic root size;	chr7:66418217	chr7:66493706~66495474:+
THCA	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	12.17	8.52e-30	1.13e-26	0.54	0.49	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
THCA	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	12.17	8.55e-30	1.13e-26	0.41	0.49	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
THCA	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	12.17	8.57e-30	1.14e-26	0.56	0.49	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
THCA	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	12.17	8.59e-30	1.14e-26	0.56	0.49	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
THCA	cis	rs10028773	0.515	rs9994488	ENSG00000245958.5	RP11-33B1.1	-12.17	8.61e-30	1.14e-26	-0.46	-0.49	Educational attainment;	chr4:119666626	chr4:119454791~119552025:+
THCA	cis	rs875971	1	rs4718357	ENSG00000237310.1	GS1-124K5.4	12.17	8.61e-30	1.14e-26	0.36	0.49	Aortic root size;	chr7:66495891	chr7:66493706~66495474:+
THCA	cis	rs11098499	0.644	rs7693919	ENSG00000245958.5	RP11-33B1.1	-12.16	8.63e-30	1.14e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119619416	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.57	rs6832740	ENSG00000245958.5	RP11-33B1.1	-12.16	8.63e-30	1.14e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119624981	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.644	rs6855918	ENSG00000245958.5	RP11-33B1.1	-12.16	8.63e-30	1.14e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119625144	chr4:119454791~119552025:+
THCA	cis	rs10463554	0.75	rs26257	ENSG00000175749.11	EIF3KP1	12.16	8.69e-30	1.15e-26	0.65	0.49	Parkinson's disease;	chr5:103214830	chr5:103032376~103033031:+
THCA	cis	rs4718428	0.705	rs62465692	ENSG00000226824.5	RP4-756H11.3	-12.16	8.7e-30	1.15e-26	-0.72	-0.49	Corneal structure;	chr7:66830758	chr7:66654538~66669855:+
THCA	cis	rs4718428	0.662	rs34577323	ENSG00000226824.5	RP4-756H11.3	-12.16	8.7e-30	1.15e-26	-0.72	-0.49	Corneal structure;	chr7:66845054	chr7:66654538~66669855:+
THCA	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-12.16	8.72e-30	1.15e-26	-0.84	-0.49	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
THCA	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-12.16	8.83e-30	1.17e-26	-0.56	-0.49	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
THCA	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	12.16	8.84e-30	1.17e-26	0.58	0.49	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
THCA	cis	rs6570726	0.791	rs9322029	ENSG00000235652.6	RP11-545I5.3	12.16	8.95e-30	1.18e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145585547	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs9403730	ENSG00000235652.6	RP11-545I5.3	12.16	8.95e-30	1.18e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145586097	chr6:145799409~145886585:+
THCA	cis	rs8040855	0.627	rs11637512	ENSG00000259295.5	CSPG4P12	12.16	8.98e-30	1.19e-26	0.73	0.49	Bulimia nervosa;	chr15:85105528	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs17541051	ENSG00000259295.5	CSPG4P12	12.16	8.98e-30	1.19e-26	0.73	0.49	Bulimia nervosa;	chr15:85106122	chr15:85191438~85213905:+
THCA	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-12.16	9.04e-30	1.2e-26	-0.37	-0.49	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-12.16	9.04e-30	1.2e-26	-0.37	-0.49	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-12.16	9.04e-30	1.2e-26	-0.37	-0.49	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
THCA	cis	rs875971	0.838	rs2173570	ENSG00000237310.1	GS1-124K5.4	-12.16	9.04e-30	1.2e-26	-0.36	-0.49	Aortic root size;	chr7:66297976	chr7:66493706~66495474:+
THCA	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-12.16	9.09e-30	1.2e-26	-0.62	-0.49	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
THCA	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	12.16	9.13e-30	1.21e-26	0.56	0.49	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
THCA	cis	rs4718428	0.705	rs68168107	ENSG00000273142.1	RP11-458F8.4	-12.16	9.2e-30	1.22e-26	-0.45	-0.49	Corneal structure;	chr7:66790251	chr7:66902857~66906297:+
THCA	cis	rs4718428	0.672	rs36038499	ENSG00000226824.5	RP4-756H11.3	-12.16	9.29e-30	1.23e-26	-0.72	-0.49	Corneal structure;	chr7:66824628	chr7:66654538~66669855:+
THCA	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	12.16	9.31e-30	1.23e-26	0.59	0.49	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
THCA	cis	rs524281	0.861	rs471484	ENSG00000255320.1	RP11-755F10.1	12.16	9.33e-30	1.23e-26	0.69	0.49	Electroencephalogram traits;	chr11:66187673	chr11:66244840~66246239:-
THCA	cis	rs6570726	0.791	rs952406	ENSG00000235652.6	RP11-545I5.3	12.16	9.35e-30	1.24e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145604480	chr6:145799409~145886585:+
THCA	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	12.16	9.38e-30	1.24e-26	0.56	0.49	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
THCA	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28111382	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28111650	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28112175	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28113851	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28114487	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28114933	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28115743	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Depression;	chr6:28116411	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-12.16	9.38e-30	1.24e-26	-0.67	-0.49	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
THCA	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	12.16	9.43e-30	1.25e-26	0.36	0.49	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
THCA	cis	rs7182621	0.639	rs36069387	ENSG00000259363.4	CTD-2054N24.2	-12.15	9.53e-30	1.26e-26	-0.58	-0.49	Colonoscopy-negative controls vs population controls;	chr15:99884540	chr15:99807023~99877148:+
THCA	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	12.15	9.55e-30	1.26e-26	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
THCA	cis	rs526231	0.543	rs8488	ENSG00000175749.11	EIF3KP1	12.15	9.56e-30	1.26e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103203051	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-12.15	9.59e-30	1.27e-26	-0.65	-0.49	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
THCA	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-12.15	9.61e-30	1.27e-26	-0.56	-0.49	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
THCA	cis	rs227275	0.527	rs12500379	ENSG00000246560.2	RP11-10L12.4	12.15	9.7e-30	1.28e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102983665	chr4:102828055~102844075:+
THCA	cis	rs3002131	0.522	rs2936031	ENSG00000225265.1	TAF1A-AS1	-12.15	9.75e-30	1.29e-26	-0.69	-0.49	Interleukin-10 levels;	chr1:222582910	chr1:222589825~222593032:+
THCA	cis	rs227275	0.556	rs4455413	ENSG00000246560.2	RP11-10L12.4	12.15	9.8e-30	1.29e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102971925	chr4:102828055~102844075:+
THCA	cis	rs12468226	0.679	rs6435133	ENSG00000273456.1	RP11-686O6.2	-12.15	9.8e-30	1.29e-26	-0.61	-0.49	Urate levels;	chr2:202209237	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.817	rs12693965	ENSG00000273456.1	RP11-686O6.2	-12.15	9.8e-30	1.29e-26	-0.61	-0.49	Urate levels;	chr2:202210188	chr2:202374932~202375604:-
THCA	cis	rs2739330	0.732	rs5760175	ENSG00000224205.1	AP000351.4	12.15	9.87e-30	1.3e-26	0.59	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23987320~23991421:-
THCA	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-12.15	9.87e-30	1.3e-26	-0.83	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
THCA	cis	rs8040855	0.627	rs11630697	ENSG00000259295.5	CSPG4P12	12.15	9.94e-30	1.31e-26	0.73	0.49	Bulimia nervosa;	chr15:85063214	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs4980357	ENSG00000259295.5	CSPG4P12	12.15	9.94e-30	1.31e-26	0.73	0.49	Bulimia nervosa;	chr15:85064878	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs4980356	ENSG00000259295.5	CSPG4P12	12.15	9.94e-30	1.31e-26	0.73	0.49	Bulimia nervosa;	chr15:85064901	chr15:85191438~85213905:+
THCA	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	12.15	1e-29	1.32e-26	0.6	0.49	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
THCA	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-12.15	1e-29	1.32e-26	-0.74	-0.49	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
THCA	cis	rs7208859	0.673	rs216411	ENSG00000263531.1	RP13-753N3.1	-12.15	1.01e-29	1.33e-26	-0.83	-0.49	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30863921~30864940:-
THCA	cis	rs7772486	0.686	rs9376961	ENSG00000235652.6	RP11-545I5.3	12.15	1.02e-29	1.35e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145727601	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.566	rs5024811	ENSG00000231760.4	RP11-350J20.5	-12.15	1.03e-29	1.35e-26	-0.7	-0.49	Lung cancer;	chr6:149924898	chr6:149796151~149826294:-
THCA	cis	rs324126	0.78	rs2059818	ENSG00000277977.1	CTD-3018O17.5	12.14	1.04e-29	1.37e-26	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52379267	chr19:52392659~52392755:+
THCA	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-12.14	1.04e-29	1.37e-26	-0.6	-0.49	Height;	chr3:53070344	chr3:53064283~53065091:-
THCA	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-12.14	1.04e-29	1.38e-26	-0.66	-0.49	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
THCA	cis	rs324126	0.78	rs34425941	ENSG00000277977.1	CTD-3018O17.5	12.14	1.05e-29	1.38e-26	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52377359	chr19:52392659~52392755:+
THCA	cis	rs324126	0.78	rs62108318	ENSG00000277977.1	CTD-3018O17.5	12.14	1.05e-29	1.38e-26	0.46	0.49	Colonoscopy-negative controls vs population controls;	chr19:52380322	chr19:52392659~52392755:+
THCA	cis	rs526231	0.511	rs28062	ENSG00000175749.11	EIF3KP1	12.14	1.05e-29	1.38e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103204500	chr5:103032376~103033031:+
THCA	cis	rs12468226	0.873	rs3769817	ENSG00000273456.1	RP11-686O6.2	-12.14	1.05e-29	1.39e-26	-0.61	-0.49	Urate levels;	chr2:202214584	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.873	rs6435134	ENSG00000273456.1	RP11-686O6.2	-12.14	1.05e-29	1.39e-26	-0.61	-0.49	Urate levels;	chr2:202214857	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.817	rs6435135	ENSG00000273456.1	RP11-686O6.2	-12.14	1.05e-29	1.39e-26	-0.61	-0.49	Urate levels;	chr2:202217469	chr2:202374932~202375604:-
THCA	cis	rs11098499	0.644	rs10050092	ENSG00000245958.5	RP11-33B1.1	-12.14	1.05e-29	1.39e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119610930	chr4:119454791~119552025:+
THCA	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	12.14	1.06e-29	1.39e-26	0.55	0.49	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
THCA	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-12.14	1.06e-29	1.39e-26	-0.39	-0.49	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	12.14	1.06e-29	1.39e-26	0.39	0.49	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	12.14	1.06e-29	1.39e-26	0.39	0.49	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
THCA	cis	rs4718428	0.705	rs12698547	ENSG00000273142.1	RP11-458F8.4	-12.14	1.06e-29	1.4e-26	-0.45	-0.49	Corneal structure;	chr7:66813271	chr7:66902857~66906297:+
THCA	cis	rs7772486	0.686	rs1004752	ENSG00000235652.6	RP11-545I5.3	-12.14	1.06e-29	1.4e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145716686	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.84	rs11547116	ENSG00000258413.1	RP11-665C16.6	-12.14	1.07e-29	1.4e-26	-0.61	-0.49	Protein biomarker;	chr14:55271447	chr14:55262767~55272075:-
THCA	cis	rs524281	0.861	rs7937281	ENSG00000255320.1	RP11-755F10.1	12.14	1.08e-29	1.42e-26	0.69	0.49	Electroencephalogram traits;	chr11:66182603	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.644	rs2389880	ENSG00000245958.5	RP11-33B1.1	-12.14	1.09e-29	1.43e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119638715	chr4:119454791~119552025:+
THCA	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-12.14	1.11e-29	1.46e-26	-0.64	-0.49	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-12.14	1.11e-29	1.46e-26	-0.64	-0.49	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-12.14	1.11e-29	1.46e-26	-0.64	-0.49	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
THCA	cis	rs9309473	0.615	rs62149774	ENSG00000163016.8	ALMS1P	12.14	1.12e-29	1.47e-26	0.85	0.49	Metabolite levels;	chr2:73560525	chr2:73644919~73685576:+
THCA	cis	rs4718428	0.705	rs10267335	ENSG00000273142.1	RP11-458F8.4	-12.14	1.13e-29	1.49e-26	-0.45	-0.49	Corneal structure;	chr7:66938233	chr7:66902857~66906297:+
THCA	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-12.13	1.15e-29	1.51e-26	-0.61	-0.49	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
THCA	cis	rs26232	0.521	rs3776855	ENSG00000175749.11	EIF3KP1	12.13	1.15e-29	1.52e-26	0.65	0.49	Rheumatoid arthritis;	chr5:103023111	chr5:103032376~103033031:+
THCA	cis	rs11105298	0.891	rs10858898	ENSG00000258302.2	RP11-981P6.1	12.13	1.17e-29	1.53e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.838	rs4842488	ENSG00000258302.2	RP11-981P6.1	12.13	1.17e-29	1.54e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs6538189	ENSG00000258302.2	RP11-981P6.1	12.13	1.17e-29	1.54e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs6538190	ENSG00000258302.2	RP11-981P6.1	12.13	1.17e-29	1.54e-26	0.46	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:89561129~89594878:+
THCA	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	12.13	1.19e-29	1.56e-26	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
THCA	cis	rs11722779	0.935	rs7681629	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Schizophrenia;	chr4:102974407	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.844	rs17033381	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Schizophrenia;	chr4:102974952	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs4699044	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102976939	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs4699045	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102977009	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs10015289	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102984956	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs6852141	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102986439	chr4:102828055~102844075:+
THCA	cis	rs228614	0.509	rs4455415	ENSG00000246560.2	RP11-10L12.4	12.13	1.19e-29	1.57e-26	0.62	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102993663	chr4:102828055~102844075:+
THCA	cis	rs673078	0.66	rs7965350	ENSG00000275759.1	RP11-131L12.3	-12.13	1.2e-29	1.57e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118266710	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs17433217	ENSG00000275759.1	RP11-131L12.3	-12.13	1.2e-29	1.57e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118269076	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs73205526	ENSG00000275759.1	RP11-131L12.3	-12.13	1.2e-29	1.57e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118273172	chr12:118428281~118428870:+
THCA	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-12.13	1.2e-29	1.57e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
THCA	cis	rs4964805	0.549	rs2292682	ENSG00000257681.1	RP11-341G23.4	12.13	1.2e-29	1.57e-26	0.58	0.49	Attention deficit hyperactivity disorder;	chr12:103762742	chr12:103746315~103768858:-
THCA	cis	rs227275	0.556	rs12508069	ENSG00000246560.2	RP11-10L12.4	12.13	1.2e-29	1.57e-26	0.62	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102983598	chr4:102828055~102844075:+
THCA	cis	rs526231	0.543	rs26523	ENSG00000175749.11	EIF3KP1	12.13	1.2e-29	1.58e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103120550	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34783	ENSG00000175749.11	EIF3KP1	12.13	1.2e-29	1.58e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103121337	chr5:103032376~103033031:+
THCA	cis	rs526231	0.512	rs28022	ENSG00000175749.11	EIF3KP1	12.13	1.2e-29	1.58e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103128663	chr5:103032376~103033031:+
THCA	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28070115	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28071237	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28074687	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28076559	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28076704	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28078391	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28080757	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28080760	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28082231	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28082261	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28082984	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28083994	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28084025	chr6:28115628~28116551:+
THCA	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28085319	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28096855	chr6:28115628~28116551:+
THCA	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28099759	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28100648	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28104824	chr6:28115628~28116551:+
THCA	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28107222	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28108492	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-12.13	1.2e-29	1.58e-26	-0.67	-0.49	Depression;	chr6:28110254	chr6:28115628~28116551:+
THCA	cis	rs526231	0.543	rs75913944	ENSG00000175749.11	EIF3KP1	12.13	1.21e-29	1.58e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103143799	chr5:103032376~103033031:+
THCA	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-12.13	1.21e-29	1.59e-26	-0.58	-0.49	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
THCA	cis	rs7772486	0.875	rs854146	ENSG00000235652.6	RP11-545I5.3	12.13	1.21e-29	1.59e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146019897	chr6:145799409~145886585:+
THCA	cis	rs875971	0.867	rs1002053	ENSG00000237310.1	GS1-124K5.4	-12.13	1.22e-29	1.59e-26	-0.36	-0.49	Aortic root size;	chr7:66333558	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6460292	ENSG00000237310.1	GS1-124K5.4	-12.13	1.22e-29	1.59e-26	-0.36	-0.49	Aortic root size;	chr7:66345088	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	12.13	1.22e-29	1.6e-26	0.56	0.49	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	12.13	1.22e-29	1.6e-26	0.56	0.49	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	12.13	1.22e-29	1.6e-26	0.56	0.49	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
THCA	cis	rs4819052	1	rs2297286	ENSG00000223768.1	LINC00205	-12.13	1.23e-29	1.61e-26	-0.5	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45293285~45297354:+
THCA	cis	rs11722779	0.787	rs6533040	ENSG00000246560.2	RP11-10L12.4	12.13	1.23e-29	1.61e-26	0.61	0.49	Schizophrenia;	chr4:102951421	chr4:102828055~102844075:+
THCA	cis	rs4964805	0.549	rs11111752	ENSG00000257681.1	RP11-341G23.4	12.13	1.23e-29	1.61e-26	0.58	0.49	Attention deficit hyperactivity disorder;	chr12:103762774	chr12:103746315~103768858:-
THCA	cis	rs4718428	0.705	rs12536410	ENSG00000226824.5	RP4-756H11.3	-12.13	1.23e-29	1.61e-26	-0.71	-0.49	Corneal structure;	chr7:66789303	chr7:66654538~66669855:+
THCA	cis	rs7772486	0.686	rs702314	ENSG00000235652.6	RP11-545I5.3	-12.13	1.24e-29	1.62e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145682374	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.624	rs9485018	ENSG00000235652.6	RP11-545I5.3	-12.13	1.24e-29	1.62e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145704595	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs2092263	ENSG00000235652.6	RP11-545I5.3	-12.13	1.24e-29	1.62e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145708551	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9390347	ENSG00000235652.6	RP11-545I5.3	-12.13	1.24e-29	1.62e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145723611	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9390348	ENSG00000235652.6	RP11-545I5.3	-12.13	1.24e-29	1.62e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145723612	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.632	rs9386128	ENSG00000235652.6	RP11-545I5.3	-12.13	1.24e-29	1.62e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145727917	chr6:145799409~145886585:+
THCA	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	12.13	1.24e-29	1.63e-26	0.62	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
THCA	cis	rs1858037	0.867	rs55945621	ENSG00000204929.10	AC074391.1	12.12	1.25e-29	1.64e-26	0.64	0.49	Rheumatoid arthritis;	chr2:65388220	chr2:65436711~66084639:+
THCA	cis	rs4718428	0.672	rs12530806	ENSG00000273142.1	RP11-458F8.4	-12.12	1.26e-29	1.64e-26	-0.45	-0.49	Corneal structure;	chr7:66925737	chr7:66902857~66906297:+
THCA	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-12.12	1.26e-29	1.64e-26	-0.6	-0.49	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-12.12	1.26e-29	1.64e-26	-0.6	-0.49	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
THCA	cis	rs1061377	0.585	rs3733271	ENSG00000249207.1	RP11-360F5.1	-12.12	1.26e-29	1.66e-26	-0.59	-0.49	Uric acid levels;	chr4:39047948	chr4:39112677~39126818:-
THCA	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-12.12	1.27e-29	1.66e-26	-0.36	-0.49	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
THCA	cis	rs853679	0.517	rs1904841	ENSG00000280107.1	AL022393.9	-12.12	1.27e-29	1.66e-26	-0.6	-0.49	Depression;	chr6:28140307	chr6:28170845~28172521:+
THCA	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-12.12	1.28e-29	1.67e-26	-0.6	-0.49	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
THCA	cis	rs7188445	0.736	rs8048539	ENSG00000261390.4	RP11-345M22.2	12.12	1.28e-29	1.68e-26	0.56	0.49	Urate levels;	chr16:79670255	chr16:79715232~79770563:-
THCA	cis	rs673078	0.66	rs11068917	ENSG00000275759.1	RP11-131L12.3	-12.12	1.28e-29	1.68e-26	-0.62	-0.49	Glucose homeostasis traits;	chr12:118353315	chr12:118428281~118428870:+
THCA	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-12.12	1.29e-29	1.69e-26	-0.63	-0.49	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
THCA	cis	rs4819052	0.851	rs914218	ENSG00000223768.1	LINC00205	-12.12	1.3e-29	1.69e-26	-0.46	-0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45293285~45297354:+
THCA	cis	rs4819052	1	rs2297285	ENSG00000223768.1	LINC00205	12.12	1.3e-29	1.69e-26	0.54	0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45293285~45297354:+
THCA	cis	rs228614	0.51	rs4699033	ENSG00000246560.2	RP11-10L12.4	12.12	1.31e-29	1.71e-26	0.61	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102897577	chr4:102828055~102844075:+
THCA	cis	rs526231	0.512	rs34797	ENSG00000175749.11	EIF3KP1	12.12	1.31e-29	1.72e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103090023	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34801	ENSG00000175749.11	EIF3KP1	12.12	1.31e-29	1.72e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103090809	chr5:103032376~103033031:+
THCA	cis	rs11105298	0.891	rs10858899	ENSG00000258302.2	RP11-981P6.1	12.12	1.31e-29	1.72e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530034	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858900	ENSG00000258302.2	RP11-981P6.1	12.12	1.31e-29	1.72e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531304	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs11105316	ENSG00000258302.2	RP11-981P6.1	12.12	1.31e-29	1.72e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89531423	chr12:89561129~89594878:+
THCA	cis	rs875971	1	rs12532998	ENSG00000237310.1	GS1-124K5.4	12.12	1.32e-29	1.73e-26	0.36	0.49	Aortic root size;	chr7:66502472	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	12.12	1.32e-29	1.73e-26	0.36	0.49	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.79	rs4280983	ENSG00000235652.6	RP11-545I5.3	-12.12	1.34e-29	1.74e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145959654	chr6:145799409~145886585:+
THCA	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-12.12	1.34e-29	1.74e-26	-0.36	-0.49	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-12.12	1.34e-29	1.74e-26	-0.36	-0.49	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs937495	ENSG00000237310.1	GS1-124K5.4	-12.12	1.34e-29	1.75e-26	-0.36	-0.49	Aortic root size;	chr7:66314811	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs2036264	ENSG00000237310.1	GS1-124K5.4	-12.12	1.34e-29	1.75e-26	-0.36	-0.49	Aortic root size;	chr7:66334917	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs7783613	ENSG00000237310.1	GS1-124K5.4	-12.12	1.34e-29	1.75e-26	-0.36	-0.49	Aortic root size;	chr7:66340274	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs778735	ENSG00000237310.1	GS1-124K5.4	12.12	1.34e-29	1.75e-26	0.36	0.49	Aortic root size;	chr7:66349822	chr7:66493706~66495474:+
THCA	cis	rs526231	0.511	rs17154965	ENSG00000175749.11	EIF3KP1	12.12	1.34e-29	1.75e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103023862	chr5:103032376~103033031:+
THCA	cis	rs6570726	0.764	rs366673	ENSG00000235652.6	RP11-545I5.3	12.12	1.35e-29	1.76e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145493492	chr6:145799409~145886585:+
THCA	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-12.12	1.36e-29	1.77e-26	-0.56	-0.49	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
THCA	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	12.12	1.36e-29	1.77e-26	0.6	0.49	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	12.12	1.37e-29	1.78e-26	0.6	0.49	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	12.12	1.37e-29	1.78e-26	0.6	0.49	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	12.12	1.37e-29	1.78e-26	0.6	0.49	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
THCA	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	12.12	1.37e-29	1.79e-26	0.39	0.49	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
THCA	cis	rs6496932	0.755	rs6497021	ENSG00000218052.5	ADAMTS7P4	-12.11	1.37e-29	1.79e-26	-0.63	-0.49	Central corneal thickness;Corneal structure;	chr15:85353036	chr15:85255369~85330334:-
THCA	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-12.11	1.38e-29	1.8e-26	-0.6	-0.49	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
THCA	cis	rs765787	0.53	rs2413775	ENSG00000259520.4	CTD-2651B20.3	12.11	1.38e-29	1.8e-26	0.59	0.49	Uric acid levels;	chr15:45252090	chr15:45251580~45279251:-
THCA	cis	rs10463554	0.727	rs34768	ENSG00000175749.11	EIF3KP1	12.11	1.38e-29	1.8e-26	0.65	0.49	Parkinson's disease;	chr5:103155798	chr5:103032376~103033031:+
THCA	cis	rs228614	0.509	rs223486	ENSG00000246560.2	RP11-10L12.4	12.11	1.41e-29	1.83e-26	0.6	0.49	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102763796	chr4:102828055~102844075:+
THCA	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-12.11	1.41e-29	1.84e-26	-0.53	-0.49	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
THCA	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	12.11	1.42e-29	1.86e-26	0.63	0.49	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
THCA	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-12.11	1.42e-29	1.86e-26	-0.64	-0.49	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
THCA	cis	rs11105298	0.891	rs10858896	ENSG00000258302.2	RP11-981P6.1	12.11	1.44e-29	1.88e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs11105312	ENSG00000258302.2	RP11-981P6.1	12.11	1.44e-29	1.88e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526956	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10777185	ENSG00000258302.2	RP11-981P6.1	12.11	1.44e-29	1.88e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527498	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.786	rs10777186	ENSG00000258302.2	RP11-981P6.1	12.11	1.44e-29	1.88e-26	0.47	0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:89561129~89594878:+
THCA	cis	rs526231	0.543	rs3776863	ENSG00000175749.11	EIF3KP1	12.11	1.46e-29	1.9e-26	0.65	0.49	Primary biliary cholangitis;	chr5:102992165	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs17154913	ENSG00000175749.11	EIF3KP1	12.11	1.46e-29	1.9e-26	0.65	0.49	Primary biliary cholangitis;	chr5:102992786	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs7714539	ENSG00000175749.11	EIF3KP1	12.11	1.46e-29	1.9e-26	0.65	0.49	Primary biliary cholangitis;	chr5:102993174	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs60633061	ENSG00000175749.11	EIF3KP1	12.11	1.46e-29	1.9e-26	0.65	0.49	Primary biliary cholangitis;	chr5:102994345	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs62362544	ENSG00000175749.11	EIF3KP1	12.11	1.46e-29	1.9e-26	0.65	0.49	Primary biliary cholangitis;	chr5:102998543	chr5:103032376~103033031:+
THCA	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-12.11	1.46e-29	1.9e-26	-0.61	-0.49	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
THCA	cis	rs4718428	0.705	rs4718422	ENSG00000273142.1	RP11-458F8.4	-12.11	1.47e-29	1.91e-26	-0.45	-0.49	Corneal structure;	chr7:66894282	chr7:66902857~66906297:+
THCA	cis	rs4718428	0.705	rs13231140	ENSG00000273142.1	RP11-458F8.4	-12.11	1.47e-29	1.91e-26	-0.45	-0.49	Corneal structure;	chr7:66896631	chr7:66902857~66906297:+
THCA	cis	rs7772486	0.603	rs2223411	ENSG00000235652.6	RP11-545I5.3	-12.11	1.47e-29	1.91e-26	-0.49	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145707631	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.651	rs1292338	ENSG00000235652.6	RP11-545I5.3	-12.11	1.47e-29	1.91e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145646335	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs1292337	ENSG00000235652.6	RP11-545I5.3	-12.11	1.47e-29	1.91e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145646671	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs857879	ENSG00000235652.6	RP11-545I5.3	-12.11	1.47e-29	1.91e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145652907	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs7762536	ENSG00000235652.6	RP11-545I5.3	12.11	1.47e-29	1.92e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145602009	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.576	rs7452592	ENSG00000231760.4	RP11-350J20.5	12.11	1.48e-29	1.92e-26	0.77	0.49	Lung cancer;	chr6:149875445	chr6:149796151~149826294:-
THCA	cis	rs227275	0.556	rs9999303	ENSG00000246560.2	RP11-10L12.4	12.11	1.5e-29	1.95e-26	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102986881	chr4:102828055~102844075:+
THCA	cis	rs11098499	0.644	rs34835603	ENSG00000245958.5	RP11-33B1.1	-12.11	1.5e-29	1.96e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119632273	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.615	rs28850368	ENSG00000245958.5	RP11-33B1.1	-12.11	1.5e-29	1.96e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119633158	chr4:119454791~119552025:+
THCA	cis	rs4718428	0.672	rs4718412	ENSG00000273142.1	RP11-458F8.4	12.11	1.5e-29	1.96e-26	0.45	0.49	Corneal structure;	chr7:66821880	chr7:66902857~66906297:+
THCA	cis	rs11722779	0.935	rs6533046	ENSG00000246560.2	RP11-10L12.4	12.1	1.51e-29	1.97e-26	0.61	0.49	Schizophrenia;	chr4:102965917	chr4:102828055~102844075:+
THCA	cis	rs9928842	0.882	rs3169330	ENSG00000280152.1	RP11-331F4.5	12.1	1.51e-29	1.97e-26	0.72	0.49	Alcoholic chronic pancreatitis;	chr16:75235369	chr16:75245994~75250077:-
THCA	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	12.1	1.52e-29	1.98e-26	0.63	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
THCA	cis	rs11722779	0.844	rs10003326	ENSG00000246560.2	RP11-10L12.4	12.1	1.52e-29	1.98e-26	0.61	0.49	Schizophrenia;	chr4:102948193	chr4:102828055~102844075:+
THCA	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	12.1	1.52e-29	1.98e-26	0.72	0.49	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
THCA	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	12.1	1.53e-29	1.98e-26	0.39	0.49	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
THCA	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	12.1	1.53e-29	1.98e-26	0.56	0.49	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	12.1	1.53e-29	1.98e-26	0.56	0.49	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
THCA	cis	rs526231	0.543	rs183752	ENSG00000175749.11	EIF3KP1	12.1	1.53e-29	1.99e-26	0.64	0.49	Primary biliary cholangitis;	chr5:103172108	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34766	ENSG00000175749.11	EIF3KP1	12.1	1.53e-29	1.99e-26	0.64	0.49	Primary biliary cholangitis;	chr5:103175219	chr5:103032376~103033031:+
THCA	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	12.1	1.54e-29	2e-26	0.39	0.49	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
THCA	cis	rs7772486	0.79	rs9497431	ENSG00000235652.6	RP11-545I5.3	-12.1	1.54e-29	2e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145927041	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs7753092	ENSG00000235652.6	RP11-545I5.3	-12.1	1.54e-29	2e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145927727	chr6:145799409~145886585:+
THCA	cis	rs56145559	1	rs56145559	ENSG00000163016.8	ALMS1P	12.1	1.56e-29	2.03e-26	0.73	0.49	Schizophrenia;	chr2:73396311	chr2:73644919~73685576:+
THCA	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-12.1	1.58e-29	2.05e-26	-0.36	-0.49	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
THCA	cis	rs9309473	0.66	rs11686541	ENSG00000163016.8	ALMS1P	12.1	1.59e-29	2.07e-26	0.84	0.49	Metabolite levels;	chr2:73477348	chr2:73644919~73685576:+
THCA	cis	rs8040855	0.627	rs4843019	ENSG00000259295.5	CSPG4P12	-12.1	1.6e-29	2.08e-26	-0.73	-0.49	Bulimia nervosa;	chr15:85101228	chr15:85191438~85213905:+
THCA	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-12.1	1.61e-29	2.09e-26	-0.35	-0.49	Height;	chr11:118749988	chr11:118791254~118793137:+
THCA	cis	rs2274273	0.84	rs66486619	ENSG00000258413.1	RP11-665C16.6	-12.1	1.61e-29	2.09e-26	-0.62	-0.49	Protein biomarker;	chr14:55402837	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.588	rs7145727	ENSG00000258413.1	RP11-665C16.6	-12.1	1.61e-29	2.09e-26	-0.63	-0.49	Protein biomarker;	chr14:55380855	chr14:55262767~55272075:-
THCA	cis	rs7772486	0.686	rs9403741	ENSG00000235652.6	RP11-545I5.3	-12.1	1.62e-29	2.1e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145709412	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9485019	ENSG00000235652.6	RP11-545I5.3	-12.1	1.62e-29	2.1e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145725245	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9322043	ENSG00000235652.6	RP11-545I5.3	12.1	1.62e-29	2.1e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:146031554	chr6:145799409~145886585:+
THCA	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-12.1	1.62e-29	2.11e-26	-0.36	-0.49	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-12.1	1.62e-29	2.11e-26	-0.36	-0.49	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
THCA	cis	rs9928842	0.941	rs1808427	ENSG00000280152.1	RP11-331F4.5	12.1	1.64e-29	2.12e-26	0.68	0.49	Alcoholic chronic pancreatitis;	chr16:75207496	chr16:75245994~75250077:-
THCA	cis	rs4718428	0.705	rs28648401	ENSG00000273142.1	RP11-458F8.4	-12.09	1.66e-29	2.15e-26	-0.45	-0.49	Corneal structure;	chr7:66902145	chr7:66902857~66906297:+
THCA	cis	rs4718428	0.607	rs66954441	ENSG00000273142.1	RP11-458F8.4	-12.09	1.66e-29	2.15e-26	-0.45	-0.49	Corneal structure;	chr7:66904222	chr7:66902857~66906297:+
THCA	cis	rs11722779	0.903	rs6830193	ENSG00000246560.2	RP11-10L12.4	12.09	1.67e-29	2.16e-26	0.61	0.49	Schizophrenia;	chr4:102955457	chr4:102828055~102844075:+
THCA	cis	rs4964805	0.594	rs954920	ENSG00000257681.1	RP11-341G23.4	12.09	1.67e-29	2.17e-26	0.57	0.49	Attention deficit hyperactivity disorder;	chr12:103779532	chr12:103746315~103768858:-
THCA	cis	rs875971	1	rs709597	ENSG00000237310.1	GS1-124K5.4	-12.09	1.69e-29	2.19e-26	-0.36	-0.49	Aortic root size;	chr7:66360996	chr7:66493706~66495474:+
THCA	cis	rs4718428	0.705	rs4718424	ENSG00000273142.1	RP11-458F8.4	-12.09	1.71e-29	2.22e-26	-0.45	-0.49	Corneal structure;	chr7:66911108	chr7:66902857~66906297:+
THCA	cis	rs9322193	0.543	rs9371533	ENSG00000268592.3	RAET1E-AS1	12.09	1.74e-29	2.26e-26	0.66	0.49	Lung cancer;	chr6:149889545	chr6:149863494~149919507:+
THCA	cis	rs8040855	0.597	rs12902942	ENSG00000259295.5	CSPG4P12	12.09	1.76e-29	2.28e-26	0.73	0.49	Bulimia nervosa;	chr15:85041573	chr15:85191438~85213905:+
THCA	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-12.09	1.76e-29	2.28e-26	-0.63	-0.49	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
THCA	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-12.09	1.77e-29	2.29e-26	-0.58	-0.49	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
THCA	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-12.09	1.78e-29	2.3e-26	-0.6	-0.49	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
THCA	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-12.09	1.78e-29	2.31e-26	-0.51	-0.49	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
THCA	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-12.09	1.78e-29	2.31e-26	-0.36	-0.49	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
THCA	cis	rs4718428	0.672	rs36038499	ENSG00000273142.1	RP11-458F8.4	-12.09	1.79e-29	2.32e-26	-0.45	-0.49	Corneal structure;	chr7:66824628	chr7:66902857~66906297:+
THCA	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-12.09	1.79e-29	2.32e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
THCA	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	12.09	1.79e-29	2.32e-26	0.61	0.49	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
THCA	cis	rs7772486	0.624	rs6930154	ENSG00000235652.6	RP11-545I5.3	-12.09	1.8e-29	2.33e-26	-0.46	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145704526	chr6:145799409~145886585:+
THCA	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	12.09	1.81e-29	2.34e-26	0.56	0.49	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
THCA	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-12.08	1.83e-29	2.36e-26	-0.37	-0.49	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-12.08	1.83e-29	2.36e-26	-0.37	-0.49	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
THCA	cis	rs4713118	0.587	rs61471148	ENSG00000280107.1	AL022393.9	-12.08	1.83e-29	2.37e-26	-0.58	-0.49	Parkinson's disease;	chr6:28069254	chr6:28170845~28172521:+
THCA	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	12.08	1.84e-29	2.38e-26	0.84	0.49	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
THCA	cis	rs3762637	1	rs10934602	ENSG00000272758.4	RP11-299J3.8	12.08	1.84e-29	2.39e-26	0.63	0.49	LDL cholesterol levels;	chr3:122504335	chr3:122416207~122443180:+
THCA	cis	rs875971	0.964	rs60193905	ENSG00000237310.1	GS1-124K5.4	12.08	1.86e-29	2.4e-26	0.36	0.49	Aortic root size;	chr7:66506273	chr7:66493706~66495474:+
THCA	cis	rs875971	0.929	rs10950041	ENSG00000237310.1	GS1-124K5.4	12.08	1.86e-29	2.4e-26	0.36	0.49	Aortic root size;	chr7:66508888	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs12533997	ENSG00000237310.1	GS1-124K5.4	12.08	1.87e-29	2.42e-26	0.36	0.49	Aortic root size;	chr7:66500390	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs10257427	ENSG00000237310.1	GS1-124K5.4	-12.08	1.89e-29	2.44e-26	-0.36	-0.49	Aortic root size;	chr7:66278221	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs10215948	ENSG00000237310.1	GS1-124K5.4	-12.08	1.89e-29	2.44e-26	-0.36	-0.49	Aortic root size;	chr7:66282799	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs55748098	ENSG00000237310.1	GS1-124K5.4	-12.08	1.89e-29	2.44e-26	-0.36	-0.49	Aortic root size;	chr7:66298631	chr7:66493706~66495474:+
THCA	cis	rs1431005	0.858	rs11132461	ENSG00000250620.1	RP11-91J3.3	-12.08	1.89e-29	2.45e-26	-0.62	-0.49	Response to statin therapy;	chr4:187509161	chr4:187413564~187415697:+
THCA	cis	rs6570726	0.846	rs7773939	ENSG00000235652.6	RP11-545I5.3	-12.08	1.89e-29	2.45e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145606248	chr6:145799409~145886585:+
THCA	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.48e-26	0.61	0.49	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.48e-26	0.61	0.49	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
THCA	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.48e-26	0.61	0.49	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.49e-26	0.6	0.49	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
THCA	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.49e-26	0.6	0.49	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
THCA	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.49e-26	0.6	0.49	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	12.08	1.92e-29	2.49e-26	0.6	0.49	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
THCA	cis	rs7772486	0.597	rs2485631	ENSG00000235652.6	RP11-545I5.3	12.08	1.94e-29	2.51e-26	0.48	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145868941	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.641	rs2253757	ENSG00000235652.6	RP11-545I5.3	12.08	1.94e-29	2.51e-26	0.48	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145878550	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.837	rs7146748	ENSG00000258413.1	RP11-665C16.6	-12.08	1.96e-29	2.53e-26	-0.62	-0.49	Protein biomarker;	chr14:55280368	chr14:55262767~55272075:-
THCA	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	12.08	1.96e-29	2.54e-26	0.39	0.49	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
THCA	cis	rs4718428	0.705	rs3800817	ENSG00000226824.5	RP4-756H11.3	-12.08	1.98e-29	2.56e-26	-0.7	-0.49	Corneal structure;	chr7:66798563	chr7:66654538~66669855:+
THCA	cis	rs853679	0.517	rs1947863	ENSG00000280107.1	AL022393.9	-12.08	1.98e-29	2.56e-26	-0.6	-0.49	Depression;	chr6:28131566	chr6:28170845~28172521:+
THCA	cis	rs526231	0.543	rs34808	ENSG00000175749.11	EIF3KP1	12.08	1.99e-29	2.57e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103093484	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs34809	ENSG00000175749.11	EIF3KP1	12.08	1.99e-29	2.57e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103094413	chr5:103032376~103033031:+
THCA	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	12.07	2e-29	2.58e-26	0.56	0.49	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
THCA	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	12.07	2.02e-29	2.6e-26	0.35	0.49	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
THCA	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	12.07	2.02e-29	2.6e-26	0.35	0.49	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	12.07	2.02e-29	2.6e-26	0.35	0.49	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	12.07	2.02e-29	2.6e-26	0.35	0.49	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	12.07	2.02e-29	2.6e-26	0.35	0.49	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
THCA	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	12.07	2.02e-29	2.61e-26	0.63	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
THCA	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	12.07	2.02e-29	2.61e-26	0.63	0.49	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	12.07	2.02e-29	2.61e-26	0.63	0.49	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
THCA	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-12.07	2.03e-29	2.62e-26	-0.52	-0.49	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
THCA	cis	rs11105298	0.891	rs11105302	ENSG00000258302.2	RP11-981P6.1	-12.07	2.03e-29	2.62e-26	-0.46	-0.49	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497589	chr12:89561129~89594878:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000228039.3	KB-1125A3.10	12.07	2.03e-29	2.62e-26	0.61	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23963780~23964374:+
THCA	cis	rs8040855	0.627	rs12909130	ENSG00000259295.5	CSPG4P12	12.07	2.05e-29	2.65e-26	0.73	0.49	Bulimia nervosa;	chr15:85047270	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.627	rs72757059	ENSG00000259295.5	CSPG4P12	12.07	2.09e-29	2.69e-26	0.73	0.49	Bulimia nervosa;	chr15:85059918	chr15:85191438~85213905:+
THCA	cis	rs673078	0.615	rs16948204	ENSG00000275759.1	RP11-131L12.3	-12.07	2.13e-29	2.75e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118258252	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs7303417	ENSG00000275759.1	RP11-131L12.3	-12.07	2.13e-29	2.75e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118258859	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs16948230	ENSG00000275759.1	RP11-131L12.3	-12.07	2.13e-29	2.75e-26	-0.75	-0.49	Glucose homeostasis traits;	chr12:118277086	chr12:118428281~118428870:+
THCA	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-12.07	2.14e-29	2.76e-26	-0.35	-0.49	Height;	chr11:118747911	chr11:118791254~118793137:+
THCA	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	12.07	2.15e-29	2.77e-26	0.36	0.49	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	12.07	2.15e-29	2.77e-26	0.36	0.49	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
THCA	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	12.07	2.15e-29	2.77e-26	0.36	0.49	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
THCA	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-12.07	2.15e-29	2.77e-26	-0.36	-0.49	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.686	rs1337841	ENSG00000235652.6	RP11-545I5.3	-12.07	2.15e-29	2.77e-26	-0.45	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145738351	chr6:145799409~145886585:+
THCA	cis	rs934734	0.532	rs62141075	ENSG00000204929.10	AC074391.1	-12.07	2.16e-29	2.79e-26	-0.59	-0.49	Rheumatoid arthritis;	chr2:65417482	chr2:65436711~66084639:+
THCA	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	12.07	2.18e-29	2.82e-26	0.56	0.49	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
THCA	cis	rs1858037	0.867	rs964505	ENSG00000204929.10	AC074391.1	12.07	2.19e-29	2.82e-26	0.63	0.49	Rheumatoid arthritis;	chr2:65396055	chr2:65436711~66084639:+
THCA	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	12.06	2.19e-29	2.82e-26	0.85	0.49	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
THCA	cis	rs12468226	0.938	rs3731700	ENSG00000273456.1	RP11-686O6.2	12.06	2.19e-29	2.83e-26	0.6	0.49	Urate levels;	chr2:202291213	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs12464254	ENSG00000273456.1	RP11-686O6.2	12.06	2.19e-29	2.83e-26	0.6	0.49	Urate levels;	chr2:202301641	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs12471060	ENSG00000273456.1	RP11-686O6.2	12.06	2.19e-29	2.83e-26	0.6	0.49	Urate levels;	chr2:202309597	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs80315897	ENSG00000273456.1	RP11-686O6.2	12.06	2.19e-29	2.83e-26	0.6	0.49	Urate levels;	chr2:202318044	chr2:202374932~202375604:-
THCA	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	12.06	2.2e-29	2.83e-26	0.61	0.49	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
THCA	cis	rs4718428	0.705	rs68168107	ENSG00000226824.5	RP4-756H11.3	-12.06	2.2e-29	2.84e-26	-0.71	-0.49	Corneal structure;	chr7:66790251	chr7:66654538~66669855:+
THCA	cis	rs5769707	0.642	rs4824070	ENSG00000188511.11	C22orf34	12.06	2.2e-29	2.84e-26	0.64	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49637873	chr22:49414524~49657542:-
THCA	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-12.06	2.23e-29	2.87e-26	-0.65	-0.49	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
THCA	cis	rs67311347	0.955	rs1129200	ENSG00000223797.4	ENTPD3-AS1	12.06	2.24e-29	2.88e-26	0.4	0.49	Renal cell carcinoma;	chr3:40490766	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs67680017	ENSG00000223797.4	ENTPD3-AS1	12.06	2.24e-29	2.88e-26	0.4	0.49	Renal cell carcinoma;	chr3:40491673	chr3:40313802~40453329:-
THCA	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	12.06	2.24e-29	2.88e-26	0.57	0.49	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
THCA	cis	rs11722779	0.903	rs13130741	ENSG00000246560.2	RP11-10L12.4	12.06	2.26e-29	2.91e-26	0.61	0.49	Schizophrenia;	chr4:103035799	chr4:102828055~102844075:+
THCA	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-12.06	2.29e-29	2.95e-26	-0.83	-0.49	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
THCA	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-12.06	2.3e-29	2.96e-26	-0.6	-0.49	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
THCA	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	12.06	2.3e-29	2.97e-26	0.36	0.49	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
THCA	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	12.06	2.3e-29	2.97e-26	0.54	0.49	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
THCA	cis	rs6570726	0.791	rs6902410	ENSG00000235652.6	RP11-545I5.3	12.06	2.31e-29	2.97e-26	0.46	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145584125	chr6:145799409~145886585:+
THCA	cis	rs12458462	0.812	rs34583578	ENSG00000274828.1	RP11-567M16.6	12.06	2.31e-29	2.98e-26	0.41	0.49	Monocyte count;	chr18:79731070	chr18:79677287~79679358:-
THCA	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-12.06	2.32e-29	2.99e-26	-0.54	-0.49	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
THCA	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	12.06	2.32e-29	2.99e-26	0.61	0.49	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
THCA	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	12.06	2.33e-29	2.99e-26	0.51	0.49	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
THCA	cis	rs875971	0.895	rs3857684	ENSG00000237310.1	GS1-124K5.4	12.06	2.33e-29	2.99e-26	0.35	0.49	Aortic root size;	chr7:66473171	chr7:66493706~66495474:+
THCA	cis	rs227275	0.554	rs223485	ENSG00000246560.2	RP11-10L12.4	12.06	2.36e-29	3.03e-26	0.59	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102764018	chr4:102828055~102844075:+
THCA	cis	rs526231	0.543	rs152134	ENSG00000175749.11	EIF3KP1	12.06	2.37e-29	3.04e-26	0.64	0.49	Primary biliary cholangitis;	chr5:103176745	chr5:103032376~103033031:+
THCA	cis	rs524281	0.861	rs535395	ENSG00000255320.1	RP11-755F10.1	-12.06	2.38e-29	3.06e-26	-0.69	-0.49	Electroencephalogram traits;	chr11:66139063	chr11:66244840~66246239:-
THCA	cis	rs11098499	0.644	rs7676296	ENSG00000245958.5	RP11-33B1.1	-12.06	2.39e-29	3.07e-26	-0.47	-0.49	Corneal astigmatism;	chr4:119634532	chr4:119454791~119552025:+
THCA	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-12.05	2.4e-29	3.09e-26	-0.54	-0.49	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
THCA	cis	rs875971	0.965	rs9969301	ENSG00000237310.1	GS1-124K5.4	-12.05	2.42e-29	3.11e-26	-0.35	-0.49	Aortic root size;	chr7:66316668	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs709595	ENSG00000237310.1	GS1-124K5.4	12.05	2.42e-29	3.11e-26	0.35	0.49	Aortic root size;	chr7:66352346	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs811880	ENSG00000237310.1	GS1-124K5.4	12.05	2.42e-29	3.11e-26	0.35	0.49	Aortic root size;	chr7:66353659	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	12.05	2.43e-29	3.12e-26	0.56	0.49	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
THCA	cis	rs4819052	0.851	rs2838855	ENSG00000223768.1	LINC00205	12.05	2.45e-29	3.15e-26	0.45	0.49	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.686	rs6933161	ENSG00000235652.6	RP11-545I5.3	-12.05	2.45e-29	3.15e-26	-0.44	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145760233	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9399565	ENSG00000235652.6	RP11-545I5.3	-12.05	2.45e-29	3.15e-26	-0.44	-0.49	Lobe attachment (rater-scored or self-reported);	chr6:145760770	chr6:145799409~145886585:+
THCA	cis	rs526231	0.543	rs40092	ENSG00000175749.11	EIF3KP1	12.05	2.45e-29	3.15e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103088509	chr5:103032376~103033031:+
THCA	cis	rs875971	1	rs11974264	ENSG00000237310.1	GS1-124K5.4	-12.05	2.46e-29	3.16e-26	-0.35	-0.49	Aortic root size;	chr7:66182595	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs1540651	ENSG00000237310.1	GS1-124K5.4	-12.05	2.46e-29	3.16e-26	-0.35	-0.49	Aortic root size;	chr7:66185134	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs778723	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66364510	chr7:66493706~66495474:+
THCA	cis	rs875971	0.929	rs778712	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66384991	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778710	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66389847	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs778708	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66391332	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778696	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66405826	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs778694	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66406571	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs4718344	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66409394	chr7:66493706~66495474:+
THCA	cis	rs875971	0.737	rs7803424	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66415618	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs7799834	ENSG00000237310.1	GS1-124K5.4	12.05	2.46e-29	3.16e-26	0.35	0.49	Aortic root size;	chr7:66415707	chr7:66493706~66495474:+
THCA	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	12.05	2.47e-29	3.17e-26	0.58	0.49	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
THCA	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	12.05	2.49e-29	3.2e-26	0.61	0.49	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
THCA	cis	rs1891275	0.551	rs2421621	ENSG00000228701.1	TNKS2-AS1	-12.05	2.49e-29	3.2e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91640344	chr10:91782839~91798291:-
THCA	cis	rs9322193	0.884	rs9397036	ENSG00000223701.3	RAET1E-AS1	12.05	2.51e-29	3.23e-26	0.66	0.49	Lung cancer;	chr6:149851787	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs9383864	ENSG00000223701.3	RAET1E-AS1	12.05	2.51e-29	3.23e-26	0.66	0.49	Lung cancer;	chr6:149851969	chr6:149884431~149919508:+
THCA	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	12.05	2.52e-29	3.24e-26	0.57	0.49	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
THCA	cis	rs1891275	0.551	rs4933681	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91643365	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs7071844	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91644092	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs4933684	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91647805	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs4933687	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91650642	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs7088831	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91652695	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.576	rs2000178	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91653287	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2027486	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91654229	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421623	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91654700	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs10881941	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91655154	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.576	rs10881942	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91655263	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.516	rs10881943	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91655373	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs7087959	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91656160	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421624	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91656659	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs7908980	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91659545	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs4933690	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91659810	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.576	rs4933216	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91659825	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs4933691	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91660200	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421628	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91662412	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-12.05	2.54e-29	3.25e-26	-0.54	-0.49	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
THCA	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	12.05	2.55e-29	3.27e-26	0.58	0.49	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
THCA	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-12.05	2.56e-29	3.28e-26	-0.52	-0.49	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
THCA	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	12.05	2.58e-29	3.3e-26	0.59	0.49	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
THCA	cis	rs10028773	0.515	rs9994651	ENSG00000245958.5	RP11-33B1.1	-12.05	2.61e-29	3.34e-26	-0.45	-0.49	Educational attainment;	chr4:119666648	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.764	rs2265468	ENSG00000235652.6	RP11-545I5.3	12.04	2.64e-29	3.38e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145897210	chr6:145799409~145886585:+
THCA	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	12.04	2.67e-29	3.42e-26	0.66	0.49	Depression;	chr6:28086929	chr6:28115628~28116551:+
THCA	cis	rs526231	0.543	rs34807	ENSG00000175749.11	EIF3KP1	12.04	2.69e-29	3.43e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103092818	chr5:103032376~103033031:+
THCA	cis	rs9928842	0.823	rs8061356	ENSG00000280152.1	RP11-331F4.5	12.04	2.7e-29	3.45e-26	0.66	0.49	Alcoholic chronic pancreatitis;	chr16:75260334	chr16:75245994~75250077:-
THCA	cis	rs526231	0.511	rs27896	ENSG00000175749.11	EIF3KP1	12.04	2.71e-29	3.47e-26	0.64	0.49	Primary biliary cholangitis;	chr5:103152867	chr5:103032376~103033031:+
THCA	cis	rs944289	0.557	rs8016147	ENSG00000257826.1	RP11-116N8.4	-12.04	2.73e-29	3.48e-26	-0.53	-0.49	Thyroid cancer;	chr14:36111685	chr14:36061026~36067190:-
THCA	cis	rs11690935	0.879	rs13017585	ENSG00000228389.1	AC068039.4	12.04	2.73e-29	3.48e-26	0.57	0.49	Schizophrenia;	chr2:171865298	chr2:171773482~171775844:+
THCA	cis	rs227275	0.556	rs6815526	ENSG00000246560.2	RP11-10L12.4	12.04	2.73e-29	3.49e-26	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102899729	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs6824070	ENSG00000246560.2	RP11-10L12.4	12.04	2.73e-29	3.49e-26	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102901676	chr4:102828055~102844075:+
THCA	cis	rs11722779	0.935	rs6856176	ENSG00000246560.2	RP11-10L12.4	12.04	2.73e-29	3.49e-26	0.61	0.49	Schizophrenia;	chr4:102902574	chr4:102828055~102844075:+
THCA	cis	rs227275	0.556	rs11722779	ENSG00000246560.2	RP11-10L12.4	12.04	2.73e-29	3.49e-26	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102906331	chr4:102828055~102844075:+
THCA	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-12.04	2.73e-29	3.49e-26	-0.54	-0.49	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
THCA	cis	rs227275	0.556	rs28367331	ENSG00000246560.2	RP11-10L12.4	12.04	2.74e-29	3.5e-26	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102900734	chr4:102828055~102844075:+
THCA	cis	rs4964805	0.672	rs11111757	ENSG00000257681.1	RP11-341G23.4	12.04	2.76e-29	3.53e-26	0.55	0.49	Attention deficit hyperactivity disorder;	chr12:103766984	chr12:103746315~103768858:-
THCA	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-12.04	2.8e-29	3.57e-26	-0.36	-0.49	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
THCA	cis	rs526231	0.575	rs55652053	ENSG00000175749.11	EIF3KP1	12.04	2.81e-29	3.58e-26	0.65	0.49	Primary biliary cholangitis;	chr5:103001466	chr5:103032376~103033031:+
THCA	cis	rs9481169	0.557	rs73534579	ENSG00000255389.1	C6orf3	-12.04	2.82e-29	3.6e-26	-0.92	-0.49	Inflammatory skin disease;	chr6:111589486	chr6:111599875~111602295:+
THCA	cis	rs4964805	0.802	rs11111778	ENSG00000257681.1	RP11-341G23.4	12.04	2.84e-29	3.62e-26	0.59	0.49	Attention deficit hyperactivity disorder;	chr12:103791653	chr12:103746315~103768858:-
THCA	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	12.04	2.84e-29	3.62e-26	0.39	0.49	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
THCA	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-12.04	2.88e-29	3.68e-26	-0.6	-0.49	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
THCA	cis	rs6496932	1	rs34434405	ENSG00000218052.5	ADAMTS7P4	12.03	2.93e-29	3.73e-26	0.67	0.49	Central corneal thickness;Corneal structure;	chr15:85281437	chr15:85255369~85330334:-
THCA	cis	rs7772486	0.686	rs1045820	ENSG00000235652.6	RP11-545I5.3	12.03	2.95e-29	3.77e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145625944	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs6570703	ENSG00000235652.6	RP11-545I5.3	12.03	2.95e-29	3.77e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145635916	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs6570705	ENSG00000235652.6	RP11-545I5.3	12.03	2.95e-29	3.77e-26	0.45	0.49	Lobe attachment (rater-scored or self-reported);	chr6:145640065	chr6:145799409~145886585:+
THCA	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-12.03	2.97e-29	3.78e-26	-0.6	-0.49	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
THCA	cis	rs875971	1	rs6958271	ENSG00000237310.1	GS1-124K5.4	12.03	3.04e-29	3.88e-26	0.35	0.49	Aortic root size;	chr7:66514344	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6958277	ENSG00000237310.1	GS1-124K5.4	12.03	3.04e-29	3.88e-26	0.35	0.49	Aortic root size;	chr7:66514362	chr7:66493706~66495474:+
THCA	cis	rs11148252	0.532	rs9536190	ENSG00000235660.1	LINC00345	-12.03	3.05e-29	3.89e-26	-0.63	-0.49	Lewy body disease;	chr13:52606909	chr13:52484161~52484680:-
THCA	cis	rs227275	0.525	rs4596243	ENSG00000246560.2	RP11-10L12.4	12.03	3.06e-29	3.89e-26	0.61	0.49	Allergic disease (asthma, hay fever or eczema);	chr4:102964411	chr4:102828055~102844075:+
THCA	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-12.03	3.08e-29	3.92e-26	-0.54	-0.49	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
THCA	cis	rs524281	0.814	rs1055615	ENSG00000255320.1	RP11-755F10.1	12.03	3.11e-29	3.96e-26	0.69	0.49	Electroencephalogram traits;	chr11:66079451	chr11:66244840~66246239:-
THCA	cis	rs934734	0.532	rs12470883	ENSG00000204929.10	AC074391.1	-12.03	3.12e-29	3.98e-26	-0.59	-0.49	Rheumatoid arthritis;	chr2:65424717	chr2:65436711~66084639:+
THCA	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	12.03	3.14e-29	3.99e-26	0.64	0.49	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
THCA	cis	rs526231	0.543	rs34765	ENSG00000175749.11	EIF3KP1	12.03	3.14e-29	4e-26	0.64	0.49	Primary biliary cholangitis;	chr5:103171160	chr5:103032376~103033031:+
THCA	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	12.02	3.18e-29	4.05e-26	0.35	0.49	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
THCA	cis	rs934734	0.571	rs7572922	ENSG00000204929.10	AC074391.1	-12.02	3.19e-29	4.05e-26	-0.59	-0.49	Rheumatoid arthritis;	chr2:65425022	chr2:65436711~66084639:+
THCA	cis	rs9928842	0.882	rs9319481	ENSG00000280152.1	RP11-331F4.5	12.02	3.22e-29	4.09e-26	0.7	0.48	Alcoholic chronic pancreatitis;	chr16:75225580	chr16:75245994~75250077:-
THCA	cis	rs9928842	0.882	rs1107593	ENSG00000280152.1	RP11-331F4.5	12.02	3.22e-29	4.09e-26	0.7	0.48	Alcoholic chronic pancreatitis;	chr16:75227431	chr16:75245994~75250077:-
THCA	cis	rs9928842	0.824	rs12924999	ENSG00000280152.1	RP11-331F4.5	12.02	3.22e-29	4.09e-26	0.7	0.48	Alcoholic chronic pancreatitis;	chr16:75228527	chr16:75245994~75250077:-
THCA	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	12.02	3.26e-29	4.14e-26	0.56	0.48	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	12.02	3.26e-29	4.14e-26	0.56	0.48	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	12.02	3.26e-29	4.14e-26	0.56	0.48	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
THCA	cis	rs7772486	0.536	rs9373467	ENSG00000235652.6	RP11-545I5.3	12.02	3.28e-29	4.17e-26	0.49	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145634469	chr6:145799409~145886585:+
THCA	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-12.02	3.28e-29	4.17e-26	-0.84	-0.48	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
THCA	cis	rs228614	0.509	rs223481	ENSG00000246560.2	RP11-10L12.4	12.02	3.31e-29	4.21e-26	0.59	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766860	chr4:102828055~102844075:+
THCA	cis	rs7773456	0.576	rs12206194	ENSG00000228412.5	RP4-625H18.2	12.02	3.31e-29	4.21e-26	0.73	0.48	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19802164~19804752:-
THCA	cis	rs5769707	0.521	rs5769719	ENSG00000188511.11	C22orf34	12.02	3.33e-29	4.24e-26	0.61	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49414524~49657542:-
THCA	cis	rs5769707	0.521	rs5769720	ENSG00000188511.11	C22orf34	12.02	3.33e-29	4.24e-26	0.61	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49414524~49657542:-
THCA	cis	rs5769707	0.521	rs5770633	ENSG00000188511.11	C22orf34	12.02	3.33e-29	4.24e-26	0.61	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49414524~49657542:-
THCA	cis	rs7772486	0.79	rs9376970	ENSG00000235652.6	RP11-545I5.3	-12.02	3.33e-29	4.24e-26	-0.45	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145920336	chr6:145799409~145886585:+
THCA	cis	rs875971	1	rs6945843	ENSG00000237310.1	GS1-124K5.4	-12.02	3.35e-29	4.25e-26	-0.35	-0.48	Aortic root size;	chr7:66269796	chr7:66493706~66495474:+
THCA	cis	rs4819052	0.851	rs914214	ENSG00000223768.1	LINC00205	-12.02	3.36e-29	4.26e-26	-0.46	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45293285~45297354:+
THCA	cis	rs228614	0.509	rs223482	ENSG00000246560.2	RP11-10L12.4	12.02	3.38e-29	4.29e-26	0.59	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102766051	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs223478	ENSG00000246560.2	RP11-10L12.4	12.02	3.38e-29	4.29e-26	0.59	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102768648	chr4:102828055~102844075:+
THCA	cis	rs228614	0.536	rs150898	ENSG00000246560.2	RP11-10L12.4	12.02	3.38e-29	4.29e-26	0.59	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102769234	chr4:102828055~102844075:+
THCA	cis	rs7182621	0.639	rs1561048	ENSG00000259363.4	CTD-2054N24.2	-12.02	3.38e-29	4.29e-26	-0.71	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99875369	chr15:99807023~99877148:+
THCA	cis	rs6496932	0.802	rs10163187	ENSG00000218052.5	ADAMTS7P4	12.02	3.38e-29	4.3e-26	0.63	0.48	Central corneal thickness;Corneal structure;	chr15:85327287	chr15:85255369~85330334:-
THCA	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	12.02	3.42e-29	4.34e-26	0.71	0.48	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
THCA	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-12.02	3.42e-29	4.35e-26	-0.6	-0.48	Height;	chr3:53093751	chr3:53064283~53065091:-
THCA	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	12.02	3.43e-29	4.36e-26	0.58	0.48	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
THCA	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	12.02	3.45e-29	4.38e-26	0.61	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	12.02	3.45e-29	4.38e-26	0.61	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
THCA	cis	rs7182621	0.883	rs10468181	ENSG00000259363.4	CTD-2054N24.2	-12.02	3.45e-29	4.38e-26	-0.59	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99885244	chr15:99807023~99877148:+
THCA	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-12.02	3.46e-29	4.39e-26	-0.45	-0.48	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
THCA	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-12.01	3.5e-29	4.44e-26	-0.55	-0.48	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
THCA	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	12.01	3.5e-29	4.44e-26	0.56	0.48	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	12.01	3.5e-29	4.44e-26	0.56	0.48	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	12.01	3.5e-29	4.44e-26	0.56	0.48	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
THCA	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-12.01	3.52e-29	4.46e-26	-0.36	-0.48	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-12.01	3.52e-29	4.46e-26	-0.36	-0.48	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-12.01	3.52e-29	4.46e-26	-0.36	-0.48	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-12.01	3.52e-29	4.46e-26	-0.36	-0.48	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	12.01	3.52e-29	4.46e-26	0.36	0.48	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	12.01	3.53e-29	4.48e-26	0.36	0.48	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	12.01	3.53e-29	4.48e-26	0.36	0.48	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	12.01	3.53e-29	4.48e-26	0.36	0.48	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	12.01	3.53e-29	4.48e-26	0.36	0.48	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
THCA	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	12.01	3.54e-29	4.49e-26	0.56	0.48	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
THCA	cis	rs853679	0.517	rs9380056	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Depression;	chr6:28136698	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380057	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Depression;	chr6:28136856	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs1947862	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Depression;	chr6:28137418	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs6941992	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Depression;	chr6:28138363	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.516	rs4713142	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Parkinson's disease;	chr6:28138569	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs4713143	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Depression;	chr6:28138981	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs4713144	ENSG00000280107.1	AL022393.9	-12.01	3.55e-29	4.5e-26	-0.59	-0.48	Depression;	chr6:28139012	chr6:28170845~28172521:+
THCA	cis	rs4819052	1	rs2297284	ENSG00000223768.1	LINC00205	-12.01	3.55e-29	4.5e-26	-0.5	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45293285~45297354:+
THCA	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-12.01	3.57e-29	4.52e-26	-0.64	-0.48	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
THCA	cis	rs9322193	0.607	rs12210822	ENSG00000231760.4	RP11-350J20.5	12.01	3.58e-29	4.53e-26	0.7	0.48	Lung cancer;	chr6:149905356	chr6:149796151~149826294:-
THCA	cis	rs7772486	0.686	rs1292336	ENSG00000235652.6	RP11-545I5.3	-12.01	3.59e-29	4.55e-26	-0.45	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145646682	chr6:145799409~145886585:+
THCA	cis	rs875971	0.895	rs4145009	ENSG00000237310.1	GS1-124K5.4	-12.01	3.6e-29	4.56e-26	-0.36	-0.48	Aortic root size;	chr7:66261628	chr7:66493706~66495474:+
THCA	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-12.01	3.6e-29	4.56e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
THCA	cis	rs11105298	0.891	rs1054807	ENSG00000258302.2	RP11-981P6.1	12.01	3.62e-29	4.58e-26	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89519642	chr12:89561129~89594878:+
THCA	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-12.01	3.64e-29	4.61e-26	-0.35	-0.48	Height;	chr11:118746590	chr11:118791254~118793137:+
THCA	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	12.01	3.66e-29	4.63e-26	0.61	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-12.01	3.67e-29	4.65e-26	-0.65	-0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
THCA	cis	rs7182621	0.512	rs71403471	ENSG00000259363.4	CTD-2054N24.2	-12.01	3.67e-29	4.65e-26	-0.71	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99807023~99877148:+
THCA	cis	rs1061377	0.585	rs12648581	ENSG00000249207.1	RP11-360F5.1	-12.01	3.68e-29	4.66e-26	-0.59	-0.48	Uric acid levels;	chr4:39054024	chr4:39112677~39126818:-
THCA	cis	rs10853057	0.85	rs35151435	ENSG00000214174.7	AMZ2P1	12.01	3.68e-29	4.66e-26	0.94	0.48	White matter microstructure (global fractional anisotropy);	chr17:65000600	chr17:64966550~64975576:-
THCA	cis	rs6570726	0.791	rs11155426	ENSG00000235652.6	RP11-545I5.3	12.01	3.69e-29	4.67e-26	0.46	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145495994	chr6:145799409~145886585:+
THCA	cis	rs944289	0.646	rs1742868	ENSG00000257826.1	RP11-116N8.4	-12.01	3.69e-29	4.67e-26	-0.49	-0.48	Thyroid cancer;	chr14:36067743	chr14:36061026~36067190:-
THCA	cis	rs8040855	0.627	rs11634975	ENSG00000259295.5	CSPG4P12	12.01	3.74e-29	4.73e-26	0.72	0.48	Bulimia nervosa;	chr15:85063247	chr15:85191438~85213905:+
THCA	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-12.01	3.75e-29	4.75e-26	-0.36	-0.48	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-12.01	3.75e-29	4.75e-26	-0.36	-0.48	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
THCA	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-12.01	3.78e-29	4.78e-26	-0.56	-0.48	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
THCA	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	12.01	3.78e-29	4.78e-26	0.36	0.48	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
THCA	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	12.01	3.78e-29	4.78e-26	0.36	0.48	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
THCA	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-12.01	3.79e-29	4.79e-26	-0.69	-0.48	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
THCA	cis	rs2283792	0.715	rs55891647	ENSG00000224086.5	LL22NC03-86G7.1	-12	3.84e-29	4.86e-26	-0.56	-0.48	Multiple sclerosis;	chr22:21824198	chr22:21938293~21977632:+
THCA	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-12	3.84e-29	4.86e-26	-0.52	-0.48	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
THCA	cis	rs4819052	0.851	rs2838832	ENSG00000223768.1	LINC00205	12	3.89e-29	4.92e-26	0.46	0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.566	rs6912330	ENSG00000231760.4	RP11-350J20.5	-12	3.93e-29	4.97e-26	-0.69	-0.48	Lung cancer;	chr6:149908811	chr6:149796151~149826294:-
THCA	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	12	3.94e-29	4.97e-26	0.36	0.48	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
THCA	cis	rs853679	0.517	rs4713146	ENSG00000280107.1	AL022393.9	-12	3.95e-29	4.99e-26	-0.6	-0.48	Depression;	chr6:28143758	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9393894	ENSG00000280107.1	AL022393.9	-12	3.95e-29	4.99e-26	-0.6	-0.48	Depression;	chr6:28144784	chr6:28170845~28172521:+
THCA	cis	rs7182621	0.546	rs11632596	ENSG00000259363.4	CTD-2054N24.2	-12	3.96e-29	5.01e-26	-0.68	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99834385	chr15:99807023~99877148:+
THCA	cis	rs11098499	0.644	rs28787668	ENSG00000245958.5	RP11-33B1.1	-12	3.99e-29	5.04e-26	-0.47	-0.48	Corneal astigmatism;	chr4:119633532	chr4:119454791~119552025:+
THCA	cis	rs765787	0.53	rs2554453	ENSG00000259520.4	CTD-2651B20.3	12	4e-29	5.05e-26	0.58	0.48	Uric acid levels;	chr15:45229909	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11858988	ENSG00000259520.4	CTD-2651B20.3	12	4e-29	5.05e-26	0.58	0.48	Uric acid levels;	chr15:45229916	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11855435	ENSG00000259520.4	CTD-2651B20.3	12	4e-29	5.05e-26	0.58	0.48	Uric acid levels;	chr15:45229919	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2458224	ENSG00000259520.4	CTD-2651B20.3	12	4e-29	5.05e-26	0.58	0.48	Uric acid levels;	chr15:45229932	chr15:45251580~45279251:-
THCA	cis	rs62103177	0.608	rs8088089	ENSG00000261126.6	RP11-795F19.1	-12	4.07e-29	5.13e-26	-0.54	-0.48	Opioid sensitivity;	chr18:80073851	chr18:80046900~80095482:+
THCA	cis	rs526231	0.543	rs246915	ENSG00000175749.11	EIF3KP1	12	4.08e-29	5.15e-26	0.65	0.48	Primary biliary cholangitis;	chr5:103222343	chr5:103032376~103033031:+
THCA	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-12	4.09e-29	5.16e-26	-0.39	-0.48	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
THCA	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	12	4.1e-29	5.17e-26	0.6	0.48	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
THCA	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	12	4.12e-29	5.2e-26	0.62	0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
THCA	cis	rs853679	0.517	rs4713145	ENSG00000280107.1	AL022393.9	-12	4.17e-29	5.26e-26	-0.59	-0.48	Depression;	chr6:28139049	chr6:28170845~28172521:+
THCA	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	11.99	4.18e-29	5.27e-26	0.56	0.48	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
THCA	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-11.99	4.2e-29	5.3e-26	-0.64	-0.48	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
THCA	cis	rs9322193	0.607	rs915140	ENSG00000231760.4	RP11-350J20.5	11.99	4.21e-29	5.31e-26	0.7	0.48	Lung cancer;	chr6:149899674	chr6:149796151~149826294:-
THCA	cis	rs7188445	0.736	rs7500666	ENSG00000261390.4	RP11-345M22.2	11.99	4.21e-29	5.31e-26	0.57	0.48	Urate levels;	chr16:79672509	chr16:79715232~79770563:-
THCA	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	11.99	4.24e-29	5.34e-26	0.55	0.48	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
THCA	cis	rs6570726	0.791	rs418701	ENSG00000235652.6	RP11-545I5.3	11.99	4.24e-29	5.35e-26	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145568856	chr6:145799409~145886585:+
THCA	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	11.99	4.27e-29	5.38e-26	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
THCA	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	11.99	4.31e-29	5.43e-26	0.64	0.48	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-11.99	4.32e-29	5.45e-26	-0.64	-0.48	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
THCA	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-11.99	4.37e-29	5.51e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
THCA	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-11.99	4.37e-29	5.51e-26	-0.35	-0.48	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
THCA	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	11.99	4.42e-29	5.57e-26	0.55	0.48	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	11.99	4.42e-29	5.57e-26	0.55	0.48	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
THCA	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	11.99	4.43e-29	5.58e-26	0.58	0.48	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
THCA	cis	rs1858037	0.867	rs876933	ENSG00000204929.10	AC074391.1	11.99	4.44e-29	5.59e-26	0.63	0.48	Rheumatoid arthritis;	chr2:65382303	chr2:65436711~66084639:+
THCA	cis	rs11673344	0.864	rs8110696	ENSG00000226686.6	LINC01535	11.99	4.48e-29	5.64e-26	0.58	0.48	Obesity-related traits;	chr19:37009449	chr19:37251912~37265535:+
THCA	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-11.99	4.48e-29	5.64e-26	-0.54	-0.48	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
THCA	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-11.99	4.49e-29	5.65e-26	-0.64	-0.48	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
THCA	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-11.99	4.54e-29	5.72e-26	-0.35	-0.48	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
THCA	cis	rs10463554	0.963	rs62364874	ENSG00000175749.11	EIF3KP1	11.99	4.55e-29	5.73e-26	0.64	0.48	Parkinson's disease;	chr5:103056475	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs62364876	ENSG00000175749.11	EIF3KP1	11.99	4.55e-29	5.73e-26	0.64	0.48	Parkinson's disease;	chr5:103058454	chr5:103032376~103033031:+
THCA	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-11.99	4.58e-29	5.76e-26	-0.64	-0.48	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-11.99	4.58e-29	5.76e-26	-0.64	-0.48	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-11.99	4.58e-29	5.76e-26	-0.64	-0.48	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-11.99	4.58e-29	5.76e-26	-0.64	-0.48	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-11.99	4.58e-29	5.76e-26	-0.64	-0.48	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
THCA	cis	rs11722779	0.844	rs3974602	ENSG00000246560.2	RP11-10L12.4	11.98	4.6e-29	5.79e-26	0.6	0.48	Schizophrenia;	chr4:102928840	chr4:102828055~102844075:+
THCA	cis	rs11105298	0.891	rs10858894	ENSG00000258302.2	RP11-981P6.1	11.98	4.63e-29	5.83e-26	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89520484	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs11105310	ENSG00000258302.2	RP11-981P6.1	11.98	4.63e-29	5.83e-26	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:89561129~89594878:+
THCA	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-11.98	4.65e-29	5.85e-26	-0.59	-0.48	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
THCA	cis	rs227275	0.525	rs13113923	ENSG00000246560.2	RP11-10L12.4	11.98	4.67e-29	5.87e-26	0.6	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102918936	chr4:102828055~102844075:+
THCA	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	11.98	4.73e-29	5.95e-26	0.56	0.48	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
THCA	cis	rs11105298	0.786	rs10858897	ENSG00000258302.2	RP11-981P6.1	11.98	4.75e-29	5.97e-26	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528255	chr12:89561129~89594878:+
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	11.98	4.81e-29	6.05e-26	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
THCA	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	11.98	4.85e-29	6.1e-26	0.56	0.48	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
THCA	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-11.98	4.87e-29	6.12e-26	-0.53	-0.48	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
THCA	cis	rs1891275	0.527	rs35812291	ENSG00000228701.1	TNKS2-AS1	-11.98	4.93e-29	6.2e-26	-0.54	-0.48	Intelligence (multi-trait analysis);	chr10:91642584	chr10:91782839~91798291:-
THCA	cis	rs526231	0.511	rs3756582	ENSG00000175749.11	EIF3KP1	11.98	4.97e-29	6.25e-26	0.64	0.48	Primary biliary cholangitis;	chr5:103003848	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs45518833	ENSG00000175749.11	EIF3KP1	11.98	4.97e-29	6.25e-26	0.64	0.48	Primary biliary cholangitis;	chr5:103007286	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs1826673	ENSG00000175749.11	EIF3KP1	11.98	4.97e-29	6.25e-26	0.64	0.48	Primary biliary cholangitis;	chr5:103010212	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs62362545	ENSG00000175749.11	EIF3KP1	11.98	4.97e-29	6.25e-26	0.64	0.48	Primary biliary cholangitis;	chr5:103011748	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs3910557	ENSG00000175749.11	EIF3KP1	11.98	4.97e-29	6.25e-26	0.64	0.48	Primary biliary cholangitis;	chr5:103014767	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs2288389	ENSG00000175749.11	EIF3KP1	11.98	4.97e-29	6.25e-26	0.64	0.48	Primary biliary cholangitis;	chr5:103018104	chr5:103032376~103033031:+
THCA	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	11.98	4.99e-29	6.26e-26	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	11.98	4.99e-29	6.26e-26	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	11.98	4.99e-29	6.26e-26	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	11.98	4.99e-29	6.26e-26	0.62	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
THCA	cis	rs11105298	0.891	rs12369685	ENSG00000258302.2	RP11-981P6.1	11.98	4.99e-29	6.26e-26	0.47	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:89561129~89594878:+
THCA	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	11.98	5.02e-29	6.3e-26	0.59	0.48	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	11.98	5.02e-29	6.3e-26	0.59	0.48	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
THCA	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-11.98	5.03e-29	6.31e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
THCA	cis	rs7772486	0.875	rs2814863	ENSG00000235652.6	RP11-545I5.3	-11.97	5.05e-29	6.34e-26	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:146026163	chr6:145799409~145886585:+
THCA	cis	rs11105298	0.891	rs11105319	ENSG00000258302.2	RP11-981P6.1	11.97	5.07e-29	6.37e-26	0.47	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89533400	chr12:89561129~89594878:+
THCA	cis	rs12458462	0.851	rs2169249	ENSG00000274828.1	RP11-567M16.6	11.97	5.1e-29	6.4e-26	0.4	0.48	Monocyte count;	chr18:79729649	chr18:79677287~79679358:-
THCA	cis	rs9322193	0.607	rs12209310	ENSG00000231760.4	RP11-350J20.5	11.97	5.11e-29	6.41e-26	0.69	0.48	Lung cancer;	chr6:149904882	chr6:149796151~149826294:-
THCA	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	11.97	5.12e-29	6.43e-26	0.35	0.48	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
THCA	cis	rs992157	0.71	rs56364928	ENSG00000261338.2	RP11-378A13.1	11.97	5.14e-29	6.46e-26	0.5	0.48	Colorectal cancer;	chr2:218194335	chr2:218255319~218257366:+
THCA	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-11.97	5.15e-29	6.47e-26	-0.35	-0.48	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-11.97	5.15e-29	6.47e-26	-0.35	-0.48	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-11.97	5.15e-29	6.47e-26	-0.35	-0.48	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
THCA	cis	rs11098499	0.644	rs10012252	ENSG00000245958.5	RP11-33B1.1	-11.97	5.16e-29	6.48e-26	-0.47	-0.48	Corneal astigmatism;	chr4:119637984	chr4:119454791~119552025:+
THCA	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-11.97	5.21e-29	6.53e-26	-0.56	-0.48	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
THCA	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-11.97	5.24e-29	6.58e-26	-0.35	-0.48	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-11.97	5.24e-29	6.58e-26	-0.35	-0.48	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-11.97	5.24e-29	6.58e-26	-0.35	-0.48	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-11.97	5.24e-29	6.58e-26	-0.35	-0.48	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs11974219	ENSG00000237310.1	GS1-124K5.4	-11.97	5.24e-29	6.58e-26	-0.35	-0.48	Aortic root size;	chr7:66182423	chr7:66493706~66495474:+
THCA	cis	rs12458462	0.892	rs3786228	ENSG00000274828.1	RP11-567M16.6	-11.97	5.29e-29	6.64e-26	-0.4	-0.48	Monocyte count;	chr18:79704170	chr18:79677287~79679358:-
THCA	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-11.97	5.31e-29	6.67e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
THCA	cis	rs853679	0.517	rs9380052	ENSG00000280107.1	AL022393.9	-11.97	5.32e-29	6.67e-26	-0.59	-0.48	Depression;	chr6:28096845	chr6:28170845~28172521:+
THCA	cis	rs6142102	0.961	rs6088360	ENSG00000276073.1	RP5-1125A11.7	-11.97	5.38e-29	6.74e-26	-0.45	-0.48	Skin pigmentation;	chr20:33969383	chr20:33985617~33988989:-
THCA	cis	rs673078	0.66	rs7970481	ENSG00000275759.1	RP11-131L12.3	-11.97	5.38e-29	6.75e-26	-0.75	-0.48	Glucose homeostasis traits;	chr12:118242112	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs58113338	ENSG00000275759.1	RP11-131L12.3	-11.97	5.38e-29	6.75e-26	-0.75	-0.48	Glucose homeostasis traits;	chr12:118251335	chr12:118428281~118428870:+
THCA	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-11.97	5.39e-29	6.75e-26	-0.36	-0.48	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
THCA	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	11.97	5.4e-29	6.76e-26	0.74	0.48	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
THCA	cis	rs67311347	0.955	rs73080163	ENSG00000223797.4	ENTPD3-AS1	11.97	5.44e-29	6.82e-26	0.4	0.48	Renal cell carcinoma;	chr3:40491570	chr3:40313802~40453329:-
THCA	cis	rs67311347	1	rs73080165	ENSG00000223797.4	ENTPD3-AS1	11.97	5.44e-29	6.82e-26	0.4	0.48	Renal cell carcinoma;	chr3:40491571	chr3:40313802~40453329:-
THCA	cis	rs9928842	0.54	rs8051363	ENSG00000280152.1	RP11-331F4.5	11.97	5.45e-29	6.83e-26	0.56	0.48	Alcoholic chronic pancreatitis;	chr16:75221319	chr16:75245994~75250077:-
THCA	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-11.97	5.46e-29	6.84e-26	-0.83	-0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
THCA	cis	rs80028505	0.908	rs7761118	ENSG00000271304.1	DPRXP2	11.97	5.49e-29	6.87e-26	0.78	0.48	Foot ulcer in diabetes and neuropathy;	chr6:36100526	chr6:35989515~35990436:-
THCA	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-11.97	5.49e-29	6.88e-26	-0.83	-0.48	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
THCA	cis	rs9322193	0.923	rs2185352	ENSG00000223701.3	RAET1E-AS1	11.97	5.5e-29	6.89e-26	0.65	0.48	Lung cancer;	chr6:149714640	chr6:149884431~149919508:+
THCA	cis	rs11690935	0.918	rs12692978	ENSG00000228389.1	AC068039.4	11.97	5.5e-29	6.89e-26	0.56	0.48	Schizophrenia;	chr2:171869471	chr2:171773482~171775844:+
THCA	cis	rs7772486	0.597	rs2246132	ENSG00000235652.6	RP11-545I5.3	11.96	5.53e-29	6.93e-26	0.48	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145861379	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs11155674	ENSG00000223701.3	RAET1E-AS1	11.96	5.53e-29	6.93e-26	0.65	0.48	Lung cancer;	chr6:149711111	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs12174349	ENSG00000223701.3	RAET1E-AS1	11.96	5.53e-29	6.93e-26	0.65	0.48	Lung cancer;	chr6:149718012	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs2297932	ENSG00000223701.3	RAET1E-AS1	11.96	5.53e-29	6.93e-26	0.65	0.48	Lung cancer;	chr6:149718225	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs2297930	ENSG00000223701.3	RAET1E-AS1	11.96	5.53e-29	6.93e-26	0.65	0.48	Lung cancer;	chr6:149718360	chr6:149884431~149919508:+
THCA	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-11.96	5.54e-29	6.93e-26	-0.35	-0.48	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
THCA	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
THCA	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
THCA	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-11.96	5.55e-29	6.95e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
THCA	cis	rs944289	0.646	rs394246	ENSG00000257826.1	RP11-116N8.4	11.96	5.58e-29	6.98e-26	0.49	0.48	Thyroid cancer;	chr14:36066074	chr14:36061026~36067190:-
THCA	cis	rs1891275	0.516	rs10881935	ENSG00000228701.1	TNKS2-AS1	-11.96	5.61e-29	7.02e-26	-0.54	-0.48	Intelligence (multi-trait analysis);	chr10:91637944	chr10:91782839~91798291:-
THCA	cis	rs227275	0.556	rs4235407	ENSG00000246560.2	RP11-10L12.4	11.96	5.61e-29	7.02e-26	0.61	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102897427	chr4:102828055~102844075:+
THCA	cis	rs3762637	0.941	rs7653592	ENSG00000272758.4	RP11-299J3.8	-11.96	5.65e-29	7.07e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122499524	chr3:122416207~122443180:+
THCA	cis	rs9322193	0.923	rs2297928	ENSG00000223701.3	RAET1E-AS1	11.96	5.66e-29	7.08e-26	0.65	0.48	Lung cancer;	chr6:149718584	chr6:149884431~149919508:+
THCA	cis	rs10463554	0.927	rs40061	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103067412	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34373	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103068590	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs158253	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103069502	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs158252	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103070546	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs154369	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103071140	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs158246	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103073145	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs158245	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103073801	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.857	rs158397	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103076497	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs158399	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103077564	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs158404	ENSG00000175749.11	EIF3KP1	11.96	5.68e-29	7.1e-26	0.64	0.48	Parkinson's disease;	chr5:103080206	chr5:103032376~103033031:+
THCA	cis	rs10078	1	rs10078	ENSG00000221990.4	EXOC3-AS1	11.96	5.71e-29	7.14e-26	0.41	0.48	Fat distribution (HIV);	chr5:437987	chr5:441498~443160:-
THCA	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-11.96	5.76e-29	7.2e-26	-0.63	-0.48	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
THCA	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-11.96	5.77e-29	7.21e-26	-0.59	-0.48	Height;	chr3:53069965	chr3:53064283~53065091:-
THCA	cis	rs6570726	0.764	rs9403731	ENSG00000235652.6	RP11-545I5.3	11.96	5.85e-29	7.31e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145586801	chr6:145799409~145886585:+
THCA	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	11.96	5.88e-29	7.34e-26	0.6	0.48	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
THCA	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	11.96	5.91e-29	7.37e-26	0.63	0.48	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
THCA	cis	rs7772486	0.846	rs9373482	ENSG00000235652.6	RP11-545I5.3	11.96	5.91e-29	7.37e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146041987	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6570692	ENSG00000235652.6	RP11-545I5.3	11.96	5.94e-29	7.4e-26	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145583265	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.851	rs2838864	ENSG00000223768.1	LINC00205	11.96	5.95e-29	7.41e-26	0.45	0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45293285~45297354:+
THCA	cis	rs875971	1	rs875971	ENSG00000237310.1	GS1-124K5.4	-11.96	5.98e-29	7.44e-26	-0.35	-0.48	Aortic root size;	chr7:66152608	chr7:66493706~66495474:+
THCA	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-11.96	6.04e-29	7.51e-26	-0.64	-0.48	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
THCA	cis	rs9322193	0.847	rs880246	ENSG00000223701.3	RAET1E-AS1	11.95	6.06e-29	7.54e-26	0.67	0.48	Lung cancer;	chr6:149845972	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.79	rs4896852	ENSG00000235652.6	RP11-545I5.3	-11.95	6.11e-29	7.6e-26	-0.45	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145963485	chr6:145799409~145886585:+
THCA	cis	rs227275	0.554	rs6810668	ENSG00000246560.2	RP11-10L12.4	11.95	6.14e-29	7.63e-26	0.61	0.48	Allergic disease (asthma, hay fever or eczema);	chr4:102987574	chr4:102828055~102844075:+
THCA	cis	rs12134133	0.752	rs6540874	ENSG00000274245.1	RP11-357P18.2	11.95	6.14e-29	7.64e-26	0.52	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207372559~207373252:+
THCA	cis	rs12134133	0.752	rs6683677	ENSG00000274245.1	RP11-357P18.2	11.95	6.14e-29	7.64e-26	0.52	0.48	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207372559~207373252:+
THCA	cis	rs875971	0.898	rs6977501	ENSG00000237310.1	GS1-124K5.4	-11.95	6.15e-29	7.65e-26	-0.35	-0.48	Aortic root size;	chr7:66228355	chr7:66493706~66495474:+
THCA	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	11.95	6.15e-29	7.65e-26	0.35	0.48	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
THCA	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	11.95	6.16e-29	7.66e-26	0.5	0.48	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
THCA	cis	rs9322193	0.884	rs9383865	ENSG00000223701.3	RAET1E-AS1	11.95	6.16e-29	7.66e-26	0.66	0.48	Lung cancer;	chr6:149852043	chr6:149884431~149919508:+
THCA	cis	rs673078	0.571	rs61945220	ENSG00000275759.1	RP11-131L12.3	-11.95	6.16e-29	7.66e-26	-0.75	-0.48	Glucose homeostasis traits;	chr12:118272924	chr12:118428281~118428870:+
THCA	cis	rs673078	0.571	rs61945221	ENSG00000275759.1	RP11-131L12.3	-11.95	6.16e-29	7.66e-26	-0.75	-0.48	Glucose homeostasis traits;	chr12:118272926	chr12:118428281~118428870:+
THCA	cis	rs853679	0.517	rs4713141	ENSG00000280107.1	AL022393.9	-11.95	6.19e-29	7.7e-26	-0.59	-0.48	Depression;	chr6:28133900	chr6:28170845~28172521:+
THCA	cis	rs2487048	0.773	rs2472493	ENSG00000226334.1	RP11-217B7.2	-11.95	6.2e-29	7.71e-26	-0.65	-0.48	Intraocular pressure;	chr9:104933567	chr9:104927553~104928892:+
THCA	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	11.95	6.26e-29	7.78e-26	0.56	0.48	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
THCA	cis	rs944289	0.646	rs375095	ENSG00000257826.1	RP11-116N8.4	11.95	6.34e-29	7.89e-26	0.49	0.48	Thyroid cancer;	chr14:36066043	chr14:36061026~36067190:-
THCA	cis	rs6570726	0.791	rs9373464	ENSG00000235652.6	RP11-545I5.3	11.95	6.53e-29	8.11e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145586031	chr6:145799409~145886585:+
THCA	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-11.95	6.53e-29	8.11e-26	-0.36	-0.48	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
THCA	cis	rs6142102	0.961	rs6059596	ENSG00000276073.1	RP5-1125A11.7	-11.95	6.54e-29	8.12e-26	-0.45	-0.48	Skin pigmentation;	chr20:33969313	chr20:33985617~33988989:-
THCA	cis	rs12458462	0.859	rs34242155	ENSG00000274828.1	RP11-567M16.6	11.95	6.54e-29	8.12e-26	0.39	0.48	Monocyte count;	chr18:79665192	chr18:79677287~79679358:-
THCA	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-11.95	6.56e-29	8.14e-26	-0.6	-0.48	Height;	chr3:53094335	chr3:53064283~53065091:-
THCA	cis	rs7182621	0.546	rs11635811	ENSG00000259363.4	CTD-2054N24.2	-11.95	6.58e-29	8.17e-26	-0.68	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99839918	chr15:99807023~99877148:+
THCA	cis	rs4819052	1	rs9306123	ENSG00000223768.1	LINC00205	-11.95	6.58e-29	8.17e-26	-0.49	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45293285~45297354:+
THCA	cis	rs10463554	0.927	rs158403	ENSG00000175749.11	EIF3KP1	11.95	6.6e-29	8.19e-26	0.64	0.48	Parkinson's disease;	chr5:103080064	chr5:103032376~103033031:+
THCA	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	11.95	6.6e-29	8.19e-26	0.89	0.48	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
THCA	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	11.94	6.65e-29	8.25e-26	0.54	0.48	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
THCA	cis	rs9322193	0.607	rs4869755	ENSG00000231760.4	RP11-350J20.5	11.94	6.65e-29	8.26e-26	0.7	0.48	Lung cancer;	chr6:149886347	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.639	rs4869756	ENSG00000231760.4	RP11-350J20.5	11.94	6.65e-29	8.26e-26	0.7	0.48	Lung cancer;	chr6:149886360	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.566	rs12528243	ENSG00000231760.4	RP11-350J20.5	11.94	6.67e-29	8.28e-26	0.69	0.48	Lung cancer;	chr6:149898491	chr6:149796151~149826294:-
THCA	cis	rs8040855	0.965	rs11073990	ENSG00000259295.5	CSPG4P12	11.94	6.73e-29	8.34e-26	0.66	0.48	Bulimia nervosa;	chr15:85168070	chr15:85191438~85213905:+
THCA	cis	rs228614	0.509	rs223476	ENSG00000246560.2	RP11-10L12.4	11.94	6.74e-29	8.35e-26	0.59	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771000	chr4:102828055~102844075:+
THCA	cis	rs228614	0.509	rs150896	ENSG00000246560.2	RP11-10L12.4	11.94	6.74e-29	8.35e-26	0.59	0.48	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102771186	chr4:102828055~102844075:+
THCA	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-11.94	6.75e-29	8.37e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
THCA	cis	rs8040855	0.603	rs10520585	ENSG00000259295.5	CSPG4P12	-11.94	6.79e-29	8.42e-26	-0.77	-0.48	Bulimia nervosa;	chr15:85118275	chr15:85191438~85213905:+
THCA	cis	rs4718428	0.705	rs4717328	ENSG00000273142.1	RP11-458F8.4	-11.94	6.91e-29	8.57e-26	-0.45	-0.48	Corneal structure;	chr7:66887678	chr7:66902857~66906297:+
THCA	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	11.94	6.93e-29	8.59e-26	0.55	0.48	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
THCA	cis	rs6570726	0.818	rs952405	ENSG00000235652.6	RP11-545I5.3	11.94	6.97e-29	8.64e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145604816	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs4896824	ENSG00000235652.6	RP11-545I5.3	11.94	6.97e-29	8.64e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145605912	chr6:145799409~145886585:+
THCA	cis	rs4718428	0.705	rs4717328	ENSG00000226824.5	RP4-756H11.3	-11.94	6.99e-29	8.66e-26	-0.71	-0.48	Corneal structure;	chr7:66887678	chr7:66654538~66669855:+
THCA	cis	rs11098499	0.644	rs10009566	ENSG00000245958.5	RP11-33B1.1	-11.94	7.03e-29	8.71e-26	-0.46	-0.48	Corneal astigmatism;	chr4:119637453	chr4:119454791~119552025:+
THCA	cis	rs992157	0.643	rs10191283	ENSG00000261338.2	RP11-378A13.1	11.94	7.03e-29	8.71e-26	0.5	0.48	Colorectal cancer;	chr2:218192032	chr2:218255319~218257366:+
THCA	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-11.94	7.05e-29	8.73e-26	-0.53	-0.48	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
THCA	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-11.94	7.09e-29	8.78e-26	-0.63	-0.48	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-11.94	7.09e-29	8.78e-26	-0.63	-0.48	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-11.94	7.09e-29	8.78e-26	-0.63	-0.48	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-11.94	7.09e-29	8.78e-26	-0.63	-0.48	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-11.94	7.09e-29	8.78e-26	-0.63	-0.48	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
THCA	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-11.94	7.09e-29	8.78e-26	-0.84	-0.48	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
THCA	cis	rs853679	0.517	rs9295761	ENSG00000280107.1	AL022393.9	-11.94	7.12e-29	8.82e-26	-0.59	-0.48	Depression;	chr6:28180209	chr6:28170845~28172521:+
THCA	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	11.94	7.12e-29	8.82e-26	0.62	0.48	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
THCA	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	11.94	7.13e-29	8.83e-26	0.54	0.48	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
THCA	cis	rs4819052	0.684	rs914216	ENSG00000223768.1	LINC00205	-11.94	7.14e-29	8.84e-26	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45293285~45297354:+
THCA	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	11.94	7.15e-29	8.86e-26	0.35	0.48	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
THCA	cis	rs3091242	0.9	rs1883427	ENSG00000224183.1	SDHDP6	-11.94	7.2e-29	8.91e-26	-0.59	-0.48	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25294164~25294643:-
THCA	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	11.94	7.27e-29	9e-26	0.6	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
THCA	cis	rs2086824	0.538	rs4785673	ENSG00000274627.1	RP11-104N10.2	11.93	7.31e-29	9.04e-26	0.46	0.48	Multiple myeloma (IgH translocation);	chr16:89470137	chr16:89516797~89522217:+
THCA	cis	rs853679	0.517	rs12332979	ENSG00000280107.1	AL022393.9	-11.93	7.32e-29	9.06e-26	-0.59	-0.48	Depression;	chr6:28173770	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs67878650	ENSG00000280107.1	AL022393.9	-11.93	7.32e-29	9.06e-26	-0.59	-0.48	Depression;	chr6:28174809	chr6:28170845~28172521:+
THCA	cis	rs853679	0.569	rs9348798	ENSG00000280107.1	AL022393.9	-11.93	7.32e-29	9.06e-26	-0.59	-0.48	Depression;	chr6:28175233	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9380065	ENSG00000280107.1	AL022393.9	-11.93	7.32e-29	9.06e-26	-0.59	-0.48	Depression;	chr6:28176973	chr6:28170845~28172521:+
THCA	cis	rs992157	0.661	rs10171839	ENSG00000261338.2	RP11-378A13.1	11.93	7.39e-29	9.14e-26	0.49	0.48	Colorectal cancer;	chr2:218186591	chr2:218255319~218257366:+
THCA	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-11.93	7.49e-29	9.27e-26	-0.56	-0.48	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
THCA	cis	rs10463554	0.963	rs158254	ENSG00000175749.11	EIF3KP1	11.93	7.54e-29	9.32e-26	0.64	0.48	Parkinson's disease;	chr5:103059179	chr5:103032376~103033031:+
THCA	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-11.93	7.59e-29	9.38e-26	-0.84	-0.48	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
THCA	cis	rs6142102	0.923	rs4911383	ENSG00000276073.1	RP5-1125A11.7	-11.93	7.61e-29	9.4e-26	-0.45	-0.48	Skin pigmentation;	chr20:33967973	chr20:33985617~33988989:-
THCA	cis	rs673078	0.66	rs73205512	ENSG00000275759.1	RP11-131L12.3	-11.93	7.65e-29	9.46e-26	-0.74	-0.48	Glucose homeostasis traits;	chr12:118235770	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945206	ENSG00000275759.1	RP11-131L12.3	-11.93	7.65e-29	9.46e-26	-0.74	-0.48	Glucose homeostasis traits;	chr12:118238295	chr12:118428281~118428870:+
THCA	cis	rs7772486	0.79	rs2254257	ENSG00000235652.6	RP11-545I5.3	11.93	7.68e-29	9.49e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145882588	chr6:145799409~145886585:+
THCA	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-11.93	7.69e-29	9.51e-26	-0.63	-0.48	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-11.93	7.69e-29	9.51e-26	-0.63	-0.48	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
THCA	cis	rs10463554	0.963	rs67068617	ENSG00000175749.11	EIF3KP1	11.93	7.7e-29	9.52e-26	0.64	0.48	Parkinson's disease;	chr5:103039977	chr5:103032376~103033031:+
THCA	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-11.93	7.71e-29	9.53e-26	-0.79	-0.48	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
THCA	cis	rs8040855	0.627	rs12900012	ENSG00000259295.5	CSPG4P12	11.93	7.74e-29	9.56e-26	0.72	0.48	Bulimia nervosa;	chr15:85046955	chr15:85191438~85213905:+
THCA	cis	rs7772486	0.875	rs2748482	ENSG00000235652.6	RP11-545I5.3	11.93	7.75e-29	9.58e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146015396	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs1331637	ENSG00000235652.6	RP11-545I5.3	11.93	7.75e-29	9.58e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146015951	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.846	rs1331636	ENSG00000235652.6	RP11-545I5.3	11.93	7.75e-29	9.58e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146017690	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs1929523	ENSG00000235652.6	RP11-545I5.3	11.93	7.75e-29	9.58e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146018853	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2224120	ENSG00000235652.6	RP11-545I5.3	11.93	7.75e-29	9.58e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146022144	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2777476	ENSG00000235652.6	RP11-545I5.3	11.93	7.75e-29	9.58e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146023888	chr6:145799409~145886585:+
THCA	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	11.93	7.76e-29	9.58e-26	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	11.93	7.76e-29	9.58e-26	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
THCA	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	11.93	7.76e-29	9.59e-26	0.52	0.48	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
THCA	cis	rs4718428	0.672	rs13241598	ENSG00000226824.5	RP4-756H11.3	-11.93	7.79e-29	9.63e-26	-0.71	-0.48	Corneal structure;	chr7:66835665	chr7:66654538~66669855:+
THCA	cis	rs673078	0.66	rs10507286	ENSG00000275759.1	RP11-131L12.3	-11.93	7.8e-29	9.63e-26	-0.74	-0.48	Glucose homeostasis traits;	chr12:118197101	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945180	ENSG00000275759.1	RP11-131L12.3	-11.93	7.8e-29	9.63e-26	-0.74	-0.48	Glucose homeostasis traits;	chr12:118216335	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945181	ENSG00000275759.1	RP11-131L12.3	-11.93	7.8e-29	9.63e-26	-0.74	-0.48	Glucose homeostasis traits;	chr12:118216651	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945183	ENSG00000275759.1	RP11-131L12.3	-11.93	7.8e-29	9.63e-26	-0.74	-0.48	Glucose homeostasis traits;	chr12:118221966	chr12:118428281~118428870:+
THCA	cis	rs9309473	0.513	rs62149782	ENSG00000163016.8	ALMS1P	11.93	7.83e-29	9.66e-26	0.82	0.48	Metabolite levels;	chr2:73591901	chr2:73644919~73685576:+
THCA	cis	rs240993	0.809	rs11153277	ENSG00000230177.1	RP5-1112D6.4	-11.93	7.84e-29	9.68e-26	-0.43	-0.48	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111277932~111278742:+
THCA	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	11.93	7.87e-29	9.71e-26	0.63	0.48	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
THCA	cis	rs7772486	0.686	rs9497380	ENSG00000235652.6	RP11-545I5.3	11.93	7.91e-29	9.77e-26	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145634169	chr6:145799409~145886585:+
THCA	cis	rs9659323	0.64	rs11800444	ENSG00000231365.4	RP11-418J17.1	-11.93	7.92e-29	9.78e-26	-0.48	-0.48	Body mass index;	chr1:119097052	chr1:119140396~119275973:+
THCA	cis	rs9389248	0.623	rs2142725	ENSG00000232876.1	CTA-212D2.2	11.92	8.13e-29	1e-25	0.61	0.48	High light scatter reticulocyte percentage of red cells;	chr6:134937804	chr6:135055033~135060550:+
THCA	cis	rs10463554	0.892	rs34830	ENSG00000175749.11	EIF3KP1	11.92	8.13e-29	1e-25	0.64	0.48	Parkinson's disease;	chr5:103108349	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs257319	ENSG00000175749.11	EIF3KP1	11.92	8.13e-29	1e-25	0.64	0.48	Parkinson's disease;	chr5:103110123	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs39666	ENSG00000175749.11	EIF3KP1	11.92	8.13e-29	1e-25	0.64	0.48	Parkinson's disease;	chr5:103111423	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34769	ENSG00000175749.11	EIF3KP1	11.92	8.13e-29	1e-25	0.64	0.48	Parkinson's disease;	chr5:103111523	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs464591	ENSG00000175749.11	EIF3KP1	11.92	8.13e-29	1e-25	0.64	0.48	Parkinson's disease;	chr5:103111600	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs34772	ENSG00000175749.11	EIF3KP1	11.92	8.13e-29	1e-25	0.64	0.48	Parkinson's disease;	chr5:103114808	chr5:103032376~103033031:+
THCA	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	11.92	8.14e-29	1e-25	0.6	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
THCA	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-11.92	8.25e-29	1.02e-25	-0.5	-0.48	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
THCA	cis	rs6142102	0.961	rs4911390	ENSG00000276073.1	RP5-1125A11.7	-11.92	8.26e-29	1.02e-25	-0.46	-0.48	Skin pigmentation;	chr20:33977401	chr20:33985617~33988989:-
THCA	cis	rs9322193	0.884	rs7769115	ENSG00000223701.3	RAET1E-AS1	11.92	8.31e-29	1.03e-25	0.66	0.48	Lung cancer;	chr6:149848796	chr6:149884431~149919508:+
THCA	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	11.92	8.34e-29	1.03e-25	0.84	0.48	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
THCA	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.43e-29	1.04e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
THCA	cis	rs9928842	0.679	rs4888361	ENSG00000280152.1	RP11-331F4.5	11.92	8.44e-29	1.04e-25	0.68	0.48	Alcoholic chronic pancreatitis;	chr16:75233778	chr16:75245994~75250077:-
THCA	cis	rs875971	1	rs1565531	ENSG00000237310.1	GS1-124K5.4	-11.92	8.48e-29	1.04e-25	-0.35	-0.48	Aortic root size;	chr7:66198126	chr7:66493706~66495474:+
THCA	cis	rs2274273	0.87	rs61210954	ENSG00000258413.1	RP11-665C16.6	-11.92	8.49e-29	1.05e-25	-0.62	-0.48	Protein biomarker;	chr14:55298684	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.923	rs9479094	ENSG00000223701.3	RAET1E-AS1	11.92	8.58e-29	1.06e-25	0.65	0.48	Lung cancer;	chr6:149725083	chr6:149884431~149919508:+
THCA	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-11.92	8.59e-29	1.06e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
THCA	cis	rs12458462	0.851	rs62097746	ENSG00000274828.1	RP11-567M16.6	11.92	8.59e-29	1.06e-25	0.4	0.48	Monocyte count;	chr18:79727508	chr18:79677287~79679358:-
THCA	cis	rs12458462	0.851	rs60298379	ENSG00000274828.1	RP11-567M16.6	11.92	8.59e-29	1.06e-25	0.4	0.48	Monocyte count;	chr18:79728422	chr18:79677287~79679358:-
THCA	cis	rs12458462	0.812	rs36073957	ENSG00000274828.1	RP11-567M16.6	11.92	8.59e-29	1.06e-25	0.4	0.48	Monocyte count;	chr18:79728441	chr18:79677287~79679358:-
THCA	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	11.92	8.65e-29	1.06e-25	0.56	0.48	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	11.92	8.65e-29	1.06e-25	0.56	0.48	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
THCA	cis	rs10463554	0.889	rs34775	ENSG00000175749.11	EIF3KP1	11.92	8.66e-29	1.07e-25	0.64	0.48	Parkinson's disease;	chr5:103115572	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34776	ENSG00000175749.11	EIF3KP1	11.92	8.66e-29	1.07e-25	0.64	0.48	Parkinson's disease;	chr5:103116090	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.667	rs34782	ENSG00000175749.11	EIF3KP1	11.92	8.66e-29	1.07e-25	0.64	0.48	Parkinson's disease;	chr5:103118766	chr5:103032376~103033031:+
THCA	cis	rs934734	0.532	rs55792977	ENSG00000204929.10	AC074391.1	-11.92	8.67e-29	1.07e-25	-0.59	-0.48	Rheumatoid arthritis;	chr2:65423730	chr2:65436711~66084639:+
THCA	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-11.92	8.67e-29	1.07e-25	-0.64	-0.48	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
THCA	cis	rs7772486	0.686	rs9390349	ENSG00000235652.6	RP11-545I5.3	-11.92	8.67e-29	1.07e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145733294	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs2072911	ENSG00000235652.6	RP11-545I5.3	-11.92	8.67e-29	1.07e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145735665	chr6:145799409~145886585:+
THCA	cis	rs9487605	1	rs9487605	ENSG00000230177.1	RP5-1112D6.4	-11.92	8.68e-29	1.07e-25	-0.43	-0.48	Inflammatory skin disease;	chr6:111261682	chr6:111277932~111278742:+
THCA	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-11.92	8.69e-29	1.07e-25	-0.61	-0.48	Height;	chr3:53097932	chr3:53064283~53065091:-
THCA	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	11.92	8.71e-29	1.07e-25	0.55	0.48	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
THCA	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-11.91	8.76e-29	1.08e-25	-0.5	-0.48	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
THCA	cis	rs875971	0.965	rs10267430	ENSG00000237310.1	GS1-124K5.4	-11.91	8.79e-29	1.08e-25	-0.35	-0.48	Aortic root size;	chr7:66278036	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.558	rs7753273	ENSG00000235652.6	RP11-545I5.3	-11.91	8.97e-29	1.1e-25	-0.48	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145744903	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.59	rs1890170	ENSG00000235652.6	RP11-545I5.3	-11.91	8.97e-29	1.1e-25	-0.48	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145750703	chr6:145799409~145886585:+
THCA	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	11.91	9e-29	1.11e-25	0.83	0.48	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
THCA	cis	rs1891275	0.551	rs2000177	ENSG00000228701.1	TNKS2-AS1	-11.91	9.04e-29	1.11e-25	-0.54	-0.48	Intelligence (multi-trait analysis);	chr10:91653237	chr10:91782839~91798291:-
THCA	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	11.91	9.13e-29	1.12e-25	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
THCA	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	11.91	9.14e-29	1.12e-25	0.6	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
THCA	cis	rs4819052	0.851	rs9977178	ENSG00000223768.1	LINC00205	-11.91	9.18e-29	1.13e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.654	rs4896829	ENSG00000235652.6	RP11-545I5.3	11.91	9.22e-29	1.13e-25	0.46	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145632539	chr6:145799409~145886585:+
THCA	cis	rs6142102	0.961	rs2284379	ENSG00000276073.1	RP5-1125A11.7	-11.91	9.27e-29	1.14e-25	-0.46	-0.48	Skin pigmentation;	chr20:34006836	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs2268080	ENSG00000276073.1	RP5-1125A11.7	-11.91	9.27e-29	1.14e-25	-0.46	-0.48	Skin pigmentation;	chr20:34009910	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs1555075	ENSG00000276073.1	RP5-1125A11.7	-11.91	9.27e-29	1.14e-25	-0.46	-0.48	Skin pigmentation;	chr20:34022595	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs4911144	ENSG00000276073.1	RP5-1125A11.7	-11.91	9.27e-29	1.14e-25	-0.46	-0.48	Skin pigmentation;	chr20:34026565	chr20:33985617~33988989:-
THCA	cis	rs4718428	0.705	rs2901311	ENSG00000273142.1	RP11-458F8.4	-11.91	9.28e-29	1.14e-25	-0.45	-0.48	Corneal structure;	chr7:66950082	chr7:66902857~66906297:+
THCA	cis	rs875971	0.965	rs28682868	ENSG00000237310.1	GS1-124K5.4	-11.91	9.28e-29	1.14e-25	-0.35	-0.48	Aortic root size;	chr7:66224822	chr7:66493706~66495474:+
THCA	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	11.91	9.31e-29	1.14e-25	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
THCA	cis	rs526231	0.511	rs26255	ENSG00000175749.11	EIF3KP1	11.91	9.34e-29	1.15e-25	0.65	0.48	Primary biliary cholangitis;	chr5:103218399	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.84	rs28568813	ENSG00000258413.1	RP11-665C16.6	-11.91	9.38e-29	1.15e-25	-0.62	-0.48	Protein biomarker;	chr14:55327396	chr14:55262767~55272075:-
THCA	cis	rs7182621	0.639	rs1561047	ENSG00000259363.4	CTD-2054N24.2	-11.91	9.42e-29	1.16e-25	-0.72	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99874606	chr15:99807023~99877148:+
THCA	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	11.91	9.45e-29	1.16e-25	0.6	0.48	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
THCA	cis	rs10463554	0.963	rs34381	ENSG00000175749.11	EIF3KP1	11.91	9.5e-29	1.17e-25	0.64	0.48	Parkinson's disease;	chr5:103060852	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.857	rs34376	ENSG00000175749.11	EIF3KP1	11.91	9.5e-29	1.17e-25	0.64	0.48	Parkinson's disease;	chr5:103065409	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34375	ENSG00000175749.11	EIF3KP1	11.91	9.5e-29	1.17e-25	0.64	0.48	Parkinson's disease;	chr5:103065419	chr5:103032376~103033031:+
THCA	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-11.91	9.52e-29	1.17e-25	-0.5	-0.48	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
THCA	cis	rs2274273	0.87	rs10149420	ENSG00000258413.1	RP11-665C16.6	-11.91	9.53e-29	1.17e-25	-0.62	-0.48	Protein biomarker;	chr14:55387539	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.566	rs9397070	ENSG00000231760.4	RP11-350J20.5	-11.91	9.54e-29	1.17e-25	-0.69	-0.48	Lung cancer;	chr6:149922073	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.884	rs7743823	ENSG00000223701.3	RAET1E-AS1	11.91	9.55e-29	1.17e-25	0.66	0.48	Lung cancer;	chr6:149849744	chr6:149884431~149919508:+
THCA	cis	rs4819052	0.851	rs2255766	ENSG00000223768.1	LINC00205	-11.91	9.57e-29	1.17e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45293285~45297354:+
THCA	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	11.9	9.6e-29	1.18e-25	0.61	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
THCA	cis	rs6142102	0.961	rs2056990	ENSG00000276073.1	RP5-1125A11.7	-11.9	9.64e-29	1.18e-25	-0.46	-0.48	Skin pigmentation;	chr20:34035658	chr20:33985617~33988989:-
THCA	cis	rs9659323	0.67	rs12096179	ENSG00000231365.4	RP11-418J17.1	-11.9	9.66e-29	1.18e-25	-0.48	-0.48	Body mass index;	chr1:119093100	chr1:119140396~119275973:+
THCA	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	11.9	9.84e-29	1.21e-25	0.59	0.48	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
THCA	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	11.9	9.93e-29	1.22e-25	0.59	0.48	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
THCA	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	11.9	9.93e-29	1.22e-25	0.59	0.48	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
THCA	cis	rs6496932	1	rs35156762	ENSG00000218052.5	ADAMTS7P4	11.9	9.98e-29	1.22e-25	0.66	0.48	Central corneal thickness;Corneal structure;	chr15:85281243	chr15:85255369~85330334:-
THCA	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	11.9	9.99e-29	1.22e-25	0.58	0.48	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
THCA	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-11.9	1e-28	1.23e-25	-0.66	-0.48	Depression;	chr6:28091242	chr6:28115628~28116551:+
THCA	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	11.9	1.01e-28	1.23e-25	0.6	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	11.9	1.01e-28	1.24e-25	0.58	0.48	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	11.9	1.01e-28	1.24e-25	0.58	0.48	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
THCA	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-11.9	1.01e-28	1.24e-25	-0.64	-0.48	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
THCA	cis	rs7772486	0.875	rs9376975	ENSG00000235652.6	RP11-545I5.3	11.9	1.02e-28	1.25e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146034445	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.846	rs9376976	ENSG00000235652.6	RP11-545I5.3	11.9	1.02e-28	1.25e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146034469	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs7761033	ENSG00000235652.6	RP11-545I5.3	11.9	1.02e-28	1.25e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146034970	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9403763	ENSG00000235652.6	RP11-545I5.3	11.9	1.02e-28	1.25e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146036519	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9403764	ENSG00000235652.6	RP11-545I5.3	11.9	1.02e-28	1.25e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146039446	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs13198450	ENSG00000235652.6	RP11-545I5.3	11.9	1.03e-28	1.27e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146049388	chr6:145799409~145886585:+
THCA	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-11.9	1.04e-28	1.27e-25	-0.55	-0.48	Temperament;	chr17:14007232	chr17:14024514~14025488:+
THCA	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-11.9	1.04e-28	1.27e-25	-0.34	-0.48	Height;	chr11:118773873	chr11:118791254~118793137:+
THCA	cis	rs10463554	0.892	rs34816	ENSG00000175749.11	EIF3KP1	11.9	1.04e-28	1.27e-25	0.64	0.48	Parkinson's disease;	chr5:103098941	chr5:103032376~103033031:+
THCA	cis	rs62103177	0.608	rs4799115	ENSG00000261126.6	RP11-795F19.1	-11.9	1.04e-28	1.27e-25	-0.54	-0.48	Opioid sensitivity;	chr18:79976365	chr18:80046900~80095482:+
THCA	cis	rs11722779	0.873	rs223346	ENSG00000246560.2	RP11-10L12.4	11.9	1.04e-28	1.27e-25	0.59	0.48	Schizophrenia;	chr4:102859339	chr4:102828055~102844075:+
THCA	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	11.9	1.05e-28	1.29e-25	0.59	0.48	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
THCA	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	11.9	1.05e-28	1.29e-25	0.59	0.48	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
THCA	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	11.9	1.05e-28	1.29e-25	0.59	0.48	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
THCA	cis	rs6570726	0.791	rs621382	ENSG00000235652.6	RP11-545I5.3	11.89	1.05e-28	1.29e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145478008	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs422099	ENSG00000235652.6	RP11-545I5.3	11.89	1.05e-28	1.29e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145485800	chr6:145799409~145886585:+
THCA	cis	rs10463554	0.892	rs257305	ENSG00000175749.11	EIF3KP1	11.89	1.06e-28	1.29e-25	0.64	0.48	Parkinson's disease;	chr5:103081533	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257306	ENSG00000175749.11	EIF3KP1	11.89	1.06e-28	1.29e-25	0.64	0.48	Parkinson's disease;	chr5:103081770	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs257307	ENSG00000175749.11	EIF3KP1	11.89	1.06e-28	1.29e-25	0.64	0.48	Parkinson's disease;	chr5:103081805	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257308	ENSG00000175749.11	EIF3KP1	11.89	1.06e-28	1.29e-25	0.64	0.48	Parkinson's disease;	chr5:103082557	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257311	ENSG00000175749.11	EIF3KP1	11.89	1.06e-28	1.29e-25	0.64	0.48	Parkinson's disease;	chr5:103083394	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257314	ENSG00000175749.11	EIF3KP1	11.89	1.06e-28	1.29e-25	0.64	0.48	Parkinson's disease;	chr5:103085391	chr5:103032376~103033031:+
THCA	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	11.89	1.06e-28	1.29e-25	0.6	0.48	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
THCA	cis	rs673078	0.66	rs56708462	ENSG00000275759.1	RP11-131L12.3	-11.89	1.07e-28	1.31e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118284135	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs7962185	ENSG00000275759.1	RP11-131L12.3	-11.89	1.07e-28	1.31e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118287842	chr12:118428281~118428870:+
THCA	cis	rs9322193	0.923	rs9322196	ENSG00000223701.3	RAET1E-AS1	11.89	1.07e-28	1.31e-25	0.64	0.48	Lung cancer;	chr6:149619645	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.846	rs1935616	ENSG00000235652.6	RP11-545I5.3	11.89	1.07e-28	1.31e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145622376	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs9399559	ENSG00000235652.6	RP11-545I5.3	11.89	1.07e-28	1.31e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145624642	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9376956	ENSG00000235652.6	RP11-545I5.3	11.89	1.07e-28	1.31e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145628708	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.658	rs6570706	ENSG00000235652.6	RP11-545I5.3	11.89	1.07e-28	1.31e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145641786	chr6:145799409~145886585:+
THCA	cis	rs4964805	1	rs73192052	ENSG00000257681.1	RP11-341G23.4	11.89	1.07e-28	1.31e-25	0.59	0.48	Attention deficit hyperactivity disorder;	chr12:103797076	chr12:103746315~103768858:-
THCA	cis	rs6570726	0.846	rs6899900	ENSG00000235652.6	RP11-545I5.3	11.89	1.08e-28	1.32e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145562737	chr6:145799409~145886585:+
THCA	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	11.89	1.08e-28	1.32e-25	0.35	0.48	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
THCA	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	11.89	1.08e-28	1.32e-25	0.35	0.48	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
THCA	cis	rs2274273	0.87	rs3825616	ENSG00000258413.1	RP11-665C16.6	-11.89	1.09e-28	1.33e-25	-0.62	-0.48	Protein biomarker;	chr14:55386570	chr14:55262767~55272075:-
THCA	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	11.89	1.09e-28	1.34e-25	0.35	0.48	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
THCA	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-11.89	1.1e-28	1.34e-25	-0.7	-0.48	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
THCA	cis	rs7727544	0.684	rs272874	ENSG00000233006.5	AC034220.3	-11.89	1.1e-28	1.34e-25	-0.38	-0.48	Blood metabolite levels;	chr5:132339353	chr5:132311285~132369916:-
THCA	cis	rs62103177	0.608	rs34383580	ENSG00000261126.6	RP11-795F19.1	-11.89	1.1e-28	1.35e-25	-0.53	-0.48	Opioid sensitivity;	chr18:80074960	chr18:80046900~80095482:+
THCA	cis	rs673078	0.66	rs16948193	ENSG00000275759.1	RP11-131L12.3	-11.89	1.11e-28	1.35e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118227115	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945187	ENSG00000275759.1	RP11-131L12.3	-11.89	1.11e-28	1.35e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118228989	chr12:118428281~118428870:+
THCA	cis	rs8100891	0.537	rs58591218	ENSG00000267213.4	AC007773.2	-11.89	1.11e-28	1.36e-25	-0.59	-0.48	Neuroticism;	chr19:32399876	chr19:32390050~32405560:-
THCA	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	11.89	1.11e-28	1.36e-25	0.61	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
THCA	cis	rs6570726	0.791	rs1280275	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145571266	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6900040	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145571998	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs6923074	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145572196	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.755	rs2092296	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145572548	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.755	rs2092297	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145572629	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.755	rs2103633	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145572885	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs9373463	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145573626	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs9322028	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145574661	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs12205752	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145574982	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs9390336	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145575687	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.738	rs6925594	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145577318	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs11155432	ENSG00000235652.6	RP11-545I5.3	11.89	1.11e-28	1.36e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145577625	chr6:145799409~145886585:+
THCA	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-11.89	1.12e-28	1.37e-25	-0.65	-0.48	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
THCA	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	11.89	1.14e-28	1.39e-25	0.58	0.48	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	11.89	1.14e-28	1.39e-25	0.58	0.48	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	11.89	1.14e-28	1.39e-25	0.58	0.48	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
THCA	cis	rs7772486	0.875	rs9322044	ENSG00000235652.6	RP11-545I5.3	11.89	1.14e-28	1.39e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146048472	chr6:145799409~145886585:+
THCA	cis	rs875971	1	rs6963646	ENSG00000237310.1	GS1-124K5.4	-11.89	1.14e-28	1.39e-25	-0.35	-0.48	Aortic root size;	chr7:66220780	chr7:66493706~66495474:+
THCA	cis	rs10463554	0.927	rs34821	ENSG00000175749.11	EIF3KP1	11.89	1.14e-28	1.39e-25	0.63	0.48	Parkinson's disease;	chr5:103101913	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34824	ENSG00000175749.11	EIF3KP1	11.89	1.14e-28	1.39e-25	0.63	0.48	Parkinson's disease;	chr5:103103227	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34825	ENSG00000175749.11	EIF3KP1	11.89	1.14e-28	1.39e-25	0.63	0.48	Parkinson's disease;	chr5:103103614	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs34826	ENSG00000175749.11	EIF3KP1	11.89	1.14e-28	1.39e-25	0.63	0.48	Parkinson's disease;	chr5:103106044	chr5:103032376~103033031:+
THCA	cis	rs12458462	0.892	rs2242174	ENSG00000274828.1	RP11-567M16.6	11.89	1.14e-28	1.4e-25	0.39	0.48	Monocyte count;	chr18:79698037	chr18:79677287~79679358:-
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-11.88	1.16e-28	1.41e-25	-0.61	-0.48	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
THCA	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	11.88	1.16e-28	1.41e-25	0.54	0.48	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
THCA	cis	rs2882667	0.537	rs13181793	ENSG00000253404.1	AC034243.1	11.88	1.17e-28	1.42e-25	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073267	chr5:138744434~138753309:-
THCA	cis	rs3931020	0.566	rs1327086	ENSG00000272864.1	RP11-17E13.2	-11.88	1.17e-28	1.43e-25	-0.54	-0.48	Resistin levels;	chr1:74805348	chr1:74698769~74699333:-
THCA	cis	rs6570726	0.818	rs9399555	ENSG00000235652.6	RP11-545I5.3	11.88	1.17e-28	1.43e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145556418	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs441290	ENSG00000235652.6	RP11-545I5.3	11.88	1.17e-28	1.43e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145562047	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs9767554	ENSG00000223701.3	RAET1E-AS1	11.88	1.18e-28	1.44e-25	0.64	0.48	Lung cancer;	chr6:149616860	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs9322210	ENSG00000223701.3	RAET1E-AS1	11.88	1.2e-28	1.46e-25	0.64	0.48	Lung cancer;	chr6:149695440	chr6:149884431~149919508:+
THCA	cis	rs853679	0.517	rs17711344	ENSG00000280107.1	AL022393.9	11.88	1.23e-28	1.49e-25	0.59	0.48	Depression;	chr6:28109824	chr6:28170845~28172521:+
THCA	cis	rs7772486	0.79	rs2250387	ENSG00000235652.6	RP11-545I5.3	11.88	1.24e-28	1.5e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145884097	chr6:145799409~145886585:+
THCA	cis	rs4713118	0.621	rs9368548	ENSG00000280107.1	AL022393.9	-11.88	1.24e-28	1.51e-25	-0.57	-0.48	Parkinson's disease;	chr6:28066959	chr6:28170845~28172521:+
THCA	cis	rs2274273	0.686	rs28631821	ENSG00000258413.1	RP11-665C16.6	-11.88	1.24e-28	1.51e-25	-0.61	-0.48	Protein biomarker;	chr14:55379269	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs946059	ENSG00000258413.1	RP11-665C16.6	-11.88	1.24e-28	1.51e-25	-0.61	-0.48	Protein biomarker;	chr14:55380748	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs10144345	ENSG00000258413.1	RP11-665C16.6	-11.88	1.24e-28	1.51e-25	-0.61	-0.48	Protein biomarker;	chr14:55381019	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs3783650	ENSG00000258413.1	RP11-665C16.6	-11.88	1.24e-28	1.51e-25	-0.61	-0.48	Protein biomarker;	chr14:55382254	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs4597235	ENSG00000258413.1	RP11-665C16.6	-11.88	1.24e-28	1.51e-25	-0.61	-0.48	Protein biomarker;	chr14:55385269	chr14:55262767~55272075:-
THCA	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-11.88	1.25e-28	1.52e-25	-0.58	-0.48	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
THCA	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-11.88	1.25e-28	1.52e-25	-0.66	-0.48	Depression;	chr6:28113616	chr6:28115628~28116551:+
THCA	cis	rs10463554	0.553	rs72785712	ENSG00000175749.11	EIF3KP1	11.88	1.25e-28	1.52e-25	0.64	0.48	Parkinson's disease;	chr5:102988693	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.84	rs7153110	ENSG00000258413.1	RP11-665C16.6	-11.88	1.25e-28	1.53e-25	-0.61	-0.48	Protein biomarker;	chr14:55353910	chr14:55262767~55272075:-
THCA	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	11.88	1.26e-28	1.53e-25	0.36	0.48	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.686	rs1292334	ENSG00000235652.6	RP11-545I5.3	11.88	1.26e-28	1.53e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145647152	chr6:145799409~145886585:+
THCA	cis	rs8040855	0.694	rs12908400	ENSG00000259295.5	CSPG4P12	11.87	1.28e-28	1.56e-25	0.69	0.48	Bulimia nervosa;	chr15:85029945	chr15:85191438~85213905:+
THCA	cis	rs524281	0.861	rs7941469	ENSG00000255320.1	RP11-755F10.1	-11.87	1.29e-28	1.57e-25	-0.67	-0.48	Electroencephalogram traits;	chr11:66132681	chr11:66244840~66246239:-
THCA	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	11.87	1.3e-28	1.58e-25	0.55	0.48	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
THCA	cis	rs9309473	1	rs10184268	ENSG00000163016.8	ALMS1P	11.87	1.3e-28	1.58e-25	0.7	0.48	Metabolite levels;	chr2:73399916	chr2:73644919~73685576:+
THCA	cis	rs6570726	0.791	rs447992	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145496048	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs425999	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145498234	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs387376	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145501429	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs1912023	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145503142	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs9376945	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145506944	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.755	rs451699	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145509458	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs401561	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145514781	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs405206	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145515737	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs374478	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145518886	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs6919684	ENSG00000235652.6	RP11-545I5.3	11.87	1.31e-28	1.59e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145562665	chr6:145799409~145886585:+
THCA	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	11.87	1.32e-28	1.6e-25	0.59	0.48	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
THCA	cis	rs9322193	0.923	rs3798761	ENSG00000223701.3	RAET1E-AS1	11.87	1.32e-28	1.6e-25	0.64	0.48	Lung cancer;	chr6:149683643	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	11.87	1.33e-28	1.61e-25	0.58	0.48	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs7767622	ENSG00000223701.3	RAET1E-AS1	11.87	1.33e-28	1.61e-25	0.64	0.48	Lung cancer;	chr6:149681766	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs4421206	ENSG00000223701.3	RAET1E-AS1	11.87	1.33e-28	1.61e-25	0.64	0.48	Lung cancer;	chr6:149682891	chr6:149884431~149919508:+
THCA	cis	rs2300206	1	rs2300206	ENSG00000276073.1	RP5-1125A11.7	-11.87	1.34e-28	1.62e-25	-0.46	-0.48	Cancer (pleiotropy);Cancer;	chr20:34002002	chr20:33985617~33988989:-
THCA	cis	rs7772486	0.659	rs9376957	ENSG00000235652.6	RP11-545I5.3	-11.87	1.34e-28	1.63e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145689928	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs9497396	ENSG00000235652.6	RP11-545I5.3	-11.87	1.34e-28	1.63e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145693827	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs9497434	ENSG00000235652.6	RP11-545I5.3	-11.87	1.35e-28	1.63e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145939617	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs6924159	ENSG00000235652.6	RP11-545I5.3	-11.87	1.35e-28	1.63e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145946737	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9403756	ENSG00000235652.6	RP11-545I5.3	-11.87	1.35e-28	1.64e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145936625	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.607	rs9383941	ENSG00000231760.4	RP11-350J20.5	-11.87	1.35e-28	1.64e-25	-0.69	-0.48	Lung cancer;	chr6:149912100	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.607	rs3798763	ENSG00000231760.4	RP11-350J20.5	11.87	1.36e-28	1.64e-25	0.7	0.48	Lung cancer;	chr6:149889964	chr6:149796151~149826294:-
THCA	cis	rs9322193	0.607	rs12204653	ENSG00000231760.4	RP11-350J20.5	11.87	1.36e-28	1.64e-25	0.7	0.48	Lung cancer;	chr6:149891885	chr6:149796151~149826294:-
THCA	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-11.87	1.36e-28	1.65e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-11.87	1.36e-28	1.65e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs7609972	ENSG00000272758.4	RP11-299J3.8	-11.87	1.36e-28	1.65e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122480579	chr3:122416207~122443180:+
THCA	cis	rs7772486	0.654	rs1011597	ENSG00000235652.6	RP11-545I5.3	-11.87	1.37e-28	1.66e-25	-0.45	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145754536	chr6:145799409~145886585:+
THCA	cis	rs9399137	0.507	rs7754722	ENSG00000232876.1	CTA-212D2.2	11.87	1.37e-28	1.66e-25	0.61	0.48	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134939165	chr6:135055033~135060550:+
THCA	cis	rs11155671	0.53	rs4458704	ENSG00000268592.3	RAET1E-AS1	11.87	1.37e-28	1.66e-25	0.65	0.48	Testicular germ cell tumor;	chr6:149911743	chr6:149863494~149919507:+
THCA	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.39e-28	1.68e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
THCA	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	11.86	1.4e-28	1.7e-25	0.7	0.48	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
THCA	cis	rs6570726	0.791	rs6913727	ENSG00000235652.6	RP11-545I5.3	11.86	1.42e-28	1.72e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145578690	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs7765687	ENSG00000235652.6	RP11-545I5.3	11.86	1.43e-28	1.73e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145593964	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs7753696	ENSG00000235652.6	RP11-545I5.3	-11.86	1.43e-28	1.74e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145957962	chr6:145799409~145886585:+
THCA	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.44e-28	1.74e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
THCA	cis	rs6570726	0.791	rs10872577	ENSG00000235652.6	RP11-545I5.3	11.86	1.44e-28	1.74e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145579424	chr6:145799409~145886585:+
THCA	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-11.86	1.44e-28	1.74e-25	-0.6	-0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
THCA	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-11.86	1.44e-28	1.75e-25	-0.34	-0.48	Height;	chr11:118742526	chr11:118791254~118793137:+
THCA	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	11.86	1.44e-28	1.75e-25	0.6	0.48	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	11.86	1.44e-28	1.75e-25	0.6	0.48	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
THCA	cis	rs7772486	0.79	rs6923545	ENSG00000235652.6	RP11-545I5.3	-11.86	1.46e-28	1.77e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145923607	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs6922507	ENSG00000235652.6	RP11-545I5.3	-11.86	1.46e-28	1.77e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145929019	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs4075694	ENSG00000235652.6	RP11-545I5.3	-11.86	1.46e-28	1.77e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145929972	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs1062068	ENSG00000235652.6	RP11-545I5.3	11.86	1.46e-28	1.77e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145886329	chr6:145799409~145886585:+
THCA	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	11.86	1.47e-28	1.78e-25	0.56	0.48	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
THCA	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	11.86	1.48e-28	1.79e-25	0.57	0.48	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
THCA	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-11.86	1.48e-28	1.8e-25	-0.35	-0.48	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
THCA	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
THCA	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-11.86	1.49e-28	1.8e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
THCA	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	11.86	1.49e-28	1.8e-25	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
THCA	cis	rs1263173	0.566	rs4225	ENSG00000254851.1	RP11-109L13.1	-11.86	1.5e-28	1.81e-25	-0.64	-0.48	HDL cholesterol;	chr11:116832955	chr11:117135528~117138582:+
THCA	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	11.86	1.5e-28	1.81e-25	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
THCA	cis	rs7772486	0.686	rs9403739	ENSG00000235652.6	RP11-545I5.3	-11.86	1.5e-28	1.82e-25	-0.45	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145694221	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.905	rs9373486	ENSG00000235652.6	RP11-545I5.3	-11.86	1.51e-28	1.83e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:146124888	chr6:145799409~145886585:+
THCA	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-11.86	1.52e-28	1.83e-25	-0.65	-0.48	Depression;	chr6:28079011	chr6:28115628~28116551:+
THCA	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-11.86	1.52e-28	1.84e-25	-0.34	-0.48	Height;	chr11:118764443	chr11:118791254~118793137:+
THCA	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-11.85	1.52e-28	1.84e-25	-0.64	-0.48	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-11.85	1.52e-28	1.84e-25	-0.64	-0.48	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
THCA	cis	rs6570726	0.791	rs407887	ENSG00000235652.6	RP11-545I5.3	11.85	1.53e-28	1.85e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145522623	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs451108	ENSG00000235652.6	RP11-545I5.3	11.85	1.53e-28	1.85e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145523173	chr6:145799409~145886585:+
THCA	cis	rs11105298	0.891	rs11105314	ENSG00000258302.2	RP11-981P6.1	11.85	1.55e-28	1.87e-25	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89530782	chr12:89561129~89594878:+
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000235689.1	AP000351.13	11.85	1.55e-28	1.87e-25	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:24006305~24008258:-
THCA	cis	rs992157	0.71	rs13026485	ENSG00000261338.2	RP11-378A13.1	-11.85	1.55e-28	1.88e-25	-0.49	-0.48	Colorectal cancer;	chr2:218193261	chr2:218255319~218257366:+
THCA	cis	rs934734	0.571	rs7565437	ENSG00000204929.10	AC074391.1	-11.85	1.56e-28	1.88e-25	-0.59	-0.48	Rheumatoid arthritis;	chr2:65419832	chr2:65436711~66084639:+
THCA	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	11.85	1.56e-28	1.88e-25	0.53	0.48	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
THCA	cis	rs12468226	0.938	rs79117531	ENSG00000273456.1	RP11-686O6.2	11.85	1.56e-28	1.89e-25	0.59	0.48	Urate levels;	chr2:202307690	chr2:202374932~202375604:-
THCA	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	11.85	1.57e-28	1.9e-25	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
THCA	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	11.85	1.58e-28	1.9e-25	0.6	0.48	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
THCA	cis	rs673078	0.66	rs6490173	ENSG00000275759.1	RP11-131L12.3	-11.85	1.58e-28	1.9e-25	-0.6	-0.48	Glucose homeostasis traits;	chr12:118278637	chr12:118428281~118428870:+
THCA	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	11.85	1.58e-28	1.91e-25	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
THCA	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	11.85	1.58e-28	1.91e-25	0.59	0.48	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
THCA	cis	rs6570726	0.791	rs1935612	ENSG00000235652.6	RP11-545I5.3	11.85	1.58e-28	1.91e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145584954	chr6:145799409~145886585:+
THCA	cis	rs8040855	0.547	rs17611171	ENSG00000259295.5	CSPG4P12	11.85	1.59e-28	1.92e-25	0.73	0.48	Bulimia nervosa;	chr15:85029468	chr15:85191438~85213905:+
THCA	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-11.85	1.61e-28	1.94e-25	-0.59	-0.48	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-11.85	1.61e-28	1.94e-25	-0.59	-0.48	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
THCA	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	11.85	1.61e-28	1.94e-25	0.66	0.48	Depression;	chr6:28109824	chr6:28115628~28116551:+
THCA	cis	rs2274273	0.773	rs8006525	ENSG00000258413.1	RP11-665C16.6	-11.85	1.62e-28	1.95e-25	-0.62	-0.48	Protein biomarker;	chr14:55346676	chr14:55262767~55272075:-
THCA	cis	rs6496932	1	rs6496932	ENSG00000218052.5	ADAMTS7P4	11.85	1.63e-28	1.96e-25	0.65	0.48	Central corneal thickness;Corneal structure;	chr15:85282336	chr15:85255369~85330334:-
THCA	cis	rs7772486	0.875	rs7766463	ENSG00000235652.6	RP11-545I5.3	11.85	1.63e-28	1.97e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146043317	chr6:145799409~145886585:+
THCA	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-11.85	1.64e-28	1.97e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-11.85	1.64e-28	1.97e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-11.85	1.64e-28	1.97e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
THCA	cis	rs7569084	0.905	rs13417564	ENSG00000281920.1	RP11-418H16.1	-11.85	1.64e-28	1.98e-25	-0.59	-0.48	Sum eosinophil basophil counts;	chr2:65438139	chr2:65623272~65628424:+
THCA	cis	rs2274273	0.87	rs10134339	ENSG00000258413.1	RP11-665C16.6	-11.85	1.64e-28	1.98e-25	-0.61	-0.48	Protein biomarker;	chr14:55347662	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs28716725	ENSG00000258413.1	RP11-665C16.6	-11.85	1.64e-28	1.98e-25	-0.61	-0.48	Protein biomarker;	chr14:55349892	chr14:55262767~55272075:-
THCA	cis	rs11673344	0.704	rs571340	ENSG00000226686.6	LINC01535	11.84	1.67e-28	2.02e-25	0.56	0.48	Obesity-related traits;	chr19:36933981	chr19:37251912~37265535:+
THCA	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	11.84	1.68e-28	2.02e-25	0.9	0.48	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
THCA	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	11.84	1.69e-28	2.03e-25	0.57	0.48	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
THCA	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-11.84	1.69e-28	2.03e-25	-0.55	-0.48	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
THCA	cis	rs12468226	0.938	rs116601501	ENSG00000273456.1	RP11-686O6.2	11.84	1.72e-28	2.07e-25	0.59	0.48	Urate levels;	chr2:202274567	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs76658848	ENSG00000273456.1	RP11-686O6.2	11.84	1.72e-28	2.07e-25	0.59	0.48	Urate levels;	chr2:202275548	chr2:202374932~202375604:-
THCA	cis	rs7772486	0.654	rs702321	ENSG00000235652.6	RP11-545I5.3	-11.84	1.72e-28	2.07e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145685559	chr6:145799409~145886585:+
THCA	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	11.84	1.73e-28	2.08e-25	0.55	0.48	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
THCA	cis	rs673078	0.66	rs7973455	ENSG00000275759.1	RP11-131L12.3	-11.84	1.73e-28	2.08e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118247490	chr12:118428281~118428870:+
THCA	cis	rs6538678	0.895	rs4762637	ENSG00000258343.1	RP11-536G4.2	-11.84	1.73e-28	2.09e-25	-0.69	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95795345~95858839:-
THCA	cis	rs8100891	0.537	rs73034207	ENSG00000267213.4	AC007773.2	-11.84	1.75e-28	2.11e-25	-0.57	-0.48	Neuroticism;	chr19:32384863	chr19:32390050~32405560:-
THCA	cis	rs6142102	0.923	rs2284377	ENSG00000276073.1	RP5-1125A11.7	-11.84	1.77e-28	2.12e-25	-0.46	-0.48	Skin pigmentation;	chr20:33998876	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs2284378	ENSG00000276073.1	RP5-1125A11.7	-11.84	1.77e-28	2.12e-25	-0.46	-0.48	Skin pigmentation;	chr20:34000289	chr20:33985617~33988989:-
THCA	cis	rs11105298	0.891	rs10858902	ENSG00000258302.2	RP11-981P6.1	11.84	1.77e-28	2.12e-25	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534012	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858903	ENSG00000258302.2	RP11-981P6.1	11.84	1.77e-28	2.12e-25	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89534195	chr12:89561129~89594878:+
THCA	cis	rs66887589	0.592	rs62320740	ENSG00000245958.5	RP11-33B1.1	-11.84	1.77e-28	2.12e-25	-0.44	-0.48	Diastolic blood pressure;	chr4:119358331	chr4:119454791~119552025:+
THCA	cis	rs9928842	1	rs7202566	ENSG00000280152.1	RP11-331F4.5	11.84	1.77e-28	2.13e-25	0.66	0.48	Alcoholic chronic pancreatitis;	chr16:75213746	chr16:75245994~75250077:-
THCA	cis	rs8040855	0.627	rs4842863	ENSG00000259295.5	CSPG4P12	11.84	1.78e-28	2.13e-25	0.71	0.48	Bulimia nervosa;	chr15:85098974	chr15:85191438~85213905:+
THCA	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-11.84	1.78e-28	2.13e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000206090.4	AP000350.7	11.84	1.8e-28	2.16e-25	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23939998~23942798:+
THCA	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-11.84	1.8e-28	2.16e-25	-0.58	-0.48	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
THCA	cis	rs10935480	0.935	rs4857414	ENSG00000239445.4	ST3GAL6-AS1	-11.84	1.81e-28	2.18e-25	-0.47	-0.48	Blood protein levels;	chr3:98713715	chr3:98714330~98732651:-
THCA	cis	rs62103177	0.608	rs551643	ENSG00000261126.6	RP11-795F19.1	-11.84	1.81e-28	2.18e-25	-0.53	-0.48	Opioid sensitivity;	chr18:80081068	chr18:80046900~80095482:+
THCA	cis	rs673078	0.66	rs61945212	ENSG00000275759.1	RP11-131L12.3	-11.84	1.82e-28	2.18e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118252351	chr12:118428281~118428870:+
THCA	cis	rs2284378	0.506	rs6142059	ENSG00000276073.1	RP5-1125A11.7	-11.84	1.82e-28	2.18e-25	-0.43	-0.48	Breast cancer;	chr20:33956521	chr20:33985617~33988989:-
THCA	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-11.84	1.82e-28	2.18e-25	-0.64	-0.48	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
THCA	cis	rs66887589	0.592	rs28580295	ENSG00000245958.5	RP11-33B1.1	-11.84	1.82e-28	2.19e-25	-0.44	-0.48	Diastolic blood pressure;	chr4:119357718	chr4:119454791~119552025:+
THCA	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	11.83	1.84e-28	2.21e-25	0.55	0.48	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
THCA	cis	rs4964805	0.954	rs10861104	ENSG00000257681.1	RP11-341G23.4	11.83	1.86e-28	2.23e-25	0.59	0.48	Attention deficit hyperactivity disorder;	chr12:103796145	chr12:103746315~103768858:-
THCA	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	11.83	1.88e-28	2.26e-25	0.55	0.48	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
THCA	cis	rs7772486	0.743	rs62433835	ENSG00000235652.6	RP11-545I5.3	-11.83	1.88e-28	2.26e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145711552	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.743	rs2092262	ENSG00000235652.6	RP11-545I5.3	-11.83	1.88e-28	2.26e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145715969	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.682	rs1337840	ENSG00000235652.6	RP11-545I5.3	-11.83	1.88e-28	2.26e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145721422	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.765	rs2838854	ENSG00000223768.1	LINC00205	-11.83	1.88e-28	2.26e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45293285~45297354:+
THCA	cis	rs10935480	1	rs10935480	ENSG00000239445.4	ST3GAL6-AS1	-11.83	1.89e-28	2.27e-25	-0.47	-0.48	Blood protein levels;	chr3:98713142	chr3:98714330~98732651:-
THCA	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-11.83	1.89e-28	2.27e-25	-0.4	-0.48	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
THCA	cis	rs6570726	0.846	rs6570698	ENSG00000235652.6	RP11-545I5.3	11.83	1.9e-28	2.27e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145597499	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs6914304	ENSG00000235652.6	RP11-545I5.3	11.83	1.9e-28	2.27e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145599881	chr6:145799409~145886585:+
THCA	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-11.83	1.9e-28	2.27e-25	-0.34	-0.48	Height;	chr11:118760944	chr11:118791254~118793137:+
THCA	cis	rs7772486	0.875	rs2474353	ENSG00000235652.6	RP11-545I5.3	11.83	1.91e-28	2.29e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146002747	chr6:145799409~145886585:+
THCA	cis	rs10463554	0.824	rs427430	ENSG00000175749.11	EIF3KP1	11.83	1.91e-28	2.29e-25	0.64	0.48	Parkinson's disease;	chr5:103096320	chr5:103032376~103033031:+
THCA	cis	rs853679	0.542	rs6934769	ENSG00000280107.1	AL022393.9	-11.83	1.91e-28	2.29e-25	-0.58	-0.48	Depression;	chr6:28123153	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs17711801	ENSG00000280107.1	AL022393.9	-11.83	1.91e-28	2.29e-25	-0.58	-0.48	Depression;	chr6:28124529	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.527	rs9461433	ENSG00000280107.1	AL022393.9	-11.83	1.91e-28	2.29e-25	-0.58	-0.48	Parkinson's disease;	chr6:28127394	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs9468292	ENSG00000280107.1	AL022393.9	-11.83	1.91e-28	2.29e-25	-0.58	-0.48	Depression;	chr6:28127577	chr6:28170845~28172521:+
THCA	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-11.83	1.91e-28	2.29e-25	-0.58	-0.48	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
THCA	cis	rs7772486	0.79	rs1854900	ENSG00000235652.6	RP11-545I5.3	11.83	1.91e-28	2.29e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146010246	chr6:145799409~145886585:+
THCA	cis	rs1858037	0.867	rs1553675	ENSG00000204929.10	AC074391.1	-11.83	1.93e-28	2.32e-25	-0.63	-0.48	Rheumatoid arthritis;	chr2:65343173	chr2:65436711~66084639:+
THCA	cis	rs26232	0.521	rs11958562	ENSG00000175749.11	EIF3KP1	11.83	1.93e-28	2.32e-25	0.63	0.48	Rheumatoid arthritis;	chr5:103027357	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.84	rs2009291	ENSG00000258413.1	RP11-665C16.6	11.83	1.97e-28	2.36e-25	0.62	0.48	Protein biomarker;	chr14:55371512	chr14:55262767~55272075:-
THCA	cis	rs6452524	0.967	rs12186460	ENSG00000249664.1	CTD-2227C6.2	11.83	1.99e-28	2.38e-25	0.6	0.48	Hypertension (SNP x SNP interaction);	chr5:83123950	chr5:83012285~83013109:-
THCA	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-11.83	1.99e-28	2.38e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
THCA	cis	rs2288884	0.559	rs9636139	ENSG00000275055.1	CTC-471J1.11	-11.83	2e-28	2.39e-25	-0.38	-0.48	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018043	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs12610953	ENSG00000275055.1	CTC-471J1.11	-11.83	2e-28	2.39e-25	-0.38	-0.48	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52018675	chr19:52049007~52049754:+
THCA	cis	rs4819052	0.851	rs35064782	ENSG00000223768.1	LINC00205	-11.82	2.02e-28	2.42e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45293285~45297354:+
THCA	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	11.82	2.03e-28	2.43e-25	0.57	0.48	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
THCA	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-11.82	2.05e-28	2.46e-25	-0.55	-0.48	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
THCA	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-11.82	2.05e-28	2.46e-25	-0.55	-0.48	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
THCA	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-11.82	2.05e-28	2.46e-25	-0.55	-0.48	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
THCA	cis	rs9322193	0.923	rs4242279	ENSG00000223701.3	RAET1E-AS1	11.82	2.08e-28	2.49e-25	0.66	0.48	Lung cancer;	chr6:149839815	chr6:149884431~149919508:+
THCA	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-11.82	2.08e-28	2.49e-25	-0.66	-0.48	Depression;	chr6:28071808	chr6:28115628~28116551:+
THCA	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	11.82	2.09e-28	2.5e-25	0.55	0.48	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
THCA	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-11.82	2.1e-28	2.52e-25	-0.59	-0.48	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-11.82	2.1e-28	2.52e-25	-0.59	-0.48	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-11.82	2.1e-28	2.52e-25	-0.59	-0.48	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-11.82	2.1e-28	2.52e-25	-0.59	-0.48	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
THCA	cis	rs1858037	0.867	rs1039765	ENSG00000204929.10	AC074391.1	-11.82	2.13e-28	2.54e-25	-0.62	-0.48	Rheumatoid arthritis;	chr2:65387228	chr2:65436711~66084639:+
THCA	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-11.82	2.15e-28	2.57e-25	-0.82	-0.48	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
THCA	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	11.82	2.16e-28	2.59e-25	0.9	0.48	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
THCA	cis	rs11098499	0.644	rs3806808	ENSG00000245958.5	RP11-33B1.1	-11.82	2.17e-28	2.6e-25	-0.46	-0.48	Corneal astigmatism;	chr4:119629930	chr4:119454791~119552025:+
THCA	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-11.81	2.2e-28	2.63e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-11.81	2.2e-28	2.63e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-11.81	2.2e-28	2.63e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs3817040	ENSG00000272758.4	RP11-299J3.8	-11.81	2.2e-28	2.63e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122535922	chr3:122416207~122443180:+
THCA	cis	rs2274273	0.87	rs7158768	ENSG00000258413.1	RP11-665C16.6	-11.81	2.23e-28	2.67e-25	-0.61	-0.48	Protein biomarker;	chr14:55296894	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs10142547	ENSG00000258413.1	RP11-665C16.6	-11.81	2.23e-28	2.67e-25	-0.61	-0.48	Protein biomarker;	chr14:55297245	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs8023197	ENSG00000258413.1	RP11-665C16.6	-11.81	2.23e-28	2.67e-25	-0.61	-0.48	Protein biomarker;	chr14:55300677	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.837	rs7148171	ENSG00000258413.1	RP11-665C16.6	-11.81	2.23e-28	2.67e-25	-0.61	-0.48	Protein biomarker;	chr14:55304026	chr14:55262767~55272075:-
THCA	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	11.81	2.24e-28	2.68e-25	0.65	0.48	Depression;	chr6:28110525	chr6:28115628~28116551:+
THCA	cis	rs6570726	0.846	rs9376954	ENSG00000235652.6	RP11-545I5.3	11.81	2.24e-28	2.68e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145622601	chr6:145799409~145886585:+
THCA	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-11.81	2.25e-28	2.68e-25	-0.55	-0.48	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
THCA	cis	rs11159086	0.941	rs11846588	ENSG00000259005.1	RP3-449M8.6	11.81	2.25e-28	2.69e-25	0.48	0.48	Advanced glycation end-product levels;	chr14:74505398	chr14:74474007~74474864:-
THCA	cis	rs7182621	0.546	rs12906587	ENSG00000259363.4	CTD-2054N24.2	11.81	2.26e-28	2.7e-25	0.66	0.48	Colonoscopy-negative controls vs population controls;	chr15:99837114	chr15:99807023~99877148:+
THCA	cis	rs853679	0.517	rs9283884	ENSG00000280107.1	AL022393.9	11.81	2.27e-28	2.71e-25	0.58	0.48	Depression;	chr6:28167882	chr6:28170845~28172521:+
THCA	cis	rs6142102	0.923	rs6057961	ENSG00000276073.1	RP5-1125A11.7	-11.81	2.29e-28	2.74e-25	-0.46	-0.48	Skin pigmentation;	chr20:33986005	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.923	rs4911394	ENSG00000276073.1	RP5-1125A11.7	-11.81	2.29e-28	2.74e-25	-0.46	-0.48	Skin pigmentation;	chr20:33989521	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs1007090	ENSG00000276073.1	RP5-1125A11.7	-11.81	2.29e-28	2.74e-25	-0.46	-0.48	Skin pigmentation;	chr20:33995065	chr20:33985617~33988989:-
THCA	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	11.81	2.29e-28	2.74e-25	0.55	0.48	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
THCA	cis	rs11214589	0.747	rs11493880	ENSG00000270179.1	RP11-159N11.4	-11.81	2.3e-28	2.74e-25	-0.51	-0.48	Neuroticism;	chr11:113354422	chr11:113368478~113369117:+
THCA	cis	rs6570726	0.791	rs401331	ENSG00000235652.6	RP11-545I5.3	11.81	2.32e-28	2.77e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145510272	chr6:145799409~145886585:+
THCA	cis	rs673078	0.66	rs61945190	ENSG00000275759.1	RP11-131L12.3	-11.81	2.34e-28	2.79e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118231345	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs7977403	ENSG00000275759.1	RP11-131L12.3	-11.81	2.34e-28	2.79e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118233446	chr12:118428281~118428870:+
THCA	cis	rs7772486	0.558	rs9497403	ENSG00000235652.6	RP11-545I5.3	-11.81	2.34e-28	2.79e-25	-0.48	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145733559	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.727	rs2235481	ENSG00000235652.6	RP11-545I5.3	-11.81	2.34e-28	2.79e-25	-0.48	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145735712	chr6:145799409~145886585:+
THCA	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	11.81	2.36e-28	2.82e-25	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
THCA	cis	rs2882667	0.537	rs7701116	ENSG00000253404.1	AC034243.1	11.81	2.37e-28	2.82e-25	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070389	chr5:138744434~138753309:-
THCA	cis	rs2274273	0.87	rs13379169	ENSG00000258413.1	RP11-665C16.6	-11.81	2.37e-28	2.82e-25	-0.61	-0.48	Protein biomarker;	chr14:55274569	chr14:55262767~55272075:-
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-11.81	2.37e-28	2.82e-25	-0.61	-0.48	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
THCA	cis	rs7772486	0.79	rs3924498	ENSG00000235652.6	RP11-545I5.3	-11.81	2.39e-28	2.85e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145912202	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9390365	ENSG00000235652.6	RP11-545I5.3	-11.81	2.39e-28	2.85e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145914490	chr6:145799409~145886585:+
THCA	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-11.81	2.39e-28	2.85e-25	-0.62	-0.48	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
THCA	cis	rs9928842	0.882	rs8048956	ENSG00000280152.1	RP11-331F4.5	-11.81	2.39e-28	2.85e-25	-0.63	-0.48	Alcoholic chronic pancreatitis;	chr16:75221068	chr16:75245994~75250077:-
THCA	cis	rs7182621	0.639	rs34701806	ENSG00000259363.4	CTD-2054N24.2	-11.81	2.4e-28	2.86e-25	-0.71	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99872953	chr15:99807023~99877148:+
THCA	cis	rs9481169	0.557	rs13194006	ENSG00000255389.1	C6orf3	-11.81	2.4e-28	2.86e-25	-0.92	-0.48	Inflammatory skin disease;	chr6:111575051	chr6:111599875~111602295:+
THCA	cis	rs9322193	0.923	rs9767652	ENSG00000223701.3	RAET1E-AS1	11.8	2.41e-28	2.87e-25	0.65	0.48	Lung cancer;	chr6:149734502	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10782314	ENSG00000223701.3	RAET1E-AS1	11.8	2.41e-28	2.87e-25	0.65	0.48	Lung cancer;	chr6:149735527	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.516	rs1999632	ENSG00000231760.4	RP11-350J20.5	11.8	2.42e-28	2.88e-25	0.7	0.48	Lung cancer;	chr6:149866737	chr6:149796151~149826294:-
THCA	cis	rs9659323	0.67	rs17023223	ENSG00000231365.4	RP11-418J17.1	-11.8	2.42e-28	2.88e-25	-0.47	-0.48	Body mass index;	chr1:119088551	chr1:119140396~119275973:+
THCA	cis	rs9659323	0.67	rs61808898	ENSG00000231365.4	RP11-418J17.1	-11.8	2.42e-28	2.88e-25	-0.47	-0.48	Body mass index;	chr1:119096232	chr1:119140396~119275973:+
THCA	cis	rs8100891	0.537	rs4805754	ENSG00000267213.4	AC007773.2	-11.8	2.43e-28	2.89e-25	-0.56	-0.48	Neuroticism;	chr19:32346260	chr19:32390050~32405560:-
THCA	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	11.8	2.44e-28	2.9e-25	0.57	0.48	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
THCA	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-11.8	2.44e-28	2.9e-25	-0.53	-0.48	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
THCA	cis	rs6496932	1	rs12917518	ENSG00000218052.5	ADAMTS7P4	11.8	2.45e-28	2.92e-25	0.65	0.48	Central corneal thickness;Corneal structure;	chr15:85284018	chr15:85255369~85330334:-
THCA	cis	rs6496932	1	rs28374025	ENSG00000218052.5	ADAMTS7P4	11.8	2.45e-28	2.92e-25	0.65	0.48	Central corneal thickness;Corneal structure;	chr15:85284107	chr15:85255369~85330334:-
THCA	cis	rs8040855	0.575	rs12912860	ENSG00000259295.5	CSPG4P12	11.8	2.48e-28	2.95e-25	0.73	0.48	Bulimia nervosa;	chr15:85030267	chr15:85191438~85213905:+
THCA	cis	rs9322193	0.923	rs4870052	ENSG00000223701.3	RAET1E-AS1	11.8	2.48e-28	2.95e-25	0.66	0.48	Lung cancer;	chr6:149839978	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.79	rs2247429	ENSG00000235652.6	RP11-545I5.3	11.8	2.48e-28	2.95e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145896633	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2247666	ENSG00000235652.6	RP11-545I5.3	11.8	2.48e-28	2.95e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145899273	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs3923579	ENSG00000235652.6	RP11-545I5.3	-11.8	2.48e-28	2.95e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145909096	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.765	rs2838852	ENSG00000223768.1	LINC00205	-11.8	2.48e-28	2.96e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45293285~45297354:+
THCA	cis	rs6142102	0.886	rs4911147	ENSG00000276073.1	RP5-1125A11.7	-11.8	2.49e-28	2.96e-25	-0.46	-0.48	Skin pigmentation;	chr20:34079801	chr20:33985617~33988989:-
THCA	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-11.8	2.49e-28	2.97e-25	-0.56	-0.48	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
THCA	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-11.8	2.51e-28	2.99e-25	-0.56	-0.48	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
THCA	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	11.8	2.51e-28	2.99e-25	0.56	0.48	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
THCA	cis	rs7772486	0.79	rs9485024	ENSG00000235652.6	RP11-545I5.3	-11.8	2.53e-28	3.01e-25	-0.47	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145821351	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.901	rs112870553	ENSG00000258413.1	RP11-665C16.6	-11.8	2.53e-28	3.01e-25	-0.61	-0.48	Protein biomarker;	chr14:55323344	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.837	rs6573017	ENSG00000258413.1	RP11-665C16.6	-11.8	2.53e-28	3.01e-25	-0.61	-0.48	Protein biomarker;	chr14:55335525	chr14:55262767~55272075:-
THCA	cis	rs12468226	0.938	rs77062060	ENSG00000273456.1	RP11-686O6.2	11.8	2.54e-28	3.02e-25	0.59	0.48	Urate levels;	chr2:202285639	chr2:202374932~202375604:-
THCA	cis	rs6142102	0.961	rs4911385	ENSG00000276073.1	RP5-1125A11.7	-11.8	2.54e-28	3.02e-25	-0.45	-0.48	Skin pigmentation;	chr20:33970787	chr20:33985617~33988989:-
THCA	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-11.8	2.54e-28	3.03e-25	-0.6	-0.48	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
THCA	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	11.8	2.56e-28	3.04e-25	0.57	0.48	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
THCA	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	11.8	2.56e-28	3.04e-25	0.59	0.48	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
THCA	cis	rs6142102	0.961	rs4911405	ENSG00000276073.1	RP5-1125A11.7	-11.8	2.58e-28	3.07e-25	-0.46	-0.48	Skin pigmentation;	chr20:34087161	chr20:33985617~33988989:-
THCA	cis	rs1858037	0.867	rs67453645	ENSG00000204929.10	AC074391.1	11.8	2.6e-28	3.09e-25	0.63	0.48	Rheumatoid arthritis;	chr2:65358908	chr2:65436711~66084639:+
THCA	cis	rs2274273	0.87	rs1109170	ENSG00000258413.1	RP11-665C16.6	-11.8	2.61e-28	3.1e-25	-0.61	-0.48	Protein biomarker;	chr14:55319070	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.837	rs10141483	ENSG00000258413.1	RP11-665C16.6	-11.8	2.61e-28	3.1e-25	-0.61	-0.48	Protein biomarker;	chr14:55320153	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.837	rs10131913	ENSG00000258413.1	RP11-665C16.6	-11.8	2.61e-28	3.1e-25	-0.61	-0.48	Protein biomarker;	chr14:55320702	chr14:55262767~55272075:-
THCA	cis	rs673078	0.66	rs17440433	ENSG00000275759.1	RP11-131L12.3	-11.8	2.61e-28	3.1e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118201507	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs17512219	ENSG00000275759.1	RP11-131L12.3	-11.8	2.61e-28	3.1e-25	-0.74	-0.48	Glucose homeostasis traits;	chr12:118211468	chr12:118428281~118428870:+
THCA	cis	rs1858037	0.867	rs61226353	ENSG00000204929.10	AC074391.1	11.8	2.62e-28	3.11e-25	0.63	0.48	Rheumatoid arthritis;	chr2:65363637	chr2:65436711~66084639:+
THCA	cis	rs9659323	0.67	rs10157346	ENSG00000231365.4	RP11-418J17.1	-11.8	2.62e-28	3.12e-25	-0.47	-0.48	Body mass index;	chr1:119090924	chr1:119140396~119275973:+
THCA	cis	rs9659323	0.67	rs12095067	ENSG00000231365.4	RP11-418J17.1	-11.8	2.62e-28	3.12e-25	-0.47	-0.48	Body mass index;	chr1:119093110	chr1:119140396~119275973:+
THCA	cis	rs9322193	0.923	rs9689716	ENSG00000223701.3	RAET1E-AS1	11.79	2.65e-28	3.14e-25	0.64	0.48	Lung cancer;	chr6:149655662	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9322207	ENSG00000223701.3	RAET1E-AS1	11.79	2.65e-28	3.14e-25	0.64	0.48	Lung cancer;	chr6:149657185	chr6:149884431~149919508:+
THCA	cis	rs6142102	0.961	rs6059649	ENSG00000276073.1	RP5-1125A11.7	-11.79	2.66e-28	3.15e-25	-0.46	-0.48	Skin pigmentation;	chr20:34056071	chr20:33985617~33988989:-
THCA	cis	rs7772486	0.623	rs9485021	ENSG00000235652.6	RP11-545I5.3	-11.79	2.67e-28	3.17e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145747661	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.714	rs7154889	ENSG00000258413.1	RP11-665C16.6	-11.79	2.67e-28	3.18e-25	-0.61	-0.48	Protein biomarker;	chr14:55340167	chr14:55262767~55272075:-
THCA	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	11.79	2.68e-28	3.18e-25	0.6	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
THCA	cis	rs7772486	0.846	rs866473	ENSG00000235652.6	RP11-545I5.3	11.79	2.7e-28	3.21e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146032278	chr6:145799409~145886585:+
THCA	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-11.79	2.71e-28	3.22e-25	-0.59	-0.48	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
THCA	cis	rs6570726	0.791	rs379040	ENSG00000235652.6	RP11-545I5.3	11.79	2.75e-28	3.26e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145567899	chr6:145799409~145886585:+
THCA	cis	rs673078	0.66	rs61943535	ENSG00000275759.1	RP11-131L12.3	-11.79	2.78e-28	3.3e-25	-0.73	-0.48	Glucose homeostasis traits;	chr12:118168307	chr12:118428281~118428870:+
THCA	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-11.79	2.8e-28	3.32e-25	-0.59	-0.48	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
THCA	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	11.79	2.8e-28	3.32e-25	0.58	0.48	Depression;	chr6:28301886	chr6:28176188~28176674:+
THCA	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	11.79	2.8e-28	3.33e-25	0.63	0.48	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	11.79	2.8e-28	3.33e-25	0.63	0.48	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	11.79	2.8e-28	3.33e-25	0.63	0.48	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
THCA	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	11.79	2.8e-28	3.33e-25	0.63	0.48	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	11.79	2.8e-28	3.33e-25	0.63	0.48	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
THCA	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	11.79	2.83e-28	3.35e-25	0.83	0.48	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
THCA	cis	rs853679	0.517	rs4713145	ENSG00000219392.1	RP1-265C24.5	-11.79	2.84e-28	3.36e-25	-0.66	-0.48	Depression;	chr6:28139049	chr6:28115628~28116551:+
THCA	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	11.79	2.84e-28	3.37e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	11.79	2.84e-28	3.37e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
THCA	cis	rs9322193	0.923	rs4870529	ENSG00000223701.3	RAET1E-AS1	11.79	2.86e-28	3.39e-25	0.64	0.48	Lung cancer;	chr6:149716436	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9767309	ENSG00000223701.3	RAET1E-AS1	11.79	2.86e-28	3.39e-25	0.64	0.48	Lung cancer;	chr6:149716807	chr6:149884431~149919508:+
THCA	cis	rs6142102	0.961	rs6057957	ENSG00000276073.1	RP5-1125A11.7	-11.79	2.87e-28	3.4e-25	-0.45	-0.48	Skin pigmentation;	chr20:33962052	chr20:33985617~33988989:-
THCA	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-11.79	2.88e-28	3.41e-25	-0.58	-0.48	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
THCA	cis	rs2283792	0.935	rs9610375	ENSG00000224086.5	LL22NC03-86G7.1	-11.78	2.91e-28	3.45e-25	-0.56	-0.48	Multiple sclerosis;	chr22:21832804	chr22:21938293~21977632:+
THCA	cis	rs853679	0.517	rs6922063	ENSG00000280107.1	AL022393.9	-11.78	2.91e-28	3.45e-25	-0.58	-0.48	Depression;	chr6:28126588	chr6:28170845~28172521:+
THCA	cis	rs853679	0.517	rs2275508	ENSG00000280107.1	AL022393.9	-11.78	2.91e-28	3.45e-25	-0.58	-0.48	Depression;	chr6:28126953	chr6:28170845~28172521:+
THCA	cis	rs6142102	0.961	rs2377957	ENSG00000276073.1	RP5-1125A11.7	-11.78	2.93e-28	3.47e-25	-0.44	-0.48	Skin pigmentation;	chr20:33966667	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.84	rs914217	ENSG00000223768.1	LINC00205	-11.78	2.93e-28	3.47e-25	-0.49	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.923	rs17745062	ENSG00000223701.3	RAET1E-AS1	11.78	2.94e-28	3.48e-25	0.64	0.48	Lung cancer;	chr6:149721079	chr6:149884431~149919508:+
THCA	cis	rs6142102	0.961	rs6059651	ENSG00000276073.1	RP5-1125A11.7	-11.78	2.94e-28	3.48e-25	-0.46	-0.48	Skin pigmentation;	chr20:34057246	chr20:33985617~33988989:-
THCA	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	11.78	2.95e-28	3.5e-25	0.4	0.48	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
THCA	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-11.78	2.96e-28	3.51e-25	-0.65	-0.48	Depression;	chr6:28123153	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-11.78	2.96e-28	3.51e-25	-0.65	-0.48	Depression;	chr6:28124529	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-11.78	2.96e-28	3.51e-25	-0.65	-0.48	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-11.78	2.96e-28	3.51e-25	-0.65	-0.48	Depression;	chr6:28127577	chr6:28115628~28116551:+
THCA	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	11.78	3e-28	3.55e-25	0.89	0.48	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	11.78	3e-28	3.55e-25	0.89	0.48	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	11.78	3e-28	3.55e-25	0.89	0.48	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	11.78	3e-28	3.55e-25	0.89	0.48	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	11.78	3e-28	3.55e-25	0.89	0.48	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
THCA	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	11.78	3.02e-28	3.57e-25	0.73	0.48	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
THCA	cis	rs6570726	0.846	rs426874	ENSG00000235652.6	RP11-545I5.3	11.78	3.04e-28	3.6e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145559494	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs4870050	ENSG00000223701.3	RAET1E-AS1	11.78	3.05e-28	3.61e-25	0.66	0.48	Lung cancer;	chr6:149838917	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs7752089	ENSG00000223701.3	RAET1E-AS1	11.78	3.05e-28	3.61e-25	0.66	0.48	Lung cancer;	chr6:149839298	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs1108889	ENSG00000268592.3	RAET1E-AS1	11.78	3.05e-28	3.61e-25	0.67	0.48	Lung cancer;	chr6:149845433	chr6:149863494~149919507:+
THCA	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-11.78	3.05e-28	3.61e-25	-0.64	-0.48	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
THCA	cis	rs526231	0.543	rs246916	ENSG00000175749.11	EIF3KP1	11.78	3.05e-28	3.61e-25	0.64	0.48	Primary biliary cholangitis;	chr5:103221814	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	11.78	3.05e-28	3.61e-25	0.63	0.48	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
THCA	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	11.78	3.07e-28	3.64e-25	0.57	0.48	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
THCA	cis	rs6142102	0.961	rs8123521	ENSG00000276073.1	RP5-1125A11.7	-11.78	3.08e-28	3.64e-25	-0.46	-0.48	Skin pigmentation;	chr20:34081079	chr20:33985617~33988989:-
THCA	cis	rs673078	0.66	rs17512177	ENSG00000275759.1	RP11-131L12.3	-11.78	3.08e-28	3.65e-25	-0.73	-0.48	Glucose homeostasis traits;	chr12:118192335	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs17512198	ENSG00000275759.1	RP11-131L12.3	-11.78	3.08e-28	3.65e-25	-0.73	-0.48	Glucose homeostasis traits;	chr12:118194217	chr12:118428281~118428870:+
THCA	cis	rs992157	0.71	rs6752254	ENSG00000261338.2	RP11-378A13.1	11.78	3.09e-28	3.66e-25	0.49	0.48	Colorectal cancer;	chr2:218194020	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.923	rs9688350	ENSG00000223701.3	RAET1E-AS1	11.78	3.1e-28	3.67e-25	0.64	0.48	Lung cancer;	chr6:149730977	chr6:149884431~149919508:+
THCA	cis	rs7188445	0.736	rs4889012	ENSG00000261390.4	RP11-345M22.2	11.78	3.11e-28	3.68e-25	0.56	0.48	Urate levels;	chr16:79667485	chr16:79715232~79770563:-
THCA	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	11.78	3.13e-28	3.7e-25	0.79	0.48	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
THCA	cis	rs62103177	0.564	rs7228971	ENSG00000261126.6	RP11-795F19.1	-11.78	3.14e-28	3.71e-25	-0.54	-0.48	Opioid sensitivity;	chr18:79978025	chr18:80046900~80095482:+
THCA	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	11.78	3.16e-28	3.73e-25	0.58	0.48	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	11.78	3.16e-28	3.73e-25	0.58	0.48	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	11.78	3.16e-28	3.73e-25	0.58	0.48	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	11.78	3.16e-28	3.73e-25	0.58	0.48	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	11.78	3.16e-28	3.73e-25	0.58	0.48	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
THCA	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	11.78	3.16e-28	3.73e-25	0.58	0.48	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
THCA	cis	rs7772486	0.686	rs4896833	ENSG00000235652.6	RP11-545I5.3	11.78	3.16e-28	3.73e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145644537	chr6:145799409~145886585:+
THCA	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-11.77	3.2e-28	3.78e-25	-0.58	-0.48	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
THCA	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	11.77	3.25e-28	3.84e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
THCA	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	11.77	3.26e-28	3.85e-25	0.57	0.48	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
THCA	cis	rs6538678	0.824	rs7307510	ENSG00000258343.1	RP11-536G4.2	-11.77	3.27e-28	3.86e-25	-0.72	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95795345~95858839:-
THCA	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	11.77	3.28e-28	3.87e-25	0.58	0.48	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
THCA	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-11.77	3.28e-28	3.88e-25	-0.63	-0.48	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
THCA	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-11.77	3.32e-28	3.92e-25	-0.55	-0.48	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
THCA	cis	rs673078	0.66	rs61946063	ENSG00000275759.1	RP11-131L12.3	-11.77	3.33e-28	3.93e-25	-0.6	-0.48	Glucose homeostasis traits;	chr12:118294448	chr12:118428281~118428870:+
THCA	cis	rs944289	0.617	rs1958617	ENSG00000257826.1	RP11-116N8.4	-11.77	3.34e-28	3.95e-25	-0.52	-0.48	Thyroid cancer;	chr14:36118418	chr14:36061026~36067190:-
THCA	cis	rs9322193	0.884	rs880245	ENSG00000268592.3	RAET1E-AS1	-11.77	3.35e-28	3.95e-25	-0.67	-0.48	Lung cancer;	chr6:149846262	chr6:149863494~149919507:+
THCA	cis	rs6570726	0.791	rs398408	ENSG00000235652.6	RP11-545I5.3	11.77	3.35e-28	3.95e-25	0.45	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145479884	chr6:145799409~145886585:+
THCA	cis	rs11105298	0.891	rs4842662	ENSG00000258302.2	RP11-981P6.1	11.77	3.37e-28	3.97e-25	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539669	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs3825330	ENSG00000258302.2	RP11-981P6.1	11.77	3.37e-28	3.97e-25	0.46	0.48	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:89561129~89594878:+
THCA	cis	rs7772486	0.875	rs9399572	ENSG00000235652.6	RP11-545I5.3	11.77	3.38e-28	3.99e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146041809	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.817	rs9386145	ENSG00000235652.6	RP11-545I5.3	11.77	3.38e-28	3.99e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146042383	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9390372	ENSG00000235652.6	RP11-545I5.3	11.77	3.38e-28	3.99e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146042502	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9373483	ENSG00000235652.6	RP11-545I5.3	11.77	3.38e-28	3.99e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146043058	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs7766595	ENSG00000235652.6	RP11-545I5.3	11.77	3.38e-28	3.99e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146043371	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	11.77	3.39e-28	4e-25	0.56	0.48	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
THCA	cis	rs6570726	0.846	rs446031	ENSG00000235652.6	RP11-545I5.3	11.77	3.4e-28	4.01e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145564456	chr6:145799409~145886585:+
THCA	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	11.77	3.43e-28	4.05e-25	0.55	0.48	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
THCA	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	11.77	3.44e-28	4.06e-25	0.56	0.48	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
THCA	cis	rs10463554	0.927	rs468844	ENSG00000175749.11	EIF3KP1	11.77	3.45e-28	4.06e-25	0.63	0.48	Parkinson's disease;	chr5:103087872	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs469094	ENSG00000175749.11	EIF3KP1	11.77	3.45e-28	4.06e-25	0.63	0.48	Parkinson's disease;	chr5:103087875	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	11.77	3.45e-28	4.06e-25	0.63	0.48	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	11.77	3.45e-28	4.06e-25	0.63	0.48	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
THCA	cis	rs673078	0.66	rs73205531	ENSG00000275759.1	RP11-131L12.3	-11.76	3.47e-28	4.09e-25	-0.73	-0.48	Glucose homeostasis traits;	chr12:118282063	chr12:118428281~118428870:+
THCA	cis	rs3762637	1	rs10049131	ENSG00000272758.4	RP11-299J3.8	-11.76	3.48e-28	4.1e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122483255	chr3:122416207~122443180:+
THCA	cis	rs7569084	1	rs7569084	ENSG00000281920.1	RP11-418H16.1	-11.76	3.48e-28	4.1e-25	-0.59	-0.48	Sum eosinophil basophil counts;	chr2:65429835	chr2:65623272~65628424:+
THCA	cis	rs6142102	0.961	rs2284387	ENSG00000276073.1	RP5-1125A11.7	-11.76	3.48e-28	4.11e-25	-0.46	-0.48	Skin pigmentation;	chr20:34056782	chr20:33985617~33988989:-
THCA	cis	rs7772486	0.558	rs702322	ENSG00000235652.6	RP11-545I5.3	-11.76	3.49e-28	4.12e-25	-0.48	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145686030	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.558	rs2142978	ENSG00000235652.6	RP11-545I5.3	-11.76	3.49e-28	4.12e-25	-0.48	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145690925	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs1569540	ENSG00000235652.6	RP11-545I5.3	-11.76	3.5e-28	4.12e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145747976	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.686	rs2142983	ENSG00000235652.6	RP11-545I5.3	-11.76	3.5e-28	4.12e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145748565	chr6:145799409~145886585:+
THCA	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-11.76	3.51e-28	4.13e-25	-0.56	-0.48	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
THCA	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	11.76	3.53e-28	4.15e-25	0.62	0.48	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
THCA	cis	rs2288884	0.559	rs6509611	ENSG00000275055.1	CTC-471J1.11	-11.76	3.56e-28	4.19e-25	-0.37	-0.48	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006953	chr19:52049007~52049754:+
THCA	cis	rs10463554	0.927	rs257316	ENSG00000175749.11	EIF3KP1	-11.76	3.59e-28	4.23e-25	-0.63	-0.48	Parkinson's disease;	chr5:103086739	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.875	rs2474356	ENSG00000235652.6	RP11-545I5.3	11.76	3.59e-28	4.23e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145975662	chr6:145799409~145886585:+
THCA	cis	rs673078	0.66	rs9943819	ENSG00000275759.1	RP11-131L12.3	-11.76	3.61e-28	4.25e-25	-0.6	-0.48	Glucose homeostasis traits;	chr12:118298917	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs61946067	ENSG00000275759.1	RP11-131L12.3	-11.76	3.61e-28	4.25e-25	-0.73	-0.48	Glucose homeostasis traits;	chr12:118303152	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61946068	ENSG00000275759.1	RP11-131L12.3	-11.76	3.61e-28	4.25e-25	-0.73	-0.48	Glucose homeostasis traits;	chr12:118305861	chr12:118428281~118428870:+
THCA	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	11.76	3.61e-28	4.25e-25	0.6	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	11.76	3.66e-28	4.3e-25	0.67	0.48	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
THCA	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-11.76	3.66e-28	4.31e-25	-0.56	-0.48	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
THCA	cis	rs11214589	0.747	rs11214582	ENSG00000270179.1	RP11-159N11.4	-11.76	3.68e-28	4.33e-25	-0.5	-0.48	Neuroticism;	chr11:113347328	chr11:113368478~113369117:+
THCA	cis	rs6538678	0.818	rs1036429	ENSG00000258343.1	RP11-536G4.2	-11.76	3.71e-28	4.37e-25	-0.71	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95795345~95858839:-
THCA	cis	rs12458462	0.665	rs2035085	ENSG00000274828.1	RP11-567M16.6	11.76	3.72e-28	4.37e-25	0.39	0.48	Monocyte count;	chr18:79725280	chr18:79677287~79679358:-
THCA	cis	rs7772486	0.686	rs1011596	ENSG00000235652.6	RP11-545I5.3	11.76	3.74e-28	4.4e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145755297	chr6:145799409~145886585:+
THCA	cis	rs638893	1	rs638893	ENSG00000278376.1	RP11-158I9.8	-11.76	3.77e-28	4.43e-25	-0.51	-0.48	Vitiligo;	chr11:118827828	chr11:118791254~118793137:+
THCA	cis	rs638893	1	rs28827279	ENSG00000278376.1	RP11-158I9.8	-11.76	3.77e-28	4.43e-25	-0.51	-0.48	Vitiligo;	chr11:118830054	chr11:118791254~118793137:+
THCA	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	11.76	3.78e-28	4.44e-25	0.57	0.48	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
THCA	cis	rs9322193	0.923	rs35961297	ENSG00000223701.3	RAET1E-AS1	11.76	3.79e-28	4.46e-25	0.64	0.48	Lung cancer;	chr6:149667929	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs35967444	ENSG00000223701.3	RAET1E-AS1	11.76	3.79e-28	4.46e-25	0.64	0.48	Lung cancer;	chr6:149675588	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs62439842	ENSG00000223701.3	RAET1E-AS1	11.76	3.79e-28	4.46e-25	0.64	0.48	Lung cancer;	chr6:149675847	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.79	rs3924499	ENSG00000235652.6	RP11-545I5.3	-11.75	3.82e-28	4.49e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145911842	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.851	rs8127834	ENSG00000223768.1	LINC00205	-11.75	3.83e-28	4.51e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45293285~45297354:+
THCA	cis	rs62103177	0.564	rs1715230	ENSG00000261126.6	RP11-795F19.1	11.75	3.86e-28	4.54e-25	0.53	0.48	Opioid sensitivity;	chr18:80090098	chr18:80046900~80095482:+
THCA	cis	rs6142102	0.961	rs4911146	ENSG00000276073.1	RP5-1125A11.7	-11.75	3.88e-28	4.56e-25	-0.46	-0.48	Skin pigmentation;	chr20:34052241	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs2838834	ENSG00000223768.1	LINC00205	-11.75	3.88e-28	4.57e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45293285~45297354:+
THCA	cis	rs274567	0.599	rs11242110	ENSG00000233006.5	AC034220.3	-11.75	3.92e-28	4.6e-25	-0.36	-0.48	Blood metabolite levels;	chr5:132408085	chr5:132311285~132369916:-
THCA	cis	rs524281	0.506	rs512421	ENSG00000255320.1	RP11-755F10.1	11.75	3.96e-28	4.65e-25	0.65	0.48	Electroencephalogram traits;	chr11:66217697	chr11:66244840~66246239:-
THCA	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-11.75	4e-28	4.7e-25	-0.56	-0.48	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
THCA	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	11.75	4.03e-28	4.73e-25	0.6	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
THCA	cis	rs1858037	0.806	rs12612780	ENSG00000204929.10	AC074391.1	11.75	4.03e-28	4.73e-25	0.63	0.48	Rheumatoid arthritis;	chr2:65355967	chr2:65436711~66084639:+
THCA	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-11.75	4.05e-28	4.75e-25	-0.65	-0.48	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
THCA	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-11.75	4.05e-28	4.75e-25	-0.59	-0.48	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
THCA	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	11.75	4.05e-28	4.76e-25	0.59	0.48	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
THCA	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	11.75	4.09e-28	4.8e-25	0.58	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
THCA	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	11.75	4.09e-28	4.8e-25	0.57	0.48	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000228039.3	KB-1125A3.10	11.75	4.12e-28	4.83e-25	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23963780~23964374:+
THCA	cis	rs6558530	0.666	rs7005699	ENSG00000253982.1	CTD-2336O2.1	11.75	4.12e-28	4.83e-25	0.46	0.48	Systolic blood pressure;	chr8:1752454	chr8:1761990~1764502:-
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-11.75	4.13e-28	4.85e-25	-0.61	-0.48	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
THCA	cis	rs7182621	0.639	rs12906050	ENSG00000259363.4	CTD-2054N24.2	-11.75	4.14e-28	4.86e-25	-0.71	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99873384	chr15:99807023~99877148:+
THCA	cis	rs7182621	0.639	rs35248328	ENSG00000259363.4	CTD-2054N24.2	-11.75	4.14e-28	4.86e-25	-0.71	-0.48	Colonoscopy-negative controls vs population controls;	chr15:99873399	chr15:99807023~99877148:+
THCA	cis	rs34375054	0.553	rs12580221	ENSG00000279233.1	RP11-158L12.4	11.75	4.16e-28	4.88e-25	0.45	0.48	Post bronchodilator FEV1/FVC ratio;	chr12:125136520	chr12:125138245~125141711:+
THCA	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-11.74	4.19e-28	4.91e-25	-0.56	-0.48	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.847	rs62439808	ENSG00000223701.3	RAET1E-AS1	11.74	4.25e-28	4.98e-25	0.63	0.48	Lung cancer;	chr6:149629690	chr6:149884431~149919508:+
THCA	cis	rs9659323	0.67	rs6701378	ENSG00000231365.4	RP11-418J17.1	-11.74	4.27e-28	5e-25	-0.47	-0.48	Body mass index;	chr1:119095930	chr1:119140396~119275973:+
THCA	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	11.74	4.27e-28	5e-25	0.59	0.48	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
THCA	cis	rs4964805	0.537	rs11111750	ENSG00000257681.1	RP11-341G23.4	11.74	4.3e-28	5.04e-25	0.55	0.48	Attention deficit hyperactivity disorder;	chr12:103761762	chr12:103746315~103768858:-
THCA	cis	rs12468226	0.938	rs74454549	ENSG00000273456.1	RP11-686O6.2	11.74	4.3e-28	5.04e-25	0.59	0.48	Urate levels;	chr2:202288044	chr2:202374932~202375604:-
THCA	cis	rs2274273	0.84	rs7159144	ENSG00000258413.1	RP11-665C16.6	-11.74	4.3e-28	5.04e-25	-0.61	-0.48	Protein biomarker;	chr14:55354606	chr14:55262767~55272075:-
THCA	cis	rs524281	0.506	rs2298466	ENSG00000255320.1	RP11-755F10.1	11.74	4.31e-28	5.04e-25	0.65	0.48	Electroencephalogram traits;	chr11:66243809	chr11:66244840~66246239:-
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000235689.1	AP000351.13	11.74	4.31e-28	5.05e-25	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:24006305~24008258:-
THCA	cis	rs7773456	0.533	rs9368127	ENSG00000228412.5	RP4-625H18.2	-11.74	4.34e-28	5.08e-25	-0.72	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19802164~19804752:-
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000235689.1	AP000351.13	11.74	4.35e-28	5.1e-25	0.61	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:24006305~24008258:-
THCA	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-11.74	4.37e-28	5.12e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-11.74	4.37e-28	5.12e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
THCA	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-11.74	4.38e-28	5.12e-25	-0.59	-0.48	Height;	chr3:53064759	chr3:53064283~53065091:-
THCA	cis	rs12468226	0.938	rs57571703	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202281997	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs78928733	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202283787	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs16841867	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202303512	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs16839065	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202308774	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs114922024	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202315958	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs77261109	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202316233	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs12466003	ENSG00000273456.1	RP11-686O6.2	11.74	4.39e-28	5.13e-25	0.59	0.48	Urate levels;	chr2:202317317	chr2:202374932~202375604:-
THCA	cis	rs9322193	0.923	rs62441279	ENSG00000223701.3	RAET1E-AS1	11.74	4.4e-28	5.15e-25	0.64	0.48	Lung cancer;	chr6:149721194	chr6:149884431~149919508:+
THCA	cis	rs8100891	0.537	rs1057397	ENSG00000267213.4	AC007773.2	-11.74	4.43e-28	5.18e-25	-0.57	-0.48	Neuroticism;	chr19:32484007	chr19:32390050~32405560:-
THCA	cis	rs8100891	0.537	rs737093	ENSG00000267213.4	AC007773.2	-11.74	4.43e-28	5.18e-25	-0.57	-0.48	Neuroticism;	chr19:32486500	chr19:32390050~32405560:-
THCA	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-11.74	4.48e-28	5.23e-25	-0.59	-0.48	Height;	chr3:53052712	chr3:53064283~53065091:-
THCA	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-11.74	4.52e-28	5.28e-25	-0.45	-0.48	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
THCA	cis	rs8100891	0.537	rs11880569	ENSG00000267213.4	AC007773.2	-11.74	4.53e-28	5.29e-25	-0.57	-0.48	Neuroticism;	chr19:32478348	chr19:32390050~32405560:-
THCA	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Depression;	chr6:28136698	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Depression;	chr6:28136856	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Depression;	chr6:28137418	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Depression;	chr6:28138363	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Depression;	chr6:28138981	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-11.74	4.54e-28	5.31e-25	-0.65	-0.48	Depression;	chr6:28139012	chr6:28115628~28116551:+
THCA	cis	rs1858037	0.867	rs4671660	ENSG00000204929.10	AC074391.1	11.74	4.55e-28	5.31e-25	0.62	0.48	Rheumatoid arthritis;	chr2:65349302	chr2:65436711~66084639:+
THCA	cis	rs2274273	0.84	rs6573013	ENSG00000258413.1	RP11-665C16.6	-11.73	4.64e-28	5.42e-25	-0.61	-0.48	Protein biomarker;	chr14:55269155	chr14:55262767~55272075:-
THCA	cis	rs12460587	0.547	rs56244227	ENSG00000275055.1	CTC-471J1.11	-11.73	4.72e-28	5.51e-25	-0.37	-0.48	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52080439	chr19:52049007~52049754:+
THCA	cis	rs526231	0.575	rs26822	ENSG00000175749.11	EIF3KP1	11.73	4.79e-28	5.58e-25	0.63	0.48	Primary biliary cholangitis;	chr5:103183094	chr5:103032376~103033031:+
THCA	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-11.73	4.79e-28	5.59e-25	-0.58	-0.48	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
THCA	cis	rs6142102	0.961	rs6059587	ENSG00000276073.1	RP5-1125A11.7	-11.73	4.82e-28	5.62e-25	-0.44	-0.48	Skin pigmentation;	chr20:33955120	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs6088355	ENSG00000276073.1	RP5-1125A11.7	-11.73	4.82e-28	5.62e-25	-0.44	-0.48	Skin pigmentation;	chr20:33958081	chr20:33985617~33988989:-
THCA	cis	rs12468226	0.873	rs60722019	ENSG00000273456.1	RP11-686O6.2	11.73	4.85e-28	5.66e-25	0.59	0.48	Urate levels;	chr2:202282060	chr2:202374932~202375604:-
THCA	cis	rs3762637	1	rs78381804	ENSG00000272758.4	RP11-299J3.8	-11.73	4.88e-28	5.69e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122503415	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs28497203	ENSG00000272758.4	RP11-299J3.8	-11.73	4.88e-28	5.69e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122512972	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs9822345	ENSG00000272758.4	RP11-299J3.8	-11.73	4.88e-28	5.69e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122526751	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs78429050	ENSG00000272758.4	RP11-299J3.8	-11.73	4.88e-28	5.69e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122533581	chr3:122416207~122443180:+
THCA	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	11.73	4.89e-28	5.7e-25	0.55	0.48	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
THCA	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	11.73	4.89e-28	5.7e-25	0.89	0.48	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
THCA	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	11.73	4.89e-28	5.7e-25	0.38	0.48	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
THCA	cis	rs7772486	0.875	rs2224121	ENSG00000235652.6	RP11-545I5.3	11.73	4.91e-28	5.72e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146022078	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.851	rs28616694	ENSG00000223768.1	LINC00205	-11.73	4.94e-28	5.75e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.79	rs2254283	ENSG00000235652.6	RP11-545I5.3	11.73	4.94e-28	5.75e-25	0.43	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145883153	chr6:145799409~145886585:+
THCA	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	11.73	4.96e-28	5.78e-25	0.84	0.48	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
THCA	cis	rs3762637	1	rs7644540	ENSG00000272758.4	RP11-299J3.8	-11.73	4.97e-28	5.8e-25	-0.63	-0.48	LDL cholesterol levels;	chr3:122491205	chr3:122416207~122443180:+
THCA	cis	rs2882667	0.537	rs11743534	ENSG00000253404.1	AC034243.1	11.72	5.02e-28	5.85e-25	0.54	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139073318	chr5:138744434~138753309:-
THCA	cis	rs7772486	0.875	rs2180192	ENSG00000235652.6	RP11-545I5.3	11.72	5.04e-28	5.87e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:146001148	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.851	rs9979545	ENSG00000223768.1	LINC00205	-11.72	5.05e-28	5.88e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45293285~45297354:+
THCA	cis	rs1858037	0.867	rs57913336	ENSG00000204929.10	AC074391.1	11.72	5.05e-28	5.89e-25	0.63	0.48	Rheumatoid arthritis;	chr2:65360485	chr2:65436711~66084639:+
THCA	cis	rs7188445	0.736	rs4243177	ENSG00000261390.4	RP11-345M22.2	11.72	5.06e-28	5.89e-25	0.55	0.48	Urate levels;	chr16:79669932	chr16:79715232~79770563:-
THCA	cis	rs4819052	0.918	rs34886433	ENSG00000223768.1	LINC00205	-11.72	5.09e-28	5.93e-25	-0.52	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45293285~45297354:+
THCA	cis	rs6570726	0.791	rs6902404	ENSG00000235652.6	RP11-545I5.3	11.72	5.12e-28	5.96e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145584118	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000228039.3	KB-1125A3.10	11.72	5.14e-28	5.98e-25	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23963780~23964374:+
THCA	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-11.72	5.18e-28	6.03e-25	-0.34	-0.48	Height;	chr11:118761813	chr11:118791254~118793137:+
THCA	cis	rs7772486	0.686	rs1415744	ENSG00000235652.6	RP11-545I5.3	11.72	5.22e-28	6.08e-25	0.44	0.48	Lobe attachment (rater-scored or self-reported);	chr6:145701395	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	11.72	5.28e-28	6.14e-25	0.6	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs9505982	ENSG00000223701.3	RAET1E-AS1	11.72	5.29e-28	6.15e-25	0.63	0.48	Lung cancer;	chr6:149618465	chr6:149884431~149919508:+
THCA	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-11.72	5.29e-28	6.15e-25	-0.35	-0.48	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
THCA	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs72958458	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122466702	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs7642869	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122471939	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs7617042	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122472138	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs6790051	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122473999	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9878699	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122475384	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs12638866	ENSG00000272758.4	RP11-299J3.8	-11.72	5.3e-28	6.16e-25	-0.62	-0.48	LDL cholesterol levels;	chr3:122475535	chr3:122416207~122443180:+
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000228039.3	KB-1125A3.10	11.72	5.32e-28	6.18e-25	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23963780~23964374:+
THCA	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-11.72	5.33e-28	6.19e-25	-0.35	-0.48	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.923	rs35830138	ENSG00000223701.3	RAET1E-AS1	11.72	5.33e-28	6.19e-25	0.64	0.48	Lung cancer;	chr6:149668635	chr6:149884431~149919508:+
THCA	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-11.72	5.4e-28	6.28e-25	-0.35	-0.48	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-11.72	5.4e-28	6.28e-25	-0.35	-0.48	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-11.72	5.4e-28	6.28e-25	-0.35	-0.48	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
THCA	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	11.72	5.4e-28	6.28e-25	0.64	0.48	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
THCA	cis	rs6496932	0.663	rs7183764	ENSG00000218052.5	ADAMTS7P4	-11.72	5.44e-28	6.32e-25	-0.61	-0.48	Central corneal thickness;Corneal structure;	chr15:85359820	chr15:85255369~85330334:-
THCA	cis	rs6496932	0.663	rs4842878	ENSG00000218052.5	ADAMTS7P4	-11.72	5.44e-28	6.32e-25	-0.61	-0.48	Central corneal thickness;Corneal structure;	chr15:85361001	chr15:85255369~85330334:-
THCA	cis	rs6496932	0.663	rs8040940	ENSG00000218052.5	ADAMTS7P4	-11.72	5.44e-28	6.32e-25	-0.61	-0.48	Central corneal thickness;Corneal structure;	chr15:85361817	chr15:85255369~85330334:-
THCA	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	11.71	5.51e-28	6.4e-25	0.55	0.48	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
THCA	cis	rs62103177	0.608	rs613847	ENSG00000261126.6	RP11-795F19.1	-11.71	5.58e-28	6.48e-25	-0.53	-0.48	Opioid sensitivity;	chr18:80087736	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.525	rs612913	ENSG00000261126.6	RP11-795F19.1	-11.71	5.58e-28	6.48e-25	-0.53	-0.48	Opioid sensitivity;	chr18:80087974	chr18:80046900~80095482:+
THCA	cis	rs7772486	0.654	rs6928007	ENSG00000235652.6	RP11-545I5.3	-11.71	5.65e-28	6.56e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145753805	chr6:145799409~145886585:+
THCA	cis	rs6142102	0.961	rs2235597	ENSG00000276073.1	RP5-1125A11.7	-11.71	5.66e-28	6.56e-25	-0.46	-0.48	Skin pigmentation;	chr20:34077808	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs9974628	ENSG00000223768.1	LINC00205	-11.71	5.68e-28	6.58e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs13047104	ENSG00000223768.1	LINC00205	-11.71	5.68e-28	6.58e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.885	rs28576202	ENSG00000223768.1	LINC00205	-11.71	5.68e-28	6.58e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs35871601	ENSG00000223768.1	LINC00205	-11.71	5.68e-28	6.58e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs28622522	ENSG00000223768.1	LINC00205	-11.71	5.68e-28	6.58e-25	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45293285~45297354:+
THCA	cis	rs853679	0.517	rs1340004	ENSG00000280107.1	AL022393.9	-11.71	5.68e-28	6.59e-25	-0.59	-0.48	Depression;	chr6:28135913	chr6:28170845~28172521:+
THCA	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	11.71	5.7e-28	6.61e-25	0.6	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
THCA	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	11.71	5.76e-28	6.68e-25	0.58	0.48	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
THCA	cis	rs673078	0.66	rs11068910	ENSG00000275759.1	RP11-131L12.3	-11.71	5.76e-28	6.68e-25	-0.6	-0.48	Glucose homeostasis traits;	chr12:118336076	chr12:118428281~118428870:+
THCA	cis	rs7772486	0.754	rs702323	ENSG00000235652.6	RP11-545I5.3	-11.71	5.78e-28	6.7e-25	-0.44	-0.48	Lobe attachment (rater-scored or self-reported);	chr6:145687138	chr6:145799409~145886585:+
THCA	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-11.71	5.79e-28	6.71e-25	-0.78	-0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
THCA	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	11.71	5.83e-28	6.76e-25	0.57	0.48	Depression;	chr6:28323463	chr6:28176188~28176674:+
THCA	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-11.71	5.83e-28	6.76e-25	-0.56	-0.48	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
THCA	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	11.71	5.93e-28	6.87e-25	0.54	0.48	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
THCA	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	11.71	5.94e-28	6.88e-25	0.57	0.48	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
THCA	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-11.71	5.98e-28	6.93e-25	-0.57	-0.48	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
THCA	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-11.71	5.98e-28	6.93e-25	-0.57	-0.48	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
THCA	cis	rs8100891	0.537	rs1057395	ENSG00000267213.4	AC007773.2	-11.71	5.98e-28	6.93e-25	-0.57	-0.48	Neuroticism;	chr19:32483832	chr19:32390050~32405560:-
THCA	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	11.7	6.03e-28	6.98e-25	0.57	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
THCA	cis	rs9322193	0.923	rs4354168	ENSG00000223701.3	RAET1E-AS1	11.7	6.11e-28	7.07e-25	0.63	0.48	Lung cancer;	chr6:149696642	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs4455682	ENSG00000223701.3	RAET1E-AS1	11.7	6.11e-28	7.07e-25	0.63	0.48	Lung cancer;	chr6:149700161	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs55993747	ENSG00000223701.3	RAET1E-AS1	11.7	6.12e-28	7.09e-25	0.64	0.48	Lung cancer;	chr6:149622016	chr6:149884431~149919508:+
THCA	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-11.7	6.16e-28	7.13e-25	-0.65	-0.47	Depression;	chr6:28133900	chr6:28115628~28116551:+
THCA	cis	rs11214589	0.747	rs10891536	ENSG00000270179.1	RP11-159N11.4	-11.7	6.21e-28	7.18e-25	-0.5	-0.47	Neuroticism;	chr11:113338706	chr11:113368478~113369117:+
THCA	cis	rs507080	0.845	rs481903	ENSG00000255422.1	AP002954.4	-11.7	6.21e-28	7.19e-25	-0.54	-0.47	Serum metabolite levels;	chr11:118697024	chr11:118704607~118750263:+
THCA	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-11.7	6.23e-28	7.21e-25	-0.58	-0.47	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
THCA	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	11.7	6.23e-28	7.21e-25	0.56	0.47	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
THCA	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-11.7	6.24e-28	7.22e-25	-0.53	-0.47	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
THCA	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-11.7	6.24e-28	7.22e-25	-0.53	-0.47	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
THCA	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-11.7	6.28e-28	7.26e-25	-0.56	-0.47	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
THCA	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-11.7	6.3e-28	7.29e-25	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
THCA	cis	rs9322193	0.923	rs9383812	ENSG00000223701.3	RAET1E-AS1	11.7	6.43e-28	7.43e-25	0.64	0.47	Lung cancer;	chr6:149712355	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.847	rs9383844	ENSG00000223701.3	RAET1E-AS1	11.7	6.43e-28	7.43e-25	0.64	0.47	Lung cancer;	chr6:149716268	chr6:149884431~149919508:+
THCA	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-11.7	6.44e-28	7.44e-25	-0.58	-0.47	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
THCA	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-11.7	6.49e-28	7.51e-25	-0.72	-0.47	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
THCA	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	11.7	6.51e-28	7.53e-25	0.63	0.47	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	11.7	6.51e-28	7.53e-25	0.63	0.47	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	11.7	6.51e-28	7.53e-25	0.63	0.47	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	11.7	6.52e-28	7.54e-25	0.63	0.47	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
THCA	cis	rs853679	0.55	rs6901017	ENSG00000280107.1	AL022393.9	-11.7	6.53e-28	7.55e-25	-0.56	-0.47	Depression;	chr6:28184805	chr6:28170845~28172521:+
THCA	cis	rs6496932	1	rs2002642	ENSG00000218052.5	ADAMTS7P4	11.69	6.63e-28	7.66e-25	0.65	0.47	Central corneal thickness;Corneal structure;	chr15:85284513	chr15:85255369~85330334:-
THCA	cis	rs6496932	1	rs4842872	ENSG00000218052.5	ADAMTS7P4	11.69	6.63e-28	7.66e-25	0.65	0.47	Central corneal thickness;Corneal structure;	chr15:85284825	chr15:85255369~85330334:-
THCA	cis	rs9322193	0.884	rs62439837	ENSG00000223701.3	RAET1E-AS1	11.69	6.65e-28	7.68e-25	0.65	0.47	Lung cancer;	chr6:149670380	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.686	rs9497395	ENSG00000235652.6	RP11-545I5.3	-11.69	6.71e-28	7.75e-25	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145692456	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs3924871	ENSG00000223701.3	RAET1E-AS1	11.69	6.79e-28	7.85e-25	0.63	0.47	Lung cancer;	chr6:149662080	chr6:149884431~149919508:+
THCA	cis	rs240993	0.909	rs11153279	ENSG00000230177.1	RP5-1112D6.4	11.69	6.82e-28	7.87e-25	0.41	0.47	Inflammatory skin disease;Psoriasis;	chr6:111266063	chr6:111277932~111278742:+
THCA	cis	rs2274273	0.805	rs10131926	ENSG00000258413.1	RP11-665C16.6	-11.69	6.84e-28	7.89e-25	-0.61	-0.47	Protein biomarker;	chr14:55246528	chr14:55262767~55272075:-
THCA	cis	rs1858037	0.836	rs1396209	ENSG00000204929.10	AC074391.1	11.69	6.85e-28	7.91e-25	0.63	0.47	Rheumatoid arthritis;	chr2:65374100	chr2:65436711~66084639:+
THCA	cis	rs2274273	0.837	rs7142857	ENSG00000258413.1	RP11-665C16.6	-11.69	6.88e-28	7.94e-25	-0.61	-0.47	Protein biomarker;	chr14:55237410	chr14:55262767~55272075:-
THCA	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-11.69	6.88e-28	7.94e-25	-0.59	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
THCA	cis	rs10463554	0.963	rs34777	ENSG00000175749.11	EIF3KP1	11.69	6.89e-28	7.95e-25	0.62	0.47	Parkinson's disease;	chr5:103116554	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs257294	ENSG00000175749.11	EIF3KP1	11.69	6.89e-28	7.95e-25	0.62	0.47	Parkinson's disease;	chr5:103131563	chr5:103032376~103033031:+
THCA	cis	rs11105298	1	rs11105298	ENSG00000258302.2	RP11-981P6.1	-11.69	6.91e-28	7.97e-25	-0.45	-0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89482366	chr12:89561129~89594878:+
THCA	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	11.69	6.94e-28	8.01e-25	0.56	0.47	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
THCA	cis	rs10463554	0.963	rs28301	ENSG00000175749.11	EIF3KP1	11.69	6.95e-28	8.02e-25	0.62	0.47	Parkinson's disease;	chr5:103105778	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs34828	ENSG00000175749.11	EIF3KP1	11.69	6.95e-28	8.02e-25	0.62	0.47	Parkinson's disease;	chr5:103107209	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.923	rs9322208	ENSG00000223701.3	RAET1E-AS1	11.69	6.96e-28	8.03e-25	0.64	0.47	Lung cancer;	chr6:149658547	chr6:149884431~149919508:+
THCA	cis	rs526231	0.543	rs62362541	ENSG00000175749.11	EIF3KP1	11.69	6.99e-28	8.06e-25	0.63	0.47	Primary biliary cholangitis;	chr5:102986744	chr5:103032376~103033031:+
THCA	cis	rs9545047	0.904	rs2760105	ENSG00000227676.3	LINC01068	11.69	7.02e-28	8.09e-25	0.61	0.47	Schizophrenia;	chr13:79535732	chr13:79566727~79571436:+
THCA	cis	rs11159086	1	rs11159087	ENSG00000259005.1	RP3-449M8.6	11.69	7.11e-28	8.2e-25	0.48	0.47	Advanced glycation end-product levels;	chr14:74504671	chr14:74474007~74474864:-
THCA	cis	rs4718428	0.672	rs4718412	ENSG00000226824.5	RP4-756H11.3	11.69	7.19e-28	8.28e-25	0.69	0.47	Corneal structure;	chr7:66821880	chr7:66654538~66669855:+
THCA	cis	rs4819052	1	rs4819052	ENSG00000223768.1	LINC00205	-11.69	7.19e-28	8.29e-25	-0.48	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.686	rs1337839	ENSG00000235652.6	RP11-545I5.3	-11.69	7.2e-28	8.29e-25	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145689103	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs7769101	ENSG00000223701.3	RAET1E-AS1	11.69	7.2e-28	8.3e-25	0.64	0.47	Lung cancer;	chr6:149848768	chr6:149884431~149919508:+
THCA	cis	rs673078	0.607	rs7307393	ENSG00000275759.1	RP11-131L12.3	-11.68	7.22e-28	8.32e-25	-0.73	-0.47	Glucose homeostasis traits;	chr12:118308537	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17440669	ENSG00000275759.1	RP11-131L12.3	-11.68	7.22e-28	8.32e-25	-0.73	-0.47	Glucose homeostasis traits;	chr12:118310397	chr12:118428281~118428870:+
THCA	cis	rs3762637	0.943	rs10222564	ENSG00000272758.4	RP11-299J3.8	-11.68	7.22e-28	8.32e-25	-0.64	-0.47	LDL cholesterol levels;	chr3:122547489	chr3:122416207~122443180:+
THCA	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-11.68	7.23e-28	8.33e-25	-0.43	-0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
THCA	cis	rs875971	0.965	rs6971509	ENSG00000237310.1	GS1-124K5.4	-11.68	7.31e-28	8.42e-25	-0.34	-0.47	Aortic root size;	chr7:66249983	chr7:66493706~66495474:+
THCA	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-11.68	7.31e-28	8.43e-25	-0.49	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
THCA	cis	rs6538678	0.818	rs7976294	ENSG00000258343.1	RP11-536G4.2	-11.68	7.32e-28	8.44e-25	-0.7	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95795345~95858839:-
THCA	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-11.68	7.34e-28	8.45e-25	-0.72	-0.47	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
THCA	cis	rs17111396	0.627	rs12100732	ENSG00000259167.2	NMNAT1P1	11.68	7.34e-28	8.46e-25	0.74	0.47	Uric acid levels;	chr14:81040141	chr14:81032529~81033404:+
THCA	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	11.68	7.36e-28	8.48e-25	0.36	0.47	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
THCA	cis	rs2288884	0.559	rs11084130	ENSG00000275055.1	CTC-471J1.11	-11.68	7.37e-28	8.49e-25	-0.38	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52009443	chr19:52049007~52049754:+
THCA	cis	rs7772486	0.714	rs1883365	ENSG00000235652.6	RP11-545I5.3	-11.68	7.39e-28	8.51e-25	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145755613	chr6:145799409~145886585:+
THCA	cis	rs11722779	0.815	rs223347	ENSG00000246560.2	RP11-10L12.4	11.68	7.41e-28	8.54e-25	0.59	0.47	Schizophrenia;	chr4:102858815	chr4:102828055~102844075:+
THCA	cis	rs6496932	1	rs12917495	ENSG00000218052.5	ADAMTS7P4	11.68	7.51e-28	8.65e-25	0.65	0.47	Central corneal thickness;Corneal structure;	chr15:85286330	chr15:85255369~85330334:-
THCA	cis	rs10740039	0.583	rs9415613	ENSG00000254271.1	RP11-131N11.4	-11.68	7.59e-28	8.74e-25	-0.64	-0.47	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60747636	chr10:60734342~60741828:+
THCA	cis	rs7772486	0.84	rs2474355	ENSG00000235652.6	RP11-545I5.3	11.68	7.6e-28	8.75e-25	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145991404	chr6:145799409~145886585:+
THCA	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-11.68	7.64e-28	8.79e-25	-0.65	-0.47	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
THCA	cis	rs673078	0.66	rs6490175	ENSG00000275759.1	RP11-131L12.3	-11.68	7.65e-28	8.81e-25	-0.6	-0.47	Glucose homeostasis traits;	chr12:118293559	chr12:118428281~118428870:+
THCA	cis	rs7182621	0.639	rs35049216	ENSG00000259363.4	CTD-2054N24.2	-11.68	7.67e-28	8.83e-25	-0.71	-0.47	Colonoscopy-negative controls vs population controls;	chr15:99872562	chr15:99807023~99877148:+
THCA	cis	rs6142102	0.961	rs1883524	ENSG00000276073.1	RP5-1125A11.7	-11.68	7.68e-28	8.83e-25	-0.44	-0.47	Skin pigmentation;	chr20:34038301	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs4911389	ENSG00000276073.1	RP5-1125A11.7	-11.68	7.68e-28	8.83e-25	-0.45	-0.47	Skin pigmentation;	chr20:33977235	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs2838840	ENSG00000223768.1	LINC00205	-11.68	7.74e-28	8.9e-25	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45293285~45297354:+
THCA	cis	rs673078	0.615	rs61943528	ENSG00000275759.1	RP11-131L12.3	-11.68	7.85e-28	9.03e-25	-0.73	-0.47	Glucose homeostasis traits;	chr12:118163134	chr12:118428281~118428870:+
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	11.67	7.93e-28	9.11e-25	0.61	0.47	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
THCA	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-11.67	8.01e-28	9.21e-25	-0.38	-0.47	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
THCA	cis	rs8062405	0.625	rs8060365	ENSG00000259982.1	CDC37P1	-11.67	8.02e-28	9.21e-25	-0.6	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28899988	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.698	rs10499	ENSG00000259982.1	CDC37P1	-11.67	8.12e-28	9.33e-25	-0.6	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28700294~28701540:-
THCA	cis	rs10463554	0.824	rs34818	ENSG00000175749.11	EIF3KP1	11.67	8.14e-28	9.35e-25	0.62	0.47	Parkinson's disease;	chr5:103100407	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.79	rs9376971	ENSG00000235652.6	RP11-545I5.3	-11.67	8.2e-28	9.42e-25	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145938369	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs4314514	ENSG00000235652.6	RP11-545I5.3	-11.67	8.2e-28	9.42e-25	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145938874	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.72	rs9403757	ENSG00000235652.6	RP11-545I5.3	-11.67	8.2e-28	9.42e-25	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145940135	chr6:145799409~145886585:+
THCA	cis	rs875971	1	rs6956179	ENSG00000237310.1	GS1-124K5.4	-11.67	8.2e-28	9.42e-25	-0.35	-0.47	Aortic root size;	chr7:66341672	chr7:66493706~66495474:+
THCA	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	11.67	8.25e-28	9.47e-25	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
THCA	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	11.67	8.25e-28	9.47e-25	0.55	0.47	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
THCA	cis	rs9309473	0.66	rs62151564	ENSG00000163016.8	ALMS1P	11.67	8.25e-28	9.48e-25	0.82	0.47	Metabolite levels;	chr2:73388321	chr2:73644919~73685576:+
THCA	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-11.67	8.33e-28	9.56e-25	-0.34	-0.47	Height;	chr11:118737823	chr11:118791254~118793137:+
THCA	cis	rs7772486	0.846	rs7755440	ENSG00000235652.6	RP11-545I5.3	11.67	8.33e-28	9.57e-25	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146054770	chr6:145799409~145886585:+
THCA	cis	rs6504950	0.745	rs12949718	ENSG00000275710.1	RP11-257O5.4	-11.67	8.38e-28	9.62e-25	-0.59	-0.47	Breast cancer;	chr17:54904492	chr17:54964474~54964679:+
THCA	cis	rs11105298	0.891	rs4842661	ENSG00000258302.2	RP11-981P6.1	11.67	8.4e-28	9.64e-25	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:89561129~89594878:+
THCA	cis	rs9322193	0.847	rs12234128	ENSG00000223701.3	RAET1E-AS1	11.67	8.41e-28	9.65e-25	0.63	0.47	Lung cancer;	chr6:149627553	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs57012784	ENSG00000223701.3	RAET1E-AS1	11.67	8.41e-28	9.65e-25	0.63	0.47	Lung cancer;	chr6:149627691	chr6:149884431~149919508:+
THCA	cis	rs524281	0.861	rs12049852	ENSG00000255320.1	RP11-755F10.1	11.67	8.49e-28	9.74e-25	0.67	0.47	Electroencephalogram traits;	chr11:66117231	chr11:66244840~66246239:-
THCA	cis	rs12468226	0.938	rs76501067	ENSG00000273456.1	RP11-686O6.2	11.67	8.56e-28	9.82e-25	0.58	0.47	Urate levels;	chr2:202318042	chr2:202374932~202375604:-
THCA	cis	rs9322193	0.923	rs9766037	ENSG00000223701.3	RAET1E-AS1	11.67	8.59e-28	9.85e-25	0.63	0.47	Lung cancer;	chr6:149616921	chr6:149884431~149919508:+
THCA	cis	rs11105298	0.891	rs3741898	ENSG00000258302.2	RP11-981P6.1	11.66	8.68e-28	9.95e-25	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539986	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs3741899	ENSG00000258302.2	RP11-981P6.1	11.66	8.68e-28	9.95e-25	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540154	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858906	ENSG00000258302.2	RP11-981P6.1	11.66	8.68e-28	9.95e-25	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89540697	chr12:89561129~89594878:+
THCA	cis	rs1858037	0.765	rs67404371	ENSG00000204929.10	AC074391.1	11.66	8.75e-28	1e-24	0.62	0.47	Rheumatoid arthritis;	chr2:65370137	chr2:65436711~66084639:+
THCA	cis	rs7772486	0.79	rs11760	ENSG00000235652.6	RP11-545I5.3	11.66	8.82e-28	1.01e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145884837	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs1062067	ENSG00000235652.6	RP11-545I5.3	11.66	8.82e-28	1.01e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145886427	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2256998	ENSG00000235652.6	RP11-545I5.3	11.66	8.82e-28	1.01e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145886521	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs6917482	ENSG00000235652.6	RP11-545I5.3	-11.66	8.82e-28	1.01e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145922445	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs4566902	ENSG00000235652.6	RP11-545I5.3	-11.66	8.82e-28	1.01e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145922992	chr6:145799409~145886585:+
THCA	cis	rs6142102	0.961	rs909884	ENSG00000276073.1	RP5-1125A11.7	-11.66	8.82e-28	1.01e-24	-0.45	-0.47	Skin pigmentation;	chr20:34058257	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs2268088	ENSG00000276073.1	RP5-1125A11.7	-11.66	8.82e-28	1.01e-24	-0.45	-0.47	Skin pigmentation;	chr20:34061258	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs4911401	ENSG00000276073.1	RP5-1125A11.7	-11.66	8.82e-28	1.01e-24	-0.45	-0.47	Skin pigmentation;	chr20:34066756	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs2284388	ENSG00000276073.1	RP5-1125A11.7	-11.66	8.82e-28	1.01e-24	-0.45	-0.47	Skin pigmentation;	chr20:34067935	chr20:33985617~33988989:-
THCA	cis	rs3762637	0.943	rs9289198	ENSG00000272758.4	RP11-299J3.8	-11.66	8.83e-28	1.01e-24	-0.64	-0.47	LDL cholesterol levels;	chr3:122558313	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs9289199	ENSG00000272758.4	RP11-299J3.8	-11.66	8.83e-28	1.01e-24	-0.64	-0.47	LDL cholesterol levels;	chr3:122558325	chr3:122416207~122443180:+
THCA	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-11.66	8.86e-28	1.01e-24	-0.65	-0.47	Depression;	chr6:28096845	chr6:28115628~28116551:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000235689.1	AP000351.13	11.66	8.87e-28	1.02e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:24006305~24008258:-
THCA	cis	rs950169	0.763	rs35372971	ENSG00000225151.9	GOLGA2P7	-11.66	8.9e-28	1.02e-24	-0.7	-0.47	Schizophrenia;	chr15:84387097	chr15:84199311~84230136:-
THCA	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-11.66	8.91e-28	1.02e-24	-0.65	-0.47	Depression;	chr6:28131566	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.923	rs2184370	ENSG00000223701.3	RAET1E-AS1	11.66	8.92e-28	1.02e-24	0.65	0.47	Lung cancer;	chr6:149843242	chr6:149884431~149919508:+
THCA	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-11.66	9.02e-28	1.03e-24	-0.4	-0.47	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
THCA	cis	rs4819052	0.885	rs9980676	ENSG00000223768.1	LINC00205	-11.66	9.04e-28	1.03e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838836	ENSG00000223768.1	LINC00205	-11.66	9.04e-28	1.03e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45293285~45297354:+
THCA	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-11.66	9.05e-28	1.04e-24	-0.65	-0.47	Depression;	chr6:28139876	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-11.66	9.05e-28	1.04e-24	-0.65	-0.47	Depression;	chr6:28139998	chr6:28115628~28116551:+
THCA	cis	rs6570726	0.72	rs412623	ENSG00000235652.6	RP11-545I5.3	11.66	9.06e-28	1.04e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145562121	chr6:145799409~145886585:+
THCA	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	11.66	9.07e-28	1.04e-24	0.64	0.47	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
THCA	cis	rs7772486	0.782	rs7747576	ENSG00000235652.6	RP11-545I5.3	-11.66	9.18e-28	1.05e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145956691	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9399571	ENSG00000235652.6	RP11-545I5.3	-11.66	9.18e-28	1.05e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145960925	chr6:145799409~145886585:+
THCA	cis	rs12468226	0.938	rs114177656	ENSG00000273456.1	RP11-686O6.2	11.66	9.19e-28	1.05e-24	0.59	0.47	Urate levels;	chr2:202291596	chr2:202374932~202375604:-
THCA	cis	rs8040855	0.627	rs12909971	ENSG00000259295.5	CSPG4P12	11.66	9.28e-28	1.06e-24	0.71	0.47	Bulimia nervosa;	chr15:85045767	chr15:85191438~85213905:+
THCA	cis	rs3762637	1	rs9836309	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122416348	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs9873842	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122416484	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs12633461	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122417050	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9879508	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122417633	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9858558	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122420895	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs7626861	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122436349	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs9842736	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122442254	chr3:122416207~122443180:+
THCA	cis	rs3762637	1	rs13321097	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122443160	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs112768052	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122450537	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs77599736	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122460662	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs10439995	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122470313	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.882	rs7630833	ENSG00000272758.4	RP11-299J3.8	-11.66	9.37e-28	1.07e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122471577	chr3:122416207~122443180:+
THCA	cis	rs12468226	0.873	rs76552560	ENSG00000273456.1	RP11-686O6.2	11.66	9.39e-28	1.07e-24	0.61	0.47	Urate levels;	chr2:202173123	chr2:202374932~202375604:-
THCA	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	11.65	9.53e-28	1.09e-24	0.61	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
THCA	cis	rs7772486	0.84	rs2814867	ENSG00000235652.6	RP11-545I5.3	11.65	9.54e-28	1.09e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146012894	chr6:145799409~145886585:+
THCA	cis	rs17111396	0.627	rs61978745	ENSG00000259167.2	NMNAT1P1	11.65	9.58e-28	1.09e-24	0.75	0.47	Uric acid levels;	chr14:81048940	chr14:81032529~81033404:+
THCA	cis	rs9322193	0.607	rs12527391	ENSG00000231760.4	RP11-350J20.5	11.65	9.64e-28	1.1e-24	0.68	0.47	Lung cancer;	chr6:149882156	chr6:149796151~149826294:-
THCA	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-11.65	9.76e-28	1.11e-24	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-11.65	9.76e-28	1.11e-24	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
THCA	cis	rs11098499	0.874	rs28452522	ENSG00000245958.5	RP11-33B1.1	-11.65	9.81e-28	1.12e-24	-0.46	-0.47	Corneal astigmatism;	chr4:119189629	chr4:119454791~119552025:+
THCA	cis	rs7712401	0.642	rs17388251	ENSG00000263432.2	RN7SL689P	11.65	9.86e-28	1.12e-24	0.5	0.47	Mean platelet volume;	chr5:123024708	chr5:123022487~123022783:-
THCA	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-11.65	9.86e-28	1.12e-24	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
THCA	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	11.65	9.91e-28	1.13e-24	0.59	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
THCA	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	11.65	9.92e-28	1.13e-24	0.57	0.47	Depression;	chr6:28303421	chr6:28176188~28176674:+
THCA	cis	rs944289	0.646	rs367883	ENSG00000257826.1	RP11-116N8.4	11.65	1e-27	1.14e-24	0.48	0.47	Thyroid cancer;	chr14:36063400	chr14:36061026~36067190:-
THCA	cis	rs944289	0.646	rs368181	ENSG00000257826.1	RP11-116N8.4	11.65	1e-27	1.14e-24	0.48	0.47	Thyroid cancer;	chr14:36065621	chr14:36061026~36067190:-
THCA	cis	rs6142102	0.961	rs2300204	ENSG00000276073.1	RP5-1125A11.7	-11.65	1e-27	1.14e-24	-0.44	-0.47	Skin pigmentation;	chr20:34000967	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs1055857	ENSG00000276073.1	RP5-1125A11.7	-11.65	1e-27	1.14e-24	-0.44	-0.47	Skin pigmentation;	chr20:34026067	chr20:33985617~33988989:-
THCA	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-11.65	1e-27	1.14e-24	-0.4	-0.47	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
THCA	cis	rs2274273	0.84	rs2341622	ENSG00000258413.1	RP11-665C16.6	-11.65	1e-27	1.14e-24	-0.6	-0.47	Protein biomarker;	chr14:55270525	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.806	rs7146752	ENSG00000258413.1	RP11-665C16.6	-11.65	1e-27	1.14e-24	-0.6	-0.47	Protein biomarker;	chr14:55272189	chr14:55262767~55272075:-
THCA	cis	rs7772486	0.875	rs2814877	ENSG00000235652.6	RP11-545I5.3	11.65	1e-27	1.14e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145978627	chr6:145799409~145886585:+
THCA	cis	rs4853012	0.775	rs12465641	ENSG00000257800.1	FNBP1P1	-11.65	1e-27	1.14e-24	-0.43	-0.47	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74120680~74123218:+
THCA	cis	rs9322193	0.923	rs9322200	ENSG00000223701.3	RAET1E-AS1	11.65	1e-27	1.14e-24	0.63	0.47	Lung cancer;	chr6:149630078	chr6:149884431~149919508:+
THCA	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-11.65	1.01e-27	1.15e-24	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
THCA	cis	rs4819052	0.851	rs7276591	ENSG00000223768.1	LINC00205	-11.65	1.01e-27	1.15e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45293285~45297354:+
THCA	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-11.65	1.01e-27	1.15e-24	-0.58	-0.47	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
THCA	cis	rs944289	0.589	rs847516	ENSG00000257826.1	RP11-116N8.4	11.65	1.01e-27	1.15e-24	0.48	0.47	Thyroid cancer;	chr14:36060593	chr14:36061026~36067190:-
THCA	cis	rs367615	0.506	rs2914684	ENSG00000249476.1	CTD-2587M2.1	-11.65	1.01e-27	1.15e-24	-0.49	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109439409	chr5:109237120~109326369:-
THCA	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	11.65	1.02e-27	1.16e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
THCA	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	11.65	1.02e-27	1.16e-24	0.57	0.47	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	11.65	1.02e-27	1.16e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	11.65	1.02e-27	1.16e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
THCA	cis	rs9481169	0.557	rs34896684	ENSG00000255389.1	C6orf3	-11.65	1.03e-27	1.18e-24	-0.88	-0.47	Inflammatory skin disease;	chr6:111572034	chr6:111599875~111602295:+
THCA	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-11.65	1.03e-27	1.18e-24	-0.56	-0.47	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
THCA	cis	rs950169	0.845	rs4502182	ENSG00000225151.9	GOLGA2P7	-11.64	1.04e-27	1.19e-24	-0.7	-0.47	Schizophrenia;	chr15:84254768	chr15:84199311~84230136:-
THCA	cis	rs673078	0.66	rs75752792	ENSG00000275759.1	RP11-131L12.3	-11.64	1.05e-27	1.19e-24	-0.72	-0.47	Glucose homeostasis traits;	chr12:118187005	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs75571641	ENSG00000275759.1	RP11-131L12.3	-11.64	1.05e-27	1.19e-24	-0.72	-0.47	Glucose homeostasis traits;	chr12:118187012	chr12:118428281~118428870:+
THCA	cis	rs9322193	0.923	rs9322214	ENSG00000223701.3	RAET1E-AS1	11.64	1.05e-27	1.19e-24	0.65	0.47	Lung cancer;	chr6:149703986	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.887	rs9767113	ENSG00000223701.3	RAET1E-AS1	11.64	1.05e-27	1.19e-24	0.65	0.47	Lung cancer;	chr6:149718157	chr6:149884431~149919508:+
THCA	cis	rs1858037	0.867	rs2118305	ENSG00000204929.10	AC074391.1	11.64	1.06e-27	1.21e-24	0.62	0.47	Rheumatoid arthritis;	chr2:65378086	chr2:65436711~66084639:+
THCA	cis	rs4964805	1	rs12228207	ENSG00000257681.1	RP11-341G23.4	11.64	1.06e-27	1.21e-24	0.58	0.47	Attention deficit hyperactivity disorder;	chr12:103802956	chr12:103746315~103768858:-
THCA	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-11.64	1.07e-27	1.22e-24	-0.49	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
THCA	cis	rs4819052	0.851	rs2838833	ENSG00000223768.1	LINC00205	-11.64	1.07e-27	1.22e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45293285~45297354:+
THCA	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	11.64	1.08e-27	1.22e-24	0.54	0.47	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
THCA	cis	rs12468226	0.938	rs116109808	ENSG00000273456.1	RP11-686O6.2	11.64	1.08e-27	1.23e-24	0.59	0.47	Urate levels;	chr2:202287356	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.873	rs78175596	ENSG00000273456.1	RP11-686O6.2	11.64	1.08e-27	1.23e-24	0.59	0.47	Urate levels;	chr2:202287993	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs56684065	ENSG00000273456.1	RP11-686O6.2	11.64	1.08e-27	1.23e-24	0.59	0.47	Urate levels;	chr2:202289528	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs1474001	ENSG00000273456.1	RP11-686O6.2	11.64	1.08e-27	1.23e-24	0.59	0.47	Urate levels;	chr2:202290230	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs76664732	ENSG00000273456.1	RP11-686O6.2	11.64	1.08e-27	1.23e-24	0.59	0.47	Urate levels;	chr2:202296298	chr2:202374932~202375604:-
THCA	cis	rs7772486	0.713	rs2328704	ENSG00000235652.6	RP11-545I5.3	-11.64	1.08e-27	1.23e-24	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145699358	chr6:145799409~145886585:+
THCA	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	11.64	1.08e-27	1.23e-24	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	11.64	1.08e-27	1.23e-24	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
THCA	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	11.64	1.08e-27	1.23e-24	0.6	0.47	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
THCA	cis	rs9322193	0.886	rs9322198	ENSG00000223701.3	RAET1E-AS1	11.64	1.08e-27	1.23e-24	0.63	0.47	Lung cancer;	chr6:149623772	chr6:149884431~149919508:+
THCA	cis	rs4819052	0.851	rs2838843	ENSG00000223768.1	LINC00205	-11.64	1.09e-27	1.24e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45293285~45297354:+
THCA	cis	rs992157	0.71	rs10167446	ENSG00000261338.2	RP11-378A13.1	11.64	1.09e-27	1.24e-24	0.49	0.47	Colorectal cancer;	chr2:218192143	chr2:218255319~218257366:+
THCA	cis	rs6570726	0.791	rs6914203	ENSG00000235652.6	RP11-545I5.3	11.64	1.1e-27	1.24e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145578839	chr6:145799409~145886585:+
THCA	cis	rs10463554	0.963	rs34774	ENSG00000175749.11	EIF3KP1	11.64	1.11e-27	1.26e-24	0.62	0.47	Parkinson's disease;	chr5:103115116	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.875	rs2814876	ENSG00000235652.6	RP11-545I5.3	11.64	1.12e-27	1.27e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145982894	chr6:145799409~145886585:+
THCA	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	11.63	1.14e-27	1.3e-24	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
THCA	cis	rs11098499	0.874	rs13123591	ENSG00000245958.5	RP11-33B1.1	-11.63	1.14e-27	1.3e-24	-0.46	-0.47	Corneal astigmatism;	chr4:119184835	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.875	rs854145	ENSG00000235652.6	RP11-545I5.3	11.63	1.15e-27	1.31e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146028514	chr6:145799409~145886585:+
THCA	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	11.63	1.16e-27	1.31e-24	0.69	0.47	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
THCA	cis	rs950169	0.84	rs72748702	ENSG00000225151.9	GOLGA2P7	-11.63	1.16e-27	1.31e-24	-0.69	-0.47	Schizophrenia;	chr15:84246494	chr15:84199311~84230136:-
THCA	cis	rs7772486	0.875	rs2777484	ENSG00000235652.6	RP11-545I5.3	11.63	1.16e-27	1.32e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146013026	chr6:145799409~145886585:+
THCA	cis	rs3762637	1	rs6777596	ENSG00000272758.4	RP11-299J3.8	-11.63	1.16e-27	1.32e-24	-0.63	-0.47	LDL cholesterol levels;	chr3:122414474	chr3:122416207~122443180:+
THCA	cis	rs2288884	0.559	rs12459268	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52002719	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs8109948	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004796	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs8109964	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004835	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs8109854	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004866	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs12461141	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005712	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs12459079	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005741	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs12461226	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005996	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.559	rs12461230	ENSG00000275055.1	CTC-471J1.11	-11.63	1.17e-27	1.33e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52006051	chr19:52049007~52049754:+
THCA	cis	rs7182621	0.512	rs34151878	ENSG00000259363.4	CTD-2054N24.2	-11.63	1.17e-27	1.33e-24	-0.68	-0.47	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99807023~99877148:+
THCA	cis	rs7182621	0.512	rs12903892	ENSG00000259363.4	CTD-2054N24.2	-11.63	1.17e-27	1.33e-24	-0.68	-0.47	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99807023~99877148:+
THCA	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	11.63	1.17e-27	1.33e-24	0.57	0.47	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	11.63	1.17e-27	1.33e-24	0.57	0.47	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
THCA	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	11.63	1.17e-27	1.33e-24	0.57	0.47	Depression;	chr6:28317705	chr6:28176188~28176674:+
THCA	cis	rs6142102	0.961	rs973409	ENSG00000276073.1	RP5-1125A11.7	-11.63	1.2e-27	1.36e-24	-0.44	-0.47	Skin pigmentation;	chr20:33948558	chr20:33985617~33988989:-
THCA	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	11.63	1.21e-27	1.37e-24	0.49	0.47	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
THCA	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-11.63	1.21e-27	1.38e-24	-0.58	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
THCA	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	11.63	1.22e-27	1.39e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
THCA	cis	rs6142102	0.961	rs4911392	ENSG00000276073.1	RP5-1125A11.7	-11.63	1.23e-27	1.39e-24	-0.44	-0.47	Skin pigmentation;	chr20:33982712	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs4911393	ENSG00000276073.1	RP5-1125A11.7	-11.63	1.23e-27	1.39e-24	-0.44	-0.47	Skin pigmentation;	chr20:33983120	chr20:33985617~33988989:-
THCA	cis	rs9322193	0.923	rs2880436	ENSG00000268592.3	RAET1E-AS1	11.63	1.23e-27	1.4e-24	0.65	0.47	Lung cancer;	chr6:149859123	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9371207	ENSG00000268592.3	RAET1E-AS1	11.63	1.24e-27	1.41e-24	0.65	0.47	Lung cancer;	chr6:149858087	chr6:149863494~149919507:+
THCA	cis	rs875971	1	rs9986696	ENSG00000237310.1	GS1-124K5.4	-11.62	1.25e-27	1.41e-24	-0.34	-0.47	Aortic root size;	chr7:66239589	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.79	rs6926657	ENSG00000235652.6	RP11-545I5.3	-11.62	1.25e-27	1.42e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145934658	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.884	rs7450246	ENSG00000223701.3	RAET1E-AS1	11.62	1.25e-27	1.42e-24	0.64	0.47	Lung cancer;	chr6:149702517	chr6:149884431~149919508:+
THCA	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	11.62	1.26e-27	1.43e-24	0.56	0.47	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
THCA	cis	rs4819052	0.851	rs2838839	ENSG00000223768.1	LINC00205	11.62	1.26e-27	1.43e-24	0.44	0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45293285~45297354:+
THCA	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	11.62	1.27e-27	1.44e-24	0.65	0.47	Depression;	chr6:28142370	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.923	rs10782310	ENSG00000223701.3	RAET1E-AS1	11.62	1.28e-27	1.44e-24	0.63	0.47	Lung cancer;	chr6:149622458	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10782311	ENSG00000223701.3	RAET1E-AS1	11.62	1.28e-27	1.44e-24	0.63	0.47	Lung cancer;	chr6:149622592	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10747275	ENSG00000223701.3	RAET1E-AS1	11.62	1.28e-27	1.44e-24	0.63	0.47	Lung cancer;	chr6:149622782	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9689723	ENSG00000223701.3	RAET1E-AS1	11.62	1.28e-27	1.44e-24	0.63	0.47	Lung cancer;	chr6:149655935	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9968911	ENSG00000223701.3	RAET1E-AS1	11.62	1.28e-27	1.44e-24	0.63	0.47	Lung cancer;	chr6:149657419	chr6:149884431~149919508:+
THCA	cis	rs17111396	0.627	rs55947533	ENSG00000259167.2	NMNAT1P1	11.62	1.28e-27	1.45e-24	0.75	0.47	Uric acid levels;	chr14:81052482	chr14:81032529~81033404:+
THCA	cis	rs6142102	0.961	rs4911407	ENSG00000276073.1	RP5-1125A11.7	-11.62	1.28e-27	1.45e-24	-0.45	-0.47	Skin pigmentation;	chr20:34095759	chr20:33985617~33988989:-
THCA	cis	rs2274273	0.84	rs6573020	ENSG00000258413.1	RP11-665C16.6	-11.62	1.28e-27	1.45e-24	-0.61	-0.47	Protein biomarker;	chr14:55404734	chr14:55262767~55272075:-
THCA	cis	rs62388641	0.539	rs56016631	ENSG00000272279.1	RP11-157J24.2	11.62	1.29e-27	1.46e-24	0.64	0.47	Daytime sleep phenotypes;	chr6:1542340	chr6:1528364~1528911:-
THCA	cis	rs8040855	0.627	rs11632658	ENSG00000259295.5	CSPG4P12	-11.62	1.29e-27	1.46e-24	-0.71	-0.47	Bulimia nervosa;	chr15:85062982	chr15:85191438~85213905:+
THCA	cis	rs1858037	0.836	rs17475335	ENSG00000204929.10	AC074391.1	11.62	1.29e-27	1.46e-24	0.62	0.47	Rheumatoid arthritis;	chr2:65378646	chr2:65436711~66084639:+
THCA	cis	rs4819052	0.851	rs28442024	ENSG00000223768.1	LINC00205	-11.62	1.29e-27	1.46e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45293285~45297354:+
THCA	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	11.62	1.3e-27	1.47e-24	0.6	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs12526675	ENSG00000223701.3	RAET1E-AS1	-11.62	1.31e-27	1.48e-24	-0.64	-0.47	Lung cancer;	chr6:149729540	chr6:149884431~149919508:+
THCA	cis	rs11105298	0.891	rs10858851	ENSG00000258302.2	RP11-981P6.1	11.62	1.32e-27	1.49e-24	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89437093	chr12:89561129~89594878:+
THCA	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	11.62	1.32e-27	1.5e-24	0.66	0.47	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
THCA	cis	rs6570726	0.791	rs1509213	ENSG00000235652.6	RP11-545I5.3	-11.62	1.34e-27	1.51e-24	-0.45	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145462224	chr6:145799409~145886585:+
THCA	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-11.62	1.34e-27	1.51e-24	-0.56	-0.47	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
THCA	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	11.62	1.34e-27	1.52e-24	0.56	0.47	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
THCA	cis	rs9322193	0.923	rs4870267	ENSG00000223701.3	RAET1E-AS1	11.62	1.35e-27	1.52e-24	0.63	0.47	Lung cancer;	chr6:149671572	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.686	rs9373473	ENSG00000235652.6	RP11-545I5.3	11.62	1.35e-27	1.52e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145761146	chr6:145799409~145886585:+
THCA	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-11.62	1.35e-27	1.53e-24	-0.59	-0.47	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
THCA	cis	rs7772486	0.817	rs12198065	ENSG00000235652.6	RP11-545I5.3	11.62	1.36e-27	1.54e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146064150	chr6:145799409~145886585:+
THCA	cis	rs12134133	0.752	rs6673080	ENSG00000274245.1	RP11-357P18.2	11.61	1.38e-27	1.56e-24	0.51	0.47	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207372559~207373252:+
THCA	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	11.61	1.38e-27	1.56e-24	0.59	0.47	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
THCA	cis	rs11098499	0.874	rs17839089	ENSG00000245958.5	RP11-33B1.1	-11.61	1.39e-27	1.56e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119189914	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.874	rs6826823	ENSG00000245958.5	RP11-33B1.1	-11.61	1.39e-27	1.56e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119190943	chr4:119454791~119552025:+
THCA	cis	rs367615	0.506	rs2963013	ENSG00000249476.1	CTD-2587M2.1	-11.61	1.39e-27	1.57e-24	-0.49	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109440110	chr5:109237120~109326369:-
THCA	cis	rs4889009	0.533	rs12596569	ENSG00000261390.4	RP11-345M22.2	11.61	1.39e-27	1.57e-24	0.53	0.47	Thyroid peroxidase antibody positivity;	chr16:79701354	chr16:79715232~79770563:-
THCA	cis	rs950169	0.887	rs3860265	ENSG00000225151.9	GOLGA2P7	-11.61	1.4e-27	1.58e-24	-0.7	-0.47	Schizophrenia;	chr15:84390487	chr15:84199311~84230136:-
THCA	cis	rs950169	0.724	rs11632668	ENSG00000225151.9	GOLGA2P7	-11.61	1.4e-27	1.58e-24	-0.7	-0.47	Schizophrenia;	chr15:84393989	chr15:84199311~84230136:-
THCA	cis	rs950169	0.881	rs34591918	ENSG00000225151.9	GOLGA2P7	-11.61	1.4e-27	1.58e-24	-0.7	-0.47	Schizophrenia;	chr15:84396135	chr15:84199311~84230136:-
THCA	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	11.61	1.41e-27	1.59e-24	0.35	0.47	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
THCA	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	11.61	1.41e-27	1.59e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
THCA	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	11.61	1.41e-27	1.59e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
THCA	cis	rs12468226	1	rs7597156	ENSG00000273456.1	RP11-686O6.2	11.61	1.41e-27	1.59e-24	0.56	0.47	Urate levels;	chr2:202329339	chr2:202374932~202375604:-
THCA	cis	rs4819052	0.851	rs1999333	ENSG00000223768.1	LINC00205	-11.61	1.42e-27	1.6e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.923	rs1934534	ENSG00000223701.3	RAET1E-AS1	11.61	1.43e-27	1.61e-24	0.63	0.47	Lung cancer;	chr6:149711896	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.79	rs2814880	ENSG00000235652.6	RP11-545I5.3	11.61	1.43e-27	1.61e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145887801	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs4435956	ENSG00000235652.6	RP11-545I5.3	-11.61	1.43e-27	1.61e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145911267	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs6926076	ENSG00000235652.6	RP11-545I5.3	-11.61	1.43e-27	1.61e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145911668	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.597	rs6912351	ENSG00000235652.6	RP11-545I5.3	-11.61	1.43e-27	1.61e-24	-0.48	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145942935	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-11.61	1.43e-27	1.61e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
THCA	cis	rs853679	0.55	rs1233699	ENSG00000280107.1	AL022393.9	-11.61	1.43e-27	1.61e-24	-0.56	-0.47	Depression;	chr6:28201380	chr6:28170845~28172521:+
THCA	cis	rs12468226	0.938	rs3843338	ENSG00000273456.1	RP11-686O6.2	-11.61	1.44e-27	1.62e-24	-0.58	-0.47	Urate levels;	chr2:202246102	chr2:202374932~202375604:-
THCA	cis	rs7772486	0.875	rs6934467	ENSG00000235652.6	RP11-545I5.3	11.61	1.44e-27	1.62e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146089393	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.84	rs11155451	ENSG00000235652.6	RP11-545I5.3	11.61	1.44e-27	1.62e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146101388	chr6:145799409~145886585:+
THCA	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	11.61	1.44e-27	1.62e-24	0.54	0.47	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
THCA	cis	rs6570726	0.791	rs4896820	ENSG00000235652.6	RP11-545I5.3	11.61	1.45e-27	1.64e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145573821	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.764	rs4896821	ENSG00000235652.6	RP11-545I5.3	11.61	1.45e-27	1.64e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145575045	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-11.61	1.45e-27	1.64e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
THCA	cis	rs673078	0.607	rs7294498	ENSG00000275759.1	RP11-131L12.3	-11.61	1.46e-27	1.64e-24	-0.6	-0.47	Glucose homeostasis traits;	chr12:118321680	chr12:118428281~118428870:+
THCA	cis	rs7772486	0.534	rs34541797	ENSG00000235652.6	RP11-545I5.3	11.61	1.46e-27	1.65e-24	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145884168	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9390377	ENSG00000235652.6	RP11-545I5.3	11.61	1.46e-27	1.65e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146065796	chr6:145799409~145886585:+
THCA	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	11.61	1.47e-27	1.66e-24	0.63	0.47	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
THCA	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	11.61	1.47e-27	1.66e-24	0.63	0.47	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
THCA	cis	rs7772486	0.79	rs2265469	ENSG00000235652.6	RP11-545I5.3	11.61	1.48e-27	1.67e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145897913	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2265918	ENSG00000235652.6	RP11-545I5.3	11.61	1.48e-27	1.67e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145898028	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2265472	ENSG00000235652.6	RP11-545I5.3	11.61	1.48e-27	1.67e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145899622	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs2265919	ENSG00000235652.6	RP11-545I5.3	11.61	1.48e-27	1.67e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145900617	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9403755	ENSG00000235652.6	RP11-545I5.3	-11.61	1.48e-27	1.67e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145910334	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.847	rs868375	ENSG00000223701.3	RAET1E-AS1	11.61	1.48e-27	1.67e-24	0.64	0.47	Lung cancer;	chr6:149844905	chr6:149884431~149919508:+
THCA	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	11.6	1.5e-27	1.69e-24	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	11.6	1.5e-27	1.69e-24	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
THCA	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	11.6	1.51e-27	1.7e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	11.6	1.51e-27	1.7e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	11.6	1.51e-27	1.7e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	11.6	1.51e-27	1.7e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
THCA	cis	rs7182621	0.639	rs12906068	ENSG00000259363.4	CTD-2054N24.2	-11.6	1.51e-27	1.7e-24	-0.71	-0.47	Colonoscopy-negative controls vs population controls;	chr15:99873422	chr15:99807023~99877148:+
THCA	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-11.6	1.52e-27	1.71e-24	-0.57	-0.47	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
THCA	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-11.6	1.52e-27	1.71e-24	-0.83	-0.47	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
THCA	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	11.6	1.54e-27	1.73e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	11.6	1.54e-27	1.73e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	11.6	1.54e-27	1.73e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	11.6	1.54e-27	1.73e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
THCA	cis	rs17111396	0.627	rs17111394	ENSG00000259167.2	NMNAT1P1	11.6	1.55e-27	1.74e-24	0.73	0.47	Uric acid levels;	chr14:81056784	chr14:81032529~81033404:+
THCA	cis	rs11214589	0.747	rs10891537	ENSG00000270179.1	RP11-159N11.4	-11.6	1.56e-27	1.75e-24	-0.5	-0.47	Neuroticism;	chr11:113340648	chr11:113368478~113369117:+
THCA	cis	rs524281	0.506	rs560393	ENSG00000255320.1	RP11-755F10.1	11.6	1.56e-27	1.75e-24	0.64	0.47	Electroencephalogram traits;	chr11:66238006	chr11:66244840~66246239:-
THCA	cis	rs9389248	0.69	rs728030	ENSG00000232876.1	CTA-212D2.2	11.6	1.56e-27	1.75e-24	0.57	0.47	High light scatter reticulocyte percentage of red cells;	chr6:134925156	chr6:135055033~135060550:+
THCA	cis	rs6558530	0.692	rs7818406	ENSG00000253982.1	CTD-2336O2.1	11.6	1.56e-27	1.76e-24	0.45	0.47	Systolic blood pressure;	chr8:1753084	chr8:1761990~1764502:-
THCA	cis	rs6558530	0.692	rs10105317	ENSG00000253982.1	CTD-2336O2.1	11.6	1.56e-27	1.76e-24	0.45	0.47	Systolic blood pressure;	chr8:1753266	chr8:1761990~1764502:-
THCA	cis	rs4819052	0.851	rs2236444	ENSG00000223768.1	LINC00205	-11.6	1.57e-27	1.76e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45293285~45297354:+
THCA	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-11.6	1.59e-27	1.79e-24	-0.52	-0.47	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
THCA	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	11.6	1.6e-27	1.8e-24	0.57	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-11.6	1.6e-27	1.8e-24	-0.61	-0.47	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
THCA	cis	rs950169	0.881	rs4842852	ENSG00000225151.9	GOLGA2P7	-11.6	1.61e-27	1.8e-24	-0.7	-0.47	Schizophrenia;	chr15:84387263	chr15:84199311~84230136:-
THCA	cis	rs950169	0.84	rs4842853	ENSG00000225151.9	GOLGA2P7	-11.6	1.61e-27	1.8e-24	-0.7	-0.47	Schizophrenia;	chr15:84387606	chr15:84199311~84230136:-
THCA	cis	rs950169	0.922	rs4842946	ENSG00000225151.9	GOLGA2P7	-11.6	1.61e-27	1.8e-24	-0.7	-0.47	Schizophrenia;	chr15:84387633	chr15:84199311~84230136:-
THCA	cis	rs950169	0.84	rs4842854	ENSG00000225151.9	GOLGA2P7	-11.6	1.61e-27	1.8e-24	-0.7	-0.47	Schizophrenia;	chr15:84387641	chr15:84199311~84230136:-
THCA	cis	rs6496932	0.635	rs12900455	ENSG00000218052.5	ADAMTS7P4	-11.6	1.61e-27	1.81e-24	-0.61	-0.47	Central corneal thickness;Corneal structure;	chr15:85362345	chr15:85255369~85330334:-
THCA	cis	rs7772486	0.597	rs6570732	ENSG00000235652.6	RP11-545I5.3	-11.6	1.61e-27	1.81e-24	-0.48	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145924015	chr6:145799409~145886585:+
THCA	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	11.6	1.61e-27	1.81e-24	0.58	0.47	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
THCA	cis	rs944289	0.51	rs2780314	ENSG00000257826.1	RP11-116N8.4	-11.6	1.63e-27	1.83e-24	-0.5	-0.47	Thyroid cancer;	chr14:36059286	chr14:36061026~36067190:-
THCA	cis	rs11098499	0.874	rs12509054	ENSG00000245958.5	RP11-33B1.1	-11.59	1.64e-27	1.84e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119193920	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.874	rs10022508	ENSG00000245958.5	RP11-33B1.1	-11.59	1.64e-27	1.84e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119194073	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.874	rs12502503	ENSG00000245958.5	RP11-33B1.1	-11.59	1.64e-27	1.84e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119195100	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.874	rs6832670	ENSG00000245958.5	RP11-33B1.1	-11.59	1.64e-27	1.84e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119197637	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.874	rs6822498	ENSG00000245958.5	RP11-33B1.1	-11.59	1.64e-27	1.84e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119199028	chr4:119454791~119552025:+
THCA	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	11.59	1.65e-27	1.85e-24	0.57	0.47	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
THCA	cis	rs4718428	0.576	rs12698546	ENSG00000226824.5	RP4-756H11.3	-11.59	1.66e-27	1.86e-24	-0.71	-0.47	Corneal structure;	chr7:66801919	chr7:66654538~66669855:+
THCA	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	11.59	1.67e-27	1.87e-24	0.59	0.47	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
THCA	cis	rs6538678	0.895	rs1436124	ENSG00000258343.1	RP11-536G4.2	-11.59	1.67e-27	1.87e-24	-0.69	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95795345~95858839:-
THCA	cis	rs7772486	0.743	rs1292339	ENSG00000235652.6	RP11-545I5.3	-11.59	1.68e-27	1.88e-24	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145645950	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.851	rs2838837	ENSG00000223768.1	LINC00205	-11.59	1.68e-27	1.88e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45293285~45297354:+
THCA	cis	rs950169	0.887	rs35986397	ENSG00000225151.9	GOLGA2P7	-11.59	1.68e-27	1.89e-24	-0.7	-0.47	Schizophrenia;	chr15:84400409	chr15:84199311~84230136:-
THCA	cis	rs6570726	0.846	rs372904	ENSG00000235652.6	RP11-545I5.3	11.59	1.69e-27	1.89e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145566289	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.791	rs414297	ENSG00000235652.6	RP11-545I5.3	11.59	1.69e-27	1.89e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145566420	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs453834	ENSG00000235652.6	RP11-545I5.3	11.59	1.69e-27	1.89e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145565125	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.959	rs8130866	ENSG00000223768.1	LINC00205	-11.59	1.7e-27	1.9e-24	-0.48	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45293285~45297354:+
THCA	cis	rs4713118	0.621	rs9295756	ENSG00000280107.1	AL022393.9	-11.59	1.7e-27	1.9e-24	-0.56	-0.47	Parkinson's disease;	chr6:28065618	chr6:28170845~28172521:+
THCA	cis	rs9322193	0.923	rs9800806	ENSG00000223701.3	RAET1E-AS1	11.59	1.71e-27	1.91e-24	0.63	0.47	Lung cancer;	chr6:149740350	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs1572229	ENSG00000223701.3	RAET1E-AS1	11.59	1.71e-27	1.91e-24	0.63	0.47	Lung cancer;	chr6:149743841	chr6:149884431~149919508:+
THCA	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-11.59	1.71e-27	1.91e-24	-0.34	-0.47	Height;	chr11:118737916	chr11:118791254~118793137:+
THCA	cis	rs526231	0.543	rs34767	ENSG00000175749.11	EIF3KP1	11.59	1.71e-27	1.92e-24	0.63	0.47	Primary biliary cholangitis;	chr5:103153807	chr5:103032376~103033031:+
THCA	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	11.59	1.71e-27	1.92e-24	0.54	0.47	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.962	rs2275045	ENSG00000223701.3	RAET1E-AS1	11.59	1.72e-27	1.92e-24	0.65	0.47	Lung cancer;	chr6:149842775	chr6:149884431~149919508:+
THCA	cis	rs4819052	1	rs3746980	ENSG00000223768.1	LINC00205	-11.59	1.75e-27	1.96e-24	-0.48	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45293285~45297354:+
THCA	cis	rs7829975	0.564	rs2976855	ENSG00000253893.2	FAM85B	-11.59	1.76e-27	1.97e-24	-0.59	-0.47	Mood instability;	chr8:8444284	chr8:8167819~8226614:-
THCA	cis	rs7772486	0.79	rs2265917	ENSG00000235652.6	RP11-545I5.3	11.59	1.77e-27	1.98e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145891149	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.884	rs62439836	ENSG00000223701.3	RAET1E-AS1	11.59	1.78e-27	1.99e-24	0.63	0.47	Lung cancer;	chr6:149669173	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs4869812	ENSG00000223701.3	RAET1E-AS1	11.59	1.78e-27	1.99e-24	0.63	0.47	Lung cancer;	chr6:149669447	chr6:149884431~149919508:+
THCA	cis	rs2274273	0.773	rs8012380	ENSG00000258413.1	RP11-665C16.6	-11.59	1.78e-27	2e-24	-0.6	-0.47	Protein biomarker;	chr14:55268292	chr14:55262767~55272075:-
THCA	cis	rs7772486	0.743	rs9376955	ENSG00000235652.6	RP11-545I5.3	11.58	1.8e-27	2.01e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145628268	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.805	rs4896831	ENSG00000235652.6	RP11-545I5.3	11.58	1.8e-27	2.01e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145638345	chr6:145799409~145886585:+
THCA	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	11.58	1.8e-27	2.01e-24	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	11.58	1.8e-27	2.01e-24	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
THCA	cis	rs8100891	0.537	rs10417152	ENSG00000267213.4	AC007773.2	-11.58	1.82e-27	2.04e-24	-0.56	-0.47	Neuroticism;	chr19:32397994	chr19:32390050~32405560:-
THCA	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-11.58	1.82e-27	2.04e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.923	rs9478291	ENSG00000223701.3	RAET1E-AS1	11.58	1.82e-27	2.04e-24	0.63	0.47	Lung cancer;	chr6:149729434	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9322209	ENSG00000223701.3	RAET1E-AS1	11.58	1.83e-27	2.05e-24	0.63	0.47	Lung cancer;	chr6:149691226	chr6:149884431~149919508:+
THCA	cis	rs673078	0.607	rs17441214	ENSG00000275759.1	RP11-131L12.3	-11.58	1.84e-27	2.05e-24	-0.72	-0.47	Glucose homeostasis traits;	chr12:118436721	chr12:118428281~118428870:+
THCA	cis	rs9322193	0.884	rs9689702	ENSG00000223701.3	RAET1E-AS1	11.58	1.84e-27	2.06e-24	0.63	0.47	Lung cancer;	chr6:149740720	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-11.58	1.84e-27	2.06e-24	-0.58	-0.47	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
THCA	cis	rs7772486	0.743	rs9390344	ENSG00000235652.6	RP11-545I5.3	-11.58	1.85e-27	2.07e-24	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145691619	chr6:145799409~145886585:+
THCA	cis	rs950169	0.887	rs12903946	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84399732	chr15:84199311~84230136:-
THCA	cis	rs950169	0.887	rs62029593	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84400482	chr15:84199311~84230136:-
THCA	cis	rs950169	0.81	rs62029594	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84400554	chr15:84199311~84230136:-
THCA	cis	rs950169	0.881	rs62029596	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84400736	chr15:84199311~84230136:-
THCA	cis	rs950169	0.881	rs4081123	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84401537	chr15:84199311~84230136:-
THCA	cis	rs950169	0.881	rs62029599	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84401867	chr15:84199311~84230136:-
THCA	cis	rs950169	0.8	rs4099846	ENSG00000225151.9	GOLGA2P7	-11.58	1.86e-27	2.08e-24	-0.7	-0.47	Schizophrenia;	chr15:84402196	chr15:84199311~84230136:-
THCA	cis	rs9322193	0.923	rs62439840	ENSG00000223701.3	RAET1E-AS1	11.58	1.86e-27	2.08e-24	0.65	0.47	Lung cancer;	chr6:149674639	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9393175	ENSG00000223701.3	RAET1E-AS1	11.58	1.86e-27	2.08e-24	0.65	0.47	Lung cancer;	chr6:149677587	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10782315	ENSG00000223701.3	RAET1E-AS1	11.58	1.86e-27	2.08e-24	0.63	0.47	Lung cancer;	chr6:149743093	chr6:149884431~149919508:+
THCA	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	11.58	1.86e-27	2.08e-24	0.64	0.47	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
THCA	cis	rs11105298	0.891	rs10858864	ENSG00000258302.2	RP11-981P6.1	11.58	1.87e-27	2.09e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs10858865	ENSG00000258302.2	RP11-981P6.1	11.58	1.87e-27	2.09e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:89561129~89594878:+
THCA	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	11.58	1.88e-27	2.1e-24	0.53	0.47	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
THCA	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-11.58	1.88e-27	2.1e-24	-0.57	-0.47	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.58	rs61938969	ENSG00000256250.1	RP11-989F5.1	11.58	1.89e-27	2.11e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130831525	chr12:130810606~130812438:+
THCA	cis	rs9322193	0.923	rs9479494	ENSG00000223701.3	RAET1E-AS1	11.58	1.89e-27	2.11e-24	0.63	0.47	Lung cancer;	chr6:149739108	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs4380763	ENSG00000223701.3	RAET1E-AS1	11.58	1.9e-27	2.12e-24	0.63	0.47	Lung cancer;	chr6:149678086	chr6:149884431~149919508:+
THCA	cis	rs950027	0.967	rs2643718	ENSG00000259520.4	CTD-2651B20.3	-11.58	1.9e-27	2.12e-24	-0.57	-0.47	Response to fenofibrate (adiponectin levels);	chr15:45502464	chr15:45251580~45279251:-
THCA	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-11.58	1.92e-27	2.14e-24	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-11.58	1.92e-27	2.14e-24	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-11.58	1.92e-27	2.14e-24	-0.58	-0.47	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
THCA	cis	rs4718428	0.705	rs13220977	ENSG00000226824.5	RP4-756H11.3	11.58	1.92e-27	2.14e-24	0.69	0.47	Corneal structure;	chr7:66872661	chr7:66654538~66669855:+
THCA	cis	rs4964805	1	rs11111791	ENSG00000257681.1	RP11-341G23.4	11.58	1.93e-27	2.15e-24	0.58	0.47	Attention deficit hyperactivity disorder;	chr12:103799493	chr12:103746315~103768858:-
THCA	cis	rs11105298	0.891	rs10858909	ENSG00000258302.2	RP11-981P6.1	11.58	1.93e-27	2.15e-24	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:89561129~89594878:+
THCA	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-11.58	1.95e-27	2.17e-24	-0.49	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
THCA	cis	rs2274273	0.744	rs8011808	ENSG00000258413.1	RP11-665C16.6	-11.57	1.96e-27	2.19e-24	-0.61	-0.47	Protein biomarker;	chr14:55356626	chr14:55262767~55272075:-
THCA	cis	rs11105298	0.838	rs10858862	ENSG00000258302.2	RP11-981P6.1	11.57	1.97e-27	2.2e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:89561129~89594878:+
THCA	cis	rs853679	0.55	rs1233704	ENSG00000280107.1	AL022393.9	11.57	1.98e-27	2.2e-24	0.56	0.47	Depression;	chr6:28199145	chr6:28170845~28172521:+
THCA	cis	rs853679	0.55	rs1237875	ENSG00000280107.1	AL022393.9	11.57	1.98e-27	2.2e-24	0.56	0.47	Depression;	chr6:28205232	chr6:28170845~28172521:+
THCA	cis	rs853679	0.55	rs1225598	ENSG00000280107.1	AL022393.9	-11.57	1.98e-27	2.2e-24	-0.56	-0.47	Depression;	chr6:28193021	chr6:28170845~28172521:+
THCA	cis	rs853679	0.55	rs1150689	ENSG00000280107.1	AL022393.9	-11.57	1.98e-27	2.2e-24	-0.56	-0.47	Depression;	chr6:28197321	chr6:28170845~28172521:+
THCA	cis	rs853679	0.55	rs1225599	ENSG00000280107.1	AL022393.9	-11.57	1.98e-27	2.2e-24	-0.56	-0.47	Depression;	chr6:28197412	chr6:28170845~28172521:+
THCA	cis	rs853679	0.574	rs1233705	ENSG00000280107.1	AL022393.9	-11.57	1.98e-27	2.2e-24	-0.56	-0.47	Depression;	chr6:28198669	chr6:28170845~28172521:+
THCA	cis	rs853679	0.55	rs1233707	ENSG00000280107.1	AL022393.9	-11.57	1.98e-27	2.2e-24	-0.56	-0.47	Depression;	chr6:28205175	chr6:28170845~28172521:+
THCA	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-11.57	1.98e-27	2.21e-24	-0.62	-0.47	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
THCA	cis	rs10463554	1	rs3776864	ENSG00000175749.11	EIF3KP1	11.57	1.99e-27	2.21e-24	0.63	0.47	Parkinson's disease;	chr5:102992164	chr5:103032376~103033031:+
THCA	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-11.57	2e-27	2.23e-24	-0.52	-0.47	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
THCA	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	11.57	2.03e-27	2.26e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	11.57	2.03e-27	2.26e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
THCA	cis	rs4819052	0.851	rs8133045	ENSG00000223768.1	LINC00205	-11.57	2.03e-27	2.27e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45293285~45297354:+
THCA	cis	rs12468226	0.938	rs4675274	ENSG00000273456.1	RP11-686O6.2	-11.57	2.04e-27	2.27e-24	-0.58	-0.47	Urate levels;	chr2:202243145	chr2:202374932~202375604:-
THCA	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	11.57	2.05e-27	2.28e-24	0.61	0.47	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	11.57	2.05e-27	2.28e-24	0.61	0.47	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
THCA	cis	rs2274273	0.87	rs6573009	ENSG00000258413.1	RP11-665C16.6	-11.57	2.06e-27	2.29e-24	-0.6	-0.47	Protein biomarker;	chr14:55215606	chr14:55262767~55272075:-
THCA	cis	rs4819052	0.851	rs12626188	ENSG00000223768.1	LINC00205	-11.57	2.06e-27	2.29e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45293285~45297354:+
THCA	cis	rs6538678	0.824	rs4762633	ENSG00000258343.1	RP11-536G4.2	-11.57	2.07e-27	2.3e-24	-0.69	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95795345~95858839:-
THCA	cis	rs7772486	0.875	rs2814875	ENSG00000235652.6	RP11-545I5.3	11.57	2.07e-27	2.3e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145984674	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2814874	ENSG00000235652.6	RP11-545I5.3	11.57	2.07e-27	2.3e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145984759	chr6:145799409~145886585:+
THCA	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-11.57	2.08e-27	2.31e-24	-0.34	-0.47	Height;	chr11:118786602	chr11:118791254~118793137:+
THCA	cis	rs950169	0.8	rs4842847	ENSG00000225151.9	GOLGA2P7	-11.57	2.08e-27	2.31e-24	-0.7	-0.47	Schizophrenia;	chr15:84262447	chr15:84199311~84230136:-
THCA	cis	rs2274273	0.934	rs8021940	ENSG00000258413.1	RP11-665C16.6	-11.57	2.08e-27	2.31e-24	-0.61	-0.47	Protein biomarker;	chr14:55252997	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.923	rs56397000	ENSG00000223701.3	RAET1E-AS1	11.57	2.08e-27	2.32e-24	0.63	0.47	Lung cancer;	chr6:149739347	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.846	rs409553	ENSG00000235652.6	RP11-545I5.3	11.57	2.09e-27	2.33e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145565827	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs371186	ENSG00000235652.6	RP11-545I5.3	11.57	2.09e-27	2.33e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145565835	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs439035	ENSG00000235652.6	RP11-545I5.3	11.57	2.09e-27	2.33e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145566854	chr6:145799409~145886585:+
THCA	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-11.57	2.13e-27	2.37e-24	-0.58	-0.47	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
THCA	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	11.57	2.14e-27	2.38e-24	0.56	0.47	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
THCA	cis	rs6570726	0.967	rs6903252	ENSG00000235652.6	RP11-545I5.3	11.56	2.16e-27	2.4e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145601641	chr6:145799409~145886585:+
THCA	cis	rs950169	0.922	rs62028133	ENSG00000225151.9	GOLGA2P7	-11.56	2.16e-27	2.4e-24	-0.69	-0.47	Schizophrenia;	chr15:84250623	chr15:84199311~84230136:-
THCA	cis	rs950169	0.723	rs17589320	ENSG00000225151.9	GOLGA2P7	-11.56	2.16e-27	2.4e-24	-0.69	-0.47	Schizophrenia;	chr15:84251244	chr15:84199311~84230136:-
THCA	cis	rs9322193	0.607	rs7764677	ENSG00000231760.4	RP11-350J20.5	11.56	2.16e-27	2.41e-24	0.67	0.47	Lung cancer;	chr6:149906197	chr6:149796151~149826294:-
THCA	cis	rs875971	1	rs1167612	ENSG00000237310.1	GS1-124K5.4	-11.56	2.17e-27	2.41e-24	-0.35	-0.47	Aortic root size;	chr7:66102989	chr7:66493706~66495474:+
THCA	cis	rs950169	0.84	rs62029595	ENSG00000225151.9	GOLGA2P7	-11.56	2.17e-27	2.42e-24	-0.7	-0.47	Schizophrenia;	chr15:84400603	chr15:84199311~84230136:-
THCA	cis	rs7772486	0.817	rs2144477	ENSG00000235652.6	RP11-545I5.3	11.56	2.19e-27	2.43e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146085112	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9403768	ENSG00000235652.6	RP11-545I5.3	11.56	2.19e-27	2.43e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146085322	chr6:145799409~145886585:+
THCA	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	11.56	2.19e-27	2.44e-24	0.54	0.47	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.886	rs9485408	ENSG00000223701.3	RAET1E-AS1	11.56	2.2e-27	2.44e-24	0.63	0.47	Lung cancer;	chr6:149618888	chr6:149884431~149919508:+
THCA	cis	rs11098499	0.874	rs9995277	ENSG00000245958.5	RP11-33B1.1	-11.56	2.2e-27	2.45e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119187448	chr4:119454791~119552025:+
THCA	cis	rs6558530	0.653	rs6984632	ENSG00000253982.1	CTD-2336O2.1	11.56	2.2e-27	2.45e-24	0.45	0.47	Systolic blood pressure;	chr8:1752268	chr8:1761990~1764502:-
THCA	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	11.56	2.2e-27	2.45e-24	0.57	0.47	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
THCA	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-11.56	2.22e-27	2.47e-24	-0.34	-0.47	Height;	chr11:118809363	chr11:118791254~118793137:+
THCA	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-11.56	2.23e-27	2.47e-24	-0.44	-0.47	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
THCA	cis	rs9322193	0.923	rs4870509	ENSG00000223701.3	RAET1E-AS1	11.56	2.23e-27	2.48e-24	0.64	0.47	Lung cancer;	chr6:149702212	chr6:149884431~149919508:+
THCA	cis	rs7945705	0.747	rs1980428	ENSG00000254860.4	TMEM9B-AS1	-11.56	2.25e-27	2.5e-24	-0.51	-0.47	Hemoglobin concentration;	chr11:8988950	chr11:8964675~8977527:+
THCA	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	11.56	2.28e-27	2.52e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	11.56	2.28e-27	2.52e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
THCA	cis	rs4819052	0.851	rs2877018	ENSG00000223768.1	LINC00205	-11.56	2.3e-27	2.54e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2330012	ENSG00000223768.1	LINC00205	-11.56	2.3e-27	2.54e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2877019	ENSG00000223768.1	LINC00205	-11.56	2.3e-27	2.54e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2877020	ENSG00000223768.1	LINC00205	-11.56	2.3e-27	2.54e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs875621	ENSG00000223768.1	LINC00205	-11.56	2.33e-27	2.57e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45293285~45297354:+
THCA	cis	rs8100891	0.537	rs73034216	ENSG00000267213.4	AC007773.2	-11.56	2.33e-27	2.57e-24	-0.57	-0.47	Neuroticism;	chr19:32392510	chr19:32390050~32405560:-
THCA	cis	rs7772486	0.875	rs865913	ENSG00000235652.6	RP11-545I5.3	11.55	2.36e-27	2.6e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145987738	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2814873	ENSG00000235652.6	RP11-545I5.3	11.55	2.36e-27	2.6e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145987796	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.84	rs2777478	ENSG00000235652.6	RP11-545I5.3	11.55	2.36e-27	2.6e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145987981	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2814872	ENSG00000235652.6	RP11-545I5.3	11.55	2.36e-27	2.6e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145989098	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs854148	ENSG00000235652.6	RP11-545I5.3	11.55	2.36e-27	2.6e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145989843	chr6:145799409~145886585:+
THCA	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	11.55	2.36e-27	2.61e-24	0.57	0.47	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	11.55	2.37e-27	2.62e-24	0.56	0.47	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
THCA	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	11.55	2.39e-27	2.64e-24	0.58	0.47	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
THCA	cis	rs3762637	0.943	rs7629285	ENSG00000272758.4	RP11-299J3.8	11.55	2.39e-27	2.64e-24	0.63	0.47	LDL cholesterol levels;	chr3:122546892	chr3:122416207~122443180:+
THCA	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-11.55	2.4e-27	2.65e-24	-0.62	-0.47	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
THCA	cis	rs7301826	0.627	rs4334059	ENSG00000256250.1	RP11-989F5.1	-11.55	2.45e-27	2.7e-24	-0.57	-0.47	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810606~130812438:+
THCA	cis	rs227275	0.525	rs7660298	ENSG00000246560.2	RP11-10L12.4	11.55	2.47e-27	2.73e-24	0.59	0.47	Allergic disease (asthma, hay fever or eczema);	chr4:103039611	chr4:102828055~102844075:+
THCA	cis	rs853679	0.517	rs6922063	ENSG00000219392.1	RP1-265C24.5	-11.55	2.48e-27	2.74e-24	-0.64	-0.47	Depression;	chr6:28126588	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs2275508	ENSG00000219392.1	RP1-265C24.5	-11.55	2.48e-27	2.74e-24	-0.64	-0.47	Depression;	chr6:28126953	chr6:28115628~28116551:+
THCA	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	11.55	2.48e-27	2.74e-24	0.54	0.47	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
THCA	cis	rs6142102	0.961	rs6119447	ENSG00000276073.1	RP5-1125A11.7	-11.55	2.48e-27	2.74e-24	-0.44	-0.47	Skin pigmentation;	chr20:34080770	chr20:33985617~33988989:-
THCA	cis	rs7301826	0.651	rs6486601	ENSG00000256250.1	RP11-989F5.1	11.55	2.49e-27	2.74e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130816692	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.627	rs61937256	ENSG00000256250.1	RP11-989F5.1	11.55	2.49e-27	2.74e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130818100	chr12:130810606~130812438:+
THCA	cis	rs7301826	0.56	rs12829294	ENSG00000256250.1	RP11-989F5.1	11.55	2.51e-27	2.76e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130825427	chr12:130810606~130812438:+
THCA	cis	rs950169	0.922	rs4338765	ENSG00000225151.9	GOLGA2P7	-11.55	2.51e-27	2.77e-24	-0.69	-0.47	Schizophrenia;	chr15:84248084	chr15:84199311~84230136:-
THCA	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-11.55	2.53e-27	2.78e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
THCA	cis	rs7569084	0.687	rs1437462	ENSG00000237979.1	AC007389.1	11.55	2.53e-27	2.79e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65449559	chr2:65500993~65502138:-
THCA	cis	rs9322193	0.884	rs9688699	ENSG00000223701.3	RAET1E-AS1	11.55	2.55e-27	2.81e-24	0.63	0.47	Lung cancer;	chr6:149733680	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs11155670	ENSG00000223701.3	RAET1E-AS1	11.55	2.55e-27	2.81e-24	0.64	0.47	Lung cancer;	chr6:149644992	chr6:149884431~149919508:+
THCA	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-11.55	2.56e-27	2.82e-24	-0.34	-0.47	Height;	chr11:118781100	chr11:118791254~118793137:+
THCA	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-11.54	2.6e-27	2.87e-24	-0.62	-0.47	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
THCA	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	11.54	2.61e-27	2.87e-24	0.63	0.47	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
THCA	cis	rs11098499	0.874	rs6851169	ENSG00000245958.5	RP11-33B1.1	-11.54	2.61e-27	2.87e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119196355	chr4:119454791~119552025:+
THCA	cis	rs11105298	0.891	rs10858852	ENSG00000258302.2	RP11-981P6.1	11.54	2.61e-27	2.87e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs4842653	ENSG00000258302.2	RP11-981P6.1	11.54	2.61e-27	2.87e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:89561129~89594878:+
THCA	cis	rs11105298	0.891	rs4842654	ENSG00000258302.2	RP11-981P6.1	11.54	2.61e-27	2.87e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:89561129~89594878:+
THCA	cis	rs11722779	0.844	rs7694724	ENSG00000246560.2	RP11-10L12.4	11.54	2.61e-27	2.87e-24	0.59	0.47	Schizophrenia;	chr4:103041375	chr4:102828055~102844075:+
THCA	cis	rs3002131	0.604	rs2936038	ENSG00000225265.1	TAF1A-AS1	-11.54	2.64e-27	2.91e-24	-0.64	-0.47	Interleukin-10 levels;	chr1:222572449	chr1:222589825~222593032:+
THCA	cis	rs4819052	1	rs13053002	ENSG00000223768.1	LINC00205	-11.54	2.66e-27	2.93e-24	-0.48	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.772	rs7738696	ENSG00000223701.3	RAET1E-AS1	11.54	2.71e-27	2.98e-24	0.64	0.47	Lung cancer;	chr6:149848985	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9688517	ENSG00000223701.3	RAET1E-AS1	11.54	2.72e-27	3e-24	0.63	0.47	Lung cancer;	chr6:149740655	chr6:149884431~149919508:+
THCA	cis	rs8062405	0.698	rs10499	ENSG00000251417.2	RP11-1348G14.4	11.54	2.72e-27	3e-24	0.48	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28904206	chr16:28802743~28817828:+
THCA	cis	rs6142102	0.961	rs2268089	ENSG00000276073.1	RP5-1125A11.7	-11.54	2.73e-27	3e-24	-0.44	-0.47	Skin pigmentation;	chr20:34079492	chr20:33985617~33988989:-
THCA	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	11.54	2.73e-27	3e-24	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	11.54	2.73e-27	3e-24	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
THCA	cis	rs853679	0.55	rs1233701	ENSG00000280107.1	AL022393.9	11.54	2.74e-27	3.01e-24	0.56	0.47	Depression;	chr6:28200948	chr6:28170845~28172521:+
THCA	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	11.54	2.74e-27	3.02e-24	0.56	0.47	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
THCA	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-11.54	2.79e-27	3.06e-24	-0.65	-0.47	Depression;	chr6:28140454	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-11.54	2.79e-27	3.06e-24	-0.65	-0.47	Depression;	chr6:28141189	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-11.54	2.79e-27	3.06e-24	-0.65	-0.47	Depression;	chr6:28141484	chr6:28115628~28116551:+
THCA	cis	rs4819052	0.851	rs2838867	ENSG00000223768.1	LINC00205	-11.53	2.82e-27	3.1e-24	-0.45	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293177	chr21:45293285~45297354:+
THCA	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-11.53	2.83e-27	3.11e-24	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
THCA	cis	rs9918079	0.6	rs61021642	ENSG00000273133.1	RP11-799M12.2	11.53	2.84e-27	3.12e-24	0.61	0.47	Obesity-related traits;	chr4:15575702	chr4:15563698~15564253:-
THCA	cis	rs9918079	0.6	rs12500587	ENSG00000273133.1	RP11-799M12.2	11.53	2.84e-27	3.12e-24	0.61	0.47	Obesity-related traits;	chr4:15579131	chr4:15563698~15564253:-
THCA	cis	rs465969	0.744	rs71562296	ENSG00000255389.1	C6orf3	-11.53	2.85e-27	3.13e-24	-0.78	-0.47	Psoriasis;	chr6:111521444	chr6:111599875~111602295:+
THCA	cis	rs465969	0.744	rs6939657	ENSG00000255389.1	C6orf3	-11.53	2.85e-27	3.13e-24	-0.78	-0.47	Psoriasis;	chr6:111521822	chr6:111599875~111602295:+
THCA	cis	rs4819052	0.851	rs2838826	ENSG00000223768.1	LINC00205	-11.53	2.87e-27	3.15e-24	-0.45	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45293285~45297354:+
THCA	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-11.53	2.87e-27	3.15e-24	-0.61	-0.47	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
THCA	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-11.53	2.87e-27	3.16e-24	-0.62	-0.47	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
THCA	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-11.53	2.88e-27	3.16e-24	-0.57	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
THCA	cis	rs9389248	0.69	rs2064101	ENSG00000232876.1	CTA-212D2.2	11.53	2.89e-27	3.18e-24	0.58	0.47	High light scatter reticulocyte percentage of red cells;	chr6:134929392	chr6:135055033~135060550:+
THCA	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	11.53	2.91e-27	3.2e-24	0.57	0.47	Depression;	chr6:28327262	chr6:28176188~28176674:+
THCA	cis	rs8062405	0.698	rs8046545	ENSG00000259982.1	CDC37P1	-11.53	2.92e-27	3.2e-24	-0.59	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28700294~28701540:-
THCA	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-11.53	2.92e-27	3.2e-24	-0.34	-0.47	Height;	chr11:118791319	chr11:118791254~118793137:+
THCA	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	11.53	2.92e-27	3.21e-24	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
THCA	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	11.53	2.92e-27	3.21e-24	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
THCA	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-11.53	2.94e-27	3.22e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-11.53	2.94e-27	3.22e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-11.53	2.94e-27	3.22e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-11.53	2.94e-27	3.22e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-11.53	2.94e-27	3.22e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
THCA	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	11.53	2.97e-27	3.26e-24	0.74	0.47	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
THCA	cis	rs4819052	0.765	rs2838868	ENSG00000223768.1	LINC00205	11.53	2.98e-27	3.27e-24	0.47	0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45293285~45297354:+
THCA	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	11.53	2.98e-27	3.27e-24	0.61	0.47	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
THCA	cis	rs3002131	0.604	rs1603742	ENSG00000225265.1	TAF1A-AS1	-11.53	2.98e-27	3.27e-24	-0.65	-0.47	Interleukin-10 levels;	chr1:222571339	chr1:222589825~222593032:+
THCA	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	11.53	3e-27	3.29e-24	0.51	0.47	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	11.53	3e-27	3.29e-24	0.51	0.47	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
THCA	cis	rs7772486	0.875	rs10457795	ENSG00000235652.6	RP11-545I5.3	11.53	3.01e-27	3.3e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146094529	chr6:145799409~145886585:+
THCA	cis	rs6142102	0.923	rs6059635	ENSG00000276073.1	RP5-1125A11.7	-11.53	3.01e-27	3.3e-24	-0.44	-0.47	Skin pigmentation;	chr20:34025687	chr20:33985617~33988989:-
THCA	cis	rs11105298	0.891	rs12369195	ENSG00000258302.2	RP11-981P6.1	11.53	3.07e-27	3.36e-24	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541195	chr12:89561129~89594878:+
THCA	cis	rs7772486	0.875	rs6938972	ENSG00000235652.6	RP11-545I5.3	11.53	3.08e-27	3.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146089472	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs12194437	ENSG00000235652.6	RP11-545I5.3	11.53	3.08e-27	3.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146090304	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs10457793	ENSG00000235652.6	RP11-545I5.3	11.53	3.08e-27	3.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146094267	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs10457794	ENSG00000235652.6	RP11-545I5.3	11.53	3.08e-27	3.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146094472	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs9403770	ENSG00000235652.6	RP11-545I5.3	11.53	3.08e-27	3.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146102198	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs11155452	ENSG00000235652.6	RP11-545I5.3	11.53	3.08e-27	3.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146103495	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.846	rs9403767	ENSG00000235652.6	RP11-545I5.3	11.52	3.08e-27	3.38e-24	0.44	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146081250	chr6:145799409~145886585:+
THCA	cis	rs6558530	0.587	rs6986102	ENSG00000253982.1	CTD-2336O2.1	11.52	3.09e-27	3.38e-24	0.45	0.47	Systolic blood pressure;	chr8:1752474	chr8:1761990~1764502:-
THCA	cis	rs673078	0.66	rs73220119	ENSG00000275759.1	RP11-131L12.3	-11.52	3.1e-27	3.4e-24	-0.73	-0.47	Glucose homeostasis traits;	chr12:118159864	chr12:118428281~118428870:+
THCA	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-11.52	3.1e-27	3.4e-24	-0.64	-0.47	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
THCA	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-11.52	3.11e-27	3.41e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
THCA	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-11.52	3.11e-27	3.41e-24	-0.57	-0.47	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
THCA	cis	rs526231	0.511	rs73179850	ENSG00000175749.11	EIF3KP1	11.52	3.12e-27	3.42e-24	0.62	0.47	Primary biliary cholangitis;	chr5:103012873	chr5:103032376~103033031:+
THCA	cis	rs7429990	1	rs319680	ENSG00000229759.1	MRPS18AP1	11.52	3.13e-27	3.42e-24	0.6	0.47	Educational attainment (years of education);	chr3:47856817	chr3:48256350~48256938:-
THCA	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	11.52	3.13e-27	3.43e-24	0.6	0.47	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
THCA	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-11.52	3.14e-27	3.44e-24	-0.69	-0.47	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
THCA	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	11.52	3.17e-27	3.47e-24	0.69	0.47	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
THCA	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	11.52	3.17e-27	3.47e-24	0.69	0.47	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
THCA	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	11.52	3.17e-27	3.47e-24	0.69	0.47	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
THCA	cis	rs10463554	0.963	rs1595553	ENSG00000175749.11	EIF3KP1	11.52	3.18e-27	3.48e-24	0.61	0.47	Parkinson's disease;	chr5:103043164	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs12655592	ENSG00000175749.11	EIF3KP1	11.52	3.18e-27	3.48e-24	0.61	0.47	Parkinson's disease;	chr5:103043715	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs12054848	ENSG00000175749.11	EIF3KP1	11.52	3.18e-27	3.48e-24	0.61	0.47	Parkinson's disease;	chr5:103044736	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs11242484	ENSG00000175749.11	EIF3KP1	11.52	3.18e-27	3.48e-24	0.61	0.47	Parkinson's disease;	chr5:103046172	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs11242485	ENSG00000175749.11	EIF3KP1	11.52	3.18e-27	3.48e-24	0.61	0.47	Parkinson's disease;	chr5:103046330	chr5:103032376~103033031:+
THCA	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	11.52	3.18e-27	3.48e-24	0.6	0.47	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
THCA	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	11.52	3.18e-27	3.48e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
THCA	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-11.52	3.19e-27	3.49e-24	-0.57	-0.47	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
THCA	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	11.52	3.2e-27	3.5e-24	0.54	0.47	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
THCA	cis	rs12468226	1	rs111542497	ENSG00000273456.1	RP11-686O6.2	11.52	3.21e-27	3.51e-24	0.53	0.47	Urate levels;	chr2:202330369	chr2:202374932~202375604:-
THCA	cis	rs7301826	0.58	rs12821464	ENSG00000256250.1	RP11-989F5.1	11.52	3.21e-27	3.52e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130838174	chr12:130810606~130812438:+
THCA	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	11.52	3.22e-27	3.53e-24	0.56	0.47	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
THCA	cis	rs9322193	0.923	rs9767123	ENSG00000223701.3	RAET1E-AS1	11.52	3.23e-27	3.53e-24	0.62	0.47	Lung cancer;	chr6:149660323	chr6:149884431~149919508:+
THCA	cis	rs367615	0.506	rs2914680	ENSG00000249476.1	CTD-2587M2.1	-11.52	3.23e-27	3.54e-24	-0.49	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109451445	chr5:109237120~109326369:-
THCA	cis	rs3762637	0.943	rs9841897	ENSG00000272758.4	RP11-299J3.8	-11.52	3.28e-27	3.59e-24	-0.64	-0.47	LDL cholesterol levels;	chr3:122563722	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.943	rs28372690	ENSG00000272758.4	RP11-299J3.8	-11.52	3.28e-27	3.59e-24	-0.64	-0.47	LDL cholesterol levels;	chr3:122564248	chr3:122416207~122443180:+
THCA	cis	rs6558530	0.626	rs6558524	ENSG00000253982.1	CTD-2336O2.1	11.52	3.29e-27	3.6e-24	0.44	0.47	Systolic blood pressure;	chr8:1754346	chr8:1761990~1764502:-
THCA	cis	rs6558530	0.692	rs6558525	ENSG00000253982.1	CTD-2336O2.1	11.52	3.29e-27	3.6e-24	0.44	0.47	Systolic blood pressure;	chr8:1754357	chr8:1761990~1764502:-
THCA	cis	rs673078	0.66	rs76621503	ENSG00000275759.1	RP11-131L12.3	-11.52	3.3e-27	3.6e-24	-0.72	-0.47	Glucose homeostasis traits;	chr12:118179370	chr12:118428281~118428870:+
THCA	cis	rs7569084	0.687	rs4671663	ENSG00000237979.1	AC007389.1	11.52	3.3e-27	3.61e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65434400	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.687	rs11692813	ENSG00000237979.1	AC007389.1	11.52	3.3e-27	3.61e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65435172	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.663	rs11126037	ENSG00000237979.1	AC007389.1	11.52	3.3e-27	3.61e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65436024	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.687	rs11126038	ENSG00000237979.1	AC007389.1	11.52	3.3e-27	3.61e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65436100	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.663	rs11694714	ENSG00000237979.1	AC007389.1	11.52	3.3e-27	3.61e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65436802	chr2:65500993~65502138:-
THCA	cis	rs4819052	0.851	rs8134392	ENSG00000223768.1	LINC00205	11.52	3.31e-27	3.62e-24	0.44	0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs10470245	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs10470258	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819038	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819039	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4818768	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819042	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs13047598	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.724	rs9753962	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.724	rs9753987	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs9753963	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs9754134	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs34101026	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs13052312	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838828	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs13049337	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838829	ENSG00000223768.1	LINC00205	-11.52	3.31e-27	3.62e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45293285~45297354:+
THCA	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	11.52	3.32e-27	3.62e-24	0.68	0.47	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
THCA	cis	rs8072100	0.84	rs9912311	ENSG00000228782.6	CTD-2026D20.3	11.52	3.33e-27	3.64e-24	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469766	chr17:47450568~47492492:-
THCA	cis	rs9903692	0.908	rs9807087	ENSG00000278765.1	RP5-890E16.5	-11.52	3.34e-27	3.64e-24	-0.62	-0.47	Pulse pressure;	chr17:48126776	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs7209730	ENSG00000278765.1	RP5-890E16.5	-11.52	3.34e-27	3.64e-24	-0.62	-0.47	Pulse pressure;	chr17:48130137	chr17:48066704~48067293:-
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000228039.3	KB-1125A3.10	11.52	3.34e-27	3.65e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23963780~23964374:+
THCA	cis	rs8072100	0.777	rs9914653	ENSG00000228782.6	CTD-2026D20.3	11.52	3.35e-27	3.66e-24	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47460029	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.744	rs34537623	ENSG00000228782.6	CTD-2026D20.3	11.52	3.35e-27	3.66e-24	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47452837	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.84	rs9893901	ENSG00000228782.6	CTD-2026D20.3	11.52	3.35e-27	3.66e-24	0.43	0.47	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47429316	chr17:47450568~47492492:-
THCA	cis	rs4819052	0.819	rs34818688	ENSG00000223768.1	LINC00205	-11.52	3.36e-27	3.67e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45293285~45297354:+
THCA	cis	rs7569084	0.663	rs1437461	ENSG00000237979.1	AC007389.1	11.51	3.38e-27	3.69e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65452578	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.687	rs7562559	ENSG00000237979.1	AC007389.1	11.51	3.38e-27	3.69e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65452719	chr2:65500993~65502138:-
THCA	cis	rs6142102	0.961	rs6120487	ENSG00000276073.1	RP5-1125A11.7	-11.51	3.43e-27	3.74e-24	-0.44	-0.47	Skin pigmentation;	chr20:34034802	chr20:33985617~33988989:-
THCA	cis	rs6558530	0.666	rs6558526	ENSG00000253982.1	CTD-2336O2.1	11.51	3.46e-27	3.77e-24	0.44	0.47	Systolic blood pressure;	chr8:1754406	chr8:1761990~1764502:-
THCA	cis	rs2288884	0.559	rs8104890	ENSG00000275055.1	CTC-471J1.11	-11.51	3.49e-27	3.8e-24	-0.38	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52016355	chr19:52049007~52049754:+
THCA	cis	rs9659323	0.622	rs6689568	ENSG00000231365.4	RP11-418J17.1	-11.51	3.5e-27	3.81e-24	-0.5	-0.47	Body mass index;	chr1:118960338	chr1:119140396~119275973:+
THCA	cis	rs4819052	0.851	rs2838831	ENSG00000223768.1	LINC00205	-11.51	3.53e-27	3.85e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45293285~45297354:+
THCA	cis	rs2274273	0.837	rs6573010	ENSG00000258413.1	RP11-665C16.6	-11.51	3.53e-27	3.85e-24	-0.61	-0.47	Protein biomarker;	chr14:55254874	chr14:55262767~55272075:-
THCA	cis	rs11098499	0.913	rs10006304	ENSG00000245958.5	RP11-33B1.1	-11.51	3.55e-27	3.87e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119203150	chr4:119454791~119552025:+
THCA	cis	rs2274273	0.87	rs10147434	ENSG00000258413.1	RP11-665C16.6	-11.51	3.57e-27	3.89e-24	-0.6	-0.47	Protein biomarker;	chr14:55208129	chr14:55262767~55272075:-
THCA	cis	rs2882667	0.537	rs7704790	ENSG00000253404.1	AC034243.1	11.51	3.59e-27	3.91e-24	0.53	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139074407	chr5:138744434~138753309:-
THCA	cis	rs7569084	0.687	rs12614851	ENSG00000237979.1	AC007389.1	11.51	3.61e-27	3.93e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65458050	chr2:65500993~65502138:-
THCA	cis	rs4713118	0.621	rs4713132	ENSG00000280107.1	AL022393.9	-11.51	3.62e-27	3.94e-24	-0.55	-0.47	Parkinson's disease;	chr6:28066257	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.621	rs4713133	ENSG00000280107.1	AL022393.9	-11.51	3.62e-27	3.94e-24	-0.55	-0.47	Parkinson's disease;	chr6:28066263	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.621	rs4713134	ENSG00000280107.1	AL022393.9	-11.51	3.62e-27	3.94e-24	-0.55	-0.47	Parkinson's disease;	chr6:28066343	chr6:28170845~28172521:+
THCA	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-11.51	3.63e-27	3.95e-24	-0.57	-0.47	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
THCA	cis	rs11105298	0.891	rs11105325	ENSG00000258302.2	RP11-981P6.1	11.51	3.65e-27	3.98e-24	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:89561129~89594878:+
THCA	cis	rs6142102	0.812	rs6059558	ENSG00000276073.1	RP5-1125A11.7	-11.5	3.72e-27	4.05e-24	-0.43	-0.47	Skin pigmentation;	chr20:33929024	chr20:33985617~33988989:-
THCA	cis	rs3779195	0.585	rs73709460	ENSG00000272950.1	RP11-307C18.1	-11.5	3.73e-27	4.06e-24	-0.74	-0.47	Sex hormone-binding globulin levels;	chr7:98265942	chr7:98322853~98323430:+
THCA	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	11.5	3.75e-27	4.08e-24	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
THCA	cis	rs17111396	0.627	rs2371467	ENSG00000259167.2	NMNAT1P1	11.5	3.75e-27	4.08e-24	0.74	0.47	Uric acid levels;	chr14:81055088	chr14:81032529~81033404:+
THCA	cis	rs17111396	0.627	rs61978747	ENSG00000259167.2	NMNAT1P1	11.5	3.75e-27	4.08e-24	0.74	0.47	Uric acid levels;	chr14:81056707	chr14:81032529~81033404:+
THCA	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-11.5	3.78e-27	4.12e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
THCA	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	11.5	3.8e-27	4.13e-24	0.69	0.47	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
THCA	cis	rs7772486	0.654	rs9376958	ENSG00000235652.6	RP11-545I5.3	-11.5	3.8e-27	4.13e-24	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145701904	chr6:145799409~145886585:+
THCA	cis	rs10463554	0.892	rs10434791	ENSG00000175749.11	EIF3KP1	11.5	3.83e-27	4.17e-24	0.62	0.47	Parkinson's disease;	chr5:103053768	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs34382	ENSG00000175749.11	EIF3KP1	11.5	3.83e-27	4.17e-24	0.62	0.47	Parkinson's disease;	chr5:103060521	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs34380	ENSG00000175749.11	EIF3KP1	11.5	3.83e-27	4.17e-24	0.62	0.47	Parkinson's disease;	chr5:103061245	chr5:103032376~103033031:+
THCA	cis	rs6570726	0.62	rs367693	ENSG00000235652.6	RP11-545I5.3	11.5	3.85e-27	4.18e-24	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145494813	chr6:145799409~145886585:+
THCA	cis	rs10463554	0.892	rs32842	ENSG00000175749.11	EIF3KP1	11.5	3.85e-27	4.19e-24	0.61	0.47	Parkinson's disease;	chr5:103142298	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs187427	ENSG00000175749.11	EIF3KP1	11.5	3.85e-27	4.19e-24	0.61	0.47	Parkinson's disease;	chr5:103177102	chr5:103032376~103033031:+
THCA	cis	rs7301826	0.651	rs7299281	ENSG00000256250.1	RP11-989F5.1	11.5	3.89e-27	4.23e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130818587	chr12:130810606~130812438:+
THCA	cis	rs9322193	0.962	rs2342764	ENSG00000223701.3	RAET1E-AS1	11.5	3.9e-27	4.24e-24	0.64	0.47	Lung cancer;	chr6:149835068	chr6:149884431~149919508:+
THCA	cis	rs7731783	1	rs7731783	ENSG00000247679.2	RP11-1277A3.1	11.5	3.91e-27	4.25e-24	0.45	0.47	Methadone dose in opioid dependence;	chr5:177633311	chr5:177611253~177619754:+
THCA	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	11.5	3.92e-27	4.26e-24	0.53	0.47	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
THCA	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	11.5	3.92e-27	4.26e-24	0.56	0.47	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
THCA	cis	rs853679	0.628	rs9368560	ENSG00000280107.1	AL022393.9	-11.5	3.93e-27	4.28e-24	-0.57	-0.47	Depression;	chr6:28192182	chr6:28170845~28172521:+
THCA	cis	rs9322193	0.923	rs9689599	ENSG00000223701.3	RAET1E-AS1	11.5	3.95e-27	4.3e-24	0.62	0.47	Lung cancer;	chr6:149631973	chr6:149884431~149919508:+
THCA	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	11.5	3.97e-27	4.31e-24	0.63	0.47	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
THCA	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	11.5	3.97e-27	4.31e-24	0.63	0.47	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
THCA	cis	rs6570726	0.62	rs12201226	ENSG00000235652.6	RP11-545I5.3	11.5	3.98e-27	4.32e-24	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145592283	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs1331640	ENSG00000235652.6	RP11-545I5.3	11.5	3.98e-27	4.33e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146106114	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs9800614	ENSG00000223701.3	RAET1E-AS1	11.5	4.02e-27	4.37e-24	0.63	0.47	Lung cancer;	chr6:149644604	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.764	rs9403726	ENSG00000235652.6	RP11-545I5.3	11.5	4.02e-27	4.37e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145580550	chr6:145799409~145886585:+
THCA	cis	rs11214589	0.747	rs7939992	ENSG00000270179.1	RP11-159N11.4	-11.5	4.02e-27	4.37e-24	-0.49	-0.47	Neuroticism;	chr11:113358943	chr11:113368478~113369117:+
THCA	cis	rs9322193	0.923	rs66516768	ENSG00000223701.3	RAET1E-AS1	11.5	4.03e-27	4.38e-24	0.63	0.47	Lung cancer;	chr6:149671999	chr6:149884431~149919508:+
THCA	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	11.49	4.05e-27	4.4e-24	0.64	0.47	Depression;	chr6:28167882	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.923	rs9800736	ENSG00000223701.3	RAET1E-AS1	11.49	4.05e-27	4.4e-24	0.63	0.47	Lung cancer;	chr6:149661281	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10872644	ENSG00000223701.3	RAET1E-AS1	11.49	4.07e-27	4.42e-24	0.63	0.47	Lung cancer;	chr6:149741819	chr6:149884431~149919508:+
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-11.49	4.11e-27	4.46e-24	-0.62	-0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
THCA	cis	rs9322193	0.884	rs11155669	ENSG00000223701.3	RAET1E-AS1	11.49	4.12e-27	4.47e-24	0.63	0.47	Lung cancer;	chr6:149633501	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.887	rs9505824	ENSG00000223701.3	RAET1E-AS1	11.49	4.12e-27	4.47e-24	0.63	0.47	Lung cancer;	chr6:149633663	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9505826	ENSG00000223701.3	RAET1E-AS1	11.49	4.12e-27	4.47e-24	0.63	0.47	Lung cancer;	chr6:149633912	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9766886	ENSG00000223701.3	RAET1E-AS1	11.49	4.12e-27	4.47e-24	0.63	0.47	Lung cancer;	chr6:149637048	chr6:149884431~149919508:+
THCA	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-11.49	4.12e-27	4.48e-24	-0.64	-0.47	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
THCA	cis	rs673078	0.66	rs61943524	ENSG00000275759.1	RP11-131L12.3	-11.49	4.14e-27	4.49e-24	-0.73	-0.47	Glucose homeostasis traits;	chr12:118151530	chr12:118428281~118428870:+
THCA	cis	rs2274273	0.84	rs10467798	ENSG00000258413.1	RP11-665C16.6	-11.49	4.14e-27	4.49e-24	-0.6	-0.47	Protein biomarker;	chr14:55258209	chr14:55262767~55272075:-
THCA	cis	rs12468226	0.938	rs10931993	ENSG00000273456.1	RP11-686O6.2	11.49	4.14e-27	4.5e-24	0.58	0.47	Urate levels;	chr2:202243017	chr2:202374932~202375604:-
THCA	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	11.49	4.15e-27	4.51e-24	0.54	0.47	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
THCA	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	11.49	4.15e-27	4.51e-24	0.57	0.47	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
THCA	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	11.49	4.18e-27	4.54e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
THCA	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-11.49	4.2e-27	4.56e-24	-0.55	-0.47	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
THCA	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-11.49	4.2e-27	4.56e-24	-0.55	-0.47	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
THCA	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	11.49	4.2e-27	4.56e-24	0.35	0.47	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
THCA	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	11.49	4.21e-27	4.56e-24	0.59	0.47	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
THCA	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	11.49	4.22e-27	4.58e-24	0.56	0.47	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	11.49	4.22e-27	4.58e-24	0.56	0.47	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
THCA	cis	rs1075265	0.933	rs7607066	ENSG00000233266.1	HMGB1P31	11.49	4.22e-27	4.58e-24	0.58	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54110054	chr2:54051334~54051760:+
THCA	cis	rs1153858	0.848	rs9806699	ENSG00000259520.4	CTD-2651B20.3	-11.49	4.24e-27	4.6e-24	-0.61	-0.47	Homoarginine levels;	chr15:45448194	chr15:45251580~45279251:-
THCA	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	11.49	4.25e-27	4.6e-24	0.87	0.47	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
THCA	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-11.49	4.25e-27	4.61e-24	-0.62	-0.47	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
THCA	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	-11.49	4.26e-27	4.62e-24	-0.49	-0.47	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
THCA	cis	rs7301826	0.61	rs7961690	ENSG00000256250.1	RP11-989F5.1	11.49	4.3e-27	4.67e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130812335	chr12:130810606~130812438:+
THCA	cis	rs1858037	0.867	rs67817304	ENSG00000204929.10	AC074391.1	11.49	4.35e-27	4.72e-24	0.62	0.47	Rheumatoid arthritis;	chr2:65346982	chr2:65436711~66084639:+
THCA	cis	rs950169	0.84	rs2896002	ENSG00000225151.9	GOLGA2P7	-11.49	4.36e-27	4.72e-24	-0.7	-0.47	Schizophrenia;	chr15:84390423	chr15:84199311~84230136:-
THCA	cis	rs7772486	0.686	rs10872579	ENSG00000235652.6	RP11-545I5.3	11.49	4.42e-27	4.79e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145644876	chr6:145799409~145886585:+
THCA	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-11.48	4.43e-27	4.8e-24	-0.34	-0.47	Height;	chr11:118808920	chr11:118791254~118793137:+
THCA	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-11.48	4.45e-27	4.82e-24	-0.59	-0.47	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
THCA	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-11.48	4.47e-27	4.84e-24	-0.58	-0.47	Height;	chr3:53047596	chr3:53064283~53065091:-
THCA	cis	rs7772486	0.681	rs9390343	ENSG00000235652.6	RP11-545I5.3	-11.48	4.49e-27	4.86e-24	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145689391	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.8	rs4819045	ENSG00000223768.1	LINC00205	-11.48	4.49e-27	4.86e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.923	rs12174716	ENSG00000223701.3	RAET1E-AS1	11.48	4.49e-27	4.86e-24	0.62	0.47	Lung cancer;	chr6:149644487	chr6:149884431~149919508:+
THCA	cis	rs6496932	0.663	rs12915663	ENSG00000218052.5	ADAMTS7P4	-11.48	4.49e-27	4.86e-24	-0.6	-0.47	Central corneal thickness;Corneal structure;	chr15:85362249	chr15:85255369~85330334:-
THCA	cis	rs26232	0.526	rs61654927	ENSG00000175749.11	EIF3KP1	11.48	4.51e-27	4.89e-24	0.61	0.47	Rheumatoid arthritis;	chr5:103047021	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs59292735	ENSG00000175749.11	EIF3KP1	11.48	4.51e-27	4.89e-24	0.61	0.47	Parkinson's disease;	chr5:103047047	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.875	rs9373485	ENSG00000235652.6	RP11-545I5.3	11.48	4.53e-27	4.9e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146080293	chr6:145799409~145886585:+
THCA	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	11.48	4.53e-27	4.91e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	11.48	4.53e-27	4.91e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	11.48	4.53e-27	4.91e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
THCA	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-11.48	4.57e-27	4.95e-24	-0.64	-0.47	Depression;	chr6:28143758	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-11.48	4.57e-27	4.95e-24	-0.64	-0.47	Depression;	chr6:28144784	chr6:28115628~28116551:+
THCA	cis	rs853679	0.55	rs9295762	ENSG00000280107.1	AL022393.9	11.48	4.59e-27	4.96e-24	0.55	0.47	Depression;	chr6:28187640	chr6:28170845~28172521:+
THCA	cis	rs6519955	0.765	rs7292527	ENSG00000231711.2	LINC00899	-11.48	4.61e-27	4.98e-24	-0.42	-0.47	Dupuytren's disease;	chr22:46027245	chr22:46039907~46044853:-
THCA	cis	rs950169	0.922	rs12906983	ENSG00000225151.9	GOLGA2P7	-11.48	4.65e-27	5.03e-24	-0.7	-0.47	Schizophrenia;	chr15:84262270	chr15:84199311~84230136:-
THCA	cis	rs4819052	0.851	rs2838842	ENSG00000223768.1	LINC00205	-11.48	4.66e-27	5.04e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45293285~45297354:+
THCA	cis	rs6570726	0.599	rs4398765	ENSG00000235652.6	RP11-545I5.3	11.48	4.67e-27	5.05e-24	0.48	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145613870	chr6:145799409~145886585:+
THCA	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	11.48	4.67e-27	5.05e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
THCA	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	11.48	4.73e-27	5.12e-24	0.56	0.47	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
THCA	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-11.48	4.76e-27	5.15e-24	-0.61	-0.47	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
THCA	cis	rs2274273	0.901	rs8011288	ENSG00000258413.1	RP11-665C16.6	-11.48	4.79e-27	5.18e-24	-0.6	-0.47	Protein biomarker;	chr14:55268394	chr14:55262767~55272075:-
THCA	cis	rs7301826	0.627	rs34103763	ENSG00000256250.1	RP11-989F5.1	11.48	4.8e-27	5.19e-24	0.57	0.47	Plasma plasminogen activator levels;	chr12:130805604	chr12:130810606~130812438:+
THCA	cis	rs9322193	0.884	rs9688794	ENSG00000223701.3	RAET1E-AS1	11.47	4.85e-27	5.24e-24	0.62	0.47	Lung cancer;	chr6:149632121	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9322204	ENSG00000223701.3	RAET1E-AS1	11.47	4.85e-27	5.24e-24	0.62	0.47	Lung cancer;	chr6:149636047	chr6:149884431~149919508:+
THCA	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-11.47	4.87e-27	5.27e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-11.47	4.87e-27	5.27e-24	-0.49	-0.47	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
THCA	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-11.47	4.88e-27	5.28e-24	-0.51	-0.47	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
THCA	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-11.47	4.88e-27	5.28e-24	-0.51	-0.47	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
THCA	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	11.47	4.89e-27	5.28e-24	0.88	0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
THCA	cis	rs367615	0.552	rs10042721	ENSG00000249476.1	CTD-2587M2.1	-11.47	4.89e-27	5.29e-24	-0.48	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109378269	chr5:109237120~109326369:-
THCA	cis	rs367615	0.552	rs2115511	ENSG00000249476.1	CTD-2587M2.1	-11.47	4.89e-27	5.29e-24	-0.48	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109389702	chr5:109237120~109326369:-
THCA	cis	rs367615	0.552	rs2963025	ENSG00000249476.1	CTD-2587M2.1	-11.47	4.89e-27	5.29e-24	-0.48	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109397555	chr5:109237120~109326369:-
THCA	cis	rs4819052	0.807	rs4819047	ENSG00000223768.1	LINC00205	-11.47	4.92e-27	5.32e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs1999335	ENSG00000223768.1	LINC00205	-11.47	4.94e-27	5.33e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838844	ENSG00000223768.1	LINC00205	-11.47	4.94e-27	5.33e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838848	ENSG00000223768.1	LINC00205	-11.47	4.94e-27	5.33e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838849	ENSG00000223768.1	LINC00205	-11.47	4.94e-27	5.33e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs7275870	ENSG00000223768.1	LINC00205	-11.47	4.94e-27	5.33e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs7275874	ENSG00000223768.1	LINC00205	-11.47	4.94e-27	5.33e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs8131143	ENSG00000223768.1	LINC00205	11.47	4.94e-27	5.33e-24	0.44	0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45293285~45297354:+
THCA	cis	rs673078	0.66	rs17440336	ENSG00000275759.1	RP11-131L12.3	11.47	4.94e-27	5.34e-24	0.71	0.47	Glucose homeostasis traits;	chr12:118163305	chr12:118428281~118428870:+
THCA	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-11.47	4.94e-27	5.34e-24	-0.57	-0.47	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
THCA	cis	rs9928842	0.941	rs8057145	ENSG00000280152.1	RP11-331F4.5	11.47	4.96e-27	5.35e-24	0.65	0.47	Alcoholic chronic pancreatitis;	chr16:75222353	chr16:75245994~75250077:-
THCA	cis	rs950169	0.922	rs2033284	ENSG00000225151.9	GOLGA2P7	-11.47	4.97e-27	5.36e-24	-0.7	-0.47	Schizophrenia;	chr15:84391575	chr15:84199311~84230136:-
THCA	cis	rs8062405	0.625	rs8060365	ENSG00000251417.2	RP11-1348G14.4	11.47	4.97e-27	5.36e-24	0.47	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28899988	chr16:28802743~28817828:+
THCA	cis	rs10463554	0.963	rs6883113	ENSG00000175749.11	EIF3KP1	11.47	4.99e-27	5.39e-24	0.61	0.47	Parkinson's disease;	chr5:103042185	chr5:103032376~103033031:+
THCA	cis	rs11105298	0.891	rs10858854	ENSG00000258302.2	RP11-981P6.1	11.47	5.12e-27	5.52e-24	0.46	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89441951	chr12:89561129~89594878:+
THCA	cis	rs9322193	0.884	rs10782312	ENSG00000223701.3	RAET1E-AS1	11.47	5.14e-27	5.54e-24	0.63	0.47	Lung cancer;	chr6:149622669	chr6:149884431~149919508:+
THCA	cis	rs4819052	0.851	rs2838858	ENSG00000223768.1	LINC00205	-11.47	5.14e-27	5.55e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45293285~45297354:+
THCA	cis	rs6558530	0.666	rs6558520	ENSG00000253982.1	CTD-2336O2.1	11.47	5.14e-27	5.55e-24	0.45	0.47	Systolic blood pressure;	chr8:1749407	chr8:1761990~1764502:-
THCA	cis	rs7569084	0.663	rs4671128	ENSG00000237979.1	AC007389.1	11.47	5.16e-27	5.57e-24	0.55	0.47	Sum eosinophil basophil counts;	chr2:65438130	chr2:65500993~65502138:-
THCA	cis	rs11676348	0.776	rs11690316	ENSG00000261338.2	RP11-378A13.1	-11.47	5.17e-27	5.58e-24	-0.48	-0.47	Ulcerative colitis;	chr2:218152739	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.923	rs1080670	ENSG00000223701.3	RAET1E-AS1	11.47	5.18e-27	5.58e-24	0.63	0.47	Lung cancer;	chr6:149620161	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs9397036	ENSG00000268592.3	RAET1E-AS1	11.47	5.18e-27	5.58e-24	0.64	0.47	Lung cancer;	chr6:149851787	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs9383864	ENSG00000268592.3	RAET1E-AS1	11.47	5.18e-27	5.58e-24	0.64	0.47	Lung cancer;	chr6:149851969	chr6:149863494~149919507:+
THCA	cis	rs2274273	0.934	rs2341621	ENSG00000258413.1	RP11-665C16.6	-11.47	5.19e-27	5.6e-24	-0.6	-0.47	Protein biomarker;	chr14:55259707	chr14:55262767~55272075:-
THCA	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-11.47	5.2e-27	5.6e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
THCA	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	11.47	5.2e-27	5.61e-24	0.63	0.47	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
THCA	cis	rs765787	0.53	rs12592055	ENSG00000259520.4	CTD-2651B20.3	-11.47	5.21e-27	5.62e-24	-0.57	-0.47	Uric acid levels;	chr15:45222279	chr15:45251580~45279251:-
THCA	cis	rs11098499	0.874	rs7661020	ENSG00000245958.5	RP11-33B1.1	-11.47	5.25e-27	5.66e-24	-0.45	-0.47	Corneal astigmatism;	chr4:119185827	chr4:119454791~119552025:+
THCA	cis	rs6142102	0.778	rs6059555	ENSG00000276073.1	RP5-1125A11.7	-11.47	5.26e-27	5.67e-24	-0.43	-0.47	Skin pigmentation;	chr20:33926518	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.778	rs4911374	ENSG00000276073.1	RP5-1125A11.7	-11.47	5.26e-27	5.67e-24	-0.43	-0.47	Skin pigmentation;	chr20:33928195	chr20:33985617~33988989:-
THCA	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	11.46	5.41e-27	5.83e-24	0.54	0.47	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	11.46	5.41e-27	5.83e-24	0.54	0.47	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	11.46	5.41e-27	5.83e-24	0.54	0.47	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
THCA	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	11.46	5.46e-27	5.88e-24	0.34	0.47	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
THCA	cis	rs2732480	0.577	rs2732479	ENSG00000258273.1	RP11-370I10.4	-11.46	5.47e-27	5.89e-24	-0.63	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.537	rs1061986	ENSG00000258273.1	RP11-370I10.4	-11.46	5.47e-27	5.89e-24	-0.63	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48333755~48333901:-
THCA	cis	rs6142102	0.812	rs6059554	ENSG00000276073.1	RP5-1125A11.7	-11.46	5.6e-27	6.03e-24	-0.43	-0.47	Skin pigmentation;	chr20:33926286	chr20:33985617~33988989:-
THCA	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	11.46	5.6e-27	6.03e-24	0.34	0.47	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
THCA	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	11.46	5.61e-27	6.04e-24	0.59	0.47	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	11.46	5.61e-27	6.04e-24	0.59	0.47	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
THCA	cis	rs801193	0.636	rs2659895	ENSG00000237310.1	GS1-124K5.4	11.46	5.63e-27	6.06e-24	0.34	0.47	Aortic root size;	chr7:66731484	chr7:66493706~66495474:+
THCA	cis	rs9903692	0.954	rs1860866	ENSG00000278765.1	RP5-890E16.5	-11.46	5.64e-27	6.07e-24	-0.61	-0.47	Pulse pressure;	chr17:48123669	chr17:48066704~48067293:-
THCA	cis	rs11098499	0.588	rs6534149	ENSG00000245958.5	RP11-33B1.1	11.46	5.66e-27	6.09e-24	0.43	0.47	Corneal astigmatism;	chr4:119638137	chr4:119454791~119552025:+
THCA	cis	rs2274273	0.87	rs7160523	ENSG00000258413.1	RP11-665C16.6	-11.46	5.67e-27	6.1e-24	-0.6	-0.47	Protein biomarker;	chr14:55127842	chr14:55262767~55272075:-
THCA	cis	rs6142102	0.812	rs761236	ENSG00000276073.1	RP5-1125A11.7	-11.46	5.69e-27	6.12e-24	-0.43	-0.47	Skin pigmentation;	chr20:33932245	chr20:33985617~33988989:-
THCA	cis	rs12022452	1	rs75936657	ENSG00000238287.1	RP11-656D10.3	-11.46	5.72e-27	6.16e-24	-0.72	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:40493157~40508661:-
THCA	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	11.46	5.75e-27	6.19e-24	0.54	0.47	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
THCA	cis	rs526231	0.511	rs3776861	ENSG00000175749.11	EIF3KP1	11.46	5.78e-27	6.22e-24	0.61	0.47	Primary biliary cholangitis;	chr5:103013958	chr5:103032376~103033031:+
THCA	cis	rs526231	0.511	rs11951374	ENSG00000175749.11	EIF3KP1	11.46	5.78e-27	6.22e-24	0.61	0.47	Primary biliary cholangitis;	chr5:103020094	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.889	rs34822	ENSG00000175749.11	EIF3KP1	11.46	5.8e-27	6.24e-24	0.61	0.47	Parkinson's disease;	chr5:103102007	chr5:103032376~103033031:+
THCA	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-11.45	5.84e-27	6.28e-24	-0.51	-0.47	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
THCA	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-11.45	5.84e-27	6.28e-24	-0.51	-0.47	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
THCA	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	11.45	5.85e-27	6.29e-24	0.66	0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
THCA	cis	rs6538678	1	rs6538678	ENSG00000258343.1	RP11-536G4.2	-11.45	5.87e-27	6.32e-24	-0.66	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95795345~95858839:-
THCA	cis	rs6142102	0.923	rs2268078	ENSG00000276073.1	RP5-1125A11.7	-11.45	5.88e-27	6.32e-24	-0.45	-0.47	Skin pigmentation;	chr20:34008898	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs13048789	ENSG00000223768.1	LINC00205	-11.45	5.93e-27	6.38e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.846	rs2748499	ENSG00000235652.6	RP11-545I5.3	11.45	5.94e-27	6.39e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145993866	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2814869	ENSG00000235652.6	RP11-545I5.3	11.45	5.94e-27	6.39e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145994373	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2748498	ENSG00000235652.6	RP11-545I5.3	11.45	5.94e-27	6.39e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145998030	chr6:145799409~145886585:+
THCA	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	11.45	5.97e-27	6.42e-24	0.49	0.47	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
THCA	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	11.45	6.02e-27	6.46e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	11.45	6.02e-27	6.46e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
THCA	cis	rs2732480	0.577	rs2732457	ENSG00000258273.1	RP11-370I10.4	11.45	6.02e-27	6.47e-24	0.62	0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48333755~48333901:-
THCA	cis	rs853679	0.55	rs1150692	ENSG00000280107.1	AL022393.9	-11.45	6.1e-27	6.55e-24	-0.56	-0.47	Depression;	chr6:28206179	chr6:28170845~28172521:+
THCA	cis	rs3931020	0.745	rs7555459	ENSG00000272864.1	RP11-17E13.2	-11.45	6.12e-27	6.57e-24	-0.51	-0.47	Resistin levels;	chr1:74808022	chr1:74698769~74699333:-
THCA	cis	rs7188445	0.736	rs4888043	ENSG00000261390.4	RP11-345M22.2	11.45	6.17e-27	6.63e-24	0.54	0.47	Urate levels;	chr16:79668744	chr16:79715232~79770563:-
THCA	cis	rs9322193	0.923	rs9505823	ENSG00000223701.3	RAET1E-AS1	11.45	6.24e-27	6.7e-24	0.62	0.47	Lung cancer;	chr6:149628899	chr6:149884431~149919508:+
THCA	cis	rs6496932	0.77	rs4843040	ENSG00000218052.5	ADAMTS7P4	11.44	6.39e-27	6.86e-24	0.59	0.47	Central corneal thickness;Corneal structure;	chr15:85295405	chr15:85255369~85330334:-
THCA	cis	rs2283792	0.765	rs7290469	ENSG00000224086.5	LL22NC03-86G7.1	-11.44	6.4e-27	6.87e-24	-0.55	-0.47	Multiple sclerosis;	chr22:21796693	chr22:21938293~21977632:+
THCA	cis	rs4819052	0.851	rs13050359	ENSG00000223768.1	LINC00205	-11.44	6.4e-27	6.87e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819049	ENSG00000223768.1	LINC00205	-11.44	6.4e-27	6.87e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs13052344	ENSG00000223768.1	LINC00205	-11.44	6.4e-27	6.87e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.808	rs11909411	ENSG00000223768.1	LINC00205	-11.44	6.4e-27	6.87e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs28676615	ENSG00000223768.1	LINC00205	-11.44	6.4e-27	6.87e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs28501512	ENSG00000223768.1	LINC00205	-11.44	6.4e-27	6.87e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819046	ENSG00000223768.1	LINC00205	-11.44	6.44e-27	6.91e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45293285~45297354:+
THCA	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	11.44	6.47e-27	6.95e-24	0.56	0.47	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
THCA	cis	rs4819052	0.808	rs2838862	ENSG00000223768.1	LINC00205	-11.44	6.48e-27	6.95e-24	-0.42	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45266811	chr21:45293285~45297354:+
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	11.44	6.52e-27	7e-24	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
THCA	cis	rs10463554	0.963	rs26262	ENSG00000175749.11	EIF3KP1	11.44	6.53e-27	7e-24	0.61	0.47	Parkinson's disease;	chr5:103209462	chr5:103032376~103033031:+
THCA	cis	rs6142102	0.659	rs6057945	ENSG00000276073.1	RP5-1125A11.7	-11.44	6.53e-27	7e-24	-0.43	-0.47	Skin pigmentation;	chr20:33929374	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs58644915	ENSG00000223768.1	LINC00205	-11.44	6.54e-27	7.01e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45293285~45297354:+
THCA	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	11.44	6.57e-27	7.05e-24	0.56	0.47	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
THCA	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	11.44	6.6e-27	7.08e-24	0.57	0.47	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
THCA	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	11.44	6.63e-27	7.11e-24	0.55	0.47	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
THCA	cis	rs465969	0.546	rs77990243	ENSG00000255389.1	C6orf3	-11.44	6.64e-27	7.12e-24	-0.78	-0.47	Psoriasis;	chr6:111513183	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs4509157	ENSG00000255389.1	C6orf3	-11.44	6.64e-27	7.12e-24	-0.78	-0.47	Psoriasis;	chr6:111513875	chr6:111599875~111602295:+
THCA	cis	rs12022452	1	rs12031278	ENSG00000238287.1	RP11-656D10.3	-11.44	6.67e-27	7.14e-24	-0.72	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:40493157~40508661:-
THCA	cis	rs4819052	0.819	rs13046807	ENSG00000223768.1	LINC00205	-11.44	6.69e-27	7.17e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45293285~45297354:+
THCA	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-11.44	6.73e-27	7.22e-24	-0.57	-0.47	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
THCA	cis	rs2288884	0.559	rs7257830	ENSG00000275055.1	CTC-471J1.11	-11.44	6.76e-27	7.24e-24	-0.36	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52005392	chr19:52049007~52049754:+
THCA	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-11.44	6.81e-27	7.3e-24	-0.62	-0.47	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
THCA	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-11.44	6.88e-27	7.37e-24	-0.65	-0.47	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
THCA	cis	rs12458462	0.779	rs34814368	ENSG00000274828.1	RP11-567M16.6	11.44	6.89e-27	7.38e-24	0.4	0.47	Monocyte count;	chr18:79734143	chr18:79677287~79679358:-
THCA	cis	rs12458462	0.779	rs35814220	ENSG00000274828.1	RP11-567M16.6	11.44	6.89e-27	7.38e-24	0.4	0.47	Monocyte count;	chr18:79734190	chr18:79677287~79679358:-
THCA	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	11.44	6.89e-27	7.38e-24	0.37	0.47	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
THCA	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-11.44	6.92e-27	7.41e-24	-0.56	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
THCA	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	11.44	6.92e-27	7.41e-24	0.69	0.47	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
THCA	cis	rs2288884	0.559	rs2903710	ENSG00000275055.1	CTC-471J1.11	-11.44	6.93e-27	7.42e-24	-0.37	-0.47	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52004285	chr19:52049007~52049754:+
THCA	cis	rs7174755	0.558	rs11071975	ENSG00000260657.2	RP11-315D16.4	-11.44	6.93e-27	7.43e-24	-0.67	-0.47	Major depressive disorder;	chr15:68037106	chr15:68267792~68277994:-
THCA	cis	rs6570726	0.967	rs7772286	ENSG00000235652.6	RP11-545I5.3	-11.43	6.95e-27	7.44e-24	-0.43	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145609287	chr6:145799409~145886585:+
THCA	cis	rs673078	0.66	rs11068891	ENSG00000275759.1	RP11-131L12.3	11.43	6.97e-27	7.46e-24	0.62	0.47	Glucose homeostasis traits;	chr12:118259814	chr12:118428281~118428870:+
THCA	cis	rs4819052	0.851	rs2838845	ENSG00000223768.1	LINC00205	-11.43	6.98e-27	7.47e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45293285~45297354:+
THCA	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	11.43	7e-27	7.49e-24	0.88	0.47	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
THCA	cis	rs3779195	0.585	rs56694862	ENSG00000272950.1	RP11-307C18.1	-11.43	7.04e-27	7.54e-24	-0.73	-0.47	Sex hormone-binding globulin levels;	chr7:98267808	chr7:98322853~98323430:+
THCA	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-11.43	7.04e-27	7.54e-24	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-11.43	7.04e-27	7.54e-24	-0.54	-0.47	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
THCA	cis	rs673078	0.571	rs7963464	ENSG00000275759.1	RP11-131L12.3	-11.43	7.05e-27	7.54e-24	-0.62	-0.47	Glucose homeostasis traits;	chr12:118264924	chr12:118428281~118428870:+
THCA	cis	rs4718428	0.705	rs11028	ENSG00000273142.1	RP11-458F8.4	-11.43	7.08e-27	7.58e-24	-0.43	-0.47	Corneal structure;	chr7:66811230	chr7:66902857~66906297:+
THCA	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-11.43	7.12e-27	7.62e-24	-0.6	-0.47	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
THCA	cis	rs4718428	0.705	rs2901311	ENSG00000226824.5	RP4-756H11.3	-11.43	7.16e-27	7.66e-24	-0.69	-0.47	Corneal structure;	chr7:66950082	chr7:66654538~66669855:+
THCA	cis	rs765787	0.53	rs12905246	ENSG00000259520.4	CTD-2651B20.3	-11.43	7.18e-27	7.68e-24	-0.57	-0.47	Uric acid levels;	chr15:45208643	chr15:45251580~45279251:-
THCA	cis	rs944289	0.675	rs398745	ENSG00000257826.1	RP11-116N8.4	11.43	7.2e-27	7.7e-24	0.47	0.47	Thyroid cancer;	chr14:36066975	chr14:36061026~36067190:-
THCA	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	11.43	7.24e-27	7.75e-24	0.54	0.47	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
THCA	cis	rs1858037	0.867	rs953312	ENSG00000204929.10	AC074391.1	11.43	7.33e-27	7.83e-24	0.62	0.47	Rheumatoid arthritis;	chr2:65340556	chr2:65436711~66084639:+
THCA	cis	rs1858037	0.867	rs9789444	ENSG00000204929.10	AC074391.1	11.43	7.33e-27	7.83e-24	0.62	0.47	Rheumatoid arthritis;	chr2:65342093	chr2:65436711~66084639:+
THCA	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-11.43	7.35e-27	7.85e-24	-0.69	-0.47	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
THCA	cis	rs11098499	0.588	rs2389874	ENSG00000245958.5	RP11-33B1.1	11.43	7.45e-27	7.96e-24	0.43	0.47	Corneal astigmatism;	chr4:119633836	chr4:119454791~119552025:+
THCA	cis	rs6142102	0.961	rs6087557	ENSG00000276073.1	RP5-1125A11.7	-11.43	7.46e-27	7.97e-24	-0.43	-0.47	Skin pigmentation;	chr20:34110469	chr20:33985617~33988989:-
THCA	cis	rs6558530	0.692	rs12335115	ENSG00000253982.1	CTD-2336O2.1	11.43	7.51e-27	8.03e-24	0.45	0.47	Systolic blood pressure;	chr8:1751686	chr8:1761990~1764502:-
THCA	cis	rs9322193	0.884	rs9383865	ENSG00000268592.3	RAET1E-AS1	11.43	7.52e-27	8.03e-24	0.64	0.47	Lung cancer;	chr6:149852043	chr6:149863494~149919507:+
THCA	cis	rs944289	0.646	rs396043	ENSG00000257826.1	RP11-116N8.4	11.43	7.6e-27	8.12e-24	0.48	0.47	Thyroid cancer;	chr14:36071815	chr14:36061026~36067190:-
THCA	cis	rs367615	0.552	rs2963024	ENSG00000249476.1	CTD-2587M2.1	-11.43	7.6e-27	8.12e-24	-0.48	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109395072	chr5:109237120~109326369:-
THCA	cis	rs673078	0.66	rs17440315	ENSG00000275759.1	RP11-131L12.3	-11.42	7.63e-27	8.15e-24	-0.72	-0.47	Glucose homeostasis traits;	chr12:118158819	chr12:118428281~118428870:+
THCA	cis	rs7772486	0.875	rs6570736	ENSG00000235652.6	RP11-545I5.3	11.42	7.65e-27	8.17e-24	0.42	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146067184	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs11155671	ENSG00000223701.3	RAET1E-AS1	11.42	7.69e-27	8.21e-24	0.62	0.47	Lung cancer;	chr6:149650996	chr6:149884431~149919508:+
THCA	cis	rs944289	0.646	rs429041	ENSG00000257826.1	RP11-116N8.4	11.42	7.7e-27	8.22e-24	0.48	0.47	Thyroid cancer;	chr14:36071930	chr14:36061026~36067190:-
THCA	cis	rs944289	0.646	rs368772	ENSG00000257826.1	RP11-116N8.4	11.42	7.7e-27	8.22e-24	0.48	0.47	Thyroid cancer;	chr14:36071955	chr14:36061026~36067190:-
THCA	cis	rs944289	0.646	rs4981320	ENSG00000257826.1	RP11-116N8.4	11.42	7.7e-27	8.22e-24	0.48	0.47	Thyroid cancer;	chr14:36072456	chr14:36061026~36067190:-
THCA	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	11.42	7.76e-27	8.29e-24	0.53	0.47	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
THCA	cis	rs9659323	0.65	rs12086486	ENSG00000231365.4	RP11-418J17.1	-11.42	7.79e-27	8.31e-24	-0.5	-0.47	Body mass index;	chr1:118946419	chr1:119140396~119275973:+
THCA	cis	rs8062405	0.698	rs8046545	ENSG00000251417.2	RP11-1348G14.4	11.42	7.92e-27	8.45e-24	0.47	0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28903896	chr16:28802743~28817828:+
THCA	cis	rs17711722	0.503	rs453835	ENSG00000226824.5	RP4-756H11.3	11.42	7.92e-27	8.45e-24	0.62	0.47	Calcium levels;	chr7:66046172	chr7:66654538~66669855:+
THCA	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	11.42	7.92e-27	8.45e-24	0.56	0.47	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
THCA	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	11.42	7.95e-27	8.47e-24	0.87	0.47	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	11.42	7.95e-27	8.47e-24	0.87	0.47	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	11.42	7.95e-27	8.47e-24	0.87	0.47	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
THCA	cis	rs4718428	0.705	rs3800817	ENSG00000273142.1	RP11-458F8.4	-11.42	7.98e-27	8.51e-24	-0.43	-0.47	Corneal structure;	chr7:66798563	chr7:66902857~66906297:+
THCA	cis	rs10463554	0.927	rs12055075	ENSG00000175749.11	EIF3KP1	11.42	7.99e-27	8.52e-24	0.61	0.47	Parkinson's disease;	chr5:103044553	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.743	rs9403742	ENSG00000235652.6	RP11-545I5.3	11.42	8.03e-27	8.56e-24	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:145739057	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.884	rs7744105	ENSG00000223701.3	RAET1E-AS1	11.42	8.14e-27	8.67e-24	0.63	0.47	Lung cancer;	chr6:149849308	chr6:149884431~149919508:+
THCA	cis	rs10935480	0.802	rs73133996	ENSG00000239445.4	ST3GAL6-AS1	-11.42	8.15e-27	8.68e-24	-0.47	-0.47	Blood protein levels;	chr3:98710375	chr3:98714330~98732651:-
THCA	cis	rs638893	0.717	rs622690	ENSG00000278376.1	RP11-158I9.8	-11.42	8.17e-27	8.71e-24	-0.5	-0.47	Vitiligo;	chr11:118833556	chr11:118791254~118793137:+
THCA	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	11.42	8.19e-27	8.72e-24	0.37	0.47	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
THCA	cis	rs2274273	0.87	rs8021583	ENSG00000258413.1	RP11-665C16.6	-11.42	8.29e-27	8.84e-24	-0.61	-0.47	Protein biomarker;	chr14:55282889	chr14:55262767~55272075:-
THCA	cis	rs9389248	0.69	rs6939543	ENSG00000232876.1	CTA-212D2.2	11.42	8.3e-27	8.84e-24	0.57	0.47	High light scatter reticulocyte percentage of red cells;	chr6:134934005	chr6:135055033~135060550:+
THCA	cis	rs9389248	0.69	rs1028314	ENSG00000232876.1	CTA-212D2.2	11.42	8.3e-27	8.84e-24	0.57	0.47	High light scatter reticulocyte percentage of red cells;	chr6:134934572	chr6:135055033~135060550:+
THCA	cis	rs6142102	0.812	rs761238	ENSG00000276073.1	RP5-1125A11.7	11.41	8.33e-27	8.87e-24	0.43	0.47	Skin pigmentation;	chr20:33932182	chr20:33985617~33988989:-
THCA	cis	rs9903692	1	rs9903692	ENSG00000278765.1	RP5-890E16.5	11.41	8.34e-27	8.88e-24	0.61	0.47	Pulse pressure;	chr17:48196567	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs9909933	ENSG00000278765.1	RP5-890E16.5	11.41	8.34e-27	8.88e-24	0.61	0.47	Pulse pressure;	chr17:48202870	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.909	rs2325885	ENSG00000278765.1	RP5-890E16.5	11.41	8.34e-27	8.88e-24	0.61	0.47	Pulse pressure;	chr17:48213013	chr17:48066704~48067293:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-11.41	8.35e-27	8.9e-24	-0.59	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
THCA	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	11.41	8.42e-27	8.97e-24	0.54	0.47	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	11.41	8.45e-27	9e-24	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
THCA	cis	rs1891275	0.601	rs1970506	ENSG00000228701.1	TNKS2-AS1	-11.41	8.45e-27	9e-24	-0.51	-0.47	Intelligence (multi-trait analysis);	chr10:91668529	chr10:91782839~91798291:-
THCA	cis	rs9322193	0.847	rs12191643	ENSG00000223701.3	RAET1E-AS1	11.41	8.46e-27	9.01e-24	0.63	0.47	Lung cancer;	chr6:149628912	chr6:149884431~149919508:+
THCA	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	11.41	8.48e-27	9.03e-24	0.48	0.47	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
THCA	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	11.41	8.48e-27	9.03e-24	0.87	0.47	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
THCA	cis	rs11676348	0.811	rs13027120	ENSG00000261338.2	RP11-378A13.1	11.41	8.5e-27	9.05e-24	0.48	0.47	Ulcerative colitis;	chr2:218156191	chr2:218255319~218257366:+
THCA	cis	rs9309473	0.558	rs11679042	ENSG00000163016.8	ALMS1P	11.41	8.52e-27	9.06e-24	0.84	0.47	Metabolite levels;	chr2:73680184	chr2:73644919~73685576:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000250470.1	AP000351.3	11.41	8.53e-27	9.08e-24	0.6	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23976904~23977585:-
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000235689.1	AP000351.13	11.41	8.57e-27	9.12e-24	0.58	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:24006305~24008258:-
THCA	cis	rs9322193	0.923	rs9688861	ENSG00000223701.3	RAET1E-AS1	11.41	8.63e-27	9.18e-24	0.62	0.47	Lung cancer;	chr6:149637924	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs7769115	ENSG00000268592.3	RAET1E-AS1	11.41	8.64e-27	9.19e-24	0.64	0.47	Lung cancer;	chr6:149848796	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs7743823	ENSG00000268592.3	RAET1E-AS1	11.41	8.67e-27	9.22e-24	0.64	0.47	Lung cancer;	chr6:149849744	chr6:149863494~149919507:+
THCA	cis	rs4713118	0.621	rs10484403	ENSG00000280107.1	AL022393.9	-11.41	8.68e-27	9.24e-24	-0.55	-0.47	Parkinson's disease;	chr6:28065745	chr6:28170845~28172521:+
THCA	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-11.41	8.69e-27	9.25e-24	-0.55	-0.47	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
THCA	cis	rs2283792	0.691	rs11913721	ENSG00000224086.5	LL22NC03-86G7.1	-11.41	8.78e-27	9.34e-24	-0.56	-0.47	Multiple sclerosis;	chr22:21855846	chr22:21938293~21977632:+
THCA	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-11.41	8.89e-27	9.45e-24	-0.57	-0.47	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
THCA	cis	rs765787	0.505	rs12593605	ENSG00000259520.4	CTD-2651B20.3	-11.41	8.9e-27	9.46e-24	-0.57	-0.47	Uric acid levels;	chr15:45205250	chr15:45251580~45279251:-
THCA	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-11.41	9.01e-27	9.57e-24	-0.55	-0.47	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
THCA	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-11.41	9.01e-27	9.57e-24	-0.59	-0.47	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
THCA	cis	rs9659323	0.65	rs1155949	ENSG00000231365.4	RP11-418J17.1	-11.41	9.05e-27	9.61e-24	-0.5	-0.47	Body mass index;	chr1:118953956	chr1:119140396~119275973:+
THCA	cis	rs4819052	0.807	rs1075788	ENSG00000223768.1	LINC00205	-11.4	9.26e-27	9.83e-24	-0.44	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45293285~45297354:+
THCA	cis	rs9918079	0.643	rs35414597	ENSG00000273133.1	RP11-799M12.2	11.4	9.26e-27	9.83e-24	0.63	0.47	Obesity-related traits;	chr4:15564113	chr4:15563698~15564253:-
THCA	cis	rs7429990	1	rs7429990	ENSG00000229759.1	MRPS18AP1	11.4	9.28e-27	9.85e-24	0.59	0.47	Educational attainment (years of education);	chr3:47860313	chr3:48256350~48256938:-
THCA	cis	rs7772486	0.597	rs7746618	ENSG00000235652.6	RP11-545I5.3	-11.4	9.37e-27	9.94e-24	-0.47	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145960231	chr6:145799409~145886585:+
THCA	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-11.4	9.5e-27	1e-23	-0.34	-0.47	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
THCA	cis	rs507080	0.922	rs478296	ENSG00000255422.1	AP002954.4	-11.4	9.55e-27	1.01e-23	-0.53	-0.47	Serum metabolite levels;	chr11:118696666	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs493834	ENSG00000255422.1	AP002954.4	-11.4	9.55e-27	1.01e-23	-0.53	-0.47	Serum metabolite levels;	chr11:118696735	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs644498	ENSG00000255422.1	AP002954.4	-11.4	9.55e-27	1.01e-23	-0.53	-0.47	Serum metabolite levels;	chr11:118696777	chr11:118704607~118750263:+
THCA	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-11.4	9.62e-27	1.02e-23	-0.64	-0.47	Depression;	chr6:28173770	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-11.4	9.62e-27	1.02e-23	-0.64	-0.47	Depression;	chr6:28174809	chr6:28115628~28116551:+
THCA	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-11.4	9.62e-27	1.02e-23	-0.64	-0.47	Depression;	chr6:28175233	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-11.4	9.62e-27	1.02e-23	-0.64	-0.47	Depression;	chr6:28176973	chr6:28115628~28116551:+
THCA	cis	rs2274273	0.905	rs10134800	ENSG00000258413.1	RP11-665C16.6	-11.4	9.67e-27	1.02e-23	-0.6	-0.47	Protein biomarker;	chr14:55168491	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.886	rs4870049	ENSG00000223701.3	RAET1E-AS1	11.4	9.7e-27	1.03e-23	0.64	0.47	Lung cancer;	chr6:149837058	chr6:149884431~149919508:+
THCA	cis	rs8055167	1	rs8055167	ENSG00000280152.1	RP11-331F4.5	11.4	9.79e-27	1.03e-23	0.51	0.47	Alcoholic chronic pancreatitis;	chr16:75220991	chr16:75245994~75250077:-
THCA	cis	rs9322193	0.809	rs9479808	ENSG00000223701.3	RAET1E-AS1	11.4	9.79e-27	1.03e-23	0.62	0.47	Lung cancer;	chr6:149751328	chr6:149884431~149919508:+
THCA	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	11.4	9.8e-27	1.04e-23	0.63	0.47	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
THCA	cis	rs2274273	0.837	rs10141552	ENSG00000258413.1	RP11-665C16.6	11.4	9.8e-27	1.04e-23	0.61	0.47	Protein biomarker;	chr14:55279373	chr14:55262767~55272075:-
THCA	cis	rs638893	0.947	rs1170396	ENSG00000278376.1	RP11-158I9.8	-11.4	9.87e-27	1.04e-23	-0.49	-0.47	Vitiligo;	chr11:118833108	chr11:118791254~118793137:+
THCA	cis	rs7104764	0.507	rs7121085	ENSG00000277290.1	RP11-326C3.16	-11.4	9.92e-27	1.05e-23	-0.55	-0.47	Menarche (age at onset);	chr11:258523	chr11:243099~243483:-
THCA	cis	rs4718428	0.705	rs13220977	ENSG00000273142.1	RP11-458F8.4	11.4	9.94e-27	1.05e-23	0.43	0.47	Corneal structure;	chr7:66872661	chr7:66902857~66906297:+
THCA	cis	rs11105298	0.891	rs4842664	ENSG00000258302.2	RP11-981P6.1	11.39	9.97e-27	1.05e-23	0.45	0.47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544253	chr12:89561129~89594878:+
THCA	cis	rs9322193	0.847	rs880246	ENSG00000268592.3	RAET1E-AS1	11.39	9.98e-27	1.05e-23	0.65	0.47	Lung cancer;	chr6:149845972	chr6:149863494~149919507:+
THCA	cis	rs12022452	1	rs12034162	ENSG00000238287.1	RP11-656D10.3	-11.39	9.99e-27	1.05e-23	-0.72	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:40493157~40508661:-
THCA	cis	rs7772486	0.875	rs2748483	ENSG00000235652.6	RP11-545I5.3	-11.39	1.01e-26	1.07e-23	-0.42	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:146014424	chr6:145799409~145886585:+
THCA	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	11.39	1.01e-26	1.07e-23	0.5	0.47	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
THCA	cis	rs2732480	0.577	rs2634678	ENSG00000258273.1	RP11-370I10.4	-11.39	1.02e-26	1.07e-23	-0.62	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs2634680	ENSG00000258273.1	RP11-370I10.4	-11.39	1.03e-26	1.09e-23	-0.62	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48333755~48333901:-
THCA	cis	rs6496932	0.663	rs4843051	ENSG00000218052.5	ADAMTS7P4	-11.39	1.03e-26	1.09e-23	-0.6	-0.47	Central corneal thickness;Corneal structure;	chr15:85360907	chr15:85255369~85330334:-
THCA	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	11.39	1.03e-26	1.09e-23	0.87	0.47	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
THCA	cis	rs9322193	0.961	rs2064520	ENSG00000223701.3	RAET1E-AS1	11.39	1.03e-26	1.09e-23	0.62	0.47	Lung cancer;	chr6:149603650	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.875	rs7739371	ENSG00000235652.6	RP11-545I5.3	11.39	1.04e-26	1.09e-23	0.43	0.47	Lobe attachment (rater-scored or self-reported);	chr6:146103217	chr6:145799409~145886585:+
THCA	cis	rs7301826	0.603	rs7975825	ENSG00000256250.1	RP11-989F5.1	-11.39	1.04e-26	1.1e-23	-0.57	-0.47	Plasma plasminogen activator levels;	chr12:130803899	chr12:130810606~130812438:+
THCA	cis	rs9322193	0.923	rs2342765	ENSG00000223701.3	RAET1E-AS1	11.39	1.04e-26	1.1e-23	0.62	0.47	Lung cancer;	chr6:149858873	chr6:149884431~149919508:+
THCA	cis	rs7301826	0.627	rs7978987	ENSG00000256250.1	RP11-989F5.1	11.39	1.04e-26	1.1e-23	0.56	0.47	Plasma plasminogen activator levels;	chr12:130796949	chr12:130810606~130812438:+
THCA	cis	rs4819052	1	rs4818769	ENSG00000223768.1	LINC00205	-11.39	1.04e-26	1.1e-23	-0.47	-0.47	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45293285~45297354:+
THCA	cis	rs6142102	0.812	rs4911375	ENSG00000276073.1	RP5-1125A11.7	-11.39	1.05e-26	1.11e-23	-0.43	-0.47	Skin pigmentation;	chr20:33928216	chr20:33985617~33988989:-
THCA	cis	rs11098499	0.913	rs12186259	ENSG00000245958.5	RP11-33B1.1	-11.39	1.06e-26	1.12e-23	-0.46	-0.47	Corneal astigmatism;	chr4:119230884	chr4:119454791~119552025:+
THCA	cis	rs6570726	0.791	rs1509214	ENSG00000235652.6	RP11-545I5.3	-11.39	1.07e-26	1.13e-23	-0.44	-0.47	Lobe attachment (rater-scored or self-reported);	chr6:145463470	chr6:145799409~145886585:+
THCA	cis	rs2732480	0.577	rs2732481	ENSG00000258273.1	RP11-370I10.4	-11.39	1.08e-26	1.14e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.557	rs2732484	ENSG00000258273.1	RP11-370I10.4	-11.39	1.08e-26	1.14e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs2732486	ENSG00000258273.1	RP11-370I10.4	-11.39	1.08e-26	1.14e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.517	rs2634676	ENSG00000258273.1	RP11-370I10.4	-11.39	1.08e-26	1.14e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48333755~48333901:-
THCA	cis	rs950169	0.922	rs12910334	ENSG00000225151.9	GOLGA2P7	-11.39	1.08e-26	1.14e-23	-0.69	-0.46	Schizophrenia;	chr15:84403620	chr15:84199311~84230136:-
THCA	cis	rs4819052	0.918	rs2330013	ENSG00000223768.1	LINC00205	-11.38	1.13e-26	1.19e-23	-0.47	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45293285~45297354:+
THCA	cis	rs6142102	0.961	rs2284386	ENSG00000276073.1	RP5-1125A11.7	-11.38	1.13e-26	1.19e-23	-0.43	-0.46	Skin pigmentation;	chr20:34056590	chr20:33985617~33988989:-
THCA	cis	rs12022452	1	rs12022452	ENSG00000238287.1	RP11-656D10.3	-11.38	1.13e-26	1.19e-23	-0.73	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr1:40487628	chr1:40493157~40508661:-
THCA	cis	rs10463554	0.963	rs154355	ENSG00000175749.11	EIF3KP1	11.38	1.13e-26	1.19e-23	0.6	0.46	Parkinson's disease;	chr5:103163177	chr5:103032376~103033031:+
THCA	cis	rs26232	0.517	rs154356	ENSG00000175749.11	EIF3KP1	11.38	1.13e-26	1.19e-23	0.6	0.46	Rheumatoid arthritis;	chr5:103163440	chr5:103032376~103033031:+
THCA	cis	rs4591358	0.648	rs7557471	ENSG00000223466.1	AC064834.2	-11.38	1.14e-26	1.2e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520713	chr2:195533035~195538681:+
THCA	cis	rs6142102	0.812	rs725478	ENSG00000276073.1	RP5-1125A11.7	11.38	1.14e-26	1.2e-23	0.43	0.46	Skin pigmentation;	chr20:33930548	chr20:33985617~33988989:-
THCA	cis	rs4819052	0.851	rs1056101	ENSG00000223768.1	LINC00205	-11.38	1.15e-26	1.21e-23	-0.44	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45293285~45297354:+
THCA	cis	rs2274273	0.87	rs8018110	ENSG00000258413.1	RP11-665C16.6	-11.38	1.16e-26	1.22e-23	-0.6	-0.46	Protein biomarker;	chr14:55174996	chr14:55262767~55272075:-
THCA	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-11.38	1.16e-26	1.22e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
THCA	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-11.38	1.17e-26	1.22e-23	-0.38	-0.46	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
THCA	cis	rs9659323	0.65	rs12093893	ENSG00000231365.4	RP11-418J17.1	-11.38	1.17e-26	1.23e-23	-0.5	-0.46	Body mass index;	chr1:118948196	chr1:119140396~119275973:+
THCA	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	11.38	1.17e-26	1.23e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
THCA	cis	rs6558530	0.653	rs7001282	ENSG00000253982.1	CTD-2336O2.1	11.38	1.18e-26	1.24e-23	0.45	0.46	Systolic blood pressure;	chr8:1752022	chr8:1761990~1764502:-
THCA	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-11.38	1.18e-26	1.24e-23	-0.64	-0.46	Depression;	chr6:28135913	chr6:28115628~28116551:+
THCA	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-11.37	1.19e-26	1.25e-23	-0.54	-0.46	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
THCA	cis	rs11098499	0.913	rs13126596	ENSG00000245958.5	RP11-33B1.1	-11.37	1.2e-26	1.26e-23	-0.45	-0.46	Corneal astigmatism;	chr4:119219574	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.764	rs2265471	ENSG00000235652.6	RP11-545I5.3	11.37	1.2e-26	1.27e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145899114	chr6:145799409~145886585:+
THCA	cis	rs6558530	0.615	rs12674711	ENSG00000253982.1	CTD-2336O2.1	11.37	1.22e-26	1.29e-23	0.45	0.46	Systolic blood pressure;	chr8:1751442	chr8:1761990~1764502:-
THCA	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-11.37	1.23e-26	1.29e-23	-0.89	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
THCA	cis	rs9659323	0.596	rs11589179	ENSG00000231365.4	RP11-418J17.1	-11.37	1.24e-26	1.3e-23	-0.5	-0.46	Body mass index;	chr1:118954962	chr1:119140396~119275973:+
THCA	cis	rs9659323	0.65	rs10923705	ENSG00000231365.4	RP11-418J17.1	-11.37	1.24e-26	1.3e-23	-0.5	-0.46	Body mass index;	chr1:118955781	chr1:119140396~119275973:+
THCA	cis	rs2283792	0.74	rs8138075	ENSG00000224086.5	LL22NC03-86G7.1	-11.37	1.24e-26	1.3e-23	-0.56	-0.46	Multiple sclerosis;	chr22:21755092	chr22:21938293~21977632:+
THCA	cis	rs944289	0.617	rs12431579	ENSG00000257826.1	RP11-116N8.4	-11.37	1.25e-26	1.31e-23	-0.51	-0.46	Thyroid cancer;	chr14:36125191	chr14:36061026~36067190:-
THCA	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	11.37	1.25e-26	1.31e-23	0.55	0.46	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
THCA	cis	rs4819052	1	rs13047688	ENSG00000223768.1	LINC00205	-11.37	1.25e-26	1.31e-23	-0.47	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45293285~45297354:+
THCA	cis	rs6558530	0.692	rs6981804	ENSG00000253982.1	CTD-2336O2.1	11.37	1.27e-26	1.32e-23	0.44	0.46	Systolic blood pressure;	chr8:1752118	chr8:1761990~1764502:-
THCA	cis	rs9659323	0.622	rs11582744	ENSG00000231365.4	RP11-418J17.1	-11.37	1.27e-26	1.33e-23	-0.49	-0.46	Body mass index;	chr1:118914781	chr1:119140396~119275973:+
THCA	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	11.37	1.28e-26	1.34e-23	0.61	0.46	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
THCA	cis	rs950169	1	rs950169	ENSG00000225151.9	GOLGA2P7	-11.37	1.29e-26	1.35e-23	-0.7	-0.46	Schizophrenia;	chr15:84037709	chr15:84199311~84230136:-
THCA	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	11.37	1.29e-26	1.35e-23	0.39	0.46	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
THCA	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	11.37	1.3e-26	1.36e-23	0.57	0.46	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
THCA	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-11.37	1.3e-26	1.36e-23	-0.63	-0.46	Depression;	chr6:28145952	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-11.37	1.3e-26	1.36e-23	-0.63	-0.46	Depression;	chr6:28147378	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-11.37	1.3e-26	1.36e-23	-0.63	-0.46	Depression;	chr6:28147406	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-11.37	1.3e-26	1.36e-23	-0.63	-0.46	Depression;	chr6:28148143	chr6:28115628~28116551:+
THCA	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	11.37	1.3e-26	1.36e-23	0.68	0.46	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
THCA	cis	rs2658782	0.547	rs4344448	ENSG00000279684.1	RP11-755E23.2	-11.37	1.3e-26	1.36e-23	-0.74	-0.46	Pulmonary function decline;	chr11:93313881	chr11:93286629~93288903:-
THCA	cis	rs2283792	0.765	rs5999749	ENSG00000224086.5	LL22NC03-86G7.1	11.36	1.31e-26	1.37e-23	0.56	0.46	Multiple sclerosis;	chr22:21833371	chr22:21938293~21977632:+
THCA	cis	rs11098499	0.913	rs68128210	ENSG00000245958.5	RP11-33B1.1	-11.36	1.31e-26	1.37e-23	-0.45	-0.46	Corneal astigmatism;	chr4:119216664	chr4:119454791~119552025:+
THCA	cis	rs9389248	0.69	rs2294321	ENSG00000232876.1	CTA-212D2.2	11.36	1.32e-26	1.38e-23	0.57	0.46	High light scatter reticulocyte percentage of red cells;	chr6:134931910	chr6:135055033~135060550:+
THCA	cis	rs9399135	0.507	rs2072825	ENSG00000232876.1	CTA-212D2.2	11.36	1.32e-26	1.38e-23	0.57	0.46	Red blood cell count;	chr6:134932313	chr6:135055033~135060550:+
THCA	cis	rs9389248	0.69	rs2072826	ENSG00000232876.1	CTA-212D2.2	11.36	1.32e-26	1.38e-23	0.57	0.46	High light scatter reticulocyte percentage of red cells;	chr6:134932420	chr6:135055033~135060550:+
THCA	cis	rs12468226	0.938	rs115418918	ENSG00000273456.1	RP11-686O6.2	11.36	1.32e-26	1.38e-23	0.58	0.46	Urate levels;	chr2:202315145	chr2:202374932~202375604:-
THCA	cis	rs1075265	0.901	rs9808326	ENSG00000233266.1	HMGB1P31	11.36	1.33e-26	1.39e-23	0.59	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54115971	chr2:54051334~54051760:+
THCA	cis	rs7104764	0.507	rs7111364	ENSG00000277290.1	RP11-326C3.16	-11.36	1.33e-26	1.39e-23	-0.54	-0.46	Menarche (age at onset);	chr11:258542	chr11:243099~243483:-
THCA	cis	rs7221109	0.677	rs7209467	ENSG00000278834.1	RP11-458J1.1	11.36	1.33e-26	1.39e-23	0.5	0.46	Type 1 diabetes;	chr17:40653033	chr17:40648300~40649718:+
THCA	cis	rs9322193	0.923	rs12529698	ENSG00000223701.3	RAET1E-AS1	11.36	1.34e-26	1.4e-23	0.62	0.46	Lung cancer;	chr6:149650951	chr6:149884431~149919508:+
THCA	cis	rs2732480	0.577	rs2634684	ENSG00000258273.1	RP11-370I10.4	11.36	1.34e-26	1.4e-23	0.62	0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48333755~48333901:-
THCA	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-11.36	1.34e-26	1.4e-23	-0.49	-0.46	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
THCA	cis	rs17507216	0.588	rs4778687	ENSG00000278603.1	RP13-608F4.5	11.36	1.36e-26	1.42e-23	0.81	0.46	Excessive daytime sleepiness;	chr15:82649085	chr15:82472203~82472426:+
THCA	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	11.36	1.36e-26	1.42e-23	0.55	0.46	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
THCA	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	11.36	1.36e-26	1.42e-23	0.55	0.46	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
THCA	cis	rs11098499	0.913	rs56122576	ENSG00000245958.5	RP11-33B1.1	-11.36	1.36e-26	1.42e-23	-0.45	-0.46	Corneal astigmatism;	chr4:119208181	chr4:119454791~119552025:+
THCA	cis	rs6890270	0.634	rs62356569	ENSG00000271828.1	CTD-2310F14.1	11.36	1.36e-26	1.42e-23	0.76	0.46	Breast cancer;	chr5:56963908	chr5:56927874~56929573:+
THCA	cis	rs765787	0.556	rs10851422	ENSG00000259520.4	CTD-2651B20.3	-11.36	1.37e-26	1.43e-23	-0.56	-0.46	Uric acid levels;	chr15:45221540	chr15:45251580~45279251:-
THCA	cis	rs1075265	0.933	rs929734	ENSG00000233266.1	HMGB1P31	11.36	1.38e-26	1.44e-23	0.58	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54111158	chr2:54051334~54051760:+
THCA	cis	rs7829975	0.627	rs876954	ENSG00000253893.2	FAM85B	-11.36	1.38e-26	1.44e-23	-0.61	-0.46	Mood instability;	chr8:8453413	chr8:8167819~8226614:-
THCA	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-11.36	1.38e-26	1.44e-23	-0.63	-0.46	Depression;	chr6:28169676	chr6:28115628~28116551:+
THCA	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	11.36	1.38e-26	1.44e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	11.36	1.38e-26	1.44e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
THCA	cis	rs2283792	0.765	rs9610374	ENSG00000224086.5	LL22NC03-86G7.1	-11.36	1.38e-26	1.44e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21832514	chr22:21938293~21977632:+
THCA	cis	rs9322193	0.962	rs3805752	ENSG00000223701.3	RAET1E-AS1	11.36	1.39e-26	1.45e-23	0.64	0.46	Lung cancer;	chr6:149795490	chr6:149884431~149919508:+
THCA	cis	rs765787	0.53	rs10851423	ENSG00000259520.4	CTD-2651B20.3	-11.36	1.39e-26	1.45e-23	-0.57	-0.46	Uric acid levels;	chr15:45223752	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12913123	ENSG00000259520.4	CTD-2651B20.3	-11.36	1.39e-26	1.45e-23	-0.57	-0.46	Uric acid levels;	chr15:45224227	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12904331	ENSG00000259520.4	CTD-2651B20.3	-11.36	1.39e-26	1.45e-23	-0.57	-0.46	Uric acid levels;	chr15:45226095	chr15:45251580~45279251:-
THCA	cis	rs6570726	0.577	rs406868	ENSG00000235652.6	RP11-545I5.3	11.36	1.4e-26	1.46e-23	0.48	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145488847	chr6:145799409~145886585:+
THCA	cis	rs12468226	0.938	rs13392645	ENSG00000273456.1	RP11-686O6.2	11.36	1.4e-26	1.46e-23	0.52	0.46	Urate levels;	chr2:202270116	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs7568159	ENSG00000273456.1	RP11-686O6.2	11.36	1.4e-26	1.46e-23	0.52	0.46	Urate levels;	chr2:202286226	chr2:202374932~202375604:-
THCA	cis	rs7301826	0.61	rs36051740	ENSG00000256250.1	RP11-989F5.1	11.36	1.41e-26	1.47e-23	0.56	0.46	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810606~130812438:+
THCA	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-11.36	1.41e-26	1.47e-23	-0.34	-0.46	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
THCA	cis	rs6142102	0.886	rs6142098	ENSG00000276073.1	RP5-1125A11.7	-11.36	1.41e-26	1.47e-23	-0.43	-0.46	Skin pigmentation;	chr20:34100488	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.961	rs2235596	ENSG00000276073.1	RP5-1125A11.7	11.36	1.41e-26	1.47e-23	0.43	0.46	Skin pigmentation;	chr20:34096503	chr20:33985617~33988989:-
THCA	cis	rs2732480	0.577	rs1489109	ENSG00000258273.1	RP11-370I10.4	-11.36	1.42e-26	1.48e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs1489108	ENSG00000258273.1	RP11-370I10.4	-11.36	1.42e-26	1.48e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48333755~48333901:-
THCA	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	11.36	1.42e-26	1.48e-23	0.59	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
THCA	cis	rs2283792	0.715	rs56227348	ENSG00000224086.5	LL22NC03-86G7.1	-11.35	1.43e-26	1.49e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21791443	chr22:21938293~21977632:+
THCA	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	11.35	1.44e-26	1.5e-23	0.6	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
THCA	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	11.35	1.44e-26	1.5e-23	0.6	0.46	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
THCA	cis	rs7221109	0.677	rs917593	ENSG00000278834.1	RP11-458J1.1	11.35	1.45e-26	1.5e-23	0.49	0.46	Type 1 diabetes;	chr17:40660274	chr17:40648300~40649718:+
THCA	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	11.35	1.45e-26	1.51e-23	0.56	0.46	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
THCA	cis	rs2274273	0.868	rs6573007	ENSG00000258413.1	RP11-665C16.6	-11.35	1.46e-26	1.51e-23	-0.6	-0.46	Protein biomarker;	chr14:55159220	chr14:55262767~55272075:-
THCA	cis	rs8100891	0.537	rs10415744	ENSG00000267213.4	AC007773.2	-11.35	1.46e-26	1.52e-23	-0.54	-0.46	Neuroticism;	chr19:32389674	chr19:32390050~32405560:-
THCA	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-11.35	1.47e-26	1.53e-23	-0.64	-0.46	Depression;	chr6:28180209	chr6:28115628~28116551:+
THCA	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	11.35	1.47e-26	1.53e-23	0.54	0.46	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
THCA	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-11.35	1.48e-26	1.54e-23	-0.58	-0.46	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
THCA	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	11.35	1.48e-26	1.54e-23	0.54	0.46	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	11.35	1.48e-26	1.54e-23	0.54	0.46	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
THCA	cis	rs11159086	0.793	rs11621693	ENSG00000270000.1	RP3-449M8.9	11.35	1.48e-26	1.54e-23	0.5	0.46	Advanced glycation end-product levels;	chr14:74472631	chr14:74471930~74472360:-
THCA	cis	rs62103177	0.565	rs473119	ENSG00000261126.6	RP11-795F19.1	-11.35	1.49e-26	1.55e-23	-0.53	-0.46	Opioid sensitivity;	chr18:80091557	chr18:80046900~80095482:+
THCA	cis	rs67311347	0.824	rs73073561	ENSG00000223797.4	ENTPD3-AS1	11.35	1.49e-26	1.55e-23	0.39	0.46	Renal cell carcinoma;	chr3:40315807	chr3:40313802~40453329:-
THCA	cis	rs950169	1	rs1818950	ENSG00000225151.9	GOLGA2P7	-11.35	1.51e-26	1.57e-23	-0.68	-0.46	Schizophrenia;	chr15:84053769	chr15:84199311~84230136:-
THCA	cis	rs6142102	0.961	rs6120519	ENSG00000276073.1	RP5-1125A11.7	-11.35	1.51e-26	1.57e-23	-0.43	-0.46	Skin pigmentation;	chr20:34100307	chr20:33985617~33988989:-
THCA	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	11.35	1.52e-26	1.58e-23	0.34	0.46	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
THCA	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	11.35	1.52e-26	1.58e-23	0.34	0.46	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
THCA	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	11.35	1.55e-26	1.61e-23	0.34	0.46	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
THCA	cis	rs6452524	0.901	rs12514607	ENSG00000249664.1	CTD-2227C6.2	-11.35	1.56e-26	1.62e-23	-0.59	-0.46	Hypertension (SNP x SNP interaction);	chr5:83209710	chr5:83012285~83013109:-
THCA	cis	rs9322193	0.924	rs9498382	ENSG00000223701.3	RAET1E-AS1	11.34	1.57e-26	1.63e-23	0.62	0.46	Lung cancer;	chr6:149610982	chr6:149884431~149919508:+
THCA	cis	rs11098499	0.615	rs59867181	ENSG00000245958.5	RP11-33B1.1	11.34	1.58e-26	1.64e-23	0.43	0.46	Corneal astigmatism;	chr4:119635312	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.562	rs2389879	ENSG00000245958.5	RP11-33B1.1	11.34	1.58e-26	1.64e-23	0.43	0.46	Corneal astigmatism;	chr4:119636529	chr4:119454791~119552025:+
THCA	cis	rs2274273	0.804	rs28428911	ENSG00000258413.1	RP11-665C16.6	-11.34	1.58e-26	1.64e-23	-0.61	-0.46	Protein biomarker;	chr14:55376878	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.805	rs28660594	ENSG00000258413.1	RP11-665C16.6	-11.34	1.58e-26	1.64e-23	-0.61	-0.46	Protein biomarker;	chr14:55379456	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs10139000	ENSG00000258413.1	RP11-665C16.6	-11.34	1.58e-26	1.64e-23	-0.61	-0.46	Protein biomarker;	chr14:55383158	chr14:55262767~55272075:-
THCA	cis	rs673078	0.66	rs7974718	ENSG00000275759.1	RP11-131L12.3	-11.34	1.58e-26	1.64e-23	-0.61	-0.46	Glucose homeostasis traits;	chr12:118243258	chr12:118428281~118428870:+
THCA	cis	rs6142102	0.812	rs2377955	ENSG00000276073.1	RP5-1125A11.7	-11.34	1.58e-26	1.65e-23	-0.43	-0.46	Skin pigmentation;	chr20:33937564	chr20:33985617~33988989:-
THCA	cis	rs673078	0.607	rs7309671	ENSG00000275759.1	RP11-131L12.3	-11.34	1.61e-26	1.67e-23	-0.71	-0.46	Glucose homeostasis traits;	chr12:118313188	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17512525	ENSG00000275759.1	RP11-131L12.3	-11.34	1.62e-26	1.68e-23	-0.71	-0.46	Glucose homeostasis traits;	chr12:118315467	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs17440774	ENSG00000275759.1	RP11-131L12.3	-11.34	1.62e-26	1.68e-23	-0.71	-0.46	Glucose homeostasis traits;	chr12:118316155	chr12:118428281~118428870:+
THCA	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	11.34	1.63e-26	1.69e-23	0.56	0.46	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
THCA	cis	rs7301826	0.651	rs34749116	ENSG00000256250.1	RP11-989F5.1	11.34	1.63e-26	1.69e-23	0.56	0.46	Plasma plasminogen activator levels;	chr12:130796207	chr12:130810606~130812438:+
THCA	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-11.34	1.64e-26	1.7e-23	-0.35	-0.46	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
THCA	cis	rs950169	1	rs12915234	ENSG00000225151.9	GOLGA2P7	-11.34	1.65e-26	1.71e-23	-0.69	-0.46	Schizophrenia;	chr15:84089549	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs34751999	ENSG00000225151.9	GOLGA2P7	-11.34	1.65e-26	1.71e-23	-0.69	-0.46	Schizophrenia;	chr15:84089667	chr15:84199311~84230136:-
THCA	cis	rs950169	0.919	rs17300292	ENSG00000225151.9	GOLGA2P7	-11.34	1.65e-26	1.71e-23	-0.69	-0.46	Schizophrenia;	chr15:84093816	chr15:84199311~84230136:-
THCA	cis	rs11214589	0.719	rs10891535	ENSG00000270179.1	RP11-159N11.4	-11.34	1.65e-26	1.71e-23	-0.5	-0.46	Neuroticism;	chr11:113330558	chr11:113368478~113369117:+
THCA	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	11.34	1.66e-26	1.72e-23	0.53	0.46	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
THCA	cis	rs12022452	0.908	rs4660423	ENSG00000238287.1	RP11-656D10.3	-11.34	1.66e-26	1.73e-23	-0.72	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:40493157~40508661:-
THCA	cis	rs9322193	0.884	rs10872646	ENSG00000223701.3	RAET1E-AS1	11.34	1.67e-26	1.73e-23	0.62	0.46	Lung cancer;	chr6:149746539	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs12528279	ENSG00000223701.3	RAET1E-AS1	11.34	1.67e-26	1.73e-23	0.62	0.46	Lung cancer;	chr6:149750892	chr6:149884431~149919508:+
THCA	cis	rs950169	0.92	rs2135551	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84039099	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs12902672	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84048234	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs12903820	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84055068	chr15:84199311~84230136:-
THCA	cis	rs950169	0.919	rs12915589	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84065712	chr15:84199311~84230136:-
THCA	cis	rs950169	0.959	rs66801143	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84067905	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs35648189	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84071996	chr15:84199311~84230136:-
THCA	cis	rs950169	0.92	rs17300048	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84080725	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs1848093	ENSG00000225151.9	GOLGA2P7	-11.34	1.68e-26	1.74e-23	-0.69	-0.46	Schizophrenia;	chr15:84086775	chr15:84199311~84230136:-
THCA	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-11.34	1.68e-26	1.75e-23	-0.63	-0.46	Depression;	chr6:28159666	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-11.34	1.68e-26	1.75e-23	-0.63	-0.46	Depression;	chr6:28162598	chr6:28115628~28116551:+
THCA	cis	rs765787	0.505	rs4439707	ENSG00000259520.4	CTD-2651B20.3	-11.34	1.69e-26	1.75e-23	-0.57	-0.46	Uric acid levels;	chr15:45232018	chr15:45251580~45279251:-
THCA	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	11.34	1.69e-26	1.75e-23	0.38	0.46	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
THCA	cis	rs9659323	0.622	rs28653656	ENSG00000231365.4	RP11-418J17.1	-11.34	1.7e-26	1.76e-23	-0.49	-0.46	Body mass index;	chr1:118943807	chr1:119140396~119275973:+
THCA	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	11.34	1.7e-26	1.76e-23	0.82	0.46	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
THCA	cis	rs7772486	0.875	rs1412081	ENSG00000235652.6	RP11-545I5.3	11.34	1.71e-26	1.77e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146088597	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs10457792	ENSG00000235652.6	RP11-545I5.3	11.34	1.71e-26	1.77e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146091279	chr6:145799409~145886585:+
THCA	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	11.34	1.71e-26	1.77e-23	0.85	0.46	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
THCA	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-11.33	1.71e-26	1.77e-23	-0.57	-0.46	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-11.33	1.71e-26	1.77e-23	-0.57	-0.46	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-11.33	1.71e-26	1.77e-23	-0.57	-0.46	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
THCA	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	11.33	1.71e-26	1.78e-23	0.59	0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
THCA	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	11.33	1.72e-26	1.78e-23	0.87	0.46	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	11.33	1.72e-26	1.78e-23	0.87	0.46	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	11.33	1.72e-26	1.78e-23	0.87	0.46	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	11.33	1.72e-26	1.78e-23	0.87	0.46	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
THCA	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	11.33	1.72e-26	1.79e-23	0.58	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
THCA	cis	rs916888	0.773	rs199533	ENSG00000232300.1	FAM215B	11.33	1.73e-26	1.79e-23	0.76	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46558830~46562795:-
THCA	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-11.33	1.76e-26	1.82e-23	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
THCA	cis	rs5769707	0.521	rs739244	ENSG00000188511.11	C22orf34	11.33	1.76e-26	1.82e-23	0.58	0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49414524~49657542:-
THCA	cis	rs6142102	0.812	rs6059578	ENSG00000276073.1	RP5-1125A11.7	-11.33	1.76e-26	1.82e-23	-0.43	-0.46	Skin pigmentation;	chr20:33939900	chr20:33985617~33988989:-
THCA	cis	rs6142102	0.886	rs6059583	ENSG00000276073.1	RP5-1125A11.7	-11.33	1.76e-26	1.82e-23	-0.43	-0.46	Skin pigmentation;	chr20:33944308	chr20:33985617~33988989:-
THCA	cis	rs2283792	0.765	rs5999752	ENSG00000224086.5	LL22NC03-86G7.1	-11.33	1.76e-26	1.83e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21833894	chr22:21938293~21977632:+
THCA	cis	rs6142102	0.961	rs4911408	ENSG00000276073.1	RP5-1125A11.7	-11.33	1.77e-26	1.83e-23	-0.45	-0.46	Skin pigmentation;	chr20:34112760	chr20:33985617~33988989:-
THCA	cis	rs7221109	0.677	rs1029792	ENSG00000278834.1	RP11-458J1.1	11.33	1.78e-26	1.84e-23	0.5	0.46	Type 1 diabetes;	chr17:40652689	chr17:40648300~40649718:+
THCA	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-11.33	1.78e-26	1.84e-23	-0.58	-0.46	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
THCA	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-11.33	1.78e-26	1.84e-23	-0.61	-0.46	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
THCA	cis	rs465969	1	rs1407644	ENSG00000255389.1	C6orf3	11.33	1.78e-26	1.84e-23	0.81	0.46	Psoriasis;	chr6:111480895	chr6:111599875~111602295:+
THCA	cis	rs6558530	0.625	rs7459507	ENSG00000253982.1	CTD-2336O2.1	11.33	1.78e-26	1.85e-23	0.45	0.46	Systolic blood pressure;	chr8:1750026	chr8:1761990~1764502:-
THCA	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	11.33	1.78e-26	1.85e-23	0.52	0.46	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
THCA	cis	rs11159086	0.793	rs28612392	ENSG00000270000.1	RP3-449M8.9	11.33	1.8e-26	1.86e-23	0.5	0.46	Advanced glycation end-product levels;	chr14:74467894	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs11625502	ENSG00000270000.1	RP3-449M8.9	11.33	1.8e-26	1.86e-23	0.5	0.46	Advanced glycation end-product levels;	chr14:74468309	chr14:74471930~74472360:-
THCA	cis	rs2283792	0.765	rs9607285	ENSG00000224086.5	LL22NC03-86G7.1	-11.33	1.81e-26	1.87e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21808704	chr22:21938293~21977632:+
THCA	cis	rs6496932	0.676	rs7183651	ENSG00000218052.5	ADAMTS7P4	-11.33	1.82e-26	1.88e-23	-0.59	-0.46	Central corneal thickness;Corneal structure;	chr15:85352490	chr15:85255369~85330334:-
THCA	cis	rs4819052	1	rs28628220	ENSG00000223768.1	LINC00205	-11.33	1.82e-26	1.89e-23	-0.47	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45293285~45297354:+
THCA	cis	rs4819052	1	rs2838830	ENSG00000223768.1	LINC00205	-11.33	1.82e-26	1.89e-23	-0.47	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45293285~45297354:+
THCA	cis	rs10463554	0.926	rs34778	ENSG00000175749.11	EIF3KP1	11.33	1.84e-26	1.9e-23	0.6	0.46	Parkinson's disease;	chr5:103116852	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs26524	ENSG00000175749.11	EIF3KP1	11.33	1.84e-26	1.9e-23	0.6	0.46	Parkinson's disease;	chr5:103120600	chr5:103032376~103033031:+
THCA	cis	rs2283792	0.765	rs9610328	ENSG00000224086.5	LL22NC03-86G7.1	-11.33	1.84e-26	1.9e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21793085	chr22:21938293~21977632:+
THCA	cis	rs2283792	0.765	rs6518968	ENSG00000224086.5	LL22NC03-86G7.1	-11.33	1.84e-26	1.9e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21793327	chr22:21938293~21977632:+
THCA	cis	rs875971	1	rs697970	ENSG00000237310.1	GS1-124K5.4	-11.33	1.85e-26	1.91e-23	-0.35	-0.46	Aortic root size;	chr7:66095065	chr7:66493706~66495474:+
THCA	cis	rs2283792	0.765	rs8139376	ENSG00000224086.5	LL22NC03-86G7.1	-11.33	1.85e-26	1.91e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21755307	chr22:21938293~21977632:+
THCA	cis	rs8040855	0.576	rs62022528	ENSG00000259295.5	CSPG4P12	11.33	1.85e-26	1.92e-23	0.73	0.46	Bulimia nervosa;	chr15:84992030	chr15:85191438~85213905:+
THCA	cis	rs9322193	0.923	rs9800871	ENSG00000223701.3	RAET1E-AS1	11.33	1.87e-26	1.93e-23	0.62	0.46	Lung cancer;	chr6:149644540	chr6:149884431~149919508:+
THCA	cis	rs2274273	0.87	rs3783652	ENSG00000258413.1	RP11-665C16.6	-11.33	1.87e-26	1.93e-23	-0.61	-0.46	Protein biomarker;	chr14:55387490	chr14:55262767~55272075:-
THCA	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	11.32	1.87e-26	1.94e-23	0.79	0.46	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
THCA	cis	rs9322193	0.923	rs57938011	ENSG00000223701.3	RAET1E-AS1	11.32	1.9e-26	1.97e-23	0.64	0.46	Lung cancer;	chr6:149642969	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9800580	ENSG00000223701.3	RAET1E-AS1	11.32	1.91e-26	1.97e-23	0.62	0.46	Lung cancer;	chr6:149632845	chr6:149884431~149919508:+
THCA	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-11.32	1.91e-26	1.97e-23	-0.48	-0.46	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-11.32	1.91e-26	1.97e-23	-0.48	-0.46	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000228039.3	KB-1125A3.10	11.32	1.91e-26	1.97e-23	0.58	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23963780~23964374:+
THCA	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-11.32	1.94e-26	2e-23	-0.48	-0.46	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-11.32	1.95e-26	2.01e-23	-0.48	-0.46	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
THCA	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	11.32	1.95e-26	2.01e-23	0.84	0.46	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
THCA	cis	rs2274273	0.87	rs11625001	ENSG00000258413.1	RP11-665C16.6	-11.32	1.96e-26	2.02e-23	-0.61	-0.46	Protein biomarker;	chr14:55291442	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs67514154	ENSG00000258413.1	RP11-665C16.6	-11.32	1.96e-26	2.02e-23	-0.61	-0.46	Protein biomarker;	chr14:55300664	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.805	rs11628437	ENSG00000258413.1	RP11-665C16.6	-11.32	1.96e-26	2.02e-23	-0.61	-0.46	Protein biomarker;	chr14:55308750	chr14:55262767~55272075:-
THCA	cis	rs4713118	0.621	rs9295755	ENSG00000280107.1	AL022393.9	11.32	1.98e-26	2.04e-23	0.55	0.46	Parkinson's disease;	chr6:28065396	chr6:28170845~28172521:+
THCA	cis	rs9322193	0.923	rs7740278	ENSG00000223701.3	RAET1E-AS1	11.32	1.98e-26	2.05e-23	0.62	0.46	Lung cancer;	chr6:149640116	chr6:149884431~149919508:+
THCA	cis	rs10463554	0.963	rs40093	ENSG00000175749.11	EIF3KP1	11.32	2e-26	2.06e-23	0.6	0.46	Parkinson's disease;	chr5:103104121	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs257318	ENSG00000175749.11	EIF3KP1	11.32	2e-26	2.06e-23	0.6	0.46	Parkinson's disease;	chr5:103109766	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs40322	ENSG00000175749.11	EIF3KP1	11.32	2e-26	2.06e-23	0.6	0.46	Parkinson's disease;	chr5:103111253	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs34773	ENSG00000175749.11	EIF3KP1	11.32	2e-26	2.06e-23	0.6	0.46	Parkinson's disease;	chr5:103114872	chr5:103032376~103033031:+
THCA	cis	rs2732480	0.557	rs2732441	ENSG00000258273.1	RP11-370I10.4	-11.32	2e-26	2.06e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs2732448	ENSG00000258273.1	RP11-370I10.4	-11.32	2e-26	2.06e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs2732466	ENSG00000258273.1	RP11-370I10.4	-11.32	2e-26	2.06e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.557	rs2634682	ENSG00000258273.1	RP11-370I10.4	-11.32	2e-26	2.06e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48333755~48333901:-
THCA	cis	rs7569084	0.687	rs1344891	ENSG00000237979.1	AC007389.1	11.32	2.01e-26	2.07e-23	0.55	0.46	Sum eosinophil basophil counts;	chr2:65458890	chr2:65500993~65502138:-
THCA	cis	rs2658782	0.507	rs4457713	ENSG00000279684.1	RP11-755E23.2	-11.32	2.02e-26	2.07e-23	-0.74	-0.46	Pulmonary function decline;	chr11:93304264	chr11:93286629~93288903:-
THCA	cis	rs16828019	0.704	rs12743340	ENSG00000235358.1	RP11-399E6.1	11.32	2.02e-26	2.08e-23	0.89	0.46	Intelligence (multi-trait analysis);	chr1:40990360	chr1:41242373~41284861:+
THCA	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	11.32	2.04e-26	2.1e-23	0.53	0.46	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000228039.3	KB-1125A3.10	-11.31	2.09e-26	2.15e-23	-0.58	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23963780~23964374:+
THCA	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	11.31	2.1e-26	2.15e-23	0.56	0.46	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
THCA	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-11.31	2.11e-26	2.17e-23	-0.56	-0.46	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
THCA	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-11.31	2.11e-26	2.17e-23	-0.56	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
THCA	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-11.31	2.12e-26	2.18e-23	-0.63	-0.46	Depression;	chr6:28151096	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-11.31	2.12e-26	2.18e-23	-0.63	-0.46	Depression;	chr6:28152885	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-11.31	2.12e-26	2.18e-23	-0.63	-0.46	Depression;	chr6:28153120	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-11.31	2.12e-26	2.18e-23	-0.63	-0.46	Depression;	chr6:28161802	chr6:28115628~28116551:+
THCA	cis	rs6142102	0.961	rs1319363	ENSG00000276073.1	RP5-1125A11.7	-11.31	2.12e-26	2.18e-23	-0.43	-0.46	Skin pigmentation;	chr20:33954070	chr20:33985617~33988989:-
THCA	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-11.31	2.13e-26	2.19e-23	-0.55	-0.46	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
THCA	cis	rs2283792	0.74	rs11912377	ENSG00000224086.5	LL22NC03-86G7.1	-11.31	2.14e-26	2.2e-23	-0.56	-0.46	Multiple sclerosis;	chr22:21864332	chr22:21938293~21977632:+
THCA	cis	rs7945705	0.837	rs2742474	ENSG00000254860.4	TMEM9B-AS1	11.31	2.15e-26	2.21e-23	0.5	0.46	Hemoglobin concentration;	chr11:8980542	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.869	rs2742471	ENSG00000254860.4	TMEM9B-AS1	11.31	2.15e-26	2.21e-23	0.5	0.46	Hemoglobin concentration;	chr11:8982406	chr11:8964675~8977527:+
THCA	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-11.31	2.15e-26	2.21e-23	-0.55	-0.46	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
THCA	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-11.31	2.15e-26	2.21e-23	-0.55	-0.46	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
THCA	cis	rs2880765	0.566	rs55899824	ENSG00000259295.5	CSPG4P12	11.31	2.16e-26	2.21e-23	0.64	0.46	Coronary artery disease;	chr15:85460860	chr15:85191438~85213905:+
THCA	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	11.31	2.16e-26	2.21e-23	0.53	0.46	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	11.31	2.16e-26	2.21e-23	0.53	0.46	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	11.31	2.16e-26	2.21e-23	0.53	0.46	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	11.31	2.16e-26	2.21e-23	0.53	0.46	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
THCA	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-11.31	2.17e-26	2.23e-23	-0.67	-0.46	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
THCA	cis	rs9659323	0.623	rs12091291	ENSG00000231365.4	RP11-418J17.1	11.31	2.17e-26	2.23e-23	0.5	0.46	Body mass index;	chr1:118936205	chr1:119140396~119275973:+
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000235689.1	AP000351.13	-11.31	2.18e-26	2.23e-23	-0.58	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:24006305~24008258:-
THCA	cis	rs2599510	0.783	rs2568464	ENSG00000276334.1	AL133243.1	-11.31	2.19e-26	2.24e-23	-0.5	-0.46	Interleukin-18 levels;	chr2:32623591	chr2:32521927~32523547:+
THCA	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	11.31	2.19e-26	2.25e-23	0.56	0.46	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	11.31	2.19e-26	2.25e-23	0.56	0.46	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
THCA	cis	rs10463554	0.926	rs26429	ENSG00000175749.11	EIF3KP1	-11.31	2.19e-26	2.25e-23	-0.59	-0.46	Parkinson's disease;	chr5:103030349	chr5:103032376~103033031:+
THCA	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-11.31	2.19e-26	2.25e-23	-0.56	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	11.31	2.2e-26	2.25e-23	0.56	0.46	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
THCA	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28154567	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28156691	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28158424	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28159056	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28159925	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28159932	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28162053	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28163375	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28163759	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28164580	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28164825	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28164948	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28165025	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28165528	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28169019	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28169249	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28169755	chr6:28115628~28116551:+
THCA	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28169791	chr6:28115628~28116551:+
THCA	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-11.31	2.22e-26	2.28e-23	-0.63	-0.46	Depression;	chr6:28170075	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.924	rs9322189	ENSG00000223701.3	RAET1E-AS1	11.3	2.24e-26	2.29e-23	0.62	0.46	Lung cancer;	chr6:149588797	chr6:149884431~149919508:+
THCA	cis	rs6558530	0.666	rs7845723	ENSG00000253982.1	CTD-2336O2.1	11.3	2.25e-26	2.31e-23	0.45	0.46	Systolic blood pressure;	chr8:1748920	chr8:1761990~1764502:-
THCA	cis	rs9322193	0.923	rs9800686	ENSG00000223701.3	RAET1E-AS1	11.3	2.27e-26	2.32e-23	0.64	0.46	Lung cancer;	chr6:149634464	chr6:149884431~149919508:+
THCA	cis	rs4591358	0.689	rs72927705	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518341	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs72927707	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518526	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs16836823	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518785	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs57244991	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519331	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs72927708	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519789	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs72927711	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520309	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs72927717	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520887	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs72927725	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529140	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs7574191	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529995	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs1500605	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530584	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.648	rs1515877	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530995	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs16837006	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533245	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs16837010	ENSG00000223466.1	AC064834.2	-11.3	2.27e-26	2.32e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533302	chr2:195533035~195538681:+
THCA	cis	rs6142102	0.961	rs2284389	ENSG00000276073.1	RP5-1125A11.7	-11.3	2.27e-26	2.33e-23	-0.43	-0.46	Skin pigmentation;	chr20:34069035	chr20:33985617~33988989:-
THCA	cis	rs4819052	1	rs733738	ENSG00000223768.1	LINC00205	11.3	2.3e-26	2.35e-23	0.47	0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45293285~45297354:+
THCA	cis	rs853679	0.517	rs1904841	ENSG00000219392.1	RP1-265C24.5	-11.3	2.3e-26	2.35e-23	-0.64	-0.46	Depression;	chr6:28140307	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.81	rs62439811	ENSG00000223701.3	RAET1E-AS1	11.3	2.34e-26	2.39e-23	0.64	0.46	Lung cancer;	chr6:149640416	chr6:149884431~149919508:+
THCA	cis	rs2274273	0.84	rs7144737	ENSG00000258413.1	RP11-665C16.6	-11.3	2.36e-26	2.42e-23	-0.61	-0.46	Protein biomarker;	chr14:55356228	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.923	rs9689084	ENSG00000223701.3	RAET1E-AS1	11.3	2.37e-26	2.43e-23	0.61	0.46	Lung cancer;	chr6:149639648	chr6:149884431~149919508:+
THCA	cis	rs4819052	0.851	rs2236445	ENSG00000223768.1	LINC00205	-11.3	2.37e-26	2.43e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45293285~45297354:+
THCA	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-11.3	2.38e-26	2.43e-23	-0.63	-0.46	Depression;	chr6:28149979	chr6:28115628~28116551:+
THCA	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	11.3	2.39e-26	2.44e-23	0.43	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
THCA	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-11.3	2.41e-26	2.46e-23	-0.59	-0.46	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
THCA	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-11.3	2.43e-26	2.48e-23	-0.55	-0.46	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
THCA	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-11.3	2.43e-26	2.48e-23	-0.56	-0.46	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
THCA	cis	rs2658782	0.547	rs4753453	ENSG00000279684.1	RP11-755E23.2	-11.3	2.44e-26	2.49e-23	-0.74	-0.46	Pulmonary function decline;	chr11:93308008	chr11:93286629~93288903:-
THCA	cis	rs9322193	1	rs9377228	ENSG00000223701.3	RAET1E-AS1	11.3	2.44e-26	2.49e-23	0.61	0.46	Lung cancer;	chr6:149600862	chr6:149884431~149919508:+
THCA	cis	rs4819052	1	rs9984901	ENSG00000223768.1	LINC00205	-11.29	2.46e-26	2.52e-23	-0.47	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.923	rs9404048	ENSG00000223701.3	RAET1E-AS1	11.29	2.48e-26	2.53e-23	0.62	0.46	Lung cancer;	chr6:149616188	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10782317	ENSG00000223701.3	RAET1E-AS1	-11.29	2.48e-26	2.53e-23	-0.62	-0.46	Lung cancer;	chr6:149753911	chr6:149884431~149919508:+
THCA	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	11.29	2.48e-26	2.54e-23	0.81	0.46	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
THCA	cis	rs950169	1	rs12916348	ENSG00000225151.9	GOLGA2P7	-11.29	2.5e-26	2.55e-23	-0.68	-0.46	Schizophrenia;	chr15:84096775	chr15:84199311~84230136:-
THCA	cis	rs7772486	0.875	rs11755334	ENSG00000235652.6	RP11-545I5.3	11.29	2.52e-26	2.57e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146078161	chr6:145799409~145886585:+
THCA	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-11.29	2.53e-26	2.58e-23	-0.54	-0.46	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
THCA	cis	rs7772486	0.817	rs9322047	ENSG00000235652.6	RP11-545I5.3	11.29	2.54e-26	2.59e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146079258	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.847	rs12210605	ENSG00000223701.3	RAET1E-AS1	11.29	2.54e-26	2.6e-23	0.64	0.46	Lung cancer;	chr6:149817267	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9371199	ENSG00000223701.3	RAET1E-AS1	11.29	2.54e-26	2.6e-23	0.64	0.46	Lung cancer;	chr6:149817526	chr6:149884431~149919508:+
THCA	cis	rs1858037	0.867	rs4671658	ENSG00000204929.10	AC074391.1	-11.29	2.55e-26	2.6e-23	-0.61	-0.46	Rheumatoid arthritis;	chr2:65334258	chr2:65436711~66084639:+
THCA	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	11.29	2.55e-26	2.6e-23	0.65	0.46	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
THCA	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	11.29	2.57e-26	2.62e-23	0.37	0.46	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
THCA	cis	rs6142102	0.961	rs761235	ENSG00000276073.1	RP5-1125A11.7	-11.29	2.57e-26	2.62e-23	-0.43	-0.46	Skin pigmentation;	chr20:33946602	chr20:33985617~33988989:-
THCA	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-11.29	2.58e-26	2.63e-23	-0.53	-0.46	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
THCA	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	11.29	2.6e-26	2.65e-23	0.66	0.46	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
THCA	cis	rs600231	0.665	rs1616810	ENSG00000245532.5	NEAT1	11.29	2.6e-26	2.65e-23	0.31	0.46	Bone mineral density;	chr11:65452634	chr11:65422774~65445540:+
THCA	cis	rs765787	0.53	rs12906537	ENSG00000259520.4	CTD-2651B20.3	-11.29	2.6e-26	2.65e-23	-0.57	-0.46	Uric acid levels;	chr15:45227863	chr15:45251580~45279251:-
THCA	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	11.29	2.61e-26	2.66e-23	0.57	0.46	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
THCA	cis	rs4591358	0.689	rs72927784	ENSG00000223466.1	AC064834.2	-11.29	2.62e-26	2.67e-23	-0.67	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195550329	chr2:195533035~195538681:+
THCA	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-11.29	2.62e-26	2.67e-23	-0.64	-0.46	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
THCA	cis	rs673078	0.66	rs73205551	ENSG00000275759.1	RP11-131L12.3	-11.29	2.63e-26	2.68e-23	-0.58	-0.46	Glucose homeostasis traits;	chr12:118330808	chr12:118428281~118428870:+
THCA	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-11.29	2.64e-26	2.69e-23	-0.63	-0.46	Depression;	chr6:28159843	chr6:28115628~28116551:+
THCA	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-11.29	2.65e-26	2.7e-23	-0.6	-0.46	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
THCA	cis	rs73219805	0.759	rs3808578	ENSG00000228451.3	SDAD1P1	-11.29	2.66e-26	2.71e-23	-0.66	-0.46	Schizophrenia;	chr8:26393906	chr8:26379259~26382953:-
THCA	cis	rs4819052	0.851	rs1056100	ENSG00000223768.1	LINC00205	-11.28	2.68e-26	2.73e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45293285~45297354:+
THCA	cis	rs801193	0.591	rs2707839	ENSG00000237310.1	GS1-124K5.4	11.28	2.68e-26	2.73e-23	0.34	0.46	Aortic root size;	chr7:66728097	chr7:66493706~66495474:+
THCA	cis	rs11676348	0.755	rs1008562	ENSG00000261338.2	RP11-378A13.1	11.28	2.69e-26	2.74e-23	0.47	0.46	Ulcerative colitis;	chr2:218162249	chr2:218255319~218257366:+
THCA	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-11.28	2.7e-26	2.75e-23	-0.53	-0.46	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
THCA	cis	rs11098499	0.526	rs10026625	ENSG00000245958.5	RP11-33B1.1	-11.28	2.71e-26	2.75e-23	-0.43	-0.46	Corneal astigmatism;	chr4:119358981	chr4:119454791~119552025:+
THCA	cis	rs4819052	0.851	rs2838857	ENSG00000223768.1	LINC00205	-11.28	2.72e-26	2.76e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45293285~45297354:+
THCA	cis	rs10463554	0.926	rs5855	ENSG00000175749.11	EIF3KP1	-11.28	2.73e-26	2.78e-23	-0.59	-0.46	Parkinson's disease;	chr5:103029482	chr5:103032376~103033031:+
THCA	cis	rs26232	0.583	rs26430	ENSG00000175749.11	EIF3KP1	-11.28	2.73e-26	2.78e-23	-0.59	-0.46	Rheumatoid arthritis;	chr5:103030228	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.89	rs26428	ENSG00000175749.11	EIF3KP1	-11.28	2.73e-26	2.78e-23	-0.59	-0.46	Parkinson's disease;	chr5:103030780	chr5:103032376~103033031:+
THCA	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	11.28	2.74e-26	2.79e-23	0.77	0.46	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
THCA	cis	rs7772486	0.875	rs9322045	ENSG00000235652.6	RP11-545I5.3	11.28	2.75e-26	2.79e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146063814	chr6:145799409~145886585:+
THCA	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	11.28	2.79e-26	2.84e-23	0.53	0.46	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
THCA	cis	rs9322193	0.962	rs3805749	ENSG00000223701.3	RAET1E-AS1	11.28	2.79e-26	2.84e-23	0.63	0.46	Lung cancer;	chr6:149772546	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.847	rs9505972	ENSG00000223701.3	RAET1E-AS1	11.28	2.79e-26	2.84e-23	0.63	0.46	Lung cancer;	chr6:149775255	chr6:149884431~149919508:+
THCA	cis	rs2732480	0.577	rs2634693	ENSG00000258273.1	RP11-370I10.4	-11.28	2.81e-26	2.86e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs2634691	ENSG00000258273.1	RP11-370I10.4	-11.28	2.81e-26	2.86e-23	-0.62	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48333755~48333901:-
THCA	cis	rs4819052	0.851	rs2838856	ENSG00000223768.1	LINC00205	-11.28	2.81e-26	2.86e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45293285~45297354:+
THCA	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	11.28	2.82e-26	2.86e-23	0.53	0.46	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
THCA	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	11.28	2.82e-26	2.87e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
THCA	cis	rs10463554	0.927	rs158250	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103071075	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs464702	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103071180	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs464720	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103071183	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs158396	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103076015	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs158401	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103079764	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257304	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103081114	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257312	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103083923	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs185387	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103084315	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs257313	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103084943	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257315	ENSG00000175749.11	EIF3KP1	11.28	2.83e-26	2.87e-23	0.6	0.46	Parkinson's disease;	chr5:103085725	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.805	rs7159808	ENSG00000258413.1	RP11-665C16.6	-11.28	2.83e-26	2.88e-23	-0.6	-0.46	Protein biomarker;	chr14:55157609	chr14:55262767~55272075:-
THCA	cis	rs9928842	0.771	rs8059190	ENSG00000280152.1	RP11-331F4.5	11.28	2.83e-26	2.88e-23	0.63	0.46	Alcoholic chronic pancreatitis;	chr16:75226899	chr16:75245994~75250077:-
THCA	cis	rs3091242	0.806	rs35189848	ENSG00000224183.1	SDHDP6	11.28	2.85e-26	2.89e-23	0.57	0.46	Erythrocyte sedimentation rate;	chr1:25461931	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.836	rs35346083	ENSG00000224183.1	SDHDP6	11.28	2.85e-26	2.89e-23	0.57	0.46	Erythrocyte sedimentation rate;	chr1:25461934	chr1:25294164~25294643:-
THCA	cis	rs2274273	0.87	rs11851169	ENSG00000258413.1	RP11-665C16.6	-11.28	2.86e-26	2.9e-23	-0.6	-0.46	Protein biomarker;	chr14:55349214	chr14:55262767~55272075:-
THCA	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	11.28	2.86e-26	2.91e-23	0.61	0.46	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
THCA	cis	rs2658782	0.547	rs10765602	ENSG00000279684.1	RP11-755E23.2	-11.28	2.87e-26	2.92e-23	-0.74	-0.46	Pulmonary function decline;	chr11:93314999	chr11:93286629~93288903:-
THCA	cis	rs8072100	0.84	rs4968319	ENSG00000228782.6	CTD-2026D20.3	11.28	2.88e-26	2.93e-23	0.43	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47387601	chr17:47450568~47492492:-
THCA	cis	rs765787	0.53	rs7167731	ENSG00000259520.4	CTD-2651B20.3	-11.28	2.88e-26	2.93e-23	-0.56	-0.46	Uric acid levels;	chr15:45218702	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12910270	ENSG00000259520.4	CTD-2651B20.3	-11.28	2.88e-26	2.93e-23	-0.56	-0.46	Uric acid levels;	chr15:45219888	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12440238	ENSG00000259520.4	CTD-2651B20.3	-11.28	2.88e-26	2.93e-23	-0.56	-0.46	Uric acid levels;	chr15:45220707	chr15:45251580~45279251:-
THCA	cis	rs4964805	0.612	rs11111758	ENSG00000257681.1	RP11-341G23.4	11.28	2.89e-26	2.94e-23	0.54	0.46	Attention deficit hyperactivity disorder;	chr12:103767306	chr12:103746315~103768858:-
THCA	cis	rs9659323	0.596	rs6656528	ENSG00000231365.4	RP11-418J17.1	-11.28	2.9e-26	2.94e-23	-0.49	-0.46	Body mass index;	chr1:118934971	chr1:119140396~119275973:+
THCA	cis	rs2283792	0.765	rs2283793	ENSG00000224086.5	LL22NC03-86G7.1	-11.28	2.91e-26	2.95e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21827189	chr22:21938293~21977632:+
THCA	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-11.28	2.92e-26	2.96e-23	-0.49	-0.46	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
THCA	cis	rs2274273	0.875	rs2075602	ENSG00000258413.1	RP11-665C16.6	-11.27	2.93e-26	2.97e-23	-0.6	-0.46	Protein biomarker;	chr14:55143056	chr14:55262767~55272075:-
THCA	cis	rs73219805	0.759	rs17055186	ENSG00000228451.3	SDAD1P1	-11.27	2.93e-26	2.97e-23	-0.66	-0.46	Schizophrenia;	chr8:26403394	chr8:26379259~26382953:-
THCA	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-11.27	2.95e-26	2.99e-23	-0.56	-0.46	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
THCA	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	11.27	2.95e-26	2.99e-23	0.34	0.46	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
THCA	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-11.27	2.95e-26	2.99e-23	-0.66	-0.46	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
THCA	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-11.27	2.97e-26	3.01e-23	-0.56	-0.46	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
THCA	cis	rs2274273	0.84	rs11626751	ENSG00000258413.1	RP11-665C16.6	-11.27	2.98e-26	3.02e-23	-0.61	-0.46	Protein biomarker;	chr14:55368509	chr14:55262767~55272075:-
THCA	cis	rs4591358	0.689	rs16836990	ENSG00000223466.1	AC064834.2	-11.27	3e-26	3.04e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195532968	chr2:195533035~195538681:+
THCA	cis	rs1858037	0.867	rs6727013	ENSG00000204929.10	AC074391.1	11.27	3.01e-26	3.06e-23	0.61	0.46	Rheumatoid arthritis;	chr2:65331241	chr2:65436711~66084639:+
THCA	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	11.27	3.03e-26	3.07e-23	0.53	0.46	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
THCA	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	11.27	3.03e-26	3.07e-23	0.55	0.46	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
THCA	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	11.27	3.05e-26	3.09e-23	0.61	0.46	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
THCA	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	11.27	3.05e-26	3.09e-23	0.86	0.46	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
THCA	cis	rs9322193	0.886	rs4870055	ENSG00000223701.3	RAET1E-AS1	11.27	3.08e-26	3.12e-23	0.61	0.46	Lung cancer;	chr6:149848433	chr6:149884431~149919508:+
THCA	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-11.27	3.09e-26	3.13e-23	-0.54	-0.46	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
THCA	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-11.27	3.1e-26	3.14e-23	-0.63	-0.46	Depression;	chr6:28168434	chr6:28115628~28116551:+
THCA	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	11.27	3.11e-26	3.15e-23	0.53	0.46	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	11.27	3.11e-26	3.15e-23	0.53	0.46	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000228039.3	KB-1125A3.10	11.27	3.12e-26	3.16e-23	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23963780~23964374:+
THCA	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	11.27	3.15e-26	3.19e-23	0.89	0.46	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
THCA	cis	rs11105298	0.891	rs10777162	ENSG00000258302.2	RP11-981P6.1	11.27	3.15e-26	3.19e-23	0.44	0.46	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436746	chr12:89561129~89594878:+
THCA	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	11.27	3.18e-26	3.22e-23	0.56	0.46	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
THCA	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	11.27	3.2e-26	3.23e-23	0.56	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
THCA	cis	rs3779195	0.524	rs76976120	ENSG00000272950.1	RP11-307C18.1	-11.26	3.21e-26	3.25e-23	-0.72	-0.46	Sex hormone-binding globulin levels;	chr7:98264860	chr7:98322853~98323430:+
THCA	cis	rs26232	0.52	rs26432	ENSG00000175749.11	EIF3KP1	-11.26	3.22e-26	3.25e-23	-0.59	-0.46	Rheumatoid arthritis;	chr5:103030006	chr5:103032376~103033031:+
THCA	cis	rs765787	0.53	rs12915804	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.23e-26	3.27e-23	-0.56	-0.46	Uric acid levels;	chr15:45220364	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12915027	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.23e-26	3.27e-23	-0.56	-0.46	Uric acid levels;	chr15:45220428	chr15:45251580~45279251:-
THCA	cis	rs765787	0.556	rs12915965	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.23e-26	3.27e-23	-0.56	-0.46	Uric acid levels;	chr15:45220449	chr15:45251580~45279251:-
THCA	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	11.26	3.24e-26	3.27e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
THCA	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	11.26	3.24e-26	3.28e-23	0.37	0.46	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
THCA	cis	rs2274273	0.837	rs59871474	ENSG00000258413.1	RP11-665C16.6	-11.26	3.26e-26	3.3e-23	-0.61	-0.46	Protein biomarker;	chr14:55312645	chr14:55262767~55272075:-
THCA	cis	rs6504950	0.925	rs8082622	ENSG00000275710.1	RP11-257O5.4	-11.26	3.28e-26	3.31e-23	-0.59	-0.46	Breast cancer;	chr17:55100206	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.925	rs244377	ENSG00000275710.1	RP11-257O5.4	-11.26	3.28e-26	3.31e-23	-0.59	-0.46	Breast cancer;	chr17:55105718	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.925	rs244348	ENSG00000275710.1	RP11-257O5.4	11.26	3.28e-26	3.31e-23	0.59	0.46	Breast cancer;	chr17:55118930	chr17:54964474~54964679:+
THCA	cis	rs2274273	0.84	rs10136596	ENSG00000258413.1	RP11-665C16.6	-11.26	3.3e-26	3.33e-23	-0.61	-0.46	Protein biomarker;	chr14:55370055	chr14:55262767~55272075:-
THCA	cis	rs10463554	0.963	rs17154959	ENSG00000175749.11	EIF3KP1	11.26	3.31e-26	3.34e-23	0.6	0.46	Parkinson's disease;	chr5:103020587	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.837	rs56949365	ENSG00000258413.1	RP11-665C16.6	-11.26	3.32e-26	3.35e-23	-0.61	-0.46	Protein biomarker;	chr14:55323360	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs4496026	ENSG00000258413.1	RP11-665C16.6	-11.26	3.32e-26	3.35e-23	-0.61	-0.46	Protein biomarker;	chr14:55323794	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs4366639	ENSG00000258413.1	RP11-665C16.6	-11.26	3.32e-26	3.35e-23	-0.61	-0.46	Protein biomarker;	chr14:55323798	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs11625423	ENSG00000258413.1	RP11-665C16.6	-11.26	3.32e-26	3.35e-23	-0.61	-0.46	Protein biomarker;	chr14:55329195	chr14:55262767~55272075:-
THCA	cis	rs4591358	0.689	rs59639651	ENSG00000223466.1	AC064834.2	-11.26	3.32e-26	3.36e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544426	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs72927766	ENSG00000223466.1	AC064834.2	-11.26	3.32e-26	3.36e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545003	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs7580459	ENSG00000223466.1	AC064834.2	-11.26	3.32e-26	3.36e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545963	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs57555936	ENSG00000223466.1	AC064834.2	-11.26	3.32e-26	3.36e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546440	chr2:195533035~195538681:+
THCA	cis	rs3002131	0.688	rs3008650	ENSG00000225265.1	TAF1A-AS1	11.26	3.33e-26	3.36e-23	0.6	0.46	Interleukin-10 levels;	chr1:222589873	chr1:222589825~222593032:+
THCA	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-11.26	3.33e-26	3.37e-23	-0.56	-0.46	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
THCA	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-11.26	3.33e-26	3.37e-23	-0.61	-0.46	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
THCA	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-11.26	3.37e-26	3.41e-23	-0.49	-0.46	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
THCA	cis	rs11159086	0.793	rs17100414	ENSG00000270000.1	RP3-449M8.9	11.26	3.38e-26	3.42e-23	0.5	0.46	Advanced glycation end-product levels;	chr14:74467918	chr14:74471930~74472360:-
THCA	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.39e-26	3.42e-23	-0.56	-0.46	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.39e-26	3.42e-23	-0.56	-0.46	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-11.26	3.39e-26	3.42e-23	-0.56	-0.46	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
THCA	cis	rs2880765	0.566	rs17553249	ENSG00000259295.5	CSPG4P12	11.26	3.41e-26	3.44e-23	0.63	0.46	Coronary artery disease;	chr15:85463463	chr15:85191438~85213905:+
THCA	cis	rs10463554	0.963	rs34771	ENSG00000175749.11	EIF3KP1	11.26	3.42e-26	3.45e-23	0.6	0.46	Parkinson's disease;	chr5:103114713	chr5:103032376~103033031:+
THCA	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-11.26	3.43e-26	3.46e-23	-0.64	-0.46	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-11.26	3.43e-26	3.46e-23	-0.64	-0.46	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
THCA	cis	rs7772486	0.875	rs10457796	ENSG00000235652.6	RP11-545I5.3	11.26	3.44e-26	3.47e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146094951	chr6:145799409~145886585:+
THCA	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	11.26	3.47e-26	3.5e-23	0.65	0.46	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
THCA	cis	rs6964833	1	rs13227433	ENSG00000123965.13	PMS2P5	11.26	3.48e-26	3.52e-23	0.79	0.46	Menarche (age at onset);	chr7:74680386	chr7:74894116~74897835:+
THCA	cis	rs875971	1	rs2220626	ENSG00000237310.1	GS1-124K5.4	-11.25	3.55e-26	3.58e-23	-0.35	-0.46	Aortic root size;	chr7:66081075	chr7:66493706~66495474:+
THCA	cis	rs4591358	0.689	rs34373729	ENSG00000223466.1	AC064834.2	-11.25	3.61e-26	3.64e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195543775	chr2:195533035~195538681:+
THCA	cis	rs8100891	0.506	rs10408437	ENSG00000267213.4	AC007773.2	-11.25	3.62e-26	3.65e-23	-0.55	-0.46	Neuroticism;	chr19:32497094	chr19:32390050~32405560:-
THCA	cis	rs4591358	0.689	rs16837051	ENSG00000223466.1	AC064834.2	-11.25	3.62e-26	3.65e-23	-0.67	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195536281	chr2:195533035~195538681:+
THCA	cis	rs8072100	0.84	rs12453233	ENSG00000228782.6	CTD-2026D20.3	11.25	3.63e-26	3.66e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377204	chr17:47450568~47492492:-
THCA	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-11.25	3.66e-26	3.68e-23	-0.79	-0.46	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
THCA	cis	rs853679	0.506	rs1150693	ENSG00000280107.1	AL022393.9	-11.25	3.66e-26	3.69e-23	-0.56	-0.46	Depression;	chr6:28206812	chr6:28170845~28172521:+
THCA	cis	rs1075265	0.933	rs918357	ENSG00000233266.1	HMGB1P31	11.25	3.69e-26	3.71e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54108826	chr2:54051334~54051760:+
THCA	cis	rs638893	0.853	rs4938549	ENSG00000278376.1	RP11-158I9.8	-11.25	3.71e-26	3.74e-23	-0.49	-0.46	Vitiligo;	chr11:118830888	chr11:118791254~118793137:+
THCA	cis	rs2274273	0.805	rs60972460	ENSG00000258413.1	RP11-665C16.6	-11.25	3.73e-26	3.75e-23	-0.59	-0.46	Protein biomarker;	chr14:55105055	chr14:55262767~55272075:-
THCA	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-11.25	3.76e-26	3.78e-23	-0.43	-0.46	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
THCA	cis	rs9322193	0.961	rs9285521	ENSG00000223701.3	RAET1E-AS1	11.25	3.76e-26	3.79e-23	0.63	0.46	Lung cancer;	chr6:149585576	chr6:149884431~149919508:+
THCA	cis	rs2283792	0.765	rs9607298	ENSG00000224086.5	LL22NC03-86G7.1	-11.25	3.78e-26	3.81e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21829844	chr22:21938293~21977632:+
THCA	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	11.25	3.79e-26	3.82e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
THCA	cis	rs6538678	0.777	rs10745736	ENSG00000258343.1	RP11-536G4.2	-11.25	3.8e-26	3.83e-23	-0.68	-0.46	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95795345~95858839:-
THCA	cis	rs228614	0.51	rs223452	ENSG00000246560.2	RP11-10L12.4	11.25	3.8e-26	3.83e-23	0.59	0.46	Primary sclerosing cholangitis;Multiple sclerosis;	chr4:102790277	chr4:102828055~102844075:+
THCA	cis	rs4819052	0.851	rs10470246	ENSG00000223768.1	LINC00205	-11.25	3.81e-26	3.83e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs10470247	ENSG00000223768.1	LINC00205	-11.25	3.81e-26	3.83e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819043	ENSG00000223768.1	LINC00205	-11.25	3.81e-26	3.83e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs4819044	ENSG00000223768.1	LINC00205	-11.25	3.81e-26	3.83e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.875	rs1331644	ENSG00000235652.6	RP11-545I5.3	11.25	3.82e-26	3.84e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146077524	chr6:145799409~145886585:+
THCA	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	11.24	3.82e-26	3.85e-23	0.53	0.46	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	11.24	3.82e-26	3.85e-23	0.53	0.46	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	11.24	3.82e-26	3.85e-23	0.53	0.46	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	11.24	3.82e-26	3.85e-23	0.53	0.46	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	11.24	3.82e-26	3.85e-23	0.53	0.46	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
THCA	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-11.24	3.83e-26	3.86e-23	-0.57	-0.46	Height;	chr3:53084188	chr3:53064283~53065091:-
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	11.24	3.84e-26	3.86e-23	0.59	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
THCA	cis	rs367615	0.506	rs2963021	ENSG00000249476.1	CTD-2587M2.1	11.24	3.91e-26	3.93e-23	0.48	0.46	Colorectal cancer (SNP x SNP interaction);	chr5:109464664	chr5:109237120~109326369:-
THCA	cis	rs494459	0.733	rs556437	ENSG00000255239.1	AP002954.6	11.24	3.92e-26	3.95e-23	0.57	0.46	Height;	chr11:118835044	chr11:118688039~118690600:-
THCA	cis	rs875971	0.964	rs697969	ENSG00000237310.1	GS1-124K5.4	-11.24	3.95e-26	3.97e-23	-0.34	-0.46	Aortic root size;	chr7:66093491	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs1182882	ENSG00000237310.1	GS1-124K5.4	-11.24	3.95e-26	3.97e-23	-0.34	-0.46	Aortic root size;	chr7:66097076	chr7:66493706~66495474:+
THCA	cis	rs11214589	0.747	rs1893695	ENSG00000270179.1	RP11-159N11.4	-11.24	3.96e-26	3.98e-23	-0.5	-0.46	Neuroticism;	chr11:113335363	chr11:113368478~113369117:+
THCA	cis	rs11214589	0.747	rs2155462	ENSG00000270179.1	RP11-159N11.4	-11.24	3.96e-26	3.98e-23	-0.5	-0.46	Neuroticism;	chr11:113336077	chr11:113368478~113369117:+
THCA	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-11.24	3.99e-26	4.01e-23	-0.51	-0.46	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-11.24	3.99e-26	4.01e-23	-0.51	-0.46	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
THCA	cis	rs12468226	0.938	rs55668474	ENSG00000273456.1	RP11-686O6.2	11.24	3.99e-26	4.01e-23	0.52	0.46	Urate levels;	chr2:202265559	chr2:202374932~202375604:-
THCA	cis	rs11690935	0.959	rs6738445	ENSG00000228389.1	AC068039.4	-11.24	3.99e-26	4.01e-23	-0.54	-0.46	Schizophrenia;	chr2:171743105	chr2:171773482~171775844:+
THCA	cis	rs765787	0.53	rs11070444	ENSG00000259520.4	CTD-2651B20.3	-11.24	4.01e-26	4.03e-23	-0.56	-0.46	Uric acid levels;	chr15:45220923	chr15:45251580~45279251:-
THCA	cis	rs765787	0.53	rs11070445	ENSG00000259520.4	CTD-2651B20.3	-11.24	4.01e-26	4.03e-23	-0.56	-0.46	Uric acid levels;	chr15:45220965	chr15:45251580~45279251:-
THCA	cis	rs2274273	0.905	rs2147961	ENSG00000258413.1	RP11-665C16.6	-11.24	4.01e-26	4.03e-23	-0.59	-0.46	Protein biomarker;	chr14:55118663	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.962	rs7740784	ENSG00000223701.3	RAET1E-AS1	11.24	4.06e-26	4.08e-23	0.64	0.46	Lung cancer;	chr6:149833364	chr6:149884431~149919508:+
THCA	cis	rs12022452	0.73	rs2297755	ENSG00000238287.1	RP11-656D10.3	-11.24	4.06e-26	4.08e-23	-0.72	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:40493157~40508661:-
THCA	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-11.24	4.08e-26	4.1e-23	-0.61	-0.46	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
THCA	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-11.24	4.09e-26	4.11e-23	-0.53	-0.46	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
THCA	cis	rs6964833	1	rs13227433	ENSG00000277053.3	GTF2IP1	-11.24	4.09e-26	4.11e-23	-0.62	-0.46	Menarche (age at onset);	chr7:74680386	chr7:75185385~75237696:-
THCA	cis	rs950169	1	rs11638394	ENSG00000225151.9	GOLGA2P7	-11.24	4.14e-26	4.16e-23	-0.68	-0.46	Schizophrenia;	chr15:84110176	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs35658069	ENSG00000225151.9	GOLGA2P7	-11.24	4.14e-26	4.16e-23	-0.68	-0.46	Schizophrenia;	chr15:84111394	chr15:84199311~84230136:-
THCA	cis	rs638893	1	rs649338	ENSG00000278376.1	RP11-158I9.8	-11.24	4.16e-26	4.18e-23	-0.49	-0.46	Vitiligo;	chr11:118834945	chr11:118791254~118793137:+
THCA	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-11.24	4.16e-26	4.18e-23	-0.56	-0.46	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
THCA	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-11.24	4.16e-26	4.18e-23	-0.53	-0.46	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
THCA	cis	rs4853012	0.539	rs9789534	ENSG00000257800.1	FNBP1P1	11.24	4.17e-26	4.19e-23	0.42	0.46	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74120680~74123218:+
THCA	cis	rs2274273	0.87	rs7153612	ENSG00000258413.1	RP11-665C16.6	-11.23	4.18e-26	4.2e-23	-0.61	-0.46	Protein biomarker;	chr14:55322044	chr14:55262767~55272075:-
THCA	cis	rs367615	0.506	rs1428932	ENSG00000249476.1	CTD-2587M2.1	-11.23	4.2e-26	4.22e-23	-0.48	-0.46	Colorectal cancer (SNP x SNP interaction);	chr5:109456778	chr5:109237120~109326369:-
THCA	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	11.23	4.21e-26	4.22e-23	0.38	0.46	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.866	rs9826419	ENSG00000223797.4	ENTPD3-AS1	11.23	4.21e-26	4.22e-23	0.38	0.46	Renal cell carcinoma;	chr3:40310560	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.866	rs3214006	ENSG00000223797.4	ENTPD3-AS1	11.23	4.21e-26	4.22e-23	0.38	0.46	Renal cell carcinoma;	chr3:40310643	chr3:40313802~40453329:-
THCA	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-11.23	4.21e-26	4.23e-23	-0.6	-0.46	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs62364875	ENSG00000175749.11	EIF3KP1	11.23	4.23e-26	4.24e-23	0.6	0.46	Parkinson's disease;	chr5:103056486	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.935	rs8004787	ENSG00000258413.1	RP11-665C16.6	-11.23	4.28e-26	4.29e-23	-0.6	-0.46	Protein biomarker;	chr14:55140648	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.905	rs2075601	ENSG00000258413.1	RP11-665C16.6	-11.23	4.28e-26	4.29e-23	-0.6	-0.46	Protein biomarker;	chr14:55142516	chr14:55262767~55272075:-
THCA	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-11.23	4.28e-26	4.3e-23	-0.55	-0.46	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
THCA	cis	rs8072100	0.84	rs9900360	ENSG00000228782.6	CTD-2026D20.3	11.23	4.29e-26	4.31e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47414613	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.84	rs56952963	ENSG00000228782.6	CTD-2026D20.3	11.23	4.29e-26	4.31e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47416460	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.84	rs1912482	ENSG00000228782.6	CTD-2026D20.3	11.23	4.3e-26	4.32e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47377517	chr17:47450568~47492492:-
THCA	cis	rs4819052	1	rs2838847	ENSG00000223768.1	LINC00205	-11.23	4.38e-26	4.39e-23	-0.46	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45293285~45297354:+
THCA	cis	rs2283792	0.765	rs2266966	ENSG00000224086.5	LL22NC03-86G7.1	-11.23	4.4e-26	4.41e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21767265	chr22:21938293~21977632:+
THCA	cis	rs9659323	0.613	rs72705339	ENSG00000231365.4	RP11-418J17.1	-11.23	4.41e-26	4.42e-23	-0.49	-0.46	Body mass index;	chr1:118929246	chr1:119140396~119275973:+
THCA	cis	rs6558530	0.64	rs7844748	ENSG00000253982.1	CTD-2336O2.1	-11.23	4.44e-26	4.45e-23	-0.45	-0.46	Systolic blood pressure;	chr8:1754177	chr8:1761990~1764502:-
THCA	cis	rs2455601	1	rs2455601	ENSG00000254860.4	TMEM9B-AS1	11.23	4.45e-26	4.46e-23	0.66	0.46	Schizophrenia;	chr11:8877853	chr11:8964675~8977527:+
THCA	cis	rs4591358	0.689	rs2889034	ENSG00000223466.1	AC064834.2	-11.23	4.46e-26	4.47e-23	-0.65	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548022	chr2:195533035~195538681:+
THCA	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	11.23	4.46e-26	4.47e-23	0.56	0.46	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	11.23	4.46e-26	4.47e-23	0.56	0.46	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
THCA	cis	rs9928842	0.771	rs2870471	ENSG00000280152.1	RP11-331F4.5	-11.23	4.49e-26	4.49e-23	-0.61	-0.46	Alcoholic chronic pancreatitis;	chr16:75240384	chr16:75245994~75250077:-
THCA	cis	rs9659323	0.689	rs10923716	ENSG00000231365.4	RP11-418J17.1	-11.23	4.5e-26	4.5e-23	-0.49	-0.46	Body mass index;	chr1:118993496	chr1:119140396~119275973:+
THCA	cis	rs9322193	0.923	rs9688452	ENSG00000223701.3	RAET1E-AS1	11.23	4.51e-26	4.52e-23	0.63	0.46	Lung cancer;	chr6:149658764	chr6:149884431~149919508:+
THCA	cis	rs526231	0.511	rs7731395	ENSG00000175749.11	EIF3KP1	11.23	4.52e-26	4.53e-23	0.6	0.46	Primary biliary cholangitis;	chr5:103026057	chr5:103032376~103033031:+
THCA	cis	rs2283792	0.765	rs2266969	ENSG00000224086.5	LL22NC03-86G7.1	-11.23	4.52e-26	4.53e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21819618	chr22:21938293~21977632:+
THCA	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-11.23	4.53e-26	4.54e-23	-0.53	-0.46	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-11.23	4.53e-26	4.54e-23	-0.53	-0.46	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
THCA	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-11.23	4.54e-26	4.54e-23	-0.57	-0.46	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
THCA	cis	rs9903692	0.954	rs8080662	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48113457	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.789	rs12601675	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48113566	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.754	rs12602948	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48113567	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.908	rs8066391	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48117934	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.908	rs11079809	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48120859	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs3744346	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48121514	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.908	rs7222136	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48122230	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs1010228	ENSG00000278765.1	RP5-890E16.5	-11.23	4.56e-26	4.57e-23	-0.6	-0.46	Pulse pressure;	chr17:48122986	chr17:48066704~48067293:-
THCA	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-11.22	4.58e-26	4.59e-23	-0.35	-0.46	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
THCA	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-11.22	4.58e-26	4.59e-23	-0.35	-0.46	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-11.22	4.58e-26	4.59e-23	-0.35	-0.46	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
THCA	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-11.22	4.58e-26	4.59e-23	-0.35	-0.46	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
THCA	cis	rs7301826	0.651	rs2277336	ENSG00000256250.1	RP11-989F5.1	11.22	4.58e-26	4.59e-23	0.56	0.46	Plasma plasminogen activator levels;	chr12:130801574	chr12:130810606~130812438:+
THCA	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	11.22	4.58e-26	4.59e-23	0.8	0.46	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
THCA	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	11.22	4.58e-26	4.59e-23	0.8	0.46	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
THCA	cis	rs4819052	0.807	rs7283915	ENSG00000223768.1	LINC00205	-11.22	4.61e-26	4.62e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2838850	ENSG00000223768.1	LINC00205	-11.22	4.61e-26	4.62e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs8130285	ENSG00000223768.1	LINC00205	-11.22	4.61e-26	4.62e-23	-0.43	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45293285~45297354:+
THCA	cis	rs6570726	0.599	rs426371	ENSG00000235652.6	RP11-545I5.3	-11.22	4.62e-26	4.62e-23	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145565333	chr6:145799409~145886585:+
THCA	cis	rs638893	0.898	rs530646	ENSG00000278376.1	RP11-158I9.8	-11.22	4.71e-26	4.71e-23	-0.49	-0.46	Vitiligo;	chr11:118830959	chr11:118791254~118793137:+
THCA	cis	rs638893	0.947	rs12808822	ENSG00000278376.1	RP11-158I9.8	-11.22	4.71e-26	4.71e-23	-0.49	-0.46	Vitiligo;	chr11:118831560	chr11:118791254~118793137:+
THCA	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-11.22	4.73e-26	4.73e-23	-0.47	-0.46	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
THCA	cis	rs11098499	0.562	rs58583086	ENSG00000245958.5	RP11-33B1.1	11.22	4.75e-26	4.75e-23	0.42	0.46	Corneal astigmatism;	chr4:119635207	chr4:119454791~119552025:+
THCA	cis	rs7772486	0.875	rs1331645	ENSG00000235652.6	RP11-545I5.3	11.22	4.78e-26	4.78e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146077271	chr6:145799409~145886585:+
THCA	cis	rs2283792	0.765	rs9610338	ENSG00000224086.5	LL22NC03-86G7.1	11.22	4.78e-26	4.78e-23	0.55	0.46	Multiple sclerosis;	chr22:21797532	chr22:21938293~21977632:+
THCA	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-11.22	4.78e-26	4.78e-23	-0.43	-0.46	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
THCA	cis	rs7221109	0.677	rs3752026	ENSG00000278834.1	RP11-458J1.1	11.22	4.86e-26	4.85e-23	0.49	0.46	Type 1 diabetes;	chr17:40648309	chr17:40648300~40649718:+
THCA	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-11.22	4.88e-26	4.87e-23	-0.47	-0.46	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
THCA	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	11.22	4.99e-26	4.98e-23	0.87	0.46	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
THCA	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	11.22	4.99e-26	4.99e-23	0.53	0.46	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
THCA	cis	rs4819052	0.851	rs2838866	ENSG00000223768.1	LINC00205	-11.21	5.01e-26	5e-23	-0.44	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45293285~45297354:+
THCA	cis	rs6570726	0.599	rs9376951	ENSG00000235652.6	RP11-545I5.3	11.21	5.03e-26	5.02e-23	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145577775	chr6:145799409~145886585:+
THCA	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-11.21	5.04e-26	5.03e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-11.21	5.04e-26	5.03e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-11.21	5.04e-26	5.03e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
THCA	cis	rs526231	0.578	rs42860	ENSG00000175749.11	EIF3KP1	11.21	5.05e-26	5.04e-23	0.6	0.46	Primary biliary cholangitis;	chr5:103092414	chr5:103032376~103033031:+
THCA	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	11.21	5.06e-26	5.05e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
THCA	cis	rs9322193	0.923	rs55849538	ENSG00000223701.3	RAET1E-AS1	11.21	5.06e-26	5.05e-23	0.63	0.46	Lung cancer;	chr6:149635330	chr6:149884431~149919508:+
THCA	cis	rs4660456	0.913	rs12743517	ENSG00000237899.1	RP4-739H11.3	11.21	5.09e-26	5.08e-23	0.59	0.46	Platelet count;	chr1:40759682	chr1:40669089~40687588:-
THCA	cis	rs9322193	0.886	rs2065663	ENSG00000223701.3	RAET1E-AS1	11.21	5.11e-26	5.1e-23	0.63	0.46	Lung cancer;	chr6:149760331	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs12205092	ENSG00000223701.3	RAET1E-AS1	11.21	5.11e-26	5.1e-23	0.63	0.46	Lung cancer;	chr6:149761375	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10872651	ENSG00000223701.3	RAET1E-AS1	11.21	5.11e-26	5.1e-23	0.63	0.46	Lung cancer;	chr6:149768273	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.599	rs455001	ENSG00000235652.6	RP11-545I5.3	11.21	5.15e-26	5.14e-23	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145533314	chr6:145799409~145886585:+
THCA	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	11.21	5.17e-26	5.16e-23	0.38	0.46	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
THCA	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	11.21	5.23e-26	5.21e-23	0.53	0.46	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
THCA	cis	rs6964833	1	rs35203738	ENSG00000123965.13	PMS2P5	11.21	5.25e-26	5.24e-23	0.79	0.46	Menarche (age at onset);	chr7:74690864	chr7:74894116~74897835:+
THCA	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	11.21	5.29e-26	5.27e-23	0.56	0.46	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
THCA	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	11.21	5.31e-26	5.29e-23	0.89	0.46	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
THCA	cis	rs11159086	0.793	rs1029703	ENSG00000270000.1	RP3-449M8.9	11.21	5.37e-26	5.35e-23	0.5	0.46	Advanced glycation end-product levels;	chr14:74473899	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs1029702	ENSG00000270000.1	RP3-449M8.9	11.21	5.37e-26	5.35e-23	0.5	0.46	Advanced glycation end-product levels;	chr14:74473909	chr14:74471930~74472360:-
THCA	cis	rs638893	1	rs636736	ENSG00000278376.1	RP11-158I9.8	-11.21	5.37e-26	5.35e-23	-0.48	-0.46	Vitiligo;	chr11:118834436	chr11:118791254~118793137:+
THCA	cis	rs4591358	0.689	rs59017643	ENSG00000223466.1	AC064834.2	-11.21	5.37e-26	5.35e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546835	chr2:195533035~195538681:+
THCA	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-11.21	5.39e-26	5.37e-23	-0.52	-0.46	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-11.21	5.39e-26	5.37e-23	-0.52	-0.46	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
THCA	cis	rs6558530	0.666	rs28376731	ENSG00000253982.1	CTD-2336O2.1	11.21	5.39e-26	5.37e-23	0.44	0.46	Systolic blood pressure;	chr8:1748086	chr8:1761990~1764502:-
THCA	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	11.21	5.41e-26	5.39e-23	0.51	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
THCA	cis	rs8100891	0.537	rs10409835	ENSG00000267213.4	AC007773.2	-11.21	5.42e-26	5.4e-23	-0.53	-0.46	Neuroticism;	chr19:32397754	chr19:32390050~32405560:-
THCA	cis	rs10463554	0.963	rs6596530	ENSG00000175749.11	EIF3KP1	11.21	5.42e-26	5.4e-23	0.6	0.46	Parkinson's disease;	chr5:103035736	chr5:103032376~103033031:+
THCA	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-11.2	5.54e-26	5.51e-23	-0.56	-0.46	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
THCA	cis	rs600231	0.651	rs2846862	ENSG00000245532.5	NEAT1	11.2	5.57e-26	5.54e-23	0.31	0.46	Bone mineral density;	chr11:65452319	chr11:65422774~65445540:+
THCA	cis	rs6142102	0.923	rs4911379	ENSG00000276073.1	RP5-1125A11.7	-11.2	5.61e-26	5.58e-23	-0.42	-0.46	Skin pigmentation;	chr20:33947499	chr20:33985617~33988989:-
THCA	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	11.2	5.62e-26	5.59e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	11.2	5.62e-26	5.59e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
THCA	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	11.2	5.68e-26	5.65e-23	0.39	0.46	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
THCA	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	11.2	5.71e-26	5.67e-23	0.67	0.46	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
THCA	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	11.2	5.73e-26	5.7e-23	0.58	0.46	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
THCA	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	11.2	5.74e-26	5.7e-23	0.6	0.46	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
THCA	cis	rs9532669	0.889	rs6560964	ENSG00000176268.5	CYCSP34	11.2	5.76e-26	5.72e-23	0.53	0.46	Cervical cancer;	chr13:40871132	chr13:40863599~40863902:-
THCA	cis	rs801193	0.66	rs2659897	ENSG00000237310.1	GS1-124K5.4	-11.2	5.76e-26	5.72e-23	-0.33	-0.46	Aortic root size;	chr7:66722728	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	11.2	5.82e-26	5.79e-23	0.5	0.46	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
THCA	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	11.2	5.83e-26	5.79e-23	0.5	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
THCA	cis	rs2880765	0.566	rs11630381	ENSG00000259295.5	CSPG4P12	11.2	5.83e-26	5.79e-23	0.63	0.46	Coronary artery disease;	chr15:85469272	chr15:85191438~85213905:+
THCA	cis	rs2880765	0.545	rs11631739	ENSG00000259295.5	CSPG4P12	11.2	5.83e-26	5.79e-23	0.63	0.46	Coronary artery disease;	chr15:85469347	chr15:85191438~85213905:+
THCA	cis	rs4819052	1	rs733739	ENSG00000223768.1	LINC00205	-11.2	5.87e-26	5.83e-23	-0.46	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45293285~45297354:+
THCA	cis	rs875971	0.825	rs59466412	ENSG00000237310.1	GS1-124K5.4	-11.2	5.88e-26	5.84e-23	-0.35	-0.46	Aortic root size;	chr7:66100371	chr7:66493706~66495474:+
THCA	cis	rs10463554	0.927	rs7717343	ENSG00000175749.11	EIF3KP1	11.2	5.89e-26	5.85e-23	0.6	0.46	Parkinson's disease;	chr5:103026279	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs7721530	ENSG00000175749.11	EIF3KP1	11.2	5.89e-26	5.85e-23	0.6	0.46	Parkinson's disease;	chr5:103026488	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.87	rs59629906	ENSG00000258413.1	RP11-665C16.6	-11.2	5.93e-26	5.89e-23	-0.6	-0.46	Protein biomarker;	chr14:55314471	chr14:55262767~55272075:-
THCA	cis	rs950169	1	rs35297609	ENSG00000225151.9	GOLGA2P7	-11.2	5.95e-26	5.91e-23	-0.68	-0.46	Schizophrenia;	chr15:84104144	chr15:84199311~84230136:-
THCA	cis	rs9659323	0.65	rs12066653	ENSG00000231365.4	RP11-418J17.1	-11.2	5.96e-26	5.92e-23	-0.49	-0.46	Body mass index;	chr1:118939885	chr1:119140396~119275973:+
THCA	cis	rs9903692	0.954	rs8065670	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48096478	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.908	rs12950402	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48102752	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs11079808	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48102870	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs4794448	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48103445	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs68175794	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48103742	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.862	rs12943543	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48104003	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs4794451	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48107419	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.862	rs4794453	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48107564	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs8077860	ENSG00000278765.1	RP5-890E16.5	-11.2	5.96e-26	5.92e-23	-0.6	-0.46	Pulse pressure;	chr17:48107973	chr17:48066704~48067293:-
THCA	cis	rs10463554	0.963	rs26821	ENSG00000175749.11	EIF3KP1	11.19	5.97e-26	5.93e-23	0.59	0.46	Parkinson's disease;	chr5:103184699	chr5:103032376~103033031:+
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000235689.1	AP000351.13	11.19	5.98e-26	5.93e-23	0.58	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:24006305~24008258:-
THCA	cis	rs10463554	0.927	rs34820	ENSG00000175749.11	EIF3KP1	11.19	6.01e-26	5.96e-23	0.59	0.46	Parkinson's disease;	chr5:103101164	chr5:103032376~103033031:+
THCA	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-11.19	6.01e-26	5.97e-23	-0.53	-0.46	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
THCA	cis	rs3762637	0.882	rs9856011	ENSG00000272758.4	RP11-299J3.8	-11.19	6.03e-26	5.99e-23	-0.61	-0.46	LDL cholesterol levels;	chr3:122374723	chr3:122416207~122443180:+
THCA	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-11.19	6.03e-26	5.99e-23	-0.59	-0.46	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
THCA	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	11.19	6.04e-26	5.99e-23	0.56	0.46	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	11.19	6.04e-26	5.99e-23	0.56	0.46	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	11.19	6.04e-26	5.99e-23	0.56	0.46	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	11.19	6.04e-26	5.99e-23	0.56	0.46	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
THCA	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-11.19	6.09e-26	6.04e-23	-0.49	-0.46	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000235689.1	AP000351.13	11.19	6.1e-26	6.05e-23	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:24006305~24008258:-
THCA	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	11.19	6.16e-26	6.11e-23	0.86	0.46	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	11.19	6.16e-26	6.11e-23	0.86	0.46	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
THCA	cis	rs9322193	0.607	rs3798763	ENSG00000223701.3	RAET1E-AS1	11.19	6.19e-26	6.14e-23	0.66	0.46	Lung cancer;	chr6:149889964	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.607	rs12204653	ENSG00000223701.3	RAET1E-AS1	11.19	6.19e-26	6.14e-23	0.66	0.46	Lung cancer;	chr6:149891885	chr6:149884431~149919508:+
THCA	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	11.19	6.2e-26	6.15e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	11.19	6.2e-26	6.15e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	11.19	6.2e-26	6.15e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	11.19	6.2e-26	6.15e-23	0.64	0.46	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	11.19	6.24e-26	6.18e-23	0.59	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	11.19	6.24e-26	6.18e-23	0.59	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
THCA	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-11.19	6.24e-26	6.19e-23	-0.56	-0.46	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
THCA	cis	rs6558530	0.579	rs6558528	ENSG00000253982.1	CTD-2336O2.1	11.19	6.25e-26	6.2e-23	0.43	0.46	Systolic blood pressure;	chr8:1754897	chr8:1761990~1764502:-
THCA	cis	rs765787	0.53	rs12323957	ENSG00000259520.4	CTD-2651B20.3	-11.19	6.28e-26	6.22e-23	-0.56	-0.46	Uric acid levels;	chr15:45198575	chr15:45251580~45279251:-
THCA	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	11.19	6.3e-26	6.24e-23	0.57	0.46	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	11.19	6.3e-26	6.24e-23	0.57	0.46	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
THCA	cis	rs2274273	0.87	rs1952087	ENSG00000258413.1	RP11-665C16.6	-11.19	6.33e-26	6.27e-23	-0.6	-0.46	Protein biomarker;	chr14:55216493	chr14:55262767~55272075:-
THCA	cis	rs10463554	0.927	rs34806	ENSG00000175749.11	EIF3KP1	11.19	6.35e-26	6.29e-23	0.6	0.46	Parkinson's disease;	chr5:103092733	chr5:103032376~103033031:+
THCA	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	11.19	6.38e-26	6.32e-23	0.56	0.46	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-11.19	6.43e-26	6.37e-23	-0.57	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
THCA	cis	rs9322193	0.884	rs7744105	ENSG00000268592.3	RAET1E-AS1	11.19	6.46e-26	6.39e-23	0.62	0.46	Lung cancer;	chr6:149849308	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.607	rs4869755	ENSG00000223701.3	RAET1E-AS1	11.19	6.5e-26	6.43e-23	0.66	0.46	Lung cancer;	chr6:149886347	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.639	rs4869756	ENSG00000223701.3	RAET1E-AS1	11.19	6.5e-26	6.43e-23	0.66	0.46	Lung cancer;	chr6:149886360	chr6:149884431~149919508:+
THCA	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	11.18	6.56e-26	6.49e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
THCA	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	11.18	6.59e-26	6.52e-23	0.56	0.46	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
THCA	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	11.18	6.61e-26	6.54e-23	0.56	0.46	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
THCA	cis	rs2283792	0.765	rs9340	ENSG00000224086.5	LL22NC03-86G7.1	-11.18	6.61e-26	6.54e-23	-0.54	-0.46	Multiple sclerosis;	chr22:21761064	chr22:21938293~21977632:+
THCA	cis	rs2283792	0.765	rs1063311	ENSG00000224086.5	LL22NC03-86G7.1	-11.18	6.61e-26	6.54e-23	-0.54	-0.46	Multiple sclerosis;	chr22:21762178	chr22:21938293~21977632:+
THCA	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-11.18	6.62e-26	6.55e-23	-0.81	-0.46	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
THCA	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-11.18	6.62e-26	6.55e-23	-0.81	-0.46	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
THCA	cis	rs10463554	0.963	rs61418746	ENSG00000175749.11	EIF3KP1	11.18	6.63e-26	6.56e-23	0.6	0.46	Parkinson's disease;	chr5:103043914	chr5:103032376~103033031:+
THCA	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-11.18	6.67e-26	6.59e-23	-0.52	-0.46	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
THCA	cis	rs7569084	0.687	rs12993075	ENSG00000237979.1	AC007389.1	11.18	6.7e-26	6.63e-23	0.54	0.46	Sum eosinophil basophil counts;	chr2:65431010	chr2:65500993~65502138:-
THCA	cis	rs7772486	0.875	rs1125461	ENSG00000235652.6	RP11-545I5.3	11.18	6.76e-26	6.69e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146096517	chr6:145799409~145886585:+
THCA	cis	rs11676348	0.755	rs13410318	ENSG00000261338.2	RP11-378A13.1	11.18	6.78e-26	6.71e-23	0.47	0.46	Ulcerative colitis;	chr2:218158187	chr2:218255319~218257366:+
THCA	cis	rs6570726	0.577	rs441982	ENSG00000235652.6	RP11-545I5.3	11.18	6.79e-26	6.71e-23	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145521712	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.577	rs403345	ENSG00000235652.6	RP11-545I5.3	11.18	6.79e-26	6.71e-23	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145524035	chr6:145799409~145886585:+
THCA	cis	rs950169	0.887	rs220333	ENSG00000225151.9	GOLGA2P7	-11.18	6.79e-26	6.71e-23	-0.67	-0.46	Schizophrenia;	chr15:84547902	chr15:84199311~84230136:-
THCA	cis	rs4591358	0.689	rs72927760	ENSG00000223466.1	AC064834.2	-11.18	6.81e-26	6.74e-23	-0.68	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544584	chr2:195533035~195538681:+
THCA	cis	rs860295	0.702	rs10796946	ENSG00000225855.5	RUSC1-AS1	11.18	6.83e-26	6.76e-23	0.32	0.46	Body mass index;	chr1:155459699	chr1:155316863~155324176:-
THCA	cis	rs860295	0.676	rs10908466	ENSG00000225855.5	RUSC1-AS1	11.18	6.83e-26	6.76e-23	0.32	0.46	Body mass index;	chr1:155459934	chr1:155316863~155324176:-
THCA	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	11.18	6.92e-26	6.84e-23	0.56	0.46	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
THCA	cis	rs6570726	0.557	rs403956	ENSG00000235652.6	RP11-545I5.3	11.18	7.04e-26	6.95e-23	0.47	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145508820	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	11.18	7.05e-26	6.96e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
THCA	cis	rs9903692	0.909	rs8078125	ENSG00000278765.1	RP5-890E16.5	11.18	7.05e-26	6.97e-23	0.6	0.46	Pulse pressure;	chr17:48068347	chr17:48066704~48067293:-
THCA	cis	rs2111504	0.887	rs68013007	ENSG00000267213.4	AC007773.2	-11.18	7.09e-26	7e-23	-0.54	-0.46	Bipolar disorder;	chr19:32447775	chr19:32390050~32405560:-
THCA	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	11.17	7.15e-26	7.06e-23	0.53	0.46	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
THCA	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-11.17	7.19e-26	7.1e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
THCA	cis	rs10463554	0.927	rs34811	ENSG00000175749.11	EIF3KP1	11.17	7.21e-26	7.11e-23	0.6	0.46	Parkinson's disease;	chr5:103096117	chr5:103032376~103033031:+
THCA	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	11.17	7.22e-26	7.13e-23	0.87	0.46	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
THCA	cis	rs12468226	0.938	rs55681656	ENSG00000273456.1	RP11-686O6.2	11.17	7.3e-26	7.21e-23	0.52	0.46	Urate levels;	chr2:202319041	chr2:202374932~202375604:-
THCA	cis	rs950169	1	rs62026530	ENSG00000225151.9	GOLGA2P7	-11.17	7.31e-26	7.21e-23	-0.68	-0.46	Schizophrenia;	chr15:84107088	chr15:84199311~84230136:-
THCA	cis	rs11676348	0.755	rs62183956	ENSG00000261338.2	RP11-378A13.1	11.17	7.36e-26	7.26e-23	0.47	0.46	Ulcerative colitis;	chr2:218181399	chr2:218255319~218257366:+
THCA	cis	rs7772486	0.875	rs9399573	ENSG00000235652.6	RP11-545I5.3	11.17	7.47e-26	7.37e-23	0.41	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146082119	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.846	rs6908063	ENSG00000235652.6	RP11-545I5.3	11.17	7.47e-26	7.37e-23	0.41	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146082482	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs13204280	ENSG00000235652.6	RP11-545I5.3	11.17	7.47e-26	7.37e-23	0.41	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146094232	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.933	rs11888384	ENSG00000233266.1	HMGB1P31	11.17	7.51e-26	7.4e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54110984	chr2:54051334~54051760:+
THCA	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	11.17	7.57e-26	7.46e-23	0.8	0.46	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
THCA	cis	rs11098499	0.562	rs13101722	ENSG00000245958.5	RP11-33B1.1	11.17	7.6e-26	7.49e-23	0.42	0.46	Corneal astigmatism;	chr4:119634820	chr4:119454791~119552025:+
THCA	cis	rs916888	0.773	rs199534	ENSG00000232300.1	FAM215B	11.17	7.62e-26	7.51e-23	0.75	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46558830~46562795:-
THCA	cis	rs2283792	0.715	rs56036797	ENSG00000224086.5	LL22NC03-86G7.1	-11.17	7.64e-26	7.53e-23	-0.55	-0.46	Multiple sclerosis;	chr22:21860875	chr22:21938293~21977632:+
THCA	cis	rs9322193	0.923	rs10782316	ENSG00000223701.3	RAET1E-AS1	11.17	7.64e-26	7.53e-23	0.61	0.46	Lung cancer;	chr6:149752755	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs11155677	ENSG00000223701.3	RAET1E-AS1	11.17	7.64e-26	7.53e-23	0.61	0.46	Lung cancer;	chr6:149756953	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs9480009	ENSG00000223701.3	RAET1E-AS1	11.17	7.64e-26	7.53e-23	0.61	0.46	Lung cancer;	chr6:149758502	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9480031	ENSG00000223701.3	RAET1E-AS1	11.17	7.64e-26	7.53e-23	0.61	0.46	Lung cancer;	chr6:149758875	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10872649	ENSG00000223701.3	RAET1E-AS1	11.17	7.64e-26	7.53e-23	0.61	0.46	Lung cancer;	chr6:149759454	chr6:149884431~149919508:+
THCA	cis	rs9903692	0.954	rs7212202	ENSG00000278765.1	RP5-890E16.5	11.17	7.66e-26	7.54e-23	0.6	0.46	Pulse pressure;	chr17:48055361	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs34750858	ENSG00000278765.1	RP5-890E16.5	11.17	7.66e-26	7.54e-23	0.6	0.46	Pulse pressure;	chr17:48055575	chr17:48066704~48067293:-
THCA	cis	rs2274273	0.84	rs10142448	ENSG00000258413.1	RP11-665C16.6	11.17	7.67e-26	7.56e-23	0.6	0.46	Protein biomarker;	chr14:55371390	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	11.17	7.69e-26	7.57e-23	0.54	0.46	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10872650	ENSG00000223701.3	RAET1E-AS1	11.17	7.69e-26	7.58e-23	0.61	0.46	Lung cancer;	chr6:149760959	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.875	rs2777483	ENSG00000235652.6	RP11-545I5.3	11.16	7.82e-26	7.7e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146008099	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2748485	ENSG00000235652.6	RP11-545I5.3	11.16	7.82e-26	7.7e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146011285	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2207785	ENSG00000235652.6	RP11-545I5.3	11.16	7.82e-26	7.7e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146011648	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.817	rs2748491	ENSG00000235652.6	RP11-545I5.3	11.16	7.83e-26	7.71e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146006623	chr6:145799409~145886585:+
THCA	cis	rs7221109	0.677	rs7219483	ENSG00000278834.1	RP11-458J1.1	11.16	7.85e-26	7.72e-23	0.49	0.46	Type 1 diabetes;	chr17:40651705	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.645	rs2014704	ENSG00000278834.1	RP11-458J1.1	11.16	7.85e-26	7.72e-23	0.49	0.46	Type 1 diabetes;	chr17:40651997	chr17:40648300~40649718:+
THCA	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-11.16	7.86e-26	7.73e-23	-0.94	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
THCA	cis	rs7221109	0.677	rs8068721	ENSG00000278834.1	RP11-458J1.1	11.16	7.89e-26	7.76e-23	0.48	0.46	Type 1 diabetes;	chr17:40657572	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.625	rs2008469	ENSG00000278834.1	RP11-458J1.1	11.16	7.89e-26	7.76e-23	0.48	0.46	Type 1 diabetes;	chr17:40660343	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.677	rs12943859	ENSG00000278834.1	RP11-458J1.1	11.16	7.89e-26	7.76e-23	0.48	0.46	Type 1 diabetes;	chr17:40661128	chr17:40648300~40649718:+
THCA	cis	rs2274273	0.967	rs8009670	ENSG00000258413.1	RP11-665C16.6	-11.16	7.98e-26	7.84e-23	-0.59	-0.46	Protein biomarker;	chr14:55116759	chr14:55262767~55272075:-
THCA	cis	rs4964805	0.913	rs11111793	ENSG00000257681.1	RP11-341G23.4	11.16	7.98e-26	7.85e-23	0.55	0.46	Attention deficit hyperactivity disorder;	chr12:103804340	chr12:103746315~103768858:-
THCA	cis	rs8072100	0.84	rs2136751	ENSG00000228782.6	CTD-2026D20.3	11.16	8e-26	7.87e-23	0.42	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47378727	chr17:47450568~47492492:-
THCA	cis	rs7772486	0.738	rs75288066	ENSG00000235652.6	RP11-545I5.3	11.16	8.07e-26	7.93e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145998250	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.713	rs79248977	ENSG00000235652.6	RP11-545I5.3	11.16	8.07e-26	7.93e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145998252	chr6:145799409~145886585:+
THCA	cis	rs673078	0.66	rs61943365	ENSG00000275759.1	RP11-131L12.3	-11.16	8.16e-26	8.02e-23	-0.59	-0.46	Glucose homeostasis traits;	chr12:118339166	chr12:118428281~118428870:+
THCA	cis	rs6964833	1	rs6964833	ENSG00000277053.3	GTF2IP1	-11.16	8.16e-26	8.02e-23	-0.62	-0.46	Menarche (age at onset);	chr7:74687575	chr7:75185385~75237696:-
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000231271.1	AP000350.8	11.16	8.19e-26	8.05e-23	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23949918~23954042:+
THCA	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	11.16	8.23e-26	8.08e-23	0.74	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
THCA	cis	rs7221109	0.585	rs6503547	ENSG00000278834.1	RP11-458J1.1	11.16	8.23e-26	8.09e-23	0.48	0.46	Type 1 diabetes;	chr17:40662956	chr17:40648300~40649718:+
THCA	cis	rs12468226	0.938	rs58834901	ENSG00000273456.1	RP11-686O6.2	11.16	8.25e-26	8.1e-23	0.52	0.46	Urate levels;	chr2:202288169	chr2:202374932~202375604:-
THCA	cis	rs6964833	1	rs35203738	ENSG00000277053.3	GTF2IP1	-11.16	8.25e-26	8.11e-23	-0.62	-0.46	Menarche (age at onset);	chr7:74690864	chr7:75185385~75237696:-
THCA	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-11.16	8.27e-26	8.12e-23	-0.58	-0.46	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-11.16	8.27e-26	8.12e-23	-0.58	-0.46	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
THCA	cis	rs10246939	0.544	rs12668089	ENSG00000228775.6	WEE2-AS1	11.16	8.28e-26	8.13e-23	0.55	0.46	Bitter taste perception;	chr7:141875111	chr7:141704338~141738346:-
THCA	cis	rs9659323	0.7	rs10923746	ENSG00000231365.4	RP11-418J17.1	-11.16	8.34e-26	8.19e-23	-0.46	-0.46	Body mass index;	chr1:119073655	chr1:119140396~119275973:+
THCA	cis	rs9903692	0.954	rs8076380	ENSG00000278765.1	RP5-890E16.5	-11.16	8.4e-26	8.24e-23	-0.6	-0.46	Pulse pressure;	chr17:48113028	chr17:48066704~48067293:-
THCA	cis	rs780096	0.546	rs6547626	ENSG00000234072.1	AC074117.10	-11.16	8.45e-26	8.29e-23	-0.36	-0.46	Total body bone mineral density;	chr2:27423903	chr2:27356246~27367622:+
THCA	cis	rs704795	0.867	rs7566052	ENSG00000234072.1	AC074117.10	-11.16	8.51e-26	8.35e-23	-0.36	-0.46	Menopause (age at onset);	chr2:27405768	chr2:27356246~27367622:+
THCA	cis	rs9903692	0.954	rs875066	ENSG00000278765.1	RP5-890E16.5	11.15	8.56e-26	8.4e-23	0.6	0.46	Pulse pressure;	chr17:48062370	chr17:48066704~48067293:-
THCA	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	11.15	8.59e-26	8.43e-23	0.86	0.46	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	11.15	8.59e-26	8.43e-23	0.86	0.46	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
THCA	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-11.15	8.59e-26	8.43e-23	-0.58	-0.46	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
THCA	cis	rs780096	0.546	rs1060525	ENSG00000234072.1	AC074117.10	-11.15	8.64e-26	8.47e-23	-0.36	-0.46	Total body bone mineral density;	chr2:27412715	chr2:27356246~27367622:+
THCA	cis	rs9322193	1	rs9399693	ENSG00000223701.3	RAET1E-AS1	11.15	8.64e-26	8.48e-23	0.61	0.46	Lung cancer;	chr6:149612718	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.738	rs9485039	ENSG00000235652.6	RP11-545I5.3	11.15	8.73e-26	8.56e-23	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145998251	chr6:145799409~145886585:+
THCA	cis	rs9532669	0.926	rs6560963	ENSG00000176268.5	CYCSP34	11.15	8.74e-26	8.57e-23	0.53	0.46	Cervical cancer;	chr13:40871126	chr13:40863599~40863902:-
THCA	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-11.15	8.75e-26	8.58e-23	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
THCA	cis	rs2274273	0.905	rs8007944	ENSG00000258413.1	RP11-665C16.6	-11.15	8.76e-26	8.59e-23	-0.59	-0.46	Protein biomarker;	chr14:55110098	chr14:55262767~55272075:-
THCA	cis	rs1075265	0.87	rs10207537	ENSG00000233266.1	HMGB1P31	11.15	8.83e-26	8.66e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54051334~54051760:+
THCA	cis	rs10463554	0.667	rs57714862	ENSG00000175749.11	EIF3KP1	11.15	8.94e-26	8.76e-23	0.59	0.46	Parkinson's disease;	chr5:103047025	chr5:103032376~103033031:+
THCA	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	11.15	8.95e-26	8.78e-23	0.51	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
THCA	cis	rs2274273	0.905	rs4652	ENSG00000258413.1	RP11-665C16.6	-11.15	9.04e-26	8.85e-23	-0.6	-0.46	Protein biomarker;	chr14:55138318	chr14:55262767~55272075:-
THCA	cis	rs950169	0.881	rs34117475	ENSG00000225151.9	GOLGA2P7	-11.15	9.09e-26	8.9e-23	-0.67	-0.46	Schizophrenia;	chr15:84565212	chr15:84199311~84230136:-
THCA	cis	rs2658782	0.688	rs2658768	ENSG00000279684.1	RP11-755E23.2	-11.15	9.09e-26	8.91e-23	-0.73	-0.46	Pulmonary function decline;	chr11:93517661	chr11:93286629~93288903:-
THCA	cis	rs9903692	0.954	rs875065	ENSG00000278765.1	RP5-890E16.5	11.15	9.17e-26	8.98e-23	0.6	0.46	Pulse pressure;	chr17:48062207	chr17:48066704~48067293:-
THCA	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	11.15	9.23e-26	9.03e-23	0.63	0.46	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000206090.4	AP000350.7	11.14	9.36e-26	9.16e-23	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23939998~23942798:+
THCA	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	11.14	9.37e-26	9.18e-23	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
THCA	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-11.14	9.45e-26	9.26e-23	-0.56	-0.46	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
THCA	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-11.14	9.57e-26	9.37e-23	-0.56	-0.46	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
THCA	cis	rs9322193	0.923	rs12660304	ENSG00000223701.3	RAET1E-AS1	11.14	9.81e-26	9.6e-23	0.62	0.46	Lung cancer;	chr6:149739647	chr6:149884431~149919508:+
THCA	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-11.14	9.98e-26	9.75e-23	-0.59	-0.46	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
THCA	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-11.14	1e-25	9.77e-23	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-11.14	1e-25	9.8e-23	-0.59	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
THCA	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-11.14	1e-25	9.81e-23	-0.54	-0.46	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
THCA	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-11.14	1e-25	9.81e-23	-0.47	-0.46	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
THCA	cis	rs9322193	0.923	rs10747276	ENSG00000223701.3	RAET1E-AS1	11.14	1.01e-25	9.84e-23	0.61	0.46	Lung cancer;	chr6:149758739	chr6:149884431~149919508:+
THCA	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	11.14	1.01e-25	9.87e-23	0.33	0.46	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
THCA	cis	rs9903692	0.866	rs11079807	ENSG00000278765.1	RP5-890E16.5	-11.14	1.01e-25	9.9e-23	-0.6	-0.46	Pulse pressure;	chr17:48098685	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs10853094	ENSG00000278765.1	RP5-890E16.5	-11.14	1.01e-25	9.9e-23	-0.6	-0.46	Pulse pressure;	chr17:48098700	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs4794441	ENSG00000278765.1	RP5-890E16.5	-11.14	1.01e-25	9.9e-23	-0.6	-0.46	Pulse pressure;	chr17:48099094	chr17:48066704~48067293:-
THCA	cis	rs6496932	0.635	rs28559998	ENSG00000218052.5	ADAMTS7P4	-11.14	1.01e-25	9.9e-23	-0.58	-0.46	Central corneal thickness;Corneal structure;	chr15:85360605	chr15:85255369~85330334:-
THCA	cis	rs6496932	0.635	rs8023859	ENSG00000218052.5	ADAMTS7P4	-11.14	1.01e-25	9.9e-23	-0.58	-0.46	Central corneal thickness;Corneal structure;	chr15:85361540	chr15:85255369~85330334:-
THCA	cis	rs934734	0.532	rs6546151	ENSG00000281920.1	RP11-418H16.1	-11.13	1.02e-25	9.96e-23	-0.55	-0.46	Rheumatoid arthritis;	chr2:65449449	chr2:65623272~65628424:+
THCA	cis	rs10463554	0.963	rs3776860	ENSG00000175749.11	EIF3KP1	11.13	1.04e-25	1.02e-22	0.6	0.46	Parkinson's disease;	chr5:103014266	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs32840	ENSG00000175749.11	EIF3KP1	11.13	1.05e-25	1.03e-22	0.59	0.46	Parkinson's disease;	chr5:103143446	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs27970	ENSG00000175749.11	EIF3KP1	11.13	1.05e-25	1.03e-22	0.59	0.46	Parkinson's disease;	chr5:103151019	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	11.13	1.05e-25	1.03e-22	0.59	0.46	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
THCA	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-11.13	1.06e-25	1.04e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
THCA	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	11.13	1.06e-25	1.04e-22	0.45	0.46	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
THCA	cis	rs17608059	0.504	rs11656981	ENSG00000141028.6	CDRT15P1	-11.13	1.07e-25	1.04e-22	-0.53	-0.46	Temperament;	chr17:14075460	chr17:14024514~14025488:+
THCA	cis	rs9322193	0.923	rs62441284	ENSG00000223701.3	RAET1E-AS1	11.13	1.07e-25	1.04e-22	0.61	0.46	Lung cancer;	chr6:149751542	chr6:149884431~149919508:+
THCA	cis	rs4591358	0.638	rs6732435	ENSG00000223466.1	AC064834.2	-11.13	1.07e-25	1.04e-22	-0.67	-0.46	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541501	chr2:195533035~195538681:+
THCA	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-11.13	1.07e-25	1.05e-22	-0.57	-0.46	Height;	chr3:53034139	chr3:53064283~53065091:-
THCA	cis	rs16828019	0.777	rs34502739	ENSG00000235358.1	RP11-399E6.1	11.13	1.08e-25	1.05e-22	0.89	0.46	Intelligence (multi-trait analysis);	chr1:40993474	chr1:41242373~41284861:+
THCA	cis	rs7221109	0.592	rs917595	ENSG00000278834.1	RP11-458J1.1	11.13	1.08e-25	1.06e-22	0.48	0.46	Type 1 diabetes;	chr17:40663246	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.677	rs7223354	ENSG00000278834.1	RP11-458J1.1	11.13	1.08e-25	1.06e-22	0.48	0.46	Type 1 diabetes;	chr17:40668420	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.677	rs6503549	ENSG00000278834.1	RP11-458J1.1	11.13	1.08e-25	1.06e-22	0.48	0.46	Type 1 diabetes;	chr17:40668492	chr17:40648300~40649718:+
THCA	cis	rs6504950	1	rs9890971	ENSG00000275710.1	RP11-257O5.4	11.13	1.09e-25	1.06e-22	0.62	0.46	Breast cancer;	chr17:54982415	chr17:54964474~54964679:+
THCA	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-11.13	1.09e-25	1.06e-22	-0.41	-0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
THCA	cis	rs2564921	0.693	rs2336721	ENSG00000242142.1	SERBP1P3	-11.13	1.09e-25	1.06e-22	-0.53	-0.46	Height;	chr3:52994359	chr3:53064283~53065091:-
THCA	cis	rs7221109	0.633	rs7209735	ENSG00000278834.1	RP11-458J1.1	11.13	1.09e-25	1.07e-22	0.48	0.46	Type 1 diabetes;	chr17:40662346	chr17:40648300~40649718:+
THCA	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	11.13	1.1e-25	1.07e-22	0.56	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
THCA	cis	rs16828019	0.777	rs67450703	ENSG00000235358.1	RP11-399E6.1	11.13	1.1e-25	1.07e-22	0.89	0.46	Intelligence (multi-trait analysis);	chr1:40994457	chr1:41242373~41284861:+
THCA	cis	rs12468226	0.938	rs6753044	ENSG00000273456.1	RP11-686O6.2	11.13	1.1e-25	1.07e-22	0.52	0.46	Urate levels;	chr2:202300710	chr2:202374932~202375604:-
THCA	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-11.13	1.11e-25	1.08e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
THCA	cis	rs6504950	0.925	rs181727	ENSG00000275710.1	RP11-257O5.4	11.13	1.11e-25	1.08e-22	0.61	0.46	Breast cancer;	chr17:55113634	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.925	rs244358	ENSG00000275710.1	RP11-257O5.4	11.13	1.11e-25	1.08e-22	0.61	0.46	Breast cancer;	chr17:55114870	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.925	rs2787497	ENSG00000275710.1	RP11-257O5.4	-11.13	1.11e-25	1.08e-22	-0.61	-0.46	Breast cancer;	chr17:55098850	chr17:54964474~54964679:+
THCA	cis	rs6558530	0.666	rs10113471	ENSG00000253982.1	CTD-2336O2.1	11.13	1.11e-25	1.08e-22	0.44	0.46	Systolic blood pressure;	chr8:1747661	chr8:1761990~1764502:-
THCA	cis	rs1075265	0.933	rs2042143	ENSG00000233266.1	HMGB1P31	11.13	1.11e-25	1.08e-22	0.58	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54051334~54051760:+
THCA	cis	rs860295	0.702	rs10796943	ENSG00000225855.5	RUSC1-AS1	11.12	1.11e-25	1.08e-22	0.32	0.46	Body mass index;	chr1:155444938	chr1:155316863~155324176:-
THCA	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	11.12	1.12e-25	1.09e-22	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
THCA	cis	rs916888	0.773	rs199448	ENSG00000232300.1	FAM215B	11.12	1.12e-25	1.09e-22	0.75	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46558830~46562795:-
THCA	cis	rs916888	0.773	rs199447	ENSG00000232300.1	FAM215B	11.12	1.12e-25	1.09e-22	0.75	0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46558830~46562795:-
THCA	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	11.12	1.12e-25	1.09e-22	0.56	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
THCA	cis	rs12468226	0.873	rs1474267	ENSG00000273456.1	RP11-686O6.2	-11.12	1.13e-25	1.1e-22	-0.58	-0.46	Urate levels;	chr2:202178596	chr2:202374932~202375604:-
THCA	cis	rs780096	0.546	rs1528533	ENSG00000234072.1	AC074117.10	-11.12	1.14e-25	1.11e-22	-0.35	-0.46	Total body bone mineral density;	chr2:27372889	chr2:27356246~27367622:+
THCA	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	11.12	1.15e-25	1.12e-22	0.54	0.46	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
THCA	cis	rs860295	0.676	rs11264374	ENSG00000225855.5	RUSC1-AS1	11.12	1.16e-25	1.12e-22	0.32	0.46	Body mass index;	chr1:155451721	chr1:155316863~155324176:-
THCA	cis	rs4819052	0.632	rs4819050	ENSG00000223768.1	LINC00205	-11.12	1.16e-25	1.13e-22	-0.42	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45293285~45297354:+
THCA	cis	rs6504950	0.889	rs1156287	ENSG00000275710.1	RP11-257O5.4	-11.12	1.17e-25	1.14e-22	-0.6	-0.46	Breast cancer;	chr17:54999438	chr17:54964474~54964679:+
THCA	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-11.12	1.17e-25	1.14e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.884	rs2064521	ENSG00000223701.3	RAET1E-AS1	-11.12	1.17e-25	1.14e-22	-0.62	-0.46	Lung cancer;	chr6:149625336	chr6:149884431~149919508:+
THCA	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	11.12	1.17e-25	1.14e-22	0.63	0.46	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
THCA	cis	rs9903692	0.954	rs2051821	ENSG00000278765.1	RP5-890E16.5	11.12	1.17e-25	1.14e-22	0.6	0.46	Pulse pressure;	chr17:48066153	chr17:48066704~48067293:-
THCA	cis	rs10246939	0.544	rs6957037	ENSG00000228775.6	WEE2-AS1	11.12	1.18e-25	1.14e-22	0.54	0.46	Bitter taste perception;	chr7:141865557	chr7:141704338~141738346:-
THCA	cis	rs9322193	0.607	rs12527391	ENSG00000223701.3	RAET1E-AS1	11.12	1.18e-25	1.14e-22	0.66	0.46	Lung cancer;	chr6:149882156	chr6:149884431~149919508:+
THCA	cis	rs62103177	0.525	rs4283293	ENSG00000261126.6	RP11-795F19.1	-11.12	1.18e-25	1.14e-22	-0.5	-0.46	Opioid sensitivity;	chr18:79999582	chr18:80046900~80095482:+
THCA	cis	rs524281	0.64	rs61895584	ENSG00000255320.1	RP11-755F10.1	-11.12	1.2e-25	1.17e-22	-0.74	-0.46	Electroencephalogram traits;	chr11:66042738	chr11:66244840~66246239:-
THCA	cis	rs4819052	0.851	rs3673	ENSG00000223768.1	LINC00205	-11.12	1.21e-25	1.17e-22	-0.42	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45293285~45297354:+
THCA	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-11.12	1.21e-25	1.17e-22	-0.49	-0.46	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
THCA	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	11.11	1.22e-25	1.18e-22	0.63	0.46	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	11.11	1.22e-25	1.18e-22	0.63	0.46	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
THCA	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-11.11	1.22e-25	1.18e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-11.11	1.22e-25	1.18e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
THCA	cis	rs4819052	1	rs13052356	ENSG00000223768.1	LINC00205	-11.11	1.22e-25	1.19e-22	-0.46	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45293285~45297354:+
THCA	cis	rs944289	0.615	rs1333312	ENSG00000257826.1	RP11-116N8.4	-11.11	1.22e-25	1.19e-22	-0.48	-0.46	Thyroid cancer;	chr14:36093396	chr14:36061026~36067190:-
THCA	cis	rs10463554	0.963	rs26816	ENSG00000175749.11	EIF3KP1	11.11	1.23e-25	1.19e-22	0.59	0.46	Parkinson's disease;	chr5:103204821	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.847	rs56103941	ENSG00000223701.3	RAET1E-AS1	11.11	1.23e-25	1.19e-22	0.62	0.46	Lung cancer;	chr6:149816095	chr6:149884431~149919508:+
THCA	cis	rs780096	0.546	rs12473776	ENSG00000234072.1	AC074117.10	-11.11	1.24e-25	1.2e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27413607	chr2:27356246~27367622:+
THCA	cis	rs780096	0.546	rs4665976	ENSG00000234072.1	AC074117.10	-11.11	1.24e-25	1.2e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27417458	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs2911713	ENSG00000234072.1	AC074117.10	-11.11	1.24e-25	1.2e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27418113	chr2:27356246~27367622:+
THCA	cis	rs780096	0.506	rs1728922	ENSG00000234072.1	AC074117.10	-11.11	1.24e-25	1.2e-22	-0.36	-0.46	Total body bone mineral density;	chr2:27421597	chr2:27356246~27367622:+
THCA	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-11.11	1.24e-25	1.2e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
THCA	cis	rs2658782	0.547	rs10741464	ENSG00000279684.1	RP11-755E23.2	-11.11	1.25e-25	1.21e-22	-0.65	-0.46	Pulmonary function decline;	chr11:93457586	chr11:93286629~93288903:-
THCA	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-11.11	1.25e-25	1.21e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
THCA	cis	rs9903692	0.954	rs11651097	ENSG00000278765.1	RP5-890E16.5	11.11	1.25e-25	1.22e-22	0.6	0.46	Pulse pressure;	chr17:48069677	chr17:48066704~48067293:-
THCA	cis	rs934734	0.673	rs754110	ENSG00000281920.1	RP11-418H16.1	11.11	1.26e-25	1.22e-22	0.55	0.46	Rheumatoid arthritis;	chr2:65464626	chr2:65623272~65628424:+
THCA	cis	rs2880765	0.566	rs12911430	ENSG00000259295.5	CSPG4P12	11.11	1.27e-25	1.23e-22	0.63	0.46	Coronary artery disease;	chr15:85468033	chr15:85191438~85213905:+
THCA	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	11.11	1.27e-25	1.24e-22	0.58	0.46	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
THCA	cis	rs11159086	0.793	rs4903229	ENSG00000270000.1	RP3-449M8.9	11.11	1.27e-25	1.24e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74489865	chr14:74471930~74472360:-
THCA	cis	rs9532669	0.926	rs7331435	ENSG00000176268.5	CYCSP34	-11.11	1.28e-25	1.25e-22	-0.53	-0.46	Cervical cancer;	chr13:40862396	chr13:40863599~40863902:-
THCA	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	11.11	1.29e-25	1.25e-22	0.41	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
THCA	cis	rs73219805	0.759	rs3758098	ENSG00000228451.3	SDAD1P1	-11.11	1.29e-25	1.25e-22	-0.66	-0.46	Schizophrenia;	chr8:26381867	chr8:26379259~26382953:-
THCA	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-11.11	1.3e-25	1.26e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
THCA	cis	rs13392177	0.672	rs4674270	ENSG00000261338.2	RP11-378A13.1	-11.11	1.32e-25	1.28e-22	-0.47	-0.46	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218188418	chr2:218255319~218257366:+
THCA	cis	rs12468226	0.938	rs16824590	ENSG00000273456.1	RP11-686O6.2	11.11	1.32e-25	1.28e-22	0.52	0.46	Urate levels;	chr2:202272624	chr2:202374932~202375604:-
THCA	cis	rs12468226	0.938	rs77018809	ENSG00000273456.1	RP11-686O6.2	11.11	1.32e-25	1.28e-22	0.52	0.46	Urate levels;	chr2:202273166	chr2:202374932~202375604:-
THCA	cis	rs9903692	0.954	rs12941295	ENSG00000278765.1	RP5-890E16.5	-11.1	1.34e-25	1.29e-22	-0.6	-0.46	Pulse pressure;	chr17:48110825	chr17:48066704~48067293:-
THCA	cis	rs6570726	0.791	rs6918814	ENSG00000235652.6	RP11-545I5.3	11.1	1.34e-25	1.3e-22	0.42	0.46	Lobe attachment (rater-scored or self-reported);	chr6:145584892	chr6:145799409~145886585:+
THCA	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	11.1	1.35e-25	1.31e-22	0.72	0.46	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
THCA	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-11.1	1.36e-25	1.32e-22	-0.54	-0.46	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
THCA	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	11.1	1.37e-25	1.33e-22	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
THCA	cis	rs944289	0.617	rs7151738	ENSG00000257826.1	RP11-116N8.4	-11.1	1.37e-25	1.33e-22	-0.49	-0.46	Thyroid cancer;	chr14:36114670	chr14:36061026~36067190:-
THCA	cis	rs10463554	0.856	rs26427	ENSG00000175749.11	EIF3KP1	-11.1	1.39e-25	1.35e-22	-0.58	-0.46	Parkinson's disease;	chr5:103031079	chr5:103032376~103033031:+
THCA	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-11.1	1.4e-25	1.35e-22	-0.59	-0.46	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
THCA	cis	rs7772486	0.875	rs7767660	ENSG00000235652.6	RP11-545I5.3	11.1	1.4e-25	1.36e-22	0.41	0.46	Lobe attachment (rater-scored or self-reported);	chr6:146115414	chr6:145799409~145886585:+
THCA	cis	rs240993	0.909	rs240991	ENSG00000230177.1	RP5-1112D6.4	-11.1	1.4e-25	1.36e-22	-0.4	-0.46	Inflammatory skin disease;Psoriasis;	chr6:111346971	chr6:111277932~111278742:+
THCA	cis	rs240993	1	rs240993	ENSG00000230177.1	RP5-1112D6.4	-11.1	1.4e-25	1.36e-22	-0.4	-0.46	Inflammatory skin disease;Psoriasis;	chr6:111352511	chr6:111277932~111278742:+
THCA	cis	rs9322193	0.607	rs12210822	ENSG00000223701.3	RAET1E-AS1	11.1	1.41e-25	1.36e-22	0.65	0.46	Lung cancer;	chr6:149905356	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.607	rs6925151	ENSG00000223701.3	RAET1E-AS1	11.1	1.41e-25	1.37e-22	0.64	0.46	Lung cancer;	chr6:149889587	chr6:149884431~149919508:+
THCA	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-11.1	1.41e-25	1.37e-22	-0.53	-0.46	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
THCA	cis	rs11159086	0.793	rs10147316	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74475688	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.838	rs10147963	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74476091	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs8021664	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74476592	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs10150696	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74476723	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs1860108	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74478562	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs11845370	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74481587	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs3784035	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74482221	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs12433382	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74482940	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs10148268	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74484261	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs11850070	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74487575	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs28378078	ENSG00000270000.1	RP3-449M8.9	11.1	1.41e-25	1.37e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74487940	chr14:74471930~74472360:-
THCA	cis	rs7221109	0.533	rs7210983	ENSG00000278834.1	RP11-458J1.1	11.1	1.43e-25	1.38e-22	0.48	0.46	Type 1 diabetes;	chr17:40660862	chr17:40648300~40649718:+
THCA	cis	rs4819052	0.851	rs7276103	ENSG00000223768.1	LINC00205	-11.1	1.44e-25	1.39e-22	-0.42	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45293285~45297354:+
THCA	cis	rs9659323	0.65	rs61528304	ENSG00000231365.4	RP11-418J17.1	-11.1	1.44e-25	1.39e-22	-0.49	-0.46	Body mass index;	chr1:118920976	chr1:119140396~119275973:+
THCA	cis	rs9903692	0.954	rs12936731	ENSG00000278765.1	RP5-890E16.5	11.1	1.44e-25	1.39e-22	0.6	0.46	Pulse pressure;	chr17:48050997	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.909	rs9899275	ENSG00000278765.1	RP5-890E16.5	11.1	1.44e-25	1.39e-22	0.6	0.46	Pulse pressure;	chr17:48051953	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs12450620	ENSG00000278765.1	RP5-890E16.5	11.1	1.44e-25	1.39e-22	0.6	0.46	Pulse pressure;	chr17:48052892	chr17:48066704~48067293:-
THCA	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-11.1	1.44e-25	1.39e-22	-0.54	-0.46	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
THCA	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	11.1	1.45e-25	1.4e-22	0.56	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
THCA	cis	rs6964833	1	rs6964833	ENSG00000123965.13	PMS2P5	11.1	1.45e-25	1.4e-22	0.78	0.46	Menarche (age at onset);	chr7:74687575	chr7:74894116~74897835:+
THCA	cis	rs7772486	0.79	rs10223507	ENSG00000235652.6	RP11-545I5.3	-11.1	1.45e-25	1.4e-22	-0.42	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145964068	chr6:145799409~145886585:+
THCA	cis	rs6558530	0.666	rs6558518	ENSG00000253982.1	CTD-2336O2.1	11.09	1.46e-25	1.41e-22	0.44	0.46	Systolic blood pressure;	chr8:1749143	chr8:1761990~1764502:-
THCA	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-11.09	1.47e-25	1.42e-22	-0.48	-0.46	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
THCA	cis	rs2658782	0.724	rs1563445	ENSG00000279684.1	RP11-755E23.2	-11.09	1.48e-25	1.43e-22	-0.73	-0.46	Pulmonary function decline;	chr11:93512876	chr11:93286629~93288903:-
THCA	cis	rs2274273	0.87	rs8013713	ENSG00000258413.1	RP11-665C16.6	11.09	1.48e-25	1.43e-22	0.6	0.46	Protein biomarker;	chr14:55374534	chr14:55262767~55272075:-
THCA	cis	rs3091242	0.933	rs34933589	ENSG00000224183.1	SDHDP6	11.09	1.48e-25	1.43e-22	0.55	0.46	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25294164~25294643:-
THCA	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-11.09	1.48e-25	1.43e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-11.09	1.48e-25	1.43e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-11.09	1.48e-25	1.43e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-11.09	1.48e-25	1.43e-22	-0.53	-0.46	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
THCA	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	11.09	1.49e-25	1.44e-22	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
THCA	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	11.09	1.49e-25	1.44e-22	0.78	0.46	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
THCA	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-11.09	1.49e-25	1.44e-22	-0.59	-0.46	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-11.09	1.49e-25	1.44e-22	-0.59	-0.46	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
THCA	cis	rs10463554	0.892	rs13340345	ENSG00000175749.11	EIF3KP1	11.09	1.5e-25	1.45e-22	0.6	0.46	Parkinson's disease;	chr5:103003518	chr5:103032376~103033031:+
THCA	cis	rs11159086	0.793	rs9285594	ENSG00000270000.1	RP3-449M8.9	11.09	1.5e-25	1.45e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74489253	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs8016972	ENSG00000270000.1	RP3-449M8.9	11.09	1.5e-25	1.45e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74491833	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs8015894	ENSG00000270000.1	RP3-449M8.9	11.09	1.5e-25	1.45e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74491917	chr14:74471930~74472360:-
THCA	cis	rs7569084	0.687	rs6755006	ENSG00000237979.1	AC007389.1	-11.09	1.5e-25	1.45e-22	-0.54	-0.46	Sum eosinophil basophil counts;	chr2:65426008	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.687	rs6755128	ENSG00000237979.1	AC007389.1	-11.09	1.5e-25	1.45e-22	-0.54	-0.46	Sum eosinophil basophil counts;	chr2:65426065	chr2:65500993~65502138:-
THCA	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	11.09	1.51e-25	1.46e-22	0.57	0.46	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	11.09	1.51e-25	1.46e-22	0.57	0.46	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
THCA	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	11.09	1.52e-25	1.46e-22	0.41	0.46	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
THCA	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	11.09	1.52e-25	1.47e-22	0.55	0.46	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
THCA	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-11.09	1.53e-25	1.48e-22	-0.6	-0.46	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
THCA	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	11.09	1.54e-25	1.48e-22	0.55	0.46	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
THCA	cis	rs8100891	0.537	rs10424665	ENSG00000267213.4	AC007773.2	-11.09	1.54e-25	1.49e-22	-0.53	-0.46	Neuroticism;	chr19:32404725	chr19:32390050~32405560:-
THCA	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	11.09	1.55e-25	1.49e-22	0.61	0.46	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
THCA	cis	rs10463554	0.892	rs158408	ENSG00000175749.11	EIF3KP1	11.09	1.56e-25	1.51e-22	0.59	0.46	Parkinson's disease;	chr5:103071670	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.927	rs257317	ENSG00000175749.11	EIF3KP1	11.09	1.56e-25	1.51e-22	0.59	0.46	Parkinson's disease;	chr5:103086881	chr5:103032376~103033031:+
THCA	cis	rs11159086	0.793	rs1029701	ENSG00000270000.1	RP3-449M8.9	11.09	1.57e-25	1.52e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74474112	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs12432412	ENSG00000270000.1	RP3-449M8.9	11.09	1.57e-25	1.52e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74474294	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs1029700	ENSG00000270000.1	RP3-449M8.9	11.09	1.57e-25	1.52e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74474309	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.793	rs1029699	ENSG00000270000.1	RP3-449M8.9	11.09	1.57e-25	1.52e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74474790	chr14:74471930~74472360:-
THCA	cis	rs11159086	0.729	rs8015872	ENSG00000270000.1	RP3-449M8.9	11.09	1.57e-25	1.52e-22	0.49	0.46	Advanced glycation end-product levels;	chr14:74475529	chr14:74471930~74472360:-
THCA	cis	rs4819052	0.851	rs9974891	ENSG00000223768.1	LINC00205	-11.09	1.58e-25	1.52e-22	-0.42	-0.46	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45293285~45297354:+
THCA	cis	rs6570726	0.577	rs9497315	ENSG00000235652.6	RP11-545I5.3	-11.09	1.58e-25	1.53e-22	-0.47	-0.46	Lobe attachment (rater-scored or self-reported);	chr6:145470831	chr6:145799409~145886585:+
THCA	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-11.08	1.59e-25	1.53e-22	-0.58	-0.46	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
THCA	cis	rs1185460	0.547	rs34150933	ENSG00000271751.1	RP11-110I1.14	11.08	1.6e-25	1.54e-22	0.56	0.46	Coronary artery disease;	chr11:119040329	chr11:119065263~119065677:-
THCA	cis	rs10463554	0.963	rs3776857	ENSG00000175749.11	EIF3KP1	11.08	1.6e-25	1.54e-22	0.6	0.46	Parkinson's disease;	chr5:103022456	chr5:103032376~103033031:+
THCA	cis	rs9659323	0.717	rs61806238	ENSG00000231365.4	RP11-418J17.1	-11.08	1.61e-25	1.55e-22	-0.49	-0.46	Body mass index;	chr1:118993755	chr1:119140396~119275973:+
THCA	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-11.08	1.61e-25	1.55e-22	-0.47	-0.46	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000235689.1	AP000351.13	11.08	1.61e-25	1.56e-22	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:24006305~24008258:-
THCA	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-11.08	1.63e-25	1.57e-22	-0.6	-0.46	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
THCA	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-11.08	1.64e-25	1.58e-22	-0.52	-0.46	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000224205.1	AP000351.4	11.08	1.65e-25	1.58e-22	0.56	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23987320~23991421:-
THCA	cis	rs2274273	0.905	rs28429419	ENSG00000258413.1	RP11-665C16.6	-11.08	1.66e-25	1.59e-22	-0.59	-0.46	Protein biomarker;	chr14:55108075	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.887	rs3777949	ENSG00000223701.3	RAET1E-AS1	11.08	1.66e-25	1.6e-22	0.61	0.46	Lung cancer;	chr6:149596021	chr6:149884431~149919508:+
THCA	cis	rs507080	0.733	rs497678	ENSG00000255422.1	AP002954.4	-11.08	1.67e-25	1.61e-22	-0.52	-0.46	Serum metabolite levels;	chr11:118697172	chr11:118704607~118750263:+
THCA	cis	rs950169	0.686	rs12906474	ENSG00000225151.9	GOLGA2P7	-11.08	1.67e-25	1.61e-22	-0.67	-0.46	Schizophrenia;	chr15:84566006	chr15:84199311~84230136:-
THCA	cis	rs950169	0.81	rs2879976	ENSG00000225151.9	GOLGA2P7	-11.08	1.67e-25	1.61e-22	-0.67	-0.46	Schizophrenia;	chr15:84566347	chr15:84199311~84230136:-
THCA	cis	rs934734	0.532	rs10184881	ENSG00000281920.1	RP11-418H16.1	-11.08	1.67e-25	1.61e-22	-0.55	-0.46	Rheumatoid arthritis;	chr2:65457018	chr2:65623272~65628424:+
THCA	cis	rs12468226	0.938	rs7585867	ENSG00000273456.1	RP11-686O6.2	11.08	1.68e-25	1.62e-22	0.52	0.46	Urate levels;	chr2:202287040	chr2:202374932~202375604:-
THCA	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	11.08	1.68e-25	1.62e-22	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
THCA	cis	rs950169	1	rs79318564	ENSG00000225151.9	GOLGA2P7	-11.08	1.69e-25	1.63e-22	-0.68	-0.46	Schizophrenia;	chr15:84117398	chr15:84199311~84230136:-
THCA	cis	rs950169	1	rs1911155	ENSG00000225151.9	GOLGA2P7	-11.08	1.69e-25	1.63e-22	-0.68	-0.46	Schizophrenia;	chr15:84118883	chr15:84199311~84230136:-
THCA	cis	rs16828019	0.777	rs35080169	ENSG00000235358.1	RP11-399E6.1	11.08	1.7e-25	1.63e-22	0.89	0.46	Intelligence (multi-trait analysis);	chr1:40989287	chr1:41242373~41284861:+
THCA	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-11.08	1.7e-25	1.64e-22	-0.52	-0.45	Height;	chr6:109432968	chr6:109382795~109383666:+
THCA	cis	rs2283792	0.74	rs8140258	ENSG00000224086.5	LL22NC03-86G7.1	-11.08	1.7e-25	1.64e-22	-0.54	-0.45	Multiple sclerosis;	chr22:21755545	chr22:21938293~21977632:+
THCA	cis	rs8040855	0.576	rs62022527	ENSG00000259295.5	CSPG4P12	11.08	1.71e-25	1.64e-22	0.71	0.45	Bulimia nervosa;	chr15:84988022	chr15:85191438~85213905:+
THCA	cis	rs6504950	0.925	rs244336	ENSG00000275710.1	RP11-257O5.4	11.08	1.71e-25	1.64e-22	0.59	0.45	Breast cancer;	chr17:55124141	chr17:54964474~54964679:+
THCA	cis	rs10463554	1	rs1593842	ENSG00000175749.11	EIF3KP1	11.08	1.72e-25	1.65e-22	0.6	0.45	Parkinson's disease;	chr5:102999018	chr5:103032376~103033031:+
THCA	cis	rs2288884	0.636	rs8101936	ENSG00000275055.1	CTC-471J1.11	-11.08	1.73e-25	1.66e-22	-0.36	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52073226	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.636	rs8105801	ENSG00000275055.1	CTC-471J1.11	-11.08	1.73e-25	1.66e-22	-0.36	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52074095	chr19:52049007~52049754:+
THCA	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-11.07	1.74e-25	1.68e-22	-0.58	-0.45	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
THCA	cis	rs526231	0.543	rs152137	ENSG00000175749.11	EIF3KP1	11.07	1.75e-25	1.68e-22	0.63	0.45	Primary biliary cholangitis;	chr5:103224362	chr5:103032376~103033031:+
THCA	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	11.07	1.75e-25	1.68e-22	0.45	0.45	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	11.07	1.76e-25	1.69e-22	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	11.07	1.76e-25	1.69e-22	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
THCA	cis	rs4591358	0.689	rs2173773	ENSG00000223466.1	AC064834.2	-11.07	1.77e-25	1.7e-22	-0.67	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549701	chr2:195533035~195538681:+
THCA	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-11.07	1.77e-25	1.7e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
THCA	cis	rs526231	0.543	rs246913	ENSG00000175749.11	EIF3KP1	11.07	1.77e-25	1.7e-22	0.63	0.45	Primary biliary cholangitis;	chr5:103224669	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.923	rs10782318	ENSG00000223701.3	RAET1E-AS1	11.07	1.78e-25	1.71e-22	0.62	0.45	Lung cancer;	chr6:149754137	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.701	rs2244308	ENSG00000235652.6	RP11-545I5.3	11.07	1.78e-25	1.71e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145892570	chr6:145799409~145886585:+
THCA	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-11.07	1.8e-25	1.72e-22	-0.58	-0.45	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
THCA	cis	rs7772486	0.875	rs2073287	ENSG00000235652.6	RP11-545I5.3	11.07	1.81e-25	1.74e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146029128	chr6:145799409~145886585:+
THCA	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	11.07	1.81e-25	1.74e-22	0.66	0.45	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
THCA	cis	rs2274273	0.84	rs10150760	ENSG00000258413.1	RP11-665C16.6	11.07	1.82e-25	1.75e-22	0.59	0.45	Protein biomarker;	chr14:55354830	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.961	rs9767713	ENSG00000223701.3	RAET1E-AS1	11.07	1.83e-25	1.75e-22	0.62	0.45	Lung cancer;	chr6:149588241	chr6:149884431~149919508:+
THCA	cis	rs12280210	0.557	rs7112937	ENSG00000254851.1	RP11-109L13.1	11.07	1.83e-25	1.75e-22	0.88	0.45	Lobe attachment (rater-scored or self-reported);	chr11:117009740	chr11:117135528~117138582:+
THCA	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	11.07	1.83e-25	1.76e-22	0.53	0.45	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
THCA	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-11.07	1.83e-25	1.76e-22	-0.58	-0.45	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-11.07	1.83e-25	1.76e-22	-0.58	-0.45	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
THCA	cis	rs4718428	0.576	rs12698546	ENSG00000273142.1	RP11-458F8.4	-11.07	1.84e-25	1.76e-22	-0.43	-0.45	Corneal structure;	chr7:66801919	chr7:66902857~66906297:+
THCA	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-11.07	1.84e-25	1.76e-22	-0.53	-0.45	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
THCA	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-11.07	1.84e-25	1.77e-22	-0.58	-0.45	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
THCA	cis	rs600231	0.665	rs1784859	ENSG00000245532.5	NEAT1	-11.07	1.85e-25	1.77e-22	-0.31	-0.45	Bone mineral density;	chr11:65453278	chr11:65422774~65445540:+
THCA	cis	rs916888	0.773	rs9896243	ENSG00000232300.1	FAM215B	11.07	1.85e-25	1.78e-22	0.75	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46558830~46562795:-
THCA	cis	rs6558530	0.666	rs11136422	ENSG00000253982.1	CTD-2336O2.1	11.07	1.85e-25	1.78e-22	0.44	0.45	Systolic blood pressure;	chr8:1747743	chr8:1761990~1764502:-
THCA	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-11.07	1.86e-25	1.79e-22	-0.47	-0.45	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
THCA	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-11.07	1.86e-25	1.79e-22	-0.47	-0.45	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
THCA	cis	rs16828019	0.929	rs35883594	ENSG00000235358.1	RP11-399E6.1	11.07	1.86e-25	1.79e-22	0.87	0.45	Intelligence (multi-trait analysis);	chr1:41278421	chr1:41242373~41284861:+
THCA	cis	rs9322193	0.887	rs11155662	ENSG00000223701.3	RAET1E-AS1	11.07	1.87e-25	1.79e-22	0.63	0.45	Lung cancer;	chr6:149592731	chr6:149884431~149919508:+
THCA	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-11.07	1.88e-25	1.8e-22	-0.58	-0.45	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
THCA	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	11.07	1.88e-25	1.8e-22	0.54	0.45	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
THCA	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-11.06	1.89e-25	1.81e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-11.06	1.89e-25	1.81e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
THCA	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-11.06	1.89e-25	1.81e-22	-0.58	-0.45	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
THCA	cis	rs2274273	0.905	rs17128183	ENSG00000258413.1	RP11-665C16.6	11.06	1.9e-25	1.82e-22	0.59	0.45	Protein biomarker;	chr14:55112795	chr14:55262767~55272075:-
THCA	cis	rs12280210	0.557	rs11216225	ENSG00000254851.1	RP11-109L13.1	11.06	1.9e-25	1.82e-22	0.88	0.45	Lobe attachment (rater-scored or self-reported);	chr11:117007298	chr11:117135528~117138582:+
THCA	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-11.06	1.9e-25	1.82e-22	-0.58	-0.45	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
THCA	cis	rs9322193	0.923	rs9377230	ENSG00000223701.3	RAET1E-AS1	11.06	1.92e-25	1.83e-22	0.61	0.45	Lung cancer;	chr6:149613607	chr6:149884431~149919508:+
THCA	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-11.06	1.92e-25	1.84e-22	-0.58	-0.45	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
THCA	cis	rs801193	0.66	rs1962050	ENSG00000237310.1	GS1-124K5.4	-11.06	1.95e-25	1.87e-22	-0.33	-0.45	Aortic root size;	chr7:66775021	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.875	rs1331639	ENSG00000235652.6	RP11-545I5.3	-11.06	1.96e-25	1.88e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:146110733	chr6:145799409~145886585:+
THCA	cis	rs2946504	0.501	rs2977092	ENSG00000251468.2	RP11-369K16.1	-11.06	1.97e-25	1.89e-22	-0.51	-0.45	Type 2 diabetes;	chr8:12949867	chr8:12958387~12962200:+
THCA	cis	rs7945705	0.902	rs2012696	ENSG00000254860.4	TMEM9B-AS1	-11.06	1.97e-25	1.89e-22	-0.5	-0.45	Hemoglobin concentration;	chr11:8974271	chr11:8964675~8977527:+
THCA	cis	rs11159086	1	rs11626856	ENSG00000270000.1	RP3-449M8.9	11.06	1.98e-25	1.89e-22	0.5	0.45	Advanced glycation end-product levels;	chr14:74469665	chr14:74471930~74472360:-
THCA	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-11.06	1.98e-25	1.89e-22	-0.53	-0.45	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
THCA	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	11.06	1.99e-25	1.9e-22	0.55	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
THCA	cis	rs4819052	0.851	rs7275468	ENSG00000223768.1	LINC00205	-11.06	1.99e-25	1.91e-22	-0.43	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45293285~45297354:+
THCA	cis	rs2274273	0.87	rs17741542	ENSG00000258413.1	RP11-665C16.6	11.06	2e-25	1.91e-22	0.6	0.45	Protein biomarker;	chr14:55339143	chr14:55262767~55272075:-
THCA	cis	rs2564921	0.73	rs56026870	ENSG00000242142.1	SERBP1P3	-11.06	2.01e-25	1.92e-22	-0.53	-0.45	Height;	chr3:52998472	chr3:53064283~53065091:-
THCA	cis	rs4591358	0.689	rs72927780	ENSG00000223466.1	AC064834.2	-11.06	2.04e-25	1.95e-22	-0.64	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548569	chr2:195533035~195538681:+
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000228039.3	KB-1125A3.10	11.06	2.05e-25	1.96e-22	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23963780~23964374:+
THCA	cis	rs10463554	0.963	rs26261	ENSG00000175749.11	EIF3KP1	11.06	2.06e-25	1.97e-22	0.59	0.45	Parkinson's disease;	chr5:103209992	chr5:103032376~103033031:+
THCA	cis	rs673078	0.66	rs7136216	ENSG00000275759.1	RP11-131L12.3	-11.05	2.08e-25	1.99e-22	-0.6	-0.45	Glucose homeostasis traits;	chr12:118170475	chr12:118428281~118428870:+
THCA	cis	rs9928842	0.771	rs4888363	ENSG00000280152.1	RP11-331F4.5	11.05	2.08e-25	1.99e-22	0.6	0.45	Alcoholic chronic pancreatitis;	chr16:75243446	chr16:75245994~75250077:-
THCA	cis	rs7772486	0.875	rs6914813	ENSG00000235652.6	RP11-545I5.3	11.05	2.08e-25	1.99e-22	0.43	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146076662	chr6:145799409~145886585:+
THCA	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-11.05	2.1e-25	2e-22	-0.6	-0.45	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-11.05	2.1e-25	2e-22	-0.6	-0.45	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-11.05	2.1e-25	2e-22	-0.6	-0.45	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
THCA	cis	rs916888	0.779	rs199528	ENSG00000232300.1	FAM215B	11.05	2.1e-25	2.01e-22	0.74	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46558830~46562795:-
THCA	cis	rs916888	0.821	rs199525	ENSG00000232300.1	FAM215B	11.05	2.1e-25	2.01e-22	0.74	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46558830~46562795:-
THCA	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-11.05	2.1e-25	2.01e-22	-0.58	-0.45	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
THCA	cis	rs1185460	0.547	rs10892323	ENSG00000271751.1	RP11-110I1.14	11.05	2.11e-25	2.01e-22	0.57	0.45	Coronary artery disease;	chr11:119032048	chr11:119065263~119065677:-
THCA	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-11.05	2.12e-25	2.03e-22	-0.58	-0.45	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	11.05	2.12e-25	2.03e-22	0.58	0.45	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
THCA	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-11.05	2.12e-25	2.03e-22	-0.58	-0.45	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
THCA	cis	rs9322193	0.923	rs9766004	ENSG00000223701.3	RAET1E-AS1	11.05	2.14e-25	2.04e-22	0.61	0.45	Lung cancer;	chr6:149754363	chr6:149884431~149919508:+
THCA	cis	rs2274273	0.805	rs28612464	ENSG00000258413.1	RP11-665C16.6	-11.05	2.16e-25	2.07e-22	-0.59	-0.45	Protein biomarker;	chr14:55349693	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.773	rs28430823	ENSG00000258413.1	RP11-665C16.6	-11.05	2.16e-25	2.07e-22	-0.59	-0.45	Protein biomarker;	chr14:55349842	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs17741831	ENSG00000258413.1	RP11-665C16.6	-11.05	2.16e-25	2.07e-22	-0.59	-0.45	Protein biomarker;	chr14:55349997	chr14:55262767~55272075:-
THCA	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	11.05	2.17e-25	2.07e-22	0.55	0.45	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
THCA	cis	rs7772486	0.875	rs10872583	ENSG00000235652.6	RP11-545I5.3	-11.05	2.19e-25	2.09e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:146075563	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	11.05	2.2e-25	2.1e-22	0.59	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
THCA	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-11.05	2.2e-25	2.1e-22	-0.58	-0.45	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
THCA	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-11.05	2.2e-25	2.1e-22	-0.58	-0.45	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
THCA	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-11.05	2.2e-25	2.1e-22	-0.58	-0.45	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-11.05	2.2e-25	2.1e-22	-0.58	-0.45	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
THCA	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-11.05	2.2e-25	2.1e-22	-0.58	-0.45	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
THCA	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	11.05	2.21e-25	2.11e-22	0.88	0.45	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	11.05	2.21e-25	2.11e-22	0.88	0.45	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	11.05	2.21e-25	2.11e-22	0.88	0.45	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	11.05	2.21e-25	2.11e-22	0.88	0.45	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	11.05	2.21e-25	2.11e-22	0.88	0.45	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
THCA	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	11.05	2.21e-25	2.11e-22	0.88	0.45	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
THCA	cis	rs9903692	0.954	rs7224014	ENSG00000278765.1	RP5-890E16.5	11.05	2.22e-25	2.12e-22	0.6	0.45	Pulse pressure;	chr17:48073499	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs2240122	ENSG00000278765.1	RP5-890E16.5	11.05	2.22e-25	2.12e-22	0.6	0.45	Pulse pressure;	chr17:48075197	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.738	rs35202025	ENSG00000278765.1	RP5-890E16.5	11.05	2.22e-25	2.12e-22	0.6	0.45	Pulse pressure;	chr17:48075355	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs7217496	ENSG00000278765.1	RP5-890E16.5	11.05	2.22e-25	2.12e-22	0.6	0.45	Pulse pressure;	chr17:48076840	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.954	rs9747001	ENSG00000278765.1	RP5-890E16.5	11.05	2.22e-25	2.12e-22	0.6	0.45	Pulse pressure;	chr17:48077307	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.909	rs12952163	ENSG00000278765.1	RP5-890E16.5	11.05	2.22e-25	2.12e-22	0.6	0.45	Pulse pressure;	chr17:48082029	chr17:48066704~48067293:-
THCA	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	11.05	2.22e-25	2.12e-22	0.53	0.45	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
THCA	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	11.05	2.22e-25	2.12e-22	0.53	0.45	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
THCA	cis	rs465969	1	rs13208890	ENSG00000255389.1	C6orf3	-11.05	2.22e-25	2.12e-22	-0.77	-0.45	Psoriasis;	chr6:111500620	chr6:111599875~111602295:+
THCA	cis	rs9532669	0.89	rs35396630	ENSG00000176268.5	CYCSP34	11.05	2.23e-25	2.13e-22	0.53	0.45	Cervical cancer;	chr13:40863135	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4942001	ENSG00000176268.5	CYCSP34	11.05	2.23e-25	2.13e-22	0.53	0.45	Cervical cancer;	chr13:40863176	chr13:40863599~40863902:-
THCA	cis	rs2274273	0.84	rs72715769	ENSG00000258413.1	RP11-665C16.6	-11.05	2.23e-25	2.13e-22	-0.6	-0.45	Protein biomarker;	chr14:55295711	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs66696758	ENSG00000258413.1	RP11-665C16.6	-11.05	2.23e-25	2.13e-22	-0.6	-0.45	Protein biomarker;	chr14:55299791	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs7153645	ENSG00000258413.1	RP11-665C16.6	-11.05	2.23e-25	2.13e-22	-0.6	-0.45	Protein biomarker;	chr14:55304800	chr14:55262767~55272075:-
THCA	cis	rs780096	0.587	rs6743819	ENSG00000234072.1	AC074117.10	-11.04	2.26e-25	2.16e-22	-0.36	-0.45	Total body bone mineral density;	chr2:27344540	chr2:27356246~27367622:+
THCA	cis	rs780096	0.587	rs10205219	ENSG00000234072.1	AC074117.10	-11.04	2.26e-25	2.16e-22	-0.36	-0.45	Total body bone mineral density;	chr2:27345698	chr2:27356246~27367622:+
THCA	cis	rs9659323	0.65	rs10802064	ENSG00000231365.4	RP11-418J17.1	-11.04	2.29e-25	2.18e-22	-0.49	-0.45	Body mass index;	chr1:118915514	chr1:119140396~119275973:+
THCA	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	11.04	2.3e-25	2.19e-22	0.56	0.45	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
THCA	cis	rs780096	0.587	rs6760828	ENSG00000234072.1	AC074117.10	-11.04	2.3e-25	2.19e-22	-0.36	-0.45	Total body bone mineral density;	chr2:27356364	chr2:27356246~27367622:+
THCA	cis	rs934734	0.532	rs6752053	ENSG00000281920.1	RP11-418H16.1	-11.04	2.3e-25	2.19e-22	-0.54	-0.45	Rheumatoid arthritis;	chr2:65439540	chr2:65623272~65628424:+
THCA	cis	rs6570726	0.577	rs399502	ENSG00000235652.6	RP11-545I5.3	11.04	2.31e-25	2.2e-22	0.47	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145484738	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.607	rs915140	ENSG00000223701.3	RAET1E-AS1	11.04	2.31e-25	2.2e-22	0.65	0.45	Lung cancer;	chr6:149899674	chr6:149884431~149919508:+
THCA	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-11.04	2.31e-25	2.2e-22	-0.58	-0.45	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-11.04	2.31e-25	2.2e-22	-0.58	-0.45	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
THCA	cis	rs10463554	1	rs12659870	ENSG00000175749.11	EIF3KP1	11.04	2.32e-25	2.21e-22	0.6	0.45	Parkinson's disease;	chr5:103000867	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs1552916	ENSG00000175749.11	EIF3KP1	11.04	2.32e-25	2.21e-22	0.6	0.45	Parkinson's disease;	chr5:103002036	chr5:103032376~103033031:+
THCA	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-11.04	2.33e-25	2.22e-22	-0.41	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
THCA	cis	rs6142102	0.778	rs6059581	ENSG00000276073.1	RP5-1125A11.7	-11.04	2.35e-25	2.23e-22	-0.42	-0.45	Skin pigmentation;	chr20:33940582	chr20:33985617~33988989:-
THCA	cis	rs1858037	0.867	rs871974	ENSG00000204929.10	AC074391.1	-11.04	2.35e-25	2.24e-22	-0.59	-0.45	Rheumatoid arthritis;	chr2:65330153	chr2:65436711~66084639:+
THCA	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	11.04	2.36e-25	2.25e-22	0.55	0.45	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
THCA	cis	rs673078	0.66	rs61945219	ENSG00000275759.1	RP11-131L12.3	-11.04	2.37e-25	2.25e-22	-0.6	-0.45	Glucose homeostasis traits;	chr12:118272916	chr12:118428281~118428870:+
THCA	cis	rs2658782	0.639	rs2100552	ENSG00000279684.1	RP11-755E23.2	-11.04	2.37e-25	2.26e-22	-0.66	-0.45	Pulmonary function decline;	chr11:93449083	chr11:93286629~93288903:-
THCA	cis	rs6504950	1	rs9892848	ENSG00000275710.1	RP11-257O5.4	11.04	2.38e-25	2.26e-22	0.62	0.45	Breast cancer;	chr17:54982414	chr17:54964474~54964679:+
THCA	cis	rs9903692	0.954	rs2109984	ENSG00000278765.1	RP5-890E16.5	11.04	2.38e-25	2.26e-22	0.6	0.45	Pulse pressure;	chr17:48093737	chr17:48066704~48067293:-
THCA	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-11.04	2.38e-25	2.26e-22	-0.6	-0.45	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
THCA	cis	rs916888	0.687	rs199456	ENSG00000232300.1	FAM215B	11.04	2.4e-25	2.28e-22	0.75	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46558830~46562795:-
THCA	cis	rs916888	0.773	rs199451	ENSG00000232300.1	FAM215B	11.04	2.4e-25	2.28e-22	0.75	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46558830~46562795:-
THCA	cis	rs748404	0.66	rs2467738	ENSG00000249839.1	AC011330.5	-11.04	2.43e-25	2.31e-22	-0.53	-0.45	Lung cancer;	chr15:43447738	chr15:43663654~43684339:-
THCA	cis	rs950169	0.922	rs12915832	ENSG00000225151.9	GOLGA2P7	-11.04	2.44e-25	2.32e-22	-0.66	-0.45	Schizophrenia;	chr15:84568226	chr15:84199311~84230136:-
THCA	cis	rs526231	0.543	rs246909	ENSG00000175749.11	EIF3KP1	11.04	2.45e-25	2.33e-22	0.63	0.45	Primary biliary cholangitis;	chr5:103227976	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs62362884	ENSG00000175749.11	EIF3KP1	11.04	2.45e-25	2.33e-22	0.63	0.45	Primary biliary cholangitis;	chr5:103231754	chr5:103032376~103033031:+
THCA	cis	rs7945705	0.818	rs2742537	ENSG00000254860.4	TMEM9B-AS1	11.04	2.47e-25	2.34e-22	0.49	0.45	Hemoglobin concentration;	chr11:8886842	chr11:8964675~8977527:+
THCA	cis	rs9903692	0.779	rs6504025	ENSG00000278765.1	RP5-890E16.5	11.03	2.48e-25	2.35e-22	0.6	0.45	Pulse pressure;	chr17:48088711	chr17:48066704~48067293:-
THCA	cis	rs3002131	0.604	rs2936037	ENSG00000225265.1	TAF1A-AS1	-11.03	2.48e-25	2.36e-22	-0.58	-0.45	Interleukin-10 levels;	chr1:222575223	chr1:222589825~222593032:+
THCA	cis	rs3002131	0.604	rs2936035	ENSG00000225265.1	TAF1A-AS1	-11.03	2.48e-25	2.36e-22	-0.58	-0.45	Interleukin-10 levels;	chr1:222575582	chr1:222589825~222593032:+
THCA	cis	rs3002131	0.525	rs2936034	ENSG00000225265.1	TAF1A-AS1	-11.03	2.48e-25	2.36e-22	-0.58	-0.45	Interleukin-10 levels;	chr1:222575661	chr1:222589825~222593032:+
THCA	cis	rs12468226	0.873	rs2350358	ENSG00000273456.1	RP11-686O6.2	-11.03	2.49e-25	2.37e-22	-0.53	-0.45	Urate levels;	chr2:202199771	chr2:202374932~202375604:-
THCA	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-11.03	2.51e-25	2.38e-22	-0.55	-0.45	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
THCA	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-11.03	2.53e-25	2.4e-22	-0.53	-0.45	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
THCA	cis	rs7569084	0.687	rs1370394	ENSG00000237979.1	AC007389.1	11.03	2.53e-25	2.4e-22	0.54	0.45	Sum eosinophil basophil counts;	chr2:65453176	chr2:65500993~65502138:-
THCA	cis	rs1976403	0.633	rs1780322	ENSG00000227001.3	NBPF2P	11.03	2.55e-25	2.42e-22	0.51	0.45	Liver enzyme levels (alkaline phosphatase);	chr1:21496583	chr1:21424625~21427967:-
THCA	cis	rs6142102	0.961	rs6088361	ENSG00000276073.1	RP5-1125A11.7	-11.03	2.57e-25	2.44e-22	-0.42	-0.45	Skin pigmentation;	chr20:33969520	chr20:33985617~33988989:-
THCA	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	11.03	2.58e-25	2.45e-22	0.63	0.45	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
THCA	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-11.03	2.58e-25	2.45e-22	-0.42	-0.45	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
THCA	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	11.03	2.58e-25	2.45e-22	0.55	0.45	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
THCA	cis	rs9828933	0.766	rs704372	ENSG00000280620.1	SCAANT1	-11.03	2.59e-25	2.45e-22	-0.73	-0.45	Type 2 diabetes;	chr3:63881777	chr3:63911518~63911772:-
THCA	cis	rs9595066	0.627	rs9562536	ENSG00000227258.4	SMIM2-AS1	11.03	2.6e-25	2.47e-22	0.62	0.45	Schizophrenia;	chr13:44157452	chr13:44110451~44240517:+
THCA	cis	rs7772486	0.79	rs2254288	ENSG00000235652.6	RP11-545I5.3	11.03	2.62e-25	2.48e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145883334	chr6:145799409~145886585:+
THCA	cis	rs4964805	0.865	rs35371470	ENSG00000257681.1	RP11-341G23.4	11.03	2.67e-25	2.53e-22	0.54	0.45	Attention deficit hyperactivity disorder;	chr12:103809942	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.865	rs4964289	ENSG00000257681.1	RP11-341G23.4	11.03	2.67e-25	2.53e-22	0.54	0.45	Attention deficit hyperactivity disorder;	chr12:103810413	chr12:103746315~103768858:-
THCA	cis	rs6452524	0.837	rs1479569	ENSG00000249664.1	CTD-2227C6.2	11.03	2.67e-25	2.53e-22	0.59	0.45	Hypertension (SNP x SNP interaction);	chr5:83081747	chr5:83012285~83013109:-
THCA	cis	rs2732480	0.538	rs1387259	ENSG00000258273.1	RP11-370I10.4	11.03	2.67e-25	2.53e-22	0.59	0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48333755~48333901:-
THCA	cis	rs860295	0.702	rs10908470	ENSG00000225855.5	RUSC1-AS1	11.03	2.68e-25	2.54e-22	0.32	0.45	Body mass index;	chr1:155557222	chr1:155316863~155324176:-
THCA	cis	rs6570726	0.967	rs373704	ENSG00000235652.6	RP11-545I5.3	11.03	2.69e-25	2.54e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145539482	chr6:145799409~145886585:+
THCA	cis	rs12468226	0.938	rs1474002	ENSG00000273456.1	RP11-686O6.2	11.03	2.7e-25	2.55e-22	0.51	0.45	Urate levels;	chr2:202290195	chr2:202374932~202375604:-
THCA	cis	rs6570726	1	rs444564	ENSG00000235652.6	RP11-545I5.3	11.02	2.7e-25	2.55e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145538659	chr6:145799409~145886585:+
THCA	cis	rs6538678	0.864	rs4762249	ENSG00000258343.1	RP11-536G4.2	11.02	2.73e-25	2.58e-22	0.62	0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95795345~95858839:-
THCA	cis	rs4591358	0.689	rs6760142	ENSG00000223466.1	AC064834.2	-11.02	2.73e-25	2.58e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553911	chr2:195533035~195538681:+
THCA	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-11.02	2.75e-25	2.6e-22	-0.56	-0.45	Height;	chr3:53015087	chr3:53064283~53065091:-
THCA	cis	rs4819052	0.679	rs28623526	ENSG00000223768.1	LINC00205	-11.02	2.8e-25	2.65e-22	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45293285~45297354:+
THCA	cis	rs4591358	0.689	rs55876968	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549015	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs55974440	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549056	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs12471810	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549969	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs2133860	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195551243	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs6759817	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553739	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs6434785	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195554142	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.638	rs16837243	ENSG00000223466.1	AC064834.2	-11.02	2.8e-25	2.65e-22	-0.63	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195556458	chr2:195533035~195538681:+
THCA	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-11.02	2.81e-25	2.66e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
THCA	cis	rs42490	1	rs6470366	ENSG00000251136.7	RP11-37B2.1	-11.02	2.83e-25	2.68e-22	-0.39	-0.45	Leprosy;	chr8:89747760	chr8:89609409~89757727:-
THCA	cis	rs9659323	0.539	rs1750331	ENSG00000231365.4	RP11-418J17.1	-11.02	2.84e-25	2.68e-22	-0.46	-0.45	Body mass index;	chr1:118952350	chr1:119140396~119275973:+
THCA	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	11.02	2.84e-25	2.69e-22	0.63	0.45	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
THCA	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	11.02	2.89e-25	2.73e-22	0.55	0.45	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
THCA	cis	rs17111396	0.627	rs72689920	ENSG00000259167.2	NMNAT1P1	11.02	2.91e-25	2.75e-22	0.74	0.45	Uric acid levels;	chr14:81037364	chr14:81032529~81033404:+
THCA	cis	rs2732480	0.557	rs923397	ENSG00000258273.1	RP11-370I10.4	-11.02	2.93e-25	2.77e-22	-0.6	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48333755~48333901:-
THCA	cis	rs875971	0.965	rs697968	ENSG00000237310.1	GS1-124K5.4	-11.02	2.94e-25	2.78e-22	-0.34	-0.45	Aortic root size;	chr7:66070046	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs1183245	ENSG00000237310.1	GS1-124K5.4	-11.02	2.94e-25	2.78e-22	-0.34	-0.45	Aortic root size;	chr7:66076198	chr7:66493706~66495474:+
THCA	cis	rs875971	1	rs1144894	ENSG00000237310.1	GS1-124K5.4	-11.02	2.94e-25	2.78e-22	-0.34	-0.45	Aortic root size;	chr7:66077907	chr7:66493706~66495474:+
THCA	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	11.02	2.94e-25	2.78e-22	0.52	0.45	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
THCA	cis	rs916888	0.773	rs199457	ENSG00000232300.1	FAM215B	11.01	2.96e-25	2.8e-22	0.75	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46558830~46562795:-
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000235689.1	AP000351.13	11.01	2.96e-25	2.8e-22	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:24006305~24008258:-
THCA	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-11.01	2.99e-25	2.82e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-11.01	2.99e-25	2.82e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-11.01	2.99e-25	2.82e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
THCA	cis	rs62103177	0.525	rs4799117	ENSG00000261126.6	RP11-795F19.1	-11.01	2.99e-25	2.82e-22	-0.49	-0.45	Opioid sensitivity;	chr18:79996604	chr18:80046900~80095482:+
THCA	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-11.01	3e-25	2.83e-22	-0.82	-0.45	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
THCA	cis	rs4819052	0.851	rs7279011	ENSG00000223768.1	LINC00205	-11.01	3e-25	2.83e-22	-0.43	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs7279182	ENSG00000223768.1	LINC00205	-11.01	3e-25	2.83e-22	-0.43	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45293285~45297354:+
THCA	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	11.01	3.01e-25	2.84e-22	0.55	0.45	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
THCA	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	11.01	3.01e-25	2.84e-22	0.55	0.45	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
THCA	cis	rs9322193	0.847	rs868375	ENSG00000268592.3	RAET1E-AS1	11.01	3.03e-25	2.86e-22	0.62	0.45	Lung cancer;	chr6:149844905	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	11.01	3.03e-25	2.86e-22	0.54	0.45	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
THCA	cis	rs9659323	0.7	rs2885226	ENSG00000231365.4	RP11-418J17.1	-11.01	3.05e-25	2.88e-22	-0.45	-0.45	Body mass index;	chr1:119081540	chr1:119140396~119275973:+
THCA	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-11.01	3.05e-25	2.88e-22	-0.53	-0.45	Height;	chr3:52994045	chr3:53064283~53065091:-
THCA	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-11.01	3.05e-25	2.88e-22	-0.53	-0.45	Height;	chr3:52994990	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.607	rs12209310	ENSG00000223701.3	RAET1E-AS1	11.01	3.06e-25	2.89e-22	0.65	0.45	Lung cancer;	chr6:149904882	chr6:149884431~149919508:+
THCA	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-11.01	3.06e-25	2.89e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
THCA	cis	rs11214589	0.747	rs10502172	ENSG00000270179.1	RP11-159N11.4	-11.01	3.07e-25	2.9e-22	-0.49	-0.45	Neuroticism;	chr11:113328424	chr11:113368478~113369117:+
THCA	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	11.01	3.09e-25	2.92e-22	0.61	0.45	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
THCA	cis	rs916888	0.773	rs199445	ENSG00000232300.1	FAM215B	11.01	3.11e-25	2.93e-22	0.73	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46558830~46562795:-
THCA	cis	rs916888	0.773	rs199443	ENSG00000232300.1	FAM215B	11.01	3.11e-25	2.93e-22	0.73	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46558830~46562795:-
THCA	cis	rs2288884	0.581	rs9636144	ENSG00000275055.1	CTC-471J1.11	-11.01	3.13e-25	2.95e-22	-0.35	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52057881	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.636	rs73066154	ENSG00000275055.1	CTC-471J1.11	-11.01	3.13e-25	2.95e-22	-0.35	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52060240	chr19:52049007~52049754:+
THCA	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-11.01	3.13e-25	2.95e-22	-0.6	-0.45	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
THCA	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-11.01	3.14e-25	2.96e-22	-0.59	-0.45	QT interval;	chr16:28824579	chr16:28700294~28701540:-
THCA	cis	rs77204473	0.549	rs12280210	ENSG00000254851.1	RP11-109L13.1	11.01	3.15e-25	2.97e-22	0.88	0.45	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117069733	chr11:117135528~117138582:+
THCA	cis	rs7772486	0.875	rs9390371	ENSG00000235652.6	RP11-545I5.3	11.01	3.16e-25	2.97e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146042044	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs6909827	ENSG00000235652.6	RP11-545I5.3	11.01	3.16e-25	2.97e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146044602	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-11.01	3.19e-25	3.01e-22	-0.57	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
THCA	cis	rs2732480	0.557	rs2732454	ENSG00000258273.1	RP11-370I10.4	-11.01	3.21e-25	3.02e-22	-0.6	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48333755~48333901:-
THCA	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-11.01	3.21e-25	3.02e-22	-0.58	-0.45	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
THCA	cis	rs6570726	0.846	rs973856	ENSG00000235652.6	RP11-545I5.3	-11.01	3.21e-25	3.02e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145460780	chr6:145799409~145886585:+
THCA	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-11	3.24e-25	3.05e-22	-0.55	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-11	3.26e-25	3.07e-22	-0.55	-0.45	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
THCA	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-11	3.26e-25	3.07e-22	-0.55	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
THCA	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-11	3.26e-25	3.07e-22	-0.55	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
THCA	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-11	3.26e-25	3.07e-22	-0.55	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
THCA	cis	rs62158211	0.691	rs1964463	ENSG00000234997.1	AC016745.3	11	3.28e-25	3.09e-22	0.51	0.45	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113311444	chr2:113424495~113425324:+
THCA	cis	rs11676348	0.774	rs57545959	ENSG00000261338.2	RP11-378A13.1	11	3.3e-25	3.1e-22	0.46	0.45	Ulcerative colitis;	chr2:218182995	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000206090.4	AP000350.7	11	3.33e-25	3.13e-22	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23939998~23942798:+
THCA	cis	rs11676348	0.774	rs13397673	ENSG00000261338.2	RP11-378A13.1	-11	3.34e-25	3.14e-22	-0.46	-0.45	Ulcerative colitis;	chr2:218183059	chr2:218255319~218257366:+
THCA	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-11	3.39e-25	3.19e-22	-0.57	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
THCA	cis	rs16828019	0.777	rs13376450	ENSG00000235358.1	RP11-399E6.1	11	3.41e-25	3.21e-22	0.87	0.45	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41242373~41284861:+
THCA	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-11	3.42e-25	3.22e-22	-0.55	-0.45	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
THCA	cis	rs934734	0.673	rs7575614	ENSG00000281920.1	RP11-418H16.1	11	3.44e-25	3.23e-22	0.54	0.45	Rheumatoid arthritis;	chr2:65462666	chr2:65623272~65628424:+
THCA	cis	rs934734	0.673	rs6742215	ENSG00000281920.1	RP11-418H16.1	11	3.44e-25	3.23e-22	0.54	0.45	Rheumatoid arthritis;	chr2:65463362	chr2:65623272~65628424:+
THCA	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-11	3.45e-25	3.24e-22	-0.53	-0.45	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
THCA	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-11	3.45e-25	3.24e-22	-0.53	-0.45	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
THCA	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	11	3.49e-25	3.28e-22	0.55	0.45	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
THCA	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	11	3.49e-25	3.28e-22	0.55	0.45	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
THCA	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-11	3.51e-25	3.29e-22	-0.55	-0.45	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
THCA	cis	rs9903692	0.909	rs1468270	ENSG00000278765.1	RP5-890E16.5	10.99	3.52e-25	3.31e-22	0.6	0.45	Pulse pressure;	chr17:48047829	chr17:48066704~48067293:-
THCA	cis	rs950169	0.84	rs62019457	ENSG00000225151.9	GOLGA2P7	-10.99	3.56e-25	3.34e-22	-0.66	-0.45	Schizophrenia;	chr15:84558911	chr15:84199311~84230136:-
THCA	cis	rs950169	0.922	rs67804993	ENSG00000225151.9	GOLGA2P7	-10.99	3.56e-25	3.34e-22	-0.66	-0.45	Schizophrenia;	chr15:84560799	chr15:84199311~84230136:-
THCA	cis	rs2288884	0.636	rs11669439	ENSG00000275055.1	CTC-471J1.11	-10.99	3.56e-25	3.34e-22	-0.35	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52069047	chr19:52049007~52049754:+
THCA	cis	rs6496932	0.663	rs7182814	ENSG00000218052.5	ADAMTS7P4	-10.99	3.59e-25	3.37e-22	-0.58	-0.45	Central corneal thickness;Corneal structure;	chr15:85362840	chr15:85255369~85330334:-
THCA	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-10.99	3.61e-25	3.39e-22	-0.53	-0.45	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
THCA	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-10.99	3.61e-25	3.39e-22	-0.53	-0.45	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-10.99	3.61e-25	3.39e-22	-0.53	-0.45	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-10.99	3.61e-25	3.39e-22	-0.53	-0.45	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
THCA	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	10.99	3.61e-25	3.39e-22	0.53	0.45	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
THCA	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	10.99	3.61e-25	3.39e-22	0.56	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
THCA	cis	rs6538678	0.864	rs10777747	ENSG00000258343.1	RP11-536G4.2	-10.99	3.62e-25	3.4e-22	-0.61	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95795345~95858839:-
THCA	cis	rs6538678	0.864	rs7308921	ENSG00000258343.1	RP11-536G4.2	10.99	3.62e-25	3.4e-22	0.61	0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95795345~95858839:-
THCA	cis	rs4266144	0.821	rs4325879	ENSG00000244515.1	KRT18P34	-10.99	3.63e-25	3.41e-22	-0.56	-0.45	Coronary artery disease;	chr3:157134195	chr3:157162663~157163932:-
THCA	cis	rs673078	0.615	rs73222058	ENSG00000275759.1	RP11-131L12.3	-10.99	3.65e-25	3.43e-22	-0.6	-0.45	Glucose homeostasis traits;	chr12:118221066	chr12:118428281~118428870:+
THCA	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-10.99	3.67e-25	3.44e-22	-0.6	-0.45	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
THCA	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-10.99	3.67e-25	3.45e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
THCA	cis	rs2880765	0.631	rs55767890	ENSG00000259295.5	CSPG4P12	10.99	3.7e-25	3.47e-22	0.62	0.45	Coronary artery disease;	chr15:85460911	chr15:85191438~85213905:+
THCA	cis	rs875971	1	rs1144895	ENSG00000237310.1	GS1-124K5.4	-10.99	3.7e-25	3.47e-22	-0.34	-0.45	Aortic root size;	chr7:66076320	chr7:66493706~66495474:+
THCA	cis	rs7945705	0.902	rs11042152	ENSG00000254860.4	TMEM9B-AS1	-10.99	3.71e-25	3.48e-22	-0.5	-0.45	Hemoglobin concentration;	chr11:8999440	chr11:8964675~8977527:+
THCA	cis	rs7772486	0.748	rs2748484	ENSG00000235652.6	RP11-545I5.3	10.99	3.71e-25	3.48e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146012517	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.846	rs1854901	ENSG00000235652.6	RP11-545I5.3	10.99	3.72e-25	3.49e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146004549	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs1960885	ENSG00000235652.6	RP11-545I5.3	10.99	3.72e-25	3.49e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146004794	chr6:145799409~145886585:+
THCA	cis	rs934734	0.532	rs7569113	ENSG00000281920.1	RP11-418H16.1	10.99	3.74e-25	3.51e-22	0.55	0.45	Rheumatoid arthritis;	chr2:65429907	chr2:65623272~65628424:+
THCA	cis	rs780096	0.546	rs7563162	ENSG00000234072.1	AC074117.10	-10.99	3.75e-25	3.52e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27408324	chr2:27356246~27367622:+
THCA	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	10.99	3.78e-25	3.54e-22	0.37	0.45	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
THCA	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	10.99	3.79e-25	3.56e-22	0.52	0.45	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
THCA	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	10.99	3.79e-25	3.56e-22	0.52	0.45	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
THCA	cis	rs673078	0.66	rs12229607	ENSG00000275759.1	RP11-131L12.3	-10.99	3.8e-25	3.56e-22	-0.59	-0.45	Glucose homeostasis traits;	chr12:118338333	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945176	ENSG00000275759.1	RP11-131L12.3	-10.99	3.81e-25	3.58e-22	-0.6	-0.45	Glucose homeostasis traits;	chr12:118204735	chr12:118428281~118428870:+
THCA	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-10.99	3.82e-25	3.58e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
THCA	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-10.99	3.82e-25	3.58e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-10.99	3.82e-25	3.58e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
THCA	cis	rs13392177	0.672	rs1877715	ENSG00000261338.2	RP11-378A13.1	10.99	3.82e-25	3.58e-22	0.47	0.45	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218187823	chr2:218255319~218257366:+
THCA	cis	rs780096	0.546	rs2911712	ENSG00000234072.1	AC074117.10	-10.99	3.83e-25	3.59e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27404078	chr2:27356246~27367622:+
THCA	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-10.98	3.84e-25	3.6e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
THCA	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	10.98	3.85e-25	3.61e-22	0.55	0.45	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
THCA	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	10.98	3.85e-25	3.61e-22	0.55	0.45	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
THCA	cis	rs950169	0.922	rs11630507	ENSG00000225151.9	GOLGA2P7	-10.98	3.88e-25	3.64e-22	-0.66	-0.45	Schizophrenia;	chr15:84552494	chr15:84199311~84230136:-
THCA	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-10.98	3.89e-25	3.65e-22	-0.54	-0.45	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
THCA	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-10.98	3.91e-25	3.66e-22	-0.56	-0.45	Height;	chr3:53009621	chr3:53064283~53065091:-
THCA	cis	rs9487094	0.689	rs699700	ENSG00000260273.1	RP11-425D10.10	10.98	3.94e-25	3.69e-22	0.52	0.45	Height;	chr6:109367528	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.689	rs11251	ENSG00000260273.1	RP11-425D10.10	10.98	3.94e-25	3.69e-22	0.52	0.45	Height;	chr6:109368704	chr6:109382795~109383666:+
THCA	cis	rs2288884	0.636	rs1560690	ENSG00000275055.1	CTC-471J1.11	-10.98	3.94e-25	3.69e-22	-0.35	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52075094	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-10.98	3.94e-25	3.69e-22	-0.35	-0.45	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
THCA	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	10.98	3.97e-25	3.72e-22	0.54	0.45	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
THCA	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-10.98	3.98e-25	3.73e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
THCA	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	10.98	4.02e-25	3.76e-22	0.62	0.45	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	10.98	4.02e-25	3.76e-22	0.62	0.45	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	10.98	4.02e-25	3.76e-22	0.62	0.45	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
THCA	cis	rs950169	0.922	rs11631096	ENSG00000225151.9	GOLGA2P7	-10.98	4.02e-25	3.76e-22	-0.66	-0.45	Schizophrenia;	chr15:84557698	chr15:84199311~84230136:-
THCA	cis	rs7772486	0.79	rs9497435	ENSG00000235652.6	RP11-545I5.3	-10.98	4.02e-25	3.76e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145944204	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9791313	ENSG00000235652.6	RP11-545I5.3	-10.98	4.02e-25	3.76e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145945036	chr6:145799409~145886585:+
THCA	cis	rs9903692	0.648	rs35361214	ENSG00000278765.1	RP5-890E16.5	10.98	4.07e-25	3.81e-22	0.6	0.45	Pulse pressure;	chr17:48087729	chr17:48066704~48067293:-
THCA	cis	rs9903692	0.697	rs6504024	ENSG00000278765.1	RP5-890E16.5	10.98	4.07e-25	3.81e-22	0.6	0.45	Pulse pressure;	chr17:48088224	chr17:48066704~48067293:-
THCA	cis	rs148406912	1	rs148406912	ENSG00000254851.1	RP11-109L13.1	10.98	4.07e-25	3.81e-22	0.88	0.45	Lobe attachment (rater-scored or self-reported);	chr11:116967001	chr11:117135528~117138582:+
THCA	cis	rs9322193	0.772	rs7738696	ENSG00000268592.3	RAET1E-AS1	10.98	4.1e-25	3.84e-22	0.62	0.45	Lung cancer;	chr6:149848985	chr6:149863494~149919507:+
THCA	cis	rs9903692	0.779	rs2285863	ENSG00000278765.1	RP5-890E16.5	10.98	4.11e-25	3.85e-22	0.59	0.45	Pulse pressure;	chr17:48048616	chr17:48066704~48067293:-
THCA	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-10.97	4.2e-25	3.93e-22	-0.58	-0.45	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
THCA	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-10.97	4.2e-25	3.93e-22	-0.58	-0.45	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
THCA	cis	rs748404	0.578	rs2584701	ENSG00000249839.1	AC011330.5	-10.97	4.21e-25	3.94e-22	-0.54	-0.45	Lung cancer;	chr15:43392741	chr15:43663654~43684339:-
THCA	cis	rs6504950	0.813	rs9889687	ENSG00000275710.1	RP11-257O5.4	-10.97	4.22e-25	3.94e-22	-0.59	-0.45	Breast cancer;	chr17:55055050	chr17:54964474~54964679:+
THCA	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	10.97	4.24e-25	3.96e-22	0.83	0.45	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
THCA	cis	rs7772486	0.764	rs9399569	ENSG00000235652.6	RP11-545I5.3	-10.97	4.25e-25	3.97e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145921806	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.754	rs4360151	ENSG00000235652.6	RP11-545I5.3	-10.97	4.25e-25	3.97e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145933943	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.851	rs2330011	ENSG00000223768.1	LINC00205	-10.97	4.26e-25	3.99e-22	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45293285~45297354:+
THCA	cis	rs2732480	0.557	rs2409004	ENSG00000258273.1	RP11-370I10.4	-10.97	4.28e-25	4e-22	-0.59	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.577	rs2450994	ENSG00000258273.1	RP11-370I10.4	-10.97	4.28e-25	4e-22	-0.59	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48333755~48333901:-
THCA	cis	rs853679	0.55	rs1150692	ENSG00000219392.1	RP1-265C24.5	-10.97	4.28e-25	4e-22	-0.61	-0.45	Depression;	chr6:28206179	chr6:28115628~28116551:+
THCA	cis	rs10463554	0.927	rs56361326	ENSG00000175749.11	EIF3KP1	10.97	4.29e-25	4.01e-22	0.59	0.45	Parkinson's disease;	chr5:103054184	chr5:103032376~103033031:+
THCA	cis	rs7221109	0.601	rs7209404	ENSG00000278834.1	RP11-458J1.1	10.97	4.29e-25	4.01e-22	0.48	0.45	Type 1 diabetes;	chr17:40668150	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.645	rs7223332	ENSG00000278834.1	RP11-458J1.1	10.97	4.29e-25	4.01e-22	0.48	0.45	Type 1 diabetes;	chr17:40668384	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.56	rs2315020	ENSG00000278834.1	RP11-458J1.1	10.97	4.29e-25	4.01e-22	0.48	0.45	Type 1 diabetes;	chr17:40671414	chr17:40648300~40649718:+
THCA	cis	rs42490	1	rs67143546	ENSG00000251136.7	RP11-37B2.1	-10.97	4.32e-25	4.03e-22	-0.39	-0.45	Leprosy;	chr8:89753950	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs385524	ENSG00000251136.7	RP11-37B2.1	-10.97	4.32e-25	4.03e-22	-0.39	-0.45	Leprosy;	chr8:89754242	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs419754	ENSG00000251136.7	RP11-37B2.1	-10.97	4.32e-25	4.03e-22	-0.39	-0.45	Leprosy;	chr8:89755452	chr8:89609409~89757727:-
THCA	cis	rs526231	0.543	rs171558	ENSG00000175749.11	EIF3KP1	10.97	4.33e-25	4.05e-22	0.63	0.45	Primary biliary cholangitis;	chr5:103242193	chr5:103032376~103033031:+
THCA	cis	rs6504950	0.925	rs244317	ENSG00000275710.1	RP11-257O5.4	-10.97	4.34e-25	4.06e-22	-0.6	-0.45	Breast cancer;	chr17:55139624	chr17:54964474~54964679:+
THCA	cis	rs42490	0.966	rs6992985	ENSG00000251136.7	RP11-37B2.1	-10.97	4.35e-25	4.06e-22	-0.39	-0.45	Leprosy;	chr8:89746330	chr8:89609409~89757727:-
THCA	cis	rs6570726	0.846	rs397311	ENSG00000235652.6	RP11-545I5.3	-10.97	4.35e-25	4.06e-22	-0.42	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145485565	chr6:145799409~145886585:+
THCA	cis	rs950169	0.887	rs71395453	ENSG00000225151.9	GOLGA2P7	-10.97	4.36e-25	4.07e-22	-0.66	-0.45	Schizophrenia;	chr15:84570259	chr15:84199311~84230136:-
THCA	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-10.97	4.37e-25	4.08e-22	-0.33	-0.45	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
THCA	cis	rs1075265	0.933	rs7573491	ENSG00000233266.1	HMGB1P31	10.97	4.39e-25	4.1e-22	0.57	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54051334~54051760:+
THCA	cis	rs7772486	0.79	rs1133832	ENSG00000235652.6	RP11-545I5.3	-10.97	4.42e-25	4.13e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145884468	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000224205.1	AP000351.4	10.97	4.47e-25	4.17e-22	0.54	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23987320~23991421:-
THCA	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-10.97	4.49e-25	4.19e-22	-0.59	-0.45	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-10.97	4.49e-25	4.19e-22	-0.59	-0.45	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
THCA	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	10.97	4.5e-25	4.2e-22	0.54	0.45	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
THCA	cis	rs9487094	0.666	rs13219952	ENSG00000260273.1	RP11-425D10.10	10.97	4.51e-25	4.21e-22	0.52	0.45	Height;	chr6:109391084	chr6:109382795~109383666:+
THCA	cis	rs6504950	0.85	rs2541242	ENSG00000275710.1	RP11-257O5.4	-10.97	4.51e-25	4.21e-22	-0.59	-0.45	Breast cancer;	chr17:55012326	chr17:54964474~54964679:+
THCA	cis	rs42490	0.966	rs218932	ENSG00000251136.7	RP11-37B2.1	-10.97	4.51e-25	4.21e-22	-0.39	-0.45	Leprosy;	chr8:89740725	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs2735878	ENSG00000251136.7	RP11-37B2.1	-10.97	4.51e-25	4.21e-22	-0.39	-0.45	Leprosy;	chr8:89742720	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs6993133	ENSG00000251136.7	RP11-37B2.1	-10.97	4.51e-25	4.21e-22	-0.39	-0.45	Leprosy;	chr8:89746396	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs13252917	ENSG00000251136.7	RP11-37B2.1	-10.97	4.51e-25	4.21e-22	-0.39	-0.45	Leprosy;	chr8:89747202	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs10112852	ENSG00000251136.7	RP11-37B2.1	-10.97	4.51e-25	4.21e-22	-0.39	-0.45	Leprosy;	chr8:89749257	chr8:89609409~89757727:-
THCA	cis	rs42490	0.934	rs10095743	ENSG00000251136.7	RP11-37B2.1	-10.97	4.51e-25	4.21e-22	-0.39	-0.45	Leprosy;	chr8:89749445	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs2644033	ENSG00000251136.7	RP11-37B2.1	10.97	4.51e-25	4.21e-22	0.39	0.45	Leprosy;	chr8:89739196	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs218936	ENSG00000251136.7	RP11-37B2.1	10.97	4.51e-25	4.21e-22	0.39	0.45	Leprosy;	chr8:89743186	chr8:89609409~89757727:-
THCA	cis	rs2599510	0.783	rs13399071	ENSG00000276334.1	AL133243.1	10.97	4.52e-25	4.22e-22	0.5	0.45	Interleukin-18 levels;	chr2:32568716	chr2:32521927~32523547:+
THCA	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-10.97	4.54e-25	4.23e-22	-0.55	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
THCA	cis	rs6504950	0.889	rs2628305	ENSG00000275710.1	RP11-257O5.4	10.97	4.55e-25	4.24e-22	0.57	0.45	Breast cancer;	chr17:55063066	chr17:54964474~54964679:+
THCA	cis	rs6570726	1	rs455109	ENSG00000235652.6	RP11-545I5.3	10.97	4.56e-25	4.25e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145551529	chr6:145799409~145886585:+
THCA	cis	rs6570726	1	rs373778	ENSG00000235652.6	RP11-545I5.3	10.97	4.56e-25	4.25e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145552116	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.87	rs10139083	ENSG00000258413.1	RP11-665C16.6	-10.97	4.57e-25	4.26e-22	-0.59	-0.45	Protein biomarker;	chr14:55316017	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.87	rs10145203	ENSG00000258413.1	RP11-665C16.6	-10.97	4.57e-25	4.26e-22	-0.59	-0.45	Protein biomarker;	chr14:55317740	chr14:55262767~55272075:-
THCA	cis	rs7772486	0.875	rs2814866	ENSG00000235652.6	RP11-545I5.3	10.96	4.58e-25	4.27e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146018278	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2328712	ENSG00000235652.6	RP11-545I5.3	10.96	4.58e-25	4.27e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146023427	chr6:145799409~145886585:+
THCA	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-10.96	4.61e-25	4.3e-22	-0.41	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
THCA	cis	rs11159086	0.793	rs10139029	ENSG00000270000.1	RP3-449M8.9	10.96	4.62e-25	4.3e-22	0.49	0.45	Advanced glycation end-product levels;	chr14:74492284	chr14:74471930~74472360:-
THCA	cis	rs7772486	0.79	rs9497424	ENSG00000235652.6	RP11-545I5.3	-10.96	4.63e-25	4.31e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145904135	chr6:145799409~145886585:+
THCA	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-10.96	4.65e-25	4.34e-22	-0.59	-0.45	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
THCA	cis	rs71403859	0.803	rs17282500	ENSG00000260886.1	TAT-AS1	10.96	4.67e-25	4.35e-22	0.81	0.45	Post bronchodilator FEV1;	chr16:71599750	chr16:71565789~71578187:+
THCA	cis	rs71403859	0.685	rs12444890	ENSG00000260886.1	TAT-AS1	10.96	4.67e-25	4.35e-22	0.81	0.45	Post bronchodilator FEV1;	chr16:71602123	chr16:71565789~71578187:+
THCA	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	10.96	4.68e-25	4.36e-22	0.56	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
THCA	cis	rs6504950	0.889	rs2787505	ENSG00000275710.1	RP11-257O5.4	-10.96	4.68e-25	4.36e-22	-0.59	-0.45	Breast cancer;	chr17:55030071	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.85	rs2787507	ENSG00000275710.1	RP11-257O5.4	-10.96	4.68e-25	4.36e-22	-0.59	-0.45	Breast cancer;	chr17:55050563	chr17:54964474~54964679:+
THCA	cis	rs11159086	1	rs17100451	ENSG00000270000.1	RP3-449M8.9	10.96	4.69e-25	4.37e-22	0.5	0.45	Advanced glycation end-product levels;	chr14:74476210	chr14:74471930~74472360:-
THCA	cis	rs6504950	0.85	rs17745534	ENSG00000275710.1	RP11-257O5.4	-10.96	4.7e-25	4.38e-22	-0.59	-0.45	Breast cancer;	chr17:55060145	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.889	rs9303363	ENSG00000275710.1	RP11-257O5.4	-10.96	4.7e-25	4.38e-22	-0.59	-0.45	Breast cancer;	chr17:55060613	chr17:54964474~54964679:+
THCA	cis	rs860295	0.702	rs10752611	ENSG00000225855.5	RUSC1-AS1	10.96	4.71e-25	4.39e-22	0.32	0.45	Body mass index;	chr1:155539316	chr1:155316863~155324176:-
THCA	cis	rs673078	0.66	rs61945217	ENSG00000275759.1	RP11-131L12.3	-10.96	4.71e-25	4.39e-22	-0.72	-0.45	Glucose homeostasis traits;	chr12:118261194	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs117091919	ENSG00000275759.1	RP11-131L12.3	-10.96	4.71e-25	4.39e-22	-0.72	-0.45	Glucose homeostasis traits;	chr12:118273228	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs7314987	ENSG00000275759.1	RP11-131L12.3	-10.96	4.71e-25	4.39e-22	-0.72	-0.45	Glucose homeostasis traits;	chr12:118274072	chr12:118428281~118428870:+
THCA	cis	rs10463554	0.963	rs32850	ENSG00000175749.11	EIF3KP1	10.96	4.77e-25	4.44e-22	0.58	0.45	Parkinson's disease;	chr5:103134325	chr5:103032376~103033031:+
THCA	cis	rs11159086	0.793	rs10136668	ENSG00000270000.1	RP3-449M8.9	10.96	4.8e-25	4.47e-22	0.49	0.45	Advanced glycation end-product levels;	chr14:74492183	chr14:74471930~74472360:-
THCA	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-10.96	4.81e-25	4.48e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
THCA	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	10.96	4.84e-25	4.5e-22	0.55	0.45	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
THCA	cis	rs7221109	0.71	rs4890093	ENSG00000278834.1	RP11-458J1.1	10.96	4.85e-25	4.52e-22	0.48	0.45	Type 1 diabetes;	chr17:40639691	chr17:40648300~40649718:+
THCA	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-10.96	4.86e-25	4.53e-22	-0.41	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
THCA	cis	rs7576126	1	rs7576126	ENSG00000281920.1	RP11-418H16.1	-10.96	4.87e-25	4.53e-22	-0.54	-0.45	Severe influenza A (H1N1) infection;	chr2:65431235	chr2:65623272~65628424:+
THCA	cis	rs7772486	0.79	rs9386141	ENSG00000235652.6	RP11-545I5.3	-10.96	4.92e-25	4.57e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145947487	chr6:145799409~145886585:+
THCA	cis	rs3762637	0.941	rs79493664	ENSG00000272758.4	RP11-299J3.8	-10.96	4.92e-25	4.57e-22	-0.6	-0.45	LDL cholesterol levels;	chr3:122390699	chr3:122416207~122443180:+
THCA	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-10.96	4.93e-25	4.58e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
THCA	cis	rs526231	0.575	rs62362523	ENSG00000175749.11	EIF3KP1	10.96	4.93e-25	4.58e-22	0.62	0.45	Primary biliary cholangitis;	chr5:102977979	chr5:103032376~103033031:+
THCA	cis	rs526231	0.575	rs62362524	ENSG00000175749.11	EIF3KP1	10.96	4.93e-25	4.58e-22	0.62	0.45	Primary biliary cholangitis;	chr5:102978523	chr5:103032376~103033031:+
THCA	cis	rs2658782	0.724	rs2658769	ENSG00000279684.1	RP11-755E23.2	-10.96	4.93e-25	4.59e-22	-0.71	-0.45	Pulmonary function decline;	chr11:93518864	chr11:93286629~93288903:-
THCA	cis	rs950169	0.92	rs12915390	ENSG00000225151.9	GOLGA2P7	-10.96	4.95e-25	4.61e-22	-0.67	-0.45	Schizophrenia;	chr15:84123317	chr15:84199311~84230136:-
THCA	cis	rs71403859	0.73	rs12931191	ENSG00000260886.1	TAT-AS1	-10.96	4.97e-25	4.62e-22	-0.8	-0.45	Post bronchodilator FEV1;	chr16:71587470	chr16:71565789~71578187:+
THCA	cis	rs7772486	0.727	rs10223508	ENSG00000235652.6	RP11-545I5.3	-10.96	4.98e-25	4.64e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145964069	chr6:145799409~145886585:+
THCA	cis	rs11676348	0.808	rs1008563	ENSG00000261338.2	RP11-378A13.1	-10.95	5e-25	4.65e-22	-0.46	-0.45	Ulcerative colitis;	chr2:218162165	chr2:218255319~218257366:+
THCA	cis	rs10935480	0.771	rs7634817	ENSG00000239445.4	ST3GAL6-AS1	10.95	5.07e-25	4.71e-22	0.45	0.45	Blood protein levels;	chr3:98743681	chr3:98714330~98732651:-
THCA	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	10.95	5.1e-25	4.74e-22	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
THCA	cis	rs4819052	0.851	rs35560973	ENSG00000223768.1	LINC00205	-10.95	5.14e-25	4.78e-22	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45293285~45297354:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	10.95	5.16e-25	4.79e-22	0.58	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
THCA	cis	rs8072100	0.84	rs12452796	ENSG00000228782.6	CTD-2026D20.3	-10.95	5.16e-25	4.8e-22	-0.42	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402367	chr17:47450568~47492492:-
THCA	cis	rs6504950	0.925	rs2787481	ENSG00000275710.1	RP11-257O5.4	-10.95	5.17e-25	4.8e-22	-0.61	-0.45	Breast cancer;	chr17:55133749	chr17:54964474~54964679:+
THCA	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-10.95	5.19e-25	4.83e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
THCA	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-10.95	5.2e-25	4.84e-22	-0.53	-0.45	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
THCA	cis	rs2564921	0.73	rs62255897	ENSG00000242142.1	SERBP1P3	-10.95	5.2e-25	4.84e-22	-0.56	-0.45	Height;	chr3:53029854	chr3:53064283~53065091:-
THCA	cis	rs673078	0.66	rs17586342	ENSG00000275759.1	RP11-131L12.3	-10.95	5.25e-25	4.87e-22	-0.59	-0.45	Glucose homeostasis traits;	chr12:118162399	chr12:118428281~118428870:+
THCA	cis	rs4819052	0.765	rs2838827	ENSG00000223768.1	LINC00205	-10.95	5.27e-25	4.89e-22	-0.43	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45293285~45297354:+
THCA	cis	rs6964833	0.873	rs4717905	ENSG00000123965.13	PMS2P5	10.95	5.27e-25	4.9e-22	0.78	0.45	Menarche (age at onset);	chr7:74668903	chr7:74894116~74897835:+
THCA	cis	rs7772486	0.875	rs7739418	ENSG00000235652.6	RP11-545I5.3	10.95	5.28e-25	4.91e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146038052	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.87	rs2016931	ENSG00000258413.1	RP11-665C16.6	-10.95	5.34e-25	4.96e-22	-0.59	-0.45	Protein biomarker;	chr14:55375614	chr14:55262767~55272075:-
THCA	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-10.95	5.36e-25	4.98e-22	-0.59	-0.45	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
THCA	cis	rs1062177	0.547	rs2915818	ENSG00000213433.5	RPLP1P6	10.95	5.36e-25	4.98e-22	0.47	0.45	Preschool internalizing problems;	chr5:151735729	chr5:151765859~151766378:-
THCA	cis	rs780096	0.506	rs2950834	ENSG00000234072.1	AC074117.10	-10.95	5.37e-25	4.99e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27404499	chr2:27356246~27367622:+
THCA	cis	rs7688014	1	rs7688014	ENSG00000246560.2	RP11-10L12.4	10.95	5.4e-25	5.01e-22	0.57	0.45	Schizophrenia;	chr4:103053903	chr4:102828055~102844075:+
THCA	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	10.95	5.42e-25	5.03e-22	0.52	0.45	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
THCA	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-10.94	5.46e-25	5.07e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
THCA	cis	rs3745672	1	rs76403598	ENSG00000219665.7	CTD-2006C1.2	-10.94	5.46e-25	5.07e-22	-1	-0.45	Multiple sclerosis;	chr19:12055367	chr19:11987617~12046275:+
THCA	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-10.94	5.48e-25	5.08e-22	-0.58	-0.45	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
THCA	cis	rs4819052	0.851	rs8126930	ENSG00000223768.1	LINC00205	-10.94	5.52e-25	5.13e-22	-0.41	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45293285~45297354:+
THCA	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	10.94	5.52e-25	5.13e-22	0.51	0.45	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
THCA	cis	rs780096	0.505	rs12475426	ENSG00000234072.1	AC074117.10	-10.94	5.54e-25	5.14e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27376265	chr2:27356246~27367622:+
THCA	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-10.94	5.54e-25	5.14e-22	-0.57	-0.45	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
THCA	cis	rs2946504	0.501	rs2946509	ENSG00000251468.2	RP11-369K16.1	-10.94	5.6e-25	5.2e-22	-0.51	-0.45	Type 2 diabetes;	chr8:12950782	chr8:12958387~12962200:+
THCA	cis	rs4964805	0.865	rs67825151	ENSG00000257681.1	RP11-341G23.4	10.94	5.61e-25	5.21e-22	0.54	0.45	Attention deficit hyperactivity disorder;	chr12:103811666	chr12:103746315~103768858:-
THCA	cis	rs10262624	1	rs11767124	ENSG00000234286.1	AC006026.13	-10.94	5.66e-25	5.25e-22	-0.58	-0.45	Schizophrenia;	chr7:23879461	chr7:23680195~23680786:-
THCA	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-10.94	5.69e-25	5.28e-22	-0.54	-0.45	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-10.94	5.69e-25	5.28e-22	-0.54	-0.45	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-10.94	5.69e-25	5.28e-22	-0.54	-0.45	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-10.94	5.69e-25	5.28e-22	-0.54	-0.45	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
THCA	cis	rs944289	0.617	rs11156905	ENSG00000257826.1	RP11-116N8.4	-10.94	5.71e-25	5.29e-22	-0.48	-0.45	Thyroid cancer;	chr14:36100314	chr14:36061026~36067190:-
THCA	cis	rs704795	0.805	rs1728926	ENSG00000234072.1	AC074117.10	-10.94	5.71e-25	5.29e-22	-0.35	-0.45	Menopause (age at onset);	chr2:27390070	chr2:27356246~27367622:+
THCA	cis	rs704795	0.836	rs1647281	ENSG00000234072.1	AC074117.10	-10.94	5.71e-25	5.29e-22	-0.35	-0.45	Menopause (age at onset);	chr2:27390071	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs809058	ENSG00000234072.1	AC074117.10	-10.94	5.71e-25	5.29e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27393923	chr2:27356246~27367622:+
THCA	cis	rs704795	0.836	rs1083865	ENSG00000234072.1	AC074117.10	-10.94	5.71e-25	5.29e-22	-0.35	-0.45	Menopause (age at onset);	chr2:27397960	chr2:27356246~27367622:+
THCA	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	10.94	5.77e-25	5.34e-22	0.54	0.45	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
THCA	cis	rs7569084	0.687	rs35839762	ENSG00000237979.1	AC007389.1	10.94	5.8e-25	5.37e-22	0.53	0.45	Sum eosinophil basophil counts;	chr2:65441318	chr2:65500993~65502138:-
THCA	cis	rs4819052	0.851	rs4819041	ENSG00000223768.1	LINC00205	-10.94	5.8e-25	5.37e-22	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45293285~45297354:+
THCA	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-10.94	5.8e-25	5.37e-22	-0.47	-0.45	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
THCA	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-10.94	5.8e-25	5.38e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
THCA	cis	rs950169	0.922	rs11630760	ENSG00000225151.9	GOLGA2P7	-10.94	5.82e-25	5.39e-22	-0.66	-0.45	Schizophrenia;	chr15:84570106	chr15:84199311~84230136:-
THCA	cis	rs6504950	0.889	rs1484776	ENSG00000275710.1	RP11-257O5.4	-10.94	5.83e-25	5.4e-22	-0.57	-0.45	Breast cancer;	chr17:55034022	chr17:54964474~54964679:+
THCA	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-10.94	5.83e-25	5.41e-22	-0.53	-0.45	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
THCA	cis	rs748404	0.69	rs1079309	ENSG00000249839.1	AC011330.5	-10.94	5.83e-25	5.41e-22	-0.53	-0.45	Lung cancer;	chr15:43490966	chr15:43663654~43684339:-
THCA	cis	rs9487094	0.517	rs3778474	ENSG00000260273.1	RP11-425D10.10	10.94	5.85e-25	5.42e-22	0.52	0.45	Height;	chr6:109374782	chr6:109382795~109383666:+
THCA	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-10.94	5.85e-25	5.42e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
THCA	cis	rs7945705	0.87	rs1109305	ENSG00000254860.4	TMEM9B-AS1	-10.94	5.89e-25	5.45e-22	-0.5	-0.45	Hemoglobin concentration;	chr11:8933725	chr11:8964675~8977527:+
THCA	cis	rs6504950	0.925	rs2787483	ENSG00000275710.1	RP11-257O5.4	10.94	5.91e-25	5.48e-22	0.61	0.45	Breast cancer;	chr17:55132953	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.925	rs2628317	ENSG00000275710.1	RP11-257O5.4	10.94	5.91e-25	5.48e-22	0.61	0.45	Breast cancer;	chr17:55135212	chr17:54964474~54964679:+
THCA	cis	rs12130219	1	rs12130219	ENSG00000237975.5	FLG-AS1	10.94	5.92e-25	5.49e-22	0.65	0.45	Inflammatory skin disease;	chr1:152189630	chr1:152168125~152445456:+
THCA	cis	rs12130219	1	rs1552994	ENSG00000237975.5	FLG-AS1	10.94	5.92e-25	5.49e-22	0.65	0.45	Inflammatory skin disease;	chr1:152198985	chr1:152168125~152445456:+
THCA	cis	rs12130219	1	rs12733173	ENSG00000237975.5	FLG-AS1	10.94	5.92e-25	5.49e-22	0.65	0.45	Inflammatory skin disease;	chr1:152201496	chr1:152168125~152445456:+
THCA	cis	rs10256972	0.9	rs4388364	ENSG00000229043.2	AC091729.9	-10.94	5.93e-25	5.49e-22	-0.48	-0.45	Endometriosis;Longevity;	chr7:993409	chr7:1160374~1165267:+
THCA	cis	rs673078	0.66	rs2280711	ENSG00000275759.1	RP11-131L12.3	-10.94	5.94e-25	5.5e-22	-0.59	-0.45	Glucose homeostasis traits;	chr12:118212149	chr12:118428281~118428870:+
THCA	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-10.93	5.97e-25	5.53e-22	-0.48	-0.45	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
THCA	cis	rs526231	0.511	rs10515341	ENSG00000175749.11	EIF3KP1	10.93	5.98e-25	5.54e-22	0.62	0.45	Primary biliary cholangitis;	chr5:102981413	chr5:103032376~103033031:+
THCA	cis	rs526231	0.575	rs10463990	ENSG00000175749.11	EIF3KP1	10.93	5.98e-25	5.54e-22	0.62	0.45	Primary biliary cholangitis;	chr5:102981714	chr5:103032376~103033031:+
THCA	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-10.93	5.98e-25	5.54e-22	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
THCA	cis	rs944289	0.617	rs1952708	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36113126	chr14:36061026~36067190:-
THCA	cis	rs944289	0.617	rs12432682	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36114058	chr14:36061026~36067190:-
THCA	cis	rs944289	0.617	rs7156229	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36114780	chr14:36061026~36067190:-
THCA	cis	rs944289	0.617	rs7156269	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36114849	chr14:36061026~36067190:-
THCA	cis	rs944289	0.617	rs2415314	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36115335	chr14:36061026~36067190:-
THCA	cis	rs944289	0.617	rs1159048	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36115428	chr14:36061026~36067190:-
THCA	cis	rs944289	0.617	rs1475715	ENSG00000257826.1	RP11-116N8.4	-10.93	6.04e-25	5.59e-22	-0.48	-0.45	Thyroid cancer;	chr14:36116017	chr14:36061026~36067190:-
THCA	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	10.93	6.04e-25	5.59e-22	0.57	0.45	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	10.93	6.07e-25	5.61e-22	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
THCA	cis	rs465969	0.744	rs9400477	ENSG00000255389.1	C6orf3	10.93	6.14e-25	5.68e-22	0.8	0.45	Psoriasis;	chr6:111469440	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs463543	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111346349	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs78945802	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111407143	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs17072683	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111410007	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs17090837	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111430650	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs35208445	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111434944	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs35248830	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111435547	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs35151650	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111436524	chr6:111599875~111602295:+
THCA	cis	rs465969	0.744	rs34089926	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111439043	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs4580915	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111439561	chr6:111599875~111602295:+
THCA	cis	rs465969	0.744	rs7758483	ENSG00000255389.1	C6orf3	-10.93	6.14e-25	5.68e-22	-0.8	-0.45	Psoriasis;	chr6:111467945	chr6:111599875~111602295:+
THCA	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	10.93	6.18e-25	5.71e-22	0.57	0.45	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
THCA	cis	rs2274273	0.84	rs1045002	ENSG00000258413.1	RP11-665C16.6	-10.93	6.18e-25	5.72e-22	-0.59	-0.45	Protein biomarker;	chr14:55351799	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.566	rs12528243	ENSG00000223701.3	RAET1E-AS1	10.93	6.22e-25	5.75e-22	0.65	0.45	Lung cancer;	chr6:149898491	chr6:149884431~149919508:+
THCA	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	10.93	6.23e-25	5.76e-22	0.59	0.45	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
THCA	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-10.93	6.23e-25	5.76e-22	-0.59	-0.45	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
THCA	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-10.93	6.24e-25	5.77e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
THCA	cis	rs10246939	0.544	rs2163953	ENSG00000228775.6	WEE2-AS1	10.93	6.27e-25	5.79e-22	0.53	0.45	Bitter taste perception;	chr7:141867769	chr7:141704338~141738346:-
THCA	cis	rs2274273	0.967	rs2340931	ENSG00000258413.1	RP11-665C16.6	-10.93	6.27e-25	5.8e-22	-0.58	-0.45	Protein biomarker;	chr14:55150219	chr14:55262767~55272075:-
THCA	cis	rs3002131	0.604	rs1319392	ENSG00000225265.1	TAF1A-AS1	-10.93	6.28e-25	5.8e-22	-0.6	-0.45	Interleukin-10 levels;	chr1:222567271	chr1:222589825~222593032:+
THCA	cis	rs2274273	0.773	rs10147765	ENSG00000258413.1	RP11-665C16.6	-10.93	6.28e-25	5.8e-22	-0.59	-0.45	Protein biomarker;	chr14:55361108	chr14:55262767~55272075:-
THCA	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-10.93	6.29e-25	5.81e-22	-0.59	-0.45	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
THCA	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-10.93	6.29e-25	5.81e-22	-0.59	-0.45	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
THCA	cis	rs950169	0.922	rs11633075	ENSG00000225151.9	GOLGA2P7	-10.93	6.33e-25	5.85e-22	-0.66	-0.45	Schizophrenia;	chr15:84570741	chr15:84199311~84230136:-
THCA	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-10.93	6.36e-25	5.88e-22	-0.67	-0.45	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
THCA	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-10.93	6.38e-25	5.9e-22	-0.59	-0.45	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
THCA	cis	rs2732480	0.538	rs1387260	ENSG00000258273.1	RP11-370I10.4	-10.93	6.41e-25	5.92e-22	-0.59	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48333755~48333901:-
THCA	cis	rs6558530	0.666	rs4242539	ENSG00000253982.1	CTD-2336O2.1	10.93	6.43e-25	5.94e-22	0.43	0.45	Systolic blood pressure;	chr8:1746070	chr8:1761990~1764502:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	10.93	6.43e-25	5.94e-22	0.58	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
THCA	cis	rs9322193	0.607	rs10457852	ENSG00000223701.3	RAET1E-AS1	10.93	6.44e-25	5.94e-22	0.65	0.45	Lung cancer;	chr6:149880584	chr6:149884431~149919508:+
THCA	cis	rs10463554	0.926	rs3776858	ENSG00000175749.11	EIF3KP1	10.93	6.45e-25	5.95e-22	0.59	0.45	Parkinson's disease;	chr5:103021790	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.923	rs9767105	ENSG00000223701.3	RAET1E-AS1	10.93	6.45e-25	5.95e-22	0.61	0.45	Lung cancer;	chr6:149659591	chr6:149884431~149919508:+
THCA	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-10.93	6.45e-25	5.96e-22	-0.51	-0.45	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
THCA	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-10.93	6.49e-25	5.99e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
THCA	cis	rs6570726	1	rs951143	ENSG00000235652.6	RP11-545I5.3	10.93	6.49e-25	5.99e-22	0.42	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145611440	chr6:145799409~145886585:+
THCA	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-10.93	6.5e-25	6e-22	-0.6	-0.45	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.962	rs9688750	ENSG00000223701.3	RAET1E-AS1	10.92	6.53e-25	6.03e-22	0.6	0.45	Lung cancer;	chr6:149657633	chr6:149884431~149919508:+
THCA	cis	rs9532669	0.926	rs9525418	ENSG00000239827.7	SUGT1P3	10.92	6.54e-25	6.04e-22	0.51	0.45	Cervical cancer;	chr13:40879081	chr13:40908159~40921774:-
THCA	cis	rs4591358	0.648	rs6732306	ENSG00000223466.1	AC064834.2	-10.92	6.56e-25	6.06e-22	-0.64	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541396	chr2:195533035~195538681:+
THCA	cis	rs4819052	0.851	rs4819040	ENSG00000223768.1	LINC00205	-10.92	6.64e-25	6.12e-22	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45293285~45297354:+
THCA	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-10.92	6.67e-25	6.15e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-10.92	6.67e-25	6.15e-22	-0.53	-0.45	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
THCA	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-10.92	6.67e-25	6.15e-22	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
THCA	cis	rs7772486	0.875	rs932522	ENSG00000235652.6	RP11-545I5.3	-10.92	6.67e-25	6.15e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:146052890	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs585292	ENSG00000235652.6	RP11-545I5.3	10.92	6.68e-25	6.16e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145541092	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.837	rs419991	ENSG00000235652.6	RP11-545I5.3	10.92	6.68e-25	6.16e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145543076	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.875	rs12524077	ENSG00000235652.6	RP11-545I5.3	10.92	6.68e-25	6.16e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145545197	chr6:145799409~145886585:+
THCA	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-10.92	6.7e-25	6.18e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
THCA	cis	rs7772486	0.79	rs9497425	ENSG00000235652.6	RP11-545I5.3	-10.92	6.73e-25	6.2e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145913061	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.79	rs9497427	ENSG00000235652.6	RP11-545I5.3	-10.92	6.73e-25	6.2e-22	-0.41	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145917166	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.902	rs373321	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145533014	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.967	rs374728	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145533462	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs369214	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145535573	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs390252	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145535760	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.875	rs373313	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145536655	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs380433	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145538465	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs367643	ENSG00000235652.6	RP11-545I5.3	10.92	6.74e-25	6.21e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145538466	chr6:145799409~145886585:+
THCA	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-10.92	6.81e-25	6.27e-22	-0.56	-0.45	Height;	chr3:53007328	chr3:53064283~53065091:-
THCA	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	10.92	6.86e-25	6.32e-22	0.53	0.45	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
THCA	cis	rs77204473	0.557	rs9971422	ENSG00000254851.1	RP11-109L13.1	10.92	6.87e-25	6.33e-22	0.87	0.45	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116966657	chr11:117135528~117138582:+
THCA	cis	rs9532669	0.926	rs7328139	ENSG00000176268.5	CYCSP34	10.92	6.88e-25	6.34e-22	0.52	0.45	Cervical cancer;	chr13:40862295	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7328145	ENSG00000176268.5	CYCSP34	10.92	6.88e-25	6.34e-22	0.52	0.45	Cervical cancer;	chr13:40862307	chr13:40863599~40863902:-
THCA	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	10.92	6.92e-25	6.37e-22	0.53	0.45	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.79	rs2247206	ENSG00000235652.6	RP11-545I5.3	10.92	6.92e-25	6.38e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145895048	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.764	rs2247211	ENSG00000235652.6	RP11-545I5.3	10.92	6.92e-25	6.38e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145895243	chr6:145799409~145886585:+
THCA	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	10.92	6.95e-25	6.4e-22	0.54	0.45	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
THCA	cis	rs4819052	0.724	rs1304487	ENSG00000223768.1	LINC00205	10.92	7e-25	6.45e-22	0.42	0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45293285~45297354:+
THCA	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-10.92	7.09e-25	6.52e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
THCA	cis	rs42490	1	rs218907	ENSG00000251136.7	RP11-37B2.1	-10.91	7.1e-25	6.54e-22	-0.39	-0.45	Leprosy;	chr8:89728164	chr8:89609409~89757727:-
THCA	cis	rs780096	0.546	rs1647284	ENSG00000234072.1	AC074117.10	-10.91	7.13e-25	6.56e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27385248	chr2:27356246~27367622:+
THCA	cis	rs860295	0.665	rs12028416	ENSG00000225855.5	RUSC1-AS1	10.91	7.15e-25	6.58e-22	0.31	0.45	Body mass index;	chr1:155431370	chr1:155316863~155324176:-
THCA	cis	rs860295	0.629	rs12026638	ENSG00000225855.5	RUSC1-AS1	10.91	7.15e-25	6.58e-22	0.31	0.45	Body mass index;	chr1:155431469	chr1:155316863~155324176:-
THCA	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-10.91	7.2e-25	6.63e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
THCA	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	10.91	7.21e-25	6.64e-22	0.6	0.45	Depression;	chr6:28200948	chr6:28115628~28116551:+
THCA	cis	rs6504950	0.889	rs2541237	ENSG00000275710.1	RP11-257O5.4	-10.91	7.23e-25	6.65e-22	-0.6	-0.45	Breast cancer;	chr17:55086676	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.889	rs1484769	ENSG00000275710.1	RP11-257O5.4	-10.91	7.23e-25	6.65e-22	-0.6	-0.45	Breast cancer;	chr17:55089290	chr17:54964474~54964679:+
THCA	cis	rs465969	1	rs34382476	ENSG00000255389.1	C6orf3	-10.91	7.27e-25	6.69e-22	-0.8	-0.45	Psoriasis;	chr6:111423551	chr6:111599875~111602295:+
THCA	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	10.91	7.3e-25	6.71e-22	0.54	0.45	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
THCA	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
THCA	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-10.91	7.31e-25	6.72e-22	-0.52	-0.45	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
THCA	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	10.91	7.32e-25	6.73e-22	0.54	0.45	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
THCA	cis	rs9532669	0.926	rs11147823	ENSG00000176268.5	CYCSP34	-10.91	7.34e-25	6.75e-22	-0.52	-0.45	Cervical cancer;	chr13:40878138	chr13:40863599~40863902:-
THCA	cis	rs780096	0.526	rs7594812	ENSG00000234072.1	AC074117.10	-10.91	7.47e-25	6.86e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27388602	chr2:27356246~27367622:+
THCA	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	10.91	7.54e-25	6.92e-22	0.56	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
THCA	cis	rs526231	0.543	rs246906	ENSG00000175749.11	EIF3KP1	10.91	7.6e-25	6.98e-22	0.62	0.45	Primary biliary cholangitis;	chr5:103230770	chr5:103032376~103033031:+
THCA	cis	rs4591358	0.689	rs1913894	ENSG00000223466.1	AC064834.2	-10.91	7.61e-25	6.99e-22	-0.67	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195534032	chr2:195533035~195538681:+
THCA	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-10.91	7.62e-25	6.99e-22	-0.6	-0.45	Depression;	chr6:28193021	chr6:28115628~28116551:+
THCA	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-10.91	7.62e-25	6.99e-22	-0.6	-0.45	Depression;	chr6:28197321	chr6:28115628~28116551:+
THCA	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-10.91	7.62e-25	6.99e-22	-0.6	-0.45	Depression;	chr6:28197412	chr6:28115628~28116551:+
THCA	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-10.91	7.62e-25	6.99e-22	-0.6	-0.45	Depression;	chr6:28198669	chr6:28115628~28116551:+
THCA	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	10.91	7.62e-25	6.99e-22	0.6	0.45	Depression;	chr6:28199145	chr6:28115628~28116551:+
THCA	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-10.91	7.62e-25	6.99e-22	-0.6	-0.45	Depression;	chr6:28205175	chr6:28115628~28116551:+
THCA	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	10.91	7.62e-25	6.99e-22	0.6	0.45	Depression;	chr6:28205232	chr6:28115628~28116551:+
THCA	cis	rs950169	0.922	rs12912934	ENSG00000225151.9	GOLGA2P7	-10.91	7.62e-25	6.99e-22	-0.66	-0.45	Schizophrenia;	chr15:84571216	chr15:84199311~84230136:-
THCA	cis	rs950169	0.922	rs62021167	ENSG00000225151.9	GOLGA2P7	-10.91	7.62e-25	6.99e-22	-0.66	-0.45	Schizophrenia;	chr15:84574820	chr15:84199311~84230136:-
THCA	cis	rs12468226	0.882	rs116437099	ENSG00000273456.1	RP11-686O6.2	10.91	7.62e-25	7e-22	0.53	0.45	Urate levels;	chr2:202299250	chr2:202374932~202375604:-
THCA	cis	rs9903692	0.954	rs9889470	ENSG00000278765.1	RP5-890E16.5	10.91	7.65e-25	7.02e-22	0.61	0.45	Pulse pressure;	chr17:48233713	chr17:48066704~48067293:-
THCA	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-10.91	7.7e-25	7.07e-22	-0.6	-0.45	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
THCA	cis	rs6504950	0.924	rs244353	ENSG00000275710.1	RP11-257O5.4	-10.91	7.72e-25	7.09e-22	-0.55	-0.45	Breast cancer;	chr17:55117408	chr17:54964474~54964679:+
THCA	cis	rs9322193	0.962	rs9478848	ENSG00000223701.3	RAET1E-AS1	10.91	7.72e-25	7.09e-22	0.6	0.45	Lung cancer;	chr6:149825080	chr6:149884431~149919508:+
THCA	cis	rs9532669	0.89	rs7333274	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40862531	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs2324737	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40862808	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4942003	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40863270	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs4942004	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40863598	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs9315791	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40863931	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.824	rs9315792	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40863951	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.684	rs7139788	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40864264	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7338617	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40870787	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.857	rs6560961	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40870878	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs6560962	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40870948	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs1055588	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40871306	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs3610	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40871334	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4942005	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40871636	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4942006	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40871862	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4942008	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40871989	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs2039118	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40872260	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4356347	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40872516	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7982346	ENSG00000176268.5	CYCSP34	10.91	7.75e-25	7.1e-22	0.52	0.45	Cervical cancer;	chr13:40873273	chr13:40863599~40863902:-
THCA	cis	rs2658782	0.547	rs2085334	ENSG00000279684.1	RP11-755E23.2	-10.9	7.78e-25	7.14e-22	-0.64	-0.45	Pulmonary function decline;	chr11:93447884	chr11:93286629~93288903:-
THCA	cis	rs6504950	0.889	rs2541245	ENSG00000275710.1	RP11-257O5.4	-10.9	7.8e-25	7.15e-22	-0.59	-0.45	Breast cancer;	chr17:55023839	chr17:54964474~54964679:+
THCA	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-10.9	7.86e-25	7.21e-22	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
THCA	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-10.9	7.93e-25	7.26e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
THCA	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-10.9	7.96e-25	7.29e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
THCA	cis	rs916888	0.773	rs199535	ENSG00000232300.1	FAM215B	10.9	7.96e-25	7.3e-22	0.72	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46558830~46562795:-
THCA	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-10.9	7.97e-25	7.3e-22	-0.52	-0.45	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
THCA	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	10.9	8e-25	7.33e-22	0.57	0.45	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
THCA	cis	rs780096	0.546	rs1104	ENSG00000234072.1	AC074117.10	-10.9	8.01e-25	7.34e-22	-0.35	-0.45	Total body bone mineral density;	chr2:27377008	chr2:27356246~27367622:+
THCA	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	10.9	8.05e-25	7.38e-22	0.38	0.45	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.923	rs6913486	ENSG00000223701.3	RAET1E-AS1	-10.9	8.06e-25	7.38e-22	-0.61	-0.45	Lung cancer;	chr6:149705060	chr6:149884431~149919508:+
THCA	cis	rs10463554	1	rs3776862	ENSG00000175749.11	EIF3KP1	10.9	8.07e-25	7.39e-22	0.58	0.45	Parkinson's disease;	chr5:102996017	chr5:103032376~103033031:+
THCA	cis	rs9532669	0.926	rs11147824	ENSG00000176268.5	CYCSP34	10.9	8.07e-25	7.39e-22	0.52	0.45	Cervical cancer;	chr13:40878183	chr13:40863599~40863902:-
THCA	cis	rs11676348	0.71	rs11894169	ENSG00000261338.2	RP11-378A13.1	10.9	8.08e-25	7.4e-22	0.46	0.45	Ulcerative colitis;	chr2:218182123	chr2:218255319~218257366:+
THCA	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-10.9	8.1e-25	7.42e-22	-0.57	-0.45	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
THCA	cis	rs3762637	0.941	rs6788746	ENSG00000272758.4	RP11-299J3.8	-10.9	8.17e-25	7.48e-22	-0.59	-0.45	LDL cholesterol levels;	chr3:122387896	chr3:122416207~122443180:+
THCA	cis	rs1075265	0.901	rs7591194	ENSG00000233266.1	HMGB1P31	-10.9	8.18e-25	7.49e-22	-0.55	-0.45	Chronotype;Morning vs. evening chronotype;	chr2:54086699	chr2:54051334~54051760:+
THCA	cis	rs6570726	0.935	rs386344	ENSG00000235652.6	RP11-545I5.3	10.9	8.21e-25	7.52e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145534486	chr6:145799409~145886585:+
THCA	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-10.9	8.22e-25	7.52e-22	-0.6	-0.45	Depression;	chr6:28184805	chr6:28115628~28116551:+
THCA	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-10.9	8.22e-25	7.52e-22	-0.62	-0.45	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
THCA	cis	rs934734	0.532	rs2860773	ENSG00000281920.1	RP11-418H16.1	-10.9	8.26e-25	7.56e-22	-0.54	-0.45	Rheumatoid arthritis;	chr2:65438507	chr2:65623272~65628424:+
THCA	cis	rs2274273	0.934	rs10137307	ENSG00000258413.1	RP11-665C16.6	-10.9	8.26e-25	7.56e-22	-0.6	-0.45	Protein biomarker;	chr14:55378467	chr14:55262767~55272075:-
THCA	cis	rs9487094	0.67	rs1885691	ENSG00000260273.1	RP11-425D10.10	10.9	8.28e-25	7.58e-22	0.52	0.45	Height;	chr6:109382188	chr6:109382795~109383666:+
THCA	cis	rs4819052	0.851	rs2236443	ENSG00000223768.1	LINC00205	-10.9	8.31e-25	7.6e-22	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45293285~45297354:+
THCA	cis	rs6570726	0.935	rs110289	ENSG00000235652.6	RP11-545I5.3	10.9	8.32e-25	7.61e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145544040	chr6:145799409~145886585:+
THCA	cis	rs4819052	0.679	rs4819053	ENSG00000223768.1	LINC00205	10.9	8.32e-25	7.61e-22	0.41	0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45293285~45297354:+
THCA	cis	rs4266144	0.632	rs56268334	ENSG00000244515.1	KRT18P34	-10.9	8.34e-25	7.63e-22	-0.63	-0.45	Coronary artery disease;	chr3:157130235	chr3:157162663~157163932:-
THCA	cis	rs7945705	0.869	rs7925728	ENSG00000254860.4	TMEM9B-AS1	10.9	8.36e-25	7.65e-22	0.49	0.45	Hemoglobin concentration;	chr11:8991455	chr11:8964675~8977527:+
THCA	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-10.9	8.41e-25	7.7e-22	-0.59	-0.45	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
THCA	cis	rs11159086	1	rs4899516	ENSG00000270000.1	RP3-449M8.9	10.9	8.43e-25	7.71e-22	0.49	0.45	Advanced glycation end-product levels;	chr14:74492825	chr14:74471930~74472360:-
THCA	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-10.9	8.45e-25	7.73e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-10.9	8.45e-25	7.73e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
THCA	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	10.89	8.5e-25	7.77e-22	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
THCA	cis	rs71403859	0.803	rs10500562	ENSG00000260886.1	TAT-AS1	10.89	8.53e-25	7.8e-22	0.81	0.45	Post bronchodilator FEV1;	chr16:71593828	chr16:71565789~71578187:+
THCA	cis	rs42490	1	rs2735873	ENSG00000251136.7	RP11-37B2.1	10.89	8.54e-25	7.81e-22	0.39	0.45	Leprosy;	chr8:89737748	chr8:89609409~89757727:-
THCA	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	10.89	8.55e-25	7.81e-22	0.55	0.45	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
THCA	cis	rs992157	0.71	rs6719789	ENSG00000261338.2	RP11-378A13.1	-10.89	8.61e-25	7.87e-22	-0.45	-0.45	Colorectal cancer;	chr2:218193087	chr2:218255319~218257366:+
THCA	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-10.89	8.7e-25	7.95e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
THCA	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-10.89	8.72e-25	7.96e-22	-0.55	-0.45	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
THCA	cis	rs9903692	0.657	rs1452665	ENSG00000278765.1	RP5-890E16.5	10.89	8.79e-25	8.02e-22	0.6	0.45	Pulse pressure;	chr17:48219789	chr17:48066704~48067293:-
THCA	cis	rs9532669	0.89	rs12865032	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40873801	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs34123829	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40873808	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4488324	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40873864	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4288867	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40873880	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4415896	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874001	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs4415897	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874035	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4389021	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874209	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.824	rs4628828	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874369	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.737	rs34354179	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874424	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9594445	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874859	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9594446	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40874863	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4402423	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40875010	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs9532628	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40875172	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532629	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40875193	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7491149	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40875216	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532630	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40875472	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs4306385	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40875641	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4406939	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876108	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4628824	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876217	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532632	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876309	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532633	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876332	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532634	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876369	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532635	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876397	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs12428959	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40876638	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.895	rs4942009	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40877243	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4334153	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40877737	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4309270	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40877827	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4270044	ENSG00000176268.5	CYCSP34	10.89	8.79e-25	8.02e-22	0.52	0.45	Cervical cancer;	chr13:40877923	chr13:40863599~40863902:-
THCA	cis	rs7569084	0.64	rs11126039	ENSG00000237979.1	AC007389.1	10.89	8.81e-25	8.04e-22	0.53	0.45	Sum eosinophil basophil counts;	chr2:65457953	chr2:65500993~65502138:-
THCA	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	10.89	8.85e-25	8.08e-22	0.54	0.45	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
THCA	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	10.89	8.85e-25	8.08e-22	0.54	0.45	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
THCA	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-10.89	8.86e-25	8.08e-22	-0.6	-0.45	Depression;	chr6:28201380	chr6:28115628~28116551:+
THCA	cis	rs3002131	0.604	rs3008641	ENSG00000225265.1	TAF1A-AS1	-10.89	8.87e-25	8.1e-22	-0.59	-0.45	Interleukin-10 levels;	chr1:222566947	chr1:222589825~222593032:+
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000206090.4	AP000350.7	10.89	8.88e-25	8.1e-22	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23939998~23942798:+
THCA	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	10.89	8.9e-25	8.12e-22	0.45	0.45	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
THCA	cis	rs9903692	0.954	rs6847	ENSG00000278765.1	RP5-890E16.5	-10.89	8.9e-25	8.12e-22	-0.59	-0.45	Pulse pressure;	chr17:48070445	chr17:48066704~48067293:-
THCA	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	10.89	8.94e-25	8.15e-22	0.32	0.45	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
THCA	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-10.89	8.94e-25	8.15e-22	-0.32	-0.45	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
THCA	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-10.89	8.94e-25	8.15e-22	-0.32	-0.45	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
THCA	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-10.89	8.94e-25	8.15e-22	-0.32	-0.45	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
THCA	cis	rs42490	0.966	rs218908	ENSG00000251136.7	RP11-37B2.1	-10.89	9.03e-25	8.23e-22	-0.39	-0.45	Leprosy;	chr8:89728886	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs218913	ENSG00000251136.7	RP11-37B2.1	-10.89	9.03e-25	8.23e-22	-0.39	-0.45	Leprosy;	chr8:89732206	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs2735870	ENSG00000251136.7	RP11-37B2.1	10.89	9.03e-25	8.23e-22	0.39	0.45	Leprosy;	chr8:89730456	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs2735871	ENSG00000251136.7	RP11-37B2.1	10.89	9.03e-25	8.23e-22	0.39	0.45	Leprosy;	chr8:89731154	chr8:89609409~89757727:-
THCA	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-10.89	9.04e-25	8.24e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-10.89	9.04e-25	8.24e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-10.89	9.04e-25	8.24e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
THCA	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-10.89	9.07e-25	8.27e-22	-0.56	-0.45	Height;	chr3:52989619	chr3:53064283~53065091:-
THCA	cis	rs42490	0.934	rs218925	ENSG00000251136.7	RP11-37B2.1	-10.89	9.08e-25	8.28e-22	-0.39	-0.45	Leprosy;	chr8:89737352	chr8:89609409~89757727:-
THCA	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-10.89	9.09e-25	8.29e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
THCA	cis	rs12130219	1	rs34428306	ENSG00000237975.5	FLG-AS1	10.89	9.1e-25	8.29e-22	0.65	0.45	Inflammatory skin disease;	chr1:152211840	chr1:152168125~152445456:+
THCA	cis	rs9322193	0.607	rs9371228	ENSG00000223701.3	RAET1E-AS1	-10.89	9.1e-25	8.29e-22	-0.64	-0.45	Lung cancer;	chr6:149921977	chr6:149884431~149919508:+
THCA	cis	rs42490	1	rs218905	ENSG00000251136.7	RP11-37B2.1	-10.89	9.11e-25	8.3e-22	-0.39	-0.45	Leprosy;	chr8:89723661	chr8:89609409~89757727:-
THCA	cis	rs9322193	0.516	rs1999632	ENSG00000223701.3	RAET1E-AS1	10.89	9.12e-25	8.31e-22	0.66	0.45	Lung cancer;	chr6:149866737	chr6:149884431~149919508:+
THCA	cis	rs4819052	0.788	rs35323494	ENSG00000223768.1	LINC00205	-10.89	9.13e-25	8.32e-22	-0.45	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45283824	chr21:45293285~45297354:+
THCA	cis	rs2658782	0.547	rs6483244	ENSG00000279684.1	RP11-755E23.2	-10.89	9.14e-25	8.33e-22	-0.65	-0.45	Pulmonary function decline;	chr11:93464769	chr11:93286629~93288903:-
THCA	cis	rs860295	0.702	rs5005770	ENSG00000225855.5	RUSC1-AS1	-10.89	9.17e-25	8.36e-22	-0.31	-0.45	Body mass index;	chr1:155375252	chr1:155316863~155324176:-
THCA	cis	rs673078	0.66	rs11068908	ENSG00000275759.1	RP11-131L12.3	-10.89	9.22e-25	8.4e-22	-0.59	-0.45	Glucose homeostasis traits;	chr12:118327265	chr12:118428281~118428870:+
THCA	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	10.89	9.24e-25	8.42e-22	0.37	0.45	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
THCA	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-10.88	9.27e-25	8.45e-22	-0.32	-0.45	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
THCA	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	10.88	9.31e-25	8.48e-22	0.54	0.45	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
THCA	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-10.88	9.36e-25	8.53e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-10.88	9.36e-25	8.53e-22	-0.52	-0.45	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
THCA	cis	rs6570726	0.967	rs450973	ENSG00000235652.6	RP11-545I5.3	10.88	9.49e-25	8.65e-22	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145541929	chr6:145799409~145886585:+
THCA	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-10.88	9.52e-25	8.67e-22	-0.5	-0.45	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
THCA	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-10.88	9.57e-25	8.72e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-10.88	9.57e-25	8.72e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-10.88	9.57e-25	8.72e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
THCA	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	10.88	9.58e-25	8.72e-22	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	10.88	9.59e-25	8.73e-22	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
THCA	cis	rs7221109	0.614	rs8076587	ENSG00000278834.1	RP11-458J1.1	10.88	9.63e-25	8.76e-22	0.48	0.45	Type 1 diabetes;	chr17:40667949	chr17:40648300~40649718:+
THCA	cis	rs42490	0.966	rs218914	ENSG00000251136.7	RP11-37B2.1	-10.88	9.66e-25	8.79e-22	-0.39	-0.45	Leprosy;	chr8:89733130	chr8:89609409~89757727:-
THCA	cis	rs9532669	0.89	rs9525417	ENSG00000176268.5	CYCSP34	10.88	9.69e-25	8.81e-22	0.52	0.45	Cervical cancer;	chr13:40878431	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs9532638	ENSG00000176268.5	CYCSP34	10.88	9.69e-25	8.81e-22	0.52	0.45	Cervical cancer;	chr13:40878471	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7997536	ENSG00000176268.5	CYCSP34	10.88	9.69e-25	8.81e-22	0.52	0.45	Cervical cancer;	chr13:40878685	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7997560	ENSG00000176268.5	CYCSP34	10.88	9.69e-25	8.81e-22	0.52	0.45	Cervical cancer;	chr13:40878723	chr13:40863599~40863902:-
THCA	cis	rs6558530	0.863	rs4595147	ENSG00000253982.1	CTD-2336O2.1	10.88	9.71e-25	8.83e-22	0.39	0.45	Systolic blood pressure;	chr8:1755403	chr8:1761990~1764502:-
THCA	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-10.88	9.72e-25	8.84e-22	-0.57	-0.45	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
THCA	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-10.88	9.77e-25	8.89e-22	-0.56	-0.45	Height;	chr3:53027969	chr3:53064283~53065091:-
THCA	cis	rs7772486	0.875	rs2748490	ENSG00000235652.6	RP11-545I5.3	10.88	9.78e-25	8.89e-22	0.4	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146008545	chr6:145799409~145886585:+
THCA	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-10.88	9.78e-25	8.9e-22	-0.55	-0.45	Height;	chr3:52992698	chr3:53064283~53065091:-
THCA	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-10.88	9.82e-25	8.93e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-10.88	9.82e-25	8.93e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-10.88	9.82e-25	8.93e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
THCA	cis	rs7772486	0.846	rs2492856	ENSG00000235652.6	RP11-545I5.3	10.88	9.83e-25	8.94e-22	0.4	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146002792	chr6:145799409~145886585:+
THCA	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-10.88	9.84e-25	8.95e-22	-0.77	-0.45	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
THCA	cis	rs860295	0.702	rs2025669	ENSG00000225855.5	RUSC1-AS1	10.88	9.92e-25	9.02e-22	0.31	0.45	Body mass index;	chr1:155387818	chr1:155316863~155324176:-
THCA	cis	rs860295	0.702	rs12081067	ENSG00000225855.5	RUSC1-AS1	10.88	9.92e-25	9.02e-22	0.31	0.45	Body mass index;	chr1:155389191	chr1:155316863~155324176:-
THCA	cis	rs860295	0.702	rs10908465	ENSG00000225855.5	RUSC1-AS1	10.88	9.92e-25	9.02e-22	0.31	0.45	Body mass index;	chr1:155419897	chr1:155316863~155324176:-
THCA	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	10.88	9.92e-25	9.02e-22	0.52	0.45	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-10.88	9.95e-25	9.05e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-10.88	9.97e-25	9.06e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-10.88	9.97e-25	9.06e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-10.88	9.97e-25	9.06e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-10.88	9.97e-25	9.06e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-10.88	9.97e-25	9.06e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
THCA	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	10.88	1e-24	9.1e-22	0.53	0.45	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
THCA	cis	rs950169	0.84	rs12905223	ENSG00000225151.9	GOLGA2P7	-10.88	1e-24	9.11e-22	-0.66	-0.45	Schizophrenia;	chr15:84571037	chr15:84199311~84230136:-
THCA	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-10.88	1.01e-24	9.16e-22	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
THCA	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	10.87	1.01e-24	9.2e-22	0.52	0.45	Height;	chr6:109440234	chr6:109382795~109383666:+
THCA	cis	rs12022452	1	rs12048678	ENSG00000238287.1	RP11-656D10.3	-10.87	1.01e-24	9.2e-22	-0.71	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:40493157~40508661:-
THCA	cis	rs11159086	0.793	rs10139122	ENSG00000270000.1	RP3-449M8.9	10.87	1.02e-24	9.23e-22	0.48	0.45	Advanced glycation end-product levels;	chr14:74492353	chr14:74471930~74472360:-
THCA	cis	rs7569084	0.663	rs6546150	ENSG00000237979.1	AC007389.1	-10.87	1.02e-24	9.24e-22	-0.52	-0.45	Sum eosinophil basophil counts;	chr2:65415066	chr2:65500993~65502138:-
THCA	cis	rs950169	1	rs11638297	ENSG00000225151.9	GOLGA2P7	-10.87	1.02e-24	9.27e-22	-0.66	-0.45	Schizophrenia;	chr15:84113665	chr15:84199311~84230136:-
THCA	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-10.87	1.04e-24	9.42e-22	-0.51	-0.45	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
THCA	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	10.87	1.04e-24	9.46e-22	0.55	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
THCA	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	10.87	1.04e-24	9.48e-22	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
THCA	cis	rs8072100	0.811	rs9889709	ENSG00000228782.6	CTD-2026D20.3	10.87	1.05e-24	9.52e-22	0.42	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47367863	chr17:47450568~47492492:-
THCA	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-10.87	1.06e-24	9.6e-22	-0.55	-0.45	Height;	chr3:52991821	chr3:53064283~53065091:-
THCA	cis	rs526231	0.543	rs6880911	ENSG00000175749.11	EIF3KP1	10.87	1.06e-24	9.61e-22	0.62	0.45	Primary biliary cholangitis;	chr5:102971767	chr5:103032376~103033031:+
THCA	cis	rs526231	0.543	rs6881225	ENSG00000175749.11	EIF3KP1	10.87	1.06e-24	9.61e-22	0.62	0.45	Primary biliary cholangitis;	chr5:102971888	chr5:103032376~103033031:+
THCA	cis	rs10463554	1	rs11949145	ENSG00000175749.11	EIF3KP1	10.87	1.07e-24	9.7e-22	0.58	0.45	Parkinson's disease;	chr5:102994552	chr5:103032376~103033031:+
THCA	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-10.87	1.07e-24	9.74e-22	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
THCA	cis	rs9322193	0.923	rs12176034	ENSG00000223701.3	RAET1E-AS1	10.87	1.08e-24	9.77e-22	0.62	0.45	Lung cancer;	chr6:149800557	chr6:149884431~149919508:+
THCA	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	10.87	1.08e-24	9.79e-22	0.48	0.45	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
THCA	cis	rs7569084	0.687	rs934731	ENSG00000237979.1	AC007389.1	10.87	1.08e-24	9.83e-22	0.52	0.45	Sum eosinophil basophil counts;	chr2:65456353	chr2:65500993~65502138:-
THCA	cis	rs7569084	0.687	rs7577452	ENSG00000237979.1	AC007389.1	10.87	1.08e-24	9.83e-22	0.52	0.45	Sum eosinophil basophil counts;	chr2:65456694	chr2:65500993~65502138:-
THCA	cis	rs11159086	1	rs8006909	ENSG00000270000.1	RP3-449M8.9	10.87	1.09e-24	9.87e-22	0.49	0.45	Advanced glycation end-product levels;	chr14:74478085	chr14:74471930~74472360:-
THCA	cis	rs11159086	1	rs8006958	ENSG00000270000.1	RP3-449M8.9	10.87	1.09e-24	9.87e-22	0.49	0.45	Advanced glycation end-product levels;	chr14:74478148	chr14:74471930~74472360:-
THCA	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-10.87	1.1e-24	9.93e-22	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
THCA	cis	rs934734	0.532	rs1437466	ENSG00000281920.1	RP11-418H16.1	-10.87	1.1e-24	9.97e-22	-0.54	-0.45	Rheumatoid arthritis;	chr2:65437216	chr2:65623272~65628424:+
THCA	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	10.86	1.1e-24	1e-21	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-10.86	1.12e-24	1.01e-21	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
THCA	cis	rs875971	1	rs1167411	ENSG00000237310.1	GS1-124K5.4	-10.86	1.12e-24	1.01e-21	-0.34	-0.45	Aortic root size;	chr7:66074277	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.566	rs9397070	ENSG00000223701.3	RAET1E-AS1	-10.86	1.12e-24	1.01e-21	-0.64	-0.45	Lung cancer;	chr6:149922073	chr6:149884431~149919508:+
THCA	cis	rs3002131	0.604	rs3002151	ENSG00000225265.1	TAF1A-AS1	-10.86	1.12e-24	1.02e-21	-0.58	-0.45	Interleukin-10 levels;	chr1:222573225	chr1:222589825~222593032:+
THCA	cis	rs10463554	0.963	rs26254	ENSG00000175749.11	EIF3KP1	10.86	1.13e-24	1.02e-21	0.59	0.45	Parkinson's disease;	chr5:103221158	chr5:103032376~103033031:+
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000206090.4	AP000350.7	10.86	1.13e-24	1.02e-21	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23939998~23942798:+
THCA	cis	rs4819052	0.679	rs2236450	ENSG00000223768.1	LINC00205	-10.86	1.13e-24	1.02e-21	-0.41	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45293285~45297354:+
THCA	cis	rs7569084	0.687	rs11675538	ENSG00000237979.1	AC007389.1	10.86	1.13e-24	1.02e-21	0.52	0.45	Sum eosinophil basophil counts;	chr2:65459327	chr2:65500993~65502138:-
THCA	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	10.86	1.13e-24	1.03e-21	0.37	0.45	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	10.86	1.13e-24	1.03e-21	0.37	0.45	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
THCA	cis	rs9487094	0.62	rs6939953	ENSG00000260273.1	RP11-425D10.10	10.86	1.13e-24	1.03e-21	0.52	0.45	Height;	chr6:109390116	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs3757235	ENSG00000260273.1	RP11-425D10.10	10.86	1.13e-24	1.03e-21	0.52	0.45	Height;	chr6:109390638	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs746794	ENSG00000260273.1	RP11-425D10.10	10.86	1.13e-24	1.03e-21	0.52	0.45	Height;	chr6:109391534	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.643	rs730089	ENSG00000260273.1	RP11-425D10.10	10.86	1.13e-24	1.03e-21	0.52	0.45	Height;	chr6:109393881	chr6:109382795~109383666:+
THCA	cis	rs7221109	0.645	rs9896791	ENSG00000278834.1	RP11-458J1.1	10.86	1.13e-24	1.03e-21	0.47	0.45	Type 1 diabetes;	chr17:40669305	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.633	rs7217237	ENSG00000278834.1	RP11-458J1.1	10.86	1.13e-24	1.03e-21	0.47	0.45	Type 1 diabetes;	chr17:40670810	chr17:40648300~40649718:+
THCA	cis	rs6570726	0.905	rs430248	ENSG00000235652.6	RP11-545I5.3	10.86	1.14e-24	1.03e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145552968	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs406343	ENSG00000235652.6	RP11-545I5.3	10.86	1.14e-24	1.03e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145553252	chr6:145799409~145886585:+
THCA	cis	rs860295	0.702	rs12239100	ENSG00000225855.5	RUSC1-AS1	10.86	1.14e-24	1.03e-21	0.32	0.45	Body mass index;	chr1:155458685	chr1:155316863~155324176:-
THCA	cis	rs6920372	0.799	rs9480947	ENSG00000260273.1	RP11-425D10.10	10.86	1.15e-24	1.04e-21	0.52	0.45	Height;	chr6:109397362	chr6:109382795~109383666:+
THCA	cis	rs7569084	0.663	rs10190233	ENSG00000237979.1	AC007389.1	-10.86	1.15e-24	1.04e-21	-0.52	-0.45	Sum eosinophil basophil counts;	chr2:65413095	chr2:65500993~65502138:-
THCA	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	10.86	1.15e-24	1.04e-21	0.52	0.45	Height;	chr6:109443332	chr6:109382795~109383666:+
THCA	cis	rs42490	1	rs218929	ENSG00000251136.7	RP11-37B2.1	-10.86	1.15e-24	1.04e-21	-0.39	-0.45	Leprosy;	chr8:89739091	chr8:89609409~89757727:-
THCA	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-10.86	1.15e-24	1.04e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
THCA	cis	rs6570726	0.935	rs388394	ENSG00000235652.6	RP11-545I5.3	10.86	1.16e-24	1.05e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145531553	chr6:145799409~145886585:+
THCA	cis	rs526231	0.543	rs62362521	ENSG00000175749.11	EIF3KP1	10.86	1.16e-24	1.05e-21	0.62	0.45	Primary biliary cholangitis;	chr5:102970357	chr5:103032376~103033031:+
THCA	cis	rs526231	0.575	rs12652973	ENSG00000175749.11	EIF3KP1	10.86	1.16e-24	1.05e-21	0.62	0.45	Primary biliary cholangitis;	chr5:102970618	chr5:103032376~103033031:+
THCA	cis	rs4819052	0.851	rs1056099	ENSG00000223768.1	LINC00205	-10.86	1.17e-24	1.06e-21	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2236446	ENSG00000223768.1	LINC00205	-10.86	1.17e-24	1.06e-21	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45293285~45297354:+
THCA	cis	rs2658782	0.724	rs2605627	ENSG00000279684.1	RP11-755E23.2	-10.86	1.17e-24	1.06e-21	-0.7	-0.45	Pulmonary function decline;	chr11:93526349	chr11:93286629~93288903:-
THCA	cis	rs6504950	0.85	rs2628309	ENSG00000275710.1	RP11-257O5.4	-10.86	1.19e-24	1.07e-21	-0.59	-0.45	Breast cancer;	chr17:55038058	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.85	rs11658717	ENSG00000275710.1	RP11-257O5.4	-10.86	1.19e-24	1.08e-21	-0.56	-0.45	Breast cancer;	chr17:54999625	chr17:54964474~54964679:+
THCA	cis	rs9322193	0.923	rs7769101	ENSG00000268592.3	RAET1E-AS1	10.86	1.19e-24	1.08e-21	0.61	0.45	Lung cancer;	chr6:149848768	chr6:149863494~149919507:+
THCA	cis	rs3002131	0.604	rs2133185	ENSG00000225265.1	TAF1A-AS1	-10.86	1.2e-24	1.08e-21	-0.59	-0.45	Interleukin-10 levels;	chr1:222565628	chr1:222589825~222593032:+
THCA	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-10.86	1.2e-24	1.08e-21	-0.86	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
THCA	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-10.85	1.2e-24	1.09e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-10.85	1.2e-24	1.09e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-10.85	1.2e-24	1.09e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-10.85	1.2e-24	1.09e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
THCA	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-10.85	1.2e-24	1.09e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-10.85	1.2e-24	1.09e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
THCA	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-10.85	1.21e-24	1.09e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-10.85	1.21e-24	1.09e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
THCA	cis	rs9532669	0.89	rs11619117	ENSG00000239827.7	SUGT1P3	-10.85	1.21e-24	1.09e-21	-0.49	-0.45	Cervical cancer;	chr13:40880020	chr13:40908159~40921774:-
THCA	cis	rs227275	0.526	rs223497	ENSG00000246560.2	RP11-10L12.4	10.85	1.21e-24	1.1e-21	0.56	0.45	Allergic disease (asthma, hay fever or eczema);	chr4:102732819	chr4:102828055~102844075:+
THCA	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	10.85	1.21e-24	1.1e-21	0.54	0.45	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
THCA	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	10.85	1.21e-24	1.1e-21	0.54	0.45	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
THCA	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-10.85	1.22e-24	1.1e-21	-0.61	-0.45	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
THCA	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-10.85	1.22e-24	1.1e-21	-0.61	-0.45	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
THCA	cis	rs9532669	0.926	rs12428966	ENSG00000176268.5	CYCSP34	10.85	1.22e-24	1.1e-21	0.52	0.45	Cervical cancer;	chr13:40876552	chr13:40863599~40863902:-
THCA	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-10.85	1.22e-24	1.11e-21	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
THCA	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-10.85	1.23e-24	1.11e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
THCA	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-10.85	1.23e-24	1.11e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
THCA	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	10.85	1.23e-24	1.11e-21	0.61	0.45	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
THCA	cis	rs860295	0.702	rs11264386	ENSG00000225855.5	RUSC1-AS1	10.85	1.24e-24	1.12e-21	0.32	0.45	Body mass index;	chr1:155589379	chr1:155316863~155324176:-
THCA	cis	rs9322193	0.607	rs9383941	ENSG00000223701.3	RAET1E-AS1	-10.85	1.26e-24	1.13e-21	-0.64	-0.45	Lung cancer;	chr6:149912100	chr6:149884431~149919508:+
THCA	cis	rs7773456	0.74	rs6917179	ENSG00000228412.5	RP4-625H18.2	-10.85	1.26e-24	1.14e-21	-0.64	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr6:19802164~19804752:-
THCA	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-10.85	1.27e-24	1.15e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-10.85	1.27e-24	1.15e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-10.85	1.27e-24	1.15e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
THCA	cis	rs465969	1	rs35856111	ENSG00000255389.1	C6orf3	-10.85	1.27e-24	1.15e-21	-0.8	-0.45	Psoriasis;	chr6:111452265	chr6:111599875~111602295:+
THCA	cis	rs465969	0.744	rs13220692	ENSG00000255389.1	C6orf3	-10.85	1.27e-24	1.15e-21	-0.8	-0.45	Psoriasis;	chr6:111455836	chr6:111599875~111602295:+
THCA	cis	rs465969	0.793	rs7752225	ENSG00000255389.1	C6orf3	10.85	1.27e-24	1.15e-21	0.8	0.45	Psoriasis;	chr6:111459412	chr6:111599875~111602295:+
THCA	cis	rs950169	0.96	rs35159785	ENSG00000225151.9	GOLGA2P7	-10.85	1.28e-24	1.15e-21	-0.68	-0.45	Schizophrenia;	chr15:84135262	chr15:84199311~84230136:-
THCA	cis	rs6570726	0.935	rs385134	ENSG00000235652.6	RP11-545I5.3	10.85	1.29e-24	1.17e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145529869	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.558	rs702316	ENSG00000235652.6	RP11-545I5.3	-10.85	1.3e-24	1.17e-21	-0.47	-0.45	Lobe attachment (rater-scored or self-reported);	chr6:145683541	chr6:145799409~145886585:+
THCA	cis	rs11155671	0.546	rs1999633	ENSG00000231760.4	RP11-350J20.5	10.85	1.3e-24	1.17e-21	0.63	0.45	Testicular germ cell tumor;	chr6:149866576	chr6:149796151~149826294:-
THCA	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	10.85	1.3e-24	1.17e-21	0.54	0.45	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
THCA	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-10.85	1.3e-24	1.18e-21	-0.56	-0.45	Height;	chr3:52977358	chr3:53064283~53065091:-
THCA	cis	rs2658782	0.547	rs3020064	ENSG00000279684.1	RP11-755E23.2	-10.85	1.31e-24	1.18e-21	-0.69	-0.45	Pulmonary function decline;	chr11:93327685	chr11:93286629~93288903:-
THCA	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-10.85	1.31e-24	1.18e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
THCA	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-10.84	1.32e-24	1.19e-21	-0.32	-0.45	Height;	chr11:118703185	chr11:118791254~118793137:+
THCA	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-10.84	1.32e-24	1.19e-21	-0.32	-0.45	Height;	chr11:118703207	chr11:118791254~118793137:+
THCA	cis	rs465969	0.744	rs36007392	ENSG00000255389.1	C6orf3	-10.84	1.32e-24	1.19e-21	-0.76	-0.45	Psoriasis;	chr6:111509287	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs13197107	ENSG00000255389.1	C6orf3	-10.84	1.32e-24	1.19e-21	-0.76	-0.45	Psoriasis;	chr6:111512031	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs7750803	ENSG00000255389.1	C6orf3	10.84	1.33e-24	1.2e-21	0.8	0.45	Psoriasis;	chr6:111478910	chr6:111599875~111602295:+
THCA	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-10.84	1.33e-24	1.2e-21	-0.52	-0.45	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000224205.1	AP000351.4	10.84	1.33e-24	1.2e-21	0.53	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23987320~23991421:-
THCA	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-10.84	1.34e-24	1.21e-21	-0.51	-0.45	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
THCA	cis	rs4591358	0.648	rs17177798	ENSG00000223466.1	AC064834.2	-10.84	1.35e-24	1.21e-21	-0.67	-0.45	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195521352	chr2:195533035~195538681:+
THCA	cis	rs11159086	0.941	rs12434836	ENSG00000270000.1	RP3-449M8.9	10.84	1.35e-24	1.21e-21	0.5	0.45	Advanced glycation end-product levels;	chr14:74468887	chr14:74471930~74472360:-
THCA	cis	rs11676348	0.808	rs61700947	ENSG00000261338.2	RP11-378A13.1	10.84	1.35e-24	1.22e-21	0.45	0.45	Ulcerative colitis;	chr2:218181448	chr2:218255319~218257366:+
THCA	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	10.84	1.35e-24	1.22e-21	0.54	0.45	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
THCA	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	10.84	1.35e-24	1.22e-21	0.54	0.45	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
THCA	cis	rs465969	1	rs459048	ENSG00000255389.1	C6orf3	-10.84	1.35e-24	1.22e-21	-0.8	-0.45	Psoriasis;	chr6:111368429	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs479343	ENSG00000255389.1	C6orf3	-10.84	1.35e-24	1.22e-21	-0.8	-0.45	Psoriasis;	chr6:111369701	chr6:111599875~111602295:+
THCA	cis	rs465969	0.744	rs458017	ENSG00000255389.1	C6orf3	-10.84	1.35e-24	1.22e-21	-0.8	-0.45	Psoriasis;	chr6:111374888	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs13213522	ENSG00000255389.1	C6orf3	-10.84	1.35e-24	1.22e-21	-0.8	-0.45	Psoriasis;	chr6:111384138	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs17510761	ENSG00000255389.1	C6orf3	-10.84	1.35e-24	1.22e-21	-0.8	-0.45	Psoriasis;	chr6:111387380	chr6:111599875~111602295:+
THCA	cis	rs465969	1	rs17510733	ENSG00000255389.1	C6orf3	-10.84	1.35e-24	1.22e-21	-0.8	-0.45	Psoriasis;	chr6:111389715	chr6:111599875~111602295:+
THCA	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-10.84	1.36e-24	1.22e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-10.84	1.36e-24	1.22e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-10.84	1.36e-24	1.22e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-10.84	1.36e-24	1.22e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
THCA	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-10.84	1.36e-24	1.22e-21	-0.51	-0.45	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
THCA	cis	rs6538678	0.833	rs1898178	ENSG00000258343.1	RP11-536G4.2	-10.84	1.36e-24	1.23e-21	-0.62	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95795345~95858839:-
THCA	cis	rs6538678	0.833	rs1898177	ENSG00000258343.1	RP11-536G4.2	-10.84	1.36e-24	1.23e-21	-0.62	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95795345~95858839:-
THCA	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	10.84	1.37e-24	1.23e-21	0.59	0.45	Depression;	chr6:28187640	chr6:28115628~28116551:+
THCA	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	10.84	1.38e-24	1.24e-21	0.51	0.45	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
THCA	cis	rs9487094	0.689	rs9487069	ENSG00000260273.1	RP11-425D10.10	10.84	1.38e-24	1.25e-21	0.52	0.45	Height;	chr6:109358652	chr6:109382795~109383666:+
THCA	cis	rs950169	0.959	rs12902070	ENSG00000225151.9	GOLGA2P7	-10.84	1.38e-24	1.25e-21	-0.68	-0.45	Schizophrenia;	chr15:84124806	chr15:84199311~84230136:-
THCA	cis	rs9322193	0.566	rs4870118	ENSG00000223701.3	RAET1E-AS1	-10.84	1.39e-24	1.25e-21	-0.64	-0.45	Lung cancer;	chr6:149923877	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.566	rs4869767	ENSG00000223701.3	RAET1E-AS1	-10.84	1.39e-24	1.25e-21	-0.64	-0.45	Lung cancer;	chr6:149923974	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.566	rs4869768	ENSG00000223701.3	RAET1E-AS1	-10.84	1.39e-24	1.25e-21	-0.64	-0.45	Lung cancer;	chr6:149924067	chr6:149884431~149919508:+
THCA	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	10.84	1.4e-24	1.26e-21	0.47	0.45	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
THCA	cis	rs6558530	0.64	rs4875889	ENSG00000253982.1	CTD-2336O2.1	10.84	1.42e-24	1.27e-21	0.43	0.45	Systolic blood pressure;	chr8:1747125	chr8:1761990~1764502:-
THCA	cis	rs9532669	0.926	rs9532654	ENSG00000239827.7	SUGT1P3	-10.84	1.42e-24	1.27e-21	-0.49	-0.45	Cervical cancer;	chr13:40909812	chr13:40908159~40921774:-
THCA	cis	rs4819052	0.851	rs2255774	ENSG00000223768.1	LINC00205	-10.84	1.42e-24	1.28e-21	-0.42	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.851	rs2256000	ENSG00000223768.1	LINC00205	-10.83	1.43e-24	1.29e-21	-0.41	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265994	chr21:45293285~45297354:+
THCA	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	10.83	1.44e-24	1.29e-21	0.54	0.45	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
THCA	cis	rs6570726	0.935	rs416987	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145525869	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.905	rs452770	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145526026	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs442254	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145527982	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs441575	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145528069	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs436212	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145528264	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs414222	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145529346	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs415590	ENSG00000235652.6	RP11-545I5.3	10.83	1.44e-24	1.29e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145530108	chr6:145799409~145886585:+
THCA	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	10.83	1.44e-24	1.3e-21	0.54	0.45	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
THCA	cis	rs950169	0.881	rs150965	ENSG00000225151.9	GOLGA2P7	-10.83	1.44e-24	1.3e-21	-0.65	-0.45	Schizophrenia;	chr15:84537296	chr15:84199311~84230136:-
THCA	cis	rs10463554	0.963	rs34829	ENSG00000175749.11	EIF3KP1	10.83	1.45e-24	1.3e-21	0.57	0.45	Parkinson's disease;	chr5:103108260	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.875	rs2492855	ENSG00000235652.6	RP11-545I5.3	10.83	1.45e-24	1.3e-21	0.4	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145975790	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.967	rs1009978	ENSG00000258413.1	RP11-665C16.6	-10.83	1.46e-24	1.31e-21	-0.58	-0.45	Protein biomarker;	chr14:55136343	chr14:55262767~55272075:-
THCA	cis	rs7945705	0.782	rs2742545	ENSG00000254860.4	TMEM9B-AS1	10.83	1.46e-24	1.31e-21	0.49	0.45	Hemoglobin concentration;	chr11:8862761	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.84	rs10840136	ENSG00000254860.4	TMEM9B-AS1	10.83	1.46e-24	1.31e-21	0.49	0.45	Hemoglobin concentration;	chr11:8863477	chr11:8964675~8977527:+
THCA	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-10.83	1.46e-24	1.31e-21	-0.49	-0.45	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
THCA	cis	rs916888	0.773	rs1378358	ENSG00000232300.1	FAM215B	10.83	1.47e-24	1.32e-21	0.75	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46558830~46562795:-
THCA	cis	rs6570726	0.935	rs421268	ENSG00000235652.6	RP11-545I5.3	10.83	1.47e-24	1.32e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145524422	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs384519	ENSG00000235652.6	RP11-545I5.3	10.83	1.47e-24	1.32e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145524881	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs454370	ENSG00000235652.6	RP11-545I5.3	10.83	1.47e-24	1.32e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145525593	chr6:145799409~145886585:+
THCA	cis	rs9487094	0.689	rs9480949	ENSG00000260273.1	RP11-425D10.10	10.83	1.47e-24	1.32e-21	0.52	0.45	Height;	chr6:109407238	chr6:109382795~109383666:+
THCA	cis	rs8062405	0.728	rs11642449	ENSG00000251417.2	RP11-1348G14.4	-10.83	1.48e-24	1.33e-21	-0.45	-0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28884694	chr16:28802743~28817828:+
THCA	cis	rs860295	0.702	rs10908471	ENSG00000225855.5	RUSC1-AS1	10.83	1.48e-24	1.33e-21	0.32	0.45	Body mass index;	chr1:155573151	chr1:155316863~155324176:-
THCA	cis	rs860295	0.702	rs10908472	ENSG00000225855.5	RUSC1-AS1	10.83	1.48e-24	1.33e-21	0.32	0.45	Body mass index;	chr1:155574465	chr1:155316863~155324176:-
THCA	cis	rs860295	0.702	rs11264383	ENSG00000225855.5	RUSC1-AS1	10.83	1.48e-24	1.33e-21	0.32	0.45	Body mass index;	chr1:155575555	chr1:155316863~155324176:-
THCA	cis	rs7772486	0.641	rs2748489	ENSG00000235652.6	RP11-545I5.3	10.83	1.49e-24	1.34e-21	0.44	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146010151	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs434298	ENSG00000235652.6	RP11-545I5.3	10.83	1.49e-24	1.34e-21	0.4	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145525737	chr6:145799409~145886585:+
THCA	cis	rs6142102	1	rs6059672	ENSG00000276073.1	RP5-1125A11.7	-10.83	1.5e-24	1.34e-21	-0.43	-0.45	Skin pigmentation;	chr20:34117662	chr20:33985617~33988989:-
THCA	cis	rs9928842	0.823	rs889514	ENSG00000280152.1	RP11-331F4.5	10.83	1.5e-24	1.35e-21	0.6	0.45	Alcoholic chronic pancreatitis;	chr16:75238614	chr16:75245994~75250077:-
THCA	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-10.83	1.5e-24	1.35e-21	-0.58	-0.45	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
THCA	cis	rs6496932	0.663	rs11074169	ENSG00000218052.5	ADAMTS7P4	-10.83	1.5e-24	1.35e-21	-0.58	-0.45	Central corneal thickness;Corneal structure;	chr15:85375721	chr15:85255369~85330334:-
THCA	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	10.83	1.5e-24	1.35e-21	0.37	0.45	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
THCA	cis	rs600231	0.665	rs2846861	ENSG00000245532.5	NEAT1	10.83	1.5e-24	1.35e-21	0.31	0.45	Bone mineral density;	chr11:65454834	chr11:65422774~65445540:+
THCA	cis	rs600231	0.665	rs1784858	ENSG00000245532.5	NEAT1	10.83	1.5e-24	1.35e-21	0.31	0.45	Bone mineral density;	chr11:65455481	chr11:65422774~65445540:+
THCA	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	10.83	1.5e-24	1.35e-21	0.5	0.45	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
THCA	cis	rs7772486	0.641	rs2777485	ENSG00000235652.6	RP11-545I5.3	10.83	1.51e-24	1.35e-21	0.44	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146013241	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.84	rs28493647	ENSG00000258413.1	RP11-665C16.6	-10.83	1.52e-24	1.36e-21	-0.58	-0.45	Protein biomarker;	chr14:55357745	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.84	rs17674463	ENSG00000258413.1	RP11-665C16.6	-10.83	1.52e-24	1.36e-21	-0.58	-0.45	Protein biomarker;	chr14:55358145	chr14:55262767~55272075:-
THCA	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	10.83	1.52e-24	1.36e-21	0.55	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
THCA	cis	rs9487094	0.689	rs8465	ENSG00000260273.1	RP11-425D10.10	10.83	1.52e-24	1.37e-21	0.52	0.45	Height;	chr6:109367335	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.923	rs9285524	ENSG00000223701.3	RAET1E-AS1	10.83	1.53e-24	1.37e-21	0.59	0.45	Lung cancer;	chr6:149694122	chr6:149884431~149919508:+
THCA	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	10.83	1.54e-24	1.38e-21	0.73	0.45	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
THCA	cis	rs9322193	0.923	rs12195866	ENSG00000223701.3	RAET1E-AS1	10.83	1.54e-24	1.39e-21	0.59	0.45	Lung cancer;	chr6:149693334	chr6:149884431~149919508:+
THCA	cis	rs526231	0.575	rs66730942	ENSG00000175749.11	EIF3KP1	10.83	1.56e-24	1.4e-21	0.62	0.45	Primary biliary cholangitis;	chr5:102971075	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.84	rs3742569	ENSG00000258413.1	RP11-665C16.6	-10.82	1.57e-24	1.4e-21	-0.58	-0.45	Protein biomarker;	chr14:55351988	chr14:55262767~55272075:-
THCA	cis	rs6907340	0.513	rs6938418	ENSG00000228412.5	RP4-625H18.2	-10.82	1.57e-24	1.41e-21	-0.64	-0.45	Endometriosis;	chr6:19808802	chr6:19802164~19804752:-
THCA	cis	rs9322193	0.923	rs7753812	ENSG00000223701.3	RAET1E-AS1	10.82	1.58e-24	1.41e-21	0.59	0.45	Lung cancer;	chr6:149690150	chr6:149884431~149919508:+
THCA	cis	rs17608059	0.901	rs11078215	ENSG00000141028.6	CDRT15P1	-10.82	1.58e-24	1.41e-21	-0.51	-0.45	Temperament;	chr17:14003617	chr17:14024514~14025488:+
THCA	cis	rs7773456	0.74	rs4140625	ENSG00000228412.5	RP4-625H18.2	-10.82	1.58e-24	1.42e-21	-0.64	-0.45	Lupus nephritis in systemic lupus erythematosus;	chr6:19818109	chr6:19802164~19804752:-
THCA	cis	rs11676348	0.808	rs4674267	ENSG00000261338.2	RP11-378A13.1	-10.82	1.59e-24	1.43e-21	-0.45	-0.45	Ulcerative colitis;	chr2:218181714	chr2:218255319~218257366:+
THCA	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	10.82	1.59e-24	1.43e-21	0.52	0.45	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
THCA	cis	rs12468226	0.938	rs6435139	ENSG00000273456.1	RP11-686O6.2	-10.82	1.6e-24	1.43e-21	-0.54	-0.45	Urate levels;	chr2:202255145	chr2:202374932~202375604:-
THCA	cis	rs7772486	0.641	rs960385	ENSG00000235652.6	RP11-545I5.3	10.82	1.61e-24	1.44e-21	0.44	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146049938	chr6:145799409~145886585:+
THCA	cis	rs465969	0.744	rs574056	ENSG00000255389.1	C6orf3	-10.82	1.61e-24	1.44e-21	-0.85	-0.45	Psoriasis;	chr6:111305787	chr6:111599875~111602295:+
THCA	cis	rs10463554	0.963	rs13340364	ENSG00000175749.11	EIF3KP1	10.82	1.61e-24	1.44e-21	0.58	0.45	Parkinson's disease;	chr5:103003406	chr5:103032376~103033031:+
THCA	cis	rs860295	0.702	rs12746592	ENSG00000225855.5	RUSC1-AS1	10.82	1.61e-24	1.45e-21	0.31	0.45	Body mass index;	chr1:155536176	chr1:155316863~155324176:-
THCA	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	10.82	1.62e-24	1.45e-21	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
THCA	cis	rs600231	0.623	rs3015966	ENSG00000245532.5	NEAT1	10.82	1.62e-24	1.45e-21	0.31	0.45	Bone mineral density;	chr11:65450118	chr11:65422774~65445540:+
THCA	cis	rs2946504	0.52	rs2272624	ENSG00000251468.2	RP11-369K16.1	-10.82	1.62e-24	1.45e-21	-0.51	-0.45	Type 2 diabetes;	chr8:12952158	chr8:12958387~12962200:+
THCA	cis	rs77204473	0.557	rs7111854	ENSG00000254851.1	RP11-109L13.1	10.82	1.63e-24	1.46e-21	0.84	0.45	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116906110	chr11:117135528~117138582:+
THCA	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	10.82	1.63e-24	1.46e-21	0.52	0.45	Height;	chr6:109454233	chr6:109382795~109383666:+
THCA	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-10.82	1.63e-24	1.46e-21	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
THCA	cis	rs12554020	0.892	rs6479483	ENSG00000227603.1	RP11-165J3.6	10.82	1.63e-24	1.46e-21	0.63	0.45	Schizophrenia;	chr9:93441746	chr9:93435332~93437121:-
THCA	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-10.82	1.64e-24	1.47e-21	-0.58	-0.45	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
THCA	cis	rs853679	0.506	rs1150693	ENSG00000219392.1	RP1-265C24.5	-10.82	1.64e-24	1.47e-21	-0.6	-0.45	Depression;	chr6:28206812	chr6:28115628~28116551:+
THCA	cis	rs8072100	0.745	rs7214410	ENSG00000228782.6	CTD-2026D20.3	10.82	1.65e-24	1.47e-21	0.41	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47345262	chr17:47450568~47492492:-
THCA	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-10.82	1.65e-24	1.48e-21	-0.56	-0.45	Height;	chr3:53029908	chr3:53064283~53065091:-
THCA	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	10.82	1.66e-24	1.49e-21	0.56	0.45	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	10.82	1.66e-24	1.49e-21	0.56	0.45	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
THCA	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	10.82	1.66e-24	1.49e-21	0.56	0.45	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
THCA	cis	rs944289	0.617	rs1958614	ENSG00000257826.1	RP11-116N8.4	-10.82	1.67e-24	1.49e-21	-0.48	-0.45	Thyroid cancer;	chr14:36118107	chr14:36061026~36067190:-
THCA	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-10.82	1.67e-24	1.5e-21	-0.55	-0.45	Height;	chr3:52949886	chr3:53064283~53065091:-
THCA	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	10.82	1.68e-24	1.5e-21	0.4	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
THCA	cis	rs9322193	0.566	rs3922947	ENSG00000223701.3	RAET1E-AS1	-10.82	1.68e-24	1.5e-21	-0.64	-0.45	Lung cancer;	chr6:149924856	chr6:149884431~149919508:+
THCA	cis	rs12022452	1	rs3738471	ENSG00000238287.1	RP11-656D10.3	-10.82	1.69e-24	1.51e-21	-0.71	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:40493157~40508661:-
THCA	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-10.82	1.7e-24	1.52e-21	-0.54	-0.45	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
THCA	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-10.82	1.7e-24	1.52e-21	-0.54	-0.45	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
THCA	cis	rs10262624	0.967	rs2188845	ENSG00000234286.1	AC006026.13	-10.82	1.7e-24	1.52e-21	-0.58	-0.45	Schizophrenia;	chr7:23882391	chr7:23680195~23680786:-
THCA	cis	rs62103177	0.683	rs62101232	ENSG00000261126.6	RP11-795F19.1	10.81	1.7e-24	1.53e-21	0.53	0.45	Opioid sensitivity;	chr18:79962454	chr18:80046900~80095482:+
THCA	cis	rs8072100	0.967	rs4338849	ENSG00000228782.6	CTD-2026D20.3	10.81	1.71e-24	1.53e-21	0.41	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47435117	chr17:47450568~47492492:-
THCA	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-10.81	1.71e-24	1.53e-21	-0.59	-0.45	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
THCA	cis	rs8072100	0.811	rs1912483	ENSG00000228782.6	CTD-2026D20.3	10.81	1.71e-24	1.53e-21	0.41	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47366128	chr17:47450568~47492492:-
THCA	cis	rs9322193	0.926	rs9383546	ENSG00000223701.3	RAET1E-AS1	10.81	1.72e-24	1.54e-21	0.59	0.45	Lung cancer;	chr6:149822743	chr6:149884431~149919508:+
THCA	cis	rs916888	0.773	rs169201	ENSG00000232300.1	FAM215B	10.81	1.72e-24	1.54e-21	0.75	0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46558830~46562795:-
THCA	cis	rs10463554	0.963	rs11955683	ENSG00000175749.11	EIF3KP1	10.81	1.72e-24	1.54e-21	0.58	0.45	Parkinson's disease;	chr5:102990992	chr5:103032376~103033031:+
THCA	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	10.81	1.72e-24	1.54e-21	0.54	0.45	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
THCA	cis	rs9487094	0.689	rs9487076	ENSG00000260273.1	RP11-425D10.10	10.81	1.74e-24	1.56e-21	0.52	0.45	Height;	chr6:109371524	chr6:109382795~109383666:+
THCA	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	10.81	1.75e-24	1.56e-21	0.45	0.45	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
THCA	cis	rs8062405	0.728	rs9931989	ENSG00000251417.2	RP11-1348G14.4	10.81	1.75e-24	1.56e-21	0.45	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28894763	chr16:28802743~28817828:+
THCA	cis	rs7772486	0.641	rs9390370	ENSG00000235652.6	RP11-545I5.3	10.81	1.75e-24	1.57e-21	0.44	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146036433	chr6:145799409~145886585:+
THCA	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-10.81	1.75e-24	1.57e-21	-0.5	-0.45	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
THCA	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-10.81	1.76e-24	1.57e-21	-0.57	-0.45	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
THCA	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	10.81	1.76e-24	1.58e-21	0.54	0.45	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
THCA	cis	rs62103177	0.525	rs10438902	ENSG00000261126.6	RP11-795F19.1	-10.81	1.77e-24	1.58e-21	-0.48	-0.45	Opioid sensitivity;	chr18:79985640	chr18:80046900~80095482:+
THCA	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-10.81	1.78e-24	1.59e-21	-0.5	-0.45	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
THCA	cis	rs9322193	0.566	rs5024811	ENSG00000223701.3	RAET1E-AS1	-10.81	1.78e-24	1.59e-21	-0.64	-0.45	Lung cancer;	chr6:149924898	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.521	rs9485017	ENSG00000235652.6	RP11-545I5.3	10.81	1.79e-24	1.6e-21	0.44	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145702190	chr6:145799409~145886585:+
THCA	cis	rs6142102	0.923	rs6059586	ENSG00000276073.1	RP5-1125A11.7	-10.81	1.79e-24	1.6e-21	-0.41	-0.45	Skin pigmentation;	chr20:33952695	chr20:33985617~33988989:-
THCA	cis	rs934734	0.532	rs7569257	ENSG00000281920.1	RP11-418H16.1	-10.81	1.79e-24	1.6e-21	-0.54	-0.45	Rheumatoid arthritis;	chr2:65429842	chr2:65623272~65628424:+
THCA	cis	rs7945705	0.818	rs2653613	ENSG00000254860.4	TMEM9B-AS1	10.81	1.81e-24	1.61e-21	0.49	0.45	Hemoglobin concentration;	chr11:8857558	chr11:8964675~8977527:+
THCA	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-10.81	1.81e-24	1.62e-21	-0.52	-0.45	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
THCA	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-10.81	1.81e-24	1.62e-21	-0.52	-0.45	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
THCA	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-10.81	1.81e-24	1.62e-21	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
THCA	cis	rs6142102	1	rs6059681	ENSG00000276073.1	RP5-1125A11.7	-10.81	1.81e-24	1.62e-21	-0.43	-0.45	Skin pigmentation;	chr20:34135535	chr20:33985617~33988989:-
THCA	cis	rs8062405	0.655	rs7184597	ENSG00000251417.2	RP11-1348G14.4	10.81	1.82e-24	1.62e-21	0.45	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28802743~28817828:+
THCA	cis	rs6558530	0.666	rs4242538	ENSG00000253982.1	CTD-2336O2.1	10.81	1.82e-24	1.63e-21	0.42	0.45	Systolic blood pressure;	chr8:1745844	chr8:1761990~1764502:-
THCA	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-10.81	1.82e-24	1.63e-21	-0.58	-0.45	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
THCA	cis	rs9487094	0.644	rs3757230	ENSG00000260273.1	RP11-425D10.10	10.81	1.83e-24	1.63e-21	0.52	0.45	Height;	chr6:109383239	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.644	rs3757231	ENSG00000260273.1	RP11-425D10.10	10.81	1.83e-24	1.63e-21	0.52	0.45	Height;	chr6:109383248	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs736830	ENSG00000260273.1	RP11-425D10.10	10.81	1.84e-24	1.64e-21	0.52	0.45	Height;	chr6:109392096	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.696	rs1853330	ENSG00000260273.1	RP11-425D10.10	10.81	1.85e-24	1.65e-21	0.52	0.45	Height;	chr6:109375548	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs2211288	ENSG00000260273.1	RP11-425D10.10	10.81	1.85e-24	1.65e-21	0.52	0.45	Height;	chr6:109383848	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs4946970	ENSG00000260273.1	RP11-425D10.10	10.81	1.85e-24	1.65e-21	0.52	0.45	Height;	chr6:109384807	chr6:109382795~109383666:+
THCA	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	10.8	1.88e-24	1.67e-21	0.54	0.45	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
THCA	cis	rs34375054	0.525	rs1080910	ENSG00000279233.1	RP11-158L12.4	10.8	1.88e-24	1.68e-21	0.43	0.45	Post bronchodilator FEV1/FVC ratio;	chr12:125123946	chr12:125138245~125141711:+
THCA	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-10.8	1.88e-24	1.68e-21	-0.51	-0.45	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
THCA	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-10.8	1.89e-24	1.68e-21	-0.5	-0.45	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
THCA	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-10.8	1.89e-24	1.68e-21	-0.38	-0.45	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
THCA	cis	rs8072100	0.905	rs9895274	ENSG00000228782.6	CTD-2026D20.3	10.8	1.9e-24	1.7e-21	0.41	0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47461751	chr17:47450568~47492492:-
THCA	cis	rs2732480	0.5	rs12828309	ENSG00000258273.1	RP11-370I10.4	-10.8	1.91e-24	1.7e-21	-0.58	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48333755~48333901:-
THCA	cis	rs673078	0.607	rs6490177	ENSG00000275409.1	RP11-131L12.4	-10.8	1.91e-24	1.71e-21	-0.47	-0.45	Glucose homeostasis traits;	chr12:118358280	chr12:118430147~118430699:+
THCA	cis	rs10463554	0.963	rs26817	ENSG00000175749.11	EIF3KP1	-10.8	1.92e-24	1.71e-21	-0.57	-0.45	Parkinson's disease;	chr5:103204665	chr5:103032376~103033031:+
THCA	cis	rs934734	0.532	rs12185610	ENSG00000281920.1	RP11-418H16.1	-10.8	1.93e-24	1.72e-21	-0.54	-0.45	Rheumatoid arthritis;	chr2:65434334	chr2:65623272~65628424:+
THCA	cis	rs7569084	0.687	rs963539	ENSG00000237979.1	AC007389.1	-10.8	1.94e-24	1.73e-21	-0.52	-0.45	Sum eosinophil basophil counts;	chr2:65421413	chr2:65500993~65502138:-
THCA	cis	rs9487094	0.689	rs9487070	ENSG00000260273.1	RP11-425D10.10	10.8	1.95e-24	1.74e-21	0.52	0.45	Height;	chr6:109361200	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs974034	ENSG00000260273.1	RP11-425D10.10	10.8	1.95e-24	1.74e-21	0.52	0.45	Height;	chr6:109368228	chr6:109382795~109383666:+
THCA	cis	rs6570726	1	rs404229	ENSG00000235652.6	RP11-545I5.3	10.8	1.97e-24	1.76e-21	0.4	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145547064	chr6:145799409~145886585:+
THCA	cis	rs6570726	1	rs405622	ENSG00000235652.6	RP11-545I5.3	10.8	1.97e-24	1.76e-21	0.4	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145550761	chr6:145799409~145886585:+
THCA	cis	rs9487094	0.689	rs1074766	ENSG00000260273.1	RP11-425D10.10	10.8	1.98e-24	1.76e-21	0.52	0.45	Height;	chr6:109360263	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.689	rs3818933	ENSG00000260273.1	RP11-425D10.10	10.8	1.98e-24	1.76e-21	0.52	0.45	Height;	chr6:109370741	chr6:109382795~109383666:+
THCA	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-10.8	1.98e-24	1.76e-21	-0.57	-0.45	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
THCA	cis	rs7211079	0.833	rs7220523	ENSG00000279259.1	RP11-334C17.3	10.8	1.99e-24	1.78e-21	0.47	0.45	Myocardial infarction;	chr17:80153896	chr17:80147250~80148596:+
THCA	cis	rs7211079	0.879	rs7221505	ENSG00000279259.1	RP11-334C17.3	10.8	1.99e-24	1.78e-21	0.47	0.45	Myocardial infarction;	chr17:80154432	chr17:80147250~80148596:+
THCA	cis	rs6570726	0.967	rs441364	ENSG00000235652.6	RP11-545I5.3	10.8	1.99e-24	1.78e-21	0.41	0.45	Lobe attachment (rater-scored or self-reported);	chr6:145532526	chr6:145799409~145886585:+
THCA	cis	rs7945705	0.869	rs4909952	ENSG00000254860.4	TMEM9B-AS1	-10.8	2e-24	1.78e-21	-0.49	-0.45	Hemoglobin concentration;	chr11:8942399	chr11:8964675~8977527:+
THCA	cis	rs2732480	0.5	rs2450989	ENSG00000258273.1	RP11-370I10.4	10.8	2.02e-24	1.8e-21	0.58	0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48333755~48333901:-
THCA	cis	rs7826238	0.535	rs2979179	ENSG00000254153.1	CTA-398F10.2	-10.8	2.03e-24	1.8e-21	-0.47	-0.45	Systolic blood pressure;	chr8:8462519	chr8:8456909~8461337:-
THCA	cis	rs9322193	0.962	rs35031906	ENSG00000223701.3	RAET1E-AS1	10.79	2.03e-24	1.81e-21	0.6	0.45	Lung cancer;	chr6:149677438	chr6:149884431~149919508:+
THCA	cis	rs3779195	0.585	rs58699591	ENSG00000272950.1	RP11-307C18.1	-10.79	2.03e-24	1.81e-21	-0.69	-0.45	Sex hormone-binding globulin levels;	chr7:98247392	chr7:98322853~98323430:+
THCA	cis	rs2658782	0.654	rs2605623	ENSG00000279684.1	RP11-755E23.2	-10.79	2.05e-24	1.83e-21	-0.71	-0.45	Pulmonary function decline;	chr11:93516193	chr11:93286629~93288903:-
THCA	cis	rs7945705	0.818	rs2742552	ENSG00000254860.4	TMEM9B-AS1	10.79	2.05e-24	1.83e-21	0.49	0.45	Hemoglobin concentration;	chr11:8855305	chr11:8964675~8977527:+
THCA	cis	rs9322193	0.683	rs113281309	ENSG00000223701.3	RAET1E-AS1	10.79	2.07e-24	1.84e-21	0.59	0.45	Lung cancer;	chr6:149787289	chr6:149884431~149919508:+
THCA	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	10.79	2.08e-24	1.85e-21	0.46	0.45	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
THCA	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	10.79	2.1e-24	1.87e-21	0.44	0.45	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
THCA	cis	rs600231	0.683	rs588298	ENSG00000245532.5	NEAT1	10.79	2.1e-24	1.87e-21	0.31	0.45	Bone mineral density;	chr11:65486103	chr11:65422774~65445540:+
THCA	cis	rs7211079	0.719	rs2289535	ENSG00000279259.1	RP11-334C17.3	10.79	2.12e-24	1.89e-21	0.44	0.45	Myocardial infarction;	chr17:80137650	chr17:80147250~80148596:+
THCA	cis	rs1075265	0.836	rs11687324	ENSG00000233266.1	HMGB1P31	10.79	2.13e-24	1.89e-21	0.55	0.45	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54051334~54051760:+
THCA	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-10.79	2.14e-24	1.9e-21	-0.57	-0.45	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
THCA	cis	rs2732480	0.5	rs2450986	ENSG00000258273.1	RP11-370I10.4	-10.79	2.16e-24	1.92e-21	-0.58	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48333755~48333901:-
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000206090.4	AP000350.7	10.79	2.18e-24	1.93e-21	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23939998~23942798:+
THCA	cis	rs950169	0.922	rs17531523	ENSG00000225151.9	GOLGA2P7	-10.79	2.18e-24	1.94e-21	-0.66	-0.45	Schizophrenia;	chr15:84589218	chr15:84199311~84230136:-
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000224205.1	AP000351.4	10.79	2.19e-24	1.95e-21	0.54	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23987320~23991421:-
THCA	cis	rs1387259	0.929	rs2634666	ENSG00000258273.1	RP11-370I10.4	-10.78	2.22e-24	1.97e-21	-0.58	-0.45	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48333755~48333901:-
THCA	cis	rs1387259	0.929	rs2956703	ENSG00000258273.1	RP11-370I10.4	-10.78	2.22e-24	1.97e-21	-0.58	-0.45	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48333755~48333901:-
THCA	cis	rs1387259	0.931	rs1107654	ENSG00000258273.1	RP11-370I10.4	-10.78	2.22e-24	1.97e-21	-0.58	-0.45	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48333755~48333901:-
THCA	cis	rs9322193	0.962	rs35443312	ENSG00000223701.3	RAET1E-AS1	10.78	2.23e-24	1.99e-21	0.6	0.45	Lung cancer;	chr6:149670625	chr6:149884431~149919508:+
THCA	cis	rs934734	0.532	rs2028150	ENSG00000281920.1	RP11-418H16.1	-10.78	2.24e-24	1.99e-21	-0.54	-0.45	Rheumatoid arthritis;	chr2:65427878	chr2:65623272~65628424:+
THCA	cis	rs934734	0.532	rs2028151	ENSG00000281920.1	RP11-418H16.1	-10.78	2.24e-24	1.99e-21	-0.54	-0.45	Rheumatoid arthritis;	chr2:65428479	chr2:65623272~65628424:+
THCA	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	10.78	2.24e-24	1.99e-21	0.55	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs9322197	ENSG00000223701.3	RAET1E-AS1	10.78	2.25e-24	2e-21	0.59	0.45	Lung cancer;	chr6:149622577	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs10872645	ENSG00000223701.3	RAET1E-AS1	10.78	2.26e-24	2.01e-21	0.59	0.45	Lung cancer;	chr6:149742840	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs12211511	ENSG00000223701.3	RAET1E-AS1	10.78	2.26e-24	2.01e-21	0.59	0.45	Lung cancer;	chr6:149745206	chr6:149884431~149919508:+
THCA	cis	rs6908034	0.66	rs7746588	ENSG00000228412.5	RP4-625H18.2	10.78	2.26e-24	2.01e-21	0.92	0.45	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804409	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.66	rs7750716	ENSG00000228412.5	RP4-625H18.2	10.78	2.26e-24	2.01e-21	0.92	0.45	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804608	chr6:19802164~19804752:-
THCA	cis	rs1387259	0.859	rs2054905	ENSG00000258273.1	RP11-370I10.4	-10.78	2.26e-24	2.01e-21	-0.59	-0.45	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.5	rs2732461	ENSG00000258273.1	RP11-370I10.4	-10.78	2.26e-24	2.01e-21	-0.59	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48333755~48333901:-
THCA	cis	rs9532669	0.926	rs4600337	ENSG00000176268.5	CYCSP34	10.78	2.27e-24	2.02e-21	0.52	0.45	Cervical cancer;	chr13:40879564	chr13:40863599~40863902:-
THCA	cis	rs780096	0.526	rs4582	ENSG00000234072.1	AC074117.10	-10.78	2.29e-24	2.03e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27381412	chr2:27356246~27367622:+
THCA	cis	rs4819052	0.565	rs35776291	ENSG00000223768.1	LINC00205	-10.78	2.29e-24	2.03e-21	-0.41	-0.45	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45293285~45297354:+
THCA	cis	rs3745672	1	rs113033627	ENSG00000219665.7	CTD-2006C1.2	-10.78	2.31e-24	2.05e-21	-0.98	-0.45	Multiple sclerosis;	chr19:12055554	chr19:11987617~12046275:+
THCA	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	10.78	2.33e-24	2.07e-21	0.54	0.45	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
THCA	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	10.78	2.38e-24	2.11e-21	0.51	0.45	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
THCA	cis	rs780096	0.506	rs1647285	ENSG00000234072.1	AC074117.10	-10.78	2.39e-24	2.12e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27491644	chr2:27356246~27367622:+
THCA	cis	rs780096	0.506	rs1647286	ENSG00000234072.1	AC074117.10	-10.78	2.39e-24	2.12e-21	-0.35	-0.45	Total body bone mineral density;	chr2:27491650	chr2:27356246~27367622:+
THCA	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-10.78	2.4e-24	2.13e-21	-0.4	-0.45	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
THCA	cis	rs7772486	0.641	rs9390374	ENSG00000235652.6	RP11-545I5.3	10.78	2.4e-24	2.13e-21	0.44	0.45	Lobe attachment (rater-scored or self-reported);	chr6:146047039	chr6:145799409~145886585:+
THCA	cis	rs7829975	0.633	rs2979181	ENSG00000253893.2	FAM85B	-10.77	2.43e-24	2.16e-21	-0.58	-0.45	Mood instability;	chr8:8465578	chr8:8167819~8226614:-
THCA	cis	rs934734	0.532	rs13383320	ENSG00000281920.1	RP11-418H16.1	-10.77	2.46e-24	2.18e-21	-0.54	-0.45	Rheumatoid arthritis;	chr2:65418003	chr2:65623272~65628424:+
THCA	cis	rs6570726	0.902	rs396681	ENSG00000235652.6	RP11-545I5.3	10.77	2.47e-24	2.19e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145532467	chr6:145799409~145886585:+
THCA	cis	rs324126	0.752	rs1054612	ENSG00000277977.1	CTD-3018O17.5	-10.77	2.49e-24	2.21e-21	-0.41	-0.44	Colonoscopy-negative controls vs population controls;	chr19:52366799	chr19:52392659~52392755:+
THCA	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-10.77	2.49e-24	2.21e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-10.77	2.49e-24	2.21e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-10.77	2.49e-24	2.21e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-10.77	2.49e-24	2.21e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
THCA	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
THCA	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-10.77	2.53e-24	2.24e-21	-0.57	-0.44	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
THCA	cis	rs62103177	0.525	rs9949598	ENSG00000261126.6	RP11-795F19.1	-10.77	2.54e-24	2.25e-21	-0.47	-0.44	Opioid sensitivity;	chr18:79993037	chr18:80046900~80095482:+
THCA	cis	rs9322193	0.923	rs4870052	ENSG00000268592.3	RAET1E-AS1	10.77	2.54e-24	2.25e-21	0.62	0.44	Lung cancer;	chr6:149839978	chr6:149863494~149919507:+
THCA	cis	rs780096	0.526	rs780106	ENSG00000234072.1	AC074117.10	-10.77	2.55e-24	2.25e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27458731	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs780107	ENSG00000234072.1	AC074117.10	-10.77	2.55e-24	2.25e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27461867	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs1406295	ENSG00000234072.1	AC074117.10	-10.77	2.55e-24	2.25e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27466833	chr2:27356246~27367622:+
THCA	cis	rs780096	0.506	rs1647265	ENSG00000234072.1	AC074117.10	-10.77	2.55e-24	2.25e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27469394	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs1647266	ENSG00000234072.1	AC074117.10	-10.77	2.55e-24	2.25e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27470618	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs780117	ENSG00000234072.1	AC074117.10	-10.77	2.55e-24	2.25e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27475476	chr2:27356246~27367622:+
THCA	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	10.77	2.55e-24	2.26e-21	0.63	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
THCA	cis	rs10246939	0.544	rs6959360	ENSG00000228775.6	WEE2-AS1	10.77	2.56e-24	2.26e-21	0.53	0.44	Bitter taste perception;	chr7:141869806	chr7:141704338~141738346:-
THCA	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-10.77	2.56e-24	2.26e-21	-0.51	-0.44	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
THCA	cis	rs11673344	0.528	rs476194	ENSG00000226686.6	LINC01535	10.77	2.56e-24	2.27e-21	0.51	0.44	Obesity-related traits;	chr19:36919831	chr19:37251912~37265535:+
THCA	cis	rs6964833	0.873	rs4717905	ENSG00000277053.3	GTF2IP1	-10.77	2.57e-24	2.27e-21	-0.6	-0.44	Menarche (age at onset);	chr7:74668903	chr7:75185385~75237696:-
THCA	cis	rs9659323	0.706	rs1409160	ENSG00000231365.4	RP11-418J17.1	-10.77	2.59e-24	2.29e-21	-0.44	-0.44	Body mass index;	chr1:119041231	chr1:119140396~119275973:+
THCA	cis	rs780096	0.565	rs780104	ENSG00000234072.1	AC074117.10	-10.77	2.59e-24	2.29e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27454824	chr2:27356246~27367622:+
THCA	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	10.77	2.6e-24	2.3e-21	0.54	0.44	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
THCA	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-10.77	2.6e-24	2.3e-21	-0.58	-0.44	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
THCA	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	10.77	2.61e-24	2.31e-21	0.52	0.44	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
THCA	cis	rs4819052	0.655	rs2330103	ENSG00000223768.1	LINC00205	-10.77	2.62e-24	2.31e-21	-0.41	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45293285~45297354:+
THCA	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-10.77	2.63e-24	2.32e-21	-0.58	-0.44	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
THCA	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	10.77	2.63e-24	2.32e-21	0.43	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
THCA	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-10.77	2.63e-24	2.33e-21	-0.55	-0.44	Height;	chr3:52975027	chr3:53064283~53065091:-
THCA	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	10.76	2.67e-24	2.36e-21	0.54	0.44	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
THCA	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	10.76	2.67e-24	2.36e-21	0.54	0.44	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
THCA	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	10.76	2.67e-24	2.36e-21	0.54	0.44	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
THCA	cis	rs916888	0.773	rs199439	ENSG00000232300.1	FAM215B	10.76	2.68e-24	2.37e-21	0.73	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46558830~46562795:-
THCA	cis	rs2274273	0.837	rs8011329	ENSG00000258413.1	RP11-665C16.6	-10.76	2.7e-24	2.39e-21	-0.58	-0.44	Protein biomarker;	chr14:55210537	chr14:55262767~55272075:-
THCA	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-10.76	2.7e-24	2.39e-21	-0.47	-0.44	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
THCA	cis	rs780096	0.527	rs59644396	ENSG00000234072.1	AC074117.10	-10.76	2.7e-24	2.39e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27423216	chr2:27356246~27367622:+
THCA	cis	rs6504950	0.924	rs244338	ENSG00000275710.1	RP11-257O5.4	10.76	2.71e-24	2.39e-21	0.54	0.44	Breast cancer;	chr17:55123057	chr17:54964474~54964679:+
THCA	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-10.76	2.71e-24	2.39e-21	-0.4	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-10.76	2.71e-24	2.39e-21	-0.4	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
THCA	cis	rs8062405	0.728	rs8056890	ENSG00000251417.2	RP11-1348G14.4	-10.76	2.71e-24	2.4e-21	-0.45	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28886131	chr16:28802743~28817828:+
THCA	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-10.76	2.73e-24	2.41e-21	-0.51	-0.44	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
THCA	cis	rs7829975	0.688	rs6995407	ENSG00000253893.2	FAM85B	-10.76	2.73e-24	2.42e-21	-0.58	-0.44	Mood instability;	chr8:8527137	chr8:8167819~8226614:-
THCA	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-10.76	2.78e-24	2.46e-21	-0.55	-0.44	Height;	chr3:52989412	chr3:53064283~53065091:-
THCA	cis	rs600231	0.665	rs1626021	ENSG00000245532.5	NEAT1	10.76	2.79e-24	2.46e-21	0.3	0.44	Bone mineral density;	chr11:65458716	chr11:65422774~65445540:+
THCA	cis	rs8062405	0.656	rs7189927	ENSG00000251417.2	RP11-1348G14.4	10.76	2.82e-24	2.49e-21	0.44	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28902466	chr16:28802743~28817828:+
THCA	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	10.76	2.83e-24	2.49e-21	0.63	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000224205.1	AP000351.4	10.76	2.84e-24	2.51e-21	0.53	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23987320~23991421:-
THCA	cis	rs2658782	0.724	rs2658770	ENSG00000279684.1	RP11-755E23.2	-10.76	2.85e-24	2.51e-21	-0.7	-0.44	Pulmonary function decline;	chr11:93528720	chr11:93286629~93288903:-
THCA	cis	rs11159086	1	rs4903232	ENSG00000270000.1	RP3-449M8.9	10.76	2.85e-24	2.52e-21	0.48	0.44	Advanced glycation end-product levels;	chr14:74496585	chr14:74471930~74472360:-
THCA	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-10.76	2.86e-24	2.52e-21	-0.4	-0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
THCA	cis	rs4819052	0.679	rs2255761	ENSG00000223768.1	LINC00205	-10.76	2.86e-24	2.53e-21	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45293285~45297354:+
THCA	cis	rs7772486	0.875	rs10872582	ENSG00000235652.6	RP11-545I5.3	10.76	2.87e-24	2.53e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146051925	chr6:145799409~145886585:+
THCA	cis	rs2732480	1	rs2732480	ENSG00000258273.1	RP11-370I10.4	10.75	2.89e-24	2.55e-21	0.55	0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48333755~48333901:-
THCA	cis	rs2658782	0.654	rs2605622	ENSG00000279684.1	RP11-755E23.2	-10.75	2.9e-24	2.56e-21	-0.71	-0.44	Pulmonary function decline;	chr11:93515076	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.654	rs2605617	ENSG00000279684.1	RP11-755E23.2	-10.75	2.9e-24	2.56e-21	-0.71	-0.44	Pulmonary function decline;	chr11:93510167	chr11:93286629~93288903:-
THCA	cis	rs4819052	0.679	rs2838860	ENSG00000223768.1	LINC00205	-10.75	2.91e-24	2.57e-21	-0.41	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45293285~45297354:+
THCA	cis	rs860295	0.729	rs11264369	ENSG00000225855.5	RUSC1-AS1	-10.75	2.92e-24	2.57e-21	-0.31	-0.44	Body mass index;	chr1:155390039	chr1:155316863~155324176:-
THCA	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-10.75	2.92e-24	2.58e-21	-0.58	-0.44	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
THCA	cis	rs7772486	0.875	rs6913797	ENSG00000235652.6	RP11-545I5.3	10.75	2.92e-24	2.58e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146092622	chr6:145799409~145886585:+
THCA	cis	rs2732480	0.5	rs1387257	ENSG00000258273.1	RP11-370I10.4	-10.75	2.95e-24	2.6e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48333755~48333901:-
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000224205.1	AP000351.4	10.75	2.95e-24	2.6e-21	0.53	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23987320~23991421:-
THCA	cis	rs7945705	0.783	rs11042125	ENSG00000254860.4	TMEM9B-AS1	10.75	2.97e-24	2.61e-21	0.48	0.44	Hemoglobin concentration;	chr11:8916502	chr11:8964675~8977527:+
THCA	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	10.75	2.98e-24	2.63e-21	0.47	0.44	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
THCA	cis	rs1387259	0.723	rs2732488	ENSG00000258273.1	RP11-370I10.4	-10.75	2.99e-24	2.63e-21	-0.59	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48333755~48333901:-
THCA	cis	rs1387259	0.758	rs2634670	ENSG00000258273.1	RP11-370I10.4	-10.75	2.99e-24	2.63e-21	-0.59	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48333755~48333901:-
THCA	cis	rs180730	0.561	rs3099888	ENSG00000251609.2	SETP12	-10.75	2.99e-24	2.63e-21	-0.62	-0.44	Fasting plasma glucose;	chr4:120882580	chr4:120895494~120897083:-
THCA	cis	rs11673344	0.528	rs573294	ENSG00000226686.6	LINC01535	10.75	3e-24	2.64e-21	0.51	0.44	Obesity-related traits;	chr19:36919260	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.528	rs579452	ENSG00000226686.6	LINC01535	10.75	3e-24	2.64e-21	0.51	0.44	Obesity-related traits;	chr19:36919936	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.528	rs491326	ENSG00000226686.6	LINC01535	10.75	3e-24	2.64e-21	0.51	0.44	Obesity-related traits;	chr19:36920037	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.528	rs563786	ENSG00000226686.6	LINC01535	10.75	3e-24	2.64e-21	0.51	0.44	Obesity-related traits;	chr19:36922012	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	10.75	3.01e-24	2.65e-21	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
THCA	cis	rs71403859	0.803	rs8063455	ENSG00000260886.1	TAT-AS1	10.75	3.02e-24	2.66e-21	0.79	0.44	Post bronchodilator FEV1;	chr16:71566074	chr16:71565789~71578187:+
THCA	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-10.75	3.03e-24	2.67e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
THCA	cis	rs9928842	0.882	rs4737	ENSG00000280152.1	RP11-331F4.5	-10.75	3.05e-24	2.68e-21	-0.63	-0.44	Alcoholic chronic pancreatitis;	chr16:75204205	chr16:75245994~75250077:-
THCA	cis	rs950169	0.922	rs11638445	ENSG00000225151.9	GOLGA2P7	-10.75	3.07e-24	2.7e-21	-0.66	-0.44	Schizophrenia;	chr15:84594463	chr15:84199311~84230136:-
THCA	cis	rs465969	0.546	rs7772141	ENSG00000255389.1	C6orf3	10.75	3.07e-24	2.71e-21	0.79	0.44	Psoriasis;	chr6:111472358	chr6:111599875~111602295:+
THCA	cis	rs465969	0.793	rs7776047	ENSG00000255389.1	C6orf3	10.75	3.07e-24	2.71e-21	0.79	0.44	Psoriasis;	chr6:111472391	chr6:111599875~111602295:+
THCA	cis	rs13392177	0.66	rs12988046	ENSG00000261338.2	RP11-378A13.1	-10.75	3.08e-24	2.71e-21	-0.46	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209081	chr2:218255319~218257366:+
THCA	cis	rs600231	0.598	rs2508712	ENSG00000245532.5	NEAT1	10.75	3.11e-24	2.74e-21	0.31	0.44	Bone mineral density;	chr11:65464790	chr11:65422774~65445540:+
THCA	cis	rs600231	0.708	rs3132767	ENSG00000245532.5	NEAT1	10.75	3.11e-24	2.74e-21	0.31	0.44	Bone mineral density;	chr11:65467389	chr11:65422774~65445540:+
THCA	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-10.75	3.12e-24	2.75e-21	-0.65	-0.44	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
THCA	cis	rs42490	0.903	rs393891	ENSG00000251136.7	RP11-37B2.1	-10.74	3.17e-24	2.79e-21	-0.38	-0.44	Leprosy;	chr8:89701556	chr8:89609409~89757727:-
THCA	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	10.74	3.19e-24	2.81e-21	0.38	0.44	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
THCA	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-10.74	3.19e-24	2.81e-21	-0.38	-0.44	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
THCA	cis	rs6570726	0.837	rs636894	ENSG00000235652.6	RP11-545I5.3	10.74	3.21e-24	2.82e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145542986	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs382910	ENSG00000235652.6	RP11-545I5.3	10.74	3.21e-24	2.82e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145544805	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.836	rs1363063	ENSG00000233266.1	HMGB1P31	10.74	3.21e-24	2.83e-21	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54051334~54051760:+
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000235689.1	AP000351.13	10.74	3.23e-24	2.84e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:24006305~24008258:-
THCA	cis	rs62103177	0.525	rs8086024	ENSG00000261126.6	RP11-795F19.1	-10.74	3.24e-24	2.85e-21	-0.47	-0.44	Opioid sensitivity;	chr18:79986623	chr18:80046900~80095482:+
THCA	cis	rs180730	0.509	rs1588521	ENSG00000251609.2	SETP12	-10.74	3.26e-24	2.86e-21	-0.62	-0.44	Fasting plasma glucose;	chr4:120881202	chr4:120895494~120897083:-
THCA	cis	rs6504950	0.732	rs244373	ENSG00000275710.1	RP11-257O5.4	-10.74	3.27e-24	2.87e-21	-0.54	-0.44	Breast cancer;	chr17:55107588	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.924	rs187242	ENSG00000275710.1	RP11-257O5.4	10.74	3.27e-24	2.87e-21	0.54	0.44	Breast cancer;	chr17:55115585	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.924	rs244342	ENSG00000275710.1	RP11-257O5.4	10.74	3.27e-24	2.87e-21	0.54	0.44	Breast cancer;	chr17:55121046	chr17:54964474~54964679:+
THCA	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	10.74	3.28e-24	2.89e-21	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
THCA	cis	rs7945705	0.902	rs2016942	ENSG00000254860.4	TMEM9B-AS1	-10.74	3.29e-24	2.89e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8917240	chr11:8964675~8977527:+
THCA	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-10.74	3.3e-24	2.91e-21	-0.56	-0.44	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
THCA	cis	rs9532669	0.926	rs4600337	ENSG00000239827.7	SUGT1P3	-10.74	3.33e-24	2.92e-21	-0.5	-0.44	Cervical cancer;	chr13:40879564	chr13:40908159~40921774:-
THCA	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	10.74	3.33e-24	2.93e-21	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
THCA	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	10.74	3.35e-24	2.95e-21	0.5	0.44	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.566	rs6912330	ENSG00000223701.3	RAET1E-AS1	-10.74	3.35e-24	2.95e-21	-0.64	-0.44	Lung cancer;	chr6:149908811	chr6:149884431~149919508:+
THCA	cis	rs7615952	0.736	rs11921945	ENSG00000171084.14	FAM86JP	10.74	3.36e-24	2.95e-21	0.6	0.44	Blood pressure (smoking interaction);	chr3:125924876	chr3:125916620~125930024:+
THCA	cis	rs4964805	0.865	rs4964780	ENSG00000257681.1	RP11-341G23.4	10.74	3.38e-24	2.97e-21	0.54	0.44	Attention deficit hyperactivity disorder;	chr12:103813081	chr12:103746315~103768858:-
THCA	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-10.74	3.38e-24	2.97e-21	-0.58	-0.44	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
THCA	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-10.74	3.41e-24	2.99e-21	-0.38	-0.44	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
THCA	cis	rs9532669	0.926	rs8002809	ENSG00000176268.5	CYCSP34	10.73	3.45e-24	3.03e-21	0.52	0.44	Cervical cancer;	chr13:40872769	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.929	rs7982421	ENSG00000176268.5	CYCSP34	10.73	3.45e-24	3.03e-21	0.52	0.44	Cervical cancer;	chr13:40872776	chr13:40863599~40863902:-
THCA	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	10.73	3.46e-24	3.04e-21	0.37	0.44	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
THCA	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	10.73	3.5e-24	3.07e-21	0.53	0.44	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
THCA	cis	rs2658782	0.724	rs2248655	ENSG00000279684.1	RP11-755E23.2	-10.73	3.5e-24	3.08e-21	-0.69	-0.44	Pulmonary function decline;	chr11:93521446	chr11:93286629~93288903:-
THCA	cis	rs9322193	0.887	rs3734295	ENSG00000223701.3	RAET1E-AS1	10.73	3.51e-24	3.08e-21	0.6	0.44	Lung cancer;	chr6:149593917	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.607	rs7764677	ENSG00000223701.3	RAET1E-AS1	10.73	3.53e-24	3.1e-21	0.63	0.44	Lung cancer;	chr6:149906197	chr6:149884431~149919508:+
THCA	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	10.73	3.54e-24	3.11e-21	0.6	0.44	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
THCA	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	10.73	3.54e-24	3.11e-21	0.37	0.44	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
THCA	cis	rs9532669	0.926	rs4555012	ENSG00000176268.5	CYCSP34	10.73	3.55e-24	3.12e-21	0.52	0.44	Cervical cancer;	chr13:40879997	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs12871420	ENSG00000176268.5	CYCSP34	10.73	3.55e-24	3.12e-21	0.52	0.44	Cervical cancer;	chr13:40880034	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs12871735	ENSG00000176268.5	CYCSP34	10.73	3.55e-24	3.12e-21	0.52	0.44	Cervical cancer;	chr13:40880169	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs12871895	ENSG00000176268.5	CYCSP34	10.73	3.55e-24	3.12e-21	0.52	0.44	Cervical cancer;	chr13:40880189	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs12872288	ENSG00000176268.5	CYCSP34	10.73	3.55e-24	3.12e-21	0.52	0.44	Cervical cancer;	chr13:40880268	chr13:40863599~40863902:-
THCA	cis	rs1891275	0.551	rs11186640	ENSG00000228701.1	TNKS2-AS1	-10.73	3.57e-24	3.13e-21	-0.49	-0.44	Intelligence (multi-trait analysis);	chr10:91640674	chr10:91782839~91798291:-
THCA	cis	rs4964805	0.773	rs4964623	ENSG00000257681.1	RP11-341G23.4	10.73	3.57e-24	3.13e-21	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103828964	chr12:103746315~103768858:-
THCA	cis	rs2274273	0.934	rs10139337	ENSG00000258413.1	RP11-665C16.6	-10.73	3.58e-24	3.14e-21	-0.59	-0.44	Protein biomarker;	chr14:55275395	chr14:55262767~55272075:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-10.73	3.59e-24	3.15e-21	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-10.73	3.59e-24	3.15e-21	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
THCA	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-10.73	3.59e-24	3.15e-21	-0.58	-0.44	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
THCA	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	10.73	3.62e-24	3.18e-21	0.54	0.44	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
THCA	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-10.73	3.64e-24	3.2e-21	-0.56	-0.44	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
THCA	cis	rs6142102	1	rs4911412	ENSG00000276073.1	RP5-1125A11.7	-10.73	3.67e-24	3.22e-21	-0.42	-0.44	Skin pigmentation;	chr20:34128629	chr20:33985617~33988989:-
THCA	cis	rs2732480	0.5	rs1552550	ENSG00000258273.1	RP11-370I10.4	-10.73	3.71e-24	3.26e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.5	rs2450991	ENSG00000258273.1	RP11-370I10.4	-10.73	3.71e-24	3.26e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48333755~48333901:-
THCA	cis	rs11673344	0.528	rs578655	ENSG00000226686.6	LINC01535	10.73	3.73e-24	3.27e-21	0.5	0.44	Obesity-related traits;	chr19:36919855	chr19:37251912~37265535:+
THCA	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	10.72	3.73e-24	3.27e-21	0.48	0.44	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
THCA	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-10.72	3.75e-24	3.28e-21	-0.56	-0.44	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
THCA	cis	rs11159086	1	rs58384818	ENSG00000270000.1	RP3-449M8.9	10.72	3.75e-24	3.29e-21	0.49	0.44	Advanced glycation end-product levels;	chr14:74487045	chr14:74471930~74472360:-
THCA	cis	rs11159086	1	rs17100588	ENSG00000270000.1	RP3-449M8.9	10.72	3.75e-24	3.29e-21	0.49	0.44	Advanced glycation end-product levels;	chr14:74487624	chr14:74471930~74472360:-
THCA	cis	rs10463554	0.963	rs3776859	ENSG00000175749.11	EIF3KP1	10.72	3.75e-24	3.29e-21	0.58	0.44	Parkinson's disease;	chr5:103016330	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.963	rs17154953	ENSG00000175749.11	EIF3KP1	10.72	3.75e-24	3.29e-21	0.58	0.44	Parkinson's disease;	chr5:103019557	chr5:103032376~103033031:+
THCA	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	10.72	3.77e-24	3.3e-21	0.42	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
THCA	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	10.72	3.77e-24	3.3e-21	0.42	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
THCA	cis	rs9532669	0.926	rs9532640	ENSG00000176268.5	CYCSP34	10.72	3.77e-24	3.3e-21	0.51	0.44	Cervical cancer;	chr13:40880628	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs9532641	ENSG00000176268.5	CYCSP34	10.72	3.77e-24	3.3e-21	0.51	0.44	Cervical cancer;	chr13:40880648	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532643	ENSG00000176268.5	CYCSP34	10.72	3.77e-24	3.3e-21	0.51	0.44	Cervical cancer;	chr13:40880800	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs9532644	ENSG00000176268.5	CYCSP34	10.72	3.77e-24	3.3e-21	0.51	0.44	Cervical cancer;	chr13:40880860	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532645	ENSG00000176268.5	CYCSP34	10.72	3.77e-24	3.3e-21	0.51	0.44	Cervical cancer;	chr13:40880898	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9525419	ENSG00000176268.5	CYCSP34	10.72	3.77e-24	3.3e-21	0.51	0.44	Cervical cancer;	chr13:40881047	chr13:40863599~40863902:-
THCA	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-10.72	3.77e-24	3.31e-21	-0.57	-0.44	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
THCA	cis	rs9928842	0.882	rs6564241	ENSG00000280152.1	RP11-331F4.5	10.72	3.8e-24	3.33e-21	0.65	0.44	Alcoholic chronic pancreatitis;	chr16:75230076	chr16:75245994~75250077:-
THCA	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-10.72	3.8e-24	3.33e-21	-0.57	-0.44	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
THCA	cis	rs6538678	0.929	rs10777744	ENSG00000258343.1	RP11-536G4.2	-10.72	3.8e-24	3.33e-21	-0.6	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95795345~95858839:-
THCA	cis	rs673078	0.66	rs61945224	ENSG00000275759.1	RP11-131L12.3	-10.72	3.81e-24	3.33e-21	-0.7	-0.44	Glucose homeostasis traits;	chr12:118288623	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61945225	ENSG00000275759.1	RP11-131L12.3	-10.72	3.81e-24	3.33e-21	-0.7	-0.44	Glucose homeostasis traits;	chr12:118288960	chr12:118428281~118428870:+
THCA	cis	rs860295	0.702	rs11264387	ENSG00000225855.5	RUSC1-AS1	10.72	3.82e-24	3.35e-21	0.31	0.44	Body mass index;	chr1:155593361	chr1:155316863~155324176:-
THCA	cis	rs9532669	0.89	rs9525420	ENSG00000176268.5	CYCSP34	10.72	3.83e-24	3.36e-21	0.52	0.44	Cervical cancer;	chr13:40882628	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7324383	ENSG00000176268.5	CYCSP34	10.72	3.83e-24	3.36e-21	0.52	0.44	Cervical cancer;	chr13:40882754	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532648	ENSG00000176268.5	CYCSP34	10.72	3.83e-24	3.36e-21	0.52	0.44	Cervical cancer;	chr13:40882795	chr13:40863599~40863902:-
THCA	cis	rs9322193	0.851	rs9322194	ENSG00000223701.3	RAET1E-AS1	10.72	3.83e-24	3.36e-21	0.6	0.44	Lung cancer;	chr6:149599113	chr6:149884431~149919508:+
THCA	cis	rs42490	0.844	rs444078	ENSG00000251136.7	RP11-37B2.1	-10.72	3.84e-24	3.36e-21	-0.38	-0.44	Leprosy;	chr8:89701558	chr8:89609409~89757727:-
THCA	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	10.72	3.85e-24	3.37e-21	0.51	0.44	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
THCA	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-10.72	3.85e-24	3.37e-21	-0.6	-0.44	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
THCA	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	10.72	3.89e-24	3.4e-21	0.54	0.44	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
THCA	cis	rs9487094	0.666	rs6920372	ENSG00000260273.1	RP11-425D10.10	10.72	3.91e-24	3.42e-21	0.52	0.44	Height;	chr6:109402736	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.644	rs9320286	ENSG00000260273.1	RP11-425D10.10	10.72	3.91e-24	3.42e-21	0.52	0.44	Height;	chr6:109403734	chr6:109382795~109383666:+
THCA	cis	rs673078	0.66	rs17512407	ENSG00000275759.1	RP11-131L12.3	-10.72	3.94e-24	3.44e-21	-0.7	-0.44	Glucose homeostasis traits;	chr12:118292705	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs61946064	ENSG00000275759.1	RP11-131L12.3	-10.72	3.94e-24	3.44e-21	-0.7	-0.44	Glucose homeostasis traits;	chr12:118294495	chr12:118428281~118428870:+
THCA	cis	rs12188164	0.932	rs2230437	ENSG00000221990.4	EXOC3-AS1	10.72	3.94e-24	3.44e-21	0.37	0.44	Cystic fibrosis severity;	chr5:476238	chr5:441498~443160:-
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-10.72	3.94e-24	3.45e-21	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
THCA	cis	rs2599510	0.811	rs2710628	ENSG00000276334.1	AL133243.1	10.72	3.95e-24	3.45e-21	0.49	0.44	Interleukin-18 levels;	chr2:32533286	chr2:32521927~32523547:+
THCA	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	10.72	3.96e-24	3.47e-21	0.51	0.44	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
THCA	cis	rs4591358	0.648	rs16836855	ENSG00000223466.1	AC064834.2	-10.72	3.97e-24	3.48e-21	-0.64	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522267	chr2:195533035~195538681:+
THCA	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	10.72	3.98e-24	3.48e-21	0.54	0.44	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
THCA	cis	rs6570726	0.902	rs4895678	ENSG00000235652.6	RP11-545I5.3	10.72	3.99e-24	3.49e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145614374	chr6:145799409~145886585:+
THCA	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-10.72	4e-24	3.5e-21	-0.63	-0.44	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
THCA	cis	rs2564921	0.73	rs12633064	ENSG00000242142.1	SERBP1P3	-10.72	4e-24	3.5e-21	-0.56	-0.44	Height;	chr3:53027361	chr3:53064283~53065091:-
THCA	cis	rs6570726	0.935	rs368848	ENSG00000235652.6	RP11-545I5.3	10.72	4e-24	3.5e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145534145	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs374000	ENSG00000235652.6	RP11-545I5.3	10.72	4e-24	3.5e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145534154	chr6:145799409~145886585:+
THCA	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-10.72	4.02e-24	3.52e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.902	rs10769980	ENSG00000254860.4	TMEM9B-AS1	-10.72	4.02e-24	3.52e-21	-0.49	-0.44	Hemoglobin concentration;	chr11:8992633	chr11:8964675~8977527:+
THCA	cis	rs7615952	0.8	rs11914298	ENSG00000171084.14	FAM86JP	10.72	4.03e-24	3.52e-21	0.62	0.44	Blood pressure (smoking interaction);	chr3:125924929	chr3:125916620~125930024:+
THCA	cis	rs600231	0.665	rs2105608	ENSG00000245532.5	NEAT1	10.71	4.11e-24	3.59e-21	0.31	0.44	Bone mineral density;	chr11:65461147	chr11:65422774~65445540:+
THCA	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-10.71	4.12e-24	3.6e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
THCA	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-10.71	4.13e-24	3.61e-21	-0.55	-0.44	Height;	chr3:52967831	chr3:53064283~53065091:-
THCA	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-10.71	4.13e-24	3.61e-21	-0.55	-0.44	Height;	chr3:52971094	chr3:53064283~53065091:-
THCA	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	10.71	4.15e-24	3.63e-21	0.51	0.44	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
THCA	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	10.71	4.16e-24	3.63e-21	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
THCA	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-10.71	4.17e-24	3.65e-21	-0.38	-0.44	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
THCA	cis	rs6570726	0.967	rs365515	ENSG00000235652.6	RP11-545I5.3	-10.71	4.18e-24	3.65e-21	-0.41	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145481697	chr6:145799409~145886585:+
THCA	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	10.71	4.19e-24	3.66e-21	0.55	0.44	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
THCA	cis	rs4591358	0.689	rs17178460	ENSG00000223466.1	AC064834.2	-10.71	4.21e-24	3.68e-21	-0.67	-0.44	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195555365	chr2:195533035~195538681:+
THCA	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	10.71	4.23e-24	3.7e-21	0.5	0.44	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
THCA	cis	rs9532669	0.926	rs4555012	ENSG00000239827.7	SUGT1P3	-10.71	4.23e-24	3.7e-21	-0.5	-0.44	Cervical cancer;	chr13:40879997	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs12871420	ENSG00000239827.7	SUGT1P3	-10.71	4.23e-24	3.7e-21	-0.5	-0.44	Cervical cancer;	chr13:40880034	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs12871735	ENSG00000239827.7	SUGT1P3	-10.71	4.23e-24	3.7e-21	-0.5	-0.44	Cervical cancer;	chr13:40880169	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs12871895	ENSG00000239827.7	SUGT1P3	-10.71	4.23e-24	3.7e-21	-0.5	-0.44	Cervical cancer;	chr13:40880189	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs12872288	ENSG00000239827.7	SUGT1P3	-10.71	4.23e-24	3.7e-21	-0.5	-0.44	Cervical cancer;	chr13:40880268	chr13:40908159~40921774:-
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	10.71	4.28e-24	3.74e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
THCA	cis	rs934734	0.532	rs7557569	ENSG00000281920.1	RP11-418H16.1	-10.71	4.28e-24	3.74e-21	-0.54	-0.44	Rheumatoid arthritis;	chr2:65417427	chr2:65623272~65628424:+
THCA	cis	rs7772486	0.712	rs1292335	ENSG00000235652.6	RP11-545I5.3	10.71	4.29e-24	3.75e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145646741	chr6:145799409~145886585:+
THCA	cis	rs950169	0.96	rs12905475	ENSG00000225151.9	GOLGA2P7	-10.71	4.3e-24	3.75e-21	-0.68	-0.44	Schizophrenia;	chr15:84131743	chr15:84199311~84230136:-
THCA	cis	rs7221109	0.601	rs2109223	ENSG00000278834.1	RP11-458J1.1	10.71	4.36e-24	3.8e-21	0.46	0.44	Type 1 diabetes;	chr17:40690602	chr17:40648300~40649718:+
THCA	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-10.71	4.38e-24	3.82e-21	-0.56	-0.44	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
THCA	cis	rs7829975	0.624	rs7823056	ENSG00000253893.2	FAM85B	-10.71	4.38e-24	3.82e-21	-0.58	-0.44	Mood instability;	chr8:8525195	chr8:8167819~8226614:-
THCA	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-10.71	4.39e-24	3.83e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.962	rs2151912	ENSG00000223701.3	RAET1E-AS1	10.71	4.4e-24	3.84e-21	0.59	0.44	Lung cancer;	chr6:149831772	chr6:149884431~149919508:+
THCA	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-10.71	4.41e-24	3.85e-21	-0.54	-0.44	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
THCA	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	10.7	4.44e-24	3.87e-21	0.53	0.44	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
THCA	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	10.7	4.45e-24	3.88e-21	0.53	0.44	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
THCA	cis	rs6570726	0.875	rs416243	ENSG00000235652.6	RP11-545I5.3	10.7	4.48e-24	3.91e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145546945	chr6:145799409~145886585:+
THCA	cis	rs9487094	0.666	rs4946967	ENSG00000260273.1	RP11-425D10.10	10.7	4.49e-24	3.92e-21	0.51	0.44	Height;	chr6:109357369	chr6:109382795~109383666:+
THCA	cis	rs860295	0.702	rs56675301	ENSG00000225855.5	RUSC1-AS1	10.7	4.5e-24	3.92e-21	0.31	0.44	Body mass index;	chr1:155394536	chr1:155316863~155324176:-
THCA	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-10.7	4.52e-24	3.94e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-10.7	4.52e-24	3.94e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
THCA	cis	rs9532669	0.926	rs9532646	ENSG00000239827.7	SUGT1P3	-10.7	4.54e-24	3.96e-21	-0.49	-0.44	Cervical cancer;	chr13:40880989	chr13:40908159~40921774:-
THCA	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-10.7	4.55e-24	3.97e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
THCA	cis	rs180730	0.561	rs343194	ENSG00000251609.2	SETP12	-10.7	4.57e-24	3.98e-21	-0.61	-0.44	Fasting plasma glucose;	chr4:120880199	chr4:120895494~120897083:-
THCA	cis	rs6142102	1	rs6142102	ENSG00000276073.1	RP5-1125A11.7	-10.7	4.58e-24	3.99e-21	-0.41	-0.44	Skin pigmentation;	chr20:34116821	chr20:33985617~33988989:-
THCA	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-10.7	4.63e-24	4.04e-21	-0.63	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
THCA	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	10.7	4.64e-24	4.04e-21	0.47	0.44	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-10.7	4.64e-24	4.04e-21	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
THCA	cis	rs2658782	0.526	rs7127240	ENSG00000279684.1	RP11-755E23.2	-10.7	4.66e-24	4.06e-21	-0.63	-0.44	Pulmonary function decline;	chr11:93451726	chr11:93286629~93288903:-
THCA	cis	rs2599510	0.811	rs2710615	ENSG00000276334.1	AL133243.1	10.7	4.66e-24	4.06e-21	0.48	0.44	Interleukin-18 levels;	chr2:32566155	chr2:32521927~32523547:+
THCA	cis	rs6570726	0.577	rs867056	ENSG00000235652.6	RP11-545I5.3	-10.7	4.66e-24	4.06e-21	-0.45	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145463669	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.719	rs4391282	ENSG00000235652.6	RP11-545I5.3	-10.7	4.66e-24	4.06e-21	-0.41	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145955644	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.934	rs17740741	ENSG00000258413.1	RP11-665C16.6	-10.7	4.69e-24	4.08e-21	-0.59	-0.44	Protein biomarker;	chr14:55295994	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.901	rs68046603	ENSG00000258413.1	RP11-665C16.6	-10.7	4.69e-24	4.08e-21	-0.59	-0.44	Protein biomarker;	chr14:55296085	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.901	rs12050099	ENSG00000258413.1	RP11-665C16.6	-10.7	4.69e-24	4.08e-21	-0.59	-0.44	Protein biomarker;	chr14:55297613	chr14:55262767~55272075:-
THCA	cis	rs780096	0.526	rs780112	ENSG00000234072.1	AC074117.10	-10.7	4.69e-24	4.08e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27442494	chr2:27356246~27367622:+
THCA	cis	rs7772486	0.846	rs2748496	ENSG00000235652.6	RP11-545I5.3	10.7	4.71e-24	4.11e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146000693	chr6:145799409~145886585:+
THCA	cis	rs2732480	0.5	rs12829841	ENSG00000258273.1	RP11-370I10.4	-10.7	4.73e-24	4.12e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.523	rs34286639	ENSG00000258273.1	RP11-370I10.4	-10.7	4.73e-24	4.12e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48333755~48333901:-
THCA	cis	rs1387259	0.929	rs11168484	ENSG00000258273.1	RP11-370I10.4	-10.7	4.73e-24	4.12e-21	-0.58	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48333755~48333901:-
THCA	cis	rs9322193	0.923	rs12175504	ENSG00000223701.3	RAET1E-AS1	10.7	4.75e-24	4.13e-21	0.59	0.44	Lung cancer;	chr6:149664079	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs62439843	ENSG00000223701.3	RAET1E-AS1	10.7	4.75e-24	4.13e-21	0.59	0.44	Lung cancer;	chr6:149676521	chr6:149884431~149919508:+
THCA	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	10.7	4.75e-24	4.14e-21	0.47	0.44	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
THCA	cis	rs2283792	0.74	rs2283791	ENSG00000224086.5	LL22NC03-86G7.1	-10.7	4.75e-24	4.14e-21	-0.54	-0.44	Multiple sclerosis;	chr22:21776656	chr22:21938293~21977632:+
THCA	cis	rs9532669	0.926	rs9532647	ENSG00000239827.7	SUGT1P3	-10.7	4.76e-24	4.15e-21	-0.49	-0.44	Cervical cancer;	chr13:40881799	chr13:40908159~40921774:-
THCA	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	10.7	4.77e-24	4.15e-21	0.43	0.44	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
THCA	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	10.7	4.79e-24	4.17e-21	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	10.7	4.79e-24	4.17e-21	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000206090.4	AP000350.7	10.7	4.79e-24	4.17e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23939998~23942798:+
THCA	cis	rs9322193	0.962	rs2275046	ENSG00000223701.3	RAET1E-AS1	10.7	4.79e-24	4.17e-21	0.59	0.44	Lung cancer;	chr6:149835865	chr6:149884431~149919508:+
THCA	cis	rs2732480	0.5	rs2932093	ENSG00000258273.1	RP11-370I10.4	-10.7	4.83e-24	4.2e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48333755~48333901:-
THCA	cis	rs1185460	0.547	rs667584	ENSG00000271751.1	RP11-110I1.14	10.69	4.84e-24	4.22e-21	0.55	0.44	Coronary artery disease;	chr11:119040834	chr11:119065263~119065677:-
THCA	cis	rs7773456	0.711	rs9358277	ENSG00000228412.5	RP4-625H18.2	-10.69	4.85e-24	4.22e-21	-0.64	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr6:19816398	chr6:19802164~19804752:-
THCA	cis	rs6538678	0.929	rs10735336	ENSG00000258343.1	RP11-536G4.2	-10.69	4.87e-24	4.23e-21	-0.6	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95795345~95858839:-
THCA	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-10.69	4.87e-24	4.24e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
THCA	cis	rs673078	0.607	rs11068906	ENSG00000275759.1	RP11-131L12.3	-10.69	4.87e-24	4.24e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118315098	chr12:118428281~118428870:+
THCA	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-10.69	4.88e-24	4.25e-21	-0.58	-0.44	QT interval;	chr16:28857143	chr16:28700294~28701540:-
THCA	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	10.69	4.96e-24	4.31e-21	0.52	0.44	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
THCA	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	10.69	4.97e-24	4.32e-21	0.43	0.44	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
THCA	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	10.69	4.97e-24	4.32e-21	0.47	0.44	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
THCA	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	10.69	4.99e-24	4.34e-21	0.52	0.44	Height;	chr6:109470427	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	10.69	4.99e-24	4.34e-21	0.52	0.44	Height;	chr6:109470900	chr6:109382795~109383666:+
THCA	cis	rs66486766	1	rs66486766	ENSG00000225151.9	GOLGA2P7	-10.69	5.02e-24	4.37e-21	-0.68	-0.44	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84199311~84230136:-
THCA	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	10.69	5.02e-24	4.37e-21	0.57	0.44	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
THCA	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-10.69	5.02e-24	4.37e-21	-0.57	-0.44	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
THCA	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	10.69	5.07e-24	4.4e-21	0.5	0.44	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
THCA	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	10.69	5.09e-24	4.42e-21	0.49	0.44	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
THCA	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	10.69	5.18e-24	4.51e-21	0.48	0.44	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
THCA	cis	rs7044106	0.887	rs1359328	ENSG00000226752.6	PSMD5-AS1	-10.69	5.21e-24	4.53e-21	-0.61	-0.44	Hip circumference adjusted for BMI;	chr9:120608544	chr9:120824828~120854385:+
THCA	cis	rs9532669	0.926	rs9532646	ENSG00000176268.5	CYCSP34	10.69	5.23e-24	4.55e-21	0.51	0.44	Cervical cancer;	chr13:40880989	chr13:40863599~40863902:-
THCA	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-10.69	5.24e-24	4.55e-21	-0.55	-0.44	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
THCA	cis	rs4964805	0.773	rs35746861	ENSG00000257681.1	RP11-341G23.4	10.69	5.25e-24	4.56e-21	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103831506	chr12:103746315~103768858:-
THCA	cis	rs7772486	0.875	rs9403765	ENSG00000235652.6	RP11-545I5.3	-10.68	5.29e-24	4.6e-21	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:146046905	chr6:145799409~145886585:+
THCA	cis	rs860295	0.665	rs11264367	ENSG00000225855.5	RUSC1-AS1	10.68	5.32e-24	4.62e-21	0.31	0.44	Body mass index;	chr1:155367547	chr1:155316863~155324176:-
THCA	cis	rs2599510	0.811	rs2583713	ENSG00000276334.1	AL133243.1	10.68	5.32e-24	4.62e-21	0.48	0.44	Interleukin-18 levels;	chr2:32597662	chr2:32521927~32523547:+
THCA	cis	rs9532669	0.89	rs11619117	ENSG00000176268.5	CYCSP34	10.68	5.33e-24	4.63e-21	0.51	0.44	Cervical cancer;	chr13:40880020	chr13:40863599~40863902:-
THCA	cis	rs9322193	0.962	rs9322220	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149782897	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs10214845	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149783124	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9767122	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149783553	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs1413654	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149783956	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9688809	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149787920	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9689242	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149787970	chr6:149884431~149919508:+
THCA	cis	rs9322193	1	rs9767077	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149788479	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.926	rs9766562	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149788709	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9688938	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149788941	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9688940	ENSG00000223701.3	RAET1E-AS1	10.68	5.34e-24	4.63e-21	0.59	0.44	Lung cancer;	chr6:149788977	chr6:149884431~149919508:+
THCA	cis	rs16828019	1	rs16828019	ENSG00000235358.1	RP11-399E6.1	10.68	5.34e-24	4.64e-21	0.86	0.44	Intelligence (multi-trait analysis);	chr1:41279363	chr1:41242373~41284861:+
THCA	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	10.68	5.34e-24	4.64e-21	0.47	0.44	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
THCA	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-10.68	5.37e-24	4.66e-21	-0.57	-0.44	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	10.68	5.37e-24	4.66e-21	0.57	0.44	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
THCA	cis	rs7772486	0.875	rs2777479	ENSG00000235652.6	RP11-545I5.3	10.68	5.37e-24	4.67e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145988042	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2777481	ENSG00000235652.6	RP11-545I5.3	10.68	5.37e-24	4.67e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145988900	chr6:145799409~145886585:+
THCA	cis	rs465969	1	rs9387010	ENSG00000255389.1	C6orf3	10.68	5.43e-24	4.71e-21	0.78	0.44	Psoriasis;	chr6:111384741	chr6:111599875~111602295:+
THCA	cis	rs9532669	0.926	rs9532647	ENSG00000176268.5	CYCSP34	10.68	5.47e-24	4.75e-21	0.51	0.44	Cervical cancer;	chr13:40881799	chr13:40863599~40863902:-
THCA	cis	rs6570726	0.935	rs407721	ENSG00000235652.6	RP11-545I5.3	10.68	5.54e-24	4.81e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145550218	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs408768	ENSG00000235652.6	RP11-545I5.3	10.68	5.54e-24	4.81e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145550599	chr6:145799409~145886585:+
THCA	cis	rs42490	0.903	rs7824932	ENSG00000251136.7	RP11-37B2.1	10.68	5.57e-24	4.84e-21	0.38	0.44	Leprosy;	chr8:89703848	chr8:89609409~89757727:-
THCA	cis	rs11159086	1	rs11159086	ENSG00000270000.1	RP3-449M8.9	10.68	5.6e-24	4.85e-21	0.48	0.44	Advanced glycation end-product levels;	chr14:74495572	chr14:74471930~74472360:-
THCA	cis	rs9659323	0.65	rs17013645	ENSG00000231365.4	RP11-418J17.1	-10.68	5.6e-24	4.86e-21	-0.47	-0.44	Body mass index;	chr1:118942226	chr1:119140396~119275973:+
THCA	cis	rs6504950	0.85	rs2628308	ENSG00000275710.1	RP11-257O5.4	-10.68	5.6e-24	4.86e-21	-0.55	-0.44	Breast cancer;	chr17:55046212	chr17:54964474~54964679:+
THCA	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-10.68	5.62e-24	4.87e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-10.68	5.62e-24	4.87e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-10.68	5.62e-24	4.87e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
THCA	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	10.68	5.65e-24	4.9e-21	0.47	0.44	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
THCA	cis	rs780096	0.526	rs1647267	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27428187	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs10182937	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27428826	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs704791	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27434300	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs780102	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27436624	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs1260341	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27440348	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs1260342	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27440549	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs4803	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27444430	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs1647276	ENSG00000234072.1	AC074117.10	-10.68	5.65e-24	4.9e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27465734	chr2:27356246~27367622:+
THCA	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	10.68	5.66e-24	4.9e-21	0.6	0.44	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
THCA	cis	rs62103177	0.608	rs4442895	ENSG00000261126.6	RP11-795F19.1	-10.68	5.66e-24	4.91e-21	-0.47	-0.44	Opioid sensitivity;	chr18:80066399	chr18:80046900~80095482:+
THCA	cis	rs17608059	0.518	rs4792436	ENSG00000141028.6	CDRT15P1	10.68	5.67e-24	4.91e-21	0.51	0.44	Temperament;	chr17:14068990	chr17:14024514~14025488:+
THCA	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	10.68	5.69e-24	4.93e-21	0.37	0.44	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
THCA	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	10.68	5.69e-24	4.94e-21	0.53	0.44	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
THCA	cis	rs3745672	1	rs7248680	ENSG00000219665.7	CTD-2006C1.2	10.68	5.7e-24	4.94e-21	0.96	0.44	Multiple sclerosis;	chr19:12054955	chr19:11987617~12046275:+
THCA	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	10.68	5.71e-24	4.95e-21	0.59	0.44	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
THCA	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	10.68	5.73e-24	4.96e-21	0.52	0.44	Height;	chr6:109462738	chr6:109382795~109383666:+
THCA	cis	rs11159086	1	rs12433848	ENSG00000270000.1	RP3-449M8.9	10.68	5.74e-24	4.97e-21	0.49	0.44	Advanced glycation end-product levels;	chr14:74497570	chr14:74471930~74472360:-
THCA	cis	rs944289	0.646	rs408283	ENSG00000257826.1	RP11-116N8.4	-10.67	5.76e-24	4.99e-21	-0.46	-0.44	Thyroid cancer;	chr14:36073503	chr14:36061026~36067190:-
THCA	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-10.67	5.77e-24	5e-21	-0.46	-0.44	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
THCA	cis	rs7829975	0.501	rs2980769	ENSG00000254153.1	CTA-398F10.2	-10.67	5.8e-24	5.02e-21	-0.47	-0.44	Mood instability;	chr8:8462781	chr8:8456909~8461337:-
THCA	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	10.67	5.8e-24	5.02e-21	0.57	0.44	QT interval;	chr16:28860645	chr16:28700294~28701540:-
THCA	cis	rs4819052	0.808	rs2838825	ENSG00000223768.1	LINC00205	-10.67	5.81e-24	5.03e-21	-0.42	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45293285~45297354:+
THCA	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	10.67	5.9e-24	5.11e-21	0.72	0.44	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
THCA	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-10.67	5.92e-24	5.12e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-10.67	5.92e-24	5.12e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
THCA	cis	rs1185460	0.565	rs657685	ENSG00000271751.1	RP11-110I1.14	10.67	5.92e-24	5.13e-21	0.55	0.44	Coronary artery disease;	chr11:119042272	chr11:119065263~119065677:-
THCA	cis	rs780096	0.565	rs813592	ENSG00000234072.1	AC074117.10	-10.67	5.95e-24	5.15e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27499104	chr2:27356246~27367622:+
THCA	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-10.67	5.96e-24	5.16e-21	-0.47	-0.44	Height;	chr2:231516587	chr2:231508426~231514339:-
THCA	cis	rs6142102	1	rs4911414	ENSG00000276073.1	RP5-1125A11.7	-10.67	5.97e-24	5.17e-21	-0.43	-0.44	Skin pigmentation;	chr20:34141638	chr20:33985617~33988989:-
THCA	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	10.67	6.02e-24	5.21e-21	0.64	0.44	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
THCA	cis	rs465969	0.744	rs13212489	ENSG00000255389.1	C6orf3	-10.67	6.02e-24	5.21e-21	-0.77	-0.44	Psoriasis;	chr6:111536863	chr6:111599875~111602295:+
THCA	cis	rs465969	0.744	rs76257900	ENSG00000255389.1	C6orf3	-10.67	6.02e-24	5.21e-21	-0.77	-0.44	Psoriasis;	chr6:111537286	chr6:111599875~111602295:+
THCA	cis	rs4819052	0.851	rs11558445	ENSG00000223768.1	LINC00205	-10.67	6.03e-24	5.22e-21	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265260	chr21:45293285~45297354:+
THCA	cis	rs42490	0.903	rs218944	ENSG00000251136.7	RP11-37B2.1	-10.67	6.04e-24	5.22e-21	-0.38	-0.44	Leprosy;	chr8:89701839	chr8:89609409~89757727:-
THCA	cis	rs9322193	0.961	rs9027	ENSG00000223701.3	RAET1E-AS1	10.67	6.04e-24	5.23e-21	0.59	0.44	Lung cancer;	chr6:149594921	chr6:149884431~149919508:+
THCA	cis	rs9322193	1	rs9322193	ENSG00000223701.3	RAET1E-AS1	10.67	6.04e-24	5.23e-21	0.59	0.44	Lung cancer;	chr6:149598007	chr6:149884431~149919508:+
THCA	cis	rs10463554	0.963	rs62362546	ENSG00000175749.11	EIF3KP1	10.67	6.06e-24	5.24e-21	0.58	0.44	Parkinson's disease;	chr5:103015615	chr5:103032376~103033031:+
THCA	cis	rs1387259	0.79	rs2732445	ENSG00000258273.1	RP11-370I10.4	-10.67	6.07e-24	5.25e-21	-0.58	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48333755~48333901:-
THCA	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-10.67	6.08e-24	5.26e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
THCA	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-10.67	6.08e-24	5.26e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
THCA	cis	rs67311347	0.713	rs73073505	ENSG00000223797.4	ENTPD3-AS1	10.67	6.09e-24	5.26e-21	0.37	0.44	Renal cell carcinoma;	chr3:40269202	chr3:40313802~40453329:-
THCA	cis	rs7772486	0.774	rs6930181	ENSG00000235652.6	RP11-545I5.3	-10.67	6.09e-24	5.26e-21	-0.41	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145859838	chr6:145799409~145886585:+
THCA	cis	rs6538678	0.929	rs7962359	ENSG00000258343.1	RP11-536G4.2	-10.67	6.09e-24	5.27e-21	-0.6	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95795345~95858839:-
THCA	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-10.67	6.18e-24	5.34e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-10.67	6.19e-24	5.35e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
THCA	cis	rs6142102	0.812	rs6120440	ENSG00000276073.1	RP5-1125A11.7	10.67	6.26e-24	5.41e-21	0.43	0.44	Skin pigmentation;	chr20:33929779	chr20:33985617~33988989:-
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000206090.4	AP000350.7	10.66	6.31e-24	5.45e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23939998~23942798:+
THCA	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-10.66	6.36e-24	5.49e-21	-0.57	-0.44	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
THCA	cis	rs73219805	0.597	rs71517887	ENSG00000228451.3	SDAD1P1	-10.66	6.37e-24	5.5e-21	-0.62	-0.44	Schizophrenia;	chr8:26374081	chr8:26379259~26382953:-
THCA	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-10.66	6.39e-24	5.52e-21	-0.58	-0.44	QT interval;	chr16:28877088	chr16:28700294~28701540:-
THCA	cis	rs6570726	0.967	rs439017	ENSG00000235652.6	RP11-545I5.3	10.66	6.39e-24	5.52e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145484987	chr6:145799409~145886585:+
THCA	cis	rs1789	0.903	rs6850422	ENSG00000273133.1	RP11-799M12.2	-10.66	6.4e-24	5.53e-21	-0.54	-0.44	Blood protein levels;	chr4:15680814	chr4:15563698~15564253:-
THCA	cis	rs9532669	0.89	rs9525420	ENSG00000239827.7	SUGT1P3	-10.66	6.42e-24	5.55e-21	-0.49	-0.44	Cervical cancer;	chr13:40882628	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7324383	ENSG00000239827.7	SUGT1P3	-10.66	6.42e-24	5.55e-21	-0.49	-0.44	Cervical cancer;	chr13:40882754	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532648	ENSG00000239827.7	SUGT1P3	-10.66	6.42e-24	5.55e-21	-0.49	-0.44	Cervical cancer;	chr13:40882795	chr13:40908159~40921774:-
THCA	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-10.66	6.48e-24	5.6e-21	-0.36	-0.44	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
THCA	cis	rs12664251	0.809	rs6931074	ENSG00000253194.1	RP11-351A11.1	10.66	6.49e-24	5.61e-21	0.62	0.44	Schizophrenia;	chr6:119020840	chr6:118934785~119031541:+
THCA	cis	rs2599510	0.783	rs62136349	ENSG00000276334.1	AL133243.1	10.66	6.52e-24	5.63e-21	0.49	0.44	Interleukin-18 levels;	chr2:32602437	chr2:32521927~32523547:+
THCA	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-10.66	6.6e-24	5.7e-21	-0.57	-0.44	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
THCA	cis	rs797680	0.576	rs55838267	ENSG00000223745.6	RP4-717I23.3	10.66	6.63e-24	5.72e-21	0.35	0.44	Eosinophil percentage of white cells;Sum eosinophil basophil counts;	chr1:93338159	chr1:93262186~93346025:-
THCA	cis	rs6504950	0.85	rs11079143	ENSG00000275710.1	RP11-257O5.4	-10.66	6.63e-24	5.72e-21	-0.55	-0.44	Breast cancer;	chr17:55005761	chr17:54964474~54964679:+
THCA	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-10.66	6.64e-24	5.73e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
THCA	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	10.66	6.67e-24	5.76e-21	0.5	0.44	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
THCA	cis	rs9322193	0.886	rs9718079	ENSG00000223701.3	RAET1E-AS1	10.66	6.68e-24	5.76e-21	0.59	0.44	Lung cancer;	chr6:149645947	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-10.66	6.68e-24	5.77e-21	-0.62	-0.44	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
THCA	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-10.66	6.7e-24	5.78e-21	-0.49	-0.44	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
THCA	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	10.66	6.72e-24	5.8e-21	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
THCA	cis	rs7772486	0.875	rs2748502	ENSG00000235652.6	RP11-545I5.3	10.66	6.72e-24	5.8e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145977103	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2777477	ENSG00000235652.6	RP11-545I5.3	10.66	6.72e-24	5.8e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145984355	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs1330939	ENSG00000235652.6	RP11-545I5.3	10.66	6.72e-24	5.8e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145987382	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs2814871	ENSG00000235652.6	RP11-545I5.3	10.66	6.73e-24	5.81e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145991138	chr6:145799409~145886585:+
THCA	cis	rs3779195	0.524	rs80195155	ENSG00000272950.1	RP11-307C18.1	-10.66	6.78e-24	5.85e-21	-0.68	-0.44	Sex hormone-binding globulin levels;	chr7:98248841	chr7:98322853~98323430:+
THCA	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	10.66	6.8e-24	5.86e-21	0.57	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
THCA	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	10.66	6.81e-24	5.87e-21	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
THCA	cis	rs9322193	0.962	rs9322206	ENSG00000223701.3	RAET1E-AS1	10.66	6.84e-24	5.9e-21	0.59	0.44	Lung cancer;	chr6:149641481	chr6:149884431~149919508:+
THCA	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-10.65	6.92e-24	5.96e-21	-0.54	-0.44	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
THCA	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-10.65	6.92e-24	5.96e-21	-0.54	-0.44	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
THCA	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-10.65	6.92e-24	5.96e-21	-0.54	-0.44	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
THCA	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-10.65	6.92e-24	5.96e-21	-0.54	-0.44	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
THCA	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-10.65	6.92e-24	5.96e-21	-0.69	-0.44	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
THCA	cis	rs7772486	0.875	rs56181683	ENSG00000235652.6	RP11-545I5.3	-10.65	6.94e-24	5.98e-21	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145965484	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.806	rs4075696	ENSG00000235652.6	RP11-545I5.3	-10.65	6.95e-24	5.99e-21	-0.41	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145929811	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.806	rs4075695	ENSG00000235652.6	RP11-545I5.3	-10.65	6.95e-24	5.99e-21	-0.41	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145929823	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-10.65	6.95e-24	5.99e-21	-0.57	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
THCA	cis	rs9532669	0.926	rs9532640	ENSG00000239827.7	SUGT1P3	-10.65	6.99e-24	6.02e-21	-0.49	-0.44	Cervical cancer;	chr13:40880628	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs9532641	ENSG00000239827.7	SUGT1P3	-10.65	6.99e-24	6.02e-21	-0.49	-0.44	Cervical cancer;	chr13:40880648	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532643	ENSG00000239827.7	SUGT1P3	-10.65	6.99e-24	6.02e-21	-0.49	-0.44	Cervical cancer;	chr13:40880800	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs9532644	ENSG00000239827.7	SUGT1P3	-10.65	6.99e-24	6.02e-21	-0.49	-0.44	Cervical cancer;	chr13:40880860	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532645	ENSG00000239827.7	SUGT1P3	-10.65	6.99e-24	6.02e-21	-0.49	-0.44	Cervical cancer;	chr13:40880898	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9525419	ENSG00000239827.7	SUGT1P3	-10.65	6.99e-24	6.02e-21	-0.49	-0.44	Cervical cancer;	chr13:40881047	chr13:40908159~40921774:-
THCA	cis	rs1387259	0.929	rs11168460	ENSG00000258273.1	RP11-370I10.4	-10.65	7.03e-24	6.06e-21	-0.58	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48333755~48333901:-
THCA	cis	rs2732480	0.5	rs7297824	ENSG00000258273.1	RP11-370I10.4	-10.65	7.03e-24	6.06e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48333755~48333901:-
THCA	cis	rs875971	0.793	rs460678	ENSG00000237310.1	GS1-124K5.4	10.65	7.04e-24	6.06e-21	0.33	0.44	Aortic root size;	chr7:66062213	chr7:66493706~66495474:+
THCA	cis	rs7772486	0.806	rs4243478	ENSG00000235652.6	RP11-545I5.3	-10.65	7.05e-24	6.07e-21	-0.41	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145963424	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.884	rs9688858	ENSG00000223701.3	RAET1E-AS1	10.65	7.05e-24	6.07e-21	0.59	0.44	Lung cancer;	chr6:149637911	chr6:149884431~149919508:+
THCA	cis	rs4927850	0.752	rs7618864	ENSG00000231464.1	AC024937.4	10.65	7.1e-24	6.11e-21	0.53	0.44	Pancreatic cancer;	chr3:196022690	chr3:195996738~195998233:+
THCA	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	10.65	7.12e-24	6.13e-21	0.71	0.44	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
THCA	cis	rs3762637	0.943	rs9289196	ENSG00000272758.4	RP11-299J3.8	-10.65	7.12e-24	6.13e-21	-0.56	-0.44	LDL cholesterol levels;	chr3:122549659	chr3:122416207~122443180:+
THCA	cis	rs6496932	0.663	rs2062238	ENSG00000218052.5	ADAMTS7P4	-10.65	7.13e-24	6.14e-21	-0.57	-0.44	Central corneal thickness;Corneal structure;	chr15:85376002	chr15:85255369~85330334:-
THCA	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	10.65	7.13e-24	6.14e-21	0.53	0.44	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
THCA	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-10.65	7.14e-24	6.15e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-10.65	7.14e-24	6.15e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-10.65	7.14e-24	6.15e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-10.65	7.14e-24	6.15e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
THCA	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-10.65	7.15e-24	6.15e-21	-0.58	-0.44	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
THCA	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-10.65	7.23e-24	6.22e-21	-0.57	-0.44	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
THCA	cis	rs2274273	0.837	rs8008119	ENSG00000258413.1	RP11-665C16.6	-10.65	7.24e-24	6.23e-21	-0.58	-0.44	Protein biomarker;	chr14:55364510	chr14:55262767~55272075:-
THCA	cis	rs673078	0.607	rs2784	ENSG00000275759.1	RP11-131L12.3	-10.65	7.39e-24	6.35e-21	-0.69	-0.44	Glucose homeostasis traits;	chr12:118311745	chr12:118428281~118428870:+
THCA	cis	rs673078	0.607	rs7302387	ENSG00000275759.1	RP11-131L12.3	-10.65	7.39e-24	6.35e-21	-0.69	-0.44	Glucose homeostasis traits;	chr12:118316546	chr12:118428281~118428870:+
THCA	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-10.65	7.39e-24	6.36e-21	-0.4	-0.44	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
THCA	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	10.65	7.41e-24	6.37e-21	0.64	0.44	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
THCA	cis	rs180730	0.561	rs2892917	ENSG00000251609.2	SETP12	-10.65	7.42e-24	6.38e-21	-0.61	-0.44	Fasting plasma glucose;	chr4:120898600	chr4:120895494~120897083:-
THCA	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	10.65	7.47e-24	6.42e-21	0.33	0.44	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
THCA	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-10.64	7.49e-24	6.44e-21	-0.52	-0.44	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
THCA	cis	rs673078	0.66	rs7961312	ENSG00000275759.1	RP11-131L12.3	-10.64	7.5e-24	6.44e-21	-0.69	-0.44	Glucose homeostasis traits;	chr12:118324431	chr12:118428281~118428870:+
THCA	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	10.64	7.5e-24	6.44e-21	0.37	0.44	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	10.64	7.5e-24	6.44e-21	0.37	0.44	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
THCA	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	10.64	7.51e-24	6.46e-21	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-10.64	7.56e-24	6.5e-21	-0.62	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
THCA	cis	rs934734	0.532	rs10166100	ENSG00000281920.1	RP11-418H16.1	-10.64	7.58e-24	6.51e-21	-0.54	-0.44	Rheumatoid arthritis;	chr2:65418616	chr2:65623272~65628424:+
THCA	cis	rs860295	0.651	rs12239114	ENSG00000225855.5	RUSC1-AS1	10.64	7.58e-24	6.51e-21	0.31	0.44	Body mass index;	chr1:155352351	chr1:155316863~155324176:-
THCA	cis	rs1075265	0.84	rs805309	ENSG00000233266.1	HMGB1P31	10.64	7.63e-24	6.55e-21	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54051334~54051760:+
THCA	cis	rs3779195	0.584	rs1688605	ENSG00000272950.1	RP11-307C18.1	-10.64	7.71e-24	6.62e-21	-0.7	-0.44	Sex hormone-binding globulin levels;	chr7:98410534	chr7:98322853~98323430:+
THCA	cis	rs9322193	0.923	rs4869750	ENSG00000223701.3	RAET1E-AS1	10.64	7.73e-24	6.64e-21	0.59	0.44	Lung cancer;	chr6:149855996	chr6:149884431~149919508:+
THCA	cis	rs2732480	0.5	rs7315820	ENSG00000258273.1	RP11-370I10.4	-10.64	7.79e-24	6.69e-21	-0.58	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48333755~48333901:-
THCA	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	10.64	7.8e-24	6.7e-21	0.37	0.44	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	10.64	7.8e-24	6.7e-21	0.37	0.44	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
THCA	cis	rs2658782	0.526	rs7131487	ENSG00000279684.1	RP11-755E23.2	-10.64	7.86e-24	6.75e-21	-0.63	-0.44	Pulmonary function decline;	chr11:93452786	chr11:93286629~93288903:-
THCA	cis	rs2599510	0.811	rs2754523	ENSG00000276334.1	AL133243.1	10.64	7.89e-24	6.78e-21	0.48	0.44	Interleukin-18 levels;	chr2:32612043	chr2:32521927~32523547:+
THCA	cis	rs9532669	0.926	rs9532690	ENSG00000176268.5	CYCSP34	10.64	7.92e-24	6.8e-21	0.48	0.44	Cervical cancer;	chr13:40968654	chr13:40863599~40863902:-
THCA	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-10.64	7.96e-24	6.84e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-10.64	7.96e-24	6.84e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
THCA	cis	rs7569084	1	rs7583469	ENSG00000281920.1	RP11-418H16.1	10.64	7.97e-24	6.84e-21	0.54	0.44	Sum eosinophil basophil counts;	chr2:65424222	chr2:65623272~65628424:+
THCA	cis	rs673078	0.607	rs56080343	ENSG00000275409.1	RP11-131L12.4	-10.64	7.97e-24	6.84e-21	-0.46	-0.44	Glucose homeostasis traits;	chr12:118439113	chr12:118430147~118430699:+
THCA	cis	rs9487094	0.666	rs7748669	ENSG00000260273.1	RP11-425D10.10	10.64	7.98e-24	6.85e-21	0.52	0.44	Height;	chr6:109424139	chr6:109382795~109383666:+
THCA	cis	rs42490	0.934	rs218947	ENSG00000251136.7	RP11-37B2.1	10.64	8e-24	6.87e-21	0.38	0.44	Leprosy;	chr8:89705148	chr8:89609409~89757727:-
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-10.64	8.04e-24	6.9e-21	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
THCA	cis	rs9487094	0.689	rs7754650	ENSG00000260273.1	RP11-425D10.10	10.64	8.09e-24	6.94e-21	0.5	0.44	Height;	chr6:109405536	chr6:109382795~109383666:+
THCA	cis	rs2274273	0.868	rs9919926	ENSG00000258413.1	RP11-665C16.6	-10.64	8.13e-24	6.97e-21	-0.58	-0.44	Protein biomarker;	chr14:55347172	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.934	rs10144418	ENSG00000258413.1	RP11-665C16.6	-10.64	8.13e-24	6.97e-21	-0.58	-0.44	Protein biomarker;	chr14:55350990	chr14:55262767~55272075:-
THCA	cis	rs4927850	0.752	rs7624460	ENSG00000231464.1	AC024937.4	10.64	8.14e-24	6.99e-21	0.53	0.44	Pancreatic cancer;	chr3:196021659	chr3:195996738~195998233:+
THCA	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	10.63	8.24e-24	7.07e-21	0.69	0.44	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
THCA	cis	rs6504950	0.889	rs2628301	ENSG00000275710.1	RP11-257O5.4	-10.63	8.25e-24	7.08e-21	-0.59	-0.44	Breast cancer;	chr17:55081912	chr17:54964474~54964679:+
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	10.63	8.27e-24	7.1e-21	0.57	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
THCA	cis	rs3745672	1	rs7246419	ENSG00000219665.7	CTD-2006C1.2	-10.63	8.35e-24	7.16e-21	-0.97	-0.44	Multiple sclerosis;	chr19:12051897	chr19:11987617~12046275:+
THCA	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-10.63	8.36e-24	7.17e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
THCA	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-10.63	8.38e-24	7.19e-21	-0.5	-0.44	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
THCA	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	10.63	8.38e-24	7.19e-21	0.58	0.44	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	10.63	8.5e-24	7.29e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
THCA	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-10.63	8.6e-24	7.37e-21	-0.57	-0.44	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
THCA	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	10.63	8.62e-24	7.39e-21	0.53	0.44	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
THCA	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-10.63	8.65e-24	7.41e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
THCA	cis	rs7772486	0.776	rs4316025	ENSG00000235652.6	RP11-545I5.3	-10.63	8.75e-24	7.5e-21	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145916896	chr6:145799409~145886585:+
THCA	cis	rs9890032	0.934	rs3760318	ENSG00000266490.1	CTD-2349P21.9	10.63	8.78e-24	7.53e-21	0.42	0.44	Hip circumference adjusted for BMI;	chr17:30920697	chr17:30792372~30792833:+
THCA	cis	rs9487094	0.689	rs4636056	ENSG00000260273.1	RP11-425D10.10	10.63	8.81e-24	7.55e-21	0.52	0.44	Height;	chr6:109409679	chr6:109382795~109383666:+
THCA	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-10.63	8.84e-24	7.58e-21	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
THCA	cis	rs7772486	0.776	rs2265467	ENSG00000235652.6	RP11-545I5.3	10.62	8.88e-24	7.61e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145897203	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	10.62	8.91e-24	7.64e-21	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
THCA	cis	rs7772486	0.597	rs9285508	ENSG00000235652.6	RP11-545I5.3	-10.62	8.94e-24	7.66e-21	-0.47	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145941561	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.806	rs2247317	ENSG00000235652.6	RP11-545I5.3	10.62	8.94e-24	7.66e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145896434	chr6:145799409~145886585:+
THCA	cis	rs2599510	0.755	rs67257914	ENSG00000276334.1	AL133243.1	10.62	9.16e-24	7.84e-21	0.49	0.44	Interleukin-18 levels;	chr2:32578951	chr2:32521927~32523547:+
THCA	cis	rs2658782	0.738	rs2605628	ENSG00000279684.1	RP11-755E23.2	-10.62	9.16e-24	7.84e-21	-0.7	-0.44	Pulmonary function decline;	chr11:93528394	chr11:93286629~93288903:-
THCA	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	10.62	9.23e-24	7.9e-21	0.54	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
THCA	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-10.62	9.23e-24	7.9e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
THCA	cis	rs7211079	0.912	rs4889831	ENSG00000279259.1	RP11-334C17.3	10.62	9.25e-24	7.92e-21	0.47	0.44	Myocardial infarction;	chr17:80140854	chr17:80147250~80148596:+
THCA	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-10.62	9.28e-24	7.94e-21	-0.49	-0.44	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
THCA	cis	rs780096	0.506	rs1262430	ENSG00000234072.1	AC074117.10	-10.62	9.29e-24	7.95e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27450931	chr2:27356246~27367622:+
THCA	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-10.62	9.29e-24	7.95e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-10.62	9.29e-24	7.95e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
THCA	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-10.62	9.34e-24	7.99e-21	-0.5	-0.44	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
THCA	cis	rs2274273	0.934	rs10140869	ENSG00000258413.1	RP11-665C16.6	-10.62	9.34e-24	7.99e-21	-0.58	-0.44	Protein biomarker;	chr14:55328565	chr14:55262767~55272075:-
THCA	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-10.62	9.43e-24	8.07e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
THCA	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	10.62	9.49e-24	8.12e-21	0.5	0.44	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
THCA	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	10.62	9.51e-24	8.13e-21	0.6	0.44	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
THCA	cis	rs4964805	1	rs34307072	ENSG00000257681.1	RP11-341G23.4	10.62	9.52e-24	8.14e-21	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103802526	chr12:103746315~103768858:-
THCA	cis	rs2283792	0.73	rs56398890	ENSG00000224086.5	LL22NC03-86G7.1	-10.62	9.55e-24	8.16e-21	-0.53	-0.44	Multiple sclerosis;	chr22:21836496	chr22:21938293~21977632:+
THCA	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-10.62	9.55e-24	8.16e-21	-0.37	-0.44	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
THCA	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-10.62	9.55e-24	8.16e-21	-0.37	-0.44	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
THCA	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-10.62	9.55e-24	8.16e-21	-0.37	-0.44	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
THCA	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-10.62	9.6e-24	8.2e-21	-0.54	-0.44	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
THCA	cis	rs780096	0.587	rs1049817	ENSG00000234072.1	AC074117.10	-10.62	9.63e-24	8.23e-21	-0.35	-0.44	Total body bone mineral density;	chr2:27328100	chr2:27356246~27367622:+
THCA	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	10.62	9.63e-24	8.23e-21	0.52	0.44	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
THCA	cis	rs13392177	0.66	rs62185964	ENSG00000261338.2	RP11-378A13.1	-10.62	9.65e-24	8.24e-21	-0.45	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209022	chr2:218255319~218257366:+
THCA	cis	rs13392177	0.684	rs62185965	ENSG00000261338.2	RP11-378A13.1	-10.62	9.65e-24	8.24e-21	-0.45	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218209056	chr2:218255319~218257366:+
THCA	cis	rs13392177	0.66	rs10932762	ENSG00000261338.2	RP11-378A13.1	-10.62	9.65e-24	8.24e-21	-0.45	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218211490	chr2:218255319~218257366:+
THCA	cis	rs13392177	0.684	rs11682371	ENSG00000261338.2	RP11-378A13.1	-10.62	9.65e-24	8.24e-21	-0.45	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218214790	chr2:218255319~218257366:+
THCA	cis	rs9532669	0.926	rs9532691	ENSG00000176268.5	CYCSP34	-10.61	9.69e-24	8.28e-21	-0.48	-0.44	Cervical cancer;	chr13:40969358	chr13:40863599~40863902:-
THCA	cis	rs9487094	0.6	rs1885690	ENSG00000260273.1	RP11-425D10.10	10.61	9.72e-24	8.3e-21	0.52	0.44	Height;	chr6:109351795	chr6:109382795~109383666:+
THCA	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	10.61	9.72e-24	8.3e-21	0.53	0.44	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
THCA	cis	rs2283792	0.646	rs9610317	ENSG00000224086.5	LL22NC03-86G7.1	-10.61	9.8e-24	8.37e-21	-0.56	-0.44	Multiple sclerosis;	chr22:21785601	chr22:21938293~21977632:+
THCA	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-10.61	9.82e-24	8.39e-21	-0.58	-0.44	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
THCA	cis	rs9487094	0.689	rs2884037	ENSG00000260273.1	RP11-425D10.10	10.61	9.86e-24	8.42e-21	0.52	0.44	Height;	chr6:109354092	chr6:109382795~109383666:+
THCA	cis	rs11159086	1	rs4899514	ENSG00000270000.1	RP3-449M8.9	-10.61	9.88e-24	8.44e-21	-0.49	-0.44	Advanced glycation end-product levels;	chr14:74473467	chr14:74471930~74472360:-
THCA	cis	rs9487094	0.644	rs9320288	ENSG00000260273.1	RP11-425D10.10	10.61	9.93e-24	8.48e-21	0.52	0.44	Height;	chr6:109446727	chr6:109382795~109383666:+
THCA	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-10.61	9.99e-24	8.53e-21	-0.53	-0.44	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
THCA	cis	rs2564921	0.73	rs62253602	ENSG00000242142.1	SERBP1P3	-10.61	1.01e-23	8.61e-21	-0.55	-0.44	Height;	chr3:52936861	chr3:53064283~53065091:-
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-10.61	1.01e-23	8.65e-21	-0.58	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
THCA	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-10.61	1.02e-23	8.7e-21	-0.53	-0.44	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
THCA	cis	rs7211079	0.843	rs73438138	ENSG00000279259.1	RP11-334C17.3	10.61	1.02e-23	8.7e-21	0.47	0.44	Myocardial infarction;	chr17:80148608	chr17:80147250~80148596:+
THCA	cis	rs9322193	0.923	rs14314	ENSG00000223701.3	RAET1E-AS1	10.61	1.02e-23	8.72e-21	0.58	0.44	Lung cancer;	chr6:149820395	chr6:149884431~149919508:+
THCA	cis	rs2658782	0.526	rs3020062	ENSG00000279684.1	RP11-755E23.2	-10.61	1.03e-23	8.76e-21	-0.67	-0.44	Pulmonary function decline;	chr11:93327993	chr11:93286629~93288903:-
THCA	cis	rs6504950	0.889	rs2628296	ENSG00000275710.1	RP11-257O5.4	-10.61	1.03e-23	8.78e-21	-0.55	-0.44	Breast cancer;	chr17:55089134	chr17:54964474~54964679:+
THCA	cis	rs934734	0.532	rs10153675	ENSG00000281920.1	RP11-418H16.1	-10.61	1.03e-23	8.78e-21	-0.54	-0.44	Rheumatoid arthritis;	chr2:65422446	chr2:65623272~65628424:+
THCA	cis	rs7772486	0.846	rs2892453	ENSG00000235652.6	RP11-545I5.3	10.61	1.03e-23	8.79e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146056581	chr6:145799409~145886585:+
THCA	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-10.61	1.04e-23	8.88e-21	-0.57	-0.44	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-10.61	1.04e-23	8.88e-21	-0.57	-0.44	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-10.61	1.04e-23	8.88e-21	-0.57	-0.44	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
THCA	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-10.61	1.05e-23	8.92e-21	-0.53	-0.44	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
THCA	cis	rs11676348	0.751	rs6715591	ENSG00000261338.2	RP11-378A13.1	-10.61	1.05e-23	8.93e-21	-0.45	-0.44	Ulcerative colitis;	chr2:218155148	chr2:218255319~218257366:+
THCA	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-10.61	1.05e-23	8.94e-21	-0.37	-0.44	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
THCA	cis	rs11105298	0.891	rs11105287	ENSG00000258302.2	RP11-981P6.1	10.61	1.05e-23	8.94e-21	0.41	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89435693	chr12:89561129~89594878:+
THCA	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	10.61	1.05e-23	8.98e-21	0.54	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.962	rs7745915	ENSG00000223701.3	RAET1E-AS1	10.6	1.06e-23	9.07e-21	0.59	0.44	Lung cancer;	chr6:149834111	chr6:149884431~149919508:+
THCA	cis	rs9487094	0.666	rs12529733	ENSG00000260273.1	RP11-425D10.10	10.6	1.07e-23	9.08e-21	0.53	0.44	Height;	chr6:109332929	chr6:109382795~109383666:+
THCA	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-10.6	1.08e-23	9.18e-21	-0.57	-0.44	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
THCA	cis	rs9659323	0.689	rs7545737	ENSG00000231365.4	RP11-418J17.1	10.6	1.08e-23	9.2e-21	0.48	0.44	Body mass index;	chr1:118991200	chr1:119140396~119275973:+
THCA	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
THCA	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
THCA	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-10.6	1.09e-23	9.29e-21	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
THCA	cis	rs7429990	0.896	rs34448818	ENSG00000229759.1	MRPS18AP1	10.6	1.1e-23	9.36e-21	0.59	0.44	Educational attainment (years of education);	chr3:47799822	chr3:48256350~48256938:-
THCA	cis	rs13392177	0.647	rs6718220	ENSG00000261338.2	RP11-378A13.1	-10.6	1.1e-23	9.4e-21	-0.45	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218201795	chr2:218255319~218257366:+
THCA	cis	rs2980439	0.557	rs2921056	ENSG00000254153.1	CTA-398F10.2	-10.6	1.11e-23	9.43e-21	-0.47	-0.44	Neuroticism;	chr8:8461672	chr8:8456909~8461337:-
THCA	cis	rs2980439	0.557	rs2976876	ENSG00000254153.1	CTA-398F10.2	-10.6	1.11e-23	9.44e-21	-0.47	-0.44	Neuroticism;	chr8:8461340	chr8:8456909~8461337:-
THCA	cis	rs465969	0.655	rs13203984	ENSG00000255389.1	C6orf3	-10.6	1.11e-23	9.44e-21	-0.78	-0.44	Psoriasis;	chr6:111388538	chr6:111599875~111602295:+
THCA	cis	rs12554020	0.892	rs7025805	ENSG00000227603.1	RP11-165J3.6	-10.6	1.11e-23	9.48e-21	-0.62	-0.44	Schizophrenia;	chr9:93481463	chr9:93435332~93437121:-
THCA	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-10.6	1.12e-23	9.49e-21	-0.6	-0.44	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
THCA	cis	rs944289	0.74	rs414155	ENSG00000257826.1	RP11-116N8.4	10.6	1.12e-23	9.52e-21	0.45	0.44	Thyroid cancer;	chr14:36076300	chr14:36061026~36067190:-
THCA	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	10.6	1.12e-23	9.52e-21	0.55	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
THCA	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-10.6	1.12e-23	9.53e-21	-0.54	-0.44	Height;	chr3:52972039	chr3:53064283~53065091:-
THCA	cis	rs860295	0.702	rs10796945	ENSG00000225855.5	RUSC1-AS1	10.6	1.12e-23	9.55e-21	0.3	0.44	Body mass index;	chr1:155457897	chr1:155316863~155324176:-
THCA	cis	rs2564921	0.704	rs62253603	ENSG00000242142.1	SERBP1P3	-10.6	1.13e-23	9.6e-21	-0.55	-0.44	Height;	chr3:52938846	chr3:53064283~53065091:-
THCA	cis	rs2564921	0.704	rs62253604	ENSG00000242142.1	SERBP1P3	-10.6	1.13e-23	9.6e-21	-0.55	-0.44	Height;	chr3:52941053	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.886	rs9767555	ENSG00000223701.3	RAET1E-AS1	10.6	1.13e-23	9.62e-21	0.61	0.44	Lung cancer;	chr6:149647022	chr6:149884431~149919508:+
THCA	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	10.6	1.13e-23	9.65e-21	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
THCA	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-10.6	1.14e-23	9.66e-21	-0.56	-0.44	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	10.6	1.14e-23	9.67e-21	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
THCA	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	10.6	1.14e-23	9.68e-21	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
THCA	cis	rs7429990	0.931	rs62262084	ENSG00000229759.1	MRPS18AP1	10.6	1.14e-23	9.68e-21	0.58	0.44	Educational attainment (years of education);	chr3:47612332	chr3:48256350~48256938:-
THCA	cis	rs860295	0.702	rs12025532	ENSG00000225855.5	RUSC1-AS1	10.6	1.14e-23	9.68e-21	0.31	0.44	Body mass index;	chr1:155399511	chr1:155316863~155324176:-
THCA	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	10.6	1.14e-23	9.71e-21	0.56	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
THCA	cis	rs1387259	0.69	rs1601985	ENSG00000258273.1	RP11-370I10.4	-10.6	1.15e-23	9.74e-21	-0.58	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48333755~48333901:-
THCA	cis	rs6570726	1	rs6570699	ENSG00000235652.6	RP11-545I5.3	10.6	1.15e-23	9.76e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145599596	chr6:145799409~145886585:+
THCA	cis	rs6570726	1	rs1935615	ENSG00000235652.6	RP11-545I5.3	10.6	1.15e-23	9.76e-21	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145599981	chr6:145799409~145886585:+
THCA	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	10.59	1.15e-23	9.81e-21	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
THCA	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	10.59	1.15e-23	9.81e-21	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
THCA	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-10.59	1.16e-23	9.82e-21	-0.57	-0.44	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
THCA	cis	rs7772486	0.806	rs2265477	ENSG00000235652.6	RP11-545I5.3	10.59	1.16e-23	9.83e-21	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145891202	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.901	rs17674563	ENSG00000258413.1	RP11-665C16.6	-10.59	1.16e-23	9.84e-21	-0.58	-0.44	Protein biomarker;	chr14:55364407	chr14:55262767~55272075:-
THCA	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-10.59	1.16e-23	9.85e-21	-0.56	-0.44	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
THCA	cis	rs934734	0.511	rs62141115	ENSG00000281920.1	RP11-418H16.1	-10.59	1.16e-23	9.9e-21	-0.53	-0.44	Rheumatoid arthritis;	chr2:65445058	chr2:65623272~65628424:+
THCA	cis	rs13392177	0.684	rs6720105	ENSG00000261338.2	RP11-378A13.1	-10.59	1.17e-23	9.96e-21	-0.45	-0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218215995	chr2:218255319~218257366:+
THCA	cis	rs7826238	0.524	rs2921055	ENSG00000254153.1	CTA-398F10.2	-10.59	1.18e-23	9.99e-21	-0.47	-0.44	Systolic blood pressure;	chr8:8461832	chr8:8456909~8461337:-
THCA	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
THCA	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
THCA	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
THCA	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
THCA	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
THCA	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-10.59	1.18e-23	1e-20	-0.49	-0.44	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
THCA	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-10.59	1.18e-23	1.01e-20	-0.43	-0.44	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
THCA	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-10.59	1.19e-23	1.01e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
THCA	cis	rs600231	0.708	rs1784860	ENSG00000245532.5	NEAT1	10.59	1.2e-23	1.02e-20	0.3	0.44	Bone mineral density;	chr11:65473241	chr11:65422774~65445540:+
THCA	cis	rs600231	0.708	rs2957269	ENSG00000245532.5	NEAT1	10.59	1.2e-23	1.02e-20	0.3	0.44	Bone mineral density;	chr11:65475536	chr11:65422774~65445540:+
THCA	cis	rs600231	0.708	rs2957268	ENSG00000245532.5	NEAT1	10.59	1.2e-23	1.02e-20	0.3	0.44	Bone mineral density;	chr11:65478345	chr11:65422774~65445540:+
THCA	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-10.59	1.2e-23	1.02e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
THCA	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-10.59	1.2e-23	1.02e-20	-0.56	-0.44	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-10.59	1.2e-23	1.02e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-10.59	1.2e-23	1.02e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
THCA	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	10.59	1.21e-23	1.03e-20	0.52	0.44	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
THCA	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-10.59	1.21e-23	1.03e-20	-0.65	-0.44	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
THCA	cis	rs4819052	0.851	rs1006779	ENSG00000223768.1	LINC00205	-10.59	1.23e-23	1.04e-20	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45293285~45297354:+
THCA	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-10.59	1.24e-23	1.06e-20	-0.69	-0.44	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
THCA	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-10.59	1.24e-23	1.06e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-10.59	1.24e-23	1.06e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
THCA	cis	rs7221109	0.677	rs4890092	ENSG00000278834.1	RP11-458J1.1	10.59	1.25e-23	1.06e-20	0.47	0.44	Type 1 diabetes;	chr17:40630199	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.633	rs9915135	ENSG00000278834.1	RP11-458J1.1	10.59	1.25e-23	1.06e-20	0.47	0.44	Type 1 diabetes;	chr17:40634823	chr17:40648300~40649718:+
THCA	cis	rs3779195	0.591	rs77968419	ENSG00000272950.1	RP11-307C18.1	-10.59	1.25e-23	1.06e-20	-0.68	-0.44	Sex hormone-binding globulin levels;	chr7:98237168	chr7:98322853~98323430:+
THCA	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	10.58	1.26e-23	1.06e-20	0.52	0.44	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
THCA	cis	rs11105298	0.891	rs11105318	ENSG00000258302.2	RP11-981P6.1	10.58	1.26e-23	1.07e-20	0.44	0.44	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89532881	chr12:89561129~89594878:+
THCA	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	10.58	1.27e-23	1.08e-20	0.49	0.44	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
THCA	cis	rs2274273	0.84	rs6573014	ENSG00000258413.1	RP11-665C16.6	10.58	1.27e-23	1.08e-20	0.54	0.44	Protein biomarker;	chr14:55269174	chr14:55262767~55272075:-
THCA	cis	rs1185460	0.547	rs1784559	ENSG00000271751.1	RP11-110I1.14	10.58	1.28e-23	1.09e-20	0.55	0.44	Coronary artery disease;	chr11:119030904	chr11:119065263~119065677:-
THCA	cis	rs1185460	0.527	rs693619	ENSG00000271751.1	RP11-110I1.14	10.58	1.28e-23	1.09e-20	0.55	0.44	Coronary artery disease;	chr11:119031235	chr11:119065263~119065677:-
THCA	cis	rs2732480	0.5	rs11168464	ENSG00000258273.1	RP11-370I10.4	-10.58	1.29e-23	1.09e-20	-0.57	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48333755~48333901:-
THCA	cis	rs526231	0.511	rs17154942	ENSG00000175749.11	EIF3KP1	-10.58	1.29e-23	1.09e-20	-0.59	-0.44	Primary biliary cholangitis;	chr5:103017014	chr5:103032376~103033031:+
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000206090.4	AP000350.7	-10.58	1.31e-23	1.11e-20	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23939998~23942798:+
THCA	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-10.58	1.31e-23	1.11e-20	-0.46	-0.44	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	10.58	1.31e-23	1.11e-20	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-10.58	1.31e-23	1.11e-20	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
THCA	cis	rs2732480	0.967	rs2732469	ENSG00000258273.1	RP11-370I10.4	-10.58	1.32e-23	1.12e-20	-0.55	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48333755~48333901:-
THCA	cis	rs6558530	0.932	rs6558531	ENSG00000253982.1	CTD-2336O2.1	10.58	1.32e-23	1.12e-20	0.38	0.44	Systolic blood pressure;	chr8:1759400	chr8:1761990~1764502:-
THCA	cis	rs957448	1	rs72674866	ENSG00000253704.1	RP11-267M23.4	10.58	1.33e-23	1.13e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94553722~94569745:+
THCA	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	10.58	1.33e-23	1.13e-20	0.54	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	10.58	1.33e-23	1.13e-20	0.54	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
THCA	cis	rs7429990	0.965	rs17785248	ENSG00000229759.1	MRPS18AP1	10.58	1.34e-23	1.13e-20	0.59	0.44	Educational attainment (years of education);	chr3:47631425	chr3:48256350~48256938:-
THCA	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-10.58	1.34e-23	1.13e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-10.58	1.34e-23	1.13e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
THCA	cis	rs7945705	0.967	rs34842234	ENSG00000254860.4	TMEM9B-AS1	-10.58	1.34e-23	1.14e-20	-0.49	-0.44	Hemoglobin concentration;	chr11:8870347	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.967	rs7123861	ENSG00000254860.4	TMEM9B-AS1	-10.58	1.34e-23	1.14e-20	-0.49	-0.44	Hemoglobin concentration;	chr11:8870776	chr11:8964675~8977527:+
THCA	cis	rs2274273	0.901	rs7147136	ENSG00000258413.1	RP11-665C16.6	-10.58	1.35e-23	1.14e-20	-0.58	-0.44	Protein biomarker;	chr14:55359970	chr14:55262767~55272075:-
THCA	cis	rs73219805	0.554	rs13266943	ENSG00000228451.3	SDAD1P1	-10.58	1.35e-23	1.15e-20	-0.62	-0.44	Schizophrenia;	chr8:26336629	chr8:26379259~26382953:-
THCA	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	10.58	1.36e-23	1.15e-20	0.54	0.44	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
THCA	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	10.58	1.36e-23	1.15e-20	0.54	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
THCA	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-10.58	1.37e-23	1.16e-20	-0.58	-0.44	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
THCA	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	10.57	1.37e-23	1.16e-20	0.52	0.44	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	10.57	1.37e-23	1.16e-20	0.52	0.44	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-10.57	1.38e-23	1.16e-20	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
THCA	cis	rs11148252	0.904	rs7321964	ENSG00000278238.1	RP11-245D16.4	-10.57	1.38e-23	1.17e-20	-0.48	-0.44	Lewy body disease;	chr13:52466687	chr13:52454775~52455331:-
THCA	cis	rs8062405	0.698	rs7188071	ENSG00000251417.2	RP11-1348G14.4	10.57	1.38e-23	1.17e-20	0.43	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28802743~28817828:+
THCA	cis	rs42490	0.903	rs184302	ENSG00000251136.7	RP11-37B2.1	-10.57	1.39e-23	1.17e-20	-0.38	-0.44	Leprosy;	chr8:89704396	chr8:89609409~89757727:-
THCA	cis	rs42490	0.903	rs218948	ENSG00000251136.7	RP11-37B2.1	-10.57	1.39e-23	1.17e-20	-0.38	-0.44	Leprosy;	chr8:89705617	chr8:89609409~89757727:-
THCA	cis	rs465969	1	rs9400478	ENSG00000255389.1	C6orf3	10.57	1.39e-23	1.18e-20	0.8	0.44	Psoriasis;	chr6:111478441	chr6:111599875~111602295:+
THCA	cis	rs673078	0.607	rs4766899	ENSG00000275409.1	RP11-131L12.4	-10.57	1.4e-23	1.18e-20	-0.44	-0.44	Glucose homeostasis traits;	chr12:118374888	chr12:118430147~118430699:+
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-10.57	1.4e-23	1.18e-20	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-10.57	1.4e-23	1.18e-20	-0.55	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
THCA	cis	rs9318086	0.712	rs1886970	ENSG00000205861.10	C1QTNF9B-AS1	-10.57	1.4e-23	1.18e-20	-0.5	-0.44	Myopia (pathological);	chr13:23866359	chr13:23888889~23897263:+
THCA	cis	rs860295	0.702	rs3738590	ENSG00000225855.5	RUSC1-AS1	10.57	1.4e-23	1.18e-20	0.31	0.44	Body mass index;	chr1:155660961	chr1:155316863~155324176:-
THCA	cis	rs71403859	1	rs71403859	ENSG00000260886.1	TAT-AS1	10.57	1.41e-23	1.19e-20	0.79	0.44	Post bronchodilator FEV1;	chr16:71606304	chr16:71565789~71578187:+
THCA	cis	rs71403859	0.803	rs34381861	ENSG00000260886.1	TAT-AS1	10.57	1.41e-23	1.19e-20	0.79	0.44	Post bronchodilator FEV1;	chr16:71606327	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	10.57	1.41e-23	1.19e-20	0.52	0.44	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
THCA	cis	rs494459	0.733	rs556437	ENSG00000278376.1	RP11-158I9.8	-10.57	1.41e-23	1.19e-20	-0.32	-0.44	Height;	chr11:118835044	chr11:118791254~118793137:+
THCA	cis	rs526231	0.543	rs34804	ENSG00000175749.11	EIF3KP1	10.57	1.41e-23	1.19e-20	0.63	0.44	Primary biliary cholangitis;	chr5:103092535	chr5:103032376~103033031:+
THCA	cis	rs9487094	0.643	rs35146243	ENSG00000260273.1	RP11-425D10.10	10.57	1.42e-23	1.2e-20	0.51	0.44	Height;	chr6:109477209	chr6:109382795~109383666:+
THCA	cis	rs2274273	0.967	rs10147667	ENSG00000258413.1	RP11-665C16.6	10.57	1.43e-23	1.21e-20	0.58	0.44	Protein biomarker;	chr14:55104131	chr14:55262767~55272075:-
THCA	cis	rs7772486	0.846	rs1474871	ENSG00000235652.6	RP11-545I5.3	10.57	1.43e-23	1.21e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146085158	chr6:145799409~145886585:+
THCA	cis	rs8100891	0.537	rs10403370	ENSG00000267213.4	AC007773.2	-10.57	1.43e-23	1.21e-20	-0.55	-0.44	Neuroticism;	chr19:32501949	chr19:32390050~32405560:-
THCA	cis	rs1976403	0.659	rs10799700	ENSG00000227001.3	NBPF2P	10.57	1.44e-23	1.21e-20	0.48	0.44	Liver enzyme levels (alkaline phosphatase);	chr1:21494475	chr1:21424625~21427967:-
THCA	cis	rs916888	0.773	rs538628	ENSG00000232300.1	FAM215B	10.57	1.44e-23	1.22e-20	0.72	0.44	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46558830~46562795:-
THCA	cis	rs780096	0.545	rs6716894	ENSG00000234072.1	AC074117.10	-10.57	1.44e-23	1.22e-20	-0.35	-0.44	Total body bone mineral density;	chr2:27360406	chr2:27356246~27367622:+
THCA	cis	rs34375054	0.525	rs10846829	ENSG00000279233.1	RP11-158L12.4	10.57	1.44e-23	1.22e-20	0.42	0.44	Post bronchodilator FEV1/FVC ratio;	chr12:125110512	chr12:125138245~125141711:+
THCA	cis	rs6570726	0.967	rs9403706	ENSG00000235652.6	RP11-545I5.3	-10.57	1.45e-23	1.22e-20	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145474051	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.967	rs373527	ENSG00000235652.6	RP11-545I5.3	10.57	1.45e-23	1.22e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145480725	chr6:145799409~145886585:+
THCA	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	10.57	1.45e-23	1.22e-20	0.54	0.44	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
THCA	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-10.57	1.45e-23	1.22e-20	-0.36	-0.44	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
THCA	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-10.57	1.45e-23	1.23e-20	-0.5	-0.44	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
THCA	cis	rs9532669	0.927	rs9532670	ENSG00000176268.5	CYCSP34	-10.57	1.45e-23	1.23e-20	-0.49	-0.44	Cervical cancer;	chr13:40927691	chr13:40863599~40863902:-
THCA	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	10.57	1.46e-23	1.23e-20	0.52	0.44	Height;	chr6:109464011	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	10.57	1.46e-23	1.23e-20	0.52	0.44	Height;	chr6:109465777	chr6:109382795~109383666:+
THCA	cis	rs2274273	0.935	rs3818451	ENSG00000258413.1	RP11-665C16.6	-10.57	1.46e-23	1.23e-20	-0.57	-0.44	Protein biomarker;	chr14:55154398	chr14:55262767~55272075:-
THCA	cis	rs780096	0.526	rs704795	ENSG00000234072.1	AC074117.10	-10.57	1.46e-23	1.24e-20	-0.35	-0.44	Total body bone mineral density;	chr2:27493627	chr2:27356246~27367622:+
THCA	cis	rs10256972	0.63	rs10282584	ENSG00000229043.2	AC091729.9	-10.57	1.47e-23	1.24e-20	-0.48	-0.44	Endometriosis;Longevity;	chr7:1041806	chr7:1160374~1165267:+
THCA	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-10.57	1.49e-23	1.25e-20	-0.37	-0.44	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-10.57	1.49e-23	1.25e-20	-0.37	-0.44	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
THCA	cis	rs600231	0.708	rs1784100	ENSG00000245532.5	NEAT1	10.56	1.49e-23	1.26e-20	0.3	0.44	Bone mineral density;	chr11:65481756	chr11:65422774~65445540:+
THCA	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-10.56	1.49e-23	1.26e-20	-0.58	-0.44	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
THCA	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	10.56	1.5e-23	1.27e-20	0.5	0.44	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000224205.1	AP000351.4	10.56	1.5e-23	1.27e-20	0.52	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23987320~23991421:-
THCA	cis	rs7772486	0.558	rs2142980	ENSG00000235652.6	RP11-545I5.3	-10.56	1.52e-23	1.28e-20	-0.46	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145759543	chr6:145799409~145886585:+
THCA	cis	rs7211079	0.957	rs935117	ENSG00000279259.1	RP11-334C17.3	10.56	1.52e-23	1.28e-20	0.47	0.44	Myocardial infarction;	chr17:80141685	chr17:80147250~80148596:+
THCA	cis	rs7211079	0.957	rs58120535	ENSG00000279259.1	RP11-334C17.3	10.56	1.52e-23	1.28e-20	0.47	0.44	Myocardial infarction;	chr17:80142225	chr17:80147250~80148596:+
THCA	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-10.56	1.53e-23	1.29e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
THCA	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	10.56	1.53e-23	1.29e-20	0.53	0.44	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
THCA	cis	rs3779195	0.52	rs17169479	ENSG00000272950.1	RP11-307C18.1	10.56	1.54e-23	1.3e-20	0.67	0.44	Sex hormone-binding globulin levels;	chr7:98238721	chr7:98322853~98323430:+
THCA	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-10.56	1.54e-23	1.3e-20	-0.53	-0.44	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
THCA	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	10.56	1.55e-23	1.31e-20	0.62	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
THCA	cis	rs2283792	0.646	rs7292584	ENSG00000224086.5	LL22NC03-86G7.1	-10.56	1.55e-23	1.31e-20	-0.55	-0.44	Multiple sclerosis;	chr22:21768458	chr22:21938293~21977632:+
THCA	cis	rs600231	0.571	rs10896000	ENSG00000245532.5	NEAT1	10.56	1.55e-23	1.31e-20	0.3	0.44	Bone mineral density;	chr11:65450547	chr11:65422774~65445540:+
THCA	cis	rs4819052	0.851	rs1999334	ENSG00000223768.1	LINC00205	-10.56	1.56e-23	1.32e-20	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45293285~45297354:+
THCA	cis	rs9309473	0.514	rs62149659	ENSG00000163016.8	ALMS1P	10.56	1.56e-23	1.32e-20	0.76	0.44	Metabolite levels;	chr2:73358068	chr2:73644919~73685576:+
THCA	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	10.56	1.57e-23	1.32e-20	0.43	0.44	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
THCA	cis	rs944289	0.617	rs1537428	ENSG00000257826.1	RP11-116N8.4	10.56	1.58e-23	1.33e-20	0.47	0.44	Thyroid cancer;	chr14:36117579	chr14:36061026~36067190:-
THCA	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-10.56	1.58e-23	1.33e-20	-0.67	-0.44	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-10.56	1.58e-23	1.33e-20	-0.67	-0.44	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
THCA	cis	rs4819052	0.788	rs9978857	ENSG00000223768.1	LINC00205	-10.56	1.58e-23	1.34e-20	-0.42	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45293285~45297354:+
THCA	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-10.56	1.59e-23	1.34e-20	-0.53	-0.44	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
THCA	cis	rs465969	1	rs459888	ENSG00000255389.1	C6orf3	10.56	1.6e-23	1.35e-20	0.75	0.44	Psoriasis;	chr6:111329953	chr6:111599875~111602295:+
THCA	cis	rs6570726	1	rs1935617	ENSG00000235652.6	RP11-545I5.3	10.56	1.61e-23	1.35e-20	0.41	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145622190	chr6:145799409~145886585:+
THCA	cis	rs600231	0.708	rs602838	ENSG00000245532.5	NEAT1	10.56	1.61e-23	1.35e-20	0.3	0.44	Bone mineral density;	chr11:65485776	chr11:65422774~65445540:+
THCA	cis	rs9322193	1	rs9377229	ENSG00000223701.3	RAET1E-AS1	10.56	1.61e-23	1.35e-20	0.58	0.44	Lung cancer;	chr6:149607655	chr6:149884431~149919508:+
THCA	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	10.55	1.64e-23	1.38e-20	0.4	0.44	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
THCA	cis	rs9487094	0.689	rs9487066	ENSG00000260273.1	RP11-425D10.10	10.55	1.64e-23	1.38e-20	0.52	0.44	Height;	chr6:109347707	chr6:109382795~109383666:+
THCA	cis	rs13392177	0.684	rs11695527	ENSG00000261338.2	RP11-378A13.1	10.55	1.65e-23	1.39e-20	0.45	0.44	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218203380	chr2:218255319~218257366:+
THCA	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-10.55	1.66e-23	1.4e-20	-0.59	-0.44	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
THCA	cis	rs2658782	0.704	rs2605614	ENSG00000279684.1	RP11-755E23.2	-10.55	1.67e-23	1.41e-20	-0.71	-0.44	Pulmonary function decline;	chr11:93499579	chr11:93286629~93288903:-
THCA	cis	rs2658782	0.615	rs2605615	ENSG00000279684.1	RP11-755E23.2	-10.55	1.67e-23	1.41e-20	-0.71	-0.44	Pulmonary function decline;	chr11:93499902	chr11:93286629~93288903:-
THCA	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-10.55	1.68e-23	1.41e-20	-0.53	-0.44	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
THCA	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	10.55	1.68e-23	1.42e-20	0.5	0.44	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
THCA	cis	rs780096	0.506	rs780100	ENSG00000234072.1	AC074117.10	-10.55	1.69e-23	1.42e-20	-0.34	-0.44	Total body bone mineral density;	chr2:27429286	chr2:27356246~27367622:+
THCA	cis	rs4713118	0.662	rs9393881	ENSG00000280107.1	AL022393.9	-10.55	1.69e-23	1.42e-20	-0.51	-0.44	Parkinson's disease;	chr6:28055973	chr6:28170845~28172521:+
THCA	cis	rs2732480	0.538	rs2732462	ENSG00000258273.1	RP11-370I10.4	-10.55	1.7e-23	1.43e-20	-0.57	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48333755~48333901:-
THCA	cis	rs600231	0.708	rs661403	ENSG00000245532.5	NEAT1	10.55	1.71e-23	1.44e-20	0.3	0.44	Bone mineral density;	chr11:65475007	chr11:65422774~65445540:+
THCA	cis	rs1789	0.903	rs4470622	ENSG00000273133.1	RP11-799M12.2	-10.55	1.71e-23	1.44e-20	-0.53	-0.44	Blood protein levels;	chr4:15672552	chr4:15563698~15564253:-
THCA	cis	rs9828933	0.678	rs704366	ENSG00000280620.1	SCAANT1	-10.55	1.71e-23	1.44e-20	-0.7	-0.44	Type 2 diabetes;	chr3:63885972	chr3:63911518~63911772:-
THCA	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	10.55	1.72e-23	1.45e-20	0.36	0.44	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	10.55	1.72e-23	1.45e-20	0.36	0.44	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
THCA	cis	rs1387259	0.899	rs7307566	ENSG00000258273.1	RP11-370I10.4	-10.55	1.72e-23	1.45e-20	-0.57	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48333755~48333901:-
THCA	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-10.55	1.73e-23	1.45e-20	-0.57	-0.44	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
THCA	cis	rs9828933	0.766	rs704361	ENSG00000280620.1	SCAANT1	-10.55	1.73e-23	1.46e-20	-0.76	-0.44	Type 2 diabetes;	chr3:63897995	chr3:63911518~63911772:-
THCA	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-10.55	1.74e-23	1.46e-20	-0.53	-0.44	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
THCA	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	10.55	1.74e-23	1.46e-20	0.43	0.44	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
THCA	cis	rs6504950	0.925	rs244315	ENSG00000275710.1	RP11-257O5.4	10.55	1.75e-23	1.47e-20	0.57	0.44	Breast cancer;	chr17:55137293	chr17:54964474~54964679:+
THCA	cis	rs4964805	0.802	rs934847	ENSG00000257681.1	RP11-341G23.4	10.55	1.76e-23	1.48e-20	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103791915	chr12:103746315~103768858:-
THCA	cis	rs10256972	0.626	rs62433138	ENSG00000229043.2	AC091729.9	-10.55	1.76e-23	1.48e-20	-0.47	-0.44	Endometriosis;Longevity;	chr7:1011241	chr7:1160374~1165267:+
THCA	cis	rs673078	0.607	rs10850967	ENSG00000275409.1	RP11-131L12.4	-10.55	1.77e-23	1.48e-20	-0.44	-0.44	Glucose homeostasis traits;	chr12:118380072	chr12:118430147~118430699:+
THCA	cis	rs6558530	0.932	rs7846610	ENSG00000253982.1	CTD-2336O2.1	10.55	1.77e-23	1.48e-20	0.38	0.44	Systolic blood pressure;	chr8:1758509	chr8:1761990~1764502:-
THCA	cis	rs9532669	0.926	rs12428966	ENSG00000239827.7	SUGT1P3	-10.55	1.77e-23	1.48e-20	-0.48	-0.44	Cervical cancer;	chr13:40876552	chr13:40908159~40921774:-
THCA	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-10.54	1.78e-23	1.49e-20	-0.56	-0.44	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
THCA	cis	rs9322193	0.923	rs9479810	ENSG00000223701.3	RAET1E-AS1	10.54	1.79e-23	1.5e-20	0.58	0.44	Lung cancer;	chr6:149751359	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.967	rs1396648	ENSG00000235652.6	RP11-545I5.3	-10.54	1.8e-23	1.51e-20	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145464112	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.902	rs9390326	ENSG00000235652.6	RP11-545I5.3	-10.54	1.8e-23	1.51e-20	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145470086	chr6:145799409~145886585:+
THCA	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-10.54	1.81e-23	1.52e-20	-0.52	-0.44	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
THCA	cis	rs957448	1	rs55897841	ENSG00000253704.1	RP11-267M23.4	10.54	1.81e-23	1.52e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94553722~94569745:+
THCA	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	10.54	1.81e-23	1.52e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
THCA	cis	rs62103177	0.564	rs55867755	ENSG00000261126.6	RP11-795F19.1	10.54	1.82e-23	1.52e-20	0.47	0.44	Opioid sensitivity;	chr18:79963434	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.564	rs59188178	ENSG00000261126.6	RP11-795F19.1	10.54	1.82e-23	1.52e-20	0.47	0.44	Opioid sensitivity;	chr18:79963435	chr18:80046900~80095482:+
THCA	cis	rs6570726	0.967	rs9497316	ENSG00000235652.6	RP11-545I5.3	-10.54	1.82e-23	1.53e-20	-0.4	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145471251	chr6:145799409~145886585:+
THCA	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-10.54	1.83e-23	1.54e-20	-0.56	-0.44	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
THCA	cis	rs7615952	0.932	rs7630077	ENSG00000171084.14	FAM86JP	10.54	1.85e-23	1.55e-20	0.61	0.44	Blood pressure (smoking interaction);	chr3:125930833	chr3:125916620~125930024:+
THCA	cis	rs9532669	0.89	rs9525417	ENSG00000239827.7	SUGT1P3	-10.54	1.87e-23	1.57e-20	-0.49	-0.44	Cervical cancer;	chr13:40878431	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs9532638	ENSG00000239827.7	SUGT1P3	-10.54	1.87e-23	1.57e-20	-0.49	-0.44	Cervical cancer;	chr13:40878471	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7997536	ENSG00000239827.7	SUGT1P3	-10.54	1.87e-23	1.57e-20	-0.49	-0.44	Cervical cancer;	chr13:40878685	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7997560	ENSG00000239827.7	SUGT1P3	-10.54	1.87e-23	1.57e-20	-0.49	-0.44	Cervical cancer;	chr13:40878723	chr13:40908159~40921774:-
THCA	cis	rs673078	0.66	rs76842574	ENSG00000275409.1	RP11-131L12.4	-10.54	1.88e-23	1.58e-20	-0.44	-0.44	Glucose homeostasis traits;	chr12:118371789	chr12:118430147~118430699:+
THCA	cis	rs673078	0.615	rs56324376	ENSG00000275409.1	RP11-131L12.4	-10.54	1.88e-23	1.58e-20	-0.44	-0.44	Glucose homeostasis traits;	chr12:118372134	chr12:118430147~118430699:+
THCA	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-10.54	1.89e-23	1.59e-20	-0.55	-0.44	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
THCA	cis	rs10463554	0.963	rs26253	ENSG00000175749.11	EIF3KP1	10.54	1.91e-23	1.6e-20	0.58	0.44	Parkinson's disease;	chr5:103221266	chr5:103032376~103033031:+
THCA	cis	rs4266144	0.562	rs56357317	ENSG00000244515.1	KRT18P34	-10.53	1.93e-23	1.62e-20	-0.57	-0.44	Coronary artery disease;	chr3:157117385	chr3:157162663~157163932:-
THCA	cis	rs67383717	0.527	rs10760718	ENSG00000175611.10	LINC00476	10.53	1.95e-23	1.63e-20	0.46	0.44	Parkinson's disease (pesticide exposure interaction);	chr9:96032397	chr9:95759231~95875977:-
THCA	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	10.53	1.95e-23	1.63e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
THCA	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-10.53	1.96e-23	1.64e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
THCA	cis	rs860295	0.702	rs12047756	ENSG00000225855.5	RUSC1-AS1	10.53	1.96e-23	1.65e-20	0.31	0.44	Body mass index;	chr1:155655153	chr1:155316863~155324176:-
THCA	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	10.53	1.98e-23	1.66e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	10.53	2e-23	1.67e-20	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
THCA	cis	rs9532669	0.926	rs4942014	ENSG00000176268.5	CYCSP34	10.53	2.01e-23	1.68e-20	0.48	0.44	Cervical cancer;	chr13:40966366	chr13:40863599~40863902:-
THCA	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-10.53	2.02e-23	1.7e-20	-0.67	-0.44	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-10.53	2.03e-23	1.7e-20	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
THCA	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	10.53	2.04e-23	1.71e-20	0.5	0.44	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
THCA	cis	rs600231	0.665	rs1621277	ENSG00000245532.5	NEAT1	-10.53	2.04e-23	1.71e-20	-0.3	-0.44	Bone mineral density;	chr11:65454483	chr11:65422774~65445540:+
THCA	cis	rs9322193	0.962	rs1413655	ENSG00000223701.3	RAET1E-AS1	10.53	2.04e-23	1.71e-20	0.58	0.44	Lung cancer;	chr6:149821815	chr6:149884431~149919508:+
THCA	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	10.53	2.05e-23	1.72e-20	0.56	0.44	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
THCA	cis	rs748404	0.586	rs2584700	ENSG00000249839.1	AC011330.5	-10.53	2.05e-23	1.72e-20	-0.52	-0.44	Lung cancer;	chr15:43393134	chr15:43663654~43684339:-
THCA	cis	rs9318086	0.648	rs9510927	ENSG00000205861.10	C1QTNF9B-AS1	-10.53	2.05e-23	1.72e-20	-0.5	-0.44	Myopia (pathological);	chr13:23893502	chr13:23888889~23897263:+
THCA	cis	rs600231	0.719	rs7114809	ENSG00000245532.5	NEAT1	10.53	2.06e-23	1.72e-20	0.3	0.44	Bone mineral density;	chr11:65483973	chr11:65422774~65445540:+
THCA	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	10.53	2.06e-23	1.73e-20	0.51	0.44	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
THCA	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-10.53	2.07e-23	1.73e-20	-0.55	-0.44	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
THCA	cis	rs73219805	0.554	rs3808569	ENSG00000228451.3	SDAD1P1	-10.53	2.07e-23	1.73e-20	-0.63	-0.44	Schizophrenia;	chr8:26356252	chr8:26379259~26382953:-
THCA	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	10.53	2.08e-23	1.74e-20	0.51	0.44	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
THCA	cis	rs7772486	0.875	rs864390	ENSG00000235652.6	RP11-545I5.3	10.53	2.08e-23	1.74e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145993899	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs447818	ENSG00000235652.6	RP11-545I5.3	10.53	2.08e-23	1.74e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145547860	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	10.53	2.09e-23	1.75e-20	0.51	0.44	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	10.53	2.09e-23	1.75e-20	0.51	0.44	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
THCA	cis	rs7945705	0.934	rs1988709	ENSG00000254860.4	TMEM9B-AS1	-10.53	2.09e-23	1.75e-20	-0.48	-0.44	Hemoglobin concentration;	chr11:8861343	chr11:8964675~8977527:+
THCA	cis	rs2732480	0.5	rs11168468	ENSG00000258273.1	RP11-370I10.4	-10.52	2.12e-23	1.78e-20	-0.57	-0.44	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48333755~48333901:-
THCA	cis	rs524281	0.861	rs6591207	ENSG00000255320.1	RP11-755F10.1	10.52	2.12e-23	1.78e-20	0.56	0.44	Electroencephalogram traits;	chr11:66182203	chr11:66244840~66246239:-
THCA	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	10.52	2.14e-23	1.79e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
THCA	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	10.52	2.15e-23	1.8e-20	0.48	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
THCA	cis	rs42490	0.934	rs218946	ENSG00000251136.7	RP11-37B2.1	-10.52	2.15e-23	1.8e-20	-0.38	-0.44	Leprosy;	chr8:89704478	chr8:89609409~89757727:-
THCA	cis	rs600231	0.623	rs587080	ENSG00000245532.5	NEAT1	10.52	2.18e-23	1.82e-20	0.3	0.44	Bone mineral density;	chr11:65486329	chr11:65422774~65445540:+
THCA	cis	rs6142102	0.962	rs2206448	ENSG00000276073.1	RP5-1125A11.7	-10.52	2.19e-23	1.83e-20	-0.41	-0.44	Skin pigmentation;	chr20:34121719	chr20:33985617~33988989:-
THCA	cis	rs1976403	0.659	rs10799699	ENSG00000227001.3	NBPF2P	10.52	2.2e-23	1.84e-20	0.48	0.44	Liver enzyme levels (alkaline phosphatase);	chr1:21494468	chr1:21424625~21427967:-
THCA	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-10.52	2.2e-23	1.84e-20	-0.36	-0.44	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
THCA	cis	rs7429990	0.965	rs11709289	ENSG00000229759.1	MRPS18AP1	10.52	2.21e-23	1.85e-20	0.58	0.44	Educational attainment (years of education);	chr3:47765159	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs5016900	ENSG00000229759.1	MRPS18AP1	10.52	2.21e-23	1.85e-20	0.58	0.44	Educational attainment (years of education);	chr3:47781387	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.93	rs13072132	ENSG00000229759.1	MRPS18AP1	10.52	2.21e-23	1.85e-20	0.58	0.44	Educational attainment (years of education);	chr3:47824671	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.965	rs34507589	ENSG00000229759.1	MRPS18AP1	10.52	2.21e-23	1.85e-20	0.58	0.44	Educational attainment (years of education);	chr3:47832552	chr3:48256350~48256938:-
THCA	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	10.52	2.23e-23	1.86e-20	0.52	0.44	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
THCA	cis	rs10256972	0.647	rs10233430	ENSG00000229043.2	AC091729.9	-10.52	2.24e-23	1.87e-20	-0.48	-0.44	Endometriosis;Longevity;	chr7:1012028	chr7:1160374~1165267:+
THCA	cis	rs6504950	0.888	rs244294	ENSG00000275710.1	RP11-257O5.4	10.52	2.24e-23	1.87e-20	0.54	0.44	Breast cancer;	chr17:55151182	chr17:54964474~54964679:+
THCA	cis	rs4819052	0.655	rs2330102	ENSG00000223768.1	LINC00205	-10.52	2.25e-23	1.88e-20	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45293285~45297354:+
THCA	cis	rs4819052	0.679	rs8132135	ENSG00000223768.1	LINC00205	-10.52	2.25e-23	1.88e-20	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45293285~45297354:+
THCA	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-10.52	2.25e-23	1.88e-20	-0.34	-0.44	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
THCA	cis	rs7772486	0.688	rs1884364	ENSG00000235652.6	RP11-545I5.3	10.52	2.26e-23	1.88e-20	0.43	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146016681	chr6:145799409~145886585:+
THCA	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	10.52	2.26e-23	1.89e-20	0.5	0.44	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
THCA	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	10.52	2.26e-23	1.89e-20	0.5	0.44	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
THCA	cis	rs12188164	1	rs34453673	ENSG00000221990.4	EXOC3-AS1	10.51	2.29e-23	1.91e-20	0.37	0.44	Cystic fibrosis severity;	chr5:434607	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs72717412	ENSG00000221990.4	EXOC3-AS1	10.51	2.29e-23	1.91e-20	0.37	0.44	Cystic fibrosis severity;	chr5:429266	chr5:441498~443160:-
THCA	cis	rs11159086	1	rs3759745	ENSG00000270000.1	RP3-449M8.9	10.51	2.29e-23	1.91e-20	0.47	0.44	Advanced glycation end-product levels;	chr14:74495967	chr14:74471930~74472360:-
THCA	cis	rs875971	0.83	rs427575	ENSG00000237310.1	GS1-124K5.4	10.51	2.3e-23	1.92e-20	0.33	0.44	Aortic root size;	chr7:66054232	chr7:66493706~66495474:+
THCA	cis	rs9487094	0.689	rs9487064	ENSG00000260273.1	RP11-425D10.10	10.51	2.3e-23	1.92e-20	0.52	0.44	Height;	chr6:109346560	chr6:109382795~109383666:+
THCA	cis	rs7772486	0.875	rs6570738	ENSG00000235652.6	RP11-545I5.3	10.51	2.3e-23	1.92e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146091559	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.875	rs1412080	ENSG00000235652.6	RP11-545I5.3	10.51	2.3e-23	1.92e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146096168	chr6:145799409~145886585:+
THCA	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	10.51	2.31e-23	1.93e-20	0.68	0.44	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	10.51	2.31e-23	1.93e-20	0.68	0.44	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
THCA	cis	rs12554020	0.892	rs59483310	ENSG00000227603.1	RP11-165J3.6	10.51	2.31e-23	1.93e-20	0.61	0.44	Schizophrenia;	chr9:93503318	chr9:93435332~93437121:-
THCA	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	10.51	2.32e-23	1.94e-20	0.53	0.44	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
THCA	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	10.51	2.33e-23	1.94e-20	0.51	0.44	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	10.51	2.33e-23	1.95e-20	0.51	0.44	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	10.51	2.33e-23	1.95e-20	0.51	0.44	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	10.51	2.33e-23	1.95e-20	0.51	0.44	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	10.51	2.33e-23	1.95e-20	0.51	0.44	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	10.51	2.34e-23	1.95e-20	0.51	0.44	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
THCA	cis	rs875971	0.83	rs587360	ENSG00000237310.1	GS1-124K5.4	10.51	2.35e-23	1.96e-20	0.33	0.44	Aortic root size;	chr7:66057711	chr7:66493706~66495474:+
THCA	cis	rs6570726	0.935	rs449377	ENSG00000235652.6	RP11-545I5.3	10.51	2.37e-23	1.97e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145531301	chr6:145799409~145886585:+
THCA	cis	rs7429990	0.965	rs35012836	ENSG00000229759.1	MRPS18AP1	10.51	2.38e-23	1.98e-20	0.58	0.44	Educational attainment (years of education);	chr3:47670000	chr3:48256350~48256938:-
THCA	cis	rs875971	0.8	rs427557	ENSG00000237310.1	GS1-124K5.4	10.51	2.39e-23	2e-20	0.33	0.44	Aortic root size;	chr7:66054263	chr7:66493706~66495474:+
THCA	cis	rs4964805	1	rs1866295	ENSG00000257681.1	RP11-341G23.4	10.51	2.4e-23	2e-20	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103793168	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.954	rs11111785	ENSG00000257681.1	RP11-341G23.4	10.51	2.42e-23	2.02e-20	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103795278	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.954	rs11111786	ENSG00000257681.1	RP11-341G23.4	10.51	2.42e-23	2.02e-20	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103795279	chr12:103746315~103768858:-
THCA	cis	rs6570726	0.905	rs421032	ENSG00000235652.6	RP11-545I5.3	10.51	2.43e-23	2.03e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145506635	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs9390329	ENSG00000235652.6	RP11-545I5.3	10.51	2.43e-23	2.03e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145506890	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs371744	ENSG00000235652.6	RP11-545I5.3	10.51	2.43e-23	2.03e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145519888	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.818	rs437978	ENSG00000235652.6	RP11-545I5.3	10.51	2.45e-23	2.04e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145487998	chr6:145799409~145886585:+
THCA	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	10.51	2.47e-23	2.05e-20	0.51	0.44	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
THCA	cis	rs7772486	0.846	rs2144478	ENSG00000235652.6	RP11-545I5.3	10.5	2.5e-23	2.08e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146060309	chr6:145799409~145886585:+
THCA	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	10.5	2.51e-23	2.09e-20	0.55	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
THCA	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	10.5	2.51e-23	2.09e-20	0.47	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
THCA	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	10.5	2.51e-23	2.09e-20	0.47	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
THCA	cis	rs12188164	1	rs72717410	ENSG00000221990.4	EXOC3-AS1	10.5	2.51e-23	2.09e-20	0.37	0.44	Cystic fibrosis severity;	chr5:428670	chr5:441498~443160:-
THCA	cis	rs7945705	0.902	rs7479407	ENSG00000254860.4	TMEM9B-AS1	-10.5	2.52e-23	2.1e-20	-0.48	-0.44	Hemoglobin concentration;	chr11:9001874	chr11:8964675~8977527:+
THCA	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-10.5	2.53e-23	2.11e-20	-0.5	-0.44	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
THCA	cis	rs2787486	1	rs2787486	ENSG00000275710.1	RP11-257O5.4	10.5	2.54e-23	2.11e-20	0.53	0.44	Breast cancer;	chr17:55132413	chr17:54964474~54964679:+
THCA	cis	rs6538678	0.929	rs10745733	ENSG00000258343.1	RP11-536G4.2	-10.5	2.54e-23	2.12e-20	-0.59	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95795345~95858839:-
THCA	cis	rs6538678	0.926	rs10745734	ENSG00000258343.1	RP11-536G4.2	-10.5	2.54e-23	2.12e-20	-0.59	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95795345~95858839:-
THCA	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-10.5	2.55e-23	2.12e-20	-0.57	-0.44	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
THCA	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-10.5	2.57e-23	2.14e-20	-0.56	-0.44	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
THCA	cis	rs11159086	1	rs4903233	ENSG00000270000.1	RP3-449M8.9	10.5	2.58e-23	2.14e-20	0.47	0.44	Advanced glycation end-product levels;	chr14:74497291	chr14:74471930~74472360:-
THCA	cis	rs12188164	1	rs56104584	ENSG00000221990.4	EXOC3-AS1	10.5	2.58e-23	2.15e-20	0.37	0.44	Cystic fibrosis severity;	chr5:437427	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs55842567	ENSG00000221990.4	EXOC3-AS1	10.5	2.58e-23	2.15e-20	0.37	0.44	Cystic fibrosis severity;	chr5:437471	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs56042615	ENSG00000221990.4	EXOC3-AS1	10.5	2.58e-23	2.15e-20	0.37	0.44	Cystic fibrosis severity;	chr5:437552	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs34847072	ENSG00000221990.4	EXOC3-AS1	10.5	2.58e-23	2.15e-20	0.37	0.44	Cystic fibrosis severity;	chr5:437747	chr5:441498~443160:-
THCA	cis	rs10463554	0.963	rs11242483	ENSG00000175749.11	EIF3KP1	10.5	2.58e-23	2.15e-20	0.57	0.44	Parkinson's disease;	chr5:102988062	chr5:103032376~103033031:+
THCA	cis	rs9903692	0.865	rs7220520	ENSG00000278765.1	RP5-890E16.5	10.5	2.58e-23	2.15e-20	0.55	0.44	Pulse pressure;	chr17:48090580	chr17:48066704~48067293:-
THCA	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-10.5	2.59e-23	2.15e-20	-0.58	-0.44	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
THCA	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	10.5	2.59e-23	2.15e-20	0.59	0.44	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
THCA	cis	rs7211079	0.917	rs4243251	ENSG00000279259.1	RP11-334C17.3	10.5	2.6e-23	2.16e-20	0.46	0.44	Myocardial infarction;	chr17:80138811	chr17:80147250~80148596:+
THCA	cis	rs7211079	0.917	rs8067991	ENSG00000279259.1	RP11-334C17.3	10.5	2.6e-23	2.16e-20	0.46	0.44	Myocardial infarction;	chr17:80145503	chr17:80147250~80148596:+
THCA	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	10.5	2.6e-23	2.16e-20	0.36	0.44	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
THCA	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-10.5	2.61e-23	2.17e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-10.5	2.61e-23	2.17e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-10.5	2.61e-23	2.17e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-10.5	2.61e-23	2.17e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
THCA	cis	rs6570726	0.935	rs392014	ENSG00000235652.6	RP11-545I5.3	10.5	2.61e-23	2.17e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145522555	chr6:145799409~145886585:+
THCA	cis	rs6570726	1	rs436066	ENSG00000235652.6	RP11-545I5.3	10.5	2.61e-23	2.17e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145525991	chr6:145799409~145886585:+
THCA	cis	rs6570726	1	rs441477	ENSG00000235652.6	RP11-545I5.3	10.5	2.61e-23	2.17e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145527107	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000224205.1	AP000351.4	10.5	2.63e-23	2.18e-20	0.53	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23987320~23991421:-
THCA	cis	rs7772486	0.875	rs6930975	ENSG00000235652.6	RP11-545I5.3	10.5	2.63e-23	2.18e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146065975	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.818	rs399516	ENSG00000235652.6	RP11-545I5.3	10.5	2.63e-23	2.19e-20	0.4	0.44	Lobe attachment (rater-scored or self-reported);	chr6:145489713	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	10.5	2.64e-23	2.2e-20	0.52	0.44	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
THCA	cis	rs7221109	0.744	rs1048573	ENSG00000278834.1	RP11-458J1.1	10.5	2.66e-23	2.21e-20	0.46	0.44	Type 1 diabetes;	chr17:40640950	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.71	rs9906785	ENSG00000278834.1	RP11-458J1.1	10.5	2.66e-23	2.21e-20	0.46	0.44	Type 1 diabetes;	chr17:40641157	chr17:40648300~40649718:+
THCA	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-10.5	2.67e-23	2.22e-20	-0.36	-0.44	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	10.5	2.67e-23	2.22e-20	0.36	0.44	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	10.5	2.67e-23	2.22e-20	0.36	0.44	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
THCA	cis	rs1043099	0.871	rs9619104	ENSG00000279699.1	RP1-102K2.9	-10.5	2.67e-23	2.22e-20	-0.62	-0.44	Rheumatoid arthritis;	chr22:30378351	chr22:30275215~30276951:-
THCA	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	10.5	2.67e-23	2.22e-20	0.6	0.44	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
THCA	cis	rs7772486	0.875	rs9322046	ENSG00000235652.6	RP11-545I5.3	10.5	2.7e-23	2.24e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146072489	chr6:145799409~145886585:+
THCA	cis	rs9318086	0.712	rs3794339	ENSG00000205861.10	C1QTNF9B-AS1	-10.5	2.7e-23	2.24e-20	-0.5	-0.44	Myopia (pathological);	chr13:23859926	chr13:23888889~23897263:+
THCA	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	10.5	2.72e-23	2.26e-20	0.51	0.44	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	10.5	2.72e-23	2.26e-20	0.51	0.44	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
THCA	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-10.5	2.72e-23	2.26e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
THCA	cis	rs6538678	0.864	rs10777749	ENSG00000258343.1	RP11-536G4.2	-10.49	2.72e-23	2.26e-20	-0.59	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95883182	chr12:95795345~95858839:-
THCA	cis	rs875971	0.83	rs427973	ENSG00000237310.1	GS1-124K5.4	10.49	2.73e-23	2.27e-20	0.33	0.44	Aortic root size;	chr7:66061661	chr7:66493706~66495474:+
THCA	cis	rs2274273	0.868	rs1572611	ENSG00000258413.1	RP11-665C16.6	-10.49	2.75e-23	2.28e-20	-0.58	-0.44	Protein biomarker;	chr14:55367156	chr14:55262767~55272075:-
THCA	cis	rs9532669	0.926	rs2183144	ENSG00000239827.7	SUGT1P3	10.49	2.76e-23	2.29e-20	0.49	0.44	Cervical cancer;	chr13:40862129	chr13:40908159~40921774:-
THCA	cis	rs465969	0.744	rs79052344	ENSG00000255389.1	C6orf3	-10.49	2.76e-23	2.29e-20	-0.76	-0.44	Psoriasis;	chr6:111550755	chr6:111599875~111602295:+
THCA	cis	rs2274273	0.673	rs2209808	ENSG00000258413.1	RP11-665C16.6	-10.49	2.77e-23	2.3e-20	-0.59	-0.44	Protein biomarker;	chr14:55340977	chr14:55262767~55272075:-
THCA	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-10.49	2.77e-23	2.3e-20	-0.5	-0.44	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
THCA	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-10.49	2.79e-23	2.31e-20	-0.51	-0.44	Height;	chr6:109360458	chr6:109382795~109383666:+
THCA	cis	rs73219805	0.554	rs3808566	ENSG00000228451.3	SDAD1P1	10.49	2.81e-23	2.33e-20	0.6	0.44	Schizophrenia;	chr8:26365942	chr8:26379259~26382953:-
THCA	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-10.49	2.81e-23	2.33e-20	-0.56	-0.44	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
THCA	cis	rs180730	0.561	rs3106314	ENSG00000251609.2	SETP12	-10.49	2.83e-23	2.34e-20	-0.61	-0.44	Fasting plasma glucose;	chr4:120895637	chr4:120895494~120897083:-
THCA	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	10.49	2.84e-23	2.35e-20	0.51	0.44	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9688412	ENSG00000223701.3	RAET1E-AS1	-10.49	2.84e-23	2.36e-20	-0.58	-0.44	Lung cancer;	chr6:149803147	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs11155683	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149779341	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs9372044	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149780867	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs11155685	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149781649	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9689269	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149791861	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs62441335	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149792658	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs4816	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149793609	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.926	rs952166	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149798774	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs952165	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149798900	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.926	rs9285525	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149801253	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs2342858	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149805967	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs6914319	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149806304	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs2095375	ENSG00000223701.3	RAET1E-AS1	10.49	2.84e-23	2.36e-20	0.58	0.44	Lung cancer;	chr6:149807037	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	10.49	2.84e-23	2.36e-20	0.52	0.44	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
THCA	cis	rs6061231	1	rs11908473	ENSG00000273619.1	RP5-908M14.9	-10.49	2.85e-23	2.36e-20	-0.34	-0.44	Colorectal cancer;	chr20:62382714	chr20:62386303~62386970:-
THCA	cis	rs6061231	1	rs13043313	ENSG00000273619.1	RP5-908M14.9	-10.49	2.85e-23	2.36e-20	-0.34	-0.44	Colorectal cancer;	chr20:62383213	chr20:62386303~62386970:-
THCA	cis	rs673078	0.66	rs78690826	ENSG00000275759.1	RP11-131L12.3	-10.49	2.85e-23	2.36e-20	-0.68	-0.44	Glucose homeostasis traits;	chr12:118176693	chr12:118428281~118428870:+
THCA	cis	rs673078	0.66	rs17512142	ENSG00000275759.1	RP11-131L12.3	-10.49	2.85e-23	2.36e-20	-0.68	-0.44	Glucose homeostasis traits;	chr12:118186186	chr12:118428281~118428870:+
THCA	cis	rs780096	0.545	rs2280737	ENSG00000234072.1	AC074117.10	-10.49	2.85e-23	2.37e-20	-0.34	-0.44	Total body bone mineral density;	chr2:27366943	chr2:27356246~27367622:+
THCA	cis	rs4964805	0.77	rs11111779	ENSG00000257681.1	RP11-341G23.4	10.49	2.86e-23	2.37e-20	0.53	0.44	Attention deficit hyperactivity disorder;	chr12:103791718	chr12:103746315~103768858:-
THCA	cis	rs9318086	0.533	rs7325450	ENSG00000205861.10	C1QTNF9B-AS1	-10.49	2.86e-23	2.37e-20	-0.51	-0.44	Myopia (pathological);	chr13:23892865	chr13:23888889~23897263:+
THCA	cis	rs9322193	0.962	rs3805753	ENSG00000223701.3	RAET1E-AS1	10.49	2.89e-23	2.39e-20	0.58	0.44	Lung cancer;	chr6:149795662	chr6:149884431~149919508:+
THCA	cis	rs4819052	0.679	rs2838859	ENSG00000223768.1	LINC00205	-10.49	2.89e-23	2.39e-20	-0.4	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45293285~45297354:+
THCA	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-10.49	2.92e-23	2.42e-20	-0.56	-0.44	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
THCA	cis	rs9318086	0.673	rs7981928	ENSG00000205861.10	C1QTNF9B-AS1	-10.49	2.93e-23	2.43e-20	-0.5	-0.44	Myopia (pathological);	chr13:23861041	chr13:23888889~23897263:+
THCA	cis	rs7569084	1	rs13385171	ENSG00000234255.7	AC012370.3	-10.49	2.94e-23	2.43e-20	-0.49	-0.44	Sum eosinophil basophil counts;	chr2:65434709	chr2:65439888~65456571:-
THCA	cis	rs62103177	0.525	rs62101233	ENSG00000261126.6	RP11-795F19.1	10.49	2.95e-23	2.44e-20	0.47	0.44	Opioid sensitivity;	chr18:79964288	chr18:80046900~80095482:+
THCA	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	10.49	2.95e-23	2.45e-20	0.53	0.44	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
THCA	cis	rs934734	0.532	rs62141075	ENSG00000281920.1	RP11-418H16.1	-10.48	2.98e-23	2.47e-20	-0.53	-0.44	Rheumatoid arthritis;	chr2:65417482	chr2:65623272~65628424:+
THCA	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-10.48	3e-23	2.49e-20	-0.51	-0.44	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
THCA	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-10.48	3.01e-23	2.49e-20	-0.48	-0.44	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
THCA	cis	rs4266144	0.563	rs61124401	ENSG00000244515.1	KRT18P34	-10.48	3.06e-23	2.53e-20	-0.57	-0.44	Coronary artery disease;	chr3:157123130	chr3:157162663~157163932:-
THCA	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-10.48	3.07e-23	2.54e-20	-0.5	-0.44	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
THCA	cis	rs2274273	0.905	rs8007614	ENSG00000258413.1	RP11-665C16.6	-10.48	3.07e-23	2.55e-20	-0.57	-0.44	Protein biomarker;	chr14:55119857	chr14:55262767~55272075:-
THCA	cis	rs9532669	0.926	rs9532654	ENSG00000176268.5	CYCSP34	10.48	3.08e-23	2.55e-20	0.5	0.44	Cervical cancer;	chr13:40909812	chr13:40863599~40863902:-
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000224205.1	AP000351.4	10.48	3.12e-23	2.58e-20	0.52	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23987320~23991421:-
THCA	cis	rs8062405	0.721	rs151181	ENSG00000251417.2	RP11-1348G14.4	-10.48	3.14e-23	2.6e-20	-0.42	-0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28802743~28817828:+
THCA	cis	rs4819052	0.959	rs9976074	ENSG00000223768.1	LINC00205	-10.48	3.16e-23	2.62e-20	-0.45	-0.44	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45293285~45297354:+
THCA	cis	rs9322193	0.962	rs4869730	ENSG00000223701.3	RAET1E-AS1	10.48	3.16e-23	2.62e-20	0.58	0.44	Lung cancer;	chr6:149808187	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs2151913	ENSG00000223701.3	RAET1E-AS1	10.48	3.16e-23	2.62e-20	0.58	0.44	Lung cancer;	chr6:149809506	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.599	rs9403725	ENSG00000235652.6	RP11-545I5.3	-10.48	3.18e-23	2.63e-20	-0.44	-0.44	Lobe attachment (rater-scored or self-reported);	chr6:145576486	chr6:145799409~145886585:+
THCA	cis	rs11098499	0.71	rs4145952	ENSG00000245958.5	RP11-33B1.1	-10.48	3.18e-23	2.63e-20	-0.4	-0.44	Corneal astigmatism;	chr4:119234651	chr4:119454791~119552025:+
THCA	cis	rs10078	0.848	rs890985	ENSG00000221990.4	EXOC3-AS1	10.48	3.2e-23	2.65e-20	0.38	0.44	Fat distribution (HIV);	chr5:479631	chr5:441498~443160:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-10.48	3.21e-23	2.65e-20	-0.54	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
THCA	cis	rs673078	0.607	rs59594854	ENSG00000275409.1	RP11-131L12.4	-10.47	3.24e-23	2.68e-20	-0.43	-0.44	Glucose homeostasis traits;	chr12:118374000	chr12:118430147~118430699:+
THCA	cis	rs7772486	0.875	rs9322048	ENSG00000235652.6	RP11-545I5.3	10.47	3.24e-23	2.68e-20	0.39	0.44	Lobe attachment (rater-scored or self-reported);	chr6:146079303	chr6:145799409~145886585:+
THCA	cis	rs2274273	0.905	rs8007620	ENSG00000258413.1	RP11-665C16.6	-10.47	3.25e-23	2.69e-20	-0.57	-0.44	Protein biomarker;	chr14:55119869	chr14:55262767~55272075:-
THCA	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	10.47	3.26e-23	2.69e-20	0.51	0.44	Height;	chr6:109634847	chr6:109382795~109383666:+
THCA	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-10.47	3.27e-23	2.7e-20	-0.73	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
THCA	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	10.47	3.27e-23	2.7e-20	0.47	0.44	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
THCA	cis	rs860295	0.702	rs34620961	ENSG00000225855.5	RUSC1-AS1	10.47	3.31e-23	2.74e-20	0.31	0.43	Body mass index;	chr1:155680036	chr1:155316863~155324176:-
THCA	cis	rs9487094	0.666	rs2236084	ENSG00000260273.1	RP11-425D10.10	10.47	3.34e-23	2.76e-20	0.51	0.43	Height;	chr6:109476101	chr6:109382795~109383666:+
THCA	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-10.47	3.37e-23	2.78e-20	-0.5	-0.43	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
THCA	cis	rs9532669	0.926	rs11147824	ENSG00000239827.7	SUGT1P3	-10.47	3.37e-23	2.78e-20	-0.49	-0.43	Cervical cancer;	chr13:40878183	chr13:40908159~40921774:-
THCA	cis	rs860295	0.702	rs12040100	ENSG00000225855.5	RUSC1-AS1	10.47	3.38e-23	2.79e-20	0.3	0.43	Body mass index;	chr1:155642056	chr1:155316863~155324176:-
THCA	cis	rs2732480	0.538	rs2468943	ENSG00000258273.1	RP11-370I10.4	10.47	3.39e-23	2.8e-20	0.56	0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48333755~48333901:-
THCA	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	10.47	3.4e-23	2.81e-20	0.47	0.43	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
THCA	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-10.47	3.42e-23	2.82e-20	-0.55	-0.43	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
THCA	cis	rs9309473	0.615	rs62151562	ENSG00000163016.8	ALMS1P	10.47	3.42e-23	2.82e-20	0.75	0.43	Metabolite levels;	chr2:73376412	chr2:73644919~73685576:+
THCA	cis	rs9322193	1	rs58189451	ENSG00000223701.3	RAET1E-AS1	10.47	3.42e-23	2.83e-20	0.59	0.43	Lung cancer;	chr6:149600252	chr6:149884431~149919508:+
THCA	cis	rs6504950	0.785	rs2628304	ENSG00000275710.1	RP11-257O5.4	-10.47	3.43e-23	2.83e-20	-0.55	-0.43	Breast cancer;	chr17:55079828	chr17:54964474~54964679:+
THCA	cis	rs1799949	1	rs4793194	ENSG00000267681.1	CTD-3199J23.6	-10.47	3.49e-23	2.87e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43066316	chr17:43144956~43145255:+
THCA	cis	rs9545047	0.645	rs9635027	ENSG00000227676.3	LINC01068	10.47	3.5e-23	2.89e-20	0.53	0.43	Schizophrenia;	chr13:79295538	chr13:79566727~79571436:+
THCA	cis	rs6558530	1	rs6558530	ENSG00000253982.1	CTD-2336O2.1	10.47	3.5e-23	2.89e-20	0.38	0.43	Systolic blood pressure;	chr8:1758041	chr8:1761990~1764502:-
THCA	cis	rs7945705	0.935	rs11042102	ENSG00000254860.4	TMEM9B-AS1	-10.46	3.55e-23	2.92e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8860617	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.902	rs10743095	ENSG00000254860.4	TMEM9B-AS1	-10.46	3.58e-23	2.95e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8915437	chr11:8964675~8977527:+
THCA	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-10.46	3.58e-23	2.95e-20	-0.55	-0.43	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
THCA	cis	rs42490	1	rs1003843	ENSG00000251136.7	RP11-37B2.1	-10.46	3.58e-23	2.95e-20	-0.38	-0.43	Leprosy;	chr8:89727252	chr8:89609409~89757727:-
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	10.46	3.59e-23	2.95e-20	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
THCA	cis	rs13392177	0.637	rs61041183	ENSG00000261338.2	RP11-378A13.1	10.46	3.61e-23	2.97e-20	0.45	0.43	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218191657	chr2:218255319~218257366:+
THCA	cis	rs11098499	0.739	rs10031033	ENSG00000245958.5	RP11-33B1.1	-10.46	3.62e-23	2.98e-20	-0.4	-0.43	Corneal astigmatism;	chr4:119230297	chr4:119454791~119552025:+
THCA	cis	rs6570726	0.902	rs406979	ENSG00000235652.6	RP11-545I5.3	10.46	3.62e-23	2.98e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145517847	chr6:145799409~145886585:+
THCA	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-10.46	3.64e-23	3e-20	-0.56	-0.43	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
THCA	cis	rs6570726	0.791	rs448939	ENSG00000235652.6	RP11-545I5.3	10.46	3.67e-23	3.02e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145487184	chr6:145799409~145886585:+
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000224205.1	AP000351.4	10.46	3.67e-23	3.02e-20	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23987320~23991421:-
THCA	cis	rs13392177	0.684	rs6720449	ENSG00000261338.2	RP11-378A13.1	-10.46	3.7e-23	3.05e-20	-0.45	-0.43	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218216255	chr2:218255319~218257366:+
THCA	cis	rs4819052	0.788	rs13049700	ENSG00000223768.1	LINC00205	-10.46	3.71e-23	3.06e-20	-0.42	-0.43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45293285~45297354:+
THCA	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	10.46	3.77e-23	3.1e-20	0.61	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
THCA	cis	rs12188164	0.965	rs1056465	ENSG00000221990.4	EXOC3-AS1	10.46	3.77e-23	3.1e-20	0.37	0.43	Cystic fibrosis severity;	chr5:442323	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs56146525	ENSG00000221990.4	EXOC3-AS1	10.46	3.77e-23	3.1e-20	0.37	0.43	Cystic fibrosis severity;	chr5:442456	chr5:441498~443160:-
THCA	cis	rs12188164	0.931	rs115554641	ENSG00000221990.4	EXOC3-AS1	10.46	3.77e-23	3.1e-20	0.37	0.43	Cystic fibrosis severity;	chr5:443121	chr5:441498~443160:-
THCA	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	10.46	3.81e-23	3.13e-20	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000206090.4	AP000350.7	10.45	3.87e-23	3.18e-20	0.53	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23939998~23942798:+
THCA	cis	rs7569084	0.905	rs13417564	ENSG00000234255.7	AC012370.3	-10.45	3.87e-23	3.18e-20	-0.49	-0.43	Sum eosinophil basophil counts;	chr2:65438139	chr2:65439888~65456571:-
THCA	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-10.45	3.89e-23	3.2e-20	-0.52	-0.43	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
THCA	cis	rs2599510	0.811	rs176410	ENSG00000276334.1	AL133243.1	-10.45	3.9e-23	3.2e-20	-0.47	-0.43	Interleukin-18 levels;	chr2:32418369	chr2:32521927~32523547:+
THCA	cis	rs3779195	0.585	rs7777991	ENSG00000272950.1	RP11-307C18.1	-10.45	3.91e-23	3.22e-20	-0.67	-0.43	Sex hormone-binding globulin levels;	chr7:98236445	chr7:98322853~98323430:+
THCA	cis	rs6504950	0.85	rs2628321	ENSG00000275710.1	RP11-257O5.4	10.45	3.94e-23	3.24e-20	0.53	0.43	Breast cancer;	chr17:55128556	chr17:54964474~54964679:+
THCA	cis	rs4964805	0.954	rs4964812	ENSG00000257681.1	RP11-341G23.4	10.45	3.96e-23	3.25e-20	0.52	0.43	Attention deficit hyperactivity disorder;	chr12:103795837	chr12:103746315~103768858:-
THCA	cis	rs8100891	0.537	rs73038232	ENSG00000267213.4	AC007773.2	-10.45	3.96e-23	3.25e-20	-0.56	-0.43	Neuroticism;	chr19:32496747	chr19:32390050~32405560:-
THCA	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	10.45	3.97e-23	3.26e-20	0.37	0.43	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
THCA	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	10.45	3.97e-23	3.26e-20	0.53	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
THCA	cis	rs73219805	0.597	rs3824232	ENSG00000228451.3	SDAD1P1	-10.45	3.98e-23	3.27e-20	-0.61	-0.43	Schizophrenia;	chr8:26370083	chr8:26379259~26382953:-
THCA	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	10.45	4.03e-23	3.31e-20	0.53	0.43	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
THCA	cis	rs9322193	0.884	rs11155689	ENSG00000223701.3	RAET1E-AS1	10.45	4.04e-23	3.32e-20	0.58	0.43	Lung cancer;	chr6:149808470	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs933055	ENSG00000223701.3	RAET1E-AS1	10.45	4.04e-23	3.32e-20	0.58	0.43	Lung cancer;	chr6:149809701	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs4869731	ENSG00000223701.3	RAET1E-AS1	10.45	4.04e-23	3.32e-20	0.58	0.43	Lung cancer;	chr6:149810072	chr6:149884431~149919508:+
THCA	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-10.45	4.05e-23	3.33e-20	-0.5	-0.43	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
THCA	cis	rs944289	0.706	rs11156904	ENSG00000257826.1	RP11-116N8.4	-10.45	4.07e-23	3.34e-20	-0.45	-0.43	Thyroid cancer;	chr14:36085688	chr14:36061026~36067190:-
THCA	cis	rs11105298	0.891	rs8181784	ENSG00000258302.2	RP11-981P6.1	10.45	4.08e-23	3.35e-20	0.41	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89434814	chr12:89561129~89594878:+
THCA	cis	rs9322193	0.632	rs3828700	ENSG00000223701.3	RAET1E-AS1	10.45	4.11e-23	3.37e-20	0.57	0.43	Lung cancer;	chr6:149791033	chr6:149884431~149919508:+
THCA	cis	rs860295	0.702	rs2175391	ENSG00000225855.5	RUSC1-AS1	-10.45	4.12e-23	3.38e-20	-0.3	-0.43	Body mass index;	chr1:155655811	chr1:155316863~155324176:-
THCA	cis	rs673078	0.66	rs61943525	ENSG00000275759.1	RP11-131L12.3	-10.45	4.15e-23	3.41e-20	-0.69	-0.43	Glucose homeostasis traits;	chr12:118152927	chr12:118428281~118428870:+
THCA	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-10.45	4.15e-23	3.41e-20	-0.65	-0.43	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
THCA	cis	rs1075265	0.744	rs2909460	ENSG00000233266.1	HMGB1P31	10.44	4.18e-23	3.43e-20	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.811	rs805308	ENSG00000233266.1	HMGB1P31	10.44	4.18e-23	3.43e-20	0.54	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54051334~54051760:+
THCA	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-10.44	4.18e-23	3.43e-20	-0.49	-0.43	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-10.44	4.21e-23	3.45e-20	-0.54	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
THCA	cis	rs9322193	0.923	rs2342857	ENSG00000223701.3	RAET1E-AS1	10.44	4.21e-23	3.45e-20	0.58	0.43	Lung cancer;	chr6:149809537	chr6:149884431~149919508:+
THCA	cis	rs9309473	0.514	rs62149630	ENSG00000163016.8	ALMS1P	10.44	4.23e-23	3.47e-20	0.75	0.43	Metabolite levels;	chr2:73354627	chr2:73644919~73685576:+
THCA	cis	rs7945705	0.935	rs11042103	ENSG00000254860.4	TMEM9B-AS1	-10.44	4.24e-23	3.48e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8867153	chr11:8964675~8977527:+
THCA	cis	rs12188164	0.965	rs56182240	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:423054	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs55948934	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:423556	chr5:441498~443160:-
THCA	cis	rs12188164	0.897	rs55932239	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:423791	chr5:441498~443160:-
THCA	cis	rs12188164	0.931	rs72717407	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:424538	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs12188678	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:428116	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs12188164	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:428121	chr5:441498~443160:-
THCA	cis	rs12188164	1	rs72717411	ENSG00000221990.4	EXOC3-AS1	10.44	4.28e-23	3.51e-20	0.37	0.43	Cystic fibrosis severity;	chr5:429009	chr5:441498~443160:-
THCA	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	10.44	4.3e-23	3.53e-20	0.64	0.43	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
THCA	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-10.44	4.32e-23	3.54e-20	-0.44	-0.43	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
THCA	cis	rs600231	0.708	rs682845	ENSG00000245532.5	NEAT1	10.44	4.33e-23	3.55e-20	0.3	0.43	Bone mineral density;	chr11:65486730	chr11:65422774~65445540:+
THCA	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	10.44	4.4e-23	3.6e-20	0.51	0.43	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	10.44	4.4e-23	3.6e-20	0.51	0.43	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	10.44	4.4e-23	3.6e-20	0.51	0.43	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
THCA	cis	rs7309	0.935	rs1921309	ENSG00000235724.7	AC009299.2	-10.44	4.41e-23	3.61e-20	-0.45	-0.43	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161222785~161308303:-
THCA	cis	rs7309	0.935	rs11884495	ENSG00000235724.7	AC009299.2	-10.44	4.41e-23	3.61e-20	-0.45	-0.43	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161222785~161308303:-
THCA	cis	rs7309	0.935	rs10930013	ENSG00000235724.7	AC009299.2	-10.44	4.41e-23	3.61e-20	-0.45	-0.43	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161222785~161308303:-
THCA	cis	rs6558530	0.897	rs7838456	ENSG00000253982.1	CTD-2336O2.1	10.44	4.45e-23	3.64e-20	0.37	0.43	Systolic blood pressure;	chr8:1759425	chr8:1761990~1764502:-
THCA	cis	rs4964805	1	rs73192053	ENSG00000257681.1	RP11-341G23.4	10.44	4.47e-23	3.66e-20	0.52	0.43	Attention deficit hyperactivity disorder;	chr12:103797077	chr12:103746315~103768858:-
THCA	cis	rs6504950	0.888	rs244320	ENSG00000275710.1	RP11-257O5.4	10.44	4.49e-23	3.68e-20	0.53	0.43	Breast cancer;	chr17:55145559	chr17:54964474~54964679:+
THCA	cis	rs6142102	1	rs6059673	ENSG00000276073.1	RP5-1125A11.7	-10.44	4.51e-23	3.69e-20	-0.42	-0.43	Skin pigmentation;	chr20:34117755	chr20:33985617~33988989:-
THCA	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-10.44	4.51e-23	3.69e-20	-0.34	-0.43	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
THCA	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-10.44	4.52e-23	3.7e-20	-0.56	-0.43	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
THCA	cis	rs6504950	0.888	rs2628315	ENSG00000275710.1	RP11-257O5.4	10.44	4.53e-23	3.7e-20	0.53	0.43	Breast cancer;	chr17:55149261	chr17:54964474~54964679:+
THCA	cis	rs7191700	0.673	rs12325495	ENSG00000262703.1	RP11-485G7.6	10.44	4.54e-23	3.72e-20	0.47	0.43	Multiple sclerosis;	chr16:11324471	chr16:11348143~11349321:-
THCA	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	10.43	4.55e-23	3.73e-20	0.51	0.43	Height;	chr6:109447092	chr6:109382795~109383666:+
THCA	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	10.43	4.56e-23	3.73e-20	0.55	0.43	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
THCA	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	10.43	4.56e-23	3.73e-20	0.63	0.43	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
THCA	cis	rs11148252	0.904	rs9568734	ENSG00000278238.1	RP11-245D16.4	-10.43	4.59e-23	3.75e-20	-0.47	-0.43	Lewy body disease;	chr13:52430087	chr13:52454775~52455331:-
THCA	cis	rs12188164	1	rs72717414	ENSG00000221990.4	EXOC3-AS1	10.43	4.59e-23	3.76e-20	0.37	0.43	Cystic fibrosis severity;	chr5:429703	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs72717415	ENSG00000221990.4	EXOC3-AS1	10.43	4.59e-23	3.76e-20	0.37	0.43	Cystic fibrosis severity;	chr5:429944	chr5:441498~443160:-
THCA	cis	rs7712401	0.715	rs6880480	ENSG00000263432.2	RN7SL689P	-10.43	4.61e-23	3.77e-20	-0.48	-0.43	Mean platelet volume;	chr5:123019031	chr5:123022487~123022783:-
THCA	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	10.43	4.61e-23	3.77e-20	0.6	0.43	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
THCA	cis	rs9322193	0.923	rs4870052	ENSG00000216906.2	RP11-350J20.9	10.43	4.61e-23	3.77e-20	0.53	0.43	Lung cancer;	chr6:149839978	chr6:149904243~149906418:+
THCA	cis	rs860295	0.702	rs2048431	ENSG00000225855.5	RUSC1-AS1	10.43	4.62e-23	3.78e-20	0.3	0.43	Body mass index;	chr1:155648839	chr1:155316863~155324176:-
THCA	cis	rs11148252	0.904	rs7990581	ENSG00000278238.1	RP11-245D16.4	-10.43	4.62e-23	3.78e-20	-0.47	-0.43	Lewy body disease;	chr13:52445298	chr13:52454775~52455331:-
THCA	cis	rs9322193	0.962	rs9689447	ENSG00000223701.3	RAET1E-AS1	10.43	4.66e-23	3.81e-20	0.57	0.43	Lung cancer;	chr6:149789350	chr6:149884431~149919508:+
THCA	cis	rs2283792	0.646	rs9610271	ENSG00000224086.5	LL22NC03-86G7.1	-10.43	4.67e-23	3.82e-20	-0.54	-0.43	Multiple sclerosis;	chr22:21758238	chr22:21938293~21977632:+
THCA	cis	rs9660180	0.62	rs34298494	ENSG00000231050.1	RP1-140A9.1	-10.43	4.68e-23	3.83e-20	-0.54	-0.43	Body mass index;	chr1:1731963	chr1:1891471~1892658:+
THCA	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	10.43	4.69e-23	3.83e-20	0.58	0.43	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
THCA	cis	rs34375054	0.525	rs7136220	ENSG00000279233.1	RP11-158L12.4	10.43	4.69e-23	3.83e-20	0.41	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125118138	chr12:125138245~125141711:+
THCA	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-10.43	4.7e-23	3.84e-20	-0.5	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
THCA	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-10.43	4.76e-23	3.89e-20	-0.48	-0.43	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
THCA	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	10.43	4.79e-23	3.91e-20	0.63	0.43	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
THCA	cis	rs11148252	0.904	rs9568732	ENSG00000278238.1	RP11-245D16.4	10.43	4.85e-23	3.96e-20	0.47	0.43	Lewy body disease;	chr13:52419277	chr13:52454775~52455331:-
THCA	cis	rs34375054	0.525	rs7398636	ENSG00000279233.1	RP11-158L12.4	10.43	4.86e-23	3.97e-20	0.42	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125114058	chr12:125138245~125141711:+
THCA	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	10.43	4.89e-23	3.99e-20	0.52	0.43	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
THCA	cis	rs9532669	0.926	rs9532689	ENSG00000176268.5	CYCSP34	10.43	4.91e-23	4.01e-20	0.48	0.43	Cervical cancer;	chr13:40957990	chr13:40863599~40863902:-
THCA	cis	rs1387259	0.931	rs11168474	ENSG00000258273.1	RP11-370I10.4	-10.43	4.92e-23	4.01e-20	-0.57	-0.43	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48333755~48333901:-
THCA	cis	rs8062405	0.789	rs240704	ENSG00000251417.2	RP11-1348G14.4	-10.43	4.93e-23	4.02e-20	-0.4	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28802743~28817828:+
THCA	cis	rs1799949	1	rs3092994	ENSG00000267681.1	CTD-3199J23.6	-10.42	5e-23	4.08e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43063808	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.962	rs3805748	ENSG00000223701.3	RAET1E-AS1	10.42	5.07e-23	4.13e-20	0.58	0.43	Lung cancer;	chr6:149772542	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.886	rs12525871	ENSG00000223701.3	RAET1E-AS1	10.42	5.07e-23	4.13e-20	0.58	0.43	Lung cancer;	chr6:149775882	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs10872653	ENSG00000223701.3	RAET1E-AS1	10.42	5.07e-23	4.13e-20	0.58	0.43	Lung cancer;	chr6:149778907	chr6:149884431~149919508:+
THCA	cis	rs6570726	0.935	rs432086	ENSG00000235652.6	RP11-545I5.3	-10.42	5.08e-23	4.14e-20	-0.4	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145520457	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs397418	ENSG00000235652.6	RP11-545I5.3	10.42	5.08e-23	4.14e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145521226	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs419854	ENSG00000235652.6	RP11-545I5.3	10.42	5.08e-23	4.14e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145522949	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs365658	ENSG00000235652.6	RP11-545I5.3	10.42	5.08e-23	4.14e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145523452	chr6:145799409~145886585:+
THCA	cis	rs944289	0.646	rs8003253	ENSG00000257826.1	RP11-116N8.4	-10.42	5.09e-23	4.15e-20	-0.45	-0.43	Thyroid cancer;	chr14:36088485	chr14:36061026~36067190:-
THCA	cis	rs10262624	0.935	rs6955725	ENSG00000234286.1	AC006026.13	-10.42	5.11e-23	4.16e-20	-0.55	-0.43	Schizophrenia;	chr7:23865523	chr7:23680195~23680786:-
THCA	cis	rs10262624	0.935	rs6955884	ENSG00000234286.1	AC006026.13	-10.42	5.11e-23	4.16e-20	-0.55	-0.43	Schizophrenia;	chr7:23865654	chr7:23680195~23680786:-
THCA	cis	rs9532669	0.89	rs9532593	ENSG00000176268.5	CYCSP34	10.42	5.14e-23	4.18e-20	0.51	0.43	Cervical cancer;	chr13:40847717	chr13:40863599~40863902:-
THCA	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	10.42	5.18e-23	4.22e-20	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
THCA	cis	rs9322193	0.847	rs4870054	ENSG00000223701.3	RAET1E-AS1	10.42	5.21e-23	4.24e-20	0.58	0.43	Lung cancer;	chr6:149848402	chr6:149884431~149919508:+
THCA	cis	rs875971	0.662	rs448725	ENSG00000237310.1	GS1-124K5.4	10.42	5.21e-23	4.25e-20	0.33	0.43	Aortic root size;	chr7:66049641	chr7:66493706~66495474:+
THCA	cis	rs3091242	0.933	rs9645452	ENSG00000261349.1	RP3-465N24.5	10.42	5.22e-23	4.25e-20	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25266102~25267136:-
THCA	cis	rs9322193	0.962	rs4870048	ENSG00000223701.3	RAET1E-AS1	10.42	5.29e-23	4.31e-20	0.58	0.43	Lung cancer;	chr6:149834324	chr6:149884431~149919508:+
THCA	cis	rs10463554	1	rs56372231	ENSG00000175749.11	EIF3KP1	10.42	5.33e-23	4.34e-20	0.56	0.43	Parkinson's disease;	chr5:102986201	chr5:103032376~103033031:+
THCA	cis	rs7772486	0.743	rs111332144	ENSG00000235652.6	RP11-545I5.3	-10.41	5.4e-23	4.4e-20	-0.4	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145735545	chr6:145799409~145886585:+
THCA	cis	rs950169	0.656	rs748455	ENSG00000259728.4	LINC00933	10.41	5.42e-23	4.41e-20	0.6	0.43	Schizophrenia;	chr15:84606344	chr15:84570649~84580175:+
THCA	cis	rs6991838	0.67	rs13275168	ENSG00000272010.1	CTD-3025N20.3	10.41	5.47e-23	4.45e-20	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65591850~65592472:-
THCA	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	10.41	5.49e-23	4.46e-20	0.5	0.43	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
THCA	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-10.41	5.49e-23	4.47e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
THCA	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-10.41	5.51e-23	4.48e-20	-0.58	-0.43	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
THCA	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-10.41	5.53e-23	4.5e-20	-0.66	-0.43	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
THCA	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-10.41	5.53e-23	4.5e-20	-0.46	-0.43	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
THCA	cis	rs8062405	0.824	rs153106	ENSG00000251417.2	RP11-1348G14.4	-10.41	5.62e-23	4.57e-20	-0.4	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28802743~28817828:+
THCA	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	10.41	5.63e-23	4.57e-20	0.6	0.43	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
THCA	cis	rs12220777	0.748	rs6584955	ENSG00000230091.5	TMEM254-AS1	10.41	5.63e-23	4.58e-20	0.76	0.43	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80100568	chr10:80046860~80078912:-
THCA	cis	rs6504950	0.888	rs244319	ENSG00000275710.1	RP11-257O5.4	10.41	5.66e-23	4.6e-20	0.53	0.43	Breast cancer;	chr17:55145513	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.813	rs244321	ENSG00000275710.1	RP11-257O5.4	10.41	5.66e-23	4.6e-20	0.53	0.43	Breast cancer;	chr17:55146637	chr17:54964474~54964679:+
THCA	cis	rs6504950	0.854	rs244322	ENSG00000275710.1	RP11-257O5.4	10.41	5.66e-23	4.6e-20	0.53	0.43	Breast cancer;	chr17:55147398	chr17:54964474~54964679:+
THCA	cis	rs4266144	0.562	rs2086667	ENSG00000244515.1	KRT18P34	-10.41	5.68e-23	4.62e-20	-0.57	-0.43	Coronary artery disease;	chr3:157118728	chr3:157162663~157163932:-
THCA	cis	rs6538678	0.746	rs12820313	ENSG00000258343.1	RP11-536G4.2	-10.41	5.7e-23	4.63e-20	-0.59	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95795345~95858839:-
THCA	cis	rs6570726	0.935	rs400968	ENSG00000235652.6	RP11-545I5.3	10.41	5.7e-23	4.63e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145498582	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs391820	ENSG00000235652.6	RP11-545I5.3	10.41	5.7e-23	4.63e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145500148	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.875	rs1883407	ENSG00000235652.6	RP11-545I5.3	10.41	5.7e-23	4.63e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145502296	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs367612	ENSG00000235652.6	RP11-545I5.3	10.41	5.7e-23	4.63e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145507851	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.905	rs375692	ENSG00000235652.6	RP11-545I5.3	10.41	5.7e-23	4.63e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145519232	chr6:145799409~145886585:+
THCA	cis	rs4964805	1	rs11111789	ENSG00000257681.1	RP11-341G23.4	10.41	5.71e-23	4.64e-20	0.52	0.43	Attention deficit hyperactivity disorder;	chr12:103797762	chr12:103746315~103768858:-
THCA	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	10.41	5.71e-23	4.64e-20	0.35	0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
THCA	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	10.41	5.72e-23	4.64e-20	0.63	0.43	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
THCA	cis	rs875971	0.658	rs432667	ENSG00000237310.1	GS1-124K5.4	10.41	5.74e-23	4.67e-20	0.33	0.43	Aortic root size;	chr7:66049646	chr7:66493706~66495474:+
THCA	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	10.41	5.79e-23	4.7e-20	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
THCA	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-10.41	5.8e-23	4.71e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
THCA	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-10.41	5.8e-23	4.71e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
THCA	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	10.4	5.88e-23	4.78e-20	0.51	0.43	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
THCA	cis	rs7772486	0.712	rs6570726	ENSG00000235652.6	RP11-545I5.3	10.4	5.9e-23	4.79e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145838324	chr6:145799409~145886585:+
THCA	cis	rs10256972	0.669	rs10229964	ENSG00000229043.2	AC091729.9	-10.4	5.91e-23	4.8e-20	-0.47	-0.43	Endometriosis;Longevity;	chr7:1012140	chr7:1160374~1165267:+
THCA	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-10.4	5.92e-23	4.81e-20	-0.51	-0.43	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
THCA	cis	rs9532669	0.889	rs9549302	ENSG00000176268.5	CYCSP34	10.4	5.95e-23	4.83e-20	0.5	0.43	Cervical cancer;	chr13:40843278	chr13:40863599~40863902:-
THCA	cis	rs6908034	0.556	rs7750703	ENSG00000228412.5	RP4-625H18.2	10.4	5.95e-23	4.83e-20	0.89	0.43	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804583	chr6:19802164~19804752:-
THCA	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-10.4	5.96e-23	4.84e-20	-0.46	-0.43	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
THCA	cis	rs9322193	0.607	rs4870078	ENSG00000223701.3	RAET1E-AS1	-10.4	5.98e-23	4.85e-20	-0.61	-0.43	Lung cancer;	chr6:149880676	chr6:149884431~149919508:+
THCA	cis	rs6991838	0.733	rs10111844	ENSG00000272010.1	CTD-3025N20.3	10.4	5.99e-23	4.86e-20	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65591850~65592472:-
THCA	cis	rs12188164	0.965	rs11739543	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:443561	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs72717430	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:444387	chr5:441498~443160:-
THCA	cis	rs12188164	0.93	rs72717436	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:448176	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs72717438	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:448548	chr5:441498~443160:-
THCA	cis	rs12188164	0.93	rs72717440	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:449586	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs11743639	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:450595	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs11745789	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:450662	chr5:441498~443160:-
THCA	cis	rs12188164	0.965	rs11744539	ENSG00000221990.4	EXOC3-AS1	10.4	5.99e-23	4.86e-20	0.37	0.43	Cystic fibrosis severity;	chr5:451310	chr5:441498~443160:-
THCA	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-10.4	6e-23	4.87e-20	-0.51	-0.43	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
THCA	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	10.4	6.01e-23	4.88e-20	0.51	0.43	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
THCA	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	10.4	6.04e-23	4.9e-20	0.47	0.43	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	10.4	6.04e-23	4.9e-20	0.51	0.43	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
THCA	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-10.4	6.11e-23	4.95e-20	-0.36	-0.43	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
THCA	cis	rs1043099	0.912	rs4820831	ENSG00000279699.1	RP1-102K2.9	10.4	6.17e-23	5e-20	0.61	0.43	Rheumatoid arthritis;	chr22:30315454	chr22:30275215~30276951:-
THCA	cis	rs2658782	0.593	rs2243410	ENSG00000279684.1	RP11-755E23.2	-10.4	6.18e-23	5e-20	-0.67	-0.43	Pulmonary function decline;	chr11:93522353	chr11:93286629~93288903:-
THCA	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	10.4	6.18e-23	5.01e-20	0.58	0.43	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
THCA	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-10.4	6.19e-23	5.01e-20	-0.56	-0.43	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-10.4	6.19e-23	5.01e-20	-0.54	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
THCA	cis	rs9545047	0.716	rs9545053	ENSG00000227676.3	LINC01068	10.4	6.2e-23	5.02e-20	0.53	0.43	Schizophrenia;	chr13:79296079	chr13:79566727~79571436:+
THCA	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	10.4	6.21e-23	5.03e-20	0.35	0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
THCA	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	10.4	6.21e-23	5.03e-20	0.35	0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
THCA	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	10.4	6.21e-23	5.03e-20	0.37	0.43	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
THCA	cis	rs9481169	0.557	rs2179070	ENSG00000255389.1	C6orf3	-10.4	6.22e-23	5.04e-20	-0.79	-0.43	Inflammatory skin disease;	chr6:111564549	chr6:111599875~111602295:+
THCA	cis	rs66887589	0.616	rs1052633	ENSG00000245958.5	RP11-33B1.1	-10.4	6.25e-23	5.06e-20	-0.39	-0.43	Diastolic blood pressure;	chr4:119294159	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.592	rs2175383	ENSG00000245958.5	RP11-33B1.1	-10.4	6.25e-23	5.06e-20	-0.39	-0.43	Diastolic blood pressure;	chr4:119294681	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	10.4	6.38e-23	5.16e-20	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
THCA	cis	rs9532669	0.89	rs12865032	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40873801	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs34123829	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40873808	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4488324	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40873864	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4288867	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40873880	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4415896	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874001	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs4415897	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874035	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4389021	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874209	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.824	rs4628828	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874369	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.737	rs34354179	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874424	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9594445	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874859	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9594446	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40874863	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4402423	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40875010	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs9532628	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40875172	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532629	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40875193	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7491149	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40875216	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532630	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40875472	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs4306385	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40875641	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4406939	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876108	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4628824	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876217	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532632	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876309	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532633	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876332	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532634	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876369	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532635	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876397	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs12428959	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40876638	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.895	rs4942009	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40877243	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4334153	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40877737	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4309270	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40877827	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4270044	ENSG00000239827.7	SUGT1P3	-10.39	6.4e-23	5.17e-20	-0.49	-0.43	Cervical cancer;	chr13:40877923	chr13:40908159~40921774:-
THCA	cis	rs7945705	0.967	rs56316046	ENSG00000254860.4	TMEM9B-AS1	-10.39	6.41e-23	5.18e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8855051	chr11:8964675~8977527:+
THCA	cis	rs12594515	0.587	rs8033024	ENSG00000273972.1	CTD-2306A12.1	-10.39	6.46e-23	5.22e-20	-0.51	-0.43	Weight;Waist circumference;	chr15:45705898	chr15:45702640~45703183:+
THCA	cis	rs12188164	0.965	rs41282625	ENSG00000221990.4	EXOC3-AS1	10.39	6.47e-23	5.23e-20	0.37	0.43	Cystic fibrosis severity;	chr5:475511	chr5:441498~443160:-
THCA	cis	rs9322193	0.962	rs9765929	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149769680	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.736	rs10457851	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149775216	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.886	rs10872652	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149775303	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.886	rs17672976	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149776207	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs2184369	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149776681	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs2342861	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149777561	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.926	rs2342860	ENSG00000223701.3	RAET1E-AS1	10.39	6.47e-23	5.23e-20	0.57	0.43	Lung cancer;	chr6:149777641	chr6:149884431~149919508:+
THCA	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	10.39	6.52e-23	5.26e-20	0.6	0.43	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
THCA	cis	rs2581828	0.618	rs6777975	ENSG00000242142.1	SERBP1P3	-10.39	6.54e-23	5.28e-20	-0.54	-0.43	Crohn's disease;	chr3:53132119	chr3:53064283~53065091:-
THCA	cis	rs9487094	0.666	rs9480956	ENSG00000260273.1	RP11-425D10.10	10.39	6.54e-23	5.28e-20	0.5	0.43	Height;	chr6:109424305	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.689	rs12214147	ENSG00000260273.1	RP11-425D10.10	10.39	6.54e-23	5.28e-20	0.5	0.43	Height;	chr6:109425054	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.689	rs17070591	ENSG00000260273.1	RP11-425D10.10	10.39	6.54e-23	5.28e-20	0.5	0.43	Height;	chr6:109426518	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.666	rs7751582	ENSG00000260273.1	RP11-425D10.10	10.39	6.54e-23	5.28e-20	0.5	0.43	Height;	chr6:109427644	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.689	rs9487103	ENSG00000260273.1	RP11-425D10.10	10.39	6.54e-23	5.28e-20	0.5	0.43	Height;	chr6:109430292	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	10.39	6.56e-23	5.3e-20	0.51	0.43	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
THCA	cis	rs7945705	0.846	rs2742540	ENSG00000254860.4	TMEM9B-AS1	-10.39	6.56e-23	5.3e-20	-0.47	-0.43	Hemoglobin concentration;	chr11:8877981	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.902	rs10743093	ENSG00000254860.4	TMEM9B-AS1	-10.39	6.57e-23	5.3e-20	-0.49	-0.43	Hemoglobin concentration;	chr11:8847582	chr11:8964675~8977527:+
THCA	cis	rs860295	0.702	rs11264381	ENSG00000225855.5	RUSC1-AS1	-10.39	6.57e-23	5.3e-20	-0.31	-0.43	Body mass index;	chr1:155552781	chr1:155316863~155324176:-
THCA	cis	rs7772486	0.754	rs702324	ENSG00000235652.6	RP11-545I5.3	-10.39	6.57e-23	5.3e-20	-0.4	-0.43	Lobe attachment (rater-scored or self-reported);	chr6:145687657	chr6:145799409~145886585:+
THCA	cis	rs66887589	0.616	rs6843509	ENSG00000245958.5	RP11-33B1.1	-10.39	6.57e-23	5.31e-20	-0.39	-0.43	Diastolic blood pressure;	chr4:119299041	chr4:119454791~119552025:+
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	10.39	6.58e-23	5.31e-20	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
THCA	cis	rs4718428	0.672	rs4718412	ENSG00000232546.1	RP11-458F8.1	10.39	6.62e-23	5.34e-20	0.41	0.43	Corneal structure;	chr7:66821880	chr7:66848496~66858136:+
THCA	cis	rs6570726	1	rs374464	ENSG00000235652.6	RP11-545I5.3	10.39	6.64e-23	5.36e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145525543	chr6:145799409~145886585:+
THCA	cis	rs6570726	1	rs450076	ENSG00000235652.6	RP11-545I5.3	10.39	6.64e-23	5.36e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145526519	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.962	rs12175575	ENSG00000223701.3	RAET1E-AS1	10.39	6.65e-23	5.36e-20	0.57	0.43	Lung cancer;	chr6:149763351	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs4869966	ENSG00000223701.3	RAET1E-AS1	10.39	6.65e-23	5.36e-20	0.57	0.43	Lung cancer;	chr6:149763714	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs1112730	ENSG00000223701.3	RAET1E-AS1	10.39	6.65e-23	5.36e-20	0.57	0.43	Lung cancer;	chr6:149766383	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs1112729	ENSG00000223701.3	RAET1E-AS1	10.39	6.65e-23	5.36e-20	0.57	0.43	Lung cancer;	chr6:149766491	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs10452626	ENSG00000223701.3	RAET1E-AS1	10.39	6.65e-23	5.36e-20	0.57	0.43	Lung cancer;	chr6:149767481	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.923	rs62441303	ENSG00000223701.3	RAET1E-AS1	10.39	6.65e-23	5.36e-20	0.57	0.43	Lung cancer;	chr6:149767547	chr6:149884431~149919508:+
THCA	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-10.39	6.66e-23	5.37e-20	-0.53	-0.43	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
THCA	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	10.39	6.73e-23	5.43e-20	0.51	0.43	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	10.39	6.73e-23	5.43e-20	0.51	0.43	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
THCA	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	10.39	6.74e-23	5.43e-20	0.35	0.43	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
THCA	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	10.39	6.78e-23	5.47e-20	0.52	0.43	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
THCA	cis	rs7569084	1	rs7569084	ENSG00000234255.7	AC012370.3	-10.39	6.8e-23	5.49e-20	-0.48	-0.43	Sum eosinophil basophil counts;	chr2:65429835	chr2:65439888~65456571:-
THCA	cis	rs7772486	0.79	rs2243665	ENSG00000235652.6	RP11-545I5.3	10.39	6.81e-23	5.49e-20	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145886984	chr6:145799409~145886585:+
THCA	cis	rs67311347	0.544	rs2278929	ENSG00000223797.4	ENTPD3-AS1	-10.39	6.81e-23	5.49e-20	-0.34	-0.43	Renal cell carcinoma;	chr3:40309517	chr3:40313802~40453329:-
THCA	cis	rs12188164	0.965	rs72717435	ENSG00000221990.4	EXOC3-AS1	10.39	6.81e-23	5.49e-20	0.37	0.43	Cystic fibrosis severity;	chr5:448087	chr5:441498~443160:-
THCA	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-10.39	6.83e-23	5.5e-20	-0.42	-0.43	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
THCA	cis	rs7309	0.935	rs6432674	ENSG00000235724.7	AC009299.2	-10.39	6.83e-23	5.51e-20	-0.45	-0.43	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161222785~161308303:-
THCA	cis	rs7309	0.81	rs11684253	ENSG00000235724.7	AC009299.2	-10.39	6.83e-23	5.51e-20	-0.45	-0.43	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161222785~161308303:-
THCA	cis	rs7665090	0.51	rs223498	ENSG00000246560.2	RP11-10L12.4	-10.39	6.86e-23	5.53e-20	-0.54	-0.43	Primary biliary cholangitis;	chr4:102730805	chr4:102828055~102844075:+
THCA	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-10.39	6.86e-23	5.53e-20	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
THCA	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-10.39	6.86e-23	5.53e-20	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
THCA	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-10.39	6.86e-23	5.53e-20	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
THCA	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-10.39	6.86e-23	5.53e-20	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-10.38	6.98e-23	5.62e-20	-0.54	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
THCA	cis	rs6991838	0.671	rs13251307	ENSG00000272010.1	CTD-3025N20.3	10.38	6.99e-23	5.63e-20	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65591850~65592472:-
THCA	cis	rs12468226	0.606	rs79092351	ENSG00000273456.1	RP11-686O6.2	10.38	7.01e-23	5.65e-20	0.47	0.43	Urate levels;	chr2:202204388	chr2:202374932~202375604:-
THCA	cis	rs6991838	0.765	rs6472219	ENSG00000272010.1	CTD-3025N20.3	10.38	7.01e-23	5.65e-20	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65591850~65592472:-
THCA	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-10.38	7.01e-23	5.65e-20	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
THCA	cis	rs6570726	1	rs386678	ENSG00000235652.6	RP11-545I5.3	10.38	7.02e-23	5.66e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145547874	chr6:145799409~145886585:+
THCA	cis	rs7772486	0.837	rs2474354	ENSG00000235652.6	RP11-545I5.3	10.38	7.02e-23	5.66e-20	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:146002659	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.926	rs9689036	ENSG00000223701.3	RAET1E-AS1	10.38	7.02e-23	5.66e-20	0.57	0.43	Lung cancer;	chr6:149780563	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9322218	ENSG00000223701.3	RAET1E-AS1	10.38	7.02e-23	5.66e-20	0.57	0.43	Lung cancer;	chr6:149782183	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9322219	ENSG00000223701.3	RAET1E-AS1	10.38	7.02e-23	5.66e-20	0.57	0.43	Lung cancer;	chr6:149782263	chr6:149884431~149919508:+
THCA	cis	rs11105298	0.891	rs10777163	ENSG00000258302.2	RP11-981P6.1	10.38	7.05e-23	5.67e-20	0.4	0.43	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:89561129~89594878:+
THCA	cis	rs9322193	0.962	rs9505974	ENSG00000223701.3	RAET1E-AS1	10.38	7.05e-23	5.68e-20	0.57	0.43	Lung cancer;	chr6:149779294	chr6:149884431~149919508:+
THCA	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	10.38	7.07e-23	5.69e-20	0.54	0.43	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
THCA	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	10.38	7.11e-23	5.72e-20	0.52	0.43	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
THCA	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-10.38	7.15e-23	5.75e-20	-0.45	-0.43	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
THCA	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-10.38	7.15e-23	5.76e-20	-0.45	-0.43	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
THCA	cis	rs4964805	0.641	rs11111755	ENSG00000257681.1	RP11-341G23.4	10.38	7.2e-23	5.8e-20	0.49	0.43	Attention deficit hyperactivity disorder;	chr12:103765889	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.641	rs10861094	ENSG00000257681.1	RP11-341G23.4	10.38	7.2e-23	5.8e-20	0.49	0.43	Attention deficit hyperactivity disorder;	chr12:103765938	chr12:103746315~103768858:-
THCA	cis	rs9903692	0.909	rs11079806	ENSG00000278765.1	RP5-890E16.5	10.38	7.24e-23	5.83e-20	0.57	0.43	Pulse pressure;	chr17:48065318	chr17:48066704~48067293:-
THCA	cis	rs765787	0.53	rs12909987	ENSG00000259520.4	CTD-2651B20.3	10.38	7.27e-23	5.85e-20	0.52	0.43	Uric acid levels;	chr15:45220009	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	10.38	7.52e-23	6.04e-20	0.52	0.43	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
THCA	cis	rs1930961	0.702	rs1930966	ENSG00000100058.11	CRYBB2P1	10.38	7.54e-23	6.06e-20	0.85	0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25448105~25520854:+
THCA	cis	rs860295	0.702	rs11264375	ENSG00000225855.5	RUSC1-AS1	-10.38	7.54e-23	6.06e-20	-0.3	-0.43	Body mass index;	chr1:155454274	chr1:155316863~155324176:-
THCA	cis	rs12188164	0.965	rs77101200	ENSG00000221990.4	EXOC3-AS1	10.38	7.54e-23	6.06e-20	0.37	0.43	Cystic fibrosis severity;	chr5:442944	chr5:441498~443160:-
THCA	cis	rs12188164	0.93	rs11743825	ENSG00000221990.4	EXOC3-AS1	10.38	7.55e-23	6.07e-20	0.37	0.43	Cystic fibrosis severity;	chr5:475348	chr5:441498~443160:-
THCA	cis	rs4964805	0.954	rs10861105	ENSG00000257681.1	RP11-341G23.4	10.38	7.55e-23	6.07e-20	0.52	0.43	Attention deficit hyperactivity disorder;	chr12:103796221	chr12:103746315~103768858:-
THCA	cis	rs6504950	0.886	rs2787500	ENSG00000275710.1	RP11-257O5.4	-10.38	7.58e-23	6.09e-20	-0.53	-0.43	Breast cancer;	chr17:55092445	chr17:54964474~54964679:+
THCA	cis	rs526231	0.543	rs72785717	ENSG00000175749.11	EIF3KP1	10.37	7.61e-23	6.12e-20	0.62	0.43	Primary biliary cholangitis;	chr5:102997401	chr5:103032376~103033031:+
THCA	cis	rs9532669	0.926	rs2183144	ENSG00000176268.5	CYCSP34	-10.37	7.64e-23	6.14e-20	-0.5	-0.43	Cervical cancer;	chr13:40862129	chr13:40863599~40863902:-
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	10.37	7.65e-23	6.15e-20	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
THCA	cis	rs7665090	0.87	rs228623	ENSG00000246560.2	RP11-10L12.4	-10.37	7.68e-23	6.17e-20	-0.53	-0.43	Primary biliary cholangitis;	chr4:102651163	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.837	rs228624	ENSG00000246560.2	RP11-10L12.4	-10.37	7.68e-23	6.17e-20	-0.53	-0.43	Primary biliary cholangitis;	chr4:102651283	chr4:102828055~102844075:+
THCA	cis	rs9926296	0.715	rs467035	ENSG00000260259.1	RP11-368I7.4	-10.37	7.69e-23	6.18e-20	-0.47	-0.43	Vitiligo;	chr16:89673877	chr16:89682620~89686569:-
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000224205.1	AP000351.4	-10.37	7.7e-23	6.19e-20	-0.51	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23987320~23991421:-
THCA	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	10.37	7.76e-23	6.23e-20	0.52	0.43	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
THCA	cis	rs673078	0.607	rs17512483	ENSG00000275759.1	RP11-131L12.3	10.37	7.77e-23	6.24e-20	0.69	0.43	Glucose homeostasis traits;	chr12:118312380	chr12:118428281~118428870:+
THCA	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	10.37	7.81e-23	6.27e-20	0.51	0.43	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	10.37	7.87e-23	6.32e-20	0.51	0.43	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
THCA	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	10.37	7.88e-23	6.32e-20	0.47	0.43	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
THCA	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-10.37	7.89e-23	6.34e-20	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
THCA	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-10.37	7.94e-23	6.37e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
THCA	cis	rs9399135	0.773	rs949895	ENSG00000232876.1	CTA-212D2.2	-10.37	7.98e-23	6.41e-20	-0.53	-0.43	Red blood cell count;	chr6:135084221	chr6:135055033~135060550:+
THCA	cis	rs7826238	0.564	rs2921053	ENSG00000253893.2	FAM85B	-10.37	8.02e-23	6.43e-20	-0.55	-0.43	Systolic blood pressure;	chr8:8462453	chr8:8167819~8226614:-
THCA	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	10.37	8.12e-23	6.52e-20	0.64	0.43	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
THCA	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	10.37	8.14e-23	6.53e-20	0.54	0.43	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
THCA	cis	rs7665090	0.87	rs228616	ENSG00000246560.2	RP11-10L12.4	-10.37	8.14e-23	6.53e-20	-0.53	-0.43	Primary biliary cholangitis;	chr4:102658534	chr4:102828055~102844075:+
THCA	cis	rs673078	0.607	rs11068919	ENSG00000275409.1	RP11-131L12.4	-10.37	8.17e-23	6.55e-20	-0.46	-0.43	Glucose homeostasis traits;	chr12:118354925	chr12:118430147~118430699:+
THCA	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	10.37	8.18e-23	6.56e-20	0.37	0.43	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	10.36	8.26e-23	6.63e-20	0.51	0.43	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
THCA	cis	rs934734	0.509	rs12185577	ENSG00000281920.1	RP11-418H16.1	-10.36	8.29e-23	6.65e-20	-0.52	-0.43	Rheumatoid arthritis;	chr2:65432354	chr2:65623272~65628424:+
THCA	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	10.36	8.31e-23	6.66e-20	0.54	0.43	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
THCA	cis	rs1799949	1	rs8176234	ENSG00000267681.1	CTD-3199J23.6	-10.36	8.36e-23	6.7e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43067763	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176233	ENSG00000267681.1	CTD-3199J23.6	-10.36	8.36e-23	6.7e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43067787	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176220	ENSG00000267681.1	CTD-3199J23.6	-10.36	8.36e-23	6.7e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43070445	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1799966	ENSG00000267681.1	CTD-3199J23.6	-10.36	8.36e-23	6.7e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43071077	chr17:43144956~43145255:+
THCA	cis	rs9532669	0.963	rs4600338	ENSG00000176268.5	CYCSP34	10.36	8.48e-23	6.8e-20	0.49	0.43	Cervical cancer;	chr13:40925175	chr13:40863599~40863902:-
THCA	cis	rs7429990	0.864	rs319693	ENSG00000229759.1	MRPS18AP1	10.36	8.51e-23	6.82e-20	0.54	0.43	Educational attainment (years of education);	chr3:47845090	chr3:48256350~48256938:-
THCA	cis	rs9318086	0.648	rs7331047	ENSG00000205861.10	C1QTNF9B-AS1	-10.36	8.51e-23	6.82e-20	-0.49	-0.43	Myopia (pathological);	chr13:23893203	chr13:23888889~23897263:+
THCA	cis	rs67311347	0.544	rs12635762	ENSG00000223797.4	ENTPD3-AS1	-10.36	8.55e-23	6.85e-20	-0.34	-0.43	Renal cell carcinoma;	chr3:40291268	chr3:40313802~40453329:-
THCA	cis	rs8062405	0.824	rs240702	ENSG00000251417.2	RP11-1348G14.4	-10.36	8.65e-23	6.92e-20	-0.4	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28802743~28817828:+
THCA	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	10.36	8.65e-23	6.93e-20	0.52	0.43	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
THCA	cis	rs9322193	0.962	rs3763163	ENSG00000223701.3	RAET1E-AS1	10.36	8.66e-23	6.93e-20	0.57	0.43	Lung cancer;	chr6:149819770	chr6:149884431~149919508:+
THCA	cis	rs8062405	0.754	rs149299	ENSG00000251417.2	RP11-1348G14.4	-10.36	8.68e-23	6.95e-20	-0.42	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28802743~28817828:+
THCA	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-10.36	8.69e-23	6.96e-20	-0.53	-0.43	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
THCA	cis	rs875971	0.964	rs160635	ENSG00000237310.1	GS1-124K5.4	10.36	8.74e-23	7e-20	0.33	0.43	Aortic root size;	chr7:66063931	chr7:66493706~66495474:+
THCA	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	10.36	8.78e-23	7.02e-20	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
THCA	cis	rs9322193	0.923	rs1984111	ENSG00000223701.3	RAET1E-AS1	10.36	8.83e-23	7.06e-20	0.57	0.43	Lung cancer;	chr6:149831720	chr6:149884431~149919508:+
THCA	cis	rs6504950	0.924	rs2628316	ENSG00000275710.1	RP11-257O5.4	-10.36	8.84e-23	7.07e-20	-0.53	-0.43	Breast cancer;	chr17:55142476	chr17:54964474~54964679:+
THCA	cis	rs9322193	0.962	rs1889473	ENSG00000223701.3	RAET1E-AS1	10.36	8.87e-23	7.1e-20	0.57	0.43	Lung cancer;	chr6:149825485	chr6:149884431~149919508:+
THCA	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	10.36	8.9e-23	7.12e-20	0.36	0.43	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
THCA	cis	rs9318086	0.624	rs9510909	ENSG00000205861.10	C1QTNF9B-AS1	-10.36	8.92e-23	7.13e-20	-0.5	-0.43	Myopia (pathological);	chr13:23862621	chr13:23888889~23897263:+
THCA	cis	rs66887589	0.616	rs6822808	ENSG00000245958.5	RP11-33B1.1	-10.36	8.93e-23	7.14e-20	-0.39	-0.43	Diastolic blood pressure;	chr4:119296210	chr4:119454791~119552025:+
THCA	cis	rs9322193	0.886	rs4870055	ENSG00000268592.3	RAET1E-AS1	10.36	8.97e-23	7.17e-20	0.58	0.43	Lung cancer;	chr6:149848433	chr6:149863494~149919507:+
THCA	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-10.36	8.98e-23	7.18e-20	-0.53	-0.43	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
THCA	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	10.36	8.99e-23	7.19e-20	0.36	0.43	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
THCA	cis	rs6142102	0.924	rs6059662	ENSG00000276073.1	RP5-1125A11.7	10.35	9.01e-23	7.21e-20	0.41	0.43	Skin pigmentation;	chr20:34087921	chr20:33985617~33988989:-
THCA	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-10.35	9.04e-23	7.23e-20	-0.47	-0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
THCA	cis	rs6538678	0.963	rs11108310	ENSG00000258343.1	RP11-536G4.2	-10.35	9.1e-23	7.27e-20	-0.58	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95795345~95858839:-
THCA	cis	rs6504950	0.886	rs2541236	ENSG00000275710.1	RP11-257O5.4	-10.35	9.14e-23	7.31e-20	-0.55	-0.43	Breast cancer;	chr17:55082471	chr17:54964474~54964679:+
THCA	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	10.35	9.15e-23	7.31e-20	0.52	0.43	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	10.35	9.15e-23	7.31e-20	0.52	0.43	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	10.35	9.15e-23	7.31e-20	0.52	0.43	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	10.35	9.15e-23	7.31e-20	0.52	0.43	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
THCA	cis	rs7945705	0.967	rs10840141	ENSG00000254860.4	TMEM9B-AS1	-10.35	9.23e-23	7.38e-20	-0.48	-0.43	Hemoglobin concentration;	chr11:8880671	chr11:8964675~8977527:+
THCA	cis	rs11148252	0.846	rs7333451	ENSG00000278238.1	RP11-245D16.4	-10.35	9.27e-23	7.4e-20	-0.48	-0.43	Lewy body disease;	chr13:52473574	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.846	rs9379	ENSG00000278238.1	RP11-245D16.4	-10.35	9.27e-23	7.4e-20	-0.48	-0.43	Lewy body disease;	chr13:52476344	chr13:52454775~52455331:-
THCA	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	10.35	9.28e-23	7.42e-20	0.36	0.43	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	10.35	9.29e-23	7.42e-20	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
THCA	cis	rs9322193	0.962	rs2065664	ENSG00000223701.3	RAET1E-AS1	10.35	9.34e-23	7.46e-20	0.57	0.43	Lung cancer;	chr6:149762485	chr6:149884431~149919508:+
THCA	cis	rs7586673	0.93	rs7591506	ENSG00000227403.1	AC009299.3	-10.35	9.36e-23	7.47e-20	-0.5	-0.43	Intelligence (multi-trait analysis);	chr2:161104414	chr2:161244739~161249050:+
THCA	cis	rs9322193	0.962	rs4552	ENSG00000223701.3	RAET1E-AS1	10.35	9.41e-23	7.51e-20	0.57	0.43	Lung cancer;	chr6:149811183	chr6:149884431~149919508:+
THCA	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	10.35	9.46e-23	7.55e-20	0.36	0.43	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
THCA	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	10.35	9.59e-23	7.65e-20	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
THCA	cis	rs11148252	0.904	rs9526927	ENSG00000278238.1	RP11-245D16.4	-10.35	9.63e-23	7.68e-20	-0.47	-0.43	Lewy body disease;	chr13:52477492	chr13:52454775~52455331:-
THCA	cis	rs12220777	0.748	rs7920814	ENSG00000230091.5	TMEM254-AS1	10.35	9.66e-23	7.71e-20	0.76	0.43	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80095713	chr10:80046860~80078912:-
THCA	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	10.35	9.69e-23	7.73e-20	0.47	0.43	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
THCA	cis	rs780096	0.526	rs7602534	ENSG00000234072.1	AC074117.10	-10.35	9.73e-23	7.76e-20	-0.34	-0.43	Total body bone mineral density;	chr2:27369556	chr2:27356246~27367622:+
THCA	cis	rs9322193	0.962	rs7818	ENSG00000223701.3	RAET1E-AS1	10.35	9.77e-23	7.79e-20	0.57	0.43	Lung cancer;	chr6:149810956	chr6:149884431~149919508:+
THCA	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	10.34	9.8e-23	7.82e-20	0.47	0.43	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
THCA	cis	rs7665090	0.87	rs228615	ENSG00000246560.2	RP11-10L12.4	-10.34	9.84e-23	7.85e-20	-0.53	-0.43	Primary biliary cholangitis;	chr4:102658303	chr4:102828055~102844075:+
THCA	cis	rs8062405	0.69	rs6498089	ENSG00000251417.2	RP11-1348G14.4	10.34	9.85e-23	7.86e-20	0.42	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28802743~28817828:+
THCA	cis	rs1043099	0.871	rs10427610	ENSG00000279699.1	RP1-102K2.9	-10.34	9.85e-23	7.86e-20	-0.61	-0.43	Rheumatoid arthritis;	chr22:30352229	chr22:30275215~30276951:-
THCA	cis	rs1043099	0.912	rs4820008	ENSG00000279699.1	RP1-102K2.9	-10.34	9.85e-23	7.86e-20	-0.61	-0.43	Rheumatoid arthritis;	chr22:30353352	chr22:30275215~30276951:-
THCA	cis	rs1043099	0.871	rs5749078	ENSG00000279699.1	RP1-102K2.9	-10.34	9.85e-23	7.86e-20	-0.61	-0.43	Rheumatoid arthritis;	chr22:30365077	chr22:30275215~30276951:-
THCA	cis	rs1799949	1	rs35330014	ENSG00000267681.1	CTD-3199J23.6	-10.34	9.94e-23	7.93e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43060530	chr17:43144956~43145255:+
THCA	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	10.34	9.97e-23	7.95e-20	0.55	0.43	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
THCA	cis	rs1043099	0.912	rs4823085	ENSG00000279699.1	RP1-102K2.9	-10.34	1e-22	7.99e-20	-0.6	-0.43	Rheumatoid arthritis;	chr22:30290237	chr22:30275215~30276951:-
THCA	cis	rs12188164	0.965	rs56346498	ENSG00000221990.4	EXOC3-AS1	10.34	1.01e-22	8.04e-20	0.37	0.43	Cystic fibrosis severity;	chr5:423480	chr5:441498~443160:-
THCA	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-10.34	1.01e-22	8.08e-20	-0.54	-0.43	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
THCA	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	10.34	1.02e-22	8.09e-20	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
THCA	cis	rs7191700	0.674	rs12597893	ENSG00000262636.1	CTD-3088G3.4	10.34	1.02e-22	8.1e-20	0.53	0.43	Multiple sclerosis;	chr16:11332474	chr16:11380859~11381118:-
THCA	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-10.34	1.02e-22	8.15e-20	-0.36	-0.43	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
THCA	cis	rs860295	0.58	rs10908463	ENSG00000225855.5	RUSC1-AS1	10.34	1.03e-22	8.22e-20	0.3	0.43	Body mass index;	chr1:155316467	chr1:155316863~155324176:-
THCA	cis	rs6061231	1	rs67941642	ENSG00000273619.1	RP5-908M14.9	-10.34	1.04e-22	8.27e-20	-0.34	-0.43	Colorectal cancer;	chr20:62383052	chr20:62386303~62386970:-
THCA	cis	rs860295	0.702	rs12039893	ENSG00000225855.5	RUSC1-AS1	10.34	1.04e-22	8.27e-20	0.3	0.43	Body mass index;	chr1:155645024	chr1:155316863~155324176:-
THCA	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	10.34	1.05e-22	8.35e-20	0.51	0.43	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
THCA	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	10.34	1.05e-22	8.35e-20	0.51	0.43	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
THCA	cis	rs7576126	0.563	rs1807337	ENSG00000281920.1	RP11-418H16.1	-10.34	1.06e-22	8.41e-20	-0.52	-0.43	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65623272~65628424:+
THCA	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	10.34	1.06e-22	8.41e-20	0.36	0.43	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	10.34	1.06e-22	8.41e-20	0.37	0.43	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	10.34	1.06e-22	8.41e-20	0.37	0.43	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
THCA	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	10.34	1.06e-22	8.45e-20	0.47	0.43	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	10.33	1.07e-22	8.52e-20	0.53	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
THCA	cis	rs11148252	0.846	rs7323666	ENSG00000278238.1	RP11-245D16.4	-10.33	1.07e-22	8.55e-20	-0.48	-0.43	Lewy body disease;	chr13:52431923	chr13:52454775~52455331:-
THCA	cis	rs7829975	0.688	rs13270194	ENSG00000253893.2	FAM85B	-10.33	1.08e-22	8.55e-20	-0.55	-0.43	Mood instability;	chr8:8520592	chr8:8167819~8226614:-
THCA	cis	rs9532669	0.926	rs9532657	ENSG00000239827.7	SUGT1P3	10.33	1.09e-22	8.63e-20	0.47	0.43	Cervical cancer;	chr13:40918208	chr13:40908159~40921774:-
THCA	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	10.33	1.09e-22	8.65e-20	0.57	0.43	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
THCA	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-10.33	1.09e-22	8.67e-20	-0.51	-0.43	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
THCA	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-10.33	1.1e-22	8.78e-20	-0.59	-0.43	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
THCA	cis	rs3096299	0.746	rs9931120	ENSG00000274627.1	RP11-104N10.2	10.33	1.12e-22	8.86e-20	0.41	0.43	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89516797~89522217:+
THCA	cis	rs7829975	0.623	rs10087493	ENSG00000253893.2	FAM85B	10.33	1.14e-22	9.07e-20	0.56	0.43	Mood instability;	chr8:8516047	chr8:8167819~8226614:-
THCA	cis	rs1799949	1	rs4793190	ENSG00000267681.1	CTD-3199J23.6	-10.33	1.15e-22	9.11e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43048092	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176297	ENSG00000267681.1	CTD-3199J23.6	-10.33	1.15e-22	9.11e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43051308	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176296	ENSG00000267681.1	CTD-3199J23.6	-10.33	1.15e-22	9.11e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43051574	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4793191	ENSG00000267681.1	CTD-3199J23.6	-10.33	1.15e-22	9.11e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43052360	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4793192	ENSG00000267681.1	CTD-3199J23.6	-10.33	1.15e-22	9.11e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43052373	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176289	ENSG00000267681.1	CTD-3199J23.6	-10.33	1.15e-22	9.11e-20	-0.5	-0.43	Menopause (age at onset);	chr17:43054039	chr17:43144956~43145255:+
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-10.33	1.15e-22	9.12e-20	-0.55	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
THCA	cis	rs6504950	0.886	rs2787501	ENSG00000275710.1	RP11-257O5.4	10.33	1.16e-22	9.18e-20	0.52	0.43	Breast cancer;	chr17:55016604	chr17:54964474~54964679:+
THCA	cis	rs2732480	0.577	rs2634681	ENSG00000258273.1	RP11-370I10.4	10.33	1.16e-22	9.2e-20	0.56	0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48333755~48333901:-
THCA	cis	rs944289	0.646	rs8007617	ENSG00000257826.1	RP11-116N8.4	-10.33	1.16e-22	9.2e-20	-0.45	-0.43	Thyroid cancer;	chr14:36088883	chr14:36061026~36067190:-
THCA	cis	rs7945705	0.87	rs4929922	ENSG00000254860.4	TMEM9B-AS1	10.32	1.18e-22	9.37e-20	0.48	0.43	Hemoglobin concentration;	chr11:8954229	chr11:8964675~8977527:+
THCA	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-10.32	1.19e-22	9.43e-20	-0.52	-0.43	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
THCA	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-10.32	1.19e-22	9.43e-20	-0.52	-0.43	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
THCA	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-10.32	1.19e-22	9.43e-20	-0.52	-0.43	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
THCA	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	10.32	1.19e-22	9.46e-20	0.59	0.43	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
THCA	cis	rs12220777	0.748	rs12259239	ENSG00000230091.5	TMEM254-AS1	10.32	1.19e-22	9.46e-20	0.76	0.43	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103265	chr10:80046860~80078912:-
THCA	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-10.32	1.21e-22	9.55e-20	-0.51	-0.43	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
THCA	cis	rs11676348	0.846	rs7607437	ENSG00000261338.2	RP11-378A13.1	-10.32	1.21e-22	9.56e-20	-0.43	-0.43	Ulcerative colitis;	chr2:218143669	chr2:218255319~218257366:+
THCA	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-10.32	1.21e-22	9.63e-20	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
THCA	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-10.32	1.22e-22	9.67e-20	-0.48	-0.43	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
THCA	cis	rs4819052	0.634	rs8128636	ENSG00000223768.1	LINC00205	-10.32	1.22e-22	9.69e-20	-0.4	-0.43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45293285~45297354:+
THCA	cis	rs7586673	0.893	rs889925	ENSG00000227403.1	AC009299.3	-10.32	1.23e-22	9.71e-20	-0.5	-0.43	Intelligence (multi-trait analysis);	chr2:161115086	chr2:161244739~161249050:+
THCA	cis	rs7586673	0.93	rs2884364	ENSG00000227403.1	AC009299.3	-10.32	1.23e-22	9.71e-20	-0.5	-0.43	Intelligence (multi-trait analysis);	chr2:161121136	chr2:161244739~161249050:+
THCA	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-10.32	1.23e-22	9.72e-20	-0.62	-0.43	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
THCA	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-10.32	1.23e-22	9.75e-20	-0.45	-0.43	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
THCA	cis	rs7211079	0.879	rs72852522	ENSG00000279259.1	RP11-334C17.3	10.32	1.23e-22	9.77e-20	0.44	0.43	Myocardial infarction;	chr17:80157691	chr17:80147250~80148596:+
THCA	cis	rs10246939	0.543	rs12538701	ENSG00000228775.6	WEE2-AS1	10.32	1.24e-22	9.82e-20	0.52	0.43	Bitter taste perception;	chr7:141893634	chr7:141704338~141738346:-
THCA	cis	rs944289	0.646	rs8008989	ENSG00000257826.1	RP11-116N8.4	-10.32	1.26e-22	9.99e-20	-0.44	-0.43	Thyroid cancer;	chr14:36088871	chr14:36061026~36067190:-
THCA	cis	rs66887589	0.616	rs11732621	ENSG00000245958.5	RP11-33B1.1	-10.31	1.28e-22	1.01e-19	-0.39	-0.43	Diastolic blood pressure;	chr4:119291728	chr4:119454791~119552025:+
THCA	cis	rs12188164	0.762	rs11745923	ENSG00000221990.4	EXOC3-AS1	10.31	1.28e-22	1.01e-19	0.37	0.43	Cystic fibrosis severity;	chr5:475293	chr5:441498~443160:-
THCA	cis	rs8062405	0.755	rs62031607	ENSG00000251417.2	RP11-1348G14.4	-10.31	1.28e-22	1.01e-19	-0.43	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28802743~28817828:+
THCA	cis	rs6991838	0.733	rs7822627	ENSG00000272010.1	CTD-3025N20.3	10.31	1.29e-22	1.02e-19	0.42	0.43	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65591850~65592472:-
THCA	cis	rs66887589	0.616	rs11731675	ENSG00000245958.5	RP11-33B1.1	-10.31	1.29e-22	1.02e-19	-0.39	-0.43	Diastolic blood pressure;	chr4:119291359	chr4:119454791~119552025:+
THCA	cis	rs6504950	0.886	rs4794551	ENSG00000275710.1	RP11-257O5.4	-10.31	1.3e-22	1.03e-19	-0.53	-0.43	Breast cancer;	chr17:54998066	chr17:54964474~54964679:+
THCA	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-10.31	1.3e-22	1.03e-19	-0.54	-0.43	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
THCA	cis	rs3091242	0.806	rs35189848	ENSG00000261349.1	RP3-465N24.5	10.31	1.31e-22	1.03e-19	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25461931	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.836	rs35346083	ENSG00000261349.1	RP3-465N24.5	10.31	1.31e-22	1.03e-19	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25461934	chr1:25266102~25267136:-
THCA	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	10.31	1.31e-22	1.04e-19	0.52	0.43	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
THCA	cis	rs42490	0.903	rs218900	ENSG00000251136.7	RP11-37B2.1	-10.31	1.32e-22	1.05e-19	-0.37	-0.43	Leprosy;	chr8:89718678	chr8:89609409~89757727:-
THCA	cis	rs42490	0.903	rs218901	ENSG00000251136.7	RP11-37B2.1	-10.31	1.32e-22	1.05e-19	-0.37	-0.43	Leprosy;	chr8:89719089	chr8:89609409~89757727:-
THCA	cis	rs8062405	0.721	rs151303	ENSG00000251417.2	RP11-1348G14.4	-10.31	1.34e-22	1.06e-19	-0.41	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28802743~28817828:+
THCA	cis	rs9487094	0.62	rs7768973	ENSG00000260273.1	RP11-425D10.10	10.31	1.35e-22	1.07e-19	0.5	0.43	Height;	chr6:109424122	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.884	rs11155675	ENSG00000223701.3	RAET1E-AS1	10.31	1.35e-22	1.07e-19	0.59	0.43	Lung cancer;	chr6:149742883	chr6:149884431~149919508:+
THCA	cis	rs8062405	0.756	rs151301	ENSG00000251417.2	RP11-1348G14.4	-10.31	1.37e-22	1.08e-19	-0.41	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28802743~28817828:+
THCA	cis	rs673078	0.66	rs61943362	ENSG00000275759.1	RP11-131L12.3	-10.31	1.37e-22	1.08e-19	-0.68	-0.43	Glucose homeostasis traits;	chr12:118322042	chr12:118428281~118428870:+
THCA	cis	rs11155671	0.546	rs1999633	ENSG00000223701.3	RAET1E-AS1	10.31	1.37e-22	1.09e-19	0.6	0.43	Testicular germ cell tumor;	chr6:149866576	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs6899661	ENSG00000223701.3	RAET1E-AS1	10.3	1.38e-22	1.09e-19	0.57	0.43	Lung cancer;	chr6:149818093	chr6:149884431~149919508:+
THCA	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-10.3	1.38e-22	1.09e-19	-0.5	-0.43	Migraine;	chr4:56956882	chr4:56960927~56961373:-
THCA	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-10.3	1.38e-22	1.09e-19	-0.5	-0.43	Migraine;	chr4:56957291	chr4:56960927~56961373:-
THCA	cis	rs11148252	0.744	rs4884354	ENSG00000278238.1	RP11-245D16.4	-10.3	1.38e-22	1.09e-19	-0.47	-0.43	Lewy body disease;	chr13:52443339	chr13:52454775~52455331:-
THCA	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	10.3	1.38e-22	1.09e-19	0.62	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
THCA	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-10.3	1.39e-22	1.09e-19	-0.63	-0.43	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
THCA	cis	rs4819052	0.788	rs2236449	ENSG00000223768.1	LINC00205	-10.3	1.39e-22	1.1e-19	-0.42	-0.43	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45293285~45297354:+
THCA	cis	rs2658782	0.724	rs2605626	ENSG00000279684.1	RP11-755E23.2	-10.3	1.39e-22	1.1e-19	-0.68	-0.43	Pulmonary function decline;	chr11:93520737	chr11:93286629~93288903:-
THCA	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-10.3	1.42e-22	1.12e-19	-0.47	-0.43	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-10.3	1.42e-22	1.12e-19	-0.47	-0.43	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
THCA	cis	rs673078	0.66	rs61945219	ENSG00000275409.1	RP11-131L12.4	-10.3	1.43e-22	1.13e-19	-0.48	-0.43	Glucose homeostasis traits;	chr12:118272916	chr12:118430147~118430699:+
THCA	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	10.3	1.43e-22	1.13e-19	0.47	0.43	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.967	rs10769973	ENSG00000254860.4	TMEM9B-AS1	-10.3	1.43e-22	1.13e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8907068	chr11:8964675~8977527:+
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	10.3	1.44e-22	1.13e-19	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
THCA	cis	rs4639966	0.589	rs480958	ENSG00000278376.1	RP11-158I9.8	-10.3	1.44e-22	1.14e-19	-0.32	-0.43	Systemic lupus erythematosus;	chr11:118707281	chr11:118791254~118793137:+
THCA	cis	rs4654748	0.507	rs10799702	ENSG00000227001.3	NBPF2P	-10.3	1.44e-22	1.14e-19	-0.49	-0.43	Folate pathway vitamin levels;	chr1:21495387	chr1:21424625~21427967:-
THCA	cis	rs957448	1	rs12543207	ENSG00000253704.1	RP11-267M23.4	10.3	1.45e-22	1.14e-19	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94553722~94569745:+
THCA	cis	rs9318086	0.648	rs7330140	ENSG00000205861.10	C1QTNF9B-AS1	-10.3	1.45e-22	1.14e-19	-0.49	-0.43	Myopia (pathological);	chr13:23898935	chr13:23888889~23897263:+
THCA	cis	rs6904897	0.563	rs4896117	ENSG00000232876.1	CTA-212D2.2	10.3	1.45e-22	1.14e-19	0.51	0.43	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134908262	chr6:135055033~135060550:+
THCA	cis	rs67311347	0.635	rs73071706	ENSG00000223797.4	ENTPD3-AS1	10.3	1.46e-22	1.15e-19	0.36	0.43	Renal cell carcinoma;	chr3:40246699	chr3:40313802~40453329:-
THCA	cis	rs1799949	0.965	rs8176323	ENSG00000267681.1	CTD-3199J23.6	-10.3	1.47e-22	1.16e-19	-0.5	-0.43	Menopause (age at onset);	chr17:43043694	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs8176322	ENSG00000267681.1	CTD-3199J23.6	-10.3	1.47e-22	1.16e-19	-0.5	-0.43	Menopause (age at onset);	chr17:43043756	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs12516	ENSG00000267681.1	CTD-3199J23.6	-10.3	1.47e-22	1.16e-19	-0.5	-0.43	Menopause (age at onset);	chr17:43044391	chr17:43144956~43145255:+
THCA	cis	rs11148252	0.846	rs1056335	ENSG00000278238.1	RP11-245D16.4	-10.3	1.47e-22	1.16e-19	-0.47	-0.43	Lewy body disease;	chr13:52415728	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.846	rs7985262	ENSG00000278238.1	RP11-245D16.4	-10.3	1.47e-22	1.16e-19	-0.47	-0.43	Lewy body disease;	chr13:52423026	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.846	rs4886077	ENSG00000278238.1	RP11-245D16.4	-10.3	1.47e-22	1.16e-19	-0.47	-0.43	Lewy body disease;	chr13:52424562	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.846	rs8001624	ENSG00000278238.1	RP11-245D16.4	-10.3	1.47e-22	1.16e-19	-0.47	-0.43	Lewy body disease;	chr13:52428860	chr13:52454775~52455331:-
THCA	cis	rs9318086	0.648	rs4067969	ENSG00000205861.10	C1QTNF9B-AS1	-10.3	1.49e-22	1.17e-19	-0.49	-0.43	Myopia (pathological);	chr13:23894981	chr13:23888889~23897263:+
THCA	cis	rs11148252	0.904	rs3892337	ENSG00000278238.1	RP11-245D16.4	-10.3	1.49e-22	1.18e-19	-0.47	-0.43	Lewy body disease;	chr13:52455350	chr13:52454775~52455331:-
THCA	cis	rs2658782	0.724	rs2605629	ENSG00000279684.1	RP11-755E23.2	10.29	1.5e-22	1.18e-19	0.67	0.43	Pulmonary function decline;	chr11:93530871	chr11:93286629~93288903:-
THCA	cis	rs11148252	0.904	rs9536079	ENSG00000278238.1	RP11-245D16.4	-10.29	1.5e-22	1.18e-19	-0.47	-0.43	Lewy body disease;	chr13:52456430	chr13:52454775~52455331:-
THCA	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-10.29	1.5e-22	1.18e-19	-0.5	-0.43	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
THCA	cis	rs8062405	0.754	rs28410083	ENSG00000251417.2	RP11-1348G14.4	10.29	1.51e-22	1.19e-19	0.43	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.789	rs1968751	ENSG00000251417.2	RP11-1348G14.4	10.29	1.51e-22	1.19e-19	0.43	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28802743~28817828:+
THCA	cis	rs7945705	0.935	rs10769971	ENSG00000254860.4	TMEM9B-AS1	-10.29	1.52e-22	1.2e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8903729	chr11:8964675~8977527:+
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-10.29	1.53e-22	1.2e-19	-0.54	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
THCA	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	10.29	1.53e-22	1.21e-19	0.63	0.43	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.651	rs9322188	ENSG00000223701.3	RAET1E-AS1	-10.29	1.54e-22	1.21e-19	-0.59	-0.43	Lung cancer;	chr6:149588355	chr6:149884431~149919508:+
THCA	cis	rs6558530	0.965	rs6558529	ENSG00000253982.1	CTD-2336O2.1	10.29	1.54e-22	1.21e-19	0.37	0.43	Systolic blood pressure;	chr8:1758040	chr8:1761990~1764502:-
THCA	cis	rs6558530	0.799	rs62477060	ENSG00000253982.1	CTD-2336O2.1	10.29	1.54e-22	1.21e-19	0.37	0.43	Systolic blood pressure;	chr8:1758332	chr8:1761990~1764502:-
THCA	cis	rs4639966	0.569	rs603486	ENSG00000278376.1	RP11-158I9.8	-10.29	1.54e-22	1.21e-19	-0.31	-0.43	Systemic lupus erythematosus;	chr11:118716638	chr11:118791254~118793137:+
THCA	cis	rs4718428	0.705	rs12536410	ENSG00000232546.1	RP11-458F8.1	-10.29	1.54e-22	1.21e-19	-0.41	-0.43	Corneal structure;	chr7:66789303	chr7:66848496~66858136:+
THCA	cis	rs950169	0.509	rs71395455	ENSG00000259728.4	LINC00933	10.29	1.55e-22	1.22e-19	0.59	0.43	Schizophrenia;	chr15:84610573	chr15:84570649~84580175:+
THCA	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	10.29	1.57e-22	1.23e-19	0.51	0.43	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
THCA	cis	rs1043099	0.912	rs5749066	ENSG00000279699.1	RP1-102K2.9	-10.29	1.57e-22	1.24e-19	-0.61	-0.43	Rheumatoid arthritis;	chr22:30340922	chr22:30275215~30276951:-
THCA	cis	rs1043099	0.912	rs5753080	ENSG00000279699.1	RP1-102K2.9	-10.29	1.57e-22	1.24e-19	-0.61	-0.43	Rheumatoid arthritis;	chr22:30342748	chr22:30275215~30276951:-
THCA	cis	rs950169	0.544	rs12913702	ENSG00000259728.4	LINC00933	10.29	1.58e-22	1.24e-19	0.59	0.43	Schizophrenia;	chr15:84609953	chr15:84570649~84580175:+
THCA	cis	rs9532669	0.857	rs9525427	ENSG00000239827.7	SUGT1P3	-10.29	1.59e-22	1.25e-19	-0.46	-0.43	Cervical cancer;	chr13:40918029	chr13:40908159~40921774:-
THCA	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	10.29	1.6e-22	1.26e-19	0.47	0.43	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
THCA	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-10.29	1.6e-22	1.26e-19	-0.62	-0.43	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-10.29	1.6e-22	1.26e-19	-0.62	-0.43	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-10.29	1.61e-22	1.26e-19	-0.36	-0.43	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
THCA	cis	rs10246939	0.511	rs62475469	ENSG00000228775.6	WEE2-AS1	10.29	1.61e-22	1.26e-19	0.5	0.43	Bitter taste perception;	chr7:141864846	chr7:141704338~141738346:-
THCA	cis	rs62103177	0.564	rs1864529	ENSG00000261126.6	RP11-795F19.1	-10.29	1.63e-22	1.28e-19	-0.47	-0.43	Opioid sensitivity;	chr18:79988975	chr18:80046900~80095482:+
THCA	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	10.29	1.63e-22	1.28e-19	0.5	0.43	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs4242279	ENSG00000268592.3	RAET1E-AS1	10.28	1.63e-22	1.28e-19	0.59	0.43	Lung cancer;	chr6:149839815	chr6:149863494~149919507:+
THCA	cis	rs10170846	0.626	rs9288575	ENSG00000261428.2	RP11-16P6.1	10.28	1.63e-22	1.28e-19	0.54	0.43	Schizophrenia (inflammation and infection response interaction);	chr2:222630414	chr2:222566899~222569719:-
THCA	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	10.28	1.64e-22	1.29e-19	0.62	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	10.28	1.64e-22	1.29e-19	0.56	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
THCA	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-10.28	1.65e-22	1.29e-19	-0.52	-0.43	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
THCA	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-10.28	1.65e-22	1.3e-19	-0.51	-0.43	Migraine;	chr4:56850720	chr4:56960927~56961373:-
THCA	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	10.28	1.65e-22	1.3e-19	0.56	0.43	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
THCA	cis	rs9318086	0.648	rs35449605	ENSG00000205861.10	C1QTNF9B-AS1	-10.28	1.65e-22	1.3e-19	-0.49	-0.43	Myopia (pathological);	chr13:23898443	chr13:23888889~23897263:+
THCA	cis	rs950169	0.8	rs34302901	ENSG00000225151.9	GOLGA2P7	-10.28	1.65e-22	1.3e-19	-0.62	-0.43	Schizophrenia;	chr15:84567712	chr15:84199311~84230136:-
THCA	cis	rs6452524	0.836	rs4343818	ENSG00000249664.1	CTD-2227C6.2	10.28	1.66e-22	1.3e-19	0.56	0.43	Hypertension (SNP x SNP interaction);	chr5:83205603	chr5:83012285~83013109:-
THCA	cis	rs7945705	0.967	rs10769970	ENSG00000254860.4	TMEM9B-AS1	-10.28	1.66e-22	1.3e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8896390	chr11:8964675~8977527:+
THCA	cis	rs12594515	0.625	rs2176866	ENSG00000273972.1	CTD-2306A12.1	-10.28	1.66e-22	1.3e-19	-0.5	-0.43	Weight;Waist circumference;	chr15:45704620	chr15:45702640~45703183:+
THCA	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-10.28	1.67e-22	1.31e-19	-0.62	-0.43	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
THCA	cis	rs9660180	0.62	rs3817856	ENSG00000231050.1	RP1-140A9.1	-10.28	1.67e-22	1.31e-19	-0.51	-0.43	Body mass index;	chr1:1732392	chr1:1891471~1892658:+
THCA	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	10.28	1.67e-22	1.31e-19	0.62	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
THCA	cis	rs7665090	0.87	rs228613	ENSG00000246560.2	RP11-10L12.4	-10.28	1.67e-22	1.31e-19	-0.53	-0.43	Primary biliary cholangitis;	chr4:102656308	chr4:102828055~102844075:+
THCA	cis	rs9399135	0.773	rs1331308	ENSG00000232876.1	CTA-212D2.2	10.28	1.67e-22	1.31e-19	0.53	0.43	Red blood cell count;	chr6:135083984	chr6:135055033~135060550:+
THCA	cis	rs4718428	0.705	rs12698547	ENSG00000232546.1	RP11-458F8.1	-10.28	1.68e-22	1.32e-19	-0.41	-0.43	Corneal structure;	chr7:66813271	chr7:66848496~66858136:+
THCA	cis	rs944289	0.616	rs6571735	ENSG00000257826.1	RP11-116N8.4	-10.28	1.69e-22	1.33e-19	-0.44	-0.43	Thyroid cancer;	chr14:36089428	chr14:36061026~36067190:-
THCA	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	10.28	1.69e-22	1.33e-19	0.47	0.43	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
THCA	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-10.28	1.7e-22	1.33e-19	-0.39	-0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
THCA	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-10.28	1.7e-22	1.33e-19	-0.56	-0.43	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
THCA	cis	rs7945705	0.967	rs10840148	ENSG00000254860.4	TMEM9B-AS1	-10.28	1.7e-22	1.33e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8901981	chr11:8964675~8977527:+
THCA	cis	rs9659323	0.73	rs10923720	ENSG00000231365.4	RP11-418J17.1	-10.28	1.7e-22	1.33e-19	-0.44	-0.43	Body mass index;	chr1:118999256	chr1:119140396~119275973:+
THCA	cis	rs11148252	0.846	rs13431	ENSG00000278238.1	RP11-245D16.4	-10.28	1.71e-22	1.34e-19	-0.47	-0.43	Lewy body disease;	chr13:52413342	chr13:52454775~52455331:-
THCA	cis	rs6142102	1	rs2143230	ENSG00000276073.1	RP5-1125A11.7	-10.28	1.71e-22	1.34e-19	-0.4	-0.43	Skin pigmentation;	chr20:34136539	chr20:33985617~33988989:-
THCA	cis	rs42490	0.873	rs218895	ENSG00000251136.7	RP11-37B2.1	-10.28	1.71e-22	1.34e-19	-0.37	-0.43	Leprosy;	chr8:89714320	chr8:89609409~89757727:-
THCA	cis	rs4718428	0.705	rs68168107	ENSG00000232546.1	RP11-458F8.1	-10.28	1.72e-22	1.35e-19	-0.41	-0.43	Corneal structure;	chr7:66790251	chr7:66848496~66858136:+
THCA	cis	rs4718428	0.672	rs36038499	ENSG00000232546.1	RP11-458F8.1	-10.28	1.72e-22	1.35e-19	-0.41	-0.43	Corneal structure;	chr7:66824628	chr7:66848496~66858136:+
THCA	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	10.28	1.73e-22	1.35e-19	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
THCA	cis	rs7945705	0.967	rs1569408	ENSG00000254860.4	TMEM9B-AS1	-10.28	1.73e-22	1.36e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8888185	chr11:8964675~8977527:+
THCA	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	10.28	1.74e-22	1.36e-19	0.47	0.43	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
THCA	cis	rs71403859	0.502	rs12708914	ENSG00000260886.1	TAT-AS1	10.28	1.75e-22	1.37e-19	0.7	0.43	Post bronchodilator FEV1;	chr16:71436733	chr16:71565789~71578187:+
THCA	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-10.28	1.76e-22	1.38e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
THCA	cis	rs526231	0.543	rs246905	ENSG00000175749.11	EIF3KP1	10.27	1.78e-22	1.4e-19	0.58	0.43	Primary biliary cholangitis;	chr5:103255242	chr5:103032376~103033031:+
THCA	cis	rs42490	1	rs402886	ENSG00000251136.7	RP11-37B2.1	-10.27	1.79e-22	1.4e-19	-0.37	-0.43	Leprosy;	chr8:89760272	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs39500	ENSG00000251136.7	RP11-37B2.1	-10.27	1.79e-22	1.4e-19	-0.37	-0.43	Leprosy;	chr8:89760437	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs39761	ENSG00000251136.7	RP11-37B2.1	-10.27	1.79e-22	1.4e-19	-0.37	-0.43	Leprosy;	chr8:89760692	chr8:89609409~89757727:-
THCA	cis	rs42490	0.934	rs43225	ENSG00000251136.7	RP11-37B2.1	-10.27	1.79e-22	1.4e-19	-0.37	-0.43	Leprosy;	chr8:89760776	chr8:89609409~89757727:-
THCA	cis	rs12280210	0.557	rs12284696	ENSG00000254851.1	RP11-109L13.1	10.27	1.8e-22	1.41e-19	0.85	0.43	Lobe attachment (rater-scored or self-reported);	chr11:117008803	chr11:117135528~117138582:+
THCA	cis	rs860295	0.557	rs10796941	ENSG00000225855.5	RUSC1-AS1	10.27	1.8e-22	1.41e-19	0.3	0.43	Body mass index;	chr1:155314470	chr1:155316863~155324176:-
THCA	cis	rs7829975	0.688	rs7837587	ENSG00000253893.2	FAM85B	-10.27	1.8e-22	1.41e-19	-0.56	-0.43	Mood instability;	chr8:8521482	chr8:8167819~8226614:-
THCA	cis	rs7221109	0.71	rs1048572	ENSG00000278834.1	RP11-458J1.1	-10.27	1.8e-22	1.41e-19	-0.45	-0.43	Type 1 diabetes;	chr17:40640990	chr17:40648300~40649718:+
THCA	cis	rs7945705	0.87	rs10840142	ENSG00000254860.4	TMEM9B-AS1	-10.27	1.81e-22	1.42e-19	-0.48	-0.43	Hemoglobin concentration;	chr11:8884531	chr11:8964675~8977527:+
THCA	cis	rs1043099	0.912	rs737950	ENSG00000279699.1	RP1-102K2.9	-10.27	1.82e-22	1.42e-19	-0.61	-0.43	Rheumatoid arthritis;	chr22:30361306	chr22:30275215~30276951:-
THCA	cis	rs7829975	0.688	rs7827182	ENSG00000253893.2	FAM85B	-10.27	1.82e-22	1.43e-19	-0.56	-0.43	Mood instability;	chr8:8522961	chr8:8167819~8226614:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	10.27	1.82e-22	1.43e-19	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	10.27	1.82e-22	1.43e-19	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
THCA	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-10.27	1.84e-22	1.44e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
THCA	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	10.27	1.85e-22	1.45e-19	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
THCA	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	10.27	1.85e-22	1.45e-19	0.47	0.43	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	10.27	1.86e-22	1.45e-19	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	10.27	1.86e-22	1.45e-19	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
THCA	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	10.27	1.86e-22	1.45e-19	0.5	0.43	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	10.27	1.86e-22	1.45e-19	0.5	0.43	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
THCA	cis	rs4718428	0.705	rs62465692	ENSG00000232546.1	RP11-458F8.1	-10.27	1.88e-22	1.46e-19	-0.41	-0.43	Corneal structure;	chr7:66830758	chr7:66848496~66858136:+
THCA	cis	rs4718428	0.662	rs34577323	ENSG00000232546.1	RP11-458F8.1	-10.27	1.88e-22	1.46e-19	-0.41	-0.43	Corneal structure;	chr7:66845054	chr7:66848496~66858136:+
THCA	cis	rs9659323	0.612	rs10923721	ENSG00000231365.4	RP11-418J17.1	-10.27	1.88e-22	1.47e-19	-0.44	-0.43	Body mass index;	chr1:118999564	chr1:119140396~119275973:+
THCA	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	10.27	1.88e-22	1.47e-19	0.52	0.43	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000224205.1	AP000351.4	10.27	1.89e-22	1.47e-19	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23987320~23991421:-
THCA	cis	rs8100891	0.537	rs1001446	ENSG00000267213.4	AC007773.2	-10.27	1.89e-22	1.47e-19	-0.49	-0.43	Neuroticism;	chr19:32410051	chr19:32390050~32405560:-
THCA	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	10.27	1.89e-22	1.48e-19	0.52	0.43	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
THCA	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-10.27	1.89e-22	1.48e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-10.27	1.89e-22	1.48e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-10.27	1.9e-22	1.49e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
THCA	cis	rs3762637	0.941	rs75344200	ENSG00000272758.4	RP11-299J3.8	-10.27	1.91e-22	1.49e-19	-0.56	-0.43	LDL cholesterol levels;	chr3:122354574	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs9289192	ENSG00000272758.4	RP11-299J3.8	-10.27	1.91e-22	1.49e-19	-0.56	-0.43	LDL cholesterol levels;	chr3:122357268	chr3:122416207~122443180:+
THCA	cis	rs11676348	0.935	rs2230054	ENSG00000261338.2	RP11-378A13.1	-10.27	1.91e-22	1.49e-19	-0.43	-0.43	Ulcerative colitis;	chr2:218135587	chr2:218255319~218257366:+
THCA	cis	rs7665090	0.87	rs228614	ENSG00000246560.2	RP11-10L12.4	-10.27	1.91e-22	1.49e-19	-0.53	-0.43	Primary biliary cholangitis;	chr4:102657480	chr4:102828055~102844075:+
THCA	cis	rs1043099	0.912	rs740219	ENSG00000279699.1	RP1-102K2.9	-10.27	1.92e-22	1.5e-19	-0.6	-0.43	Rheumatoid arthritis;	chr22:30318695	chr22:30275215~30276951:-
THCA	cis	rs1043099	0.912	rs5753071	ENSG00000279699.1	RP1-102K2.9	-10.27	1.92e-22	1.5e-19	-0.6	-0.43	Rheumatoid arthritis;	chr22:30330837	chr22:30275215~30276951:-
THCA	cis	rs1043099	0.912	rs10376	ENSG00000279699.1	RP1-102K2.9	-10.27	1.92e-22	1.5e-19	-0.6	-0.43	Rheumatoid arthritis;	chr22:30332367	chr22:30275215~30276951:-
THCA	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	10.27	1.92e-22	1.5e-19	0.53	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
THCA	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	10.27	1.93e-22	1.5e-19	0.35	0.43	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	10.27	1.93e-22	1.5e-19	0.35	0.43	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	10.27	1.93e-22	1.5e-19	0.35	0.43	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	10.27	1.93e-22	1.5e-19	0.35	0.43	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
THCA	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-10.26	1.93e-22	1.51e-19	-0.55	-0.43	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
THCA	cis	rs1799949	1	rs11659028	ENSG00000267681.1	CTD-3199J23.6	-10.26	1.93e-22	1.51e-19	-0.5	-0.43	Menopause (age at onset);	chr17:43043008	chr17:43144956~43145255:+
THCA	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	10.26	1.93e-22	1.51e-19	0.45	0.43	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	10.26	1.93e-22	1.51e-19	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
THCA	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	10.26	1.95e-22	1.52e-19	0.53	0.43	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	10.26	1.95e-22	1.52e-19	0.53	0.43	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	10.26	1.95e-22	1.52e-19	0.53	0.43	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
THCA	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	10.26	1.96e-22	1.53e-19	0.52	0.43	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	10.26	1.96e-22	1.53e-19	0.52	0.43	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000206090.4	AP000350.7	10.26	1.97e-22	1.53e-19	0.52	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23939998~23942798:+
THCA	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	10.26	1.98e-22	1.54e-19	0.47	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
THCA	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-10.26	1.98e-22	1.54e-19	-0.49	-0.43	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-10.26	1.98e-22	1.54e-19	-0.49	-0.43	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
THCA	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-10.26	1.98e-22	1.54e-19	-0.49	-0.43	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
THCA	cis	rs6558530	0.932	rs9022	ENSG00000253982.1	CTD-2336O2.1	10.26	1.98e-22	1.54e-19	0.38	0.43	Systolic blood pressure;	chr8:1762811	chr8:1761990~1764502:-
THCA	cis	rs7772486	0.875	rs2748497	ENSG00000235652.6	RP11-545I5.3	10.26	1.98e-22	1.55e-19	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145998281	chr6:145799409~145886585:+
THCA	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	10.26	1.99e-22	1.55e-19	0.51	0.43	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
THCA	cis	rs42490	1	rs40452	ENSG00000251136.7	RP11-37B2.1	-10.26	2.01e-22	1.57e-19	-0.37	-0.43	Leprosy;	chr8:89765931	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs39503	ENSG00000251136.7	RP11-37B2.1	-10.26	2.01e-22	1.57e-19	-0.37	-0.43	Leprosy;	chr8:89767579	chr8:89609409~89757727:-
THCA	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	10.26	2.02e-22	1.57e-19	0.47	0.43	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-10.26	2.02e-22	1.57e-19	-0.47	-0.43	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
THCA	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	10.26	2.02e-22	1.57e-19	0.5	0.43	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
THCA	cis	rs2599510	0.811	rs176413	ENSG00000276334.1	AL133243.1	-10.26	2.04e-22	1.58e-19	-0.46	-0.43	Interleukin-18 levels;	chr2:32421779	chr2:32521927~32523547:+
THCA	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	10.26	2.04e-22	1.59e-19	0.36	0.43	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	10.26	2.04e-22	1.59e-19	0.36	0.43	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	10.26	2.04e-22	1.59e-19	0.36	0.43	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
THCA	cis	rs2599510	0.811	rs62136345	ENSG00000276334.1	AL133243.1	10.26	2.05e-22	1.6e-19	0.46	0.43	Interleukin-18 levels;	chr2:32582156	chr2:32521927~32523547:+
THCA	cis	rs2599510	0.811	rs2754520	ENSG00000276334.1	AL133243.1	10.26	2.05e-22	1.6e-19	0.46	0.43	Interleukin-18 levels;	chr2:32585226	chr2:32521927~32523547:+
THCA	cis	rs7211079	0.879	rs66693363	ENSG00000279259.1	RP11-334C17.3	10.26	2.06e-22	1.6e-19	0.46	0.43	Myocardial infarction;	chr17:80155136	chr17:80147250~80148596:+
THCA	cis	rs67311347	0.668	rs73071710	ENSG00000223797.4	ENTPD3-AS1	10.26	2.06e-22	1.6e-19	0.36	0.43	Renal cell carcinoma;	chr3:40247096	chr3:40313802~40453329:-
THCA	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-10.26	2.06e-22	1.61e-19	-0.51	-0.43	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
THCA	cis	rs916888	0.61	rs199529	ENSG00000232300.1	FAM215B	10.26	2.06e-22	1.61e-19	0.67	0.43	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46558830~46562795:-
THCA	cis	rs42490	1	rs447618	ENSG00000251136.7	RP11-37B2.1	-10.26	2.08e-22	1.62e-19	-0.37	-0.43	Leprosy;	chr8:89773457	chr8:89609409~89757727:-
THCA	cis	rs71403859	0.73	rs12923781	ENSG00000260886.1	TAT-AS1	10.26	2.08e-22	1.62e-19	0.78	0.43	Post bronchodilator FEV1;	chr16:71619561	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	10.26	2.09e-22	1.63e-19	0.5	0.43	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	10.26	2.09e-22	1.63e-19	0.5	0.43	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
THCA	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	10.26	2.1e-22	1.63e-19	0.51	0.43	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
THCA	cis	rs9322193	0.962	rs9322223	ENSG00000223701.3	RAET1E-AS1	10.25	2.11e-22	1.64e-19	0.56	0.43	Lung cancer;	chr6:149801509	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	10.25	2.11e-22	1.64e-19	0.5	0.43	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
THCA	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-10.25	2.12e-22	1.65e-19	-0.4	-0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
THCA	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	10.25	2.12e-22	1.65e-19	0.5	0.43	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
THCA	cis	rs12188164	0.965	rs11742144	ENSG00000221990.4	EXOC3-AS1	10.25	2.12e-22	1.65e-19	0.37	0.43	Cystic fibrosis severity;	chr5:422063	chr5:441498~443160:-
THCA	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	10.25	2.13e-22	1.65e-19	0.52	0.43	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
THCA	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	10.25	2.13e-22	1.66e-19	0.5	0.43	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
THCA	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-10.25	2.14e-22	1.66e-19	-0.82	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
THCA	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-10.25	2.14e-22	1.67e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
THCA	cis	rs7191700	0.673	rs12325495	ENSG00000262636.1	CTD-3088G3.4	10.25	2.14e-22	1.67e-19	0.52	0.43	Multiple sclerosis;	chr16:11324471	chr16:11380859~11381118:-
THCA	cis	rs9545047	0.704	rs3742120	ENSG00000227676.3	LINC01068	10.25	2.16e-22	1.68e-19	0.52	0.43	Schizophrenia;	chr13:79386700	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs3742122	ENSG00000227676.3	LINC01068	10.25	2.16e-22	1.68e-19	0.52	0.43	Schizophrenia;	chr13:79387061	chr13:79566727~79571436:+
THCA	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	10.25	2.16e-22	1.68e-19	0.67	0.43	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
THCA	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-10.25	2.19e-22	1.7e-19	-0.7	-0.43	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
THCA	cis	rs6142102	0.847	rs4911413	ENSG00000276073.1	RP5-1125A11.7	-10.25	2.2e-22	1.7e-19	-0.4	-0.43	Skin pigmentation;	chr20:34133969	chr20:33985617~33988989:-
THCA	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	10.25	2.2e-22	1.71e-19	0.44	0.43	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
THCA	cis	rs6991838	0.702	rs34496943	ENSG00000272010.1	CTD-3025N20.3	10.25	2.21e-22	1.71e-19	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.733	rs13281090	ENSG00000272010.1	CTD-3025N20.3	10.25	2.21e-22	1.71e-19	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.701	rs17395275	ENSG00000272010.1	CTD-3025N20.3	10.25	2.21e-22	1.71e-19	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65591850~65592472:-
THCA	cis	rs8062405	0.824	rs4788084	ENSG00000251417.2	RP11-1348G14.4	-10.25	2.22e-22	1.72e-19	-0.4	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28802743~28817828:+
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	10.25	2.23e-22	1.73e-19	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
THCA	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-10.25	2.24e-22	1.74e-19	-0.54	-0.43	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
THCA	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-10.25	2.24e-22	1.74e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
THCA	cis	rs42490	0.903	rs218899	ENSG00000251136.7	RP11-37B2.1	-10.25	2.26e-22	1.75e-19	-0.37	-0.43	Leprosy;	chr8:89717279	chr8:89609409~89757727:-
THCA	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-10.25	2.26e-22	1.76e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-10.25	2.26e-22	1.76e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
THCA	cis	rs9309711	0.643	rs4264589	ENSG00000225234.1	TRAPPC12-AS1	-10.25	2.27e-22	1.76e-19	-0.41	-0.43	Neurofibrillary tangles;	chr2:3477327	chr2:3481242~3482409:-
THCA	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	10.25	2.28e-22	1.77e-19	0.62	0.43	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	10.25	2.28e-22	1.77e-19	0.62	0.43	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
THCA	cis	rs860295	0.702	rs12043132	ENSG00000225855.5	RUSC1-AS1	10.24	2.33e-22	1.8e-19	0.3	0.43	Body mass index;	chr1:155592576	chr1:155316863~155324176:-
THCA	cis	rs944289	0.74	rs1742869	ENSG00000257826.1	RP11-116N8.4	10.24	2.33e-22	1.8e-19	0.43	0.43	Thyroid cancer;	chr14:36067601	chr14:36061026~36067190:-
THCA	cis	rs875971	0.564	rs313804	ENSG00000237310.1	GS1-124K5.4	10.24	2.33e-22	1.81e-19	0.32	0.43	Aortic root size;	chr7:66049635	chr7:66493706~66495474:+
THCA	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-10.24	2.34e-22	1.81e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
THCA	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	10.24	2.35e-22	1.82e-19	0.45	0.43	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	10.24	2.35e-22	1.82e-19	0.45	0.43	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
THCA	cis	rs9322193	0.962	rs6903998	ENSG00000223701.3	RAET1E-AS1	10.24	2.36e-22	1.82e-19	0.56	0.43	Lung cancer;	chr6:149831357	chr6:149884431~149919508:+
THCA	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	10.24	2.36e-22	1.83e-19	0.35	0.43	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	10.24	2.37e-22	1.84e-19	0.5	0.43	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
THCA	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-10.24	2.38e-22	1.84e-19	-0.52	-0.43	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
THCA	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	10.24	2.38e-22	1.84e-19	0.5	0.43	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	10.24	2.38e-22	1.84e-19	0.5	0.43	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
THCA	cis	rs1043099	0.912	rs2041199	ENSG00000279699.1	RP1-102K2.9	-10.24	2.38e-22	1.85e-19	-0.61	-0.43	Rheumatoid arthritis;	chr22:30336247	chr22:30275215~30276951:-
THCA	cis	rs9322193	0.923	rs9688452	ENSG00000268592.3	RAET1E-AS1	10.24	2.4e-22	1.86e-19	0.59	0.43	Lung cancer;	chr6:149658764	chr6:149863494~149919507:+
THCA	cis	rs42490	1	rs405734	ENSG00000251136.7	RP11-37B2.1	-10.24	2.4e-22	1.86e-19	-0.37	-0.43	Leprosy;	chr8:89756211	chr8:89609409~89757727:-
THCA	cis	rs6570726	0.935	rs366621	ENSG00000235652.6	RP11-545I5.3	10.24	2.4e-22	1.86e-19	0.38	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145540139	chr6:145799409~145886585:+
THCA	cis	rs1035539	1	rs1035539	ENSG00000280152.1	RP11-331F4.5	10.24	2.4e-22	1.86e-19	0.43	0.43	Alcoholic chronic pancreatitis;	chr16:75242877	chr16:75245994~75250077:-
THCA	cis	rs1043099	1	rs1043099	ENSG00000279699.1	RP1-102K2.9	-10.24	2.4e-22	1.86e-19	-0.59	-0.43	Rheumatoid arthritis;	chr22:30285268	chr22:30275215~30276951:-
THCA	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	10.24	2.42e-22	1.88e-19	0.45	0.43	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
THCA	cis	rs9322193	0.962	rs2342764	ENSG00000268592.3	RAET1E-AS1	10.24	2.43e-22	1.88e-19	0.59	0.43	Lung cancer;	chr6:149835068	chr6:149863494~149919507:+
THCA	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-10.24	2.43e-22	1.88e-19	-0.53	-0.43	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-10.24	2.43e-22	1.88e-19	-0.53	-0.43	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-10.24	2.43e-22	1.88e-19	-0.53	-0.43	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
THCA	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-10.24	2.43e-22	1.88e-19	-0.48	-0.43	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
THCA	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	10.24	2.43e-22	1.88e-19	0.52	0.43	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	10.24	2.43e-22	1.88e-19	0.52	0.43	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
THCA	cis	rs11676348	0.846	rs7594532	ENSG00000261338.2	RP11-378A13.1	-10.24	2.44e-22	1.88e-19	-0.43	-0.43	Ulcerative colitis;	chr2:218143277	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	10.24	2.44e-22	1.89e-19	0.5	0.43	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	10.24	2.45e-22	1.89e-19	0.5	0.43	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	10.24	2.45e-22	1.89e-19	0.5	0.43	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
THCA	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	10.24	2.45e-22	1.9e-19	0.5	0.43	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
THCA	cis	rs9532669	0.926	rs4941995	ENSG00000176268.5	CYCSP34	10.24	2.46e-22	1.9e-19	0.5	0.43	Cervical cancer;	chr13:40850117	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9315789	ENSG00000176268.5	CYCSP34	10.24	2.46e-22	1.9e-19	0.5	0.43	Cervical cancer;	chr13:40852898	chr13:40863599~40863902:-
THCA	cis	rs9926296	0.568	rs417323	ENSG00000260259.1	RP11-368I7.4	10.24	2.48e-22	1.92e-19	0.47	0.43	Vitiligo;	chr16:89679869	chr16:89682620~89686569:-
THCA	cis	rs9322193	0.926	rs3805751	ENSG00000223701.3	RAET1E-AS1	10.23	2.49e-22	1.92e-19	0.57	0.43	Lung cancer;	chr6:149791193	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs10872656	ENSG00000223701.3	RAET1E-AS1	10.23	2.49e-22	1.92e-19	0.57	0.43	Lung cancer;	chr6:149799444	chr6:149884431~149919508:+
THCA	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-10.23	2.49e-22	1.92e-19	-0.5	-0.43	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
THCA	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	10.23	2.49e-22	1.93e-19	0.51	0.43	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
THCA	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-10.23	2.5e-22	1.93e-19	-0.51	-0.43	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
THCA	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-10.23	2.5e-22	1.93e-19	-0.51	-0.43	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
THCA	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-10.23	2.5e-22	1.93e-19	-0.51	-0.43	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000224205.1	AP000351.4	10.23	2.5e-22	1.93e-19	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23987320~23991421:-
THCA	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	10.23	2.51e-22	1.94e-19	0.56	0.43	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	10.23	2.51e-22	1.94e-19	0.56	0.43	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
THCA	cis	rs12554020	0.892	rs7028729	ENSG00000227603.1	RP11-165J3.6	10.23	2.52e-22	1.95e-19	0.58	0.43	Schizophrenia;	chr9:93443206	chr9:93435332~93437121:-
THCA	cis	rs10740039	0.768	rs920646	ENSG00000254271.1	RP11-131N11.4	10.23	2.52e-22	1.95e-19	0.53	0.43	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703767	chr10:60734342~60741828:+
THCA	cis	rs7712401	0.715	rs6862366	ENSG00000263432.2	RN7SL689P	-10.23	2.52e-22	1.95e-19	-0.47	-0.43	Mean platelet volume;	chr5:123024463	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs407392	ENSG00000263432.2	RN7SL689P	-10.23	2.52e-22	1.95e-19	-0.47	-0.43	Mean platelet volume;	chr5:123025299	chr5:123022487~123022783:-
THCA	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	10.23	2.53e-22	1.96e-19	0.5	0.43	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
THCA	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	10.23	2.54e-22	1.96e-19	0.36	0.43	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
THCA	cis	rs780096	0.526	rs2010087	ENSG00000234072.1	AC074117.10	-10.23	2.56e-22	1.98e-19	-0.34	-0.43	Total body bone mineral density;	chr2:27414368	chr2:27356246~27367622:+
THCA	cis	rs7712401	0.715	rs15577	ENSG00000263432.2	RN7SL689P	-10.23	2.57e-22	1.98e-19	-0.47	-0.43	Mean platelet volume;	chr5:123023495	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs451195	ENSG00000263432.2	RN7SL689P	-10.23	2.57e-22	1.98e-19	-0.47	-0.43	Mean platelet volume;	chr5:123023945	chr5:123022487~123022783:-
THCA	cis	rs4713118	0.662	rs149900	ENSG00000280107.1	AL022393.9	-10.23	2.57e-22	1.98e-19	-0.49	-0.43	Parkinson's disease;	chr6:28046819	chr6:28170845~28172521:+
THCA	cis	rs9532669	0.89	rs7333274	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40862531	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs2324737	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40862808	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4942003	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40863270	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs4942004	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40863598	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs9315791	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40863931	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.824	rs9315792	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40863951	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.684	rs7139788	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40864264	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7338617	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40870787	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.857	rs6560961	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40870878	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs6560962	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40870948	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs1055588	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40871306	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs3610	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40871334	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4942005	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40871636	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4942006	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40871862	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4942008	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40871989	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs2039118	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40872260	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4356347	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40872516	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7982346	ENSG00000239827.7	SUGT1P3	-10.23	2.57e-22	1.98e-19	-0.48	-0.43	Cervical cancer;	chr13:40873273	chr13:40908159~40921774:-
THCA	cis	rs9903692	0.954	rs9899461	ENSG00000278765.1	RP5-890E16.5	-10.23	2.58e-22	1.99e-19	-0.57	-0.43	Pulse pressure;	chr17:48051991	chr17:48066704~48067293:-
THCA	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	10.23	2.58e-22	1.99e-19	0.47	0.43	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
THCA	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	10.23	2.59e-22	2e-19	0.62	0.43	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-10.23	2.59e-22	2e-19	-0.62	-0.43	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-10.23	2.59e-22	2e-19	-0.62	-0.43	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
THCA	cis	rs66887589	0.592	rs11731571	ENSG00000245958.5	RP11-33B1.1	-10.23	2.6e-22	2.01e-19	-0.39	-0.43	Diastolic blood pressure;	chr4:119300030	chr4:119454791~119552025:+
THCA	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	10.23	2.62e-22	2.02e-19	0.52	0.43	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
THCA	cis	rs4927850	0.666	rs4927853	ENSG00000231464.1	AC024937.4	10.23	2.62e-22	2.02e-19	0.59	0.43	Pancreatic cancer;	chr3:196025182	chr3:195996738~195998233:+
THCA	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	10.23	2.62e-22	2.02e-19	0.46	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
THCA	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	10.23	2.62e-22	2.02e-19	0.46	0.43	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
THCA	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	10.23	2.65e-22	2.05e-19	0.67	0.43	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	10.23	2.66e-22	2.05e-19	0.54	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
THCA	cis	rs42490	0.837	rs218916	ENSG00000251136.7	RP11-37B2.1	-10.23	2.67e-22	2.06e-19	-0.37	-0.43	Leprosy;	chr8:89688709	chr8:89609409~89757727:-
THCA	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-10.23	2.68e-22	2.06e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
THCA	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-10.23	2.7e-22	2.08e-19	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
THCA	cis	rs8062405	0.824	rs28698667	ENSG00000251417.2	RP11-1348G14.4	-10.23	2.7e-22	2.08e-19	-0.4	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28802743~28817828:+
THCA	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	10.23	2.7e-22	2.08e-19	0.36	0.43	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
THCA	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-10.23	2.7e-22	2.08e-19	-0.51	-0.43	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
THCA	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-10.23	2.7e-22	2.08e-19	-0.51	-0.43	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
THCA	cis	rs2946504	0.705	rs1879487	ENSG00000251468.2	RP11-369K16.1	-10.23	2.7e-22	2.08e-19	-0.49	-0.43	Type 2 diabetes;	chr8:12947413	chr8:12958387~12962200:+
THCA	cis	rs9545047	0.716	rs9530920	ENSG00000227676.3	LINC01068	10.22	2.71e-22	2.09e-19	0.52	0.43	Schizophrenia;	chr13:79423254	chr13:79566727~79571436:+
THCA	cis	rs1043099	0.871	rs2108093	ENSG00000279699.1	RP1-102K2.9	-10.22	2.72e-22	2.1e-19	-0.59	-0.43	Rheumatoid arthritis;	chr22:30283398	chr22:30275215~30276951:-
THCA	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	10.22	2.73e-22	2.1e-19	0.5	0.43	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
THCA	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	10.22	2.74e-22	2.11e-19	0.56	0.43	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
THCA	cis	rs9532669	0.889	rs6560964	ENSG00000239827.7	SUGT1P3	-10.22	2.74e-22	2.11e-19	-0.47	-0.43	Cervical cancer;	chr13:40871132	chr13:40908159~40921774:-
THCA	cis	rs8072100	0.676	rs7221345	ENSG00000228782.6	CTD-2026D20.3	10.22	2.75e-22	2.12e-19	0.4	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47327778	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.676	rs9905308	ENSG00000228782.6	CTD-2026D20.3	10.22	2.75e-22	2.12e-19	0.4	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47332020	chr17:47450568~47492492:-
THCA	cis	rs6496932	0.635	rs11632761	ENSG00000218052.5	ADAMTS7P4	-10.22	2.76e-22	2.13e-19	-0.56	-0.43	Central corneal thickness;Corneal structure;	chr15:85387562	chr15:85255369~85330334:-
THCA	cis	rs6496932	0.635	rs67659163	ENSG00000218052.5	ADAMTS7P4	-10.22	2.76e-22	2.13e-19	-0.56	-0.43	Central corneal thickness;Corneal structure;	chr15:85387673	chr15:85255369~85330334:-
THCA	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-10.22	2.79e-22	2.15e-19	-0.41	-0.43	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
THCA	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-10.22	2.79e-22	2.15e-19	-0.41	-0.43	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
THCA	cis	rs6570726	0.967	rs413880	ENSG00000235652.6	RP11-545I5.3	10.22	2.79e-22	2.15e-19	0.39	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145483686	chr6:145799409~145886585:+
THCA	cis	rs7829975	0.688	rs6601703	ENSG00000253893.2	FAM85B	-10.22	2.79e-22	2.15e-19	-0.55	-0.43	Mood instability;	chr8:8522714	chr8:8167819~8226614:-
THCA	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-10.22	2.79e-22	2.15e-19	-0.57	-0.43	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
THCA	cis	rs10463554	0.963	rs10463555	ENSG00000175749.11	EIF3KP1	10.22	2.83e-22	2.18e-19	0.56	0.43	Parkinson's disease;	chr5:102983333	chr5:103032376~103033031:+
THCA	cis	rs673078	0.607	rs2036489	ENSG00000275409.1	RP11-131L12.4	-10.22	2.86e-22	2.2e-19	-0.43	-0.43	Glucose homeostasis traits;	chr12:118364643	chr12:118430147~118430699:+
THCA	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	10.22	2.88e-22	2.21e-19	0.45	0.43	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
THCA	cis	rs6558530	0.931	rs4639549	ENSG00000253982.1	CTD-2336O2.1	10.22	2.88e-22	2.22e-19	0.37	0.43	Systolic blood pressure;	chr8:1759878	chr8:1761990~1764502:-
THCA	cis	rs367615	0.513	rs11741087	ENSG00000249476.1	CTD-2587M2.1	10.22	2.9e-22	2.23e-19	0.45	0.43	Colorectal cancer (SNP x SNP interaction);	chr5:109472059	chr5:109237120~109326369:-
THCA	cis	rs4713118	0.662	rs149961	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28047791	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9357060	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28056708	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9468271	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28056792	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9380045	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28057501	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.616	rs9348789	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28057708	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9468274	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28058299	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9468275	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28058358	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9468276	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28059910	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9468277	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28060612	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs9468278	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28060704	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs13218430	ENSG00000280107.1	AL022393.9	-10.22	2.93e-22	2.25e-19	-0.49	-0.43	Parkinson's disease;	chr6:28062059	chr6:28170845~28172521:+
THCA	cis	rs9322193	0.923	rs12174035	ENSG00000223701.3	RAET1E-AS1	10.22	2.94e-22	2.26e-19	0.57	0.43	Lung cancer;	chr6:149763311	chr6:149884431~149919508:+
THCA	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	10.21	2.95e-22	2.27e-19	0.67	0.43	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	10.21	2.95e-22	2.27e-19	0.67	0.43	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	10.21	2.96e-22	2.27e-19	0.53	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
THCA	cis	rs673078	0.607	rs10082823	ENSG00000275409.1	RP11-131L12.4	-10.21	2.96e-22	2.27e-19	-0.43	-0.43	Glucose homeostasis traits;	chr12:118365386	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs2062519	ENSG00000275409.1	RP11-131L12.4	-10.21	2.96e-22	2.27e-19	-0.43	-0.43	Glucose homeostasis traits;	chr12:118367577	chr12:118430147~118430699:+
THCA	cis	rs7429990	0.52	rs78838427	ENSG00000229759.1	MRPS18AP1	-10.21	2.96e-22	2.28e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47595561	chr3:48256350~48256938:-
THCA	cis	rs9532669	0.929	rs9532601	ENSG00000176268.5	CYCSP34	10.21	2.98e-22	2.28e-19	0.51	0.43	Cervical cancer;	chr13:40861086	chr13:40863599~40863902:-
THCA	cis	rs860295	0.58	rs6672284	ENSG00000225855.5	RUSC1-AS1	10.21	2.99e-22	2.3e-19	0.29	0.43	Body mass index;	chr1:155308172	chr1:155316863~155324176:-
THCA	cis	rs4964805	0.913	rs3812803	ENSG00000257681.1	RP11-341G23.4	10.21	2.99e-22	2.3e-19	0.51	0.43	Attention deficit hyperactivity disorder;	chr12:103806682	chr12:103746315~103768858:-
THCA	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	10.21	2.99e-22	2.3e-19	0.5	0.43	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
THCA	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	10.21	2.99e-22	2.3e-19	0.52	0.43	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
THCA	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-10.21	3e-22	2.31e-19	-0.65	-0.43	Depression;	chr6:28103220	chr6:28115628~28116551:+
THCA	cis	rs944289	0.708	rs34613409	ENSG00000257826.1	RP11-116N8.4	-10.21	3.01e-22	2.31e-19	-0.44	-0.43	Thyroid cancer;	chr14:36096489	chr14:36061026~36067190:-
THCA	cis	rs944289	0.774	rs2415312	ENSG00000257826.1	RP11-116N8.4	-10.21	3.01e-22	2.31e-19	-0.44	-0.43	Thyroid cancer;	chr14:36097145	chr14:36061026~36067190:-
THCA	cis	rs860295	0.702	rs1556488	ENSG00000225855.5	RUSC1-AS1	10.21	3.01e-22	2.31e-19	0.3	0.43	Body mass index;	chr1:155570869	chr1:155316863~155324176:-
THCA	cis	rs4591358	0.689	rs72927794	ENSG00000223466.1	AC064834.2	-10.21	3.01e-22	2.31e-19	-0.61	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195558607	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.689	rs2102745	ENSG00000223466.1	AC064834.2	-10.21	3.01e-22	2.31e-19	-0.61	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559315	chr2:195533035~195538681:+
THCA	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	10.21	3.01e-22	2.31e-19	0.51	0.43	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
THCA	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	10.21	3.02e-22	2.32e-19	0.52	0.43	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	10.21	3.02e-22	2.32e-19	0.52	0.43	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	10.21	3.02e-22	2.32e-19	0.52	0.43	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
THCA	cis	rs524281	1	rs524281	ENSG00000255320.1	RP11-755F10.1	-10.21	3.03e-22	2.33e-19	-0.58	-0.43	Electroencephalogram traits;	chr11:66119191	chr11:66244840~66246239:-
THCA	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	10.21	3.04e-22	2.33e-19	0.5	0.43	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
THCA	cis	rs6570726	0.967	rs403584	ENSG00000235652.6	RP11-545I5.3	10.21	3.07e-22	2.35e-19	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145485874	chr6:145799409~145886585:+
THCA	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-10.21	3.07e-22	2.36e-19	-0.41	-0.43	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
THCA	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-10.21	3.07e-22	2.36e-19	-0.49	-0.43	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
THCA	cis	rs860295	0.702	rs11264380	ENSG00000225855.5	RUSC1-AS1	10.21	3.11e-22	2.38e-19	0.3	0.43	Body mass index;	chr1:155550353	chr1:155316863~155324176:-
THCA	cis	rs9545047	0.716	rs943710	ENSG00000227676.3	LINC01068	10.21	3.12e-22	2.39e-19	0.52	0.43	Schizophrenia;	chr13:79282987	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-10.21	3.13e-22	2.4e-19	-0.52	-0.43	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-10.21	3.13e-22	2.4e-19	-0.52	-0.43	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-10.21	3.13e-22	2.4e-19	-0.52	-0.43	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	10.21	3.13e-22	2.4e-19	0.52	0.43	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	10.21	3.13e-22	2.4e-19	0.52	0.43	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	10.21	3.13e-22	2.4e-19	0.52	0.43	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
THCA	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-10.21	3.13e-22	2.4e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-10.21	3.13e-22	2.4e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
THCA	cis	rs860295	0.702	rs10908479	ENSG00000225855.5	RUSC1-AS1	10.21	3.14e-22	2.4e-19	0.3	0.43	Body mass index;	chr1:155673612	chr1:155316863~155324176:-
THCA	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	10.21	3.14e-22	2.41e-19	0.53	0.43	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
THCA	cis	rs9487094	0.689	rs9480936	ENSG00000260273.1	RP11-425D10.10	10.21	3.15e-22	2.42e-19	0.51	0.43	Height;	chr6:109358227	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.923	rs57938011	ENSG00000268592.3	RAET1E-AS1	10.21	3.16e-22	2.42e-19	0.59	0.43	Lung cancer;	chr6:149642969	chr6:149863494~149919507:+
THCA	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-10.21	3.16e-22	2.42e-19	-0.44	-0.43	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
THCA	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-10.21	3.18e-22	2.44e-19	-0.51	-0.43	Migraine;	chr4:56853383	chr4:56960927~56961373:-
THCA	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	10.21	3.2e-22	2.45e-19	0.5	0.43	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
THCA	cis	rs7829975	0.688	rs7817376	ENSG00000253893.2	FAM85B	10.21	3.2e-22	2.45e-19	0.55	0.43	Mood instability;	chr8:8523020	chr8:8167819~8226614:-
THCA	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	10.21	3.2e-22	2.45e-19	0.47	0.43	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
THCA	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	10.2	3.21e-22	2.46e-19	0.52	0.43	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	10.2	3.21e-22	2.46e-19	0.52	0.43	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
THCA	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	10.2	3.21e-22	2.46e-19	0.51	0.43	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
THCA	cis	rs9318086	0.712	rs9510916	ENSG00000205861.10	C1QTNF9B-AS1	-10.2	3.21e-22	2.46e-19	-0.48	-0.43	Myopia (pathological);	chr13:23868650	chr13:23888889~23897263:+
THCA	cis	rs8062405	0.824	rs62034319	ENSG00000251417.2	RP11-1348G14.4	-10.2	3.23e-22	2.48e-19	-0.4	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28802743~28817828:+
THCA	cis	rs4774565	0.8	rs34174311	ENSG00000244879.4	GABPB1-AS1	-10.2	3.26e-22	2.49e-19	-0.38	-0.43	Breast cancer;	chr15:50381084	chr15:50354959~50372202:+
THCA	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	10.2	3.26e-22	2.49e-19	0.51	0.43	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
THCA	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-10.2	3.26e-22	2.49e-19	-0.54	-0.43	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
THCA	cis	rs9890032	0.967	rs7342976	ENSG00000266490.1	CTD-2349P21.9	10.2	3.29e-22	2.51e-19	0.41	0.43	Hip circumference adjusted for BMI;	chr17:30863001	chr17:30792372~30792833:+
THCA	cis	rs9890032	1	rs28539246	ENSG00000266490.1	CTD-2349P21.9	10.2	3.29e-22	2.51e-19	0.41	0.43	Hip circumference adjusted for BMI;	chr17:30899612	chr17:30792372~30792833:+
THCA	cis	rs9890032	0.967	rs9897628	ENSG00000266490.1	CTD-2349P21.9	10.2	3.29e-22	2.51e-19	0.41	0.43	Hip circumference adjusted for BMI;	chr17:30899634	chr17:30792372~30792833:+
THCA	cis	rs2948294	0.524	rs13270062	ENSG00000253893.2	FAM85B	-10.2	3.3e-22	2.52e-19	-0.55	-0.43	Red cell distribution width;	chr8:8255128	chr8:8167819~8226614:-
THCA	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-10.2	3.3e-22	2.52e-19	-0.5	-0.43	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
THCA	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-10.2	3.3e-22	2.52e-19	-0.51	-0.43	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
THCA	cis	rs8072100	0.934	rs6504872	ENSG00000228782.6	CTD-2026D20.3	10.2	3.3e-22	2.53e-19	0.39	0.43	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47361586	chr17:47450568~47492492:-
THCA	cis	rs780096	0.587	rs4665969	ENSG00000234072.1	AC074117.10	10.2	3.32e-22	2.54e-19	0.33	0.43	Total body bone mineral density;	chr2:27352086	chr2:27356246~27367622:+
THCA	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	10.2	3.32e-22	2.54e-19	0.54	0.43	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
THCA	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	10.2	3.32e-22	2.54e-19	0.54	0.43	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
THCA	cis	rs860295	0.665	rs12079134	ENSG00000225855.5	RUSC1-AS1	10.2	3.33e-22	2.55e-19	0.3	0.43	Body mass index;	chr1:155496993	chr1:155316863~155324176:-
THCA	cis	rs4713118	0.629	rs203890	ENSG00000280107.1	AL022393.9	-10.2	3.34e-22	2.55e-19	-0.5	-0.43	Parkinson's disease;	chr6:28054470	chr6:28170845~28172521:+
THCA	cis	rs42490	1	rs43134	ENSG00000251136.7	RP11-37B2.1	10.2	3.36e-22	2.57e-19	0.37	0.43	Leprosy;	chr8:89775732	chr8:89609409~89757727:-
THCA	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-10.2	3.39e-22	2.59e-19	-0.42	-0.43	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
THCA	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-10.2	3.39e-22	2.59e-19	-0.42	-0.43	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
THCA	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	10.2	3.39e-22	2.59e-19	0.61	0.43	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-10.2	3.41e-22	2.61e-19	-0.53	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
THCA	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	10.2	3.41e-22	2.61e-19	0.45	0.43	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
THCA	cis	rs6991838	0.701	rs7829434	ENSG00000272010.1	CTD-3025N20.3	10.2	3.42e-22	2.61e-19	0.43	0.43	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65591850~65592472:-
THCA	cis	rs10246939	0.543	rs10952509	ENSG00000228775.6	WEE2-AS1	10.2	3.42e-22	2.61e-19	0.51	0.43	Bitter taste perception;	chr7:141890884	chr7:141704338~141738346:-
THCA	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	10.2	3.42e-22	2.61e-19	0.45	0.43	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
THCA	cis	rs7429990	0.803	rs13319205	ENSG00000229759.1	MRPS18AP1	10.2	3.43e-22	2.62e-19	0.54	0.43	Educational attainment (years of education);	chr3:47758726	chr3:48256350~48256938:-
THCA	cis	rs6570726	0.935	rs453609	ENSG00000235652.6	RP11-545I5.3	10.2	3.43e-22	2.62e-19	0.4	0.43	Lobe attachment (rater-scored or self-reported);	chr6:145491196	chr6:145799409~145886585:+
THCA	cis	rs66887589	0.616	rs10032299	ENSG00000245958.5	RP11-33B1.1	-10.2	3.45e-22	2.63e-19	-0.39	-0.43	Diastolic blood pressure;	chr4:119285264	chr4:119454791~119552025:+
THCA	cis	rs9532669	0.926	rs2324747	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40988883	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs2324748	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40989452	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4245311	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40990003	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9525439	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40992645	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs35073784	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40993428	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs9594473	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40997997	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs1543589	ENSG00000176268.5	CYCSP34	10.2	3.45e-22	2.64e-19	0.48	0.43	Cervical cancer;	chr13:40999064	chr13:40863599~40863902:-
THCA	cis	rs673078	0.66	rs6490175	ENSG00000275409.1	RP11-131L12.4	-10.2	3.45e-22	2.64e-19	-0.45	-0.43	Glucose homeostasis traits;	chr12:118293559	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	10.2	3.47e-22	2.65e-19	0.51	0.43	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
THCA	cis	rs860295	0.702	rs4971095	ENSG00000225855.5	RUSC1-AS1	-10.2	3.48e-22	2.65e-19	-0.3	-0.43	Body mass index;	chr1:155636433	chr1:155316863~155324176:-
THCA	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	10.19	3.49e-22	2.66e-19	0.48	0.43	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
THCA	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	10.19	3.51e-22	2.68e-19	0.51	0.43	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
THCA	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-10.19	3.52e-22	2.68e-19	-0.62	-0.43	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
THCA	cis	rs3745672	1	rs111259072	ENSG00000219665.7	CTD-2006C1.2	-10.19	3.52e-22	2.68e-19	-0.93	-0.43	Multiple sclerosis;	chr19:12045754	chr19:11987617~12046275:+
THCA	cis	rs3745672	0.661	rs112152876	ENSG00000219665.7	CTD-2006C1.2	-10.19	3.52e-22	2.68e-19	-0.93	-0.43	Multiple sclerosis;	chr19:12045864	chr19:11987617~12046275:+
THCA	cis	rs3745672	1	rs10417006	ENSG00000219665.7	CTD-2006C1.2	-10.19	3.52e-22	2.68e-19	-0.93	-0.43	Multiple sclerosis;	chr19:12046438	chr19:11987617~12046275:+
THCA	cis	rs3745672	1	rs7255420	ENSG00000219665.7	CTD-2006C1.2	-10.19	3.52e-22	2.68e-19	-0.93	-0.43	Multiple sclerosis;	chr19:12047024	chr19:11987617~12046275:+
THCA	cis	rs9322193	0.923	rs2184370	ENSG00000268592.3	RAET1E-AS1	10.19	3.52e-22	2.69e-19	0.59	0.43	Lung cancer;	chr6:149843242	chr6:149863494~149919507:+
THCA	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	10.19	3.53e-22	2.7e-19	0.64	0.43	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	10.19	3.53e-22	2.7e-19	0.64	0.43	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
THCA	cis	rs2599510	0.693	rs2754514	ENSG00000276334.1	AL133243.1	10.19	3.54e-22	2.7e-19	0.45	0.43	Interleukin-18 levels;	chr2:32563769	chr2:32521927~32523547:+
THCA	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-10.19	3.54e-22	2.7e-19	-0.62	-0.43	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
THCA	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	10.19	3.55e-22	2.71e-19	0.52	0.43	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
THCA	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-10.19	3.55e-22	2.71e-19	-0.35	-0.43	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
THCA	cis	rs6142102	1	rs12480839	ENSG00000276073.1	RP5-1125A11.7	-10.19	3.55e-22	2.71e-19	-0.4	-0.43	Skin pigmentation;	chr20:34139624	chr20:33985617~33988989:-
THCA	cis	rs6142102	1	rs4911409	ENSG00000276073.1	RP5-1125A11.7	-10.19	3.55e-22	2.71e-19	-0.39	-0.43	Skin pigmentation;	chr20:34122904	chr20:33985617~33988989:-
THCA	cis	rs7826238	0.564	rs2921053	ENSG00000254153.1	CTA-398F10.2	-10.19	3.56e-22	2.71e-19	-0.46	-0.43	Systolic blood pressure;	chr8:8462453	chr8:8456909~8461337:-
THCA	cis	rs673078	0.66	rs9943819	ENSG00000275409.1	RP11-131L12.4	-10.19	3.56e-22	2.71e-19	-0.45	-0.43	Glucose homeostasis traits;	chr12:118298917	chr12:118430147~118430699:+
THCA	cis	rs8062405	0.754	rs62034323	ENSG00000251417.2	RP11-1348G14.4	-10.19	3.58e-22	2.73e-19	-0.39	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.824	rs62034324	ENSG00000251417.2	RP11-1348G14.4	-10.19	3.58e-22	2.73e-19	-0.39	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.824	rs62034326	ENSG00000251417.2	RP11-1348G14.4	-10.19	3.58e-22	2.73e-19	-0.39	-0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28802743~28817828:+
THCA	cis	rs748404	0.578	rs478028	ENSG00000249839.1	AC011330.5	-10.19	3.61e-22	2.75e-19	-0.5	-0.43	Lung cancer;	chr15:43318574	chr15:43663654~43684339:-
THCA	cis	rs748404	0.578	rs552701	ENSG00000249839.1	AC011330.5	-10.19	3.61e-22	2.75e-19	-0.5	-0.43	Lung cancer;	chr15:43321612	chr15:43663654~43684339:-
THCA	cis	rs748404	0.578	rs573615	ENSG00000249839.1	AC011330.5	-10.19	3.61e-22	2.75e-19	-0.5	-0.43	Lung cancer;	chr15:43322083	chr15:43663654~43684339:-
THCA	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	10.19	3.61e-22	2.75e-19	0.47	0.43	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	10.19	3.61e-22	2.75e-19	0.47	0.43	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	10.19	3.61e-22	2.75e-19	0.47	0.43	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	10.19	3.61e-22	2.75e-19	0.47	0.43	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
THCA	cis	rs6504950	0.886	rs12449538	ENSG00000275710.1	RP11-257O5.4	-10.19	3.61e-22	2.75e-19	-0.52	-0.43	Breast cancer;	chr17:55033760	chr17:54964474~54964679:+
THCA	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	10.19	3.62e-22	2.76e-19	0.4	0.43	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000228039.3	KB-1125A3.10	10.19	3.67e-22	2.79e-19	0.52	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23963780~23964374:+
THCA	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-10.19	3.67e-22	2.8e-19	-0.48	-0.43	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
THCA	cis	rs7772486	0.641	rs67882056	ENSG00000235652.6	RP11-545I5.3	10.19	3.71e-22	2.83e-19	0.42	0.43	Lobe attachment (rater-scored or self-reported);	chr6:146095165	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.962	rs9397022	ENSG00000223701.3	RAET1E-AS1	10.19	3.72e-22	2.83e-19	0.56	0.43	Lung cancer;	chr6:149812052	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.962	rs9397357	ENSG00000223701.3	RAET1E-AS1	10.19	3.72e-22	2.83e-19	0.56	0.43	Lung cancer;	chr6:149812465	chr6:149884431~149919508:+
THCA	cis	rs12468226	0.689	rs17651413	ENSG00000273456.1	RP11-686O6.2	10.19	3.73e-22	2.84e-19	0.54	0.43	Urate levels;	chr2:202104086	chr2:202374932~202375604:-
THCA	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	10.19	3.75e-22	2.85e-19	0.5	0.43	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
THCA	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	10.19	3.75e-22	2.86e-19	0.45	0.43	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
THCA	cis	rs7665090	0.806	rs434644	ENSG00000246560.2	RP11-10L12.4	-10.19	3.77e-22	2.87e-19	-0.53	-0.43	Primary biliary cholangitis;	chr4:102662032	chr4:102828055~102844075:+
THCA	cis	rs780096	0.526	rs12476704	ENSG00000234072.1	AC074117.10	-10.19	3.77e-22	2.87e-19	-0.34	-0.43	Total body bone mineral density;	chr2:27390164	chr2:27356246~27367622:+
THCA	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	10.19	3.78e-22	2.87e-19	0.35	0.43	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
THCA	cis	rs6142102	1	rs4911410	ENSG00000276073.1	RP5-1125A11.7	-10.19	3.79e-22	2.88e-19	-0.39	-0.43	Skin pigmentation;	chr20:34123168	chr20:33985617~33988989:-
THCA	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	10.19	3.79e-22	2.89e-19	0.51	0.43	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
THCA	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-10.18	3.8e-22	2.9e-19	-0.51	-0.43	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
THCA	cis	rs42490	0.903	rs218902	ENSG00000251136.7	RP11-37B2.1	10.18	3.81e-22	2.9e-19	0.37	0.43	Leprosy;	chr8:89719986	chr8:89609409~89757727:-
THCA	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	10.18	3.82e-22	2.9e-19	0.61	0.43	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
THCA	cis	rs9322193	0.81	rs62439811	ENSG00000268592.3	RAET1E-AS1	10.18	3.83e-22	2.91e-19	0.59	0.43	Lung cancer;	chr6:149640416	chr6:149863494~149919507:+
THCA	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-10.18	3.85e-22	2.93e-19	-0.5	-0.43	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
THCA	cis	rs8062405	0.688	rs3924376	ENSG00000251417.2	RP11-1348G14.4	10.18	3.85e-22	2.93e-19	0.43	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28802743~28817828:+
THCA	cis	rs12468226	0.606	rs10445793	ENSG00000273456.1	RP11-686O6.2	10.18	3.85e-22	2.93e-19	0.47	0.43	Urate levels;	chr2:202190799	chr2:202374932~202375604:-
THCA	cis	rs67311347	0.544	rs7644181	ENSG00000223797.4	ENTPD3-AS1	-10.18	3.86e-22	2.94e-19	-0.34	-0.43	Renal cell carcinoma;	chr3:40314174	chr3:40313802~40453329:-
THCA	cis	rs180730	0.561	rs3115313	ENSG00000251609.2	SETP12	-10.18	3.87e-22	2.95e-19	-0.59	-0.43	Fasting plasma glucose;	chr4:120887708	chr4:120895494~120897083:-
THCA	cis	rs9890032	1	rs9890032	ENSG00000266490.1	CTD-2349P21.9	-10.18	3.89e-22	2.96e-19	-0.4	-0.43	Hip circumference adjusted for BMI;	chr17:30838916	chr17:30792372~30792833:+
THCA	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-10.18	3.9e-22	2.96e-19	-0.49	-0.43	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000235689.1	AP000351.13	10.18	3.9e-22	2.97e-19	0.52	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:24006305~24008258:-
THCA	cis	rs11148252	0.716	rs3803262	ENSG00000278238.1	RP11-245D16.4	-10.18	3.9e-22	2.97e-19	-0.48	-0.43	Lewy body disease;	chr13:52462263	chr13:52454775~52455331:-
THCA	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	10.18	3.91e-22	2.98e-19	0.5	0.43	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
THCA	cis	rs780096	0.526	rs75855890	ENSG00000234072.1	AC074117.10	-10.18	3.91e-22	2.98e-19	-0.34	-0.43	Total body bone mineral density;	chr2:27402138	chr2:27356246~27367622:+
THCA	cis	rs748404	0.578	rs507178	ENSG00000249839.1	AC011330.5	-10.18	3.92e-22	2.98e-19	-0.5	-0.43	Lung cancer;	chr15:43317937	chr15:43663654~43684339:-
THCA	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	10.18	3.92e-22	2.98e-19	0.5	0.43	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	10.18	3.92e-22	2.98e-19	0.5	0.43	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
THCA	cis	rs6558530	0.932	rs4370560	ENSG00000253982.1	CTD-2336O2.1	10.18	3.93e-22	2.99e-19	0.37	0.43	Systolic blood pressure;	chr8:1760028	chr8:1761990~1764502:-
THCA	cis	rs10885396	1	rs10885396	ENSG00000233547.1	RP11-57H14.2	-10.18	3.94e-22	3e-19	-0.39	-0.43	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112951996	chr10:112950646~112951875:-
THCA	cis	rs10885396	0.967	rs7094871	ENSG00000233547.1	RP11-57H14.2	-10.18	3.94e-22	3e-19	-0.39	-0.43	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952395	chr10:112950646~112951875:-
THCA	cis	rs9659323	0.804	rs10923722	ENSG00000231365.4	RP11-418J17.1	-10.18	3.94e-22	3e-19	-0.44	-0.43	Body mass index;	chr1:119000863	chr1:119140396~119275973:+
THCA	cis	rs9659323	0.745	rs10923723	ENSG00000231365.4	RP11-418J17.1	-10.18	3.94e-22	3e-19	-0.44	-0.43	Body mass index;	chr1:119001379	chr1:119140396~119275973:+
THCA	cis	rs9322193	0.923	rs9800686	ENSG00000268592.3	RAET1E-AS1	10.18	3.96e-22	3.01e-19	0.59	0.43	Lung cancer;	chr6:149634464	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs3763162	ENSG00000223701.3	RAET1E-AS1	-10.18	3.96e-22	3.01e-19	-0.56	-0.43	Lung cancer;	chr6:149819674	chr6:149884431~149919508:+
THCA	cis	rs9532669	0.926	rs7328139	ENSG00000239827.7	SUGT1P3	-10.18	3.97e-22	3.01e-19	-0.47	-0.43	Cervical cancer;	chr13:40862295	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7328145	ENSG00000239827.7	SUGT1P3	-10.18	3.97e-22	3.01e-19	-0.47	-0.43	Cervical cancer;	chr13:40862307	chr13:40908159~40921774:-
THCA	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-10.18	3.99e-22	3.03e-19	-0.45	-0.43	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
THCA	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-10.18	3.99e-22	3.03e-19	-0.62	-0.43	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-10.18	3.99e-22	3.03e-19	-0.62	-0.43	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
THCA	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-10.18	3.99e-22	3.03e-19	-0.5	-0.43	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
THCA	cis	rs11907546	1	rs11907546	ENSG00000276073.1	RP5-1125A11.7	-10.18	3.99e-22	3.03e-19	-0.39	-0.43	Cancer (pleiotropy);Cancer;	chr20:34131991	chr20:33985617~33988989:-
THCA	cis	rs6538678	0.712	rs10777748	ENSG00000258343.1	RP11-536G4.2	-10.18	4.03e-22	3.06e-19	-0.59	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95880227	chr12:95795345~95858839:-
THCA	cis	rs9532669	0.926	rs9532671	ENSG00000176268.5	CYCSP34	10.18	4.07e-22	3.09e-19	0.48	0.42	Cervical cancer;	chr13:40927761	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.833	rs9532672	ENSG00000176268.5	CYCSP34	10.18	4.07e-22	3.09e-19	0.48	0.42	Cervical cancer;	chr13:40928285	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs7324625	ENSG00000176268.5	CYCSP34	10.18	4.07e-22	3.09e-19	0.48	0.42	Cervical cancer;	chr13:40928606	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4454835	ENSG00000176268.5	CYCSP34	10.18	4.07e-22	3.09e-19	0.48	0.42	Cervical cancer;	chr13:40928978	chr13:40863599~40863902:-
THCA	cis	rs6570726	0.935	rs906774	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145492634	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs366308	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145493396	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs384806	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145493753	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs385185	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145493856	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs384453	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145494009	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs372378	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145495091	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.905	rs388728	ENSG00000235652.6	RP11-545I5.3	10.18	4.07e-22	3.09e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145495283	chr6:145799409~145886585:+
THCA	cis	rs9532669	0.926	rs9525438	ENSG00000176268.5	CYCSP34	10.18	4.08e-22	3.09e-19	0.47	0.42	Cervical cancer;	chr13:40964123	chr13:40863599~40863902:-
THCA	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	10.18	4.11e-22	3.12e-19	0.53	0.42	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
THCA	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	10.18	4.11e-22	3.12e-19	0.51	0.42	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	10.18	4.11e-22	3.12e-19	0.51	0.42	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
THCA	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-10.17	4.15e-22	3.15e-19	-0.45	-0.42	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
THCA	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-10.17	4.15e-22	3.15e-19	-0.35	-0.42	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	10.17	4.17e-22	3.16e-19	0.36	0.42	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
THCA	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	10.17	4.17e-22	3.17e-19	0.45	0.42	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	10.17	4.17e-22	3.17e-19	0.45	0.42	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
THCA	cis	rs932287	0.666	rs10840161	ENSG00000254860.4	TMEM9B-AS1	-10.17	4.18e-22	3.17e-19	-0.47	-0.42	Colonoscopy-negative controls vs population controls;	chr11:9032277	chr11:8964675~8977527:+
THCA	cis	rs71403859	0.73	rs12927768	ENSG00000260886.1	TAT-AS1	10.17	4.19e-22	3.18e-19	0.78	0.42	Post bronchodilator FEV1;	chr16:71611360	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	10.17	4.19e-22	3.18e-19	0.51	0.42	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
THCA	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	10.17	4.21e-22	3.19e-19	0.35	0.42	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
THCA	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	10.17	4.21e-22	3.19e-19	0.35	0.42	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	10.17	4.21e-22	3.19e-19	0.35	0.42	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-10.17	4.21e-22	3.19e-19	-0.35	-0.42	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-10.17	4.21e-22	3.19e-19	-0.35	-0.42	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-10.17	4.21e-22	3.19e-19	-0.35	-0.42	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
THCA	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-10.17	4.23e-22	3.21e-19	-0.5	-0.42	Migraine;	chr4:56851192	chr4:56960927~56961373:-
THCA	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-10.17	4.23e-22	3.21e-19	-0.5	-0.42	Migraine;	chr4:56852087	chr4:56960927~56961373:-
THCA	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	10.17	4.24e-22	3.22e-19	0.35	0.42	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
THCA	cis	rs673078	0.571	rs7963464	ENSG00000275409.1	RP11-131L12.4	-10.17	4.25e-22	3.22e-19	-0.47	-0.42	Glucose homeostasis traits;	chr12:118264924	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.923	rs4870050	ENSG00000268592.3	RAET1E-AS1	10.17	4.26e-22	3.23e-19	0.59	0.42	Lung cancer;	chr6:149838917	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs7752089	ENSG00000268592.3	RAET1E-AS1	10.17	4.26e-22	3.23e-19	0.59	0.42	Lung cancer;	chr6:149839298	chr6:149863494~149919507:+
THCA	cis	rs860295	0.702	rs11264397	ENSG00000225855.5	RUSC1-AS1	10.17	4.26e-22	3.23e-19	0.3	0.42	Body mass index;	chr1:155641694	chr1:155316863~155324176:-
THCA	cis	rs9532669	0.926	rs7331435	ENSG00000239827.7	SUGT1P3	10.17	4.26e-22	3.23e-19	0.47	0.42	Cervical cancer;	chr13:40862396	chr13:40908159~40921774:-
THCA	cis	rs4591358	0.638	rs6704955	ENSG00000223466.1	AC064834.2	-10.17	4.27e-22	3.23e-19	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559393	chr2:195533035~195538681:+
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	10.17	4.28e-22	3.24e-19	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
THCA	cis	rs7665090	0.806	rs413967	ENSG00000246560.2	RP11-10L12.4	-10.17	4.28e-22	3.24e-19	-0.53	-0.42	Primary biliary cholangitis;	chr4:102662039	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.806	rs404574	ENSG00000246560.2	RP11-10L12.4	-10.17	4.28e-22	3.24e-19	-0.53	-0.42	Primary biliary cholangitis;	chr4:102662051	chr4:102828055~102844075:+
THCA	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-10.17	4.3e-22	3.26e-19	-0.5	-0.42	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
THCA	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-10.17	4.3e-22	3.26e-19	-0.5	-0.42	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
THCA	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-10.17	4.33e-22	3.28e-19	-0.61	-0.42	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	10.17	4.33e-22	3.28e-19	0.5	0.42	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	10.17	4.35e-22	3.3e-19	0.5	0.42	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
THCA	cis	rs3762637	0.941	rs9810996	ENSG00000272758.4	RP11-299J3.8	-10.17	4.35e-22	3.3e-19	-0.56	-0.42	LDL cholesterol levels;	chr3:122355540	chr3:122416207~122443180:+
THCA	cis	rs3762637	0.941	rs9810999	ENSG00000272758.4	RP11-299J3.8	-10.17	4.35e-22	3.3e-19	-0.56	-0.42	LDL cholesterol levels;	chr3:122355544	chr3:122416207~122443180:+
THCA	cis	rs916888	0.821	rs70600	ENSG00000232300.1	FAM215B	10.17	4.36e-22	3.3e-19	0.69	0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46558830~46562795:-
THCA	cis	rs1799949	1	rs8176120	ENSG00000267681.1	CTD-3199J23.6	-10.17	4.42e-22	3.35e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43109216	chr17:43144956~43145255:+
THCA	cis	rs9595066	0.627	rs4942290	ENSG00000227258.4	SMIM2-AS1	10.17	4.43e-22	3.35e-19	0.58	0.42	Schizophrenia;	chr13:44183203	chr13:44110451~44240517:+
THCA	cis	rs6570726	0.935	rs387965	ENSG00000235652.6	RP11-545I5.3	10.17	4.44e-22	3.36e-19	0.38	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145548230	chr6:145799409~145886585:+
THCA	cis	rs7945705	0.837	rs10769981	ENSG00000254860.4	TMEM9B-AS1	-10.17	4.44e-22	3.36e-19	-0.48	-0.42	Hemoglobin concentration;	chr11:9002913	chr11:8964675~8977527:+
THCA	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	10.17	4.45e-22	3.37e-19	0.5	0.42	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
THCA	cis	rs2599510	0.811	rs2710625	ENSG00000276334.1	AL133243.1	10.17	4.47e-22	3.39e-19	0.46	0.42	Interleukin-18 levels;	chr2:32597890	chr2:32521927~32523547:+
THCA	cis	rs2980439	0.517	rs793753	ENSG00000253893.2	FAM85B	10.17	4.49e-22	3.39e-19	0.55	0.42	Neuroticism;	chr8:8247837	chr8:8167819~8226614:-
THCA	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-10.16	4.49e-22	3.4e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
THCA	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-10.16	4.49e-22	3.4e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
THCA	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-10.16	4.49e-22	3.4e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
THCA	cis	rs9318086	0.6	rs9507185	ENSG00000205861.10	C1QTNF9B-AS1	-10.16	4.5e-22	3.4e-19	-0.48	-0.42	Myopia (pathological);	chr13:23899595	chr13:23888889~23897263:+
THCA	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	10.16	4.51e-22	3.41e-19	0.5	0.42	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
THCA	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-10.16	4.51e-22	3.41e-19	-0.53	-0.42	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
THCA	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	10.16	4.53e-22	3.43e-19	0.36	0.42	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	10.16	4.53e-22	3.43e-19	0.5	0.42	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	10.16	4.53e-22	3.43e-19	0.5	0.42	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
THCA	cis	rs4713118	0.629	rs203889	ENSG00000280107.1	AL022393.9	-10.16	4.54e-22	3.43e-19	-0.49	-0.42	Parkinson's disease;	chr6:28053997	chr6:28170845~28172521:+
THCA	cis	rs12554020	0.786	rs6479482	ENSG00000227603.1	RP11-165J3.6	10.16	4.56e-22	3.45e-19	0.58	0.42	Schizophrenia;	chr9:93435814	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs7035657	ENSG00000227603.1	RP11-165J3.6	-10.16	4.56e-22	3.45e-19	-0.58	-0.42	Schizophrenia;	chr9:93434769	chr9:93435332~93437121:-
THCA	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	10.16	4.56e-22	3.45e-19	0.36	0.42	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	10.16	4.56e-22	3.45e-19	0.36	0.42	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	10.16	4.56e-22	3.45e-19	0.36	0.42	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	10.16	4.56e-22	3.45e-19	0.36	0.42	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	10.16	4.56e-22	3.45e-19	0.36	0.42	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
THCA	cis	rs780096	0.545	rs11695549	ENSG00000234072.1	AC074117.10	-10.16	4.58e-22	3.46e-19	-0.34	-0.42	Total body bone mineral density;	chr2:27363288	chr2:27356246~27367622:+
THCA	cis	rs9890032	1	rs3764419	ENSG00000266490.1	CTD-2349P21.9	10.16	4.59e-22	3.47e-19	0.4	0.42	Hip circumference adjusted for BMI;	chr17:30837005	chr17:30792372~30792833:+
THCA	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	10.16	4.59e-22	3.47e-19	0.36	0.42	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
THCA	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	10.16	4.6e-22	3.48e-19	0.45	0.42	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
THCA	cis	rs7829975	0.688	rs7826654	ENSG00000253893.2	FAM85B	-10.16	4.61e-22	3.48e-19	-0.55	-0.42	Mood instability;	chr8:8521596	chr8:8167819~8226614:-
THCA	cis	rs7829975	0.688	rs7826660	ENSG00000253893.2	FAM85B	-10.16	4.61e-22	3.48e-19	-0.55	-0.42	Mood instability;	chr8:8521597	chr8:8167819~8226614:-
THCA	cis	rs932287	0.54	rs4910442	ENSG00000254860.4	TMEM9B-AS1	-10.16	4.66e-22	3.52e-19	-0.47	-0.42	Colonoscopy-negative controls vs population controls;	chr11:9022790	chr11:8964675~8977527:+
THCA	cis	rs9532669	1	rs9532669	ENSG00000176268.5	CYCSP34	10.16	4.66e-22	3.52e-19	0.48	0.42	Cervical cancer;	chr13:40927414	chr13:40863599~40863902:-
THCA	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-10.16	4.66e-22	3.52e-19	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
THCA	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	10.16	4.68e-22	3.54e-19	0.49	0.42	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
THCA	cis	rs1799949	1	rs72829113	ENSG00000267681.1	CTD-3199J23.6	-10.16	4.68e-22	3.54e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43029818	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11653253	ENSG00000267681.1	CTD-3199J23.6	-10.16	4.68e-22	3.54e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43030645	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs12951869	ENSG00000267681.1	CTD-3199J23.6	-10.16	4.68e-22	3.54e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43035550	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11654452	ENSG00000267681.1	CTD-3199J23.6	-10.16	4.68e-22	3.54e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43037366	chr17:43144956~43145255:+
THCA	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-10.16	4.69e-22	3.54e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
THCA	cis	rs780096	0.526	rs13472	ENSG00000234072.1	AC074117.10	-10.16	4.69e-22	3.54e-19	-0.34	-0.42	Total body bone mineral density;	chr2:27377372	chr2:27356246~27367622:+
THCA	cis	rs7665090	0.87	rs227361	ENSG00000246560.2	RP11-10L12.4	10.16	4.72e-22	3.56e-19	0.51	0.42	Primary biliary cholangitis;	chr4:102665820	chr4:102828055~102844075:+
THCA	cis	rs1799949	1	rs8176145	ENSG00000267681.1	CTD-3199J23.6	-10.16	4.72e-22	3.57e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43097077	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs8176140	ENSG00000267681.1	CTD-3199J23.6	-10.16	4.72e-22	3.57e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43099629	chr17:43144956~43145255:+
THCA	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-10.16	4.75e-22	3.59e-19	-0.52	-0.42	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
THCA	cis	rs9322193	0.607	rs9322229	ENSG00000223701.3	RAET1E-AS1	10.16	4.78e-22	3.61e-19	0.6	0.42	Lung cancer;	chr6:149908949	chr6:149884431~149919508:+
THCA	cis	rs934734	0.532	rs12470883	ENSG00000281920.1	RP11-418H16.1	-10.16	4.79e-22	3.61e-19	-0.51	-0.42	Rheumatoid arthritis;	chr2:65424717	chr2:65623272~65628424:+
THCA	cis	rs3762637	1	rs76599189	ENSG00000272758.4	RP11-299J3.8	-10.16	4.8e-22	3.63e-19	-0.57	-0.42	LDL cholesterol levels;	chr3:122405229	chr3:122416207~122443180:+
THCA	cis	rs8062405	0.824	rs4788085	ENSG00000251417.2	RP11-1348G14.4	-10.16	4.82e-22	3.63e-19	-0.39	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.824	rs28772958	ENSG00000251417.2	RP11-1348G14.4	-10.16	4.82e-22	3.63e-19	-0.39	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.789	rs2106480	ENSG00000251417.2	RP11-1348G14.4	-10.16	4.82e-22	3.63e-19	-0.39	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28802743~28817828:+
THCA	cis	rs7945705	0.902	rs7930026	ENSG00000254860.4	TMEM9B-AS1	-10.16	4.86e-22	3.67e-19	-0.48	-0.42	Hemoglobin concentration;	chr11:8992092	chr11:8964675~8977527:+
THCA	cis	rs71403859	0.73	rs12447672	ENSG00000260886.1	TAT-AS1	10.16	4.88e-22	3.68e-19	0.79	0.42	Post bronchodilator FEV1;	chr16:71681228	chr16:71565789~71578187:+
THCA	cis	rs6570726	0.935	rs447247	ENSG00000235652.6	RP11-545I5.3	10.15	4.91e-22	3.71e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145491542	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs369458	ENSG00000235652.6	RP11-545I5.3	10.15	4.91e-22	3.71e-19	0.4	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145491673	chr6:145799409~145886585:+
THCA	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	10.15	4.92e-22	3.71e-19	0.35	0.42	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
THCA	cis	rs4964805	0.913	rs35945096	ENSG00000257681.1	RP11-341G23.4	10.15	4.94e-22	3.72e-19	0.51	0.42	Attention deficit hyperactivity disorder;	chr12:103808151	chr12:103746315~103768858:-
THCA	cis	rs1799949	1	rs8176109	ENSG00000267681.1	CTD-3199J23.6	-10.15	4.96e-22	3.74e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43113759	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.896	rs8176098	ENSG00000267681.1	CTD-3199J23.6	-10.15	4.96e-22	3.74e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43116189	chr17:43144956~43145255:+
THCA	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-10.15	5.02e-22	3.78e-19	-0.45	-0.42	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
THCA	cis	rs66887589	0.616	rs11098497	ENSG00000245958.5	RP11-33B1.1	-10.15	5.05e-22	3.8e-19	-0.38	-0.42	Diastolic blood pressure;	chr4:119265913	chr4:119454791~119552025:+
THCA	cis	rs6570726	0.902	rs973855	ENSG00000235652.6	RP11-545I5.3	-10.15	5.06e-22	3.81e-19	-0.39	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145460714	chr6:145799409~145886585:+
THCA	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-10.15	5.1e-22	3.84e-19	-0.32	-0.42	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
THCA	cis	rs42490	0.966	rs39505	ENSG00000251136.7	RP11-37B2.1	-10.15	5.11e-22	3.85e-19	-0.37	-0.42	Leprosy;	chr8:89779838	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs39506	ENSG00000251136.7	RP11-37B2.1	-10.15	5.11e-22	3.85e-19	-0.37	-0.42	Leprosy;	chr8:89779899	chr8:89609409~89757727:-
THCA	cis	rs9322193	0.962	rs2275045	ENSG00000268592.3	RAET1E-AS1	10.15	5.14e-22	3.87e-19	0.59	0.42	Lung cancer;	chr6:149842775	chr6:149863494~149919507:+
THCA	cis	rs1799949	1	rs11657053	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.15e-22	3.88e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43039112	chr17:43144956~43145255:+
THCA	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-10.15	5.15e-22	3.88e-19	-0.32	-0.42	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
THCA	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-10.15	5.16e-22	3.88e-19	-0.57	-0.42	QT interval;	chr16:28845498	chr16:28700294~28701540:-
THCA	cis	rs1799949	1	rs2292595	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.16e-22	3.88e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43138657	chr17:43144956~43145255:+
THCA	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	10.15	5.19e-22	3.91e-19	0.51	0.42	Depression;	chr6:28314871	chr6:28176188~28176674:+
THCA	cis	rs9322193	0.923	rs55849538	ENSG00000268592.3	RAET1E-AS1	10.15	5.2e-22	3.91e-19	0.59	0.42	Lung cancer;	chr6:149635330	chr6:149863494~149919507:+
THCA	cis	rs1799949	1	rs3950989	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.25e-22	3.95e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43085936	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs2070834	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.25e-22	3.95e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43090268	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs16942	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.25e-22	3.95e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43091983	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11656097	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.27e-22	3.96e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43138596	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11658754	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.27e-22	3.96e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43140722	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.93	rs33968979	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.27e-22	3.96e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43145975	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs12952790	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.27e-22	3.96e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43147590	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs12950607	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.27e-22	3.96e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43147911	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11079056	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.27e-22	3.96e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43148782	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	10.15	5.28e-22	3.97e-19	0.49	0.42	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
THCA	cis	rs42490	1	rs40545	ENSG00000251136.7	RP11-37B2.1	-10.15	5.29e-22	3.98e-19	-0.37	-0.42	Leprosy;	chr8:89777483	chr8:89609409~89757727:-
THCA	cis	rs1799949	1	rs12944458	ENSG00000267681.1	CTD-3199J23.6	-10.15	5.3e-22	3.98e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43028755	chr17:43144956~43145255:+
THCA	cis	rs217727	0.524	rs7483477	ENSG00000226416.1	MRPL23-AS1	-10.15	5.3e-22	3.98e-19	-0.53	-0.42	Breast cancer;	chr11:1899025	chr11:1983237~1989920:-
THCA	cis	rs7945705	0.967	rs10769968	ENSG00000254860.4	TMEM9B-AS1	-10.14	5.34e-22	4.01e-19	-0.47	-0.42	Hemoglobin concentration;	chr11:8886036	chr11:8964675~8977527:+
THCA	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	10.14	5.35e-22	4.02e-19	0.5	0.42	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
THCA	cis	rs1799949	0.896	rs35908185	ENSG00000267681.1	CTD-3199J23.6	-10.14	5.41e-22	4.07e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43103094	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	10.14	5.41e-22	4.07e-19	0.51	0.42	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	10.14	5.41e-22	4.07e-19	0.51	0.42	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
THCA	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-10.14	5.48e-22	4.11e-19	-0.37	-0.42	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
THCA	cis	rs9322193	0.923	rs9688452	ENSG00000216906.2	RP11-350J20.9	10.14	5.48e-22	4.11e-19	0.51	0.42	Lung cancer;	chr6:149658764	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs13215691	ENSG00000223701.3	RAET1E-AS1	10.14	5.51e-22	4.14e-19	0.56	0.42	Lung cancer;	chr6:149792666	chr6:149884431~149919508:+
THCA	cis	rs950169	0.922	rs4842939	ENSG00000225151.9	GOLGA2P7	10.14	5.51e-22	4.14e-19	0.55	0.42	Schizophrenia;	chr15:84159214	chr15:84199311~84230136:-
THCA	cis	rs11673344	0.667	rs504549	ENSG00000226686.6	LINC01535	10.14	5.51e-22	4.14e-19	0.51	0.42	Obesity-related traits;	chr19:36946299	chr19:37251912~37265535:+
THCA	cis	rs8062405	0.558	rs3743963	ENSG00000259982.1	CDC37P1	10.14	5.52e-22	4.14e-19	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28593365	chr16:28700294~28701540:-
THCA	cis	rs17608059	0.611	rs62052300	ENSG00000141028.6	CDRT15P1	-10.14	5.53e-22	4.15e-19	-0.48	-0.42	Temperament;	chr17:14013482	chr17:14024514~14025488:+
THCA	cis	rs1799949	1	rs35668327	ENSG00000267681.1	CTD-3199J23.6	-10.14	5.55e-22	4.16e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43121078	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	10.14	5.56e-22	4.17e-19	0.5	0.42	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
THCA	cis	rs1799949	0.965	rs8176130	ENSG00000267681.1	CTD-3199J23.6	-10.14	5.57e-22	4.18e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43106026	chr17:43144956~43145255:+
THCA	cis	rs66887589	0.616	rs7659403	ENSG00000245958.5	RP11-33B1.1	-10.14	5.59e-22	4.2e-19	-0.38	-0.42	Diastolic blood pressure;	chr4:119286099	chr4:119454791~119552025:+
THCA	cis	rs9532669	0.926	rs6560963	ENSG00000239827.7	SUGT1P3	-10.14	5.6e-22	4.2e-19	-0.47	-0.42	Cervical cancer;	chr13:40871126	chr13:40908159~40921774:-
THCA	cis	rs7429990	0.864	rs1464614	ENSG00000229759.1	MRPS18AP1	10.14	5.6e-22	4.2e-19	0.5	0.42	Educational attainment (years of education);	chr3:47612885	chr3:48256350~48256938:-
THCA	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-10.14	5.61e-22	4.21e-19	-0.52	-0.42	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-10.14	5.61e-22	4.21e-19	-0.52	-0.42	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-10.14	5.61e-22	4.21e-19	-0.52	-0.42	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
THCA	cis	rs12554020	0.786	rs7036984	ENSG00000227603.1	RP11-165J3.6	10.14	5.61e-22	4.21e-19	0.58	0.42	Schizophrenia;	chr9:93438258	chr9:93435332~93437121:-
THCA	cis	rs9532669	0.926	rs7799	ENSG00000176268.5	CYCSP34	10.14	5.63e-22	4.23e-19	0.47	0.42	Cervical cancer;	chr13:40958916	chr13:40863599~40863902:-
THCA	cis	rs526231	0.543	rs246901	ENSG00000175749.11	EIF3KP1	10.14	5.64e-22	4.23e-19	0.61	0.42	Primary biliary cholangitis;	chr5:103248477	chr5:103032376~103033031:+
THCA	cis	rs4718428	0.672	rs13241598	ENSG00000232546.1	RP11-458F8.1	-10.14	5.68e-22	4.26e-19	-0.4	-0.42	Corneal structure;	chr7:66835665	chr7:66848496~66858136:+
THCA	cis	rs6991838	0.702	rs13274205	ENSG00000272010.1	CTD-3025N20.3	10.14	5.69e-22	4.27e-19	0.42	0.42	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65591850~65592472:-
THCA	cis	rs748404	0.534	rs489509	ENSG00000249839.1	AC011330.5	-10.14	5.7e-22	4.27e-19	-0.5	-0.42	Lung cancer;	chr15:43294709	chr15:43663654~43684339:-
THCA	cis	rs9322193	0.962	rs17673294	ENSG00000223701.3	RAET1E-AS1	10.14	5.72e-22	4.29e-19	0.56	0.42	Lung cancer;	chr6:149813857	chr6:149884431~149919508:+
THCA	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-10.14	5.72e-22	4.29e-19	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
THCA	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	10.14	5.73e-22	4.3e-19	0.51	0.42	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
THCA	cis	rs12468226	0.689	rs17656903	ENSG00000273456.1	RP11-686O6.2	-10.14	5.73e-22	4.3e-19	-0.53	-0.42	Urate levels;	chr2:202106312	chr2:202374932~202375604:-
THCA	cis	rs6452524	0.836	rs1015440	ENSG00000249664.1	CTD-2227C6.2	10.14	5.74e-22	4.31e-19	0.56	0.42	Hypertension (SNP x SNP interaction);	chr5:83202986	chr5:83012285~83013109:-
THCA	cis	rs6538678	0.833	rs10859966	ENSG00000258343.1	RP11-536G4.2	10.14	5.75e-22	4.31e-19	0.56	0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95859597	chr12:95795345~95858839:-
THCA	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-10.14	5.75e-22	4.31e-19	-0.45	-0.42	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
THCA	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-10.13	5.8e-22	4.35e-19	-0.62	-0.42	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
THCA	cis	rs11676348	1	rs11676348	ENSG00000261338.2	RP11-378A13.1	-10.13	5.85e-22	4.38e-19	-0.43	-0.42	Ulcerative colitis;	chr2:218145423	chr2:218255319~218257366:+
THCA	cis	rs1075265	0.749	rs805434	ENSG00000233266.1	HMGB1P31	10.13	5.9e-22	4.42e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54051334~54051760:+
THCA	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	10.13	5.95e-22	4.46e-19	0.58	0.42	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
THCA	cis	rs673078	0.66	rs11068891	ENSG00000275409.1	RP11-131L12.4	10.13	5.97e-22	4.47e-19	0.47	0.42	Glucose homeostasis traits;	chr12:118259814	chr12:118430147~118430699:+
THCA	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-10.13	5.98e-22	4.47e-19	-0.49	-0.42	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
THCA	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	10.13	6e-22	4.49e-19	0.45	0.42	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
THCA	cis	rs1799949	0.965	rs8176161	ENSG00000267681.1	CTD-3199J23.6	-10.13	6e-22	4.49e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43089373	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.894	rs8176160	ENSG00000267681.1	CTD-3199J23.6	-10.13	6e-22	4.49e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43089486	chr17:43144956~43145255:+
THCA	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	10.13	6e-22	4.49e-19	0.42	0.42	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	10.13	6e-22	4.49e-19	0.42	0.42	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
THCA	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	10.13	6e-22	4.49e-19	0.42	0.42	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
THCA	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	10.13	6.03e-22	4.51e-19	0.5	0.42	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
THCA	cis	rs748404	0.578	rs576557	ENSG00000249839.1	AC011330.5	-10.13	6.04e-22	4.52e-19	-0.5	-0.42	Lung cancer;	chr15:43305539	chr15:43663654~43684339:-
THCA	cis	rs1799949	1	rs2298862	ENSG00000267681.1	CTD-3199J23.6	-10.13	6.09e-22	4.56e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43024671	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs36036395	ENSG00000267681.1	CTD-3199J23.6	-10.13	6.09e-22	4.56e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43029280	chr17:43144956~43145255:+
THCA	cis	rs12220777	0.748	rs11201641	ENSG00000230091.5	TMEM254-AS1	10.13	6.16e-22	4.61e-19	0.74	0.42	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80091975	chr10:80046860~80078912:-
THCA	cis	rs4964805	0.913	rs12830701	ENSG00000257681.1	RP11-341G23.4	10.13	6.17e-22	4.61e-19	0.51	0.42	Attention deficit hyperactivity disorder;	chr12:103807904	chr12:103746315~103768858:-
THCA	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	10.13	6.19e-22	4.63e-19	0.51	0.42	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
THCA	cis	rs6142102	0.961	rs4911411	ENSG00000276073.1	RP5-1125A11.7	-10.13	6.19e-22	4.63e-19	-0.39	-0.42	Skin pigmentation;	chr20:34128036	chr20:33985617~33988989:-
THCA	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	10.13	6.22e-22	4.65e-19	0.62	0.42	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
THCA	cis	rs4713118	0.629	rs149899	ENSG00000280107.1	AL022393.9	-10.12	6.31e-22	4.71e-19	-0.49	-0.42	Parkinson's disease;	chr6:28052201	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.629	rs172165	ENSG00000280107.1	AL022393.9	-10.12	6.31e-22	4.71e-19	-0.49	-0.42	Parkinson's disease;	chr6:28053036	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.597	rs172166	ENSG00000280107.1	AL022393.9	-10.12	6.31e-22	4.71e-19	-0.49	-0.42	Parkinson's disease;	chr6:28053042	chr6:28170845~28172521:+
THCA	cis	rs944289	0.533	rs2780313	ENSG00000257826.1	RP11-116N8.4	10.12	6.31e-22	4.71e-19	0.44	0.42	Thyroid cancer;	chr14:36059216	chr14:36061026~36067190:-
THCA	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	10.12	6.32e-22	4.72e-19	0.5	0.42	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	10.12	6.32e-22	4.72e-19	0.5	0.42	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
THCA	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-10.12	6.36e-22	4.75e-19	-0.5	-0.42	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
THCA	cis	rs71403859	0.73	rs17356316	ENSG00000260886.1	TAT-AS1	10.12	6.37e-22	4.75e-19	0.78	0.42	Post bronchodilator FEV1;	chr16:71713018	chr16:71565789~71578187:+
THCA	cis	rs62103177	0.564	rs3930043	ENSG00000261126.6	RP11-795F19.1	10.12	6.39e-22	4.77e-19	0.46	0.42	Opioid sensitivity;	chr18:79963832	chr18:80046900~80095482:+
THCA	cis	rs8062405	0.789	rs28676837	ENSG00000251417.2	RP11-1348G14.4	10.12	6.4e-22	4.77e-19	0.42	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28802743~28817828:+
THCA	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	10.12	6.42e-22	4.79e-19	0.46	0.42	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
THCA	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	10.12	6.43e-22	4.79e-19	0.52	0.42	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
THCA	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	10.12	6.43e-22	4.8e-19	0.49	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
THCA	cis	rs6570726	0.905	rs377143	ENSG00000235652.6	RP11-545I5.3	10.12	6.44e-22	4.8e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145513084	chr6:145799409~145886585:+
THCA	cis	rs944289	0.74	rs414755	ENSG00000257826.1	RP11-116N8.4	10.12	6.48e-22	4.84e-19	0.43	0.42	Thyroid cancer;	chr14:36073387	chr14:36061026~36067190:-
THCA	cis	rs7429990	0.833	rs869508	ENSG00000229759.1	MRPS18AP1	10.12	6.49e-22	4.84e-19	0.52	0.42	Educational attainment (years of education);	chr3:47571812	chr3:48256350~48256938:-
THCA	cis	rs4674676	1	rs4674676	ENSG00000261428.2	RP11-16P6.1	10.12	6.5e-22	4.85e-19	0.53	0.42	Chin dimples;	chr2:222664393	chr2:222566899~222569719:-
THCA	cis	rs9322193	0.847	rs12210605	ENSG00000268592.3	RAET1E-AS1	10.12	6.51e-22	4.86e-19	0.59	0.42	Lung cancer;	chr6:149817267	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9371199	ENSG00000268592.3	RAET1E-AS1	10.12	6.51e-22	4.86e-19	0.59	0.42	Lung cancer;	chr6:149817526	chr6:149863494~149919507:+
THCA	cis	rs180730	0.519	rs1470696	ENSG00000251609.2	SETP12	10.12	6.56e-22	4.89e-19	0.58	0.42	Fasting plasma glucose;	chr4:120921412	chr4:120895494~120897083:-
THCA	cis	rs9318086	0.648	rs9507184	ENSG00000205861.10	C1QTNF9B-AS1	-10.12	6.56e-22	4.89e-19	-0.48	-0.42	Myopia (pathological);	chr13:23899503	chr13:23888889~23897263:+
THCA	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-10.12	6.63e-22	4.94e-19	-0.51	-0.42	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
THCA	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-10.12	6.63e-22	4.94e-19	-0.51	-0.42	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
THCA	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-10.12	6.64e-22	4.95e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-10.12	6.64e-22	4.95e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-10.12	6.64e-22	4.95e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
THCA	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	10.12	6.68e-22	4.98e-19	0.58	0.42	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
THCA	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	10.12	6.72e-22	5.01e-19	0.58	0.42	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
THCA	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	10.12	6.72e-22	5.01e-19	0.58	0.42	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
THCA	cis	rs860295	0.702	rs12067371	ENSG00000225855.5	RUSC1-AS1	10.12	6.77e-22	5.04e-19	0.29	0.42	Body mass index;	chr1:155467878	chr1:155316863~155324176:-
THCA	cis	rs1799949	1	rs4793189	ENSG00000267681.1	CTD-3199J23.6	-10.12	6.78e-22	5.05e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43038698	chr17:43144956~43145255:+
THCA	cis	rs860295	0.702	rs475550	ENSG00000225855.5	RUSC1-AS1	10.12	6.78e-22	5.05e-19	0.3	0.42	Body mass index;	chr1:155682290	chr1:155316863~155324176:-
THCA	cis	rs9532669	0.926	rs2324742	ENSG00000239827.7	SUGT1P3	-10.12	6.81e-22	5.07e-19	-0.46	-0.42	Cervical cancer;	chr13:40919059	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.857	rs9594455	ENSG00000239827.7	SUGT1P3	-10.12	6.81e-22	5.07e-19	-0.46	-0.42	Cervical cancer;	chr13:40919452	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532659	ENSG00000239827.7	SUGT1P3	-10.12	6.81e-22	5.07e-19	-0.46	-0.42	Cervical cancer;	chr13:40920380	chr13:40908159~40921774:-
THCA	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	10.12	6.82e-22	5.07e-19	0.49	0.42	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
THCA	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	10.12	6.82e-22	5.07e-19	0.49	0.42	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
THCA	cis	rs1387259	0.759	rs7960122	ENSG00000258273.1	RP11-370I10.4	10.12	6.83e-22	5.08e-19	0.57	0.42	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48383217	chr12:48333755~48333901:-
THCA	cis	rs6558530	0.965	rs6558535	ENSG00000253982.1	CTD-2336O2.1	10.11	6.88e-22	5.12e-19	0.37	0.42	Systolic blood pressure;	chr8:1762466	chr8:1761990~1764502:-
THCA	cis	rs7429990	0.864	rs3888	ENSG00000229759.1	MRPS18AP1	-10.11	6.89e-22	5.12e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47816085	chr3:48256350~48256938:-
THCA	cis	rs12220777	0.748	rs11201633	ENSG00000230091.5	TMEM254-AS1	10.11	6.91e-22	5.14e-19	0.78	0.42	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80090068	chr10:80046860~80078912:-
THCA	cis	rs9318086	0.648	rs78881146	ENSG00000205861.10	C1QTNF9B-AS1	-10.11	6.98e-22	5.19e-19	-0.49	-0.42	Myopia (pathological);	chr13:23894565	chr13:23888889~23897263:+
THCA	cis	rs524281	0.731	rs10896075	ENSG00000255320.1	RP11-755F10.1	-10.11	7.01e-22	5.21e-19	-0.65	-0.42	Electroencephalogram traits;	chr11:66024742	chr11:66244840~66246239:-
THCA	cis	rs1799949	0.965	rs8176193	ENSG00000267681.1	CTD-3199J23.6	-10.11	7.08e-22	5.26e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43079499	chr17:43144956~43145255:+
THCA	cis	rs860295	0.639	rs10908469	ENSG00000225855.5	RUSC1-AS1	10.11	7.1e-22	5.27e-19	0.29	0.42	Body mass index;	chr1:155498941	chr1:155316863~155324176:-
THCA	cis	rs1799949	0.832	rs2070835	ENSG00000267681.1	CTD-3199J23.6	-10.11	7.12e-22	5.29e-19	-0.5	-0.42	Menopause (age at onset);	chr17:43022008	chr17:43144956~43145255:+
THCA	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	10.11	7.13e-22	5.3e-19	0.47	0.42	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
THCA	cis	rs6558530	0.965	rs730379	ENSG00000253982.1	CTD-2336O2.1	10.11	7.2e-22	5.34e-19	0.36	0.42	Systolic blood pressure;	chr8:1759927	chr8:1761990~1764502:-
THCA	cis	rs180730	0.519	rs1901135	ENSG00000251609.2	SETP12	10.11	7.21e-22	5.35e-19	0.59	0.42	Fasting plasma glucose;	chr4:120907364	chr4:120895494~120897083:-
THCA	cis	rs180730	0.539	rs3804178	ENSG00000251609.2	SETP12	10.11	7.21e-22	5.35e-19	0.59	0.42	Fasting plasma glucose;	chr4:120907911	chr4:120895494~120897083:-
THCA	cis	rs4380275	0.782	rs11127506	ENSG00000272342.1	RP13-539J13.1	-10.11	7.23e-22	5.36e-19	-0.49	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:751300	chr2:739588~740164:-
THCA	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	10.11	7.23e-22	5.36e-19	0.52	0.42	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	10.11	7.23e-22	5.36e-19	0.52	0.42	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
THCA	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-10.11	7.24e-22	5.37e-19	-0.49	-0.42	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
THCA	cis	rs524281	1	rs527897	ENSG00000255320.1	RP11-755F10.1	10.11	7.25e-22	5.38e-19	0.57	0.42	Electroencephalogram traits;	chr11:66133306	chr11:66244840~66246239:-
THCA	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	10.11	7.34e-22	5.45e-19	0.49	0.42	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
THCA	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-10.11	7.35e-22	5.45e-19	-0.54	-0.42	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
THCA	cis	rs524281	0.814	rs2270448	ENSG00000255320.1	RP11-755F10.1	10.11	7.35e-22	5.45e-19	0.63	0.42	Electroencephalogram traits;	chr11:66068460	chr11:66244840~66246239:-
THCA	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-10.11	7.35e-22	5.45e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
THCA	cis	rs10759883	0.587	rs2405134	ENSG00000175611.10	LINC00476	-10.11	7.39e-22	5.48e-19	-0.48	-0.42	Nicotine dependence;	chr9:95795179	chr9:95759231~95875977:-
THCA	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-10.11	7.42e-22	5.5e-19	-0.62	-0.42	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-10.11	7.42e-22	5.5e-19	-0.62	-0.42	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	10.1	7.52e-22	5.57e-19	0.5	0.42	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.886	rs9767555	ENSG00000268592.3	RAET1E-AS1	10.1	7.52e-22	5.58e-19	0.59	0.42	Lung cancer;	chr6:149647022	chr6:149863494~149919507:+
THCA	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-10.1	7.53e-22	5.58e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
THCA	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-10.1	7.53e-22	5.58e-19	-0.62	-0.42	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
THCA	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	10.1	7.55e-22	5.6e-19	0.53	0.42	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
THCA	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-10.1	7.6e-22	5.63e-19	-0.46	-0.42	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
THCA	cis	rs42490	0.868	rs4961158	ENSG00000251136.7	RP11-37B2.1	10.1	7.65e-22	5.66e-19	0.37	0.42	Leprosy;	chr8:89685607	chr8:89609409~89757727:-
THCA	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	10.1	7.7e-22	5.7e-19	0.45	0.42	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
THCA	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	10.1	7.73e-22	5.72e-19	0.53	0.42	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
THCA	cis	rs9532669	0.89	rs35396630	ENSG00000239827.7	SUGT1P3	-10.1	7.74e-22	5.73e-19	-0.47	-0.42	Cervical cancer;	chr13:40863135	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4942001	ENSG00000239827.7	SUGT1P3	-10.1	7.74e-22	5.73e-19	-0.47	-0.42	Cervical cancer;	chr13:40863176	chr13:40908159~40921774:-
THCA	cis	rs6142102	0.812	rs6059574	ENSG00000276073.1	RP5-1125A11.7	10.1	7.75e-22	5.74e-19	0.38	0.42	Skin pigmentation;	chr20:33935366	chr20:33985617~33988989:-
THCA	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	10.1	7.75e-22	5.74e-19	0.44	0.42	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
THCA	cis	rs227275	0.53	rs3960788	ENSG00000246560.2	RP11-10L12.4	10.1	7.8e-22	5.77e-19	0.52	0.42	Allergic disease (asthma, hay fever or eczema);	chr4:102994461	chr4:102828055~102844075:+
THCA	cis	rs9318086	0.712	rs9318100	ENSG00000205861.10	C1QTNF9B-AS1	10.1	7.8e-22	5.77e-19	0.48	0.42	Myopia (pathological);	chr13:23868343	chr13:23888889~23897263:+
THCA	cis	rs780094	0.606	rs6729709	ENSG00000234072.1	AC074117.10	-10.1	7.81e-22	5.78e-19	-0.33	-0.42	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27360289	chr2:27356246~27367622:+
THCA	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	10.1	7.86e-22	5.81e-19	0.49	0.42	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
THCA	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-10.1	7.89e-22	5.84e-19	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
THCA	cis	rs4718428	0.705	rs28648401	ENSG00000232546.1	RP11-458F8.1	-10.1	7.91e-22	5.86e-19	-0.4	-0.42	Corneal structure;	chr7:66902145	chr7:66848496~66858136:+
THCA	cis	rs4718428	0.607	rs66954441	ENSG00000232546.1	RP11-458F8.1	-10.1	7.91e-22	5.86e-19	-0.4	-0.42	Corneal structure;	chr7:66904222	chr7:66848496~66858136:+
THCA	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	10.1	7.94e-22	5.87e-19	0.52	0.42	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
THCA	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-10.1	7.94e-22	5.88e-19	-0.49	-0.42	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
THCA	cis	rs9532669	0.926	rs4516083	ENSG00000176268.5	CYCSP34	10.1	7.94e-22	5.88e-19	0.48	0.42	Cervical cancer;	chr13:40951783	chr13:40863599~40863902:-
THCA	cis	rs597539	0.652	rs673821	ENSG00000250508.1	RP11-757G1.6	-10.1	7.97e-22	5.89e-19	-0.5	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911250	chr11:68870664~68874542:+
THCA	cis	rs6570726	0.935	rs430561	ENSG00000235652.6	RP11-545I5.3	10.1	7.98e-22	5.91e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145492004	chr6:145799409~145886585:+
THCA	cis	rs62355901	0.609	rs66893416	ENSG00000271828.1	CTD-2310F14.1	10.1	8e-22	5.92e-19	0.71	0.42	Breast cancer;	chr5:56755769	chr5:56927874~56929573:+
THCA	cis	rs9532669	0.89	rs9594457	ENSG00000239827.7	SUGT1P3	-10.1	8e-22	5.92e-19	-0.46	-0.42	Cervical cancer;	chr13:40920439	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9594458	ENSG00000239827.7	SUGT1P3	-10.1	8e-22	5.92e-19	-0.46	-0.42	Cervical cancer;	chr13:40920448	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9590562	ENSG00000239827.7	SUGT1P3	-10.1	8e-22	5.92e-19	-0.46	-0.42	Cervical cancer;	chr13:40920503	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs12857052	ENSG00000239827.7	SUGT1P3	-10.1	8e-22	5.92e-19	-0.46	-0.42	Cervical cancer;	chr13:40920831	chr13:40908159~40921774:-
THCA	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-10.1	8.02e-22	5.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
THCA	cis	rs7712401	0.715	rs434789	ENSG00000263432.2	RN7SL689P	-10.1	8.04e-22	5.94e-19	-0.47	-0.42	Mean platelet volume;	chr5:123021615	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs1139334	ENSG00000263432.2	RN7SL689P	-10.1	8.04e-22	5.94e-19	-0.47	-0.42	Mean platelet volume;	chr5:123022724	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs1062350	ENSG00000263432.2	RN7SL689P	-10.1	8.04e-22	5.94e-19	-0.47	-0.42	Mean platelet volume;	chr5:123022811	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.678	rs401535	ENSG00000263432.2	RN7SL689P	-10.1	8.04e-22	5.94e-19	-0.47	-0.42	Mean platelet volume;	chr5:123022990	chr5:123022487~123022783:-
THCA	cis	rs9532669	0.7	rs9525406	ENSG00000176268.5	CYCSP34	10.09	8.09e-22	5.98e-19	0.49	0.42	Cervical cancer;	chr13:40860812	chr13:40863599~40863902:-
THCA	cis	rs66887589	0.616	rs11098498	ENSG00000245958.5	RP11-33B1.1	-10.09	8.09e-22	5.98e-19	-0.38	-0.42	Diastolic blood pressure;	chr4:119265964	chr4:119454791~119552025:+
THCA	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-10.09	8.1e-22	5.99e-19	-0.5	-0.42	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
THCA	cis	rs67311347	0.577	rs2887951	ENSG00000223797.4	ENTPD3-AS1	10.09	8.1e-22	5.99e-19	0.34	0.42	Renal cell carcinoma;	chr3:40240613	chr3:40313802~40453329:-
THCA	cis	rs6570726	0.967	rs418662	ENSG00000235652.6	RP11-545I5.3	10.09	8.11e-22	5.99e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145527696	chr6:145799409~145886585:+
THCA	cis	rs944289	0.708	rs11622885	ENSG00000257826.1	RP11-116N8.4	-10.09	8.11e-22	6e-19	-0.44	-0.42	Thyroid cancer;	chr14:36095036	chr14:36061026~36067190:-
THCA	cis	rs673078	0.66	rs7974718	ENSG00000275409.1	RP11-131L12.4	-10.09	8.15e-22	6.02e-19	-0.47	-0.42	Glucose homeostasis traits;	chr12:118243258	chr12:118430147~118430699:+
THCA	cis	rs934734	0.532	rs55792977	ENSG00000281920.1	RP11-418H16.1	-10.09	8.17e-22	6.04e-19	-0.52	-0.42	Rheumatoid arthritis;	chr2:65423730	chr2:65623272~65628424:+
THCA	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	10.09	8.17e-22	6.04e-19	0.5	0.42	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
THCA	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-10.09	8.19e-22	6.05e-19	-0.51	-0.42	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
THCA	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	10.09	8.22e-22	6.07e-19	0.5	0.42	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
THCA	cis	rs67311347	0.544	rs13097602	ENSG00000223797.4	ENTPD3-AS1	-10.09	8.27e-22	6.11e-19	-0.34	-0.42	Renal cell carcinoma;	chr3:40297756	chr3:40313802~40453329:-
THCA	cis	rs524281	0.692	rs10791845	ENSG00000255320.1	RP11-755F10.1	-10.09	8.31e-22	6.14e-19	-0.58	-0.42	Electroencephalogram traits;	chr11:66066869	chr11:66244840~66246239:-
THCA	cis	rs673078	0.607	rs2036314	ENSG00000275409.1	RP11-131L12.4	-10.09	8.34e-22	6.16e-19	-0.45	-0.42	Glucose homeostasis traits;	chr12:118367132	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943369	ENSG00000275409.1	RP11-131L12.4	-10.09	8.34e-22	6.16e-19	-0.45	-0.42	Glucose homeostasis traits;	chr12:118368145	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	10.09	8.36e-22	6.17e-19	0.5	0.42	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
THCA	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	10.09	8.4e-22	6.2e-19	0.51	0.42	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
THCA	cis	rs4964805	0.586	rs934846	ENSG00000257681.1	RP11-341G23.4	10.09	8.45e-22	6.24e-19	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103791519	chr12:103746315~103768858:-
THCA	cis	rs7191700	0.674	rs12597893	ENSG00000262703.1	RP11-485G7.6	10.09	8.51e-22	6.28e-19	0.47	0.42	Multiple sclerosis;	chr16:11332474	chr16:11348143~11349321:-
THCA	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	10.09	8.55e-22	6.31e-19	0.49	0.42	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
THCA	cis	rs10256972	0.504	rs3735687	ENSG00000229043.2	AC091729.9	-10.09	8.59e-22	6.33e-19	-0.46	-0.42	Endometriosis;Longevity;	chr7:1026661	chr7:1160374~1165267:+
THCA	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	10.09	8.6e-22	6.34e-19	0.52	0.42	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
THCA	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	10.09	8.64e-22	6.37e-19	0.44	0.42	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
THCA	cis	rs1185460	0.546	rs7114961	ENSG00000271751.1	RP11-110I1.14	10.09	8.66e-22	6.39e-19	0.53	0.42	Coronary artery disease;	chr11:119043677	chr11:119065263~119065677:-
THCA	cis	rs4964805	0.865	rs11111796	ENSG00000257681.1	RP11-341G23.4	10.09	8.72e-22	6.43e-19	0.51	0.42	Attention deficit hyperactivity disorder;	chr12:103812150	chr12:103746315~103768858:-
THCA	cis	rs10853057	0.717	rs62062479	ENSG00000214174.7	AMZ2P1	10.09	8.73e-22	6.43e-19	0.79	0.42	White matter microstructure (global fractional anisotropy);	chr17:65060017	chr17:64966550~64975576:-
THCA	cis	rs7772486	0.902	rs2777480	ENSG00000235652.6	RP11-545I5.3	10.09	8.75e-22	6.45e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145988847	chr6:145799409~145886585:+
THCA	cis	rs748404	0.578	rs510108	ENSG00000249839.1	AC011330.5	-10.08	8.81e-22	6.49e-19	-0.49	-0.42	Lung cancer;	chr15:43313241	chr15:43663654~43684339:-
THCA	cis	rs7712401	0.715	rs436160	ENSG00000263432.2	RN7SL689P	-10.08	8.83e-22	6.51e-19	-0.47	-0.42	Mean platelet volume;	chr5:123020258	chr5:123022487~123022783:-
THCA	cis	rs10256972	0.64	rs10271082	ENSG00000229043.2	AC091729.9	-10.08	8.86e-22	6.53e-19	-0.47	-0.42	Endometriosis;Longevity;	chr7:1041926	chr7:1160374~1165267:+
THCA	cis	rs62103177	0.564	rs3930042	ENSG00000261126.6	RP11-795F19.1	10.08	8.87e-22	6.53e-19	0.46	0.42	Opioid sensitivity;	chr18:79963843	chr18:80046900~80095482:+
THCA	cis	rs9322193	0.962	rs2275045	ENSG00000216906.2	RP11-350J20.9	10.08	8.88e-22	6.54e-19	0.51	0.42	Lung cancer;	chr6:149842775	chr6:149904243~149906418:+
THCA	cis	rs9318086	0.687	rs9507182	ENSG00000205861.10	C1QTNF9B-AS1	-10.08	8.97e-22	6.6e-19	-0.48	-0.42	Myopia (pathological);	chr13:23868226	chr13:23888889~23897263:+
THCA	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	10.08	9e-22	6.62e-19	0.44	0.42	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
THCA	cis	rs9532669	0.963	rs9315794	ENSG00000239827.7	SUGT1P3	-10.08	9.02e-22	6.64e-19	-0.46	-0.42	Cervical cancer;	chr13:40939489	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	10.08	9.02e-22	6.64e-19	0.5	0.42	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
THCA	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-10.08	9.08e-22	6.68e-19	-0.51	-0.42	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
THCA	cis	rs11696845	0.787	rs6017408	ENSG00000276223.1	RP4-781B1.5	-10.08	9.09e-22	6.69e-19	-0.51	-0.42	Obesity-related traits;	chr20:44734888	chr20:44746642~44747201:+
THCA	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-10.08	9.11e-22	6.71e-19	-0.35	-0.42	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
THCA	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-10.08	9.14e-22	6.73e-19	-0.53	-0.42	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
THCA	cis	rs42490	0.868	rs1605996	ENSG00000251136.7	RP11-37B2.1	10.08	9.22e-22	6.78e-19	0.36	0.42	Leprosy;	chr8:89655674	chr8:89609409~89757727:-
THCA	cis	rs13392177	0.647	rs10932761	ENSG00000261338.2	RP11-378A13.1	-10.08	9.22e-22	6.78e-19	-0.45	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218199668	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	10.08	9.23e-22	6.79e-19	0.5	0.42	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
THCA	cis	rs9532669	0.963	rs9532681	ENSG00000176268.5	CYCSP34	10.08	9.4e-22	6.91e-19	0.48	0.42	Cervical cancer;	chr13:40951633	chr13:40863599~40863902:-
THCA	cis	rs2946504	0.628	rs2946510	ENSG00000251468.2	RP11-369K16.1	-10.08	9.41e-22	6.92e-19	-0.48	-0.42	Type 2 diabetes;	chr8:12950371	chr8:12958387~12962200:+
THCA	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	10.08	9.41e-22	6.92e-19	0.5	0.42	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	10.08	9.41e-22	6.92e-19	0.5	0.42	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
THCA	cis	rs7429990	0.864	rs6785669	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47715771	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs6442079	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47721044	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs13094264	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47722723	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4858851	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47724165	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs34777284	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47726585	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs7649393	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47727501	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7638103	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47727585	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs11130148	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47729797	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs1486915	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47781053	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.828	rs6792350	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47797451	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4858860	ENSG00000229759.1	MRPS18AP1	-10.08	9.43e-22	6.93e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47817344	chr3:48256350~48256938:-
THCA	cis	rs4718428	0.705	rs4717331	ENSG00000232546.1	RP11-458F8.1	-10.08	9.47e-22	6.96e-19	-0.4	-0.42	Corneal structure;	chr7:66913899	chr7:66848496~66858136:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000224205.1	AP000351.4	10.08	9.48e-22	6.97e-19	0.5	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23987320~23991421:-
THCA	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-10.08	9.5e-22	6.98e-19	-0.61	-0.42	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
THCA	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	10.07	9.6e-22	7.05e-19	0.48	0.42	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
THCA	cis	rs673078	0.615	rs73222058	ENSG00000275409.1	RP11-131L12.4	-10.07	9.62e-22	7.07e-19	-0.47	-0.42	Glucose homeostasis traits;	chr12:118221066	chr12:118430147~118430699:+
THCA	cis	rs10853057	0.717	rs62062478	ENSG00000214174.7	AMZ2P1	10.07	9.63e-22	7.07e-19	0.78	0.42	White matter microstructure (global fractional anisotropy);	chr17:65059458	chr17:64966550~64975576:-
THCA	cis	rs4964805	0.913	rs7134701	ENSG00000257681.1	RP11-341G23.4	10.07	9.64e-22	7.08e-19	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103808913	chr12:103746315~103768858:-
THCA	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	10.07	9.64e-22	7.08e-19	0.62	0.42	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
THCA	cis	rs71403859	0.502	rs35981926	ENSG00000260886.1	TAT-AS1	10.07	9.65e-22	7.09e-19	0.78	0.42	Post bronchodilator FEV1;	chr16:71466852	chr16:71565789~71578187:+
THCA	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-10.07	9.71e-22	7.13e-19	-0.49	-0.42	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
THCA	cis	rs10853057	0.717	rs58524282	ENSG00000214174.7	AMZ2P1	10.07	9.71e-22	7.13e-19	0.79	0.42	White matter microstructure (global fractional anisotropy);	chr17:65060479	chr17:64966550~64975576:-
THCA	cis	rs10759883	0.627	rs12000073	ENSG00000175611.10	LINC00476	10.07	9.73e-22	7.14e-19	0.47	0.42	Nicotine dependence;	chr9:95853844	chr9:95759231~95875977:-
THCA	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-10.07	9.82e-22	7.21e-19	-0.41	-0.42	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
THCA	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	10.07	9.85e-22	7.22e-19	0.51	0.42	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
THCA	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	10.07	9.88e-22	7.24e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
THCA	cis	rs524281	0.692	rs2302884	ENSG00000255320.1	RP11-755F10.1	10.07	1e-21	7.33e-19	0.59	0.42	Electroencephalogram traits;	chr11:66056613	chr11:66244840~66246239:-
THCA	cis	rs524281	0.647	rs2302883	ENSG00000255320.1	RP11-755F10.1	10.07	1e-21	7.33e-19	0.59	0.42	Electroencephalogram traits;	chr11:66057523	chr11:66244840~66246239:-
THCA	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	10.07	1.01e-21	7.37e-19	0.49	0.42	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
THCA	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-10.07	1.03e-21	7.51e-19	-0.45	-0.42	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
THCA	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	10.07	1.03e-21	7.52e-19	0.5	0.42	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
THCA	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	10.07	1.03e-21	7.56e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
THCA	cis	rs6558530	0.965	rs7460287	ENSG00000253982.1	CTD-2336O2.1	10.07	1.03e-21	7.56e-19	0.37	0.42	Systolic blood pressure;	chr8:1760108	chr8:1761990~1764502:-
THCA	cis	rs9532669	0.926	rs9532657	ENSG00000176268.5	CYCSP34	-10.07	1.03e-21	7.58e-19	-0.47	-0.42	Cervical cancer;	chr13:40918208	chr13:40863599~40863902:-
THCA	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-10.07	1.04e-21	7.58e-19	-0.49	-0.42	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
THCA	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	10.06	1.04e-21	7.62e-19	0.49	0.42	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
THCA	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-10.06	1.04e-21	7.62e-19	-0.55	-0.42	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
THCA	cis	rs9322193	0.923	rs11155670	ENSG00000268592.3	RAET1E-AS1	10.06	1.04e-21	7.64e-19	0.57	0.42	Lung cancer;	chr6:149644992	chr6:149863494~149919507:+
THCA	cis	rs7712401	0.715	rs6859163	ENSG00000263432.2	RN7SL689P	-10.06	1.05e-21	7.65e-19	-0.47	-0.42	Mean platelet volume;	chr5:123019225	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs385996	ENSG00000263432.2	RN7SL689P	-10.06	1.05e-21	7.65e-19	-0.47	-0.42	Mean platelet volume;	chr5:123019533	chr5:123022487~123022783:-
THCA	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	10.06	1.05e-21	7.65e-19	0.54	0.42	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
THCA	cis	rs13392177	0.543	rs12623716	ENSG00000261338.2	RP11-378A13.1	-10.06	1.05e-21	7.68e-19	-0.44	-0.42	Pyoderma gangrenosum in inflammatory bowel disease;	chr2:218208295	chr2:218255319~218257366:+
THCA	cis	rs9532669	0.857	rs7327018	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40856376	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7327315	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40856383	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7327059	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40856458	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9594433	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40856935	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9525403	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40858292	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7318768	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40859140	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs4942000	ENSG00000176268.5	CYCSP34	10.06	1.05e-21	7.7e-19	0.49	0.42	Cervical cancer;	chr13:40859979	chr13:40863599~40863902:-
THCA	cis	rs673078	0.66	rs61943365	ENSG00000275409.1	RP11-131L12.4	-10.06	1.06e-21	7.73e-19	-0.46	-0.42	Glucose homeostasis traits;	chr12:118339166	chr12:118430147~118430699:+
THCA	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	10.06	1.06e-21	7.74e-19	0.36	0.42	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	10.06	1.06e-21	7.74e-19	0.36	0.42	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	10.06	1.06e-21	7.74e-19	0.49	0.42	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
THCA	cis	rs9318086	0.663	rs2312295	ENSG00000205861.10	C1QTNF9B-AS1	-10.06	1.07e-21	7.78e-19	-0.48	-0.42	Myopia (pathological);	chr13:23883605	chr13:23888889~23897263:+
THCA	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-10.06	1.07e-21	7.78e-19	-0.41	-0.42	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
THCA	cis	rs6496932	0.635	rs11074191	ENSG00000218052.5	ADAMTS7P4	-10.06	1.07e-21	7.79e-19	-0.56	-0.42	Central corneal thickness;Corneal structure;	chr15:85388794	chr15:85255369~85330334:-
THCA	cis	rs42490	0.899	rs1397308	ENSG00000251136.7	RP11-37B2.1	10.06	1.07e-21	7.8e-19	0.37	0.42	Leprosy;	chr8:89628493	chr8:89609409~89757727:-
THCA	cis	rs10759883	0.627	rs10739622	ENSG00000175611.10	LINC00476	10.06	1.08e-21	7.85e-19	0.47	0.42	Nicotine dependence;	chr9:95852889	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs10760269	ENSG00000175611.10	LINC00476	10.06	1.08e-21	7.85e-19	0.47	0.42	Nicotine dependence;	chr9:95852897	chr9:95759231~95875977:-
THCA	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-10.06	1.08e-21	7.89e-19	-0.61	-0.42	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
THCA	cis	rs780096	0.506	rs72819512	ENSG00000234072.1	AC074117.10	-10.06	1.09e-21	7.92e-19	-0.34	-0.42	Total body bone mineral density;	chr2:27391582	chr2:27356246~27367622:+
THCA	cis	rs9322193	0.923	rs2184370	ENSG00000216906.2	RP11-350J20.9	10.06	1.09e-21	7.99e-19	0.51	0.42	Lung cancer;	chr6:149843242	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9322214	ENSG00000268592.3	RAET1E-AS1	10.06	1.1e-21	7.99e-19	0.58	0.42	Lung cancer;	chr6:149703986	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.887	rs9767113	ENSG00000268592.3	RAET1E-AS1	10.06	1.1e-21	7.99e-19	0.58	0.42	Lung cancer;	chr6:149718157	chr6:149863494~149919507:+
THCA	cis	rs10759883	0.627	rs12343734	ENSG00000175611.10	LINC00476	10.06	1.1e-21	8.04e-19	0.47	0.42	Nicotine dependence;	chr9:95847873	chr9:95759231~95875977:-
THCA	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	10.06	1.11e-21	8.08e-19	0.49	0.42	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	10.06	1.11e-21	8.08e-19	0.49	0.42	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	10.06	1.11e-21	8.08e-19	0.49	0.42	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	10.06	1.11e-21	8.08e-19	0.49	0.42	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
THCA	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	10.06	1.11e-21	8.11e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
THCA	cis	rs4660456	0.504	rs2744805	ENSG00000237899.1	RP4-739H11.3	10.06	1.11e-21	8.12e-19	0.59	0.42	Platelet count;	chr1:40654827	chr1:40669089~40687588:-
THCA	cis	rs673078	0.607	rs11068926	ENSG00000275409.1	RP11-131L12.4	-10.06	1.12e-21	8.18e-19	-0.45	-0.42	Glucose homeostasis traits;	chr12:118367320	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs4442583	ENSG00000275409.1	RP11-131L12.4	-10.06	1.12e-21	8.18e-19	-0.45	-0.42	Glucose homeostasis traits;	chr12:118367914	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943370	ENSG00000275409.1	RP11-131L12.4	-10.06	1.12e-21	8.18e-19	-0.45	-0.42	Glucose homeostasis traits;	chr12:118369469	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943371	ENSG00000275409.1	RP11-131L12.4	-10.06	1.12e-21	8.18e-19	-0.45	-0.42	Glucose homeostasis traits;	chr12:118369600	chr12:118430147~118430699:+
THCA	cis	rs7772486	0.869	rs2777473	ENSG00000235652.6	RP11-545I5.3	10.06	1.12e-21	8.19e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145980358	chr6:145799409~145886585:+
THCA	cis	rs71403859	0.502	rs34380814	ENSG00000260886.1	TAT-AS1	10.05	1.13e-21	8.24e-19	0.68	0.42	Post bronchodilator FEV1;	chr16:71454272	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	10.05	1.13e-21	8.26e-19	0.49	0.42	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
THCA	cis	rs67311347	0.577	rs1880763	ENSG00000223797.4	ENTPD3-AS1	-10.05	1.13e-21	8.26e-19	-0.34	-0.42	Renal cell carcinoma;	chr3:40241764	chr3:40313802~40453329:-
THCA	cis	rs6496932	1	rs35796484	ENSG00000218052.5	ADAMTS7P4	10.05	1.13e-21	8.27e-19	0.6	0.42	Central corneal thickness;Corneal structure;	chr15:85282019	chr15:85255369~85330334:-
THCA	cis	rs9322193	0.923	rs9688350	ENSG00000268592.3	RAET1E-AS1	10.05	1.14e-21	8.32e-19	0.57	0.42	Lung cancer;	chr6:149730977	chr6:149863494~149919507:+
THCA	cis	rs42490	0.868	rs4961155	ENSG00000251136.7	RP11-37B2.1	10.05	1.14e-21	8.33e-19	0.36	0.42	Leprosy;	chr8:89666035	chr8:89609409~89757727:-
THCA	cis	rs1426063	0.748	rs7654088	ENSG00000260265.1	RP11-44F21.5	-10.05	1.14e-21	8.34e-19	-0.62	-0.42	QT interval;	chr4:75107103	chr4:75081702~75084717:-
THCA	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-10.05	1.15e-21	8.34e-19	-0.51	-0.42	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
THCA	cis	rs2274273	0.529	rs10131562	ENSG00000258413.1	RP11-665C16.6	-10.05	1.15e-21	8.37e-19	-0.57	-0.42	Protein biomarker;	chr14:55380297	chr14:55262767~55272075:-
THCA	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-10.05	1.15e-21	8.39e-19	-0.55	-0.42	Depression;	chr6:28229408	chr6:28115628~28116551:+
THCA	cis	rs67180937	0.542	rs61824282	ENSG00000272750.1	RP11-378J18.8	-10.05	1.16e-21	8.42e-19	-0.46	-0.42	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647869	chr1:222658867~222661512:-
THCA	cis	rs1075265	0.749	rs805436	ENSG00000233266.1	HMGB1P31	10.05	1.16e-21	8.42e-19	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54051334~54051760:+
THCA	cis	rs1799949	0.896	rs8176086	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43122761	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.93	rs3765640	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43124230	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176077	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43124331	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs12947782	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43127865	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs33945274	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43128056	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11653069	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43131360	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs33988650	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.16e-21	8.44e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43135863	chr17:43144956~43145255:+
THCA	cis	rs9928842	0.941	rs6564239	ENSG00000280152.1	RP11-331F4.5	10.05	1.16e-21	8.48e-19	0.65	0.42	Alcoholic chronic pancreatitis;	chr16:75219906	chr16:75245994~75250077:-
THCA	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-10.05	1.17e-21	8.5e-19	-0.53	-0.42	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
THCA	cis	rs860295	0.702	rs11264366	ENSG00000225855.5	RUSC1-AS1	10.05	1.17e-21	8.51e-19	0.29	0.42	Body mass index;	chr1:155365620	chr1:155316863~155324176:-
THCA	cis	rs4964805	1	rs11111792	ENSG00000257681.1	RP11-341G23.4	10.05	1.17e-21	8.51e-19	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103801079	chr12:103746315~103768858:-
THCA	cis	rs67311347	0.544	rs2887965	ENSG00000223797.4	ENTPD3-AS1	-10.05	1.18e-21	8.55e-19	-0.33	-0.42	Renal cell carcinoma;	chr3:40292663	chr3:40313802~40453329:-
THCA	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	10.05	1.18e-21	8.61e-19	0.49	0.42	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
THCA	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	10.05	1.18e-21	8.62e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
THCA	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	10.05	1.19e-21	8.63e-19	0.35	0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
THCA	cis	rs11676348	0.808	rs12694430	ENSG00000261338.2	RP11-378A13.1	-10.05	1.19e-21	8.63e-19	-0.43	-0.42	Ulcerative colitis;	chr2:218151076	chr2:218255319~218257366:+
THCA	cis	rs9532669	0.963	rs3736953	ENSG00000176268.5	CYCSP34	10.05	1.19e-21	8.66e-19	0.47	0.42	Cervical cancer;	chr13:40951450	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7322399	ENSG00000176268.5	CYCSP34	10.05	1.19e-21	8.66e-19	0.47	0.42	Cervical cancer;	chr13:40952511	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs7322097	ENSG00000176268.5	CYCSP34	10.05	1.19e-21	8.66e-19	0.47	0.42	Cervical cancer;	chr13:40952513	chr13:40863599~40863902:-
THCA	cis	rs10759883	0.627	rs10760261	ENSG00000175611.10	LINC00476	10.05	1.19e-21	8.68e-19	0.47	0.42	Nicotine dependence;	chr9:95850229	chr9:95759231~95875977:-
THCA	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	10.05	1.19e-21	8.69e-19	0.49	0.42	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
THCA	cis	rs1799949	1	rs2175957	ENSG00000267681.1	CTD-3199J23.6	-10.05	1.19e-21	8.69e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43134805	chr17:43144956~43145255:+
THCA	cis	rs11148252	0.819	rs7336679	ENSG00000278238.1	RP11-245D16.4	-10.05	1.2e-21	8.69e-19	-0.47	-0.42	Lewy body disease;	chr13:52469198	chr13:52454775~52455331:-
THCA	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	10.05	1.21e-21	8.77e-19	0.49	0.42	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
THCA	cis	rs4718428	0.705	rs4718424	ENSG00000232546.1	RP11-458F8.1	-10.05	1.21e-21	8.79e-19	-0.4	-0.42	Corneal structure;	chr7:66911108	chr7:66848496~66858136:+
THCA	cis	rs853679	0.517	rs4713135	ENSG00000226314.6	ZNF192P1	-10.05	1.21e-21	8.79e-19	-0.57	-0.42	Depression;	chr6:28071808	chr6:28161781~28169594:+
THCA	cis	rs4718428	0.672	rs12530806	ENSG00000232546.1	RP11-458F8.1	-10.05	1.21e-21	8.79e-19	-0.4	-0.42	Corneal structure;	chr7:66925737	chr7:66848496~66858136:+
THCA	cis	rs6570726	0.934	rs430003	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145498370	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs395948	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145499049	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs452552	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145499645	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs451349	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145499758	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.905	rs406799	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145500701	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs1883406	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145502069	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.87	rs370653	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145502506	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs391524	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145502708	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs429306	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145505880	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs428659	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145505903	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs419847	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145506142	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs419850	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145506145	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs411641	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145506396	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs376991	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145506937	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs379164	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145507957	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs401888	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145510399	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs414646	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145510549	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs454614	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145511497	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.846	rs411468	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145511656	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs425731	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145513015	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs421690	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145513458	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs399169	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145515217	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs377130	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145515496	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs408723	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145517399	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs425717	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145517484	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs424263	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145518937	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.905	rs419575	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145519038	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs409725	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145519204	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs386823	ENSG00000235652.6	RP11-545I5.3	10.05	1.22e-21	8.84e-19	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145520229	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	10.05	1.22e-21	8.86e-19	0.49	0.42	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
THCA	cis	rs9318086	0.712	rs9510917	ENSG00000205861.10	C1QTNF9B-AS1	-10.05	1.22e-21	8.89e-19	-0.48	-0.42	Myopia (pathological);	chr13:23868707	chr13:23888889~23897263:+
THCA	cis	rs9322193	0.923	rs2342765	ENSG00000268592.3	RAET1E-AS1	10.05	1.22e-21	8.89e-19	0.57	0.42	Lung cancer;	chr6:149858873	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.75	rs9532598	ENSG00000176268.5	CYCSP34	10.05	1.23e-21	8.9e-19	0.49	0.42	Cervical cancer;	chr13:40860627	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.611	rs9532599	ENSG00000176268.5	CYCSP34	10.05	1.23e-21	8.9e-19	0.49	0.42	Cervical cancer;	chr13:40860633	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.571	rs9525405	ENSG00000176268.5	CYCSP34	10.05	1.23e-21	8.9e-19	0.49	0.42	Cervical cancer;	chr13:40860638	chr13:40863599~40863902:-
THCA	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-10.05	1.23e-21	8.91e-19	-0.62	-0.42	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
THCA	cis	rs8062405	0.792	rs12446550	ENSG00000251417.2	RP11-1348G14.4	-10.04	1.23e-21	8.95e-19	-0.39	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28802743~28817828:+
THCA	cis	rs7429990	0.803	rs6773732	ENSG00000229759.1	MRPS18AP1	-10.04	1.23e-21	8.95e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47677772	chr3:48256350~48256938:-
THCA	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-10.04	1.24e-21	8.99e-19	-0.49	-0.42	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
THCA	cis	rs4713118	0.662	rs9380046	ENSG00000280107.1	AL022393.9	-10.04	1.24e-21	8.99e-19	-0.49	-0.42	Parkinson's disease;	chr6:28062721	chr6:28170845~28172521:+
THCA	cis	rs10759883	0.58	rs10818738	ENSG00000175611.10	LINC00476	10.04	1.24e-21	9e-19	0.47	0.42	Nicotine dependence;	chr9:95846938	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs10818746	ENSG00000175611.10	LINC00476	10.04	1.24e-21	9e-19	0.47	0.42	Nicotine dependence;	chr9:95848031	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs10985769	ENSG00000175611.10	LINC00476	10.04	1.24e-21	9e-19	0.47	0.42	Nicotine dependence;	chr9:95848094	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs11998982	ENSG00000175611.10	LINC00476	10.04	1.24e-21	9e-19	0.47	0.42	Nicotine dependence;	chr9:95851142	chr9:95759231~95875977:-
THCA	cis	rs6570726	0.537	rs1280279	ENSG00000235652.6	RP11-545I5.3	10.04	1.26e-21	9.12e-19	0.45	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145562912	chr6:145799409~145886585:+
THCA	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-10.04	1.26e-21	9.14e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.833	rs6442072	ENSG00000229759.1	MRPS18AP1	-10.04	1.26e-21	9.14e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47642960	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs2882611	ENSG00000229759.1	MRPS18AP1	-10.04	1.26e-21	9.14e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47651532	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-10.04	1.26e-21	9.14e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs7429162	ENSG00000229759.1	MRPS18AP1	-10.04	1.26e-21	9.14e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47683845	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs4410463	ENSG00000229759.1	MRPS18AP1	-10.04	1.26e-21	9.14e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47693907	chr3:48256350~48256938:-
THCA	cis	rs6538678	0.746	rs703693	ENSG00000258343.1	RP11-536G4.2	-10.04	1.27e-21	9.18e-19	-0.58	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95795345~95858839:-
THCA	cis	rs7429990	0.864	rs13061412	ENSG00000229759.1	MRPS18AP1	-10.04	1.27e-21	9.19e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47660092	chr3:48256350~48256938:-
THCA	cis	rs11676348	0.901	rs7562334	ENSG00000261338.2	RP11-378A13.1	-10.04	1.27e-21	9.2e-19	-0.42	-0.42	Ulcerative colitis;	chr2:218138637	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.967	rs4672873	ENSG00000261338.2	RP11-378A13.1	-10.04	1.27e-21	9.2e-19	-0.42	-0.42	Ulcerative colitis;	chr2:218140487	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-10.04	1.27e-21	9.22e-19	-0.53	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
THCA	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	10.04	1.27e-21	9.24e-19	0.44	0.42	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
THCA	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	10.04	1.28e-21	9.28e-19	0.49	0.42	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
THCA	cis	rs17826219	0.733	rs7221691	ENSG00000263531.1	RP13-753N3.1	-10.04	1.28e-21	9.28e-19	-0.78	-0.42	Body mass index;	chr17:30396601	chr17:30863921~30864940:-
THCA	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-10.04	1.28e-21	9.28e-19	-0.61	-0.42	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
THCA	cis	rs2581828	0.618	rs9828221	ENSG00000242142.1	SERBP1P3	-10.04	1.28e-21	9.29e-19	-0.53	-0.42	Crohn's disease;	chr3:53132643	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-10.04	1.3e-21	9.39e-19	-0.51	-0.42	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
THCA	cis	rs1799949	1	rs8176103	ENSG00000267681.1	CTD-3199J23.6	-10.04	1.31e-21	9.46e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43115033	chr17:43144956~43145255:+
THCA	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-10.04	1.31e-21	9.48e-19	-0.53	-0.42	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-10.04	1.31e-21	9.48e-19	-0.53	-0.42	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
THCA	cis	rs9928842	0.823	rs12918452	ENSG00000280152.1	RP11-331F4.5	10.04	1.31e-21	9.51e-19	0.61	0.42	Alcoholic chronic pancreatitis;	chr16:75201536	chr16:75245994~75250077:-
THCA	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	10.04	1.32e-21	9.54e-19	0.49	0.42	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	10.04	1.32e-21	9.54e-19	0.49	0.42	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	10.04	1.32e-21	9.55e-19	0.49	0.42	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
THCA	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-10.04	1.32e-21	9.55e-19	-0.51	-0.42	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
THCA	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-10.04	1.32e-21	9.57e-19	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
THCA	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-10.04	1.32e-21	9.57e-19	-0.44	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
THCA	cis	rs4718428	0.705	rs10267335	ENSG00000232546.1	RP11-458F8.1	-10.04	1.33e-21	9.59e-19	-0.4	-0.42	Corneal structure;	chr7:66938233	chr7:66848496~66858136:+
THCA	cis	rs780094	0.585	rs7586601	ENSG00000234072.1	AC074117.10	-10.03	1.33e-21	9.65e-19	-0.33	-0.42	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27361799	chr2:27356246~27367622:+
THCA	cis	rs1799949	0.93	rs2298861	ENSG00000267681.1	CTD-3199J23.6	-10.03	1.35e-21	9.73e-19	-0.49	-0.42	Menopause (age at onset);	chr17:43024814	chr17:43144956~43145255:+
THCA	cis	rs4964805	1	rs4964806	ENSG00000257681.1	RP11-341G23.4	10.03	1.35e-21	9.74e-19	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103798982	chr12:103746315~103768858:-
THCA	cis	rs4964805	1	rs4964805	ENSG00000257681.1	RP11-341G23.4	10.03	1.35e-21	9.74e-19	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103799046	chr12:103746315~103768858:-
THCA	cis	rs7429990	0.864	rs13091913	ENSG00000229759.1	MRPS18AP1	-10.03	1.35e-21	9.77e-19	-0.5	-0.42	Educational attainment (years of education);	chr3:47762307	chr3:48256350~48256938:-
THCA	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	10.03	1.36e-21	9.82e-19	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	10.03	1.36e-21	9.83e-19	0.49	0.42	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
THCA	cis	rs881375	0.678	rs10760129	ENSG00000226752.6	PSMD5-AS1	-10.03	1.37e-21	9.87e-19	-0.52	-0.42	Rheumatoid arthritis;	chr9:120937905	chr9:120824828~120854385:+
THCA	cis	rs9595066	0.667	rs3809350	ENSG00000227258.4	SMIM2-AS1	10.03	1.37e-21	9.88e-19	0.56	0.42	Schizophrenia;	chr13:44162043	chr13:44110451~44240517:+
THCA	cis	rs944289	0.74	rs368187	ENSG00000257826.1	RP11-116N8.4	10.03	1.37e-21	9.91e-19	0.42	0.42	Thyroid cancer;	chr14:36063370	chr14:36061026~36067190:-
THCA	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-10.03	1.38e-21	9.95e-19	-0.61	-0.42	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
THCA	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-10.03	1.4e-21	1.01e-18	-0.51	-0.42	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
THCA	cis	rs4819052	0.851	rs2838865	ENSG00000215447.6	BX322557.10	-10.03	1.4e-21	1.01e-18	-0.35	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45288052~45291738:+
THCA	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-10.03	1.4e-21	1.01e-18	-0.49	-0.42	Height;	chr6:109501793	chr6:109382795~109383666:+
THCA	cis	rs6558530	0.965	rs4372027	ENSG00000253982.1	CTD-2336O2.1	10.03	1.41e-21	1.02e-18	0.36	0.42	Systolic blood pressure;	chr8:1759792	chr8:1761990~1764502:-
THCA	cis	rs524281	1	rs565198	ENSG00000255320.1	RP11-755F10.1	-10.03	1.41e-21	1.02e-18	-0.57	-0.42	Electroencephalogram traits;	chr11:66146037	chr11:66244840~66246239:-
THCA	cis	rs10759883	0.627	rs10818574	ENSG00000175611.10	LINC00476	10.03	1.42e-21	1.03e-18	0.46	0.42	Nicotine dependence;	chr9:95836685	chr9:95759231~95875977:-
THCA	cis	rs881375	0.678	rs10760130	ENSG00000226752.6	PSMD5-AS1	-10.03	1.42e-21	1.03e-18	-0.52	-0.42	Rheumatoid arthritis;	chr9:120939712	chr9:120824828~120854385:+
THCA	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	10.03	1.42e-21	1.03e-18	0.35	0.42	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
THCA	cis	rs7429990	0.833	rs3755638	ENSG00000229759.1	MRPS18AP1	-10.03	1.43e-21	1.03e-18	-0.5	-0.42	Educational attainment (years of education);	chr3:47580841	chr3:48256350~48256938:-
THCA	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-10.03	1.43e-21	1.03e-18	-0.45	-0.42	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
THCA	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-10.03	1.43e-21	1.04e-18	-0.61	-0.42	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-10.03	1.43e-21	1.04e-18	-0.61	-0.42	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
THCA	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	10.03	1.44e-21	1.04e-18	0.56	0.42	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
THCA	cis	rs2732480	0.5	rs7966829	ENSG00000258273.1	RP11-370I10.4	-10.03	1.45e-21	1.05e-18	-0.55	-0.42	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48333755~48333901:-
THCA	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-10.02	1.45e-21	1.05e-18	-0.62	-0.42	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
THCA	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-10.02	1.46e-21	1.05e-18	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000250470.1	AP000351.3	-10.02	1.48e-21	1.07e-18	-0.6	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23976904~23977585:-
THCA	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-10.02	1.48e-21	1.07e-18	-0.45	-0.42	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
THCA	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	10.02	1.48e-21	1.07e-18	0.44	0.42	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
THCA	cis	rs9322193	0.962	rs7740784	ENSG00000268592.3	RAET1E-AS1	10.02	1.48e-21	1.07e-18	0.58	0.42	Lung cancer;	chr6:149833364	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	10.02	1.49e-21	1.07e-18	0.49	0.42	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
THCA	cis	rs9532669	0.963	rs7989303	ENSG00000176268.5	CYCSP34	10.02	1.49e-21	1.08e-18	0.47	0.42	Cervical cancer;	chr13:40950087	chr13:40863599~40863902:-
THCA	cis	rs6558530	0.932	rs10102731	ENSG00000253982.1	CTD-2336O2.1	10.02	1.49e-21	1.08e-18	0.37	0.42	Systolic blood pressure;	chr8:1760854	chr8:1761990~1764502:-
THCA	cis	rs957448	1	rs1023767	ENSG00000253704.1	RP11-267M23.4	10.02	1.5e-21	1.08e-18	0.45	0.42	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94553722~94569745:+
THCA	cis	rs1043099	0.912	rs929454	ENSG00000279699.1	RP1-102K2.9	10.02	1.5e-21	1.08e-18	0.58	0.42	Rheumatoid arthritis;	chr22:30296364	chr22:30275215~30276951:-
THCA	cis	rs6570726	0.934	rs9484995	ENSG00000235652.6	RP11-545I5.3	-10.02	1.51e-21	1.09e-18	-0.39	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145459978	chr6:145799409~145886585:+
THCA	cis	rs4718428	0.705	rs2901311	ENSG00000232546.1	RP11-458F8.1	-10.02	1.53e-21	1.1e-18	-0.41	-0.42	Corneal structure;	chr7:66950082	chr7:66848496~66858136:+
THCA	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	10.02	1.53e-21	1.1e-18	0.52	0.42	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
THCA	cis	rs1799949	0.965	rs33925201	ENSG00000267681.1	CTD-3199J23.6	-10.02	1.53e-21	1.1e-18	-0.49	-0.42	Menopause (age at onset);	chr17:43128665	chr17:43144956~43145255:+
THCA	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-10.02	1.53e-21	1.1e-18	-0.51	-0.42	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
THCA	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	10.02	1.53e-21	1.1e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
THCA	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-10.02	1.54e-21	1.11e-18	-0.35	-0.42	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
THCA	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-10.02	1.54e-21	1.11e-18	-0.48	-0.42	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
THCA	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-10.02	1.55e-21	1.11e-18	-0.45	-0.42	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
THCA	cis	rs6904897	0.563	rs6569976	ENSG00000232876.1	CTA-212D2.2	-10.02	1.56e-21	1.12e-18	-0.5	-0.42	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903615	chr6:135055033~135060550:+
THCA	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	10.02	1.56e-21	1.13e-18	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
THCA	cis	rs2599510	0.703	rs58852184	ENSG00000276334.1	AL133243.1	10.01	1.58e-21	1.14e-18	0.46	0.42	Interleukin-18 levels;	chr2:32504696	chr2:32521927~32523547:+
THCA	cis	rs6558530	0.965	rs730377	ENSG00000253982.1	CTD-2336O2.1	10.01	1.59e-21	1.14e-18	0.36	0.42	Systolic blood pressure;	chr8:1759785	chr8:1761990~1764502:-
THCA	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-10.01	1.61e-21	1.16e-18	-0.62	-0.42	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-10.01	1.61e-21	1.16e-18	-0.62	-0.42	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
THCA	cis	rs7429990	0.864	rs12497826	ENSG00000229759.1	MRPS18AP1	-10.01	1.62e-21	1.16e-18	-0.5	-0.42	Educational attainment (years of education);	chr3:47628059	chr3:48256350~48256938:-
THCA	cis	rs1043099	0.912	rs4339043	ENSG00000279699.1	RP1-102K2.9	10.01	1.64e-21	1.18e-18	0.6	0.42	Rheumatoid arthritis;	chr22:30339919	chr22:30275215~30276951:-
THCA	cis	rs1799949	1	rs11655505	ENSG00000267681.1	CTD-3199J23.6	-10.01	1.66e-21	1.19e-18	-0.49	-0.42	Menopause (age at onset);	chr17:43126360	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs4793204	ENSG00000267681.1	CTD-3199J23.6	-10.01	1.66e-21	1.19e-18	-0.49	-0.42	Menopause (age at onset);	chr17:43127281	chr17:43144956~43145255:+
THCA	cis	rs9532669	0.926	rs9566582	ENSG00000176268.5	CYCSP34	10.01	1.66e-21	1.19e-18	0.48	0.42	Cervical cancer;	chr13:40852121	chr13:40863599~40863902:-
THCA	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	10.01	1.66e-21	1.19e-18	0.49	0.42	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
THCA	cis	rs2283792	0.624	rs2876981	ENSG00000224086.5	LL22NC03-86G7.1	-10.01	1.66e-21	1.19e-18	-0.53	-0.42	Multiple sclerosis;	chr22:21851322	chr22:21938293~21977632:+
THCA	cis	rs7598759	0.548	rs6750795	ENSG00000181798.2	LINC00471	-10.01	1.66e-21	1.2e-18	-0.51	-0.42	Noise-induced hearing loss;	chr2:231513520	chr2:231508426~231514339:-
THCA	cis	rs6570726	0.818	rs398812	ENSG00000235652.6	RP11-545I5.3	10.01	1.67e-21	1.2e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145496135	chr6:145799409~145886585:+
THCA	cis	rs9532669	0.926	rs9532693	ENSG00000176268.5	CYCSP34	10.01	1.67e-21	1.2e-18	0.47	0.42	Cervical cancer;	chr13:40980557	chr13:40863599~40863902:-
THCA	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-10.01	1.67e-21	1.2e-18	-0.48	-0.42	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-10.01	1.67e-21	1.2e-18	-0.48	-0.42	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
THCA	cis	rs9322193	0.923	rs12526675	ENSG00000268592.3	RAET1E-AS1	-10.01	1.67e-21	1.2e-18	-0.57	-0.42	Lung cancer;	chr6:149729540	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	10.01	1.67e-21	1.2e-18	0.49	0.42	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	10.01	1.67e-21	1.2e-18	0.49	0.42	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
THCA	cis	rs10740039	0.804	rs4948424	ENSG00000254271.1	RP11-131N11.4	10.01	1.68e-21	1.21e-18	0.51	0.42	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60681812	chr10:60734342~60741828:+
THCA	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-10.01	1.69e-21	1.21e-18	-0.44	-0.42	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
THCA	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	10.01	1.69e-21	1.21e-18	0.49	0.42	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
THCA	cis	rs4266144	0.821	rs56237906	ENSG00000244515.1	KRT18P34	-10.01	1.69e-21	1.22e-18	-0.5	-0.42	Coronary artery disease;	chr3:157134684	chr3:157162663~157163932:-
THCA	cis	rs9322193	0.923	rs4870509	ENSG00000268592.3	RAET1E-AS1	10.01	1.7e-21	1.22e-18	0.58	0.42	Lung cancer;	chr6:149702212	chr6:149863494~149919507:+
THCA	cis	rs1577917	0.687	rs34618171	ENSG00000203875.9	SNHG5	-10.01	1.71e-21	1.23e-18	-0.52	-0.42	Response to antipsychotic treatment;	chr6:86101447	chr6:85660950~85678736:-
THCA	cis	rs6061231	0.834	rs2427307	ENSG00000273619.1	RP5-908M14.9	-10	1.72e-21	1.23e-18	-0.33	-0.42	Colorectal cancer;	chr20:62391630	chr20:62386303~62386970:-
THCA	cis	rs1976403	0.51	rs1697421	ENSG00000227001.3	NBPF2P	10	1.72e-21	1.23e-18	0.46	0.42	Liver enzyme levels (alkaline phosphatase);	chr1:21496799	chr1:21424625~21427967:-
THCA	cis	rs11676348	0.805	rs13007219	ENSG00000261338.2	RP11-378A13.1	-10	1.72e-21	1.24e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218099136	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.935	rs13007992	ENSG00000261338.2	RP11-378A13.1	-10	1.72e-21	1.24e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218099328	chr2:218255319~218257366:+
THCA	cis	rs4964805	0.683	rs12424737	ENSG00000257681.1	RP11-341G23.4	10	1.73e-21	1.24e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103802443	chr12:103746315~103768858:-
THCA	cis	rs950169	0.922	rs12910334	ENSG00000259728.4	LINC00933	10	1.73e-21	1.24e-18	0.57	0.42	Schizophrenia;	chr15:84403620	chr15:84570649~84580175:+
THCA	cis	rs597539	0.552	rs6591361	ENSG00000250508.1	RP11-757G1.6	-10	1.74e-21	1.25e-18	-0.5	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951815	chr11:68870664~68874542:+
THCA	cis	rs6904897	0.538	rs4639353	ENSG00000232876.1	CTA-212D2.2	10	1.74e-21	1.25e-18	0.5	0.42	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr6:134903190	chr6:135055033~135060550:+
THCA	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-10	1.74e-21	1.25e-18	-0.49	-0.42	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
THCA	cis	rs6570726	0.935	rs12663204	ENSG00000235652.6	RP11-545I5.3	10	1.75e-21	1.25e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145497237	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs12663205	ENSG00000235652.6	RP11-545I5.3	10	1.75e-21	1.25e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145497242	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs12663211	ENSG00000235652.6	RP11-545I5.3	10	1.75e-21	1.25e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145497291	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs422540	ENSG00000235652.6	RP11-545I5.3	10	1.75e-21	1.25e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145516679	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs409121	ENSG00000235652.6	RP11-545I5.3	10	1.75e-21	1.25e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145518657	chr6:145799409~145886585:+
THCA	cis	rs56080343	0.688	rs10083190	ENSG00000275409.1	RP11-131L12.4	-10	1.75e-21	1.26e-18	-0.43	-0.42	Neuroticism;	chr12:118365385	chr12:118430147~118430699:+
THCA	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	10	1.76e-21	1.26e-18	0.43	0.42	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
THCA	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-10	1.76e-21	1.26e-18	-0.43	-0.42	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
THCA	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-10	1.76e-21	1.26e-18	-0.43	-0.42	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
THCA	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-10	1.76e-21	1.26e-18	-0.43	-0.42	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
THCA	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-10	1.76e-21	1.26e-18	-0.5	-0.42	Migraine;	chr4:56852029	chr4:56960927~56961373:-
THCA	cis	rs7208859	0.573	rs8070182	ENSG00000266490.1	CTD-2349P21.9	10	1.77e-21	1.27e-18	0.56	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30792372~30792833:+
THCA	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	10	1.78e-21	1.28e-18	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
THCA	cis	rs597539	0.552	rs6591360	ENSG00000250508.1	RP11-757G1.6	-10	1.78e-21	1.28e-18	-0.5	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951200	chr11:68870664~68874542:+
THCA	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	10	1.78e-21	1.28e-18	0.51	0.42	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
THCA	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-10	1.78e-21	1.28e-18	-0.49	-0.42	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
THCA	cis	rs4964805	0.657	rs4964813	ENSG00000257681.1	RP11-341G23.4	10	1.8e-21	1.29e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103795776	chr12:103746315~103768858:-
THCA	cis	rs9322193	0.923	rs62439840	ENSG00000268592.3	RAET1E-AS1	10	1.8e-21	1.29e-18	0.58	0.42	Lung cancer;	chr6:149674639	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9393175	ENSG00000268592.3	RAET1E-AS1	10	1.8e-21	1.29e-18	0.58	0.42	Lung cancer;	chr6:149677587	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-10	1.81e-21	1.29e-18	-0.49	-0.42	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
THCA	cis	rs10759883	0.627	rs10985499	ENSG00000175611.10	LINC00476	10	1.82e-21	1.31e-18	0.47	0.42	Nicotine dependence;	chr9:95840724	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.603	rs10760262	ENSG00000175611.10	LINC00476	10	1.82e-21	1.31e-18	0.47	0.42	Nicotine dependence;	chr9:95850234	chr9:95759231~95875977:-
THCA	cis	rs9532669	0.963	rs9562238	ENSG00000239827.7	SUGT1P3	-10	1.83e-21	1.31e-18	-0.45	-0.42	Cervical cancer;	chr13:40924785	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.884	rs62439837	ENSG00000268592.3	RAET1E-AS1	10	1.84e-21	1.32e-18	0.58	0.42	Lung cancer;	chr6:149670380	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	10	1.85e-21	1.32e-18	0.49	0.42	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
THCA	cis	rs1426063	0.748	rs6534607	ENSG00000260265.1	RP11-44F21.5	10	1.86e-21	1.33e-18	0.62	0.42	QT interval;	chr4:75106366	chr4:75081702~75084717:-
THCA	cis	rs737008	0.5	rs7189239	ENSG00000262703.1	RP11-485G7.6	9.99	1.87e-21	1.34e-18	0.47	0.42	Obesity-related traits;	chr16:11308658	chr16:11348143~11349321:-
THCA	cis	rs6908034	0.769	rs6916589	ENSG00000228412.5	RP4-625H18.2	9.99	1.87e-21	1.34e-18	0.89	0.42	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19761132	chr6:19802164~19804752:-
THCA	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-9.99	1.88e-21	1.34e-18	-0.32	-0.42	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
THCA	cis	rs4964805	1	rs4964794	ENSG00000257681.1	RP11-341G23.4	9.99	1.88e-21	1.34e-18	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103800640	chr12:103746315~103768858:-
THCA	cis	rs1799949	1	rs8176126	ENSG00000267681.1	CTD-3199J23.6	9.99	1.89e-21	1.35e-18	0.48	0.42	Menopause (age at onset);	chr17:43107032	chr17:43144956~43145255:+
THCA	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	9.99	1.89e-21	1.35e-18	0.36	0.42	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.923	rs9371486	ENSG00000223701.3	RAET1E-AS1	9.99	1.89e-21	1.35e-18	0.57	0.42	Lung cancer;	chr6:149832090	chr6:149884431~149919508:+
THCA	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	9.99	1.89e-21	1.35e-18	0.57	0.42	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
THCA	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	9.99	1.9e-21	1.36e-18	0.57	0.42	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
THCA	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	9.99	1.9e-21	1.36e-18	0.57	0.42	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
THCA	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	9.99	1.9e-21	1.36e-18	0.57	0.42	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
THCA	cis	rs10463554	1	rs10463554	ENSG00000175749.11	EIF3KP1	9.99	1.9e-21	1.36e-18	0.55	0.42	Parkinson's disease;	chr5:102983270	chr5:103032376~103033031:+
THCA	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-9.99	1.92e-21	1.37e-18	-0.58	-0.42	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
THCA	cis	rs2455601	0.679	rs2653559	ENSG00000254860.4	TMEM9B-AS1	9.99	1.93e-21	1.38e-18	0.56	0.42	Schizophrenia;	chr11:8878847	chr11:8964675~8977527:+
THCA	cis	rs4964805	0.657	rs73192049	ENSG00000257681.1	RP11-341G23.4	9.99	1.94e-21	1.39e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103794215	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.632	rs9706225	ENSG00000257681.1	RP11-341G23.4	9.99	1.94e-21	1.39e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103794308	chr12:103746315~103768858:-
THCA	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	9.99	1.95e-21	1.39e-18	0.49	0.42	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
THCA	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-9.99	1.95e-21	1.39e-18	-0.55	-0.42	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
THCA	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	9.99	1.96e-21	1.4e-18	0.44	0.42	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
THCA	cis	rs780096	0.525	rs13388159	ENSG00000234072.1	AC074117.10	-9.99	1.96e-21	1.4e-18	-0.33	-0.42	Total body bone mineral density;	chr2:27425417	chr2:27356246~27367622:+
THCA	cis	rs17826219	0.562	rs719600	ENSG00000263531.1	RP13-753N3.1	-9.99	1.96e-21	1.4e-18	-0.76	-0.42	Body mass index;	chr17:30404244	chr17:30863921~30864940:-
THCA	cis	rs9322193	0.884	rs9371201	ENSG00000223701.3	RAET1E-AS1	9.99	1.98e-21	1.41e-18	0.57	0.42	Lung cancer;	chr6:149823865	chr6:149884431~149919508:+
THCA	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	9.99	1.98e-21	1.41e-18	0.54	0.42	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
THCA	cis	rs9322193	0.847	rs56103941	ENSG00000268592.3	RAET1E-AS1	9.99	1.98e-21	1.41e-18	0.58	0.42	Lung cancer;	chr6:149816095	chr6:149863494~149919507:+
THCA	cis	rs4964805	0.606	rs7312606	ENSG00000257681.1	RP11-341G23.4	9.99	1.98e-21	1.41e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103794607	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.581	rs7312825	ENSG00000257681.1	RP11-341G23.4	9.99	1.98e-21	1.41e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103794610	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.657	rs11111783	ENSG00000257681.1	RP11-341G23.4	9.99	1.98e-21	1.41e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103794745	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.657	rs4964814	ENSG00000257681.1	RP11-341G23.4	-9.99	1.98e-21	1.41e-18	-0.49	-0.42	Attention deficit hyperactivity disorder;	chr12:103795606	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.657	rs11111787	ENSG00000257681.1	RP11-341G23.4	9.99	1.98e-21	1.41e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103795721	chr12:103746315~103768858:-
THCA	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-9.99	1.99e-21	1.42e-18	-0.52	-0.42	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-9.99	1.99e-21	1.42e-18	-0.52	-0.42	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-9.99	1.99e-21	1.42e-18	-0.52	-0.42	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-9.99	1.99e-21	1.42e-18	-0.52	-0.42	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
THCA	cis	rs71403859	0.73	rs35390364	ENSG00000260886.1	TAT-AS1	9.99	1.99e-21	1.42e-18	0.77	0.42	Post bronchodilator FEV1;	chr16:71706146	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	9.99	1.99e-21	1.42e-18	0.5	0.42	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
THCA	cis	rs6570726	0.905	rs1355146	ENSG00000235652.6	RP11-545I5.3	-9.99	2e-21	1.43e-18	-0.39	-0.42	Lobe attachment (rater-scored or self-reported);	chr6:145460605	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.607	rs6557165	ENSG00000223701.3	RAET1E-AS1	-9.99	2.01e-21	1.43e-18	-0.6	-0.42	Lung cancer;	chr6:149906883	chr6:149884431~149919508:+
THCA	cis	rs6061231	1	rs6061231	ENSG00000273619.1	RP5-908M14.9	-9.99	2.02e-21	1.44e-18	-0.33	-0.42	Colorectal cancer;	chr20:62381861	chr20:62386303~62386970:-
THCA	cis	rs1862618	0.573	rs185220	ENSG00000271828.1	CTD-2310F14.1	9.98	2.03e-21	1.44e-18	0.67	0.42	Initial pursuit acceleration;	chr5:56909530	chr5:56927874~56929573:+
THCA	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-9.98	2.04e-21	1.46e-18	-0.49	-0.42	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
THCA	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	9.98	2.05e-21	1.46e-18	0.49	0.42	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs1125	ENSG00000223701.3	RAET1E-AS1	9.98	2.06e-21	1.47e-18	0.56	0.42	Lung cancer;	chr6:149658280	chr6:149884431~149919508:+
THCA	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	9.98	2.07e-21	1.48e-18	0.58	0.42	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
THCA	cis	rs12931792	0.748	rs11150585	ENSG00000183604.13	SMG1P5	9.98	2.08e-21	1.48e-18	0.44	0.42	Tonsillectomy;	chr16:30172965	chr16:30267553~30335374:-
THCA	cis	rs42490	0.834	rs10102245	ENSG00000251136.7	RP11-37B2.1	9.98	2.09e-21	1.49e-18	0.36	0.42	Leprosy;	chr8:89638317	chr8:89609409~89757727:-
THCA	cis	rs860295	0.541	rs11264359	ENSG00000225855.5	RUSC1-AS1	9.98	2.1e-21	1.5e-18	0.28	0.42	Body mass index;	chr1:155313038	chr1:155316863~155324176:-
THCA	cis	rs6061231	0.958	rs2427305	ENSG00000273619.1	RP5-908M14.9	-9.98	2.1e-21	1.5e-18	-0.34	-0.42	Colorectal cancer;	chr20:62378693	chr20:62386303~62386970:-
THCA	cis	rs8062405	0.824	rs4788083	ENSG00000251417.2	RP11-1348G14.4	-9.98	2.11e-21	1.5e-18	-0.39	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28802743~28817828:+
THCA	cis	rs11676348	0.846	rs4674260	ENSG00000261338.2	RP11-378A13.1	-9.98	2.12e-21	1.51e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218137653	chr2:218255319~218257366:+
THCA	cis	rs6570726	0.935	rs380883	ENSG00000235652.6	RP11-545I5.3	9.98	2.12e-21	1.51e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145501856	chr6:145799409~145886585:+
THCA	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	9.98	2.12e-21	1.51e-18	0.5	0.42	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
THCA	cis	rs9595066	0.548	rs9562537	ENSG00000227258.4	SMIM2-AS1	9.98	2.14e-21	1.52e-18	0.56	0.42	Schizophrenia;	chr13:44181651	chr13:44110451~44240517:+
THCA	cis	rs524281	0.731	rs1125078	ENSG00000255320.1	RP11-755F10.1	-9.98	2.14e-21	1.52e-18	-0.62	-0.42	Electroencephalogram traits;	chr11:66042404	chr11:66244840~66246239:-
THCA	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	9.98	2.15e-21	1.53e-18	0.49	0.42	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	9.98	2.15e-21	1.53e-18	0.49	0.42	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
THCA	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-9.98	2.16e-21	1.53e-18	-0.49	-0.42	Migraine;	chr4:56937339	chr4:56960927~56961373:-
THCA	cis	rs597539	0.652	rs516425	ENSG00000250508.1	RP11-757G1.6	-9.98	2.16e-21	1.54e-18	-0.5	-0.42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68948206	chr11:68870664~68874542:+
THCA	cis	rs4964805	0.657	rs1866293	ENSG00000257681.1	RP11-341G23.4	9.98	2.17e-21	1.54e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103792877	chr12:103746315~103768858:-
THCA	cis	rs4964805	0.71	rs1866296	ENSG00000257681.1	RP11-341G23.4	9.98	2.17e-21	1.54e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103793314	chr12:103746315~103768858:-
THCA	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-9.98	2.17e-21	1.54e-18	-0.66	-0.42	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-9.98	2.17e-21	1.54e-18	-0.66	-0.42	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
THCA	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-9.98	2.17e-21	1.54e-18	-0.66	-0.42	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
THCA	cis	rs11676348	0.967	rs4674258	ENSG00000261338.2	RP11-378A13.1	-9.98	2.18e-21	1.55e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218125863	chr2:218255319~218257366:+
THCA	cis	rs950169	0.887	rs35986397	ENSG00000259728.4	LINC00933	9.98	2.19e-21	1.55e-18	0.58	0.42	Schizophrenia;	chr15:84400409	chr15:84570649~84580175:+
THCA	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-9.98	2.19e-21	1.56e-18	-0.53	-0.42	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
THCA	cis	rs524281	0.954	rs549187	ENSG00000255320.1	RP11-755F10.1	9.98	2.2e-21	1.56e-18	0.56	0.42	Electroencephalogram traits;	chr11:66131160	chr11:66244840~66246239:-
THCA	cis	rs12931792	0.687	rs8057425	ENSG00000183604.13	SMG1P5	9.97	2.21e-21	1.57e-18	0.44	0.42	Tonsillectomy;	chr16:30171220	chr16:30267553~30335374:-
THCA	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	9.97	2.23e-21	1.58e-18	0.49	0.42	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
THCA	cis	rs42490	0.8	rs56291556	ENSG00000251136.7	RP11-37B2.1	9.97	2.24e-21	1.59e-18	0.36	0.42	Leprosy;	chr8:89662546	chr8:89609409~89757727:-
THCA	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	9.97	2.24e-21	1.59e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	9.97	2.24e-21	1.59e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	9.97	2.24e-21	1.59e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
THCA	cis	rs881375	0.9	rs2241003	ENSG00000226752.6	PSMD5-AS1	-9.97	2.24e-21	1.59e-18	-0.51	-0.42	Rheumatoid arthritis;	chr9:120904499	chr9:120824828~120854385:+
THCA	cis	rs71403859	0.73	rs12446333	ENSG00000260886.1	TAT-AS1	9.97	2.25e-21	1.6e-18	0.77	0.42	Post bronchodilator FEV1;	chr16:71718254	chr16:71565789~71578187:+
THCA	cis	rs4964805	0.657	rs1866294	ENSG00000257681.1	RP11-341G23.4	9.97	2.25e-21	1.6e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103793017	chr12:103746315~103768858:-
THCA	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	9.97	2.26e-21	1.61e-18	0.49	0.42	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
THCA	cis	rs524281	0.692	rs11227395	ENSG00000255320.1	RP11-755F10.1	9.97	2.27e-21	1.61e-18	0.59	0.42	Electroencephalogram traits;	chr11:66062166	chr11:66244840~66246239:-
THCA	cis	rs4964805	0.657	rs11111781	ENSG00000257681.1	RP11-341G23.4	9.97	2.27e-21	1.61e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103793662	chr12:103746315~103768858:-
THCA	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-9.97	2.28e-21	1.62e-18	-0.63	-0.42	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
THCA	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-9.97	2.28e-21	1.62e-18	-0.69	-0.42	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
THCA	cis	rs12188164	0.9	rs72717425	ENSG00000221990.4	EXOC3-AS1	9.97	2.28e-21	1.62e-18	0.34	0.42	Cystic fibrosis severity;	chr5:438694	chr5:441498~443160:-
THCA	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	9.97	2.28e-21	1.62e-18	0.49	0.42	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
THCA	cis	rs2948294	0.588	rs7011221	ENSG00000253893.2	FAM85B	-9.97	2.31e-21	1.64e-18	-0.54	-0.42	Red cell distribution width;	chr8:8256724	chr8:8167819~8226614:-
THCA	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-9.97	2.31e-21	1.64e-18	-0.54	-0.42	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
THCA	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	9.97	2.32e-21	1.64e-18	0.49	0.42	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	9.97	2.32e-21	1.64e-18	0.49	0.42	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	9.97	2.32e-21	1.64e-18	0.49	0.42	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	9.97	2.32e-21	1.64e-18	0.49	0.42	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	9.97	2.32e-21	1.64e-18	0.49	0.42	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
THCA	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	9.97	2.32e-21	1.64e-18	0.57	0.42	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
THCA	cis	rs6496932	1	rs11638110	ENSG00000218052.5	ADAMTS7P4	9.97	2.32e-21	1.65e-18	0.61	0.42	Central corneal thickness;Corneal structure;	chr15:85279653	chr15:85255369~85330334:-
THCA	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	9.97	2.32e-21	1.65e-18	0.57	0.42	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
THCA	cis	rs9322193	0.923	rs12529698	ENSG00000268592.3	RAET1E-AS1	9.97	2.33e-21	1.65e-18	0.57	0.42	Lung cancer;	chr6:149650951	chr6:149863494~149919507:+
THCA	cis	rs4591358	0.53	rs72927723	ENSG00000223466.1	AC064834.2	-9.97	2.33e-21	1.66e-18	-0.66	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522498	chr2:195533035~195538681:+
THCA	cis	rs7829975	0.681	rs2271342	ENSG00000253893.2	FAM85B	-9.97	2.34e-21	1.66e-18	-0.53	-0.42	Mood instability;	chr8:8786428	chr8:8167819~8226614:-
THCA	cis	rs4964805	0.526	rs934845	ENSG00000257681.1	RP11-341G23.4	9.97	2.34e-21	1.66e-18	0.49	0.42	Attention deficit hyperactivity disorder;	chr12:103791479	chr12:103746315~103768858:-
THCA	cis	rs6570726	0.935	rs413916	ENSG00000235652.6	RP11-545I5.3	9.97	2.37e-21	1.68e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145510264	chr6:145799409~145886585:+
THCA	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	9.96	2.41e-21	1.7e-18	0.44	0.42	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
THCA	cis	rs8062405	0.756	rs151182	ENSG00000251417.2	RP11-1348G14.4	-9.96	2.43e-21	1.72e-18	-0.4	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.789	rs151174	ENSG00000251417.2	RP11-1348G14.4	-9.96	2.45e-21	1.73e-18	-0.41	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28496748	chr16:28802743~28817828:+
THCA	cis	rs1185460	0.565	rs1043314	ENSG00000271751.1	RP11-110I1.14	9.96	2.47e-21	1.75e-18	0.52	0.42	Coronary artery disease;	chr11:119045232	chr11:119065263~119065677:-
THCA	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	9.96	2.48e-21	1.75e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
THCA	cis	rs6061231	0.958	rs2379126	ENSG00000273619.1	RP5-908M14.9	-9.96	2.5e-21	1.77e-18	-0.34	-0.42	Colorectal cancer;	chr20:62377949	chr20:62386303~62386970:-
THCA	cis	rs6061231	0.958	rs2427304	ENSG00000273619.1	RP5-908M14.9	-9.96	2.5e-21	1.77e-18	-0.34	-0.42	Colorectal cancer;	chr20:62378528	chr20:62386303~62386970:-
THCA	cis	rs71403859	0.73	rs17356206	ENSG00000260886.1	TAT-AS1	9.96	2.5e-21	1.77e-18	0.77	0.42	Post bronchodilator FEV1;	chr16:71702456	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	9.96	2.5e-21	1.77e-18	0.49	0.42	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
THCA	cis	rs673078	0.66	rs17619932	ENSG00000275409.1	RP11-131L12.4	-9.96	2.51e-21	1.77e-18	-0.44	-0.42	Glucose homeostasis traits;	chr12:118352228	chr12:118430147~118430699:+
THCA	cis	rs2948294	0.566	rs13274039	ENSG00000253893.2	FAM85B	-9.96	2.53e-21	1.79e-18	-0.54	-0.42	Red cell distribution width;	chr8:8254137	chr8:8167819~8226614:-
THCA	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-9.96	2.56e-21	1.81e-18	-0.53	-0.42	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
THCA	cis	rs9322193	0.923	rs9767652	ENSG00000268592.3	RAET1E-AS1	9.96	2.57e-21	1.82e-18	0.57	0.42	Lung cancer;	chr6:149734502	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs10782314	ENSG00000268592.3	RAET1E-AS1	9.96	2.57e-21	1.82e-18	0.57	0.42	Lung cancer;	chr6:149735527	chr6:149863494~149919507:+
THCA	cis	rs11676348	0.818	rs1126579	ENSG00000261338.2	RP11-378A13.1	-9.96	2.58e-21	1.82e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218136011	chr2:218255319~218257366:+
THCA	cis	rs4964805	0.913	rs36034617	ENSG00000257681.1	RP11-341G23.4	9.96	2.59e-21	1.83e-18	0.5	0.42	Attention deficit hyperactivity disorder;	chr12:103809837	chr12:103746315~103768858:-
THCA	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
THCA	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
THCA	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
THCA	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
THCA	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
THCA	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
THCA	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	9.96	2.59e-21	1.83e-18	0.57	0.42	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
THCA	cis	rs7429990	0.833	rs3755637	ENSG00000229759.1	MRPS18AP1	-9.95	2.61e-21	1.85e-18	-0.49	-0.42	Educational attainment (years of education);	chr3:47580720	chr3:48256350~48256938:-
THCA	cis	rs7712401	0.715	rs13163098	ENSG00000263432.2	RN7SL689P	-9.95	2.62e-21	1.85e-18	-0.47	-0.42	Mean platelet volume;	chr5:123010841	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs13164161	ENSG00000263432.2	RN7SL689P	-9.95	2.62e-21	1.85e-18	-0.47	-0.42	Mean platelet volume;	chr5:123011202	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs401226	ENSG00000263432.2	RN7SL689P	-9.95	2.62e-21	1.85e-18	-0.47	-0.42	Mean platelet volume;	chr5:123012031	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs395981	ENSG00000263432.2	RN7SL689P	-9.95	2.62e-21	1.85e-18	-0.47	-0.42	Mean platelet volume;	chr5:123012216	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs424247	ENSG00000263432.2	RN7SL689P	-9.95	2.62e-21	1.85e-18	-0.47	-0.42	Mean platelet volume;	chr5:123012298	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.715	rs424262	ENSG00000263432.2	RN7SL689P	-9.95	2.62e-21	1.85e-18	-0.47	-0.42	Mean platelet volume;	chr5:123012317	chr5:123022487~123022783:-
THCA	cis	rs6683071	0.689	rs12063226	ENSG00000272750.1	RP11-378J18.8	-9.95	2.63e-21	1.86e-18	-0.58	-0.42	Cognitive performance;	chr1:222753913	chr1:222658867~222661512:-
THCA	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-9.95	2.64e-21	1.86e-18	-0.47	-0.42	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
THCA	cis	rs6479874	0.681	rs9415727	ENSG00000223502.1	RP11-96B5.3	-9.95	2.64e-21	1.87e-18	-0.45	-0.42	Migraine;	chr10:51126376	chr10:51062579~51068553:-
THCA	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	9.95	2.65e-21	1.87e-18	0.34	0.42	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
THCA	cis	rs7712401	0.601	rs2126935	ENSG00000263432.2	RN7SL689P	-9.95	2.67e-21	1.89e-18	-0.46	-0.42	Mean platelet volume;	chr5:122977876	chr5:123022487~123022783:-
THCA	cis	rs6570726	0.935	rs446242	ENSG00000235652.6	RP11-545I5.3	9.95	2.67e-21	1.89e-18	0.39	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145522730	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.736	rs3828701	ENSG00000223701.3	RAET1E-AS1	9.95	2.67e-21	1.89e-18	0.55	0.42	Lung cancer;	chr6:149791063	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.736	rs3805750	ENSG00000223701.3	RAET1E-AS1	9.95	2.67e-21	1.89e-18	0.55	0.42	Lung cancer;	chr6:149791065	chr6:149884431~149919508:+
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	9.95	2.71e-21	1.91e-18	0.53	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
THCA	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-9.95	2.74e-21	1.93e-18	-0.49	-0.42	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
THCA	cis	rs2455601	0.507	rs7948452	ENSG00000254860.4	TMEM9B-AS1	9.95	2.76e-21	1.94e-18	0.48	0.42	Schizophrenia;	chr11:8856157	chr11:8964675~8977527:+
THCA	cis	rs67311347	0.544	rs1902073	ENSG00000223797.4	ENTPD3-AS1	9.95	2.76e-21	1.95e-18	0.33	0.42	Renal cell carcinoma;	chr3:40292006	chr3:40313802~40453329:-
THCA	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	9.95	2.77e-21	1.95e-18	0.44	0.42	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
THCA	cis	rs4718428	0.705	rs3800817	ENSG00000232546.1	RP11-458F8.1	-9.95	2.79e-21	1.97e-18	-0.39	-0.42	Corneal structure;	chr7:66798563	chr7:66848496~66858136:+
THCA	cis	rs496547	0.719	rs476246	ENSG00000278376.1	RP11-158I9.8	9.95	2.8e-21	1.97e-18	0.31	0.42	Hip minimal joint space width;	chr11:118747211	chr11:118791254~118793137:+
THCA	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	9.95	2.8e-21	1.97e-18	0.5	0.42	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
THCA	cis	rs4718428	0.705	rs4718422	ENSG00000232546.1	RP11-458F8.1	-9.95	2.8e-21	1.98e-18	-0.39	-0.42	Corneal structure;	chr7:66894282	chr7:66848496~66858136:+
THCA	cis	rs4718428	0.705	rs13231140	ENSG00000232546.1	RP11-458F8.1	-9.95	2.8e-21	1.98e-18	-0.39	-0.42	Corneal structure;	chr7:66896631	chr7:66848496~66858136:+
THCA	cis	rs2581828	0.58	rs4687570	ENSG00000242142.1	SERBP1P3	9.95	2.81e-21	1.98e-18	0.52	0.42	Crohn's disease;	chr3:53136484	chr3:53064283~53065091:-
THCA	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-9.95	2.81e-21	1.98e-18	-0.31	-0.42	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
THCA	cis	rs9322193	0.923	rs9689716	ENSG00000268592.3	RAET1E-AS1	9.95	2.82e-21	1.99e-18	0.56	0.42	Lung cancer;	chr6:149655662	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9322207	ENSG00000268592.3	RAET1E-AS1	9.95	2.82e-21	1.99e-18	0.56	0.42	Lung cancer;	chr6:149657185	chr6:149863494~149919507:+
THCA	cis	rs950169	0.922	rs12912934	ENSG00000259728.4	LINC00933	9.94	2.82e-21	1.99e-18	0.57	0.42	Schizophrenia;	chr15:84571216	chr15:84570649~84580175:+
THCA	cis	rs950169	0.922	rs62021167	ENSG00000259728.4	LINC00933	9.94	2.82e-21	1.99e-18	0.57	0.42	Schizophrenia;	chr15:84574820	chr15:84570649~84580175:+
THCA	cis	rs9322193	0.576	rs7452592	ENSG00000223701.3	RAET1E-AS1	9.94	2.84e-21	2e-18	0.66	0.42	Lung cancer;	chr6:149875445	chr6:149884431~149919508:+
THCA	cis	rs4819052	1	rs2297285	ENSG00000215447.6	BX322557.10	9.94	2.85e-21	2e-18	0.41	0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.884	rs9688699	ENSG00000268592.3	RAET1E-AS1	9.94	2.85e-21	2.01e-18	0.57	0.42	Lung cancer;	chr6:149733680	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	9.94	2.85e-21	2.01e-18	0.49	0.42	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000228039.3	KB-1125A3.10	9.94	2.86e-21	2.01e-18	0.52	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23963780~23964374:+
THCA	cis	rs6061231	0.624	rs8668	ENSG00000273619.1	RP5-908M14.9	9.94	2.87e-21	2.02e-18	0.32	0.42	Colorectal cancer;	chr20:62389008	chr20:62386303~62386970:-
THCA	cis	rs9659323	0.601	rs12033970	ENSG00000231365.4	RP11-418J17.1	-9.94	2.88e-21	2.02e-18	-0.4	-0.42	Body mass index;	chr1:119097778	chr1:119140396~119275973:+
THCA	cis	rs4591358	0.549	rs10200021	ENSG00000223466.1	AC064834.2	-9.94	2.9e-21	2.04e-18	-0.56	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549863	chr2:195533035~195538681:+
THCA	cis	rs11676348	0.818	rs7426289	ENSG00000261338.2	RP11-378A13.1	-9.94	2.91e-21	2.05e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218101592	chr2:218255319~218257366:+
THCA	cis	rs8062405	0.754	rs151179	ENSG00000251417.2	RP11-1348G14.4	-9.94	2.91e-21	2.05e-18	-0.4	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28802743~28817828:+
THCA	cis	rs9487094	0.67	rs2024849	ENSG00000260273.1	RP11-425D10.10	9.94	2.92e-21	2.05e-18	0.49	0.42	Height;	chr6:109497088	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs2024853	ENSG00000260273.1	RP11-425D10.10	9.94	2.92e-21	2.05e-18	0.49	0.42	Height;	chr6:109498751	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12197180	ENSG00000260273.1	RP11-425D10.10	9.94	2.92e-21	2.05e-18	0.49	0.42	Height;	chr6:109500687	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.6	rs10457193	ENSG00000260273.1	RP11-425D10.10	9.94	2.92e-21	2.05e-18	0.49	0.42	Height;	chr6:109507364	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.558	rs10457194	ENSG00000260273.1	RP11-425D10.10	9.94	2.92e-21	2.05e-18	0.49	0.42	Height;	chr6:109507366	chr6:109382795~109383666:+
THCA	cis	rs67311347	0.544	rs4974040	ENSG00000223797.4	ENTPD3-AS1	9.94	2.92e-21	2.06e-18	0.33	0.42	Renal cell carcinoma;	chr3:40289568	chr3:40313802~40453329:-
THCA	cis	rs10463554	1	rs6596529	ENSG00000175749.11	EIF3KP1	9.94	2.97e-21	2.09e-18	0.55	0.42	Parkinson's disease;	chr5:102981338	chr5:103032376~103033031:+
THCA	cis	rs7567389	0.511	rs61185143	ENSG00000236682.1	AC068282.3	9.94	3e-21	2.11e-18	0.58	0.42	Self-rated health;	chr2:127407902	chr2:127389130~127400580:+
THCA	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	9.94	3e-21	2.11e-18	0.35	0.42	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
THCA	cis	rs4718428	0.705	rs11028	ENSG00000232546.1	RP11-458F8.1	-9.94	3.02e-21	2.13e-18	-0.39	-0.42	Corneal structure;	chr7:66811230	chr7:66848496~66858136:+
THCA	cis	rs673078	0.607	rs7295288	ENSG00000275409.1	RP11-131L12.4	-9.94	3.03e-21	2.13e-18	-0.48	-0.42	Glucose homeostasis traits;	chr12:118418008	chr12:118430147~118430699:+
THCA	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	9.94	3.04e-21	2.14e-18	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
THCA	cis	rs853679	0.517	rs868987	ENSG00000226314.6	ZNF192P1	9.94	3.04e-21	2.14e-18	0.56	0.42	Depression;	chr6:28142370	chr6:28161781~28169594:+
THCA	cis	rs4819052	1	rs2297284	ENSG00000215447.6	BX322557.10	-9.94	3.04e-21	2.14e-18	-0.38	-0.42	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.923	rs9322208	ENSG00000268592.3	RAET1E-AS1	9.94	3.04e-21	2.14e-18	0.56	0.42	Lung cancer;	chr6:149658547	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs55993747	ENSG00000268592.3	RAET1E-AS1	9.94	3.05e-21	2.14e-18	0.57	0.42	Lung cancer;	chr6:149622016	chr6:149863494~149919507:+
THCA	cis	rs10463554	1	rs17154893	ENSG00000175749.11	EIF3KP1	9.94	3.06e-21	2.15e-18	0.55	0.42	Parkinson's disease;	chr5:102980902	chr5:103032376~103033031:+
THCA	cis	rs944289	0.708	rs1930765	ENSG00000257826.1	RP11-116N8.4	-9.93	3.08e-21	2.16e-18	-0.42	-0.42	Thyroid cancer;	chr14:36110053	chr14:36061026~36067190:-
THCA	cis	rs10885396	0.967	rs7094463	ENSG00000233547.1	RP11-57H14.2	9.93	3.08e-21	2.17e-18	0.38	0.42	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr10:112952224	chr10:112950646~112951875:-
THCA	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	9.93	3.11e-21	2.18e-18	0.43	0.42	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
THCA	cis	rs9487094	0.67	rs2024852	ENSG00000260273.1	RP11-425D10.10	9.93	3.11e-21	2.18e-18	0.49	0.42	Height;	chr6:109498586	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs13203587	ENSG00000260273.1	RP11-425D10.10	9.93	3.11e-21	2.18e-18	0.49	0.42	Height;	chr6:109499759	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12212476	ENSG00000260273.1	RP11-425D10.10	9.93	3.11e-21	2.18e-18	0.49	0.42	Height;	chr6:109501402	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12198938	ENSG00000260273.1	RP11-425D10.10	9.93	3.11e-21	2.18e-18	0.49	0.42	Height;	chr6:109501429	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs13220915	ENSG00000260273.1	RP11-425D10.10	9.93	3.11e-21	2.18e-18	0.49	0.42	Height;	chr6:109503623	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.626	rs10457192	ENSG00000260273.1	RP11-425D10.10	9.93	3.11e-21	2.18e-18	0.49	0.42	Height;	chr6:109507271	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.923	rs9383812	ENSG00000268592.3	RAET1E-AS1	9.93	3.11e-21	2.18e-18	0.56	0.42	Lung cancer;	chr6:149712355	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.847	rs9383844	ENSG00000268592.3	RAET1E-AS1	9.93	3.11e-21	2.18e-18	0.56	0.42	Lung cancer;	chr6:149716268	chr6:149863494~149919507:+
THCA	cis	rs73219805	1	rs73217798	ENSG00000228451.3	SDAD1P1	-9.93	3.12e-21	2.19e-18	-0.53	-0.42	Schizophrenia;	chr8:26406847	chr8:26379259~26382953:-
THCA	cis	rs1799949	1	rs12936816	ENSG00000267681.1	CTD-3199J23.6	-9.93	3.13e-21	2.2e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43149692	chr17:43144956~43145255:+
THCA	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	9.93	3.14e-21	2.2e-18	0.57	0.42	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
THCA	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	9.93	3.15e-21	2.21e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	9.93	3.15e-21	2.21e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
THCA	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-9.93	3.15e-21	2.21e-18	-0.49	-0.42	Migraine;	chr4:56940917	chr4:56960927~56961373:-
THCA	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	9.93	3.15e-21	2.21e-18	0.49	0.42	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
THCA	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-9.93	3.16e-21	2.22e-18	-0.51	-0.42	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
THCA	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-9.93	3.19e-21	2.24e-18	-0.53	-0.42	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-9.93	3.19e-21	2.24e-18	-0.53	-0.42	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-9.93	3.19e-21	2.24e-18	-0.53	-0.42	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
THCA	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	9.93	3.19e-21	2.24e-18	0.49	0.42	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
THCA	cis	rs7221109	0.56	rs2429549	ENSG00000278834.1	RP11-458J1.1	-9.93	3.2e-21	2.24e-18	-0.44	-0.42	Type 1 diabetes;	chr17:40698154	chr17:40648300~40649718:+
THCA	cis	rs9322193	0.886	rs9718079	ENSG00000216906.2	RP11-350J20.9	9.93	3.21e-21	2.25e-18	0.49	0.42	Lung cancer;	chr6:149645947	chr6:149904243~149906418:+
THCA	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-9.93	3.22e-21	2.25e-18	-0.38	-0.42	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
THCA	cis	rs9532669	0.824	rs4941998	ENSG00000176268.5	CYCSP34	9.93	3.24e-21	2.27e-18	0.49	0.42	Cervical cancer;	chr13:40859901	chr13:40863599~40863902:-
THCA	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	9.93	3.27e-21	2.3e-18	0.49	0.42	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
THCA	cis	rs4660456	0.504	rs587963	ENSG00000237899.1	RP4-739H11.3	9.93	3.3e-21	2.31e-18	0.56	0.42	Platelet count;	chr1:40640045	chr1:40669089~40687588:-
THCA	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	9.93	3.31e-21	2.32e-18	0.54	0.42	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
THCA	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
THCA	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	9.93	3.31e-21	2.32e-18	0.49	0.42	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
THCA	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-9.93	3.33e-21	2.33e-18	-0.61	-0.42	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
THCA	cis	rs7849270	0.959	rs4836641	ENSG00000268707.1	RP11-247A12.7	9.92	3.33e-21	2.33e-18	0.55	0.42	Blood metabolite ratios;	chr9:129149953	chr9:129170434~129170940:+
THCA	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-9.92	3.34e-21	2.34e-18	-0.53	-0.42	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
THCA	cis	rs524281	0.731	rs12576969	ENSG00000255320.1	RP11-755F10.1	-9.92	3.36e-21	2.35e-18	-0.62	-0.42	Electroencephalogram traits;	chr11:66035007	chr11:66244840~66246239:-
THCA	cis	rs1799949	1	rs33926631	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43152446	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1960605	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43153380	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs2037076	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43153866	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs12950779	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43154506	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.929	rs12937015	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43155456	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4340367	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43155755	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4792981	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43156257	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs35521261	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43161595	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.896	rs33933393	ENSG00000267681.1	CTD-3199J23.6	-9.92	3.36e-21	2.35e-18	-0.48	-0.42	Menopause (age at onset);	chr17:43165415	chr17:43144956~43145255:+
THCA	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	9.92	3.37e-21	2.36e-18	0.5	0.42	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
THCA	cis	rs7615952	0.515	rs4441610	ENSG00000171084.14	FAM86JP	9.92	3.37e-21	2.36e-18	0.51	0.42	Blood pressure (smoking interaction);	chr3:125962464	chr3:125916620~125930024:+
THCA	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	9.92	3.38e-21	2.37e-18	0.48	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
THCA	cis	rs17826219	0.585	rs8064302	ENSG00000263531.1	RP13-753N3.1	-9.92	3.41e-21	2.38e-18	-0.77	-0.42	Body mass index;	chr17:30397920	chr17:30863921~30864940:-
THCA	cis	rs67311347	0.544	rs6599088	ENSG00000223797.4	ENTPD3-AS1	9.92	3.41e-21	2.39e-18	0.33	0.42	Renal cell carcinoma;	chr3:40287797	chr3:40313802~40453329:-
THCA	cis	rs780094	0.585	rs3739095	ENSG00000234072.1	AC074117.10	-9.92	3.42e-21	2.39e-18	-0.32	-0.42	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27333854	chr2:27356246~27367622:+
THCA	cis	rs62388641	0.547	rs9391923	ENSG00000272279.1	RP11-157J24.2	-9.92	3.44e-21	2.41e-18	-0.56	-0.42	Daytime sleep phenotypes;	chr6:1554089	chr6:1528364~1528911:-
THCA	cis	rs7849270	0.959	rs3118628	ENSG00000268707.1	RP11-247A12.7	9.92	3.45e-21	2.41e-18	0.55	0.42	Blood metabolite ratios;	chr9:129123000	chr9:129170434~129170940:+
THCA	cis	rs11159086	1	rs72730186	ENSG00000259005.1	RP3-449M8.6	9.92	3.46e-21	2.42e-18	0.5	0.42	Advanced glycation end-product levels;	chr14:74475610	chr14:74474007~74474864:-
THCA	cis	rs9532669	0.963	rs1571116	ENSG00000239827.7	SUGT1P3	-9.92	3.47e-21	2.42e-18	-0.45	-0.42	Cervical cancer;	chr13:40929765	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs9532673	ENSG00000239827.7	SUGT1P3	-9.92	3.47e-21	2.42e-18	-0.45	-0.42	Cervical cancer;	chr13:40930412	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.962	rs3805752	ENSG00000268592.3	RAET1E-AS1	9.92	3.49e-21	2.44e-18	0.57	0.42	Lung cancer;	chr6:149795490	chr6:149863494~149919507:+
THCA	cis	rs673078	0.66	rs6490173	ENSG00000275409.1	RP11-131L12.4	-9.92	3.49e-21	2.44e-18	-0.44	-0.42	Glucose homeostasis traits;	chr12:118278637	chr12:118430147~118430699:+
THCA	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	9.92	3.51e-21	2.45e-18	0.55	0.42	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
THCA	cis	rs9532669	0.857	rs9525427	ENSG00000176268.5	CYCSP34	9.92	3.51e-21	2.45e-18	0.46	0.42	Cervical cancer;	chr13:40918029	chr13:40863599~40863902:-
THCA	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-9.92	3.51e-21	2.46e-18	-0.35	-0.42	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
THCA	cis	rs2919917	0.614	rs10102877	ENSG00000254352.1	RP11-578O24.2	9.92	3.53e-21	2.47e-18	0.43	0.42	Lymphocyte counts;	chr8:78686127	chr8:78723796~78724136:-
THCA	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-9.92	3.54e-21	2.47e-18	-0.52	-0.42	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.884	rs10872647	ENSG00000223701.3	RAET1E-AS1	9.92	3.57e-21	2.49e-18	0.56	0.42	Lung cancer;	chr6:149758687	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs10872648	ENSG00000223701.3	RAET1E-AS1	9.92	3.57e-21	2.49e-18	0.56	0.42	Lung cancer;	chr6:149758699	chr6:149884431~149919508:+
THCA	cis	rs9322193	0.884	rs11155679	ENSG00000223701.3	RAET1E-AS1	9.92	3.57e-21	2.49e-18	0.56	0.42	Lung cancer;	chr6:149758881	chr6:149884431~149919508:+
THCA	cis	rs7772486	0.902	rs2748500	ENSG00000235652.6	RP11-545I5.3	9.92	3.57e-21	2.5e-18	0.38	0.42	Lobe attachment (rater-scored or self-reported);	chr6:145993716	chr6:145799409~145886585:+
THCA	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	9.92	3.57e-21	2.5e-18	0.51	0.42	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
THCA	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-9.92	3.58e-21	2.5e-18	-0.35	-0.42	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
THCA	cis	rs950169	0.922	rs11633075	ENSG00000259728.4	LINC00933	9.92	3.6e-21	2.51e-18	0.57	0.42	Schizophrenia;	chr15:84570741	chr15:84570649~84580175:+
THCA	cis	rs2581828	0.618	rs9824325	ENSG00000242142.1	SERBP1P3	-9.92	3.61e-21	2.52e-18	-0.53	-0.42	Crohn's disease;	chr3:53132494	chr3:53064283~53065091:-
THCA	cis	rs73219805	0.818	rs117325001	ENSG00000228451.3	SDAD1P1	-9.91	3.62e-21	2.53e-18	-0.53	-0.42	Schizophrenia;	chr8:26384756	chr8:26379259~26382953:-
THCA	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	9.91	3.63e-21	2.54e-18	0.52	0.42	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
THCA	cis	rs4789693	0.518	rs6502117	ENSG00000265458.1	RP13-20L14.6	9.91	3.64e-21	2.54e-18	0.4	0.42	Glucocorticoid-induced osteonecrosis;	chr17:82494716	chr17:82454273~82458521:-
THCA	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	9.91	3.65e-21	2.55e-18	0.48	0.42	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
THCA	cis	rs11676348	0.935	rs4674248	ENSG00000261338.2	RP11-378A13.1	-9.91	3.65e-21	2.55e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218095408	chr2:218255319~218257366:+
THCA	cis	rs860295	0.651	rs6692183	ENSG00000225855.5	RUSC1-AS1	9.91	3.66e-21	2.56e-18	0.29	0.42	Body mass index;	chr1:155334536	chr1:155316863~155324176:-
THCA	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-9.91	3.66e-21	2.56e-18	-0.56	-0.42	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
THCA	cis	rs9322193	0.847	rs12191643	ENSG00000268592.3	RAET1E-AS1	9.91	3.75e-21	2.61e-18	0.57	0.42	Lung cancer;	chr6:149628912	chr6:149863494~149919507:+
THCA	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-9.91	3.76e-21	2.62e-18	-0.54	-0.42	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
THCA	cis	rs9318086	0.904	rs9580769	ENSG00000205861.10	C1QTNF9B-AS1	9.91	3.81e-21	2.65e-18	0.46	0.42	Myopia (pathological);	chr13:23865585	chr13:23888889~23897263:+
THCA	cis	rs11676348	0.935	rs6716276	ENSG00000261338.2	RP11-378A13.1	-9.91	3.81e-21	2.66e-18	-0.42	-0.42	Ulcerative colitis;	chr2:218097482	chr2:218255319~218257366:+
THCA	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-9.91	3.81e-21	2.66e-18	-0.48	-0.42	Migraine;	chr4:56950140	chr4:56960927~56961373:-
THCA	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	9.91	3.82e-21	2.66e-18	0.49	0.42	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
THCA	cis	rs9532669	0.75	rs9532598	ENSG00000239827.7	SUGT1P3	-9.91	3.85e-21	2.69e-18	-0.47	-0.42	Cervical cancer;	chr13:40860627	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.611	rs9532599	ENSG00000239827.7	SUGT1P3	-9.91	3.85e-21	2.69e-18	-0.47	-0.42	Cervical cancer;	chr13:40860633	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.571	rs9525405	ENSG00000239827.7	SUGT1P3	-9.91	3.85e-21	2.69e-18	-0.47	-0.42	Cervical cancer;	chr13:40860638	chr13:40908159~40921774:-
THCA	cis	rs4722166	0.508	rs2069832	ENSG00000179428.2	AC073072.5	-9.91	3.86e-21	2.69e-18	-0.54	-0.42	Lung cancer;	chr7:22727814	chr7:22725395~22727620:-
THCA	cis	rs1800795	0.901	rs2069833	ENSG00000179428.2	AC073072.5	-9.91	3.86e-21	2.69e-18	-0.54	-0.42	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22728045	chr7:22725395~22727620:-
THCA	cis	rs7772486	0.902	rs2144476	ENSG00000235652.6	RP11-545I5.3	9.91	3.87e-21	2.7e-18	0.38	0.42	Lobe attachment (rater-scored or self-reported);	chr6:146001348	chr6:145799409~145886585:+
THCA	cis	rs1799949	1	rs8176242	ENSG00000267681.1	CTD-3199J23.6	-9.91	3.9e-21	2.72e-18	-0.49	-0.42	Menopause (age at onset);	chr17:43065857	chr17:43144956~43145255:+
THCA	cis	rs9532669	0.926	rs11147823	ENSG00000239827.7	SUGT1P3	9.91	3.9e-21	2.72e-18	0.46	0.42	Cervical cancer;	chr13:40878138	chr13:40908159~40921774:-
THCA	cis	rs9545047	0.716	rs6563096	ENSG00000227676.3	LINC01068	-9.91	3.9e-21	2.72e-18	-0.5	-0.42	Schizophrenia;	chr13:79284100	chr13:79566727~79571436:+
THCA	cis	rs9322193	0.923	rs6913486	ENSG00000268592.3	RAET1E-AS1	-9.9	3.94e-21	2.75e-18	-0.57	-0.42	Lung cancer;	chr6:149705060	chr6:149863494~149919507:+
THCA	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	9.9	3.95e-21	2.75e-18	0.49	0.42	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
THCA	cis	rs4718428	0.705	rs4717328	ENSG00000232546.1	RP11-458F8.1	-9.9	3.97e-21	2.76e-18	-0.4	-0.42	Corneal structure;	chr7:66887678	chr7:66848496~66858136:+
THCA	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	9.9	3.98e-21	2.77e-18	0.48	0.42	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
THCA	cis	rs6991838	0.67	rs869151	ENSG00000272010.1	CTD-3025N20.3	9.9	3.98e-21	2.77e-18	0.41	0.42	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65591850~65592472:-
THCA	cis	rs4718428	0.576	rs12698546	ENSG00000232546.1	RP11-458F8.1	-9.9	3.98e-21	2.77e-18	-0.41	-0.42	Corneal structure;	chr7:66801919	chr7:66848496~66858136:+
THCA	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	9.9	4e-21	2.78e-18	0.53	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	9.9	4.02e-21	2.79e-18	0.48	0.42	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
THCA	cis	rs7208859	0.573	rs73267865	ENSG00000266490.1	CTD-2349P21.9	9.9	4.04e-21	2.81e-18	0.55	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30792372~30792833:+
THCA	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-9.9	4.06e-21	2.82e-18	-0.61	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
THCA	cis	rs780096	0.506	rs2288155	ENSG00000234072.1	AC074117.10	-9.9	4.06e-21	2.82e-18	-0.33	-0.42	Total body bone mineral density;	chr2:27491659	chr2:27356246~27367622:+
THCA	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	9.9	4.06e-21	2.82e-18	0.57	0.42	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
THCA	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	9.9	4.06e-21	2.82e-18	0.57	0.42	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
THCA	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	9.9	4.06e-21	2.82e-18	0.57	0.42	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
THCA	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	9.9	4.06e-21	2.82e-18	0.57	0.42	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
THCA	cis	rs7208859	0.623	rs55814012	ENSG00000266490.1	CTD-2349P21.9	9.9	4.06e-21	2.83e-18	0.56	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30792372~30792833:+
THCA	cis	rs934734	0.532	rs7569113	ENSG00000234255.7	AC012370.3	9.9	4.07e-21	2.83e-18	0.45	0.42	Rheumatoid arthritis;	chr2:65429907	chr2:65439888~65456571:-
THCA	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	9.9	4.08e-21	2.84e-18	0.54	0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
THCA	cis	rs11051970	0.513	rs7972023	ENSG00000274964.1	RP11-817I4.1	-9.9	4.09e-21	2.84e-18	-0.53	-0.42	Response to tocilizumab in rheumatoid arthritis;	chr12:32312174	chr12:32339368~32340724:+
THCA	cis	rs7727544	0.669	rs113823725	ENSG00000237714.1	P4HA2-AS1	9.9	4.1e-21	2.85e-18	0.55	0.42	Blood metabolite levels;	chr5:132227808	chr5:132184876~132192808:+
THCA	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-9.9	4.11e-21	2.85e-18	-0.49	-0.42	Height;	chr6:109497253	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.886	rs4870049	ENSG00000268592.3	RAET1E-AS1	9.9	4.15e-21	2.88e-18	0.57	0.42	Lung cancer;	chr6:149837058	chr6:149863494~149919507:+
THCA	cis	rs11676348	0.846	rs13009946	ENSG00000261338.2	RP11-378A13.1	-9.9	4.17e-21	2.9e-18	-0.41	-0.42	Ulcerative colitis;	chr2:218143029	chr2:218255319~218257366:+
THCA	cis	rs2599510	0.783	rs2710630	ENSG00000276334.1	AL133243.1	-9.9	4.17e-21	2.9e-18	-0.47	-0.42	Interleukin-18 levels;	chr2:32540930	chr2:32521927~32523547:+
THCA	cis	rs9532669	0.963	rs9562238	ENSG00000176268.5	CYCSP34	9.9	4.18e-21	2.9e-18	0.47	0.42	Cervical cancer;	chr13:40924785	chr13:40863599~40863902:-
THCA	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-9.9	4.18e-21	2.91e-18	-0.62	-0.42	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-9.9	4.18e-21	2.91e-18	-0.62	-0.42	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-9.9	4.18e-21	2.91e-18	-0.62	-0.42	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-9.9	4.18e-21	2.91e-18	-0.62	-0.42	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-9.9	4.18e-21	2.91e-18	-0.62	-0.42	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
THCA	cis	rs6452524	0.805	rs2731850	ENSG00000249664.1	CTD-2227C6.2	-9.9	4.23e-21	2.93e-18	-0.55	-0.42	Hypertension (SNP x SNP interaction);	chr5:83213024	chr5:83012285~83013109:-
THCA	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-9.9	4.23e-21	2.93e-18	-0.5	-0.42	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
THCA	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-9.9	4.24e-21	2.94e-18	-0.49	-0.42	Height;	chr2:231490121	chr2:231508426~231514339:-
THCA	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-9.9	4.24e-21	2.94e-18	-0.31	-0.42	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
THCA	cis	rs950169	0.922	rs12906983	ENSG00000259728.4	LINC00933	9.9	4.26e-21	2.96e-18	0.57	0.42	Schizophrenia;	chr15:84262270	chr15:84570649~84580175:+
THCA	cis	rs71403859	0.667	rs12924650	ENSG00000260886.1	TAT-AS1	9.9	4.27e-21	2.96e-18	0.74	0.42	Post bronchodilator FEV1;	chr16:71672005	chr16:71565789~71578187:+
THCA	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-9.89	4.28e-21	2.97e-18	-0.42	-0.42	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
THCA	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	9.89	4.3e-21	2.98e-18	0.48	0.42	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
THCA	cis	rs1858037	0.867	rs72621551	ENSG00000281920.1	RP11-418H16.1	9.89	4.34e-21	3.01e-18	0.54	0.42	Rheumatoid arthritis;	chr2:65388087	chr2:65623272~65628424:+
THCA	cis	rs10759883	0.603	rs13299166	ENSG00000175611.10	LINC00476	9.89	4.34e-21	3.01e-18	0.47	0.42	Nicotine dependence;	chr9:95833249	chr9:95759231~95875977:-
THCA	cis	rs9532669	0.963	rs4343141	ENSG00000239827.7	SUGT1P3	-9.89	4.35e-21	3.01e-18	-0.45	-0.42	Cervical cancer;	chr13:40940497	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs3887418	ENSG00000239827.7	SUGT1P3	-9.89	4.35e-21	3.01e-18	-0.45	-0.42	Cervical cancer;	chr13:40940560	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs1056820	ENSG00000239827.7	SUGT1P3	-9.89	4.35e-21	3.01e-18	-0.45	-0.42	Cervical cancer;	chr13:40941150	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9532678	ENSG00000239827.7	SUGT1P3	-9.89	4.35e-21	3.01e-18	-0.45	-0.42	Cervical cancer;	chr13:40941862	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-9.89	4.35e-21	3.01e-18	-0.49	-0.42	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
THCA	cis	rs9532669	0.89	rs9532676	ENSG00000239827.7	SUGT1P3	-9.89	4.36e-21	3.02e-18	-0.45	-0.42	Cervical cancer;	chr13:40935626	chr13:40908159~40921774:-
THCA	cis	rs524281	0.692	rs2452681	ENSG00000255320.1	RP11-755F10.1	-9.89	4.37e-21	3.03e-18	-0.57	-0.42	Electroencephalogram traits;	chr11:66047371	chr11:66244840~66246239:-
THCA	cis	rs780096	0.526	rs72819536	ENSG00000234072.1	AC074117.10	-9.89	4.4e-21	3.05e-18	-0.33	-0.42	Total body bone mineral density;	chr2:27459983	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs11127013	ENSG00000234072.1	AC074117.10	-9.89	4.4e-21	3.05e-18	-0.33	-0.42	Total body bone mineral density;	chr2:27470106	chr2:27356246~27367622:+
THCA	cis	rs780096	0.506	rs2303369	ENSG00000234072.1	AC074117.10	-9.89	4.4e-21	3.05e-18	-0.33	-0.42	Total body bone mineral density;	chr2:27492549	chr2:27356246~27367622:+
THCA	cis	rs180730	0.519	rs13105248	ENSG00000251609.2	SETP12	9.89	4.41e-21	3.05e-18	0.58	0.42	Fasting plasma glucose;	chr4:120945433	chr4:120895494~120897083:-
THCA	cis	rs73219805	1	rs3808581	ENSG00000228451.3	SDAD1P1	-9.89	4.41e-21	3.06e-18	-0.53	-0.42	Schizophrenia;	chr8:26392531	chr8:26379259~26382953:-
THCA	cis	rs1075265	0.73	rs6713088	ENSG00000233266.1	HMGB1P31	9.89	4.44e-21	3.08e-18	0.52	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54118332	chr2:54051334~54051760:+
THCA	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-9.89	4.45e-21	3.08e-18	-0.56	-0.42	Depression;	chr6:28226851	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	9.89	4.46e-21	3.09e-18	0.49	0.42	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
THCA	cis	rs7849270	0.959	rs9408986	ENSG00000268707.1	RP11-247A12.7	9.89	4.46e-21	3.09e-18	0.55	0.42	Blood metabolite ratios;	chr9:129126156	chr9:129170434~129170940:+
THCA	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-9.89	4.48e-21	3.1e-18	-0.33	-0.42	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.884	rs7450246	ENSG00000268592.3	RAET1E-AS1	9.89	4.53e-21	3.14e-18	0.56	0.41	Lung cancer;	chr6:149702517	chr6:149863494~149919507:+
THCA	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	9.89	4.53e-21	3.14e-18	0.48	0.41	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
THCA	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	9.89	4.53e-21	3.14e-18	0.49	0.41	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
THCA	cis	rs860295	0.557	rs11264372	ENSG00000225855.5	RUSC1-AS1	9.89	4.54e-21	3.14e-18	0.3	0.41	Body mass index;	chr1:155443139	chr1:155316863~155324176:-
THCA	cis	rs997154	0.655	rs2008345	ENSG00000279656.1	RP11-298I3.6	9.89	4.54e-21	3.14e-18	0.61	0.41	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22932233	chr14:23023083~23024217:-
THCA	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-9.89	4.55e-21	3.15e-18	-0.68	-0.41	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
THCA	cis	rs71403859	0.614	rs12149533	ENSG00000260886.1	TAT-AS1	9.89	4.55e-21	3.15e-18	0.78	0.41	Post bronchodilator FEV1;	chr16:71768043	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs9767554	ENSG00000268592.3	RAET1E-AS1	9.89	4.56e-21	3.16e-18	0.56	0.41	Lung cancer;	chr6:149616860	chr6:149863494~149919507:+
THCA	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-9.89	4.57e-21	3.16e-18	-0.5	-0.41	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-9.89	4.57e-21	3.16e-18	-0.5	-0.41	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
THCA	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	9.89	4.57e-21	3.16e-18	0.36	0.41	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
THCA	cis	rs2274273	0.588	rs7155054	ENSG00000258413.1	RP11-665C16.6	-9.89	4.64e-21	3.21e-18	-0.57	-0.41	Protein biomarker;	chr14:55283944	chr14:55262767~55272075:-
THCA	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-9.88	4.65e-21	3.21e-18	-0.36	-0.41	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
THCA	cis	rs1799949	0.931	rs34410138	ENSG00000267681.1	CTD-3199J23.6	-9.88	4.66e-21	3.22e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43127753	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.884	rs9689702	ENSG00000268592.3	RAET1E-AS1	9.88	4.67e-21	3.23e-18	0.56	0.41	Lung cancer;	chr6:149740720	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.886	rs2065663	ENSG00000268592.3	RAET1E-AS1	9.88	4.68e-21	3.24e-18	0.57	0.41	Lung cancer;	chr6:149760331	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs12205092	ENSG00000268592.3	RAET1E-AS1	9.88	4.68e-21	3.24e-18	0.57	0.41	Lung cancer;	chr6:149761375	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs10872651	ENSG00000268592.3	RAET1E-AS1	9.88	4.68e-21	3.24e-18	0.57	0.41	Lung cancer;	chr6:149768273	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs56397000	ENSG00000268592.3	RAET1E-AS1	9.88	4.7e-21	3.25e-18	0.56	0.41	Lung cancer;	chr6:149739347	chr6:149863494~149919507:+
THCA	cis	rs4713118	0.662	rs149946	ENSG00000280107.1	AL022393.9	9.88	4.72e-21	3.27e-18	0.48	0.41	Parkinson's disease;	chr6:28002253	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs156744	ENSG00000280107.1	AL022393.9	-9.88	4.72e-21	3.27e-18	-0.48	-0.41	Parkinson's disease;	chr6:27999496	chr6:28170845~28172521:+
THCA	cis	rs881375	0.702	rs3761847	ENSG00000226752.6	PSMD5-AS1	-9.88	4.74e-21	3.27e-18	-0.49	-0.41	Rheumatoid arthritis;	chr9:120927961	chr9:120824828~120854385:+
THCA	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-9.88	4.74e-21	3.27e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
THCA	cis	rs4819052	0.851	rs2838864	ENSG00000215447.6	BX322557.10	9.88	4.76e-21	3.29e-18	0.34	0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45288052~45291738:+
THCA	cis	rs1930961	1	rs59226697	ENSG00000100058.11	CRYBB2P1	9.88	4.77e-21	3.3e-18	0.91	0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25448105~25520854:+
THCA	cis	rs240993	0.812	rs6568677	ENSG00000230177.1	RP5-1112D6.4	-9.88	4.77e-21	3.3e-18	-0.41	-0.41	Inflammatory skin disease;Psoriasis;	chr6:111392099	chr6:111277932~111278742:+
THCA	cis	rs950169	0.922	rs4842940	ENSG00000259728.4	LINC00933	-9.88	4.79e-21	3.31e-18	-0.56	-0.41	Schizophrenia;	chr15:84162473	chr15:84570649~84580175:+
THCA	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-9.88	4.79e-21	3.31e-18	-0.56	-0.41	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
THCA	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-9.88	4.79e-21	3.31e-18	-0.56	-0.41	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
THCA	cis	rs704795	0.902	rs11887784	ENSG00000234072.1	AC074117.10	-9.88	4.8e-21	3.31e-18	-0.33	-0.41	Menopause (age at onset);	chr2:27457052	chr2:27356246~27367622:+
THCA	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-9.88	4.82e-21	3.33e-18	-0.51	-0.41	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
THCA	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	9.88	4.85e-21	3.35e-18	0.43	0.41	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
THCA	cis	rs9532669	0.963	rs1571116	ENSG00000176268.5	CYCSP34	9.88	4.86e-21	3.36e-18	0.47	0.41	Cervical cancer;	chr13:40929765	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs9532673	ENSG00000176268.5	CYCSP34	9.88	4.86e-21	3.36e-18	0.47	0.41	Cervical cancer;	chr13:40930412	chr13:40863599~40863902:-
THCA	cis	rs1426063	0.668	rs6534595	ENSG00000260265.1	RP11-44F21.5	9.88	4.89e-21	3.38e-18	0.61	0.41	QT interval;	chr4:75104432	chr4:75081702~75084717:-
THCA	cis	rs11676348	0.818	rs6436031	ENSG00000261338.2	RP11-378A13.1	-9.88	4.93e-21	3.4e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218114536	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.818	rs6436033	ENSG00000261338.2	RP11-378A13.1	-9.88	4.93e-21	3.4e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218119040	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.846	rs6723449	ENSG00000261338.2	RP11-378A13.1	9.88	4.93e-21	3.4e-18	0.42	0.41	Ulcerative colitis;	chr2:218132857	chr2:218255319~218257366:+
THCA	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-9.88	4.93e-21	3.4e-18	-0.62	-0.41	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
THCA	cis	rs7208859	0.573	rs7223803	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.5	rs2449749	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Body mass index;	chr17:30751280	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9894709	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9896603	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8080882	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73269974	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs34756112	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs60724269	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs76633166	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs1061346	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs1061343	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73269988	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9899525	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs11653098	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9911784	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9911997	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9890862	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs78071511	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs2035494	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs8064686	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11657369	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8075341	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73271842	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs8077116	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs28760584	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7212991	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs28627615	ENSG00000266490.1	CTD-2349P21.9	9.88	4.94e-21	3.41e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30792372~30792833:+
THCA	cis	rs2836950	0.501	rs35994303	ENSG00000255568.3	BRWD1-AS2	-9.88	4.96e-21	3.42e-18	-0.34	-0.41	Menarche (age at onset);	chr21:39314094	chr21:39313935~39314962:+
THCA	cis	rs11676348	0.818	rs7425447	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218115460	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.783	rs4674252	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218119755	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.714	rs4674254	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218121354	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.811	rs4674255	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218122602	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.818	rs4674256	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218123170	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.846	rs4674257	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218124051	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.846	rs3890158	ENSG00000261338.2	RP11-378A13.1	-9.88	4.98e-21	3.43e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218125569	chr2:218255319~218257366:+
THCA	cis	rs2455601	0.744	rs11042107	ENSG00000254860.4	TMEM9B-AS1	9.88	4.99e-21	3.44e-18	0.58	0.41	Schizophrenia;	chr11:8884324	chr11:8964675~8977527:+
THCA	cis	rs71403859	0.73	rs17355804	ENSG00000260886.1	TAT-AS1	9.88	5e-21	3.45e-18	0.76	0.41	Post bronchodilator FEV1;	chr16:71683311	chr16:71565789~71578187:+
THCA	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-9.88	5.01e-21	3.45e-18	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
THCA	cis	rs2599510	0.783	rs2710626	ENSG00000276334.1	AL133243.1	9.88	5.02e-21	3.46e-18	0.45	0.41	Interleukin-18 levels;	chr2:32533687	chr2:32521927~32523547:+
THCA	cis	rs7208859	0.623	rs7219361	ENSG00000266490.1	CTD-2349P21.9	9.88	5.02e-21	3.46e-18	0.56	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs77498725	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.5	rs57005940	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Body mass index;	chr17:30739311	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs73267872	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs57670615	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.5	rs2874724	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Body mass index;	chr17:30745415	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.568	rs9898097	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Body mass index;	chr17:30745654	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9911490	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7503542	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs11656278	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs6505207	ENSG00000266490.1	CTD-2349P21.9	9.88	5.03e-21	3.46e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30792372~30792833:+
THCA	cis	rs12554020	0.786	rs6479495	ENSG00000227603.1	RP11-165J3.6	9.87	5.04e-21	3.47e-18	0.58	0.41	Schizophrenia;	chr9:93572320	chr9:93435332~93437121:-
THCA	cis	rs934734	0.532	rs6752053	ENSG00000234255.7	AC012370.3	-9.87	5.04e-21	3.47e-18	-0.45	-0.41	Rheumatoid arthritis;	chr2:65439540	chr2:65439888~65456571:-
THCA	cis	rs9322193	0.923	rs10782315	ENSG00000268592.3	RAET1E-AS1	9.87	5.05e-21	3.48e-18	0.56	0.41	Lung cancer;	chr6:149743093	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	9.87	5.06e-21	3.48e-18	0.48	0.41	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
THCA	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	9.87	5.06e-21	3.48e-18	0.52	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	9.87	5.07e-21	3.49e-18	0.49	0.41	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
THCA	cis	rs1426063	0.614	rs77982391	ENSG00000260265.1	RP11-44F21.5	9.87	5.07e-21	3.49e-18	0.9	0.41	QT interval;	chr4:75125224	chr4:75081702~75084717:-
THCA	cis	rs17826219	0.636	rs4055314	ENSG00000266490.1	CTD-2349P21.9	9.87	5.09e-21	3.5e-18	0.56	0.41	Body mass index;	chr17:30752751	chr17:30792372~30792833:+
THCA	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-9.87	5.12e-21	3.52e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-9.87	5.13e-21	3.53e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
THCA	cis	rs1799949	1	rs11652332	ENSG00000267681.1	CTD-3199J23.6	-9.87	5.15e-21	3.54e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43143472	chr17:43144956~43145255:+
THCA	cis	rs10256972	0.804	rs10275585	ENSG00000229043.2	AC091729.9	-9.87	5.16e-21	3.55e-18	-0.44	-0.41	Endometriosis;Longevity;	chr7:977703	chr7:1160374~1165267:+
THCA	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-9.87	5.16e-21	3.55e-18	-0.68	-0.41	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
THCA	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	9.87	5.18e-21	3.56e-18	0.49	0.41	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
THCA	cis	rs11676348	0.846	rs4674259	ENSG00000261338.2	RP11-378A13.1	-9.87	5.22e-21	3.59e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218126282	chr2:218255319~218257366:+
THCA	cis	rs67311347	0.544	rs9877105	ENSG00000223797.4	ENTPD3-AS1	9.87	5.24e-21	3.6e-18	0.33	0.41	Renal cell carcinoma;	chr3:40291875	chr3:40313802~40453329:-
THCA	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	9.87	5.27e-21	3.62e-18	0.48	0.41	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
THCA	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-9.87	5.28e-21	3.63e-18	-0.48	-0.41	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
THCA	cis	rs7208859	0.623	rs55811708	ENSG00000266490.1	CTD-2349P21.9	9.87	5.31e-21	3.65e-18	0.56	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30792372~30792833:+
THCA	cis	rs7772486	0.902	rs1125462	ENSG00000235652.6	RP11-545I5.3	9.87	5.31e-21	3.65e-18	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146096696	chr6:145799409~145886585:+
THCA	cis	rs1185460	0.565	rs2276060	ENSG00000271751.1	RP11-110I1.14	9.87	5.33e-21	3.66e-18	0.52	0.41	Coronary artery disease;	chr11:119048420	chr11:119065263~119065677:-
THCA	cis	rs4819052	0.704	rs2297283	ENSG00000223768.1	LINC00205	-9.87	5.33e-21	3.67e-18	-0.39	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263675	chr21:45293285~45297354:+
THCA	cis	rs11051970	0.592	rs12227991	ENSG00000274964.1	RP11-817I4.1	-9.87	5.35e-21	3.67e-18	-0.55	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32387111	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051973	ENSG00000274964.1	RP11-817I4.1	-9.87	5.35e-21	3.67e-18	-0.55	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32388978	chr12:32339368~32340724:+
THCA	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-9.87	5.37e-21	3.69e-18	-0.49	-0.41	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
THCA	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-9.87	5.37e-21	3.69e-18	-0.69	-0.41	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
THCA	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	9.87	5.38e-21	3.7e-18	0.62	0.41	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
THCA	cis	rs9532669	0.926	rs8002809	ENSG00000239827.7	SUGT1P3	-9.87	5.42e-21	3.73e-18	-0.47	-0.41	Cervical cancer;	chr13:40872769	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.929	rs7982421	ENSG00000239827.7	SUGT1P3	-9.87	5.42e-21	3.73e-18	-0.47	-0.41	Cervical cancer;	chr13:40872776	chr13:40908159~40921774:-
THCA	cis	rs1858037	0.836	rs2576923	ENSG00000281920.1	RP11-418H16.1	-9.87	5.45e-21	3.74e-18	-0.54	-0.41	Rheumatoid arthritis;	chr2:65406750	chr2:65623272~65628424:+
THCA	cis	rs2980439	0.556	rs2921059	ENSG00000254153.1	CTA-398F10.2	-9.87	5.45e-21	3.75e-18	-0.45	-0.41	Neuroticism;	chr8:8460377	chr8:8456909~8461337:-
THCA	cis	rs7208859	0.623	rs7220289	ENSG00000266490.1	CTD-2349P21.9	9.87	5.45e-21	3.75e-18	0.56	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30792372~30792833:+
THCA	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-9.87	5.46e-21	3.75e-18	-0.62	-0.41	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
THCA	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	9.86	5.48e-21	3.76e-18	0.54	0.41	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
THCA	cis	rs17826219	0.568	rs11658027	ENSG00000266490.1	CTD-2349P21.9	-9.86	5.48e-21	3.76e-18	-0.55	-0.41	Body mass index;	chr17:30767864	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.5	rs28452421	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Body mass index;	chr17:30756962	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs28779471	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.5	rs61685770	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Body mass index;	chr17:30758695	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs57486336	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs12103440	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11657777	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs8065744	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.706	rs8071236	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Body mass index;	chr17:30772984	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs56163556	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8075163	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.706	rs8075107	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Body mass index;	chr17:30779631	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7223209	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7223404	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9916725	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9916727	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73269945	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9897728	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs1054400	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9890558	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9912283	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs3752020	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9890855	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9893422	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9891166	ENSG00000266490.1	CTD-2349P21.9	9.86	5.48e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs56031503	ENSG00000266490.1	CTD-2349P21.9	9.86	5.49e-21	3.76e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30792372~30792833:+
THCA	cis	rs9532669	0.853	rs9315795	ENSG00000176268.5	CYCSP34	9.86	5.53e-21	3.79e-18	0.47	0.41	Cervical cancer;	chr13:40943382	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs3764056	ENSG00000176268.5	CYCSP34	9.86	5.53e-21	3.79e-18	0.47	0.41	Cervical cancer;	chr13:40943849	chr13:40863599~40863902:-
THCA	cis	rs10759883	0.627	rs690528	ENSG00000175611.10	LINC00476	9.86	5.55e-21	3.8e-18	0.46	0.41	Nicotine dependence;	chr9:95876006	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs689697	ENSG00000175611.10	LINC00476	9.86	5.55e-21	3.8e-18	0.46	0.41	Nicotine dependence;	chr9:95876560	chr9:95759231~95875977:-
THCA	cis	rs950169	0.922	rs11630760	ENSG00000259728.4	LINC00933	9.86	5.56e-21	3.81e-18	0.56	0.41	Schizophrenia;	chr15:84570106	chr15:84570649~84580175:+
THCA	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-9.86	5.58e-21	3.82e-18	-0.54	-0.41	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
THCA	cis	rs7208859	0.623	rs9915566	ENSG00000266490.1	CTD-2349P21.9	9.86	5.59e-21	3.83e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30792372~30792833:+
THCA	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-9.86	5.6e-21	3.84e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
THCA	cis	rs6844153	0.715	rs73813220	ENSG00000240005.4	RP11-293A21.1	-9.86	5.61e-21	3.84e-18	-0.49	-0.41	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26920224	chr4:26859806~26860599:-
THCA	cis	rs881375	0.678	rs1930782	ENSG00000226752.6	PSMD5-AS1	-9.86	5.65e-21	3.87e-18	-0.5	-0.41	Rheumatoid arthritis;	chr9:120925627	chr9:120824828~120854385:+
THCA	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-9.86	5.67e-21	3.88e-18	-0.41	-0.41	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
THCA	cis	rs1426063	0.748	rs10005117	ENSG00000260265.1	RP11-44F21.5	9.86	5.74e-21	3.93e-18	0.6	0.41	QT interval;	chr4:75108281	chr4:75081702~75084717:-
THCA	cis	rs944289	0.74	rs404131	ENSG00000257826.1	RP11-116N8.4	9.86	5.75e-21	3.93e-18	0.42	0.41	Thyroid cancer;	chr14:36075287	chr14:36061026~36067190:-
THCA	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-9.86	5.78e-21	3.96e-18	-0.51	-0.41	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	9.86	5.79e-21	3.96e-18	0.49	0.41	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9689599	ENSG00000268592.3	RAET1E-AS1	9.86	5.79e-21	3.96e-18	0.55	0.41	Lung cancer;	chr6:149631973	chr6:149863494~149919507:+
THCA	cis	rs8062405	0.691	rs11646653	ENSG00000251417.2	RP11-1348G14.4	9.86	5.79e-21	3.96e-18	0.41	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28802743~28817828:+
THCA	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-9.86	5.8e-21	3.97e-18	-0.53	-0.41	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
THCA	cis	rs9487094	0.67	rs1476388	ENSG00000260273.1	RP11-425D10.10	9.86	5.81e-21	3.97e-18	0.49	0.41	Height;	chr6:109518783	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	9.86	5.84e-21	4e-18	0.48	0.41	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	9.86	5.84e-21	4e-18	0.48	0.41	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
THCA	cis	rs71403859	0.502	rs35394108	ENSG00000260886.1	TAT-AS1	9.86	5.9e-21	4.03e-18	0.73	0.41	Post bronchodilator FEV1;	chr16:71506736	chr16:71565789~71578187:+
THCA	cis	rs66887589	0.72	rs11724758	ENSG00000245958.5	RP11-33B1.1	-9.86	5.91e-21	4.04e-18	-0.38	-0.41	Diastolic blood pressure;	chr4:119318723	chr4:119454791~119552025:+
THCA	cis	rs860295	0.58	rs12032720	ENSG00000225855.5	RUSC1-AS1	9.86	5.92e-21	4.05e-18	0.29	0.41	Body mass index;	chr1:155305169	chr1:155316863~155324176:-
THCA	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-9.86	5.92e-21	4.05e-18	-0.57	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
THCA	cis	rs9322193	0.923	rs9800736	ENSG00000268592.3	RAET1E-AS1	9.85	5.94e-21	4.06e-18	0.56	0.41	Lung cancer;	chr6:149661281	chr6:149863494~149919507:+
THCA	cis	rs10740039	0.804	rs1372714	ENSG00000254271.1	RP11-131N11.4	9.85	5.94e-21	4.06e-18	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60686640	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.671	rs7919726	ENSG00000254271.1	RP11-131N11.4	9.85	5.94e-21	4.06e-18	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60689748	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.804	rs10821824	ENSG00000254271.1	RP11-131N11.4	9.85	5.94e-21	4.06e-18	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60690449	chr10:60734342~60741828:+
THCA	cis	rs1858037	0.867	rs55945621	ENSG00000281920.1	RP11-418H16.1	9.85	5.96e-21	4.07e-18	0.54	0.41	Rheumatoid arthritis;	chr2:65388220	chr2:65623272~65628424:+
THCA	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	9.85	5.97e-21	4.08e-18	0.54	0.41	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
THCA	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	9.85	5.98e-21	4.09e-18	0.56	0.41	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
THCA	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	9.85	5.99e-21	4.09e-18	0.43	0.41	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
THCA	cis	rs8062405	0.824	rs7191618	ENSG00000251417.2	RP11-1348G14.4	-9.85	6.03e-21	4.12e-18	-0.39	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.754	rs3859172	ENSG00000251417.2	RP11-1348G14.4	-9.85	6.03e-21	4.12e-18	-0.39	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28802743~28817828:+
THCA	cis	rs944289	0.74	rs7145145	ENSG00000257826.1	RP11-116N8.4	-9.85	6.06e-21	4.14e-18	-0.43	-0.41	Thyroid cancer;	chr14:36110724	chr14:36061026~36067190:-
THCA	cis	rs944289	0.708	rs7145311	ENSG00000257826.1	RP11-116N8.4	-9.85	6.06e-21	4.14e-18	-0.43	-0.41	Thyroid cancer;	chr14:36110738	chr14:36061026~36067190:-
THCA	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-9.85	6.06e-21	4.14e-18	-0.68	-0.41	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
THCA	cis	rs9926296	0.712	rs447735	ENSG00000260259.1	RP11-368I7.4	9.85	6.08e-21	4.15e-18	0.46	0.41	Vitiligo;	chr16:89667941	chr16:89682620~89686569:-
THCA	cis	rs9322193	0.847	rs12234128	ENSG00000268592.3	RAET1E-AS1	9.85	6.1e-21	4.17e-18	0.56	0.41	Lung cancer;	chr6:149627553	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs57012784	ENSG00000268592.3	RAET1E-AS1	9.85	6.1e-21	4.17e-18	0.56	0.41	Lung cancer;	chr6:149627691	chr6:149863494~149919507:+
THCA	cis	rs11676348	0.755	rs6436026	ENSG00000261338.2	RP11-378A13.1	-9.85	6.11e-21	4.17e-18	-0.41	-0.41	Ulcerative colitis;	chr2:218087015	chr2:218255319~218257366:+
THCA	cis	rs11676348	0.791	rs6726126	ENSG00000261338.2	RP11-378A13.1	-9.85	6.11e-21	4.17e-18	-0.41	-0.41	Ulcerative colitis;	chr2:218087510	chr2:218255319~218257366:+
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-9.85	6.11e-21	4.17e-18	-0.51	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
THCA	cis	rs9322193	0.962	rs3805749	ENSG00000268592.3	RAET1E-AS1	9.85	6.11e-21	4.17e-18	0.57	0.41	Lung cancer;	chr6:149772546	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.847	rs9505972	ENSG00000268592.3	RAET1E-AS1	9.85	6.11e-21	4.17e-18	0.57	0.41	Lung cancer;	chr6:149775255	chr6:149863494~149919507:+
THCA	cis	rs4713118	0.662	rs149947	ENSG00000280107.1	AL022393.9	-9.85	6.12e-21	4.18e-18	-0.48	-0.41	Parkinson's disease;	chr6:28004655	chr6:28170845~28172521:+
THCA	cis	rs67311347	0.577	rs1317217	ENSG00000223797.4	ENTPD3-AS1	9.85	6.13e-21	4.19e-18	0.34	0.41	Renal cell carcinoma;	chr3:40230206	chr3:40313802~40453329:-
THCA	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	9.85	6.13e-21	4.19e-18	0.35	0.41	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
THCA	cis	rs10935480	0.577	rs10804683	ENSG00000239445.4	ST3GAL6-AS1	-9.85	6.18e-21	4.22e-18	-0.42	-0.41	Blood protein levels;	chr3:98661882	chr3:98714330~98732651:-
THCA	cis	rs9532669	0.89	rs9532676	ENSG00000176268.5	CYCSP34	9.85	6.2e-21	4.23e-18	0.47	0.41	Cervical cancer;	chr13:40935626	chr13:40863599~40863902:-
THCA	cis	rs34081947	0.5	rs1930766	ENSG00000257826.1	RP11-116N8.4	-9.85	6.22e-21	4.24e-18	-0.48	-0.41	Papillary thyroid cancer;Differentiated thyroid cancer;	chr14:36081037	chr14:36061026~36067190:-
THCA	cis	rs1537424	0.513	rs944845	ENSG00000257826.1	RP11-116N8.4	-9.85	6.22e-21	4.24e-18	-0.48	-0.41	Thyroid hormone levels;	chr14:36081480	chr14:36061026~36067190:-
THCA	cis	rs1537424	0.513	rs1615453	ENSG00000257826.1	RP11-116N8.4	9.85	6.22e-21	4.24e-18	0.48	0.41	Thyroid hormone levels;	chr14:36077246	chr14:36061026~36067190:-
THCA	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	9.85	6.24e-21	4.26e-18	0.49	0.41	Height;	chr6:109586733	chr6:109382795~109383666:+
THCA	cis	rs17684571	0.687	rs13214893	ENSG00000231441.1	RP11-472M19.2	9.85	6.27e-21	4.28e-18	0.55	0.41	Schizophrenia;	chr6:56865425	chr6:56844002~56864078:+
THCA	cis	rs944289	0.679	rs12050116	ENSG00000257826.1	RP11-116N8.4	-9.85	6.28e-21	4.28e-18	-0.42	-0.41	Thyroid cancer;	chr14:36103725	chr14:36061026~36067190:-
THCA	cis	rs4713118	0.629	rs203888	ENSG00000280107.1	AL022393.9	-9.85	6.29e-21	4.29e-18	-0.47	-0.41	Parkinson's disease;	chr6:28053811	chr6:28170845~28172521:+
THCA	cis	rs934734	0.571	rs7572922	ENSG00000281920.1	RP11-418H16.1	-9.85	6.3e-21	4.3e-18	-0.5	-0.41	Rheumatoid arthritis;	chr2:65425022	chr2:65623272~65628424:+
THCA	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-9.85	6.32e-21	4.31e-18	-0.6	-0.41	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
THCA	cis	rs9487094	0.67	rs7755941	ENSG00000260273.1	RP11-425D10.10	9.85	6.41e-21	4.37e-18	0.49	0.41	Height;	chr6:109494148	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.626	rs12195904	ENSG00000260273.1	RP11-425D10.10	9.85	6.41e-21	4.37e-18	0.49	0.41	Height;	chr6:109494760	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs1406899	ENSG00000260273.1	RP11-425D10.10	9.85	6.41e-21	4.37e-18	0.49	0.41	Height;	chr6:109495102	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs11754455	ENSG00000260273.1	RP11-425D10.10	9.85	6.41e-21	4.37e-18	0.49	0.41	Height;	chr6:109496680	chr6:109382795~109383666:+
THCA	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-9.84	6.46e-21	4.4e-18	-0.52	-0.41	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	9.84	6.46e-21	4.41e-18	0.5	0.41	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	9.84	6.46e-21	4.41e-18	0.5	0.41	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
THCA	cis	rs4819052	0.851	rs8127834	ENSG00000215447.6	BX322557.10	-9.84	6.48e-21	4.41e-18	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45288052~45291738:+
THCA	cis	rs9487094	0.67	rs34928881	ENSG00000260273.1	RP11-425D10.10	9.84	6.54e-21	4.45e-18	0.48	0.41	Height;	chr6:109526846	chr6:109382795~109383666:+
THCA	cis	rs10740039	0.883	rs10994468	ENSG00000254271.1	RP11-131N11.4	9.84	6.54e-21	4.46e-18	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60666533	chr10:60734342~60741828:+
THCA	cis	rs9322193	0.923	rs66516768	ENSG00000268592.3	RAET1E-AS1	9.84	6.58e-21	4.49e-18	0.56	0.41	Lung cancer;	chr6:149671999	chr6:149863494~149919507:+
THCA	cis	rs10935480	0.551	rs34070949	ENSG00000239445.4	ST3GAL6-AS1	-9.84	6.59e-21	4.49e-18	-0.42	-0.41	Blood protein levels;	chr3:98635347	chr3:98714330~98732651:-
THCA	cis	rs1799949	0.93	rs3092987	ENSG00000267681.1	CTD-3199J23.6	-9.84	6.62e-21	4.51e-18	-0.49	-0.41	Menopause (age at onset);	chr17:43070706	chr17:43144956~43145255:+
THCA	cis	rs7208859	0.623	rs73269916	ENSG00000266490.1	CTD-2349P21.9	9.84	6.64e-21	4.53e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30792372~30792833:+
THCA	cis	rs780096	0.526	rs3845687	ENSG00000234072.1	AC074117.10	-9.84	6.67e-21	4.54e-18	-0.33	-0.41	Total body bone mineral density;	chr2:27467032	chr2:27356246~27367622:+
THCA	cis	rs780096	0.506	rs8395	ENSG00000234072.1	AC074117.10	-9.84	6.67e-21	4.54e-18	-0.33	-0.41	Total body bone mineral density;	chr2:27492340	chr2:27356246~27367622:+
THCA	cis	rs66887589	0.72	rs2036858	ENSG00000245958.5	RP11-33B1.1	-9.84	6.67e-21	4.55e-18	-0.38	-0.41	Diastolic blood pressure;	chr4:119328082	chr4:119454791~119552025:+
THCA	cis	rs7191700	0.644	rs12149160	ENSG00000262703.1	RP11-485G7.6	-9.84	6.67e-21	4.55e-18	-0.47	-0.41	Multiple sclerosis;	chr16:11345446	chr16:11348143~11349321:-
THCA	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-9.84	6.71e-21	4.57e-18	-0.57	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
THCA	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	9.84	6.71e-21	4.57e-18	0.48	0.41	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	9.84	6.73e-21	4.58e-18	0.48	0.41	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
THCA	cis	rs9532669	0.853	rs9315795	ENSG00000239827.7	SUGT1P3	-9.84	6.74e-21	4.59e-18	-0.45	-0.41	Cervical cancer;	chr13:40943382	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs3764056	ENSG00000239827.7	SUGT1P3	-9.84	6.74e-21	4.59e-18	-0.45	-0.41	Cervical cancer;	chr13:40943849	chr13:40908159~40921774:-
THCA	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-9.84	6.77e-21	4.61e-18	-0.49	-0.41	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
THCA	cis	rs673078	0.66	rs11068910	ENSG00000275409.1	RP11-131L12.4	-9.84	6.78e-21	4.62e-18	-0.44	-0.41	Glucose homeostasis traits;	chr12:118336076	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-9.84	6.81e-21	4.64e-18	-0.48	-0.41	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	9.84	6.81e-21	4.64e-18	0.48	0.41	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
THCA	cis	rs9487094	0.626	rs7773950	ENSG00000260273.1	RP11-425D10.10	9.84	6.83e-21	4.65e-18	0.49	0.41	Height;	chr6:109494237	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs11153183	ENSG00000260273.1	RP11-425D10.10	9.84	6.83e-21	4.65e-18	0.49	0.41	Height;	chr6:109496073	chr6:109382795~109383666:+
THCA	cis	rs17684571	0.687	rs17752213	ENSG00000231441.1	RP11-472M19.2	9.84	6.83e-21	4.65e-18	0.55	0.41	Schizophrenia;	chr6:56864627	chr6:56844002~56864078:+
THCA	cis	rs4660456	0.504	rs587064	ENSG00000237899.1	RP4-739H11.3	9.84	6.85e-21	4.66e-18	0.56	0.41	Platelet count;	chr1:40640238	chr1:40669089~40687588:-
THCA	cis	rs10740039	0.883	rs10761542	ENSG00000254271.1	RP11-131N11.4	9.84	6.88e-21	4.68e-18	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655465	chr10:60734342~60741828:+
THCA	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-9.84	6.9e-21	4.69e-18	-0.5	-0.41	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
THCA	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-9.84	6.9e-21	4.7e-18	-0.61	-0.41	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-9.84	6.9e-21	4.7e-18	-0.61	-0.41	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-9.84	6.9e-21	4.7e-18	-0.61	-0.41	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
THCA	cis	rs12460587	0.622	rs7247612	ENSG00000275055.1	CTC-471J1.11	-9.84	6.96e-21	4.73e-18	-0.32	-0.41	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52082336	chr19:52049007~52049754:+
THCA	cis	rs934734	0.571	rs7565437	ENSG00000281920.1	RP11-418H16.1	-9.84	6.97e-21	4.74e-18	-0.51	-0.41	Rheumatoid arthritis;	chr2:65419832	chr2:65623272~65628424:+
THCA	cis	rs9532669	0.963	rs4941391	ENSG00000239827.7	SUGT1P3	-9.84	6.98e-21	4.74e-18	-0.45	-0.41	Cervical cancer;	chr13:40939787	chr13:40908159~40921774:-
THCA	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-9.83	7.01e-21	4.77e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
THCA	cis	rs1858037	0.867	rs964505	ENSG00000281920.1	RP11-418H16.1	9.83	7.08e-21	4.82e-18	0.54	0.41	Rheumatoid arthritis;	chr2:65396055	chr2:65623272~65628424:+
THCA	cis	rs9532669	0.963	rs4343141	ENSG00000176268.5	CYCSP34	9.83	7.08e-21	4.82e-18	0.47	0.41	Cervical cancer;	chr13:40940497	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs3887418	ENSG00000176268.5	CYCSP34	9.83	7.08e-21	4.82e-18	0.47	0.41	Cervical cancer;	chr13:40940560	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs1056820	ENSG00000176268.5	CYCSP34	9.83	7.08e-21	4.82e-18	0.47	0.41	Cervical cancer;	chr13:40941150	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532678	ENSG00000176268.5	CYCSP34	9.83	7.08e-21	4.82e-18	0.47	0.41	Cervical cancer;	chr13:40941862	chr13:40863599~40863902:-
THCA	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	9.83	7.1e-21	4.82e-18	0.48	0.41	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
THCA	cis	rs10759883	0.627	rs10760189	ENSG00000175611.10	LINC00476	9.83	7.1e-21	4.83e-18	0.46	0.41	Nicotine dependence;	chr9:95838543	chr9:95759231~95875977:-
THCA	cis	rs1799810	0.899	rs7599210	ENSG00000236682.1	AC068282.3	-9.83	7.12e-21	4.84e-18	-0.57	-0.41	Self-rated health;	chr2:127406601	chr2:127389130~127400580:+
THCA	cis	rs860295	0.557	rs12035524	ENSG00000225855.5	RUSC1-AS1	9.83	7.14e-21	4.85e-18	0.31	0.41	Body mass index;	chr1:155697311	chr1:155316863~155324176:-
THCA	cis	rs9487094	0.67	rs2277114	ENSG00000260273.1	RP11-425D10.10	9.83	7.16e-21	4.86e-18	0.49	0.41	Height;	chr6:109506513	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	9.83	7.17e-21	4.87e-18	0.48	0.41	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	9.83	7.17e-21	4.87e-18	0.48	0.41	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	9.83	7.17e-21	4.87e-18	0.48	0.41	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
THCA	cis	rs673078	0.66	rs2280711	ENSG00000275409.1	RP11-131L12.4	-9.83	7.18e-21	4.88e-18	-0.46	-0.41	Glucose homeostasis traits;	chr12:118212149	chr12:118430147~118430699:+
THCA	cis	rs7727544	0.716	rs72793283	ENSG00000237714.1	P4HA2-AS1	9.83	7.19e-21	4.88e-18	0.55	0.41	Blood metabolite levels;	chr5:132231248	chr5:132184876~132192808:+
THCA	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-9.83	7.2e-21	4.89e-18	-0.5	-0.41	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
THCA	cis	rs17826219	0.568	rs2626985	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Body mass index;	chr17:30750419	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.636	rs7221463	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Body mass index;	chr17:30753533	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7219712	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs8078656	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs1061342	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs55938328	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs55961983	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs7222803	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.568	rs7213925	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Body mass index;	chr17:30794616	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11658945	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11657990	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11650982	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9915546	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9895815	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.706	rs73271850	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Body mass index;	chr17:30815122	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.636	rs79565452	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Body mass index;	chr17:30815823	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7208088	ENSG00000266490.1	CTD-2349P21.9	9.83	7.22e-21	4.9e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30792372~30792833:+
THCA	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-9.83	7.27e-21	4.94e-18	-0.43	-0.41	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
THCA	cis	rs12554020	0.892	rs6479494	ENSG00000227603.1	RP11-165J3.6	-9.83	7.3e-21	4.95e-18	-0.57	-0.41	Schizophrenia;	chr9:93568217	chr9:93435332~93437121:-
THCA	cis	rs11676348	0.904	rs10804264	ENSG00000261338.2	RP11-378A13.1	-9.83	7.34e-21	4.98e-18	-0.42	-0.41	Ulcerative colitis;	chr2:218091086	chr2:218255319~218257366:+
THCA	cis	rs9926296	0.744	rs6860	ENSG00000260259.1	RP11-368I7.4	9.83	7.35e-21	4.99e-18	0.46	0.41	Vitiligo;	chr16:89644712	chr16:89682620~89686569:-
THCA	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-9.83	7.37e-21	5e-18	-0.46	-0.41	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
THCA	cis	rs17826219	0.706	rs9893922	ENSG00000266490.1	CTD-2349P21.9	9.83	7.38e-21	5e-18	0.55	0.41	Body mass index;	chr17:30741407	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.5	rs9891256	ENSG00000266490.1	CTD-2349P21.9	9.83	7.38e-21	5e-18	0.55	0.41	Body mass index;	chr17:30745674	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7503335	ENSG00000266490.1	CTD-2349P21.9	9.83	7.38e-21	5e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30792372~30792833:+
THCA	cis	rs67311347	0.544	rs6769627	ENSG00000223797.4	ENTPD3-AS1	9.83	7.38e-21	5e-18	0.33	0.41	Renal cell carcinoma;	chr3:40286354	chr3:40313802~40453329:-
THCA	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	9.83	7.4e-21	5.02e-18	0.55	0.41	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
THCA	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-9.83	7.43e-21	5.03e-18	-0.42	-0.41	Height;	chr11:118703185	chr11:118704607~118750263:+
THCA	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-9.83	7.43e-21	5.03e-18	-0.42	-0.41	Height;	chr11:118703207	chr11:118704607~118750263:+
THCA	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-9.83	7.44e-21	5.04e-18	-0.44	-0.41	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
THCA	cis	rs17684571	0.683	rs13215883	ENSG00000231441.1	RP11-472M19.2	9.83	7.44e-21	5.04e-18	0.55	0.41	Schizophrenia;	chr6:56858927	chr6:56844002~56864078:+
THCA	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-9.83	7.48e-21	5.07e-18	-0.5	-0.41	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
THCA	cis	rs950169	0.887	rs71395453	ENSG00000259728.4	LINC00933	9.83	7.49e-21	5.08e-18	0.56	0.41	Schizophrenia;	chr15:84570259	chr15:84570649~84580175:+
THCA	cis	rs10740039	0.804	rs1837950	ENSG00000254271.1	RP11-131N11.4	-9.83	7.5e-21	5.08e-18	-0.51	-0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60685207	chr10:60734342~60741828:+
THCA	cis	rs180730	0.519	rs6822124	ENSG00000251609.2	SETP12	9.83	7.51e-21	5.09e-18	0.57	0.41	Fasting plasma glucose;	chr4:120940658	chr4:120895494~120897083:-
THCA	cis	rs7208859	0.623	rs8081299	ENSG00000266490.1	CTD-2349P21.9	9.83	7.53e-21	5.1e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8068645	ENSG00000266490.1	CTD-2349P21.9	9.83	7.53e-21	5.1e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30792372~30792833:+
THCA	cis	rs916888	0.697	rs199516	ENSG00000232300.1	FAM215B	-9.83	7.53e-21	5.1e-18	-0.66	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46558830~46562795:-
THCA	cis	rs7772486	0.902	rs1331643	ENSG00000235652.6	RP11-545I5.3	9.83	7.56e-21	5.12e-18	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146077737	chr6:145799409~145886585:+
THCA	cis	rs1858037	0.867	rs67453645	ENSG00000281920.1	RP11-418H16.1	9.82	7.61e-21	5.15e-18	0.55	0.41	Rheumatoid arthritis;	chr2:65358908	chr2:65623272~65628424:+
THCA	cis	rs10740039	0.729	rs7091383	ENSG00000254271.1	RP11-131N11.4	9.82	7.63e-21	5.17e-18	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60676419	chr10:60734342~60741828:+
THCA	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-9.82	7.63e-21	5.17e-18	-0.31	-0.41	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
THCA	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-9.82	7.63e-21	5.17e-18	-0.31	-0.41	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
THCA	cis	rs853679	0.517	rs9393891	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28111382	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9468286	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28111650	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.516	rs7739216	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Parkinson's disease;	chr6:28112168	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs35512245	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28112175	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380055	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28113851	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368553	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28114487	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368554	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28114933	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs4713137	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28115743	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9348793	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Depression;	chr6:28116411	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.586	rs6905516	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Parkinson's disease;	chr6:28118700	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.586	rs6905522	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Parkinson's disease;	chr6:28118701	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.586	rs9468290	ENSG00000226314.6	ZNF192P1	-9.82	7.63e-21	5.17e-18	-0.55	-0.41	Parkinson's disease;	chr6:28119896	chr6:28161781~28169594:+
THCA	cis	rs10759883	0.627	rs12349742	ENSG00000175611.10	LINC00476	9.82	7.64e-21	5.18e-18	0.46	0.41	Nicotine dependence;	chr9:95857698	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.58	rs2026031	ENSG00000175611.10	LINC00476	9.82	7.64e-21	5.18e-18	0.46	0.41	Nicotine dependence;	chr9:95859068	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs689986	ENSG00000175611.10	LINC00476	9.82	7.64e-21	5.18e-18	0.46	0.41	Nicotine dependence;	chr9:95866867	chr9:95759231~95875977:-
THCA	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	9.82	7.64e-21	5.18e-18	0.48	0.41	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	9.82	7.64e-21	5.18e-18	0.48	0.41	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
THCA	cis	rs11676348	0.783	rs13035513	ENSG00000261338.2	RP11-378A13.1	-9.82	7.65e-21	5.18e-18	-0.41	-0.41	Ulcerative colitis;	chr2:218095957	chr2:218255319~218257366:+
THCA	cis	rs2599510	0.744	rs2254106	ENSG00000276334.1	AL133243.1	9.82	7.71e-21	5.22e-18	0.43	0.41	Interleukin-18 levels;	chr2:32543730	chr2:32521927~32523547:+
THCA	cis	rs2599510	0.729	rs1135484	ENSG00000276334.1	AL133243.1	9.82	7.73e-21	5.23e-18	0.45	0.41	Interleukin-18 levels;	chr2:32523993	chr2:32521927~32523547:+
THCA	cis	rs9322193	0.923	rs9689723	ENSG00000268592.3	RAET1E-AS1	9.82	7.73e-21	5.23e-18	0.56	0.41	Lung cancer;	chr6:149655935	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9968911	ENSG00000268592.3	RAET1E-AS1	9.82	7.73e-21	5.23e-18	0.56	0.41	Lung cancer;	chr6:149657419	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.926	rs7329302	ENSG00000176268.5	CYCSP34	-9.82	7.75e-21	5.24e-18	-0.46	-0.41	Cervical cancer;	chr13:40962396	chr13:40863599~40863902:-
THCA	cis	rs240993	0.812	rs383022	ENSG00000230177.1	RP5-1112D6.4	-9.82	7.76e-21	5.25e-18	-0.41	-0.41	Inflammatory skin disease;Psoriasis;	chr6:111382506	chr6:111277932~111278742:+
THCA	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	9.82	7.8e-21	5.28e-18	0.48	0.41	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	9.82	7.8e-21	5.28e-18	0.48	0.41	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
THCA	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-9.82	7.8e-21	5.28e-18	-0.5	-0.41	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
THCA	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-9.82	7.8e-21	5.28e-18	-0.5	-0.41	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
THCA	cis	rs1858037	0.867	rs61226353	ENSG00000281920.1	RP11-418H16.1	9.82	7.81e-21	5.28e-18	0.54	0.41	Rheumatoid arthritis;	chr2:65363637	chr2:65623272~65628424:+
THCA	cis	rs17608059	0.71	rs8080167	ENSG00000141028.6	CDRT15P1	-9.82	7.87e-21	5.32e-18	-0.47	-0.41	Temperament;	chr17:14046511	chr17:14024514~14025488:+
THCA	cis	rs6570726	0.905	rs442435	ENSG00000235652.6	RP11-545I5.3	9.82	7.87e-21	5.33e-18	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145494423	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.905	rs396492	ENSG00000235652.6	RP11-545I5.3	9.82	7.87e-21	5.33e-18	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145495044	chr6:145799409~145886585:+
THCA	cis	rs6570726	0.935	rs7757387	ENSG00000235652.6	RP11-545I5.3	9.82	7.87e-21	5.33e-18	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145495590	chr6:145799409~145886585:+
THCA	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	9.82	7.9e-21	5.34e-18	0.66	0.41	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
THCA	cis	rs944289	0.708	rs34232378	ENSG00000257826.1	RP11-116N8.4	-9.82	7.9e-21	5.34e-18	-0.42	-0.41	Thyroid cancer;	chr14:36102879	chr14:36061026~36067190:-
THCA	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	9.82	7.92e-21	5.35e-18	0.51	0.41	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
THCA	cis	rs11051970	0.559	rs2036304	ENSG00000274964.1	RP11-817I4.1	-9.82	7.96e-21	5.38e-18	-0.52	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32325441	chr12:32339368~32340724:+
THCA	cis	rs17608059	0.679	rs9898056	ENSG00000141028.6	CDRT15P1	-9.82	7.98e-21	5.39e-18	-0.47	-0.41	Temperament;	chr17:14048649	chr17:14024514~14025488:+
THCA	cis	rs7208859	0.623	rs9898084	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs28556733	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs28433704	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.706	rs55764512	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Body mass index;	chr17:30758740	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs12103508	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs11653605	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73269913	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs7217984	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs60114476	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.636	rs2449770	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Body mass index;	chr17:30774046	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.524	rs59913838	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8067338	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs4055105	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.562	rs8078897	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9914499	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs12006	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs3752021	ENSG00000266490.1	CTD-2349P21.9	9.82	7.99e-21	5.4e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30792372~30792833:+
THCA	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-9.82	8e-21	5.41e-18	-0.47	-0.41	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
THCA	cis	rs71403859	0.803	rs7203606	ENSG00000260886.1	TAT-AS1	9.82	8.05e-21	5.44e-18	0.72	0.41	Post bronchodilator FEV1;	chr16:71556608	chr16:71565789~71578187:+
THCA	cis	rs12554020	1	rs59582399	ENSG00000227603.1	RP11-165J3.6	9.82	8.07e-21	5.46e-18	0.56	0.41	Schizophrenia;	chr9:93523881	chr9:93435332~93437121:-
THCA	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	9.82	8.11e-21	5.48e-18	0.49	0.41	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
THCA	cis	rs9532669	0.963	rs1056835	ENSG00000239827.7	SUGT1P3	-9.82	8.2e-21	5.53e-18	-0.45	-0.41	Cervical cancer;	chr13:40932585	chr13:40908159~40921774:-
THCA	cis	rs597539	0.652	rs667989	ENSG00000250508.1	RP11-757G1.6	-9.82	8.2e-21	5.54e-18	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68918308	chr11:68870664~68874542:+
THCA	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-9.82	8.21e-21	5.54e-18	-0.61	-0.41	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
THCA	cis	rs10740039	0.883	rs7898504	ENSG00000254271.1	RP11-131N11.4	9.81	8.26e-21	5.58e-18	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658233	chr10:60734342~60741828:+
THCA	cis	rs944289	0.74	rs885535	ENSG00000257826.1	RP11-116N8.4	-9.81	8.29e-21	5.6e-18	-0.42	-0.41	Thyroid cancer;	chr14:36082574	chr14:36061026~36067190:-
THCA	cis	rs9322193	0.923	rs9322200	ENSG00000268592.3	RAET1E-AS1	9.81	8.38e-21	5.66e-18	0.55	0.41	Lung cancer;	chr6:149630078	chr6:149863494~149919507:+
THCA	cis	rs3762637	1	rs7615930	ENSG00000272758.4	RP11-299J3.8	-9.81	8.4e-21	5.67e-18	-0.54	-0.41	LDL cholesterol levels;	chr3:122406903	chr3:122416207~122443180:+
THCA	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	9.81	8.44e-21	5.69e-18	0.48	0.41	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
THCA	cis	rs4722166	0.508	rs1474348	ENSG00000179428.2	AC073072.5	-9.81	8.45e-21	5.7e-18	-0.53	-0.41	Lung cancer;	chr7:22728289	chr7:22725395~22727620:-
THCA	cis	rs1799949	1	rs8176273	ENSG00000267681.1	CTD-3199J23.6	-9.81	8.47e-21	5.71e-18	-0.49	-0.41	Menopause (age at onset);	chr17:43059636	chr17:43144956~43145255:+
THCA	cis	rs12931792	0.782	rs6565176	ENSG00000183604.13	SMG1P5	9.81	8.48e-21	5.72e-18	0.43	0.41	Tonsillectomy;	chr16:30163605	chr16:30267553~30335374:-
THCA	cis	rs12931792	0.72	rs12102320	ENSG00000183604.13	SMG1P5	9.81	8.48e-21	5.72e-18	0.43	0.41	Tonsillectomy;	chr16:30167195	chr16:30267553~30335374:-
THCA	cis	rs9532669	0.963	rs4942012	ENSG00000239827.7	SUGT1P3	-9.81	8.49e-21	5.72e-18	-0.44	-0.41	Cervical cancer;	chr13:40939112	chr13:40908159~40921774:-
THCA	cis	rs881375	0.678	rs3761846	ENSG00000226752.6	PSMD5-AS1	-9.81	8.53e-21	5.75e-18	-0.49	-0.41	Rheumatoid arthritis;	chr9:120927319	chr9:120824828~120854385:+
THCA	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	9.81	8.54e-21	5.76e-18	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
THCA	cis	rs11148252	0.532	rs9526975	ENSG00000235660.1	LINC00345	-9.81	8.62e-21	5.82e-18	-0.52	-0.41	Lewy body disease;	chr13:52681669	chr13:52484161~52484680:-
THCA	cis	rs1858037	0.867	rs1553675	ENSG00000281920.1	RP11-418H16.1	-9.81	8.67e-21	5.85e-18	-0.54	-0.41	Rheumatoid arthritis;	chr2:65343173	chr2:65623272~65628424:+
THCA	cis	rs9487094	0.626	rs12192776	ENSG00000260273.1	RP11-425D10.10	9.81	8.69e-21	5.86e-18	0.48	0.41	Height;	chr6:109634150	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12194157	ENSG00000260273.1	RP11-425D10.10	9.81	8.69e-21	5.86e-18	0.48	0.41	Height;	chr6:109640141	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12197950	ENSG00000260273.1	RP11-425D10.10	9.81	8.69e-21	5.86e-18	0.48	0.41	Height;	chr6:109642186	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs7767525	ENSG00000260273.1	RP11-425D10.10	9.81	8.69e-21	5.86e-18	0.48	0.41	Height;	chr6:109646187	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.504	rs71541003	ENSG00000260273.1	RP11-425D10.10	9.81	8.69e-21	5.86e-18	0.48	0.41	Height;	chr6:109652694	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs3899233	ENSG00000260273.1	RP11-425D10.10	9.81	8.69e-21	5.86e-18	0.48	0.41	Height;	chr6:109655791	chr6:109382795~109383666:+
THCA	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-9.81	8.74e-21	5.89e-18	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
THCA	cis	rs916888	0.821	rs199506	ENSG00000232300.1	FAM215B	-9.81	8.74e-21	5.89e-18	-0.67	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46558830~46562795:-
THCA	cis	rs4660456	0.504	rs491619	ENSG00000237899.1	RP4-739H11.3	9.81	8.77e-21	5.91e-18	0.56	0.41	Platelet count;	chr1:40641688	chr1:40669089~40687588:-
THCA	cis	rs9532669	0.929	rs9532601	ENSG00000239827.7	SUGT1P3	-9.81	8.8e-21	5.93e-18	-0.47	-0.41	Cervical cancer;	chr13:40861086	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	9.81	8.82e-21	5.94e-18	0.49	0.41	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	9.81	8.82e-21	5.94e-18	0.49	0.41	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	9.81	8.82e-21	5.94e-18	0.49	0.41	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000228039.3	KB-1125A3.10	9.81	8.83e-21	5.94e-18	0.52	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23963780~23964374:+
THCA	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-9.81	8.83e-21	5.95e-18	-0.49	-0.41	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
THCA	cis	rs9532669	1	rs9532669	ENSG00000239827.7	SUGT1P3	-9.81	8.88e-21	5.98e-18	-0.45	-0.41	Cervical cancer;	chr13:40927414	chr13:40908159~40921774:-
THCA	cis	rs950169	0.84	rs12905223	ENSG00000259728.4	LINC00933	9.81	8.89e-21	5.98e-18	0.56	0.41	Schizophrenia;	chr15:84571037	chr15:84570649~84580175:+
THCA	cis	rs9532669	0.89	rs2324738	ENSG00000176268.5	CYCSP34	9.81	8.89e-21	5.98e-18	0.46	0.41	Cervical cancer;	chr13:40925242	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs2324739	ENSG00000176268.5	CYCSP34	9.81	8.89e-21	5.98e-18	0.46	0.41	Cervical cancer;	chr13:40925479	chr13:40863599~40863902:-
THCA	cis	rs780096	0.526	rs3845686	ENSG00000234072.1	AC074117.10	-9.81	8.96e-21	6.03e-18	-0.33	-0.41	Total body bone mineral density;	chr2:27432580	chr2:27356246~27367622:+
THCA	cis	rs780096	0.526	rs11126999	ENSG00000234072.1	AC074117.10	-9.81	8.96e-21	6.03e-18	-0.33	-0.41	Total body bone mineral density;	chr2:27447440	chr2:27356246~27367622:+
THCA	cis	rs780096	0.506	rs56076827	ENSG00000234072.1	AC074117.10	-9.81	8.96e-21	6.03e-18	-0.33	-0.41	Total body bone mineral density;	chr2:27453420	chr2:27356246~27367622:+
THCA	cis	rs9318086	0.935	rs9652081	ENSG00000205861.10	C1QTNF9B-AS1	9.8	8.98e-21	6.05e-18	0.46	0.41	Myopia (pathological);	chr13:23861371	chr13:23888889~23897263:+
THCA	cis	rs673078	0.66	rs61946063	ENSG00000275409.1	RP11-131L12.4	-9.8	9.1e-21	6.12e-18	-0.43	-0.41	Glucose homeostasis traits;	chr12:118294448	chr12:118430147~118430699:+
THCA	cis	rs71403859	0.502	rs71403847	ENSG00000260886.1	TAT-AS1	9.8	9.14e-21	6.15e-18	0.73	0.41	Post bronchodilator FEV1;	chr16:71434323	chr16:71565789~71578187:+
THCA	cis	rs10759883	0.627	rs689804	ENSG00000175611.10	LINC00476	9.8	9.17e-21	6.17e-18	0.46	0.41	Nicotine dependence;	chr9:95868574	chr9:95759231~95875977:-
THCA	cis	rs7208859	0.623	rs56812022	ENSG00000266490.1	CTD-2349P21.9	9.8	9.18e-21	6.17e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30792372~30792833:+
THCA	cis	rs1799949	1	rs33946455	ENSG00000267681.1	CTD-3199J23.6	-9.8	9.18e-21	6.17e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43169829	chr17:43144956~43145255:+
THCA	cis	rs524281	0.682	rs34274349	ENSG00000255320.1	RP11-755F10.1	-9.8	9.25e-21	6.22e-18	-0.62	-0.41	Electroencephalogram traits;	chr11:66030595	chr11:66244840~66246239:-
THCA	cis	rs524281	0.731	rs730787	ENSG00000255320.1	RP11-755F10.1	-9.8	9.25e-21	6.22e-18	-0.62	-0.41	Electroencephalogram traits;	chr11:66031488	chr11:66244840~66246239:-
THCA	cis	rs4660456	0.542	rs850009	ENSG00000237899.1	RP4-739H11.3	9.8	9.28e-21	6.24e-18	0.56	0.41	Platelet count;	chr1:40643593	chr1:40669089~40687588:-
THCA	cis	rs10740039	0.766	rs2119917	ENSG00000254271.1	RP11-131N11.4	9.8	9.3e-21	6.25e-18	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677626	chr10:60734342~60741828:+
THCA	cis	rs950169	0.922	rs17531523	ENSG00000259728.4	LINC00933	9.8	9.34e-21	6.28e-18	0.57	0.41	Schizophrenia;	chr15:84589218	chr15:84570649~84580175:+
THCA	cis	rs6452524	0.713	rs2386245	ENSG00000249664.1	CTD-2227C6.2	-9.8	9.38e-21	6.3e-18	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83214866	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.836	rs2731852	ENSG00000249664.1	CTD-2227C6.2	-9.8	9.4e-21	6.32e-18	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83212591	chr5:83012285~83013109:-
THCA	cis	rs7727544	0.642	rs7705189	ENSG00000237714.1	P4HA2-AS1	-9.8	9.41e-21	6.32e-18	-0.54	-0.41	Blood metabolite levels;	chr5:132287665	chr5:132184876~132192808:+
THCA	cis	rs673078	0.66	rs17586342	ENSG00000275409.1	RP11-131L12.4	-9.8	9.41e-21	6.32e-18	-0.45	-0.41	Glucose homeostasis traits;	chr12:118162399	chr12:118430147~118430699:+
THCA	cis	rs7712401	0.601	rs30048	ENSG00000263432.2	RN7SL689P	9.8	9.42e-21	6.33e-18	0.45	0.41	Mean platelet volume;	chr5:122934698	chr5:123022487~123022783:-
THCA	cis	rs1858037	0.806	rs12612780	ENSG00000281920.1	RP11-418H16.1	9.8	9.44e-21	6.34e-18	0.54	0.41	Rheumatoid arthritis;	chr2:65355967	chr2:65623272~65628424:+
THCA	cis	rs12554020	0.786	rs79469056	ENSG00000227603.1	RP11-165J3.6	9.8	9.57e-21	6.42e-18	0.71	0.41	Schizophrenia;	chr9:93453807	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs12554164	ENSG00000227603.1	RP11-165J3.6	9.8	9.57e-21	6.42e-18	0.71	0.41	Schizophrenia;	chr9:93456677	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs16909158	ENSG00000227603.1	RP11-165J3.6	9.8	9.57e-21	6.42e-18	0.71	0.41	Schizophrenia;	chr9:93457882	chr9:93435332~93437121:-
THCA	cis	rs9595066	0.627	rs9562538	ENSG00000227258.4	SMIM2-AS1	9.8	9.57e-21	6.42e-18	0.57	0.41	Schizophrenia;	chr13:44183532	chr13:44110451~44240517:+
THCA	cis	rs11676348	0.818	rs7423433	ENSG00000261338.2	RP11-378A13.1	-9.8	9.59e-21	6.44e-18	-0.41	-0.41	Ulcerative colitis;	chr2:218120361	chr2:218255319~218257366:+
THCA	cis	rs944289	0.74	rs379426	ENSG00000257826.1	RP11-116N8.4	9.8	9.6e-21	6.44e-18	0.42	0.41	Thyroid cancer;	chr14:36075253	chr14:36061026~36067190:-
THCA	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-9.8	9.6e-21	6.44e-18	-0.45	-0.41	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-9.8	9.6e-21	6.44e-18	-0.45	-0.41	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
THCA	cis	rs11051970	0.592	rs7132235	ENSG00000274964.1	RP11-817I4.1	-9.8	9.6e-21	6.44e-18	-0.55	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32383369	chr12:32339368~32340724:+
THCA	cis	rs1799810	0.739	rs13030284	ENSG00000236682.1	AC068282.3	9.8	9.67e-21	6.49e-18	0.61	0.41	Self-rated health;	chr2:127401143	chr2:127389130~127400580:+
THCA	cis	rs7727544	0.647	rs72793280	ENSG00000237714.1	P4HA2-AS1	9.8	9.69e-21	6.5e-18	0.55	0.41	Blood metabolite levels;	chr5:132227207	chr5:132184876~132192808:+
THCA	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-9.8	9.71e-21	6.52e-18	-0.61	-0.41	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	9.79	9.74e-21	6.53e-18	0.48	0.41	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
THCA	cis	rs12554020	0.579	rs74740549	ENSG00000227603.1	RP11-165J3.6	9.79	9.78e-21	6.56e-18	0.72	0.41	Schizophrenia;	chr9:93480399	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs79804179	ENSG00000227603.1	RP11-165J3.6	9.79	9.78e-21	6.56e-18	0.72	0.41	Schizophrenia;	chr9:93486200	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.681	rs74816254	ENSG00000227603.1	RP11-165J3.6	9.79	9.78e-21	6.56e-18	0.72	0.41	Schizophrenia;	chr9:93486661	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs79068125	ENSG00000227603.1	RP11-165J3.6	9.79	9.78e-21	6.56e-18	0.72	0.41	Schizophrenia;	chr9:93486957	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs79330192	ENSG00000227603.1	RP11-165J3.6	9.79	9.78e-21	6.56e-18	0.72	0.41	Schizophrenia;	chr9:93487542	chr9:93435332~93437121:-
THCA	cis	rs6570726	0.875	rs368744	ENSG00000235652.6	RP11-545I5.3	9.79	9.86e-21	6.61e-18	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145491486	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	9.79	9.92e-21	6.65e-18	0.48	0.41	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	9.79	9.92e-21	6.65e-18	0.48	0.41	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	9.79	9.92e-21	6.65e-18	0.48	0.41	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
THCA	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	9.79	9.92e-21	6.65e-18	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
THCA	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	9.79	9.93e-21	6.65e-18	0.35	0.41	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
THCA	cis	rs7665090	0.665	rs227277	ENSG00000246560.2	RP11-10L12.4	-9.79	9.95e-21	6.67e-18	-0.5	-0.41	Primary biliary cholangitis;	chr4:102673781	chr4:102828055~102844075:+
THCA	cis	rs6452524	0.836	rs2089565	ENSG00000249664.1	CTD-2227C6.2	-9.79	9.98e-21	6.69e-18	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83214410	chr5:83012285~83013109:-
THCA	cis	rs7429990	0.774	rs3772402	ENSG00000229759.1	MRPS18AP1	-9.79	1e-20	6.7e-18	-0.49	-0.41	Educational attainment (years of education);	chr3:47574661	chr3:48256350~48256938:-
THCA	cis	rs957448	1	rs957448	ENSG00000253704.1	RP11-267M23.4	9.79	1e-20	6.72e-18	0.43	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94553722~94569745:+
THCA	cis	rs957448	1	rs72674855	ENSG00000253704.1	RP11-267M23.4	9.79	1e-20	6.72e-18	0.43	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94553722~94569745:+
THCA	cis	rs860295	0.665	rs11264393	ENSG00000225855.5	RUSC1-AS1	9.79	1e-20	6.72e-18	0.29	0.41	Body mass index;	chr1:155604680	chr1:155316863~155324176:-
THCA	cis	rs984222	0.527	rs2794315	ENSG00000231365.4	RP11-418J17.1	-9.79	1e-20	6.73e-18	-0.4	-0.41	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035043	chr1:119140396~119275973:+
THCA	cis	rs984222	0.527	rs2247883	ENSG00000231365.4	RP11-418J17.1	-9.79	1e-20	6.73e-18	-0.4	-0.41	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119035214	chr1:119140396~119275973:+
THCA	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-9.79	1.01e-20	6.75e-18	-0.49	-0.41	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
THCA	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-9.79	1.01e-20	6.75e-18	-0.49	-0.41	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
THCA	cis	rs4380275	0.782	rs4854369	ENSG00000272342.1	RP13-539J13.1	9.79	1.01e-20	6.76e-18	0.48	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:739588~740164:-
THCA	cis	rs860295	0.702	rs3851912	ENSG00000225855.5	RUSC1-AS1	9.79	1.01e-20	6.77e-18	0.29	0.41	Body mass index;	chr1:155616653	chr1:155316863~155324176:-
THCA	cis	rs4927850	0.709	rs6783079	ENSG00000231464.1	AC024937.4	9.79	1.01e-20	6.79e-18	0.59	0.41	Pancreatic cancer;	chr3:195925837	chr3:195996738~195998233:+
THCA	cis	rs4927850	0.709	rs6765762	ENSG00000231464.1	AC024937.4	9.79	1.01e-20	6.79e-18	0.59	0.41	Pancreatic cancer;	chr3:195925980	chr3:195996738~195998233:+
THCA	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-9.79	1.02e-20	6.81e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
THCA	cis	rs9322193	0.847	rs4870054	ENSG00000268592.3	RAET1E-AS1	9.79	1.02e-20	6.82e-18	0.56	0.41	Lung cancer;	chr6:149848402	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.926	rs2324742	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40919059	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.857	rs9594455	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40919452	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9532659	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40920380	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.89	rs9594457	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40920439	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9594458	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40920448	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.926	rs9590562	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40920503	chr13:40863599~40863902:-
THCA	cis	rs9532669	0.963	rs12857052	ENSG00000176268.5	CYCSP34	9.79	1.03e-20	6.88e-18	0.47	0.41	Cervical cancer;	chr13:40920831	chr13:40863599~40863902:-
THCA	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-9.79	1.04e-20	6.93e-18	-0.66	-0.41	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
THCA	cis	rs7712401	0.601	rs34126945	ENSG00000263432.2	RN7SL689P	-9.79	1.05e-20	7.04e-18	-0.45	-0.41	Mean platelet volume;	chr5:122994034	chr5:123022487~123022783:-
THCA	cis	rs8062405	0.72	rs9926245	ENSG00000251417.2	RP11-1348G14.4	-9.78	1.06e-20	7.09e-18	-0.39	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28802743~28817828:+
THCA	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-9.78	1.06e-20	7.1e-18	-0.6	-0.41	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
THCA	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	9.78	1.06e-20	7.11e-18	0.49	0.41	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
THCA	cis	rs10463554	0.889	rs246911	ENSG00000175749.11	EIF3KP1	9.78	1.06e-20	7.12e-18	0.56	0.41	Parkinson's disease;	chr5:103227502	chr5:103032376~103033031:+
THCA	cis	rs1799949	1	rs8176269	ENSG00000267681.1	CTD-3199J23.6	-9.78	1.07e-20	7.13e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43061609	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs8176265	ENSG00000267681.1	CTD-3199J23.6	-9.78	1.07e-20	7.13e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43061979	chr17:43144956~43145255:+
THCA	cis	rs2836950	0.545	rs2836940	ENSG00000255568.3	BRWD1-AS2	-9.78	1.07e-20	7.14e-18	-0.33	-0.41	Menarche (age at onset);	chr21:39216770	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.565	rs2836942	ENSG00000255568.3	BRWD1-AS2	-9.78	1.07e-20	7.14e-18	-0.33	-0.41	Menarche (age at onset);	chr21:39219455	chr21:39313935~39314962:+
THCA	cis	rs10463554	0.889	rs246912	ENSG00000175749.11	EIF3KP1	9.78	1.07e-20	7.18e-18	0.56	0.41	Parkinson's disease;	chr5:103225140	chr5:103032376~103033031:+
THCA	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-9.78	1.08e-20	7.21e-18	-0.48	-0.41	Migraine;	chr4:56943905	chr4:56960927~56961373:-
THCA	cis	rs9322193	0.607	rs4869755	ENSG00000268592.3	RAET1E-AS1	9.78	1.08e-20	7.22e-18	0.6	0.41	Lung cancer;	chr6:149886347	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.639	rs4869756	ENSG00000268592.3	RAET1E-AS1	9.78	1.08e-20	7.22e-18	0.6	0.41	Lung cancer;	chr6:149886360	chr6:149863494~149919507:+
THCA	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	9.78	1.09e-20	7.26e-18	0.68	0.41	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
THCA	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-9.78	1.09e-20	7.31e-18	-0.62	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
THCA	cis	rs9322193	0.923	rs9766037	ENSG00000268592.3	RAET1E-AS1	9.78	1.09e-20	7.31e-18	0.55	0.41	Lung cancer;	chr6:149616921	chr6:149863494~149919507:+
THCA	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	9.78	1.1e-20	7.34e-18	0.66	0.41	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
THCA	cis	rs9532669	0.963	rs4941391	ENSG00000176268.5	CYCSP34	9.78	1.1e-20	7.37e-18	0.47	0.41	Cervical cancer;	chr13:40939787	chr13:40863599~40863902:-
THCA	cis	rs9487094	0.67	rs749517	ENSG00000260273.1	RP11-425D10.10	-9.78	1.1e-20	7.37e-18	-0.48	-0.41	Height;	chr6:109531713	chr6:109382795~109383666:+
THCA	cis	rs10759883	0.603	rs10985156	ENSG00000175611.10	LINC00476	9.78	1.1e-20	7.38e-18	0.46	0.41	Nicotine dependence;	chr9:95831462	chr9:95759231~95875977:-
THCA	cis	rs7576126	1	rs7576126	ENSG00000234255.7	AC012370.3	-9.78	1.11e-20	7.39e-18	-0.45	-0.41	Severe influenza A (H1N1) infection;	chr2:65431235	chr2:65439888~65456571:-
THCA	cis	rs950169	0.922	rs11630507	ENSG00000259728.4	LINC00933	9.78	1.11e-20	7.42e-18	0.55	0.41	Schizophrenia;	chr15:84552494	chr15:84570649~84580175:+
THCA	cis	rs2288884	0.559	rs12611043	ENSG00000275055.1	CTC-471J1.11	-9.78	1.11e-20	7.42e-18	-0.32	-0.41	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52084372	chr19:52049007~52049754:+
THCA	cis	rs10759883	0.627	rs690633	ENSG00000175611.10	LINC00476	9.78	1.11e-20	7.42e-18	0.46	0.41	Nicotine dependence;	chr9:95867894	chr9:95759231~95875977:-
THCA	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-9.78	1.11e-20	7.43e-18	-0.42	-0.41	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
THCA	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	9.78	1.11e-20	7.43e-18	0.54	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
THCA	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-9.78	1.11e-20	7.44e-18	-0.61	-0.41	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
THCA	cis	rs944289	0.74	rs884384	ENSG00000257826.1	RP11-116N8.4	-9.78	1.12e-20	7.44e-18	-0.42	-0.41	Thyroid cancer;	chr14:36081801	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs884383	ENSG00000257826.1	RP11-116N8.4	-9.78	1.12e-20	7.44e-18	-0.42	-0.41	Thyroid cancer;	chr14:36081936	chr14:36061026~36067190:-
THCA	cis	rs7221109	0.56	rs2159430	ENSG00000278834.1	RP11-458J1.1	-9.78	1.12e-20	7.49e-18	-0.44	-0.41	Type 1 diabetes;	chr17:40704360	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.56	rs2462963	ENSG00000278834.1	RP11-458J1.1	-9.78	1.12e-20	7.49e-18	-0.44	-0.41	Type 1 diabetes;	chr17:40705505	chr17:40648300~40649718:+
THCA	cis	rs944289	0.708	rs8016762	ENSG00000257826.1	RP11-116N8.4	-9.78	1.13e-20	7.52e-18	-0.42	-0.41	Thyroid cancer;	chr14:36108538	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs1623766	ENSG00000257826.1	RP11-116N8.4	9.78	1.13e-20	7.55e-18	0.42	0.41	Thyroid cancer;	chr14:36075632	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs416664	ENSG00000257826.1	RP11-116N8.4	9.78	1.13e-20	7.55e-18	0.42	0.41	Thyroid cancer;	chr14:36076319	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs1617130	ENSG00000257826.1	RP11-116N8.4	9.78	1.13e-20	7.55e-18	0.42	0.41	Thyroid cancer;	chr14:36077059	chr14:36061026~36067190:-
THCA	cis	rs2836950	0.509	rs4816618	ENSG00000255568.3	BRWD1-AS2	-9.78	1.14e-20	7.62e-18	-0.34	-0.41	Menarche (age at onset);	chr21:39227603	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.527	rs2836948	ENSG00000255568.3	BRWD1-AS2	-9.78	1.14e-20	7.62e-18	-0.34	-0.41	Menarche (age at onset);	chr21:39227751	chr21:39313935~39314962:+
THCA	cis	rs9322193	0.607	rs12527391	ENSG00000268592.3	RAET1E-AS1	9.78	1.14e-20	7.62e-18	0.6	0.41	Lung cancer;	chr6:149882156	chr6:149863494~149919507:+
THCA	cis	rs4380275	0.809	rs6753699	ENSG00000272342.1	RP13-539J13.1	9.78	1.15e-20	7.65e-18	0.48	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:739588~740164:-
THCA	cis	rs10463554	0.655	rs152138	ENSG00000175749.11	EIF3KP1	9.77	1.15e-20	7.66e-18	0.56	0.41	Parkinson's disease;	chr5:103223727	chr5:103032376~103033031:+
THCA	cis	rs9532669	0.926	rs2875421	ENSG00000239827.7	SUGT1P3	-9.77	1.15e-20	7.66e-18	-0.45	-0.41	Cervical cancer;	chr13:40936536	chr13:40908159~40921774:-
THCA	cis	rs3813579	0.679	rs4329928	ENSG00000261390.4	RP11-345M22.2	9.77	1.15e-20	7.69e-18	0.45	0.41	Thyroid volume;	chr16:79713988	chr16:79715232~79770563:-
THCA	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	9.77	1.16e-20	7.75e-18	0.57	0.41	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
THCA	cis	rs73219805	1	rs17310286	ENSG00000228451.3	SDAD1P1	9.77	1.16e-20	7.76e-18	0.53	0.41	Schizophrenia;	chr8:26411516	chr8:26379259~26382953:-
THCA	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-9.77	1.17e-20	7.78e-18	-0.83	-0.41	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
THCA	cis	rs1799949	1	rs8176318	ENSG00000267681.1	CTD-3199J23.6	-9.77	1.17e-20	7.79e-18	-0.47	-0.41	Menopause (age at onset);	chr17:43045257	chr17:43144956~43145255:+
THCA	cis	rs42490	1	rs13252013	ENSG00000251136.7	RP11-37B2.1	-9.77	1.17e-20	7.8e-18	-0.35	-0.41	Leprosy;	chr8:89746881	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs13279023	ENSG00000251136.7	RP11-37B2.1	-9.77	1.17e-20	7.8e-18	-0.35	-0.41	Leprosy;	chr8:89748816	chr8:89609409~89757727:-
THCA	cis	rs12550612	0.614	rs4268128	ENSG00000253616.4	RP11-875O11.3	9.77	1.17e-20	7.83e-18	0.56	0.41	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23080343	chr8:23071377~23074488:-
THCA	cis	rs12554020	1	rs7048853	ENSG00000227603.1	RP11-165J3.6	9.77	1.18e-20	7.88e-18	0.55	0.41	Schizophrenia;	chr9:93490896	chr9:93435332~93437121:-
THCA	cis	rs7208859	0.623	rs56018041	ENSG00000266490.1	CTD-2349P21.9	9.77	1.18e-20	7.89e-18	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30792372~30792833:+
THCA	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	9.77	1.18e-20	7.89e-18	0.48	0.41	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
THCA	cis	rs2948294	0.566	rs13261997	ENSG00000253893.2	FAM85B	-9.77	1.19e-20	7.9e-18	-0.53	-0.41	Red cell distribution width;	chr8:8254773	chr8:8167819~8226614:-
THCA	cis	rs10759883	0.627	rs10125109	ENSG00000175611.10	LINC00476	-9.77	1.19e-20	7.92e-18	-0.46	-0.41	Nicotine dependence;	chr9:95799228	chr9:95759231~95875977:-
THCA	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-9.77	1.19e-20	7.95e-18	-0.56	-0.41	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
THCA	cis	rs10759883	0.627	rs596413	ENSG00000175611.10	LINC00476	9.77	1.19e-20	7.95e-18	0.47	0.41	Nicotine dependence;	chr9:95871561	chr9:95759231~95875977:-
THCA	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	9.77	1.21e-20	8.05e-18	0.65	0.41	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
THCA	cis	rs2274273	0.624	rs7151754	ENSG00000258413.1	RP11-665C16.6	-9.77	1.21e-20	8.06e-18	-0.57	-0.41	Protein biomarker;	chr14:55321783	chr14:55262767~55272075:-
THCA	cis	rs42490	1	rs454441	ENSG00000251136.7	RP11-37B2.1	-9.77	1.21e-20	8.08e-18	-0.35	-0.41	Leprosy;	chr8:89750842	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs40246	ENSG00000251136.7	RP11-37B2.1	-9.77	1.21e-20	8.08e-18	-0.35	-0.41	Leprosy;	chr8:89752944	chr8:89609409~89757727:-
THCA	cis	rs12554020	0.786	rs76640831	ENSG00000227603.1	RP11-165J3.6	9.77	1.22e-20	8.1e-18	0.72	0.41	Schizophrenia;	chr9:93474133	chr9:93435332~93437121:-
THCA	cis	rs8072100	0.871	rs7206971	ENSG00000228782.6	CTD-2026D20.3	-9.77	1.23e-20	8.16e-18	-0.38	-0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47347749	chr17:47450568~47492492:-
THCA	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	9.77	1.23e-20	8.17e-18	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
THCA	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	9.77	1.23e-20	8.17e-18	0.48	0.41	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	9.77	1.23e-20	8.17e-18	0.48	0.41	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	9.77	1.23e-20	8.17e-18	0.48	0.41	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
THCA	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	9.77	1.23e-20	8.18e-18	0.56	0.41	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
THCA	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	9.77	1.23e-20	8.18e-18	0.51	0.41	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
THCA	cis	rs934734	0.532	rs2028150	ENSG00000234255.7	AC012370.3	-9.77	1.23e-20	8.22e-18	-0.45	-0.41	Rheumatoid arthritis;	chr2:65427878	chr2:65439888~65456571:-
THCA	cis	rs934734	0.532	rs2028151	ENSG00000234255.7	AC012370.3	-9.77	1.23e-20	8.22e-18	-0.45	-0.41	Rheumatoid arthritis;	chr2:65428479	chr2:65439888~65456571:-
THCA	cis	rs748404	0.588	rs506120	ENSG00000249839.1	AC011330.5	-9.77	1.24e-20	8.26e-18	-0.49	-0.41	Lung cancer;	chr15:43509826	chr15:43663654~43684339:-
THCA	cis	rs1799949	1	rs3092988	ENSG00000267681.1	CTD-3199J23.6	-9.77	1.24e-20	8.26e-18	-0.48	-0.41	Menopause (age at onset);	chr17:43049685	chr17:43144956~43145255:+
THCA	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	9.76	1.25e-20	8.29e-18	0.59	0.41	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
THCA	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-9.76	1.25e-20	8.32e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
THCA	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-9.76	1.26e-20	8.36e-18	-0.5	-0.41	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-9.76	1.26e-20	8.36e-18	-0.5	-0.41	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
THCA	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	9.76	1.26e-20	8.37e-18	0.61	0.41	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
THCA	cis	rs6570726	0.935	rs398060	ENSG00000235652.6	RP11-545I5.3	-9.76	1.27e-20	8.42e-18	-0.38	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145520379	chr6:145799409~145886585:+
THCA	cis	rs8091660	0.893	rs1567656	ENSG00000278983.1	RP11-426J5.3	-9.76	1.27e-20	8.43e-18	-0.53	-0.41	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568420	chr18:48564795~48568342:+
THCA	cis	rs9322193	0.607	rs3798763	ENSG00000268592.3	RAET1E-AS1	9.76	1.27e-20	8.46e-18	0.6	0.41	Lung cancer;	chr6:149889964	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.607	rs12204653	ENSG00000268592.3	RAET1E-AS1	9.76	1.27e-20	8.46e-18	0.6	0.41	Lung cancer;	chr6:149891885	chr6:149863494~149919507:+
THCA	cis	rs12554020	0.786	rs16909150	ENSG00000227603.1	RP11-165J3.6	-9.76	1.27e-20	8.46e-18	-0.71	-0.41	Schizophrenia;	chr9:93454464	chr9:93435332~93437121:-
THCA	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	9.76	1.27e-20	8.47e-18	0.6	0.41	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
THCA	cis	rs9926296	0.712	rs459920	ENSG00000260259.1	RP11-368I7.4	9.76	1.27e-20	8.47e-18	0.46	0.41	Vitiligo;	chr16:89664419	chr16:89682620~89686569:-
THCA	cis	rs67311347	0.577	rs11712626	ENSG00000223797.4	ENTPD3-AS1	9.76	1.28e-20	8.51e-18	0.34	0.41	Renal cell carcinoma;	chr3:40218436	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.577	rs11129870	ENSG00000223797.4	ENTPD3-AS1	9.76	1.28e-20	8.51e-18	0.34	0.41	Renal cell carcinoma;	chr3:40218915	chr3:40313802~40453329:-
THCA	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	9.76	1.28e-20	8.54e-18	0.56	0.41	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	9.76	1.28e-20	8.54e-18	0.48	0.41	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	9.76	1.29e-20	8.54e-18	0.48	0.41	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	9.76	1.29e-20	8.54e-18	0.48	0.41	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	9.76	1.29e-20	8.54e-18	0.48	0.41	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
THCA	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-9.76	1.29e-20	8.55e-18	-0.78	-0.41	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
THCA	cis	rs853679	0.517	rs9380047	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28070115	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs7755442	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28071237	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs12174753	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28074687	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs55747925	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28076559	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs56310871	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28076704	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs34716816	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28078391	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380049	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28080757	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380050	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28080760	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393885	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28082231	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393886	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28082261	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.515	rs9368549	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Parkinson's disease;	chr6:28082269	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs56364346	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28082984	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9357061	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28083994	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368550	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28084025	chr6:28161781~28169594:+
THCA	cis	rs853679	0.542	rs2295594	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28085319	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9366715	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28096855	chr6:28161781~28169594:+
THCA	cis	rs853679	0.598	rs9380054	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28099759	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.547	rs2116981	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Parkinson's disease;	chr6:28100173	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368552	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28100648	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs2281588	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28104824	chr6:28161781~28169594:+
THCA	cis	rs853679	0.542	rs34131763	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28107222	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs35193936	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28108492	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs36078605	ENSG00000226314.6	ZNF192P1	-9.76	1.3e-20	8.61e-18	-0.55	-0.41	Depression;	chr6:28110254	chr6:28161781~28169594:+
THCA	cis	rs524281	0.731	rs7931167	ENSG00000255320.1	RP11-755F10.1	-9.76	1.3e-20	8.62e-18	-0.61	-0.41	Electroencephalogram traits;	chr11:66036279	chr11:66244840~66246239:-
THCA	cis	rs524281	0.638	rs4261293	ENSG00000255320.1	RP11-755F10.1	-9.76	1.3e-20	8.62e-18	-0.61	-0.41	Electroencephalogram traits;	chr11:66037664	chr11:66244840~66246239:-
THCA	cis	rs524281	0.682	rs6591202	ENSG00000255320.1	RP11-755F10.1	-9.76	1.3e-20	8.62e-18	-0.61	-0.41	Electroencephalogram traits;	chr11:66038622	chr11:66244840~66246239:-
THCA	cis	rs524281	0.731	rs6591203	ENSG00000255320.1	RP11-755F10.1	-9.76	1.3e-20	8.62e-18	-0.61	-0.41	Electroencephalogram traits;	chr11:66038758	chr11:66244840~66246239:-
THCA	cis	rs2274273	0.719	rs17740551	ENSG00000258413.1	RP11-665C16.6	-9.76	1.3e-20	8.66e-18	-0.57	-0.41	Protein biomarker;	chr14:55284607	chr14:55262767~55272075:-
THCA	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-9.76	1.31e-20	8.67e-18	-0.47	-0.41	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
THCA	cis	rs673078	0.66	rs61945176	ENSG00000275409.1	RP11-131L12.4	-9.76	1.31e-20	8.68e-18	-0.45	-0.41	Glucose homeostasis traits;	chr12:118204735	chr12:118430147~118430699:+
THCA	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	9.76	1.31e-20	8.69e-18	0.49	0.41	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
THCA	cis	rs10759883	0.563	rs689738	ENSG00000175611.10	LINC00476	9.76	1.31e-20	8.71e-18	0.46	0.41	Nicotine dependence;	chr9:95939738	chr9:95759231~95875977:-
THCA	cis	rs71403859	0.502	rs12927006	ENSG00000260886.1	TAT-AS1	9.76	1.31e-20	8.71e-18	0.73	0.41	Post bronchodilator FEV1;	chr16:71516008	chr16:71565789~71578187:+
THCA	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-9.76	1.31e-20	8.71e-18	-0.61	-0.41	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-9.76	1.31e-20	8.71e-18	-0.61	-0.41	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
THCA	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	9.76	1.32e-20	8.74e-18	0.56	0.41	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
THCA	cis	rs6750795	0.569	rs1667305	ENSG00000181798.2	LINC00471	-9.76	1.34e-20	8.89e-18	-0.47	-0.41	Height;	chr2:231539118	chr2:231508426~231514339:-
THCA	cis	rs66887589	0.616	rs13113885	ENSG00000245958.5	RP11-33B1.1	-9.76	1.34e-20	8.9e-18	-0.38	-0.41	Diastolic blood pressure;	chr4:119300021	chr4:119454791~119552025:+
THCA	cis	rs12554020	0.786	rs56073019	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93491169	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs75576302	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93492940	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs76703294	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93493884	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs12553389	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93500979	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs78865387	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93501827	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.792	rs79419498	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93504701	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs78046549	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93506196	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs76977206	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93518181	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs883785	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93519841	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.681	rs883783	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93519987	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs16909273	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93532820	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs12551084	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93538013	chr9:93435332~93437121:-
THCA	cis	rs12554020	1	rs35540150	ENSG00000227603.1	RP11-165J3.6	9.76	1.34e-20	8.91e-18	0.72	0.41	Schizophrenia;	chr9:93538572	chr9:93435332~93437121:-
THCA	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-9.76	1.35e-20	8.92e-18	-0.56	-0.41	Depression;	chr6:28192182	chr6:28115628~28116551:+
THCA	cis	rs780096	0.526	rs13391837	ENSG00000234072.1	AC074117.10	-9.75	1.36e-20	8.98e-18	-0.33	-0.41	Total body bone mineral density;	chr2:27426508	chr2:27356246~27367622:+
THCA	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-9.75	1.36e-20	8.99e-18	-0.44	-0.41	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
THCA	cis	rs6051080	1	rs6051080	ENSG00000274973.1	RP13-401N8.7	-9.75	1.36e-20	9.01e-18	-0.45	-0.41	Colorectal or endometrial cancer;	chr20:25995038	chr20:25845497~25845862:+
THCA	cis	rs67311347	0.506	rs55962832	ENSG00000223797.4	ENTPD3-AS1	9.75	1.37e-20	9.05e-18	0.34	0.41	Renal cell carcinoma;	chr3:40202960	chr3:40313802~40453329:-
THCA	cis	rs7727544	0.716	rs11955347	ENSG00000237714.1	P4HA2-AS1	9.75	1.37e-20	9.07e-18	0.54	0.41	Blood metabolite levels;	chr5:132232231	chr5:132184876~132192808:+
THCA	cis	rs67311347	0.524	rs11129869	ENSG00000223797.4	ENTPD3-AS1	9.75	1.37e-20	9.1e-18	0.34	0.41	Renal cell carcinoma;	chr3:40218247	chr3:40313802~40453329:-
THCA	cis	rs9487094	0.67	rs12194061	ENSG00000260273.1	RP11-425D10.10	9.75	1.38e-20	9.13e-18	0.48	0.41	Height;	chr6:109546439	chr6:109382795~109383666:+
THCA	cis	rs6920372	0.731	rs2357124	ENSG00000260273.1	RP11-425D10.10	9.75	1.38e-20	9.13e-18	0.48	0.41	Height;	chr6:109551060	chr6:109382795~109383666:+
THCA	cis	rs7829975	0.774	rs11249893	ENSG00000253893.2	FAM85B	-9.75	1.38e-20	9.13e-18	-0.54	-0.41	Mood instability;	chr8:8843341	chr8:8167819~8226614:-
THCA	cis	rs10872587	0.555	rs9497426	ENSG00000235652.6	RP11-545I5.3	-9.75	1.38e-20	9.13e-18	-0.47	-0.41	Lobe attachment (rater-scored or self-reported);	chr6:145913508	chr6:145799409~145886585:+
THCA	cis	rs950169	0.65	rs12902052	ENSG00000259728.4	LINC00933	9.75	1.38e-20	9.16e-18	0.57	0.41	Schizophrenia;	chr15:84582607	chr15:84570649~84580175:+
THCA	cis	rs7945705	0.935	rs1883098	ENSG00000254860.4	TMEM9B-AS1	9.75	1.39e-20	9.21e-18	0.45	0.41	Hemoglobin concentration;	chr11:8869047	chr11:8964675~8977527:+
THCA	cis	rs9318086	0.935	rs2025701	ENSG00000205861.10	C1QTNF9B-AS1	-9.75	1.39e-20	9.22e-18	-0.45	-0.41	Myopia (pathological);	chr13:23866442	chr13:23888889~23897263:+
THCA	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-9.75	1.4e-20	9.24e-18	-0.43	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
THCA	cis	rs673078	0.607	rs7294498	ENSG00000275409.1	RP11-131L12.4	-9.75	1.42e-20	9.38e-18	-0.44	-0.41	Glucose homeostasis traits;	chr12:118321680	chr12:118430147~118430699:+
THCA	cis	rs950169	0.92	rs2135551	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84039099	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs12902672	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84048234	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs12903820	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84055068	chr15:84570649~84580175:+
THCA	cis	rs950169	0.919	rs12915589	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84065712	chr15:84570649~84580175:+
THCA	cis	rs950169	0.959	rs66801143	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84067905	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs35648189	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84071996	chr15:84570649~84580175:+
THCA	cis	rs950169	0.92	rs17300048	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84080725	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs1848093	ENSG00000259728.4	LINC00933	9.75	1.42e-20	9.4e-18	0.56	0.41	Schizophrenia;	chr15:84086775	chr15:84570649~84580175:+
THCA	cis	rs9322193	0.923	rs2297928	ENSG00000268592.3	RAET1E-AS1	9.75	1.42e-20	9.4e-18	0.55	0.41	Lung cancer;	chr6:149718584	chr6:149863494~149919507:+
THCA	cis	rs17684571	0.751	rs1610157	ENSG00000231441.1	RP11-472M19.2	9.75	1.43e-20	9.44e-18	0.55	0.41	Schizophrenia;	chr6:56844035	chr6:56844002~56864078:+
THCA	cis	rs71403859	0.502	rs34766979	ENSG00000260886.1	TAT-AS1	9.75	1.43e-20	9.45e-18	0.73	0.41	Post bronchodilator FEV1;	chr16:71441608	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	9.75	1.44e-20	9.54e-18	0.48	0.41	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
THCA	cis	rs10872587	0.555	rs2265470	ENSG00000235652.6	RP11-545I5.3	9.75	1.45e-20	9.58e-18	0.47	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145898096	chr6:145799409~145886585:+
THCA	cis	rs9322193	0.923	rs11155674	ENSG00000268592.3	RAET1E-AS1	9.75	1.45e-20	9.59e-18	0.55	0.41	Lung cancer;	chr6:149711111	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs12174349	ENSG00000268592.3	RAET1E-AS1	9.75	1.45e-20	9.59e-18	0.55	0.41	Lung cancer;	chr6:149718012	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs2297932	ENSG00000268592.3	RAET1E-AS1	9.75	1.45e-20	9.59e-18	0.55	0.41	Lung cancer;	chr6:149718225	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs2297930	ENSG00000268592.3	RAET1E-AS1	9.75	1.45e-20	9.59e-18	0.55	0.41	Lung cancer;	chr6:149718360	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs2185352	ENSG00000268592.3	RAET1E-AS1	9.75	1.46e-20	9.61e-18	0.55	0.41	Lung cancer;	chr6:149714640	chr6:149863494~149919507:+
THCA	cis	rs2599510	0.744	rs4952212	ENSG00000276334.1	AL133243.1	-9.75	1.46e-20	9.61e-18	-0.45	-0.41	Interleukin-18 levels;	chr2:32393425	chr2:32521927~32523547:+
THCA	cis	rs12550612	0.561	rs11784599	ENSG00000253616.4	RP11-875O11.3	9.75	1.46e-20	9.65e-18	0.58	0.41	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23074609	chr8:23071377~23074488:-
THCA	cis	rs853679	0.517	rs6932109	ENSG00000226314.6	ZNF192P1	9.74	1.47e-20	9.69e-18	0.55	0.41	Depression;	chr6:28110525	chr6:28161781~28169594:+
THCA	cis	rs4380275	0.782	rs4854276	ENSG00000272342.1	RP13-539J13.1	9.74	1.47e-20	9.73e-18	0.46	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:739588~740164:-
THCA	cis	rs7727544	0.654	rs4705849	ENSG00000237714.1	P4HA2-AS1	9.74	1.48e-20	9.74e-18	0.53	0.41	Blood metabolite levels;	chr5:132223506	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.716	rs72793278	ENSG00000237714.1	P4HA2-AS1	9.74	1.48e-20	9.74e-18	0.53	0.41	Blood metabolite levels;	chr5:132225679	chr5:132184876~132192808:+
THCA	cis	rs9487094	0.67	rs13199135	ENSG00000260273.1	RP11-425D10.10	9.74	1.48e-20	9.76e-18	0.48	0.41	Height;	chr6:109588639	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12193719	ENSG00000260273.1	RP11-425D10.10	9.74	1.48e-20	9.76e-18	0.48	0.41	Height;	chr6:109589051	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.644	rs1960325	ENSG00000260273.1	RP11-425D10.10	9.74	1.48e-20	9.76e-18	0.48	0.41	Height;	chr6:109592105	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12528781	ENSG00000260273.1	RP11-425D10.10	9.74	1.48e-20	9.76e-18	0.48	0.41	Height;	chr6:109608105	chr6:109382795~109383666:+
THCA	cis	rs10740039	0.804	rs894383	ENSG00000254271.1	RP11-131N11.4	9.74	1.48e-20	9.77e-18	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60683359	chr10:60734342~60741828:+
THCA	cis	rs9640161	0.742	rs2108854	ENSG00000261305.1	RP4-584D14.7	-9.74	1.48e-20	9.78e-18	-0.5	-0.41	Blood protein levels;Circulating chemerin levels;	chr7:150320319	chr7:150341771~150342607:+
THCA	cis	rs9322193	0.923	rs10747276	ENSG00000268592.3	RAET1E-AS1	9.74	1.49e-20	9.8e-18	0.55	0.41	Lung cancer;	chr6:149758739	chr6:149863494~149919507:+
THCA	cis	rs929843	1	rs929843	ENSG00000196696.11	PDXDC2P	-9.74	1.49e-20	9.84e-18	-0.38	-0.41	Menarche (age at onset);	chr16:70011845	chr16:69976297~70065948:-
THCA	cis	rs7727544	0.716	rs4705926	ENSG00000237714.1	P4HA2-AS1	9.74	1.49e-20	9.84e-18	0.53	0.41	Blood metabolite levels;	chr5:132226065	chr5:132184876~132192808:+
THCA	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	9.74	1.49e-20	9.85e-18	0.51	0.41	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
THCA	cis	rs8062405	0.823	rs7202948	ENSG00000251417.2	RP11-1348G14.4	-9.74	1.5e-20	9.88e-18	-0.39	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28802743~28817828:+
THCA	cis	rs9322193	0.847	rs62439808	ENSG00000268592.3	RAET1E-AS1	9.74	1.51e-20	9.95e-18	0.55	0.41	Lung cancer;	chr6:149629690	chr6:149863494~149919507:+
THCA	cis	rs950169	1	rs12915234	ENSG00000259728.4	LINC00933	9.74	1.51e-20	9.96e-18	0.56	0.41	Schizophrenia;	chr15:84089549	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs34751999	ENSG00000259728.4	LINC00933	9.74	1.51e-20	9.96e-18	0.56	0.41	Schizophrenia;	chr15:84089667	chr15:84570649~84580175:+
THCA	cis	rs950169	0.919	rs17300292	ENSG00000259728.4	LINC00933	9.74	1.51e-20	9.96e-18	0.56	0.41	Schizophrenia;	chr15:84093816	chr15:84570649~84580175:+
THCA	cis	rs6844153	0.68	rs11729927	ENSG00000240005.4	RP11-293A21.1	-9.74	1.51e-20	9.96e-18	-0.5	-0.41	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922178	chr4:26859806~26860599:-
THCA	cis	rs9309711	0.666	rs4321399	ENSG00000225234.1	TRAPPC12-AS1	-9.74	1.52e-20	1e-17	-0.39	-0.41	Neurofibrillary tangles;	chr2:3477888	chr2:3481242~3482409:-
THCA	cis	rs10463554	0.889	rs246908	ENSG00000175749.11	EIF3KP1	9.74	1.52e-20	1e-17	0.55	0.41	Parkinson's disease;	chr5:103228476	chr5:103032376~103033031:+
THCA	cis	rs944289	0.718	rs12878623	ENSG00000257826.1	RP11-116N8.4	-9.74	1.53e-20	1.01e-17	-0.42	-0.41	Thyroid cancer;	chr14:36081499	chr14:36061026~36067190:-
THCA	cis	rs1858037	0.867	rs57913336	ENSG00000281920.1	RP11-418H16.1	9.74	1.55e-20	1.02e-17	0.54	0.41	Rheumatoid arthritis;	chr2:65360485	chr2:65623272~65628424:+
THCA	cis	rs853679	0.542	rs9393892	ENSG00000226314.6	ZNF192P1	-9.74	1.55e-20	1.02e-17	-0.55	-0.41	Depression;	chr6:28113616	chr6:28161781~28169594:+
THCA	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-9.74	1.55e-20	1.02e-17	-0.57	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
THCA	cis	rs853679	0.517	rs6922063	ENSG00000226314.6	ZNF192P1	-9.74	1.55e-20	1.02e-17	-0.55	-0.41	Depression;	chr6:28126588	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs2275508	ENSG00000226314.6	ZNF192P1	-9.74	1.55e-20	1.02e-17	-0.55	-0.41	Depression;	chr6:28126953	chr6:28161781~28169594:+
THCA	cis	rs673078	0.66	rs7136216	ENSG00000275409.1	RP11-131L12.4	-9.74	1.55e-20	1.02e-17	-0.45	-0.41	Glucose homeostasis traits;	chr12:118170475	chr12:118430147~118430699:+
THCA	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-9.74	1.57e-20	1.03e-17	-0.35	-0.41	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
THCA	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-9.74	1.57e-20	1.03e-17	-0.49	-0.41	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
THCA	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	9.74	1.57e-20	1.04e-17	0.48	0.41	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
THCA	cis	rs4819052	0.851	rs2838834	ENSG00000215447.6	BX322557.10	-9.74	1.57e-20	1.04e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45288052~45291738:+
THCA	cis	rs11051970	0.559	rs7956708	ENSG00000274964.1	RP11-817I4.1	-9.74	1.57e-20	1.04e-17	-0.53	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32315908	chr12:32339368~32340724:+
THCA	cis	rs6570726	0.811	rs375873	ENSG00000235652.6	RP11-545I5.3	9.74	1.58e-20	1.04e-17	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145491235	chr6:145799409~145886585:+
THCA	cis	rs9487094	0.67	rs12214639	ENSG00000260273.1	RP11-425D10.10	9.74	1.58e-20	1.04e-17	0.48	0.41	Height;	chr6:109576414	chr6:109382795~109383666:+
THCA	cis	rs9322193	0.923	rs9478291	ENSG00000268592.3	RAET1E-AS1	9.74	1.58e-20	1.04e-17	0.55	0.41	Lung cancer;	chr6:149729434	chr6:149863494~149919507:+
THCA	cis	rs57677839	1	rs57677839	ENSG00000184669.7	OR7E14P	-9.74	1.58e-20	1.04e-17	-0.54	-0.41	Coronary artery disease;	chr11:17006642	chr11:17013998~17053024:+
THCA	cis	rs10740039	0.768	rs7895268	ENSG00000254271.1	RP11-131N11.4	9.74	1.58e-20	1.04e-17	0.51	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703479	chr10:60734342~60741828:+
THCA	cis	rs597539	0.652	rs11603827	ENSG00000250508.1	RP11-757G1.6	-9.74	1.59e-20	1.05e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68951752	chr11:68870664~68874542:+
THCA	cis	rs10759883	0.563	rs12348051	ENSG00000175611.10	LINC00476	9.73	1.59e-20	1.05e-17	0.47	0.41	Nicotine dependence;	chr9:95905928	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs689710	ENSG00000175611.10	LINC00476	9.73	1.59e-20	1.05e-17	0.47	0.41	Nicotine dependence;	chr9:95908339	chr9:95759231~95875977:-
THCA	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-9.73	1.6e-20	1.05e-17	-0.35	-0.41	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
THCA	cis	rs2599510	0.783	rs2038534	ENSG00000276334.1	AL133243.1	9.73	1.6e-20	1.06e-17	0.46	0.41	Interleukin-18 levels;	chr2:32434421	chr2:32521927~32523547:+
THCA	cis	rs853679	0.517	rs9393884	ENSG00000226314.6	ZNF192P1	-9.73	1.61e-20	1.06e-17	-0.55	-0.41	Depression;	chr6:28079011	chr6:28161781~28169594:+
THCA	cis	rs733592	0.507	rs10875739	ENSG00000240399.1	RP1-228P16.1	9.73	1.61e-20	1.06e-17	0.38	0.41	Plateletcrit;	chr12:48087136	chr12:48054813~48055591:-
THCA	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	9.73	1.61e-20	1.06e-17	0.48	0.41	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	9.73	1.61e-20	1.06e-17	0.48	0.41	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	9.73	1.61e-20	1.06e-17	0.48	0.41	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	9.73	1.61e-20	1.06e-17	0.48	0.41	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	9.73	1.61e-20	1.06e-17	0.48	0.41	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	9.73	1.61e-20	1.06e-17	0.48	0.41	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
THCA	cis	rs7772486	0.774	rs2247571	ENSG00000235652.6	RP11-545I5.3	9.73	1.64e-20	1.08e-17	0.38	0.41	Lobe attachment (rater-scored or self-reported);	chr6:145898397	chr6:145799409~145886585:+
THCA	cis	rs7615952	0.688	rs4422259	ENSG00000171084.14	FAM86JP	9.73	1.64e-20	1.08e-17	0.52	0.41	Blood pressure (smoking interaction);	chr3:125826988	chr3:125916620~125930024:+
THCA	cis	rs9322193	0.923	rs10872644	ENSG00000268592.3	RAET1E-AS1	9.73	1.65e-20	1.08e-17	0.55	0.41	Lung cancer;	chr6:149741819	chr6:149863494~149919507:+
THCA	cis	rs9926296	0.712	rs258319	ENSG00000260259.1	RP11-368I7.4	9.73	1.65e-20	1.08e-17	0.46	0.41	Vitiligo;	chr16:89665616	chr16:89682620~89686569:-
THCA	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	9.73	1.66e-20	1.09e-17	0.35	0.41	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
THCA	cis	rs7665090	0.728	rs227275	ENSG00000246560.2	RP11-10L12.4	-9.73	1.66e-20	1.09e-17	-0.5	-0.41	Primary biliary cholangitis;	chr4:102672741	chr4:102828055~102844075:+
THCA	cis	rs9322193	0.923	rs9800871	ENSG00000268592.3	RAET1E-AS1	9.73	1.69e-20	1.11e-17	0.55	0.41	Lung cancer;	chr6:149644540	chr6:149863494~149919507:+
THCA	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	9.73	1.69e-20	1.11e-17	0.38	0.41	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
THCA	cis	rs1075265	0.836	rs10208233	ENSG00000233266.1	HMGB1P31	9.73	1.69e-20	1.11e-17	0.54	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs10782317	ENSG00000268592.3	RAET1E-AS1	-9.73	1.7e-20	1.11e-17	-0.55	-0.41	Lung cancer;	chr6:149753911	chr6:149863494~149919507:+
THCA	cis	rs1858037	0.867	rs4671660	ENSG00000281920.1	RP11-418H16.1	9.73	1.7e-20	1.11e-17	0.54	0.41	Rheumatoid arthritis;	chr2:65349302	chr2:65623272~65628424:+
THCA	cis	rs2274273	0.624	rs7150234	ENSG00000258413.1	RP11-665C16.6	-9.73	1.7e-20	1.12e-17	-0.56	-0.41	Protein biomarker;	chr14:55335463	chr14:55262767~55272075:-
THCA	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-9.73	1.72e-20	1.13e-17	-0.31	-0.41	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
THCA	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-9.73	1.72e-20	1.13e-17	-0.31	-0.41	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
THCA	cis	rs4591358	0.508	rs11884880	ENSG00000223466.1	AC064834.2	-9.73	1.72e-20	1.13e-17	-0.6	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195562897	chr2:195533035~195538681:+
THCA	cis	rs4380275	0.782	rs11691064	ENSG00000272342.1	RP13-539J13.1	9.72	1.73e-20	1.13e-17	0.47	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:739588~740164:-
THCA	cis	rs10740039	0.729	rs6479728	ENSG00000254271.1	RP11-131N11.4	-9.72	1.74e-20	1.14e-17	-0.51	-0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60731043	chr10:60734342~60741828:+
THCA	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-9.72	1.75e-20	1.14e-17	-0.49	-0.41	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
THCA	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-9.72	1.77e-20	1.16e-17	-0.35	-0.41	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
THCA	cis	rs9926296	0.682	rs645019	ENSG00000260259.1	RP11-368I7.4	9.72	1.78e-20	1.17e-17	0.46	0.41	Vitiligo;	chr16:89650475	chr16:89682620~89686569:-
THCA	cis	rs9322193	0.923	rs9800614	ENSG00000268592.3	RAET1E-AS1	9.72	1.78e-20	1.17e-17	0.55	0.41	Lung cancer;	chr6:149644604	chr6:149863494~149919507:+
THCA	cis	rs9926296	0.712	rs2434872	ENSG00000260259.1	RP11-368I7.4	9.72	1.79e-20	1.17e-17	0.46	0.41	Vitiligo;	chr16:89650507	chr16:89682620~89686569:-
THCA	cis	rs9926296	0.682	rs467357	ENSG00000260259.1	RP11-368I7.4	9.72	1.79e-20	1.17e-17	0.46	0.41	Vitiligo;	chr16:89650989	chr16:89682620~89686569:-
THCA	cis	rs950169	1	rs12916348	ENSG00000259728.4	LINC00933	9.72	1.8e-20	1.18e-17	0.56	0.41	Schizophrenia;	chr15:84096775	chr15:84570649~84580175:+
THCA	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-9.72	1.8e-20	1.18e-17	-0.46	-0.41	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-9.72	1.8e-20	1.18e-17	-0.46	-0.41	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
THCA	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-9.72	1.81e-20	1.18e-17	-0.53	-0.41	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
THCA	cis	rs860295	0.702	rs12041534	ENSG00000225855.5	RUSC1-AS1	-9.72	1.81e-20	1.18e-17	-0.27	-0.41	Body mass index;	chr1:155437305	chr1:155316863~155324176:-
THCA	cis	rs950169	0.881	rs150965	ENSG00000259728.4	LINC00933	9.72	1.82e-20	1.19e-17	0.55	0.41	Schizophrenia;	chr15:84537296	chr15:84570649~84580175:+
THCA	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	9.72	1.83e-20	1.2e-17	0.53	0.41	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
THCA	cis	rs1799949	1	rs4793229	ENSG00000267681.1	CTD-3199J23.6	9.72	1.83e-20	1.2e-17	0.47	0.41	Menopause (age at onset);	chr17:43340966	chr17:43144956~43145255:+
THCA	cis	rs2274273	0.624	rs67412516	ENSG00000258413.1	RP11-665C16.6	-9.72	1.83e-20	1.2e-17	-0.56	-0.41	Protein biomarker;	chr14:55386519	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.923	rs12660304	ENSG00000268592.3	RAET1E-AS1	9.72	1.83e-20	1.2e-17	0.56	0.41	Lung cancer;	chr6:149739647	chr6:149863494~149919507:+
THCA	cis	rs7191700	0.712	rs7187741	ENSG00000262636.1	CTD-3088G3.4	-9.72	1.83e-20	1.2e-17	-0.52	-0.41	Multiple sclerosis;	chr16:11339246	chr16:11380859~11381118:-
THCA	cis	rs7829975	0.591	rs12677543	ENSG00000253893.2	FAM85B	-9.72	1.83e-20	1.2e-17	-0.52	-0.41	Mood instability;	chr8:8786764	chr8:8167819~8226614:-
THCA	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-9.72	1.84e-20	1.2e-17	-0.57	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
THCA	cis	rs4819052	0.765	rs2838852	ENSG00000215447.6	BX322557.10	-9.72	1.84e-20	1.2e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs7281263	ENSG00000215447.6	BX322557.10	-9.72	1.84e-20	1.21e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45288052~45291738:+
THCA	cis	rs7208859	0.623	rs7208441	ENSG00000266490.1	CTD-2349P21.9	9.72	1.85e-20	1.21e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30792372~30792833:+
THCA	cis	rs9322193	0.923	rs7740278	ENSG00000268592.3	RAET1E-AS1	9.72	1.85e-20	1.21e-17	0.55	0.41	Lung cancer;	chr6:149640116	chr6:149863494~149919507:+
THCA	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-9.72	1.87e-20	1.22e-17	-0.59	-0.41	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-9.72	1.87e-20	1.22e-17	-0.59	-0.41	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-9.72	1.87e-20	1.22e-17	-0.59	-0.41	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-9.72	1.87e-20	1.22e-17	-0.59	-0.41	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
THCA	cis	rs9487094	0.67	rs11754340	ENSG00000260273.1	RP11-425D10.10	9.72	1.87e-20	1.22e-17	0.48	0.41	Height;	chr6:109584789	chr6:109382795~109383666:+
THCA	cis	rs73219805	1	rs1042992	ENSG00000228451.3	SDAD1P1	9.71	1.88e-20	1.23e-17	0.52	0.41	Schizophrenia;	chr8:26411675	chr8:26379259~26382953:-
THCA	cis	rs950169	0.887	rs220333	ENSG00000259728.4	LINC00933	9.71	1.89e-20	1.23e-17	0.55	0.41	Schizophrenia;	chr15:84547902	chr15:84570649~84580175:+
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000235689.1	AP000351.13	9.71	1.89e-20	1.24e-17	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:24006305~24008258:-
THCA	cis	rs71403859	0.73	rs71386933	ENSG00000260886.1	TAT-AS1	9.71	1.91e-20	1.25e-17	0.77	0.41	Post bronchodilator FEV1;	chr16:71787897	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs9800580	ENSG00000268592.3	RAET1E-AS1	9.71	1.93e-20	1.26e-17	0.55	0.41	Lung cancer;	chr6:149632845	chr6:149863494~149919507:+
THCA	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-9.71	1.94e-20	1.27e-17	-0.34	-0.41	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
THCA	cis	rs7586673	1	rs16845584	ENSG00000227403.1	AC009299.3	9.71	1.94e-20	1.27e-17	0.48	0.41	Intelligence (multi-trait analysis);	chr2:161067319	chr2:161244739~161249050:+
THCA	cis	rs9487094	0.696	rs11153188	ENSG00000260273.1	RP11-425D10.10	9.71	1.94e-20	1.27e-17	0.48	0.41	Height;	chr6:109558247	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs11752791	ENSG00000260273.1	RP11-425D10.10	9.71	1.94e-20	1.27e-17	0.48	0.41	Height;	chr6:109564443	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs4490694	ENSG00000260273.1	RP11-425D10.10	9.71	1.94e-20	1.27e-17	0.48	0.41	Height;	chr6:109571489	chr6:109382795~109383666:+
THCA	cis	rs7211079	0.879	rs61357240	ENSG00000279259.1	RP11-334C17.3	9.71	1.95e-20	1.27e-17	0.43	0.41	Myocardial infarction;	chr17:80157976	chr17:80147250~80148596:+
THCA	cis	rs9487094	0.67	rs10782163	ENSG00000260273.1	RP11-425D10.10	9.71	1.95e-20	1.28e-17	0.48	0.41	Height;	chr6:109533040	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs10457195	ENSG00000260273.1	RP11-425D10.10	9.71	1.95e-20	1.28e-17	0.48	0.41	Height;	chr6:109534269	chr6:109382795~109383666:+
THCA	cis	rs7945705	1	rs7937298	ENSG00000254860.4	TMEM9B-AS1	-9.71	1.96e-20	1.28e-17	-0.46	-0.41	Hemoglobin concentration;	chr11:8845962	chr11:8964675~8977527:+
THCA	cis	rs4819052	0.851	rs914218	ENSG00000215447.6	BX322557.10	-9.71	1.96e-20	1.28e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.886	rs9718079	ENSG00000268592.3	RAET1E-AS1	9.71	1.97e-20	1.29e-17	0.55	0.41	Lung cancer;	chr6:149645947	chr6:149863494~149919507:+
THCA	cis	rs7189233	0.531	rs11859538	ENSG00000279344.1	RP11-44F14.7	9.71	1.97e-20	1.29e-17	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53463133	chr16:53478957~53481550:-
THCA	cis	rs12554020	1	rs12554020	ENSG00000227603.1	RP11-165J3.6	9.71	1.97e-20	1.29e-17	0.55	0.41	Schizophrenia;	chr9:93507955	chr9:93435332~93437121:-
THCA	cis	rs4819052	0.808	rs2246697	ENSG00000215447.6	BX322557.10	-9.71	1.97e-20	1.29e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.819	rs7279136	ENSG00000215447.6	BX322557.10	-9.71	1.97e-20	1.29e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.788	rs4819051	ENSG00000215447.6	BX322557.10	-9.71	1.97e-20	1.29e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.819	rs8134084	ENSG00000215447.6	BX322557.10	-9.71	1.97e-20	1.29e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs7276828	ENSG00000215447.6	BX322557.10	-9.71	1.97e-20	1.29e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45288052~45291738:+
THCA	cis	rs853679	0.542	rs6934769	ENSG00000226314.6	ZNF192P1	-9.71	1.98e-20	1.29e-17	-0.55	-0.41	Depression;	chr6:28123153	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs17711801	ENSG00000226314.6	ZNF192P1	-9.71	1.98e-20	1.29e-17	-0.55	-0.41	Depression;	chr6:28124529	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.527	rs9461433	ENSG00000226314.6	ZNF192P1	-9.71	1.98e-20	1.29e-17	-0.55	-0.41	Parkinson's disease;	chr6:28127394	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9468292	ENSG00000226314.6	ZNF192P1	-9.71	1.98e-20	1.29e-17	-0.55	-0.41	Depression;	chr6:28127577	chr6:28161781~28169594:+
THCA	cis	rs2836950	0.501	rs2836980	ENSG00000255568.3	BRWD1-AS2	-9.71	1.99e-20	1.3e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39315692	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.545	rs8132143	ENSG00000255568.3	BRWD1-AS2	-9.71	1.99e-20	1.3e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39212332	chr21:39313935~39314962:+
THCA	cis	rs1799949	1	rs12942277	ENSG00000267681.1	CTD-3199J23.6	-9.71	2.01e-20	1.31e-17	-0.48	-0.41	Menopause (age at onset);	chr17:43035957	chr17:43144956~43145255:+
THCA	cis	rs71403859	0.667	rs12920890	ENSG00000260886.1	TAT-AS1	9.71	2.01e-20	1.31e-17	0.74	0.41	Post bronchodilator FEV1;	chr16:71753685	chr16:71565789~71578187:+
THCA	cis	rs8040855	0.52	rs67613323	ENSG00000259295.5	CSPG4P12	9.71	2.02e-20	1.32e-17	0.67	0.41	Bulimia nervosa;	chr15:84986541	chr15:85191438~85213905:+
THCA	cis	rs8040855	0.52	rs11629962	ENSG00000259295.5	CSPG4P12	9.71	2.02e-20	1.32e-17	0.67	0.41	Bulimia nervosa;	chr15:84986797	chr15:85191438~85213905:+
THCA	cis	rs11676348	0.935	rs4674250	ENSG00000261338.2	RP11-378A13.1	-9.71	2.03e-20	1.32e-17	-0.41	-0.41	Ulcerative colitis;	chr2:218112808	chr2:218255319~218257366:+
THCA	cis	rs2274273	0.648	rs58553156	ENSG00000258413.1	RP11-665C16.6	-9.7	2.04e-20	1.33e-17	-0.56	-0.41	Protein biomarker;	chr14:55115976	chr14:55262767~55272075:-
THCA	cis	rs4964805	0.913	rs12229276	ENSG00000257681.1	RP11-341G23.4	-9.7	2.04e-20	1.33e-17	-0.48	-0.41	Attention deficit hyperactivity disorder;	chr12:103810993	chr12:103746315~103768858:-
THCA	cis	rs9322193	0.884	rs11155669	ENSG00000268592.3	RAET1E-AS1	9.7	2.05e-20	1.34e-17	0.55	0.41	Lung cancer;	chr6:149633501	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.887	rs9505824	ENSG00000268592.3	RAET1E-AS1	9.7	2.05e-20	1.34e-17	0.55	0.41	Lung cancer;	chr6:149633663	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9505826	ENSG00000268592.3	RAET1E-AS1	9.7	2.05e-20	1.34e-17	0.55	0.41	Lung cancer;	chr6:149633912	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9766886	ENSG00000268592.3	RAET1E-AS1	9.7	2.05e-20	1.34e-17	0.55	0.41	Lung cancer;	chr6:149637048	chr6:149863494~149919507:+
THCA	cis	rs2599510	0.703	rs762023	ENSG00000276334.1	AL133243.1	9.7	2.06e-20	1.34e-17	0.44	0.41	Interleukin-18 levels;	chr2:32488103	chr2:32521927~32523547:+
THCA	cis	rs944289	0.774	rs7150539	ENSG00000257826.1	RP11-116N8.4	-9.7	2.06e-20	1.35e-17	-0.42	-0.41	Thyroid cancer;	chr14:36086408	chr14:36061026~36067190:-
THCA	cis	rs524281	1	rs475805	ENSG00000255320.1	RP11-755F10.1	-9.7	2.07e-20	1.35e-17	-0.55	-0.41	Electroencephalogram traits;	chr11:66081267	chr11:66244840~66246239:-
THCA	cis	rs950169	0.922	rs12915832	ENSG00000259728.4	LINC00933	9.7	2.07e-20	1.35e-17	0.55	0.41	Schizophrenia;	chr15:84568226	chr15:84570649~84580175:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-9.7	2.08e-20	1.35e-17	-0.51	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
THCA	cis	rs4380275	0.782	rs60367761	ENSG00000272342.1	RP13-539J13.1	9.7	2.12e-20	1.38e-17	0.48	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:739588~740164:-
THCA	cis	rs4819052	0.851	rs8133045	ENSG00000215447.6	BX322557.10	-9.7	2.12e-20	1.38e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45288052~45291738:+
THCA	cis	rs2836950	0.545	rs8132424	ENSG00000255568.3	BRWD1-AS2	9.7	2.12e-20	1.38e-17	0.33	0.41	Menarche (age at onset);	chr21:39212486	chr21:39313935~39314962:+
THCA	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	9.7	2.14e-20	1.39e-17	0.59	0.41	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	9.7	2.14e-20	1.39e-17	0.59	0.41	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	9.7	2.14e-20	1.39e-17	0.59	0.41	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-9.7	2.14e-20	1.39e-17	-0.59	-0.41	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
THCA	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-9.7	2.14e-20	1.39e-17	-0.59	-0.41	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
THCA	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-9.7	2.14e-20	1.39e-17	-0.59	-0.41	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
THCA	cis	rs704795	0.775	rs4665975	ENSG00000234072.1	AC074117.10	-9.7	2.15e-20	1.4e-17	-0.33	-0.41	Menopause (age at onset);	chr2:27403150	chr2:27356246~27367622:+
THCA	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	9.7	2.15e-20	1.4e-17	0.48	0.41	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	9.7	2.15e-20	1.4e-17	0.48	0.41	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
THCA	cis	rs950169	0.881	rs34117475	ENSG00000259728.4	LINC00933	9.7	2.15e-20	1.4e-17	0.55	0.41	Schizophrenia;	chr15:84565212	chr15:84570649~84580175:+
THCA	cis	rs10740039	0.883	rs7905018	ENSG00000254271.1	RP11-131N11.4	9.7	2.15e-20	1.4e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647585	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.842	rs10761537	ENSG00000254271.1	RP11-131N11.4	9.7	2.15e-20	1.4e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649263	chr10:60734342~60741828:+
THCA	cis	rs6061231	0.544	rs2427314	ENSG00000273619.1	RP5-908M14.9	-9.7	2.16e-20	1.4e-17	-0.31	-0.41	Colorectal cancer;	chr20:62398610	chr20:62386303~62386970:-
THCA	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	9.7	2.16e-20	1.4e-17	0.35	0.41	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
THCA	cis	rs67311347	0.568	rs9864544	ENSG00000223797.4	ENTPD3-AS1	9.7	2.16e-20	1.41e-17	0.33	0.41	Renal cell carcinoma;	chr3:40294713	chr3:40313802~40453329:-
THCA	cis	rs944289	0.708	rs6571736	ENSG00000257826.1	RP11-116N8.4	-9.7	2.17e-20	1.41e-17	-0.42	-0.41	Thyroid cancer;	chr14:36111271	chr14:36061026~36067190:-
THCA	cis	rs944289	0.679	rs8016148	ENSG00000257826.1	RP11-116N8.4	-9.7	2.17e-20	1.41e-17	-0.42	-0.41	Thyroid cancer;	chr14:36111688	chr14:36061026~36067190:-
THCA	cis	rs944289	0.708	rs2415315	ENSG00000257826.1	RP11-116N8.4	-9.7	2.17e-20	1.41e-17	-0.42	-0.41	Thyroid cancer;	chr14:36115338	chr14:36061026~36067190:-
THCA	cis	rs944289	0.708	rs1475716	ENSG00000257826.1	RP11-116N8.4	-9.7	2.17e-20	1.41e-17	-0.42	-0.41	Thyroid cancer;	chr14:36116033	chr14:36061026~36067190:-
THCA	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	9.7	2.18e-20	1.42e-17	0.49	0.41	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
THCA	cis	rs524281	0.731	rs9326365	ENSG00000255320.1	RP11-755F10.1	-9.7	2.2e-20	1.43e-17	-0.61	-0.41	Electroencephalogram traits;	chr11:66040414	chr11:66244840~66246239:-
THCA	cis	rs7189233	0.531	rs17801498	ENSG00000279344.1	RP11-44F14.7	9.7	2.2e-20	1.43e-17	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53478957~53481550:-
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-9.69	2.21e-20	1.44e-17	-0.51	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
THCA	cis	rs950169	0.686	rs12906474	ENSG00000259728.4	LINC00933	9.69	2.22e-20	1.44e-17	0.55	0.41	Schizophrenia;	chr15:84566006	chr15:84570649~84580175:+
THCA	cis	rs950169	0.81	rs2879976	ENSG00000259728.4	LINC00933	9.69	2.22e-20	1.44e-17	0.55	0.41	Schizophrenia;	chr15:84566347	chr15:84570649~84580175:+
THCA	cis	rs9322193	0.884	rs9322210	ENSG00000268592.3	RAET1E-AS1	9.69	2.22e-20	1.44e-17	0.55	0.41	Lung cancer;	chr6:149695440	chr6:149863494~149919507:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000228039.3	KB-1125A3.10	9.69	2.22e-20	1.44e-17	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23963780~23964374:+
THCA	cis	rs860295	0.702	rs34124416	ENSG00000225855.5	RUSC1-AS1	9.69	2.23e-20	1.45e-17	0.29	0.41	Body mass index;	chr1:155608258	chr1:155316863~155324176:-
THCA	cis	rs9595066	0.627	rs4941486	ENSG00000227258.4	SMIM2-AS1	9.69	2.23e-20	1.45e-17	0.54	0.41	Schizophrenia;	chr13:44175021	chr13:44110451~44240517:+
THCA	cis	rs6061231	0.761	rs2427312	ENSG00000273619.1	RP5-908M14.9	-9.69	2.24e-20	1.45e-17	-0.38	-0.41	Colorectal cancer;	chr20:62395535	chr20:62386303~62386970:-
THCA	cis	rs1799949	1	rs8176202	ENSG00000267681.1	CTD-3199J23.6	-9.69	2.24e-20	1.46e-17	-0.48	-0.41	Menopause (age at onset);	chr17:43078211	chr17:43144956~43145255:+
THCA	cis	rs2274273	0.967	rs8013027	ENSG00000258413.1	RP11-665C16.6	-9.69	2.24e-20	1.46e-17	-0.54	-0.41	Protein biomarker;	chr14:55144222	chr14:55262767~55272075:-
THCA	cis	rs1075265	0.73	rs2111868	ENSG00000233266.1	HMGB1P31	9.69	2.24e-20	1.46e-17	0.52	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54051334~54051760:+
THCA	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	9.69	2.26e-20	1.47e-17	0.53	0.41	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
THCA	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-9.69	2.27e-20	1.47e-17	-0.45	-0.41	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
THCA	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	9.69	2.27e-20	1.48e-17	0.47	0.41	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
THCA	cis	rs10759883	0.563	rs623438	ENSG00000175611.10	LINC00476	9.69	2.27e-20	1.48e-17	0.47	0.41	Nicotine dependence;	chr9:95938114	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.539	rs966217	ENSG00000175611.10	LINC00476	9.69	2.27e-20	1.48e-17	0.47	0.41	Nicotine dependence;	chr9:95943247	chr9:95759231~95875977:-
THCA	cis	rs9532669	0.963	rs9315794	ENSG00000176268.5	CYCSP34	9.69	2.28e-20	1.48e-17	0.46	0.41	Cervical cancer;	chr13:40939489	chr13:40863599~40863902:-
THCA	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	9.69	2.28e-20	1.48e-17	0.62	0.41	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
THCA	cis	rs11159086	0.941	rs11846588	ENSG00000270000.1	RP3-449M8.9	9.69	2.28e-20	1.48e-17	0.43	0.41	Advanced glycation end-product levels;	chr14:74505398	chr14:74471930~74472360:-
THCA	cis	rs9532669	0.7	rs9525406	ENSG00000239827.7	SUGT1P3	-9.69	2.28e-20	1.48e-17	-0.46	-0.41	Cervical cancer;	chr13:40860812	chr13:40908159~40921774:-
THCA	cis	rs8072100	0.807	rs4561509	ENSG00000228782.6	CTD-2026D20.3	9.69	2.29e-20	1.49e-17	0.37	0.41	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704433	chr17:47450568~47492492:-
THCA	cis	rs17684571	0.751	rs13195601	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56836186	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs35828379	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56839003	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs71564863	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56840372	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs13192540	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56842637	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs13192931	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56842921	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs35242294	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56846131	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs35080938	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56847992	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs13207768	ENSG00000231441.1	RP11-472M19.2	9.69	2.3e-20	1.49e-17	0.55	0.41	Schizophrenia;	chr6:56851277	chr6:56844002~56864078:+
THCA	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	9.69	2.3e-20	1.49e-17	0.35	0.41	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
THCA	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	9.69	2.31e-20	1.5e-17	0.34	0.41	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
THCA	cis	rs67311347	0.544	rs13062243	ENSG00000223797.4	ENTPD3-AS1	9.69	2.31e-20	1.5e-17	0.32	0.41	Renal cell carcinoma;	chr3:40295298	chr3:40313802~40453329:-
THCA	cis	rs42490	0.868	rs12675281	ENSG00000251136.7	RP11-37B2.1	9.69	2.32e-20	1.5e-17	0.35	0.41	Leprosy;	chr8:89681561	chr8:89609409~89757727:-
THCA	cis	rs185968827	1	rs185968827	ENSG00000231441.1	RP11-472M19.2	9.69	2.32e-20	1.5e-17	0.54	0.41	Alzheimer disease and age of onset;	chr6:56843712	chr6:56844002~56864078:+
THCA	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-9.69	2.32e-20	1.51e-17	-0.42	-0.41	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
THCA	cis	rs67311347	0.544	rs2278930	ENSG00000223797.4	ENTPD3-AS1	9.69	2.33e-20	1.51e-17	0.33	0.41	Renal cell carcinoma;	chr3:40309601	chr3:40313802~40453329:-
THCA	cis	rs9322193	0.923	rs9505823	ENSG00000268592.3	RAET1E-AS1	9.69	2.34e-20	1.52e-17	0.55	0.41	Lung cancer;	chr6:149628899	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs7767622	ENSG00000268592.3	RAET1E-AS1	9.69	2.36e-20	1.53e-17	0.55	0.41	Lung cancer;	chr6:149681766	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs4421206	ENSG00000268592.3	RAET1E-AS1	9.69	2.36e-20	1.53e-17	0.55	0.41	Lung cancer;	chr6:149682891	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs3798761	ENSG00000268592.3	RAET1E-AS1	9.69	2.36e-20	1.53e-17	0.55	0.41	Lung cancer;	chr6:149683643	chr6:149863494~149919507:+
THCA	cis	rs17684571	0.751	rs17684941	ENSG00000231441.1	RP11-472M19.2	-9.69	2.37e-20	1.54e-17	-0.55	-0.41	Schizophrenia;	chr6:56862636	chr6:56844002~56864078:+
THCA	cis	rs9322193	0.923	rs12174716	ENSG00000268592.3	RAET1E-AS1	9.69	2.37e-20	1.54e-17	0.55	0.41	Lung cancer;	chr6:149644487	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.857	rs7327018	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40856376	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7327315	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40856383	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7327059	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40856458	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9594433	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40856935	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9525403	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40858292	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7318768	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40859140	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4942000	ENSG00000239827.7	SUGT1P3	-9.69	2.37e-20	1.54e-17	-0.46	-0.41	Cervical cancer;	chr13:40859979	chr13:40908159~40921774:-
THCA	cis	rs7500321	1	rs7500321	ENSG00000251417.2	RP11-1348G14.4	9.69	2.38e-20	1.54e-17	0.42	0.41	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28802743~28817828:+
THCA	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-9.69	2.38e-20	1.54e-17	-0.44	-0.41	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000235689.1	AP000351.13	9.69	2.39e-20	1.55e-17	0.51	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:24006305~24008258:-
THCA	cis	rs10740039	1	rs10994460	ENSG00000254271.1	RP11-131N11.4	9.69	2.39e-20	1.55e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60659033	chr10:60734342~60741828:+
THCA	cis	rs950169	0.509	rs71395455	ENSG00000225151.9	GOLGA2P7	-9.68	2.41e-20	1.56e-17	-0.61	-0.41	Schizophrenia;	chr15:84610573	chr15:84199311~84230136:-
THCA	cis	rs4713118	0.662	rs175954	ENSG00000280107.1	AL022393.9	-9.68	2.43e-20	1.57e-17	-0.47	-0.41	Parkinson's disease;	chr6:28043807	chr6:28170845~28172521:+
THCA	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-9.68	2.43e-20	1.58e-17	-0.56	-0.41	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
THCA	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-9.68	2.43e-20	1.58e-17	-0.51	-0.41	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
THCA	cis	rs9487094	0.626	rs1980591	ENSG00000260273.1	RP11-425D10.10	9.68	2.44e-20	1.58e-17	0.48	0.41	Height;	chr6:109618620	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.696	rs12191353	ENSG00000260273.1	RP11-425D10.10	9.68	2.44e-20	1.58e-17	0.48	0.41	Height;	chr6:109620772	chr6:109382795~109383666:+
THCA	cis	rs9640161	0.75	rs1983440	ENSG00000261305.1	RP4-584D14.7	9.68	2.44e-20	1.58e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150326852	chr7:150341771~150342607:+
THCA	cis	rs9322193	0.923	rs9479094	ENSG00000268592.3	RAET1E-AS1	9.68	2.44e-20	1.58e-17	0.55	0.41	Lung cancer;	chr6:149725083	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.89	rs2324738	ENSG00000239827.7	SUGT1P3	-9.68	2.46e-20	1.59e-17	-0.44	-0.41	Cervical cancer;	chr13:40925242	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs2324739	ENSG00000239827.7	SUGT1P3	-9.68	2.46e-20	1.59e-17	-0.44	-0.41	Cervical cancer;	chr13:40925479	chr13:40908159~40921774:-
THCA	cis	rs73219805	0.793	rs3808573	ENSG00000228451.3	SDAD1P1	-9.68	2.46e-20	1.59e-17	-0.52	-0.41	Schizophrenia;	chr8:26339117	chr8:26379259~26382953:-
THCA	cis	rs2599510	0.811	rs2243844	ENSG00000276334.1	AL133243.1	9.68	2.47e-20	1.6e-17	0.44	0.41	Interleukin-18 levels;	chr2:32550917	chr2:32521927~32523547:+
THCA	cis	rs853679	0.517	rs2273564	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28089816	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs1853097	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28090857	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393888	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28091439	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9357063	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28092227	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs3823180	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28093966	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368551	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28094014	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393890	ENSG00000226314.6	ZNF192P1	-9.68	2.48e-20	1.6e-17	-0.55	-0.41	Depression;	chr6:28096077	chr6:28161781~28169594:+
THCA	cis	rs67311347	0.544	rs9864664	ENSG00000223797.4	ENTPD3-AS1	9.68	2.48e-20	1.61e-17	0.32	0.41	Renal cell carcinoma;	chr3:40294735	chr3:40313802~40453329:-
THCA	cis	rs6046396	1	rs6046404	ENSG00000275142.1	RP5-999L4.2	-9.68	2.5e-20	1.61e-17	-0.58	-0.41	Bipolar disorder and schizophrenia;	chr20:19882918	chr20:19871891~19872284:+
THCA	cis	rs9640161	0.742	rs2159236	ENSG00000261305.1	RP4-584D14.7	9.68	2.5e-20	1.62e-17	0.5	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150320125	chr7:150341771~150342607:+
THCA	cis	rs9322193	0.923	rs9689084	ENSG00000268592.3	RAET1E-AS1	9.68	2.52e-20	1.63e-17	0.55	0.41	Lung cancer;	chr6:149639648	chr6:149863494~149919507:+
THCA	cis	rs42490	0.868	rs1605997	ENSG00000251136.7	RP11-37B2.1	9.68	2.52e-20	1.63e-17	0.35	0.41	Leprosy;	chr8:89655885	chr8:89609409~89757727:-
THCA	cis	rs9322193	0.923	rs9322196	ENSG00000268592.3	RAET1E-AS1	9.68	2.52e-20	1.63e-17	0.55	0.41	Lung cancer;	chr6:149619645	chr6:149863494~149919507:+
THCA	cis	rs7772486	0.875	rs969694	ENSG00000235652.6	RP11-545I5.3	9.68	2.55e-20	1.65e-17	0.36	0.41	Lobe attachment (rater-scored or self-reported);	chr6:146073519	chr6:145799409~145886585:+
THCA	cis	rs2274273	1	rs7142704	ENSG00000258413.1	RP11-665C16.6	-9.68	2.56e-20	1.66e-17	-0.53	-0.41	Protein biomarker;	chr14:55163885	chr14:55262767~55272075:-
THCA	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	9.67	2.61e-20	1.69e-17	0.53	0.41	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
THCA	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-9.67	2.62e-20	1.69e-17	-0.46	-0.41	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
THCA	cis	rs9322193	0.923	rs4869750	ENSG00000268592.3	RAET1E-AS1	9.67	2.62e-20	1.7e-17	0.55	0.41	Lung cancer;	chr6:149855996	chr6:149863494~149919507:+
THCA	cis	rs17684571	0.751	rs34896026	ENSG00000231441.1	RP11-472M19.2	9.67	2.65e-20	1.72e-17	0.54	0.41	Schizophrenia;	chr6:56829383	chr6:56844002~56864078:+
THCA	cis	rs67311347	0.568	rs57287242	ENSG00000223797.4	ENTPD3-AS1	9.67	2.66e-20	1.72e-17	0.32	0.41	Renal cell carcinoma;	chr3:40294047	chr3:40313802~40453329:-
THCA	cis	rs1858037	0.867	rs67817304	ENSG00000281920.1	RP11-418H16.1	9.67	2.66e-20	1.72e-17	0.54	0.41	Rheumatoid arthritis;	chr2:65346982	chr2:65623272~65628424:+
THCA	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	9.67	2.67e-20	1.72e-17	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
THCA	cis	rs9595066	0.712	rs4391951	ENSG00000227258.4	SMIM2-AS1	-9.67	2.67e-20	1.73e-17	-0.54	-0.41	Schizophrenia;	chr13:44180935	chr13:44110451~44240517:+
THCA	cis	rs2836950	0.509	rs11088466	ENSG00000255568.3	BRWD1-AS2	-9.67	2.68e-20	1.73e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39208091	chr21:39313935~39314962:+
THCA	cis	rs944289	0.708	rs1958615	ENSG00000257826.1	RP11-116N8.4	-9.67	2.69e-20	1.74e-17	-0.42	-0.41	Thyroid cancer;	chr14:36118282	chr14:36061026~36067190:-
THCA	cis	rs944289	0.708	rs1537426	ENSG00000257826.1	RP11-116N8.4	9.67	2.69e-20	1.74e-17	0.42	0.41	Thyroid cancer;	chr14:36117961	chr14:36061026~36067190:-
THCA	cis	rs34375054	0.525	rs12316499	ENSG00000279233.1	RP11-158L12.4	9.67	2.69e-20	1.74e-17	0.39	0.41	Post bronchodilator FEV1/FVC ratio;	chr12:125108772	chr12:125138245~125141711:+
THCA	cis	rs597539	0.616	rs10896386	ENSG00000250508.1	RP11-757G1.6	-9.67	2.69e-20	1.74e-17	-0.48	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68955225	chr11:68870664~68874542:+
THCA	cis	rs7189233	0.531	rs1131220	ENSG00000279344.1	RP11-44F14.7	9.67	2.69e-20	1.74e-17	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53470022	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.513	rs10748	ENSG00000279344.1	RP11-44F14.7	9.67	2.69e-20	1.74e-17	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53470809	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs8045674	ENSG00000279344.1	RP11-44F14.7	9.67	2.69e-20	1.74e-17	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53476024	chr16:53478957~53481550:-
THCA	cis	rs944289	0.74	rs376927	ENSG00000257826.1	RP11-116N8.4	-9.67	2.7e-20	1.74e-17	-0.42	-0.41	Thyroid cancer;	chr14:36078725	chr14:36061026~36067190:-
THCA	cis	rs4713118	0.662	rs149969	ENSG00000280107.1	AL022393.9	-9.67	2.71e-20	1.75e-17	-0.47	-0.41	Parkinson's disease;	chr6:28009959	chr6:28170845~28172521:+
THCA	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-9.67	2.71e-20	1.75e-17	-0.59	-0.41	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
THCA	cis	rs4964805	0.913	rs11111795	ENSG00000257681.1	RP11-341G23.4	9.67	2.71e-20	1.75e-17	0.48	0.41	Attention deficit hyperactivity disorder;	chr12:103811052	chr12:103746315~103768858:-
THCA	cis	rs2274273	0.624	rs7150763	ENSG00000258413.1	RP11-665C16.6	-9.67	2.72e-20	1.76e-17	-0.56	-0.41	Protein biomarker;	chr14:55373083	chr14:55262767~55272075:-
THCA	cis	rs7189233	0.531	rs1072911	ENSG00000279344.1	RP11-44F14.7	9.67	2.73e-20	1.76e-17	0.4	0.41	Intelligence (multi-trait analysis);	chr16:53465813	chr16:53478957~53481550:-
THCA	cis	rs9926296	0.712	rs2437957	ENSG00000260259.1	RP11-368I7.4	9.67	2.73e-20	1.76e-17	0.46	0.41	Vitiligo;	chr16:89649240	chr16:89682620~89686569:-
THCA	cis	rs9322193	0.923	rs9800806	ENSG00000268592.3	RAET1E-AS1	9.67	2.74e-20	1.77e-17	0.55	0.41	Lung cancer;	chr6:149740350	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs1572229	ENSG00000268592.3	RAET1E-AS1	9.67	2.74e-20	1.77e-17	0.55	0.41	Lung cancer;	chr6:149743841	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.926	rs9562254	ENSG00000176268.5	CYCSP34	-9.67	2.75e-20	1.77e-17	-0.45	-0.41	Cervical cancer;	chr13:40960902	chr13:40863599~40863902:-
THCA	cis	rs9322193	0.923	rs9479494	ENSG00000268592.3	RAET1E-AS1	9.67	2.75e-20	1.78e-17	0.55	0.41	Lung cancer;	chr6:149739108	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs9688794	ENSG00000268592.3	RAET1E-AS1	9.67	2.75e-20	1.78e-17	0.55	0.41	Lung cancer;	chr6:149632121	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9322204	ENSG00000268592.3	RAET1E-AS1	9.67	2.75e-20	1.78e-17	0.55	0.41	Lung cancer;	chr6:149636047	chr6:149863494~149919507:+
THCA	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-9.67	2.77e-20	1.79e-17	-0.45	-0.41	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
THCA	cis	rs853679	0.517	rs3757187	ENSG00000226314.6	ZNF192P1	-9.67	2.77e-20	1.79e-17	-0.55	-0.41	Depression;	chr6:28139876	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs3757185	ENSG00000226314.6	ZNF192P1	-9.67	2.77e-20	1.79e-17	-0.55	-0.41	Depression;	chr6:28139998	chr6:28161781~28169594:+
THCA	cis	rs9640161	0.742	rs2159235	ENSG00000261305.1	RP4-584D14.7	9.67	2.79e-20	1.8e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150320139	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.742	rs2108853	ENSG00000261305.1	RP4-584D14.7	9.67	2.79e-20	1.8e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150320500	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.789	rs1464752	ENSG00000261305.1	RP4-584D14.7	9.67	2.8e-20	1.81e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150324195	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.789	rs1464753	ENSG00000261305.1	RP4-584D14.7	9.67	2.8e-20	1.81e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150324261	chr7:150341771~150342607:+
THCA	cis	rs9322193	0.607	rs10457852	ENSG00000268592.3	RAET1E-AS1	9.67	2.8e-20	1.81e-17	0.59	0.41	Lung cancer;	chr6:149880584	chr6:149863494~149919507:+
THCA	cis	rs7586673	1	rs7586673	ENSG00000227403.1	AC009299.3	-9.67	2.81e-20	1.81e-17	-0.48	-0.41	Intelligence (multi-trait analysis);	chr2:161067009	chr2:161244739~161249050:+
THCA	cis	rs67311347	0.544	rs12054197	ENSG00000223797.4	ENTPD3-AS1	9.66	2.82e-20	1.82e-17	0.32	0.41	Renal cell carcinoma;	chr3:40296071	chr3:40313802~40453329:-
THCA	cis	rs524281	1	rs472518	ENSG00000255320.1	RP11-755F10.1	-9.66	2.82e-20	1.82e-17	-0.54	-0.41	Electroencephalogram traits;	chr11:66084431	chr11:66244840~66246239:-
THCA	cis	rs7208859	0.623	rs9912440	ENSG00000266490.1	CTD-2349P21.9	9.66	2.83e-20	1.83e-17	0.56	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30792372~30792833:+
THCA	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	9.66	2.84e-20	1.83e-17	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
THCA	cis	rs11986414	1	rs11986414	ENSG00000253982.1	CTD-2336O2.1	9.66	2.84e-20	1.83e-17	0.41	0.41	Gaucher disease severity;	chr8:1798784	chr8:1761990~1764502:-
THCA	cis	rs9532669	0.963	rs4600338	ENSG00000239827.7	SUGT1P3	-9.66	2.85e-20	1.84e-17	-0.44	-0.41	Cervical cancer;	chr13:40925175	chr13:40908159~40921774:-
THCA	cis	rs9640161	0.742	rs2108852	ENSG00000261305.1	RP4-584D14.7	9.66	2.85e-20	1.84e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150322539	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.742	rs2108851	ENSG00000261305.1	RP4-584D14.7	9.66	2.85e-20	1.84e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150322545	chr7:150341771~150342607:+
THCA	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-9.66	2.86e-20	1.85e-17	-0.48	-0.41	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
THCA	cis	rs889312	0.504	rs62355900	ENSG00000271828.1	CTD-2310F14.1	9.66	2.86e-20	1.85e-17	0.68	0.41	Breast cancer (early onset);Breast cancer;	chr5:56756868	chr5:56927874~56929573:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000224205.1	AP000351.4	9.66	2.87e-20	1.85e-17	0.48	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23987320~23991421:-
THCA	cis	rs8062405	0.573	rs6565300	ENSG00000259982.1	CDC37P1	9.66	2.87e-20	1.85e-17	0.52	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28700294~28701540:-
THCA	cis	rs10740039	0.883	rs7902632	ENSG00000254271.1	RP11-131N11.4	9.66	2.88e-20	1.86e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643811	chr10:60734342~60741828:+
THCA	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-9.66	2.88e-20	1.86e-17	-0.35	-0.41	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
THCA	cis	rs9532669	0.963	rs1056824	ENSG00000176268.5	CYCSP34	9.66	2.9e-20	1.87e-17	0.45	0.41	Cervical cancer;	chr13:40932748	chr13:40863599~40863902:-
THCA	cis	rs8062405	0.573	rs11645306	ENSG00000259982.1	CDC37P1	-9.66	2.91e-20	1.88e-17	-0.52	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28700294~28701540:-
THCA	cis	rs10971721	0.643	rs7040130	ENSG00000260947.1	RP11-384P7.7	9.66	2.92e-20	1.88e-17	0.97	0.41	Body mass index;	chr9:33785075	chr9:33697459~33700986:+
THCA	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	9.66	2.92e-20	1.88e-17	0.43	0.41	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
THCA	cis	rs6452524	0.78	rs10078661	ENSG00000249664.1	CTD-2227C6.2	9.66	2.92e-20	1.88e-17	0.54	0.41	Hypertension (SNP x SNP interaction);	chr5:83182136	chr5:83012285~83013109:-
THCA	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-9.66	2.95e-20	1.9e-17	-0.34	-0.41	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
THCA	cis	rs597539	0.652	rs569777	ENSG00000250508.1	RP11-757G1.6	-9.66	2.96e-20	1.91e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68939380	chr11:68870664~68874542:+
THCA	cis	rs2836950	0.501	rs4818018	ENSG00000255568.3	BRWD1-AS2	-9.66	2.97e-20	1.91e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39322146	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.501	rs4818019	ENSG00000255568.3	BRWD1-AS2	-9.66	2.97e-20	1.91e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39322530	chr21:39313935~39314962:+
THCA	cis	rs17826219	0.636	rs12946563	ENSG00000266490.1	CTD-2349P21.9	9.66	2.98e-20	1.92e-17	0.56	0.41	Body mass index;	chr17:30776148	chr17:30792372~30792833:+
THCA	cis	rs1537424	0.513	rs1953119	ENSG00000257826.1	RP11-116N8.4	-9.66	2.98e-20	1.92e-17	-0.47	-0.41	Thyroid hormone levels;	chr14:36091618	chr14:36061026~36067190:-
THCA	cis	rs916888	0.821	rs199514	ENSG00000232300.1	FAM215B	-9.66	2.99e-20	1.92e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46558830~46562795:-
THCA	cis	rs3743772	0.5	rs2388117	ENSG00000279722.1	RP11-44F14.6	9.66	2.99e-20	1.93e-17	0.54	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53413692	chr16:53487607~53489943:-
THCA	cis	rs3743772	0.5	rs28415605	ENSG00000279722.1	RP11-44F14.6	9.66	2.99e-20	1.93e-17	0.54	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53415274	chr16:53487607~53489943:-
THCA	cis	rs3743772	0.5	rs2160290	ENSG00000279722.1	RP11-44F14.6	9.66	2.99e-20	1.93e-17	0.54	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53415763	chr16:53487607~53489943:-
THCA	cis	rs9322193	0.923	rs35961297	ENSG00000268592.3	RAET1E-AS1	9.66	2.99e-20	1.93e-17	0.55	0.41	Lung cancer;	chr6:149667929	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs35967444	ENSG00000268592.3	RAET1E-AS1	9.66	2.99e-20	1.93e-17	0.55	0.41	Lung cancer;	chr6:149675588	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs62439842	ENSG00000268592.3	RAET1E-AS1	9.66	2.99e-20	1.93e-17	0.55	0.41	Lung cancer;	chr6:149675847	chr6:149863494~149919507:+
THCA	cis	rs2836950	0.565	rs2836945	ENSG00000255568.3	BRWD1-AS2	-9.66	3e-20	1.93e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39224831	chr21:39313935~39314962:+
THCA	cis	rs9322193	0.923	rs11155671	ENSG00000268592.3	RAET1E-AS1	9.66	3.01e-20	1.94e-17	0.55	0.41	Lung cancer;	chr6:149650996	chr6:149863494~149919507:+
THCA	cis	rs12554020	0.786	rs3893381	ENSG00000227603.1	RP11-165J3.6	-9.66	3.01e-20	1.94e-17	-0.66	-0.41	Schizophrenia;	chr9:93519576	chr9:93435332~93437121:-
THCA	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	9.66	3.01e-20	1.94e-17	0.59	0.41	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
THCA	cis	rs944289	0.708	rs2755194	ENSG00000257826.1	RP11-116N8.4	-9.66	3.02e-20	1.95e-17	-0.41	-0.41	Thyroid cancer;	chr14:36079176	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs11156902	ENSG00000257826.1	RP11-116N8.4	-9.66	3.02e-20	1.95e-17	-0.41	-0.41	Thyroid cancer;	chr14:36080016	chr14:36061026~36067190:-
THCA	cis	rs944289	0.712	rs35736442	ENSG00000257826.1	RP11-116N8.4	-9.66	3.02e-20	1.95e-17	-0.41	-0.41	Thyroid cancer;	chr14:36081119	chr14:36061026~36067190:-
THCA	cis	rs853679	0.517	rs9393887	ENSG00000226314.6	ZNF192P1	-9.66	3.04e-20	1.96e-17	-0.54	-0.41	Depression;	chr6:28091242	chr6:28161781~28169594:+
THCA	cis	rs7208859	0.614	rs216474	ENSG00000263531.1	RP13-753N3.1	-9.66	3.04e-20	1.96e-17	-0.74	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30538073	chr17:30863921~30864940:-
THCA	cis	rs11051970	0.559	rs11051928	ENSG00000274964.1	RP11-817I4.1	-9.66	3.05e-20	1.97e-17	-0.51	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32319580	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051929	ENSG00000274964.1	RP11-817I4.1	-9.66	3.05e-20	1.97e-17	-0.51	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32319617	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.592	rs58926489	ENSG00000274964.1	RP11-817I4.1	-9.66	3.05e-20	1.97e-17	-0.51	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32319949	chr12:32339368~32340724:+
THCA	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	9.66	3.05e-20	1.97e-17	0.47	0.41	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
THCA	cis	rs597539	0.518	rs35093305	ENSG00000250508.1	RP11-757G1.6	-9.65	3.06e-20	1.97e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963260	chr11:68870664~68874542:+
THCA	cis	rs7208859	0.623	rs1054397	ENSG00000266490.1	CTD-2349P21.9	9.65	3.07e-20	1.97e-17	0.54	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30792372~30792833:+
THCA	cis	rs944289	0.74	rs398501	ENSG00000257826.1	RP11-116N8.4	-9.65	3.07e-20	1.97e-17	-0.41	-0.41	Thyroid cancer;	chr14:36078452	chr14:36061026~36067190:-
THCA	cis	rs10740039	1	rs10740040	ENSG00000254271.1	RP11-131N11.4	9.65	3.08e-20	1.98e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654985	chr10:60734342~60741828:+
THCA	cis	rs7208859	0.524	rs59923796	ENSG00000266490.1	CTD-2349P21.9	9.65	3.08e-20	1.98e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30792372~30792833:+
THCA	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-9.65	3.1e-20	1.99e-17	-0.68	-0.41	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
THCA	cis	rs6504950	0.679	rs2628298	ENSG00000275710.1	RP11-257O5.4	-9.65	3.1e-20	1.99e-17	-0.57	-0.41	Breast cancer;	chr17:55086117	chr17:54964474~54964679:+
THCA	cis	rs9322193	0.923	rs17745062	ENSG00000268592.3	RAET1E-AS1	9.65	3.1e-20	2e-17	0.55	0.41	Lung cancer;	chr6:149721079	chr6:149863494~149919507:+
THCA	cis	rs1799949	0.501	rs2343819	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.12e-20	2e-17	-0.47	-0.41	Menopause (age at onset);	chr17:43332285	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.501	rs35399157	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.12e-20	2e-17	-0.47	-0.41	Menopause (age at onset);	chr17:43334234	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.602	rs4600503	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.12e-20	2e-17	-0.47	-0.41	Menopause (age at onset);	chr17:43336956	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.501	rs9675035	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.12e-20	2e-17	-0.47	-0.41	Menopause (age at onset);	chr17:43337648	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs11649954	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.12e-20	2e-17	-0.47	-0.41	Menopause (age at onset);	chr17:43342667	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1824889	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.12e-20	2e-17	-0.47	-0.41	Menopause (age at onset);	chr17:43344508	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs12944597	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.13e-20	2.01e-17	-0.48	-0.41	Menopause (age at onset);	chr17:43035667	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs34616041	ENSG00000267681.1	CTD-3199J23.6	-9.65	3.13e-20	2.01e-17	-0.48	-0.41	Menopause (age at onset);	chr17:43036769	chr17:43144956~43145255:+
THCA	cis	rs7208859	0.623	rs3794796	ENSG00000266490.1	CTD-2349P21.9	9.65	3.13e-20	2.01e-17	0.56	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30792372~30792833:+
THCA	cis	rs597539	0.652	rs674654	ENSG00000250508.1	RP11-757G1.6	-9.65	3.17e-20	2.04e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931294	chr11:68870664~68874542:+
THCA	cis	rs597539	0.616	rs513476	ENSG00000250508.1	RP11-757G1.6	-9.65	3.17e-20	2.04e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931528	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs478647	ENSG00000250508.1	RP11-757G1.6	-9.65	3.17e-20	2.04e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68932956	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs622082	ENSG00000250508.1	RP11-757G1.6	-9.65	3.17e-20	2.04e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936491	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs546382	ENSG00000250508.1	RP11-757G1.6	-9.65	3.17e-20	2.04e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68936796	chr11:68870664~68874542:+
THCA	cis	rs934734	0.532	rs7569257	ENSG00000234255.7	AC012370.3	-9.65	3.18e-20	2.04e-17	-0.45	-0.41	Rheumatoid arthritis;	chr2:65429842	chr2:65439888~65456571:-
THCA	cis	rs9322193	0.923	rs3924871	ENSG00000268592.3	RAET1E-AS1	9.65	3.19e-20	2.05e-17	0.55	0.41	Lung cancer;	chr6:149662080	chr6:149863494~149919507:+
THCA	cis	rs10759883	0.549	rs816680	ENSG00000175611.10	LINC00476	-9.65	3.19e-20	2.05e-17	-0.45	-0.41	Nicotine dependence;	chr9:95804111	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-9.65	3.19e-20	2.05e-17	-0.45	-0.41	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-9.65	3.19e-20	2.05e-17	-0.45	-0.41	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
THCA	cis	rs7727544	0.716	rs10058655	ENSG00000237714.1	P4HA2-AS1	9.65	3.2e-20	2.05e-17	0.54	0.41	Blood metabolite levels;	chr5:132235203	chr5:132184876~132192808:+
THCA	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	9.65	3.21e-20	2.06e-17	0.44	0.41	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
THCA	cis	rs7208859	0.623	rs11657662	ENSG00000266490.1	CTD-2349P21.9	-9.65	3.21e-20	2.06e-17	-0.55	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9895785	ENSG00000266490.1	CTD-2349P21.9	-9.65	3.21e-20	2.06e-17	-0.56	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780690	chr17:30792372~30792833:+
THCA	cis	rs7712401	0.601	rs154501	ENSG00000263432.2	RN7SL689P	9.65	3.23e-20	2.07e-17	0.45	0.41	Mean platelet volume;	chr5:122875899	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246271	ENSG00000263432.2	RN7SL689P	9.65	3.23e-20	2.07e-17	0.45	0.41	Mean platelet volume;	chr5:122877127	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs257813	ENSG00000263432.2	RN7SL689P	9.65	3.23e-20	2.07e-17	0.45	0.41	Mean platelet volume;	chr5:122881473	chr5:123022487~123022783:-
THCA	cis	rs780096	0.546	rs1260320	ENSG00000234072.1	AC074117.10	9.65	3.23e-20	2.07e-17	0.32	0.41	Total body bone mineral density;	chr2:27499549	chr2:27356246~27367622:+
THCA	cis	rs67311347	0.544	rs35112505	ENSG00000223797.4	ENTPD3-AS1	9.65	3.23e-20	2.07e-17	0.32	0.41	Renal cell carcinoma;	chr3:40295584	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.544	rs67533651	ENSG00000223797.4	ENTPD3-AS1	9.65	3.23e-20	2.07e-17	0.32	0.41	Renal cell carcinoma;	chr3:40296876	chr3:40313802~40453329:-
THCA	cis	rs6452524	0.836	rs2731849	ENSG00000249664.1	CTD-2227C6.2	-9.65	3.23e-20	2.07e-17	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83214060	chr5:83012285~83013109:-
THCA	cis	rs7615952	0.512	rs34085484	ENSG00000171084.14	FAM86JP	9.65	3.24e-20	2.08e-17	0.53	0.41	Blood pressure (smoking interaction);	chr3:125825343	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.608	rs35668111	ENSG00000171084.14	FAM86JP	9.65	3.24e-20	2.08e-17	0.53	0.41	Blood pressure (smoking interaction);	chr3:125825792	chr3:125916620~125930024:+
THCA	cis	rs9322193	0.923	rs1080670	ENSG00000268592.3	RAET1E-AS1	9.65	3.24e-20	2.08e-17	0.55	0.41	Lung cancer;	chr6:149620161	chr6:149863494~149919507:+
THCA	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-9.65	3.24e-20	2.08e-17	-0.45	-0.41	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
THCA	cis	rs853679	0.517	rs3734573	ENSG00000226314.6	ZNF192P1	-9.65	3.25e-20	2.09e-17	-0.54	-0.41	Depression;	chr6:28091659	chr6:28161781~28169594:+
THCA	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-9.65	3.26e-20	2.09e-17	-0.46	-0.41	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
THCA	cis	rs7712401	0.645	rs154497	ENSG00000263432.2	RN7SL689P	9.65	3.27e-20	2.1e-17	0.45	0.41	Mean platelet volume;	chr5:122885725	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs144597	ENSG00000263432.2	RN7SL689P	9.65	3.27e-20	2.1e-17	0.45	0.41	Mean platelet volume;	chr5:122887537	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246282	ENSG00000263432.2	RN7SL689P	9.65	3.27e-20	2.1e-17	0.45	0.41	Mean platelet volume;	chr5:122889910	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.623	rs538424	ENSG00000263432.2	RN7SL689P	9.65	3.27e-20	2.1e-17	0.45	0.41	Mean platelet volume;	chr5:122893068	chr5:123022487~123022783:-
THCA	cis	rs597539	0.652	rs604524	ENSG00000250508.1	RP11-757G1.6	-9.65	3.29e-20	2.11e-17	-0.48	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862461	chr11:68870664~68874542:+
THCA	cis	rs9309711	0.544	rs9752130	ENSG00000225234.1	TRAPPC12-AS1	-9.65	3.29e-20	2.11e-17	-0.41	-0.41	Neurofibrillary tangles;	chr2:3484731	chr2:3481242~3482409:-
THCA	cis	rs9532669	0.926	rs9532671	ENSG00000239827.7	SUGT1P3	-9.65	3.29e-20	2.11e-17	-0.44	-0.41	Cervical cancer;	chr13:40927761	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.833	rs9532672	ENSG00000239827.7	SUGT1P3	-9.65	3.29e-20	2.11e-17	-0.44	-0.41	Cervical cancer;	chr13:40928285	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.963	rs7324625	ENSG00000239827.7	SUGT1P3	-9.65	3.29e-20	2.11e-17	-0.44	-0.41	Cervical cancer;	chr13:40928606	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4454835	ENSG00000239827.7	SUGT1P3	-9.65	3.29e-20	2.11e-17	-0.44	-0.41	Cervical cancer;	chr13:40928978	chr13:40908159~40921774:-
THCA	cis	rs7208859	0.623	rs7214570	ENSG00000266490.1	CTD-2349P21.9	9.65	3.3e-20	2.12e-17	0.54	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30792372~30792833:+
THCA	cis	rs8062405	0.573	rs7140	ENSG00000259982.1	CDC37P1	-9.65	3.3e-20	2.12e-17	-0.52	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28700294~28701540:-
THCA	cis	rs10935480	0.634	rs1585488	ENSG00000239445.4	ST3GAL6-AS1	-9.65	3.3e-20	2.12e-17	-0.41	-0.41	Blood protein levels;	chr3:98640819	chr3:98714330~98732651:-
THCA	cis	rs6452524	0.836	rs62374402	ENSG00000249664.1	CTD-2227C6.2	9.65	3.31e-20	2.12e-17	0.54	0.41	Hypertension (SNP x SNP interaction);	chr5:83207343	chr5:83012285~83013109:-
THCA	cis	rs9322193	0.923	rs9688861	ENSG00000268592.3	RAET1E-AS1	9.64	3.32e-20	2.13e-17	0.55	0.41	Lung cancer;	chr6:149637924	chr6:149863494~149919507:+
THCA	cis	rs944289	0.708	rs7158599	ENSG00000257826.1	RP11-116N8.4	-9.64	3.33e-20	2.13e-17	-0.42	-0.41	Thyroid cancer;	chr14:36111976	chr14:36061026~36067190:-
THCA	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	9.64	3.33e-20	2.14e-17	0.48	0.41	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
THCA	cis	rs7712401	0.601	rs152039	ENSG00000263432.2	RN7SL689P	9.64	3.34e-20	2.14e-17	0.45	0.41	Mean platelet volume;	chr5:122884970	chr5:123022487~123022783:-
THCA	cis	rs780094	0.564	rs4665978	ENSG00000234072.1	AC074117.10	-9.64	3.34e-20	2.14e-17	-0.32	-0.41	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27425859	chr2:27356246~27367622:+
THCA	cis	rs10463554	1	rs6879788	ENSG00000175749.11	EIF3KP1	9.64	3.34e-20	2.14e-17	0.54	0.41	Parkinson's disease;	chr5:102978353	chr5:103032376~103033031:+
THCA	cis	rs9828933	0.701	rs7621544	ENSG00000280620.1	SCAANT1	9.64	3.34e-20	2.14e-17	0.63	0.41	Type 2 diabetes;	chr3:63943005	chr3:63911518~63911772:-
THCA	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	9.64	3.36e-20	2.15e-17	0.56	0.41	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
THCA	cis	rs10740039	0.842	rs10821819	ENSG00000254271.1	RP11-131N11.4	9.64	3.37e-20	2.16e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658857	chr10:60734342~60741828:+
THCA	cis	rs4819052	0.807	rs4819047	ENSG00000215447.6	BX322557.10	-9.64	3.38e-20	2.17e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45288052~45291738:+
THCA	cis	rs12468226	0.752	rs79058237	ENSG00000273456.1	RP11-686O6.2	9.64	3.38e-20	2.17e-17	0.51	0.41	Urate levels;	chr2:202140247	chr2:202374932~202375604:-
THCA	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-9.64	3.41e-20	2.19e-17	-0.67	-0.41	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
THCA	cis	rs7712401	0.601	rs30027	ENSG00000263432.2	RN7SL689P	9.64	3.42e-20	2.19e-17	0.46	0.41	Mean platelet volume;	chr5:122947695	chr5:123022487~123022783:-
THCA	cis	rs73219805	0.838	rs17055172	ENSG00000228451.3	SDAD1P1	-9.64	3.42e-20	2.19e-17	-0.51	-0.41	Schizophrenia;	chr8:26368096	chr8:26379259~26382953:-
THCA	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	9.64	3.43e-20	2.2e-17	0.43	0.41	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
THCA	cis	rs2980439	0.525	rs1850511	ENSG00000253893.2	FAM85B	-9.64	3.44e-20	2.2e-17	-0.51	-0.41	Neuroticism;	chr8:8312807	chr8:8167819~8226614:-
THCA	cis	rs950169	1	rs35297609	ENSG00000259728.4	LINC00933	9.64	3.44e-20	2.2e-17	0.56	0.41	Schizophrenia;	chr15:84104144	chr15:84570649~84580175:+
THCA	cis	rs7945705	0.818	rs1988708	ENSG00000254860.4	TMEM9B-AS1	9.64	3.44e-20	2.2e-17	0.44	0.41	Hemoglobin concentration;	chr11:8861346	chr11:8964675~8977527:+
THCA	cis	rs9322193	0.886	rs9322198	ENSG00000268592.3	RAET1E-AS1	9.64	3.45e-20	2.21e-17	0.55	0.41	Lung cancer;	chr6:149623772	chr6:149863494~149919507:+
THCA	cis	rs71403859	0.73	rs12922775	ENSG00000260886.1	TAT-AS1	9.64	3.45e-20	2.21e-17	0.72	0.41	Post bronchodilator FEV1;	chr16:71550451	chr16:71565789~71578187:+
THCA	cis	rs7712401	0.601	rs2910136	ENSG00000263432.2	RN7SL689P	-9.64	3.45e-20	2.21e-17	-0.45	-0.41	Mean platelet volume;	chr5:122918322	chr5:123022487~123022783:-
THCA	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	9.64	3.47e-20	2.22e-17	0.51	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
THCA	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-9.64	3.47e-20	2.22e-17	-0.35	-0.41	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
THCA	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	9.64	3.47e-20	2.22e-17	0.49	0.41	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
THCA	cis	rs6452524	0.836	rs11949301	ENSG00000249664.1	CTD-2227C6.2	-9.64	3.48e-20	2.23e-17	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83209334	chr5:83012285~83013109:-
THCA	cis	rs2581828	0.58	rs6799837	ENSG00000242142.1	SERBP1P3	-9.64	3.48e-20	2.23e-17	-0.51	-0.41	Crohn's disease;	chr3:53133838	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.58	rs57514626	ENSG00000242142.1	SERBP1P3	-9.64	3.48e-20	2.23e-17	-0.51	-0.41	Crohn's disease;	chr3:53135286	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.58	rs61296683	ENSG00000242142.1	SERBP1P3	-9.64	3.48e-20	2.23e-17	-0.51	-0.41	Crohn's disease;	chr3:53135307	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.58	rs9867590	ENSG00000242142.1	SERBP1P3	-9.64	3.48e-20	2.23e-17	-0.51	-0.41	Crohn's disease;	chr3:53135635	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.58	rs9834111	ENSG00000242142.1	SERBP1P3	-9.64	3.48e-20	2.23e-17	-0.51	-0.41	Crohn's disease;	chr3:53136028	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.58	rs9817467	ENSG00000242142.1	SERBP1P3	-9.64	3.48e-20	2.23e-17	-0.51	-0.41	Crohn's disease;	chr3:53136609	chr3:53064283~53065091:-
THCA	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-9.64	3.48e-20	2.23e-17	-0.56	-0.41	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
THCA	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-9.64	3.48e-20	2.23e-17	-0.35	-0.41	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
THCA	cis	rs71403859	0.667	rs12149264	ENSG00000260886.1	TAT-AS1	9.64	3.52e-20	2.25e-17	0.72	0.41	Post bronchodilator FEV1;	chr16:71687018	chr16:71565789~71578187:+
THCA	cis	rs2599510	0.84	rs466146	ENSG00000276334.1	AL133243.1	9.64	3.52e-20	2.25e-17	0.43	0.41	Interleukin-18 levels;	chr2:32314167	chr2:32521927~32523547:+
THCA	cis	rs2581828	0.58	rs9872260	ENSG00000242142.1	SERBP1P3	-9.64	3.53e-20	2.26e-17	-0.51	-0.41	Crohn's disease;	chr3:53136158	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.923	rs9688517	ENSG00000268592.3	RAET1E-AS1	9.64	3.54e-20	2.26e-17	0.55	0.41	Lung cancer;	chr6:149740655	chr6:149863494~149919507:+
THCA	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	9.64	3.55e-20	2.27e-17	0.45	0.41	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
THCA	cis	rs10411161	1	rs8108477	ENSG00000269483.1	AC006272.1	9.64	3.55e-20	2.27e-17	0.57	0.41	Breast cancer;	chr19:51861649	chr19:51839924~51843324:-
THCA	cis	rs950169	0.922	rs11631096	ENSG00000259728.4	LINC00933	9.64	3.56e-20	2.27e-17	0.55	0.41	Schizophrenia;	chr15:84557698	chr15:84570649~84580175:+
THCA	cis	rs9532669	0.963	rs1056824	ENSG00000239827.7	SUGT1P3	-9.64	3.56e-20	2.28e-17	-0.43	-0.41	Cervical cancer;	chr13:40932748	chr13:40908159~40921774:-
THCA	cis	rs4660456	0.504	rs2253835	ENSG00000237899.1	RP4-739H11.3	9.64	3.57e-20	2.28e-17	0.56	0.41	Platelet count;	chr1:40635900	chr1:40669089~40687588:-
THCA	cis	rs597539	0.616	rs631001	ENSG00000250508.1	RP11-757G1.6	-9.64	3.57e-20	2.28e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68875506	chr11:68870664~68874542:+
THCA	cis	rs7712401	0.601	rs246268	ENSG00000263432.2	RN7SL689P	9.64	3.57e-20	2.28e-17	0.45	0.41	Mean platelet volume;	chr5:122920647	chr5:123022487~123022783:-
THCA	cis	rs944289	0.708	rs2899845	ENSG00000257826.1	RP11-116N8.4	-9.64	3.58e-20	2.29e-17	-0.42	-0.41	Thyroid cancer;	chr14:36116632	chr14:36061026~36067190:-
THCA	cis	rs6750795	0.87	rs6754952	ENSG00000181798.2	LINC00471	9.64	3.59e-20	2.29e-17	0.47	0.41	Height;	chr2:231516534	chr2:231508426~231514339:-
THCA	cis	rs7712401	0.601	rs30028	ENSG00000263432.2	RN7SL689P	9.63	3.61e-20	2.3e-17	0.45	0.41	Mean platelet volume;	chr5:122947574	chr5:123022487~123022783:-
THCA	cis	rs2274273	1	rs7160110	ENSG00000258413.1	RP11-665C16.6	-9.63	3.63e-20	2.32e-17	-0.53	-0.41	Protein biomarker;	chr14:55127917	chr14:55262767~55272075:-
THCA	cis	rs9640161	0.789	rs1464751	ENSG00000261305.1	RP4-584D14.7	9.63	3.63e-20	2.32e-17	0.49	0.41	Blood protein levels;Circulating chemerin levels;	chr7:150324193	chr7:150341771~150342607:+
THCA	cis	rs2274273	0.624	rs66464079	ENSG00000258413.1	RP11-665C16.6	-9.63	3.65e-20	2.33e-17	-0.56	-0.41	Protein biomarker;	chr14:55299446	chr14:55262767~55272075:-
THCA	cis	rs2836950	0.545	rs2297256	ENSG00000255568.3	BRWD1-AS2	-9.63	3.66e-20	2.34e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39186495	chr21:39313935~39314962:+
THCA	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-9.63	3.67e-20	2.34e-17	-0.5	-0.41	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
THCA	cis	rs2836950	0.545	rs2836959	ENSG00000255568.3	BRWD1-AS2	-9.63	3.67e-20	2.35e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39251742	chr21:39313935~39314962:+
THCA	cis	rs597539	0.58	rs7935851	ENSG00000250508.1	RP11-757G1.6	-9.63	3.68e-20	2.35e-17	-0.49	-0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68963653	chr11:68870664~68874542:+
THCA	cis	rs9890032	0.934	rs7225461	ENSG00000266490.1	CTD-2349P21.9	9.63	3.69e-20	2.36e-17	0.39	0.41	Hip circumference adjusted for BMI;	chr17:30932881	chr17:30792372~30792833:+
THCA	cis	rs3743772	0.5	rs35346613	ENSG00000279722.1	RP11-44F14.6	9.63	3.7e-20	2.36e-17	0.54	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53408246	chr16:53487607~53489943:-
THCA	cis	rs3743772	0.5	rs62048485	ENSG00000279722.1	RP11-44F14.6	9.63	3.7e-20	2.36e-17	0.54	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53414065	chr16:53487607~53489943:-
THCA	cis	rs9659323	0.632	rs10923743	ENSG00000231365.4	RP11-418J17.1	-9.63	3.7e-20	2.36e-17	-0.39	-0.41	Body mass index;	chr1:119070009	chr1:119140396~119275973:+
THCA	cis	rs1009647	0.656	rs10147254	ENSG00000258413.1	RP11-665C16.6	-9.63	3.7e-20	2.36e-17	-0.55	-0.41	Testicular germ cell tumor;	chr14:55383597	chr14:55262767~55272075:-
THCA	cis	rs12468226	0.938	rs10166594	ENSG00000273456.1	RP11-686O6.2	9.63	3.71e-20	2.37e-17	0.47	0.41	Urate levels;	chr2:202250262	chr2:202374932~202375604:-
THCA	cis	rs67311347	0.544	rs9821440	ENSG00000223797.4	ENTPD3-AS1	9.63	3.71e-20	2.37e-17	0.32	0.41	Renal cell carcinoma;	chr3:40300856	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.544	rs9864601	ENSG00000223797.4	ENTPD3-AS1	9.63	3.71e-20	2.37e-17	0.32	0.41	Renal cell carcinoma;	chr3:40303827	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.544	rs9868700	ENSG00000223797.4	ENTPD3-AS1	9.63	3.71e-20	2.37e-17	0.32	0.41	Renal cell carcinoma;	chr3:40303917	chr3:40313802~40453329:-
THCA	cis	rs494459	0.536	rs7103067	ENSG00000255239.1	AP002954.6	9.63	3.74e-20	2.39e-17	0.5	0.41	Height;	chr11:118852670	chr11:118688039~118690600:-
THCA	cis	rs1858037	0.836	rs1396209	ENSG00000281920.1	RP11-418H16.1	9.63	3.75e-20	2.39e-17	0.54	0.41	Rheumatoid arthritis;	chr2:65374100	chr2:65623272~65628424:+
THCA	cis	rs9322193	0.923	rs10782318	ENSG00000268592.3	RAET1E-AS1	9.63	3.76e-20	2.4e-17	0.56	0.41	Lung cancer;	chr6:149754137	chr6:149863494~149919507:+
THCA	cis	rs1858037	0.867	rs1039765	ENSG00000281920.1	RP11-418H16.1	-9.63	3.76e-20	2.4e-17	-0.53	-0.41	Rheumatoid arthritis;	chr2:65387228	chr2:65623272~65628424:+
THCA	cis	rs916888	0.821	rs415430	ENSG00000232300.1	FAM215B	-9.63	3.76e-20	2.4e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46558830~46562795:-
THCA	cis	rs916888	0.779	rs430685	ENSG00000232300.1	FAM215B	-9.63	3.76e-20	2.4e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46558830~46562795:-
THCA	cis	rs4819052	0.851	rs28616694	ENSG00000215447.6	BX322557.10	-9.63	3.76e-20	2.4e-17	-0.34	-0.41	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.923	rs35830138	ENSG00000268592.3	RAET1E-AS1	9.63	3.76e-20	2.4e-17	0.55	0.41	Lung cancer;	chr6:149668635	chr6:149863494~149919507:+
THCA	cis	rs7208859	0.524	rs8069400	ENSG00000266490.1	CTD-2349P21.9	9.63	3.77e-20	2.4e-17	0.58	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748949	chr17:30792372~30792833:+
THCA	cis	rs7712401	0.601	rs30045	ENSG00000263432.2	RN7SL689P	9.63	3.78e-20	2.41e-17	0.45	0.41	Mean platelet volume;	chr5:122935924	chr5:123022487~123022783:-
THCA	cis	rs10740039	0.961	rs2083696	ENSG00000254271.1	RP11-131N11.4	9.63	3.78e-20	2.41e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60656430	chr10:60734342~60741828:+
THCA	cis	rs10740039	1	rs10821818	ENSG00000254271.1	RP11-131N11.4	9.63	3.78e-20	2.41e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657178	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs6479722	ENSG00000254271.1	RP11-131N11.4	9.63	3.78e-20	2.41e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657923	chr10:60734342~60741828:+
THCA	cis	rs10740039	1	rs6479723	ENSG00000254271.1	RP11-131N11.4	9.63	3.78e-20	2.41e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658127	chr10:60734342~60741828:+
THCA	cis	rs10740039	1	rs10761545	ENSG00000254271.1	RP11-131N11.4	9.63	3.78e-20	2.41e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658811	chr10:60734342~60741828:+
THCA	cis	rs67311347	0.544	rs1454492	ENSG00000223797.4	ENTPD3-AS1	9.63	3.8e-20	2.42e-17	0.33	0.41	Renal cell carcinoma;	chr3:40311393	chr3:40313802~40453329:-
THCA	cis	rs597539	0.552	rs10896384	ENSG00000250508.1	RP11-757G1.6	9.63	3.82e-20	2.44e-17	0.48	0.41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68952542	chr11:68870664~68874542:+
THCA	cis	rs950169	0.922	rs11635505	ENSG00000259728.4	LINC00933	-9.63	3.82e-20	2.44e-17	-0.55	-0.41	Schizophrenia;	chr15:84553803	chr15:84570649~84580175:+
THCA	cis	rs71403859	0.614	rs12935422	ENSG00000260886.1	TAT-AS1	9.63	3.84e-20	2.45e-17	0.72	0.41	Post bronchodilator FEV1;	chr16:71630322	chr16:71565789~71578187:+
THCA	cis	rs2033711	0.87	rs7259841	ENSG00000268912.1	CTD-2619J13.17	-9.63	3.85e-20	2.45e-17	-0.32	-0.41	Uric acid clearance;	chr19:58439756	chr19:58428632~58431148:-
THCA	cis	rs62103177	0.564	rs2115996	ENSG00000261126.6	RP11-795F19.1	9.63	3.87e-20	2.47e-17	0.45	0.41	Opioid sensitivity;	chr18:79941007	chr18:80046900~80095482:+
THCA	cis	rs9828933	0.882	rs3816156	ENSG00000280620.1	SCAANT1	9.63	3.87e-20	2.47e-17	0.65	0.41	Type 2 diabetes;	chr3:64014036	chr3:63911518~63911772:-
THCA	cis	rs1789	0.706	rs8180240	ENSG00000273133.1	RP11-799M12.2	-9.63	3.87e-20	2.47e-17	-0.56	-0.41	Blood protein levels;	chr4:15699952	chr4:15563698~15564253:-
THCA	cis	rs2839186	0.585	rs2839154	ENSG00000239415.1	AP001469.9	-9.63	3.88e-20	2.47e-17	-0.43	-0.41	Testicular germ cell tumor;	chr21:46217846	chr21:46251549~46254133:-
THCA	cis	rs1075265	0.87	rs6724389	ENSG00000233266.1	HMGB1P31	9.63	3.9e-20	2.48e-17	0.53	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54051334~54051760:+
THCA	cis	rs2274273	0.624	rs7147247	ENSG00000258413.1	RP11-665C16.6	-9.63	3.9e-20	2.48e-17	-0.56	-0.41	Protein biomarker;	chr14:55310995	chr14:55262767~55272075:-
THCA	cis	rs10740039	0.768	rs10761549	ENSG00000254271.1	RP11-131N11.4	9.62	3.9e-20	2.49e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60701902	chr10:60734342~60741828:+
THCA	cis	rs9322193	0.923	rs4870529	ENSG00000268592.3	RAET1E-AS1	9.62	3.91e-20	2.49e-17	0.54	0.41	Lung cancer;	chr6:149716436	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9767309	ENSG00000268592.3	RAET1E-AS1	9.62	3.91e-20	2.49e-17	0.54	0.41	Lung cancer;	chr6:149716807	chr6:149863494~149919507:+
THCA	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-9.62	3.92e-20	2.5e-17	-0.59	-0.41	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
THCA	cis	rs780096	0.546	rs2293572	ENSG00000234072.1	AC074117.10	9.62	3.92e-20	2.5e-17	0.32	0.41	Total body bone mineral density;	chr2:27505910	chr2:27356246~27367622:+
THCA	cis	rs7712401	0.601	rs30039	ENSG00000263432.2	RN7SL689P	-9.62	3.94e-20	2.51e-17	-0.46	-0.41	Mean platelet volume;	chr5:122941484	chr5:123022487~123022783:-
THCA	cis	rs950169	1	rs62026530	ENSG00000259728.4	LINC00933	9.62	3.97e-20	2.53e-17	0.55	0.41	Schizophrenia;	chr15:84107088	chr15:84570649~84580175:+
THCA	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-9.62	3.97e-20	2.53e-17	-0.52	-0.41	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
THCA	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	9.62	3.98e-20	2.54e-17	0.59	0.41	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
THCA	cis	rs10463554	0.853	rs246907	ENSG00000175749.11	EIF3KP1	9.62	4.01e-20	2.55e-17	0.55	0.41	Parkinson's disease;	chr5:103230577	chr5:103032376~103033031:+
THCA	cis	rs11676348	0.703	rs6737563	ENSG00000261338.2	RP11-378A13.1	-9.62	4.02e-20	2.56e-17	-0.42	-0.41	Ulcerative colitis;	chr2:218080951	chr2:218255319~218257366:+
THCA	cis	rs10740039	0.883	rs34168977	ENSG00000254271.1	RP11-131N11.4	9.62	4.02e-20	2.56e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632916	chr10:60734342~60741828:+
THCA	cis	rs7712401	0.601	rs404442	ENSG00000263432.2	RN7SL689P	-9.62	4.02e-20	2.56e-17	-0.46	-0.41	Mean platelet volume;	chr5:123009236	chr5:123022487~123022783:-
THCA	cis	rs944289	0.74	rs2780302	ENSG00000257826.1	RP11-116N8.4	-9.62	4.04e-20	2.57e-17	-0.41	-0.41	Thyroid cancer;	chr14:36079456	chr14:36061026~36067190:-
THCA	cis	rs1799949	1	rs915945	ENSG00000267681.1	CTD-3199J23.6	-9.62	4.04e-20	2.57e-17	-0.48	-0.41	Menopause (age at onset);	chr17:43027847	chr17:43144956~43145255:+
THCA	cis	rs6046396	1	rs2145552	ENSG00000275142.1	RP5-999L4.2	-9.62	4.05e-20	2.58e-17	-0.58	-0.41	Bipolar disorder and schizophrenia;	chr20:19881604	chr20:19871891~19872284:+
THCA	cis	rs9318086	0.935	rs9553083	ENSG00000205861.10	C1QTNF9B-AS1	9.62	4.06e-20	2.58e-17	0.45	0.41	Myopia (pathological);	chr13:23867386	chr13:23888889~23897263:+
THCA	cis	rs6452524	0.804	rs2048215	ENSG00000249664.1	CTD-2227C6.2	-9.62	4.07e-20	2.59e-17	-0.54	-0.41	Hypertension (SNP x SNP interaction);	chr5:83208589	chr5:83012285~83013109:-
THCA	cis	rs9532669	0.824	rs4941998	ENSG00000239827.7	SUGT1P3	-9.62	4.09e-20	2.6e-17	-0.46	-0.41	Cervical cancer;	chr13:40859901	chr13:40908159~40921774:-
THCA	cis	rs11051970	0.592	rs58236386	ENSG00000274964.1	RP11-817I4.1	-9.62	4.11e-20	2.62e-17	-0.51	-0.41	Response to tocilizumab in rheumatoid arthritis;	chr12:32320143	chr12:32339368~32340724:+
THCA	cis	rs7208859	0.623	rs59447372	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8079891	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73267858	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs56095789	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11656844	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11652533	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11652631	ENSG00000266490.1	CTD-2349P21.9	9.62	4.12e-20	2.62e-17	0.55	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30792372~30792833:+
THCA	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	9.62	4.12e-20	2.62e-17	0.47	0.41	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
THCA	cis	rs673078	0.66	rs12229607	ENSG00000275409.1	RP11-131L12.4	-9.62	4.13e-20	2.63e-17	-0.45	-0.41	Glucose homeostasis traits;	chr12:118338333	chr12:118430147~118430699:+
THCA	cis	rs916888	0.738	rs199515	ENSG00000232300.1	FAM215B	-9.62	4.14e-20	2.63e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46558830~46562795:-
THCA	cis	rs71403859	0.502	rs17345863	ENSG00000260886.1	TAT-AS1	9.62	4.15e-20	2.63e-17	0.72	0.41	Post bronchodilator FEV1;	chr16:71489358	chr16:71565789~71578187:+
THCA	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-9.62	4.17e-20	2.65e-17	-0.35	-0.41	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
THCA	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-9.62	4.17e-20	2.65e-17	-0.35	-0.41	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
THCA	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-9.62	4.18e-20	2.65e-17	-0.43	-0.41	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
THCA	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-9.62	4.18e-20	2.65e-17	-0.5	-0.41	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-9.62	4.18e-20	2.65e-17	-0.5	-0.41	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
THCA	cis	rs7712401	0.601	rs30072	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122956525	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30069	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122957331	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30067	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122957973	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs187405	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122959300	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs40818	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122959378	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs30062	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122960681	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30060	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122961005	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.525	rs2910150	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122961050	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30059	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122961814	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30058	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122962008	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.623	rs30057	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122962423	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.584	rs39820	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122964226	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30055	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122965384	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs39819	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122965981	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30054	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122966304	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs30053	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122967948	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs30052	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122969314	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30049	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122970402	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246321	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122972604	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246320	ENSG00000263432.2	RN7SL689P	9.62	4.19e-20	2.66e-17	0.45	0.41	Mean platelet volume;	chr5:122972886	chr5:123022487~123022783:-
THCA	cis	rs180730	0.5	rs6810734	ENSG00000251609.2	SETP12	9.62	4.19e-20	2.66e-17	0.56	0.41	Fasting plasma glucose;	chr4:120935625	chr4:120895494~120897083:-
THCA	cis	rs180730	0.519	rs6848268	ENSG00000251609.2	SETP12	9.62	4.19e-20	2.66e-17	0.56	0.41	Fasting plasma glucose;	chr4:120936802	chr4:120895494~120897083:-
THCA	cis	rs67311347	0.544	rs2278927	ENSG00000223797.4	ENTPD3-AS1	9.62	4.19e-20	2.66e-17	0.32	0.41	Renal cell carcinoma;	chr3:40308956	chr3:40313802~40453329:-
THCA	cis	rs10740039	1	rs10761543	ENSG00000254271.1	RP11-131N11.4	9.62	4.23e-20	2.68e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655633	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10761544	ENSG00000254271.1	RP11-131N11.4	9.62	4.23e-20	2.68e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655647	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.804	rs7900848	ENSG00000254271.1	RP11-131N11.4	9.62	4.23e-20	2.68e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655893	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.671	rs7913549	ENSG00000254271.1	RP11-131N11.4	9.62	4.23e-20	2.68e-17	0.5	0.41	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658474	chr10:60734342~60741828:+
THCA	cis	rs12554020	0.892	rs3815563	ENSG00000227603.1	RP11-165J3.6	9.61	4.24e-20	2.69e-17	0.53	0.41	Schizophrenia;	chr9:93450864	chr9:93435332~93437121:-
THCA	cis	rs12554020	1	rs7853605	ENSG00000227603.1	RP11-165J3.6	9.61	4.24e-20	2.69e-17	0.53	0.41	Schizophrenia;	chr9:93451247	chr9:93435332~93437121:-
THCA	cis	rs9487094	0.67	rs12197838	ENSG00000260273.1	RP11-425D10.10	9.61	4.25e-20	2.69e-17	0.47	0.41	Height;	chr6:109672088	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs6911700	ENSG00000260273.1	RP11-425D10.10	9.61	4.25e-20	2.69e-17	0.47	0.41	Height;	chr6:109676091	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.626	rs12201444	ENSG00000260273.1	RP11-425D10.10	9.61	4.26e-20	2.7e-17	0.48	0.41	Height;	chr6:109738751	chr6:109382795~109383666:+
THCA	cis	rs67311347	0.503	rs11719968	ENSG00000223797.4	ENTPD3-AS1	9.61	4.27e-20	2.71e-17	0.34	0.41	Renal cell carcinoma;	chr3:40200109	chr3:40313802~40453329:-
THCA	cis	rs17684571	0.751	rs34866877	ENSG00000231441.1	RP11-472M19.2	9.61	4.28e-20	2.72e-17	0.54	0.41	Schizophrenia;	chr6:56829507	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs35407078	ENSG00000231441.1	RP11-472M19.2	9.61	4.28e-20	2.72e-17	0.54	0.41	Schizophrenia;	chr6:56830216	chr6:56844002~56864078:+
THCA	cis	rs2836950	0.527	rs2836958	ENSG00000255568.3	BRWD1-AS2	-9.61	4.29e-20	2.72e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39251600	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.565	rs7278297	ENSG00000255568.3	BRWD1-AS2	-9.61	4.29e-20	2.72e-17	-0.33	-0.41	Menarche (age at onset);	chr21:39253826	chr21:39313935~39314962:+
THCA	cis	rs2274273	0.6	rs10131730	ENSG00000258413.1	RP11-665C16.6	-9.61	4.33e-20	2.74e-17	-0.56	-0.41	Protein biomarker;	chr14:55373374	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs12050123	ENSG00000258413.1	RP11-665C16.6	-9.61	4.33e-20	2.74e-17	-0.56	-0.41	Protein biomarker;	chr14:55373668	chr14:55262767~55272075:-
THCA	cis	rs12554020	0.786	rs78271342	ENSG00000227603.1	RP11-165J3.6	9.61	4.34e-20	2.75e-17	0.71	0.41	Schizophrenia;	chr9:93468959	chr9:93435332~93437121:-
THCA	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-9.61	4.34e-20	2.75e-17	-0.53	-0.41	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
THCA	cis	rs1858037	0.765	rs67404371	ENSG00000281920.1	RP11-418H16.1	9.61	4.35e-20	2.76e-17	0.54	0.41	Rheumatoid arthritis;	chr2:65370137	chr2:65623272~65628424:+
THCA	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	9.61	4.36e-20	2.76e-17	0.57	0.41	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
THCA	cis	rs9926296	0.712	rs258332	ENSG00000260259.1	RP11-368I7.4	9.61	4.37e-20	2.77e-17	0.45	0.41	Vitiligo;	chr16:89661275	chr16:89682620~89686569:-
THCA	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-9.61	4.38e-20	2.78e-17	-0.4	-0.41	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
THCA	cis	rs1858037	0.867	rs2118305	ENSG00000281920.1	RP11-418H16.1	9.61	4.39e-20	2.78e-17	0.54	0.41	Rheumatoid arthritis;	chr2:65378086	chr2:65623272~65628424:+
THCA	cis	rs3743772	0.5	rs28804772	ENSG00000279722.1	RP11-44F14.6	9.61	4.39e-20	2.78e-17	0.54	0.41	Depressive symptoms (SSRI exposure interaction);	chr16:53411252	chr16:53487607~53489943:-
THCA	cis	rs7727544	0.904	rs58835386	ENSG00000233006.5	AC034220.3	9.61	4.39e-20	2.78e-17	0.32	0.41	Blood metabolite levels;	chr5:132264866	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.904	rs7736102	ENSG00000233006.5	AC034220.3	9.61	4.39e-20	2.78e-17	0.32	0.41	Blood metabolite levels;	chr5:132268564	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.904	rs6897575	ENSG00000233006.5	AC034220.3	9.61	4.39e-20	2.78e-17	0.32	0.41	Blood metabolite levels;	chr5:132268842	chr5:132311285~132369916:-
THCA	cis	rs1075265	0.901	rs1118618	ENSG00000233266.1	HMGB1P31	9.61	4.45e-20	2.82e-17	0.54	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54051334~54051760:+
THCA	cis	rs2274273	0.624	rs10143136	ENSG00000258413.1	RP11-665C16.6	-9.61	4.48e-20	2.84e-17	-0.56	-0.41	Protein biomarker;	chr14:55276810	chr14:55262767~55272075:-
THCA	cis	rs7727544	0.836	rs10463892	ENSG00000233006.5	AC034220.3	9.61	4.51e-20	2.85e-17	0.32	0.41	Blood metabolite levels;	chr5:132263012	chr5:132311285~132369916:-
THCA	cis	rs7727544	0.901	rs55633655	ENSG00000233006.5	AC034220.3	9.61	4.51e-20	2.85e-17	0.32	0.41	Blood metabolite levels;	chr5:132263063	chr5:132311285~132369916:-
THCA	cis	rs9318086	0.935	rs9652080	ENSG00000205861.10	C1QTNF9B-AS1	9.61	4.51e-20	2.85e-17	0.45	0.41	Myopia (pathological);	chr13:23861287	chr13:23888889~23897263:+
THCA	cis	rs7945705	0.935	rs2568061	ENSG00000254860.4	TMEM9B-AS1	9.61	4.51e-20	2.86e-17	0.44	0.41	Hemoglobin concentration;	chr11:8864713	chr11:8964675~8977527:+
THCA	cis	rs11676348	0.741	rs12694425	ENSG00000261338.2	RP11-378A13.1	9.61	4.52e-20	2.86e-17	0.41	0.41	Ulcerative colitis;	chr2:218077590	chr2:218255319~218257366:+
THCA	cis	rs17826219	0.706	rs57698184	ENSG00000266490.1	CTD-2349P21.9	9.61	4.52e-20	2.86e-17	0.55	0.41	Body mass index;	chr17:30737900	chr17:30792372~30792833:+
THCA	cis	rs7712401	0.562	rs30073	ENSG00000263432.2	RN7SL689P	9.61	4.54e-20	2.87e-17	0.45	0.41	Mean platelet volume;	chr5:122954814	chr5:123022487~123022783:-
THCA	cis	rs27432	0.608	rs2927619	ENSG00000248734.2	CTD-2260A17.1	9.61	4.55e-20	2.88e-17	0.43	0.41	Psoriasis vulgaris;	chr5:96847014	chr5:96784777~96785999:+
THCA	cis	rs2274273	1	rs8011834	ENSG00000258413.1	RP11-665C16.6	-9.61	4.55e-20	2.88e-17	-0.53	-0.41	Protein biomarker;	chr14:55159259	chr14:55262767~55272075:-
THCA	cis	rs1062177	0.502	rs10463321	ENSG00000213433.5	RPLP1P6	-9.61	4.55e-20	2.88e-17	-0.45	-0.41	Preschool internalizing problems;	chr5:151944344	chr5:151765859~151766378:-
THCA	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-9.61	4.56e-20	2.88e-17	-0.31	-0.41	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
THCA	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-9.61	4.56e-20	2.89e-17	-0.51	-0.41	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
THCA	cis	rs17684571	0.7	rs36037734	ENSG00000231441.1	RP11-472M19.2	9.61	4.56e-20	2.89e-17	0.55	0.41	Schizophrenia;	chr6:56801202	chr6:56844002~56864078:+
THCA	cis	rs950169	0.84	rs62019457	ENSG00000259728.4	LINC00933	9.61	4.57e-20	2.89e-17	0.55	0.41	Schizophrenia;	chr15:84558911	chr15:84570649~84580175:+
THCA	cis	rs950169	0.922	rs67804993	ENSG00000259728.4	LINC00933	9.61	4.57e-20	2.89e-17	0.55	0.41	Schizophrenia;	chr15:84560799	chr15:84570649~84580175:+
THCA	cis	rs71403859	0.502	rs17280181	ENSG00000260886.1	TAT-AS1	9.6	4.6e-20	2.91e-17	0.72	0.41	Post bronchodilator FEV1;	chr16:71489611	chr16:71565789~71578187:+
THCA	cis	rs9322193	0.923	rs10782310	ENSG00000268592.3	RAET1E-AS1	9.6	4.62e-20	2.92e-17	0.54	0.41	Lung cancer;	chr6:149622458	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs10782311	ENSG00000268592.3	RAET1E-AS1	9.6	4.62e-20	2.92e-17	0.54	0.41	Lung cancer;	chr6:149622592	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs10747275	ENSG00000268592.3	RAET1E-AS1	9.6	4.62e-20	2.92e-17	0.54	0.41	Lung cancer;	chr6:149622782	chr6:149863494~149919507:+
THCA	cis	rs10759883	0.563	rs624075	ENSG00000175611.10	LINC00476	9.6	4.62e-20	2.92e-17	0.45	0.41	Nicotine dependence;	chr9:95902665	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	9.6	4.62e-20	2.92e-17	0.45	0.41	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	9.6	4.62e-20	2.92e-17	0.45	0.41	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	9.6	4.62e-20	2.92e-17	0.45	0.41	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	9.6	4.62e-20	2.92e-17	0.45	0.41	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	9.6	4.62e-20	2.92e-17	0.45	0.41	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
THCA	cis	rs916888	0.821	rs199512	ENSG00000232300.1	FAM215B	-9.6	4.63e-20	2.93e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46558830~46562795:-
THCA	cis	rs916888	0.821	rs199509	ENSG00000232300.1	FAM215B	-9.6	4.63e-20	2.93e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46558830~46562795:-
THCA	cis	rs916888	0.821	rs199507	ENSG00000232300.1	FAM215B	-9.6	4.63e-20	2.93e-17	-0.65	-0.41	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46558830~46562795:-
THCA	cis	rs73219805	1	rs73219805	ENSG00000228451.3	SDAD1P1	-9.6	4.64e-20	2.93e-17	-0.51	-0.41	Schizophrenia;	chr8:26415252	chr8:26379259~26382953:-
THCA	cis	rs11159086	0.938	rs11623040	ENSG00000259005.1	RP3-449M8.6	9.6	4.64e-20	2.93e-17	0.49	0.41	Advanced glycation end-product levels;	chr14:74496743	chr14:74474007~74474864:-
THCA	cis	rs9487094	0.67	rs12192268	ENSG00000260273.1	RP11-425D10.10	9.6	4.66e-20	2.95e-17	0.48	0.41	Height;	chr6:109690255	chr6:109382795~109383666:+
THCA	cis	rs1537424	0.513	rs944290	ENSG00000257826.1	RP11-116N8.4	-9.6	4.67e-20	2.95e-17	-0.47	-0.41	Thyroid hormone levels;	chr14:36095493	chr14:36061026~36067190:-
THCA	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-9.6	4.67e-20	2.95e-17	-0.5	-0.4	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-9.6	4.68e-20	2.96e-17	-0.48	-0.4	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
THCA	cis	rs1799949	0.93	rs66499067	ENSG00000267681.1	CTD-3199J23.6	-9.6	4.7e-20	2.97e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43096467	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.809	rs9479808	ENSG00000268592.3	RAET1E-AS1	9.6	4.7e-20	2.97e-17	0.55	0.4	Lung cancer;	chr6:149751328	chr6:149863494~149919507:+
THCA	cis	rs4819052	0.851	rs2255766	ENSG00000215447.6	BX322557.10	-9.6	4.74e-20	3e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45288052~45291738:+
THCA	cis	rs12468226	0.752	rs77319662	ENSG00000273456.1	RP11-686O6.2	9.6	4.77e-20	3.01e-17	0.51	0.4	Urate levels;	chr2:202126928	chr2:202374932~202375604:-
THCA	cis	rs10740039	1	rs10761541	ENSG00000254271.1	RP11-131N11.4	9.6	4.81e-20	3.04e-17	0.47	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655383	chr10:60734342~60741828:+
THCA	cis	rs8062405	0.573	rs7140	ENSG00000251417.2	RP11-1348G14.4	9.6	4.83e-20	3.05e-17	0.41	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28984436	chr16:28802743~28817828:+
THCA	cis	rs7208859	0.573	rs79505916	ENSG00000266490.1	CTD-2349P21.9	9.6	4.87e-20	3.07e-17	0.55	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30792372~30792833:+
THCA	cis	rs875971	0.577	rs35072105	ENSG00000237310.1	GS1-124K5.4	-9.6	4.88e-20	3.08e-17	-0.29	-0.4	Aortic root size;	chr7:66144830	chr7:66493706~66495474:+
THCA	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	9.6	4.89e-20	3.09e-17	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
THCA	cis	rs180730	0.519	rs13132472	ENSG00000251609.2	SETP12	9.6	4.91e-20	3.1e-17	0.56	0.4	Fasting plasma glucose;	chr4:120954156	chr4:120895494~120897083:-
THCA	cis	rs9532669	0.89	rs4941999	ENSG00000176268.5	CYCSP34	9.6	4.92e-20	3.1e-17	0.46	0.4	Cervical cancer;	chr13:40859926	chr13:40863599~40863902:-
THCA	cis	rs7712401	0.601	rs246322	ENSG00000263432.2	RN7SL689P	-9.6	4.94e-20	3.11e-17	-0.46	-0.4	Mean platelet volume;	chr5:122971574	chr5:123022487~123022783:-
THCA	cis	rs4819052	1	rs4819052	ENSG00000215447.6	BX322557.10	-9.6	4.94e-20	3.11e-17	-0.36	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45288052~45291738:+
THCA	cis	rs853679	0.517	rs16893666	ENSG00000226314.6	ZNF192P1	9.6	4.94e-20	3.12e-17	0.54	0.4	Depression;	chr6:28086929	chr6:28161781~28169594:+
THCA	cis	rs67311347	0.544	rs9814779	ENSG00000223797.4	ENTPD3-AS1	9.6	4.94e-20	3.12e-17	0.32	0.4	Renal cell carcinoma;	chr3:40298940	chr3:40313802~40453329:-
THCA	cis	rs1799949	1	rs8176133	ENSG00000267681.1	CTD-3199J23.6	-9.6	4.96e-20	3.13e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43105441	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs16940	ENSG00000267681.1	CTD-3199J23.6	-9.59	4.98e-20	3.14e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43093220	chr17:43144956~43145255:+
THCA	cis	rs453301	0.682	rs2929308	ENSG00000253893.2	FAM85B	9.59	4.99e-20	3.15e-17	0.51	0.4	Joint mobility (Beighton score);	chr8:9226611	chr8:8167819~8226614:-
THCA	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-9.59	5.02e-20	3.16e-17	-0.6	-0.4	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
THCA	cis	rs1426063	0.614	rs76512224	ENSG00000260265.1	RP11-44F21.5	9.59	5.03e-20	3.17e-17	0.88	0.4	QT interval;	chr4:75144808	chr4:75081702~75084717:-
THCA	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	9.59	5.04e-20	3.18e-17	0.43	0.4	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
THCA	cis	rs7712401	0.584	rs30037	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122942295	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30035	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122942850	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246306	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122943523	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs2927639	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122943971	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246274	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122945108	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246273	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122945280	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30026	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122948873	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30022	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122950021	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.546	rs30021	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122950199	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246328	ENSG00000263432.2	RN7SL689P	9.59	5.07e-20	3.19e-17	0.45	0.4	Mean platelet volume;	chr5:122951933	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs28892	ENSG00000263432.2	RN7SL689P	-9.59	5.07e-20	3.19e-17	-0.45	-0.4	Mean platelet volume;	chr5:122948131	chr5:123022487~123022783:-
THCA	cis	rs1858037	0.867	rs876933	ENSG00000281920.1	RP11-418H16.1	9.59	5.08e-20	3.2e-17	0.53	0.4	Rheumatoid arthritis;	chr2:65382303	chr2:65623272~65628424:+
THCA	cis	rs62158211	0.955	rs1823125	ENSG00000272563.1	RP11-480C16.1	9.59	5.1e-20	3.21e-17	0.53	0.4	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113332835	chr2:113432600~113436042:+
THCA	cis	rs1799949	0.794	rs116409325	ENSG00000267681.1	CTD-3199J23.6	-9.59	5.11e-20	3.22e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43368092	chr17:43144956~43145255:+
THCA	cis	rs6844153	0.752	rs58968032	ENSG00000240005.4	RP11-293A21.1	-9.59	5.11e-20	3.22e-17	-0.5	-0.4	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884674	chr4:26859806~26860599:-
THCA	cis	rs957448	0.687	rs10104041	ENSG00000253704.1	RP11-267M23.4	9.59	5.12e-20	3.23e-17	0.41	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94559374	chr8:94553722~94569745:+
THCA	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-9.59	5.14e-20	3.24e-17	-0.29	-0.4	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
THCA	cis	rs7945705	0.935	rs2568062	ENSG00000254860.4	TMEM9B-AS1	9.59	5.15e-20	3.24e-17	0.44	0.4	Hemoglobin concentration;	chr11:8866398	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.935	rs2653567	ENSG00000254860.4	TMEM9B-AS1	9.59	5.15e-20	3.24e-17	0.44	0.4	Hemoglobin concentration;	chr11:8868083	chr11:8964675~8977527:+
THCA	cis	rs934734	0.532	rs7557569	ENSG00000234255.7	AC012370.3	-9.59	5.18e-20	3.26e-17	-0.45	-0.4	Rheumatoid arthritis;	chr2:65417427	chr2:65439888~65456571:-
THCA	cis	rs950169	0.656	rs748455	ENSG00000225151.9	GOLGA2P7	-9.59	5.19e-20	3.27e-17	-0.61	-0.4	Schizophrenia;	chr15:84606344	chr15:84199311~84230136:-
THCA	cis	rs2836950	0.502	rs2150411	ENSG00000255568.3	BRWD1-AS2	-9.59	5.2e-20	3.27e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39202626	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.545	rs4818001	ENSG00000255568.3	BRWD1-AS2	-9.59	5.2e-20	3.27e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39203162	chr21:39313935~39314962:+
THCA	cis	rs7191700	0.644	rs12149160	ENSG00000262636.1	CTD-3088G3.4	-9.59	5.2e-20	3.27e-17	-0.51	-0.4	Multiple sclerosis;	chr16:11345446	chr16:11380859~11381118:-
THCA	cis	rs2274273	0.624	rs8014540	ENSG00000258413.1	RP11-665C16.6	-9.59	5.24e-20	3.3e-17	-0.56	-0.4	Protein biomarker;	chr14:55374970	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs3783651	ENSG00000258413.1	RP11-665C16.6	-9.59	5.24e-20	3.3e-17	-0.56	-0.4	Protein biomarker;	chr14:55384255	chr14:55262767~55272075:-
THCA	cis	rs1799949	1	rs16941	ENSG00000267681.1	CTD-3199J23.6	-9.59	5.24e-20	3.3e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43092418	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs67060599	ENSG00000267681.1	CTD-3199J23.6	-9.59	5.24e-20	3.3e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43103085	chr17:43144956~43145255:+
THCA	cis	rs7221109	0.884	rs7226035	ENSG00000278834.1	RP11-458J1.1	9.59	5.26e-20	3.31e-17	0.43	0.4	Type 1 diabetes;	chr17:40626034	chr17:40648300~40649718:+
THCA	cis	rs9926296	0.712	rs258330	ENSG00000260259.1	RP11-368I7.4	9.59	5.27e-20	3.32e-17	0.45	0.4	Vitiligo;	chr16:89663166	chr16:89682620~89686569:-
THCA	cis	rs9322193	0.923	rs1934534	ENSG00000268592.3	RAET1E-AS1	9.59	5.28e-20	3.32e-17	0.54	0.4	Lung cancer;	chr6:149711896	chr6:149863494~149919507:+
THCA	cis	rs853679	0.517	rs9380056	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Depression;	chr6:28136698	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380057	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Depression;	chr6:28136856	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs1947862	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Depression;	chr6:28137418	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs6941992	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Depression;	chr6:28138363	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.516	rs4713142	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Parkinson's disease;	chr6:28138569	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs4713143	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Depression;	chr6:28138981	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs4713144	ENSG00000226314.6	ZNF192P1	-9.59	5.3e-20	3.33e-17	-0.54	-0.4	Depression;	chr6:28139012	chr6:28161781~28169594:+
THCA	cis	rs2836950	0.565	rs7276046	ENSG00000255568.3	BRWD1-AS2	-9.59	5.32e-20	3.35e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39209367	chr21:39313935~39314962:+
THCA	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-9.59	5.32e-20	3.35e-17	-0.35	-0.4	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
THCA	cis	rs9532669	0.963	rs3736953	ENSG00000239827.7	SUGT1P3	-9.59	5.37e-20	3.38e-17	-0.44	-0.4	Cervical cancer;	chr13:40951450	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7322399	ENSG00000239827.7	SUGT1P3	-9.59	5.37e-20	3.38e-17	-0.44	-0.4	Cervical cancer;	chr13:40952511	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs7322097	ENSG00000239827.7	SUGT1P3	-9.59	5.37e-20	3.38e-17	-0.44	-0.4	Cervical cancer;	chr13:40952513	chr13:40908159~40921774:-
THCA	cis	rs11676348	0.873	rs10210012	ENSG00000261338.2	RP11-378A13.1	-9.58	5.44e-20	3.42e-17	-0.42	-0.4	Ulcerative colitis;	chr2:218148611	chr2:218255319~218257366:+
THCA	cis	rs10759883	0.627	rs816673	ENSG00000175611.10	LINC00476	-9.58	5.44e-20	3.42e-17	-0.45	-0.4	Nicotine dependence;	chr9:95811134	chr9:95759231~95875977:-
THCA	cis	rs9532669	0.963	rs7989303	ENSG00000239827.7	SUGT1P3	-9.58	5.45e-20	3.43e-17	-0.44	-0.4	Cervical cancer;	chr13:40950087	chr13:40908159~40921774:-
THCA	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	9.58	5.47e-20	3.44e-17	0.47	0.4	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
THCA	cis	rs860295	0.812	rs10908481	ENSG00000225855.5	RUSC1-AS1	9.58	5.51e-20	3.47e-17	0.28	0.4	Body mass index;	chr1:155743859	chr1:155316863~155324176:-
THCA	cis	rs944289	0.624	rs55775461	ENSG00000257826.1	RP11-116N8.4	-9.58	5.51e-20	3.47e-17	-0.41	-0.4	Thyroid cancer;	chr14:36108166	chr14:36061026~36067190:-
THCA	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-9.58	5.52e-20	3.47e-17	-0.48	-0.4	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000224205.1	AP000351.4	-9.58	5.52e-20	3.47e-17	-0.47	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23987320~23991421:-
THCA	cis	rs9487094	0.626	rs2273752	ENSG00000260273.1	RP11-425D10.10	9.58	5.52e-20	3.47e-17	0.48	0.4	Height;	chr6:109738307	chr6:109382795~109383666:+
THCA	cis	rs9532669	0.926	rs11147831	ENSG00000176268.5	CYCSP34	9.58	5.57e-20	3.5e-17	0.45	0.4	Cervical cancer;	chr13:40978593	chr13:40863599~40863902:-
THCA	cis	rs1426063	0.614	rs79750906	ENSG00000260265.1	RP11-44F21.5	9.58	5.6e-20	3.52e-17	0.88	0.4	QT interval;	chr4:75139193	chr4:75081702~75084717:-
THCA	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-9.58	5.61e-20	3.53e-17	-0.28	-0.4	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
THCA	cis	rs7945705	0.902	rs2568059	ENSG00000254860.4	TMEM9B-AS1	9.58	5.62e-20	3.53e-17	0.44	0.4	Hemoglobin concentration;	chr11:8862614	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.875	rs2653616	ENSG00000254860.4	TMEM9B-AS1	9.58	5.62e-20	3.53e-17	0.44	0.4	Hemoglobin concentration;	chr11:8864345	chr11:8964675~8977527:+
THCA	cis	rs67311347	0.544	rs4974047	ENSG00000223797.4	ENTPD3-AS1	9.58	5.63e-20	3.54e-17	0.32	0.4	Renal cell carcinoma;	chr3:40298162	chr3:40313802~40453329:-
THCA	cis	rs10971721	0.643	rs10971699	ENSG00000260947.1	RP11-384P7.7	9.58	5.63e-20	3.54e-17	1.11	0.4	Body mass index;	chr9:33777186	chr9:33697459~33700986:+
THCA	cis	rs860295	0.812	rs2297775	ENSG00000225855.5	RUSC1-AS1	-9.58	5.65e-20	3.55e-17	-0.28	-0.4	Body mass index;	chr1:155765221	chr1:155316863~155324176:-
THCA	cis	rs2274273	0.624	rs7151581	ENSG00000258413.1	RP11-665C16.6	9.58	5.69e-20	3.57e-17	0.56	0.4	Protein biomarker;	chr14:55321727	chr14:55262767~55272075:-
THCA	cis	rs1823874	1	rs1823874	ENSG00000182397.13	DNM1P46	-9.58	5.7e-20	3.58e-17	-0.45	-0.4	IgG glycosylation;	chr15:99817230	chr15:99790156~99806927:-
THCA	cis	rs1799949	1	rs4793197	ENSG00000267681.1	CTD-3199J23.6	-9.58	5.73e-20	3.6e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43079885	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1060915	ENSG00000267681.1	CTD-3199J23.6	-9.58	5.73e-20	3.6e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43082453	chr17:43144956~43145255:+
THCA	cis	rs4819052	0.807	rs1075788	ENSG00000215447.6	BX322557.10	-9.58	5.75e-20	3.61e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45288052~45291738:+
THCA	cis	rs1426063	0.614	rs76087197	ENSG00000260265.1	RP11-44F21.5	9.58	5.75e-20	3.61e-17	0.88	0.4	QT interval;	chr4:75134108	chr4:75081702~75084717:-
THCA	cis	rs9322193	0.886	rs9485408	ENSG00000268592.3	RAET1E-AS1	9.58	5.76e-20	3.62e-17	0.54	0.4	Lung cancer;	chr6:149618888	chr6:149863494~149919507:+
THCA	cis	rs7712401	0.601	rs30029	ENSG00000263432.2	RN7SL689P	-9.58	5.78e-20	3.62e-17	-0.45	-0.4	Mean platelet volume;	chr5:122947475	chr5:123022487~123022783:-
THCA	cis	rs17608059	0.611	rs2108591	ENSG00000141028.6	CDRT15P1	-9.58	5.8e-20	3.64e-17	-0.47	-0.4	Temperament;	chr17:14019308	chr17:14024514~14025488:+
THCA	cis	rs17826219	0.706	rs28469200	ENSG00000266490.1	CTD-2349P21.9	9.58	5.8e-20	3.64e-17	0.54	0.4	Body mass index;	chr17:30806554	chr17:30792372~30792833:+
THCA	cis	rs8062405	0.573	rs7187575	ENSG00000259982.1	CDC37P1	-9.58	5.83e-20	3.66e-17	-0.52	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28700294~28701540:-
THCA	cis	rs853679	0.517	rs4713145	ENSG00000226314.6	ZNF192P1	-9.58	5.85e-20	3.67e-17	-0.54	-0.4	Depression;	chr6:28139049	chr6:28161781~28169594:+
THCA	cis	rs10411161	1	rs3764540	ENSG00000269483.1	AC006272.1	9.58	5.85e-20	3.67e-17	0.59	0.4	Breast cancer;	chr19:51877428	chr19:51839924~51843324:-
THCA	cis	rs17826219	0.706	rs8075357	ENSG00000266490.1	CTD-2349P21.9	9.57	5.87e-20	3.68e-17	0.55	0.4	Body mass index;	chr17:30730179	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.706	rs61643715	ENSG00000266490.1	CTD-2349P21.9	9.57	5.87e-20	3.68e-17	0.55	0.4	Body mass index;	chr17:30730744	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.636	rs8080829	ENSG00000266490.1	CTD-2349P21.9	9.57	5.87e-20	3.68e-17	0.55	0.4	Body mass index;	chr17:30731712	chr17:30792372~30792833:+
THCA	cis	rs2836950	0.501	rs11088470	ENSG00000255568.3	BRWD1-AS2	-9.57	5.89e-20	3.69e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39317236	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.501	rs2836983	ENSG00000255568.3	BRWD1-AS2	-9.57	5.89e-20	3.69e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39317410	chr21:39313935~39314962:+
THCA	cis	rs9487094	0.626	rs11153213	ENSG00000260273.1	RP11-425D10.10	9.57	5.9e-20	3.7e-17	0.48	0.4	Height;	chr6:109693890	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.67	rs12201356	ENSG00000260273.1	RP11-425D10.10	9.57	5.9e-20	3.7e-17	0.48	0.4	Height;	chr6:109694672	chr6:109382795~109383666:+
THCA	cis	rs950169	0.96	rs35159785	ENSG00000259728.4	LINC00933	9.57	5.91e-20	3.7e-17	0.57	0.4	Schizophrenia;	chr15:84135262	chr15:84570649~84580175:+
THCA	cis	rs12554020	0.792	rs11975	ENSG00000227603.1	RP11-165J3.6	9.57	5.91e-20	3.71e-17	0.55	0.4	Schizophrenia;	chr9:93565409	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs7870210	ENSG00000227603.1	RP11-165J3.6	9.57	5.91e-20	3.71e-17	0.55	0.4	Schizophrenia;	chr9:93569534	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs7860098	ENSG00000227603.1	RP11-165J3.6	9.57	5.91e-20	3.71e-17	0.55	0.4	Schizophrenia;	chr9:93569562	chr9:93435332~93437121:-
THCA	cis	rs9322193	0.923	rs4354168	ENSG00000268592.3	RAET1E-AS1	9.57	5.94e-20	3.72e-17	0.54	0.4	Lung cancer;	chr6:149696642	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs4455682	ENSG00000268592.3	RAET1E-AS1	9.57	5.94e-20	3.72e-17	0.54	0.4	Lung cancer;	chr6:149700161	chr6:149863494~149919507:+
THCA	cis	rs944289	0.774	rs7147401	ENSG00000257826.1	RP11-116N8.4	-9.57	5.95e-20	3.73e-17	-0.42	-0.4	Thyroid cancer;	chr14:36089461	chr14:36061026~36067190:-
THCA	cis	rs944289	0.774	rs34081947	ENSG00000257826.1	RP11-116N8.4	-9.57	5.95e-20	3.73e-17	-0.42	-0.4	Thyroid cancer;	chr14:36090325	chr14:36061026~36067190:-
THCA	cis	rs7712401	0.601	rs246285	ENSG00000263432.2	RN7SL689P	-9.57	5.99e-20	3.75e-17	-0.44	-0.4	Mean platelet volume;	chr5:122909273	chr5:123022487~123022783:-
THCA	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-9.57	6e-20	3.76e-17	-0.82	-0.4	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.884	rs10872646	ENSG00000268592.3	RAET1E-AS1	9.57	6.01e-20	3.76e-17	0.54	0.4	Lung cancer;	chr6:149746539	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs12528279	ENSG00000268592.3	RAET1E-AS1	9.57	6.01e-20	3.76e-17	0.54	0.4	Lung cancer;	chr6:149750892	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9322209	ENSG00000268592.3	RAET1E-AS1	9.57	6.01e-20	3.77e-17	0.54	0.4	Lung cancer;	chr6:149691226	chr6:149863494~149919507:+
THCA	cis	rs2581828	0.58	rs9845021	ENSG00000242142.1	SERBP1P3	-9.57	6.03e-20	3.77e-17	-0.51	-0.4	Crohn's disease;	chr3:53138096	chr3:53064283~53065091:-
THCA	cis	rs67311347	0.577	rs2371129	ENSG00000223797.4	ENTPD3-AS1	-9.57	6.04e-20	3.78e-17	-0.33	-0.4	Renal cell carcinoma;	chr3:40206902	chr3:40313802~40453329:-
THCA	cis	rs7712401	0.54	rs27617	ENSG00000263432.2	RN7SL689P	9.57	6.05e-20	3.79e-17	0.46	0.4	Mean platelet volume;	chr5:122900839	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs431878	ENSG00000263432.2	RN7SL689P	-9.57	6.06e-20	3.8e-17	-0.45	-0.4	Mean platelet volume;	chr5:122926096	chr5:123022487~123022783:-
THCA	cis	rs1799949	1	rs34942571	ENSG00000267681.1	CTD-3199J23.6	-9.57	6.06e-20	3.8e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43121362	chr17:43144956~43145255:+
THCA	cis	rs7712401	0.607	rs246270	ENSG00000263432.2	RN7SL689P	9.57	6.08e-20	3.81e-17	0.45	0.4	Mean platelet volume;	chr5:122922954	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs377316	ENSG00000263432.2	RN7SL689P	9.57	6.08e-20	3.81e-17	0.45	0.4	Mean platelet volume;	chr5:122924180	chr5:123022487~123022783:-
THCA	cis	rs597539	0.652	rs559032	ENSG00000250508.1	RP11-757G1.6	-9.57	6.11e-20	3.82e-17	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68943379	chr11:68870664~68874542:+
THCA	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	9.57	6.12e-20	3.83e-17	0.43	0.4	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
THCA	cis	rs7712401	0.562	rs246267	ENSG00000263432.2	RN7SL689P	9.57	6.15e-20	3.85e-17	0.45	0.4	Mean platelet volume;	chr5:122920409	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246269	ENSG00000263432.2	RN7SL689P	9.57	6.15e-20	3.85e-17	0.45	0.4	Mean platelet volume;	chr5:122921046	chr5:123022487~123022783:-
THCA	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	9.57	6.18e-20	3.87e-17	0.47	0.4	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
THCA	cis	rs9640161	0.742	rs11983355	ENSG00000261305.1	RP4-584D14.7	9.57	6.18e-20	3.87e-17	0.49	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150319608	chr7:150341771~150342607:+
THCA	cis	rs2274273	0.624	rs10129505	ENSG00000258413.1	RP11-665C16.6	-9.57	6.22e-20	3.89e-17	-0.56	-0.4	Protein biomarker;	chr14:55309657	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs68138420	ENSG00000258413.1	RP11-665C16.6	-9.57	6.22e-20	3.89e-17	-0.56	-0.4	Protein biomarker;	chr14:55311249	chr14:55262767~55272075:-
THCA	cis	rs71403859	0.502	rs8051974	ENSG00000260886.1	TAT-AS1	9.57	6.22e-20	3.89e-17	0.68	0.4	Post bronchodilator FEV1;	chr16:71454868	chr16:71565789~71578187:+
THCA	cis	rs7712401	0.54	rs416763	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122981546	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35339188	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122981990	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs36099390	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122982024	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35157167	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122982506	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs396941	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122982570	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs439739	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122982726	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs371604	ENSG00000263432.2	RN7SL689P	-9.57	6.25e-20	3.91e-17	-0.45	-0.4	Mean platelet volume;	chr5:122982737	chr5:123022487~123022783:-
THCA	cis	rs2836950	0.565	rs2150414	ENSG00000255568.3	BRWD1-AS2	-9.57	6.26e-20	3.91e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39243062	chr21:39313935~39314962:+
THCA	cis	rs934734	0.532	rs1437466	ENSG00000234255.7	AC012370.3	-9.57	6.28e-20	3.93e-17	-0.44	-0.4	Rheumatoid arthritis;	chr2:65437216	chr2:65439888~65456571:-
THCA	cis	rs7712401	0.601	rs386602	ENSG00000263432.2	RN7SL689P	-9.57	6.28e-20	3.93e-17	-0.45	-0.4	Mean platelet volume;	chr5:122986262	chr5:123022487~123022783:-
THCA	cis	rs957448	0.698	rs116348949	ENSG00000253704.1	RP11-267M23.4	9.57	6.29e-20	3.93e-17	0.41	0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94557488	chr8:94553722~94569745:+
THCA	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	9.57	6.31e-20	3.94e-17	0.47	0.4	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
THCA	cis	rs12550612	0.614	rs6983885	ENSG00000253616.4	RP11-875O11.3	9.57	6.33e-20	3.96e-17	0.57	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23087574	chr8:23071377~23074488:-
THCA	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-9.57	6.33e-20	3.96e-17	-0.56	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
THCA	cis	rs2274273	0.624	rs11848456	ENSG00000258413.1	RP11-665C16.6	-9.57	6.33e-20	3.96e-17	-0.56	-0.4	Protein biomarker;	chr14:55288674	chr14:55262767~55272075:-
THCA	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	9.57	6.35e-20	3.97e-17	0.61	0.4	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
THCA	cis	rs11676348	0.846	rs11677534	ENSG00000261338.2	RP11-378A13.1	-9.56	6.35e-20	3.97e-17	-0.4	-0.4	Ulcerative colitis;	chr2:218142337	chr2:218255319~218257366:+
THCA	cis	rs1799949	1	rs35956818	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.36e-20	3.97e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43345617	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.93	rs4584865	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.36e-20	3.97e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43347551	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs8176087	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.36e-20	3.97e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43118649	chr17:43144956~43145255:+
THCA	cis	rs853679	0.517	rs1904841	ENSG00000226314.6	ZNF192P1	-9.56	6.37e-20	3.98e-17	-0.55	-0.4	Depression;	chr6:28140307	chr6:28161781~28169594:+
THCA	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-9.56	6.38e-20	3.99e-17	-0.49	-0.4	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
THCA	cis	rs7712401	0.601	rs34707663	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122984768	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs385547	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122986138	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs454617	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122986232	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs442427	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122986570	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs436546	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122987095	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs397731	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122987264	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs35902490	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122987703	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs383638	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122988983	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs62377399	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122988984	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs415534	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122989606	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs442911	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122989856	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs425573	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122990313	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs364723	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122990769	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35847506	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122991413	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs390234	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122995828	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs4555798	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122996419	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs62377424	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122996627	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35699701	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122998061	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35256179	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122998560	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35858098	ENSG00000263432.2	RN7SL689P	-9.56	6.38e-20	3.99e-17	-0.45	-0.4	Mean platelet volume;	chr5:122998670	chr5:123022487~123022783:-
THCA	cis	rs10411161	1	rs10402988	ENSG00000269483.1	AC006272.1	9.56	6.39e-20	3.99e-17	0.56	0.4	Breast cancer;	chr19:51859851	chr19:51839924~51843324:-
THCA	cis	rs10411161	1	rs2867318	ENSG00000269483.1	AC006272.1	9.56	6.39e-20	3.99e-17	0.56	0.4	Breast cancer;	chr19:51860219	chr19:51839924~51843324:-
THCA	cis	rs10411161	1	rs6509581	ENSG00000269483.1	AC006272.1	9.56	6.39e-20	3.99e-17	0.56	0.4	Breast cancer;	chr19:51860629	chr19:51839924~51843324:-
THCA	cis	rs10411161	1	rs8109345	ENSG00000269483.1	AC006272.1	9.56	6.39e-20	3.99e-17	0.56	0.4	Breast cancer;	chr19:51861680	chr19:51839924~51843324:-
THCA	cis	rs10411161	1	rs8108583	ENSG00000269483.1	AC006272.1	9.56	6.39e-20	3.99e-17	0.56	0.4	Breast cancer;	chr19:51861724	chr19:51839924~51843324:-
THCA	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-9.56	6.41e-20	4e-17	-0.45	-0.4	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
THCA	cis	rs9659323	0.632	rs6658479	ENSG00000231365.4	RP11-418J17.1	-9.56	6.41e-20	4.01e-17	-0.39	-0.4	Body mass index;	chr1:119085233	chr1:119140396~119275973:+
THCA	cis	rs748404	0.518	rs2927085	ENSG00000205771.5	CATSPER2P1	-9.56	6.42e-20	4.01e-17	-0.43	-0.4	Lung cancer;	chr15:43697332	chr15:43726918~43747094:-
THCA	cis	rs4819052	0.684	rs914216	ENSG00000215447.6	BX322557.10	-9.56	6.44e-20	4.02e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.923	rs62441279	ENSG00000268592.3	RAET1E-AS1	9.56	6.49e-20	4.05e-17	0.54	0.4	Lung cancer;	chr6:149721194	chr6:149863494~149919507:+
THCA	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-9.56	6.5e-20	4.06e-17	-0.49	-0.4	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
THCA	cis	rs950169	0.922	rs11633534	ENSG00000259728.4	LINC00933	9.56	6.52e-20	4.07e-17	0.56	0.4	Schizophrenia;	chr15:84581411	chr15:84570649~84580175:+
THCA	cis	rs1799949	1	rs8176083	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.52e-20	4.07e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43123134	chr17:43144956~43145255:+
THCA	cis	rs853679	0.517	rs9380052	ENSG00000226314.6	ZNF192P1	-9.56	6.57e-20	4.1e-17	-0.54	-0.4	Depression;	chr6:28096845	chr6:28161781~28169594:+
THCA	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-9.56	6.6e-20	4.12e-17	-0.5	-0.4	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
THCA	cis	rs8062405	0.573	rs8045689	ENSG00000259982.1	CDC37P1	-9.56	6.61e-20	4.12e-17	-0.51	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28700294~28701540:-
THCA	cis	rs12554020	0.892	rs12341488	ENSG00000227603.1	RP11-165J3.6	9.56	6.62e-20	4.13e-17	0.55	0.4	Schizophrenia;	chr9:93568889	chr9:93435332~93437121:-
THCA	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	9.56	6.64e-20	4.14e-17	0.56	0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
THCA	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-9.56	6.64e-20	4.14e-17	-0.56	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
THCA	cis	rs7712401	0.601	rs1990890	ENSG00000263432.2	RN7SL689P	9.56	6.66e-20	4.15e-17	0.45	0.4	Mean platelet volume;	chr5:122847275	chr5:123022487~123022783:-
THCA	cis	rs1799949	1	rs2271574	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.69e-20	4.17e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43175631	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs33994002	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.69e-20	4.17e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43176801	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs33920795	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.69e-20	4.17e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43176993	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs33918839	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.69e-20	4.17e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43177155	chr17:43144956~43145255:+
THCA	cis	rs12468226	0.702	rs114634431	ENSG00000273456.1	RP11-686O6.2	9.56	6.72e-20	4.19e-17	0.52	0.4	Urate levels;	chr2:202142530	chr2:202374932~202375604:-
THCA	cis	rs11098499	0.739	rs4833612	ENSG00000245958.5	RP11-33B1.1	9.56	6.75e-20	4.2e-17	0.37	0.4	Corneal astigmatism;	chr4:119226441	chr4:119454791~119552025:+
THCA	cis	rs11098499	0.739	rs10013032	ENSG00000245958.5	RP11-33B1.1	9.56	6.75e-20	4.2e-17	0.37	0.4	Corneal astigmatism;	chr4:119228264	chr4:119454791~119552025:+
THCA	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-9.56	6.75e-20	4.21e-17	-0.5	-0.4	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
THCA	cis	rs6061231	1	rs11696991	ENSG00000273619.1	RP5-908M14.9	-9.56	6.76e-20	4.21e-17	-0.32	-0.4	Colorectal cancer;	chr20:62384638	chr20:62386303~62386970:-
THCA	cis	rs860295	0.812	rs3820594	ENSG00000225855.5	RUSC1-AS1	9.56	6.79e-20	4.23e-17	0.28	0.4	Body mass index;	chr1:155859720	chr1:155316863~155324176:-
THCA	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	9.56	6.8e-20	4.24e-17	0.45	0.4	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	9.56	6.8e-20	4.24e-17	0.45	0.4	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	9.56	6.8e-20	4.24e-17	0.45	0.4	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
THCA	cis	rs180730	0.519	rs2122511	ENSG00000251609.2	SETP12	9.56	6.8e-20	4.24e-17	0.56	0.4	Fasting plasma glucose;	chr4:120955639	chr4:120895494~120897083:-
THCA	cis	rs1799949	0.93	rs8176194	ENSG00000267681.1	CTD-3199J23.6	-9.56	6.81e-20	4.24e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43079204	chr17:43144956~43145255:+
THCA	cis	rs2836950	0.501	rs2836984	ENSG00000255568.3	BRWD1-AS2	-9.56	6.84e-20	4.26e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39329023	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.565	rs8130320	ENSG00000255568.3	BRWD1-AS2	-9.56	6.85e-20	4.26e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39208332	chr21:39313935~39314962:+
THCA	cis	rs10800713	0.607	rs6682828	ENSG00000260088.1	RP11-92G12.3	-9.56	6.85e-20	4.27e-17	-0.58	-0.4	Tandem gait;	chr1:200537968	chr1:200669507~200694250:+
THCA	cis	rs7712401	0.601	rs193539	ENSG00000263432.2	RN7SL689P	9.56	6.86e-20	4.27e-17	0.45	0.4	Mean platelet volume;	chr5:122921922	chr5:123022487~123022783:-
THCA	cis	rs7189233	0.55	rs4783811	ENSG00000279344.1	RP11-44F14.7	9.56	6.86e-20	4.27e-17	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53449464	chr16:53478957~53481550:-
THCA	cis	rs7712401	0.601	rs246275	ENSG00000263432.2	RN7SL689P	9.56	6.87e-20	4.28e-17	0.45	0.4	Mean platelet volume;	chr5:122895718	chr5:123022487~123022783:-
THCA	cis	rs73219805	0.838	rs7840859	ENSG00000228451.3	SDAD1P1	-9.56	6.88e-20	4.28e-17	-0.51	-0.4	Schizophrenia;	chr8:26377501	chr8:26379259~26382953:-
THCA	cis	rs1800795	0.652	rs7802307	ENSG00000179428.2	AC073072.5	-9.55	6.89e-20	4.29e-17	-0.52	-0.4	Cerebrospinal fluid clusterin levels in APOEe4- carriers;	chr7:22726814	chr7:22725395~22727620:-
THCA	cis	rs2274273	0.624	rs10132453	ENSG00000258413.1	RP11-665C16.6	-9.55	6.91e-20	4.3e-17	-0.56	-0.4	Protein biomarker;	chr14:55374133	chr14:55262767~55272075:-
THCA	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	9.55	6.94e-20	4.32e-17	0.49	0.4	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
THCA	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	9.55	6.94e-20	4.32e-17	0.45	0.4	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
THCA	cis	rs7712401	0.601	rs417268	ENSG00000263432.2	RN7SL689P	-9.55	6.96e-20	4.33e-17	-0.45	-0.4	Mean platelet volume;	chr5:123009317	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs398142	ENSG00000263432.2	RN7SL689P	-9.55	6.96e-20	4.33e-17	-0.45	-0.4	Mean platelet volume;	chr5:123009881	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs383262	ENSG00000263432.2	RN7SL689P	-9.55	6.96e-20	4.33e-17	-0.45	-0.4	Mean platelet volume;	chr5:123009989	chr5:123022487~123022783:-
THCA	cis	rs6750795	0.569	rs1667313	ENSG00000181798.2	LINC00471	-9.55	6.97e-20	4.34e-17	-0.45	-0.4	Height;	chr2:231543307	chr2:231508426~231514339:-
THCA	cis	rs4819052	0.851	rs2838833	ENSG00000215447.6	BX322557.10	-9.55	6.98e-20	4.34e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45288052~45291738:+
THCA	cis	rs1799949	0.827	rs74252763	ENSG00000267681.1	CTD-3199J23.6	-9.55	7.03e-20	4.37e-17	-0.48	-0.4	Menopause (age at onset);	chr17:43324652	chr17:43144956~43145255:+
THCA	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-9.55	7.05e-20	4.39e-17	-0.49	-0.4	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
THCA	cis	rs9828933	0.766	rs864975	ENSG00000280620.1	SCAANT1	-9.55	7.05e-20	4.39e-17	-0.72	-0.4	Type 2 diabetes;	chr3:63899939	chr3:63911518~63911772:-
THCA	cis	rs7712401	0.601	rs246265	ENSG00000263432.2	RN7SL689P	9.55	7.09e-20	4.41e-17	0.45	0.4	Mean platelet volume;	chr5:122919255	chr5:123022487~123022783:-
THCA	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	9.55	7.12e-20	4.43e-17	0.46	0.4	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
THCA	cis	rs1858037	0.867	rs953312	ENSG00000281920.1	RP11-418H16.1	9.55	7.12e-20	4.43e-17	0.54	0.4	Rheumatoid arthritis;	chr2:65340556	chr2:65623272~65628424:+
THCA	cis	rs1858037	0.867	rs9789444	ENSG00000281920.1	RP11-418H16.1	9.55	7.12e-20	4.43e-17	0.54	0.4	Rheumatoid arthritis;	chr2:65342093	chr2:65623272~65628424:+
THCA	cis	rs597539	0.652	rs627731	ENSG00000250508.1	RP11-757G1.6	-9.55	7.15e-20	4.45e-17	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68931195	chr11:68870664~68874542:+
THCA	cis	rs2836950	0.565	rs2836934	ENSG00000255568.3	BRWD1-AS2	-9.55	7.15e-20	4.45e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39192959	chr21:39313935~39314962:+
THCA	cis	rs9322193	0.607	rs6925151	ENSG00000268592.3	RAET1E-AS1	9.55	7.19e-20	4.47e-17	0.57	0.4	Lung cancer;	chr6:149889587	chr6:149863494~149919507:+
THCA	cis	rs11696845	0.787	rs6031771	ENSG00000276223.1	RP4-781B1.5	-9.55	7.19e-20	4.47e-17	-0.49	-0.4	Obesity-related traits;	chr20:44734949	chr20:44746642~44747201:+
THCA	cis	rs12554020	0.786	rs60076242	ENSG00000227603.1	RP11-165J3.6	9.55	7.2e-20	4.47e-17	0.55	0.4	Schizophrenia;	chr9:93571634	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.786	rs10429558	ENSG00000227603.1	RP11-165J3.6	9.55	7.2e-20	4.47e-17	0.55	0.4	Schizophrenia;	chr9:93574508	chr9:93435332~93437121:-
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000235689.1	AP000351.13	9.55	7.2e-20	4.48e-17	0.5	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:24006305~24008258:-
THCA	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	9.55	7.33e-20	4.55e-17	0.45	0.4	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	9.55	7.33e-20	4.55e-17	0.45	0.4	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	9.55	7.33e-20	4.55e-17	0.45	0.4	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
THCA	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-9.55	7.33e-20	4.56e-17	-0.67	-0.4	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
THCA	cis	rs1426063	0.614	rs74949513	ENSG00000260265.1	RP11-44F21.5	9.55	7.35e-20	4.57e-17	0.88	0.4	QT interval;	chr4:75124631	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.541	rs116664844	ENSG00000260265.1	RP11-44F21.5	9.55	7.35e-20	4.57e-17	0.88	0.4	QT interval;	chr4:75125677	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.541	rs114162294	ENSG00000260265.1	RP11-44F21.5	9.55	7.35e-20	4.57e-17	0.88	0.4	QT interval;	chr4:75125682	chr4:75081702~75084717:-
THCA	cis	rs4819052	0.851	rs2838839	ENSG00000215447.6	BX322557.10	9.55	7.36e-20	4.57e-17	0.33	0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45288052~45291738:+
THCA	cis	rs7712401	0.623	rs426877	ENSG00000263432.2	RN7SL689P	-9.55	7.37e-20	4.58e-17	-0.45	-0.4	Mean platelet volume;	chr5:122978940	chr5:123022487~123022783:-
THCA	cis	rs2836950	0.501	rs2056844	ENSG00000255568.3	BRWD1-AS2	-9.55	7.39e-20	4.59e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39298534	chr21:39313935~39314962:+
THCA	cis	rs193541	0.545	rs112390044	ENSG00000263432.2	RN7SL689P	-9.55	7.4e-20	4.6e-17	-0.46	-0.4	Glucose homeostasis traits;	chr5:122976307	chr5:123022487~123022783:-
THCA	cis	rs2274273	0.624	rs66551709	ENSG00000258413.1	RP11-665C16.6	-9.55	7.41e-20	4.6e-17	-0.56	-0.4	Protein biomarker;	chr14:55324304	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.6	rs10134317	ENSG00000258413.1	RP11-665C16.6	-9.55	7.41e-20	4.6e-17	-0.56	-0.4	Protein biomarker;	chr14:55326730	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs67795323	ENSG00000258413.1	RP11-665C16.6	-9.55	7.41e-20	4.6e-17	-0.56	-0.4	Protein biomarker;	chr14:55331115	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs8005450	ENSG00000258413.1	RP11-665C16.6	-9.55	7.41e-20	4.6e-17	-0.56	-0.4	Protein biomarker;	chr14:55332447	chr14:55262767~55272075:-
THCA	cis	rs7712401	0.601	rs173480	ENSG00000263432.2	RN7SL689P	9.55	7.42e-20	4.61e-17	0.45	0.4	Mean platelet volume;	chr5:122918436	chr5:123022487~123022783:-
THCA	cis	rs860295	0.812	rs4278368	ENSG00000225855.5	RUSC1-AS1	9.55	7.46e-20	4.63e-17	0.28	0.4	Body mass index;	chr1:155752766	chr1:155316863~155324176:-
THCA	cis	rs524281	0.692	rs2254388	ENSG00000255320.1	RP11-755F10.1	-9.54	7.52e-20	4.67e-17	-0.54	-0.4	Electroencephalogram traits;	chr11:66070128	chr11:66244840~66246239:-
THCA	cis	rs673078	0.66	rs73205551	ENSG00000275409.1	RP11-131L12.4	-9.54	7.57e-20	4.7e-17	-0.43	-0.4	Glucose homeostasis traits;	chr12:118330808	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.884	rs10782312	ENSG00000268592.3	RAET1E-AS1	9.54	7.58e-20	4.7e-17	0.54	0.4	Lung cancer;	chr6:149622669	chr6:149863494~149919507:+
THCA	cis	rs4819052	0.885	rs9980676	ENSG00000215447.6	BX322557.10	-9.54	7.59e-20	4.71e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838836	ENSG00000215447.6	BX322557.10	-9.54	7.59e-20	4.71e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45288052~45291738:+
THCA	cis	rs2274273	0.624	rs72717738	ENSG00000258413.1	RP11-665C16.6	-9.54	7.59e-20	4.71e-17	-0.56	-0.4	Protein biomarker;	chr14:55376043	chr14:55262767~55272075:-
THCA	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	9.54	7.63e-20	4.73e-17	0.45	0.4	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	9.54	7.63e-20	4.73e-17	0.45	0.4	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	9.54	7.63e-20	4.73e-17	0.45	0.4	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	9.54	7.63e-20	4.73e-17	0.45	0.4	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	9.54	7.63e-20	4.73e-17	0.45	0.4	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
THCA	cis	rs2274273	0.624	rs4580079	ENSG00000258413.1	RP11-665C16.6	-9.54	7.66e-20	4.75e-17	-0.56	-0.4	Protein biomarker;	chr14:55313648	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.6	rs35112084	ENSG00000258413.1	RP11-665C16.6	-9.54	7.66e-20	4.75e-17	-0.56	-0.4	Protein biomarker;	chr14:55314382	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs7157308	ENSG00000258413.1	RP11-665C16.6	-9.54	7.66e-20	4.75e-17	-0.56	-0.4	Protein biomarker;	chr14:55315325	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs1972221	ENSG00000258413.1	RP11-665C16.6	-9.54	7.66e-20	4.75e-17	-0.56	-0.4	Protein biomarker;	chr14:55318663	chr14:55262767~55272075:-
THCA	cis	rs4819052	0.851	rs2838840	ENSG00000215447.6	BX322557.10	-9.54	7.66e-20	4.75e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45288052~45291738:+
THCA	cis	rs853679	0.517	rs9380058	ENSG00000226314.6	ZNF192P1	-9.54	7.68e-20	4.76e-17	-0.54	-0.4	Depression;	chr6:28159666	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393898	ENSG00000226314.6	ZNF192P1	-9.54	7.68e-20	4.76e-17	-0.54	-0.4	Depression;	chr6:28162598	chr6:28161781~28169594:+
THCA	cis	rs860295	0.812	rs11264413	ENSG00000225855.5	RUSC1-AS1	9.54	7.69e-20	4.77e-17	0.28	0.4	Body mass index;	chr1:155818865	chr1:155316863~155324176:-
THCA	cis	rs8062405	0.755	rs4788074	ENSG00000251417.2	RP11-1348G14.4	9.54	7.7e-20	4.77e-17	0.41	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28802743~28817828:+
THCA	cis	rs7208859	0.573	rs7214313	ENSG00000266490.1	CTD-2349P21.9	9.54	7.7e-20	4.78e-17	0.54	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30792372~30792833:+
THCA	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	9.54	7.72e-20	4.79e-17	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
THCA	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	9.54	7.73e-20	4.79e-17	0.5	0.4	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
THCA	cis	rs528808	1	rs528808	ENSG00000279170.1	RP1-199J3.6	9.54	7.74e-20	4.8e-17	0.7	0.4	Age-related hearing impairment;	chr6:99656413	chr6:99587611~99589898:+
THCA	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-9.54	7.76e-20	4.81e-17	-0.42	-0.4	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-9.54	7.76e-20	4.81e-17	-0.42	-0.4	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-9.54	7.76e-20	4.81e-17	-0.42	-0.4	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
THCA	cis	rs9322193	0.962	rs9688750	ENSG00000268592.3	RAET1E-AS1	9.54	7.81e-20	4.84e-17	0.54	0.4	Lung cancer;	chr6:149657633	chr6:149863494~149919507:+
THCA	cis	rs3743772	0.5	rs11866060	ENSG00000279722.1	RP11-44F14.6	9.54	7.84e-20	4.86e-17	0.54	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53394937	chr16:53487607~53489943:-
THCA	cis	rs9322193	0.923	rs10872650	ENSG00000268592.3	RAET1E-AS1	9.54	7.85e-20	4.86e-17	0.54	0.4	Lung cancer;	chr6:149760959	chr6:149863494~149919507:+
THCA	cis	rs1799949	1	rs8074136	ENSG00000267681.1	CTD-3199J23.6	-9.54	7.87e-20	4.88e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43190296	chr17:43144956~43145255:+
THCA	cis	rs2033711	0.87	rs11084545	ENSG00000268912.1	CTD-2619J13.17	-9.54	7.88e-20	4.88e-17	-0.31	-0.4	Uric acid clearance;	chr19:58440326	chr19:58428632~58431148:-
THCA	cis	rs780096	0.527	rs11127044	ENSG00000234072.1	AC074117.10	-9.54	7.89e-20	4.89e-17	-0.32	-0.4	Total body bone mineral density;	chr2:27517537	chr2:27356246~27367622:+
THCA	cis	rs9926296	0.682	rs258328	ENSG00000260259.1	RP11-368I7.4	9.54	7.89e-20	4.89e-17	0.45	0.4	Vitiligo;	chr16:89663906	chr16:89682620~89686569:-
THCA	cis	rs62158211	0.955	rs7556815	ENSG00000272563.1	RP11-480C16.1	-9.54	7.9e-20	4.89e-17	-0.54	-0.4	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113328208	chr2:113432600~113436042:+
THCA	cis	rs2274273	0.624	rs7140628	ENSG00000258413.1	RP11-665C16.6	-9.54	7.91e-20	4.9e-17	-0.56	-0.4	Protein biomarker;	chr14:55293963	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs7159824	ENSG00000258413.1	RP11-665C16.6	-9.54	7.91e-20	4.9e-17	-0.56	-0.4	Protein biomarker;	chr14:55305818	chr14:55262767~55272075:-
THCA	cis	rs853679	0.517	rs1904840	ENSG00000226314.6	ZNF192P1	-9.54	7.91e-20	4.9e-17	-0.54	-0.4	Depression;	chr6:28140454	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368555	ENSG00000226314.6	ZNF192P1	-9.54	7.91e-20	4.9e-17	-0.54	-0.4	Depression;	chr6:28141189	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393893	ENSG00000226314.6	ZNF192P1	-9.54	7.91e-20	4.9e-17	-0.54	-0.4	Depression;	chr6:28141484	chr6:28161781~28169594:+
THCA	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-9.54	7.93e-20	4.91e-17	-0.56	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
THCA	cis	rs1185460	0.546	rs17075	ENSG00000271751.1	RP11-110I1.14	9.54	7.93e-20	4.91e-17	0.51	0.4	Coronary artery disease;	chr11:119088621	chr11:119065263~119065677:-
THCA	cis	rs853679	0.517	rs9468297	ENSG00000226314.6	ZNF192P1	-9.54	7.99e-20	4.94e-17	-0.54	-0.4	Depression;	chr6:28151096	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9295758	ENSG00000226314.6	ZNF192P1	-9.54	7.99e-20	4.94e-17	-0.54	-0.4	Depression;	chr6:28152885	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs17774663	ENSG00000226314.6	ZNF192P1	-9.54	7.99e-20	4.94e-17	-0.54	-0.4	Depression;	chr6:28153120	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9357065	ENSG00000226314.6	ZNF192P1	-9.54	7.99e-20	4.94e-17	-0.54	-0.4	Depression;	chr6:28161802	chr6:28161781~28169594:+
THCA	cis	rs3091242	0.933	rs28530483	ENSG00000261349.1	RP3-465N24.5	-9.54	8e-20	4.95e-17	-0.43	-0.4	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25266102~25267136:-
THCA	cis	rs853679	0.513	rs9468296	ENSG00000226314.6	ZNF192P1	-9.54	8e-20	4.95e-17	-0.54	-0.4	Depression;	chr6:28145952	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs4711164	ENSG00000226314.6	ZNF192P1	-9.54	8e-20	4.95e-17	-0.54	-0.4	Depression;	chr6:28147378	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs4711165	ENSG00000226314.6	ZNF192P1	-9.54	8e-20	4.95e-17	-0.54	-0.4	Depression;	chr6:28147406	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs4713148	ENSG00000226314.6	ZNF192P1	-9.54	8e-20	4.95e-17	-0.54	-0.4	Depression;	chr6:28148143	chr6:28161781~28169594:+
THCA	cis	rs9322193	0.923	rs10782316	ENSG00000268592.3	RAET1E-AS1	9.54	8e-20	4.95e-17	0.54	0.4	Lung cancer;	chr6:149752755	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs11155677	ENSG00000268592.3	RAET1E-AS1	9.54	8e-20	4.95e-17	0.54	0.4	Lung cancer;	chr6:149756953	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs9480009	ENSG00000268592.3	RAET1E-AS1	9.54	8e-20	4.95e-17	0.54	0.4	Lung cancer;	chr6:149758502	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9480031	ENSG00000268592.3	RAET1E-AS1	9.54	8e-20	4.95e-17	0.54	0.4	Lung cancer;	chr6:149758875	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs10872649	ENSG00000268592.3	RAET1E-AS1	9.54	8e-20	4.95e-17	0.54	0.4	Lung cancer;	chr6:149759454	chr6:149863494~149919507:+
THCA	cis	rs780096	0.546	rs715325	ENSG00000234072.1	AC074117.10	-9.54	8.01e-20	4.95e-17	-0.31	-0.4	Total body bone mineral density;	chr2:27502705	chr2:27356246~27367622:+
THCA	cis	rs780096	0.546	rs8179225	ENSG00000234072.1	AC074117.10	-9.54	8.03e-20	4.97e-17	-0.32	-0.4	Total body bone mineral density;	chr2:27514314	chr2:27356246~27367622:+
THCA	cis	rs9322193	0.962	rs4380763	ENSG00000268592.3	RAET1E-AS1	9.54	8.05e-20	4.98e-17	0.54	0.4	Lung cancer;	chr6:149678086	chr6:149863494~149919507:+
THCA	cis	rs67311347	0.544	rs13098483	ENSG00000223797.4	ENTPD3-AS1	9.53	8.11e-20	5.02e-17	0.32	0.4	Renal cell carcinoma;	chr3:40301252	chr3:40313802~40453329:-
THCA	cis	rs9322193	0.923	rs9505982	ENSG00000268592.3	RAET1E-AS1	9.53	8.12e-20	5.02e-17	0.54	0.4	Lung cancer;	chr6:149618465	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs62439836	ENSG00000268592.3	RAET1E-AS1	9.53	8.15e-20	5.04e-17	0.54	0.4	Lung cancer;	chr6:149669173	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs4869812	ENSG00000268592.3	RAET1E-AS1	9.53	8.15e-20	5.04e-17	0.54	0.4	Lung cancer;	chr6:149669447	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs4870267	ENSG00000268592.3	RAET1E-AS1	9.53	8.16e-20	5.05e-17	0.54	0.4	Lung cancer;	chr6:149671572	chr6:149863494~149919507:+
THCA	cis	rs950169	0.922	rs11638445	ENSG00000259728.4	LINC00933	9.53	8.17e-20	5.05e-17	0.55	0.4	Schizophrenia;	chr15:84594463	chr15:84570649~84580175:+
THCA	cis	rs3743772	0.5	rs4784308	ENSG00000279722.1	RP11-44F14.6	9.53	8.17e-20	5.05e-17	0.54	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53406387	chr16:53487607~53489943:-
THCA	cis	rs1799949	1	rs11657835	ENSG00000267681.1	CTD-3199J23.6	-9.53	8.19e-20	5.07e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43139936	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1135214	ENSG00000267681.1	CTD-3199J23.6	-9.53	8.19e-20	5.07e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43140306	chr17:43144956~43145255:+
THCA	cis	rs7569084	1	rs7583469	ENSG00000234255.7	AC012370.3	9.53	8.23e-20	5.09e-17	0.45	0.4	Sum eosinophil basophil counts;	chr2:65424222	chr2:65439888~65456571:-
THCA	cis	rs780094	0.544	rs780108	ENSG00000234072.1	AC074117.10	-9.53	8.24e-20	5.09e-17	-0.31	-0.4	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462090	chr2:27356246~27367622:+
THCA	cis	rs950169	1	rs1818950	ENSG00000259728.4	LINC00933	9.53	8.29e-20	5.12e-17	0.55	0.4	Schizophrenia;	chr15:84053769	chr15:84570649~84580175:+
THCA	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	9.53	8.33e-20	5.15e-17	0.49	0.4	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
THCA	cis	rs7615952	0.866	rs6438949	ENSG00000171084.14	FAM86JP	9.53	8.34e-20	5.15e-17	0.55	0.4	Blood pressure (smoking interaction);	chr3:125931221	chr3:125916620~125930024:+
THCA	cis	rs9322193	0.923	rs9767123	ENSG00000268592.3	RAET1E-AS1	9.53	8.38e-20	5.18e-17	0.54	0.4	Lung cancer;	chr6:149660323	chr6:149863494~149919507:+
THCA	cis	rs7727544	0.716	rs7701414	ENSG00000237714.1	P4HA2-AS1	9.53	8.47e-20	5.23e-17	0.53	0.4	Blood metabolite levels;	chr5:132250265	chr5:132184876~132192808:+
THCA	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-9.53	8.48e-20	5.24e-17	-0.48	-0.4	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
THCA	cis	rs9309711	0.506	rs9284794	ENSG00000225234.1	TRAPPC12-AS1	-9.53	8.5e-20	5.25e-17	-0.39	-0.4	Neurofibrillary tangles;	chr2:3488281	chr2:3481242~3482409:-
THCA	cis	rs7208859	0.524	rs73988172	ENSG00000266490.1	CTD-2349P21.9	9.53	8.51e-20	5.25e-17	0.54	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs8067035	ENSG00000266490.1	CTD-2349P21.9	9.53	8.51e-20	5.25e-17	0.54	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30792372~30792833:+
THCA	cis	rs860295	0.812	rs12024257	ENSG00000225855.5	RUSC1-AS1	9.53	8.52e-20	5.26e-17	0.28	0.4	Body mass index;	chr1:155810745	chr1:155316863~155324176:-
THCA	cis	rs860295	0.812	rs6657670	ENSG00000225855.5	RUSC1-AS1	9.53	8.52e-20	5.26e-17	0.28	0.4	Body mass index;	chr1:155818076	chr1:155316863~155324176:-
THCA	cis	rs780094	0.544	rs2303370	ENSG00000234072.1	AC074117.10	-9.53	8.53e-20	5.27e-17	-0.31	-0.4	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27428508	chr2:27356246~27367622:+
THCA	cis	rs4819052	0.851	rs9977178	ENSG00000215447.6	BX322557.10	-9.53	8.53e-20	5.27e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45288052~45291738:+
THCA	cis	rs10463554	0.889	rs246899	ENSG00000175749.11	EIF3KP1	9.53	8.54e-20	5.27e-17	0.54	0.4	Parkinson's disease;	chr5:103241438	chr5:103032376~103033031:+
THCA	cis	rs11159086	1	rs11159087	ENSG00000270000.1	RP3-449M8.9	9.53	8.55e-20	5.28e-17	0.43	0.4	Advanced glycation end-product levels;	chr14:74504671	chr14:74471930~74472360:-
THCA	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	9.53	8.59e-20	5.3e-17	0.45	0.4	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
THCA	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-9.53	8.62e-20	5.32e-17	-0.48	-0.4	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
THCA	cis	rs9532669	0.926	rs4941995	ENSG00000239827.7	SUGT1P3	-9.53	8.64e-20	5.33e-17	-0.45	-0.4	Cervical cancer;	chr13:40850117	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9315789	ENSG00000239827.7	SUGT1P3	-9.53	8.64e-20	5.33e-17	-0.45	-0.4	Cervical cancer;	chr13:40852898	chr13:40908159~40921774:-
THCA	cis	rs7712401	0.623	rs30032	ENSG00000263432.2	RN7SL689P	9.53	8.69e-20	5.36e-17	0.45	0.4	Mean platelet volume;	chr5:122902692	chr5:123022487~123022783:-
THCA	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-9.53	8.73e-20	5.39e-17	-0.5	-0.4	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
THCA	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-9.53	8.73e-20	5.39e-17	-0.5	-0.4	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
THCA	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	9.53	8.73e-20	5.39e-17	0.47	0.4	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
THCA	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	9.53	8.73e-20	5.39e-17	0.47	0.4	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
THCA	cis	rs67311347	0.605	rs1880762	ENSG00000223797.4	ENTPD3-AS1	9.53	8.74e-20	5.39e-17	0.33	0.4	Renal cell carcinoma;	chr3:40241724	chr3:40313802~40453329:-
THCA	cis	rs2274273	1	rs6573006	ENSG00000258413.1	RP11-665C16.6	-9.53	8.76e-20	5.41e-17	-0.53	-0.4	Protein biomarker;	chr14:55143714	chr14:55262767~55272075:-
THCA	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	9.53	8.77e-20	5.41e-17	0.47	0.4	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
THCA	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	9.52	8.82e-20	5.44e-17	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
THCA	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-9.52	8.84e-20	5.45e-17	-0.48	-0.4	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-9.52	8.84e-20	5.45e-17	-0.49	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
THCA	cis	rs66887589	0.777	rs4643791	ENSG00000245958.5	RP11-33B1.1	9.52	8.84e-20	5.46e-17	0.36	0.4	Diastolic blood pressure;	chr4:119344464	chr4:119454791~119552025:+
THCA	cis	rs2836950	0.501	rs13047518	ENSG00000255568.3	BRWD1-AS2	-9.52	8.86e-20	5.47e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39335381	chr21:39313935~39314962:+
THCA	cis	rs733592	0.929	rs4760678	ENSG00000240399.1	RP1-228P16.1	-9.52	8.87e-20	5.47e-17	-0.37	-0.4	Plateletcrit;	chr12:48067798	chr12:48054813~48055591:-
THCA	cis	rs4819052	0.851	rs914214	ENSG00000215447.6	BX322557.10	-9.52	8.89e-20	5.48e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45288052~45291738:+
THCA	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	9.52	8.94e-20	5.52e-17	0.39	0.4	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
THCA	cis	rs4819052	0.851	rs13050359	ENSG00000215447.6	BX322557.10	-9.52	8.96e-20	5.53e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4819049	ENSG00000215447.6	BX322557.10	-9.52	8.96e-20	5.53e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs13052344	ENSG00000215447.6	BX322557.10	-9.52	8.96e-20	5.53e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.808	rs11909411	ENSG00000215447.6	BX322557.10	-9.52	8.96e-20	5.53e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs28676615	ENSG00000215447.6	BX322557.10	-9.52	8.96e-20	5.53e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs28501512	ENSG00000215447.6	BX322557.10	-9.52	8.96e-20	5.53e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45288052~45291738:+
THCA	cis	rs9318086	0.753	rs9553094	ENSG00000205861.10	C1QTNF9B-AS1	9.52	8.96e-20	5.53e-17	0.46	0.4	Myopia (pathological);	chr13:23900474	chr13:23888889~23897263:+
THCA	cis	rs2274273	0.901	rs10140801	ENSG00000258413.1	RP11-665C16.6	-9.52	8.98e-20	5.54e-17	-0.49	-0.4	Protein biomarker;	chr14:55263686	chr14:55262767~55272075:-
THCA	cis	rs6546847	0.531	rs2567602	ENSG00000163016.8	ALMS1P	9.52	8.99e-20	5.54e-17	0.76	0.4	Urinary metabolites (H-NMR features);	chr2:73758409	chr2:73644919~73685576:+
THCA	cis	rs7191700	0.712	rs7187741	ENSG00000262703.1	RP11-485G7.6	-9.52	9.01e-20	5.55e-17	-0.45	-0.4	Multiple sclerosis;	chr16:11339246	chr16:11348143~11349321:-
THCA	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-9.52	9.01e-20	5.55e-17	-0.53	-0.4	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
THCA	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-9.52	9.01e-20	5.55e-17	-0.38	-0.4	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
THCA	cis	rs9322193	0.516	rs1999632	ENSG00000268592.3	RAET1E-AS1	9.52	9.02e-20	5.56e-17	0.59	0.4	Lung cancer;	chr6:149866737	chr6:149863494~149919507:+
THCA	cis	rs11051970	0.559	rs3748276	ENSG00000274964.1	RP11-817I4.1	-9.52	9.05e-20	5.58e-17	-0.51	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32328643	chr12:32339368~32340724:+
THCA	cis	rs6822297	0.542	rs35499018	ENSG00000240005.4	RP11-293A21.1	-9.52	9.06e-20	5.58e-17	-0.46	-0.4	Obesity-related traits;	chr4:27004489	chr4:26859806~26860599:-
THCA	cis	rs71403859	0.502	rs71403849	ENSG00000260886.1	TAT-AS1	9.52	9.06e-20	5.58e-17	0.68	0.4	Post bronchodilator FEV1;	chr16:71450462	chr16:71565789~71578187:+
THCA	cis	rs9487094	0.67	rs1998811	ENSG00000260273.1	RP11-425D10.10	9.52	9.08e-20	5.59e-17	0.47	0.4	Height;	chr6:109490935	chr6:109382795~109383666:+
THCA	cis	rs11098499	0.739	rs9884728	ENSG00000245958.5	RP11-33B1.1	9.52	9.09e-20	5.6e-17	0.37	0.4	Corneal astigmatism;	chr4:119205924	chr4:119454791~119552025:+
THCA	cis	rs4964805	0.865	rs3935416	ENSG00000257681.1	RP11-341G23.4	9.52	9.1e-20	5.61e-17	0.48	0.4	Attention deficit hyperactivity disorder;	chr12:103813177	chr12:103746315~103768858:-
THCA	cis	rs934734	0.532	rs10166100	ENSG00000234255.7	AC012370.3	-9.52	9.13e-20	5.62e-17	-0.45	-0.4	Rheumatoid arthritis;	chr2:65418616	chr2:65439888~65456571:-
THCA	cis	rs1799949	1	rs11653231	ENSG00000267681.1	CTD-3199J23.6	-9.52	9.14e-20	5.63e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43179443	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1399323	ENSG00000267681.1	CTD-3199J23.6	-9.52	9.14e-20	5.63e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43180313	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs35954893	ENSG00000267681.1	CTD-3199J23.6	-9.52	9.14e-20	5.63e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43181769	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.93	rs4445938	ENSG00000267681.1	CTD-3199J23.6	-9.52	9.14e-20	5.63e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43185883	chr17:43144956~43145255:+
THCA	cis	rs916888	0.821	rs199505	ENSG00000232300.1	FAM215B	-9.52	9.16e-20	5.64e-17	-0.64	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46558830~46562795:-
THCA	cis	rs916888	0.821	rs70602	ENSG00000232300.1	FAM215B	-9.52	9.16e-20	5.64e-17	-0.64	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46558830~46562795:-
THCA	cis	rs934734	0.532	rs2860773	ENSG00000234255.7	AC012370.3	-9.52	9.18e-20	5.65e-17	-0.44	-0.4	Rheumatoid arthritis;	chr2:65438507	chr2:65439888~65456571:-
THCA	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	9.52	9.19e-20	5.66e-17	0.49	0.4	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
THCA	cis	rs950169	1	rs79318564	ENSG00000259728.4	LINC00933	9.52	9.19e-20	5.66e-17	0.55	0.4	Schizophrenia;	chr15:84117398	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs1911155	ENSG00000259728.4	LINC00933	9.52	9.19e-20	5.66e-17	0.55	0.4	Schizophrenia;	chr15:84118883	chr15:84570649~84580175:+
THCA	cis	rs524281	0.731	rs6591201	ENSG00000255320.1	RP11-755F10.1	-9.52	9.2e-20	5.66e-17	-0.6	-0.4	Electroencephalogram traits;	chr11:66038499	chr11:66244840~66246239:-
THCA	cis	rs10463554	0.853	rs458598	ENSG00000175749.11	EIF3KP1	9.52	9.23e-20	5.69e-17	0.54	0.4	Parkinson's disease;	chr5:103233677	chr5:103032376~103033031:+
THCA	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	9.52	9.29e-20	5.72e-17	0.51	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	9.52	9.3e-20	5.72e-17	0.47	0.4	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
THCA	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-9.52	9.3e-20	5.73e-17	-0.55	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
THCA	cis	rs7945705	0.905	rs2568054	ENSG00000254860.4	TMEM9B-AS1	9.52	9.32e-20	5.74e-17	0.44	0.4	Hemoglobin concentration;	chr11:8854482	chr11:8964675~8977527:+
THCA	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	9.52	9.35e-20	5.75e-17	0.29	0.4	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
THCA	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	9.52	9.41e-20	5.79e-17	0.39	0.4	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
THCA	cis	rs2274273	0.564	rs3783649	ENSG00000258413.1	RP11-665C16.6	-9.52	9.41e-20	5.79e-17	-0.55	-0.4	Protein biomarker;	chr14:55367692	chr14:55262767~55272075:-
THCA	cis	rs1858037	0.836	rs17475335	ENSG00000281920.1	RP11-418H16.1	9.52	9.42e-20	5.8e-17	0.53	0.4	Rheumatoid arthritis;	chr2:65378646	chr2:65623272~65628424:+
THCA	cis	rs7712401	0.645	rs246316	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122930502	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246315	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122930743	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.623	rs30043	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122936598	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs185009	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122938072	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.541	rs42537	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122938993	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs185008	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122939039	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs30041	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122939658	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs42536	ENSG00000263432.2	RN7SL689P	9.52	9.42e-20	5.8e-17	0.45	0.4	Mean platelet volume;	chr5:122940728	chr5:123022487~123022783:-
THCA	cis	rs2274273	1	rs1009977	ENSG00000258413.1	RP11-665C16.6	-9.52	9.46e-20	5.82e-17	-0.53	-0.4	Protein biomarker;	chr14:55136284	chr14:55262767~55272075:-
THCA	cis	rs597539	0.652	rs496616	ENSG00000250508.1	RP11-757G1.6	-9.51	9.53e-20	5.86e-17	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68905332	chr11:68870664~68874542:+
THCA	cis	rs1799949	0.965	rs4793233	ENSG00000267681.1	CTD-3199J23.6	-9.51	9.55e-20	5.88e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43358069	chr17:43144956~43145255:+
THCA	cis	rs4819052	0.851	rs9974628	ENSG00000215447.6	BX322557.10	-9.51	9.61e-20	5.91e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs13047104	ENSG00000215447.6	BX322557.10	-9.51	9.61e-20	5.91e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.885	rs28576202	ENSG00000215447.6	BX322557.10	-9.51	9.61e-20	5.91e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs35871601	ENSG00000215447.6	BX322557.10	-9.51	9.61e-20	5.91e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs28622522	ENSG00000215447.6	BX322557.10	-9.51	9.61e-20	5.91e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45288052~45291738:+
THCA	cis	rs4591358	0.773	rs13002794	ENSG00000223466.1	AC064834.2	-9.51	9.64e-20	5.93e-17	-0.55	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195517175	chr2:195533035~195538681:+
THCA	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	9.51	9.69e-20	5.96e-17	0.5	0.4	Height;	chr11:118856460	chr11:118688039~118690600:-
THCA	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	9.51	9.69e-20	5.96e-17	0.5	0.4	Height;	chr11:118856623	chr11:118688039~118690600:-
THCA	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	9.51	9.69e-20	5.96e-17	0.5	0.4	Height;	chr11:118857611	chr11:118688039~118690600:-
THCA	cis	rs2274273	0.624	rs7152390	ENSG00000258413.1	RP11-665C16.6	-9.51	9.72e-20	5.97e-17	-0.55	-0.4	Protein biomarker;	chr14:55344983	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.588	rs9919923	ENSG00000258413.1	RP11-665C16.6	-9.51	9.72e-20	5.97e-17	-0.55	-0.4	Protein biomarker;	chr14:55347181	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.588	rs9919932	ENSG00000258413.1	RP11-665C16.6	-9.51	9.72e-20	5.97e-17	-0.55	-0.4	Protein biomarker;	chr14:55347362	chr14:55262767~55272075:-
THCA	cis	rs7712401	0.601	rs246303	ENSG00000263432.2	RN7SL689P	9.51	9.73e-20	5.98e-17	0.45	0.4	Mean platelet volume;	chr5:122916022	chr5:123022487~123022783:-
THCA	cis	rs2274273	0.624	rs10141396	ENSG00000258413.1	RP11-665C16.6	-9.51	9.83e-20	6.04e-17	-0.56	-0.4	Protein biomarker;	chr14:55350207	chr14:55262767~55272075:-
THCA	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	9.51	9.84e-20	6.05e-17	0.65	0.4	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
THCA	cis	rs7712401	0.601	rs154500	ENSG00000263432.2	RN7SL689P	9.51	9.85e-20	6.05e-17	0.45	0.4	Mean platelet volume;	chr5:122876296	chr5:123022487~123022783:-
THCA	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-9.51	9.86e-20	6.06e-17	-0.49	-0.4	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
THCA	cis	rs733592	0.965	rs1978161	ENSG00000240399.1	RP1-228P16.1	-9.51	9.89e-20	6.08e-17	-0.37	-0.4	Plateletcrit;	chr12:48073938	chr12:48054813~48055591:-
THCA	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	9.51	9.92e-20	6.1e-17	0.59	0.4	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
THCA	cis	rs12931792	0.782	rs13331817	ENSG00000183604.13	SMG1P5	9.51	9.93e-20	6.1e-17	0.43	0.4	Tonsillectomy;	chr16:30161306	chr16:30267553~30335374:-
THCA	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-9.51	9.96e-20	6.12e-17	-0.48	-0.4	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
THCA	cis	rs7712401	0.601	rs154496	ENSG00000263432.2	RN7SL689P	9.51	9.97e-20	6.13e-17	0.45	0.4	Mean platelet volume;	chr5:122886036	chr5:123022487~123022783:-
THCA	cis	rs853679	0.517	rs17711344	ENSG00000226314.6	ZNF192P1	9.51	9.98e-20	6.13e-17	0.54	0.4	Depression;	chr6:28109824	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9348794	ENSG00000226314.6	ZNF192P1	-9.51	1e-19	6.15e-17	-0.54	-0.4	Depression;	chr6:28149979	chr6:28161781~28169594:+
THCA	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	9.51	1e-19	6.16e-17	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
THCA	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	9.51	1e-19	6.16e-17	0.45	0.4	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
THCA	cis	rs7945705	0.935	rs2653593	ENSG00000254860.4	TMEM9B-AS1	9.51	1e-19	6.16e-17	0.44	0.4	Hemoglobin concentration;	chr11:8855770	chr11:8964675~8977527:+
THCA	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-9.51	1.01e-19	6.17e-17	-0.52	-0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
THCA	cis	rs4718428	0.705	rs13220977	ENSG00000232546.1	RP11-458F8.1	9.51	1.01e-19	6.2e-17	0.38	0.4	Corneal structure;	chr7:66872661	chr7:66848496~66858136:+
THCA	cis	rs17826219	0.706	rs2322197	ENSG00000266490.1	CTD-2349P21.9	9.51	1.01e-19	6.22e-17	0.54	0.4	Body mass index;	chr17:30778787	chr17:30792372~30792833:+
THCA	cis	rs4819052	0.84	rs914217	ENSG00000215447.6	BX322557.10	-9.51	1.01e-19	6.23e-17	-0.36	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45288052~45291738:+
THCA	cis	rs10740039	0.883	rs7476720	ENSG00000254271.1	RP11-131N11.4	9.51	1.01e-19	6.23e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650610	chr10:60734342~60741828:+
THCA	cis	rs7208859	0.623	rs60890550	ENSG00000266490.1	CTD-2349P21.9	9.51	1.02e-19	6.25e-17	0.56	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30792372~30792833:+
THCA	cis	rs597539	0.615	rs629426	ENSG00000250508.1	RP11-757G1.6	-9.51	1.02e-19	6.26e-17	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68903636	chr11:68870664~68874542:+
THCA	cis	rs2836950	0.52	rs59916147	ENSG00000255568.3	BRWD1-AS2	-9.51	1.02e-19	6.29e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39262776	chr21:39313935~39314962:+
THCA	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-9.51	1.03e-19	6.3e-17	-0.5	-0.4	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
THCA	cis	rs7189233	0.55	rs17193176	ENSG00000279344.1	RP11-44F14.7	9.51	1.03e-19	6.3e-17	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53484316	chr16:53478957~53481550:-
THCA	cis	rs1799949	0.864	rs60309406	ENSG00000267681.1	CTD-3199J23.6	-9.51	1.03e-19	6.31e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43358297	chr17:43144956~43145255:+
THCA	cis	rs4819052	0.851	rs2236444	ENSG00000215447.6	BX322557.10	-9.51	1.03e-19	6.31e-17	-0.34	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45288052~45291738:+
THCA	cis	rs4722166	0.564	rs1800797	ENSG00000179428.2	AC073072.5	-9.51	1.03e-19	6.31e-17	-0.53	-0.4	Lung cancer;	chr7:22726602	chr7:22725395~22727620:-
THCA	cis	rs6496932	0.865	rs4843049	ENSG00000218052.5	ADAMTS7P4	9.51	1.03e-19	6.32e-17	0.59	0.4	Central corneal thickness;Corneal structure;	chr15:85331141	chr15:85255369~85330334:-
THCA	cis	rs526231	0.578	rs3776870	ENSG00000175749.11	EIF3KP1	9.5	1.03e-19	6.34e-17	0.53	0.4	Primary biliary cholangitis;	chr5:102959366	chr5:103032376~103033031:+
THCA	cis	rs2274273	0.588	rs2297816	ENSG00000258413.1	RP11-665C16.6	-9.5	1.03e-19	6.34e-17	-0.56	-0.4	Protein biomarker;	chr14:55366320	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.923	rs62441284	ENSG00000268592.3	RAET1E-AS1	9.5	1.03e-19	6.34e-17	0.54	0.4	Lung cancer;	chr6:149751542	chr6:149863494~149919507:+
THCA	cis	rs7189233	0.513	rs8044091	ENSG00000279344.1	RP11-44F14.7	9.5	1.03e-19	6.35e-17	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53487086	chr16:53478957~53481550:-
THCA	cis	rs2274273	1	rs61508494	ENSG00000258413.1	RP11-665C16.6	-9.5	1.04e-19	6.35e-17	-0.52	-0.4	Protein biomarker;	chr14:55120579	chr14:55262767~55272075:-
THCA	cis	rs934734	0.532	rs10153675	ENSG00000234255.7	AC012370.3	-9.5	1.04e-19	6.36e-17	-0.45	-0.4	Rheumatoid arthritis;	chr2:65422446	chr2:65439888~65456571:-
THCA	cis	rs2836950	0.52	rs8133927	ENSG00000255568.3	BRWD1-AS2	-9.5	1.04e-19	6.38e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39318035	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.52	rs8133928	ENSG00000255568.3	BRWD1-AS2	-9.5	1.04e-19	6.38e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39318037	chr21:39313935~39314962:+
THCA	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	9.5	1.04e-19	6.38e-17	0.43	0.4	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
THCA	cis	rs1799949	1	rs11651341	ENSG00000267681.1	CTD-3199J23.6	-9.5	1.04e-19	6.39e-17	-0.46	-0.4	Menopause (age at onset);	chr17:43350693	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs34572725	ENSG00000267681.1	CTD-3199J23.6	-9.5	1.04e-19	6.39e-17	-0.46	-0.4	Menopause (age at onset);	chr17:43351298	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4534897	ENSG00000267681.1	CTD-3199J23.6	-9.5	1.04e-19	6.39e-17	-0.46	-0.4	Menopause (age at onset);	chr17:43354440	chr17:43144956~43145255:+
THCA	cis	rs180730	0.519	rs2892920	ENSG00000251609.2	SETP12	9.5	1.04e-19	6.4e-17	0.56	0.4	Fasting plasma glucose;	chr4:120953389	chr4:120895494~120897083:-
THCA	cis	rs2274273	0.588	rs17675223	ENSG00000258413.1	RP11-665C16.6	-9.5	1.05e-19	6.46e-17	-0.55	-0.4	Protein biomarker;	chr14:55395518	chr14:55262767~55272075:-
THCA	cis	rs597539	0.616	rs473997	ENSG00000250508.1	RP11-757G1.6	-9.5	1.06e-19	6.49e-17	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68872013	chr11:68870664~68874542:+
THCA	cis	rs9926296	0.687	rs258317	ENSG00000260259.1	RP11-368I7.4	9.5	1.06e-19	6.49e-17	0.45	0.4	Vitiligo;	chr16:89665830	chr16:89682620~89686569:-
THCA	cis	rs10759883	0.563	rs10819668	ENSG00000175611.10	LINC00476	9.5	1.06e-19	6.5e-17	0.45	0.4	Nicotine dependence;	chr9:95959848	chr9:95759231~95875977:-
THCA	cis	rs8062405	0.723	rs35175818	ENSG00000251417.2	RP11-1348G14.4	-9.5	1.06e-19	6.5e-17	-0.42	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28802743~28817828:+
THCA	cis	rs7727544	0.678	rs7735891	ENSG00000237714.1	P4HA2-AS1	9.5	1.06e-19	6.51e-17	0.53	0.4	Blood metabolite levels;	chr5:132261312	chr5:132184876~132192808:+
THCA	cis	rs801193	1	rs17566701	ENSG00000237310.1	GS1-124K5.4	9.5	1.06e-19	6.52e-17	0.29	0.4	Aortic root size;	chr7:66728196	chr7:66493706~66495474:+
THCA	cis	rs11051970	0.559	rs2270786	ENSG00000274964.1	RP11-817I4.1	-9.5	1.06e-19	6.52e-17	-0.53	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32337830	chr12:32339368~32340724:+
THCA	cis	rs780096	0.565	rs10169261	ENSG00000234072.1	AC074117.10	-9.5	1.06e-19	6.52e-17	-0.32	-0.4	Total body bone mineral density;	chr2:27504447	chr2:27356246~27367622:+
THCA	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	9.5	1.07e-19	6.53e-17	0.49	0.4	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
THCA	cis	rs1537424	0.513	rs1333313	ENSG00000257826.1	RP11-116N8.4	-9.5	1.07e-19	6.54e-17	-0.47	-0.4	Thyroid hormone levels;	chr14:36093440	chr14:36061026~36067190:-
THCA	cis	rs11148252	0.774	rs7334583	ENSG00000278238.1	RP11-245D16.4	9.5	1.07e-19	6.54e-17	0.44	0.4	Lewy body disease;	chr13:52356217	chr13:52454775~52455331:-
THCA	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-9.5	1.07e-19	6.55e-17	-0.42	-0.4	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
THCA	cis	rs2274273	0.624	rs78205412	ENSG00000258413.1	RP11-665C16.6	-9.5	1.07e-19	6.57e-17	-0.56	-0.4	Protein biomarker;	chr14:55314532	chr14:55262767~55272075:-
THCA	cis	rs4842666	0.915	rs11105376	ENSG00000258302.2	RP11-981P6.1	9.5	1.08e-19	6.6e-17	0.4	0.4	Blood pressure;	chr12:89694991	chr12:89561129~89594878:+
THCA	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	9.5	1.08e-19	6.63e-17	0.48	0.4	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
THCA	cis	rs7221109	0.921	rs4890117	ENSG00000278834.1	RP11-458J1.1	9.5	1.08e-19	6.63e-17	0.43	0.4	Type 1 diabetes;	chr17:40622236	chr17:40648300~40649718:+
THCA	cis	rs6844153	0.627	rs11730235	ENSG00000240005.4	RP11-293A21.1	-9.5	1.08e-19	6.64e-17	-0.49	-0.4	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26922822	chr4:26859806~26860599:-
THCA	cis	rs11971779	0.648	rs6947309	ENSG00000273391.1	RP11-634H22.1	9.5	1.09e-19	6.65e-17	0.37	0.4	Diisocyanate-induced asthma;	chr7:139351084	chr7:139359032~139359566:-
THCA	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	9.5	1.09e-19	6.66e-17	0.45	0.4	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
THCA	cis	rs7712401	0.601	rs438196	ENSG00000263432.2	RN7SL689P	9.5	1.09e-19	6.66e-17	0.45	0.4	Mean platelet volume;	chr5:122927368	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs401729	ENSG00000263432.2	RN7SL689P	9.5	1.09e-19	6.66e-17	0.45	0.4	Mean platelet volume;	chr5:122928590	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs2910140	ENSG00000263432.2	RN7SL689P	9.5	1.09e-19	6.66e-17	0.45	0.4	Mean platelet volume;	chr5:122928700	chr5:123022487~123022783:-
THCA	cis	rs4819052	1	rs9306123	ENSG00000215447.6	BX322557.10	-9.5	1.09e-19	6.67e-17	-0.36	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45288052~45291738:+
THCA	cis	rs8091660	0.929	rs11082685	ENSG00000278983.1	RP11-426J5.3	9.5	1.09e-19	6.68e-17	0.52	0.4	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48566806	chr18:48564795~48568342:+
THCA	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	9.5	1.09e-19	6.69e-17	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
THCA	cis	rs597539	0.652	rs507520	ENSG00000250508.1	RP11-757G1.6	-9.5	1.09e-19	6.69e-17	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68898586	chr11:68870664~68874542:+
THCA	cis	rs62103177	0.564	rs11874805	ENSG00000261126.6	RP11-795F19.1	9.5	1.09e-19	6.69e-17	0.44	0.4	Opioid sensitivity;	chr18:79937110	chr18:80046900~80095482:+
THCA	cis	rs3743772	0.5	rs9924562	ENSG00000279722.1	RP11-44F14.6	9.5	1.09e-19	6.69e-17	0.54	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53415152	chr16:53487607~53489943:-
THCA	cis	rs4819052	0.851	rs2838837	ENSG00000215447.6	BX322557.10	-9.5	1.09e-19	6.7e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45288052~45291738:+
THCA	cis	rs10740039	0.883	rs7068934	ENSG00000254271.1	RP11-131N11.4	9.5	1.1e-19	6.74e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636490	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10740038	ENSG00000254271.1	RP11-131N11.4	9.5	1.1e-19	6.74e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643479	chr10:60734342~60741828:+
THCA	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	9.5	1.1e-19	6.75e-17	0.47	0.4	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
THCA	cis	rs7829975	0.533	rs35900578	ENSG00000253893.2	FAM85B	-9.5	1.11e-19	6.77e-17	-0.53	-0.4	Mood instability;	chr8:8862003	chr8:8167819~8226614:-
THCA	cis	rs9828933	0.766	rs3774725	ENSG00000280620.1	SCAANT1	9.5	1.11e-19	6.78e-17	0.68	0.4	Type 2 diabetes;	chr3:63988582	chr3:63911518~63911772:-
THCA	cis	rs7615952	0.688	rs9754526	ENSG00000171084.14	FAM86JP	9.5	1.11e-19	6.81e-17	0.52	0.4	Blood pressure (smoking interaction);	chr3:125824023	chr3:125916620~125930024:+
THCA	cis	rs6546847	0.531	rs2567601	ENSG00000163016.8	ALMS1P	9.5	1.11e-19	6.81e-17	0.76	0.4	Urinary metabolites (H-NMR features);	chr2:73758040	chr2:73644919~73685576:+
THCA	cis	rs597539	0.69	rs635529	ENSG00000250508.1	RP11-757G1.6	-9.49	1.12e-19	6.85e-17	-0.49	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858826	chr11:68870664~68874542:+
THCA	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-9.49	1.13e-19	6.91e-17	-0.54	-0.4	QT interval;	chr16:28884339	chr16:28700294~28701540:-
THCA	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	9.49	1.14e-19	6.95e-17	0.33	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
THCA	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	9.49	1.14e-19	6.95e-17	0.33	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
THCA	cis	rs7586673	0.964	rs34444368	ENSG00000227403.1	AC009299.3	-9.49	1.14e-19	6.95e-17	-0.48	-0.4	Intelligence (multi-trait analysis);	chr2:161097706	chr2:161244739~161249050:+
THCA	cis	rs934734	0.532	rs13383320	ENSG00000234255.7	AC012370.3	-9.49	1.14e-19	6.97e-17	-0.44	-0.4	Rheumatoid arthritis;	chr2:65418003	chr2:65439888~65456571:-
THCA	cis	rs2274273	0.967	rs2094102	ENSG00000258413.1	RP11-665C16.6	-9.49	1.14e-19	6.99e-17	-0.52	-0.4	Protein biomarker;	chr14:55124380	chr14:55262767~55272075:-
THCA	cis	rs950169	1	rs11638394	ENSG00000259728.4	LINC00933	9.49	1.15e-19	7.01e-17	0.55	0.4	Schizophrenia;	chr15:84110176	chr15:84570649~84580175:+
THCA	cis	rs950169	1	rs35658069	ENSG00000259728.4	LINC00933	9.49	1.15e-19	7.01e-17	0.55	0.4	Schizophrenia;	chr15:84111394	chr15:84570649~84580175:+
THCA	cis	rs2274273	0.624	rs11158034	ENSG00000258413.1	RP11-665C16.6	-9.49	1.15e-19	7.02e-17	-0.55	-0.4	Protein biomarker;	chr14:55286842	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.607	rs4870078	ENSG00000268592.3	RAET1E-AS1	-9.49	1.16e-19	7.06e-17	-0.57	-0.4	Lung cancer;	chr6:149880676	chr6:149863494~149919507:+
THCA	cis	rs950169	0.92	rs12915390	ENSG00000259728.4	LINC00933	9.49	1.16e-19	7.07e-17	0.55	0.4	Schizophrenia;	chr15:84123317	chr15:84570649~84580175:+
THCA	cis	rs597539	0.652	rs10792001	ENSG00000250508.1	RP11-757G1.6	-9.49	1.16e-19	7.08e-17	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870269	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs613128	ENSG00000250508.1	RP11-757G1.6	-9.49	1.16e-19	7.08e-17	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870590	chr11:68870664~68874542:+
THCA	cis	rs7712401	0.601	rs154502	ENSG00000263432.2	RN7SL689P	9.49	1.16e-19	7.09e-17	0.45	0.4	Mean platelet volume;	chr5:122871351	chr5:123022487~123022783:-
THCA	cis	rs853679	0.517	rs9468298	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28154567	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9295759	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28156691	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9348796	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28158424	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs11552219	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28159056	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393896	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28159925	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393897	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28159932	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9357066	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28162053	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368556	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28163375	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368557	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28163759	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380059	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28164580	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380060	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28164825	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs35227624	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28164948	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380061	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28165025	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9368558	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28165528	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.587	rs9393899	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Parkinson's disease;	chr6:28165750	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.527	rs4713151	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Parkinson's disease;	chr6:28168578	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393901	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28169019	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs3173443	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28169249	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9348797	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28169755	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380062	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28169791	chr6:28161781~28169594:+
THCA	cis	rs853679	0.542	rs9380063	ENSG00000226314.6	ZNF192P1	-9.49	1.16e-19	7.1e-17	-0.54	-0.4	Depression;	chr6:28170075	chr6:28161781~28169594:+
THCA	cis	rs9926296	0.744	rs154656	ENSG00000260259.1	RP11-368I7.4	9.49	1.16e-19	7.11e-17	0.43	0.4	Vitiligo;	chr16:89641595	chr16:89682620~89686569:-
THCA	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	9.49	1.16e-19	7.11e-17	0.52	0.4	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
THCA	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-9.49	1.17e-19	7.12e-17	-0.29	-0.4	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
THCA	cis	rs916888	0.821	rs199504	ENSG00000232300.1	FAM215B	-9.49	1.17e-19	7.13e-17	-0.64	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46558830~46562795:-
THCA	cis	rs7208859	0.623	rs7220999	ENSG00000266490.1	CTD-2349P21.9	9.49	1.17e-19	7.16e-17	0.54	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs55638872	ENSG00000266490.1	CTD-2349P21.9	9.49	1.17e-19	7.16e-17	0.54	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30792372~30792833:+
THCA	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-9.49	1.18e-19	7.2e-17	-0.34	-0.4	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
THCA	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-9.49	1.19e-19	7.24e-17	-0.56	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
THCA	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	9.49	1.19e-19	7.26e-17	0.44	0.4	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
THCA	cis	rs11168351	0.517	rs10875754	ENSG00000240399.1	RP1-228P16.1	9.49	1.19e-19	7.28e-17	0.37	0.4	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48054813~48055591:-
THCA	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	9.49	1.19e-19	7.29e-17	0.46	0.4	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
THCA	cis	rs10759883	0.563	rs686048	ENSG00000175611.10	LINC00476	9.49	1.2e-19	7.31e-17	0.45	0.4	Nicotine dependence;	chr9:95967100	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.539	rs649819	ENSG00000175611.10	LINC00476	9.49	1.2e-19	7.31e-17	0.45	0.4	Nicotine dependence;	chr9:95969323	chr9:95759231~95875977:-
THCA	cis	rs7727544	0.716	rs2089855	ENSG00000237714.1	P4HA2-AS1	9.49	1.2e-19	7.34e-17	0.54	0.4	Blood metabolite levels;	chr5:132237836	chr5:132184876~132192808:+
THCA	cis	rs597539	0.615	rs583182	ENSG00000250508.1	RP11-757G1.6	-9.48	1.22e-19	7.42e-17	-0.46	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68911166	chr11:68870664~68874542:+
THCA	cis	rs2836950	0.502	rs12627205	ENSG00000255568.3	BRWD1-AS2	-9.48	1.22e-19	7.44e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39258101	chr21:39313935~39314962:+
THCA	cis	rs10463554	0.963	rs6889592	ENSG00000175749.11	EIF3KP1	9.48	1.22e-19	7.44e-17	0.53	0.4	Parkinson's disease;	chr5:102978235	chr5:103032376~103033031:+
THCA	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	9.48	1.22e-19	7.45e-17	0.49	0.4	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
THCA	cis	rs4819052	0.851	rs875621	ENSG00000215447.6	BX322557.10	-9.48	1.22e-19	7.46e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45288052~45291738:+
THCA	cis	rs780096	0.546	rs4425043	ENSG00000234072.1	AC074117.10	-9.48	1.22e-19	7.46e-17	-0.32	-0.4	Total body bone mineral density;	chr2:27510585	chr2:27356246~27367622:+
THCA	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-9.48	1.23e-19	7.46e-17	-0.46	-0.4	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-9.48	1.23e-19	7.47e-17	-0.46	-0.4	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
THCA	cis	rs9402743	0.632	rs9399167	ENSG00000231028.7	LINC00271	-9.48	1.23e-19	7.47e-17	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135792678	chr6:135497801~135716055:+
THCA	cis	rs780094	0.544	rs780110	ENSG00000234072.1	AC074117.10	-9.48	1.23e-19	7.49e-17	-0.31	-0.4	Urate levels in overweight individuals;C-reactive protein;Metabolic syndrome;Red blood cell count;Renal underexcretion gout;Nonalcoholic fatty liver disease;Age-related diseases, mortality and associated endophenotypes;Crohn's disease;Calcium levels;Fasting plasma glucose;Metabolic traits;Fasting blood glucose;Fasting blood insulin;Urate levels in obese individuals;Alcohol consumption (drinks per week);Height;Urate levels;Gondoic acid (20:1n-9) levels;Uric acid levels;Age-related disease endophenotypes;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Homeostasis model assessment of insulin resistance;Alcohol consumption;Fasting blood insulin (BMI interaction);Triglycerides;Fasting blood glucose (BMI interaction);Hypertriglyceridemia;LDL cholesterol;Type 2 diabetes;Triglyceride levels;	chr2:27462521	chr2:27356246~27367622:+
THCA	cis	rs2836950	0.501	rs11702505	ENSG00000255568.3	BRWD1-AS2	-9.48	1.24e-19	7.54e-17	-0.32	-0.4	Menarche (age at onset);	chr21:39328688	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.501	rs2836985	ENSG00000255568.3	BRWD1-AS2	-9.48	1.24e-19	7.54e-17	-0.32	-0.4	Menarche (age at onset);	chr21:39329243	chr21:39313935~39314962:+
THCA	cis	rs944289	0.74	rs950319	ENSG00000257826.1	RP11-116N8.4	-9.48	1.24e-19	7.55e-17	-0.41	-0.4	Thyroid cancer;	chr14:36096786	chr14:36061026~36067190:-
THCA	cis	rs11051970	0.559	rs11051932	ENSG00000274964.1	RP11-817I4.1	-9.48	1.24e-19	7.57e-17	-0.5	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32320701	chr12:32339368~32340724:+
THCA	cis	rs71403859	0.502	rs12927456	ENSG00000260886.1	TAT-AS1	9.48	1.25e-19	7.6e-17	0.71	0.4	Post bronchodilator FEV1;	chr16:71471803	chr16:71565789~71578187:+
THCA	cis	rs7569084	0.566	rs7584295	ENSG00000204929.10	AC074391.1	9.48	1.25e-19	7.61e-17	0.52	0.4	Sum eosinophil basophil counts;	chr2:65353940	chr2:65436711~66084639:+
THCA	cis	rs934734	0.563	rs11695373	ENSG00000204929.10	AC074391.1	9.48	1.25e-19	7.61e-17	0.52	0.4	Rheumatoid arthritis;	chr2:65354066	chr2:65436711~66084639:+
THCA	cis	rs853679	0.517	rs4713152	ENSG00000226314.6	ZNF192P1	-9.48	1.25e-19	7.61e-17	-0.54	-0.4	Depression;	chr6:28169676	chr6:28161781~28169594:+
THCA	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-9.48	1.25e-19	7.64e-17	-0.3	-0.4	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
THCA	cis	rs853679	0.517	rs1947863	ENSG00000226314.6	ZNF192P1	-9.48	1.26e-19	7.65e-17	-0.54	-0.4	Depression;	chr6:28131566	chr6:28161781~28169594:+
THCA	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-9.48	1.26e-19	7.66e-17	-0.48	-0.4	Height;	chr6:109636120	chr6:109382795~109383666:+
THCA	cis	rs6496932	0.865	rs4842874	ENSG00000218052.5	ADAMTS7P4	9.48	1.26e-19	7.67e-17	0.58	0.4	Central corneal thickness;Corneal structure;	chr15:85323464	chr15:85255369~85330334:-
THCA	cis	rs7712401	0.601	rs34233716	ENSG00000263432.2	RN7SL689P	-9.48	1.27e-19	7.74e-17	-0.45	-0.4	Mean platelet volume;	chr5:122980670	chr5:123022487~123022783:-
THCA	cis	rs9640161	0.789	rs2159234	ENSG00000261305.1	RP4-584D14.7	9.48	1.27e-19	7.75e-17	0.48	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150323333	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.702	rs3735175	ENSG00000261305.1	RP4-584D14.7	9.48	1.27e-19	7.75e-17	0.48	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150323368	chr7:150341771~150342607:+
THCA	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-9.48	1.28e-19	7.78e-17	-0.55	-0.4	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
THCA	cis	rs11051970	0.559	rs11051925	ENSG00000274964.1	RP11-817I4.1	-9.48	1.28e-19	7.81e-17	-0.51	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32314860	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs10431283	ENSG00000274964.1	RP11-817I4.1	-9.48	1.28e-19	7.81e-17	-0.51	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32315070	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs10431225	ENSG00000274964.1	RP11-817I4.1	-9.48	1.28e-19	7.81e-17	-0.51	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32315177	chr12:32339368~32340724:+
THCA	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-9.48	1.28e-19	7.81e-17	-0.3	-0.4	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
THCA	cis	rs4380275	0.782	rs4335978	ENSG00000272342.1	RP13-539J13.1	9.48	1.29e-19	7.83e-17	0.48	0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:739588~740164:-
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	9.48	1.31e-19	7.96e-17	0.49	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
THCA	cis	rs853679	0.513	rs13437444	ENSG00000280107.1	AL022393.9	-9.48	1.31e-19	7.97e-17	-0.54	-0.4	Depression;	chr6:28103220	chr6:28170845~28172521:+
THCA	cis	rs2274273	0.624	rs11848575	ENSG00000258413.1	RP11-665C16.6	-9.48	1.31e-19	7.98e-17	-0.55	-0.4	Protein biomarker;	chr14:55289070	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs67386901	ENSG00000258413.1	RP11-665C16.6	-9.48	1.31e-19	7.98e-17	-0.55	-0.4	Protein biomarker;	chr14:55290646	chr14:55262767~55272075:-
THCA	cis	rs934734	0.532	rs12185610	ENSG00000234255.7	AC012370.3	-9.47	1.31e-19	7.99e-17	-0.44	-0.4	Rheumatoid arthritis;	chr2:65434334	chr2:65439888~65456571:-
THCA	cis	rs7712401	0.525	rs246312	ENSG00000263432.2	RN7SL689P	9.47	1.32e-19	8.03e-17	0.45	0.4	Mean platelet volume;	chr5:122933760	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs246308	ENSG00000263432.2	RN7SL689P	9.47	1.32e-19	8.03e-17	0.45	0.4	Mean platelet volume;	chr5:122934395	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs30047	ENSG00000263432.2	RN7SL689P	9.47	1.32e-19	8.03e-17	0.45	0.4	Mean platelet volume;	chr5:122934829	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.562	rs30046	ENSG00000263432.2	RN7SL689P	9.47	1.32e-19	8.03e-17	0.45	0.4	Mean platelet volume;	chr5:122935538	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.623	rs30044	ENSG00000263432.2	RN7SL689P	9.47	1.32e-19	8.03e-17	0.45	0.4	Mean platelet volume;	chr5:122936385	chr5:123022487~123022783:-
THCA	cis	rs597539	0.617	rs672853	ENSG00000250508.1	RP11-757G1.6	-9.47	1.32e-19	8.03e-17	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868894	chr11:68870664~68874542:+
THCA	cis	rs934734	0.563	rs1858037	ENSG00000204929.10	AC074391.1	9.47	1.32e-19	8.03e-17	0.52	0.4	Rheumatoid arthritis;	chr2:65371166	chr2:65436711~66084639:+
THCA	cis	rs1799949	0.965	rs4793234	ENSG00000267681.1	CTD-3199J23.6	-9.47	1.32e-19	8.03e-17	-0.47	-0.4	Menopause (age at onset);	chr17:43358815	chr17:43144956~43145255:+
THCA	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	9.47	1.32e-19	8.04e-17	0.49	0.4	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	9.47	1.32e-19	8.04e-17	0.49	0.4	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	9.47	1.33e-19	8.05e-17	0.49	0.4	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
THCA	cis	rs4819052	1	rs2297286	ENSG00000215447.6	BX322557.10	-9.47	1.33e-19	8.08e-17	-0.36	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45288052~45291738:+
THCA	cis	rs2274273	0.624	rs7154796	ENSG00000258413.1	RP11-665C16.6	-9.47	1.33e-19	8.1e-17	-0.55	-0.4	Protein biomarker;	chr14:55304740	chr14:55262767~55272075:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000224205.1	AP000351.4	9.47	1.34e-19	8.14e-17	0.47	0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23987320~23991421:-
THCA	cis	rs10759883	0.539	rs684455	ENSG00000175611.10	LINC00476	9.47	1.34e-19	8.17e-17	0.45	0.4	Nicotine dependence;	chr9:95964061	chr9:95759231~95875977:-
THCA	cis	rs11098499	0.739	rs951570	ENSG00000245958.5	RP11-33B1.1	9.47	1.35e-19	8.18e-17	0.37	0.4	Corneal astigmatism;	chr4:119229312	chr4:119454791~119552025:+
THCA	cis	rs4591358	0.773	rs35785148	ENSG00000223466.1	AC064834.2	-9.47	1.35e-19	8.21e-17	-0.55	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195516751	chr2:195533035~195538681:+
THCA	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	9.47	1.36e-19	8.25e-17	0.28	0.4	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
THCA	cis	rs8062405	0.573	rs7187575	ENSG00000251417.2	RP11-1348G14.4	9.47	1.36e-19	8.28e-17	0.41	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28978780	chr16:28802743~28817828:+
THCA	cis	rs66887589	0.777	rs2017058	ENSG00000245958.5	RP11-33B1.1	-9.47	1.36e-19	8.28e-17	-0.36	-0.4	Diastolic blood pressure;	chr4:119336584	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.777	rs1814815	ENSG00000245958.5	RP11-33B1.1	-9.47	1.36e-19	8.28e-17	-0.36	-0.4	Diastolic blood pressure;	chr4:119336936	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.748	rs28439855	ENSG00000245958.5	RP11-33B1.1	-9.47	1.36e-19	8.28e-17	-0.36	-0.4	Diastolic blood pressure;	chr4:119341101	chr4:119454791~119552025:+
THCA	cis	rs71403859	0.73	rs17347255	ENSG00000260886.1	TAT-AS1	9.47	1.37e-19	8.29e-17	0.71	0.4	Post bronchodilator FEV1;	chr16:71553322	chr16:71565789~71578187:+
THCA	cis	rs875971	0.66	rs6460308	ENSG00000237310.1	GS1-124K5.4	-9.47	1.37e-19	8.3e-17	-0.29	-0.4	Aortic root size;	chr7:66619753	chr7:66493706~66495474:+
THCA	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-9.47	1.38e-19	8.38e-17	-0.44	-0.4	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
THCA	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	9.47	1.39e-19	8.42e-17	0.49	0.4	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
THCA	cis	rs9659323	0.632	rs10923744	ENSG00000231365.4	RP11-418J17.1	-9.47	1.39e-19	8.42e-17	-0.38	-0.4	Body mass index;	chr1:119071318	chr1:119140396~119275973:+
THCA	cis	rs944289	0.598	rs56359141	ENSG00000257826.1	RP11-116N8.4	-9.47	1.39e-19	8.44e-17	-0.41	-0.4	Thyroid cancer;	chr14:36108167	chr14:36061026~36067190:-
THCA	cis	rs875971	0.66	rs79009421	ENSG00000237310.1	GS1-124K5.4	-9.47	1.4e-19	8.46e-17	-0.29	-0.4	Aortic root size;	chr7:66603522	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-9.47	1.4e-19	8.46e-17	-0.29	-0.4	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
THCA	cis	rs875971	0.638	rs35986979	ENSG00000237310.1	GS1-124K5.4	-9.47	1.4e-19	8.46e-17	-0.29	-0.4	Aortic root size;	chr7:66624003	chr7:66493706~66495474:+
THCA	cis	rs875971	0.642	rs35526611	ENSG00000237310.1	GS1-124K5.4	-9.47	1.4e-19	8.49e-17	-0.29	-0.4	Aortic root size;	chr7:66629021	chr7:66493706~66495474:+
THCA	cis	rs4819052	0.851	rs10470246	ENSG00000215447.6	BX322557.10	-9.47	1.4e-19	8.5e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs10470247	ENSG00000215447.6	BX322557.10	-9.47	1.4e-19	8.5e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4819043	ENSG00000215447.6	BX322557.10	-9.47	1.4e-19	8.5e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4819044	ENSG00000215447.6	BX322557.10	-9.47	1.4e-19	8.5e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45288052~45291738:+
THCA	cis	rs2288884	0.649	rs11667001	ENSG00000275055.1	CTC-471J1.11	-9.47	1.4e-19	8.5e-17	-0.45	-0.4	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049416	chr19:52049007~52049754:+
THCA	cis	rs9487094	0.626	rs4947016	ENSG00000260273.1	RP11-425D10.10	9.47	1.41e-19	8.55e-17	0.47	0.4	Height;	chr6:109740895	chr6:109382795~109383666:+
THCA	cis	rs860295	0.651	rs6677385	ENSG00000225855.5	RUSC1-AS1	9.47	1.42e-19	8.6e-17	0.28	0.4	Body mass index;	chr1:155334790	chr1:155316863~155324176:-
THCA	cis	rs7429990	0.864	rs34616865	ENSG00000229759.1	MRPS18AP1	-9.47	1.42e-19	8.61e-17	-0.47	-0.4	Educational attainment (years of education);	chr3:47608508	chr3:48256350~48256938:-
THCA	cis	rs7429990	0.864	rs1014228	ENSG00000229759.1	MRPS18AP1	-9.47	1.42e-19	8.61e-17	-0.47	-0.4	Educational attainment (years of education);	chr3:47611149	chr3:48256350~48256938:-
THCA	cis	rs4819052	0.851	rs13048789	ENSG00000215447.6	BX322557.10	-9.46	1.42e-19	8.64e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45288052~45291738:+
THCA	cis	rs8062405	0.789	rs28676837	ENSG00000259982.1	CDC37P1	-9.46	1.43e-19	8.67e-17	-0.5	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28615742	chr16:28700294~28701540:-
THCA	cis	rs4819052	0.851	rs10470245	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs10470258	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4819038	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4819039	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4818768	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs4819042	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs13047598	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.724	rs9753962	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.724	rs9753987	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs9753963	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs9754134	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs34101026	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs13052312	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838828	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs13049337	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838829	ENSG00000215447.6	BX322557.10	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs8134392	ENSG00000215447.6	BX322557.10	9.46	1.43e-19	8.69e-17	0.33	0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45288052~45291738:+
THCA	cis	rs2836950	0.585	rs1029004	ENSG00000255568.3	BRWD1-AS2	-9.46	1.43e-19	8.69e-17	-0.33	-0.4	Menarche (age at onset);	chr21:39243417	chr21:39313935~39314962:+
THCA	cis	rs10740039	0.96	rs10443928	ENSG00000254271.1	RP11-131N11.4	9.46	1.44e-19	8.71e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645718	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10443929	ENSG00000254271.1	RP11-131N11.4	9.46	1.44e-19	8.71e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645852	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.842	rs7915540	ENSG00000254271.1	RP11-131N11.4	9.46	1.44e-19	8.71e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60646538	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs7920170	ENSG00000254271.1	RP11-131N11.4	9.46	1.44e-19	8.71e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647766	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10761538	ENSG00000254271.1	RP11-131N11.4	9.46	1.44e-19	8.71e-17	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649463	chr10:60734342~60741828:+
THCA	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-9.46	1.44e-19	8.73e-17	-0.5	-0.4	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
THCA	cis	rs11676348	0.808	rs4674261	ENSG00000261338.2	RP11-378A13.1	-9.46	1.45e-19	8.78e-17	-0.4	-0.4	Ulcerative colitis;	chr2:218140286	chr2:218255319~218257366:+
THCA	cis	rs11051970	0.559	rs10844179	ENSG00000274964.1	RP11-817I4.1	9.46	1.45e-19	8.8e-17	0.51	0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32316667	chr12:32339368~32340724:+
THCA	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	9.46	1.46e-19	8.83e-17	0.49	0.4	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
THCA	cis	rs934734	0.532	rs6546151	ENSG00000234255.7	AC012370.3	-9.46	1.46e-19	8.83e-17	-0.43	-0.4	Rheumatoid arthritis;	chr2:65449449	chr2:65439888~65456571:-
THCA	cis	rs7615952	0.575	rs35949599	ENSG00000171084.14	FAM86JP	9.46	1.46e-19	8.84e-17	0.52	0.4	Blood pressure (smoking interaction);	chr3:125825359	chr3:125916620~125930024:+
THCA	cis	rs8062405	0.789	rs1968752	ENSG00000251417.2	RP11-1348G14.4	-9.46	1.46e-19	8.86e-17	-0.38	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28802743~28817828:+
THCA	cis	rs11098499	0.739	rs2203039	ENSG00000245958.5	RP11-33B1.1	9.46	1.46e-19	8.87e-17	0.37	0.4	Corneal astigmatism;	chr4:119211192	chr4:119454791~119552025:+
THCA	cis	rs9487094	0.626	rs4141930	ENSG00000260273.1	RP11-425D10.10	9.46	1.47e-19	8.87e-17	0.47	0.4	Height;	chr6:109739615	chr6:109382795~109383666:+
THCA	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	9.46	1.47e-19	8.9e-17	0.48	0.4	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
THCA	cis	rs10463554	0.784	rs187424	ENSG00000175749.11	EIF3KP1	9.46	1.47e-19	8.93e-17	0.54	0.4	Parkinson's disease;	chr5:103251882	chr5:103032376~103033031:+
THCA	cis	rs11098499	0.739	rs6534130	ENSG00000245958.5	RP11-33B1.1	9.46	1.48e-19	8.94e-17	0.37	0.4	Corneal astigmatism;	chr4:119210184	chr4:119454791~119552025:+
THCA	cis	rs1823874	0.962	rs12906206	ENSG00000182397.13	DNM1P46	-9.46	1.48e-19	8.96e-17	-0.44	-0.4	IgG glycosylation;	chr15:99818921	chr15:99790156~99806927:-
THCA	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-9.46	1.49e-19	9e-17	-0.48	-0.4	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
THCA	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-9.46	1.49e-19	9.01e-17	-0.3	-0.4	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
THCA	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	9.46	1.49e-19	9.02e-17	0.49	0.4	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
THCA	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-9.46	1.49e-19	9.03e-17	-0.47	-0.4	Height;	chr6:109731677	chr6:109382795~109383666:+
THCA	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-9.46	1.5e-19	9.06e-17	-0.53	-0.4	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
THCA	cis	rs7221109	0.921	rs1013971	ENSG00000278834.1	RP11-458J1.1	9.46	1.5e-19	9.08e-17	0.42	0.4	Type 1 diabetes;	chr17:40624926	chr17:40648300~40649718:+
THCA	cis	rs3743772	0.5	rs28671196	ENSG00000279722.1	RP11-44F14.6	9.46	1.5e-19	9.1e-17	0.53	0.4	Depressive symptoms (SSRI exposure interaction);	chr16:53404024	chr16:53487607~53489943:-
THCA	cis	rs7208859	0.614	rs216477	ENSG00000263531.1	RP13-753N3.1	-9.46	1.51e-19	9.13e-17	-0.72	-0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30539726	chr17:30863921~30864940:-
THCA	cis	rs875971	0.638	rs801205	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66557157	chr7:66493706~66495474:+
THCA	cis	rs875971	0.617	rs810400	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66557902	chr7:66493706~66495474:+
THCA	cis	rs875971	0.638	rs3898855	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66571411	chr7:66493706~66495474:+
THCA	cis	rs875971	0.638	rs10278816	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66572000	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs10281080	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66577454	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs10950044	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66577989	chr7:66493706~66495474:+
THCA	cis	rs875971	0.522	rs1968127	ENSG00000237310.1	GS1-124K5.4	-9.46	1.52e-19	9.17e-17	-0.29	-0.4	Aortic root size;	chr7:66591816	chr7:66493706~66495474:+
THCA	cis	rs4819052	0.851	rs2877018	ENSG00000215447.6	BX322557.10	-9.46	1.52e-19	9.18e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2330012	ENSG00000215447.6	BX322557.10	-9.46	1.52e-19	9.18e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2877019	ENSG00000215447.6	BX322557.10	-9.46	1.52e-19	9.18e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2877020	ENSG00000215447.6	BX322557.10	-9.46	1.52e-19	9.18e-17	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45288052~45291738:+
THCA	cis	rs10411161	1	rs72626249	ENSG00000269483.1	AC006272.1	9.46	1.52e-19	9.18e-17	0.55	0.4	Breast cancer;	chr19:51861622	chr19:51839924~51843324:-
THCA	cis	rs7712401	0.601	rs30038	ENSG00000263432.2	RN7SL689P	9.46	1.53e-19	9.23e-17	0.45	0.4	Mean platelet volume;	chr5:122941667	chr5:123022487~123022783:-
THCA	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-9.46	1.53e-19	9.24e-17	-0.66	-0.4	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
THCA	cis	rs875971	0.66	rs62465434	ENSG00000237310.1	GS1-124K5.4	9.46	1.53e-19	9.26e-17	0.29	0.4	Aortic root size;	chr7:66540165	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs13224319	ENSG00000237310.1	GS1-124K5.4	9.46	1.53e-19	9.26e-17	0.29	0.4	Aortic root size;	chr7:66542376	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs801217	ENSG00000237310.1	GS1-124K5.4	-9.46	1.53e-19	9.26e-17	-0.29	-0.4	Aortic root size;	chr7:66545590	chr7:66493706~66495474:+
THCA	cis	rs875971	0.638	rs801216	ENSG00000237310.1	GS1-124K5.4	-9.46	1.53e-19	9.26e-17	-0.29	-0.4	Aortic root size;	chr7:66546680	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs801211	ENSG00000237310.1	GS1-124K5.4	-9.46	1.53e-19	9.26e-17	-0.29	-0.4	Aortic root size;	chr7:66550702	chr7:66493706~66495474:+
THCA	cis	rs934734	0.532	rs10184881	ENSG00000234255.7	AC012370.3	-9.46	1.54e-19	9.28e-17	-0.43	-0.4	Rheumatoid arthritis;	chr2:65457018	chr2:65439888~65456571:-
THCA	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	9.45	1.55e-19	9.34e-17	0.49	0.4	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
THCA	cis	rs2274273	0.624	rs10146637	ENSG00000258413.1	RP11-665C16.6	-9.45	1.55e-19	9.35e-17	-0.55	-0.4	Protein biomarker;	chr14:55278092	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.624	rs7155954	ENSG00000258413.1	RP11-665C16.6	-9.45	1.55e-19	9.35e-17	-0.55	-0.4	Protein biomarker;	chr14:55284225	chr14:55262767~55272075:-
THCA	cis	rs7712401	0.601	rs34348084	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:122999419	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs35334805	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:122999566	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs13164134	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:123002246	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs13185741	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:123002315	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs418229	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:123005969	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs374403	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:123006018	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs446782	ENSG00000263432.2	RN7SL689P	-9.45	1.55e-19	9.36e-17	-0.45	-0.4	Mean platelet volume;	chr5:123006173	chr5:123022487~123022783:-
THCA	cis	rs9487094	0.626	rs11153215	ENSG00000260273.1	RP11-425D10.10	9.45	1.55e-19	9.38e-17	0.47	0.4	Height;	chr6:109732518	chr6:109382795~109383666:+
THCA	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	9.45	1.55e-19	9.39e-17	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
THCA	cis	rs7945705	0.875	rs2568065	ENSG00000254860.4	TMEM9B-AS1	9.45	1.56e-19	9.4e-17	0.44	0.4	Hemoglobin concentration;	chr11:8868101	chr11:8964675~8977527:+
THCA	cis	rs950169	0.881	rs72750843	ENSG00000259728.4	LINC00933	9.45	1.56e-19	9.4e-17	0.55	0.4	Schizophrenia;	chr15:84592552	chr15:84570649~84580175:+
THCA	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	9.45	1.56e-19	9.42e-17	0.45	0.4	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
THCA	cis	rs12554020	0.786	rs7857183	ENSG00000227603.1	RP11-165J3.6	9.45	1.58e-19	9.53e-17	0.55	0.4	Schizophrenia;	chr9:93569762	chr9:93435332~93437121:-
THCA	cis	rs673078	0.66	rs11068908	ENSG00000275409.1	RP11-131L12.4	-9.45	1.58e-19	9.54e-17	-0.44	-0.4	Glucose homeostasis traits;	chr12:118327265	chr12:118430147~118430699:+
THCA	cis	rs6920372	0.748	rs12190372	ENSG00000260273.1	RP11-425D10.10	9.45	1.59e-19	9.61e-17	0.47	0.4	Height;	chr6:109763331	chr6:109382795~109383666:+
THCA	cis	rs950169	0.544	rs12913702	ENSG00000225151.9	GOLGA2P7	-9.45	1.6e-19	9.63e-17	-0.6	-0.4	Schizophrenia;	chr15:84609953	chr15:84199311~84230136:-
THCA	cis	rs9322193	0.923	rs12176034	ENSG00000268592.3	RAET1E-AS1	9.45	1.6e-19	9.63e-17	0.56	0.4	Lung cancer;	chr6:149800557	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9322206	ENSG00000268592.3	RAET1E-AS1	9.45	1.6e-19	9.64e-17	0.53	0.4	Lung cancer;	chr6:149641481	chr6:149863494~149919507:+
THCA	cis	rs9640161	0.658	rs60467296	ENSG00000261305.1	RP4-584D14.7	9.45	1.6e-19	9.65e-17	0.48	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150318382	chr7:150341771~150342607:+
THCA	cis	rs4842666	0.915	rs117742247	ENSG00000258302.2	RP11-981P6.1	9.45	1.6e-19	9.66e-17	0.42	0.4	Blood pressure;	chr12:89597536	chr12:89561129~89594878:+
THCA	cis	rs7712401	0.601	rs13155907	ENSG00000263432.2	RN7SL689P	-9.45	1.6e-19	9.66e-17	-0.45	-0.4	Mean platelet volume;	chr5:122998938	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs62377430	ENSG00000263432.2	RN7SL689P	-9.45	1.6e-19	9.66e-17	-0.45	-0.4	Mean platelet volume;	chr5:122998993	chr5:123022487~123022783:-
THCA	cis	rs8062405	0.573	rs11645306	ENSG00000251417.2	RP11-1348G14.4	9.45	1.6e-19	9.66e-17	0.41	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28972615	chr16:28802743~28817828:+
THCA	cis	rs11098499	0.71	rs6851130	ENSG00000245958.5	RP11-33B1.1	9.45	1.61e-19	9.7e-17	0.37	0.4	Corneal astigmatism;	chr4:119212557	chr4:119454791~119552025:+
THCA	cis	rs984222	0.527	rs2645291	ENSG00000231365.4	RP11-418J17.1	-9.45	1.61e-19	9.71e-17	-0.39	-0.4	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119029918	chr1:119140396~119275973:+
THCA	cis	rs9659323	0.632	rs12045138	ENSG00000231365.4	RP11-418J17.1	-9.45	1.62e-19	9.79e-17	-0.38	-0.4	Body mass index;	chr1:119076825	chr1:119140396~119275973:+
THCA	cis	rs1075265	0.749	rs805430	ENSG00000233266.1	HMGB1P31	9.45	1.63e-19	9.84e-17	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53848279	chr2:54051334~54051760:+
THCA	cis	rs4713118	0.587	rs61471148	ENSG00000226314.6	ZNF192P1	-9.45	1.63e-19	9.84e-17	-0.52	-0.4	Parkinson's disease;	chr6:28069254	chr6:28161781~28169594:+
THCA	cis	rs7712401	0.623	rs26372	ENSG00000263432.2	RN7SL689P	-9.45	1.64e-19	9.9e-17	-0.45	-0.4	Mean platelet volume;	chr5:122870752	chr5:123022487~123022783:-
THCA	cis	rs9322193	0.884	rs9688858	ENSG00000268592.3	RAET1E-AS1	9.45	1.64e-19	9.9e-17	0.53	0.4	Lung cancer;	chr6:149637911	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9404048	ENSG00000268592.3	RAET1E-AS1	9.45	1.64e-19	9.91e-17	0.54	0.4	Lung cancer;	chr6:149616188	chr6:149863494~149919507:+
THCA	cis	rs11098499	0.739	rs7441137	ENSG00000245958.5	RP11-33B1.1	9.45	1.65e-19	9.97e-17	0.37	0.4	Corneal astigmatism;	chr4:119212066	chr4:119454791~119552025:+
THCA	cis	rs934734	0.563	rs1858036	ENSG00000204929.10	AC074391.1	9.45	1.65e-19	9.97e-17	0.52	0.4	Rheumatoid arthritis;	chr2:65371107	chr2:65436711~66084639:+
THCA	cis	rs4713118	0.621	rs9368548	ENSG00000226314.6	ZNF192P1	-9.45	1.66e-19	9.99e-17	-0.52	-0.4	Parkinson's disease;	chr6:28066959	chr6:28161781~28169594:+
THCA	cis	rs597539	0.652	rs482172	ENSG00000250508.1	RP11-757G1.6	-9.45	1.66e-19	1e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900969	chr11:68870664~68874542:+
THCA	cis	rs11148252	0.774	rs9596649	ENSG00000278238.1	RP11-245D16.4	9.45	1.66e-19	1e-16	0.44	0.4	Lewy body disease;	chr13:52360475	chr13:52454775~52455331:-
THCA	cis	rs10759883	0.627	rs700962	ENSG00000175611.10	LINC00476	-9.44	1.69e-19	1.02e-16	-0.44	-0.4	Nicotine dependence;	chr9:95815766	chr9:95759231~95875977:-
THCA	cis	rs1799949	0.965	rs33961729	ENSG00000267681.1	CTD-3199J23.6	-9.44	1.7e-19	1.02e-16	-0.47	-0.4	Menopause (age at onset);	chr17:43135907	chr17:43144956~43145255:+
THCA	cis	rs875971	0.66	rs12698534	ENSG00000237310.1	GS1-124K5.4	9.44	1.7e-19	1.03e-16	0.29	0.4	Aortic root size;	chr7:66521858	chr7:66493706~66495474:+
THCA	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-9.44	1.71e-19	1.03e-16	-0.28	-0.4	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
THCA	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-9.44	1.71e-19	1.03e-16	-0.28	-0.4	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
THCA	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-9.44	1.71e-19	1.03e-16	-0.28	-0.4	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
THCA	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-9.44	1.71e-19	1.03e-16	-0.28	-0.4	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
THCA	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-9.44	1.72e-19	1.03e-16	-0.42	-0.4	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
THCA	cis	rs4819052	0.851	rs2838832	ENSG00000215447.6	BX322557.10	9.44	1.73e-19	1.04e-16	0.33	0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45288052~45291738:+
THCA	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	9.44	1.73e-19	1.04e-16	0.51	0.4	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
THCA	cis	rs66887589	0.777	rs10015883	ENSG00000245958.5	RP11-33B1.1	-9.44	1.74e-19	1.04e-16	-0.36	-0.4	Diastolic blood pressure;	chr4:119346991	chr4:119454791~119552025:+
THCA	cis	rs7829975	0.626	rs332040	ENSG00000253893.2	FAM85B	-9.44	1.74e-19	1.05e-16	-0.52	-0.4	Mood instability;	chr8:8872978	chr8:8167819~8226614:-
THCA	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-9.44	1.74e-19	1.05e-16	-0.5	-0.4	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
THCA	cis	rs7569084	1	rs13385171	ENSG00000237979.1	AC007389.1	-9.44	1.74e-19	1.05e-16	-0.46	-0.4	Sum eosinophil basophil counts;	chr2:65434709	chr2:65500993~65502138:-
THCA	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-9.44	1.76e-19	1.06e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
THCA	cis	rs7712401	0.601	rs246287	ENSG00000263432.2	RN7SL689P	9.44	1.76e-19	1.06e-16	0.44	0.4	Mean platelet volume;	chr5:122909731	chr5:123022487~123022783:-
THCA	cis	rs944289	0.74	rs1467794	ENSG00000257826.1	RP11-116N8.4	9.44	1.77e-19	1.06e-16	0.41	0.4	Thyroid cancer;	chr14:36097617	chr14:36061026~36067190:-
THCA	cis	rs66486766	1	rs66486766	ENSG00000259728.4	LINC00933	9.44	1.77e-19	1.06e-16	0.57	0.4	Bipolar disorder lithium response (categorical) or schizophrenia;	chr15:84137308	chr15:84570649~84580175:+
THCA	cis	rs597539	0.652	rs501799	ENSG00000250508.1	RP11-757G1.6	-9.44	1.77e-19	1.06e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863772	chr11:68870664~68874542:+
THCA	cis	rs7569084	0.522	rs906577	ENSG00000204929.10	AC074391.1	9.44	1.78e-19	1.07e-16	0.52	0.4	Sum eosinophil basophil counts;	chr2:65369523	chr2:65436711~66084639:+
THCA	cis	rs3813579	0.568	rs4506909	ENSG00000261390.4	RP11-345M22.2	-9.44	1.78e-19	1.07e-16	-0.44	-0.4	Thyroid volume;	chr16:79719622	chr16:79715232~79770563:-
THCA	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	9.44	1.78e-19	1.07e-16	0.48	0.4	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
THCA	cis	rs780096	0.546	rs35073769	ENSG00000234072.1	AC074117.10	-9.44	1.79e-19	1.07e-16	-0.32	-0.4	Total body bone mineral density;	chr2:27508509	chr2:27356246~27367622:+
THCA	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	9.44	1.79e-19	1.08e-16	0.48	0.4	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
THCA	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-9.44	1.79e-19	1.08e-16	-0.59	-0.4	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
THCA	cis	rs2274273	0.588	rs7154831	ENSG00000258413.1	RP11-665C16.6	-9.44	1.8e-19	1.08e-16	-0.55	-0.4	Protein biomarker;	chr14:55357247	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.588	rs58296156	ENSG00000258413.1	RP11-665C16.6	-9.44	1.8e-19	1.08e-16	-0.55	-0.4	Protein biomarker;	chr14:55361609	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.588	rs7158791	ENSG00000258413.1	RP11-665C16.6	-9.44	1.8e-19	1.08e-16	-0.55	-0.4	Protein biomarker;	chr14:55361889	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.588	rs11158037	ENSG00000258413.1	RP11-665C16.6	-9.44	1.8e-19	1.08e-16	-0.55	-0.4	Protein biomarker;	chr14:55365434	chr14:55262767~55272075:-
THCA	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-9.44	1.81e-19	1.09e-16	-0.54	-0.4	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
THCA	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	9.43	1.82e-19	1.09e-16	0.34	0.4	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
THCA	cis	rs2836950	0.545	rs11701805	ENSG00000255568.3	BRWD1-AS2	-9.43	1.82e-19	1.09e-16	-0.33	-0.4	Menarche (age at onset);	chr21:39246757	chr21:39313935~39314962:+
THCA	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	9.43	1.82e-19	1.1e-16	0.28	0.4	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
THCA	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-9.43	1.82e-19	1.1e-16	-0.28	-0.4	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
THCA	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-9.43	1.82e-19	1.1e-16	-0.28	-0.4	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
THCA	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-9.43	1.82e-19	1.1e-16	-0.28	-0.4	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
THCA	cis	rs9532669	0.926	rs7799	ENSG00000239827.7	SUGT1P3	-9.43	1.83e-19	1.1e-16	-0.43	-0.4	Cervical cancer;	chr13:40958916	chr13:40908159~40921774:-
THCA	cis	rs7727544	0.716	rs4705928	ENSG00000237714.1	P4HA2-AS1	-9.43	1.83e-19	1.1e-16	-0.52	-0.4	Blood metabolite levels;	chr5:132242944	chr5:132184876~132192808:+
THCA	cis	rs9926296	0.715	rs2115401	ENSG00000260259.1	RP11-368I7.4	-9.43	1.83e-19	1.1e-16	-0.42	-0.4	Vitiligo;	chr16:89674201	chr16:89682620~89686569:-
THCA	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-9.43	1.84e-19	1.1e-16	-0.46	-0.4	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
THCA	cis	rs853679	0.517	rs4713150	ENSG00000226314.6	ZNF192P1	-9.43	1.84e-19	1.11e-16	-0.54	-0.4	Depression;	chr6:28168434	chr6:28161781~28169594:+
THCA	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	9.43	1.85e-19	1.11e-16	0.48	0.4	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
THCA	cis	rs1075265	0.749	rs805375	ENSG00000233266.1	HMGB1P31	9.43	1.85e-19	1.11e-16	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54051334~54051760:+
THCA	cis	rs1799949	1	rs4793236	ENSG00000267681.1	CTD-3199J23.6	-9.43	1.86e-19	1.11e-16	-0.47	-0.4	Menopause (age at onset);	chr17:43359072	chr17:43144956~43145255:+
THCA	cis	rs2836950	0.565	rs2150413	ENSG00000255568.3	BRWD1-AS2	-9.43	1.86e-19	1.12e-16	-0.32	-0.4	Menarche (age at onset);	chr21:39242952	chr21:39313935~39314962:+
THCA	cis	rs2115630	0.691	rs61322921	ENSG00000225151.9	GOLGA2P7	9.43	1.86e-19	1.12e-16	0.51	0.4	P wave terminal force;	chr15:84620407	chr15:84199311~84230136:-
THCA	cis	rs2836950	0.545	rs2836956	ENSG00000255568.3	BRWD1-AS2	9.43	1.87e-19	1.12e-16	0.33	0.4	Menarche (age at onset);	chr21:39251092	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.52	rs11911087	ENSG00000255568.3	BRWD1-AS2	-9.43	1.89e-19	1.13e-16	-0.32	-0.4	Menarche (age at onset);	chr21:39293266	chr21:39313935~39314962:+
THCA	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-9.43	1.9e-19	1.14e-16	-0.28	-0.4	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
THCA	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-9.43	1.9e-19	1.14e-16	-0.28	-0.4	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
THCA	cis	rs1823874	0.924	rs4965542	ENSG00000182397.13	DNM1P46	-9.43	1.9e-19	1.14e-16	-0.44	-0.4	IgG glycosylation;	chr15:99816414	chr15:99790156~99806927:-
THCA	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-9.43	1.9e-19	1.14e-16	-0.79	-0.4	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
THCA	cis	rs10740039	0.883	rs7918897	ENSG00000254271.1	RP11-131N11.4	9.43	1.91e-19	1.14e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643754	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.804	rs7902456	ENSG00000254271.1	RP11-131N11.4	9.43	1.91e-19	1.14e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643937	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.96	rs10761536	ENSG00000254271.1	RP11-131N11.4	9.43	1.91e-19	1.14e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644657	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10994455	ENSG00000254271.1	RP11-131N11.4	9.43	1.91e-19	1.14e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645589	chr10:60734342~60741828:+
THCA	cis	rs7189233	0.531	rs8055642	ENSG00000279344.1	RP11-44F14.7	9.43	1.91e-19	1.15e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr16:53503669	chr16:53478957~53481550:-
THCA	cis	rs8091660	0.929	rs4939780	ENSG00000278983.1	RP11-426J5.3	9.43	1.91e-19	1.15e-16	0.51	0.4	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48568873	chr18:48564795~48568342:+
THCA	cis	rs8062405	0.723	rs62031562	ENSG00000251417.2	RP11-1348G14.4	-9.43	1.92e-19	1.15e-16	-0.41	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28802743~28817828:+
THCA	cis	rs8072100	0.869	rs4439799	ENSG00000228782.6	CTD-2026D20.3	9.43	1.93e-19	1.16e-16	0.36	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704233	chr17:47450568~47492492:-
THCA	cis	rs6920372	0.708	rs13198852	ENSG00000260273.1	RP11-425D10.10	9.43	1.93e-19	1.16e-16	0.47	0.4	Height;	chr6:109747119	chr6:109382795~109383666:+
THCA	cis	rs934734	0.563	rs11673956	ENSG00000204929.10	AC074391.1	9.43	1.94e-19	1.16e-16	0.52	0.4	Rheumatoid arthritis;	chr2:65370523	chr2:65436711~66084639:+
THCA	cis	rs934734	0.563	rs11673987	ENSG00000204929.10	AC074391.1	9.43	1.94e-19	1.16e-16	0.52	0.4	Rheumatoid arthritis;	chr2:65370537	chr2:65436711~66084639:+
THCA	cis	rs67311347	0.544	rs9833640	ENSG00000223797.4	ENTPD3-AS1	9.43	1.94e-19	1.16e-16	0.32	0.4	Renal cell carcinoma;	chr3:40313450	chr3:40313802~40453329:-
THCA	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-9.43	1.95e-19	1.17e-16	-0.48	-0.4	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
THCA	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-9.43	1.95e-19	1.17e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
THCA	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-9.43	1.95e-19	1.17e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
THCA	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-9.43	1.95e-19	1.17e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
THCA	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-9.43	1.95e-19	1.17e-16	-0.45	-0.4	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
THCA	cis	rs7221109	0.601	rs2462964	ENSG00000278834.1	RP11-458J1.1	-9.43	1.96e-19	1.17e-16	-0.43	-0.4	Type 1 diabetes;	chr17:40706276	chr17:40648300~40649718:+
THCA	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	9.42	1.96e-19	1.17e-16	0.6	0.4	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
THCA	cis	rs17772222	0.63	rs7146241	ENSG00000258789.1	RP11-507K2.3	9.42	1.97e-19	1.18e-16	0.38	0.4	Coronary artery calcification;	chr14:88551622	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.63	rs930181	ENSG00000258789.1	RP11-507K2.3	9.42	1.97e-19	1.18e-16	0.38	0.4	Coronary artery calcification;	chr14:88552364	chr14:88551597~88552493:+
THCA	cis	rs875971	0.66	rs3764903	ENSG00000237310.1	GS1-124K5.4	-9.42	1.97e-19	1.18e-16	-0.29	-0.4	Aortic root size;	chr7:66633495	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs1860470	ENSG00000237310.1	GS1-124K5.4	-9.42	1.97e-19	1.18e-16	-0.29	-0.4	Aortic root size;	chr7:66638707	chr7:66493706~66495474:+
THCA	cis	rs11148252	0.774	rs6561666	ENSG00000278238.1	RP11-245D16.4	-9.42	1.98e-19	1.19e-16	-0.44	-0.4	Lewy body disease;	chr13:52355910	chr13:52454775~52455331:-
THCA	cis	rs934734	0.563	rs11126035	ENSG00000204929.10	AC074391.1	9.42	1.98e-19	1.19e-16	0.52	0.4	Rheumatoid arthritis;	chr2:65369932	chr2:65436711~66084639:+
THCA	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	9.42	1.99e-19	1.19e-16	0.41	0.4	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
THCA	cis	rs1858037	0.867	rs6727013	ENSG00000281920.1	RP11-418H16.1	9.42	1.99e-19	1.19e-16	0.53	0.4	Rheumatoid arthritis;	chr2:65331241	chr2:65623272~65628424:+
THCA	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-9.42	2e-19	1.19e-16	-0.55	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
THCA	cis	rs2836950	0.52	rs2836966	ENSG00000255568.3	BRWD1-AS2	-9.42	2e-19	1.2e-16	-0.32	-0.4	Menarche (age at onset);	chr21:39265595	chr21:39313935~39314962:+
THCA	cis	rs6920372	0.748	rs12528392	ENSG00000260273.1	RP11-425D10.10	9.42	2e-19	1.2e-16	0.47	0.4	Height;	chr6:109747411	chr6:109382795~109383666:+
THCA	cis	rs6920372	0.692	rs11153216	ENSG00000260273.1	RP11-425D10.10	9.42	2e-19	1.2e-16	0.47	0.4	Height;	chr6:109748819	chr6:109382795~109383666:+
THCA	cis	rs6920372	0.748	rs2025147	ENSG00000260273.1	RP11-425D10.10	9.42	2e-19	1.2e-16	0.47	0.4	Height;	chr6:109749564	chr6:109382795~109383666:+
THCA	cis	rs11696845	0.787	rs13043441	ENSG00000276223.1	RP4-781B1.5	-9.42	2.03e-19	1.21e-16	-0.49	-0.4	Obesity-related traits;	chr20:44735667	chr20:44746642~44747201:+
THCA	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-9.42	2.03e-19	1.21e-16	-0.67	-0.4	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
THCA	cis	rs8062405	0.573	rs8045689	ENSG00000251417.2	RP11-1348G14.4	9.42	2.03e-19	1.21e-16	0.41	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28976948	chr16:28802743~28817828:+
THCA	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-9.42	2.03e-19	1.21e-16	-0.55	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
THCA	cis	rs7615952	0.515	rs4267608	ENSG00000171084.14	FAM86JP	9.42	2.03e-19	1.21e-16	0.5	0.4	Blood pressure (smoking interaction);	chr3:125961657	chr3:125916620~125930024:+
THCA	cis	rs860295	0.627	rs11264410	ENSG00000225855.5	RUSC1-AS1	9.42	2.03e-19	1.21e-16	0.28	0.4	Body mass index;	chr1:155775558	chr1:155316863~155324176:-
THCA	cis	rs17684571	0.7	rs13200768	ENSG00000231441.1	RP11-472M19.2	9.42	2.03e-19	1.21e-16	0.54	0.4	Schizophrenia;	chr6:56786828	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13204466	ENSG00000231441.1	RP11-472M19.2	9.42	2.03e-19	1.21e-16	0.54	0.4	Schizophrenia;	chr6:56787376	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs34612783	ENSG00000231441.1	RP11-472M19.2	9.42	2.03e-19	1.21e-16	0.54	0.4	Schizophrenia;	chr6:56787851	chr6:56844002~56864078:+
THCA	cis	rs526231	0.578	rs1898672	ENSG00000175749.11	EIF3KP1	-9.42	2.03e-19	1.22e-16	-0.52	-0.4	Primary biliary cholangitis;	chr5:102958149	chr5:103032376~103033031:+
THCA	cis	rs9640161	0.659	rs59572505	ENSG00000261305.1	RP4-584D14.7	9.42	2.05e-19	1.22e-16	0.48	0.4	Blood protein levels;Circulating chemerin levels;	chr7:150317897	chr7:150341771~150342607:+
THCA	cis	rs526231	0.578	rs59323174	ENSG00000175749.11	EIF3KP1	9.42	2.05e-19	1.22e-16	0.53	0.4	Primary biliary cholangitis;	chr5:102932165	chr5:103032376~103033031:+
THCA	cis	rs7712401	0.601	rs448505	ENSG00000263432.2	RN7SL689P	-9.42	2.05e-19	1.22e-16	-0.45	-0.4	Mean platelet volume;	chr5:123000995	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs2164773	ENSG00000263432.2	RN7SL689P	-9.42	2.05e-19	1.22e-16	-0.45	-0.4	Mean platelet volume;	chr5:123003222	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.601	rs418562	ENSG00000263432.2	RN7SL689P	-9.42	2.05e-19	1.22e-16	-0.45	-0.4	Mean platelet volume;	chr5:123004567	chr5:123022487~123022783:-
THCA	cis	rs17826219	0.789	rs4794873	ENSG00000263531.1	RP13-753N3.1	9.42	2.05e-19	1.23e-16	0.72	0.4	Body mass index;	chr17:30421334	chr17:30863921~30864940:-
THCA	cis	rs916888	0.821	rs199513	ENSG00000232300.1	FAM215B	-9.42	2.06e-19	1.23e-16	-0.63	-0.4	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46558830~46562795:-
THCA	cis	rs7727544	0.631	rs13357280	ENSG00000237714.1	P4HA2-AS1	9.42	2.07e-19	1.24e-16	0.53	0.4	Blood metabolite levels;	chr5:132264494	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.594	rs10479000	ENSG00000237714.1	P4HA2-AS1	9.42	2.07e-19	1.24e-16	0.53	0.4	Blood metabolite levels;	chr5:132271709	chr5:132184876~132192808:+
THCA	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-9.42	2.07e-19	1.24e-16	-0.59	-0.4	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
THCA	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-9.42	2.1e-19	1.25e-16	-0.49	-0.4	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
THCA	cis	rs1061377	0.861	rs35739603	ENSG00000249685.1	RP11-360F5.3	9.42	2.11e-19	1.26e-16	0.49	0.4	Uric acid levels;	chr4:39107938	chr4:39133913~39135608:+
THCA	cis	rs875971	0.66	rs10263935	ENSG00000237310.1	GS1-124K5.4	9.41	2.13e-19	1.27e-16	0.29	0.4	Aortic root size;	chr7:66631041	chr7:66493706~66495474:+
THCA	cis	rs597539	0.652	rs513359	ENSG00000250508.1	RP11-757G1.6	9.41	2.14e-19	1.28e-16	0.47	0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68902028	chr11:68870664~68874542:+
THCA	cis	rs62103177	0.535	rs4799109	ENSG00000261126.6	RP11-795F19.1	9.41	2.14e-19	1.28e-16	0.45	0.4	Opioid sensitivity;	chr18:79915188	chr18:80046900~80095482:+
THCA	cis	rs1858037	0.867	rs4671658	ENSG00000281920.1	RP11-418H16.1	-9.41	2.15e-19	1.28e-16	-0.53	-0.4	Rheumatoid arthritis;	chr2:65334258	chr2:65623272~65628424:+
THCA	cis	rs7189233	0.531	rs1362429	ENSG00000279344.1	RP11-44F14.7	9.41	2.16e-19	1.29e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr16:53445172	chr16:53478957~53481550:-
THCA	cis	rs9487094	0.626	rs2025148	ENSG00000260273.1	RP11-425D10.10	9.41	2.16e-19	1.29e-16	0.47	0.4	Height;	chr6:109706740	chr6:109382795~109383666:+
THCA	cis	rs11051970	0.527	rs7977938	ENSG00000274964.1	RP11-817I4.1	-9.41	2.17e-19	1.3e-16	-0.5	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32322406	chr12:32339368~32340724:+
THCA	cis	rs4819052	0.8	rs4819045	ENSG00000215447.6	BX322557.10	-9.41	2.17e-19	1.3e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45288052~45291738:+
THCA	cis	rs6496932	0.909	rs74024818	ENSG00000218052.5	ADAMTS7P4	9.41	2.18e-19	1.3e-16	0.59	0.4	Central corneal thickness;Corneal structure;	chr15:85339299	chr15:85255369~85330334:-
THCA	cis	rs9487094	0.626	rs1322124	ENSG00000260273.1	RP11-425D10.10	9.41	2.18e-19	1.3e-16	0.47	0.4	Height;	chr6:109741670	chr6:109382795~109383666:+
THCA	cis	rs10740039	0.883	rs1561850	ENSG00000254271.1	RP11-131N11.4	9.41	2.18e-19	1.3e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60631583	chr10:60734342~60741828:+
THCA	cis	rs853679	0.517	rs4713141	ENSG00000226314.6	ZNF192P1	-9.41	2.19e-19	1.3e-16	-0.54	-0.4	Depression;	chr6:28133900	chr6:28161781~28169594:+
THCA	cis	rs4660456	0.504	rs570671	ENSG00000237899.1	RP4-739H11.3	9.41	2.19e-19	1.3e-16	0.55	0.4	Platelet count;	chr1:40625455	chr1:40669089~40687588:-
THCA	cis	rs3931020	0.616	rs277381	ENSG00000272864.1	RP11-17E13.2	9.41	2.19e-19	1.31e-16	0.47	0.4	Resistin levels;	chr1:74801131	chr1:74698769~74699333:-
THCA	cis	rs1387259	0.698	rs4579969	ENSG00000258273.1	RP11-370I10.4	9.41	2.2e-19	1.31e-16	0.5	0.4	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48333755~48333901:-
THCA	cis	rs526231	0.697	rs253759	ENSG00000175749.11	EIF3KP1	9.41	2.2e-19	1.31e-16	0.6	0.4	Primary biliary cholangitis;	chr5:103279974	chr5:103032376~103033031:+
THCA	cis	rs4713118	0.868	rs2893928	ENSG00000219392.1	RP1-265C24.5	-9.41	2.21e-19	1.32e-16	-0.55	-0.4	Parkinson's disease;	chr6:27770651	chr6:28115628~28116551:+
THCA	cis	rs9926296	0.744	rs460984	ENSG00000260259.1	RP11-368I7.4	9.41	2.21e-19	1.32e-16	0.45	0.4	Vitiligo;	chr16:89646766	chr16:89682620~89686569:-
THCA	cis	rs62103177	0.608	rs59300126	ENSG00000261126.6	RP11-795F19.1	9.41	2.22e-19	1.32e-16	0.44	0.4	Opioid sensitivity;	chr18:79934439	chr18:80046900~80095482:+
THCA	cis	rs9322193	0.923	rs9377230	ENSG00000268592.3	RAET1E-AS1	9.41	2.22e-19	1.32e-16	0.54	0.4	Lung cancer;	chr6:149613607	chr6:149863494~149919507:+
THCA	cis	rs597539	0.652	rs602805	ENSG00000250508.1	RP11-757G1.6	-9.41	2.22e-19	1.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894608	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs602364	ENSG00000250508.1	RP11-757G1.6	-9.41	2.22e-19	1.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68894699	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs668576	ENSG00000250508.1	RP11-757G1.6	-9.41	2.22e-19	1.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68900740	chr11:68870664~68874542:+
THCA	cis	rs10411161	0.935	rs8107422	ENSG00000269483.1	AC006272.1	9.41	2.23e-19	1.33e-16	0.55	0.4	Breast cancer;	chr19:51865522	chr19:51839924~51843324:-
THCA	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	9.41	2.24e-19	1.33e-16	0.51	0.4	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
THCA	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	9.41	2.24e-19	1.33e-16	0.51	0.4	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
THCA	cis	rs881375	0.526	rs1930785	ENSG00000226752.6	PSMD5-AS1	-9.41	2.24e-19	1.34e-16	-0.48	-0.4	Rheumatoid arthritis;	chr9:120928959	chr9:120824828~120854385:+
THCA	cis	rs7826238	0.601	rs2979206	ENSG00000253893.2	FAM85B	-9.41	2.25e-19	1.34e-16	-0.53	-0.4	Systolic blood pressure;	chr8:8488071	chr8:8167819~8226614:-
THCA	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-9.41	2.28e-19	1.36e-16	-0.78	-0.4	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-9.41	2.28e-19	1.36e-16	-0.78	-0.4	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
THCA	cis	rs934734	0.563	rs11126034	ENSG00000204929.10	AC074391.1	-9.41	2.28e-19	1.36e-16	-0.52	-0.4	Rheumatoid arthritis;	chr2:65353087	chr2:65436711~66084639:+
THCA	cis	rs6046396	1	rs6112627	ENSG00000275142.1	RP5-999L4.2	-9.41	2.29e-19	1.37e-16	-0.54	-0.4	Bipolar disorder and schizophrenia;	chr20:19877342	chr20:19871891~19872284:+
THCA	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	9.41	2.29e-19	1.37e-16	0.33	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
THCA	cis	rs1075265	0.749	rs805380	ENSG00000233266.1	HMGB1P31	9.41	2.3e-19	1.37e-16	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54051334~54051760:+
THCA	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-9.4	2.31e-19	1.38e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
THCA	cis	rs597539	0.652	rs584108	ENSG00000250508.1	RP11-757G1.6	9.4	2.32e-19	1.38e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68862814	chr11:68870664~68874542:+
THCA	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	9.4	2.33e-19	1.38e-16	0.28	0.4	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
THCA	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-9.4	2.33e-19	1.39e-16	-0.55	-0.4	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
THCA	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-9.4	2.33e-19	1.39e-16	-0.5	-0.4	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
THCA	cis	rs780096	0.565	rs8179252	ENSG00000234072.1	AC074117.10	-9.4	2.34e-19	1.39e-16	-0.32	-0.4	Total body bone mineral density;	chr2:27523965	chr2:27356246~27367622:+
THCA	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	9.4	2.34e-19	1.39e-16	0.48	0.4	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
THCA	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-9.4	2.34e-19	1.39e-16	-0.38	-0.4	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
THCA	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	9.4	2.35e-19	1.4e-16	0.52	0.4	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
THCA	cis	rs4819052	0.851	rs1999333	ENSG00000215447.6	BX322557.10	-9.4	2.35e-19	1.4e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45288052~45291738:+
THCA	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	9.4	2.35e-19	1.4e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
THCA	cis	rs9532669	0.889	rs9549302	ENSG00000239827.7	SUGT1P3	-9.4	2.36e-19	1.4e-16	-0.45	-0.4	Cervical cancer;	chr13:40843278	chr13:40908159~40921774:-
THCA	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	9.4	2.36e-19	1.4e-16	0.47	0.4	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
THCA	cis	rs6908034	0.607	rs73378506	ENSG00000228412.5	RP4-625H18.2	9.4	2.36e-19	1.41e-16	0.8	0.4	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819756	chr6:19802164~19804752:-
THCA	cis	rs17772222	0.682	rs4904452	ENSG00000258789.1	RP11-507K2.3	9.4	2.36e-19	1.41e-16	0.38	0.4	Coronary artery calcification;	chr14:88517329	chr14:88551597~88552493:+
THCA	cis	rs9926296	0.744	rs154657	ENSG00000260259.1	RP11-368I7.4	-9.4	2.37e-19	1.41e-16	-0.43	-0.4	Vitiligo;	chr16:89641688	chr16:89682620~89686569:-
THCA	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	9.4	2.37e-19	1.41e-16	0.52	0.4	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
THCA	cis	rs1862618	0.529	rs978406	ENSG00000271828.1	CTD-2310F14.1	-9.4	2.37e-19	1.41e-16	-0.63	-0.4	Initial pursuit acceleration;	chr5:56963981	chr5:56927874~56929573:+
THCA	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	9.4	2.37e-19	1.41e-16	0.58	0.4	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
THCA	cis	rs597539	0.689	rs596874	ENSG00000250508.1	RP11-757G1.6	9.4	2.38e-19	1.41e-16	0.46	0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68863406	chr11:68870664~68874542:+
THCA	cis	rs6565180	0.525	rs1132812	ENSG00000183604.13	SMG1P5	9.4	2.38e-19	1.42e-16	0.43	0.4	Tonsillectomy;	chr16:30186830	chr16:30267553~30335374:-
THCA	cis	rs4819052	0.851	rs2838831	ENSG00000215447.6	BX322557.10	-9.4	2.39e-19	1.42e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45288052~45291738:+
THCA	cis	rs6750795	0.569	rs1667308	ENSG00000181798.2	LINC00471	-9.4	2.39e-19	1.42e-16	-0.45	-0.4	Height;	chr2:231541633	chr2:231508426~231514339:-
THCA	cis	rs10740039	0.734	rs10821815	ENSG00000254271.1	RP11-131N11.4	9.4	2.4e-19	1.43e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644843	chr10:60734342~60741828:+
THCA	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-9.4	2.41e-19	1.43e-16	-0.48	-0.4	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
THCA	cis	rs597539	0.654	rs655816	ENSG00000250508.1	RP11-757G1.6	-9.4	2.41e-19	1.43e-16	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858937	chr11:68870664~68874542:+
THCA	cis	rs11098499	0.739	rs9996382	ENSG00000245958.5	RP11-33B1.1	-9.4	2.42e-19	1.44e-16	-0.37	-0.4	Corneal astigmatism;	chr4:119229857	chr4:119454791~119552025:+
THCA	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-9.4	2.42e-19	1.44e-16	-0.62	-0.4	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
THCA	cis	rs848490	0.674	rs17807185	ENSG00000214293.7	APTR	9.4	2.45e-19	1.46e-16	0.29	0.4	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678978	chr7:77657660~77696265:-
THCA	cis	rs10411161	1	rs10414104	ENSG00000269483.1	AC006272.1	9.39	2.51e-19	1.49e-16	0.55	0.4	Breast cancer;	chr19:51864879	chr19:51839924~51843324:-
THCA	cis	rs10740039	0.883	rs10994446	ENSG00000254271.1	RP11-131N11.4	9.39	2.51e-19	1.49e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639433	chr10:60734342~60741828:+
THCA	cis	rs748404	0.697	rs546722	ENSG00000249839.1	AC011330.5	-9.39	2.55e-19	1.51e-16	-0.47	-0.4	Lung cancer;	chr15:43288621	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.765	rs2838854	ENSG00000215447.6	BX322557.10	-9.39	2.56e-19	1.52e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45288052~45291738:+
THCA	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	9.39	2.59e-19	1.54e-16	0.49	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
THCA	cis	rs853679	0.517	rs9393895	ENSG00000226314.6	ZNF192P1	-9.39	2.6e-19	1.54e-16	-0.53	-0.4	Depression;	chr6:28159843	chr6:28161781~28169594:+
THCA	cis	rs12550612	0.614	rs11135696	ENSG00000253616.4	RP11-875O11.3	9.39	2.6e-19	1.54e-16	0.55	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084410	chr8:23071377~23074488:-
THCA	cis	rs848490	0.651	rs7810273	ENSG00000214293.7	APTR	9.39	2.62e-19	1.56e-16	0.29	0.4	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685327	chr7:77657660~77696265:-
THCA	cis	rs8062405	0.755	rs2077031	ENSG00000251417.2	RP11-1348G14.4	-9.39	2.66e-19	1.58e-16	-0.41	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.723	rs762633	ENSG00000251417.2	RP11-1348G14.4	-9.39	2.67e-19	1.58e-16	-0.41	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28802743~28817828:+
THCA	cis	rs524281	0.731	rs10791838	ENSG00000255320.1	RP11-755F10.1	9.39	2.68e-19	1.58e-16	0.63	0.4	Electroencephalogram traits;	chr11:66022383	chr11:66244840~66246239:-
THCA	cis	rs7221109	0.56	rs2253717	ENSG00000278834.1	RP11-458J1.1	-9.39	2.68e-19	1.59e-16	-0.41	-0.4	Type 1 diabetes;	chr17:40711984	chr17:40648300~40649718:+
THCA	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	9.39	2.68e-19	1.59e-16	0.38	0.4	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
THCA	cis	rs9322193	0.923	rs9322197	ENSG00000268592.3	RAET1E-AS1	9.39	2.69e-19	1.59e-16	0.53	0.4	Lung cancer;	chr6:149622577	chr6:149863494~149919507:+
THCA	cis	rs11676348	0.838	rs17844697	ENSG00000261338.2	RP11-378A13.1	-9.39	2.7e-19	1.6e-16	-0.4	-0.4	Ulcerative colitis;	chr2:218134532	chr2:218255319~218257366:+
THCA	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-9.38	2.72e-19	1.61e-16	-0.47	-0.4	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
THCA	cis	rs4819052	0.851	rs2838843	ENSG00000215447.6	BX322557.10	-9.38	2.73e-19	1.61e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45288052~45291738:+
THCA	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	9.38	2.73e-19	1.61e-16	0.51	0.4	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
THCA	cis	rs7829975	0.711	rs1039916	ENSG00000253893.2	FAM85B	-9.38	2.73e-19	1.61e-16	-0.51	-0.4	Mood instability;	chr8:8828344	chr8:8167819~8226614:-
THCA	cis	rs7826238	0.601	rs2976907	ENSG00000253893.2	FAM85B	-9.38	2.73e-19	1.61e-16	-0.53	-0.4	Systolic blood pressure;	chr8:8487658	chr8:8167819~8226614:-
THCA	cis	rs73219805	0.793	rs1564576	ENSG00000228451.3	SDAD1P1	-9.38	2.73e-19	1.61e-16	-0.5	-0.4	Schizophrenia;	chr8:26333320	chr8:26379259~26382953:-
THCA	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	9.38	2.73e-19	1.62e-16	0.52	0.4	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
THCA	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	9.38	2.75e-19	1.63e-16	0.52	0.4	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
THCA	cis	rs11051970	0.559	rs11536026	ENSG00000274964.1	RP11-817I4.1	-9.38	2.78e-19	1.64e-16	-0.53	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32316593	chr12:32339368~32340724:+
THCA	cis	rs2274273	0.563	rs79163357	ENSG00000258413.1	RP11-665C16.6	-9.38	2.78e-19	1.64e-16	-0.55	-0.4	Protein biomarker;	chr14:55271731	chr14:55262767~55272075:-
THCA	cis	rs12468226	0.752	rs116078354	ENSG00000273456.1	RP11-686O6.2	9.38	2.79e-19	1.65e-16	0.5	0.4	Urate levels;	chr2:202136356	chr2:202374932~202375604:-
THCA	cis	rs10740039	0.883	rs1470237	ENSG00000254271.1	RP11-131N11.4	9.38	2.79e-19	1.65e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653381	chr10:60734342~60741828:+
THCA	cis	rs17608059	0.634	rs10852819	ENSG00000141028.6	CDRT15P1	-9.38	2.79e-19	1.65e-16	-0.46	-0.4	Temperament;	chr17:14018109	chr17:14024514~14025488:+
THCA	cis	rs801193	1	rs7782320	ENSG00000237310.1	GS1-124K5.4	9.38	2.79e-19	1.65e-16	0.29	0.4	Aortic root size;	chr7:66712111	chr7:66493706~66495474:+
THCA	cis	rs7727544	0.716	rs6863213	ENSG00000237714.1	P4HA2-AS1	9.38	2.8e-19	1.65e-16	0.53	0.4	Blood metabolite levels;	chr5:132240239	chr5:132184876~132192808:+
THCA	cis	rs4819052	0.918	rs34886433	ENSG00000215447.6	BX322557.10	-9.38	2.8e-19	1.66e-16	-0.38	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260623	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.884	rs1125	ENSG00000216906.2	RP11-350J20.9	9.38	2.8e-19	1.66e-16	0.46	0.4	Lung cancer;	chr6:149658280	chr6:149904243~149906418:+
THCA	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-9.38	2.82e-19	1.67e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
THCA	cis	rs9402743	0.6	rs9376151	ENSG00000231028.7	LINC00271	-9.38	2.83e-19	1.67e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135789599	chr6:135497801~135716055:+
THCA	cis	rs7727544	1	rs7727038	ENSG00000233006.5	AC034220.3	9.38	2.83e-19	1.67e-16	0.31	0.4	Blood metabolite levels;	chr5:132254564	chr5:132311285~132369916:-
THCA	cis	rs7727544	1	rs7727544	ENSG00000233006.5	AC034220.3	9.38	2.83e-19	1.67e-16	0.31	0.4	Blood metabolite levels;	chr5:132254841	chr5:132311285~132369916:-
THCA	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	9.38	2.83e-19	1.67e-16	0.33	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
THCA	cis	rs73219805	0.671	rs13267955	ENSG00000228451.3	SDAD1P1	-9.38	2.84e-19	1.68e-16	-0.5	-0.4	Schizophrenia;	chr8:26367077	chr8:26379259~26382953:-
THCA	cis	rs7727544	1	rs10076701	ENSG00000233006.5	AC034220.3	9.38	2.85e-19	1.68e-16	0.31	0.4	Blood metabolite levels;	chr5:132260726	chr5:132311285~132369916:-
THCA	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-9.38	2.86e-19	1.69e-16	-0.51	-0.4	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
THCA	cis	rs1799949	1	rs2037075	ENSG00000267681.1	CTD-3199J23.6	-9.38	2.86e-19	1.69e-16	-0.46	-0.4	Menopause (age at onset);	chr17:43153809	chr17:43144956~43145255:+
THCA	cis	rs67311347	0.549	rs60249586	ENSG00000223797.4	ENTPD3-AS1	9.38	2.87e-19	1.7e-16	0.32	0.4	Renal cell carcinoma;	chr3:40205168	chr3:40313802~40453329:-
THCA	cis	rs7208859	0.573	rs55661352	ENSG00000266490.1	CTD-2349P21.9	9.38	2.87e-19	1.7e-16	0.55	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30792372~30792833:+
THCA	cis	rs9487094	0.626	rs3799845	ENSG00000260273.1	RP11-425D10.10	9.38	2.89e-19	1.71e-16	0.47	0.4	Height;	chr6:109706514	chr6:109382795~109383666:+
THCA	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-9.38	2.89e-19	1.71e-16	-0.29	-0.4	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
THCA	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	9.38	2.91e-19	1.72e-16	0.49	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
THCA	cis	rs2274273	0.624	rs8015211	ENSG00000258413.1	RP11-665C16.6	-9.38	2.91e-19	1.72e-16	-0.55	-0.4	Protein biomarker;	chr14:55374729	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.607	rs12210822	ENSG00000268592.3	RAET1E-AS1	9.38	2.92e-19	1.72e-16	0.57	0.4	Lung cancer;	chr6:149905356	chr6:149863494~149919507:+
THCA	cis	rs9318086	0.901	rs7336730	ENSG00000205861.10	C1QTNF9B-AS1	9.37	2.93e-19	1.73e-16	0.44	0.4	Myopia (pathological);	chr13:23877965	chr13:23888889~23897263:+
THCA	cis	rs944289	0.774	rs12589124	ENSG00000257826.1	RP11-116N8.4	-9.37	2.93e-19	1.73e-16	-0.41	-0.4	Thyroid cancer;	chr14:36094718	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs2183451	ENSG00000257826.1	RP11-116N8.4	-9.37	2.93e-19	1.73e-16	-0.41	-0.4	Thyroid cancer;	chr14:36095227	chr14:36061026~36067190:-
THCA	cis	rs944289	0.774	rs884090	ENSG00000257826.1	RP11-116N8.4	-9.37	2.93e-19	1.73e-16	-0.41	-0.4	Thyroid cancer;	chr14:36095741	chr14:36061026~36067190:-
THCA	cis	rs7189233	0.531	rs1074182	ENSG00000279344.1	RP11-44F14.7	9.37	2.93e-19	1.73e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr16:53437445	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs9921587	ENSG00000279344.1	RP11-44F14.7	9.37	2.93e-19	1.73e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr16:53441738	chr16:53478957~53481550:-
THCA	cis	rs11051970	0.559	rs7963887	ENSG00000274964.1	RP11-817I4.1	-9.37	2.93e-19	1.73e-16	-0.5	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32323073	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs10844184	ENSG00000274964.1	RP11-817I4.1	-9.37	2.93e-19	1.73e-16	-0.5	-0.4	Response to tocilizumab in rheumatoid arthritis;	chr12:32323918	chr12:32339368~32340724:+
THCA	cis	rs1577917	0.687	rs13197828	ENSG00000203875.9	SNHG5	-9.37	2.93e-19	1.73e-16	-0.49	-0.4	Response to antipsychotic treatment;	chr6:86095912	chr6:85660950~85678736:-
THCA	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-9.37	2.94e-19	1.74e-16	-0.41	-0.4	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
THCA	cis	rs1799949	1	rs1973646	ENSG00000267681.1	CTD-3199J23.6	-9.37	2.95e-19	1.74e-16	-0.46	-0.4	Menopause (age at onset);	chr17:43158478	chr17:43144956~43145255:+
THCA	cis	rs597539	0.652	rs553875	ENSG00000250508.1	RP11-757G1.6	-9.37	2.96e-19	1.75e-16	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68927676	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs513615	ENSG00000250508.1	RP11-757G1.6	-9.37	2.96e-19	1.75e-16	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68938036	chr11:68870664~68874542:+
THCA	cis	rs71403859	0.667	rs35538253	ENSG00000260886.1	TAT-AS1	9.37	2.96e-19	1.75e-16	0.72	0.4	Post bronchodilator FEV1;	chr16:71644072	chr16:71565789~71578187:+
THCA	cis	rs11971779	0.68	rs17691238	ENSG00000273391.1	RP11-634H22.1	-9.37	2.98e-19	1.76e-16	-0.37	-0.4	Diisocyanate-induced asthma;	chr7:139367538	chr7:139359032~139359566:-
THCA	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-9.37	2.99e-19	1.76e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
THCA	cis	rs12922040	0.651	rs35288467	ENSG00000263335.1	AF001548.5	-9.37	3.01e-19	1.78e-16	-0.44	-0.4	Serum uric acid levels in response to allopurinol in gout;	chr16:15773097	chr16:15726674~15732993:+
THCA	cis	rs597539	0.616	rs72945243	ENSG00000250508.1	RP11-757G1.6	-9.37	3.02e-19	1.78e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68865890	chr11:68870664~68874542:+
THCA	cis	rs9926296	0.744	rs164747	ENSG00000260259.1	RP11-368I7.4	9.37	3.03e-19	1.79e-16	0.44	0.4	Vitiligo;	chr16:89642272	chr16:89682620~89686569:-
THCA	cis	rs860295	0.756	rs7546258	ENSG00000225855.5	RUSC1-AS1	9.37	3.05e-19	1.8e-16	0.28	0.4	Body mass index;	chr1:155728854	chr1:155316863~155324176:-
THCA	cis	rs10740039	0.883	rs1442540	ENSG00000254271.1	RP11-131N11.4	-9.37	3.05e-19	1.8e-16	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653548	chr10:60734342~60741828:+
THCA	cis	rs7208859	0.623	rs56325146	ENSG00000266490.1	CTD-2349P21.9	9.37	3.07e-19	1.81e-16	0.54	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30792372~30792833:+
THCA	cis	rs673078	0.66	rs11068917	ENSG00000275409.1	RP11-131L12.4	-9.37	3.08e-19	1.81e-16	-0.42	-0.4	Glucose homeostasis traits;	chr12:118353315	chr12:118430147~118430699:+
THCA	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-9.37	3.08e-19	1.81e-16	-0.44	-0.4	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
THCA	cis	rs7712401	0.601	rs154506	ENSG00000263432.2	RN7SL689P	9.37	3.09e-19	1.82e-16	0.44	0.4	Mean platelet volume;	chr5:122867086	chr5:123022487~123022783:-
THCA	cis	rs9322193	0.923	rs9767105	ENSG00000268592.3	RAET1E-AS1	9.37	3.09e-19	1.82e-16	0.54	0.4	Lung cancer;	chr6:149659591	chr6:149863494~149919507:+
THCA	cis	rs848490	0.674	rs62460676	ENSG00000214293.7	APTR	9.37	3.09e-19	1.82e-16	0.29	0.4	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680405	chr7:77657660~77696265:-
THCA	cis	rs11690935	0.655	rs12997093	ENSG00000228389.1	AC068039.4	-9.37	3.1e-19	1.83e-16	-0.41	-0.4	Schizophrenia;	chr2:171707928	chr2:171773482~171775844:+
THCA	cis	rs11676348	0.772	rs12471105	ENSG00000261338.2	RP11-378A13.1	-9.37	3.1e-19	1.83e-16	-0.39	-0.4	Ulcerative colitis;	chr2:218085486	chr2:218255319~218257366:+
THCA	cis	rs950169	0.544	rs2036949	ENSG00000259728.4	LINC00933	9.37	3.11e-19	1.83e-16	0.55	0.4	Schizophrenia;	chr15:84620374	chr15:84570649~84580175:+
THCA	cis	rs10411161	1	rs4514789	ENSG00000269483.1	AC006272.1	9.37	3.11e-19	1.83e-16	0.55	0.4	Breast cancer;	chr19:51862401	chr19:51839924~51843324:-
THCA	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-9.37	3.11e-19	1.83e-16	-0.45	-0.4	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
THCA	cis	rs67311347	0.544	rs6762121	ENSG00000223797.4	ENTPD3-AS1	9.37	3.11e-19	1.83e-16	0.32	0.4	Renal cell carcinoma;	chr3:40313822	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.544	rs6787516	ENSG00000223797.4	ENTPD3-AS1	9.37	3.11e-19	1.83e-16	0.32	0.4	Renal cell carcinoma;	chr3:40314125	chr3:40313802~40453329:-
THCA	cis	rs67311347	0.524	rs7649168	ENSG00000223797.4	ENTPD3-AS1	9.37	3.11e-19	1.83e-16	0.32	0.4	Renal cell carcinoma;	chr3:40314667	chr3:40313802~40453329:-
THCA	cis	rs10740039	0.883	rs7088404	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633320	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs1837946	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633676	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs1837945	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633757	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs7089287	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634006	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs7089720	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634063	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs7093573	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634611	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.804	rs7093882	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634863	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs7097818	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635106	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.842	rs2119913	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635631	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.586	rs7068462	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636240	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs7069814	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637001	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10740037	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637747	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.804	rs10761531	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638177	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.846	rs2165690	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639609	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs2119912	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639754	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs2119911	ENSG00000254271.1	RP11-131N11.4	9.37	3.11e-19	1.83e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639808	chr10:60734342~60741828:+
THCA	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-9.37	3.12e-19	1.83e-16	-0.78	-0.4	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs801192	ENSG00000237310.1	GS1-124K5.4	-9.37	3.13e-19	1.84e-16	-0.28	-0.4	Aortic root size;	chr7:66566965	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs801190	ENSG00000237310.1	GS1-124K5.4	-9.37	3.13e-19	1.84e-16	-0.28	-0.4	Aortic root size;	chr7:66568046	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs3857686	ENSG00000237310.1	GS1-124K5.4	-9.37	3.13e-19	1.84e-16	-0.28	-0.4	Aortic root size;	chr7:66571204	chr7:66493706~66495474:+
THCA	cis	rs875971	0.638	rs6460305	ENSG00000237310.1	GS1-124K5.4	-9.37	3.13e-19	1.84e-16	-0.28	-0.4	Aortic root size;	chr7:66595421	chr7:66493706~66495474:+
THCA	cis	rs875971	0.66	rs10272357	ENSG00000237310.1	GS1-124K5.4	-9.37	3.13e-19	1.84e-16	-0.28	-0.4	Aortic root size;	chr7:66598087	chr7:66493706~66495474:+
THCA	cis	rs10740039	0.842	rs1442541	ENSG00000254271.1	RP11-131N11.4	9.37	3.15e-19	1.85e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626285	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs1867081	ENSG00000254271.1	RP11-131N11.4	9.37	3.15e-19	1.85e-16	0.49	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626569	chr10:60734342~60741828:+
THCA	cis	rs7189233	0.531	rs6499617	ENSG00000279344.1	RP11-44F14.7	9.37	3.15e-19	1.86e-16	0.39	0.4	Intelligence (multi-trait analysis);	chr16:53433810	chr16:53478957~53481550:-
THCA	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-9.37	3.15e-19	1.86e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
THCA	cis	rs875971	0.66	rs28698552	ENSG00000237310.1	GS1-124K5.4	9.37	3.16e-19	1.86e-16	0.28	0.4	Aortic root size;	chr7:66540031	chr7:66493706~66495474:+
THCA	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	9.36	3.17e-19	1.87e-16	0.49	0.4	Height;	chr11:118854014	chr11:118688039~118690600:-
THCA	cis	rs875971	0.638	rs10249404	ENSG00000237310.1	GS1-124K5.4	-9.36	3.18e-19	1.87e-16	-0.28	-0.4	Aortic root size;	chr7:66581737	chr7:66493706~66495474:+
THCA	cis	rs7189233	0.531	rs13332071	ENSG00000279344.1	RP11-44F14.7	9.36	3.22e-19	1.89e-16	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53409724	chr16:53478957~53481550:-
THCA	cis	rs1075265	0.756	rs2160931	ENSG00000233266.1	HMGB1P31	9.36	3.23e-19	1.9e-16	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54051334~54051760:+
THCA	cis	rs944289	0.74	rs1537425	ENSG00000257826.1	RP11-116N8.4	9.36	3.24e-19	1.9e-16	0.4	0.4	Thyroid cancer;	chr14:36098954	chr14:36061026~36067190:-
THCA	cis	rs11676348	0.772	rs6738953	ENSG00000261338.2	RP11-378A13.1	-9.36	3.24e-19	1.9e-16	-0.4	-0.4	Ulcerative colitis;	chr2:218085313	chr2:218255319~218257366:+
THCA	cis	rs7829975	0.742	rs7832968	ENSG00000253893.2	FAM85B	-9.36	3.26e-19	1.91e-16	-0.5	-0.4	Mood instability;	chr8:8795379	chr8:8167819~8226614:-
THCA	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	9.36	3.28e-19	1.93e-16	0.6	0.4	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
THCA	cis	rs944289	0.708	rs1958622	ENSG00000257826.1	RP11-116N8.4	-9.36	3.29e-19	1.93e-16	-0.42	-0.4	Thyroid cancer;	chr14:36127289	chr14:36061026~36067190:-
THCA	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-9.36	3.29e-19	1.93e-16	-0.33	-0.4	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
THCA	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	9.36	3.3e-19	1.94e-16	0.64	0.4	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
THCA	cis	rs4819052	0.851	rs2838866	ENSG00000215447.6	BX322557.10	-9.36	3.3e-19	1.94e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45288052~45291738:+
THCA	cis	rs597539	0.654	rs619727	ENSG00000250508.1	RP11-757G1.6	-9.36	3.3e-19	1.94e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68860067	chr11:68870664~68874542:+
THCA	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-9.36	3.32e-19	1.95e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-9.36	3.32e-19	1.95e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-9.36	3.32e-19	1.95e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-9.36	3.32e-19	1.95e-16	-0.77	-0.4	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
THCA	cis	rs62355901	1	rs62355901	ENSG00000271828.1	CTD-2310F14.1	9.36	3.33e-19	1.95e-16	0.66	0.4	Breast cancer;	chr5:56757708	chr5:56927874~56929573:+
THCA	cis	rs12188164	0.686	rs56279338	ENSG00000221990.4	EXOC3-AS1	9.36	3.33e-19	1.95e-16	0.35	0.4	Cystic fibrosis severity;	chr5:416003	chr5:441498~443160:-
THCA	cis	rs12188164	0.686	rs72711365	ENSG00000221990.4	EXOC3-AS1	9.36	3.33e-19	1.95e-16	0.35	0.4	Cystic fibrosis severity;	chr5:416557	chr5:441498~443160:-
THCA	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	9.36	3.33e-19	1.96e-16	0.48	0.4	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
THCA	cis	rs10740039	0.883	rs10821809	ENSG00000254271.1	RP11-131N11.4	9.36	3.34e-19	1.96e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637612	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs10761533	ENSG00000254271.1	RP11-131N11.4	9.36	3.34e-19	1.96e-16	0.48	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638573	chr10:60734342~60741828:+
THCA	cis	rs853679	0.517	rs4713146	ENSG00000226314.6	ZNF192P1	-9.36	3.35e-19	1.96e-16	-0.54	-0.4	Depression;	chr6:28143758	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9393894	ENSG00000226314.6	ZNF192P1	-9.36	3.35e-19	1.96e-16	-0.54	-0.4	Depression;	chr6:28144784	chr6:28161781~28169594:+
THCA	cis	rs1799949	0.93	rs35292991	ENSG00000267681.1	CTD-3199J23.6	-9.36	3.35e-19	1.97e-16	-0.46	-0.4	Menopause (age at onset);	chr17:43181999	chr17:43144956~43145255:+
THCA	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	9.36	3.35e-19	1.97e-16	0.49	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
THCA	cis	rs4819052	0.851	rs2838855	ENSG00000215447.6	BX322557.10	9.36	3.37e-19	1.98e-16	0.33	0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45288052~45291738:+
THCA	cis	rs7826238	0.72	rs12546760	ENSG00000253893.2	FAM85B	9.36	3.37e-19	1.98e-16	0.51	0.4	Systolic blood pressure;	chr8:8517326	chr8:8167819~8226614:-
THCA	cis	rs7615952	0.515	rs7630575	ENSG00000171084.14	FAM86JP	9.36	3.39e-19	1.99e-16	0.49	0.4	Blood pressure (smoking interaction);	chr3:125963487	chr3:125916620~125930024:+
THCA	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	9.36	3.4e-19	1.99e-16	0.47	0.4	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
THCA	cis	rs9402743	0.632	rs6570029	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135757894	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs9399161	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135759326	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.665	rs6933507	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135760018	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.665	rs4896172	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135760664	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs6570031	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135762018	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs4896173	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135762413	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs4896174	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135762421	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs4896175	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135762568	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs2093330	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135763534	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs2104132	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135763810	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs9389324	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135765375	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs6900101	ENSG00000231028.7	LINC00271	-9.36	3.4e-19	1.99e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135773766	chr6:135497801~135716055:+
THCA	cis	rs8062405	0.723	rs12445744	ENSG00000251417.2	RP11-1348G14.4	-9.36	3.4e-19	2e-16	-0.4	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.755	rs4787455	ENSG00000251417.2	RP11-1348G14.4	-9.36	3.4e-19	2e-16	-0.4	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28802743~28817828:+
THCA	cis	rs9532669	0.926	rs2875421	ENSG00000176268.5	CYCSP34	9.36	3.41e-19	2e-16	0.45	0.4	Cervical cancer;	chr13:40936536	chr13:40863599~40863902:-
THCA	cis	rs17772222	0.63	rs12437422	ENSG00000258789.1	RP11-507K2.3	9.35	3.44e-19	2.02e-16	0.38	0.4	Coronary artery calcification;	chr14:88529621	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.605	rs4899955	ENSG00000258789.1	RP11-507K2.3	9.35	3.44e-19	2.02e-16	0.38	0.4	Coronary artery calcification;	chr14:88530381	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.63	rs4904454	ENSG00000258789.1	RP11-507K2.3	9.35	3.44e-19	2.02e-16	0.38	0.4	Coronary artery calcification;	chr14:88537777	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.63	rs2033418	ENSG00000258789.1	RP11-507K2.3	9.35	3.44e-19	2.02e-16	0.38	0.4	Coronary artery calcification;	chr14:88539331	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.63	rs10873392	ENSG00000258789.1	RP11-507K2.3	9.35	3.44e-19	2.02e-16	0.38	0.4	Coronary artery calcification;	chr14:88545124	chr14:88551597~88552493:+
THCA	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	9.35	3.44e-19	2.02e-16	0.5	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
THCA	cis	rs10740039	1	rs10740039	ENSG00000254271.1	RP11-131N11.4	9.35	3.46e-19	2.03e-16	0.46	0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654924	chr10:60734342~60741828:+
THCA	cis	rs947583	0.517	rs6935371	ENSG00000231028.7	LINC00271	-9.35	3.46e-19	2.03e-16	-0.31	-0.4	Phosphorus levels;	chr6:135779380	chr6:135497801~135716055:+
THCA	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	9.35	3.46e-19	2.03e-16	0.52	0.4	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
THCA	cis	rs1799949	0.931	rs34474989	ENSG00000267681.1	CTD-3199J23.6	-9.35	3.47e-19	2.03e-16	-0.45	-0.4	Menopause (age at onset);	chr17:43368042	chr17:43144956~43145255:+
THCA	cis	rs2836950	0.565	rs2836943	ENSG00000255568.3	BRWD1-AS2	-9.35	3.5e-19	2.05e-16	-0.32	-0.4	Menarche (age at onset);	chr21:39220685	chr21:39313935~39314962:+
THCA	cis	rs4819052	0.851	rs2838842	ENSG00000215447.6	BX322557.10	-9.35	3.5e-19	2.05e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45288052~45291738:+
THCA	cis	rs348196	0.767	rs12744132	ENSG00000225855.5	RUSC1-AS1	9.35	3.5e-19	2.05e-16	0.29	0.4	Breast cancer;	chr1:155693535	chr1:155316863~155324176:-
THCA	cis	rs6860806	0.507	rs169256	ENSG00000233006.5	AC034220.3	9.35	3.5e-19	2.05e-16	0.37	0.4	Breast cancer;	chr5:132352840	chr5:132311285~132369916:-
THCA	cis	rs6844153	0.68	rs6833053	ENSG00000240005.4	RP11-293A21.1	-9.35	3.51e-19	2.06e-16	-0.48	-0.4	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26870838	chr4:26859806~26860599:-
THCA	cis	rs875971	0.619	rs12533585	ENSG00000237310.1	GS1-124K5.4	9.35	3.52e-19	2.06e-16	0.28	0.4	Aortic root size;	chr7:66519618	chr7:66493706~66495474:+
THCA	cis	rs2115630	0.645	rs1107179	ENSG00000225151.9	GOLGA2P7	-9.35	3.53e-19	2.07e-16	-0.51	-0.4	P wave terminal force;	chr15:84655131	chr15:84199311~84230136:-
THCA	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-9.35	3.53e-19	2.07e-16	-0.41	-0.4	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-9.35	3.53e-19	2.07e-16	-0.41	-0.4	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-9.35	3.53e-19	2.07e-16	-0.41	-0.4	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-9.35	3.53e-19	2.07e-16	-0.41	-0.4	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
THCA	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-9.35	3.54e-19	2.08e-16	-0.6	-0.4	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
THCA	cis	rs17684571	0.7	rs35873865	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56790203	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13203327	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56792498	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs71564854	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56794662	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs4457154	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56805653	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13194904	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56811443	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs34805046	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56815813	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.765	rs34425815	ENSG00000231441.1	RP11-472M19.2	9.35	3.58e-19	2.1e-16	0.53	0.4	Schizophrenia;	chr6:56816040	chr6:56844002~56864078:+
THCA	cis	rs11148252	0.553	rs9536236	ENSG00000235660.1	LINC00345	-9.35	3.59e-19	2.1e-16	-0.51	-0.4	Lewy body disease;	chr13:52680877	chr13:52484161~52484680:-
THCA	cis	rs9532669	0.926	rs4516083	ENSG00000239827.7	SUGT1P3	-9.35	3.6e-19	2.11e-16	-0.43	-0.4	Cervical cancer;	chr13:40951783	chr13:40908159~40921774:-
THCA	cis	rs950169	0.959	rs12902070	ENSG00000259728.4	LINC00933	9.35	3.64e-19	2.13e-16	0.55	0.4	Schizophrenia;	chr15:84124806	chr15:84570649~84580175:+
THCA	cis	rs2243480	1	rs160634	ENSG00000226824.5	RP4-756H11.3	9.35	3.67e-19	2.15e-16	0.77	0.4	Diabetic kidney disease;	chr7:66063677	chr7:66654538~66669855:+
THCA	cis	rs4819052	1	rs13053002	ENSG00000215447.6	BX322557.10	-9.35	3.69e-19	2.16e-16	-0.36	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45288052~45291738:+
THCA	cis	rs7225151	0.522	rs56229705	ENSG00000234327.6	AC012146.7	-9.35	3.7e-19	2.16e-16	-0.53	-0.4	Alzheimer's disease (late onset);	chr17:5111494	chr17:5111468~5115004:+
THCA	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	9.34	3.72e-19	2.17e-16	0.48	0.4	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
THCA	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	9.34	3.72e-19	2.17e-16	0.3	0.4	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
THCA	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	9.34	3.73e-19	2.18e-16	0.51	0.4	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
THCA	cis	rs934734	0.563	rs11684155	ENSG00000204929.10	AC074391.1	9.34	3.74e-19	2.19e-16	0.52	0.4	Rheumatoid arthritis;	chr2:65354166	chr2:65436711~66084639:+
THCA	cis	rs7015263	0.818	rs57644875	ENSG00000254231.1	CTD-2284J15.1	-9.34	3.75e-19	2.19e-16	-0.39	-0.4	Intelligence (multi-trait analysis);	chr8:86371118	chr8:86333274~86343314:-
THCA	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-9.34	3.76e-19	2.2e-16	-0.44	-0.4	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
THCA	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	9.34	3.76e-19	2.2e-16	0.44	0.4	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
THCA	cis	rs875971	0.54	rs35510581	ENSG00000237310.1	GS1-124K5.4	-9.34	3.78e-19	2.21e-16	-0.29	-0.4	Aortic root size;	chr7:66113790	chr7:66493706~66495474:+
THCA	cis	rs17772222	0.63	rs1344747	ENSG00000258789.1	RP11-507K2.3	9.34	3.79e-19	2.22e-16	0.38	0.4	Coronary artery calcification;	chr14:88548091	chr14:88551597~88552493:+
THCA	cis	rs4819052	0.851	rs4819046	ENSG00000215447.6	BX322557.10	-9.34	3.81e-19	2.23e-16	-0.33	-0.4	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45288052~45291738:+
THCA	cis	rs1799949	0.931	rs9912203	ENSG00000267681.1	CTD-3199J23.6	9.34	3.81e-19	2.23e-16	0.45	0.4	Menopause (age at onset);	chr17:43367777	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4793212	ENSG00000267681.1	CTD-3199J23.6	-9.34	3.84e-19	2.24e-16	-0.46	-0.4	Menopause (age at onset);	chr17:43150733	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs34534709	ENSG00000267681.1	CTD-3199J23.6	-9.34	3.84e-19	2.24e-16	-0.46	-0.4	Menopause (age at onset);	chr17:43150923	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs34059614	ENSG00000267681.1	CTD-3199J23.6	-9.34	3.84e-19	2.24e-16	-0.46	-0.4	Menopause (age at onset);	chr17:43151054	chr17:43144956~43145255:+
THCA	cis	rs2243480	1	rs313813	ENSG00000273142.1	RP11-458F8.4	-9.34	3.84e-19	2.25e-16	-0.5	-0.4	Diabetic kidney disease;	chr7:66038513	chr7:66902857~66906297:+
THCA	cis	rs67311347	0.544	rs7644643	ENSG00000223797.4	ENTPD3-AS1	-9.34	3.85e-19	2.25e-16	-0.31	-0.4	Renal cell carcinoma;	chr3:40308718	chr3:40313802~40453329:-
THCA	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	9.34	3.86e-19	2.25e-16	0.59	0.4	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
THCA	cis	rs12550612	0.567	rs7834950	ENSG00000253616.4	RP11-875O11.3	9.34	3.86e-19	2.26e-16	0.56	0.4	Myeloid white cell count;Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;White blood cell count;Sum neutrophil eosinophil counts;	chr8:23084305	chr8:23071377~23074488:-
THCA	cis	rs526231	0.578	rs17154825	ENSG00000175749.11	EIF3KP1	9.34	3.86e-19	2.26e-16	0.53	0.4	Primary biliary cholangitis;	chr5:102910365	chr5:103032376~103033031:+
THCA	cis	rs526231	0.578	rs35100629	ENSG00000175749.11	EIF3KP1	9.34	3.86e-19	2.26e-16	0.53	0.4	Primary biliary cholangitis;	chr5:102910381	chr5:103032376~103033031:+
THCA	cis	rs526231	0.578	rs10463553	ENSG00000175749.11	EIF3KP1	9.34	3.86e-19	2.26e-16	0.53	0.4	Primary biliary cholangitis;	chr5:102913503	chr5:103032376~103033031:+
THCA	cis	rs526231	0.578	rs6876278	ENSG00000175749.11	EIF3KP1	9.34	3.86e-19	2.26e-16	0.53	0.4	Primary biliary cholangitis;	chr5:102913842	chr5:103032376~103033031:+
THCA	cis	rs11148252	0.74	rs9536052	ENSG00000278238.1	RP11-245D16.4	9.34	3.88e-19	2.27e-16	0.45	0.4	Lewy body disease;	chr13:52386574	chr13:52454775~52455331:-
THCA	cis	rs7189233	0.531	rs1861351	ENSG00000279344.1	RP11-44F14.7	9.34	3.89e-19	2.27e-16	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53499315	chr16:53478957~53481550:-
THCA	cis	rs1799949	0.859	rs11657004	ENSG00000267681.1	CTD-3199J23.6	-9.34	3.91e-19	2.28e-16	-0.45	-0.4	Menopause (age at onset);	chr17:43365383	chr17:43144956~43145255:+
THCA	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	9.34	3.92e-19	2.29e-16	0.51	0.4	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
THCA	cis	rs9402743	0.597	rs9399162	ENSG00000231028.7	LINC00271	-9.34	3.93e-19	2.3e-16	-0.31	-0.4	Systemic lupus erythematosus;	chr6:135759368	chr6:135497801~135716055:+
THCA	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	9.34	3.98e-19	2.32e-16	0.53	0.4	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
THCA	cis	rs597539	0.617	rs598353	ENSG00000250508.1	RP11-757G1.6	-9.34	3.99e-19	2.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868302	chr11:68870664~68874542:+
THCA	cis	rs597539	0.617	rs686348	ENSG00000250508.1	RP11-757G1.6	-9.34	3.99e-19	2.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869528	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs686877	ENSG00000250508.1	RP11-757G1.6	-9.34	3.99e-19	2.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68869701	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs579136	ENSG00000250508.1	RP11-757G1.6	-9.34	3.99e-19	2.33e-16	-0.47	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68870008	chr11:68870664~68874542:+
THCA	cis	rs597539	0.69	rs497149	ENSG00000250508.1	RP11-757G1.6	-9.34	3.99e-19	2.33e-16	-0.48	-0.4	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68859171	chr11:68870664~68874542:+
THCA	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-9.34	4.01e-19	2.34e-16	-0.37	-0.4	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
THCA	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-9.34	4.01e-19	2.34e-16	-0.37	-0.4	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
THCA	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-9.34	4.01e-19	2.34e-16	-0.37	-0.4	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
THCA	cis	rs934734	0.563	rs955903	ENSG00000204929.10	AC074391.1	9.34	4.02e-19	2.34e-16	0.52	0.4	Rheumatoid arthritis;	chr2:65348419	chr2:65436711~66084639:+
THCA	cis	rs11676348	0.772	rs11687200	ENSG00000261338.2	RP11-378A13.1	-9.33	4.1e-19	2.39e-16	-0.39	-0.4	Ulcerative colitis;	chr2:218079892	chr2:218255319~218257366:+
THCA	cis	rs2836950	0.545	rs2836952	ENSG00000255568.3	BRWD1-AS2	-9.33	4.1e-19	2.39e-16	-0.32	-0.4	Menarche (age at onset);	chr21:39244725	chr21:39313935~39314962:+
THCA	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-9.33	4.11e-19	2.4e-16	-0.45	-0.4	Temperament;	chr17:14007198	chr17:14024514~14025488:+
THCA	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-9.33	4.12e-19	2.4e-16	-0.41	-0.4	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
THCA	cis	rs11971779	0.68	rs1862879	ENSG00000273391.1	RP11-634H22.1	9.33	4.14e-19	2.41e-16	0.37	0.4	Diisocyanate-induced asthma;	chr7:139335205	chr7:139359032~139359566:-
THCA	cis	rs2274273	0.588	rs2880103	ENSG00000258413.1	RP11-665C16.6	-9.33	4.14e-19	2.42e-16	-0.54	-0.4	Protein biomarker;	chr14:55271114	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.553	rs56166765	ENSG00000258413.1	RP11-665C16.6	-9.33	4.14e-19	2.42e-16	-0.54	-0.4	Protein biomarker;	chr14:55271300	chr14:55262767~55272075:-
THCA	cis	rs673078	0.607	rs8467	ENSG00000275409.1	RP11-131L12.4	-9.33	4.15e-19	2.42e-16	-0.47	-0.4	Glucose homeostasis traits;	chr12:118417479	chr12:118430147~118430699:+
THCA	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-9.33	4.16e-19	2.42e-16	-0.5	-0.4	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
THCA	cis	rs4927850	1	rs7627706	ENSG00000273009.1	RP11-352G9.1	-9.33	4.16e-19	2.43e-16	-0.44	-0.4	Pancreatic cancer;	chr3:196026482	chr3:195913078~195913683:-
THCA	cis	rs4927850	0.881	rs7630489	ENSG00000273009.1	RP11-352G9.1	-9.33	4.16e-19	2.43e-16	-0.44	-0.4	Pancreatic cancer;	chr3:196026530	chr3:195913078~195913683:-
THCA	cis	rs4927850	1	rs7627868	ENSG00000273009.1	RP11-352G9.1	-9.33	4.16e-19	2.43e-16	-0.44	-0.4	Pancreatic cancer;	chr3:196026602	chr3:195913078~195913683:-
THCA	cis	rs950169	1	rs11638297	ENSG00000259728.4	LINC00933	9.33	4.16e-19	2.43e-16	0.54	0.4	Schizophrenia;	chr15:84113665	chr15:84570649~84580175:+
THCA	cis	rs10971721	0.643	rs12378415	ENSG00000260947.1	RP11-384P7.7	9.33	4.2e-19	2.45e-16	1.09	0.4	Body mass index;	chr9:33797335	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.643	rs41315997	ENSG00000260947.1	RP11-384P7.7	9.33	4.2e-19	2.45e-16	1.09	0.4	Body mass index;	chr9:33798840	chr9:33697459~33700986:+
THCA	cis	rs11676348	0.805	rs12694428	ENSG00000261338.2	RP11-378A13.1	-9.33	4.21e-19	2.45e-16	-0.4	-0.4	Ulcerative colitis;	chr2:218094097	chr2:218255319~218257366:+
THCA	cis	rs7576126	0.563	rs1807337	ENSG00000234255.7	AC012370.3	-9.33	4.21e-19	2.45e-16	-0.43	-0.4	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65439888~65456571:-
THCA	cis	rs240993	0.715	rs7742724	ENSG00000230177.1	RP5-1112D6.4	9.33	4.21e-19	2.45e-16	0.37	0.4	Inflammatory skin disease;Psoriasis;	chr6:111517816	chr6:111277932~111278742:+
THCA	cis	rs7829975	0.511	rs2976906	ENSG00000253893.2	FAM85B	-9.33	4.23e-19	2.46e-16	-0.53	-0.4	Mood instability;	chr8:8484905	chr8:8167819~8226614:-
THCA	cis	rs9532669	0.963	rs9532681	ENSG00000239827.7	SUGT1P3	-9.33	4.24e-19	2.47e-16	-0.43	-0.4	Cervical cancer;	chr13:40951633	chr13:40908159~40921774:-
THCA	cis	rs9487094	0.6	rs3799842	ENSG00000260273.1	RP11-425D10.10	9.33	4.24e-19	2.47e-16	0.47	0.4	Height;	chr6:109471826	chr6:109382795~109383666:+
THCA	cis	rs8062405	0.69	rs7187604	ENSG00000251417.2	RP11-1348G14.4	-9.33	4.29e-19	2.5e-16	-0.4	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28802743~28817828:+
THCA	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	9.33	4.32e-19	2.51e-16	0.5	0.4	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
THCA	cis	rs950169	1	rs950169	ENSG00000259728.4	LINC00933	9.33	4.34e-19	2.53e-16	0.55	0.4	Schizophrenia;	chr15:84037709	chr15:84570649~84580175:+
THCA	cis	rs7189233	0.531	rs8061398	ENSG00000279344.1	RP11-44F14.7	9.33	4.35e-19	2.54e-16	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53420239	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs1978337	ENSG00000279344.1	RP11-44F14.7	9.33	4.35e-19	2.54e-16	0.4	0.4	Intelligence (multi-trait analysis);	chr16:53425833	chr16:53478957~53481550:-
THCA	cis	rs17807185	0.653	rs9641271	ENSG00000214293.7	APTR	9.32	4.37e-19	2.55e-16	0.28	0.4	Height;	chr7:77668098	chr7:77657660~77696265:-
THCA	cis	rs9532669	0.889	rs7333447	ENSG00000239827.7	SUGT1P3	-9.32	4.4e-19	2.56e-16	-0.42	-0.4	Cervical cancer;	chr13:40917586	chr13:40908159~40921774:-
THCA	cis	rs9828933	0.938	rs2578011	ENSG00000280620.1	SCAANT1	9.32	4.4e-19	2.56e-16	0.66	0.4	Type 2 diabetes;	chr3:64019143	chr3:63911518~63911772:-
THCA	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	9.32	4.43e-19	2.58e-16	0.41	0.4	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
THCA	cis	rs9487094	0.621	rs9398202	ENSG00000260273.1	RP11-425D10.10	9.32	4.44e-19	2.58e-16	0.47	0.4	Height;	chr6:109458989	chr6:109382795~109383666:+
THCA	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-9.32	4.44e-19	2.59e-16	-0.37	-0.4	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
THCA	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	9.32	4.46e-19	2.59e-16	0.6	0.4	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
THCA	cis	rs9322193	0.607	rs6557165	ENSG00000268592.3	RAET1E-AS1	-9.32	4.47e-19	2.6e-16	-0.57	-0.4	Lung cancer;	chr6:149906883	chr6:149863494~149919507:+
THCA	cis	rs7189233	0.531	rs8056349	ENSG00000279344.1	RP11-44F14.7	9.32	4.5e-19	2.62e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53434114	chr16:53478957~53481550:-
THCA	cis	rs801193	0.935	rs2659899	ENSG00000237310.1	GS1-124K5.4	9.32	4.52e-19	2.63e-16	0.28	0.39	Aortic root size;	chr7:66721734	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs1553609	ENSG00000237310.1	GS1-124K5.4	9.32	4.52e-19	2.63e-16	0.28	0.39	Aortic root size;	chr7:66732152	chr7:66493706~66495474:+
THCA	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	9.32	4.52e-19	2.63e-16	0.28	0.39	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	9.32	4.52e-19	2.63e-16	0.28	0.39	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
THCA	cis	rs12188164	0.714	rs11741954	ENSG00000221990.4	EXOC3-AS1	9.32	4.53e-19	2.63e-16	0.35	0.39	Cystic fibrosis severity;	chr5:421340	chr5:441498~443160:-
THCA	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	9.32	4.54e-19	2.64e-16	0.47	0.39	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
THCA	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	9.32	4.57e-19	2.66e-16	0.59	0.39	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
THCA	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-9.32	4.58e-19	2.66e-16	-0.49	-0.39	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
THCA	cis	rs950169	0.58	rs11635597	ENSG00000259728.4	LINC00933	9.32	4.59e-19	2.67e-16	0.54	0.39	Schizophrenia;	chr15:84622468	chr15:84570649~84580175:+
THCA	cis	rs67311347	0.502	rs3924444	ENSG00000223797.4	ENTPD3-AS1	9.32	4.61e-19	2.68e-16	0.32	0.39	Renal cell carcinoma;	chr3:40534570	chr3:40313802~40453329:-
THCA	cis	rs7189233	0.513	rs1344491	ENSG00000279344.1	RP11-44F14.7	9.32	4.62e-19	2.68e-16	0.4	0.39	Intelligence (multi-trait analysis);	chr16:53405497	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.513	rs28759393	ENSG00000279344.1	RP11-44F14.7	9.32	4.62e-19	2.68e-16	0.4	0.39	Intelligence (multi-trait analysis);	chr16:53411446	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs8063294	ENSG00000279344.1	RP11-44F14.7	9.32	4.62e-19	2.68e-16	0.4	0.39	Intelligence (multi-trait analysis);	chr16:53412845	chr16:53478957~53481550:-
THCA	cis	rs597539	0.652	rs646586	ENSG00000250508.1	RP11-757G1.6	9.32	4.65e-19	2.7e-16	0.47	0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68914185	chr11:68870664~68874542:+
THCA	cis	rs875971	0.651	rs313829	ENSG00000237310.1	GS1-124K5.4	-9.32	4.66e-19	2.71e-16	-0.32	-0.39	Aortic root size;	chr7:66087510	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs62466794	ENSG00000237310.1	GS1-124K5.4	9.32	4.66e-19	2.71e-16	0.28	0.39	Aortic root size;	chr7:66726592	chr7:66493706~66495474:+
THCA	cis	rs10971721	0.643	rs10971702	ENSG00000260947.1	RP11-384P7.7	9.32	4.66e-19	2.71e-16	1.09	0.39	Body mass index;	chr9:33784104	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.643	rs12375483	ENSG00000260947.1	RP11-384P7.7	9.32	4.66e-19	2.71e-16	1.09	0.39	Body mass index;	chr9:33784910	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.643	rs72711741	ENSG00000260947.1	RP11-384P7.7	9.32	4.66e-19	2.71e-16	1.09	0.39	Body mass index;	chr9:33785113	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.554	rs55917897	ENSG00000260947.1	RP11-384P7.7	9.32	4.66e-19	2.71e-16	1.09	0.39	Body mass index;	chr9:33795952	chr9:33697459~33700986:+
THCA	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	9.32	4.67e-19	2.72e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
THCA	cis	rs9402743	0.632	rs6570038	ENSG00000231028.7	LINC00271	-9.32	4.68e-19	2.72e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135775465	chr6:135497801~135716055:+
THCA	cis	rs28510890	0.754	rs11074080	ENSG00000260337.3	RP11-386M24.6	9.32	4.72e-19	2.74e-16	0.48	0.39	Lung cancer in ever smokers;	chr15:92595272	chr15:92592574~92596462:-
THCA	cis	rs733592	0.524	rs10875726	ENSG00000240399.1	RP1-228P16.1	-9.31	4.75e-19	2.76e-16	-0.37	-0.39	Plateletcrit;	chr12:48032209	chr12:48054813~48055591:-
THCA	cis	rs733592	0.524	rs10875727	ENSG00000240399.1	RP1-228P16.1	-9.31	4.75e-19	2.76e-16	-0.37	-0.39	Plateletcrit;	chr12:48032360	chr12:48054813~48055591:-
THCA	cis	rs4819052	0.851	rs2838858	ENSG00000215447.6	BX322557.10	-9.31	4.76e-19	2.77e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45288052~45291738:+
THCA	cis	rs1707322	0.691	rs11211174	ENSG00000234329.1	RP11-767N6.2	9.31	4.76e-19	2.77e-16	0.38	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45651039~45651826:-
THCA	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	9.31	4.77e-19	2.77e-16	0.48	0.39	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
THCA	cis	rs7727544	0.716	rs11949055	ENSG00000237714.1	P4HA2-AS1	9.31	4.77e-19	2.77e-16	0.52	0.39	Blood metabolite levels;	chr5:132241044	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.716	rs3844312	ENSG00000237714.1	P4HA2-AS1	9.31	4.77e-19	2.77e-16	0.52	0.39	Blood metabolite levels;	chr5:132246663	chr5:132184876~132192808:+
THCA	cis	rs12188164	0.686	rs11741946	ENSG00000221990.4	EXOC3-AS1	9.31	4.81e-19	2.79e-16	0.35	0.39	Cystic fibrosis severity;	chr5:421288	chr5:441498~443160:-
THCA	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-9.31	4.81e-19	2.8e-16	-0.48	-0.39	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
THCA	cis	rs11051970	0.559	rs4931012	ENSG00000274964.1	RP11-817I4.1	-9.31	4.82e-19	2.8e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32328970	chr12:32339368~32340724:+
THCA	cis	rs4964805	0.632	rs11111782	ENSG00000257681.1	RP11-341G23.4	-9.31	4.83e-19	2.81e-16	-0.46	-0.39	Attention deficit hyperactivity disorder;	chr12:103794698	chr12:103746315~103768858:-
THCA	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	9.31	4.86e-19	2.82e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
THCA	cis	rs3091242	0.933	rs34933589	ENSG00000261349.1	RP3-465N24.5	9.31	4.87e-19	2.83e-16	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25461707	chr1:25266102~25267136:-
THCA	cis	rs7829975	1	rs7829975	ENSG00000253893.2	FAM85B	9.31	4.88e-19	2.83e-16	0.5	0.39	Mood instability;	chr8:8690607	chr8:8167819~8226614:-
THCA	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	9.31	4.89e-19	2.84e-16	0.49	0.39	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	9.31	4.9e-19	2.84e-16	0.48	0.39	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
THCA	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	9.31	4.92e-19	2.86e-16	0.51	0.39	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
THCA	cis	rs2599510	0.807	rs176416	ENSG00000276334.1	AL133243.1	-9.31	4.92e-19	2.86e-16	-0.43	-0.39	Interleukin-18 levels;	chr2:32427155	chr2:32521927~32523547:+
THCA	cis	rs2439831	0.85	rs3816792	ENSG00000249839.1	AC011330.5	9.31	4.94e-19	2.87e-16	0.62	0.39	Lung cancer in ever smokers;	chr15:43824788	chr15:43663654~43684339:-
THCA	cis	rs11051970	0.559	rs11051939	ENSG00000274964.1	RP11-817I4.1	9.31	4.94e-19	2.87e-16	0.5	0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32330107	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs16919727	ENSG00000274964.1	RP11-817I4.1	-9.31	4.94e-19	2.87e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32329976	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051940	ENSG00000274964.1	RP11-817I4.1	-9.31	4.94e-19	2.87e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32330187	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051941	ENSG00000274964.1	RP11-817I4.1	-9.31	4.94e-19	2.87e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32330338	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051942	ENSG00000274964.1	RP11-817I4.1	-9.31	4.94e-19	2.87e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32330344	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs4316592	ENSG00000274964.1	RP11-817I4.1	-9.31	4.94e-19	2.87e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32331076	chr12:32339368~32340724:+
THCA	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	9.31	4.95e-19	2.87e-16	0.51	0.39	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
THCA	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	9.31	4.96e-19	2.88e-16	0.44	0.39	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
THCA	cis	rs597539	0.617	rs669659	ENSG00000250508.1	RP11-757G1.6	-9.31	4.97e-19	2.88e-16	-0.47	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68868155	chr11:68870664~68874542:+
THCA	cis	rs17772222	0.63	rs8017811	ENSG00000258789.1	RP11-507K2.3	9.31	4.97e-19	2.89e-16	0.38	0.39	Coronary artery calcification;	chr14:88534559	chr14:88551597~88552493:+
THCA	cis	rs944289	0.74	rs4982333	ENSG00000257826.1	RP11-116N8.4	-9.31	5.04e-19	2.92e-16	-0.41	-0.39	Thyroid cancer;	chr14:36100842	chr14:36061026~36067190:-
THCA	cis	rs7712401	0.601	rs27976	ENSG00000263432.2	RN7SL689P	-9.31	5.04e-19	2.92e-16	-0.44	-0.39	Mean platelet volume;	chr5:122870765	chr5:123022487~123022783:-
THCA	cis	rs801193	1	rs4717310	ENSG00000237310.1	GS1-124K5.4	9.31	5.06e-19	2.93e-16	0.28	0.39	Aortic root size;	chr7:66696020	chr7:66493706~66495474:+
THCA	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-9.31	5.06e-19	2.94e-16	-0.48	-0.39	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
THCA	cis	rs737008	0.5	rs7189239	ENSG00000262636.1	CTD-3088G3.4	9.31	5.07e-19	2.94e-16	0.49	0.39	Obesity-related traits;	chr16:11308658	chr16:11380859~11381118:-
THCA	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	9.31	5.07e-19	2.94e-16	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
THCA	cis	rs12188164	0.686	rs72711369	ENSG00000221990.4	EXOC3-AS1	9.31	5.07e-19	2.94e-16	0.35	0.39	Cystic fibrosis severity;	chr5:420402	chr5:441498~443160:-
THCA	cis	rs2243480	1	rs316315	ENSG00000226824.5	RP4-756H11.3	9.31	5.08e-19	2.94e-16	0.68	0.39	Diabetic kidney disease;	chr7:66126218	chr7:66654538~66669855:+
THCA	cis	rs2033711	0.87	rs6510152	ENSG00000268912.1	CTD-2619J13.17	-9.31	5.08e-19	2.95e-16	-0.31	-0.39	Uric acid clearance;	chr19:58441952	chr19:58428632~58431148:-
THCA	cis	rs11051970	0.559	rs3748275	ENSG00000274964.1	RP11-817I4.1	-9.31	5.1e-19	2.96e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32328159	chr12:32339368~32340724:+
THCA	cis	rs4819052	0.851	rs9979545	ENSG00000215447.6	BX322557.10	-9.31	5.1e-19	2.96e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45288052~45291738:+
THCA	cis	rs7189233	0.531	rs9941254	ENSG00000279344.1	RP11-44F14.7	9.31	5.11e-19	2.96e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53453306	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs7194730	ENSG00000279344.1	RP11-44F14.7	9.31	5.11e-19	2.96e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53455278	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs13332406	ENSG00000279344.1	RP11-44F14.7	9.31	5.11e-19	2.96e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53455793	chr16:53478957~53481550:-
THCA	cis	rs7849270	0.918	rs746873	ENSG00000268707.1	RP11-247A12.7	9.3	5.12e-19	2.97e-16	0.53	0.39	Blood metabolite ratios;	chr9:129102671	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.959	rs746872	ENSG00000268707.1	RP11-247A12.7	9.3	5.12e-19	2.97e-16	0.53	0.39	Blood metabolite ratios;	chr9:129102748	chr9:129170434~129170940:+
THCA	cis	rs2288884	0.537	rs4145658	ENSG00000275055.1	CTC-471J1.11	-9.3	5.12e-19	2.97e-16	-0.31	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52085465	chr19:52049007~52049754:+
THCA	cis	rs71403859	0.502	rs36122765	ENSG00000260886.1	TAT-AS1	9.3	5.13e-19	2.97e-16	0.69	0.39	Post bronchodilator FEV1;	chr16:71470280	chr16:71565789~71578187:+
THCA	cis	rs2274273	0.588	rs9323285	ENSG00000258413.1	RP11-665C16.6	9.3	5.13e-19	2.98e-16	0.55	0.39	Protein biomarker;	chr14:55397111	chr14:55262767~55272075:-
THCA	cis	rs12188164	0.686	rs72711370	ENSG00000221990.4	EXOC3-AS1	9.3	5.14e-19	2.98e-16	0.35	0.39	Cystic fibrosis severity;	chr5:420942	chr5:441498~443160:-
THCA	cis	rs9640161	0.789	rs60283368	ENSG00000261305.1	RP4-584D14.7	9.3	5.14e-19	2.98e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150326169	chr7:150341771~150342607:+
THCA	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-9.3	5.14e-19	2.98e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
THCA	cis	rs950169	0.8	rs34302901	ENSG00000259728.4	LINC00933	9.3	5.15e-19	2.99e-16	0.53	0.39	Schizophrenia;	chr15:84567712	chr15:84570649~84580175:+
THCA	cis	rs748404	0.697	rs572959	ENSG00000249839.1	AC011330.5	-9.3	5.16e-19	2.99e-16	-0.46	-0.39	Lung cancer;	chr15:43258304	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs554001	ENSG00000249839.1	AC011330.5	-9.3	5.16e-19	2.99e-16	-0.46	-0.39	Lung cancer;	chr15:43259721	chr15:43663654~43684339:-
THCA	cis	rs10971721	0.643	rs10971701	ENSG00000260947.1	RP11-384P7.7	9.3	5.17e-19	3e-16	1.09	0.39	Body mass index;	chr9:33781900	chr9:33697459~33700986:+
THCA	cis	rs17684571	0.7	rs17684802	ENSG00000231441.1	RP11-472M19.2	-9.3	5.21e-19	3.02e-16	-0.51	-0.39	Schizophrenia;	chr6:56813854	chr6:56844002~56864078:+
THCA	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	9.3	5.22e-19	3.02e-16	0.64	0.39	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
THCA	cis	rs934734	0.509	rs12185577	ENSG00000234255.7	AC012370.3	-9.3	5.22e-19	3.03e-16	-0.43	-0.39	Rheumatoid arthritis;	chr2:65432354	chr2:65439888~65456571:-
THCA	cis	rs875971	0.558	rs4433015	ENSG00000237310.1	GS1-124K5.4	-9.3	5.25e-19	3.04e-16	-0.28	-0.39	Aortic root size;	chr7:66174736	chr7:66493706~66495474:+
THCA	cis	rs1799949	0.965	rs1842147	ENSG00000267681.1	CTD-3199J23.6	-9.3	5.29e-19	3.06e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43357824	chr17:43144956~43145255:+
THCA	cis	rs673078	0.607	rs11068906	ENSG00000275409.1	RP11-131L12.4	-9.3	5.3e-19	3.07e-16	-0.43	-0.39	Glucose homeostasis traits;	chr12:118315098	chr12:118430147~118430699:+
THCA	cis	rs4842666	0.85	rs11105328	ENSG00000258302.2	RP11-981P6.1	9.3	5.33e-19	3.09e-16	0.4	0.39	Blood pressure;	chr12:89548613	chr12:89561129~89594878:+
THCA	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-9.3	5.34e-19	3.09e-16	-0.41	-0.39	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
THCA	cis	rs2739330	0.892	rs5751776	ENSG00000206090.4	AP000350.7	9.3	5.37e-19	3.11e-16	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23939998~23942798:+
THCA	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-9.3	5.37e-19	3.11e-16	-0.54	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
THCA	cis	rs9532669	0.963	rs1056835	ENSG00000176268.5	CYCSP34	9.3	5.41e-19	3.13e-16	0.45	0.39	Cervical cancer;	chr13:40932585	chr13:40863599~40863902:-
THCA	cis	rs7727544	0.716	rs7720230	ENSG00000237714.1	P4HA2-AS1	9.3	5.42e-19	3.14e-16	0.52	0.39	Blood metabolite levels;	chr5:132256712	chr5:132184876~132192808:+
THCA	cis	rs9322193	0.607	rs915140	ENSG00000268592.3	RAET1E-AS1	9.3	5.45e-19	3.15e-16	0.57	0.39	Lung cancer;	chr6:149899674	chr6:149863494~149919507:+
THCA	cis	rs10740039	0.842	rs10761539	ENSG00000254271.1	RP11-131N11.4	9.3	5.47e-19	3.16e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649733	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs1442546	ENSG00000254271.1	RP11-131N11.4	9.3	5.47e-19	3.16e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650240	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs1442545	ENSG00000254271.1	RP11-131N11.4	9.3	5.47e-19	3.16e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650268	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.883	rs1975442	ENSG00000254271.1	RP11-131N11.4	9.3	5.47e-19	3.16e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60651161	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.842	rs7090892	ENSG00000254271.1	RP11-131N11.4	9.3	5.47e-19	3.16e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652093	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.804	rs7094818	ENSG00000254271.1	RP11-131N11.4	9.3	5.47e-19	3.16e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652213	chr10:60734342~60741828:+
THCA	cis	rs2980439	0.517	rs712253	ENSG00000253893.2	FAM85B	9.3	5.48e-19	3.17e-16	0.51	0.39	Neuroticism;	chr8:8246260	chr8:8167819~8226614:-
THCA	cis	rs8062405	0.508	rs9929088	ENSG00000259982.1	CDC37P1	-9.3	5.51e-19	3.19e-16	-0.51	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28990139	chr16:28700294~28701540:-
THCA	cis	rs9318086	1	rs9318086	ENSG00000205861.10	C1QTNF9B-AS1	9.3	5.51e-19	3.19e-16	0.45	0.39	Myopia (pathological);	chr13:23858328	chr13:23888889~23897263:+
THCA	cis	rs10759883	0.563	rs689761	ENSG00000175611.10	LINC00476	-9.3	5.53e-19	3.2e-16	-0.45	-0.39	Nicotine dependence;	chr9:95970902	chr9:95759231~95875977:-
THCA	cis	rs2033711	0.902	rs4801589	ENSG00000268912.1	CTD-2619J13.17	-9.29	5.54e-19	3.2e-16	-0.31	-0.39	Uric acid clearance;	chr19:58442031	chr19:58428632~58431148:-
THCA	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-9.29	5.6e-19	3.24e-16	-0.32	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
THCA	cis	rs7826238	0.623	rs2976893	ENSG00000253893.2	FAM85B	9.29	5.61e-19	3.25e-16	0.52	0.39	Systolic blood pressure;	chr8:8480709	chr8:8167819~8226614:-
THCA	cis	rs2032366	0.606	rs1377171	ENSG00000267279.1	RP11-879F14.2	-9.29	5.62e-19	3.25e-16	-0.42	-0.39	Obesity-related traits;	chr18:61606810	chr18:61585746~61606916:-
THCA	cis	rs11051970	0.559	rs11051938	ENSG00000274964.1	RP11-817I4.1	-9.29	5.65e-19	3.27e-16	-0.5	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32329882	chr12:32339368~32340724:+
THCA	cis	rs9402743	0.597	rs34266043	ENSG00000231028.7	LINC00271	-9.29	5.66e-19	3.27e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135763663	chr6:135497801~135716055:+
THCA	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	9.29	5.67e-19	3.28e-16	0.59	0.39	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	9.29	5.67e-19	3.28e-16	0.59	0.39	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	9.29	5.67e-19	3.28e-16	0.59	0.39	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	9.29	5.67e-19	3.28e-16	0.59	0.39	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	9.29	5.67e-19	3.28e-16	0.59	0.39	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	9.29	5.67e-19	3.28e-16	0.59	0.39	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
THCA	cis	rs9402743	0.632	rs9399166	ENSG00000231028.7	LINC00271	-9.29	5.68e-19	3.28e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135776762	chr6:135497801~135716055:+
THCA	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	9.29	5.68e-19	3.28e-16	0.48	0.39	Height;	chr11:118855938	chr11:118688039~118690600:-
THCA	cis	rs9322193	0.607	rs12209310	ENSG00000268592.3	RAET1E-AS1	9.29	5.68e-19	3.28e-16	0.57	0.39	Lung cancer;	chr6:149904882	chr6:149863494~149919507:+
THCA	cis	rs12931792	0.782	rs12927190	ENSG00000183604.13	SMG1P5	9.29	5.69e-19	3.29e-16	0.42	0.39	Tonsillectomy;	chr16:30158072	chr16:30267553~30335374:-
THCA	cis	rs4819052	0.819	rs13046807	ENSG00000215447.6	BX322557.10	-9.29	5.7e-19	3.29e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45288052~45291738:+
THCA	cis	rs11676348	0.772	rs11676275	ENSG00000261338.2	RP11-378A13.1	-9.29	5.74e-19	3.32e-16	-0.39	-0.39	Ulcerative colitis;	chr2:218080085	chr2:218255319~218257366:+
THCA	cis	rs801193	0.935	rs11772264	ENSG00000237310.1	GS1-124K5.4	9.29	5.75e-19	3.32e-16	0.29	0.39	Aortic root size;	chr7:66711400	chr7:66493706~66495474:+
THCA	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-9.29	5.76e-19	3.33e-16	-0.44	-0.39	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
THCA	cis	rs494459	0.536	rs10790267	ENSG00000278376.1	RP11-158I9.8	-9.29	5.76e-19	3.33e-16	-0.29	-0.39	Height;	chr11:118856460	chr11:118791254~118793137:+
THCA	cis	rs494459	0.536	rs11217067	ENSG00000278376.1	RP11-158I9.8	-9.29	5.76e-19	3.33e-16	-0.29	-0.39	Height;	chr11:118856623	chr11:118791254~118793137:+
THCA	cis	rs2510897	0.675	rs4936442	ENSG00000278376.1	RP11-158I9.8	-9.29	5.76e-19	3.33e-16	-0.29	-0.39	Height;	chr11:118857611	chr11:118791254~118793137:+
THCA	cis	rs984222	0.508	rs2645303	ENSG00000231365.4	RP11-418J17.1	-9.29	5.78e-19	3.34e-16	-0.39	-0.39	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119012523	chr1:119140396~119275973:+
THCA	cis	rs11690935	0.589	rs2271758	ENSG00000228389.1	AC068039.4	-9.29	5.78e-19	3.34e-16	-0.41	-0.39	Schizophrenia;	chr2:171844647	chr2:171773482~171775844:+
THCA	cis	rs748404	0.697	rs513970	ENSG00000249839.1	AC011330.5	-9.29	5.81e-19	3.35e-16	-0.47	-0.39	Lung cancer;	chr15:43287368	chr15:43663654~43684339:-
THCA	cis	rs2243480	1	rs316327	ENSG00000226824.5	RP4-756H11.3	9.29	5.85e-19	3.38e-16	0.77	0.39	Diabetic kidney disease;	chr7:66144214	chr7:66654538~66669855:+
THCA	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	9.29	5.86e-19	3.38e-16	0.52	0.39	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
THCA	cis	rs10463554	0.892	rs1837256	ENSG00000175749.11	EIF3KP1	9.29	5.86e-19	3.38e-16	0.53	0.39	Parkinson's disease;	chr5:102968852	chr5:103032376~103033031:+
THCA	cis	rs3743772	0.5	rs11859135	ENSG00000279722.1	RP11-44F14.6	9.29	5.87e-19	3.39e-16	0.53	0.39	Depressive symptoms (SSRI exposure interaction);	chr16:53404267	chr16:53487607~53489943:-
THCA	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-9.29	5.88e-19	3.39e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	9.29	5.93e-19	3.42e-16	0.8	0.39	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	9.29	5.93e-19	3.42e-16	0.8	0.39	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	9.29	5.93e-19	3.42e-16	0.8	0.39	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
THCA	cis	rs4819052	0.851	rs12626188	ENSG00000215447.6	BX322557.10	-9.29	5.95e-19	3.44e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45288052~45291738:+
THCA	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-9.29	5.98e-19	3.45e-16	-0.37	-0.39	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
THCA	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	9.28	6.02e-19	3.47e-16	0.48	0.39	Height;	chr11:118855233	chr11:118688039~118690600:-
THCA	cis	rs9322193	0.683	rs113281309	ENSG00000268592.3	RAET1E-AS1	9.28	6.03e-19	3.48e-16	0.53	0.39	Lung cancer;	chr6:149787289	chr6:149863494~149919507:+
THCA	cis	rs4819052	0.851	rs58644915	ENSG00000215447.6	BX322557.10	-9.28	6.05e-19	3.49e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45288052~45291738:+
THCA	cis	rs860295	0.812	rs12407800	ENSG00000225855.5	RUSC1-AS1	9.28	6.08e-19	3.51e-16	0.28	0.39	Body mass index;	chr1:155790951	chr1:155316863~155324176:-
THCA	cis	rs9640161	0.659	rs7806429	ENSG00000261305.1	RP4-584D14.7	9.28	6.09e-19	3.51e-16	0.45	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150316304	chr7:150341771~150342607:+
THCA	cis	rs934734	0.511	rs62141115	ENSG00000234255.7	AC012370.3	-9.28	6.11e-19	3.52e-16	-0.43	-0.39	Rheumatoid arthritis;	chr2:65445058	chr2:65439888~65456571:-
THCA	cis	rs4819052	0.851	rs28442024	ENSG00000215447.6	BX322557.10	-9.28	6.13e-19	3.53e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45288052~45291738:+
THCA	cis	rs2836950	0.565	rs7279497	ENSG00000255568.3	BRWD1-AS2	9.28	6.17e-19	3.55e-16	0.32	0.39	Menarche (age at onset);	chr21:39159380	chr21:39313935~39314962:+
THCA	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	9.28	6.18e-19	3.56e-16	0.58	0.39	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
THCA	cis	rs17684571	0.751	rs6918949	ENSG00000231441.1	RP11-472M19.2	-9.28	6.19e-19	3.56e-16	-0.5	-0.39	Schizophrenia;	chr6:56845183	chr6:56844002~56864078:+
THCA	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	9.28	6.21e-19	3.58e-16	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
THCA	cis	rs860295	0.812	rs12081192	ENSG00000225855.5	RUSC1-AS1	9.28	6.24e-19	3.59e-16	0.28	0.39	Body mass index;	chr1:155768253	chr1:155316863~155324176:-
THCA	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	9.28	6.29e-19	3.62e-16	0.8	0.39	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	9.28	6.29e-19	3.62e-16	0.8	0.39	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	9.28	6.29e-19	3.62e-16	0.8	0.39	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
THCA	cis	rs7189233	0.531	rs6499613	ENSG00000279344.1	RP11-44F14.7	9.28	6.29e-19	3.62e-16	0.4	0.39	Intelligence (multi-trait analysis);	chr16:53429506	chr16:53478957~53481550:-
THCA	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	9.28	6.31e-19	3.63e-16	0.38	0.39	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
THCA	cis	rs17684571	0.7	rs35440822	ENSG00000231441.1	RP11-472M19.2	9.28	6.31e-19	3.63e-16	0.51	0.39	Schizophrenia;	chr6:56801006	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.575	rs71564855	ENSG00000231441.1	RP11-472M19.2	9.28	6.31e-19	3.63e-16	0.51	0.39	Schizophrenia;	chr6:56801117	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13218913	ENSG00000231441.1	RP11-472M19.2	9.28	6.31e-19	3.63e-16	0.51	0.39	Schizophrenia;	chr6:56801247	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs71564856	ENSG00000231441.1	RP11-472M19.2	9.28	6.31e-19	3.63e-16	0.51	0.39	Schizophrenia;	chr6:56803447	chr6:56844002~56864078:+
THCA	cis	rs10411161	1	rs10402727	ENSG00000269483.1	AC006272.1	9.28	6.32e-19	3.64e-16	0.55	0.39	Breast cancer;	chr19:51867126	chr19:51839924~51843324:-
THCA	cis	rs10411161	1	rs10409331	ENSG00000269483.1	AC006272.1	9.28	6.32e-19	3.64e-16	0.55	0.39	Breast cancer;	chr19:51867709	chr19:51839924~51843324:-
THCA	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	9.28	6.32e-19	3.64e-16	0.48	0.39	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
THCA	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	9.28	6.32e-19	3.64e-16	0.8	0.39	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	9.28	6.32e-19	3.64e-16	0.8	0.39	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	9.28	6.32e-19	3.64e-16	0.8	0.39	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
THCA	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	9.28	6.33e-19	3.65e-16	0.59	0.39	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
THCA	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-9.28	6.36e-19	3.66e-16	-0.37	-0.39	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
THCA	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-9.28	6.38e-19	3.67e-16	-0.59	-0.39	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
THCA	cis	rs2841233	0.692	rs2028416	ENSG00000258701.1	LINC00638	9.28	6.4e-19	3.68e-16	0.41	0.39	IgG glycosylation;	chr14:104882215	chr14:104821201~104823718:+
THCA	cis	rs10740039	0.804	rs894384	ENSG00000254271.1	RP11-131N11.4	9.28	6.42e-19	3.69e-16	0.49	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60692535	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.842	rs7069157	ENSG00000254271.1	RP11-131N11.4	9.28	6.42e-19	3.7e-16	0.48	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60629475	chr10:60734342~60741828:+
THCA	cis	rs2243480	1	rs313814	ENSG00000273142.1	RP11-458F8.4	-9.28	6.45e-19	3.71e-16	-0.5	-0.39	Diabetic kidney disease;	chr7:66038306	chr7:66902857~66906297:+
THCA	cis	rs10181042	0.581	rs1177285	ENSG00000271889.1	RP11-493E12.1	9.28	6.46e-19	3.71e-16	0.39	0.39	Crohn's disease;	chr2:61123002	chr2:61151433~61162105:-
THCA	cis	rs7429990	0.727	rs319695	ENSG00000229759.1	MRPS18AP1	-9.28	6.47e-19	3.72e-16	-0.48	-0.39	Educational attainment (years of education);	chr3:47842749	chr3:48256350~48256938:-
THCA	cis	rs2599510	1	rs2599510	ENSG00000276334.1	AL133243.1	9.27	6.49e-19	3.73e-16	0.41	0.39	Interleukin-18 levels;	chr2:32600935	chr2:32521927~32523547:+
THCA	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	9.27	6.52e-19	3.75e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
THCA	cis	rs860295	0.812	rs7556519	ENSG00000225855.5	RUSC1-AS1	9.27	6.54e-19	3.76e-16	0.28	0.39	Body mass index;	chr1:155857755	chr1:155316863~155324176:-
THCA	cis	rs9322193	0.566	rs12528243	ENSG00000268592.3	RAET1E-AS1	9.27	6.55e-19	3.76e-16	0.57	0.39	Lung cancer;	chr6:149898491	chr6:149863494~149919507:+
THCA	cis	rs9532669	0.963	rs4942012	ENSG00000176268.5	CYCSP34	9.27	6.55e-19	3.77e-16	0.44	0.39	Cervical cancer;	chr13:40939112	chr13:40863599~40863902:-
THCA	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	9.27	6.57e-19	3.78e-16	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
THCA	cis	rs28510890	0.828	rs56874300	ENSG00000260337.3	RP11-386M24.6	9.27	6.57e-19	3.78e-16	0.48	0.39	Lung cancer in ever smokers;	chr15:92583525	chr15:92592574~92596462:-
THCA	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-9.27	6.58e-19	3.78e-16	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
THCA	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	9.27	6.59e-19	3.79e-16	0.59	0.39	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
THCA	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	9.27	6.59e-19	3.79e-16	0.37	0.39	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
THCA	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-9.27	6.59e-19	3.79e-16	-0.37	-0.39	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
THCA	cis	rs934734	0.532	rs12470883	ENSG00000234255.7	AC012370.3	-9.27	6.61e-19	3.8e-16	-0.43	-0.39	Rheumatoid arthritis;	chr2:65424717	chr2:65439888~65456571:-
THCA	cis	rs2739330	0.929	rs5751775	ENSG00000206090.4	AP000350.7	9.27	6.64e-19	3.82e-16	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23939998~23942798:+
THCA	cis	rs8091660	0.929	rs2175564	ENSG00000278983.1	RP11-426J5.3	9.27	6.65e-19	3.82e-16	0.5	0.39	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48570838	chr18:48564795~48568342:+
THCA	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-9.27	6.66e-19	3.83e-16	-0.78	-0.39	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
THCA	cis	rs7829975	0.626	rs907183	ENSG00000253893.2	FAM85B	9.27	6.67e-19	3.83e-16	0.51	0.39	Mood instability;	chr8:8872251	chr8:8167819~8226614:-
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000228039.3	KB-1125A3.10	9.27	6.74e-19	3.87e-16	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23963780~23964374:+
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000228039.3	KB-1125A3.10	9.27	6.74e-19	3.87e-16	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23963780~23964374:+
THCA	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	9.27	6.75e-19	3.88e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
THCA	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	9.27	6.76e-19	3.88e-16	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
THCA	cis	rs8062405	0.69	rs762634	ENSG00000251417.2	RP11-1348G14.4	-9.27	6.76e-19	3.88e-16	-0.41	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28802743~28817828:+
THCA	cis	rs62034325	0.697	rs710410	ENSG00000251417.2	RP11-1348G14.4	-9.27	6.76e-19	3.88e-16	-0.41	-0.39	Body mass index;	chr16:28592021	chr16:28802743~28817828:+
THCA	cis	rs9640161	0.789	rs10952250	ENSG00000261305.1	RP4-584D14.7	9.27	6.78e-19	3.89e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150328877	chr7:150341771~150342607:+
THCA	cis	rs7211079	0.843	rs73438138	ENSG00000275479.1	RP11-334C17.6	9.27	6.81e-19	3.91e-16	0.39	0.39	Myocardial infarction;	chr17:80148608	chr17:80149627~80149798:+
THCA	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-9.27	6.82e-19	3.91e-16	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
THCA	cis	rs9322193	0.566	rs9397070	ENSG00000268592.3	RAET1E-AS1	-9.27	6.83e-19	3.92e-16	-0.56	-0.39	Lung cancer;	chr6:149922073	chr6:149863494~149919507:+
THCA	cis	rs4927850	1	rs7614767	ENSG00000273009.1	RP11-352G9.1	-9.27	6.84e-19	3.93e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196026580	chr3:195913078~195913683:-
THCA	cis	rs9322193	0.924	rs9498382	ENSG00000268592.3	RAET1E-AS1	9.27	6.84e-19	3.93e-16	0.53	0.39	Lung cancer;	chr6:149610982	chr6:149863494~149919507:+
THCA	cis	rs7712401	0.601	rs35479600	ENSG00000263432.2	RN7SL689P	-9.27	6.86e-19	3.94e-16	-0.44	-0.39	Mean platelet volume;	chr5:122988775	chr5:123022487~123022783:-
THCA	cis	rs1009647	0.961	rs1009648	ENSG00000258413.1	RP11-665C16.6	-9.27	6.87e-19	3.95e-16	-0.58	-0.39	Testicular germ cell tumor;	chr14:55413451	chr14:55262767~55272075:-
THCA	cis	rs9487094	0.6	rs9372213	ENSG00000260273.1	RP11-425D10.10	9.27	6.98e-19	4e-16	0.47	0.39	Height;	chr6:109370985	chr6:109382795~109383666:+
THCA	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-9.26	7.03e-19	4.04e-16	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
THCA	cis	rs9402743	0.597	rs9483879	ENSG00000231028.7	LINC00271	-9.26	7.07e-19	4.06e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135778024	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs9494383	ENSG00000231028.7	LINC00271	-9.26	7.07e-19	4.06e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135778026	chr6:135497801~135716055:+
THCA	cis	rs11971779	0.68	rs4398844	ENSG00000273391.1	RP11-634H22.1	9.26	7.11e-19	4.08e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139358393	chr7:139359032~139359566:-
THCA	cis	rs733592	0.507	rs7299704	ENSG00000240399.1	RP1-228P16.1	9.26	7.11e-19	4.08e-16	0.37	0.39	Plateletcrit;	chr12:48050705	chr12:48054813~48055591:-
THCA	cis	rs6061231	0.675	rs755726	ENSG00000273619.1	RP5-908M14.9	-9.26	7.17e-19	4.11e-16	-0.3	-0.39	Colorectal cancer;	chr20:62387568	chr20:62386303~62386970:-
THCA	cis	rs9828933	0.938	rs831691	ENSG00000280620.1	SCAANT1	9.26	7.19e-19	4.13e-16	0.61	0.39	Type 2 diabetes;	chr3:64021538	chr3:63911518~63911772:-
THCA	cis	rs9532669	0.926	rs9525438	ENSG00000239827.7	SUGT1P3	-9.26	7.27e-19	4.17e-16	-0.42	-0.39	Cervical cancer;	chr13:40964123	chr13:40908159~40921774:-
THCA	cis	rs2032366	0.63	rs1894094	ENSG00000267279.1	RP11-879F14.2	-9.26	7.27e-19	4.17e-16	-0.42	-0.39	Obesity-related traits;	chr18:61606390	chr18:61585746~61606916:-
THCA	cis	rs10463554	0.818	rs2241564	ENSG00000175749.11	EIF3KP1	9.26	7.31e-19	4.19e-16	0.52	0.39	Parkinson's disease;	chr5:102966547	chr5:103032376~103033031:+
THCA	cis	rs2599510	0.748	rs6718214	ENSG00000276334.1	AL133243.1	-9.26	7.34e-19	4.21e-16	-0.43	-0.39	Interleukin-18 levels;	chr2:32325416	chr2:32521927~32523547:+
THCA	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	9.26	7.35e-19	4.21e-16	0.59	0.39	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
THCA	cis	rs932287	0.505	rs2742536	ENSG00000254860.4	TMEM9B-AS1	9.26	7.37e-19	4.22e-16	0.42	0.39	Colonoscopy-negative controls vs population controls;	chr11:8888269	chr11:8964675~8977527:+
THCA	cis	rs5769707	0.967	rs5769698	ENSG00000235111.1	RP1-29C18.8	-9.26	7.37e-19	4.22e-16	-0.45	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49612657~49615716:-
THCA	cis	rs4380275	0.782	rs4468850	ENSG00000272342.1	RP13-539J13.1	9.26	7.38e-19	4.23e-16	0.47	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:739588~740164:-
THCA	cis	rs733592	0.894	rs886589	ENSG00000240399.1	RP1-228P16.1	-9.26	7.39e-19	4.24e-16	-0.37	-0.39	Plateletcrit;	chr12:48083414	chr12:48054813~48055591:-
THCA	cis	rs4819052	0.851	rs2838867	ENSG00000215447.6	BX322557.10	-9.26	7.44e-19	4.26e-16	-0.34	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293177	chr21:45288052~45291738:+
THCA	cis	rs11971779	0.711	rs6961204	ENSG00000273391.1	RP11-634H22.1	9.26	7.46e-19	4.27e-16	0.41	0.39	Diisocyanate-induced asthma;	chr7:139362653	chr7:139359032~139359566:-
THCA	cis	rs1799949	1	rs11653460	ENSG00000267681.1	CTD-3199J23.6	-9.26	7.51e-19	4.3e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43179289	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs11650913	ENSG00000267681.1	CTD-3199J23.6	-9.26	7.51e-19	4.3e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43179580	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs12936831	ENSG00000267681.1	CTD-3199J23.6	-9.26	7.51e-19	4.3e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43179799	chr17:43144956~43145255:+
THCA	cis	rs2115630	0.645	rs2292463	ENSG00000225151.9	GOLGA2P7	9.26	7.55e-19	4.33e-16	0.51	0.39	P wave terminal force;	chr15:84632519	chr15:84199311~84230136:-
THCA	cis	rs4927850	0.957	rs4927851	ENSG00000273009.1	RP11-352G9.1	-9.26	7.56e-19	4.33e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196024982	chr3:195913078~195913683:-
THCA	cis	rs4927850	0.918	rs4361313	ENSG00000273009.1	RP11-352G9.1	-9.26	7.56e-19	4.33e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196025389	chr3:195913078~195913683:-
THCA	cis	rs11971779	0.68	rs11765421	ENSG00000273391.1	RP11-634H22.1	9.25	7.61e-19	4.36e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139340348	chr7:139359032~139359566:-
THCA	cis	rs62355901	0.505	rs12657396	ENSG00000271828.1	CTD-2310F14.1	9.25	7.63e-19	4.37e-16	0.77	0.39	Breast cancer;	chr5:56930778	chr5:56927874~56929573:+
THCA	cis	rs9532669	0.89	rs9532593	ENSG00000239827.7	SUGT1P3	-9.25	7.66e-19	4.38e-16	-0.44	-0.39	Cervical cancer;	chr13:40847717	chr13:40908159~40921774:-
THCA	cis	rs2836950	0.501	rs62223052	ENSG00000255568.3	BRWD1-AS2	-9.25	7.74e-19	4.43e-16	-0.32	-0.39	Menarche (age at onset);	chr21:39336776	chr21:39313935~39314962:+
THCA	cis	rs853679	0.517	rs12332979	ENSG00000226314.6	ZNF192P1	-9.25	7.74e-19	4.43e-16	-0.53	-0.39	Depression;	chr6:28173770	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs67878650	ENSG00000226314.6	ZNF192P1	-9.25	7.74e-19	4.43e-16	-0.53	-0.39	Depression;	chr6:28174809	chr6:28161781~28169594:+
THCA	cis	rs853679	0.569	rs9348798	ENSG00000226314.6	ZNF192P1	-9.25	7.74e-19	4.43e-16	-0.53	-0.39	Depression;	chr6:28175233	chr6:28161781~28169594:+
THCA	cis	rs853679	0.517	rs9380065	ENSG00000226314.6	ZNF192P1	-9.25	7.74e-19	4.43e-16	-0.53	-0.39	Depression;	chr6:28176973	chr6:28161781~28169594:+
THCA	cis	rs11971779	0.68	rs10229358	ENSG00000273391.1	RP11-634H22.1	-9.25	7.77e-19	4.44e-16	-0.37	-0.39	Diisocyanate-induced asthma;	chr7:139367799	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs10230407	ENSG00000273391.1	RP11-634H22.1	9.25	7.78e-19	4.45e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139419147	chr7:139359032~139359566:-
THCA	cis	rs324126	1	rs324126	ENSG00000277977.1	CTD-3018O17.5	-9.25	7.78e-19	4.45e-16	-0.37	-0.39	Colonoscopy-negative controls vs population controls;	chr19:52382884	chr19:52392659~52392755:+
THCA	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-9.25	7.81e-19	4.47e-16	-0.78	-0.39	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-9.25	7.81e-19	4.47e-16	-0.78	-0.39	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-9.25	7.81e-19	4.47e-16	-0.78	-0.39	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
THCA	cis	rs9402743	0.632	rs7766804	ENSG00000231028.7	LINC00271	-9.25	7.81e-19	4.47e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135772118	chr6:135497801~135716055:+
THCA	cis	rs2115630	0.645	rs6496284	ENSG00000275120.1	RP11-182J1.17	-9.25	7.81e-19	4.47e-16	-0.42	-0.39	P wave terminal force;	chr15:84635039	chr15:84599434~84606463:-
THCA	cis	rs17684571	0.687	rs34083827	ENSG00000231441.1	RP11-472M19.2	9.25	7.83e-19	4.48e-16	0.53	0.39	Schizophrenia;	chr6:56866498	chr6:56844002~56864078:+
THCA	cis	rs1075265	0.722	rs805374	ENSG00000233266.1	HMGB1P31	9.25	7.84e-19	4.48e-16	0.5	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53862720	chr2:54051334~54051760:+
THCA	cis	rs10759883	0.563	rs589362	ENSG00000175611.10	LINC00476	9.25	7.89e-19	4.51e-16	0.44	0.39	Nicotine dependence;	chr9:95966906	chr9:95759231~95875977:-
THCA	cis	rs11051970	0.592	rs11051987	ENSG00000274964.1	RP11-817I4.1	-9.25	7.9e-19	4.52e-16	-0.52	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32402472	chr12:32339368~32340724:+
THCA	cis	rs9402743	0.632	rs6570040	ENSG00000231028.7	LINC00271	-9.25	7.95e-19	4.54e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135779557	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs7754830	ENSG00000231028.7	LINC00271	-9.25	7.95e-19	4.54e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135779904	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs2104133	ENSG00000231028.7	LINC00271	-9.25	7.95e-19	4.54e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135781149	chr6:135497801~135716055:+
THCA	cis	rs4842666	0.915	rs73437338	ENSG00000258302.2	RP11-981P6.1	9.25	7.97e-19	4.56e-16	0.4	0.39	Blood pressure;	chr12:89660842	chr12:89561129~89594878:+
THCA	cis	rs17684571	0.751	rs7775182	ENSG00000231441.1	RP11-472M19.2	9.25	7.97e-19	4.56e-16	0.51	0.39	Schizophrenia;	chr6:56831848	chr6:56844002~56864078:+
THCA	cis	rs2243480	1	rs73150014	ENSG00000273142.1	RP11-458F8.4	-9.25	8.02e-19	4.58e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:65985932	chr7:66902857~66906297:+
THCA	cis	rs10411161	1	rs8111316	ENSG00000269483.1	AC006272.1	9.25	8.05e-19	4.6e-16	0.54	0.39	Breast cancer;	chr19:51865816	chr19:51839924~51843324:-
THCA	cis	rs1387259	0.839	rs7487682	ENSG00000258273.1	RP11-370I10.4	9.25	8.1e-19	4.62e-16	0.5	0.39	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48333755~48333901:-
THCA	cis	rs4927850	0.881	rs7624638	ENSG00000273009.1	RP11-352G9.1	-9.25	8.15e-19	4.65e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196021858	chr3:195913078~195913683:-
THCA	cis	rs4819052	0.851	rs35064782	ENSG00000215447.6	BX322557.10	-9.25	8.2e-19	4.68e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45288052~45291738:+
THCA	cis	rs6046396	1	rs6046396	ENSG00000275142.1	RP5-999L4.2	9.25	8.2e-19	4.68e-16	0.53	0.39	Bipolar disorder and schizophrenia;	chr20:19871859	chr20:19871891~19872284:+
THCA	cis	rs4819052	0.819	rs34818688	ENSG00000215447.6	BX322557.10	-9.25	8.2e-19	4.68e-16	-0.33	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45288052~45291738:+
THCA	cis	rs9640161	0.75	rs59211922	ENSG00000261305.1	RP4-584D14.7	9.25	8.2e-19	4.68e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150326701	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.711	rs60268791	ENSG00000261305.1	RP4-584D14.7	9.25	8.2e-19	4.68e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150326711	chr7:150341771~150342607:+
THCA	cis	rs9322193	0.962	rs6899661	ENSG00000268592.3	RAET1E-AS1	9.25	8.22e-19	4.69e-16	0.52	0.39	Lung cancer;	chr6:149818093	chr6:149863494~149919507:+
THCA	cis	rs62355901	0.505	rs62356561	ENSG00000271828.1	CTD-2310F14.1	9.24	8.23e-19	4.7e-16	0.77	0.39	Breast cancer;	chr5:56933826	chr5:56927874~56929573:+
THCA	cis	rs848490	0.651	rs12113119	ENSG00000214293.7	APTR	9.24	8.23e-19	4.7e-16	0.29	0.39	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685501	chr7:77657660~77696265:-
THCA	cis	rs28510890	0.547	rs12443027	ENSG00000260337.3	RP11-386M24.6	9.24	8.27e-19	4.72e-16	0.53	0.39	Lung cancer in ever smokers;	chr15:92612013	chr15:92592574~92596462:-
THCA	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-9.24	8.28e-19	4.72e-16	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
THCA	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-9.24	8.34e-19	4.76e-16	-0.39	-0.39	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
THCA	cis	rs2243480	1	rs1723267	ENSG00000273142.1	RP11-458F8.4	-9.24	8.41e-19	4.79e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66008327	chr7:66902857~66906297:+
THCA	cis	rs853679	0.517	rs9295761	ENSG00000226314.6	ZNF192P1	-9.24	8.43e-19	4.81e-16	-0.53	-0.39	Depression;	chr6:28180209	chr6:28161781~28169594:+
THCA	cis	rs62388641	0.547	rs4513844	ENSG00000272279.1	RP11-157J24.2	-9.24	8.45e-19	4.82e-16	-0.53	-0.39	Daytime sleep phenotypes;	chr6:1551747	chr6:1528364~1528911:-
THCA	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-9.24	8.46e-19	4.82e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
THCA	cis	rs4927850	1	rs7630875	ENSG00000273009.1	RP11-352G9.1	-9.24	8.48e-19	4.84e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196026895	chr3:195913078~195913683:-
THCA	cis	rs9322193	0.607	rs7764677	ENSG00000268592.3	RAET1E-AS1	9.24	8.5e-19	4.85e-16	0.56	0.39	Lung cancer;	chr6:149906197	chr6:149863494~149919507:+
THCA	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-9.24	8.5e-19	4.85e-16	-0.45	-0.39	Temperament;	chr17:14007316	chr17:14024514~14025488:+
THCA	cis	rs17608059	0.545	rs9915045	ENSG00000141028.6	CDRT15P1	-9.24	8.5e-19	4.85e-16	-0.45	-0.39	Temperament;	chr17:13999319	chr17:14024514~14025488:+
THCA	cis	rs673078	0.607	rs61943443	ENSG00000275409.1	RP11-131L12.4	-9.24	8.52e-19	4.86e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118416602	chr12:118430147~118430699:+
THCA	cis	rs56080343	0.808	rs1045552	ENSG00000275409.1	RP11-131L12.4	-9.24	8.52e-19	4.86e-16	-0.47	-0.39	Neuroticism;	chr12:118417678	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7305647	ENSG00000275409.1	RP11-131L12.4	-9.24	8.52e-19	4.86e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118417761	chr12:118430147~118430699:+
THCA	cis	rs2243480	1	rs427044	ENSG00000273142.1	RP11-458F8.4	-9.24	8.57e-19	4.88e-16	-0.5	-0.39	Diabetic kidney disease;	chr7:66043558	chr7:66902857~66906297:+
THCA	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	9.24	8.61e-19	4.91e-16	0.5	0.39	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
THCA	cis	rs7772486	0.742	rs4896851	ENSG00000235652.6	RP11-545I5.3	-9.24	8.62e-19	4.91e-16	-0.36	-0.39	Lobe attachment (rater-scored or self-reported);	chr6:145957823	chr6:145799409~145886585:+
THCA	cis	rs67311347	0.544	rs6804545	ENSG00000223797.4	ENTPD3-AS1	9.24	8.65e-19	4.93e-16	0.32	0.39	Renal cell carcinoma;	chr3:40312549	chr3:40313802~40453329:-
THCA	cis	rs2115630	0.653	rs61394864	ENSG00000225151.9	GOLGA2P7	9.24	8.66e-19	4.94e-16	0.5	0.39	P wave terminal force;	chr15:84626943	chr15:84199311~84230136:-
THCA	cis	rs12188164	0.686	rs72711367	ENSG00000221990.4	EXOC3-AS1	9.24	8.74e-19	4.98e-16	0.34	0.39	Cystic fibrosis severity;	chr5:418379	chr5:441498~443160:-
THCA	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	9.24	8.76e-19	4.99e-16	0.28	0.39	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
THCA	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	9.24	8.76e-19	4.99e-16	0.28	0.39	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
THCA	cis	rs71403859	0.502	rs7195767	ENSG00000260886.1	TAT-AS1	9.24	8.77e-19	4.99e-16	0.68	0.39	Post bronchodilator FEV1;	chr16:71431040	chr16:71565789~71578187:+
THCA	cis	rs848490	0.674	rs7803449	ENSG00000214293.7	APTR	9.24	8.78e-19	5e-16	0.29	0.39	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77679660	chr7:77657660~77696265:-
THCA	cis	rs1062177	1	rs17741826	ENSG00000253921.1	CTB-113P19.3	9.24	8.79e-19	5.01e-16	0.48	0.39	Preschool internalizing problems;	chr5:151769701	chr5:151753992~151767247:+
THCA	cis	rs860295	0.841	rs7556102	ENSG00000225855.5	RUSC1-AS1	-9.24	8.8e-19	5.01e-16	-0.26	-0.39	Body mass index;	chr1:155398412	chr1:155316863~155324176:-
THCA	cis	rs28510890	0.828	rs77955994	ENSG00000260337.3	RP11-386M24.6	9.24	8.8e-19	5.01e-16	0.48	0.39	Lung cancer in ever smokers;	chr15:92582299	chr15:92592574~92596462:-
THCA	cis	rs8062405	0.755	rs4788076	ENSG00000251417.2	RP11-1348G14.4	-9.24	8.82e-19	5.02e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28802743~28817828:+
THCA	cis	rs62103177	0.584	rs9956207	ENSG00000261126.6	RP11-795F19.1	-9.24	8.89e-19	5.06e-16	-0.42	-0.39	Opioid sensitivity;	chr18:80210509	chr18:80046900~80095482:+
THCA	cis	rs9309473	0.687	rs6710659	ENSG00000163016.8	ALMS1P	9.23	8.92e-19	5.08e-16	0.52	0.39	Metabolite levels;	chr2:73380382	chr2:73644919~73685576:+
THCA	cis	rs11971779	0.648	rs6967836	ENSG00000273391.1	RP11-634H22.1	9.23	8.94e-19	5.09e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139395198	chr7:139359032~139359566:-
THCA	cis	rs9402743	0.632	rs4896178	ENSG00000231028.7	LINC00271	-9.23	8.94e-19	5.09e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135783957	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs7773035	ENSG00000231028.7	LINC00271	-9.23	8.94e-19	5.09e-16	-0.31	-0.39	Systemic lupus erythematosus;	chr6:135784743	chr6:135497801~135716055:+
THCA	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-9.23	8.94e-19	5.09e-16	-0.51	-0.39	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
THCA	cis	rs6844153	0.68	rs61047003	ENSG00000240005.4	RP11-293A21.1	-9.23	8.95e-19	5.09e-16	-0.46	-0.39	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26937139	chr4:26859806~26860599:-
THCA	cis	rs524281	0.731	rs10791840	ENSG00000255320.1	RP11-755F10.1	9.23	9.02e-19	5.13e-16	0.62	0.39	Electroencephalogram traits;	chr11:66035912	chr11:66244840~66246239:-
THCA	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-9.23	9.02e-19	5.13e-16	-0.78	-0.39	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
THCA	cis	rs9640161	0.702	rs11765692	ENSG00000261305.1	RP4-584D14.7	9.23	9.1e-19	5.18e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150329478	chr7:150341771~150342607:+
THCA	cis	rs944289	0.774	rs12050449	ENSG00000257826.1	RP11-116N8.4	-9.23	9.11e-19	5.18e-16	-0.4	-0.39	Thyroid cancer;	chr14:36101949	chr14:36061026~36067190:-
THCA	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	9.23	9.11e-19	5.18e-16	0.59	0.39	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
THCA	cis	rs944289	0.708	rs1537424	ENSG00000257826.1	RP11-116N8.4	-9.23	9.11e-19	5.18e-16	-0.4	-0.39	Thyroid cancer;	chr14:36104812	chr14:36061026~36067190:-
THCA	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	9.23	9.14e-19	5.2e-16	0.59	0.39	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
THCA	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-9.23	9.15e-19	5.2e-16	-0.51	-0.39	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
THCA	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	9.23	9.16e-19	5.21e-16	0.48	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	9.23	9.16e-19	5.21e-16	0.48	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
THCA	cis	rs10463554	0.853	rs2241565	ENSG00000175749.11	EIF3KP1	9.23	9.17e-19	5.21e-16	0.52	0.39	Parkinson's disease;	chr5:102966233	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.962	rs9322220	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149782897	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs10214845	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149783124	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9767122	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149783553	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs1413654	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149783956	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9688809	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149787920	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9689242	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149787970	chr6:149863494~149919507:+
THCA	cis	rs9322193	1	rs9767077	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149788479	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.926	rs9766562	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149788709	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9688938	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149788941	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9688940	ENSG00000268592.3	RAET1E-AS1	9.23	9.19e-19	5.22e-16	0.52	0.39	Lung cancer;	chr6:149788977	chr6:149863494~149919507:+
THCA	cis	rs17684571	0.687	rs35461301	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56832577	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.687	rs35851452	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56832602	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs17752106	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56837455	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs17684878	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56838178	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs17684884	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56838852	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs7761501	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56839187	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs35073881	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56842410	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs1610156	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56844274	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs74777312	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56845568	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs6905603	ENSG00000231441.1	RP11-472M19.2	9.23	9.19e-19	5.22e-16	0.5	0.39	Schizophrenia;	chr6:56848145	chr6:56844002~56864078:+
THCA	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	9.23	9.21e-19	5.23e-16	0.51	0.39	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
THCA	cis	rs12444156	1	rs12444156	ENSG00000260886.1	TAT-AS1	9.23	9.22e-19	5.24e-16	0.75	0.39	Post bronchodilator FEV1;	chr16:71807354	chr16:71565789~71578187:+
THCA	cis	rs780096	0.527	rs12471703	ENSG00000234072.1	AC074117.10	-9.23	9.24e-19	5.25e-16	-0.31	-0.39	Total body bone mineral density;	chr2:27515987	chr2:27356246~27367622:+
THCA	cis	rs801193	1	rs1553610	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66732246	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2707845	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66733811	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
THCA	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
THCA	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	9.23	9.25e-19	5.25e-16	0.28	0.39	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
THCA	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	9.23	9.25e-19	5.25e-16	0.32	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
THCA	cis	rs2033711	0.87	rs11669741	ENSG00000268912.1	CTD-2619J13.17	9.23	9.26e-19	5.26e-16	0.3	0.39	Uric acid clearance;	chr19:58449114	chr19:58428632~58431148:-
THCA	cis	rs9322193	0.607	rs9371228	ENSG00000268592.3	RAET1E-AS1	-9.23	9.26e-19	5.26e-16	-0.56	-0.39	Lung cancer;	chr6:149921977	chr6:149863494~149919507:+
THCA	cis	rs9640161	0.663	rs1916932	ENSG00000261305.1	RP4-584D14.7	9.23	9.29e-19	5.28e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150324555	chr7:150341771~150342607:+
THCA	cis	rs4819052	0.959	rs8130866	ENSG00000215447.6	BX322557.10	-9.23	9.29e-19	5.28e-16	-0.36	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45288052~45291738:+
THCA	cis	rs673078	0.607	rs1060964	ENSG00000275409.1	RP11-131L12.4	-9.23	9.35e-19	5.31e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118414906	chr12:118430147~118430699:+
THCA	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-9.23	9.37e-19	5.32e-16	-0.49	-0.39	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
THCA	cis	rs4927850	1	rs10881564	ENSG00000273009.1	RP11-352G9.1	-9.23	9.44e-19	5.36e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196023455	chr3:195913078~195913683:-
THCA	cis	rs2033711	0.84	rs4801590	ENSG00000268912.1	CTD-2619J13.17	-9.23	9.49e-19	5.39e-16	-0.31	-0.39	Uric acid clearance;	chr19:58450446	chr19:58428632~58431148:-
THCA	cis	rs17772222	0.63	rs12436642	ENSG00000258789.1	RP11-507K2.3	9.23	9.51e-19	5.4e-16	0.38	0.39	Coronary artery calcification;	chr14:88559032	chr14:88551597~88552493:+
THCA	cis	rs801193	1	rs62466793	ENSG00000237310.1	GS1-124K5.4	9.23	9.53e-19	5.4e-16	0.28	0.39	Aortic root size;	chr7:66726530	chr7:66493706~66495474:+
THCA	cis	rs9532669	0.926	rs9566582	ENSG00000239827.7	SUGT1P3	-9.23	9.53e-19	5.4e-16	-0.43	-0.39	Cervical cancer;	chr13:40852121	chr13:40908159~40921774:-
THCA	cis	rs673078	0.607	rs17441061	ENSG00000275409.1	RP11-131L12.4	-9.23	9.53e-19	5.41e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118409847	chr12:118430147~118430699:+
THCA	cis	rs4722166	0.63	rs4722168	ENSG00000179428.2	AC073072.5	-9.23	9.62e-19	5.45e-16	-0.51	-0.39	Lung cancer;	chr7:22739383	chr7:22725395~22727620:-
THCA	cis	rs2115630	0.645	rs3825877	ENSG00000275120.1	RP11-182J1.17	-9.22	9.67e-19	5.48e-16	-0.41	-0.39	P wave terminal force;	chr15:84631400	chr15:84599434~84606463:-
THCA	cis	rs2115630	0.645	rs3825878	ENSG00000275120.1	RP11-182J1.17	-9.22	9.67e-19	5.48e-16	-0.41	-0.39	P wave terminal force;	chr15:84631524	chr15:84599434~84606463:-
THCA	cis	rs12554020	0.892	rs6479487	ENSG00000227603.1	RP11-165J3.6	9.22	9.67e-19	5.48e-16	0.52	0.39	Schizophrenia;	chr9:93475091	chr9:93435332~93437121:-
THCA	cis	rs11676348	0.791	rs4133195	ENSG00000261338.2	RP11-378A13.1	9.22	9.69e-19	5.49e-16	0.38	0.39	Ulcerative colitis;	chr2:218086522	chr2:218255319~218257366:+
THCA	cis	rs1799949	0.965	rs11658499	ENSG00000267681.1	CTD-3199J23.6	-9.22	9.69e-19	5.49e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43182732	chr17:43144956~43145255:+
THCA	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-9.22	9.71e-19	5.5e-16	-0.59	-0.39	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	9.22	9.71e-19	5.5e-16	0.59	0.39	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
THCA	cis	rs9318086	0.776	rs1326130	ENSG00000205861.10	C1QTNF9B-AS1	-9.22	9.72e-19	5.51e-16	-0.44	-0.39	Myopia (pathological);	chr13:23873525	chr13:23888889~23897263:+
THCA	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-9.22	9.73e-19	5.51e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-9.22	9.73e-19	5.51e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-9.22	9.73e-19	5.51e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
THCA	cis	rs526231	0.578	rs17154821	ENSG00000175749.11	EIF3KP1	9.22	9.73e-19	5.51e-16	0.52	0.39	Primary biliary cholangitis;	chr5:102905637	chr5:103032376~103033031:+
THCA	cis	rs1185460	0.546	rs549893	ENSG00000271751.1	RP11-110I1.14	9.22	9.76e-19	5.53e-16	0.49	0.39	Coronary artery disease;	chr11:119089022	chr11:119065263~119065677:-
THCA	cis	rs673078	0.607	rs7136676	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118403605	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17441033	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118404101	chr12:118430147~118430699:+
THCA	cis	rs673078	0.562	rs61943405	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118405030	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943406	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118405767	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17441075	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118410542	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs965524	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118412361	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs74685643	ENSG00000275409.1	RP11-131L12.4	-9.22	9.79e-19	5.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118412761	chr12:118430147~118430699:+
THCA	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	9.22	9.81e-19	5.56e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
THCA	cis	rs9640161	0.789	rs3735172	ENSG00000261305.1	RP4-584D14.7	-9.22	9.85e-19	5.58e-16	-0.45	-0.39	Blood protein levels;Circulating chemerin levels;	chr7:150331869	chr7:150341771~150342607:+
THCA	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-9.22	9.88e-19	5.59e-16	-0.6	-0.39	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
THCA	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	9.22	9.88e-19	5.59e-16	0.52	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
THCA	cis	rs8062405	0.722	rs3785354	ENSG00000251417.2	RP11-1348G14.4	-9.22	9.89e-19	5.6e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28802743~28817828:+
THCA	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	9.22	9.92e-19	5.61e-16	0.46	0.39	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
THCA	cis	rs801193	0.967	rs2420827	ENSG00000237310.1	GS1-124K5.4	-9.22	1.01e-18	5.69e-16	-0.28	-0.39	Aortic root size;	chr7:66682114	chr7:66493706~66495474:+
THCA	cis	rs1799949	1	rs4793215	ENSG00000267681.1	CTD-3199J23.6	-9.22	1.01e-18	5.73e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43166915	chr17:43144956~43145255:+
THCA	cis	rs2243480	1	rs35396113	ENSG00000273142.1	RP11-458F8.4	-9.22	1.02e-18	5.78e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66030474	chr7:66902857~66906297:+
THCA	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-9.22	1.03e-18	5.82e-16	-0.43	-0.39	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
THCA	cis	rs7569084	0.905	rs13417564	ENSG00000237979.1	AC007389.1	-9.22	1.03e-18	5.83e-16	-0.45	-0.39	Sum eosinophil basophil counts;	chr2:65438139	chr2:65500993~65502138:-
THCA	cis	rs7772486	0.777	rs1546966	ENSG00000235652.6	RP11-545I5.3	9.22	1.04e-18	5.85e-16	0.37	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146064882	chr6:145799409~145886585:+
THCA	cis	rs801193	1	rs2707836	ENSG00000237310.1	GS1-124K5.4	9.22	1.04e-18	5.85e-16	0.28	0.39	Aortic root size;	chr7:66695448	chr7:66493706~66495474:+
THCA	cis	rs801193	0.844	rs7779971	ENSG00000237310.1	GS1-124K5.4	9.22	1.04e-18	5.85e-16	0.28	0.39	Aortic root size;	chr7:66696803	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2659906	ENSG00000237310.1	GS1-124K5.4	9.22	1.04e-18	5.85e-16	0.28	0.39	Aortic root size;	chr7:66700323	chr7:66493706~66495474:+
THCA	cis	rs7191700	0.583	rs243314	ENSG00000262703.1	RP11-485G7.6	9.22	1.04e-18	5.86e-16	0.43	0.39	Multiple sclerosis;	chr16:11291247	chr16:11348143~11349321:-
THCA	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-9.22	1.04e-18	5.87e-16	-0.61	-0.39	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
THCA	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	9.21	1.04e-18	5.9e-16	0.51	0.39	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
THCA	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	9.21	1.04e-18	5.9e-16	0.51	0.39	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
THCA	cis	rs4713118	0.516	rs6931858	ENSG00000226314.6	ZNF192P1	-9.21	1.04e-18	5.9e-16	-0.52	-0.39	Parkinson's disease;	chr6:28110633	chr6:28161781~28169594:+
THCA	cis	rs11148252	0.508	rs11148260	ENSG00000235660.1	LINC00345	-9.21	1.05e-18	5.91e-16	-0.48	-0.39	Lewy body disease;	chr13:52588508	chr13:52484161~52484680:-
THCA	cis	rs6496932	0.874	rs11074061	ENSG00000218052.5	ADAMTS7P4	9.21	1.06e-18	5.96e-16	0.55	0.39	Central corneal thickness;Corneal structure;	chr15:85274962	chr15:85255369~85330334:-
THCA	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	9.21	1.06e-18	5.97e-16	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
THCA	cis	rs4722166	0.63	rs12700390	ENSG00000179428.2	AC073072.5	-9.21	1.06e-18	5.99e-16	-0.51	-0.39	Lung cancer;	chr7:22737510	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.63	rs12700391	ENSG00000179428.2	AC073072.5	-9.21	1.06e-18	5.99e-16	-0.51	-0.39	Lung cancer;	chr7:22737708	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.63	rs7781534	ENSG00000179428.2	AC073072.5	-9.21	1.06e-18	5.99e-16	-0.51	-0.39	Lung cancer;	chr7:22738973	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.63	rs1581497	ENSG00000179428.2	AC073072.5	-9.21	1.06e-18	5.99e-16	-0.51	-0.39	Lung cancer;	chr7:22739884	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.63	rs1829927	ENSG00000179428.2	AC073072.5	-9.21	1.06e-18	5.99e-16	-0.51	-0.39	Lung cancer;	chr7:22740299	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.573	rs35436671	ENSG00000179428.2	AC073072.5	-9.21	1.06e-18	6e-16	-0.51	-0.39	Lung cancer;	chr7:22735889	chr7:22725395~22727620:-
THCA	cis	rs11676348	0.712	rs11687434	ENSG00000261338.2	RP11-378A13.1	-9.21	1.07e-18	6.02e-16	-0.39	-0.39	Ulcerative colitis;	chr2:218080420	chr2:218255319~218257366:+
THCA	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-9.21	1.07e-18	6.02e-16	-0.4	-0.39	QT interval;	chr12:29287150	chr12:29280418~29317848:-
THCA	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	9.21	1.07e-18	6.04e-16	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
THCA	cis	rs875971	0.66	rs10229345	ENSG00000237310.1	GS1-124K5.4	9.21	1.07e-18	6.05e-16	0.29	0.39	Aortic root size;	chr7:66517181	chr7:66493706~66495474:+
THCA	cis	rs748404	0.65	rs556851	ENSG00000249839.1	AC011330.5	-9.21	1.08e-18	6.07e-16	-0.46	-0.39	Lung cancer;	chr15:43279021	chr15:43663654~43684339:-
THCA	cis	rs7727544	0.716	rs4594848	ENSG00000237714.1	P4HA2-AS1	9.21	1.08e-18	6.09e-16	0.52	0.39	Blood metabolite levels;	chr5:132250905	chr5:132184876~132192808:+
THCA	cis	rs10740039	0.804	rs2028563	ENSG00000254271.1	RP11-131N11.4	-9.21	1.08e-18	6.1e-16	-0.49	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677139	chr10:60734342~60741828:+
THCA	cis	rs28510890	0.789	rs17704141	ENSG00000260337.3	RP11-386M24.6	-9.21	1.08e-18	6.1e-16	-0.48	-0.39	Lung cancer in ever smokers;	chr15:92593271	chr15:92592574~92596462:-
THCA	cis	rs172166	0.543	rs1150691	ENSG00000219392.1	RP1-265C24.5	-9.21	1.08e-18	6.11e-16	-0.43	-0.39	Cardiac Troponin-T levels;	chr6:28200255	chr6:28115628~28116551:+
THCA	cis	rs2032366	0.606	rs9965972	ENSG00000267279.1	RP11-879F14.2	-9.21	1.08e-18	6.11e-16	-0.41	-0.39	Obesity-related traits;	chr18:61609468	chr18:61585746~61606916:-
THCA	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-9.21	1.09e-18	6.12e-16	-0.31	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
THCA	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-9.21	1.09e-18	6.12e-16	-0.31	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
THCA	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	9.21	1.09e-18	6.12e-16	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
THCA	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-9.21	1.09e-18	6.13e-16	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
THCA	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-9.21	1.09e-18	6.13e-16	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
THCA	cis	rs11676348	0.772	rs10932745	ENSG00000261338.2	RP11-378A13.1	-9.21	1.09e-18	6.16e-16	-0.39	-0.39	Ulcerative colitis;	chr2:218078253	chr2:218255319~218257366:+
THCA	cis	rs6546847	0.531	rs2567603	ENSG00000163016.8	ALMS1P	9.21	1.09e-18	6.17e-16	0.72	0.39	Urinary metabolites (H-NMR features);	chr2:73758998	chr2:73644919~73685576:+
THCA	cis	rs1799949	0.86	rs8176279	ENSG00000267681.1	CTD-3199J23.6	-9.21	1.1e-18	6.2e-16	-0.45	-0.39	Menopause (age at onset);	chr17:43058379	chr17:43144956~43145255:+
THCA	cis	rs2658782	0.654	rs2605620	ENSG00000279684.1	RP11-755E23.2	-9.21	1.1e-18	6.21e-16	-0.6	-0.39	Pulmonary function decline;	chr11:93514480	chr11:93286629~93288903:-
THCA	cis	rs4591358	0.773	rs35070116	ENSG00000223466.1	AC064834.2	-9.21	1.1e-18	6.22e-16	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515729	chr2:195533035~195538681:+
THCA	cis	rs2408955	0.504	rs11168441	ENSG00000258273.1	RP11-370I10.4	-9.21	1.11e-18	6.25e-16	-0.51	-0.39	Glycated hemoglobin levels;	chr12:48182271	chr12:48333755~48333901:-
THCA	cis	rs507080	0.769	rs12290522	ENSG00000255422.1	AP002954.4	-9.21	1.11e-18	6.26e-16	-0.44	-0.39	Serum metabolite levels;	chr11:118615610	chr11:118704607~118750263:+
THCA	cis	rs8062405	0.755	rs4787457	ENSG00000251417.2	RP11-1348G14.4	-9.21	1.11e-18	6.27e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.755	rs4788080	ENSG00000251417.2	RP11-1348G14.4	-9.21	1.11e-18	6.27e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.755	rs4787456	ENSG00000251417.2	RP11-1348G14.4	-9.21	1.11e-18	6.27e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.755	rs4788078	ENSG00000251417.2	RP11-1348G14.4	-9.21	1.11e-18	6.27e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.723	rs4788079	ENSG00000251417.2	RP11-1348G14.4	-9.21	1.11e-18	6.28e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28802743~28817828:+
THCA	cis	rs673078	0.607	rs7132753	ENSG00000275409.1	RP11-131L12.4	-9.21	1.12e-18	6.3e-16	-0.48	-0.39	Glucose homeostasis traits;	chr12:118420383	chr12:118430147~118430699:+
THCA	cis	rs944289	0.684	rs8016315	ENSG00000257826.1	RP11-116N8.4	-9.21	1.12e-18	6.31e-16	-0.4	-0.39	Thyroid cancer;	chr14:36101158	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs4982334	ENSG00000257826.1	RP11-116N8.4	-9.21	1.12e-18	6.31e-16	-0.4	-0.39	Thyroid cancer;	chr14:36101396	chr14:36061026~36067190:-
THCA	cis	rs9322193	1	rs58189451	ENSG00000268592.3	RAET1E-AS1	9.21	1.12e-18	6.31e-16	0.54	0.39	Lung cancer;	chr6:149600252	chr6:149863494~149919507:+
THCA	cis	rs2288884	0.708	rs61574510	ENSG00000275055.1	CTC-471J1.11	-9.21	1.12e-18	6.33e-16	-0.37	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52017354	chr19:52049007~52049754:+
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000224205.1	AP000351.4	9.21	1.12e-18	6.33e-16	0.46	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23987320~23991421:-
THCA	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	9.21	1.12e-18	6.34e-16	0.77	0.39	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.962	rs9397022	ENSG00000268592.3	RAET1E-AS1	9.21	1.13e-18	6.34e-16	0.52	0.39	Lung cancer;	chr6:149812052	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9397357	ENSG00000268592.3	RAET1E-AS1	9.21	1.13e-18	6.34e-16	0.52	0.39	Lung cancer;	chr6:149812465	chr6:149863494~149919507:+
THCA	cis	rs17684571	0.751	rs28360570	ENSG00000231441.1	RP11-472M19.2	9.21	1.13e-18	6.34e-16	0.5	0.39	Schizophrenia;	chr6:56852832	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs13198597	ENSG00000231441.1	RP11-472M19.2	9.21	1.13e-18	6.34e-16	0.5	0.39	Schizophrenia;	chr6:56852929	chr6:56844002~56864078:+
THCA	cis	rs11051970	0.592	rs11051985	ENSG00000274964.1	RP11-817I4.1	-9.21	1.13e-18	6.34e-16	-0.51	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32402156	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051986	ENSG00000274964.1	RP11-817I4.1	-9.21	1.13e-18	6.34e-16	-0.51	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32402339	chr12:32339368~32340724:+
THCA	cis	rs9532669	0.926	rs9532689	ENSG00000239827.7	SUGT1P3	-9.21	1.13e-18	6.35e-16	-0.42	-0.39	Cervical cancer;	chr13:40957990	chr13:40908159~40921774:-
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-9.2	1.13e-18	6.37e-16	-0.53	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
THCA	cis	rs2658782	0.724	rs2248020	ENSG00000279684.1	RP11-755E23.2	-9.2	1.13e-18	6.38e-16	-0.58	-0.39	Pulmonary function decline;	chr11:93526799	chr11:93286629~93288903:-
THCA	cis	rs875971	0.66	rs1860468	ENSG00000237310.1	GS1-124K5.4	-9.2	1.14e-18	6.4e-16	-0.28	-0.39	Aortic root size;	chr7:66642265	chr7:66493706~66495474:+
THCA	cis	rs950169	0.959	rs12911210	ENSG00000259728.4	LINC00933	9.2	1.14e-18	6.43e-16	0.53	0.39	Schizophrenia;	chr15:84123331	chr15:84570649~84580175:+
THCA	cis	rs4927850	0.958	rs1975582	ENSG00000273009.1	RP11-352G9.1	-9.2	1.14e-18	6.44e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196024568	chr3:195913078~195913683:-
THCA	cis	rs7829975	0.54	rs2976909	ENSG00000253893.2	FAM85B	9.2	1.14e-18	6.44e-16	0.52	0.39	Mood instability;	chr8:8489180	chr8:8167819~8226614:-
THCA	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	9.2	1.14e-18	6.44e-16	0.44	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
THCA	cis	rs28510890	0.789	rs10852177	ENSG00000260337.3	RP11-386M24.6	9.2	1.15e-18	6.47e-16	0.48	0.39	Lung cancer in ever smokers;	chr15:92594248	chr15:92592574~92596462:-
THCA	cis	rs9640161	0.659	rs7788316	ENSG00000261305.1	RP4-584D14.7	9.2	1.15e-18	6.48e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150316906	chr7:150341771~150342607:+
THCA	cis	rs4713118	0.621	rs4713132	ENSG00000226314.6	ZNF192P1	-9.2	1.15e-18	6.48e-16	-0.51	-0.39	Parkinson's disease;	chr6:28066257	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.621	rs4713133	ENSG00000226314.6	ZNF192P1	-9.2	1.15e-18	6.48e-16	-0.51	-0.39	Parkinson's disease;	chr6:28066263	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.621	rs4713134	ENSG00000226314.6	ZNF192P1	-9.2	1.15e-18	6.48e-16	-0.51	-0.39	Parkinson's disease;	chr6:28066343	chr6:28161781~28169594:+
THCA	cis	rs11676348	0.729	rs13013361	ENSG00000261338.2	RP11-378A13.1	-9.2	1.15e-18	6.5e-16	-0.39	-0.39	Ulcerative colitis;	chr2:218082792	chr2:218255319~218257366:+
THCA	cis	rs10463554	0.853	rs246903	ENSG00000175749.11	EIF3KP1	9.2	1.16e-18	6.52e-16	0.51	0.39	Parkinson's disease;	chr5:103253753	chr5:103032376~103033031:+
THCA	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-9.2	1.16e-18	6.55e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
THCA	cis	rs3813579	0.654	rs4480821	ENSG00000261390.4	RP11-345M22.2	-9.2	1.17e-18	6.56e-16	-0.44	-0.39	Thyroid volume;	chr16:79711416	chr16:79715232~79770563:-
THCA	cis	rs9928842	0.765	rs6564220	ENSG00000280152.1	RP11-331F4.5	9.2	1.17e-18	6.56e-16	0.57	0.39	Alcoholic chronic pancreatitis;	chr16:75190296	chr16:75245994~75250077:-
THCA	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	9.2	1.17e-18	6.58e-16	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
THCA	cis	rs2980439	0.517	rs17594065	ENSG00000253893.2	FAM85B	9.2	1.17e-18	6.58e-16	0.51	0.39	Neuroticism;	chr8:8247883	chr8:8167819~8226614:-
THCA	cis	rs9928842	0.765	rs2870467	ENSG00000280152.1	RP11-331F4.5	9.2	1.17e-18	6.58e-16	0.57	0.39	Alcoholic chronic pancreatitis;	chr16:75189983	chr16:75245994~75250077:-
THCA	cis	rs944289	0.774	rs1958624	ENSG00000257826.1	RP11-116N8.4	9.2	1.18e-18	6.61e-16	0.4	0.39	Thyroid cancer;	chr14:36128692	chr14:36061026~36067190:-
THCA	cis	rs11971779	0.688	rs8137	ENSG00000273391.1	RP11-634H22.1	-9.2	1.18e-18	6.62e-16	-0.36	-0.39	Diisocyanate-induced asthma;	chr7:139419715	chr7:139359032~139359566:-
THCA	cis	rs7211079	0.833	rs7220523	ENSG00000275479.1	RP11-334C17.6	9.2	1.19e-18	6.67e-16	0.39	0.39	Myocardial infarction;	chr17:80153896	chr17:80149627~80149798:+
THCA	cis	rs7211079	0.879	rs7221505	ENSG00000275479.1	RP11-334C17.6	9.2	1.19e-18	6.67e-16	0.39	0.39	Myocardial infarction;	chr17:80154432	chr17:80149627~80149798:+
THCA	cis	rs9640161	0.789	rs4554381	ENSG00000261305.1	RP4-584D14.7	9.2	1.19e-18	6.71e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150328478	chr7:150341771~150342607:+
THCA	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	9.2	1.19e-18	6.71e-16	0.59	0.39	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
THCA	cis	rs10411161	1	rs10412080	ENSG00000269483.1	AC006272.1	9.2	1.2e-18	6.73e-16	0.55	0.39	Breast cancer;	chr19:51870255	chr19:51839924~51843324:-
THCA	cis	rs2836950	0.561	rs34705151	ENSG00000255568.3	BRWD1-AS2	-9.2	1.2e-18	6.77e-16	-0.32	-0.39	Menarche (age at onset);	chr21:39181418	chr21:39313935~39314962:+
THCA	cis	rs67311347	0.521	rs2887963	ENSG00000223797.4	ENTPD3-AS1	-9.2	1.21e-18	6.78e-16	-0.31	-0.39	Renal cell carcinoma;	chr3:40201975	chr3:40313802~40453329:-
THCA	cis	rs17684571	0.751	rs13194625	ENSG00000231441.1	RP11-472M19.2	9.2	1.21e-18	6.78e-16	0.53	0.39	Schizophrenia;	chr6:56820446	chr6:56844002~56864078:+
THCA	cis	rs2033711	0.783	rs11671113	ENSG00000268912.1	CTD-2619J13.17	-9.2	1.21e-18	6.79e-16	-0.3	-0.39	Uric acid clearance;	chr19:58446720	chr19:58428632~58431148:-
THCA	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-9.2	1.21e-18	6.79e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-9.2	1.21e-18	6.79e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-9.2	1.21e-18	6.79e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-9.2	1.21e-18	6.79e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
THCA	cis	rs57481061	1	rs57481061	ENSG00000258302.2	RP11-981P6.1	9.2	1.21e-18	6.81e-16	0.4	0.39	Coronary artery disease;	chr12:89625401	chr12:89561129~89594878:+
THCA	cis	rs748404	0.697	rs505249	ENSG00000249839.1	AC011330.5	-9.2	1.21e-18	6.81e-16	-0.45	-0.39	Lung cancer;	chr15:43267762	chr15:43663654~43684339:-
THCA	cis	rs7015263	0.875	rs10093238	ENSG00000254231.1	CTD-2284J15.1	-9.2	1.22e-18	6.83e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86454867	chr8:86333274~86343314:-
THCA	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-9.2	1.22e-18	6.84e-16	-0.46	-0.39	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
THCA	cis	rs947583	0.517	rs9376144	ENSG00000231028.7	LINC00271	-9.19	1.22e-18	6.87e-16	-0.3	-0.39	Phosphorus levels;	chr6:135756247	chr6:135497801~135716055:+
THCA	cis	rs7429990	0.833	rs2280567	ENSG00000229759.1	MRPS18AP1	-9.19	1.22e-18	6.87e-16	-0.46	-0.39	Educational attainment (years of education);	chr3:47572923	chr3:48256350~48256938:-
THCA	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-9.19	1.22e-18	6.88e-16	-0.32	-0.39	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
THCA	cis	rs860295	0.557	rs11264371	ENSG00000225855.5	RUSC1-AS1	9.19	1.23e-18	6.9e-16	0.28	0.39	Body mass index;	chr1:155442246	chr1:155316863~155324176:-
THCA	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-9.19	1.23e-18	6.9e-16	-0.43	-0.39	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
THCA	cis	rs11971779	0.715	rs10265	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139341406	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs6965143	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139341862	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs11771715	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139342750	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs4732367	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139343356	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7808740	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139344209	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs6943973	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139345147	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs4077889	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139349168	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs11980313	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139349897	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.584	rs6962029	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139349973	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6962186	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139350060	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.523	rs10234578	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139353242	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs7784192	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139354903	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs3924296	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139357181	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.527	rs4379397	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139358639	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.774	rs6467838	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139358755	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6961812	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139359062	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6962366	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139359121	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs3924445	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139359426	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.585	rs3922848	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139361464	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.59	rs6944104	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139366374	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs6944244	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139366440	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6962637	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139366604	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7799598	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139367087	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.553	rs7799742	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139367132	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs10229249	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139367764	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs11772026	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139367843	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs1133067	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139368323	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs1133068	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139368397	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs9656512	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139369300	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6949599	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139369442	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs6949963	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139369579	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.555	rs6950143	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139369672	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6954531	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139369960	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6954547	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139369988	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7788777	ENSG00000273391.1	RP11-634H22.1	9.19	1.23e-18	6.9e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139370447	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7801613	ENSG00000273391.1	RP11-634H22.1	-9.19	1.23e-18	6.9e-16	-0.36	-0.39	Diisocyanate-induced asthma;	chr7:139355181	chr7:139359032~139359566:-
THCA	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-9.19	1.24e-18	6.94e-16	-0.51	-0.39	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
THCA	cis	rs2243480	1	rs4149468	ENSG00000273142.1	RP11-458F8.4	-9.19	1.24e-18	6.95e-16	-0.5	-0.39	Diabetic kidney disease;	chr7:66360703	chr7:66902857~66906297:+
THCA	cis	rs8062405	0.691	rs743590	ENSG00000251417.2	RP11-1348G14.4	-9.19	1.24e-18	6.95e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28802743~28817828:+
THCA	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	9.19	1.25e-18	7.02e-16	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
THCA	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-9.19	1.27e-18	7.15e-16	-0.51	-0.39	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
THCA	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-9.19	1.27e-18	7.15e-16	-0.51	-0.39	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
THCA	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-9.19	1.27e-18	7.15e-16	-0.51	-0.39	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
THCA	cis	rs11971779	0.68	rs17613690	ENSG00000273391.1	RP11-634H22.1	-9.19	1.28e-18	7.16e-16	-0.36	-0.39	Diisocyanate-induced asthma;	chr7:139403655	chr7:139359032~139359566:-
THCA	cis	rs9402743	0.597	rs9483880	ENSG00000231028.7	LINC00271	-9.19	1.28e-18	7.18e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135781474	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.632	rs4895458	ENSG00000231028.7	LINC00271	-9.19	1.28e-18	7.18e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135783235	chr6:135497801~135716055:+
THCA	cis	rs11971779	0.68	rs111461944	ENSG00000273391.1	RP11-634H22.1	9.19	1.28e-18	7.19e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139393157	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs12154842	ENSG00000273391.1	RP11-634H22.1	9.19	1.28e-18	7.19e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139393738	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6467846	ENSG00000273391.1	RP11-634H22.1	9.19	1.28e-18	7.19e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139394639	chr7:139359032~139359566:-
THCA	cis	rs875971	0.66	rs10215132	ENSG00000237310.1	GS1-124K5.4	-9.19	1.28e-18	7.2e-16	-0.28	-0.39	Aortic root size;	chr7:66589419	chr7:66493706~66495474:+
THCA	cis	rs9640161	0.789	rs2373751	ENSG00000261305.1	RP4-584D14.7	9.19	1.29e-18	7.22e-16	0.49	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150324510	chr7:150341771~150342607:+
THCA	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-9.19	1.29e-18	7.25e-16	-0.46	-0.39	Migraine;	chr4:56879297	chr4:56960927~56961373:-
THCA	cis	rs2836950	0.565	rs3171465	ENSG00000255568.3	BRWD1-AS2	-9.19	1.3e-18	7.26e-16	-0.32	-0.39	Menarche (age at onset);	chr21:39180381	chr21:39313935~39314962:+
THCA	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-9.19	1.3e-18	7.29e-16	-0.28	-0.39	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
THCA	cis	rs9402743	0.598	rs2327654	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135758303	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.703	rs6933668	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135760013	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.703	rs7756751	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135761314	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.703	rs6570030	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135761688	chr6:135497801~135716055:+
THCA	cis	rs947583	0.517	rs6909996	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Phosphorus levels;	chr6:135763365	chr6:135497801~135716055:+
THCA	cis	rs947583	0.517	rs9399164	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Phosphorus levels;	chr6:135765408	chr6:135497801~135716055:+
THCA	cis	rs947583	0.517	rs4385331	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Phosphorus levels;	chr6:135772025	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.641	rs9402752	ENSG00000231028.7	LINC00271	-9.19	1.3e-18	7.29e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135772549	chr6:135497801~135716055:+
THCA	cis	rs11148252	0.711	rs61957304	ENSG00000278238.1	RP11-245D16.4	-9.19	1.31e-18	7.33e-16	-0.44	-0.39	Lewy body disease;	chr13:52224288	chr13:52454775~52455331:-
THCA	cis	rs7429990	0.833	rs3732530	ENSG00000229759.1	MRPS18AP1	-9.19	1.31e-18	7.35e-16	-0.46	-0.39	Educational attainment (years of education);	chr3:47577463	chr3:48256350~48256938:-
THCA	cis	rs7851660	0.967	rs13288000	ENSG00000236130.1	PTCSC2	-9.19	1.32e-18	7.37e-16	-0.3	-0.39	Strep throat;	chr9:97846698	chr9:97805935~97810008:-
THCA	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	9.19	1.32e-18	7.37e-16	0.59	0.39	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
THCA	cis	rs2115630	0.645	rs4842978	ENSG00000225151.9	GOLGA2P7	9.18	1.32e-18	7.39e-16	0.51	0.39	P wave terminal force;	chr15:84654022	chr15:84199311~84230136:-
THCA	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	9.18	1.32e-18	7.41e-16	0.8	0.39	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
THCA	cis	rs1009647	0.961	rs946056	ENSG00000258413.1	RP11-665C16.6	-9.18	1.33e-18	7.42e-16	-0.57	-0.39	Testicular germ cell tumor;	chr14:55414012	chr14:55262767~55272075:-
THCA	cis	rs10759883	0.627	rs7871709	ENSG00000175611.10	LINC00476	-9.18	1.33e-18	7.43e-16	-0.4	-0.39	Nicotine dependence;	chr9:95798328	chr9:95759231~95875977:-
THCA	cis	rs2243480	1	rs781156	ENSG00000273142.1	RP11-458F8.4	-9.18	1.33e-18	7.43e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66014154	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs451396	ENSG00000273142.1	RP11-458F8.4	-9.18	1.33e-18	7.43e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66019087	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1715235	ENSG00000273142.1	RP11-458F8.4	-9.18	1.33e-18	7.43e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66023407	chr7:66902857~66906297:+
THCA	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	9.18	1.33e-18	7.43e-16	0.28	0.39	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
THCA	cis	rs9640161	0.75	rs3735173	ENSG00000261305.1	RP4-584D14.7	9.18	1.33e-18	7.44e-16	0.46	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150323437	chr7:150341771~150342607:+
THCA	cis	rs11971779	0.68	rs4732369	ENSG00000273391.1	RP11-634H22.1	9.18	1.33e-18	7.45e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139384427	chr7:139359032~139359566:-
THCA	cis	rs1062177	1	rs62377945	ENSG00000253921.1	CTB-113P19.3	-9.18	1.34e-18	7.48e-16	-0.48	-0.39	Preschool internalizing problems;	chr5:151828443	chr5:151753992~151767247:+
THCA	cis	rs62355901	0.505	rs62356565	ENSG00000271828.1	CTD-2310F14.1	9.18	1.34e-18	7.49e-16	0.77	0.39	Breast cancer;	chr5:56948139	chr5:56927874~56929573:+
THCA	cis	rs11971779	0.68	rs2355786	ENSG00000273391.1	RP11-634H22.1	-9.18	1.34e-18	7.49e-16	-0.37	-0.39	Diisocyanate-induced asthma;	chr7:139380876	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7795520	ENSG00000273391.1	RP11-634H22.1	9.18	1.34e-18	7.5e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139394461	chr7:139359032~139359566:-
THCA	cis	rs8062405	0.508	rs9929088	ENSG00000251417.2	RP11-1348G14.4	9.18	1.35e-18	7.53e-16	0.41	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28990139	chr16:28802743~28817828:+
THCA	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	9.18	1.35e-18	7.54e-16	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
THCA	cis	rs7015263	0.875	rs7006017	ENSG00000254231.1	CTD-2284J15.1	-9.18	1.35e-18	7.55e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86399325	chr8:86333274~86343314:-
THCA	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	9.18	1.35e-18	7.56e-16	0.59	0.39	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
THCA	cis	rs9926296	0.744	rs164748	ENSG00000260259.1	RP11-368I7.4	9.18	1.35e-18	7.56e-16	0.43	0.39	Vitiligo;	chr16:89641884	chr16:89682620~89686569:-
THCA	cis	rs1062177	1	rs2016409	ENSG00000253921.1	CTB-113P19.3	9.18	1.35e-18	7.57e-16	0.48	0.39	Preschool internalizing problems;	chr5:151746763	chr5:151753992~151767247:+
THCA	cis	rs10463554	0.926	rs26433	ENSG00000175749.11	EIF3KP1	9.18	1.36e-18	7.59e-16	0.49	0.39	Parkinson's disease;	chr5:103028154	chr5:103032376~103033031:+
THCA	cis	rs950169	0.544	rs62021193	ENSG00000259728.4	LINC00933	9.18	1.36e-18	7.59e-16	0.53	0.39	Schizophrenia;	chr15:84627352	chr15:84570649~84580175:+
THCA	cis	rs2946504	0.906	rs2946511	ENSG00000251468.2	RP11-369K16.1	9.18	1.36e-18	7.6e-16	0.45	0.39	Type 2 diabetes;	chr8:12949796	chr8:12958387~12962200:+
THCA	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	9.18	1.36e-18	7.61e-16	0.49	0.39	Myopia;	chr6:28302807	chr6:28176188~28176674:+
THCA	cis	rs1062177	1	rs2915878	ENSG00000253921.1	CTB-113P19.3	-9.18	1.36e-18	7.62e-16	-0.47	-0.39	Preschool internalizing problems;	chr5:151770101	chr5:151753992~151767247:+
THCA	cis	rs947583	0.517	rs9376148	ENSG00000231028.7	LINC00271	-9.18	1.36e-18	7.63e-16	-0.3	-0.39	Phosphorus levels;	chr6:135777362	chr6:135497801~135716055:+
THCA	cis	rs11971779	0.616	rs10269683	ENSG00000273391.1	RP11-634H22.1	9.18	1.37e-18	7.64e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139416122	chr7:139359032~139359566:-
THCA	cis	rs7015263	0.875	rs10088739	ENSG00000254231.1	CTD-2284J15.1	9.18	1.37e-18	7.66e-16	0.38	0.39	Intelligence (multi-trait analysis);	chr8:86438922	chr8:86333274~86343314:-
THCA	cis	rs4591358	0.773	rs16836736	ENSG00000223466.1	AC064834.2	-9.18	1.37e-18	7.67e-16	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511283	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.773	rs13035516	ENSG00000223466.1	AC064834.2	-9.18	1.37e-18	7.67e-16	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195513234	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.773	rs34475459	ENSG00000223466.1	AC064834.2	-9.18	1.37e-18	7.67e-16	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515682	chr2:195533035~195538681:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000235689.1	AP000351.13	9.18	1.38e-18	7.71e-16	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:24006305~24008258:-
THCA	cis	rs7208859	0.623	rs9899268	ENSG00000266490.1	CTD-2349P21.9	9.18	1.38e-18	7.71e-16	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30792372~30792833:+
THCA	cis	rs11051970	0.527	rs7962680	ENSG00000274964.1	RP11-817I4.1	-9.18	1.39e-18	7.76e-16	-0.53	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32322377	chr12:32339368~32340724:+
THCA	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-9.18	1.39e-18	7.76e-16	-0.4	-0.39	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
THCA	cis	rs7826238	0.653	rs2979202	ENSG00000253893.2	FAM85B	-9.18	1.39e-18	7.77e-16	-0.51	-0.39	Systolic blood pressure;	chr8:8486617	chr8:8167819~8226614:-
THCA	cis	rs748404	0.697	rs501884	ENSG00000249839.1	AC011330.5	-9.18	1.39e-18	7.78e-16	-0.46	-0.39	Lung cancer;	chr15:43261784	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs504417	ENSG00000249839.1	AC011330.5	-9.18	1.39e-18	7.78e-16	-0.46	-0.39	Lung cancer;	chr15:43262028	chr15:43663654~43684339:-
THCA	cis	rs748404	0.723	rs560134	ENSG00000249839.1	AC011330.5	-9.18	1.39e-18	7.78e-16	-0.46	-0.39	Lung cancer;	chr15:43263501	chr15:43663654~43684339:-
THCA	cis	rs12468226	0.689	rs60584169	ENSG00000273456.1	RP11-686O6.2	9.18	1.39e-18	7.79e-16	0.47	0.39	Urate levels;	chr2:202111695	chr2:202374932~202375604:-
THCA	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-9.18	1.4e-18	7.83e-16	-0.58	-0.39	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
THCA	cis	rs2243480	1	rs1964692	ENSG00000273142.1	RP11-458F8.4	-9.18	1.4e-18	7.84e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:65989196	chr7:66902857~66906297:+
THCA	cis	rs10463554	0.892	rs62362519	ENSG00000175749.11	EIF3KP1	9.18	1.4e-18	7.84e-16	0.51	0.39	Parkinson's disease;	chr5:102965759	chr5:103032376~103033031:+
THCA	cis	rs4819052	1	rs733738	ENSG00000215447.6	BX322557.10	9.18	1.41e-18	7.85e-16	0.35	0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45288052~45291738:+
THCA	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-9.18	1.41e-18	7.86e-16	-0.31	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
THCA	cis	rs950169	0.96	rs12905475	ENSG00000259728.4	LINC00933	9.18	1.42e-18	7.91e-16	0.56	0.39	Schizophrenia;	chr15:84131743	chr15:84570649~84580175:+
THCA	cis	rs733592	1	rs733592	ENSG00000240399.1	RP1-228P16.1	-9.18	1.42e-18	7.92e-16	-0.36	-0.39	Plateletcrit;	chr12:48035993	chr12:48054813~48055591:-
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-9.18	1.42e-18	7.93e-16	-0.55	-0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
THCA	cis	rs4927850	1	rs7625570	ENSG00000273009.1	RP11-352G9.1	-9.17	1.44e-18	8.02e-16	-0.43	-0.39	Pancreatic cancer;	chr3:196020527	chr3:195913078~195913683:-
THCA	cis	rs28510890	0.547	rs35070516	ENSG00000260337.3	RP11-386M24.6	-9.17	1.44e-18	8.02e-16	-0.5	-0.39	Lung cancer in ever smokers;	chr15:92607968	chr15:92592574~92596462:-
THCA	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-9.17	1.44e-18	8.03e-16	-0.78	-0.39	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.566	rs6912330	ENSG00000268592.3	RAET1E-AS1	-9.17	1.44e-18	8.05e-16	-0.56	-0.39	Lung cancer;	chr6:149908811	chr6:149863494~149919507:+
THCA	cis	rs9402743	0.632	rs9389329	ENSG00000231028.7	LINC00271	9.17	1.45e-18	8.1e-16	0.3	0.39	Systemic lupus erythematosus;	chr6:135777966	chr6:135497801~135716055:+
THCA	cis	rs934734	0.571	rs7572922	ENSG00000234255.7	AC012370.3	-9.17	1.45e-18	8.11e-16	-0.43	-0.39	Rheumatoid arthritis;	chr2:65425022	chr2:65439888~65456571:-
THCA	cis	rs1799949	1	rs11654731	ENSG00000267681.1	CTD-3199J23.6	-9.17	1.47e-18	8.2e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43174923	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs11651623	ENSG00000267681.1	CTD-3199J23.6	-9.17	1.47e-18	8.2e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43177830	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs11657883	ENSG00000267681.1	CTD-3199J23.6	-9.17	1.47e-18	8.2e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43178007	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs11656945	ENSG00000267681.1	CTD-3199J23.6	-9.17	1.47e-18	8.2e-16	-0.46	-0.39	Menopause (age at onset);	chr17:43178248	chr17:43144956~43145255:+
THCA	cis	rs4722166	0.508	rs1474347	ENSG00000179428.2	AC073072.5	9.17	1.48e-18	8.24e-16	0.5	0.39	Lung cancer;	chr7:22728505	chr7:22725395~22727620:-
THCA	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-9.17	1.48e-18	8.26e-16	-0.48	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
THCA	cis	rs4591358	0.773	rs34480328	ENSG00000223466.1	AC064834.2	-9.17	1.48e-18	8.27e-16	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510684	chr2:195533035~195538681:+
THCA	cis	rs4713118	0.621	rs9295755	ENSG00000226314.6	ZNF192P1	9.17	1.49e-18	8.29e-16	0.51	0.39	Parkinson's disease;	chr6:28065396	chr6:28161781~28169594:+
THCA	cis	rs1707322	0.821	rs11211182	ENSG00000234329.1	RP11-767N6.2	9.17	1.49e-18	8.29e-16	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45651039~45651826:-
THCA	cis	rs11971779	0.715	rs7781459	ENSG00000273391.1	RP11-634H22.1	9.17	1.49e-18	8.29e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139409136	chr7:139359032~139359566:-
THCA	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-9.17	1.49e-18	8.32e-16	-0.46	-0.39	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
THCA	cis	rs7221109	0.56	rs2469818	ENSG00000278834.1	RP11-458J1.1	-9.17	1.5e-18	8.35e-16	-0.41	-0.39	Type 1 diabetes;	chr17:40708479	chr17:40648300~40649718:+
THCA	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	9.17	1.5e-18	8.35e-16	0.46	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
THCA	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	9.17	1.5e-18	8.36e-16	0.77	0.39	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
THCA	cis	rs10411161	0.702	rs11879336	ENSG00000269483.1	AC006272.1	9.17	1.51e-18	8.42e-16	0.57	0.39	Breast cancer;	chr19:51886374	chr19:51839924~51843324:-
THCA	cis	rs4819052	0.807	rs7283915	ENSG00000215447.6	BX322557.10	-9.17	1.52e-18	8.45e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838850	ENSG00000215447.6	BX322557.10	-9.17	1.52e-18	8.45e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs8130285	ENSG00000215447.6	BX322557.10	-9.17	1.52e-18	8.45e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45288052~45291738:+
THCA	cis	rs9402743	0.666	rs9385737	ENSG00000231028.7	LINC00271	-9.17	1.52e-18	8.45e-16	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135759379	chr6:135497801~135716055:+
THCA	cis	rs673078	0.607	rs61943404	ENSG00000275409.1	RP11-131L12.4	-9.17	1.52e-18	8.47e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118402062	chr12:118430147~118430699:+
THCA	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	9.17	1.52e-18	8.48e-16	0.49	0.39	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
THCA	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	9.17	1.52e-18	8.49e-16	0.41	0.39	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
THCA	cis	rs944289	0.712	rs12050121	ENSG00000257826.1	RP11-116N8.4	-9.17	1.52e-18	8.5e-16	-0.4	-0.39	Thyroid cancer;	chr14:36103742	chr14:36061026~36067190:-
THCA	cis	rs12468226	0.689	rs73989731	ENSG00000273456.1	RP11-686O6.2	9.17	1.53e-18	8.5e-16	0.47	0.39	Urate levels;	chr2:202109309	chr2:202374932~202375604:-
THCA	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-9.17	1.54e-18	8.55e-16	-0.36	-0.39	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
THCA	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	9.17	1.54e-18	8.56e-16	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
THCA	cis	rs526231	0.697	rs253754	ENSG00000175749.11	EIF3KP1	9.17	1.54e-18	8.56e-16	0.58	0.39	Primary biliary cholangitis;	chr5:103296261	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.607	rs9383941	ENSG00000268592.3	RAET1E-AS1	-9.17	1.54e-18	8.59e-16	-0.56	-0.39	Lung cancer;	chr6:149912100	chr6:149863494~149919507:+
THCA	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-9.17	1.55e-18	8.61e-16	-0.76	-0.39	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
THCA	cis	rs11971779	0.68	rs10242419	ENSG00000273391.1	RP11-634H22.1	-9.16	1.55e-18	8.61e-16	-0.36	-0.39	Diisocyanate-induced asthma;	chr7:139404634	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6467848	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139395459	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs6467849	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139395766	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs1986447	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139397334	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.59	rs9642120	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139399225	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.618	rs9640925	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139400542	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7804388	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139401667	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs4732373	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139401789	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.618	rs6943788	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139402951	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.523	rs10279160	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139406015	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.59	rs4732374	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139406707	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs9642121	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139407875	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.584	rs7786469	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139409875	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.584	rs17613864	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139410841	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.555	rs4728466	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139411619	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs4732376	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139413278	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs10085708	ENSG00000273391.1	RP11-634H22.1	9.16	1.55e-18	8.61e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139426208	chr7:139359032~139359566:-
THCA	cis	rs673078	0.607	rs882927	ENSG00000275409.1	RP11-131L12.4	-9.16	1.56e-18	8.7e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118406737	chr12:118430147~118430699:+
THCA	cis	rs1707322	0.827	rs6683274	ENSG00000234329.1	RP11-767N6.2	9.16	1.57e-18	8.72e-16	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45651039~45651826:-
THCA	cis	rs4591358	0.773	rs35261538	ENSG00000223466.1	AC064834.2	-9.16	1.57e-18	8.75e-16	-0.54	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509681	chr2:195533035~195538681:+
THCA	cis	rs8062405	0.755	rs62034350	ENSG00000251417.2	RP11-1348G14.4	-9.16	1.57e-18	8.76e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28802743~28817828:+
THCA	cis	rs11971779	0.616	rs6467836	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139338771	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6467837	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139338829	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6963867	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139375218	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.618	rs10085814	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139379343	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs10085527	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139379614	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.65	rs10085842	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139379836	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs28754644	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139380311	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs6954219	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139380364	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6467840	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139380655	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.564	rs6467841	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139381346	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs7792752	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139381450	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs6974907	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139383983	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.584	rs10236055	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139385245	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.584	rs6942519	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139385344	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6467843	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139385777	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs2355785	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139386237	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.588	rs6972408	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139386728	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.625	rs2355784	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139387747	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs2883772	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139388010	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs28579232	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139388370	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs2355783	ENSG00000273391.1	RP11-634H22.1	9.16	1.58e-18	8.77e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139391133	chr7:139359032~139359566:-
THCA	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	9.16	1.58e-18	8.79e-16	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
THCA	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	9.16	1.58e-18	8.79e-16	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
THCA	cis	rs8062405	0.573	rs6565300	ENSG00000251417.2	RP11-1348G14.4	-9.16	1.59e-18	8.82e-16	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28981728	chr16:28802743~28817828:+
THCA	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	9.16	1.59e-18	8.86e-16	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
THCA	cis	rs17684571	0.751	rs13190854	ENSG00000231441.1	RP11-472M19.2	9.16	1.6e-18	8.88e-16	0.5	0.39	Schizophrenia;	chr6:56827020	chr6:56844002~56864078:+
THCA	cis	rs2243480	1	rs431318	ENSG00000273142.1	RP11-458F8.4	-9.16	1.6e-18	8.88e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66046610	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs313803	ENSG00000273142.1	RP11-458F8.4	-9.16	1.6e-18	8.88e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66049744	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs313802	ENSG00000273142.1	RP11-458F8.4	-9.16	1.6e-18	8.88e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66051386	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.803	rs403089	ENSG00000273142.1	RP11-458F8.4	-9.16	1.6e-18	8.88e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66052736	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs458291	ENSG00000273142.1	RP11-458F8.4	-9.16	1.6e-18	8.88e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66055492	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs464895	ENSG00000273142.1	RP11-458F8.4	-9.16	1.6e-18	8.88e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66062119	chr7:66902857~66906297:+
THCA	cis	rs944289	0.774	rs1537423	ENSG00000257826.1	RP11-116N8.4	9.16	1.61e-18	8.93e-16	0.4	0.39	Thyroid cancer;	chr14:36104863	chr14:36061026~36067190:-
THCA	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	9.16	1.61e-18	8.95e-16	0.58	0.39	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
THCA	cis	rs11676348	0.774	rs4672870	ENSG00000261338.2	RP11-378A13.1	-9.16	1.61e-18	8.96e-16	-0.4	-0.39	Ulcerative colitis;	chr2:218077193	chr2:218255319~218257366:+
THCA	cis	rs7569084	0.687	rs6755006	ENSG00000234255.7	AC012370.3	-9.16	1.62e-18	8.99e-16	-0.44	-0.39	Sum eosinophil basophil counts;	chr2:65426008	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.687	rs6755128	ENSG00000234255.7	AC012370.3	-9.16	1.62e-18	8.99e-16	-0.44	-0.39	Sum eosinophil basophil counts;	chr2:65426065	chr2:65439888~65456571:-
THCA	cis	rs4722166	0.63	rs12537614	ENSG00000179428.2	AC073072.5	-9.16	1.62e-18	9e-16	-0.51	-0.39	Lung cancer;	chr7:22749932	chr7:22725395~22727620:-
THCA	cis	rs801193	0.967	rs3800823	ENSG00000237310.1	GS1-124K5.4	-9.16	1.62e-18	9.02e-16	-0.28	-0.39	Aortic root size;	chr7:66682123	chr7:66493706~66495474:+
THCA	cis	rs4927850	0.666	rs4927853	ENSG00000242086.7	LINC00969	9.16	1.63e-18	9.06e-16	0.43	0.39	Pancreatic cancer;	chr3:196025182	chr3:195658062~195739964:+
THCA	cis	rs801193	1	rs2055682	ENSG00000237310.1	GS1-124K5.4	9.16	1.63e-18	9.06e-16	0.28	0.39	Aortic root size;	chr7:66795302	chr7:66493706~66495474:+
THCA	cis	rs17807185	0.653	rs7802732	ENSG00000214293.7	APTR	9.16	1.64e-18	9.09e-16	0.28	0.39	Height;	chr7:77658613	chr7:77657660~77696265:-
THCA	cis	rs7189233	0.531	rs7204758	ENSG00000279344.1	RP11-44F14.7	9.16	1.64e-18	9.11e-16	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53448453	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs9921627	ENSG00000279344.1	RP11-44F14.7	9.16	1.64e-18	9.11e-16	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53448780	chr16:53478957~53481550:-
THCA	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	9.16	1.65e-18	9.15e-16	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
THCA	cis	rs1799949	0.965	rs2236762	ENSG00000267681.1	CTD-3199J23.6	-9.16	1.65e-18	9.16e-16	-0.45	-0.39	Menopause (age at onset);	chr17:43074658	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.961	rs9767713	ENSG00000268592.3	RAET1E-AS1	9.16	1.65e-18	9.18e-16	0.54	0.39	Lung cancer;	chr6:149588241	chr6:149863494~149919507:+
THCA	cis	rs7191700	0.583	rs243314	ENSG00000262636.1	CTD-3088G3.4	9.16	1.66e-18	9.21e-16	0.47	0.39	Multiple sclerosis;	chr16:11291247	chr16:11380859~11381118:-
THCA	cis	rs9532669	0.89	rs4941999	ENSG00000239827.7	SUGT1P3	-9.16	1.66e-18	9.21e-16	-0.43	-0.39	Cervical cancer;	chr13:40859926	chr13:40908159~40921774:-
THCA	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-9.16	1.66e-18	9.23e-16	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
THCA	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-9.16	1.66e-18	9.23e-16	-0.41	-0.39	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
THCA	cis	rs748404	0.697	rs530188	ENSG00000249839.1	AC011330.5	-9.15	1.67e-18	9.29e-16	-0.45	-0.39	Lung cancer;	chr15:43253116	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs475227	ENSG00000249839.1	AC011330.5	-9.15	1.67e-18	9.29e-16	-0.45	-0.39	Lung cancer;	chr15:43254248	chr15:43663654~43684339:-
THCA	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-9.15	1.67e-18	9.29e-16	-0.49	-0.39	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
THCA	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	9.15	1.68e-18	9.31e-16	0.48	0.39	Height;	chr11:118860890	chr11:118688039~118690600:-
THCA	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	9.15	1.68e-18	9.31e-16	0.48	0.39	Height;	chr11:118861053	chr11:118688039~118690600:-
THCA	cis	rs848490	0.651	rs11489586	ENSG00000214293.7	APTR	9.15	1.68e-18	9.31e-16	0.29	0.39	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685900	chr7:77657660~77696265:-
THCA	cis	rs17684571	0.7	rs34228698	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56795962	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.637	rs34359353	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56800963	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13198204	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56804057	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13201639	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56804329	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.637	rs17751966	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56804850	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs71564861	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56806793	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs35251663	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56806940	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.654	rs4348308	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56815545	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs34640766	ENSG00000231441.1	RP11-472M19.2	9.15	1.68e-18	9.31e-16	0.5	0.39	Schizophrenia;	chr6:56815876	chr6:56844002~56864078:+
THCA	cis	rs240993	0.761	rs9400480	ENSG00000230177.1	RP5-1112D6.4	9.15	1.69e-18	9.35e-16	0.39	0.39	Inflammatory skin disease;Psoriasis;	chr6:111529394	chr6:111277932~111278742:+
THCA	cis	rs4380275	0.965	rs12621177	ENSG00000272342.1	RP13-539J13.1	9.15	1.69e-18	9.37e-16	0.46	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:757786	chr2:739588~740164:-
THCA	cis	rs4380275	1	rs4854376	ENSG00000272342.1	RP13-539J13.1	9.15	1.69e-18	9.37e-16	0.46	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:763683	chr2:739588~740164:-
THCA	cis	rs11971779	0.59	rs6467839	ENSG00000273391.1	RP11-634H22.1	9.15	1.7e-18	9.41e-16	0.37	0.39	Diisocyanate-induced asthma;	chr7:139378044	chr7:139359032~139359566:-
THCA	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-9.15	1.7e-18	9.44e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	9.15	1.7e-18	9.44e-16	0.77	0.39	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
THCA	cis	rs947583	0.517	rs9376147	ENSG00000231028.7	LINC00271	-9.15	1.7e-18	9.45e-16	-0.3	-0.39	Phosphorus levels;	chr6:135774774	chr6:135497801~135716055:+
THCA	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-9.15	1.71e-18	9.5e-16	-0.77	-0.39	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
THCA	cis	rs9828933	0.752	rs832192	ENSG00000280620.1	SCAANT1	-9.15	1.72e-18	9.53e-16	-0.7	-0.39	Type 2 diabetes;	chr3:63867747	chr3:63911518~63911772:-
THCA	cis	rs673078	0.607	rs61943444	ENSG00000275409.1	RP11-131L12.4	-9.15	1.72e-18	9.54e-16	-0.47	-0.39	Glucose homeostasis traits;	chr12:118421641	chr12:118430147~118430699:+
THCA	cis	rs1062177	1	rs2964584	ENSG00000253921.1	CTB-113P19.3	-9.15	1.72e-18	9.54e-16	-0.47	-0.39	Preschool internalizing problems;	chr5:151763317	chr5:151753992~151767247:+
THCA	cis	rs1861353	0.863	rs16952252	ENSG00000279344.1	RP11-44F14.7	9.15	1.72e-18	9.54e-16	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53450068	chr16:53478957~53481550:-
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000228039.3	KB-1125A3.10	9.15	1.73e-18	9.56e-16	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23963780~23964374:+
THCA	cis	rs875971	0.706	rs1643374	ENSG00000237310.1	GS1-124K5.4	9.15	1.73e-18	9.56e-16	0.28	0.39	Aortic root size;	chr7:66407695	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.962	rs35031906	ENSG00000268592.3	RAET1E-AS1	9.15	1.73e-18	9.57e-16	0.52	0.39	Lung cancer;	chr6:149677438	chr6:149863494~149919507:+
THCA	cis	rs11971779	0.68	rs4732370	ENSG00000273391.1	RP11-634H22.1	-9.15	1.73e-18	9.6e-16	-0.37	-0.39	Diisocyanate-induced asthma;	chr7:139392494	chr7:139359032~139359566:-
THCA	cis	rs7015263	0.572	rs7830128	ENSG00000254231.1	CTD-2284J15.1	-9.15	1.74e-18	9.64e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86361011	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.572	rs62509419	ENSG00000254231.1	CTD-2284J15.1	-9.15	1.74e-18	9.64e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86363013	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.572	rs11787036	ENSG00000254231.1	CTD-2284J15.1	-9.15	1.74e-18	9.64e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86363647	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.572	rs56122638	ENSG00000254231.1	CTD-2284J15.1	-9.15	1.74e-18	9.64e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86366036	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.572	rs11775728	ENSG00000254231.1	CTD-2284J15.1	-9.15	1.74e-18	9.64e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86375722	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.539	rs9642913	ENSG00000254231.1	CTD-2284J15.1	-9.15	1.74e-18	9.64e-16	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86377719	chr8:86333274~86343314:-
THCA	cis	rs2033711	0.87	rs7409473	ENSG00000268912.1	CTD-2619J13.17	-9.15	1.75e-18	9.68e-16	-0.3	-0.39	Uric acid clearance;	chr19:58427798	chr19:58428632~58431148:-
THCA	cis	rs2033711	0.87	rs7408188	ENSG00000268912.1	CTD-2619J13.17	-9.15	1.75e-18	9.68e-16	-0.3	-0.39	Uric acid clearance;	chr19:58428022	chr19:58428632~58431148:-
THCA	cis	rs2033711	0.87	rs1051500	ENSG00000268912.1	CTD-2619J13.17	-9.15	1.75e-18	9.68e-16	-0.3	-0.39	Uric acid clearance;	chr19:58433035	chr19:58428632~58431148:-
THCA	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	9.15	1.75e-18	9.69e-16	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
THCA	cis	rs11971779	0.648	rs7799165	ENSG00000273391.1	RP11-634H22.1	9.15	1.75e-18	9.71e-16	0.36	0.39	Diisocyanate-induced asthma;	chr7:139400211	chr7:139359032~139359566:-
THCA	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	9.15	1.76e-18	9.76e-16	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
THCA	cis	rs4819052	0.851	rs1999335	ENSG00000215447.6	BX322557.10	-9.15	1.78e-18	9.86e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838844	ENSG00000215447.6	BX322557.10	-9.15	1.78e-18	9.86e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838848	ENSG00000215447.6	BX322557.10	-9.15	1.78e-18	9.86e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838849	ENSG00000215447.6	BX322557.10	-9.15	1.78e-18	9.86e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs7275870	ENSG00000215447.6	BX322557.10	-9.15	1.78e-18	9.86e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs7275874	ENSG00000215447.6	BX322557.10	-9.15	1.78e-18	9.86e-16	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs8131143	ENSG00000215447.6	BX322557.10	9.15	1.78e-18	9.86e-16	0.32	0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45288052~45291738:+
THCA	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	9.15	1.78e-18	9.88e-16	0.79	0.39	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	9.15	1.78e-18	9.88e-16	0.79	0.39	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
THCA	cis	rs9640161	0.659	rs77354576	ENSG00000261305.1	RP4-584D14.7	9.15	1.79e-18	9.89e-16	0.45	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150316211	chr7:150341771~150342607:+
THCA	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	9.15	1.79e-18	9.9e-16	0.46	0.39	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
THCA	cis	rs9322193	0.923	rs9285524	ENSG00000268592.3	RAET1E-AS1	9.15	1.79e-18	9.92e-16	0.52	0.39	Lung cancer;	chr6:149694122	chr6:149863494~149919507:+
THCA	cis	rs367615	0.704	rs55956735	ENSG00000249476.1	CTD-2587M2.1	9.15	1.79e-18	9.92e-16	0.41	0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109509341	chr5:109237120~109326369:-
THCA	cis	rs7829975	0.711	rs4481596	ENSG00000253893.2	FAM85B	-9.15	1.79e-18	9.92e-16	-0.5	-0.39	Mood instability;	chr8:8846820	chr8:8167819~8226614:-
THCA	cis	rs11971779	0.666	rs6467847	ENSG00000273391.1	RP11-634H22.1	9.15	1.8e-18	9.94e-16	0.38	0.39	Diisocyanate-induced asthma;	chr7:139394690	chr7:139359032~139359566:-
THCA	cis	rs748404	0.697	rs498227	ENSG00000249839.1	AC011330.5	-9.15	1.8e-18	9.95e-16	-0.46	-0.39	Lung cancer;	chr15:43280854	chr15:43663654~43684339:-
THCA	cis	rs2243480	1	rs437889	ENSG00000273142.1	RP11-458F8.4	-9.15	1.81e-18	9.99e-16	-0.49	-0.39	Diabetic kidney disease;	chr7:66044247	chr7:66902857~66906297:+
THCA	cis	rs6496932	0.913	rs4843037	ENSG00000218052.5	ADAMTS7P4	9.15	1.81e-18	9.99e-16	0.54	0.39	Central corneal thickness;Corneal structure;	chr15:85274674	chr15:85255369~85330334:-
THCA	cis	rs860295	0.812	rs12131079	ENSG00000225855.5	RUSC1-AS1	-9.14	1.82e-18	1.01e-15	-0.26	-0.39	Body mass index;	chr1:155349877	chr1:155316863~155324176:-
THCA	cis	rs17684571	0.751	rs35225175	ENSG00000231441.1	RP11-472M19.2	9.14	1.82e-18	1.01e-15	0.53	0.39	Schizophrenia;	chr6:56822783	chr6:56844002~56864078:+
THCA	cis	rs9322193	0.923	rs7753812	ENSG00000268592.3	RAET1E-AS1	9.14	1.82e-18	1.01e-15	0.52	0.39	Lung cancer;	chr6:149690150	chr6:149863494~149919507:+
THCA	cis	rs748404	0.697	rs493444	ENSG00000249839.1	AC011330.5	-9.14	1.84e-18	1.02e-15	-0.46	-0.39	Lung cancer;	chr15:43274272	chr15:43663654~43684339:-
THCA	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	9.14	1.85e-18	1.02e-15	0.58	0.39	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	9.14	1.85e-18	1.02e-15	0.58	0.39	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
THCA	cis	rs9322193	0.923	rs12195866	ENSG00000268592.3	RAET1E-AS1	9.14	1.86e-18	1.03e-15	0.52	0.39	Lung cancer;	chr6:149693334	chr6:149863494~149919507:+
THCA	cis	rs10411161	0.702	rs7251571	ENSG00000269483.1	AC006272.1	9.14	1.87e-18	1.03e-15	0.54	0.39	Breast cancer;	chr19:51885804	chr19:51839924~51843324:-
THCA	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	9.14	1.87e-18	1.03e-15	0.45	0.39	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
THCA	cis	rs2243480	1	rs781142	ENSG00000273142.1	RP11-458F8.4	-9.14	1.87e-18	1.04e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:65973791	chr7:66902857~66906297:+
THCA	cis	rs1075265	0.749	rs805379	ENSG00000233266.1	HMGB1P31	9.14	1.89e-18	1.04e-15	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54051334~54051760:+
THCA	cis	rs4722166	0.604	rs2390715	ENSG00000179428.2	AC073072.5	-9.14	1.89e-18	1.04e-15	-0.5	-0.39	Lung cancer;	chr7:22744259	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.63	rs4722169	ENSG00000179428.2	AC073072.5	-9.14	1.89e-18	1.04e-15	-0.5	-0.39	Lung cancer;	chr7:22745800	chr7:22725395~22727620:-
THCA	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	9.14	1.89e-18	1.04e-15	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
THCA	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-9.14	1.89e-18	1.04e-15	-0.8	-0.39	Gout;	chr7:66661502	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-9.14	1.89e-18	1.04e-15	-0.8	-0.39	Gout;	chr7:66679692	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	9.14	1.89e-18	1.04e-15	0.8	0.39	Gout;	chr7:66682070	chr7:66654538~66669855:+
THCA	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	9.14	1.89e-18	1.04e-15	0.8	0.39	Gout;	chr7:66682162	chr7:66654538~66669855:+
THCA	cis	rs4819052	1	rs4818769	ENSG00000215447.6	BX322557.10	-9.14	1.89e-18	1.05e-15	-0.35	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45288052~45291738:+
THCA	cis	rs6565180	0.963	rs4787642	ENSG00000183604.13	SMG1P5	-9.14	1.89e-18	1.05e-15	-0.41	-0.39	Tonsillectomy;	chr16:30348087	chr16:30267553~30335374:-
THCA	cis	rs10411161	0.702	rs7250138	ENSG00000269483.1	AC006272.1	9.14	1.89e-18	1.05e-15	0.55	0.39	Breast cancer;	chr19:51881979	chr19:51839924~51843324:-
THCA	cis	rs2032366	0.606	rs7226896	ENSG00000267279.1	RP11-879F14.2	-9.14	1.9e-18	1.05e-15	-0.41	-0.39	Obesity-related traits;	chr18:61608946	chr18:61585746~61606916:-
THCA	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	9.14	1.9e-18	1.05e-15	0.58	0.39	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
THCA	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-9.14	1.9e-18	1.05e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
THCA	cis	rs8062405	0.69	rs62034351	ENSG00000251417.2	RP11-1348G14.4	-9.14	1.9e-18	1.05e-15	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28802743~28817828:+
THCA	cis	rs9640161	0.636	rs56190213	ENSG00000261305.1	RP4-584D14.7	9.14	1.9e-18	1.05e-15	0.49	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150328631	chr7:150341771~150342607:+
THCA	cis	rs4819052	0.679	rs28623526	ENSG00000215447.6	BX322557.10	-9.14	1.91e-18	1.05e-15	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292409	chr21:45288052~45291738:+
THCA	cis	rs11603023	0.805	rs687190	ENSG00000255239.1	AP002954.6	9.14	1.91e-18	1.06e-15	0.5	0.39	Cholesterol, total;	chr11:118671674	chr11:118688039~118690600:-
THCA	cis	rs2032366	0.606	rs713485	ENSG00000267279.1	RP11-879F14.2	-9.14	1.92e-18	1.06e-15	-0.41	-0.39	Obesity-related traits;	chr18:61603692	chr18:61585746~61606916:-
THCA	cis	rs8027521	0.521	rs11631861	ENSG00000280362.1	RP11-643A5.3	-9.14	1.92e-18	1.06e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53925421	chr15:53910769~53914712:+
THCA	cis	rs4591358	0.689	rs7578371	ENSG00000223466.1	AC064834.2	-9.14	1.93e-18	1.06e-15	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510222	chr2:195533035~195538681:+
THCA	cis	rs9828933	0.938	rs3816157	ENSG00000280620.1	SCAANT1	9.14	1.93e-18	1.06e-15	0.66	0.39	Type 2 diabetes;	chr3:64013646	chr3:63911518~63911772:-
THCA	cis	rs10463554	0.892	rs1560040	ENSG00000175749.11	EIF3KP1	9.14	1.94e-18	1.07e-15	0.52	0.39	Parkinson's disease;	chr5:102964363	chr5:103032376~103033031:+
THCA	cis	rs853679	0.517	rs1340004	ENSG00000226314.6	ZNF192P1	-9.14	1.94e-18	1.07e-15	-0.53	-0.39	Depression;	chr6:28135913	chr6:28161781~28169594:+
THCA	cis	rs2739330	0.929	rs5751777	ENSG00000206090.4	AP000350.7	9.14	1.95e-18	1.07e-15	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23939998~23942798:+
THCA	cis	rs2115630	0.645	rs3825877	ENSG00000225151.9	GOLGA2P7	9.14	1.95e-18	1.08e-15	0.51	0.39	P wave terminal force;	chr15:84631400	chr15:84199311~84230136:-
THCA	cis	rs2115630	0.645	rs3825878	ENSG00000225151.9	GOLGA2P7	9.14	1.95e-18	1.08e-15	0.51	0.39	P wave terminal force;	chr15:84631524	chr15:84199311~84230136:-
THCA	cis	rs748404	0.697	rs1814323	ENSG00000249839.1	AC011330.5	9.13	1.96e-18	1.08e-15	0.46	0.39	Lung cancer;	chr15:43271039	chr15:43663654~43684339:-
THCA	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	9.13	1.96e-18	1.08e-15	0.58	0.39	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
THCA	cis	rs11676348	0.772	rs12694427	ENSG00000261338.2	RP11-378A13.1	-9.13	1.96e-18	1.08e-15	-0.39	-0.39	Ulcerative colitis;	chr2:218080322	chr2:218255319~218257366:+
THCA	cis	rs1499614	1	rs2707840	ENSG00000273142.1	RP11-458F8.4	-9.13	1.96e-18	1.08e-15	-0.51	-0.39	Gout;	chr7:66693028	chr7:66902857~66906297:+
THCA	cis	rs7189233	0.531	rs7199401	ENSG00000279344.1	RP11-44F14.7	9.13	1.97e-18	1.08e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53483038	chr16:53478957~53481550:-
THCA	cis	rs9532669	0.926	rs9562254	ENSG00000239827.7	SUGT1P3	9.13	1.97e-18	1.09e-15	0.42	0.39	Cervical cancer;	chr13:40960902	chr13:40908159~40921774:-
THCA	cis	rs1799949	1	rs12944430	ENSG00000267681.1	CTD-3199J23.6	-9.13	1.98e-18	1.09e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43178803	chr17:43144956~43145255:+
THCA	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	9.13	1.98e-18	1.09e-15	0.66	0.39	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	9.13	1.98e-18	1.09e-15	0.66	0.39	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-9.13	1.98e-18	1.09e-15	-0.66	-0.39	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
THCA	cis	rs11676348	0.772	rs7422358	ENSG00000261338.2	RP11-378A13.1	-9.13	1.99e-18	1.1e-15	-0.38	-0.39	Ulcerative colitis;	chr2:218088055	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.566	rs4870118	ENSG00000268592.3	RAET1E-AS1	-9.13	1.99e-18	1.1e-15	-0.56	-0.39	Lung cancer;	chr6:149923877	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.566	rs4869767	ENSG00000268592.3	RAET1E-AS1	-9.13	1.99e-18	1.1e-15	-0.56	-0.39	Lung cancer;	chr6:149923974	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.566	rs4869768	ENSG00000268592.3	RAET1E-AS1	-9.13	1.99e-18	1.1e-15	-0.56	-0.39	Lung cancer;	chr6:149924067	chr6:149863494~149919507:+
THCA	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	9.13	2e-18	1.1e-15	0.39	0.39	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
THCA	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-9.13	2e-18	1.1e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
THCA	cis	rs143626010	1	rs143626010	ENSG00000251417.2	RP11-1348G14.4	-9.13	2e-18	1.1e-15	-0.39	-0.39	Mosquito bite size;	chr16:28528081	chr16:28802743~28817828:+
THCA	cis	rs4591358	0.689	rs72925794	ENSG00000223466.1	AC064834.2	-9.13	2e-18	1.1e-15	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511813	chr2:195533035~195538681:+
THCA	cis	rs4591358	0.773	rs72925795	ENSG00000223466.1	AC064834.2	-9.13	2e-18	1.1e-15	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511814	chr2:195533035~195538681:+
THCA	cis	rs9322193	0.884	rs2064521	ENSG00000268592.3	RAET1E-AS1	-9.13	2.01e-18	1.11e-15	-0.53	-0.39	Lung cancer;	chr6:149625336	chr6:149863494~149919507:+
THCA	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	9.13	2.01e-18	1.11e-15	0.48	0.39	Height;	chr11:118859432	chr11:118688039~118690600:-
THCA	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	9.13	2.01e-18	1.11e-15	0.51	0.39	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
THCA	cis	rs2243480	1	rs402418	ENSG00000273142.1	RP11-458F8.4	-9.13	2.01e-18	1.11e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66044482	chr7:66902857~66906297:+
THCA	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-9.13	2.01e-18	1.11e-15	-0.49	-0.39	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
THCA	cis	rs2243480	1	rs383402	ENSG00000273142.1	RP11-458F8.4	9.13	2.03e-18	1.12e-15	0.48	0.39	Diabetic kidney disease;	chr7:66121666	chr7:66902857~66906297:+
THCA	cis	rs11971779	0.648	rs6974099	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139413820	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs10261557	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139414291	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.553	rs11973507	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139414715	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs10265718	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139415322	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.553	rs10085770	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139415603	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs2355788	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139417151	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.618	rs3778931	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139417744	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs10278377	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139418325	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.618	rs13068	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139419395	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs6946113	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139421380	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6946393	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139421423	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.553	rs10269108	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139421586	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs9683	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139422993	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs10085901	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139424243	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs10085902	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139424359	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.617	rs66652773	ENSG00000273391.1	RP11-634H22.1	9.13	2.03e-18	1.12e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139424827	chr7:139359032~139359566:-
THCA	cis	rs12682352	0.605	rs60707155	ENSG00000253893.2	FAM85B	-9.13	2.04e-18	1.12e-15	-0.51	-0.39	Neuroticism;	chr8:8866905	chr8:8167819~8226614:-
THCA	cis	rs934734	0.532	rs62141075	ENSG00000234255.7	AC012370.3	-9.13	2.04e-18	1.12e-15	-0.43	-0.39	Rheumatoid arthritis;	chr2:65417482	chr2:65439888~65456571:-
THCA	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-9.13	2.04e-18	1.12e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
THCA	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	9.13	2.05e-18	1.13e-15	0.41	0.39	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
THCA	cis	rs4819052	0.851	rs7276103	ENSG00000215447.6	BX322557.10	-9.13	2.05e-18	1.13e-15	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.566	rs3922947	ENSG00000268592.3	RAET1E-AS1	-9.13	2.05e-18	1.13e-15	-0.56	-0.39	Lung cancer;	chr6:149924856	chr6:149863494~149919507:+
THCA	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	9.13	2.05e-18	1.13e-15	0.67	0.39	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
THCA	cis	rs8027521	0.521	rs12901163	ENSG00000280362.1	RP11-643A5.3	-9.13	2.06e-18	1.13e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53924379	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.521	rs12903076	ENSG00000280362.1	RP11-643A5.3	-9.13	2.06e-18	1.13e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53924766	chr15:53910769~53914712:+
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000224205.1	AP000351.4	9.13	2.06e-18	1.13e-15	0.46	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23987320~23991421:-
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000224205.1	AP000351.4	9.13	2.06e-18	1.13e-15	0.46	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23987320~23991421:-
THCA	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	9.13	2.07e-18	1.14e-15	0.45	0.39	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
THCA	cis	rs1062177	1	rs2964585	ENSG00000253921.1	CTB-113P19.3	-9.13	2.07e-18	1.14e-15	-0.48	-0.39	Preschool internalizing problems;	chr5:151762334	chr5:151753992~151767247:+
THCA	cis	rs1062177	1	rs2964578	ENSG00000253921.1	CTB-113P19.3	-9.13	2.07e-18	1.14e-15	-0.48	-0.39	Preschool internalizing problems;	chr5:151767637	chr5:151753992~151767247:+
THCA	cis	rs11051970	0.592	rs73086040	ENSG00000274964.1	RP11-817I4.1	-9.13	2.07e-18	1.14e-15	-0.51	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32414501	chr12:32339368~32340724:+
THCA	cis	rs7208859	0.623	rs170051	ENSG00000266490.1	CTD-2349P21.9	9.13	2.07e-18	1.14e-15	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587135	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.51	rs216402	ENSG00000266490.1	CTD-2349P21.9	9.13	2.07e-18	1.14e-15	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30590108	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216434	ENSG00000266490.1	CTD-2349P21.9	9.13	2.07e-18	1.14e-15	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595317	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216436	ENSG00000266490.1	CTD-2349P21.9	9.13	2.07e-18	1.14e-15	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595882	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11651857	ENSG00000266490.1	CTD-2349P21.9	9.13	2.07e-18	1.14e-15	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30599344	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216439	ENSG00000266490.1	CTD-2349P21.9	9.13	2.07e-18	1.14e-15	0.54	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30600866	chr17:30792372~30792833:+
THCA	cis	rs8027521	0.521	rs11633302	ENSG00000280362.1	RP11-643A5.3	-9.13	2.07e-18	1.14e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53926595	chr15:53910769~53914712:+
THCA	cis	rs11051970	0.559	rs113700251	ENSG00000274964.1	RP11-817I4.1	-9.13	2.07e-18	1.14e-15	-0.51	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32409337	chr12:32339368~32340724:+
THCA	cis	rs1707322	0.785	rs10890348	ENSG00000234329.1	RP11-767N6.2	9.13	2.08e-18	1.14e-15	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45651039~45651826:-
THCA	cis	rs11148252	0.774	rs7993748	ENSG00000278238.1	RP11-245D16.4	-9.13	2.08e-18	1.14e-15	-0.42	-0.39	Lewy body disease;	chr13:52367496	chr13:52454775~52455331:-
THCA	cis	rs7291412	0.662	rs7292297	ENSG00000231711.2	LINC00899	9.13	2.08e-18	1.15e-15	0.32	0.39	Dupuytren's disease;Subjective well-being;	chr22:46062243	chr22:46039907~46044853:-
THCA	cis	rs17684571	0.7	rs13200559	ENSG00000231441.1	RP11-472M19.2	9.13	2.09e-18	1.15e-15	0.53	0.39	Schizophrenia;	chr6:56777522	chr6:56844002~56864078:+
THCA	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	9.13	2.1e-18	1.15e-15	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
THCA	cis	rs8027521	0.521	rs35926061	ENSG00000280362.1	RP11-643A5.3	-9.13	2.1e-18	1.15e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53927514	chr15:53910769~53914712:+
THCA	cis	rs7712401	0.562	rs384483	ENSG00000263432.2	RN7SL689P	-9.13	2.1e-18	1.15e-15	-0.43	-0.39	Mean platelet volume;	chr5:122925878	chr5:123022487~123022783:-
THCA	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	9.13	2.1e-18	1.16e-15	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
THCA	cis	rs28510890	0.785	rs11074079	ENSG00000260337.3	RP11-386M24.6	9.13	2.11e-18	1.16e-15	0.45	0.39	Lung cancer in ever smokers;	chr15:92581719	chr15:92592574~92596462:-
THCA	cis	rs9640161	0.742	rs11767726	ENSG00000261305.1	RP4-584D14.7	-9.13	2.11e-18	1.16e-15	-0.45	-0.39	Blood protein levels;Circulating chemerin levels;	chr7:150321007	chr7:150341771~150342607:+
THCA	cis	rs7015263	0.776	rs55727343	ENSG00000254231.1	CTD-2284J15.1	-9.13	2.11e-18	1.16e-15	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86384204	chr8:86333274~86343314:-
THCA	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	9.12	2.12e-18	1.17e-15	0.58	0.39	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
THCA	cis	rs17772222	0.63	rs7141608	ENSG00000258789.1	RP11-507K2.3	9.12	2.12e-18	1.17e-15	0.37	0.39	Coronary artery calcification;	chr14:88514045	chr14:88551597~88552493:+
THCA	cis	rs947583	0.517	rs6570039	ENSG00000231028.7	LINC00271	-9.12	2.13e-18	1.17e-15	-0.3	-0.39	Phosphorus levels;	chr6:135775602	chr6:135497801~135716055:+
THCA	cis	rs9402743	0.641	rs6906211	ENSG00000231028.7	LINC00271	-9.12	2.13e-18	1.17e-15	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135778283	chr6:135497801~135716055:+
THCA	cis	rs947583	0.517	rs6906845	ENSG00000231028.7	LINC00271	-9.12	2.13e-18	1.17e-15	-0.3	-0.39	Phosphorus levels;	chr6:135778363	chr6:135497801~135716055:+
THCA	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	9.12	2.14e-18	1.17e-15	0.5	0.39	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
THCA	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-9.12	2.14e-18	1.18e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
THCA	cis	rs4713118	0.662	rs464312	ENSG00000280107.1	AL022393.9	-9.12	2.15e-18	1.18e-15	-0.44	-0.39	Parkinson's disease;	chr6:27999813	chr6:28170845~28172521:+
THCA	cis	rs10170846	0.53	rs56353541	ENSG00000261428.2	RP11-16P6.1	9.12	2.15e-18	1.18e-15	0.4	0.39	Schizophrenia (inflammation and infection response interaction);	chr2:222556468	chr2:222566899~222569719:-
THCA	cis	rs2243480	0.803	rs13224048	ENSG00000273142.1	RP11-458F8.4	-9.12	2.16e-18	1.19e-15	-0.51	-0.39	Diabetic kidney disease;	chr7:66528779	chr7:66902857~66906297:+
THCA	cis	rs11148252	0.74	rs9536046	ENSG00000278238.1	RP11-245D16.4	-9.12	2.16e-18	1.19e-15	-0.44	-0.39	Lewy body disease;	chr13:52381764	chr13:52454775~52455331:-
THCA	cis	rs8062405	0.723	rs4788077	ENSG00000251417.2	RP11-1348G14.4	-9.12	2.17e-18	1.19e-15	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28802743~28817828:+
THCA	cis	rs2681472	0.524	rs7314459	ENSG00000258302.2	RP11-981P6.1	9.12	2.17e-18	1.19e-15	0.39	0.39	Hypertension;Coronary artery disease;Myocardial infarction;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Systolic blood pressure;Diastolic blood pressure;	chr12:89562564	chr12:89561129~89594878:+
THCA	cis	rs2243480	0.711	rs1626926	ENSG00000273142.1	RP11-458F8.4	-9.12	2.17e-18	1.19e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:65970805	chr7:66902857~66906297:+
THCA	cis	rs7829975	0.777	rs560544	ENSG00000253893.2	FAM85B	9.12	2.17e-18	1.19e-15	0.49	0.39	Mood instability;	chr8:8779919	chr8:8167819~8226614:-
THCA	cis	rs9322193	0.923	rs10872645	ENSG00000268592.3	RAET1E-AS1	9.12	2.17e-18	1.19e-15	0.52	0.39	Lung cancer;	chr6:149742840	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs12211511	ENSG00000268592.3	RAET1E-AS1	9.12	2.17e-18	1.19e-15	0.52	0.39	Lung cancer;	chr6:149745206	chr6:149863494~149919507:+
THCA	cis	rs9487094	0.626	rs12204548	ENSG00000260273.1	RP11-425D10.10	9.12	2.18e-18	1.2e-15	0.46	0.39	Height;	chr6:109715504	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.626	rs3799849	ENSG00000260273.1	RP11-425D10.10	9.12	2.18e-18	1.2e-15	0.46	0.39	Height;	chr6:109715560	chr6:109382795~109383666:+
THCA	cis	rs8062405	0.755	rs17640009	ENSG00000251417.2	RP11-1348G14.4	-9.12	2.19e-18	1.2e-15	-0.39	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28802743~28817828:+
THCA	cis	rs7189233	0.55	rs3803657	ENSG00000279344.1	RP11-44F14.7	9.12	2.19e-18	1.2e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs8046307	ENSG00000279344.1	RP11-44F14.7	9.12	2.19e-18	1.2e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53484774	chr16:53478957~53481550:-
THCA	cis	rs11971779	0.68	rs10274480	ENSG00000273391.1	RP11-634H22.1	9.12	2.22e-18	1.22e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139367682	chr7:139359032~139359566:-
THCA	cis	rs17608059	0.545	rs9944522	ENSG00000141028.6	CDRT15P1	-9.12	2.22e-18	1.22e-15	-0.45	-0.39	Temperament;	chr17:14015466	chr17:14024514~14025488:+
THCA	cis	rs11690935	0.61	rs59844139	ENSG00000228389.1	AC068039.4	-9.12	2.22e-18	1.22e-15	-0.41	-0.39	Schizophrenia;	chr2:171875473	chr2:171773482~171775844:+
THCA	cis	rs62355902	1	rs62355902	ENSG00000271828.1	CTD-2310F14.1	9.12	2.22e-18	1.22e-15	0.64	0.39	Breast cancer;Breast cancer (estrogen-receptor negative);	chr5:56757896	chr5:56927874~56929573:+
THCA	cis	rs2243480	1	rs2533288	ENSG00000273142.1	RP11-458F8.4	-9.12	2.23e-18	1.22e-15	-0.5	-0.39	Diabetic kidney disease;	chr7:66591724	chr7:66902857~66906297:+
THCA	cis	rs8062405	0.755	rs4149398	ENSG00000251417.2	RP11-1348G14.4	-9.12	2.24e-18	1.23e-15	-0.4	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28802743~28817828:+
THCA	cis	rs367615	0.704	rs7705399	ENSG00000249476.1	CTD-2587M2.1	9.12	2.24e-18	1.23e-15	0.41	0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109514650	chr5:109237120~109326369:-
THCA	cis	rs748404	0.723	rs11853991	ENSG00000249839.1	AC011330.5	-9.12	2.24e-18	1.23e-15	-0.45	-0.39	Lung cancer;	chr15:43265351	chr15:43663654~43684339:-
THCA	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-9.12	2.24e-18	1.23e-15	-0.49	-0.39	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-9.12	2.24e-18	1.23e-15	-0.49	-0.39	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
THCA	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-9.12	2.24e-18	1.23e-15	-0.44	-0.39	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
THCA	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-9.12	2.24e-18	1.23e-15	-0.78	-0.39	Gout;	chr7:66671562	chr7:66654538~66669855:+
THCA	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-9.12	2.25e-18	1.23e-15	-0.46	-0.39	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
THCA	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	9.12	2.25e-18	1.23e-15	0.47	0.39	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
THCA	cis	rs4591358	0.773	rs13008940	ENSG00000223466.1	AC064834.2	-9.12	2.26e-18	1.24e-15	-0.53	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509828	chr2:195533035~195538681:+
THCA	cis	rs11051970	0.559	rs73086036	ENSG00000274964.1	RP11-817I4.1	-9.12	2.27e-18	1.24e-15	-0.51	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32411651	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051992	ENSG00000274964.1	RP11-817I4.1	-9.12	2.27e-18	1.24e-15	-0.51	-0.39	Response to tocilizumab in rheumatoid arthritis;	chr12:32411733	chr12:32339368~32340724:+
THCA	cis	rs4713118	0.621	rs9295756	ENSG00000226314.6	ZNF192P1	-9.12	2.27e-18	1.25e-15	-0.5	-0.39	Parkinson's disease;	chr6:28065618	chr6:28161781~28169594:+
THCA	cis	rs2243480	1	rs1039664	ENSG00000273142.1	RP11-458F8.4	-9.12	2.28e-18	1.25e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65984729	chr7:66902857~66906297:+
THCA	cis	rs2111504	0.806	rs7252443	ENSG00000267213.4	AC007773.2	-9.12	2.28e-18	1.25e-15	-0.39	-0.39	Bipolar disorder;	chr19:32449827	chr19:32390050~32405560:-
THCA	cis	rs9322193	0.962	rs4552	ENSG00000268592.3	RAET1E-AS1	9.11	2.29e-18	1.25e-15	0.52	0.39	Lung cancer;	chr6:149811183	chr6:149863494~149919507:+
THCA	cis	rs8091660	0.929	rs3744827	ENSG00000278983.1	RP11-426J5.3	-9.11	2.29e-18	1.25e-15	-0.49	-0.39	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48569572	chr18:48564795~48568342:+
THCA	cis	rs780096	0.565	rs13022659	ENSG00000234072.1	AC074117.10	-9.11	2.29e-18	1.26e-15	-0.31	-0.39	Total body bone mineral density;	chr2:27520763	chr2:27356246~27367622:+
THCA	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-9.11	2.29e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-9.11	2.29e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-9.11	2.29e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-9.11	2.29e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-9.11	2.29e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-9.11	2.29e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
THCA	cis	rs10853057	1	rs10853057	ENSG00000214174.7	AMZ2P1	9.11	2.3e-18	1.26e-15	0.66	0.39	White matter microstructure (global fractional anisotropy);	chr17:65001905	chr17:64966550~64975576:-
THCA	cis	rs2243480	1	rs313807	ENSG00000273142.1	RP11-458F8.4	-9.11	2.3e-18	1.26e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66034494	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-9.11	2.3e-18	1.26e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
THCA	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-9.11	2.31e-18	1.27e-15	-0.28	-0.39	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2003301	ENSG00000237310.1	GS1-124K5.4	-9.11	2.31e-18	1.27e-15	-0.28	-0.39	Aortic root size;	chr7:66682669	chr7:66493706~66495474:+
THCA	cis	rs348196	0.672	rs670876	ENSG00000225855.5	RUSC1-AS1	9.11	2.32e-18	1.27e-15	0.29	0.39	Breast cancer;	chr1:155701887	chr1:155316863~155324176:-
THCA	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-9.11	2.33e-18	1.28e-15	-0.44	-0.39	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
THCA	cis	rs7189233	0.531	rs4783813	ENSG00000279344.1	RP11-44F14.7	9.11	2.33e-18	1.28e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53484458	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs13337544	ENSG00000279344.1	RP11-44F14.7	9.11	2.33e-18	1.28e-15	0.38	0.39	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53478957~53481550:-
THCA	cis	rs2111504	0.806	rs10421787	ENSG00000267213.4	AC007773.2	-9.11	2.34e-18	1.28e-15	-0.39	-0.39	Bipolar disorder;	chr19:32460316	chr19:32390050~32405560:-
THCA	cis	rs1062177	1	rs12654573	ENSG00000253921.1	CTB-113P19.3	-9.11	2.34e-18	1.28e-15	-0.46	-0.39	Preschool internalizing problems;	chr5:151827912	chr5:151753992~151767247:+
THCA	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	9.11	2.35e-18	1.29e-15	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
THCA	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	9.11	2.35e-18	1.29e-15	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
THCA	cis	rs11148252	0.774	rs9536066	ENSG00000278238.1	RP11-245D16.4	-9.11	2.35e-18	1.29e-15	-0.42	-0.39	Lewy body disease;	chr13:52409846	chr13:52454775~52455331:-
THCA	cis	rs62158211	0.908	rs62158169	ENSG00000272563.1	RP11-480C16.1	-9.11	2.35e-18	1.29e-15	-0.53	-0.39	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113324250	chr2:113432600~113436042:+
THCA	cis	rs9322193	0.923	rs12175504	ENSG00000268592.3	RAET1E-AS1	9.11	2.35e-18	1.29e-15	0.52	0.39	Lung cancer;	chr6:149664079	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs62439843	ENSG00000268592.3	RAET1E-AS1	9.11	2.35e-18	1.29e-15	0.52	0.39	Lung cancer;	chr6:149676521	chr6:149863494~149919507:+
THCA	cis	rs7211079	0.912	rs4889831	ENSG00000275479.1	RP11-334C17.6	9.11	2.36e-18	1.29e-15	0.39	0.39	Myocardial infarction;	chr17:80140854	chr17:80149627~80149798:+
THCA	cis	rs748404	0.65	rs518234	ENSG00000249839.1	AC011330.5	-9.11	2.37e-18	1.3e-15	-0.45	-0.39	Lung cancer;	chr15:43281223	chr15:43663654~43684339:-
THCA	cis	rs748404	0.65	rs518261	ENSG00000249839.1	AC011330.5	-9.11	2.37e-18	1.3e-15	-0.45	-0.39	Lung cancer;	chr15:43281231	chr15:43663654~43684339:-
THCA	cis	rs801193	1	rs2659909	ENSG00000237310.1	GS1-124K5.4	9.11	2.37e-18	1.3e-15	0.28	0.39	Aortic root size;	chr7:66695292	chr7:66493706~66495474:+
THCA	cis	rs9322193	0.961	rs2064520	ENSG00000268592.3	RAET1E-AS1	9.11	2.37e-18	1.3e-15	0.52	0.39	Lung cancer;	chr6:149603650	chr6:149863494~149919507:+
THCA	cis	rs2243480	1	rs34970380	ENSG00000273142.1	RP11-458F8.4	-9.11	2.37e-18	1.3e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:65966506	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1723270	ENSG00000273142.1	RP11-458F8.4	-9.11	2.37e-18	1.3e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66004843	chr7:66902857~66906297:+
THCA	cis	rs10463554	0.895	rs12656561	ENSG00000175749.11	EIF3KP1	9.11	2.39e-18	1.31e-15	0.48	0.39	Parkinson's disease;	chr5:102989988	chr5:103032376~103033031:+
THCA	cis	rs9309473	0.687	rs6747145	ENSG00000163016.8	ALMS1P	9.11	2.39e-18	1.31e-15	0.51	0.39	Metabolite levels;	chr2:73382049	chr2:73644919~73685576:+
THCA	cis	rs4722166	0.63	rs6969258	ENSG00000179428.2	AC073072.5	-9.11	2.39e-18	1.31e-15	-0.5	-0.39	Lung cancer;	chr7:22742909	chr7:22725395~22727620:-
THCA	cis	rs4927850	1	rs6799572	ENSG00000273009.1	RP11-352G9.1	-9.11	2.39e-18	1.31e-15	-0.43	-0.39	Pancreatic cancer;	chr3:196013537	chr3:195913078~195913683:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000235689.1	AP000351.13	9.11	2.39e-18	1.31e-15	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:24006305~24008258:-
THCA	cis	rs4722166	0.598	rs4722171	ENSG00000179428.2	AC073072.5	-9.11	2.4e-18	1.31e-15	-0.5	-0.39	Lung cancer;	chr7:22746098	chr7:22725395~22727620:-
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-9.11	2.4e-18	1.31e-15	-0.51	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
THCA	cis	rs7015263	0.818	rs56096624	ENSG00000254231.1	CTD-2284J15.1	-9.11	2.4e-18	1.32e-15	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86403298	chr8:86333274~86343314:-
THCA	cis	rs801193	1	rs7785213	ENSG00000237310.1	GS1-124K5.4	-9.11	2.4e-18	1.32e-15	-0.28	-0.39	Aortic root size;	chr7:66673991	chr7:66493706~66495474:+
THCA	cis	rs801193	0.967	rs2707841	ENSG00000237310.1	GS1-124K5.4	9.11	2.4e-18	1.32e-15	0.28	0.39	Aortic root size;	chr7:66692033	chr7:66493706~66495474:+
THCA	cis	rs2439831	0.85	rs8032649	ENSG00000249839.1	AC011330.5	9.11	2.41e-18	1.32e-15	0.62	0.39	Lung cancer in ever smokers;	chr15:43842724	chr15:43663654~43684339:-
THCA	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-9.11	2.41e-18	1.32e-15	-0.44	-0.39	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs313832	ENSG00000273142.1	RP11-458F8.4	-9.11	2.42e-18	1.32e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66085904	chr7:66902857~66906297:+
THCA	cis	rs4842666	0.831	rs11105337	ENSG00000258302.2	RP11-981P6.1	9.11	2.42e-18	1.32e-15	0.39	0.39	Blood pressure;	chr12:89599730	chr12:89561129~89594878:+
THCA	cis	rs7191700	0.644	rs918738	ENSG00000262636.1	CTD-3088G3.4	-9.11	2.42e-18	1.32e-15	-0.48	-0.39	Multiple sclerosis;	chr16:11345822	chr16:11380859~11381118:-
THCA	cis	rs9322193	0.924	rs9322189	ENSG00000268592.3	RAET1E-AS1	9.11	2.42e-18	1.32e-15	0.52	0.39	Lung cancer;	chr6:149588797	chr6:149863494~149919507:+
THCA	cis	rs12908161	0.96	rs34452033	ENSG00000259728.4	LINC00933	9.11	2.43e-18	1.33e-15	0.52	0.39	Schizophrenia;	chr15:84678762	chr15:84570649~84580175:+
THCA	cis	rs62355901	0.505	rs12655082	ENSG00000271828.1	CTD-2310F14.1	9.11	2.44e-18	1.34e-15	0.76	0.39	Breast cancer;	chr5:56930384	chr5:56927874~56929573:+
THCA	cis	rs17684571	0.751	rs13203148	ENSG00000231441.1	RP11-472M19.2	9.11	2.45e-18	1.34e-15	0.53	0.39	Schizophrenia;	chr6:56822235	chr6:56844002~56864078:+
THCA	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	9.11	2.45e-18	1.34e-15	0.71	0.39	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
THCA	cis	rs2599510	0.934	rs2710634	ENSG00000276334.1	AL133243.1	9.11	2.45e-18	1.34e-15	0.41	0.39	Interleukin-18 levels;	chr2:32583737	chr2:32521927~32523547:+
THCA	cis	rs1499614	1	rs2141924	ENSG00000273142.1	RP11-458F8.4	-9.11	2.45e-18	1.34e-15	-0.51	-0.39	Gout;	chr7:66721259	chr7:66902857~66906297:+
THCA	cis	rs8027521	0.521	rs12906405	ENSG00000280362.1	RP11-643A5.3	-9.11	2.46e-18	1.34e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53930395	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.521	rs11633398	ENSG00000280362.1	RP11-643A5.3	-9.11	2.46e-18	1.35e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53926827	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.521	rs11633403	ENSG00000280362.1	RP11-643A5.3	-9.11	2.46e-18	1.35e-15	-0.54	-0.39	Circulating chemerin levels;	chr15:53926957	chr15:53910769~53914712:+
THCA	cis	rs944289	0.708	rs1953120	ENSG00000257826.1	RP11-116N8.4	-9.11	2.46e-18	1.35e-15	-0.39	-0.39	Thyroid cancer;	chr14:36105724	chr14:36061026~36067190:-
THCA	cis	rs73186030	0.546	rs73188388	ENSG00000272758.4	RP11-299J3.8	9.1	2.47e-18	1.35e-15	0.45	0.39	Serum parathyroid hormone levels;	chr3:122399229	chr3:122416207~122443180:+
THCA	cis	rs2033711	0.87	rs3764534	ENSG00000268912.1	CTD-2619J13.17	-9.1	2.48e-18	1.35e-15	-0.3	-0.39	Uric acid clearance;	chr19:58417769	chr19:58428632~58431148:-
THCA	cis	rs2243480	1	rs2707844	ENSG00000273142.1	RP11-458F8.4	-9.1	2.48e-18	1.36e-15	-0.5	-0.39	Diabetic kidney disease;	chr7:66594522	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1796220	ENSG00000273142.1	RP11-458F8.4	-9.1	2.48e-18	1.36e-15	-0.5	-0.39	Diabetic kidney disease;	chr7:66597113	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs2707831	ENSG00000273142.1	RP11-458F8.4	-9.1	2.48e-18	1.36e-15	-0.5	-0.39	Diabetic kidney disease;	chr7:66597524	chr7:66902857~66906297:+
THCA	cis	rs2946505	1	rs2946503	ENSG00000251468.2	RP11-369K16.1	9.1	2.5e-18	1.37e-15	0.5	0.39	Migraine;	chr8:12954366	chr8:12958387~12962200:+
THCA	cis	rs11676348	0.774	rs11683524	ENSG00000261338.2	RP11-378A13.1	-9.1	2.5e-18	1.37e-15	-0.39	-0.39	Ulcerative colitis;	chr2:218119881	chr2:218255319~218257366:+
THCA	cis	rs9322193	0.926	rs9689036	ENSG00000268592.3	RAET1E-AS1	9.1	2.5e-18	1.37e-15	0.51	0.39	Lung cancer;	chr6:149780563	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9322218	ENSG00000268592.3	RAET1E-AS1	9.1	2.5e-18	1.37e-15	0.51	0.39	Lung cancer;	chr6:149782183	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9322219	ENSG00000268592.3	RAET1E-AS1	9.1	2.5e-18	1.37e-15	0.51	0.39	Lung cancer;	chr6:149782263	chr6:149863494~149919507:+
THCA	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-9.1	2.51e-18	1.37e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
THCA	cis	rs4819052	0.851	rs7276591	ENSG00000215447.6	BX322557.10	-9.1	2.51e-18	1.37e-15	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45288052~45291738:+
THCA	cis	rs7211079	0.879	rs66693363	ENSG00000275479.1	RP11-334C17.6	9.1	2.51e-18	1.37e-15	0.39	0.39	Myocardial infarction;	chr17:80155136	chr17:80149627~80149798:+
THCA	cis	rs875971	0.628	rs6974355	ENSG00000237310.1	GS1-124K5.4	9.1	2.52e-18	1.37e-15	0.28	0.39	Aortic root size;	chr7:66376994	chr7:66493706~66495474:+
THCA	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	9.1	2.52e-18	1.38e-15	0.32	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
THCA	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-9.1	2.52e-18	1.38e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	9.1	2.52e-18	1.38e-15	0.76	0.39	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs57126451	ENSG00000273142.1	RP11-458F8.4	-9.1	2.57e-18	1.4e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65951319	chr7:66902857~66906297:+
THCA	cis	rs875971	0.577	rs34888281	ENSG00000237310.1	GS1-124K5.4	-9.1	2.57e-18	1.4e-15	-0.28	-0.39	Aortic root size;	chr7:66120784	chr7:66493706~66495474:+
THCA	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-9.1	2.58e-18	1.41e-15	-0.46	-0.39	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
THCA	cis	rs2111504	0.806	rs2903738	ENSG00000267213.4	AC007773.2	-9.1	2.59e-18	1.41e-15	-0.39	-0.39	Bipolar disorder;	chr19:32455137	chr19:32390050~32405560:-
THCA	cis	rs2280018	0.526	rs2966129	ENSG00000188599.16	NPIPP1	9.1	2.59e-18	1.41e-15	0.32	0.39	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15104312~15123498:-
THCA	cis	rs9322193	0.962	rs9505974	ENSG00000268592.3	RAET1E-AS1	9.1	2.59e-18	1.41e-15	0.51	0.39	Lung cancer;	chr6:149779294	chr6:149863494~149919507:+
THCA	cis	rs4713118	0.621	rs10484403	ENSG00000226314.6	ZNF192P1	-9.1	2.6e-18	1.42e-15	-0.5	-0.39	Parkinson's disease;	chr6:28065745	chr6:28161781~28169594:+
THCA	cis	rs7208859	0.614	rs7216394	ENSG00000263531.1	RP13-753N3.1	-9.1	2.61e-18	1.42e-15	-0.69	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30498738	chr17:30863921~30864940:-
THCA	cis	rs1426063	0.614	rs75345649	ENSG00000260265.1	RP11-44F21.5	9.1	2.61e-18	1.42e-15	0.84	0.39	QT interval;	chr4:75100963	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs77333523	ENSG00000260265.1	RP11-44F21.5	9.1	2.61e-18	1.42e-15	0.84	0.39	QT interval;	chr4:75101024	chr4:75081702~75084717:-
THCA	cis	rs4591358	0.648	rs56906982	ENSG00000223466.1	AC064834.2	-9.1	2.62e-18	1.43e-15	-0.52	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512939	chr2:195533035~195538681:+
THCA	cis	rs9322193	0.923	rs9766004	ENSG00000268592.3	RAET1E-AS1	9.1	2.62e-18	1.43e-15	0.52	0.39	Lung cancer;	chr6:149754363	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs17673294	ENSG00000268592.3	RAET1E-AS1	9.1	2.63e-18	1.43e-15	0.52	0.39	Lung cancer;	chr6:149813857	chr6:149863494~149919507:+
THCA	cis	rs494459	0.536	rs11217063	ENSG00000278376.1	RP11-158I9.8	-9.1	2.65e-18	1.45e-15	-0.28	-0.39	Height;	chr11:118855233	chr11:118791254~118793137:+
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000228039.3	KB-1125A3.10	9.1	2.65e-18	1.45e-15	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23963780~23964374:+
THCA	cis	rs748404	0.697	rs546170	ENSG00000249839.1	AC011330.5	-9.1	2.65e-18	1.45e-15	-0.46	-0.39	Lung cancer;	chr15:43272651	chr15:43663654~43684339:-
THCA	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	9.1	2.66e-18	1.45e-15	0.35	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
THCA	cis	rs10461617	0.531	rs2662033	ENSG00000271828.1	CTD-2310F14.1	9.1	2.67e-18	1.46e-15	0.61	0.39	Type 2 diabetes;	chr5:56917583	chr5:56927874~56929573:+
THCA	cis	rs7727544	0.571	rs12521097	ENSG00000237714.1	P4HA2-AS1	9.1	2.67e-18	1.46e-15	0.51	0.39	Blood metabolite levels;	chr5:132239645	chr5:132184876~132192808:+
THCA	cis	rs860295	0.557	rs12091730	ENSG00000225855.5	RUSC1-AS1	9.09	2.68e-18	1.46e-15	0.3	0.39	Body mass index;	chr1:155587180	chr1:155316863~155324176:-
THCA	cis	rs526231	0.547	rs72783895	ENSG00000175749.11	EIF3KP1	9.09	2.68e-18	1.46e-15	0.55	0.39	Primary biliary cholangitis;	chr5:102951792	chr5:103032376~103033031:+
THCA	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-9.09	2.69e-18	1.46e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-9.09	2.69e-18	1.46e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-9.09	2.69e-18	1.46e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
THCA	cis	rs62103177	0.525	rs1835410	ENSG00000261126.6	RP11-795F19.1	-9.09	2.7e-18	1.47e-15	-0.43	-0.39	Opioid sensitivity;	chr18:79942025	chr18:80046900~80095482:+
THCA	cis	rs4713118	0.662	rs469228	ENSG00000280107.1	AL022393.9	-9.09	2.7e-18	1.47e-15	-0.44	-0.39	Parkinson's disease;	chr6:28002926	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.54	rs469227	ENSG00000280107.1	AL022393.9	-9.09	2.7e-18	1.47e-15	-0.44	-0.39	Parkinson's disease;	chr6:28002927	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.662	rs149948	ENSG00000280107.1	AL022393.9	-9.09	2.7e-18	1.47e-15	-0.44	-0.39	Parkinson's disease;	chr6:28007039	chr6:28170845~28172521:+
THCA	cis	rs860295	0.776	rs11264362	ENSG00000225855.5	RUSC1-AS1	-9.09	2.7e-18	1.47e-15	-0.26	-0.39	Body mass index;	chr1:155345824	chr1:155316863~155324176:-
THCA	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-9.09	2.71e-18	1.48e-15	-0.43	-0.39	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
THCA	cis	rs8062405	0.723	rs113208333	ENSG00000251417.2	RP11-1348G14.4	-9.09	2.72e-18	1.48e-15	-0.39	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28802743~28817828:+
THCA	cis	rs11148252	0.74	rs9596648	ENSG00000278238.1	RP11-245D16.4	9.09	2.72e-18	1.48e-15	0.44	0.39	Lewy body disease;	chr13:52360434	chr13:52454775~52455331:-
THCA	cis	rs934734	0.544	rs4671127	ENSG00000204929.10	AC074391.1	9.09	2.72e-18	1.48e-15	0.51	0.39	Rheumatoid arthritis;	chr2:65335836	chr2:65436711~66084639:+
THCA	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	9.09	2.73e-18	1.48e-15	0.58	0.39	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
THCA	cis	rs1499614	1	rs2659913	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66692349	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs2659911	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66693433	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs2707838	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66694214	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs60326618	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66701371	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs2707830	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66702658	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs2707828	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66706390	chr7:66902857~66906297:+
THCA	cis	rs1499614	0.803	rs1922723	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66710076	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs2659903	ENSG00000273142.1	RP11-458F8.4	-9.09	2.73e-18	1.49e-15	-0.51	-0.39	Gout;	chr7:66715944	chr7:66902857~66906297:+
THCA	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	9.09	2.74e-18	1.49e-15	0.43	0.39	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
THCA	cis	rs62103177	0.535	rs34299914	ENSG00000261126.6	RP11-795F19.1	9.09	2.74e-18	1.49e-15	0.45	0.39	Opioid sensitivity;	chr18:80191353	chr18:80046900~80095482:+
THCA	cis	rs494459	0.536	rs11217065	ENSG00000278376.1	RP11-158I9.8	-9.09	2.74e-18	1.49e-15	-0.28	-0.39	Height;	chr11:118855938	chr11:118791254~118793137:+
THCA	cis	rs17772222	0.56	rs3742681	ENSG00000258789.1	RP11-507K2.3	9.09	2.75e-18	1.5e-15	0.37	0.39	Coronary artery calcification;	chr14:88554903	chr14:88551597~88552493:+
THCA	cis	rs1062177	1	rs2915882	ENSG00000253921.1	CTB-113P19.3	-9.09	2.75e-18	1.5e-15	-0.48	-0.39	Preschool internalizing problems;	chr5:151765875	chr5:151753992~151767247:+
THCA	cis	rs1062177	1	rs2915880	ENSG00000253921.1	CTB-113P19.3	-9.09	2.75e-18	1.5e-15	-0.48	-0.39	Preschool internalizing problems;	chr5:151767773	chr5:151753992~151767247:+
THCA	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-9.09	2.76e-18	1.5e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
THCA	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-9.09	2.76e-18	1.5e-15	-0.44	-0.39	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
THCA	cis	rs11148252	0.74	rs3803264	ENSG00000278238.1	RP11-245D16.4	9.09	2.77e-18	1.51e-15	0.43	0.39	Lewy body disease;	chr13:52397758	chr13:52454775~52455331:-
THCA	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	9.09	2.77e-18	1.51e-15	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
THCA	cis	rs10463554	0.746	rs6876072	ENSG00000175749.11	EIF3KP1	9.09	2.79e-18	1.52e-15	0.51	0.39	Parkinson's disease;	chr5:103251872	chr5:103032376~103033031:+
THCA	cis	rs2284219	0.565	rs2284217	ENSG00000244480.1	AC005154.7	-9.09	2.79e-18	1.52e-15	-0.35	-0.39	Type 2 diabetes;	chr7:30673992	chr7:30523143~30524535:-
THCA	cis	rs11971779	0.616	rs1862878	ENSG00000273391.1	RP11-634H22.1	9.09	2.8e-18	1.52e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139335168	chr7:139359032~139359566:-
THCA	cis	rs42490	1	rs431264	ENSG00000251136.7	RP11-37B2.1	-9.09	2.8e-18	1.52e-15	-0.33	-0.39	Leprosy;	chr8:89765282	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs42490	ENSG00000251136.7	RP11-37B2.1	-9.09	2.8e-18	1.52e-15	-0.33	-0.39	Leprosy;	chr8:89766285	chr8:89609409~89757727:-
THCA	cis	rs42490	1	rs40544	ENSG00000251136.7	RP11-37B2.1	-9.09	2.8e-18	1.52e-15	-0.33	-0.39	Leprosy;	chr8:89768867	chr8:89609409~89757727:-
THCA	cis	rs42490	0.966	rs40377	ENSG00000251136.7	RP11-37B2.1	-9.09	2.8e-18	1.52e-15	-0.33	-0.39	Leprosy;	chr8:89769725	chr8:89609409~89757727:-
THCA	cis	rs9322193	1	rs9399693	ENSG00000268592.3	RAET1E-AS1	9.09	2.8e-18	1.52e-15	0.52	0.39	Lung cancer;	chr6:149612718	chr6:149863494~149919507:+
THCA	cis	rs934734	0.532	rs55792977	ENSG00000234255.7	AC012370.3	-9.09	2.8e-18	1.52e-15	-0.43	-0.39	Rheumatoid arthritis;	chr2:65423730	chr2:65439888~65456571:-
THCA	cis	rs2243480	0.803	rs34804747	ENSG00000273142.1	RP11-458F8.4	-9.09	2.8e-18	1.52e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65947955	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs59794892	ENSG00000273142.1	RP11-458F8.4	-9.09	2.8e-18	1.52e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65950886	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.803	rs36004293	ENSG00000273142.1	RP11-458F8.4	-9.09	2.8e-18	1.52e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65951525	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.803	rs35268390	ENSG00000273142.1	RP11-458F8.4	-9.09	2.8e-18	1.52e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65951549	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs11538349	ENSG00000273142.1	RP11-458F8.4	-9.09	2.8e-18	1.52e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65956884	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	9.09	2.83e-18	1.54e-15	0.79	0.39	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
THCA	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	9.09	2.84e-18	1.54e-15	0.58	0.39	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
THCA	cis	rs8062405	0.755	rs62034325	ENSG00000251417.2	RP11-1348G14.4	-9.09	2.85e-18	1.55e-15	-0.39	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28802743~28817828:+
THCA	cis	rs7015263	0.875	rs17608967	ENSG00000254231.1	CTD-2284J15.1	-9.09	2.87e-18	1.56e-15	-0.38	-0.39	Intelligence (multi-trait analysis);	chr8:86413780	chr8:86333274~86343314:-
THCA	cis	rs71403859	0.502	rs12919417	ENSG00000260886.1	TAT-AS1	-9.09	2.87e-18	1.56e-15	-0.71	-0.39	Post bronchodilator FEV1;	chr16:71545808	chr16:71565789~71578187:+
THCA	cis	rs9532669	0.926	rs9532691	ENSG00000239827.7	SUGT1P3	9.09	2.88e-18	1.56e-15	0.41	0.39	Cervical cancer;	chr13:40969358	chr13:40908159~40921774:-
THCA	cis	rs9659323	1	rs10923715	ENSG00000231365.4	RP11-418J17.1	9.09	2.89e-18	1.57e-15	0.39	0.39	Body mass index;	chr1:118992711	chr1:119140396~119275973:+
THCA	cis	rs7015263	0.875	rs10092164	ENSG00000254231.1	CTD-2284J15.1	9.09	2.89e-18	1.57e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86440801	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.875	rs10096443	ENSG00000254231.1	CTD-2284J15.1	9.09	2.89e-18	1.57e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86441374	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.875	rs6981299	ENSG00000254231.1	CTD-2284J15.1	9.09	2.89e-18	1.57e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86443220	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.875	rs10088389	ENSG00000254231.1	CTD-2284J15.1	9.09	2.89e-18	1.57e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86446578	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.875	rs6471349	ENSG00000254231.1	CTD-2284J15.1	9.09	2.89e-18	1.57e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86457559	chr8:86333274~86343314:-
THCA	cis	rs780096	0.565	rs11681351	ENSG00000234072.1	AC074117.10	-9.08	2.9e-18	1.57e-15	-0.31	-0.39	Total body bone mineral density;	chr2:27520556	chr2:27356246~27367622:+
THCA	cis	rs1707322	0.963	rs4630155	ENSG00000234329.1	RP11-767N6.2	9.08	2.91e-18	1.58e-15	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs4508055	ENSG00000234329.1	RP11-767N6.2	9.08	2.91e-18	1.58e-15	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs12076580	ENSG00000234329.1	RP11-767N6.2	9.08	2.91e-18	1.58e-15	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45651039~45651826:-
THCA	cis	rs4819052	1	rs9984901	ENSG00000215447.6	BX322557.10	-9.08	2.92e-18	1.58e-15	-0.35	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45288052~45291738:+
THCA	cis	rs673078	0.607	rs61943451	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118438929	chr12:118430147~118430699:+
THCA	cis	rs673078	0.518	rs61943452	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118438990	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943454	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118439140	chr12:118430147~118430699:+
THCA	cis	rs673078	0.517	rs61943455	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118439414	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs73207566	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118439471	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs2393416	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118439968	chr12:118430147~118430699:+
THCA	cis	rs673078	0.56	rs4406856	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118440094	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs4457791	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118440144	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943456	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118440326	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17513006	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118440383	chr12:118430147~118430699:+
THCA	cis	rs673078	0.56	rs61943457	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118440487	chr12:118430147~118430699:+
THCA	cis	rs673078	0.562	rs55883417	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118440801	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs55842338	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118441259	chr12:118430147~118430699:+
THCA	cis	rs673078	0.518	rs17441251	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118441361	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17513013	ENSG00000275409.1	RP11-131L12.4	-9.08	2.92e-18	1.58e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118442070	chr12:118430147~118430699:+
THCA	cis	rs2243480	0.708	rs35825036	ENSG00000273142.1	RP11-458F8.4	-9.08	2.93e-18	1.59e-15	-0.51	-0.39	Diabetic kidney disease;	chr7:66521515	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs13237037	ENSG00000273142.1	RP11-458F8.4	-9.08	2.93e-18	1.59e-15	-0.51	-0.39	Diabetic kidney disease;	chr7:66532895	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1796228	ENSG00000273142.1	RP11-458F8.4	-9.08	2.93e-18	1.59e-15	-0.51	-0.39	Diabetic kidney disease;	chr7:66568097	chr7:66902857~66906297:+
THCA	cis	rs9640161	0.75	rs73170185	ENSG00000261305.1	RP4-584D14.7	9.08	2.94e-18	1.6e-15	0.48	0.39	Blood protein levels;Circulating chemerin levels;	chr7:150333102	chr7:150341771~150342607:+
THCA	cis	rs7191700	0.644	rs918738	ENSG00000262703.1	RP11-485G7.6	-9.08	2.94e-18	1.6e-15	-0.42	-0.39	Multiple sclerosis;	chr16:11345822	chr16:11348143~11349321:-
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000228039.3	KB-1125A3.10	9.08	2.96e-18	1.6e-15	0.48	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23963780~23964374:+
THCA	cis	rs7015263	0.875	rs10956853	ENSG00000254231.1	CTD-2284J15.1	9.08	2.96e-18	1.6e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86459496	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.875	rs6471352	ENSG00000254231.1	CTD-2284J15.1	9.08	2.96e-18	1.6e-15	0.37	0.39	Intelligence (multi-trait analysis);	chr8:86470095	chr8:86333274~86343314:-
THCA	cis	rs7291412	0.579	rs11090867	ENSG00000231711.2	LINC00899	9.08	2.98e-18	1.61e-15	0.31	0.39	Dupuytren's disease;Subjective well-being;	chr22:46058912	chr22:46039907~46044853:-
THCA	cis	rs524281	0.731	rs10791841	ENSG00000255320.1	RP11-755F10.1	9.08	2.98e-18	1.62e-15	0.61	0.39	Electroencephalogram traits;	chr11:66041116	chr11:66244840~66246239:-
THCA	cis	rs1707322	0.752	rs6678444	ENSG00000234329.1	RP11-767N6.2	9.08	2.98e-18	1.62e-15	0.37	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45651039~45651826:-
THCA	cis	rs9322193	0.962	rs2065664	ENSG00000268592.3	RAET1E-AS1	9.08	2.99e-18	1.62e-15	0.52	0.39	Lung cancer;	chr6:149762485	chr6:149863494~149919507:+
THCA	cis	rs673078	0.607	rs73207504	ENSG00000275409.1	RP11-131L12.4	-9.08	2.99e-18	1.62e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118427914	chr12:118430147~118430699:+
THCA	cis	rs2115630	0.645	rs1107179	ENSG00000275120.1	RP11-182J1.17	9.08	3e-18	1.63e-15	0.4	0.39	P wave terminal force;	chr15:84655131	chr15:84599434~84606463:-
THCA	cis	rs9309473	0.687	rs12465867	ENSG00000163016.8	ALMS1P	9.08	3.01e-18	1.63e-15	0.52	0.39	Metabolite levels;	chr2:73384974	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.583	rs35885918	ENSG00000163016.8	ALMS1P	9.08	3.01e-18	1.63e-15	0.52	0.39	Metabolite levels;	chr2:73385106	chr2:73644919~73685576:+
THCA	cis	rs17684571	0.7	rs62411376	ENSG00000231441.1	RP11-472M19.2	9.08	3.02e-18	1.64e-15	0.5	0.39	Schizophrenia;	chr6:56794436	chr6:56844002~56864078:+
THCA	cis	rs367615	0.679	rs11241021	ENSG00000249476.1	CTD-2587M2.1	9.08	3.02e-18	1.64e-15	0.41	0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109476389	chr5:109237120~109326369:-
THCA	cis	rs9322193	0.961	rs9285521	ENSG00000268592.3	RAET1E-AS1	9.08	3.02e-18	1.64e-15	0.53	0.39	Lung cancer;	chr6:149585576	chr6:149863494~149919507:+
THCA	cis	rs10463554	0.853	rs246902	ENSG00000175749.11	EIF3KP1	9.08	3.03e-18	1.64e-15	0.51	0.39	Parkinson's disease;	chr5:103253553	chr5:103032376~103033031:+
THCA	cis	rs9402743	0.64	rs9494384	ENSG00000231028.7	LINC00271	-9.08	3.03e-18	1.64e-15	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135779072	chr6:135497801~135716055:+
THCA	cis	rs947583	0.517	rs6570041	ENSG00000231028.7	LINC00271	-9.08	3.03e-18	1.64e-15	-0.3	-0.39	Phosphorus levels;	chr6:135780515	chr6:135497801~135716055:+
THCA	cis	rs947583	0.517	rs6923513	ENSG00000231028.7	LINC00271	-9.08	3.03e-18	1.64e-15	-0.3	-0.39	Phosphorus levels;	chr6:135780784	chr6:135497801~135716055:+
THCA	cis	rs4591358	0.773	rs13035226	ENSG00000223466.1	AC064834.2	-9.08	3.03e-18	1.64e-15	-0.52	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512957	chr2:195533035~195538681:+
THCA	cis	rs11971779	0.715	rs11772771	ENSG00000273391.1	RP11-634H22.1	9.08	3.04e-18	1.64e-15	0.37	0.39	Diisocyanate-induced asthma;	chr7:139374057	chr7:139359032~139359566:-
THCA	cis	rs2243480	1	rs313831	ENSG00000273142.1	RP11-458F8.4	-9.08	3.04e-18	1.65e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66086239	chr7:66902857~66906297:+
THCA	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-9.08	3.04e-18	1.65e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
THCA	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-9.08	3.04e-18	1.65e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
THCA	cis	rs11676348	0.712	rs12694426	ENSG00000261338.2	RP11-378A13.1	-9.08	3.04e-18	1.65e-15	-0.39	-0.39	Ulcerative colitis;	chr2:218077628	chr2:218255319~218257366:+
THCA	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-9.08	3.05e-18	1.65e-15	-0.46	-0.39	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
THCA	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	9.08	3.05e-18	1.65e-15	0.58	0.39	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
THCA	cis	rs1799949	1	rs8077486	ENSG00000267681.1	CTD-3199J23.6	-9.08	3.06e-18	1.65e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43060788	chr17:43144956~43145255:+
THCA	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	9.08	3.06e-18	1.66e-15	0.78	0.39	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
THCA	cis	rs77204473	0.655	rs11216183	ENSG00000254851.1	RP11-109L13.1	9.08	3.07e-18	1.66e-15	0.83	0.39	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116910829	chr11:117135528~117138582:+
THCA	cis	rs9640161	0.75	rs11769348	ENSG00000261305.1	RP4-584D14.7	-9.08	3.07e-18	1.66e-15	-0.48	-0.39	Blood protein levels;Circulating chemerin levels;	chr7:150329664	chr7:150341771~150342607:+
THCA	cis	rs11971779	0.68	rs10271297	ENSG00000273391.1	RP11-634H22.1	9.08	3.07e-18	1.66e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139367564	chr7:139359032~139359566:-
THCA	cis	rs62158211	1	rs62158211	ENSG00000272563.1	RP11-480C16.1	-9.08	3.08e-18	1.66e-15	-0.53	-0.39	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113348562	chr2:113432600~113436042:+
THCA	cis	rs11971779	0.838	rs58074268	ENSG00000273391.1	RP11-634H22.1	9.08	3.08e-18	1.66e-15	0.39	0.39	Diisocyanate-induced asthma;	chr7:139424179	chr7:139359032~139359566:-
THCA	cis	rs10411161	1	rs10411161	ENSG00000269483.1	AC006272.1	9.08	3.08e-18	1.66e-15	0.54	0.39	Breast cancer;	chr19:51869723	chr19:51839924~51843324:-
THCA	cis	rs10463554	0.853	rs257309	ENSG00000175749.11	EIF3KP1	9.08	3.08e-18	1.67e-15	0.48	0.39	Parkinson's disease;	chr5:103082900	chr5:103032376~103033031:+
THCA	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-9.08	3.09e-18	1.67e-15	-0.55	-0.39	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
THCA	cis	rs848490	0.674	rs4727461	ENSG00000214293.7	APTR	9.08	3.1e-18	1.67e-15	0.29	0.39	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77691071	chr7:77657660~77696265:-
THCA	cis	rs9402743	0.667	rs4896179	ENSG00000231028.7	LINC00271	-9.08	3.1e-18	1.68e-15	-0.3	-0.39	Systemic lupus erythematosus;	chr6:135788352	chr6:135497801~135716055:+
THCA	cis	rs10411161	1	rs8106929	ENSG00000269483.1	AC006272.1	9.08	3.11e-18	1.68e-15	0.54	0.39	Breast cancer;	chr19:51865214	chr19:51839924~51843324:-
THCA	cis	rs6496932	0.913	rs7403354	ENSG00000218052.5	ADAMTS7P4	9.08	3.11e-18	1.68e-15	0.54	0.39	Central corneal thickness;Corneal structure;	chr15:85277624	chr15:85255369~85330334:-
THCA	cis	rs1799949	1	rs2271573	ENSG00000267681.1	CTD-3199J23.6	-9.08	3.11e-18	1.68e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43175604	chr17:43144956~43145255:+
THCA	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	9.08	3.12e-18	1.69e-15	0.67	0.39	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	9.08	3.12e-18	1.69e-15	0.67	0.39	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
THCA	cis	rs1799949	0.965	rs7212284	ENSG00000267681.1	CTD-3199J23.6	-9.07	3.13e-18	1.69e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43053924	chr17:43144956~43145255:+
THCA	cis	rs2243480	1	rs781149	ENSG00000273142.1	RP11-458F8.4	-9.07	3.13e-18	1.69e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66016297	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs58207111	ENSG00000273142.1	RP11-458F8.4	-9.07	3.13e-18	1.69e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66021736	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1167613	ENSG00000273142.1	RP11-458F8.4	-9.07	3.13e-18	1.69e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66022452	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs313799	ENSG00000273142.1	RP11-458F8.4	-9.07	3.13e-18	1.69e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66029343	chr7:66902857~66906297:+
THCA	cis	rs496547	0.756	rs562059	ENSG00000278376.1	RP11-158I9.8	-9.07	3.13e-18	1.69e-15	-0.3	-0.39	Hip minimal joint space width;	chr11:118731349	chr11:118791254~118793137:+
THCA	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	9.07	3.14e-18	1.7e-15	0.5	0.39	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
THCA	cis	rs2243480	1	rs2462569	ENSG00000273142.1	RP11-458F8.4	9.07	3.15e-18	1.7e-15	0.48	0.39	Diabetic kidney disease;	chr7:66009859	chr7:66902857~66906297:+
THCA	cis	rs1075265	0.73	rs7601692	ENSG00000233266.1	HMGB1P31	9.07	3.15e-18	1.7e-15	0.49	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54051334~54051760:+
THCA	cis	rs9309473	0.718	rs10175529	ENSG00000163016.8	ALMS1P	9.07	3.16e-18	1.71e-15	0.52	0.39	Metabolite levels;	chr2:73378965	chr2:73644919~73685576:+
THCA	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	9.07	3.17e-18	1.71e-15	0.58	0.39	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
THCA	cis	rs9329221	0.512	rs12546887	ENSG00000261451.1	RP11-981G7.1	9.07	3.2e-18	1.73e-15	0.47	0.39	Neuroticism;	chr8:10435366	chr8:10433672~10438312:+
THCA	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-9.07	3.21e-18	1.73e-15	-0.41	-0.39	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
THCA	cis	rs860295	0.836	rs1360554	ENSG00000225855.5	RUSC1-AS1	-9.07	3.22e-18	1.74e-15	-0.25	-0.39	Body mass index;	chr1:155503565	chr1:155316863~155324176:-
THCA	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-9.07	3.22e-18	1.74e-15	-0.54	-0.39	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
THCA	cis	rs597539	0.652	rs686390	ENSG00000250508.1	RP11-757G1.6	-9.07	3.24e-18	1.75e-15	-0.47	-0.39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68888609	chr11:68870664~68874542:+
THCA	cis	rs10740039	0.842	rs7080024	ENSG00000254271.1	RP11-131N11.4	-9.07	3.25e-18	1.75e-15	-0.47	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632033	chr10:60734342~60741828:+
THCA	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	9.07	3.25e-18	1.75e-15	0.58	0.39	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	9.07	3.25e-18	1.75e-15	0.58	0.39	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	9.07	3.25e-18	1.75e-15	0.58	0.39	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	9.07	3.25e-18	1.75e-15	0.58	0.39	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	9.07	3.25e-18	1.75e-15	0.58	0.39	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
THCA	cis	rs4819052	1	rs3746980	ENSG00000215447.6	BX322557.10	-9.07	3.27e-18	1.76e-15	-0.35	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45288052~45291738:+
THCA	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	9.07	3.27e-18	1.77e-15	0.53	0.39	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
THCA	cis	rs17684571	0.7	rs13205667	ENSG00000231441.1	RP11-472M19.2	9.07	3.27e-18	1.77e-15	0.53	0.39	Schizophrenia;	chr6:56775176	chr6:56844002~56864078:+
THCA	cis	rs2288884	0.767	rs28379522	ENSG00000275055.1	CTC-471J1.11	-9.07	3.27e-18	1.77e-15	-0.36	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52036234	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.708	rs11665783	ENSG00000275055.1	CTC-471J1.11	-9.07	3.28e-18	1.77e-15	-0.36	-0.39	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52014641	chr19:52049007~52049754:+
THCA	cis	rs2115630	0.645	rs4842978	ENSG00000275120.1	RP11-182J1.17	-9.07	3.28e-18	1.77e-15	-0.41	-0.39	P wave terminal force;	chr15:84654022	chr15:84599434~84606463:-
THCA	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-9.07	3.29e-18	1.77e-15	-0.58	-0.39	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
THCA	cis	rs11971779	0.616	rs6967932	ENSG00000273391.1	RP11-634H22.1	9.07	3.29e-18	1.78e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139337635	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs6960876	ENSG00000273391.1	RP11-634H22.1	-9.07	3.29e-18	1.78e-15	-0.36	-0.39	Diisocyanate-induced asthma;	chr7:139427430	chr7:139359032~139359566:-
THCA	cis	rs950169	0.541	rs10795	ENSG00000259728.4	LINC00933	9.07	3.29e-18	1.78e-15	0.53	0.39	Schizophrenia;	chr15:84634066	chr15:84570649~84580175:+
THCA	cis	rs950169	0.58	rs36126054	ENSG00000259728.4	LINC00933	9.07	3.29e-18	1.78e-15	0.53	0.39	Schizophrenia;	chr15:84634492	chr15:84570649~84580175:+
THCA	cis	rs10181042	0.612	rs1177282	ENSG00000271889.1	RP11-493E12.1	9.07	3.3e-18	1.78e-15	0.39	0.39	Crohn's disease;	chr2:61130642	chr2:61151433~61162105:-
THCA	cis	rs2439831	0.85	rs7179388	ENSG00000249839.1	AC011330.5	-9.07	3.31e-18	1.79e-15	-0.63	-0.39	Lung cancer in ever smokers;	chr15:43831747	chr15:43663654~43684339:-
THCA	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-9.07	3.33e-18	1.79e-15	-0.41	-0.39	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-9.07	3.33e-18	1.79e-15	-0.41	-0.39	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
THCA	cis	rs9322193	0.962	rs35443312	ENSG00000268592.3	RAET1E-AS1	9.07	3.33e-18	1.8e-15	0.52	0.39	Lung cancer;	chr6:149670625	chr6:149863494~149919507:+
THCA	cis	rs4927850	1	rs4927850	ENSG00000273009.1	RP11-352G9.1	9.07	3.34e-18	1.8e-15	0.43	0.39	Pancreatic cancer;	chr3:196024759	chr3:195913078~195913683:-
THCA	cis	rs9322193	0.962	rs9322223	ENSG00000268592.3	RAET1E-AS1	9.07	3.37e-18	1.82e-15	0.51	0.39	Lung cancer;	chr6:149801509	chr6:149863494~149919507:+
THCA	cis	rs673078	0.562	rs56347775	ENSG00000275409.1	RP11-131L12.4	-9.07	3.37e-18	1.82e-15	-0.46	-0.39	Glucose homeostasis traits;	chr12:118438002	chr12:118430147~118430699:+
THCA	cis	rs11148252	0.74	rs9596643	ENSG00000278238.1	RP11-245D16.4	9.07	3.37e-18	1.82e-15	0.44	0.39	Lewy body disease;	chr13:52338245	chr13:52454775~52455331:-
THCA	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-9.07	3.37e-18	1.82e-15	-0.42	-0.39	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
THCA	cis	rs11690935	0.632	rs6737308	ENSG00000228389.1	AC068039.4	-9.07	3.38e-18	1.82e-15	-0.42	-0.39	Schizophrenia;	chr2:172007137	chr2:171773482~171775844:+
THCA	cis	rs2243480	0.901	rs2456483	ENSG00000273142.1	RP11-458F8.4	-9.06	3.39e-18	1.83e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:65996588	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1701750	ENSG00000273142.1	RP11-458F8.4	-9.06	3.39e-18	1.83e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66002158	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1701758	ENSG00000273142.1	RP11-458F8.4	-9.06	3.39e-18	1.83e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66005214	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs1701759	ENSG00000273142.1	RP11-458F8.4	-9.06	3.39e-18	1.83e-15	-0.49	-0.39	Diabetic kidney disease;	chr7:66005945	chr7:66902857~66906297:+
THCA	cis	rs17684571	0.7	rs17684784	ENSG00000231441.1	RP11-472M19.2	-9.06	3.43e-18	1.85e-15	-0.49	-0.39	Schizophrenia;	chr6:56813644	chr6:56844002~56864078:+
THCA	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-9.06	3.46e-18	1.86e-15	-0.68	-0.39	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
THCA	cis	rs42490	0.966	rs39499	ENSG00000251136.7	RP11-37B2.1	-9.06	3.46e-18	1.86e-15	-0.33	-0.39	Leprosy;	chr8:89758381	chr8:89609409~89757727:-
THCA	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-9.06	3.46e-18	1.86e-15	-0.57	-0.39	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
THCA	cis	rs2033711	0.84	rs3764533	ENSG00000268912.1	CTD-2619J13.17	-9.06	3.46e-18	1.86e-15	-0.29	-0.39	Uric acid clearance;	chr19:58417827	chr19:58428632~58431148:-
THCA	cis	rs673078	0.66	rs61945212	ENSG00000275409.1	RP11-131L12.4	-9.06	3.46e-18	1.86e-15	-0.5	-0.39	Glucose homeostasis traits;	chr12:118252351	chr12:118430147~118430699:+
THCA	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-9.06	3.46e-18	1.86e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
THCA	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	9.06	3.46e-18	1.87e-15	0.4	0.39	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
THCA	cis	rs2439831	0.85	rs28413704	ENSG00000249839.1	AC011330.5	-9.06	3.47e-18	1.87e-15	-0.63	-0.39	Lung cancer in ever smokers;	chr15:43856229	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.851	rs2255774	ENSG00000215447.6	BX322557.10	-9.06	3.48e-18	1.88e-15	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45288052~45291738:+
THCA	cis	rs7208859	0.614	rs4794874	ENSG00000263531.1	RP13-753N3.1	-9.06	3.49e-18	1.88e-15	-0.69	-0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30514300	chr17:30863921~30864940:-
THCA	cis	rs11971779	0.715	rs7787398	ENSG00000273391.1	RP11-634H22.1	9.06	3.5e-18	1.88e-15	0.37	0.39	Diisocyanate-induced asthma;	chr7:139377100	chr7:139359032~139359566:-
THCA	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	9.06	3.51e-18	1.89e-15	0.45	0.39	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
THCA	cis	rs9322193	0.962	rs9689447	ENSG00000268592.3	RAET1E-AS1	9.06	3.52e-18	1.89e-15	0.51	0.39	Lung cancer;	chr6:149789350	chr6:149863494~149919507:+
THCA	cis	rs11971779	0.68	rs66491565	ENSG00000273391.1	RP11-634H22.1	9.06	3.52e-18	1.9e-15	0.37	0.39	Diisocyanate-induced asthma;	chr7:139404231	chr7:139359032~139359566:-
THCA	cis	rs1062177	1	rs2915877	ENSG00000253921.1	CTB-113P19.3	-9.06	3.54e-18	1.9e-15	-0.47	-0.39	Preschool internalizing problems;	chr5:151771040	chr5:151753992~151767247:+
THCA	cis	rs1062177	1	rs2964576	ENSG00000253921.1	CTB-113P19.3	-9.06	3.54e-18	1.9e-15	-0.47	-0.39	Preschool internalizing problems;	chr5:151771041	chr5:151753992~151767247:+
THCA	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-9.06	3.55e-18	1.91e-15	-0.48	-0.39	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
THCA	cis	rs2243480	1	rs937108	ENSG00000273142.1	RP11-458F8.4	-9.06	3.56e-18	1.92e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65963465	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-9.06	3.56e-18	1.92e-15	-0.78	-0.39	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
THCA	cis	rs66887589	0.807	rs9799664	ENSG00000245958.5	RP11-33B1.1	-9.06	3.57e-18	1.92e-15	-0.34	-0.39	Diastolic blood pressure;	chr4:119405523	chr4:119454791~119552025:+
THCA	cis	rs947583	0.517	rs7764412	ENSG00000231028.7	LINC00271	-9.06	3.57e-18	1.92e-15	-0.29	-0.39	Phosphorus levels;	chr6:135787214	chr6:135497801~135716055:+
THCA	cis	rs10463554	0.892	rs1561404	ENSG00000175749.11	EIF3KP1	9.06	3.59e-18	1.93e-15	0.51	0.39	Parkinson's disease;	chr5:102963647	chr5:103032376~103033031:+
THCA	cis	rs9322193	0.962	rs4869730	ENSG00000268592.3	RAET1E-AS1	9.06	3.6e-18	1.94e-15	0.52	0.39	Lung cancer;	chr6:149808187	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs2151913	ENSG00000268592.3	RAET1E-AS1	9.06	3.6e-18	1.94e-15	0.52	0.39	Lung cancer;	chr6:149809506	chr6:149863494~149919507:+
THCA	cis	rs2033711	0.837	rs3764535	ENSG00000268912.1	CTD-2619J13.17	-9.06	3.61e-18	1.94e-15	-0.29	-0.39	Uric acid clearance;	chr19:58417685	chr19:58428632~58431148:-
THCA	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	9.06	3.63e-18	1.95e-15	0.58	0.39	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
THCA	cis	rs9322193	0.887	rs11155662	ENSG00000268592.3	RAET1E-AS1	9.06	3.64e-18	1.96e-15	0.54	0.39	Lung cancer;	chr6:149592731	chr6:149863494~149919507:+
THCA	cis	rs950169	0.58	rs4603535	ENSG00000259728.4	LINC00933	9.06	3.64e-18	1.96e-15	0.53	0.39	Schizophrenia;	chr15:84630641	chr15:84570649~84580175:+
THCA	cis	rs853679	0.517	rs9283884	ENSG00000226314.6	ZNF192P1	9.06	3.64e-18	1.96e-15	0.52	0.39	Depression;	chr6:28167882	chr6:28161781~28169594:+
THCA	cis	rs848490	0.508	rs6975810	ENSG00000214293.7	APTR	9.06	3.65e-18	1.96e-15	0.27	0.39	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77659701	chr7:77657660~77696265:-
THCA	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-9.06	3.65e-18	1.96e-15	-0.77	-0.39	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
THCA	cis	rs494459	0.536	rs57719838	ENSG00000278376.1	RP11-158I9.8	-9.06	3.66e-18	1.96e-15	-0.28	-0.39	Height;	chr11:118854014	chr11:118791254~118793137:+
THCA	cis	rs8062405	0.755	rs62034358	ENSG00000251417.2	RP11-1348G14.4	-9.05	3.66e-18	1.97e-15	-0.39	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.755	rs12445823	ENSG00000251417.2	RP11-1348G14.4	-9.05	3.66e-18	1.97e-15	-0.39	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28802743~28817828:+
THCA	cis	rs860295	0.871	rs34632540	ENSG00000225855.5	RUSC1-AS1	-9.05	3.67e-18	1.97e-15	-0.26	-0.39	Body mass index;	chr1:155642406	chr1:155316863~155324176:-
THCA	cis	rs950169	0.58	rs11630887	ENSG00000259728.4	LINC00933	9.05	3.68e-18	1.98e-15	0.52	0.39	Schizophrenia;	chr15:84649784	chr15:84570649~84580175:+
THCA	cis	rs17684571	0.7	rs13220851	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56796753	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs59432342	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56797506	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs34171958	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56800000	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13201733	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56804226	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs17684730	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56804425	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs4371846	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56805767	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs17684748	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56809419	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs17751977	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56809820	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs17684772	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56810415	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs17752002	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56812209	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs4299824	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56815697	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs13200166	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56816414	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs17752046	ENSG00000231441.1	RP11-472M19.2	9.05	3.68e-18	1.98e-15	0.49	0.39	Schizophrenia;	chr6:56816550	chr6:56844002~56864078:+
THCA	cis	rs860295	0.557	rs10796944	ENSG00000225855.5	RUSC1-AS1	9.05	3.69e-18	1.98e-15	0.3	0.39	Body mass index;	chr1:155446537	chr1:155316863~155324176:-
THCA	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-9.05	3.69e-18	1.98e-15	-0.76	-0.39	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
THCA	cis	rs1858037	0.867	rs871974	ENSG00000281920.1	RP11-418H16.1	-9.05	3.69e-18	1.98e-15	-0.51	-0.39	Rheumatoid arthritis;	chr2:65330153	chr2:65623272~65628424:+
THCA	cis	rs36229146	1	rs36229146	ENSG00000179428.2	AC073072.5	-9.05	3.73e-18	2e-15	-0.5	-0.39	Eosinophil percentage of granulocytes;Eosinophil counts;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;	chr7:22744893	chr7:22725395~22727620:-
THCA	cis	rs9543976	1	rs9543976	ENSG00000261553.4	RP11-29G8.3	9.05	3.74e-18	2.01e-15	0.48	0.39	Diabetic retinopathy;	chr13:75562512	chr13:75549773~75807120:+
THCA	cis	rs1062177	1	rs17804178	ENSG00000253921.1	CTB-113P19.3	-9.05	3.75e-18	2.01e-15	-0.47	-0.39	Preschool internalizing problems;	chr5:151818168	chr5:151753992~151767247:+
THCA	cis	rs1062177	1	rs2964612	ENSG00000253921.1	CTB-113P19.3	-9.05	3.75e-18	2.01e-15	-0.47	-0.39	Preschool internalizing problems;	chr5:151819189	chr5:151753992~151767247:+
THCA	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	9.05	3.76e-18	2.02e-15	0.46	0.39	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	9.05	3.76e-18	2.02e-15	0.46	0.39	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
THCA	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	9.05	3.76e-18	2.02e-15	0.46	0.39	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
THCA	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	9.05	3.76e-18	2.02e-15	0.48	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
THCA	cis	rs875971	0.66	rs2013222	ENSG00000237310.1	GS1-124K5.4	-9.05	3.77e-18	2.02e-15	-0.28	-0.39	Aortic root size;	chr7:66570949	chr7:66493706~66495474:+
THCA	cis	rs1799949	0.55	rs2343818	ENSG00000267681.1	CTD-3199J23.6	-9.05	3.79e-18	2.03e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43332406	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.526	rs4352088	ENSG00000267681.1	CTD-3199J23.6	-9.05	3.79e-18	2.03e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43337311	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs34633610	ENSG00000267681.1	CTD-3199J23.6	-9.05	3.79e-18	2.03e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43342017	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs11654051	ENSG00000267681.1	CTD-3199J23.6	-9.05	3.79e-18	2.03e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43342288	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.93	rs56729776	ENSG00000267681.1	CTD-3199J23.6	-9.05	3.79e-18	2.03e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43344763	chr17:43144956~43145255:+
THCA	cis	rs11971779	0.648	rs6467852	ENSG00000273391.1	RP11-634H22.1	9.05	3.79e-18	2.03e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139427845	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.616	rs7779314	ENSG00000273391.1	RP11-634H22.1	9.05	3.79e-18	2.03e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139427950	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs7779390	ENSG00000273391.1	RP11-634H22.1	9.05	3.79e-18	2.03e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139428207	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.584	rs34762928	ENSG00000273391.1	RP11-634H22.1	9.05	3.79e-18	2.03e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139428422	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.68	rs11760420	ENSG00000273391.1	RP11-634H22.1	9.05	3.79e-18	2.03e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139430022	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.553	rs10228643	ENSG00000273391.1	RP11-634H22.1	9.05	3.79e-18	2.03e-15	0.36	0.39	Diisocyanate-induced asthma;	chr7:139430674	chr7:139359032~139359566:-
THCA	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	9.05	3.79e-18	2.03e-15	0.58	0.39	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
THCA	cis	rs11971779	0.68	rs4728465	ENSG00000273391.1	RP11-634H22.1	9.05	3.8e-18	2.04e-15	0.37	0.39	Diisocyanate-induced asthma;	chr7:139384315	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs55714903	ENSG00000273391.1	RP11-634H22.1	9.05	3.8e-18	2.04e-15	0.37	0.39	Diisocyanate-induced asthma;	chr7:139389844	chr7:139359032~139359566:-
THCA	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-9.05	3.8e-18	2.04e-15	-0.4	-0.39	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
THCA	cis	rs1707322	0.685	rs11211177	ENSG00000234329.1	RP11-767N6.2	9.05	3.8e-18	2.04e-15	0.36	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45651039~45651826:-
THCA	cis	rs9322193	1	rs9377228	ENSG00000268592.3	RAET1E-AS1	9.05	3.82e-18	2.05e-15	0.52	0.39	Lung cancer;	chr6:149600862	chr6:149863494~149919507:+
THCA	cis	rs8062405	0.755	rs4788073	ENSG00000251417.2	RP11-1348G14.4	-9.05	3.83e-18	2.06e-15	-0.39	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28802743~28817828:+
THCA	cis	rs9322193	0.962	rs3763163	ENSG00000268592.3	RAET1E-AS1	9.05	3.83e-18	2.06e-15	0.51	0.39	Lung cancer;	chr6:149819770	chr6:149863494~149919507:+
THCA	cis	rs673078	0.607	rs73207564	ENSG00000275409.1	RP11-131L12.4	-9.05	3.84e-18	2.06e-15	-0.47	-0.39	Glucose homeostasis traits;	chr12:118429566	chr12:118430147~118430699:+
THCA	cis	rs1799949	0.965	rs7223952	ENSG00000267681.1	CTD-3199J23.6	-9.05	3.84e-18	2.06e-15	-0.45	-0.39	Menopause (age at onset);	chr17:43042868	chr17:43144956~43145255:+
THCA	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	9.05	3.85e-18	2.06e-15	0.58	0.39	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
THCA	cis	rs947583	0.517	rs9402757	ENSG00000231028.7	LINC00271	9.05	3.85e-18	2.07e-15	0.29	0.39	Phosphorus levels;	chr6:135799947	chr6:135497801~135716055:+
THCA	cis	rs4713118	0.662	rs149901	ENSG00000280107.1	AL022393.9	-9.05	3.85e-18	2.07e-15	-0.43	-0.39	Parkinson's disease;	chr6:27997725	chr6:28170845~28172521:+
THCA	cis	rs7665090	0.806	rs7674004	ENSG00000246560.2	RP11-10L12.4	9.05	3.86e-18	2.07e-15	0.46	0.39	Primary biliary cholangitis;	chr4:102619156	chr4:102828055~102844075:+
THCA	cis	rs950169	0.58	rs17598114	ENSG00000259728.4	LINC00933	9.05	3.87e-18	2.07e-15	0.53	0.39	Schizophrenia;	chr15:84628086	chr15:84570649~84580175:+
THCA	cis	rs950169	0.58	rs11634322	ENSG00000259728.4	LINC00933	9.05	3.87e-18	2.07e-15	0.53	0.39	Schizophrenia;	chr15:84628978	chr15:84570649~84580175:+
THCA	cis	rs2243480	1	rs12698509	ENSG00000273142.1	RP11-458F8.4	-9.05	3.87e-18	2.07e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:65953889	chr7:66902857~66906297:+
THCA	cis	rs7772486	0.84	rs2814864	ENSG00000235652.6	RP11-545I5.3	9.05	3.87e-18	2.07e-15	0.36	0.39	Lobe attachment (rater-scored or self-reported);	chr6:146023910	chr6:145799409~145886585:+
THCA	cis	rs812925	0.512	rs7558954	ENSG00000271889.1	RP11-493E12.1	9.05	3.88e-18	2.08e-15	0.37	0.39	Immature fraction of reticulocytes;	chr2:61157771	chr2:61151433~61162105:-
THCA	cis	rs812925	0.553	rs1177307	ENSG00000271889.1	RP11-493E12.1	9.05	3.88e-18	2.08e-15	0.37	0.39	Immature fraction of reticulocytes;	chr2:61160253	chr2:61151433~61162105:-
THCA	cis	rs812925	0.512	rs1729674	ENSG00000271889.1	RP11-493E12.1	9.05	3.88e-18	2.08e-15	0.37	0.39	Immature fraction of reticulocytes;	chr2:61162602	chr2:61151433~61162105:-
THCA	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-9.05	3.88e-18	2.08e-15	-0.3	-0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
THCA	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	9.05	3.89e-18	2.09e-15	0.39	0.39	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
THCA	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	9.05	3.9e-18	2.09e-15	0.78	0.39	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	9.05	3.9e-18	2.09e-15	0.78	0.39	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
THCA	cis	rs4819052	1	rs28628220	ENSG00000215447.6	BX322557.10	-9.05	3.9e-18	2.09e-15	-0.35	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45288052~45291738:+
THCA	cis	rs4819052	1	rs2838830	ENSG00000215447.6	BX322557.10	-9.05	3.9e-18	2.09e-15	-0.35	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45288052~45291738:+
THCA	cis	rs2033711	0.728	rs4801586	ENSG00000268912.1	CTD-2619J13.17	-9.05	3.9e-18	2.09e-15	-0.3	-0.39	Uric acid clearance;	chr19:58423161	chr19:58428632~58431148:-
THCA	cis	rs875971	0.638	rs6960778	ENSG00000237310.1	GS1-124K5.4	-9.05	3.91e-18	2.09e-15	-0.28	-0.39	Aortic root size;	chr7:66606610	chr7:66493706~66495474:+
THCA	cis	rs10411161	0.702	rs8110531	ENSG00000269483.1	AC006272.1	9.05	3.92e-18	2.1e-15	0.54	0.39	Breast cancer;	chr19:51880257	chr19:51839924~51843324:-
THCA	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	9.05	3.92e-18	2.1e-15	0.58	0.39	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
THCA	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	9.05	3.92e-18	2.1e-15	0.65	0.39	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
THCA	cis	rs7829975	0.533	rs1039917	ENSG00000253893.2	FAM85B	-9.05	3.93e-18	2.11e-15	-0.5	-0.39	Mood instability;	chr8:8861340	chr8:8167819~8226614:-
THCA	cis	rs6496932	0.866	rs4842870	ENSG00000218052.5	ADAMTS7P4	9.05	3.95e-18	2.11e-15	0.54	0.39	Central corneal thickness;Corneal structure;	chr15:85277568	chr15:85255369~85330334:-
THCA	cis	rs66887589	0.837	rs7661498	ENSG00000245958.5	RP11-33B1.1	-9.04	3.95e-18	2.12e-15	-0.34	-0.39	Diastolic blood pressure;	chr4:119486953	chr4:119454791~119552025:+
THCA	cis	rs2243480	1	rs316322	ENSG00000273142.1	RP11-458F8.4	-9.04	3.98e-18	2.13e-15	-0.48	-0.39	Diabetic kidney disease;	chr7:66146246	chr7:66902857~66906297:+
THCA	cis	rs367615	0.66	rs10061221	ENSG00000249476.1	CTD-2587M2.1	9.04	3.98e-18	2.13e-15	0.41	0.39	Colorectal cancer (SNP x SNP interaction);	chr5:109503337	chr5:109237120~109326369:-
THCA	cis	rs4819052	0.851	rs2236445	ENSG00000215447.6	BX322557.10	-9.04	3.98e-18	2.13e-15	-0.32	-0.39	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45288052~45291738:+
THCA	cis	rs1062177	1	rs2915887	ENSG00000253921.1	CTB-113P19.3	-9.04	3.98e-18	2.13e-15	-0.47	-0.39	Preschool internalizing problems;	chr5:151825943	chr5:151753992~151767247:+
THCA	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	9.04	3.99e-18	2.14e-15	0.58	0.39	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	9.04	3.99e-18	2.14e-15	0.58	0.39	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	9.04	3.99e-18	2.14e-15	0.58	0.39	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
THCA	cis	rs12908161	0.959	rs2175567	ENSG00000259728.4	LINC00933	9.04	3.99e-18	2.14e-15	0.53	0.39	Schizophrenia;	chr15:84657715	chr15:84570649~84580175:+
THCA	cis	rs2033711	0.783	rs8113810	ENSG00000268912.1	CTD-2619J13.17	-9.04	3.99e-18	2.14e-15	-0.3	-0.39	Uric acid clearance;	chr19:58420739	chr19:58428632~58431148:-
THCA	cis	rs2033711	0.87	rs4801270	ENSG00000268912.1	CTD-2619J13.17	-9.04	3.99e-18	2.14e-15	-0.3	-0.39	Uric acid clearance;	chr19:58421395	chr19:58428632~58431148:-
THCA	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	9.04	4.01e-18	2.15e-15	0.58	0.38	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
THCA	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-9.04	4.02e-18	2.15e-15	-0.46	-0.38	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
THCA	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-9.04	4.02e-18	2.15e-15	-0.76	-0.38	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-9.04	4.02e-18	2.15e-15	-0.76	-0.38	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
THCA	cis	rs10463554	0.856	rs26260	ENSG00000175749.11	EIF3KP1	9.04	4.07e-18	2.18e-15	0.48	0.38	Parkinson's disease;	chr5:103211493	chr5:103032376~103033031:+
THCA	cis	rs3813579	0.606	rs3813583	ENSG00000261390.4	RP11-345M22.2	-9.04	4.07e-18	2.18e-15	-0.43	-0.38	Thyroid volume;	chr16:79721183	chr16:79715232~79770563:-
THCA	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	9.04	4.08e-18	2.18e-15	0.58	0.38	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
THCA	cis	rs9322193	0.884	rs11155689	ENSG00000268592.3	RAET1E-AS1	9.04	4.08e-18	2.19e-15	0.51	0.38	Lung cancer;	chr6:149808470	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs933055	ENSG00000268592.3	RAET1E-AS1	9.04	4.08e-18	2.19e-15	0.51	0.38	Lung cancer;	chr6:149809701	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs4869731	ENSG00000268592.3	RAET1E-AS1	9.04	4.08e-18	2.19e-15	0.51	0.38	Lung cancer;	chr6:149810072	chr6:149863494~149919507:+
THCA	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	9.04	4.09e-18	2.19e-15	0.48	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
THCA	cis	rs7829975	0.511	rs2976902	ENSG00000253893.2	FAM85B	-9.04	4.09e-18	2.19e-15	-0.51	-0.38	Mood instability;	chr8:8483595	chr8:8167819~8226614:-
THCA	cis	rs9322193	0.923	rs2342857	ENSG00000268592.3	RAET1E-AS1	9.04	4.1e-18	2.19e-15	0.51	0.38	Lung cancer;	chr6:149809537	chr6:149863494~149919507:+
THCA	cis	rs4722166	0.63	rs6461667	ENSG00000179428.2	AC073072.5	-9.04	4.12e-18	2.2e-15	-0.5	-0.38	Lung cancer;	chr7:22757124	chr7:22725395~22727620:-
THCA	cis	rs7208859	0.623	rs79607958	ENSG00000266490.1	CTD-2349P21.9	9.04	4.12e-18	2.2e-15	0.54	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607530	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs75136574	ENSG00000266490.1	CTD-2349P21.9	9.04	4.12e-18	2.2e-15	0.54	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607531	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs77544470	ENSG00000266490.1	CTD-2349P21.9	9.04	4.12e-18	2.2e-15	0.54	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30607532	chr17:30792372~30792833:+
THCA	cis	rs2243480	0.901	rs778730	ENSG00000273142.1	RP11-458F8.4	-9.04	4.15e-18	2.22e-15	-0.49	-0.38	Diabetic kidney disease;	chr7:66358338	chr7:66902857~66906297:+
THCA	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	9.04	4.16e-18	2.23e-15	0.67	0.38	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
THCA	cis	rs494459	0.536	rs7103067	ENSG00000278376.1	RP11-158I9.8	-9.04	4.17e-18	2.23e-15	-0.28	-0.38	Height;	chr11:118852670	chr11:118791254~118793137:+
THCA	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	9.04	4.19e-18	2.24e-15	0.46	0.38	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
THCA	cis	rs11148252	0.74	rs9526914	ENSG00000278238.1	RP11-245D16.4	-9.04	4.22e-18	2.26e-15	-0.43	-0.38	Lewy body disease;	chr13:52402165	chr13:52454775~52455331:-
THCA	cis	rs375066	0.935	rs417699	ENSG00000267058.1	RP11-15A1.3	-9.04	4.23e-18	2.26e-15	-0.31	-0.38	Breast cancer;	chr19:43913423	chr19:43891804~43901805:-
THCA	cis	rs66887589	0.807	rs13134517	ENSG00000245958.5	RP11-33B1.1	-9.04	4.24e-18	2.26e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119484107	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.837	rs6534135	ENSG00000245958.5	RP11-33B1.1	-9.04	4.24e-18	2.26e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119485147	chr4:119454791~119552025:+
THCA	cis	rs1799949	0.965	rs9911630	ENSG00000267681.1	CTD-3199J23.6	-9.04	4.24e-18	2.27e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43036325	chr17:43144956~43145255:+
THCA	cis	rs4819052	0.918	rs2330013	ENSG00000215447.6	BX322557.10	-9.04	4.26e-18	2.28e-15	-0.35	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45288052~45291738:+
THCA	cis	rs4713118	0.786	rs200503	ENSG00000219392.1	RP1-265C24.5	-9.04	4.26e-18	2.28e-15	-0.51	-0.38	Parkinson's disease;	chr6:27818104	chr6:28115628~28116551:+
THCA	cis	rs2243480	0.901	rs313808	ENSG00000273142.1	RP11-458F8.4	-9.04	4.27e-18	2.28e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66034886	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-9.03	4.29e-18	2.29e-15	-0.77	-0.38	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	9.03	4.3e-18	2.3e-15	0.75	0.38	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
THCA	cis	rs4819052	1	rs733739	ENSG00000215447.6	BX322557.10	-9.03	4.33e-18	2.31e-15	-0.34	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45288052~45291738:+
THCA	cis	rs6496932	0.913	rs34896088	ENSG00000218052.5	ADAMTS7P4	9.03	4.33e-18	2.32e-15	0.54	0.38	Central corneal thickness;Corneal structure;	chr15:85278393	chr15:85255369~85330334:-
THCA	cis	rs10463554	0.895	rs3756583	ENSG00000175749.11	EIF3KP1	9.03	4.35e-18	2.32e-15	0.48	0.38	Parkinson's disease;	chr5:102998340	chr5:103032376~103033031:+
THCA	cis	rs673078	0.607	rs61943447	ENSG00000275409.1	RP11-131L12.4	-9.03	4.37e-18	2.33e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118430598	chr12:118430147~118430699:+
THCA	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	9.03	4.37e-18	2.33e-15	0.52	0.38	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
THCA	cis	rs10411161	0.702	rs8110546	ENSG00000269483.1	AC006272.1	9.03	4.37e-18	2.33e-15	0.54	0.38	Breast cancer;	chr19:51880303	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs8110461	ENSG00000269483.1	AC006272.1	9.03	4.37e-18	2.33e-15	0.54	0.38	Breast cancer;	chr19:51880316	chr19:51839924~51843324:-
THCA	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	9.03	4.37e-18	2.33e-15	0.45	0.38	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
THCA	cis	rs944289	0.774	rs1958623	ENSG00000257826.1	RP11-116N8.4	-9.03	4.37e-18	2.34e-15	-0.4	-0.38	Thyroid cancer;	chr14:36128417	chr14:36061026~36067190:-
THCA	cis	rs947583	0.517	rs9494390	ENSG00000231028.7	LINC00271	-9.03	4.38e-18	2.34e-15	-0.29	-0.38	Phosphorus levels;	chr6:135794875	chr6:135497801~135716055:+
THCA	cis	rs7727544	0.617	rs3843503	ENSG00000237714.1	P4HA2-AS1	9.03	4.38e-18	2.34e-15	0.51	0.38	Blood metabolite levels;	chr5:132130936	chr5:132184876~132192808:+
THCA	cis	rs524281	0.731	rs3829937	ENSG00000255320.1	RP11-755F10.1	9.03	4.4e-18	2.35e-15	0.61	0.38	Electroencephalogram traits;	chr11:66020195	chr11:66244840~66246239:-
THCA	cis	rs66887589	0.774	rs9307477	ENSG00000245958.5	RP11-33B1.1	-9.03	4.41e-18	2.35e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119500654	chr4:119454791~119552025:+
THCA	cis	rs7189233	0.531	rs9932007	ENSG00000279344.1	RP11-44F14.7	9.03	4.42e-18	2.36e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr16:53422749	chr16:53478957~53481550:-
THCA	cis	rs2243480	0.708	rs781141	ENSG00000273142.1	RP11-458F8.4	-9.03	4.42e-18	2.36e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65973566	chr7:66902857~66906297:+
THCA	cis	rs944289	0.774	rs1958625	ENSG00000257826.1	RP11-116N8.4	-9.03	4.43e-18	2.36e-15	-0.41	-0.38	Thyroid cancer;	chr14:36133470	chr14:36061026~36067190:-
THCA	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-9.03	4.43e-18	2.36e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
THCA	cis	rs11971779	0.68	rs7805767	ENSG00000273391.1	RP11-634H22.1	9.03	4.45e-18	2.37e-15	0.36	0.38	Diisocyanate-induced asthma;	chr7:139426669	chr7:139359032~139359566:-
THCA	cis	rs9322193	0.962	rs4870048	ENSG00000268592.3	RAET1E-AS1	9.03	4.45e-18	2.37e-15	0.52	0.38	Lung cancer;	chr6:149834324	chr6:149863494~149919507:+
THCA	cis	rs11051970	0.559	rs56670459	ENSG00000274964.1	RP11-817I4.1	-9.03	4.46e-18	2.38e-15	-0.53	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32390391	chr12:32339368~32340724:+
THCA	cis	rs875971	0.666	rs13242072	ENSG00000237310.1	GS1-124K5.4	-9.03	4.47e-18	2.39e-15	-0.28	-0.38	Aortic root size;	chr7:66301001	chr7:66493706~66495474:+
THCA	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-9.03	4.53e-18	2.42e-15	-0.4	-0.38	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
THCA	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-9.03	4.54e-18	2.42e-15	-0.66	-0.38	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
THCA	cis	rs2243480	1	rs35542501	ENSG00000273142.1	RP11-458F8.4	-9.03	4.56e-18	2.43e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65966228	chr7:66902857~66906297:+
THCA	cis	rs8027521	0.521	rs11629463	ENSG00000280362.1	RP11-643A5.3	-9.03	4.56e-18	2.43e-15	-0.54	-0.38	Circulating chemerin levels;	chr15:53941503	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.502	rs11629468	ENSG00000280362.1	RP11-643A5.3	-9.03	4.56e-18	2.43e-15	-0.54	-0.38	Circulating chemerin levels;	chr15:53941519	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.502	rs7183339	ENSG00000280362.1	RP11-643A5.3	-9.03	4.56e-18	2.43e-15	-0.54	-0.38	Circulating chemerin levels;	chr15:53941796	chr15:53910769~53914712:+
THCA	cis	rs2243480	0.711	rs2460426	ENSG00000273142.1	RP11-458F8.4	9.03	4.58e-18	2.44e-15	0.48	0.38	Diabetic kidney disease;	chr7:66158142	chr7:66902857~66906297:+
THCA	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	9.03	4.6e-18	2.45e-15	0.46	0.38	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	9.03	4.6e-18	2.45e-15	0.46	0.38	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
THCA	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	9.03	4.6e-18	2.45e-15	0.46	0.38	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
THCA	cis	rs10266483	0.96	rs13221291	ENSG00000227986.1	TRIM60P18	-9.03	4.6e-18	2.45e-15	-0.3	-0.38	Response to statin therapy;	chr7:64279114	chr7:64355078~64356199:+
THCA	cis	rs490608	0.628	rs678157	ENSG00000225855.5	RUSC1-AS1	9.02	4.63e-18	2.47e-15	0.28	0.38	Inflammatory bowel disease;	chr1:155688550	chr1:155316863~155324176:-
THCA	cis	rs131777	0.577	rs131748	ENSG00000205559.3	CHKB-AS1	9.02	4.63e-18	2.47e-15	0.46	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586408	chr22:50583026~50583877:+
THCA	cis	rs10740039	0.81	rs10159646	ENSG00000254271.1	RP11-131N11.4	9.02	4.63e-18	2.47e-15	0.49	0.38	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60620366	chr10:60734342~60741828:+
THCA	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	9.02	4.63e-18	2.47e-15	0.4	0.38	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
THCA	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	9.02	4.64e-18	2.47e-15	0.27	0.38	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs6958520	ENSG00000237310.1	GS1-124K5.4	9.02	4.64e-18	2.47e-15	0.27	0.38	Aortic root size;	chr7:66686466	chr7:66493706~66495474:+
THCA	cis	rs801193	0.967	rs2707849	ENSG00000237310.1	GS1-124K5.4	9.02	4.64e-18	2.47e-15	0.27	0.38	Aortic root size;	chr7:66687725	chr7:66493706~66495474:+
THCA	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs6975195	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66659787	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs3857688	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66662819	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs2286684	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66664843	chr7:66493706~66495474:+
THCA	cis	rs801193	0.935	rs2286683	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66664856	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs10274773	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66668591	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs11773829	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66676087	chr7:66493706~66495474:+
THCA	cis	rs801193	1	rs7788576	ENSG00000237310.1	GS1-124K5.4	-9.02	4.64e-18	2.47e-15	-0.27	-0.38	Aortic root size;	chr7:66683315	chr7:66493706~66495474:+
THCA	cis	rs2243480	1	rs465359	ENSG00000273142.1	RP11-458F8.4	-9.02	4.65e-18	2.48e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66093177	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs462853	ENSG00000273142.1	RP11-458F8.4	-9.02	4.65e-18	2.48e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66093180	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs160642	ENSG00000273142.1	RP11-458F8.4	-9.02	4.65e-18	2.48e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66093386	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.614	rs34032527	ENSG00000273142.1	RP11-458F8.4	-9.02	4.65e-18	2.48e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66100154	chr7:66902857~66906297:+
THCA	cis	rs8091660	0.929	rs12456253	ENSG00000278983.1	RP11-426J5.3	-9.02	4.67e-18	2.49e-15	-0.49	-0.38	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550603	chr18:48564795~48568342:+
THCA	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-9.02	4.68e-18	2.49e-15	-0.5	-0.38	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
THCA	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-9.02	4.68e-18	2.49e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000224205.1	AP000351.4	9.02	4.68e-18	2.49e-15	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23987320~23991421:-
THCA	cis	rs4722166	0.603	rs7801406	ENSG00000179428.2	AC073072.5	-9.02	4.7e-18	2.51e-15	-0.5	-0.38	Lung cancer;	chr7:22748655	chr7:22725395~22727620:-
THCA	cis	rs17772222	0.63	rs816069	ENSG00000258789.1	RP11-507K2.3	9.02	4.7e-18	2.51e-15	0.37	0.38	Coronary artery calcification;	chr14:88500992	chr14:88551597~88552493:+
THCA	cis	rs947583	0.517	rs4895457	ENSG00000231028.7	LINC00271	-9.02	4.72e-18	2.51e-15	-0.29	-0.38	Phosphorus levels;	chr6:135783172	chr6:135497801~135716055:+
THCA	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	9.02	4.72e-18	2.51e-15	0.46	0.38	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.857	rs9608229	ENSG00000099984.9	GSTT2	-9.02	4.73e-18	2.52e-15	-0.48	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24002918	chr22:23980123~23983911:+
THCA	cis	rs1061377	0.965	rs12504238	ENSG00000249685.1	RP11-360F5.3	9.02	4.73e-18	2.52e-15	0.48	0.38	Uric acid levels;	chr4:39142824	chr4:39133913~39135608:+
THCA	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-9.02	4.73e-18	2.52e-15	-0.5	-0.38	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
THCA	cis	rs9322193	0.566	rs5024811	ENSG00000268592.3	RAET1E-AS1	-9.02	4.74e-18	2.53e-15	-0.56	-0.38	Lung cancer;	chr6:149924898	chr6:149863494~149919507:+
THCA	cis	rs9640161	0.789	rs3735174	ENSG00000261305.1	RP4-584D14.7	9.02	4.76e-18	2.54e-15	0.45	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150323400	chr7:150341771~150342607:+
THCA	cis	rs2243480	1	rs160646	ENSG00000273142.1	RP11-458F8.4	-9.02	4.76e-18	2.54e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66091293	chr7:66902857~66906297:+
THCA	cis	rs7221109	0.522	rs2462970	ENSG00000278834.1	RP11-458J1.1	-9.02	4.76e-18	2.54e-15	-0.4	-0.38	Type 1 diabetes;	chr17:40714797	chr17:40648300~40649718:+
THCA	cis	rs673078	0.607	rs17512644	ENSG00000275409.1	RP11-131L12.4	-9.02	4.77e-18	2.54e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118359963	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17512652	ENSG00000275409.1	RP11-131L12.4	-9.02	4.77e-18	2.54e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118361278	chr12:118430147~118430699:+
THCA	cis	rs2288884	0.731	rs11673450	ENSG00000275055.1	CTC-471J1.11	-9.02	4.77e-18	2.54e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037441	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.731	rs11673398	ENSG00000275055.1	CTC-471J1.11	-9.02	4.77e-18	2.54e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52037444	chr19:52049007~52049754:+
THCA	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	9.02	4.78e-18	2.54e-15	0.76	0.38	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
THCA	cis	rs1075265	0.73	rs4413193	ENSG00000233266.1	HMGB1P31	9.02	4.78e-18	2.54e-15	0.48	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54051334~54051760:+
THCA	cis	rs1707322	0.752	rs4660313	ENSG00000234329.1	RP11-767N6.2	-9.02	4.78e-18	2.55e-15	-0.37	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45651039~45651826:-
THCA	cis	rs2243480	1	rs778729	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66359432	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs778687	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66370832	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs778679	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66375924	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs778704	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66398480	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs778693	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66407358	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs778691	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66408105	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs13235972	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66418618	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs34192067	ENSG00000273142.1	RP11-458F8.4	-9.02	4.8e-18	2.55e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66422670	chr7:66902857~66906297:+
THCA	cis	rs10510102	0.688	rs56094144	ENSG00000276742.1	RP11-500G22.4	9.02	4.8e-18	2.56e-15	0.58	0.38	Breast cancer;	chr10:121903941	chr10:121956782~121957098:+
THCA	cis	rs9532669	0.926	rs9532693	ENSG00000239827.7	SUGT1P3	-9.02	4.84e-18	2.58e-15	-0.41	-0.38	Cervical cancer;	chr13:40980557	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.887	rs3734295	ENSG00000216906.2	RP11-350J20.9	9.02	4.85e-18	2.58e-15	0.46	0.38	Lung cancer;	chr6:149593917	chr6:149904243~149906418:+
THCA	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-9.02	4.86e-18	2.59e-15	-0.79	-0.38	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
THCA	cis	rs673078	0.66	rs17440433	ENSG00000275409.1	RP11-131L12.4	-9.02	4.86e-18	2.59e-15	-0.5	-0.38	Glucose homeostasis traits;	chr12:118201507	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs17512219	ENSG00000275409.1	RP11-131L12.4	-9.02	4.86e-18	2.59e-15	-0.5	-0.38	Glucose homeostasis traits;	chr12:118211468	chr12:118430147~118430699:+
THCA	cis	rs17684571	0.751	rs10498812	ENSG00000231441.1	RP11-472M19.2	9.02	4.86e-18	2.59e-15	0.53	0.38	Schizophrenia;	chr6:56819412	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs13220628	ENSG00000231441.1	RP11-472M19.2	9.02	4.86e-18	2.59e-15	0.53	0.38	Schizophrenia;	chr6:56819445	chr6:56844002~56864078:+
THCA	cis	rs8062405	0.755	rs55792032	ENSG00000251417.2	RP11-1348G14.4	-9.02	4.88e-18	2.6e-15	-0.39	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28802743~28817828:+
THCA	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-9.02	4.92e-18	2.62e-15	-0.51	-0.38	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000224205.1	AP000351.4	9.02	4.93e-18	2.62e-15	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23987320~23991421:-
THCA	cis	rs4722166	0.63	rs10950916	ENSG00000179428.2	AC073072.5	-9.02	4.95e-18	2.63e-15	-0.5	-0.38	Lung cancer;	chr7:22760048	chr7:22725395~22727620:-
THCA	cis	rs71403859	0.502	rs34015581	ENSG00000260886.1	TAT-AS1	9.02	4.95e-18	2.63e-15	0.67	0.38	Post bronchodilator FEV1;	chr16:71474326	chr16:71565789~71578187:+
THCA	cis	rs10463554	0.892	rs72783889	ENSG00000175749.11	EIF3KP1	9.02	4.95e-18	2.63e-15	0.51	0.38	Parkinson's disease;	chr5:102938835	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs72783890	ENSG00000175749.11	EIF3KP1	9.02	4.95e-18	2.63e-15	0.51	0.38	Parkinson's disease;	chr5:102938836	chr5:103032376~103033031:+
THCA	cis	rs12188164	0.502	rs55929184	ENSG00000221990.4	EXOC3-AS1	9.02	4.97e-18	2.64e-15	0.33	0.38	Cystic fibrosis severity;	chr5:405461	chr5:441498~443160:-
THCA	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-9.01	5.01e-18	2.66e-15	-0.4	-0.38	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
THCA	cis	rs7015263	0.535	rs55754530	ENSG00000254231.1	CTD-2284J15.1	-9.01	5.01e-18	2.66e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86361976	chr8:86333274~86343314:-
THCA	cis	rs9322193	0.887	rs11155662	ENSG00000216906.2	RP11-350J20.9	9.01	5.02e-18	2.67e-15	0.47	0.38	Lung cancer;	chr6:149592731	chr6:149904243~149906418:+
THCA	cis	rs6600671	0.691	rs6600662	ENSG00000223345.3	HIST2H2BA	9.01	5.03e-18	2.68e-15	0.44	0.38	Hip geometry;	chr1:121488992	chr1:121108210~121117257:-
THCA	cis	rs11051970	0.527	rs7313432	ENSG00000274964.1	RP11-817I4.1	-9.01	5.04e-18	2.68e-15	-0.5	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32419335	chr12:32339368~32340724:+
THCA	cis	rs673078	0.66	rs7973455	ENSG00000275409.1	RP11-131L12.4	-9.01	5.04e-18	2.68e-15	-0.5	-0.38	Glucose homeostasis traits;	chr12:118247490	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.962	rs3805753	ENSG00000268592.3	RAET1E-AS1	9.01	5.05e-18	2.68e-15	0.51	0.38	Lung cancer;	chr6:149795662	chr6:149863494~149919507:+
THCA	cis	rs801193	1	rs2659912	ENSG00000237310.1	GS1-124K5.4	9.01	5.05e-18	2.68e-15	0.27	0.38	Aortic root size;	chr7:66693012	chr7:66493706~66495474:+
THCA	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-9.01	5.05e-18	2.68e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
THCA	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	9.01	5.05e-18	2.68e-15	0.46	0.38	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
THCA	cis	rs673078	0.607	rs73207578	ENSG00000275409.1	RP11-131L12.4	-9.01	5.06e-18	2.69e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447080	chr12:118430147~118430699:+
THCA	cis	rs7569084	0.663	rs6546150	ENSG00000234255.7	AC012370.3	-9.01	5.06e-18	2.69e-15	-0.44	-0.38	Sum eosinophil basophil counts;	chr2:65415066	chr2:65439888~65456571:-
THCA	cis	rs9322193	0.962	rs9688412	ENSG00000268592.3	RAET1E-AS1	-9.01	5.07e-18	2.69e-15	-0.51	-0.38	Lung cancer;	chr6:149803147	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs11155683	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149779341	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs9372044	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149780867	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs11155685	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149781649	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs9689269	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149791861	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs62441335	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149792658	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs4816	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149793609	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.926	rs952166	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149798774	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs952165	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149798900	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.926	rs9285525	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149801253	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs2342858	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149805967	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs6914319	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149806304	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs2095375	ENSG00000268592.3	RAET1E-AS1	9.01	5.07e-18	2.69e-15	0.51	0.38	Lung cancer;	chr6:149807037	chr6:149863494~149919507:+
THCA	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	9.01	5.08e-18	2.7e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
THCA	cis	rs733592	0.931	rs765260	ENSG00000240399.1	RP1-228P16.1	-9.01	5.09e-18	2.71e-15	-0.36	-0.38	Plateletcrit;	chr12:48038153	chr12:48054813~48055591:-
THCA	cis	rs10463554	0.856	rs257292	ENSG00000175749.11	EIF3KP1	9.01	5.1e-18	2.71e-15	0.48	0.38	Parkinson's disease;	chr5:103159047	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.856	rs257293	ENSG00000175749.11	EIF3KP1	9.01	5.1e-18	2.71e-15	0.48	0.38	Parkinson's disease;	chr5:103159824	chr5:103032376~103033031:+
THCA	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	9.01	5.13e-18	2.72e-15	0.4	0.38	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
THCA	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	9.01	5.14e-18	2.73e-15	0.46	0.38	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
THCA	cis	rs1707322	0.752	rs7541962	ENSG00000234329.1	RP11-767N6.2	9.01	5.17e-18	2.74e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45651039~45651826:-
THCA	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	9.01	5.18e-18	2.75e-15	0.45	0.38	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
THCA	cis	rs9532669	0.963	rs9532662	ENSG00000239827.7	SUGT1P3	-9.01	5.2e-18	2.76e-15	-0.4	-0.38	Cervical cancer;	chr13:40926215	chr13:40908159~40921774:-
THCA	cis	rs7189233	0.531	rs7203132	ENSG00000279344.1	RP11-44F14.7	-9.01	5.2e-18	2.76e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr16:53395863	chr16:53478957~53481550:-
THCA	cis	rs11971779	0.838	rs11764161	ENSG00000273391.1	RP11-634H22.1	9.01	5.21e-18	2.76e-15	0.39	0.38	Diisocyanate-induced asthma;	chr7:139430452	chr7:139359032~139359566:-
THCA	cis	rs2243480	1	rs4718334	ENSG00000273142.1	RP11-458F8.4	9.01	5.21e-18	2.76e-15	0.49	0.38	Diabetic kidney disease;	chr7:66324467	chr7:66902857~66906297:+
THCA	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-9.01	5.22e-18	2.77e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
THCA	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-9.01	5.22e-18	2.77e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
THCA	cis	rs1062177	1	rs72802204	ENSG00000253921.1	CTB-113P19.3	-9.01	5.22e-18	2.77e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151803622	chr5:151753992~151767247:+
THCA	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-9.01	5.24e-18	2.78e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
THCA	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-9.01	5.24e-18	2.78e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
THCA	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-9.01	5.24e-18	2.78e-15	-0.79	-0.38	Gout;	chr7:66642037	chr7:66654538~66669855:+
THCA	cis	rs848490	0.894	rs17233275	ENSG00000214293.7	APTR	9.01	5.25e-18	2.78e-15	0.28	0.38	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680725	chr7:77657660~77696265:-
THCA	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	9.01	5.25e-18	2.78e-15	0.58	0.38	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	9.01	5.25e-18	2.78e-15	0.58	0.38	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
THCA	cis	rs2439831	0.85	rs12440573	ENSG00000249839.1	AC011330.5	-9.01	5.25e-18	2.78e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43816799	chr15:43663654~43684339:-
THCA	cis	rs494459	0.504	rs7929520	ENSG00000278376.1	RP11-158I9.8	-9.01	5.25e-18	2.78e-15	-0.28	-0.38	Height;	chr11:118859432	chr11:118791254~118793137:+
THCA	cis	rs853679	0.55	rs6901017	ENSG00000226314.6	ZNF192P1	-9.01	5.26e-18	2.79e-15	-0.5	-0.38	Depression;	chr6:28184805	chr6:28161781~28169594:+
THCA	cis	rs1062177	1	rs12515762	ENSG00000253921.1	CTB-113P19.3	-9.01	5.33e-18	2.82e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151830361	chr5:151753992~151767247:+
THCA	cis	rs947583	0.517	rs4896181	ENSG00000231028.7	LINC00271	-9.01	5.33e-18	2.82e-15	-0.29	-0.38	Phosphorus levels;	chr6:135788742	chr6:135497801~135716055:+
THCA	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	9.01	5.33e-18	2.83e-15	0.51	0.38	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
THCA	cis	rs860295	0.812	rs11264363	ENSG00000225855.5	RUSC1-AS1	9.01	5.33e-18	2.83e-15	0.25	0.38	Body mass index;	chr1:155348517	chr1:155316863~155324176:-
THCA	cis	rs2243480	1	rs781157	ENSG00000273142.1	RP11-458F8.4	-9.01	5.34e-18	2.83e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66013324	chr7:66902857~66906297:+
THCA	cis	rs9640161	0.711	rs55881542	ENSG00000261305.1	RP4-584D14.7	9.01	5.37e-18	2.85e-15	0.48	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150328645	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.75	rs11765644	ENSG00000261305.1	RP4-584D14.7	9.01	5.37e-18	2.85e-15	0.48	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150329250	chr7:150341771~150342607:+
THCA	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	9.01	5.38e-18	2.85e-15	0.67	0.38	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
THCA	cis	rs494459	0.536	rs34561290	ENSG00000278376.1	RP11-158I9.8	-9.01	5.39e-18	2.85e-15	-0.28	-0.38	Height;	chr11:118860890	chr11:118791254~118793137:+
THCA	cis	rs494459	0.536	rs11217072	ENSG00000278376.1	RP11-158I9.8	-9.01	5.39e-18	2.85e-15	-0.28	-0.38	Height;	chr11:118861053	chr11:118791254~118793137:+
THCA	cis	rs10411161	0.702	rs8113584	ENSG00000269483.1	AC006272.1	9.01	5.39e-18	2.86e-15	0.53	0.38	Breast cancer;	chr19:51880621	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs8113685	ENSG00000269483.1	AC006272.1	9.01	5.39e-18	2.86e-15	0.53	0.38	Breast cancer;	chr19:51880637	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs8113768	ENSG00000269483.1	AC006272.1	9.01	5.39e-18	2.86e-15	0.53	0.38	Breast cancer;	chr19:51880685	chr19:51839924~51843324:-
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000224205.1	AP000351.4	-9	5.41e-18	2.86e-15	-0.45	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23987320~23991421:-
THCA	cis	rs2243480	1	rs160644	ENSG00000273142.1	RP11-458F8.4	-9	5.43e-18	2.88e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66093199	chr7:66902857~66906297:+
THCA	cis	rs10411161	0.702	rs8100716	ENSG00000269483.1	AC006272.1	9	5.46e-18	2.89e-15	0.53	0.38	Breast cancer;	chr19:51880808	chr19:51839924~51843324:-
THCA	cis	rs367615	0.704	rs7726991	ENSG00000249476.1	CTD-2587M2.1	9	5.5e-18	2.91e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109511733	chr5:109237120~109326369:-
THCA	cis	rs2243480	0.831	rs57294491	ENSG00000273142.1	RP11-458F8.4	9	5.5e-18	2.92e-15	0.49	0.38	Diabetic kidney disease;	chr7:66219914	chr7:66902857~66906297:+
THCA	cis	rs4819052	0.851	rs1056101	ENSG00000215447.6	BX322557.10	-9	5.52e-18	2.93e-15	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2838845	ENSG00000215447.6	BX322557.10	-9	5.54e-18	2.93e-15	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45288052~45291738:+
THCA	cis	rs2522056	0.808	rs1016988	ENSG00000233006.5	AC034220.3	-9	5.54e-18	2.94e-15	-0.34	-0.38	Fibrinogen;Lymphocyte counts;	chr5:132408882	chr5:132311285~132369916:-
THCA	cis	rs11971779	0.68	rs6965212	ENSG00000273391.1	RP11-634H22.1	9	5.55e-18	2.94e-15	0.37	0.38	Diisocyanate-induced asthma;	chr7:139341719	chr7:139359032~139359566:-
THCA	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-9	5.56e-18	2.94e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000099984.9	GSTT2	-9	5.6e-18	2.97e-15	-0.47	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23980123~23983911:+
THCA	cis	rs2946505	1	rs2946505	ENSG00000251468.2	RP11-369K16.1	9	5.61e-18	2.97e-15	0.5	0.38	Migraine;	chr8:12953643	chr8:12958387~12962200:+
THCA	cis	rs11690935	0.632	rs62183783	ENSG00000228389.1	AC068039.4	-9	5.61e-18	2.97e-15	-0.41	-0.38	Schizophrenia;	chr2:172000868	chr2:171773482~171775844:+
THCA	cis	rs2280018	0.526	rs2966128	ENSG00000188599.16	NPIPP1	-9	5.61e-18	2.97e-15	-0.32	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15104312~15123498:-
THCA	cis	rs597539	0.652	rs592697	ENSG00000250508.1	RP11-757G1.6	-9	5.62e-18	2.97e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68882596	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs654071	ENSG00000250508.1	RP11-757G1.6	-9	5.62e-18	2.97e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885964	chr11:68870664~68874542:+
THCA	cis	rs6991838	1	rs6991838	ENSG00000272010.1	CTD-3025N20.3	-9	5.64e-18	2.98e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:65558727	chr8:65591850~65592472:-
THCA	cis	rs748404	0.697	rs567357	ENSG00000249839.1	AC011330.5	-9	5.66e-18	2.99e-15	-0.45	-0.38	Lung cancer;	chr15:43279192	chr15:43663654~43684339:-
THCA	cis	rs12908161	0.92	rs12904605	ENSG00000259728.4	LINC00933	9	5.68e-18	3e-15	0.52	0.38	Schizophrenia;	chr15:84658188	chr15:84570649~84580175:+
THCA	cis	rs11971779	0.68	rs7805824	ENSG00000273391.1	RP11-634H22.1	-9	5.68e-18	3.01e-15	-0.35	-0.38	Diisocyanate-induced asthma;	chr7:139426423	chr7:139359032~139359566:-
THCA	cis	rs9640161	0.659	rs11974980	ENSG00000261305.1	RP4-584D14.7	9	5.69e-18	3.01e-15	0.46	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150312749	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.659	rs11975886	ENSG00000261305.1	RP4-584D14.7	9	5.69e-18	3.01e-15	0.46	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150313273	chr7:150341771~150342607:+
THCA	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-9	5.7e-18	3.02e-15	-0.77	-0.38	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
THCA	cis	rs1499614	0.901	rs3936	ENSG00000273142.1	RP11-458F8.4	-9	5.72e-18	3.03e-15	-0.5	-0.38	Gout;	chr7:66661502	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs1638731	ENSG00000273142.1	RP11-458F8.4	-9	5.72e-18	3.03e-15	-0.5	-0.38	Gout;	chr7:66679692	chr7:66902857~66906297:+
THCA	cis	rs1499614	1	rs1882655	ENSG00000273142.1	RP11-458F8.4	9	5.72e-18	3.03e-15	0.5	0.38	Gout;	chr7:66682070	chr7:66902857~66906297:+
THCA	cis	rs1499614	0.831	rs3800822	ENSG00000273142.1	RP11-458F8.4	9	5.72e-18	3.03e-15	0.5	0.38	Gout;	chr7:66682162	chr7:66902857~66906297:+
THCA	cis	rs2439831	0.85	rs28564774	ENSG00000249839.1	AC011330.5	-9	5.76e-18	3.05e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43833277	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs12441984	ENSG00000249839.1	AC011330.5	-9	5.76e-18	3.05e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43834087	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs7169322	ENSG00000249839.1	AC011330.5	-9	5.76e-18	3.05e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43838816	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28707214	ENSG00000249839.1	AC011330.5	-9	5.76e-18	3.05e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43839425	chr15:43663654~43684339:-
THCA	cis	rs10463554	0.892	rs2195272	ENSG00000175749.11	EIF3KP1	9	5.76e-18	3.05e-15	0.5	0.38	Parkinson's disease;	chr5:102959800	chr5:103032376~103033031:+
THCA	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-9	5.83e-18	3.08e-15	-0.45	-0.38	Migraine;	chr4:56880007	chr4:56960927~56961373:-
THCA	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-9	5.83e-18	3.08e-15	-0.45	-0.38	Migraine;	chr4:56880190	chr4:56960927~56961373:-
THCA	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-9	5.83e-18	3.08e-15	-0.45	-0.38	Migraine;	chr4:56880659	chr4:56960927~56961373:-
THCA	cis	rs7211079	0.957	rs935117	ENSG00000275479.1	RP11-334C17.6	8.99	5.84e-18	3.09e-15	0.38	0.38	Myocardial infarction;	chr17:80141685	chr17:80149627~80149798:+
THCA	cis	rs7211079	0.957	rs58120535	ENSG00000275479.1	RP11-334C17.6	8.99	5.84e-18	3.09e-15	0.38	0.38	Myocardial infarction;	chr17:80142225	chr17:80149627~80149798:+
THCA	cis	rs4842666	0.915	rs11105364	ENSG00000258302.2	RP11-981P6.1	8.99	5.88e-18	3.11e-15	0.38	0.38	Blood pressure;	chr12:89675499	chr12:89561129~89594878:+
THCA	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	8.99	5.92e-18	3.13e-15	0.57	0.38	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
THCA	cis	rs4842666	0.915	rs73437358	ENSG00000258302.2	RP11-981P6.1	8.99	5.92e-18	3.13e-15	0.38	0.38	Blood pressure;	chr12:89678299	chr12:89561129~89594878:+
THCA	cis	rs4842666	0.915	rs11105368	ENSG00000258302.2	RP11-981P6.1	8.99	5.92e-18	3.13e-15	0.38	0.38	Blood pressure;	chr12:89680664	chr12:89561129~89594878:+
THCA	cis	rs4842666	0.765	rs4842675	ENSG00000258302.2	RP11-981P6.1	8.99	5.92e-18	3.13e-15	0.38	0.38	Blood pressure;	chr12:89681466	chr12:89561129~89594878:+
THCA	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-8.99	5.94e-18	3.14e-15	-0.39	-0.38	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
THCA	cis	rs4819052	0.851	rs2838856	ENSG00000215447.6	BX322557.10	-8.99	5.97e-18	3.15e-15	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45288052~45291738:+
THCA	cis	rs7189233	0.513	rs2908797	ENSG00000279344.1	RP11-44F14.7	8.99	5.99e-18	3.17e-15	0.39	0.38	Intelligence (multi-trait analysis);	chr16:53395261	chr16:53478957~53481550:-
THCA	cis	rs4819052	0.851	rs2838857	ENSG00000215447.6	BX322557.10	-8.99	5.99e-18	3.17e-15	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45288052~45291738:+
THCA	cis	rs7189233	0.531	rs8055279	ENSG00000279344.1	RP11-44F14.7	8.99	6.01e-18	3.17e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr16:53488837	chr16:53478957~53481550:-
THCA	cis	rs2836950	0.565	rs4816617	ENSG00000255568.3	BRWD1-AS2	-8.99	6.02e-18	3.18e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39168764	chr21:39313935~39314962:+
THCA	cis	rs12554020	0.686	rs77734990	ENSG00000227603.1	RP11-165J3.6	8.99	6.02e-18	3.18e-15	0.69	0.38	Schizophrenia;	chr9:93561870	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.686	rs56275034	ENSG00000227603.1	RP11-165J3.6	8.99	6.02e-18	3.18e-15	0.69	0.38	Schizophrenia;	chr9:93563474	chr9:93435332~93437121:-
THCA	cis	rs12908161	0.959	rs1051168	ENSG00000259728.4	LINC00933	8.99	6.03e-18	3.18e-15	0.52	0.38	Schizophrenia;	chr15:84657289	chr15:84570649~84580175:+
THCA	cis	rs11971779	0.715	rs10954646	ENSG00000273391.1	RP11-634H22.1	-8.99	6.04e-18	3.19e-15	-0.37	-0.38	Diisocyanate-induced asthma;	chr7:139376323	chr7:139359032~139359566:-
THCA	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-8.99	6.06e-18	3.2e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
THCA	cis	rs2439831	0.85	rs28513374	ENSG00000249839.1	AC011330.5	-8.99	6.06e-18	3.2e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43833297	chr15:43663654~43684339:-
THCA	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	8.99	6.07e-18	3.21e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
THCA	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	8.99	6.09e-18	3.21e-15	0.44	0.38	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
THCA	cis	rs7208859	0.573	rs73267829	ENSG00000266490.1	CTD-2349P21.9	8.99	6.11e-18	3.23e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30792372~30792833:+
THCA	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	8.99	6.14e-18	3.24e-15	0.31	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
THCA	cis	rs1426063	0.614	rs115279737	ENSG00000260265.1	RP11-44F21.5	8.99	6.15e-18	3.25e-15	0.83	0.38	QT interval;	chr4:75107557	chr4:75081702~75084717:-
THCA	cis	rs7221109	0.961	rs757411	ENSG00000278834.1	RP11-458J1.1	8.99	6.18e-18	3.26e-15	0.4	0.38	Type 1 diabetes;	chr17:40618898	chr17:40648300~40649718:+
THCA	cis	rs7221109	0.961	rs9911533	ENSG00000278834.1	RP11-458J1.1	8.99	6.18e-18	3.26e-15	0.4	0.38	Type 1 diabetes;	chr17:40619224	chr17:40648300~40649718:+
THCA	cis	rs673078	0.607	rs2393418	ENSG00000275409.1	RP11-131L12.4	-8.99	6.18e-18	3.26e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445995	chr12:118430147~118430699:+
THCA	cis	rs4713118	0.662	rs149970	ENSG00000280107.1	AL022393.9	-8.99	6.2e-18	3.27e-15	-0.43	-0.38	Parkinson's disease;	chr6:28012442	chr6:28170845~28172521:+
THCA	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	8.99	6.22e-18	3.28e-15	0.78	0.38	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
THCA	cis	rs11148252	0.74	rs7983971	ENSG00000278238.1	RP11-245D16.4	-8.99	6.23e-18	3.29e-15	-0.44	-0.38	Lewy body disease;	chr13:52216565	chr13:52454775~52455331:-
THCA	cis	rs1707322	0.685	rs56177313	ENSG00000234329.1	RP11-767N6.2	8.99	6.24e-18	3.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs11211178	ENSG00000234329.1	RP11-767N6.2	8.99	6.24e-18	3.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4660314	ENSG00000234329.1	RP11-767N6.2	8.99	6.24e-18	3.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10890346	ENSG00000234329.1	RP11-767N6.2	-8.99	6.24e-18	3.29e-15	-0.36	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45651039~45651826:-
THCA	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-8.99	6.26e-18	3.3e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
THCA	cis	rs10411161	0.721	rs10401778	ENSG00000269483.1	AC006272.1	8.99	6.27e-18	3.31e-15	0.53	0.38	Breast cancer;	chr19:51881062	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs10402630	ENSG00000269483.1	AC006272.1	8.99	6.27e-18	3.31e-15	0.53	0.38	Breast cancer;	chr19:51881317	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.752	rs10402107	ENSG00000269483.1	AC006272.1	8.99	6.27e-18	3.31e-15	0.53	0.38	Breast cancer;	chr19:51881347	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs16983196	ENSG00000269483.1	AC006272.1	8.99	6.27e-18	3.31e-15	0.53	0.38	Breast cancer;	chr19:51881526	chr19:51839924~51843324:-
THCA	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-8.99	6.29e-18	3.32e-15	-0.43	-0.38	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
THCA	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-8.99	6.29e-18	3.32e-15	-0.43	-0.38	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
THCA	cis	rs2243480	1	rs466983	ENSG00000273142.1	RP11-458F8.4	-8.99	6.3e-18	3.32e-15	-0.49	-0.38	Diabetic kidney disease;	chr7:66055509	chr7:66902857~66906297:+
THCA	cis	rs1426063	0.614	rs114761716	ENSG00000260265.1	RP11-44F21.5	8.99	6.3e-18	3.33e-15	0.82	0.38	QT interval;	chr4:75107209	chr4:75081702~75084717:-
THCA	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	8.99	6.3e-18	3.33e-15	0.49	0.38	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	8.99	6.3e-18	3.33e-15	0.49	0.38	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
THCA	cis	rs11098499	0.575	rs9996586	ENSG00000245958.5	RP11-33B1.1	-8.99	6.3e-18	3.33e-15	-0.34	-0.38	Corneal astigmatism;	chr4:119405787	chr4:119454791~119552025:+
THCA	cis	rs12468226	0.574	rs4675271	ENSG00000273456.1	RP11-686O6.2	-8.98	6.35e-18	3.35e-15	-0.42	-0.38	Urate levels;	chr2:202170967	chr2:202374932~202375604:-
THCA	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-8.98	6.36e-18	3.35e-15	-0.45	-0.38	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-8.98	6.36e-18	3.35e-15	-0.45	-0.38	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
THCA	cis	rs2836974	0.583	rs9981884	ENSG00000255568.3	BRWD1-AS2	8.98	6.36e-18	3.36e-15	0.32	0.38	Cognitive function;	chr21:39213707	chr21:39313935~39314962:+
THCA	cis	rs7208859	0.573	rs11654035	ENSG00000266490.1	CTD-2349P21.9	8.98	6.37e-18	3.36e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30792372~30792833:+
THCA	cis	rs2274273	0.743	rs7161656	ENSG00000258413.1	RP11-665C16.6	-8.98	6.37e-18	3.36e-15	-0.51	-0.38	Protein biomarker;	chr14:55057812	chr14:55262767~55272075:-
THCA	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	8.98	6.38e-18	3.37e-15	0.57	0.38	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
THCA	cis	rs7569084	1	rs7569084	ENSG00000237979.1	AC007389.1	-8.98	6.38e-18	3.37e-15	-0.44	-0.38	Sum eosinophil basophil counts;	chr2:65429835	chr2:65500993~65502138:-
THCA	cis	rs7829975	0.806	rs2428	ENSG00000253893.2	FAM85B	-8.98	6.43e-18	3.39e-15	-0.47	-0.38	Mood instability;	chr8:8783635	chr8:8167819~8226614:-
THCA	cis	rs2032366	0.606	rs6567225	ENSG00000267279.1	RP11-879F14.2	8.98	6.47e-18	3.41e-15	0.41	0.38	Obesity-related traits;	chr18:61607418	chr18:61585746~61606916:-
THCA	cis	rs28510890	0.547	rs12441705	ENSG00000260337.3	RP11-386M24.6	8.98	6.49e-18	3.42e-15	0.51	0.38	Lung cancer in ever smokers;	chr15:92609319	chr15:92592574~92596462:-
THCA	cis	rs11971779	0.68	rs6978680	ENSG00000273391.1	RP11-634H22.1	-8.98	6.53e-18	3.44e-15	-0.36	-0.38	Diisocyanate-induced asthma;	chr7:139427302	chr7:139359032~139359566:-
THCA	cis	rs7849270	0.84	rs3118639	ENSG00000268707.1	RP11-247A12.7	8.98	6.53e-18	3.44e-15	0.52	0.38	Blood metabolite ratios;	chr9:129093324	chr9:129170434~129170940:+
THCA	cis	rs7208859	0.562	rs11650923	ENSG00000266490.1	CTD-2349P21.9	8.98	6.56e-18	3.46e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs56378576	ENSG00000266490.1	CTD-2349P21.9	8.98	6.56e-18	3.46e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs35916850	ENSG00000266490.1	CTD-2349P21.9	8.98	6.56e-18	3.46e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30792372~30792833:+
THCA	cis	rs10463554	0.824	rs60588319	ENSG00000175749.11	EIF3KP1	8.98	6.58e-18	3.47e-15	0.52	0.38	Parkinson's disease;	chr5:102988656	chr5:103032376~103033031:+
THCA	cis	rs1707322	0.752	rs12062535	ENSG00000234329.1	RP11-767N6.2	8.98	6.6e-18	3.48e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45651039~45651826:-
THCA	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-8.98	6.6e-18	3.48e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
THCA	cis	rs597539	0.652	rs611046	ENSG00000250508.1	RP11-757G1.6	-8.98	6.6e-18	3.48e-15	-0.47	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68864236	chr11:68870664~68874542:+
THCA	cis	rs11690935	0.55	rs4280427	ENSG00000228389.1	AC068039.4	-8.98	6.63e-18	3.49e-15	-0.41	-0.38	Schizophrenia;	chr2:171956692	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.531	rs4280428	ENSG00000228389.1	AC068039.4	-8.98	6.63e-18	3.49e-15	-0.41	-0.38	Schizophrenia;	chr2:171956693	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.962	rs13215691	ENSG00000268592.3	RAET1E-AS1	8.98	6.64e-18	3.49e-15	0.51	0.38	Lung cancer;	chr6:149792666	chr6:149863494~149919507:+
THCA	cis	rs2658782	0.654	rs2248531	ENSG00000279684.1	RP11-755E23.2	-8.98	6.65e-18	3.5e-15	-0.58	-0.38	Pulmonary function decline;	chr11:93522197	chr11:93286629~93288903:-
THCA	cis	rs7189233	0.531	rs9931702	ENSG00000279344.1	RP11-44F14.7	8.98	6.69e-18	3.52e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr16:53492639	chr16:53478957~53481550:-
THCA	cis	rs34375054	0.641	rs34624329	ENSG00000279233.1	RP11-158L12.4	8.98	6.72e-18	3.54e-15	0.36	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125123482	chr12:125138245~125141711:+
THCA	cis	rs66887589	0.627	rs3872807	ENSG00000245958.5	RP11-33B1.1	-8.98	6.75e-18	3.55e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119439096	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.56	rs9684327	ENSG00000245958.5	RP11-33B1.1	-8.98	6.75e-18	3.55e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119444286	chr4:119454791~119552025:+
THCA	cis	rs673078	0.607	rs61943367	ENSG00000275409.1	RP11-131L12.4	-8.98	6.75e-18	3.55e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118366316	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943368	ENSG00000275409.1	RP11-131L12.4	-8.98	6.75e-18	3.55e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118366568	chr12:118430147~118430699:+
THCA	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-8.98	6.78e-18	3.57e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
THCA	cis	rs17684571	0.637	rs35566812	ENSG00000231441.1	RP11-472M19.2	8.98	6.79e-18	3.57e-15	0.49	0.38	Schizophrenia;	chr6:56792077	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs62411375	ENSG00000231441.1	RP11-472M19.2	8.98	6.79e-18	3.57e-15	0.49	0.38	Schizophrenia;	chr6:56794361	chr6:56844002~56864078:+
THCA	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	8.98	6.8e-18	3.58e-15	0.46	0.38	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
THCA	cis	rs2836950	0.565	rs2836930	ENSG00000255568.3	BRWD1-AS2	-8.98	6.81e-18	3.58e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39173730	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.565	rs2836931	ENSG00000255568.3	BRWD1-AS2	-8.98	6.81e-18	3.58e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39174643	chr21:39313935~39314962:+
THCA	cis	rs1799949	0.965	rs8070179	ENSG00000267681.1	CTD-3199J23.6	-8.97	6.82e-18	3.59e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43050671	chr17:43144956~43145255:+
THCA	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-8.97	6.82e-18	3.59e-15	-0.4	-0.38	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
THCA	cis	rs8072100	0.817	rs9912101	ENSG00000228782.6	CTD-2026D20.3	8.97	6.89e-18	3.63e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469712	chr17:47450568~47492492:-
THCA	cis	rs5769707	0.933	rs2157444	ENSG00000235111.1	RP1-29C18.8	-8.97	6.93e-18	3.65e-15	-0.45	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49612657~49615716:-
THCA	cis	rs9322193	0.926	rs3805751	ENSG00000268592.3	RAET1E-AS1	8.97	6.93e-18	3.65e-15	0.51	0.38	Lung cancer;	chr6:149791193	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs10872656	ENSG00000268592.3	RAET1E-AS1	8.97	6.93e-18	3.65e-15	0.51	0.38	Lung cancer;	chr6:149799444	chr6:149863494~149919507:+
THCA	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	8.97	6.93e-18	3.65e-15	0.57	0.38	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
THCA	cis	rs9322193	0.607	rs6925151	ENSG00000216906.2	RP11-350J20.9	8.97	6.95e-18	3.66e-15	0.48	0.38	Lung cancer;	chr6:149889587	chr6:149904243~149906418:+
THCA	cis	rs7208859	0.623	rs11658022	ENSG00000266490.1	CTD-2349P21.9	8.97	6.97e-18	3.66e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73269923	ENSG00000266490.1	CTD-2349P21.9	8.97	6.97e-18	3.66e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30792372~30792833:+
THCA	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-8.97	6.97e-18	3.67e-15	-0.32	-0.38	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
THCA	cis	rs8072100	0.817	rs12449647	ENSG00000228782.6	CTD-2026D20.3	8.97	6.98e-18	3.67e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47471592	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.748	rs9908016	ENSG00000228782.6	CTD-2026D20.3	8.97	6.98e-18	3.67e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47473995	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.782	rs28507314	ENSG00000228782.6	CTD-2026D20.3	8.97	6.98e-18	3.67e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47474036	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.748	rs9912592	ENSG00000228782.6	CTD-2026D20.3	8.97	6.98e-18	3.67e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47479579	chr17:47450568~47492492:-
THCA	cis	rs1799949	0.965	rs799912	ENSG00000267681.1	CTD-3199J23.6	-8.97	6.99e-18	3.68e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43105117	chr17:43144956~43145255:+
THCA	cis	rs2243480	1	rs1618893	ENSG00000273142.1	RP11-458F8.4	-8.97	6.99e-18	3.68e-15	-0.46	-0.38	Diabetic kidney disease;	chr7:66631132	chr7:66902857~66906297:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000235689.1	AP000351.13	-8.97	7e-18	3.68e-15	-0.53	-0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:24006305~24008258:-
THCA	cis	rs1062177	1	rs12653926	ENSG00000253921.1	CTB-113P19.3	-8.97	7.01e-18	3.69e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151870687	chr5:151753992~151767247:+
THCA	cis	rs1075265	0.572	rs3770405	ENSG00000233266.1	HMGB1P31	8.97	7.02e-18	3.69e-15	0.5	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53694884	chr2:54051334~54051760:+
THCA	cis	rs1707322	0.927	rs6690386	ENSG00000234329.1	RP11-767N6.2	8.97	7.02e-18	3.69e-15	0.37	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45651039~45651826:-
THCA	cis	rs6991838	0.765	rs6472219	ENSG00000200714.1	Y_RNA	8.97	7.03e-18	3.69e-15	0.45	0.38	Intelligence (multi-trait analysis);	chr8:65644487	chr8:65592731~65592820:+
THCA	cis	rs673078	0.571	rs61945220	ENSG00000275409.1	RP11-131L12.4	-8.97	7.03e-18	3.7e-15	-0.5	-0.38	Glucose homeostasis traits;	chr12:118272924	chr12:118430147~118430699:+
THCA	cis	rs673078	0.571	rs61945221	ENSG00000275409.1	RP11-131L12.4	-8.97	7.03e-18	3.7e-15	-0.5	-0.38	Glucose homeostasis traits;	chr12:118272926	chr12:118430147~118430699:+
THCA	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	8.97	7.05e-18	3.71e-15	0.48	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
THCA	cis	rs9640161	0.659	rs17837498	ENSG00000261305.1	RP4-584D14.7	8.97	7.07e-18	3.71e-15	0.46	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150312590	chr7:150341771~150342607:+
THCA	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	8.97	7.08e-18	3.72e-15	0.68	0.38	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
THCA	cis	rs2288884	0.767	rs3752119	ENSG00000275055.1	CTC-471J1.11	-8.97	7.08e-18	3.72e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52048245	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.767	rs3450	ENSG00000275055.1	CTC-471J1.11	-8.97	7.08e-18	3.72e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52049746	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.708	rs59104696	ENSG00000275055.1	CTC-471J1.11	-8.97	7.08e-18	3.72e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52051917	chr19:52049007~52049754:+
THCA	cis	rs9322193	0.632	rs3828700	ENSG00000268592.3	RAET1E-AS1	8.97	7.1e-18	3.73e-15	0.51	0.38	Lung cancer;	chr6:149791033	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	8.97	7.11e-18	3.74e-15	0.45	0.38	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
THCA	cis	rs673078	0.615	rs16948204	ENSG00000275409.1	RP11-131L12.4	-8.97	7.11e-18	3.74e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118258252	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs7303417	ENSG00000275409.1	RP11-131L12.4	-8.97	7.11e-18	3.74e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118258859	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs16948230	ENSG00000275409.1	RP11-131L12.4	-8.97	7.11e-18	3.74e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118277086	chr12:118430147~118430699:+
THCA	cis	rs1062177	1	rs2964571	ENSG00000253921.1	CTB-113P19.3	-8.97	7.12e-18	3.74e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151791695	chr5:151753992~151767247:+
THCA	cis	rs1062177	1	rs2915869	ENSG00000253921.1	CTB-113P19.3	-8.97	7.12e-18	3.74e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151791948	chr5:151753992~151767247:+
THCA	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	8.97	7.13e-18	3.75e-15	0.65	0.38	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	8.97	7.14e-18	3.75e-15	0.65	0.38	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
THCA	cis	rs34375054	0.672	rs58416336	ENSG00000279233.1	RP11-158L12.4	8.97	7.14e-18	3.75e-15	0.36	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125121882	chr12:125138245~125141711:+
THCA	cis	rs4819052	0.851	rs7275468	ENSG00000215447.6	BX322557.10	-8.97	7.15e-18	3.75e-15	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45288052~45291738:+
THCA	cis	rs1799949	0.965	rs11650132	ENSG00000267681.1	CTD-3199J23.6	-8.97	7.15e-18	3.76e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43174070	chr17:43144956~43145255:+
THCA	cis	rs2243480	1	rs422164	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66121618	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316313	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66128561	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316312	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66131504	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs419603	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66132354	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs387676	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66133233	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs13310597	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66133553	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs431076	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66135333	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs2460422	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66136518	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316334	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66137139	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316330	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66140385	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316326	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66144466	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316325	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66144531	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316321	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66146626	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316318	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66147917	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316317	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66148650	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316304	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66151907	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs2465120	ENSG00000273142.1	RP11-458F8.4	-8.97	7.16e-18	3.76e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66155987	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.908	rs2460431	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66157859	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs4718309	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66162777	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6460274	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66163497	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs7787230	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66164112	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.711	rs2420172	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66170354	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6974723	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66172952	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs9769882	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66177938	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6966322	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66181767	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs4145008	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66182524	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs4718315	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66183554	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs4718316	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66183744	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1873494	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66184912	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6959002	ENSG00000273142.1	RP11-458F8.4	8.97	7.16e-18	3.76e-15	0.48	0.38	Diabetic kidney disease;	chr7:66185509	chr7:66902857~66906297:+
THCA	cis	rs10463554	0.856	rs2432169	ENSG00000175749.11	EIF3KP1	8.97	7.16e-18	3.76e-15	0.48	0.38	Parkinson's disease;	chr5:103179056	chr5:103032376~103033031:+
THCA	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-8.97	7.19e-18	3.77e-15	-0.79	-0.38	Gout;	chr7:66645053	chr7:66654538~66669855:+
THCA	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-8.97	7.19e-18	3.77e-15	-0.79	-0.38	Gout;	chr7:66654674	chr7:66654538~66669855:+
THCA	cis	rs860295	0.871	rs6696888	ENSG00000225855.5	RUSC1-AS1	-8.97	7.19e-18	3.78e-15	-0.25	-0.38	Body mass index;	chr1:155539091	chr1:155316863~155324176:-
THCA	cis	rs7646881	0.812	rs74618709	ENSG00000240207.5	RP11-379F4.4	-8.97	7.21e-18	3.79e-15	-0.53	-0.38	Tetralogy of Fallot;	chr3:158737492	chr3:158732263~158784070:+
THCA	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-8.97	7.23e-18	3.79e-15	-0.4	-0.38	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
THCA	cis	rs4819052	0.851	rs1056100	ENSG00000215447.6	BX322557.10	-8.97	7.25e-18	3.81e-15	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45288052~45291738:+
THCA	cis	rs9640161	0.702	rs1962004	ENSG00000261305.1	RP4-584D14.7	8.97	7.28e-18	3.82e-15	0.49	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150323292	chr7:150341771~150342607:+
THCA	cis	rs2274273	0.624	rs8014477	ENSG00000258413.1	RP11-665C16.6	8.97	7.3e-18	3.83e-15	0.52	0.38	Protein biomarker;	chr14:55374759	chr14:55262767~55272075:-
THCA	cis	rs1426063	0.614	rs17199632	ENSG00000260265.1	RP11-44F21.5	8.97	7.3e-18	3.83e-15	0.83	0.38	QT interval;	chr4:75103663	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs76931926	ENSG00000260265.1	RP11-44F21.5	8.97	7.3e-18	3.83e-15	0.83	0.38	QT interval;	chr4:75106902	chr4:75081702~75084717:-
THCA	cis	rs2243480	0.901	rs778732	ENSG00000273142.1	RP11-458F8.4	-8.97	7.3e-18	3.83e-15	-0.49	-0.38	Diabetic kidney disease;	chr7:66357373	chr7:66902857~66906297:+
THCA	cis	rs2288884	0.767	rs17835716	ENSG00000275055.1	CTC-471J1.11	-8.97	7.32e-18	3.84e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52047789	chr19:52049007~52049754:+
THCA	cis	rs12554020	0.892	rs75775593	ENSG00000227603.1	RP11-165J3.6	8.97	7.33e-18	3.84e-15	0.68	0.38	Schizophrenia;	chr9:93568611	chr9:93435332~93437121:-
THCA	cis	rs950169	0.58	rs2271431	ENSG00000259728.4	LINC00933	8.97	7.33e-18	3.85e-15	0.52	0.38	Schizophrenia;	chr15:84646233	chr15:84570649~84580175:+
THCA	cis	rs944289	0.74	rs56400346	ENSG00000257826.1	RP11-116N8.4	-8.97	7.34e-18	3.85e-15	-0.4	-0.38	Thyroid cancer;	chr14:36114681	chr14:36061026~36067190:-
THCA	cis	rs673078	0.607	rs61943391	ENSG00000275409.1	RP11-131L12.4	-8.97	7.35e-18	3.85e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118382603	chr12:118430147~118430699:+
THCA	cis	rs1075265	0.722	rs13414216	ENSG00000233266.1	HMGB1P31	8.97	7.36e-18	3.86e-15	0.49	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53699166	chr2:54051334~54051760:+
THCA	cis	rs9322193	0.923	rs9479810	ENSG00000268592.3	RAET1E-AS1	8.96	7.36e-18	3.86e-15	0.51	0.38	Lung cancer;	chr6:149751359	chr6:149863494~149919507:+
THCA	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	8.96	7.37e-18	3.86e-15	0.5	0.38	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
THCA	cis	rs7208859	0.573	rs216442	ENSG00000266490.1	CTD-2349P21.9	8.96	7.39e-18	3.87e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604179	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216445	ENSG00000266490.1	CTD-2349P21.9	8.96	7.39e-18	3.87e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606558	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216446	ENSG00000266490.1	CTD-2349P21.9	8.96	7.39e-18	3.87e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30606700	chr17:30792372~30792833:+
THCA	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	8.96	7.42e-18	3.89e-15	0.57	0.38	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
THCA	cis	rs1061377	0.965	rs1137714	ENSG00000249685.1	RP11-360F5.3	8.96	7.43e-18	3.89e-15	0.47	0.38	Uric acid levels;	chr4:39143105	chr4:39133913~39135608:+
THCA	cis	rs2243480	1	rs160655	ENSG00000273142.1	RP11-458F8.4	-8.96	7.44e-18	3.9e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66068227	chr7:66902857~66906297:+
THCA	cis	rs8062405	0.755	rs7193402	ENSG00000251417.2	RP11-1348G14.4	-8.96	7.44e-18	3.9e-15	-0.39	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28802743~28817828:+
THCA	cis	rs367615	0.704	rs11747622	ENSG00000249476.1	CTD-2587M2.1	8.96	7.45e-18	3.9e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109509019	chr5:109237120~109326369:-
THCA	cis	rs673078	0.607	rs950288	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118392201	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943399	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118393628	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17440942	ENSG00000275409.1	RP11-131L12.4	8.96	7.45e-18	3.91e-15	0.46	0.38	Glucose homeostasis traits;	chr12:118394030	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7137055	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118395030	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7137184	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118395163	chr12:118430147~118430699:+
THCA	cis	rs673078	0.562	rs4767672	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118397048	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs73205594	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118397168	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943400	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118398236	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943401	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118398527	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943402	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118398808	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17512763	ENSG00000275409.1	RP11-131L12.4	-8.96	7.45e-18	3.91e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118400974	chr12:118430147~118430699:+
THCA	cis	rs9532669	0.926	rs2039119	ENSG00000239827.7	SUGT1P3	8.96	7.47e-18	3.92e-15	0.42	0.38	Cervical cancer;	chr13:40872432	chr13:40908159~40921774:-
THCA	cis	rs1799949	1	rs9646417	ENSG00000267681.1	CTD-3199J23.6	-8.96	7.48e-18	3.92e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43346885	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs1545764	ENSG00000267681.1	CTD-3199J23.6	-8.96	7.48e-18	3.92e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43347197	chr17:43144956~43145255:+
THCA	cis	rs8072100	0.817	rs9892497	ENSG00000228782.6	CTD-2026D20.3	8.96	7.51e-18	3.93e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47468553	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.817	rs9905581	ENSG00000228782.6	CTD-2026D20.3	8.96	7.51e-18	3.93e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47469819	chr17:47450568~47492492:-
THCA	cis	rs2243480	1	rs1546059	ENSG00000273142.1	RP11-458F8.4	8.96	7.53e-18	3.95e-15	0.48	0.38	Diabetic kidney disease;	chr7:66189722	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs2420170	ENSG00000273142.1	RP11-458F8.4	8.96	7.53e-18	3.95e-15	0.48	0.38	Diabetic kidney disease;	chr7:66191066	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6958289	ENSG00000273142.1	RP11-458F8.4	8.96	7.53e-18	3.95e-15	0.48	0.38	Diabetic kidney disease;	chr7:66192124	chr7:66902857~66906297:+
THCA	cis	rs673078	0.607	rs61943385	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118370339	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943388	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118374590	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943389	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118377467	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7299040	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118380660	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7968011	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118382001	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943393	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118383650	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs73205576	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118384268	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs2055534	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118386527	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs56157623	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118388162	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs4767669	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118390651	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs4767670	ENSG00000275409.1	RP11-131L12.4	-8.96	7.53e-18	3.95e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118390737	chr12:118430147~118430699:+
THCA	cis	rs1062177	1	rs12518722	ENSG00000253921.1	CTB-113P19.3	-8.96	7.56e-18	3.96e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151851899	chr5:151753992~151767247:+
THCA	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-8.96	7.57e-18	3.96e-15	-0.78	-0.38	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
THCA	cis	rs11971779	0.68	rs7783619	ENSG00000273391.1	RP11-634H22.1	8.96	7.58e-18	3.97e-15	0.36	0.38	Diisocyanate-induced asthma;	chr7:139376691	chr7:139359032~139359566:-
THCA	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	8.96	7.58e-18	3.97e-15	0.45	0.38	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
THCA	cis	rs1062177	0.951	rs2915876	ENSG00000253921.1	CTB-113P19.3	-8.96	7.6e-18	3.98e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151771184	chr5:151753992~151767247:+
THCA	cis	rs875971	0.597	rs11771318	ENSG00000237310.1	GS1-124K5.4	-8.96	7.6e-18	3.98e-15	-0.29	-0.38	Aortic root size;	chr7:66597493	chr7:66493706~66495474:+
THCA	cis	rs2033711	0.84	rs10423138	ENSG00000268912.1	CTD-2619J13.17	-8.96	7.6e-18	3.98e-15	-0.29	-0.38	Uric acid clearance;	chr19:58416935	chr19:58428632~58431148:-
THCA	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	8.96	7.63e-18	4e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
THCA	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	8.96	7.65e-18	4.01e-15	0.58	0.38	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
THCA	cis	rs2946504	0.607	rs2977080	ENSG00000251468.2	RP11-369K16.1	-8.96	7.66e-18	4.01e-15	-0.44	-0.38	Type 2 diabetes;	chr8:12959492	chr8:12958387~12962200:+
THCA	cis	rs2946504	0.553	rs2977079	ENSG00000251468.2	RP11-369K16.1	-8.96	7.66e-18	4.01e-15	-0.44	-0.38	Type 2 diabetes;	chr8:12959500	chr8:12958387~12962200:+
THCA	cis	rs2243480	1	rs313824	ENSG00000273142.1	RP11-458F8.4	-8.96	7.66e-18	4.01e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66116220	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs186378	ENSG00000273142.1	RP11-458F8.4	-8.96	7.66e-18	4.01e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66117071	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs160637	ENSG00000273142.1	RP11-458F8.4	-8.96	7.66e-18	4.01e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66119331	chr7:66902857~66906297:+
THCA	cis	rs17684571	0.872	rs13203000	ENSG00000231441.1	RP11-472M19.2	8.96	7.66e-18	4.01e-15	0.54	0.38	Schizophrenia;	chr6:56758921	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs13217390	ENSG00000231441.1	RP11-472M19.2	8.96	7.66e-18	4.01e-15	0.54	0.38	Schizophrenia;	chr6:56758953	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs34803237	ENSG00000231441.1	RP11-472M19.2	8.96	7.66e-18	4.01e-15	0.54	0.38	Schizophrenia;	chr6:56759620	chr6:56844002~56864078:+
THCA	cis	rs673078	0.66	rs7970481	ENSG00000275409.1	RP11-131L12.4	-8.96	7.68e-18	4.02e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118242112	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs58113338	ENSG00000275409.1	RP11-131L12.4	-8.96	7.68e-18	4.02e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118251335	chr12:118430147~118430699:+
THCA	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-8.96	7.68e-18	4.02e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-8.96	7.68e-18	4.02e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-8.96	7.68e-18	4.02e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-8.96	7.68e-18	4.02e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-8.96	7.68e-18	4.02e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	8.96	7.68e-18	4.02e-15	0.49	0.38	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	8.96	7.68e-18	4.02e-15	0.49	0.38	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
THCA	cis	rs9322193	0.962	rs9478848	ENSG00000268592.3	RAET1E-AS1	8.96	7.69e-18	4.03e-15	0.51	0.38	Lung cancer;	chr6:149825080	chr6:149863494~149919507:+
THCA	cis	rs673078	0.66	rs73205512	ENSG00000275409.1	RP11-131L12.4	-8.96	7.74e-18	4.05e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118235770	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61945206	ENSG00000275409.1	RP11-131L12.4	-8.96	7.74e-18	4.05e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118238295	chr12:118430147~118430699:+
THCA	cis	rs1707322	0.721	rs10430123	ENSG00000234329.1	RP11-767N6.2	8.96	7.74e-18	4.05e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45651039~45651826:-
THCA	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	8.96	7.77e-18	4.06e-15	0.25	0.38	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
THCA	cis	rs9322193	0.962	rs3805748	ENSG00000268592.3	RAET1E-AS1	8.96	7.79e-18	4.07e-15	0.51	0.38	Lung cancer;	chr6:149772542	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.886	rs12525871	ENSG00000268592.3	RAET1E-AS1	8.96	7.79e-18	4.07e-15	0.51	0.38	Lung cancer;	chr6:149775882	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs10872653	ENSG00000268592.3	RAET1E-AS1	8.96	7.79e-18	4.07e-15	0.51	0.38	Lung cancer;	chr6:149778907	chr6:149863494~149919507:+
THCA	cis	rs1707322	1	rs785484	ENSG00000234329.1	RP11-767N6.2	-8.96	7.82e-18	4.09e-15	-0.37	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45651039~45651826:-
THCA	cis	rs2243480	0.708	rs13242216	ENSG00000273142.1	RP11-458F8.4	-8.96	7.82e-18	4.09e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66433290	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs58669269	ENSG00000273142.1	RP11-458F8.4	-8.96	7.82e-18	4.09e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66486966	chr7:66902857~66906297:+
THCA	cis	rs9532669	0.926	rs7329302	ENSG00000239827.7	SUGT1P3	8.96	7.85e-18	4.11e-15	0.41	0.38	Cervical cancer;	chr13:40962396	chr13:40908159~40921774:-
THCA	cis	rs1061377	0.965	rs12511857	ENSG00000249685.1	RP11-360F5.3	8.96	7.87e-18	4.12e-15	0.47	0.38	Uric acid levels;	chr4:39143252	chr4:39133913~39135608:+
THCA	cis	rs7211079	0.917	rs8067991	ENSG00000275479.1	RP11-334C17.6	8.96	7.89e-18	4.12e-15	0.38	0.38	Myocardial infarction;	chr17:80145503	chr17:80149627~80149798:+
THCA	cis	rs17684571	0.872	rs34455199	ENSG00000231441.1	RP11-472M19.2	8.96	7.9e-18	4.13e-15	0.54	0.38	Schizophrenia;	chr6:56759780	chr6:56844002~56864078:+
THCA	cis	rs2243480	0.803	rs423187	ENSG00000273142.1	RP11-458F8.4	-8.96	7.91e-18	4.13e-15	-0.49	-0.38	Diabetic kidney disease;	chr7:66044512	chr7:66902857~66906297:+
THCA	cis	rs524281	0.731	rs78578425	ENSG00000255320.1	RP11-755F10.1	8.96	7.93e-18	4.15e-15	0.61	0.38	Electroencephalogram traits;	chr11:66042768	chr11:66244840~66246239:-
THCA	cis	rs673078	0.66	rs7965350	ENSG00000275409.1	RP11-131L12.4	-8.96	7.95e-18	4.16e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118266710	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs17433217	ENSG00000275409.1	RP11-131L12.4	-8.96	7.95e-18	4.16e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118269076	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs73205526	ENSG00000275409.1	RP11-131L12.4	-8.96	7.95e-18	4.16e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118273172	chr12:118430147~118430699:+
THCA	cis	rs673078	0.571	rs7954330	ENSG00000275409.1	RP11-131L12.4	-8.96	7.95e-18	4.16e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118275284	chr12:118430147~118430699:+
THCA	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-8.95	7.97e-18	4.17e-15	-0.4	-0.38	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
THCA	cis	rs7208859	0.623	rs609063	ENSG00000266490.1	CTD-2349P21.9	8.95	8.07e-18	4.21e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs383436	ENSG00000266490.1	CTD-2349P21.9	8.95	8.07e-18	4.21e-15	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.714	rs11650821	ENSG00000266490.1	CTD-2349P21.9	8.95	8.07e-18	4.21e-15	0.53	0.38	Body mass index;	chr17:30641132	chr17:30792372~30792833:+
THCA	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-8.95	8.08e-18	4.22e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
THCA	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-8.95	8.08e-18	4.22e-15	-0.44	-0.38	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
THCA	cis	rs4722166	0.63	rs13311155	ENSG00000179428.2	AC073072.5	-8.95	8.09e-18	4.23e-15	-0.5	-0.38	Lung cancer;	chr7:22750170	chr7:22725395~22727620:-
THCA	cis	rs4722166	0.63	rs13311199	ENSG00000179428.2	AC073072.5	-8.95	8.09e-18	4.23e-15	-0.5	-0.38	Lung cancer;	chr7:22750174	chr7:22725395~22727620:-
THCA	cis	rs4266144	1	rs12487629	ENSG00000244515.1	KRT18P34	-8.95	8.11e-18	4.23e-15	-0.44	-0.38	Coronary artery disease;	chr3:157134416	chr3:157162663~157163932:-
THCA	cis	rs1799949	0.965	rs11080034	ENSG00000267681.1	CTD-3199J23.6	-8.95	8.11e-18	4.23e-15	-0.44	-0.38	Menopause (age at onset);	chr17:43365646	chr17:43144956~43145255:+
THCA	cis	rs8027521	0.521	rs10851550	ENSG00000280362.1	RP11-643A5.3	-8.95	8.11e-18	4.24e-15	-0.53	-0.38	Circulating chemerin levels;	chr15:53949189	chr15:53910769~53914712:+
THCA	cis	rs2243480	0.803	rs160649	ENSG00000273142.1	RP11-458F8.4	-8.95	8.12e-18	4.24e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66078212	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs160648	ENSG00000273142.1	RP11-458F8.4	-8.95	8.12e-18	4.24e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66078397	chr7:66902857~66906297:+
THCA	cis	rs860295	0.65	rs28662267	ENSG00000225855.5	RUSC1-AS1	8.95	8.13e-18	4.25e-15	0.26	0.38	Body mass index;	chr1:155710658	chr1:155316863~155324176:-
THCA	cis	rs2243480	1	rs316307	ENSG00000273142.1	RP11-458F8.4	-8.95	8.15e-18	4.26e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66105184	chr7:66902857~66906297:+
THCA	cis	rs9659323	1	rs6680737	ENSG00000231365.4	RP11-418J17.1	-8.95	8.17e-18	4.27e-15	-0.39	-0.38	Body mass index;	chr1:118979008	chr1:119140396~119275973:+
THCA	cis	rs1707322	0.827	rs12125508	ENSG00000234329.1	RP11-767N6.2	8.95	8.18e-18	4.27e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45651039~45651826:-
THCA	cis	rs150992	0.609	rs539024	ENSG00000248489.1	CTD-2007H13.3	8.95	8.19e-18	4.28e-15	0.37	0.38	Body mass index;	chr5:98997103	chr5:98929171~98995013:+
THCA	cis	rs150992	0.532	rs416750	ENSG00000248489.1	CTD-2007H13.3	8.95	8.19e-18	4.28e-15	0.37	0.38	Body mass index;	chr5:98999046	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs819232	ENSG00000248489.1	CTD-2007H13.3	8.95	8.19e-18	4.28e-15	0.37	0.38	Body mass index;	chr5:98999416	chr5:98929171~98995013:+
THCA	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-8.95	8.2e-18	4.28e-15	-0.4	-0.38	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
THCA	cis	rs9640161	0.673	rs11773351	ENSG00000261305.1	RP4-584D14.7	8.95	8.21e-18	4.29e-15	0.49	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150333874	chr7:150341771~150342607:+
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000228039.3	KB-1125A3.10	8.95	8.21e-18	4.29e-15	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23963780~23964374:+
THCA	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-8.95	8.21e-18	4.29e-15	-0.4	-0.38	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	8.95	8.22e-18	4.29e-15	0.49	0.38	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	8.95	8.22e-18	4.29e-15	0.49	0.38	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
THCA	cis	rs1707322	0.721	rs12069121	ENSG00000234329.1	RP11-767N6.2	8.95	8.25e-18	4.3e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45651039~45651826:-
THCA	cis	rs7829975	0.774	rs13259216	ENSG00000253893.2	FAM85B	-8.95	8.27e-18	4.32e-15	-0.48	-0.38	Mood instability;	chr8:8816091	chr8:8167819~8226614:-
THCA	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-8.95	8.35e-18	4.36e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
THCA	cis	rs597539	0.652	rs1249474	ENSG00000250508.1	RP11-757G1.6	-8.95	8.37e-18	4.37e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68887306	chr11:68870664~68874542:+
THCA	cis	rs6844153	0.752	rs28497454	ENSG00000240005.4	RP11-293A21.1	-8.95	8.37e-18	4.37e-15	-0.45	-0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26906230	chr4:26859806~26860599:-
THCA	cis	rs12922040	0.701	rs12149912	ENSG00000263335.1	AF001548.5	-8.95	8.38e-18	4.37e-15	-0.42	-0.38	Serum uric acid levels in response to allopurinol in gout;	chr16:15774798	chr16:15726674~15732993:+
THCA	cis	rs4266144	0.926	rs4368453	ENSG00000244515.1	KRT18P34	-8.95	8.38e-18	4.37e-15	-0.44	-0.38	Coronary artery disease;	chr3:157134352	chr3:157162663~157163932:-
THCA	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-8.95	8.4e-18	4.38e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
THCA	cis	rs6723226	0.557	rs62136260	ENSG00000276334.1	AL133243.1	-8.95	8.41e-18	4.39e-15	-0.42	-0.38	Intelligence (multi-trait analysis);	chr2:32350379	chr2:32521927~32523547:+
THCA	cis	rs7131987	0.65	rs16934135	ENSG00000257176.2	RP11-996F15.2	-8.95	8.46e-18	4.41e-15	-0.39	-0.38	QT interval;	chr12:29331030	chr12:29280418~29317848:-
THCA	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	8.95	8.46e-18	4.41e-15	0.25	0.38	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
THCA	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	8.95	8.48e-18	4.42e-15	0.75	0.38	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	8.95	8.48e-18	4.42e-15	0.75	0.38	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	8.95	8.48e-18	4.42e-15	0.75	0.38	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
THCA	cis	rs673078	0.607	rs61943392	ENSG00000275409.1	RP11-131L12.4	-8.95	8.52e-18	4.44e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118382618	chr12:118430147~118430699:+
THCA	cis	rs1062177	1	rs1062177	ENSG00000253921.1	CTB-113P19.3	-8.95	8.52e-18	4.44e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151805140	chr5:151753992~151767247:+
THCA	cis	rs2243480	0.901	rs57126451	ENSG00000226824.5	RP4-756H11.3	-8.95	8.53e-18	4.45e-15	-0.75	-0.38	Diabetic kidney disease;	chr7:65951319	chr7:66654538~66669855:+
THCA	cis	rs2115630	0.691	rs8040066	ENSG00000225151.9	GOLGA2P7	8.95	8.59e-18	4.48e-15	0.48	0.38	P wave terminal force;	chr15:84633234	chr15:84199311~84230136:-
THCA	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	8.94	8.6e-18	4.48e-15	0.35	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
THCA	cis	rs17684571	0.7	rs62411366	ENSG00000231441.1	RP11-472M19.2	8.94	8.61e-18	4.49e-15	0.53	0.38	Schizophrenia;	chr6:56773015	chr6:56844002~56864078:+
THCA	cis	rs8062405	0.755	rs7186573	ENSG00000251417.2	RP11-1348G14.4	-8.94	8.61e-18	4.49e-15	-0.38	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28802743~28817828:+
THCA	cis	rs2243480	1	rs160652	ENSG00000273142.1	RP11-458F8.4	-8.94	8.63e-18	4.5e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:66073444	chr7:66902857~66906297:+
THCA	cis	rs11051970	0.559	rs11051944	ENSG00000274964.1	RP11-817I4.1	-8.94	8.63e-18	4.5e-15	-0.47	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32332984	chr12:32339368~32340724:+
THCA	cis	rs11971779	0.68	rs6947215	ENSG00000273391.1	RP11-634H22.1	8.94	8.64e-18	4.5e-15	0.34	0.38	Diisocyanate-induced asthma;	chr7:139341892	chr7:139359032~139359566:-
THCA	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	8.94	8.66e-18	4.51e-15	0.5	0.38	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.857	rs3776871	ENSG00000175749.11	EIF3KP1	8.94	8.66e-18	4.51e-15	0.5	0.38	Parkinson's disease;	chr5:102956507	chr5:103032376~103033031:+
THCA	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-8.94	8.68e-18	4.52e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
THCA	cis	rs7665090	1	rs735403	ENSG00000246560.2	RP11-10L12.4	-8.94	8.68e-18	4.52e-15	-0.46	-0.38	Primary biliary cholangitis;	chr4:102632386	chr4:102828055~102844075:+
THCA	cis	rs4819052	0.765	rs2838868	ENSG00000215447.6	BX322557.10	8.94	8.71e-18	4.54e-15	0.34	0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	8.94	8.77e-18	4.57e-15	0.45	0.38	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
THCA	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	8.94	8.78e-18	4.58e-15	0.73	0.38	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
THCA	cis	rs17684571	0.7	rs36022925	ENSG00000231441.1	RP11-472M19.2	8.94	8.79e-18	4.58e-15	0.5	0.38	Schizophrenia;	chr6:56818169	chr6:56844002~56864078:+
THCA	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-8.94	8.8e-18	4.58e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
THCA	cis	rs9322193	0.962	rs9765929	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149769680	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.736	rs10457851	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149775216	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.886	rs10872652	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149775303	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.886	rs17672976	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149776207	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs2184369	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149776681	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs2342861	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149777561	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.926	rs2342860	ENSG00000268592.3	RAET1E-AS1	8.94	8.81e-18	4.59e-15	0.51	0.38	Lung cancer;	chr6:149777641	chr6:149863494~149919507:+
THCA	cis	rs2948294	0.588	rs4840913	ENSG00000253893.2	FAM85B	-8.94	8.86e-18	4.62e-15	-0.49	-0.38	Red cell distribution width;	chr8:8259384	chr8:8167819~8226614:-
THCA	cis	rs66887589	0.807	rs7694483	ENSG00000245958.5	RP11-33B1.1	-8.94	8.87e-18	4.62e-15	-0.33	-0.38	Diastolic blood pressure;	chr4:119484774	chr4:119454791~119552025:+
THCA	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	8.94	8.89e-18	4.63e-15	0.41	0.38	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	8.94	8.89e-18	4.63e-15	0.41	0.38	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
THCA	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-8.94	8.89e-18	4.63e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
THCA	cis	rs2274273	0.522	rs2251366	ENSG00000258413.1	RP11-665C16.6	-8.94	8.92e-18	4.64e-15	-0.5	-0.38	Protein biomarker;	chr14:55051438	chr14:55262767~55272075:-
THCA	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-8.94	8.93e-18	4.65e-15	-0.53	-0.38	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
THCA	cis	rs673078	0.607	rs4766900	ENSG00000275409.1	RP11-131L12.4	-8.94	8.97e-18	4.67e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118375139	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs884844	ENSG00000275409.1	RP11-131L12.4	-8.94	8.97e-18	4.67e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118377033	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7304342	ENSG00000275409.1	RP11-131L12.4	-8.94	8.97e-18	4.67e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118390166	chr12:118430147~118430699:+
THCA	cis	rs673078	0.615	rs61943397	ENSG00000275409.1	RP11-131L12.4	-8.94	8.97e-18	4.67e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118390996	chr12:118430147~118430699:+
THCA	cis	rs9322193	0.962	rs12175575	ENSG00000268592.3	RAET1E-AS1	8.94	8.97e-18	4.67e-15	0.51	0.38	Lung cancer;	chr6:149763351	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs4869966	ENSG00000268592.3	RAET1E-AS1	8.94	8.97e-18	4.67e-15	0.51	0.38	Lung cancer;	chr6:149763714	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs1112730	ENSG00000268592.3	RAET1E-AS1	8.94	8.97e-18	4.67e-15	0.51	0.38	Lung cancer;	chr6:149766383	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs1112729	ENSG00000268592.3	RAET1E-AS1	8.94	8.97e-18	4.67e-15	0.51	0.38	Lung cancer;	chr6:149766491	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.962	rs10452626	ENSG00000268592.3	RAET1E-AS1	8.94	8.97e-18	4.67e-15	0.51	0.38	Lung cancer;	chr6:149767481	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.923	rs62441303	ENSG00000268592.3	RAET1E-AS1	8.94	8.97e-18	4.67e-15	0.51	0.38	Lung cancer;	chr6:149767547	chr6:149863494~149919507:+
THCA	cis	rs7567389	0.505	rs1518760	ENSG00000236682.1	AC068282.3	-8.94	8.98e-18	4.67e-15	-0.56	-0.38	Self-rated health;	chr2:127382924	chr2:127389130~127400580:+
THCA	cis	rs2836950	0.565	rs2836926	ENSG00000255568.3	BRWD1-AS2	-8.94	9e-18	4.69e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39164864	chr21:39313935~39314962:+
THCA	cis	rs2836950	0.565	rs8131132	ENSG00000255568.3	BRWD1-AS2	-8.94	9e-18	4.69e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39166330	chr21:39313935~39314962:+
THCA	cis	rs2288884	0.767	rs12462359	ENSG00000275055.1	CTC-471J1.11	-8.94	9.02e-18	4.69e-15	-0.36	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032168	chr19:52049007~52049754:+
THCA	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-8.94	9.03e-18	4.7e-15	-0.77	-0.38	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
THCA	cis	rs944289	0.745	rs1537427	ENSG00000257826.1	RP11-116N8.4	8.94	9.06e-18	4.71e-15	0.4	0.38	Thyroid cancer;	chr14:36117640	chr14:36061026~36067190:-
THCA	cis	rs2274273	0.682	rs7141975	ENSG00000258413.1	RP11-665C16.6	-8.94	9.08e-18	4.72e-15	-0.51	-0.38	Protein biomarker;	chr14:55075498	chr14:55262767~55272075:-
THCA	cis	rs1707322	0.682	rs10890335	ENSG00000234329.1	RP11-767N6.2	8.94	9.1e-18	4.73e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45651039~45651826:-
THCA	cis	rs71403859	0.614	rs12447033	ENSG00000260886.1	TAT-AS1	8.94	9.1e-18	4.74e-15	0.66	0.38	Post bronchodilator FEV1;	chr16:71549752	chr16:71565789~71578187:+
THCA	cis	rs944289	0.74	rs10498332	ENSG00000257826.1	RP11-116N8.4	-8.94	9.11e-18	4.74e-15	-0.39	-0.38	Thyroid cancer;	chr14:36102348	chr14:36061026~36067190:-
THCA	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	8.94	9.13e-18	4.75e-15	0.57	0.38	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	8.94	9.13e-18	4.75e-15	0.57	0.38	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
THCA	cis	rs17608059	0.545	rs736261	ENSG00000141028.6	CDRT15P1	-8.94	9.2e-18	4.79e-15	-0.45	-0.38	Temperament;	chr17:14033087	chr17:14024514~14025488:+
THCA	cis	rs9309711	0.56	rs6548164	ENSG00000225234.1	TRAPPC12-AS1	8.94	9.24e-18	4.81e-15	0.37	0.38	Neurofibrillary tangles;	chr2:3468894	chr2:3481242~3482409:-
THCA	cis	rs7945705	0.52	rs1984791	ENSG00000254860.4	TMEM9B-AS1	-8.94	9.26e-18	4.82e-15	-0.44	-0.38	Hemoglobin concentration;	chr11:9013480	chr11:8964675~8977527:+
THCA	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-8.94	9.28e-18	4.82e-15	-0.5	-0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
THCA	cis	rs944289	0.774	rs8013429	ENSG00000257826.1	RP11-116N8.4	-8.93	9.31e-18	4.84e-15	-0.4	-0.38	Thyroid cancer;	chr14:36131855	chr14:36061026~36067190:-
THCA	cis	rs4819052	0.851	rs3673	ENSG00000215447.6	BX322557.10	-8.93	9.32e-18	4.84e-15	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45288052~45291738:+
THCA	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-8.93	9.33e-18	4.85e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
THCA	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-8.93	9.33e-18	4.85e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
THCA	cis	rs12468226	0.808	rs77251002	ENSG00000273456.1	RP11-686O6.2	8.93	9.37e-18	4.87e-15	0.48	0.38	Urate levels;	chr2:202150236	chr2:202374932~202375604:-
THCA	cis	rs7586673	0.857	rs16845580	ENSG00000227403.1	AC009299.3	-8.93	9.39e-18	4.88e-15	-0.45	-0.38	Intelligence (multi-trait analysis);	chr2:161064373	chr2:161244739~161249050:+
THCA	cis	rs217727	0.818	rs2525883	ENSG00000226416.1	MRPL23-AS1	8.93	9.39e-18	4.88e-15	0.53	0.38	Breast cancer;	chr11:2000750	chr11:1983237~1989920:-
THCA	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	8.93	9.41e-18	4.89e-15	0.49	0.38	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
THCA	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-8.93	9.42e-18	4.9e-15	-0.4	-0.38	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
THCA	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-8.93	9.44e-18	4.91e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
THCA	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-8.93	9.44e-18	4.91e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
THCA	cis	rs2243480	1	rs7804223	ENSG00000273142.1	RP11-458F8.4	8.93	9.46e-18	4.91e-15	0.49	0.38	Diabetic kidney disease;	chr7:66199572	chr7:66902857~66906297:+
THCA	cis	rs17684571	0.751	rs16888184	ENSG00000231441.1	RP11-472M19.2	8.93	9.49e-18	4.93e-15	0.47	0.38	Schizophrenia;	chr6:56861347	chr6:56844002~56864078:+
THCA	cis	rs367615	0.679	rs4259216	ENSG00000249476.1	CTD-2587M2.1	8.93	9.51e-18	4.94e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109506116	chr5:109237120~109326369:-
THCA	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	8.93	9.52e-18	4.95e-15	0.44	0.38	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
THCA	cis	rs7727544	0.625	rs4705916	ENSG00000237714.1	P4HA2-AS1	8.93	9.53e-18	4.95e-15	0.51	0.38	Blood metabolite levels;	chr5:132071800	chr5:132184876~132192808:+
THCA	cis	rs801193	0.901	rs4273746	ENSG00000237310.1	GS1-124K5.4	-8.93	9.57e-18	4.97e-15	-0.28	-0.38	Aortic root size;	chr7:66836124	chr7:66493706~66495474:+
THCA	cis	rs597539	0.652	rs636049	ENSG00000250508.1	RP11-757G1.6	-8.93	9.57e-18	4.97e-15	-0.44	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68899730	chr11:68870664~68874542:+
THCA	cis	rs9928842	0.765	rs4479268	ENSG00000280152.1	RP11-331F4.5	-8.93	9.58e-18	4.97e-15	-0.53	-0.38	Alcoholic chronic pancreatitis;	chr16:75190835	chr16:75245994~75250077:-
THCA	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-8.93	9.59e-18	4.98e-15	-0.74	-0.38	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
THCA	cis	rs7665090	0.84	rs7674640	ENSG00000246560.2	RP11-10L12.4	8.93	9.6e-18	4.99e-15	0.46	0.38	Primary biliary cholangitis;	chr4:102619623	chr4:102828055~102844075:+
THCA	cis	rs4819052	0.851	rs2838865	ENSG00000237664.1	LINC00316	-8.93	9.61e-18	4.99e-15	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45292384	chr21:45338590~45341990:-
THCA	cis	rs9828933	0.752	rs13433909	ENSG00000280620.1	SCAANT1	8.93	9.62e-18	5e-15	0.63	0.38	Type 2 diabetes;	chr3:63962933	chr3:63911518~63911772:-
THCA	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	8.93	9.63e-18	5e-15	0.49	0.38	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
THCA	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-8.93	9.66e-18	5.02e-15	-0.4	-0.38	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
THCA	cis	rs524281	0.731	rs3814744	ENSG00000255320.1	RP11-755F10.1	8.93	9.66e-18	5.02e-15	0.6	0.38	Electroencephalogram traits;	chr11:66042292	chr11:66244840~66246239:-
THCA	cis	rs524281	0.648	rs4565902	ENSG00000255320.1	RP11-755F10.1	8.93	9.66e-18	5.02e-15	0.6	0.38	Electroencephalogram traits;	chr11:66042574	chr11:66244840~66246239:-
THCA	cis	rs2283792	0.764	rs2298432	ENSG00000224086.5	LL22NC03-86G7.1	-8.93	9.69e-18	5.03e-15	-0.48	-0.38	Multiple sclerosis;	chr22:21768900	chr22:21938293~21977632:+
THCA	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	8.93	9.69e-18	5.03e-15	0.44	0.38	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
THCA	cis	rs1707322	0.752	rs11488313	ENSG00000234329.1	RP11-767N6.2	8.93	9.71e-18	5.04e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45651039~45651826:-
THCA	cis	rs673078	0.607	rs61944661	ENSG00000275409.1	RP11-131L12.4	-8.93	9.71e-18	5.04e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445514	chr12:118430147~118430699:+
THCA	cis	rs4819052	0.851	rs9974891	ENSG00000215447.6	BX322557.10	-8.93	9.73e-18	5.05e-15	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45288052~45291738:+
THCA	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-8.93	9.76e-18	5.07e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
THCA	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	8.93	9.78e-18	5.07e-15	0.78	0.38	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
THCA	cis	rs7727544	0.526	rs17516457	ENSG00000237714.1	P4HA2-AS1	8.93	9.79e-18	5.08e-15	0.52	0.38	Blood metabolite levels;	chr5:132254694	chr5:132184876~132192808:+
THCA	cis	rs673078	0.607	rs7958551	ENSG00000275409.1	RP11-131L12.4	-8.93	9.87e-18	5.12e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118442585	chr12:118430147~118430699:+
THCA	cis	rs8062405	0.755	rs111693583	ENSG00000251417.2	RP11-1348G14.4	-8.93	9.88e-18	5.13e-15	-0.38	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28802743~28817828:+
THCA	cis	rs7772486	0.774	rs2748503	ENSG00000235652.6	RP11-545I5.3	8.93	9.89e-18	5.13e-15	0.36	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145973906	chr6:145799409~145886585:+
THCA	cis	rs7851660	0.967	rs10818133	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97848066	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.933	rs12341377	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97848100	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs7851552	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97848370	chr9:97805935~97810008:-
THCA	cis	rs7851660	1	rs7851660	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97848477	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs12348304	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97848951	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs3758251	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97851418	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs10046805	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97851674	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs3758249	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97851858	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs3758248	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97852319	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs907577	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97852835	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.933	rs13302470	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97853271	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.933	rs1867277	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97853632	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.87	rs1867278	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97853667	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs1867280	ENSG00000236130.1	PTCSC2	-8.93	9.89e-18	5.13e-15	-0.29	-0.38	Strep throat;	chr9:97853784	chr9:97805935~97810008:-
THCA	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	8.93	9.89e-18	5.13e-15	0.46	0.38	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
THCA	cis	rs673078	0.615	rs61943528	ENSG00000275409.1	RP11-131L12.4	-8.93	9.95e-18	5.16e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118163134	chr12:118430147~118430699:+
THCA	cis	rs2439831	0.702	rs8033995	ENSG00000249839.1	AC011330.5	-8.93	9.95e-18	5.16e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43721311	chr15:43663654~43684339:-
THCA	cis	rs7851660	0.967	rs3021526	ENSG00000236130.1	PTCSC2	-8.93	9.98e-18	5.18e-15	-0.29	-0.38	Strep throat;	chr9:97854739	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs1443434	ENSG00000236130.1	PTCSC2	-8.93	9.98e-18	5.18e-15	-0.29	-0.38	Strep throat;	chr9:97855197	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs1443435	ENSG00000236130.1	PTCSC2	-8.93	9.98e-18	5.18e-15	-0.29	-0.38	Strep throat;	chr9:97855301	chr9:97805935~97810008:-
THCA	cis	rs62103177	0.568	rs2365388	ENSG00000261126.6	RP11-795F19.1	8.93	9.99e-18	5.18e-15	0.42	0.38	Opioid sensitivity;	chr18:80215819	chr18:80046900~80095482:+
THCA	cis	rs2243480	0.901	rs13237344	ENSG00000273142.1	RP11-458F8.4	-8.93	1e-17	5.19e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66557269	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1267820	ENSG00000273142.1	RP11-458F8.4	-8.93	1e-17	5.19e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66585308	chr7:66902857~66906297:+
THCA	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-8.93	1e-17	5.19e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
THCA	cis	rs673078	0.607	rs7958652	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118442630	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs111607725	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118442957	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs76809232	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118444979	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61944660	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445326	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61944662	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445520	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs4254101	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445877	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs4622305	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118445912	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs73207575	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118446711	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61944663	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118446886	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs73207577	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447012	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs73207579	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447123	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61944664	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447145	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7969871	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447331	chr12:118430147~118430699:+
THCA	cis	rs673078	0.56	rs7970361	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118447723	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61944669	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118448530	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61944670	ENSG00000275409.1	RP11-131L12.4	-8.93	1e-17	5.19e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118448697	chr12:118430147~118430699:+
THCA	cis	rs8062405	0.755	rs56272201	ENSG00000251417.2	RP11-1348G14.4	-8.93	1e-17	5.19e-15	-0.39	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28802743~28817828:+
THCA	cis	rs8062405	0.755	rs62034355	ENSG00000251417.2	RP11-1348G14.4	-8.93	1e-17	5.19e-15	-0.39	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28802743~28817828:+
THCA	cis	rs2439831	0.702	rs16977724	ENSG00000249839.1	AC011330.5	-8.92	1.01e-17	5.21e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43859101	chr15:43663654~43684339:-
THCA	cis	rs11971779	0.68	rs7779900	ENSG00000273391.1	RP11-634H22.1	8.92	1.01e-17	5.23e-15	0.35	0.38	Diisocyanate-induced asthma;	chr7:139398241	chr7:139359032~139359566:-
THCA	cis	rs2033711	0.811	rs9304814	ENSG00000268912.1	CTD-2619J13.17	-8.92	1.01e-17	5.23e-15	-0.3	-0.38	Uric acid clearance;	chr19:58440444	chr19:58428632~58431148:-
THCA	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	8.92	1.01e-17	5.23e-15	0.72	0.38	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	8.92	1.01e-17	5.23e-15	0.72	0.38	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
THCA	cis	rs17807185	0.676	rs4273781	ENSG00000214293.7	APTR	8.92	1.01e-17	5.25e-15	0.27	0.38	Height;	chr7:77671806	chr7:77657660~77696265:-
THCA	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	8.92	1.01e-17	5.25e-15	0.81	0.38	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
THCA	cis	rs8027521	0.521	rs12905498	ENSG00000280362.1	RP11-643A5.3	-8.92	1.02e-17	5.26e-15	-0.53	-0.38	Circulating chemerin levels;	chr15:53943052	chr15:53910769~53914712:+
THCA	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	8.92	1.02e-17	5.27e-15	0.64	0.38	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
THCA	cis	rs6844153	0.752	rs73811400	ENSG00000240005.4	RP11-293A21.1	-8.92	1.02e-17	5.27e-15	-0.45	-0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887701	chr4:26859806~26860599:-
THCA	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-8.92	1.02e-17	5.28e-15	-0.42	-0.38	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
THCA	cis	rs801193	1	rs2420824	ENSG00000237310.1	GS1-124K5.4	-8.92	1.02e-17	5.28e-15	-0.27	-0.38	Aortic root size;	chr7:66666129	chr7:66493706~66495474:+
THCA	cis	rs1707322	0.682	rs10890334	ENSG00000234329.1	RP11-767N6.2	8.92	1.02e-17	5.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.716	rs6694889	ENSG00000234329.1	RP11-767N6.2	8.92	1.02e-17	5.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.682	rs12041197	ENSG00000234329.1	RP11-767N6.2	8.92	1.02e-17	5.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs11211145	ENSG00000234329.1	RP11-767N6.2	8.92	1.02e-17	5.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs11211146	ENSG00000234329.1	RP11-767N6.2	8.92	1.02e-17	5.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs11211147	ENSG00000234329.1	RP11-767N6.2	8.92	1.02e-17	5.29e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45651039~45651826:-
THCA	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-8.92	1.02e-17	5.29e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs313820	ENSG00000273142.1	RP11-458F8.4	-8.92	1.02e-17	5.3e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66109479	chr7:66902857~66906297:+
THCA	cis	rs9322193	0.926	rs9383546	ENSG00000268592.3	RAET1E-AS1	8.92	1.03e-17	5.31e-15	0.51	0.38	Lung cancer;	chr6:149822743	chr6:149863494~149919507:+
THCA	cis	rs1707322	0.752	rs11211152	ENSG00000234329.1	RP11-767N6.2	8.92	1.03e-17	5.31e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs4607935	ENSG00000234329.1	RP11-767N6.2	8.92	1.03e-17	5.31e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.681	rs12048866	ENSG00000234329.1	RP11-767N6.2	8.92	1.03e-17	5.31e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs3811436	ENSG00000234329.1	RP11-767N6.2	8.92	1.03e-17	5.31e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45651039~45651826:-
THCA	cis	rs8062405	0.755	rs12447461	ENSG00000251417.2	RP11-1348G14.4	-8.92	1.03e-17	5.33e-15	-0.38	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28802743~28817828:+
THCA	cis	rs9532669	0.926	rs9532690	ENSG00000239827.7	SUGT1P3	-8.92	1.03e-17	5.34e-15	-0.4	-0.38	Cervical cancer;	chr13:40968654	chr13:40908159~40921774:-
THCA	cis	rs2243480	1	rs316329	ENSG00000273142.1	RP11-458F8.4	-8.92	1.04e-17	5.37e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66143429	chr7:66902857~66906297:+
THCA	cis	rs11148252	0.712	rs61957257	ENSG00000278238.1	RP11-245D16.4	-8.92	1.04e-17	5.37e-15	-0.43	-0.38	Lewy body disease;	chr13:52195567	chr13:52454775~52455331:-
THCA	cis	rs2243480	1	rs67536397	ENSG00000273142.1	RP11-458F8.4	-8.92	1.04e-17	5.38e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66482930	chr7:66902857~66906297:+
THCA	cis	rs367615	0.704	rs72802966	ENSG00000249476.1	CTD-2587M2.1	8.92	1.04e-17	5.38e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109511053	chr5:109237120~109326369:-
THCA	cis	rs367615	0.704	rs72804385	ENSG00000249476.1	CTD-2587M2.1	8.92	1.04e-17	5.38e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109512442	chr5:109237120~109326369:-
THCA	cis	rs3747113	1	rs34949904	ENSG00000128262.7	POM121L9P	-8.92	1.04e-17	5.39e-15	-0.42	-0.38	Gut microbiome composition (summer);	chr22:24299330	chr22:24251828~24265525:+
THCA	cis	rs367615	0.704	rs17161885	ENSG00000249476.1	CTD-2587M2.1	8.92	1.05e-17	5.41e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109516941	chr5:109237120~109326369:-
THCA	cis	rs9309473	0.687	rs6748040	ENSG00000163016.8	ALMS1P	-8.92	1.05e-17	5.42e-15	-0.51	-0.38	Metabolite levels;	chr2:73382800	chr2:73644919~73685576:+
THCA	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	8.92	1.05e-17	5.44e-15	0.54	0.38	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
THCA	cis	rs34375054	0.66	rs58624919	ENSG00000279233.1	RP11-158L12.4	8.92	1.05e-17	5.44e-15	0.39	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125111912	chr12:125138245~125141711:+
THCA	cis	rs7567389	0.505	rs56273408	ENSG00000236682.1	AC068282.3	-8.92	1.05e-17	5.45e-15	-0.56	-0.38	Self-rated health;	chr2:127338012	chr2:127389130~127400580:+
THCA	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	8.92	1.05e-17	5.45e-15	0.25	0.38	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
THCA	cis	rs2288884	0.708	rs12460617	ENSG00000275055.1	CTC-471J1.11	-8.92	1.06e-17	5.46e-15	-0.35	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032581	chr19:52049007~52049754:+
THCA	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-8.92	1.06e-17	5.46e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
THCA	cis	rs4819052	0.851	rs2236443	ENSG00000215447.6	BX322557.10	-8.92	1.06e-17	5.47e-15	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45288052~45291738:+
THCA	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-8.92	1.06e-17	5.49e-15	-0.43	-0.38	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
THCA	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	8.92	1.06e-17	5.5e-15	0.25	0.38	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
THCA	cis	rs1062177	1	rs62394155	ENSG00000253921.1	CTB-113P19.3	-8.92	1.06e-17	5.51e-15	-0.47	-0.38	Preschool internalizing problems;	chr5:151868508	chr5:151753992~151767247:+
THCA	cis	rs2243480	0.803	rs36127118	ENSG00000273142.1	RP11-458F8.4	-8.92	1.07e-17	5.52e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66100518	chr7:66902857~66906297:+
THCA	cis	rs4819052	0.851	rs4819041	ENSG00000215447.6	BX322557.10	-8.92	1.07e-17	5.53e-15	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45288052~45291738:+
THCA	cis	rs11690935	0.589	rs62182403	ENSG00000228389.1	AC068039.4	-8.92	1.07e-17	5.53e-15	-0.41	-0.38	Schizophrenia;	chr2:171890672	chr2:171773482~171775844:+
THCA	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-8.92	1.07e-17	5.53e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
THCA	cis	rs66887589	0.775	rs6843229	ENSG00000245958.5	RP11-33B1.1	-8.92	1.07e-17	5.55e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119502932	chr4:119454791~119552025:+
THCA	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-8.92	1.07e-17	5.55e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
THCA	cis	rs2115630	0.645	rs6496284	ENSG00000225151.9	GOLGA2P7	8.92	1.07e-17	5.55e-15	0.5	0.38	P wave terminal force;	chr15:84635039	chr15:84199311~84230136:-
THCA	cis	rs673078	0.66	rs10507286	ENSG00000275409.1	RP11-131L12.4	-8.92	1.08e-17	5.57e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118197101	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61945180	ENSG00000275409.1	RP11-131L12.4	-8.92	1.08e-17	5.57e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118216335	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61945181	ENSG00000275409.1	RP11-131L12.4	-8.92	1.08e-17	5.57e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118216651	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61945183	ENSG00000275409.1	RP11-131L12.4	-8.92	1.08e-17	5.57e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118221966	chr12:118430147~118430699:+
THCA	cis	rs2243480	0.615	rs34363376	ENSG00000273142.1	RP11-458F8.4	-8.92	1.08e-17	5.58e-15	-0.5	-0.38	Diabetic kidney disease;	chr7:66474549	chr7:66902857~66906297:+
THCA	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-8.92	1.08e-17	5.6e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
THCA	cis	rs673078	0.66	rs16948193	ENSG00000275409.1	RP11-131L12.4	-8.91	1.09e-17	5.61e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118227115	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61945187	ENSG00000275409.1	RP11-131L12.4	-8.91	1.09e-17	5.61e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118228989	chr12:118430147~118430699:+
THCA	cis	rs7851660	0.933	rs894673	ENSG00000236130.1	PTCSC2	-8.91	1.09e-17	5.62e-15	-0.29	-0.38	Strep throat;	chr9:97849988	chr9:97805935~97810008:-
THCA	cis	rs1707322	0.821	rs10749857	ENSG00000234329.1	RP11-767N6.2	8.91	1.09e-17	5.63e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45651039~45651826:-
THCA	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	8.91	1.09e-17	5.65e-15	0.57	0.38	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
THCA	cis	rs2836950	0.545	rs2836922	ENSG00000255568.3	BRWD1-AS2	-8.91	1.09e-17	5.65e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39144382	chr21:39313935~39314962:+
THCA	cis	rs9309473	0.607	rs10196402	ENSG00000163016.8	ALMS1P	8.91	1.09e-17	5.65e-15	0.5	0.38	Metabolite levels;	chr2:73344953	chr2:73644919~73685576:+
THCA	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	8.91	1.1e-17	5.67e-15	0.74	0.38	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
THCA	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-8.91	1.1e-17	5.67e-15	-0.27	-0.38	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
THCA	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-8.91	1.1e-17	5.67e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
THCA	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-8.91	1.1e-17	5.67e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
THCA	cis	rs853679	0.628	rs9368560	ENSG00000226314.6	ZNF192P1	-8.91	1.1e-17	5.68e-15	-0.51	-0.38	Depression;	chr6:28192182	chr6:28161781~28169594:+
THCA	cis	rs7851660	0.901	rs7873389	ENSG00000236130.1	PTCSC2	-8.91	1.1e-17	5.69e-15	-0.29	-0.38	Strep throat;	chr9:97846948	chr9:97805935~97810008:-
THCA	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-8.91	1.11e-17	5.71e-15	-0.76	-0.38	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-8.91	1.11e-17	5.71e-15	-0.76	-0.38	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
THCA	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	8.91	1.11e-17	5.72e-15	0.51	0.38	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
THCA	cis	rs2946504	0.506	rs9644017	ENSG00000251468.2	RP11-369K16.1	-8.91	1.11e-17	5.73e-15	-0.44	-0.38	Type 2 diabetes;	chr8:12961375	chr8:12958387~12962200:+
THCA	cis	rs62388641	0.547	rs2317966	ENSG00000272279.1	RP11-157J24.2	-8.91	1.11e-17	5.73e-15	-0.5	-0.38	Daytime sleep phenotypes;	chr6:1550651	chr6:1528364~1528911:-
THCA	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
THCA	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	8.91	1.11e-17	5.73e-15	0.57	0.38	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
THCA	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	8.91	1.11e-17	5.73e-15	0.57	0.38	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.831	rs7806717	ENSG00000273142.1	RP11-458F8.4	8.91	1.11e-17	5.73e-15	0.48	0.38	Diabetic kidney disease;	chr7:65928187	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs34136756	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65916269	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs34933526	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65918212	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6949812	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65922114	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6970243	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65923503	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.708	rs35310401	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65925372	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs35058610	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65925938	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs35087093	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65940221	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs35046236	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65943626	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs36068983	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65944004	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs68189316	ENSG00000273142.1	RP11-458F8.4	-8.91	1.11e-17	5.73e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65944182	chr7:66902857~66906297:+
THCA	cis	rs10463554	0.892	rs66759661	ENSG00000175749.11	EIF3KP1	8.91	1.11e-17	5.74e-15	0.5	0.38	Parkinson's disease;	chr5:102925894	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs6872442	ENSG00000175749.11	EIF3KP1	8.91	1.11e-17	5.74e-15	0.5	0.38	Parkinson's disease;	chr5:102930818	chr5:103032376~103033031:+
THCA	cis	rs9828933	0.938	rs9809432	ENSG00000280620.1	SCAANT1	8.91	1.12e-17	5.75e-15	0.64	0.38	Type 2 diabetes;	chr3:64017277	chr3:63911518~63911772:-
THCA	cis	rs2946504	0.553	rs2977078	ENSG00000251468.2	RP11-369K16.1	-8.91	1.12e-17	5.76e-15	-0.44	-0.38	Type 2 diabetes;	chr8:12959997	chr8:12958387~12962200:+
THCA	cis	rs947583	0.517	rs7756915	ENSG00000231028.7	LINC00271	-8.91	1.12e-17	5.78e-15	-0.29	-0.38	Phosphorus levels;	chr6:135798177	chr6:135497801~135716055:+
THCA	cis	rs73081554	0.611	rs4681852	ENSG00000272360.1	RP11-359I18.5	-8.91	1.12e-17	5.79e-15	-0.54	-0.38	Rheumatoid arthritis;	chr3:58423446	chr3:58490830~58491291:-
THCA	cis	rs7829975	0.714	rs12544992	ENSG00000253893.2	FAM85B	-8.91	1.12e-17	5.8e-15	-0.48	-0.38	Mood instability;	chr8:8804171	chr8:8167819~8226614:-
THCA	cis	rs860295	0.836	rs35615695	ENSG00000225855.5	RUSC1-AS1	-8.91	1.13e-17	5.81e-15	-0.25	-0.38	Body mass index;	chr1:155531223	chr1:155316863~155324176:-
THCA	cis	rs2015599	0.56	rs11050147	ENSG00000275476.1	RP11-996F15.4	-8.91	1.13e-17	5.81e-15	-0.4	-0.38	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29277397~29277882:-
THCA	cis	rs1707322	0.721	rs7519900	ENSG00000234329.1	RP11-767N6.2	8.91	1.13e-17	5.83e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45651039~45651826:-
THCA	cis	rs10740039	0.81	rs9415605	ENSG00000254271.1	RP11-131N11.4	-8.91	1.13e-17	5.83e-15	-0.5	-0.38	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60616809	chr10:60734342~60741828:+
THCA	cis	rs4927850	0.958	rs2044599	ENSG00000273009.1	RP11-352G9.1	-8.91	1.13e-17	5.84e-15	-0.43	-0.38	Pancreatic cancer;	chr3:196009869	chr3:195913078~195913683:-
THCA	cis	rs4927850	1	rs4927704	ENSG00000273009.1	RP11-352G9.1	-8.91	1.13e-17	5.84e-15	-0.43	-0.38	Pancreatic cancer;	chr3:196011357	chr3:195913078~195913683:-
THCA	cis	rs4927850	1	rs4927848	ENSG00000273009.1	RP11-352G9.1	-8.91	1.13e-17	5.84e-15	-0.43	-0.38	Pancreatic cancer;	chr3:196011535	chr3:195913078~195913683:-
THCA	cis	rs673078	0.607	rs73207573	ENSG00000275409.1	RP11-131L12.4	-8.91	1.14e-17	5.86e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118444664	chr12:118430147~118430699:+
THCA	cis	rs77204473	0.744	rs2046149	ENSG00000254851.1	RP11-109L13.1	8.91	1.14e-17	5.88e-15	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117183993	chr11:117135528~117138582:+
THCA	cis	rs4713118	0.786	rs200502	ENSG00000219392.1	RP1-265C24.5	-8.91	1.14e-17	5.89e-15	-0.5	-0.38	Parkinson's disease;	chr6:27820284	chr6:28115628~28116551:+
THCA	cis	rs673078	0.607	rs61943398	ENSG00000275409.1	RP11-131L12.4	-8.91	1.15e-17	5.91e-15	-0.45	-0.38	Glucose homeostasis traits;	chr12:118393280	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs61943403	ENSG00000275409.1	RP11-131L12.4	-8.91	1.15e-17	5.91e-15	-0.45	-0.38	Glucose homeostasis traits;	chr12:118399887	chr12:118430147~118430699:+
THCA	cis	rs10463554	0.892	rs1898673	ENSG00000175749.11	EIF3KP1	8.91	1.15e-17	5.93e-15	0.5	0.38	Parkinson's disease;	chr5:102957676	chr5:103032376~103033031:+
THCA	cis	rs10028773	0.546	rs13117947	ENSG00000245958.5	RP11-33B1.1	-8.91	1.15e-17	5.93e-15	-0.34	-0.38	Educational attainment;	chr4:119335905	chr4:119454791~119552025:+
THCA	cis	rs2243480	0.908	rs313822	ENSG00000273142.1	RP11-458F8.4	-8.91	1.15e-17	5.95e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66108952	chr7:66902857~66906297:+
THCA	cis	rs6600671	0.692	rs11249430	ENSG00000223345.3	HIST2H2BA	8.91	1.15e-17	5.95e-15	0.43	0.38	Hip geometry;	chr1:121547115	chr1:121108210~121117257:-
THCA	cis	rs673078	0.571	rs17440823	ENSG00000275409.1	RP11-131L12.4	-8.91	1.16e-17	5.97e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118353023	chr12:118430147~118430699:+
THCA	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	8.91	1.16e-17	5.98e-15	0.25	0.38	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	8.91	1.16e-17	5.98e-15	0.25	0.38	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	8.91	1.16e-17	5.98e-15	0.25	0.38	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	8.91	1.16e-17	5.98e-15	0.25	0.38	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
THCA	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-8.91	1.16e-17	5.99e-15	-0.51	-0.38	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
THCA	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-8.91	1.17e-17	6e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
THCA	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-8.91	1.17e-17	6.02e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
THCA	cis	rs1707322	0.752	rs12024590	ENSG00000234329.1	RP11-767N6.2	8.91	1.17e-17	6.02e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs12027622	ENSG00000234329.1	RP11-767N6.2	8.91	1.17e-17	6.02e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4415615	ENSG00000234329.1	RP11-767N6.2	8.91	1.17e-17	6.02e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs7529699	ENSG00000234329.1	RP11-767N6.2	8.91	1.17e-17	6.02e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.716	rs6699444	ENSG00000234329.1	RP11-767N6.2	8.91	1.17e-17	6.02e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs10430105	ENSG00000234329.1	RP11-767N6.2	8.91	1.17e-17	6.02e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45651039~45651826:-
THCA	cis	rs7569084	0.663	rs4671128	ENSG00000234255.7	AC012370.3	8.9	1.17e-17	6.03e-15	0.43	0.38	Sum eosinophil basophil counts;	chr2:65438130	chr2:65439888~65456571:-
THCA	cis	rs17684571	0.688	rs35440408	ENSG00000231441.1	RP11-472M19.2	8.9	1.17e-17	6.04e-15	0.47	0.38	Schizophrenia;	chr6:56866055	chr6:56844002~56864078:+
THCA	cis	rs9322193	1	rs9377229	ENSG00000268592.3	RAET1E-AS1	8.9	1.17e-17	6.04e-15	0.51	0.38	Lung cancer;	chr6:149607655	chr6:149863494~149919507:+
THCA	cis	rs10759883	0.539	rs10115110	ENSG00000175611.10	LINC00476	8.9	1.17e-17	6.04e-15	0.43	0.38	Nicotine dependence;	chr9:96033023	chr9:95759231~95875977:-
THCA	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-8.9	1.17e-17	6.04e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-8.9	1.17e-17	6.04e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
THCA	cis	rs367615	0.679	rs10070786	ENSG00000249476.1	CTD-2587M2.1	8.9	1.18e-17	6.06e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109479380	chr5:109237120~109326369:-
THCA	cis	rs3747113	1	rs9624447	ENSG00000128262.7	POM121L9P	-8.9	1.18e-17	6.07e-15	-0.41	-0.38	Gut microbiome composition (summer);	chr22:24285587	chr22:24251828~24265525:+
THCA	cis	rs934734	0.571	rs7565437	ENSG00000234255.7	AC012370.3	-8.9	1.18e-17	6.07e-15	-0.42	-0.38	Rheumatoid arthritis;	chr2:65419832	chr2:65439888~65456571:-
THCA	cis	rs2243480	0.764	rs2460423	ENSG00000273142.1	RP11-458F8.4	-8.9	1.18e-17	6.09e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66136229	chr7:66902857~66906297:+
THCA	cis	rs932287	0.536	rs10840160	ENSG00000254860.4	TMEM9B-AS1	8.9	1.18e-17	6.09e-15	0.42	0.38	Colonoscopy-negative controls vs population controls;	chr11:9031989	chr11:8964675~8977527:+
THCA	cis	rs1799949	0.965	rs799910	ENSG00000267681.1	CTD-3199J23.6	-8.9	1.18e-17	6.09e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43127544	chr17:43144956~43145255:+
THCA	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-8.9	1.19e-17	6.11e-15	-0.39	-0.38	QT interval;	chr12:29309811	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-8.9	1.19e-17	6.11e-15	-0.39	-0.38	QT interval;	chr12:29310155	chr12:29280418~29317848:-
THCA	cis	rs66887589	0.87	rs10518336	ENSG00000245958.5	RP11-33B1.1	-8.9	1.19e-17	6.12e-15	-0.34	-0.38	Diastolic blood pressure;	chr4:119601779	chr4:119454791~119552025:+
THCA	cis	rs4819052	1	rs13052356	ENSG00000215447.6	BX322557.10	-8.9	1.19e-17	6.13e-15	-0.34	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45288052~45291738:+
THCA	cis	rs1707322	0.686	rs61784833	ENSG00000234329.1	RP11-767N6.2	8.9	1.2e-17	6.16e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45651039~45651826:-
THCA	cis	rs367615	0.704	rs4286723	ENSG00000249476.1	CTD-2587M2.1	8.9	1.2e-17	6.17e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109500258	chr5:109237120~109326369:-
THCA	cis	rs748404	0.697	rs1095389	ENSG00000249839.1	AC011330.5	-8.9	1.2e-17	6.18e-15	-0.45	-0.38	Lung cancer;	chr15:43274473	chr15:43663654~43684339:-
THCA	cis	rs10740039	0.883	rs2393676	ENSG00000254271.1	RP11-131N11.4	8.9	1.2e-17	6.18e-15	0.46	0.38	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60630500	chr10:60734342~60741828:+
THCA	cis	rs673078	0.607	rs7309484	ENSG00000275409.1	RP11-131L12.4	-8.9	1.2e-17	6.18e-15	-0.46	-0.38	Glucose homeostasis traits;	chr12:118400833	chr12:118430147~118430699:+
THCA	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-8.9	1.2e-17	6.19e-15	-0.75	-0.38	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
THCA	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	8.9	1.2e-17	6.19e-15	0.24	0.38	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
THCA	cis	rs6142102	0.527	rs1015362	ENSG00000276073.1	RP5-1125A11.7	8.9	1.21e-17	6.2e-15	0.36	0.38	Skin pigmentation;	chr20:34150806	chr20:33985617~33988989:-
THCA	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-8.9	1.21e-17	6.2e-15	-0.39	-0.38	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.962	rs2275046	ENSG00000268592.3	RAET1E-AS1	8.9	1.21e-17	6.21e-15	0.51	0.38	Lung cancer;	chr6:149835865	chr6:149863494~149919507:+
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000228039.3	KB-1125A3.10	8.9	1.21e-17	6.23e-15	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23963780~23964374:+
THCA	cis	rs1799949	1	rs9646412	ENSG00000267681.1	CTD-3199J23.6	-8.9	1.22e-17	6.27e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43348525	chr17:43144956~43145255:+
THCA	cis	rs1799949	1	rs4793231	ENSG00000267681.1	CTD-3199J23.6	-8.9	1.22e-17	6.27e-15	-0.45	-0.38	Menopause (age at onset);	chr17:43350101	chr17:43144956~43145255:+
THCA	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-8.9	1.22e-17	6.27e-15	-0.44	-0.38	Migraine;	chr4:56879851	chr4:56960927~56961373:-
THCA	cis	rs2946504	0.553	rs2946498	ENSG00000251468.2	RP11-369K16.1	-8.9	1.23e-17	6.3e-15	-0.44	-0.38	Type 2 diabetes;	chr8:12960578	chr8:12958387~12962200:+
THCA	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	8.9	1.23e-17	6.32e-15	0.39	0.38	QT interval;	chr12:29284120	chr12:29280418~29317848:-
THCA	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-8.9	1.23e-17	6.32e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-8.9	1.23e-17	6.32e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
THCA	cis	rs9532669	0.926	rs4942007	ENSG00000176268.5	CYCSP34	8.9	1.23e-17	6.33e-15	0.44	0.38	Cervical cancer;	chr13:40871887	chr13:40863599~40863902:-
THCA	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66692349	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66693433	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66694214	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66701371	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66702658	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66706390	chr7:66654538~66669855:+
THCA	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66710076	chr7:66654538~66669855:+
THCA	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-8.9	1.23e-17	6.34e-15	-0.78	-0.38	Gout;	chr7:66715944	chr7:66654538~66669855:+
THCA	cis	rs12554020	0.892	rs12555047	ENSG00000227603.1	RP11-165J3.6	8.9	1.23e-17	6.34e-15	0.54	0.38	Schizophrenia;	chr9:93424208	chr9:93435332~93437121:-
THCA	cis	rs7851660	0.967	rs12348691	ENSG00000236130.1	PTCSC2	-8.9	1.24e-17	6.36e-15	-0.29	-0.38	Strep throat;	chr9:97846400	chr9:97805935~97810008:-
THCA	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-8.9	1.24e-17	6.38e-15	-0.48	-0.38	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
THCA	cis	rs6822297	0.504	rs10010180	ENSG00000240005.4	RP11-293A21.1	8.9	1.24e-17	6.38e-15	0.43	0.38	Obesity-related traits;	chr4:26984359	chr4:26859806~26860599:-
THCA	cis	rs8062405	0.755	rs56209193	ENSG00000251417.2	RP11-1348G14.4	-8.9	1.24e-17	6.39e-15	-0.38	-0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28802743~28817828:+
THCA	cis	rs2243480	0.908	rs55876148	ENSG00000273142.1	RP11-458F8.4	-8.9	1.24e-17	6.39e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65914813	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	8.9	1.24e-17	6.39e-15	0.49	0.38	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	8.9	1.24e-17	6.39e-15	0.49	0.38	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	8.9	1.24e-17	6.39e-15	0.49	0.38	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
THCA	cis	rs7131987	0.65	rs3782509	ENSG00000257176.2	RP11-996F15.2	-8.9	1.25e-17	6.41e-15	-0.4	-0.38	QT interval;	chr12:29300845	chr12:29280418~29317848:-
THCA	cis	rs6564219	1	rs6564219	ENSG00000280152.1	RP11-331F4.5	8.9	1.25e-17	6.44e-15	0.54	0.38	Alcoholic chronic pancreatitis;	chr16:75188108	chr16:75245994~75250077:-
THCA	cis	rs4819052	0.724	rs1304487	ENSG00000215447.6	BX322557.10	8.9	1.25e-17	6.44e-15	0.31	0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45288052~45291738:+
THCA	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	8.9	1.26e-17	6.45e-15	0.49	0.38	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	8.9	1.26e-17	6.45e-15	0.49	0.38	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	8.9	1.26e-17	6.45e-15	0.49	0.38	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
THCA	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-8.9	1.26e-17	6.45e-15	-0.47	-0.38	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
THCA	cis	rs10411161	0.702	rs10424202	ENSG00000269483.1	AC006272.1	8.9	1.26e-17	6.45e-15	0.53	0.38	Breast cancer;	chr19:51884044	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs10423835	ENSG00000269483.1	AC006272.1	8.9	1.26e-17	6.45e-15	0.53	0.38	Breast cancer;	chr19:51884069	chr19:51839924~51843324:-
THCA	cis	rs9928842	0.712	rs8057843	ENSG00000280152.1	RP11-331F4.5	8.9	1.26e-17	6.47e-15	0.54	0.38	Alcoholic chronic pancreatitis;	chr16:75187657	chr16:75245994~75250077:-
THCA	cis	rs7189233	0.531	rs9302648	ENSG00000279344.1	RP11-44F14.7	8.9	1.26e-17	6.47e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr16:53493869	chr16:53478957~53481550:-
THCA	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-8.9	1.26e-17	6.48e-15	-0.39	-0.38	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
THCA	cis	rs1707322	0.827	rs6694302	ENSG00000234329.1	RP11-767N6.2	8.89	1.27e-17	6.51e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45651039~45651826:-
THCA	cis	rs34375054	0.672	rs10400509	ENSG00000279233.1	RP11-158L12.4	8.89	1.27e-17	6.52e-15	0.36	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125107627	chr12:125138245~125141711:+
THCA	cis	rs860295	0.871	rs6688636	ENSG00000225855.5	RUSC1-AS1	-8.89	1.27e-17	6.52e-15	-0.25	-0.38	Body mass index;	chr1:155509106	chr1:155316863~155324176:-
THCA	cis	rs11051970	0.659	rs73088096	ENSG00000274964.1	RP11-817I4.1	-8.89	1.27e-17	6.53e-15	-0.49	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32431469	chr12:32339368~32340724:+
THCA	cis	rs2836950	0.52	rs1980407	ENSG00000255568.3	BRWD1-AS2	-8.89	1.28e-17	6.57e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39172035	chr21:39313935~39314962:+
THCA	cis	rs11971779	0.553	rs36002669	ENSG00000273391.1	RP11-634H22.1	8.89	1.29e-17	6.59e-15	0.35	0.38	Diisocyanate-induced asthma;	chr7:139428415	chr7:139359032~139359566:-
THCA	cis	rs2236295	0.814	rs1848797	ENSG00000238280.1	RP11-436D10.3	-8.89	1.29e-17	6.6e-15	-0.48	-0.38	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr10:62793174	chr10:62793562~62805887:-
THCA	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-8.89	1.29e-17	6.62e-15	-0.78	-0.38	Gout;	chr7:66693028	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	8.89	1.29e-17	6.63e-15	0.48	0.38	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	8.89	1.29e-17	6.63e-15	0.48	0.38	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
THCA	cis	rs1426063	0.614	rs78784058	ENSG00000260265.1	RP11-44F21.5	8.89	1.3e-17	6.66e-15	0.81	0.38	QT interval;	chr4:75108738	chr4:75081702~75084717:-
THCA	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-8.89	1.3e-17	6.67e-15	-0.5	-0.38	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
THCA	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	8.89	1.3e-17	6.67e-15	0.41	0.38	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
THCA	cis	rs12188164	0.515	rs17562461	ENSG00000221990.4	EXOC3-AS1	8.89	1.3e-17	6.68e-15	0.32	0.38	Cystic fibrosis severity;	chr5:411246	chr5:441498~443160:-
THCA	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	8.89	1.3e-17	6.68e-15	0.48	0.38	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
THCA	cis	rs673078	0.66	rs61943535	ENSG00000275409.1	RP11-131L12.4	-8.89	1.33e-17	6.79e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118168307	chr12:118430147~118430699:+
THCA	cis	rs2408955	0.521	rs11168437	ENSG00000258273.1	RP11-370I10.4	-8.89	1.33e-17	6.8e-15	-0.5	-0.38	Glycated hemoglobin levels;	chr12:48172373	chr12:48333755~48333901:-
THCA	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	8.89	1.33e-17	6.82e-15	0.45	0.38	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
THCA	cis	rs2243480	0.901	rs2949697	ENSG00000273142.1	RP11-458F8.4	-8.89	1.33e-17	6.83e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65999249	chr7:66902857~66906297:+
THCA	cis	rs73081554	0.611	rs35975336	ENSG00000272360.1	RP11-359I18.5	-8.89	1.33e-17	6.83e-15	-0.54	-0.38	Rheumatoid arthritis;	chr3:58465907	chr3:58490830~58491291:-
THCA	cis	rs9322193	0.962	rs1413655	ENSG00000268592.3	RAET1E-AS1	8.89	1.33e-17	6.84e-15	0.51	0.38	Lung cancer;	chr6:149821815	chr6:149863494~149919507:+
THCA	cis	rs4819052	0.679	rs4819053	ENSG00000215447.6	BX322557.10	8.89	1.33e-17	6.84e-15	0.3	0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291442	chr21:45288052~45291738:+
THCA	cis	rs7015263	0.689	rs10956803	ENSG00000254231.1	CTD-2284J15.1	-8.89	1.34e-17	6.85e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86350845	chr8:86333274~86343314:-
THCA	cis	rs10759883	0.563	rs690286	ENSG00000175611.10	LINC00476	8.89	1.34e-17	6.88e-15	0.44	0.38	Nicotine dependence;	chr9:96034685	chr9:95759231~95875977:-
THCA	cis	rs2439831	0.85	rs28524541	ENSG00000249839.1	AC011330.5	-8.89	1.34e-17	6.89e-15	-0.62	-0.38	Lung cancer in ever smokers;	chr15:43832633	chr15:43663654~43684339:-
THCA	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-8.89	1.35e-17	6.94e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-8.89	1.35e-17	6.94e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-8.89	1.35e-17	6.94e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-8.89	1.35e-17	6.94e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
THCA	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	8.89	1.36e-17	6.96e-15	0.53	0.38	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
THCA	cis	rs2115630	0.691	rs2292462	ENSG00000225151.9	GOLGA2P7	8.89	1.36e-17	6.97e-15	0.48	0.38	P wave terminal force;	chr15:84657523	chr15:84199311~84230136:-
THCA	cis	rs6600671	0.693	rs1853731	ENSG00000223345.3	HIST2H2BA	8.89	1.36e-17	6.97e-15	0.43	0.38	Hip geometry;	chr1:121510262	chr1:121108210~121117257:-
THCA	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	8.89	1.36e-17	6.98e-15	0.65	0.38	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
THCA	cis	rs950169	0.58	rs11636189	ENSG00000259728.4	LINC00933	8.89	1.36e-17	6.98e-15	0.51	0.38	Schizophrenia;	chr15:84650323	chr15:84570649~84580175:+
THCA	cis	rs950169	0.58	rs35516100	ENSG00000259728.4	LINC00933	8.89	1.36e-17	6.98e-15	0.51	0.38	Schizophrenia;	chr15:84652199	chr15:84570649~84580175:+
THCA	cis	rs950169	0.58	rs62021208	ENSG00000259728.4	LINC00933	8.89	1.36e-17	6.98e-15	0.51	0.38	Schizophrenia;	chr15:84653013	chr15:84570649~84580175:+
THCA	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-8.88	1.37e-17	7.03e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
THCA	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	8.88	1.38e-17	7.05e-15	0.39	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
THCA	cis	rs77204473	0.744	rs2306472	ENSG00000254851.1	RP11-109L13.1	8.88	1.38e-17	7.05e-15	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117187346	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs3213459	ENSG00000254851.1	RP11-109L13.1	8.88	1.38e-17	7.05e-15	0.88	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117191773	chr11:117135528~117138582:+
THCA	cis	rs56046484	0.956	rs34345801	ENSG00000259295.5	CSPG4P12	8.88	1.38e-17	7.06e-15	0.6	0.38	Testicular germ cell tumor;	chr15:85101842	chr15:85191438~85213905:+
THCA	cis	rs34375054	0.66	rs57491100	ENSG00000279233.1	RP11-158L12.4	8.88	1.38e-17	7.06e-15	0.39	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125108464	chr12:125138245~125141711:+
THCA	cis	rs34375054	0.66	rs57031290	ENSG00000279233.1	RP11-158L12.4	8.88	1.38e-17	7.06e-15	0.39	0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125108507	chr12:125138245~125141711:+
THCA	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-8.88	1.38e-17	7.08e-15	-0.44	-0.38	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
THCA	cis	rs4713118	0.824	rs9468225	ENSG00000219392.1	RP1-265C24.5	-8.88	1.38e-17	7.09e-15	-0.5	-0.38	Parkinson's disease;	chr6:27777940	chr6:28115628~28116551:+
THCA	cis	rs4819052	1	rs13047688	ENSG00000215447.6	BX322557.10	-8.88	1.39e-17	7.09e-15	-0.34	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45288052~45291738:+
THCA	cis	rs7851660	0.87	rs55960649	ENSG00000236130.1	PTCSC2	-8.88	1.39e-17	7.1e-15	-0.29	-0.38	Strep throat;	chr9:97836413	chr9:97805935~97810008:-
THCA	cis	rs7015263	0.643	rs7460251	ENSG00000254231.1	CTD-2284J15.1	-8.88	1.39e-17	7.1e-15	-0.39	-0.38	Intelligence (multi-trait analysis);	chr8:86505759	chr8:86333274~86343314:-
THCA	cis	rs11696845	0.761	rs11698203	ENSG00000276223.1	RP4-781B1.5	8.88	1.39e-17	7.14e-15	0.46	0.38	Obesity-related traits;	chr20:44729258	chr20:44746642~44747201:+
THCA	cis	rs77204473	0.744	rs3781985	ENSG00000254851.1	RP11-109L13.1	8.88	1.4e-17	7.17e-15	0.87	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194350	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs11606480	ENSG00000254851.1	RP11-109L13.1	8.88	1.4e-17	7.17e-15	0.87	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117194817	chr11:117135528~117138582:+
THCA	cis	rs7569084	0.687	rs12993075	ENSG00000234255.7	AC012370.3	8.88	1.41e-17	7.24e-15	0.43	0.38	Sum eosinophil basophil counts;	chr2:65431010	chr2:65439888~65456571:-
THCA	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-8.88	1.42e-17	7.27e-15	-0.56	-0.38	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
THCA	cis	rs7131987	0.65	rs67146951	ENSG00000257176.2	RP11-996F15.2	-8.88	1.42e-17	7.27e-15	-0.39	-0.38	QT interval;	chr12:29297620	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.65	rs10843382	ENSG00000257176.2	RP11-996F15.2	-8.88	1.42e-17	7.27e-15	-0.39	-0.38	QT interval;	chr12:29298788	chr12:29280418~29317848:-
THCA	cis	rs2033711	0.87	rs4801583	ENSG00000268912.1	CTD-2619J13.17	-8.88	1.42e-17	7.28e-15	-0.29	-0.38	Uric acid clearance;	chr19:58407038	chr19:58428632~58431148:-
THCA	cis	rs11603023	0.874	rs483598	ENSG00000255239.1	AP002954.6	8.88	1.42e-17	7.28e-15	0.48	0.38	Cholesterol, total;	chr11:118638950	chr11:118688039~118690600:-
THCA	cis	rs2243480	1	rs2420171	ENSG00000273142.1	RP11-458F8.4	8.88	1.43e-17	7.3e-15	0.47	0.38	Diabetic kidney disease;	chr7:66172773	chr7:66902857~66906297:+
THCA	cis	rs1075265	0.622	rs4671529	ENSG00000233266.1	HMGB1P31	8.88	1.43e-17	7.31e-15	0.49	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53697167	chr2:54051334~54051760:+
THCA	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-8.88	1.43e-17	7.33e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
THCA	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-8.88	1.43e-17	7.33e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
THCA	cis	rs11971779	0.68	rs2355787	ENSG00000273391.1	RP11-634H22.1	-8.88	1.44e-17	7.37e-15	-0.35	-0.38	Diisocyanate-induced asthma;	chr7:139405182	chr7:139359032~139359566:-
THCA	cis	rs600231	0.706	rs4244811	ENSG00000245532.5	NEAT1	-8.88	1.44e-17	7.37e-15	-0.27	-0.38	Bone mineral density;	chr11:65553309	chr11:65422774~65445540:+
THCA	cis	rs7849270	1	rs3124511	ENSG00000268707.1	RP11-247A12.7	8.88	1.44e-17	7.38e-15	0.47	0.38	Blood metabolite ratios;	chr9:129139179	chr9:129170434~129170940:+
THCA	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-8.88	1.44e-17	7.38e-15	-0.76	-0.38	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	8.88	1.44e-17	7.38e-15	0.76	0.38	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	8.88	1.44e-17	7.38e-15	0.76	0.38	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
THCA	cis	rs10463554	0.927	rs55641526	ENSG00000175749.11	EIF3KP1	8.88	1.46e-17	7.44e-15	0.5	0.38	Parkinson's disease;	chr5:102915301	chr5:103032376~103033031:+
THCA	cis	rs7211079	0.719	rs2289535	ENSG00000275479.1	RP11-334C17.6	8.88	1.46e-17	7.44e-15	0.35	0.38	Myocardial infarction;	chr17:80137650	chr17:80149627~80149798:+
THCA	cis	rs7665090	1	rs4586937	ENSG00000246560.2	RP11-10L12.4	-8.88	1.46e-17	7.44e-15	-0.45	-0.38	Primary biliary cholangitis;	chr4:102635305	chr4:102828055~102844075:+
THCA	cis	rs10411161	0.938	rs17778649	ENSG00000269483.1	AC006272.1	8.88	1.46e-17	7.47e-15	0.55	0.38	Breast cancer;	chr19:51878363	chr19:51839924~51843324:-
THCA	cis	rs56046484	0.956	rs17541572	ENSG00000259295.5	CSPG4P12	-8.88	1.46e-17	7.48e-15	-0.67	-0.38	Testicular germ cell tumor;	chr15:85122016	chr15:85191438~85213905:+
THCA	cis	rs2243480	1	rs56016656	ENSG00000273142.1	RP11-458F8.4	-8.88	1.47e-17	7.51e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65918494	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs56291018	ENSG00000273142.1	RP11-458F8.4	-8.88	1.47e-17	7.51e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65925352	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs36033484	ENSG00000273142.1	RP11-458F8.4	-8.88	1.47e-17	7.51e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65925571	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs34560516	ENSG00000273142.1	RP11-458F8.4	-8.88	1.47e-17	7.51e-15	-0.48	-0.38	Diabetic kidney disease;	chr7:65939105	chr7:66902857~66906297:+
THCA	cis	rs944289	0.868	rs2415316	ENSG00000257826.1	RP11-116N8.4	-8.88	1.48e-17	7.53e-15	-0.4	-0.38	Thyroid cancer;	chr14:36139806	chr14:36061026~36067190:-
THCA	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-8.87	1.48e-17	7.54e-15	-0.4	-0.38	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
THCA	cis	rs8072100	0.512	rs9674670	ENSG00000228782.6	CTD-2026D20.3	8.87	1.49e-17	7.59e-15	0.35	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47308791	chr17:47450568~47492492:-
THCA	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	8.87	1.49e-17	7.59e-15	0.52	0.38	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
THCA	cis	rs1707322	0.752	rs28550303	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.716	rs28375469	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28545085	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28719889	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28812624	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28507722	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28568986	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs28396194	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs28752166	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs10890345	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10789471	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs11211173	ENSG00000234329.1	RP11-767N6.2	8.87	1.49e-17	7.62e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45651039~45651826:-
THCA	cis	rs780096	0.546	rs2293571	ENSG00000234072.1	AC074117.10	-8.87	1.5e-17	7.67e-15	-0.3	-0.38	Total body bone mineral density;	chr2:27506613	chr2:27356246~27367622:+
THCA	cis	rs950169	0.58	rs1061737	ENSG00000259728.4	LINC00933	8.87	1.51e-17	7.71e-15	0.52	0.38	Schizophrenia;	chr15:84640559	chr15:84570649~84580175:+
THCA	cis	rs7851660	0.967	rs6478437	ENSG00000236130.1	PTCSC2	-8.87	1.51e-17	7.72e-15	-0.29	-0.38	Strep throat;	chr9:97845215	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.901	rs2401639	ENSG00000236130.1	PTCSC2	-8.87	1.51e-17	7.72e-15	-0.29	-0.38	Strep throat;	chr9:97845555	chr9:97805935~97810008:-
THCA	cis	rs944289	0.74	rs7150440	ENSG00000257826.1	RP11-116N8.4	-8.87	1.51e-17	7.72e-15	-0.39	-0.38	Thyroid cancer;	chr14:36114691	chr14:36061026~36067190:-
THCA	cis	rs944289	0.74	rs7150768	ENSG00000257826.1	RP11-116N8.4	-8.87	1.51e-17	7.72e-15	-0.39	-0.38	Thyroid cancer;	chr14:36114699	chr14:36061026~36067190:-
THCA	cis	rs9341808	0.529	rs2322765	ENSG00000272129.1	RP11-250B2.6	8.87	1.52e-17	7.74e-15	0.47	0.38	Sitting height ratio;	chr6:80354879	chr6:80355424~80356859:+
THCA	cis	rs367615	0.704	rs60538082	ENSG00000249476.1	CTD-2587M2.1	8.87	1.52e-17	7.76e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109493400	chr5:109237120~109326369:-
THCA	cis	rs367615	0.66	rs10477972	ENSG00000249476.1	CTD-2587M2.1	8.87	1.52e-17	7.76e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109496250	chr5:109237120~109326369:-
THCA	cis	rs367615	0.66	rs4632850	ENSG00000249476.1	CTD-2587M2.1	8.87	1.52e-17	7.76e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109497182	chr5:109237120~109326369:-
THCA	cis	rs367615	0.704	rs6889301	ENSG00000249476.1	CTD-2587M2.1	8.87	1.52e-17	7.76e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109499480	chr5:109237120~109326369:-
THCA	cis	rs367615	0.661	rs9326775	ENSG00000249476.1	CTD-2587M2.1	8.87	1.52e-17	7.76e-15	0.4	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109501224	chr5:109237120~109326369:-
THCA	cis	rs642803	0.591	rs620088	ENSG00000214659.4	KRT8P26	-8.87	1.53e-17	7.79e-15	-0.33	-0.38	Urate levels;	chr11:65741515	chr11:65726939~65728214:+
THCA	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	8.87	1.53e-17	7.8e-15	0.27	0.38	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
THCA	cis	rs1499614	1	rs1267817	ENSG00000273142.1	RP11-458F8.4	-8.87	1.53e-17	7.8e-15	-0.49	-0.38	Gout;	chr7:66645053	chr7:66902857~66906297:+
THCA	cis	rs1499614	0.803	rs1796229	ENSG00000273142.1	RP11-458F8.4	-8.87	1.53e-17	7.8e-15	-0.49	-0.38	Gout;	chr7:66654674	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs34807232	ENSG00000273142.1	RP11-458F8.4	-8.87	1.53e-17	7.82e-15	-0.49	-0.38	Diabetic kidney disease;	chr7:66500146	chr7:66902857~66906297:+
THCA	cis	rs2243480	0.901	rs35823062	ENSG00000273142.1	RP11-458F8.4	-8.87	1.53e-17	7.82e-15	-0.49	-0.38	Diabetic kidney disease;	chr7:66500834	chr7:66902857~66906297:+
THCA	cis	rs1707322	0.826	rs10890349	ENSG00000234329.1	RP11-767N6.2	8.87	1.53e-17	7.82e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.758	rs10789474	ENSG00000234329.1	RP11-767N6.2	8.87	1.53e-17	7.82e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45651039~45651826:-
THCA	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	8.87	1.53e-17	7.82e-15	0.65	0.38	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
THCA	cis	rs11051970	0.592	rs11052002	ENSG00000274964.1	RP11-817I4.1	-8.87	1.54e-17	7.85e-15	-0.5	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32437920	chr12:32339368~32340724:+
THCA	cis	rs944289	0.74	rs12891345	ENSG00000257826.1	RP11-116N8.4	-8.87	1.54e-17	7.86e-15	-0.4	-0.38	Thyroid cancer;	chr14:36126977	chr14:36061026~36067190:-
THCA	cis	rs62103177	0.535	rs62101568	ENSG00000261126.6	RP11-795F19.1	8.87	1.55e-17	7.89e-15	0.43	0.38	Opioid sensitivity;	chr18:80176788	chr18:80046900~80095482:+
THCA	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	8.87	1.55e-17	7.91e-15	0.25	0.38	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	8.87	1.55e-17	7.91e-15	0.25	0.38	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	8.87	1.55e-17	7.91e-15	0.25	0.38	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	8.87	1.55e-17	7.91e-15	0.25	0.38	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-8.87	1.56e-17	7.93e-15	-0.48	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
THCA	cis	rs2288884	0.767	rs58329304	ENSG00000275055.1	CTC-471J1.11	-8.87	1.56e-17	7.95e-15	-0.35	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52031919	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.767	rs12460118	ENSG00000275055.1	CTC-471J1.11	-8.87	1.56e-17	7.95e-15	-0.35	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52032550	chr19:52049007~52049754:+
THCA	cis	rs524281	1	rs547087	ENSG00000255320.1	RP11-755F10.1	-8.87	1.56e-17	7.96e-15	-0.51	-0.38	Electroencephalogram traits;	chr11:66078793	chr11:66244840~66246239:-
THCA	cis	rs733592	0.723	rs10875766	ENSG00000240399.1	RP1-228P16.1	8.87	1.56e-17	7.96e-15	0.36	0.38	Plateletcrit;	chr12:48199797	chr12:48054813~48055591:-
THCA	cis	rs642803	0.551	rs1308020	ENSG00000214659.4	KRT8P26	-8.87	1.56e-17	7.96e-15	-0.33	-0.38	Urate levels;	chr11:65730087	chr11:65726939~65728214:+
THCA	cis	rs28510890	0.547	rs11853339	ENSG00000260337.3	RP11-386M24.6	8.87	1.58e-17	8.03e-15	0.48	0.38	Lung cancer in ever smokers;	chr15:92605654	chr15:92592574~92596462:-
THCA	cis	rs17684571	0.872	rs34832779	ENSG00000231441.1	RP11-472M19.2	8.87	1.58e-17	8.07e-15	0.53	0.38	Schizophrenia;	chr6:56758350	chr6:56844002~56864078:+
THCA	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-8.87	1.59e-17	8.11e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-8.86	1.6e-17	8.15e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
THCA	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-8.86	1.6e-17	8.15e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
THCA	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	8.86	1.6e-17	8.17e-15	0.5	0.38	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
THCA	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-8.86	1.61e-17	8.18e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
THCA	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-8.86	1.61e-17	8.18e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-8.86	1.61e-17	8.2e-15	-0.47	-0.38	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
THCA	cis	rs2274273	0.682	rs8008134	ENSG00000258413.1	RP11-665C16.6	-8.86	1.62e-17	8.23e-15	-0.5	-0.38	Protein biomarker;	chr14:55040802	chr14:55262767~55272075:-
THCA	cis	rs848490	0.615	rs2428939	ENSG00000214293.7	APTR	-8.86	1.62e-17	8.26e-15	-0.28	-0.38	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77932977	chr7:77657660~77696265:-
THCA	cis	rs1799949	0.965	rs8071278	ENSG00000267681.1	CTD-3199J23.6	-8.86	1.63e-17	8.29e-15	-0.44	-0.38	Menopause (age at onset);	chr17:43041893	chr17:43144956~43145255:+
THCA	cis	rs12188164	0.515	rs11742006	ENSG00000221990.4	EXOC3-AS1	8.86	1.63e-17	8.29e-15	0.32	0.38	Cystic fibrosis severity;	chr5:408414	chr5:441498~443160:-
THCA	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-8.86	1.64e-17	8.34e-15	-0.47	-0.38	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
THCA	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	8.86	1.64e-17	8.34e-15	0.71	0.38	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
THCA	cis	rs2836950	0.52	rs8130240	ENSG00000255568.3	BRWD1-AS2	-8.86	1.64e-17	8.36e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39166182	chr21:39313935~39314962:+
THCA	cis	rs6142102	0.59	rs6059691	ENSG00000276073.1	RP5-1125A11.7	8.86	1.66e-17	8.43e-15	0.36	0.38	Skin pigmentation;	chr20:34149161	chr20:33985617~33988989:-
THCA	cis	rs4842666	0.831	rs11105378	ENSG00000258302.2	RP11-981P6.1	8.86	1.66e-17	8.44e-15	0.37	0.38	Blood pressure;	chr12:89696964	chr12:89561129~89594878:+
THCA	cis	rs4713118	0.868	rs10484401	ENSG00000219392.1	RP1-265C24.5	8.86	1.67e-17	8.48e-15	0.52	0.38	Parkinson's disease;	chr6:27778811	chr6:28115628~28116551:+
THCA	cis	rs950169	0.58	rs11634320	ENSG00000259728.4	LINC00933	-8.86	1.67e-17	8.49e-15	-0.52	-0.38	Schizophrenia;	chr15:84628952	chr15:84570649~84580175:+
THCA	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-8.86	1.68e-17	8.53e-15	-0.5	-0.38	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
THCA	cis	rs7829975	0.774	rs35431455	ENSG00000253893.2	FAM85B	-8.86	1.68e-17	8.57e-15	-0.48	-0.38	Mood instability;	chr8:8816226	chr8:8167819~8226614:-
THCA	cis	rs73186030	0.546	rs67818421	ENSG00000272758.4	RP11-299J3.8	8.86	1.69e-17	8.57e-15	0.44	0.38	Serum parathyroid hormone levels;	chr3:122389871	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	8.86	1.69e-17	8.57e-15	0.44	0.38	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
THCA	cis	rs4713118	0.588	rs200994	ENSG00000219392.1	RP1-265C24.5	8.86	1.7e-17	8.63e-15	0.51	0.38	Parkinson's disease;	chr6:27846035	chr6:28115628~28116551:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000228039.3	KB-1125A3.10	8.86	1.7e-17	8.64e-15	0.47	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23963780~23964374:+
THCA	cis	rs7015263	0.689	rs56268009	ENSG00000254231.1	CTD-2284J15.1	-8.86	1.71e-17	8.68e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86492358	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs6994005	ENSG00000254231.1	CTD-2284J15.1	-8.86	1.71e-17	8.68e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86495633	chr8:86333274~86343314:-
THCA	cis	rs1062177	0.906	rs2964573	ENSG00000253921.1	CTB-113P19.3	-8.86	1.71e-17	8.7e-15	-0.46	-0.38	Preschool internalizing problems;	chr5:151780561	chr5:151753992~151767247:+
THCA	cis	rs2243480	1	rs2257790	ENSG00000273142.1	RP11-458F8.4	-8.86	1.71e-17	8.7e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66135463	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs316332	ENSG00000273142.1	RP11-458F8.4	-8.86	1.71e-17	8.7e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66139312	chr7:66902857~66906297:+
THCA	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	8.86	1.72e-17	8.73e-15	0.27	0.38	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
THCA	cis	rs1707322	0.721	rs4660883	ENSG00000234329.1	RP11-767N6.2	8.86	1.72e-17	8.74e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45651039~45651826:-
THCA	cis	rs2243480	1	rs4718317	ENSG00000273142.1	RP11-458F8.4	8.86	1.72e-17	8.74e-15	0.47	0.38	Diabetic kidney disease;	chr7:66183914	chr7:66902857~66906297:+
THCA	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-8.85	1.74e-17	8.83e-15	-0.36	-0.38	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
THCA	cis	rs812925	0.515	rs1177308	ENSG00000271889.1	RP11-493E12.1	8.85	1.75e-17	8.87e-15	0.36	0.38	Immature fraction of reticulocytes;	chr2:61160119	chr2:61151433~61162105:-
THCA	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-8.85	1.75e-17	8.88e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
THCA	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-8.85	1.75e-17	8.88e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-8.85	1.75e-17	8.88e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-8.85	1.75e-17	8.88e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-8.85	1.75e-17	8.88e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
THCA	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-8.85	1.75e-17	8.91e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
THCA	cis	rs11603691	1	rs11603691	ENSG00000254662.1	RP11-872D17.4	-8.85	1.76e-17	8.91e-15	-0.71	-0.38	Low high density lipoprotein cholesterol levels;	chr11:57340143	chr11:57325603~57327958:+
THCA	cis	rs2836950	0.565	rs8134214	ENSG00000255568.3	BRWD1-AS2	-8.85	1.76e-17	8.93e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39170441	chr21:39313935~39314962:+
THCA	cis	rs150992	0.714	rs76798907	ENSG00000248489.1	CTD-2007H13.3	8.85	1.76e-17	8.94e-15	0.37	0.38	Body mass index;	chr5:98990780	chr5:98929171~98995013:+
THCA	cis	rs1799949	0.93	rs34210004	ENSG00000267681.1	CTD-3199J23.6	-8.85	1.76e-17	8.94e-15	-0.44	-0.38	Menopause (age at onset);	chr17:43218318	chr17:43144956~43145255:+
THCA	cis	rs7015263	0.689	rs10956800	ENSG00000254231.1	CTD-2284J15.1	8.85	1.76e-17	8.95e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86324220	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs11997234	ENSG00000254231.1	CTD-2284J15.1	8.85	1.76e-17	8.95e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86326916	chr8:86333274~86343314:-
THCA	cis	rs9322193	0.962	rs1889473	ENSG00000268592.3	RAET1E-AS1	8.85	1.76e-17	8.96e-15	0.5	0.38	Lung cancer;	chr6:149825485	chr6:149863494~149919507:+
THCA	cis	rs7849270	0.959	rs2900271	ENSG00000268707.1	RP11-247A12.7	8.85	1.77e-17	8.99e-15	0.47	0.38	Blood metabolite ratios;	chr9:129132655	chr9:129170434~129170940:+
THCA	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	8.85	1.77e-17	8.99e-15	0.74	0.38	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
THCA	cis	rs6750795	0.569	rs1797387	ENSG00000181798.2	LINC00471	-8.85	1.77e-17	9.01e-15	-0.43	-0.38	Height;	chr2:231549981	chr2:231508426~231514339:-
THCA	cis	rs8114671	0.967	rs6088734	ENSG00000269202.1	RP4-614O4.12	-8.85	1.78e-17	9.03e-15	-0.32	-0.38	Height;	chr20:35157243	chr20:35201747~35203288:-
THCA	cis	rs9532669	0.819	rs9532652	ENSG00000239827.7	SUGT1P3	-8.85	1.78e-17	9.05e-15	-0.45	-0.38	Cervical cancer;	chr13:40903300	chr13:40908159~40921774:-
THCA	cis	rs597539	0.652	rs660614	ENSG00000250508.1	RP11-757G1.6	-8.85	1.79e-17	9.06e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68892020	chr11:68870664~68874542:+
THCA	cis	rs9322193	0.962	rs2151912	ENSG00000268592.3	RAET1E-AS1	8.85	1.79e-17	9.08e-15	0.51	0.38	Lung cancer;	chr6:149831772	chr6:149863494~149919507:+
THCA	cis	rs1707322	0.721	rs10890341	ENSG00000234329.1	RP11-767N6.2	8.85	1.79e-17	9.08e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45651039~45651826:-
THCA	cis	rs4266144	1	rs4266144	ENSG00000244515.1	KRT18P34	-8.85	1.79e-17	9.1e-15	-0.43	-0.38	Coronary artery disease;	chr3:157134803	chr3:157162663~157163932:-
THCA	cis	rs2243480	1	rs160639	ENSG00000273142.1	RP11-458F8.4	-8.85	1.8e-17	9.12e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66115000	chr7:66902857~66906297:+
THCA	cis	rs12554020	0.892	rs78816659	ENSG00000227603.1	RP11-165J3.6	8.85	1.8e-17	9.12e-15	0.68	0.38	Schizophrenia;	chr9:93575141	chr9:93435332~93437121:-
THCA	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-8.85	1.8e-17	9.12e-15	-0.39	-0.38	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
THCA	cis	rs9322193	0.923	rs1984111	ENSG00000268592.3	RAET1E-AS1	8.85	1.8e-17	9.14e-15	0.5	0.38	Lung cancer;	chr6:149831720	chr6:149863494~149919507:+
THCA	cis	rs4819052	0.851	rs2256000	ENSG00000215447.6	BX322557.10	-8.85	1.81e-17	9.16e-15	-0.3	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265994	chr21:45288052~45291738:+
THCA	cis	rs597539	0.652	rs514833	ENSG00000250508.1	RP11-757G1.6	-8.85	1.81e-17	9.17e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890266	chr11:68870664~68874542:+
THCA	cis	rs597539	0.652	rs488363	ENSG00000250508.1	RP11-757G1.6	-8.85	1.81e-17	9.17e-15	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68890830	chr11:68870664~68874542:+
THCA	cis	rs4842666	0.915	rs6538195	ENSG00000258302.2	RP11-981P6.1	8.85	1.81e-17	9.18e-15	0.37	0.38	Blood pressure;	chr12:89668599	chr12:89561129~89594878:+
THCA	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-8.85	1.81e-17	9.18e-15	-0.48	-0.38	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
THCA	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	8.85	1.82e-17	9.22e-15	0.46	0.38	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
THCA	cis	rs2754412	1	rs2754412	ENSG00000263064.2	RP11-291L22.7	8.85	1.82e-17	9.22e-15	0.43	0.38	Breast cancer;	chr10:38338906	chr10:38448689~38448949:+
THCA	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-8.85	1.82e-17	9.23e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
THCA	cis	rs7015263	0.651	rs7461767	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86330049	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs6471279	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86331563	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs6471281	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86337013	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.614	rs7825405	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86337259	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs7462727	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86338405	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs7824469	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86338693	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs10107072	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86339204	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.651	rs4581032	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86339553	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs7015490	ENSG00000254231.1	CTD-2284J15.1	8.85	1.85e-17	9.34e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86342081	chr8:86333274~86343314:-
THCA	cis	rs853679	0.55	rs9295762	ENSG00000226314.6	ZNF192P1	8.85	1.85e-17	9.36e-15	0.49	0.38	Depression;	chr6:28187640	chr6:28161781~28169594:+
THCA	cis	rs7015263	0.689	rs7017719	ENSG00000254231.1	CTD-2284J15.1	-8.84	1.86e-17	9.41e-15	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86321739	chr8:86333274~86343314:-
THCA	cis	rs2836950	0.545	rs1888489	ENSG00000255568.3	BRWD1-AS2	-8.84	1.87e-17	9.45e-15	-0.31	-0.38	Menarche (age at onset);	chr21:39161238	chr21:39313935~39314962:+
THCA	cis	rs7829975	0.777	rs486781	ENSG00000253893.2	FAM85B	8.84	1.87e-17	9.46e-15	0.48	0.38	Mood instability;	chr8:8782230	chr8:8167819~8226614:-
THCA	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-8.84	1.87e-17	9.48e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
THCA	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-8.84	1.87e-17	9.48e-15	-0.45	-0.38	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
THCA	cis	rs673078	0.66	rs73220119	ENSG00000275409.1	RP11-131L12.4	-8.84	1.88e-17	9.51e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118159864	chr12:118430147~118430699:+
THCA	cis	rs9640161	0.659	rs7781827	ENSG00000261305.1	RP4-584D14.7	8.84	1.89e-17	9.55e-15	0.45	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150311769	chr7:150341771~150342607:+
THCA	cis	rs673078	0.66	rs61945190	ENSG00000275409.1	RP11-131L12.4	-8.84	1.89e-17	9.55e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118231345	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs7977403	ENSG00000275409.1	RP11-131L12.4	-8.84	1.89e-17	9.55e-15	-0.49	-0.38	Glucose homeostasis traits;	chr12:118233446	chr12:118430147~118430699:+
THCA	cis	rs62355901	0.545	rs16886256	ENSG00000271828.1	CTD-2310F14.1	-8.84	1.89e-17	9.57e-15	-0.65	-0.38	Breast cancer;	chr5:56765737	chr5:56927874~56929573:+
THCA	cis	rs7772486	0.811	rs2777475	ENSG00000235652.6	RP11-545I5.3	8.84	1.9e-17	9.6e-15	0.36	0.38	Lobe attachment (rater-scored or self-reported);	chr6:145983467	chr6:145799409~145886585:+
THCA	cis	rs4927850	1	rs10881563	ENSG00000273009.1	RP11-352G9.1	-8.84	1.91e-17	9.64e-15	-0.42	-0.38	Pancreatic cancer;	chr3:196023354	chr3:195913078~195913683:-
THCA	cis	rs944289	0.774	rs2415313	ENSG00000257826.1	RP11-116N8.4	-8.84	1.91e-17	9.67e-15	-0.39	-0.38	Thyroid cancer;	chr14:36115246	chr14:36061026~36067190:-
THCA	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	8.84	1.91e-17	9.67e-15	0.49	0.38	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
THCA	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-8.84	1.91e-17	9.67e-15	-0.52	-0.38	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
THCA	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-8.84	1.91e-17	9.68e-15	-0.46	-0.38	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
THCA	cis	rs10463554	0.856	rs26522	ENSG00000175749.11	EIF3KP1	-8.84	1.92e-17	9.7e-15	-0.47	-0.38	Parkinson's disease;	chr5:103148695	chr5:103032376~103033031:+
THCA	cis	rs4819052	0.851	rs2838855	ENSG00000237664.1	LINC00316	8.84	1.92e-17	9.73e-15	0.38	0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260651	chr21:45338590~45341990:-
THCA	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	8.84	1.92e-17	9.73e-15	0.5	0.38	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
THCA	cis	rs7015263	0.714	rs3883910	ENSG00000254231.1	CTD-2284J15.1	8.84	1.93e-17	9.74e-15	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86503659	chr8:86333274~86343314:-
THCA	cis	rs1799949	0.965	rs6503727	ENSG00000267681.1	CTD-3199J23.6	-8.84	1.93e-17	9.74e-15	-0.44	-0.38	Menopause (age at onset);	chr17:43160842	chr17:43144956~43145255:+
THCA	cis	rs7714584	1	rs11743488	ENSG00000197083.10	ZNF300P1	8.84	1.93e-17	9.74e-15	0.66	0.38	Crohn's disease;	chr5:150899656	chr5:150930645~150946289:-
THCA	cis	rs7727544	0.544	rs55722650	ENSG00000237714.1	P4HA2-AS1	8.84	1.93e-17	9.75e-15	0.51	0.38	Blood metabolite levels;	chr5:132271607	chr5:132184876~132192808:+
THCA	cis	rs10411161	0.702	rs17835311	ENSG00000269483.1	AC006272.1	8.84	1.93e-17	9.76e-15	0.53	0.38	Breast cancer;	chr19:51883528	chr19:51839924~51843324:-
THCA	cis	rs2018683	0.624	rs6462119	ENSG00000228421.2	AC005013.5	8.84	1.94e-17	9.79e-15	0.42	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28964109	chr7:28957667~28959345:+
THCA	cis	rs6545883	0.507	rs4411680	ENSG00000271889.1	RP11-493E12.1	-8.84	1.94e-17	9.81e-15	-0.36	-0.38	Tuberculosis;	chr2:61356970	chr2:61151433~61162105:-
THCA	cis	rs2946504	0.822	rs2977097	ENSG00000251468.2	RP11-369K16.1	8.84	1.95e-17	9.84e-15	0.45	0.38	Type 2 diabetes;	chr8:12946592	chr8:12958387~12962200:+
THCA	cis	rs950169	0.526	rs698620	ENSG00000225151.9	GOLGA2P7	8.84	1.95e-17	9.84e-15	0.48	0.38	Schizophrenia;	chr15:84633977	chr15:84199311~84230136:-
THCA	cis	rs2018683	0.6	rs6948880	ENSG00000228421.2	AC005013.5	8.84	1.95e-17	9.85e-15	0.42	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28963862	chr7:28957667~28959345:+
THCA	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	8.84	1.95e-17	9.85e-15	0.65	0.38	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	8.84	1.95e-17	9.85e-15	0.65	0.38	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
THCA	cis	rs6496932	0.874	rs2003294	ENSG00000218052.5	ADAMTS7P4	8.84	1.95e-17	9.85e-15	0.52	0.38	Central corneal thickness;Corneal structure;	chr15:85274141	chr15:85255369~85330334:-
THCA	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-8.84	1.95e-17	9.85e-15	-0.47	-0.38	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
THCA	cis	rs4819052	0.851	rs35560973	ENSG00000215447.6	BX322557.10	-8.84	1.95e-17	9.87e-15	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45288052~45291738:+
THCA	cis	rs2243480	1	rs160633	ENSG00000273142.1	RP11-458F8.4	-8.84	1.96e-17	9.91e-15	-0.47	-0.38	Diabetic kidney disease;	chr7:66063241	chr7:66902857~66906297:+
THCA	cis	rs10875746	0.855	rs10875729	ENSG00000240399.1	RP1-228P16.1	-8.84	1.96e-17	9.91e-15	-0.43	-0.38	Longevity (90 years and older);	chr12:48032943	chr12:48054813~48055591:-
THCA	cis	rs1707322	0.721	rs28501477	ENSG00000234329.1	RP11-767N6.2	8.84	1.97e-17	9.93e-15	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.716	rs10890342	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs6658700	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs12047629	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs11211169	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs11211171	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28623463	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.716	rs28370457	ENSG00000234329.1	RP11-767N6.2	8.84	1.98e-17	1e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45651039~45651826:-
THCA	cis	rs7208859	0.673	rs11653955	ENSG00000266490.1	CTD-2349P21.9	8.84	1.98e-17	1e-14	0.53	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30792372~30792833:+
THCA	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-8.84	1.98e-17	1e-14	-0.61	-0.38	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
THCA	cis	rs2439831	0.85	rs2228368	ENSG00000249839.1	AC011330.5	-8.84	1.98e-17	1e-14	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43809812	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs3736180	ENSG00000249839.1	AC011330.5	-8.84	1.98e-17	1e-14	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43814426	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28684672	ENSG00000249839.1	AC011330.5	-8.84	1.98e-17	1e-14	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43815464	chr15:43663654~43684339:-
THCA	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-8.84	1.99e-17	1e-14	-0.5	-0.38	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
THCA	cis	rs2658782	0.654	rs2248524	ENSG00000279684.1	RP11-755E23.2	-8.84	1.99e-17	1e-14	-0.57	-0.38	Pulmonary function decline;	chr11:93522549	chr11:93286629~93288903:-
THCA	cis	rs1707322	0.717	rs11211161	ENSG00000234329.1	RP11-767N6.2	8.84	1.99e-17	1.01e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs61784793	ENSG00000234329.1	RP11-767N6.2	8.84	1.99e-17	1.01e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs4586014	ENSG00000234329.1	RP11-767N6.2	8.84	1.99e-17	1.01e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.648	rs4439382	ENSG00000234329.1	RP11-767N6.2	8.84	1.99e-17	1.01e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45651039~45651826:-
THCA	cis	rs10411161	0.702	rs11878580	ENSG00000269483.1	AC006272.1	8.84	2e-17	1.01e-14	0.53	0.38	Breast cancer;	chr19:51885232	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs11878586	ENSG00000269483.1	AC006272.1	8.84	2e-17	1.01e-14	0.53	0.38	Breast cancer;	chr19:51885323	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs7251755	ENSG00000269483.1	AC006272.1	8.84	2e-17	1.01e-14	0.53	0.38	Breast cancer;	chr19:51885695	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs7251689	ENSG00000269483.1	AC006272.1	8.84	2e-17	1.01e-14	0.53	0.38	Breast cancer;	chr19:51885864	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.69	rs7252336	ENSG00000269483.1	AC006272.1	8.84	2e-17	1.01e-14	0.53	0.38	Breast cancer;	chr19:51886261	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs11878583	ENSG00000269483.1	AC006272.1	-8.84	2e-17	1.01e-14	-0.53	-0.38	Breast cancer;	chr19:51885293	chr19:51839924~51843324:-
THCA	cis	rs9322193	0.961	rs9027	ENSG00000268592.3	RAET1E-AS1	8.83	2.01e-17	1.02e-14	0.5	0.38	Lung cancer;	chr6:149594921	chr6:149863494~149919507:+
THCA	cis	rs9322193	1	rs9322193	ENSG00000268592.3	RAET1E-AS1	8.83	2.01e-17	1.02e-14	0.5	0.38	Lung cancer;	chr6:149598007	chr6:149863494~149919507:+
THCA	cis	rs4819052	0.851	rs8126930	ENSG00000215447.6	BX322557.10	-8.83	2.02e-17	1.02e-14	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251800	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.766	rs4819035	ENSG00000223768.1	LINC00205	-8.83	2.02e-17	1.02e-14	-0.4	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45225800	chr21:45293285~45297354:+
THCA	cis	rs4713118	0.696	rs2394002	ENSG00000219392.1	RP1-265C24.5	-8.83	2.02e-17	1.02e-14	-0.5	-0.38	Parkinson's disease;	chr6:27780236	chr6:28115628~28116551:+
THCA	cis	rs9532669	0.926	rs11147831	ENSG00000239827.7	SUGT1P3	-8.83	2.02e-17	1.02e-14	-0.41	-0.38	Cervical cancer;	chr13:40978593	chr13:40908159~40921774:-
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000228039.3	KB-1125A3.10	8.83	2.02e-17	1.02e-14	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23963780~23964374:+
THCA	cis	rs7637701	0.517	rs66538320	ENSG00000243926.1	TIPARP-AS1	8.83	2.02e-17	1.02e-14	0.38	0.38	Breast cancer;	chr3:156674346	chr3:156671862~156674378:-
THCA	cis	rs9543976	0.92	rs9543972	ENSG00000261553.4	RP11-29G8.3	8.83	2.02e-17	1.02e-14	0.48	0.38	Diabetic retinopathy;	chr13:75547539	chr13:75549773~75807120:+
THCA	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	8.83	2.03e-17	1.02e-14	0.47	0.38	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
THCA	cis	rs10411161	0.579	rs59305384	ENSG00000269483.1	AC006272.1	8.83	2.03e-17	1.02e-14	0.51	0.38	Breast cancer;	chr19:51883811	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs10423838	ENSG00000269483.1	AC006272.1	8.83	2.03e-17	1.02e-14	0.51	0.38	Breast cancer;	chr19:51884030	chr19:51839924~51843324:-
THCA	cis	rs2836950	0.545	rs11700449	ENSG00000255568.3	BRWD1-AS2	-8.83	2.04e-17	1.03e-14	-0.31	-0.38	Menarche (age at onset);	chr21:39150493	chr21:39313935~39314962:+
THCA	cis	rs7131987	0.65	rs11050187	ENSG00000257176.2	RP11-996F15.2	-8.83	2.04e-17	1.03e-14	-0.39	-0.38	QT interval;	chr12:29319943	chr12:29280418~29317848:-
THCA	cis	rs7945705	0.967	rs7123429	ENSG00000254860.4	TMEM9B-AS1	8.83	2.05e-17	1.03e-14	0.42	0.38	Hemoglobin concentration;	chr11:8845261	chr11:8964675~8977527:+
THCA	cis	rs5769707	0.967	rs17182154	ENSG00000235111.1	RP1-29C18.8	-8.83	2.05e-17	1.04e-14	-0.45	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49612657~49615716:-
THCA	cis	rs1707322	0.963	rs6429581	ENSG00000234329.1	RP11-767N6.2	8.83	2.06e-17	1.04e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45651039~45651826:-
THCA	cis	rs7849270	1	rs2768630	ENSG00000268707.1	RP11-247A12.7	8.83	2.07e-17	1.04e-14	0.48	0.38	Blood metabolite ratios;	chr9:129104109	chr9:129170434~129170940:+
THCA	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-8.83	2.07e-17	1.05e-14	-0.39	-0.38	QT interval;	chr12:29314736	chr12:29280418~29317848:-
THCA	cis	rs9543976	1	rs7989568	ENSG00000261553.4	RP11-29G8.3	8.83	2.07e-17	1.05e-14	0.49	0.38	Diabetic retinopathy;	chr13:75581428	chr13:75549773~75807120:+
THCA	cis	rs367615	0.661	rs9326773	ENSG00000249476.1	CTD-2587M2.1	8.83	2.08e-17	1.05e-14	0.39	0.38	Colorectal cancer (SNP x SNP interaction);	chr5:109497822	chr5:109237120~109326369:-
THCA	cis	rs34081947	0.521	rs11623102	ENSG00000257826.1	RP11-116N8.4	-8.83	2.09e-17	1.05e-14	-0.45	-0.38	Papillary thyroid cancer;Differentiated thyroid cancer;	chr14:36130459	chr14:36061026~36067190:-
THCA	cis	rs673078	0.66	rs61943524	ENSG00000275409.1	RP11-131L12.4	-8.83	2.1e-17	1.06e-14	-0.49	-0.38	Glucose homeostasis traits;	chr12:118151530	chr12:118430147~118430699:+
THCA	cis	rs1707322	0.721	rs11211151	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs12045096	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4609469	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs12049027	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs10789467	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10890337	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs3811435	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45651039~45651826:-
THCA	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-8.83	2.1e-17	1.06e-14	-0.48	-0.38	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
THCA	cis	rs1707322	0.721	rs10890333	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs12043945	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs12091503	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10890336	ENSG00000234329.1	RP11-767N6.2	8.83	2.1e-17	1.06e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs2330011	ENSG00000215447.6	BX322557.10	-8.83	2.1e-17	1.06e-14	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45288052~45291738:+
THCA	cis	rs9640161	0.617	rs56019796	ENSG00000261305.1	RP4-584D14.7	8.83	2.11e-17	1.06e-14	0.44	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150312137	chr7:150341771~150342607:+
THCA	cis	rs11148252	1	rs11148252	ENSG00000278238.1	RP11-245D16.4	-8.83	2.11e-17	1.06e-14	-0.42	-0.38	Lewy body disease;	chr13:52434913	chr13:52454775~52455331:-
THCA	cis	rs2439831	0.702	rs9989313	ENSG00000249839.1	AC011330.5	-8.83	2.11e-17	1.06e-14	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43860619	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs61390361	ENSG00000249839.1	AC011330.5	-8.83	2.11e-17	1.06e-14	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43867644	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs11856795	ENSG00000249839.1	AC011330.5	-8.83	2.11e-17	1.06e-14	-0.61	-0.38	Lung cancer in ever smokers;	chr15:43868384	chr15:43663654~43684339:-
THCA	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-8.83	2.11e-17	1.07e-14	-0.47	-0.38	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
THCA	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	8.83	2.12e-17	1.07e-14	0.49	0.38	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1404147	ENSG00000226824.5	RP4-756H11.3	-8.83	2.12e-17	1.07e-14	-0.71	-0.38	Diabetic kidney disease;	chr7:65799537	chr7:66654538~66669855:+
THCA	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	8.83	2.13e-17	1.07e-14	0.64	0.38	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	8.83	2.13e-17	1.07e-14	0.64	0.38	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
THCA	cis	rs7727544	0.581	rs10075801	ENSG00000237714.1	P4HA2-AS1	8.83	2.13e-17	1.07e-14	0.49	0.38	Blood metabolite levels;	chr5:132341949	chr5:132184876~132192808:+
THCA	cis	rs375066	0.901	rs12977303	ENSG00000267058.1	RP11-15A1.3	-8.83	2.15e-17	1.08e-14	-0.3	-0.38	Breast cancer;	chr19:43873517	chr19:43891804~43901805:-
THCA	cis	rs3096299	0.933	rs2965934	ENSG00000274627.1	RP11-104N10.2	8.83	2.15e-17	1.09e-14	0.37	0.38	Multiple myeloma (IgH translocation);	chr16:89414821	chr16:89516797~89522217:+
THCA	cis	rs748404	0.518	rs480108	ENSG00000205771.5	CATSPER2P1	-8.83	2.16e-17	1.09e-14	-0.4	-0.38	Lung cancer;	chr15:43525208	chr15:43726918~43747094:-
THCA	cis	rs748404	0.56	rs572837	ENSG00000205771.5	CATSPER2P1	-8.83	2.16e-17	1.09e-14	-0.4	-0.38	Lung cancer;	chr15:43531615	chr15:43726918~43747094:-
THCA	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	8.83	2.16e-17	1.09e-14	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
THCA	cis	rs375066	0.935	rs430308	ENSG00000267058.1	RP11-15A1.3	-8.83	2.16e-17	1.09e-14	-0.31	-0.38	Breast cancer;	chr19:43896223	chr19:43891804~43901805:-
THCA	cis	rs2115630	0.645	rs2292463	ENSG00000275120.1	RP11-182J1.17	-8.83	2.16e-17	1.09e-14	-0.39	-0.38	P wave terminal force;	chr15:84632519	chr15:84599434~84606463:-
THCA	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	8.83	2.16e-17	1.09e-14	0.48	0.38	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
THCA	cis	rs7189233	0.55	rs9927982	ENSG00000279344.1	RP11-44F14.7	8.83	2.16e-17	1.09e-14	0.37	0.38	Intelligence (multi-trait analysis);	chr16:53440196	chr16:53478957~53481550:-
THCA	cis	rs7189233	0.531	rs17800577	ENSG00000279344.1	RP11-44F14.7	8.83	2.16e-17	1.09e-14	0.37	0.38	Intelligence (multi-trait analysis);	chr16:53442892	chr16:53478957~53481550:-
THCA	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	8.82	2.17e-17	1.09e-14	0.64	0.38	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
THCA	cis	rs2243480	1	rs67728539	ENSG00000273142.1	RP11-458F8.4	-8.82	2.17e-17	1.09e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65913137	chr7:66902857~66906297:+
THCA	cis	rs673078	0.66	rs17440315	ENSG00000275409.1	RP11-131L12.4	-8.82	2.17e-17	1.09e-14	-0.49	-0.38	Glucose homeostasis traits;	chr12:118158819	chr12:118430147~118430699:+
THCA	cis	rs2274273	0.661	rs8019978	ENSG00000258413.1	RP11-665C16.6	8.82	2.18e-17	1.1e-14	0.49	0.38	Protein biomarker;	chr14:55090566	chr14:55262767~55272075:-
THCA	cis	rs9847710	0.744	rs2115780	ENSG00000242142.1	SERBP1P3	8.82	2.2e-17	1.11e-14	0.46	0.38	Ulcerative colitis;	chr3:53108964	chr3:53064283~53065091:-
THCA	cis	rs1707322	1	rs6672115	ENSG00000234329.1	RP11-767N6.2	8.82	2.21e-17	1.11e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45651039~45651826:-
THCA	cis	rs7829975	0.714	rs6994038	ENSG00000253893.2	FAM85B	-8.82	2.21e-17	1.11e-14	-0.48	-0.38	Mood instability;	chr8:8803028	chr8:8167819~8226614:-
THCA	cis	rs10875746	0.768	rs4760609	ENSG00000240399.1	RP1-228P16.1	8.82	2.21e-17	1.11e-14	0.4	0.38	Longevity (90 years and older);	chr12:48021974	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-8.82	2.22e-17	1.11e-14	-0.76	-0.38	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
THCA	cis	rs9322193	0.923	rs9371486	ENSG00000268592.3	RAET1E-AS1	8.82	2.22e-17	1.12e-14	0.51	0.38	Lung cancer;	chr6:149832090	chr6:149863494~149919507:+
THCA	cis	rs7569084	0.687	rs963539	ENSG00000234255.7	AC012370.3	-8.82	2.22e-17	1.12e-14	-0.43	-0.38	Sum eosinophil basophil counts;	chr2:65421413	chr2:65439888~65456571:-
THCA	cis	rs12701220	0.503	rs12531999	ENSG00000229043.2	AC091729.9	-8.82	2.22e-17	1.12e-14	-0.56	-0.38	Bronchopulmonary dysplasia;	chr7:1141965	chr7:1160374~1165267:+
THCA	cis	rs11690935	0.55	rs55653103	ENSG00000228389.1	AC068039.4	-8.82	2.22e-17	1.12e-14	-0.41	-0.38	Schizophrenia;	chr2:171996909	chr2:171773482~171775844:+
THCA	cis	rs7899628	1	rs7899628	ENSG00000276742.1	RP11-500G22.4	-8.82	2.23e-17	1.12e-14	-0.45	-0.38	Breast cancer;	chr10:121904429	chr10:121956782~121957098:+
THCA	cis	rs2274273	0.745	rs748017	ENSG00000258413.1	RP11-665C16.6	-8.82	2.23e-17	1.12e-14	-0.51	-0.38	Protein biomarker;	chr14:55075582	chr14:55262767~55272075:-
THCA	cis	rs10411161	0.702	rs7250193	ENSG00000269483.1	AC006272.1	-8.82	2.24e-17	1.12e-14	-0.52	-0.38	Breast cancer;	chr19:51882267	chr19:51839924~51843324:-
THCA	cis	rs4819052	0.808	rs2838862	ENSG00000215447.6	BX322557.10	-8.82	2.24e-17	1.13e-14	-0.3	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45266811	chr21:45288052~45291738:+
THCA	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-8.82	2.24e-17	1.13e-14	-0.78	-0.38	Gout;	chr7:66721259	chr7:66654538~66669855:+
THCA	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-8.82	2.24e-17	1.13e-14	-0.39	-0.38	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
THCA	cis	rs1707322	0.964	rs785516	ENSG00000234329.1	RP11-767N6.2	-8.82	2.25e-17	1.13e-14	-0.36	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785517	ENSG00000234329.1	RP11-767N6.2	-8.82	2.25e-17	1.13e-14	-0.36	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45651039~45651826:-
THCA	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-8.82	2.25e-17	1.13e-14	-0.48	-0.38	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-8.82	2.25e-17	1.13e-14	-0.48	-0.38	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
THCA	cis	rs6844153	0.752	rs12644073	ENSG00000240005.4	RP11-293A21.1	-8.82	2.25e-17	1.13e-14	-0.45	-0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26895436	chr4:26859806~26860599:-
THCA	cis	rs67311347	0.594	rs12629111	ENSG00000223797.4	ENTPD3-AS1	8.82	2.26e-17	1.13e-14	0.3	0.38	Renal cell carcinoma;	chr3:40243860	chr3:40313802~40453329:-
THCA	cis	rs6991838	0.67	rs13275168	ENSG00000200714.1	Y_RNA	8.82	2.26e-17	1.14e-14	0.44	0.38	Intelligence (multi-trait analysis);	chr8:65685107	chr8:65592731~65592820:+
THCA	cis	rs28510890	0.789	rs10852176	ENSG00000260337.3	RP11-386M24.6	8.82	2.27e-17	1.14e-14	0.47	0.38	Lung cancer in ever smokers;	chr15:92588701	chr15:92592574~92596462:-
THCA	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	8.82	2.27e-17	1.14e-14	0.43	0.38	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
THCA	cis	rs11971779	0.752	rs4732371	ENSG00000273391.1	RP11-634H22.1	8.82	2.27e-17	1.14e-14	0.37	0.38	Diisocyanate-induced asthma;	chr7:139392571	chr7:139359032~139359566:-
THCA	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-8.82	2.27e-17	1.14e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
THCA	cis	rs2274273	0.712	rs1002054	ENSG00000258413.1	RP11-665C16.6	-8.82	2.27e-17	1.14e-14	-0.5	-0.38	Protein biomarker;	chr14:55062195	chr14:55262767~55272075:-
THCA	cis	rs1707322	0.752	rs28890893	ENSG00000234329.1	RP11-767N6.2	8.82	2.28e-17	1.15e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45651039~45651826:-
THCA	cis	rs73607972	0.575	rs12926468	ENSG00000275191.1	RP11-36I17.2	-8.82	2.28e-17	1.15e-14	-0.52	-0.38	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53555488	chr16:53628256~53628816:-
THCA	cis	rs11051970	0.559	rs7300646	ENSG00000274964.1	RP11-817I4.1	-8.82	2.29e-17	1.15e-14	-0.46	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32335695	chr12:32339368~32340724:+
THCA	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-8.82	2.29e-17	1.15e-14	-0.74	-0.38	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
THCA	cis	rs2946505	0.516	rs2954193	ENSG00000251468.2	RP11-369K16.1	8.82	2.29e-17	1.15e-14	0.57	0.38	Migraine;	chr8:12960864	chr8:12958387~12962200:+
THCA	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	8.82	2.29e-17	1.15e-14	0.37	0.38	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	8.82	2.29e-17	1.15e-14	0.37	0.38	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	8.82	2.29e-17	1.15e-14	0.37	0.38	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
THCA	cis	rs150992	0.587	rs10040066	ENSG00000248489.1	CTD-2007H13.3	-8.82	2.3e-17	1.16e-14	-0.37	-0.38	Body mass index;	chr5:99001333	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs4565239	ENSG00000248489.1	CTD-2007H13.3	-8.82	2.3e-17	1.16e-14	-0.37	-0.38	Body mass index;	chr5:99002144	chr5:98929171~98995013:+
THCA	cis	rs1930961	0.85	rs5996945	ENSG00000100058.11	CRYBB2P1	-8.82	2.31e-17	1.16e-14	-0.6	-0.38	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25448105~25520854:+
THCA	cis	rs1707322	0.789	rs10789473	ENSG00000234329.1	RP11-767N6.2	8.82	2.31e-17	1.16e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45651039~45651826:-
THCA	cis	rs10266483	0.654	rs6962076	ENSG00000271550.1	BNIP3P11	-8.82	2.31e-17	1.16e-14	-0.52	-0.38	Response to statin therapy;	chr7:64559214	chr7:64678954~64687393:-
THCA	cis	rs4842666	0.831	rs12230074	ENSG00000258302.2	RP11-981P6.1	8.82	2.31e-17	1.16e-14	0.37	0.38	Blood pressure;	chr12:89697090	chr12:89561129~89594878:+
THCA	cis	rs1387259	0.839	rs7486941	ENSG00000258273.1	RP11-370I10.4	8.82	2.31e-17	1.16e-14	0.47	0.38	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48333755~48333901:-
THCA	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-8.82	2.32e-17	1.16e-14	-0.49	-0.38	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
THCA	cis	rs2274273	0.682	rs10145268	ENSG00000258413.1	RP11-665C16.6	-8.82	2.32e-17	1.17e-14	-0.5	-0.38	Protein biomarker;	chr14:55037796	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.923	rs14314	ENSG00000268592.3	RAET1E-AS1	8.82	2.32e-17	1.17e-14	0.5	0.38	Lung cancer;	chr6:149820395	chr6:149863494~149919507:+
THCA	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	8.82	2.32e-17	1.17e-14	0.65	0.38	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
THCA	cis	rs4819052	0.851	rs1056099	ENSG00000215447.6	BX322557.10	-8.82	2.33e-17	1.17e-14	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs2236446	ENSG00000215447.6	BX322557.10	-8.82	2.33e-17	1.17e-14	-0.31	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45288052~45291738:+
THCA	cis	rs11051970	0.559	rs3789975	ENSG00000274964.1	RP11-817I4.1	-8.82	2.33e-17	1.17e-14	-0.46	-0.38	Response to tocilizumab in rheumatoid arthritis;	chr12:32331469	chr12:32339368~32340724:+
THCA	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	8.82	2.33e-17	1.17e-14	0.48	0.38	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000224205.1	AP000351.4	8.81	2.35e-17	1.18e-14	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23987320~23991421:-
THCA	cis	rs3747113	1	rs1041748	ENSG00000128262.7	POM121L9P	-8.81	2.36e-17	1.18e-14	-0.41	-0.38	Gut microbiome composition (summer);	chr22:24304886	chr22:24251828~24265525:+
THCA	cis	rs11148252	1	rs4886018	ENSG00000278238.1	RP11-245D16.4	-8.81	2.36e-17	1.18e-14	-0.42	-0.38	Lewy body disease;	chr13:52416582	chr13:52454775~52455331:-
THCA	cis	rs13129231	1	rs13129231	ENSG00000206820.1	RNU1-138P	-8.81	2.36e-17	1.18e-14	-0.46	-0.38	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113431725	chr4:113420323~113420486:+
THCA	cis	rs11690935	0.589	rs6729945	ENSG00000228389.1	AC068039.4	-8.81	2.36e-17	1.18e-14	-0.41	-0.38	Schizophrenia;	chr2:171999788	chr2:171773482~171775844:+
THCA	cis	rs77204473	0.744	rs2170317	ENSG00000254851.1	RP11-109L13.1	8.81	2.36e-17	1.19e-14	0.86	0.38	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117200024	chr11:117135528~117138582:+
THCA	cis	rs1499614	1	rs1267818	ENSG00000273142.1	RP11-458F8.4	-8.81	2.37e-17	1.19e-14	-0.49	-0.38	Gout;	chr7:66642037	chr7:66902857~66906297:+
THCA	cis	rs600231	0.706	rs1111934	ENSG00000245532.5	NEAT1	8.81	2.37e-17	1.19e-14	0.28	0.38	Bone mineral density;	chr11:65561921	chr11:65422774~65445540:+
THCA	cis	rs1707322	0.721	rs9793568	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs11211157	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs11211158	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs6429575	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.685	rs6690926	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs8179402	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs8179296	ENSG00000234329.1	RP11-767N6.2	8.81	2.37e-17	1.19e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45651039~45651826:-
THCA	cis	rs597539	0.69	rs608810	ENSG00000250508.1	RP11-757G1.6	-8.81	2.37e-17	1.19e-14	-0.46	-0.38	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856650	chr11:68870664~68874542:+
THCA	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-8.81	2.38e-17	1.19e-14	-0.48	-0.38	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
THCA	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-8.81	2.39e-17	1.2e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-8.81	2.39e-17	1.2e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-8.81	2.39e-17	1.2e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
THCA	cis	rs7727544	0.606	rs17622208	ENSG00000237714.1	P4HA2-AS1	8.81	2.39e-17	1.2e-14	0.49	0.38	Blood metabolite levels;	chr5:132381358	chr5:132184876~132192808:+
THCA	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-8.81	2.4e-17	1.2e-14	-0.44	-0.38	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
THCA	cis	rs7849270	0.879	rs2229419	ENSG00000268707.1	RP11-247A12.7	8.81	2.4e-17	1.2e-14	0.46	0.38	Blood metabolite ratios;	chr9:129095351	chr9:129170434~129170940:+
THCA	cis	rs9640161	0.75	rs3800780	ENSG00000261305.1	RP4-584D14.7	8.81	2.41e-17	1.21e-14	0.46	0.38	Blood protein levels;Circulating chemerin levels;	chr7:150330195	chr7:150341771~150342607:+
THCA	cis	rs860295	0.871	rs11582072	ENSG00000225855.5	RUSC1-AS1	-8.81	2.41e-17	1.21e-14	-0.25	-0.38	Body mass index;	chr1:155507779	chr1:155316863~155324176:-
THCA	cis	rs2243480	1	rs73142162	ENSG00000273142.1	RP11-458F8.4	-8.81	2.41e-17	1.21e-14	-0.48	-0.38	Diabetic kidney disease;	chr7:65909309	chr7:66902857~66906297:+
THCA	cis	rs848490	0.546	rs7384722	ENSG00000214293.7	APTR	8.81	2.41e-17	1.21e-14	0.26	0.38	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77646106	chr7:77657660~77696265:-
THCA	cis	rs12908161	1	rs12908161	ENSG00000259728.4	LINC00933	8.81	2.41e-17	1.21e-14	0.52	0.38	Schizophrenia;	chr15:84664594	chr15:84570649~84580175:+
THCA	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-8.81	2.42e-17	1.21e-14	-0.39	-0.38	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.589	rs62183782	ENSG00000228389.1	AC068039.4	-8.81	2.43e-17	1.22e-14	-0.4	-0.38	Schizophrenia;	chr2:172000102	chr2:171773482~171775844:+
THCA	cis	rs10411161	0.702	rs16983200	ENSG00000269483.1	AC006272.1	8.81	2.44e-17	1.22e-14	0.53	0.38	Breast cancer;	chr19:51883470	chr19:51839924~51843324:-
THCA	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-8.81	2.44e-17	1.23e-14	-0.44	-0.38	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
THCA	cis	rs5769707	0.967	rs2051626	ENSG00000235111.1	RP1-29C18.8	-8.81	2.45e-17	1.23e-14	-0.44	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49612657~49615716:-
THCA	cis	rs673078	0.66	rs17512609	ENSG00000275409.1	RP11-131L12.4	-8.81	2.46e-17	1.23e-14	-0.46	-0.38	Glucose homeostasis traits;	chr12:118354072	chr12:118430147~118430699:+
THCA	cis	rs9543976	1	rs3818355	ENSG00000261553.4	RP11-29G8.3	8.81	2.5e-17	1.25e-14	0.49	0.38	Diabetic retinopathy;	chr13:75622731	chr13:75549773~75807120:+
THCA	cis	rs2408955	0.521	rs10875753	ENSG00000258273.1	RP11-370I10.4	-8.81	2.5e-17	1.25e-14	-0.49	-0.38	Glycated hemoglobin levels;	chr12:48163358	chr12:48333755~48333901:-
THCA	cis	rs150992	0.721	rs2937706	ENSG00000248489.1	CTD-2007H13.3	8.81	2.51e-17	1.26e-14	0.37	0.38	Body mass index;	chr5:98990434	chr5:98929171~98995013:+
THCA	cis	rs11690935	0.55	rs62183784	ENSG00000228389.1	AC068039.4	-8.81	2.51e-17	1.26e-14	-0.4	-0.38	Schizophrenia;	chr2:172001789	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.55	rs62183785	ENSG00000228389.1	AC068039.4	-8.81	2.51e-17	1.26e-14	-0.4	-0.38	Schizophrenia;	chr2:172002068	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.531	rs62183800	ENSG00000228389.1	AC068039.4	-8.81	2.51e-17	1.26e-14	-0.4	-0.38	Schizophrenia;	chr2:172002365	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.55	rs62183801	ENSG00000228389.1	AC068039.4	-8.81	2.51e-17	1.26e-14	-0.4	-0.38	Schizophrenia;	chr2:172002567	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.55	rs6718013	ENSG00000228389.1	AC068039.4	-8.81	2.51e-17	1.26e-14	-0.4	-0.38	Schizophrenia;	chr2:172004277	chr2:171773482~171775844:+
THCA	cis	rs56080343	0.515	rs73222056	ENSG00000275759.1	RP11-131L12.3	-8.81	2.52e-17	1.26e-14	-0.56	-0.38	Neuroticism;	chr12:118215875	chr12:118428281~118428870:+
THCA	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	8.81	2.52e-17	1.26e-14	0.62	0.38	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
THCA	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-8.8	2.53e-17	1.27e-14	-0.41	-0.38	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs78803505	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65917585	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs34577383	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65920739	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs55895244	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65922691	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs7795242	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65925107	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs2177703	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65926730	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs35432774	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65928032	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs56985706	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65929575	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs60683927	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65929781	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs58062456	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65929865	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs34529418	ENSG00000273142.1	RP11-458F8.4	-8.8	2.53e-17	1.27e-14	-0.47	-0.38	Diabetic kidney disease;	chr7:65938222	chr7:66902857~66906297:+
THCA	cis	rs1707322	0.964	rs6675259	ENSG00000234329.1	RP11-767N6.2	-8.8	2.53e-17	1.27e-14	-0.36	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45651039~45651826:-
THCA	cis	rs150992	0.609	rs78254063	ENSG00000248489.1	CTD-2007H13.3	8.8	2.53e-17	1.27e-14	0.36	0.38	Body mass index;	chr5:98990803	chr5:98929171~98995013:+
THCA	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-8.8	2.54e-17	1.27e-14	-0.38	-0.38	Height;	chr11:118737823	chr11:118704607~118750263:+
THCA	cis	rs4842666	0.915	rs111478946	ENSG00000258302.2	RP11-981P6.1	8.8	2.55e-17	1.27e-14	0.37	0.38	Blood pressure;	chr12:89665065	chr12:89561129~89594878:+
THCA	cis	rs8027521	0.521	rs12903875	ENSG00000280362.1	RP11-643A5.3	-8.8	2.55e-17	1.27e-14	-0.52	-0.38	Circulating chemerin levels;	chr15:53951346	chr15:53910769~53914712:+
THCA	cis	rs7015263	0.689	rs55807259	ENSG00000254231.1	CTD-2284J15.1	-8.8	2.55e-17	1.27e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86355487	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.643	rs17681618	ENSG00000254231.1	CTD-2284J15.1	-8.8	2.55e-17	1.27e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86356156	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.666	rs56268675	ENSG00000254231.1	CTD-2284J15.1	-8.8	2.55e-17	1.27e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86358580	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs62509421	ENSG00000254231.1	CTD-2284J15.1	-8.8	2.55e-17	1.27e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86367267	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs12543856	ENSG00000254231.1	CTD-2284J15.1	-8.8	2.55e-17	1.27e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86369559	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.643	rs17608598	ENSG00000254231.1	CTD-2284J15.1	-8.8	2.55e-17	1.27e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86375035	chr8:86333274~86343314:-
THCA	cis	rs5769707	0.846	rs5770610	ENSG00000235111.1	RP1-29C18.8	-8.8	2.57e-17	1.29e-14	-0.44	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49612657~49615716:-
THCA	cis	rs673078	0.66	rs73205531	ENSG00000275409.1	RP11-131L12.4	-8.8	2.58e-17	1.29e-14	-0.49	-0.38	Glucose homeostasis traits;	chr12:118282063	chr12:118430147~118430699:+
THCA	cis	rs7829975	0.511	rs2921028	ENSG00000253893.2	FAM85B	-8.8	2.58e-17	1.29e-14	-0.49	-0.38	Mood instability;	chr8:8482967	chr8:8167819~8226614:-
THCA	cis	rs7727544	0.557	rs715285	ENSG00000237714.1	P4HA2-AS1	8.8	2.59e-17	1.29e-14	0.47	0.38	Blood metabolite levels;	chr5:132149690	chr5:132184876~132192808:+
THCA	cis	rs11148252	0.669	rs4884320	ENSG00000278238.1	RP11-245D16.4	-8.8	2.6e-17	1.3e-14	-0.44	-0.38	Lewy body disease;	chr13:52432779	chr13:52454775~52455331:-
THCA	cis	rs2018683	0.624	rs2286219	ENSG00000228421.2	AC005013.5	8.8	2.61e-17	1.3e-14	0.42	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959047	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.624	rs2286220	ENSG00000228421.2	AC005013.5	8.8	2.61e-17	1.3e-14	0.42	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959083	chr7:28957667~28959345:+
THCA	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	-8.8	2.61e-17	1.31e-14	-0.39	-0.38	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
THCA	cis	rs11603023	0.874	rs577396	ENSG00000255239.1	AP002954.6	8.8	2.62e-17	1.31e-14	0.48	0.38	Cholesterol, total;	chr11:118628753	chr11:118688039~118690600:-
THCA	cis	rs11603023	0.874	rs11216934	ENSG00000255239.1	AP002954.6	8.8	2.62e-17	1.31e-14	0.48	0.38	Cholesterol, total;	chr11:118630742	chr11:118688039~118690600:-
THCA	cis	rs9543976	0.858	rs8192763	ENSG00000261553.4	RP11-29G8.3	8.8	2.62e-17	1.31e-14	0.49	0.38	Diabetic retinopathy;	chr13:75605034	chr13:75549773~75807120:+
THCA	cis	rs9543976	1	rs1535724	ENSG00000261553.4	RP11-29G8.3	8.8	2.62e-17	1.31e-14	0.49	0.38	Diabetic retinopathy;	chr13:75609137	chr13:75549773~75807120:+
THCA	cis	rs7727544	0.582	rs4361509	ENSG00000237714.1	P4HA2-AS1	-8.8	2.62e-17	1.31e-14	-0.47	-0.38	Blood metabolite levels;	chr5:132201060	chr5:132184876~132192808:+
THCA	cis	rs12188164	0.515	rs11745246	ENSG00000221990.4	EXOC3-AS1	8.8	2.65e-17	1.32e-14	0.32	0.38	Cystic fibrosis severity;	chr5:410828	chr5:441498~443160:-
THCA	cis	rs1062177	1	rs41494545	ENSG00000253921.1	CTB-113P19.3	8.8	2.65e-17	1.32e-14	0.46	0.38	Preschool internalizing problems;	chr5:151855533	chr5:151753992~151767247:+
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000228039.3	KB-1125A3.10	-8.8	2.66e-17	1.33e-14	-0.47	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23963780~23964374:+
THCA	cis	rs950169	0.58	rs11633762	ENSG00000259728.4	LINC00933	8.8	2.67e-17	1.33e-14	0.51	0.38	Schizophrenia;	chr15:84643921	chr15:84570649~84580175:+
THCA	cis	rs2018683	0.584	rs4722880	ENSG00000228421.2	AC005013.5	8.8	2.67e-17	1.33e-14	0.42	0.38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28959581	chr7:28957667~28959345:+
THCA	cis	rs150992	0.609	rs447044	ENSG00000248489.1	CTD-2007H13.3	8.8	2.67e-17	1.33e-14	0.36	0.38	Body mass index;	chr5:98995572	chr5:98929171~98995013:+
THCA	cis	rs9532669	0.927	rs9532670	ENSG00000239827.7	SUGT1P3	8.8	2.67e-17	1.34e-14	0.41	0.38	Cervical cancer;	chr13:40927691	chr13:40908159~40921774:-
THCA	cis	rs2243480	1	rs1723269	ENSG00000273142.1	RP11-458F8.4	-8.8	2.69e-17	1.34e-14	-0.48	-0.38	Diabetic kidney disease;	chr7:66007799	chr7:66902857~66906297:+
THCA	cis	rs11603691	0.901	rs11228995	ENSG00000254662.1	RP11-872D17.4	-8.8	2.69e-17	1.34e-14	-0.7	-0.38	Low high density lipoprotein cholesterol levels;	chr11:57316061	chr11:57325603~57327958:+
THCA	cis	rs4722166	0.63	rs2091115	ENSG00000179428.2	AC073072.5	-8.8	2.7e-17	1.35e-14	-0.49	-0.38	Lung cancer;	chr7:22770547	chr7:22725395~22727620:-
THCA	cis	rs6061231	0.755	rs11699160	ENSG00000273619.1	RP5-908M14.9	-8.8	2.7e-17	1.35e-14	-0.29	-0.38	Colorectal cancer;	chr20:62383595	chr20:62386303~62386970:-
THCA	cis	rs7829975	0.774	rs35039922	ENSG00000253893.2	FAM85B	-8.8	2.72e-17	1.36e-14	-0.48	-0.38	Mood instability;	chr8:8817815	chr8:8167819~8226614:-
THCA	cis	rs7015263	0.689	rs12544731	ENSG00000254231.1	CTD-2284J15.1	-8.79	2.77e-17	1.38e-14	-0.38	-0.38	Intelligence (multi-trait analysis);	chr8:86320785	chr8:86333274~86343314:-
THCA	cis	rs1707322	0.717	rs1135812	ENSG00000234329.1	RP11-767N6.2	8.79	2.77e-17	1.38e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs6703748	ENSG00000234329.1	RP11-767N6.2	8.79	2.77e-17	1.38e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45651039~45651826:-
THCA	cis	rs7569084	0.663	rs10190233	ENSG00000234255.7	AC012370.3	-8.79	2.78e-17	1.38e-14	-0.42	-0.38	Sum eosinophil basophil counts;	chr2:65413095	chr2:65439888~65456571:-
THCA	cis	rs150992	0.517	rs326464	ENSG00000248489.1	CTD-2007H13.3	8.79	2.78e-17	1.39e-14	0.37	0.38	Body mass index;	chr5:98906499	chr5:98929171~98995013:+
THCA	cis	rs1501911	0.53	rs162150	ENSG00000248489.1	CTD-2007H13.3	8.79	2.78e-17	1.39e-14	0.37	0.38	Lung function (FEV1/FVC);	chr5:98913909	chr5:98929171~98995013:+
THCA	cis	rs2243480	0.808	rs12698508	ENSG00000273142.1	RP11-458F8.4	-8.79	2.81e-17	1.4e-14	-0.48	-0.38	Diabetic kidney disease;	chr7:65946971	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs2961102	ENSG00000273142.1	RP11-458F8.4	-8.79	2.81e-17	1.4e-14	-0.48	-0.38	Diabetic kidney disease;	chr7:65959671	chr7:66902857~66906297:+
THCA	cis	rs28510890	0.547	rs11853583	ENSG00000260337.3	RP11-386M24.6	8.79	2.82e-17	1.4e-14	0.48	0.38	Lung cancer in ever smokers;	chr15:92605846	chr15:92592574~92596462:-
THCA	cis	rs1799949	0.93	rs1554063	ENSG00000267681.1	CTD-3199J23.6	-8.79	2.82e-17	1.41e-14	-0.44	-0.38	Menopause (age at onset);	chr17:43135128	chr17:43144956~43145255:+
THCA	cis	rs9322193	0.962	rs3763162	ENSG00000268592.3	RAET1E-AS1	-8.79	2.83e-17	1.41e-14	-0.5	-0.38	Lung cancer;	chr6:149819674	chr6:149863494~149919507:+
THCA	cis	rs2288884	0.537	rs16983434	ENSG00000275055.1	CTC-471J1.11	-8.79	2.83e-17	1.41e-14	-0.3	-0.38	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52088180	chr19:52049007~52049754:+
THCA	cis	rs10759883	0.587	rs10818899	ENSG00000175611.10	LINC00476	8.79	2.83e-17	1.41e-14	0.39	0.38	Nicotine dependence;	chr9:95860129	chr9:95759231~95875977:-
THCA	cis	rs673078	0.607	rs61946067	ENSG00000275409.1	RP11-131L12.4	-8.79	2.84e-17	1.42e-14	-0.49	-0.38	Glucose homeostasis traits;	chr12:118303152	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61946068	ENSG00000275409.1	RP11-131L12.4	-8.79	2.84e-17	1.42e-14	-0.49	-0.38	Glucose homeostasis traits;	chr12:118305861	chr12:118430147~118430699:+
THCA	cis	rs1501911	0.53	rs162149	ENSG00000248489.1	CTD-2007H13.3	8.79	2.84e-17	1.42e-14	0.37	0.38	Lung function (FEV1/FVC);	chr5:98913851	chr5:98929171~98995013:+
THCA	cis	rs9532669	0.926	rs4254182	ENSG00000239827.7	SUGT1P3	-8.79	2.84e-17	1.42e-14	-0.41	-0.38	Cervical cancer;	chr13:40879120	chr13:40908159~40921774:-
THCA	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	8.79	2.86e-17	1.42e-14	0.49	0.38	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
THCA	cis	rs7015263	0.689	rs10096168	ENSG00000254231.1	CTD-2284J15.1	8.79	2.86e-17	1.43e-14	0.38	0.38	Intelligence (multi-trait analysis);	chr8:86321176	chr8:86333274~86343314:-
THCA	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	8.79	2.87e-17	1.43e-14	0.37	0.38	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
THCA	cis	rs7665090	1	rs735404	ENSG00000246560.2	RP11-10L12.4	8.79	2.88e-17	1.43e-14	0.45	0.38	Primary biliary cholangitis;	chr4:102632508	chr4:102828055~102844075:+
THCA	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-8.79	2.88e-17	1.43e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
THCA	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-8.79	2.88e-17	1.44e-14	-0.39	-0.38	QT interval;	chr12:29302457	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-8.79	2.88e-17	1.44e-14	-0.39	-0.38	QT interval;	chr12:29302458	chr12:29280418~29317848:-
THCA	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	8.79	2.89e-17	1.44e-14	0.48	0.38	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	8.79	2.89e-17	1.44e-14	0.48	0.38	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	8.79	2.89e-17	1.44e-14	0.48	0.38	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
THCA	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	8.79	2.89e-17	1.44e-14	0.56	0.38	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
THCA	cis	rs7211079	0.917	rs4243251	ENSG00000275479.1	RP11-334C17.6	8.79	2.9e-17	1.44e-14	0.38	0.38	Myocardial infarction;	chr17:80138811	chr17:80149627~80149798:+
THCA	cis	rs10463554	0.892	rs10463988	ENSG00000175749.11	EIF3KP1	8.79	2.91e-17	1.45e-14	0.5	0.38	Parkinson's disease;	chr5:102913595	chr5:103032376~103033031:+
THCA	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	8.79	2.91e-17	1.45e-14	0.5	0.38	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
THCA	cis	rs1707322	1	rs12097761	ENSG00000234329.1	RP11-767N6.2	8.79	2.92e-17	1.45e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs10789478	ENSG00000234329.1	RP11-767N6.2	8.79	2.92e-17	1.45e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10789479	ENSG00000234329.1	RP11-767N6.2	8.79	2.92e-17	1.45e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs7512395	ENSG00000234329.1	RP11-767N6.2	8.79	2.92e-17	1.45e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45651039~45651826:-
THCA	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	8.79	2.93e-17	1.46e-14	0.56	0.38	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
THCA	cis	rs4819052	0.851	rs914214	ENSG00000237664.1	LINC00316	-8.79	2.93e-17	1.46e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45277905	chr21:45338590~45341990:-
THCA	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-8.79	2.94e-17	1.46e-14	-0.78	-0.38	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
THCA	cis	rs5769707	0.967	rs739248	ENSG00000235111.1	RP1-29C18.8	-8.78	2.94e-17	1.46e-14	-0.44	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49612657~49615716:-
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000235689.1	AP000351.13	8.78	2.95e-17	1.47e-14	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:24006305~24008258:-
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000235689.1	AP000351.13	8.78	2.95e-17	1.47e-14	0.46	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:24006305~24008258:-
THCA	cis	rs2836950	0.545	rs11700813	ENSG00000255568.3	BRWD1-AS2	-8.78	2.95e-17	1.47e-14	-0.3	-0.38	Menarche (age at onset);	chr21:39145543	chr21:39313935~39314962:+
THCA	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-8.78	2.96e-17	1.47e-14	-0.47	-0.38	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
THCA	cis	rs2946505	1	rs2977086	ENSG00000251468.2	RP11-369K16.1	8.78	2.97e-17	1.48e-14	0.49	0.38	Migraine;	chr8:12953436	chr8:12958387~12962200:+
THCA	cis	rs4819052	0.808	rs2246697	ENSG00000237664.1	LINC00316	-8.78	2.97e-17	1.48e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270084	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.819	rs7279136	ENSG00000237664.1	LINC00316	-8.78	2.97e-17	1.48e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45272372	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.788	rs4819051	ENSG00000237664.1	LINC00316	-8.78	2.97e-17	1.48e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273213	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.819	rs8134084	ENSG00000237664.1	LINC00316	-8.78	2.97e-17	1.48e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273380	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs7276828	ENSG00000237664.1	LINC00316	-8.78	2.97e-17	1.48e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275124	chr21:45338590~45341990:-
THCA	cis	rs9322193	0.962	rs7745915	ENSG00000268592.3	RAET1E-AS1	8.78	2.98e-17	1.48e-14	0.5	0.38	Lung cancer;	chr6:149834111	chr6:149863494~149919507:+
THCA	cis	rs11603023	0.874	rs613243	ENSG00000255239.1	AP002954.6	8.78	2.99e-17	1.49e-14	0.48	0.38	Cholesterol, total;	chr11:118643304	chr11:118688039~118690600:-
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000228039.3	KB-1125A3.10	-8.78	3e-17	1.49e-14	-0.47	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23963780~23964374:+
THCA	cis	rs6844153	0.752	rs10029307	ENSG00000240005.4	RP11-293A21.1	-8.78	3.01e-17	1.5e-14	-0.45	-0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902591	chr4:26859806~26860599:-
THCA	cis	rs11690935	0.55	rs6746701	ENSG00000228389.1	AC068039.4	-8.78	3.03e-17	1.51e-14	-0.4	-0.38	Schizophrenia;	chr2:172004347	chr2:171773482~171775844:+
THCA	cis	rs1707322	0.963	rs10890373	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.685	rs28617418	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.682	rs28490344	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs28641748	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs6697821	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4330955	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.691	rs12031182	ENSG00000234329.1	RP11-767N6.2	8.78	3.04e-17	1.51e-14	0.35	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45651039~45651826:-
THCA	cis	rs11148252	0.669	rs61958050	ENSG00000278238.1	RP11-245D16.4	-8.78	3.04e-17	1.51e-14	-0.45	-0.38	Lewy body disease;	chr13:52420292	chr13:52454775~52455331:-
THCA	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	8.78	3.05e-17	1.52e-14	0.56	0.38	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000224205.1	AP000351.4	8.78	3.06e-17	1.52e-14	0.45	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23987320~23991421:-
THCA	cis	rs4819052	0.679	rs2236450	ENSG00000215447.6	BX322557.10	-8.78	3.07e-17	1.53e-14	-0.3	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282638	chr21:45288052~45291738:+
THCA	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-8.78	3.09e-17	1.53e-14	-0.51	-0.38	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
THCA	cis	rs6061231	0.74	rs11698650	ENSG00000273619.1	RP5-908M14.9	-8.78	3.11e-17	1.54e-14	-0.29	-0.38	Colorectal cancer;	chr20:62383318	chr20:62386303~62386970:-
THCA	cis	rs4819052	0.765	rs2838854	ENSG00000237664.1	LINC00316	-8.78	3.11e-17	1.54e-14	-0.37	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260449	chr21:45338590~45341990:-
THCA	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	8.78	3.11e-17	1.54e-14	0.44	0.38	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
THCA	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	8.78	3.13e-17	1.56e-14	0.37	0.38	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	8.78	3.13e-17	1.56e-14	0.37	0.38	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
THCA	cis	rs4819052	0.851	rs11558445	ENSG00000215447.6	BX322557.10	-8.78	3.14e-17	1.56e-14	-0.3	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45265260	chr21:45288052~45291738:+
THCA	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-8.78	3.14e-17	1.56e-14	-0.47	-0.38	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
THCA	cis	rs2280018	0.526	rs1510148	ENSG00000188599.16	NPIPP1	-8.77	3.18e-17	1.58e-14	-0.3	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15104312~15123498:-
THCA	cis	rs7945705	0.791	rs7944560	ENSG00000254860.4	TMEM9B-AS1	-8.77	3.19e-17	1.58e-14	-0.4	-0.38	Hemoglobin concentration;	chr11:8795729	chr11:8964675~8977527:+
THCA	cis	rs853679	0.55	rs1233704	ENSG00000226314.6	ZNF192P1	8.77	3.19e-17	1.58e-14	0.49	0.38	Depression;	chr6:28199145	chr6:28161781~28169594:+
THCA	cis	rs853679	0.55	rs1237875	ENSG00000226314.6	ZNF192P1	8.77	3.19e-17	1.58e-14	0.49	0.38	Depression;	chr6:28205232	chr6:28161781~28169594:+
THCA	cis	rs853679	0.55	rs1225598	ENSG00000226314.6	ZNF192P1	-8.77	3.19e-17	1.58e-14	-0.49	-0.38	Depression;	chr6:28193021	chr6:28161781~28169594:+
THCA	cis	rs853679	0.55	rs1150689	ENSG00000226314.6	ZNF192P1	-8.77	3.19e-17	1.58e-14	-0.49	-0.38	Depression;	chr6:28197321	chr6:28161781~28169594:+
THCA	cis	rs853679	0.55	rs1225599	ENSG00000226314.6	ZNF192P1	-8.77	3.19e-17	1.58e-14	-0.49	-0.38	Depression;	chr6:28197412	chr6:28161781~28169594:+
THCA	cis	rs853679	0.574	rs1233705	ENSG00000226314.6	ZNF192P1	-8.77	3.19e-17	1.58e-14	-0.49	-0.38	Depression;	chr6:28198669	chr6:28161781~28169594:+
THCA	cis	rs853679	0.55	rs1233707	ENSG00000226314.6	ZNF192P1	-8.77	3.19e-17	1.58e-14	-0.49	-0.38	Depression;	chr6:28205175	chr6:28161781~28169594:+
THCA	cis	rs9543976	1	rs9565177	ENSG00000261553.4	RP11-29G8.3	-8.77	3.19e-17	1.58e-14	-0.49	-0.38	Diabetic retinopathy;	chr13:75621267	chr13:75549773~75807120:+
THCA	cis	rs56046484	0.956	rs16974820	ENSG00000259295.5	CSPG4P12	8.77	3.2e-17	1.59e-14	0.6	0.38	Testicular germ cell tumor;	chr15:85084075	chr15:85191438~85213905:+
THCA	cis	rs10411161	1	rs3848562	ENSG00000269483.1	AC006272.1	-8.77	3.2e-17	1.59e-14	-0.51	-0.38	Breast cancer;	chr19:51876582	chr19:51839924~51843324:-
THCA	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-8.77	3.2e-17	1.59e-14	-0.77	-0.38	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
THCA	cis	rs1707322	1	rs11211232	ENSG00000234329.1	RP11-767N6.2	8.77	3.21e-17	1.59e-14	0.36	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs2838826	ENSG00000215447.6	BX322557.10	-8.77	3.22e-17	1.6e-14	-0.32	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45288052~45291738:+
THCA	cis	rs7714584	1	rs73282234	ENSG00000197083.10	ZNF300P1	8.77	3.22e-17	1.6e-14	0.66	0.38	Crohn's disease;	chr5:150816362	chr5:150930645~150946289:-
THCA	cis	rs2274273	0.774	rs9323278	ENSG00000258413.1	RP11-665C16.6	-8.77	3.23e-17	1.6e-14	-0.5	-0.38	Protein biomarker;	chr14:55074856	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.962	rs7818	ENSG00000268592.3	RAET1E-AS1	8.77	3.23e-17	1.6e-14	0.5	0.38	Lung cancer;	chr6:149810956	chr6:149863494~149919507:+
THCA	cis	rs7646881	1	rs59918529	ENSG00000240207.5	RP11-379F4.4	-8.77	3.23e-17	1.6e-14	-0.5	-0.38	Tetralogy of Fallot;	chr3:158734916	chr3:158732263~158784070:+
THCA	cis	rs748404	0.56	rs1060939	ENSG00000205771.5	CATSPER2P1	-8.77	3.25e-17	1.61e-14	-0.4	-0.38	Lung cancer;	chr15:43524719	chr15:43726918~43747094:-
THCA	cis	rs507080	0.733	rs489126	ENSG00000278376.1	RP11-158I9.8	-8.77	3.26e-17	1.62e-14	-0.29	-0.38	Serum metabolite levels;	chr11:118702038	chr11:118791254~118793137:+
THCA	cis	rs4819052	0.851	rs7281263	ENSG00000237664.1	LINC00316	-8.77	3.26e-17	1.62e-14	-0.38	-0.38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45275691	chr21:45338590~45341990:-
THCA	cis	rs28510890	0.51	rs3825982	ENSG00000260337.3	RP11-386M24.6	8.77	3.28e-17	1.62e-14	0.52	0.38	Lung cancer in ever smokers;	chr15:92617015	chr15:92592574~92596462:-
THCA	cis	rs7131987	0.65	rs10843384	ENSG00000257176.2	RP11-996F15.2	-8.77	3.28e-17	1.63e-14	-0.38	-0.38	QT interval;	chr12:29319476	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.65	rs11050188	ENSG00000257176.2	RP11-996F15.2	-8.77	3.28e-17	1.63e-14	-0.38	-0.38	QT interval;	chr12:29320175	chr12:29280418~29317848:-
THCA	cis	rs7674212	0.507	rs223413	ENSG00000251288.2	RP11-10L12.2	8.77	3.31e-17	1.64e-14	0.5	0.37	Type 2 diabetes;	chr4:102811709	chr4:102751401~102752641:+
THCA	cis	rs12908161	1	rs11638290	ENSG00000259728.4	LINC00933	8.77	3.31e-17	1.64e-14	0.52	0.37	Schizophrenia;	chr15:84684405	chr15:84570649~84580175:+
THCA	cis	rs12908161	0.959	rs34028043	ENSG00000259728.4	LINC00933	8.77	3.31e-17	1.64e-14	0.52	0.37	Schizophrenia;	chr15:84688354	chr15:84570649~84580175:+
THCA	cis	rs12908161	0.959	rs34784022	ENSG00000259728.4	LINC00933	8.77	3.31e-17	1.64e-14	0.52	0.37	Schizophrenia;	chr15:84688675	chr15:84570649~84580175:+
THCA	cis	rs2243480	1	rs316327	ENSG00000273142.1	RP11-458F8.4	8.77	3.35e-17	1.66e-14	0.47	0.37	Diabetic kidney disease;	chr7:66144214	chr7:66902857~66906297:+
THCA	cis	rs1707322	1	rs1707317	ENSG00000234329.1	RP11-767N6.2	-8.77	3.35e-17	1.66e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45651039~45651826:-
THCA	cis	rs2243480	1	rs313809	ENSG00000273142.1	RP11-458F8.4	-8.77	3.35e-17	1.66e-14	-0.48	-0.37	Diabetic kidney disease;	chr7:66034996	chr7:66902857~66906297:+
THCA	cis	rs1799949	0.929	rs799906	ENSG00000267681.1	CTD-3199J23.6	-8.77	3.36e-17	1.66e-14	-0.44	-0.37	Menopause (age at onset);	chr17:43126099	chr17:43144956~43145255:+
THCA	cis	rs1799949	0.965	rs799908	ENSG00000267681.1	CTD-3199J23.6	-8.77	3.36e-17	1.66e-14	-0.44	-0.37	Menopause (age at onset);	chr17:43126899	chr17:43144956~43145255:+
THCA	cis	rs10510102	0.872	rs12248004	ENSG00000276742.1	RP11-500G22.4	8.77	3.36e-17	1.67e-14	0.58	0.37	Breast cancer;	chr10:121972215	chr10:121956782~121957098:+
THCA	cis	rs1707322	0.717	rs12023439	ENSG00000234329.1	RP11-767N6.2	8.77	3.38e-17	1.67e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45651039~45651826:-
THCA	cis	rs7727544	0.57	rs7701237	ENSG00000237714.1	P4HA2-AS1	8.77	3.38e-17	1.68e-14	0.47	0.37	Blood metabolite levels;	chr5:132198688	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.582	rs3749756	ENSG00000237714.1	P4HA2-AS1	8.77	3.38e-17	1.68e-14	0.47	0.37	Blood metabolite levels;	chr5:132198806	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.582	rs3805683	ENSG00000237714.1	P4HA2-AS1	8.77	3.38e-17	1.68e-14	0.47	0.37	Blood metabolite levels;	chr5:132199432	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.582	rs2278398	ENSG00000237714.1	P4HA2-AS1	-8.77	3.38e-17	1.68e-14	-0.47	-0.37	Blood metabolite levels;	chr5:132194748	chr5:132184876~132192808:+
THCA	cis	rs77204473	0.744	rs2269399	ENSG00000254851.1	RP11-109L13.1	8.77	3.39e-17	1.68e-14	0.85	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117195637	chr11:117135528~117138582:+
THCA	cis	rs7727544	0.508	rs10900804	ENSG00000237714.1	P4HA2-AS1	8.77	3.39e-17	1.68e-14	0.5	0.37	Blood metabolite levels;	chr5:132066152	chr5:132184876~132192808:+
THCA	cis	rs1707322	0.721	rs11211149	ENSG00000234329.1	RP11-767N6.2	8.77	3.4e-17	1.68e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45651039~45651826:-
THCA	cis	rs1499614	0.901	rs2178742	ENSG00000273142.1	RP11-458F8.4	-8.77	3.4e-17	1.69e-14	-0.49	-0.37	Gout;	chr7:66732812	chr7:66902857~66906297:+
THCA	cis	rs801193	0.904	rs4718405	ENSG00000237310.1	GS1-124K5.4	8.77	3.42e-17	1.69e-14	0.27	0.37	Aortic root size;	chr7:66789659	chr7:66493706~66495474:+
THCA	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	8.77	3.42e-17	1.7e-14	0.57	0.37	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
THCA	cis	rs2274273	0.713	rs56725788	ENSG00000258413.1	RP11-665C16.6	-8.76	3.44e-17	1.7e-14	-0.5	-0.37	Protein biomarker;	chr14:55073383	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.743	rs13379159	ENSG00000258413.1	RP11-665C16.6	-8.76	3.44e-17	1.7e-14	-0.5	-0.37	Protein biomarker;	chr14:55074083	chr14:55262767~55272075:-
THCA	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	8.76	3.45e-17	1.71e-14	0.64	0.37	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
THCA	cis	rs2243480	1	rs1499614	ENSG00000273142.1	RP11-458F8.4	-8.76	3.45e-17	1.71e-14	-0.48	-0.37	Diabetic kidney disease;	chr7:66265811	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs1638734	ENSG00000273142.1	RP11-458F8.4	-8.76	3.46e-17	1.71e-14	-0.49	-0.37	Diabetic kidney disease;	chr7:66632552	chr7:66902857~66906297:+
THCA	cis	rs1062177	0.826	rs1549920	ENSG00000253921.1	CTB-113P19.3	-8.76	3.46e-17	1.71e-14	-0.45	-0.37	Preschool internalizing problems;	chr5:151761283	chr5:151753992~151767247:+
THCA	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	8.76	3.47e-17	1.72e-14	0.4	0.37	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
THCA	cis	rs9543976	0.858	rs9530447	ENSG00000261553.4	RP11-29G8.3	8.76	3.47e-17	1.72e-14	0.48	0.37	Diabetic retinopathy;	chr13:75592666	chr13:75549773~75807120:+
THCA	cis	rs748404	0.697	rs493177	ENSG00000249839.1	AC011330.5	-8.76	3.48e-17	1.72e-14	-0.44	-0.37	Lung cancer;	chr15:43251060	chr15:43663654~43684339:-
THCA	cis	rs8027521	0.521	rs17551329	ENSG00000280362.1	RP11-643A5.3	8.76	3.48e-17	1.72e-14	0.51	0.37	Circulating chemerin levels;	chr15:53926069	chr15:53910769~53914712:+
THCA	cis	rs1707322	1	rs785490	ENSG00000234329.1	RP11-767N6.2	-8.76	3.51e-17	1.73e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785493	ENSG00000234329.1	RP11-767N6.2	-8.76	3.51e-17	1.73e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs785496	ENSG00000234329.1	RP11-767N6.2	-8.76	3.51e-17	1.73e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785497	ENSG00000234329.1	RP11-767N6.2	-8.76	3.51e-17	1.73e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs785499	ENSG00000234329.1	RP11-767N6.2	-8.76	3.51e-17	1.73e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45651039~45651826:-
THCA	cis	rs11148252	0.967	rs4286007	ENSG00000278238.1	RP11-245D16.4	-8.76	3.51e-17	1.74e-14	-0.41	-0.37	Lewy body disease;	chr13:52448383	chr13:52454775~52455331:-
THCA	cis	rs910316	0.692	rs7156586	ENSG00000279594.1	RP11-950C14.10	8.76	3.52e-17	1.74e-14	0.36	0.37	Height;	chr14:75039527	chr14:75011269~75012851:-
THCA	cis	rs524281	0.731	rs2430979	ENSG00000255320.1	RP11-755F10.1	-8.76	3.54e-17	1.75e-14	-0.55	-0.37	Electroencephalogram traits;	chr11:66045912	chr11:66244840~66246239:-
THCA	cis	rs2408955	0.5	rs12816820	ENSG00000258273.1	RP11-370I10.4	-8.76	3.54e-17	1.75e-14	-0.49	-0.37	Glycated hemoglobin levels;	chr12:48164542	chr12:48333755~48333901:-
THCA	cis	rs73081554	0.611	rs4681851	ENSG00000272360.1	RP11-359I18.5	-8.76	3.55e-17	1.75e-14	-0.52	-0.37	Rheumatoid arthritis;	chr3:58410164	chr3:58490830~58491291:-
THCA	cis	rs6600671	0.764	rs6600673	ENSG00000223345.3	HIST2H2BA	8.76	3.55e-17	1.76e-14	0.42	0.37	Hip geometry;	chr1:121426988	chr1:121108210~121117257:-
THCA	cis	rs9322193	0.884	rs11155675	ENSG00000268592.3	RAET1E-AS1	8.76	3.56e-17	1.76e-14	0.51	0.37	Lung cancer;	chr6:149742883	chr6:149863494~149919507:+
THCA	cis	rs1426063	0.614	rs17000261	ENSG00000260265.1	RP11-44F21.5	8.76	3.56e-17	1.76e-14	0.8	0.37	QT interval;	chr4:75108766	chr4:75081702~75084717:-
THCA	cis	rs17608059	0.566	rs6502327	ENSG00000141028.6	CDRT15P1	-8.76	3.57e-17	1.77e-14	-0.45	-0.37	Temperament;	chr17:14042870	chr17:14024514~14025488:+
THCA	cis	rs5760092	0.755	rs915589	ENSG00000235689.1	AP000351.13	-8.76	3.58e-17	1.77e-14	-0.54	-0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:24006305~24008258:-
THCA	cis	rs748404	0.697	rs471122	ENSG00000249839.1	AC011330.5	8.76	3.61e-17	1.78e-14	0.43	0.37	Lung cancer;	chr15:43266376	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs473016	ENSG00000249839.1	AC011330.5	-8.76	3.61e-17	1.78e-14	-0.43	-0.37	Lung cancer;	chr15:43266625	chr15:43663654~43684339:-
THCA	cis	rs11971779	0.938	rs11981688	ENSG00000273391.1	RP11-634H22.1	8.76	3.62e-17	1.79e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139404149	chr7:139359032~139359566:-
THCA	cis	rs7015263	0.689	rs7460286	ENSG00000254231.1	CTD-2284J15.1	-8.76	3.62e-17	1.79e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86322968	chr8:86333274~86343314:-
THCA	cis	rs9402743	0.632	rs6570028	ENSG00000231028.7	LINC00271	-8.76	3.62e-17	1.79e-14	-0.3	-0.37	Systemic lupus erythematosus;	chr6:135754784	chr6:135497801~135716055:+
THCA	cis	rs1501911	0.53	rs161942	ENSG00000248489.1	CTD-2007H13.3	8.76	3.62e-17	1.79e-14	0.37	0.37	Lung function (FEV1/FVC);	chr5:98868016	chr5:98929171~98995013:+
THCA	cis	rs7849270	1	rs2254230	ENSG00000268707.1	RP11-247A12.7	8.76	3.63e-17	1.79e-14	0.47	0.37	Blood metabolite ratios;	chr9:129142898	chr9:129170434~129170940:+
THCA	cis	rs6844153	0.752	rs28520489	ENSG00000240005.4	RP11-293A21.1	-8.76	3.63e-17	1.79e-14	-0.45	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26896082	chr4:26859806~26860599:-
THCA	cis	rs1707322	1	rs4606257	ENSG00000234329.1	RP11-767N6.2	8.76	3.63e-17	1.8e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45651039~45651826:-
THCA	cis	rs10411161	0.657	rs67462252	ENSG00000269483.1	AC006272.1	8.76	3.64e-17	1.8e-14	0.52	0.37	Breast cancer;	chr19:51879598	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs8110073	ENSG00000269483.1	AC006272.1	8.76	3.64e-17	1.8e-14	0.52	0.37	Breast cancer;	chr19:51879870	chr19:51839924~51843324:-
THCA	cis	rs56046484	0.797	rs907260	ENSG00000259295.5	CSPG4P12	-8.76	3.65e-17	1.81e-14	-0.62	-0.37	Testicular germ cell tumor;	chr15:85133526	chr15:85191438~85213905:+
THCA	cis	rs1707322	0.963	rs12145287	ENSG00000234329.1	RP11-767N6.2	8.76	3.66e-17	1.81e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45651039~45651826:-
THCA	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	8.76	3.67e-17	1.81e-14	0.44	0.37	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
THCA	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-8.76	3.67e-17	1.81e-14	-0.53	-0.37	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
THCA	cis	rs62355901	0.505	rs3733951	ENSG00000271828.1	CTD-2310F14.1	-8.76	3.67e-17	1.81e-14	-0.76	-0.37	Breast cancer;	chr5:56833976	chr5:56927874~56929573:+
THCA	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-8.76	3.7e-17	1.83e-14	-0.39	-0.37	QT interval;	chr12:29344573	chr12:29280418~29317848:-
THCA	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-8.75	3.71e-17	1.83e-14	-0.49	-0.37	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
THCA	cis	rs7015263	0.541	rs61117517	ENSG00000254231.1	CTD-2284J15.1	-8.75	3.71e-17	1.83e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86263167	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.573	rs4425734	ENSG00000254231.1	CTD-2284J15.1	-8.75	3.71e-17	1.83e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86265346	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.573	rs17680608	ENSG00000254231.1	CTD-2284J15.1	-8.75	3.71e-17	1.83e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86270695	chr8:86333274~86343314:-
THCA	cis	rs7727544	0.547	rs10076758	ENSG00000237714.1	P4HA2-AS1	8.75	3.71e-17	1.83e-14	0.47	0.37	Blood metabolite levels;	chr5:132188606	chr5:132184876~132192808:+
THCA	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	8.75	3.71e-17	1.83e-14	0.37	0.37	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
THCA	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	8.75	3.71e-17	1.83e-14	0.56	0.37	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
THCA	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-8.75	3.72e-17	1.84e-14	-0.39	-0.37	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
THCA	cis	rs5769707	0.935	rs5770594	ENSG00000235111.1	RP1-29C18.8	-8.75	3.75e-17	1.85e-14	-0.44	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49612657~49615716:-
THCA	cis	rs5769707	0.967	rs4524218	ENSG00000235111.1	RP1-29C18.8	-8.75	3.75e-17	1.85e-14	-0.44	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49612657~49615716:-
THCA	cis	rs62355900	0.627	rs16886407	ENSG00000271828.1	CTD-2310F14.1	8.75	3.82e-17	1.88e-14	0.71	0.37	Endometriosis;	chr5:56845540	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs16886419	ENSG00000271828.1	CTD-2310F14.1	8.75	3.82e-17	1.88e-14	0.71	0.37	Endometriosis;	chr5:56847034	chr5:56927874~56929573:+
THCA	cis	rs62355901	0.545	rs1862621	ENSG00000271828.1	CTD-2310F14.1	8.75	3.82e-17	1.88e-14	0.71	0.37	Breast cancer;	chr5:56847332	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs62358076	ENSG00000271828.1	CTD-2310F14.1	8.75	3.82e-17	1.88e-14	0.71	0.37	Endometriosis;	chr5:56848189	chr5:56927874~56929573:+
THCA	cis	rs9532669	0.889	rs7320344	ENSG00000239827.7	SUGT1P3	-8.75	3.82e-17	1.89e-14	-0.43	-0.37	Cervical cancer;	chr13:40885502	chr13:40908159~40921774:-
THCA	cis	rs3762637	0.769	rs13317855	ENSG00000272758.4	RP11-299J3.8	-8.75	3.83e-17	1.89e-14	-0.63	-0.37	LDL cholesterol levels;	chr3:122385387	chr3:122416207~122443180:+
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-8.75	3.84e-17	1.89e-14	-0.46	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
THCA	cis	rs2243480	0.803	rs55700941	ENSG00000273142.1	RP11-458F8.4	-8.75	3.84e-17	1.9e-14	-0.48	-0.37	Diabetic kidney disease;	chr7:65924813	chr7:66902857~66906297:+
THCA	cis	rs7211079	0.879	rs72852522	ENSG00000275479.1	RP11-334C17.6	8.75	3.85e-17	1.9e-14	0.36	0.37	Myocardial infarction;	chr17:80157691	chr17:80149627~80149798:+
THCA	cis	rs7665090	1	rs7665090	ENSG00000246560.2	RP11-10L12.4	-8.75	3.85e-17	1.9e-14	-0.44	-0.37	Primary biliary cholangitis;	chr4:102630446	chr4:102828055~102844075:+
THCA	cis	rs516805	0.847	rs520046	ENSG00000279453.1	RP3-425C14.4	-8.75	3.85e-17	1.9e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122446048	chr6:122436789~122439223:-
THCA	cis	rs1426063	0.614	rs17000260	ENSG00000260265.1	RP11-44F21.5	8.75	3.87e-17	1.91e-14	0.79	0.37	QT interval;	chr4:75108576	chr4:75081702~75084717:-
THCA	cis	rs1062177	0.826	rs2915879	ENSG00000253921.1	CTB-113P19.3	-8.75	3.88e-17	1.91e-14	-0.45	-0.37	Preschool internalizing problems;	chr5:151767881	chr5:151753992~151767247:+
THCA	cis	rs4713118	0.868	rs9468220	ENSG00000219392.1	RP1-265C24.5	8.75	3.91e-17	1.93e-14	0.52	0.37	Parkinson's disease;	chr6:27765197	chr6:28115628~28116551:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000235689.1	AP000351.13	8.75	3.91e-17	1.93e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:24006305~24008258:-
THCA	cis	rs9532669	0.926	rs2324747	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40988883	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs2324748	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40989452	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs4245311	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40990003	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.926	rs9525439	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40992645	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs35073784	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40993428	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs9594473	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40997997	chr13:40908159~40921774:-
THCA	cis	rs9532669	0.89	rs1543589	ENSG00000239827.7	SUGT1P3	-8.75	3.91e-17	1.93e-14	-0.4	-0.37	Cervical cancer;	chr13:40999064	chr13:40908159~40921774:-
THCA	cis	rs7772486	0.875	rs2777482	ENSG00000235652.6	RP11-545I5.3	8.75	3.91e-17	1.93e-14	0.35	0.37	Lobe attachment (rater-scored or self-reported);	chr6:145999205	chr6:145799409~145886585:+
THCA	cis	rs853679	0.55	rs1233699	ENSG00000226314.6	ZNF192P1	-8.75	3.92e-17	1.93e-14	-0.49	-0.37	Depression;	chr6:28201380	chr6:28161781~28169594:+
THCA	cis	rs11148252	0.967	rs11620062	ENSG00000278238.1	RP11-245D16.4	-8.75	3.92e-17	1.93e-14	-0.41	-0.37	Lewy body disease;	chr13:52419891	chr13:52454775~52455331:-
THCA	cis	rs9322193	0.736	rs3828701	ENSG00000268592.3	RAET1E-AS1	8.75	3.92e-17	1.93e-14	0.5	0.37	Lung cancer;	chr6:149791063	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.736	rs3805750	ENSG00000268592.3	RAET1E-AS1	8.75	3.92e-17	1.93e-14	0.5	0.37	Lung cancer;	chr6:149791065	chr6:149863494~149919507:+
THCA	cis	rs10411161	0.702	rs7251929	ENSG00000269483.1	AC006272.1	8.75	3.93e-17	1.94e-14	0.52	0.37	Breast cancer;	chr19:51886005	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.64	rs7252303	ENSG00000269483.1	AC006272.1	8.75	3.93e-17	1.94e-14	0.52	0.37	Breast cancer;	chr19:51886104	chr19:51839924~51843324:-
THCA	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	8.75	3.93e-17	1.94e-14	0.56	0.37	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
THCA	cis	rs11690935	0.55	rs7584187	ENSG00000228389.1	AC068039.4	8.75	3.94e-17	1.94e-14	0.4	0.37	Schizophrenia;	chr2:172001198	chr2:171773482~171775844:+
THCA	cis	rs12908161	1	rs12905057	ENSG00000259728.4	LINC00933	8.75	3.95e-17	1.95e-14	0.51	0.37	Schizophrenia;	chr15:84667534	chr15:84570649~84580175:+
THCA	cis	rs1707322	0.721	rs11211163	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs12037803	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10789470	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs61784796	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10749856	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10890344	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4564187	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.752	rs28438704	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs28442079	ENSG00000234329.1	RP11-767N6.2	8.75	3.96e-17	1.95e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.65	rs4553239	ENSG00000234329.1	RP11-767N6.2	8.75	3.97e-17	1.96e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45651039~45651826:-
THCA	cis	rs1799949	0.965	rs4793237	ENSG00000267681.1	CTD-3199J23.6	-8.75	3.98e-17	1.96e-14	-0.44	-0.37	Menopause (age at onset);	chr17:43359227	chr17:43144956~43145255:+
THCA	cis	rs9659323	1	rs12073056	ENSG00000231365.4	RP11-418J17.1	-8.74	4e-17	1.97e-14	-0.37	-0.37	Body mass index;	chr1:118965777	chr1:119140396~119275973:+
THCA	cis	rs1707322	0.721	rs11211165	ENSG00000234329.1	RP11-767N6.2	8.74	4.01e-17	1.97e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs11211166	ENSG00000234329.1	RP11-767N6.2	8.74	4.01e-17	1.97e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7539800	ENSG00000234329.1	RP11-767N6.2	-8.74	4.02e-17	1.98e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45651039~45651826:-
THCA	cis	rs10411161	0.702	rs1433081	ENSG00000269483.1	AC006272.1	8.74	4.03e-17	1.98e-14	0.53	0.37	Breast cancer;	chr19:51887457	chr19:51839924~51843324:-
THCA	cis	rs11051970	0.559	rs11051991	ENSG00000274964.1	RP11-817I4.1	8.74	4.05e-17	1.99e-14	0.49	0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32410998	chr12:32339368~32340724:+
THCA	cis	rs8040855	0.624	rs12903975	ENSG00000259295.5	CSPG4P12	8.74	4.05e-17	1.99e-14	0.53	0.37	Bulimia nervosa;	chr15:85006004	chr15:85191438~85213905:+
THCA	cis	rs9926296	0.744	rs352939	ENSG00000260259.1	RP11-368I7.4	8.74	4.06e-17	2e-14	0.41	0.37	Vitiligo;	chr16:89643970	chr16:89682620~89686569:-
THCA	cis	rs11051970	0.513	rs4931013	ENSG00000274964.1	RP11-817I4.1	-8.74	4.08e-17	2.01e-14	-0.48	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32407788	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.546	rs11051989	ENSG00000274964.1	RP11-817I4.1	-8.74	4.08e-17	2.01e-14	-0.48	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32407956	chr12:32339368~32340724:+
THCA	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	8.74	4.1e-17	2.01e-14	0.71	0.37	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
THCA	cis	rs4713118	0.738	rs200465	ENSG00000219392.1	RP1-265C24.5	-8.74	4.1e-17	2.01e-14	-0.49	-0.37	Parkinson's disease;	chr6:27789875	chr6:28115628~28116551:+
THCA	cis	rs9532669	0.926	rs4942014	ENSG00000239827.7	SUGT1P3	-8.74	4.13e-17	2.03e-14	-0.39	-0.37	Cervical cancer;	chr13:40966366	chr13:40908159~40921774:-
THCA	cis	rs7291412	0.601	rs7292407	ENSG00000231711.2	LINC00899	-8.74	4.13e-17	2.03e-14	-0.3	-0.37	Dupuytren's disease;Subjective well-being;	chr22:46057832	chr22:46039907~46044853:-
THCA	cis	rs17684571	0.751	rs7758867	ENSG00000231441.1	RP11-472M19.2	8.74	4.14e-17	2.04e-14	0.45	0.37	Schizophrenia;	chr6:56836000	chr6:56844002~56864078:+
THCA	cis	rs5769707	0.967	rs9616701	ENSG00000235111.1	RP1-29C18.8	-8.74	4.14e-17	2.04e-14	-0.44	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49612657~49615716:-
THCA	cis	rs6545883	0.507	rs59981505	ENSG00000271889.1	RP11-493E12.1	-8.74	4.15e-17	2.04e-14	-0.36	-0.37	Tuberculosis;	chr2:61353394	chr2:61151433~61162105:-
THCA	cis	rs4819052	0.565	rs35776291	ENSG00000215447.6	BX322557.10	-8.74	4.16e-17	2.05e-14	-0.3	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45286227	chr21:45288052~45291738:+
THCA	cis	rs12682352	0.652	rs3789843	ENSG00000253893.2	FAM85B	-8.74	4.17e-17	2.05e-14	-0.5	-0.37	Neuroticism;	chr8:8866747	chr8:8167819~8226614:-
THCA	cis	rs12682352	0.652	rs3827806	ENSG00000253893.2	FAM85B	-8.74	4.17e-17	2.05e-14	-0.5	-0.37	Neuroticism;	chr8:8866766	chr8:8167819~8226614:-
THCA	cis	rs910316	0.646	rs11546525	ENSG00000279594.1	RP11-950C14.10	8.74	4.18e-17	2.05e-14	0.36	0.37	Height;	chr14:75070678	chr14:75011269~75012851:-
THCA	cis	rs11148252	0.74	rs9596642	ENSG00000278238.1	RP11-245D16.4	8.74	4.18e-17	2.06e-14	0.43	0.37	Lewy body disease;	chr13:52326744	chr13:52454775~52455331:-
THCA	cis	rs4819052	0.885	rs9980676	ENSG00000237664.1	LINC00316	-8.74	4.19e-17	2.06e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245515	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838836	ENSG00000237664.1	LINC00316	-8.74	4.19e-17	2.06e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245960	chr21:45338590~45341990:-
THCA	cis	rs673078	0.66	rs16948197	ENSG00000275409.1	RP11-131L12.4	8.74	4.21e-17	2.07e-14	0.48	0.37	Glucose homeostasis traits;	chr12:118239135	chr12:118430147~118430699:+
THCA	cis	rs950169	0.58	rs17532346	ENSG00000259728.4	LINC00933	8.74	4.21e-17	2.07e-14	0.51	0.37	Schizophrenia;	chr15:84628264	chr15:84570649~84580175:+
THCA	cis	rs1707322	1	rs4074225	ENSG00000234329.1	RP11-767N6.2	8.74	4.21e-17	2.07e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4134387	ENSG00000234329.1	RP11-767N6.2	8.74	4.21e-17	2.07e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10890376	ENSG00000234329.1	RP11-767N6.2	8.74	4.21e-17	2.07e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10789485	ENSG00000234329.1	RP11-767N6.2	8.74	4.21e-17	2.07e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45651039~45651826:-
THCA	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	8.74	4.22e-17	2.07e-14	0.37	0.37	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
THCA	cis	rs2243480	1	rs35820085	ENSG00000273142.1	RP11-458F8.4	-8.74	4.24e-17	2.08e-14	-0.48	-0.37	Diabetic kidney disease;	chr7:65977771	chr7:66902857~66906297:+
THCA	cis	rs7829975	0.714	rs4840362	ENSG00000253893.2	FAM85B	8.74	4.25e-17	2.09e-14	0.47	0.37	Mood instability;	chr8:8812572	chr8:8167819~8226614:-
THCA	cis	rs10740039	0.81	rs4440977	ENSG00000254271.1	RP11-131N11.4	8.74	4.26e-17	2.09e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60618163	chr10:60734342~60741828:+
THCA	cis	rs2274273	0.745	rs8005399	ENSG00000258413.1	RP11-665C16.6	-8.74	4.28e-17	2.1e-14	-0.5	-0.37	Protein biomarker;	chr14:55076127	chr14:55262767~55272075:-
THCA	cis	rs11690935	0.55	rs6730085	ENSG00000228389.1	AC068039.4	-8.74	4.28e-17	2.1e-14	-0.4	-0.37	Schizophrenia;	chr2:171999938	chr2:171773482~171775844:+
THCA	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	8.74	4.29e-17	2.11e-14	0.73	0.37	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs781150	ENSG00000273142.1	RP11-458F8.4	-8.74	4.29e-17	2.11e-14	-0.47	-0.37	Diabetic kidney disease;	chr7:66015986	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs313798	ENSG00000273142.1	RP11-458F8.4	-8.74	4.29e-17	2.11e-14	-0.47	-0.37	Diabetic kidney disease;	chr7:66028044	chr7:66902857~66906297:+
THCA	cis	rs2439831	0.85	rs16977798	ENSG00000249839.1	AC011330.5	-8.74	4.29e-17	2.11e-14	-0.59	-0.37	Lung cancer in ever smokers;	chr15:43859750	chr15:43663654~43684339:-
THCA	cis	rs4591358	0.731	rs34634374	ENSG00000223466.1	AC064834.2	-8.74	4.3e-17	2.11e-14	-0.52	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509437	chr2:195533035~195538681:+
THCA	cis	rs5769707	0.839	rs73176988	ENSG00000235111.1	RP1-29C18.8	-8.73	4.31e-17	2.12e-14	-0.45	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49612657~49615716:-
THCA	cis	rs2439831	0.85	rs10438303	ENSG00000249839.1	AC011330.5	-8.73	4.32e-17	2.12e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43724219	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.851	rs2838839	ENSG00000237664.1	LINC00316	8.73	4.32e-17	2.12e-14	0.37	0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247943	chr21:45338590~45341990:-
THCA	cis	rs1501911	0.53	rs161933	ENSG00000248489.1	CTD-2007H13.3	8.73	4.33e-17	2.12e-14	0.37	0.37	Lung function (FEV1/FVC);	chr5:98874643	chr5:98929171~98995013:+
THCA	cis	rs1501911	0.53	rs161938	ENSG00000248489.1	CTD-2007H13.3	8.73	4.33e-17	2.12e-14	0.37	0.37	Lung function (FEV1/FVC);	chr5:98875501	chr5:98929171~98995013:+
THCA	cis	rs7674212	0.507	rs223471	ENSG00000251288.2	RP11-10L12.2	-8.73	4.34e-17	2.13e-14	-0.5	-0.37	Type 2 diabetes;	chr4:102777629	chr4:102751401~102752641:+
THCA	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-8.73	4.35e-17	2.14e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-8.73	4.35e-17	2.14e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
THCA	cis	rs597539	0.731	rs664229	ENSG00000250508.1	RP11-757G1.6	-8.73	4.37e-17	2.14e-14	-0.46	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857015	chr11:68870664~68874542:+
THCA	cis	rs6061231	0.701	rs6061505	ENSG00000273619.1	RP5-908M14.9	-8.73	4.37e-17	2.15e-14	-0.28	-0.37	Colorectal cancer;	chr20:62385155	chr20:62386303~62386970:-
THCA	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-8.73	4.38e-17	2.15e-14	-0.45	-0.37	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-8.73	4.38e-17	2.15e-14	-0.45	-0.37	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-8.73	4.38e-17	2.15e-14	-0.45	-0.37	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-8.73	4.38e-17	2.15e-14	-0.45	-0.37	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000224205.1	AP000351.4	-8.73	4.38e-17	2.15e-14	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23987320~23991421:-
THCA	cis	rs2033711	0.755	rs4801587	ENSG00000268912.1	CTD-2619J13.17	-8.73	4.4e-17	2.16e-14	-0.29	-0.37	Uric acid clearance;	chr19:58425312	chr19:58428632~58431148:-
THCA	cis	rs4713118	0.868	rs35069907	ENSG00000219392.1	RP1-265C24.5	-8.73	4.4e-17	2.16e-14	-0.51	-0.37	Parkinson's disease;	chr6:27778913	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.884	rs9371201	ENSG00000268592.3	RAET1E-AS1	8.73	4.42e-17	2.17e-14	0.51	0.37	Lung cancer;	chr6:149823865	chr6:149863494~149919507:+
THCA	cis	rs2439831	0.85	rs12441127	ENSG00000249839.1	AC011330.5	-8.73	4.43e-17	2.17e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43728977	chr15:43663654~43684339:-
THCA	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-8.73	4.43e-17	2.17e-14	-0.38	-0.37	QT interval;	chr12:29306799	chr12:29280418~29317848:-
THCA	cis	rs4819052	0.851	rs7276591	ENSG00000237664.1	LINC00316	-8.73	4.43e-17	2.18e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260241	chr21:45338590~45341990:-
THCA	cis	rs1707322	0.789	rs7540578	ENSG00000234329.1	RP11-767N6.2	8.73	4.47e-17	2.19e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45651039~45651826:-
THCA	cis	rs2280018	0.526	rs2941257	ENSG00000188599.16	NPIPP1	-8.73	4.47e-17	2.19e-14	-0.3	-0.37	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15104312~15123498:-
THCA	cis	rs11051970	0.559	rs2291420	ENSG00000274964.1	RP11-817I4.1	-8.73	4.47e-17	2.19e-14	-0.46	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32334816	chr12:32339368~32340724:+
THCA	cis	rs748404	0.723	rs512431	ENSG00000249839.1	AC011330.5	8.73	4.47e-17	2.19e-14	0.44	0.37	Lung cancer;	chr15:43249741	chr15:43663654~43684339:-
THCA	cis	rs2274273	0.624	rs8003279	ENSG00000258413.1	RP11-665C16.6	-8.73	4.48e-17	2.2e-14	-0.53	-0.37	Protein biomarker;	chr14:55397412	chr14:55262767~55272075:-
THCA	cis	rs1799949	0.965	rs8067269	ENSG00000267681.1	CTD-3199J23.6	-8.73	4.5e-17	2.21e-14	-0.43	-0.37	Menopause (age at onset);	chr17:43083782	chr17:43144956~43145255:+
THCA	cis	rs6844153	0.752	rs12650172	ENSG00000240005.4	RP11-293A21.1	-8.73	4.5e-17	2.21e-14	-0.44	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872784	chr4:26859806~26860599:-
THCA	cis	rs6844153	0.752	rs12641261	ENSG00000240005.4	RP11-293A21.1	-8.73	4.5e-17	2.21e-14	-0.44	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26872814	chr4:26859806~26860599:-
THCA	cis	rs7015263	0.689	rs5024450	ENSG00000254231.1	CTD-2284J15.1	8.73	4.54e-17	2.23e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86352009	chr8:86333274~86343314:-
THCA	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	8.73	4.54e-17	2.23e-14	0.24	0.37	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	8.73	4.54e-17	2.23e-14	0.24	0.37	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	8.73	4.54e-17	2.23e-14	0.24	0.37	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
THCA	cis	rs9659323	1	rs9659323	ENSG00000231365.4	RP11-418J17.1	-8.73	4.54e-17	2.23e-14	-0.38	-0.37	Body mass index;	chr1:118961738	chr1:119140396~119275973:+
THCA	cis	rs9659323	1	rs9658899	ENSG00000231365.4	RP11-418J17.1	-8.73	4.54e-17	2.23e-14	-0.38	-0.37	Body mass index;	chr1:118961920	chr1:119140396~119275973:+
THCA	cis	rs11155671	0.546	rs1999633	ENSG00000216906.2	RP11-350J20.9	8.73	4.55e-17	2.23e-14	0.46	0.37	Testicular germ cell tumor;	chr6:149866576	chr6:149904243~149906418:+
THCA	cis	rs507080	0.771	rs687664	ENSG00000278376.1	RP11-158I9.8	-8.73	4.55e-17	2.23e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118703476	chr11:118791254~118793137:+
THCA	cis	rs507080	0.771	rs523715	ENSG00000278376.1	RP11-158I9.8	-8.73	4.55e-17	2.23e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118703479	chr11:118791254~118793137:+
THCA	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	8.73	4.55e-17	2.23e-14	0.56	0.37	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	8.73	4.55e-17	2.23e-14	0.56	0.37	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
THCA	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	8.73	4.56e-17	2.23e-14	0.44	0.37	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
THCA	cis	rs1707322	0.691	rs61784803	ENSG00000234329.1	RP11-767N6.2	-8.73	4.56e-17	2.23e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.663	rs3935296	ENSG00000234329.1	RP11-767N6.2	-8.73	4.56e-17	2.23e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs28817701	ENSG00000234329.1	RP11-767N6.2	8.73	4.56e-17	2.23e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.691	rs28495425	ENSG00000234329.1	RP11-767N6.2	8.73	4.56e-17	2.23e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45651039~45651826:-
THCA	cis	rs17684571	0.7	rs34520435	ENSG00000231441.1	RP11-472M19.2	8.73	4.56e-17	2.24e-14	0.48	0.37	Schizophrenia;	chr6:56818319	chr6:56844002~56864078:+
THCA	cis	rs375066	0.935	rs429027	ENSG00000267058.1	RP11-15A1.3	-8.73	4.57e-17	2.24e-14	-0.3	-0.37	Breast cancer;	chr19:43891337	chr19:43891804~43901805:-
THCA	cis	rs2439831	0.85	rs68079546	ENSG00000249839.1	AC011330.5	-8.73	4.58e-17	2.24e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43844759	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs56909447	ENSG00000249839.1	AC011330.5	-8.73	4.58e-17	2.24e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43845420	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28476182	ENSG00000249839.1	AC011330.5	-8.73	4.58e-17	2.24e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43847445	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28696802	ENSG00000249839.1	AC011330.5	-8.73	4.58e-17	2.24e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43848197	chr15:43663654~43684339:-
THCA	cis	rs465969	1	rs465969	ENSG00000255389.1	C6orf3	-8.73	4.58e-17	2.25e-14	-0.56	-0.37	Psoriasis;	chr6:111334327	chr6:111599875~111602295:+
THCA	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	8.73	4.58e-17	2.25e-14	0.64	0.37	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
THCA	cis	rs11971779	0.646	rs58682779	ENSG00000273391.1	RP11-634H22.1	8.73	4.59e-17	2.25e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139399966	chr7:139359032~139359566:-
THCA	cis	rs2243480	0.901	rs73148097	ENSG00000273142.1	RP11-458F8.4	-8.73	4.59e-17	2.25e-14	-0.48	-0.37	Diabetic kidney disease;	chr7:65966800	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs906134	ENSG00000273142.1	RP11-458F8.4	-8.73	4.59e-17	2.25e-14	-0.48	-0.37	Diabetic kidney disease;	chr7:65979301	chr7:66902857~66906297:+
THCA	cis	rs9322193	0.887	rs3734295	ENSG00000268592.3	RAET1E-AS1	8.73	4.6e-17	2.25e-14	0.51	0.37	Lung cancer;	chr6:149593917	chr6:149863494~149919507:+
THCA	cis	rs748404	0.723	rs573169	ENSG00000249839.1	AC011330.5	-8.73	4.61e-17	2.26e-14	-0.43	-0.37	Lung cancer;	chr15:43258383	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs524547	ENSG00000249839.1	AC011330.5	-8.73	4.61e-17	2.26e-14	-0.43	-0.37	Lung cancer;	chr15:43258825	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs564946	ENSG00000249839.1	AC011330.5	-8.73	4.61e-17	2.26e-14	-0.43	-0.37	Lung cancer;	chr15:43264074	chr15:43663654~43684339:-
THCA	cis	rs748404	0.723	rs565658	ENSG00000249839.1	AC011330.5	-8.73	4.61e-17	2.26e-14	-0.43	-0.37	Lung cancer;	chr15:43264109	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs579651	ENSG00000249839.1	AC011330.5	-8.73	4.61e-17	2.26e-14	-0.43	-0.37	Lung cancer;	chr15:43266178	chr15:43663654~43684339:-
THCA	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-8.73	4.63e-17	2.27e-14	-0.38	-0.37	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
THCA	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	8.73	4.63e-17	2.27e-14	0.47	0.37	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
THCA	cis	rs9813712	0.571	rs9836814	ENSG00000228252.7	COL6A4P2	8.73	4.64e-17	2.27e-14	0.38	0.37	Response to amphetamines;	chr3:130216054	chr3:130212823~130273806:+
THCA	cis	rs7712401	0.562	rs2407403	ENSG00000263432.2	RN7SL689P	8.73	4.64e-17	2.27e-14	0.42	0.37	Mean platelet volume;	chr5:122838336	chr5:123022487~123022783:-
THCA	cis	rs375066	0.868	rs368079	ENSG00000267058.1	RP11-15A1.3	-8.72	4.65e-17	2.28e-14	-0.3	-0.37	Breast cancer;	chr19:43889204	chr19:43891804~43901805:-
THCA	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	8.72	4.65e-17	2.28e-14	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
THCA	cis	rs2836950	0.501	rs2070865	ENSG00000255568.3	BRWD1-AS2	-8.72	4.68e-17	2.29e-14	-0.31	-0.37	Menarche (age at onset);	chr21:39343593	chr21:39313935~39314962:+
THCA	cis	rs642803	0.613	rs565427	ENSG00000214659.4	KRT8P26	-8.72	4.69e-17	2.3e-14	-0.33	-0.37	Urate levels;	chr11:65765354	chr11:65726939~65728214:+
THCA	cis	rs6723226	0.572	rs176411	ENSG00000276334.1	AL133243.1	8.72	4.71e-17	2.31e-14	0.41	0.37	Intelligence (multi-trait analysis);	chr2:32418460	chr2:32521927~32523547:+
THCA	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-8.72	4.72e-17	2.31e-14	-0.42	-0.37	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
THCA	cis	rs2243480	1	rs709607	ENSG00000273142.1	RP11-458F8.4	8.72	4.72e-17	2.31e-14	0.48	0.37	Diabetic kidney disease;	chr7:65984554	chr7:66902857~66906297:+
THCA	cis	rs2439831	0.85	rs28858500	ENSG00000249839.1	AC011330.5	-8.72	4.73e-17	2.31e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43864744	chr15:43663654~43684339:-
THCA	cis	rs507080	0.733	rs611733	ENSG00000278376.1	RP11-158I9.8	-8.72	4.73e-17	2.32e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118702051	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs552079	ENSG00000278376.1	RP11-158I9.8	-8.72	4.73e-17	2.32e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118702313	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs673547	ENSG00000278376.1	RP11-158I9.8	-8.72	4.73e-17	2.32e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118702630	chr11:118791254~118793137:+
THCA	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-8.72	4.74e-17	2.32e-14	-0.47	-0.37	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
THCA	cis	rs597539	0.69	rs578791	ENSG00000250508.1	RP11-757G1.6	-8.72	4.75e-17	2.33e-14	-0.46	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858341	chr11:68870664~68874542:+
THCA	cis	rs7727544	0.582	rs10478998	ENSG00000237714.1	P4HA2-AS1	8.72	4.76e-17	2.33e-14	0.47	0.37	Blood metabolite levels;	chr5:132180838	chr5:132184876~132192808:+
THCA	cis	rs5769707	0.967	rs2071904	ENSG00000235111.1	RP1-29C18.8	-8.72	4.76e-17	2.33e-14	-0.44	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49612657~49615716:-
THCA	cis	rs7665090	0.967	rs5026469	ENSG00000246560.2	RP11-10L12.4	8.72	4.76e-17	2.33e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102633556	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs5026470	ENSG00000246560.2	RP11-10L12.4	8.72	4.76e-17	2.33e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102633565	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs5026471	ENSG00000246560.2	RP11-10L12.4	8.72	4.76e-17	2.33e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102633576	chr4:102828055~102844075:+
THCA	cis	rs4819052	0.851	rs914218	ENSG00000237664.1	LINC00316	-8.72	4.78e-17	2.34e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278530	chr21:45338590~45341990:-
THCA	cis	rs673078	0.607	rs61944671	ENSG00000275409.1	RP11-131L12.4	-8.72	4.78e-17	2.34e-14	-0.46	-0.37	Glucose homeostasis traits;	chr12:118450046	chr12:118430147~118430699:+
THCA	cis	rs9813712	0.571	rs11715351	ENSG00000228252.7	COL6A4P2	-8.72	4.8e-17	2.35e-14	-0.38	-0.37	Response to amphetamines;	chr3:130214704	chr3:130212823~130273806:+
THCA	cis	rs597539	0.652	rs544370	ENSG00000250508.1	RP11-757G1.6	-8.72	4.8e-17	2.35e-14	-0.44	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68885764	chr11:68870664~68874542:+
THCA	cis	rs4819052	0.851	rs9979545	ENSG00000237664.1	LINC00316	-8.72	4.8e-17	2.35e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259890	chr21:45338590~45341990:-
THCA	cis	rs12188164	0.575	rs112126699	ENSG00000221990.4	EXOC3-AS1	8.72	4.81e-17	2.35e-14	0.32	0.37	Cystic fibrosis severity;	chr5:419347	chr5:441498~443160:-
THCA	cis	rs2274273	0.712	rs6572999	ENSG00000258413.1	RP11-665C16.6	-8.72	4.83e-17	2.36e-14	-0.5	-0.37	Protein biomarker;	chr14:55060656	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.712	rs17832311	ENSG00000258413.1	RP11-665C16.6	-8.72	4.83e-17	2.36e-14	-0.5	-0.37	Protein biomarker;	chr14:55067748	chr14:55262767~55272075:-
THCA	cis	rs597539	0.69	rs552517	ENSG00000250508.1	RP11-757G1.6	-8.72	4.83e-17	2.36e-14	-0.46	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68857818	chr11:68870664~68874542:+
THCA	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-8.72	4.85e-17	2.37e-14	-0.4	-0.37	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
THCA	cis	rs9543976	0.925	rs2876706	ENSG00000261553.4	RP11-29G8.3	8.72	4.85e-17	2.37e-14	0.48	0.37	Diabetic retinopathy;	chr13:75612169	chr13:75549773~75807120:+
THCA	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-8.72	4.85e-17	2.37e-14	-0.42	-0.37	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
THCA	cis	rs7849270	1	rs1107328	ENSG00000268707.1	RP11-247A12.7	8.72	4.85e-17	2.37e-14	0.47	0.37	Blood metabolite ratios;	chr9:129155255	chr9:129170434~129170940:+
THCA	cis	rs6844153	0.887	rs62302533	ENSG00000240005.4	RP11-293A21.1	-8.72	4.86e-17	2.38e-14	-0.5	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26955309	chr4:26859806~26860599:-
THCA	cis	rs748404	0.631	rs7163288	ENSG00000205771.5	CATSPER2P1	-8.72	4.9e-17	2.39e-14	-0.39	-0.37	Lung cancer;	chr15:43379157	chr15:43726918~43747094:-
THCA	cis	rs860295	0.557	rs348196	ENSG00000225855.5	RUSC1-AS1	8.72	4.9e-17	2.4e-14	0.27	0.37	Body mass index;	chr1:155697170	chr1:155316863~155324176:-
THCA	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	8.72	4.9e-17	2.4e-14	0.24	0.37	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
THCA	cis	rs934734	0.673	rs754110	ENSG00000234255.7	AC012370.3	8.72	4.91e-17	2.4e-14	0.41	0.37	Rheumatoid arthritis;	chr2:65464626	chr2:65439888~65456571:-
THCA	cis	rs8114671	0.935	rs6058198	ENSG00000269202.1	RP4-614O4.12	-8.72	4.91e-17	2.4e-14	-0.32	-0.37	Height;	chr20:35160450	chr20:35201747~35203288:-
THCA	cis	rs9532669	0.889	rs1989252	ENSG00000239827.7	SUGT1P3	8.72	4.94e-17	2.41e-14	0.4	0.37	Cervical cancer;	chr13:40911532	chr13:40908159~40921774:-
THCA	cis	rs950169	0.519	rs7237	ENSG00000259728.4	LINC00933	8.72	4.96e-17	2.42e-14	0.52	0.37	Schizophrenia;	chr15:84643346	chr15:84570649~84580175:+
THCA	cis	rs748404	0.697	rs531910	ENSG00000249839.1	AC011330.5	-8.72	4.98e-17	2.43e-14	-0.43	-0.37	Lung cancer;	chr15:43268409	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs492743	ENSG00000249839.1	AC011330.5	-8.72	4.98e-17	2.43e-14	-0.43	-0.37	Lung cancer;	chr15:43268747	chr15:43663654~43684339:-
THCA	cis	rs7567389	0.535	rs4150416	ENSG00000236682.1	AC068282.3	8.72	4.98e-17	2.44e-14	0.55	0.37	Self-rated health;	chr2:127288972	chr2:127389130~127400580:+
THCA	cis	rs55665837	1	rs10832276	ENSG00000251991.1	RNU7-49P	8.72	4.98e-17	2.44e-14	0.42	0.37	Vitamin D levels;	chr11:14461728	chr11:14478892~14478953:+
THCA	cis	rs2522056	0.808	rs7704457	ENSG00000233006.5	AC034220.3	8.72	4.99e-17	2.44e-14	0.33	0.37	Fibrinogen;Lymphocyte counts;	chr5:132409098	chr5:132311285~132369916:-
THCA	cis	rs7015263	0.689	rs56039487	ENSG00000254231.1	CTD-2284J15.1	-8.72	4.99e-17	2.44e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86347208	chr8:86333274~86343314:-
THCA	cis	rs1501911	0.53	rs326468	ENSG00000248489.1	CTD-2007H13.3	8.72	5e-17	2.44e-14	0.37	0.37	Lung function (FEV1/FVC);	chr5:98897105	chr5:98929171~98995013:+
THCA	cis	rs2439831	0.85	rs28590651	ENSG00000249839.1	AC011330.5	-8.72	5e-17	2.44e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43820818	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.851	rs2838840	ENSG00000237664.1	LINC00316	-8.71	5.04e-17	2.46e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45248579	chr21:45338590~45341990:-
THCA	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-8.71	5.04e-17	2.46e-14	-0.47	-0.37	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
THCA	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-8.71	5.04e-17	2.46e-14	-0.47	-0.37	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
THCA	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	8.71	5.05e-17	2.46e-14	0.42	0.37	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
THCA	cis	rs12908161	1	rs12911736	ENSG00000259728.4	LINC00933	8.71	5.06e-17	2.47e-14	0.51	0.37	Schizophrenia;	chr15:84696777	chr15:84570649~84580175:+
THCA	cis	rs12908161	0.959	rs12908699	ENSG00000259728.4	LINC00933	8.71	5.06e-17	2.47e-14	0.51	0.37	Schizophrenia;	chr15:84697172	chr15:84570649~84580175:+
THCA	cis	rs3096299	0.967	rs2965935	ENSG00000274627.1	RP11-104N10.2	-8.71	5.08e-17	2.48e-14	-0.36	-0.37	Multiple myeloma (IgH translocation);	chr16:89414866	chr16:89516797~89522217:+
THCA	cis	rs597539	0.69	rs647661	ENSG00000250508.1	RP11-757G1.6	-8.71	5.1e-17	2.49e-14	-0.46	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68858407	chr11:68870664~68874542:+
THCA	cis	rs1707322	0.662	rs11211160	ENSG00000234329.1	RP11-767N6.2	8.71	5.1e-17	2.49e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4559551	ENSG00000234329.1	RP11-767N6.2	8.71	5.12e-17	2.5e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45651039~45651826:-
THCA	cis	rs1799949	1	rs35070007	ENSG00000267681.1	CTD-3199J23.6	8.71	5.13e-17	2.5e-14	0.43	0.37	Menopause (age at onset);	chr17:43164730	chr17:43144956~43145255:+
THCA	cis	rs9640161	0.711	rs3735170	ENSG00000261305.1	RP4-584D14.7	8.71	5.14e-17	2.51e-14	0.47	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150337095	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.75	rs3735169	ENSG00000261305.1	RP4-584D14.7	8.71	5.14e-17	2.51e-14	0.47	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150337289	chr7:150341771~150342607:+
THCA	cis	rs4819052	1	rs2838847	ENSG00000215447.6	BX322557.10	-8.71	5.14e-17	2.51e-14	-0.33	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45288052~45291738:+
THCA	cis	rs375066	0.935	rs4803662	ENSG00000267058.1	RP11-15A1.3	-8.71	5.16e-17	2.52e-14	-0.3	-0.37	Breast cancer;	chr19:43855412	chr19:43891804~43901805:-
THCA	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-8.71	5.17e-17	2.52e-14	-0.3	-0.37	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
THCA	cis	rs12908161	1	rs35316992	ENSG00000259728.4	LINC00933	8.71	5.17e-17	2.52e-14	0.51	0.37	Schizophrenia;	chr15:84704902	chr15:84570649~84580175:+
THCA	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-8.71	5.17e-17	2.52e-14	-0.37	-0.37	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
THCA	cis	rs28510890	0.828	rs78417563	ENSG00000260337.3	RP11-386M24.6	8.71	5.17e-17	2.52e-14	0.46	0.37	Lung cancer in ever smokers;	chr15:92580224	chr15:92592574~92596462:-
THCA	cis	rs6844153	0.752	rs7681462	ENSG00000240005.4	RP11-293A21.1	-8.71	5.17e-17	2.52e-14	-0.44	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26894272	chr4:26859806~26860599:-
THCA	cis	rs10875746	0.669	rs61940962	ENSG00000240399.1	RP1-228P16.1	-8.71	5.2e-17	2.54e-14	-0.42	-0.37	Longevity (90 years and older);	chr12:48201694	chr12:48054813~48055591:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-8.71	5.2e-17	2.54e-14	-0.46	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
THCA	cis	rs7015263	0.689	rs4961190	ENSG00000254231.1	CTD-2284J15.1	-8.71	5.21e-17	2.54e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86402670	chr8:86333274~86343314:-
THCA	cis	rs7727544	0.647	rs7721882	ENSG00000237714.1	P4HA2-AS1	8.71	5.22e-17	2.54e-14	0.5	0.37	Blood metabolite levels;	chr5:132083255	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.625	rs3864277	ENSG00000237714.1	P4HA2-AS1	8.71	5.22e-17	2.54e-14	0.5	0.37	Blood metabolite levels;	chr5:132084556	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.647	rs6898270	ENSG00000237714.1	P4HA2-AS1	8.71	5.22e-17	2.54e-14	0.5	0.37	Blood metabolite levels;	chr5:132085497	chr5:132184876~132192808:+
THCA	cis	rs375066	0.935	rs432454	ENSG00000267058.1	RP11-15A1.3	-8.71	5.22e-17	2.55e-14	-0.3	-0.37	Breast cancer;	chr19:43894679	chr19:43891804~43901805:-
THCA	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	8.71	5.23e-17	2.55e-14	0.24	0.37	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
THCA	cis	rs7291412	1	rs7291412	ENSG00000231711.2	LINC00899	8.71	5.24e-17	2.55e-14	0.32	0.37	Dupuytren's disease;Subjective well-being;	chr22:46063252	chr22:46039907~46044853:-
THCA	cis	rs7829975	0.714	rs60315134	ENSG00000253893.2	FAM85B	-8.71	5.26e-17	2.56e-14	-0.47	-0.37	Mood instability;	chr8:8813089	chr8:8167819~8226614:-
THCA	cis	rs2439831	0.85	rs8042868	ENSG00000249839.1	AC011330.5	-8.71	5.27e-17	2.57e-14	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43647444	chr15:43663654~43684339:-
THCA	cis	rs7586673	0.866	rs7579662	ENSG00000227403.1	AC009299.3	-8.71	5.27e-17	2.57e-14	-0.43	-0.37	Intelligence (multi-trait analysis);	chr2:161059299	chr2:161244739~161249050:+
THCA	cis	rs7851660	0.967	rs4743134	ENSG00000236130.1	PTCSC2	-8.71	5.27e-17	2.57e-14	-0.28	-0.37	Strep throat;	chr9:97836286	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs4743135	ENSG00000236130.1	PTCSC2	-8.71	5.27e-17	2.57e-14	-0.28	-0.37	Strep throat;	chr9:97837211	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs7049054	ENSG00000236130.1	PTCSC2	-8.71	5.27e-17	2.57e-14	-0.28	-0.37	Strep throat;	chr9:97837687	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.967	rs7860598	ENSG00000236130.1	PTCSC2	-8.71	5.27e-17	2.57e-14	-0.28	-0.37	Strep throat;	chr9:97838420	chr9:97805935~97810008:-
THCA	cis	rs7851660	0.935	rs10818124	ENSG00000236130.1	PTCSC2	-8.71	5.27e-17	2.57e-14	-0.28	-0.37	Strep throat;	chr9:97840726	chr9:97805935~97810008:-
THCA	cis	rs1799949	0.965	rs8176310	ENSG00000267681.1	CTD-3199J23.6	-8.71	5.28e-17	2.58e-14	-0.43	-0.37	Menopause (age at onset);	chr17:43047896	chr17:43144956~43145255:+
THCA	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-8.71	5.29e-17	2.58e-14	-0.38	-0.37	Height;	chr11:118737916	chr11:118704607~118750263:+
THCA	cis	rs4713118	0.868	rs7756968	ENSG00000219392.1	RP1-265C24.5	-8.71	5.32e-17	2.59e-14	-0.51	-0.37	Parkinson's disease;	chr6:27767175	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.826	rs2893929	ENSG00000219392.1	RP1-265C24.5	-8.71	5.32e-17	2.59e-14	-0.51	-0.37	Parkinson's disease;	chr6:27770953	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.666	rs4140646	ENSG00000219392.1	RP1-265C24.5	-8.71	5.32e-17	2.59e-14	-0.51	-0.37	Parkinson's disease;	chr6:27771022	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.666	rs2893930	ENSG00000219392.1	RP1-265C24.5	-8.71	5.32e-17	2.59e-14	-0.51	-0.37	Parkinson's disease;	chr6:27771027	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.868	rs742047	ENSG00000219392.1	RP1-265C24.5	-8.71	5.32e-17	2.59e-14	-0.51	-0.37	Parkinson's disease;	chr6:27771601	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.868	rs760587	ENSG00000219392.1	RP1-265C24.5	-8.71	5.32e-17	2.59e-14	-0.51	-0.37	Parkinson's disease;	chr6:27772521	chr6:28115628~28116551:+
THCA	cis	rs5769707	0.967	rs763127	ENSG00000235111.1	RP1-29C18.8	-8.71	5.32e-17	2.59e-14	-0.42	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49612657~49615716:-
THCA	cis	rs5769707	0.935	rs1109320	ENSG00000235111.1	RP1-29C18.8	-8.71	5.33e-17	2.6e-14	-0.45	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49612657~49615716:-
THCA	cis	rs7829975	0.744	rs2409092	ENSG00000253893.2	FAM85B	-8.71	5.34e-17	2.6e-14	-0.48	-0.37	Mood instability;	chr8:8824682	chr8:8167819~8226614:-
THCA	cis	rs9543976	1	rs7339146	ENSG00000261553.4	RP11-29G8.3	-8.71	5.34e-17	2.6e-14	-0.48	-0.37	Diabetic retinopathy;	chr13:75599583	chr13:75549773~75807120:+
THCA	cis	rs9543976	1	rs4885324	ENSG00000261553.4	RP11-29G8.3	8.71	5.34e-17	2.6e-14	0.48	0.37	Diabetic retinopathy;	chr13:75599611	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.92	rs9543992	ENSG00000261553.4	RP11-29G8.3	8.71	5.34e-17	2.6e-14	0.48	0.37	Diabetic retinopathy;	chr13:75600938	chr13:75549773~75807120:+
THCA	cis	rs9543976	1	rs8192762	ENSG00000261553.4	RP11-29G8.3	8.71	5.34e-17	2.6e-14	0.48	0.37	Diabetic retinopathy;	chr13:75602544	chr13:75549773~75807120:+
THCA	cis	rs367615	0.918	rs10070104	ENSG00000249476.1	CTD-2587M2.1	-8.71	5.37e-17	2.62e-14	-0.41	-0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109530737	chr5:109237120~109326369:-
THCA	cis	rs2274273	0.682	rs7151224	ENSG00000258413.1	RP11-665C16.6	-8.71	5.39e-17	2.63e-14	-0.49	-0.37	Protein biomarker;	chr14:55050544	chr14:55262767~55272075:-
THCA	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-8.71	5.4e-17	2.63e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
THCA	cis	rs4713118	0.739	rs2893931	ENSG00000219392.1	RP1-265C24.5	-8.71	5.41e-17	2.63e-14	-0.49	-0.37	Parkinson's disease;	chr6:27780231	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.824	rs2092075	ENSG00000219392.1	RP1-265C24.5	-8.71	5.41e-17	2.63e-14	-0.49	-0.37	Parkinson's disease;	chr6:27781551	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.824	rs13211701	ENSG00000219392.1	RP1-265C24.5	-8.71	5.41e-17	2.63e-14	-0.49	-0.37	Parkinson's disease;	chr6:27782300	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.824	rs9468229	ENSG00000219392.1	RP1-265C24.5	-8.71	5.41e-17	2.63e-14	-0.49	-0.37	Parkinson's disease;	chr6:27782307	chr6:28115628~28116551:+
THCA	cis	rs13129231	0.882	rs6835088	ENSG00000206820.1	RNU1-138P	-8.7	5.42e-17	2.64e-14	-0.46	-0.37	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113436700	chr4:113420323~113420486:+
THCA	cis	rs6683071	0.557	rs2378605	ENSG00000272750.1	RP11-378J18.8	-8.7	5.46e-17	2.66e-14	-0.55	-0.37	Cognitive performance;	chr1:222732211	chr1:222658867~222661512:-
THCA	cis	rs12908161	0.959	rs11637728	ENSG00000259728.4	LINC00933	8.7	5.47e-17	2.67e-14	0.51	0.37	Schizophrenia;	chr15:84660161	chr15:84570649~84580175:+
THCA	cis	rs1799949	0.965	rs799917	ENSG00000267681.1	CTD-3199J23.6	-8.7	5.48e-17	2.67e-14	-0.44	-0.37	Menopause (age at onset);	chr17:43092919	chr17:43144956~43145255:+
THCA	cis	rs1062177	0.756	rs2964592	ENSG00000253921.1	CTB-113P19.3	8.7	5.48e-17	2.67e-14	0.44	0.37	Preschool internalizing problems;	chr5:151736127	chr5:151753992~151767247:+
THCA	cis	rs507080	0.733	rs517445	ENSG00000278376.1	RP11-158I9.8	-8.7	5.52e-17	2.69e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118702826	chr11:118791254~118793137:+
THCA	cis	rs673078	0.607	rs7307393	ENSG00000275409.1	RP11-131L12.4	-8.7	5.52e-17	2.69e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118308537	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17440669	ENSG00000275409.1	RP11-131L12.4	-8.7	5.52e-17	2.69e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118310397	chr12:118430147~118430699:+
THCA	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-8.7	5.53e-17	2.69e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
THCA	cis	rs7569084	0.687	rs4671663	ENSG00000234255.7	AC012370.3	8.7	5.53e-17	2.69e-14	0.43	0.37	Sum eosinophil basophil counts;	chr2:65434400	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.687	rs11692813	ENSG00000234255.7	AC012370.3	8.7	5.53e-17	2.69e-14	0.43	0.37	Sum eosinophil basophil counts;	chr2:65435172	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.663	rs11126037	ENSG00000234255.7	AC012370.3	8.7	5.53e-17	2.69e-14	0.43	0.37	Sum eosinophil basophil counts;	chr2:65436024	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.687	rs11126038	ENSG00000234255.7	AC012370.3	8.7	5.53e-17	2.69e-14	0.43	0.37	Sum eosinophil basophil counts;	chr2:65436100	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.663	rs11694714	ENSG00000234255.7	AC012370.3	8.7	5.53e-17	2.69e-14	0.43	0.37	Sum eosinophil basophil counts;	chr2:65436802	chr2:65439888~65456571:-
THCA	cis	rs7015263	0.666	rs10956802	ENSG00000254231.1	CTD-2284J15.1	-8.7	5.54e-17	2.69e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86350477	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs7835743	ENSG00000254231.1	CTD-2284J15.1	-8.7	5.54e-17	2.69e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86365089	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs57326273	ENSG00000254231.1	CTD-2284J15.1	-8.7	5.54e-17	2.69e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86408714	chr8:86333274~86343314:-
THCA	cis	rs1707322	1	rs785510	ENSG00000234329.1	RP11-767N6.2	-8.7	5.55e-17	2.7e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45651039~45651826:-
THCA	cis	rs7015263	0.689	rs56365416	ENSG00000254231.1	CTD-2284J15.1	-8.7	5.56e-17	2.7e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86469187	chr8:86333274~86343314:-
THCA	cis	rs673078	0.66	rs56708462	ENSG00000275409.1	RP11-131L12.4	-8.7	5.57e-17	2.71e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118284135	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs7962185	ENSG00000275409.1	RP11-131L12.4	-8.7	5.57e-17	2.71e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118287842	chr12:118430147~118430699:+
THCA	cis	rs7131987	0.65	rs6487808	ENSG00000257176.2	RP11-996F15.2	8.7	5.58e-17	2.71e-14	0.38	0.37	QT interval;	chr12:29310426	chr12:29280418~29317848:-
THCA	cis	rs13129231	0.882	rs2882986	ENSG00000206820.1	RNU1-138P	-8.7	5.58e-17	2.72e-14	-0.46	-0.37	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113434504	chr4:113420323~113420486:+
THCA	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-8.7	5.59e-17	2.72e-14	-0.38	-0.37	Height;	chr11:118742526	chr11:118704607~118750263:+
THCA	cis	rs2274273	0.623	rs1187877	ENSG00000258413.1	RP11-665C16.6	8.7	5.59e-17	2.72e-14	0.5	0.37	Protein biomarker;	chr14:55028443	chr14:55262767~55272075:-
THCA	cis	rs17265703	0.524	rs12107092	ENSG00000272758.4	RP11-299J3.8	8.7	5.63e-17	2.74e-14	0.44	0.37	Phosphorus levels;	chr3:122405001	chr3:122416207~122443180:+
THCA	cis	rs1707322	0.827	rs10890347	ENSG00000234329.1	RP11-767N6.2	-8.7	5.64e-17	2.74e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45651039~45651826:-
THCA	cis	rs7727544	0.557	rs2897096	ENSG00000237714.1	P4HA2-AS1	8.7	5.64e-17	2.74e-14	0.47	0.37	Blood metabolite levels;	chr5:132150591	chr5:132184876~132192808:+
THCA	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-8.7	5.66e-17	2.75e-14	-0.47	-0.37	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
THCA	cis	rs7131987	0.683	rs12366505	ENSG00000257176.2	RP11-996F15.2	-8.7	5.67e-17	2.76e-14	-0.38	-0.37	QT interval;	chr12:29321177	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.65	rs12366527	ENSG00000257176.2	RP11-996F15.2	-8.7	5.67e-17	2.76e-14	-0.38	-0.37	QT interval;	chr12:29321323	chr12:29280418~29317848:-
THCA	cis	rs7131987	0.65	rs7311912	ENSG00000257176.2	RP11-996F15.2	-8.7	5.67e-17	2.76e-14	-0.38	-0.37	QT interval;	chr12:29322770	chr12:29280418~29317848:-
THCA	cis	rs1799949	0.965	rs4239149	ENSG00000267681.1	CTD-3199J23.6	8.7	5.67e-17	2.76e-14	0.44	0.37	Menopause (age at onset);	chr17:43176078	chr17:43144956~43145255:+
THCA	cis	rs3847687	1	rs3847688	ENSG00000256810.1	RP11-76C10.2	8.7	5.68e-17	2.76e-14	0.44	0.37	Longevity;	chr12:131040765	chr12:131030570~131035487:-
THCA	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	8.7	5.68e-17	2.76e-14	0.44	0.37	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	8.7	5.68e-17	2.76e-14	0.44	0.37	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	8.7	5.68e-17	2.76e-14	0.44	0.37	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.962	rs6903998	ENSG00000268592.3	RAET1E-AS1	8.7	5.69e-17	2.76e-14	0.5	0.37	Lung cancer;	chr6:149831357	chr6:149863494~149919507:+
THCA	cis	rs9828933	1	rs9828933	ENSG00000280620.1	SCAANT1	8.7	5.7e-17	2.77e-14	0.61	0.37	Type 2 diabetes;	chr3:64017221	chr3:63911518~63911772:-
THCA	cis	rs9828933	0.938	rs7617036	ENSG00000280620.1	SCAANT1	8.7	5.7e-17	2.77e-14	0.61	0.37	Type 2 diabetes;	chr3:64017319	chr3:63911518~63911772:-
THCA	cis	rs1799949	0.683	rs55737636	ENSG00000267681.1	CTD-3199J23.6	-8.7	5.7e-17	2.77e-14	-0.44	-0.37	Menopause (age at onset);	chr17:43112722	chr17:43144956~43145255:+
THCA	cis	rs11133665	0.683	rs7719875	ENSG00000249201.2	CTD-3080P12.3	8.7	5.71e-17	2.78e-14	0.44	0.37	Urinary metabolites;	chr5:1189973	chr5:1173141~1178605:-
THCA	cis	rs9659323	1	rs56897173	ENSG00000231365.4	RP11-418J17.1	-8.7	5.72e-17	2.78e-14	-0.37	-0.37	Body mass index;	chr1:118973109	chr1:119140396~119275973:+
THCA	cis	rs1707322	0.964	rs12067716	ENSG00000234329.1	RP11-767N6.2	8.7	5.73e-17	2.78e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45651039~45651826:-
THCA	cis	rs853679	0.55	rs1233701	ENSG00000226314.6	ZNF192P1	8.7	5.73e-17	2.79e-14	0.49	0.37	Depression;	chr6:28200948	chr6:28161781~28169594:+
THCA	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-8.7	5.73e-17	2.79e-14	-0.46	-0.37	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
THCA	cis	rs7586673	0.93	rs6432667	ENSG00000227403.1	AC009299.3	-8.7	5.76e-17	2.8e-14	-0.44	-0.37	Intelligence (multi-trait analysis);	chr2:161048490	chr2:161244739~161249050:+
THCA	cis	rs6565180	0.962	rs35480350	ENSG00000183604.13	SMG1P5	-8.7	5.76e-17	2.8e-14	-0.4	-0.37	Tonsillectomy;	chr16:30354718	chr16:30267553~30335374:-
THCA	cis	rs934734	0.673	rs7575614	ENSG00000234255.7	AC012370.3	8.7	5.79e-17	2.81e-14	0.4	0.37	Rheumatoid arthritis;	chr2:65462666	chr2:65439888~65456571:-
THCA	cis	rs934734	0.673	rs6742215	ENSG00000234255.7	AC012370.3	8.7	5.79e-17	2.81e-14	0.4	0.37	Rheumatoid arthritis;	chr2:65463362	chr2:65439888~65456571:-
THCA	cis	rs56046484	0.871	rs7177110	ENSG00000259295.5	CSPG4P12	8.7	5.81e-17	2.82e-14	0.61	0.37	Testicular germ cell tumor;	chr15:85128524	chr15:85191438~85213905:+
THCA	cis	rs1707322	1	rs10890382	ENSG00000234329.1	RP11-767N6.2	8.7	5.81e-17	2.82e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660335	ENSG00000234329.1	RP11-767N6.2	8.7	5.81e-17	2.82e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45651039~45651826:-
THCA	cis	rs9659323	1	rs10923714	ENSG00000231365.4	RP11-418J17.1	-8.7	5.81e-17	2.82e-14	-0.37	-0.37	Body mass index;	chr1:118970290	chr1:119140396~119275973:+
THCA	cis	rs7586673	0.866	rs747003	ENSG00000227403.1	AC009299.3	8.7	5.81e-17	2.82e-14	0.44	0.37	Intelligence (multi-trait analysis);	chr2:161059898	chr2:161244739~161249050:+
THCA	cis	rs9516	0.544	rs664679	ENSG00000254974.1	RP11-702H23.2	8.7	5.82e-17	2.83e-14	0.4	0.37	Facial morphology (factor 15, philtrum width);	chr11:74475254	chr11:74485580~74486051:-
THCA	cis	rs7131987	0.621	rs3782506	ENSG00000257176.2	RP11-996F15.2	8.7	5.82e-17	2.83e-14	0.38	0.37	QT interval;	chr12:29292489	chr12:29280418~29317848:-
THCA	cis	rs673078	0.66	rs17512177	ENSG00000275409.1	RP11-131L12.4	-8.7	5.83e-17	2.83e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118192335	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs17512198	ENSG00000275409.1	RP11-131L12.4	-8.7	5.83e-17	2.83e-14	-0.48	-0.37	Glucose homeostasis traits;	chr12:118194217	chr12:118430147~118430699:+
THCA	cis	rs2033711	0.87	rs1465789	ENSG00000268912.1	CTD-2619J13.17	-8.69	5.89e-17	2.86e-14	-0.29	-0.37	Uric acid clearance;	chr19:58434689	chr19:58428632~58431148:-
THCA	cis	rs4819052	0.851	rs2838834	ENSG00000237664.1	LINC00316	-8.69	5.92e-17	2.87e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245293	chr21:45338590~45341990:-
THCA	cis	rs9322193	0.851	rs9322194	ENSG00000268592.3	RAET1E-AS1	8.69	5.93e-17	2.88e-14	0.51	0.37	Lung cancer;	chr6:149599113	chr6:149863494~149919507:+
THCA	cis	rs150992	0.632	rs1472622	ENSG00000248489.1	CTD-2007H13.3	-8.69	5.95e-17	2.89e-14	-0.36	-0.37	Body mass index;	chr5:99000749	chr5:98929171~98995013:+
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000224205.1	AP000351.4	8.69	5.95e-17	2.89e-14	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23987320~23991421:-
THCA	cis	rs7851660	0.967	rs7847126	ENSG00000236130.1	PTCSC2	-8.69	5.96e-17	2.89e-14	-0.28	-0.37	Strep throat;	chr9:97838353	chr9:97805935~97810008:-
THCA	cis	rs7829975	0.774	rs1039915	ENSG00000253893.2	FAM85B	-8.69	5.96e-17	2.9e-14	-0.48	-0.37	Mood instability;	chr8:8822104	chr8:8167819~8226614:-
THCA	cis	rs7829975	0.774	rs57312668	ENSG00000253893.2	FAM85B	-8.69	5.99e-17	2.91e-14	-0.48	-0.37	Mood instability;	chr8:8822967	chr8:8167819~8226614:-
THCA	cis	rs748404	0.697	rs530683	ENSG00000249839.1	AC011330.5	8.69	6.03e-17	2.93e-14	0.44	0.37	Lung cancer;	chr15:43276801	chr15:43663654~43684339:-
THCA	cis	rs2274273	0.712	rs7144652	ENSG00000258413.1	RP11-665C16.6	-8.69	6.04e-17	2.93e-14	-0.49	-0.37	Protein biomarker;	chr14:55071000	chr14:55262767~55272075:-
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000228039.3	KB-1125A3.10	8.69	6.07e-17	2.94e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23963780~23964374:+
THCA	cis	rs17684571	0.7	rs13208409	ENSG00000231441.1	RP11-472M19.2	8.69	6.07e-17	2.95e-14	0.51	0.37	Schizophrenia;	chr6:56763747	chr6:56844002~56864078:+
THCA	cis	rs12922040	0.607	rs11641649	ENSG00000263335.1	AF001548.5	-8.69	6.08e-17	2.95e-14	-0.41	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15773707	chr16:15726674~15732993:+
THCA	cis	rs375066	0.935	rs397913	ENSG00000267058.1	RP11-15A1.3	8.69	6.08e-17	2.95e-14	0.3	0.37	Breast cancer;	chr19:43894788	chr19:43891804~43901805:-
THCA	cis	rs9659323	1	rs6700415	ENSG00000231365.4	RP11-418J17.1	-8.69	6.08e-17	2.95e-14	-0.37	-0.37	Body mass index;	chr1:118973551	chr1:119140396~119275973:+
THCA	cis	rs7665090	0.967	rs6533022	ENSG00000246560.2	RP11-10L12.4	8.69	6.08e-17	2.95e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102637794	chr4:102828055~102844075:+
THCA	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-8.69	6.14e-17	2.98e-14	-0.29	-0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
THCA	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	8.69	6.17e-17	2.99e-14	0.39	0.37	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
THCA	cis	rs1799949	0.965	rs799916	ENSG00000267681.1	CTD-3199J23.6	8.69	6.18e-17	2.99e-14	0.44	0.37	Menopause (age at onset);	chr17:43091173	chr17:43144956~43145255:+
THCA	cis	rs7727544	0.606	rs10060615	ENSG00000237714.1	P4HA2-AS1	8.69	6.19e-17	3e-14	0.48	0.37	Blood metabolite levels;	chr5:132373185	chr5:132184876~132192808:+
THCA	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	8.69	6.22e-17	3.02e-14	0.4	0.37	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
THCA	cis	rs1426063	0.614	rs17000262	ENSG00000260265.1	RP11-44F21.5	8.69	6.23e-17	3.02e-14	0.77	0.37	QT interval;	chr4:75108836	chr4:75081702~75084717:-
THCA	cis	rs7015263	0.689	rs7819454	ENSG00000254231.1	CTD-2284J15.1	8.69	6.24e-17	3.03e-14	0.38	0.37	Intelligence (multi-trait analysis);	chr8:86344120	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs10103691	ENSG00000254231.1	CTD-2284J15.1	8.69	6.24e-17	3.03e-14	0.38	0.37	Intelligence (multi-trait analysis);	chr8:86344683	chr8:86333274~86343314:-
THCA	cis	rs4713118	0.824	rs742046	ENSG00000219392.1	RP1-265C24.5	-8.69	6.27e-17	3.04e-14	-0.5	-0.37	Parkinson's disease;	chr6:27771475	chr6:28115628~28116551:+
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000235689.1	AP000351.13	-8.69	6.27e-17	3.04e-14	-0.46	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:24006305~24008258:-
THCA	cis	rs4819052	0.819	rs13046807	ENSG00000237664.1	LINC00316	-8.69	6.29e-17	3.05e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252371	chr21:45338590~45341990:-
THCA	cis	rs17684571	0.81	rs41267675	ENSG00000231441.1	RP11-472M19.2	8.69	6.3e-17	3.05e-14	0.52	0.37	Schizophrenia;	chr6:56735323	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs34566275	ENSG00000231441.1	RP11-472M19.2	8.69	6.3e-17	3.05e-14	0.52	0.37	Schizophrenia;	chr6:56740130	chr6:56844002~56864078:+
THCA	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-8.68	6.3e-17	3.05e-14	-0.38	-0.37	QT interval;	chr12:29303562	chr12:29280418~29317848:-
THCA	cis	rs516805	0.63	rs499825	ENSG00000279453.1	RP3-425C14.4	-8.68	6.31e-17	3.06e-14	-0.38	-0.37	Lymphocyte counts;	chr6:122454050	chr6:122436789~122439223:-
THCA	cis	rs1387259	0.57	rs12368659	ENSG00000258273.1	RP11-370I10.4	-8.68	6.32e-17	3.06e-14	-0.49	-0.37	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48333755~48333901:-
THCA	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-8.68	6.33e-17	3.07e-14	-0.42	-0.37	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
THCA	cis	rs12931792	0.875	rs58175255	ENSG00000183604.13	SMG1P5	8.68	6.33e-17	3.07e-14	0.38	0.37	Tonsillectomy;	chr16:30143969	chr16:30267553~30335374:-
THCA	cis	rs1799949	0.965	rs9646418	ENSG00000267681.1	CTD-3199J23.6	-8.68	6.35e-17	3.07e-14	-0.43	-0.37	Menopause (age at onset);	chr17:43348533	chr17:43144956~43145255:+
THCA	cis	rs2288884	0.579	rs6509603	ENSG00000275055.1	CTC-471J1.11	-8.68	6.35e-17	3.08e-14	-0.36	-0.37	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51960977	chr19:52049007~52049754:+
THCA	cis	rs12468226	0.689	rs73989733	ENSG00000273456.1	RP11-686O6.2	8.68	6.35e-17	3.08e-14	0.45	0.37	Urate levels;	chr2:202115241	chr2:202374932~202375604:-
THCA	cis	rs1005277	0.529	rs1780125	ENSG00000263064.2	RP11-291L22.7	8.68	6.36e-17	3.08e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38448689~38448949:+
THCA	cis	rs9322193	0.923	rs12174035	ENSG00000268592.3	RAET1E-AS1	8.68	6.36e-17	3.08e-14	0.5	0.37	Lung cancer;	chr6:149763311	chr6:149863494~149919507:+
THCA	cis	rs7015263	0.689	rs10093379	ENSG00000254231.1	CTD-2284J15.1	8.68	6.36e-17	3.08e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86435831	chr8:86333274~86343314:-
THCA	cis	rs7665090	1	rs5026472	ENSG00000246560.2	RP11-10L12.4	8.68	6.36e-17	3.08e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102633616	chr4:102828055~102844075:+
THCA	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	8.68	6.37e-17	3.09e-14	0.37	0.37	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
THCA	cis	rs2032366	0.63	rs1377172	ENSG00000267279.1	RP11-879F14.2	-8.68	6.38e-17	3.09e-14	-0.39	-0.37	Obesity-related traits;	chr18:61629148	chr18:61585746~61606916:-
THCA	cis	rs2032366	0.63	rs12457579	ENSG00000267279.1	RP11-879F14.2	-8.68	6.38e-17	3.09e-14	-0.39	-0.37	Obesity-related traits;	chr18:61629575	chr18:61585746~61606916:-
THCA	cis	rs7727544	0.606	rs200838	ENSG00000237714.1	P4HA2-AS1	-8.68	6.41e-17	3.1e-14	-0.49	-0.37	Blood metabolite levels;	chr5:132374707	chr5:132184876~132192808:+
THCA	cis	rs6504950	0.566	rs12937360	ENSG00000275710.1	RP11-257O5.4	8.68	6.41e-17	3.1e-14	0.43	0.37	Breast cancer;	chr17:54968937	chr17:54964474~54964679:+
THCA	cis	rs1426063	0.614	rs17000264	ENSG00000260265.1	RP11-44F21.5	8.68	6.41e-17	3.1e-14	0.78	0.37	QT interval;	chr4:75108962	chr4:75081702~75084717:-
THCA	cis	rs375066	0.935	rs425217	ENSG00000267058.1	RP11-15A1.3	-8.68	6.42e-17	3.11e-14	-0.3	-0.37	Breast cancer;	chr19:43889823	chr19:43891804~43901805:-
THCA	cis	rs7665090	0.934	rs35112949	ENSG00000246560.2	RP11-10L12.4	8.68	6.42e-17	3.11e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102638473	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.87	rs34349956	ENSG00000246560.2	RP11-10L12.4	8.68	6.42e-17	3.11e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102638476	chr4:102828055~102844075:+
THCA	cis	rs1009647	1	rs1009647	ENSG00000258413.1	RP11-665C16.6	-8.68	6.43e-17	3.11e-14	-0.56	-0.37	Testicular germ cell tumor;	chr14:55413329	chr14:55262767~55272075:-
THCA	cis	rs4819052	1	rs3746980	ENSG00000237664.1	LINC00316	-8.68	6.44e-17	3.12e-14	-0.41	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291665	chr21:45338590~45341990:-
THCA	cis	rs56046484	1	rs56046484	ENSG00000259295.5	CSPG4P12	8.68	6.44e-17	3.12e-14	0.59	0.37	Testicular germ cell tumor;	chr15:85062196	chr15:85191438~85213905:+
THCA	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-8.68	6.45e-17	3.12e-14	-0.38	-0.37	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
THCA	cis	rs1707322	1	rs785467	ENSG00000234329.1	RP11-767N6.2	-8.68	6.46e-17	3.12e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45651039~45651826:-
THCA	cis	rs9640161	0.75	rs4395803	ENSG00000261305.1	RP4-584D14.7	8.68	6.46e-17	3.13e-14	0.45	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150328278	chr7:150341771~150342607:+
THCA	cis	rs56046484	0.957	rs35127646	ENSG00000259295.5	CSPG4P12	8.68	6.46e-17	3.13e-14	0.59	0.37	Testicular germ cell tumor;	chr15:85058640	chr15:85191438~85213905:+
THCA	cis	rs812925	0.533	rs60997156	ENSG00000271889.1	RP11-493E12.1	8.68	6.47e-17	3.13e-14	0.36	0.37	Immature fraction of reticulocytes;	chr2:61169404	chr2:61151433~61162105:-
THCA	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-8.68	6.52e-17	3.16e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
THCA	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	8.68	6.53e-17	3.16e-14	0.49	0.37	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
THCA	cis	rs150992	0.609	rs709390	ENSG00000248489.1	CTD-2007H13.3	8.68	6.54e-17	3.16e-14	0.36	0.37	Body mass index;	chr5:98993771	chr5:98929171~98995013:+
THCA	cis	rs62355900	0.627	rs16886424	ENSG00000271828.1	CTD-2310F14.1	8.68	6.54e-17	3.16e-14	0.7	0.37	Endometriosis;	chr5:56850866	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	8.68	6.54e-17	3.16e-14	0.7	0.37	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs62358104	ENSG00000271828.1	CTD-2310F14.1	8.68	6.54e-17	3.16e-14	0.7	0.37	Endometriosis;	chr5:56863344	chr5:56927874~56929573:+
THCA	cis	rs12922040	0.607	rs8059739	ENSG00000263335.1	AF001548.5	-8.68	6.54e-17	3.17e-14	-0.41	-0.37	Serum uric acid levels in response to allopurinol in gout;	chr16:15772869	chr16:15726674~15732993:+
THCA	cis	rs2439831	0.85	rs3825783	ENSG00000249839.1	AC011330.5	-8.68	6.57e-17	3.18e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43810111	chr15:43663654~43684339:-
THCA	cis	rs7015263	0.689	rs13251647	ENSG00000254231.1	CTD-2284J15.1	8.68	6.57e-17	3.18e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86465366	chr8:86333274~86343314:-
THCA	cis	rs4819052	0.684	rs914216	ENSG00000237664.1	LINC00316	-8.68	6.57e-17	3.18e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278383	chr21:45338590~45341990:-
THCA	cis	rs642803	0.613	rs489574	ENSG00000214659.4	KRT8P26	-8.68	6.58e-17	3.18e-14	-0.33	-0.37	Urate levels;	chr11:65775268	chr11:65726939~65728214:+
THCA	cis	rs597539	0.69	rs7129960	ENSG00000250508.1	RP11-757G1.6	-8.68	6.58e-17	3.18e-14	-0.45	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854988	chr11:68870664~68874542:+
THCA	cis	rs7849270	1	rs7037163	ENSG00000268707.1	RP11-247A12.7	-8.68	6.6e-17	3.19e-14	-0.46	-0.37	Blood metabolite ratios;	chr9:129132061	chr9:129170434~129170940:+
THCA	cis	rs792448	0.581	rs1663626	ENSG00000226251.4	RP11-15I11.3	-8.68	6.63e-17	3.2e-14	-0.48	-0.37	White blood cell count (basophil);	chr1:212249225	chr1:212225278~212238977:-
THCA	cis	rs17684571	0.751	rs7771085	ENSG00000231441.1	RP11-472M19.2	8.68	6.64e-17	3.21e-14	0.49	0.37	Schizophrenia;	chr6:56818631	chr6:56844002~56864078:+
THCA	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-8.68	6.66e-17	3.22e-14	-0.4	-0.37	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
THCA	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-8.68	6.66e-17	3.22e-14	-0.4	-0.37	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
THCA	cis	rs7665090	1	rs2866406	ENSG00000246560.2	RP11-10L12.4	8.68	6.67e-17	3.22e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102632862	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2866407	ENSG00000246560.2	RP11-10L12.4	8.68	6.67e-17	3.22e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102632951	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2866408	ENSG00000246560.2	RP11-10L12.4	8.68	6.67e-17	3.22e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102632956	chr4:102828055~102844075:+
THCA	cis	rs9640161	0.711	rs3800781	ENSG00000261305.1	RP4-584D14.7	8.68	6.71e-17	3.24e-14	0.45	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150330235	chr7:150341771~150342607:+
THCA	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	8.68	6.71e-17	3.24e-14	0.45	0.37	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
THCA	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	8.68	6.71e-17	3.24e-14	0.45	0.37	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
THCA	cis	rs4713118	0.824	rs9366702	ENSG00000219392.1	RP1-265C24.5	-8.68	6.72e-17	3.25e-14	-0.5	-0.37	Parkinson's disease;	chr6:27766691	chr6:28115628~28116551:+
THCA	cis	rs3096299	0.933	rs2965823	ENSG00000274627.1	RP11-104N10.2	8.68	6.72e-17	3.25e-14	0.36	0.37	Multiple myeloma (IgH translocation);	chr16:89388516	chr16:89516797~89522217:+
THCA	cis	rs7665090	1	rs1054029	ENSG00000246560.2	RP11-10L12.4	8.68	6.75e-17	3.26e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631896	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs3194585	ENSG00000246560.2	RP11-10L12.4	8.68	6.75e-17	3.26e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631933	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs735405	ENSG00000246560.2	RP11-10L12.4	8.68	6.75e-17	3.26e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102632759	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs1077358	ENSG00000246560.2	RP11-10L12.4	8.68	6.75e-17	3.26e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102632769	chr4:102828055~102844075:+
THCA	cis	rs375066	0.935	rs421512	ENSG00000267058.1	RP11-15A1.3	-8.68	6.75e-17	3.26e-14	-0.3	-0.37	Breast cancer;	chr19:43911428	chr19:43891804~43901805:-
THCA	cis	rs2439831	0.702	rs7171750	ENSG00000249839.1	AC011330.5	-8.68	6.77e-17	3.27e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43733660	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs11070408	ENSG00000249839.1	AC011330.5	-8.68	6.77e-17	3.27e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43742590	chr15:43663654~43684339:-
THCA	cis	rs1005277	0.579	rs2800485	ENSG00000263064.2	RP11-291L22.7	8.68	6.77e-17	3.27e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38448689~38448949:+
THCA	cis	rs748404	0.697	rs473554	ENSG00000249839.1	AC011330.5	-8.68	6.78e-17	3.28e-14	-0.44	-0.37	Lung cancer;	chr15:43276009	chr15:43663654~43684339:-
THCA	cis	rs2243480	0.711	rs1626926	ENSG00000226824.5	RP4-756H11.3	-8.68	6.79e-17	3.28e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65970805	chr7:66654538~66669855:+
THCA	cis	rs1707322	1	rs1612419	ENSG00000234329.1	RP11-767N6.2	-8.67	6.8e-17	3.28e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45651039~45651826:-
THCA	cis	rs17684571	0.7	rs13220618	ENSG00000231441.1	RP11-472M19.2	8.67	6.8e-17	3.28e-14	0.49	0.37	Schizophrenia;	chr6:56819388	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.751	rs35081015	ENSG00000231441.1	RP11-472M19.2	8.67	6.8e-17	3.29e-14	0.49	0.37	Schizophrenia;	chr6:56819757	chr6:56844002~56864078:+
THCA	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-8.67	6.82e-17	3.29e-14	-0.44	-0.37	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
THCA	cis	rs375066	0.901	rs376069	ENSG00000267058.1	RP11-15A1.3	-8.67	6.84e-17	3.31e-14	-0.3	-0.37	Breast cancer;	chr19:43913143	chr19:43891804~43901805:-
THCA	cis	rs2439831	0.85	rs28718261	ENSG00000249839.1	AC011330.5	-8.67	6.86e-17	3.31e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43751595	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28595038	ENSG00000249839.1	AC011330.5	-8.67	6.86e-17	3.31e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43752661	chr15:43663654~43684339:-
THCA	cis	rs189798	0.738	rs330908	ENSG00000254340.1	RP11-10A14.3	8.67	6.87e-17	3.32e-14	0.4	0.37	Myopia (pathological);	chr8:9137656	chr8:9141424~9145435:+
THCA	cis	rs1707322	0.752	rs11211168	ENSG00000234329.1	RP11-767N6.2	8.67	6.89e-17	3.33e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45651039~45651826:-
THCA	cis	rs10208649	0.611	rs12616263	ENSG00000272156.1	RP11-477N3.1	8.67	6.91e-17	3.33e-14	0.51	0.37	Body mass index;	chr2:54039235	chr2:54082554~54085066:+
THCA	cis	rs748404	0.697	rs574065	ENSG00000249839.1	AC011330.5	8.67	6.92e-17	3.34e-14	0.43	0.37	Lung cancer;	chr15:43258457	chr15:43663654~43684339:-
THCA	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-8.67	6.93e-17	3.35e-14	-0.49	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
THCA	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	8.67	6.93e-17	3.35e-14	0.37	0.37	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
THCA	cis	rs375066	0.935	rs423765	ENSG00000267058.1	RP11-15A1.3	-8.67	6.93e-17	3.35e-14	-0.3	-0.37	Breast cancer;	chr19:43912047	chr19:43891804~43901805:-
THCA	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	8.67	6.94e-17	3.35e-14	0.43	0.37	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
THCA	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-8.67	6.96e-17	3.36e-14	-0.44	-0.37	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
THCA	cis	rs507080	0.733	rs7108144	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118698985	chr11:118791254~118793137:+
THCA	cis	rs507080	0.663	rs523793	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118699988	chr11:118791254~118793137:+
THCA	cis	rs507080	0.736	rs659564	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700205	chr11:118791254~118793137:+
THCA	cis	rs507080	0.736	rs642224	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700210	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs541631	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700314	chr11:118791254~118793137:+
THCA	cis	rs507080	0.736	rs658676	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700414	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs488141	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700459	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs657769	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700607	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs544452	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118700648	chr11:118791254~118793137:+
THCA	cis	rs507080	0.697	rs656287	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118701081	chr11:118791254~118793137:+
THCA	cis	rs507080	0.733	rs570949	ENSG00000278376.1	RP11-158I9.8	-8.67	6.96e-17	3.36e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118701202	chr11:118791254~118793137:+
THCA	cis	rs9543976	1	rs55927305	ENSG00000261553.4	RP11-29G8.3	-8.67	6.98e-17	3.37e-14	-0.49	-0.37	Diabetic retinopathy;	chr13:75561213	chr13:75549773~75807120:+
THCA	cis	rs62355901	0.545	rs6895844	ENSG00000271828.1	CTD-2310F14.1	8.67	6.99e-17	3.37e-14	0.64	0.37	Breast cancer;	chr5:56762113	chr5:56927874~56929573:+
THCA	cis	rs8062405	0.755	rs1074631	ENSG00000251417.2	RP11-1348G14.4	8.67	6.99e-17	3.37e-14	0.38	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28802743~28817828:+
THCA	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-8.67	7e-17	3.38e-14	-0.35	-0.37	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
THCA	cis	rs12908161	1	rs4643294	ENSG00000259728.4	LINC00933	8.67	7.01e-17	3.39e-14	0.51	0.37	Schizophrenia;	chr15:84707022	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs62021219	ENSG00000259728.4	LINC00933	8.67	7.01e-17	3.39e-14	0.51	0.37	Schizophrenia;	chr15:84712928	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs34900908	ENSG00000259728.4	LINC00933	8.67	7.01e-17	3.39e-14	0.51	0.37	Schizophrenia;	chr15:84714368	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs35524990	ENSG00000259728.4	LINC00933	8.67	7.01e-17	3.39e-14	0.51	0.37	Schizophrenia;	chr15:84714972	chr15:84570649~84580175:+
THCA	cis	rs3096299	0.967	rs2911256	ENSG00000274627.1	RP11-104N10.2	8.67	7.05e-17	3.4e-14	0.37	0.37	Multiple myeloma (IgH translocation);	chr16:89418688	chr16:89516797~89522217:+
THCA	cis	rs4819052	0.851	rs7279011	ENSG00000215447.6	BX322557.10	-8.67	7.05e-17	3.4e-14	-0.31	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.851	rs7279182	ENSG00000215447.6	BX322557.10	-8.67	7.05e-17	3.4e-14	-0.31	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45288052~45291738:+
THCA	cis	rs4713118	0.866	rs2179094	ENSG00000219392.1	RP1-265C24.5	-8.67	7.05e-17	3.4e-14	-0.49	-0.37	Parkinson's disease;	chr6:27774046	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.824	rs2179095	ENSG00000219392.1	RP1-265C24.5	8.67	7.05e-17	3.4e-14	0.49	0.37	Parkinson's disease;	chr6:27783079	chr6:28115628~28116551:+
THCA	cis	rs9322193	0.884	rs1125	ENSG00000268592.3	RAET1E-AS1	8.67	7.07e-17	3.41e-14	0.5	0.37	Lung cancer;	chr6:149658280	chr6:149863494~149919507:+
THCA	cis	rs1426063	0.614	rs17199779	ENSG00000260265.1	RP11-44F21.5	-8.67	7.08e-17	3.42e-14	-0.76	-0.37	QT interval;	chr4:75105647	chr4:75081702~75084717:-
THCA	cis	rs4819052	0.765	rs2838827	ENSG00000215447.6	BX322557.10	-8.67	7.08e-17	3.42e-14	-0.31	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45288052~45291738:+
THCA	cis	rs375066	0.935	rs422457	ENSG00000267058.1	RP11-15A1.3	-8.67	7.09e-17	3.42e-14	-0.3	-0.37	Breast cancer;	chr19:43905259	chr19:43891804~43901805:-
THCA	cis	rs62103177	0.733	rs80114941	ENSG00000261126.6	RP11-795F19.1	8.67	7.12e-17	3.43e-14	0.43	0.37	Opioid sensitivity;	chr18:79911740	chr18:80046900~80095482:+
THCA	cis	rs375066	0.901	rs1050054	ENSG00000267058.1	RP11-15A1.3	-8.67	7.13e-17	3.44e-14	-0.3	-0.37	Breast cancer;	chr19:43872529	chr19:43891804~43901805:-
THCA	cis	rs2739330	0.685	rs4822453	ENSG00000206090.4	AP000350.7	8.67	7.15e-17	3.45e-14	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23939998~23942798:+
THCA	cis	rs1850744	0.702	rs7434744	ENSG00000250942.1	ENPP7P11	8.67	7.15e-17	3.45e-14	0.48	0.37	Economic and political preferences;	chr4:9671064	chr4:9677308~9677934:+
THCA	cis	rs950169	0.58	rs11636189	ENSG00000225151.9	GOLGA2P7	-8.67	7.17e-17	3.46e-14	-0.54	-0.37	Schizophrenia;	chr15:84650323	chr15:84199311~84230136:-
THCA	cis	rs950169	0.58	rs35516100	ENSG00000225151.9	GOLGA2P7	-8.67	7.17e-17	3.46e-14	-0.54	-0.37	Schizophrenia;	chr15:84652199	chr15:84199311~84230136:-
THCA	cis	rs950169	0.58	rs62021208	ENSG00000225151.9	GOLGA2P7	-8.67	7.17e-17	3.46e-14	-0.54	-0.37	Schizophrenia;	chr15:84653013	chr15:84199311~84230136:-
THCA	cis	rs4819052	0.851	rs1999333	ENSG00000237664.1	LINC00316	-8.67	7.19e-17	3.46e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250486	chr21:45338590~45341990:-
THCA	cis	rs9640161	0.75	rs11764936	ENSG00000261305.1	RP4-584D14.7	8.67	7.19e-17	3.47e-14	0.45	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150328826	chr7:150341771~150342607:+
THCA	cis	rs7829975	0.902	rs485107	ENSG00000253893.2	FAM85B	8.67	7.19e-17	3.47e-14	0.47	0.37	Mood instability;	chr8:8723898	chr8:8167819~8226614:-
THCA	cis	rs375066	0.901	rs372491	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43897641	chr19:43891804~43901805:-
THCA	cis	rs375066	0.868	rs453950	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43898903	chr19:43891804~43901805:-
THCA	cis	rs375066	0.934	rs440784	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43900190	chr19:43891804~43901805:-
THCA	cis	rs375066	0.901	rs374307	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43900246	chr19:43891804~43901805:-
THCA	cis	rs375066	0.967	rs441344	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43900530	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs398099	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43901129	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs385321	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43901135	chr19:43891804~43901805:-
THCA	cis	rs375066	0.967	rs376328	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43903335	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs365556	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43904047	chr19:43891804~43901805:-
THCA	cis	rs375066	0.901	rs451945	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43904601	chr19:43891804~43901805:-
THCA	cis	rs375066	0.934	rs454813	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43904821	chr19:43891804~43901805:-
THCA	cis	rs375066	0.967	rs417400	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43906694	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs439665	ENSG00000267058.1	RP11-15A1.3	-8.67	7.2e-17	3.47e-14	-0.3	-0.37	Breast cancer;	chr19:43910315	chr19:43891804~43901805:-
THCA	cis	rs4842666	0.915	rs11105352	ENSG00000258302.2	RP11-981P6.1	8.67	7.2e-17	3.47e-14	0.37	0.37	Blood pressure;	chr12:89632685	chr12:89561129~89594878:+
THCA	cis	rs4842666	0.915	rs11105353	ENSG00000258302.2	RP11-981P6.1	8.67	7.2e-17	3.47e-14	0.37	0.37	Blood pressure;	chr12:89632686	chr12:89561129~89594878:+
THCA	cis	rs4842666	0.915	rs11105354	ENSG00000258302.2	RP11-981P6.1	8.67	7.2e-17	3.47e-14	0.37	0.37	Blood pressure;	chr12:89632746	chr12:89561129~89594878:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000235689.1	AP000351.13	8.67	7.21e-17	3.47e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:24006305~24008258:-
THCA	cis	rs1707322	1	rs785507	ENSG00000234329.1	RP11-767N6.2	-8.67	7.21e-17	3.48e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45651039~45651826:-
THCA	cis	rs597539	0.652	rs514296	ENSG00000250508.1	RP11-757G1.6	-8.67	7.23e-17	3.48e-14	-0.43	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:68870664~68874542:+
THCA	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	8.67	7.24e-17	3.49e-14	0.37	0.37	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
THCA	cis	rs11971779	0.941	rs6954453	ENSG00000273391.1	RP11-634H22.1	8.67	7.24e-17	3.49e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139347048	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.941	rs4732368	ENSG00000273391.1	RP11-634H22.1	8.67	7.24e-17	3.49e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139349461	chr7:139359032~139359566:-
THCA	cis	rs7646881	0.951	rs6441222	ENSG00000240207.5	RP11-379F4.4	-8.67	7.24e-17	3.49e-14	-0.49	-0.37	Tetralogy of Fallot;	chr3:158731978	chr3:158732263~158784070:+
THCA	cis	rs875971	0.522	rs1917563	ENSG00000237310.1	GS1-124K5.4	-8.67	7.24e-17	3.49e-14	-0.27	-0.37	Aortic root size;	chr7:65950660	chr7:66493706~66495474:+
THCA	cis	rs77204473	0.744	rs6589606	ENSG00000254851.1	RP11-109L13.1	8.67	7.27e-17	3.5e-14	0.86	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117222170	chr11:117135528~117138582:+
THCA	cis	rs11971779	0.816	rs11979272	ENSG00000273391.1	RP11-634H22.1	8.67	7.27e-17	3.5e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139389323	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.941	rs7800795	ENSG00000273391.1	RP11-634H22.1	8.67	7.27e-17	3.5e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139395602	chr7:139359032~139359566:-
THCA	cis	rs4722166	0.597	rs1554606	ENSG00000179428.2	AC073072.5	-8.67	7.29e-17	3.51e-14	-0.45	-0.37	Lung cancer;	chr7:22729088	chr7:22725395~22727620:-
THCA	cis	rs507080	0.733	rs4486664	ENSG00000278376.1	RP11-158I9.8	-8.67	7.33e-17	3.53e-14	-0.29	-0.37	Serum metabolite levels;	chr11:118698358	chr11:118791254~118793137:+
THCA	cis	rs2274273	0.638	rs11622636	ENSG00000258413.1	RP11-665C16.6	-8.66	7.35e-17	3.54e-14	-0.54	-0.37	Protein biomarker;	chr14:55181122	chr14:55262767~55272075:-
THCA	cis	rs4842666	0.915	rs17249754	ENSG00000258302.2	RP11-981P6.1	-8.66	7.36e-17	3.54e-14	-0.36	-0.37	Blood pressure;	chr12:89666809	chr12:89561129~89594878:+
THCA	cis	rs9543976	1	rs9573592	ENSG00000261553.4	RP11-29G8.3	-8.66	7.36e-17	3.55e-14	-0.49	-0.37	Diabetic retinopathy;	chr13:75623707	chr13:75549773~75807120:+
THCA	cis	rs9341808	0.559	rs7762895	ENSG00000272129.1	RP11-250B2.6	8.66	7.38e-17	3.55e-14	0.46	0.37	Sitting height ratio;	chr6:80351714	chr6:80355424~80356859:+
THCA	cis	rs748404	0.697	rs491804	ENSG00000249839.1	AC011330.5	-8.66	7.41e-17	3.57e-14	-0.43	-0.37	Lung cancer;	chr15:43268627	chr15:43663654~43684339:-
THCA	cis	rs2929278	0.617	rs694461	ENSG00000166763.7	STRCP1	-8.66	7.42e-17	3.58e-14	-0.41	-0.37	Schizophrenia;	chr15:43803865	chr15:43699488~43718184:-
THCA	cis	rs4718428	0.672	rs4718412	ENSG00000230295.1	RP11-458F8.2	8.66	7.45e-17	3.59e-14	0.33	0.37	Corneal structure;	chr7:66821880	chr7:66880708~66882981:+
THCA	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-8.66	7.45e-17	3.59e-14	-0.47	-0.37	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
THCA	cis	rs17684571	0.872	rs34587484	ENSG00000231441.1	RP11-472M19.2	8.66	7.46e-17	3.59e-14	0.52	0.37	Schizophrenia;	chr6:56742926	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs34465210	ENSG00000231441.1	RP11-472M19.2	8.66	7.46e-17	3.59e-14	0.52	0.37	Schizophrenia;	chr6:56742930	chr6:56844002~56864078:+
THCA	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-8.66	7.47e-17	3.6e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-8.66	7.47e-17	3.6e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
THCA	cis	rs7015263	0.573	rs62509370	ENSG00000254231.1	CTD-2284J15.1	-8.66	7.47e-17	3.6e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86275982	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.573	rs62509372	ENSG00000254231.1	CTD-2284J15.1	-8.66	7.47e-17	3.6e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86280971	chr8:86333274~86343314:-
THCA	cis	rs9516	0.544	rs681179	ENSG00000254974.1	RP11-702H23.2	8.66	7.48e-17	3.6e-14	0.4	0.37	Facial morphology (factor 15, philtrum width);	chr11:74475791	chr11:74485580~74486051:-
THCA	cis	rs1009647	1	rs35502084	ENSG00000258413.1	RP11-665C16.6	-8.66	7.49e-17	3.61e-14	-0.57	-0.37	Testicular germ cell tumor;	chr14:55409545	chr14:55262767~55272075:-
THCA	cis	rs9813712	0.571	rs9855777	ENSG00000228252.7	COL6A4P2	8.66	7.51e-17	3.61e-14	0.38	0.37	Response to amphetamines;	chr3:130214805	chr3:130212823~130273806:+
THCA	cis	rs7829975	0.871	rs7829826	ENSG00000253893.2	FAM85B	8.66	7.51e-17	3.62e-14	0.47	0.37	Mood instability;	chr8:8720610	chr8:8167819~8226614:-
THCA	cis	rs1707322	0.691	rs61784799	ENSG00000234329.1	RP11-767N6.2	-8.66	7.55e-17	3.63e-14	-0.36	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45651039~45651826:-
THCA	cis	rs673078	0.607	rs7967900	ENSG00000275409.1	RP11-131L12.4	8.66	7.58e-17	3.65e-14	0.45	0.37	Glucose homeostasis traits;	chr12:118381902	chr12:118430147~118430699:+
THCA	cis	rs10510102	0.516	rs10887034	ENSG00000276742.1	RP11-500G22.4	8.66	7.59e-17	3.65e-14	0.6	0.37	Breast cancer;	chr10:121973996	chr10:121956782~121957098:+
THCA	cis	rs1707322	0.752	rs4660880	ENSG00000234329.1	RP11-767N6.2	8.66	7.59e-17	3.65e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45651039~45651826:-
THCA	cis	rs7665090	1	rs4013	ENSG00000246560.2	RP11-10L12.4	8.66	7.6e-17	3.66e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631656	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs4019	ENSG00000246560.2	RP11-10L12.4	8.66	7.6e-17	3.66e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631673	chr4:102828055~102844075:+
THCA	cis	rs1707322	1	rs10890381	ENSG00000234329.1	RP11-767N6.2	8.66	7.62e-17	3.67e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45651039~45651826:-
THCA	cis	rs8028182	0.537	rs4371118	ENSG00000260269.4	CTD-2323K18.1	-8.66	7.63e-17	3.67e-14	-0.63	-0.37	Sudden cardiac arrest;	chr15:75606549	chr15:75527150~75601205:-
THCA	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-8.66	7.66e-17	3.69e-14	-0.42	-0.37	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
THCA	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	8.66	7.68e-17	3.69e-14	0.43	0.37	Migraine;	chr4:56881468	chr4:56960927~56961373:-
THCA	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-8.66	7.69e-17	3.7e-14	-0.4	-0.37	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
THCA	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-8.66	7.73e-17	3.72e-14	-0.49	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
THCA	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-8.66	7.73e-17	3.72e-14	-0.49	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
THCA	cis	rs7221109	0.56	rs758630	ENSG00000278834.1	RP11-458J1.1	-8.66	7.76e-17	3.73e-14	-0.39	-0.37	Type 1 diabetes;	chr17:40713053	chr17:40648300~40649718:+
THCA	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-8.66	7.78e-17	3.74e-14	-0.29	-0.37	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
THCA	cis	rs375066	0.901	rs376457	ENSG00000267058.1	RP11-15A1.3	-8.66	7.79e-17	3.74e-14	-0.3	-0.37	Breast cancer;	chr19:43908605	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs430667	ENSG00000267058.1	RP11-15A1.3	-8.66	7.79e-17	3.74e-14	-0.3	-0.37	Breast cancer;	chr19:43909101	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs398964	ENSG00000267058.1	RP11-15A1.3	-8.66	7.79e-17	3.74e-14	-0.3	-0.37	Breast cancer;	chr19:43909732	chr19:43891804~43901805:-
THCA	cis	rs7849270	0.879	rs7042928	ENSG00000268707.1	RP11-247A12.7	8.66	7.79e-17	3.75e-14	0.45	0.37	Blood metabolite ratios;	chr9:129092996	chr9:129170434~129170940:+
THCA	cis	rs10740039	0.81	rs6479720	ENSG00000254271.1	RP11-131N11.4	8.66	7.79e-17	3.75e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60610935	chr10:60734342~60741828:+
THCA	cis	rs1707322	1	rs4660332	ENSG00000234329.1	RP11-767N6.2	8.66	7.8e-17	3.75e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45651039~45651826:-
THCA	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-8.66	7.82e-17	3.76e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-8.66	7.82e-17	3.76e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-8.66	7.82e-17	3.76e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-8.66	7.82e-17	3.76e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
THCA	cis	rs1799949	0.773	rs2137990	ENSG00000267681.1	CTD-3199J23.6	8.66	7.88e-17	3.78e-14	0.43	0.37	Menopause (age at onset);	chr17:43165879	chr17:43144956~43145255:+
THCA	cis	rs2439831	0.85	rs60883262	ENSG00000249839.1	AC011330.5	-8.66	7.88e-17	3.79e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43784305	chr15:43663654~43684339:-
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000228039.3	KB-1125A3.10	8.66	7.9e-17	3.79e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23963780~23964374:+
THCA	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-8.65	7.9e-17	3.8e-14	-0.47	-0.37	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
THCA	cis	rs7208859	0.573	rs216443	ENSG00000266490.1	CTD-2349P21.9	8.65	7.91e-17	3.8e-14	0.52	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30604853	chr17:30792372~30792833:+
THCA	cis	rs17684571	0.751	rs10498813	ENSG00000231441.1	RP11-472M19.2	8.65	7.92e-17	3.81e-14	0.49	0.37	Schizophrenia;	chr6:56819921	chr6:56844002~56864078:+
THCA	cis	rs9322193	0.884	rs10872647	ENSG00000268592.3	RAET1E-AS1	8.65	7.95e-17	3.82e-14	0.51	0.37	Lung cancer;	chr6:149758687	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs10872648	ENSG00000268592.3	RAET1E-AS1	8.65	7.95e-17	3.82e-14	0.51	0.37	Lung cancer;	chr6:149758699	chr6:149863494~149919507:+
THCA	cis	rs9322193	0.884	rs11155679	ENSG00000268592.3	RAET1E-AS1	8.65	7.95e-17	3.82e-14	0.51	0.37	Lung cancer;	chr6:149758881	chr6:149863494~149919507:+
THCA	cis	rs12554020	0.681	rs78759589	ENSG00000227603.1	RP11-165J3.6	8.65	7.96e-17	3.82e-14	0.62	0.37	Schizophrenia;	chr9:93409518	chr9:93435332~93437121:-
THCA	cis	rs73186030	0.92	rs55784797	ENSG00000272758.4	RP11-299J3.8	8.65	7.99e-17	3.84e-14	0.45	0.37	Serum parathyroid hormone levels;	chr3:122335788	chr3:122416207~122443180:+
THCA	cis	rs2439831	0.85	rs9944216	ENSG00000249839.1	AC011330.5	8.65	8e-17	3.84e-14	0.59	0.37	Lung cancer in ever smokers;	chr15:43868575	chr15:43663654~43684339:-
THCA	cis	rs8018967	0.622	rs2041073	ENSG00000258695.2	RP3-414A15.2	8.65	8.01e-17	3.85e-14	0.45	0.37	Blood metabolite ratios;	chr14:73505831	chr14:73522878~73530610:+
THCA	cis	rs375066	0.935	rs368089	ENSG00000267058.1	RP11-15A1.3	-8.65	8.01e-17	3.85e-14	-0.3	-0.37	Breast cancer;	chr19:43894932	chr19:43891804~43901805:-
THCA	cis	rs934734	0.532	rs6752053	ENSG00000237979.1	AC007389.1	-8.65	8.05e-17	3.86e-14	-0.42	-0.37	Rheumatoid arthritis;	chr2:65439540	chr2:65500993~65502138:-
THCA	cis	rs8091660	1	rs8091660	ENSG00000278983.1	RP11-426J5.3	8.65	8.07e-17	3.87e-14	0.47	0.37	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48561565	chr18:48564795~48568342:+
THCA	cis	rs1707322	1	rs12124847	ENSG00000234329.1	RP11-767N6.2	8.65	8.07e-17	3.88e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45651039~45651826:-
THCA	cis	rs7665090	1	rs2866409	ENSG00000246560.2	RP11-10L12.4	8.65	8.1e-17	3.89e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102633104	chr4:102828055~102844075:+
THCA	cis	rs11148252	0.716	rs2760772	ENSG00000278238.1	RP11-245D16.4	-8.65	8.12e-17	3.9e-14	-0.43	-0.37	Lewy body disease;	chr13:52206238	chr13:52454775~52455331:-
THCA	cis	rs2439831	0.85	rs3759790	ENSG00000249839.1	AC011330.5	-8.65	8.13e-17	3.9e-14	-0.59	-0.37	Lung cancer in ever smokers;	chr15:43828832	chr15:43663654~43684339:-
THCA	cis	rs2274273	0.662	rs67588230	ENSG00000258413.1	RP11-665C16.6	-8.65	8.13e-17	3.9e-14	-0.53	-0.37	Protein biomarker;	chr14:55200312	chr14:55262767~55272075:-
THCA	cis	rs597539	0.69	rs615644	ENSG00000250508.1	RP11-757G1.6	-8.65	8.16e-17	3.91e-14	-0.45	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68854338	chr11:68870664~68874542:+
THCA	cis	rs1707322	1	rs12077974	ENSG00000234329.1	RP11-767N6.2	8.65	8.2e-17	3.93e-14	0.36	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45651039~45651826:-
THCA	cis	rs453301	0.571	rs2929456	ENSG00000253893.2	FAM85B	8.65	8.21e-17	3.94e-14	0.46	0.37	Joint mobility (Beighton score);	chr8:9225906	chr8:8167819~8226614:-
THCA	cis	rs2274273	0.638	rs67416413	ENSG00000258413.1	RP11-665C16.6	-8.65	8.23e-17	3.95e-14	-0.52	-0.37	Protein biomarker;	chr14:55235545	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.615	rs67008693	ENSG00000258413.1	RP11-665C16.6	-8.65	8.23e-17	3.95e-14	-0.52	-0.37	Protein biomarker;	chr14:55235975	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.653	rs1209087	ENSG00000258413.1	RP11-665C16.6	8.65	8.24e-17	3.95e-14	0.49	0.37	Protein biomarker;	chr14:55026502	chr14:55262767~55272075:-
THCA	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-8.65	8.29e-17	3.98e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
THCA	cis	rs6545883	0.507	rs12478192	ENSG00000271889.1	RP11-493E12.1	-8.65	8.3e-17	3.98e-14	-0.36	-0.37	Tuberculosis;	chr2:61364040	chr2:61151433~61162105:-
THCA	cis	rs12554020	0.685	rs55893789	ENSG00000227603.1	RP11-165J3.6	8.65	8.3e-17	3.98e-14	0.62	0.37	Schizophrenia;	chr9:93408608	chr9:93435332~93437121:-
THCA	cis	rs9532669	0.926	rs9594450	ENSG00000239827.7	SUGT1P3	-8.65	8.31e-17	3.98e-14	-0.43	-0.37	Cervical cancer;	chr13:40880067	chr13:40908159~40921774:-
THCA	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-8.65	8.34e-17	4e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-8.65	8.34e-17	4e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-8.65	8.34e-17	4e-14	-0.77	-0.37	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
THCA	cis	rs10740039	0.768	rs10821801	ENSG00000254271.1	RP11-131N11.4	8.65	8.36e-17	4.01e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60612017	chr10:60734342~60741828:+
THCA	cis	rs7665090	1	rs5026473	ENSG00000246560.2	RP11-10L12.4	8.65	8.37e-17	4.01e-14	0.45	0.37	Primary biliary cholangitis;	chr4:102633636	chr4:102828055~102844075:+
THCA	cis	rs150992	0.609	rs77892628	ENSG00000248489.1	CTD-2007H13.3	8.65	8.37e-17	4.02e-14	0.36	0.37	Body mass index;	chr5:98990624	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs77231989	ENSG00000248489.1	CTD-2007H13.3	8.65	8.37e-17	4.02e-14	0.36	0.37	Body mass index;	chr5:98990650	chr5:98929171~98995013:+
THCA	cis	rs150992	0.631	rs79191251	ENSG00000248489.1	CTD-2007H13.3	8.65	8.37e-17	4.02e-14	0.36	0.37	Body mass index;	chr5:98990680	chr5:98929171~98995013:+
THCA	cis	rs4780355	0.776	rs9936459	ENSG00000262636.1	CTD-3088G3.4	-8.65	8.39e-17	4.02e-14	-0.49	-0.37	Crohn's disease and psoriasis;	chr16:11343922	chr16:11380859~11381118:-
THCA	cis	rs9322193	0.887	rs3777949	ENSG00000268592.3	RAET1E-AS1	8.65	8.42e-17	4.04e-14	0.5	0.37	Lung cancer;	chr6:149596021	chr6:149863494~149919507:+
THCA	cis	rs526231	0.697	rs422115	ENSG00000175749.11	EIF3KP1	8.65	8.42e-17	4.04e-14	0.56	0.37	Primary biliary cholangitis;	chr5:103298639	chr5:103032376~103033031:+
THCA	cis	rs56046484	1	rs28718705	ENSG00000259295.5	CSPG4P12	8.65	8.43e-17	4.04e-14	0.58	0.37	Testicular germ cell tumor;	chr15:85074579	chr15:85191438~85213905:+
THCA	cis	rs56046484	1	rs2304415	ENSG00000259295.5	CSPG4P12	8.65	8.43e-17	4.04e-14	0.58	0.37	Testicular germ cell tumor;	chr15:85075610	chr15:85191438~85213905:+
THCA	cis	rs150992	0.609	rs363929	ENSG00000248489.1	CTD-2007H13.3	8.65	8.44e-17	4.04e-14	0.36	0.37	Body mass index;	chr5:98985933	chr5:98929171~98995013:+
THCA	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-8.65	8.45e-17	4.05e-14	-0.76	-0.37	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-8.65	8.45e-17	4.05e-14	-0.76	-0.37	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
THCA	cis	rs673078	0.607	rs17441172	ENSG00000275409.1	RP11-131L12.4	8.65	8.46e-17	4.05e-14	0.44	0.37	Glucose homeostasis traits;	chr12:118430456	chr12:118430147~118430699:+
THCA	cis	rs1005277	0.579	rs1740735	ENSG00000263064.2	RP11-291L22.7	8.65	8.46e-17	4.06e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38448689~38448949:+
THCA	cis	rs516805	0.961	rs510283	ENSG00000279453.1	RP3-425C14.4	-8.65	8.46e-17	4.06e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122451547	chr6:122436789~122439223:-
THCA	cis	rs848490	0.762	rs7796089	ENSG00000214293.7	APTR	8.65	8.47e-17	4.06e-14	0.27	0.37	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77882781	chr7:77657660~77696265:-
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000235689.1	AP000351.13	-8.65	8.5e-17	4.08e-14	-0.47	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:24006305~24008258:-
THCA	cis	rs7665090	1	rs5026476	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102633753	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs6812747	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634260	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs6839064	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634519	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2272695	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634646	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2272696	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634664	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2272697	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634835	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2866413	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102635920	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs4547797	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102636035	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2866414	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102636062	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs9996834	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102636372	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs2903283	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102636596	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs4579121	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102637012	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs6810869	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102637357	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.934	rs6533020	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102637648	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.934	rs6533021	ENSG00000246560.2	RP11-10L12.4	8.65	8.52e-17	4.08e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102637696	chr4:102828055~102844075:+
THCA	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	8.64	8.53e-17	4.08e-14	0.37	0.37	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
THCA	cis	rs6545883	0.524	rs2463101	ENSG00000271889.1	RP11-493E12.1	-8.64	8.55e-17	4.09e-14	-0.36	-0.37	Tuberculosis;	chr2:61347287	chr2:61151433~61162105:-
THCA	cis	rs2946505	0.608	rs2466257	ENSG00000251468.2	RP11-369K16.1	8.64	8.56e-17	4.1e-14	0.6	0.37	Migraine;	chr8:12954754	chr8:12958387~12962200:+
THCA	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	8.64	8.57e-17	4.11e-14	0.37	0.37	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
THCA	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	8.64	8.57e-17	4.11e-14	0.7	0.37	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
THCA	cis	rs6565180	0.962	rs6565182	ENSG00000183604.13	SMG1P5	-8.64	8.59e-17	4.11e-14	-0.39	-0.37	Tonsillectomy;	chr16:30363060	chr16:30267553~30335374:-
THCA	cis	rs11690935	0.632	rs12998411	ENSG00000228389.1	AC068039.4	-8.64	8.6e-17	4.12e-14	-0.4	-0.37	Schizophrenia;	chr2:171674197	chr2:171773482~171775844:+
THCA	cis	rs9928842	0.765	rs6564222	ENSG00000280152.1	RP11-331F4.5	8.64	8.63e-17	4.13e-14	0.54	0.37	Alcoholic chronic pancreatitis;	chr16:75191146	chr16:75245994~75250077:-
THCA	cis	rs11971779	0.941	rs1127424	ENSG00000273391.1	RP11-634H22.1	8.64	8.66e-17	4.15e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139422914	chr7:139359032~139359566:-
THCA	cis	rs673078	0.66	rs17440336	ENSG00000275409.1	RP11-131L12.4	8.64	8.67e-17	4.15e-14	0.47	0.37	Glucose homeostasis traits;	chr12:118163305	chr12:118430147~118430699:+
THCA	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-8.64	8.67e-17	4.15e-14	-0.46	-0.37	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
THCA	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-8.64	8.67e-17	4.15e-14	-0.46	-0.37	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000250470.1	AP000351.3	8.64	8.69e-17	4.16e-14	0.49	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23976904~23977585:-
THCA	cis	rs2274273	1	rs72718804	ENSG00000258413.1	RP11-665C16.6	-8.64	8.72e-17	4.18e-14	-0.49	-0.37	Protein biomarker;	chr14:55163892	chr14:55262767~55272075:-
THCA	cis	rs62355901	0.505	rs56984944	ENSG00000271828.1	CTD-2310F14.1	8.64	8.73e-17	4.18e-14	0.76	0.37	Breast cancer;	chr5:56927671	chr5:56927874~56929573:+
THCA	cis	rs11148252	0.574	rs61958118	ENSG00000235660.1	LINC00345	-8.64	8.82e-17	4.22e-14	-0.46	-0.37	Lewy body disease;	chr13:52596091	chr13:52484161~52484680:-
THCA	cis	rs5769707	0.967	rs1018812	ENSG00000235111.1	RP1-29C18.8	-8.64	8.82e-17	4.22e-14	-0.43	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49612657~49615716:-
THCA	cis	rs150992	0.609	rs393697	ENSG00000248489.1	CTD-2007H13.3	8.64	8.85e-17	4.24e-14	0.36	0.37	Body mass index;	chr5:98991357	chr5:98929171~98995013:+
THCA	cis	rs2274273	0.638	rs58269011	ENSG00000258413.1	RP11-665C16.6	-8.64	8.87e-17	4.25e-14	-0.52	-0.37	Protein biomarker;	chr14:55217670	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.638	rs9919921	ENSG00000258413.1	RP11-665C16.6	-8.64	8.87e-17	4.25e-14	-0.52	-0.37	Protein biomarker;	chr14:55228787	chr14:55262767~55272075:-
THCA	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-8.64	8.89e-17	4.25e-14	-0.41	-0.37	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
THCA	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-8.64	8.89e-17	4.25e-14	-0.47	-0.37	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
THCA	cis	rs8114671	0.527	rs6088650	ENSG00000269202.1	RP4-614O4.12	8.64	8.92e-17	4.27e-14	0.31	0.37	Height;	chr20:34926662	chr20:35201747~35203288:-
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000224205.1	AP000351.4	-8.64	8.95e-17	4.28e-14	-0.45	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23987320~23991421:-
THCA	cis	rs2946505	0.569	rs2460359	ENSG00000251468.2	RP11-369K16.1	8.64	8.96e-17	4.29e-14	0.59	0.37	Migraine;	chr8:12955509	chr8:12958387~12962200:+
THCA	cis	rs7637701	0.517	rs3851992	ENSG00000243926.1	TIPARP-AS1	8.64	8.98e-17	4.3e-14	0.37	0.37	Breast cancer;	chr3:156681391	chr3:156671862~156674378:-
THCA	cis	rs4819052	0.851	rs2838837	ENSG00000237664.1	LINC00316	-8.64	8.99e-17	4.3e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246073	chr21:45338590~45341990:-
THCA	cis	rs150992	0.609	rs116183885	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98990735	chr5:98929171~98995013:+
THCA	cis	rs150992	0.534	rs115121903	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98990736	chr5:98929171~98995013:+
THCA	cis	rs150992	0.592	rs2455423	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98990844	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs559574	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991122	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs443726	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991163	chr5:98929171~98995013:+
THCA	cis	rs150992	0.592	rs407562	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991512	chr5:98929171~98995013:+
THCA	cis	rs150992	0.632	rs395668	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991611	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs449204	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991775	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs378089	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991818	chr5:98929171~98995013:+
THCA	cis	rs150992	0.587	rs422127	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98991984	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs113423144	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98992055	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs380156	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98992386	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs2937709	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98993120	chr5:98929171~98995013:+
THCA	cis	rs150992	0.632	rs1104262	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98993145	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs2927654	ENSG00000248489.1	CTD-2007H13.3	8.64	9.01e-17	4.31e-14	0.36	0.37	Body mass index;	chr5:98993195	chr5:98929171~98995013:+
THCA	cis	rs526231	0.697	rs168820	ENSG00000175749.11	EIF3KP1	8.64	9.05e-17	4.33e-14	0.57	0.37	Primary biliary cholangitis;	chr5:103306972	chr5:103032376~103033031:+
THCA	cis	rs11148252	0.774	rs56033750	ENSG00000278238.1	RP11-245D16.4	-8.64	9.09e-17	4.34e-14	-0.41	-0.37	Lewy body disease;	chr13:52173143	chr13:52454775~52455331:-
THCA	cis	rs6061231	0.561	rs67072353	ENSG00000273619.1	RP5-908M14.9	-8.64	9.09e-17	4.35e-14	-0.35	-0.37	Colorectal cancer;	chr20:62365646	chr20:62386303~62386970:-
THCA	cis	rs1005277	0.557	rs2983338	ENSG00000263064.2	RP11-291L22.7	8.64	9.1e-17	4.35e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38448689~38448949:+
THCA	cis	rs375066	0.935	rs406968	ENSG00000267058.1	RP11-15A1.3	-8.64	9.1e-17	4.35e-14	-0.3	-0.37	Breast cancer;	chr19:43914191	chr19:43891804~43901805:-
THCA	cis	rs9543976	1	rs2328964	ENSG00000261553.4	RP11-29G8.3	8.64	9.11e-17	4.35e-14	0.48	0.37	Diabetic retinopathy;	chr13:75564694	chr13:75549773~75807120:+
THCA	cis	rs4819052	0.851	rs4819040	ENSG00000215447.6	BX322557.10	-8.64	9.12e-17	4.36e-14	-0.3	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45288052~45291738:+
THCA	cis	rs7826238	0.543	rs2976908	ENSG00000253893.2	FAM85B	-8.64	9.17e-17	4.39e-14	-0.5	-0.37	Systolic blood pressure;	chr8:8488264	chr8:8167819~8226614:-
THCA	cis	rs2720460	0.502	rs223374	ENSG00000251288.2	RP11-10L12.2	-8.63	9.22e-17	4.41e-14	-0.5	-0.37	Testicular germ cell tumor;	chr4:102837144	chr4:102751401~102752641:+
THCA	cis	rs4819052	0.851	rs2838843	ENSG00000237664.1	LINC00316	-8.63	9.24e-17	4.42e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249369	chr21:45338590~45341990:-
THCA	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-8.63	9.27e-17	4.43e-14	-0.38	-0.37	Height;	chr11:118749988	chr11:118704607~118750263:+
THCA	cis	rs17684571	0.872	rs13198399	ENSG00000231441.1	RP11-472M19.2	8.63	9.27e-17	4.43e-14	0.51	0.37	Schizophrenia;	chr6:56733196	chr6:56844002~56864078:+
THCA	cis	rs150992	0.609	rs1093794	ENSG00000248489.1	CTD-2007H13.3	-8.63	9.37e-17	4.48e-14	-0.36	-0.37	Body mass index;	chr5:98993334	chr5:98929171~98995013:+
THCA	cis	rs10759883	0.563	rs666093	ENSG00000175611.10	LINC00476	8.63	9.37e-17	4.48e-14	0.42	0.37	Nicotine dependence;	chr9:95983820	chr9:95759231~95875977:-
THCA	cis	rs10759883	0.563	rs667705	ENSG00000175611.10	LINC00476	8.63	9.37e-17	4.48e-14	0.42	0.37	Nicotine dependence;	chr9:95984132	chr9:95759231~95875977:-
THCA	cis	rs597539	0.69	rs11228383	ENSG00000250508.1	RP11-757G1.6	-8.63	9.38e-17	4.48e-14	-0.45	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68855760	chr11:68870664~68874542:+
THCA	cis	rs597539	0.654	rs7107137	ENSG00000250508.1	RP11-757G1.6	-8.63	9.38e-17	4.48e-14	-0.45	-0.37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68856244	chr11:68870664~68874542:+
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000228039.3	KB-1125A3.10	-8.63	9.38e-17	4.48e-14	-0.47	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23963780~23964374:+
THCA	cis	rs9659323	1	rs11584380	ENSG00000231365.4	RP11-418J17.1	-8.63	9.41e-17	4.49e-14	-0.37	-0.37	Body mass index;	chr1:118974797	chr1:119140396~119275973:+
THCA	cis	rs10740039	0.81	rs1442543	ENSG00000254271.1	RP11-131N11.4	8.63	9.45e-17	4.51e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613704	chr10:60734342~60741828:+
THCA	cis	rs1062177	0.826	rs2915822	ENSG00000253921.1	CTB-113P19.3	8.63	9.46e-17	4.52e-14	0.44	0.37	Preschool internalizing problems;	chr5:151751340	chr5:151753992~151767247:+
THCA	cis	rs11971779	0.818	rs12056045	ENSG00000273391.1	RP11-634H22.1	8.63	9.46e-17	4.52e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139340684	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.941	rs74299967	ENSG00000273391.1	RP11-634H22.1	8.63	9.46e-17	4.52e-14	0.39	0.37	Diisocyanate-induced asthma;	chr7:139359023	chr7:139359032~139359566:-
THCA	cis	rs881375	0.933	rs2239657	ENSG00000226752.6	PSMD5-AS1	8.63	9.52e-17	4.54e-14	0.46	0.37	Rheumatoid arthritis;	chr9:120909242	chr9:120824828~120854385:+
THCA	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-8.63	9.52e-17	4.55e-14	-0.68	-0.37	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
THCA	cis	rs150992	0.609	rs113868271	ENSG00000248489.1	CTD-2007H13.3	8.63	9.53e-17	4.55e-14	0.36	0.37	Body mass index;	chr5:98992741	chr5:98929171~98995013:+
THCA	cis	rs150992	0.631	rs112393710	ENSG00000248489.1	CTD-2007H13.3	8.63	9.53e-17	4.55e-14	0.36	0.37	Body mass index;	chr5:98992761	chr5:98929171~98995013:+
THCA	cis	rs150992	0.631	rs111871078	ENSG00000248489.1	CTD-2007H13.3	8.63	9.53e-17	4.55e-14	0.36	0.37	Body mass index;	chr5:98992766	chr5:98929171~98995013:+
THCA	cis	rs9659323	0.931	rs113197996	ENSG00000231365.4	RP11-418J17.1	-8.63	9.53e-17	4.55e-14	-0.38	-0.37	Body mass index;	chr1:118979803	chr1:119140396~119275973:+
THCA	cis	rs812925	0.533	rs35507645	ENSG00000271889.1	RP11-493E12.1	8.63	9.56e-17	4.56e-14	0.36	0.37	Immature fraction of reticulocytes;	chr2:61169631	chr2:61151433~61162105:-
THCA	cis	rs11148252	0.624	rs6561682	ENSG00000278238.1	RP11-245D16.4	8.63	9.58e-17	4.57e-14	0.45	0.37	Lewy body disease;	chr13:52692162	chr13:52454775~52455331:-
THCA	cis	rs860295	1	rs10908482	ENSG00000225855.5	RUSC1-AS1	8.63	9.58e-17	4.57e-14	0.25	0.37	Body mass index;	chr1:155744082	chr1:155316863~155324176:-
THCA	cis	rs1799949	1	rs8070085	ENSG00000267681.1	CTD-3199J23.6	8.63	9.6e-17	4.58e-14	0.42	0.37	Menopause (age at onset);	chr17:43189967	chr17:43144956~43145255:+
THCA	cis	rs2274273	0.688	rs6573001	ENSG00000258413.1	RP11-665C16.6	-8.63	9.6e-17	4.58e-14	-0.48	-0.37	Protein biomarker;	chr14:55089784	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.684	rs2340921	ENSG00000258413.1	RP11-665C16.6	-8.63	9.6e-17	4.58e-14	-0.48	-0.37	Protein biomarker;	chr14:55096987	chr14:55262767~55272075:-
THCA	cis	rs7665090	0.875	rs6813322	ENSG00000246560.2	RP11-10L12.4	8.63	9.61e-17	4.59e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634462	chr4:102828055~102844075:+
THCA	cis	rs673078	0.66	rs16948234	ENSG00000275409.1	RP11-131L12.4	8.63	9.71e-17	4.64e-14	0.47	0.37	Glucose homeostasis traits;	chr12:118282464	chr12:118430147~118430699:+
THCA	cis	rs2946505	0.608	rs2977083	ENSG00000251468.2	RP11-369K16.1	8.63	9.72e-17	4.64e-14	0.6	0.37	Migraine;	chr8:12957393	chr8:12958387~12962200:+
THCA	cis	rs7727544	0.606	rs10058074	ENSG00000237714.1	P4HA2-AS1	8.63	9.75e-17	4.65e-14	0.48	0.37	Blood metabolite levels;	chr5:132350453	chr5:132184876~132192808:+
THCA	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	8.63	9.8e-17	4.68e-14	0.56	0.37	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
THCA	cis	rs7665090	1	rs7664828	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102630219	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs7690123	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102630602	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs7665659	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102630661	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs7665854	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102630752	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.846	rs7690700	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102630911	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs13112557	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631096	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs12644381	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631273	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs1054037	ENSG00000246560.2	RP11-10L12.4	8.63	9.82e-17	4.68e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102631552	chr4:102828055~102844075:+
THCA	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-8.63	9.83e-17	4.69e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
THCA	cis	rs9309473	0.632	rs7599076	ENSG00000163016.8	ALMS1P	8.63	9.85e-17	4.7e-14	0.49	0.37	Metabolite levels;	chr2:73358391	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.583	rs11126397	ENSG00000163016.8	ALMS1P	8.63	9.85e-17	4.7e-14	0.49	0.37	Metabolite levels;	chr2:73361605	chr2:73644919~73685576:+
THCA	cis	rs10740039	0.81	rs1372709	ENSG00000254271.1	RP11-131N11.4	8.63	9.88e-17	4.71e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60621666	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.768	rs10994432	ENSG00000254271.1	RP11-131N11.4	8.63	9.88e-17	4.71e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60623831	chr10:60734342~60741828:+
THCA	cis	rs6496932	0.865	rs10520600	ENSG00000218052.5	ADAMTS7P4	8.63	9.91e-17	4.72e-14	0.57	0.37	Central corneal thickness;Corneal structure;	chr15:85365171	chr15:85255369~85330334:-
THCA	cis	rs7665090	1	rs3733202	ENSG00000246560.2	RP11-10L12.4	8.62	9.93e-17	4.74e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102635704	chr4:102828055~102844075:+
THCA	cis	rs1799949	0.894	rs71367985	ENSG00000267681.1	CTD-3199J23.6	-8.62	9.94e-17	4.74e-14	-0.43	-0.37	Menopause (age at onset);	chr17:43222443	chr17:43144956~43145255:+
THCA	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	8.62	9.97e-17	4.75e-14	0.42	0.37	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
THCA	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-8.62	9.99e-17	4.76e-14	-0.45	-0.37	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-8.62	9.99e-17	4.76e-14	-0.45	-0.37	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
THCA	cis	rs73081554	0.611	rs13071861	ENSG00000272360.1	RP11-359I18.5	-8.62	1e-16	4.77e-14	-0.52	-0.37	Rheumatoid arthritis;	chr3:58385605	chr3:58490830~58491291:-
THCA	cis	rs2274273	1	rs66871576	ENSG00000258413.1	RP11-665C16.6	-8.62	1e-16	4.78e-14	-0.49	-0.37	Protein biomarker;	chr14:55162332	chr14:55262767~55272075:-
THCA	cis	rs6683071	0.557	rs4240934	ENSG00000272750.1	RP11-378J18.8	8.62	1e-16	4.78e-14	0.54	0.37	Cognitive performance;	chr1:222730956	chr1:222658867~222661512:-
THCA	cis	rs860295	1	rs7541060	ENSG00000225855.5	RUSC1-AS1	8.62	1.01e-16	4.79e-14	0.25	0.37	Body mass index;	chr1:155758297	chr1:155316863~155324176:-
THCA	cis	rs11971779	0.68	rs11768023	ENSG00000273391.1	RP11-634H22.1	8.62	1.01e-16	4.81e-14	0.34	0.37	Diisocyanate-induced asthma;	chr7:139369649	chr7:139359032~139359566:-
THCA	cis	rs17684571	0.872	rs35494794	ENSG00000231441.1	RP11-472M19.2	8.62	1.01e-16	4.82e-14	0.51	0.37	Schizophrenia;	chr6:56716124	chr6:56844002~56864078:+
THCA	cis	rs7015263	0.536	rs7460027	ENSG00000254231.1	CTD-2284J15.1	8.62	1.01e-16	4.83e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86330012	chr8:86333274~86343314:-
THCA	cis	rs11690935	0.632	rs12052246	ENSG00000228389.1	AC068039.4	-8.62	1.02e-16	4.84e-14	-0.38	-0.37	Schizophrenia;	chr2:172030703	chr2:171773482~171775844:+
THCA	cis	rs950169	0.544	rs62021193	ENSG00000225151.9	GOLGA2P7	-8.62	1.02e-16	4.87e-14	-0.55	-0.37	Schizophrenia;	chr15:84627352	chr15:84199311~84230136:-
THCA	cis	rs1707322	1	rs1622208	ENSG00000234329.1	RP11-767N6.2	-8.62	1.02e-16	4.87e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45651039~45651826:-
THCA	cis	rs4591358	0.636	rs6712400	ENSG00000223466.1	AC064834.2	-8.62	1.03e-16	4.89e-14	-0.48	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195506646	chr2:195533035~195538681:+
THCA	cis	rs2929278	0.617	rs693919	ENSG00000166763.7	STRCP1	-8.62	1.03e-16	4.89e-14	-0.4	-0.37	Schizophrenia;	chr15:43810130	chr15:43699488~43718184:-
THCA	cis	rs17772222	0.582	rs1288122	ENSG00000258789.1	RP11-507K2.3	8.62	1.03e-16	4.89e-14	0.35	0.37	Coronary artery calcification;	chr14:88472736	chr14:88551597~88552493:+
THCA	cis	rs12908161	0.959	rs17598603	ENSG00000259728.4	LINC00933	-8.62	1.03e-16	4.9e-14	-0.51	-0.37	Schizophrenia;	chr15:84656980	chr15:84570649~84580175:+
THCA	cis	rs860295	1	rs6427286	ENSG00000225855.5	RUSC1-AS1	8.62	1.03e-16	4.9e-14	0.25	0.37	Body mass index;	chr1:155753506	chr1:155316863~155324176:-
THCA	cis	rs860295	1	rs6427287	ENSG00000225855.5	RUSC1-AS1	8.62	1.03e-16	4.9e-14	0.25	0.37	Body mass index;	chr1:155753629	chr1:155316863~155324176:-
THCA	cis	rs150992	0.609	rs161935	ENSG00000248489.1	CTD-2007H13.3	8.62	1.03e-16	4.9e-14	0.35	0.37	Body mass index;	chr5:98982733	chr5:98929171~98995013:+
THCA	cis	rs150992	0.632	rs161936	ENSG00000248489.1	CTD-2007H13.3	8.62	1.03e-16	4.9e-14	0.35	0.37	Body mass index;	chr5:98982953	chr5:98929171~98995013:+
THCA	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-8.62	1.03e-16	4.92e-14	-0.45	-0.37	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
THCA	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	8.62	1.03e-16	4.93e-14	0.36	0.37	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
THCA	cis	rs10740039	0.81	rs10821800	ENSG00000254271.1	RP11-131N11.4	8.62	1.04e-16	4.94e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607812	chr10:60734342~60741828:+
THCA	cis	rs150992	0.72	rs469018	ENSG00000248489.1	CTD-2007H13.3	8.62	1.04e-16	4.94e-14	0.35	0.37	Body mass index;	chr5:98953530	chr5:98929171~98995013:+
THCA	cis	rs8114671	0.804	rs6060139	ENSG00000269202.1	RP4-614O4.12	-8.62	1.04e-16	4.96e-14	-0.31	-0.37	Height;	chr20:34978696	chr20:35201747~35203288:-
THCA	cis	rs7569084	0.687	rs1344891	ENSG00000234255.7	AC012370.3	8.62	1.04e-16	4.97e-14	0.42	0.37	Sum eosinophil basophil counts;	chr2:65458890	chr2:65439888~65456571:-
THCA	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	8.62	1.04e-16	4.97e-14	0.41	0.37	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
THCA	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-8.62	1.05e-16	4.98e-14	-0.38	-0.37	Height;	chr11:118764443	chr11:118704607~118750263:+
THCA	cis	rs2274273	0.662	rs4040064	ENSG00000258413.1	RP11-665C16.6	-8.62	1.05e-16	5e-14	-0.52	-0.37	Protein biomarker;	chr14:55211370	chr14:55262767~55272075:-
THCA	cis	rs4713118	0.824	rs9468223	ENSG00000219392.1	RP1-265C24.5	-8.62	1.05e-16	5e-14	-0.49	-0.37	Parkinson's disease;	chr6:27772887	chr6:28115628~28116551:+
THCA	cis	rs9640161	0.75	rs11538922	ENSG00000261305.1	RP4-584D14.7	8.62	1.05e-16	5.02e-14	0.47	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150338094	chr7:150341771~150342607:+
THCA	cis	rs73186030	0.841	rs112779893	ENSG00000272758.4	RP11-299J3.8	8.62	1.06e-16	5.02e-14	0.45	0.37	Serum parathyroid hormone levels;	chr3:122334433	chr3:122416207~122443180:+
THCA	cis	rs748404	0.646	rs2253268	ENSG00000205771.5	CATSPER2P1	-8.62	1.06e-16	5.03e-14	-0.39	-0.37	Lung cancer;	chr15:43508770	chr15:43726918~43747094:-
THCA	cis	rs9309473	0.687	rs11693531	ENSG00000163016.8	ALMS1P	8.62	1.06e-16	5.04e-14	0.5	0.37	Metabolite levels;	chr2:73381486	chr2:73644919~73685576:+
THCA	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-8.62	1.06e-16	5.05e-14	-0.38	-0.37	Height;	chr11:118791319	chr11:118704607~118750263:+
THCA	cis	rs1062177	0.826	rs2053063	ENSG00000253921.1	CTB-113P19.3	-8.62	1.06e-16	5.05e-14	-0.45	-0.37	Preschool internalizing problems;	chr5:151787203	chr5:151753992~151767247:+
THCA	cis	rs375066	0.935	rs376032	ENSG00000267058.1	RP11-15A1.3	-8.62	1.06e-16	5.05e-14	-0.29	-0.37	Breast cancer;	chr19:43903412	chr19:43891804~43901805:-
THCA	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	8.62	1.06e-16	5.05e-14	0.32	0.37	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
THCA	cis	rs10510102	0.872	rs3862129	ENSG00000276742.1	RP11-500G22.4	8.62	1.06e-16	5.06e-14	0.55	0.37	Breast cancer;	chr10:121824460	chr10:121956782~121957098:+
THCA	cis	rs11051970	0.559	rs11051945	ENSG00000274964.1	RP11-817I4.1	-8.62	1.06e-16	5.06e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32336191	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs11051946	ENSG00000274964.1	RP11-817I4.1	-8.62	1.06e-16	5.06e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32336335	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.527	rs2388989	ENSG00000274964.1	RP11-817I4.1	-8.62	1.06e-16	5.06e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32337341	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs2388988	ENSG00000274964.1	RP11-817I4.1	-8.62	1.06e-16	5.06e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32337414	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs4604975	ENSG00000274964.1	RP11-817I4.1	-8.62	1.06e-16	5.06e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32337441	chr12:32339368~32340724:+
THCA	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	8.62	1.06e-16	5.06e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
THCA	cis	rs10411161	0.702	rs11879319	ENSG00000269483.1	AC006272.1	8.62	1.07e-16	5.07e-14	0.51	0.37	Breast cancer;	chr19:51886339	chr19:51839924~51843324:-
THCA	cis	rs8114671	0.805	rs4616	ENSG00000269202.1	RP4-614O4.12	8.62	1.07e-16	5.07e-14	0.32	0.37	Height;	chr20:35002555	chr20:35201747~35203288:-
THCA	cis	rs737008	0.922	rs28567501	ENSG00000262703.1	RP11-485G7.6	-8.62	1.07e-16	5.07e-14	-0.42	-0.37	Obesity-related traits;	chr16:11285071	chr16:11348143~11349321:-
THCA	cis	rs4819052	0.851	rs2838858	ENSG00000237664.1	LINC00316	-8.62	1.07e-16	5.08e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261178	chr21:45338590~45341990:-
THCA	cis	rs6844153	0.752	rs6815719	ENSG00000240005.4	RP11-293A21.1	-8.61	1.07e-16	5.09e-14	-0.44	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26880232	chr4:26859806~26860599:-
THCA	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	8.61	1.07e-16	5.1e-14	0.46	0.37	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
THCA	cis	rs13129231	0.842	rs2882987	ENSG00000206820.1	RNU1-138P	-8.61	1.07e-16	5.11e-14	-0.45	-0.37	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113434406	chr4:113420323~113420486:+
THCA	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-8.61	1.08e-16	5.11e-14	-0.47	-0.37	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
THCA	cis	rs638893	0.617	rs7933007	ENSG00000278376.1	RP11-158I9.8	8.61	1.08e-16	5.13e-14	0.32	0.37	Vitiligo;	chr11:118859960	chr11:118791254~118793137:+
THCA	cis	rs11690935	0.655	rs17614941	ENSG00000228389.1	AC068039.4	-8.61	1.08e-16	5.14e-14	-0.39	-0.37	Schizophrenia;	chr2:171684868	chr2:171773482~171775844:+
THCA	cis	rs2274273	0.682	rs1187876	ENSG00000258413.1	RP11-665C16.6	8.61	1.08e-16	5.14e-14	0.49	0.37	Protein biomarker;	chr14:55028481	chr14:55262767~55272075:-
THCA	cis	rs1799949	0.929	rs799905	ENSG00000267681.1	CTD-3199J23.6	-8.61	1.08e-16	5.14e-14	-0.43	-0.37	Menopause (age at onset);	chr17:43125170	chr17:43144956~43145255:+
THCA	cis	rs6844153	1	rs57663175	ENSG00000240005.4	RP11-293A21.1	-8.61	1.08e-16	5.15e-14	-0.49	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26917770	chr4:26859806~26860599:-
THCA	cis	rs5769707	0.967	rs5770585	ENSG00000235111.1	RP1-29C18.8	-8.61	1.09e-16	5.17e-14	-0.42	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49612657~49615716:-
THCA	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-8.61	1.09e-16	5.17e-14	-0.38	-0.37	Height;	chr11:118781100	chr11:118704607~118750263:+
THCA	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-8.61	1.09e-16	5.18e-14	-0.36	-0.37	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
THCA	cis	rs2032366	0.606	rs1452597	ENSG00000267279.1	RP11-879F14.2	-8.61	1.09e-16	5.18e-14	-0.39	-0.37	Obesity-related traits;	chr18:61590985	chr18:61585746~61606916:-
THCA	cis	rs2274273	0.712	rs9806049	ENSG00000258413.1	RP11-665C16.6	-8.61	1.09e-16	5.18e-14	-0.49	-0.37	Protein biomarker;	chr14:55058871	chr14:55262767~55272075:-
THCA	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-8.61	1.09e-16	5.19e-14	-0.47	-0.37	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
THCA	cis	rs7727544	0.582	rs3805681	ENSG00000237714.1	P4HA2-AS1	8.61	1.1e-16	5.21e-14	0.46	0.37	Blood metabolite levels;	chr5:132202167	chr5:132184876~132192808:+
THCA	cis	rs1005277	0.579	rs1621040	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780136	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780138	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780139	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.602	rs1780141	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.541	rs1740741	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.528	rs2057228	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1740742	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.602	rs1740743	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1740745	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1740747	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1740749	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780115	ENSG00000263064.2	RP11-291L22.7	8.61	1.1e-16	5.22e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38448689~38448949:+
THCA	cis	rs150992	0.57	rs398436	ENSG00000248489.1	CTD-2007H13.3	8.61	1.1e-16	5.24e-14	0.36	0.37	Body mass index;	chr5:98991352	chr5:98929171~98995013:+
THCA	cis	rs4713118	0.911	rs9295746	ENSG00000219392.1	RP1-265C24.5	-8.61	1.1e-16	5.24e-14	-0.5	-0.37	Parkinson's disease;	chr6:27762285	chr6:28115628~28116551:+
THCA	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	8.61	1.11e-16	5.26e-14	0.73	0.37	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs35087093	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65940221	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35046236	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65943626	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs36068983	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65944004	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs68189316	ENSG00000226824.5	RP4-756H11.3	-8.61	1.11e-16	5.26e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65944182	chr7:66654538~66669855:+
THCA	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-8.61	1.11e-16	5.26e-14	-0.48	-0.37	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
THCA	cis	rs375066	0.935	rs384522	ENSG00000267058.1	RP11-15A1.3	-8.61	1.11e-16	5.27e-14	-0.3	-0.37	Breast cancer;	chr19:43900892	chr19:43891804~43901805:-
THCA	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	8.61	1.11e-16	5.28e-14	0.39	0.37	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
THCA	cis	rs947583	0.663	rs7765436	ENSG00000231028.7	LINC00271	-8.61	1.11e-16	5.3e-14	-0.29	-0.37	Phosphorus levels;	chr6:135804721	chr6:135497801~135716055:+
THCA	cis	rs8062405	0.69	rs4787458	ENSG00000251417.2	RP11-1348G14.4	-8.61	1.12e-16	5.3e-14	-0.38	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28802743~28817828:+
THCA	cis	rs2243480	1	rs316331	ENSG00000273142.1	RP11-458F8.4	8.61	1.12e-16	5.3e-14	0.46	0.37	Diabetic kidney disease;	chr7:66139635	chr7:66902857~66906297:+
THCA	cis	rs71403859	0.568	rs12149489	ENSG00000260886.1	TAT-AS1	8.61	1.12e-16	5.31e-14	0.64	0.37	Post bronchodilator FEV1;	chr16:71779877	chr16:71565789~71578187:+
THCA	cis	rs1707322	0.717	rs2275086	ENSG00000234329.1	RP11-767N6.2	-8.61	1.12e-16	5.32e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45651039~45651826:-
THCA	cis	rs17684571	0.872	rs13219942	ENSG00000231441.1	RP11-472M19.2	8.61	1.12e-16	5.32e-14	0.51	0.37	Schizophrenia;	chr6:56713977	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs35326806	ENSG00000231441.1	RP11-472M19.2	8.61	1.12e-16	5.32e-14	0.51	0.37	Schizophrenia;	chr6:56714216	chr6:56844002~56864078:+
THCA	cis	rs6545883	0.524	rs778159	ENSG00000271889.1	RP11-493E12.1	-8.61	1.12e-16	5.34e-14	-0.35	-0.37	Tuberculosis;	chr2:61329609	chr2:61151433~61162105:-
THCA	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-8.61	1.13e-16	5.35e-14	-0.36	-0.37	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
THCA	cis	rs1501911	0.509	rs330421	ENSG00000248489.1	CTD-2007H13.3	8.61	1.14e-16	5.39e-14	0.36	0.37	Lung function (FEV1/FVC);	chr5:98859077	chr5:98929171~98995013:+
THCA	cis	rs367615	0.918	rs10054960	ENSG00000249476.1	CTD-2587M2.1	8.61	1.14e-16	5.4e-14	0.41	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109530747	chr5:109237120~109326369:-
THCA	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	8.61	1.14e-16	5.4e-14	0.41	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
THCA	cis	rs367615	0.84	rs113540823	ENSG00000249476.1	CTD-2587M2.1	8.61	1.14e-16	5.4e-14	0.41	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109543383	chr5:109237120~109326369:-
THCA	cis	rs367615	0.879	rs56689485	ENSG00000249476.1	CTD-2587M2.1	8.61	1.14e-16	5.4e-14	0.41	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109544127	chr5:109237120~109326369:-
THCA	cis	rs11148252	0.967	rs11618716	ENSG00000278238.1	RP11-245D16.4	8.61	1.14e-16	5.42e-14	0.41	0.37	Lewy body disease;	chr13:52472701	chr13:52454775~52455331:-
THCA	cis	rs10875746	0.624	rs11168498	ENSG00000240399.1	RP1-228P16.1	-8.61	1.14e-16	5.42e-14	-0.41	-0.37	Longevity (90 years and older);	chr12:48261305	chr12:48054813~48055591:-
THCA	cis	rs2739330	0.892	rs4822455	ENSG00000206090.4	AP000350.7	8.61	1.14e-16	5.42e-14	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23939998~23942798:+
THCA	cis	rs4819052	0.765	rs2838852	ENSG00000237664.1	LINC00316	-8.61	1.14e-16	5.43e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257122	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs58644915	ENSG00000237664.1	LINC00316	-8.61	1.15e-16	5.43e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249997	chr21:45338590~45341990:-
THCA	cis	rs2946505	0.569	rs2466267	ENSG00000251468.2	RP11-369K16.1	8.61	1.15e-16	5.44e-14	0.59	0.37	Migraine;	chr8:12961793	chr8:12958387~12962200:+
THCA	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-8.61	1.15e-16	5.46e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
THCA	cis	rs741668	0.641	rs9562637	ENSG00000235903.6	CPB2-AS1	-8.61	1.15e-16	5.47e-14	-0.47	-0.37	Cerebrospinal fluid clusterin levels;	chr13:46071410	chr13:46052806~46113332:+
THCA	cis	rs6750795	0.507	rs1667320	ENSG00000181798.2	LINC00471	-8.61	1.15e-16	5.47e-14	-0.42	-0.37	Height;	chr2:231553603	chr2:231508426~231514339:-
THCA	cis	rs12655019	0.92	rs6882657	ENSG00000271828.1	CTD-2310F14.1	8.6	1.15e-16	5.47e-14	0.82	0.37	Breast cancer (early onset);	chr5:56926912	chr5:56927874~56929573:+
THCA	cis	rs6750795	0.542	rs1797388	ENSG00000181798.2	LINC00471	-8.6	1.16e-16	5.48e-14	-0.42	-0.37	Height;	chr2:231551270	chr2:231508426~231514339:-
THCA	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-8.6	1.16e-16	5.49e-14	-0.38	-0.37	Height;	chr11:118773873	chr11:118704607~118750263:+
THCA	cis	rs9659323	0.632	rs10802074	ENSG00000231365.4	RP11-418J17.1	-8.6	1.16e-16	5.5e-14	-0.34	-0.37	Body mass index;	chr1:119082373	chr1:119140396~119275973:+
THCA	cis	rs11690935	0.655	rs1028127	ENSG00000228389.1	AC068039.4	-8.6	1.16e-16	5.51e-14	-0.39	-0.37	Schizophrenia;	chr2:171673526	chr2:171773482~171775844:+
THCA	cis	rs736801	0.607	rs11739135	ENSG00000237714.1	P4HA2-AS1	8.6	1.16e-16	5.51e-14	0.5	0.37	Mosquito bite size;Breast cancer;	chr5:132397705	chr5:132184876~132192808:+
THCA	cis	rs7665090	0.936	rs5026474	ENSG00000246560.2	RP11-10L12.4	8.6	1.16e-16	5.51e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102633653	chr4:102828055~102844075:+
THCA	cis	rs10411161	0.702	rs10414472	ENSG00000269483.1	AC006272.1	8.6	1.17e-16	5.54e-14	0.51	0.37	Breast cancer;	chr19:51895344	chr19:51839924~51843324:-
THCA	cis	rs375066	0.935	rs399098	ENSG00000267058.1	RP11-15A1.3	-8.6	1.18e-16	5.57e-14	-0.3	-0.37	Breast cancer;	chr19:43914672	chr19:43891804~43901805:-
THCA	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	8.6	1.18e-16	5.59e-14	0.71	0.37	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	8.6	1.18e-16	5.59e-14	0.71	0.37	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	8.6	1.18e-16	5.59e-14	0.71	0.37	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	8.6	1.18e-16	5.59e-14	0.71	0.37	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	8.6	1.18e-16	5.59e-14	0.71	0.37	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	8.6	1.18e-16	5.59e-14	0.71	0.37	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
THCA	cis	rs7727544	0.547	rs56083751	ENSG00000237714.1	P4HA2-AS1	8.6	1.18e-16	5.59e-14	0.48	0.37	Blood metabolite levels;	chr5:132328945	chr5:132184876~132192808:+
THCA	cis	rs4819052	0.84	rs914217	ENSG00000237664.1	LINC00316	-8.6	1.18e-16	5.59e-14	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45278384	chr21:45338590~45341990:-
THCA	cis	rs11051970	0.559	rs10844188	ENSG00000274964.1	RP11-817I4.1	-8.6	1.18e-16	5.59e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32334710	chr12:32339368~32340724:+
THCA	cis	rs2929278	0.561	rs62018952	ENSG00000166763.7	STRCP1	-8.6	1.18e-16	5.6e-14	-0.4	-0.37	Schizophrenia;	chr15:43788539	chr15:43699488~43718184:-
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000235689.1	AP000351.13	8.6	1.18e-16	5.61e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:24006305~24008258:-
THCA	cis	rs1707322	1	rs1707322	ENSG00000234329.1	RP11-767N6.2	8.6	1.19e-16	5.63e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45651039~45651826:-
THCA	cis	rs2239557	0.529	rs2041185	ENSG00000259065.1	RP5-1021I20.1	8.6	1.2e-16	5.68e-14	0.46	0.37	Common traits (Other);	chr14:73815387	chr14:73787360~73803270:+
THCA	cis	rs516805	0.961	rs483933	ENSG00000279453.1	RP3-425C14.4	-8.6	1.2e-16	5.69e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122460377	chr6:122436789~122439223:-
THCA	cis	rs7829975	0.742	rs882462	ENSG00000253893.2	FAM85B	-8.6	1.2e-16	5.69e-14	-0.47	-0.37	Mood instability;	chr8:8821020	chr8:8167819~8226614:-
THCA	cis	rs7665090	1	rs2125211	ENSG00000246560.2	RP11-10L12.4	-8.6	1.2e-16	5.69e-14	-0.44	-0.37	Primary biliary cholangitis;	chr4:102638719	chr4:102828055~102844075:+
THCA	cis	rs150992	0.609	rs78721487	ENSG00000248489.1	CTD-2007H13.3	8.6	1.2e-16	5.7e-14	0.35	0.37	Body mass index;	chr5:98992926	chr5:98929171~98995013:+
THCA	cis	rs8114671	0.562	rs6120757	ENSG00000269202.1	RP4-614O4.12	-8.6	1.2e-16	5.7e-14	-0.31	-0.37	Height;	chr20:34900968	chr20:35201747~35203288:-
THCA	cis	rs4789693	0.872	rs28612648	ENSG00000265458.1	RP13-20L14.6	8.6	1.2e-16	5.7e-14	0.38	0.37	Glucocorticoid-induced osteonecrosis;	chr17:82445510	chr17:82454273~82458521:-
THCA	cis	rs1005277	0.579	rs2103938	ENSG00000263064.2	RP11-291L22.7	8.6	1.2e-16	5.7e-14	0.42	0.37	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38448689~38448949:+
THCA	cis	rs2946504	0.861	rs2977085	ENSG00000251468.2	RP11-369K16.1	-8.6	1.2e-16	5.71e-14	-0.45	-0.37	Type 2 diabetes;	chr8:12956237	chr8:12958387~12962200:+
THCA	cis	rs17772222	0.655	rs816072	ENSG00000258789.1	RP11-507K2.3	8.6	1.21e-16	5.72e-14	0.35	0.37	Coronary artery calcification;	chr14:88484335	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.655	rs1152376	ENSG00000258789.1	RP11-507K2.3	8.6	1.21e-16	5.72e-14	0.35	0.37	Coronary artery calcification;	chr14:88495121	chr14:88551597~88552493:+
THCA	cis	rs4819052	0.851	rs9977178	ENSG00000237664.1	LINC00316	-8.6	1.22e-16	5.79e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244616	chr21:45338590~45341990:-
THCA	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	8.6	1.22e-16	5.79e-14	0.6	0.37	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
THCA	cis	rs7646881	1	rs73015652	ENSG00000240207.5	RP11-379F4.4	-8.6	1.23e-16	5.8e-14	-0.49	-0.37	Tetralogy of Fallot;	chr3:158733594	chr3:158732263~158784070:+
THCA	cis	rs748404	0.516	rs523156	ENSG00000205771.5	CATSPER2P1	8.6	1.23e-16	5.82e-14	0.39	0.37	Lung cancer;	chr15:43519645	chr15:43726918~43747094:-
THCA	cis	rs11690935	0.55	rs11676438	ENSG00000228389.1	AC068039.4	-8.6	1.23e-16	5.83e-14	-0.39	-0.37	Schizophrenia;	chr2:171970147	chr2:171773482~171775844:+
THCA	cis	rs7849270	0.76	rs1075650	ENSG00000268707.1	RP11-247A12.7	8.6	1.23e-16	5.84e-14	0.48	0.37	Blood metabolite ratios;	chr9:129176634	chr9:129170434~129170940:+
THCA	cis	rs4819052	0.851	rs2255766	ENSG00000237664.1	LINC00316	-8.6	1.23e-16	5.84e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263862	chr21:45338590~45341990:-
THCA	cis	rs950169	0.58	rs11630887	ENSG00000225151.9	GOLGA2P7	-8.6	1.23e-16	5.84e-14	-0.54	-0.37	Schizophrenia;	chr15:84649784	chr15:84199311~84230136:-
THCA	cis	rs748404	0.588	rs2255410	ENSG00000205771.5	CATSPER2P1	-8.6	1.24e-16	5.86e-14	-0.39	-0.37	Lung cancer;	chr15:43538899	chr15:43726918~43747094:-
THCA	cis	rs2946504	0.861	rs2954171	ENSG00000251468.2	RP11-369K16.1	-8.6	1.24e-16	5.87e-14	-0.45	-0.37	Type 2 diabetes;	chr8:12956087	chr8:12958387~12962200:+
THCA	cis	rs7849270	0.84	rs12346996	ENSG00000268707.1	RP11-247A12.7	-8.6	1.24e-16	5.88e-14	-0.5	-0.37	Blood metabolite ratios;	chr9:129078577	chr9:129170434~129170940:+
THCA	cis	rs4819052	0.851	rs9974628	ENSG00000237664.1	LINC00316	-8.59	1.25e-16	5.9e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252732	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs13047104	ENSG00000237664.1	LINC00316	-8.59	1.25e-16	5.9e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253647	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.885	rs28576202	ENSG00000237664.1	LINC00316	-8.59	1.25e-16	5.9e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254769	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs35871601	ENSG00000237664.1	LINC00316	-8.59	1.25e-16	5.9e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45255299	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs28622522	ENSG00000237664.1	LINC00316	-8.59	1.25e-16	5.9e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256684	chr21:45338590~45341990:-
THCA	cis	rs7674212	0.507	rs223413	ENSG00000246560.2	RP11-10L12.4	-8.59	1.25e-16	5.91e-14	-0.46	-0.37	Type 2 diabetes;	chr4:102811709	chr4:102828055~102844075:+
THCA	cis	rs2274273	0.967	rs17832359	ENSG00000258413.1	RP11-665C16.6	-8.59	1.25e-16	5.92e-14	-0.49	-0.37	Protein biomarker;	chr14:55149223	chr14:55262767~55272075:-
THCA	cis	rs2274273	1	rs11621351	ENSG00000258413.1	RP11-665C16.6	-8.59	1.25e-16	5.92e-14	-0.49	-0.37	Protein biomarker;	chr14:55150022	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-8.59	1.25e-16	5.93e-14	-0.46	-0.37	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
THCA	cis	rs7829975	0.774	rs11775523	ENSG00000253893.2	FAM85B	-8.59	1.25e-16	5.93e-14	-0.47	-0.37	Mood instability;	chr8:8821666	chr8:8167819~8226614:-
THCA	cis	rs9813712	0.548	rs9880123	ENSG00000228252.7	COL6A4P2	-8.59	1.25e-16	5.93e-14	-0.38	-0.37	Response to amphetamines;	chr3:130215275	chr3:130212823~130273806:+
THCA	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	8.59	1.26e-16	5.96e-14	0.46	0.37	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
THCA	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	8.59	1.26e-16	5.96e-14	0.38	0.37	QT interval;	chr12:29304617	chr12:29280418~29317848:-
THCA	cis	rs8062405	0.755	rs17707300	ENSG00000251417.2	RP11-1348G14.4	-8.59	1.26e-16	5.98e-14	-0.37	-0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28802743~28817828:+
THCA	cis	rs7849270	0.76	rs882616	ENSG00000268707.1	RP11-247A12.7	8.59	1.27e-16	5.99e-14	0.48	0.37	Blood metabolite ratios;	chr9:129178586	chr9:129170434~129170940:+
THCA	cis	rs1062177	0.756	rs2964588	ENSG00000253921.1	CTB-113P19.3	8.59	1.27e-16	6e-14	0.44	0.37	Preschool internalizing problems;	chr5:151738825	chr5:151753992~151767247:+
THCA	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-8.59	1.27e-16	6e-14	-0.64	-0.37	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
THCA	cis	rs375066	0.935	rs425221	ENSG00000267058.1	RP11-15A1.3	8.59	1.27e-16	6.02e-14	0.3	0.37	Breast cancer;	chr19:43914392	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs388706	ENSG00000267058.1	RP11-15A1.3	-8.59	1.27e-16	6.02e-14	-0.3	-0.37	Breast cancer;	chr19:43914541	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs373168	ENSG00000267058.1	RP11-15A1.3	-8.59	1.27e-16	6.02e-14	-0.3	-0.37	Breast cancer;	chr19:43926717	chr19:43891804~43901805:-
THCA	cis	rs12554020	1	rs55846141	ENSG00000227603.1	RP11-165J3.6	8.59	1.28e-16	6.03e-14	0.62	0.37	Schizophrenia;	chr9:93427679	chr9:93435332~93437121:-
THCA	cis	rs516805	0.924	rs809770	ENSG00000279453.1	RP3-425C14.4	-8.59	1.28e-16	6.03e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122440061	chr6:122436789~122439223:-
THCA	cis	rs516805	0.924	rs476215	ENSG00000279453.1	RP3-425C14.4	-8.59	1.28e-16	6.03e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122440739	chr6:122436789~122439223:-
THCA	cis	rs1707322	0.647	rs6686944	ENSG00000234329.1	RP11-767N6.2	8.59	1.28e-16	6.03e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45651039~45651826:-
THCA	cis	rs17772222	0.63	rs2778936	ENSG00000258789.1	RP11-507K2.3	8.59	1.28e-16	6.05e-14	0.35	0.37	Coronary artery calcification;	chr14:88505959	chr14:88551597~88552493:+
THCA	cis	rs1015362	0.869	rs6088411	ENSG00000276073.1	RP5-1125A11.7	8.59	1.28e-16	6.05e-14	0.35	0.37	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:34152101	chr20:33985617~33988989:-
THCA	cis	rs5769707	0.837	rs5770599	ENSG00000235111.1	RP1-29C18.8	-8.59	1.28e-16	6.05e-14	-0.44	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49612657~49615716:-
THCA	cis	rs1061377	1	rs56119980	ENSG00000249685.1	RP11-360F5.3	8.59	1.29e-16	6.11e-14	0.45	0.37	Uric acid levels;	chr4:39139390	chr4:39133913~39135608:+
THCA	cis	rs12554020	0.786	rs17532098	ENSG00000227603.1	RP11-165J3.6	8.59	1.3e-16	6.12e-14	0.7	0.37	Schizophrenia;	chr9:93500443	chr9:93435332~93437121:-
THCA	cis	rs6558530	0.836	rs7461159	ENSG00000253982.1	CTD-2336O2.1	8.59	1.3e-16	6.13e-14	0.32	0.37	Systolic blood pressure;	chr8:1768450	chr8:1761990~1764502:-
THCA	cis	rs9309473	0.607	rs7604588	ENSG00000163016.8	ALMS1P	8.59	1.3e-16	6.13e-14	0.49	0.37	Metabolite levels;	chr2:73344289	chr2:73644919~73685576:+
THCA	cis	rs7829975	0.774	rs1703982	ENSG00000253893.2	FAM85B	8.59	1.3e-16	6.15e-14	0.47	0.37	Mood instability;	chr8:8740878	chr8:8167819~8226614:-
THCA	cis	rs10740039	0.729	rs6479721	ENSG00000254271.1	RP11-131N11.4	8.59	1.31e-16	6.2e-14	0.46	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613364	chr10:60734342~60741828:+
THCA	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-8.59	1.31e-16	6.21e-14	-0.38	-0.37	QT interval;	chr12:29349303	chr12:29280418~29317848:-
THCA	cis	rs10740039	0.732	rs10160182	ENSG00000254271.1	RP11-131N11.4	8.59	1.32e-16	6.23e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602693	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.768	rs10159993	ENSG00000254271.1	RP11-131N11.4	8.59	1.32e-16	6.23e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602788	chr10:60734342~60741828:+
THCA	cis	rs10740039	0.768	rs1372710	ENSG00000254271.1	RP11-131N11.4	8.59	1.32e-16	6.23e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60603200	chr10:60734342~60741828:+
THCA	cis	rs2439831	0.85	rs10163054	ENSG00000249839.1	AC011330.5	-8.59	1.32e-16	6.25e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43755440	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs12442129	ENSG00000249839.1	AC011330.5	-8.59	1.32e-16	6.25e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43763658	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.702	rs7175032	ENSG00000249839.1	AC011330.5	-8.59	1.32e-16	6.25e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43768038	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs2277531	ENSG00000249839.1	AC011330.5	-8.59	1.32e-16	6.25e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43776871	chr15:43663654~43684339:-
THCA	cis	rs12188164	0.515	rs11744936	ENSG00000221990.4	EXOC3-AS1	8.59	1.33e-16	6.26e-14	0.31	0.37	Cystic fibrosis severity;	chr5:411997	chr5:441498~443160:-
THCA	cis	rs11051970	0.559	rs12578899	ENSG00000274964.1	RP11-817I4.1	-8.59	1.33e-16	6.28e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32332017	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.559	rs2291421	ENSG00000274964.1	RP11-817I4.1	-8.59	1.33e-16	6.28e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32334173	chr12:32339368~32340724:+
THCA	cis	rs12554020	0.786	rs75395683	ENSG00000227603.1	RP11-165J3.6	8.59	1.33e-16	6.29e-14	0.62	0.37	Schizophrenia;	chr9:93415128	chr9:93435332~93437121:-
THCA	cis	rs6844153	0.887	rs62302535	ENSG00000240005.4	RP11-293A21.1	-8.59	1.33e-16	6.29e-14	-0.5	-0.37	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957254	chr4:26859806~26860599:-
THCA	cis	rs6545883	0.524	rs811871	ENSG00000271889.1	RP11-493E12.1	-8.59	1.33e-16	6.3e-14	-0.35	-0.37	Tuberculosis;	chr2:61350814	chr2:61151433~61162105:-
THCA	cis	rs7829975	0.714	rs59046059	ENSG00000253893.2	FAM85B	-8.59	1.33e-16	6.3e-14	-0.47	-0.37	Mood instability;	chr8:8813226	chr8:8167819~8226614:-
THCA	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	8.59	1.34e-16	6.31e-14	0.28	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
THCA	cis	rs4713118	0.699	rs573179	ENSG00000219392.1	RP1-265C24.5	-8.59	1.34e-16	6.33e-14	-0.5	-0.37	Parkinson's disease;	chr6:27881898	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.699	rs200978	ENSG00000219392.1	RP1-265C24.5	-8.59	1.34e-16	6.33e-14	-0.5	-0.37	Parkinson's disease;	chr6:27885390	chr6:28115628~28116551:+
THCA	cis	rs62103177	0.81	rs62103197	ENSG00000261126.6	RP11-795F19.1	8.58	1.34e-16	6.33e-14	0.43	0.37	Opioid sensitivity;	chr18:79872923	chr18:80046900~80095482:+
THCA	cis	rs2439831	0.85	rs7168158	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43758178	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs7174208	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43760484	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs12101756	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43761689	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs3862142	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43772608	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.702	rs2788	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43772688	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28891769	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43780662	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs28578398	ENSG00000249839.1	AC011330.5	-8.58	1.34e-16	6.33e-14	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43782848	chr15:43663654~43684339:-
THCA	cis	rs13068223	0.503	rs34277251	ENSG00000243926.1	TIPARP-AS1	8.58	1.34e-16	6.33e-14	0.38	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr3:156703736	chr3:156671862~156674378:-
THCA	cis	rs2243480	0.803	rs34804747	ENSG00000226824.5	RP4-756H11.3	-8.58	1.34e-16	6.34e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65947955	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs59794892	ENSG00000226824.5	RP4-756H11.3	-8.58	1.34e-16	6.34e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65950886	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.803	rs36004293	ENSG00000226824.5	RP4-756H11.3	-8.58	1.34e-16	6.34e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65951525	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.803	rs35268390	ENSG00000226824.5	RP4-756H11.3	-8.58	1.34e-16	6.34e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65951549	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs11538349	ENSG00000226824.5	RP4-756H11.3	-8.58	1.34e-16	6.34e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65956884	chr7:66654538~66669855:+
THCA	cis	rs1799949	0.894	rs36062488	ENSG00000267681.1	CTD-3199J23.6	8.58	1.34e-16	6.35e-14	0.43	0.37	Menopause (age at onset);	chr17:43185455	chr17:43144956~43145255:+
THCA	cis	rs516805	0.961	rs693669	ENSG00000279453.1	RP3-425C14.4	-8.58	1.35e-16	6.35e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122465690	chr6:122436789~122439223:-
THCA	cis	rs1799949	0.965	rs9897425	ENSG00000267681.1	CTD-3199J23.6	-8.58	1.35e-16	6.35e-14	-0.42	-0.37	Menopause (age at onset);	chr17:43352811	chr17:43144956~43145255:+
THCA	cis	rs7727544	0.548	rs2069614	ENSG00000237714.1	P4HA2-AS1	8.58	1.35e-16	6.37e-14	0.48	0.37	Blood metabolite levels;	chr5:132071908	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.548	rs2069616	ENSG00000237714.1	P4HA2-AS1	8.58	1.35e-16	6.37e-14	0.48	0.37	Blood metabolite levels;	chr5:132072384	chr5:132184876~132192808:+
THCA	cis	rs4819052	0.851	rs2838833	ENSG00000237664.1	LINC00316	-8.58	1.35e-16	6.37e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245245	chr21:45338590~45341990:-
THCA	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-8.58	1.35e-16	6.38e-14	-0.41	-0.37	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
THCA	cis	rs7015263	0.714	rs56321721	ENSG00000254231.1	CTD-2284J15.1	-8.58	1.35e-16	6.38e-14	-0.38	-0.37	Intelligence (multi-trait analysis);	chr8:86527798	chr8:86333274~86343314:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000228039.3	KB-1125A3.10	8.58	1.35e-16	6.39e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23963780~23964374:+
THCA	cis	rs7044106	0.655	rs1359329	ENSG00000226752.6	PSMD5-AS1	-8.58	1.36e-16	6.4e-14	-0.58	-0.37	Hip circumference adjusted for BMI;	chr9:120608707	chr9:120824828~120854385:+
THCA	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-8.58	1.36e-16	6.4e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
THCA	cis	rs4591358	0.773	rs17781713	ENSG00000223466.1	AC064834.2	-8.58	1.37e-16	6.45e-14	-0.5	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195506827	chr2:195533035~195538681:+
THCA	cis	rs2946504	0.861	rs2946502	ENSG00000251468.2	RP11-369K16.1	-8.58	1.37e-16	6.45e-14	-0.44	-0.37	Type 2 diabetes;	chr8:12955445	chr8:12958387~12962200:+
THCA	cis	rs10411161	0.702	rs6509591	ENSG00000269483.1	AC006272.1	8.58	1.37e-16	6.48e-14	0.5	0.37	Breast cancer;	chr19:51888687	chr19:51839924~51843324:-
THCA	cis	rs12701220	0.655	rs6463317	ENSG00000229043.2	AC091729.9	-8.58	1.38e-16	6.49e-14	-0.48	-0.37	Bronchopulmonary dysplasia;	chr7:1119607	chr7:1160374~1165267:+
THCA	cis	rs7429990	0.864	rs1403579	ENSG00000229759.1	MRPS18AP1	8.58	1.38e-16	6.49e-14	0.44	0.37	Educational attainment (years of education);	chr3:47617889	chr3:48256350~48256938:-
THCA	cis	rs2946504	0.861	rs6986271	ENSG00000251468.2	RP11-369K16.1	-8.58	1.38e-16	6.49e-14	-0.45	-0.37	Type 2 diabetes;	chr8:12959345	chr8:12958387~12962200:+
THCA	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-8.58	1.38e-16	6.5e-14	-0.36	-0.37	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
THCA	cis	rs7727544	0.564	rs3852206	ENSG00000237714.1	P4HA2-AS1	8.58	1.38e-16	6.51e-14	0.5	0.37	Blood metabolite levels;	chr5:132079743	chr5:132184876~132192808:+
THCA	cis	rs7727544	0.618	rs2631367	ENSG00000237714.1	P4HA2-AS1	-8.58	1.38e-16	6.52e-14	-0.48	-0.37	Blood metabolite levels;	chr5:132369766	chr5:132184876~132192808:+
THCA	cis	rs516805	0.781	rs502103	ENSG00000279453.1	RP3-425C14.4	-8.58	1.38e-16	6.53e-14	-0.37	-0.37	Lymphocyte counts;	chr6:122446062	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs511279	ENSG00000279453.1	RP3-425C14.4	-8.58	1.38e-16	6.53e-14	-0.37	-0.37	Lymphocyte counts;	chr6:122451385	chr6:122436789~122439223:-
THCA	cis	rs150992	0.631	rs112047336	ENSG00000248489.1	CTD-2007H13.3	8.58	1.39e-16	6.53e-14	0.36	0.37	Body mass index;	chr5:98990041	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs112042355	ENSG00000248489.1	CTD-2007H13.3	8.58	1.39e-16	6.53e-14	0.36	0.37	Body mass index;	chr5:98990046	chr5:98929171~98995013:+
THCA	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	8.58	1.39e-16	6.53e-14	0.5	0.37	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
THCA	cis	rs6545883	0.542	rs10177225	ENSG00000271889.1	RP11-493E12.1	-8.58	1.39e-16	6.55e-14	-0.36	-0.37	Tuberculosis;	chr2:61367363	chr2:61151433~61162105:-
THCA	cis	rs150992	0.861	rs151102	ENSG00000248489.1	CTD-2007H13.3	-8.58	1.39e-16	6.56e-14	-0.35	-0.37	Body mass index;	chr5:98947626	chr5:98929171~98995013:+
THCA	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	8.58	1.4e-16	6.58e-14	0.47	0.37	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
THCA	cis	rs2274273	0.638	rs3825614	ENSG00000258413.1	RP11-665C16.6	-8.58	1.4e-16	6.6e-14	-0.52	-0.37	Protein biomarker;	chr14:55262669	chr14:55262767~55272075:-
THCA	cis	rs2439831	0.85	rs7183809	ENSG00000249839.1	AC011330.5	-8.58	1.4e-16	6.61e-14	-0.59	-0.37	Lung cancer in ever smokers;	chr15:43828670	chr15:43663654~43684339:-
THCA	cis	rs853679	0.55	rs1150692	ENSG00000226314.6	ZNF192P1	-8.58	1.4e-16	6.62e-14	-0.49	-0.37	Depression;	chr6:28206179	chr6:28161781~28169594:+
THCA	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-8.58	1.41e-16	6.64e-14	-0.43	-0.37	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
THCA	cis	rs2274273	0.661	rs2147964	ENSG00000258413.1	RP11-665C16.6	-8.58	1.41e-16	6.66e-14	-0.48	-0.37	Protein biomarker;	chr14:55097677	chr14:55262767~55272075:-
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000235689.1	AP000351.13	8.58	1.41e-16	6.66e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:24006305~24008258:-
THCA	cis	rs17684571	0.751	rs13203681	ENSG00000231441.1	RP11-472M19.2	8.58	1.41e-16	6.67e-14	0.46	0.37	Schizophrenia;	chr6:56841361	chr6:56844002~56864078:+
THCA	cis	rs3847687	0.966	rs3847689	ENSG00000256810.1	RP11-76C10.2	8.58	1.42e-16	6.69e-14	0.43	0.37	Longevity;	chr12:131040989	chr12:131030570~131035487:-
THCA	cis	rs1799949	0.536	rs4793227	ENSG00000267681.1	CTD-3199J23.6	-8.58	1.42e-16	6.7e-14	-0.42	-0.37	Menopause (age at onset);	chr17:43334882	chr17:43144956~43145255:+
THCA	cis	rs7829975	0.871	rs777709	ENSG00000253893.2	FAM85B	8.58	1.42e-16	6.71e-14	0.46	0.37	Mood instability;	chr8:8726362	chr8:8167819~8226614:-
THCA	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-8.58	1.42e-16	6.71e-14	-0.45	-0.37	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
THCA	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-8.58	1.43e-16	6.72e-14	-0.38	-0.37	QT interval;	chr12:29343291	chr12:29280418~29317848:-
THCA	cis	rs7714584	1	rs59980321	ENSG00000197083.10	ZNF300P1	8.58	1.43e-16	6.73e-14	0.6	0.37	Crohn's disease;	chr5:150862251	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	8.58	1.43e-16	6.73e-14	0.6	0.37	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
THCA	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	8.58	1.43e-16	6.74e-14	0.71	0.37	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
THCA	cis	rs3096299	0.9	rs3114867	ENSG00000274627.1	RP11-104N10.2	8.58	1.44e-16	6.77e-14	0.35	0.37	Multiple myeloma (IgH translocation);	chr16:89362559	chr16:89516797~89522217:+
THCA	cis	rs7665090	0.875	rs6813687	ENSG00000246560.2	RP11-10L12.4	8.58	1.44e-16	6.78e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102634455	chr4:102828055~102844075:+
THCA	cis	rs2946504	0.861	rs2977081	ENSG00000251468.2	RP11-369K16.1	-8.58	1.44e-16	6.79e-14	-0.45	-0.37	Type 2 diabetes;	chr8:12958272	chr8:12958387~12962200:+
THCA	cis	rs17772222	0.655	rs7160717	ENSG00000258789.1	RP11-507K2.3	-8.58	1.44e-16	6.79e-14	-0.34	-0.37	Coronary artery calcification;	chr14:88498232	chr14:88551597~88552493:+
THCA	cis	rs2274273	0.638	rs17672364	ENSG00000258413.1	RP11-665C16.6	-8.58	1.44e-16	6.8e-14	-0.52	-0.37	Protein biomarker;	chr14:55239186	chr14:55262767~55272075:-
THCA	cis	rs4713118	0.824	rs7759217	ENSG00000219392.1	RP1-265C24.5	-8.57	1.45e-16	6.81e-14	-0.49	-0.37	Parkinson's disease;	chr6:27762684	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.784	rs9468219	ENSG00000219392.1	RP1-265C24.5	-8.57	1.45e-16	6.81e-14	-0.49	-0.37	Parkinson's disease;	chr6:27763976	chr6:28115628~28116551:+
THCA	cis	rs6504950	0.566	rs7226272	ENSG00000275710.1	RP11-257O5.4	8.57	1.45e-16	6.81e-14	0.43	0.37	Breast cancer;	chr17:54969086	chr17:54964474~54964679:+
THCA	cis	rs748404	0.697	rs555001	ENSG00000249839.1	AC011330.5	-8.57	1.45e-16	6.82e-14	-0.43	-0.37	Lung cancer;	chr15:43253530	chr15:43663654~43684339:-
THCA	cis	rs748404	0.697	rs475261	ENSG00000249839.1	AC011330.5	-8.57	1.45e-16	6.82e-14	-0.43	-0.37	Lung cancer;	chr15:43254258	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.851	rs2838831	ENSG00000237664.1	LINC00316	-8.57	1.45e-16	6.82e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244860	chr21:45338590~45341990:-
THCA	cis	rs6723226	0.521	rs1991626	ENSG00000276334.1	AL133243.1	-8.57	1.45e-16	6.84e-14	-0.41	-0.37	Intelligence (multi-trait analysis);	chr2:32377382	chr2:32521927~32523547:+
THCA	cis	rs2274273	0.662	rs67958555	ENSG00000258413.1	RP11-665C16.6	-8.57	1.46e-16	6.86e-14	-0.52	-0.37	Protein biomarker;	chr14:55204148	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.662	rs67092614	ENSG00000258413.1	RP11-665C16.6	-8.57	1.46e-16	6.86e-14	-0.52	-0.37	Protein biomarker;	chr14:55205337	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.615	rs17672058	ENSG00000258413.1	RP11-665C16.6	-8.57	1.46e-16	6.86e-14	-0.52	-0.37	Protein biomarker;	chr14:55206676	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.662	rs67215571	ENSG00000258413.1	RP11-665C16.6	-8.57	1.46e-16	6.86e-14	-0.52	-0.37	Protein biomarker;	chr14:55207005	chr14:55262767~55272075:-
THCA	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-8.57	1.46e-16	6.87e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-8.57	1.46e-16	6.87e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-8.57	1.46e-16	6.87e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
THCA	cis	rs453301	0.571	rs2929454	ENSG00000253893.2	FAM85B	8.57	1.46e-16	6.87e-14	0.46	0.37	Joint mobility (Beighton score);	chr8:9226344	chr8:8167819~8226614:-
THCA	cis	rs2274273	0.967	rs10137409	ENSG00000258413.1	RP11-665C16.6	-8.57	1.46e-16	6.89e-14	-0.49	-0.37	Protein biomarker;	chr14:55144723	chr14:55262767~55272075:-
THCA	cis	rs516805	0.781	rs477425	ENSG00000279453.1	RP3-425C14.4	-8.57	1.47e-16	6.9e-14	-0.37	-0.37	Lymphocyte counts;	chr6:122393627	chr6:122436789~122439223:-
THCA	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	8.57	1.47e-16	6.91e-14	0.37	0.37	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
THCA	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-8.57	1.47e-16	6.91e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-8.57	1.47e-16	6.91e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-8.57	1.47e-16	6.91e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
THCA	cis	rs10759883	0.563	rs657451	ENSG00000175611.10	LINC00476	-8.57	1.47e-16	6.91e-14	-0.41	-0.37	Nicotine dependence;	chr9:96003496	chr9:95759231~95875977:-
THCA	cis	rs9543976	1	rs73223984	ENSG00000261553.4	RP11-29G8.3	-8.57	1.47e-16	6.93e-14	-0.49	-0.37	Diabetic retinopathy;	chr13:75607005	chr13:75549773~75807120:+
THCA	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	8.57	1.48e-16	6.96e-14	0.24	0.37	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
THCA	cis	rs7665090	1	rs7677509	ENSG00000246560.2	RP11-10L12.4	8.57	1.48e-16	6.97e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102628849	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs7699231	ENSG00000246560.2	RP11-10L12.4	8.57	1.48e-16	6.97e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102628918	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs7699678	ENSG00000246560.2	RP11-10L12.4	8.57	1.48e-16	6.97e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102628939	chr4:102828055~102844075:+
THCA	cis	rs7665090	1	rs11724614	ENSG00000246560.2	RP11-10L12.4	8.57	1.48e-16	6.97e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102629091	chr4:102828055~102844075:+
THCA	cis	rs77204473	0.744	rs2301174	ENSG00000254851.1	RP11-109L13.1	8.57	1.49e-16	6.99e-14	0.85	0.37	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117192993	chr11:117135528~117138582:+
THCA	cis	rs1153858	0.562	rs8025019	ENSG00000259520.4	CTD-2651B20.3	-8.57	1.49e-16	7.02e-14	-0.7	-0.37	Homoarginine levels;	chr15:45443667	chr15:45251580~45279251:-
THCA	cis	rs7727544	0.606	rs2631360	ENSG00000237714.1	P4HA2-AS1	8.57	1.49e-16	7.02e-14	0.48	0.37	Blood metabolite levels;	chr5:132371737	chr5:132184876~132192808:+
THCA	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	8.57	1.5e-16	7.05e-14	0.39	0.37	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
THCA	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-8.57	1.5e-16	7.05e-14	-0.47	-0.37	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
THCA	cis	rs367615	0.959	rs2201016	ENSG00000249476.1	CTD-2587M2.1	8.57	1.5e-16	7.07e-14	0.39	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109611586	chr5:109237120~109326369:-
THCA	cis	rs2032366	0.591	rs7241479	ENSG00000267279.1	RP11-879F14.2	-8.57	1.51e-16	7.1e-14	-0.39	-0.37	Obesity-related traits;	chr18:61631923	chr18:61585746~61606916:-
THCA	cis	rs2032366	0.654	rs7227661	ENSG00000267279.1	RP11-879F14.2	-8.57	1.51e-16	7.1e-14	-0.39	-0.37	Obesity-related traits;	chr18:61632275	chr18:61585746~61606916:-
THCA	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-8.57	1.51e-16	7.11e-14	-0.4	-0.37	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
THCA	cis	rs6565180	0.962	rs11642676	ENSG00000183604.13	SMG1P5	-8.57	1.52e-16	7.13e-14	-0.39	-0.37	Tonsillectomy;	chr16:30360334	chr16:30267553~30335374:-
THCA	cis	rs4591358	0.773	rs17781737	ENSG00000223466.1	AC064834.2	-8.57	1.52e-16	7.13e-14	-0.5	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508251	chr2:195533035~195538681:+
THCA	cis	rs11155671	0.546	rs1999633	ENSG00000268592.3	RAET1E-AS1	8.57	1.52e-16	7.13e-14	0.52	0.37	Testicular germ cell tumor;	chr6:149866576	chr6:149863494~149919507:+
THCA	cis	rs7727544	0.548	rs4705938	ENSG00000237714.1	P4HA2-AS1	8.57	1.52e-16	7.14e-14	0.48	0.37	Blood metabolite levels;	chr5:132358384	chr5:132184876~132192808:+
THCA	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-8.57	1.53e-16	7.17e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
THCA	cis	rs7849270	0.837	rs4642748	ENSG00000268707.1	RP11-247A12.7	-8.57	1.53e-16	7.17e-14	-0.45	-0.37	Blood metabolite ratios;	chr9:129092668	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.692	rs4397510	ENSG00000268707.1	RP11-247A12.7	-8.57	1.53e-16	7.17e-14	-0.45	-0.37	Blood metabolite ratios;	chr9:129092671	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.879	rs10739741	ENSG00000268707.1	RP11-247A12.7	-8.57	1.53e-16	7.17e-14	-0.45	-0.37	Blood metabolite ratios;	chr9:129092881	chr9:129170434~129170940:+
THCA	cis	rs1062177	0.855	rs6896664	ENSG00000253921.1	CTB-113P19.3	-8.57	1.53e-16	7.19e-14	-0.43	-0.37	Preschool internalizing problems;	chr5:151885713	chr5:151753992~151767247:+
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000228039.3	KB-1125A3.10	8.57	1.53e-16	7.2e-14	0.46	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23963780~23964374:+
THCA	cis	rs736801	0.704	rs56399423	ENSG00000237714.1	P4HA2-AS1	8.57	1.53e-16	7.21e-14	0.5	0.37	Mosquito bite size;Breast cancer;	chr5:132336964	chr5:132184876~132192808:+
THCA	cis	rs150992	0.585	rs331931	ENSG00000248489.1	CTD-2007H13.3	8.57	1.54e-16	7.22e-14	0.36	0.37	Body mass index;	chr5:98834012	chr5:98929171~98995013:+
THCA	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	8.57	1.54e-16	7.23e-14	0.45	0.37	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
THCA	cis	rs375066	0.935	rs426534	ENSG00000267058.1	RP11-15A1.3	-8.57	1.54e-16	7.23e-14	-0.3	-0.37	Breast cancer;	chr19:43908431	chr19:43891804~43901805:-
THCA	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	8.57	1.54e-16	7.25e-14	0.36	0.37	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
THCA	cis	rs17772222	0.675	rs1099698	ENSG00000258789.1	RP11-507K2.3	8.57	1.55e-16	7.26e-14	0.35	0.37	Coronary artery calcification;	chr14:88414904	chr14:88551597~88552493:+
THCA	cis	rs1707322	0.717	rs3014246	ENSG00000234329.1	RP11-767N6.2	-8.57	1.55e-16	7.26e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs2838832	ENSG00000237664.1	LINC00316	8.57	1.55e-16	7.28e-14	0.37	0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244989	chr21:45338590~45341990:-
THCA	cis	rs2274273	1	rs2147972	ENSG00000258413.1	RP11-665C16.6	-8.57	1.55e-16	7.29e-14	-0.49	-0.37	Protein biomarker;	chr14:55131312	chr14:55262767~55272075:-
THCA	cis	rs2274273	1	rs57970196	ENSG00000258413.1	RP11-665C16.6	-8.57	1.55e-16	7.29e-14	-0.49	-0.37	Protein biomarker;	chr14:55133687	chr14:55262767~55272075:-
THCA	cis	rs42490	0.638	rs28144	ENSG00000251136.7	RP11-37B2.1	-8.56	1.56e-16	7.33e-14	-0.31	-0.37	Leprosy;	chr8:89810531	chr8:89609409~89757727:-
THCA	cis	rs848490	0.674	rs6971555	ENSG00000214293.7	APTR	8.56	1.56e-16	7.33e-14	0.28	0.37	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77777422	chr7:77657660~77696265:-
THCA	cis	rs367615	0.879	rs4351197	ENSG00000249476.1	CTD-2587M2.1	8.56	1.58e-16	7.4e-14	0.4	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109530966	chr5:109237120~109326369:-
THCA	cis	rs367615	0.918	rs4576198	ENSG00000249476.1	CTD-2587M2.1	8.56	1.58e-16	7.4e-14	0.4	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109531649	chr5:109237120~109326369:-
THCA	cis	rs367615	0.918	rs4270746	ENSG00000249476.1	CTD-2587M2.1	8.56	1.58e-16	7.4e-14	0.4	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109541138	chr5:109237120~109326369:-
THCA	cis	rs367615	0.918	rs72797472	ENSG00000249476.1	CTD-2587M2.1	8.56	1.58e-16	7.4e-14	0.4	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109545642	chr5:109237120~109326369:-
THCA	cis	rs516805	0.961	rs1267942	ENSG00000279453.1	RP3-425C14.4	-8.56	1.58e-16	7.43e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122472375	chr6:122436789~122439223:-
THCA	cis	rs516805	0.961	rs471620	ENSG00000279453.1	RP3-425C14.4	-8.56	1.58e-16	7.43e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122473532	chr6:122436789~122439223:-
THCA	cis	rs4819052	0.788	rs35323494	ENSG00000215447.6	BX322557.10	-8.56	1.59e-16	7.45e-14	-0.32	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45283824	chr21:45288052~45291738:+
THCA	cis	rs7189233	0.55	rs1861350	ENSG00000279344.1	RP11-44F14.7	8.56	1.59e-16	7.45e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr16:53499430	chr16:53478957~53481550:-
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000235689.1	AP000351.13	-8.56	1.59e-16	7.46e-14	-0.45	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:24006305~24008258:-
THCA	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-8.56	1.59e-16	7.46e-14	-0.45	-0.37	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
THCA	cis	rs7615952	0.736	rs9866347	ENSG00000171084.14	FAM86JP	8.56	1.59e-16	7.47e-14	0.55	0.37	Blood pressure (smoking interaction);	chr3:125951082	chr3:125916620~125930024:+
THCA	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	8.56	1.59e-16	7.49e-14	0.24	0.37	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
THCA	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-8.56	1.6e-16	7.53e-14	-0.38	-0.37	Height;	chr11:118786602	chr11:118704607~118750263:+
THCA	cis	rs11051970	0.559	rs4931621	ENSG00000274964.1	RP11-817I4.1	-8.56	1.61e-16	7.54e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32333569	chr12:32339368~32340724:+
THCA	cis	rs2274273	0.588	rs17128145	ENSG00000258413.1	RP11-665C16.6	8.56	1.61e-16	7.54e-14	0.5	0.37	Protein biomarker;	chr14:55069688	chr14:55262767~55272075:-
THCA	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-8.56	1.61e-16	7.56e-14	-0.59	-0.37	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
THCA	cis	rs748404	0.66	rs690012	ENSG00000205771.5	CATSPER2P1	-8.56	1.61e-16	7.56e-14	-0.38	-0.37	Lung cancer;	chr15:43427557	chr15:43726918~43747094:-
THCA	cis	rs10875746	0.556	rs4760619	ENSG00000240399.1	RP1-228P16.1	-8.56	1.61e-16	7.57e-14	-0.46	-0.37	Longevity (90 years and older);	chr12:48106148	chr12:48054813~48055591:-
THCA	cis	rs11051970	0.559	rs3816819	ENSG00000274964.1	RP11-817I4.1	-8.56	1.61e-16	7.58e-14	-0.45	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32334123	chr12:32339368~32340724:+
THCA	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	8.56	1.62e-16	7.59e-14	0.44	0.37	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
THCA	cis	rs4819052	0.851	rs12626188	ENSG00000237664.1	LINC00316	-8.56	1.62e-16	7.6e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249343	chr21:45338590~45341990:-
THCA	cis	rs11971779	0.793	rs4732366	ENSG00000273391.1	RP11-634H22.1	8.56	1.62e-16	7.6e-14	0.36	0.37	Diisocyanate-induced asthma;	chr7:139343099	chr7:139359032~139359566:-
THCA	cis	rs2018683	0.624	rs1006521	ENSG00000228421.2	AC005013.5	8.56	1.62e-16	7.61e-14	0.41	0.37	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28956604	chr7:28957667~28959345:+
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000224205.1	AP000351.4	8.56	1.63e-16	7.63e-14	0.43	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23987320~23991421:-
THCA	cis	rs10847980	0.623	rs7955367	ENSG00000256092.2	RP13-942N8.1	8.56	1.64e-16	7.67e-14	0.55	0.37	Adiponectin levels;	chr12:123344245	chr12:123363868~123366113:+
THCA	cis	rs10847980	0.623	rs28613486	ENSG00000256092.2	RP13-942N8.1	8.56	1.64e-16	7.67e-14	0.55	0.37	Adiponectin levels;	chr12:123382721	chr12:123363868~123366113:+
THCA	cis	rs516805	0.59	rs13371	ENSG00000279453.1	RP3-425C14.4	-8.56	1.64e-16	7.67e-14	-0.37	-0.37	Lymphocyte counts;	chr6:122443881	chr6:122436789~122439223:-
THCA	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-8.56	1.64e-16	7.69e-14	-0.54	-0.37	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
THCA	cis	rs673078	0.66	rs76621503	ENSG00000275409.1	RP11-131L12.4	-8.56	1.65e-16	7.71e-14	-0.47	-0.37	Glucose homeostasis traits;	chr12:118179370	chr12:118430147~118430699:+
THCA	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-8.56	1.65e-16	7.74e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
THCA	cis	rs853679	0.506	rs1150693	ENSG00000226314.6	ZNF192P1	-8.56	1.66e-16	7.75e-14	-0.49	-0.37	Depression;	chr6:28206812	chr6:28161781~28169594:+
THCA	cis	rs10740039	0.81	rs10761528	ENSG00000254271.1	RP11-131N11.4	8.56	1.66e-16	7.77e-14	0.47	0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607902	chr10:60734342~60741828:+
THCA	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	8.56	1.66e-16	7.78e-14	0.68	0.37	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
THCA	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-8.56	1.67e-16	7.82e-14	-0.37	-0.37	Height;	chr11:118760944	chr11:118704607~118750263:+
THCA	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	-8.56	1.67e-16	7.83e-14	-0.38	-0.37	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
THCA	cis	rs516805	0.961	rs573709	ENSG00000279453.1	RP3-425C14.4	8.55	1.69e-16	7.88e-14	0.33	0.37	Lymphocyte counts;	chr6:122457673	chr6:122436789~122439223:-
THCA	cis	rs1799949	0.965	rs9646413	ENSG00000267681.1	CTD-3199J23.6	-8.55	1.69e-16	7.91e-14	-0.42	-0.37	Menopause (age at onset);	chr17:43348789	chr17:43144956~43145255:+
THCA	cis	rs875971	0.522	rs1701760	ENSG00000237310.1	GS1-124K5.4	8.55	1.7e-16	7.93e-14	0.27	0.37	Aortic root size;	chr7:66008701	chr7:66493706~66495474:+
THCA	cis	rs2946505	0.689	rs2977087	ENSG00000251468.2	RP11-369K16.1	8.55	1.7e-16	7.94e-14	0.6	0.37	Migraine;	chr8:12953432	chr8:12958387~12962200:+
THCA	cis	rs7015263	0.689	rs12543887	ENSG00000254231.1	CTD-2284J15.1	-8.55	1.71e-16	7.99e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86408311	chr8:86333274~86343314:-
THCA	cis	rs11096990	0.634	rs6531703	ENSG00000249685.1	RP11-360F5.3	-8.55	1.71e-16	8e-14	-0.43	-0.37	Cognitive function;	chr4:39281786	chr4:39133913~39135608:+
THCA	cis	rs737008	0.96	rs11640295	ENSG00000262703.1	RP11-485G7.6	8.55	1.71e-16	8.01e-14	0.43	0.37	Obesity-related traits;	chr16:11296871	chr16:11348143~11349321:-
THCA	cis	rs9309473	0.687	rs10165862	ENSG00000163016.8	ALMS1P	8.55	1.72e-16	8.02e-14	0.48	0.37	Metabolite levels;	chr2:73383615	chr2:73644919~73685576:+
THCA	cis	rs2274273	0.638	rs3759667	ENSG00000258413.1	RP11-665C16.6	-8.55	1.72e-16	8.03e-14	-0.53	-0.37	Protein biomarker;	chr14:55191703	chr14:55262767~55272075:-
THCA	cis	rs516805	0.673	rs561953	ENSG00000279453.1	RP3-425C14.4	-8.55	1.72e-16	8.06e-14	-0.37	-0.37	Lymphocyte counts;	chr6:122440341	chr6:122436789~122439223:-
THCA	cis	rs7727544	0.505	rs721121	ENSG00000237714.1	P4HA2-AS1	8.55	1.73e-16	8.08e-14	0.48	0.37	Blood metabolite levels;	chr5:132070740	chr5:132184876~132192808:+
THCA	cis	rs62103177	0.81	rs62103195	ENSG00000261126.6	RP11-795F19.1	8.55	1.73e-16	8.09e-14	0.43	0.37	Opioid sensitivity;	chr18:79869693	chr18:80046900~80095482:+
THCA	cis	rs1075265	0.547	rs6743627	ENSG00000233266.1	HMGB1P31	-8.55	1.74e-16	8.13e-14	-0.47	-0.37	Chronotype;Morning vs. evening chronotype;	chr2:53687024	chr2:54051334~54051760:+
THCA	cis	rs748404	0.578	rs2584701	ENSG00000205771.5	CATSPER2P1	-8.55	1.74e-16	8.13e-14	-0.39	-0.37	Lung cancer;	chr15:43392741	chr15:43726918~43747094:-
THCA	cis	rs6565180	0.926	rs4787643	ENSG00000183604.13	SMG1P5	8.55	1.74e-16	8.15e-14	0.39	0.37	Tonsillectomy;	chr16:30382339	chr16:30267553~30335374:-
THCA	cis	rs6565180	0.926	rs4788409	ENSG00000183604.13	SMG1P5	8.55	1.74e-16	8.15e-14	0.39	0.37	Tonsillectomy;	chr16:30382450	chr16:30267553~30335374:-
THCA	cis	rs1009647	1	rs1890256	ENSG00000258413.1	RP11-665C16.6	-8.55	1.75e-16	8.16e-14	-0.55	-0.37	Testicular germ cell tumor;	chr14:55414558	chr14:55262767~55272075:-
THCA	cis	rs2946504	0.822	rs2977095	ENSG00000251468.2	RP11-369K16.1	8.55	1.75e-16	8.16e-14	0.43	0.37	Type 2 diabetes;	chr8:12947706	chr8:12958387~12962200:+
THCA	cis	rs7615952	0.673	rs34072288	ENSG00000171084.14	FAM86JP	8.55	1.75e-16	8.18e-14	0.62	0.37	Blood pressure (smoking interaction);	chr3:125825186	chr3:125916620~125930024:+
THCA	cis	rs9309473	0.579	rs6728128	ENSG00000163016.8	ALMS1P	8.55	1.75e-16	8.18e-14	0.49	0.37	Metabolite levels;	chr2:73368854	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.607	rs7567343	ENSG00000163016.8	ALMS1P	8.55	1.75e-16	8.18e-14	0.49	0.37	Metabolite levels;	chr2:73369477	chr2:73644919~73685576:+
THCA	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-8.55	1.75e-16	8.2e-14	-0.37	-0.37	Height;	chr11:118746590	chr11:118704607~118750263:+
THCA	cis	rs2929278	0.617	rs575082	ENSG00000166763.7	STRCP1	-8.55	1.76e-16	8.22e-14	-0.4	-0.37	Schizophrenia;	chr15:43817944	chr15:43699488~43718184:-
THCA	cis	rs9813712	0.571	rs9855426	ENSG00000228252.7	COL6A4P2	8.55	1.76e-16	8.22e-14	0.37	0.37	Response to amphetamines;	chr3:130214475	chr3:130212823~130273806:+
THCA	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	8.55	1.76e-16	8.23e-14	0.55	0.37	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
THCA	cis	rs1075265	0.572	rs2193682	ENSG00000233266.1	HMGB1P31	8.55	1.77e-16	8.25e-14	0.48	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53695119	chr2:54051334~54051760:+
THCA	cis	rs10411161	0.702	rs6509592	ENSG00000269483.1	AC006272.1	8.55	1.77e-16	8.26e-14	0.51	0.37	Breast cancer;	chr19:51889897	chr19:51839924~51843324:-
THCA	cis	rs4819052	0.851	rs8127834	ENSG00000237664.1	LINC00316	-8.55	1.77e-16	8.26e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45276194	chr21:45338590~45341990:-
THCA	cis	rs516805	0.961	rs527978	ENSG00000279453.1	RP3-425C14.4	-8.55	1.78e-16	8.29e-14	-0.33	-0.37	Lymphocyte counts;	chr6:122475225	chr6:122436789~122439223:-
THCA	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-8.55	1.78e-16	8.31e-14	-0.44	-0.37	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
THCA	cis	rs516805	0.706	rs1267943	ENSG00000279453.1	RP3-425C14.4	-8.55	1.78e-16	8.32e-14	-0.37	-0.37	Lymphocyte counts;	chr6:122462498	chr6:122436789~122439223:-
THCA	cis	rs35260072	1	rs35260072	ENSG00000237714.1	P4HA2-AS1	8.55	1.78e-16	8.33e-14	0.5	0.37	Itch intensity from mosquito bite;	chr5:132295159	chr5:132184876~132192808:+
THCA	cis	rs7015263	0.689	rs56395805	ENSG00000254231.1	CTD-2284J15.1	-8.55	1.78e-16	8.33e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86401033	chr8:86333274~86343314:-
THCA	cis	rs11148252	0.508	rs6561671	ENSG00000235660.1	LINC00345	-8.55	1.79e-16	8.34e-14	-0.44	-0.37	Lewy body disease;	chr13:52608179	chr13:52484161~52484680:-
THCA	cis	rs7015263	0.579	rs34895735	ENSG00000254231.1	CTD-2284J15.1	-8.55	1.79e-16	8.35e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86393165	chr8:86333274~86343314:-
THCA	cis	rs17684571	0.751	rs36094082	ENSG00000231441.1	RP11-472M19.2	8.55	1.79e-16	8.35e-14	0.46	0.37	Schizophrenia;	chr6:56842153	chr6:56844002~56864078:+
THCA	cis	rs61041384	0.661	rs74240781	ENSG00000256092.2	RP13-942N8.1	-8.55	1.79e-16	8.36e-14	-0.55	-0.37	Schizophrenia;	chr12:123308154	chr12:123363868~123366113:+
THCA	cis	rs6600671	0.719	rs9728991	ENSG00000223345.3	HIST2H2BA	8.55	1.8e-16	8.38e-14	0.41	0.37	Hip geometry;	chr1:121522281	chr1:121108210~121117257:-
THCA	cis	rs9926296	0.744	rs460879	ENSG00000260259.1	RP11-368I7.4	8.55	1.8e-16	8.4e-14	0.39	0.37	Vitiligo;	chr16:89646481	chr16:89682620~89686569:-
THCA	cis	rs150992	0.79	rs161731	ENSG00000248489.1	CTD-2007H13.3	8.55	1.8e-16	8.41e-14	0.36	0.37	Body mass index;	chr5:98984339	chr5:98929171~98995013:+
THCA	cis	rs2929278	0.588	rs1975364	ENSG00000166763.7	STRCP1	8.55	1.81e-16	8.42e-14	0.4	0.37	Schizophrenia;	chr15:43857991	chr15:43699488~43718184:-
THCA	cis	rs1862618	0.853	rs252910	ENSG00000271828.1	CTD-2310F14.1	8.55	1.81e-16	8.43e-14	0.57	0.37	Initial pursuit acceleration;	chr5:56897156	chr5:56927874~56929573:+
THCA	cis	rs16846053	0.515	rs7588198	ENSG00000227403.1	AC009299.3	-8.55	1.81e-16	8.43e-14	-0.59	-0.37	Blood osmolality (transformed sodium);	chr2:161508691	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs10202267	ENSG00000227403.1	AC009299.3	-8.55	1.81e-16	8.43e-14	-0.59	-0.37	Blood osmolality (transformed sodium);	chr2:161509616	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs7595197	ENSG00000227403.1	AC009299.3	-8.55	1.81e-16	8.43e-14	-0.59	-0.37	Blood osmolality (transformed sodium);	chr2:161510325	chr2:161244739~161249050:+
THCA	cis	rs2274273	0.682	rs1201378	ENSG00000258413.1	RP11-665C16.6	8.55	1.81e-16	8.43e-14	0.48	0.37	Protein biomarker;	chr14:55026690	chr14:55262767~55272075:-
THCA	cis	rs7829975	0.714	rs4841040	ENSG00000253893.2	FAM85B	-8.54	1.82e-16	8.48e-14	-0.46	-0.37	Mood instability;	chr8:8797017	chr8:8167819~8226614:-
THCA	cis	rs1707322	0.686	rs2275085	ENSG00000234329.1	RP11-767N6.2	-8.54	1.82e-16	8.5e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45651039~45651826:-
THCA	cis	rs7849270	1	rs1977447	ENSG00000268707.1	RP11-247A12.7	8.54	1.82e-16	8.5e-14	0.46	0.37	Blood metabolite ratios;	chr9:129105917	chr9:129170434~129170940:+
THCA	cis	rs11603691	0.901	rs11228997	ENSG00000254662.1	RP11-872D17.4	-8.54	1.83e-16	8.53e-14	-0.68	-0.37	Low high density lipoprotein cholesterol levels;	chr11:57316555	chr11:57325603~57327958:+
THCA	cis	rs62229266	0.618	rs11088334	ENSG00000231106.2	LINC01436	8.54	1.83e-16	8.55e-14	0.44	0.37	Mitral valve prolapse;	chr21:36094531	chr21:36005338~36007838:+
THCA	cis	rs8114671	0.836	rs6060140	ENSG00000269202.1	RP4-614O4.12	-8.54	1.84e-16	8.57e-14	-0.31	-0.37	Height;	chr20:34978704	chr20:35201747~35203288:-
THCA	cis	rs4819052	0.851	rs4819046	ENSG00000237664.1	LINC00316	-8.54	1.84e-16	8.57e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245040	chr21:45338590~45341990:-
THCA	cis	rs2929278	0.617	rs4617832	ENSG00000166763.7	STRCP1	-8.54	1.84e-16	8.58e-14	-0.4	-0.37	Schizophrenia;	chr15:43738381	chr15:43699488~43718184:-
THCA	cis	rs17507216	0.56	rs28493687	ENSG00000278603.1	RP13-608F4.5	8.54	1.84e-16	8.59e-14	0.52	0.37	Excessive daytime sleepiness;	chr15:82560062	chr15:82472203~82472426:+
THCA	cis	rs950169	0.58	rs11635597	ENSG00000225151.9	GOLGA2P7	-8.54	1.85e-16	8.61e-14	-0.54	-0.37	Schizophrenia;	chr15:84622468	chr15:84199311~84230136:-
THCA	cis	rs11971779	0.68	rs10273527	ENSG00000273391.1	RP11-634H22.1	-8.54	1.85e-16	8.62e-14	-0.33	-0.37	Diisocyanate-induced asthma;	chr7:139351852	chr7:139359032~139359566:-
THCA	cis	rs6545883	0.507	rs2442025	ENSG00000271889.1	RP11-493E12.1	-8.54	1.86e-16	8.65e-14	-0.35	-0.37	Tuberculosis;	chr2:61344310	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.524	rs2593631	ENSG00000271889.1	RP11-493E12.1	-8.54	1.86e-16	8.65e-14	-0.35	-0.37	Tuberculosis;	chr2:61345151	chr2:61151433~61162105:-
THCA	cis	rs6545883	0.542	rs2593628	ENSG00000271889.1	RP11-493E12.1	-8.54	1.86e-16	8.65e-14	-0.35	-0.37	Tuberculosis;	chr2:61346152	chr2:61151433~61162105:-
THCA	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-8.54	1.86e-16	8.65e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
THCA	cis	rs7727544	0.582	rs10075459	ENSG00000237714.1	P4HA2-AS1	8.54	1.86e-16	8.66e-14	0.46	0.37	Blood metabolite levels;	chr5:132205670	chr5:132184876~132192808:+
THCA	cis	rs7849270	0.879	rs3124496	ENSG00000268707.1	RP11-247A12.7	8.54	1.86e-16	8.69e-14	0.47	0.37	Blood metabolite ratios;	chr9:129094583	chr9:129170434~129170940:+
THCA	cis	rs526231	0.667	rs187580	ENSG00000175749.11	EIF3KP1	8.54	1.87e-16	8.69e-14	0.58	0.37	Primary biliary cholangitis;	chr5:103291654	chr5:103032376~103033031:+
THCA	cis	rs7646881	0.767	rs58152433	ENSG00000240207.5	RP11-379F4.4	-8.54	1.87e-16	8.73e-14	-0.51	-0.37	Tetralogy of Fallot;	chr3:158738851	chr3:158732263~158784070:+
THCA	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	8.54	1.88e-16	8.74e-14	0.43	0.37	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
THCA	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-8.54	1.88e-16	8.74e-14	-0.43	-0.37	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
THCA	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-8.54	1.88e-16	8.74e-14	-0.43	-0.37	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
THCA	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-8.54	1.88e-16	8.75e-14	-0.41	-0.37	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
THCA	cis	rs7015263	0.573	rs6983925	ENSG00000254231.1	CTD-2284J15.1	-8.54	1.88e-16	8.76e-14	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86277028	chr8:86333274~86343314:-
THCA	cis	rs10510102	0.872	rs56108883	ENSG00000276742.1	RP11-500G22.4	8.54	1.89e-16	8.79e-14	0.56	0.37	Breast cancer;	chr10:121825567	chr10:121956782~121957098:+
THCA	cis	rs4819052	1	rs9306123	ENSG00000237664.1	LINC00316	-8.54	1.89e-16	8.81e-14	-0.4	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45290007	chr21:45338590~45341990:-
THCA	cis	rs17684571	0.872	rs13198938	ENSG00000231441.1	RP11-472M19.2	8.54	1.89e-16	8.82e-14	0.49	0.37	Schizophrenia;	chr6:56733628	chr6:56844002~56864078:+
THCA	cis	rs2929278	0.617	rs2955969	ENSG00000166763.7	STRCP1	-8.54	1.9e-16	8.85e-14	-0.4	-0.37	Schizophrenia;	chr15:43822329	chr15:43699488~43718184:-
THCA	cis	rs1707322	0.721	rs6699418	ENSG00000234329.1	RP11-767N6.2	8.54	1.91e-16	8.88e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs4431884	ENSG00000234329.1	RP11-767N6.2	8.54	1.91e-16	8.88e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.65	rs4660879	ENSG00000234329.1	RP11-767N6.2	8.54	1.91e-16	8.88e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10789468	ENSG00000234329.1	RP11-767N6.2	8.54	1.91e-16	8.88e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs6429574	ENSG00000234329.1	RP11-767N6.2	8.54	1.91e-16	8.88e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45651039~45651826:-
THCA	cis	rs7851660	0.967	rs7043885	ENSG00000236130.1	PTCSC2	-8.54	1.91e-16	8.89e-14	-0.28	-0.37	Strep throat;	chr9:97834157	chr9:97805935~97810008:-
THCA	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-8.54	1.91e-16	8.91e-14	-0.74	-0.37	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
THCA	cis	rs747687	0.655	rs7218037	ENSG00000262133.1	RP11-676J12.6	8.54	1.92e-16	8.93e-14	0.61	0.37	Blood pressure;	chr17:866227	chr17:877902~880093:+
THCA	cis	rs2243480	1	rs937108	ENSG00000226824.5	RP4-756H11.3	-8.54	1.92e-16	8.96e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65963465	chr7:66654538~66669855:+
THCA	cis	rs12701220	0.553	rs13245507	ENSG00000229043.2	AC091729.9	-8.54	1.93e-16	8.97e-14	-0.53	-0.37	Bronchopulmonary dysplasia;	chr7:1124058	chr7:1160374~1165267:+
THCA	cis	rs56046484	0.912	rs12914674	ENSG00000259295.5	CSPG4P12	8.54	1.93e-16	8.97e-14	0.63	0.37	Testicular germ cell tumor;	chr15:85119829	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs34889576	ENSG00000259295.5	CSPG4P12	8.54	1.93e-16	8.97e-14	0.63	0.37	Testicular germ cell tumor;	chr15:85121445	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs34076898	ENSG00000259295.5	CSPG4P12	8.54	1.93e-16	8.97e-14	0.63	0.37	Testicular germ cell tumor;	chr15:85121569	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs35533990	ENSG00000259295.5	CSPG4P12	8.54	1.93e-16	8.97e-14	0.63	0.37	Testicular germ cell tumor;	chr15:85121590	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs35045545	ENSG00000259295.5	CSPG4P12	8.54	1.93e-16	8.97e-14	0.63	0.37	Testicular germ cell tumor;	chr15:85121720	chr15:85191438~85213905:+
THCA	cis	rs736801	0.569	rs12517950	ENSG00000237714.1	P4HA2-AS1	8.54	1.93e-16	8.97e-14	0.49	0.37	Mosquito bite size;Breast cancer;	chr5:132395634	chr5:132184876~132192808:+
THCA	cis	rs10875746	0.855	rs10875728	ENSG00000240399.1	RP1-228P16.1	-8.54	1.93e-16	8.97e-14	-0.41	-0.37	Longevity (90 years and older);	chr12:48032609	chr12:48054813~48055591:-
THCA	cis	rs62355901	0.545	rs6882255	ENSG00000271828.1	CTD-2310F14.1	8.54	1.93e-16	8.99e-14	0.63	0.37	Breast cancer;	chr5:56762344	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.636	rs12654584	ENSG00000271828.1	CTD-2310F14.1	8.54	1.93e-16	8.99e-14	0.63	0.37	Endometriosis;	chr5:56762588	chr5:56927874~56929573:+
THCA	cis	rs4819052	0.851	rs10470245	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238997	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs10470258	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239074	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4819038	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239478	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4819039	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239543	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4818768	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239903	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4819042	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240157	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs13047598	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240862	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.724	rs9753962	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241469	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.724	rs9753987	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241474	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs9753963	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241522	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs9754134	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45241836	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs34101026	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242285	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs13052312	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242444	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838828	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243508	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs13049337	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243545	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs8134392	ENSG00000237664.1	LINC00316	8.54	1.94e-16	9.01e-14	0.37	0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243875	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838829	ENSG00000237664.1	LINC00316	-8.54	1.94e-16	9.01e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244125	chr21:45338590~45341990:-
THCA	cis	rs8072100	0.537	rs9912450	ENSG00000228782.6	CTD-2026D20.3	8.54	1.94e-16	9.02e-14	0.35	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47324842	chr17:47450568~47492492:-
THCA	cis	rs10510102	0.566	rs885543	ENSG00000276742.1	RP11-500G22.4	8.54	1.94e-16	9.02e-14	0.58	0.37	Breast cancer;	chr10:121973536	chr10:121956782~121957098:+
THCA	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	8.54	1.95e-16	9.06e-14	0.45	0.37	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
THCA	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	8.53	1.95e-16	9.07e-14	0.27	0.37	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
THCA	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-8.53	1.96e-16	9.1e-14	-0.45	-0.37	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
THCA	cis	rs947583	0.955	rs7760254	ENSG00000231028.7	LINC00271	8.53	1.96e-16	9.12e-14	0.3	0.37	Phosphorus levels;	chr6:135811157	chr6:135497801~135716055:+
THCA	cis	rs7712401	0.765	rs10079941	ENSG00000263432.2	RN7SL689P	8.53	1.97e-16	9.16e-14	0.41	0.37	Mean platelet volume;	chr5:123045668	chr5:123022487~123022783:-
THCA	cis	rs1707322	0.717	rs3014245	ENSG00000234329.1	RP11-767N6.2	-8.53	1.97e-16	9.16e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs1135850	ENSG00000234329.1	RP11-767N6.2	8.53	1.98e-16	9.2e-14	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.655	rs3014240	ENSG00000234329.1	RP11-767N6.2	-8.53	1.98e-16	9.2e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.686	rs3014235	ENSG00000234329.1	RP11-767N6.2	-8.53	1.98e-16	9.2e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45651039~45651826:-
THCA	cis	rs11690935	0.527	rs7586556	ENSG00000228389.1	AC068039.4	-8.53	1.98e-16	9.21e-14	-0.38	-0.37	Schizophrenia;	chr2:172036983	chr2:171773482~171775844:+
THCA	cis	rs1062177	0.756	rs2964591	ENSG00000253921.1	CTB-113P19.3	8.53	1.99e-16	9.25e-14	0.44	0.37	Preschool internalizing problems;	chr5:151737836	chr5:151753992~151767247:+
THCA	cis	rs17684571	0.625	rs16888186	ENSG00000231441.1	RP11-472M19.2	8.53	1.99e-16	9.26e-14	0.46	0.37	Schizophrenia;	chr6:56866906	chr6:56844002~56864078:+
THCA	cis	rs2946504	0.861	rs2946497	ENSG00000251468.2	RP11-369K16.1	-8.53	1.99e-16	9.27e-14	-0.45	-0.37	Type 2 diabetes;	chr8:12960804	chr8:12958387~12962200:+
THCA	cis	rs4819052	0.819	rs34818688	ENSG00000237664.1	LINC00316	-8.53	2e-16	9.31e-14	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252501	chr21:45338590~45341990:-
THCA	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-8.53	2.01e-16	9.33e-14	-0.46	-0.37	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
THCA	cis	rs10971721	0.818	rs10971708	ENSG00000260947.1	RP11-384P7.7	8.53	2.01e-16	9.33e-14	0.93	0.37	Body mass index;	chr9:33803273	chr9:33697459~33700986:+
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000235689.1	AP000351.13	8.53	2.01e-16	9.35e-14	0.45	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:24006305~24008258:-
THCA	cis	rs4819052	0.679	rs2838860	ENSG00000215447.6	BX322557.10	-8.53	2.02e-16	9.39e-14	-0.3	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264989	chr21:45288052~45291738:+
THCA	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-8.53	2.03e-16	9.42e-14	-0.45	-0.37	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
THCA	cis	rs2243480	1	rs160634	ENSG00000273142.1	RP11-458F8.4	8.53	2.03e-16	9.44e-14	0.45	0.37	Diabetic kidney disease;	chr7:66063677	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs7456042	ENSG00000226824.5	RP4-756H11.3	-8.53	2.04e-16	9.46e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65834791	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs73142121	ENSG00000226824.5	RP4-756H11.3	-8.53	2.04e-16	9.46e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65846219	chr7:66654538~66669855:+
THCA	cis	rs7829975	0.533	rs13274028	ENSG00000253893.2	FAM85B	-8.53	2.04e-16	9.48e-14	-0.47	-0.37	Mood instability;	chr8:8871683	chr8:8167819~8226614:-
THCA	cis	rs11971779	0.793	rs11543827	ENSG00000273391.1	RP11-634H22.1	8.53	2.05e-16	9.5e-14	0.36	0.37	Diisocyanate-induced asthma;	chr7:139347947	chr7:139359032~139359566:-
THCA	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-8.53	2.05e-16	9.5e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-8.53	2.05e-16	9.5e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-8.53	2.05e-16	9.5e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-8.53	2.05e-16	9.5e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34702770	ENSG00000226824.5	RP4-756H11.3	-8.53	2.05e-16	9.5e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65879836	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34637256	ENSG00000226824.5	RP4-756H11.3	-8.53	2.05e-16	9.5e-14	-0.72	-0.37	Diabetic kidney disease;	chr7:65895144	chr7:66654538~66669855:+
THCA	cis	rs1501911	0.53	rs751878	ENSG00000248489.1	CTD-2007H13.3	8.53	2.05e-16	9.5e-14	0.36	0.37	Lung function (FEV1/FVC);	chr5:98827240	chr5:98929171~98995013:+
THCA	cis	rs1501911	0.53	rs331926	ENSG00000248489.1	CTD-2007H13.3	8.53	2.05e-16	9.5e-14	0.36	0.37	Lung function (FEV1/FVC);	chr5:98828697	chr5:98929171~98995013:+
THCA	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	8.53	2.05e-16	9.51e-14	0.36	0.37	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
THCA	cis	rs2439831	0.85	rs28413881	ENSG00000249839.1	AC011330.5	-8.53	2.06e-16	9.55e-14	-0.59	-0.37	Lung cancer in ever smokers;	chr15:43881901	chr15:43663654~43684339:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000224205.1	AP000351.4	8.53	2.06e-16	9.55e-14	0.44	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23987320~23991421:-
THCA	cis	rs7569084	0.687	rs1437462	ENSG00000234255.7	AC012370.3	8.53	2.06e-16	9.56e-14	0.42	0.37	Sum eosinophil basophil counts;	chr2:65449559	chr2:65439888~65456571:-
THCA	cis	rs736801	0.607	rs11746555	ENSG00000237714.1	P4HA2-AS1	8.53	2.06e-16	9.58e-14	0.49	0.37	Mosquito bite size;Breast cancer;	chr5:132391341	chr5:132184876~132192808:+
THCA	cis	rs9813712	0.571	rs9824426	ENSG00000228252.7	COL6A4P2	-8.53	2.06e-16	9.58e-14	-0.37	-0.37	Response to amphetamines;	chr3:130226115	chr3:130212823~130273806:+
THCA	cis	rs17772222	0.682	rs1152377	ENSG00000258789.1	RP11-507K2.3	8.53	2.06e-16	9.58e-14	0.35	0.37	Coronary artery calcification;	chr14:88496243	chr14:88551597~88552493:+
THCA	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	8.53	2.07e-16	9.59e-14	0.5	0.37	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
THCA	cis	rs150992	0.711	rs331918	ENSG00000248489.1	CTD-2007H13.3	8.53	2.07e-16	9.61e-14	0.36	0.37	Body mass index;	chr5:98823040	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs331929	ENSG00000248489.1	CTD-2007H13.3	8.53	2.07e-16	9.61e-14	0.36	0.37	Body mass index;	chr5:98830528	chr5:98929171~98995013:+
THCA	cis	rs7665090	0.967	rs13106325	ENSG00000246560.2	RP11-10L12.4	8.53	2.07e-16	9.62e-14	0.44	0.37	Primary biliary cholangitis;	chr4:102633835	chr4:102828055~102844075:+
THCA	cis	rs6545883	0.524	rs12992614	ENSG00000271889.1	RP11-493E12.1	-8.53	2.07e-16	9.62e-14	-0.35	-0.37	Tuberculosis;	chr2:61365941	chr2:61151433~61162105:-
THCA	cis	rs4842666	0.915	rs12579302	ENSG00000258302.2	RP11-981P6.1	-8.53	2.08e-16	9.64e-14	-0.36	-0.37	Blood pressure;	chr12:89656726	chr12:89561129~89594878:+
THCA	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	8.53	2.08e-16	9.64e-14	0.41	0.37	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
THCA	cis	rs2274273	1	rs67805055	ENSG00000258413.1	RP11-665C16.6	-8.53	2.08e-16	9.67e-14	-0.48	-0.37	Protein biomarker;	chr14:55120834	chr14:55262767~55272075:-
THCA	cis	rs529866	0.519	rs4451969	ENSG00000262636.1	CTD-3088G3.4	-8.53	2.09e-16	9.68e-14	-0.47	-0.37	Inflammatory bowel disease;Crohn's disease;	chr16:11289662	chr16:11380859~11381118:-
THCA	cis	rs2836974	0.563	rs6517522	ENSG00000255568.3	BRWD1-AS2	8.53	2.09e-16	9.69e-14	0.3	0.37	Cognitive function;	chr21:39181919	chr21:39313935~39314962:+
THCA	cis	rs150992	0.593	rs326491	ENSG00000248489.1	CTD-2007H13.3	8.53	2.1e-16	9.73e-14	0.35	0.37	Body mass index;	chr5:98972225	chr5:98929171~98995013:+
THCA	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	8.53	2.1e-16	9.74e-14	0.38	0.37	QT interval;	chr12:29379056	chr12:29280418~29317848:-
THCA	cis	rs10181042	0.514	rs1177288	ENSG00000271889.1	RP11-493E12.1	8.52	2.1e-16	9.75e-14	0.35	0.37	Crohn's disease;	chr2:61125850	chr2:61151433~61162105:-
THCA	cis	rs10181042	0.514	rs1177289	ENSG00000271889.1	RP11-493E12.1	8.52	2.1e-16	9.75e-14	0.35	0.37	Crohn's disease;	chr2:61126121	chr2:61151433~61162105:-
THCA	cis	rs2274273	1	rs67098772	ENSG00000258413.1	RP11-665C16.6	-8.52	2.1e-16	9.76e-14	-0.48	-0.37	Protein biomarker;	chr14:55128524	chr14:55262767~55272075:-
THCA	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-8.52	2.11e-16	9.78e-14	-0.46	-0.37	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-8.52	2.11e-16	9.78e-14	-0.46	-0.37	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
THCA	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-8.52	2.11e-16	9.78e-14	-0.46	-0.37	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
THCA	cis	rs673078	0.66	rs61945217	ENSG00000275409.1	RP11-131L12.4	-8.52	2.11e-16	9.8e-14	-0.49	-0.37	Glucose homeostasis traits;	chr12:118261194	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs117091919	ENSG00000275409.1	RP11-131L12.4	-8.52	2.11e-16	9.8e-14	-0.49	-0.37	Glucose homeostasis traits;	chr12:118273228	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs7314987	ENSG00000275409.1	RP11-131L12.4	-8.52	2.11e-16	9.8e-14	-0.49	-0.37	Glucose homeostasis traits;	chr12:118274072	chr12:118430147~118430699:+
THCA	cis	rs9309473	0.687	rs6546827	ENSG00000163016.8	ALMS1P	8.52	2.11e-16	9.81e-14	0.48	0.37	Metabolite levels;	chr2:73379365	chr2:73644919~73685576:+
THCA	cis	rs4819052	0.851	rs2838867	ENSG00000237664.1	LINC00316	-8.52	2.12e-16	9.81e-14	-0.38	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293177	chr21:45338590~45341990:-
THCA	cis	rs1707322	0.717	rs2253862	ENSG00000234329.1	RP11-767N6.2	-8.52	2.12e-16	9.81e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs2991988	ENSG00000234329.1	RP11-767N6.2	-8.52	2.12e-16	9.81e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs2991989	ENSG00000234329.1	RP11-767N6.2	-8.52	2.12e-16	9.81e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45651039~45651826:-
THCA	cis	rs737008	0.959	rs11865598	ENSG00000262703.1	RP11-485G7.6	8.52	2.12e-16	9.82e-14	0.43	0.37	Obesity-related traits;	chr16:11309575	chr16:11348143~11349321:-
THCA	cis	rs7829975	0.902	rs777707	ENSG00000253893.2	FAM85B	-8.52	2.12e-16	9.84e-14	-0.46	-0.37	Mood instability;	chr8:8726834	chr8:8167819~8226614:-
THCA	cis	rs9475752	0.552	rs17685045	ENSG00000231441.1	RP11-472M19.2	8.52	2.12e-16	9.84e-14	0.49	0.37	Menarche (age at onset);	chr6:56880135	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.552	rs13203600	ENSG00000231441.1	RP11-472M19.2	8.52	2.12e-16	9.84e-14	0.49	0.37	Menarche (age at onset);	chr6:56880364	chr6:56844002~56864078:+
THCA	cis	rs7851660	0.935	rs4460498	ENSG00000236130.1	PTCSC2	-8.52	2.13e-16	9.88e-14	-0.28	-0.37	Strep throat;	chr9:97858130	chr9:97805935~97810008:-
THCA	cis	rs2274273	0.745	rs56262555	ENSG00000258413.1	RP11-665C16.6	-8.52	2.13e-16	9.89e-14	-0.49	-0.37	Protein biomarker;	chr14:55095244	chr14:55262767~55272075:-
THCA	cis	rs1707322	0.717	rs1547925	ENSG00000234329.1	RP11-767N6.2	-8.52	2.14e-16	9.92e-14	-0.35	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45651039~45651826:-
THCA	cis	rs12701220	0.655	rs34696066	ENSG00000229043.2	AC091729.9	-8.52	2.14e-16	9.93e-14	-0.49	-0.37	Bronchopulmonary dysplasia;	chr7:1101283	chr7:1160374~1165267:+
THCA	cis	rs9309473	0.607	rs7574291	ENSG00000163016.8	ALMS1P	8.52	2.14e-16	9.94e-14	0.48	0.37	Metabolite levels;	chr2:73367813	chr2:73644919~73685576:+
THCA	cis	rs7674212	0.581	rs10516496	ENSG00000246560.2	RP11-10L12.4	8.52	2.14e-16	9.94e-14	0.46	0.37	Type 2 diabetes;	chr4:103021008	chr4:102828055~102844075:+
THCA	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-8.52	2.15e-16	9.94e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-8.52	2.15e-16	9.94e-14	-0.73	-0.37	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
THCA	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	8.52	2.15e-16	9.96e-14	0.47	0.37	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
THCA	cis	rs2243480	1	rs7794661	ENSG00000273142.1	RP11-458F8.4	-8.52	2.15e-16	9.96e-14	-0.46	-0.37	Diabetic kidney disease;	chr7:65924743	chr7:66902857~66906297:+
THCA	cis	rs10050311	0.79	rs61651372	ENSG00000251411.1	RP11-397E7.4	-8.52	2.15e-16	9.96e-14	-0.44	-0.37	Insulin-related traits;	chr4:86912903	chr4:86913266~86914817:-
THCA	cis	rs2408955	0.521	rs10875749	ENSG00000258273.1	RP11-370I10.4	8.52	2.15e-16	9.97e-14	0.48	0.37	Glycated hemoglobin levels;	chr12:48138134	chr12:48333755~48333901:-
THCA	cis	rs2408955	0.521	rs7301003	ENSG00000258273.1	RP11-370I10.4	-8.52	2.15e-16	9.97e-14	-0.48	-0.37	Glycated hemoglobin levels;	chr12:48156444	chr12:48333755~48333901:-
THCA	cis	rs7015263	0.689	rs6471354	ENSG00000254231.1	CTD-2284J15.1	8.52	2.15e-16	9.98e-14	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86473254	chr8:86333274~86343314:-
THCA	cis	rs7727544	0.582	rs10052046	ENSG00000237714.1	P4HA2-AS1	8.52	2.16e-16	1e-13	0.46	0.37	Blood metabolite levels;	chr5:132208773	chr5:132184876~132192808:+
THCA	cis	rs9640161	0.75	rs3735167	ENSG00000261305.1	RP4-584D14.7	8.52	2.16e-16	1e-13	0.47	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150342466	chr7:150341771~150342607:+
THCA	cis	rs7712401	0.546	rs10044921	ENSG00000263432.2	RN7SL689P	8.52	2.16e-16	1e-13	0.41	0.37	Mean platelet volume;	chr5:122843662	chr5:123022487~123022783:-
THCA	cis	rs55665837	0.922	rs12287212	ENSG00000251991.1	RNU7-49P	8.52	2.16e-16	1e-13	0.41	0.37	Vitamin D levels;	chr11:14428315	chr11:14478892~14478953:+
THCA	cis	rs1707322	0.721	rs11211181	ENSG00000234329.1	RP11-767N6.2	8.52	2.17e-16	1e-13	0.34	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45651039~45651826:-
THCA	cis	rs7665090	1	rs12498722	ENSG00000246560.2	RP11-10L12.4	8.52	2.17e-16	1e-13	0.44	0.37	Primary biliary cholangitis;	chr4:102633365	chr4:102828055~102844075:+
THCA	cis	rs11148252	0.532	rs9536185	ENSG00000278238.1	RP11-245D16.4	-8.52	2.17e-16	1e-13	-0.42	-0.37	Lewy body disease;	chr13:52605666	chr13:52454775~52455331:-
THCA	cis	rs17684571	0.751	rs6910414	ENSG00000231441.1	RP11-472M19.2	8.52	2.17e-16	1.01e-13	0.45	0.37	Schizophrenia;	chr6:56861939	chr6:56844002~56864078:+
THCA	cis	rs748404	0.56	rs2255663	ENSG00000205771.5	CATSPER2P1	8.52	2.17e-16	1.01e-13	0.38	0.37	Lung cancer;	chr15:43536810	chr15:43726918~43747094:-
THCA	cis	rs748404	0.56	rs689797	ENSG00000205771.5	CATSPER2P1	-8.52	2.17e-16	1.01e-13	-0.38	-0.37	Lung cancer;	chr15:43534359	chr15:43726918~43747094:-
THCA	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	8.52	2.18e-16	1.01e-13	0.43	0.37	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
THCA	cis	rs910316	0.523	rs4026175	ENSG00000279594.1	RP11-950C14.10	8.52	2.18e-16	1.01e-13	0.35	0.37	Height;	chr14:75035537	chr14:75011269~75012851:-
THCA	cis	rs7015263	0.603	rs56102132	ENSG00000254231.1	CTD-2284J15.1	-8.52	2.18e-16	1.01e-13	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86425798	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs62510798	ENSG00000254231.1	CTD-2284J15.1	-8.52	2.18e-16	1.01e-13	-0.37	-0.37	Intelligence (multi-trait analysis);	chr8:86432337	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.714	rs6471345	ENSG00000254231.1	CTD-2284J15.1	8.52	2.18e-16	1.01e-13	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86445357	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs6988601	ENSG00000254231.1	CTD-2284J15.1	8.52	2.18e-16	1.01e-13	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86451366	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.689	rs10095129	ENSG00000254231.1	CTD-2284J15.1	8.52	2.18e-16	1.01e-13	0.37	0.37	Intelligence (multi-trait analysis);	chr8:86454079	chr8:86333274~86343314:-
THCA	cis	rs8072100	0.512	rs9303533	ENSG00000228782.6	CTD-2026D20.3	8.52	2.19e-16	1.01e-13	0.34	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309174	chr17:47450568~47492492:-
THCA	cis	rs2243480	1	rs2243480	ENSG00000273142.1	RP11-458F8.4	-8.52	2.2e-16	1.02e-13	-0.45	-0.37	Diabetic kidney disease;	chr7:66134209	chr7:66902857~66906297:+
THCA	cis	rs150992	0.525	rs331930	ENSG00000248489.1	CTD-2007H13.3	8.52	2.2e-16	1.02e-13	0.36	0.37	Body mass index;	chr5:98833559	chr5:98929171~98995013:+
THCA	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-8.52	2.21e-16	1.02e-13	-0.57	-0.37	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
THCA	cis	rs7727544	0.582	rs3828675	ENSG00000237714.1	P4HA2-AS1	8.52	2.21e-16	1.02e-13	0.46	0.37	Blood metabolite levels;	chr5:132211175	chr5:132184876~132192808:+
THCA	cis	rs748404	0.578	rs507178	ENSG00000205771.5	CATSPER2P1	-8.52	2.21e-16	1.02e-13	-0.38	-0.37	Lung cancer;	chr15:43317937	chr15:43726918~43747094:-
THCA	cis	rs516805	0.706	rs541551	ENSG00000279453.1	RP3-425C14.4	-8.52	2.22e-16	1.02e-13	-0.37	-0.37	Lymphocyte counts;	chr6:122462736	chr6:122436789~122439223:-
THCA	cis	rs11464691	1	rs11464691	ENSG00000278834.1	RP11-458J1.1	8.52	2.22e-16	1.03e-13	0.38	0.37	Allergic disease (asthma, hay fever or eczema);	chr17:40614389	chr17:40648300~40649718:+
THCA	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	-8.52	2.22e-16	1.03e-13	-0.39	-0.37	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
THCA	cis	rs17826219	0.568	rs59858012	ENSG00000266490.1	CTD-2349P21.9	8.52	2.22e-16	1.03e-13	0.56	0.37	Body mass index;	chr17:30751564	chr17:30792372~30792833:+
THCA	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-8.52	2.22e-16	1.03e-13	-0.44	-0.37	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
THCA	cis	rs12188164	0.61	rs57433159	ENSG00000221990.4	EXOC3-AS1	8.52	2.22e-16	1.03e-13	0.31	0.37	Cystic fibrosis severity;	chr5:418610	chr5:441498~443160:-
THCA	cis	rs673078	0.607	rs4767671	ENSG00000275409.1	RP11-131L12.4	-8.52	2.22e-16	1.03e-13	-0.45	-0.37	Glucose homeostasis traits;	chr12:118396038	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7312555	ENSG00000275409.1	RP11-131L12.4	-8.52	2.22e-16	1.03e-13	-0.45	-0.37	Glucose homeostasis traits;	chr12:118414120	chr12:118430147~118430699:+
THCA	cis	rs2929278	0.617	rs12908467	ENSG00000166763.7	STRCP1	-8.52	2.22e-16	1.03e-13	-0.4	-0.37	Schizophrenia;	chr15:43755232	chr15:43699488~43718184:-
THCA	cis	rs2720460	0.502	rs223374	ENSG00000246560.2	RP11-10L12.4	8.52	2.24e-16	1.04e-13	0.46	0.37	Testicular germ cell tumor;	chr4:102837144	chr4:102828055~102844075:+
THCA	cis	rs673078	0.607	rs55929628	ENSG00000275409.1	RP11-131L12.4	-8.52	2.24e-16	1.04e-13	-0.45	-0.37	Glucose homeostasis traits;	chr12:118371332	chr12:118430147~118430699:+
THCA	cis	rs673078	0.517	rs73205578	ENSG00000275409.1	RP11-131L12.4	-8.52	2.24e-16	1.04e-13	-0.45	-0.37	Glucose homeostasis traits;	chr12:118385113	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs73205579	ENSG00000275409.1	RP11-131L12.4	-8.52	2.24e-16	1.04e-13	-0.45	-0.37	Glucose homeostasis traits;	chr12:118385125	chr12:118430147~118430699:+
THCA	cis	rs367615	0.918	rs10051855	ENSG00000249476.1	CTD-2587M2.1	8.52	2.25e-16	1.04e-13	0.4	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109524257	chr5:109237120~109326369:-
THCA	cis	rs367615	0.918	rs10055528	ENSG00000249476.1	CTD-2587M2.1	8.52	2.25e-16	1.04e-13	0.4	0.37	Colorectal cancer (SNP x SNP interaction);	chr5:109525428	chr5:109237120~109326369:-
THCA	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	8.52	2.25e-16	1.04e-13	0.44	0.37	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
THCA	cis	rs1707322	0.721	rs10430124	ENSG00000234329.1	RP11-767N6.2	8.52	2.25e-16	1.04e-13	0.35	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45651039~45651826:-
THCA	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	8.52	2.26e-16	1.04e-13	0.24	0.37	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	8.52	2.26e-16	1.04e-13	0.24	0.37	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
THCA	cis	rs10759883	0.539	rs7847393	ENSG00000175611.10	LINC00476	8.52	2.26e-16	1.04e-13	0.41	0.37	Nicotine dependence;	chr9:96033431	chr9:95759231~95875977:-
THCA	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-8.52	2.26e-16	1.04e-13	-0.45	-0.37	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
THCA	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	8.52	2.26e-16	1.04e-13	0.24	0.37	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
THCA	cis	rs6545883	0.507	rs12617371	ENSG00000271889.1	RP11-493E12.1	-8.51	2.27e-16	1.05e-13	-0.35	-0.37	Tuberculosis;	chr2:61341999	chr2:61151433~61162105:-
THCA	cis	rs8072100	0.512	rs3809863	ENSG00000228782.6	CTD-2026D20.3	8.51	2.28e-16	1.05e-13	0.34	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47307646	chr17:47450568~47492492:-
THCA	cis	rs4819052	0.679	rs2255761	ENSG00000215447.6	BX322557.10	-8.51	2.28e-16	1.05e-13	-0.3	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263707	chr21:45288052~45291738:+
THCA	cis	rs934734	0.752	rs2661795	ENSG00000204929.10	AC074391.1	-8.51	2.28e-16	1.05e-13	-0.45	-0.37	Rheumatoid arthritis;	chr2:65399672	chr2:65436711~66084639:+
THCA	cis	rs7674212	0.556	rs223401	ENSG00000251288.2	RP11-10L12.2	-8.51	2.28e-16	1.05e-13	-0.49	-0.37	Type 2 diabetes;	chr4:102817815	chr4:102751401~102752641:+
THCA	cis	rs1005277	0.502	rs2800484	ENSG00000263064.2	RP11-291L22.7	8.51	2.28e-16	1.05e-13	0.41	0.37	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38448689~38448949:+
THCA	cis	rs922182	0.556	rs10851734	ENSG00000275785.1	RP11-111E14.2	-8.51	2.29e-16	1.06e-13	-0.44	-0.37	Blood protein levels;	chr15:63924048	chr15:63890030~63890317:+
THCA	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	8.51	2.29e-16	1.06e-13	0.6	0.37	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
THCA	cis	rs5769707	0.521	rs74351010	ENSG00000188511.11	C22orf34	-8.51	2.29e-16	1.06e-13	-0.6	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49643172	chr22:49414524~49657542:-
THCA	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	8.51	2.29e-16	1.06e-13	0.47	0.37	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
THCA	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	8.51	2.29e-16	1.06e-13	0.5	0.37	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
THCA	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	8.51	2.3e-16	1.06e-13	0.71	0.37	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
THCA	cis	rs9659323	0.73	rs10802070	ENSG00000231365.4	RP11-418J17.1	-8.51	2.3e-16	1.06e-13	-0.36	-0.37	Body mass index;	chr1:118998863	chr1:119140396~119275973:+
THCA	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-8.51	2.3e-16	1.06e-13	-0.47	-0.37	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
THCA	cis	rs5769707	0.837	rs1573726	ENSG00000235111.1	RP1-29C18.8	-8.51	2.31e-16	1.07e-13	-0.43	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49639224	chr22:49612657~49615716:-
THCA	cis	rs736801	0.569	rs11748193	ENSG00000237714.1	P4HA2-AS1	8.51	2.32e-16	1.07e-13	0.49	0.37	Mosquito bite size;Breast cancer;	chr5:132389637	chr5:132184876~132192808:+
THCA	cis	rs1062177	0.756	rs2915826	ENSG00000253921.1	CTB-113P19.3	8.51	2.33e-16	1.08e-13	0.44	0.37	Preschool internalizing problems;	chr5:151740402	chr5:151753992~151767247:+
THCA	cis	rs1062177	0.756	rs2964587	ENSG00000253921.1	CTB-113P19.3	8.51	2.33e-16	1.08e-13	0.44	0.37	Preschool internalizing problems;	chr5:151740411	chr5:151753992~151767247:+
THCA	cis	rs375066	0.935	rs408549	ENSG00000267058.1	RP11-15A1.3	-8.51	2.33e-16	1.08e-13	-0.3	-0.37	Breast cancer;	chr19:43921467	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs398388	ENSG00000267058.1	RP11-15A1.3	-8.51	2.33e-16	1.08e-13	-0.3	-0.37	Breast cancer;	chr19:43921530	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs403137	ENSG00000267058.1	RP11-15A1.3	-8.51	2.33e-16	1.08e-13	-0.3	-0.37	Breast cancer;	chr19:43923474	chr19:43891804~43901805:-
THCA	cis	rs375066	0.869	rs379785	ENSG00000267058.1	RP11-15A1.3	-8.51	2.33e-16	1.08e-13	-0.3	-0.37	Breast cancer;	chr19:43923949	chr19:43891804~43901805:-
THCA	cis	rs1005277	0.579	rs1780133	ENSG00000263064.2	RP11-291L22.7	8.51	2.34e-16	1.08e-13	0.41	0.37	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38448689~38448949:+
THCA	cis	rs2243480	1	rs73142166	ENSG00000273142.1	RP11-458F8.4	-8.51	2.34e-16	1.08e-13	-0.47	-0.37	Diabetic kidney disease;	chr7:65910845	chr7:66902857~66906297:+
THCA	cis	rs12701220	0.553	rs9639882	ENSG00000229043.2	AC091729.9	-8.51	2.35e-16	1.09e-13	-0.49	-0.37	Bronchopulmonary dysplasia;	chr7:1094095	chr7:1160374~1165267:+
THCA	cis	rs950169	0.58	rs11633762	ENSG00000225151.9	GOLGA2P7	-8.51	2.36e-16	1.09e-13	-0.54	-0.37	Schizophrenia;	chr15:84643921	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs58416181	ENSG00000259728.4	LINC00933	8.51	2.37e-16	1.09e-13	0.5	0.37	Schizophrenia;	chr15:84721230	chr15:84570649~84580175:+
THCA	cis	rs1707322	1	rs1707337	ENSG00000234329.1	RP11-767N6.2	-8.51	2.37e-16	1.09e-13	-0.34	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1768807	ENSG00000234329.1	RP11-767N6.2	-8.51	2.37e-16	1.09e-13	-0.34	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45651039~45651826:-
THCA	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-8.51	2.38e-16	1.1e-13	-0.49	-0.37	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
THCA	cis	rs9595066	0.627	rs4432167	ENSG00000227258.4	SMIM2-AS1	-8.51	2.38e-16	1.1e-13	-0.45	-0.37	Schizophrenia;	chr13:44178225	chr13:44110451~44240517:+
THCA	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-8.51	2.38e-16	1.1e-13	-0.45	-0.37	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
THCA	cis	rs9532669	0.926	rs4942007	ENSG00000239827.7	SUGT1P3	-8.51	2.39e-16	1.1e-13	-0.41	-0.37	Cervical cancer;	chr13:40871887	chr13:40908159~40921774:-
THCA	cis	rs1799949	0.965	rs6503726	ENSG00000267681.1	CTD-3199J23.6	-8.51	2.4e-16	1.11e-13	-0.43	-0.37	Menopause (age at onset);	chr17:43132725	chr17:43144956~43145255:+
THCA	cis	rs6504950	0.566	rs7208403	ENSG00000275710.1	RP11-257O5.4	8.51	2.41e-16	1.11e-13	0.42	0.37	Breast cancer;	chr17:54969306	chr17:54964474~54964679:+
THCA	cis	rs1005277	0.579	rs1740732	ENSG00000263064.2	RP11-291L22.7	8.51	2.42e-16	1.12e-13	0.41	0.37	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38448689~38448949:+
THCA	cis	rs465969	0.793	rs34288099	ENSG00000255389.1	C6orf3	-8.51	2.43e-16	1.12e-13	-0.56	-0.37	Psoriasis;	chr6:111424034	chr6:111599875~111602295:+
THCA	cis	rs812925	0.512	rs1177309	ENSG00000271889.1	RP11-493E12.1	8.51	2.44e-16	1.12e-13	0.35	0.37	Immature fraction of reticulocytes;	chr2:61158113	chr2:61151433~61162105:-
THCA	cis	rs2274273	0.662	rs2147970	ENSG00000258413.1	RP11-665C16.6	-8.5	2.44e-16	1.13e-13	-0.52	-0.37	Protein biomarker;	chr14:55193499	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.662	rs66476033	ENSG00000258413.1	RP11-665C16.6	-8.5	2.44e-16	1.13e-13	-0.52	-0.37	Protein biomarker;	chr14:55194145	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.662	rs2094436	ENSG00000258413.1	RP11-665C16.6	-8.5	2.44e-16	1.13e-13	-0.52	-0.37	Protein biomarker;	chr14:55194777	chr14:55262767~55272075:-
THCA	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	8.5	2.45e-16	1.13e-13	0.44	0.37	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
THCA	cis	rs375066	0.935	rs407731	ENSG00000267058.1	RP11-15A1.3	8.5	2.45e-16	1.13e-13	0.3	0.37	Breast cancer;	chr19:43913925	chr19:43891804~43901805:-
THCA	cis	rs4819052	0.851	rs2877018	ENSG00000237664.1	LINC00316	-8.5	2.45e-16	1.13e-13	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238391	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2330012	ENSG00000237664.1	LINC00316	-8.5	2.45e-16	1.13e-13	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238677	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2877019	ENSG00000237664.1	LINC00316	-8.5	2.45e-16	1.13e-13	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238732	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2877020	ENSG00000237664.1	LINC00316	-8.5	2.45e-16	1.13e-13	-0.37	-0.37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238827	chr21:45338590~45341990:-
THCA	cis	rs1043099	0.731	rs5763923	ENSG00000279699.1	RP1-102K2.9	-8.5	2.47e-16	1.14e-13	-0.49	-0.37	Rheumatoid arthritis;	chr22:30279228	chr22:30275215~30276951:-
THCA	cis	rs375066	0.967	rs436249	ENSG00000267058.1	RP11-15A1.3	-8.5	2.47e-16	1.14e-13	-0.29	-0.37	Breast cancer;	chr19:43895413	chr19:43891804~43901805:-
THCA	cis	rs11971779	0.793	rs11764426	ENSG00000273391.1	RP11-634H22.1	8.5	2.48e-16	1.14e-13	0.36	0.37	Diisocyanate-induced asthma;	chr7:139339304	chr7:139359032~139359566:-
THCA	cis	rs42490	0.664	rs43227	ENSG00000251136.7	RP11-37B2.1	-8.5	2.49e-16	1.15e-13	-0.31	-0.37	Leprosy;	chr8:89809351	chr8:89609409~89757727:-
THCA	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	8.5	2.49e-16	1.15e-13	0.41	0.37	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
THCA	cis	rs9828933	0.626	rs73119018	ENSG00000280620.1	SCAANT1	8.5	2.49e-16	1.15e-13	0.67	0.37	Type 2 diabetes;	chr3:63989652	chr3:63911518~63911772:-
THCA	cis	rs34787248	1	rs34787248	ENSG00000219392.1	RP1-265C24.5	-8.5	2.5e-16	1.15e-13	-0.52	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28115628~28116551:+
THCA	cis	rs7849270	1	rs3118625	ENSG00000268707.1	RP11-247A12.7	8.5	2.5e-16	1.15e-13	0.46	0.37	Blood metabolite ratios;	chr9:129110977	chr9:129170434~129170940:+
THCA	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-8.5	2.5e-16	1.15e-13	-0.47	-0.37	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
THCA	cis	rs10847980	0.623	rs28681105	ENSG00000256092.2	RP13-942N8.1	8.5	2.51e-16	1.16e-13	0.55	0.37	Adiponectin levels;	chr12:123390978	chr12:123363868~123366113:+
THCA	cis	rs10847980	0.623	rs28501453	ENSG00000256092.2	RP13-942N8.1	8.5	2.51e-16	1.16e-13	0.55	0.37	Adiponectin levels;	chr12:123392765	chr12:123363868~123366113:+
THCA	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-8.5	2.51e-16	1.16e-13	-0.54	-0.37	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
THCA	cis	rs2274273	1	rs3825613	ENSG00000258413.1	RP11-665C16.6	-8.5	2.51e-16	1.16e-13	-0.48	-0.37	Protein biomarker;	chr14:55126454	chr14:55262767~55272075:-
THCA	cis	rs375066	0.935	rs428505	ENSG00000267058.1	RP11-15A1.3	-8.5	2.52e-16	1.16e-13	-0.3	-0.37	Breast cancer;	chr19:43924759	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs367741	ENSG00000267058.1	RP11-15A1.3	-8.5	2.52e-16	1.16e-13	-0.3	-0.37	Breast cancer;	chr19:43925028	chr19:43891804~43901805:-
THCA	cis	rs2243480	1	rs410128	ENSG00000273142.1	RP11-458F8.4	-8.5	2.52e-16	1.16e-13	-0.47	-0.37	Diabetic kidney disease;	chr7:66138186	chr7:66902857~66906297:+
THCA	cis	rs375066	0.935	rs454559	ENSG00000267058.1	RP11-15A1.3	-8.5	2.53e-16	1.16e-13	-0.29	-0.37	Breast cancer;	chr19:43924968	chr19:43891804~43901805:-
THCA	cis	rs8091660	0.929	rs12606093	ENSG00000278983.1	RP11-426J5.3	8.5	2.53e-16	1.17e-13	0.47	0.37	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48550924	chr18:48564795~48568342:+
THCA	cis	rs9640161	0.617	rs73170169	ENSG00000261305.1	RP4-584D14.7	8.5	2.54e-16	1.17e-13	0.47	0.37	Blood protein levels;Circulating chemerin levels;	chr7:150310947	chr7:150341771~150342607:+
THCA	cis	rs673078	0.562	rs61944668	ENSG00000275409.1	RP11-131L12.4	-8.5	2.55e-16	1.17e-13	-0.45	-0.36	Glucose homeostasis traits;	chr12:118448446	chr12:118430147~118430699:+
THCA	cis	rs4842666	0.834	rs2681492	ENSG00000258302.2	RP11-981P6.1	8.5	2.55e-16	1.18e-13	0.36	0.36	Blood pressure;	chr12:89619312	chr12:89561129~89594878:+
THCA	cis	rs7674212	0.507	rs223331	ENSG00000251288.2	RP11-10L12.2	-8.5	2.56e-16	1.18e-13	-0.48	-0.36	Type 2 diabetes;	chr4:102872408	chr4:102751401~102752641:+
THCA	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-8.5	2.57e-16	1.18e-13	-0.44	-0.36	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
THCA	cis	rs4380275	1	rs4450634	ENSG00000272342.1	RP13-539J13.1	8.5	2.57e-16	1.18e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773257	chr2:739588~740164:-
THCA	cis	rs4380275	1	rs4380275	ENSG00000272342.1	RP13-539J13.1	8.5	2.57e-16	1.18e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773278	chr2:739588~740164:-
THCA	cis	rs4380275	1	rs6548253	ENSG00000272342.1	RP13-539J13.1	8.5	2.57e-16	1.18e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773655	chr2:739588~740164:-
THCA	cis	rs4380275	1	rs73143802	ENSG00000272342.1	RP13-539J13.1	8.5	2.57e-16	1.18e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773826	chr2:739588~740164:-
THCA	cis	rs4380275	1	rs4359695	ENSG00000272342.1	RP13-539J13.1	8.5	2.57e-16	1.18e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774214	chr2:739588~740164:-
THCA	cis	rs4380275	0.931	rs4538239	ENSG00000272342.1	RP13-539J13.1	8.5	2.57e-16	1.18e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774238	chr2:739588~740164:-
THCA	cis	rs10181042	0.514	rs1177283	ENSG00000271889.1	RP11-493E12.1	8.5	2.57e-16	1.18e-13	0.35	0.36	Crohn's disease;	chr2:61121669	chr2:61151433~61162105:-
THCA	cis	rs7727544	0.606	rs72795121	ENSG00000237714.1	P4HA2-AS1	8.5	2.57e-16	1.18e-13	0.48	0.36	Blood metabolite levels;	chr5:132302631	chr5:132184876~132192808:+
THCA	cis	rs736801	0.729	rs1050152	ENSG00000237714.1	P4HA2-AS1	8.5	2.58e-16	1.18e-13	0.49	0.36	Mosquito bite size;Breast cancer;	chr5:132340627	chr5:132184876~132192808:+
THCA	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	8.5	2.58e-16	1.19e-13	0.44	0.36	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
THCA	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-8.5	2.58e-16	1.19e-13	-0.44	-0.36	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-8.5	2.58e-16	1.19e-13	-0.44	-0.36	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
THCA	cis	rs4819052	0.851	rs2838842	ENSG00000237664.1	LINC00316	-8.5	2.59e-16	1.19e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249302	chr21:45338590~45341990:-
THCA	cis	rs8114671	0.562	rs6088653	ENSG00000269202.1	RP4-614O4.12	-8.5	2.59e-16	1.19e-13	-0.31	-0.36	Height;	chr20:34932518	chr20:35201747~35203288:-
THCA	cis	rs7829975	0.714	rs7823757	ENSG00000253893.2	FAM85B	-8.5	2.6e-16	1.2e-13	-0.46	-0.36	Mood instability;	chr8:8812667	chr8:8167819~8226614:-
THCA	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-8.5	2.6e-16	1.2e-13	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
THCA	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-8.5	2.6e-16	1.2e-13	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
THCA	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-8.5	2.6e-16	1.2e-13	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
THCA	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-8.5	2.6e-16	1.2e-13	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
THCA	cis	rs10050311	0.79	rs17751557	ENSG00000251411.1	RP11-397E7.4	-8.5	2.61e-16	1.2e-13	-0.44	-0.36	Insulin-related traits;	chr4:86913454	chr4:86913266~86914817:-
THCA	cis	rs848490	0.656	rs55714086	ENSG00000214293.7	APTR	8.5	2.61e-16	1.2e-13	0.26	0.36	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77807168	chr7:77657660~77696265:-
THCA	cis	rs7849270	0.959	rs3124509	ENSG00000268707.1	RP11-247A12.7	8.5	2.61e-16	1.2e-13	0.45	0.36	Blood metabolite ratios;	chr9:129134720	chr9:129170434~129170940:+
THCA	cis	rs4819052	0.851	rs1999334	ENSG00000215447.6	BX322557.10	-8.5	2.61e-16	1.2e-13	-0.3	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45288052~45291738:+
THCA	cis	rs2274273	1	rs2075603	ENSG00000258413.1	RP11-665C16.6	-8.5	2.62e-16	1.2e-13	-0.49	-0.36	Protein biomarker;	chr14:55143237	chr14:55262767~55272075:-
THCA	cis	rs7665090	1	rs6821119	ENSG00000246560.2	RP11-10L12.4	8.5	2.62e-16	1.2e-13	0.44	0.36	Primary biliary cholangitis;	chr4:102634076	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.934	rs6844332	ENSG00000246560.2	RP11-10L12.4	8.5	2.62e-16	1.2e-13	0.44	0.36	Primary biliary cholangitis;	chr4:102634095	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.967	rs6821133	ENSG00000246560.2	RP11-10L12.4	8.5	2.62e-16	1.2e-13	0.44	0.36	Primary biliary cholangitis;	chr4:102634096	chr4:102828055~102844075:+
THCA	cis	rs150992	0.79	rs45931	ENSG00000248489.1	CTD-2007H13.3	8.5	2.62e-16	1.2e-13	0.35	0.36	Body mass index;	chr5:98978344	chr5:98929171~98995013:+
THCA	cis	rs7851660	0.935	rs12347191	ENSG00000236130.1	PTCSC2	-8.5	2.63e-16	1.21e-13	-0.28	-0.36	Strep throat;	chr9:97857437	chr9:97805935~97810008:-
THCA	cis	rs11971779	0.793	rs11772447	ENSG00000273391.1	RP11-634H22.1	8.49	2.63e-16	1.21e-13	0.35	0.36	Diisocyanate-induced asthma;	chr7:139348843	chr7:139359032~139359566:-
THCA	cis	rs9532669	0.89	rs9532627	ENSG00000239827.7	SUGT1P3	-8.49	2.64e-16	1.21e-13	-0.4	-0.36	Cervical cancer;	chr13:40874811	chr13:40908159~40921774:-
THCA	cis	rs4819052	0.851	rs8131143	ENSG00000237664.1	LINC00316	8.49	2.64e-16	1.21e-13	0.36	0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251731	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs1999335	ENSG00000237664.1	LINC00316	-8.49	2.64e-16	1.21e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250698	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838844	ENSG00000237664.1	LINC00316	-8.49	2.64e-16	1.21e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250818	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838848	ENSG00000237664.1	LINC00316	-8.49	2.64e-16	1.21e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251102	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838849	ENSG00000237664.1	LINC00316	-8.49	2.64e-16	1.21e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251112	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs7275870	ENSG00000237664.1	LINC00316	-8.49	2.64e-16	1.21e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251299	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs7275874	ENSG00000237664.1	LINC00316	-8.49	2.64e-16	1.21e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251308	chr21:45338590~45341990:-
THCA	cis	rs8072100	0.875	rs7208530	ENSG00000228782.6	CTD-2026D20.3	8.49	2.65e-16	1.22e-13	0.33	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47466741	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.875	rs12451409	ENSG00000228782.6	CTD-2026D20.3	8.49	2.65e-16	1.22e-13	0.33	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47467490	chr17:47450568~47492492:-
THCA	cis	rs150992	0.64	rs326485	ENSG00000248489.1	CTD-2007H13.3	8.49	2.65e-16	1.22e-13	0.36	0.36	Body mass index;	chr5:98845717	chr5:98929171~98995013:+
THCA	cis	rs1062177	0.855	rs62395861	ENSG00000253921.1	CTB-113P19.3	-8.49	2.67e-16	1.23e-13	-0.45	-0.36	Preschool internalizing problems;	chr5:151889709	chr5:151753992~151767247:+
THCA	cis	rs1062177	0.95	rs59580263	ENSG00000253921.1	CTB-113P19.3	-8.49	2.67e-16	1.23e-13	-0.45	-0.36	Preschool internalizing problems;	chr5:151890016	chr5:151753992~151767247:+
THCA	cis	rs2921036	0.529	rs2979192	ENSG00000253893.2	FAM85B	-8.49	2.68e-16	1.23e-13	-0.48	-0.36	Neuroticism;	chr8:8480637	chr8:8167819~8226614:-
THCA	cis	rs7665090	1	rs11727546	ENSG00000246560.2	RP11-10L12.4	8.49	2.68e-16	1.23e-13	0.43	0.36	Primary biliary cholangitis;	chr4:102636507	chr4:102828055~102844075:+
THCA	cis	rs2243480	1	rs34193460	ENSG00000273142.1	RP11-458F8.4	-8.49	2.68e-16	1.23e-13	-0.47	-0.36	Diabetic kidney disease;	chr7:65928123	chr7:66902857~66906297:+
THCA	cis	rs2243480	1	rs57057549	ENSG00000273142.1	RP11-458F8.4	-8.49	2.68e-16	1.23e-13	-0.47	-0.36	Diabetic kidney disease;	chr7:65940751	chr7:66902857~66906297:+
THCA	cis	rs11159086	1	rs72730186	ENSG00000270000.1	RP3-449M8.9	8.49	2.68e-16	1.23e-13	0.46	0.36	Advanced glycation end-product levels;	chr14:74475610	chr14:74471930~74472360:-
THCA	cis	rs748404	0.56	rs570933	ENSG00000205771.5	CATSPER2P1	-8.49	2.69e-16	1.23e-13	-0.38	-0.36	Lung cancer;	chr15:43531832	chr15:43726918~43747094:-
THCA	cis	rs11051970	0.527	rs7309590	ENSG00000274964.1	RP11-817I4.1	-8.49	2.69e-16	1.24e-13	-0.44	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32337915	chr12:32339368~32340724:+
THCA	cis	rs516805	0.748	rs562616	ENSG00000279453.1	RP3-425C14.4	-8.49	2.7e-16	1.24e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122467041	chr6:122436789~122439223:-
THCA	cis	rs944289	0.966	rs1169124	ENSG00000257826.1	RP11-116N8.4	-8.49	2.7e-16	1.24e-13	-0.39	-0.36	Thyroid cancer;	chr14:36150082	chr14:36061026~36067190:-
THCA	cis	rs944289	0.899	rs1169125	ENSG00000257826.1	RP11-116N8.4	-8.49	2.7e-16	1.24e-13	-0.39	-0.36	Thyroid cancer;	chr14:36150560	chr14:36061026~36067190:-
THCA	cis	rs944289	0.966	rs1169129	ENSG00000257826.1	RP11-116N8.4	-8.49	2.7e-16	1.24e-13	-0.39	-0.36	Thyroid cancer;	chr14:36152619	chr14:36061026~36067190:-
THCA	cis	rs748404	0.586	rs2584700	ENSG00000205771.5	CATSPER2P1	-8.49	2.71e-16	1.24e-13	-0.39	-0.36	Lung cancer;	chr15:43393134	chr15:43726918~43747094:-
THCA	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-8.49	2.72e-16	1.25e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
THCA	cis	rs1707322	0.506	rs2991983	ENSG00000234329.1	RP11-767N6.2	-8.49	2.72e-16	1.25e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.717	rs3014249	ENSG00000234329.1	RP11-767N6.2	-8.49	2.72e-16	1.25e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45651039~45651826:-
THCA	cis	rs17711722	0.565	rs4275112	ENSG00000164669.11	INTS4P1	8.49	2.74e-16	1.26e-13	0.46	0.36	Calcium levels;	chr7:65733651	chr7:65141225~65234216:+
THCA	cis	rs375066	0.806	rs415168	ENSG00000267058.1	RP11-15A1.3	-8.49	2.74e-16	1.26e-13	-0.29	-0.36	Breast cancer;	chr19:43898422	chr19:43891804~43901805:-
THCA	cis	rs1501911	0.53	rs193072	ENSG00000248489.1	CTD-2007H13.3	8.49	2.74e-16	1.26e-13	0.36	0.36	Lung function (FEV1/FVC);	chr5:98822171	chr5:98929171~98995013:+
THCA	cis	rs4713118	0.662	rs9393881	ENSG00000226314.6	ZNF192P1	-8.49	2.74e-16	1.26e-13	-0.47	-0.36	Parkinson's disease;	chr6:28055973	chr6:28161781~28169594:+
THCA	cis	rs11051970	0.918	rs12229856	ENSG00000274964.1	RP11-817I4.1	-8.49	2.75e-16	1.26e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32378286	chr12:32339368~32340724:+
THCA	cis	rs748404	0.56	rs1869258	ENSG00000205771.5	CATSPER2P1	-8.49	2.75e-16	1.26e-13	-0.38	-0.36	Lung cancer;	chr15:43511423	chr15:43726918~43747094:-
THCA	cis	rs9813712	0.571	rs9289368	ENSG00000228252.7	COL6A4P2	-8.49	2.76e-16	1.26e-13	-0.37	-0.36	Response to amphetamines;	chr3:130225562	chr3:130212823~130273806:+
THCA	cis	rs9813712	0.571	rs6774141	ENSG00000228252.7	COL6A4P2	-8.49	2.76e-16	1.26e-13	-0.37	-0.36	Response to amphetamines;	chr3:130225599	chr3:130212823~130273806:+
THCA	cis	rs4718428	0.705	rs12536410	ENSG00000230295.1	RP11-458F8.2	-8.49	2.76e-16	1.27e-13	-0.32	-0.36	Corneal structure;	chr7:66789303	chr7:66880708~66882981:+
THCA	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-8.49	2.76e-16	1.27e-13	-0.48	-0.36	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
THCA	cis	rs7849270	1	rs3739847	ENSG00000268707.1	RP11-247A12.7	8.49	2.76e-16	1.27e-13	0.45	0.36	Blood metabolite ratios;	chr9:129149295	chr9:129170434~129170940:+
THCA	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	8.49	2.77e-16	1.27e-13	0.6	0.36	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
THCA	cis	rs860295	1	rs822478	ENSG00000225855.5	RUSC1-AS1	-8.49	2.77e-16	1.27e-13	-0.25	-0.36	Body mass index;	chr1:155824178	chr1:155316863~155324176:-
THCA	cis	rs150992	0.587	rs75001231	ENSG00000248489.1	CTD-2007H13.3	8.49	2.77e-16	1.27e-13	0.35	0.36	Body mass index;	chr5:98990085	chr5:98929171~98995013:+
THCA	cis	rs150992	0.609	rs2927647	ENSG00000248489.1	CTD-2007H13.3	8.49	2.77e-16	1.27e-13	0.35	0.36	Body mass index;	chr5:98990161	chr5:98929171~98995013:+
THCA	cis	rs375066	0.934	rs411803	ENSG00000267058.1	RP11-15A1.3	8.49	2.77e-16	1.27e-13	0.3	0.36	Breast cancer;	chr19:43928688	chr19:43891804~43901805:-
THCA	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-8.49	2.77e-16	1.27e-13	-0.75	-0.36	Gout;	chr7:66732812	chr7:66654538~66669855:+
THCA	cis	rs516805	0.781	rs574462	ENSG00000279453.1	RP3-425C14.4	-8.49	2.78e-16	1.27e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122404863	chr6:122436789~122439223:-
THCA	cis	rs11603691	1	rs11602266	ENSG00000254662.1	RP11-872D17.4	-8.49	2.78e-16	1.27e-13	-0.68	-0.36	Low high density lipoprotein cholesterol levels;	chr11:57327035	chr11:57325603~57327958:+
THCA	cis	rs2946504	0.861	rs2946501	ENSG00000251468.2	RP11-369K16.1	8.49	2.78e-16	1.27e-13	0.44	0.36	Type 2 diabetes;	chr8:12955922	chr8:12958387~12962200:+
THCA	cis	rs16846053	0.515	rs6432688	ENSG00000227403.1	AC009299.3	-8.49	2.78e-16	1.28e-13	-0.58	-0.36	Blood osmolality (transformed sodium);	chr2:161522146	chr2:161244739~161249050:+
THCA	cis	rs7621025	0.5	rs16844241	ENSG00000239213.4	NCK1-AS1	-8.49	2.79e-16	1.28e-13	-0.39	-0.36	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136841726~136862054:-
THCA	cis	rs934734	0.532	rs7569113	ENSG00000237979.1	AC007389.1	8.49	2.79e-16	1.28e-13	0.41	0.36	Rheumatoid arthritis;	chr2:65429907	chr2:65500993~65502138:-
THCA	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	8.49	2.8e-16	1.28e-13	0.36	0.36	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
THCA	cis	rs5769707	0.837	rs5769709	ENSG00000235111.1	RP1-29C18.8	-8.49	2.8e-16	1.29e-13	-0.43	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49612657~49615716:-
THCA	cis	rs7849270	0.842	rs184457	ENSG00000268707.1	RP11-247A12.7	8.49	2.8e-16	1.29e-13	0.48	0.36	Blood metabolite ratios;	chr9:129177740	chr9:129170434~129170940:+
THCA	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-8.49	2.81e-16	1.29e-13	-0.41	-0.36	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
THCA	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	8.49	2.81e-16	1.29e-13	0.44	0.36	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
THCA	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	8.49	2.81e-16	1.29e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
THCA	cis	rs748404	0.56	rs529611	ENSG00000205771.5	CATSPER2P1	-8.49	2.81e-16	1.29e-13	-0.38	-0.36	Lung cancer;	chr15:43513790	chr15:43726918~43747094:-
THCA	cis	rs4718428	0.705	rs68168107	ENSG00000230295.1	RP11-458F8.2	-8.49	2.82e-16	1.29e-13	-0.32	-0.36	Corneal structure;	chr7:66790251	chr7:66880708~66882981:+
THCA	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	8.49	2.82e-16	1.29e-13	0.41	0.36	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
THCA	cis	rs8114671	0.869	rs2145559	ENSG00000269202.1	RP4-614O4.12	8.49	2.83e-16	1.3e-13	0.31	0.36	Height;	chr20:35063922	chr20:35201747~35203288:-
THCA	cis	rs673078	0.607	rs17512525	ENSG00000275409.1	RP11-131L12.4	-8.48	2.84e-16	1.3e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118315467	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs17440774	ENSG00000275409.1	RP11-131L12.4	-8.48	2.84e-16	1.3e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118316155	chr12:118430147~118430699:+
THCA	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-8.48	2.84e-16	1.3e-13	-0.62	-0.36	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
THCA	cis	rs55665837	1	rs11023215	ENSG00000251991.1	RNU7-49P	8.48	2.84e-16	1.3e-13	0.41	0.36	Vitamin D levels;	chr11:14415424	chr11:14478892~14478953:+
THCA	cis	rs516805	0.748	rs563084	ENSG00000279453.1	RP3-425C14.4	8.48	2.84e-16	1.3e-13	0.37	0.36	Lymphocyte counts;	chr6:122397105	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs512063	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122409206	chr6:122436789~122439223:-
THCA	cis	rs516805	0.706	rs572674	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122411239	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs492250	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122421808	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs9320872	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122425438	chr6:122436789~122439223:-
THCA	cis	rs516805	0.63	rs505749	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122425751	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs502252	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122436330	chr6:122436789~122439223:-
THCA	cis	rs516805	0.706	rs577049	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122438204	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs577838	ENSG00000279453.1	RP3-425C14.4	-8.48	2.84e-16	1.3e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122438270	chr6:122436789~122439223:-
THCA	cis	rs1707322	0.89	rs2297883	ENSG00000234329.1	RP11-767N6.2	-8.48	2.84e-16	1.3e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1707338	ENSG00000234329.1	RP11-767N6.2	-8.48	2.84e-16	1.3e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs1707339	ENSG00000234329.1	RP11-767N6.2	-8.48	2.84e-16	1.3e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1768818	ENSG00000234329.1	RP11-767N6.2	-8.48	2.84e-16	1.3e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1768817	ENSG00000234329.1	RP11-767N6.2	-8.48	2.84e-16	1.3e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785470	ENSG00000234329.1	RP11-767N6.2	-8.48	2.84e-16	1.3e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45651039~45651826:-
THCA	cis	rs4718428	0.705	rs28648401	ENSG00000230295.1	RP11-458F8.2	-8.48	2.84e-16	1.3e-13	-0.32	-0.36	Corneal structure;	chr7:66902145	chr7:66880708~66882981:+
THCA	cis	rs4718428	0.607	rs66954441	ENSG00000230295.1	RP11-458F8.2	-8.48	2.84e-16	1.3e-13	-0.32	-0.36	Corneal structure;	chr7:66904222	chr7:66880708~66882981:+
THCA	cis	rs7674212	0.507	rs223471	ENSG00000246560.2	RP11-10L12.4	8.48	2.85e-16	1.31e-13	0.45	0.36	Type 2 diabetes;	chr4:102777629	chr4:102828055~102844075:+
THCA	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-8.48	2.85e-16	1.31e-13	-0.46	-0.36	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
THCA	cis	rs13129231	0.92	rs17676840	ENSG00000206820.1	RNU1-138P	8.48	2.86e-16	1.31e-13	0.44	0.36	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113439469	chr4:113420323~113420486:+
THCA	cis	rs8114671	0.562	rs6088655	ENSG00000269202.1	RP4-614O4.12	-8.48	2.87e-16	1.31e-13	-0.31	-0.36	Height;	chr20:34940035	chr20:35201747~35203288:-
THCA	cis	rs2032366	0.606	rs9783923	ENSG00000267279.1	RP11-879F14.2	-8.48	2.88e-16	1.32e-13	-0.39	-0.36	Obesity-related traits;	chr18:61635518	chr18:61585746~61606916:-
THCA	cis	rs516805	0.748	rs155460	ENSG00000279453.1	RP3-425C14.4	-8.48	2.88e-16	1.32e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122499180	chr6:122436789~122439223:-
THCA	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-8.48	2.88e-16	1.32e-13	-0.37	-0.36	QT interval;	chr12:29306357	chr12:29280418~29317848:-
THCA	cis	rs17507216	0.56	rs2871011	ENSG00000278603.1	RP13-608F4.5	8.48	2.89e-16	1.32e-13	0.51	0.36	Excessive daytime sleepiness;	chr15:82560792	chr15:82472203~82472426:+
THCA	cis	rs7727544	0.548	rs35696821	ENSG00000237714.1	P4HA2-AS1	8.48	2.91e-16	1.33e-13	0.46	0.36	Blood metabolite levels;	chr5:132172324	chr5:132184876~132192808:+
THCA	cis	rs7665090	0.967	rs13106304	ENSG00000246560.2	RP11-10L12.4	8.48	2.91e-16	1.33e-13	0.43	0.36	Primary biliary cholangitis;	chr4:102633818	chr4:102828055~102844075:+
THCA	cis	rs28510890	0.547	rs10152637	ENSG00000260337.3	RP11-386M24.6	8.48	2.92e-16	1.34e-13	0.47	0.36	Lung cancer in ever smokers;	chr15:92602409	chr15:92592574~92596462:-
THCA	cis	rs4819052	1	rs4819052	ENSG00000237664.1	LINC00316	-8.48	2.92e-16	1.34e-13	-0.39	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45279862	chr21:45338590~45341990:-
THCA	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	8.48	2.92e-16	1.34e-13	0.35	0.36	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
THCA	cis	rs2243480	1	rs35542501	ENSG00000226824.5	RP4-756H11.3	-8.48	2.93e-16	1.34e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65966228	chr7:66654538~66669855:+
THCA	cis	rs7727544	0.582	rs3792894	ENSG00000237714.1	P4HA2-AS1	8.48	2.93e-16	1.34e-13	0.46	0.36	Blood metabolite levels;	chr5:132211578	chr5:132184876~132192808:+
THCA	cis	rs1707322	0.717	rs1972410	ENSG00000234329.1	RP11-767N6.2	8.48	2.93e-16	1.34e-13	0.35	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45651039~45651826:-
THCA	cis	rs6844153	1	rs74356465	ENSG00000240005.4	RP11-293A21.1	-8.48	2.93e-16	1.34e-13	-0.49	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26902405	chr4:26859806~26860599:-
THCA	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-8.48	2.94e-16	1.34e-13	-0.45	-0.36	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
THCA	cis	rs9341808	0.529	rs9350851	ENSG00000272129.1	RP11-250B2.6	8.48	2.94e-16	1.34e-13	0.45	0.36	Sitting height ratio;	chr6:80349471	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.529	rs9352826	ENSG00000272129.1	RP11-250B2.6	8.48	2.94e-16	1.34e-13	0.45	0.36	Sitting height ratio;	chr6:80349654	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.529	rs4706840	ENSG00000272129.1	RP11-250B2.6	8.48	2.94e-16	1.35e-13	0.45	0.36	Sitting height ratio;	chr6:80348052	chr6:80355424~80356859:+
THCA	cis	rs4819052	0.655	rs2330102	ENSG00000215447.6	BX322557.10	-8.48	2.95e-16	1.35e-13	-0.3	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45271053	chr21:45288052~45291738:+
THCA	cis	rs4819052	0.679	rs8132135	ENSG00000215447.6	BX322557.10	-8.48	2.95e-16	1.35e-13	-0.3	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274867	chr21:45288052~45291738:+
THCA	cis	rs9500256	1	rs9500256	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-8.48	2.96e-16	1.35e-13	-0.37	-0.36	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57855891~57856468:-
THCA	cis	rs42490	0.625	rs427854	ENSG00000251136.7	RP11-37B2.1	-8.48	2.96e-16	1.35e-13	-0.32	-0.36	Leprosy;	chr8:89843518	chr8:89609409~89757727:-
THCA	cis	rs7849270	1	rs3118632	ENSG00000268707.1	RP11-247A12.7	8.48	2.96e-16	1.36e-13	0.45	0.36	Blood metabolite ratios;	chr9:129139005	chr9:129170434~129170940:+
THCA	cis	rs6545883	0.507	rs34668697	ENSG00000271889.1	RP11-493E12.1	-8.48	2.97e-16	1.36e-13	-0.35	-0.36	Tuberculosis;	chr2:61341214	chr2:61151433~61162105:-
THCA	cis	rs16846053	0.515	rs918964	ENSG00000227403.1	AC009299.3	-8.48	2.98e-16	1.36e-13	-0.58	-0.36	Blood osmolality (transformed sodium);	chr2:161440405	chr2:161244739~161249050:+
THCA	cis	rs150992	0.609	rs2927648	ENSG00000248489.1	CTD-2007H13.3	8.48	2.98e-16	1.36e-13	0.35	0.36	Body mass index;	chr5:98990273	chr5:98929171~98995013:+
THCA	cis	rs6597981	0.592	rs10902218	ENSG00000255284.1	AP006621.5	-8.48	2.98e-16	1.36e-13	-0.25	-0.36	Breast cancer;	chr11:743813	chr11:777578~784297:+
THCA	cis	rs2032366	0.63	rs7235404	ENSG00000267279.1	RP11-879F14.2	8.48	2.98e-16	1.36e-13	0.39	0.36	Obesity-related traits;	chr18:61628753	chr18:61585746~61606916:-
THCA	cis	rs4819052	0.808	rs2838825	ENSG00000215447.6	BX322557.10	-8.48	2.99e-16	1.37e-13	-0.31	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45288052~45291738:+
THCA	cis	rs1062177	0.774	rs2964574	ENSG00000253921.1	CTB-113P19.3	-8.48	2.99e-16	1.37e-13	-0.44	-0.36	Preschool internalizing problems;	chr5:151776150	chr5:151753992~151767247:+
THCA	cis	rs4819052	0.851	rs2838845	ENSG00000237664.1	LINC00316	-8.48	2.99e-16	1.37e-13	-0.37	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250897	chr21:45338590~45341990:-
THCA	cis	rs1707322	0.964	rs785483	ENSG00000234329.1	RP11-767N6.2	-8.48	2.99e-16	1.37e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs796773	ENSG00000234329.1	RP11-767N6.2	-8.48	2.99e-16	1.37e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.896	rs785518	ENSG00000234329.1	RP11-767N6.2	-8.48	2.99e-16	1.37e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785519	ENSG00000234329.1	RP11-767N6.2	-8.48	2.99e-16	1.37e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45651039~45651826:-
THCA	cis	rs638893	0.673	rs538645	ENSG00000278376.1	RP11-158I9.8	8.48	2.99e-16	1.37e-13	0.31	0.36	Vitiligo;	chr11:118840360	chr11:118791254~118793137:+
THCA	cis	rs11051970	0.513	rs2892655	ENSG00000274964.1	RP11-817I4.1	-8.48	3e-16	1.37e-13	-0.44	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32337295	chr12:32339368~32340724:+
THCA	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	8.48	3e-16	1.37e-13	0.69	0.36	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	8.48	3e-16	1.37e-13	0.69	0.36	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
THCA	cis	rs17684571	0.751	rs4415160	ENSG00000231441.1	RP11-472M19.2	-8.48	3.02e-16	1.38e-13	-0.47	-0.36	Schizophrenia;	chr6:56821424	chr6:56844002~56864078:+
THCA	cis	rs11690935	0.549	rs796839	ENSG00000228389.1	AC068039.4	-8.48	3.02e-16	1.38e-13	-0.38	-0.36	Schizophrenia;	chr2:172051486	chr2:171773482~171775844:+
THCA	cis	rs11690935	0.549	rs2129475	ENSG00000228389.1	AC068039.4	-8.48	3.02e-16	1.38e-13	-0.38	-0.36	Schizophrenia;	chr2:172052044	chr2:171773482~171775844:+
THCA	cis	rs7945705	0.791	rs6484484	ENSG00000254860.4	TMEM9B-AS1	-8.48	3.02e-16	1.38e-13	-0.39	-0.36	Hemoglobin concentration;	chr11:8795659	chr11:8964675~8977527:+
THCA	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-8.48	3.02e-16	1.38e-13	-0.44	-0.36	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
THCA	cis	rs934734	0.532	rs2028150	ENSG00000237979.1	AC007389.1	-8.48	3.03e-16	1.38e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65427878	chr2:65500993~65502138:-
THCA	cis	rs934734	0.532	rs2028151	ENSG00000237979.1	AC007389.1	-8.48	3.03e-16	1.38e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65428479	chr2:65500993~65502138:-
THCA	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-8.48	3.03e-16	1.39e-13	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
THCA	cis	rs2408955	0.541	rs11168428	ENSG00000258273.1	RP11-370I10.4	8.48	3.03e-16	1.39e-13	0.47	0.36	Glycated hemoglobin levels;	chr12:48153345	chr12:48333755~48333901:-
THCA	cis	rs2243480	1	rs34815098	ENSG00000226824.5	RP4-756H11.3	-8.48	3.05e-16	1.39e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65827267	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35735127	ENSG00000226824.5	RP4-756H11.3	-8.48	3.05e-16	1.39e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65835436	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.901	rs35256305	ENSG00000226824.5	RP4-756H11.3	-8.48	3.05e-16	1.39e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65841418	chr7:66654538~66669855:+
THCA	cis	rs2243480	0.803	rs34004500	ENSG00000226824.5	RP4-756H11.3	-8.48	3.05e-16	1.39e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65847191	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35825738	ENSG00000226824.5	RP4-756H11.3	-8.48	3.05e-16	1.39e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65853040	chr7:66654538~66669855:+
THCA	cis	rs7727544	0.582	rs7703009	ENSG00000237714.1	P4HA2-AS1	8.47	3.06e-16	1.4e-13	0.46	0.36	Blood metabolite levels;	chr5:132216692	chr5:132184876~132192808:+
THCA	cis	rs3096299	0.933	rs28608022	ENSG00000274627.1	RP11-104N10.2	8.47	3.06e-16	1.4e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89387884	chr16:89516797~89522217:+
THCA	cis	rs12701220	0.522	rs1881116	ENSG00000229043.2	AC091729.9	-8.47	3.07e-16	1.4e-13	-0.43	-0.36	Bronchopulmonary dysplasia;	chr7:1014322	chr7:1160374~1165267:+
THCA	cis	rs7665090	0.905	rs2866410	ENSG00000246560.2	RP11-10L12.4	8.47	3.08e-16	1.4e-13	0.44	0.36	Primary biliary cholangitis;	chr4:102633178	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.936	rs2866411	ENSG00000246560.2	RP11-10L12.4	8.47	3.08e-16	1.4e-13	0.44	0.36	Primary biliary cholangitis;	chr4:102633183	chr4:102828055~102844075:+
THCA	cis	rs7665090	0.936	rs2866412	ENSG00000246560.2	RP11-10L12.4	8.47	3.08e-16	1.4e-13	0.44	0.36	Primary biliary cholangitis;	chr4:102633193	chr4:102828055~102844075:+
THCA	cis	rs2243480	0.803	rs35480979	ENSG00000226824.5	RP4-756H11.3	-8.47	3.08e-16	1.4e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65892097	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs35391607	ENSG00000226824.5	RP4-756H11.3	-8.47	3.08e-16	1.4e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65895842	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-8.47	3.08e-16	1.4e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-8.47	3.08e-16	1.4e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
THCA	cis	rs7712401	0.511	rs30068	ENSG00000263432.2	RN7SL689P	8.47	3.08e-16	1.4e-13	0.4	0.36	Mean platelet volume;	chr5:122957914	chr5:123022487~123022783:-
THCA	cis	rs7674212	0.507	rs223361	ENSG00000251288.2	RP11-10L12.2	-8.47	3.09e-16	1.41e-13	-0.49	-0.36	Type 2 diabetes;	chr4:102848147	chr4:102751401~102752641:+
THCA	cis	rs9813712	0.571	rs6795143	ENSG00000228252.7	COL6A4P2	-8.47	3.09e-16	1.41e-13	-0.37	-0.36	Response to amphetamines;	chr3:130224355	chr3:130212823~130273806:+
THCA	cis	rs9813712	0.571	rs9289366	ENSG00000228252.7	COL6A4P2	-8.47	3.09e-16	1.41e-13	-0.37	-0.36	Response to amphetamines;	chr3:130225267	chr3:130212823~130273806:+
THCA	cis	rs9813712	0.571	rs9289367	ENSG00000228252.7	COL6A4P2	-8.47	3.09e-16	1.41e-13	-0.37	-0.36	Response to amphetamines;	chr3:130225286	chr3:130212823~130273806:+
THCA	cis	rs748404	0.587	rs690276	ENSG00000205771.5	CATSPER2P1	-8.47	3.1e-16	1.41e-13	-0.38	-0.36	Lung cancer;	chr15:43412360	chr15:43726918~43747094:-
THCA	cis	rs6565180	0.791	rs4247355	ENSG00000183604.13	SMG1P5	8.47	3.1e-16	1.41e-13	0.39	0.36	Tonsillectomy;	chr16:30380778	chr16:30267553~30335374:-
THCA	cis	rs375066	0.901	rs438517	ENSG00000267058.1	RP11-15A1.3	-8.47	3.1e-16	1.41e-13	-0.29	-0.36	Breast cancer;	chr19:43915506	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs446674	ENSG00000267058.1	RP11-15A1.3	-8.47	3.1e-16	1.41e-13	-0.29	-0.36	Breast cancer;	chr19:43916855	chr19:43891804~43901805:-
THCA	cis	rs1005277	0.579	rs2474595	ENSG00000263064.2	RP11-291L22.7	-8.47	3.1e-16	1.42e-13	-0.41	-0.36	Extrinsic epigenetic age acceleration;	chr10:38137854	chr10:38448689~38448949:+
THCA	cis	rs7829975	0.714	rs11777085	ENSG00000253893.2	FAM85B	-8.47	3.11e-16	1.42e-13	-0.46	-0.36	Mood instability;	chr8:8814919	chr8:8167819~8226614:-
THCA	cis	rs7569084	0.663	rs1437461	ENSG00000234255.7	AC012370.3	8.47	3.12e-16	1.42e-13	0.42	0.36	Sum eosinophil basophil counts;	chr2:65452578	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.687	rs7562559	ENSG00000234255.7	AC012370.3	8.47	3.12e-16	1.42e-13	0.42	0.36	Sum eosinophil basophil counts;	chr2:65452719	chr2:65439888~65456571:-
THCA	cis	rs12701220	0.604	rs34904312	ENSG00000229043.2	AC091729.9	-8.47	3.12e-16	1.42e-13	-0.49	-0.36	Bronchopulmonary dysplasia;	chr7:1096247	chr7:1160374~1165267:+
THCA	cis	rs950169	0.544	rs2036949	ENSG00000225151.9	GOLGA2P7	-8.47	3.13e-16	1.43e-13	-0.54	-0.36	Schizophrenia;	chr15:84620374	chr15:84199311~84230136:-
THCA	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-8.47	3.14e-16	1.43e-13	-0.43	-0.36	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.733	rs10111844	ENSG00000200714.1	Y_RNA	8.47	3.14e-16	1.43e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65690374	chr8:65592731~65592820:+
THCA	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	8.47	3.14e-16	1.43e-13	0.49	0.36	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
THCA	cis	rs150992	0.711	rs326489	ENSG00000248489.1	CTD-2007H13.3	8.47	3.15e-16	1.44e-13	0.36	0.36	Body mass index;	chr5:98841105	chr5:98929171~98995013:+
THCA	cis	rs4718428	0.705	rs12698547	ENSG00000230295.1	RP11-458F8.2	-8.47	3.15e-16	1.44e-13	-0.32	-0.36	Corneal structure;	chr7:66813271	chr7:66880708~66882981:+
THCA	cis	rs2439831	0.85	rs7169988	ENSG00000249839.1	AC011330.5	-8.47	3.16e-16	1.44e-13	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43768237	chr15:43663654~43684339:-
THCA	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-8.47	3.16e-16	1.44e-13	-0.41	-0.36	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
THCA	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-8.47	3.16e-16	1.44e-13	-0.38	-0.36	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
THCA	cis	rs9828933	0.882	rs3733127	ENSG00000280620.1	SCAANT1	8.47	3.17e-16	1.45e-13	0.6	0.36	Type 2 diabetes;	chr3:64002498	chr3:63911518~63911772:-
THCA	cis	rs10463554	0.892	rs1438687	ENSG00000175749.11	EIF3KP1	8.47	3.19e-16	1.46e-13	0.48	0.36	Parkinson's disease;	chr5:102968792	chr5:103032376~103033031:+
THCA	cis	rs875971	0.54	rs781152	ENSG00000237310.1	GS1-124K5.4	8.47	3.2e-16	1.46e-13	0.27	0.36	Aortic root size;	chr7:66014585	chr7:66493706~66495474:+
THCA	cis	rs17711722	0.727	rs781151	ENSG00000237310.1	GS1-124K5.4	8.47	3.2e-16	1.46e-13	0.27	0.36	Calcium levels;	chr7:66014891	chr7:66493706~66495474:+
THCA	cis	rs2439831	0.85	rs7181039	ENSG00000249839.1	AC011330.5	-8.47	3.21e-16	1.46e-13	-0.6	-0.36	Lung cancer in ever smokers;	chr15:43886914	chr15:43663654~43684339:-
THCA	cis	rs7211079	0.879	rs61357240	ENSG00000275479.1	RP11-334C17.6	8.47	3.21e-16	1.46e-13	0.36	0.36	Myocardial infarction;	chr17:80157976	chr17:80149627~80149798:+
THCA	cis	rs73186030	0.591	rs56098325	ENSG00000272758.4	RP11-299J3.8	8.47	3.22e-16	1.47e-13	0.47	0.36	Serum parathyroid hormone levels;	chr3:122342362	chr3:122416207~122443180:+
THCA	cis	rs4819052	0.851	rs35064782	ENSG00000237664.1	LINC00316	-8.47	3.23e-16	1.47e-13	-0.37	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254445	chr21:45338590~45341990:-
THCA	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	8.47	3.23e-16	1.47e-13	0.43	0.36	Temperament;	chr17:13996939	chr17:14024514~14025488:+
THCA	cis	rs8114671	0.562	rs725521	ENSG00000269202.1	RP4-614O4.12	-8.47	3.23e-16	1.47e-13	-0.3	-0.36	Height;	chr20:34928268	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6087651	ENSG00000269202.1	RP4-614O4.12	-8.47	3.23e-16	1.47e-13	-0.3	-0.36	Height;	chr20:34930550	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6119545	ENSG00000269202.1	RP4-614O4.12	-8.47	3.23e-16	1.47e-13	-0.3	-0.36	Height;	chr20:34935066	chr20:35201747~35203288:-
THCA	cis	rs1799949	0.965	rs8176198	ENSG00000267681.1	CTD-3199J23.6	-8.47	3.24e-16	1.48e-13	-0.42	-0.36	Menopause (age at onset);	chr17:43078520	chr17:43144956~43145255:+
THCA	cis	rs6844153	1	rs57686546	ENSG00000240005.4	RP11-293A21.1	-8.47	3.24e-16	1.48e-13	-0.49	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915162	chr4:26859806~26860599:-
THCA	cis	rs17772222	0.675	rs845769	ENSG00000258789.1	RP11-507K2.3	8.47	3.26e-16	1.48e-13	0.35	0.36	Coronary artery calcification;	chr14:88461455	chr14:88551597~88552493:+
THCA	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	8.47	3.26e-16	1.48e-13	0.71	0.36	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
THCA	cis	rs4819052	0.851	rs13048789	ENSG00000237664.1	LINC00316	-8.47	3.26e-16	1.49e-13	-0.37	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240799	chr21:45338590~45341990:-
THCA	cis	rs673078	0.66	rs17440364	ENSG00000275409.1	RP11-131L12.4	-8.47	3.27e-16	1.49e-13	-0.46	-0.36	Glucose homeostasis traits;	chr12:118186613	chr12:118430147~118430699:+
THCA	cis	rs1062177	0.756	rs2915827	ENSG00000253921.1	CTB-113P19.3	8.47	3.28e-16	1.5e-13	0.44	0.36	Preschool internalizing problems;	chr5:151740144	chr5:151753992~151767247:+
THCA	cis	rs516805	0.748	rs155467	ENSG00000279453.1	RP3-425C14.4	-8.46	3.3e-16	1.5e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122512451	chr6:122436789~122439223:-
THCA	cis	rs1707322	0.686	rs3014242	ENSG00000234329.1	RP11-767N6.2	-8.46	3.3e-16	1.5e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45651039~45651826:-
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000228039.3	KB-1125A3.10	-8.46	3.32e-16	1.51e-13	-0.5	-0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23963780~23964374:+
THCA	cis	rs832187	0.629	rs59971314	ENSG00000280620.1	SCAANT1	8.46	3.33e-16	1.52e-13	0.49	0.36	Schizophrenia;	chr3:63928942	chr3:63911518~63911772:-
THCA	cis	rs950169	0.58	rs1061737	ENSG00000225151.9	GOLGA2P7	-8.46	3.34e-16	1.52e-13	-0.54	-0.36	Schizophrenia;	chr15:84640559	chr15:84199311~84230136:-
THCA	cis	rs3096299	0.967	rs2965827	ENSG00000274627.1	RP11-104N10.2	-8.46	3.35e-16	1.52e-13	-0.35	-0.36	Multiple myeloma (IgH translocation);	chr16:89390942	chr16:89516797~89522217:+
THCA	cis	rs6822297	0.504	rs12152700	ENSG00000240005.4	RP11-293A21.1	8.46	3.36e-16	1.53e-13	0.41	0.36	Obesity-related traits;	chr4:27005029	chr4:26859806~26860599:-
THCA	cis	rs150992	0.547	rs325217	ENSG00000248489.1	CTD-2007H13.3	8.46	3.37e-16	1.53e-13	0.36	0.36	Body mass index;	chr5:98844109	chr5:98929171~98995013:+
THCA	cis	rs11148252	0.774	rs6561666	ENSG00000235660.1	LINC00345	-8.46	3.37e-16	1.53e-13	-0.45	-0.36	Lewy body disease;	chr13:52355910	chr13:52484161~52484680:-
THCA	cis	rs4819052	0.851	rs2838864	ENSG00000237664.1	LINC00316	8.46	3.37e-16	1.53e-13	0.36	0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45291559	chr21:45338590~45341990:-
THCA	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	8.46	3.37e-16	1.54e-13	0.57	0.36	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
THCA	cis	rs2274273	0.554	rs3742564	ENSG00000258413.1	RP11-665C16.6	8.46	3.38e-16	1.54e-13	0.49	0.36	Protein biomarker;	chr14:55063402	chr14:55262767~55272075:-
THCA	cis	rs4718428	0.705	rs62465692	ENSG00000230295.1	RP11-458F8.2	-8.46	3.38e-16	1.54e-13	-0.32	-0.36	Corneal structure;	chr7:66830758	chr7:66880708~66882981:+
THCA	cis	rs4718428	0.662	rs34577323	ENSG00000230295.1	RP11-458F8.2	-8.46	3.38e-16	1.54e-13	-0.32	-0.36	Corneal structure;	chr7:66845054	chr7:66880708~66882981:+
THCA	cis	rs375066	0.935	rs387689	ENSG00000267058.1	RP11-15A1.3	-8.46	3.4e-16	1.55e-13	-0.29	-0.36	Breast cancer;	chr19:43915959	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs398193	ENSG00000267058.1	RP11-15A1.3	-8.46	3.4e-16	1.55e-13	-0.29	-0.36	Breast cancer;	chr19:43916268	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs450308	ENSG00000267058.1	RP11-15A1.3	-8.46	3.4e-16	1.55e-13	-0.29	-0.36	Breast cancer;	chr19:43918206	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs424729	ENSG00000267058.1	RP11-15A1.3	-8.46	3.4e-16	1.55e-13	-0.29	-0.36	Breast cancer;	chr19:43918650	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs423320	ENSG00000267058.1	RP11-15A1.3	-8.46	3.4e-16	1.55e-13	-0.29	-0.36	Breast cancer;	chr19:43918830	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs423752	ENSG00000267058.1	RP11-15A1.3	-8.46	3.4e-16	1.55e-13	-0.29	-0.36	Breast cancer;	chr19:43919043	chr19:43891804~43901805:-
THCA	cis	rs4819052	0.807	rs1075788	ENSG00000237664.1	LINC00316	-8.46	3.42e-16	1.55e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246649	chr21:45338590~45341990:-
THCA	cis	rs2274273	1	rs4644	ENSG00000258413.1	RP11-665C16.6	-8.46	3.42e-16	1.55e-13	-0.49	-0.36	Protein biomarker;	chr14:55138217	chr14:55262767~55272075:-
THCA	cis	rs13068223	0.84	rs1469536	ENSG00000243926.1	TIPARP-AS1	8.46	3.42e-16	1.56e-13	0.35	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr3:156710038	chr3:156671862~156674378:-
THCA	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	8.46	3.43e-16	1.56e-13	0.46	0.36	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
THCA	cis	rs4819052	0.632	rs4819050	ENSG00000215447.6	BX322557.10	-8.46	3.44e-16	1.56e-13	-0.3	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45273028	chr21:45288052~45291738:+
THCA	cis	rs7015263	0.714	rs7465350	ENSG00000254231.1	CTD-2284J15.1	8.46	3.45e-16	1.57e-13	0.37	0.36	Intelligence (multi-trait analysis);	chr8:86525480	chr8:86333274~86343314:-
THCA	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	8.46	3.45e-16	1.57e-13	0.24	0.36	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	8.46	3.45e-16	1.57e-13	0.24	0.36	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
THCA	cis	rs673078	0.66	rs75752792	ENSG00000275409.1	RP11-131L12.4	-8.46	3.45e-16	1.57e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118187005	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs75571641	ENSG00000275409.1	RP11-131L12.4	-8.46	3.45e-16	1.57e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118187012	chr12:118430147~118430699:+
THCA	cis	rs2929278	0.589	rs2411284	ENSG00000166763.7	STRCP1	-8.46	3.46e-16	1.57e-13	-0.39	-0.36	Schizophrenia;	chr15:43746701	chr15:43699488~43718184:-
THCA	cis	rs7727544	0.582	rs2301579	ENSG00000237714.1	P4HA2-AS1	8.46	3.47e-16	1.58e-13	0.46	0.36	Blood metabolite levels;	chr5:132217647	chr5:132184876~132192808:+
THCA	cis	rs9640161	0.789	rs34311995	ENSG00000261305.1	RP4-584D14.7	8.46	3.49e-16	1.58e-13	0.43	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150362166	chr7:150341771~150342607:+
THCA	cis	rs11148252	0.532	rs9536190	ENSG00000278238.1	RP11-245D16.4	-8.46	3.49e-16	1.59e-13	-0.42	-0.36	Lewy body disease;	chr13:52606909	chr13:52454775~52455331:-
THCA	cis	rs860295	0.836	rs6684889	ENSG00000225855.5	RUSC1-AS1	-8.46	3.5e-16	1.59e-13	-0.25	-0.36	Body mass index;	chr1:155457271	chr1:155316863~155324176:-
THCA	cis	rs524281	1	rs489337	ENSG00000255320.1	RP11-755F10.1	-8.46	3.51e-16	1.59e-13	-0.5	-0.36	Electroencephalogram traits;	chr11:66087090	chr11:66244840~66246239:-
THCA	cis	rs4927850	1	rs10881564	ENSG00000226155.1	AC124944.3	-8.46	3.52e-16	1.6e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196023455	chr3:195912049~195913986:+
THCA	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	8.46	3.53e-16	1.6e-13	0.38	0.36	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
THCA	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	8.46	3.54e-16	1.61e-13	0.35	0.36	Breast size;	chr12:9232939	chr12:9277235~9313241:+
THCA	cis	rs10208649	0.808	rs11886366	ENSG00000272156.1	RP11-477N3.1	8.46	3.54e-16	1.61e-13	0.66	0.36	Body mass index;	chr2:53997126	chr2:54082554~54085066:+
THCA	cis	rs1707322	1	rs6677777	ENSG00000234329.1	RP11-767N6.2	8.45	3.54e-16	1.61e-13	0.35	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45651039~45651826:-
THCA	cis	rs12554020	1	rs12335532	ENSG00000227603.1	RP11-165J3.6	8.45	3.55e-16	1.61e-13	0.47	0.36	Schizophrenia;	chr9:93431673	chr9:93435332~93437121:-
THCA	cis	rs41157	0.528	rs15888	ENSG00000279159.1	RP3-394A18.1	8.45	3.55e-16	1.61e-13	0.36	0.36	Cerebrospinal P-tau181p levels;	chr22:30030346	chr22:29978950~30028236:-
THCA	cis	rs10740039	0.81	rs10740036	ENSG00000254271.1	RP11-131N11.4	8.45	3.55e-16	1.61e-13	0.46	0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60606216	chr10:60734342~60741828:+
THCA	cis	rs150992	0.79	rs40075	ENSG00000248489.1	CTD-2007H13.3	8.45	3.55e-16	1.61e-13	0.35	0.36	Body mass index;	chr5:98976743	chr5:98929171~98995013:+
THCA	cis	rs600231	0.706	rs3782091	ENSG00000245532.5	NEAT1	-8.45	3.56e-16	1.62e-13	-0.26	-0.36	Bone mineral density;	chr11:65569012	chr11:65422774~65445540:+
THCA	cis	rs17772222	0.682	rs1864744	ENSG00000258789.1	RP11-507K2.3	8.45	3.57e-16	1.62e-13	0.35	0.36	Coronary artery calcification;	chr14:88484662	chr14:88551597~88552493:+
THCA	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-8.45	3.57e-16	1.62e-13	-0.42	-0.36	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
THCA	cis	rs9309473	0.632	rs6546825	ENSG00000163016.8	ALMS1P	8.45	3.57e-16	1.62e-13	0.48	0.36	Metabolite levels;	chr2:73365125	chr2:73644919~73685576:+
THCA	cis	rs4718428	0.705	rs4717331	ENSG00000230295.1	RP11-458F8.2	-8.45	3.57e-16	1.62e-13	-0.32	-0.36	Corneal structure;	chr7:66913899	chr7:66880708~66882981:+
THCA	cis	rs1707322	0.721	rs10890343	ENSG00000234329.1	RP11-767N6.2	8.45	3.58e-16	1.62e-13	0.34	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45651039~45651826:-
THCA	cis	rs4722166	0.597	rs2069845	ENSG00000179428.2	AC073072.5	-8.45	3.58e-16	1.63e-13	-0.44	-0.36	Lung cancer;	chr7:22730530	chr7:22725395~22727620:-
THCA	cis	rs987724	0.592	rs9858861	ENSG00000240875.4	LINC00886	-8.45	3.59e-16	1.63e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156824848	chr3:156747346~156817062:-
THCA	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	8.45	3.6e-16	1.63e-13	0.6	0.36	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
THCA	cis	rs11096990	0.634	rs6531702	ENSG00000249685.1	RP11-360F5.3	8.45	3.61e-16	1.64e-13	0.43	0.36	Cognitive function;	chr4:39273774	chr4:39133913~39135608:+
THCA	cis	rs922182	0.595	rs7176387	ENSG00000275785.1	RP11-111E14.2	-8.45	3.62e-16	1.64e-13	-0.43	-0.36	Blood protein levels;	chr15:63926909	chr15:63890030~63890317:+
THCA	cis	rs56046484	1	rs2304416	ENSG00000259295.5	CSPG4P12	-8.45	3.62e-16	1.64e-13	-0.58	-0.36	Testicular germ cell tumor;	chr15:85075651	chr15:85191438~85213905:+
THCA	cis	rs8114671	0.967	rs1415774	ENSG00000269202.1	RP4-614O4.12	8.45	3.62e-16	1.64e-13	0.3	0.36	Height;	chr20:35177813	chr20:35201747~35203288:-
THCA	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	8.45	3.63e-16	1.65e-13	0.56	0.36	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
THCA	cis	rs748404	0.578	rs478028	ENSG00000205771.5	CATSPER2P1	-8.45	3.63e-16	1.65e-13	-0.38	-0.36	Lung cancer;	chr15:43318574	chr15:43726918~43747094:-
THCA	cis	rs748404	0.578	rs552701	ENSG00000205771.5	CATSPER2P1	-8.45	3.63e-16	1.65e-13	-0.38	-0.36	Lung cancer;	chr15:43321612	chr15:43726918~43747094:-
THCA	cis	rs748404	0.578	rs573615	ENSG00000205771.5	CATSPER2P1	-8.45	3.63e-16	1.65e-13	-0.38	-0.36	Lung cancer;	chr15:43322083	chr15:43726918~43747094:-
THCA	cis	rs10510102	0.623	rs10159856	ENSG00000276742.1	RP11-500G22.4	8.45	3.65e-16	1.66e-13	0.55	0.36	Breast cancer;	chr10:121988292	chr10:121956782~121957098:+
THCA	cis	rs987724	0.512	rs9842198	ENSG00000240875.4	LINC00886	-8.45	3.66e-16	1.66e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156821415	chr3:156747346~156817062:-
THCA	cis	rs10208649	0.611	rs61740458	ENSG00000272156.1	RP11-477N3.1	8.45	3.66e-16	1.66e-13	0.51	0.36	Body mass index;	chr2:54065503	chr2:54082554~54085066:+
THCA	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	8.45	3.68e-16	1.67e-13	0.45	0.36	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
THCA	cis	rs1707322	1	rs785465	ENSG00000234329.1	RP11-767N6.2	8.45	3.68e-16	1.67e-13	0.34	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45651039~45651826:-
THCA	cis	rs516805	0.748	rs1267941	ENSG00000279453.1	RP3-425C14.4	-8.45	3.69e-16	1.67e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122471888	chr6:122436789~122439223:-
THCA	cis	rs2274273	0.967	rs67756714	ENSG00000258413.1	RP11-665C16.6	-8.45	3.69e-16	1.67e-13	-0.48	-0.36	Protein biomarker;	chr14:55123105	chr14:55262767~55272075:-
THCA	cis	rs4819052	0.851	rs875621	ENSG00000237664.1	LINC00316	-8.45	3.71e-16	1.68e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45262380	chr21:45338590~45341990:-
THCA	cis	rs7569084	0.687	rs12614851	ENSG00000234255.7	AC012370.3	8.45	3.71e-16	1.68e-13	0.42	0.36	Sum eosinophil basophil counts;	chr2:65458050	chr2:65439888~65456571:-
THCA	cis	rs4718428	0.672	rs13241598	ENSG00000230295.1	RP11-458F8.2	-8.45	3.73e-16	1.69e-13	-0.32	-0.36	Corneal structure;	chr7:66835665	chr7:66880708~66882981:+
THCA	cis	rs12682352	0.652	rs1567398	ENSG00000253893.2	FAM85B	8.45	3.74e-16	1.69e-13	0.49	0.36	Neuroticism;	chr8:8869294	chr8:8167819~8226614:-
THCA	cis	rs673078	0.607	rs7309671	ENSG00000275409.1	RP11-131L12.4	-8.45	3.75e-16	1.7e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118313188	chr12:118430147~118430699:+
THCA	cis	rs2274273	1	rs10149435	ENSG00000258413.1	RP11-665C16.6	-8.45	3.76e-16	1.7e-13	-0.48	-0.36	Protein biomarker;	chr14:55160771	chr14:55262767~55272075:-
THCA	cis	rs375066	0.868	rs378112	ENSG00000267058.1	RP11-15A1.3	-8.45	3.76e-16	1.7e-13	-0.29	-0.36	Breast cancer;	chr19:43917777	chr19:43891804~43901805:-
THCA	cis	rs375066	0.868	rs378109	ENSG00000267058.1	RP11-15A1.3	-8.45	3.76e-16	1.7e-13	-0.29	-0.36	Breast cancer;	chr19:43917785	chr19:43891804~43901805:-
THCA	cis	rs1062177	0.826	rs2915873	ENSG00000253921.1	CTB-113P19.3	-8.45	3.77e-16	1.71e-13	-0.44	-0.36	Preschool internalizing problems;	chr5:151777097	chr5:151753992~151767247:+
THCA	cis	rs4722166	0.63	rs7808457	ENSG00000179428.2	AC073072.5	8.45	3.78e-16	1.71e-13	0.5	0.36	Lung cancer;	chr7:22758646	chr7:22725395~22727620:-
THCA	cis	rs10759883	0.627	rs13294931	ENSG00000175611.10	LINC00476	-8.45	3.79e-16	1.72e-13	-0.41	-0.36	Nicotine dependence;	chr9:95833220	chr9:95759231~95875977:-
THCA	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-8.45	3.79e-16	1.72e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
THCA	cis	rs1707322	1	rs785504	ENSG00000234329.1	RP11-767N6.2	-8.45	3.8e-16	1.72e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45651039~45651826:-
THCA	cis	rs375066	0.935	rs388685	ENSG00000267058.1	RP11-15A1.3	-8.45	3.81e-16	1.73e-13	-0.29	-0.36	Breast cancer;	chr19:43914528	chr19:43891804~43901805:-
THCA	cis	rs4819052	1	rs2297286	ENSG00000237664.1	LINC00316	-8.45	3.81e-16	1.73e-13	-0.4	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45287982	chr21:45338590~45341990:-
THCA	cis	rs11148252	0.512	rs9526950	ENSG00000278238.1	RP11-245D16.4	-8.44	3.83e-16	1.73e-13	-0.42	-0.36	Lewy body disease;	chr13:52600328	chr13:52454775~52455331:-
THCA	cis	rs17772222	0.682	rs7142053	ENSG00000258789.1	RP11-507K2.3	-8.44	3.83e-16	1.73e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88511594	chr14:88551597~88552493:+
THCA	cis	rs4842666	0.667	rs1401981	ENSG00000258302.2	RP11-981P6.1	8.44	3.84e-16	1.74e-13	0.37	0.36	Blood pressure;	chr12:89697669	chr12:89561129~89594878:+
THCA	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-8.44	3.84e-16	1.74e-13	-0.47	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
THCA	cis	rs7015263	0.676	rs7460439	ENSG00000254231.1	CTD-2284J15.1	8.44	3.85e-16	1.74e-13	0.36	0.36	Intelligence (multi-trait analysis);	chr8:86501861	chr8:86333274~86343314:-
THCA	cis	rs55665837	1	rs10832275	ENSG00000251991.1	RNU7-49P	8.44	3.87e-16	1.75e-13	0.41	0.36	Vitamin D levels;	chr11:14456678	chr11:14478892~14478953:+
THCA	cis	rs1707322	0.686	rs1547924	ENSG00000234329.1	RP11-767N6.2	8.44	3.89e-16	1.76e-13	0.35	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.686	rs3014236	ENSG00000234329.1	RP11-767N6.2	-8.44	3.89e-16	1.76e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45651039~45651826:-
THCA	cis	rs4591358	0.773	rs17177580	ENSG00000223466.1	AC064834.2	8.44	3.89e-16	1.76e-13	0.49	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508426	chr2:195533035~195538681:+
THCA	cis	rs801193	1	rs13239306	ENSG00000237310.1	GS1-124K5.4	-8.44	3.92e-16	1.77e-13	-0.27	-0.36	Aortic root size;	chr7:66671030	chr7:66493706~66495474:+
THCA	cis	rs150992	0.632	rs34489	ENSG00000248489.1	CTD-2007H13.3	-8.44	3.92e-16	1.78e-13	-0.35	-0.36	Body mass index;	chr5:98977180	chr5:98929171~98995013:+
THCA	cis	rs4819052	0.851	rs28616694	ENSG00000237664.1	LINC00316	-8.44	3.93e-16	1.78e-13	-0.37	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254871	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.8	rs4819045	ENSG00000237664.1	LINC00316	-8.44	3.93e-16	1.78e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240223	chr21:45338590~45341990:-
THCA	cis	rs3847687	1	rs3847687	ENSG00000256810.1	RP11-76C10.2	8.44	3.94e-16	1.78e-13	0.42	0.36	Longevity;	chr12:131040508	chr12:131030570~131035487:-
THCA	cis	rs12594515	0.6	rs12903858	ENSG00000273972.1	CTD-2306A12.1	-8.44	3.94e-16	1.79e-13	-0.39	-0.36	Weight;Waist circumference;	chr15:45679968	chr15:45702640~45703183:+
THCA	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-8.44	3.97e-16	1.8e-13	-0.57	-0.36	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
THCA	cis	rs4718428	0.705	rs3800817	ENSG00000230295.1	RP11-458F8.2	-8.44	3.97e-16	1.8e-13	-0.32	-0.36	Corneal structure;	chr7:66798563	chr7:66880708~66882981:+
THCA	cis	rs910316	0.575	rs12889133	ENSG00000279594.1	RP11-950C14.10	8.44	3.98e-16	1.8e-13	0.35	0.36	Height;	chr14:74998386	chr14:75011269~75012851:-
THCA	cis	rs7674212	0.556	rs223401	ENSG00000246560.2	RP11-10L12.4	8.44	3.98e-16	1.8e-13	0.45	0.36	Type 2 diabetes;	chr4:102817815	chr4:102828055~102844075:+
THCA	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-8.44	3.98e-16	1.8e-13	-0.37	-0.36	Height;	chr11:118809363	chr11:118704607~118750263:+
THCA	cis	rs9532669	0.889	rs7339089	ENSG00000176268.5	CYCSP34	8.44	3.98e-16	1.8e-13	0.41	0.36	Cervical cancer;	chr13:40863790	chr13:40863599~40863902:-
THCA	cis	rs9595066	0.627	rs4394973	ENSG00000227258.4	SMIM2-AS1	-8.44	3.98e-16	1.8e-13	-0.45	-0.36	Schizophrenia;	chr13:44179173	chr13:44110451~44240517:+
THCA	cis	rs11603691	1	rs11607950	ENSG00000254662.1	RP11-872D17.4	-8.44	3.99e-16	1.81e-13	-0.68	-0.36	Low high density lipoprotein cholesterol levels;	chr11:57339887	chr11:57325603~57327958:+
THCA	cis	rs11603691	1	rs11229003	ENSG00000254662.1	RP11-872D17.4	-8.44	3.99e-16	1.81e-13	-0.68	-0.36	Low high density lipoprotein cholesterol levels;	chr11:57340817	chr11:57325603~57327958:+
THCA	cis	rs1005277	0.579	rs1780116	ENSG00000263064.2	RP11-291L22.7	8.44	3.99e-16	1.81e-13	0.41	0.36	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780121	ENSG00000263064.2	RP11-291L22.7	8.44	3.99e-16	1.81e-13	0.41	0.36	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780122	ENSG00000263064.2	RP11-291L22.7	8.44	3.99e-16	1.81e-13	0.41	0.36	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780145	ENSG00000263064.2	RP11-291L22.7	8.44	3.99e-16	1.81e-13	0.41	0.36	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38448689~38448949:+
THCA	cis	rs4819052	0.655	rs2330103	ENSG00000215447.6	BX322557.10	-8.44	3.99e-16	1.81e-13	-0.29	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45274599	chr21:45288052~45291738:+
THCA	cis	rs1707322	1	rs785469	ENSG00000234329.1	RP11-767N6.2	-8.44	4.01e-16	1.82e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785468	ENSG00000234329.1	RP11-767N6.2	-8.44	4.01e-16	1.82e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45651039~45651826:-
THCA	cis	rs944289	0.966	rs2415317	ENSG00000257826.1	RP11-116N8.4	8.44	4.02e-16	1.82e-13	0.38	0.36	Thyroid cancer;	chr14:36140472	chr14:36061026~36067190:-
THCA	cis	rs9309473	0.607	rs7567017	ENSG00000163016.8	ALMS1P	8.44	4.02e-16	1.82e-13	0.48	0.36	Metabolite levels;	chr2:73369142	chr2:73644919~73685576:+
THCA	cis	rs7811142	1	rs7803454	ENSG00000242294.5	STAG3L5P	8.44	4.04e-16	1.83e-13	0.25	0.36	Platelet count;	chr7:100393925	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.943	rs11769886	ENSG00000242294.5	STAG3L5P	8.44	4.04e-16	1.83e-13	0.25	0.36	Platelet count;	chr7:100400984	chr7:100336079~100351900:+
THCA	cis	rs10463554	0.824	rs3776868	ENSG00000175749.11	EIF3KP1	8.44	4.05e-16	1.83e-13	0.47	0.36	Parkinson's disease;	chr5:102963012	chr5:103032376~103033031:+
THCA	cis	rs8114671	0.869	rs1407202	ENSG00000269202.1	RP4-614O4.12	8.44	4.05e-16	1.83e-13	0.31	0.36	Height;	chr20:35064164	chr20:35201747~35203288:-
THCA	cis	rs4718428	0.672	rs36038499	ENSG00000230295.1	RP11-458F8.2	-8.44	4.06e-16	1.84e-13	-0.32	-0.36	Corneal structure;	chr7:66824628	chr7:66880708~66882981:+
THCA	cis	rs9309473	0.607	rs6740173	ENSG00000163016.8	ALMS1P	8.44	4.07e-16	1.84e-13	0.49	0.36	Metabolite levels;	chr2:73375138	chr2:73644919~73685576:+
THCA	cis	rs524281	0.731	rs2452682	ENSG00000255320.1	RP11-755F10.1	8.44	4.07e-16	1.84e-13	0.53	0.36	Electroencephalogram traits;	chr11:66045138	chr11:66244840~66246239:-
THCA	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	8.44	4.09e-16	1.85e-13	0.24	0.36	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
THCA	cis	rs17772222	0.545	rs1758846	ENSG00000258789.1	RP11-507K2.3	8.44	4.09e-16	1.85e-13	0.35	0.36	Coronary artery calcification;	chr14:88449288	chr14:88551597~88552493:+
THCA	cis	rs8114671	0.967	rs6060285	ENSG00000269202.1	RP4-614O4.12	-8.44	4.1e-16	1.85e-13	-0.3	-0.36	Height;	chr20:35182684	chr20:35201747~35203288:-
THCA	cis	rs11148252	0.595	rs4885117	ENSG00000235660.1	LINC00345	-8.44	4.11e-16	1.86e-13	-0.46	-0.36	Lewy body disease;	chr13:52578892	chr13:52484161~52484680:-
THCA	cis	rs2408955	0.501	rs8716	ENSG00000258273.1	RP11-370I10.4	-8.43	4.11e-16	1.86e-13	-0.48	-0.36	Glycated hemoglobin levels;	chr12:48145699	chr12:48333755~48333901:-
THCA	cis	rs8114671	0.935	rs6060282	ENSG00000269202.1	RP4-614O4.12	-8.43	4.12e-16	1.86e-13	-0.3	-0.36	Height;	chr20:35179263	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs2065978	ENSG00000269202.1	RP4-614O4.12	-8.43	4.12e-16	1.86e-13	-0.3	-0.36	Height;	chr20:35179488	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs2065979	ENSG00000269202.1	RP4-614O4.12	-8.43	4.12e-16	1.86e-13	-0.3	-0.36	Height;	chr20:35179887	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs6088753	ENSG00000269202.1	RP4-614O4.12	-8.43	4.12e-16	1.86e-13	-0.3	-0.36	Height;	chr20:35180449	chr20:35201747~35203288:-
THCA	cis	rs150992	0.632	rs34491	ENSG00000248489.1	CTD-2007H13.3	8.43	4.13e-16	1.86e-13	0.35	0.36	Body mass index;	chr5:98974118	chr5:98929171~98995013:+
THCA	cis	rs7849270	1	rs10819464	ENSG00000268707.1	RP11-247A12.7	-8.43	4.13e-16	1.87e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129113998	chr9:129170434~129170940:+
THCA	cis	rs934734	0.532	rs7557569	ENSG00000237979.1	AC007389.1	-8.43	4.14e-16	1.87e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65417427	chr2:65500993~65502138:-
THCA	cis	rs8114671	0.562	rs6088646	ENSG00000269202.1	RP4-614O4.12	-8.43	4.15e-16	1.88e-13	-0.3	-0.36	Height;	chr20:34918134	chr20:35201747~35203288:-
THCA	cis	rs9309473	0.607	rs6546824	ENSG00000163016.8	ALMS1P	8.43	4.15e-16	1.88e-13	0.48	0.36	Metabolite levels;	chr2:73360203	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.607	rs4641966	ENSG00000163016.8	ALMS1P	8.43	4.15e-16	1.88e-13	0.48	0.36	Metabolite levels;	chr2:73363678	chr2:73644919~73685576:+
THCA	cis	rs516805	1	rs516805	ENSG00000279453.1	RP3-425C14.4	-8.43	4.16e-16	1.88e-13	-0.33	-0.36	Lymphocyte counts;	chr6:122398486	chr6:122436789~122439223:-
THCA	cis	rs4718428	0.705	rs11028	ENSG00000230295.1	RP11-458F8.2	-8.43	4.16e-16	1.88e-13	-0.32	-0.36	Corneal structure;	chr7:66811230	chr7:66880708~66882981:+
THCA	cis	rs11096990	0.634	rs17431358	ENSG00000249685.1	RP11-360F5.3	-8.43	4.17e-16	1.88e-13	-0.43	-0.36	Cognitive function;	chr4:39275676	chr4:39133913~39135608:+
THCA	cis	rs2929278	0.561	rs3099045	ENSG00000166763.7	STRCP1	8.43	4.18e-16	1.89e-13	0.4	0.36	Schizophrenia;	chr15:43631757	chr15:43699488~43718184:-
THCA	cis	rs9309473	0.632	rs6706179	ENSG00000163016.8	ALMS1P	8.43	4.19e-16	1.89e-13	0.48	0.36	Metabolite levels;	chr2:73351449	chr2:73644919~73685576:+
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000228039.3	KB-1125A3.10	8.43	4.19e-16	1.89e-13	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23963780~23964374:+
THCA	cis	rs1707322	0.686	rs3014239	ENSG00000234329.1	RP11-767N6.2	-8.43	4.2e-16	1.9e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45651039~45651826:-
THCA	cis	rs507080	0.733	rs4393358	ENSG00000278376.1	RP11-158I9.8	-8.43	4.2e-16	1.9e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118698388	chr11:118791254~118793137:+
THCA	cis	rs9322193	0.651	rs9322188	ENSG00000268592.3	RAET1E-AS1	-8.43	4.21e-16	1.9e-13	-0.5	-0.36	Lung cancer;	chr6:149588355	chr6:149863494~149919507:+
THCA	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	8.43	4.21e-16	1.9e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
THCA	cis	rs2712184	0.846	rs7598172	ENSG00000229352.1	AC007563.3	-8.43	4.21e-16	1.9e-13	-0.44	-0.36	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216813276	chr2:216799608~216805335:+
THCA	cis	rs6844153	1	rs80197589	ENSG00000240005.4	RP11-293A21.1	-8.43	4.21e-16	1.9e-13	-0.48	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26887030	chr4:26859806~26860599:-
THCA	cis	rs1707322	0.686	rs2230659	ENSG00000234329.1	RP11-767N6.2	-8.43	4.25e-16	1.92e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45651039~45651826:-
THCA	cis	rs6991838	0.733	rs7822627	ENSG00000200714.1	Y_RNA	8.43	4.29e-16	1.94e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65714139	chr8:65592731~65592820:+
THCA	cis	rs1005277	0.579	rs2008449	ENSG00000263064.2	RP11-291L22.7	-8.43	4.31e-16	1.94e-13	-0.4	-0.36	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38448689~38448949:+
THCA	cis	rs2439831	0.85	rs8023458	ENSG00000249839.1	AC011330.5	-8.43	4.32e-16	1.95e-13	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43788741	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.85	rs16963953	ENSG00000249839.1	AC011330.5	-8.43	4.32e-16	1.95e-13	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43789521	chr15:43663654~43684339:-
THCA	cis	rs7829975	0.658	rs2409096	ENSG00000253893.2	FAM85B	-8.43	4.35e-16	1.96e-13	-0.47	-0.36	Mood instability;	chr8:8834967	chr8:8167819~8226614:-
THCA	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-8.43	4.35e-16	1.96e-13	-0.46	-0.36	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
THCA	cis	rs8114671	0.967	rs1415773	ENSG00000269202.1	RP4-614O4.12	-8.43	4.35e-16	1.96e-13	-0.3	-0.36	Height;	chr20:35177782	chr20:35201747~35203288:-
THCA	cis	rs7712401	0.584	rs4836382	ENSG00000263432.2	RN7SL689P	8.43	4.36e-16	1.97e-13	0.41	0.36	Mean platelet volume;	chr5:123040946	chr5:123022487~123022783:-
THCA	cis	rs13068223	0.562	rs346003	ENSG00000243926.1	TIPARP-AS1	-8.43	4.36e-16	1.97e-13	-0.36	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr3:156705283	chr3:156671862~156674378:-
THCA	cis	rs62158211	1	rs4618068	ENSG00000272563.1	RP11-480C16.1	-8.43	4.36e-16	1.97e-13	-0.49	-0.36	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113351778	chr2:113432600~113436042:+
THCA	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	8.43	4.36e-16	1.97e-13	0.68	0.36	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
THCA	cis	rs7646881	0.812	rs7624161	ENSG00000240207.5	RP11-379F4.4	-8.43	4.37e-16	1.97e-13	-0.51	-0.36	Tetralogy of Fallot;	chr3:158742125	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.812	rs113166116	ENSG00000240207.5	RP11-379F4.4	-8.43	4.37e-16	1.97e-13	-0.51	-0.36	Tetralogy of Fallot;	chr3:158742467	chr3:158732263~158784070:+
THCA	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-8.43	4.38e-16	1.97e-13	-0.53	-0.36	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
THCA	cis	rs17772222	0.701	rs1627444	ENSG00000258789.1	RP11-507K2.3	8.43	4.39e-16	1.98e-13	0.34	0.36	Coronary artery calcification;	chr14:88413784	chr14:88551597~88552493:+
THCA	cis	rs7674212	0.507	rs223317	ENSG00000246560.2	RP11-10L12.4	8.43	4.39e-16	1.98e-13	0.45	0.36	Type 2 diabetes;	chr4:102881667	chr4:102828055~102844075:+
THCA	cis	rs73186030	0.92	rs73186050	ENSG00000272758.4	RP11-299J3.8	8.43	4.39e-16	1.98e-13	0.45	0.36	Serum parathyroid hormone levels;	chr3:122321081	chr3:122416207~122443180:+
THCA	cis	rs4718428	0.705	rs4717328	ENSG00000230295.1	RP11-458F8.2	-8.43	4.4e-16	1.98e-13	-0.32	-0.36	Corneal structure;	chr7:66887678	chr7:66880708~66882981:+
THCA	cis	rs741668	0.641	rs1022951	ENSG00000235903.6	CPB2-AS1	8.43	4.41e-16	1.99e-13	0.46	0.36	Cerebrospinal fluid clusterin levels;	chr13:46075319	chr13:46052806~46113332:+
THCA	cis	rs934734	0.532	rs7569257	ENSG00000237979.1	AC007389.1	-8.43	4.41e-16	1.99e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65429842	chr2:65500993~65502138:-
THCA	cis	rs4819052	0.851	rs8133045	ENSG00000237664.1	LINC00316	-8.43	4.42e-16	1.99e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238222	chr21:45338590~45341990:-
THCA	cis	rs10740039	0.846	rs10761529	ENSG00000254271.1	RP11-131N11.4	8.43	4.43e-16	2e-13	0.45	0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60627052	chr10:60734342~60741828:+
THCA	cis	rs1707322	0.721	rs56255771	ENSG00000234329.1	RP11-767N6.2	8.43	4.43e-16	2e-13	0.34	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45651039~45651826:-
THCA	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	8.42	4.43e-16	2e-13	0.24	0.36	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	8.42	4.43e-16	2e-13	0.24	0.36	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	8.42	4.43e-16	2e-13	0.24	0.36	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
THCA	cis	rs55665837	1	rs12276938	ENSG00000251991.1	RNU7-49P	8.42	4.44e-16	2e-13	0.41	0.36	Vitamin D levels;	chr11:14441942	chr11:14478892~14478953:+
THCA	cis	rs2274273	0.686	rs17253695	ENSG00000258413.1	RP11-665C16.6	8.42	4.45e-16	2.01e-13	0.52	0.36	Protein biomarker;	chr14:55107892	chr14:55262767~55272075:-
THCA	cis	rs6991838	0.671	rs13251307	ENSG00000200714.1	Y_RNA	8.42	4.45e-16	2.01e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65664911	chr8:65592731~65592820:+
THCA	cis	rs1707322	1	rs785486	ENSG00000234329.1	RP11-767N6.2	-8.42	4.46e-16	2.01e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.865	rs785501	ENSG00000234329.1	RP11-767N6.2	-8.42	4.46e-16	2.01e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.929	rs785500	ENSG00000234329.1	RP11-767N6.2	-8.42	4.46e-16	2.01e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45651039~45651826:-
THCA	cis	rs8114671	0.967	rs2378337	ENSG00000269202.1	RP4-614O4.12	-8.42	4.46e-16	2.01e-13	-0.3	-0.36	Height;	chr20:35183632	chr20:35201747~35203288:-
THCA	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	8.42	4.48e-16	2.02e-13	0.45	0.36	Depression;	chr6:28273214	chr6:28176188~28176674:+
THCA	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	8.42	4.48e-16	2.02e-13	0.45	0.36	Depression;	chr6:28273215	chr6:28176188~28176674:+
THCA	cis	rs950169	0.58	rs4603535	ENSG00000225151.9	GOLGA2P7	-8.42	4.48e-16	2.02e-13	-0.54	-0.36	Schizophrenia;	chr15:84630641	chr15:84199311~84230136:-
THCA	cis	rs3096299	0.933	rs2930219	ENSG00000274627.1	RP11-104N10.2	8.42	4.49e-16	2.02e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89516797~89522217:+
THCA	cis	rs6545883	0.507	rs62149712	ENSG00000271889.1	RP11-493E12.1	-8.42	4.53e-16	2.04e-13	-0.35	-0.36	Tuberculosis;	chr2:61374137	chr2:61151433~61162105:-
THCA	cis	rs7811142	0.887	rs35111986	ENSG00000242294.5	STAG3L5P	8.42	4.53e-16	2.04e-13	0.24	0.36	Platelet count;	chr7:100402651	chr7:100336079~100351900:+
THCA	cis	rs240993	0.516	rs241004	ENSG00000230177.1	RP5-1112D6.4	-8.42	4.55e-16	2.05e-13	-0.39	-0.36	Inflammatory skin disease;Psoriasis;	chr6:111275341	chr6:111277932~111278742:+
THCA	cis	rs2739330	0.752	rs2330634	ENSG00000206090.4	AP000350.7	8.42	4.55e-16	2.05e-13	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23939998~23942798:+
THCA	cis	rs8114671	0.935	rs945960	ENSG00000269202.1	RP4-614O4.12	-8.42	4.55e-16	2.05e-13	-0.3	-0.36	Height;	chr20:35175051	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs2069952	ENSG00000269202.1	RP4-614O4.12	-8.42	4.55e-16	2.05e-13	-0.3	-0.36	Height;	chr20:35176148	chr20:35201747~35203288:-
THCA	cis	rs1707322	0.686	rs3014251	ENSG00000234329.1	RP11-767N6.2	-8.42	4.55e-16	2.05e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45651039~45651826:-
THCA	cis	rs737008	0.922	rs2070923	ENSG00000262703.1	RP11-485G7.6	8.42	4.55e-16	2.05e-13	0.42	0.36	Obesity-related traits;	chr16:11275998	chr16:11348143~11349321:-
THCA	cis	rs2946505	0.569	rs2977084	ENSG00000251468.2	RP11-369K16.1	8.42	4.55e-16	2.05e-13	0.58	0.36	Migraine;	chr8:12956634	chr8:12958387~12962200:+
THCA	cis	rs7015263	0.714	rs56122533	ENSG00000254231.1	CTD-2284J15.1	-8.42	4.56e-16	2.05e-13	-0.37	-0.36	Intelligence (multi-trait analysis);	chr8:86517828	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.714	rs7461624	ENSG00000254231.1	CTD-2284J15.1	-8.42	4.56e-16	2.05e-13	-0.37	-0.36	Intelligence (multi-trait analysis);	chr8:86527639	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.714	rs62510845	ENSG00000254231.1	CTD-2284J15.1	-8.42	4.56e-16	2.05e-13	-0.37	-0.36	Intelligence (multi-trait analysis);	chr8:86534823	chr8:86333274~86343314:-
THCA	cis	rs42490	0.7	rs410663	ENSG00000251136.7	RP11-37B2.1	8.42	4.6e-16	2.07e-13	0.32	0.36	Leprosy;	chr8:89859461	chr8:89609409~89757727:-
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000228039.3	KB-1125A3.10	8.42	4.63e-16	2.08e-13	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23963780~23964374:+
THCA	cis	rs516805	0.847	rs520867	ENSG00000279453.1	RP3-425C14.4	-8.42	4.66e-16	2.1e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122465501	chr6:122436789~122439223:-
THCA	cis	rs853679	0.882	rs9461432	ENSG00000219392.1	RP1-265C24.5	-8.42	4.66e-16	2.1e-13	-0.61	-0.36	Depression;	chr6:28119105	chr6:28115628~28116551:+
THCA	cis	rs2274273	0.686	rs68083077	ENSG00000258413.1	RP11-665C16.6	-8.42	4.67e-16	2.1e-13	-0.51	-0.36	Protein biomarker;	chr14:55107710	chr14:55262767~55272075:-
THCA	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	8.42	4.67e-16	2.1e-13	0.37	0.36	Height;	chr11:118758322	chr11:118704607~118750263:+
THCA	cis	rs9475752	0.552	rs13205022	ENSG00000231441.1	RP11-472M19.2	-8.42	4.68e-16	2.11e-13	-0.48	-0.36	Menarche (age at onset);	chr6:56875620	chr6:56844002~56864078:+
THCA	cis	rs8114671	0.836	rs6142294	ENSG00000269202.1	RP4-614O4.12	8.42	4.69e-16	2.11e-13	0.31	0.36	Height;	chr20:35083694	chr20:35201747~35203288:-
THCA	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	8.42	4.7e-16	2.12e-13	0.43	0.36	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000224205.1	AP000351.4	8.42	4.71e-16	2.12e-13	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23987320~23991421:-
THCA	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-8.42	4.71e-16	2.12e-13	-0.46	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
THCA	cis	rs17711722	0.565	rs4717276	ENSG00000164669.11	INTS4P1	-8.42	4.72e-16	2.12e-13	-0.45	-0.36	Calcium levels;	chr7:65829754	chr7:65141225~65234216:+
THCA	cis	rs748404	0.631	rs7167882	ENSG00000205771.5	CATSPER2P1	-8.42	4.72e-16	2.12e-13	-0.38	-0.36	Lung cancer;	chr15:43386465	chr15:43726918~43747094:-
THCA	cis	rs950169	0.58	rs17598114	ENSG00000225151.9	GOLGA2P7	-8.42	4.73e-16	2.13e-13	-0.53	-0.36	Schizophrenia;	chr15:84628086	chr15:84199311~84230136:-
THCA	cis	rs950169	0.58	rs11634322	ENSG00000225151.9	GOLGA2P7	-8.42	4.73e-16	2.13e-13	-0.53	-0.36	Schizophrenia;	chr15:84628978	chr15:84199311~84230136:-
THCA	cis	rs367615	0.918	rs17161895	ENSG00000249476.1	CTD-2587M2.1	8.42	4.74e-16	2.13e-13	0.4	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109520130	chr5:109237120~109326369:-
THCA	cis	rs1799949	0.965	rs4793230	ENSG00000267681.1	CTD-3199J23.6	-8.42	4.74e-16	2.13e-13	-0.42	-0.36	Menopause (age at onset);	chr17:43350035	chr17:43144956~43145255:+
THCA	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	8.42	4.75e-16	2.13e-13	0.56	0.36	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
THCA	cis	rs42490	0.664	rs453266	ENSG00000251136.7	RP11-37B2.1	-8.42	4.75e-16	2.14e-13	-0.31	-0.36	Leprosy;	chr8:89823789	chr8:89609409~89757727:-
THCA	cis	rs42490	0.638	rs369771	ENSG00000251136.7	RP11-37B2.1	-8.42	4.75e-16	2.14e-13	-0.31	-0.36	Leprosy;	chr8:89823884	chr8:89609409~89757727:-
THCA	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-8.42	4.76e-16	2.14e-13	-0.46	-0.36	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
THCA	cis	rs150992	0.711	rs161735	ENSG00000248489.1	CTD-2007H13.3	8.42	4.76e-16	2.14e-13	0.36	0.36	Body mass index;	chr5:98862026	chr5:98929171~98995013:+
THCA	cis	rs11148252	0.774	rs9596649	ENSG00000235660.1	LINC00345	8.41	4.77e-16	2.15e-13	0.45	0.36	Lewy body disease;	chr13:52360475	chr13:52484161~52484680:-
THCA	cis	rs3096299	0.967	rs2965937	ENSG00000274627.1	RP11-104N10.2	8.41	4.79e-16	2.16e-13	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89422371	chr16:89516797~89522217:+
THCA	cis	rs56046484	0.871	rs71397837	ENSG00000259295.5	CSPG4P12	8.41	4.81e-16	2.16e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85020330	chr15:85191438~85213905:+
THCA	cis	rs10740039	0.81	rs2165691	ENSG00000254271.1	RP11-131N11.4	8.41	4.82e-16	2.17e-13	0.46	0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60611891	chr10:60734342~60741828:+
THCA	cis	rs6504663	0.558	rs11871603	ENSG00000275897.1	RP11-94C24.13	8.41	4.83e-16	2.17e-13	0.34	0.36	Visceral fat;	chr17:50481676	chr17:50475819~50478391:+
THCA	cis	rs748404	0.66	rs693510	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43422427	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs690512	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43425480	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs542898	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43427194	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs2249952	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43428335	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs689767	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43429879	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs2439845	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43430412	chr15:43726918~43747094:-
THCA	cis	rs748404	0.631	rs2467745	ENSG00000205771.5	CATSPER2P1	-8.41	4.84e-16	2.17e-13	-0.37	-0.36	Lung cancer;	chr15:43430544	chr15:43726918~43747094:-
THCA	cis	rs4927850	1	rs7630875	ENSG00000226155.1	AC124944.3	-8.41	4.84e-16	2.17e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196026895	chr3:195912049~195913986:+
THCA	cis	rs1707322	0.686	rs11211179	ENSG00000234329.1	RP11-767N6.2	8.41	4.85e-16	2.18e-13	0.34	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.721	rs10157795	ENSG00000234329.1	RP11-767N6.2	8.41	4.85e-16	2.18e-13	0.34	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45651039~45651826:-
THCA	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	8.41	4.85e-16	2.18e-13	0.42	0.36	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
THCA	cis	rs11295209	1	rs11295209	ENSG00000245958.5	RP11-33B1.1	8.41	4.89e-16	2.2e-13	0.32	0.36	Plateletcrit;	chr4:119559079	chr4:119454791~119552025:+
THCA	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-8.41	4.89e-16	2.2e-13	-0.37	-0.36	Height;	chr11:118808920	chr11:118704607~118750263:+
THCA	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-8.41	4.91e-16	2.2e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-8.41	4.91e-16	2.2e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
THCA	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-8.41	4.91e-16	2.2e-13	-0.51	-0.36	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
THCA	cis	rs2408955	0.521	rs1476607	ENSG00000258273.1	RP11-370I10.4	8.41	4.92e-16	2.21e-13	0.48	0.36	Glycated hemoglobin levels;	chr12:48131021	chr12:48333755~48333901:-
THCA	cis	rs375066	0.935	rs10406290	ENSG00000267058.1	RP11-15A1.3	-8.41	4.92e-16	2.21e-13	-0.29	-0.36	Breast cancer;	chr19:43874725	chr19:43891804~43901805:-
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000235689.1	AP000351.13	8.41	4.92e-16	2.21e-13	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:24006305~24008258:-
THCA	cis	rs2408955	0.568	rs12099462	ENSG00000258273.1	RP11-370I10.4	8.41	4.93e-16	2.21e-13	0.48	0.36	Glycated hemoglobin levels;	chr12:48109321	chr12:48333755~48333901:-
THCA	cis	rs7189233	0.531	rs3929	ENSG00000279344.1	RP11-44F14.7	-8.41	4.93e-16	2.22e-13	-0.35	-0.36	Intelligence (multi-trait analysis);	chr16:53490396	chr16:53478957~53481550:-
THCA	cis	rs4842666	0.915	rs2681472	ENSG00000258302.2	RP11-981P6.1	8.41	4.94e-16	2.22e-13	0.36	0.36	Blood pressure;	chr12:89615182	chr12:89561129~89594878:+
THCA	cis	rs9640161	0.789	rs2098053	ENSG00000261305.1	RP4-584D14.7	8.41	4.94e-16	2.22e-13	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150346116	chr7:150341771~150342607:+
THCA	cis	rs4789693	1	rs4789693	ENSG00000265458.1	RP13-20L14.6	8.41	4.94e-16	2.22e-13	0.36	0.36	Glucocorticoid-induced osteonecrosis;	chr17:82463994	chr17:82454273~82458521:-
THCA	cis	rs4927850	0.881	rs7624638	ENSG00000226155.1	AC124944.3	-8.41	4.95e-16	2.22e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196021858	chr3:195912049~195913986:+
THCA	cis	rs860295	1	rs860295	ENSG00000225855.5	RUSC1-AS1	-8.41	4.95e-16	2.22e-13	-0.24	-0.36	Body mass index;	chr1:155797917	chr1:155316863~155324176:-
THCA	cis	rs56046484	0.956	rs35204319	ENSG00000259295.5	CSPG4P12	8.41	4.96e-16	2.23e-13	0.62	0.36	Testicular germ cell tumor;	chr15:85107246	chr15:85191438~85213905:+
THCA	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-8.41	4.97e-16	2.23e-13	-0.38	-0.36	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
THCA	cis	rs8114671	0.562	rs6120763	ENSG00000269202.1	RP4-614O4.12	-8.41	4.98e-16	2.23e-13	-0.3	-0.36	Height;	chr20:34918597	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs3746450	ENSG00000269202.1	RP4-614O4.12	-8.41	4.98e-16	2.23e-13	-0.3	-0.36	Height;	chr20:34920785	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6087649	ENSG00000269202.1	RP4-614O4.12	-8.41	4.98e-16	2.23e-13	-0.3	-0.36	Height;	chr20:34922859	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs4911449	ENSG00000269202.1	RP4-614O4.12	-8.41	4.98e-16	2.23e-13	-0.3	-0.36	Height;	chr20:34924433	chr20:35201747~35203288:-
THCA	cis	rs795484	0.507	rs795482	ENSG00000275759.1	RP11-131L12.3	8.41	4.99e-16	2.24e-13	0.34	0.36	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118153011	chr12:118428281~118428870:+
THCA	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-8.41	5e-16	2.24e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
THCA	cis	rs9926296	0.744	rs164746	ENSG00000260259.1	RP11-368I7.4	8.41	5e-16	2.25e-13	0.4	0.36	Vitiligo;	chr16:89642611	chr16:89682620~89686569:-
THCA	cis	rs4380275	1	rs7562792	ENSG00000272342.1	RP13-539J13.1	8.41	5.02e-16	2.25e-13	0.44	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774469	chr2:739588~740164:-
THCA	cis	rs795484	0.507	rs2249624	ENSG00000275759.1	RP11-131L12.3	8.41	5.02e-16	2.25e-13	0.34	0.36	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;	chr12:118151264	chr12:118428281~118428870:+
THCA	cis	rs9902453	0.505	rs11080107	ENSG00000264007.1	RP11-68I3.10	-8.41	5.03e-16	2.26e-13	-0.42	-0.36	Coffee consumption (cups per day);	chr17:29611406	chr17:29621617~29622254:-
THCA	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	8.41	5.05e-16	2.26e-13	0.46	0.36	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
THCA	cis	rs9475752	0.503	rs60563401	ENSG00000231441.1	RP11-472M19.2	8.41	5.05e-16	2.27e-13	0.44	0.36	Menarche (age at onset);	chr6:56873580	chr6:56844002~56864078:+
THCA	cis	rs4380275	1	rs4268954	ENSG00000272342.1	RP13-539J13.1	8.41	5.05e-16	2.27e-13	0.43	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772834	chr2:739588~740164:-
THCA	cis	rs12701220	0.655	rs9638973	ENSG00000229043.2	AC091729.9	-8.41	5.07e-16	2.28e-13	-0.48	-0.36	Bronchopulmonary dysplasia;	chr7:1094042	chr7:1160374~1165267:+
THCA	cis	rs62355900	0.627	rs62355943	ENSG00000271828.1	CTD-2310F14.1	8.41	5.08e-16	2.28e-13	0.69	0.36	Endometriosis;	chr5:56814472	chr5:56927874~56929573:+
THCA	cis	rs62355900	0.627	rs72758038	ENSG00000271828.1	CTD-2310F14.1	8.41	5.08e-16	2.28e-13	0.69	0.36	Endometriosis;	chr5:56814857	chr5:56927874~56929573:+
THCA	cis	rs7309	0.87	rs2358016	ENSG00000227403.1	AC009299.3	8.41	5.09e-16	2.28e-13	0.39	0.36	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161150919	chr2:161244739~161249050:+
THCA	cis	rs11148252	0.904	rs7321964	ENSG00000235660.1	LINC00345	-8.41	5.1e-16	2.29e-13	-0.45	-0.36	Lewy body disease;	chr13:52466687	chr13:52484161~52484680:-
THCA	cis	rs1062177	0.724	rs2915828	ENSG00000253921.1	CTB-113P19.3	8.41	5.12e-16	2.3e-13	0.44	0.36	Preschool internalizing problems;	chr5:151738560	chr5:151753992~151767247:+
THCA	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	8.41	5.12e-16	2.3e-13	0.24	0.36	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	8.41	5.12e-16	2.3e-13	0.24	0.36	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
THCA	cis	rs4718428	0.705	rs10267335	ENSG00000230295.1	RP11-458F8.2	-8.41	5.13e-16	2.3e-13	-0.32	-0.36	Corneal structure;	chr7:66938233	chr7:66880708~66882981:+
THCA	cis	rs4819052	0.634	rs8128636	ENSG00000215447.6	BX322557.10	-8.4	5.14e-16	2.3e-13	-0.3	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45270718	chr21:45288052~45291738:+
THCA	cis	rs11148252	0.595	rs4884522	ENSG00000235660.1	LINC00345	-8.4	5.15e-16	2.31e-13	-0.46	-0.36	Lewy body disease;	chr13:52479633	chr13:52484161~52484680:-
THCA	cis	rs1707322	0.964	rs1768802	ENSG00000234329.1	RP11-767N6.2	-8.4	5.16e-16	2.32e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1588663	ENSG00000234329.1	RP11-767N6.2	-8.4	5.16e-16	2.32e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1768801	ENSG00000234329.1	RP11-767N6.2	-8.4	5.16e-16	2.32e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs1768800	ENSG00000234329.1	RP11-767N6.2	-8.4	5.16e-16	2.32e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45651039~45651826:-
THCA	cis	rs11148252	0.74	rs7981050	ENSG00000278238.1	RP11-245D16.4	-8.4	5.17e-16	2.32e-13	-0.41	-0.36	Lewy body disease;	chr13:52181014	chr13:52454775~52455331:-
THCA	cis	rs56046484	0.871	rs62021203	ENSG00000259295.5	CSPG4P12	8.4	5.18e-16	2.32e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85020846	chr15:85191438~85213905:+
THCA	cis	rs9322193	0.576	rs7452592	ENSG00000268592.3	RAET1E-AS1	8.4	5.19e-16	2.33e-13	0.58	0.36	Lung cancer;	chr6:149875445	chr6:149863494~149919507:+
THCA	cis	rs2712184	0.875	rs1015784	ENSG00000229352.1	AC007563.3	-8.4	5.2e-16	2.33e-13	-0.44	-0.36	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216817110	chr2:216799608~216805335:+
THCA	cis	rs4819052	0.807	rs4819047	ENSG00000237664.1	LINC00316	-8.4	5.21e-16	2.34e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45245224	chr21:45338590~45341990:-
THCA	cis	rs2274273	1	rs3742566	ENSG00000258413.1	RP11-665C16.6	-8.4	5.22e-16	2.34e-13	-0.48	-0.36	Protein biomarker;	chr14:55129121	chr14:55262767~55272075:-
THCA	cis	rs2274273	1	rs1047556	ENSG00000258413.1	RP11-665C16.6	-8.4	5.22e-16	2.34e-13	-0.48	-0.36	Protein biomarker;	chr14:55133564	chr14:55262767~55272075:-
THCA	cis	rs7849270	0.879	rs7046990	ENSG00000268707.1	RP11-247A12.7	-8.4	5.24e-16	2.35e-13	-0.45	-0.36	Blood metabolite ratios;	chr9:129093859	chr9:129170434~129170940:+
THCA	cis	rs1707322	0.686	rs2230658	ENSG00000234329.1	RP11-767N6.2	-8.4	5.26e-16	2.36e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.686	rs2991986	ENSG00000234329.1	RP11-767N6.2	-8.4	5.26e-16	2.36e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.686	rs2991987	ENSG00000234329.1	RP11-767N6.2	-8.4	5.26e-16	2.36e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45651039~45651826:-
THCA	cis	rs7849270	0.879	rs3124495	ENSG00000268707.1	RP11-247A12.7	8.4	5.27e-16	2.36e-13	0.46	0.36	Blood metabolite ratios;	chr9:129093731	chr9:129170434~129170940:+
THCA	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-8.4	5.28e-16	2.37e-13	-0.57	-0.36	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
THCA	cis	rs8114671	0.967	rs9574	ENSG00000269202.1	RP4-614O4.12	-8.4	5.28e-16	2.37e-13	-0.3	-0.36	Height;	chr20:35176829	chr20:35201747~35203288:-
THCA	cis	rs860295	0.967	rs6665227	ENSG00000225855.5	RUSC1-AS1	8.4	5.3e-16	2.38e-13	0.24	0.36	Body mass index;	chr1:155740669	chr1:155316863~155324176:-
THCA	cis	rs11148252	0.574	rs3742297	ENSG00000235660.1	LINC00345	-8.4	5.31e-16	2.38e-13	-0.45	-0.36	Lewy body disease;	chr13:52703932	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.574	rs9536247	ENSG00000235660.1	LINC00345	-8.4	5.31e-16	2.38e-13	-0.45	-0.36	Lewy body disease;	chr13:52705407	chr13:52484161~52484680:-
THCA	cis	rs7646881	0.812	rs7635704	ENSG00000240207.5	RP11-379F4.4	-8.4	5.31e-16	2.38e-13	-0.51	-0.36	Tetralogy of Fallot;	chr3:158741931	chr3:158732263~158784070:+
THCA	cis	rs9659323	0.73	rs7512189	ENSG00000231365.4	RP11-418J17.1	-8.4	5.31e-16	2.38e-13	-0.35	-0.36	Body mass index;	chr1:118999909	chr1:119140396~119275973:+
THCA	cis	rs416603	0.967	rs7191538	ENSG00000262636.1	CTD-3088G3.4	-8.4	5.32e-16	2.38e-13	-0.45	-0.36	Type 1 diabetes;	chr16:11269532	chr16:11380859~11381118:-
THCA	cis	rs748404	0.66	rs2467742	ENSG00000205771.5	CATSPER2P1	-8.4	5.35e-16	2.39e-13	-0.37	-0.36	Lung cancer;	chr15:43458039	chr15:43726918~43747094:-
THCA	cis	rs748404	0.69	rs2244981	ENSG00000205771.5	CATSPER2P1	-8.4	5.35e-16	2.39e-13	-0.37	-0.36	Lung cancer;	chr15:43460553	chr15:43726918~43747094:-
THCA	cis	rs10463554	0.927	rs11952361	ENSG00000175749.11	EIF3KP1	8.4	5.36e-16	2.4e-13	0.47	0.36	Parkinson's disease;	chr5:102952216	chr5:103032376~103033031:+
THCA	cis	rs42490	0.59	rs39771	ENSG00000251136.7	RP11-37B2.1	-8.4	5.36e-16	2.4e-13	-0.31	-0.36	Leprosy;	chr8:89826378	chr8:89609409~89757727:-
THCA	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-8.4	5.37e-16	2.4e-13	-0.45	-0.36	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
THCA	cis	rs1850744	0.702	rs13104360	ENSG00000250942.1	ENPP7P11	8.4	5.39e-16	2.41e-13	0.49	0.36	Economic and political preferences;	chr4:9683180	chr4:9677308~9677934:+
THCA	cis	rs8114671	0.562	rs4911447	ENSG00000269202.1	RP4-614O4.12	-8.4	5.39e-16	2.41e-13	-0.3	-0.36	Height;	chr20:34891642	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6088642	ENSG00000269202.1	RP4-614O4.12	-8.4	5.39e-16	2.41e-13	-0.3	-0.36	Height;	chr20:34895383	chr20:35201747~35203288:-
THCA	cis	rs2274273	1	rs7140872	ENSG00000258413.1	RP11-665C16.6	-8.4	5.41e-16	2.42e-13	-0.48	-0.36	Protein biomarker;	chr14:55146026	chr14:55262767~55272075:-
THCA	cis	rs2274273	1	rs7493394	ENSG00000258413.1	RP11-665C16.6	-8.4	5.41e-16	2.42e-13	-0.48	-0.36	Protein biomarker;	chr14:55151037	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.967	rs11622740	ENSG00000258413.1	RP11-665C16.6	-8.4	5.41e-16	2.42e-13	-0.48	-0.36	Protein biomarker;	chr14:55151126	chr14:55262767~55272075:-
THCA	cis	rs2274273	1	rs15870	ENSG00000258413.1	RP11-665C16.6	-8.4	5.41e-16	2.42e-13	-0.48	-0.36	Protein biomarker;	chr14:55152593	chr14:55262767~55272075:-
THCA	cis	rs8114671	0.967	rs2069948	ENSG00000269202.1	RP4-614O4.12	-8.4	5.42e-16	2.43e-13	-0.3	-0.36	Height;	chr20:35174686	chr20:35201747~35203288:-
THCA	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	8.4	5.42e-16	2.43e-13	0.52	0.36	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
THCA	cis	rs673078	0.607	rs17440956	ENSG00000275409.1	RP11-131L12.4	8.4	5.43e-16	2.43e-13	0.45	0.36	Glucose homeostasis traits;	chr12:118394639	chr12:118430147~118430699:+
THCA	cis	rs375066	0.935	rs367283	ENSG00000267058.1	RP11-15A1.3	-8.4	5.52e-16	2.47e-13	-0.29	-0.36	Breast cancer;	chr19:43901975	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs448823	ENSG00000267058.1	RP11-15A1.3	-8.4	5.52e-16	2.47e-13	-0.29	-0.36	Breast cancer;	chr19:43902139	chr19:43891804~43901805:-
THCA	cis	rs375066	0.868	rs448829	ENSG00000267058.1	RP11-15A1.3	-8.4	5.52e-16	2.47e-13	-0.29	-0.36	Breast cancer;	chr19:43902169	chr19:43891804~43901805:-
THCA	cis	rs3747113	1	rs13056719	ENSG00000128262.7	POM121L9P	-8.39	5.54e-16	2.48e-13	-0.4	-0.36	Gut microbiome composition (summer);	chr22:24328131	chr22:24251828~24265525:+
THCA	cis	rs56046484	1	rs12911330	ENSG00000259295.5	CSPG4P12	8.39	5.55e-16	2.48e-13	0.62	0.36	Testicular germ cell tumor;	chr15:85087103	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs34919315	ENSG00000259295.5	CSPG4P12	8.39	5.55e-16	2.48e-13	0.62	0.36	Testicular germ cell tumor;	chr15:85088675	chr15:85191438~85213905:+
THCA	cis	rs950169	0.541	rs10795	ENSG00000225151.9	GOLGA2P7	-8.39	5.55e-16	2.48e-13	-0.53	-0.36	Schizophrenia;	chr15:84634066	chr15:84199311~84230136:-
THCA	cis	rs950169	0.58	rs36126054	ENSG00000225151.9	GOLGA2P7	-8.39	5.55e-16	2.48e-13	-0.53	-0.36	Schizophrenia;	chr15:84634492	chr15:84199311~84230136:-
THCA	cis	rs7646881	0.904	rs112493023	ENSG00000240207.5	RP11-379F4.4	-8.39	5.56e-16	2.49e-13	-0.48	-0.36	Tetralogy of Fallot;	chr3:158730487	chr3:158732263~158784070:+
THCA	cis	rs748404	0.66	rs509306	ENSG00000205771.5	CATSPER2P1	-8.39	5.57e-16	2.49e-13	-0.37	-0.36	Lung cancer;	chr15:43422973	chr15:43726918~43747094:-
THCA	cis	rs934734	0.532	rs10153675	ENSG00000237979.1	AC007389.1	-8.39	5.58e-16	2.5e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65422446	chr2:65500993~65502138:-
THCA	cis	rs56046484	0.871	rs34493704	ENSG00000259295.5	CSPG4P12	8.39	5.6e-16	2.5e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85015539	chr15:85191438~85213905:+
THCA	cis	rs748404	0.66	rs518288	ENSG00000205771.5	CATSPER2P1	-8.39	5.6e-16	2.5e-13	-0.37	-0.36	Lung cancer;	chr15:43471801	chr15:43726918~43747094:-
THCA	cis	rs9309473	0.687	rs6706409	ENSG00000163016.8	ALMS1P	-8.39	5.61e-16	2.51e-13	-0.48	-0.36	Metabolite levels;	chr2:73379380	chr2:73644919~73685576:+
THCA	cis	rs9595066	0.627	rs2246432	ENSG00000227258.4	SMIM2-AS1	-8.39	5.61e-16	2.51e-13	-0.45	-0.36	Schizophrenia;	chr13:44182648	chr13:44110451~44240517:+
THCA	cis	rs375066	0.868	rs370190	ENSG00000267058.1	RP11-15A1.3	-8.39	5.62e-16	2.51e-13	-0.29	-0.36	Breast cancer;	chr19:43920102	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs413093	ENSG00000267058.1	RP11-15A1.3	-8.39	5.62e-16	2.51e-13	-0.29	-0.36	Breast cancer;	chr19:43922113	chr19:43891804~43901805:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000224205.1	AP000351.4	8.39	5.64e-16	2.52e-13	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23987320~23991421:-
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000224205.1	AP000351.4	8.39	5.64e-16	2.52e-13	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23987320~23991421:-
THCA	cis	rs6504663	0.558	rs7627	ENSG00000275897.1	RP11-94C24.13	8.39	5.64e-16	2.52e-13	0.35	0.36	Visceral fat;	chr17:50474793	chr17:50475819~50478391:+
THCA	cis	rs11971779	0.68	rs11764236	ENSG00000273391.1	RP11-634H22.1	8.39	5.65e-16	2.52e-13	0.34	0.36	Diisocyanate-induced asthma;	chr7:139433768	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.648	rs66463279	ENSG00000273391.1	RP11-634H22.1	8.39	5.65e-16	2.52e-13	0.34	0.36	Diisocyanate-induced asthma;	chr7:139433915	chr7:139359032~139359566:-
THCA	cis	rs56046484	0.871	rs35000527	ENSG00000259295.5	CSPG4P12	8.39	5.67e-16	2.54e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85010550	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.826	rs35816571	ENSG00000259295.5	CSPG4P12	8.39	5.67e-16	2.54e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85010891	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.871	rs12900736	ENSG00000259295.5	CSPG4P12	8.39	5.67e-16	2.54e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85014909	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.871	rs12904958	ENSG00000259295.5	CSPG4P12	8.39	5.67e-16	2.54e-13	0.65	0.36	Testicular germ cell tumor;	chr15:85014956	chr15:85191438~85213905:+
THCA	cis	rs2562456	0.876	rs62110202	ENSG00000268555.1	RP11-678G14.3	8.39	5.7e-16	2.55e-13	0.5	0.36	Pain;	chr19:21571799	chr19:21570822~21587322:-
THCA	cis	rs73607972	0.569	rs34115013	ENSG00000275191.1	RP11-36I17.2	-8.39	5.7e-16	2.55e-13	-0.49	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53534324	chr16:53628256~53628816:-
THCA	cis	rs73186030	0.92	rs17265703	ENSG00000272758.4	RP11-299J3.8	-8.39	5.73e-16	2.56e-13	-0.45	-0.36	Serum parathyroid hormone levels;	chr3:122329797	chr3:122416207~122443180:+
THCA	cis	rs7291412	0.662	rs6520015	ENSG00000231711.2	LINC00899	-8.39	5.75e-16	2.57e-13	-0.3	-0.36	Dupuytren's disease;Subjective well-being;	chr22:46067551	chr22:46039907~46044853:-
THCA	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	8.39	5.75e-16	2.57e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
THCA	cis	rs9640161	0.673	rs34489187	ENSG00000261305.1	RP4-584D14.7	8.39	5.76e-16	2.57e-13	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150347290	chr7:150341771~150342607:+
THCA	cis	rs7674212	0.531	rs2866416	ENSG00000246560.2	RP11-10L12.4	8.39	5.76e-16	2.57e-13	0.45	0.36	Type 2 diabetes;	chr4:102959554	chr4:102828055~102844075:+
THCA	cis	rs16846053	0.515	rs4664047	ENSG00000227403.1	AC009299.3	-8.39	5.78e-16	2.58e-13	-0.58	-0.36	Blood osmolality (transformed sodium);	chr2:161649360	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs6432699	ENSG00000227403.1	AC009299.3	-8.39	5.78e-16	2.58e-13	-0.58	-0.36	Blood osmolality (transformed sodium);	chr2:161652729	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs6758760	ENSG00000227403.1	AC009299.3	-8.39	5.78e-16	2.58e-13	-0.58	-0.36	Blood osmolality (transformed sodium);	chr2:161654331	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.551	rs12692640	ENSG00000227403.1	AC009299.3	-8.39	5.78e-16	2.58e-13	-0.58	-0.36	Blood osmolality (transformed sodium);	chr2:161669405	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs3849355	ENSG00000227403.1	AC009299.3	-8.39	5.78e-16	2.58e-13	-0.57	-0.36	Blood osmolality (transformed sodium);	chr2:161531204	chr2:161244739~161249050:+
THCA	cis	rs7637701	0.818	rs11717133	ENSG00000240875.4	LINC00886	-8.39	5.79e-16	2.59e-13	-0.29	-0.36	Breast cancer;	chr3:156816792	chr3:156747346~156817062:-
THCA	cis	rs748404	0.66	rs690446	ENSG00000205771.5	CATSPER2P1	-8.39	5.8e-16	2.59e-13	-0.37	-0.36	Lung cancer;	chr15:43469066	chr15:43726918~43747094:-
THCA	cis	rs748404	0.631	rs560191	ENSG00000205771.5	CATSPER2P1	-8.39	5.8e-16	2.59e-13	-0.37	-0.36	Lung cancer;	chr15:43475576	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs2444251	ENSG00000205771.5	CATSPER2P1	-8.39	5.8e-16	2.59e-13	-0.37	-0.36	Lung cancer;	chr15:43496397	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs548704	ENSG00000205771.5	CATSPER2P1	-8.39	5.8e-16	2.59e-13	-0.37	-0.36	Lung cancer;	chr15:43499508	chr15:43726918~43747094:-
THCA	cis	rs748404	0.69	rs2924369	ENSG00000205771.5	CATSPER2P1	8.39	5.8e-16	2.59e-13	0.37	0.36	Lung cancer;	chr15:43485787	chr15:43726918~43747094:-
THCA	cis	rs9309473	0.607	rs7586361	ENSG00000163016.8	ALMS1P	8.39	5.83e-16	2.6e-13	0.48	0.36	Metabolite levels;	chr2:73374478	chr2:73644919~73685576:+
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000228039.3	KB-1125A3.10	8.39	5.84e-16	2.61e-13	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23963780~23964374:+
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000228039.3	KB-1125A3.10	8.39	5.84e-16	2.61e-13	0.45	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23963780~23964374:+
THCA	cis	rs9813712	0.596	rs2587988	ENSG00000228252.7	COL6A4P2	-8.39	5.88e-16	2.62e-13	-0.38	-0.36	Response to amphetamines;	chr3:130201415	chr3:130212823~130273806:+
THCA	cis	rs848490	0.722	rs4729772	ENSG00000214293.7	APTR	8.39	5.89e-16	2.63e-13	0.26	0.36	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77826582	chr7:77657660~77696265:-
THCA	cis	rs2929278	0.562	rs8033846	ENSG00000166763.7	STRCP1	-8.39	5.9e-16	2.63e-13	-0.39	-0.36	Schizophrenia;	chr15:43743165	chr15:43699488~43718184:-
THCA	cis	rs6558530	0.836	rs7461600	ENSG00000253982.1	CTD-2336O2.1	8.39	5.94e-16	2.65e-13	0.32	0.36	Systolic blood pressure;	chr8:1766476	chr8:1761990~1764502:-
THCA	cis	rs150992	0.593	rs34497	ENSG00000248489.1	CTD-2007H13.3	8.39	5.94e-16	2.65e-13	0.35	0.36	Body mass index;	chr5:98962885	chr5:98929171~98995013:+
THCA	cis	rs150992	0.593	rs34496	ENSG00000248489.1	CTD-2007H13.3	8.39	5.94e-16	2.65e-13	0.35	0.36	Body mass index;	chr5:98963812	chr5:98929171~98995013:+
THCA	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	8.39	5.94e-16	2.65e-13	0.35	0.36	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
THCA	cis	rs16846053	0.515	rs4001644	ENSG00000227403.1	AC009299.3	-8.39	5.95e-16	2.65e-13	-0.57	-0.36	Blood osmolality (transformed sodium);	chr2:161542357	chr2:161244739~161249050:+
THCA	cis	rs7849270	0.798	rs7865337	ENSG00000268707.1	RP11-247A12.7	-8.38	5.96e-16	2.66e-13	-0.46	-0.36	Blood metabolite ratios;	chr9:129091799	chr9:129170434~129170940:+
THCA	cis	rs6844153	0.887	rs6835631	ENSG00000240005.4	RP11-293A21.1	8.38	5.96e-16	2.66e-13	0.48	0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26946864	chr4:26859806~26860599:-
THCA	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	8.38	5.97e-16	2.66e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
THCA	cis	rs7044106	0.578	rs4837788	ENSG00000226752.6	PSMD5-AS1	-8.38	5.97e-16	2.66e-13	-0.57	-0.36	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120824828~120854385:+
THCA	cis	rs56046484	0.956	rs17540501	ENSG00000259295.5	CSPG4P12	8.38	5.97e-16	2.66e-13	0.62	0.36	Testicular germ cell tumor;	chr15:85094870	chr15:85191438~85213905:+
THCA	cis	rs748404	0.631	rs6493083	ENSG00000205771.5	CATSPER2P1	-8.38	5.97e-16	2.66e-13	-0.38	-0.36	Lung cancer;	chr15:43345787	chr15:43726918~43747094:-
THCA	cis	rs910316	1	rs4903289	ENSG00000279594.1	RP11-950C14.10	-8.38	5.98e-16	2.67e-13	-0.34	-0.36	Height;	chr14:75157285	chr14:75011269~75012851:-
THCA	cis	rs516805	0.923	rs491171	ENSG00000279453.1	RP3-425C14.4	-8.38	5.99e-16	2.67e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122408021	chr6:122436789~122439223:-
THCA	cis	rs516805	0.923	rs556675	ENSG00000279453.1	RP3-425C14.4	-8.38	5.99e-16	2.67e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122408083	chr6:122436789~122439223:-
THCA	cis	rs516805	0.923	rs487487	ENSG00000279453.1	RP3-425C14.4	-8.38	5.99e-16	2.67e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122422357	chr6:122436789~122439223:-
THCA	cis	rs516805	0.961	rs556439	ENSG00000279453.1	RP3-425C14.4	-8.38	5.99e-16	2.67e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122423864	chr6:122436789~122439223:-
THCA	cis	rs516805	0.961	rs572632	ENSG00000279453.1	RP3-425C14.4	-8.38	5.99e-16	2.67e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122437753	chr6:122436789~122439223:-
THCA	cis	rs748404	0.578	rs576557	ENSG00000205771.5	CATSPER2P1	-8.38	6.01e-16	2.68e-13	-0.37	-0.36	Lung cancer;	chr15:43305539	chr15:43726918~43747094:-
THCA	cis	rs3096299	0.933	rs2965824	ENSG00000274627.1	RP11-104N10.2	8.38	6.02e-16	2.68e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89388898	chr16:89516797~89522217:+
THCA	cis	rs17772222	0.839	rs2274735	ENSG00000258789.1	RP11-507K2.3	-8.38	6.03e-16	2.69e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88505414	chr14:88551597~88552493:+
THCA	cis	rs11673344	0.523	rs10420330	ENSG00000226686.6	LINC01535	8.38	6.05e-16	2.7e-13	0.39	0.36	Obesity-related traits;	chr19:37111269	chr19:37251912~37265535:+
THCA	cis	rs1707322	0.686	rs2991977	ENSG00000234329.1	RP11-767N6.2	-8.38	6.07e-16	2.71e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.656	rs2991981	ENSG00000234329.1	RP11-767N6.2	-8.38	6.07e-16	2.71e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.656	rs3014210	ENSG00000234329.1	RP11-767N6.2	-8.38	6.07e-16	2.71e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45651039~45651826:-
THCA	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	8.38	6.09e-16	2.71e-13	0.23	0.36	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000224205.1	AP000351.4	8.38	6.1e-16	2.72e-13	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23987320~23991421:-
THCA	cis	rs7714584	1	rs4958422	ENSG00000197083.10	ZNF300P1	8.38	6.14e-16	2.73e-13	0.64	0.36	Crohn's disease;	chr5:150807172	chr5:150930645~150946289:-
THCA	cis	rs507080	0.961	rs642530	ENSG00000278376.1	RP11-158I9.8	-8.38	6.14e-16	2.73e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118680047	chr11:118791254~118793137:+
THCA	cis	rs4819052	0.679	rs2838859	ENSG00000215447.6	BX322557.10	-8.38	6.15e-16	2.74e-13	-0.29	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45264602	chr21:45288052~45291738:+
THCA	cis	rs11148252	0.574	rs73186430	ENSG00000235660.1	LINC00345	-8.38	6.18e-16	2.75e-13	-0.45	-0.36	Lewy body disease;	chr13:52658756	chr13:52484161~52484680:-
THCA	cis	rs8114671	0.562	rs6120758	ENSG00000269202.1	RP4-614O4.12	-8.38	6.18e-16	2.75e-13	-0.3	-0.36	Height;	chr20:34904720	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs7266550	ENSG00000269202.1	RP4-614O4.12	-8.38	6.18e-16	2.75e-13	-0.3	-0.36	Height;	chr20:34907707	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs2378294	ENSG00000269202.1	RP4-614O4.12	-8.38	6.18e-16	2.75e-13	-0.3	-0.36	Height;	chr20:34912575	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs2076667	ENSG00000269202.1	RP4-614O4.12	-8.38	6.18e-16	2.75e-13	-0.3	-0.36	Height;	chr20:34919161	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs3818273	ENSG00000269202.1	RP4-614O4.12	-8.38	6.18e-16	2.75e-13	-0.3	-0.36	Height;	chr20:34921472	chr20:35201747~35203288:-
THCA	cis	rs1062177	0.756	rs2915815	ENSG00000253921.1	CTB-113P19.3	8.38	6.18e-16	2.75e-13	0.44	0.36	Preschool internalizing problems;	chr5:151736322	chr5:151753992~151767247:+
THCA	cis	rs7674212	0.507	rs223361	ENSG00000246560.2	RP11-10L12.4	8.38	6.19e-16	2.76e-13	0.45	0.36	Type 2 diabetes;	chr4:102848147	chr4:102828055~102844075:+
THCA	cis	rs28510890	0.754	rs8033582	ENSG00000260337.3	RP11-386M24.6	8.38	6.19e-16	2.76e-13	0.4	0.36	Lung cancer in ever smokers;	chr15:92582658	chr15:92592574~92596462:-
THCA	cis	rs737008	0.922	rs2550475	ENSG00000262703.1	RP11-485G7.6	8.38	6.2e-16	2.76e-13	0.42	0.36	Obesity-related traits;	chr16:11278129	chr16:11348143~11349321:-
THCA	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-8.38	6.21e-16	2.76e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
THCA	cis	rs8114671	0.967	rs4911472	ENSG00000269202.1	RP4-614O4.12	-8.38	6.21e-16	2.77e-13	-0.3	-0.36	Height;	chr20:35187574	chr20:35201747~35203288:-
THCA	cis	rs7191700	0.511	rs8043625	ENSG00000262636.1	CTD-3088G3.4	-8.38	6.22e-16	2.77e-13	-0.45	-0.36	Multiple sclerosis;	chr16:11268038	chr16:11380859~11381118:-
THCA	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	8.38	6.23e-16	2.77e-13	0.24	0.36	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
THCA	cis	rs1707322	0.752	rs6662164	ENSG00000234329.1	RP11-767N6.2	8.38	6.24e-16	2.78e-13	0.34	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45651039~45651826:-
THCA	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-8.38	6.25e-16	2.78e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-8.38	6.25e-16	2.78e-13	-0.73	-0.36	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
THCA	cis	rs7727544	0.625	rs3091338	ENSG00000237714.1	P4HA2-AS1	8.38	6.27e-16	2.79e-13	0.48	0.36	Blood metabolite levels;	chr5:132067045	chr5:132184876~132192808:+
THCA	cis	rs7849270	0.801	rs10819475	ENSG00000268707.1	RP11-247A12.7	8.38	6.27e-16	2.79e-13	0.46	0.36	Blood metabolite ratios;	chr9:129168561	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.76	rs419636	ENSG00000268707.1	RP11-247A12.7	8.38	6.27e-16	2.79e-13	0.46	0.36	Blood metabolite ratios;	chr9:129168998	chr9:129170434~129170940:+
THCA	cis	rs3847687	1	rs11061303	ENSG00000256810.1	RP11-76C10.2	8.38	6.27e-16	2.79e-13	0.43	0.36	Longevity;	chr12:131041777	chr12:131030570~131035487:-
THCA	cis	rs984222	0.62	rs10923763	ENSG00000231365.4	RP11-418J17.1	8.38	6.28e-16	2.79e-13	0.35	0.36	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119175597	chr1:119140396~119275973:+
THCA	cis	rs667920	0.573	rs9682783	ENSG00000239213.4	NCK1-AS1	8.38	6.28e-16	2.8e-13	0.38	0.36	Coronary artery disease;	chr3:136820847	chr3:136841726~136862054:-
THCA	cis	rs8114671	0.836	rs6141526	ENSG00000269202.1	RP4-614O4.12	8.38	6.28e-16	2.8e-13	0.31	0.36	Height;	chr20:35027452	chr20:35201747~35203288:-
THCA	cis	rs73186030	0.92	rs73186053	ENSG00000272758.4	RP11-299J3.8	8.38	6.29e-16	2.8e-13	0.45	0.36	Serum parathyroid hormone levels;	chr3:122322009	chr3:122416207~122443180:+
THCA	cis	rs11690935	0.549	rs62183819	ENSG00000228389.1	AC068039.4	-8.38	6.32e-16	2.81e-13	-0.37	-0.36	Schizophrenia;	chr2:172039610	chr2:171773482~171775844:+
THCA	cis	rs7191700	0.578	rs243324	ENSG00000262636.1	CTD-3088G3.4	8.38	6.33e-16	2.82e-13	0.45	0.36	Multiple sclerosis;	chr16:11261113	chr16:11380859~11381118:-
THCA	cis	rs910316	0.763	rs175057	ENSG00000279594.1	RP11-950C14.10	-8.38	6.34e-16	2.82e-13	-0.34	-0.36	Height;	chr14:75022929	chr14:75011269~75012851:-
THCA	cis	rs4927850	0.957	rs4927851	ENSG00000226155.1	AC124944.3	-8.38	6.35e-16	2.82e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196024982	chr3:195912049~195913986:+
THCA	cis	rs4927850	0.918	rs4361313	ENSG00000226155.1	AC124944.3	-8.38	6.35e-16	2.82e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196025389	chr3:195912049~195913986:+
THCA	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-8.38	6.35e-16	2.83e-13	-0.37	-0.36	Height;	chr11:118761813	chr11:118704607~118750263:+
THCA	cis	rs3096299	0.933	rs889576	ENSG00000274627.1	RP11-104N10.2	-8.37	6.42e-16	2.85e-13	-0.35	-0.36	Multiple myeloma (IgH translocation);	chr16:89363245	chr16:89516797~89522217:+
THCA	cis	rs150992	0.751	rs172874	ENSG00000248489.1	CTD-2007H13.3	8.37	6.42e-16	2.85e-13	0.35	0.36	Body mass index;	chr5:98969402	chr5:98929171~98995013:+
THCA	cis	rs8114671	0.562	rs1060615	ENSG00000269202.1	RP4-614O4.12	8.37	6.43e-16	2.86e-13	0.3	0.36	Height;	chr20:34890578	chr20:35201747~35203288:-
THCA	cis	rs5769707	0.872	rs5770604	ENSG00000235111.1	RP1-29C18.8	-8.37	6.43e-16	2.86e-13	-0.42	-0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49637024	chr22:49612657~49615716:-
THCA	cis	rs4380275	0.965	rs4315562	ENSG00000272342.1	RP13-539J13.1	8.37	6.45e-16	2.87e-13	0.43	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772723	chr2:739588~740164:-
THCA	cis	rs4927850	1	rs7627706	ENSG00000226155.1	AC124944.3	-8.37	6.46e-16	2.87e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196026482	chr3:195912049~195913986:+
THCA	cis	rs4927850	0.881	rs7630489	ENSG00000226155.1	AC124944.3	-8.37	6.46e-16	2.87e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196026530	chr3:195912049~195913986:+
THCA	cis	rs4927850	1	rs7627868	ENSG00000226155.1	AC124944.3	-8.37	6.46e-16	2.87e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196026602	chr3:195912049~195913986:+
THCA	cis	rs1707322	0.656	rs9429172	ENSG00000234329.1	RP11-767N6.2	-8.37	6.47e-16	2.88e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45651039~45651826:-
THCA	cis	rs42490	0.664	rs39515	ENSG00000251136.7	RP11-37B2.1	-8.37	6.5e-16	2.89e-13	-0.31	-0.36	Leprosy;	chr8:89816761	chr8:89609409~89757727:-
THCA	cis	rs9543976	1	rs73223968	ENSG00000261553.4	RP11-29G8.3	-8.37	6.5e-16	2.89e-13	-0.48	-0.36	Diabetic retinopathy;	chr13:75567585	chr13:75549773~75807120:+
THCA	cis	rs9543976	1	rs2296146	ENSG00000261553.4	RP11-29G8.3	-8.37	6.5e-16	2.89e-13	-0.48	-0.36	Diabetic retinopathy;	chr13:75569436	chr13:75549773~75807120:+
THCA	cis	rs10740039	0.732	rs10159808	ENSG00000254271.1	RP11-131N11.4	8.37	6.51e-16	2.89e-13	0.46	0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60602432	chr10:60734342~60741828:+
THCA	cis	rs10875746	0.624	rs10875777	ENSG00000240399.1	RP1-228P16.1	-8.37	6.51e-16	2.9e-13	-0.39	-0.36	Longevity (90 years and older);	chr12:48228288	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.669	rs61941006	ENSG00000240399.1	RP1-228P16.1	-8.37	6.51e-16	2.9e-13	-0.39	-0.36	Longevity (90 years and older);	chr12:48237350	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.669	rs1021313	ENSG00000240399.1	RP1-228P16.1	-8.37	6.51e-16	2.9e-13	-0.39	-0.36	Longevity (90 years and older);	chr12:48244258	chr12:48054813~48055591:-
THCA	cis	rs61041384	0.661	rs4474478	ENSG00000256092.2	RP13-942N8.1	-8.37	6.54e-16	2.9e-13	-0.55	-0.36	Schizophrenia;	chr12:123249821	chr12:123363868~123366113:+
THCA	cis	rs61041384	0.661	rs4759411	ENSG00000256092.2	RP13-942N8.1	-8.37	6.54e-16	2.9e-13	-0.55	-0.36	Schizophrenia;	chr12:123256296	chr12:123363868~123366113:+
THCA	cis	rs55665837	1	rs12364959	ENSG00000251991.1	RNU7-49P	8.37	6.55e-16	2.91e-13	0.4	0.36	Vitamin D levels;	chr11:14485889	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs2305305	ENSG00000251991.1	RNU7-49P	8.37	6.55e-16	2.91e-13	0.4	0.36	Vitamin D levels;	chr11:14519396	chr11:14478892~14478953:+
THCA	cis	rs7247513	0.78	rs4804725	ENSG00000230310.1	CTD-2192J16.11	-8.37	6.57e-16	2.92e-13	-0.44	-0.36	Bipolar disorder;	chr19:12612331	chr19:12552597~12553644:+
THCA	cis	rs8114671	0.562	rs6087653	ENSG00000269202.1	RP4-614O4.12	-8.37	6.58e-16	2.92e-13	-0.3	-0.36	Height;	chr20:34934251	chr20:35201747~35203288:-
THCA	cis	rs12701220	0.655	rs7799656	ENSG00000229043.2	AC091729.9	-8.37	6.59e-16	2.93e-13	-0.48	-0.36	Bronchopulmonary dysplasia;	chr7:1100879	chr7:1160374~1165267:+
THCA	cis	rs987724	0.571	rs7641929	ENSG00000240875.4	LINC00886	-8.37	6.6e-16	2.93e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156811605	chr3:156747346~156817062:-
THCA	cis	rs987724	0.531	rs12492804	ENSG00000240875.4	LINC00886	-8.37	6.6e-16	2.93e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156814356	chr3:156747346~156817062:-
THCA	cis	rs987724	0.592	rs12497539	ENSG00000240875.4	LINC00886	-8.37	6.6e-16	2.93e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816148	chr3:156747346~156817062:-
THCA	cis	rs987724	0.571	rs59717073	ENSG00000240875.4	LINC00886	-8.37	6.6e-16	2.93e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156816456	chr3:156747346~156817062:-
THCA	cis	rs7727544	0.606	rs11950562	ENSG00000237714.1	P4HA2-AS1	8.37	6.6e-16	2.93e-13	0.47	0.36	Blood metabolite levels;	chr5:132316836	chr5:132184876~132192808:+
THCA	cis	rs7829975	0.807	rs519019	ENSG00000253893.2	FAM85B	8.37	6.61e-16	2.93e-13	0.45	0.36	Mood instability;	chr8:8737594	chr8:8167819~8226614:-
THCA	cis	rs10050311	0.79	rs17751427	ENSG00000251411.1	RP11-397E7.4	-8.37	6.61e-16	2.94e-13	-0.44	-0.36	Insulin-related traits;	chr4:86909939	chr4:86913266~86914817:-
THCA	cis	rs11096990	0.634	rs2276888	ENSG00000249685.1	RP11-360F5.3	-8.37	6.62e-16	2.94e-13	-0.43	-0.36	Cognitive function;	chr4:39278287	chr4:39133913~39135608:+
THCA	cis	rs748404	0.578	rs510108	ENSG00000205771.5	CATSPER2P1	-8.37	6.62e-16	2.94e-13	-0.37	-0.36	Lung cancer;	chr15:43313241	chr15:43726918~43747094:-
THCA	cis	rs1930961	1	rs59226697	ENSG00000272977.1	CTA-390C10.10	-8.37	6.62e-16	2.94e-13	-0.76	-0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25476218~25479971:+
THCA	cis	rs375066	0.935	rs371875	ENSG00000267058.1	RP11-15A1.3	-8.37	6.63e-16	2.94e-13	-0.29	-0.36	Breast cancer;	chr19:43889105	chr19:43891804~43901805:-
THCA	cis	rs7665090	1	rs909349	ENSG00000246560.2	RP11-10L12.4	-8.37	6.63e-16	2.95e-13	-0.43	-0.36	Primary biliary cholangitis;	chr4:102635159	chr4:102828055~102844075:+
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000224205.1	AP000351.4	8.37	6.66e-16	2.96e-13	0.42	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23987320~23991421:-
THCA	cis	rs42490	0.638	rs40637	ENSG00000251136.7	RP11-37B2.1	-8.37	6.67e-16	2.96e-13	-0.31	-0.36	Leprosy;	chr8:89811082	chr8:89609409~89757727:-
THCA	cis	rs8114671	0.528	rs6119542	ENSG00000269202.1	RP4-614O4.12	-8.37	6.68e-16	2.97e-13	-0.3	-0.36	Height;	chr20:34896742	chr20:35201747~35203288:-
THCA	cis	rs1005277	0.579	rs1740737	ENSG00000263064.2	RP11-291L22.7	8.37	6.69e-16	2.97e-13	0.41	0.36	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38448689~38448949:+
THCA	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-8.37	6.7e-16	2.97e-13	-0.45	-0.36	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
THCA	cis	rs8114671	0.562	rs6087642	ENSG00000269202.1	RP4-614O4.12	-8.37	6.71e-16	2.98e-13	-0.3	-0.36	Height;	chr20:34880503	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6088636	ENSG00000269202.1	RP4-614O4.12	-8.37	6.71e-16	2.98e-13	-0.3	-0.36	Height;	chr20:34881943	chr20:35201747~35203288:-
THCA	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	8.37	6.73e-16	2.99e-13	0.24	0.36	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
THCA	cis	rs8114671	0.967	rs6058202	ENSG00000269202.1	RP4-614O4.12	-8.37	6.73e-16	2.99e-13	-0.3	-0.36	Height;	chr20:35190180	chr20:35201747~35203288:-
THCA	cis	rs62355901	0.545	rs12654176	ENSG00000271828.1	CTD-2310F14.1	8.37	6.73e-16	2.99e-13	0.63	0.36	Breast cancer;	chr5:56762660	chr5:56927874~56929573:+
THCA	cis	rs1062177	0.724	rs2964590	ENSG00000253921.1	CTB-113P19.3	8.37	6.75e-16	3e-13	0.44	0.36	Preschool internalizing problems;	chr5:151738585	chr5:151753992~151767247:+
THCA	cis	rs10740039	0.81	rs1006956	ENSG00000254271.1	RP11-131N11.4	-8.37	6.76e-16	3e-13	-0.46	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60608218	chr10:60734342~60741828:+
THCA	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-8.37	6.76e-16	3e-13	-0.5	-0.36	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
THCA	cis	rs1062177	0.694	rs2915816	ENSG00000253921.1	CTB-113P19.3	8.37	6.77e-16	3e-13	0.42	0.36	Preschool internalizing problems;	chr5:151736296	chr5:151753992~151767247:+
THCA	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-8.37	6.77e-16	3e-13	-0.42	-0.36	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
THCA	cis	rs55665837	1	rs10832257	ENSG00000251991.1	RNU7-49P	8.37	6.77e-16	3.01e-13	0.4	0.36	Vitamin D levels;	chr11:14421770	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs12288873	ENSG00000251991.1	RNU7-49P	8.37	6.77e-16	3.01e-13	0.4	0.36	Vitamin D levels;	chr11:14428919	chr11:14478892~14478953:+
THCA	cis	rs7674212	0.507	rs223322	ENSG00000246560.2	RP11-10L12.4	8.37	6.78e-16	3.01e-13	0.45	0.36	Type 2 diabetes;	chr4:102879037	chr4:102828055~102844075:+
THCA	cis	rs9309473	0.687	rs11126399	ENSG00000163016.8	ALMS1P	8.37	6.8e-16	3.02e-13	0.49	0.36	Metabolite levels;	chr2:73386213	chr2:73644919~73685576:+
THCA	cis	rs7576126	1	rs7576126	ENSG00000237979.1	AC007389.1	-8.37	6.81e-16	3.02e-13	-0.4	-0.36	Severe influenza A (H1N1) infection;	chr2:65431235	chr2:65500993~65502138:-
THCA	cis	rs17772222	0.682	rs2401751	ENSG00000258789.1	RP11-507K2.3	8.37	6.81e-16	3.02e-13	0.35	0.36	Coronary artery calcification;	chr14:88480278	chr14:88551597~88552493:+
THCA	cis	rs1707322	0.686	rs1541131	ENSG00000234329.1	RP11-767N6.2	-8.37	6.82e-16	3.03e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45651039~45651826:-
THCA	cis	rs748404	0.66	rs2467738	ENSG00000205771.5	CATSPER2P1	-8.37	6.84e-16	3.03e-13	-0.37	-0.36	Lung cancer;	chr15:43447738	chr15:43726918~43747094:-
THCA	cis	rs950169	0.649	rs12911612	ENSG00000225151.9	GOLGA2P7	-8.37	6.84e-16	3.03e-13	-0.56	-0.36	Schizophrenia;	chr15:84022262	chr15:84199311~84230136:-
THCA	cis	rs950169	0.649	rs12905952	ENSG00000225151.9	GOLGA2P7	-8.37	6.84e-16	3.03e-13	-0.56	-0.36	Schizophrenia;	chr15:84022509	chr15:84199311~84230136:-
THCA	cis	rs950169	0.61	rs34529571	ENSG00000225151.9	GOLGA2P7	-8.37	6.84e-16	3.03e-13	-0.56	-0.36	Schizophrenia;	chr15:84023055	chr15:84199311~84230136:-
THCA	cis	rs9918079	1	rs9918079	ENSG00000273133.1	RP11-799M12.2	8.37	6.85e-16	3.04e-13	0.56	0.36	Obesity-related traits;	chr4:15543787	chr4:15563698~15564253:-
THCA	cis	rs7727544	0.582	rs6896703	ENSG00000237714.1	P4HA2-AS1	-8.37	6.86e-16	3.04e-13	-0.46	-0.36	Blood metabolite levels;	chr5:132185602	chr5:132184876~132192808:+
THCA	cis	rs55665837	1	rs34980103	ENSG00000251991.1	RNU7-49P	8.37	6.9e-16	3.06e-13	0.4	0.36	Vitamin D levels;	chr11:14491339	chr11:14478892~14478953:+
THCA	cis	rs875971	0.522	rs2949690	ENSG00000237310.1	GS1-124K5.4	-8.37	6.9e-16	3.06e-13	-0.26	-0.36	Aortic root size;	chr7:66018255	chr7:66493706~66495474:+
THCA	cis	rs13068223	0.584	rs345985	ENSG00000243926.1	TIPARP-AS1	-8.36	6.9e-16	3.06e-13	-0.35	-0.36	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679385	chr3:156671862~156674378:-
THCA	cis	rs922182	0.556	rs12443020	ENSG00000275785.1	RP11-111E14.2	8.36	6.9e-16	3.06e-13	0.43	0.36	Blood protein levels;	chr15:63923624	chr15:63890030~63890317:+
THCA	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	8.36	6.92e-16	3.07e-13	0.44	0.36	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
THCA	cis	rs55665837	1	rs10766182	ENSG00000251991.1	RNU7-49P	8.36	6.95e-16	3.08e-13	0.4	0.36	Vitamin D levels;	chr11:14477990	chr11:14478892~14478953:+
THCA	cis	rs1005277	0.579	rs932538	ENSG00000263064.2	RP11-291L22.7	8.36	6.96e-16	3.08e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.541	rs2472177	ENSG00000263064.2	RP11-291L22.7	8.36	6.96e-16	3.08e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472178	ENSG00000263064.2	RP11-291L22.7	8.36	6.96e-16	3.08e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474572	ENSG00000263064.2	RP11-291L22.7	8.36	6.96e-16	3.08e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2505198	ENSG00000263064.2	RP11-291L22.7	8.36	6.96e-16	3.08e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38448689~38448949:+
THCA	cis	rs7811142	1	rs60257855	ENSG00000242294.5	STAG3L5P	8.36	6.96e-16	3.08e-13	0.24	0.36	Platelet count;	chr7:100429157	chr7:100336079~100351900:+
THCA	cis	rs7849270	1	rs3124513	ENSG00000268707.1	RP11-247A12.7	8.36	6.96e-16	3.09e-13	0.45	0.36	Blood metabolite ratios;	chr9:129142314	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs3124514	ENSG00000268707.1	RP11-247A12.7	8.36	6.96e-16	3.09e-13	0.45	0.36	Blood metabolite ratios;	chr9:129142329	chr9:129170434~129170940:+
THCA	cis	rs16846053	0.515	rs6750756	ENSG00000227403.1	AC009299.3	-8.36	6.99e-16	3.1e-13	-0.57	-0.36	Blood osmolality (transformed sodium);	chr2:161659798	chr2:161244739~161249050:+
THCA	cis	rs1850744	0.702	rs10939428	ENSG00000250942.1	ENPP7P11	8.36	7.02e-16	3.11e-13	0.49	0.36	Economic and political preferences;	chr4:9628417	chr4:9677308~9677934:+
THCA	cis	rs4713118	0.629	rs203887	ENSG00000280107.1	AL022393.9	-8.36	7.02e-16	3.11e-13	-0.45	-0.36	Parkinson's disease;	chr6:28053491	chr6:28170845~28172521:+
THCA	cis	rs1707322	1	rs1707303	ENSG00000234329.1	RP11-767N6.2	-8.36	7.02e-16	3.11e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs13050359	ENSG00000237664.1	LINC00316	-8.36	7.07e-16	3.13e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252756	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4819049	ENSG00000237664.1	LINC00316	-8.36	7.07e-16	3.13e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45253171	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs13052344	ENSG00000237664.1	LINC00316	-8.36	7.07e-16	3.13e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256186	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.808	rs11909411	ENSG00000237664.1	LINC00316	-8.36	7.07e-16	3.13e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256641	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs28676615	ENSG00000237664.1	LINC00316	-8.36	7.07e-16	3.13e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256661	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs28501512	ENSG00000237664.1	LINC00316	-8.36	7.07e-16	3.13e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45256787	chr21:45338590~45341990:-
THCA	cis	rs737008	0.96	rs34764020	ENSG00000262703.1	RP11-485G7.6	-8.36	7.11e-16	3.15e-13	-0.41	-0.36	Obesity-related traits;	chr16:11284502	chr16:11348143~11349321:-
THCA	cis	rs7615952	0.576	rs17523380	ENSG00000250012.1	RP11-124N2.1	-8.36	7.17e-16	3.17e-13	-0.31	-0.36	Blood pressure (smoking interaction);	chr3:126084031	chr3:126084220~126095349:+
THCA	cis	rs11096990	0.634	rs60016848	ENSG00000249685.1	RP11-360F5.3	-8.36	7.22e-16	3.2e-13	-0.43	-0.36	Cognitive function;	chr4:39281436	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.577	rs6830736	ENSG00000249685.1	RP11-360F5.3	-8.36	7.22e-16	3.2e-13	-0.43	-0.36	Cognitive function;	chr4:39281467	chr4:39133913~39135608:+
THCA	cis	rs2439831	0.85	rs12442297	ENSG00000249839.1	AC011330.5	-8.36	7.22e-16	3.2e-13	-0.58	-0.36	Lung cancer in ever smokers;	chr15:43876272	chr15:43663654~43684339:-
THCA	cis	rs17711722	0.74	rs7809991	ENSG00000237310.1	GS1-124K5.4	8.36	7.23e-16	3.2e-13	0.26	0.36	Calcium levels;	chr7:65941231	chr7:66493706~66495474:+
THCA	cis	rs42490	0.727	rs42481	ENSG00000251136.7	RP11-37B2.1	8.36	7.23e-16	3.2e-13	0.31	0.36	Leprosy;	chr8:89825486	chr8:89609409~89757727:-
THCA	cis	rs1499614	1	rs2707832	ENSG00000273142.1	RP11-458F8.4	-8.36	7.23e-16	3.2e-13	-0.46	-0.36	Gout;	chr7:66671562	chr7:66902857~66906297:+
THCA	cis	rs270601	0.77	rs10463891	ENSG00000233006.5	AC034220.3	-8.36	7.25e-16	3.21e-13	-0.28	-0.36	Acylcarnitine levels;	chr5:132261699	chr5:132311285~132369916:-
THCA	cis	rs600231	0.706	rs10896016	ENSG00000245532.5	NEAT1	-8.36	7.26e-16	3.21e-13	-0.26	-0.36	Bone mineral density;	chr11:65568234	chr11:65422774~65445540:+
THCA	cis	rs516805	0.961	rs544099	ENSG00000279453.1	RP3-425C14.4	8.36	7.28e-16	3.22e-13	0.32	0.36	Lymphocyte counts;	chr6:122479837	chr6:122436789~122439223:-
THCA	cis	rs8114671	0.933	rs6087683	ENSG00000269202.1	RP4-614O4.12	-8.36	7.28e-16	3.22e-13	-0.3	-0.36	Height;	chr20:35186641	chr20:35201747~35203288:-
THCA	cis	rs934734	0.532	rs13383320	ENSG00000237979.1	AC007389.1	-8.36	7.3e-16	3.23e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65418003	chr2:65500993~65502138:-
THCA	cis	rs853679	0.882	rs9468300	ENSG00000280107.1	AL022393.9	-8.36	7.31e-16	3.24e-13	-0.55	-0.36	Depression;	chr6:28159062	chr6:28170845~28172521:+
THCA	cis	rs3096299	0.967	rs28689480	ENSG00000274627.1	RP11-104N10.2	8.36	7.31e-16	3.24e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89393685	chr16:89516797~89522217:+
THCA	cis	rs7646881	1	rs61558956	ENSG00000240207.5	RP11-379F4.4	-8.36	7.31e-16	3.24e-13	-0.48	-0.36	Tetralogy of Fallot;	chr3:158734866	chr3:158732263~158784070:+
THCA	cis	rs875971	0.522	rs4502988	ENSG00000237310.1	GS1-124K5.4	8.36	7.32e-16	3.24e-13	0.26	0.36	Aortic root size;	chr7:65832759	chr7:66493706~66495474:+
THCA	cis	rs875971	0.522	rs10807697	ENSG00000237310.1	GS1-124K5.4	8.36	7.32e-16	3.24e-13	0.26	0.36	Aortic root size;	chr7:65951183	chr7:66493706~66495474:+
THCA	cis	rs910316	1	rs10136948	ENSG00000279594.1	RP11-950C14.10	8.36	7.32e-16	3.24e-13	0.33	0.36	Height;	chr14:75044372	chr14:75011269~75012851:-
THCA	cis	rs66887589	0.967	rs56173225	ENSG00000245958.5	RP11-33B1.1	8.36	7.33e-16	3.25e-13	0.31	0.36	Diastolic blood pressure;	chr4:119588817	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.967	rs7678973	ENSG00000245958.5	RP11-33B1.1	8.36	7.33e-16	3.25e-13	0.31	0.36	Diastolic blood pressure;	chr4:119590662	chr4:119454791~119552025:+
THCA	cis	rs2562456	0.876	rs11085468	ENSG00000268555.1	RP11-678G14.3	8.36	7.35e-16	3.25e-13	0.5	0.36	Pain;	chr19:21569087	chr19:21570822~21587322:-
THCA	cis	rs516805	0.781	rs560717	ENSG00000279453.1	RP3-425C14.4	-8.36	7.36e-16	3.26e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122482909	chr6:122436789~122439223:-
THCA	cis	rs7208859	0.778	rs6505219	ENSG00000263531.1	RP13-753N3.1	8.36	7.36e-16	3.26e-13	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30938603	chr17:30863921~30864940:-
THCA	cis	rs9532669	0.89	rs9532627	ENSG00000176268.5	CYCSP34	8.36	7.38e-16	3.27e-13	0.41	0.36	Cervical cancer;	chr13:40874811	chr13:40863599~40863902:-
THCA	cis	rs748404	0.66	rs493377	ENSG00000205771.5	CATSPER2P1	-8.36	7.4e-16	3.27e-13	-0.37	-0.36	Lung cancer;	chr15:43481269	chr15:43726918~43747094:-
THCA	cis	rs947583	1	rs6570043	ENSG00000231028.7	LINC00271	-8.36	7.4e-16	3.27e-13	-0.29	-0.36	Phosphorus levels;	chr6:135812960	chr6:135497801~135716055:+
THCA	cis	rs453301	0.653	rs7005133	ENSG00000253893.2	FAM85B	-8.36	7.4e-16	3.28e-13	-0.44	-0.36	Joint mobility (Beighton score);	chr8:9043712	chr8:8167819~8226614:-
THCA	cis	rs9309473	0.607	rs11686504	ENSG00000163016.8	ALMS1P	8.35	7.46e-16	3.3e-13	0.48	0.36	Metabolite levels;	chr2:73352684	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.607	rs7573719	ENSG00000163016.8	ALMS1P	8.35	7.46e-16	3.3e-13	0.48	0.36	Metabolite levels;	chr2:73355858	chr2:73644919~73685576:+
THCA	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	8.35	7.47e-16	3.3e-13	0.44	0.36	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
THCA	cis	rs9309473	0.554	rs4330127	ENSG00000163016.8	ALMS1P	8.35	7.49e-16	3.31e-13	0.48	0.36	Metabolite levels;	chr2:73354192	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.718	rs6546829	ENSG00000163016.8	ALMS1P	8.35	7.52e-16	3.32e-13	0.48	0.36	Metabolite levels;	chr2:73386661	chr2:73644919~73685576:+
THCA	cis	rs17772222	0.682	rs28711639	ENSG00000258789.1	RP11-507K2.3	-8.35	7.53e-16	3.33e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88482277	chr14:88551597~88552493:+
THCA	cis	rs9309473	0.687	rs7576824	ENSG00000163016.8	ALMS1P	-8.35	7.56e-16	3.34e-13	-0.48	-0.36	Metabolite levels;	chr2:73384153	chr2:73644919~73685576:+
THCA	cis	rs13129231	0.806	rs17676882	ENSG00000206820.1	RNU1-138P	-8.35	7.58e-16	3.35e-13	-0.44	-0.36	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113451912	chr4:113420323~113420486:+
THCA	cis	rs7221109	1	rs7221109	ENSG00000278834.1	RP11-458J1.1	8.35	7.62e-16	3.37e-13	0.37	0.36	Type 1 diabetes;	chr17:40614034	chr17:40648300~40649718:+
THCA	cis	rs9847710	0.67	rs36051354	ENSG00000242142.1	SERBP1P3	8.35	7.67e-16	3.39e-13	0.43	0.36	Ulcerative colitis;	chr3:52951996	chr3:53064283~53065091:-
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000235689.1	AP000351.13	8.35	7.69e-16	3.4e-13	0.44	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:24006305~24008258:-
THCA	cis	rs9640161	0.636	rs3735171	ENSG00000261305.1	RP4-584D14.7	8.35	7.73e-16	3.41e-13	0.45	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150336793	chr7:150341771~150342607:+
THCA	cis	rs42490	0.664	rs376110	ENSG00000251136.7	RP11-37B2.1	-8.35	7.77e-16	3.43e-13	-0.31	-0.36	Leprosy;	chr8:89819362	chr8:89609409~89757727:-
THCA	cis	rs9813712	0.526	rs13065659	ENSG00000228252.7	COL6A4P2	-8.35	7.79e-16	3.44e-13	-0.37	-0.36	Response to amphetamines;	chr3:130231945	chr3:130212823~130273806:+
THCA	cis	rs42490	0.57	rs454561	ENSG00000251136.7	RP11-37B2.1	-8.35	7.79e-16	3.44e-13	-0.31	-0.36	Leprosy;	chr8:89824387	chr8:89609409~89757727:-
THCA	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	8.35	7.8e-16	3.44e-13	0.24	0.36	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
THCA	cis	rs42490	0.635	rs42186	ENSG00000251136.7	RP11-37B2.1	-8.35	7.81e-16	3.45e-13	-0.31	-0.36	Leprosy;	chr8:89827257	chr8:89609409~89757727:-
THCA	cis	rs42490	0.7	rs40250	ENSG00000251136.7	RP11-37B2.1	-8.35	7.81e-16	3.45e-13	-0.31	-0.36	Leprosy;	chr8:89828779	chr8:89609409~89757727:-
THCA	cis	rs42490	0.7	rs419890	ENSG00000251136.7	RP11-37B2.1	-8.35	7.81e-16	3.45e-13	-0.31	-0.36	Leprosy;	chr8:89829012	chr8:89609409~89757727:-
THCA	cis	rs11051970	0.918	rs11051969	ENSG00000274964.1	RP11-817I4.1	-8.35	7.81e-16	3.45e-13	-0.41	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32384189	chr12:32339368~32340724:+
THCA	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	8.35	7.82e-16	3.46e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	8.35	7.82e-16	3.46e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	8.35	7.82e-16	3.46e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
THCA	cis	rs7569084	0.687	rs35839762	ENSG00000234255.7	AC012370.3	8.35	7.83e-16	3.46e-13	0.41	0.36	Sum eosinophil basophil counts;	chr2:65441318	chr2:65439888~65456571:-
THCA	cis	rs1707322	1	rs2458400	ENSG00000234329.1	RP11-767N6.2	-8.35	7.85e-16	3.47e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45651039~45651826:-
THCA	cis	rs7712401	0.691	rs62377436	ENSG00000263432.2	RN7SL689P	-8.35	7.85e-16	3.47e-13	-0.42	-0.36	Mean platelet volume;	chr5:123018007	chr5:123022487~123022783:-
THCA	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-8.35	7.85e-16	3.47e-13	-0.4	-0.36	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
THCA	cis	rs6504108	0.624	rs1860863	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48127316	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs1860862	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48127474	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.602	rs3944039	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48127708	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs2041572	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48127911	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs758999	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48128653	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs7225865	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48132602	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs34949267	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48134690	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs12941830	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48141769	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs7220768	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48147467	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs7220922	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48147546	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs7225550	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48147881	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs7223867	ENSG00000278765.1	RP5-890E16.5	-8.35	7.9e-16	3.49e-13	-0.4	-0.36	Body mass index;	chr17:48152794	chr17:48066704~48067293:-
THCA	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	8.35	7.91e-16	3.49e-13	0.55	0.36	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	8.35	7.91e-16	3.49e-13	0.55	0.36	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	8.35	7.91e-16	3.49e-13	0.55	0.36	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
THCA	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	8.35	7.91e-16	3.49e-13	0.55	0.36	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
THCA	cis	rs4718428	0.705	rs4718422	ENSG00000230295.1	RP11-458F8.2	-8.35	7.92e-16	3.5e-13	-0.32	-0.36	Corneal structure;	chr7:66894282	chr7:66880708~66882981:+
THCA	cis	rs4718428	0.705	rs13231140	ENSG00000230295.1	RP11-458F8.2	-8.35	7.92e-16	3.5e-13	-0.32	-0.36	Corneal structure;	chr7:66896631	chr7:66880708~66882981:+
THCA	cis	rs4718428	0.672	rs12530806	ENSG00000230295.1	RP11-458F8.2	-8.35	7.96e-16	3.51e-13	-0.32	-0.36	Corneal structure;	chr7:66925737	chr7:66880708~66882981:+
THCA	cis	rs1062177	0.855	rs1346489	ENSG00000253921.1	CTB-113P19.3	-8.35	7.99e-16	3.53e-13	-0.41	-0.36	Preschool internalizing problems;	chr5:151886973	chr5:151753992~151767247:+
THCA	cis	rs66887589	0.967	rs6844263	ENSG00000245958.5	RP11-33B1.1	-8.35	7.99e-16	3.53e-13	-0.32	-0.36	Diastolic blood pressure;	chr4:119512652	chr4:119454791~119552025:+
THCA	cis	rs8114671	0.935	rs633198	ENSG00000269202.1	RP4-614O4.12	8.34	8.01e-16	3.54e-13	0.3	0.36	Height;	chr20:35190631	chr20:35201747~35203288:-
THCA	cis	rs150992	0.609	rs4703049	ENSG00000248489.1	CTD-2007H13.3	8.34	8.01e-16	3.54e-13	0.34	0.36	Body mass index;	chr5:99004679	chr5:98929171~98995013:+
THCA	cis	rs1062177	0.756	rs2915817	ENSG00000253921.1	CTB-113P19.3	8.34	8.02e-16	3.54e-13	0.44	0.36	Preschool internalizing problems;	chr5:151735956	chr5:151753992~151767247:+
THCA	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	8.34	8.03e-16	3.54e-13	0.34	0.36	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
THCA	cis	rs2712184	0.875	rs2541381	ENSG00000229352.1	AC007563.3	-8.34	8.03e-16	3.54e-13	-0.45	-0.36	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216819113	chr2:216799608~216805335:+
THCA	cis	rs4927850	0.958	rs1975582	ENSG00000226155.1	AC124944.3	-8.34	8.04e-16	3.55e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196024568	chr3:195912049~195913986:+
THCA	cis	rs367615	0.879	rs2201015	ENSG00000249476.1	CTD-2587M2.1	8.34	8.05e-16	3.55e-13	0.38	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109611749	chr5:109237120~109326369:-
THCA	cis	rs7727544	0.716	rs7701414	ENSG00000224431.1	AC063976.7	8.34	8.06e-16	3.56e-13	0.31	0.36	Blood metabolite levels;	chr5:132250265	chr5:132199456~132203487:+
THCA	cis	rs9928842	0.765	rs6564221	ENSG00000280152.1	RP11-331F4.5	8.34	8.06e-16	3.56e-13	0.51	0.36	Alcoholic chronic pancreatitis;	chr16:75191073	chr16:75245994~75250077:-
THCA	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	8.34	8.09e-16	3.57e-13	0.45	0.36	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
THCA	cis	rs7208859	0.673	rs9915139	ENSG00000266490.1	CTD-2349P21.9	8.34	8.09e-16	3.57e-13	0.5	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831497	chr17:30792372~30792833:+
THCA	cis	rs7714584	1	rs59715748	ENSG00000197083.10	ZNF300P1	8.34	8.11e-16	3.58e-13	0.63	0.36	Crohn's disease;	chr5:150809725	chr5:150930645~150946289:-
THCA	cis	rs1707322	0.896	rs809774	ENSG00000234329.1	RP11-767N6.2	-8.34	8.12e-16	3.58e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45651039~45651826:-
THCA	cis	rs66887589	0.967	rs13104219	ENSG00000245958.5	RP11-33B1.1	-8.34	8.13e-16	3.59e-13	-0.32	-0.36	Diastolic blood pressure;	chr4:119517019	chr4:119454791~119552025:+
THCA	cis	rs2929278	0.589	rs7174732	ENSG00000166763.7	STRCP1	-8.34	8.14e-16	3.59e-13	-0.39	-0.36	Schizophrenia;	chr15:43746265	chr15:43699488~43718184:-
THCA	cis	rs2929278	0.617	rs11070410	ENSG00000166763.7	STRCP1	-8.34	8.15e-16	3.59e-13	-0.39	-0.36	Schizophrenia;	chr15:43764847	chr15:43699488~43718184:-
THCA	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	8.34	8.15e-16	3.59e-13	0.45	0.36	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
THCA	cis	rs2243480	1	rs34703416	ENSG00000226824.5	RP4-756H11.3	-8.34	8.15e-16	3.59e-13	-0.71	-0.36	Diabetic kidney disease;	chr7:65835655	chr7:66654538~66669855:+
THCA	cis	rs2274273	0.686	rs57033289	ENSG00000258413.1	RP11-665C16.6	-8.34	8.18e-16	3.61e-13	-0.52	-0.36	Protein biomarker;	chr14:55156599	chr14:55262767~55272075:-
THCA	cis	rs2274273	0.686	rs11624679	ENSG00000258413.1	RP11-665C16.6	-8.34	8.18e-16	3.61e-13	-0.52	-0.36	Protein biomarker;	chr14:55157526	chr14:55262767~55272075:-
THCA	cis	rs9309473	0.607	rs6546826	ENSG00000163016.8	ALMS1P	-8.34	8.18e-16	3.61e-13	-0.48	-0.36	Metabolite levels;	chr2:73372680	chr2:73644919~73685576:+
THCA	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	8.34	8.18e-16	3.61e-13	0.43	0.36	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
THCA	cis	rs2243480	1	rs316315	ENSG00000273142.1	RP11-458F8.4	8.34	8.18e-16	3.61e-13	0.39	0.36	Diabetic kidney disease;	chr7:66126218	chr7:66902857~66906297:+
THCA	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	8.34	8.19e-16	3.61e-13	0.23	0.36	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
THCA	cis	rs4819052	0.851	rs1006779	ENSG00000215447.6	BX322557.10	-8.34	8.19e-16	3.61e-13	-0.29	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45288052~45291738:+
THCA	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	8.34	8.2e-16	3.61e-13	0.23	0.36	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
THCA	cis	rs375066	1	rs375066	ENSG00000267058.1	RP11-15A1.3	-8.34	8.2e-16	3.62e-13	-0.29	-0.36	Breast cancer;	chr19:43919418	chr19:43891804~43901805:-
THCA	cis	rs73186030	0.92	rs73186057	ENSG00000272758.4	RP11-299J3.8	8.34	8.2e-16	3.62e-13	0.45	0.36	Serum parathyroid hormone levels;	chr3:122325058	chr3:122416207~122443180:+
THCA	cis	rs748404	0.66	rs694725	ENSG00000205771.5	CATSPER2P1	-8.34	8.21e-16	3.62e-13	-0.37	-0.36	Lung cancer;	chr15:43464012	chr15:43726918~43747094:-
THCA	cis	rs7829975	0.658	rs907181	ENSG00000253893.2	FAM85B	-8.34	8.22e-16	3.62e-13	-0.45	-0.36	Mood instability;	chr8:8845365	chr8:8167819~8226614:-
THCA	cis	rs1859596	0.646	rs6964644	ENSG00000234456.6	MAGI2-AS3	8.34	8.25e-16	3.64e-13	0.34	0.36	Reading or mathematical ability;	chr7:79463506	chr7:79452877~79471208:+
THCA	cis	rs11696845	1	rs6073534	ENSG00000276223.1	RP4-781B1.5	-8.34	8.28e-16	3.65e-13	-0.44	-0.36	Obesity-related traits;	chr20:44736863	chr20:44746642~44747201:+
THCA	cis	rs55665837	1	rs55665837	ENSG00000251991.1	RNU7-49P	8.34	8.3e-16	3.66e-13	0.4	0.36	Vitamin D levels;	chr11:14473503	chr11:14478892~14478953:+
THCA	cis	rs8114671	0.562	rs6087641	ENSG00000269202.1	RP4-614O4.12	-8.34	8.33e-16	3.67e-13	-0.3	-0.36	Height;	chr20:34879914	chr20:35201747~35203288:-
THCA	cis	rs6601450	0.519	rs34906836	ENSG00000261451.1	RP11-981G7.1	8.34	8.33e-16	3.67e-13	0.43	0.36	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;	chr8:10431482	chr8:10433672~10438312:+
THCA	cis	rs9532669	0.89	rs2149570	ENSG00000176268.5	CYCSP34	8.34	8.34e-16	3.67e-13	0.42	0.36	Cervical cancer;	chr13:40858533	chr13:40863599~40863902:-
THCA	cis	rs507080	0.733	rs497678	ENSG00000278376.1	RP11-158I9.8	-8.34	8.34e-16	3.67e-13	-0.29	-0.36	Serum metabolite levels;	chr11:118697172	chr11:118791254~118793137:+
THCA	cis	rs8114671	0.804	rs6088666	ENSG00000269202.1	RP4-614O4.12	-8.34	8.35e-16	3.68e-13	-0.31	-0.36	Height;	chr20:34976767	chr20:35201747~35203288:-
THCA	cis	rs8027521	0.56	rs1961236	ENSG00000280362.1	RP11-643A5.3	8.34	8.39e-16	3.7e-13	0.47	0.36	Circulating chemerin levels;	chr15:53934476	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.56	rs1961237	ENSG00000280362.1	RP11-643A5.3	8.34	8.39e-16	3.7e-13	0.47	0.36	Circulating chemerin levels;	chr15:53934488	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.56	rs1351095	ENSG00000280362.1	RP11-643A5.3	8.34	8.39e-16	3.7e-13	0.47	0.36	Circulating chemerin levels;	chr15:53934855	chr15:53910769~53914712:+
THCA	cis	rs12931792	0.682	rs12373113	ENSG00000183604.13	SMG1P5	8.34	8.39e-16	3.7e-13	0.36	0.36	Tonsillectomy;	chr16:30176192	chr16:30267553~30335374:-
THCA	cis	rs12931792	0.682	rs12373078	ENSG00000183604.13	SMG1P5	8.34	8.39e-16	3.7e-13	0.36	0.36	Tonsillectomy;	chr16:30176355	chr16:30267553~30335374:-
THCA	cis	rs748404	0.66	rs690472	ENSG00000205771.5	CATSPER2P1	-8.34	8.39e-16	3.7e-13	-0.37	-0.36	Lung cancer;	chr15:43472170	chr15:43726918~43747094:-
THCA	cis	rs748404	0.69	rs1079309	ENSG00000205771.5	CATSPER2P1	-8.34	8.39e-16	3.7e-13	-0.37	-0.36	Lung cancer;	chr15:43490966	chr15:43726918~43747094:-
THCA	cis	rs73607972	0.518	rs8060020	ENSG00000275191.1	RP11-36I17.2	-8.34	8.4e-16	3.7e-13	-0.48	-0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53554152	chr16:53628256~53628816:-
THCA	cis	rs507080	1	rs507080	ENSG00000278376.1	RP11-158I9.8	-8.34	8.4e-16	3.7e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118678873	chr11:118791254~118793137:+
THCA	cis	rs1707322	0.963	rs1768815	ENSG00000234329.1	RP11-767N6.2	-8.34	8.42e-16	3.71e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45651039~45651826:-
THCA	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	8.34	8.46e-16	3.72e-13	0.28	0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
THCA	cis	rs875971	0.522	rs2008188	ENSG00000237310.1	GS1-124K5.4	8.34	8.47e-16	3.73e-13	0.26	0.36	Aortic root size;	chr7:65964026	chr7:66493706~66495474:+
THCA	cis	rs7191700	0.511	rs8058983	ENSG00000262636.1	CTD-3088G3.4	-8.34	8.51e-16	3.75e-13	-0.44	-0.36	Multiple sclerosis;	chr16:11266992	chr16:11380859~11381118:-
THCA	cis	rs11096990	0.576	rs2008679	ENSG00000249685.1	RP11-360F5.3	-8.34	8.55e-16	3.76e-13	-0.43	-0.36	Cognitive function;	chr4:39266385	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.593	rs6531700	ENSG00000249685.1	RP11-360F5.3	-8.34	8.55e-16	3.76e-13	-0.43	-0.36	Cognitive function;	chr4:39269265	chr4:39133913~39135608:+
THCA	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-8.34	8.56e-16	3.77e-13	-0.43	-0.36	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
THCA	cis	rs516805	0.748	rs72962455	ENSG00000279453.1	RP3-425C14.4	8.34	8.56e-16	3.77e-13	0.37	0.36	Lymphocyte counts;	chr6:122563378	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs197685	ENSG00000279453.1	RP3-425C14.4	-8.34	8.56e-16	3.77e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122554622	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs1989254	ENSG00000279453.1	RP3-425C14.4	-8.34	8.56e-16	3.77e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122556317	chr6:122436789~122439223:-
THCA	cis	rs11763147	1	rs11763147	ENSG00000237310.1	GS1-124K5.4	-8.34	8.58e-16	3.77e-13	-0.26	-0.36	Corneal structure;	chr7:65861834	chr7:66493706~66495474:+
THCA	cis	rs367615	0.959	rs17161951	ENSG00000249476.1	CTD-2587M2.1	-8.34	8.6e-16	3.78e-13	-0.39	-0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109594889	chr5:109237120~109326369:-
THCA	cis	rs4713118	0.629	rs203890	ENSG00000226314.6	ZNF192P1	-8.33	8.61e-16	3.79e-13	-0.46	-0.36	Parkinson's disease;	chr6:28054470	chr6:28161781~28169594:+
THCA	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	8.33	8.63e-16	3.8e-13	0.59	0.36	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
THCA	cis	rs987724	0.592	rs1430410	ENSG00000240875.4	LINC00886	-8.33	8.64e-16	3.8e-13	-0.28	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807773	chr3:156747346~156817062:-
THCA	cis	rs11603691	1	rs7129491	ENSG00000254662.1	RP11-872D17.4	-8.33	8.64e-16	3.8e-13	-0.67	-0.36	Low high density lipoprotein cholesterol levels;	chr11:57327608	chr11:57325603~57327958:+
THCA	cis	rs516805	0.748	rs197693	ENSG00000279453.1	RP3-425C14.4	-8.33	8.64e-16	3.8e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122521294	chr6:122436789~122439223:-
THCA	cis	rs55665837	1	rs10047429	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14417486	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs10047457	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14417913	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs3923294	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14419856	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs12283797	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14420716	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs10832256	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14421329	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.961	rs12795972	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14422229	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs12287715	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14423029	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs12295723	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14428655	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs12295888	ENSG00000251991.1	RNU7-49P	8.33	8.65e-16	3.81e-13	0.4	0.36	Vitamin D levels;	chr11:14428985	chr11:14478892~14478953:+
THCA	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	8.33	8.65e-16	3.81e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
THCA	cis	rs516805	0.667	rs197676	ENSG00000279453.1	RP3-425C14.4	-8.33	8.66e-16	3.81e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122532410	chr6:122436789~122439223:-
THCA	cis	rs7191700	0.578	rs243324	ENSG00000262703.1	RP11-485G7.6	8.33	8.66e-16	3.81e-13	0.4	0.36	Multiple sclerosis;	chr16:11261113	chr16:11348143~11349321:-
THCA	cis	rs150992	0.574	rs2927655	ENSG00000248489.1	CTD-2007H13.3	8.33	8.69e-16	3.82e-13	0.36	0.36	Body mass index;	chr5:98839049	chr5:98929171~98995013:+
THCA	cis	rs11603023	0.967	rs494560	ENSG00000255239.1	AP002954.6	-8.33	8.7e-16	3.83e-13	-0.47	-0.36	Cholesterol, total;	chr11:118650844	chr11:118688039~118690600:-
THCA	cis	rs17711722	1	rs17711722	ENSG00000237310.1	GS1-124K5.4	-8.33	8.7e-16	3.83e-13	-0.26	-0.36	Calcium levels;	chr7:65806210	chr7:66493706~66495474:+
THCA	cis	rs17711722	0.675	rs6947132	ENSG00000237310.1	GS1-124K5.4	-8.33	8.7e-16	3.83e-13	-0.26	-0.36	Calcium levels;	chr7:65808508	chr7:66493706~66495474:+
THCA	cis	rs2274273	0.686	rs2296489	ENSG00000258413.1	RP11-665C16.6	-8.33	8.73e-16	3.84e-13	-0.52	-0.36	Protein biomarker;	chr14:55158259	chr14:55262767~55272075:-
THCA	cis	rs4819052	1	rs2297284	ENSG00000237664.1	LINC00316	-8.33	8.75e-16	3.85e-13	-0.4	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285430	chr21:45338590~45341990:-
THCA	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	8.33	8.76e-16	3.85e-13	0.24	0.36	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
THCA	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	8.33	8.77e-16	3.86e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
THCA	cis	rs6822297	0.504	rs7681802	ENSG00000240005.4	RP11-293A21.1	8.33	8.79e-16	3.86e-13	0.41	0.36	Obesity-related traits;	chr4:26989777	chr4:26859806~26860599:-
THCA	cis	rs9649213	0.502	rs6465680	ENSG00000272950.1	RP11-307C18.1	8.33	8.8e-16	3.87e-13	0.44	0.36	Prostate cancer (SNP x SNP interaction);	chr7:98376466	chr7:98322853~98323430:+
THCA	cis	rs910316	1	rs7142235	ENSG00000279594.1	RP11-950C14.10	8.33	8.81e-16	3.87e-13	0.33	0.36	Height;	chr14:75093260	chr14:75011269~75012851:-
THCA	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	8.33	8.82e-16	3.88e-13	0.55	0.36	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
THCA	cis	rs11696845	0.966	rs6073535	ENSG00000276223.1	RP4-781B1.5	-8.33	8.87e-16	3.9e-13	-0.44	-0.36	Obesity-related traits;	chr20:44745218	chr20:44746642~44747201:+
THCA	cis	rs17711722	0.727	rs1880555	ENSG00000237310.1	GS1-124K5.4	8.33	9.02e-16	3.96e-13	0.26	0.36	Calcium levels;	chr7:65967580	chr7:66493706~66495474:+
THCA	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	8.33	9.06e-16	3.98e-13	0.35	0.36	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
THCA	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	8.33	9.06e-16	3.98e-13	0.35	0.36	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
THCA	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	8.33	9.06e-16	3.98e-13	0.35	0.36	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
THCA	cis	rs7674212	0.507	rs6843738	ENSG00000251288.2	RP11-10L12.2	-8.33	9.07e-16	3.98e-13	-0.49	-0.36	Type 2 diabetes;	chr4:103014844	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.507	rs223317	ENSG00000251288.2	RP11-10L12.2	-8.33	9.09e-16	3.99e-13	-0.48	-0.36	Type 2 diabetes;	chr4:102881667	chr4:102751401~102752641:+
THCA	cis	rs1850744	0.702	rs2077679	ENSG00000250942.1	ENPP7P11	-8.33	9.09e-16	3.99e-13	-0.52	-0.36	Economic and political preferences;	chr4:9606465	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs1961552	ENSG00000250942.1	ENPP7P11	-8.33	9.09e-16	3.99e-13	-0.52	-0.36	Economic and political preferences;	chr4:9606682	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs4974816	ENSG00000250942.1	ENPP7P11	-8.33	9.09e-16	3.99e-13	-0.52	-0.36	Economic and political preferences;	chr4:9611443	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs4974812	ENSG00000250942.1	ENPP7P11	-8.33	9.09e-16	3.99e-13	-0.52	-0.36	Economic and political preferences;	chr4:9612974	chr4:9677308~9677934:+
THCA	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-8.33	9.09e-16	3.99e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
THCA	cis	rs66887589	0.967	rs3775842	ENSG00000245958.5	RP11-33B1.1	-8.33	9.12e-16	4e-13	-0.32	-0.36	Diastolic blood pressure;	chr4:119506577	chr4:119454791~119552025:+
THCA	cis	rs73186030	0.591	rs28630628	ENSG00000272758.4	RP11-299J3.8	8.33	9.13e-16	4.01e-13	0.42	0.36	Serum parathyroid hormone levels;	chr3:122386769	chr3:122416207~122443180:+
THCA	cis	rs11148252	0.774	rs7334583	ENSG00000235660.1	LINC00345	8.33	9.18e-16	4.03e-13	0.44	0.36	Lewy body disease;	chr13:52356217	chr13:52484161~52484680:-
THCA	cis	rs2929278	0.546	rs686666	ENSG00000166763.7	STRCP1	8.33	9.18e-16	4.03e-13	0.39	0.36	Schizophrenia;	chr15:43869352	chr15:43699488~43718184:-
THCA	cis	rs947583	0.866	rs7759326	ENSG00000231028.7	LINC00271	-8.33	9.19e-16	4.03e-13	-0.29	-0.36	Phosphorus levels;	chr6:135816421	chr6:135497801~135716055:+
THCA	cis	rs10510102	0.608	rs4752607	ENSG00000276742.1	RP11-500G22.4	-8.33	9.22e-16	4.04e-13	-0.43	-0.36	Breast cancer;	chr10:121835426	chr10:121956782~121957098:+
THCA	cis	rs1707322	0.682	rs12037459	ENSG00000234329.1	RP11-767N6.2	8.33	9.23e-16	4.05e-13	0.35	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45651039~45651826:-
THCA	cis	rs367615	0.959	rs4957830	ENSG00000249476.1	CTD-2587M2.1	8.33	9.25e-16	4.06e-13	0.39	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109576057	chr5:109237120~109326369:-
THCA	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-8.32	9.27e-16	4.07e-13	-0.71	-0.36	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
THCA	cis	rs922182	0.557	rs730589	ENSG00000275785.1	RP11-111E14.2	8.32	9.28e-16	4.07e-13	0.44	0.36	Blood protein levels;	chr15:63901974	chr15:63890030~63890317:+
THCA	cis	rs10208649	0.572	rs7585466	ENSG00000272156.1	RP11-477N3.1	8.32	9.28e-16	4.07e-13	0.49	0.36	Body mass index;	chr2:54098988	chr2:54082554~54085066:+
THCA	cis	rs10510102	0.608	rs4486560	ENSG00000276742.1	RP11-500G22.4	8.32	9.28e-16	4.07e-13	0.42	0.36	Breast cancer;	chr10:121844840	chr10:121956782~121957098:+
THCA	cis	rs8114671	0.901	rs6119581	ENSG00000269202.1	RP4-614O4.12	-8.32	9.3e-16	4.08e-13	-0.3	-0.36	Height;	chr20:35185886	chr20:35201747~35203288:-
THCA	cis	rs10740039	0.81	rs7098097	ENSG00000254271.1	RP11-131N11.4	8.32	9.3e-16	4.08e-13	0.45	0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60605233	chr10:60734342~60741828:+
THCA	cis	rs748404	0.69	rs2467737	ENSG00000205771.5	CATSPER2P1	-8.32	9.3e-16	4.08e-13	-0.37	-0.36	Lung cancer;	chr15:43444990	chr15:43726918~43747094:-
THCA	cis	rs1850744	0.702	rs4974858	ENSG00000250942.1	ENPP7P11	-8.32	9.32e-16	4.09e-13	-0.52	-0.36	Economic and political preferences;	chr4:9605498	chr4:9677308~9677934:+
THCA	cis	rs42490	0.7	rs40459	ENSG00000251136.7	RP11-37B2.1	8.32	9.36e-16	4.1e-13	0.31	0.36	Leprosy;	chr8:89833998	chr8:89609409~89757727:-
THCA	cis	rs910316	0.726	rs175040	ENSG00000279594.1	RP11-950C14.10	-8.32	9.38e-16	4.11e-13	-0.33	-0.36	Height;	chr14:75002852	chr14:75011269~75012851:-
THCA	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	8.32	9.4e-16	4.12e-13	0.46	0.36	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
THCA	cis	rs7829975	0.51	rs332037	ENSG00000253893.2	FAM85B	-8.32	9.4e-16	4.12e-13	-0.48	-0.36	Mood instability;	chr8:8865165	chr8:8167819~8226614:-
THCA	cis	rs6142102	0.607	rs6088408	ENSG00000276073.1	RP5-1125A11.7	8.32	9.41e-16	4.13e-13	0.36	0.36	Skin pigmentation;	chr20:34146800	chr20:33985617~33988989:-
THCA	cis	rs516805	0.563	rs571706	ENSG00000279453.1	RP3-425C14.4	-8.32	9.42e-16	4.13e-13	-0.36	-0.36	Lymphocyte counts;	chr6:122393787	chr6:122436789~122439223:-
THCA	cis	rs1799949	0.602	rs8176257	ENSG00000267681.1	CTD-3199J23.6	-8.32	9.42e-16	4.13e-13	-0.44	-0.36	Menopause (age at onset);	chr17:43064188	chr17:43144956~43145255:+
THCA	cis	rs1426063	0.8	rs28861517	ENSG00000260265.1	RP11-44F21.5	8.32	9.43e-16	4.13e-13	0.58	0.36	QT interval;	chr4:75092995	chr4:75081702~75084717:-
THCA	cis	rs17772222	0.582	rs11625009	ENSG00000258789.1	RP11-507K2.3	8.32	9.43e-16	4.13e-13	0.35	0.36	Coronary artery calcification;	chr14:88521018	chr14:88551597~88552493:+
THCA	cis	rs7208859	0.673	rs9907197	ENSG00000266490.1	CTD-2349P21.9	8.32	9.44e-16	4.14e-13	0.46	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9915963	ENSG00000266490.1	CTD-2349P21.9	8.32	9.44e-16	4.14e-13	0.46	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30792372~30792833:+
THCA	cis	rs8114671	0.562	rs4911163	ENSG00000269202.1	RP4-614O4.12	-8.32	9.45e-16	4.14e-13	-0.3	-0.36	Height;	chr20:34882891	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6088640	ENSG00000269202.1	RP4-614O4.12	-8.32	9.45e-16	4.14e-13	-0.3	-0.36	Height;	chr20:34884706	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs6087643	ENSG00000269202.1	RP4-614O4.12	-8.32	9.45e-16	4.14e-13	-0.3	-0.36	Height;	chr20:34886659	chr20:35201747~35203288:-
THCA	cis	rs516805	0.923	rs538457	ENSG00000279453.1	RP3-425C14.4	-8.32	9.47e-16	4.15e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122485610	chr6:122436789~122439223:-
THCA	cis	rs516805	0.961	rs9385248	ENSG00000279453.1	RP3-425C14.4	-8.32	9.47e-16	4.15e-13	-0.32	-0.36	Lymphocyte counts;	chr6:122490982	chr6:122436789~122439223:-
THCA	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-8.32	9.48e-16	4.16e-13	-0.36	-0.36	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-8.32	9.48e-16	4.16e-13	-0.36	-0.36	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
THCA	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	8.32	9.48e-16	4.16e-13	0.44	0.36	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
THCA	cis	rs853679	0.527	rs9461443	ENSG00000280107.1	AL022393.9	-8.32	9.49e-16	4.16e-13	-0.43	-0.36	Depression;	chr6:28226851	chr6:28170845~28172521:+
THCA	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	8.32	9.51e-16	4.16e-13	0.56	0.36	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
THCA	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-8.32	9.53e-16	4.17e-13	-0.39	-0.36	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
THCA	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-8.32	9.53e-16	4.17e-13	-0.42	-0.36	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
THCA	cis	rs8027521	0.56	rs2019408	ENSG00000280362.1	RP11-643A5.3	8.32	9.54e-16	4.18e-13	0.47	0.36	Circulating chemerin levels;	chr15:53934014	chr15:53910769~53914712:+
THCA	cis	rs720475	1	rs720475	ENSG00000204959.4	ARHGEF34P	-8.32	9.56e-16	4.19e-13	-0.45	-0.36	Breast cancer;	chr7:144377836	chr7:144272445~144286966:-
THCA	cis	rs7849270	1	rs10819469	ENSG00000268707.1	RP11-247A12.7	-8.32	9.56e-16	4.19e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129119788	chr9:129170434~129170940:+
THCA	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	8.32	9.57e-16	4.19e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
THCA	cis	rs367615	1	rs58931051	ENSG00000249476.1	CTD-2587M2.1	8.32	9.57e-16	4.19e-13	0.4	0.36	Colorectal cancer (SNP x SNP interaction);	chr5:109572031	chr5:109237120~109326369:-
THCA	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	8.32	9.57e-16	4.19e-13	0.24	0.36	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
THCA	cis	rs3096299	0.935	rs3102387	ENSG00000274627.1	RP11-104N10.2	8.32	9.59e-16	4.2e-13	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89365868	chr16:89516797~89522217:+
THCA	cis	rs8114671	0.967	rs3746427	ENSG00000269202.1	RP4-614O4.12	-8.32	9.59e-16	4.2e-13	-0.3	-0.36	Height;	chr20:35142661	chr20:35201747~35203288:-
THCA	cis	rs7621025	0.5	rs4678275	ENSG00000239213.4	NCK1-AS1	8.32	9.59e-16	4.2e-13	0.38	0.36	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136841726~136862054:-
THCA	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-8.32	9.6e-16	4.2e-13	-0.43	-0.36	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
THCA	cis	rs3096299	0.933	rs3096297	ENSG00000274627.1	RP11-104N10.2	8.32	9.63e-16	4.22e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89386747	chr16:89516797~89522217:+
THCA	cis	rs6822297	0.522	rs9998971	ENSG00000240005.4	RP11-293A21.1	8.32	9.64e-16	4.22e-13	0.41	0.36	Obesity-related traits;	chr4:27000082	chr4:26859806~26860599:-
THCA	cis	rs11603691	1	rs61888887	ENSG00000254662.1	RP11-872D17.4	-8.32	9.65e-16	4.23e-13	-0.67	-0.36	Low high density lipoprotein cholesterol levels;	chr11:57331577	chr11:57325603~57327958:+
THCA	cis	rs910316	0.763	rs175036	ENSG00000279594.1	RP11-950C14.10	-8.32	9.67e-16	4.23e-13	-0.33	-0.36	Height;	chr14:74997592	chr14:75011269~75012851:-
THCA	cis	rs910316	0.712	rs175037	ENSG00000279594.1	RP11-950C14.10	-8.32	9.67e-16	4.23e-13	-0.33	-0.36	Height;	chr14:74998335	chr14:75011269~75012851:-
THCA	cis	rs62355901	0.505	rs55698001	ENSG00000271828.1	CTD-2310F14.1	8.32	9.69e-16	4.24e-13	0.76	0.36	Breast cancer;	chr5:56949313	chr5:56927874~56929573:+
THCA	cis	rs66887589	0.967	rs59516282	ENSG00000245958.5	RP11-33B1.1	8.32	9.73e-16	4.26e-13	0.31	0.36	Diastolic blood pressure;	chr4:119580861	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.934	rs12648182	ENSG00000245958.5	RP11-33B1.1	8.32	9.73e-16	4.26e-13	0.31	0.36	Diastolic blood pressure;	chr4:119582736	chr4:119454791~119552025:+
THCA	cis	rs7829975	0.653	rs13259070	ENSG00000253893.2	FAM85B	-8.32	9.75e-16	4.27e-13	-0.46	-0.36	Mood instability;	chr8:8833277	chr8:8167819~8226614:-
THCA	cis	rs11168351	0.864	rs12228750	ENSG00000258273.1	RP11-370I10.4	8.32	9.77e-16	4.27e-13	0.47	0.36	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48333755~48333901:-
THCA	cis	rs11168351	0.864	rs10875743	ENSG00000258273.1	RP11-370I10.4	8.32	9.77e-16	4.27e-13	0.47	0.36	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48333755~48333901:-
THCA	cis	rs6991838	0.702	rs13274205	ENSG00000200714.1	Y_RNA	8.32	9.79e-16	4.28e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65708124	chr8:65592731~65592820:+
THCA	cis	rs8091660	0.862	rs12607412	ENSG00000278983.1	RP11-426J5.3	8.32	9.8e-16	4.29e-13	0.47	0.36	Response to carboplatin in ovarian cancer (MTT IC50);	chr18:48545949	chr18:48564795~48568342:+
THCA	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	8.32	9.8e-16	4.29e-13	0.55	0.36	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
THCA	cis	rs853679	0.76	rs2299029	ENSG00000219392.1	RP1-265C24.5	-8.32	9.85e-16	4.31e-13	-0.5	-0.36	Depression;	chr6:28231053	chr6:28115628~28116551:+
THCA	cis	rs4927850	1	rs7625570	ENSG00000226155.1	AC124944.3	-8.32	9.86e-16	4.31e-13	-0.43	-0.36	Pancreatic cancer;	chr3:196020527	chr3:195912049~195913986:+
THCA	cis	rs17772222	0.682	rs10132554	ENSG00000258789.1	RP11-507K2.3	-8.32	9.86e-16	4.31e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88473090	chr14:88551597~88552493:+
THCA	cis	rs55665837	1	rs34382046	ENSG00000251991.1	RNU7-49P	8.32	9.87e-16	4.31e-13	0.4	0.36	Vitamin D levels;	chr11:14429772	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs7945167	ENSG00000251991.1	RNU7-49P	8.32	9.87e-16	4.31e-13	0.4	0.36	Vitamin D levels;	chr11:14430274	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.961	rs60622588	ENSG00000251991.1	RNU7-49P	8.32	9.87e-16	4.31e-13	0.4	0.36	Vitamin D levels;	chr11:14435452	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs11023223	ENSG00000251991.1	RNU7-49P	8.32	9.87e-16	4.31e-13	0.4	0.36	Vitamin D levels;	chr11:14435566	chr11:14478892~14478953:+
THCA	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	8.32	9.88e-16	4.32e-13	0.34	0.36	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
THCA	cis	rs1707322	0.721	rs7520123	ENSG00000234329.1	RP11-767N6.2	8.32	9.89e-16	4.33e-13	0.33	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45651039~45651826:-
THCA	cis	rs180730	1	rs343198	ENSG00000251609.2	SETP12	-8.31	9.98e-16	4.36e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120877031	chr4:120895494~120897083:-
THCA	cis	rs11051970	0.918	rs6488050	ENSG00000274964.1	RP11-817I4.1	-8.31	9.98e-16	4.36e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32379565	chr12:32339368~32340724:+
THCA	cis	rs910316	1	rs175512	ENSG00000279594.1	RP11-950C14.10	-8.31	9.98e-16	4.37e-13	-0.33	-0.36	Height;	chr14:75056679	chr14:75011269~75012851:-
THCA	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	8.31	1e-15	4.38e-13	0.42	0.36	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
THCA	cis	rs507080	0.922	rs533646	ENSG00000278376.1	RP11-158I9.8	-8.31	1e-15	4.39e-13	-0.29	-0.36	Serum metabolite levels;	chr11:118696037	chr11:118791254~118793137:+
THCA	cis	rs987724	0.592	rs1430411	ENSG00000240875.4	LINC00886	-8.31	1e-15	4.39e-13	-0.29	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156807607	chr3:156747346~156817062:-
THCA	cis	rs2243480	1	rs4548056	ENSG00000226824.5	RP4-756H11.3	-8.31	1.01e-15	4.41e-13	-0.71	-0.36	Diabetic kidney disease;	chr7:65833886	chr7:66654538~66669855:+
THCA	cis	rs8114671	0.662	rs3761143	ENSG00000269202.1	RP4-614O4.12	-8.31	1.01e-15	4.42e-13	-0.31	-0.36	Height;	chr20:34957942	chr20:35201747~35203288:-
THCA	cis	rs910316	1	rs12590452	ENSG00000279594.1	RP11-950C14.10	8.31	1.02e-15	4.44e-13	0.33	0.36	Height;	chr14:75082053	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs1043674	ENSG00000279594.1	RP11-950C14.10	8.31	1.02e-15	4.44e-13	0.33	0.36	Height;	chr14:75082667	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs10142865	ENSG00000279594.1	RP11-950C14.10	8.31	1.02e-15	4.44e-13	0.33	0.36	Height;	chr14:75088921	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs10142626	ENSG00000279594.1	RP11-950C14.10	8.31	1.02e-15	4.44e-13	0.33	0.36	Height;	chr14:75088933	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs2010678	ENSG00000279594.1	RP11-950C14.10	8.31	1.02e-15	4.44e-13	0.33	0.36	Height;	chr14:75100475	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs4899545	ENSG00000279594.1	RP11-950C14.10	8.31	1.02e-15	4.44e-13	0.33	0.36	Height;	chr14:75101435	chr14:75011269~75012851:-
THCA	cis	rs516805	0.667	rs197679	ENSG00000279453.1	RP3-425C14.4	-8.31	1.02e-15	4.44e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122548188	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs197681	ENSG00000279453.1	RP3-425C14.4	-8.31	1.02e-15	4.44e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122551788	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs197682	ENSG00000279453.1	RP3-425C14.4	-8.31	1.02e-15	4.44e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122551848	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs197683	ENSG00000279453.1	RP3-425C14.4	-8.31	1.02e-15	4.44e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122552277	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs197684	ENSG00000279453.1	RP3-425C14.4	-8.31	1.02e-15	4.44e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122553697	chr6:122436789~122439223:-
THCA	cis	rs72807246	1	rs72807246	ENSG00000228701.1	TNKS2-AS1	8.31	1.02e-15	4.45e-13	0.64	0.36	Breast cancer;	chr10:92172529	chr10:91782839~91798291:-
THCA	cis	rs516805	0.748	rs647178	ENSG00000279453.1	RP3-425C14.4	-8.31	1.03e-15	4.48e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122543602	chr6:122436789~122439223:-
THCA	cis	rs180730	1	rs343197	ENSG00000251609.2	SETP12	8.31	1.03e-15	4.49e-13	0.57	0.36	Fasting plasma glucose;	chr4:120877330	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs171069	ENSG00000251609.2	SETP12	-8.31	1.03e-15	4.49e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120880210	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs3115314	ENSG00000251609.2	SETP12	-8.31	1.03e-15	4.49e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120888621	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs184668	ENSG00000251609.2	SETP12	-8.31	1.03e-15	4.49e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120888812	chr4:120895494~120897083:-
THCA	cis	rs6844153	1	rs6844153	ENSG00000240005.4	RP11-293A21.1	-8.31	1.03e-15	4.51e-13	-0.49	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26942692	chr4:26859806~26860599:-
THCA	cis	rs11673344	0.523	rs1402468	ENSG00000226686.6	LINC01535	8.31	1.03e-15	4.52e-13	0.39	0.36	Obesity-related traits;	chr19:37129346	chr19:37251912~37265535:+
THCA	cis	rs375066	0.935	rs384329	ENSG00000267058.1	RP11-15A1.3	-8.31	1.03e-15	4.52e-13	-0.29	-0.36	Breast cancer;	chr19:43919829	chr19:43891804~43901805:-
THCA	cis	rs11051970	0.918	rs7309115	ENSG00000274964.1	RP11-817I4.1	-8.31	1.04e-15	4.53e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32388307	chr12:32339368~32340724:+
THCA	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	8.31	1.04e-15	4.56e-13	0.46	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
THCA	cis	rs1062177	0.855	rs919262	ENSG00000253921.1	CTB-113P19.3	8.31	1.04e-15	4.56e-13	0.42	0.36	Preschool internalizing problems;	chr5:151886523	chr5:151753992~151767247:+
THCA	cis	rs17684571	0.7	rs35642890	ENSG00000231441.1	RP11-472M19.2	8.31	1.05e-15	4.57e-13	0.43	0.36	Schizophrenia;	chr6:56809919	chr6:56844002~56864078:+
THCA	cis	rs11096990	0.634	rs6854358	ENSG00000249685.1	RP11-360F5.3	-8.31	1.05e-15	4.57e-13	-0.43	-0.36	Cognitive function;	chr4:39281492	chr4:39133913~39135608:+
THCA	cis	rs56046484	0.956	rs2174218	ENSG00000259295.5	CSPG4P12	-8.31	1.05e-15	4.59e-13	-0.61	-0.36	Testicular germ cell tumor;	chr15:85081425	chr15:85191438~85213905:+
THCA	cis	rs4660456	0.504	rs542214	ENSG00000237899.1	RP4-739H11.3	8.31	1.05e-15	4.59e-13	0.5	0.36	Platelet count;	chr1:40632806	chr1:40669089~40687588:-
THCA	cis	rs7945705	0.902	rs11042088	ENSG00000254860.4	TMEM9B-AS1	-8.31	1.05e-15	4.59e-13	-0.41	-0.36	Hemoglobin concentration;	chr11:8821968	chr11:8964675~8977527:+
THCA	cis	rs1707322	0.717	rs3014237	ENSG00000234329.1	RP11-767N6.2	-8.31	1.06e-15	4.61e-13	-0.35	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45651039~45651826:-
THCA	cis	rs875971	0.505	rs2462573	ENSG00000237310.1	GS1-124K5.4	-8.31	1.06e-15	4.62e-13	-0.26	-0.36	Aortic root size;	chr7:66042405	chr7:66493706~66495474:+
THCA	cis	rs8072100	0.846	rs6503796	ENSG00000228782.6	CTD-2026D20.3	8.31	1.06e-15	4.62e-13	0.32	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47687883	chr17:47450568~47492492:-
THCA	cis	rs737008	0.922	rs1559394	ENSG00000262703.1	RP11-485G7.6	-8.31	1.06e-15	4.62e-13	-0.41	-0.36	Obesity-related traits;	chr16:11275348	chr16:11348143~11349321:-
THCA	cis	rs12701220	0.655	rs10215292	ENSG00000229043.2	AC091729.9	-8.31	1.06e-15	4.63e-13	-0.48	-0.36	Bronchopulmonary dysplasia;	chr7:1095627	chr7:1160374~1165267:+
THCA	cis	rs11096990	0.634	rs4975001	ENSG00000249685.1	RP11-360F5.3	-8.31	1.07e-15	4.66e-13	-0.43	-0.36	Cognitive function;	chr4:39264844	chr4:39133913~39135608:+
THCA	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-8.31	1.07e-15	4.66e-13	-0.35	-0.36	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
THCA	cis	rs13631	0.965	rs9411307	ENSG00000268996.3	MAN1B1-AS1	8.31	1.07e-15	4.66e-13	0.3	0.36	Cerebrospinal fluid biomarker levels;	chr9:137100495	chr9:137084946~137086817:-
THCA	cis	rs55665837	1	rs11023246	ENSG00000251991.1	RNU7-49P	8.31	1.07e-15	4.67e-13	0.4	0.36	Vitamin D levels;	chr11:14515410	chr11:14478892~14478953:+
THCA	cis	rs516805	0.748	rs12211993	ENSG00000279453.1	RP3-425C14.4	8.3	1.07e-15	4.69e-13	0.37	0.36	Lymphocyte counts;	chr6:122570216	chr6:122436789~122439223:-
THCA	cis	rs16846053	0.515	rs7557876	ENSG00000227403.1	AC009299.3	-8.3	1.08e-15	4.69e-13	-0.56	-0.36	Blood osmolality (transformed sodium);	chr2:161633024	chr2:161244739~161249050:+
THCA	cis	rs10411161	0.721	rs1433082	ENSG00000269483.1	AC006272.1	-8.3	1.08e-15	4.7e-13	-0.48	-0.36	Breast cancer;	chr19:51887473	chr19:51839924~51843324:-
THCA	cis	rs17772222	0.682	rs28371093	ENSG00000258789.1	RP11-507K2.3	-8.3	1.08e-15	4.7e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88486112	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.655	rs10150594	ENSG00000258789.1	RP11-507K2.3	-8.3	1.08e-15	4.7e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88489613	chr14:88551597~88552493:+
THCA	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-8.3	1.08e-15	4.71e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
THCA	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-8.3	1.08e-15	4.72e-13	-0.43	-0.36	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
THCA	cis	rs4591358	0.678	rs13015934	ENSG00000223466.1	AC064834.2	-8.3	1.08e-15	4.73e-13	-0.5	-0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195504897	chr2:195533035~195538681:+
THCA	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-8.3	1.09e-15	4.73e-13	-0.43	-0.36	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
THCA	cis	rs812925	0.537	rs10865324	ENSG00000271889.1	RP11-493E12.1	-8.3	1.09e-15	4.74e-13	-0.34	-0.36	Immature fraction of reticulocytes;	chr2:61394172	chr2:61151433~61162105:-
THCA	cis	rs11971779	0.878	rs4732378	ENSG00000273391.1	RP11-634H22.1	8.3	1.09e-15	4.75e-13	0.38	0.36	Diisocyanate-induced asthma;	chr7:139435649	chr7:139359032~139359566:-
THCA	cis	rs2274273	0.529	rs7149965	ENSG00000258413.1	RP11-665C16.6	-8.3	1.1e-15	4.77e-13	-0.49	-0.36	Protein biomarker;	chr14:55041473	chr14:55262767~55272075:-
THCA	cis	rs55665837	1	rs12792120	ENSG00000251991.1	RNU7-49P	8.3	1.1e-15	4.77e-13	0.4	0.36	Vitamin D levels;	chr11:14447897	chr11:14478892~14478953:+
THCA	cis	rs910316	1	rs12589876	ENSG00000279594.1	RP11-950C14.10	8.3	1.1e-15	4.79e-13	0.33	0.36	Height;	chr14:75077486	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs10246	ENSG00000279594.1	RP11-950C14.10	8.3	1.1e-15	4.79e-13	0.33	0.36	Height;	chr14:75077767	chr14:75011269~75012851:-
THCA	cis	rs2439831	0.85	rs28504496	ENSG00000249839.1	AC011330.5	-8.3	1.1e-15	4.81e-13	-0.57	-0.36	Lung cancer in ever smokers;	chr15:43724685	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.702	rs28699233	ENSG00000249839.1	AC011330.5	-8.3	1.1e-15	4.81e-13	-0.61	-0.36	Lung cancer in ever smokers;	chr15:43830668	chr15:43663654~43684339:-
THCA	cis	rs11096990	0.613	rs6829660	ENSG00000249685.1	RP11-360F5.3	8.3	1.11e-15	4.82e-13	0.42	0.36	Cognitive function;	chr4:39280943	chr4:39133913~39135608:+
THCA	cis	rs910316	1	rs4903281	ENSG00000279594.1	RP11-950C14.10	8.3	1.11e-15	4.85e-13	0.33	0.36	Height;	chr14:75087658	chr14:75011269~75012851:-
THCA	cis	rs2274273	1	rs2274273	ENSG00000258413.1	RP11-665C16.6	8.3	1.11e-15	4.85e-13	0.47	0.36	Protein biomarker;	chr14:55147918	chr14:55262767~55272075:-
THCA	cis	rs7621025	0.5	rs12629000	ENSG00000239213.4	NCK1-AS1	8.3	1.12e-15	4.86e-13	0.38	0.36	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136841726~136862054:-
THCA	cis	rs7621025	0.5	rs1965107	ENSG00000239213.4	NCK1-AS1	8.3	1.12e-15	4.86e-13	0.38	0.36	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136841726~136862054:-
THCA	cis	rs934734	0.752	rs1039764	ENSG00000204929.10	AC074391.1	-8.3	1.12e-15	4.86e-13	-0.44	-0.36	Rheumatoid arthritis;	chr2:65387479	chr2:65436711~66084639:+
THCA	cis	rs875971	0.54	rs4717275	ENSG00000237310.1	GS1-124K5.4	-8.3	1.12e-15	4.88e-13	-0.26	-0.36	Aortic root size;	chr7:65800193	chr7:66493706~66495474:+
THCA	cis	rs3745672	1	rs279170	ENSG00000219665.7	CTD-2006C1.2	-8.3	1.12e-15	4.88e-13	-0.73	-0.36	Multiple sclerosis;	chr19:12025708	chr19:11987617~12046275:+
THCA	cis	rs11096990	0.634	rs2086752	ENSG00000249685.1	RP11-360F5.3	-8.3	1.12e-15	4.89e-13	-0.42	-0.36	Cognitive function;	chr4:39280486	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.594	rs2381373	ENSG00000249685.1	RP11-360F5.3	-8.3	1.12e-15	4.89e-13	-0.42	-0.36	Cognitive function;	chr4:39280683	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.6	rs6835337	ENSG00000249685.1	RP11-360F5.3	-8.3	1.12e-15	4.89e-13	-0.42	-0.36	Cognitive function;	chr4:39281189	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs6531704	ENSG00000249685.1	RP11-360F5.3	-8.3	1.12e-15	4.89e-13	-0.42	-0.36	Cognitive function;	chr4:39282126	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs7654501	ENSG00000249685.1	RP11-360F5.3	-8.3	1.12e-15	4.89e-13	-0.42	-0.36	Cognitive function;	chr4:39282364	chr4:39133913~39135608:+
THCA	cis	rs4819052	0.851	rs10470246	ENSG00000237664.1	LINC00316	-8.3	1.12e-15	4.89e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239102	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs10470247	ENSG00000237664.1	LINC00316	-8.3	1.12e-15	4.89e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239103	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4819043	ENSG00000237664.1	LINC00316	-8.3	1.12e-15	4.89e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240163	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs4819044	ENSG00000237664.1	LINC00316	-8.3	1.12e-15	4.89e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240203	chr21:45338590~45341990:-
THCA	cis	rs1707322	1	rs9429186	ENSG00000234329.1	RP11-767N6.2	-8.3	1.13e-15	4.9e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785506	ENSG00000234329.1	RP11-767N6.2	-8.3	1.13e-15	4.9e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45651039~45651826:-
THCA	cis	rs11673344	0.543	rs8108429	ENSG00000226686.6	LINC01535	8.3	1.13e-15	4.91e-13	0.39	0.36	Obesity-related traits;	chr19:37145874	chr19:37251912~37265535:+
THCA	cis	rs7811142	1	rs11761725	ENSG00000242294.5	STAG3L5P	8.3	1.13e-15	4.92e-13	0.24	0.36	Platelet count;	chr7:100442192	chr7:100336079~100351900:+
THCA	cis	rs910316	0.763	rs175047	ENSG00000279594.1	RP11-950C14.10	-8.3	1.13e-15	4.92e-13	-0.33	-0.36	Height;	chr14:75012336	chr14:75011269~75012851:-
THCA	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-8.3	1.13e-15	4.93e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
THCA	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	8.3	1.14e-15	4.94e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
THCA	cis	rs9640161	0.83	rs12703061	ENSG00000261305.1	RP4-584D14.7	8.3	1.14e-15	4.96e-13	0.43	0.36	Blood protein levels;Circulating chemerin levels;	chr7:150365456	chr7:150341771~150342607:+
THCA	cis	rs10510102	0.516	rs10159759	ENSG00000276742.1	RP11-500G22.4	8.3	1.14e-15	4.97e-13	0.55	0.36	Breast cancer;	chr10:121986533	chr10:121956782~121957098:+
THCA	cis	rs6723226	0.572	rs176404	ENSG00000276334.1	AL133243.1	-8.3	1.14e-15	4.97e-13	-0.4	-0.36	Intelligence (multi-trait analysis);	chr2:32413778	chr2:32521927~32523547:+
THCA	cis	rs62355901	0.505	rs62356567	ENSG00000271828.1	CTD-2310F14.1	8.3	1.15e-15	5e-13	0.75	0.36	Breast cancer;	chr5:56953442	chr5:56927874~56929573:+
THCA	cis	rs7569084	0.687	rs1370394	ENSG00000234255.7	AC012370.3	8.3	1.15e-15	5.01e-13	0.41	0.36	Sum eosinophil basophil counts;	chr2:65453176	chr2:65439888~65456571:-
THCA	cis	rs62355900	0.627	rs62355941	ENSG00000271828.1	CTD-2310F14.1	8.3	1.15e-15	5.01e-13	0.68	0.36	Endometriosis;	chr5:56807871	chr5:56927874~56929573:+
THCA	cis	rs7674212	0.507	rs223331	ENSG00000246560.2	RP11-10L12.4	8.3	1.16e-15	5.02e-13	0.44	0.36	Type 2 diabetes;	chr4:102872408	chr4:102828055~102844075:+
THCA	cis	rs56046484	0.913	rs17611290	ENSG00000259295.5	CSPG4P12	8.29	1.16e-15	5.02e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85031188	chr15:85191438~85213905:+
THCA	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-8.29	1.16e-15	5.03e-13	-0.42	-0.36	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
THCA	cis	rs4713118	0.699	rs573179	ENSG00000280107.1	AL022393.9	-8.29	1.16e-15	5.04e-13	-0.43	-0.36	Parkinson's disease;	chr6:27881898	chr6:28170845~28172521:+
THCA	cis	rs4713118	0.699	rs200978	ENSG00000280107.1	AL022393.9	-8.29	1.16e-15	5.04e-13	-0.43	-0.36	Parkinson's disease;	chr6:27885390	chr6:28170845~28172521:+
THCA	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	8.29	1.16e-15	5.04e-13	0.24	0.36	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
THCA	cis	rs6504108	0.581	rs55982346	ENSG00000278765.1	RP5-890E16.5	-8.29	1.16e-15	5.05e-13	-0.4	-0.36	Body mass index;	chr17:48198512	chr17:48066704~48067293:-
THCA	cis	rs2712184	0.875	rs2541382	ENSG00000229352.1	AC007563.3	-8.29	1.16e-15	5.06e-13	-0.44	-0.36	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216815311	chr2:216799608~216805335:+
THCA	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-8.29	1.16e-15	5.06e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
THCA	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	8.29	1.16e-15	5.06e-13	0.55	0.36	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
THCA	cis	rs6504108	0.624	rs2278868	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48184809	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs11079814	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48191077	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.602	rs11872095	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48193810	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs12452956	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48196575	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs8075270	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48197648	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs8072282	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48199496	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs8069064	ENSG00000278765.1	RP5-890E16.5	-8.29	1.17e-15	5.07e-13	-0.4	-0.36	Body mass index;	chr17:48203301	chr17:48066704~48067293:-
THCA	cis	rs240993	0.516	rs241006	ENSG00000230177.1	RP5-1112D6.4	-8.29	1.17e-15	5.08e-13	-0.39	-0.36	Inflammatory skin disease;Psoriasis;	chr6:111279910	chr6:111277932~111278742:+
THCA	cis	rs875971	0.505	rs1723275	ENSG00000237310.1	GS1-124K5.4	-8.29	1.17e-15	5.09e-13	-0.26	-0.36	Aortic root size;	chr7:66039646	chr7:66493706~66495474:+
THCA	cis	rs4789693	0.808	rs12935995	ENSG00000265458.1	RP13-20L14.6	8.29	1.17e-15	5.09e-13	0.37	0.36	Glucocorticoid-induced osteonecrosis;	chr17:82437007	chr17:82454273~82458521:-
THCA	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-8.29	1.17e-15	5.09e-13	-0.43	-0.36	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
THCA	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	8.29	1.17e-15	5.09e-13	0.34	0.36	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
THCA	cis	rs8114671	0.967	rs6088747	ENSG00000269202.1	RP4-614O4.12	-8.29	1.18e-15	5.11e-13	-0.3	-0.36	Height;	chr20:35166801	chr20:35201747~35203288:-
THCA	cis	rs12701220	0.696	rs12112029	ENSG00000229043.2	AC091729.9	-8.29	1.18e-15	5.12e-13	-0.47	-0.36	Bronchopulmonary dysplasia;	chr7:1098253	chr7:1160374~1165267:+
THCA	cis	rs3847687	1	rs78233646	ENSG00000256810.1	RP11-76C10.2	8.29	1.18e-15	5.12e-13	0.42	0.36	Longevity;	chr12:131035625	chr12:131030570~131035487:-
THCA	cis	rs7665090	1	rs10027437	ENSG00000246560.2	RP11-10L12.4	8.29	1.18e-15	5.13e-13	0.43	0.36	Primary biliary cholangitis;	chr4:102636094	chr4:102828055~102844075:+
THCA	cis	rs56046484	0.956	rs35885781	ENSG00000259295.5	CSPG4P12	8.29	1.18e-15	5.14e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85047852	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs34105012	ENSG00000259295.5	CSPG4P12	8.29	1.18e-15	5.14e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85048455	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs34054841	ENSG00000259295.5	CSPG4P12	8.29	1.18e-15	5.14e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85058115	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.956	rs12908535	ENSG00000259295.5	CSPG4P12	8.29	1.18e-15	5.14e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85058294	chr15:85191438~85213905:+
THCA	cis	rs11148252	0.712	rs61957257	ENSG00000235660.1	LINC00345	-8.29	1.18e-15	5.14e-13	-0.45	-0.36	Lewy body disease;	chr13:52195567	chr13:52484161~52484680:-
THCA	cis	rs7849270	1	rs932835	ENSG00000268707.1	RP11-247A12.7	-8.29	1.18e-15	5.14e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129124792	chr9:129170434~129170940:+
THCA	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	8.29	1.19e-15	5.15e-13	0.35	0.36	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
THCA	cis	rs853679	0.882	rs9461432	ENSG00000280107.1	AL022393.9	-8.29	1.19e-15	5.15e-13	-0.54	-0.36	Depression;	chr6:28119105	chr6:28170845~28172521:+
THCA	cis	rs1707322	1	rs785498	ENSG00000234329.1	RP11-767N6.2	-8.29	1.19e-15	5.16e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45651039~45651826:-
THCA	cis	rs180730	0.898	rs343200	ENSG00000251609.2	SETP12	-8.29	1.19e-15	5.17e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120876657	chr4:120895494~120897083:-
THCA	cis	rs11096990	0.634	rs6852967	ENSG00000249685.1	RP11-360F5.3	-8.29	1.2e-15	5.19e-13	-0.42	-0.36	Cognitive function;	chr4:39281526	chr4:39133913~39135608:+
THCA	cis	rs6545883	0.507	rs2123111	ENSG00000271889.1	RP11-493E12.1	-8.29	1.2e-15	5.19e-13	-0.34	-0.36	Tuberculosis;	chr2:61223319	chr2:61151433~61162105:-
THCA	cis	rs1799949	0.602	rs8176235	ENSG00000267681.1	CTD-3199J23.6	-8.29	1.2e-15	5.2e-13	-0.44	-0.36	Menopause (age at onset);	chr17:43067543	chr17:43144956~43145255:+
THCA	cis	rs11673344	0.583	rs7254411	ENSG00000226686.6	LINC01535	8.29	1.21e-15	5.25e-13	0.39	0.36	Obesity-related traits;	chr19:37034969	chr19:37251912~37265535:+
THCA	cis	rs7829975	0.84	rs555617	ENSG00000253893.2	FAM85B	8.29	1.22e-15	5.27e-13	0.45	0.36	Mood instability;	chr8:8735335	chr8:8167819~8226614:-
THCA	cis	rs853679	0.76	rs9468317	ENSG00000219392.1	RP1-265C24.5	-8.29	1.22e-15	5.27e-13	-0.5	-0.36	Depression;	chr6:28230678	chr6:28115628~28116551:+
THCA	cis	rs56046484	0.913	rs12906544	ENSG00000259295.5	CSPG4P12	8.29	1.22e-15	5.29e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85032832	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.871	rs34978449	ENSG00000259295.5	CSPG4P12	8.29	1.22e-15	5.29e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85036917	chr15:85191438~85213905:+
THCA	cis	rs56046484	0.871	rs62021230	ENSG00000259295.5	CSPG4P12	8.29	1.22e-15	5.29e-13	0.61	0.36	Testicular germ cell tumor;	chr15:85040721	chr15:85191438~85213905:+
THCA	cis	rs9549328	0.7	rs2185001	ENSG00000267868.1	RP11-120K24.3	8.29	1.22e-15	5.29e-13	0.37	0.36	Systolic blood pressure;	chr13:112962055	chr13:112964835~112966131:-
THCA	cis	rs17711722	0.64	rs13237956	ENSG00000237310.1	GS1-124K5.4	8.29	1.22e-15	5.29e-13	0.26	0.36	Calcium levels;	chr7:65853042	chr7:66493706~66495474:+
THCA	cis	rs875971	0.516	rs6945322	ENSG00000237310.1	GS1-124K5.4	8.29	1.22e-15	5.29e-13	0.26	0.36	Aortic root size;	chr7:65871069	chr7:66493706~66495474:+
THCA	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	8.29	1.22e-15	5.31e-13	0.68	0.36	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
THCA	cis	rs55665837	1	rs2305306	ENSG00000251991.1	RNU7-49P	8.29	1.23e-15	5.32e-13	0.4	0.36	Vitamin D levels;	chr11:14513453	chr11:14478892~14478953:+
THCA	cis	rs2032366	0.591	rs9783921	ENSG00000267279.1	RP11-879F14.2	8.29	1.23e-15	5.32e-13	0.38	0.36	Obesity-related traits;	chr18:61635219	chr18:61585746~61606916:-
THCA	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	8.29	1.23e-15	5.33e-13	0.43	0.36	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	8.29	1.23e-15	5.33e-13	0.43	0.36	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
THCA	cis	rs3096299	1	rs3096299	ENSG00000274627.1	RP11-104N10.2	8.29	1.23e-15	5.34e-13	0.35	0.36	Multiple myeloma (IgH translocation);	chr16:89382255	chr16:89516797~89522217:+
THCA	cis	rs673078	0.66	rs61943525	ENSG00000275409.1	RP11-131L12.4	-8.29	1.23e-15	5.35e-13	-0.48	-0.36	Glucose homeostasis traits;	chr12:118152927	chr12:118430147~118430699:+
THCA	cis	rs73186030	0.92	rs73186060	ENSG00000272758.4	RP11-299J3.8	8.29	1.23e-15	5.35e-13	0.45	0.36	Serum parathyroid hormone levels;	chr3:122333507	chr3:122416207~122443180:+
THCA	cis	rs11214589	0.87	rs10789942	ENSG00000270179.1	RP11-159N11.4	8.29	1.23e-15	5.35e-13	0.37	0.36	Neuroticism;	chr11:113365477	chr11:113368478~113369117:+
THCA	cis	rs180730	1	rs2667176	ENSG00000251609.2	SETP12	-8.29	1.23e-15	5.35e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120881498	chr4:120895494~120897083:-
THCA	cis	rs875971	0.505	rs1167386	ENSG00000237310.1	GS1-124K5.4	-8.29	1.24e-15	5.36e-13	-0.26	-0.36	Aortic root size;	chr7:66048109	chr7:66493706~66495474:+
THCA	cis	rs875971	0.505	rs1167385	ENSG00000237310.1	GS1-124K5.4	-8.29	1.24e-15	5.36e-13	-0.26	-0.36	Aortic root size;	chr7:66048321	chr7:66493706~66495474:+
THCA	cis	rs2120243	0.533	rs1500921	ENSG00000244515.1	KRT18P34	-8.29	1.24e-15	5.37e-13	-0.4	-0.36	Hepatocellular carcinoma in hepatitis B infection;	chr3:157337638	chr3:157162663~157163932:-
THCA	cis	rs2120243	0.533	rs62278578	ENSG00000244515.1	KRT18P34	-8.29	1.24e-15	5.37e-13	-0.4	-0.36	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338078	chr3:157162663~157163932:-
THCA	cis	rs875971	0.522	rs34973832	ENSG00000237310.1	GS1-124K5.4	8.29	1.24e-15	5.37e-13	0.26	0.36	Aortic root size;	chr7:65931217	chr7:66493706~66495474:+
THCA	cis	rs741668	0.641	rs9534306	ENSG00000235903.6	CPB2-AS1	8.29	1.24e-15	5.38e-13	0.45	0.36	Cerebrospinal fluid clusterin levels;	chr13:46069100	chr13:46052806~46113332:+
THCA	cis	rs12594515	0.625	rs2176866	ENSG00000259200.1	RP11-718O11.1	-8.29	1.24e-15	5.39e-13	-0.46	-0.36	Weight;Waist circumference;	chr15:45704620	chr15:45705078~45931069:+
THCA	cis	rs7849270	1	rs7023900	ENSG00000268707.1	RP11-247A12.7	-8.28	1.24e-15	5.39e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129128873	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs7036114	ENSG00000268707.1	RP11-247A12.7	-8.28	1.24e-15	5.39e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129131127	chr9:129170434~129170940:+
THCA	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	8.28	1.25e-15	5.4e-13	0.45	0.36	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
THCA	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	8.28	1.25e-15	5.41e-13	0.45	0.36	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
THCA	cis	rs12468226	0.808	rs73992849	ENSG00000273456.1	RP11-686O6.2	8.28	1.25e-15	5.42e-13	0.43	0.36	Urate levels;	chr2:202152444	chr2:202374932~202375604:-
THCA	cis	rs7191700	0.511	rs243330	ENSG00000262636.1	CTD-3088G3.4	8.28	1.26e-15	5.45e-13	0.44	0.36	Multiple sclerosis;	chr16:11257134	chr16:11380859~11381118:-
THCA	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	8.28	1.26e-15	5.46e-13	0.4	0.36	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
THCA	cis	rs7015263	0.714	rs3903247	ENSG00000254231.1	CTD-2284J15.1	-8.28	1.26e-15	5.47e-13	-0.36	-0.36	Intelligence (multi-trait analysis);	chr8:86526184	chr8:86333274~86343314:-
THCA	cis	rs875971	0.522	rs4718285	ENSG00000237310.1	GS1-124K5.4	8.28	1.26e-15	5.47e-13	0.26	0.36	Aortic root size;	chr7:65827018	chr7:66493706~66495474:+
THCA	cis	rs1850744	0.609	rs6448959	ENSG00000250942.1	ENPP7P11	8.28	1.26e-15	5.48e-13	0.49	0.36	Economic and political preferences;	chr4:9682303	chr4:9677308~9677934:+
THCA	cis	rs1858037	0.867	rs4671660	ENSG00000237979.1	AC007389.1	8.28	1.26e-15	5.48e-13	0.44	0.36	Rheumatoid arthritis;	chr2:65349302	chr2:65500993~65502138:-
THCA	cis	rs9543976	1	rs2031236	ENSG00000261553.4	RP11-29G8.3	-8.28	1.27e-15	5.49e-13	-0.47	-0.36	Diabetic retinopathy;	chr13:75595641	chr13:75549773~75807120:+
THCA	cis	rs11971779	0.648	rs59791374	ENSG00000273391.1	RP11-634H22.1	8.28	1.27e-15	5.5e-13	0.33	0.36	Diisocyanate-induced asthma;	chr7:139432216	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.59	rs59602547	ENSG00000273391.1	RP11-634H22.1	8.28	1.27e-15	5.5e-13	0.33	0.36	Diisocyanate-induced asthma;	chr7:139432277	chr7:139359032~139359566:-
THCA	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-8.28	1.27e-15	5.5e-13	-0.35	-0.36	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-8.28	1.27e-15	5.5e-13	-0.35	-0.36	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
THCA	cis	rs875971	0.54	rs1723268	ENSG00000237310.1	GS1-124K5.4	8.28	1.27e-15	5.5e-13	0.26	0.36	Aortic root size;	chr7:66008093	chr7:66493706~66495474:+
THCA	cis	rs10266483	0.741	rs10254313	ENSG00000227986.1	TRIM60P18	-8.28	1.27e-15	5.52e-13	-0.29	-0.36	Response to statin therapy;	chr7:64278935	chr7:64355078~64356199:+
THCA	cis	rs10266483	0.741	rs35244017	ENSG00000227986.1	TRIM60P18	-8.28	1.27e-15	5.52e-13	-0.29	-0.36	Response to statin therapy;	chr7:64278939	chr7:64355078~64356199:+
THCA	cis	rs10266483	0.843	rs10272639	ENSG00000227986.1	TRIM60P18	-8.28	1.27e-15	5.52e-13	-0.29	-0.36	Response to statin therapy;	chr7:64278944	chr7:64355078~64356199:+
THCA	cis	rs6991838	0.702	rs34496943	ENSG00000200714.1	Y_RNA	8.28	1.27e-15	5.52e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65676978	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.733	rs13281090	ENSG00000200714.1	Y_RNA	8.28	1.27e-15	5.52e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65678244	chr8:65592731~65592820:+
THCA	cis	rs6991838	0.701	rs17395275	ENSG00000200714.1	Y_RNA	8.28	1.27e-15	5.52e-13	0.43	0.36	Intelligence (multi-trait analysis);	chr8:65679003	chr8:65592731~65592820:+
THCA	cis	rs1005277	0.579	rs2504148	ENSG00000263064.2	RP11-291L22.7	8.28	1.27e-15	5.52e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs176886	ENSG00000263064.2	RP11-291L22.7	8.28	1.27e-15	5.52e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.557	rs176887	ENSG00000263064.2	RP11-291L22.7	8.28	1.27e-15	5.52e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474594	ENSG00000263064.2	RP11-291L22.7	8.28	1.27e-15	5.52e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs11011461	ENSG00000263064.2	RP11-291L22.7	8.28	1.27e-15	5.52e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38448689~38448949:+
THCA	cis	rs2562456	0.917	rs2650825	ENSG00000268555.1	RP11-678G14.3	8.28	1.28e-15	5.53e-13	0.5	0.36	Pain;	chr19:21516423	chr19:21570822~21587322:-
THCA	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-8.28	1.28e-15	5.54e-13	-0.36	-0.36	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
THCA	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-8.28	1.28e-15	5.54e-13	-0.36	-0.36	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
THCA	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	8.28	1.28e-15	5.55e-13	0.45	0.36	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
THCA	cis	rs180730	1	rs343195	ENSG00000251609.2	SETP12	-8.28	1.28e-15	5.56e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120879311	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs180730	ENSG00000251609.2	SETP12	-8.28	1.28e-15	5.56e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120880635	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs1901136	ENSG00000251609.2	SETP12	-8.28	1.28e-15	5.56e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120881574	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs2667175	ENSG00000251609.2	SETP12	-8.28	1.28e-15	5.56e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120882099	chr4:120895494~120897083:-
THCA	cis	rs180730	0.948	rs3115312	ENSG00000251609.2	SETP12	-8.28	1.28e-15	5.56e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120882651	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs3106313	ENSG00000251609.2	SETP12	-8.28	1.28e-15	5.56e-13	-0.57	-0.36	Fasting plasma glucose;	chr4:120882815	chr4:120895494~120897083:-
THCA	cis	rs180730	1	rs1450472	ENSG00000251609.2	SETP12	8.28	1.28e-15	5.56e-13	0.57	0.36	Fasting plasma glucose;	chr4:120882137	chr4:120895494~120897083:-
THCA	cis	rs4927850	0.723	rs7630825	ENSG00000242086.7	LINC00969	8.28	1.29e-15	5.57e-13	0.34	0.36	Pancreatic cancer;	chr3:196026869	chr3:195658062~195739964:+
THCA	cis	rs934734	0.532	rs10166100	ENSG00000237979.1	AC007389.1	-8.28	1.29e-15	5.58e-13	-0.41	-0.36	Rheumatoid arthritis;	chr2:65418616	chr2:65500993~65502138:-
THCA	cis	rs4834770	0.746	rs2389747	ENSG00000245958.5	RP11-33B1.1	-8.28	1.29e-15	5.59e-13	-0.33	-0.36	Blood protein levels;	chr4:119314947	chr4:119454791~119552025:+
THCA	cis	rs4834770	0.717	rs1022146	ENSG00000245958.5	RP11-33B1.1	-8.28	1.29e-15	5.59e-13	-0.33	-0.36	Blood protein levels;	chr4:119314948	chr4:119454791~119552025:+
THCA	cis	rs17711722	0.701	rs4467826	ENSG00000237310.1	GS1-124K5.4	8.28	1.29e-15	5.59e-13	0.26	0.36	Calcium levels;	chr7:65903721	chr7:66493706~66495474:+
THCA	cis	rs748404	0.631	rs3809482	ENSG00000205771.5	CATSPER2P1	-8.28	1.29e-15	5.6e-13	-0.37	-0.36	Lung cancer;	chr15:43369604	chr15:43726918~43747094:-
THCA	cis	rs11603023	0.967	rs4245184	ENSG00000255239.1	AP002954.6	-8.28	1.29e-15	5.6e-13	-0.46	-0.36	Cholesterol, total;	chr11:118639844	chr11:118688039~118690600:-
THCA	cis	rs11603023	0.967	rs644273	ENSG00000255239.1	AP002954.6	-8.28	1.29e-15	5.6e-13	-0.46	-0.36	Cholesterol, total;	chr11:118640634	chr11:118688039~118690600:-
THCA	cis	rs11603023	0.967	rs654423	ENSG00000255239.1	AP002954.6	-8.28	1.29e-15	5.6e-13	-0.46	-0.36	Cholesterol, total;	chr11:118641039	chr11:118688039~118690600:-
THCA	cis	rs7191700	0.601	rs243329	ENSG00000262636.1	CTD-3088G3.4	8.28	1.29e-15	5.6e-13	0.44	0.36	Multiple sclerosis;	chr16:11258456	chr16:11380859~11381118:-
THCA	cis	rs6504108	0.624	rs4794505	ENSG00000278765.1	RP5-890E16.5	-8.28	1.3e-15	5.62e-13	-0.4	-0.36	Body mass index;	chr17:48205944	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.647	rs12150533	ENSG00000278765.1	RP5-890E16.5	-8.28	1.3e-15	5.62e-13	-0.4	-0.36	Body mass index;	chr17:48210179	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs4794517	ENSG00000278765.1	RP5-890E16.5	-8.28	1.3e-15	5.62e-13	-0.4	-0.36	Body mass index;	chr17:48214491	chr17:48066704~48067293:-
THCA	cis	rs11148252	0.716	rs1887360	ENSG00000278238.1	RP11-245D16.4	-8.28	1.3e-15	5.63e-13	-0.43	-0.36	Lewy body disease;	chr13:52205031	chr13:52454775~52455331:-
THCA	cis	rs1850744	0.702	rs11724183	ENSG00000250942.1	ENPP7P11	-8.28	1.3e-15	5.64e-13	-0.52	-0.36	Economic and political preferences;	chr4:9608270	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.826	rs11735475	ENSG00000250942.1	ENPP7P11	-8.28	1.3e-15	5.64e-13	-0.52	-0.36	Economic and political preferences;	chr4:9613302	chr4:9677308~9677934:+
THCA	cis	rs1005277	0.579	rs2474584	ENSG00000263064.2	RP11-291L22.7	8.28	1.31e-15	5.66e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474586	ENSG00000263064.2	RP11-291L22.7	8.28	1.31e-15	5.66e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38448689~38448949:+
THCA	cis	rs17772222	0.682	rs8017689	ENSG00000258789.1	RP11-507K2.3	-8.28	1.31e-15	5.68e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88483442	chr14:88551597~88552493:+
THCA	cis	rs9532669	0.926	rs4254182	ENSG00000176268.5	CYCSP34	8.28	1.32e-15	5.7e-13	0.41	0.36	Cervical cancer;	chr13:40879120	chr13:40863599~40863902:-
THCA	cis	rs7849270	1	rs713219	ENSG00000268707.1	RP11-247A12.7	-8.28	1.32e-15	5.71e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129138641	chr9:129170434~129170940:+
THCA	cis	rs2562456	0.682	rs11085464	ENSG00000268555.1	RP11-678G14.3	8.28	1.32e-15	5.72e-13	0.49	0.36	Pain;	chr19:21568976	chr19:21570822~21587322:-
THCA	cis	rs150992	0.609	rs366353	ENSG00000248489.1	CTD-2007H13.3	-8.28	1.32e-15	5.72e-13	-0.34	-0.36	Body mass index;	chr5:98995663	chr5:98929171~98995013:+
THCA	cis	rs9309473	0.607	rs10198301	ENSG00000163016.8	ALMS1P	8.28	1.33e-15	5.75e-13	0.48	0.36	Metabolite levels;	chr2:73354472	chr2:73644919~73685576:+
THCA	cis	rs1729407	0.933	rs1729405	ENSG00000254851.1	RP11-109L13.1	-8.28	1.33e-15	5.75e-13	-0.46	-0.36	Apolipoprotein A-IV levels;	chr11:116808044	chr11:117135528~117138582:+
THCA	cis	rs7727544	0.642	rs7705189	ENSG00000224431.1	AC063976.7	-8.28	1.33e-15	5.76e-13	-0.31	-0.36	Blood metabolite levels;	chr5:132287665	chr5:132199456~132203487:+
THCA	cis	rs9500256	0.967	rs1012500	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-8.28	1.33e-15	5.76e-13	-0.36	-0.36	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57855891~57856468:-
THCA	cis	rs875971	0.522	rs4718286	ENSG00000237310.1	GS1-124K5.4	8.28	1.34e-15	5.77e-13	0.26	0.36	Aortic root size;	chr7:65827777	chr7:66493706~66495474:+
THCA	cis	rs17711722	0.585	rs6942660	ENSG00000237310.1	GS1-124K5.4	8.28	1.34e-15	5.77e-13	0.26	0.36	Calcium levels;	chr7:65837419	chr7:66493706~66495474:+
THCA	cis	rs17711722	0.701	rs55773927	ENSG00000237310.1	GS1-124K5.4	8.28	1.34e-15	5.77e-13	0.26	0.36	Calcium levels;	chr7:65872915	chr7:66493706~66495474:+
THCA	cis	rs73186030	1	rs5008830	ENSG00000272758.4	RP11-299J3.8	8.28	1.34e-15	5.77e-13	0.44	0.36	Serum parathyroid hormone levels;	chr3:122311615	chr3:122416207~122443180:+
THCA	cis	rs1275468	0.798	rs10879928	ENSG00000257497.2	RP11-585P4.5	8.28	1.34e-15	5.77e-13	0.5	0.36	Polycystic ovary syndrome;	chr12:75531996	chr12:75483454~75489820:-
THCA	cis	rs55665837	1	rs11023224	ENSG00000251991.1	RNU7-49P	8.27	1.34e-15	5.79e-13	0.4	0.36	Vitamin D levels;	chr11:14436193	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.961	rs11023226	ENSG00000251991.1	RNU7-49P	8.27	1.34e-15	5.79e-13	0.4	0.36	Vitamin D levels;	chr11:14437271	chr11:14478892~14478953:+
THCA	cis	rs4834770	0.718	rs4833618	ENSG00000245958.5	RP11-33B1.1	8.27	1.34e-15	5.8e-13	0.33	0.36	Blood protein levels;	chr4:119388345	chr4:119454791~119552025:+
THCA	cis	rs9928842	0.765	rs6564223	ENSG00000280152.1	RP11-331F4.5	8.27	1.34e-15	5.81e-13	0.54	0.36	Alcoholic chronic pancreatitis;	chr16:75192001	chr16:75245994~75250077:-
THCA	cis	rs42490	0.664	rs394108	ENSG00000251136.7	RP11-37B2.1	-8.27	1.34e-15	5.81e-13	-0.31	-0.36	Leprosy;	chr8:89812991	chr8:89609409~89757727:-
THCA	cis	rs11096990	0.634	rs745642	ENSG00000249685.1	RP11-360F5.3	-8.27	1.35e-15	5.81e-13	-0.42	-0.36	Cognitive function;	chr4:39279642	chr4:39133913~39135608:+
THCA	cis	rs875971	0.522	rs7784623	ENSG00000237310.1	GS1-124K5.4	8.27	1.36e-15	5.86e-13	0.26	0.36	Aortic root size;	chr7:65930047	chr7:66493706~66495474:+
THCA	cis	rs516805	0.748	rs155463	ENSG00000279453.1	RP3-425C14.4	-8.27	1.36e-15	5.86e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122501474	chr6:122436789~122439223:-
THCA	cis	rs516805	0.715	rs197691	ENSG00000279453.1	RP3-425C14.4	-8.27	1.36e-15	5.86e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122513394	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs197692	ENSG00000279453.1	RP3-425C14.4	-8.27	1.36e-15	5.86e-13	-0.37	-0.36	Lymphocyte counts;	chr6:122515260	chr6:122436789~122439223:-
THCA	cis	rs4266144	0.569	rs729257	ENSG00000244515.1	KRT18P34	-8.27	1.36e-15	5.86e-13	-0.39	-0.36	Coronary artery disease;	chr3:157111034	chr3:157162663~157163932:-
THCA	cis	rs7945705	0.967	rs4554887	ENSG00000254860.4	TMEM9B-AS1	-8.27	1.36e-15	5.89e-13	-0.41	-0.36	Hemoglobin concentration;	chr11:8818776	chr11:8964675~8977527:+
THCA	cis	rs17772222	0.638	rs11159859	ENSG00000258789.1	RP11-507K2.3	-8.27	1.37e-15	5.9e-13	-0.35	-0.36	Coronary artery calcification;	chr14:88561547	chr14:88551597~88552493:+
THCA	cis	rs507080	0.922	rs478371	ENSG00000278376.1	RP11-158I9.8	-8.27	1.37e-15	5.9e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118694627	chr11:118791254~118793137:+
THCA	cis	rs9902453	0.584	rs3809790	ENSG00000264007.1	RP11-68I3.10	-8.27	1.37e-15	5.91e-13	-0.4	-0.36	Coffee consumption (cups per day);	chr17:29628522	chr17:29621617~29622254:-
THCA	cis	rs1005277	0.603	rs1998062	ENSG00000263064.2	RP11-291L22.7	8.27	1.37e-15	5.93e-13	0.41	0.36	Extrinsic epigenetic age acceleration;	chr10:38168724	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.563	rs2505215	ENSG00000263064.2	RP11-291L22.7	8.27	1.37e-15	5.93e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.563	rs2505216	ENSG00000263064.2	RP11-291L22.7	8.27	1.37e-15	5.93e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2749612	ENSG00000263064.2	RP11-291L22.7	8.27	1.37e-15	5.93e-13	0.4	0.36	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38448689~38448949:+
THCA	cis	rs4819052	0.807	rs7283915	ENSG00000237664.1	LINC00316	-8.27	1.38e-15	5.93e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251373	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2838850	ENSG00000237664.1	LINC00316	-8.27	1.38e-15	5.93e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251530	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs8130285	ENSG00000237664.1	LINC00316	-8.27	1.38e-15	5.93e-13	-0.36	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251786	chr21:45338590~45341990:-
THCA	cis	rs17772222	0.682	rs2297129	ENSG00000258789.1	RP11-507K2.3	-8.27	1.38e-15	5.94e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88469581	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.682	rs61542857	ENSG00000258789.1	RP11-507K2.3	-8.27	1.38e-15	5.94e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88470358	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.682	rs3783889	ENSG00000258789.1	RP11-507K2.3	-8.27	1.38e-15	5.94e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88475637	chr14:88551597~88552493:+
THCA	cis	rs1707322	0.682	rs28508523	ENSG00000234329.1	RP11-767N6.2	8.27	1.38e-15	5.94e-13	0.33	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.691	rs11211175	ENSG00000234329.1	RP11-767N6.2	8.27	1.38e-15	5.94e-13	0.33	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45651039~45651826:-
THCA	cis	rs17711722	0.727	rs35850374	ENSG00000237310.1	GS1-124K5.4	8.27	1.38e-15	5.94e-13	0.26	0.36	Calcium levels;	chr7:65892789	chr7:66493706~66495474:+
THCA	cis	rs7849270	1	rs34055941	ENSG00000268707.1	RP11-247A12.7	-8.27	1.38e-15	5.97e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129132797	chr9:129170434~129170940:+
THCA	cis	rs10411161	0.702	rs7247017	ENSG00000269483.1	AC006272.1	8.27	1.38e-15	5.97e-13	0.5	0.36	Breast cancer;	chr19:51888516	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs7256926	ENSG00000269483.1	AC006272.1	8.27	1.38e-15	5.97e-13	0.5	0.36	Breast cancer;	chr19:51888735	chr19:51839924~51843324:-
THCA	cis	rs4380275	0.965	rs4375894	ENSG00000272342.1	RP13-539J13.1	8.27	1.39e-15	6e-13	0.43	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772567	chr2:739588~740164:-
THCA	cis	rs4713118	1	rs1139226	ENSG00000219392.1	RP1-265C24.5	-8.27	1.39e-15	6.02e-13	-0.45	-0.36	Parkinson's disease;	chr6:27707511	chr6:28115628~28116551:+
THCA	cis	rs4713118	1	rs9468195	ENSG00000219392.1	RP1-265C24.5	-8.27	1.39e-15	6.02e-13	-0.45	-0.36	Parkinson's disease;	chr6:27708530	chr6:28115628~28116551:+
THCA	cis	rs6504108	0.624	rs17620033	ENSG00000278765.1	RP5-890E16.5	-8.27	1.4e-15	6.03e-13	-0.4	-0.36	Body mass index;	chr17:48214052	chr17:48066704~48067293:-
THCA	cis	rs3096299	0.591	rs748940	ENSG00000274627.1	RP11-104N10.2	8.27	1.4e-15	6.04e-13	0.36	0.36	Multiple myeloma (IgH translocation);	chr16:89374349	chr16:89516797~89522217:+
THCA	cis	rs4718428	0.705	rs4718424	ENSG00000230295.1	RP11-458F8.2	-8.27	1.4e-15	6.05e-13	-0.31	-0.36	Corneal structure;	chr7:66911108	chr7:66880708~66882981:+
THCA	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	8.27	1.4e-15	6.05e-13	0.38	0.36	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
THCA	cis	rs1707322	0.686	rs1084086	ENSG00000234329.1	RP11-767N6.2	-8.27	1.41e-15	6.08e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45651039~45651826:-
THCA	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	8.27	1.42e-15	6.1e-13	0.35	0.36	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
THCA	cis	rs42490	0.625	rs438485	ENSG00000251136.7	RP11-37B2.1	-8.27	1.42e-15	6.12e-13	-0.31	-0.36	Leprosy;	chr8:89831190	chr8:89609409~89757727:-
THCA	cis	rs11096990	0.634	rs7659894	ENSG00000249685.1	RP11-360F5.3	-8.27	1.42e-15	6.14e-13	-0.42	-0.36	Cognitive function;	chr4:39282815	chr4:39133913~39135608:+
THCA	cis	rs7849270	0.959	rs713218	ENSG00000268707.1	RP11-247A12.7	-8.27	1.43e-15	6.15e-13	-0.43	-0.36	Blood metabolite ratios;	chr9:129138491	chr9:129170434~129170940:+
THCA	cis	rs507080	0.961	rs4938523	ENSG00000278376.1	RP11-158I9.8	-8.27	1.43e-15	6.16e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118678129	chr11:118791254~118793137:+
THCA	cis	rs11971779	0.688	rs1862880	ENSG00000273391.1	RP11-634H22.1	8.27	1.43e-15	6.17e-13	0.35	0.36	Diisocyanate-induced asthma;	chr7:139335354	chr7:139359032~139359566:-
THCA	cis	rs8114671	0.836	rs6142280	ENSG00000269202.1	RP4-614O4.12	8.27	1.44e-15	6.18e-13	0.3	0.36	Height;	chr20:35034439	chr20:35201747~35203288:-
THCA	cis	rs2522056	1	rs10900807	ENSG00000233006.5	AC034220.3	-8.26	1.44e-15	6.21e-13	-0.32	-0.36	Fibrinogen;Lymphocyte counts;	chr5:132421788	chr5:132311285~132369916:-
THCA	cis	rs638893	0.588	rs2156755	ENSG00000278376.1	RP11-158I9.8	-8.26	1.44e-15	6.22e-13	-0.31	-0.36	Vitiligo;	chr11:118855521	chr11:118791254~118793137:+
THCA	cis	rs7714584	1	rs6874560	ENSG00000197083.10	ZNF300P1	8.26	1.44e-15	6.22e-13	0.63	0.36	Crohn's disease;	chr5:150803151	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11748553	ENSG00000197083.10	ZNF300P1	8.26	1.44e-15	6.22e-13	0.63	0.36	Crohn's disease;	chr5:150804991	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11746560	ENSG00000197083.10	ZNF300P1	8.26	1.44e-15	6.22e-13	0.63	0.36	Crohn's disease;	chr5:150806363	chr5:150930645~150946289:-
THCA	cis	rs1859596	0.646	rs10252126	ENSG00000234456.6	MAGI2-AS3	8.26	1.44e-15	6.22e-13	0.34	0.36	Reading or mathematical ability;	chr7:79468167	chr7:79452877~79471208:+
THCA	cis	rs55665837	1	rs10832278	ENSG00000251991.1	RNU7-49P	8.26	1.45e-15	6.23e-13	0.4	0.36	Vitamin D levels;	chr11:14475073	chr11:14478892~14478953:+
THCA	cis	rs6504108	0.624	rs4794525	ENSG00000278765.1	RP5-890E16.5	-8.26	1.45e-15	6.23e-13	-0.4	-0.36	Body mass index;	chr17:48220996	chr17:48066704~48067293:-
THCA	cis	rs7829975	0.593	rs2921077	ENSG00000254153.1	CTA-398F10.2	-8.26	1.45e-15	6.23e-13	-0.38	-0.36	Mood instability;	chr8:8446992	chr8:8456909~8461337:-
THCA	cis	rs507080	0.922	rs7114458	ENSG00000278376.1	RP11-158I9.8	-8.26	1.45e-15	6.23e-13	-0.29	-0.36	Serum metabolite levels;	chr11:118695466	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs7114216	ENSG00000278376.1	RP11-158I9.8	-8.26	1.45e-15	6.23e-13	-0.29	-0.36	Serum metabolite levels;	chr11:118695525	chr11:118791254~118793137:+
THCA	cis	rs1949733	0.628	rs1543246	ENSG00000205959.3	RP11-689P11.2	-8.26	1.45e-15	6.24e-13	-0.28	-0.36	Response to antineoplastic agents;	chr4:8503182	chr4:8482270~8512610:+
THCA	cis	rs8114671	0.662	rs6058146	ENSG00000269202.1	RP4-614O4.12	-8.26	1.45e-15	6.24e-13	-0.31	-0.36	Height;	chr20:34952726	chr20:35201747~35203288:-
THCA	cis	rs10050311	0.79	rs72667716	ENSG00000251411.1	RP11-397E7.4	-8.26	1.45e-15	6.24e-13	-0.44	-0.36	Insulin-related traits;	chr4:86912775	chr4:86913266~86914817:-
THCA	cis	rs7811142	1	rs2406255	ENSG00000242294.5	STAG3L5P	8.26	1.45e-15	6.25e-13	0.24	0.36	Platelet count;	chr7:100456067	chr7:100336079~100351900:+
THCA	cis	rs1858037	0.806	rs12612780	ENSG00000237979.1	AC007389.1	8.26	1.46e-15	6.29e-13	0.44	0.36	Rheumatoid arthritis;	chr2:65355967	chr2:65500993~65502138:-
THCA	cis	rs9309473	0.687	rs6706235	ENSG00000163016.8	ALMS1P	8.26	1.46e-15	6.29e-13	0.48	0.36	Metabolite levels;	chr2:73386430	chr2:73644919~73685576:+
THCA	cis	rs1075265	0.68	rs805396	ENSG00000233266.1	HMGB1P31	8.26	1.47e-15	6.33e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54051334~54051760:+
THCA	cis	rs6545883	0.507	rs6545855	ENSG00000271889.1	RP11-493E12.1	-8.26	1.47e-15	6.34e-13	-0.34	-0.36	Tuberculosis;	chr2:61305725	chr2:61151433~61162105:-
THCA	cis	rs11096990	0.634	rs746678	ENSG00000249685.1	RP11-360F5.3	-8.26	1.48e-15	6.35e-13	-0.42	-0.36	Cognitive function;	chr4:39279035	chr4:39133913~39135608:+
THCA	cis	rs1707322	0.686	rs2050376	ENSG00000234329.1	RP11-767N6.2	8.26	1.48e-15	6.37e-13	0.35	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45651039~45651826:-
THCA	cis	rs748404	0.588	rs506120	ENSG00000205771.5	CATSPER2P1	-8.26	1.48e-15	6.38e-13	-0.38	-0.36	Lung cancer;	chr15:43509826	chr15:43726918~43747094:-
THCA	cis	rs17772222	0.637	rs7161660	ENSG00000258789.1	RP11-507K2.3	-8.26	1.48e-15	6.38e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88471832	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.682	rs7141363	ENSG00000258789.1	RP11-507K2.3	-8.26	1.48e-15	6.38e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88471879	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.637	rs879932	ENSG00000258789.1	RP11-507K2.3	-8.26	1.48e-15	6.38e-13	-0.34	-0.36	Coronary artery calcification;	chr14:88479247	chr14:88551597~88552493:+
THCA	cis	rs947583	0.71	rs6570045	ENSG00000231028.7	LINC00271	-8.26	1.48e-15	6.38e-13	-0.28	-0.36	Phosphorus levels;	chr6:135815734	chr6:135497801~135716055:+
THCA	cis	rs1858037	0.765	rs67404371	ENSG00000237979.1	AC007389.1	8.26	1.48e-15	6.38e-13	0.44	0.36	Rheumatoid arthritis;	chr2:65370137	chr2:65500993~65502138:-
THCA	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-8.26	1.48e-15	6.38e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
THCA	cis	rs73186030	0.546	rs6791616	ENSG00000272758.4	RP11-299J3.8	8.26	1.48e-15	6.38e-13	0.41	0.36	Serum parathyroid hormone levels;	chr3:122388388	chr3:122416207~122443180:+
THCA	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-8.26	1.49e-15	6.39e-13	-0.46	-0.36	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
THCA	cis	rs507080	0.922	rs518028	ENSG00000278376.1	RP11-158I9.8	-8.26	1.49e-15	6.39e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118694273	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs519982	ENSG00000278376.1	RP11-158I9.8	-8.26	1.49e-15	6.39e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118694522	chr11:118791254~118793137:+
THCA	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-8.26	1.49e-15	6.4e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
THCA	cis	rs11051970	0.918	rs7309706	ENSG00000274964.1	RP11-817I4.1	-8.26	1.49e-15	6.41e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32385274	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.918	rs76930558	ENSG00000274964.1	RP11-817I4.1	-8.26	1.49e-15	6.41e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32385905	chr12:32339368~32340724:+
THCA	cis	rs11051970	0.918	rs73084099	ENSG00000274964.1	RP11-817I4.1	-8.26	1.49e-15	6.41e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32386817	chr12:32339368~32340724:+
THCA	cis	rs2288884	0.596	rs12459638	ENSG00000275055.1	CTC-471J1.11	-8.26	1.49e-15	6.41e-13	-0.37	-0.36	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51998549	chr19:52049007~52049754:+
THCA	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	8.26	1.49e-15	6.42e-13	0.69	0.36	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
THCA	cis	rs673078	0.66	rs61945224	ENSG00000275409.1	RP11-131L12.4	-8.26	1.49e-15	6.42e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118288623	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61945225	ENSG00000275409.1	RP11-131L12.4	-8.26	1.49e-15	6.42e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118288960	chr12:118430147~118430699:+
THCA	cis	rs910316	0.737	rs175071	ENSG00000279594.1	RP11-950C14.10	-8.26	1.5e-15	6.43e-13	-0.32	-0.36	Height;	chr14:75031474	chr14:75011269~75012851:-
THCA	cis	rs5769707	0.967	rs763126	ENSG00000235111.1	RP1-29C18.8	8.26	1.5e-15	6.43e-13	0.42	0.36	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49612657~49615716:-
THCA	cis	rs910316	0.763	rs13712	ENSG00000279594.1	RP11-950C14.10	8.26	1.5e-15	6.45e-13	0.32	0.36	Height;	chr14:75017109	chr14:75011269~75012851:-
THCA	cis	rs55665837	1	rs11023227	ENSG00000251991.1	RNU7-49P	8.26	1.5e-15	6.45e-13	0.4	0.36	Vitamin D levels;	chr11:14437541	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs11023229	ENSG00000251991.1	RNU7-49P	8.26	1.5e-15	6.45e-13	0.4	0.36	Vitamin D levels;	chr11:14439455	chr11:14478892~14478953:+
THCA	cis	rs17684571	0.751	rs7761729	ENSG00000231441.1	RP11-472M19.2	8.26	1.5e-15	6.45e-13	0.44	0.36	Schizophrenia;	chr6:56846478	chr6:56844002~56864078:+
THCA	cis	rs1707322	0.627	rs3014213	ENSG00000234329.1	RP11-767N6.2	-8.26	1.5e-15	6.47e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.686	rs2152078	ENSG00000234329.1	RP11-767N6.2	-8.26	1.5e-15	6.47e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.686	rs2991979	ENSG00000234329.1	RP11-767N6.2	-8.26	1.5e-15	6.47e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45651039~45651826:-
THCA	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-8.26	1.51e-15	6.48e-13	-0.44	-0.36	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
THCA	cis	rs150992	0.673	rs161747	ENSG00000248489.1	CTD-2007H13.3	-8.26	1.51e-15	6.48e-13	-0.35	-0.36	Body mass index;	chr5:98920433	chr5:98929171~98995013:+
THCA	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-8.26	1.51e-15	6.48e-13	-0.44	-0.36	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
THCA	cis	rs4819052	0.851	rs28442024	ENSG00000237664.1	LINC00316	-8.26	1.51e-15	6.49e-13	-0.35	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45254560	chr21:45338590~45341990:-
THCA	cis	rs875971	0.522	rs6960048	ENSG00000237310.1	GS1-124K5.4	8.26	1.51e-15	6.51e-13	0.26	0.36	Aortic root size;	chr7:65943052	chr7:66493706~66495474:+
THCA	cis	rs7569084	1	rs7583469	ENSG00000237979.1	AC007389.1	8.26	1.52e-15	6.51e-13	0.41	0.36	Sum eosinophil basophil counts;	chr2:65424222	chr2:65500993~65502138:-
THCA	cis	rs1707322	0.721	rs6665808	ENSG00000234329.1	RP11-767N6.2	8.26	1.52e-15	6.52e-13	0.33	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45651039~45651826:-
THCA	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	8.26	1.52e-15	6.52e-13	0.43	0.36	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
THCA	cis	rs55665837	1	rs10832268	ENSG00000251991.1	RNU7-49P	8.26	1.52e-15	6.53e-13	0.4	0.36	Vitamin D levels;	chr11:14443522	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs10832269	ENSG00000251991.1	RNU7-49P	8.26	1.52e-15	6.53e-13	0.4	0.36	Vitamin D levels;	chr11:14443523	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs10832271	ENSG00000251991.1	RNU7-49P	8.26	1.52e-15	6.53e-13	0.4	0.36	Vitamin D levels;	chr11:14445373	chr11:14478892~14478953:+
THCA	cis	rs55665837	0.961	rs12576926	ENSG00000251991.1	RNU7-49P	8.26	1.52e-15	6.53e-13	0.4	0.36	Vitamin D levels;	chr11:14458746	chr11:14478892~14478953:+
THCA	cis	rs1858037	0.867	rs67453645	ENSG00000237979.1	AC007389.1	8.26	1.52e-15	6.54e-13	0.44	0.36	Rheumatoid arthritis;	chr2:65358908	chr2:65500993~65502138:-
THCA	cis	rs4819052	0.851	rs2838857	ENSG00000237664.1	LINC00316	-8.26	1.52e-15	6.55e-13	-0.35	-0.36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261085	chr21:45338590~45341990:-
THCA	cis	rs2032366	0.63	rs6567226	ENSG00000267279.1	RP11-879F14.2	-8.26	1.53e-15	6.57e-13	-0.38	-0.36	Obesity-related traits;	chr18:61635689	chr18:61585746~61606916:-
THCA	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-8.26	1.54e-15	6.61e-13	-0.43	-0.36	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
THCA	cis	rs2562456	0.876	rs11085467	ENSG00000268555.1	RP11-678G14.3	8.26	1.55e-15	6.64e-13	0.49	0.36	Pain;	chr19:21569041	chr19:21570822~21587322:-
THCA	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-8.25	1.55e-15	6.67e-13	-0.43	-0.36	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-8.25	1.55e-15	6.67e-13	-0.43	-0.36	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
THCA	cis	rs507080	0.922	rs519848	ENSG00000278376.1	RP11-158I9.8	-8.25	1.55e-15	6.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118682006	chr11:118791254~118793137:+
THCA	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	8.25	1.55e-15	6.67e-13	0.51	0.36	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
THCA	cis	rs7727544	0.716	rs72793283	ENSG00000224431.1	AC063976.7	8.25	1.56e-15	6.68e-13	0.31	0.36	Blood metabolite levels;	chr5:132231248	chr5:132199456~132203487:+
THCA	cis	rs1850744	0.702	rs10939427	ENSG00000250942.1	ENPP7P11	8.25	1.56e-15	6.69e-13	0.52	0.36	Economic and political preferences;	chr4:9626914	chr4:9677308~9677934:+
THCA	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	8.25	1.56e-15	6.69e-13	0.42	0.36	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
THCA	cis	rs507080	0.922	rs642662	ENSG00000278376.1	RP11-158I9.8	-8.25	1.56e-15	6.7e-13	-0.29	-0.36	Serum metabolite levels;	chr11:118696311	chr11:118791254~118793137:+
THCA	cis	rs11673344	0.543	rs1818748	ENSG00000226686.6	LINC01535	8.25	1.56e-15	6.71e-13	0.39	0.36	Obesity-related traits;	chr19:37065416	chr19:37251912~37265535:+
THCA	cis	rs17711722	0.701	rs781143	ENSG00000237310.1	GS1-124K5.4	8.25	1.56e-15	6.71e-13	0.26	0.36	Calcium levels;	chr7:65974892	chr7:66493706~66495474:+
THCA	cis	rs10759883	0.539	rs10117340	ENSG00000175611.10	LINC00476	-8.25	1.57e-15	6.72e-13	-0.37	-0.36	Nicotine dependence;	chr9:96032530	chr9:95759231~95875977:-
THCA	cis	rs910316	1	rs4899544	ENSG00000279594.1	RP11-950C14.10	8.25	1.57e-15	6.72e-13	0.33	0.36	Height;	chr14:75079853	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs4903279	ENSG00000279594.1	RP11-950C14.10	8.25	1.57e-15	6.72e-13	0.33	0.36	Height;	chr14:75079880	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs1071989	ENSG00000279594.1	RP11-950C14.10	8.25	1.57e-15	6.72e-13	0.33	0.36	Height;	chr14:75097956	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs9805979	ENSG00000279594.1	RP11-950C14.10	8.25	1.57e-15	6.72e-13	0.33	0.36	Height;	chr14:75099506	chr14:75011269~75012851:-
THCA	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-8.25	1.57e-15	6.73e-13	-0.37	-0.36	Height;	chr11:118747911	chr11:118704607~118750263:+
THCA	cis	rs16846053	0.515	rs1510094	ENSG00000227403.1	AC009299.3	8.25	1.57e-15	6.74e-13	0.56	0.36	Blood osmolality (transformed sodium);	chr2:161632681	chr2:161244739~161249050:+
THCA	cis	rs910316	1	rs12589376	ENSG00000279594.1	RP11-950C14.10	8.25	1.57e-15	6.75e-13	0.33	0.36	Height;	chr14:75094449	chr14:75011269~75012851:-
THCA	cis	rs507080	0.883	rs656575	ENSG00000278376.1	RP11-158I9.8	-8.25	1.57e-15	6.75e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679199	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs656505	ENSG00000278376.1	RP11-158I9.8	-8.25	1.57e-15	6.75e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679245	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs660489	ENSG00000278376.1	RP11-158I9.8	-8.25	1.57e-15	6.75e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679255	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs543327	ENSG00000278376.1	RP11-158I9.8	-8.25	1.57e-15	6.75e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679276	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs543413	ENSG00000278376.1	RP11-158I9.8	-8.25	1.57e-15	6.75e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679308	chr11:118791254~118793137:+
THCA	cis	rs1858037	0.867	rs61226353	ENSG00000237979.1	AC007389.1	8.25	1.58e-15	6.76e-13	0.44	0.36	Rheumatoid arthritis;	chr2:65363637	chr2:65500993~65502138:-
THCA	cis	rs1850744	0.536	rs114344194	ENSG00000250942.1	ENPP7P11	-8.25	1.58e-15	6.76e-13	-0.52	-0.36	Economic and political preferences;	chr4:9605096	chr4:9677308~9677934:+
THCA	cis	rs910316	1	rs12589815	ENSG00000279594.1	RP11-950C14.10	8.25	1.58e-15	6.76e-13	0.33	0.36	Height;	chr14:75077398	chr14:75011269~75012851:-
THCA	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	8.25	1.59e-15	6.8e-13	0.43	0.36	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	8.25	1.59e-15	6.8e-13	0.43	0.36	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	8.25	1.59e-15	6.8e-13	0.43	0.36	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
THCA	cis	rs10411161	0.752	rs10404812	ENSG00000269483.1	AC006272.1	8.25	1.59e-15	6.81e-13	0.51	0.36	Breast cancer;	chr19:51897438	chr19:51839924~51843324:-
THCA	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-8.25	1.59e-15	6.81e-13	-0.45	-0.36	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
THCA	cis	rs9500256	1	rs9500256	ENSG00000215190.7	LINC00680	-8.25	1.59e-15	6.83e-13	-0.41	-0.36	Eosinophilic esophagitis (pediatric);	chr6:57982677	chr6:57946074~57961501:-
THCA	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	8.25	1.59e-15	6.83e-13	0.69	0.36	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
THCA	cis	rs748404	0.66	rs2602141	ENSG00000205771.5	CATSPER2P1	-8.25	1.6e-15	6.84e-13	-0.37	-0.36	Lung cancer;	chr15:43432448	chr15:43726918~43747094:-
THCA	cis	rs150992	0.609	rs7711061	ENSG00000248489.1	CTD-2007H13.3	-8.25	1.6e-15	6.85e-13	-0.34	-0.36	Body mass index;	chr5:99003535	chr5:98929171~98995013:+
THCA	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-8.25	1.6e-15	6.86e-13	-0.46	-0.36	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
THCA	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-8.25	1.6e-15	6.88e-13	-0.43	-0.36	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-8.25	1.6e-15	6.88e-13	-0.43	-0.36	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-8.25	1.6e-15	6.88e-13	-0.43	-0.36	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
THCA	cis	rs270601	0.77	rs932019	ENSG00000233006.5	AC034220.3	8.25	1.61e-15	6.89e-13	0.28	0.36	Acylcarnitine levels;	chr5:132263677	chr5:132311285~132369916:-
THCA	cis	rs910316	1	rs7156105	ENSG00000279594.1	RP11-950C14.10	8.25	1.61e-15	6.89e-13	0.33	0.36	Height;	chr14:75075251	chr14:75011269~75012851:-
THCA	cis	rs7646881	1	rs73015655	ENSG00000240207.5	RP11-379F4.4	-8.25	1.61e-15	6.91e-13	-0.48	-0.36	Tetralogy of Fallot;	chr3:158734093	chr3:158732263~158784070:+
THCA	cis	rs55665837	1	rs10832254	ENSG00000251991.1	RNU7-49P	8.25	1.62e-15	6.93e-13	0.4	0.36	Vitamin D levels;	chr11:14413152	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs11023214	ENSG00000251991.1	RNU7-49P	8.25	1.62e-15	6.93e-13	0.4	0.36	Vitamin D levels;	chr11:14414713	chr11:14478892~14478953:+
THCA	cis	rs55665837	1	rs11023216	ENSG00000251991.1	RNU7-49P	8.25	1.62e-15	6.93e-13	0.4	0.36	Vitamin D levels;	chr11:14415607	chr11:14478892~14478953:+
THCA	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	8.25	1.62e-15	6.94e-13	0.42	0.36	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
THCA	cis	rs7727544	0.669	rs113823725	ENSG00000224431.1	AC063976.7	8.25	1.62e-15	6.95e-13	0.31	0.36	Blood metabolite levels;	chr5:132227808	chr5:132199456~132203487:+
THCA	cis	rs11051970	0.918	rs1055876	ENSG00000274964.1	RP11-817I4.1	-8.25	1.63e-15	6.97e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32383266	chr12:32339368~32340724:+
THCA	cis	rs270601	0.77	rs4361510	ENSG00000233006.5	AC034220.3	8.25	1.63e-15	6.97e-13	0.28	0.36	Acylcarnitine levels;	chr5:132263954	chr5:132311285~132369916:-
THCA	cis	rs270601	0.77	rs61352298	ENSG00000233006.5	AC034220.3	8.25	1.63e-15	6.97e-13	0.28	0.36	Acylcarnitine levels;	chr5:132264896	chr5:132311285~132369916:-
THCA	cis	rs270601	0.739	rs1979981	ENSG00000233006.5	AC034220.3	8.25	1.63e-15	6.97e-13	0.28	0.36	Acylcarnitine levels;	chr5:132266027	chr5:132311285~132369916:-
THCA	cis	rs270601	0.77	rs1007602	ENSG00000233006.5	AC034220.3	8.25	1.63e-15	6.97e-13	0.28	0.36	Acylcarnitine levels;	chr5:132266473	chr5:132311285~132369916:-
THCA	cis	rs270601	0.71	rs4705852	ENSG00000233006.5	AC034220.3	8.25	1.63e-15	6.97e-13	0.28	0.36	Acylcarnitine levels;	chr5:132267114	chr5:132311285~132369916:-
THCA	cis	rs673078	0.66	rs17512407	ENSG00000275409.1	RP11-131L12.4	-8.25	1.63e-15	6.97e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118292705	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs61946064	ENSG00000275409.1	RP11-131L12.4	-8.25	1.63e-15	6.97e-13	-0.47	-0.36	Glucose homeostasis traits;	chr12:118294495	chr12:118430147~118430699:+
THCA	cis	rs1075265	0.537	rs2160929	ENSG00000233266.1	HMGB1P31	8.25	1.63e-15	6.99e-13	0.47	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53654735	chr2:54051334~54051760:+
THCA	cis	rs507080	0.733	rs601318	ENSG00000278376.1	RP11-158I9.8	-8.25	1.63e-15	6.99e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118648845	chr11:118791254~118793137:+
THCA	cis	rs507080	0.697	rs653008	ENSG00000278376.1	RP11-158I9.8	-8.25	1.63e-15	6.99e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118649775	chr11:118791254~118793137:+
THCA	cis	rs3096299	0.967	rs2911257	ENSG00000274627.1	RP11-104N10.2	8.25	1.63e-15	6.99e-13	0.34	0.36	Multiple myeloma (IgH translocation);	chr16:89417726	chr16:89516797~89522217:+
THCA	cis	rs7849270	1	rs7021449	ENSG00000268707.1	RP11-247A12.7	-8.25	1.64e-15	7.01e-13	-0.44	-0.36	Blood metabolite ratios;	chr9:129137033	chr9:129170434~129170940:+
THCA	cis	rs922182	0.535	rs28729238	ENSG00000275785.1	RP11-111E14.2	8.25	1.64e-15	7.04e-13	0.42	0.36	Blood protein levels;	chr15:63902953	chr15:63890030~63890317:+
THCA	cis	rs11603691	0.901	rs61888886	ENSG00000254662.1	RP11-872D17.4	-8.25	1.64e-15	7.04e-13	-0.67	-0.36	Low high density lipoprotein cholesterol levels;	chr11:57325698	chr11:57325603~57327958:+
THCA	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-8.25	1.65e-15	7.05e-13	-0.45	-0.36	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
THCA	cis	rs875971	0.522	rs709604	ENSG00000237310.1	GS1-124K5.4	-8.25	1.65e-15	7.06e-13	-0.26	-0.36	Aortic root size;	chr7:66032447	chr7:66493706~66495474:+
THCA	cis	rs7727544	0.716	rs4705928	ENSG00000224431.1	AC063976.7	-8.25	1.65e-15	7.07e-13	-0.31	-0.36	Blood metabolite levels;	chr5:132242944	chr5:132199456~132203487:+
THCA	cis	rs2739330	0.703	rs5760112	ENSG00000099984.9	GSTT2	-8.25	1.65e-15	7.07e-13	-0.45	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23980123~23983911:+
THCA	cis	rs7714584	0.826	rs12655654	ENSG00000197083.10	ZNF300P1	8.25	1.65e-15	7.08e-13	0.63	0.36	Crohn's disease;	chr5:150794733	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs74955473	ENSG00000197083.10	ZNF300P1	8.25	1.65e-15	7.08e-13	0.63	0.36	Crohn's disease;	chr5:150794996	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs79780973	ENSG00000197083.10	ZNF300P1	8.25	1.65e-15	7.08e-13	0.63	0.36	Crohn's disease;	chr5:150795248	chr5:150930645~150946289:-
THCA	cis	rs1005277	0.54	rs2474598	ENSG00000263064.2	RP11-291L22.7	-8.25	1.65e-15	7.08e-13	-0.4	-0.36	Extrinsic epigenetic age acceleration;	chr10:38141368	chr10:38448689~38448949:+
THCA	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	8.25	1.65e-15	7.08e-13	0.42	0.36	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
THCA	cis	rs910316	0.967	rs11159116	ENSG00000279594.1	RP11-950C14.10	8.25	1.66e-15	7.1e-13	0.33	0.36	Height;	chr14:75083881	chr14:75011269~75012851:-
THCA	cis	rs748404	0.66	rs2439846	ENSG00000205771.5	CATSPER2P1	-8.25	1.67e-15	7.13e-13	-0.37	-0.36	Lung cancer;	chr15:43448772	chr15:43726918~43747094:-
THCA	cis	rs748404	0.66	rs2467741	ENSG00000205771.5	CATSPER2P1	-8.25	1.67e-15	7.13e-13	-0.37	-0.36	Lung cancer;	chr15:43450428	chr15:43726918~43747094:-
THCA	cis	rs1707322	0.929	rs785513	ENSG00000234329.1	RP11-767N6.2	-8.24	1.67e-15	7.15e-13	-0.34	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45651039~45651826:-
THCA	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-8.24	1.67e-15	7.16e-13	-0.43	-0.36	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-8.24	1.67e-15	7.16e-13	-0.43	-0.36	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-8.24	1.67e-15	7.16e-13	-0.43	-0.36	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-8.24	1.67e-15	7.16e-13	-0.43	-0.36	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-8.24	1.67e-15	7.16e-13	-0.43	-0.36	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
THCA	cis	rs1858037	0.867	rs57913336	ENSG00000237979.1	AC007389.1	8.24	1.68e-15	7.17e-13	0.44	0.36	Rheumatoid arthritis;	chr2:65360485	chr2:65500993~65502138:-
THCA	cis	rs6844153	1	rs7655686	ENSG00000240005.4	RP11-293A21.1	-8.24	1.68e-15	7.18e-13	-0.48	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26897955	chr4:26859806~26860599:-
THCA	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	8.24	1.68e-15	7.18e-13	0.43	0.36	Depression;	chr6:28363475	chr6:28176188~28176674:+
THCA	cis	rs62355901	0.505	rs115495921	ENSG00000271828.1	CTD-2310F14.1	8.24	1.68e-15	7.19e-13	0.74	0.36	Breast cancer;	chr5:56833021	chr5:56927874~56929573:+
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000224205.1	AP000351.4	8.24	1.68e-15	7.19e-13	0.42	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23987320~23991421:-
THCA	cis	rs934734	0.752	rs2661797	ENSG00000204929.10	AC074391.1	-8.24	1.68e-15	7.19e-13	-0.44	-0.36	Rheumatoid arthritis;	chr2:65406056	chr2:65436711~66084639:+
THCA	cis	rs4713118	0.629	rs203889	ENSG00000226314.6	ZNF192P1	-8.24	1.68e-15	7.19e-13	-0.45	-0.36	Parkinson's disease;	chr6:28053997	chr6:28161781~28169594:+
THCA	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-8.24	1.68e-15	7.19e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
THCA	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-8.24	1.68e-15	7.19e-13	-0.72	-0.36	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
THCA	cis	rs6504108	0.624	rs2021811	ENSG00000278765.1	RP5-890E16.5	-8.24	1.68e-15	7.2e-13	-0.4	-0.36	Body mass index;	chr17:48160420	chr17:48066704~48067293:-
THCA	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-8.24	1.69e-15	7.22e-13	-0.43	-0.36	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
THCA	cis	rs7712401	0.541	rs6867714	ENSG00000263432.2	RN7SL689P	8.24	1.7e-15	7.29e-13	0.42	0.36	Mean platelet volume;	chr5:123046364	chr5:123022487~123022783:-
THCA	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	8.24	1.71e-15	7.31e-13	0.47	0.36	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
THCA	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	8.24	1.71e-15	7.31e-13	0.42	0.36	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
THCA	cis	rs2274273	0.686	rs2182207	ENSG00000258413.1	RP11-665C16.6	-8.24	1.71e-15	7.32e-13	-0.51	-0.36	Protein biomarker;	chr14:55123085	chr14:55262767~55272075:-
THCA	cis	rs17711722	0.701	rs781145	ENSG00000237310.1	GS1-124K5.4	8.24	1.71e-15	7.32e-13	0.26	0.36	Calcium levels;	chr7:65975383	chr7:66493706~66495474:+
THCA	cis	rs9847710	0.696	rs2581777	ENSG00000242142.1	SERBP1P3	8.24	1.71e-15	7.33e-13	0.44	0.36	Ulcerative colitis;	chr3:53020711	chr3:53064283~53065091:-
THCA	cis	rs73607972	0.518	rs7193898	ENSG00000275191.1	RP11-36I17.2	8.24	1.72e-15	7.35e-13	0.46	0.36	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53551009	chr16:53628256~53628816:-
THCA	cis	rs7849270	1	rs3124510	ENSG00000268707.1	RP11-247A12.7	8.24	1.72e-15	7.36e-13	0.44	0.36	Blood metabolite ratios;	chr9:129137411	chr9:129170434~129170940:+
THCA	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	8.24	1.72e-15	7.37e-13	0.42	0.36	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
THCA	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-8.24	1.73e-15	7.39e-13	-0.43	-0.36	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-8.24	1.73e-15	7.39e-13	-0.43	-0.36	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
THCA	cis	rs17826219	0.561	rs11655876	ENSG00000266490.1	CTD-2349P21.9	8.24	1.73e-15	7.41e-13	0.46	0.36	Body mass index;	chr17:30690132	chr17:30792372~30792833:+
THCA	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	8.24	1.73e-15	7.41e-13	0.72	0.36	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
THCA	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	8.24	1.74e-15	7.42e-13	0.33	0.36	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
THCA	cis	rs7191700	0.578	rs243327	ENSG00000262703.1	RP11-485G7.6	-8.24	1.74e-15	7.43e-13	-0.39	-0.36	Multiple sclerosis;	chr16:11259447	chr16:11348143~11349321:-
THCA	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-8.24	1.75e-15	7.46e-13	-0.4	-0.36	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-8.24	1.75e-15	7.46e-13	-0.4	-0.36	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
THCA	cis	rs6504663	0.596	rs7208018	ENSG00000275897.1	RP11-94C24.13	-8.24	1.75e-15	7.47e-13	-0.34	-0.36	Visceral fat;	chr17:50480502	chr17:50475819~50478391:+
THCA	cis	rs1501911	0.53	rs162473	ENSG00000248489.1	CTD-2007H13.3	-8.24	1.75e-15	7.47e-13	-0.35	-0.36	Lung function (FEV1/FVC);	chr5:98805276	chr5:98929171~98995013:+
THCA	cis	rs9847710	0.67	rs2564933	ENSG00000242142.1	SERBP1P3	8.24	1.75e-15	7.49e-13	0.43	0.36	Ulcerative colitis;	chr3:52989357	chr3:53064283~53065091:-
THCA	cis	rs11051970	0.918	rs73084101	ENSG00000274964.1	RP11-817I4.1	-8.24	1.75e-15	7.5e-13	-0.42	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32391405	chr12:32339368~32340724:+
THCA	cis	rs8081395	0.801	rs2665404	ENSG00000266992.1	DHX40P1	8.24	1.76e-15	7.51e-13	0.41	0.36	White blood cell count;	chr17:59798035	chr17:59976009~60002384:-
THCA	cis	rs9475752	0.552	rs13209099	ENSG00000231441.1	RP11-472M19.2	8.24	1.76e-15	7.51e-13	0.48	0.36	Menarche (age at onset);	chr6:56869254	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.552	rs71564864	ENSG00000231441.1	RP11-472M19.2	8.24	1.76e-15	7.51e-13	0.48	0.36	Menarche (age at onset);	chr6:56869596	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.552	rs13216793	ENSG00000231441.1	RP11-472M19.2	8.24	1.76e-15	7.51e-13	0.48	0.36	Menarche (age at onset);	chr6:56874589	chr6:56844002~56864078:+
THCA	cis	rs6496932	0.563	rs2344083	ENSG00000259630.2	CTD-2262B20.1	-8.24	1.76e-15	7.51e-13	-0.43	-0.36	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85415228~85415633:+
THCA	cis	rs11696845	0.965	rs34485448	ENSG00000276223.1	RP4-781B1.5	-8.24	1.76e-15	7.52e-13	-0.44	-0.36	Obesity-related traits;	chr20:44741878	chr20:44746642~44747201:+
THCA	cis	rs9532669	0.889	rs7339089	ENSG00000239827.7	SUGT1P3	-8.24	1.76e-15	7.53e-13	-0.39	-0.36	Cervical cancer;	chr13:40863790	chr13:40908159~40921774:-
THCA	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	8.24	1.77e-15	7.54e-13	0.42	0.36	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	8.24	1.77e-15	7.54e-13	0.42	0.36	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	8.24	1.77e-15	7.54e-13	0.42	0.36	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	8.24	1.77e-15	7.54e-13	0.42	0.36	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	8.24	1.77e-15	7.54e-13	0.42	0.36	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
THCA	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-8.24	1.77e-15	7.55e-13	-0.43	-0.36	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
THCA	cis	rs11971779	0.68	rs4728467	ENSG00000273391.1	RP11-634H22.1	8.24	1.77e-15	7.55e-13	0.35	0.36	Diisocyanate-induced asthma;	chr7:139435816	chr7:139359032~139359566:-
THCA	cis	rs77204473	0.744	rs2239678	ENSG00000254851.1	RP11-109L13.1	8.24	1.77e-15	7.58e-13	0.84	0.36	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117199880	chr11:117135528~117138582:+
THCA	cis	rs1075265	0.575	rs2692531	ENSG00000233266.1	HMGB1P31	8.24	1.78e-15	7.6e-13	0.45	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54051334~54051760:+
THCA	cis	rs4789693	0.809	rs8071692	ENSG00000265458.1	RP13-20L14.6	8.24	1.78e-15	7.61e-13	0.36	0.36	Glucocorticoid-induced osteonecrosis;	chr17:82434457	chr17:82454273~82458521:-
THCA	cis	rs6844153	1	rs4557251	ENSG00000240005.4	RP11-293A21.1	-8.24	1.79e-15	7.63e-13	-0.5	-0.36	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26848285	chr4:26859806~26860599:-
THCA	cis	rs7569084	0.64	rs11126039	ENSG00000234255.7	AC012370.3	8.24	1.79e-15	7.65e-13	0.4	0.36	Sum eosinophil basophil counts;	chr2:65457953	chr2:65439888~65456571:-
THCA	cis	rs910316	1	rs4899546	ENSG00000279594.1	RP11-950C14.10	8.24	1.79e-15	7.65e-13	0.33	0.36	Height;	chr14:75128243	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs11159117	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75118164	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs28626045	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75122492	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs12890371	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75127136	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs12889309	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75127199	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs4322591	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75133994	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs876403	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75136131	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs4903285	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75142565	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs7147118	ENSG00000279594.1	RP11-950C14.10	8.23	1.79e-15	7.66e-13	0.33	0.36	Height;	chr14:75143467	chr14:75011269~75012851:-
THCA	cis	rs507080	0.961	rs600969	ENSG00000278376.1	RP11-158I9.8	-8.23	1.8e-15	7.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118675087	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs12577485	ENSG00000278376.1	RP11-158I9.8	-8.23	1.8e-15	7.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118676793	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs1784298	ENSG00000278376.1	RP11-158I9.8	-8.23	1.8e-15	7.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118677956	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs4938522	ENSG00000278376.1	RP11-158I9.8	-8.23	1.8e-15	7.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118677962	chr11:118791254~118793137:+
THCA	cis	rs507080	1	rs659969	ENSG00000278376.1	RP11-158I9.8	-8.23	1.8e-15	7.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679094	chr11:118791254~118793137:+
THCA	cis	rs507080	0.961	rs673770	ENSG00000278376.1	RP11-158I9.8	-8.23	1.8e-15	7.67e-13	-0.28	-0.36	Serum metabolite levels;	chr11:118679892	chr11:118791254~118793137:+
THCA	cis	rs2562456	0.561	rs12610883	ENSG00000268555.1	RP11-678G14.3	8.23	1.8e-15	7.69e-13	0.49	0.36	Pain;	chr19:21567257	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs7259708	ENSG00000268555.1	RP11-678G14.3	8.23	1.8e-15	7.69e-13	0.49	0.36	Pain;	chr19:21567846	chr19:21570822~21587322:-
THCA	cis	rs4664293	0.51	rs72961735	ENSG00000226266.5	AC009961.3	8.23	1.81e-15	7.72e-13	0.42	0.36	Monocyte percentage of white cells;	chr2:159708009	chr2:159670708~159712435:-
THCA	cis	rs910316	1	rs12879542	ENSG00000279594.1	RP11-950C14.10	8.23	1.81e-15	7.74e-13	0.33	0.36	Height;	chr14:75040822	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs4903275	ENSG00000279594.1	RP11-950C14.10	8.23	1.81e-15	7.74e-13	0.33	0.36	Height;	chr14:75045806	chr14:75011269~75012851:-
THCA	cis	rs4927850	1	rs6799572	ENSG00000242086.7	LINC00969	8.23	1.82e-15	7.75e-13	0.35	0.36	Pancreatic cancer;	chr3:196013537	chr3:195658062~195739964:+
THCA	cis	rs7621025	0.5	rs71630059	ENSG00000239213.4	NCK1-AS1	-8.23	1.82e-15	7.76e-13	-0.39	-0.36	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136841726~136862054:-
THCA	cis	rs11096990	0.634	rs12648082	ENSG00000249685.1	RP11-360F5.3	-8.23	1.82e-15	7.79e-13	-0.42	-0.36	Cognitive function;	chr4:39278104	chr4:39133913~39135608:+
THCA	cis	rs853679	0.76	rs9393910	ENSG00000219392.1	RP1-265C24.5	-8.23	1.83e-15	7.82e-13	-0.5	-0.35	Depression;	chr6:28240414	chr6:28115628~28116551:+
THCA	cis	rs853679	0.76	rs9368563	ENSG00000219392.1	RP1-265C24.5	-8.23	1.83e-15	7.82e-13	-0.5	-0.35	Depression;	chr6:28240780	chr6:28115628~28116551:+
THCA	cis	rs853679	0.76	rs9295768	ENSG00000219392.1	RP1-265C24.5	-8.23	1.83e-15	7.82e-13	-0.5	-0.35	Depression;	chr6:28241324	chr6:28115628~28116551:+
THCA	cis	rs2439831	0.557	rs13329084	ENSG00000249839.1	AC011330.5	8.23	1.84e-15	7.84e-13	0.64	0.35	Lung cancer in ever smokers;	chr15:43858865	chr15:43663654~43684339:-
THCA	cis	rs2712184	0.756	rs2712163	ENSG00000229352.1	AC007563.3	-8.23	1.84e-15	7.86e-13	-0.42	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216795623	chr2:216799608~216805335:+
THCA	cis	rs6504108	0.624	rs3792692	ENSG00000278765.1	RP5-890E16.5	-8.23	1.85e-15	7.9e-13	-0.39	-0.35	Body mass index;	chr17:48177730	chr17:48066704~48067293:-
THCA	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-8.23	1.85e-15	7.91e-13	-0.43	-0.35	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
THCA	cis	rs853679	0.766	rs9368561	ENSG00000280107.1	AL022393.9	-8.23	1.86e-15	7.92e-13	-0.55	-0.35	Depression;	chr6:28200565	chr6:28170845~28172521:+
THCA	cis	rs4819052	0.851	rs3673	ENSG00000237664.1	LINC00316	-8.23	1.86e-15	7.93e-13	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45261860	chr21:45338590~45341990:-
THCA	cis	rs853679	0.55	rs34477097	ENSG00000280107.1	AL022393.9	-8.23	1.86e-15	7.93e-13	-0.41	-0.35	Depression;	chr6:28229408	chr6:28170845~28172521:+
THCA	cis	rs2439831	0.85	rs67541383	ENSG00000249839.1	AC011330.5	-8.23	1.86e-15	7.93e-13	-0.59	-0.35	Lung cancer in ever smokers;	chr15:43880350	chr15:43663654~43684339:-
THCA	cis	rs910316	1	rs10146482	ENSG00000279594.1	RP11-950C14.10	8.23	1.86e-15	7.95e-13	0.33	0.35	Height;	chr14:75107384	chr14:75011269~75012851:-
THCA	cis	rs2522056	0.935	rs1981524	ENSG00000233006.5	AC034220.3	-8.23	1.87e-15	7.96e-13	-0.31	-0.35	Fibrinogen;Lymphocyte counts;	chr5:132420814	chr5:132311285~132369916:-
THCA	cis	rs853679	0.699	rs9468318	ENSG00000219392.1	RP1-265C24.5	-8.23	1.87e-15	7.98e-13	-0.5	-0.35	Depression;	chr6:28241753	chr6:28115628~28116551:+
THCA	cis	rs9649213	0.574	rs6961790	ENSG00000272950.1	RP11-307C18.1	8.23	1.88e-15	8.01e-13	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98378681	chr7:98322853~98323430:+
THCA	cis	rs4713118	0.955	rs9468200	ENSG00000219392.1	RP1-265C24.5	-8.23	1.88e-15	8.03e-13	-0.46	-0.35	Parkinson's disease;	chr6:27715284	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs34752872	ENSG00000219392.1	RP1-265C24.5	-8.23	1.88e-15	8.03e-13	-0.46	-0.35	Parkinson's disease;	chr6:27715465	chr6:28115628~28116551:+
THCA	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-8.23	1.89e-15	8.04e-13	-0.43	-0.35	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
THCA	cis	rs910316	1	rs11845639	ENSG00000279594.1	RP11-950C14.10	8.23	1.9e-15	8.08e-13	0.33	0.35	Height;	chr14:75103590	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs8017642	ENSG00000279594.1	RP11-950C14.10	8.23	1.9e-15	8.08e-13	0.33	0.35	Height;	chr14:75124119	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs2268617	ENSG00000279594.1	RP11-950C14.10	8.23	1.9e-15	8.08e-13	0.33	0.35	Height;	chr14:75142025	chr14:75011269~75012851:-
THCA	cis	rs1005277	0.579	rs1548255	ENSG00000263064.2	RP11-291L22.7	8.23	1.9e-15	8.1e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38448689~38448949:+
THCA	cis	rs737008	1	rs737008	ENSG00000262703.1	RP11-485G7.6	-8.23	1.9e-15	8.1e-13	-0.41	-0.35	Obesity-related traits;	chr16:11281009	chr16:11348143~11349321:-
THCA	cis	rs55665837	1	rs10832264	ENSG00000251991.1	RNU7-49P	8.23	1.91e-15	8.12e-13	0.4	0.35	Vitamin D levels;	chr11:14438436	chr11:14478892~14478953:+
THCA	cis	rs6504108	0.577	rs2109982	ENSG00000278765.1	RP5-890E16.5	-8.23	1.92e-15	8.18e-13	-0.39	-0.35	Body mass index;	chr17:48167407	chr17:48066704~48067293:-
THCA	cis	rs1707322	0.686	rs1250	ENSG00000234329.1	RP11-767N6.2	8.23	1.92e-15	8.19e-13	0.34	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45651039~45651826:-
THCA	cis	rs910316	1	rs3742773	ENSG00000279594.1	RP11-950C14.10	8.23	1.92e-15	8.19e-13	0.33	0.35	Height;	chr14:75112940	chr14:75011269~75012851:-
THCA	cis	rs9640161	0.83	rs13307276	ENSG00000261305.1	RP4-584D14.7	8.23	1.93e-15	8.2e-13	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150364436	chr7:150341771~150342607:+
THCA	cis	rs7674212	0.531	rs6816370	ENSG00000251288.2	RP11-10L12.2	-8.23	1.93e-15	8.21e-13	-0.48	-0.35	Type 2 diabetes;	chr4:103018276	chr4:102751401~102752641:+
THCA	cis	rs1707322	0.721	rs61784800	ENSG00000234329.1	RP11-767N6.2	-8.22	1.93e-15	8.21e-13	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45651039~45651826:-
THCA	cis	rs4927850	0.957	rs4927851	ENSG00000242086.7	LINC00969	8.22	1.93e-15	8.22e-13	0.35	0.35	Pancreatic cancer;	chr3:196024982	chr3:195658062~195739964:+
THCA	cis	rs4927850	0.918	rs4361313	ENSG00000242086.7	LINC00969	8.22	1.93e-15	8.22e-13	0.35	0.35	Pancreatic cancer;	chr3:196025389	chr3:195658062~195739964:+
THCA	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	8.22	1.94e-15	8.24e-13	0.41	0.35	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
THCA	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-8.22	1.94e-15	8.26e-13	-0.43	-0.35	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
THCA	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-8.22	1.94e-15	8.26e-13	-0.58	-0.35	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
THCA	cis	rs7015263	1	rs7459811	ENSG00000254231.1	CTD-2284J15.1	8.22	1.95e-15	8.28e-13	0.34	0.35	Intelligence (multi-trait analysis);	chr8:86493174	chr8:86333274~86343314:-
THCA	cis	rs7191700	0.578	rs243327	ENSG00000262636.1	CTD-3088G3.4	-8.22	1.95e-15	8.28e-13	-0.44	-0.35	Multiple sclerosis;	chr16:11259447	chr16:11380859~11381118:-
THCA	cis	rs7712401	0.56	rs13168225	ENSG00000263432.2	RN7SL689P	-8.22	1.96e-15	8.32e-13	-0.42	-0.35	Mean platelet volume;	chr5:123011569	chr5:123022487~123022783:-
THCA	cis	rs180730	1	rs3114955	ENSG00000251609.2	SETP12	-8.22	1.96e-15	8.35e-13	-0.56	-0.35	Fasting plasma glucose;	chr4:120884835	chr4:120895494~120897083:-
THCA	cis	rs9649213	0.593	rs3779194	ENSG00000272950.1	RP11-307C18.1	8.22	1.97e-15	8.37e-13	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98380965	chr7:98322853~98323430:+
THCA	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-8.22	1.97e-15	8.38e-13	-0.42	-0.35	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
THCA	cis	rs9500256	0.655	rs12209098	ENSG00000215190.7	LINC00680	8.22	1.97e-15	8.38e-13	0.44	0.35	Eosinophilic esophagitis (pediatric);	chr6:58014194	chr6:57946074~57961501:-
THCA	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	8.22	1.97e-15	8.38e-13	0.43	0.35	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
THCA	cis	rs8081395	0.801	rs2665405	ENSG00000266992.1	DHX40P1	-8.22	1.97e-15	8.38e-13	-0.41	-0.35	White blood cell count;	chr17:59797931	chr17:59976009~60002384:-
THCA	cis	rs17772222	0.682	rs28482235	ENSG00000258789.1	RP11-507K2.3	-8.22	1.97e-15	8.4e-13	-0.34	-0.35	Coronary artery calcification;	chr14:88472857	chr14:88551597~88552493:+
THCA	cis	rs3745672	1	rs7250427	ENSG00000219665.7	CTD-2006C1.2	-8.22	1.98e-15	8.42e-13	-0.72	-0.35	Multiple sclerosis;	chr19:12036386	chr19:11987617~12046275:+
THCA	cis	rs2712184	0.756	rs2541393	ENSG00000229352.1	AC007563.3	-8.22	1.98e-15	8.43e-13	-0.42	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216786507	chr2:216799608~216805335:+
THCA	cis	rs6504108	0.602	rs2938483	ENSG00000278765.1	RP5-890E16.5	-8.22	1.98e-15	8.44e-13	-0.4	-0.35	Body mass index;	chr17:48240642	chr17:48066704~48067293:-
THCA	cis	rs910316	1	rs7303	ENSG00000279594.1	RP11-950C14.10	8.22	1.99e-15	8.45e-13	0.33	0.35	Height;	chr14:75053362	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs10143132	ENSG00000279594.1	RP11-950C14.10	8.22	1.99e-15	8.45e-13	0.33	0.35	Height;	chr14:75059147	chr14:75011269~75012851:-
THCA	cis	rs11159086	0.938	rs11623040	ENSG00000270000.1	RP3-449M8.9	8.22	1.99e-15	8.45e-13	0.46	0.35	Advanced glycation end-product levels;	chr14:74496743	chr14:74471930~74472360:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-8.22	1.99e-15	8.46e-13	-0.58	-0.35	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
THCA	cis	rs8114671	0.562	rs1013677	ENSG00000269202.1	RP4-614O4.12	-8.22	1.99e-15	8.46e-13	-0.3	-0.35	Height;	chr20:34880990	chr20:35201747~35203288:-
THCA	cis	rs9532669	0.926	rs4356344	ENSG00000239827.7	SUGT1P3	-8.22	1.99e-15	8.48e-13	-0.41	-0.35	Cervical cancer;	chr13:40874086	chr13:40908159~40921774:-
THCA	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-8.22	2e-15	8.49e-13	-0.44	-0.35	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
THCA	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-8.22	2e-15	8.5e-13	-0.44	-0.35	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
THCA	cis	rs7208859	0.673	rs11652370	ENSG00000266490.1	CTD-2349P21.9	8.22	2e-15	8.51e-13	0.46	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30792372~30792833:+
THCA	cis	rs8072100	0.817	rs7213086	ENSG00000228782.6	CTD-2026D20.3	8.22	2.01e-15	8.54e-13	0.32	0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47674944	chr17:47450568~47492492:-
THCA	cis	rs2288884	0.541	rs7508746	ENSG00000275055.1	CTC-471J1.11	-8.22	2.02e-15	8.57e-13	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51990246	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.634	rs74476955	ENSG00000275055.1	CTC-471J1.11	-8.22	2.02e-15	8.57e-13	-0.37	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51997806	chr19:52049007~52049754:+
THCA	cis	rs2522056	1	rs1003533	ENSG00000233006.5	AC034220.3	-8.22	2.02e-15	8.58e-13	-0.31	-0.35	Fibrinogen;Lymphocyte counts;	chr5:132419959	chr5:132311285~132369916:-
THCA	cis	rs507080	0.961	rs34413584	ENSG00000278376.1	RP11-158I9.8	-8.22	2.02e-15	8.58e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118675072	chr11:118791254~118793137:+
THCA	cis	rs7945705	0.967	rs11042082	ENSG00000254860.4	TMEM9B-AS1	-8.22	2.02e-15	8.6e-13	-0.41	-0.35	Hemoglobin concentration;	chr11:8817682	chr11:8964675~8977527:+
THCA	cis	rs4713118	0.866	rs9468217	ENSG00000219392.1	RP1-265C24.5	-8.22	2.03e-15	8.64e-13	-0.48	-0.35	Parkinson's disease;	chr6:27758688	chr6:28115628~28116551:+
THCA	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-8.22	2.03e-15	8.65e-13	-0.44	-0.35	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
THCA	cis	rs2284378	0.506	rs6142059	ENSG00000275784.1	RP5-1125A11.6	-8.22	2.04e-15	8.65e-13	-0.35	-0.35	Breast cancer;	chr20:33956521	chr20:33989480~33991818:-
THCA	cis	rs741668	0.641	rs4942472	ENSG00000235903.6	CPB2-AS1	-8.22	2.04e-15	8.65e-13	-0.46	-0.35	Cerebrospinal fluid clusterin levels;	chr13:46070980	chr13:46052806~46113332:+
THCA	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	8.22	2.04e-15	8.66e-13	0.52	0.35	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
THCA	cis	rs7569084	0.687	rs934731	ENSG00000234255.7	AC012370.3	8.22	2.04e-15	8.66e-13	0.4	0.35	Sum eosinophil basophil counts;	chr2:65456353	chr2:65439888~65456571:-
THCA	cis	rs7569084	0.687	rs7577452	ENSG00000234255.7	AC012370.3	8.22	2.04e-15	8.66e-13	0.4	0.35	Sum eosinophil basophil counts;	chr2:65456694	chr2:65439888~65456571:-
THCA	cis	rs1005277	0.579	rs2474571	ENSG00000263064.2	RP11-291L22.7	8.22	2.04e-15	8.66e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38448689~38448949:+
THCA	cis	rs7849270	0.921	rs7019373	ENSG00000268707.1	RP11-247A12.7	-8.22	2.05e-15	8.7e-13	-0.43	-0.35	Blood metabolite ratios;	chr9:129134942	chr9:129170434~129170940:+
THCA	cis	rs9601248	0.838	rs2783130	ENSG00000227676.3	LINC01068	-8.22	2.05e-15	8.7e-13	-0.45	-0.35	Major depressive disorder;	chr13:79596025	chr13:79566727~79571436:+
THCA	cis	rs7849270	0.885	rs10760588	ENSG00000268707.1	RP11-247A12.7	-8.22	2.05e-15	8.72e-13	-0.43	-0.35	Blood metabolite ratios;	chr9:129115195	chr9:129170434~129170940:+
THCA	cis	rs1005277	0.579	rs2505248	ENSG00000263064.2	RP11-291L22.7	8.22	2.05e-15	8.72e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38448689~38448949:+
THCA	cis	rs507080	0.922	rs502601	ENSG00000278376.1	RP11-158I9.8	-8.22	2.05e-15	8.72e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118694970	chr11:118791254~118793137:+
THCA	cis	rs10411161	0.702	rs10403189	ENSG00000269483.1	AC006272.1	-8.22	2.06e-15	8.74e-13	-0.5	-0.35	Breast cancer;	chr19:51897420	chr19:51839924~51843324:-
THCA	cis	rs1005277	0.541	rs2505193	ENSG00000263064.2	RP11-291L22.7	8.22	2.06e-15	8.75e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474580	ENSG00000263064.2	RP11-291L22.7	8.22	2.06e-15	8.75e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38448689~38448949:+
THCA	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	8.22	2.06e-15	8.75e-13	0.23	0.35	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
THCA	cis	rs6504108	0.624	rs2021752	ENSG00000278765.1	RP5-890E16.5	8.22	2.06e-15	8.75e-13	0.39	0.35	Body mass index;	chr17:48162901	chr17:48066704~48067293:-
THCA	cis	rs1005277	0.579	rs2474608	ENSG00000263064.2	RP11-291L22.7	8.22	2.06e-15	8.77e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38448689~38448949:+
THCA	cis	rs910316	1	rs10140851	ENSG00000279594.1	RP11-950C14.10	8.22	2.06e-15	8.77e-13	0.33	0.35	Height;	chr14:75045909	chr14:75011269~75012851:-
THCA	cis	rs9902453	0.542	rs3809789	ENSG00000264007.1	RP11-68I3.10	8.22	2.07e-15	8.78e-13	0.41	0.35	Coffee consumption (cups per day);	chr17:29628743	chr17:29621617~29622254:-
THCA	cis	rs4819052	0.851	rs2236444	ENSG00000237664.1	LINC00316	-8.21	2.08e-15	8.82e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258311	chr21:45338590~45341990:-
THCA	cis	rs4713118	0.662	rs149900	ENSG00000226314.6	ZNF192P1	-8.21	2.08e-15	8.83e-13	-0.45	-0.35	Parkinson's disease;	chr6:28046819	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.629	rs149899	ENSG00000226314.6	ZNF192P1	-8.21	2.08e-15	8.83e-13	-0.45	-0.35	Parkinson's disease;	chr6:28052201	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.629	rs172165	ENSG00000226314.6	ZNF192P1	-8.21	2.08e-15	8.83e-13	-0.45	-0.35	Parkinson's disease;	chr6:28053036	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.597	rs172166	ENSG00000226314.6	ZNF192P1	-8.21	2.08e-15	8.83e-13	-0.45	-0.35	Parkinson's disease;	chr6:28053042	chr6:28161781~28169594:+
THCA	cis	rs910316	1	rs12435391	ENSG00000279594.1	RP11-950C14.10	8.21	2.08e-15	8.84e-13	0.33	0.35	Height;	chr14:75135034	chr14:75011269~75012851:-
THCA	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	8.21	2.08e-15	8.85e-13	0.34	0.35	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
THCA	cis	rs934734	0.752	rs1876518	ENSG00000204929.10	AC074391.1	-8.21	2.08e-15	8.85e-13	-0.44	-0.35	Rheumatoid arthritis;	chr2:65381775	chr2:65436711~66084639:+
THCA	cis	rs9309473	0.528	rs11126395	ENSG00000163016.8	ALMS1P	8.21	2.09e-15	8.88e-13	0.47	0.35	Metabolite levels;	chr2:73337836	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.528	rs11898362	ENSG00000163016.8	ALMS1P	8.21	2.09e-15	8.88e-13	0.47	0.35	Metabolite levels;	chr2:73338165	chr2:73644919~73685576:+
THCA	cis	rs4713118	0.869	rs9283883	ENSG00000219392.1	RP1-265C24.5	-8.21	2.1e-15	8.91e-13	-0.46	-0.35	Parkinson's disease;	chr6:27747691	chr6:28115628~28116551:+
THCA	cis	rs6504108	0.647	rs3805370	ENSG00000278765.1	RP5-890E16.5	-8.21	2.1e-15	8.93e-13	-0.39	-0.35	Body mass index;	chr17:48181731	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.647	rs3805371	ENSG00000278765.1	RP5-890E16.5	-8.21	2.1e-15	8.93e-13	-0.39	-0.35	Body mass index;	chr17:48181739	chr17:48066704~48067293:-
THCA	cis	rs13068223	0.819	rs8792	ENSG00000243926.1	TIPARP-AS1	-8.21	2.11e-15	8.95e-13	-0.35	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747639	chr3:156671862~156674378:-
THCA	cis	rs4927850	1	rs6799572	ENSG00000226155.1	AC124944.3	-8.21	2.11e-15	8.95e-13	-0.42	-0.35	Pancreatic cancer;	chr3:196013537	chr3:195912049~195913986:+
THCA	cis	rs6565180	1	rs11862806	ENSG00000183604.13	SMG1P5	-8.21	2.11e-15	8.96e-13	-0.36	-0.35	Tonsillectomy;	chr16:30352750	chr16:30267553~30335374:-
THCA	cis	rs13068223	0.617	rs13061457	ENSG00000243926.1	TIPARP-AS1	8.21	2.11e-15	8.97e-13	0.37	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156725596	chr3:156671862~156674378:-
THCA	cis	rs507080	0.961	rs4457789	ENSG00000278376.1	RP11-158I9.8	-8.21	2.11e-15	8.97e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118668461	chr11:118791254~118793137:+
THCA	cis	rs7727544	0.514	rs3846728	ENSG00000237714.1	P4HA2-AS1	8.21	2.12e-15	8.99e-13	0.45	0.35	Blood metabolite levels;	chr5:132100524	chr5:132184876~132192808:+
THCA	cis	rs375066	0.935	rs10414702	ENSG00000267058.1	RP11-15A1.3	-8.21	2.12e-15	9e-13	-0.29	-0.35	Breast cancer;	chr19:43876384	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs10421518	ENSG00000267058.1	RP11-15A1.3	-8.21	2.12e-15	9e-13	-0.29	-0.35	Breast cancer;	chr19:43877134	chr19:43891804~43901805:-
THCA	cis	rs375066	0.87	rs7258418	ENSG00000267058.1	RP11-15A1.3	-8.21	2.12e-15	9e-13	-0.29	-0.35	Breast cancer;	chr19:43878931	chr19:43891804~43901805:-
THCA	cis	rs934734	0.532	rs1437466	ENSG00000237979.1	AC007389.1	-8.21	2.13e-15	9.02e-13	-0.4	-0.35	Rheumatoid arthritis;	chr2:65437216	chr2:65500993~65502138:-
THCA	cis	rs7829975	0.714	rs11784052	ENSG00000253893.2	FAM85B	-8.21	2.13e-15	9.02e-13	-0.45	-0.35	Mood instability;	chr8:8814452	chr8:8167819~8226614:-
THCA	cis	rs13068223	0.607	rs184695	ENSG00000243926.1	TIPARP-AS1	-8.21	2.13e-15	9.02e-13	-0.34	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679600	chr3:156671862~156674378:-
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000164669.11	INTS4P1	-8.21	2.13e-15	9.03e-13	-0.44	-0.35	Calcium levels;	chr7:65751755	chr7:65141225~65234216:+
THCA	cis	rs507080	0.922	rs644867	ENSG00000278376.1	RP11-158I9.8	-8.21	2.13e-15	9.03e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118696836	chr11:118791254~118793137:+
THCA	cis	rs7714584	1	rs1816256	ENSG00000197083.10	ZNF300P1	8.21	2.13e-15	9.05e-13	0.58	0.35	Crohn's disease;	chr5:150893291	chr5:150930645~150946289:-
THCA	cis	rs4072705	0.967	rs6478677	ENSG00000224020.1	MIR181A2HG	-8.21	2.14e-15	9.07e-13	-0.32	-0.35	Menarche (age at onset);	chr9:124659900	chr9:124658467~124698631:+
THCA	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-8.21	2.14e-15	9.08e-13	-0.43	-0.35	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
THCA	cis	rs17684571	0.872	rs3002011	ENSG00000231441.1	RP11-472M19.2	8.21	2.15e-15	9.1e-13	0.45	0.35	Schizophrenia;	chr6:56760325	chr6:56844002~56864078:+
THCA	cis	rs11971779	0.65	rs6969699	ENSG00000273391.1	RP11-634H22.1	8.21	2.15e-15	9.11e-13	0.34	0.35	Diisocyanate-induced asthma;	chr7:139443532	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs11772551	ENSG00000273391.1	RP11-634H22.1	8.21	2.15e-15	9.11e-13	0.34	0.35	Diisocyanate-induced asthma;	chr7:139444232	chr7:139359032~139359566:-
THCA	cis	rs1005277	0.563	rs2800550	ENSG00000263064.2	RP11-291L22.7	8.21	2.15e-15	9.11e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38448689~38448949:+
THCA	cis	rs6504108	0.624	rs3805363	ENSG00000278765.1	RP5-890E16.5	-8.21	2.16e-15	9.15e-13	-0.39	-0.35	Body mass index;	chr17:48164260	chr17:48066704~48067293:-
THCA	cis	rs516805	0.748	rs510471	ENSG00000279453.1	RP3-425C14.4	-8.21	2.16e-15	9.17e-13	-0.35	-0.35	Lymphocyte counts;	chr6:122391714	chr6:122436789~122439223:-
THCA	cis	rs66887589	0.967	rs2892869	ENSG00000245958.5	RP11-33B1.1	8.21	2.16e-15	9.17e-13	0.31	0.35	Diastolic blood pressure;	chr4:119600142	chr4:119454791~119552025:+
THCA	cis	rs17772222	1	rs61977058	ENSG00000258983.2	RP11-507K2.2	8.21	2.16e-15	9.17e-13	0.45	0.35	Coronary artery calcification;	chr14:88415571	chr14:88499334~88515502:+
THCA	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-8.21	2.17e-15	9.18e-13	-0.42	-0.35	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
THCA	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-8.21	2.17e-15	9.22e-13	-0.34	-0.35	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
THCA	cis	rs17772222	1	rs12589480	ENSG00000258983.2	RP11-507K2.2	8.21	2.17e-15	9.22e-13	0.45	0.35	Coronary artery calcification;	chr14:88414926	chr14:88499334~88515502:+
THCA	cis	rs2739330	0.76	rs5751761	ENSG00000206090.4	AP000350.7	-8.21	2.18e-15	9.24e-13	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23939998~23942798:+
THCA	cis	rs9847710	0.733	rs2581790	ENSG00000242142.1	SERBP1P3	8.21	2.18e-15	9.26e-13	0.43	0.35	Ulcerative colitis;	chr3:53067764	chr3:53064283~53065091:-
THCA	cis	rs9341808	0.556	rs10455370	ENSG00000272129.1	RP11-250B2.6	-8.21	2.18e-15	9.26e-13	-0.44	-0.35	Sitting height ratio;	chr6:80331150	chr6:80355424~80356859:+
THCA	cis	rs910316	0.839	rs35977276	ENSG00000279594.1	RP11-950C14.10	-8.21	2.19e-15	9.28e-13	-0.33	-0.35	Height;	chr14:75170656	chr14:75011269~75012851:-
THCA	cis	rs3822625	0.541	rs10042998	ENSG00000271828.1	CTD-2310F14.1	8.21	2.19e-15	9.29e-13	0.75	0.35	Breast cancer (early onset);	chr5:56909472	chr5:56927874~56929573:+
THCA	cis	rs4072705	0.967	rs4838200	ENSG00000224020.1	MIR181A2HG	8.21	2.2e-15	9.31e-13	0.32	0.35	Menarche (age at onset);	chr9:124688778	chr9:124658467~124698631:+
THCA	cis	rs10463554	0.892	rs66505956	ENSG00000175749.11	EIF3KP1	8.21	2.2e-15	9.32e-13	0.46	0.35	Parkinson's disease;	chr5:102943853	chr5:103032376~103033031:+
THCA	cis	rs7727544	0.678	rs7735891	ENSG00000224431.1	AC063976.7	8.21	2.2e-15	9.34e-13	0.31	0.35	Blood metabolite levels;	chr5:132261312	chr5:132199456~132203487:+
THCA	cis	rs375066	0.935	rs396874	ENSG00000267058.1	RP11-15A1.3	-8.21	2.21e-15	9.35e-13	-0.29	-0.35	Breast cancer;	chr19:43893073	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs397346	ENSG00000267058.1	RP11-15A1.3	-8.21	2.21e-15	9.35e-13	-0.29	-0.35	Breast cancer;	chr19:43894963	chr19:43891804~43901805:-
THCA	cis	rs4819052	0.851	rs2838866	ENSG00000237664.1	LINC00316	-8.21	2.21e-15	9.36e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45293099	chr21:45338590~45341990:-
THCA	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	8.21	2.21e-15	9.37e-13	0.68	0.35	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
THCA	cis	rs4819052	0.851	rs2255774	ENSG00000237664.1	LINC00316	-8.21	2.21e-15	9.38e-13	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263936	chr21:45338590~45341990:-
THCA	cis	rs1075265	0.547	rs7587217	ENSG00000233266.1	HMGB1P31	8.21	2.22e-15	9.39e-13	0.45	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53675029	chr2:54051334~54051760:+
THCA	cis	rs3747113	0.954	rs2298378	ENSG00000128262.7	POM121L9P	-8.21	2.22e-15	9.41e-13	-0.39	-0.35	Gut microbiome composition (summer);	chr22:24323637	chr22:24251828~24265525:+
THCA	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-8.21	2.22e-15	9.41e-13	-0.42	-0.35	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-8.21	2.22e-15	9.41e-13	-0.42	-0.35	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-8.21	2.22e-15	9.41e-13	-0.42	-0.35	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-8.21	2.22e-15	9.41e-13	-0.42	-0.35	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-8.2	2.23e-15	9.45e-13	-0.42	-0.35	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-8.2	2.23e-15	9.45e-13	-0.43	-0.35	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
THCA	cis	rs1005277	0.579	rs1985707	ENSG00000263064.2	RP11-291L22.7	8.2	2.23e-15	9.46e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38448689~38448949:+
THCA	cis	rs507080	0.922	rs4938524	ENSG00000278376.1	RP11-158I9.8	-8.2	2.24e-15	9.48e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118681365	chr11:118791254~118793137:+
THCA	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-8.2	2.24e-15	9.49e-13	-0.42	-0.35	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
THCA	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-8.2	2.24e-15	9.49e-13	-0.42	-0.35	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
THCA	cis	rs1005277	0.579	rs2472173	ENSG00000263064.2	RP11-291L22.7	8.2	2.24e-15	9.49e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472174	ENSG00000263064.2	RP11-291L22.7	8.2	2.24e-15	9.49e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474563	ENSG00000263064.2	RP11-291L22.7	8.2	2.24e-15	9.49e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs9418322	ENSG00000263064.2	RP11-291L22.7	8.2	2.24e-15	9.49e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs9299760	ENSG00000263064.2	RP11-291L22.7	8.2	2.24e-15	9.49e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2023351	ENSG00000263064.2	RP11-291L22.7	8.2	2.24e-15	9.49e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38448689~38448949:+
THCA	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-8.2	2.24e-15	9.5e-13	-0.23	-0.35	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
THCA	cis	rs375066	0.967	rs8104290	ENSG00000267058.1	RP11-15A1.3	-8.2	2.25e-15	9.52e-13	-0.29	-0.35	Breast cancer;	chr19:43863186	chr19:43891804~43901805:-
THCA	cis	rs375066	0.934	rs2191564	ENSG00000267058.1	RP11-15A1.3	-8.2	2.25e-15	9.52e-13	-0.29	-0.35	Breast cancer;	chr19:43863459	chr19:43891804~43901805:-
THCA	cis	rs375066	0.935	rs11673020	ENSG00000267058.1	RP11-15A1.3	-8.2	2.25e-15	9.52e-13	-0.29	-0.35	Breast cancer;	chr19:43870479	chr19:43891804~43901805:-
THCA	cis	rs2412819	0.599	rs2470120	ENSG00000166763.7	STRCP1	8.2	2.25e-15	9.52e-13	0.39	0.35	Lung cancer;	chr15:43636872	chr15:43699488~43718184:-
THCA	cis	rs9500256	0.966	rs1322446	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-8.2	2.25e-15	9.53e-13	-0.36	-0.35	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57855891~57856468:-
THCA	cis	rs2408955	0.522	rs11168408	ENSG00000258273.1	RP11-370I10.4	8.2	2.25e-15	9.54e-13	0.47	0.35	Glycated hemoglobin levels;	chr12:48104544	chr12:48333755~48333901:-
THCA	cis	rs860295	1	rs708611	ENSG00000225855.5	RUSC1-AS1	-8.2	2.26e-15	9.55e-13	-0.24	-0.35	Body mass index;	chr1:155773519	chr1:155316863~155324176:-
THCA	cis	rs375066	0.901	rs368316	ENSG00000267058.1	RP11-15A1.3	-8.2	2.26e-15	9.58e-13	-0.29	-0.35	Breast cancer;	chr19:43927742	chr19:43891804~43901805:-
THCA	cis	rs10954213	0.525	rs11770589	ENSG00000275106.1	RP11-309L24.10	-8.2	2.27e-15	9.59e-13	-0.47	-0.35	Sjögren's syndrome;	chr7:128949434	chr7:128952527~128953316:-
THCA	cis	rs934734	0.752	rs2661796	ENSG00000204929.10	AC074391.1	-8.2	2.27e-15	9.6e-13	-0.43	-0.35	Rheumatoid arthritis;	chr2:65400272	chr2:65436711~66084639:+
THCA	cis	rs2032366	0.583	rs1452594	ENSG00000267279.1	RP11-879F14.2	-8.2	2.27e-15	9.62e-13	-0.37	-0.35	Obesity-related traits;	chr18:61590689	chr18:61585746~61606916:-
THCA	cis	rs934734	0.673	rs7575614	ENSG00000237979.1	AC007389.1	8.2	2.28e-15	9.63e-13	0.39	0.35	Rheumatoid arthritis;	chr2:65462666	chr2:65500993~65502138:-
THCA	cis	rs934734	0.673	rs6742215	ENSG00000237979.1	AC007389.1	8.2	2.28e-15	9.63e-13	0.39	0.35	Rheumatoid arthritis;	chr2:65463362	chr2:65500993~65502138:-
THCA	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-8.2	2.28e-15	9.63e-13	-0.44	-0.35	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
THCA	cis	rs42490	0.738	rs39509	ENSG00000251136.7	RP11-37B2.1	-8.2	2.28e-15	9.63e-13	-0.3	-0.35	Leprosy;	chr8:89791937	chr8:89609409~89757727:-
THCA	cis	rs42490	0.752	rs411279	ENSG00000251136.7	RP11-37B2.1	-8.2	2.28e-15	9.63e-13	-0.3	-0.35	Leprosy;	chr8:89795929	chr8:89609409~89757727:-
THCA	cis	rs10411161	0.702	rs79180893	ENSG00000269483.1	AC006272.1	8.2	2.28e-15	9.65e-13	0.5	0.35	Breast cancer;	chr19:51892362	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs11879436	ENSG00000269483.1	AC006272.1	8.2	2.28e-15	9.65e-13	0.5	0.35	Breast cancer;	chr19:51894562	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs10420224	ENSG00000269483.1	AC006272.1	8.2	2.28e-15	9.65e-13	0.5	0.35	Breast cancer;	chr19:51895702	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs75647161	ENSG00000269483.1	AC006272.1	8.2	2.28e-15	9.65e-13	0.5	0.35	Breast cancer;	chr19:51895731	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs17778790	ENSG00000269483.1	AC006272.1	8.2	2.28e-15	9.65e-13	0.5	0.35	Breast cancer;	chr19:51896306	chr19:51839924~51843324:-
THCA	cis	rs11148252	0.595	rs4885325	ENSG00000235660.1	LINC00345	-8.2	2.28e-15	9.65e-13	-0.45	-0.35	Lewy body disease;	chr13:52597182	chr13:52484161~52484680:-
THCA	cis	rs6504108	0.647	rs7210149	ENSG00000278765.1	RP5-890E16.5	-8.2	2.28e-15	9.66e-13	-0.4	-0.35	Body mass index;	chr17:48220260	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.602	rs1452667	ENSG00000278765.1	RP5-890E16.5	-8.2	2.28e-15	9.66e-13	-0.4	-0.35	Body mass index;	chr17:48225053	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs4793779	ENSG00000278765.1	RP5-890E16.5	-8.2	2.28e-15	9.66e-13	-0.4	-0.35	Body mass index;	chr17:48229235	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs1452666	ENSG00000278765.1	RP5-890E16.5	-8.2	2.28e-15	9.66e-13	-0.4	-0.35	Body mass index;	chr17:48230388	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs1377201	ENSG00000278765.1	RP5-890E16.5	-8.2	2.28e-15	9.66e-13	-0.4	-0.35	Body mass index;	chr17:48234766	chr17:48066704~48067293:-
THCA	cis	rs748404	0.578	rs2278856	ENSG00000205771.5	CATSPER2P1	-8.2	2.29e-15	9.67e-13	-0.37	-0.35	Lung cancer;	chr15:43339158	chr15:43726918~43747094:-
THCA	cis	rs9649213	0.593	rs7787858	ENSG00000272950.1	RP11-307C18.1	8.2	2.29e-15	9.67e-13	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98380602	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs3801254	ENSG00000272950.1	RP11-307C18.1	8.2	2.29e-15	9.67e-13	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98381499	chr7:98322853~98323430:+
THCA	cis	rs7849270	0.879	rs10988200	ENSG00000268707.1	RP11-247A12.7	-8.2	2.29e-15	9.68e-13	-0.44	-0.35	Blood metabolite ratios;	chr9:129094306	chr9:129170434~129170940:+
THCA	cis	rs507080	0.961	rs520543	ENSG00000278376.1	RP11-158I9.8	-8.2	2.29e-15	9.69e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118667448	chr11:118791254~118793137:+
THCA	cis	rs507080	0.883	rs692750	ENSG00000278376.1	RP11-158I9.8	-8.2	2.29e-15	9.69e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118667599	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs4589335	ENSG00000278376.1	RP11-158I9.8	-8.2	2.29e-15	9.69e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118668431	chr11:118791254~118793137:+
THCA	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-8.2	2.29e-15	9.7e-13	-0.43	-0.35	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs2297112	ENSG00000268707.1	RP11-247A12.7	-8.2	2.29e-15	9.7e-13	-0.43	-0.35	Blood metabolite ratios;	chr9:129137901	chr9:129170434~129170940:+
THCA	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	8.2	2.29e-15	9.7e-13	0.34	0.35	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
THCA	cis	rs10463554	0.892	rs11952337	ENSG00000175749.11	EIF3KP1	8.2	2.29e-15	9.7e-13	0.46	0.35	Parkinson's disease;	chr5:102928043	chr5:103032376~103033031:+
THCA	cis	rs10463554	0.892	rs6871715	ENSG00000175749.11	EIF3KP1	8.2	2.29e-15	9.7e-13	0.46	0.35	Parkinson's disease;	chr5:102930398	chr5:103032376~103033031:+
THCA	cis	rs9649213	0.593	rs6961438	ENSG00000272950.1	RP11-307C18.1	8.2	2.3e-15	9.72e-13	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98376537	chr7:98322853~98323430:+
THCA	cis	rs11696845	0.966	rs1467474	ENSG00000276223.1	RP4-781B1.5	-8.2	2.3e-15	9.75e-13	-0.43	-0.35	Obesity-related traits;	chr20:44743364	chr20:44746642~44747201:+
THCA	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	8.2	2.3e-15	9.75e-13	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
THCA	cis	rs11096990	0.634	rs2381372	ENSG00000249685.1	RP11-360F5.3	8.2	2.31e-15	9.75e-13	0.42	0.35	Cognitive function;	chr4:39271471	chr4:39133913~39135608:+
THCA	cis	rs66887589	0.934	rs56843000	ENSG00000245958.5	RP11-33B1.1	8.2	2.31e-15	9.75e-13	0.31	0.35	Diastolic blood pressure;	chr4:119595442	chr4:119454791~119552025:+
THCA	cis	rs6504108	0.602	rs7219967	ENSG00000278765.1	RP5-890E16.5	-8.2	2.31e-15	9.79e-13	-0.4	-0.35	Body mass index;	chr17:48216712	chr17:48066704~48067293:-
THCA	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	8.2	2.32e-15	9.79e-13	0.42	0.35	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
THCA	cis	rs1707322	0.964	rs785508	ENSG00000234329.1	RP11-767N6.2	-8.2	2.32e-15	9.8e-13	-0.34	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs785509	ENSG00000234329.1	RP11-767N6.2	-8.2	2.32e-15	9.8e-13	-0.34	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45651039~45651826:-
THCA	cis	rs910316	1	rs7156328	ENSG00000279594.1	RP11-950C14.10	8.2	2.32e-15	9.8e-13	0.33	0.35	Height;	chr14:75066238	chr14:75011269~75012851:-
THCA	cis	rs507080	0.961	rs642497	ENSG00000278376.1	RP11-158I9.8	-8.2	2.32e-15	9.81e-13	-0.28	-0.35	Serum metabolite levels;	chr11:118680075	chr11:118791254~118793137:+
THCA	cis	rs7208859	0.673	rs1347360	ENSG00000266490.1	CTD-2349P21.9	8.2	2.32e-15	9.81e-13	0.46	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587514	chr17:30792372~30792833:+
THCA	cis	rs1005277	0.579	rs176880	ENSG00000263064.2	RP11-291L22.7	-8.2	2.32e-15	9.82e-13	-0.4	-0.35	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38448689~38448949:+
THCA	cis	rs62103177	0.713	rs62103186	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79867574	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.81	rs62103187	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79867633	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.81	rs62103188	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79867661	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.81	rs62103189	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79867815	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.81	rs62103191	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79868769	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.81	rs62103192	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79869050	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.733	rs62103193	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79869217	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.81	rs62103194	ENSG00000261126.6	RP11-795F19.1	8.2	2.32e-15	9.83e-13	0.41	0.35	Opioid sensitivity;	chr18:79869482	chr18:80046900~80095482:+
THCA	cis	rs2929278	0.588	rs688009	ENSG00000166763.7	STRCP1	8.2	2.33e-15	9.83e-13	0.38	0.35	Schizophrenia;	chr15:43864104	chr15:43699488~43718184:-
THCA	cis	rs42490	0.653	rs40453	ENSG00000251136.7	RP11-37B2.1	-8.2	2.33e-15	9.84e-13	-0.3	-0.35	Leprosy;	chr8:89789817	chr8:89609409~89757727:-
THCA	cis	rs922182	0.617	rs55694045	ENSG00000275785.1	RP11-111E14.2	8.2	2.33e-15	9.84e-13	0.42	0.35	Blood protein levels;	chr15:63953744	chr15:63890030~63890317:+
THCA	cis	rs1005277	0.579	rs2474567	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472175	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472176	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474568	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2983343	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474569	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.602	rs2504142	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472181	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474574	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2504140	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474575	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472182	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.541	rs2263163	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2021649	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2472183	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2505197	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2505196	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.557	rs1854563	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2505237	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474599	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2505240	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.54	rs2224248	ENSG00000263064.2	RP11-291L22.7	8.2	2.33e-15	9.84e-13	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38448689~38448949:+
THCA	cis	rs1501911	0.53	rs162611	ENSG00000248489.1	CTD-2007H13.3	-8.2	2.33e-15	9.84e-13	-0.35	-0.35	Lung function (FEV1/FVC);	chr5:98809801	chr5:98929171~98995013:+
THCA	cis	rs922182	0.617	rs28737203	ENSG00000275785.1	RP11-111E14.2	8.2	2.33e-15	9.86e-13	0.41	0.35	Blood protein levels;	chr15:63948970	chr15:63890030~63890317:+
THCA	cis	rs3096299	0.967	rs753852	ENSG00000274627.1	RP11-104N10.2	8.2	2.34e-15	9.87e-13	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89380011	chr16:89516797~89522217:+
THCA	cis	rs3096299	0.967	rs753853	ENSG00000274627.1	RP11-104N10.2	8.2	2.34e-15	9.87e-13	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89380117	chr16:89516797~89522217:+
THCA	cis	rs77204473	0.744	rs11606672	ENSG00000254851.1	RP11-109L13.1	8.2	2.34e-15	9.88e-13	0.82	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117185343	chr11:117135528~117138582:+
THCA	cis	rs42490	0.752	rs400411	ENSG00000251136.7	RP11-37B2.1	-8.2	2.34e-15	9.89e-13	-0.3	-0.35	Leprosy;	chr8:89789871	chr8:89609409~89757727:-
THCA	cis	rs11096990	0.634	rs11096988	ENSG00000249685.1	RP11-360F5.3	8.2	2.34e-15	9.9e-13	0.42	0.35	Cognitive function;	chr4:39264081	chr4:39133913~39135608:+
THCA	cis	rs7714584	0.793	rs2161363	ENSG00000197083.10	ZNF300P1	8.2	2.35e-15	9.91e-13	0.61	0.35	Crohn's disease;	chr5:150802517	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs6875011	ENSG00000197083.10	ZNF300P1	8.2	2.35e-15	9.91e-13	0.61	0.35	Crohn's disease;	chr5:150803148	chr5:150930645~150946289:-
THCA	cis	rs910316	1	rs12588240	ENSG00000279594.1	RP11-950C14.10	8.2	2.35e-15	9.91e-13	0.33	0.35	Height;	chr14:75145380	chr14:75011269~75012851:-
THCA	cis	rs9847710	0.696	rs2564932	ENSG00000242142.1	SERBP1P3	-8.2	2.35e-15	9.92e-13	-0.43	-0.35	Ulcerative colitis;	chr3:52987994	chr3:53064283~53065091:-
THCA	cis	rs2562456	0.724	rs58001930	ENSG00000268555.1	RP11-678G14.3	8.2	2.35e-15	9.93e-13	0.49	0.35	Pain;	chr19:21560061	chr19:21570822~21587322:-
THCA	cis	rs11148252	0.711	rs61957304	ENSG00000235660.1	LINC00345	-8.2	2.36e-15	9.98e-13	-0.45	-0.35	Lewy body disease;	chr13:52224288	chr13:52484161~52484680:-
THCA	cis	rs1707322	0.682	rs3014241	ENSG00000234329.1	RP11-767N6.2	-8.2	2.36e-15	9.99e-13	-0.34	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45651039~45651826:-
THCA	cis	rs910316	1	rs10149880	ENSG00000279594.1	RP11-950C14.10	-8.2	2.37e-15	9.99e-13	-0.33	-0.35	Height;	chr14:75166305	chr14:75011269~75012851:-
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000235689.1	AP000351.13	8.2	2.38e-15	1e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:24006305~24008258:-
THCA	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-8.2	2.38e-15	1e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-8.2	2.38e-15	1e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
THCA	cis	rs2562456	0.837	rs11085462	ENSG00000268555.1	RP11-678G14.3	8.2	2.38e-15	1e-12	0.49	0.35	Pain;	chr19:21567449	chr19:21570822~21587322:-
THCA	cis	rs7191700	0.511	rs12923756	ENSG00000262636.1	CTD-3088G3.4	-8.2	2.39e-15	1.01e-12	-0.43	-0.35	Multiple sclerosis;	chr16:11265818	chr16:11380859~11381118:-
THCA	cis	rs853679	0.76	rs11967137	ENSG00000219392.1	RP1-265C24.5	-8.2	2.39e-15	1.01e-12	-0.49	-0.35	Depression;	chr6:28231986	chr6:28115628~28116551:+
THCA	cis	rs1005277	0.579	rs2504143	ENSG00000263064.2	RP11-291L22.7	8.2	2.39e-15	1.01e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38448689~38448949:+
THCA	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-8.2	2.39e-15	1.01e-12	-0.43	-0.35	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
THCA	cis	rs4927850	0.709	rs6783079	ENSG00000242086.7	LINC00969	8.19	2.4e-15	1.01e-12	0.4	0.35	Pancreatic cancer;	chr3:195925837	chr3:195658062~195739964:+
THCA	cis	rs4927850	0.709	rs6765762	ENSG00000242086.7	LINC00969	8.19	2.4e-15	1.01e-12	0.4	0.35	Pancreatic cancer;	chr3:195925980	chr3:195658062~195739964:+
THCA	cis	rs673078	0.66	rs7961312	ENSG00000275409.1	RP11-131L12.4	-8.19	2.4e-15	1.01e-12	-0.47	-0.35	Glucose homeostasis traits;	chr12:118324431	chr12:118430147~118430699:+
THCA	cis	rs6504108	0.624	rs3792694	ENSG00000278765.1	RP5-890E16.5	8.19	2.4e-15	1.01e-12	0.39	0.35	Body mass index;	chr17:48183080	chr17:48066704~48067293:-
THCA	cis	rs9473147	0.516	rs4715018	ENSG00000270761.1	RP11-385F7.1	-8.19	2.41e-15	1.02e-12	-0.29	-0.35	Platelet distribution width;Mean platelet volume;	chr6:47474135	chr6:47477243~47477572:-
THCA	cis	rs150992	0.587	rs4703340	ENSG00000248489.1	CTD-2007H13.3	-8.19	2.41e-15	1.02e-12	-0.34	-0.35	Body mass index;	chr5:99009083	chr5:98929171~98995013:+
THCA	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-8.19	2.41e-15	1.02e-12	-0.43	-0.35	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
THCA	cis	rs1005277	0.579	rs2505241	ENSG00000263064.2	RP11-291L22.7	8.19	2.41e-15	1.02e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38448689~38448949:+
THCA	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-8.19	2.42e-15	1.02e-12	-0.37	-0.35	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
THCA	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-8.19	2.42e-15	1.02e-12	-0.37	-0.35	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
THCA	cis	rs11723261	0.664	rs4627799	ENSG00000275426.1	CH17-262A2.1	8.19	2.42e-15	1.02e-12	0.44	0.35	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:149738~150317:+
THCA	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-8.19	2.42e-15	1.02e-12	-0.42	-0.35	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
THCA	cis	rs910316	1	rs10873275	ENSG00000279594.1	RP11-950C14.10	8.19	2.43e-15	1.02e-12	0.33	0.35	Height;	chr14:75064757	chr14:75011269~75012851:-
THCA	cis	rs3096299	0.809	rs2911264	ENSG00000274627.1	RP11-104N10.2	8.19	2.44e-15	1.03e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89432864	chr16:89516797~89522217:+
THCA	cis	rs922182	0.557	rs7161764	ENSG00000275785.1	RP11-111E14.2	-8.19	2.44e-15	1.03e-12	-0.42	-0.35	Blood protein levels;	chr15:63910545	chr15:63890030~63890317:+
THCA	cis	rs7727544	0.716	rs11955347	ENSG00000224431.1	AC063976.7	8.19	2.46e-15	1.04e-12	0.31	0.35	Blood metabolite levels;	chr5:132232231	chr5:132199456~132203487:+
THCA	cis	rs853679	0.76	rs9357067	ENSG00000219392.1	RP1-265C24.5	-8.19	2.46e-15	1.04e-12	-0.5	-0.35	Depression;	chr6:28242515	chr6:28115628~28116551:+
THCA	cis	rs853679	0.76	rs967005	ENSG00000219392.1	RP1-265C24.5	-8.19	2.46e-15	1.04e-12	-0.5	-0.35	Depression;	chr6:28242910	chr6:28115628~28116551:+
THCA	cis	rs10875746	0.669	rs11168496	ENSG00000240399.1	RP1-228P16.1	-8.19	2.47e-15	1.04e-12	-0.38	-0.35	Longevity (90 years and older);	chr12:48257072	chr12:48054813~48055591:-
THCA	cis	rs2408955	0.522	rs973398	ENSG00000258273.1	RP11-370I10.4	8.19	2.47e-15	1.04e-12	0.47	0.35	Glycated hemoglobin levels;	chr12:48097265	chr12:48333755~48333901:-
THCA	cis	rs910316	1	rs3742780	ENSG00000279594.1	RP11-950C14.10	8.19	2.47e-15	1.04e-12	0.33	0.35	Height;	chr14:75038305	chr14:75011269~75012851:-
THCA	cis	rs3847687	1	rs34853396	ENSG00000256810.1	RP11-76C10.2	8.19	2.48e-15	1.04e-12	0.42	0.35	Longevity;	chr12:131034720	chr12:131030570~131035487:-
THCA	cis	rs2688482	0.512	rs3103954	ENSG00000224769.1	AC069213.1	8.19	2.48e-15	1.05e-12	0.53	0.35	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195614947~195620233:+
THCA	cis	rs9649213	0.555	rs67132564	ENSG00000272950.1	RP11-307C18.1	8.19	2.49e-15	1.05e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98385588	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6465682	ENSG00000272950.1	RP11-307C18.1	8.19	2.49e-15	1.05e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98387105	chr7:98322853~98323430:+
THCA	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	8.19	2.49e-15	1.05e-12	0.42	0.35	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
THCA	cis	rs11096990	0.634	rs12651217	ENSG00000249685.1	RP11-360F5.3	8.19	2.49e-15	1.05e-12	0.42	0.35	Cognitive function;	chr4:39271964	chr4:39133913~39135608:+
THCA	cis	rs2439831	0.85	rs16965120	ENSG00000249839.1	AC011330.5	-8.19	2.5e-15	1.05e-12	-0.57	-0.35	Lung cancer in ever smokers;	chr15:43808144	chr15:43663654~43684339:-
THCA	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	8.19	2.5e-15	1.05e-12	0.43	0.35	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
THCA	cis	rs4713118	0.911	rs9461406	ENSG00000219392.1	RP1-265C24.5	8.19	2.5e-15	1.05e-12	0.48	0.35	Parkinson's disease;	chr6:27751985	chr6:28115628~28116551:+
THCA	cis	rs9847710	0.696	rs2244461	ENSG00000242142.1	SERBP1P3	8.19	2.51e-15	1.06e-12	0.43	0.35	Ulcerative colitis;	chr3:53021826	chr3:53064283~53065091:-
THCA	cis	rs17772222	1	rs17124700	ENSG00000258983.2	RP11-507K2.2	8.19	2.51e-15	1.06e-12	0.45	0.35	Coronary artery calcification;	chr14:88439285	chr14:88499334~88515502:+
THCA	cis	rs34375054	0.66	rs35941060	ENSG00000279233.1	RP11-158L12.4	8.19	2.51e-15	1.06e-12	0.35	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125109699	chr12:125138245~125141711:+
THCA	cis	rs2439831	0.702	rs3759791	ENSG00000249839.1	AC011330.5	-8.19	2.51e-15	1.06e-12	-0.57	-0.35	Lung cancer in ever smokers;	chr15:43798600	chr15:43663654~43684339:-
THCA	cis	rs12655019	0.92	rs7725377	ENSG00000271828.1	CTD-2310F14.1	-8.19	2.51e-15	1.06e-12	-0.71	-0.35	Breast cancer (early onset);	chr5:56960769	chr5:56927874~56929573:+
THCA	cis	rs17711722	0.727	rs2658585	ENSG00000237310.1	GS1-124K5.4	8.19	2.52e-15	1.06e-12	0.26	0.35	Calcium levels;	chr7:65996954	chr7:66493706~66495474:+
THCA	cis	rs934734	0.673	rs754110	ENSG00000237979.1	AC007389.1	8.19	2.52e-15	1.06e-12	0.4	0.35	Rheumatoid arthritis;	chr2:65464626	chr2:65500993~65502138:-
THCA	cis	rs55665837	1	rs10466412	ENSG00000251991.1	RNU7-49P	8.19	2.52e-15	1.06e-12	0.4	0.35	Vitamin D levels;	chr11:14483643	chr11:14478892~14478953:+
THCA	cis	rs4713118	0.629	rs203888	ENSG00000226314.6	ZNF192P1	-8.19	2.52e-15	1.06e-12	-0.44	-0.35	Parkinson's disease;	chr6:28053811	chr6:28161781~28169594:+
THCA	cis	rs9473147	0.516	rs1931837	ENSG00000270761.1	RP11-385F7.1	-8.19	2.52e-15	1.06e-12	-0.29	-0.35	Platelet distribution width;Mean platelet volume;	chr6:47474641	chr6:47477243~47477572:-
THCA	cis	rs11971779	0.588	rs6969786	ENSG00000273391.1	RP11-634H22.1	8.19	2.53e-15	1.07e-12	0.34	0.35	Diisocyanate-induced asthma;	chr7:139443364	chr7:139359032~139359566:-
THCA	cis	rs3096299	0.967	rs28575874	ENSG00000274627.1	RP11-104N10.2	8.19	2.53e-15	1.07e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89403482	chr16:89516797~89522217:+
THCA	cis	rs2712184	0.875	rs7586692	ENSG00000229352.1	AC007563.3	-8.19	2.53e-15	1.07e-12	-0.43	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216809980	chr2:216799608~216805335:+
THCA	cis	rs7176527	1	rs7176527	ENSG00000188388.10	GOLGA6L3	8.19	2.54e-15	1.07e-12	0.53	0.35	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84597563	chr15:85240472~85247170:+
THCA	cis	rs8081395	0.801	rs2777895	ENSG00000266992.1	DHX40P1	-8.19	2.54e-15	1.07e-12	-0.4	-0.35	White blood cell count;	chr17:59802249	chr17:59976009~60002384:-
THCA	cis	rs8081395	0.769	rs12449331	ENSG00000266992.1	DHX40P1	-8.19	2.54e-15	1.07e-12	-0.4	-0.35	White blood cell count;	chr17:59806285	chr17:59976009~60002384:-
THCA	cis	rs1707322	0.896	rs785512	ENSG00000234329.1	RP11-767N6.2	-8.19	2.54e-15	1.07e-12	-0.34	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45651039~45651826:-
THCA	cis	rs240993	0.715	rs9400483	ENSG00000230177.1	RP5-1112D6.4	8.19	2.55e-15	1.07e-12	0.35	0.35	Inflammatory skin disease;Psoriasis;	chr6:111535073	chr6:111277932~111278742:+
THCA	cis	rs9649213	0.593	rs62478233	ENSG00000272950.1	RP11-307C18.1	8.19	2.55e-15	1.07e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98393780	chr7:98322853~98323430:+
THCA	cis	rs2562456	0.876	rs62110163	ENSG00000268555.1	RP11-678G14.3	8.19	2.56e-15	1.08e-12	0.49	0.35	Pain;	chr19:21546020	chr19:21570822~21587322:-
THCA	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-8.19	2.56e-15	1.08e-12	-0.46	-0.35	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
THCA	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-8.19	2.57e-15	1.08e-12	-0.42	-0.35	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
THCA	cis	rs4713118	0.662	rs149961	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28047791	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9357060	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28056708	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9468271	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28056792	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9380045	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28057501	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.616	rs9348789	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28057708	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9468274	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28058299	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9468275	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28058358	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9468276	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28059910	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9468277	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28060612	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs9468278	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28060704	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs13218430	ENSG00000226314.6	ZNF192P1	-8.19	2.57e-15	1.08e-12	-0.45	-0.35	Parkinson's disease;	chr6:28062059	chr6:28161781~28169594:+
THCA	cis	rs16846053	0.515	rs2892770	ENSG00000227403.1	AC009299.3	-8.19	2.57e-15	1.08e-12	-0.55	-0.35	Blood osmolality (transformed sodium);	chr2:161638321	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs3843853	ENSG00000227403.1	AC009299.3	-8.19	2.57e-15	1.08e-12	-0.55	-0.35	Blood osmolality (transformed sodium);	chr2:161645081	chr2:161244739~161249050:+
THCA	cis	rs16846053	0.515	rs1510084	ENSG00000227403.1	AC009299.3	-8.19	2.57e-15	1.08e-12	-0.55	-0.35	Blood osmolality (transformed sodium);	chr2:161647233	chr2:161244739~161249050:+
THCA	cis	rs7811142	0.83	rs11761253	ENSG00000078319.8	PMS2P1	-8.19	2.57e-15	1.08e-12	-0.5	-0.35	Platelet count;	chr7:100341698	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	8.19	2.58e-15	1.08e-12	0.23	0.35	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	8.19	2.58e-15	1.08e-12	0.23	0.35	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	8.19	2.58e-15	1.08e-12	0.23	0.35	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
THCA	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	8.18	2.58e-15	1.09e-12	0.37	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
THCA	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-8.18	2.59e-15	1.09e-12	-0.42	-0.35	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
THCA	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-8.18	2.59e-15	1.09e-12	-0.45	-0.35	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
THCA	cis	rs8114671	0.57	rs3761144	ENSG00000269202.1	RP4-614O4.12	-8.18	2.6e-15	1.09e-12	-0.3	-0.35	Height;	chr20:34956272	chr20:35201747~35203288:-
THCA	cis	rs62355901	0.505	rs62355944	ENSG00000271828.1	CTD-2310F14.1	8.18	2.6e-15	1.09e-12	0.73	0.35	Breast cancer;	chr5:56816871	chr5:56927874~56929573:+
THCA	cis	rs4664293	0.51	rs3903306	ENSG00000226266.5	AC009961.3	8.18	2.6e-15	1.09e-12	0.42	0.35	Monocyte percentage of white cells;	chr2:159592171	chr2:159670708~159712435:-
THCA	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
THCA	cis	rs2120243	0.504	rs114107407	ENSG00000244515.1	KRT18P34	-8.18	2.61e-15	1.1e-12	-0.4	-0.35	Hepatocellular carcinoma in hepatitis B infection;	chr3:157344846	chr3:157162663~157163932:-
THCA	cis	rs11096990	0.634	rs12648793	ENSG00000249685.1	RP11-360F5.3	-8.18	2.61e-15	1.1e-12	-0.42	-0.35	Cognitive function;	chr4:39284473	chr4:39133913~39135608:+
THCA	cis	rs1859596	0.608	rs2269991	ENSG00000234456.6	MAGI2-AS3	8.18	2.64e-15	1.11e-12	0.34	0.35	Reading or mathematical ability;	chr7:79460820	chr7:79452877~79471208:+
THCA	cis	rs2274273	0.71	rs67395212	ENSG00000258413.1	RP11-665C16.6	-8.18	2.64e-15	1.11e-12	-0.5	-0.35	Protein biomarker;	chr14:55125221	chr14:55262767~55272075:-
THCA	cis	rs9640161	0.783	rs1132261	ENSG00000261305.1	RP4-584D14.7	8.18	2.64e-15	1.11e-12	0.42	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150362898	chr7:150341771~150342607:+
THCA	cis	rs7621025	0.5	rs9845460	ENSG00000239213.4	NCK1-AS1	8.18	2.64e-15	1.11e-12	0.37	0.35	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136841726~136862054:-
THCA	cis	rs6723226	0.65	rs6729952	ENSG00000276334.1	AL133243.1	8.18	2.64e-15	1.11e-12	0.39	0.35	Intelligence (multi-trait analysis);	chr2:32539855	chr2:32521927~32523547:+
THCA	cis	rs7015263	0.573	rs4484676	ENSG00000254231.1	CTD-2284J15.1	8.18	2.65e-15	1.11e-12	0.35	0.35	Intelligence (multi-trait analysis);	chr8:86259547	chr8:86333274~86343314:-
THCA	cis	rs4789693	0.938	rs8078595	ENSG00000265458.1	RP13-20L14.6	8.18	2.65e-15	1.12e-12	0.35	0.35	Glucocorticoid-induced osteonecrosis;	chr17:82469112	chr17:82454273~82458521:-
THCA	cis	rs9473147	0.543	rs1004173	ENSG00000270761.1	RP11-385F7.1	-8.18	2.66e-15	1.12e-12	-0.28	-0.35	Platelet distribution width;Mean platelet volume;	chr6:47477281	chr6:47477243~47477572:-
THCA	cis	rs7727544	0.716	rs10058655	ENSG00000224431.1	AC063976.7	8.18	2.66e-15	1.12e-12	0.31	0.35	Blood metabolite levels;	chr5:132235203	chr5:132199456~132203487:+
THCA	cis	rs910316	1	rs10138183	ENSG00000279594.1	RP11-950C14.10	8.18	2.66e-15	1.12e-12	0.33	0.35	Height;	chr14:75148524	chr14:75011269~75012851:-
THCA	cis	rs10463554	0.824	rs34374	ENSG00000175749.11	EIF3KP1	8.18	2.66e-15	1.12e-12	0.44	0.35	Parkinson's disease;	chr5:103068317	chr5:103032376~103033031:+
THCA	cis	rs10510102	0.608	rs4077606	ENSG00000276742.1	RP11-500G22.4	-8.18	2.67e-15	1.12e-12	-0.42	-0.35	Breast cancer;	chr10:121849907	chr10:121956782~121957098:+
THCA	cis	rs7849270	1	rs4713	ENSG00000268707.1	RP11-247A12.7	8.18	2.67e-15	1.12e-12	0.43	0.35	Blood metabolite ratios;	chr9:129148526	chr9:129170434~129170940:+
THCA	cis	rs2243480	0.706	rs34466769	ENSG00000273142.1	RP11-458F8.4	-8.18	2.67e-15	1.12e-12	-0.41	-0.35	Diabetic kidney disease;	chr7:65988305	chr7:66902857~66906297:+
THCA	cis	rs55665837	0.961	rs11023237	ENSG00000251991.1	RNU7-49P	8.18	2.67e-15	1.12e-12	0.4	0.35	Vitamin D levels;	chr11:14478788	chr11:14478892~14478953:+
THCA	cis	rs4664293	0.528	rs56027129	ENSG00000226266.5	AC009961.3	8.18	2.7e-15	1.13e-12	0.42	0.35	Monocyte percentage of white cells;	chr2:159600091	chr2:159670708~159712435:-
THCA	cis	rs7727544	0.581	rs10075801	ENSG00000224431.1	AC063976.7	8.18	2.71e-15	1.14e-12	0.31	0.35	Blood metabolite levels;	chr5:132341949	chr5:132199456~132203487:+
THCA	cis	rs12554020	0.581	rs4255201	ENSG00000227603.1	RP11-165J3.6	8.18	2.71e-15	1.14e-12	0.59	0.35	Schizophrenia;	chr9:93401055	chr9:93435332~93437121:-
THCA	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-8.18	2.72e-15	1.14e-12	-0.42	-0.35	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
THCA	cis	rs2562456	0.837	rs62110205	ENSG00000268555.1	RP11-678G14.3	8.18	2.72e-15	1.14e-12	0.49	0.35	Pain;	chr19:21577269	chr19:21570822~21587322:-
THCA	cis	rs8114671	0.869	rs66535333	ENSG00000269202.1	RP4-614O4.12	8.18	2.72e-15	1.14e-12	0.3	0.35	Height;	chr20:35068863	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.869	rs1544047	ENSG00000269202.1	RP4-614O4.12	8.18	2.72e-15	1.14e-12	0.3	0.35	Height;	chr20:35082950	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.836	rs17404569	ENSG00000269202.1	RP4-614O4.12	8.18	2.72e-15	1.14e-12	0.3	0.35	Height;	chr20:35086274	chr20:35201747~35203288:-
THCA	cis	rs910316	1	rs12897094	ENSG00000279594.1	RP11-950C14.10	8.18	2.73e-15	1.15e-12	0.33	0.35	Height;	chr14:75112713	chr14:75011269~75012851:-
THCA	cis	rs2439831	0.85	rs3742982	ENSG00000249839.1	AC011330.5	-8.18	2.73e-15	1.15e-12	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43884483	chr15:43663654~43684339:-
THCA	cis	rs934734	0.789	rs4303705	ENSG00000204929.10	AC074391.1	-8.18	2.74e-15	1.15e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65392576	chr2:65436711~66084639:+
THCA	cis	rs910316	1	rs4903284	ENSG00000279594.1	RP11-950C14.10	8.18	2.75e-15	1.15e-12	0.33	0.35	Height;	chr14:75125780	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs2024653	ENSG00000279594.1	RP11-950C14.10	8.18	2.75e-15	1.15e-12	0.33	0.35	Height;	chr14:75128451	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs1047418	ENSG00000279594.1	RP11-950C14.10	8.18	2.75e-15	1.15e-12	0.33	0.35	Height;	chr14:75139089	chr14:75011269~75012851:-
THCA	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	8.18	2.75e-15	1.15e-12	0.42	0.35	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
THCA	cis	rs2739330	0.828	rs2186366	ENSG00000206090.4	AP000350.7	-8.18	2.76e-15	1.16e-12	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23939998~23942798:+
THCA	cis	rs1707322	1	rs4660334	ENSG00000234329.1	RP11-767N6.2	8.18	2.76e-15	1.16e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45651039~45651826:-
THCA	cis	rs12908161	0.92	rs12904605	ENSG00000225151.9	GOLGA2P7	-8.18	2.77e-15	1.16e-12	-0.52	-0.35	Schizophrenia;	chr15:84658188	chr15:84199311~84230136:-
THCA	cis	rs2712184	0.729	rs2541390	ENSG00000229352.1	AC007563.3	-8.18	2.77e-15	1.16e-12	-0.42	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216799297	chr2:216799608~216805335:+
THCA	cis	rs2115630	0.641	rs11073613	ENSG00000225151.9	GOLGA2P7	8.17	2.78e-15	1.17e-12	0.46	0.35	P wave terminal force;	chr15:84642662	chr15:84199311~84230136:-
THCA	cis	rs8027521	0.56	rs2725563	ENSG00000280362.1	RP11-643A5.3	8.17	2.79e-15	1.17e-12	0.46	0.35	Circulating chemerin levels;	chr15:53938222	chr15:53910769~53914712:+
THCA	cis	rs8027521	0.56	rs1119201	ENSG00000280362.1	RP11-643A5.3	8.17	2.79e-15	1.17e-12	0.46	0.35	Circulating chemerin levels;	chr15:53938705	chr15:53910769~53914712:+
THCA	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	8.17	2.83e-15	1.19e-12	0.49	0.35	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
THCA	cis	rs72772090	0.539	rs17405676	ENSG00000248734.2	CTD-2260A17.1	-8.17	2.83e-15	1.19e-12	-0.56	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96846912	chr5:96784777~96785999:+
THCA	cis	rs62158211	1	rs1807282	ENSG00000272563.1	RP11-480C16.1	-8.17	2.84e-15	1.19e-12	-0.48	-0.35	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113352459	chr2:113432600~113436042:+
THCA	cis	rs62103177	0.81	rs3902996	ENSG00000261126.6	RP11-795F19.1	8.17	2.84e-15	1.19e-12	0.4	0.35	Opioid sensitivity;	chr18:79870571	chr18:80046900~80095482:+
THCA	cis	rs17772222	0.682	rs2274736	ENSG00000258789.1	RP11-507K2.3	-8.17	2.84e-15	1.19e-12	-0.33	-0.35	Coronary artery calcification;	chr14:88472308	chr14:88551597~88552493:+
THCA	cis	rs9649213	0.593	rs2394854	ENSG00000272950.1	RP11-307C18.1	8.17	2.84e-15	1.19e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98397994	chr7:98322853~98323430:+
THCA	cis	rs73186030	0.92	rs73186048	ENSG00000272758.4	RP11-299J3.8	8.17	2.84e-15	1.19e-12	0.44	0.35	Serum parathyroid hormone levels;	chr3:122316515	chr3:122416207~122443180:+
THCA	cis	rs736801	0.78	rs12521868	ENSG00000237714.1	P4HA2-AS1	-8.17	2.85e-15	1.19e-12	-0.48	-0.35	Mosquito bite size;Breast cancer;	chr5:132448701	chr5:132184876~132192808:+
THCA	cis	rs4072705	0.967	rs4836986	ENSG00000224020.1	MIR181A2HG	-8.17	2.86e-15	1.2e-12	-0.31	-0.35	Menarche (age at onset);	chr9:124645780	chr9:124658467~124698631:+
THCA	cis	rs8081395	0.836	rs1295926	ENSG00000266992.1	DHX40P1	-8.17	2.86e-15	1.2e-12	-0.4	-0.35	White blood cell count;	chr17:59832012	chr17:59976009~60002384:-
THCA	cis	rs6545883	0.507	rs4672427	ENSG00000271889.1	RP11-493E12.1	-8.17	2.87e-15	1.2e-12	-0.34	-0.35	Tuberculosis;	chr2:61242115	chr2:61151433~61162105:-
THCA	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	8.17	2.87e-15	1.2e-12	0.56	0.35	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
THCA	cis	rs6565180	1	rs68051857	ENSG00000183604.13	SMG1P5	-8.17	2.87e-15	1.21e-12	-0.35	-0.35	Tonsillectomy;	chr16:30348690	chr16:30267553~30335374:-
THCA	cis	rs6565180	1	rs6565180	ENSG00000183604.13	SMG1P5	-8.17	2.87e-15	1.21e-12	-0.35	-0.35	Tonsillectomy;	chr16:30350020	chr16:30267553~30335374:-
THCA	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	8.17	2.88e-15	1.21e-12	0.35	0.35	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
THCA	cis	rs9649213	0.593	rs55825602	ENSG00000272950.1	RP11-307C18.1	8.17	2.88e-15	1.21e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98383727	chr7:98322853~98323430:+
THCA	cis	rs4072705	1	rs4838201	ENSG00000224020.1	MIR181A2HG	-8.17	2.88e-15	1.21e-12	-0.31	-0.35	Menarche (age at onset);	chr9:124698338	chr9:124658467~124698631:+
THCA	cis	rs10050311	0.79	rs55831707	ENSG00000251411.1	RP11-397E7.4	-8.17	2.9e-15	1.21e-12	-0.44	-0.35	Insulin-related traits;	chr4:86918376	chr4:86913266~86914817:-
THCA	cis	rs10050311	0.79	rs4693154	ENSG00000251411.1	RP11-397E7.4	-8.17	2.9e-15	1.21e-12	-0.44	-0.35	Insulin-related traits;	chr4:86922109	chr4:86913266~86914817:-
THCA	cis	rs10050311	0.79	rs72667724	ENSG00000251411.1	RP11-397E7.4	-8.17	2.9e-15	1.21e-12	-0.44	-0.35	Insulin-related traits;	chr4:86929931	chr4:86913266~86914817:-
THCA	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-8.17	2.9e-15	1.22e-12	-0.42	-0.35	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
THCA	cis	rs957448	0.554	rs12540967	ENSG00000253704.1	RP11-267M23.4	8.17	2.9e-15	1.22e-12	0.37	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94553722~94569745:+
THCA	cis	rs957448	0.554	rs4735297	ENSG00000253704.1	RP11-267M23.4	8.17	2.9e-15	1.22e-12	0.37	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94553722~94569745:+
THCA	cis	rs957448	0.554	rs72674877	ENSG00000253704.1	RP11-267M23.4	8.17	2.9e-15	1.22e-12	0.37	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94553722~94569745:+
THCA	cis	rs9649213	0.574	rs3801251	ENSG00000272950.1	RP11-307C18.1	8.17	2.91e-15	1.22e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98398306	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs3779193	ENSG00000272950.1	RP11-307C18.1	8.17	2.91e-15	1.22e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98399154	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs12704989	ENSG00000272950.1	RP11-307C18.1	8.17	2.91e-15	1.22e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98400126	chr7:98322853~98323430:+
THCA	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-8.17	2.92e-15	1.22e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
THCA	cis	rs73607972	0.598	rs35726119	ENSG00000275191.1	RP11-36I17.2	-8.17	2.94e-15	1.23e-12	-0.52	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53521927	chr16:53628256~53628816:-
THCA	cis	rs7015263	0.573	rs6999654	ENSG00000254231.1	CTD-2284J15.1	-8.17	2.95e-15	1.23e-12	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:86275434	chr8:86333274~86343314:-
THCA	cis	rs7015263	0.573	rs17680712	ENSG00000254231.1	CTD-2284J15.1	-8.17	2.95e-15	1.23e-12	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:86288546	chr8:86333274~86343314:-
THCA	cis	rs910316	0.783	rs11850751	ENSG00000279594.1	RP11-950C14.10	8.17	2.96e-15	1.24e-12	0.33	0.35	Height;	chr14:75123410	chr14:75011269~75012851:-
THCA	cis	rs7208859	0.673	rs7211776	ENSG00000266490.1	CTD-2349P21.9	8.17	2.96e-15	1.24e-12	0.46	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30792372~30792833:+
THCA	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-8.17	2.97e-15	1.24e-12	-0.42	-0.35	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
THCA	cis	rs7849270	1	rs1571229	ENSG00000268707.1	RP11-247A12.7	-8.17	2.97e-15	1.24e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129151432	chr9:129170434~129170940:+
THCA	cis	rs9649213	0.593	rs56286037	ENSG00000272950.1	RP11-307C18.1	8.17	2.97e-15	1.24e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98390210	chr7:98322853~98323430:+
THCA	cis	rs7811142	0.83	rs11771936	ENSG00000078319.8	PMS2P1	-8.17	2.98e-15	1.25e-12	-0.5	-0.35	Platelet count;	chr7:100345660	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.779	rs77370288	ENSG00000078319.8	PMS2P1	-8.17	2.98e-15	1.25e-12	-0.5	-0.35	Platelet count;	chr7:100350274	chr7:100320992~100341908:-
THCA	cis	rs910316	1	rs2300601	ENSG00000279594.1	RP11-950C14.10	8.17	2.98e-15	1.25e-12	0.33	0.35	Height;	chr14:75172868	chr14:75011269~75012851:-
THCA	cis	rs9473147	0.516	rs9369695	ENSG00000270761.1	RP11-385F7.1	-8.17	2.98e-15	1.25e-12	-0.29	-0.35	Platelet distribution width;Mean platelet volume;	chr6:47472829	chr6:47477243~47477572:-
THCA	cis	rs1005277	0.579	rs1614236	ENSG00000263064.2	RP11-291L22.7	8.17	2.98e-15	1.25e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2749616	ENSG00000263064.2	RP11-291L22.7	8.17	2.98e-15	1.25e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780146	ENSG00000263064.2	RP11-291L22.7	8.17	2.98e-15	1.25e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38448689~38448949:+
THCA	cis	rs17684571	0.751	rs1903332	ENSG00000231441.1	RP11-472M19.2	-8.17	2.98e-15	1.25e-12	-0.42	-0.35	Schizophrenia;	chr6:56857437	chr6:56844002~56864078:+
THCA	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	8.16	2.99e-15	1.25e-12	0.39	0.35	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
THCA	cis	rs11673344	0.504	rs8105065	ENSG00000226686.6	LINC01535	8.16	2.99e-15	1.25e-12	0.39	0.35	Obesity-related traits;	chr19:37141003	chr19:37251912~37265535:+
THCA	cis	rs6565180	0.889	rs8051096	ENSG00000183604.13	SMG1P5	-8.16	3.01e-15	1.26e-12	-0.36	-0.35	Tonsillectomy;	chr16:30336410	chr16:30267553~30335374:-
THCA	cis	rs2439831	0.867	rs496584	ENSG00000249839.1	AC011330.5	-8.16	3.01e-15	1.26e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43539725	chr15:43663654~43684339:-
THCA	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	8.16	3.01e-15	1.26e-12	0.33	0.35	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
THCA	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-8.16	3.02e-15	1.26e-12	-0.42	-0.35	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-8.16	3.02e-15	1.26e-12	-0.42	-0.35	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-8.16	3.02e-15	1.26e-12	-0.42	-0.35	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
THCA	cis	rs11673344	0.504	rs2118208	ENSG00000226686.6	LINC01535	8.16	3.02e-15	1.26e-12	0.39	0.35	Obesity-related traits;	chr19:37135573	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs2118209	ENSG00000226686.6	LINC01535	8.16	3.02e-15	1.26e-12	0.39	0.35	Obesity-related traits;	chr19:37135618	chr19:37251912~37265535:+
THCA	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	8.16	3.03e-15	1.27e-12	0.42	0.35	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
THCA	cis	rs6452524	0.522	rs13161662	ENSG00000249664.1	CTD-2227C6.2	-8.16	3.05e-15	1.27e-12	-0.46	-0.35	Hypertension (SNP x SNP interaction);	chr5:83209777	chr5:83012285~83013109:-
THCA	cis	rs9640161	0.83	rs36069544	ENSG00000261305.1	RP4-584D14.7	8.16	3.05e-15	1.27e-12	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150364449	chr7:150341771~150342607:+
THCA	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-8.16	3.06e-15	1.28e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
THCA	cis	rs34375054	0.558	rs67041765	ENSG00000279233.1	RP11-158L12.4	8.16	3.06e-15	1.28e-12	0.35	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125188367	chr12:125138245~125141711:+
THCA	cis	rs11673344	0.523	rs2891766	ENSG00000226686.6	LINC01535	8.16	3.06e-15	1.28e-12	0.39	0.35	Obesity-related traits;	chr19:37037057	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs7245453	ENSG00000226686.6	LINC01535	8.16	3.06e-15	1.28e-12	0.39	0.35	Obesity-related traits;	chr19:37043447	chr19:37251912~37265535:+
THCA	cis	rs2562456	0.833	rs2562507	ENSG00000268555.1	RP11-678G14.3	-8.16	3.06e-15	1.28e-12	-0.49	-0.35	Pain;	chr19:21543535	chr19:21570822~21587322:-
THCA	cis	rs12594515	0.587	rs8033024	ENSG00000259200.1	RP11-718O11.1	-8.16	3.06e-15	1.28e-12	-0.45	-0.35	Weight;Waist circumference;	chr15:45705898	chr15:45705078~45931069:+
THCA	cis	rs7569084	0.687	rs11675538	ENSG00000234255.7	AC012370.3	8.16	3.07e-15	1.28e-12	0.4	0.35	Sum eosinophil basophil counts;	chr2:65459327	chr2:65439888~65456571:-
THCA	cis	rs2243480	1	rs160643	ENSG00000226824.5	RP4-756H11.3	-8.16	3.07e-15	1.28e-12	-0.69	-0.35	Diabetic kidney disease;	chr7:66093235	chr7:66654538~66669855:+
THCA	cis	rs922182	0.557	rs4776662	ENSG00000275785.1	RP11-111E14.2	-8.16	3.07e-15	1.28e-12	-0.42	-0.35	Blood protein levels;	chr15:63911363	chr15:63890030~63890317:+
THCA	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	8.16	3.08e-15	1.29e-12	0.43	0.35	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
THCA	cis	rs673078	0.607	rs2784	ENSG00000275409.1	RP11-131L12.4	-8.16	3.08e-15	1.29e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118311745	chr12:118430147~118430699:+
THCA	cis	rs673078	0.607	rs7302387	ENSG00000275409.1	RP11-131L12.4	-8.16	3.08e-15	1.29e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118316546	chr12:118430147~118430699:+
THCA	cis	rs12468226	0.752	rs34829484	ENSG00000273456.1	RP11-686O6.2	-8.16	3.09e-15	1.29e-12	-0.41	-0.35	Urate levels;	chr2:202137267	chr2:202374932~202375604:-
THCA	cis	rs3733309	0.648	rs10016631	ENSG00000269949.1	RP11-738E22.3	8.16	3.09e-15	1.29e-12	0.5	0.35	Height;	chr4:57019797	chr4:56960927~56961373:-
THCA	cis	rs6504108	0.624	rs1316657	ENSG00000278765.1	RP5-890E16.5	-8.16	3.09e-15	1.29e-12	-0.39	-0.35	Body mass index;	chr17:48174029	chr17:48066704~48067293:-
THCA	cis	rs6504108	0.624	rs1002330	ENSG00000278765.1	RP5-890E16.5	-8.16	3.09e-15	1.29e-12	-0.39	-0.35	Body mass index;	chr17:48176153	chr17:48066704~48067293:-
THCA	cis	rs910316	0.763	rs175016	ENSG00000279594.1	RP11-950C14.10	-8.16	3.1e-15	1.29e-12	-0.32	-0.35	Height;	chr14:74992930	chr14:75011269~75012851:-
THCA	cis	rs910316	0.935	rs3742771	ENSG00000279594.1	RP11-950C14.10	8.16	3.1e-15	1.29e-12	0.33	0.35	Height;	chr14:75132944	chr14:75011269~75012851:-
THCA	cis	rs748404	0.604	rs2278857	ENSG00000205771.5	CATSPER2P1	-8.16	3.1e-15	1.3e-12	-0.36	-0.35	Lung cancer;	chr15:43340351	chr15:43726918~43747094:-
THCA	cis	rs2562456	0.754	rs55771551	ENSG00000268555.1	RP11-678G14.3	8.16	3.1e-15	1.3e-12	0.49	0.35	Pain;	chr19:21563578	chr19:21570822~21587322:-
THCA	cis	rs4664293	0.51	rs57575372	ENSG00000226266.5	AC009961.3	8.16	3.1e-15	1.3e-12	0.42	0.35	Monocyte percentage of white cells;	chr2:159569253	chr2:159670708~159712435:-
THCA	cis	rs66887589	0.967	rs1155577	ENSG00000245958.5	RP11-33B1.1	8.16	3.1e-15	1.3e-12	0.31	0.35	Diastolic blood pressure;	chr4:119528655	chr4:119454791~119552025:+
THCA	cis	rs7396835	0.866	rs6589570	ENSG00000254851.1	RP11-109L13.1	-8.16	3.11e-15	1.3e-12	-0.61	-0.35	Quantitative traits;	chr11:116804578	chr11:117135528~117138582:+
THCA	cis	rs42490	0.625	rs43229	ENSG00000251136.7	RP11-37B2.1	-8.16	3.11e-15	1.3e-12	-0.3	-0.35	Leprosy;	chr8:89826558	chr8:89609409~89757727:-
THCA	cis	rs3747113	1	rs35303215	ENSG00000128262.7	POM121L9P	-8.16	3.11e-15	1.3e-12	-0.4	-0.35	Gut microbiome composition (summer);	chr22:24405567	chr22:24251828~24265525:+
THCA	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	8.16	3.11e-15	1.3e-12	0.33	0.35	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
THCA	cis	rs11096990	0.593	rs7662880	ENSG00000249685.1	RP11-360F5.3	-8.16	3.12e-15	1.3e-12	-0.42	-0.35	Cognitive function;	chr4:39283604	chr4:39133913~39135608:+
THCA	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	8.16	3.13e-15	1.31e-12	0.4	0.35	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
THCA	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-8.16	3.13e-15	1.31e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-8.16	3.13e-15	1.31e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-8.16	3.13e-15	1.31e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
THCA	cis	rs7714584	1	rs73282209	ENSG00000197083.10	ZNF300P1	8.16	3.13e-15	1.31e-12	0.61	0.35	Crohn's disease;	chr5:150795397	chr5:150930645~150946289:-
THCA	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-8.16	3.13e-15	1.31e-12	-0.42	-0.35	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
THCA	cis	rs2839186	0.77	rs2330353	ENSG00000239415.1	AP001469.9	8.16	3.13e-15	1.31e-12	0.37	0.35	Testicular germ cell tumor;	chr21:46249734	chr21:46251549~46254133:-
THCA	cis	rs11673344	0.504	rs4805204	ENSG00000226686.6	LINC01535	8.16	3.14e-15	1.31e-12	0.39	0.35	Obesity-related traits;	chr19:37136666	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs4805205	ENSG00000226686.6	LINC01535	8.16	3.14e-15	1.31e-12	0.39	0.35	Obesity-related traits;	chr19:37136693	chr19:37251912~37265535:+
THCA	cis	rs367615	0.918	rs17161889	ENSG00000249476.1	CTD-2587M2.1	-8.16	3.14e-15	1.31e-12	-0.39	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109519550	chr5:109237120~109326369:-
THCA	cis	rs7674212	0.556	rs34475639	ENSG00000246560.2	RP11-10L12.4	8.16	3.14e-15	1.31e-12	0.45	0.35	Type 2 diabetes;	chr4:103033694	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.507	rs223322	ENSG00000251288.2	RP11-10L12.2	-8.16	3.15e-15	1.32e-12	-0.47	-0.35	Type 2 diabetes;	chr4:102879037	chr4:102751401~102752641:+
THCA	cis	rs6504108	0.624	rs17681336	ENSG00000278765.1	RP5-890E16.5	-8.16	3.16e-15	1.32e-12	-0.39	-0.35	Body mass index;	chr17:48172430	chr17:48066704~48067293:-
THCA	cis	rs9329221	0.527	rs4452832	ENSG00000261451.1	RP11-981G7.1	-8.16	3.16e-15	1.32e-12	-0.45	-0.35	Neuroticism;	chr8:10463044	chr8:10433672~10438312:+
THCA	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	8.16	3.17e-15	1.32e-12	0.42	0.35	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	8.16	3.17e-15	1.32e-12	0.42	0.35	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	8.16	3.17e-15	1.32e-12	0.42	0.35	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	8.16	3.18e-15	1.33e-12	0.42	0.35	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
THCA	cis	rs11603023	0.569	rs573905	ENSG00000255422.1	AP002954.4	-8.16	3.18e-15	1.33e-12	-0.4	-0.35	Cholesterol, total;	chr11:118701558	chr11:118704607~118750263:+
THCA	cis	rs516805	0.715	rs11154087	ENSG00000279453.1	RP3-425C14.4	8.16	3.18e-15	1.33e-12	0.37	0.35	Lymphocyte counts;	chr6:122575484	chr6:122436789~122439223:-
THCA	cis	rs516805	0.748	rs11968579	ENSG00000279453.1	RP3-425C14.4	8.16	3.18e-15	1.33e-12	0.37	0.35	Lymphocyte counts;	chr6:122575950	chr6:122436789~122439223:-
THCA	cis	rs812925	0.519	rs2463099	ENSG00000271889.1	RP11-493E12.1	-8.16	3.18e-15	1.33e-12	-0.33	-0.35	Immature fraction of reticulocytes;	chr2:61391176	chr2:61151433~61162105:-
THCA	cis	rs1005277	0.579	rs2505194	ENSG00000263064.2	RP11-291L22.7	8.16	3.19e-15	1.33e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38448689~38448949:+
THCA	cis	rs11673344	0.504	rs11666786	ENSG00000226686.6	LINC01535	8.16	3.19e-15	1.33e-12	0.39	0.35	Obesity-related traits;	chr19:37133947	chr19:37251912~37265535:+
THCA	cis	rs7674212	0.531	rs10006474	ENSG00000251288.2	RP11-10L12.2	-8.16	3.19e-15	1.33e-12	-0.47	-0.35	Type 2 diabetes;	chr4:103006890	chr4:102751401~102752641:+
THCA	cis	rs2562456	0.761	rs35008138	ENSG00000268555.1	RP11-678G14.3	8.16	3.2e-15	1.34e-12	0.49	0.35	Pain;	chr19:21548822	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.833	rs2681388	ENSG00000268555.1	RP11-678G14.3	8.16	3.2e-15	1.34e-12	0.49	0.35	Pain;	chr19:21549451	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.876	rs2681370	ENSG00000268555.1	RP11-678G14.3	8.16	3.2e-15	1.34e-12	0.49	0.35	Pain;	chr19:21554036	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.876	rs11668606	ENSG00000268555.1	RP11-678G14.3	8.16	3.2e-15	1.34e-12	0.49	0.35	Pain;	chr19:21554618	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.876	rs2681395	ENSG00000268555.1	RP11-678G14.3	8.16	3.2e-15	1.34e-12	0.49	0.35	Pain;	chr19:21555338	chr19:21570822~21587322:-
THCA	cis	rs1275468	0.798	rs1275474	ENSG00000257497.2	RP11-585P4.5	-8.16	3.2e-15	1.34e-12	-0.5	-0.35	Polycystic ovary syndrome;	chr12:75525870	chr12:75483454~75489820:-
THCA	cis	rs11696845	0.966	rs1467473	ENSG00000276223.1	RP4-781B1.5	8.15	3.21e-15	1.34e-12	0.43	0.35	Obesity-related traits;	chr20:44743337	chr20:44746642~44747201:+
THCA	cis	rs6545883	0.524	rs2694618	ENSG00000271889.1	RP11-493E12.1	8.15	3.21e-15	1.34e-12	0.34	0.35	Tuberculosis;	chr2:61309849	chr2:61151433~61162105:-
THCA	cis	rs240993	0.812	rs118203	ENSG00000230177.1	RP5-1112D6.4	-8.15	3.22e-15	1.34e-12	-0.36	-0.35	Inflammatory skin disease;Psoriasis;	chr6:111337017	chr6:111277932~111278742:+
THCA	cis	rs7849270	0.959	rs1410017	ENSG00000268707.1	RP11-247A12.7	-8.15	3.22e-15	1.34e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129151151	chr9:129170434~129170940:+
THCA	cis	rs72772090	0.539	rs35898772	ENSG00000248734.2	CTD-2260A17.1	-8.15	3.23e-15	1.35e-12	-0.57	-0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96843982	chr5:96784777~96785999:+
THCA	cis	rs2739330	0.731	rs4822450	ENSG00000099984.9	GSTT2	-8.15	3.24e-15	1.35e-12	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23980123~23983911:+
THCA	cis	rs9341808	0.586	rs3805869	ENSG00000272129.1	RP11-250B2.6	8.15	3.24e-15	1.35e-12	0.44	0.35	Sitting height ratio;	chr6:80336200	chr6:80355424~80356859:+
THCA	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-8.15	3.26e-15	1.36e-12	-0.42	-0.35	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
THCA	cis	rs62103177	0.81	rs62096745	ENSG00000261126.6	RP11-795F19.1	8.15	3.26e-15	1.36e-12	0.42	0.35	Opioid sensitivity;	chr18:79859135	chr18:80046900~80095482:+
THCA	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	8.15	3.26e-15	1.36e-12	0.43	0.35	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	8.15	3.26e-15	1.36e-12	0.43	0.35	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	8.15	3.26e-15	1.36e-12	0.43	0.35	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	8.15	3.26e-15	1.36e-12	0.43	0.35	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	8.15	3.26e-15	1.36e-12	0.43	0.35	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
THCA	cis	rs4819052	0.851	rs2838826	ENSG00000237664.1	LINC00316	-8.15	3.26e-15	1.36e-12	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235870	chr21:45338590~45341990:-
THCA	cis	rs10411161	0.702	rs892039	ENSG00000269483.1	AC006272.1	8.15	3.27e-15	1.36e-12	0.5	0.35	Breast cancer;	chr19:51893288	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.702	rs2867319	ENSG00000269483.1	AC006272.1	8.15	3.27e-15	1.36e-12	0.5	0.35	Breast cancer;	chr19:51893907	chr19:51839924~51843324:-
THCA	cis	rs42490	0.664	rs43226	ENSG00000251136.7	RP11-37B2.1	-8.15	3.27e-15	1.36e-12	-0.3	-0.35	Leprosy;	chr8:89809048	chr8:89609409~89757727:-
THCA	cis	rs42490	0.664	rs422559	ENSG00000251136.7	RP11-37B2.1	-8.15	3.27e-15	1.36e-12	-0.3	-0.35	Leprosy;	chr8:89809121	chr8:89609409~89757727:-
THCA	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	8.15	3.27e-15	1.36e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
THCA	cis	rs4713118	0.699	rs200969	ENSG00000280107.1	AL022393.9	-8.15	3.27e-15	1.36e-12	-0.42	-0.35	Parkinson's disease;	chr6:27891675	chr6:28170845~28172521:+
THCA	cis	rs73186030	0.92	rs73186059	ENSG00000272758.4	RP11-299J3.8	8.15	3.27e-15	1.36e-12	0.44	0.35	Serum parathyroid hormone levels;	chr3:122332336	chr3:122416207~122443180:+
THCA	cis	rs11603023	0.967	rs7936556	ENSG00000255239.1	AP002954.6	-8.15	3.28e-15	1.37e-12	-0.45	-0.35	Cholesterol, total;	chr11:118630582	chr11:118688039~118690600:-
THCA	cis	rs62103177	0.81	rs62103175	ENSG00000261126.6	RP11-795F19.1	8.15	3.28e-15	1.37e-12	0.4	0.35	Opioid sensitivity;	chr18:79862467	chr18:80046900~80095482:+
THCA	cis	rs2408955	0.561	rs9971924	ENSG00000258273.1	RP11-370I10.4	8.15	3.29e-15	1.37e-12	0.46	0.35	Glycated hemoglobin levels;	chr12:48086049	chr12:48333755~48333901:-
THCA	cis	rs2408955	0.522	rs7139330	ENSG00000258273.1	RP11-370I10.4	8.15	3.29e-15	1.37e-12	0.46	0.35	Glycated hemoglobin levels;	chr12:48089701	chr12:48333755~48333901:-
THCA	cis	rs2408955	0.522	rs2051851	ENSG00000258273.1	RP11-370I10.4	8.15	3.29e-15	1.37e-12	0.46	0.35	Glycated hemoglobin levels;	chr12:48092157	chr12:48333755~48333901:-
THCA	cis	rs6452524	0.766	rs2252179	ENSG00000249664.1	CTD-2227C6.2	-8.15	3.29e-15	1.37e-12	-0.46	-0.35	Hypertension (SNP x SNP interaction);	chr5:83145630	chr5:83012285~83013109:-
THCA	cis	rs7849270	1	rs3814492	ENSG00000268707.1	RP11-247A12.7	-8.15	3.29e-15	1.37e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129110943	chr9:129170434~129170940:+
THCA	cis	rs7712401	0.584	rs28373879	ENSG00000263432.2	RN7SL689P	8.15	3.29e-15	1.37e-12	0.4	0.35	Mean platelet volume;	chr5:123036707	chr5:123022487~123022783:-
THCA	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-8.15	3.3e-15	1.37e-12	-0.45	-0.35	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
THCA	cis	rs9813712	0.526	rs62281641	ENSG00000228252.7	COL6A4P2	-8.15	3.3e-15	1.38e-12	-0.35	-0.35	Response to amphetamines;	chr3:130235668	chr3:130212823~130273806:+
THCA	cis	rs507080	0.922	rs592280	ENSG00000278376.1	RP11-158I9.8	-8.15	3.31e-15	1.38e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118682509	chr11:118791254~118793137:+
THCA	cis	rs17684571	0.872	rs3002010	ENSG00000231441.1	RP11-472M19.2	8.15	3.32e-15	1.38e-12	0.45	0.35	Schizophrenia;	chr6:56760050	chr6:56844002~56864078:+
THCA	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	8.15	3.32e-15	1.38e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
THCA	cis	rs910316	1	rs175492	ENSG00000279594.1	RP11-950C14.10	8.15	3.32e-15	1.38e-12	0.32	0.35	Height;	chr14:75078517	chr14:75011269~75012851:-
THCA	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-8.15	3.33e-15	1.39e-12	-0.42	-0.35	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
THCA	cis	rs922182	0.557	rs7161953	ENSG00000275785.1	RP11-111E14.2	-8.15	3.33e-15	1.39e-12	-0.42	-0.35	Blood protein levels;	chr15:63910688	chr15:63890030~63890317:+
THCA	cis	rs4819052	0.851	rs9974891	ENSG00000237664.1	LINC00316	-8.15	3.33e-15	1.39e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260852	chr21:45338590~45341990:-
THCA	cis	rs4814920	0.818	rs4813376	ENSG00000233895.1	RP1-122P22.2	8.15	3.34e-15	1.39e-12	0.38	0.35	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19757708~19809675:+
THCA	cis	rs853679	0.513	rs13437444	ENSG00000226314.6	ZNF192P1	-8.15	3.34e-15	1.39e-12	-0.53	-0.35	Depression;	chr6:28103220	chr6:28161781~28169594:+
THCA	cis	rs11148252	0.553	rs2147692	ENSG00000235660.1	LINC00345	-8.15	3.34e-15	1.39e-12	-0.44	-0.35	Lewy body disease;	chr13:52712888	chr13:52484161~52484680:-
THCA	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	8.15	3.35e-15	1.39e-12	0.33	0.35	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
THCA	cis	rs1005277	0.565	rs2474565	ENSG00000263064.2	RP11-291L22.7	8.15	3.35e-15	1.39e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38448689~38448949:+
THCA	cis	rs2712184	0.756	rs2712164	ENSG00000229352.1	AC007563.3	-8.15	3.35e-15	1.4e-12	-0.42	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216795193	chr2:216799608~216805335:+
THCA	cis	rs9828933	0.832	rs3774723	ENSG00000280620.1	SCAANT1	8.15	3.36e-15	1.4e-12	0.56	0.35	Type 2 diabetes;	chr3:63976663	chr3:63911518~63911772:-
THCA	cis	rs9847710	0.524	rs11712910	ENSG00000242142.1	SERBP1P3	8.15	3.36e-15	1.4e-12	0.44	0.35	Ulcerative colitis;	chr3:53060178	chr3:53064283~53065091:-
THCA	cis	rs7849270	0.921	rs7868476	ENSG00000268707.1	RP11-247A12.7	-8.15	3.37e-15	1.4e-12	-0.44	-0.35	Blood metabolite ratios;	chr9:129155854	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.959	rs2094704	ENSG00000268707.1	RP11-247A12.7	-8.15	3.37e-15	1.4e-12	-0.44	-0.35	Blood metabolite ratios;	chr9:129156015	chr9:129170434~129170940:+
THCA	cis	rs7208859	0.673	rs2470251	ENSG00000266490.1	CTD-2349P21.9	8.15	3.38e-15	1.41e-12	0.45	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30792372~30792833:+
THCA	cis	rs910316	0.591	rs7157158	ENSG00000279594.1	RP11-950C14.10	8.15	3.38e-15	1.41e-12	0.32	0.35	Height;	chr14:74990535	chr14:75011269~75012851:-
THCA	cis	rs9500256	0.966	rs1322446	ENSG00000215190.7	LINC00680	-8.15	3.38e-15	1.41e-12	-0.4	-0.35	Eosinophilic esophagitis (pediatric);	chr6:57985672	chr6:57946074~57961501:-
THCA	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-8.15	3.39e-15	1.41e-12	-0.37	-0.35	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
THCA	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-8.15	3.41e-15	1.42e-12	-0.42	-0.35	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
THCA	cis	rs9640161	0.83	rs17173681	ENSG00000261305.1	RP4-584D14.7	-8.15	3.41e-15	1.42e-12	-0.42	-0.35	Blood protein levels;Circulating chemerin levels;	chr7:150362325	chr7:150341771~150342607:+
THCA	cis	rs4819052	0.808	rs2838825	ENSG00000237664.1	LINC00316	-8.15	3.41e-15	1.42e-12	-0.36	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235736	chr21:45338590~45341990:-
THCA	cis	rs11603023	0.804	rs527619	ENSG00000255239.1	AP002954.6	-8.15	3.42e-15	1.42e-12	-0.46	-0.35	Cholesterol, total;	chr11:118692577	chr11:118688039~118690600:-
THCA	cis	rs1707322	1	rs10789486	ENSG00000234329.1	RP11-767N6.2	8.15	3.42e-15	1.42e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45651039~45651826:-
THCA	cis	rs4664293	0.528	rs72960224	ENSG00000226266.5	AC009961.3	8.15	3.44e-15	1.43e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159563993	chr2:159670708~159712435:-
THCA	cis	rs1062177	0.855	rs919263	ENSG00000253921.1	CTB-113P19.3	-8.15	3.45e-15	1.43e-12	-0.41	-0.35	Preschool internalizing problems;	chr5:151886292	chr5:151753992~151767247:+
THCA	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-8.14	3.45e-15	1.44e-12	-0.43	-0.35	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
THCA	cis	rs375066	0.935	rs396973	ENSG00000267058.1	RP11-15A1.3	8.14	3.46e-15	1.44e-12	0.29	0.35	Breast cancer;	chr19:43895154	chr19:43891804~43901805:-
THCA	cis	rs11096990	0.656	rs7686161	ENSG00000249685.1	RP11-360F5.3	-8.14	3.46e-15	1.44e-12	-0.42	-0.35	Cognitive function;	chr4:39283201	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs3733281	ENSG00000249685.1	RP11-360F5.3	-8.14	3.46e-15	1.44e-12	-0.42	-0.35	Cognitive function;	chr4:39270293	chr4:39133913~39135608:+
THCA	cis	rs11148252	0.904	rs9526927	ENSG00000235660.1	LINC00345	-8.14	3.47e-15	1.44e-12	-0.43	-0.35	Lewy body disease;	chr13:52477492	chr13:52484161~52484680:-
THCA	cis	rs4934494	0.911	rs7081788	ENSG00000232936.4	RP11-80H5.2	8.14	3.47e-15	1.44e-12	0.46	0.35	Red blood cell count;	chr10:89648999	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.911	rs34486602	ENSG00000232936.4	RP11-80H5.2	8.14	3.47e-15	1.44e-12	0.46	0.35	Red blood cell count;	chr10:89655895	chr10:89645282~89650667:+
THCA	cis	rs4934494	0.911	rs6586213	ENSG00000232936.4	RP11-80H5.2	8.14	3.47e-15	1.44e-12	0.46	0.35	Red blood cell count;	chr10:89656327	chr10:89645282~89650667:+
THCA	cis	rs4819052	0.851	rs1056100	ENSG00000237664.1	LINC00316	-8.14	3.47e-15	1.44e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258796	chr21:45338590~45341990:-
THCA	cis	rs673078	0.607	rs17441214	ENSG00000275409.1	RP11-131L12.4	-8.14	3.48e-15	1.45e-12	-0.45	-0.35	Glucose homeostasis traits;	chr12:118436721	chr12:118430147~118430699:+
THCA	cis	rs1510272	0.515	rs6807235	ENSG00000243926.1	TIPARP-AS1	-8.14	3.48e-15	1.45e-12	-0.45	-0.35	Testicular germ cell tumor;	chr3:156623812	chr3:156671862~156674378:-
THCA	cis	rs1707322	1	rs7538978	ENSG00000234329.1	RP11-767N6.2	-8.14	3.48e-15	1.45e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45651039~45651826:-
THCA	cis	rs416603	0.967	rs11640138	ENSG00000262636.1	CTD-3088G3.4	8.14	3.49e-15	1.45e-12	0.44	0.35	Type 1 diabetes;	chr16:11268872	chr16:11380859~11381118:-
THCA	cis	rs947583	0.588	rs9321530	ENSG00000231028.7	LINC00271	-8.14	3.49e-15	1.45e-12	-0.28	-0.35	Phosphorus levels;	chr6:135790941	chr6:135497801~135716055:+
THCA	cis	rs7811142	0.945	rs6974282	ENSG00000242294.5	STAG3L5P	8.14	3.5e-15	1.45e-12	0.24	0.35	Platelet count;	chr7:100500672	chr7:100336079~100351900:+
THCA	cis	rs9649213	0.593	rs1076272	ENSG00000272950.1	RP11-307C18.1	8.14	3.5e-15	1.46e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98401693	chr7:98322853~98323430:+
THCA	cis	rs73607972	0.696	rs7194983	ENSG00000275191.1	RP11-36I17.2	-8.14	3.5e-15	1.46e-12	-0.5	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53525100	chr16:53628256~53628816:-
THCA	cis	rs7291412	0.54	rs9627391	ENSG00000231711.2	LINC00899	8.14	3.53e-15	1.47e-12	0.29	0.35	Dupuytren's disease;Subjective well-being;	chr22:46051217	chr22:46039907~46044853:-
THCA	cis	rs6452524	0.692	rs1382367	ENSG00000249664.1	CTD-2227C6.2	-8.14	3.53e-15	1.47e-12	-0.46	-0.35	Hypertension (SNP x SNP interaction);	chr5:83155393	chr5:83012285~83013109:-
THCA	cis	rs2712184	0.655	rs1003622	ENSG00000229352.1	AC007563.3	-8.14	3.53e-15	1.47e-12	-0.42	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216788885	chr2:216799608~216805335:+
THCA	cis	rs7208859	0.673	rs9912122	ENSG00000266490.1	CTD-2349P21.9	8.14	3.53e-15	1.47e-12	0.45	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30792372~30792833:+
THCA	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-8.14	3.54e-15	1.47e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
THCA	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-8.14	3.54e-15	1.47e-12	-0.42	-0.35	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
THCA	cis	rs4927850	0.958	rs2044599	ENSG00000242086.7	LINC00969	8.14	3.55e-15	1.47e-12	0.35	0.35	Pancreatic cancer;	chr3:196009869	chr3:195658062~195739964:+
THCA	cis	rs4927850	1	rs4927704	ENSG00000242086.7	LINC00969	8.14	3.55e-15	1.47e-12	0.35	0.35	Pancreatic cancer;	chr3:196011357	chr3:195658062~195739964:+
THCA	cis	rs4927850	1	rs4927848	ENSG00000242086.7	LINC00969	8.14	3.55e-15	1.47e-12	0.35	0.35	Pancreatic cancer;	chr3:196011535	chr3:195658062~195739964:+
THCA	cis	rs8072100	0.817	rs6505049	ENSG00000228782.6	CTD-2026D20.3	-8.14	3.56e-15	1.48e-12	-0.32	-0.35	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47598415	chr17:47450568~47492492:-
THCA	cis	rs2739330	0.76	rs5751760	ENSG00000099984.9	GSTT2	-8.14	3.58e-15	1.49e-12	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23980123~23983911:+
THCA	cis	rs1858037	0.867	rs55945621	ENSG00000237979.1	AC007389.1	8.14	3.58e-15	1.49e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65388220	chr2:65500993~65502138:-
THCA	cis	rs2562456	0.755	rs1879234	ENSG00000268555.1	RP11-678G14.3	-8.14	3.58e-15	1.49e-12	-0.49	-0.35	Pain;	chr19:21521677	chr19:21570822~21587322:-
THCA	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	8.14	3.59e-15	1.49e-12	0.42	0.35	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
THCA	cis	rs748404	0.631	rs1133395	ENSG00000205771.5	CATSPER2P1	-8.14	3.61e-15	1.5e-12	-0.37	-0.35	Lung cancer;	chr15:43358186	chr15:43726918~43747094:-
THCA	cis	rs7015263	0.573	rs7007174	ENSG00000254231.1	CTD-2284J15.1	-8.14	3.61e-15	1.5e-12	-0.35	-0.35	Intelligence (multi-trait analysis);	chr8:86275422	chr8:86333274~86343314:-
THCA	cis	rs9309473	0.583	rs6718864	ENSG00000163016.8	ALMS1P	8.14	3.61e-15	1.5e-12	0.46	0.35	Metabolite levels;	chr2:73347463	chr2:73644919~73685576:+
THCA	cis	rs7849270	1	rs1360172	ENSG00000268707.1	RP11-247A12.7	-8.14	3.61e-15	1.5e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129145701	chr9:129170434~129170940:+
THCA	cis	rs66887589	0.967	rs1480933	ENSG00000245958.5	RP11-33B1.1	-8.14	3.62e-15	1.5e-12	-0.31	-0.35	Diastolic blood pressure;	chr4:119512093	chr4:119454791~119552025:+
THCA	cis	rs13631	0.965	rs7853589	ENSG00000268996.3	MAN1B1-AS1	-8.14	3.63e-15	1.51e-12	-0.29	-0.35	Cerebrospinal fluid biomarker levels;	chr9:137109392	chr9:137084946~137086817:-
THCA	cis	rs2929278	0.561	rs2927071	ENSG00000166763.7	STRCP1	8.14	3.63e-15	1.51e-12	0.39	0.35	Schizophrenia;	chr15:43626883	chr15:43699488~43718184:-
THCA	cis	rs17772222	1	rs2295135	ENSG00000258983.2	RP11-507K2.2	8.14	3.63e-15	1.51e-12	0.45	0.35	Coronary artery calcification;	chr14:88427866	chr14:88499334~88515502:+
THCA	cis	rs12682352	0.602	rs6988939	ENSG00000253893.2	FAM85B	-8.14	3.64e-15	1.51e-12	-0.46	-0.35	Neuroticism;	chr8:8809406	chr8:8167819~8226614:-
THCA	cis	rs984222	0.617	rs12123458	ENSG00000231365.4	RP11-418J17.1	8.14	3.65e-15	1.51e-12	0.35	0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119211635	chr1:119140396~119275973:+
THCA	cis	rs4664293	0.528	rs12477092	ENSG00000226266.5	AC009961.3	8.14	3.65e-15	1.52e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159577170	chr2:159670708~159712435:-
THCA	cis	rs1858037	0.867	rs72621551	ENSG00000237979.1	AC007389.1	8.14	3.66e-15	1.52e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65388087	chr2:65500993~65502138:-
THCA	cis	rs56046484	0.956	rs12904410	ENSG00000259295.5	CSPG4P12	8.14	3.67e-15	1.52e-12	0.59	0.35	Testicular germ cell tumor;	chr15:85066557	chr15:85191438~85213905:+
THCA	cis	rs7829975	0.517	rs12542733	ENSG00000253893.2	FAM85B	8.14	3.68e-15	1.53e-12	0.44	0.35	Mood instability;	chr8:8967348	chr8:8167819~8226614:-
THCA	cis	rs6840258	0.547	rs72667721	ENSG00000251411.1	RP11-397E7.4	-8.14	3.68e-15	1.53e-12	-0.44	-0.35	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86919644	chr4:86913266~86914817:-
THCA	cis	rs11696845	1	rs1467472	ENSG00000276223.1	RP4-781B1.5	-8.14	3.68e-15	1.53e-12	-0.43	-0.35	Obesity-related traits;	chr20:44742910	chr20:44746642~44747201:+
THCA	cis	rs7811142	1	rs7794485	ENSG00000242294.5	STAG3L5P	8.14	3.69e-15	1.53e-12	0.24	0.35	Platelet count;	chr7:100471313	chr7:100336079~100351900:+
THCA	cis	rs42490	0.614	rs445172	ENSG00000251136.7	RP11-37B2.1	-8.14	3.69e-15	1.53e-12	-0.3	-0.35	Leprosy;	chr8:89808322	chr8:89609409~89757727:-
THCA	cis	rs853679	0.723	rs9366718	ENSG00000219392.1	RP1-265C24.5	-8.14	3.7e-15	1.53e-12	-0.49	-0.35	Depression;	chr6:28237724	chr6:28115628~28116551:+
THCA	cis	rs9309473	0.555	rs2901437	ENSG00000163016.8	ALMS1P	8.14	3.7e-15	1.54e-12	0.46	0.35	Metabolite levels;	chr2:73369896	chr2:73644919~73685576:+
THCA	cis	rs11673344	0.504	rs10402907	ENSG00000226686.6	LINC01535	8.13	3.71e-15	1.54e-12	0.39	0.35	Obesity-related traits;	chr19:37112874	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.563	rs4805199	ENSG00000226686.6	LINC01535	8.13	3.71e-15	1.54e-12	0.39	0.35	Obesity-related traits;	chr19:37115527	chr19:37251912~37265535:+
THCA	cis	rs957448	0.607	rs12680842	ENSG00000253704.1	RP11-267M23.4	8.13	3.71e-15	1.54e-12	0.36	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94553722~94569745:+
THCA	cis	rs957448	0.554	rs12680855	ENSG00000253704.1	RP11-267M23.4	8.13	3.71e-15	1.54e-12	0.36	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94553722~94569745:+
THCA	cis	rs4819052	1	rs13053002	ENSG00000237664.1	LINC00316	-8.13	3.71e-15	1.54e-12	-0.38	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45257939	chr21:45338590~45341990:-
THCA	cis	rs4072705	0.967	rs10818985	ENSG00000224020.1	MIR181A2HG	-8.13	3.71e-15	1.54e-12	-0.31	-0.35	Menarche (age at onset);	chr9:124688292	chr9:124658467~124698631:+
THCA	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-8.13	3.72e-15	1.54e-12	-0.42	-0.35	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
THCA	cis	rs7849270	1	rs746489	ENSG00000268707.1	RP11-247A12.7	-8.13	3.73e-15	1.55e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129147814	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.959	rs913275	ENSG00000268707.1	RP11-247A12.7	-8.13	3.73e-15	1.55e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129148365	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs7869804	ENSG00000268707.1	RP11-247A12.7	-8.13	3.73e-15	1.55e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129150865	chr9:129170434~129170940:+
THCA	cis	rs7208859	0.623	rs8082537	ENSG00000266490.1	CTD-2349P21.9	8.13	3.73e-15	1.55e-12	0.46	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30792372~30792833:+
THCA	cis	rs11332131	1	rs11332131	ENSG00000266992.1	DHX40P1	8.13	3.74e-15	1.55e-12	0.4	0.35	Platelet distribution width;	chr17:59849031	chr17:59976009~60002384:-
THCA	cis	rs7811142	0.83	rs6979910	ENSG00000078319.8	PMS2P1	-8.13	3.75e-15	1.55e-12	-0.49	-0.35	Platelet count;	chr7:100343007	chr7:100320992~100341908:-
THCA	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-8.13	3.75e-15	1.55e-12	-0.42	-0.35	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
THCA	cis	rs8114671	0.836	rs6120778	ENSG00000269202.1	RP4-614O4.12	-8.13	3.76e-15	1.56e-12	-0.3	-0.35	Height;	chr20:34977366	chr20:35201747~35203288:-
THCA	cis	rs11096990	0.634	rs1451818	ENSG00000249685.1	RP11-360F5.3	8.13	3.77e-15	1.56e-12	0.42	0.35	Cognitive function;	chr4:39257151	chr4:39133913~39135608:+
THCA	cis	rs4819052	0.851	rs2838856	ENSG00000237664.1	LINC00316	-8.13	3.77e-15	1.56e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45260851	chr21:45338590~45341990:-
THCA	cis	rs2739330	0.828	rs5760107	ENSG00000206090.4	AP000350.7	8.13	3.77e-15	1.56e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23939998~23942798:+
THCA	cis	rs2739330	0.789	rs5760109	ENSG00000206090.4	AP000350.7	8.13	3.77e-15	1.56e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23939998~23942798:+
THCA	cis	rs2522056	0.808	rs17771891	ENSG00000233006.5	AC034220.3	8.13	3.77e-15	1.56e-12	0.31	0.35	Fibrinogen;Lymphocyte counts;	chr5:132408510	chr5:132311285~132369916:-
THCA	cis	rs11148252	0.5	rs342768	ENSG00000235660.1	LINC00345	-8.13	3.78e-15	1.56e-12	-0.42	-0.35	Lewy body disease;	chr13:52634747	chr13:52484161~52484680:-
THCA	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	8.13	3.78e-15	1.57e-12	0.42	0.35	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
THCA	cis	rs2120243	0.533	rs1392798	ENSG00000244515.1	KRT18P34	8.13	3.79e-15	1.57e-12	0.4	0.35	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338498	chr3:157162663~157163932:-
THCA	cis	rs11673344	0.504	rs8110796	ENSG00000226686.6	LINC01535	8.13	3.79e-15	1.57e-12	0.39	0.35	Obesity-related traits;	chr19:37132682	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs8111285	ENSG00000226686.6	LINC01535	8.13	3.79e-15	1.57e-12	0.39	0.35	Obesity-related traits;	chr19:37132747	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs6510591	ENSG00000226686.6	LINC01535	8.13	3.79e-15	1.57e-12	0.39	0.35	Obesity-related traits;	chr19:37133186	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs6510592	ENSG00000226686.6	LINC01535	8.13	3.79e-15	1.57e-12	0.39	0.35	Obesity-related traits;	chr19:37133430	chr19:37251912~37265535:+
THCA	cis	rs947583	0.588	rs9321532	ENSG00000231028.7	LINC00271	8.13	3.79e-15	1.57e-12	0.28	0.35	Phosphorus levels;	chr6:135791078	chr6:135497801~135716055:+
THCA	cis	rs11673344	0.504	rs8099987	ENSG00000226686.6	LINC01535	8.13	3.8e-15	1.58e-12	0.39	0.35	Obesity-related traits;	chr19:37132570	chr19:37251912~37265535:+
THCA	cis	rs62355901	0.545	rs56008823	ENSG00000271828.1	CTD-2310F14.1	8.13	3.81e-15	1.58e-12	0.66	0.35	Breast cancer;	chr5:56772187	chr5:56927874~56929573:+
THCA	cis	rs6545883	0.524	rs7561697	ENSG00000271889.1	RP11-493E12.1	-8.13	3.81e-15	1.58e-12	-0.34	-0.35	Tuberculosis;	chr2:61292030	chr2:61151433~61162105:-
THCA	cis	rs860295	0.966	rs821551	ENSG00000225855.5	RUSC1-AS1	8.13	3.82e-15	1.58e-12	0.24	0.35	Body mass index;	chr1:155718789	chr1:155316863~155324176:-
THCA	cis	rs812925	0.537	rs2593620	ENSG00000271889.1	RP11-493E12.1	-8.13	3.82e-15	1.58e-12	-0.34	-0.35	Immature fraction of reticulocytes;	chr2:61386126	chr2:61151433~61162105:-
THCA	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-8.13	3.82e-15	1.58e-12	-0.36	-0.35	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
THCA	cis	rs6844153	1	rs74642474	ENSG00000240005.4	RP11-293A21.1	-8.13	3.84e-15	1.59e-12	-0.5	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26854979	chr4:26859806~26860599:-
THCA	cis	rs595244	0.706	rs4775770	ENSG00000259705.1	RP11-227D13.1	-8.13	3.85e-15	1.59e-12	-0.51	-0.35	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48652366	chr15:48645951~48652016:+
THCA	cis	rs2739330	0.76	rs5760095	ENSG00000099984.9	GSTT2	-8.13	3.85e-15	1.59e-12	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23980123~23983911:+
THCA	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	8.13	3.85e-15	1.6e-12	0.43	0.35	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
THCA	cis	rs2739330	0.652	rs2000469	ENSG00000231271.1	AP000350.8	8.13	3.86e-15	1.6e-12	0.45	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23949918~23954042:+
THCA	cis	rs150992	0.57	rs7710032	ENSG00000248489.1	CTD-2007H13.3	-8.13	3.86e-15	1.6e-12	-0.34	-0.35	Body mass index;	chr5:99007501	chr5:98929171~98995013:+
THCA	cis	rs910316	0.763	rs1548807	ENSG00000279594.1	RP11-950C14.10	8.13	3.87e-15	1.6e-12	0.32	0.35	Height;	chr14:75012879	chr14:75011269~75012851:-
THCA	cis	rs2524005	1	rs2524005	ENSG00000228078.1	HLA-U	-8.13	3.88e-15	1.6e-12	-0.55	-0.35	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29934101~29934286:+
THCA	cis	rs7727544	0.631	rs13357280	ENSG00000224431.1	AC063976.7	8.13	3.88e-15	1.61e-12	0.31	0.35	Blood metabolite levels;	chr5:132264494	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.594	rs10479000	ENSG00000224431.1	AC063976.7	8.13	3.88e-15	1.61e-12	0.31	0.35	Blood metabolite levels;	chr5:132271709	chr5:132199456~132203487:+
THCA	cis	rs910316	0.874	rs61980828	ENSG00000279594.1	RP11-950C14.10	-8.13	3.89e-15	1.61e-12	-0.33	-0.35	Height;	chr14:75163675	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs910316	ENSG00000279594.1	RP11-950C14.10	8.13	3.89e-15	1.61e-12	0.33	0.35	Height;	chr14:75159339	chr14:75011269~75012851:-
THCA	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	8.13	3.89e-15	1.61e-12	0.42	0.35	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
THCA	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	8.13	3.9e-15	1.61e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
THCA	cis	rs13113518	0.729	rs12641881	ENSG00000249700.7	SRD5A3-AS1	8.13	3.9e-15	1.61e-12	0.47	0.35	Height;	chr4:55401306	chr4:55363971~55395847:-
THCA	cis	rs910316	0.935	rs11159119	ENSG00000279594.1	RP11-950C14.10	-8.13	3.9e-15	1.61e-12	-0.33	-0.35	Height;	chr14:75170264	chr14:75011269~75012851:-
THCA	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	8.13	3.9e-15	1.62e-12	0.22	0.35	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
THCA	cis	rs12188164	0.61	rs6555242	ENSG00000221990.4	EXOC3-AS1	8.13	3.91e-15	1.62e-12	0.29	0.35	Cystic fibrosis severity;	chr5:416431	chr5:441498~443160:-
THCA	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	8.13	3.91e-15	1.62e-12	0.56	0.35	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
THCA	cis	rs62103177	0.683	rs13838	ENSG00000261126.6	RP11-795F19.1	8.13	3.92e-15	1.62e-12	0.4	0.35	Opioid sensitivity;	chr18:79903409	chr18:80046900~80095482:+
THCA	cis	rs812925	0.537	rs10196146	ENSG00000271889.1	RP11-493E12.1	-8.13	3.92e-15	1.62e-12	-0.34	-0.35	Immature fraction of reticulocytes;	chr2:61378244	chr2:61151433~61162105:-
THCA	cis	rs748404	0.578	rs4547312	ENSG00000205771.5	CATSPER2P1	-8.13	3.92e-15	1.62e-12	-0.36	-0.35	Lung cancer;	chr15:43339940	chr15:43726918~43747094:-
THCA	cis	rs957448	0.554	rs12682601	ENSG00000253704.1	RP11-267M23.4	8.13	3.93e-15	1.63e-12	0.37	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94553722~94569745:+
THCA	cis	rs11696845	1	rs1555299	ENSG00000276223.1	RP4-781B1.5	-8.13	3.94e-15	1.63e-12	-0.43	-0.35	Obesity-related traits;	chr20:44741465	chr20:44746642~44747201:+
THCA	cis	rs11696845	1	rs13038016	ENSG00000276223.1	RP4-781B1.5	-8.13	3.94e-15	1.63e-12	-0.43	-0.35	Obesity-related traits;	chr20:44741856	chr20:44746642~44747201:+
THCA	cis	rs11696845	1	rs13037759	ENSG00000276223.1	RP4-781B1.5	-8.13	3.94e-15	1.63e-12	-0.43	-0.35	Obesity-related traits;	chr20:44742051	chr20:44746642~44747201:+
THCA	cis	rs11696845	0.965	rs13038381	ENSG00000276223.1	RP4-781B1.5	-8.13	3.94e-15	1.63e-12	-0.43	-0.35	Obesity-related traits;	chr20:44742106	chr20:44746642~44747201:+
THCA	cis	rs4819052	0.765	rs2838868	ENSG00000237664.1	LINC00316	8.13	3.94e-15	1.63e-12	0.37	0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45294726	chr21:45338590~45341990:-
THCA	cis	rs507080	0.922	rs516153	ENSG00000278376.1	RP11-158I9.8	-8.13	3.95e-15	1.63e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118694053	chr11:118791254~118793137:+
THCA	cis	rs2836950	0.772	rs62222988	ENSG00000255568.3	BRWD1-AS2	-8.13	3.96e-15	1.64e-12	-0.29	-0.35	Menarche (age at onset);	chr21:39197582	chr21:39313935~39314962:+
THCA	cis	rs2274273	0.686	rs66531545	ENSG00000258413.1	RP11-665C16.6	-8.13	3.97e-15	1.64e-12	-0.5	-0.35	Protein biomarker;	chr14:55120742	chr14:55262767~55272075:-
THCA	cis	rs2562456	0.917	rs2562466	ENSG00000268555.1	RP11-678G14.3	-8.13	3.97e-15	1.64e-12	-0.49	-0.35	Pain;	chr19:21531402	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs2562468	ENSG00000268555.1	RP11-678G14.3	-8.13	3.97e-15	1.64e-12	-0.49	-0.35	Pain;	chr19:21532048	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs2562471	ENSG00000268555.1	RP11-678G14.3	-8.13	3.97e-15	1.64e-12	-0.49	-0.35	Pain;	chr19:21533017	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs2681377	ENSG00000268555.1	RP11-678G14.3	-8.13	3.97e-15	1.64e-12	-0.49	-0.35	Pain;	chr19:21533718	chr19:21570822~21587322:-
THCA	cis	rs2288884	0.634	rs80309583	ENSG00000275055.1	CTC-471J1.11	-8.13	3.97e-15	1.64e-12	-0.34	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51996949	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.634	rs17835649	ENSG00000275055.1	CTC-471J1.11	-8.13	3.97e-15	1.64e-12	-0.34	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51997362	chr19:52049007~52049754:+
THCA	cis	rs853679	0.882	rs4713140	ENSG00000219392.1	RP1-265C24.5	-8.13	3.97e-15	1.64e-12	-0.6	-0.35	Depression;	chr6:28129415	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs10214440	ENSG00000219392.1	RP1-265C24.5	-8.13	3.98e-15	1.64e-12	-0.45	-0.35	Parkinson's disease;	chr6:27734661	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs6902689	ENSG00000219392.1	RP1-265C24.5	-8.13	3.98e-15	1.64e-12	-0.45	-0.35	Parkinson's disease;	chr6:27741662	chr6:28115628~28116551:+
THCA	cis	rs910316	0.967	rs175479	ENSG00000279594.1	RP11-950C14.10	-8.13	3.98e-15	1.65e-12	-0.33	-0.35	Height;	chr14:75095168	chr14:75011269~75012851:-
THCA	cis	rs75422866	0.867	rs73102188	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47662993	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102195	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47666309	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102201	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47669269	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104103	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47669604	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104104	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47671986	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104111	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47673994	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104115	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47684843	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104116	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47685023	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104138	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47692302	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.717	rs73104143	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47693449	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104144	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47694390	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104148	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47696732	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104152	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47699091	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73104155	ENSG00000257433.4	RP1-197B17.3	8.12	3.99e-15	1.65e-12	0.55	0.35	Pneumonia;	chr12:47700790	chr12:47706085~47742294:+
THCA	cis	rs910316	1	rs876402	ENSG00000279594.1	RP11-950C14.10	-8.12	3.99e-15	1.65e-12	-0.33	-0.35	Height;	chr14:75135159	chr14:75011269~75012851:-
THCA	cis	rs1707322	1	rs10890365	ENSG00000234329.1	RP11-767N6.2	8.12	4e-15	1.65e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45651039~45651826:-
THCA	cis	rs4819052	0.851	rs1056101	ENSG00000237664.1	LINC00316	-8.12	4.01e-15	1.66e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258787	chr21:45338590~45341990:-
THCA	cis	rs2439831	0.85	rs12441861	ENSG00000249839.1	AC011330.5	-8.12	4.02e-15	1.66e-12	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43768685	chr15:43663654~43684339:-
THCA	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	8.12	4.02e-15	1.66e-12	0.24	0.35	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
THCA	cis	rs9640161	0.783	rs35435439	ENSG00000261305.1	RP4-584D14.7	8.12	4.03e-15	1.67e-12	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150366445	chr7:150341771~150342607:+
THCA	cis	rs732716	0.785	rs11667543	ENSG00000267980.1	AC007292.6	-8.12	4.03e-15	1.67e-12	-0.41	-0.35	Mean corpuscular volume;	chr19:4374853	chr19:4363789~4364640:+
THCA	cis	rs7208859	0.673	rs56846352	ENSG00000266490.1	CTD-2349P21.9	8.12	4.04e-15	1.67e-12	0.45	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30792372~30792833:+
THCA	cis	rs2562456	0.958	rs2562508	ENSG00000268555.1	RP11-678G14.3	-8.12	4.04e-15	1.67e-12	-0.48	-0.35	Pain;	chr19:21543479	chr19:21570822~21587322:-
THCA	cis	rs10411161	0.752	rs4584941	ENSG00000269483.1	AC006272.1	8.12	4.04e-15	1.67e-12	0.51	0.35	Breast cancer;	chr19:51888888	chr19:51839924~51843324:-
THCA	cis	rs17772222	0.958	rs61579615	ENSG00000258983.2	RP11-507K2.2	8.12	4.05e-15	1.67e-12	0.45	0.35	Coronary artery calcification;	chr14:88400054	chr14:88499334~88515502:+
THCA	cis	rs1858037	0.867	rs2118305	ENSG00000237979.1	AC007389.1	8.12	4.05e-15	1.67e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65378086	chr2:65500993~65502138:-
THCA	cis	rs6723226	0.638	rs6543657	ENSG00000276334.1	AL133243.1	8.12	4.05e-15	1.67e-12	0.39	0.35	Intelligence (multi-trait analysis);	chr2:32480017	chr2:32521927~32523547:+
THCA	cis	rs10875746	0.669	rs11168459	ENSG00000240399.1	RP1-228P16.1	-8.12	4.06e-15	1.68e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48202458	chr12:48054813~48055591:-
THCA	cis	rs8114671	0.967	rs6142320	ENSG00000269202.1	RP4-614O4.12	8.12	4.06e-15	1.68e-12	0.29	0.35	Height;	chr20:35200390	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs6142321	ENSG00000269202.1	RP4-614O4.12	8.12	4.06e-15	1.68e-12	0.29	0.35	Height;	chr20:35200671	chr20:35201747~35203288:-
THCA	cis	rs8081395	0.801	rs12938273	ENSG00000266992.1	DHX40P1	-8.12	4.07e-15	1.68e-12	-0.4	-0.35	White blood cell count;	chr17:59824291	chr17:59976009~60002384:-
THCA	cis	rs8081395	0.836	rs1292061	ENSG00000266992.1	DHX40P1	-8.12	4.07e-15	1.68e-12	-0.4	-0.35	White blood cell count;	chr17:59833869	chr17:59976009~60002384:-
THCA	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	8.12	4.08e-15	1.69e-12	0.42	0.35	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
THCA	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-8.12	4.09e-15	1.69e-12	-0.42	-0.35	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
THCA	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-8.12	4.09e-15	1.69e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
THCA	cis	rs9640161	0.83	rs11768108	ENSG00000261305.1	RP4-584D14.7	8.12	4.09e-15	1.69e-12	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150367061	chr7:150341771~150342607:+
THCA	cis	rs8114671	0.836	rs734308	ENSG00000269202.1	RP4-614O4.12	8.12	4.1e-15	1.69e-12	0.3	0.35	Height;	chr20:34984293	chr20:35201747~35203288:-
THCA	cis	rs11148252	0.904	rs7990581	ENSG00000235660.1	LINC00345	-8.12	4.12e-15	1.7e-12	-0.43	-0.35	Lewy body disease;	chr13:52445298	chr13:52484161~52484680:-
THCA	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-8.12	4.13e-15	1.7e-12	-0.49	-0.35	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
THCA	cis	rs17772222	0.958	rs60213984	ENSG00000258983.2	RP11-507K2.2	8.12	4.13e-15	1.7e-12	0.45	0.35	Coronary artery calcification;	chr14:88401473	chr14:88499334~88515502:+
THCA	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-8.12	4.13e-15	1.71e-12	-0.42	-0.35	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.911	rs2394000	ENSG00000219392.1	RP1-265C24.5	-8.12	4.13e-15	1.71e-12	-0.45	-0.35	Parkinson's disease;	chr6:27719212	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs9393847	ENSG00000219392.1	RP1-265C24.5	-8.12	4.13e-15	1.71e-12	-0.45	-0.35	Parkinson's disease;	chr6:27720194	chr6:28115628~28116551:+
THCA	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	8.12	4.14e-15	1.71e-12	0.42	0.35	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
THCA	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-8.12	4.14e-15	1.71e-12	-0.42	-0.35	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
THCA	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-8.12	4.14e-15	1.71e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
THCA	cis	rs11148252	0.904	rs9568734	ENSG00000235660.1	LINC00345	-8.12	4.16e-15	1.71e-12	-0.43	-0.35	Lewy body disease;	chr13:52430087	chr13:52484161~52484680:-
THCA	cis	rs4664293	0.528	rs1549386	ENSG00000226266.5	AC009961.3	8.12	4.16e-15	1.72e-12	0.42	0.35	Monocyte percentage of white cells;	chr2:159558015	chr2:159670708~159712435:-
THCA	cis	rs7182621	0.509	rs12917012	ENSG00000259363.4	CTD-2054N24.2	-8.12	4.16e-15	1.72e-12	-0.42	-0.35	Colonoscopy-negative controls vs population controls;	chr15:99868778	chr15:99807023~99877148:+
THCA	cis	rs7247513	0.964	rs12104149	ENSG00000230310.1	CTD-2192J16.11	-8.12	4.18e-15	1.72e-12	-0.42	-0.35	Bipolar disorder;	chr19:12610274	chr19:12552597~12553644:+
THCA	cis	rs8081395	0.801	rs2645479	ENSG00000266992.1	DHX40P1	8.12	4.18e-15	1.72e-12	0.41	0.35	White blood cell count;	chr17:59843171	chr17:59976009~60002384:-
THCA	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-8.12	4.2e-15	1.73e-12	-0.42	-0.35	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-8.12	4.2e-15	1.73e-12	-0.42	-0.35	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-8.12	4.2e-15	1.73e-12	-0.42	-0.35	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-8.12	4.2e-15	1.73e-12	-0.42	-0.35	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
THCA	cis	rs3747113	0.865	rs9620384	ENSG00000128262.7	POM121L9P	-8.12	4.21e-15	1.74e-12	-0.39	-0.35	Gut microbiome composition (summer);	chr22:24379380	chr22:24251828~24265525:+
THCA	cis	rs9309473	0.528	rs11126396	ENSG00000163016.8	ALMS1P	8.12	4.21e-15	1.74e-12	0.47	0.35	Metabolite levels;	chr2:73338015	chr2:73644919~73685576:+
THCA	cis	rs737008	0.922	rs11074957	ENSG00000262703.1	RP11-485G7.6	-8.12	4.22e-15	1.74e-12	-0.41	-0.35	Obesity-related traits;	chr16:11284294	chr16:11348143~11349321:-
THCA	cis	rs526231	0.584	rs246914	ENSG00000175749.11	EIF3KP1	8.12	4.23e-15	1.75e-12	0.55	0.35	Primary biliary cholangitis;	chr5:103223706	chr5:103032376~103033031:+
THCA	cis	rs4706831	0.663	rs1984242	ENSG00000272129.1	RP11-250B2.6	8.12	4.24e-15	1.75e-12	0.43	0.35	Joint mobility (Beighton score);	chr6:80341528	chr6:80355424~80356859:+
THCA	cis	rs1005277	0.602	rs1831315	ENSG00000263064.2	RP11-291L22.7	8.12	4.24e-15	1.75e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs1780130	ENSG00000263064.2	RP11-291L22.7	8.12	4.24e-15	1.75e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38448689~38448949:+
THCA	cis	rs9640161	0.83	rs76741564	ENSG00000261305.1	RP4-584D14.7	8.12	4.24e-15	1.75e-12	0.42	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150362440	chr7:150341771~150342607:+
THCA	cis	rs7665090	0.846	rs4496586	ENSG00000246560.2	RP11-10L12.4	8.12	4.25e-15	1.75e-12	0.42	0.35	Primary biliary cholangitis;	chr4:102636154	chr4:102828055~102844075:+
THCA	cis	rs17772222	0.701	rs453112	ENSG00000258789.1	RP11-507K2.3	8.12	4.25e-15	1.75e-12	0.34	0.35	Coronary artery calcification;	chr14:88392657	chr14:88551597~88552493:+
THCA	cis	rs11148252	0.904	rs9536079	ENSG00000235660.1	LINC00345	-8.12	4.26e-15	1.76e-12	-0.43	-0.35	Lewy body disease;	chr13:52456430	chr13:52484161~52484680:-
THCA	cis	rs9549328	0.731	rs2873371	ENSG00000267868.1	RP11-120K24.3	8.12	4.26e-15	1.76e-12	0.37	0.35	Systolic blood pressure;	chr13:112961928	chr13:112964835~112966131:-
THCA	cis	rs1005277	0.579	rs2474587	ENSG00000263064.2	RP11-291L22.7	8.12	4.26e-15	1.76e-12	0.39	0.35	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38448689~38448949:+
THCA	cis	rs1005277	0.579	rs2474588	ENSG00000263064.2	RP11-291L22.7	8.12	4.26e-15	1.76e-12	0.39	0.35	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38448689~38448949:+
THCA	cis	rs984222	0.648	rs6428801	ENSG00000231365.4	RP11-418J17.1	-8.12	4.26e-15	1.76e-12	-0.34	-0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119145867	chr1:119140396~119275973:+
THCA	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-8.12	4.28e-15	1.76e-12	-0.44	-0.35	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
THCA	cis	rs1858037	0.867	rs1553675	ENSG00000237979.1	AC007389.1	-8.11	4.29e-15	1.77e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65343173	chr2:65500993~65502138:-
THCA	cis	rs7176527	1	rs3762169	ENSG00000188388.10	GOLGA6L3	8.11	4.3e-15	1.77e-12	0.52	0.35	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85240472~85247170:+
THCA	cis	rs11603691	1	rs117981067	ENSG00000254662.1	RP11-872D17.4	-8.11	4.3e-15	1.77e-12	-0.67	-0.35	Low high density lipoprotein cholesterol levels;	chr11:57296638	chr11:57325603~57327958:+
THCA	cis	rs11148252	0.904	rs3892337	ENSG00000235660.1	LINC00345	-8.11	4.3e-15	1.77e-12	-0.43	-0.35	Lewy body disease;	chr13:52455350	chr13:52484161~52484680:-
THCA	cis	rs853679	0.76	rs11962305	ENSG00000219392.1	RP1-265C24.5	-8.11	4.3e-15	1.77e-12	-0.5	-0.35	Depression;	chr6:28232159	chr6:28115628~28116551:+
THCA	cis	rs8114671	0.628	rs6060130	ENSG00000269202.1	RP4-614O4.12	-8.11	4.31e-15	1.78e-12	-0.3	-0.35	Height;	chr20:34961516	chr20:35201747~35203288:-
THCA	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	8.11	4.31e-15	1.78e-12	0.33	0.35	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
THCA	cis	rs922182	0.617	rs12324438	ENSG00000275785.1	RP11-111E14.2	-8.11	4.32e-15	1.78e-12	-0.42	-0.35	Blood protein levels;	chr15:63951237	chr15:63890030~63890317:+
THCA	cis	rs7727544	0.606	rs10058074	ENSG00000224431.1	AC063976.7	8.11	4.34e-15	1.78e-12	0.31	0.35	Blood metabolite levels;	chr5:132350453	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.604	rs2069803	ENSG00000237714.1	P4HA2-AS1	8.11	4.34e-15	1.79e-12	0.47	0.35	Blood metabolite levels;	chr5:132064740	chr5:132184876~132192808:+
THCA	cis	rs10208649	0.611	rs75340524	ENSG00000272156.1	RP11-477N3.1	8.11	4.35e-15	1.79e-12	0.51	0.35	Body mass index;	chr2:54068793	chr2:54082554~54085066:+
THCA	cis	rs2739330	0.828	rs4822454	ENSG00000206090.4	AP000350.7	8.11	4.35e-15	1.79e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23939998~23942798:+
THCA	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-8.11	4.36e-15	1.79e-12	-0.42	-0.35	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-8.11	4.36e-15	1.79e-12	-0.42	-0.35	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-8.11	4.36e-15	1.8e-12	-0.42	-0.35	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
THCA	cis	rs240993	0.516	rs173287	ENSG00000230177.1	RP5-1112D6.4	-8.11	4.37e-15	1.8e-12	-0.38	-0.35	Inflammatory skin disease;Psoriasis;	chr6:111276236	chr6:111277932~111278742:+
THCA	cis	rs380904	0.926	rs7842979	ENSG00000254859.1	RP11-661A12.5	-8.11	4.38e-15	1.8e-12	-0.51	-0.35	Venous thromboembolism (SNP x SNP interaction);	chr8:143519726	chr8:143541973~143549729:-
THCA	cis	rs7727544	0.513	rs10065787	ENSG00000237714.1	P4HA2-AS1	8.11	4.39e-15	1.81e-12	0.45	0.35	Blood metabolite levels;	chr5:132100793	chr5:132184876~132192808:+
THCA	cis	rs7674212	0.581	rs13150953	ENSG00000246560.2	RP11-10L12.4	8.11	4.4e-15	1.81e-12	0.43	0.35	Type 2 diabetes;	chr4:103021341	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.556	rs13151569	ENSG00000246560.2	RP11-10L12.4	8.11	4.4e-15	1.81e-12	0.43	0.35	Type 2 diabetes;	chr4:103021633	chr4:102828055~102844075:+
THCA	cis	rs10463554	0.675	rs444020	ENSG00000175749.11	EIF3KP1	8.11	4.41e-15	1.81e-12	0.44	0.35	Parkinson's disease;	chr5:103092139	chr5:103032376~103033031:+
THCA	cis	rs1707322	0.964	rs10890358	ENSG00000234329.1	RP11-767N6.2	8.11	4.41e-15	1.81e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45651039~45651826:-
THCA	cis	rs950169	0.614	rs765524	ENSG00000259728.4	LINC00933	8.11	4.42e-15	1.82e-12	0.5	0.35	Schizophrenia;	chr15:84013030	chr15:84570649~84580175:+
THCA	cis	rs1858037	0.836	rs1396209	ENSG00000237979.1	AC007389.1	8.11	4.42e-15	1.82e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65374100	chr2:65500993~65502138:-
THCA	cis	rs3096299	0.9	rs4785663	ENSG00000274627.1	RP11-104N10.2	8.11	4.44e-15	1.83e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89368480	chr16:89516797~89522217:+
THCA	cis	rs507080	0.769	rs745663	ENSG00000278376.1	RP11-158I9.8	-8.11	4.45e-15	1.83e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118658886	chr11:118791254~118793137:+
THCA	cis	rs507080	0.769	rs7389	ENSG00000278376.1	RP11-158I9.8	8.11	4.45e-15	1.83e-12	0.27	0.35	Serum metabolite levels;	chr11:118657756	chr11:118791254~118793137:+
THCA	cis	rs11096990	0.634	rs2381371	ENSG00000249685.1	RP11-360F5.3	8.11	4.45e-15	1.83e-12	0.42	0.35	Cognitive function;	chr4:39271414	chr4:39133913~39135608:+
THCA	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-8.11	4.46e-15	1.84e-12	-0.44	-0.35	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
THCA	cis	rs12682352	0.602	rs6993494	ENSG00000253893.2	FAM85B	-8.11	4.48e-15	1.84e-12	-0.46	-0.35	Neuroticism;	chr8:8809934	chr8:8167819~8226614:-
THCA	cis	rs7208859	0.623	rs122898	ENSG00000266490.1	CTD-2349P21.9	-8.11	4.48e-15	1.84e-12	-0.48	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30792372~30792833:+
THCA	cis	rs10208649	0.908	rs7559651	ENSG00000272156.1	RP11-477N3.1	8.11	4.48e-15	1.84e-12	0.64	0.35	Body mass index;	chr2:53981801	chr2:54082554~54085066:+
THCA	cis	rs7674212	0.531	rs6816370	ENSG00000246560.2	RP11-10L12.4	8.11	4.48e-15	1.84e-12	0.44	0.35	Type 2 diabetes;	chr4:103018276	chr4:102828055~102844075:+
THCA	cis	rs11096990	0.634	rs11736790	ENSG00000249685.1	RP11-360F5.3	8.11	4.49e-15	1.84e-12	0.42	0.35	Cognitive function;	chr4:39254704	chr4:39133913~39135608:+
THCA	cis	rs240993	0.812	rs9487668	ENSG00000230177.1	RP5-1112D6.4	8.11	4.49e-15	1.85e-12	0.36	0.35	Inflammatory skin disease;Psoriasis;	chr6:111553466	chr6:111277932~111278742:+
THCA	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	8.11	4.49e-15	1.85e-12	0.24	0.35	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
THCA	cis	rs1005277	0.579	rs2505257	ENSG00000263064.2	RP11-291L22.7	8.11	4.5e-15	1.85e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38448689~38448949:+
THCA	cis	rs11673344	0.523	rs36096221	ENSG00000226686.6	LINC01535	8.11	4.51e-15	1.85e-12	0.39	0.35	Obesity-related traits;	chr19:37060838	chr19:37251912~37265535:+
THCA	cis	rs1859596	0.625	rs6946634	ENSG00000234456.6	MAGI2-AS3	8.11	4.52e-15	1.86e-12	0.33	0.35	Reading or mathematical ability;	chr7:79463780	chr7:79452877~79471208:+
THCA	cis	rs1859596	0.646	rs6964015	ENSG00000234456.6	MAGI2-AS3	8.11	4.52e-15	1.86e-12	0.33	0.35	Reading or mathematical ability;	chr7:79463836	chr7:79452877~79471208:+
THCA	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-8.11	4.52e-15	1.86e-12	-0.4	-0.35	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
THCA	cis	rs507080	0.845	rs667982	ENSG00000278376.1	RP11-158I9.8	-8.11	4.52e-15	1.86e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118692058	chr11:118791254~118793137:+
THCA	cis	rs10463554	0.927	rs62362489	ENSG00000175749.11	EIF3KP1	8.11	4.54e-15	1.86e-12	0.46	0.35	Parkinson's disease;	chr5:102909841	chr5:103032376~103033031:+
THCA	cis	rs853679	0.882	rs3757188	ENSG00000280107.1	AL022393.9	-8.11	4.54e-15	1.87e-12	-0.54	-0.35	Depression;	chr6:28139579	chr6:28170845~28172521:+
THCA	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	8.11	4.56e-15	1.87e-12	0.24	0.35	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
THCA	cis	rs1850744	0.702	rs116079424	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9591580	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs115282360	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9591752	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.826	rs114657516	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9592233	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs73805540	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9592340	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.826	rs116509172	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9592499	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.59	rs35509001	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9593247	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.793	rs34495260	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9593700	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs9799502	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9594318	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs57171822	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9594831	chr4:9677308~9677934:+
THCA	cis	rs1850744	1	rs76469957	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9595993	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.793	rs75043790	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9596032	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.826	rs76738832	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9596185	chr4:9677308~9677934:+
THCA	cis	rs1850744	1	rs114290083	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9596370	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs114945335	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9596567	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs73802906	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9596824	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs78422890	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9599141	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs11735905	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9600133	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs73802912	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9600873	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.702	rs73802915	ENSG00000250942.1	ENPP7P11	-8.11	4.56e-15	1.87e-12	-0.51	-0.35	Economic and political preferences;	chr4:9601576	chr4:9677308~9677934:+
THCA	cis	rs7811142	0.83	rs11768967	ENSG00000078319.8	PMS2P1	-8.11	4.57e-15	1.88e-12	-0.48	-0.35	Platelet count;	chr7:100370021	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs7792959	ENSG00000078319.8	PMS2P1	-8.11	4.57e-15	1.88e-12	-0.48	-0.35	Platelet count;	chr7:100374780	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs6975660	ENSG00000078319.8	PMS2P1	-8.11	4.57e-15	1.88e-12	-0.48	-0.35	Platelet count;	chr7:100377643	chr7:100320992~100341908:-
THCA	cis	rs4664293	0.528	rs12466650	ENSG00000226266.5	AC009961.3	8.11	4.58e-15	1.88e-12	0.42	0.35	Monocyte percentage of white cells;	chr2:159552252	chr2:159670708~159712435:-
THCA	cis	rs7811142	0.72	rs7795656	ENSG00000078319.8	PMS2P1	-8.11	4.58e-15	1.88e-12	-0.49	-0.35	Platelet count;	chr7:100352674	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs78256546	ENSG00000078319.8	PMS2P1	-8.11	4.58e-15	1.88e-12	-0.49	-0.35	Platelet count;	chr7:100355347	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs41280971	ENSG00000078319.8	PMS2P1	-8.11	4.58e-15	1.88e-12	-0.49	-0.35	Platelet count;	chr7:100356834	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs11761426	ENSG00000078319.8	PMS2P1	-8.11	4.58e-15	1.88e-12	-0.49	-0.35	Platelet count;	chr7:100359270	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs77861211	ENSG00000078319.8	PMS2P1	-8.11	4.58e-15	1.88e-12	-0.49	-0.35	Platelet count;	chr7:100364473	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs11769057	ENSG00000078319.8	PMS2P1	-8.11	4.58e-15	1.88e-12	-0.49	-0.35	Platelet count;	chr7:100367038	chr7:100320992~100341908:-
THCA	cis	rs6991838	0.67	rs869151	ENSG00000200714.1	Y_RNA	8.11	4.6e-15	1.89e-12	0.41	0.35	Intelligence (multi-trait analysis);	chr8:65726487	chr8:65592731~65592820:+
THCA	cis	rs2439831	0.85	rs16950562	ENSG00000249839.1	AC011330.5	-8.1	4.6e-15	1.89e-12	-0.56	-0.35	Lung cancer in ever smokers;	chr15:43744166	chr15:43663654~43684339:-
THCA	cis	rs11696845	0.899	rs2868198	ENSG00000276223.1	RP4-781B1.5	-8.1	4.61e-15	1.89e-12	-0.43	-0.35	Obesity-related traits;	chr20:44739294	chr20:44746642~44747201:+
THCA	cis	rs748404	0.631	rs2412781	ENSG00000205771.5	CATSPER2P1	8.1	4.62e-15	1.9e-12	0.37	0.35	Lung cancer;	chr15:43375702	chr15:43726918~43747094:-
THCA	cis	rs12908161	0.96	rs17599989	ENSG00000259728.4	LINC00933	8.1	4.62e-15	1.9e-12	0.47	0.35	Schizophrenia;	chr15:84742305	chr15:84570649~84580175:+
THCA	cis	rs11673344	0.523	rs7248948	ENSG00000226686.6	LINC01535	8.1	4.63e-15	1.9e-12	0.39	0.35	Obesity-related traits;	chr19:37056317	chr19:37251912~37265535:+
THCA	cis	rs2408955	0.522	rs3997	ENSG00000258273.1	RP11-370I10.4	8.1	4.63e-15	1.9e-12	0.46	0.35	Glycated hemoglobin levels;	chr12:48087804	chr12:48333755~48333901:-
THCA	cis	rs73607972	0.501	rs73614583	ENSG00000275191.1	RP11-36I17.2	-8.1	4.63e-15	1.9e-12	-0.51	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53554597	chr16:53628256~53628816:-
THCA	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-8.1	4.64e-15	1.9e-12	-0.38	-0.35	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
THCA	cis	rs7015263	1	rs6415565	ENSG00000254231.1	CTD-2284J15.1	-8.1	4.66e-15	1.91e-12	-0.34	-0.35	Intelligence (multi-trait analysis);	chr8:86500667	chr8:86333274~86343314:-
THCA	cis	rs7015263	1	rs7817738	ENSG00000254231.1	CTD-2284J15.1	8.1	4.66e-15	1.91e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr8:86490903	chr8:86333274~86343314:-
THCA	cis	rs7015263	1	rs7459897	ENSG00000254231.1	CTD-2284J15.1	8.1	4.66e-15	1.91e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr8:86493522	chr8:86333274~86343314:-
THCA	cis	rs7015263	1	rs12546331	ENSG00000254231.1	CTD-2284J15.1	8.1	4.66e-15	1.91e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr8:86493739	chr8:86333274~86343314:-
THCA	cis	rs7015263	1	rs9773093	ENSG00000254231.1	CTD-2284J15.1	8.1	4.66e-15	1.91e-12	0.34	0.35	Intelligence (multi-trait analysis);	chr8:86496855	chr8:86333274~86343314:-
THCA	cis	rs9649213	0.593	rs6465683	ENSG00000272950.1	RP11-307C18.1	8.1	4.66e-15	1.91e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98396780	chr7:98322853~98323430:+
THCA	cis	rs7811142	0.83	rs6945952	ENSG00000078319.8	PMS2P1	-8.1	4.67e-15	1.91e-12	-0.49	-0.35	Platelet count;	chr7:100384152	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs73401450	ENSG00000078319.8	PMS2P1	-8.1	4.67e-15	1.91e-12	-0.49	-0.35	Platelet count;	chr7:100384236	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs73401451	ENSG00000078319.8	PMS2P1	-8.1	4.67e-15	1.91e-12	-0.49	-0.35	Platelet count;	chr7:100384272	chr7:100320992~100341908:-
THCA	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	8.1	4.68e-15	1.92e-12	0.42	0.35	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	8.1	4.68e-15	1.92e-12	0.42	0.35	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	8.1	4.68e-15	1.92e-12	0.42	0.35	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	8.1	4.68e-15	1.92e-12	0.42	0.35	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-8.1	4.68e-15	1.92e-12	-0.42	-0.35	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	8.1	4.68e-15	1.92e-12	0.42	0.35	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
THCA	cis	rs7849270	0.837	rs10819463	ENSG00000268707.1	RP11-247A12.7	-8.1	4.69e-15	1.92e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129100958	chr9:129170434~129170940:+
THCA	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-8.1	4.7e-15	1.92e-12	-0.42	-0.35	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
THCA	cis	rs116175783	0.557	rs62194490	ENSG00000227403.1	AC009299.3	8.1	4.7e-15	1.93e-12	0.62	0.35	Intelligence (multi-trait analysis);	chr2:161344287	chr2:161244739~161249050:+
THCA	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	8.1	4.71e-15	1.93e-12	0.42	0.35	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	8.1	4.71e-15	1.93e-12	0.42	0.35	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	8.1	4.71e-15	1.93e-12	0.42	0.35	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	8.1	4.71e-15	1.93e-12	0.42	0.35	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	8.1	4.71e-15	1.93e-12	0.42	0.35	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	8.1	4.71e-15	1.93e-12	0.42	0.35	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
THCA	cis	rs1061377	0.965	rs7690465	ENSG00000249685.1	RP11-360F5.3	8.1	4.73e-15	1.94e-12	0.43	0.35	Uric acid levels;	chr4:39147015	chr4:39133913~39135608:+
THCA	cis	rs3096299	0.9	rs744327	ENSG00000274627.1	RP11-104N10.2	8.1	4.73e-15	1.94e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89372862	chr16:89516797~89522217:+
THCA	cis	rs932287	0.858	rs7109896	ENSG00000254860.4	TMEM9B-AS1	-8.1	4.73e-15	1.94e-12	-0.39	-0.35	Colonoscopy-negative controls vs population controls;	chr11:9032975	chr11:8964675~8977527:+
THCA	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	8.1	4.73e-15	1.94e-12	0.42	0.35	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
THCA	cis	rs1707322	1	rs11211205	ENSG00000234329.1	RP11-767N6.2	8.1	4.74e-15	1.94e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45651039~45651826:-
THCA	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	8.1	4.75e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
THCA	cis	rs853679	0.882	rs9393908	ENSG00000280107.1	AL022393.9	-8.1	4.75e-15	1.95e-12	-0.55	-0.35	Depression;	chr6:28223052	chr6:28170845~28172521:+
THCA	cis	rs853679	0.882	rs9366717	ENSG00000280107.1	AL022393.9	-8.1	4.75e-15	1.95e-12	-0.55	-0.35	Depression;	chr6:28223279	chr6:28170845~28172521:+
THCA	cis	rs7811142	1	rs73161762	ENSG00000242294.5	STAG3L5P	8.1	4.76e-15	1.95e-12	0.24	0.35	Platelet count;	chr7:100417223	chr7:100336079~100351900:+
THCA	cis	rs7674212	0.581	rs11946020	ENSG00000251288.2	RP11-10L12.2	-8.1	4.76e-15	1.95e-12	-0.47	-0.35	Type 2 diabetes;	chr4:103023585	chr4:102751401~102752641:+
THCA	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	8.1	4.77e-15	1.95e-12	0.42	0.35	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
THCA	cis	rs17772222	0.958	rs2297128	ENSG00000258983.2	RP11-507K2.2	8.1	4.77e-15	1.95e-12	0.45	0.35	Coronary artery calcification;	chr14:88469910	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.837	rs1864748	ENSG00000258983.2	RP11-507K2.2	8.1	4.77e-15	1.95e-12	0.45	0.35	Coronary artery calcification;	chr14:88488847	chr14:88499334~88515502:+
THCA	cis	rs7247513	0.859	rs35945052	ENSG00000230310.1	CTD-2192J16.11	-8.1	4.78e-15	1.96e-12	-0.42	-0.35	Bipolar disorder;	chr19:12592416	chr19:12552597~12553644:+
THCA	cis	rs8114671	0.586	rs734111	ENSG00000269202.1	RP4-614O4.12	-8.1	4.78e-15	1.96e-12	-0.3	-0.35	Height;	chr20:34945933	chr20:35201747~35203288:-
THCA	cis	rs910316	0.726	rs12882664	ENSG00000279594.1	RP11-950C14.10	8.1	4.79e-15	1.96e-12	0.32	0.35	Height;	chr14:74980075	chr14:75011269~75012851:-
THCA	cis	rs9532669	0.889	rs1989252	ENSG00000176268.5	CYCSP34	-8.1	4.79e-15	1.96e-12	-0.39	-0.35	Cervical cancer;	chr13:40911532	chr13:40863599~40863902:-
THCA	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	8.1	4.79e-15	1.96e-12	0.33	0.35	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
THCA	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	8.1	4.8e-15	1.96e-12	0.42	0.35	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
THCA	cis	rs17711722	0.522	rs62469933	ENSG00000164669.11	INTS4P1	-8.1	4.82e-15	1.97e-12	-0.44	-0.35	Calcium levels;	chr7:65800652	chr7:65141225~65234216:+
THCA	cis	rs13068223	0.819	rs11917436	ENSG00000243926.1	TIPARP-AS1	8.1	4.84e-15	1.98e-12	0.34	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747839	chr3:156671862~156674378:-
THCA	cis	rs9545047	0.567	rs7321186	ENSG00000227676.3	LINC01068	8.1	4.84e-15	1.98e-12	0.43	0.35	Schizophrenia;	chr13:79383403	chr13:79566727~79571436:+
THCA	cis	rs848490	0.722	rs6976860	ENSG00000214293.7	APTR	8.1	4.84e-15	1.98e-12	0.26	0.35	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77822829	chr7:77657660~77696265:-
THCA	cis	rs4927850	0.958	rs1975582	ENSG00000242086.7	LINC00969	8.1	4.84e-15	1.98e-12	0.34	0.35	Pancreatic cancer;	chr3:196024568	chr3:195658062~195739964:+
THCA	cis	rs3747113	1	rs11703914	ENSG00000128262.7	POM121L9P	-8.1	4.85e-15	1.99e-12	-0.39	-0.35	Gut microbiome composition (summer);	chr22:24371634	chr22:24251828~24265525:+
THCA	cis	rs193541	0.632	rs2910135	ENSG00000263432.2	RN7SL689P	8.1	4.86e-15	1.99e-12	0.41	0.35	Glucose homeostasis traits;	chr5:122894095	chr5:123022487~123022783:-
THCA	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	8.1	4.87e-15	1.99e-12	0.48	0.35	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
THCA	cis	rs748404	0.631	rs6493084	ENSG00000205771.5	CATSPER2P1	-8.1	4.88e-15	1.99e-12	-0.37	-0.35	Lung cancer;	chr15:43355429	chr15:43726918~43747094:-
THCA	cis	rs748404	0.631	rs12905772	ENSG00000205771.5	CATSPER2P1	-8.1	4.88e-15	1.99e-12	-0.37	-0.35	Lung cancer;	chr15:43356246	chr15:43726918~43747094:-
THCA	cis	rs748404	0.676	rs4401024	ENSG00000205771.5	CATSPER2P1	-8.1	4.88e-15	1.99e-12	-0.37	-0.35	Lung cancer;	chr15:43358137	chr15:43726918~43747094:-
THCA	cis	rs17711722	0.522	rs6957759	ENSG00000164669.11	INTS4P1	-8.1	4.88e-15	2e-12	-0.44	-0.35	Calcium levels;	chr7:65806798	chr7:65141225~65234216:+
THCA	cis	rs507080	0.769	rs527290	ENSG00000278376.1	RP11-158I9.8	-8.1	4.88e-15	2e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118644898	chr11:118791254~118793137:+
THCA	cis	rs8114671	0.662	rs6088664	ENSG00000269202.1	RP4-614O4.12	-8.1	4.88e-15	2e-12	-0.3	-0.35	Height;	chr20:34963297	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.836	rs745849	ENSG00000269202.1	RP4-614O4.12	8.1	4.89e-15	2e-12	0.3	0.35	Height;	chr20:34984375	chr20:35201747~35203288:-
THCA	cis	rs1075265	0.597	rs10490471	ENSG00000233266.1	HMGB1P31	8.1	4.9e-15	2e-12	0.44	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54051334~54051760:+
THCA	cis	rs6545883	0.507	rs10169662	ENSG00000271889.1	RP11-493E12.1	-8.1	4.92e-15	2.01e-12	-0.34	-0.35	Tuberculosis;	chr2:61280801	chr2:61151433~61162105:-
THCA	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	8.1	4.92e-15	2.01e-12	0.56	0.35	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
THCA	cis	rs516805	0.886	rs557528	ENSG00000279453.1	RP3-425C14.4	-8.1	4.92e-15	2.01e-12	-0.32	-0.35	Lymphocyte counts;	chr6:122482793	chr6:122436789~122439223:-
THCA	cis	rs516805	0.961	rs559721	ENSG00000279453.1	RP3-425C14.4	-8.1	4.92e-15	2.01e-12	-0.32	-0.35	Lymphocyte counts;	chr6:122482796	chr6:122436789~122439223:-
THCA	cis	rs7811142	0.83	rs6948685	ENSG00000078319.8	PMS2P1	-8.1	4.92e-15	2.01e-12	-0.49	-0.35	Platelet count;	chr7:100372565	chr7:100320992~100341908:-
THCA	cis	rs6545883	0.524	rs12713435	ENSG00000271889.1	RP11-493E12.1	-8.1	4.94e-15	2.02e-12	-0.34	-0.35	Tuberculosis;	chr2:61272654	chr2:61151433~61162105:-
THCA	cis	rs7554547	0.667	rs4846072	ENSG00000199347.1	RNU5E-1	8.1	4.94e-15	2.02e-12	0.47	0.35	Nonsyndromic cleft lip with cleft palate;	chr1:11890334	chr1:11908152~11908271:+
THCA	cis	rs910316	1	rs7145159	ENSG00000279594.1	RP11-950C14.10	8.09	4.96e-15	2.03e-12	0.32	0.35	Height;	chr14:75116565	chr14:75011269~75012851:-
THCA	cis	rs947583	0.588	rs9494389	ENSG00000231028.7	LINC00271	-8.09	4.96e-15	2.03e-12	-0.28	-0.35	Phosphorus levels;	chr6:135794369	chr6:135497801~135716055:+
THCA	cis	rs3096299	0.606	rs4785573	ENSG00000274627.1	RP11-104N10.2	8.09	4.96e-15	2.03e-12	0.39	0.35	Multiple myeloma (IgH translocation);	chr16:89498995	chr16:89516797~89522217:+
THCA	cis	rs66887589	0.87	rs59590064	ENSG00000245958.5	RP11-33B1.1	8.09	4.97e-15	2.03e-12	0.3	0.35	Diastolic blood pressure;	chr4:119618598	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.934	rs6817317	ENSG00000245958.5	RP11-33B1.1	8.09	4.97e-15	2.03e-12	0.3	0.35	Diastolic blood pressure;	chr4:119621672	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.934	rs7672519	ENSG00000245958.5	RP11-33B1.1	8.09	4.97e-15	2.03e-12	0.3	0.35	Diastolic blood pressure;	chr4:119622957	chr4:119454791~119552025:+
THCA	cis	rs11148252	0.904	rs9568732	ENSG00000235660.1	LINC00345	8.09	4.99e-15	2.04e-12	0.43	0.35	Lewy body disease;	chr13:52419277	chr13:52484161~52484680:-
THCA	cis	rs7208859	0.623	rs73271869	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73271872	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.568	rs9907834	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Body mass index;	chr17:30826995	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73271887	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9898858	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs55658077	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9899692	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9906957	ENSG00000266490.1	CTD-2349P21.9	8.09	5e-15	2.04e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30792372~30792833:+
THCA	cis	rs4819052	0.704	rs2297283	ENSG00000215447.6	BX322557.10	-8.09	5e-15	2.04e-12	-0.29	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45263675	chr21:45288052~45291738:+
THCA	cis	rs6991838	0.701	rs7829434	ENSG00000200714.1	Y_RNA	8.09	5e-15	2.04e-12	0.42	0.35	Intelligence (multi-trait analysis);	chr8:65716909	chr8:65592731~65592820:+
THCA	cis	rs9309473	0.607	rs6720094	ENSG00000163016.8	ALMS1P	8.09	5e-15	2.04e-12	0.46	0.35	Metabolite levels;	chr2:73360948	chr2:73644919~73685576:+
THCA	cis	rs17684571	0.808	rs6938003	ENSG00000231441.1	RP11-472M19.2	8.09	5.01e-15	2.05e-12	0.44	0.35	Schizophrenia;	chr6:56753365	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs3002008	ENSG00000231441.1	RP11-472M19.2	8.09	5.01e-15	2.05e-12	0.44	0.35	Schizophrenia;	chr6:56757527	chr6:56844002~56864078:+
THCA	cis	rs10463554	0.895	rs3733939	ENSG00000175749.11	EIF3KP1	8.09	5.01e-15	2.05e-12	0.45	0.35	Parkinson's disease;	chr5:102974462	chr5:103032376~103033031:+
THCA	cis	rs42490	0.664	rs372981	ENSG00000251136.7	RP11-37B2.1	-8.09	5.02e-15	2.05e-12	-0.3	-0.35	Leprosy;	chr8:89784740	chr8:89609409~89757727:-
THCA	cis	rs11603023	1	rs11603023	ENSG00000255239.1	AP002954.6	8.09	5.03e-15	2.05e-12	0.46	0.35	Cholesterol, total;	chr11:118615352	chr11:118688039~118690600:-
THCA	cis	rs7220401	0.789	rs4794859	ENSG00000264007.1	RP11-68I3.10	-8.09	5.03e-15	2.05e-12	-0.4	-0.35	Coronary artery disease;	chr17:29635375	chr17:29621617~29622254:-
THCA	cis	rs3096299	0.933	rs747485	ENSG00000274627.1	RP11-104N10.2	8.09	5.03e-15	2.05e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89407686	chr16:89516797~89522217:+
THCA	cis	rs1850744	0.702	rs55813730	ENSG00000250942.1	ENPP7P11	-8.09	5.03e-15	2.05e-12	-0.51	-0.35	Economic and political preferences;	chr4:9593994	chr4:9677308~9677934:+
THCA	cis	rs1707322	1	rs11211190	ENSG00000234329.1	RP11-767N6.2	8.09	5.03e-15	2.05e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6429580	ENSG00000234329.1	RP11-767N6.2	8.09	5.03e-15	2.05e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45651039~45651826:-
THCA	cis	rs150992	0.57	rs10050423	ENSG00000248489.1	CTD-2007H13.3	-8.09	5.03e-15	2.06e-12	-0.34	-0.35	Body mass index;	chr5:99006312	chr5:98929171~98995013:+
THCA	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-8.09	5.04e-15	2.06e-12	-0.42	-0.35	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
THCA	cis	rs4927850	1	rs7625570	ENSG00000242086.7	LINC00969	8.09	5.07e-15	2.07e-12	0.34	0.35	Pancreatic cancer;	chr3:196020527	chr3:195658062~195739964:+
THCA	cis	rs934734	0.752	rs268132	ENSG00000204929.10	AC074391.1	8.09	5.08e-15	2.07e-12	0.45	0.35	Rheumatoid arthritis;	chr2:65382543	chr2:65436711~66084639:+
THCA	cis	rs875971	0.522	rs781144	ENSG00000237310.1	GS1-124K5.4	8.09	5.08e-15	2.08e-12	0.26	0.35	Aortic root size;	chr7:65975357	chr7:66493706~66495474:+
THCA	cis	rs9828933	0.752	rs17069507	ENSG00000280620.1	SCAANT1	8.09	5.09e-15	2.08e-12	0.71	0.35	Type 2 diabetes;	chr3:63939280	chr3:63911518~63911772:-
THCA	cis	rs17772222	0.701	rs845757	ENSG00000258789.1	RP11-507K2.3	8.09	5.09e-15	2.08e-12	0.33	0.35	Coronary artery calcification;	chr14:88455372	chr14:88551597~88552493:+
THCA	cis	rs270601	0.739	rs3900945	ENSG00000233006.5	AC034220.3	8.09	5.1e-15	2.08e-12	0.27	0.35	Acylcarnitine levels;	chr5:132257177	chr5:132311285~132369916:-
THCA	cis	rs7829975	0.782	rs6990746	ENSG00000253893.2	FAM85B	8.09	5.11e-15	2.09e-12	0.44	0.35	Mood instability;	chr8:8690301	chr8:8167819~8226614:-
THCA	cis	rs4713118	0.869	rs4713121	ENSG00000219392.1	RP1-265C24.5	-8.09	5.12e-15	2.09e-12	-0.47	-0.35	Parkinson's disease;	chr6:27754285	chr6:28115628~28116551:+
THCA	cis	rs2836950	0.805	rs2836961	ENSG00000255568.3	BRWD1-AS2	-8.09	5.13e-15	2.1e-12	-0.28	-0.35	Menarche (age at onset);	chr21:39255094	chr21:39313935~39314962:+
THCA	cis	rs193541	0.632	rs154512	ENSG00000263432.2	RN7SL689P	8.09	5.14e-15	2.1e-12	0.41	0.35	Glucose homeostasis traits;	chr5:122859345	chr5:123022487~123022783:-
THCA	cis	rs4713118	0.869	rs7773070	ENSG00000219392.1	RP1-265C24.5	-8.09	5.15e-15	2.1e-12	-0.45	-0.35	Parkinson's disease;	chr6:27761048	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs7776351	ENSG00000219392.1	RP1-265C24.5	8.09	5.15e-15	2.1e-12	0.45	0.35	Parkinson's disease;	chr6:27758952	chr6:28115628~28116551:+
THCA	cis	rs4072705	0.967	rs4838195	ENSG00000224020.1	MIR181A2HG	-8.09	5.16e-15	2.1e-12	-0.31	-0.35	Menarche (age at onset);	chr9:124588938	chr9:124658467~124698631:+
THCA	cis	rs1707322	0.963	rs11211229	ENSG00000234329.1	RP11-767N6.2	8.09	5.16e-15	2.11e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45651039~45651826:-
THCA	cis	rs5769707	0.967	rs2187891	ENSG00000235111.1	RP1-29C18.8	-8.09	5.17e-15	2.11e-12	-0.41	-0.35	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49612657~49615716:-
THCA	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	8.09	5.19e-15	2.12e-12	0.33	0.35	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
THCA	cis	rs7849270	0.879	rs10819461	ENSG00000268707.1	RP11-247A12.7	-8.09	5.19e-15	2.12e-12	-0.44	-0.35	Blood metabolite ratios;	chr9:129079608	chr9:129170434~129170940:+
THCA	cis	rs4927850	0.881	rs7624638	ENSG00000242086.7	LINC00969	8.09	5.2e-15	2.12e-12	0.34	0.35	Pancreatic cancer;	chr3:196021858	chr3:195658062~195739964:+
THCA	cis	rs12908161	1	rs60957376	ENSG00000259728.4	LINC00933	8.09	5.21e-15	2.12e-12	0.47	0.35	Schizophrenia;	chr15:84737561	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs11632465	ENSG00000259728.4	LINC00933	8.09	5.21e-15	2.12e-12	0.47	0.35	Schizophrenia;	chr15:84738814	chr15:84570649~84580175:+
THCA	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-8.09	5.23e-15	2.13e-12	-0.42	-0.35	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
THCA	cis	rs375066	0.935	rs108775	ENSG00000267058.1	RP11-15A1.3	-8.09	5.24e-15	2.14e-12	-0.29	-0.35	Breast cancer;	chr19:43901770	chr19:43891804~43901805:-
THCA	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	8.09	5.24e-15	2.14e-12	0.46	0.35	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
THCA	cis	rs77204473	0.744	rs12281009	ENSG00000254851.1	RP11-109L13.1	8.09	5.26e-15	2.14e-12	0.85	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117162243	chr11:117135528~117138582:+
THCA	cis	rs507080	0.845	rs481903	ENSG00000278376.1	RP11-158I9.8	-8.09	5.27e-15	2.15e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118697024	chr11:118791254~118793137:+
THCA	cis	rs7714584	1	rs1428551	ENSG00000197083.10	ZNF300P1	8.09	5.27e-15	2.15e-12	0.57	0.35	Crohn's disease;	chr5:150880270	chr5:150930645~150946289:-
THCA	cis	rs4819052	0.788	rs9978857	ENSG00000215447.6	BX322557.10	-8.09	5.27e-15	2.15e-12	-0.3	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285240	chr21:45288052~45291738:+
THCA	cis	rs9309473	0.583	rs6709853	ENSG00000163016.8	ALMS1P	8.09	5.28e-15	2.15e-12	0.46	0.35	Metabolite levels;	chr2:73348937	chr2:73644919~73685576:+
THCA	cis	rs4072705	0.967	rs10760369	ENSG00000224020.1	MIR181A2HG	-8.09	5.28e-15	2.15e-12	-0.31	-0.35	Menarche (age at onset);	chr9:124635121	chr9:124658467~124698631:+
THCA	cis	rs9549328	0.731	rs7983602	ENSG00000267868.1	RP11-120K24.3	8.09	5.29e-15	2.16e-12	0.36	0.35	Systolic blood pressure;	chr13:112966168	chr13:112964835~112966131:-
THCA	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	8.09	5.3e-15	2.16e-12	0.34	0.35	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
THCA	cis	rs9532669	0.963	rs9532662	ENSG00000176268.5	CYCSP34	8.09	5.3e-15	2.16e-12	0.38	0.35	Cervical cancer;	chr13:40926215	chr13:40863599~40863902:-
THCA	cis	rs4713118	0.869	rs9468214	ENSG00000219392.1	RP1-265C24.5	-8.09	5.31e-15	2.17e-12	-0.45	-0.35	Parkinson's disease;	chr6:27745520	chr6:28115628~28116551:+
THCA	cis	rs1850744	0.702	rs6836184	ENSG00000250942.1	ENPP7P11	8.08	5.35e-15	2.18e-12	0.48	0.35	Economic and political preferences;	chr4:9632087	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.536	rs6843869	ENSG00000250942.1	ENPP7P11	8.08	5.35e-15	2.18e-12	0.48	0.35	Economic and political preferences;	chr4:9632827	chr4:9677308~9677934:+
THCA	cis	rs75422866	0.867	rs78912815	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47612065	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73113117	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47617299	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73113139	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47622826	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73113143	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47623060	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.717	rs73113159	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47631318	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.717	rs73113161	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47632361	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs117022227	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47633282	chr12:47706085~47742294:+
THCA	cis	rs75422866	1	rs73102120	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47637280	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs12422974	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47644559	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102127	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47645341	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102140	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47647497	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102148	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47648013	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102151	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47648023	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs75568526	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47649718	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs116302411	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47649788	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102166	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47653769	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102168	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47654010	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs73102171	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47656077	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs76100981	ENSG00000257433.4	RP1-197B17.3	8.08	5.35e-15	2.18e-12	0.54	0.35	Pneumonia;	chr12:47660092	chr12:47706085~47742294:+
THCA	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-8.08	5.35e-15	2.18e-12	-0.64	-0.35	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
THCA	cis	rs7674212	0.531	rs4698875	ENSG00000251288.2	RP11-10L12.2	-8.08	5.36e-15	2.18e-12	-0.48	-0.35	Type 2 diabetes;	chr4:103012211	chr4:102751401~102752641:+
THCA	cis	rs673078	0.607	rs17440893	ENSG00000275409.1	RP11-131L12.4	-8.08	5.37e-15	2.19e-12	-0.43	-0.35	Glucose homeostasis traits;	chr12:118362532	chr12:118430147~118430699:+
THCA	cis	rs507080	0.885	rs693037	ENSG00000278376.1	RP11-158I9.8	-8.08	5.37e-15	2.19e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118682617	chr11:118791254~118793137:+
THCA	cis	rs10266483	0.921	rs687547	ENSG00000227986.1	TRIM60P18	-8.08	5.38e-15	2.19e-12	-0.29	-0.35	Response to statin therapy;	chr7:64284551	chr7:64355078~64356199:+
THCA	cis	rs42490	0.664	rs389848	ENSG00000251136.7	RP11-37B2.1	-8.08	5.38e-15	2.19e-12	-0.3	-0.35	Leprosy;	chr8:89784739	chr8:89609409~89757727:-
THCA	cis	rs934734	0.752	rs268136	ENSG00000204929.10	AC074391.1	-8.08	5.38e-15	2.19e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65380409	chr2:65436711~66084639:+
THCA	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	8.08	5.38e-15	2.19e-12	0.42	0.35	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
THCA	cis	rs934734	0.532	rs6546151	ENSG00000237979.1	AC007389.1	-8.08	5.39e-15	2.2e-12	-0.39	-0.35	Rheumatoid arthritis;	chr2:65449449	chr2:65500993~65502138:-
THCA	cis	rs2274273	0.805	rs8012156	ENSG00000258413.1	RP11-665C16.6	-8.08	5.39e-15	2.2e-12	-0.47	-0.35	Protein biomarker;	chr14:55085782	chr14:55262767~55272075:-
THCA	cis	rs9309473	0.528	rs2091022	ENSG00000163016.8	ALMS1P	8.08	5.41e-15	2.2e-12	0.47	0.35	Metabolite levels;	chr2:73337442	chr2:73644919~73685576:+
THCA	cis	rs1858037	0.867	rs876933	ENSG00000237979.1	AC007389.1	8.08	5.42e-15	2.21e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65382303	chr2:65500993~65502138:-
THCA	cis	rs4927850	1	rs10881564	ENSG00000242086.7	LINC00969	8.08	5.42e-15	2.21e-12	0.34	0.35	Pancreatic cancer;	chr3:196023455	chr3:195658062~195739964:+
THCA	cis	rs2739330	0.828	rs2154593	ENSG00000235689.1	AP000351.13	8.08	5.44e-15	2.21e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:24006305~24008258:-
THCA	cis	rs3096299	0.934	rs9927904	ENSG00000274627.1	RP11-104N10.2	8.08	5.44e-15	2.21e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89396439	chr16:89516797~89522217:+
THCA	cis	rs12168402	0.51	rs1076116	ENSG00000235209.1	CTA-150C2.13	8.08	5.44e-15	2.22e-12	0.45	0.35	Subjective well-being;	chr22:38841832	chr22:38921227~38924708:+
THCA	cis	rs507080	0.922	rs582630	ENSG00000278376.1	RP11-158I9.8	-8.08	5.45e-15	2.22e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118692090	chr11:118791254~118793137:+
THCA	cis	rs507080	0.883	rs527475	ENSG00000278376.1	RP11-158I9.8	-8.08	5.45e-15	2.22e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118692530	chr11:118791254~118793137:+
THCA	cis	rs189798	0.738	rs330911	ENSG00000254340.1	RP11-10A14.3	8.08	5.46e-15	2.22e-12	0.4	0.35	Myopia (pathological);	chr8:9138763	chr8:9141424~9145435:+
THCA	cis	rs922182	0.557	rs6494452	ENSG00000275785.1	RP11-111E14.2	8.08	5.46e-15	2.22e-12	0.41	0.35	Blood protein levels;	chr15:63907009	chr15:63890030~63890317:+
THCA	cis	rs10208649	0.908	rs11887593	ENSG00000272156.1	RP11-477N3.1	8.08	5.47e-15	2.22e-12	0.64	0.35	Body mass index;	chr2:54040638	chr2:54082554~54085066:+
THCA	cis	rs8114671	0.933	rs2103971	ENSG00000269202.1	RP4-614O4.12	8.08	5.48e-15	2.23e-12	0.29	0.35	Height;	chr20:35198453	chr20:35201747~35203288:-
THCA	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	8.08	5.49e-15	2.24e-12	0.35	0.35	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
THCA	cis	rs12554020	1	rs7859267	ENSG00000227603.1	RP11-165J3.6	8.08	5.5e-15	2.24e-12	0.46	0.35	Schizophrenia;	chr9:93426827	chr9:93435332~93437121:-
THCA	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-8.08	5.51e-15	2.24e-12	-0.52	-0.35	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
THCA	cis	rs10208649	0.908	rs9678301	ENSG00000272156.1	RP11-477N3.1	8.08	5.52e-15	2.24e-12	0.67	0.35	Body mass index;	chr2:54014373	chr2:54082554~54085066:+
THCA	cis	rs736801	0.808	rs72797303	ENSG00000237714.1	P4HA2-AS1	8.08	5.52e-15	2.24e-12	0.47	0.35	Mosquito bite size;Breast cancer;	chr5:132460471	chr5:132184876~132192808:+
THCA	cis	rs736801	0.808	rs72797306	ENSG00000237714.1	P4HA2-AS1	8.08	5.52e-15	2.24e-12	0.47	0.35	Mosquito bite size;Breast cancer;	chr5:132465058	chr5:132184876~132192808:+
THCA	cis	rs7811142	0.83	rs3087502	ENSG00000078319.8	PMS2P1	-8.08	5.52e-15	2.25e-12	-0.49	-0.35	Platelet count;	chr7:100357741	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.83	rs61735533	ENSG00000078319.8	PMS2P1	-8.08	5.52e-15	2.25e-12	-0.49	-0.35	Platelet count;	chr7:100358243	chr7:100320992~100341908:-
THCA	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	8.08	5.53e-15	2.25e-12	0.42	0.35	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
THCA	cis	rs13068223	1	rs13095806	ENSG00000243926.1	TIPARP-AS1	-8.08	5.56e-15	2.26e-12	-0.34	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156738271	chr3:156671862~156674378:-
THCA	cis	rs4713118	0.662	rs9380046	ENSG00000226314.6	ZNF192P1	-8.08	5.58e-15	2.27e-12	-0.44	-0.35	Parkinson's disease;	chr6:28062721	chr6:28161781~28169594:+
THCA	cis	rs11992186	0.505	rs7845203	ENSG00000253893.2	FAM85B	-8.08	5.59e-15	2.27e-12	-0.44	-0.35	Neuroticism;	chr8:8287918	chr8:8167819~8226614:-
THCA	cis	rs7176527	0.519	rs12148368	ENSG00000230373.7	GOLGA6L5P	8.08	5.59e-15	2.27e-12	0.37	0.35	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84563274	chr15:84507885~84516814:-
THCA	cis	rs66887589	1	rs66887589	ENSG00000245958.5	RP11-33B1.1	8.08	5.6e-15	2.28e-12	0.31	0.35	Diastolic blood pressure;	chr4:119588124	chr4:119454791~119552025:+
THCA	cis	rs73186030	1	rs55838400	ENSG00000272758.4	RP11-299J3.8	8.08	5.6e-15	2.28e-12	0.43	0.35	Serum parathyroid hormone levels;	chr3:122313446	chr3:122416207~122443180:+
THCA	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-8.08	5.61e-15	2.28e-12	-0.38	-0.35	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
THCA	cis	rs8114671	0.836	rs62213676	ENSG00000269202.1	RP4-614O4.12	8.08	5.61e-15	2.28e-12	0.29	0.35	Height;	chr20:35024873	chr20:35201747~35203288:-
THCA	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	8.08	5.61e-15	2.28e-12	0.42	0.35	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
THCA	cis	rs193541	0.586	rs11241662	ENSG00000263432.2	RN7SL689P	-8.08	5.63e-15	2.29e-12	-0.41	-0.35	Glucose homeostasis traits;	chr5:122846280	chr5:123022487~123022783:-
THCA	cis	rs8114671	0.742	rs6058161	ENSG00000269202.1	RP4-614O4.12	8.08	5.64e-15	2.29e-12	0.29	0.35	Height;	chr20:35032223	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.836	rs4911461	ENSG00000269202.1	RP4-614O4.12	8.08	5.65e-15	2.3e-12	0.29	0.35	Height;	chr20:35042190	chr20:35201747~35203288:-
THCA	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-8.08	5.66e-15	2.3e-12	-0.38	-0.35	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
THCA	cis	rs17772222	0.701	rs376698	ENSG00000258789.1	RP11-507K2.3	8.08	5.68e-15	2.31e-12	0.34	0.35	Coronary artery calcification;	chr14:88391886	chr14:88551597~88552493:+
THCA	cis	rs7674212	0.531	rs4698876	ENSG00000251288.2	RP11-10L12.2	-8.08	5.69e-15	2.31e-12	-0.47	-0.35	Type 2 diabetes;	chr4:103012410	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.531	rs7665026	ENSG00000251288.2	RP11-10L12.2	-8.08	5.69e-15	2.31e-12	-0.47	-0.35	Type 2 diabetes;	chr4:103015491	chr4:102751401~102752641:+
THCA	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	8.07	5.72e-15	2.32e-12	0.56	0.35	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	8.07	5.72e-15	2.32e-12	0.56	0.35	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
THCA	cis	rs180730	1	rs343166	ENSG00000251609.2	SETP12	-8.07	5.73e-15	2.33e-12	-0.56	-0.35	Fasting plasma glucose;	chr4:120897567	chr4:120895494~120897083:-
THCA	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-8.07	5.73e-15	2.33e-12	-0.44	-0.35	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
THCA	cis	rs11673344	0.504	rs4239587	ENSG00000226686.6	LINC01535	8.07	5.73e-15	2.33e-12	0.38	0.35	Obesity-related traits;	chr19:37136211	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs4805202	ENSG00000226686.6	LINC01535	8.07	5.73e-15	2.33e-12	0.38	0.35	Obesity-related traits;	chr19:37136499	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs4805203	ENSG00000226686.6	LINC01535	8.07	5.73e-15	2.33e-12	0.38	0.35	Obesity-related traits;	chr19:37136586	chr19:37251912~37265535:+
THCA	cis	rs42490	0.653	rs40247	ENSG00000251136.7	RP11-37B2.1	-8.07	5.74e-15	2.33e-12	-0.3	-0.35	Leprosy;	chr8:89789744	chr8:89609409~89757727:-
THCA	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-8.07	5.75e-15	2.33e-12	-0.42	-0.35	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	8.07	5.75e-15	2.33e-12	0.42	0.35	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
THCA	cis	rs8081395	0.836	rs2063353	ENSG00000266992.1	DHX40P1	-8.07	5.75e-15	2.33e-12	-0.4	-0.35	White blood cell count;	chr17:59811831	chr17:59976009~60002384:-
THCA	cis	rs984222	0.617	rs4659152	ENSG00000231365.4	RP11-418J17.1	8.07	5.76e-15	2.34e-12	0.34	0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119216235	chr1:119140396~119275973:+
THCA	cis	rs4934494	0.911	rs7098233	ENSG00000232936.4	RP11-80H5.2	-8.07	5.76e-15	2.34e-12	-0.45	-0.35	Red blood cell count;	chr10:89663111	chr10:89645282~89650667:+
THCA	cis	rs11673344	0.504	rs12984458	ENSG00000226686.6	LINC01535	-8.07	5.76e-15	2.34e-12	-0.38	-0.35	Obesity-related traits;	chr19:37138189	chr19:37251912~37265535:+
THCA	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-8.07	5.77e-15	2.34e-12	-0.42	-0.35	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
THCA	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	8.07	5.77e-15	2.34e-12	0.24	0.35	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	8.07	5.77e-15	2.34e-12	0.24	0.35	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
THCA	cis	rs875971	0.522	rs1880556	ENSG00000237310.1	GS1-124K5.4	8.07	5.79e-15	2.35e-12	0.26	0.35	Aortic root size;	chr7:65967557	chr7:66493706~66495474:+
THCA	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	8.07	5.8e-15	2.35e-12	0.42	0.35	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
THCA	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-8.07	5.8e-15	2.36e-12	-0.38	-0.35	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
THCA	cis	rs4934494	1	rs4934494	ENSG00000232936.4	RP11-80H5.2	8.07	5.81e-15	2.36e-12	0.46	0.35	Red blood cell count;	chr10:89687662	chr10:89645282~89650667:+
THCA	cis	rs193541	0.593	rs154499	ENSG00000263432.2	RN7SL689P	8.07	5.82e-15	2.36e-12	0.41	0.35	Glucose homeostasis traits;	chr5:122883971	chr5:123022487~123022783:-
THCA	cis	rs4819052	0.959	rs8130866	ENSG00000237664.1	LINC00316	-8.07	5.82e-15	2.36e-12	-0.38	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45252197	chr21:45338590~45341990:-
THCA	cis	rs4713118	0.869	rs6922574	ENSG00000219392.1	RP1-265C24.5	-8.07	5.83e-15	2.37e-12	-0.45	-0.35	Parkinson's disease;	chr6:27725224	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9348775	ENSG00000219392.1	RP1-265C24.5	-8.07	5.83e-15	2.37e-12	-0.45	-0.35	Parkinson's disease;	chr6:27727550	chr6:28115628~28116551:+
THCA	cis	rs2115630	0.755	rs7169629	ENSG00000225151.9	GOLGA2P7	-8.07	5.84e-15	2.37e-12	-0.44	-0.35	P wave terminal force;	chr15:84648043	chr15:84199311~84230136:-
THCA	cis	rs34375054	0.526	rs883315	ENSG00000279233.1	RP11-158L12.4	8.07	5.84e-15	2.37e-12	0.33	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125192343	chr12:125138245~125141711:+
THCA	cis	rs34375054	0.526	rs2343638	ENSG00000279233.1	RP11-158L12.4	8.07	5.84e-15	2.37e-12	0.33	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125192576	chr12:125138245~125141711:+
THCA	cis	rs8114671	0.869	rs2038503	ENSG00000269202.1	RP4-614O4.12	8.07	5.84e-15	2.37e-12	0.29	0.35	Height;	chr20:35088097	chr20:35201747~35203288:-
THCA	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	8.07	5.85e-15	2.37e-12	0.42	0.35	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
THCA	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-8.07	5.85e-15	2.37e-12	-0.44	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
THCA	cis	rs507080	0.769	rs645637	ENSG00000278376.1	RP11-158I9.8	-8.07	5.86e-15	2.38e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118634373	chr11:118791254~118793137:+
THCA	cis	rs9649213	0.574	rs62478236	ENSG00000272950.1	RP11-307C18.1	8.07	5.86e-15	2.38e-12	0.43	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98401065	chr7:98322853~98323430:+
THCA	cis	rs748404	0.534	rs489509	ENSG00000205771.5	CATSPER2P1	-8.07	5.88e-15	2.39e-12	-0.36	-0.35	Lung cancer;	chr15:43294709	chr15:43726918~43747094:-
THCA	cis	rs34375054	0.526	rs7302475	ENSG00000279233.1	RP11-158L12.4	8.07	5.9e-15	2.39e-12	0.33	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125193340	chr12:125138245~125141711:+
THCA	cis	rs922182	0.617	rs17777266	ENSG00000275785.1	RP11-111E14.2	8.07	5.9e-15	2.39e-12	0.4	0.35	Blood protein levels;	chr15:63949043	chr15:63890030~63890317:+
THCA	cis	rs11971779	0.554	rs11772686	ENSG00000273391.1	RP11-634H22.1	8.07	5.91e-15	2.4e-12	0.34	0.35	Diisocyanate-induced asthma;	chr7:139444625	chr7:139359032~139359566:-
THCA	cis	rs507080	0.922	rs585039	ENSG00000278376.1	RP11-158I9.8	-8.07	5.91e-15	2.4e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118692672	chr11:118791254~118793137:+
THCA	cis	rs11168351	0.833	rs6580652	ENSG00000258273.1	RP11-370I10.4	8.07	5.92e-15	2.4e-12	0.46	0.35	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48333755~48333901:-
THCA	cis	rs1707322	1	rs10890380	ENSG00000234329.1	RP11-767N6.2	8.07	5.93e-15	2.4e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45651039~45651826:-
THCA	cis	rs4713118	0.955	rs9393848	ENSG00000219392.1	RP1-265C24.5	-8.07	5.93e-15	2.4e-12	-0.45	-0.35	Parkinson's disease;	chr6:27720590	chr6:28115628~28116551:+
THCA	cis	rs367615	0.55	rs10060801	ENSG00000249476.1	CTD-2587M2.1	8.07	5.96e-15	2.42e-12	0.35	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109546081	chr5:109237120~109326369:-
THCA	cis	rs3096299	0.566	rs4129126	ENSG00000274627.1	RP11-104N10.2	8.07	5.96e-15	2.42e-12	0.38	0.35	Multiple myeloma (IgH translocation);	chr16:89495067	chr16:89516797~89522217:+
THCA	cis	rs7849270	0.959	rs913276	ENSG00000268707.1	RP11-247A12.7	-8.07	5.98e-15	2.42e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129154885	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs7868408	ENSG00000268707.1	RP11-247A12.7	-8.07	5.98e-15	2.42e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129155585	chr9:129170434~129170940:+
THCA	cis	rs8114671	0.904	rs6060197	ENSG00000269202.1	RP4-614O4.12	8.07	5.99e-15	2.43e-12	0.29	0.35	Height;	chr20:35066512	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.839	rs6142290	ENSG00000269202.1	RP4-614O4.12	8.07	5.99e-15	2.43e-12	0.29	0.35	Height;	chr20:35066869	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.869	rs6060199	ENSG00000269202.1	RP4-614O4.12	8.07	5.99e-15	2.43e-12	0.29	0.35	Height;	chr20:35066970	chr20:35201747~35203288:-
THCA	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	8.07	6e-15	2.43e-12	0.5	0.35	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
THCA	cis	rs7688540	0.61	rs6830496	ENSG00000275426.1	CH17-262A2.1	8.07	6.01e-15	2.43e-12	0.49	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:149738~150317:+
THCA	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	8.07	6.01e-15	2.44e-12	0.42	0.35	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
THCA	cis	rs13068223	0.607	rs193197	ENSG00000243926.1	TIPARP-AS1	-8.07	6.03e-15	2.44e-12	-0.34	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156693943	chr3:156671862~156674378:-
THCA	cis	rs367615	0.659	rs13435970	ENSG00000249476.1	CTD-2587M2.1	8.07	6.03e-15	2.44e-12	0.38	0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109548959	chr5:109237120~109326369:-
THCA	cis	rs8062405	0.54	rs480400	ENSG00000251417.2	RP11-1348G14.4	-8.07	6.04e-15	2.45e-12	-0.33	-0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28802743~28817828:+
THCA	cis	rs7829975	0.66	rs10093926	ENSG00000253893.2	FAM85B	8.07	6.05e-15	2.45e-12	0.45	0.35	Mood instability;	chr8:8691510	chr8:8167819~8226614:-
THCA	cis	rs4934494	0.822	rs3962370	ENSG00000232936.4	RP11-80H5.2	8.07	6.05e-15	2.45e-12	0.45	0.35	Red blood cell count;	chr10:89777763	chr10:89645282~89650667:+
THCA	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-8.07	6.05e-15	2.45e-12	-0.42	-0.35	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
THCA	cis	rs116175783	0.557	rs72876083	ENSG00000227403.1	AC009299.3	8.07	6.06e-15	2.45e-12	0.62	0.35	Intelligence (multi-trait analysis);	chr2:161327527	chr2:161244739~161249050:+
THCA	cis	rs11673344	0.504	rs7252940	ENSG00000226686.6	LINC01535	8.07	6.06e-15	2.46e-12	0.38	0.35	Obesity-related traits;	chr19:37138589	chr19:37251912~37265535:+
THCA	cis	rs9640161	0.83	rs17173682	ENSG00000261305.1	RP4-584D14.7	8.07	6.07e-15	2.46e-12	0.42	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150362513	chr7:150341771~150342607:+
THCA	cis	rs875971	0.505	rs6955582	ENSG00000237310.1	GS1-124K5.4	8.07	6.08e-15	2.47e-12	0.26	0.35	Aortic root size;	chr7:65966699	chr7:66493706~66495474:+
THCA	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-8.07	6.09e-15	2.47e-12	-0.42	-0.35	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
THCA	cis	rs507080	0.883	rs558593	ENSG00000278376.1	RP11-158I9.8	-8.07	6.1e-15	2.47e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118691811	chr11:118791254~118793137:+
THCA	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-8.07	6.1e-15	2.47e-12	-0.42	-0.35	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
THCA	cis	rs7811142	0.83	rs73401443	ENSG00000078319.8	PMS2P1	-8.07	6.11e-15	2.47e-12	-0.48	-0.35	Platelet count;	chr7:100379959	chr7:100320992~100341908:-
THCA	cis	rs934734	0.532	rs10184881	ENSG00000237979.1	AC007389.1	-8.07	6.12e-15	2.48e-12	-0.39	-0.35	Rheumatoid arthritis;	chr2:65457018	chr2:65500993~65502138:-
THCA	cis	rs8114671	0.74	rs3761141	ENSG00000269202.1	RP4-614O4.12	-8.07	6.14e-15	2.49e-12	-0.3	-0.35	Height;	chr20:35150021	chr20:35201747~35203288:-
THCA	cis	rs812925	0.502	rs778150	ENSG00000271889.1	RP11-493E12.1	-8.06	6.16e-15	2.5e-12	-0.33	-0.35	Immature fraction of reticulocytes;	chr2:61381237	chr2:61151433~61162105:-
THCA	cis	rs950169	0.649	rs12911612	ENSG00000259728.4	LINC00933	8.06	6.17e-15	2.5e-12	0.5	0.35	Schizophrenia;	chr15:84022262	chr15:84570649~84580175:+
THCA	cis	rs950169	0.649	rs12905952	ENSG00000259728.4	LINC00933	8.06	6.17e-15	2.5e-12	0.5	0.35	Schizophrenia;	chr15:84022509	chr15:84570649~84580175:+
THCA	cis	rs950169	0.61	rs34529571	ENSG00000259728.4	LINC00933	8.06	6.17e-15	2.5e-12	0.5	0.35	Schizophrenia;	chr15:84023055	chr15:84570649~84580175:+
THCA	cis	rs12554020	1	rs3933797	ENSG00000227603.1	RP11-165J3.6	8.06	6.19e-15	2.51e-12	0.45	0.35	Schizophrenia;	chr9:93423049	chr9:93435332~93437121:-
THCA	cis	rs12554020	1	rs3933796	ENSG00000227603.1	RP11-165J3.6	8.06	6.19e-15	2.51e-12	0.45	0.35	Schizophrenia;	chr9:93423123	chr9:93435332~93437121:-
THCA	cis	rs910316	0.737	rs175072	ENSG00000279594.1	RP11-950C14.10	-8.06	6.19e-15	2.51e-12	-0.32	-0.35	Height;	chr14:75036124	chr14:75011269~75012851:-
THCA	cis	rs910316	0.712	rs175074	ENSG00000279594.1	RP11-950C14.10	-8.06	6.19e-15	2.51e-12	-0.32	-0.35	Height;	chr14:75037751	chr14:75011269~75012851:-
THCA	cis	rs736801	0.808	rs2248116	ENSG00000237714.1	P4HA2-AS1	-8.06	6.23e-15	2.52e-12	-0.46	-0.35	Mosquito bite size;Breast cancer;	chr5:132468655	chr5:132184876~132192808:+
THCA	cis	rs944289	1	rs944289	ENSG00000257826.1	RP11-116N8.4	-8.06	6.23e-15	2.52e-12	-0.37	-0.35	Thyroid cancer;	chr14:36180040	chr14:36061026~36067190:-
THCA	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	8.06	6.24e-15	2.53e-12	0.44	0.35	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
THCA	cis	rs367615	0.842	rs2578484	ENSG00000249476.1	CTD-2587M2.1	-8.06	6.24e-15	2.53e-12	-0.37	-0.35	Colorectal cancer (SNP x SNP interaction);	chr5:109615107	chr5:109237120~109326369:-
THCA	cis	rs1707322	0.928	rs7527244	ENSG00000234329.1	RP11-767N6.2	8.06	6.26e-15	2.53e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45651039~45651826:-
THCA	cis	rs4664293	0.51	rs890096	ENSG00000226266.5	AC009961.3	8.06	6.27e-15	2.54e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159604849	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.51	rs747707	ENSG00000226266.5	AC009961.3	8.06	6.27e-15	2.54e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159609003	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.51	rs6731277	ENSG00000226266.5	AC009961.3	8.06	6.27e-15	2.54e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159610606	chr2:159670708~159712435:-
THCA	cis	rs62103177	0.81	rs62103178	ENSG00000261126.6	RP11-795F19.1	8.06	6.29e-15	2.55e-12	0.4	0.35	Opioid sensitivity;	chr18:79864555	chr18:80046900~80095482:+
THCA	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-8.06	6.31e-15	2.55e-12	-0.56	-0.35	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
THCA	cis	rs812925	0.519	rs1186706	ENSG00000271889.1	RP11-493E12.1	8.06	6.31e-15	2.56e-12	0.33	0.35	Immature fraction of reticulocytes;	chr2:61446259	chr2:61151433~61162105:-
THCA	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-8.06	6.33e-15	2.56e-12	-0.38	-0.35	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
THCA	cis	rs4927850	0.752	rs7618864	ENSG00000242086.7	LINC00969	8.06	6.34e-15	2.57e-12	0.33	0.35	Pancreatic cancer;	chr3:196022690	chr3:195658062~195739964:+
THCA	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	8.06	6.36e-15	2.57e-12	0.42	0.35	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
THCA	cis	rs7829975	0.593	rs2921051	ENSG00000254153.1	CTA-398F10.2	-8.06	6.38e-15	2.58e-12	-0.37	-0.35	Mood instability;	chr8:8462594	chr8:8456909~8461337:-
THCA	cis	rs2836950	0.84	rs12482317	ENSG00000255568.3	BRWD1-AS2	-8.06	6.39e-15	2.58e-12	-0.28	-0.35	Menarche (age at onset);	chr21:39216315	chr21:39313935~39314962:+
THCA	cis	rs66887589	0.934	rs2389873	ENSG00000245958.5	RP11-33B1.1	8.06	6.4e-15	2.59e-12	0.3	0.35	Diastolic blood pressure;	chr4:119633559	chr4:119454791~119552025:+
THCA	cis	rs66887589	0.934	rs4834792	ENSG00000245958.5	RP11-33B1.1	8.06	6.4e-15	2.59e-12	0.3	0.35	Diastolic blood pressure;	chr4:119634541	chr4:119454791~119552025:+
THCA	cis	rs7674212	0.531	rs4698875	ENSG00000246560.2	RP11-10L12.4	8.06	6.42e-15	2.59e-12	0.44	0.35	Type 2 diabetes;	chr4:103012211	chr4:102828055~102844075:+
THCA	cis	rs1707322	1	rs3922887	ENSG00000234329.1	RP11-767N6.2	8.06	6.42e-15	2.59e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs3922886	ENSG00000234329.1	RP11-767N6.2	8.06	6.42e-15	2.59e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45651039~45651826:-
THCA	cis	rs17772222	0.958	rs2274737	ENSG00000258983.2	RP11-507K2.2	8.06	6.42e-15	2.59e-12	0.44	0.35	Coronary artery calcification;	chr14:88469307	chr14:88499334~88515502:+
THCA	cis	rs748404	0.587	rs9920879	ENSG00000205771.5	CATSPER2P1	-8.06	6.44e-15	2.6e-12	-0.37	-0.35	Lung cancer;	chr15:43347572	chr15:43726918~43747094:-
THCA	cis	rs748404	0.631	rs7166812	ENSG00000205771.5	CATSPER2P1	-8.06	6.44e-15	2.6e-12	-0.37	-0.35	Lung cancer;	chr15:43352562	chr15:43726918~43747094:-
THCA	cis	rs7015263	1	rs11781016	ENSG00000254231.1	CTD-2284J15.1	-8.06	6.45e-15	2.61e-12	-0.34	-0.35	Intelligence (multi-trait analysis);	chr8:86517069	chr8:86333274~86343314:-
THCA	cis	rs4664293	0.51	rs66537229	ENSG00000226266.5	AC009961.3	8.06	6.47e-15	2.61e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159624095	chr2:159670708~159712435:-
THCA	cis	rs1993293	1	rs1993293	ENSG00000259363.4	CTD-2054N24.2	8.06	6.48e-15	2.62e-12	0.41	0.35	Coronary artery calcification;	chr15:99757458	chr15:99807023~99877148:+
THCA	cis	rs2712184	0.729	rs4674115	ENSG00000229352.1	AC007563.3	-8.06	6.52e-15	2.63e-12	-0.42	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216794905	chr2:216799608~216805335:+
THCA	cis	rs7714584	1	rs2004711	ENSG00000197083.10	ZNF300P1	8.06	6.58e-15	2.66e-12	0.57	0.35	Crohn's disease;	chr5:150845506	chr5:150930645~150946289:-
THCA	cis	rs9649213	0.593	rs6465662	ENSG00000272950.1	RP11-307C18.1	8.05	6.61e-15	2.67e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98288489	chr7:98322853~98323430:+
THCA	cis	rs11673344	0.504	rs4806407	ENSG00000226686.6	LINC01535	-8.05	6.61e-15	2.67e-12	-0.38	-0.35	Obesity-related traits;	chr19:37097849	chr19:37251912~37265535:+
THCA	cis	rs4927850	0.752	rs7624460	ENSG00000242086.7	LINC00969	8.05	6.61e-15	2.67e-12	0.33	0.35	Pancreatic cancer;	chr3:196021659	chr3:195658062~195739964:+
THCA	cis	rs42490	0.716	rs40547	ENSG00000251136.7	RP11-37B2.1	-8.05	6.62e-15	2.67e-12	-0.29	-0.35	Leprosy;	chr8:89817685	chr8:89609409~89757727:-
THCA	cis	rs944289	0.966	rs1169146	ENSG00000257826.1	RP11-116N8.4	-8.05	6.62e-15	2.67e-12	-0.37	-0.35	Thyroid cancer;	chr14:36163563	chr14:36061026~36067190:-
THCA	cis	rs9649213	0.593	rs7458551	ENSG00000272950.1	RP11-307C18.1	8.05	6.63e-15	2.68e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98322855	chr7:98322853~98323430:+
THCA	cis	rs1859596	0.625	rs7791175	ENSG00000234456.6	MAGI2-AS3	8.05	6.63e-15	2.68e-12	0.33	0.35	Reading or mathematical ability;	chr7:79474901	chr7:79452877~79471208:+
THCA	cis	rs73607972	0.696	rs7201237	ENSG00000275191.1	RP11-36I17.2	-8.05	6.64e-15	2.68e-12	-0.49	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53526005	chr16:53628256~53628816:-
THCA	cis	rs9309473	0.583	rs6705203	ENSG00000163016.8	ALMS1P	8.05	6.65e-15	2.69e-12	0.47	0.35	Metabolite levels;	chr2:73347472	chr2:73644919~73685576:+
THCA	cis	rs6545883	0.558	rs7587389	ENSG00000271889.1	RP11-493E12.1	-8.05	6.65e-15	2.69e-12	-0.34	-0.35	Tuberculosis;	chr2:61422656	chr2:61151433~61162105:-
THCA	cis	rs375066	0.901	rs1978723	ENSG00000267058.1	RP11-15A1.3	8.05	6.66e-15	2.69e-12	0.28	0.35	Breast cancer;	chr19:43879648	chr19:43891804~43901805:-
THCA	cis	rs4664293	0.546	rs72956113	ENSG00000226266.5	AC009961.3	8.05	6.67e-15	2.69e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159631132	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.51	rs66571608	ENSG00000226266.5	AC009961.3	8.05	6.67e-15	2.69e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159635851	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.51	rs66589863	ENSG00000226266.5	AC009961.3	8.05	6.67e-15	2.69e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159649684	chr2:159670708~159712435:-
THCA	cis	rs12908161	0.959	rs1051168	ENSG00000225151.9	GOLGA2P7	-8.05	6.67e-15	2.69e-12	-0.51	-0.35	Schizophrenia;	chr15:84657289	chr15:84199311~84230136:-
THCA	cis	rs7208859	0.623	rs9899268	ENSG00000264538.5	SUZ12P1	-8.05	6.68e-15	2.7e-12	-0.36	-0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30709299~30790908:+
THCA	cis	rs6565180	0.888	rs8060853	ENSG00000183604.13	SMG1P5	8.05	6.68e-15	2.7e-12	0.38	0.35	Tonsillectomy;	chr16:30392537	chr16:30267553~30335374:-
THCA	cis	rs1858037	0.867	rs964505	ENSG00000237979.1	AC007389.1	8.05	6.69e-15	2.7e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65396055	chr2:65500993~65502138:-
THCA	cis	rs1858037	0.867	rs67817304	ENSG00000237979.1	AC007389.1	8.05	6.69e-15	2.7e-12	0.43	0.35	Rheumatoid arthritis;	chr2:65346982	chr2:65500993~65502138:-
THCA	cis	rs7849270	1	rs9697030	ENSG00000268707.1	RP11-247A12.7	-8.05	6.72e-15	2.71e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129157902	chr9:129170434~129170940:+
THCA	cis	rs4927850	0.501	rs9881504	ENSG00000231464.1	AC024937.4	8.05	6.72e-15	2.71e-12	0.43	0.35	Pancreatic cancer;	chr3:195929743	chr3:195996738~195998233:+
THCA	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	8.05	6.72e-15	2.71e-12	0.23	0.35	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	8.05	6.72e-15	2.71e-12	0.23	0.35	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	8.05	6.72e-15	2.71e-12	0.23	0.35	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	8.05	6.72e-15	2.71e-12	0.23	0.35	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	8.05	6.72e-15	2.71e-12	0.23	0.35	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
THCA	cis	rs8114671	0.836	rs1885114	ENSG00000269202.1	RP4-614O4.12	8.05	6.72e-15	2.71e-12	0.3	0.35	Height;	chr20:34989558	chr20:35201747~35203288:-
THCA	cis	rs42490	0.625	rs39519	ENSG00000251136.7	RP11-37B2.1	8.05	6.72e-15	2.71e-12	0.3	0.35	Leprosy;	chr8:89833814	chr8:89609409~89757727:-
THCA	cis	rs2562456	0.874	rs2562408	ENSG00000268555.1	RP11-678G14.3	-8.05	6.74e-15	2.72e-12	-0.48	-0.35	Pain;	chr19:21527079	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.874	rs2562417	ENSG00000268555.1	RP11-678G14.3	-8.05	6.74e-15	2.72e-12	-0.48	-0.35	Pain;	chr19:21528400	chr19:21570822~21587322:-
THCA	cis	rs1707322	1	rs4660331	ENSG00000234329.1	RP11-767N6.2	8.05	6.76e-15	2.73e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45651039~45651826:-
THCA	cis	rs847577	0.646	rs10270222	ENSG00000272950.1	RP11-307C18.1	-8.05	6.76e-15	2.73e-12	-0.43	-0.35	Breast cancer;	chr7:98152487	chr7:98322853~98323430:+
THCA	cis	rs10266483	0.921	rs624257	ENSG00000227986.1	TRIM60P18	8.05	6.78e-15	2.74e-12	0.28	0.35	Response to statin therapy;	chr7:64284848	chr7:64355078~64356199:+
THCA	cis	rs10050311	0.79	rs76583174	ENSG00000251411.1	RP11-397E7.4	-8.05	6.78e-15	2.74e-12	-0.44	-0.35	Insulin-related traits;	chr4:86917234	chr4:86913266~86914817:-
THCA	cis	rs2712184	0.756	rs2712182	ENSG00000229352.1	AC007563.3	-8.05	6.78e-15	2.74e-12	-0.41	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216782802	chr2:216799608~216805335:+
THCA	cis	rs8081395	0.805	rs1295927	ENSG00000266992.1	DHX40P1	8.05	6.79e-15	2.74e-12	0.4	0.35	White blood cell count;	chr17:59852174	chr17:59976009~60002384:-
THCA	cis	rs10463554	0.927	rs6862616	ENSG00000175749.11	EIF3KP1	8.05	6.79e-15	2.74e-12	0.45	0.35	Parkinson's disease;	chr5:102910334	chr5:103032376~103033031:+
THCA	cis	rs1707322	1	rs4298677	ENSG00000234329.1	RP11-767N6.2	8.05	6.79e-15	2.74e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45651039~45651826:-
THCA	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-8.05	6.8e-15	2.74e-12	-0.5	-0.35	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
THCA	cis	rs910316	1	rs175449	ENSG00000279594.1	RP11-950C14.10	-8.05	6.8e-15	2.74e-12	-0.32	-0.35	Height;	chr14:75124143	chr14:75011269~75012851:-
THCA	cis	rs910316	0.935	rs175448	ENSG00000279594.1	RP11-950C14.10	-8.05	6.8e-15	2.74e-12	-0.32	-0.35	Height;	chr14:75124368	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs175442	ENSG00000279594.1	RP11-950C14.10	-8.05	6.8e-15	2.74e-12	-0.32	-0.35	Height;	chr14:75136861	chr14:75011269~75012851:-
THCA	cis	rs910316	1	rs8003506	ENSG00000279594.1	RP11-950C14.10	-8.05	6.8e-15	2.75e-12	-0.32	-0.35	Height;	chr14:75119585	chr14:75011269~75012851:-
THCA	cis	rs12928939	0.637	rs8046629	ENSG00000260886.1	TAT-AS1	8.05	6.81e-15	2.75e-12	0.46	0.35	Post bronchodilator FEV1;	chr16:71609213	chr16:71565789~71578187:+
THCA	cis	rs6844153	0.938	rs12646473	ENSG00000240005.4	RP11-293A21.1	-8.05	6.81e-15	2.75e-12	-0.47	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26873833	chr4:26859806~26860599:-
THCA	cis	rs2562456	0.876	rs11085465	ENSG00000268555.1	RP11-678G14.3	-8.05	6.81e-15	2.75e-12	-0.48	-0.35	Pain;	chr19:21568988	chr19:21570822~21587322:-
THCA	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-8.05	6.81e-15	2.75e-12	-0.42	-0.35	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
THCA	cis	rs7849270	1	rs10760589	ENSG00000268707.1	RP11-247A12.7	-8.05	6.81e-15	2.75e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129144014	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.851	rs1819381	ENSG00000268707.1	RP11-247A12.7	-8.05	6.81e-15	2.75e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129145728	chr9:129170434~129170940:+
THCA	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-8.05	6.82e-15	2.75e-12	-0.42	-0.35	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
THCA	cis	rs910316	0.789	rs12894419	ENSG00000279594.1	RP11-950C14.10	8.05	6.82e-15	2.75e-12	0.32	0.35	Height;	chr14:75005099	chr14:75011269~75012851:-
THCA	cis	rs8114671	0.836	rs6060165	ENSG00000269202.1	RP4-614O4.12	8.05	6.83e-15	2.75e-12	0.29	0.35	Height;	chr20:35031677	chr20:35201747~35203288:-
THCA	cis	rs7849270	1	rs10988223	ENSG00000268707.1	RP11-247A12.7	-8.05	6.83e-15	2.76e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129140742	chr9:129170434~129170940:+
THCA	cis	rs7191700	0.601	rs243329	ENSG00000262703.1	RP11-485G7.6	8.05	6.84e-15	2.76e-12	0.38	0.35	Multiple sclerosis;	chr16:11258456	chr16:11348143~11349321:-
THCA	cis	rs17711722	0.523	rs313812	ENSG00000164669.11	INTS4P1	8.05	6.84e-15	2.76e-12	0.44	0.35	Calcium levels;	chr7:66040056	chr7:65141225~65234216:+
THCA	cis	rs3096299	0.606	rs8052103	ENSG00000274627.1	RP11-104N10.2	-8.05	6.87e-15	2.77e-12	-0.38	-0.35	Multiple myeloma (IgH translocation);	chr16:89474835	chr16:89516797~89522217:+
THCA	cis	rs42490	0.716	rs42346	ENSG00000251136.7	RP11-37B2.1	8.05	6.87e-15	2.77e-12	0.29	0.35	Leprosy;	chr8:89816829	chr8:89609409~89757727:-
THCA	cis	rs910316	0.763	rs12588981	ENSG00000279594.1	RP11-950C14.10	8.05	6.88e-15	2.77e-12	0.32	0.35	Height;	chr14:74993858	chr14:75011269~75012851:-
THCA	cis	rs11214589	0.905	rs2186799	ENSG00000270179.1	RP11-159N11.4	-8.05	6.88e-15	2.77e-12	-0.36	-0.35	Neuroticism;	chr11:113371811	chr11:113368478~113369117:+
THCA	cis	rs737008	0.922	rs1559394	ENSG00000262636.1	CTD-3088G3.4	-8.05	6.88e-15	2.78e-12	-0.45	-0.35	Obesity-related traits;	chr16:11275348	chr16:11380859~11381118:-
THCA	cis	rs7849270	0.959	rs10760591	ENSG00000268707.1	RP11-247A12.7	-8.05	6.89e-15	2.78e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129152749	chr9:129170434~129170940:+
THCA	cis	rs7849270	1	rs10988232	ENSG00000268707.1	RP11-247A12.7	-8.05	6.89e-15	2.78e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129153069	chr9:129170434~129170940:+
THCA	cis	rs7849270	0.959	rs10988233	ENSG00000268707.1	RP11-247A12.7	-8.05	6.89e-15	2.78e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129153647	chr9:129170434~129170940:+
THCA	cis	rs8114671	0.836	rs3746432	ENSG00000269202.1	RP4-614O4.12	8.05	6.9e-15	2.78e-12	0.29	0.35	Height;	chr20:35004960	chr20:35201747~35203288:-
THCA	cis	rs62103177	0.733	rs62103232	ENSG00000261126.6	RP11-795F19.1	8.05	6.91e-15	2.79e-12	0.4	0.35	Opioid sensitivity;	chr18:79875553	chr18:80046900~80095482:+
THCA	cis	rs8114671	0.836	rs6142284	ENSG00000269202.1	RP4-614O4.12	8.05	6.91e-15	2.79e-12	0.29	0.35	Height;	chr20:35053564	chr20:35201747~35203288:-
THCA	cis	rs9500256	0.967	rs1012500	ENSG00000215190.7	LINC00680	-8.05	6.91e-15	2.79e-12	-0.4	-0.35	Eosinophilic esophagitis (pediatric);	chr6:57978391	chr6:57946074~57961501:-
THCA	cis	rs673078	0.607	rs17512483	ENSG00000275409.1	RP11-131L12.4	8.05	6.93e-15	2.8e-12	0.47	0.35	Glucose homeostasis traits;	chr12:118312380	chr12:118430147~118430699:+
THCA	cis	rs11051970	0.879	rs73081911	ENSG00000274964.1	RP11-817I4.1	-8.05	6.94e-15	2.8e-12	-0.41	-0.35	Response to tocilizumab in rheumatoid arthritis;	chr12:32386190	chr12:32339368~32340724:+
THCA	cis	rs6545883	0.56	rs11677776	ENSG00000271889.1	RP11-493E12.1	-8.05	6.96e-15	2.81e-12	-0.34	-0.35	Tuberculosis;	chr2:61275978	chr2:61151433~61162105:-
THCA	cis	rs42490	0.716	rs43135	ENSG00000251136.7	RP11-37B2.1	-8.05	6.96e-15	2.81e-12	-0.29	-0.35	Leprosy;	chr8:89823722	chr8:89609409~89757727:-
THCA	cis	rs2688482	0.512	rs3103953	ENSG00000224769.1	AC069213.1	-8.05	6.97e-15	2.81e-12	-0.53	-0.35	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195614947~195620233:+
THCA	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	8.05	6.97e-15	2.81e-12	0.42	0.35	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
THCA	cis	rs1707322	1	rs10890350	ENSG00000234329.1	RP11-767N6.2	8.05	6.98e-15	2.81e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45651039~45651826:-
THCA	cis	rs10875746	0.669	rs10467101	ENSG00000240399.1	RP1-228P16.1	-8.05	7.04e-15	2.84e-12	-0.38	-0.35	Longevity (90 years and older);	chr12:48213954	chr12:48054813~48055591:-
THCA	cis	rs73607972	0.696	rs7197014	ENSG00000275191.1	RP11-36I17.2	-8.05	7.05e-15	2.84e-12	-0.49	-0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53525165	chr16:53628256~53628816:-
THCA	cis	rs507080	0.922	rs12788848	ENSG00000278376.1	RP11-158I9.8	-8.05	7.07e-15	2.85e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118683079	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs4474473	ENSG00000278376.1	RP11-158I9.8	-8.05	7.07e-15	2.85e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118683180	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs12796373	ENSG00000278376.1	RP11-158I9.8	-8.05	7.07e-15	2.85e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118684230	chr11:118791254~118793137:+
THCA	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	8.04	7.1e-15	2.86e-12	0.47	0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000235689.1	AP000351.13	8.04	7.11e-15	2.86e-12	0.44	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:24006305~24008258:-
THCA	cis	rs8081395	0.836	rs2150879	ENSG00000266992.1	DHX40P1	-8.04	7.13e-15	2.87e-12	-0.4	-0.35	White blood cell count;	chr17:59781849	chr17:59976009~60002384:-
THCA	cis	rs812925	0.537	rs2463097	ENSG00000271889.1	RP11-493E12.1	-8.04	7.13e-15	2.87e-12	-0.33	-0.35	Immature fraction of reticulocytes;	chr2:61387166	chr2:61151433~61162105:-
THCA	cis	rs7015263	1	rs4961196	ENSG00000254231.1	CTD-2284J15.1	-8.04	7.15e-15	2.88e-12	-0.34	-0.35	Intelligence (multi-trait analysis);	chr8:86489481	chr8:86333274~86343314:-
THCA	cis	rs2562456	0.917	rs2681376	ENSG00000268555.1	RP11-678G14.3	-8.04	7.16e-15	2.88e-12	-0.49	-0.35	Pain;	chr19:21532723	chr19:21570822~21587322:-
THCA	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-8.04	7.17e-15	2.89e-12	-0.42	-0.35	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
THCA	cis	rs7811142	0.775	rs1636980	ENSG00000078319.8	PMS2P1	8.04	7.19e-15	2.9e-12	0.49	0.35	Platelet count;	chr7:100341241	chr7:100320992~100341908:-
THCA	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	8.04	7.23e-15	2.91e-12	0.42	0.35	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
THCA	cis	rs193541	0.555	rs2438151	ENSG00000263432.2	RN7SL689P	8.04	7.23e-15	2.91e-12	0.41	0.35	Glucose homeostasis traits;	chr5:122863502	chr5:123022487~123022783:-
THCA	cis	rs507080	0.885	rs4938530	ENSG00000278376.1	RP11-158I9.8	-8.04	7.23e-15	2.91e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118689861	chr11:118791254~118793137:+
THCA	cis	rs7727544	0.716	rs7720230	ENSG00000224431.1	AC063976.7	8.04	7.24e-15	2.91e-12	0.31	0.35	Blood metabolite levels;	chr5:132256712	chr5:132199456~132203487:+
THCA	cis	rs7580658	0.637	rs9636236	ENSG00000236682.1	AC068282.3	-8.04	7.26e-15	2.92e-12	-0.45	-0.35	Protein C levels;	chr2:127225365	chr2:127389130~127400580:+
THCA	cis	rs910316	0.763	rs4556	ENSG00000279594.1	RP11-950C14.10	8.04	7.26e-15	2.92e-12	0.32	0.35	Height;	chr14:75009368	chr14:75011269~75012851:-
THCA	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-8.04	7.26e-15	2.92e-12	-0.59	-0.35	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
THCA	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	8.04	7.27e-15	2.93e-12	0.35	0.35	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
THCA	cis	rs7849270	0.959	rs2297111	ENSG00000268707.1	RP11-247A12.7	-8.04	7.28e-15	2.93e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129142015	chr9:129170434~129170940:+
THCA	cis	rs6545883	0.542	rs7584500	ENSG00000271889.1	RP11-493E12.1	8.04	7.28e-15	2.93e-12	0.33	0.35	Tuberculosis;	chr2:61464980	chr2:61151433~61162105:-
THCA	cis	rs11673344	0.523	rs7258438	ENSG00000226686.6	LINC01535	8.04	7.29e-15	2.93e-12	0.38	0.35	Obesity-related traits;	chr19:37032534	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.503	rs10414520	ENSG00000226686.6	LINC01535	8.04	7.29e-15	2.93e-12	0.38	0.35	Obesity-related traits;	chr19:37057279	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.503	rs1829603	ENSG00000226686.6	LINC01535	8.04	7.29e-15	2.93e-12	0.38	0.35	Obesity-related traits;	chr19:37065396	chr19:37251912~37265535:+
THCA	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-8.04	7.3e-15	2.94e-12	-0.33	-0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
THCA	cis	rs2427308	0.643	rs477859	ENSG00000273619.1	RP5-908M14.9	8.04	7.34e-15	2.95e-12	0.31	0.35	Colorectal cancer;	chr20:62362541	chr20:62386303~62386970:-
THCA	cis	rs9475752	0.552	rs6925518	ENSG00000231441.1	RP11-472M19.2	8.04	7.35e-15	2.96e-12	0.42	0.35	Menarche (age at onset);	chr6:56876405	chr6:56844002~56864078:+
THCA	cis	rs9475752	0.552	rs6905658	ENSG00000231441.1	RP11-472M19.2	8.04	7.35e-15	2.96e-12	0.42	0.35	Menarche (age at onset);	chr6:56876523	chr6:56844002~56864078:+
THCA	cis	rs4927850	1	rs10881563	ENSG00000226155.1	AC124944.3	-8.04	7.35e-15	2.96e-12	-0.42	-0.35	Pancreatic cancer;	chr3:196023354	chr3:195912049~195913986:+
THCA	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-8.04	7.39e-15	2.97e-12	-0.41	-0.35	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-8.04	7.39e-15	2.97e-12	-0.41	-0.35	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
THCA	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-8.04	7.41e-15	2.98e-12	-0.42	-0.35	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
THCA	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-8.04	7.42e-15	2.98e-12	-0.41	-0.35	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-8.04	7.42e-15	2.98e-12	-0.41	-0.35	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-8.04	7.42e-15	2.98e-12	-0.41	-0.35	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
THCA	cis	rs831571	0.955	rs35839	ENSG00000280620.1	SCAANT1	8.04	7.44e-15	2.99e-12	0.56	0.35	Type 2 diabetes;	chr3:64027741	chr3:63911518~63911772:-
THCA	cis	rs736801	0.74	rs12515180	ENSG00000237714.1	P4HA2-AS1	8.04	7.44e-15	2.99e-12	0.48	0.35	Mosquito bite size;Breast cancer;	chr5:132449992	chr5:132184876~132192808:+
THCA	cis	rs748404	0.631	rs28702649	ENSG00000205771.5	CATSPER2P1	-8.04	7.44e-15	2.99e-12	-0.37	-0.35	Lung cancer;	chr15:43356431	chr15:43726918~43747094:-
THCA	cis	rs9640161	0.83	rs35840727	ENSG00000261305.1	RP4-584D14.7	8.04	7.46e-15	3e-12	0.43	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150366115	chr7:150341771~150342607:+
THCA	cis	rs881375	0.902	rs7021880	ENSG00000226752.6	PSMD5-AS1	8.04	7.47e-15	3e-12	0.46	0.35	Rheumatoid arthritis;	chr9:120911612	chr9:120824828~120854385:+
THCA	cis	rs9473147	0.543	rs4715019	ENSG00000270761.1	RP11-385F7.1	-8.04	7.47e-15	3e-12	-0.28	-0.35	Platelet distribution width;Mean platelet volume;	chr6:47479305	chr6:47477243~47477572:-
THCA	cis	rs910316	1	rs3742778	ENSG00000279594.1	RP11-950C14.10	-8.04	7.48e-15	3.01e-12	-0.32	-0.35	Height;	chr14:75071514	chr14:75011269~75012851:-
THCA	cis	rs2836950	0.805	rs62223042	ENSG00000255568.3	BRWD1-AS2	-8.04	7.5e-15	3.01e-12	-0.28	-0.35	Menarche (age at onset);	chr21:39311814	chr21:39313935~39314962:+
THCA	cis	rs7247513	0.964	rs4414604	ENSG00000230310.1	CTD-2192J16.11	-8.04	7.5e-15	3.01e-12	-0.42	-0.35	Bipolar disorder;	chr19:12591623	chr19:12552597~12553644:+
THCA	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	8.04	7.51e-15	3.02e-12	0.48	0.35	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
THCA	cis	rs860295	1	rs822527	ENSG00000225855.5	RUSC1-AS1	-8.04	7.56e-15	3.04e-12	-0.23	-0.35	Body mass index;	chr1:155768262	chr1:155316863~155324176:-
THCA	cis	rs507080	0.922	rs558781	ENSG00000278376.1	RP11-158I9.8	-8.04	7.56e-15	3.04e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118693688	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs508640	ENSG00000278376.1	RP11-158I9.8	-8.04	7.56e-15	3.04e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118693704	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs471227	ENSG00000278376.1	RP11-158I9.8	-8.04	7.56e-15	3.04e-12	-0.28	-0.35	Serum metabolite levels;	chr11:118693892	chr11:118791254~118793137:+
THCA	cis	rs4934494	0.727	rs1590566	ENSG00000232936.4	RP11-80H5.2	8.04	7.57e-15	3.04e-12	0.45	0.35	Red blood cell count;	chr10:89778781	chr10:89645282~89650667:+
THCA	cis	rs7247513	0.964	rs2042946	ENSG00000230310.1	CTD-2192J16.11	-8.04	7.57e-15	3.04e-12	-0.42	-0.35	Bipolar disorder;	chr19:12594540	chr19:12552597~12553644:+
THCA	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	8.04	7.58e-15	3.04e-12	0.42	0.35	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
THCA	cis	rs1707322	1	rs7531911	ENSG00000234329.1	RP11-767N6.2	8.04	7.58e-15	3.05e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45651039~45651826:-
THCA	cis	rs748404	0.631	rs11070399	ENSG00000205771.5	CATSPER2P1	-8.04	7.58e-15	3.05e-12	-0.37	-0.35	Lung cancer;	chr15:43354149	chr15:43726918~43747094:-
THCA	cis	rs7580658	0.711	rs12469035	ENSG00000236682.1	AC068282.3	-8.04	7.59e-15	3.05e-12	-0.45	-0.35	Protein C levels;	chr2:127227341	chr2:127389130~127400580:+
THCA	cis	rs6558530	0.777	rs3812477	ENSG00000253982.1	CTD-2336O2.1	8.04	7.59e-15	3.05e-12	0.31	0.35	Systolic blood pressure;	chr8:1786286	chr8:1761990~1764502:-
THCA	cis	rs150992	0.587	rs12189335	ENSG00000248489.1	CTD-2007H13.3	-8.04	7.59e-15	3.05e-12	-0.34	-0.35	Body mass index;	chr5:99009311	chr5:98929171~98995013:+
THCA	cis	rs1858037	0.836	rs2576923	ENSG00000237979.1	AC007389.1	-8.03	7.62e-15	3.06e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65406750	chr2:65500993~65502138:-
THCA	cis	rs7247513	0.93	rs2861408	ENSG00000230310.1	CTD-2192J16.11	-8.03	7.62e-15	3.06e-12	-0.42	-0.35	Bipolar disorder;	chr19:12591285	chr19:12552597~12553644:+
THCA	cis	rs4073416	0.707	rs8003811	ENSG00000276116.2	FUT8-AS1	8.03	7.64e-15	3.07e-12	0.37	0.35	N-glycan levels;	chr14:65744532	chr14:65411170~65412690:-
THCA	cis	rs4073416	0.707	rs761830	ENSG00000276116.2	FUT8-AS1	8.03	7.64e-15	3.07e-12	0.37	0.35	N-glycan levels;	chr14:65746268	chr14:65411170~65412690:-
THCA	cis	rs9649213	0.593	rs6465673	ENSG00000272950.1	RP11-307C18.1	8.03	7.65e-15	3.07e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98339575	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6465677	ENSG00000272950.1	RP11-307C18.1	8.03	7.66e-15	3.08e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98374240	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6465678	ENSG00000272950.1	RP11-307C18.1	8.03	7.66e-15	3.08e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98374745	chr7:98322853~98323430:+
THCA	cis	rs4950322	0.542	rs115179956	ENSG00000237188.3	RP11-337C18.8	8.03	7.67e-15	3.08e-12	0.4	0.35	Protein quantitative trait loci;	chr1:147172620	chr1:147172771~147211568:+
THCA	cis	rs7811142	0.945	rs6978739	ENSG00000242294.5	STAG3L5P	8.03	7.67e-15	3.08e-12	0.24	0.35	Platelet count;	chr7:100501057	chr7:100336079~100351900:+
THCA	cis	rs62103177	1	rs62103177	ENSG00000261126.6	RP11-795F19.1	8.03	7.69e-15	3.09e-12	0.4	0.35	Opioid sensitivity;	chr18:79864479	chr18:80046900~80095482:+
THCA	cis	rs7849270	1	rs1009242	ENSG00000268707.1	RP11-247A12.7	-8.03	7.71e-15	3.1e-12	-0.43	-0.35	Blood metabolite ratios;	chr9:129154553	chr9:129170434~129170940:+
THCA	cis	rs8114671	0.804	rs3803936	ENSG00000269202.1	RP4-614O4.12	8.03	7.72e-15	3.1e-12	0.29	0.35	Height;	chr20:35044972	chr20:35201747~35203288:-
THCA	cis	rs737008	0.922	rs2550475	ENSG00000262636.1	CTD-3088G3.4	8.03	7.72e-15	3.1e-12	0.45	0.35	Obesity-related traits;	chr16:11278129	chr16:11380859~11381118:-
THCA	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	8.03	7.73e-15	3.1e-12	0.42	0.35	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
THCA	cis	rs6545883	0.524	rs4599092	ENSG00000271889.1	RP11-493E12.1	-8.03	7.73e-15	3.1e-12	-0.34	-0.35	Tuberculosis;	chr2:61271833	chr2:61151433~61162105:-
THCA	cis	rs1062177	0.756	rs2964589	ENSG00000253921.1	CTB-113P19.3	8.03	7.74e-15	3.1e-12	0.42	0.35	Preschool internalizing problems;	chr5:151738628	chr5:151753992~151767247:+
THCA	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	8.03	7.76e-15	3.11e-12	0.42	0.35	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
THCA	cis	rs3096299	0.967	rs2965932	ENSG00000274627.1	RP11-104N10.2	-8.03	7.77e-15	3.12e-12	-0.35	-0.35	Multiple myeloma (IgH translocation);	chr16:89410643	chr16:89516797~89522217:+
THCA	cis	rs9649213	0.593	rs6963210	ENSG00000272950.1	RP11-307C18.1	8.03	7.77e-15	3.12e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98315674	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.574	rs9648908	ENSG00000272950.1	RP11-307C18.1	8.03	7.77e-15	3.12e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98315924	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs7797943	ENSG00000272950.1	RP11-307C18.1	8.03	7.77e-15	3.12e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98317590	chr7:98322853~98323430:+
THCA	cis	rs9847710	0.733	rs11923593	ENSG00000242142.1	SERBP1P3	8.03	7.78e-15	3.12e-12	0.43	0.35	Ulcerative colitis;	chr3:53054774	chr3:53064283~53065091:-
THCA	cis	rs910316	0.763	rs6574205	ENSG00000279594.1	RP11-950C14.10	8.03	7.79e-15	3.12e-12	0.32	0.35	Height;	chr14:74986336	chr14:75011269~75012851:-
THCA	cis	rs1850744	0.826	rs115893429	ENSG00000250942.1	ENPP7P11	-8.03	7.79e-15	3.12e-12	-0.51	-0.35	Economic and political preferences;	chr4:9592194	chr4:9677308~9677934:+
THCA	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	8.03	7.8e-15	3.13e-12	0.56	0.35	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
THCA	cis	rs9649213	0.593	rs3801264	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98321308	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs1468338	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98321806	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs2158553	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98321819	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs10808107	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98322359	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.613	rs10953256	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98322574	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.613	rs2286074	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98322699	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs7789380	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98326868	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6948540	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98330754	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.574	rs6979373	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98332532	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.574	rs34717219	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98332959	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs62478177	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98335299	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs3801263	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98335704	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.555	rs12667634	ENSG00000272950.1	RP11-307C18.1	8.03	7.8e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98336130	chr7:98322853~98323430:+
THCA	cis	rs8114671	0.836	rs2425012	ENSG00000269202.1	RP4-614O4.12	8.03	7.8e-15	3.13e-12	0.29	0.35	Height;	chr20:34994152	chr20:35201747~35203288:-
THCA	cis	rs9649213	0.593	rs7795176	ENSG00000272950.1	RP11-307C18.1	8.03	7.81e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98348975	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs62478200	ENSG00000272950.1	RP11-307C18.1	8.03	7.81e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98350733	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6465675	ENSG00000272950.1	RP11-307C18.1	-8.03	7.81e-15	3.13e-12	-0.42	-0.35	Prostate cancer (SNP x SNP interaction);	chr7:98352791	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs2107716	ENSG00000272950.1	RP11-307C18.1	8.03	7.81e-15	3.13e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98315432	chr7:98322853~98323430:+
THCA	cis	rs9309473	0.607	rs1403412	ENSG00000163016.8	ALMS1P	8.03	7.82e-15	3.13e-12	0.46	0.35	Metabolite levels;	chr2:73370964	chr2:73644919~73685576:+
THCA	cis	rs17711722	0.653	rs2460421	ENSG00000237310.1	GS1-124K5.4	-8.03	7.82e-15	3.14e-12	-0.25	-0.35	Calcium levels;	chr7:66026136	chr7:66493706~66495474:+
THCA	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	8.03	7.82e-15	3.14e-12	0.42	0.35	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	8.03	7.82e-15	3.14e-12	0.42	0.35	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	8.03	7.82e-15	3.14e-12	0.42	0.35	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	8.03	7.82e-15	3.14e-12	0.42	0.35	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
THCA	cis	rs1707322	1	rs7547189	ENSG00000234329.1	RP11-767N6.2	8.03	7.83e-15	3.14e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7547284	ENSG00000234329.1	RP11-767N6.2	8.03	7.83e-15	3.14e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45651039~45651826:-
THCA	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-8.03	7.84e-15	3.14e-12	-0.41	-0.35	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-8.03	7.84e-15	3.14e-12	-0.41	-0.35	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-8.03	7.84e-15	3.14e-12	-0.41	-0.35	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-8.03	7.84e-15	3.14e-12	-0.41	-0.35	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
THCA	cis	rs2276314	1	rs56050783	ENSG00000278986.1	RP11-723J4.3	-8.03	7.84e-15	3.14e-12	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35973828	chr18:35972151~35973916:+
THCA	cis	rs2276314	1	rs58054756	ENSG00000278986.1	RP11-723J4.3	-8.03	7.84e-15	3.14e-12	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35974090	chr18:35972151~35973916:+
THCA	cis	rs2276314	1	rs1540042	ENSG00000278986.1	RP11-723J4.3	-8.03	7.84e-15	3.14e-12	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35975273	chr18:35972151~35973916:+
THCA	cis	rs2408955	0.522	rs4760679	ENSG00000258273.1	RP11-370I10.4	8.03	7.85e-15	3.14e-12	0.46	0.35	Glycated hemoglobin levels;	chr12:48067852	chr12:48333755~48333901:-
THCA	cis	rs9649213	0.593	rs6955647	ENSG00000272950.1	RP11-307C18.1	8.03	7.85e-15	3.14e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98375250	chr7:98322853~98323430:+
THCA	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	8.03	7.85e-15	3.15e-12	0.42	0.35	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
THCA	cis	rs116175783	0.557	rs62188136	ENSG00000227403.1	AC009299.3	8.03	7.86e-15	3.15e-12	0.61	0.35	Intelligence (multi-trait analysis);	chr2:161399439	chr2:161244739~161249050:+
THCA	cis	rs944289	0.966	rs34992253	ENSG00000257826.1	RP11-116N8.4	-8.03	7.86e-15	3.15e-12	-0.37	-0.35	Thyroid cancer;	chr14:36177957	chr14:36061026~36067190:-
THCA	cis	rs9649213	0.593	rs13246942	ENSG00000272950.1	RP11-307C18.1	8.03	7.87e-15	3.15e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98285709	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6968144	ENSG00000272950.1	RP11-307C18.1	8.03	7.87e-15	3.15e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98286385	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.574	rs62479853	ENSG00000272950.1	RP11-307C18.1	8.03	7.87e-15	3.15e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98287846	chr7:98322853~98323430:+
THCA	cis	rs17772222	0.958	rs74074098	ENSG00000258983.2	RP11-507K2.2	8.03	7.87e-15	3.15e-12	0.44	0.35	Coronary artery calcification;	chr14:88484213	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.876	rs12587528	ENSG00000258983.2	RP11-507K2.2	8.03	7.87e-15	3.15e-12	0.44	0.35	Coronary artery calcification;	chr14:88487652	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.916	rs77306894	ENSG00000258983.2	RP11-507K2.2	8.03	7.87e-15	3.15e-12	0.44	0.35	Coronary artery calcification;	chr14:88494507	chr14:88499334~88515502:+
THCA	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-8.03	7.87e-15	3.15e-12	-0.42	-0.35	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
THCA	cis	rs934734	0.789	rs268122	ENSG00000204929.10	AC074391.1	-8.03	7.88e-15	3.16e-12	-0.44	-0.35	Rheumatoid arthritis;	chr2:65374975	chr2:65436711~66084639:+
THCA	cis	rs7674212	0.556	rs6533039	ENSG00000251288.2	RP11-10L12.2	-8.03	7.88e-15	3.16e-12	-0.46	-0.35	Type 2 diabetes;	chr4:102938381	chr4:102751401~102752641:+
THCA	cis	rs4819052	0.788	rs13049700	ENSG00000215447.6	BX322557.10	-8.03	7.88e-15	3.16e-12	-0.3	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45281994	chr21:45288052~45291738:+
THCA	cis	rs2562456	0.917	rs2681392	ENSG00000268555.1	RP11-678G14.3	-8.03	7.9e-15	3.16e-12	-0.48	-0.35	Pain;	chr19:21513185	chr19:21570822~21587322:-
THCA	cis	rs910316	1	rs13099	ENSG00000279594.1	RP11-950C14.10	-8.03	7.91e-15	3.17e-12	-0.32	-0.35	Height;	chr14:75132452	chr14:75011269~75012851:-
THCA	cis	rs17772222	0.917	rs10143767	ENSG00000258983.2	RP11-507K2.2	8.03	7.91e-15	3.17e-12	0.43	0.35	Coronary artery calcification;	chr14:88514867	chr14:88499334~88515502:+
THCA	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-8.03	7.92e-15	3.17e-12	-0.26	-0.35	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
THCA	cis	rs41307935	0.908	rs17162313	ENSG00000260063.1	RP5-968P14.2	8.03	7.92e-15	3.17e-12	0.65	0.35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26849628	chr1:26692132~26694131:-
THCA	cis	rs9649213	0.593	rs13232181	ENSG00000272950.1	RP11-307C18.1	8.03	7.92e-15	3.17e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98306359	chr7:98322853~98323430:+
THCA	cis	rs66887589	0.934	rs7681980	ENSG00000245958.5	RP11-33B1.1	8.03	7.94e-15	3.18e-12	0.3	0.35	Diastolic blood pressure;	chr4:119612068	chr4:119454791~119552025:+
THCA	cis	rs9649213	0.555	rs6968193	ENSG00000272950.1	RP11-307C18.1	8.03	7.94e-15	3.18e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98286590	chr7:98322853~98323430:+
THCA	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-8.03	7.95e-15	3.18e-12	-0.42	-0.35	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
THCA	cis	rs9309473	0.607	rs12478346	ENSG00000163016.8	ALMS1P	8.03	7.97e-15	3.19e-12	0.46	0.35	Metabolite levels;	chr2:73357232	chr2:73644919~73685576:+
THCA	cis	rs1707322	1	rs6661500	ENSG00000234329.1	RP11-767N6.2	8.03	7.97e-15	3.19e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45651039~45651826:-
THCA	cis	rs2439831	0.867	rs11856184	ENSG00000275601.1	AC011330.13	-8.03	7.97e-15	3.19e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43626964	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2927072	ENSG00000275601.1	AC011330.13	-8.03	7.97e-15	3.19e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43630200	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2920781	ENSG00000275601.1	AC011330.13	-8.03	7.97e-15	3.19e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43632484	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.764	rs2447193	ENSG00000275601.1	AC011330.13	-8.03	7.97e-15	3.19e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43637535	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2447211	ENSG00000275601.1	AC011330.13	-8.03	7.97e-15	3.19e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43644153	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.571	rs2470121	ENSG00000275601.1	AC011330.13	-8.03	7.97e-15	3.19e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43645420	chr15:43642389~43643023:-
THCA	cis	rs9649213	0.593	rs13246725	ENSG00000272950.1	RP11-307C18.1	8.03	7.98e-15	3.19e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98285586	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs11766808	ENSG00000272950.1	RP11-307C18.1	8.03	7.98e-15	3.19e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98286064	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs35941058	ENSG00000272950.1	RP11-307C18.1	8.03	7.98e-15	3.19e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98288847	chr7:98322853~98323430:+
THCA	cis	rs55757919	1	rs55757919	ENSG00000237595.3	RP11-112L6.3	8.03	7.98e-15	3.2e-12	0.41	0.35	Monocyte percentage of white cells;	chr20:50132011	chr20:50162765~50166102:-
THCA	cis	rs7829975	0.846	rs11779061	ENSG00000253893.2	FAM85B	8.03	7.99e-15	3.2e-12	0.45	0.35	Mood instability;	chr8:8691922	chr8:8167819~8226614:-
THCA	cis	rs2839186	0.709	rs2156117	ENSG00000239415.1	AP001469.9	8.03	8e-15	3.2e-12	0.36	0.35	Testicular germ cell tumor;	chr21:46249386	chr21:46251549~46254133:-
THCA	cis	rs7221109	0.857	rs11658582	ENSG00000278834.1	RP11-458J1.1	8.03	8e-15	3.2e-12	0.36	0.35	Type 1 diabetes;	chr17:40606948	chr17:40648300~40649718:+
THCA	cis	rs9341808	0.53	rs3805877	ENSG00000272129.1	RP11-250B2.6	8.03	8.01e-15	3.2e-12	0.44	0.35	Sitting height ratio;	chr6:80321812	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.53	rs3805876	ENSG00000272129.1	RP11-250B2.6	8.03	8.01e-15	3.2e-12	0.44	0.35	Sitting height ratio;	chr6:80321822	chr6:80355424~80356859:+
THCA	cis	rs9649213	0.537	rs6971825	ENSG00000272950.1	RP11-307C18.1	8.03	8.02e-15	3.21e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98350236	chr7:98322853~98323430:+
THCA	cis	rs4819052	0.959	rs9976074	ENSG00000215447.6	BX322557.10	-8.03	8.02e-15	3.21e-12	-0.32	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45235723	chr21:45288052~45291738:+
THCA	cis	rs1510272	0.515	rs2089735	ENSG00000243926.1	TIPARP-AS1	-8.03	8.02e-15	3.21e-12	-0.43	-0.35	Testicular germ cell tumor;	chr3:156624763	chr3:156671862~156674378:-
THCA	cis	rs1707322	1	rs10890359	ENSG00000234329.1	RP11-767N6.2	8.03	8.03e-15	3.21e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45651039~45651826:-
THCA	cis	rs9649213	0.537	rs6465663	ENSG00000272950.1	RP11-307C18.1	8.03	8.03e-15	3.21e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98289571	chr7:98322853~98323430:+
THCA	cis	rs7247513	0.866	rs7247171	ENSG00000230310.1	CTD-2192J16.11	-8.03	8.03e-15	3.21e-12	-0.42	-0.35	Bipolar disorder;	chr19:12595186	chr19:12552597~12553644:+
THCA	cis	rs9649213	0.593	rs6973775	ENSG00000272950.1	RP11-307C18.1	8.03	8.05e-15	3.22e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98375373	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.613	rs7777415	ENSG00000272950.1	RP11-307C18.1	8.03	8.05e-15	3.22e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98329902	chr7:98322853~98323430:+
THCA	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-8.03	8.07e-15	3.23e-12	-0.41	-0.35	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.634	rs60016848	ENSG00000249207.1	RP11-360F5.1	8.03	8.08e-15	3.23e-12	0.42	0.35	Cognitive function;	chr4:39281436	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.577	rs6830736	ENSG00000249207.1	RP11-360F5.1	8.03	8.08e-15	3.23e-12	0.42	0.35	Cognitive function;	chr4:39281467	chr4:39112677~39126818:-
THCA	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-8.03	8.08e-15	3.23e-12	-0.41	-0.35	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-8.03	8.08e-15	3.23e-12	-0.41	-0.35	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
THCA	cis	rs2286503	0.65	rs1990279	ENSG00000228649.7	AC005682.5	8.03	8.1e-15	3.24e-12	0.41	0.35	Fibrinogen;	chr7:22851123	chr7:22854178~22861579:+
THCA	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	8.03	8.1e-15	3.24e-12	0.42	0.35	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
THCA	cis	rs11673344	0.504	rs4806409	ENSG00000226686.6	LINC01535	8.03	8.11e-15	3.24e-12	0.38	0.35	Obesity-related traits;	chr19:37097923	chr19:37251912~37265535:+
THCA	cis	rs1707322	1	rs6429588	ENSG00000234329.1	RP11-767N6.2	8.03	8.11e-15	3.24e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs12097799	ENSG00000234329.1	RP11-767N6.2	8.03	8.11e-15	3.24e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45651039~45651826:-
THCA	cis	rs507080	0.769	rs12290522	ENSG00000278376.1	RP11-158I9.8	-8.03	8.13e-15	3.25e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118615610	chr11:118791254~118793137:+
THCA	cis	rs7015263	1	rs7823154	ENSG00000254231.1	CTD-2284J15.1	8.03	8.14e-15	3.26e-12	0.33	0.35	Intelligence (multi-trait analysis);	chr8:86524742	chr8:86333274~86343314:-
THCA	cis	rs7291412	0.929	rs7289457	ENSG00000231711.2	LINC00899	8.03	8.14e-15	3.26e-12	0.3	0.35	Dupuytren's disease;Subjective well-being;	chr22:46060723	chr22:46039907~46044853:-
THCA	cis	rs116175783	0.557	rs16845844	ENSG00000227403.1	AC009299.3	-8.03	8.15e-15	3.26e-12	-0.61	-0.35	Intelligence (multi-trait analysis);	chr2:161408759	chr2:161244739~161249050:+
THCA	cis	rs73607972	0.597	rs1111487	ENSG00000275191.1	RP11-36I17.2	8.02	8.2e-15	3.28e-12	0.47	0.35	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53528217	chr16:53628256~53628816:-
THCA	cis	rs2839186	0.721	rs3788252	ENSG00000239415.1	AP001469.9	8.02	8.2e-15	3.28e-12	0.37	0.35	Testicular germ cell tumor;	chr21:46241321	chr21:46251549~46254133:-
THCA	cis	rs7015263	0.936	rs7463186	ENSG00000254231.1	CTD-2284J15.1	8.02	8.2e-15	3.28e-12	0.33	0.35	Intelligence (multi-trait analysis);	chr8:86504972	chr8:86333274~86343314:-
THCA	cis	rs7015263	1	rs7006629	ENSG00000254231.1	CTD-2284J15.1	8.02	8.2e-15	3.28e-12	0.33	0.35	Intelligence (multi-trait analysis);	chr8:86507313	chr8:86333274~86343314:-
THCA	cis	rs10411161	0.671	rs8105497	ENSG00000269483.1	AC006272.1	8.02	8.21e-15	3.28e-12	0.45	0.35	Breast cancer;	chr19:51847134	chr19:51839924~51843324:-
THCA	cis	rs4713118	0.955	rs9468204	ENSG00000219392.1	RP1-265C24.5	-8.02	8.22e-15	3.28e-12	-0.45	-0.35	Parkinson's disease;	chr6:27721030	chr6:28115628~28116551:+
THCA	cis	rs189798	0.845	rs330904	ENSG00000254340.1	RP11-10A14.3	-8.02	8.24e-15	3.29e-12	-0.39	-0.35	Myopia (pathological);	chr8:9134315	chr8:9141424~9145435:+
THCA	cis	rs16846053	0.748	rs890076	ENSG00000227403.1	AC009299.3	-8.02	8.24e-15	3.29e-12	-0.59	-0.35	Blood osmolality (transformed sodium);	chr2:161424237	chr2:161244739~161249050:+
THCA	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-8.02	8.25e-15	3.3e-12	-0.42	-0.35	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
THCA	cis	rs7430456	0.874	rs7428501	ENSG00000228221.4	LINC00578	8.02	8.25e-15	3.3e-12	0.46	0.35	Breast cancer;	chr3:177751974	chr3:177441921~177752305:+
THCA	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	8.02	8.27e-15	3.3e-12	0.42	0.35	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
THCA	cis	rs1707322	1	rs4660906	ENSG00000234329.1	RP11-767N6.2	8.02	8.27e-15	3.31e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45651039~45651826:-
THCA	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-8.02	8.28e-15	3.31e-12	-0.43	-0.35	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
THCA	cis	rs7727544	0.716	rs6863213	ENSG00000224431.1	AC063976.7	8.02	8.3e-15	3.32e-12	0.31	0.35	Blood metabolite levels;	chr5:132240239	chr5:132199456~132203487:+
THCA	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	8.02	8.3e-15	3.32e-12	0.33	0.35	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
THCA	cis	rs7727544	0.606	rs200838	ENSG00000233006.5	AC034220.3	-8.02	8.31e-15	3.32e-12	-0.27	-0.35	Blood metabolite levels;	chr5:132374707	chr5:132311285~132369916:-
THCA	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-8.02	8.33e-15	3.33e-12	-0.42	-0.35	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
THCA	cis	rs2880765	0.525	rs35899940	ENSG00000259295.5	CSPG4P12	8.02	8.34e-15	3.33e-12	0.51	0.35	Coronary artery disease;	chr15:85510466	chr15:85191438~85213905:+
THCA	cis	rs416603	0.967	rs11644184	ENSG00000262636.1	CTD-3088G3.4	-8.02	8.36e-15	3.34e-12	-0.43	-0.35	Type 1 diabetes;	chr16:11271247	chr16:11380859~11381118:-
THCA	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-8.02	8.38e-15	3.35e-12	-0.54	-0.35	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
THCA	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-8.02	8.39e-15	3.35e-12	-0.41	-0.35	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
THCA	cis	rs7811142	0.83	rs6955367	ENSG00000078319.8	PMS2P1	-8.02	8.43e-15	3.36e-12	-0.48	-0.35	Platelet count;	chr7:100363571	chr7:100320992~100341908:-
THCA	cis	rs42490	0.625	rs425312	ENSG00000251136.7	RP11-37B2.1	-8.02	8.45e-15	3.38e-12	-0.3	-0.35	Leprosy;	chr8:89834127	chr8:89609409~89757727:-
THCA	cis	rs11673344	0.504	rs2385374	ENSG00000226686.6	LINC01535	8.02	8.46e-15	3.38e-12	0.38	0.35	Obesity-related traits;	chr19:37092115	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs4254428	ENSG00000226686.6	LINC01535	8.02	8.46e-15	3.38e-12	0.38	0.35	Obesity-related traits;	chr19:37093748	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs8109501	ENSG00000226686.6	LINC01535	8.02	8.46e-15	3.38e-12	0.38	0.35	Obesity-related traits;	chr19:37102194	chr19:37251912~37265535:+
THCA	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-8.02	8.5e-15	3.39e-12	-0.64	-0.35	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
THCA	cis	rs934734	0.752	rs268131	ENSG00000204929.10	AC074391.1	-8.02	8.53e-15	3.4e-12	-0.42	-0.35	Rheumatoid arthritis;	chr2:65383337	chr2:65436711~66084639:+
THCA	cis	rs673078	0.66	rs78690826	ENSG00000275409.1	RP11-131L12.4	-8.02	8.53e-15	3.41e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118176693	chr12:118430147~118430699:+
THCA	cis	rs673078	0.66	rs17512142	ENSG00000275409.1	RP11-131L12.4	-8.02	8.53e-15	3.41e-12	-0.46	-0.35	Glucose homeostasis traits;	chr12:118186186	chr12:118430147~118430699:+
THCA	cis	rs6844153	0.713	rs11734308	ENSG00000240005.4	RP11-293A21.1	-8.02	8.54e-15	3.41e-12	-0.4	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26934877	chr4:26859806~26860599:-
THCA	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	8.02	8.54e-15	3.41e-12	0.42	0.35	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
THCA	cis	rs227932	0.614	rs4722260	ENSG00000234286.1	AC006026.13	8.02	8.54e-15	3.41e-12	0.6	0.35	Schizophrenia;	chr7:23719851	chr7:23680195~23680786:-
THCA	cis	rs1707322	1	rs12403666	ENSG00000234329.1	RP11-767N6.2	8.02	8.54e-15	3.41e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45651039~45651826:-
THCA	cis	rs812925	0.537	rs778153	ENSG00000271889.1	RP11-493E12.1	-8.02	8.58e-15	3.42e-12	-0.33	-0.35	Immature fraction of reticulocytes;	chr2:61381517	chr2:61151433~61162105:-
THCA	cis	rs1707322	0.964	rs6697830	ENSG00000234329.1	RP11-767N6.2	8.02	8.58e-15	3.43e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs12060274	ENSG00000234329.1	RP11-767N6.2	8.02	8.58e-15	3.43e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45651039~45651826:-
THCA	cis	rs2712184	0.729	rs2541397	ENSG00000229352.1	AC007563.3	-8.02	8.6e-15	3.43e-12	-0.41	-0.35	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216781970	chr2:216799608~216805335:+
THCA	cis	rs7208859	0.623	rs55724095	ENSG00000266490.1	CTD-2349P21.9	8.02	8.6e-15	3.43e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.568	rs9903854	ENSG00000266490.1	CTD-2349P21.9	8.02	8.6e-15	3.43e-12	0.49	0.35	Body mass index;	chr17:30826980	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs80355557	ENSG00000266490.1	CTD-2349P21.9	8.02	8.6e-15	3.43e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9911173	ENSG00000266490.1	CTD-2349P21.9	8.02	8.6e-15	3.43e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30792372~30792833:+
THCA	cis	rs7727544	0.716	rs4594848	ENSG00000224431.1	AC063976.7	8.02	8.6e-15	3.43e-12	0.31	0.35	Blood metabolite levels;	chr5:132250905	chr5:132199456~132203487:+
THCA	cis	rs910316	0.967	rs175502	ENSG00000279594.1	RP11-950C14.10	-8.02	8.63e-15	3.44e-12	-0.32	-0.35	Height;	chr14:75066976	chr14:75011269~75012851:-
THCA	cis	rs3096299	0.542	rs1078578	ENSG00000274627.1	RP11-104N10.2	8.02	8.63e-15	3.44e-12	0.36	0.35	Multiple myeloma (IgH translocation);	chr16:89320526	chr16:89516797~89522217:+
THCA	cis	rs7208859	0.673	rs216424	ENSG00000266490.1	CTD-2349P21.9	8.02	8.63e-15	3.44e-12	0.44	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30792372~30792833:+
THCA	cis	rs7247513	0.93	rs34321000	ENSG00000230310.1	CTD-2192J16.11	-8.02	8.64e-15	3.45e-12	-0.42	-0.35	Bipolar disorder;	chr19:12602274	chr19:12552597~12553644:+
THCA	cis	rs9329221	0.527	rs34259385	ENSG00000261451.1	RP11-981G7.1	-8.02	8.65e-15	3.45e-12	-0.44	-0.35	Neuroticism;	chr8:10467946	chr8:10433672~10438312:+
THCA	cis	rs7247513	0.93	rs35275129	ENSG00000230310.1	CTD-2192J16.11	-8.02	8.66e-15	3.45e-12	-0.41	-0.35	Bipolar disorder;	chr19:12605679	chr19:12552597~12553644:+
THCA	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	8.02	8.66e-15	3.45e-12	0.4	0.35	Migraine;	chr4:56861145	chr4:56960927~56961373:-
THCA	cis	rs4780355	0.619	rs918737	ENSG00000262636.1	CTD-3088G3.4	-8.02	8.7e-15	3.47e-12	-0.46	-0.35	Crohn's disease and psoriasis;	chr16:11345782	chr16:11380859~11381118:-
THCA	cis	rs748404	0.631	rs8042688	ENSG00000205771.5	CATSPER2P1	-8.02	8.7e-15	3.47e-12	-0.37	-0.35	Lung cancer;	chr15:43346327	chr15:43726918~43747094:-
THCA	cis	rs748404	0.631	rs4296223	ENSG00000205771.5	CATSPER2P1	-8.02	8.7e-15	3.47e-12	-0.37	-0.35	Lung cancer;	chr15:43353048	chr15:43726918~43747094:-
THCA	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	8.02	8.72e-15	3.47e-12	0.23	0.35	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	8.02	8.72e-15	3.47e-12	0.23	0.35	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	8.02	8.72e-15	3.47e-12	0.23	0.35	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
THCA	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	8.02	8.72e-15	3.47e-12	0.23	0.35	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
THCA	cis	rs9649213	0.574	rs3801257	ENSG00000272950.1	RP11-307C18.1	8.02	8.72e-15	3.48e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98362480	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs7803372	ENSG00000272950.1	RP11-307C18.1	8.02	8.72e-15	3.48e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98362945	chr7:98322853~98323430:+
THCA	cis	rs4664293	0.51	rs2113861	ENSG00000226266.5	AC009961.3	8.02	8.73e-15	3.48e-12	0.41	0.35	Monocyte percentage of white cells;	chr2:159585233	chr2:159670708~159712435:-
THCA	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	8.02	8.76e-15	3.49e-12	0.33	0.35	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
THCA	cis	rs922182	0.617	rs13329183	ENSG00000275785.1	RP11-111E14.2	8.02	8.77e-15	3.49e-12	0.4	0.35	Blood protein levels;	chr15:63948610	chr15:63890030~63890317:+
THCA	cis	rs922182	0.579	rs13329518	ENSG00000275785.1	RP11-111E14.2	8.02	8.77e-15	3.49e-12	0.4	0.35	Blood protein levels;	chr15:63948881	chr15:63890030~63890317:+
THCA	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	8.02	8.77e-15	3.49e-12	0.24	0.35	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
THCA	cis	rs910316	1	rs12889472	ENSG00000279594.1	RP11-950C14.10	8.02	8.77e-15	3.5e-12	0.32	0.35	Height;	chr14:75077276	chr14:75011269~75012851:-
THCA	cis	rs9649213	0.593	rs7776638	ENSG00000272950.1	RP11-307C18.1	8.01	8.81e-15	3.51e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98364194	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.574	rs36099592	ENSG00000272950.1	RP11-307C18.1	8.01	8.81e-15	3.51e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98373019	chr7:98322853~98323430:+
THCA	cis	rs2562456	0.917	rs9304987	ENSG00000268555.1	RP11-678G14.3	-8.01	8.82e-15	3.51e-12	-0.48	-0.35	Pain;	chr19:21499472	chr19:21570822~21587322:-
THCA	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	8.01	8.83e-15	3.52e-12	0.42	0.35	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
THCA	cis	rs11696845	0.896	rs61356009	ENSG00000276223.1	RP4-781B1.5	-8.01	8.84e-15	3.52e-12	-0.42	-0.35	Obesity-related traits;	chr20:44743750	chr20:44746642~44747201:+
THCA	cis	rs11673344	0.504	rs11084874	ENSG00000226686.6	LINC01535	8.01	8.87e-15	3.53e-12	0.38	0.35	Obesity-related traits;	chr19:37096667	chr19:37251912~37265535:+
THCA	cis	rs4664293	0.631	rs13019272	ENSG00000226266.5	AC009961.3	-8.01	8.87e-15	3.53e-12	-0.41	-0.35	Monocyte percentage of white cells;	chr2:159802352	chr2:159670708~159712435:-
THCA	cis	rs9400467	0.528	rs56827	ENSG00000230177.1	RP5-1112D6.4	-8.01	8.88e-15	3.54e-12	-0.27	-0.35	Amino acid levels;Blood metabolite levels;	chr6:111302000	chr6:111277932~111278742:+
THCA	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	8.01	8.89e-15	3.54e-12	0.42	0.35	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	8.01	8.89e-15	3.54e-12	0.42	0.35	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
THCA	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	8.01	8.89e-15	3.54e-12	0.42	0.35	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
THCA	cis	rs736801	0.78	rs11951091	ENSG00000237714.1	P4HA2-AS1	8.01	8.92e-15	3.55e-12	0.47	0.35	Mosquito bite size;Breast cancer;	chr5:132450903	chr5:132184876~132192808:+
THCA	cis	rs1707322	1	rs785480	ENSG00000234329.1	RP11-767N6.2	8.01	8.93e-15	3.55e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45651039~45651826:-
THCA	cis	rs11971779	0.638	rs77668044	ENSG00000273391.1	RP11-634H22.1	8.01	8.93e-15	3.56e-12	0.4	0.35	Diisocyanate-induced asthma;	chr7:139426339	chr7:139359032~139359566:-
THCA	cis	rs910316	1	rs175426	ENSG00000279594.1	RP11-950C14.10	-8.01	8.95e-15	3.56e-12	-0.32	-0.35	Height;	chr14:75157431	chr14:75011269~75012851:-
THCA	cis	rs112721625	1	rs112721625	ENSG00000266992.1	DHX40P1	8.01	8.95e-15	3.57e-12	0.41	0.35	Monocyte count;	chr17:59850066	chr17:59976009~60002384:-
THCA	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-8.01	8.98e-15	3.58e-12	-0.45	-0.35	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
THCA	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-8.01	9e-15	3.58e-12	-0.41	-0.35	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
THCA	cis	rs7674212	0.556	rs6533039	ENSG00000246560.2	RP11-10L12.4	8.01	9e-15	3.58e-12	0.43	0.35	Type 2 diabetes;	chr4:102938381	chr4:102828055~102844075:+
THCA	cis	rs1859596	0.646	rs6957474	ENSG00000234456.6	MAGI2-AS3	8.01	9e-15	3.58e-12	0.33	0.35	Reading or mathematical ability;	chr7:79458308	chr7:79452877~79471208:+
THCA	cis	rs10208649	0.908	rs13395751	ENSG00000272156.1	RP11-477N3.1	8.01	9.02e-15	3.59e-12	0.64	0.35	Body mass index;	chr2:54011657	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs6715161	ENSG00000272156.1	RP11-477N3.1	8.01	9.02e-15	3.59e-12	0.64	0.35	Body mass index;	chr2:54012968	chr2:54082554~54085066:+
THCA	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	8.01	9.03e-15	3.59e-12	0.33	0.35	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
THCA	cis	rs1707322	1	rs4390216	ENSG00000234329.1	RP11-767N6.2	8.01	9.04e-15	3.6e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.964	rs10437063	ENSG00000234329.1	RP11-767N6.2	8.01	9.04e-15	3.6e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6676982	ENSG00000234329.1	RP11-767N6.2	8.01	9.04e-15	3.6e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.927	rs11211194	ENSG00000234329.1	RP11-767N6.2	8.01	9.04e-15	3.6e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45651039~45651826:-
THCA	cis	rs9649213	0.593	rs34534766	ENSG00000272950.1	RP11-307C18.1	8.01	9.05e-15	3.6e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98291559	chr7:98322853~98323430:+
THCA	cis	rs527616	0.93	rs604702	ENSG00000265369.3	PCAT18	8.01	9.06e-15	3.61e-12	0.43	0.35	Breast cancer;	chr18:26751502	chr18:26687621~26703638:-
THCA	cis	rs910316	0.737	rs2098251	ENSG00000279594.1	RP11-950C14.10	8.01	9.07e-15	3.61e-12	0.32	0.35	Height;	chr14:75025993	chr14:75011269~75012851:-
THCA	cis	rs910316	0.664	rs2098252	ENSG00000279594.1	RP11-950C14.10	8.01	9.07e-15	3.61e-12	0.32	0.35	Height;	chr14:75026029	chr14:75011269~75012851:-
THCA	cis	rs910316	0.737	rs28687415	ENSG00000279594.1	RP11-950C14.10	8.01	9.07e-15	3.61e-12	0.32	0.35	Height;	chr14:75028779	chr14:75011269~75012851:-
THCA	cis	rs67311347	0.544	rs7652439	ENSG00000223797.4	ENTPD3-AS1	8.01	9.07e-15	3.61e-12	0.25	0.35	Renal cell carcinoma;	chr3:40308457	chr3:40313802~40453329:-
THCA	cis	rs507080	0.769	rs570836	ENSG00000278376.1	RP11-158I9.8	-8.01	9.07e-15	3.61e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118641444	chr11:118791254~118793137:+
THCA	cis	rs984222	0.586	rs12742258	ENSG00000231365.4	RP11-418J17.1	8.01	9.08e-15	3.61e-12	0.34	0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119199678	chr1:119140396~119275973:+
THCA	cis	rs9649213	0.574	rs7791321	ENSG00000272950.1	RP11-307C18.1	8.01	9.1e-15	3.62e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98314813	chr7:98322853~98323430:+
THCA	cis	rs2562456	0.917	rs11085463	ENSG00000268555.1	RP11-678G14.3	8.01	9.11e-15	3.63e-12	0.47	0.35	Pain;	chr19:21568500	chr19:21570822~21587322:-
THCA	cis	rs507080	0.885	rs7926959	ENSG00000278376.1	RP11-158I9.8	-8.01	9.12e-15	3.63e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118689157	chr11:118791254~118793137:+
THCA	cis	rs507080	0.663	rs7926970	ENSG00000278376.1	RP11-158I9.8	-8.01	9.12e-15	3.63e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118689172	chr11:118791254~118793137:+
THCA	cis	rs9649213	0.593	rs7807555	ENSG00000272950.1	RP11-307C18.1	8.01	9.13e-15	3.63e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98328205	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs7807455	ENSG00000272950.1	RP11-307C18.1	8.01	9.13e-15	3.63e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98328310	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6465667	ENSG00000272950.1	RP11-307C18.1	8.01	9.13e-15	3.63e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98328573	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6949214	ENSG00000272950.1	RP11-307C18.1	8.01	9.13e-15	3.63e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98330921	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.537	rs35997266	ENSG00000272950.1	RP11-307C18.1	8.01	9.13e-15	3.63e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98336254	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6945554	ENSG00000272950.1	RP11-307C18.1	8.01	9.13e-15	3.63e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98343634	chr7:98322853~98323430:+
THCA	cis	rs2288884	0.79	rs7253849	ENSG00000275055.1	CTC-471J1.11	-8.01	9.15e-15	3.64e-12	-0.31	-0.35	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056992	chr19:52049007~52049754:+
THCA	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-8.01	9.18e-15	3.65e-12	-0.44	-0.35	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
THCA	cis	rs1707322	1	rs946527	ENSG00000234329.1	RP11-767N6.2	8.01	9.18e-15	3.65e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45651039~45651826:-
THCA	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	8.01	9.19e-15	3.65e-12	0.33	0.35	Breast size;	chr12:9220132	chr12:9277235~9313241:+
THCA	cis	rs4718428	0.576	rs12698546	ENSG00000230295.1	RP11-458F8.2	-8.01	9.22e-15	3.67e-12	-0.32	-0.35	Corneal structure;	chr7:66801919	chr7:66880708~66882981:+
THCA	cis	rs2929278	0.617	rs663214	ENSG00000166763.7	STRCP1	-8.01	9.23e-15	3.67e-12	-0.37	-0.35	Schizophrenia;	chr15:43821584	chr15:43699488~43718184:-
THCA	cis	rs6545883	0.56	rs11677775	ENSG00000271889.1	RP11-493E12.1	-8.01	9.24e-15	3.67e-12	-0.34	-0.35	Tuberculosis;	chr2:61275975	chr2:61151433~61162105:-
THCA	cis	rs9649213	0.593	rs1859482	ENSG00000272950.1	RP11-307C18.1	8.01	9.24e-15	3.67e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98354462	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs13246868	ENSG00000272950.1	RP11-307C18.1	8.01	9.24e-15	3.67e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98357141	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs12672092	ENSG00000272950.1	RP11-307C18.1	8.01	9.24e-15	3.67e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98357245	chr7:98322853~98323430:+
THCA	cis	rs853679	0.825	rs8180562	ENSG00000280107.1	AL022393.9	-8.01	9.24e-15	3.68e-12	-0.53	-0.35	Depression;	chr6:28173682	chr6:28170845~28172521:+
THCA	cis	rs853679	0.882	rs9380064	ENSG00000280107.1	AL022393.9	-8.01	9.24e-15	3.68e-12	-0.53	-0.35	Depression;	chr6:28175340	chr6:28170845~28172521:+
THCA	cis	rs11673344	0.504	rs7258360	ENSG00000226686.6	LINC01535	8.01	9.25e-15	3.68e-12	0.38	0.35	Obesity-related traits;	chr19:37115015	chr19:37251912~37265535:+
THCA	cis	rs7727544	0.606	rs10060615	ENSG00000224431.1	AC063976.7	8.01	9.26e-15	3.68e-12	0.3	0.35	Blood metabolite levels;	chr5:132373185	chr5:132199456~132203487:+
THCA	cis	rs7208859	0.673	rs3764420	ENSG00000266490.1	CTD-2349P21.9	8.01	9.26e-15	3.68e-12	0.49	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30792372~30792833:+
THCA	cis	rs507080	0.769	rs11603616	ENSG00000278376.1	RP11-158I9.8	-8.01	9.26e-15	3.68e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118625350	chr11:118791254~118793137:+
THCA	cis	rs507080	0.769	rs571001	ENSG00000278376.1	RP11-158I9.8	-8.01	9.26e-15	3.68e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118629457	chr11:118791254~118793137:+
THCA	cis	rs507080	0.769	rs570952	ENSG00000278376.1	RP11-158I9.8	-8.01	9.26e-15	3.68e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118629477	chr11:118791254~118793137:+
THCA	cis	rs507080	0.769	rs483283	ENSG00000278376.1	RP11-158I9.8	-8.01	9.26e-15	3.68e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118635684	chr11:118791254~118793137:+
THCA	cis	rs7727544	0.716	rs11949055	ENSG00000224431.1	AC063976.7	8.01	9.26e-15	3.68e-12	0.31	0.35	Blood metabolite levels;	chr5:132241044	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.716	rs3844312	ENSG00000224431.1	AC063976.7	8.01	9.26e-15	3.68e-12	0.31	0.35	Blood metabolite levels;	chr5:132246663	chr5:132199456~132203487:+
THCA	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	8.01	9.28e-15	3.69e-12	0.41	0.35	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
THCA	cis	rs507080	0.883	rs12798453	ENSG00000278376.1	RP11-158I9.8	-8.01	9.28e-15	3.69e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118690701	chr11:118791254~118793137:+
THCA	cis	rs11214589	0.905	rs10891539	ENSG00000270179.1	RP11-159N11.4	-8.01	9.28e-15	3.69e-12	-0.36	-0.35	Neuroticism;	chr11:113365770	chr11:113368478~113369117:+
THCA	cis	rs7714584	1	rs4958843	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150845362	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs4958424	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150845474	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11748151	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150846730	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10058821	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150846823	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10051804	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150846862	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10058943	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150847024	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10051924	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150847077	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs17111376	ENSG00000197083.10	ZNF300P1	8.01	9.28e-15	3.69e-12	0.56	0.35	Crohn's disease;	chr5:150847337	chr5:150930645~150946289:-
THCA	cis	rs1005277	0.579	rs1780137	ENSG00000263064.2	RP11-291L22.7	8.01	9.29e-15	3.69e-12	0.4	0.35	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38448689~38448949:+
THCA	cis	rs922182	0.595	rs9302232	ENSG00000275785.1	RP11-111E14.2	8.01	9.33e-15	3.71e-12	0.41	0.35	Blood protein levels;	chr15:63913159	chr15:63890030~63890317:+
THCA	cis	rs77204473	1	rs35184536	ENSG00000254851.1	RP11-109L13.1	8.01	9.33e-15	3.71e-12	0.9	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116908097	chr11:117135528~117138582:+
THCA	cis	rs2015599	0.549	rs7956305	ENSG00000257176.2	RP11-996F15.2	8.01	9.33e-15	3.71e-12	0.35	0.35	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.543	rs6487807	ENSG00000257176.2	RP11-996F15.2	8.01	9.33e-15	3.71e-12	0.35	0.35	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29280418~29317848:-
THCA	cis	rs934734	0.967	rs17534670	ENSG00000204929.10	AC074391.1	-8.01	9.33e-15	3.71e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65388294	chr2:65436711~66084639:+
THCA	cis	rs6504108	0.624	rs10853098	ENSG00000278765.1	RP5-890E16.5	-8.01	9.34e-15	3.71e-12	-0.39	-0.35	Body mass index;	chr17:48159219	chr17:48066704~48067293:-
THCA	cis	rs812925	0.511	rs11886950	ENSG00000271889.1	RP11-493E12.1	8.01	9.34e-15	3.71e-12	0.33	0.35	Immature fraction of reticulocytes;	chr2:61172182	chr2:61151433~61162105:-
THCA	cis	rs922182	0.617	rs11852732	ENSG00000275785.1	RP11-111E14.2	8.01	9.35e-15	3.71e-12	0.4	0.35	Blood protein levels;	chr15:63947708	chr15:63890030~63890317:+
THCA	cis	rs922182	0.579	rs11856257	ENSG00000275785.1	RP11-111E14.2	8.01	9.35e-15	3.71e-12	0.4	0.35	Blood protein levels;	chr15:63947742	chr15:63890030~63890317:+
THCA	cis	rs922182	0.617	rs28621460	ENSG00000275785.1	RP11-111E14.2	8.01	9.35e-15	3.71e-12	0.4	0.35	Blood protein levels;	chr15:63948033	chr15:63890030~63890317:+
THCA	cis	rs922182	0.617	rs2899697	ENSG00000275785.1	RP11-111E14.2	8.01	9.35e-15	3.71e-12	0.4	0.35	Blood protein levels;	chr15:63948237	chr15:63890030~63890317:+
THCA	cis	rs9649213	0.593	rs3823740	ENSG00000272950.1	RP11-307C18.1	8.01	9.35e-15	3.72e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98327792	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs35535338	ENSG00000272950.1	RP11-307C18.1	8.01	9.35e-15	3.72e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98333007	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs36017146	ENSG00000272950.1	RP11-307C18.1	8.01	9.35e-15	3.72e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98345305	chr7:98322853~98323430:+
THCA	cis	rs2946504	0.861	rs2946494	ENSG00000251468.2	RP11-369K16.1	-8.01	9.4e-15	3.73e-12	-0.43	-0.35	Type 2 diabetes;	chr8:12962601	chr8:12958387~12962200:+
THCA	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	8	9.45e-15	3.75e-12	0.41	0.35	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
THCA	cis	rs516805	0.748	rs577744	ENSG00000279453.1	RP3-425C14.4	-8	9.47e-15	3.76e-12	-0.36	-0.35	Lymphocyte counts;	chr6:122447712	chr6:122436789~122439223:-
THCA	cis	rs984222	0.617	rs2003365	ENSG00000231365.4	RP11-418J17.1	8	9.47e-15	3.76e-12	0.34	0.35	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119219414	chr1:119140396~119275973:+
THCA	cis	rs1707322	1	rs11211248	ENSG00000234329.1	RP11-767N6.2	8	9.49e-15	3.77e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7532204	ENSG00000234329.1	RP11-767N6.2	-8	9.49e-15	3.77e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.835	rs946525	ENSG00000234329.1	RP11-767N6.2	-8	9.49e-15	3.77e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs946524	ENSG00000234329.1	RP11-767N6.2	-8	9.49e-15	3.77e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660336	ENSG00000234329.1	RP11-767N6.2	-8	9.49e-15	3.77e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45651039~45651826:-
THCA	cis	rs62355901	0.505	rs72758017	ENSG00000271828.1	CTD-2310F14.1	8	9.52e-15	3.78e-12	0.71	0.35	Breast cancer;	chr5:56797732	chr5:56927874~56929573:+
THCA	cis	rs2276314	0.947	rs4799831	ENSG00000278986.1	RP11-723J4.3	-8	9.53e-15	3.78e-12	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35974812	chr18:35972151~35973916:+
THCA	cis	rs6597981	0.592	rs28625355	ENSG00000255284.1	AP006621.5	8	9.55e-15	3.79e-12	0.24	0.35	Breast cancer;	chr11:736334	chr11:777578~784297:+
THCA	cis	rs17459044	1	rs17459044	ENSG00000268707.1	RP11-247A12.7	-8	9.56e-15	3.8e-12	-0.43	-0.35	Pelvic organ prolapse (moderate/severe);	chr9:129091345	chr9:129170434~129170940:+
THCA	cis	rs4713118	0.662	rs149946	ENSG00000226314.6	ZNF192P1	8	9.6e-15	3.81e-12	0.44	0.35	Parkinson's disease;	chr6:28002253	chr6:28161781~28169594:+
THCA	cis	rs4713118	0.662	rs156744	ENSG00000226314.6	ZNF192P1	-8	9.6e-15	3.81e-12	-0.44	-0.35	Parkinson's disease;	chr6:27999496	chr6:28161781~28169594:+
THCA	cis	rs62158211	0.826	rs62158168	ENSG00000272563.1	RP11-480C16.1	-8	9.61e-15	3.81e-12	-0.46	-0.35	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;	chr2:113320804	chr2:113432600~113436042:+
THCA	cis	rs2276314	1	rs4799832	ENSG00000278986.1	RP11-723J4.3	-8	9.61e-15	3.82e-12	-0.39	-0.35	Endometriosis;Drug-induced torsades de pointes;	chr18:35979683	chr18:35972151~35973916:+
THCA	cis	rs200972	1	rs200972	ENSG00000216901.1	AL022393.7	8	9.66e-15	3.83e-12	0.43	0.35	Urinary tract infection frequency;	chr6:27891059	chr6:28176188~28176674:+
THCA	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	8	9.69e-15	3.85e-12	0.34	0.35	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
THCA	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	8	9.69e-15	3.85e-12	0.34	0.35	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
THCA	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	8	9.69e-15	3.85e-12	0.34	0.35	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
THCA	cis	rs673078	0.66	rs17512574	ENSG00000275409.1	RP11-131L12.4	-8	9.69e-15	3.85e-12	-0.38	-0.35	Glucose homeostasis traits;	chr12:118350198	chr12:118430147~118430699:+
THCA	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	8	9.78e-15	3.88e-12	0.45	0.35	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
THCA	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	8	9.79e-15	3.88e-12	0.64	0.35	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
THCA	cis	rs7247513	0.964	rs4804200	ENSG00000230310.1	CTD-2192J16.11	-8	9.8e-15	3.89e-12	-0.43	-0.35	Bipolar disorder;	chr19:12599938	chr19:12552597~12553644:+
THCA	cis	rs7247513	0.964	rs4371272	ENSG00000230310.1	CTD-2192J16.11	-8	9.8e-15	3.89e-12	-0.43	-0.35	Bipolar disorder;	chr19:12600467	chr19:12552597~12553644:+
THCA	cis	rs9649213	0.593	rs35983874	ENSG00000272950.1	RP11-307C18.1	8	9.84e-15	3.9e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98287149	chr7:98322853~98323430:+
THCA	cis	rs1799949	0.602	rs8176199	ENSG00000267681.1	CTD-3199J23.6	-8	9.86e-15	3.91e-12	-0.46	-0.35	Menopause (age at onset);	chr17:43078507	chr17:43144956~43145255:+
THCA	cis	rs11096990	0.634	rs2062229	ENSG00000249685.1	RP11-360F5.3	8	9.9e-15	3.92e-12	0.41	0.35	Cognitive function;	chr4:39285146	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs7564	ENSG00000249685.1	RP11-360F5.3	-8	9.9e-15	3.92e-12	-0.41	-0.35	Cognitive function;	chr4:39285702	chr4:39133913~39135608:+
THCA	cis	rs7674212	0.531	rs2866416	ENSG00000251288.2	RP11-10L12.2	-8	9.9e-15	3.93e-12	-0.47	-0.35	Type 2 diabetes;	chr4:102959554	chr4:102751401~102752641:+
THCA	cis	rs11096990	0.656	rs2123027	ENSG00000249685.1	RP11-360F5.3	-8	9.94e-15	3.94e-12	-0.41	-0.35	Cognitive function;	chr4:39289493	chr4:39133913~39135608:+
THCA	cis	rs2274273	0.623	rs1187881	ENSG00000258413.1	RP11-665C16.6	8	9.96e-15	3.95e-12	0.47	0.35	Protein biomarker;	chr14:55022479	chr14:55262767~55272075:-
THCA	cis	rs2408955	0.542	rs7975632	ENSG00000258273.1	RP11-370I10.4	-8	9.97e-15	3.95e-12	-0.45	-0.35	Glycated hemoglobin levels;	chr12:48049265	chr12:48333755~48333901:-
THCA	cis	rs7247513	0.964	rs1864083	ENSG00000230310.1	CTD-2192J16.11	-8	9.97e-15	3.95e-12	-0.42	-0.35	Bipolar disorder;	chr19:12596488	chr19:12552597~12553644:+
THCA	cis	rs7714584	0.793	rs35707106	ENSG00000197083.10	ZNF300P1	8	9.98e-15	3.96e-12	0.56	0.35	Crohn's disease;	chr5:150845815	chr5:150930645~150946289:-
THCA	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	8	9.98e-15	3.96e-12	0.34	0.35	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
THCA	cis	rs77204473	0.744	rs12419178	ENSG00000254851.1	RP11-109L13.1	8	9.98e-15	3.96e-12	0.83	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117180202	chr11:117135528~117138582:+
THCA	cis	rs2562456	0.874	rs9304986	ENSG00000268555.1	RP11-678G14.3	-8	1e-14	3.96e-12	-0.48	-0.35	Pain;	chr19:21499260	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs2650805	ENSG00000268555.1	RP11-678G14.3	-8	1e-14	3.96e-12	-0.48	-0.35	Pain;	chr19:21505137	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs10420016	ENSG00000268555.1	RP11-678G14.3	-8	1e-14	3.96e-12	-0.48	-0.35	Pain;	chr19:21505800	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs2681389	ENSG00000268555.1	RP11-678G14.3	-8	1e-14	3.97e-12	-0.48	-0.35	Pain;	chr19:21509773	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.917	rs6511256	ENSG00000268555.1	RP11-678G14.3	-8	1e-14	3.97e-12	-0.48	-0.35	Pain;	chr19:21510513	chr19:21570822~21587322:-
THCA	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	8	1.01e-14	3.99e-12	0.42	0.35	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
THCA	cis	rs9326248	0.813	rs588534	ENSG00000280143.1	AP000892.6	8	1.01e-14	4e-12	0.49	0.35	Blood protein levels;	chr11:117197788	chr11:117204967~117210292:+
THCA	cis	rs9649213	0.593	rs6944262	ENSG00000272950.1	RP11-307C18.1	8	1.01e-14	4e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98356103	chr7:98322853~98323430:+
THCA	cis	rs77204473	0.744	rs2306471	ENSG00000254851.1	RP11-109L13.1	7.99	1.02e-14	4.04e-12	0.91	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117145734	chr11:117135528~117138582:+
THCA	cis	rs7674212	0.531	rs4698876	ENSG00000246560.2	RP11-10L12.4	7.99	1.02e-14	4.04e-12	0.43	0.35	Type 2 diabetes;	chr4:103012410	chr4:102828055~102844075:+
THCA	cis	rs7674212	0.531	rs7665026	ENSG00000246560.2	RP11-10L12.4	7.99	1.02e-14	4.04e-12	0.43	0.35	Type 2 diabetes;	chr4:103015491	chr4:102828055~102844075:+
THCA	cis	rs240993	0.516	rs173286	ENSG00000230177.1	RP5-1112D6.4	-7.99	1.02e-14	4.04e-12	-0.38	-0.35	Inflammatory skin disease;Psoriasis;	chr6:111292391	chr6:111277932~111278742:+
THCA	cis	rs116175783	0.557	rs2303318	ENSG00000227403.1	AC009299.3	7.99	1.02e-14	4.04e-12	0.61	0.35	Intelligence (multi-trait analysis);	chr2:161367984	chr2:161244739~161249050:+
THCA	cis	rs2839186	0.77	rs2839171	ENSG00000239415.1	AP001469.9	-7.99	1.02e-14	4.05e-12	-0.36	-0.35	Testicular germ cell tumor;	chr21:46253333	chr21:46251549~46254133:-
THCA	cis	rs9341808	0.5	rs2223873	ENSG00000272129.1	RP11-250B2.6	7.99	1.02e-14	4.05e-12	0.42	0.35	Sitting height ratio;	chr6:80338571	chr6:80355424~80356859:+
THCA	cis	rs4819052	1	rs4818769	ENSG00000237664.1	LINC00316	-7.99	1.03e-14	4.06e-12	-0.37	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45247536	chr21:45338590~45341990:-
THCA	cis	rs7829975	0.755	rs3789849	ENSG00000253893.2	FAM85B	-7.99	1.03e-14	4.07e-12	-0.43	-0.35	Mood instability;	chr8:8829544	chr8:8167819~8226614:-
THCA	cis	rs10875746	0.669	rs4760701	ENSG00000240399.1	RP1-228P16.1	-7.99	1.03e-14	4.07e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48304735	chr12:48054813~48055591:-
THCA	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-7.99	1.03e-14	4.08e-12	-0.42	-0.35	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
THCA	cis	rs1707322	1	rs10890353	ENSG00000234329.1	RP11-767N6.2	7.99	1.03e-14	4.08e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45651039~45651826:-
THCA	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-7.99	1.03e-14	4.08e-12	-0.56	-0.35	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
THCA	cis	rs9649213	0.593	rs1468340	ENSG00000272950.1	RP11-307C18.1	7.99	1.03e-14	4.09e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98358364	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.555	rs6956686	ENSG00000272950.1	RP11-307C18.1	7.99	1.03e-14	4.09e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98368633	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs13246843	ENSG00000272950.1	RP11-307C18.1	7.99	1.03e-14	4.09e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98373349	chr7:98322853~98323430:+
THCA	cis	rs4072705	1	rs7874367	ENSG00000224020.1	MIR181A2HG	7.99	1.04e-14	4.1e-12	0.3	0.35	Menarche (age at onset);	chr9:124615501	chr9:124658467~124698631:+
THCA	cis	rs13068223	0.935	rs1560414	ENSG00000243926.1	TIPARP-AS1	7.99	1.04e-14	4.1e-12	0.33	0.35	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723960	chr3:156671862~156674378:-
THCA	cis	rs17684571	0.872	rs36068365	ENSG00000231441.1	RP11-472M19.2	7.99	1.04e-14	4.1e-12	0.43	0.35	Schizophrenia;	chr6:56716358	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs11968575	ENSG00000231441.1	RP11-472M19.2	7.99	1.04e-14	4.1e-12	0.43	0.35	Schizophrenia;	chr6:56728107	chr6:56844002~56864078:+
THCA	cis	rs42490	0.674	rs447989	ENSG00000251136.7	RP11-37B2.1	-7.99	1.04e-14	4.11e-12	-0.3	-0.35	Leprosy;	chr8:89848575	chr8:89609409~89757727:-
THCA	cis	rs7714584	0.826	rs34005003	ENSG00000197083.10	ZNF300P1	7.99	1.04e-14	4.11e-12	0.56	0.35	Crohn's disease;	chr5:150845637	chr5:150930645~150946289:-
THCA	cis	rs9309473	0.579	rs1852644	ENSG00000163016.8	ALMS1P	7.99	1.04e-14	4.12e-12	0.46	0.35	Metabolite levels;	chr2:73370590	chr2:73644919~73685576:+
THCA	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	7.99	1.04e-14	4.12e-12	0.33	0.35	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
THCA	cis	rs73186030	1	rs73186044	ENSG00000272758.4	RP11-299J3.8	7.99	1.04e-14	4.12e-12	0.43	0.35	Serum parathyroid hormone levels;	chr3:122309629	chr3:122416207~122443180:+
THCA	cis	rs4927850	1	rs7614767	ENSG00000226155.1	AC124944.3	-7.99	1.04e-14	4.12e-12	-0.41	-0.35	Pancreatic cancer;	chr3:196026580	chr3:195912049~195913986:+
THCA	cis	rs17772222	0.958	rs17798341	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.12e-12	0.43	0.35	Coronary artery calcification;	chr14:88548201	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.958	rs10134008	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.12e-12	0.43	0.35	Coronary artery calcification;	chr14:88549183	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.958	rs891750	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.12e-12	0.43	0.35	Coronary artery calcification;	chr14:88550856	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.958	rs891749	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.12e-12	0.43	0.35	Coronary artery calcification;	chr14:88550893	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs61984683	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.12e-12	0.43	0.35	Coronary artery calcification;	chr14:88553162	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs61984684	ENSG00000258983.2	RP11-507K2.2	7.99	1.04e-14	4.12e-12	0.43	0.35	Coronary artery calcification;	chr14:88559104	chr14:88499334~88515502:+
THCA	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	7.99	1.05e-14	4.13e-12	0.48	0.35	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
THCA	cis	rs2562456	0.792	rs2562398	ENSG00000268555.1	RP11-678G14.3	-7.99	1.05e-14	4.14e-12	-0.48	-0.35	Pain;	chr19:21540147	chr19:21570822~21587322:-
THCA	cis	rs75422866	0.867	rs73102125	ENSG00000257433.4	RP1-197B17.3	7.99	1.05e-14	4.15e-12	0.53	0.35	Pneumonia;	chr12:47637869	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs12426849	ENSG00000257433.4	RP1-197B17.3	7.99	1.05e-14	4.15e-12	0.53	0.35	Pneumonia;	chr12:47638975	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs117950951	ENSG00000257433.4	RP1-197B17.3	7.99	1.05e-14	4.15e-12	0.53	0.35	Pneumonia;	chr12:47639794	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs7954764	ENSG00000257433.4	RP1-197B17.3	7.99	1.05e-14	4.15e-12	0.53	0.35	Pneumonia;	chr12:47641136	chr12:47706085~47742294:+
THCA	cis	rs847577	0.677	rs10242903	ENSG00000272950.1	RP11-307C18.1	-7.99	1.05e-14	4.16e-12	-0.43	-0.35	Breast cancer;	chr7:98112483	chr7:98322853~98323430:+
THCA	cis	rs1707322	1	rs10890370	ENSG00000234329.1	RP11-767N6.2	7.99	1.05e-14	4.17e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45651039~45651826:-
THCA	cis	rs4266144	0.544	rs7340627	ENSG00000244515.1	KRT18P34	-7.99	1.05e-14	4.17e-12	-0.38	-0.35	Coronary artery disease;	chr3:157114604	chr3:157162663~157163932:-
THCA	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-7.99	1.06e-14	4.17e-12	-0.57	-0.35	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
THCA	cis	rs7302981	0.967	rs12815871	ENSG00000272368.2	RP4-605O3.4	7.99	1.06e-14	4.19e-12	0.21	0.35	Systolic blood pressure;	chr12:50157165	chr12:50112197~50165618:+
THCA	cis	rs17711722	0.523	rs365896	ENSG00000164669.11	INTS4P1	7.99	1.06e-14	4.2e-12	0.43	0.35	Calcium levels;	chr7:66045710	chr7:65141225~65234216:+
THCA	cis	rs9649213	0.593	rs6969234	ENSG00000272950.1	RP11-307C18.1	7.99	1.06e-14	4.2e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98358674	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs3801256	ENSG00000272950.1	RP11-307C18.1	7.99	1.06e-14	4.2e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98362783	chr7:98322853~98323430:+
THCA	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-7.99	1.06e-14	4.2e-12	-0.41	-0.35	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
THCA	cis	rs7615952	0.576	rs17523380	ENSG00000171084.14	FAM86JP	7.99	1.07e-14	4.21e-12	0.39	0.35	Blood pressure (smoking interaction);	chr3:126084031	chr3:125916620~125930024:+
THCA	cis	rs7727544	0.618	rs2631367	ENSG00000233006.5	AC034220.3	-7.99	1.07e-14	4.21e-12	-0.27	-0.35	Blood metabolite levels;	chr5:132369766	chr5:132311285~132369916:-
THCA	cis	rs9309473	0.583	rs6546822	ENSG00000163016.8	ALMS1P	7.99	1.07e-14	4.22e-12	0.46	0.35	Metabolite levels;	chr2:73347970	chr2:73644919~73685576:+
THCA	cis	rs10800713	0.954	rs4623737	ENSG00000260088.1	RP11-92G12.3	-7.99	1.07e-14	4.22e-12	-0.45	-0.35	Tandem gait;	chr1:200594578	chr1:200669507~200694250:+
THCA	cis	rs4713118	1	rs13215072	ENSG00000219392.1	RP1-265C24.5	-7.99	1.07e-14	4.22e-12	-0.44	-0.35	Parkinson's disease;	chr6:27709949	chr6:28115628~28116551:+
THCA	cis	rs507080	0.922	rs514143	ENSG00000278376.1	RP11-158I9.8	-7.99	1.07e-14	4.23e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118687740	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs558907	ENSG00000278376.1	RP11-158I9.8	-7.99	1.07e-14	4.23e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118687746	chr11:118791254~118793137:+
THCA	cis	rs737008	0.922	rs28567501	ENSG00000262636.1	CTD-3088G3.4	-7.99	1.07e-14	4.23e-12	-0.44	-0.35	Obesity-related traits;	chr16:11285071	chr16:11380859~11381118:-
THCA	cis	rs11096990	0.634	rs11947159	ENSG00000249685.1	RP11-360F5.3	-7.99	1.07e-14	4.23e-12	-0.41	-0.35	Cognitive function;	chr4:39286900	chr4:39133913~39135608:+
THCA	cis	rs10936632	0.565	rs9865021	ENSG00000242578.1	RP11-469J4.3	-7.99	1.07e-14	4.24e-12	-0.38	-0.35	Prostate cancer;	chr3:170429093	chr3:170410512~170418615:+
THCA	cis	rs507080	0.769	rs2077173	ENSG00000278376.1	RP11-158I9.8	-7.99	1.07e-14	4.24e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118621876	chr11:118791254~118793137:+
THCA	cis	rs10208649	0.71	rs10190353	ENSG00000272156.1	RP11-477N3.1	7.99	1.07e-14	4.24e-12	0.64	0.35	Body mass index;	chr2:54015688	chr2:54082554~54085066:+
THCA	cis	rs3096299	0.583	rs889574	ENSG00000274627.1	RP11-104N10.2	7.99	1.08e-14	4.25e-12	0.36	0.35	Multiple myeloma (IgH translocation);	chr16:89320400	chr16:89516797~89522217:+
THCA	cis	rs9649213	0.593	rs3801255	ENSG00000272950.1	RP11-307C18.1	7.99	1.08e-14	4.25e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98371617	chr7:98322853~98323430:+
THCA	cis	rs62355901	0.505	rs61193961	ENSG00000271828.1	CTD-2310F14.1	7.99	1.08e-14	4.25e-12	0.71	0.35	Breast cancer;	chr5:56792343	chr5:56927874~56929573:+
THCA	cis	rs6142102	0.602	rs6142069	ENSG00000275784.1	RP5-1125A11.6	-7.99	1.08e-14	4.26e-12	-0.34	-0.35	Skin pigmentation;	chr20:33972736	chr20:33989480~33991818:-
THCA	cis	rs193541	0.632	rs154504	ENSG00000263432.2	RN7SL689P	7.99	1.08e-14	4.26e-12	0.41	0.35	Glucose homeostasis traits;	chr5:122868391	chr5:123022487~123022783:-
THCA	cis	rs4927850	1	rs10881563	ENSG00000242086.7	LINC00969	7.99	1.08e-14	4.26e-12	0.34	0.35	Pancreatic cancer;	chr3:196023354	chr3:195658062~195739964:+
THCA	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	7.99	1.08e-14	4.27e-12	0.35	0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
THCA	cis	rs28510890	0.72	rs17704001	ENSG00000260337.3	RP11-386M24.6	7.99	1.08e-14	4.28e-12	0.38	0.35	Lung cancer in ever smokers;	chr15:92583935	chr15:92592574~92596462:-
THCA	cis	rs9649213	0.593	rs2240349	ENSG00000272950.1	RP11-307C18.1	7.99	1.09e-14	4.28e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98355351	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs13307593	ENSG00000272950.1	RP11-307C18.1	7.99	1.09e-14	4.28e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98356834	chr7:98322853~98323430:+
THCA	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	7.99	1.09e-14	4.29e-12	0.41	0.35	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
THCA	cis	rs10875746	0.551	rs2054904	ENSG00000240399.1	RP1-228P16.1	-7.99	1.09e-14	4.3e-12	-0.39	-0.35	Longevity (90 years and older);	chr12:48330571	chr12:48054813~48055591:-
THCA	cis	rs1707322	1	rs34694458	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6671754	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs6666763	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4489497	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211235	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.893	rs9919275	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211236	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660328	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.928	rs61785614	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs9793167	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211237	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs11211238	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4460583	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs4459051	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211239	ENSG00000234329.1	RP11-767N6.2	7.98	1.09e-14	4.3e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45651039~45651826:-
THCA	cis	rs9649213	0.593	rs7778015	ENSG00000272950.1	RP11-307C18.1	7.98	1.09e-14	4.31e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98290958	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs1132971	ENSG00000272950.1	RP11-307C18.1	7.98	1.09e-14	4.31e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98292221	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs6465664	ENSG00000272950.1	RP11-307C18.1	7.98	1.09e-14	4.31e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98292522	chr7:98322853~98323430:+
THCA	cis	rs7727544	0.606	rs10060615	ENSG00000233006.5	AC034220.3	7.98	1.1e-14	4.32e-12	0.27	0.35	Blood metabolite levels;	chr5:132373185	chr5:132311285~132369916:-
THCA	cis	rs2439831	0.867	rs2447208	ENSG00000275601.1	AC011330.13	-7.98	1.1e-14	4.34e-12	-0.54	-0.35	Lung cancer in ever smokers;	chr15:43641697	chr15:43642389~43643023:-
THCA	cis	rs529866	0.5	rs918739	ENSG00000262636.1	CTD-3088G3.4	-7.98	1.1e-14	4.34e-12	-0.45	-0.35	Inflammatory bowel disease;Crohn's disease;	chr16:11345876	chr16:11380859~11381118:-
THCA	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-7.98	1.1e-14	4.34e-12	-0.41	-0.35	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
THCA	cis	rs1707322	0.964	rs7546237	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211200	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7553924	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4641257	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6693336	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4539075	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211219	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211222	ENSG00000234329.1	RP11-767N6.2	7.98	1.1e-14	4.35e-12	0.32	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45651039~45651826:-
THCA	cis	rs8114671	0.805	rs6060168	ENSG00000269202.1	RP4-614O4.12	-7.98	1.1e-14	4.36e-12	-0.29	-0.35	Height;	chr20:35033214	chr20:35201747~35203288:-
THCA	cis	rs9640161	0.83	rs35635199	ENSG00000261305.1	RP4-584D14.7	7.98	1.11e-14	4.36e-12	0.42	0.35	Blood protein levels;Circulating chemerin levels;	chr7:150366253	chr7:150341771~150342607:+
THCA	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-7.98	1.11e-14	4.36e-12	-0.41	-0.35	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
THCA	cis	rs1707322	1	rs11211243	ENSG00000234329.1	RP11-767N6.2	7.98	1.11e-14	4.37e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211244	ENSG00000234329.1	RP11-767N6.2	7.98	1.11e-14	4.37e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660903	ENSG00000234329.1	RP11-767N6.2	7.98	1.11e-14	4.37e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660905	ENSG00000234329.1	RP11-767N6.2	-7.98	1.11e-14	4.37e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45651039~45651826:-
THCA	cis	rs507080	0.807	rs7926944	ENSG00000278376.1	RP11-158I9.8	-7.98	1.11e-14	4.37e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118689119	chr11:118791254~118793137:+
THCA	cis	rs737008	0.922	rs2070923	ENSG00000262636.1	CTD-3088G3.4	7.98	1.11e-14	4.38e-12	0.45	0.35	Obesity-related traits;	chr16:11275998	chr16:11380859~11381118:-
THCA	cis	rs7621025	0.5	rs4678275	ENSG00000273486.1	RP11-731C17.2	7.98	1.11e-14	4.38e-12	0.35	0.35	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136934841	chr3:136837338~136839021:-
THCA	cis	rs12908161	1	rs11638290	ENSG00000225151.9	GOLGA2P7	-7.98	1.11e-14	4.38e-12	-0.51	-0.35	Schizophrenia;	chr15:84684405	chr15:84199311~84230136:-
THCA	cis	rs12908161	0.959	rs34028043	ENSG00000225151.9	GOLGA2P7	-7.98	1.11e-14	4.38e-12	-0.51	-0.35	Schizophrenia;	chr15:84688354	chr15:84199311~84230136:-
THCA	cis	rs12908161	0.959	rs34784022	ENSG00000225151.9	GOLGA2P7	-7.98	1.11e-14	4.38e-12	-0.51	-0.35	Schizophrenia;	chr15:84688675	chr15:84199311~84230136:-
THCA	cis	rs77204473	0.744	rs80351364	ENSG00000254851.1	RP11-109L13.1	7.98	1.11e-14	4.39e-12	0.9	0.35	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221678	chr11:117135528~117138582:+
THCA	cis	rs910316	0.687	rs175059	ENSG00000279594.1	RP11-950C14.10	-7.98	1.11e-14	4.39e-12	-0.31	-0.35	Height;	chr14:75023964	chr14:75011269~75012851:-
THCA	cis	rs17772222	0.958	rs60878614	ENSG00000258983.2	RP11-507K2.2	7.98	1.11e-14	4.39e-12	0.43	0.35	Coronary artery calcification;	chr14:88513871	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.958	rs76559451	ENSG00000258983.2	RP11-507K2.2	7.98	1.11e-14	4.39e-12	0.43	0.35	Coronary artery calcification;	chr14:88523193	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.958	rs12436326	ENSG00000258983.2	RP11-507K2.2	7.98	1.11e-14	4.39e-12	0.43	0.35	Coronary artery calcification;	chr14:88533632	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.958	rs17203789	ENSG00000258983.2	RP11-507K2.2	7.98	1.11e-14	4.39e-12	0.43	0.35	Coronary artery calcification;	chr14:88541362	chr14:88499334~88515502:+
THCA	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-7.98	1.11e-14	4.39e-12	-0.42	-0.35	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
THCA	cis	rs11603691	0.901	rs61888888	ENSG00000254662.1	RP11-872D17.4	-7.98	1.12e-14	4.39e-12	-0.65	-0.35	Low high density lipoprotein cholesterol levels;	chr11:57336210	chr11:57325603~57327958:+
THCA	cis	rs7942368	1	rs1440977	ENSG00000254632.1	RP11-21L23.4	7.98	1.12e-14	4.4e-12	0.5	0.35	Endometriosis;	chr11:76765385	chr11:76759916~76768223:-
THCA	cis	rs12680842	0.883	rs13265241	ENSG00000253704.1	RP11-267M23.4	7.98	1.12e-14	4.41e-12	0.36	0.35	Body mass index;	chr8:94575129	chr8:94553722~94569745:+
THCA	cis	rs9926296	0.744	rs164749	ENSG00000260259.1	RP11-368I7.4	7.98	1.12e-14	4.41e-12	0.36	0.35	Vitiligo;	chr16:89641816	chr16:89682620~89686569:-
THCA	cis	rs8062405	0.757	rs2411453	ENSG00000251417.2	RP11-1348G14.4	7.98	1.12e-14	4.43e-12	0.32	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28802743~28817828:+
THCA	cis	rs4713118	1	rs4713118	ENSG00000219392.1	RP1-265C24.5	-7.98	1.12e-14	4.43e-12	-0.44	-0.35	Parkinson's disease;	chr6:27709015	chr6:28115628~28116551:+
THCA	cis	rs17772222	0.582	rs12050316	ENSG00000258789.1	RP11-507K2.3	-7.98	1.13e-14	4.43e-12	-0.33	-0.35	Coronary artery calcification;	chr14:88522097	chr14:88551597~88552493:+
THCA	cis	rs4072705	1	rs4836991	ENSG00000224020.1	MIR181A2HG	7.98	1.13e-14	4.44e-12	0.31	0.35	Menarche (age at onset);	chr9:124749761	chr9:124658467~124698631:+
THCA	cis	rs7247513	0.927	rs34956595	ENSG00000230310.1	CTD-2192J16.11	-7.98	1.13e-14	4.45e-12	-0.42	-0.35	Bipolar disorder;	chr19:12591983	chr19:12552597~12553644:+
THCA	cis	rs9649213	0.574	rs12873	ENSG00000272950.1	RP11-307C18.1	7.98	1.13e-14	4.45e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98293461	chr7:98322853~98323430:+
THCA	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-7.98	1.13e-14	4.45e-12	-0.56	-0.35	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
THCA	cis	rs748404	0.578	rs512628	ENSG00000205771.5	CATSPER2P1	-7.98	1.13e-14	4.46e-12	-0.36	-0.35	Lung cancer;	chr15:43326536	chr15:43726918~43747094:-
THCA	cis	rs507080	0.922	rs625513	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118685010	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs546890	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118686489	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs555356	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118687369	chr11:118791254~118793137:+
THCA	cis	rs507080	0.883	rs693306	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118687624	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs561845	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118688118	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs638805	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118688180	chr11:118791254~118793137:+
THCA	cis	rs507080	0.845	rs510408	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118688192	chr11:118791254~118793137:+
THCA	cis	rs507080	0.845	rs509641	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118688243	chr11:118791254~118793137:+
THCA	cis	rs507080	0.883	rs563549	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118688244	chr11:118791254~118793137:+
THCA	cis	rs507080	0.885	rs533144	ENSG00000278376.1	RP11-158I9.8	-7.98	1.14e-14	4.47e-12	-0.27	-0.35	Serum metabolite levels;	chr11:118688538	chr11:118791254~118793137:+
THCA	cis	rs812925	0.537	rs778146	ENSG00000271889.1	RP11-493E12.1	-7.98	1.14e-14	4.49e-12	-0.33	-0.35	Immature fraction of reticulocytes;	chr2:61379340	chr2:61151433~61162105:-
THCA	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	7.98	1.14e-14	4.49e-12	0.33	0.35	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
THCA	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	7.98	1.14e-14	4.49e-12	0.48	0.35	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
THCA	cis	rs812925	0.519	rs2694638	ENSG00000271889.1	RP11-493E12.1	-7.98	1.14e-14	4.49e-12	-0.34	-0.35	Immature fraction of reticulocytes;	chr2:61408228	chr2:61151433~61162105:-
THCA	cis	rs6840258	0.547	rs17012170	ENSG00000251411.1	RP11-397E7.4	-7.98	1.14e-14	4.49e-12	-0.44	-0.35	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86939692	chr4:86913266~86914817:-
THCA	cis	rs8081395	0.651	rs1292067	ENSG00000266992.1	DHX40P1	-7.98	1.15e-14	4.52e-12	-0.41	-0.35	White blood cell count;	chr17:59853285	chr17:59976009~60002384:-
THCA	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-7.98	1.15e-14	4.54e-12	-0.37	-0.35	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-7.98	1.15e-14	4.54e-12	-0.37	-0.35	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-7.98	1.15e-14	4.54e-12	-0.37	-0.35	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-7.98	1.15e-14	4.54e-12	-0.37	-0.35	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-7.98	1.15e-14	4.54e-12	-0.37	-0.35	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
THCA	cis	rs42490	0.716	rs40638	ENSG00000251136.7	RP11-37B2.1	-7.98	1.15e-14	4.54e-12	-0.29	-0.35	Leprosy;	chr8:89815824	chr8:89609409~89757727:-
THCA	cis	rs42490	0.716	rs370282	ENSG00000251136.7	RP11-37B2.1	-7.98	1.15e-14	4.54e-12	-0.29	-0.35	Leprosy;	chr8:89816117	chr8:89609409~89757727:-
THCA	cis	rs3747113	1	rs3747113	ENSG00000128262.7	POM121L9P	7.98	1.15e-14	4.54e-12	0.37	0.35	Gut microbiome composition (summer);	chr22:24321550	chr22:24251828~24265525:+
THCA	cis	rs7674212	0.507	rs10516495	ENSG00000251288.2	RP11-10L12.2	-7.98	1.16e-14	4.55e-12	-0.47	-0.35	Type 2 diabetes;	chr4:102978933	chr4:102751401~102752641:+
THCA	cis	rs193541	0.545	rs12518979	ENSG00000263432.2	RN7SL689P	-7.98	1.16e-14	4.56e-12	-0.4	-0.35	Glucose homeostasis traits;	chr5:122846092	chr5:123022487~123022783:-
THCA	cis	rs9309473	0.607	rs1522926	ENSG00000163016.8	ALMS1P	7.98	1.16e-14	4.57e-12	0.46	0.35	Metabolite levels;	chr2:73364113	chr2:73644919~73685576:+
THCA	cis	rs1707322	1	rs10890378	ENSG00000234329.1	RP11-767N6.2	-7.98	1.16e-14	4.58e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs785478	ENSG00000234329.1	RP11-767N6.2	-7.98	1.16e-14	4.58e-12	-0.33	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6657720	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7519181	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10890372	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.928	rs6681068	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211228	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs9803784	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs12022335	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10890375	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10890377	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs10789484	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7527079	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs34446427	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs4660900	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4454479	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs7517560	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs12077546	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs12124291	ENSG00000234329.1	RP11-767N6.2	7.98	1.16e-14	4.58e-12	0.33	0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45651039~45651826:-
THCA	cis	rs934734	0.532	rs12185610	ENSG00000237979.1	AC007389.1	-7.98	1.17e-14	4.58e-12	-0.39	-0.35	Rheumatoid arthritis;	chr2:65434334	chr2:65500993~65502138:-
THCA	cis	rs3096299	0.583	rs1078577	ENSG00000274627.1	RP11-104N10.2	7.97	1.18e-14	4.62e-12	0.36	0.35	Multiple myeloma (IgH translocation);	chr16:89320680	chr16:89516797~89522217:+
THCA	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-7.97	1.18e-14	4.63e-12	-0.41	-0.35	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
THCA	cis	rs1859596	0.625	rs10260483	ENSG00000234456.6	MAGI2-AS3	-7.97	1.18e-14	4.63e-12	-0.33	-0.35	Reading or mathematical ability;	chr7:79470338	chr7:79452877~79471208:+
THCA	cis	rs910316	0.967	rs10142770	ENSG00000279594.1	RP11-950C14.10	7.97	1.18e-14	4.63e-12	0.32	0.35	Height;	chr14:75058746	chr14:75011269~75012851:-
THCA	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-7.97	1.18e-14	4.63e-12	-0.41	-0.35	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
THCA	cis	rs2880765	0.525	rs2062234	ENSG00000259295.5	CSPG4P12	7.97	1.18e-14	4.65e-12	0.51	0.35	Coronary artery disease;	chr15:85511259	chr15:85191438~85213905:+
THCA	cis	rs7247513	0.93	rs1864082	ENSG00000230310.1	CTD-2192J16.11	-7.97	1.18e-14	4.66e-12	-0.42	-0.35	Bipolar disorder;	chr19:12597090	chr19:12552597~12553644:+
THCA	cis	rs11603691	1	rs10896608	ENSG00000254662.1	RP11-872D17.4	-7.97	1.19e-14	4.67e-12	-0.61	-0.35	Low high density lipoprotein cholesterol levels;	chr11:57341437	chr11:57325603~57327958:+
THCA	cis	rs934734	0.789	rs906579	ENSG00000204929.10	AC074391.1	-7.97	1.19e-14	4.67e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65374464	chr2:65436711~66084639:+
THCA	cis	rs934734	0.789	rs906578	ENSG00000204929.10	AC074391.1	-7.97	1.19e-14	4.67e-12	-0.43	-0.35	Rheumatoid arthritis;	chr2:65374466	chr2:65436711~66084639:+
THCA	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-7.97	1.19e-14	4.67e-12	-0.37	-0.35	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
THCA	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-7.97	1.19e-14	4.67e-12	-0.42	-0.35	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
THCA	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	7.97	1.19e-14	4.68e-12	0.42	0.35	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
THCA	cis	rs748404	0.631	rs6493086	ENSG00000205771.5	CATSPER2P1	-7.97	1.19e-14	4.68e-12	-0.36	-0.35	Lung cancer;	chr15:43363196	chr15:43726918~43747094:-
THCA	cis	rs638893	0.617	rs4938558	ENSG00000278376.1	RP11-158I9.8	-7.97	1.19e-14	4.68e-12	-0.3	-0.35	Vitiligo;	chr11:118847220	chr11:118791254~118793137:+
THCA	cis	rs10208649	0.908	rs114837028	ENSG00000272156.1	RP11-477N3.1	7.97	1.19e-14	4.69e-12	0.72	0.35	Body mass index;	chr2:53983416	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs74930210	ENSG00000272156.1	RP11-477N3.1	7.97	1.19e-14	4.69e-12	0.72	0.35	Body mass index;	chr2:53995287	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.808	rs115322634	ENSG00000272156.1	RP11-477N3.1	7.97	1.19e-14	4.69e-12	0.72	0.35	Body mass index;	chr2:53997572	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs78688150	ENSG00000272156.1	RP11-477N3.1	7.97	1.19e-14	4.69e-12	0.72	0.35	Body mass index;	chr2:53997658	chr2:54082554~54085066:+
THCA	cis	rs42490	0.689	rs43228	ENSG00000251136.7	RP11-37B2.1	-7.97	1.19e-14	4.69e-12	-0.29	-0.35	Leprosy;	chr8:89816790	chr8:89609409~89757727:-
THCA	cis	rs9649213	0.593	rs6967457	ENSG00000272950.1	RP11-307C18.1	7.97	1.2e-14	4.69e-12	0.42	0.35	Prostate cancer (SNP x SNP interaction);	chr7:98282909	chr7:98322853~98323430:+
THCA	cis	rs10208649	0.908	rs2161083	ENSG00000272156.1	RP11-477N3.1	7.97	1.2e-14	4.71e-12	0.63	0.35	Body mass index;	chr2:54024661	chr2:54082554~54085066:+
THCA	cis	rs10208649	1	rs2112120	ENSG00000272156.1	RP11-477N3.1	7.97	1.2e-14	4.71e-12	0.63	0.35	Body mass index;	chr2:54024957	chr2:54082554~54085066:+
THCA	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	7.97	1.2e-14	4.72e-12	0.46	0.35	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
THCA	cis	rs2739330	0.796	rs2154594	ENSG00000206090.4	AP000350.7	-7.97	1.2e-14	4.72e-12	-0.43	-0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23939998~23942798:+
THCA	cis	rs4819052	0.851	rs7279011	ENSG00000237664.1	LINC00316	-7.97	1.2e-14	4.73e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236080	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs7279182	ENSG00000237664.1	LINC00316	-7.97	1.2e-14	4.73e-12	-0.35	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236197	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs7276103	ENSG00000237664.1	LINC00316	-7.97	1.2e-14	4.73e-12	-0.34	-0.35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246163	chr21:45338590~45341990:-
THCA	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	7.97	1.21e-14	4.74e-12	0.46	0.35	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
THCA	cis	rs9649213	0.593	rs10953257	ENSG00000272950.1	RP11-307C18.1	-7.97	1.21e-14	4.76e-12	-0.42	-0.35	Prostate cancer (SNP x SNP interaction);	chr7:98331352	chr7:98322853~98323430:+
THCA	cis	rs4950322	0.542	rs4950382	ENSG00000237188.3	RP11-337C18.8	7.97	1.22e-14	4.77e-12	0.39	0.35	Protein quantitative trait loci;	chr1:147176645	chr1:147172771~147211568:+
THCA	cis	rs9532669	0.89	rs2149570	ENSG00000239827.7	SUGT1P3	-7.97	1.22e-14	4.77e-12	-0.39	-0.35	Cervical cancer;	chr13:40858533	chr13:40908159~40921774:-
THCA	cis	rs6840258	0.547	rs72667727	ENSG00000251411.1	RP11-397E7.4	-7.97	1.22e-14	4.79e-12	-0.44	-0.35	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86936370	chr4:86913266~86914817:-
THCA	cis	rs732716	0.785	rs11085073	ENSG00000267980.1	AC007292.6	7.97	1.22e-14	4.8e-12	0.4	0.35	Mean corpuscular volume;	chr19:4375165	chr19:4363789~4364640:+
THCA	cis	rs2739330	0.828	rs2330635	ENSG00000206090.4	AP000350.7	7.97	1.22e-14	4.8e-12	0.43	0.35	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23939998~23942798:+
THCA	cis	rs77683187	1	rs77683187	ENSG00000254851.1	RP11-109L13.1	7.97	1.22e-14	4.81e-12	0.8	0.34	Breast cancer;	chr11:117214494	chr11:117135528~117138582:+
THCA	cis	rs736801	0.808	rs4705950	ENSG00000237714.1	P4HA2-AS1	7.97	1.23e-14	4.82e-12	0.46	0.34	Mosquito bite size;Breast cancer;	chr5:132457594	chr5:132184876~132192808:+
THCA	cis	rs11971779	0.838	rs4728468	ENSG00000273391.1	RP11-634H22.1	7.97	1.23e-14	4.83e-12	0.34	0.34	Diisocyanate-induced asthma;	chr7:139438232	chr7:139359032~139359566:-
THCA	cis	rs367615	1	rs367615	ENSG00000249476.1	CTD-2587M2.1	-7.97	1.23e-14	4.83e-12	-0.37	-0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109613236	chr5:109237120~109326369:-
THCA	cis	rs9649213	0.593	rs7796611	ENSG00000272950.1	RP11-307C18.1	7.97	1.24e-14	4.86e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98278911	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.574	rs13238610	ENSG00000272950.1	RP11-307C18.1	7.97	1.24e-14	4.86e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98279965	chr7:98322853~98323430:+
THCA	cis	rs8114671	0.836	rs13042358	ENSG00000269202.1	RP4-614O4.12	7.97	1.24e-14	4.86e-12	0.29	0.34	Height;	chr20:35046676	chr20:35201747~35203288:-
THCA	cis	rs910316	0.836	rs6574212	ENSG00000279594.1	RP11-950C14.10	-7.97	1.24e-14	4.86e-12	-0.32	-0.34	Height;	chr14:75204956	chr14:75011269~75012851:-
THCA	cis	rs1387259	0.64	rs10783243	ENSG00000258273.1	RP11-370I10.4	7.97	1.24e-14	4.88e-12	0.4	0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48333755~48333901:-
THCA	cis	rs77204473	0.744	rs12418705	ENSG00000254851.1	RP11-109L13.1	7.97	1.24e-14	4.88e-12	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117213680	chr11:117135528~117138582:+
THCA	cis	rs10208649	0.908	rs114242964	ENSG00000272156.1	RP11-477N3.1	7.97	1.24e-14	4.88e-12	0.72	0.34	Body mass index;	chr2:54013985	chr2:54082554~54085066:+
THCA	cis	rs2712184	0.756	rs715049	ENSG00000229352.1	AC007563.3	-7.97	1.24e-14	4.88e-12	-0.41	-0.34	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216792379	chr2:216799608~216805335:+
THCA	cis	rs17695224	0.545	rs8099997	ENSG00000269483.1	AC006272.1	7.97	1.25e-14	4.88e-12	0.37	0.34	HDL cholesterol;HDL cholesterol levels;	chr19:51842216	chr19:51839924~51843324:-
THCA	cis	rs7829975	0.811	rs7011229	ENSG00000253893.2	FAM85B	7.97	1.25e-14	4.89e-12	0.43	0.34	Mood instability;	chr8:8685814	chr8:8167819~8226614:-
THCA	cis	rs7811142	0.83	rs28495773	ENSG00000078319.8	PMS2P1	-7.97	1.25e-14	4.89e-12	-0.49	-0.34	Platelet count;	chr7:100345960	chr7:100320992~100341908:-
THCA	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-7.97	1.25e-14	4.89e-12	-0.42	-0.34	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
THCA	cis	rs8072100	0.967	rs11871606	ENSG00000228782.6	CTD-2026D20.3	-7.97	1.25e-14	4.91e-12	-0.31	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655408	chr17:47450568~47492492:-
THCA	cis	rs7772486	0.84	rs854144	ENSG00000235652.6	RP11-545I5.3	-7.97	1.25e-14	4.92e-12	-0.34	-0.34	Lobe attachment (rater-scored or self-reported);	chr6:146039744	chr6:145799409~145886585:+
THCA	cis	rs8114671	0.562	rs1801310	ENSG00000269202.1	RP4-614O4.12	-7.97	1.26e-14	4.92e-12	-0.29	-0.34	Height;	chr20:34929211	chr20:35201747~35203288:-
THCA	cis	rs4308124	0.708	rs7585313	ENSG00000227992.1	AC108463.2	-7.97	1.26e-14	4.92e-12	-0.48	-0.34	Vitiligo;	chr2:111217626	chr2:111203964~111206215:-
THCA	cis	rs5752326	0.764	rs5997093	ENSG00000261188.1	CTA-445C9.14	-7.97	1.26e-14	4.92e-12	-0.34	-0.34	Ischemic stroke;	chr22:26455862	chr22:26512537~26514568:+
THCA	cis	rs7208859	0.623	rs7220999	ENSG00000264538.5	SUZ12P1	-7.96	1.26e-14	4.93e-12	-0.35	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs55638872	ENSG00000264538.5	SUZ12P1	-7.96	1.26e-14	4.93e-12	-0.35	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30709299~30790908:+
THCA	cis	rs7621025	0.5	rs12629000	ENSG00000273486.1	RP11-731C17.2	7.96	1.26e-14	4.93e-12	0.35	0.34	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136924729	chr3:136837338~136839021:-
THCA	cis	rs7621025	0.5	rs1965107	ENSG00000273486.1	RP11-731C17.2	7.96	1.26e-14	4.93e-12	0.35	0.34	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136929801	chr3:136837338~136839021:-
THCA	cis	rs13631	0.928	rs9411308	ENSG00000268996.3	MAN1B1-AS1	7.96	1.26e-14	4.94e-12	0.29	0.34	Cerebrospinal fluid biomarker levels;	chr9:137105663	chr9:137084946~137086817:-
THCA	cis	rs42490	0.716	rs40636	ENSG00000251136.7	RP11-37B2.1	-7.96	1.26e-14	4.94e-12	-0.29	-0.34	Leprosy;	chr8:89809079	chr8:89609409~89757727:-
THCA	cis	rs4713118	0.662	rs149947	ENSG00000226314.6	ZNF192P1	-7.96	1.26e-14	4.94e-12	-0.44	-0.34	Parkinson's disease;	chr6:28004655	chr6:28161781~28169594:+
THCA	cis	rs12682352	0.602	rs28399241	ENSG00000253893.2	FAM85B	-7.96	1.26e-14	4.95e-12	-0.45	-0.34	Neuroticism;	chr8:8805705	chr8:8167819~8226614:-
THCA	cis	rs7580658	0.637	rs9636235	ENSG00000236682.1	AC068282.3	-7.96	1.27e-14	4.96e-12	-0.44	-0.34	Protein C levels;	chr2:127223975	chr2:127389130~127400580:+
THCA	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	7.96	1.27e-14	4.97e-12	0.66	0.34	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
THCA	cis	rs947583	0.955	rs927330	ENSG00000231028.7	LINC00271	7.96	1.27e-14	4.97e-12	0.28	0.34	Phosphorus levels;	chr6:135810618	chr6:135497801~135716055:+
THCA	cis	rs7712401	0.58	rs10066632	ENSG00000263432.2	RN7SL689P	7.96	1.27e-14	4.97e-12	0.41	0.34	Mean platelet volume;	chr5:123028988	chr5:123022487~123022783:-
THCA	cis	rs7712401	0.58	rs10076327	ENSG00000263432.2	RN7SL689P	7.96	1.27e-14	4.97e-12	0.41	0.34	Mean platelet volume;	chr5:123031652	chr5:123022487~123022783:-
THCA	cis	rs507080	0.922	rs478296	ENSG00000278376.1	RP11-158I9.8	-7.96	1.27e-14	4.98e-12	-0.28	-0.34	Serum metabolite levels;	chr11:118696666	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs493834	ENSG00000278376.1	RP11-158I9.8	-7.96	1.27e-14	4.98e-12	-0.28	-0.34	Serum metabolite levels;	chr11:118696735	chr11:118791254~118793137:+
THCA	cis	rs507080	0.922	rs644498	ENSG00000278376.1	RP11-158I9.8	-7.96	1.27e-14	4.98e-12	-0.28	-0.34	Serum metabolite levels;	chr11:118696777	chr11:118791254~118793137:+
THCA	cis	rs507080	0.845	rs613377	ENSG00000278376.1	RP11-158I9.8	-7.96	1.27e-14	4.99e-12	-0.27	-0.34	Serum metabolite levels;	chr11:118685375	chr11:118791254~118793137:+
THCA	cis	rs10208649	0.908	rs10199995	ENSG00000272156.1	RP11-477N3.1	7.96	1.27e-14	4.99e-12	0.65	0.34	Body mass index;	chr2:53981138	chr2:54082554~54085066:+
THCA	cis	rs11673344	0.523	rs10406110	ENSG00000226686.6	LINC01535	7.96	1.29e-14	5.04e-12	0.38	0.34	Obesity-related traits;	chr19:37160027	chr19:37251912~37265535:+
THCA	cis	rs11096990	0.613	rs4974996	ENSG00000249685.1	RP11-360F5.3	7.96	1.29e-14	5.05e-12	0.41	0.34	Cognitive function;	chr4:39225928	chr4:39133913~39135608:+
THCA	cis	rs847577	0.677	rs951988	ENSG00000272950.1	RP11-307C18.1	-7.96	1.29e-14	5.05e-12	-0.43	-0.34	Breast cancer;	chr7:98133162	chr7:98322853~98323430:+
THCA	cis	rs8114671	0.967	rs2093058	ENSG00000269202.1	RP4-614O4.12	7.96	1.29e-14	5.05e-12	0.29	0.34	Height;	chr20:35203478	chr20:35201747~35203288:-
THCA	cis	rs2276314	1	rs8086395	ENSG00000278986.1	RP11-723J4.3	-7.96	1.29e-14	5.06e-12	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35984629	chr18:35972151~35973916:+
THCA	cis	rs7849270	0.801	rs6478868	ENSG00000268707.1	RP11-247A12.7	7.96	1.29e-14	5.07e-12	0.44	0.34	Blood metabolite ratios;	chr9:129164813	chr9:129170434~129170940:+
THCA	cis	rs922182	0.557	rs2004231	ENSG00000275785.1	RP11-111E14.2	7.96	1.3e-14	5.08e-12	0.41	0.34	Blood protein levels;	chr15:63903570	chr15:63890030~63890317:+
THCA	cis	rs4789693	0.746	rs4789775	ENSG00000265458.1	RP13-20L14.6	7.96	1.3e-14	5.09e-12	0.35	0.34	Glucocorticoid-induced osteonecrosis;	chr17:82434029	chr17:82454273~82458521:-
THCA	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	7.96	1.3e-14	5.1e-12	0.41	0.34	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
THCA	cis	rs11603691	0.901	rs7111339	ENSG00000254662.1	RP11-872D17.4	-7.96	1.3e-14	5.1e-12	-0.64	-0.34	Low high density lipoprotein cholesterol levels;	chr11:57323498	chr11:57325603~57327958:+
THCA	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-7.96	1.3e-14	5.1e-12	-0.53	-0.34	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
THCA	cis	rs8072100	0.967	rs4794001	ENSG00000228782.6	CTD-2026D20.3	7.96	1.3e-14	5.11e-12	0.31	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47643483	chr17:47450568~47492492:-
THCA	cis	rs62445005	1	rs62445005	ENSG00000211699.2	TRGV3	7.96	1.31e-14	5.12e-12	0.37	0.34	Shingles;	chr7:38346957	chr7:38358512~38359162:-
THCA	cis	rs34375054	0.526	rs34764657	ENSG00000279233.1	RP11-158L12.4	7.96	1.31e-14	5.13e-12	0.33	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125195093	chr12:125138245~125141711:+
THCA	cis	rs12908161	0.96	rs62019463	ENSG00000259728.4	LINC00933	7.96	1.31e-14	5.13e-12	0.46	0.34	Schizophrenia;	chr15:84744856	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs62019464	ENSG00000259728.4	LINC00933	7.96	1.31e-14	5.13e-12	0.46	0.34	Schizophrenia;	chr15:84751238	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs11637142	ENSG00000259728.4	LINC00933	7.96	1.31e-14	5.13e-12	0.46	0.34	Schizophrenia;	chr15:84752696	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs12910012	ENSG00000259728.4	LINC00933	7.96	1.31e-14	5.13e-12	0.46	0.34	Schizophrenia;	chr15:84755431	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs12899981	ENSG00000259728.4	LINC00933	7.96	1.31e-14	5.13e-12	0.46	0.34	Schizophrenia;	chr15:84759142	chr15:84570649~84580175:+
THCA	cis	rs11673344	0.523	rs2562605	ENSG00000226686.6	LINC01535	7.96	1.32e-14	5.15e-12	0.38	0.34	Obesity-related traits;	chr19:37029302	chr19:37251912~37265535:+
THCA	cis	rs1707322	1	rs4660889	ENSG00000234329.1	RP11-767N6.2	7.96	1.32e-14	5.16e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs10890355	ENSG00000234329.1	RP11-767N6.2	7.96	1.32e-14	5.16e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211204	ENSG00000234329.1	RP11-767N6.2	7.96	1.32e-14	5.16e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs11211217	ENSG00000234329.1	RP11-767N6.2	7.96	1.32e-14	5.16e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45651039~45651826:-
THCA	cis	rs2412819	0.571	rs12900924	ENSG00000249839.1	AC011330.5	-7.96	1.32e-14	5.17e-12	-0.52	-0.34	Lung cancer;	chr15:43737329	chr15:43663654~43684339:-
THCA	cis	rs2412819	0.571	rs7174260	ENSG00000249839.1	AC011330.5	-7.96	1.32e-14	5.17e-12	-0.52	-0.34	Lung cancer;	chr15:43751988	chr15:43663654~43684339:-
THCA	cis	rs4819052	0.851	rs1056099	ENSG00000237664.1	LINC00316	-7.96	1.33e-14	5.18e-12	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258977	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2236446	ENSG00000237664.1	LINC00316	-7.96	1.33e-14	5.18e-12	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45259070	chr21:45338590~45341990:-
THCA	cis	rs7811142	0.83	rs75636500	ENSG00000078319.8	PMS2P1	-7.96	1.33e-14	5.18e-12	-0.5	-0.34	Platelet count;	chr7:100350034	chr7:100320992~100341908:-
THCA	cis	rs7208859	0.623	rs56325146	ENSG00000264538.5	SUZ12P1	-7.96	1.33e-14	5.19e-12	-0.35	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30709299~30790908:+
THCA	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	7.96	1.33e-14	5.19e-12	0.43	0.34	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
THCA	cis	rs1707322	1	rs6675222	ENSG00000234329.1	RP11-767N6.2	7.96	1.33e-14	5.19e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660895	ENSG00000234329.1	RP11-767N6.2	7.96	1.33e-14	5.19e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660318	ENSG00000234329.1	RP11-767N6.2	7.96	1.33e-14	5.19e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45651039~45651826:-
THCA	cis	rs2439831	0.867	rs2255051	ENSG00000249839.1	AC011330.5	-7.96	1.33e-14	5.21e-12	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43553963	chr15:43663654~43684339:-
THCA	cis	rs957448	0.503	rs752460	ENSG00000253704.1	RP11-267M23.4	7.96	1.33e-14	5.21e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94477994	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.801	rs4735293	ENSG00000253704.1	RP11-267M23.4	7.96	1.33e-14	5.21e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94478175	chr8:94553722~94569745:+
THCA	cis	rs11673344	0.523	rs6510584	ENSG00000226686.6	LINC01535	7.96	1.33e-14	5.21e-12	0.38	0.34	Obesity-related traits;	chr19:37058699	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.503	rs7246720	ENSG00000226686.6	LINC01535	7.96	1.33e-14	5.21e-12	0.38	0.34	Obesity-related traits;	chr19:37073726	chr19:37251912~37265535:+
THCA	cis	rs9473147	0.543	rs4711880	ENSG00000270761.1	RP11-385F7.1	-7.96	1.34e-14	5.24e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47512940	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs9473126	ENSG00000270761.1	RP11-385F7.1	-7.96	1.34e-14	5.24e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47514097	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs4715025	ENSG00000270761.1	RP11-385F7.1	-7.96	1.34e-14	5.24e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47515917	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs7767350	ENSG00000270761.1	RP11-385F7.1	-7.96	1.34e-14	5.24e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47517390	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.516	rs10948363	ENSG00000270761.1	RP11-385F7.1	-7.96	1.34e-14	5.24e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47520026	chr6:47477243~47477572:-
THCA	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	7.96	1.34e-14	5.25e-12	0.41	0.34	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
THCA	cis	rs1005277	0.691	rs2474558	ENSG00000263064.2	RP11-291L22.7	-7.96	1.34e-14	5.26e-12	-0.4	-0.34	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38448689~38448949:+
THCA	cis	rs910316	0.663	rs175034	ENSG00000279594.1	RP11-950C14.10	-7.96	1.35e-14	5.26e-12	-0.32	-0.34	Height;	chr14:74996984	chr14:75011269~75012851:-
THCA	cis	rs957448	0.554	rs10956919	ENSG00000253704.1	RP11-267M23.4	7.96	1.35e-14	5.26e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94553722~94569745:+
THCA	cis	rs4819052	1	rs733739	ENSG00000237664.1	LINC00316	-7.96	1.35e-14	5.26e-12	-0.37	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246295	chr21:45338590~45341990:-
THCA	cis	rs7714584	1	rs80075680	ENSG00000197083.10	ZNF300P1	7.96	1.35e-14	5.27e-12	0.56	0.34	Crohn's disease;	chr5:150844175	chr5:150930645~150946289:-
THCA	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	7.96	1.35e-14	5.27e-12	0.53	0.34	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
THCA	cis	rs11148252	0.574	rs7139495	ENSG00000235660.1	LINC00345	-7.96	1.35e-14	5.27e-12	-0.44	-0.34	Lewy body disease;	chr13:52709183	chr13:52484161~52484680:-
THCA	cis	rs853679	0.882	rs4713139	ENSG00000219392.1	RP1-265C24.5	-7.95	1.35e-14	5.27e-12	-0.59	-0.34	Depression;	chr6:28124907	chr6:28115628~28116551:+
THCA	cis	rs77204473	0.744	rs2238005	ENSG00000254851.1	RP11-109L13.1	7.95	1.35e-14	5.28e-12	0.89	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117217366	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs2239009	ENSG00000254851.1	RP11-109L13.1	7.95	1.35e-14	5.28e-12	0.89	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117219006	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs78628783	ENSG00000254851.1	RP11-109L13.1	7.95	1.35e-14	5.28e-12	0.89	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117221335	chr11:117135528~117138582:+
THCA	cis	rs737008	1	rs737008	ENSG00000262636.1	CTD-3088G3.4	-7.95	1.35e-14	5.28e-12	-0.45	-0.34	Obesity-related traits;	chr16:11281009	chr16:11380859~11381118:-
THCA	cis	rs984222	0.563	rs7518538	ENSG00000231365.4	RP11-418J17.1	7.95	1.35e-14	5.28e-12	0.34	0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119207788	chr1:119140396~119275973:+
THCA	cis	rs116175783	0.557	rs62197081	ENSG00000227403.1	AC009299.3	7.95	1.35e-14	5.29e-12	0.61	0.34	Intelligence (multi-trait analysis);	chr2:161336814	chr2:161244739~161249050:+
THCA	cis	rs72772090	0.539	rs72775817	ENSG00000248734.2	CTD-2260A17.1	-7.95	1.35e-14	5.29e-12	-0.56	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96855006	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs72775818	ENSG00000248734.2	CTD-2260A17.1	-7.95	1.35e-14	5.29e-12	-0.56	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96857512	chr5:96784777~96785999:+
THCA	cis	rs8114671	0.967	rs6142323	ENSG00000269202.1	RP4-614O4.12	7.95	1.36e-14	5.3e-12	0.29	0.34	Height;	chr20:35201180	chr20:35201747~35203288:-
THCA	cis	rs11673344	0.504	rs4806408	ENSG00000226686.6	LINC01535	7.95	1.36e-14	5.31e-12	0.38	0.34	Obesity-related traits;	chr19:37097875	chr19:37251912~37265535:+
THCA	cis	rs12908161	0.92	rs35738019	ENSG00000259728.4	LINC00933	7.95	1.36e-14	5.31e-12	0.47	0.34	Schizophrenia;	chr15:84736979	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs34570071	ENSG00000259728.4	LINC00933	7.95	1.36e-14	5.31e-12	0.47	0.34	Schizophrenia;	chr15:84736981	chr15:84570649~84580175:+
THCA	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-7.95	1.37e-14	5.34e-12	-0.41	-0.34	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
THCA	cis	rs77204473	0.744	rs77171490	ENSG00000254851.1	RP11-109L13.1	7.95	1.37e-14	5.36e-12	0.91	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117168025	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs77678768	ENSG00000254851.1	RP11-109L13.1	7.95	1.37e-14	5.36e-12	0.91	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117169789	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs80353869	ENSG00000254851.1	RP11-109L13.1	7.95	1.37e-14	5.36e-12	0.91	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117177406	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs76883864	ENSG00000254851.1	RP11-109L13.1	7.95	1.37e-14	5.36e-12	0.91	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117181009	chr11:117135528~117138582:+
THCA	cis	rs138491296	1	rs138491296	ENSG00000264007.1	RP11-68I3.10	-7.95	1.37e-14	5.37e-12	-0.39	-0.34	White blood cell count;	chr17:29634549	chr17:29621617~29622254:-
THCA	cis	rs9326248	0.813	rs474488	ENSG00000280143.1	AP000892.6	7.95	1.37e-14	5.37e-12	0.49	0.34	Blood protein levels;	chr11:117198261	chr11:117204967~117210292:+
THCA	cis	rs4713118	0.955	rs9468206	ENSG00000219392.1	RP1-265C24.5	-7.95	1.38e-14	5.39e-12	-0.44	-0.34	Parkinson's disease;	chr6:27722674	chr6:28115628~28116551:+
THCA	cis	rs4819052	1	rs2838847	ENSG00000237664.1	LINC00316	-7.95	1.38e-14	5.4e-12	-0.37	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45251043	chr21:45338590~45341990:-
THCA	cis	rs910316	0.763	rs175042	ENSG00000279594.1	RP11-950C14.10	-7.95	1.38e-14	5.4e-12	-0.32	-0.34	Height;	chr14:75004130	chr14:75011269~75012851:-
THCA	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-7.95	1.39e-14	5.42e-12	-0.62	-0.34	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
THCA	cis	rs9649213	0.593	rs10953255	ENSG00000272950.1	RP11-307C18.1	7.95	1.39e-14	5.42e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98293886	chr7:98322853~98323430:+
THCA	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	7.95	1.39e-14	5.43e-12	0.42	0.34	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
THCA	cis	rs11603691	1	rs10896598	ENSG00000254662.1	RP11-872D17.4	-7.95	1.39e-14	5.43e-12	-0.66	-0.34	Low high density lipoprotein cholesterol levels;	chr11:57284533	chr11:57325603~57327958:+
THCA	cis	rs7714584	1	rs10065172	ENSG00000197083.10	ZNF300P1	7.95	1.4e-14	5.44e-12	0.56	0.34	Crohn's disease;	chr5:150848436	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7705542	ENSG00000197083.10	ZNF300P1	7.95	1.4e-14	5.44e-12	0.56	0.34	Crohn's disease;	chr5:150848756	chr5:150930645~150946289:-
THCA	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-7.95	1.4e-14	5.45e-12	-0.39	-0.34	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
THCA	cis	rs1858037	0.836	rs17475335	ENSG00000237979.1	AC007389.1	7.95	1.4e-14	5.46e-12	0.42	0.34	Rheumatoid arthritis;	chr2:65378646	chr2:65500993~65502138:-
THCA	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	7.95	1.4e-14	5.46e-12	0.43	0.34	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
THCA	cis	rs910316	0.699	rs175039	ENSG00000279594.1	RP11-950C14.10	-7.95	1.4e-14	5.47e-12	-0.32	-0.34	Height;	chr14:75002247	chr14:75011269~75012851:-
THCA	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	7.95	1.4e-14	5.47e-12	0.23	0.34	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
THCA	cis	rs13068223	0.904	rs13322900	ENSG00000243926.1	TIPARP-AS1	7.95	1.4e-14	5.47e-12	0.33	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156732229	chr3:156671862~156674378:-
THCA	cis	rs1707322	1	rs10890360	ENSG00000234329.1	RP11-767N6.2	7.95	1.41e-14	5.49e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6682683	ENSG00000234329.1	RP11-767N6.2	7.95	1.41e-14	5.49e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45651039~45651826:-
THCA	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-7.95	1.41e-14	5.5e-12	-0.43	-0.34	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
THCA	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	7.95	1.41e-14	5.51e-12	0.24	0.34	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
THCA	cis	rs2787702	0.5	rs11598488	ENSG00000237233.2	TMEM26-AS1	7.95	1.41e-14	5.51e-12	0.56	0.34	Response to taxane treatment (placlitaxel);	chr10:61576492	chr10:61452639~61481956:+
THCA	cis	rs7811142	0.83	rs7341507	ENSG00000078319.8	PMS2P1	-7.95	1.42e-14	5.51e-12	-0.49	-0.34	Platelet count;	chr7:100353692	chr7:100320992~100341908:-
THCA	cis	rs3096299	0.874	rs3102342	ENSG00000274627.1	RP11-104N10.2	7.95	1.42e-14	5.51e-12	0.34	0.34	Multiple myeloma (IgH translocation);	chr16:89385167	chr16:89516797~89522217:+
THCA	cis	rs2439831	0.867	rs486301	ENSG00000249839.1	AC011330.5	-7.95	1.42e-14	5.52e-12	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43544751	chr15:43663654~43684339:-
THCA	cis	rs11673344	0.523	rs2562607	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37031358	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs2385415	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37035291	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs7246739	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37040829	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs7260488	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37058883	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs8110158	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37063491	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.562	rs7257320	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37080933	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs10403975	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37082172	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs2385375	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37087620	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs35162188	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37088908	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.562	rs7250507	ENSG00000226686.6	LINC01535	7.95	1.42e-14	5.54e-12	0.38	0.34	Obesity-related traits;	chr19:37095772	chr19:37251912~37265535:+
THCA	cis	rs72772090	0.539	rs72775809	ENSG00000248734.2	CTD-2260A17.1	-7.95	1.42e-14	5.55e-12	-0.56	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96847853	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs72775810	ENSG00000248734.2	CTD-2260A17.1	-7.95	1.42e-14	5.55e-12	-0.56	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96849604	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11750671	ENSG00000248734.2	CTD-2260A17.1	-7.95	1.42e-14	5.55e-12	-0.56	-0.34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96852779	chr5:96784777~96785999:+
THCA	cis	rs736801	0.74	rs17622378	ENSG00000237714.1	P4HA2-AS1	7.95	1.43e-14	5.55e-12	0.47	0.34	Mosquito bite size;Breast cancer;	chr5:132442760	chr5:132184876~132192808:+
THCA	cis	rs7674212	0.507	rs6843738	ENSG00000246560.2	RP11-10L12.4	7.95	1.43e-14	5.55e-12	0.44	0.34	Type 2 diabetes;	chr4:103014844	chr4:102828055~102844075:+
THCA	cis	rs2470135	1	rs2470135	ENSG00000166763.7	STRCP1	7.95	1.43e-14	5.55e-12	0.37	0.34	Diastolic blood pressure;	chr15:43703591	chr15:43699488~43718184:-
THCA	cis	rs10208649	0.656	rs12623097	ENSG00000272156.1	RP11-477N3.1	7.95	1.43e-14	5.56e-12	0.52	0.34	Body mass index;	chr2:54071182	chr2:54082554~54085066:+
THCA	cis	rs7119038	0.615	rs10892274	ENSG00000255239.1	AP002954.6	-7.95	1.43e-14	5.56e-12	-0.48	-0.34	Sjögren's syndrome;	chr11:118734754	chr11:118688039~118690600:-
THCA	cis	rs11673344	0.523	rs7245520	ENSG00000226686.6	LINC01535	7.95	1.43e-14	5.57e-12	0.38	0.34	Obesity-related traits;	chr19:37036416	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs7256380	ENSG00000226686.6	LINC01535	7.95	1.43e-14	5.57e-12	0.38	0.34	Obesity-related traits;	chr19:37041178	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs6510585	ENSG00000226686.6	LINC01535	7.95	1.43e-14	5.57e-12	0.38	0.34	Obesity-related traits;	chr19:37063081	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs17206540	ENSG00000226686.6	LINC01535	7.95	1.43e-14	5.57e-12	0.38	0.34	Obesity-related traits;	chr19:37069009	chr19:37251912~37265535:+
THCA	cis	rs9649213	0.593	rs6975156	ENSG00000272950.1	RP11-307C18.1	7.95	1.44e-14	5.58e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98296222	chr7:98322853~98323430:+
THCA	cis	rs56080343	0.515	rs73222056	ENSG00000275409.1	RP11-131L12.4	-7.95	1.44e-14	5.58e-12	-0.43	-0.34	Neuroticism;	chr12:118215875	chr12:118430147~118430699:+
THCA	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	7.95	1.44e-14	5.6e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
THCA	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-7.95	1.44e-14	5.6e-12	-0.44	-0.34	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
THCA	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-7.95	1.44e-14	5.6e-12	-0.56	-0.34	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
THCA	cis	rs11148252	0.557	rs9536223	ENSG00000235660.1	LINC00345	-7.95	1.45e-14	5.62e-12	-0.44	-0.34	Lewy body disease;	chr13:52659059	chr13:52484161~52484680:-
THCA	cis	rs77204473	0.793	rs11216206	ENSG00000254851.1	RP11-109L13.1	7.95	1.45e-14	5.62e-12	0.7	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116972709	chr11:117135528~117138582:+
THCA	cis	rs6545883	0.524	rs2694619	ENSG00000271889.1	RP11-493E12.1	-7.94	1.45e-14	5.63e-12	-0.34	-0.34	Tuberculosis;	chr2:61309766	chr2:61151433~61162105:-
THCA	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-7.94	1.45e-14	5.63e-12	-0.42	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
THCA	cis	rs9473147	0.516	rs9381564	ENSG00000270761.1	RP11-385F7.1	-7.94	1.45e-14	5.64e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47476070	chr6:47477243~47477572:-
THCA	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-7.94	1.46e-14	5.65e-12	-0.42	-0.34	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
THCA	cis	rs9649213	0.593	rs6465672	ENSG00000272950.1	RP11-307C18.1	-7.94	1.46e-14	5.66e-12	-0.42	-0.34	Prostate cancer (SNP x SNP interaction);	chr7:98334405	chr7:98322853~98323430:+
THCA	cis	rs11673344	0.504	rs10403728	ENSG00000226686.6	LINC01535	7.94	1.46e-14	5.66e-12	0.38	0.34	Obesity-related traits;	chr19:37091569	chr19:37251912~37265535:+
THCA	cis	rs9309473	0.583	rs11899517	ENSG00000163016.8	ALMS1P	7.94	1.46e-14	5.67e-12	0.46	0.34	Metabolite levels;	chr2:73346133	chr2:73644919~73685576:+
THCA	cis	rs10875746	0.551	rs1471998	ENSG00000240399.1	RP1-228P16.1	-7.94	1.46e-14	5.68e-12	-0.39	-0.34	Longevity (90 years and older);	chr12:48318219	chr12:48054813~48055591:-
THCA	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	7.94	1.47e-14	5.71e-12	0.34	0.34	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
THCA	cis	rs8062405	0.558	rs3743963	ENSG00000251417.2	RP11-1348G14.4	-7.94	1.47e-14	5.71e-12	-0.32	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28593365	chr16:28802743~28817828:+
THCA	cis	rs62103177	0.759	rs7227794	ENSG00000261126.6	RP11-795F19.1	7.94	1.47e-14	5.72e-12	0.4	0.34	Opioid sensitivity;	chr18:79850925	chr18:80046900~80095482:+
THCA	cis	rs380904	1	rs12543128	ENSG00000254859.1	RP11-661A12.5	-7.94	1.47e-14	5.73e-12	-0.5	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:143512872	chr8:143541973~143549729:-
THCA	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	7.94	1.48e-14	5.74e-12	0.33	0.34	Breast size;	chr12:9219433	chr12:9277235~9313241:+
THCA	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	7.94	1.48e-14	5.74e-12	0.33	0.34	Breast size;	chr12:9220266	chr12:9277235~9313241:+
THCA	cis	rs9473147	0.516	rs2171089	ENSG00000270761.1	RP11-385F7.1	-7.94	1.48e-14	5.74e-12	-0.28	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47548075	chr6:47477243~47477572:-
THCA	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	7.94	1.48e-14	5.74e-12	0.23	0.34	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
THCA	cis	rs3747113	0.913	rs34999116	ENSG00000128262.7	POM121L9P	-7.94	1.48e-14	5.76e-12	-0.39	-0.34	Gut microbiome composition (summer);	chr22:24418657	chr22:24251828~24265525:+
THCA	cis	rs8113308	0.81	rs55810059	ENSG00000269235.1	ZNF350-AS1	7.94	1.49e-14	5.77e-12	0.53	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51947475	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs7255377	ENSG00000269235.1	ZNF350-AS1	7.94	1.49e-14	5.77e-12	0.53	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948085	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs7254930	ENSG00000269235.1	ZNF350-AS1	7.94	1.49e-14	5.77e-12	0.53	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51948274	chr19:51949134~51981367:+
THCA	cis	rs4819052	0.851	rs2236445	ENSG00000237664.1	LINC00316	-7.94	1.49e-14	5.78e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258538	chr21:45338590~45341990:-
THCA	cis	rs11715604	1	rs11715604	ENSG00000239213.4	NCK1-AS1	-7.94	1.49e-14	5.78e-12	-0.42	-0.34	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);	chr3:136870707	chr3:136841726~136862054:-
THCA	cis	rs984222	0.559	rs61807010	ENSG00000231365.4	RP11-418J17.1	7.94	1.49e-14	5.79e-12	0.34	0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119200568	chr1:119140396~119275973:+
THCA	cis	rs7811142	0.83	rs6965458	ENSG00000078319.8	PMS2P1	-7.94	1.5e-14	5.81e-12	-0.5	-0.34	Platelet count;	chr7:100375779	chr7:100320992~100341908:-
THCA	cis	rs9649213	0.593	rs6949718	ENSG00000272950.1	RP11-307C18.1	7.94	1.5e-14	5.81e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98295171	chr7:98322853~98323430:+
THCA	cis	rs736801	0.78	rs2188962	ENSG00000237714.1	P4HA2-AS1	7.94	1.5e-14	5.82e-12	0.47	0.34	Mosquito bite size;Breast cancer;	chr5:132435113	chr5:132184876~132192808:+
THCA	cis	rs11148252	0.774	rs9536066	ENSG00000235660.1	LINC00345	-7.94	1.5e-14	5.83e-12	-0.42	-0.34	Lewy body disease;	chr13:52409846	chr13:52484161~52484680:-
THCA	cis	rs1555322	0.53	rs2425049	ENSG00000126005.14	MMP24-AS1	-7.94	1.5e-14	5.84e-12	-0.4	-0.34	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35216462~35278131:-
THCA	cis	rs812925	0.502	rs13028833	ENSG00000271889.1	RP11-493E12.1	-7.94	1.51e-14	5.84e-12	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61417194	chr2:61151433~61162105:-
THCA	cis	rs4713118	0.869	rs2056925	ENSG00000219392.1	RP1-265C24.5	-7.94	1.51e-14	5.84e-12	-0.44	-0.34	Parkinson's disease;	chr6:27723126	chr6:28115628~28116551:+
THCA	cis	rs7811142	0.83	rs10085549	ENSG00000078319.8	PMS2P1	-7.94	1.51e-14	5.84e-12	-0.48	-0.34	Platelet count;	chr7:100385512	chr7:100320992~100341908:-
THCA	cis	rs7811142	1	rs6953107	ENSG00000242294.5	STAG3L5P	7.94	1.51e-14	5.87e-12	0.23	0.34	Platelet count;	chr7:100498041	chr7:100336079~100351900:+
THCA	cis	rs853679	0.824	rs34712084	ENSG00000219392.1	RP1-265C24.5	-7.94	1.51e-14	5.87e-12	-0.59	-0.34	Depression;	chr6:28076050	chr6:28115628~28116551:+
THCA	cis	rs853679	0.824	rs1321505	ENSG00000219392.1	RP1-265C24.5	-7.94	1.51e-14	5.87e-12	-0.59	-0.34	Depression;	chr6:28085045	chr6:28115628~28116551:+
THCA	cis	rs853679	0.882	rs9468287	ENSG00000219392.1	RP1-265C24.5	-7.94	1.51e-14	5.87e-12	-0.59	-0.34	Depression;	chr6:28111963	chr6:28115628~28116551:+
THCA	cis	rs4789693	0.873	rs8069111	ENSG00000265458.1	RP13-20L14.6	7.94	1.51e-14	5.87e-12	0.35	0.34	Glucocorticoid-induced osteonecrosis;	chr17:82437581	chr17:82454273~82458521:-
THCA	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-7.94	1.52e-14	5.89e-12	-0.37	-0.34	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
THCA	cis	rs737008	0.96	rs34764020	ENSG00000262636.1	CTD-3088G3.4	-7.94	1.52e-14	5.91e-12	-0.44	-0.34	Obesity-related traits;	chr16:11284502	chr16:11380859~11381118:-
THCA	cis	rs5760092	0.618	rs5996631	ENSG00000235689.1	AP000351.13	-7.94	1.53e-14	5.92e-12	-0.46	-0.34	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:24006305~24008258:-
THCA	cis	rs2712184	0.875	rs35925637	ENSG00000229352.1	AC007563.3	7.94	1.53e-14	5.92e-12	0.42	0.34	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216811905	chr2:216799608~216805335:+
THCA	cis	rs2921073	0.604	rs2979140	ENSG00000253893.2	FAM85B	-7.94	1.53e-14	5.93e-12	-0.43	-0.34	Parkinson's disease;	chr8:8409692	chr8:8167819~8226614:-
THCA	cis	rs7674212	0.531	rs4699048	ENSG00000246560.2	RP11-10L12.4	7.94	1.53e-14	5.94e-12	0.43	0.34	Type 2 diabetes;	chr4:103005570	chr4:102828055~102844075:+
THCA	cis	rs934734	0.752	rs1194849	ENSG00000204929.10	AC074391.1	-7.94	1.53e-14	5.94e-12	-0.42	-0.34	Rheumatoid arthritis;	chr2:65379519	chr2:65436711~66084639:+
THCA	cis	rs6908034	0.66	rs12525506	ENSG00000228412.5	RP4-625H18.2	7.94	1.53e-14	5.94e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19794003	chr6:19802164~19804752:-
THCA	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-7.94	1.53e-14	5.95e-12	-0.37	-0.34	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
THCA	cis	rs860295	1	rs822490	ENSG00000225855.5	RUSC1-AS1	7.94	1.54e-14	5.96e-12	0.23	0.34	Body mass index;	chr1:155853180	chr1:155316863~155324176:-
THCA	cis	rs10932679	0.532	rs2712162	ENSG00000229352.1	AC007563.3	-7.94	1.54e-14	5.97e-12	-0.43	-0.34	Pulse pressure;	chr2:216797065	chr2:216799608~216805335:+
THCA	cis	rs4722166	0.695	rs7787893	ENSG00000179428.2	AC073072.5	-7.94	1.54e-14	5.97e-12	-0.42	-0.34	Lung cancer;	chr7:22734818	chr7:22725395~22727620:-
THCA	cis	rs12655019	0.92	rs16886496	ENSG00000271828.1	CTD-2310F14.1	-7.94	1.54e-14	5.98e-12	-0.78	-0.34	Breast cancer (early onset);	chr5:56921702	chr5:56927874~56929573:+
THCA	cis	rs7849270	0.879	rs7859344	ENSG00000268707.1	RP11-247A12.7	-7.94	1.54e-14	5.99e-12	-0.42	-0.34	Blood metabolite ratios;	chr9:129086103	chr9:129170434~129170940:+
THCA	cis	rs8072100	0.764	rs4794371	ENSG00000228782.6	CTD-2026D20.3	-7.94	1.55e-14	5.99e-12	-0.31	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47550327	chr17:47450568~47492492:-
THCA	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-7.94	1.55e-14	5.99e-12	-0.54	-0.34	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
THCA	cis	rs11096990	0.613	rs2060805	ENSG00000249685.1	RP11-360F5.3	7.93	1.56e-14	6.03e-12	0.41	0.34	Cognitive function;	chr4:39232788	chr4:39133913~39135608:+
THCA	cis	rs4927850	0.958	rs2044599	ENSG00000226155.1	AC124944.3	-7.93	1.56e-14	6.04e-12	-0.42	-0.34	Pancreatic cancer;	chr3:196009869	chr3:195912049~195913986:+
THCA	cis	rs4927850	1	rs4927704	ENSG00000226155.1	AC124944.3	-7.93	1.56e-14	6.04e-12	-0.42	-0.34	Pancreatic cancer;	chr3:196011357	chr3:195912049~195913986:+
THCA	cis	rs4927850	1	rs4927848	ENSG00000226155.1	AC124944.3	-7.93	1.56e-14	6.04e-12	-0.42	-0.34	Pancreatic cancer;	chr3:196011535	chr3:195912049~195913986:+
THCA	cis	rs7309	0.622	rs4664396	ENSG00000227403.1	AC009299.3	7.93	1.56e-14	6.04e-12	0.39	0.34	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161045139	chr2:161244739~161249050:+
THCA	cis	rs9649213	0.593	rs6969731	ENSG00000272950.1	RP11-307C18.1	7.93	1.56e-14	6.06e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98295259	chr7:98322853~98323430:+
THCA	cis	rs1598856	0.873	rs230510	ENSG00000246560.2	RP11-10L12.4	-7.93	1.57e-14	6.07e-12	-0.41	-0.34	Primary biliary cholangitis;	chr4:102555009	chr4:102828055~102844075:+
THCA	cis	rs934734	0.789	rs11689314	ENSG00000204929.10	AC074391.1	-7.93	1.57e-14	6.08e-12	-0.43	-0.34	Rheumatoid arthritis;	chr2:65378274	chr2:65436711~66084639:+
THCA	cis	rs507080	0.961	rs607527	ENSG00000278376.1	RP11-158I9.8	7.93	1.57e-14	6.09e-12	0.27	0.34	Serum metabolite levels;	chr11:118667478	chr11:118791254~118793137:+
THCA	cis	rs7208859	0.673	rs28588622	ENSG00000266490.1	CTD-2349P21.9	7.93	1.58e-14	6.1e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30792372~30792833:+
THCA	cis	rs10875746	0.669	rs10875767	ENSG00000240399.1	RP1-228P16.1	-7.93	1.58e-14	6.12e-12	-0.37	-0.34	Longevity (90 years and older);	chr12:48205474	chr12:48054813~48055591:-
THCA	cis	rs812925	0.502	rs6545868	ENSG00000271889.1	RP11-493E12.1	-7.93	1.58e-14	6.12e-12	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61428230	chr2:61151433~61162105:-
THCA	cis	rs7851660	0.679	rs7033765	ENSG00000236130.1	PTCSC2	7.93	1.58e-14	6.12e-12	0.27	0.34	Strep throat;	chr9:97829423	chr9:97805935~97810008:-
THCA	cis	rs12701220	0.522	rs868833	ENSG00000229043.2	AC091729.9	-7.93	1.58e-14	6.13e-12	-0.4	-0.34	Bronchopulmonary dysplasia;	chr7:1015337	chr7:1160374~1165267:+
THCA	cis	rs7811142	0.667	rs3873746	ENSG00000078319.8	PMS2P1	-7.93	1.59e-14	6.14e-12	-0.47	-0.34	Platelet count;	chr7:100337474	chr7:100320992~100341908:-
THCA	cis	rs7714584	1	rs73282255	ENSG00000197083.10	ZNF300P1	7.93	1.59e-14	6.14e-12	0.56	0.34	Crohn's disease;	chr5:150844085	chr5:150930645~150946289:-
THCA	cis	rs7945705	0.776	rs11042069	ENSG00000254860.4	TMEM9B-AS1	-7.93	1.59e-14	6.15e-12	-0.38	-0.34	Hemoglobin concentration;	chr11:8795768	chr11:8964675~8977527:+
THCA	cis	rs9649213	0.593	rs11760930	ENSG00000272950.1	RP11-307C18.1	7.93	1.59e-14	6.15e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98286477	chr7:98322853~98323430:+
THCA	cis	rs1707322	1	rs11211223	ENSG00000234329.1	RP11-767N6.2	7.93	1.6e-14	6.19e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45651039~45651826:-
THCA	cis	rs75422866	0.867	rs73111258	ENSG00000257433.4	RP1-197B17.3	7.93	1.6e-14	6.19e-12	0.54	0.34	Pneumonia;	chr12:47597313	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs117388682	ENSG00000257433.4	RP1-197B17.3	7.93	1.6e-14	6.19e-12	0.54	0.34	Pneumonia;	chr12:47599713	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs79113930	ENSG00000257433.4	RP1-197B17.3	7.93	1.6e-14	6.19e-12	0.54	0.34	Pneumonia;	chr12:47600628	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs35044089	ENSG00000257433.4	RP1-197B17.3	7.93	1.6e-14	6.19e-12	0.54	0.34	Pneumonia;	chr12:47610881	chr12:47706085~47742294:+
THCA	cis	rs73607972	0.518	rs35618081	ENSG00000275191.1	RP11-36I17.2	-7.93	1.6e-14	6.19e-12	-0.45	-0.34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53536855	chr16:53628256~53628816:-
THCA	cis	rs17695224	0.545	rs4802884	ENSG00000269483.1	AC006272.1	7.93	1.6e-14	6.19e-12	0.37	0.34	HDL cholesterol;HDL cholesterol levels;	chr19:51845202	chr19:51839924~51843324:-
THCA	cis	rs1387259	0.619	rs7134565	ENSG00000258273.1	RP11-370I10.4	7.93	1.6e-14	6.2e-12	0.4	0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48333755~48333901:-
THCA	cis	rs1387259	0.619	rs2130095	ENSG00000258273.1	RP11-370I10.4	7.93	1.6e-14	6.2e-12	0.4	0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48333755~48333901:-
THCA	cis	rs2739330	0.796	rs5760106	ENSG00000235689.1	AP000351.13	-7.93	1.61e-14	6.22e-12	-0.42	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:24006305~24008258:-
THCA	cis	rs4713118	0.869	rs9461405	ENSG00000219392.1	RP1-265C24.5	-7.93	1.61e-14	6.22e-12	-0.44	-0.34	Parkinson's disease;	chr6:27751596	chr6:28115628~28116551:+
THCA	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	7.93	1.61e-14	6.22e-12	0.23	0.34	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
THCA	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	7.93	1.61e-14	6.22e-12	0.41	0.34	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
THCA	cis	rs1858037	0.867	rs953312	ENSG00000237979.1	AC007389.1	7.93	1.61e-14	6.22e-12	0.43	0.34	Rheumatoid arthritis;	chr2:65340556	chr2:65500993~65502138:-
THCA	cis	rs1858037	0.867	rs9789444	ENSG00000237979.1	AC007389.1	7.93	1.61e-14	6.22e-12	0.43	0.34	Rheumatoid arthritis;	chr2:65342093	chr2:65500993~65502138:-
THCA	cis	rs227932	0.51	rs10950957	ENSG00000234286.1	AC006026.13	7.93	1.61e-14	6.25e-12	0.59	0.34	Schizophrenia;	chr7:23723661	chr7:23680195~23680786:-
THCA	cis	rs12681366	0.881	rs2931631	ENSG00000253704.1	RP11-267M23.4	7.93	1.61e-14	6.25e-12	0.37	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94401415	chr8:94553722~94569745:+
THCA	cis	rs7208859	0.673	rs11651802	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs17826219	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs61223749	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs3764421	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11651858	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs36056619	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9909497	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11080135	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9894876	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73277967	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs60020217	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs73277974	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73277978	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.706	rs9905827	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Body mass index;	chr17:30865150	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11657391	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs58089675	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73263755	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9899349	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11652358	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11656845	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9891179	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9891413	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73263776	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11650271	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11657270	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73263785	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs55904046	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9889968	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30893110	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs61348930	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30894745	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.614	rs28758251	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896294	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9899943	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896907	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11080138	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30897524	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73265612	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30898965	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11658435	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30901543	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73265624	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905048	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs2269915	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906326	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs2269916	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906745	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11649765	ENSG00000266490.1	CTD-2349P21.9	7.93	1.62e-14	6.28e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30906870	chr17:30792372~30792833:+
THCA	cis	rs453301	0.653	rs11784393	ENSG00000253893.2	FAM85B	-7.93	1.63e-14	6.3e-12	-0.42	-0.34	Joint mobility (Beighton score);	chr8:9045624	chr8:8167819~8226614:-
THCA	cis	rs4718428	0.705	rs2901311	ENSG00000230295.1	RP11-458F8.2	-7.93	1.63e-14	6.31e-12	-0.31	-0.34	Corneal structure;	chr7:66950082	chr7:66880708~66882981:+
THCA	cis	rs934734	0.532	rs55792977	ENSG00000237979.1	AC007389.1	-7.93	1.63e-14	6.32e-12	-0.39	-0.34	Rheumatoid arthritis;	chr2:65423730	chr2:65500993~65502138:-
THCA	cis	rs2427308	0.607	rs1741635	ENSG00000273619.1	RP5-908M14.9	7.93	1.64e-14	6.34e-12	0.3	0.34	Colorectal cancer;	chr20:62363141	chr20:62386303~62386970:-
THCA	cis	rs7811142	0.83	rs1063945	ENSG00000078319.8	PMS2P1	-7.93	1.64e-14	6.36e-12	-0.48	-0.34	Platelet count;	chr7:100332824	chr7:100320992~100341908:-
THCA	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-7.93	1.65e-14	6.36e-12	-0.44	-0.34	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
THCA	cis	rs11096990	0.634	rs4975002	ENSG00000249685.1	RP11-360F5.3	-7.93	1.65e-14	6.39e-12	-0.41	-0.34	Cognitive function;	chr4:39286733	chr4:39133913~39135608:+
THCA	cis	rs2929278	0.589	rs11638972	ENSG00000166763.7	STRCP1	-7.93	1.66e-14	6.41e-12	-0.37	-0.34	Schizophrenia;	chr15:43782493	chr15:43699488~43718184:-
THCA	cis	rs9309473	0.607	rs6716776	ENSG00000163016.8	ALMS1P	7.93	1.66e-14	6.42e-12	0.47	0.34	Metabolite levels;	chr2:73360585	chr2:73644919~73685576:+
THCA	cis	rs9309473	0.607	rs2421488	ENSG00000163016.8	ALMS1P	7.93	1.66e-14	6.42e-12	0.47	0.34	Metabolite levels;	chr2:73363497	chr2:73644919~73685576:+
THCA	cis	rs7567389	0.564	rs10209483	ENSG00000236682.1	AC068282.3	7.93	1.66e-14	6.42e-12	0.52	0.34	Self-rated health;	chr2:127401061	chr2:127389130~127400580:+
THCA	cis	rs172166	0.637	rs1225597	ENSG00000219392.1	RP1-265C24.5	-7.93	1.66e-14	6.43e-12	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28194309	chr6:28115628~28116551:+
THCA	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-7.93	1.66e-14	6.43e-12	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
THCA	cis	rs2274273	0.623	rs1187883	ENSG00000258413.1	RP11-665C16.6	7.93	1.67e-14	6.44e-12	0.47	0.34	Protein biomarker;	chr14:55021516	chr14:55262767~55272075:-
THCA	cis	rs2276314	0.947	rs3898595	ENSG00000278986.1	RP11-723J4.3	-7.93	1.67e-14	6.44e-12	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35985922	chr18:35972151~35973916:+
THCA	cis	rs2276314	1	rs4799834	ENSG00000278986.1	RP11-723J4.3	-7.93	1.67e-14	6.44e-12	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35986280	chr18:35972151~35973916:+
THCA	cis	rs9649213	0.593	rs6947340	ENSG00000272950.1	RP11-307C18.1	-7.92	1.67e-14	6.46e-12	-0.42	-0.34	Prostate cancer (SNP x SNP interaction);	chr7:98282929	chr7:98322853~98323430:+
THCA	cis	rs4713118	0.869	rs9295743	ENSG00000219392.1	RP1-265C24.5	-7.92	1.67e-14	6.46e-12	-0.44	-0.34	Parkinson's disease;	chr6:27747323	chr6:28115628~28116551:+
THCA	cis	rs7302981	1	rs7308356	ENSG00000272368.2	RP4-605O3.4	-7.92	1.67e-14	6.46e-12	-0.21	-0.34	Systolic blood pressure;	chr12:50145828	chr12:50112197~50165618:+
THCA	cis	rs7302981	0.934	rs7301649	ENSG00000272368.2	RP4-605O3.4	-7.92	1.67e-14	6.46e-12	-0.21	-0.34	Systolic blood pressure;	chr12:50147087	chr12:50112197~50165618:+
THCA	cis	rs6908034	0.607	rs73376657	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805729	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs74573060	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805801	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs113894708	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805835	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs62404179	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806041	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.546	rs73376662	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806109	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs12529148	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19806566	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs112659166	ENSG00000228412.5	RP4-625H18.2	7.92	1.67e-14	6.46e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807178	chr6:19802164~19804752:-
THCA	cis	rs7811142	0.83	rs705866	ENSG00000078319.8	PMS2P1	-7.92	1.67e-14	6.46e-12	-0.5	-0.34	Platelet count;	chr7:100367662	chr7:100320992~100341908:-
THCA	cis	rs9649213	0.574	rs60077733	ENSG00000272950.1	RP11-307C18.1	7.92	1.67e-14	6.47e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98340825	chr7:98322853~98323430:+
THCA	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-7.92	1.67e-14	6.47e-12	-0.41	-0.34	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
THCA	cis	rs42490	0.664	rs40457	ENSG00000251136.7	RP11-37B2.1	-7.92	1.68e-14	6.49e-12	-0.3	-0.34	Leprosy;	chr8:89811459	chr8:89609409~89757727:-
THCA	cis	rs7811142	0.83	rs7792525	ENSG00000078319.8	PMS2P1	-7.92	1.68e-14	6.49e-12	-0.49	-0.34	Platelet count;	chr7:100374499	chr7:100320992~100341908:-
THCA	cis	rs6142102	0.651	rs6088412	ENSG00000276073.1	RP5-1125A11.7	7.92	1.68e-14	6.49e-12	0.34	0.34	Skin pigmentation;	chr20:34154262	chr20:33985617~33988989:-
THCA	cis	rs7302981	0.934	rs7294548	ENSG00000272368.2	RP4-605O3.4	-7.92	1.68e-14	6.5e-12	-0.2	-0.34	Systolic blood pressure;	chr12:50149418	chr12:50112197~50165618:+
THCA	cis	rs7302981	0.967	rs6580729	ENSG00000272368.2	RP4-605O3.4	7.92	1.68e-14	6.5e-12	0.2	0.34	Systolic blood pressure;	chr12:50153255	chr12:50112197~50165618:+
THCA	cis	rs9928842	0.765	rs8055472	ENSG00000280152.1	RP11-331F4.5	7.92	1.69e-14	6.51e-12	0.45	0.34	Alcoholic chronic pancreatitis;	chr16:75191650	chr16:75245994~75250077:-
THCA	cis	rs7849270	1	rs10988224	ENSG00000268707.1	RP11-247A12.7	-7.92	1.69e-14	6.52e-12	-0.42	-0.34	Blood metabolite ratios;	chr9:129141055	chr9:129170434~129170940:+
THCA	cis	rs932287	1	rs932287	ENSG00000254860.4	TMEM9B-AS1	7.92	1.69e-14	6.52e-12	0.38	0.34	Colonoscopy-negative controls vs population controls;	chr11:9023220	chr11:8964675~8977527:+
THCA	cis	rs934734	0.509	rs12185577	ENSG00000237979.1	AC007389.1	-7.92	1.69e-14	6.54e-12	-0.39	-0.34	Rheumatoid arthritis;	chr2:65432354	chr2:65500993~65502138:-
THCA	cis	rs910316	1	rs2098297	ENSG00000279594.1	RP11-950C14.10	-7.92	1.69e-14	6.54e-12	-0.32	-0.34	Height;	chr14:75152415	chr14:75011269~75012851:-
THCA	cis	rs2946504	1	rs2946504	ENSG00000251468.2	RP11-369K16.1	-7.92	1.7e-14	6.55e-12	-0.42	-0.34	Type 2 diabetes;	chr8:12954071	chr8:12958387~12962200:+
THCA	cis	rs9649213	0.593	rs6970990	ENSG00000272950.1	RP11-307C18.1	7.92	1.7e-14	6.55e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98296070	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.555	rs34695842	ENSG00000272950.1	RP11-307C18.1	7.92	1.7e-14	6.55e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98301750	chr7:98322853~98323430:+
THCA	cis	rs6558530	0.73	rs6991773	ENSG00000253982.1	CTD-2336O2.1	7.92	1.7e-14	6.55e-12	0.29	0.34	Systolic blood pressure;	chr8:1775011	chr8:1761990~1764502:-
THCA	cis	rs11096990	0.656	rs9993224	ENSG00000249685.1	RP11-360F5.3	-7.92	1.7e-14	6.56e-12	-0.41	-0.34	Cognitive function;	chr4:39298578	chr4:39133913~39135608:+
THCA	cis	rs17772222	0.638	rs11629164	ENSG00000258789.1	RP11-507K2.3	7.92	1.7e-14	6.56e-12	0.34	0.34	Coronary artery calcification;	chr14:88564740	chr14:88551597~88552493:+
THCA	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-7.92	1.7e-14	6.58e-12	-0.41	-0.34	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
THCA	cis	rs9326248	0.906	rs171052	ENSG00000280143.1	AP000892.6	-7.92	1.71e-14	6.6e-12	-0.43	-0.34	Blood protein levels;	chr11:117211047	chr11:117204967~117210292:+
THCA	cis	rs2522056	1	rs11242113	ENSG00000233006.5	AC034220.3	-7.92	1.71e-14	6.6e-12	-0.3	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132441542	chr5:132311285~132369916:-
THCA	cis	rs737008	0.821	rs28671554	ENSG00000262703.1	RP11-485G7.6	7.92	1.71e-14	6.61e-12	0.38	0.34	Obesity-related traits;	chr16:11309896	chr16:11348143~11349321:-
THCA	cis	rs11148252	0.5	rs342768	ENSG00000278238.1	RP11-245D16.4	-7.92	1.71e-14	6.61e-12	-0.37	-0.34	Lewy body disease;	chr13:52634747	chr13:52454775~52455331:-
THCA	cis	rs2276314	1	rs62101367	ENSG00000278986.1	RP11-723J4.3	-7.92	1.71e-14	6.62e-12	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35970921	chr18:35972151~35973916:+
THCA	cis	rs8114671	0.935	rs35193912	ENSG00000269202.1	RP4-614O4.12	7.92	1.72e-14	6.62e-12	0.28	0.34	Height;	chr20:35197247	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs34515766	ENSG00000269202.1	RP4-614O4.12	7.92	1.72e-14	6.62e-12	0.28	0.34	Height;	chr20:35197418	chr20:35201747~35203288:-
THCA	cis	rs1707322	1	rs7526369	ENSG00000234329.1	RP11-767N6.2	7.92	1.72e-14	6.63e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs10890371	ENSG00000234329.1	RP11-767N6.2	7.92	1.72e-14	6.63e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45651039~45651826:-
THCA	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-7.92	1.72e-14	6.63e-12	-0.41	-0.34	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
THCA	cis	rs7621025	0.5	rs71630059	ENSG00000273486.1	RP11-731C17.2	-7.92	1.72e-14	6.65e-12	-0.36	-0.34	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136862769	chr3:136837338~136839021:-
THCA	cis	rs6908034	0.66	rs6918235	ENSG00000228412.5	RP4-625H18.2	7.92	1.72e-14	6.65e-12	0.81	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19788196	chr6:19802164~19804752:-
THCA	cis	rs8114671	0.967	rs4911476	ENSG00000269202.1	RP4-614O4.12	7.92	1.72e-14	6.66e-12	0.29	0.34	Height;	chr20:35192965	chr20:35201747~35203288:-
THCA	cis	rs9649213	0.593	rs6970801	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98295928	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs12704982	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98296741	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs34129434	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98297152	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs12704983	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98297733	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs7781916	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98300426	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs736753	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98302177	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs736754	ENSG00000272950.1	RP11-307C18.1	7.92	1.72e-14	6.66e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98302247	chr7:98322853~98323430:+
THCA	cis	rs10208649	1	rs72904915	ENSG00000272156.1	RP11-477N3.1	7.92	1.72e-14	6.66e-12	0.63	0.34	Body mass index;	chr2:54000213	chr2:54082554~54085066:+
THCA	cis	rs7208859	0.623	rs426434	ENSG00000266490.1	CTD-2349P21.9	7.92	1.73e-14	6.66e-12	0.44	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30598335	chr17:30792372~30792833:+
THCA	cis	rs12682352	0.65	rs13265731	ENSG00000253893.2	FAM85B	-7.92	1.73e-14	6.66e-12	-0.45	-0.34	Neuroticism;	chr8:8815810	chr8:8167819~8226614:-
THCA	cis	rs9400467	0.528	rs457492	ENSG00000230177.1	RP5-1112D6.4	-7.92	1.73e-14	6.67e-12	-0.27	-0.34	Amino acid levels;Blood metabolite levels;	chr6:111320647	chr6:111277932~111278742:+
THCA	cis	rs7208859	0.573	rs73267873	ENSG00000266490.1	CTD-2349P21.9	7.92	1.73e-14	6.69e-12	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30792372~30792833:+
THCA	cis	rs17826219	0.561	rs4085382	ENSG00000266490.1	CTD-2349P21.9	7.92	1.73e-14	6.69e-12	0.43	0.34	Body mass index;	chr17:30744184	chr17:30792372~30792833:+
THCA	cis	rs9649213	0.613	rs6961129	ENSG00000272950.1	RP11-307C18.1	7.92	1.73e-14	6.69e-12	0.41	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98346230	chr7:98322853~98323430:+
THCA	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-7.92	1.74e-14	6.71e-12	-0.64	-0.34	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
THCA	cis	rs7942368	1	rs10437754	ENSG00000254632.1	RP11-21L23.4	7.92	1.74e-14	6.72e-12	0.5	0.34	Endometriosis;	chr11:76766823	chr11:76759916~76768223:-
THCA	cis	rs1510272	0.515	rs6762762	ENSG00000243926.1	TIPARP-AS1	-7.92	1.74e-14	6.72e-12	-0.44	-0.34	Testicular germ cell tumor;	chr3:156625194	chr3:156671862~156674378:-
THCA	cis	rs180730	1	rs1376109	ENSG00000251609.2	SETP12	-7.92	1.76e-14	6.78e-12	-0.54	-0.34	Fasting plasma glucose;	chr4:120917160	chr4:120895494~120897083:-
THCA	cis	rs812925	0.519	rs967968	ENSG00000271889.1	RP11-493E12.1	-7.92	1.76e-14	6.79e-12	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61428921	chr2:61151433~61162105:-
THCA	cis	rs9309473	0.607	rs2421489	ENSG00000163016.8	ALMS1P	7.92	1.77e-14	6.84e-12	0.46	0.34	Metabolite levels;	chr2:73366320	chr2:73644919~73685576:+
THCA	cis	rs17772222	0.958	rs1123421	ENSG00000258983.2	RP11-507K2.2	7.92	1.77e-14	6.84e-12	0.42	0.34	Coronary artery calcification;	chr14:88524651	chr14:88499334~88515502:+
THCA	cis	rs12908161	1	rs17601029	ENSG00000259728.4	LINC00933	7.92	1.77e-14	6.84e-12	0.46	0.34	Schizophrenia;	chr15:84804478	chr15:84570649~84580175:+
THCA	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-7.92	1.78e-14	6.86e-12	-0.45	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
THCA	cis	rs8072100	0.967	rs7219303	ENSG00000228782.6	CTD-2026D20.3	-7.92	1.78e-14	6.86e-12	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47660335	chr17:47450568~47492492:-
THCA	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	7.92	1.78e-14	6.87e-12	0.23	0.34	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
THCA	cis	rs950169	0.579	rs62027818	ENSG00000225151.9	GOLGA2P7	-7.92	1.78e-14	6.88e-12	-0.53	-0.34	Schizophrenia;	chr15:83992393	chr15:84199311~84230136:-
THCA	cis	rs240993	0.502	rs240966	ENSG00000230177.1	RP5-1112D6.4	-7.92	1.79e-14	6.88e-12	-0.37	-0.34	Inflammatory skin disease;Psoriasis;	chr6:111323462	chr6:111277932~111278742:+
THCA	cis	rs9506514	0.509	rs9509294	ENSG00000222726.1	RNU2-7P	-7.92	1.79e-14	6.89e-12	-0.42	-0.34	Coronary artery calcification;	chr13:20600506	chr13:20612161~20612338:+
THCA	cis	rs736801	0.808	rs2706396	ENSG00000237714.1	P4HA2-AS1	-7.92	1.79e-14	6.89e-12	-0.46	-0.34	Mosquito bite size;Breast cancer;	chr5:132461117	chr5:132184876~132192808:+
THCA	cis	rs736801	0.836	rs2522052	ENSG00000237714.1	P4HA2-AS1	-7.92	1.79e-14	6.89e-12	-0.46	-0.34	Mosquito bite size;Breast cancer;	chr5:132462795	chr5:132184876~132192808:+
THCA	cis	rs736801	0.808	rs2706403	ENSG00000237714.1	P4HA2-AS1	-7.92	1.79e-14	6.89e-12	-0.46	-0.34	Mosquito bite size;Breast cancer;	chr5:132463320	chr5:132184876~132192808:+
THCA	cis	rs736801	0.754	rs2706336	ENSG00000237714.1	P4HA2-AS1	-7.92	1.79e-14	6.89e-12	-0.46	-0.34	Mosquito bite size;Breast cancer;	chr5:132464269	chr5:132184876~132192808:+
THCA	cis	rs12655019	0.92	rs74455703	ENSG00000271828.1	CTD-2310F14.1	7.92	1.79e-14	6.9e-12	0.79	0.34	Breast cancer (early onset);	chr5:56949442	chr5:56927874~56929573:+
THCA	cis	rs55665837	0.778	rs11023212	ENSG00000251991.1	RNU7-49P	7.91	1.79e-14	6.91e-12	0.4	0.34	Vitamin D levels;	chr11:14410163	chr11:14478892~14478953:+
THCA	cis	rs6908034	0.607	rs76413455	ENSG00000228412.5	RP4-625H18.2	7.91	1.8e-14	6.92e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808733	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs76525593	ENSG00000228412.5	RP4-625H18.2	7.91	1.8e-14	6.92e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808939	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.546	rs74514942	ENSG00000228412.5	RP4-625H18.2	7.91	1.8e-14	6.92e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810289	chr6:19802164~19804752:-
THCA	cis	rs9388451	0.839	rs980014	ENSG00000237742.5	RP11-624M8.1	-7.91	1.8e-14	6.95e-12	-0.29	-0.34	Brugada syndrome;	chr6:125746855	chr6:125578558~125749190:-
THCA	cis	rs7302981	0.967	rs35998534	ENSG00000272368.2	RP4-605O3.4	7.91	1.81e-14	6.96e-12	0.2	0.34	Systolic blood pressure;	chr12:50162999	chr12:50112197~50165618:+
THCA	cis	rs7714584	1	rs1863998	ENSG00000197083.10	ZNF300P1	7.91	1.81e-14	6.98e-12	0.56	0.34	Crohn's disease;	chr5:150892191	chr5:150930645~150946289:-
THCA	cis	rs812925	0.502	rs2084318	ENSG00000271889.1	RP11-493E12.1	-7.91	1.81e-14	6.98e-12	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61425466	chr2:61151433~61162105:-
THCA	cis	rs28510890	0.789	rs11853354	ENSG00000260337.3	RP11-386M24.6	7.91	1.81e-14	6.99e-12	0.45	0.34	Lung cancer in ever smokers;	chr15:92568575	chr15:92592574~92596462:-
THCA	cis	rs4664293	0.718	rs4477859	ENSG00000226266.5	AC009961.3	7.91	1.82e-14	7e-12	0.4	0.34	Monocyte percentage of white cells;	chr2:159738616	chr2:159670708~159712435:-
THCA	cis	rs12655019	0.92	rs12514633	ENSG00000271828.1	CTD-2310F14.1	7.91	1.82e-14	7e-12	0.79	0.34	Breast cancer (early onset);	chr5:56940186	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs16886525	ENSG00000271828.1	CTD-2310F14.1	7.91	1.82e-14	7e-12	0.79	0.34	Breast cancer (early onset);	chr5:56941838	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs75713680	ENSG00000271828.1	CTD-2310F14.1	7.91	1.82e-14	7e-12	0.79	0.34	Breast cancer (early onset);	chr5:56942377	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs76797434	ENSG00000271828.1	CTD-2310F14.1	7.91	1.82e-14	7e-12	0.79	0.34	Breast cancer (early onset);	chr5:56945862	chr5:56927874~56929573:+
THCA	cis	rs12681366	0.881	rs12674614	ENSG00000253704.1	RP11-267M23.4	7.91	1.82e-14	7.01e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94396605	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.881	rs3019155	ENSG00000253704.1	RP11-267M23.4	7.91	1.82e-14	7.01e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94405359	chr8:94553722~94569745:+
THCA	cis	rs7220401	0.789	rs3760456	ENSG00000264007.1	RP11-68I3.10	-7.91	1.82e-14	7.01e-12	-0.39	-0.34	Coronary artery disease;	chr17:29621826	chr17:29621617~29622254:-
THCA	cis	rs17684571	0.872	rs34429594	ENSG00000231441.1	RP11-472M19.2	7.91	1.82e-14	7.03e-12	0.43	0.34	Schizophrenia;	chr6:56714954	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs11961141	ENSG00000231441.1	RP11-472M19.2	7.91	1.82e-14	7.03e-12	0.43	0.34	Schizophrenia;	chr6:56717580	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.81	rs60498201	ENSG00000231441.1	RP11-472M19.2	7.91	1.82e-14	7.03e-12	0.43	0.34	Schizophrenia;	chr6:56718021	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs35807277	ENSG00000231441.1	RP11-472M19.2	7.91	1.82e-14	7.03e-12	0.43	0.34	Schizophrenia;	chr6:56718783	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs34812826	ENSG00000231441.1	RP11-472M19.2	7.91	1.82e-14	7.03e-12	0.43	0.34	Schizophrenia;	chr6:56721893	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs59085778	ENSG00000231441.1	RP11-472M19.2	7.91	1.82e-14	7.03e-12	0.43	0.34	Schizophrenia;	chr6:56723357	chr6:56844002~56864078:+
THCA	cis	rs240993	0.715	rs7776346	ENSG00000230177.1	RP5-1112D6.4	7.91	1.83e-14	7.04e-12	0.33	0.34	Inflammatory skin disease;Psoriasis;	chr6:111540162	chr6:111277932~111278742:+
THCA	cis	rs11148252	0.553	rs7999849	ENSG00000235660.1	LINC00345	-7.91	1.83e-14	7.04e-12	-0.43	-0.34	Lewy body disease;	chr13:52675279	chr13:52484161~52484680:-
THCA	cis	rs934734	0.511	rs62141115	ENSG00000237979.1	AC007389.1	-7.91	1.83e-14	7.05e-12	-0.39	-0.34	Rheumatoid arthritis;	chr2:65445058	chr2:65500993~65502138:-
THCA	cis	rs12701220	0.522	rs12334290	ENSG00000229043.2	AC091729.9	-7.91	1.83e-14	7.05e-12	-0.4	-0.34	Bronchopulmonary dysplasia;	chr7:1014881	chr7:1160374~1165267:+
THCA	cis	rs7811142	0.83	rs11765869	ENSG00000078319.8	PMS2P1	-7.91	1.84e-14	7.07e-12	-0.5	-0.34	Platelet count;	chr7:100367166	chr7:100320992~100341908:-
THCA	cis	rs11096990	0.613	rs9997015	ENSG00000249685.1	RP11-360F5.3	-7.91	1.85e-14	7.1e-12	-0.41	-0.34	Cognitive function;	chr4:39222677	chr4:39133913~39135608:+
THCA	cis	rs13631	0.728	rs7848423	ENSG00000268996.3	MAN1B1-AS1	7.91	1.85e-14	7.11e-12	0.31	0.34	Cerebrospinal fluid biomarker levels;	chr9:137093304	chr9:137084946~137086817:-
THCA	cis	rs7045138	1	rs7045138	ENSG00000236130.1	PTCSC2	-7.91	1.85e-14	7.13e-12	-0.27	-0.34	Thyroid hormone levels;	chr9:97829181	chr9:97805935~97810008:-
THCA	cis	rs11673344	0.523	rs7255724	ENSG00000226686.6	LINC01535	7.91	1.86e-14	7.17e-12	0.38	0.34	Obesity-related traits;	chr19:37158675	chr19:37251912~37265535:+
THCA	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	7.91	1.87e-14	7.18e-12	0.41	0.34	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
THCA	cis	rs910316	0.737	rs175055	ENSG00000279594.1	RP11-950C14.10	-7.91	1.87e-14	7.21e-12	-0.31	-0.34	Height;	chr14:75022243	chr14:75011269~75012851:-
THCA	cis	rs8114671	0.967	rs2069945	ENSG00000269202.1	RP4-614O4.12	-7.91	1.87e-14	7.21e-12	-0.29	-0.34	Height;	chr20:35174034	chr20:35201747~35203288:-
THCA	cis	rs7015263	1	rs7015263	ENSG00000254231.1	CTD-2284J15.1	7.91	1.88e-14	7.24e-12	0.33	0.34	Intelligence (multi-trait analysis);	chr8:86513963	chr8:86333274~86343314:-
THCA	cis	rs2712184	0.756	rs2024489	ENSG00000229352.1	AC007563.3	-7.91	1.89e-14	7.25e-12	-0.41	-0.34	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216796807	chr2:216799608~216805335:+
THCA	cis	rs2712184	0.756	rs2712161	ENSG00000229352.1	AC007563.3	-7.91	1.89e-14	7.25e-12	-0.41	-0.34	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216797661	chr2:216799608~216805335:+
THCA	cis	rs17772222	0.917	rs61977053	ENSG00000258983.2	RP11-507K2.2	7.91	1.89e-14	7.26e-12	0.44	0.34	Coronary artery calcification;	chr14:88380876	chr14:88499334~88515502:+
THCA	cis	rs7811142	1	rs73405353	ENSG00000242294.5	STAG3L5P	7.91	1.89e-14	7.26e-12	0.23	0.34	Platelet count;	chr7:100493592	chr7:100336079~100351900:+
THCA	cis	rs1707322	1	rs10158032	ENSG00000234329.1	RP11-767N6.2	7.91	1.89e-14	7.28e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45651039~45651826:-
THCA	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	7.91	1.89e-14	7.28e-12	0.37	0.34	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
THCA	cis	rs7811142	0.562	rs7786844	ENSG00000078319.8	PMS2P1	-7.91	1.89e-14	7.28e-12	-0.47	-0.34	Platelet count;	chr7:100336385	chr7:100320992~100341908:-
THCA	cis	rs6142102	0.602	rs2268079	ENSG00000275784.1	RP5-1125A11.6	-7.91	1.9e-14	7.29e-12	-0.34	-0.34	Skin pigmentation;	chr20:34008944	chr20:33989480~33991818:-
THCA	cis	rs910316	0.967	rs175505	ENSG00000279594.1	RP11-950C14.10	-7.91	1.9e-14	7.3e-12	-0.32	-0.34	Height;	chr14:75062916	chr14:75011269~75012851:-
THCA	cis	rs638893	0.617	rs4938565	ENSG00000278376.1	RP11-158I9.8	7.91	1.91e-14	7.33e-12	0.3	0.34	Vitiligo;	chr11:118850289	chr11:118791254~118793137:+
THCA	cis	rs2276314	1	rs2276314	ENSG00000278986.1	RP11-723J4.3	7.91	1.91e-14	7.34e-12	0.39	0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35977503	chr18:35972151~35973916:+
THCA	cis	rs6558530	0.73	rs7014327	ENSG00000253982.1	CTD-2336O2.1	7.91	1.91e-14	7.35e-12	0.29	0.34	Systolic blood pressure;	chr8:1775886	chr8:1761990~1764502:-
THCA	cis	rs9649213	0.593	rs12728	ENSG00000272950.1	RP11-307C18.1	7.91	1.92e-14	7.36e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98293539	chr7:98322853~98323430:+
THCA	cis	rs10050311	0.585	rs113536481	ENSG00000251411.1	RP11-397E7.4	-7.91	1.92e-14	7.37e-12	-0.43	-0.34	Insulin-related traits;	chr4:86943979	chr4:86913266~86914817:-
THCA	cis	rs17772222	0.675	rs845758	ENSG00000258789.1	RP11-507K2.3	7.91	1.92e-14	7.38e-12	0.32	0.34	Coronary artery calcification;	chr14:88433746	chr14:88551597~88552493:+
THCA	cis	rs875971	0.54	rs736270	ENSG00000237310.1	GS1-124K5.4	7.91	1.92e-14	7.38e-12	0.25	0.34	Aortic root size;	chr7:65963835	chr7:66493706~66495474:+
THCA	cis	rs4072705	0.967	rs10818979	ENSG00000224020.1	MIR181A2HG	-7.91	1.92e-14	7.39e-12	-0.31	-0.34	Menarche (age at onset);	chr9:124574634	chr9:124658467~124698631:+
THCA	cis	rs4713118	0.505	rs156740	ENSG00000219392.1	RP1-265C24.5	-7.9	1.92e-14	7.4e-12	-0.37	-0.34	Parkinson's disease;	chr6:27992657	chr6:28115628~28116551:+
THCA	cis	rs4819052	0.788	rs2236449	ENSG00000215447.6	BX322557.10	-7.9	1.93e-14	7.41e-12	-0.3	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45282591	chr21:45288052~45291738:+
THCA	cis	rs910316	0.875	rs12588099	ENSG00000279594.1	RP11-950C14.10	7.9	1.93e-14	7.41e-12	0.32	0.34	Height;	chr14:75127759	chr14:75011269~75012851:-
THCA	cis	rs1075265	0.54	rs2542587	ENSG00000233266.1	HMGB1P31	7.9	1.93e-14	7.42e-12	0.43	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54051334~54051760:+
THCA	cis	rs1075265	0.563	rs2692537	ENSG00000233266.1	HMGB1P31	7.9	1.93e-14	7.42e-12	0.43	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54051334~54051760:+
THCA	cis	rs7208859	0.573	rs8070182	ENSG00000264538.5	SUZ12P1	-7.9	1.93e-14	7.42e-12	-0.34	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30709299~30790908:+
THCA	cis	rs2439831	0.867	rs2245715	ENSG00000249839.1	AC011330.5	-7.9	1.93e-14	7.42e-12	-0.52	-0.34	Lung cancer in ever smokers;	chr15:43525854	chr15:43663654~43684339:-
THCA	cis	rs4713118	0.869	rs9283881	ENSG00000219392.1	RP1-265C24.5	-7.9	1.94e-14	7.45e-12	-0.44	-0.34	Parkinson's disease;	chr6:27747476	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9283882	ENSG00000219392.1	RP1-265C24.5	-7.9	1.94e-14	7.45e-12	-0.44	-0.34	Parkinson's disease;	chr6:27747479	chr6:28115628~28116551:+
THCA	cis	rs732716	0.785	rs7769	ENSG00000267980.1	AC007292.6	-7.9	1.94e-14	7.45e-12	-0.4	-0.34	Mean corpuscular volume;	chr19:4360546	chr19:4363789~4364640:+
THCA	cis	rs12908161	1	rs12911736	ENSG00000225151.9	GOLGA2P7	-7.9	1.94e-14	7.46e-12	-0.51	-0.34	Schizophrenia;	chr15:84696777	chr15:84199311~84230136:-
THCA	cis	rs12908161	0.959	rs12908699	ENSG00000225151.9	GOLGA2P7	-7.9	1.94e-14	7.46e-12	-0.51	-0.34	Schizophrenia;	chr15:84697172	chr15:84199311~84230136:-
THCA	cis	rs1707322	0.963	rs34907901	ENSG00000234329.1	RP11-767N6.2	7.9	1.94e-14	7.47e-12	0.33	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45651039~45651826:-
THCA	cis	rs2276314	0.857	rs28651028	ENSG00000278986.1	RP11-723J4.3	-7.9	1.94e-14	7.47e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36058947	chr18:35972151~35973916:+
THCA	cis	rs6908034	0.607	rs34109983	ENSG00000228412.5	RP4-625H18.2	7.9	1.95e-14	7.48e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807811	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs73376680	ENSG00000228412.5	RP4-625H18.2	7.9	1.95e-14	7.48e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807868	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs73376681	ENSG00000228412.5	RP4-625H18.2	7.9	1.95e-14	7.48e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19807944	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs80355837	ENSG00000228412.5	RP4-625H18.2	7.9	1.95e-14	7.48e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19808112	chr6:19802164~19804752:-
THCA	cis	rs6723226	0.679	rs116617324	ENSG00000276334.1	AL133243.1	-7.9	1.95e-14	7.49e-12	-0.39	-0.34	Intelligence (multi-trait analysis);	chr2:32397641	chr2:32521927~32523547:+
THCA	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-7.9	1.95e-14	7.49e-12	-0.38	-0.34	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
THCA	cis	rs7811142	0.775	rs1059129	ENSG00000078319.8	PMS2P1	-7.9	1.95e-14	7.5e-12	-0.47	-0.34	Platelet count;	chr7:100328899	chr7:100320992~100341908:-
THCA	cis	rs4713118	0.869	rs9283880	ENSG00000219392.1	RP1-265C24.5	-7.9	1.95e-14	7.5e-12	-0.44	-0.34	Parkinson's disease;	chr6:27747464	chr6:28115628~28116551:+
THCA	cis	rs172166	0.637	rs1233691	ENSG00000219392.1	RP1-265C24.5	-7.9	1.96e-14	7.51e-12	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28186119	chr6:28115628~28116551:+
THCA	cis	rs910316	1	rs175425	ENSG00000279594.1	RP11-950C14.10	-7.9	1.96e-14	7.52e-12	-0.32	-0.34	Height;	chr14:75159428	chr14:75011269~75012851:-
THCA	cis	rs910316	0.935	rs175422	ENSG00000279594.1	RP11-950C14.10	-7.9	1.96e-14	7.52e-12	-0.32	-0.34	Height;	chr14:75160616	chr14:75011269~75012851:-
THCA	cis	rs910316	0.967	rs35446981	ENSG00000279594.1	RP11-950C14.10	-7.9	1.96e-14	7.52e-12	-0.32	-0.34	Height;	chr14:75170648	chr14:75011269~75012851:-
THCA	cis	rs934734	0.532	rs2860773	ENSG00000237979.1	AC007389.1	-7.9	1.96e-14	7.52e-12	-0.38	-0.34	Rheumatoid arthritis;	chr2:65438507	chr2:65500993~65502138:-
THCA	cis	rs12682352	0.602	rs13260419	ENSG00000253893.2	FAM85B	-7.9	1.96e-14	7.53e-12	-0.45	-0.34	Neuroticism;	chr8:8817666	chr8:8167819~8226614:-
THCA	cis	rs172166	0.637	rs1225592	ENSG00000219392.1	RP1-265C24.5	-7.9	1.96e-14	7.53e-12	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28182464	chr6:28115628~28116551:+
THCA	cis	rs172166	0.637	rs1225595	ENSG00000219392.1	RP1-265C24.5	-7.9	1.96e-14	7.53e-12	-0.41	-0.34	Cardiac Troponin-T levels;	chr6:28183562	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs6901520	ENSG00000219392.1	RP1-265C24.5	-7.9	1.96e-14	7.54e-12	-0.44	-0.34	Parkinson's disease;	chr6:27746796	chr6:28115628~28116551:+
THCA	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	7.9	1.97e-14	7.56e-12	0.23	0.34	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
THCA	cis	rs4819052	0.765	rs2838827	ENSG00000237664.1	LINC00316	-7.9	1.97e-14	7.58e-12	-0.35	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236231	chr21:45338590~45341990:-
THCA	cis	rs4072705	0.967	rs4838208	ENSG00000224020.1	MIR181A2HG	-7.9	1.98e-14	7.62e-12	-0.31	-0.34	Menarche (age at onset);	chr9:124765756	chr9:124658467~124698631:+
THCA	cis	rs4072705	0.967	rs4838209	ENSG00000224020.1	MIR181A2HG	-7.9	1.98e-14	7.62e-12	-0.31	-0.34	Menarche (age at onset);	chr9:124766563	chr9:124658467~124698631:+
THCA	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	7.9	1.99e-14	7.62e-12	0.41	0.34	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
THCA	cis	rs9329221	0.527	rs7833781	ENSG00000261451.1	RP11-981G7.1	7.9	1.99e-14	7.63e-12	0.44	0.34	Neuroticism;	chr8:10475967	chr8:10433672~10438312:+
THCA	cis	rs7945705	0.875	rs11042059	ENSG00000254860.4	TMEM9B-AS1	-7.9	1.99e-14	7.64e-12	-0.37	-0.34	Hemoglobin concentration;	chr11:8773533	chr11:8964675~8977527:+
THCA	cis	rs984222	0.677	rs6428792	ENSG00000231365.4	RP11-418J17.1	-7.9	1.99e-14	7.65e-12	-0.34	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119114244	chr1:119140396~119275973:+
THCA	cis	rs10800713	0.908	rs6686605	ENSG00000260088.1	RP11-92G12.3	-7.9	1.99e-14	7.65e-12	-0.53	-0.34	Tandem gait;	chr1:200539440	chr1:200669507~200694250:+
THCA	cis	rs7811142	0.945	rs34989573	ENSG00000242294.5	STAG3L5P	7.9	2e-14	7.66e-12	0.23	0.34	Platelet count;	chr7:100500272	chr7:100336079~100351900:+
THCA	cis	rs9847710	0.566	rs2564951	ENSG00000242142.1	SERBP1P3	7.9	2e-14	7.66e-12	0.43	0.34	Ulcerative colitis;	chr3:53026433	chr3:53064283~53065091:-
THCA	cis	rs10411161	0.81	rs4267442	ENSG00000269483.1	AC006272.1	7.9	2e-14	7.67e-12	0.57	0.34	Breast cancer;	chr19:51860474	chr19:51839924~51843324:-
THCA	cis	rs62289301	0.5	rs10007081	ENSG00000273133.1	RP11-799M12.2	-7.9	2e-14	7.67e-12	-0.48	-0.34	Joint mobility (Beighton score);	chr4:15509764	chr4:15563698~15564253:-
THCA	cis	rs4789693	0.938	rs4789694	ENSG00000265458.1	RP13-20L14.6	-7.9	2e-14	7.68e-12	-0.34	-0.34	Glucocorticoid-induced osteonecrosis;	chr17:82470223	chr17:82454273~82458521:-
THCA	cis	rs12701220	0.522	rs12701455	ENSG00000229043.2	AC091729.9	-7.9	2e-14	7.68e-12	-0.4	-0.34	Bronchopulmonary dysplasia;	chr7:1015773	chr7:1160374~1165267:+
THCA	cis	rs673078	0.66	rs61943362	ENSG00000275409.1	RP11-131L12.4	-7.9	2e-14	7.68e-12	-0.45	-0.34	Glucose homeostasis traits;	chr12:118322042	chr12:118430147~118430699:+
THCA	cis	rs12655019	0.92	rs1466010	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56917329	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs16886497	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56924887	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs79354983	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56925710	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs113772507	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56929449	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs16886510	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56932618	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs78075120	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56932640	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs76869724	ENSG00000271828.1	CTD-2310F14.1	7.9	2e-14	7.69e-12	0.79	0.34	Breast cancer (early onset);	chr5:56932668	chr5:56927874~56929573:+
THCA	cis	rs944289	0.562	rs12431566	ENSG00000257826.1	RP11-116N8.4	7.9	2e-14	7.69e-12	0.36	0.34	Thyroid cancer;	chr14:36051211	chr14:36061026~36067190:-
THCA	cis	rs17772222	0.917	rs2004329	ENSG00000258983.2	RP11-507K2.2	7.9	2.01e-14	7.69e-12	0.42	0.34	Coronary artery calcification;	chr14:88532965	chr14:88499334~88515502:+
THCA	cis	rs9473147	0.543	rs9367279	ENSG00000270761.1	RP11-385F7.1	-7.9	2.01e-14	7.7e-12	-0.27	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47480600	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs9473119	ENSG00000270761.1	RP11-385F7.1	-7.9	2.01e-14	7.7e-12	-0.27	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47482882	chr6:47477243~47477572:-
THCA	cis	rs9473147	0.543	rs9296559	ENSG00000270761.1	RP11-385F7.1	-7.9	2.01e-14	7.7e-12	-0.27	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47484534	chr6:47477243~47477572:-
THCA	cis	rs6723226	0.75	rs1033751	ENSG00000276334.1	AL133243.1	7.9	2.01e-14	7.71e-12	0.38	0.34	Intelligence (multi-trait analysis);	chr2:32470691	chr2:32521927~32523547:+
THCA	cis	rs944289	0.966	rs1182929	ENSG00000257826.1	RP11-116N8.4	-7.9	2.01e-14	7.71e-12	-0.36	-0.34	Thyroid cancer;	chr14:36165946	chr14:36061026~36067190:-
THCA	cis	rs9329221	0.527	rs10903328	ENSG00000261451.1	RP11-981G7.1	7.9	2.01e-14	7.72e-12	0.44	0.34	Neuroticism;	chr8:10474657	chr8:10433672~10438312:+
THCA	cis	rs910316	1	rs11623413	ENSG00000279594.1	RP11-950C14.10	-7.9	2.01e-14	7.73e-12	-0.32	-0.34	Height;	chr14:75122121	chr14:75011269~75012851:-
THCA	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	7.9	2.02e-14	7.75e-12	0.41	0.34	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
THCA	cis	rs12908161	1	rs12903134	ENSG00000259728.4	LINC00933	7.9	2.02e-14	7.75e-12	0.46	0.34	Schizophrenia;	chr15:84794468	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs35726233	ENSG00000259728.4	LINC00933	7.9	2.02e-14	7.75e-12	0.46	0.34	Schizophrenia;	chr15:84794569	chr15:84570649~84580175:+
THCA	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	7.9	2.03e-14	7.77e-12	0.42	0.34	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
THCA	cis	rs853679	0.882	rs4713140	ENSG00000280107.1	AL022393.9	-7.9	2.03e-14	7.77e-12	-0.52	-0.34	Depression;	chr6:28129415	chr6:28170845~28172521:+
THCA	cis	rs116175783	0.557	rs62188138	ENSG00000227403.1	AC009299.3	7.9	2.03e-14	7.77e-12	0.6	0.34	Intelligence (multi-trait analysis);	chr2:161410935	chr2:161244739~161249050:+
THCA	cis	rs116175783	0.557	rs6710414	ENSG00000227403.1	AC009299.3	7.9	2.03e-14	7.77e-12	0.6	0.34	Intelligence (multi-trait analysis);	chr2:161412004	chr2:161244739~161249050:+
THCA	cis	rs4266144	0.544	rs13080798	ENSG00000244515.1	KRT18P34	-7.9	2.03e-14	7.77e-12	-0.38	-0.34	Coronary artery disease;	chr3:157114612	chr3:157162663~157163932:-
THCA	cis	rs8062405	0.558	rs231976	ENSG00000251417.2	RP11-1348G14.4	-7.9	2.04e-14	7.81e-12	-0.32	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28802743~28817828:+
THCA	cis	rs42490	0.789	rs416324	ENSG00000251136.7	RP11-37B2.1	7.9	2.04e-14	7.81e-12	0.29	0.34	Leprosy;	chr8:89803007	chr8:89609409~89757727:-
THCA	cis	rs12681366	0.881	rs2381793	ENSG00000253704.1	RP11-267M23.4	7.9	2.04e-14	7.83e-12	0.37	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94388167	chr8:94553722~94569745:+
THCA	cis	rs62355901	0.505	rs16886257	ENSG00000271828.1	CTD-2310F14.1	7.9	2.05e-14	7.85e-12	0.68	0.34	Breast cancer;	chr5:56766994	chr5:56927874~56929573:+
THCA	cis	rs2562456	0.834	rs2173727	ENSG00000268555.1	RP11-678G14.3	-7.9	2.05e-14	7.85e-12	-0.47	-0.34	Pain;	chr19:21491155	chr19:21570822~21587322:-
THCA	cis	rs7674212	0.531	rs4699048	ENSG00000251288.2	RP11-10L12.2	-7.9	2.05e-14	7.85e-12	-0.46	-0.34	Type 2 diabetes;	chr4:103005570	chr4:102751401~102752641:+
THCA	cis	rs2787702	0.5	rs28793568	ENSG00000237233.2	TMEM26-AS1	7.9	2.05e-14	7.85e-12	0.56	0.34	Response to taxane treatment (placlitaxel);	chr10:61584797	chr10:61452639~61481956:+
THCA	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-7.9	2.05e-14	7.86e-12	-0.42	-0.34	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
THCA	cis	rs12682352	0.602	rs1473029	ENSG00000253893.2	FAM85B	-7.9	2.06e-14	7.9e-12	-0.44	-0.34	Neuroticism;	chr8:8811407	chr8:8167819~8226614:-
THCA	cis	rs7811142	0.83	rs76798830	ENSG00000078319.8	PMS2P1	-7.9	2.06e-14	7.91e-12	-0.5	-0.34	Platelet count;	chr7:100355205	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.775	rs6946768	ENSG00000078319.8	PMS2P1	-7.9	2.06e-14	7.91e-12	-0.5	-0.34	Platelet count;	chr7:100356770	chr7:100320992~100341908:-
THCA	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-7.9	2.06e-14	7.91e-12	-0.44	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
THCA	cis	rs4308124	0.708	rs6749633	ENSG00000227992.1	AC108463.2	7.9	2.06e-14	7.91e-12	0.48	0.34	Vitiligo;	chr2:111230439	chr2:111203964~111206215:-
THCA	cis	rs12681366	0.801	rs6981551	ENSG00000253704.1	RP11-267M23.4	7.9	2.06e-14	7.91e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94466421	chr8:94553722~94569745:+
THCA	cis	rs6496932	0.503	rs10220820	ENSG00000218052.5	ADAMTS7P4	-7.89	2.07e-14	7.92e-12	-0.45	-0.34	Central corneal thickness;Corneal structure;	chr15:85441932	chr15:85255369~85330334:-
THCA	cis	rs7851660	0.679	rs4297160	ENSG00000236130.1	PTCSC2	-7.89	2.07e-14	7.93e-12	-0.27	-0.34	Strep throat;	chr9:97823224	chr9:97805935~97810008:-
THCA	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-7.89	2.08e-14	7.98e-12	-0.48	-0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
THCA	cis	rs7182621	0.512	rs71403471	ENSG00000182397.13	DNM1P46	7.89	2.08e-14	7.98e-12	0.46	0.34	Colonoscopy-negative controls vs population controls;	chr15:99870656	chr15:99790156~99806927:-
THCA	cis	rs12681366	0.801	rs12549544	ENSG00000253704.1	RP11-267M23.4	7.89	2.08e-14	7.98e-12	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94471329	chr8:94553722~94569745:+
THCA	cis	rs9388451	0.839	rs3966775	ENSG00000237742.5	RP11-624M8.1	-7.89	2.09e-14	7.99e-12	-0.29	-0.34	Brugada syndrome;	chr6:125746509	chr6:125578558~125749190:-
THCA	cis	rs10411161	0.81	rs77458785	ENSG00000269483.1	AC006272.1	7.89	2.09e-14	8e-12	0.58	0.34	Breast cancer;	chr19:51881042	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.81	rs60981935	ENSG00000269483.1	AC006272.1	7.89	2.09e-14	8e-12	0.58	0.34	Breast cancer;	chr19:51882028	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.81	rs57171871	ENSG00000269483.1	AC006272.1	7.89	2.09e-14	8e-12	0.58	0.34	Breast cancer;	chr19:51882079	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.81	rs59911578	ENSG00000269483.1	AC006272.1	7.89	2.09e-14	8e-12	0.58	0.34	Breast cancer;	chr19:51882344	chr19:51839924~51843324:-
THCA	cis	rs2015599	0.525	rs10771514	ENSG00000257176.2	RP11-996F15.2	7.89	2.09e-14	8e-12	0.35	0.34	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29280418~29317848:-
THCA	cis	rs934734	0.752	rs198478	ENSG00000204929.10	AC074391.1	-7.89	2.09e-14	8.01e-12	-0.42	-0.34	Rheumatoid arthritis;	chr2:65379877	chr2:65436711~66084639:+
THCA	cis	rs7727544	0.647	rs72793280	ENSG00000224431.1	AC063976.7	7.89	2.09e-14	8.02e-12	0.3	0.34	Blood metabolite levels;	chr5:132227207	chr5:132199456~132203487:+
THCA	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-7.89	2.1e-14	8.03e-12	-0.44	-0.34	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
THCA	cis	rs11148252	0.774	rs7993748	ENSG00000235660.1	LINC00345	-7.89	2.1e-14	8.05e-12	-0.42	-0.34	Lewy body disease;	chr13:52367496	chr13:52484161~52484680:-
THCA	cis	rs12908161	1	rs4643294	ENSG00000225151.9	GOLGA2P7	-7.89	2.11e-14	8.07e-12	-0.51	-0.34	Schizophrenia;	chr15:84707022	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs62021219	ENSG00000225151.9	GOLGA2P7	-7.89	2.11e-14	8.07e-12	-0.51	-0.34	Schizophrenia;	chr15:84712928	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs34900908	ENSG00000225151.9	GOLGA2P7	-7.89	2.11e-14	8.07e-12	-0.51	-0.34	Schizophrenia;	chr15:84714368	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs35524990	ENSG00000225151.9	GOLGA2P7	-7.89	2.11e-14	8.07e-12	-0.51	-0.34	Schizophrenia;	chr15:84714972	chr15:84199311~84230136:-
THCA	cis	rs7714584	1	rs7732643	ENSG00000197083.10	ZNF300P1	7.89	2.11e-14	8.07e-12	0.55	0.34	Crohn's disease;	chr5:150881874	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs2344181	ENSG00000197083.10	ZNF300P1	7.89	2.11e-14	8.07e-12	0.55	0.34	Crohn's disease;	chr5:150883012	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs2344180	ENSG00000197083.10	ZNF300P1	7.89	2.11e-14	8.07e-12	0.55	0.34	Crohn's disease;	chr5:150887795	chr5:150930645~150946289:-
THCA	cis	rs7727544	0.716	rs2089855	ENSG00000224431.1	AC063976.7	7.89	2.11e-14	8.08e-12	0.31	0.34	Blood metabolite levels;	chr5:132237836	chr5:132199456~132203487:+
THCA	cis	rs9487094	0.778	rs13214717	ENSG00000260273.1	RP11-425D10.10	7.89	2.12e-14	8.1e-12	0.45	0.34	Height;	chr6:109573151	chr6:109382795~109383666:+
THCA	cis	rs7714584	1	rs76548544	ENSG00000197083.10	ZNF300P1	7.89	2.12e-14	8.1e-12	0.55	0.34	Crohn's disease;	chr5:150843953	chr5:150930645~150946289:-
THCA	cis	rs7918232	0.574	rs10458708	ENSG00000262412.1	RP11-85G18.6	7.89	2.12e-14	8.11e-12	0.4	0.34	Breast cancer;	chr10:27166676	chr10:27243130~27250804:+
THCA	cis	rs10208649	1	rs10208649	ENSG00000272156.1	RP11-477N3.1	-7.89	2.12e-14	8.11e-12	-0.61	-0.34	Body mass index;	chr2:53934226	chr2:54082554~54085066:+
THCA	cis	rs910316	0.935	rs2268620	ENSG00000279594.1	RP11-950C14.10	-7.89	2.12e-14	8.13e-12	-0.32	-0.34	Height;	chr14:75173700	chr14:75011269~75012851:-
THCA	cis	rs10129255	0.5	rs4774008	ENSG00000223648.3	IGHV3-64	7.89	2.13e-14	8.14e-12	0.2	0.34	Kawasaki disease;	chr14:106681273	chr14:106643132~106658258:-
THCA	cis	rs6142102	0.602	rs4911395	ENSG00000275784.1	RP5-1125A11.6	-7.89	2.13e-14	8.16e-12	-0.33	-0.34	Skin pigmentation;	chr20:33992095	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.602	rs4911396	ENSG00000275784.1	RP5-1125A11.6	-7.89	2.13e-14	8.16e-12	-0.33	-0.34	Skin pigmentation;	chr20:33992139	chr20:33989480~33991818:-
THCA	cis	rs4072705	0.967	rs4144630	ENSG00000224020.1	MIR181A2HG	-7.89	2.14e-14	8.18e-12	-0.31	-0.34	Menarche (age at onset);	chr9:124676921	chr9:124658467~124698631:+
THCA	cis	rs8114671	0.836	rs2425006	ENSG00000269202.1	RP4-614O4.12	7.89	2.15e-14	8.21e-12	0.29	0.34	Height;	chr20:34983425	chr20:35201747~35203288:-
THCA	cis	rs7714584	1	rs75294883	ENSG00000197083.10	ZNF300P1	7.89	2.15e-14	8.22e-12	0.63	0.34	Crohn's disease;	chr5:150816941	chr5:150930645~150946289:-
THCA	cis	rs4713118	0.662	rs149969	ENSG00000226314.6	ZNF192P1	-7.89	2.15e-14	8.23e-12	-0.43	-0.34	Parkinson's disease;	chr6:28009959	chr6:28161781~28169594:+
THCA	cis	rs9649213	0.574	rs7790229	ENSG00000272950.1	RP11-307C18.1	7.89	2.15e-14	8.23e-12	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98290026	chr7:98322853~98323430:+
THCA	cis	rs10853057	0.717	rs4791242	ENSG00000214174.7	AMZ2P1	-7.89	2.15e-14	8.24e-12	-0.54	-0.34	White matter microstructure (global fractional anisotropy);	chr17:65061533	chr17:64966550~64975576:-
THCA	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	7.89	2.16e-14	8.25e-12	0.43	0.34	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	7.89	2.16e-14	8.25e-12	0.43	0.34	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	7.89	2.16e-14	8.25e-12	0.43	0.34	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	7.89	2.16e-14	8.25e-12	0.43	0.34	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	7.89	2.16e-14	8.25e-12	0.43	0.34	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
THCA	cis	rs910316	0.81	rs77939209	ENSG00000279594.1	RP11-950C14.10	-7.89	2.16e-14	8.27e-12	-0.32	-0.34	Height;	chr14:75203367	chr14:75011269~75012851:-
THCA	cis	rs2276314	0.857	rs16967327	ENSG00000278986.1	RP11-723J4.3	-7.89	2.16e-14	8.27e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36007073	chr18:35972151~35973916:+
THCA	cis	rs11096990	0.656	rs3796513	ENSG00000249685.1	RP11-360F5.3	-7.89	2.16e-14	8.27e-12	-0.41	-0.34	Cognitive function;	chr4:39289462	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs10029074	ENSG00000249685.1	RP11-360F5.3	-7.89	2.16e-14	8.27e-12	-0.41	-0.34	Cognitive function;	chr4:39290882	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs1564710	ENSG00000249685.1	RP11-360F5.3	-7.89	2.16e-14	8.27e-12	-0.41	-0.34	Cognitive function;	chr4:39291178	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.634	rs6815855	ENSG00000249685.1	RP11-360F5.3	-7.89	2.16e-14	8.27e-12	-0.41	-0.34	Cognitive function;	chr4:39294926	chr4:39133913~39135608:+
THCA	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-7.89	2.18e-14	8.33e-12	-0.44	-0.34	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
THCA	cis	rs1707322	1	rs6687301	ENSG00000234329.1	RP11-767N6.2	7.89	2.18e-14	8.33e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45651039~45651826:-
THCA	cis	rs4308124	0.708	rs61358692	ENSG00000227992.1	AC108463.2	-7.89	2.18e-14	8.35e-12	-0.48	-0.34	Vitiligo;	chr2:111207582	chr2:111203964~111206215:-
THCA	cis	rs7811142	1	rs67040465	ENSG00000242294.5	STAG3L5P	7.89	2.18e-14	8.35e-12	0.23	0.34	Platelet count;	chr7:100485455	chr7:100336079~100351900:+
THCA	cis	rs78579487	1	rs78579487	ENSG00000240875.4	LINC00886	-7.89	2.19e-14	8.36e-12	-0.28	-0.34	Breast cancer;	chr3:156800879	chr3:156747346~156817062:-
THCA	cis	rs987724	0.551	rs1835372	ENSG00000240875.4	LINC00886	-7.89	2.19e-14	8.36e-12	-0.28	-0.34	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156801238	chr3:156747346~156817062:-
THCA	cis	rs2712184	0.756	rs2024487	ENSG00000229352.1	AC007563.3	7.89	2.19e-14	8.38e-12	0.4	0.34	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216798548	chr2:216799608~216805335:+
THCA	cis	rs2276314	0.762	rs3826600	ENSG00000278986.1	RP11-723J4.3	-7.89	2.2e-14	8.4e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36029090	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs72883058	ENSG00000278986.1	RP11-723J4.3	-7.89	2.2e-14	8.4e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36032954	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs8097597	ENSG00000278986.1	RP11-723J4.3	-7.89	2.2e-14	8.4e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36039485	chr18:35972151~35973916:+
THCA	cis	rs7247513	0.964	rs8105902	ENSG00000230310.1	CTD-2192J16.11	-7.89	2.2e-14	8.42e-12	-0.41	-0.34	Bipolar disorder;	chr19:12607537	chr19:12552597~12553644:+
THCA	cis	rs7646881	0.812	rs73017539	ENSG00000240207.5	RP11-379F4.4	-7.89	2.21e-14	8.42e-12	-0.49	-0.34	Tetralogy of Fallot;	chr3:158742954	chr3:158732263~158784070:+
THCA	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	7.89	2.21e-14	8.43e-12	0.23	0.34	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	7.89	2.21e-14	8.43e-12	0.23	0.34	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	7.89	2.21e-14	8.43e-12	0.23	0.34	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	7.89	2.21e-14	8.43e-12	0.23	0.34	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	7.89	2.21e-14	8.43e-12	0.23	0.34	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	7.89	2.21e-14	8.43e-12	0.23	0.34	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
THCA	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	7.88	2.22e-14	8.47e-12	0.43	0.34	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
THCA	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	7.88	2.22e-14	8.47e-12	0.23	0.34	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	7.88	2.22e-14	8.47e-12	0.23	0.34	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
THCA	cis	rs6142102	0.602	rs1054534	ENSG00000275784.1	RP5-1125A11.6	-7.88	2.22e-14	8.47e-12	-0.33	-0.34	Skin pigmentation;	chr20:34017521	chr20:33989480~33991818:-
THCA	cis	rs11096990	0.634	rs10019594	ENSG00000249685.1	RP11-360F5.3	-7.88	2.22e-14	8.49e-12	-0.41	-0.34	Cognitive function;	chr4:39287127	chr4:39133913~39135608:+
THCA	cis	rs12554020	1	rs55766809	ENSG00000227603.1	RP11-165J3.6	7.88	2.22e-14	8.5e-12	0.46	0.34	Schizophrenia;	chr9:93428436	chr9:93435332~93437121:-
THCA	cis	rs910316	0.712	rs175015	ENSG00000279594.1	RP11-950C14.10	-7.88	2.23e-14	8.5e-12	-0.31	-0.34	Height;	chr14:74990372	chr14:75011269~75012851:-
THCA	cis	rs910316	0.763	rs735452	ENSG00000279594.1	RP11-950C14.10	-7.88	2.23e-14	8.52e-12	-0.32	-0.34	Height;	chr14:75031281	chr14:75011269~75012851:-
THCA	cis	rs11096990	0.634	rs3733287	ENSG00000249685.1	RP11-360F5.3	7.88	2.23e-14	8.52e-12	0.41	0.34	Cognitive function;	chr4:39215732	chr4:39133913~39135608:+
THCA	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	7.88	2.23e-14	8.52e-12	0.42	0.34	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
THCA	cis	rs4819052	1	rs13047688	ENSG00000237664.1	LINC00316	-7.88	2.23e-14	8.52e-12	-0.37	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45249375	chr21:45338590~45341990:-
THCA	cis	rs6844153	0.941	rs73116683	ENSG00000240005.4	RP11-293A21.1	-7.88	2.23e-14	8.53e-12	-0.44	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26955376	chr4:26859806~26860599:-
THCA	cis	rs8114671	0.836	rs2038504	ENSG00000269202.1	RP4-614O4.12	7.88	2.25e-14	8.58e-12	0.29	0.34	Height;	chr20:35060384	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.836	rs2104083	ENSG00000269202.1	RP4-614O4.12	7.88	2.25e-14	8.58e-12	0.29	0.34	Height;	chr20:35061330	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.839	rs2104084	ENSG00000269202.1	RP4-614O4.12	7.88	2.25e-14	8.58e-12	0.29	0.34	Height;	chr20:35061414	chr20:35201747~35203288:-
THCA	cis	rs934734	0.532	rs62141075	ENSG00000237979.1	AC007389.1	-7.88	2.25e-14	8.6e-12	-0.39	-0.34	Rheumatoid arthritis;	chr2:65417482	chr2:65500993~65502138:-
THCA	cis	rs8072100	0.967	rs4239162	ENSG00000228782.6	CTD-2026D20.3	7.88	2.25e-14	8.6e-12	0.31	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678444	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.967	rs4239163	ENSG00000228782.6	CTD-2026D20.3	7.88	2.25e-14	8.6e-12	0.31	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47678588	chr17:47450568~47492492:-
THCA	cis	rs11096990	0.634	rs6829064	ENSG00000249685.1	RP11-360F5.3	-7.88	2.26e-14	8.61e-12	-0.41	-0.34	Cognitive function;	chr4:39290192	chr4:39133913~39135608:+
THCA	cis	rs733592	0.504	rs2261608	ENSG00000240399.1	RP1-228P16.1	7.88	2.26e-14	8.61e-12	0.32	0.34	Plateletcrit;	chr12:48327851	chr12:48054813~48055591:-
THCA	cis	rs2439831	0.717	rs28495368	ENSG00000275601.1	AC011330.13	-7.88	2.26e-14	8.62e-12	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43603444	chr15:43642389~43643023:-
THCA	cis	rs11651753	0.598	rs4794286	ENSG00000264920.1	RP11-6N17.4	-7.88	2.26e-14	8.63e-12	-0.31	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47913231	chr17:47891255~47895812:-
THCA	cis	rs7208859	0.673	rs78799101	ENSG00000266490.1	CTD-2349P21.9	7.88	2.26e-14	8.64e-12	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30792372~30792833:+
THCA	cis	rs2739330	0.828	rs4820572	ENSG00000206090.4	AP000350.7	7.88	2.27e-14	8.64e-12	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23939998~23942798:+
THCA	cis	rs7615952	0.599	rs16834938	ENSG00000171084.14	FAM86JP	7.88	2.27e-14	8.65e-12	0.42	0.34	Blood pressure (smoking interaction);	chr3:125987203	chr3:125916620~125930024:+
THCA	cis	rs1707322	1	rs4073847	ENSG00000234329.1	RP11-767N6.2	-7.88	2.27e-14	8.66e-12	-0.32	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45651039~45651826:-
THCA	cis	rs7208859	0.562	rs216408	ENSG00000266490.1	CTD-2349P21.9	-7.88	2.27e-14	8.66e-12	-0.44	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30580739	chr17:30792372~30792833:+
THCA	cis	rs12908161	1	rs12908161	ENSG00000225151.9	GOLGA2P7	-7.88	2.27e-14	8.67e-12	-0.5	-0.34	Schizophrenia;	chr15:84664594	chr15:84199311~84230136:-
THCA	cis	rs12931792	0.712	rs56399904	ENSG00000183604.13	SMG1P5	7.88	2.28e-14	8.69e-12	0.34	0.34	Tonsillectomy;	chr16:30154862	chr16:30267553~30335374:-
THCA	cis	rs6908034	0.556	rs113071446	ENSG00000228412.5	RP4-625H18.2	7.88	2.28e-14	8.7e-12	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19810604	chr6:19802164~19804752:-
THCA	cis	rs28510890	0.688	rs12593253	ENSG00000260337.3	RP11-386M24.6	7.88	2.28e-14	8.71e-12	0.38	0.34	Lung cancer in ever smokers;	chr15:92587690	chr15:92592574~92596462:-
THCA	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	7.88	2.28e-14	8.71e-12	0.33	0.34	Breast size;	chr12:9228263	chr12:9277235~9313241:+
THCA	cis	rs1075265	0.563	rs2692536	ENSG00000233266.1	HMGB1P31	7.88	2.29e-14	8.74e-12	0.44	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54051334~54051760:+
THCA	cis	rs11096990	0.634	rs2839765	ENSG00000249685.1	RP11-360F5.3	-7.88	2.29e-14	8.74e-12	-0.41	-0.34	Cognitive function;	chr4:39293933	chr4:39133913~39135608:+
THCA	cis	rs17684571	0.872	rs3002009	ENSG00000231441.1	RP11-472M19.2	7.88	2.3e-14	8.76e-12	0.43	0.34	Schizophrenia;	chr6:56757983	chr6:56844002~56864078:+
THCA	cis	rs71403859	0.502	rs75986475	ENSG00000260886.1	TAT-AS1	7.88	2.31e-14	8.8e-12	0.62	0.34	Post bronchodilator FEV1;	chr16:71430155	chr16:71565789~71578187:+
THCA	cis	rs1150668	0.965	rs1150690	ENSG00000219392.1	RP1-265C24.5	-7.88	2.31e-14	8.83e-12	-0.38	-0.34	Pubertal anthropometrics;	chr6:28197520	chr6:28115628~28116551:+
THCA	cis	rs62103177	0.759	rs9956512	ENSG00000261126.6	RP11-795F19.1	7.88	2.32e-14	8.84e-12	0.4	0.34	Opioid sensitivity;	chr18:79847517	chr18:80046900~80095482:+
THCA	cis	rs7674212	0.581	rs11946020	ENSG00000246560.2	RP11-10L12.4	7.88	2.32e-14	8.84e-12	0.43	0.34	Type 2 diabetes;	chr4:103023585	chr4:102828055~102844075:+
THCA	cis	rs9500256	0.967	rs4928431	ENSG00000272541.1	XXbac-BPGBPG55C20.1	7.88	2.32e-14	8.85e-12	0.36	0.34	Eosinophilic esophagitis (pediatric);	chr6:57979980	chr6:57855891~57856468:-
THCA	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	7.88	2.32e-14	8.86e-12	0.41	0.34	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
THCA	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	7.88	2.32e-14	8.86e-12	0.41	0.34	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
THCA	cis	rs12681366	0.881	rs10464877	ENSG00000253704.1	RP11-267M23.4	7.88	2.32e-14	8.86e-12	0.37	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94385615	chr8:94553722~94569745:+
THCA	cis	rs2466254	0.657	rs2460915	ENSG00000251468.2	RP11-369K16.1	7.88	2.32e-14	8.86e-12	0.54	0.34	Pneumonia;	chr8:12968527	chr8:12958387~12962200:+
THCA	cis	rs2839186	0.708	rs17183123	ENSG00000239415.1	AP001469.9	7.88	2.33e-14	8.87e-12	0.35	0.34	Testicular germ cell tumor;	chr21:46252047	chr21:46251549~46254133:-
THCA	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-7.88	2.33e-14	8.9e-12	-0.39	-0.34	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
THCA	cis	rs7945705	0.738	rs11042067	ENSG00000254860.4	TMEM9B-AS1	7.88	2.34e-14	8.91e-12	0.36	0.34	Hemoglobin concentration;	chr11:8793906	chr11:8964675~8977527:+
THCA	cis	rs736801	0.808	rs6866614	ENSG00000237714.1	P4HA2-AS1	-7.88	2.34e-14	8.91e-12	-0.47	-0.34	Mosquito bite size;Breast cancer;	chr5:132451445	chr5:132184876~132192808:+
THCA	cis	rs9309473	0.583	rs6713196	ENSG00000163016.8	ALMS1P	7.88	2.34e-14	8.94e-12	0.46	0.34	Metabolite levels;	chr2:73349277	chr2:73644919~73685576:+
THCA	cis	rs853679	0.824	rs34712084	ENSG00000280107.1	AL022393.9	-7.88	2.35e-14	8.96e-12	-0.53	-0.34	Depression;	chr6:28076050	chr6:28170845~28172521:+
THCA	cis	rs853679	0.824	rs1321505	ENSG00000280107.1	AL022393.9	-7.88	2.35e-14	8.96e-12	-0.53	-0.34	Depression;	chr6:28085045	chr6:28170845~28172521:+
THCA	cis	rs853679	0.882	rs9468287	ENSG00000280107.1	AL022393.9	-7.88	2.35e-14	8.96e-12	-0.53	-0.34	Depression;	chr6:28111963	chr6:28170845~28172521:+
THCA	cis	rs8027521	0.54	rs11639036	ENSG00000280362.1	RP11-643A5.3	7.88	2.35e-14	8.96e-12	0.52	0.34	Circulating chemerin levels;	chr15:53944693	chr15:53910769~53914712:+
THCA	cis	rs12681366	0.881	rs3019145	ENSG00000253704.1	RP11-267M23.4	7.88	2.35e-14	8.97e-12	0.37	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94401324	chr8:94553722~94569745:+
THCA	cis	rs10971721	0.584	rs10971938	ENSG00000260947.1	RP11-384P7.7	-7.88	2.35e-14	8.97e-12	-0.78	-0.34	Body mass index;	chr9:34120722	chr9:33697459~33700986:+
THCA	cis	rs9309473	0.607	rs1851546	ENSG00000163016.8	ALMS1P	7.88	2.36e-14	8.98e-12	0.46	0.34	Metabolite levels;	chr2:73363999	chr2:73644919~73685576:+
THCA	cis	rs4072705	1	rs6478680	ENSG00000224020.1	MIR181A2HG	-7.88	2.36e-14	8.98e-12	-0.3	-0.34	Menarche (age at onset);	chr9:124696189	chr9:124658467~124698631:+
THCA	cis	rs2712184	0.756	rs2541388	ENSG00000229352.1	AC007563.3	7.88	2.36e-14	8.99e-12	0.4	0.34	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216799561	chr2:216799608~216805335:+
THCA	cis	rs11673344	0.504	rs6510593	ENSG00000226686.6	LINC01535	7.88	2.37e-14	9.03e-12	0.38	0.34	Obesity-related traits;	chr19:37143153	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs7259332	ENSG00000226686.6	LINC01535	7.88	2.37e-14	9.03e-12	0.38	0.34	Obesity-related traits;	chr19:37143389	chr19:37251912~37265535:+
THCA	cis	rs7576126	0.563	rs1807337	ENSG00000237979.1	AC007389.1	-7.88	2.38e-14	9.05e-12	-0.39	-0.34	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65500993~65502138:-
THCA	cis	rs4072705	1	rs7032937	ENSG00000224020.1	MIR181A2HG	-7.88	2.38e-14	9.06e-12	-0.3	-0.34	Menarche (age at onset);	chr9:124575894	chr9:124658467~124698631:+
THCA	cis	rs11096990	0.593	rs1026235	ENSG00000249685.1	RP11-360F5.3	7.88	2.38e-14	9.06e-12	0.41	0.34	Cognitive function;	chr4:39226629	chr4:39133913~39135608:+
THCA	cis	rs9309473	0.607	rs7560272	ENSG00000163016.8	ALMS1P	7.88	2.38e-14	9.06e-12	0.46	0.34	Metabolite levels;	chr2:73334357	chr2:73644919~73685576:+
THCA	cis	rs7247513	0.964	rs8100964	ENSG00000230310.1	CTD-2192J16.11	-7.87	2.39e-14	9.11e-12	-0.41	-0.34	Bipolar disorder;	chr19:12609817	chr19:12552597~12553644:+
THCA	cis	rs11214589	0.807	rs2155463	ENSG00000270179.1	RP11-159N11.4	-7.87	2.39e-14	9.12e-12	-0.35	-0.34	Neuroticism;	chr11:113371579	chr11:113368478~113369117:+
THCA	cis	rs116175783	0.557	rs16845770	ENSG00000227403.1	AC009299.3	7.87	2.4e-14	9.13e-12	0.62	0.34	Intelligence (multi-trait analysis);	chr2:161325276	chr2:161244739~161249050:+
THCA	cis	rs11096990	0.656	rs2123028	ENSG00000249685.1	RP11-360F5.3	-7.87	2.4e-14	9.14e-12	-0.41	-0.34	Cognitive function;	chr4:39301859	chr4:39133913~39135608:+
THCA	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	7.87	2.4e-14	9.14e-12	0.43	0.34	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
THCA	cis	rs11096990	0.634	rs7666632	ENSG00000249685.1	RP11-360F5.3	7.87	2.4e-14	9.16e-12	0.41	0.34	Cognitive function;	chr4:39238568	chr4:39133913~39135608:+
THCA	cis	rs7727544	0.606	rs10058074	ENSG00000233006.5	AC034220.3	7.87	2.41e-14	9.17e-12	0.27	0.34	Blood metabolite levels;	chr5:132350453	chr5:132311285~132369916:-
THCA	cis	rs7811142	1	rs6979335	ENSG00000242294.5	STAG3L5P	7.87	2.41e-14	9.17e-12	0.23	0.34	Platelet count;	chr7:100492237	chr7:100336079~100351900:+
THCA	cis	rs34375054	0.623	rs2297478	ENSG00000279233.1	RP11-158L12.4	7.87	2.41e-14	9.18e-12	0.34	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125107298	chr12:125138245~125141711:+
THCA	cis	rs116175783	0.557	rs7349280	ENSG00000227403.1	AC009299.3	7.87	2.42e-14	9.22e-12	0.62	0.34	Intelligence (multi-trait analysis);	chr2:161354120	chr2:161244739~161249050:+
THCA	cis	rs11148252	0.774	rs56033750	ENSG00000235660.1	LINC00345	-7.87	2.43e-14	9.25e-12	-0.42	-0.34	Lewy body disease;	chr13:52173143	chr13:52484161~52484680:-
THCA	cis	rs7208859	0.623	rs3752019	ENSG00000266490.1	CTD-2349P21.9	7.87	2.43e-14	9.26e-12	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs56146117	ENSG00000266490.1	CTD-2349P21.9	7.87	2.43e-14	9.26e-12	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30792372~30792833:+
THCA	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-7.87	2.44e-14	9.29e-12	-0.44	-0.34	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
THCA	cis	rs9601248	0.845	rs1932197	ENSG00000227676.3	LINC01068	7.87	2.44e-14	9.3e-12	0.43	0.34	Major depressive disorder;	chr13:79609218	chr13:79566727~79571436:+
THCA	cis	rs2018683	0.768	rs10282015	ENSG00000228421.2	AC005013.5	7.87	2.44e-14	9.3e-12	0.38	0.34	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982522	chr7:28957667~28959345:+
THCA	cis	rs2018683	0.77	rs10951208	ENSG00000228421.2	AC005013.5	7.87	2.44e-14	9.3e-12	0.38	0.34	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;	chr7:28982888	chr7:28957667~28959345:+
THCA	cis	rs9400467	0.528	rs11153280	ENSG00000230177.1	RP5-1112D6.4	-7.87	2.45e-14	9.32e-12	-0.27	-0.34	Amino acid levels;Blood metabolite levels;	chr6:111268090	chr6:111277932~111278742:+
THCA	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	7.87	2.45e-14	9.34e-12	0.32	0.34	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
THCA	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	7.87	2.45e-14	9.34e-12	0.32	0.34	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
THCA	cis	rs10208649	1	rs72906711	ENSG00000272156.1	RP11-477N3.1	7.87	2.46e-14	9.35e-12	0.62	0.34	Body mass index;	chr2:54036465	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs13387890	ENSG00000272156.1	RP11-477N3.1	7.87	2.46e-14	9.35e-12	0.62	0.34	Body mass index;	chr2:54039249	chr2:54082554~54085066:+
THCA	cis	rs7714584	1	rs7724036	ENSG00000197083.10	ZNF300P1	-7.87	2.46e-14	9.36e-12	-0.54	-0.34	Crohn's disease;	chr5:150905246	chr5:150930645~150946289:-
THCA	cis	rs7015263	0.715	rs6999022	ENSG00000254231.1	CTD-2284J15.1	7.87	2.46e-14	9.36e-12	0.34	0.34	Intelligence (multi-trait analysis);	chr8:86510941	chr8:86333274~86343314:-
THCA	cis	rs595244	0.764	rs6493333	ENSG00000259705.1	RP11-227D13.1	-7.87	2.48e-14	9.43e-12	-0.46	-0.34	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48646849	chr15:48645951~48652016:+
THCA	cis	rs732716	0.752	rs11085072	ENSG00000267980.1	AC007292.6	-7.87	2.48e-14	9.44e-12	-0.41	-0.34	Mean corpuscular volume;	chr19:4368145	chr19:4363789~4364640:+
THCA	cis	rs7829975	0.846	rs1879957	ENSG00000253893.2	FAM85B	7.87	2.48e-14	9.45e-12	0.42	0.34	Mood instability;	chr8:8687298	chr8:8167819~8226614:-
THCA	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	7.87	2.49e-14	9.47e-12	0.43	0.34	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
THCA	cis	rs2688482	0.557	rs3103952	ENSG00000224769.1	AC069213.1	7.87	2.5e-14	9.49e-12	0.51	0.34	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195614947~195620233:+
THCA	cis	rs150992	0.587	rs10076291	ENSG00000248489.1	CTD-2007H13.3	-7.87	2.5e-14	9.5e-12	-0.33	-0.34	Body mass index;	chr5:99012954	chr5:98929171~98995013:+
THCA	cis	rs12682352	0.602	rs11783966	ENSG00000253893.2	FAM85B	7.87	2.5e-14	9.52e-12	0.44	0.34	Neuroticism;	chr8:8807637	chr8:8167819~8226614:-
THCA	cis	rs7430456	0.839	rs9824506	ENSG00000228221.4	LINC00578	-7.87	2.51e-14	9.53e-12	-0.46	-0.34	Breast cancer;	chr3:177751431	chr3:177441921~177752305:+
THCA	cis	rs2015599	0.525	rs7298031	ENSG00000257176.2	RP11-996F15.2	7.87	2.51e-14	9.54e-12	0.35	0.34	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.525	rs2016832	ENSG00000257176.2	RP11-996F15.2	7.87	2.51e-14	9.54e-12	0.35	0.34	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29280418~29317848:-
THCA	cis	rs6908034	0.607	rs73376650	ENSG00000228412.5	RP4-625H18.2	7.87	2.51e-14	9.54e-12	0.78	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805275	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs112599867	ENSG00000228412.5	RP4-625H18.2	7.87	2.51e-14	9.54e-12	0.78	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805301	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs73376651	ENSG00000228412.5	RP4-625H18.2	7.87	2.51e-14	9.54e-12	0.78	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805328	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs73376655	ENSG00000228412.5	RP4-625H18.2	7.87	2.51e-14	9.54e-12	0.78	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805433	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs113592672	ENSG00000228412.5	RP4-625H18.2	7.87	2.51e-14	9.54e-12	0.78	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19805832	chr6:19802164~19804752:-
THCA	cis	rs11651753	0.561	rs60580012	ENSG00000264920.1	RP11-6N17.4	-7.87	2.51e-14	9.55e-12	-0.31	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892442	chr17:47891255~47895812:-
THCA	cis	rs11651753	0.561	rs61422354	ENSG00000264920.1	RP11-6N17.4	-7.87	2.51e-14	9.55e-12	-0.31	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47892443	chr17:47891255~47895812:-
THCA	cis	rs1707322	0.963	rs11211202	ENSG00000234329.1	RP11-767N6.2	7.87	2.52e-14	9.57e-12	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45651039~45651826:-
THCA	cis	rs10875746	0.551	rs1471997	ENSG00000240399.1	RP1-228P16.1	-7.87	2.52e-14	9.58e-12	-0.38	-0.34	Longevity (90 years and older);	chr12:48329812	chr12:48054813~48055591:-
THCA	cis	rs1075265	0.587	rs2542585	ENSG00000233266.1	HMGB1P31	7.87	2.52e-14	9.59e-12	0.44	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54051334~54051760:+
THCA	cis	rs847577	0.575	rs41278842	ENSG00000272950.1	RP11-307C18.1	-7.87	2.53e-14	9.61e-12	-0.42	-0.34	Breast cancer;	chr7:98186687	chr7:98322853~98323430:+
THCA	cis	rs4722166	0.645	rs1404006	ENSG00000179428.2	AC073072.5	-7.87	2.53e-14	9.62e-12	-0.43	-0.34	Lung cancer;	chr7:22755458	chr7:22725395~22727620:-
THCA	cis	rs8114671	0.562	rs6088647	ENSG00000269202.1	RP4-614O4.12	-7.87	2.53e-14	9.62e-12	-0.29	-0.34	Height;	chr20:34918194	chr20:35201747~35203288:-
THCA	cis	rs2439831	0.867	rs2255440	ENSG00000249839.1	AC011330.5	-7.87	2.53e-14	9.63e-12	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43538269	chr15:43663654~43684339:-
THCA	cis	rs131777	0.526	rs86337	ENSG00000205559.3	CHKB-AS1	-7.87	2.54e-14	9.67e-12	-0.41	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50582239	chr22:50583026~50583877:+
THCA	cis	rs2439831	0.717	rs2470132	ENSG00000249839.1	AC011330.5	-7.86	2.56e-14	9.71e-12	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43543283	chr15:43663654~43684339:-
THCA	cis	rs2439831	0.867	rs2251844	ENSG00000249839.1	AC011330.5	-7.86	2.56e-14	9.71e-12	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43544280	chr15:43663654~43684339:-
THCA	cis	rs4664293	0.769	rs1365798	ENSG00000226266.5	AC009961.3	7.86	2.56e-14	9.72e-12	0.41	0.34	Monocyte percentage of white cells;	chr2:159795853	chr2:159670708~159712435:-
THCA	cis	rs9649213	0.593	rs6465666	ENSG00000272950.1	RP11-307C18.1	-7.86	2.57e-14	9.75e-12	-0.42	-0.34	Prostate cancer (SNP x SNP interaction);	chr7:98307946	chr7:98322853~98323430:+
THCA	cis	rs7849270	0.798	rs10988198	ENSG00000268707.1	RP11-247A12.7	-7.86	2.57e-14	9.76e-12	-0.42	-0.34	Blood metabolite ratios;	chr9:129083846	chr9:129170434~129170940:+
THCA	cis	rs2276314	1	rs2298715	ENSG00000278986.1	RP11-723J4.3	-7.86	2.57e-14	9.76e-12	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35972462	chr18:35972151~35973916:+
THCA	cis	rs2276314	1	rs4573997	ENSG00000278986.1	RP11-723J4.3	-7.86	2.57e-14	9.76e-12	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35972605	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs6507158	ENSG00000278986.1	RP11-723J4.3	-7.86	2.58e-14	9.79e-12	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36056103	chr18:35972151~35973916:+
THCA	cis	rs11673344	0.543	rs12980849	ENSG00000226686.6	LINC01535	7.86	2.59e-14	9.83e-12	0.38	0.34	Obesity-related traits;	chr19:37160812	chr19:37251912~37265535:+
THCA	cis	rs7621025	0.5	rs9845460	ENSG00000273486.1	RP11-731C17.2	7.86	2.59e-14	9.84e-12	0.34	0.34	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136868275	chr3:136837338~136839021:-
THCA	cis	rs9388451	0.868	rs10457467	ENSG00000237742.5	RP11-624M8.1	-7.86	2.6e-14	9.87e-12	-0.3	-0.34	Brugada syndrome;	chr6:125724002	chr6:125578558~125749190:-
THCA	cis	rs944289	0.932	rs1169151	ENSG00000257826.1	RP11-116N8.4	7.86	2.6e-14	9.89e-12	0.36	0.34	Thyroid cancer;	chr14:36171395	chr14:36061026~36067190:-
THCA	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-7.86	2.62e-14	9.93e-12	-0.39	-0.34	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
THCA	cis	rs172166	0.538	rs1150686	ENSG00000219392.1	RP1-265C24.5	-7.86	2.62e-14	9.94e-12	-0.37	-0.34	Cardiac Troponin-T levels;	chr6:28193493	chr6:28115628~28116551:+
THCA	cis	rs1150688	1	rs1150688	ENSG00000219392.1	RP1-265C24.5	-7.86	2.62e-14	9.94e-12	-0.37	-0.34	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28115628~28116551:+
THCA	cis	rs860295	0.676	rs2666826	ENSG00000225855.5	RUSC1-AS1	7.86	2.62e-14	9.94e-12	0.24	0.34	Body mass index;	chr1:155688294	chr1:155316863~155324176:-
THCA	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	7.86	2.62e-14	9.95e-12	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
THCA	cis	rs4713118	0.955	rs9468201	ENSG00000219392.1	RP1-265C24.5	-7.86	2.63e-14	9.97e-12	-0.44	-0.34	Parkinson's disease;	chr6:27719256	chr6:28115628~28116551:+
THCA	cis	rs9341808	0.528	rs2322753	ENSG00000272129.1	RP11-250B2.6	7.86	2.63e-14	9.99e-12	0.41	0.34	Sitting height ratio;	chr6:80333148	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.556	rs2223875	ENSG00000272129.1	RP11-250B2.6	7.86	2.63e-14	9.99e-12	0.41	0.34	Sitting height ratio;	chr6:80335735	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.587	rs3805859	ENSG00000272129.1	RP11-250B2.6	7.86	2.63e-14	9.99e-12	0.41	0.34	Sitting height ratio;	chr6:80339229	chr6:80355424~80356859:+
THCA	cis	rs11148252	0.595	rs9526974	ENSG00000235660.1	LINC00345	-7.86	2.63e-14	9.99e-12	-0.44	-0.34	Lewy body disease;	chr13:52676905	chr13:52484161~52484680:-
THCA	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-7.86	2.63e-14	1e-11	-0.37	-0.34	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-7.86	2.63e-14	1e-11	-0.37	-0.34	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-7.86	2.63e-14	1e-11	-0.37	-0.34	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-7.86	2.63e-14	1e-11	-0.37	-0.34	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-7.86	2.63e-14	1e-11	-0.37	-0.34	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
THCA	cis	rs453301	0.624	rs2979265	ENSG00000253893.2	FAM85B	-7.86	2.65e-14	1.01e-11	-0.43	-0.34	Joint mobility (Beighton score);	chr8:9001207	chr8:8167819~8226614:-
THCA	cis	rs11051970	0.559	rs60162504	ENSG00000274964.1	RP11-817I4.1	-7.86	2.65e-14	1.01e-11	-0.45	-0.34	Response to tocilizumab in rheumatoid arthritis;	chr12:32320687	chr12:32339368~32340724:+
THCA	cis	rs7714584	1	rs4560537	ENSG00000197083.10	ZNF300P1	7.86	2.66e-14	1.01e-11	0.54	0.34	Crohn's disease;	chr5:150883024	chr5:150930645~150946289:-
THCA	cis	rs13129231	0.889	rs4833427	ENSG00000206820.1	RNU1-138P	-7.86	2.67e-14	1.01e-11	-0.4	-0.34	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113421407	chr4:113420323~113420486:+
THCA	cis	rs116175783	0.793	rs1267044	ENSG00000227403.1	AC009299.3	7.86	2.67e-14	1.01e-11	0.59	0.34	Intelligence (multi-trait analysis);	chr2:161271100	chr2:161244739~161249050:+
THCA	cis	rs10800713	0.954	rs6660637	ENSG00000260088.1	RP11-92G12.3	-7.86	2.67e-14	1.01e-11	-0.53	-0.34	Tandem gait;	chr1:200550893	chr1:200669507~200694250:+
THCA	cis	rs10800713	0.954	rs10737572	ENSG00000260088.1	RP11-92G12.3	-7.86	2.67e-14	1.01e-11	-0.53	-0.34	Tandem gait;	chr1:200552003	chr1:200669507~200694250:+
THCA	cis	rs4927850	1	rs4927850	ENSG00000226155.1	AC124944.3	7.86	2.67e-14	1.01e-11	0.41	0.34	Pancreatic cancer;	chr3:196024759	chr3:195912049~195913986:+
THCA	cis	rs11096990	0.634	rs6531706	ENSG00000249685.1	RP11-360F5.3	-7.86	2.68e-14	1.02e-11	-0.41	-0.34	Cognitive function;	chr4:39294547	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.656	rs4580661	ENSG00000249685.1	RP11-360F5.3	-7.86	2.68e-14	1.02e-11	-0.41	-0.34	Cognitive function;	chr4:39294730	chr4:39133913~39135608:+
THCA	cis	rs12908161	1	rs35316992	ENSG00000225151.9	GOLGA2P7	-7.86	2.69e-14	1.02e-11	-0.51	-0.34	Schizophrenia;	chr15:84704902	chr15:84199311~84230136:-
THCA	cis	rs2739330	0.828	rs5760102	ENSG00000235689.1	AP000351.13	7.86	2.69e-14	1.02e-11	0.43	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:24006305~24008258:-
THCA	cis	rs9649213	0.593	rs6947208	ENSG00000272950.1	RP11-307C18.1	7.86	2.69e-14	1.02e-11	0.41	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98282892	chr7:98322853~98323430:+
THCA	cis	rs7646881	0.812	rs7624408	ENSG00000240207.5	RP11-379F4.4	-7.86	2.7e-14	1.03e-11	-0.49	-0.34	Tetralogy of Fallot;	chr3:158742269	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.812	rs7636023	ENSG00000240207.5	RP11-379F4.4	-7.86	2.7e-14	1.03e-11	-0.49	-0.34	Tetralogy of Fallot;	chr3:158742270	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.812	rs73017536	ENSG00000240207.5	RP11-379F4.4	-7.86	2.7e-14	1.03e-11	-0.49	-0.34	Tetralogy of Fallot;	chr3:158742813	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.812	rs73017540	ENSG00000240207.5	RP11-379F4.4	-7.86	2.7e-14	1.03e-11	-0.49	-0.34	Tetralogy of Fallot;	chr3:158742999	chr3:158732263~158784070:+
THCA	cis	rs17772222	0.958	rs1816372	ENSG00000258983.2	RP11-507K2.2	7.86	2.71e-14	1.03e-11	0.43	0.34	Coronary artery calcification;	chr14:88507033	chr14:88499334~88515502:+
THCA	cis	rs7714584	1	rs1896707	ENSG00000197083.10	ZNF300P1	7.86	2.71e-14	1.03e-11	0.55	0.34	Crohn's disease;	chr5:150865567	chr5:150930645~150946289:-
THCA	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-7.86	2.71e-14	1.03e-11	-0.4	-0.34	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
THCA	cis	rs2120243	0.533	rs34263112	ENSG00000244515.1	KRT18P34	-7.86	2.71e-14	1.03e-11	-0.38	-0.34	Hepatocellular carcinoma in hepatitis B infection;	chr3:157338259	chr3:157162663~157163932:-
THCA	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-7.86	2.72e-14	1.03e-11	-0.36	-0.34	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	7.86	2.72e-14	1.03e-11	0.45	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
THCA	cis	rs73186030	0.764	rs66508963	ENSG00000272758.4	RP11-299J3.8	7.86	2.72e-14	1.03e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122365682	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs55744726	ENSG00000272758.4	RP11-299J3.8	7.86	2.72e-14	1.03e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122368907	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs73186095	ENSG00000272758.4	RP11-299J3.8	7.86	2.72e-14	1.03e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122372769	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs67446552	ENSG00000272758.4	RP11-299J3.8	7.86	2.72e-14	1.03e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122377448	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs67706840	ENSG00000272758.4	RP11-299J3.8	7.86	2.72e-14	1.03e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122377717	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs16833078	ENSG00000272758.4	RP11-299J3.8	7.86	2.72e-14	1.03e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122380747	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-7.86	2.72e-14	1.03e-11	-0.4	-0.34	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
THCA	cis	rs4718428	0.705	rs13220977	ENSG00000230295.1	RP11-458F8.2	7.86	2.72e-14	1.03e-11	0.3	0.34	Corneal structure;	chr7:66872661	chr7:66880708~66882981:+
THCA	cis	rs812925	0.519	rs1186696	ENSG00000271889.1	RP11-493E12.1	7.86	2.73e-14	1.03e-11	0.33	0.34	Immature fraction of reticulocytes;	chr2:61433348	chr2:61151433~61162105:-
THCA	cis	rs7015630	0.618	rs28405481	ENSG00000251136.7	RP11-37B2.1	-7.86	2.73e-14	1.03e-11	-0.37	-0.34	Inflammatory bowel disease;Crohn's disease;	chr8:89807501	chr8:89609409~89757727:-
THCA	cis	rs7712401	0.601	rs36180885	ENSG00000263432.2	RN7SL689P	-7.86	2.74e-14	1.04e-11	-0.4	-0.34	Mean platelet volume;	chr5:123020708	chr5:123022487~123022783:-
THCA	cis	rs189798	0.807	rs12785	ENSG00000254340.1	RP11-10A14.3	7.85	2.74e-14	1.04e-11	0.38	0.34	Myopia (pathological);	chr8:9137426	chr8:9141424~9145435:+
THCA	cis	rs9902453	0.9	rs56195309	ENSG00000264007.1	RP11-68I3.10	7.85	2.74e-14	1.04e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:30126735	chr17:29621617~29622254:-
THCA	cis	rs11971779	0.774	rs7785906	ENSG00000273391.1	RP11-634H22.1	7.85	2.75e-14	1.04e-11	0.34	0.34	Diisocyanate-induced asthma;	chr7:139437906	chr7:139359032~139359566:-
THCA	cis	rs2284219	0.894	rs1076291	ENSG00000196295.10	AC005154.6	-7.85	2.75e-14	1.04e-11	-0.25	-0.34	Type 2 diabetes;	chr7:30672979	chr7:30516309~30594809:-
THCA	cis	rs2284219	0.894	rs1076292	ENSG00000196295.10	AC005154.6	-7.85	2.75e-14	1.04e-11	-0.25	-0.34	Type 2 diabetes;	chr7:30673085	chr7:30516309~30594809:-
THCA	cis	rs2284219	0.894	rs2251002	ENSG00000196295.10	AC005154.6	-7.85	2.75e-14	1.04e-11	-0.25	-0.34	Type 2 diabetes;	chr7:30673228	chr7:30516309~30594809:-
THCA	cis	rs12908161	1	rs12905057	ENSG00000225151.9	GOLGA2P7	-7.85	2.76e-14	1.05e-11	-0.5	-0.34	Schizophrenia;	chr15:84667534	chr15:84199311~84230136:-
THCA	cis	rs6723226	0.75	rs3769597	ENSG00000276334.1	AL133243.1	7.85	2.76e-14	1.05e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr2:32466332	chr2:32521927~32523547:+
THCA	cis	rs11690935	0.688	rs7600835	ENSG00000228389.1	AC068039.4	7.85	2.77e-14	1.05e-11	0.38	0.34	Schizophrenia;	chr2:171665317	chr2:171773482~171775844:+
THCA	cis	rs9640161	0.789	rs28432021	ENSG00000261305.1	RP4-584D14.7	7.85	2.78e-14	1.05e-11	0.41	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150349146	chr7:150341771~150342607:+
THCA	cis	rs17684571	0.872	rs16888135	ENSG00000231441.1	RP11-472M19.2	7.85	2.78e-14	1.05e-11	0.43	0.34	Schizophrenia;	chr6:56734969	chr6:56844002~56864078:+
THCA	cis	rs7727544	0.548	rs4705938	ENSG00000233006.5	AC034220.3	7.85	2.78e-14	1.05e-11	0.27	0.34	Blood metabolite levels;	chr5:132358384	chr5:132311285~132369916:-
THCA	cis	rs1707322	1	rs4524994	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs9787412	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs4660896	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.928	rs10732844	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs12133129	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs4553121	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45651039~45651826:-
THCA	cis	rs1707322	0.963	rs6690652	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45651039~45651826:-
THCA	cis	rs1707322	1	rs6695421	ENSG00000234329.1	RP11-767N6.2	7.85	2.79e-14	1.06e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45651039~45651826:-
THCA	cis	rs17772222	0.917	rs1998670	ENSG00000258983.2	RP11-507K2.2	7.85	2.79e-14	1.06e-11	0.43	0.34	Coronary artery calcification;	chr14:88504581	chr14:88499334~88515502:+
THCA	cis	rs4784934	0.921	rs4784938	ENSG00000260186.4	RP11-481J2.2	7.85	2.8e-14	1.06e-11	0.49	0.34	QT interval;	chr16:58433949	chr16:58421326~58462470:+
THCA	cis	rs2839186	0.77	rs2839984	ENSG00000239415.1	AP001469.9	7.85	2.8e-14	1.06e-11	0.35	0.34	Testicular germ cell tumor;	chr21:46251776	chr21:46251549~46254133:-
THCA	cis	rs11096990	0.656	rs2066786	ENSG00000249685.1	RP11-360F5.3	7.85	2.81e-14	1.06e-11	0.41	0.34	Cognitive function;	chr4:39300409	chr4:39133913~39135608:+
THCA	cis	rs12681366	0.801	rs2919668	ENSG00000253704.1	RP11-267M23.4	7.85	2.81e-14	1.07e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94449193	chr8:94553722~94569745:+
THCA	cis	rs8114671	0.527	rs6060112	ENSG00000269202.1	RP4-614O4.12	-7.85	2.82e-14	1.07e-11	-0.29	-0.34	Height;	chr20:34901473	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs2064454	ENSG00000269202.1	RP4-614O4.12	-7.85	2.82e-14	1.07e-11	-0.29	-0.34	Height;	chr20:34908366	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs2273683	ENSG00000269202.1	RP4-614O4.12	-7.85	2.82e-14	1.07e-11	-0.29	-0.34	Height;	chr20:34921720	chr20:35201747~35203288:-
THCA	cis	rs12681366	0.881	rs12682038	ENSG00000253704.1	RP11-267M23.4	7.85	2.82e-14	1.07e-11	0.37	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94393252	chr8:94553722~94569745:+
THCA	cis	rs10411161	0.81	rs8102738	ENSG00000269483.1	AC006272.1	7.85	2.82e-14	1.07e-11	0.59	0.34	Breast cancer;	chr19:51884976	chr19:51839924~51843324:-
THCA	cis	rs9341808	0.556	rs1474791	ENSG00000272129.1	RP11-250B2.6	7.85	2.83e-14	1.07e-11	0.43	0.34	Sitting height ratio;	chr6:80323380	chr6:80355424~80356859:+
THCA	cis	rs10411161	0.81	rs77082285	ENSG00000269483.1	AC006272.1	7.85	2.83e-14	1.07e-11	0.59	0.34	Breast cancer;	chr19:51884330	chr19:51839924~51843324:-
THCA	cis	rs6908034	0.66	rs76322282	ENSG00000228412.5	RP4-625H18.2	7.85	2.83e-14	1.07e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801429	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs111533721	ENSG00000228412.5	RP4-625H18.2	7.85	2.83e-14	1.07e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803514	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.505	rs76709285	ENSG00000228412.5	RP4-625H18.2	7.85	2.83e-14	1.07e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804099	chr6:19802164~19804752:-
THCA	cis	rs7945705	0.818	rs4929916	ENSG00000254860.4	TMEM9B-AS1	-7.85	2.83e-14	1.07e-11	-0.37	-0.34	Hemoglobin concentration;	chr11:8803449	chr11:8964675~8977527:+
THCA	cis	rs12681366	0.881	rs3019150	ENSG00000253704.1	RP11-267M23.4	7.85	2.83e-14	1.07e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94420055	chr8:94553722~94569745:+
THCA	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	7.85	2.84e-14	1.07e-11	0.43	0.34	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
THCA	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	7.85	2.84e-14	1.07e-11	0.43	0.34	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
THCA	cis	rs6558530	0.73	rs7341635	ENSG00000253982.1	CTD-2336O2.1	7.85	2.84e-14	1.07e-11	0.29	0.34	Systolic blood pressure;	chr8:1773477	chr8:1761990~1764502:-
THCA	cis	rs934734	0.752	rs268139	ENSG00000204929.10	AC074391.1	-7.85	2.84e-14	1.08e-11	-0.42	-0.34	Rheumatoid arthritis;	chr2:65379857	chr2:65436711~66084639:+
THCA	cis	rs950169	0.519	rs7237	ENSG00000225151.9	GOLGA2P7	-7.85	2.84e-14	1.08e-11	-0.51	-0.34	Schizophrenia;	chr15:84643346	chr15:84199311~84230136:-
THCA	cis	rs71636778	0.509	rs12760759	ENSG00000260063.1	RP5-968P14.2	7.85	2.86e-14	1.08e-11	0.62	0.34	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26831853	chr1:26692132~26694131:-
THCA	cis	rs4713118	0.955	rs9468203	ENSG00000219392.1	RP1-265C24.5	-7.85	2.87e-14	1.09e-11	-0.44	-0.34	Parkinson's disease;	chr6:27720888	chr6:28115628~28116551:+
THCA	cis	rs6840258	0.547	rs2053771	ENSG00000251411.1	RP11-397E7.4	-7.85	2.87e-14	1.09e-11	-0.43	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86937396	chr4:86913266~86914817:-
THCA	cis	rs1949733	0.655	rs2631736	ENSG00000205959.3	RP11-689P11.2	7.85	2.87e-14	1.09e-11	0.28	0.34	Response to antineoplastic agents;	chr4:8476694	chr4:8482270~8512610:+
THCA	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-7.85	2.88e-14	1.09e-11	-0.37	-0.34	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-7.85	2.88e-14	1.09e-11	-0.37	-0.34	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-7.85	2.88e-14	1.09e-11	-0.37	-0.34	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
THCA	cis	rs2439831	0.867	rs2255042	ENSG00000249839.1	AC011330.5	7.85	2.89e-14	1.09e-11	0.51	0.34	Lung cancer in ever smokers;	chr15:43542120	chr15:43663654~43684339:-
THCA	cis	rs638893	0.617	rs4938561	ENSG00000278376.1	RP11-158I9.8	-7.85	2.89e-14	1.09e-11	-0.29	-0.34	Vitiligo;	chr11:118847776	chr11:118791254~118793137:+
THCA	cis	rs180730	0.95	rs2198032	ENSG00000251609.2	SETP12	7.85	2.89e-14	1.09e-11	0.54	0.34	Fasting plasma glucose;	chr4:120918993	chr4:120895494~120897083:-
THCA	cis	rs2739330	0.828	rs4822451	ENSG00000235689.1	AP000351.13	7.85	2.89e-14	1.09e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:24006305~24008258:-
THCA	cis	rs2739330	0.828	rs5760099	ENSG00000235689.1	AP000351.13	7.85	2.89e-14	1.09e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:24006305~24008258:-
THCA	cis	rs16846053	0.515	rs1567981	ENSG00000227403.1	AC009299.3	-7.85	2.89e-14	1.09e-11	-0.55	-0.34	Blood osmolality (transformed sodium);	chr2:161692589	chr2:161244739~161249050:+
THCA	cis	rs12681366	0.801	rs2919658	ENSG00000253704.1	RP11-267M23.4	7.85	2.9e-14	1.1e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94459550	chr8:94553722~94569745:+
THCA	cis	rs10129255	0.5	rs9324092	ENSG00000223648.3	IGHV3-64	-7.85	2.91e-14	1.1e-11	-0.2	-0.34	Kawasaki disease;	chr14:106683806	chr14:106643132~106658258:-
THCA	cis	rs853679	0.882	rs4713139	ENSG00000280107.1	AL022393.9	-7.85	2.91e-14	1.1e-11	-0.52	-0.34	Depression;	chr6:28124907	chr6:28170845~28172521:+
THCA	cis	rs9329221	0.502	rs11777364	ENSG00000261451.1	RP11-981G7.1	7.85	2.92e-14	1.1e-11	0.42	0.34	Neuroticism;	chr8:10431036	chr8:10433672~10438312:+
THCA	cis	rs66887589	0.934	rs41464847	ENSG00000245958.5	RP11-33B1.1	7.85	2.92e-14	1.1e-11	0.3	0.34	Diastolic blood pressure;	chr4:119611246	chr4:119454791~119552025:+
THCA	cis	rs4713118	0.955	rs9380010	ENSG00000219392.1	RP1-265C24.5	-7.85	2.93e-14	1.11e-11	-0.44	-0.34	Parkinson's disease;	chr6:27715793	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs9368528	ENSG00000219392.1	RP1-265C24.5	-7.85	2.93e-14	1.11e-11	-0.44	-0.34	Parkinson's disease;	chr6:27716019	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs9380011	ENSG00000219392.1	RP1-265C24.5	-7.85	2.93e-14	1.11e-11	-0.44	-0.34	Parkinson's disease;	chr6:27716145	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs9368529	ENSG00000219392.1	RP1-265C24.5	-7.85	2.93e-14	1.11e-11	-0.44	-0.34	Parkinson's disease;	chr6:27716852	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.955	rs9380012	ENSG00000219392.1	RP1-265C24.5	-7.85	2.93e-14	1.11e-11	-0.44	-0.34	Parkinson's disease;	chr6:27716875	chr6:28115628~28116551:+
THCA	cis	rs10800713	0.826	rs6427834	ENSG00000260088.1	RP11-92G12.3	-7.84	2.94e-14	1.11e-11	-0.52	-0.34	Tandem gait;	chr1:200561936	chr1:200669507~200694250:+
THCA	cis	rs75422866	0.867	rs73104163	ENSG00000257433.4	RP1-197B17.3	7.84	2.95e-14	1.12e-11	0.54	0.34	Pneumonia;	chr12:47706187	chr12:47706085~47742294:+
THCA	cis	rs75422866	1	rs12423045	ENSG00000257433.4	RP1-197B17.3	7.84	2.95e-14	1.12e-11	0.54	0.34	Pneumonia;	chr12:47706275	chr12:47706085~47742294:+
THCA	cis	rs7208859	0.673	rs2433	ENSG00000266490.1	CTD-2349P21.9	7.84	2.96e-14	1.12e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30792372~30792833:+
THCA	cis	rs7945705	0.776	rs2316865	ENSG00000254860.4	TMEM9B-AS1	-7.84	2.96e-14	1.12e-11	-0.37	-0.34	Hemoglobin concentration;	chr11:8793923	chr11:8964675~8977527:+
THCA	cis	rs7580658	0.724	rs4662711	ENSG00000236682.1	AC068282.3	-7.84	2.96e-14	1.12e-11	-0.44	-0.34	Protein C levels;	chr2:127233264	chr2:127389130~127400580:+
THCA	cis	rs8113308	0.748	rs7251478	ENSG00000269235.1	ZNF350-AS1	7.84	2.97e-14	1.12e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51979258	chr19:51949134~51981367:+
THCA	cis	rs11096990	0.613	rs4974995	ENSG00000249685.1	RP11-360F5.3	-7.84	2.97e-14	1.12e-11	-0.41	-0.34	Cognitive function;	chr4:39216503	chr4:39133913~39135608:+
THCA	cis	rs180730	1	rs1530799	ENSG00000251609.2	SETP12	7.84	2.98e-14	1.13e-11	0.54	0.34	Fasting plasma glucose;	chr4:120923267	chr4:120895494~120897083:-
THCA	cis	rs453301	0.653	rs7853	ENSG00000253893.2	FAM85B	-7.84	2.98e-14	1.13e-11	-0.42	-0.34	Joint mobility (Beighton score);	chr8:9033304	chr8:8167819~8226614:-
THCA	cis	rs198389	0.617	rs503040	ENSG00000242349.4	NPPA-AS1	-7.84	2.98e-14	1.13e-11	-0.32	-0.34	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11830638	chr1:11841017~11848079:+
THCA	cis	rs4814920	0.756	rs6075586	ENSG00000233895.1	RP1-122P22.2	-7.84	2.99e-14	1.13e-11	-0.37	-0.34	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19757708~19809675:+
THCA	cis	rs10971721	0.543	rs72731230	ENSG00000260947.1	RP11-384P7.7	7.84	2.99e-14	1.13e-11	0.77	0.34	Body mass index;	chr9:34133733	chr9:33697459~33700986:+
THCA	cis	rs42490	0.635	rs418634	ENSG00000251136.7	RP11-37B2.1	-7.84	3e-14	1.13e-11	-0.29	-0.34	Leprosy;	chr8:89847469	chr8:89609409~89757727:-
THCA	cis	rs2276314	0.857	rs62101393	ENSG00000278986.1	RP11-723J4.3	-7.84	3e-14	1.13e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36012205	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs62101394	ENSG00000278986.1	RP11-723J4.3	-7.84	3e-14	1.13e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36012336	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs4799409	ENSG00000278986.1	RP11-723J4.3	-7.84	3e-14	1.13e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36012639	chr18:35972151~35973916:+
THCA	cis	rs2836950	0.762	rs8134638	ENSG00000255568.3	BRWD1-AS2	-7.84	3e-14	1.13e-11	-0.28	-0.34	Menarche (age at onset);	chr21:39272244	chr21:39313935~39314962:+
THCA	cis	rs10208649	1	rs74627832	ENSG00000272156.1	RP11-477N3.1	7.84	3.01e-14	1.14e-11	0.7	0.34	Body mass index;	chr2:53933972	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.731	rs724387	ENSG00000272156.1	RP11-477N3.1	7.84	3.01e-14	1.14e-11	0.71	0.34	Body mass index;	chr2:53672707	chr2:54082554~54085066:+
THCA	cis	rs8114671	0.562	rs2223881	ENSG00000269202.1	RP4-614O4.12	-7.84	3.02e-14	1.14e-11	-0.29	-0.34	Height;	chr20:34918660	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs4911450	ENSG00000269202.1	RP4-614O4.12	-7.84	3.02e-14	1.14e-11	-0.29	-0.34	Height;	chr20:34924603	chr20:35201747~35203288:-
THCA	cis	rs116175783	0.557	rs10490567	ENSG00000227403.1	AC009299.3	7.84	3.02e-14	1.14e-11	0.59	0.34	Intelligence (multi-trait analysis);	chr2:161317267	chr2:161244739~161249050:+
THCA	cis	rs7247513	0.964	rs35235213	ENSG00000230310.1	CTD-2192J16.11	-7.84	3.02e-14	1.14e-11	-0.41	-0.34	Bipolar disorder;	chr19:12602342	chr19:12552597~12553644:+
THCA	cis	rs4072705	1	rs10760372	ENSG00000224020.1	MIR181A2HG	-7.84	3.03e-14	1.14e-11	-0.31	-0.34	Menarche (age at onset);	chr9:124706537	chr9:124658467~124698631:+
THCA	cis	rs116175783	0.557	rs62188123	ENSG00000227403.1	AC009299.3	7.84	3.03e-14	1.14e-11	0.62	0.34	Intelligence (multi-trait analysis);	chr2:161385335	chr2:161244739~161249050:+
THCA	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-7.84	3.03e-14	1.14e-11	-0.37	-0.34	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-7.84	3.03e-14	1.14e-11	-0.37	-0.34	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
THCA	cis	rs2522056	1	rs7730247	ENSG00000233006.5	AC034220.3	-7.84	3.03e-14	1.15e-11	-0.3	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132445596	chr5:132311285~132369916:-
THCA	cis	rs2442825	0.693	rs2728928	ENSG00000206573.7	THUMPD3-AS1	-7.84	3.04e-14	1.15e-11	-0.2	-0.34	Cerebrospinal fluid clusterin levels;	chr3:9388275	chr3:9349689~9398579:-
THCA	cis	rs4664293	0.51	rs12469374	ENSG00000226266.5	AC009961.3	7.84	3.04e-14	1.15e-11	0.4	0.34	Monocyte percentage of white cells;	chr2:159720393	chr2:159670708~159712435:-
THCA	cis	rs9918079	0.884	rs11728037	ENSG00000273133.1	RP11-799M12.2	-7.84	3.05e-14	1.15e-11	-0.5	-0.34	Obesity-related traits;	chr4:15593275	chr4:15563698~15564253:-
THCA	cis	rs11148252	0.875	rs4884452	ENSG00000278238.1	RP11-245D16.4	7.84	3.05e-14	1.15e-11	0.39	0.34	Lewy body disease;	chr13:52375649	chr13:52454775~52455331:-
THCA	cis	rs638893	0.617	rs7103314	ENSG00000278376.1	RP11-158I9.8	-7.84	3.05e-14	1.15e-11	-0.3	-0.34	Vitiligo;	chr11:118852828	chr11:118791254~118793137:+
THCA	cis	rs4819052	0.851	rs4819040	ENSG00000237664.1	LINC00316	-7.84	3.05e-14	1.15e-11	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45239847	chr21:45338590~45341990:-
THCA	cis	rs2288884	0.505	rs11666461	ENSG00000275055.1	CTC-471J1.11	-7.84	3.07e-14	1.16e-11	-0.37	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51934234	chr19:52049007~52049754:+
THCA	cis	rs7727544	0.571	rs12521097	ENSG00000224431.1	AC063976.7	7.84	3.07e-14	1.16e-11	0.3	0.34	Blood metabolite levels;	chr5:132239645	chr5:132199456~132203487:+
THCA	cis	rs950169	0.614	rs12903883	ENSG00000225151.9	GOLGA2P7	-7.84	3.07e-14	1.16e-11	-0.52	-0.34	Schizophrenia;	chr15:84011801	chr15:84199311~84230136:-
THCA	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-7.84	3.1e-14	1.17e-11	-0.39	-0.34	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
THCA	cis	rs853679	0.713	rs200991	ENSG00000219392.1	RP1-265C24.5	7.84	3.1e-14	1.17e-11	0.49	0.34	Depression;	chr6:27847716	chr6:28115628~28116551:+
THCA	cis	rs7621025	0.5	rs16844241	ENSG00000273486.1	RP11-731C17.2	-7.84	3.11e-14	1.17e-11	-0.35	-0.34	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136916329	chr3:136837338~136839021:-
THCA	cis	rs2297363	1	rs16888669	ENSG00000213073.4	RP11-288H12.3	-7.84	3.11e-14	1.17e-11	-0.36	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160082862	chr6:160093082~160096212:+
THCA	cis	rs2562456	0.516	rs56072098	ENSG00000268555.1	RP11-678G14.3	-7.84	3.12e-14	1.18e-11	-0.47	-0.34	Pain;	chr19:21469158	chr19:21570822~21587322:-
THCA	cis	rs11971779	0.715	rs6467856	ENSG00000273391.1	RP11-634H22.1	7.84	3.12e-14	1.18e-11	0.33	0.34	Diisocyanate-induced asthma;	chr7:139442553	chr7:139359032~139359566:-
THCA	cis	rs193541	0.632	rs4835896	ENSG00000263432.2	RN7SL689P	-7.84	3.13e-14	1.18e-11	-0.41	-0.34	Glucose homeostasis traits;	chr5:122785545	chr5:123022487~123022783:-
THCA	cis	rs7430456	0.81	rs6443489	ENSG00000228221.4	LINC00578	7.84	3.13e-14	1.18e-11	0.45	0.34	Breast cancer;	chr3:177737489	chr3:177441921~177752305:+
THCA	cis	rs2284219	1	rs2284219	ENSG00000196295.10	AC005154.6	-7.84	3.13e-14	1.18e-11	-0.25	-0.34	Type 2 diabetes;	chr7:30674820	chr7:30516309~30594809:-
THCA	cis	rs2284219	0.964	rs733453	ENSG00000196295.10	AC005154.6	-7.84	3.13e-14	1.18e-11	-0.25	-0.34	Type 2 diabetes;	chr7:30675157	chr7:30516309~30594809:-
THCA	cis	rs2284219	1	rs2267715	ENSG00000196295.10	AC005154.6	-7.84	3.13e-14	1.18e-11	-0.25	-0.34	Type 2 diabetes;	chr7:30676471	chr7:30516309~30594809:-
THCA	cis	rs2297363	1	rs2297363	ENSG00000213073.4	RP11-288H12.3	-7.84	3.13e-14	1.18e-11	-0.35	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160085430	chr6:160093082~160096212:+
THCA	cis	rs77204473	0.744	rs114221654	ENSG00000254851.1	RP11-109L13.1	7.84	3.13e-14	1.18e-11	0.88	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117109963	chr11:117135528~117138582:+
THCA	cis	rs7714584	1	rs10078968	ENSG00000197083.10	ZNF300P1	7.84	3.14e-14	1.18e-11	0.55	0.34	Crohn's disease;	chr5:150864711	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs1896709	ENSG00000197083.10	ZNF300P1	7.84	3.14e-14	1.18e-11	0.55	0.34	Crohn's disease;	chr5:150865470	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs6862814	ENSG00000197083.10	ZNF300P1	7.84	3.14e-14	1.18e-11	0.55	0.34	Crohn's disease;	chr5:150865697	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7709388	ENSG00000197083.10	ZNF300P1	7.84	3.14e-14	1.18e-11	0.55	0.34	Crohn's disease;	chr5:150866977	chr5:150930645~150946289:-
THCA	cis	rs7714584	0.793	rs7709721	ENSG00000197083.10	ZNF300P1	7.84	3.14e-14	1.18e-11	0.55	0.34	Crohn's disease;	chr5:150867296	chr5:150930645~150946289:-
THCA	cis	rs686320	1	rs686320	ENSG00000245532.5	NEAT1	7.84	3.14e-14	1.18e-11	0.31	0.34	Hip circumference adjusted for BMI;	chr11:65477067	chr11:65422774~65445540:+
THCA	cis	rs686320	1	rs667196	ENSG00000245532.5	NEAT1	7.84	3.14e-14	1.18e-11	0.31	0.34	Hip circumference adjusted for BMI;	chr11:65479621	chr11:65422774~65445540:+
THCA	cis	rs812925	0.519	rs2922089	ENSG00000271889.1	RP11-493E12.1	-7.84	3.15e-14	1.19e-11	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61397994	chr2:61151433~61162105:-
THCA	cis	rs812925	0.519	rs2694627	ENSG00000271889.1	RP11-493E12.1	-7.84	3.15e-14	1.19e-11	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61398371	chr2:61151433~61162105:-
THCA	cis	rs7714584	1	rs60134818	ENSG00000197083.10	ZNF300P1	7.84	3.15e-14	1.19e-11	0.55	0.34	Crohn's disease;	chr5:150881481	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7714415	ENSG00000197083.10	ZNF300P1	7.84	3.15e-14	1.19e-11	0.55	0.34	Crohn's disease;	chr5:150890730	chr5:150930645~150946289:-
THCA	cis	rs10800713	0.862	rs7533417	ENSG00000260088.1	RP11-92G12.3	-7.83	3.16e-14	1.19e-11	-0.52	-0.34	Tandem gait;	chr1:200558177	chr1:200669507~200694250:+
THCA	cis	rs1949733	0.675	rs2010758	ENSG00000205959.3	RP11-689P11.2	-7.83	3.16e-14	1.19e-11	-0.27	-0.34	Response to antineoplastic agents;	chr4:8473896	chr4:8482270~8512610:+
THCA	cis	rs12931792	0.712	rs4787495	ENSG00000183604.13	SMG1P5	-7.83	3.18e-14	1.2e-11	-0.34	-0.34	Tonsillectomy;	chr16:30154404	chr16:30267553~30335374:-
THCA	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	7.83	3.2e-14	1.21e-11	0.45	0.34	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
THCA	cis	rs7849270	0.959	rs10739742	ENSG00000268707.1	RP11-247A12.7	-7.83	3.21e-14	1.21e-11	-0.41	-0.34	Blood metabolite ratios;	chr9:129159389	chr9:129170434~129170940:+
THCA	cis	rs11096990	0.679	rs6531707	ENSG00000249685.1	RP11-360F5.3	-7.83	3.21e-14	1.21e-11	-0.41	-0.34	Cognitive function;	chr4:39296064	chr4:39133913~39135608:+
THCA	cis	rs1949733	0.628	rs2688231	ENSG00000205959.3	RP11-689P11.2	-7.83	3.22e-14	1.21e-11	-0.28	-0.34	Response to antineoplastic agents;	chr4:8489254	chr4:8482270~8512610:+
THCA	cis	rs950169	0.614	rs12911536	ENSG00000225151.9	GOLGA2P7	-7.83	3.22e-14	1.21e-11	-0.52	-0.34	Schizophrenia;	chr15:84004278	chr15:84199311~84230136:-
THCA	cis	rs2562456	0.917	rs6511253	ENSG00000268555.1	RP11-678G14.3	-7.83	3.23e-14	1.22e-11	-0.47	-0.34	Pain;	chr19:21495996	chr19:21570822~21587322:-
THCA	cis	rs4819052	0.851	rs35560973	ENSG00000237664.1	LINC00316	-7.83	3.24e-14	1.22e-11	-0.33	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45242658	chr21:45338590~45341990:-
THCA	cis	rs7615952	0.599	rs12485717	ENSG00000171084.14	FAM86JP	-7.83	3.24e-14	1.22e-11	-0.42	-0.34	Blood pressure (smoking interaction);	chr3:125988232	chr3:125916620~125930024:+
THCA	cis	rs9601248	0.838	rs6563121	ENSG00000227676.3	LINC01068	-7.83	3.25e-14	1.22e-11	-0.43	-0.34	Major depressive disorder;	chr13:79600865	chr13:79566727~79571436:+
THCA	cis	rs201673768	1	rs201673768	ENSG00000240399.1	RP1-228P16.1	7.83	3.25e-14	1.22e-11	0.32	0.34	Platelet count;	chr12:48305834	chr12:48054813~48055591:-
THCA	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	7.83	3.25e-14	1.22e-11	0.48	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
THCA	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	7.83	3.25e-14	1.22e-11	0.48	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
THCA	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	7.83	3.25e-14	1.22e-11	0.48	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
THCA	cis	rs6142102	0.602	rs10485503	ENSG00000275784.1	RP5-1125A11.6	-7.83	3.26e-14	1.23e-11	-0.33	-0.34	Skin pigmentation;	chr20:33970036	chr20:33989480~33991818:-
THCA	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-7.83	3.26e-14	1.23e-11	-0.43	-0.34	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
THCA	cis	rs910316	1	rs175436	ENSG00000279594.1	RP11-950C14.10	-7.83	3.27e-14	1.23e-11	-0.32	-0.34	Height;	chr14:75141980	chr14:75011269~75012851:-
THCA	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-7.83	3.29e-14	1.24e-11	-0.58	-0.34	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
THCA	cis	rs638893	0.617	rs2156750	ENSG00000278376.1	RP11-158I9.8	-7.83	3.29e-14	1.24e-11	-0.29	-0.34	Vitiligo;	chr11:118848545	chr11:118791254~118793137:+
THCA	cis	rs638893	0.561	rs2156749	ENSG00000278376.1	RP11-158I9.8	-7.83	3.29e-14	1.24e-11	-0.29	-0.34	Vitiligo;	chr11:118848696	chr11:118791254~118793137:+
THCA	cis	rs638893	0.617	rs7116715	ENSG00000278376.1	RP11-158I9.8	-7.83	3.29e-14	1.24e-11	-0.29	-0.34	Vitiligo;	chr11:118849033	chr11:118791254~118793137:+
THCA	cis	rs12681366	0.763	rs3019277	ENSG00000253704.1	RP11-267M23.4	7.83	3.29e-14	1.24e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94428195	chr8:94553722~94569745:+
THCA	cis	rs17772222	0.606	rs449338	ENSG00000258789.1	RP11-507K2.3	7.83	3.3e-14	1.24e-11	0.31	0.34	Coronary artery calcification;	chr14:88411690	chr14:88551597~88552493:+
THCA	cis	rs10411161	0.748	rs17835306	ENSG00000269483.1	AC006272.1	7.83	3.3e-14	1.24e-11	0.58	0.34	Breast cancer;	chr19:51882013	chr19:51839924~51843324:-
THCA	cis	rs7176527	0.5	rs895571	ENSG00000230373.7	GOLGA6L5P	7.83	3.3e-14	1.24e-11	0.37	0.34	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84573922	chr15:84507885~84516814:-
THCA	cis	rs150992	0.587	rs11960896	ENSG00000248489.1	CTD-2007H13.3	-7.83	3.3e-14	1.24e-11	-0.33	-0.34	Body mass index;	chr5:99014294	chr5:98929171~98995013:+
THCA	cis	rs75422866	0.764	rs73104177	ENSG00000257433.4	RP1-197B17.3	7.83	3.3e-14	1.24e-11	0.54	0.34	Pneumonia;	chr12:47713550	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.764	rs73104184	ENSG00000257433.4	RP1-197B17.3	7.83	3.3e-14	1.24e-11	0.54	0.34	Pneumonia;	chr12:47715623	chr12:47706085~47742294:+
THCA	cis	rs8114671	0.562	rs4911164	ENSG00000269202.1	RP4-614O4.12	-7.83	3.31e-14	1.25e-11	-0.29	-0.34	Height;	chr20:34891685	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs2378292	ENSG00000269202.1	RP4-614O4.12	-7.83	3.31e-14	1.25e-11	-0.29	-0.34	Height;	chr20:34897375	chr20:35201747~35203288:-
THCA	cis	rs7208859	0.573	rs73277960	ENSG00000266490.1	CTD-2349P21.9	7.83	3.31e-14	1.25e-11	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs73263788	ENSG00000266490.1	CTD-2349P21.9	7.83	3.31e-14	1.25e-11	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889472	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs12949860	ENSG00000266490.1	CTD-2349P21.9	7.83	3.31e-14	1.25e-11	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30896014	chr17:30792372~30792833:+
THCA	cis	rs2348418	0.864	rs2137073	ENSG00000247934.4	RP11-967K21.1	-7.83	3.31e-14	1.25e-11	-0.29	-0.34	Lung function (FEV1);Lung function (FVC);	chr12:28564151	chr12:28163298~28190738:-
THCA	cis	rs7208859	0.673	rs11655623	ENSG00000266490.1	CTD-2349P21.9	7.83	3.33e-14	1.25e-11	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30792372~30792833:+
THCA	cis	rs2522056	0.932	rs1012793	ENSG00000233006.5	AC034220.3	-7.83	3.34e-14	1.26e-11	-0.3	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132445653	chr5:132311285~132369916:-
THCA	cis	rs4266144	0.544	rs6805781	ENSG00000244515.1	KRT18P34	7.83	3.35e-14	1.26e-11	0.37	0.34	Coronary artery disease;	chr3:157112780	chr3:157162663~157163932:-
THCA	cis	rs7302981	0.809	rs66768395	ENSG00000272368.2	RP4-605O3.4	7.83	3.35e-14	1.26e-11	0.21	0.34	Systolic blood pressure;	chr12:50174482	chr12:50112197~50165618:+
THCA	cis	rs7302981	0.809	rs1044370	ENSG00000272368.2	RP4-605O3.4	7.83	3.35e-14	1.26e-11	0.21	0.34	Systolic blood pressure;	chr12:50176827	chr12:50112197~50165618:+
THCA	cis	rs1598856	1	rs93059	ENSG00000246560.2	RP11-10L12.4	7.83	3.36e-14	1.26e-11	0.41	0.34	Primary biliary cholangitis;	chr4:102547361	chr4:102828055~102844075:+
THCA	cis	rs2115630	0.846	rs8024538	ENSG00000225151.9	GOLGA2P7	7.83	3.37e-14	1.27e-11	0.44	0.34	P wave terminal force;	chr15:84825188	chr15:84199311~84230136:-
THCA	cis	rs9500256	0.655	rs12208465	ENSG00000215190.7	LINC00680	-7.83	3.37e-14	1.27e-11	-0.42	-0.34	Eosinophilic esophagitis (pediatric);	chr6:58004603	chr6:57946074~57961501:-
THCA	cis	rs9500256	0.655	rs12210275	ENSG00000215190.7	LINC00680	-7.83	3.37e-14	1.27e-11	-0.42	-0.34	Eosinophilic esophagitis (pediatric);	chr6:58005481	chr6:57946074~57961501:-
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000206090.4	AP000350.7	7.83	3.37e-14	1.27e-11	0.41	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23939998~23942798:+
THCA	cis	rs10266483	0.96	rs679883	ENSG00000227986.1	TRIM60P18	7.83	3.38e-14	1.27e-11	0.28	0.34	Response to statin therapy;	chr7:64289990	chr7:64355078~64356199:+
THCA	cis	rs193541	0.632	rs1460040	ENSG00000263432.2	RN7SL689P	7.82	3.39e-14	1.27e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122769537	chr5:123022487~123022783:-
THCA	cis	rs75422866	0.867	rs7303895	ENSG00000257433.4	RP1-197B17.3	7.82	3.39e-14	1.28e-11	0.49	0.34	Pneumonia;	chr12:47683290	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.867	rs7304743	ENSG00000257433.4	RP1-197B17.3	-7.82	3.39e-14	1.28e-11	-0.49	-0.34	Pneumonia;	chr12:47683658	chr12:47706085~47742294:+
THCA	cis	rs150992	0.587	rs1393210	ENSG00000248489.1	CTD-2007H13.3	-7.82	3.39e-14	1.28e-11	-0.33	-0.34	Body mass index;	chr5:99025892	chr5:98929171~98995013:+
THCA	cis	rs150992	0.587	rs11242567	ENSG00000248489.1	CTD-2007H13.3	-7.82	3.39e-14	1.28e-11	-0.33	-0.34	Body mass index;	chr5:99028686	chr5:98929171~98995013:+
THCA	cis	rs9640161	0.711	rs10259796	ENSG00000261305.1	RP4-584D14.7	7.82	3.39e-14	1.28e-11	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150353338	chr7:150341771~150342607:+
THCA	cis	rs42490	0.652	rs374957	ENSG00000251136.7	RP11-37B2.1	-7.82	3.4e-14	1.28e-11	-0.29	-0.34	Leprosy;	chr8:89825402	chr8:89609409~89757727:-
THCA	cis	rs8113308	0.81	rs11881650	ENSG00000269235.1	ZNF350-AS1	-7.82	3.4e-14	1.28e-11	-0.52	-0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946886	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.688	rs7259507	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942475	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs7259622	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942484	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs73582180	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943284	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs8105910	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51943815	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs11880193	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51945416	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs16983256	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946228	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs8100521	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946390	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs8100541	ENSG00000269235.1	ZNF350-AS1	7.82	3.4e-14	1.28e-11	0.52	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946442	chr19:51949134~51981367:+
THCA	cis	rs8114671	0.562	rs8117491	ENSG00000269202.1	RP4-614O4.12	-7.82	3.41e-14	1.28e-11	-0.29	-0.34	Height;	chr20:34922317	chr20:35201747~35203288:-
THCA	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	7.82	3.41e-14	1.28e-11	0.44	0.34	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
THCA	cis	rs12701220	0.553	rs34062359	ENSG00000229043.2	AC091729.9	-7.82	3.42e-14	1.28e-11	-0.52	-0.34	Bronchopulmonary dysplasia;	chr7:1099440	chr7:1160374~1165267:+
THCA	cis	rs4819052	1	rs733738	ENSG00000237664.1	LINC00316	7.82	3.42e-14	1.29e-11	0.37	0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45246481	chr21:45338590~45341990:-
THCA	cis	rs11148252	0.574	rs2038826	ENSG00000235660.1	LINC00345	-7.82	3.42e-14	1.29e-11	-0.43	-0.34	Lewy body disease;	chr13:52705878	chr13:52484161~52484680:-
THCA	cis	rs7615952	0.599	rs66532274	ENSG00000171084.14	FAM86JP	7.82	3.42e-14	1.29e-11	0.41	0.34	Blood pressure (smoking interaction);	chr3:126013002	chr3:125916620~125930024:+
THCA	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-7.82	3.43e-14	1.29e-11	-0.37	-0.34	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
THCA	cis	rs77204473	0.744	rs74955808	ENSG00000254851.1	RP11-109L13.1	7.82	3.43e-14	1.29e-11	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117121969	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs12420361	ENSG00000254851.1	RP11-109L13.1	7.82	3.43e-14	1.29e-11	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117123072	chr11:117135528~117138582:+
THCA	cis	rs8072100	0.967	rs4794058	ENSG00000228782.6	CTD-2026D20.3	-7.82	3.45e-14	1.3e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47519732	chr17:47450568~47492492:-
THCA	cis	rs416603	0.967	rs7191538	ENSG00000262703.1	RP11-485G7.6	-7.82	3.46e-14	1.3e-11	-0.37	-0.34	Type 1 diabetes;	chr16:11269532	chr16:11348143~11349321:-
THCA	cis	rs4072705	0.967	rs4240486	ENSG00000224020.1	MIR181A2HG	-7.82	3.46e-14	1.3e-11	-0.3	-0.34	Menarche (age at onset);	chr9:124578831	chr9:124658467~124698631:+
THCA	cis	rs6908034	0.66	rs111509549	ENSG00000228412.5	RP4-625H18.2	7.82	3.46e-14	1.3e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19798139	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.6	rs79733895	ENSG00000228412.5	RP4-625H18.2	7.82	3.46e-14	1.3e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19799310	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.66	rs111231540	ENSG00000228412.5	RP4-625H18.2	7.82	3.46e-14	1.3e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19801995	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.556	rs77486465	ENSG00000228412.5	RP4-625H18.2	7.82	3.46e-14	1.3e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19803631	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs112824001	ENSG00000228412.5	RP4-625H18.2	7.82	3.46e-14	1.3e-11	0.79	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804460	chr6:19802164~19804752:-
THCA	cis	rs7247513	0.79	rs8112964	ENSG00000230310.1	CTD-2192J16.11	-7.82	3.46e-14	1.3e-11	-0.41	-0.34	Bipolar disorder;	chr19:12641359	chr19:12552597~12553644:+
THCA	cis	rs11672691	0.871	rs2191139	ENSG00000267107.5	PCAT19	7.82	3.46e-14	1.3e-11	0.35	0.34	Prostate cancer;	chr19:41495302	chr19:41454169~41500649:-
THCA	cis	rs7208859	0.673	rs216440	ENSG00000266490.1	CTD-2349P21.9	7.82	3.48e-14	1.31e-11	0.43	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30601291	chr17:30792372~30792833:+
THCA	cis	rs116175783	0.557	rs72877940	ENSG00000227403.1	AC009299.3	7.82	3.48e-14	1.31e-11	0.62	0.34	Intelligence (multi-trait analysis);	chr2:161403965	chr2:161244739~161249050:+
THCA	cis	rs7945705	0.791	rs12421789	ENSG00000254860.4	TMEM9B-AS1	7.82	3.48e-14	1.31e-11	0.36	0.34	Hemoglobin concentration;	chr11:8792409	chr11:8964675~8977527:+
THCA	cis	rs7945705	0.791	rs10769958	ENSG00000254860.4	TMEM9B-AS1	7.82	3.48e-14	1.31e-11	0.36	0.34	Hemoglobin concentration;	chr11:8793568	chr11:8964675~8977527:+
THCA	cis	rs4308124	0.708	rs6727313	ENSG00000227992.1	AC108463.2	-7.82	3.49e-14	1.31e-11	-0.48	-0.34	Vitiligo;	chr2:111213963	chr2:111203964~111206215:-
THCA	cis	rs4308124	0.708	rs10178095	ENSG00000227992.1	AC108463.2	-7.82	3.49e-14	1.31e-11	-0.48	-0.34	Vitiligo;	chr2:111214939	chr2:111203964~111206215:-
THCA	cis	rs2439831	0.85	rs694985	ENSG00000249839.1	AC011330.5	-7.82	3.49e-14	1.31e-11	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43521189	chr15:43663654~43684339:-
THCA	cis	rs17772222	1	rs55722539	ENSG00000258983.2	RP11-507K2.2	7.82	3.5e-14	1.31e-11	0.43	0.34	Coronary artery calcification;	chr14:88411691	chr14:88499334~88515502:+
THCA	cis	rs11696845	0.666	rs6073533	ENSG00000276223.1	RP4-781B1.5	7.82	3.51e-14	1.32e-11	0.41	0.34	Obesity-related traits;	chr20:44732441	chr20:44746642~44747201:+
THCA	cis	rs10411161	0.81	rs17778661	ENSG00000269483.1	AC006272.1	7.82	3.51e-14	1.32e-11	0.59	0.34	Breast cancer;	chr19:51880035	chr19:51839924~51843324:-
THCA	cis	rs2522056	1	rs62385693	ENSG00000233006.5	AC034220.3	-7.82	3.51e-14	1.32e-11	-0.3	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132437982	chr5:132311285~132369916:-
THCA	cis	rs9649213	0.593	rs6465665	ENSG00000272950.1	RP11-307C18.1	7.82	3.51e-14	1.32e-11	0.41	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98304838	chr7:98322853~98323430:+
THCA	cis	rs1150668	0.799	rs2142730	ENSG00000219392.1	RP1-265C24.5	-7.82	3.52e-14	1.32e-11	-0.37	-0.34	Pubertal anthropometrics;	chr6:28298372	chr6:28115628~28116551:+
THCA	cis	rs6545883	0.501	rs935860	ENSG00000271889.1	RP11-493E12.1	7.82	3.52e-14	1.32e-11	0.32	0.34	Tuberculosis;	chr2:61179426	chr2:61151433~61162105:-
THCA	cis	rs7015630	0.563	rs28461337	ENSG00000251136.7	RP11-37B2.1	-7.82	3.52e-14	1.32e-11	-0.36	-0.34	Inflammatory bowel disease;Crohn's disease;	chr8:89812907	chr8:89609409~89757727:-
THCA	cis	rs2739330	0.753	rs4822452	ENSG00000206090.4	AP000350.7	7.82	3.52e-14	1.32e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23939998~23942798:+
THCA	cis	rs193541	0.632	rs168913	ENSG00000263432.2	RN7SL689P	7.82	3.53e-14	1.33e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122890098	chr5:123022487~123022783:-
THCA	cis	rs947583	0.913	rs2027516	ENSG00000231028.7	LINC00271	-7.82	3.54e-14	1.33e-11	-0.27	-0.34	Phosphorus levels;	chr6:135810750	chr6:135497801~135716055:+
THCA	cis	rs6723226	0.721	rs3769600	ENSG00000276334.1	AL133243.1	-7.82	3.54e-14	1.33e-11	-0.38	-0.34	Intelligence (multi-trait analysis);	chr2:32391811	chr2:32521927~32523547:+
THCA	cis	rs12681366	0.801	rs2011246	ENSG00000253704.1	RP11-267M23.4	7.82	3.54e-14	1.33e-11	0.35	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94450846	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.801	rs2043988	ENSG00000253704.1	RP11-267M23.4	7.82	3.54e-14	1.33e-11	0.35	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94457327	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.801	rs2930956	ENSG00000253704.1	RP11-267M23.4	7.82	3.54e-14	1.33e-11	0.35	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94460840	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.801	rs55963151	ENSG00000253704.1	RP11-267M23.4	7.82	3.54e-14	1.33e-11	0.35	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94466198	chr8:94553722~94569745:+
THCA	cis	rs77204473	0.744	rs74882651	ENSG00000254851.1	RP11-109L13.1	7.82	3.54e-14	1.33e-11	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117114475	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs17120344	ENSG00000254851.1	RP11-109L13.1	-7.82	3.54e-14	1.33e-11	-0.89	-0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117125629	chr11:117135528~117138582:+
THCA	cis	rs7714584	1	rs4958852	ENSG00000197083.10	ZNF300P1	7.82	3.55e-14	1.33e-11	0.62	0.34	Crohn's disease;	chr5:150951069	chr5:150930645~150946289:-
THCA	cis	rs4713118	0.869	rs9366700	ENSG00000219392.1	RP1-265C24.5	-7.82	3.55e-14	1.33e-11	-0.43	-0.34	Parkinson's disease;	chr6:27729172	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs6456802	ENSG00000219392.1	RP1-265C24.5	-7.82	3.55e-14	1.33e-11	-0.43	-0.34	Parkinson's disease;	chr6:27730576	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9393851	ENSG00000219392.1	RP1-265C24.5	-7.82	3.55e-14	1.33e-11	-0.43	-0.34	Parkinson's disease;	chr6:27731802	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9461400	ENSG00000219392.1	RP1-265C24.5	-7.82	3.55e-14	1.33e-11	-0.43	-0.34	Parkinson's disease;	chr6:27732780	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9295742	ENSG00000219392.1	RP1-265C24.5	-7.82	3.55e-14	1.33e-11	-0.43	-0.34	Parkinson's disease;	chr6:27735053	chr6:28115628~28116551:+
THCA	cis	rs4713118	0.869	rs9461401	ENSG00000219392.1	RP1-265C24.5	-7.82	3.55e-14	1.33e-11	-0.43	-0.34	Parkinson's disease;	chr6:27735512	chr6:28115628~28116551:+
THCA	cis	rs2276314	0.857	rs62101402	ENSG00000278986.1	RP11-723J4.3	-7.82	3.55e-14	1.33e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36049472	chr18:35972151~35973916:+
THCA	cis	rs7665090	0.528	rs4235405	ENSG00000246560.2	RP11-10L12.4	7.82	3.56e-14	1.34e-11	0.41	0.34	Primary biliary cholangitis;	chr4:102595654	chr4:102828055~102844075:+
THCA	cis	rs7119038	0.609	rs11216999	ENSG00000255239.1	AP002954.6	-7.82	3.56e-14	1.34e-11	-0.48	-0.34	Sjögren's syndrome;	chr11:118734232	chr11:118688039~118690600:-
THCA	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-7.82	3.57e-14	1.34e-11	-0.44	-0.34	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
THCA	cis	rs524281	0.729	rs12790034	ENSG00000255320.1	RP11-755F10.1	-7.82	3.58e-14	1.34e-11	-0.5	-0.34	Electroencephalogram traits;	chr11:66018268	chr11:66244840~66246239:-
THCA	cis	rs950169	0.545	rs4842841	ENSG00000259728.4	LINC00933	7.82	3.58e-14	1.34e-11	0.49	0.34	Schizophrenia;	chr15:83972373	chr15:84570649~84580175:+
THCA	cis	rs934734	0.967	rs702875	ENSG00000204929.10	AC074391.1	7.82	3.59e-14	1.35e-11	0.42	0.34	Rheumatoid arthritis;	chr2:65387063	chr2:65436711~66084639:+
THCA	cis	rs686320	1	rs679643	ENSG00000245532.5	NEAT1	7.82	3.59e-14	1.35e-11	0.3	0.34	Hip circumference adjusted for BMI;	chr11:65483119	chr11:65422774~65445540:+
THCA	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-7.82	3.6e-14	1.35e-11	-0.39	-0.34	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
THCA	cis	rs1850744	0.826	rs13101880	ENSG00000250942.1	ENPP7P11	7.82	3.6e-14	1.35e-11	0.48	0.34	Economic and political preferences;	chr4:9706203	chr4:9677308~9677934:+
THCA	cis	rs7302981	0.967	rs35549836	ENSG00000272368.2	RP4-605O3.4	7.82	3.61e-14	1.35e-11	0.2	0.34	Systolic blood pressure;	chr12:50159419	chr12:50112197~50165618:+
THCA	cis	rs2276314	1	rs9304154	ENSG00000278986.1	RP11-723J4.3	-7.82	3.61e-14	1.35e-11	-0.39	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35982264	chr18:35972151~35973916:+
THCA	cis	rs42490	0.59	rs441547	ENSG00000251136.7	RP11-37B2.1	-7.82	3.61e-14	1.35e-11	-0.29	-0.34	Leprosy;	chr8:89807954	chr8:89609409~89757727:-
THCA	cis	rs42490	0.614	rs441548	ENSG00000251136.7	RP11-37B2.1	-7.82	3.61e-14	1.35e-11	-0.29	-0.34	Leprosy;	chr8:89807955	chr8:89609409~89757727:-
THCA	cis	rs4664293	0.967	rs10202187	ENSG00000226266.5	AC009961.3	-7.82	3.61e-14	1.36e-11	-0.4	-0.34	Monocyte percentage of white cells;	chr2:159571135	chr2:159670708~159712435:-
THCA	cis	rs7267979	0.903	rs6050482	ENSG00000274414.1	RP5-965G21.4	-7.82	3.62e-14	1.36e-11	-0.4	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.706	rs6037069	ENSG00000274414.1	RP5-965G21.4	-7.82	3.62e-14	1.36e-11	-0.4	-0.34	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25239007~25245229:-
THCA	cis	rs4072705	0.934	rs4838194	ENSG00000224020.1	MIR181A2HG	-7.82	3.62e-14	1.36e-11	-0.3	-0.34	Menarche (age at onset);	chr9:124580536	chr9:124658467~124698631:+
THCA	cis	rs1009647	0.592	rs1045004	ENSG00000258413.1	RP11-665C16.6	-7.82	3.62e-14	1.36e-11	-0.56	-0.34	Testicular germ cell tumor;	chr14:55353073	chr14:55262767~55272075:-
THCA	cis	rs2337406	0.866	rs2301535	ENSG00000274576.2	IGHV2-70	-7.81	3.63e-14	1.36e-11	-0.29	-0.34	Alzheimer's disease (late onset);	chr14:106790663	chr14:106770577~106771020:-
THCA	cis	rs7712401	0.58	rs4288111	ENSG00000263432.2	RN7SL689P	-7.81	3.63e-14	1.36e-11	-0.38	-0.34	Mean platelet volume;	chr5:123052487	chr5:123022487~123022783:-
THCA	cis	rs9326248	0.954	rs8521	ENSG00000280143.1	AP000892.6	7.81	3.63e-14	1.36e-11	0.43	0.34	Blood protein levels;	chr11:117196983	chr11:117204967~117210292:+
THCA	cis	rs4819052	0.724	rs1304487	ENSG00000237664.1	LINC00316	7.81	3.64e-14	1.37e-11	0.33	0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45237368	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2236443	ENSG00000237664.1	LINC00316	-7.81	3.65e-14	1.37e-11	-0.34	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45258259	chr21:45338590~45341990:-
THCA	cis	rs4819052	0.851	rs2330011	ENSG00000237664.1	LINC00316	-7.81	3.66e-14	1.37e-11	-0.33	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238583	chr21:45338590~45341990:-
THCA	cis	rs13068223	1	rs9868587	ENSG00000243926.1	TIPARP-AS1	7.81	3.67e-14	1.38e-11	0.32	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743800	chr3:156671862~156674378:-
THCA	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	7.81	3.68e-14	1.38e-11	0.42	0.34	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
THCA	cis	rs8072100	0.935	rs8070759	ENSG00000228782.6	CTD-2026D20.3	-7.81	3.68e-14	1.38e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47561394	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.764	rs2644349	ENSG00000228782.6	CTD-2026D20.3	-7.81	3.68e-14	1.38e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47564377	chr17:47450568~47492492:-
THCA	cis	rs12681366	0.801	rs72674819	ENSG00000253704.1	RP11-267M23.4	7.81	3.69e-14	1.38e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94468072	chr8:94553722~94569745:+
THCA	cis	rs4713118	0.662	rs175954	ENSG00000226314.6	ZNF192P1	-7.81	3.7e-14	1.38e-11	-0.43	-0.34	Parkinson's disease;	chr6:28043807	chr6:28161781~28169594:+
THCA	cis	rs10208649	0.808	rs6730494	ENSG00000272156.1	RP11-477N3.1	7.81	3.7e-14	1.39e-11	0.63	0.34	Body mass index;	chr2:53992049	chr2:54082554~54085066:+
THCA	cis	rs2276314	1	rs9304153	ENSG00000278986.1	RP11-723J4.3	-7.81	3.71e-14	1.39e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35982187	chr18:35972151~35973916:+
THCA	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	7.81	3.71e-14	1.39e-11	0.38	0.34	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
THCA	cis	rs11096990	0.634	rs1057807	ENSG00000249685.1	RP11-360F5.3	-7.81	3.72e-14	1.39e-11	-0.41	-0.34	Cognitive function;	chr4:39287853	chr4:39133913~39135608:+
THCA	cis	rs1707322	1	rs34444543	ENSG00000234329.1	RP11-767N6.2	7.81	3.72e-14	1.39e-11	0.32	0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45651039~45651826:-
THCA	cis	rs2015599	0.525	rs7959145	ENSG00000257176.2	RP11-996F15.2	7.81	3.73e-14	1.4e-11	0.35	0.34	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29280418~29317848:-
THCA	cis	rs2015599	0.525	rs7961943	ENSG00000257176.2	RP11-996F15.2	7.81	3.73e-14	1.4e-11	0.35	0.34	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29280418~29317848:-
THCA	cis	rs4789693	0.938	rs12952655	ENSG00000265458.1	RP13-20L14.6	-7.81	3.74e-14	1.4e-11	-0.34	-0.34	Glucocorticoid-induced osteonecrosis;	chr17:82463263	chr17:82454273~82458521:-
THCA	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-7.81	3.74e-14	1.4e-11	-0.37	-0.34	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-7.81	3.74e-14	1.4e-11	-0.37	-0.34	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
THCA	cis	rs2562456	0.72	rs6511250	ENSG00000268555.1	RP11-678G14.3	-7.81	3.75e-14	1.4e-11	-0.47	-0.34	Pain;	chr19:21473244	chr19:21570822~21587322:-
THCA	cis	rs116175783	0.557	rs1146025	ENSG00000227403.1	AC009299.3	7.81	3.75e-14	1.41e-11	0.59	0.34	Intelligence (multi-trait analysis);	chr2:161283301	chr2:161244739~161249050:+
THCA	cis	rs116175783	0.557	rs62197071	ENSG00000227403.1	AC009299.3	7.81	3.75e-14	1.41e-11	0.59	0.34	Intelligence (multi-trait analysis);	chr2:161292703	chr2:161244739~161249050:+
THCA	cis	rs116175783	0.557	rs16845757	ENSG00000227403.1	AC009299.3	7.81	3.75e-14	1.41e-11	0.59	0.34	Intelligence (multi-trait analysis);	chr2:161299749	chr2:161244739~161249050:+
THCA	cis	rs17684571	0.872	rs13210876	ENSG00000231441.1	RP11-472M19.2	-7.81	3.76e-14	1.41e-11	-0.43	-0.34	Schizophrenia;	chr6:56739425	chr6:56844002~56864078:+
THCA	cis	rs6142102	0.651	rs6119463	ENSG00000276073.1	RP5-1125A11.7	7.81	3.76e-14	1.41e-11	0.32	0.34	Skin pigmentation;	chr20:34149412	chr20:33985617~33988989:-
THCA	cis	rs2439831	0.867	rs12443102	ENSG00000275601.1	AC011330.13	-7.81	3.77e-14	1.41e-11	-0.53	-0.34	Lung cancer in ever smokers;	chr15:43639905	chr15:43642389~43643023:-
THCA	cis	rs13068223	0.84	rs11709829	ENSG00000243926.1	TIPARP-AS1	7.81	3.77e-14	1.41e-11	0.33	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156716300	chr3:156671862~156674378:-
THCA	cis	rs7942368	0.941	rs12290350	ENSG00000254632.1	RP11-21L23.4	-7.81	3.77e-14	1.41e-11	-0.5	-0.34	Endometriosis;	chr11:76769211	chr11:76759916~76768223:-
THCA	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	7.81	3.78e-14	1.41e-11	0.38	0.34	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
THCA	cis	rs7247513	0.93	rs28368916	ENSG00000230310.1	CTD-2192J16.11	-7.81	3.78e-14	1.41e-11	-0.41	-0.34	Bipolar disorder;	chr19:12590763	chr19:12552597~12553644:+
THCA	cis	rs6723226	0.75	rs762019	ENSG00000276334.1	AL133243.1	7.81	3.78e-14	1.42e-11	0.38	0.34	Intelligence (multi-trait analysis);	chr2:32463533	chr2:32521927~32523547:+
THCA	cis	rs453301	0.686	rs17702602	ENSG00000253893.2	FAM85B	7.81	3.79e-14	1.42e-11	0.44	0.34	Joint mobility (Beighton score);	chr8:9051086	chr8:8167819~8226614:-
THCA	cis	rs11603691	1	rs11228973	ENSG00000254662.1	RP11-872D17.4	-7.81	3.79e-14	1.42e-11	-0.64	-0.34	Low high density lipoprotein cholesterol levels;	chr11:57262770	chr11:57325603~57327958:+
THCA	cis	rs10869777	0.519	rs2501939	ENSG00000234618.1	RPSAP9	7.81	3.8e-14	1.42e-11	0.36	0.34	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr9:76371314	chr9:76398699~76399586:+
THCA	cis	rs728616	0.867	rs61860039	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80180150	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860041	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860042	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860043	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186642	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860044	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186782	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs12415870	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs12414521	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189778	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs55666905	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80193883	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs56008106	ENSG00000225484.5	NUTM2B-AS1	-7.81	3.81e-14	1.42e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80194020	chr10:79663088~79826594:-
THCA	cis	rs11673344	0.504	rs35579954	ENSG00000226686.6	LINC01535	7.81	3.81e-14	1.43e-11	0.37	0.34	Obesity-related traits;	chr19:37139308	chr19:37251912~37265535:+
THCA	cis	rs17826219	0.561	rs562840	ENSG00000266490.1	CTD-2349P21.9	7.81	3.82e-14	1.43e-11	0.43	0.34	Body mass index;	chr17:30622372	chr17:30792372~30792833:+
THCA	cis	rs984222	0.617	rs1891222	ENSG00000231365.4	RP11-418J17.1	-7.81	3.83e-14	1.43e-11	-0.34	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119208379	chr1:119140396~119275973:+
THCA	cis	rs2297363	1	rs1130861	ENSG00000213073.4	RP11-288H12.3	-7.81	3.84e-14	1.44e-11	-0.36	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160090322	chr6:160093082~160096212:+
THCA	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	7.81	3.85e-14	1.44e-11	0.23	0.34	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
THCA	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-7.81	3.86e-14	1.45e-11	-0.52	-0.34	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
THCA	cis	rs11096990	0.613	rs6840578	ENSG00000249685.1	RP11-360F5.3	7.81	3.88e-14	1.45e-11	0.41	0.34	Cognitive function;	chr4:39206996	chr4:39133913~39135608:+
THCA	cis	rs9649213	0.593	rs1468341	ENSG00000272950.1	RP11-307C18.1	7.8	3.9e-14	1.46e-11	0.42	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98358384	chr7:98322853~98323430:+
THCA	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	7.8	3.9e-14	1.46e-11	0.2	0.34	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
THCA	cis	rs950169	0.579	rs12913054	ENSG00000259728.4	LINC00933	7.8	3.91e-14	1.46e-11	0.49	0.34	Schizophrenia;	chr15:83995704	chr15:84570649~84580175:+
THCA	cis	rs910316	0.904	rs7156089	ENSG00000279594.1	RP11-950C14.10	-7.8	3.92e-14	1.47e-11	-0.32	-0.34	Height;	chr14:75178824	chr14:75011269~75012851:-
THCA	cis	rs6908034	0.607	rs78402429	ENSG00000228412.5	RP4-625H18.2	7.8	3.93e-14	1.47e-11	0.81	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19811459	chr6:19802164~19804752:-
THCA	cis	rs62103177	0.713	rs3744886	ENSG00000261126.6	RP11-795F19.1	7.8	3.93e-14	1.47e-11	0.41	0.34	Opioid sensitivity;	chr18:79899561	chr18:80046900~80095482:+
THCA	cis	rs11651753	0.561	rs4794261	ENSG00000264920.1	RP11-6N17.4	-7.8	3.93e-14	1.47e-11	-0.31	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47904980	chr17:47891255~47895812:-
THCA	cis	rs11651753	0.561	rs7211859	ENSG00000264920.1	RP11-6N17.4	-7.8	3.93e-14	1.47e-11	-0.31	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47908916	chr17:47891255~47895812:-
THCA	cis	rs9549328	0.577	rs4907477	ENSG00000267868.1	RP11-120K24.3	7.8	3.94e-14	1.47e-11	0.35	0.34	Systolic blood pressure;	chr13:112964170	chr13:112964835~112966131:-
THCA	cis	rs9549328	0.577	rs4907478	ENSG00000267868.1	RP11-120K24.3	7.8	3.94e-14	1.47e-11	0.35	0.34	Systolic blood pressure;	chr13:112964173	chr13:112964835~112966131:-
THCA	cis	rs17772222	1	rs17772222	ENSG00000258983.2	RP11-507K2.2	-7.8	3.94e-14	1.47e-11	-0.43	-0.34	Coronary artery calcification;	chr14:88360138	chr14:88499334~88515502:+
THCA	cis	rs7208859	0.673	rs11654331	ENSG00000266490.1	CTD-2349P21.9	7.8	3.94e-14	1.47e-11	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30792372~30792833:+
THCA	cis	rs6597981	0.675	rs4963120	ENSG00000255284.1	AP006621.5	-7.8	3.94e-14	1.47e-11	-0.23	-0.34	Breast cancer;	chr11:825777	chr11:777578~784297:+
THCA	cis	rs2243480	0.522	rs12698511	ENSG00000226824.5	RP4-756H11.3	-7.8	3.97e-14	1.49e-11	-0.79	-0.34	Diabetic kidney disease;	chr7:66009932	chr7:66654538~66669855:+
THCA	cis	rs9902453	0.845	rs7501472	ENSG00000264007.1	RP11-68I3.10	7.8	3.98e-14	1.49e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29683610	chr17:29621617~29622254:-
THCA	cis	rs7208859	0.673	rs999797	ENSG00000266490.1	CTD-2349P21.9	7.8	3.98e-14	1.49e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30792372~30792833:+
THCA	cis	rs1075265	0.563	rs2542588	ENSG00000233266.1	HMGB1P31	-7.8	3.99e-14	1.49e-11	-0.42	-0.34	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54051334~54051760:+
THCA	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	7.8	4e-14	1.5e-11	0.22	0.34	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
THCA	cis	rs728616	0.867	rs4633405	ENSG00000225484.5	NUTM2B-AS1	-7.8	4e-14	1.5e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80167690	chr10:79663088~79826594:-
THCA	cis	rs1858037	0.867	rs6727013	ENSG00000237979.1	AC007389.1	7.8	4.01e-14	1.5e-11	0.42	0.34	Rheumatoid arthritis;	chr2:65331241	chr2:65500993~65502138:-
THCA	cis	rs7191700	0.511	rs8043625	ENSG00000262703.1	RP11-485G7.6	-7.8	4.01e-14	1.5e-11	-0.38	-0.34	Multiple sclerosis;	chr16:11268038	chr16:11348143~11349321:-
THCA	cis	rs7208859	0.673	rs9911989	ENSG00000266490.1	CTD-2349P21.9	-7.8	4.01e-14	1.5e-11	-0.49	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs12103759	ENSG00000266490.1	CTD-2349P21.9	7.8	4.01e-14	1.5e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs59029591	ENSG00000266490.1	CTD-2349P21.9	7.8	4.01e-14	1.5e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73265633	ENSG00000266490.1	CTD-2349P21.9	7.8	4.01e-14	1.5e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9913782	ENSG00000266490.1	CTD-2349P21.9	7.8	4.01e-14	1.5e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30792372~30792833:+
THCA	cis	rs7714584	0.793	rs11949375	ENSG00000197083.10	ZNF300P1	7.8	4.01e-14	1.5e-11	0.55	0.34	Crohn's disease;	chr5:150823418	chr5:150930645~150946289:-
THCA	cis	rs17772222	1	rs11159856	ENSG00000258983.2	RP11-507K2.2	7.8	4.03e-14	1.5e-11	0.43	0.34	Coronary artery calcification;	chr14:88417585	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.917	rs17124652	ENSG00000258983.2	RP11-507K2.2	7.8	4.03e-14	1.5e-11	0.43	0.34	Coronary artery calcification;	chr14:88424384	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.876	rs4375590	ENSG00000258983.2	RP11-507K2.2	7.8	4.03e-14	1.5e-11	0.43	0.34	Coronary artery calcification;	chr14:88451334	chr14:88499334~88515502:+
THCA	cis	rs2015599	0.525	rs10743656	ENSG00000257176.2	RP11-996F15.2	7.8	4.03e-14	1.51e-11	0.35	0.34	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29280418~29317848:-
THCA	cis	rs7208859	0.673	rs3816780	ENSG00000266490.1	CTD-2349P21.9	7.8	4.03e-14	1.51e-11	0.48	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834340	chr17:30792372~30792833:+
THCA	cis	rs7714584	1	rs11748158	ENSG00000197083.10	ZNF300P1	7.8	4.04e-14	1.51e-11	0.55	0.34	Crohn's disease;	chr5:150846783	chr5:150930645~150946289:-
THCA	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	7.8	4.05e-14	1.51e-11	0.38	0.34	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
THCA	cis	rs11096990	0.634	rs10010352	ENSG00000249685.1	RP11-360F5.3	7.8	4.05e-14	1.51e-11	0.41	0.34	Cognitive function;	chr4:39240657	chr4:39133913~39135608:+
THCA	cis	rs11651753	0.561	rs1108833	ENSG00000264920.1	RP11-6N17.4	-7.8	4.05e-14	1.51e-11	-0.31	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47905431	chr17:47891255~47895812:-
THCA	cis	rs6840258	0.547	rs4693795	ENSG00000251411.1	RP11-397E7.4	-7.8	4.05e-14	1.51e-11	-0.42	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86946904	chr4:86913266~86914817:-
THCA	cis	rs16928809	0.52	rs74050440	ENSG00000183562.3	CTC-343N3.1	7.8	4.06e-14	1.52e-11	0.66	0.34	Bilirubin levels;	chr11:2941213	chr11:2989863~2991344:+
THCA	cis	rs12681366	0.843	rs3019147	ENSG00000253704.1	RP11-267M23.4	7.8	4.06e-14	1.52e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94412804	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.881	rs3019149	ENSG00000253704.1	RP11-267M23.4	7.8	4.06e-14	1.52e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94418351	chr8:94553722~94569745:+
THCA	cis	rs934734	0.532	rs12470883	ENSG00000237979.1	AC007389.1	-7.8	4.06e-14	1.52e-11	-0.38	-0.34	Rheumatoid arthritis;	chr2:65424717	chr2:65500993~65502138:-
THCA	cis	rs6565180	1	rs8049108	ENSG00000183604.13	SMG1P5	-7.8	4.08e-14	1.52e-11	-0.33	-0.34	Tonsillectomy;	chr16:30365165	chr16:30267553~30335374:-
THCA	cis	rs8114671	1	rs8114671	ENSG00000269202.1	RP4-614O4.12	7.8	4.08e-14	1.52e-11	0.28	0.34	Height;	chr20:35201339	chr20:35201747~35203288:-
THCA	cis	rs193541	0.593	rs154517	ENSG00000263432.2	RN7SL689P	7.8	4.09e-14	1.53e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122854130	chr5:123022487~123022783:-
THCA	cis	rs193541	0.632	rs152038	ENSG00000263432.2	RN7SL689P	7.8	4.09e-14	1.53e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122860151	chr5:123022487~123022783:-
THCA	cis	rs4273100	0.79	rs60606605	ENSG00000228157.4	AC007952.5	7.8	4.1e-14	1.53e-11	0.52	0.34	Schizophrenia;	chr17:19373831	chr17:19092974~19096837:+
THCA	cis	rs6452524	0.836	rs10514249	ENSG00000249664.1	CTD-2227C6.2	-7.8	4.11e-14	1.53e-11	-0.42	-0.34	Hypertension (SNP x SNP interaction);	chr5:83209037	chr5:83012285~83013109:-
THCA	cis	rs17695224	0.545	rs11666614	ENSG00000269483.1	AC006272.1	7.8	4.11e-14	1.53e-11	0.37	0.34	HDL cholesterol;HDL cholesterol levels;	chr19:51842833	chr19:51839924~51843324:-
THCA	cis	rs13068223	0.584	rs345986	ENSG00000243926.1	TIPARP-AS1	-7.8	4.11e-14	1.53e-11	-0.33	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156677540	chr3:156671862~156674378:-
THCA	cis	rs8100891	0.922	rs7255223	ENSG00000267213.4	AC007773.2	7.8	4.11e-14	1.54e-11	0.32	0.34	Neuroticism;	chr19:32333404	chr19:32390050~32405560:-
THCA	cis	rs11096990	0.613	rs7690414	ENSG00000249685.1	RP11-360F5.3	7.8	4.11e-14	1.54e-11	0.41	0.34	Cognitive function;	chr4:39210669	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.593	rs7685619	ENSG00000249685.1	RP11-360F5.3	7.8	4.11e-14	1.54e-11	0.41	0.34	Cognitive function;	chr4:39211779	chr4:39133913~39135608:+
THCA	cis	rs12681366	0.801	rs1372048	ENSG00000253704.1	RP11-267M23.4	7.8	4.12e-14	1.54e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94455013	chr8:94553722~94569745:+
THCA	cis	rs8072100	0.902	rs12051716	ENSG00000228782.6	CTD-2026D20.3	-7.8	4.12e-14	1.54e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505029	chr17:47450568~47492492:-
THCA	cis	rs2297363	1	rs3777404	ENSG00000213073.4	RP11-288H12.3	-7.8	4.12e-14	1.54e-11	-0.35	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160077017	chr6:160093082~160096212:+
THCA	cis	rs2749592	0.531	rs1208559	ENSG00000263064.2	RP11-291L22.7	-7.8	4.14e-14	1.54e-11	-0.38	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr10:37932442	chr10:38448689~38448949:+
THCA	cis	rs13068223	0.716	rs344067	ENSG00000243926.1	TIPARP-AS1	-7.8	4.14e-14	1.54e-11	-0.33	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723825	chr3:156671862~156674378:-
THCA	cis	rs934734	0.789	rs2661798	ENSG00000204929.10	AC074391.1	-7.8	4.14e-14	1.55e-11	-0.43	-0.34	Rheumatoid arthritis;	chr2:65408554	chr2:65436711~66084639:+
THCA	cis	rs7208859	0.673	rs79541516	ENSG00000266490.1	CTD-2349P21.9	7.8	4.15e-14	1.55e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30792372~30792833:+
THCA	cis	rs11096990	0.656	rs3733284	ENSG00000249685.1	RP11-360F5.3	-7.8	4.15e-14	1.55e-11	-0.4	-0.34	Cognitive function;	chr4:39299714	chr4:39133913~39135608:+
THCA	cis	rs4072705	1	rs4072705	ENSG00000224020.1	MIR181A2HG	-7.8	4.17e-14	1.55e-11	-0.3	-0.34	Menarche (age at onset);	chr9:124611184	chr9:124658467~124698631:+
THCA	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	7.8	4.17e-14	1.56e-11	0.47	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
THCA	cis	rs9532669	0.889	rs7333447	ENSG00000176268.5	CYCSP34	7.8	4.17e-14	1.56e-11	0.38	0.34	Cervical cancer;	chr13:40917586	chr13:40863599~40863902:-
THCA	cis	rs4308124	0.708	rs10179596	ENSG00000227992.1	AC108463.2	-7.79	4.18e-14	1.56e-11	-0.48	-0.34	Vitiligo;	chr2:111212803	chr2:111203964~111206215:-
THCA	cis	rs4273100	0.85	rs11204306	ENSG00000228157.4	AC007952.5	7.79	4.18e-14	1.56e-11	0.52	0.34	Schizophrenia;	chr17:19364058	chr17:19092974~19096837:+
THCA	cis	rs4273100	0.79	rs2048230	ENSG00000228157.4	AC007952.5	7.79	4.18e-14	1.56e-11	0.52	0.34	Schizophrenia;	chr17:19372886	chr17:19092974~19096837:+
THCA	cis	rs853679	0.517	rs4713135	ENSG00000272009.1	RP1-313I6.12	-7.79	4.19e-14	1.56e-11	-0.4	-0.34	Depression;	chr6:28071808	chr6:28078792~28081130:-
THCA	cis	rs2880765	0.506	rs719138	ENSG00000259295.5	CSPG4P12	7.79	4.19e-14	1.56e-11	0.51	0.34	Coronary artery disease;	chr15:85511831	chr15:85191438~85213905:+
THCA	cis	rs2522056	1	rs2106854	ENSG00000233006.5	AC034220.3	-7.79	4.2e-14	1.57e-11	-0.3	-0.34	Fibrinogen;Lymphocyte counts;	chr5:132433482	chr5:132311285~132369916:-
THCA	cis	rs7674212	0.556	rs34475639	ENSG00000251288.2	RP11-10L12.2	-7.79	4.2e-14	1.57e-11	-0.46	-0.34	Type 2 diabetes;	chr4:103033694	chr4:102751401~102752641:+
THCA	cis	rs1667284	0.935	rs1791161	ENSG00000266521.1	RP11-650P15.1	7.79	4.21e-14	1.57e-11	0.42	0.34	Problematic alcohol use in trauma-exposed individuals;	chr18:31624247	chr18:31496645~31497195:-
THCA	cis	rs2466254	0.657	rs2203834	ENSG00000251468.2	RP11-369K16.1	-7.79	4.21e-14	1.57e-11	-0.54	-0.34	Pneumonia;	chr8:12967384	chr8:12958387~12962200:+
THCA	cis	rs9326248	1	rs585849	ENSG00000280143.1	AP000892.6	7.79	4.22e-14	1.57e-11	0.43	0.34	Blood protein levels;	chr11:117198345	chr11:117204967~117210292:+
THCA	cis	rs7714584	1	rs9324660	ENSG00000197083.10	ZNF300P1	7.79	4.22e-14	1.57e-11	0.54	0.34	Crohn's disease;	chr5:150877492	chr5:150930645~150946289:-
THCA	cis	rs1850744	0.702	rs13136217	ENSG00000250942.1	ENPP7P11	7.79	4.22e-14	1.57e-11	0.44	0.34	Economic and political preferences;	chr4:9720668	chr4:9677308~9677934:+
THCA	cis	rs1850744	0.609	rs2037315	ENSG00000250942.1	ENPP7P11	7.79	4.22e-14	1.57e-11	0.44	0.34	Economic and political preferences;	chr4:9720784	chr4:9677308~9677934:+
THCA	cis	rs831571	1	rs166230	ENSG00000280620.1	SCAANT1	-7.79	4.23e-14	1.58e-11	-0.52	-0.34	Type 2 diabetes;	chr3:64067531	chr3:63911518~63911772:-
THCA	cis	rs77204473	1	rs17120177	ENSG00000254851.1	RP11-109L13.1	7.79	4.23e-14	1.58e-11	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116956653	chr11:117135528~117138582:+
THCA	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-7.79	4.23e-14	1.58e-11	-0.33	-0.34	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
THCA	cis	rs812925	0.537	rs10208769	ENSG00000271889.1	RP11-493E12.1	-7.79	4.24e-14	1.58e-11	-0.32	-0.34	Immature fraction of reticulocytes;	chr2:61378479	chr2:61151433~61162105:-
THCA	cis	rs62103177	0.789	rs7242289	ENSG00000261126.6	RP11-795F19.1	7.79	4.25e-14	1.58e-11	0.4	0.34	Opioid sensitivity;	chr18:79843291	chr18:80046900~80095482:+
THCA	cis	rs1150668	0.768	rs1150716	ENSG00000219392.1	RP1-265C24.5	-7.79	4.25e-14	1.59e-11	-0.37	-0.34	Pubertal anthropometrics;	chr6:28294921	chr6:28115628~28116551:+
THCA	cis	rs860295	0.702	rs1325908	ENSG00000225855.5	RUSC1-AS1	7.79	4.25e-14	1.59e-11	0.23	0.34	Body mass index;	chr1:155443513	chr1:155316863~155324176:-
THCA	cis	rs7727544	0.584	rs7714191	ENSG00000237714.1	P4HA2-AS1	7.79	4.26e-14	1.59e-11	0.45	0.34	Blood metabolite levels;	chr5:132005848	chr5:132184876~132192808:+
THCA	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-7.79	4.27e-14	1.59e-11	-0.52	-0.34	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
THCA	cis	rs7208859	0.673	rs216411	ENSG00000266490.1	CTD-2349P21.9	-7.79	4.27e-14	1.59e-11	-0.42	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30576475	chr17:30792372~30792833:+
THCA	cis	rs17695224	0.545	rs7252508	ENSG00000269483.1	AC006272.1	7.79	4.27e-14	1.59e-11	0.36	0.34	HDL cholesterol;HDL cholesterol levels;	chr19:51831530	chr19:51839924~51843324:-
THCA	cis	rs28510890	0.75	rs12592167	ENSG00000260337.3	RP11-386M24.6	7.79	4.28e-14	1.59e-11	0.46	0.34	Lung cancer in ever smokers;	chr15:92565835	chr15:92592574~92596462:-
THCA	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-7.79	4.3e-14	1.6e-11	-0.55	-0.34	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
THCA	cis	rs7727544	0.606	rs17622208	ENSG00000233006.5	AC034220.3	7.79	4.3e-14	1.6e-11	0.26	0.34	Blood metabolite levels;	chr5:132381358	chr5:132311285~132369916:-
THCA	cis	rs9549328	0.577	rs4907571	ENSG00000267868.1	RP11-120K24.3	7.79	4.31e-14	1.6e-11	0.35	0.34	Systolic blood pressure;	chr13:112964182	chr13:112964835~112966131:-
THCA	cis	rs6452524	0.772	rs13156510	ENSG00000249664.1	CTD-2227C6.2	-7.79	4.31e-14	1.6e-11	-0.42	-0.34	Hypertension (SNP x SNP interaction);	chr5:83208668	chr5:83012285~83013109:-
THCA	cis	rs61041384	0.661	rs74240770	ENSG00000256092.2	RP13-942N8.1	-7.79	4.32e-14	1.61e-11	-0.49	-0.34	Schizophrenia;	chr12:123207195	chr12:123363868~123366113:+
THCA	cis	rs2297363	1	rs3777399	ENSG00000213073.4	RP11-288H12.3	-7.79	4.32e-14	1.61e-11	-0.35	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160092761	chr6:160093082~160096212:+
THCA	cis	rs910316	0.967	rs2268619	ENSG00000279594.1	RP11-950C14.10	-7.79	4.33e-14	1.61e-11	-0.32	-0.34	Height;	chr14:75173651	chr14:75011269~75012851:-
THCA	cis	rs7430456	0.87	rs9864169	ENSG00000228221.4	LINC00578	7.79	4.33e-14	1.61e-11	0.45	0.34	Breast cancer;	chr3:177746841	chr3:177441921~177752305:+
THCA	cis	rs7430456	0.901	rs12696448	ENSG00000228221.4	LINC00578	7.79	4.33e-14	1.61e-11	0.45	0.34	Breast cancer;	chr3:177746860	chr3:177441921~177752305:+
THCA	cis	rs7247513	0.856	rs6511828	ENSG00000230310.1	CTD-2192J16.11	-7.79	4.34e-14	1.62e-11	-0.41	-0.34	Bipolar disorder;	chr19:12634985	chr19:12552597~12553644:+
THCA	cis	rs4664293	0.769	rs10171236	ENSG00000226266.5	AC009961.3	-7.79	4.35e-14	1.62e-11	-0.41	-0.34	Monocyte percentage of white cells;	chr2:159729752	chr2:159670708~159712435:-
THCA	cis	rs4819052	1	rs28628220	ENSG00000237664.1	LINC00316	-7.79	4.35e-14	1.62e-11	-0.37	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243826	chr21:45338590~45341990:-
THCA	cis	rs4819052	1	rs2838830	ENSG00000237664.1	LINC00316	-7.79	4.35e-14	1.62e-11	-0.37	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244312	chr21:45338590~45341990:-
THCA	cis	rs35160687	0.722	rs6728029	ENSG00000273080.1	RP11-301O19.1	-7.79	4.36e-14	1.62e-11	-0.36	-0.34	Night sleep phenotypes;	chr2:86328258	chr2:86195590~86196049:+
THCA	cis	rs17684571	0.872	rs3002007	ENSG00000231441.1	RP11-472M19.2	7.79	4.38e-14	1.63e-11	0.42	0.34	Schizophrenia;	chr6:56753962	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs2967963	ENSG00000231441.1	RP11-472M19.2	7.79	4.38e-14	1.63e-11	0.42	0.34	Schizophrenia;	chr6:56756819	chr6:56844002~56864078:+
THCA	cis	rs6908034	0.607	rs77791009	ENSG00000228412.5	RP4-625H18.2	7.79	4.43e-14	1.65e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812371	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs75060331	ENSG00000228412.5	RP4-625H18.2	7.79	4.43e-14	1.65e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812725	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs77753186	ENSG00000228412.5	RP4-625H18.2	7.79	4.43e-14	1.65e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812749	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs79162793	ENSG00000228412.5	RP4-625H18.2	7.79	4.43e-14	1.65e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812834	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs76245225	ENSG00000228412.5	RP4-625H18.2	7.79	4.43e-14	1.65e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19812957	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs75110577	ENSG00000228412.5	RP4-625H18.2	7.79	4.43e-14	1.65e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814292	chr6:19802164~19804752:-
THCA	cis	rs910316	0.935	rs175076	ENSG00000279594.1	RP11-950C14.10	-7.79	4.43e-14	1.65e-11	-0.31	-0.34	Height;	chr14:75038783	chr14:75011269~75012851:-
THCA	cis	rs9500256	0.903	rs726783	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-7.79	4.43e-14	1.65e-11	-0.35	-0.34	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57855891~57856468:-
THCA	cis	rs7208859	0.623	rs11657662	ENSG00000264538.5	SUZ12P1	7.79	4.46e-14	1.66e-11	0.34	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30709299~30790908:+
THCA	cis	rs7945705	0.875	rs10769955	ENSG00000254860.4	TMEM9B-AS1	-7.79	4.47e-14	1.66e-11	-0.37	-0.34	Hemoglobin concentration;	chr11:8763100	chr11:8964675~8977527:+
THCA	cis	rs8114671	0.935	rs6142313	ENSG00000269202.1	RP4-614O4.12	7.78	4.51e-14	1.68e-11	0.28	0.34	Height;	chr20:35192624	chr20:35201747~35203288:-
THCA	cis	rs2412819	0.571	rs56226333	ENSG00000249839.1	AC011330.5	-7.78	4.51e-14	1.68e-11	-0.51	-0.34	Lung cancer;	chr15:43632410	chr15:43663654~43684339:-
THCA	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-7.78	4.52e-14	1.68e-11	-0.37	-0.34	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
THCA	cis	rs9640161	0.789	rs10282458	ENSG00000261305.1	RP4-584D14.7	7.78	4.54e-14	1.69e-11	0.4	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150348213	chr7:150341771~150342607:+
THCA	cis	rs42490	0.589	rs39772	ENSG00000251136.7	RP11-37B2.1	-7.78	4.54e-14	1.69e-11	-0.29	-0.34	Leprosy;	chr8:89831636	chr8:89609409~89757727:-
THCA	cis	rs116175783	0.557	rs16845829	ENSG00000227403.1	AC009299.3	7.78	4.57e-14	1.7e-11	0.62	0.34	Intelligence (multi-trait analysis);	chr2:161399960	chr2:161244739~161249050:+
THCA	cis	rs10936632	0.565	rs6794467	ENSG00000242578.1	RP11-469J4.3	-7.78	4.59e-14	1.7e-11	-0.37	-0.34	Prostate cancer;	chr3:170430203	chr3:170410512~170418615:+
THCA	cis	rs11096990	0.656	rs6531710	ENSG00000249685.1	RP11-360F5.3	-7.78	4.59e-14	1.71e-11	-0.4	-0.34	Cognitive function;	chr4:39300658	chr4:39133913~39135608:+
THCA	cis	rs741668	0.507	rs9567620	ENSG00000235903.6	CPB2-AS1	7.78	4.59e-14	1.71e-11	0.44	0.34	Cerebrospinal fluid clusterin levels;	chr13:46088455	chr13:46052806~46113332:+
THCA	cis	rs9500256	0.683	rs10458024	ENSG00000215190.7	LINC00680	-7.78	4.59e-14	1.71e-11	-0.42	-0.34	Eosinophilic esophagitis (pediatric);	chr6:57997811	chr6:57946074~57961501:-
THCA	cis	rs9487094	0.813	rs3799835	ENSG00000260273.1	RP11-425D10.10	7.78	4.59e-14	1.71e-11	0.44	0.34	Height;	chr6:109372084	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.813	rs34131679	ENSG00000260273.1	RP11-425D10.10	7.78	4.59e-14	1.71e-11	0.44	0.34	Height;	chr6:109375848	chr6:109382795~109383666:+
THCA	cis	rs193541	0.632	rs154503	ENSG00000263432.2	RN7SL689P	7.78	4.61e-14	1.71e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122868804	chr5:123022487~123022783:-
THCA	cis	rs12681366	0.843	rs3019156	ENSG00000253704.1	RP11-267M23.4	7.78	4.61e-14	1.71e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94409552	chr8:94553722~94569745:+
THCA	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-7.78	4.62e-14	1.72e-11	-0.52	-0.34	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
THCA	cis	rs11096990	0.634	rs17754	ENSG00000249685.1	RP11-360F5.3	7.78	4.62e-14	1.72e-11	0.4	0.34	Cognitive function;	chr4:39287688	chr4:39133913~39135608:+
THCA	cis	rs193541	0.564	rs407230	ENSG00000263432.2	RN7SL689P	-7.78	4.63e-14	1.72e-11	-0.4	-0.34	Glucose homeostasis traits;	chr5:123010032	chr5:123022487~123022783:-
THCA	cis	rs10256972	0.605	rs10251094	ENSG00000229043.2	AC091729.9	-7.78	4.63e-14	1.72e-11	-0.37	-0.34	Endometriosis;Longevity;	chr7:977447	chr7:1160374~1165267:+
THCA	cis	rs11148252	0.508	rs6561671	ENSG00000278238.1	RP11-245D16.4	-7.78	4.63e-14	1.72e-11	-0.36	-0.34	Lewy body disease;	chr13:52608179	chr13:52454775~52455331:-
THCA	cis	rs7811142	1	rs6972167	ENSG00000242294.5	STAG3L5P	7.78	4.65e-14	1.73e-11	0.23	0.34	Platelet count;	chr7:100482390	chr7:100336079~100351900:+
THCA	cis	rs9326248	0.817	rs1242127	ENSG00000280143.1	AP000892.6	-7.78	4.66e-14	1.73e-11	-0.44	-0.34	Blood protein levels;	chr11:117205848	chr11:117204967~117210292:+
THCA	cis	rs189798	1	rs189798	ENSG00000254340.1	RP11-10A14.3	-7.78	4.66e-14	1.73e-11	-0.37	-0.34	Myopia (pathological);	chr8:9133067	chr8:9141424~9145435:+
THCA	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	7.78	4.67e-14	1.74e-11	0.4	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
THCA	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	7.78	4.68e-14	1.74e-11	0.47	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
THCA	cis	rs77204473	0.744	rs117901629	ENSG00000254851.1	RP11-109L13.1	7.78	4.7e-14	1.75e-11	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117008963	chr11:117135528~117138582:+
THCA	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	7.78	4.71e-14	1.75e-11	0.44	0.34	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
THCA	cis	rs17684571	0.751	rs11970648	ENSG00000231441.1	RP11-472M19.2	7.78	4.71e-14	1.75e-11	0.43	0.34	Schizophrenia;	chr6:56762797	chr6:56844002~56864078:+
THCA	cis	rs6908034	0.607	rs12525152	ENSG00000228412.5	RP4-625H18.2	7.78	4.71e-14	1.75e-11	0.78	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19809193	chr6:19802164~19804752:-
THCA	cis	rs2248020	0.501	rs2263368	ENSG00000279684.1	RP11-755E23.2	-7.78	4.72e-14	1.75e-11	-0.47	-0.34	Insulin levels in response to oral glucose tolerance test (30 minutes);	chr11:93531514	chr11:93286629~93288903:-
THCA	cis	rs1501911	0.713	rs10479344	ENSG00000248489.1	CTD-2007H13.3	-7.78	4.72e-14	1.75e-11	-0.33	-0.34	Lung function (FEV1/FVC);	chr5:99012676	chr5:98929171~98995013:+
THCA	cis	rs7714584	1	rs11167526	ENSG00000197083.10	ZNF300P1	7.78	4.72e-14	1.75e-11	0.61	0.34	Crohn's disease;	chr5:150952919	chr5:150930645~150946289:-
THCA	cis	rs7727544	0.606	rs2631360	ENSG00000233006.5	AC034220.3	7.78	4.72e-14	1.75e-11	0.26	0.34	Blood metabolite levels;	chr5:132371737	chr5:132311285~132369916:-
THCA	cis	rs4819052	1	rs2297285	ENSG00000237664.1	LINC00316	7.78	4.73e-14	1.76e-11	0.4	0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45285706	chr21:45338590~45341990:-
THCA	cis	rs7247513	0.856	rs2162863	ENSG00000230310.1	CTD-2192J16.11	-7.78	4.74e-14	1.76e-11	-0.42	-0.34	Bipolar disorder;	chr19:12588963	chr19:12552597~12553644:+
THCA	cis	rs7247513	1	rs8104385	ENSG00000230310.1	CTD-2192J16.11	-7.78	4.74e-14	1.76e-11	-0.42	-0.34	Bipolar disorder;	chr19:12589470	chr19:12552597~12553644:+
THCA	cis	rs10411161	0.748	rs58120918	ENSG00000269483.1	AC006272.1	7.78	4.74e-14	1.76e-11	0.56	0.34	Breast cancer;	chr19:51865093	chr19:51839924~51843324:-
THCA	cis	rs8114671	0.562	rs6120746	ENSG00000269202.1	RP4-614O4.12	-7.78	4.74e-14	1.76e-11	-0.29	-0.34	Height;	chr20:34860693	chr20:35201747~35203288:-
THCA	cis	rs17684571	0.872	rs3002004	ENSG00000231441.1	RP11-472M19.2	7.78	4.75e-14	1.76e-11	0.42	0.34	Schizophrenia;	chr6:56743331	chr6:56844002~56864078:+
THCA	cis	rs10208649	0.908	rs11884857	ENSG00000272156.1	RP11-477N3.1	7.78	4.76e-14	1.77e-11	0.62	0.34	Body mass index;	chr2:54033185	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.901	rs6748686	ENSG00000272156.1	RP11-477N3.1	7.78	4.76e-14	1.77e-11	0.62	0.34	Body mass index;	chr2:54037481	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.808	rs77805752	ENSG00000272156.1	RP11-477N3.1	7.78	4.76e-14	1.77e-11	0.62	0.34	Body mass index;	chr2:54037506	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs6719990	ENSG00000272156.1	RP11-477N3.1	7.78	4.76e-14	1.77e-11	0.62	0.34	Body mass index;	chr2:54037515	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs72906714	ENSG00000272156.1	RP11-477N3.1	7.78	4.76e-14	1.77e-11	0.62	0.34	Body mass index;	chr2:54038423	chr2:54082554~54085066:+
THCA	cis	rs12908161	0.959	rs11637728	ENSG00000225151.9	GOLGA2P7	-7.78	4.77e-14	1.77e-11	-0.5	-0.34	Schizophrenia;	chr15:84660161	chr15:84199311~84230136:-
THCA	cis	rs7714584	1	rs11167521	ENSG00000197083.10	ZNF300P1	7.78	4.78e-14	1.77e-11	0.55	0.34	Crohn's disease;	chr5:150892223	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10057988	ENSG00000197083.10	ZNF300P1	7.78	4.78e-14	1.77e-11	0.55	0.34	Crohn's disease;	chr5:150892500	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10052606	ENSG00000197083.10	ZNF300P1	7.78	4.78e-14	1.77e-11	0.55	0.34	Crohn's disease;	chr5:150892655	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs57001853	ENSG00000197083.10	ZNF300P1	7.78	4.78e-14	1.77e-11	0.55	0.34	Crohn's disease;	chr5:150892890	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs2217266	ENSG00000197083.10	ZNF300P1	7.78	4.78e-14	1.77e-11	0.55	0.34	Crohn's disease;	chr5:150893059	chr5:150930645~150946289:-
THCA	cis	rs7646881	0.812	rs61387735	ENSG00000240207.5	RP11-379F4.4	-7.78	4.78e-14	1.77e-11	-0.48	-0.34	Tetralogy of Fallot;	chr3:158738372	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.767	rs73015669	ENSG00000240207.5	RP11-379F4.4	-7.78	4.78e-14	1.77e-11	-0.48	-0.34	Tetralogy of Fallot;	chr3:158738529	chr3:158732263~158784070:+
THCA	cis	rs1009647	0.645	rs17742719	ENSG00000258413.1	RP11-665C16.6	7.78	4.79e-14	1.78e-11	0.56	0.34	Testicular germ cell tumor;	chr14:55388878	chr14:55262767~55272075:-
THCA	cis	rs8113308	0.81	rs8104281	ENSG00000269235.1	ZNF350-AS1	7.78	4.79e-14	1.78e-11	0.51	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939766	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs8104121	ENSG00000269235.1	ZNF350-AS1	7.78	4.79e-14	1.78e-11	0.51	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939810	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs8104323	ENSG00000269235.1	ZNF350-AS1	7.78	4.79e-14	1.78e-11	0.51	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51939992	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs8108525	ENSG00000269235.1	ZNF350-AS1	7.78	4.79e-14	1.78e-11	0.51	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51940883	chr19:51949134~51981367:+
THCA	cis	rs8113308	0.81	rs7258701	ENSG00000269235.1	ZNF350-AS1	7.78	4.79e-14	1.78e-11	0.51	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51941816	chr19:51949134~51981367:+
THCA	cis	rs8070463	0.515	rs11655943	ENSG00000228782.6	CTD-2026D20.3	7.78	4.79e-14	1.78e-11	0.31	0.34	Multiple sclerosis;Ankylosing spondylitis;	chr17:47308274	chr17:47450568~47492492:-
THCA	cis	rs12188164	0.515	rs2672744	ENSG00000221990.4	EXOC3-AS1	-7.78	4.81e-14	1.78e-11	-0.28	-0.34	Cystic fibrosis severity;	chr5:410932	chr5:441498~443160:-
THCA	cis	rs7015263	0.606	rs10102749	ENSG00000254231.1	CTD-2284J15.1	-7.77	4.82e-14	1.79e-11	-0.34	-0.34	Intelligence (multi-trait analysis);	chr8:86395104	chr8:86333274~86343314:-
THCA	cis	rs10208649	0.908	rs60776154	ENSG00000272156.1	RP11-477N3.1	7.77	4.82e-14	1.79e-11	0.62	0.34	Body mass index;	chr2:54026676	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.831	rs72906704	ENSG00000272156.1	RP11-477N3.1	7.77	4.82e-14	1.79e-11	0.62	0.34	Body mass index;	chr2:54028088	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs7556936	ENSG00000272156.1	RP11-477N3.1	7.77	4.82e-14	1.79e-11	0.62	0.34	Body mass index;	chr2:54028594	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.908	rs7583508	ENSG00000272156.1	RP11-477N3.1	7.77	4.82e-14	1.79e-11	0.62	0.34	Body mass index;	chr2:54028648	chr2:54082554~54085066:+
THCA	cis	rs1061377	0.748	rs12506723	ENSG00000249685.1	RP11-360F5.3	7.77	4.83e-14	1.79e-11	0.41	0.34	Uric acid levels;	chr4:39103152	chr4:39133913~39135608:+
THCA	cis	rs748404	0.588	rs2255410	ENSG00000166763.7	STRCP1	7.77	4.83e-14	1.79e-11	0.36	0.34	Lung cancer;	chr15:43538899	chr15:43699488~43718184:-
THCA	cis	rs1707322	0.896	rs946528	ENSG00000234329.1	RP11-767N6.2	-7.77	4.83e-14	1.79e-11	-0.32	-0.34	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45651039~45651826:-
THCA	cis	rs728616	0.867	rs61860034	ENSG00000225484.5	NUTM2B-AS1	-7.77	4.85e-14	1.8e-11	-0.67	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80172092	chr10:79663088~79826594:-
THCA	cis	rs227932	0.764	rs78660981	ENSG00000234286.1	AC006026.13	-7.77	4.85e-14	1.8e-11	-0.62	-0.34	Schizophrenia;	chr7:23719296	chr7:23680195~23680786:-
THCA	cis	rs9640161	0.789	rs28439010	ENSG00000261305.1	RP4-584D14.7	7.77	4.91e-14	1.82e-11	0.4	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150349187	chr7:150341771~150342607:+
THCA	cis	rs13068223	1	rs13068223	ENSG00000243926.1	TIPARP-AS1	7.77	4.93e-14	1.83e-11	0.33	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156753166	chr3:156671862~156674378:-
THCA	cis	rs7714584	1	rs1428554	ENSG00000197083.10	ZNF300P1	7.77	4.95e-14	1.84e-11	0.54	0.34	Crohn's disease;	chr5:150878054	chr5:150930645~150946289:-
THCA	cis	rs9487094	0.813	rs13195517	ENSG00000260273.1	RP11-425D10.10	7.77	4.96e-14	1.84e-11	0.44	0.34	Height;	chr6:109415050	chr6:109382795~109383666:+
THCA	cis	rs8081395	0.775	rs2645482	ENSG00000266992.1	DHX40P1	7.77	4.96e-14	1.84e-11	0.39	0.34	White blood cell count;	chr17:59865754	chr17:59976009~60002384:-
THCA	cis	rs8081395	0.805	rs2645485	ENSG00000266992.1	DHX40P1	7.77	4.96e-14	1.84e-11	0.39	0.34	White blood cell count;	chr17:59866920	chr17:59976009~60002384:-
THCA	cis	rs9902453	0.808	rs1986555	ENSG00000264007.1	RP11-68I3.10	7.77	4.97e-14	1.84e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29687430	chr17:29621617~29622254:-
THCA	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	7.77	4.97e-14	1.84e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
THCA	cis	rs950169	0.579	rs881983	ENSG00000225151.9	GOLGA2P7	-7.77	4.98e-14	1.84e-11	-0.52	-0.34	Schizophrenia;	chr15:83978556	chr15:84199311~84230136:-
THCA	cis	rs4784934	0.959	rs2042401	ENSG00000260186.4	RP11-481J2.2	7.77	4.98e-14	1.85e-11	0.49	0.34	QT interval;	chr16:58430171	chr16:58421326~58462470:+
THCA	cis	rs17684571	0.7	rs61601344	ENSG00000231441.1	RP11-472M19.2	7.77	4.99e-14	1.85e-11	0.41	0.34	Schizophrenia;	chr6:56797356	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs35609883	ENSG00000231441.1	RP11-472M19.2	7.77	4.99e-14	1.85e-11	0.41	0.34	Schizophrenia;	chr6:56807034	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.7	rs35886823	ENSG00000231441.1	RP11-472M19.2	7.77	4.99e-14	1.85e-11	0.41	0.34	Schizophrenia;	chr6:56816682	chr6:56844002~56864078:+
THCA	cis	rs1426063	0.541	rs58959724	ENSG00000260265.1	RP11-44F21.5	7.77	5.01e-14	1.86e-11	0.84	0.34	QT interval;	chr4:75073543	chr4:75081702~75084717:-
THCA	cis	rs1318937	1	rs11713836	ENSG00000224660.1	SH3BP5-AS1	7.77	5.02e-14	1.86e-11	0.25	0.34	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253304	chr3:15254184~15264493:+
THCA	cis	rs6844153	1	rs74895929	ENSG00000240005.4	RP11-293A21.1	-7.77	5.03e-14	1.86e-11	-0.45	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26846035	chr4:26859806~26860599:-
THCA	cis	rs4713118	0.869	rs6930992	ENSG00000219392.1	RP1-265C24.5	-7.77	5.03e-14	1.87e-11	-0.43	-0.34	Parkinson's disease;	chr6:27744341	chr6:28115628~28116551:+
THCA	cis	rs17772222	0.958	rs59136503	ENSG00000258983.2	RP11-507K2.2	7.77	5.04e-14	1.87e-11	0.43	0.34	Coronary artery calcification;	chr14:88501921	chr14:88499334~88515502:+
THCA	cis	rs9329221	0.527	rs34308302	ENSG00000261451.1	RP11-981G7.1	-7.77	5.04e-14	1.87e-11	-0.44	-0.34	Neuroticism;	chr8:10474512	chr8:10433672~10438312:+
THCA	cis	rs12681366	0.801	rs12682524	ENSG00000253704.1	RP11-267M23.4	7.77	5.04e-14	1.87e-11	0.35	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94472071	chr8:94553722~94569745:+
THCA	cis	rs62103177	0.81	rs62096746	ENSG00000261126.6	RP11-795F19.1	7.77	5.06e-14	1.87e-11	0.39	0.34	Opioid sensitivity;	chr18:79859556	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.733	rs62096747	ENSG00000261126.6	RP11-795F19.1	7.77	5.06e-14	1.87e-11	0.39	0.34	Opioid sensitivity;	chr18:79859568	chr18:80046900~80095482:+
THCA	cis	rs62103177	0.733	rs62096748	ENSG00000261126.6	RP11-795F19.1	7.77	5.06e-14	1.87e-11	0.39	0.34	Opioid sensitivity;	chr18:79859699	chr18:80046900~80095482:+
THCA	cis	rs11214589	0.774	rs877137	ENSG00000270179.1	RP11-159N11.4	-7.77	5.07e-14	1.88e-11	-0.36	-0.34	Neuroticism;	chr11:113385608	chr11:113368478~113369117:+
THCA	cis	rs1150668	0.768	rs1233713	ENSG00000219392.1	RP1-265C24.5	-7.77	5.08e-14	1.88e-11	-0.37	-0.34	Pubertal anthropometrics;	chr6:28230503	chr6:28115628~28116551:+
THCA	cis	rs7191700	0.511	rs243330	ENSG00000262703.1	RP11-485G7.6	7.77	5.08e-14	1.88e-11	0.37	0.34	Multiple sclerosis;	chr16:11257134	chr16:11348143~11349321:-
THCA	cis	rs9902453	0.967	rs61240589	ENSG00000264007.1	RP11-68I3.10	7.77	5.08e-14	1.88e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:30122017	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs55748380	ENSG00000264007.1	RP11-68I3.10	7.77	5.08e-14	1.88e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:30142764	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.933	rs60694493	ENSG00000264007.1	RP11-68I3.10	7.77	5.08e-14	1.88e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:30146238	chr17:29621617~29622254:-
THCA	cis	rs950169	0.579	rs12912716	ENSG00000259728.4	LINC00933	7.77	5.11e-14	1.89e-11	0.49	0.34	Schizophrenia;	chr15:83995511	chr15:84570649~84580175:+
THCA	cis	rs4713118	0.869	rs6914924	ENSG00000219392.1	RP1-265C24.5	-7.77	5.11e-14	1.89e-11	-0.43	-0.34	Parkinson's disease;	chr6:27743751	chr6:28115628~28116551:+
THCA	cis	rs2439831	0.571	rs689883	ENSG00000249839.1	AC011330.5	-7.77	5.12e-14	1.89e-11	-0.51	-0.34	Lung cancer in ever smokers;	chr15:43520398	chr15:43663654~43684339:-
THCA	cis	rs77204473	0.744	rs77661993	ENSG00000254851.1	RP11-109L13.1	7.77	5.12e-14	1.9e-11	0.9	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117139758	chr11:117135528~117138582:+
THCA	cis	rs2739330	0.731	rs2000468	ENSG00000099984.9	GSTT2	-7.77	5.14e-14	1.9e-11	-0.42	-0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23980123~23983911:+
THCA	cis	rs7942368	1	rs1440978	ENSG00000254632.1	RP11-21L23.4	7.77	5.14e-14	1.9e-11	0.49	0.34	Endometriosis;	chr11:76765236	chr11:76759916~76768223:-
THCA	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-7.77	5.15e-14	1.91e-11	-0.44	-0.34	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
THCA	cis	rs910316	1	rs175443	ENSG00000279594.1	RP11-950C14.10	-7.77	5.15e-14	1.91e-11	-0.32	-0.34	Height;	chr14:75135260	chr14:75011269~75012851:-
THCA	cis	rs17826219	0.706	rs2322197	ENSG00000264538.5	SUZ12P1	-7.77	5.15e-14	1.91e-11	-0.34	-0.34	Body mass index;	chr17:30778787	chr17:30709299~30790908:+
THCA	cis	rs4460629	0.905	rs4971077	ENSG00000160766.13	GBAP1	-7.76	5.16e-14	1.91e-11	-0.36	-0.34	Serum magnesium levels;	chr1:155156241	chr1:155213821~155227422:-
THCA	cis	rs1150668	0.835	rs1233696	ENSG00000219392.1	RP1-265C24.5	-7.76	5.16e-14	1.91e-11	-0.37	-0.34	Pubertal anthropometrics;	chr6:28175232	chr6:28115628~28116551:+
THCA	cis	rs367615	0.731	rs58241713	ENSG00000249476.1	CTD-2587M2.1	7.76	5.18e-14	1.92e-11	0.35	0.34	Colorectal cancer (SNP x SNP interaction);	chr5:109517963	chr5:109237120~109326369:-
THCA	cis	rs7646881	0.812	rs59957986	ENSG00000240207.5	RP11-379F4.4	-7.76	5.18e-14	1.92e-11	-0.48	-0.34	Tetralogy of Fallot;	chr3:158741124	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.812	rs59192661	ENSG00000240207.5	RP11-379F4.4	-7.76	5.18e-14	1.92e-11	-0.48	-0.34	Tetralogy of Fallot;	chr3:158741238	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.812	rs6788069	ENSG00000240207.5	RP11-379F4.4	7.76	5.18e-14	1.92e-11	0.48	0.34	Tetralogy of Fallot;	chr3:158741670	chr3:158732263~158784070:+
THCA	cis	rs12908161	0.959	rs12906348	ENSG00000259728.4	LINC00933	7.76	5.19e-14	1.92e-11	0.46	0.34	Schizophrenia;	chr15:84786190	chr15:84570649~84580175:+
THCA	cis	rs12908161	0.959	rs34342559	ENSG00000259728.4	LINC00933	7.76	5.19e-14	1.92e-11	0.46	0.34	Schizophrenia;	chr15:84788040	chr15:84570649~84580175:+
THCA	cis	rs12908161	0.959	rs62019472	ENSG00000259728.4	LINC00933	7.76	5.19e-14	1.92e-11	0.46	0.34	Schizophrenia;	chr15:84788262	chr15:84570649~84580175:+
THCA	cis	rs12908161	0.959	rs35557864	ENSG00000259728.4	LINC00933	7.76	5.19e-14	1.92e-11	0.46	0.34	Schizophrenia;	chr15:84788398	chr15:84570649~84580175:+
THCA	cis	rs9649213	0.555	rs6948346	ENSG00000272950.1	RP11-307C18.1	7.76	5.21e-14	1.93e-11	0.41	0.34	Prostate cancer (SNP x SNP interaction);	chr7:98330644	chr7:98322853~98323430:+
THCA	cis	rs62355901	0.505	rs12657615	ENSG00000271828.1	CTD-2310F14.1	7.76	5.22e-14	1.93e-11	0.68	0.34	Breast cancer;	chr5:56768306	chr5:56927874~56929573:+
THCA	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	7.76	5.22e-14	1.93e-11	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
THCA	cis	rs6496044	0.547	rs1564719	ENSG00000259295.5	CSPG4P12	7.76	5.22e-14	1.93e-11	0.44	0.34	Interstitial lung disease;	chr15:85511035	chr15:85191438~85213905:+
THCA	cis	rs11651753	0.561	rs11654010	ENSG00000264920.1	RP11-6N17.4	7.76	5.22e-14	1.93e-11	0.3	0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47883499	chr17:47891255~47895812:-
THCA	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	7.76	5.23e-14	1.93e-11	0.39	0.34	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	7.76	5.23e-14	1.93e-11	0.39	0.34	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
THCA	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-7.76	5.23e-14	1.94e-11	-0.36	-0.34	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-7.76	5.23e-14	1.94e-11	-0.36	-0.34	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-7.76	5.23e-14	1.94e-11	-0.36	-0.34	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
THCA	cis	rs910316	0.967	rs175451	ENSG00000279594.1	RP11-950C14.10	-7.76	5.26e-14	1.95e-11	-0.32	-0.34	Height;	chr14:75123026	chr14:75011269~75012851:-
THCA	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	7.76	5.27e-14	1.95e-11	0.22	0.34	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
THCA	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	7.76	5.27e-14	1.95e-11	0.22	0.34	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
THCA	cis	rs10875746	0.669	rs11168516	ENSG00000240399.1	RP1-228P16.1	-7.76	5.28e-14	1.95e-11	-0.38	-0.34	Longevity (90 years and older);	chr12:48308282	chr12:48054813~48055591:-
THCA	cis	rs2276314	1	rs1789513	ENSG00000278986.1	RP11-723J4.3	7.76	5.28e-14	1.95e-11	0.39	0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35965667	chr18:35972151~35973916:+
THCA	cis	rs1075265	0.62	rs10192626	ENSG00000233266.1	HMGB1P31	7.76	5.29e-14	1.96e-11	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54051334~54051760:+
THCA	cis	rs12928939	0.769	rs34680964	ENSG00000260886.1	TAT-AS1	7.76	5.29e-14	1.96e-11	0.44	0.34	Post bronchodilator FEV1;	chr16:71624691	chr16:71565789~71578187:+
THCA	cis	rs516805	0.748	rs6908508	ENSG00000279453.1	RP3-425C14.4	7.76	5.3e-14	1.96e-11	0.33	0.34	Lymphocyte counts;	chr6:122387857	chr6:122436789~122439223:-
THCA	cis	rs12908161	0.96	rs34452033	ENSG00000225151.9	GOLGA2P7	-7.76	5.3e-14	1.96e-11	-0.49	-0.34	Schizophrenia;	chr15:84678762	chr15:84199311~84230136:-
THCA	cis	rs4950322	0.542	rs12046706	ENSG00000237188.3	RP11-337C18.8	7.76	5.3e-14	1.96e-11	0.38	0.34	Protein quantitative trait loci;	chr1:147189758	chr1:147172771~147211568:+
THCA	cis	rs812925	0.555	rs12616433	ENSG00000271889.1	RP11-493E12.1	7.76	5.31e-14	1.96e-11	0.32	0.34	Immature fraction of reticulocytes;	chr2:61469353	chr2:61151433~61162105:-
THCA	cis	rs2839186	0.814	rs2839167	ENSG00000239415.1	AP001469.9	7.76	5.31e-14	1.96e-11	0.35	0.34	Testicular germ cell tumor;	chr21:46241673	chr21:46251549~46254133:-
THCA	cis	rs7714584	1	rs11749391	ENSG00000197083.10	ZNF300P1	7.76	5.31e-14	1.96e-11	0.54	0.34	Crohn's disease;	chr5:150849504	chr5:150930645~150946289:-
THCA	cis	rs5769707	0.616	rs135869	ENSG00000235111.1	RP1-29C18.8	-7.76	5.31e-14	1.97e-11	-0.44	-0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49614718	chr22:49612657~49615716:-
THCA	cis	rs10800713	0.866	rs6703783	ENSG00000260088.1	RP11-92G12.3	-7.76	5.32e-14	1.97e-11	-0.53	-0.34	Tandem gait;	chr1:200544290	chr1:200669507~200694250:+
THCA	cis	rs9388451	0.839	rs3799709	ENSG00000237742.5	RP11-624M8.1	-7.76	5.32e-14	1.97e-11	-0.29	-0.34	Brugada syndrome;	chr6:125757215	chr6:125578558~125749190:-
THCA	cis	rs7191700	0.511	rs8058983	ENSG00000262703.1	RP11-485G7.6	-7.76	5.33e-14	1.97e-11	-0.37	-0.34	Multiple sclerosis;	chr16:11266992	chr16:11348143~11349321:-
THCA	cis	rs910316	0.967	rs175432	ENSG00000279594.1	RP11-950C14.10	-7.76	5.34e-14	1.97e-11	-0.32	-0.34	Height;	chr14:75148543	chr14:75011269~75012851:-
THCA	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	7.76	5.34e-14	1.97e-11	0.34	0.34	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
THCA	cis	rs9500256	0.711	rs6588685	ENSG00000215190.7	LINC00680	-7.76	5.35e-14	1.98e-11	-0.42	-0.34	Eosinophilic esophagitis (pediatric);	chr6:57993375	chr6:57946074~57961501:-
THCA	cis	rs11673344	0.523	rs2562609	ENSG00000226686.6	LINC01535	7.76	5.35e-14	1.98e-11	0.37	0.34	Obesity-related traits;	chr19:37036255	chr19:37251912~37265535:+
THCA	cis	rs42490	0.664	rs421411	ENSG00000251136.7	RP11-37B2.1	-7.76	5.35e-14	1.98e-11	-0.29	-0.34	Leprosy;	chr8:89808665	chr8:89609409~89757727:-
THCA	cis	rs853679	0.882	rs3757188	ENSG00000219392.1	RP1-265C24.5	-7.76	5.36e-14	1.98e-11	-0.58	-0.34	Depression;	chr6:28139579	chr6:28115628~28116551:+
THCA	cis	rs11214589	0.875	rs10891540	ENSG00000270179.1	RP11-159N11.4	7.76	5.37e-14	1.98e-11	0.35	0.34	Neuroticism;	chr11:113368360	chr11:113368478~113369117:+
THCA	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	7.76	5.37e-14	1.98e-11	0.33	0.34	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
THCA	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	7.76	5.37e-14	1.98e-11	0.33	0.34	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
THCA	cis	rs12908161	1	rs62019469	ENSG00000259728.4	LINC00933	7.76	5.37e-14	1.99e-11	0.46	0.34	Schizophrenia;	chr15:84777989	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs12908549	ENSG00000259728.4	LINC00933	7.76	5.37e-14	1.99e-11	0.46	0.34	Schizophrenia;	chr15:84779120	chr15:84570649~84580175:+
THCA	cis	rs4072705	1	rs4838196	ENSG00000224020.1	MIR181A2HG	-7.76	5.37e-14	1.99e-11	-0.29	-0.34	Menarche (age at onset);	chr9:124595399	chr9:124658467~124698631:+
THCA	cis	rs638893	0.617	rs4938564	ENSG00000278376.1	RP11-158I9.8	-7.76	5.38e-14	1.99e-11	-0.29	-0.34	Vitiligo;	chr11:118849881	chr11:118791254~118793137:+
THCA	cis	rs638893	0.588	rs4938566	ENSG00000278376.1	RP11-158I9.8	-7.76	5.38e-14	1.99e-11	-0.29	-0.34	Vitiligo;	chr11:118850480	chr11:118791254~118793137:+
THCA	cis	rs638893	0.617	rs4938567	ENSG00000278376.1	RP11-158I9.8	-7.76	5.38e-14	1.99e-11	-0.29	-0.34	Vitiligo;	chr11:118850540	chr11:118791254~118793137:+
THCA	cis	rs638893	0.617	rs11217059	ENSG00000278376.1	RP11-158I9.8	-7.76	5.38e-14	1.99e-11	-0.29	-0.34	Vitiligo;	chr11:118852378	chr11:118791254~118793137:+
THCA	cis	rs686320	1	rs35940245	ENSG00000245532.5	NEAT1	7.76	5.38e-14	1.99e-11	0.3	0.34	Hip circumference adjusted for BMI;	chr11:65465202	chr11:65422774~65445540:+
THCA	cis	rs4308124	0.708	rs6747657	ENSG00000227992.1	AC108463.2	-7.76	5.39e-14	1.99e-11	-0.47	-0.34	Vitiligo;	chr2:111245586	chr2:111203964~111206215:-
THCA	cis	rs42490	0.576	rs432457	ENSG00000251136.7	RP11-37B2.1	-7.76	5.39e-14	1.99e-11	-0.3	-0.34	Leprosy;	chr8:89853680	chr8:89609409~89757727:-
THCA	cis	rs240993	0.812	rs7751272	ENSG00000230177.1	RP5-1112D6.4	-7.76	5.4e-14	1.99e-11	-0.35	-0.34	Inflammatory skin disease;Psoriasis;	chr6:111419068	chr6:111277932~111278742:+
THCA	cis	rs9847710	0.733	rs2581806	ENSG00000242142.1	SERBP1P3	7.76	5.42e-14	2e-11	0.42	0.34	Ulcerative colitis;	chr3:53029344	chr3:53064283~53065091:-
THCA	cis	rs7665090	0.528	rs3774968	ENSG00000246560.2	RP11-10L12.4	7.76	5.43e-14	2e-11	0.41	0.34	Primary biliary cholangitis;	chr4:102609955	chr4:102828055~102844075:+
THCA	cis	rs4308124	0.708	rs67816163	ENSG00000227992.1	AC108463.2	-7.76	5.43e-14	2.01e-11	-0.47	-0.34	Vitiligo;	chr2:111205733	chr2:111203964~111206215:-
THCA	cis	rs4308124	0.679	rs7600458	ENSG00000227992.1	AC108463.2	-7.76	5.43e-14	2.01e-11	-0.47	-0.34	Vitiligo;	chr2:111206013	chr2:111203964~111206215:-
THCA	cis	rs4308124	0.708	rs56693625	ENSG00000227992.1	AC108463.2	-7.76	5.43e-14	2.01e-11	-0.47	-0.34	Vitiligo;	chr2:111207578	chr2:111203964~111206215:-
THCA	cis	rs180730	0.847	rs1450459	ENSG00000251609.2	SETP12	7.76	5.43e-14	2.01e-11	0.53	0.34	Fasting plasma glucose;	chr4:120925312	chr4:120895494~120897083:-
THCA	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	7.76	5.44e-14	2.01e-11	0.47	0.34	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
THCA	cis	rs7712401	0.502	rs30066	ENSG00000263432.2	RN7SL689P	7.76	5.44e-14	2.01e-11	0.41	0.34	Mean platelet volume;	chr5:122958007	chr5:123022487~123022783:-
THCA	cis	rs193541	0.632	rs30063	ENSG00000263432.2	RN7SL689P	7.76	5.44e-14	2.01e-11	0.41	0.34	Glucose homeostasis traits;	chr5:122959998	chr5:123022487~123022783:-
THCA	cis	rs1426063	0.614	rs76325897	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75084747	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs76093954	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75087994	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs114977200	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75088736	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs77625282	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75089646	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs75112697	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75089725	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs7684790	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75090873	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs7671634	ENSG00000260265.1	RP11-44F21.5	7.76	5.44e-14	2.01e-11	0.84	0.34	QT interval;	chr4:75090883	chr4:75081702~75084717:-
THCA	cis	rs8114671	0.967	rs4911478	ENSG00000269202.1	RP4-614O4.12	7.76	5.44e-14	2.01e-11	0.28	0.34	Height;	chr20:35194822	chr20:35201747~35203288:-
THCA	cis	rs748404	0.697	rs493177	ENSG00000205771.5	CATSPER2P1	-7.76	5.45e-14	2.01e-11	-0.35	-0.34	Lung cancer;	chr15:43251060	chr15:43726918~43747094:-
THCA	cis	rs11673344	0.523	rs8108509	ENSG00000226686.6	LINC01535	7.76	5.46e-14	2.02e-11	0.37	0.34	Obesity-related traits;	chr19:37060370	chr19:37251912~37265535:+
THCA	cis	rs9543976	0.623	rs6562915	ENSG00000261553.4	RP11-29G8.3	7.76	5.52e-14	2.04e-11	0.41	0.34	Diabetic retinopathy;	chr13:75596750	chr13:75549773~75807120:+
THCA	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	7.76	5.53e-14	2.04e-11	0.36	0.34	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
THCA	cis	rs6908034	0.607	rs77386860	ENSG00000228412.5	RP4-625H18.2	7.75	5.57e-14	2.05e-11	0.82	0.34	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19814524	chr6:19802164~19804752:-
THCA	cis	rs7247513	0.759	rs8110545	ENSG00000230310.1	CTD-2192J16.11	-7.75	5.58e-14	2.06e-11	-0.4	-0.34	Bipolar disorder;	chr19:12644084	chr19:12552597~12553644:+
THCA	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	7.75	5.58e-14	2.06e-11	0.32	0.34	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
THCA	cis	rs9473147	0.543	rs9369716	ENSG00000270761.1	RP11-385F7.1	-7.75	5.59e-14	2.06e-11	-0.27	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47584444	chr6:47477243~47477572:-
THCA	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-7.75	5.6e-14	2.06e-11	-0.52	-0.34	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
THCA	cis	rs1005277	0.579	rs176838	ENSG00000263064.2	RP11-291L22.7	-7.75	5.6e-14	2.07e-11	-0.38	-0.34	Extrinsic epigenetic age acceleration;	chr10:38082971	chr10:38448689~38448949:+
THCA	cis	rs12701220	0.52	rs7803208	ENSG00000229043.2	AC091729.9	-7.75	5.61e-14	2.07e-11	-0.4	-0.34	Bronchopulmonary dysplasia;	chr7:1122448	chr7:1160374~1165267:+
THCA	cis	rs12908161	0.92	rs35758837	ENSG00000259728.4	LINC00933	7.75	5.62e-14	2.07e-11	0.46	0.34	Schizophrenia;	chr15:84768151	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs17600551	ENSG00000259728.4	LINC00933	7.75	5.62e-14	2.07e-11	0.46	0.34	Schizophrenia;	chr15:84776027	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs36033486	ENSG00000259728.4	LINC00933	7.75	5.62e-14	2.07e-11	0.46	0.34	Schizophrenia;	chr15:84776461	chr15:84570649~84580175:+
THCA	cis	rs11096990	0.656	rs6531709	ENSG00000249685.1	RP11-360F5.3	-7.75	5.63e-14	2.08e-11	-0.4	-0.34	Cognitive function;	chr4:39300629	chr4:39133913~39135608:+
THCA	cis	rs950169	0.579	rs12912716	ENSG00000225151.9	GOLGA2P7	-7.75	5.64e-14	2.08e-11	-0.52	-0.34	Schizophrenia;	chr15:83995511	chr15:84199311~84230136:-
THCA	cis	rs8114671	0.562	rs7263157	ENSG00000269202.1	RP4-614O4.12	-7.75	5.65e-14	2.08e-11	-0.29	-0.34	Height;	chr20:34871324	chr20:35201747~35203288:-
THCA	cis	rs7851660	0.527	rs7859751	ENSG00000236130.1	PTCSC2	-7.75	5.65e-14	2.08e-11	-0.27	-0.34	Strep throat;	chr9:97813606	chr9:97805935~97810008:-
THCA	cis	rs6558530	0.73	rs10100341	ENSG00000253982.1	CTD-2336O2.1	7.75	5.65e-14	2.09e-11	0.29	0.34	Systolic blood pressure;	chr8:1775583	chr8:1761990~1764502:-
THCA	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-7.75	5.66e-14	2.09e-11	-0.36	-0.34	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
THCA	cis	rs812925	0.519	rs10199672	ENSG00000271889.1	RP11-493E12.1	-7.75	5.66e-14	2.09e-11	-0.33	-0.34	Immature fraction of reticulocytes;	chr2:61400499	chr2:61151433~61162105:-
THCA	cis	rs2442825	0.693	rs2600194	ENSG00000206573.7	THUMPD3-AS1	7.75	5.67e-14	2.09e-11	0.2	0.34	Cerebrospinal fluid clusterin levels;	chr3:9382941	chr3:9349689~9398579:-
THCA	cis	rs12908161	0.959	rs3748376	ENSG00000259728.4	LINC00933	7.75	5.67e-14	2.09e-11	0.46	0.34	Schizophrenia;	chr15:84785121	chr15:84570649~84580175:+
THCA	cis	rs831571	0.955	rs35837	ENSG00000280620.1	SCAANT1	7.75	5.69e-14	2.1e-11	0.53	0.34	Type 2 diabetes;	chr3:64027573	chr3:63911518~63911772:-
THCA	cis	rs6142102	1	rs2378078	ENSG00000276073.1	RP5-1125A11.7	-7.75	5.7e-14	2.1e-11	-0.34	-0.34	Skin pigmentation;	chr20:34126922	chr20:33985617~33988989:-
THCA	cis	rs9473147	0.543	rs9296558	ENSG00000270761.1	RP11-385F7.1	-7.75	5.71e-14	2.11e-11	-0.27	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47484147	chr6:47477243~47477572:-
THCA	cis	rs950169	0.579	rs11633088	ENSG00000225151.9	GOLGA2P7	7.75	5.72e-14	2.11e-11	0.51	0.34	Schizophrenia;	chr15:84003429	chr15:84199311~84230136:-
THCA	cis	rs17772222	0.674	rs112788894	ENSG00000258983.2	RP11-507K2.2	7.75	5.73e-14	2.11e-11	0.43	0.34	Coronary artery calcification;	chr14:88442850	chr14:88499334~88515502:+
THCA	cis	rs5769707	0.667	rs4824069	ENSG00000235111.1	RP1-29C18.8	-7.75	5.75e-14	2.12e-11	-0.44	-0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49612657~49615716:-
THCA	cis	rs12928939	0.859	rs11670	ENSG00000260886.1	TAT-AS1	7.75	5.77e-14	2.13e-11	0.45	0.34	Post bronchodilator FEV1;	chr16:71645124	chr16:71565789~71578187:+
THCA	cis	rs875971	0.522	rs9530	ENSG00000237310.1	GS1-124K5.4	7.75	5.78e-14	2.13e-11	0.25	0.34	Aortic root size;	chr7:65960907	chr7:66493706~66495474:+
THCA	cis	rs4722166	0.695	rs7808122	ENSG00000179428.2	AC073072.5	-7.75	5.78e-14	2.13e-11	-0.41	-0.34	Lung cancer;	chr7:22758461	chr7:22725395~22727620:-
THCA	cis	rs16846053	0.515	rs1399650	ENSG00000227403.1	AC009299.3	-7.75	5.78e-14	2.13e-11	-0.54	-0.34	Blood osmolality (transformed sodium);	chr2:161695208	chr2:161244739~161249050:+
THCA	cis	rs62103177	0.513	rs9945153	ENSG00000261126.6	RP11-795F19.1	7.75	5.78e-14	2.13e-11	0.4	0.34	Opioid sensitivity;	chr18:79838450	chr18:80046900~80095482:+
THCA	cis	rs950169	0.579	rs881983	ENSG00000259728.4	LINC00933	7.75	5.79e-14	2.13e-11	0.48	0.34	Schizophrenia;	chr15:83978556	chr15:84570649~84580175:+
THCA	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	7.75	5.79e-14	2.13e-11	0.2	0.34	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
THCA	cis	rs9601248	0.874	rs9545154	ENSG00000227676.3	LINC01068	7.75	5.79e-14	2.13e-11	0.42	0.34	Major depressive disorder;	chr13:79617682	chr13:79566727~79571436:+
THCA	cis	rs9601248	0.874	rs9545155	ENSG00000227676.3	LINC01068	7.75	5.79e-14	2.13e-11	0.42	0.34	Major depressive disorder;	chr13:79617738	chr13:79566727~79571436:+
THCA	cis	rs11673344	0.504	rs6510588	ENSG00000226686.6	LINC01535	-7.75	5.79e-14	2.13e-11	-0.37	-0.34	Obesity-related traits;	chr19:37106493	chr19:37251912~37265535:+
THCA	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-7.75	5.79e-14	2.13e-11	-0.51	-0.34	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-7.75	5.79e-14	2.13e-11	-0.51	-0.34	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
THCA	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-7.75	5.79e-14	2.13e-11	-0.51	-0.34	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
THCA	cis	rs13631	0.728	rs7466635	ENSG00000268996.3	MAN1B1-AS1	-7.75	5.8e-14	2.13e-11	-0.29	-0.34	Cerebrospinal fluid biomarker levels;	chr9:137085965	chr9:137084946~137086817:-
THCA	cis	rs8114671	0.562	rs6088635	ENSG00000269202.1	RP4-614O4.12	-7.75	5.8e-14	2.14e-11	-0.29	-0.34	Height;	chr20:34878698	chr20:35201747~35203288:-
THCA	cis	rs17684571	0.7	rs16888171	ENSG00000231441.1	RP11-472M19.2	7.75	5.8e-14	2.14e-11	0.41	0.34	Schizophrenia;	chr6:56810369	chr6:56844002~56864078:+
THCA	cis	rs910316	0.87	rs7147712	ENSG00000279594.1	RP11-950C14.10	-7.75	5.8e-14	2.14e-11	-0.32	-0.34	Height;	chr14:75204004	chr14:75011269~75012851:-
THCA	cis	rs7208859	0.614	rs73265646	ENSG00000266490.1	CTD-2349P21.9	7.75	5.81e-14	2.14e-11	0.49	0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30792372~30792833:+
THCA	cis	rs595244	0.706	rs2289136	ENSG00000259705.1	RP11-227D13.1	-7.75	5.81e-14	2.14e-11	-0.48	-0.34	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr15:48652075	chr15:48645951~48652016:+
THCA	cis	rs710216	0.571	rs11210772	ENSG00000227533.4	SLC2A1-AS1	-7.75	5.83e-14	2.14e-11	-0.46	-0.34	Red cell distribution width;	chr1:42982828	chr1:42959049~42983358:+
THCA	cis	rs77204473	0.744	rs2046150	ENSG00000254851.1	RP11-109L13.1	7.75	5.83e-14	2.15e-11	0.82	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117182717	chr11:117135528~117138582:+
THCA	cis	rs11651753	0.561	rs35336840	ENSG00000264920.1	RP11-6N17.4	-7.75	5.83e-14	2.15e-11	-0.3	-0.34	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47888742	chr17:47891255~47895812:-
THCA	cis	rs1426063	0.614	rs115690958	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75078364	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs78681370	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75081556	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs17000212	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75081611	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs77018380	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75081621	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs75846524	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75083172	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs78046076	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75091818	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs74670563	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75094656	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs115338890	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75094719	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.541	rs116304289	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75095072	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs76204704	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75097804	chr4:75081702~75084717:-
THCA	cis	rs1426063	0.614	rs80030693	ENSG00000260265.1	RP11-44F21.5	7.75	5.84e-14	2.15e-11	0.84	0.34	QT interval;	chr4:75099929	chr4:75081702~75084717:-
THCA	cis	rs638893	0.588	rs4936440	ENSG00000278376.1	RP11-158I9.8	-7.75	5.84e-14	2.15e-11	-0.29	-0.34	Vitiligo;	chr11:118849975	chr11:118791254~118793137:+
THCA	cis	rs12908161	1	rs35630683	ENSG00000259728.4	LINC00933	7.75	5.86e-14	2.16e-11	0.46	0.34	Schizophrenia;	chr15:84806000	chr15:84570649~84580175:+
THCA	cis	rs35828350	1	rs35828350	ENSG00000259728.4	LINC00933	7.75	5.86e-14	2.16e-11	0.46	0.34	Autism spectrum disorder or schizophrenia;	chr15:84812610	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs56864281	ENSG00000259728.4	LINC00933	7.75	5.86e-14	2.16e-11	0.46	0.34	Schizophrenia;	chr15:84814418	chr15:84570649~84580175:+
THCA	cis	rs741668	0.759	rs12428399	ENSG00000235903.6	CPB2-AS1	7.75	5.86e-14	2.16e-11	0.44	0.34	Cerebrospinal fluid clusterin levels;	chr13:46060804	chr13:46052806~46113332:+
THCA	cis	rs73607972	0.696	rs9931018	ENSG00000275191.1	RP11-36I17.2	-7.75	5.86e-14	2.16e-11	-0.47	-0.34	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53529205	chr16:53628256~53628816:-
THCA	cis	rs172166	0.516	rs1150670	ENSG00000219392.1	RP1-265C24.5	-7.75	5.87e-14	2.16e-11	-0.37	-0.34	Cardiac Troponin-T levels;	chr6:28162781	chr6:28115628~28116551:+
THCA	cis	rs7674212	0.833	rs61075040	ENSG00000251288.2	RP11-10L12.2	-7.75	5.88e-14	2.16e-11	-0.46	-0.34	Type 2 diabetes;	chr4:103052804	chr4:102751401~102752641:+
THCA	cis	rs7208859	0.623	rs9912440	ENSG00000264538.5	SUZ12P1	-7.75	5.88e-14	2.16e-11	-0.34	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30821754	chr17:30709299~30790908:+
THCA	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	7.75	5.91e-14	2.17e-11	0.2	0.34	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
THCA	cis	rs2243480	1	rs160643	ENSG00000273142.1	RP11-458F8.4	-7.75	5.92e-14	2.18e-11	-0.42	-0.34	Diabetic kidney disease;	chr7:66093235	chr7:66902857~66906297:+
THCA	cis	rs728616	0.867	rs726289	ENSG00000225484.5	NUTM2B-AS1	-7.75	5.92e-14	2.18e-11	-0.64	-0.34	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79947195	chr10:79663088~79826594:-
THCA	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-7.75	5.92e-14	2.18e-11	-0.5	-0.34	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
THCA	cis	rs4819052	0.918	rs2330013	ENSG00000237664.1	LINC00316	-7.75	5.92e-14	2.18e-11	-0.36	-0.34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45238747	chr21:45338590~45341990:-
THCA	cis	rs7829975	0.593	rs2979241	ENSG00000254153.1	CTA-398F10.2	-7.75	5.93e-14	2.18e-11	-0.35	-0.34	Mood instability;	chr8:8445843	chr8:8456909~8461337:-
THCA	cis	rs17772222	0.727	rs3179969	ENSG00000258789.1	RP11-507K2.3	-7.75	5.93e-14	2.18e-11	-0.32	-0.34	Coronary artery calcification;	chr14:88396185	chr14:88551597~88552493:+
THCA	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	7.74	5.95e-14	2.19e-11	0.2	0.34	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
THCA	cis	rs11971779	0.793	rs4728464	ENSG00000273391.1	RP11-634H22.1	-7.74	5.95e-14	2.19e-11	-0.33	-0.34	Diisocyanate-induced asthma;	chr7:139332924	chr7:139359032~139359566:-
THCA	cis	rs8114671	0.967	rs1577924	ENSG00000269202.1	RP4-614O4.12	7.74	5.96e-14	2.19e-11	0.28	0.34	Height;	chr20:35196485	chr20:35201747~35203288:-
THCA	cis	rs12928939	0.815	rs61753635	ENSG00000260886.1	TAT-AS1	7.74	5.96e-14	2.19e-11	0.43	0.34	Post bronchodilator FEV1;	chr16:71626501	chr16:71565789~71578187:+
THCA	cis	rs73186030	0.764	rs2332179	ENSG00000272758.4	RP11-299J3.8	7.74	5.97e-14	2.19e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122360583	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs6438725	ENSG00000272758.4	RP11-299J3.8	7.74	5.97e-14	2.19e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122369259	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs9834317	ENSG00000272758.4	RP11-299J3.8	7.74	5.97e-14	2.19e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122370512	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs9881201	ENSG00000272758.4	RP11-299J3.8	7.74	5.97e-14	2.19e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122375838	chr3:122416207~122443180:+
THCA	cis	rs73186030	0.764	rs56236741	ENSG00000272758.4	RP11-299J3.8	7.74	5.97e-14	2.19e-11	0.4	0.34	Serum parathyroid hormone levels;	chr3:122379136	chr3:122416207~122443180:+
THCA	cis	rs4308124	0.708	rs28766030	ENSG00000227992.1	AC108463.2	-7.74	5.99e-14	2.2e-11	-0.47	-0.34	Vitiligo;	chr2:111204852	chr2:111203964~111206215:-
THCA	cis	rs6496932	0.503	rs4564526	ENSG00000218052.5	ADAMTS7P4	-7.74	6e-14	2.2e-11	-0.45	-0.34	Central corneal thickness;Corneal structure;	chr15:85455914	chr15:85255369~85330334:-
THCA	cis	rs4664293	0.934	rs1365800	ENSG00000226266.5	AC009961.3	-7.74	6e-14	2.21e-11	-0.4	-0.34	Monocyte percentage of white cells;	chr2:159699112	chr2:159670708~159712435:-
THCA	cis	rs4308124	0.708	rs6716091	ENSG00000227992.1	AC108463.2	-7.74	6e-14	2.21e-11	-0.48	-0.34	Vitiligo;	chr2:111233556	chr2:111203964~111206215:-
THCA	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-7.74	6.01e-14	2.21e-11	-0.36	-0.34	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
THCA	cis	rs10971721	0.584	rs72731218	ENSG00000260947.1	RP11-384P7.7	7.74	6.01e-14	2.21e-11	0.76	0.34	Body mass index;	chr9:34119678	chr9:33697459~33700986:+
THCA	cis	rs193541	0.632	rs34486978	ENSG00000263432.2	RN7SL689P	-7.74	6.01e-14	2.21e-11	-0.41	-0.34	Glucose homeostasis traits;	chr5:122976848	chr5:123022487~123022783:-
THCA	cis	rs8081395	0.899	rs2645477	ENSG00000266992.1	DHX40P1	-7.74	6.02e-14	2.21e-11	-0.39	-0.34	White blood cell count;	chr17:59768263	chr17:59976009~60002384:-
THCA	cis	rs2288884	0.505	rs6509602	ENSG00000275055.1	CTC-471J1.11	-7.74	6.02e-14	2.21e-11	-0.34	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51956892	chr19:52049007~52049754:+
THCA	cis	rs7727544	0.716	rs4705926	ENSG00000224431.1	AC063976.7	7.74	6.02e-14	2.21e-11	0.29	0.34	Blood metabolite levels;	chr5:132226065	chr5:132199456~132203487:+
THCA	cis	rs934734	0.571	rs7565437	ENSG00000237979.1	AC007389.1	-7.74	6.05e-14	2.23e-11	-0.39	-0.34	Rheumatoid arthritis;	chr2:65419832	chr2:65500993~65502138:-
THCA	cis	rs12280210	0.655	rs76169968	ENSG00000254851.1	RP11-109L13.1	7.74	6.06e-14	2.23e-11	0.74	0.34	Lobe attachment (rater-scored or self-reported);	chr11:117212250	chr11:117135528~117138582:+
THCA	cis	rs453301	0.606	rs7462373	ENSG00000253893.2	FAM85B	7.74	6.07e-14	2.23e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9041808	chr8:8167819~8226614:-
THCA	cis	rs8072100	0.967	rs4289035	ENSG00000228782.6	CTD-2026D20.3	7.74	6.08e-14	2.23e-11	0.3	0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47629845	chr17:47450568~47492492:-
THCA	cis	rs9500256	0.655	rs12191043	ENSG00000215190.7	LINC00680	-7.74	6.08e-14	2.24e-11	-0.43	-0.34	Eosinophilic esophagitis (pediatric);	chr6:58020205	chr6:57946074~57961501:-
THCA	cis	rs1075265	0.621	rs2542593	ENSG00000233266.1	HMGB1P31	7.74	6.09e-14	2.24e-11	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54051334~54051760:+
THCA	cis	rs7714584	1	rs34156253	ENSG00000197083.10	ZNF300P1	7.74	6.1e-14	2.24e-11	0.55	0.34	Crohn's disease;	chr5:150846668	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs61270113	ENSG00000197083.10	ZNF300P1	7.74	6.1e-14	2.24e-11	0.55	0.34	Crohn's disease;	chr5:150846701	chr5:150930645~150946289:-
THCA	cis	rs12701220	0.503	rs12702024	ENSG00000229043.2	AC091729.9	-7.74	6.11e-14	2.24e-11	-0.52	-0.34	Bronchopulmonary dysplasia;	chr7:1090184	chr7:1160374~1165267:+
THCA	cis	rs13068223	0.568	rs7636965	ENSG00000243926.1	TIPARP-AS1	7.74	6.11e-14	2.25e-11	0.33	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156700615	chr3:156671862~156674378:-
THCA	cis	rs42490	0.614	rs402434	ENSG00000251136.7	RP11-37B2.1	-7.74	6.12e-14	2.25e-11	-0.29	-0.34	Leprosy;	chr8:89808088	chr8:89609409~89757727:-
THCA	cis	rs42490	0.614	rs452694	ENSG00000251136.7	RP11-37B2.1	-7.74	6.12e-14	2.25e-11	-0.29	-0.34	Leprosy;	chr8:89808293	chr8:89609409~89757727:-
THCA	cis	rs42490	0.59	rs447611	ENSG00000251136.7	RP11-37B2.1	-7.74	6.12e-14	2.25e-11	-0.29	-0.34	Leprosy;	chr8:89808359	chr8:89609409~89757727:-
THCA	cis	rs9601248	0.874	rs4141825	ENSG00000227676.3	LINC01068	7.74	6.12e-14	2.25e-11	0.42	0.34	Major depressive disorder;	chr13:79616713	chr13:79566727~79571436:+
THCA	cis	rs853679	1	rs7740487	ENSG00000280107.1	AL022393.9	-7.74	6.13e-14	2.25e-11	-0.49	-0.34	Depression;	chr6:28248708	chr6:28170845~28172521:+
THCA	cis	rs853679	1	rs68141011	ENSG00000280107.1	AL022393.9	-7.74	6.13e-14	2.25e-11	-0.49	-0.34	Depression;	chr6:28250019	chr6:28170845~28172521:+
THCA	cis	rs853679	1	rs13200462	ENSG00000280107.1	AL022393.9	-7.74	6.13e-14	2.25e-11	-0.49	-0.34	Depression;	chr6:28250421	chr6:28170845~28172521:+
THCA	cis	rs13068223	0.74	rs344003	ENSG00000243926.1	TIPARP-AS1	-7.74	6.15e-14	2.26e-11	-0.32	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156739931	chr3:156671862~156674378:-
THCA	cis	rs6840258	0.66	rs72667736	ENSG00000251411.1	RP11-397E7.4	-7.74	6.15e-14	2.26e-11	-0.42	-0.34	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86954803	chr4:86913266~86914817:-
THCA	cis	rs7829975	0.667	rs1877119	ENSG00000253893.2	FAM85B	-7.74	6.15e-14	2.26e-11	-0.43	-0.34	Mood instability;	chr8:8849687	chr8:8167819~8226614:-
THCA	cis	rs6142102	0.602	rs4911145	ENSG00000275784.1	RP5-1125A11.6	7.74	6.17e-14	2.26e-11	0.33	0.34	Skin pigmentation;	chr20:34027417	chr20:33989480~33991818:-
THCA	cis	rs193541	0.632	rs1903260	ENSG00000263432.2	RN7SL689P	7.74	6.2e-14	2.28e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122799493	chr5:123022487~123022783:-
THCA	cis	rs11603691	1	rs2155233	ENSG00000254662.1	RP11-872D17.4	-7.74	6.2e-14	2.28e-11	-0.61	-0.34	Low high density lipoprotein cholesterol levels;	chr11:57274518	chr11:57325603~57327958:+
THCA	cis	rs11214589	0.651	rs12360992	ENSG00000270179.1	RP11-159N11.4	-7.74	6.21e-14	2.28e-11	-0.36	-0.34	Neuroticism;	chr11:113392178	chr11:113368478~113369117:+
THCA	cis	rs2276314	1	rs9956938	ENSG00000278986.1	RP11-723J4.3	-7.74	6.22e-14	2.28e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35987098	chr18:35972151~35973916:+
THCA	cis	rs17684571	0.7	rs6904535	ENSG00000231441.1	RP11-472M19.2	7.74	6.22e-14	2.28e-11	0.41	0.34	Schizophrenia;	chr6:56767178	chr6:56844002~56864078:+
THCA	cis	rs11971779	0.715	rs6467854	ENSG00000273391.1	RP11-634H22.1	7.74	6.23e-14	2.29e-11	0.32	0.34	Diisocyanate-induced asthma;	chr7:139442337	chr7:139359032~139359566:-
THCA	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	7.74	6.25e-14	2.3e-11	0.43	0.34	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
THCA	cis	rs2739330	0.796	rs5760097	ENSG00000235689.1	AP000351.13	7.74	6.26e-14	2.3e-11	0.42	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:24006305~24008258:-
THCA	cis	rs34375054	0.687	rs12303572	ENSG00000279233.1	RP11-158L12.4	7.74	6.26e-14	2.3e-11	0.34	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125126725	chr12:125138245~125141711:+
THCA	cis	rs453301	0.653	rs7016139	ENSG00000253893.2	FAM85B	7.74	6.26e-14	2.3e-11	0.41	0.34	Joint mobility (Beighton score);	chr8:9037960	chr8:8167819~8226614:-
THCA	cis	rs8072100	0.967	rs8078880	ENSG00000228782.6	CTD-2026D20.3	-7.74	6.27e-14	2.3e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599160	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.935	rs12943464	ENSG00000228782.6	CTD-2026D20.3	-7.74	6.27e-14	2.3e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47612985	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.935	rs4793978	ENSG00000228782.6	CTD-2026D20.3	-7.74	6.27e-14	2.3e-11	-0.3	-0.34	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47620809	chr17:47450568~47492492:-
THCA	cis	rs7646881	0.812	rs61696028	ENSG00000240207.5	RP11-379F4.4	-7.74	6.27e-14	2.3e-11	-0.48	-0.34	Tetralogy of Fallot;	chr3:158737914	chr3:158732263~158784070:+
THCA	cis	rs9473147	0.543	rs9349407	ENSG00000270761.1	RP11-385F7.1	-7.74	6.28e-14	2.31e-11	-0.27	-0.34	Platelet distribution width;Mean platelet volume;	chr6:47485642	chr6:47477243~47477572:-
THCA	cis	rs934734	0.571	rs7572922	ENSG00000237979.1	AC007389.1	-7.74	6.29e-14	2.31e-11	-0.38	-0.34	Rheumatoid arthritis;	chr2:65425022	chr2:65500993~65502138:-
THCA	cis	rs172166	0.637	rs1233708	ENSG00000219392.1	RP1-265C24.5	-7.74	6.29e-14	2.31e-11	-0.4	-0.34	Cardiac Troponin-T levels;	chr6:28205441	chr6:28115628~28116551:+
THCA	cis	rs7714584	1	rs7715981	ENSG00000197083.10	ZNF300P1	7.74	6.33e-14	2.32e-11	0.54	0.34	Crohn's disease;	chr5:150878545	chr5:150930645~150946289:-
THCA	cis	rs910316	0.737	rs175065	ENSG00000279594.1	RP11-950C14.10	-7.74	6.35e-14	2.33e-11	-0.31	-0.34	Height;	chr14:75028280	chr14:75011269~75012851:-
THCA	cis	rs2297363	1	rs13207901	ENSG00000213073.4	RP11-288H12.3	-7.74	6.36e-14	2.33e-11	-0.35	-0.34	Total cholesterol levels;Blood protein levels;	chr6:160081428	chr6:160093082~160096212:+
THCA	cis	rs10129255	0.518	rs28378320	ENSG00000223648.3	IGHV3-64	7.73	6.36e-14	2.33e-11	0.2	0.34	Kawasaki disease;	chr14:106808609	chr14:106643132~106658258:-
THCA	cis	rs4780355	0.918	rs243318	ENSG00000262636.1	CTD-3088G3.4	7.73	6.37e-14	2.34e-11	0.44	0.34	Crohn's disease and psoriasis;	chr16:11264161	chr16:11380859~11381118:-
THCA	cis	rs7727544	0.654	rs4705849	ENSG00000224431.1	AC063976.7	7.73	6.38e-14	2.34e-11	0.29	0.34	Blood metabolite levels;	chr5:132223506	chr5:132199456~132203487:+
THCA	cis	rs7727544	0.716	rs72793278	ENSG00000224431.1	AC063976.7	7.73	6.38e-14	2.34e-11	0.29	0.34	Blood metabolite levels;	chr5:132225679	chr5:132199456~132203487:+
THCA	cis	rs11148252	0.538	rs2408609	ENSG00000235660.1	LINC00345	-7.73	6.39e-14	2.34e-11	-0.41	-0.34	Lewy body disease;	chr13:52139907	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.538	rs2897976	ENSG00000235660.1	LINC00345	-7.73	6.39e-14	2.34e-11	-0.41	-0.34	Lewy body disease;	chr13:52141808	chr13:52484161~52484680:-
THCA	cis	rs193541	0.556	rs30024	ENSG00000263432.2	RN7SL689P	7.73	6.39e-14	2.34e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122949465	chr5:123022487~123022783:-
THCA	cis	rs9902453	0.899	rs1979572	ENSG00000264007.1	RP11-68I3.10	7.73	6.39e-14	2.34e-11	0.37	0.34	Coffee consumption (cups per day);	chr17:30184960	chr17:29621617~29622254:-
THCA	cis	rs9640161	0.789	rs34495356	ENSG00000261305.1	RP4-584D14.7	7.73	6.39e-14	2.34e-11	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150360702	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.789	rs36035506	ENSG00000261305.1	RP4-584D14.7	7.73	6.39e-14	2.34e-11	0.42	0.34	Blood protein levels;Circulating chemerin levels;	chr7:150360754	chr7:150341771~150342607:+
THCA	cis	rs7760535	0.794	rs12529158	ENSG00000230177.1	RP5-1112D6.4	7.73	6.4e-14	2.35e-11	0.27	0.34	Metabolic traits;	chr6:111501244	chr6:111277932~111278742:+
THCA	cis	rs4664293	1	rs10432413	ENSG00000226266.5	AC009961.3	-7.73	6.42e-14	2.36e-11	-0.4	-0.34	Monocyte percentage of white cells;	chr2:159639243	chr2:159670708~159712435:-
THCA	cis	rs4664293	0.967	rs13397722	ENSG00000226266.5	AC009961.3	-7.73	6.42e-14	2.36e-11	-0.4	-0.34	Monocyte percentage of white cells;	chr2:159659140	chr2:159670708~159712435:-
THCA	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	7.73	6.43e-14	2.36e-11	0.38	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
THCA	cis	rs732716	0.785	rs62130979	ENSG00000267980.1	AC007292.6	-7.73	6.44e-14	2.36e-11	-0.38	-0.34	Mean corpuscular volume;	chr19:4432447	chr19:4363789~4364640:+
THCA	cis	rs2274273	0.662	rs4525413	ENSG00000258413.1	RP11-665C16.6	-7.73	6.44e-14	2.36e-11	-0.47	-0.34	Protein biomarker;	chr14:55194420	chr14:55262767~55272075:-
THCA	cis	rs7714584	1	rs11747270	ENSG00000197083.10	ZNF300P1	-7.73	6.45e-14	2.36e-11	-0.54	-0.34	Crohn's disease;	chr5:150879305	chr5:150930645~150946289:-
THCA	cis	rs4072705	0.967	rs10739651	ENSG00000224020.1	MIR181A2HG	-7.73	6.45e-14	2.36e-11	-0.31	-0.34	Menarche (age at onset);	chr9:124561794	chr9:124658467~124698631:+
THCA	cis	rs2688608	0.592	rs7923045	ENSG00000271816.1	BMS1P4	7.73	6.46e-14	2.37e-11	0.34	0.34	Inflammatory bowel disease;	chr10:73727740	chr10:73699151~73730487:-
THCA	cis	rs3820443	0.83	rs57294801	ENSG00000234020.1	CHIAP3	-7.73	6.46e-14	2.37e-11	-0.43	-0.34	Late-onset Alzheimer's disease;	chr1:111353909	chr1:111353275~111367409:-
THCA	cis	rs910316	0.967	rs175498	ENSG00000279594.1	RP11-950C14.10	-7.73	6.46e-14	2.37e-11	-0.31	-0.34	Height;	chr14:75069666	chr14:75011269~75012851:-
THCA	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-7.73	6.47e-14	2.37e-11	-0.51	-0.34	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
THCA	cis	rs193541	0.632	rs10037044	ENSG00000263432.2	RN7SL689P	-7.73	6.49e-14	2.38e-11	-0.4	-0.34	Glucose homeostasis traits;	chr5:122787604	chr5:123022487~123022783:-
THCA	cis	rs7851660	0.527	rs7870540	ENSG00000236130.1	PTCSC2	-7.73	6.5e-14	2.38e-11	-0.27	-0.34	Strep throat;	chr9:97811643	chr9:97805935~97810008:-
THCA	cis	rs9902453	0.845	rs72823935	ENSG00000264007.1	RP11-68I3.10	7.73	6.52e-14	2.39e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29681577	chr17:29621617~29622254:-
THCA	cis	rs5769707	0.605	rs6009791	ENSG00000235111.1	RP1-29C18.8	-7.73	6.52e-14	2.39e-11	-0.44	-0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49612657~49615716:-
THCA	cis	rs7208859	0.623	rs3794796	ENSG00000264538.5	SUZ12P1	-7.73	6.52e-14	2.39e-11	-0.34	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30709299~30790908:+
THCA	cis	rs1858037	0.867	rs1039765	ENSG00000237979.1	AC007389.1	-7.73	6.53e-14	2.39e-11	-0.41	-0.34	Rheumatoid arthritis;	chr2:65387228	chr2:65500993~65502138:-
THCA	cis	rs9813712	0.597	rs11711883	ENSG00000228252.7	COL6A4P2	-7.73	6.54e-14	2.4e-11	-0.33	-0.34	Response to amphetamines;	chr3:130241367	chr3:130212823~130273806:+
THCA	cis	rs9813712	0.574	rs62281647	ENSG00000228252.7	COL6A4P2	-7.73	6.54e-14	2.4e-11	-0.33	-0.34	Response to amphetamines;	chr3:130242670	chr3:130212823~130273806:+
THCA	cis	rs17684571	0.748	rs3002006	ENSG00000231441.1	RP11-472M19.2	7.73	6.54e-14	2.4e-11	0.42	0.34	Schizophrenia;	chr6:56750916	chr6:56844002~56864078:+
THCA	cis	rs910316	0.737	rs91144	ENSG00000279594.1	RP11-950C14.10	-7.73	6.54e-14	2.4e-11	-0.31	-0.34	Height;	chr14:74982814	chr14:75011269~75012851:-
THCA	cis	rs6597981	0.592	rs28625355	ENSG00000255142.1	AP006621.6	7.73	6.55e-14	2.4e-11	0.24	0.34	Breast cancer;	chr11:736334	chr11:781645~782105:+
THCA	cis	rs11148252	0.595	rs9526968	ENSG00000235660.1	LINC00345	-7.73	6.57e-14	2.41e-11	-0.43	-0.34	Lewy body disease;	chr13:52666048	chr13:52484161~52484680:-
THCA	cis	rs2284219	0.929	rs12533248	ENSG00000196295.10	AC005154.6	-7.73	6.57e-14	2.41e-11	-0.24	-0.34	Type 2 diabetes;	chr7:30678973	chr7:30516309~30594809:-
THCA	cis	rs7945705	0.846	rs4929911	ENSG00000254860.4	TMEM9B-AS1	-7.73	6.58e-14	2.41e-11	-0.37	-0.34	Hemoglobin concentration;	chr11:8794948	chr11:8964675~8977527:+
THCA	cis	rs7615952	0.599	rs2333408	ENSG00000171084.14	FAM86JP	7.73	6.58e-14	2.41e-11	0.4	0.34	Blood pressure (smoking interaction);	chr3:126013255	chr3:125916620~125930024:+
THCA	cis	rs10411161	0.81	rs11667971	ENSG00000269483.1	AC006272.1	7.73	6.58e-14	2.41e-11	0.57	0.34	Breast cancer;	chr19:51904441	chr19:51839924~51843324:-
THCA	cis	rs6496044	0.526	rs4291869	ENSG00000259295.5	CSPG4P12	7.73	6.58e-14	2.41e-11	0.43	0.34	Interstitial lung disease;	chr15:85511292	chr15:85191438~85213905:+
THCA	cis	rs453301	0.658	rs6983877	ENSG00000253893.2	FAM85B	7.73	6.6e-14	2.42e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9047129	chr8:8167819~8226614:-
THCA	cis	rs12928939	0.769	rs1056303	ENSG00000260886.1	TAT-AS1	7.73	6.61e-14	2.42e-11	0.43	0.34	Post bronchodilator FEV1;	chr16:71636163	chr16:71565789~71578187:+
THCA	cis	rs783540	0.846	rs783539	ENSG00000278603.1	RP13-608F4.5	-7.73	6.61e-14	2.42e-11	-0.42	-0.34	Schizophrenia;	chr15:82585320	chr15:82472203~82472426:+
THCA	cis	rs984222	0.501	rs1325943	ENSG00000231365.4	RP11-418J17.1	-7.73	6.65e-14	2.43e-11	-0.33	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118942984	chr1:119140396~119275973:+
THCA	cis	rs984222	0.501	rs1325945	ENSG00000231365.4	RP11-418J17.1	-7.73	6.65e-14	2.43e-11	-0.33	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118943148	chr1:119140396~119275973:+
THCA	cis	rs984222	0.501	rs1779420	ENSG00000231365.4	RP11-418J17.1	-7.73	6.65e-14	2.43e-11	-0.33	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118943840	chr1:119140396~119275973:+
THCA	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	7.73	6.66e-14	2.44e-11	0.67	0.34	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
THCA	cis	rs984222	0.529	rs1325946	ENSG00000231365.4	RP11-418J17.1	-7.73	6.67e-14	2.44e-11	-0.33	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118943299	chr1:119140396~119275973:+
THCA	cis	rs7247513	0.897	rs12979146	ENSG00000230310.1	CTD-2192J16.11	-7.73	6.67e-14	2.44e-11	-0.4	-0.34	Bipolar disorder;	chr19:12607090	chr19:12552597~12553644:+
THCA	cis	rs6558530	0.73	rs13256424	ENSG00000253982.1	CTD-2336O2.1	7.73	6.68e-14	2.44e-11	0.29	0.34	Systolic blood pressure;	chr8:1776838	chr8:1761990~1764502:-
THCA	cis	rs380904	0.963	rs410822	ENSG00000254859.1	RP11-661A12.5	-7.73	6.68e-14	2.44e-11	-0.49	-0.34	Venous thromboembolism (SNP x SNP interaction);	chr8:143492441	chr8:143541973~143549729:-
THCA	cis	rs2787702	0.5	rs72822011	ENSG00000237233.2	TMEM26-AS1	7.73	6.68e-14	2.44e-11	0.57	0.34	Response to taxane treatment (placlitaxel);	chr10:61573852	chr10:61452639~61481956:+
THCA	cis	rs11148252	0.508	rs11148260	ENSG00000278238.1	RP11-245D16.4	-7.73	6.69e-14	2.45e-11	-0.37	-0.34	Lewy body disease;	chr13:52588508	chr13:52454775~52455331:-
THCA	cis	rs12682352	0.715	rs332039	ENSG00000253893.2	FAM85B	-7.73	6.69e-14	2.45e-11	-0.44	-0.34	Neuroticism;	chr8:8866141	chr8:8167819~8226614:-
THCA	cis	rs11673344	0.504	rs7245882	ENSG00000226686.6	LINC01535	-7.73	6.7e-14	2.45e-11	-0.37	-0.34	Obesity-related traits;	chr19:37089513	chr19:37251912~37265535:+
THCA	cis	rs416603	0.901	rs149597	ENSG00000262636.1	CTD-3088G3.4	-7.73	6.71e-14	2.46e-11	-0.42	-0.34	Type 1 diabetes;	chr16:11250085	chr16:11380859~11381118:-
THCA	cis	rs9326248	0.911	rs11216284	ENSG00000280143.1	AP000892.6	7.73	6.71e-14	2.46e-11	0.43	0.34	Blood protein levels;	chr11:117132344	chr11:117204967~117210292:+
THCA	cis	rs984222	0.501	rs1325941	ENSG00000231365.4	RP11-418J17.1	-7.73	6.73e-14	2.46e-11	-0.33	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118941193	chr1:119140396~119275973:+
THCA	cis	rs984222	0.501	rs1750333	ENSG00000231365.4	RP11-418J17.1	-7.73	6.73e-14	2.46e-11	-0.33	-0.34	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118941315	chr1:119140396~119275973:+
THCA	cis	rs2276314	1	rs16967317	ENSG00000278986.1	RP11-723J4.3	-7.73	6.73e-14	2.46e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:35993437	chr18:35972151~35973916:+
THCA	cis	rs116175783	0.557	rs3769963	ENSG00000227403.1	AC009299.3	7.73	6.74e-14	2.47e-11	0.61	0.34	Intelligence (multi-trait analysis);	chr2:161350999	chr2:161244739~161249050:+
THCA	cis	rs11096990	0.613	rs12643415	ENSG00000249685.1	RP11-360F5.3	-7.73	6.75e-14	2.47e-11	-0.41	-0.34	Cognitive function;	chr4:39270375	chr4:39133913~39135608:+
THCA	cis	rs1949733	0.701	rs1880024	ENSG00000205959.3	RP11-689P11.2	-7.73	6.78e-14	2.48e-11	-0.28	-0.34	Response to antineoplastic agents;	chr4:8452912	chr4:8482270~8512610:+
THCA	cis	rs8114671	0.562	rs6058137	ENSG00000269202.1	RP4-614O4.12	-7.73	6.78e-14	2.48e-11	-0.29	-0.34	Height;	chr20:34887271	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.562	rs8116657	ENSG00000269202.1	RP4-614O4.12	-7.73	6.78e-14	2.48e-11	-0.29	-0.34	Height;	chr20:34888671	chr20:35201747~35203288:-
THCA	cis	rs12928939	0.815	rs12446005	ENSG00000260886.1	TAT-AS1	7.73	6.79e-14	2.48e-11	0.43	0.34	Post bronchodilator FEV1;	chr16:71621132	chr16:71565789~71578187:+
THCA	cis	rs193541	0.632	rs7729834	ENSG00000263432.2	RN7SL689P	7.73	6.79e-14	2.48e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122786464	chr5:123022487~123022783:-
THCA	cis	rs1858037	0.867	rs4671658	ENSG00000237979.1	AC007389.1	-7.73	6.81e-14	2.49e-11	-0.42	-0.34	Rheumatoid arthritis;	chr2:65334258	chr2:65500993~65502138:-
THCA	cis	rs17772222	1	rs17772288	ENSG00000258983.2	RP11-507K2.2	7.72	6.82e-14	2.49e-11	0.43	0.34	Coronary artery calcification;	chr14:88361022	chr14:88499334~88515502:+
THCA	cis	rs77204473	0.744	rs12417098	ENSG00000254851.1	RP11-109L13.1	7.72	6.82e-14	2.5e-11	0.89	0.34	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117134137	chr11:117135528~117138582:+
THCA	cis	rs12908161	1	rs35960805	ENSG00000259728.4	LINC00933	7.72	6.83e-14	2.5e-11	0.45	0.34	Schizophrenia;	chr15:84800749	chr15:84570649~84580175:+
THCA	cis	rs12908161	1	rs12912388	ENSG00000259728.4	LINC00933	7.72	6.83e-14	2.5e-11	0.45	0.34	Schizophrenia;	chr15:84801319	chr15:84570649~84580175:+
THCA	cis	rs13068223	0.663	rs12107178	ENSG00000243926.1	TIPARP-AS1	7.72	6.83e-14	2.5e-11	0.34	0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156756735	chr3:156671862~156674378:-
THCA	cis	rs2274273	1	rs10140857	ENSG00000258413.1	RP11-665C16.6	-7.72	6.83e-14	2.5e-11	-0.45	-0.34	Protein biomarker;	chr14:55152893	chr14:55262767~55272075:-
THCA	cis	rs2274273	1	rs74617736	ENSG00000258413.1	RP11-665C16.6	-7.72	6.83e-14	2.5e-11	-0.45	-0.34	Protein biomarker;	chr14:55154201	chr14:55262767~55272075:-
THCA	cis	rs11148252	0.538	rs2296349	ENSG00000235660.1	LINC00345	-7.72	6.84e-14	2.5e-11	-0.41	-0.34	Lewy body disease;	chr13:52135922	chr13:52484161~52484680:-
THCA	cis	rs9543976	0.623	rs7317250	ENSG00000261553.4	RP11-29G8.3	7.72	6.86e-14	2.51e-11	0.4	0.34	Diabetic retinopathy;	chr13:75593005	chr13:75549773~75807120:+
THCA	cis	rs947583	0.588	rs6925090	ENSG00000231028.7	LINC00271	-7.72	6.88e-14	2.51e-11	-0.26	-0.34	Phosphorus levels;	chr6:135795339	chr6:135497801~135716055:+
THCA	cis	rs7942368	1	rs1440977	ENSG00000254761.1	RP11-672A2.1	7.72	6.89e-14	2.52e-11	0.47	0.34	Endometriosis;	chr11:76765385	chr11:76712396~76719608:-
THCA	cis	rs9388451	0.839	rs3757217	ENSG00000237742.5	RP11-624M8.1	-7.72	6.89e-14	2.52e-11	-0.29	-0.34	Brugada syndrome;	chr6:125748490	chr6:125578558~125749190:-
THCA	cis	rs1150668	0.799	rs853684	ENSG00000219392.1	RP1-265C24.5	-7.72	6.91e-14	2.53e-11	-0.37	-0.34	Pubertal anthropometrics;	chr6:28326773	chr6:28115628~28116551:+
THCA	cis	rs4072705	0.967	rs4076333	ENSG00000224020.1	MIR181A2HG	-7.72	6.91e-14	2.53e-11	-0.3	-0.34	Menarche (age at onset);	chr9:124623330	chr9:124658467~124698631:+
THCA	cis	rs710216	0.595	rs4660697	ENSG00000227533.4	SLC2A1-AS1	-7.72	6.91e-14	2.53e-11	-0.48	-0.34	Red cell distribution width;	chr1:42992579	chr1:42959049~42983358:+
THCA	cis	rs11971779	0.941	rs7802779	ENSG00000273391.1	RP11-634H22.1	7.72	6.91e-14	2.53e-11	0.34	0.34	Diisocyanate-induced asthma;	chr7:139437833	chr7:139359032~139359566:-
THCA	cis	rs198389	0.589	rs12404124	ENSG00000242349.4	NPPA-AS1	-7.72	6.94e-14	2.54e-11	-0.31	-0.34	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11813812	chr1:11841017~11848079:+
THCA	cis	rs2880765	0.835	rs7180923	ENSG00000259295.5	CSPG4P12	7.72	6.98e-14	2.55e-11	0.43	0.34	Coronary artery disease;	chr15:85507659	chr15:85191438~85213905:+
THCA	cis	rs9543976	0.623	rs8192764	ENSG00000261553.4	RP11-29G8.3	7.72	6.99e-14	2.56e-11	0.41	0.34	Diabetic retinopathy;	chr13:75605079	chr13:75549773~75807120:+
THCA	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-7.72	6.99e-14	2.56e-11	-0.51	-0.34	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
THCA	cis	rs9902453	0.967	rs8067576	ENSG00000264007.1	RP11-68I3.10	7.72	7e-14	2.56e-11	0.38	0.34	Coffee consumption (cups per day);	chr17:30117236	chr17:29621617~29622254:-
THCA	cis	rs9388451	0.839	rs1811852	ENSG00000237742.5	RP11-624M8.1	-7.72	7.02e-14	2.56e-11	-0.29	-0.34	Brugada syndrome;	chr6:125750429	chr6:125578558~125749190:-
THCA	cis	rs910316	0.737	rs175424	ENSG00000279594.1	RP11-950C14.10	-7.72	7.03e-14	2.57e-11	-0.31	-0.34	Height;	chr14:75159554	chr14:75011269~75012851:-
THCA	cis	rs910316	0.763	rs2080201	ENSG00000279594.1	RP11-950C14.10	-7.72	7.03e-14	2.57e-11	-0.31	-0.34	Height;	chr14:75163269	chr14:75011269~75012851:-
THCA	cis	rs2839186	0.814	rs12482209	ENSG00000239415.1	AP001469.9	-7.72	7.03e-14	2.57e-11	-0.35	-0.34	Testicular germ cell tumor;	chr21:46244361	chr21:46251549~46254133:-
THCA	cis	rs9341808	0.739	rs4706831	ENSG00000272129.1	RP11-250B2.6	7.72	7.05e-14	2.58e-11	0.42	0.34	Sitting height ratio;	chr6:80297982	chr6:80355424~80356859:+
THCA	cis	rs9326248	0.953	rs634960	ENSG00000280143.1	AP000892.6	-7.72	7.05e-14	2.58e-11	-0.42	-0.34	Blood protein levels;	chr11:117202247	chr11:117204967~117210292:+
THCA	cis	rs2276314	0.857	rs9304155	ENSG00000278986.1	RP11-723J4.3	-7.72	7.05e-14	2.58e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36005747	chr18:35972151~35973916:+
THCA	cis	rs9902453	0.845	rs3102558	ENSG00000264007.1	RP11-68I3.10	7.72	7.06e-14	2.58e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29696124	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs2321331	ENSG00000264007.1	RP11-68I3.10	7.72	7.06e-14	2.58e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29698510	chr17:29621617~29622254:-
THCA	cis	rs11214589	0.935	rs2186800	ENSG00000270179.1	RP11-159N11.4	-7.72	7.07e-14	2.58e-11	-0.35	-0.34	Neuroticism;	chr11:113372138	chr11:113368478~113369117:+
THCA	cis	rs453301	0.522	rs2929309	ENSG00000253893.2	FAM85B	7.72	7.07e-14	2.58e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9226261	chr8:8167819~8226614:-
THCA	cis	rs10208649	0.908	rs11904365	ENSG00000272156.1	RP11-477N3.1	-7.72	7.08e-14	2.59e-11	-0.61	-0.34	Body mass index;	chr2:53998444	chr2:54082554~54085066:+
THCA	cis	rs9813712	0.597	rs62281648	ENSG00000228252.7	COL6A4P2	-7.72	7.1e-14	2.59e-11	-0.33	-0.34	Response to amphetamines;	chr3:130244794	chr3:130212823~130273806:+
THCA	cis	rs453301	0.522	rs2929455	ENSG00000253893.2	FAM85B	7.72	7.1e-14	2.59e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9225923	chr8:8167819~8226614:-
THCA	cis	rs1150668	0.799	rs9301	ENSG00000219392.1	RP1-265C24.5	-7.72	7.1e-14	2.59e-11	-0.37	-0.34	Pubertal anthropometrics;	chr6:28324929	chr6:28115628~28116551:+
THCA	cis	rs13068223	0.74	rs343999	ENSG00000243926.1	TIPARP-AS1	-7.72	7.12e-14	2.6e-11	-0.32	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr3:156734050	chr3:156671862~156674378:-
THCA	cis	rs7727544	0.606	rs72795121	ENSG00000224431.1	AC063976.7	7.72	7.13e-14	2.6e-11	0.3	0.34	Blood metabolite levels;	chr5:132302631	chr5:132199456~132203487:+
THCA	cis	rs5769707	0.605	rs9616702	ENSG00000235111.1	RP1-29C18.8	-7.72	7.13e-14	2.61e-11	-0.44	-0.34	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49612657~49615716:-
THCA	cis	rs950169	0.579	rs12913054	ENSG00000225151.9	GOLGA2P7	-7.72	7.15e-14	2.61e-11	-0.52	-0.34	Schizophrenia;	chr15:83995704	chr15:84199311~84230136:-
THCA	cis	rs193541	0.593	rs30042	ENSG00000263432.2	RN7SL689P	7.72	7.15e-14	2.61e-11	0.4	0.34	Glucose homeostasis traits;	chr5:122936946	chr5:123022487~123022783:-
THCA	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	7.72	7.15e-14	2.61e-11	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	7.72	7.15e-14	2.61e-11	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	7.72	7.15e-14	2.61e-11	0.39	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
THCA	cis	rs2288884	0.676	rs58197197	ENSG00000275055.1	CTC-471J1.11	-7.72	7.16e-14	2.61e-11	-0.34	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52000405	chr19:52049007~52049754:+
THCA	cis	rs9326248	0.652	rs7128382	ENSG00000280143.1	AP000892.6	7.72	7.16e-14	2.62e-11	0.48	0.34	Blood protein levels;	chr11:117152771	chr11:117204967~117210292:+
THCA	cis	rs42490	0.557	rs426240	ENSG00000251136.7	RP11-37B2.1	-7.72	7.17e-14	2.62e-11	-0.29	-0.34	Leprosy;	chr8:89834573	chr8:89609409~89757727:-
THCA	cis	rs9902453	0.934	rs4427857	ENSG00000264007.1	RP11-68I3.10	7.72	7.17e-14	2.62e-11	0.37	0.34	Coffee consumption (cups per day);	chr17:30130971	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.868	rs9896012	ENSG00000264007.1	RP11-68I3.10	7.72	7.17e-14	2.62e-11	0.37	0.34	Coffee consumption (cups per day);	chr17:30143073	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.868	rs9890075	ENSG00000264007.1	RP11-68I3.10	7.72	7.17e-14	2.62e-11	0.37	0.34	Coffee consumption (cups per day);	chr17:30143446	chr17:29621617~29622254:-
THCA	cis	rs4780355	0.843	rs243325	ENSG00000262636.1	CTD-3088G3.4	7.72	7.17e-14	2.62e-11	0.44	0.34	Crohn's disease and psoriasis;	chr16:11260640	chr16:11380859~11381118:-
THCA	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-7.72	7.19e-14	2.62e-11	-0.36	-0.34	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
THCA	cis	rs4820539	1	rs3827316	ENSG00000221069.1	AC000029.1	-7.72	7.19e-14	2.63e-11	-0.4	-0.34	Bone mineral density;	chr22:23126351	chr22:23136620~23136710:+
THCA	cis	rs7714584	1	rs1428552	ENSG00000197083.10	ZNF300P1	7.72	7.2e-14	2.63e-11	0.54	0.34	Crohn's disease;	chr5:150880269	chr5:150930645~150946289:-
THCA	cis	rs1667284	0.935	rs1791171	ENSG00000266521.1	RP11-650P15.1	7.72	7.22e-14	2.64e-11	0.42	0.34	Problematic alcohol use in trauma-exposed individuals;	chr18:31636194	chr18:31496645~31497195:-
THCA	cis	rs7714584	1	rs7736554	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150878746	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7736873	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150878920	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7716903	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150879012	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11167518	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150879358	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10463310	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150881343	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs73284126	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150881745	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7732945	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150882039	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs1820682	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150882580	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11746108	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150885060	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11739619	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150885100	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11167519	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150885845	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11167520	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150886077	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs73284141	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150886524	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs3906527	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150886830	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs2345001	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150886956	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs3906528	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150887156	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs2880791	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150887814	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs3857422	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150889047	chr5:150930645~150946289:-
THCA	cis	rs7714584	0.59	rs4352593	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150889770	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7709464	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150889879	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10053750	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150890489	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7714584	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150890858	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs6579806	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150891522	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs4958848	ENSG00000197083.10	ZNF300P1	7.72	7.23e-14	2.64e-11	0.54	0.34	Crohn's disease;	chr5:150891560	chr5:150930645~150946289:-
THCA	cis	rs922182	0.557	rs8039736	ENSG00000275785.1	RP11-111E14.2	7.72	7.26e-14	2.65e-11	0.41	0.34	Blood protein levels;	chr15:63896052	chr15:63890030~63890317:+
THCA	cis	rs7247513	0.866	rs2861405	ENSG00000230310.1	CTD-2192J16.11	-7.72	7.29e-14	2.66e-11	-0.4	-0.34	Bipolar disorder;	chr19:12611518	chr19:12552597~12553644:+
THCA	cis	rs2276314	0.857	rs59649576	ENSG00000278986.1	RP11-723J4.3	-7.72	7.3e-14	2.66e-11	-0.38	-0.34	Endometriosis;Drug-induced torsades de pointes;	chr18:36036112	chr18:35972151~35973916:+
THCA	cis	rs17684571	0.872	rs34824960	ENSG00000231441.1	RP11-472M19.2	7.71	7.31e-14	2.67e-11	0.42	0.34	Schizophrenia;	chr6:56722732	chr6:56844002~56864078:+
THCA	cis	rs2253762	0.507	rs12264894	ENSG00000276742.1	RP11-500G22.4	7.71	7.34e-14	2.68e-11	0.49	0.34	Breast cancer;	chr10:121992087	chr10:121956782~121957098:+
THCA	cis	rs3847687	1	rs3847688	ENSG00000279128.1	RP11-76C10.4	7.71	7.35e-14	2.68e-11	0.38	0.34	Longevity;	chr12:131040765	chr12:131022769~131024741:-
THCA	cis	rs75422866	0.764	rs67408202	ENSG00000257433.4	RP1-197B17.3	7.71	7.35e-14	2.68e-11	0.51	0.34	Pneumonia;	chr12:47713564	chr12:47706085~47742294:+
THCA	cis	rs17772222	0.565	rs845759	ENSG00000258789.1	RP11-507K2.3	7.71	7.36e-14	2.68e-11	0.32	0.34	Coronary artery calcification;	chr14:88415538	chr14:88551597~88552493:+
THCA	cis	rs12681366	0.881	rs2960121	ENSG00000253704.1	RP11-267M23.4	7.71	7.36e-14	2.68e-11	0.36	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94417678	chr8:94553722~94569745:+
THCA	cis	rs747687	0.655	rs9674522	ENSG00000262133.1	RP11-676J12.6	-7.71	7.37e-14	2.69e-11	-0.56	-0.34	Blood pressure;	chr17:864995	chr17:877902~880093:+
THCA	cis	rs17772222	0.651	rs12586714	ENSG00000258789.1	RP11-507K2.3	-7.71	7.37e-14	2.69e-11	-0.31	-0.34	Coronary artery calcification;	chr14:88360497	chr14:88551597~88552493:+
THCA	cis	rs10853057	0.717	rs11079553	ENSG00000214174.7	AMZ2P1	-7.71	7.37e-14	2.69e-11	-0.54	-0.34	White matter microstructure (global fractional anisotropy);	chr17:65061877	chr17:64966550~64975576:-
THCA	cis	rs7727544	0.581	rs10075801	ENSG00000233006.5	AC034220.3	7.71	7.38e-14	2.69e-11	0.26	0.34	Blood metabolite levels;	chr5:132341949	chr5:132311285~132369916:-
THCA	cis	rs8113308	0.81	rs11879040	ENSG00000269235.1	ZNF350-AS1	7.71	7.39e-14	2.69e-11	0.51	0.34	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51946856	chr19:51949134~51981367:+
THCA	cis	rs9902453	0.845	rs2617865	ENSG00000264007.1	RP11-68I3.10	-7.71	7.39e-14	2.69e-11	-0.39	-0.34	Coffee consumption (cups per day);	chr17:29722786	chr17:29621617~29622254:-
THCA	cis	rs11018904	0.636	rs61903695	ENSG00000280385.1	AP000648.5	-7.71	7.4e-14	2.7e-11	-0.39	-0.34	Intelligence (multi-trait analysis);	chr11:90189249	chr11:90193614~90198120:+
THCA	cis	rs75422866	0.867	rs57848393	ENSG00000257433.4	RP1-197B17.3	7.71	7.41e-14	2.7e-11	0.51	0.34	Pneumonia;	chr12:47714734	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.764	rs67201012	ENSG00000257433.4	RP1-197B17.3	7.71	7.41e-14	2.7e-11	0.51	0.34	Pneumonia;	chr12:47715881	chr12:47706085~47742294:+
THCA	cis	rs860295	0.719	rs490608	ENSG00000225855.5	RUSC1-AS1	7.71	7.43e-14	2.71e-11	0.22	0.34	Body mass index;	chr1:155713079	chr1:155316863~155324176:-
THCA	cis	rs11148252	0.532	rs9536262	ENSG00000235660.1	LINC00345	7.71	7.43e-14	2.71e-11	0.43	0.34	Lewy body disease;	chr13:52728939	chr13:52484161~52484680:-
THCA	cis	rs8114671	0.836	rs6058154	ENSG00000269202.1	RP4-614O4.12	7.71	7.45e-14	2.71e-11	0.28	0.34	Height;	chr20:34998031	chr20:35201747~35203288:-
THCA	cis	rs9902453	0.845	rs3115101	ENSG00000264007.1	RP11-68I3.10	7.71	7.49e-14	2.73e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29714609	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs3102556	ENSG00000264007.1	RP11-68I3.10	7.71	7.49e-14	2.73e-11	0.39	0.34	Coffee consumption (cups per day);	chr17:29715524	chr17:29621617~29622254:-
THCA	cis	rs453301	0.606	rs6601279	ENSG00000253893.2	FAM85B	7.71	7.5e-14	2.73e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9050721	chr8:8167819~8226614:-
THCA	cis	rs453301	0.606	rs6981060	ENSG00000253893.2	FAM85B	7.71	7.5e-14	2.73e-11	0.42	0.34	Joint mobility (Beighton score);	chr8:9050725	chr8:8167819~8226614:-
THCA	cis	rs9902453	0.967	rs4493117	ENSG00000264007.1	RP11-68I3.10	7.71	7.51e-14	2.73e-11	0.37	0.34	Coffee consumption (cups per day);	chr17:30162752	chr17:29621617~29622254:-
THCA	cis	rs9341808	0.556	rs1535075	ENSG00000272129.1	RP11-250B2.6	7.71	7.51e-14	2.73e-11	0.42	0.34	Sitting height ratio;	chr6:80325089	chr6:80355424~80356859:+
THCA	cis	rs2288884	0.505	rs75919042	ENSG00000275055.1	CTC-471J1.11	-7.71	7.53e-14	2.74e-11	-0.36	-0.34	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51973246	chr19:52049007~52049754:+
THCA	cis	rs66887589	0.87	rs2389875	ENSG00000245958.5	RP11-33B1.1	7.71	7.53e-14	2.74e-11	0.3	0.34	Diastolic blood pressure;	chr4:119635859	chr4:119454791~119552025:+
THCA	cis	rs10208649	0.908	rs11889527	ENSG00000272156.1	RP11-477N3.1	7.71	7.58e-14	2.76e-11	0.62	0.34	Body mass index;	chr2:53999178	chr2:54082554~54085066:+
THCA	cis	rs6700559	0.595	rs11581339	ENSG00000260088.1	RP11-92G12.3	7.71	7.59e-14	2.76e-11	0.43	0.34	Coronary artery disease;	chr1:200686105	chr1:200669507~200694250:+
THCA	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	7.71	7.59e-14	2.76e-11	0.46	0.34	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
THCA	cis	rs4820539	1	rs2157710	ENSG00000221069.1	AC000029.1	-7.71	7.61e-14	2.77e-11	-0.4	-0.34	Bone mineral density;	chr22:23115299	chr22:23136620~23136710:+
THCA	cis	rs1167827	0.68	rs1167796	ENSG00000127957.15	PMS2P3	7.71	7.61e-14	2.77e-11	0.29	0.34	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75502930~75528148:-
THCA	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	7.71	7.61e-14	2.77e-11	0.3	0.34	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
THCA	cis	rs10411161	0.81	rs72626248	ENSG00000269483.1	AC006272.1	7.71	7.62e-14	2.77e-11	0.55	0.34	Breast cancer;	chr19:51853993	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.63	rs7252101	ENSG00000269483.1	AC006272.1	7.71	7.62e-14	2.77e-11	0.55	0.34	Breast cancer;	chr19:51856119	chr19:51839924~51843324:-
THCA	cis	rs2839186	0.709	rs2839176	ENSG00000239415.1	AP001469.9	7.71	7.63e-14	2.78e-11	0.34	0.34	Testicular germ cell tumor;	chr21:46258259	chr21:46251549~46254133:-
THCA	cis	rs2739330	0.587	rs4820571	ENSG00000224205.1	AP000351.4	7.71	7.66e-14	2.79e-11	0.39	0.34	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23987320~23991421:-
THCA	cis	rs934734	0.563	rs1858037	ENSG00000281920.1	RP11-418H16.1	7.71	7.66e-14	2.79e-11	0.44	0.34	Rheumatoid arthritis;	chr2:65371166	chr2:65623272~65628424:+
THCA	cis	rs9902453	0.933	rs7221154	ENSG00000264007.1	RP11-68I3.10	-7.71	7.67e-14	2.79e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:30178006	chr17:29621617~29622254:-
THCA	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	7.71	7.68e-14	2.79e-11	0.39	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
THCA	cis	rs9902453	0.791	rs3115086	ENSG00000264007.1	RP11-68I3.10	7.71	7.69e-14	2.8e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:29698931	chr17:29621617~29622254:-
THCA	cis	rs910316	0.763	rs175490	ENSG00000279594.1	RP11-950C14.10	7.71	7.7e-14	2.8e-11	0.31	0.33	Height;	chr14:75078982	chr14:75011269~75012851:-
THCA	cis	rs910316	0.737	rs175048	ENSG00000279594.1	RP11-950C14.10	-7.71	7.7e-14	2.8e-11	-0.31	-0.33	Height;	chr14:75013191	chr14:75011269~75012851:-
THCA	cis	rs2274273	0.686	rs66842809	ENSG00000258413.1	RP11-665C16.6	-7.71	7.71e-14	2.8e-11	-0.47	-0.33	Protein biomarker;	chr14:55163853	chr14:55262767~55272075:-
THCA	cis	rs7942368	1	rs7933092	ENSG00000254632.1	RP11-21L23.4	7.71	7.72e-14	2.81e-11	0.48	0.33	Endometriosis;	chr11:76764444	chr11:76759916~76768223:-
THCA	cis	rs7615952	0.599	rs7652883	ENSG00000171084.14	FAM86JP	7.71	7.72e-14	2.81e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125989134	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.599	rs6803160	ENSG00000171084.14	FAM86JP	7.71	7.72e-14	2.81e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125990711	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.688	rs12485622	ENSG00000171084.14	FAM86JP	7.71	7.72e-14	2.81e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125991896	chr3:125916620~125930024:+
THCA	cis	rs5760092	0.755	rs4585126	ENSG00000224205.1	AP000351.4	-7.71	7.73e-14	2.81e-11	-0.44	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23987320~23991421:-
THCA	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-7.71	7.75e-14	2.82e-11	-0.36	-0.33	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-7.71	7.75e-14	2.82e-11	-0.36	-0.33	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
THCA	cis	rs914615	0.552	rs11264339	ENSG00000160766.13	GBAP1	7.71	7.76e-14	2.82e-11	0.36	0.33	Urinary albumin-to-creatinine ratio;	chr1:155168172	chr1:155213821~155227422:-
THCA	cis	rs4664293	0.51	rs72961751	ENSG00000226266.5	AC009961.3	7.71	7.78e-14	2.83e-11	0.39	0.33	Monocyte percentage of white cells;	chr2:159738067	chr2:159670708~159712435:-
THCA	cis	rs11673344	0.562	rs6510580	ENSG00000226686.6	LINC01535	7.71	7.79e-14	2.83e-11	0.37	0.33	Obesity-related traits;	chr19:37038452	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs2082009	ENSG00000226686.6	LINC01535	7.71	7.79e-14	2.83e-11	0.37	0.33	Obesity-related traits;	chr19:37039834	chr19:37251912~37265535:+
THCA	cis	rs10208649	0.831	rs76039968	ENSG00000272156.1	RP11-477N3.1	7.71	7.79e-14	2.83e-11	0.7	0.33	Body mass index;	chr2:53694900	chr2:54082554~54085066:+
THCA	cis	rs1850744	0.536	rs2037313	ENSG00000250942.1	ENPP7P11	7.71	7.81e-14	2.84e-11	0.43	0.33	Economic and political preferences;	chr4:9723087	chr4:9677308~9677934:+
THCA	cis	rs10208649	1	rs75213010	ENSG00000272156.1	RP11-477N3.1	7.71	7.81e-14	2.84e-11	0.71	0.33	Body mass index;	chr2:53709320	chr2:54082554~54085066:+
THCA	cis	rs11673344	0.523	rs2082010	ENSG00000226686.6	LINC01535	7.7	7.83e-14	2.85e-11	0.37	0.33	Obesity-related traits;	chr19:37039874	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.563	rs55825113	ENSG00000226686.6	LINC01535	7.7	7.84e-14	2.85e-11	0.37	0.33	Obesity-related traits;	chr19:37191523	chr19:37251912~37265535:+
THCA	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	7.7	7.85e-14	2.85e-11	0.43	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
THCA	cis	rs8100891	1	rs8100891	ENSG00000267213.4	AC007773.2	-7.7	7.86e-14	2.86e-11	-0.32	-0.33	Neuroticism;	chr19:32338607	chr19:32390050~32405560:-
THCA	cis	rs9309473	1	rs13384952	ENSG00000163016.8	ALMS1P	-7.7	7.89e-14	2.87e-11	-0.67	-0.33	Metabolite levels;	chr2:73496832	chr2:73644919~73685576:+
THCA	cis	rs2243480	1	rs1618893	ENSG00000226824.5	RP4-756H11.3	-7.7	7.9e-14	2.87e-11	-0.63	-0.33	Diabetic kidney disease;	chr7:66631132	chr7:66654538~66669855:+
THCA	cis	rs1949733	0.666	rs3103070	ENSG00000205959.3	RP11-689P11.2	7.7	7.9e-14	2.87e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8507098	chr4:8482270~8512610:+
THCA	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	7.7	7.91e-14	2.87e-11	0.38	0.33	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
THCA	cis	rs193541	0.632	rs6595413	ENSG00000263432.2	RN7SL689P	7.7	7.91e-14	2.87e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122821254	chr5:123022487~123022783:-
THCA	cis	rs2442825	0.693	rs2596913	ENSG00000206573.7	THUMPD3-AS1	7.7	7.91e-14	2.88e-11	0.2	0.33	Cerebrospinal fluid clusterin levels;	chr3:9394788	chr3:9349689~9398579:-
THCA	cis	rs66823261	0.741	rs7841786	ENSG00000223508.5	RPL23AP53	7.7	7.97e-14	2.9e-11	0.42	0.33	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:241746	chr8:213186~232231:-
THCA	cis	rs7191700	0.511	rs12923756	ENSG00000262703.1	RP11-485G7.6	-7.7	7.98e-14	2.9e-11	-0.37	-0.33	Multiple sclerosis;	chr16:11265818	chr16:11348143~11349321:-
THCA	cis	rs5760092	0.755	rs915589	ENSG00000228039.3	KB-1125A3.10	-7.7	7.98e-14	2.9e-11	-0.49	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23963780~23964374:+
THCA	cis	rs9400467	0.528	rs456865	ENSG00000230177.1	RP5-1112D6.4	-7.7	7.99e-14	2.9e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111311725	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.508	rs1676863	ENSG00000230177.1	RP5-1112D6.4	-7.7	7.99e-14	2.9e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111320387	chr6:111277932~111278742:+
THCA	cis	rs10208649	1	rs10188834	ENSG00000272156.1	RP11-477N3.1	7.7	8.02e-14	2.92e-11	0.62	0.33	Body mass index;	chr2:53937236	chr2:54082554~54085066:+
THCA	cis	rs832187	0.665	rs7627690	ENSG00000280620.1	SCAANT1	7.7	8.03e-14	2.92e-11	0.45	0.33	Schizophrenia;	chr3:63914801	chr3:63911518~63911772:-
THCA	cis	rs172166	0.516	rs2791333	ENSG00000219392.1	RP1-265C24.5	-7.7	8.03e-14	2.92e-11	-0.37	-0.33	Cardiac Troponin-T levels;	chr6:28143336	chr6:28115628~28116551:+
THCA	cis	rs198389	0.589	rs535107	ENSG00000242349.4	NPPA-AS1	7.7	8.04e-14	2.92e-11	0.31	0.33	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11829411	chr1:11841017~11848079:+
THCA	cis	rs10971721	0.822	rs56160720	ENSG00000260947.1	RP11-384P7.7	7.7	8.07e-14	2.93e-11	0.82	0.33	Body mass index;	chr9:33899827	chr9:33697459~33700986:+
THCA	cis	rs2880765	0.835	rs7178991	ENSG00000259295.5	CSPG4P12	7.7	8.08e-14	2.94e-11	0.42	0.33	Coronary artery disease;	chr15:85507713	chr15:85191438~85213905:+
THCA	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-7.7	8.09e-14	2.94e-11	-0.51	-0.33	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
THCA	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-7.7	8.09e-14	2.94e-11	-0.51	-0.33	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
THCA	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-7.7	8.09e-14	2.94e-11	-0.51	-0.33	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
THCA	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-7.7	8.09e-14	2.94e-11	-0.51	-0.33	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
THCA	cis	rs1043099	0.571	rs5753111	ENSG00000279699.1	RP1-102K2.9	-7.7	8.11e-14	2.94e-11	-0.42	-0.33	Rheumatoid arthritis;	chr22:30383222	chr22:30275215~30276951:-
THCA	cis	rs4664293	0.51	rs2042781	ENSG00000226266.5	AC009961.3	7.7	8.12e-14	2.95e-11	0.4	0.33	Monocyte percentage of white cells;	chr2:159789899	chr2:159670708~159712435:-
THCA	cis	rs4950322	0.57	rs4950315	ENSG00000237188.3	RP11-337C18.8	-7.7	8.12e-14	2.95e-11	-0.42	-0.33	Protein quantitative trait loci;	chr1:147264433	chr1:147172771~147211568:+
THCA	cis	rs10411161	0.671	rs10412377	ENSG00000269483.1	AC006272.1	-7.7	8.12e-14	2.95e-11	-0.43	-0.33	Breast cancer;	chr19:51847419	chr19:51839924~51843324:-
THCA	cis	rs9487094	0.813	rs13203252	ENSG00000260273.1	RP11-425D10.10	7.7	8.13e-14	2.95e-11	0.43	0.33	Height;	chr6:109351533	chr6:109382795~109383666:+
THCA	cis	rs7942368	0.818	rs10793194	ENSG00000254761.1	RP11-672A2.1	7.7	8.14e-14	2.96e-11	0.47	0.33	Endometriosis;	chr11:76764685	chr11:76712396~76719608:-
THCA	cis	rs66887589	0.776	rs10518337	ENSG00000245958.5	RP11-33B1.1	7.7	8.15e-14	2.96e-11	0.29	0.33	Diastolic blood pressure;	chr4:119653719	chr4:119454791~119552025:+
THCA	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-7.7	8.16e-14	2.96e-11	-0.36	-0.33	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
THCA	cis	rs193541	0.593	rs246309	ENSG00000263432.2	RN7SL689P	7.7	8.17e-14	2.97e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122934024	chr5:123022487~123022783:-
THCA	cis	rs7727544	0.606	rs17622208	ENSG00000224431.1	AC063976.7	7.7	8.18e-14	2.97e-11	0.29	0.33	Blood metabolite levels;	chr5:132381358	chr5:132199456~132203487:+
THCA	cis	rs17772222	1	rs3814855	ENSG00000258983.2	RP11-507K2.2	7.7	8.18e-14	2.97e-11	0.43	0.33	Coronary artery calcification;	chr14:88467016	chr14:88499334~88515502:+
THCA	cis	rs6496932	0.503	rs4842882	ENSG00000218052.5	ADAMTS7P4	-7.7	8.2e-14	2.98e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85440952	chr15:85255369~85330334:-
THCA	cis	rs6496932	0.503	rs7176605	ENSG00000218052.5	ADAMTS7P4	-7.7	8.2e-14	2.98e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85443491	chr15:85255369~85330334:-
THCA	cis	rs8081395	0.729	rs12453125	ENSG00000266992.1	DHX40P1	-7.7	8.2e-14	2.98e-11	-0.39	-0.33	White blood cell count;	chr17:59968715	chr17:59976009~60002384:-
THCA	cis	rs2288884	0.505	rs12459170	ENSG00000275055.1	CTC-471J1.11	-7.7	8.23e-14	2.99e-11	-0.36	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51955005	chr19:52049007~52049754:+
THCA	cis	rs17684571	0.751	rs6934714	ENSG00000231441.1	RP11-472M19.2	7.7	8.23e-14	2.99e-11	0.41	0.33	Schizophrenia;	chr6:56821811	chr6:56844002~56864078:+
THCA	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-7.7	8.25e-14	2.99e-11	-0.22	-0.33	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
THCA	cis	rs9400467	0.528	rs6933627	ENSG00000230177.1	RP5-1112D6.4	-7.7	8.26e-14	3e-11	-0.27	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111279606	chr6:111277932~111278742:+
THCA	cis	rs801193	0.66	rs2659914	ENSG00000232559.3	GS1-124K5.12	7.7	8.29e-14	3.01e-11	0.31	0.33	Aortic root size;	chr7:66691927	chr7:66554588~66576923:-
THCA	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	7.7	8.29e-14	3.01e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
THCA	cis	rs9902453	0.765	rs9890747	ENSG00000264007.1	RP11-68I3.10	7.7	8.29e-14	3.01e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:29680424	chr17:29621617~29622254:-
THCA	cis	rs9543976	0.623	rs9543990	ENSG00000261553.4	RP11-29G8.3	7.7	8.33e-14	3.02e-11	0.4	0.33	Diabetic retinopathy;	chr13:75598298	chr13:75549773~75807120:+
THCA	cis	rs10971721	1	rs10971721	ENSG00000260947.1	RP11-384P7.7	7.7	8.33e-14	3.02e-11	0.8	0.33	Body mass index;	chr9:33827696	chr9:33697459~33700986:+
THCA	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-7.7	8.35e-14	3.03e-11	-0.42	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
THCA	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-7.7	8.35e-14	3.03e-11	-0.42	-0.33	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
THCA	cis	rs11673344	0.542	rs826327	ENSG00000226686.6	LINC01535	7.7	8.36e-14	3.03e-11	0.37	0.33	Obesity-related traits;	chr19:37004397	chr19:37251912~37265535:+
THCA	cis	rs9902453	0.935	rs4310926	ENSG00000264007.1	RP11-68I3.10	7.7	8.38e-14	3.04e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30106257	chr17:29621617~29622254:-
THCA	cis	rs2466254	0.657	rs2460351	ENSG00000251468.2	RP11-369K16.1	7.7	8.38e-14	3.04e-11	0.54	0.33	Pneumonia;	chr8:12968785	chr8:12958387~12962200:+
THCA	cis	rs17772222	1	rs74071851	ENSG00000258983.2	RP11-507K2.2	7.7	8.39e-14	3.04e-11	0.43	0.33	Coronary artery calcification;	chr14:88415858	chr14:88499334~88515502:+
THCA	cis	rs910316	0.789	rs175457	ENSG00000279594.1	RP11-950C14.10	-7.69	8.41e-14	3.05e-11	-0.31	-0.33	Height;	chr14:75117804	chr14:75011269~75012851:-
THCA	cis	rs368187	0.71	rs2780303	ENSG00000257826.1	RP11-116N8.4	7.69	8.41e-14	3.05e-11	0.36	0.33	Thyroid cancer;	chr14:36045580	chr14:36061026~36067190:-
THCA	cis	rs8114671	0.562	rs6058120	ENSG00000269202.1	RP4-614O4.12	-7.69	8.42e-14	3.05e-11	-0.28	-0.33	Height;	chr20:34815026	chr20:35201747~35203288:-
THCA	cis	rs180730	1	rs1450479	ENSG00000251609.2	SETP12	7.69	8.43e-14	3.06e-11	0.53	0.33	Fasting plasma glucose;	chr4:120916718	chr4:120895494~120897083:-
THCA	cis	rs12681366	0.839	rs3019282	ENSG00000253704.1	RP11-267M23.4	7.69	8.43e-14	3.06e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94439898	chr8:94553722~94569745:+
THCA	cis	rs9640161	0.789	rs13223702	ENSG00000261305.1	RP4-584D14.7	7.69	8.43e-14	3.06e-11	0.41	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150361879	chr7:150341771~150342607:+
THCA	cis	rs11971779	0.527	rs1076349	ENSG00000273391.1	RP11-634H22.1	7.69	8.44e-14	3.06e-11	0.31	0.33	Diisocyanate-induced asthma;	chr7:139441748	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.65	rs4732380	ENSG00000273391.1	RP11-634H22.1	7.69	8.44e-14	3.06e-11	0.31	0.33	Diisocyanate-induced asthma;	chr7:139442113	chr7:139359032~139359566:-
THCA	cis	rs11971779	0.715	rs6467853	ENSG00000273391.1	RP11-634H22.1	7.69	8.44e-14	3.06e-11	0.31	0.33	Diisocyanate-induced asthma;	chr7:139442281	chr7:139359032~139359566:-
THCA	cis	rs7942368	0.941	rs10160769	ENSG00000254761.1	RP11-672A2.1	7.69	8.44e-14	3.06e-11	0.47	0.33	Endometriosis;	chr11:76763783	chr11:76712396~76719608:-
THCA	cis	rs11651753	0.561	rs17616603	ENSG00000264920.1	RP11-6N17.4	-7.69	8.44e-14	3.06e-11	-0.3	-0.33	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);	chr17:47882254	chr17:47891255~47895812:-
THCA	cis	rs7208859	0.623	rs9914242	ENSG00000266490.1	CTD-2349P21.9	7.69	8.44e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30889227	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73277964	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11652409	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9896095	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs58920731	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73277984	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs73277986	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs12103588	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.614	rs9914534	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs4131618	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11658344	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs9900144	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.573	rs11656121	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs11650973	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs56085216	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30890216	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11650305	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902343	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs11654914	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30902406	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs9914271	ENSG00000266490.1	CTD-2349P21.9	7.69	8.45e-14	3.06e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30905607	chr17:30792372~30792833:+
THCA	cis	rs9543976	0.623	rs8192756	ENSG00000261553.4	RP11-29G8.3	7.69	8.47e-14	3.07e-11	0.4	0.33	Diabetic retinopathy;	chr13:75590802	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.623	rs3783028	ENSG00000261553.4	RP11-29G8.3	7.69	8.47e-14	3.07e-11	0.4	0.33	Diabetic retinopathy;	chr13:75591146	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.623	rs7139740	ENSG00000261553.4	RP11-29G8.3	7.69	8.47e-14	3.07e-11	0.4	0.33	Diabetic retinopathy;	chr13:75592806	chr13:75549773~75807120:+
THCA	cis	rs9400467	0.528	rs465796	ENSG00000230177.1	RP5-1112D6.4	-7.69	8.49e-14	3.08e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111298522	chr6:111277932~111278742:+
THCA	cis	rs2276314	0.857	rs56230698	ENSG00000278986.1	RP11-723J4.3	-7.69	8.49e-14	3.08e-11	-0.38	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36048922	chr18:35972151~35973916:+
THCA	cis	rs9902453	0.967	rs28792710	ENSG00000264007.1	RP11-68I3.10	7.69	8.5e-14	3.08e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30122997	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.933	rs8074028	ENSG00000264007.1	RP11-68I3.10	7.69	8.5e-14	3.08e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30134669	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.933	rs9908901	ENSG00000264007.1	RP11-68I3.10	7.69	8.5e-14	3.08e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30142695	chr17:29621617~29622254:-
THCA	cis	rs7942368	0.941	rs10160769	ENSG00000254632.1	RP11-21L23.4	7.69	8.51e-14	3.08e-11	0.48	0.33	Endometriosis;	chr11:76763783	chr11:76759916~76768223:-
THCA	cis	rs812925	0.537	rs778139	ENSG00000271889.1	RP11-493E12.1	-7.69	8.51e-14	3.09e-11	-0.32	-0.33	Immature fraction of reticulocytes;	chr2:61457429	chr2:61151433~61162105:-
THCA	cis	rs4845875	0.513	rs198397	ENSG00000242349.4	NPPA-AS1	-7.69	8.52e-14	3.09e-11	-0.31	-0.33	Midregional pro atrial natriuretic peptide levels;	chr1:11823275	chr1:11841017~11848079:+
THCA	cis	rs42490	0.536	rs365871	ENSG00000251136.7	RP11-37B2.1	-7.69	8.55e-14	3.1e-11	-0.3	-0.33	Leprosy;	chr8:89861458	chr8:89609409~89757727:-
THCA	cis	rs42490	0.536	rs386857	ENSG00000251136.7	RP11-37B2.1	-7.69	8.55e-14	3.1e-11	-0.3	-0.33	Leprosy;	chr8:89862824	chr8:89609409~89757727:-
THCA	cis	rs2712184	0.756	rs2712181	ENSG00000229352.1	AC007563.3	7.69	8.56e-14	3.1e-11	0.39	0.33	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216790146	chr2:216799608~216805335:+
THCA	cis	rs7208859	0.673	rs75142521	ENSG00000264538.5	SUZ12P1	-7.69	8.56e-14	3.1e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30709299~30790908:+
THCA	cis	rs4950322	0.542	rs2883434	ENSG00000237188.3	RP11-337C18.8	7.69	8.58e-14	3.11e-11	0.38	0.33	Protein quantitative trait loci;	chr1:147177505	chr1:147172771~147211568:+
THCA	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	7.69	8.6e-14	3.11e-11	0.3	0.33	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
THCA	cis	rs4950322	0.542	rs1932977	ENSG00000237188.3	RP11-337C18.8	7.69	8.6e-14	3.11e-11	0.39	0.33	Protein quantitative trait loci;	chr1:147217371	chr1:147172771~147211568:+
THCA	cis	rs812925	0.502	rs2053750	ENSG00000271889.1	RP11-493E12.1	-7.69	8.6e-14	3.11e-11	-0.32	-0.33	Immature fraction of reticulocytes;	chr2:61429138	chr2:61151433~61162105:-
THCA	cis	rs9902453	0.933	rs9898353	ENSG00000264007.1	RP11-68I3.10	7.69	8.62e-14	3.12e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30124847	chr17:29621617~29622254:-
THCA	cis	rs829880	0.57	rs4488248	ENSG00000227825.4	SLC9A7P1	7.69	8.64e-14	3.13e-11	0.3	0.33	Colonoscopy-negative controls vs population controls;	chr12:98459910	chr12:98453835~98457145:-
THCA	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-7.69	8.64e-14	3.13e-11	-0.36	-0.33	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-7.69	8.64e-14	3.13e-11	-0.36	-0.33	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-7.69	8.64e-14	3.13e-11	-0.36	-0.33	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
THCA	cis	rs11096990	0.613	rs1451821	ENSG00000249685.1	RP11-360F5.3	-7.69	8.65e-14	3.13e-11	-0.4	-0.33	Cognitive function;	chr4:39178797	chr4:39133913~39135608:+
THCA	cis	rs6487679	1	rs6487679	ENSG00000111788.10	RP11-22B23.1	7.69	8.67e-14	3.14e-11	0.4	0.33	Non-alcoholic fatty liver disease histology (AST);	chr12:9218736	chr12:9277235~9313241:+
THCA	cis	rs7208859	0.673	rs11656462	ENSG00000266490.1	CTD-2349P21.9	7.69	8.67e-14	3.14e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.673	rs216418	ENSG00000266490.1	CTD-2349P21.9	7.69	8.7e-14	3.15e-11	0.43	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30609519	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216423	ENSG00000266490.1	CTD-2349P21.9	7.69	8.7e-14	3.15e-11	0.43	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30615091	chr17:30792372~30792833:+
THCA	cis	rs9543976	0.623	rs9318361	ENSG00000261553.4	RP11-29G8.3	7.69	8.72e-14	3.16e-11	0.4	0.33	Diabetic retinopathy;	chr13:75602944	chr13:75549773~75807120:+
THCA	cis	rs6558530	0.73	rs10097891	ENSG00000253982.1	CTD-2336O2.1	7.69	8.72e-14	3.16e-11	0.29	0.33	Systolic blood pressure;	chr8:1778643	chr8:1761990~1764502:-
THCA	cis	rs13631	0.728	rs10118245	ENSG00000268996.3	MAN1B1-AS1	7.69	8.76e-14	3.17e-11	0.3	0.33	Cerebrospinal fluid biomarker levels;	chr9:137085140	chr9:137084946~137086817:-
THCA	cis	rs7942368	1	rs10437754	ENSG00000254761.1	RP11-672A2.1	7.69	8.76e-14	3.17e-11	0.48	0.33	Endometriosis;	chr11:76766823	chr11:76712396~76719608:-
THCA	cis	rs10411161	0.552	rs2191668	ENSG00000269483.1	AC006272.1	7.69	8.78e-14	3.18e-11	0.48	0.33	Breast cancer;	chr19:51832524	chr19:51839924~51843324:-
THCA	cis	rs2337406	0.866	rs78462736	ENSG00000274576.2	IGHV2-70	-7.69	8.8e-14	3.18e-11	-0.29	-0.33	Alzheimer's disease (late onset);	chr14:106779942	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs8016203	ENSG00000274576.2	IGHV2-70	-7.69	8.8e-14	3.18e-11	-0.29	-0.33	Alzheimer's disease (late onset);	chr14:106780575	chr14:106770577~106771020:-
THCA	cis	rs9902453	0.967	rs9913074	ENSG00000264007.1	RP11-68I3.10	7.69	8.81e-14	3.19e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30154181	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.934	rs7211246	ENSG00000264007.1	RP11-68I3.10	7.69	8.81e-14	3.19e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30158744	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.933	rs7216487	ENSG00000264007.1	RP11-68I3.10	7.69	8.81e-14	3.19e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30175624	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.933	rs7216494	ENSG00000264007.1	RP11-68I3.10	7.69	8.81e-14	3.19e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30175633	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.933	rs1532042	ENSG00000264007.1	RP11-68I3.10	7.69	8.81e-14	3.19e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30177371	chr17:29621617~29622254:-
THCA	cis	rs12908161	1	rs12903134	ENSG00000225151.9	GOLGA2P7	-7.69	8.82e-14	3.19e-11	-0.49	-0.33	Schizophrenia;	chr15:84794468	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs35726233	ENSG00000225151.9	GOLGA2P7	-7.69	8.82e-14	3.19e-11	-0.49	-0.33	Schizophrenia;	chr15:84794569	chr15:84199311~84230136:-
THCA	cis	rs6603134	0.502	rs10411185	ENSG00000267939.1	CTD-2325M2.1	-7.69	8.84e-14	3.2e-11	-0.35	-0.33	Blood protein levels;	chr19:8038997	chr19:8008729~8016025:+
THCA	cis	rs849141	0.925	rs508347	ENSG00000234336.5	JAZF1-AS1	-7.69	8.84e-14	3.2e-11	-0.37	-0.33	Height;Hip circumference adjusted for BMI;	chr7:28173205	chr7:28180322~28243917:+
THCA	cis	rs2976388	0.647	rs13272904	ENSG00000253741.1	CTD-2292P10.4	-7.69	8.84e-14	3.2e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142701196	chr8:142702252~142726973:-
THCA	cis	rs11214589	0.905	rs1078	ENSG00000270179.1	RP11-159N11.4	-7.69	8.85e-14	3.2e-11	-0.35	-0.33	Neuroticism;	chr11:113371155	chr11:113368478~113369117:+
THCA	cis	rs193541	0.593	rs1035372	ENSG00000263432.2	RN7SL689P	7.69	8.85e-14	3.2e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122833753	chr5:123022487~123022783:-
THCA	cis	rs667920	0.573	rs9682783	ENSG00000273486.1	RP11-731C17.2	7.69	8.89e-14	3.21e-11	0.34	0.33	Coronary artery disease;	chr3:136820847	chr3:136837338~136839021:-
THCA	cis	rs7247513	0.639	rs12984441	ENSG00000230310.1	CTD-2192J16.11	-7.69	8.9e-14	3.22e-11	-0.39	-0.33	Bipolar disorder;	chr19:12649473	chr19:12552597~12553644:+
THCA	cis	rs8113308	0.81	rs17695737	ENSG00000269235.1	ZNF350-AS1	7.69	8.91e-14	3.22e-11	0.51	0.33	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51942283	chr19:51949134~51981367:+
THCA	cis	rs240993	0.516	rs181294	ENSG00000230177.1	RP5-1112D6.4	-7.69	8.91e-14	3.22e-11	-0.36	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111298999	chr6:111277932~111278742:+
THCA	cis	rs17695224	0.606	rs10411054	ENSG00000269483.1	AC006272.1	7.69	8.91e-14	3.22e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51831208	chr19:51839924~51843324:-
THCA	cis	rs10208649	0.831	rs77308271	ENSG00000272156.1	RP11-477N3.1	7.69	8.92e-14	3.22e-11	0.71	0.33	Body mass index;	chr2:54075827	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.831	rs75447473	ENSG00000272156.1	RP11-477N3.1	7.69	8.92e-14	3.22e-11	0.71	0.33	Body mass index;	chr2:54077507	chr2:54082554~54085066:+
THCA	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-7.69	8.92e-14	3.22e-11	-0.36	-0.33	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
THCA	cis	rs6487679	1	rs7298108	ENSG00000111788.10	RP11-22B23.1	-7.69	8.94e-14	3.23e-11	-0.39	-0.33	Non-alcoholic fatty liver disease histology (AST);	chr12:9223572	chr12:9277235~9313241:+
THCA	cis	rs73219805	0.536	rs77690628	ENSG00000228451.3	SDAD1P1	-7.69	8.97e-14	3.24e-11	-0.75	-0.33	Schizophrenia;	chr8:26331707	chr8:26379259~26382953:-
THCA	cis	rs73219805	0.536	rs73217710	ENSG00000228451.3	SDAD1P1	-7.69	8.97e-14	3.24e-11	-0.75	-0.33	Schizophrenia;	chr8:26340717	chr8:26379259~26382953:-
THCA	cis	rs367615	0.704	rs7704824	ENSG00000249476.1	CTD-2587M2.1	7.69	8.98e-14	3.25e-11	0.34	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109514577	chr5:109237120~109326369:-
THCA	cis	rs7674212	0.865	rs13149311	ENSG00000251288.2	RP11-10L12.2	-7.69	8.98e-14	3.25e-11	-0.45	-0.33	Type 2 diabetes;	chr4:103056543	chr4:102751401~102752641:+
THCA	cis	rs11971779	0.588	rs2003531	ENSG00000273391.1	RP11-634H22.1	7.69	8.99e-14	3.25e-11	0.32	0.33	Diisocyanate-induced asthma;	chr7:139441832	chr7:139359032~139359566:-
THCA	cis	rs2337406	0.852	rs12050239	ENSG00000274576.2	IGHV2-70	-7.68	9e-14	3.25e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106781132	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092535	ENSG00000274576.2	IGHV2-70	-7.68	9e-14	3.25e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106781722	chr14:106770577~106771020:-
THCA	cis	rs11148252	0.811	rs9536030	ENSG00000278238.1	RP11-245D16.4	7.68	9e-14	3.25e-11	0.38	0.33	Lewy body disease;	chr13:52364156	chr13:52454775~52455331:-
THCA	cis	rs11148252	0.875	rs9596651	ENSG00000278238.1	RP11-245D16.4	7.68	9e-14	3.25e-11	0.38	0.33	Lewy body disease;	chr13:52364447	chr13:52454775~52455331:-
THCA	cis	rs4820539	1	rs6003518	ENSG00000221069.1	AC000029.1	-7.68	9.03e-14	3.26e-11	-0.39	-0.33	Bone mineral density;	chr22:23129346	chr22:23136620~23136710:+
THCA	cis	rs910316	0.934	rs4903278	ENSG00000279594.1	RP11-950C14.10	7.68	9.04e-14	3.27e-11	0.31	0.33	Height;	chr14:75068316	chr14:75011269~75012851:-
THCA	cis	rs9326248	0.953	rs488962	ENSG00000280143.1	AP000892.6	-7.68	9.04e-14	3.27e-11	-0.42	-0.33	Blood protein levels;	chr11:117201809	chr11:117204967~117210292:+
THCA	cis	rs11672691	0.829	rs8112363	ENSG00000267107.5	PCAT19	7.68	9.04e-14	3.27e-11	0.35	0.33	Prostate cancer;	chr19:41483803	chr19:41454169~41500649:-
THCA	cis	rs984222	0.501	rs1419289	ENSG00000231365.4	RP11-418J17.1	-7.68	9.05e-14	3.27e-11	-0.32	-0.33	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:118944613	chr1:119140396~119275973:+
THCA	cis	rs7714584	1	rs7734778	ENSG00000197083.10	ZNF300P1	7.68	9.05e-14	3.27e-11	0.52	0.33	Crohn's disease;	chr5:150876994	chr5:150930645~150946289:-
THCA	cis	rs270601	0.721	rs162894	ENSG00000233006.5	AC034220.3	7.68	9.06e-14	3.27e-11	0.26	0.33	Acylcarnitine levels;	chr5:132276179	chr5:132311285~132369916:-
THCA	cis	rs77204473	0.744	rs12421425	ENSG00000254851.1	RP11-109L13.1	7.68	9.08e-14	3.28e-11	0.89	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117131244	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs17120367	ENSG00000254851.1	RP11-109L13.1	7.68	9.08e-14	3.28e-11	0.89	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132112	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs17120370	ENSG00000254851.1	RP11-109L13.1	7.68	9.08e-14	3.28e-11	0.89	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132672	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs74735277	ENSG00000254851.1	RP11-109L13.1	7.68	9.08e-14	3.28e-11	0.89	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132702	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs75208249	ENSG00000254851.1	RP11-109L13.1	7.68	9.08e-14	3.28e-11	0.89	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117132907	chr11:117135528~117138582:+
THCA	cis	rs10971721	0.643	rs7040130	ENSG00000281128.1	PTENP1-AS	7.68	9.1e-14	3.29e-11	0.73	0.33	Body mass index;	chr9:33785075	chr9:33677268~33688011:+
THCA	cis	rs28510890	0.75	rs12591974	ENSG00000260337.3	RP11-386M24.6	7.68	9.12e-14	3.29e-11	0.46	0.33	Lung cancer in ever smokers;	chr15:92565541	chr15:92592574~92596462:-
THCA	cis	rs7727544	0.526	rs4705908	ENSG00000237714.1	P4HA2-AS1	7.68	9.13e-14	3.3e-11	0.45	0.33	Blood metabolite levels;	chr5:132011827	chr5:132184876~132192808:+
THCA	cis	rs6908034	0.607	rs79406203	ENSG00000228412.5	RP4-625H18.2	7.68	9.15e-14	3.31e-11	0.82	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19815990	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.607	rs74559916	ENSG00000228412.5	RP4-625H18.2	7.68	9.15e-14	3.31e-11	0.82	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818486	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.505	rs76391302	ENSG00000228412.5	RP4-625H18.2	7.68	9.15e-14	3.31e-11	0.82	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19818885	chr6:19802164~19804752:-
THCA	cis	rs6908034	0.505	rs77880623	ENSG00000228412.5	RP4-625H18.2	7.68	9.15e-14	3.31e-11	0.82	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819223	chr6:19802164~19804752:-
THCA	cis	rs17826219	0.706	rs28469200	ENSG00000264538.5	SUZ12P1	-7.68	9.16e-14	3.31e-11	-0.33	-0.33	Body mass index;	chr17:30806554	chr17:30709299~30790908:+
THCA	cis	rs9902453	0.845	rs3115099	ENSG00000264007.1	RP11-68I3.10	7.68	9.16e-14	3.31e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:29692275	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs58606097	ENSG00000264007.1	RP11-68I3.10	7.68	9.16e-14	3.31e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:29693361	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.845	rs3102559	ENSG00000264007.1	RP11-68I3.10	7.68	9.16e-14	3.31e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:29702705	chr17:29621617~29622254:-
THCA	cis	rs875971	0.522	rs1617484	ENSG00000237310.1	GS1-124K5.4	7.68	9.2e-14	3.32e-11	0.25	0.33	Aortic root size;	chr7:65998108	chr7:66493706~66495474:+
THCA	cis	rs12908161	1	rs58416181	ENSG00000225151.9	GOLGA2P7	-7.68	9.21e-14	3.32e-11	-0.49	-0.33	Schizophrenia;	chr15:84721230	chr15:84199311~84230136:-
THCA	cis	rs193541	0.632	rs1363200	ENSG00000263432.2	RN7SL689P	7.68	9.26e-14	3.34e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122828107	chr5:123022487~123022783:-
THCA	cis	rs2153535	0.563	rs1796687	ENSG00000230939.1	RP11-314C16.1	-7.68	9.27e-14	3.34e-11	-0.36	-0.33	Motion sickness;	chr6:8535885	chr6:8784178~8785445:+
THCA	cis	rs686320	1	rs2957267	ENSG00000245532.5	NEAT1	7.68	9.3e-14	3.36e-11	0.31	0.33	Hip circumference adjusted for BMI;	chr11:65468321	chr11:65422774~65445540:+
THCA	cis	rs950169	0.579	rs62027818	ENSG00000259728.4	LINC00933	7.68	9.32e-14	3.36e-11	0.48	0.33	Schizophrenia;	chr15:83992393	chr15:84570649~84580175:+
THCA	cis	rs9487094	0.744	rs2275652	ENSG00000260273.1	RP11-425D10.10	7.68	9.33e-14	3.36e-11	0.43	0.33	Height;	chr6:109382480	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.744	rs13199519	ENSG00000260273.1	RP11-425D10.10	7.68	9.33e-14	3.36e-11	0.43	0.33	Height;	chr6:109387972	chr6:109382795~109383666:+
THCA	cis	rs1598856	0.932	rs230530	ENSG00000246560.2	RP11-10L12.4	-7.68	9.34e-14	3.37e-11	-0.4	-0.33	Primary biliary cholangitis;	chr4:102532823	chr4:102828055~102844075:+
THCA	cis	rs1198430	0.789	rs1198423	ENSG00000232482.2	RP4-654C18.1	-7.68	9.36e-14	3.38e-11	-0.57	-0.33	Total cholesterol levels;	chr1:23408748	chr1:23410832~23412146:+
THCA	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-7.68	9.36e-14	3.38e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
THCA	cis	rs10936632	0.565	rs7610584	ENSG00000242578.1	RP11-469J4.3	-7.68	9.37e-14	3.38e-11	-0.38	-0.33	Prostate cancer;	chr3:170435395	chr3:170410512~170418615:+
THCA	cis	rs72772090	0.539	rs56395748	ENSG00000248734.2	CTD-2260A17.1	-7.68	9.39e-14	3.39e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96841190	chr5:96784777~96785999:+
THCA	cis	rs11096990	0.593	rs35937374	ENSG00000249685.1	RP11-360F5.3	7.68	9.42e-14	3.4e-11	0.4	0.33	Cognitive function;	chr4:39184735	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.574	rs34070258	ENSG00000249685.1	RP11-360F5.3	7.68	9.42e-14	3.4e-11	0.4	0.33	Cognitive function;	chr4:39188132	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.613	rs35391082	ENSG00000249685.1	RP11-360F5.3	7.68	9.42e-14	3.4e-11	0.4	0.33	Cognitive function;	chr4:39191033	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.613	rs4974990	ENSG00000249685.1	RP11-360F5.3	7.68	9.42e-14	3.4e-11	0.4	0.33	Cognitive function;	chr4:39191645	chr4:39133913~39135608:+
THCA	cis	rs910316	0.737	rs175080	ENSG00000279594.1	RP11-950C14.10	-7.68	9.44e-14	3.4e-11	-0.31	-0.33	Height;	chr14:75047125	chr14:75011269~75012851:-
THCA	cis	rs7829975	0.559	rs4841025	ENSG00000253893.2	FAM85B	7.68	9.47e-14	3.42e-11	0.42	0.33	Mood instability;	chr8:8745650	chr8:8167819~8226614:-
THCA	cis	rs193541	0.632	rs2407402	ENSG00000263432.2	RN7SL689P	7.68	9.48e-14	3.42e-11	0.39	0.33	Glucose homeostasis traits;	chr5:122771410	chr5:123022487~123022783:-
THCA	cis	rs1949733	0.701	rs940134	ENSG00000205959.3	RP11-689P11.2	-7.68	9.5e-14	3.42e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8453143	chr4:8482270~8512610:+
THCA	cis	rs1949733	0.701	rs871768	ENSG00000205959.3	RP11-689P11.2	-7.68	9.5e-14	3.42e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8453211	chr4:8482270~8512610:+
THCA	cis	rs77204473	1	rs17120099	ENSG00000254851.1	RP11-109L13.1	7.68	9.5e-14	3.43e-11	0.87	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116864744	chr11:117135528~117138582:+
THCA	cis	rs7131987	0.65	rs11050208	ENSG00000257176.2	RP11-996F15.2	-7.68	9.5e-14	3.43e-11	-0.35	-0.33	QT interval;	chr12:29357436	chr12:29280418~29317848:-
THCA	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-7.68	9.53e-14	3.44e-11	-0.36	-0.33	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
THCA	cis	rs193541	0.632	rs119449	ENSG00000263432.2	RN7SL689P	7.68	9.54e-14	3.44e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122948046	chr5:123022487~123022783:-
THCA	cis	rs801193	0.66	rs974239	ENSG00000232559.3	GS1-124K5.12	7.68	9.58e-14	3.45e-11	0.32	0.33	Aortic root size;	chr7:66748504	chr7:66554588~66576923:-
THCA	cis	rs9543976	0.623	rs7986566	ENSG00000261553.4	RP11-29G8.3	7.68	9.6e-14	3.46e-11	0.4	0.33	Diabetic retinopathy;	chr13:75623795	chr13:75549773~75807120:+
THCA	cis	rs5769707	0.732	rs135865	ENSG00000235111.1	RP1-29C18.8	-7.68	9.61e-14	3.46e-11	-0.4	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49612657~49615716:-
THCA	cis	rs4780355	0.918	rs243323	ENSG00000262636.1	CTD-3088G3.4	7.68	9.64e-14	3.47e-11	0.44	0.33	Crohn's disease and psoriasis;	chr16:11267345	chr16:11380859~11381118:-
THCA	cis	rs11214589	0.774	rs10891544	ENSG00000270179.1	RP11-159N11.4	7.68	9.64e-14	3.47e-11	0.36	0.33	Neuroticism;	chr11:113385430	chr11:113368478~113369117:+
THCA	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	7.67	9.66e-14	3.48e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
THCA	cis	rs4819052	1	rs9984901	ENSG00000237664.1	LINC00316	-7.67	9.67e-14	3.48e-11	-0.36	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45244037	chr21:45338590~45341990:-
THCA	cis	rs853679	0.825	rs8180562	ENSG00000219392.1	RP1-265C24.5	-7.67	9.67e-14	3.48e-11	-0.58	-0.33	Depression;	chr6:28173682	chr6:28115628~28116551:+
THCA	cis	rs853679	0.882	rs9380064	ENSG00000219392.1	RP1-265C24.5	-7.67	9.67e-14	3.48e-11	-0.58	-0.33	Depression;	chr6:28175340	chr6:28115628~28116551:+
THCA	cis	rs1667284	1	rs1667275	ENSG00000266521.1	RP11-650P15.1	7.67	9.69e-14	3.49e-11	0.42	0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31633302	chr18:31496645~31497195:-
THCA	cis	rs7945705	0.806	rs12224436	ENSG00000254860.4	TMEM9B-AS1	-7.67	9.7e-14	3.49e-11	-0.37	-0.33	Hemoglobin concentration;	chr11:8794278	chr11:8964675~8977527:+
THCA	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	7.67	9.72e-14	3.5e-11	0.42	0.33	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
THCA	cis	rs1150668	1	rs1150668	ENSG00000219392.1	RP1-265C24.5	-7.67	9.72e-14	3.5e-11	-0.37	-0.33	Pubertal anthropometrics;	chr6:28162011	chr6:28115628~28116551:+
THCA	cis	rs4591358	0.608	rs72927762	ENSG00000223466.1	AC064834.2	-7.67	9.72e-14	3.5e-11	-0.6	-0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544921	chr2:195533035~195538681:+
THCA	cis	rs34375054	0.66	rs12305181	ENSG00000279233.1	RP11-158L12.4	7.67	9.73e-14	3.5e-11	0.33	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125109610	chr12:125138245~125141711:+
THCA	cis	rs9487094	0.567	rs13198879	ENSG00000260273.1	RP11-425D10.10	7.67	9.74e-14	3.51e-11	0.43	0.33	Height;	chr6:109769861	chr6:109382795~109383666:+
THCA	cis	rs13068223	1	rs34111024	ENSG00000243926.1	TIPARP-AS1	7.67	9.74e-14	3.51e-11	0.32	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156748947	chr3:156671862~156674378:-
THCA	cis	rs13068223	1	rs36126086	ENSG00000243926.1	TIPARP-AS1	7.67	9.74e-14	3.51e-11	0.32	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156749028	chr3:156671862~156674378:-
THCA	cis	rs910316	0.967	rs119076	ENSG00000279594.1	RP11-950C14.10	-7.67	9.75e-14	3.51e-11	-0.31	-0.33	Height;	chr14:75105716	chr14:75011269~75012851:-
THCA	cis	rs12681366	0.801	rs2919657	ENSG00000253704.1	RP11-267M23.4	7.67	9.76e-14	3.52e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94460724	chr8:94553722~94569745:+
THCA	cis	rs7208859	0.623	rs56378576	ENSG00000264538.5	SUZ12P1	-7.67	9.77e-14	3.52e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30683102	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs35916850	ENSG00000264538.5	SUZ12P1	-7.67	9.77e-14	3.52e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30684155	chr17:30709299~30790908:+
THCA	cis	rs17695224	0.545	rs7252805	ENSG00000269483.1	AC006272.1	7.67	9.8e-14	3.53e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51840169	chr19:51839924~51843324:-
THCA	cis	rs3812049	0.784	rs2568928	ENSG00000245937.6	LINC01184	-7.67	9.8e-14	3.53e-11	-0.38	-0.33	Lymphocyte counts;Red cell distribution width;	chr5:128151911	chr5:127940426~128083172:-
THCA	cis	rs1275468	0.798	rs2366987	ENSG00000257497.2	RP11-585P4.5	-7.67	9.8e-14	3.53e-11	-0.47	-0.33	Polycystic ovary syndrome;	chr12:75536346	chr12:75483454~75489820:-
THCA	cis	rs728616	0.867	rs1923534	ENSG00000225484.5	NUTM2B-AS1	-7.67	9.82e-14	3.53e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79950729	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs12414096	ENSG00000225484.5	NUTM2B-AS1	-7.67	9.82e-14	3.53e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79953873	chr10:79663088~79826594:-
THCA	cis	rs728616	0.557	rs17107449	ENSG00000225484.5	NUTM2B-AS1	-7.67	9.82e-14	3.53e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79955940	chr10:79663088~79826594:-
THCA	cis	rs9902453	0.757	rs12453308	ENSG00000264007.1	RP11-68I3.10	7.67	9.82e-14	3.54e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30114586	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs60176674	ENSG00000264007.1	RP11-68I3.10	7.67	9.82e-14	3.54e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30152836	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs61014003	ENSG00000264007.1	RP11-68I3.10	7.67	9.82e-14	3.54e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30158215	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs56326816	ENSG00000264007.1	RP11-68I3.10	7.67	9.82e-14	3.54e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30165787	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs4533341	ENSG00000264007.1	RP11-68I3.10	7.67	9.82e-14	3.54e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30168654	chr17:29621617~29622254:-
THCA	cis	rs8114671	0.585	rs2236271	ENSG00000269202.1	RP4-614O4.12	7.67	9.83e-14	3.54e-11	0.29	0.33	Height;	chr20:34936037	chr20:35201747~35203288:-
THCA	cis	rs9388451	0.839	rs3799711	ENSG00000237742.5	RP11-624M8.1	7.67	9.84e-14	3.54e-11	0.29	0.33	Brugada syndrome;	chr6:125754167	chr6:125578558~125749190:-
THCA	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-7.67	9.84e-14	3.54e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
THCA	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	7.67	9.85e-14	3.54e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
THCA	cis	rs10971721	0.908	rs10971722	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33828166	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971723	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33829604	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.908	rs12376055	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33831957	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.908	rs55684780	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33833210	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.908	rs10971728	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33834635	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.642	rs114466241	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33835731	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs12378261	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33837174	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725374	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33840651	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.749	rs72725375	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33840706	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725376	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33841931	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725377	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33842228	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725378	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33842896	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs12380143	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33847588	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725381	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33851167	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971735	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33851801	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.642	rs10971736	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33854376	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.749	rs10971741	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33856869	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs56253239	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33860068	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs115554740	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33860888	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725387	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33863673	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs72725388	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33864624	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs117687546	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33864931	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs56172788	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33865752	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs10971750	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33869783	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971753	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33870438	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971754	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33871714	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971755	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33872007	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725398	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33875920	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971758	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33876071	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs72725402	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33878358	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs72727303	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33878378	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971763	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33879779	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971764	ENSG00000260947.1	RP11-384P7.7	7.67	9.85e-14	3.54e-11	0.81	0.33	Body mass index;	chr9:33880102	chr9:33697459~33700986:+
THCA	cis	rs172166	0.56	rs203878	ENSG00000219392.1	RP1-265C24.5	-7.67	9.85e-14	3.55e-11	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:28081218	chr6:28115628~28116551:+
THCA	cis	rs9388451	0.872	rs2008027	ENSG00000237742.5	RP11-624M8.1	-7.67	9.88e-14	3.56e-11	-0.29	-0.33	Brugada syndrome;	chr6:125731213	chr6:125578558~125749190:-
THCA	cis	rs3096299	0.869	rs748941	ENSG00000274627.1	RP11-104N10.2	7.67	9.89e-14	3.56e-11	0.33	0.33	Multiple myeloma (IgH translocation);	chr16:89374346	chr16:89516797~89522217:+
THCA	cis	rs1667284	0.967	rs895888	ENSG00000266521.1	RP11-650P15.1	7.67	9.89e-14	3.56e-11	0.42	0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31648224	chr18:31496645~31497195:-
THCA	cis	rs10971721	0.822	rs10971773	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33898781	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971774	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33900111	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727318	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33901802	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs10971782	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33909466	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.908	rs10971787	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33914414	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727327	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33918818	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971791	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33920912	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971792	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33920955	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727329	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33921666	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs11848	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33921921	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727332	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33929479	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727335	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33931720	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727336	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33931795	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971802	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33933284	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971803	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33933289	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs41314578	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33933943	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs56274755	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33934273	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs118115128	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33935451	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727340	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33936736	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727341	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33936878	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727342	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33938084	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs117733169	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33938101	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727344	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33939122	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971807	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33939557	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727345	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33940200	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727346	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33940420	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727350	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33944732	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727351	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33950434	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727353	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33950824	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971817	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33951886	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs10971819	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33954149	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727362	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33957324	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727367	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33965180	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727369	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33965777	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971826	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33972035	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971827	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33972469	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971828	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33973417	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727378	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33975792	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727389	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33987030	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs72727392	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33988921	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72727399	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33997271	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971838	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33997948	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.686	rs10971839	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:33998410	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72729305	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34000293	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72729316	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34008175	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971845	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34009879	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971847	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34011460	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971848	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34012504	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971850	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34013910	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs10814061	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34014032	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs12380173	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34018500	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs12377970	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34021269	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.731	rs10971857	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34021621	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.908	rs72729329	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34022884	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.908	rs10971858	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34023693	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72729341	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34031693	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72729344	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34034032	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971866	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34043163	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971867	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34046758	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72729361	ENSG00000260947.1	RP11-384P7.7	7.67	9.91e-14	3.56e-11	0.81	0.33	Body mass index;	chr9:34047525	chr9:33697459~33700986:+
THCA	cis	rs10181042	0.565	rs2564117	ENSG00000271889.1	RP11-493E12.1	7.67	9.92e-14	3.57e-11	0.31	0.33	Crohn's disease;	chr2:61005887	chr2:61151433~61162105:-
THCA	cis	rs9902453	0.967	rs1906450	ENSG00000264007.1	RP11-68I3.10	7.67	9.94e-14	3.57e-11	0.39	0.33	Coffee consumption (cups per day);	chr17:30188726	chr17:29621617~29622254:-
THCA	cis	rs1150668	0.965	rs1654774	ENSG00000219392.1	RP1-265C24.5	-7.67	9.94e-14	3.57e-11	-0.37	-0.33	Pubertal anthropometrics;	chr6:28128502	chr6:28115628~28116551:+
THCA	cis	rs9640161	0.789	rs11767409	ENSG00000261305.1	RP4-584D14.7	7.67	9.95e-14	3.58e-11	0.41	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150360954	chr7:150341771~150342607:+
THCA	cis	rs934734	0.563	rs11126034	ENSG00000281920.1	RP11-418H16.1	-7.67	9.96e-14	3.58e-11	-0.43	-0.33	Rheumatoid arthritis;	chr2:65353087	chr2:65623272~65628424:+
THCA	cis	rs8081395	0.834	rs11650106	ENSG00000266992.1	DHX40P1	-7.67	9.96e-14	3.58e-11	-0.39	-0.33	White blood cell count;	chr17:59772890	chr17:59976009~60002384:-
THCA	cis	rs11148252	0.875	rs4885953	ENSG00000278238.1	RP11-245D16.4	-7.67	9.97e-14	3.58e-11	-0.38	-0.33	Lewy body disease;	chr13:52402356	chr13:52454775~52455331:-
THCA	cis	rs12681366	0.839	rs2931632	ENSG00000253704.1	RP11-267M23.4	7.67	9.98e-14	3.59e-11	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94406560	chr8:94553722~94569745:+
THCA	cis	rs9487094	0.744	rs13192476	ENSG00000260273.1	RP11-425D10.10	7.67	9.98e-14	3.59e-11	0.43	0.33	Height;	chr6:109403951	chr6:109382795~109383666:+
THCA	cis	rs9543976	0.623	rs7982517	ENSG00000261553.4	RP11-29G8.3	7.67	9.98e-14	3.59e-11	0.4	0.33	Diabetic retinopathy;	chr13:75587903	chr13:75549773~75807120:+
THCA	cis	rs3812049	0.737	rs1993878	ENSG00000245937.6	LINC01184	7.67	1e-13	3.59e-11	0.38	0.33	Lymphocyte counts;Red cell distribution width;	chr5:128141279	chr5:127940426~128083172:-
THCA	cis	rs7176527	1	rs3762168	ENSG00000188388.10	GOLGA6L3	7.67	1e-13	3.6e-11	0.5	0.33	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84599416	chr15:85240472~85247170:+
THCA	cis	rs1061377	0.748	rs1036034	ENSG00000249685.1	RP11-360F5.3	7.67	1e-13	3.6e-11	0.41	0.33	Uric acid levels;	chr4:39105299	chr4:39133913~39135608:+
THCA	cis	rs10971721	0.822	rs72725392	ENSG00000260947.1	RP11-384P7.7	7.67	1e-13	3.61e-11	0.82	0.33	Body mass index;	chr9:33867780	chr9:33697459~33700986:+
THCA	cis	rs17826219	0.706	rs9893922	ENSG00000264538.5	SUZ12P1	-7.67	1e-13	3.61e-11	-0.33	-0.33	Body mass index;	chr17:30741407	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.5	rs9891256	ENSG00000264538.5	SUZ12P1	-7.67	1e-13	3.61e-11	-0.33	-0.33	Body mass index;	chr17:30745674	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7503335	ENSG00000264538.5	SUZ12P1	-7.67	1e-13	3.61e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30709299~30790908:+
THCA	cis	rs2276314	0.857	rs28435069	ENSG00000278986.1	RP11-723J4.3	-7.67	1e-13	3.61e-11	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36048512	chr18:35972151~35973916:+
THCA	cis	rs2276314	0.857	rs8087539	ENSG00000278986.1	RP11-723J4.3	-7.67	1e-13	3.61e-11	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36051574	chr18:35972151~35973916:+
THCA	cis	rs4718428	1	rs4718428	ENSG00000273142.1	RP11-458F8.4	-7.67	1e-13	3.61e-11	-0.27	-0.33	Corneal structure;	chr7:66956459	chr7:66902857~66906297:+
THCA	cis	rs847577	0.677	rs1495525	ENSG00000272950.1	RP11-307C18.1	-7.67	1.01e-13	3.61e-11	-0.42	-0.33	Breast cancer;	chr7:98196920	chr7:98322853~98323430:+
THCA	cis	rs150992	0.587	rs4448016	ENSG00000248489.1	CTD-2007H13.3	7.67	1.01e-13	3.61e-11	0.32	0.33	Body mass index;	chr5:99037904	chr5:98929171~98995013:+
THCA	cis	rs16846053	0.515	rs971027	ENSG00000227403.1	AC009299.3	-7.67	1.01e-13	3.61e-11	-0.53	-0.33	Blood osmolality (transformed sodium);	chr2:161588104	chr2:161244739~161249050:+
THCA	cis	rs9543976	0.623	rs4611344	ENSG00000261553.4	RP11-29G8.3	7.67	1.01e-13	3.62e-11	0.4	0.33	Diabetic retinopathy;	chr13:75601192	chr13:75549773~75807120:+
THCA	cis	rs1501911	0.509	rs330422	ENSG00000248489.1	CTD-2007H13.3	7.67	1.01e-13	3.62e-11	0.33	0.33	Lung function (FEV1/FVC);	chr5:98859184	chr5:98929171~98995013:+
THCA	cis	rs10971721	0.584	rs72731221	ENSG00000260947.1	RP11-384P7.7	7.67	1.01e-13	3.63e-11	0.75	0.33	Body mass index;	chr9:34122376	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs72731222	ENSG00000260947.1	RP11-384P7.7	7.67	1.01e-13	3.63e-11	0.75	0.33	Body mass index;	chr9:34122864	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs10971939	ENSG00000260947.1	RP11-384P7.7	7.67	1.01e-13	3.63e-11	0.75	0.33	Body mass index;	chr9:34123437	chr9:33697459~33700986:+
THCA	cis	rs2976388	0.647	rs2572898	ENSG00000253741.1	CTD-2292P10.4	-7.67	1.01e-13	3.63e-11	-0.42	-0.33	Urinary tract infection frequency;	chr8:142700856	chr8:142702252~142726973:-
THCA	cis	rs2281636	0.798	rs3184991	ENSG00000233690.1	EBAG9P1	-7.67	1.01e-13	3.64e-11	-0.36	-0.33	Obesity-related traits;	chr10:99755559	chr10:99697407~99697949:-
THCA	cis	rs7665090	0.603	rs17033015	ENSG00000246560.2	RP11-10L12.4	7.67	1.01e-13	3.64e-11	0.4	0.33	Primary biliary cholangitis;	chr4:102625147	chr4:102828055~102844075:+
THCA	cis	rs2522056	1	rs2057655	ENSG00000233006.5	AC034220.3	7.67	1.01e-13	3.64e-11	0.29	0.33	Fibrinogen;Lymphocyte counts;	chr5:132471932	chr5:132311285~132369916:-
THCA	cis	rs748404	0.516	rs523156	ENSG00000166763.7	STRCP1	-7.67	1.02e-13	3.64e-11	-0.36	-0.33	Lung cancer;	chr15:43519645	chr15:43699488~43718184:-
THCA	cis	rs7208859	0.623	rs58908911	ENSG00000266490.1	CTD-2349P21.9	7.67	1.02e-13	3.65e-11	0.49	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30792372~30792833:+
THCA	cis	rs7302981	0.741	rs76919525	ENSG00000272368.2	RP4-605O3.4	-7.67	1.02e-13	3.65e-11	-0.21	-0.33	Systolic blood pressure;	chr12:50147950	chr12:50112197~50165618:+
THCA	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	7.67	1.02e-13	3.65e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
THCA	cis	rs12681366	0.839	rs3019278	ENSG00000253704.1	RP11-267M23.4	7.67	1.02e-13	3.66e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94434339	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.839	rs2930964	ENSG00000253704.1	RP11-267M23.4	7.67	1.02e-13	3.66e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94435906	chr8:94553722~94569745:+
THCA	cis	rs2408955	0.522	rs4760612	ENSG00000258273.1	RP11-370I10.4	7.67	1.02e-13	3.67e-11	0.44	0.33	Glycated hemoglobin levels;	chr12:48028073	chr12:48333755~48333901:-
THCA	cis	rs5769707	0.681	rs2071902	ENSG00000235111.1	RP1-29C18.8	-7.67	1.02e-13	3.68e-11	-0.44	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49640890	chr22:49612657~49615716:-
THCA	cis	rs17772222	0.917	rs61984708	ENSG00000258983.2	RP11-507K2.2	7.67	1.03e-13	3.69e-11	0.41	0.33	Coronary artery calcification;	chr14:88565523	chr14:88499334~88515502:+
THCA	cis	rs7267979	0.903	rs6132819	ENSG00000274414.1	RP5-965G21.4	-7.67	1.03e-13	3.7e-11	-0.4	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25237982	chr20:25239007~25245229:-
THCA	cis	rs4784934	0.879	rs9931547	ENSG00000260186.4	RP11-481J2.2	7.67	1.03e-13	3.71e-11	0.49	0.33	QT interval;	chr16:58432203	chr16:58421326~58462470:+
THCA	cis	rs736801	0.808	rs2522057	ENSG00000237714.1	P4HA2-AS1	7.66	1.04e-13	3.72e-11	0.44	0.33	Mosquito bite size;Breast cancer;	chr5:132466255	chr5:132184876~132192808:+
THCA	cis	rs8072100	0.544	rs9284377	ENSG00000228782.6	CTD-2026D20.3	7.66	1.04e-13	3.72e-11	0.31	0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47309046	chr17:47450568~47492492:-
THCA	cis	rs10971721	0.584	rs10971900	ENSG00000260947.1	RP11-384P7.7	7.66	1.04e-13	3.74e-11	0.77	0.33	Body mass index;	chr9:34085079	chr9:33697459~33700986:+
THCA	cis	rs853679	1	rs11965538	ENSG00000219392.1	RP1-265C24.5	-7.66	1.04e-13	3.74e-11	-0.53	-0.33	Depression;	chr6:28272137	chr6:28115628~28116551:+
THCA	cis	rs853679	0.882	rs2743555	ENSG00000219392.1	RP1-265C24.5	-7.66	1.04e-13	3.74e-11	-0.53	-0.33	Depression;	chr6:28273304	chr6:28115628~28116551:+
THCA	cis	rs853679	1	rs1419183	ENSG00000219392.1	RP1-265C24.5	-7.66	1.04e-13	3.74e-11	-0.53	-0.33	Depression;	chr6:28275017	chr6:28115628~28116551:+
THCA	cis	rs853679	1	rs6901575	ENSG00000219392.1	RP1-265C24.5	-7.66	1.04e-13	3.74e-11	-0.53	-0.33	Depression;	chr6:28283207	chr6:28115628~28116551:+
THCA	cis	rs853679	1	rs1679709	ENSG00000219392.1	RP1-265C24.5	7.66	1.04e-13	3.74e-11	0.53	0.33	Depression;	chr6:28260564	chr6:28115628~28116551:+
THCA	cis	rs853679	1	rs1778511	ENSG00000219392.1	RP1-265C24.5	7.66	1.04e-13	3.74e-11	0.53	0.33	Depression;	chr6:28261633	chr6:28115628~28116551:+
THCA	cis	rs1949733	0.701	rs4696828	ENSG00000205959.3	RP11-689P11.2	7.66	1.05e-13	3.77e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8453877	chr4:8482270~8512610:+
THCA	cis	rs172166	0.516	rs2021826	ENSG00000219392.1	RP1-265C24.5	-7.66	1.05e-13	3.77e-11	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:28164978	chr6:28115628~28116551:+
THCA	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	7.66	1.05e-13	3.77e-11	0.43	0.33	Height;	chr6:109339681	chr6:109382795~109383666:+
THCA	cis	rs516805	0.748	rs155458	ENSG00000279453.1	RP3-425C14.4	7.66	1.05e-13	3.77e-11	0.34	0.33	Lymphocyte counts;	chr6:122493636	chr6:122436789~122439223:-
THCA	cis	rs4845875	0.514	rs198392	ENSG00000242349.4	NPPA-AS1	-7.66	1.06e-13	3.78e-11	-0.31	-0.33	Midregional pro atrial natriuretic peptide levels;	chr1:11819105	chr1:11841017~11848079:+
THCA	cis	rs10971721	0.822	rs56370320	ENSG00000260947.1	RP11-384P7.7	7.66	1.06e-13	3.79e-11	0.81	0.33	Body mass index;	chr9:33865630	chr9:33697459~33700986:+
THCA	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-7.66	1.06e-13	3.79e-11	-0.36	-0.33	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
THCA	cis	rs9649213	0.574	rs7802560	ENSG00000272950.1	RP11-307C18.1	-7.66	1.06e-13	3.79e-11	-0.41	-0.33	Prostate cancer (SNP x SNP interaction);	chr7:98274494	chr7:98322853~98323430:+
THCA	cis	rs7208859	0.573	rs7214313	ENSG00000264538.5	SUZ12P1	-7.66	1.06e-13	3.79e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30709299~30790908:+
THCA	cis	rs7851660	0.548	rs1156850	ENSG00000236130.1	PTCSC2	-7.66	1.06e-13	3.79e-11	-0.27	-0.33	Strep throat;	chr9:97810882	chr9:97805935~97810008:-
THCA	cis	rs9487094	0.813	rs3799840	ENSG00000260273.1	RP11-425D10.10	7.66	1.06e-13	3.8e-11	0.43	0.33	Height;	chr6:109381443	chr6:109382795~109383666:+
THCA	cis	rs4722166	0.695	rs56061963	ENSG00000179428.2	AC073072.5	-7.66	1.06e-13	3.8e-11	-0.42	-0.33	Lung cancer;	chr7:22760778	chr7:22725395~22727620:-
THCA	cis	rs11024102	0.83	rs11024110	ENSG00000184669.7	OR7E14P	-7.66	1.06e-13	3.8e-11	-0.43	-0.33	Glaucoma (primary angle closure);	chr11:17006843	chr11:17013998~17053024:+
THCA	cis	rs9329221	0.506	rs6993610	ENSG00000261451.1	RP11-981G7.1	-7.66	1.06e-13	3.8e-11	-0.43	-0.33	Neuroticism;	chr8:10473484	chr8:10433672~10438312:+
THCA	cis	rs2466254	0.657	rs2466265	ENSG00000251468.2	RP11-369K16.1	7.66	1.06e-13	3.81e-11	0.54	0.33	Pneumonia;	chr8:12972212	chr8:12958387~12962200:+
THCA	cis	rs6496932	0.503	rs8037726	ENSG00000218052.5	ADAMTS7P4	-7.66	1.06e-13	3.81e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85408154	chr15:85255369~85330334:-
THCA	cis	rs2562456	0.917	rs2650804	ENSG00000268555.1	RP11-678G14.3	7.66	1.07e-13	3.82e-11	0.46	0.33	Pain;	chr19:21497382	chr19:21570822~21587322:-
THCA	cis	rs8062405	0.558	rs151228	ENSG00000251417.2	RP11-1348G14.4	-7.66	1.07e-13	3.82e-11	-0.31	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28802743~28817828:+
THCA	cis	rs6908034	0.556	rs79028848	ENSG00000228412.5	RP4-625H18.2	7.66	1.07e-13	3.82e-11	0.8	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782922	chr6:19802164~19804752:-
THCA	cis	rs2337406	0.866	rs79901786	ENSG00000274576.2	IGHV2-70	-7.66	1.07e-13	3.83e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106777623	chr14:106770577~106771020:-
THCA	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-7.66	1.07e-13	3.84e-11	-0.38	-0.33	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
THCA	cis	rs9400467	0.528	rs10872066	ENSG00000230177.1	RP5-1112D6.4	-7.66	1.07e-13	3.84e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111272408	chr6:111277932~111278742:+
THCA	cis	rs2712184	0.721	rs2541401	ENSG00000229352.1	AC007563.3	-7.66	1.07e-13	3.84e-11	-0.4	-0.33	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216776283	chr2:216799608~216805335:+
THCA	cis	rs189798	0.807	rs330912	ENSG00000254340.1	RP11-10A14.3	7.66	1.08e-13	3.86e-11	0.38	0.33	Myopia (pathological);	chr8:9138784	chr8:9141424~9145435:+
THCA	cis	rs17684571	0.872	rs13219546	ENSG00000231441.1	RP11-472M19.2	7.66	1.08e-13	3.86e-11	0.42	0.33	Schizophrenia;	chr6:56741480	chr6:56844002~56864078:+
THCA	cis	rs2284219	0.964	rs2284218	ENSG00000196295.10	AC005154.6	-7.66	1.08e-13	3.86e-11	-0.24	-0.33	Type 2 diabetes;	chr7:30674717	chr7:30516309~30594809:-
THCA	cis	rs2739330	0.828	rs5760098	ENSG00000206090.4	AP000350.7	7.66	1.08e-13	3.86e-11	0.42	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23939998~23942798:+
THCA	cis	rs7942368	0.941	rs10899279	ENSG00000254632.1	RP11-21L23.4	7.66	1.08e-13	3.86e-11	0.48	0.33	Endometriosis;	chr11:76766200	chr11:76759916~76768223:-
THCA	cis	rs66823261	0.778	rs2906332	ENSG00000223508.5	RPL23AP53	7.66	1.08e-13	3.87e-11	0.43	0.33	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:213186~232231:-
THCA	cis	rs2562456	0.833	rs8106025	ENSG00000268555.1	RP11-678G14.3	-7.66	1.08e-13	3.88e-11	-0.47	-0.33	Pain;	chr19:21451922	chr19:21570822~21587322:-
THCA	cis	rs9543976	0.623	rs9544004	ENSG00000261553.4	RP11-29G8.3	7.66	1.08e-13	3.88e-11	0.4	0.33	Diabetic retinopathy;	chr13:75617748	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.588	rs7324195	ENSG00000261553.4	RP11-29G8.3	7.66	1.08e-13	3.88e-11	0.4	0.33	Diabetic retinopathy;	chr13:75618386	chr13:75549773~75807120:+
THCA	cis	rs10411161	0.748	rs56705839	ENSG00000269483.1	AC006272.1	7.66	1.09e-13	3.89e-11	0.54	0.33	Breast cancer;	chr19:51873983	chr19:51839924~51843324:-
THCA	cis	rs9329221	0.527	rs4841351	ENSG00000261451.1	RP11-981G7.1	-7.66	1.09e-13	3.89e-11	-0.43	-0.33	Neuroticism;	chr8:10469857	chr8:10433672~10438312:+
THCA	cis	rs2243480	0.522	rs1638736	ENSG00000226824.5	RP4-756H11.3	-7.66	1.09e-13	3.9e-11	-0.84	-0.33	Diabetic kidney disease;	chr7:66627321	chr7:66654538~66669855:+
THCA	cis	rs2288884	0.505	rs8110213	ENSG00000275055.1	CTC-471J1.11	-7.66	1.09e-13	3.9e-11	-0.36	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51958730	chr19:52049007~52049754:+
THCA	cis	rs10129255	0.5	rs2027903	ENSG00000223648.3	IGHV3-64	7.66	1.09e-13	3.9e-11	0.2	0.33	Kawasaki disease;	chr14:106807047	chr14:106643132~106658258:-
THCA	cis	rs737008	0.922	rs376374	ENSG00000262703.1	RP11-485G7.6	-7.66	1.09e-13	3.91e-11	-0.38	-0.33	Obesity-related traits;	chr16:11276759	chr16:11348143~11349321:-
THCA	cis	rs13129231	0.847	rs12499647	ENSG00000206820.1	RNU1-138P	-7.66	1.09e-13	3.91e-11	-0.38	-0.33	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113447561	chr4:113420323~113420486:+
THCA	cis	rs8062405	0.54	rs151226	ENSG00000251417.2	RP11-1348G14.4	-7.66	1.09e-13	3.92e-11	-0.31	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28802743~28817828:+
THCA	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	7.66	1.1e-13	3.92e-11	0.4	0.33	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
THCA	cis	rs9902453	0.933	rs4470197	ENSG00000264007.1	RP11-68I3.10	7.66	1.1e-13	3.93e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30137456	chr17:29621617~29622254:-
THCA	cis	rs75422866	0.558	rs73104190	ENSG00000257433.4	RP1-197B17.3	7.66	1.1e-13	3.93e-11	0.5	0.33	Pneumonia;	chr12:47716040	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.51	rs73104197	ENSG00000257433.4	RP1-197B17.3	7.66	1.1e-13	3.93e-11	0.5	0.33	Pneumonia;	chr12:47717273	chr12:47706085~47742294:+
THCA	cis	rs4819052	1	rs13052356	ENSG00000237664.1	LINC00316	-7.66	1.1e-13	3.95e-11	-0.36	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45243673	chr21:45338590~45341990:-
THCA	cis	rs10971721	0.584	rs55857848	ENSG00000260947.1	RP11-384P7.7	7.66	1.1e-13	3.95e-11	0.75	0.33	Body mass index;	chr9:34121512	chr9:33697459~33700986:+
THCA	cis	rs748404	0.56	rs689797	ENSG00000166763.7	STRCP1	7.65	1.11e-13	3.97e-11	0.36	0.33	Lung cancer;	chr15:43534359	chr15:43699488~43718184:-
THCA	cis	rs748404	0.56	rs2255663	ENSG00000166763.7	STRCP1	-7.65	1.11e-13	3.97e-11	-0.36	-0.33	Lung cancer;	chr15:43536810	chr15:43699488~43718184:-
THCA	cis	rs42490	0.536	rs400571	ENSG00000251136.7	RP11-37B2.1	-7.65	1.11e-13	3.97e-11	-0.3	-0.33	Leprosy;	chr8:89863336	chr8:89609409~89757727:-
THCA	cis	rs72772090	0.539	rs72775807	ENSG00000248734.2	CTD-2260A17.1	-7.65	1.11e-13	3.97e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96844058	chr5:96784777~96785999:+
THCA	cis	rs7208859	0.623	rs56812022	ENSG00000264538.5	SUZ12P1	-7.65	1.11e-13	3.97e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30709299~30790908:+
THCA	cis	rs172166	0.516	rs2622322	ENSG00000219392.1	RP1-265C24.5	-7.65	1.11e-13	3.98e-11	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:28149665	chr6:28115628~28116551:+
THCA	cis	rs11148252	0.875	rs9568728	ENSG00000278238.1	RP11-245D16.4	-7.65	1.11e-13	3.98e-11	-0.38	-0.33	Lewy body disease;	chr13:52372458	chr13:52454775~52455331:-
THCA	cis	rs2929278	0.617	rs3087657	ENSG00000166763.7	STRCP1	7.65	1.12e-13	3.99e-11	0.37	0.33	Schizophrenia;	chr15:43771661	chr15:43699488~43718184:-
THCA	cis	rs11148252	0.538	rs2274202	ENSG00000235660.1	LINC00345	-7.65	1.12e-13	4e-11	-0.41	-0.33	Lewy body disease;	chr13:52148663	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.538	rs9526842	ENSG00000235660.1	LINC00345	-7.65	1.12e-13	4e-11	-0.41	-0.33	Lewy body disease;	chr13:52153588	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.538	rs9535887	ENSG00000235660.1	LINC00345	-7.65	1.12e-13	4e-11	-0.41	-0.33	Lewy body disease;	chr13:52156626	chr13:52484161~52484680:-
THCA	cis	rs9902453	0.967	rs1906451	ENSG00000264007.1	RP11-68I3.10	7.65	1.12e-13	4.01e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30188461	chr17:29621617~29622254:-
THCA	cis	rs172166	0.61	rs276369	ENSG00000219392.1	RP1-265C24.5	-7.65	1.12e-13	4.01e-11	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:27951465	chr6:28115628~28116551:+
THCA	cis	rs193541	0.632	rs246276	ENSG00000263432.2	RN7SL689P	7.65	1.13e-13	4.02e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122904262	chr5:123022487~123022783:-
THCA	cis	rs4819052	0.851	rs7275468	ENSG00000237664.1	LINC00316	-7.65	1.13e-13	4.03e-11	-0.33	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45236584	chr21:45338590~45341990:-
THCA	cis	rs8113308	0.81	rs8104626	ENSG00000269235.1	ZNF350-AS1	7.65	1.13e-13	4.04e-11	0.52	0.33	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51977364	chr19:51949134~51981367:+
THCA	cis	rs5769707	0.681	rs8140095	ENSG00000235111.1	RP1-29C18.8	-7.65	1.13e-13	4.04e-11	-0.44	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49650147	chr22:49612657~49615716:-
THCA	cis	rs9500256	0.903	rs726783	ENSG00000215190.7	LINC00680	-7.65	1.13e-13	4.04e-11	-0.38	-0.33	Eosinophilic esophagitis (pediatric);	chr6:58006583	chr6:57946074~57961501:-
THCA	cis	rs516805	0.748	rs11154070	ENSG00000279453.1	RP3-425C14.4	7.65	1.13e-13	4.04e-11	0.34	0.33	Lymphocyte counts;	chr6:122362886	chr6:122436789~122439223:-
THCA	cis	rs934734	0.563	rs1858036	ENSG00000281920.1	RP11-418H16.1	7.65	1.14e-13	4.06e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65371107	chr2:65623272~65628424:+
THCA	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-7.65	1.14e-13	4.07e-11	-0.36	-0.33	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-7.65	1.14e-13	4.07e-11	-0.36	-0.33	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-7.65	1.14e-13	4.07e-11	-0.36	-0.33	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
THCA	cis	rs12908161	1	rs35808647	ENSG00000259728.4	LINC00933	7.65	1.14e-13	4.08e-11	0.45	0.33	Schizophrenia;	chr15:84834210	chr15:84570649~84580175:+
THCA	cis	rs8114671	0.539	rs2064453	ENSG00000269202.1	RP4-614O4.12	-7.65	1.15e-13	4.09e-11	-0.29	-0.33	Height;	chr20:34873007	chr20:35201747~35203288:-
THCA	cis	rs686320	1	rs1787666	ENSG00000245532.5	NEAT1	7.65	1.15e-13	4.09e-11	0.3	0.33	Hip circumference adjusted for BMI;	chr11:65481618	chr11:65422774~65445540:+
THCA	cis	rs728616	0.867	rs723191	ENSG00000225484.5	NUTM2B-AS1	-7.65	1.15e-13	4.09e-11	-0.63	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948164	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs723193	ENSG00000225484.5	NUTM2B-AS1	-7.65	1.15e-13	4.09e-11	-0.63	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79948399	chr10:79663088~79826594:-
THCA	cis	rs853679	0.666	rs200956	ENSG00000219392.1	RP1-265C24.5	-7.65	1.15e-13	4.1e-11	-0.47	-0.33	Depression;	chr6:27871968	chr6:28115628~28116551:+
THCA	cis	rs8072100	0.87	rs10432035	ENSG00000228782.6	CTD-2026D20.3	-7.65	1.15e-13	4.11e-11	-0.3	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47547547	chr17:47450568~47492492:-
THCA	cis	rs7942368	0.818	rs10793194	ENSG00000254632.1	RP11-21L23.4	7.65	1.15e-13	4.12e-11	0.48	0.33	Endometriosis;	chr11:76764685	chr11:76759916~76768223:-
THCA	cis	rs11603691	1	rs2155232	ENSG00000254662.1	RP11-872D17.4	-7.65	1.15e-13	4.12e-11	-0.59	-0.33	Low high density lipoprotein cholesterol levels;	chr11:57273904	chr11:57325603~57327958:+
THCA	cis	rs9326248	1	rs664922	ENSG00000280143.1	AP000892.6	7.65	1.16e-13	4.13e-11	0.42	0.33	Blood protein levels;	chr11:117200179	chr11:117204967~117210292:+
THCA	cis	rs9326248	1	rs664082	ENSG00000280143.1	AP000892.6	7.65	1.16e-13	4.13e-11	0.42	0.33	Blood protein levels;	chr11:117200354	chr11:117204967~117210292:+
THCA	cis	rs6603134	0.502	rs6603133	ENSG00000267939.1	CTD-2325M2.1	-7.65	1.16e-13	4.14e-11	-0.36	-0.33	Blood protein levels;	chr19:8038352	chr19:8008729~8016025:+
THCA	cis	rs11148252	0.875	rs7987115	ENSG00000278238.1	RP11-245D16.4	-7.65	1.16e-13	4.14e-11	-0.37	-0.33	Lewy body disease;	chr13:52387962	chr13:52454775~52455331:-
THCA	cis	rs10971721	0.822	rs12376279	ENSG00000260947.1	RP11-384P7.7	7.65	1.16e-13	4.14e-11	0.81	0.33	Body mass index;	chr9:33804256	chr9:33697459~33700986:+
THCA	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-7.65	1.16e-13	4.14e-11	-0.36	-0.33	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
THCA	cis	rs9902453	0.9	rs9910970	ENSG00000264007.1	RP11-68I3.10	7.65	1.16e-13	4.14e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30151311	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.934	rs8079028	ENSG00000264007.1	RP11-68I3.10	7.65	1.16e-13	4.14e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30157216	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.833	rs7216631	ENSG00000264007.1	RP11-68I3.10	7.65	1.16e-13	4.14e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30168094	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.868	rs9902340	ENSG00000264007.1	RP11-68I3.10	-7.65	1.16e-13	4.14e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:30149440	chr17:29621617~29622254:-
THCA	cis	rs1667284	1	rs1667284	ENSG00000266521.1	RP11-650P15.1	-7.65	1.16e-13	4.14e-11	-0.42	-0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31646245	chr18:31496645~31497195:-
THCA	cis	rs17695224	0.545	rs10500309	ENSG00000269483.1	AC006272.1	7.65	1.16e-13	4.15e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51829123	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.545	rs8111469	ENSG00000269483.1	AC006272.1	7.65	1.16e-13	4.15e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51829272	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.565	rs61681419	ENSG00000269483.1	AC006272.1	7.65	1.16e-13	4.15e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51830726	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.545	rs13346095	ENSG00000269483.1	AC006272.1	7.65	1.16e-13	4.15e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51831092	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.5	rs13346104	ENSG00000269483.1	AC006272.1	7.65	1.16e-13	4.15e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51831173	chr19:51839924~51843324:-
THCA	cis	rs860295	0.871	rs12724079	ENSG00000225855.5	RUSC1-AS1	-7.65	1.16e-13	4.15e-11	-0.21	-0.33	Body mass index;	chr1:155464151	chr1:155316863~155324176:-
THCA	cis	rs922182	0.663	rs7180057	ENSG00000275785.1	RP11-111E14.2	7.65	1.17e-13	4.16e-11	0.39	0.33	Blood protein levels;	chr15:63971596	chr15:63890030~63890317:+
THCA	cis	rs6496932	0.503	rs10520588	ENSG00000218052.5	ADAMTS7P4	-7.65	1.17e-13	4.17e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85419479	chr15:85255369~85330334:-
THCA	cis	rs7849270	0.725	rs59012667	ENSG00000268707.1	RP11-247A12.7	-7.65	1.17e-13	4.18e-11	-0.41	-0.33	Blood metabolite ratios;	chr9:129088202	chr9:129170434~129170940:+
THCA	cis	rs11673344	0.542	rs1667380	ENSG00000226686.6	LINC01535	7.65	1.17e-13	4.19e-11	0.37	0.33	Obesity-related traits;	chr19:37001848	chr19:37251912~37265535:+
THCA	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	7.65	1.18e-13	4.19e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
THCA	cis	rs9813712	0.574	rs35856399	ENSG00000228252.7	COL6A4P2	-7.65	1.18e-13	4.19e-11	-0.32	-0.33	Response to amphetamines;	chr3:130241961	chr3:130212823~130273806:+
THCA	cis	rs11603691	0.901	rs10896604	ENSG00000254662.1	RP11-872D17.4	7.65	1.18e-13	4.2e-11	0.59	0.33	Low high density lipoprotein cholesterol levels;	chr11:57317739	chr11:57325603~57327958:+
THCA	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-7.65	1.18e-13	4.2e-11	-0.36	-0.33	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
THCA	cis	rs9473147	0.571	rs9463335	ENSG00000270761.1	RP11-385F7.1	-7.65	1.18e-13	4.2e-11	-0.27	-0.33	Platelet distribution width;Mean platelet volume;	chr6:47511400	chr6:47477243~47477572:-
THCA	cis	rs17695224	0.5	rs4801897	ENSG00000269483.1	AC006272.1	7.65	1.18e-13	4.21e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51831942	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.5	rs4802876	ENSG00000269483.1	AC006272.1	7.65	1.18e-13	4.21e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51831964	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.5	rs4802877	ENSG00000269483.1	AC006272.1	7.65	1.18e-13	4.21e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51831991	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.52	rs4801898	ENSG00000269483.1	AC006272.1	7.65	1.18e-13	4.21e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51832064	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.545	rs17761960	ENSG00000269483.1	AC006272.1	7.65	1.18e-13	4.21e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51832275	chr19:51839924~51843324:-
THCA	cis	rs10971721	0.822	rs10971793	ENSG00000260947.1	RP11-384P7.7	7.65	1.18e-13	4.21e-11	0.82	0.33	Body mass index;	chr9:33922628	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs10971794	ENSG00000260947.1	RP11-384P7.7	7.65	1.18e-13	4.21e-11	0.82	0.33	Body mass index;	chr9:33924314	chr9:33697459~33700986:+
THCA	cis	rs61041384	1	rs76872194	ENSG00000256092.2	RP13-942N8.1	-7.65	1.18e-13	4.21e-11	-0.49	-0.33	Schizophrenia;	chr12:123208816	chr12:123363868~123366113:+
THCA	cis	rs61041384	0.661	rs74240771	ENSG00000256092.2	RP13-942N8.1	-7.65	1.18e-13	4.21e-11	-0.49	-0.33	Schizophrenia;	chr12:123212416	chr12:123363868~123366113:+
THCA	cis	rs4950322	0.542	rs17159914	ENSG00000237188.3	RP11-337C18.8	-7.65	1.19e-13	4.23e-11	-0.38	-0.33	Protein quantitative trait loci;	chr1:147183226	chr1:147172771~147211568:+
THCA	cis	rs2562456	0.917	rs2650793	ENSG00000268555.1	RP11-678G14.3	-7.65	1.19e-13	4.23e-11	-0.45	-0.33	Pain;	chr19:21493313	chr19:21570822~21587322:-
THCA	cis	rs9543976	0.623	rs4885323	ENSG00000261553.4	RP11-29G8.3	7.64	1.19e-13	4.24e-11	0.4	0.33	Diabetic retinopathy;	chr13:75598278	chr13:75549773~75807120:+
THCA	cis	rs9400467	0.508	rs11153283	ENSG00000230177.1	RP5-1112D6.4	-7.64	1.19e-13	4.24e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111275940	chr6:111277932~111278742:+
THCA	cis	rs150992	0.609	rs451141	ENSG00000248489.1	CTD-2007H13.3	-7.64	1.19e-13	4.24e-11	-0.32	-0.33	Body mass index;	chr5:98991691	chr5:98929171~98995013:+
THCA	cis	rs4073416	0.707	rs1054218	ENSG00000276116.2	FUT8-AS1	-7.64	1.19e-13	4.25e-11	-0.35	-0.33	N-glycan levels;	chr14:65742472	chr14:65411170~65412690:-
THCA	cis	rs2439831	0.867	rs3101443	ENSG00000275601.1	AC011330.13	-7.64	1.19e-13	4.25e-11	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43620174	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.867	rs2614811	ENSG00000275601.1	AC011330.13	-7.64	1.19e-13	4.25e-11	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43621289	chr15:43642389~43643023:-
THCA	cis	rs10971721	0.731	rs12377117	ENSG00000260947.1	RP11-384P7.7	7.64	1.19e-13	4.25e-11	0.81	0.33	Body mass index;	chr9:33806586	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.73	rs72725361	ENSG00000260947.1	RP11-384P7.7	7.64	1.19e-13	4.25e-11	0.81	0.33	Body mass index;	chr9:33806615	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs12376664	ENSG00000260947.1	RP11-384P7.7	7.64	1.19e-13	4.25e-11	0.81	0.33	Body mass index;	chr9:33808705	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.822	rs72725368	ENSG00000260947.1	RP11-384P7.7	7.64	1.19e-13	4.25e-11	0.81	0.33	Body mass index;	chr9:33815457	chr9:33697459~33700986:+
THCA	cis	rs9309473	0.528	rs10191517	ENSG00000163016.8	ALMS1P	7.64	1.19e-13	4.25e-11	0.44	0.33	Metabolite levels;	chr2:73331275	chr2:73644919~73685576:+
THCA	cis	rs10875746	0.551	rs12322347	ENSG00000240399.1	RP1-228P16.1	-7.64	1.19e-13	4.26e-11	-0.38	-0.33	Longevity (90 years and older);	chr12:48313915	chr12:48054813~48055591:-
THCA	cis	rs10875746	0.551	rs12322348	ENSG00000240399.1	RP1-228P16.1	-7.64	1.19e-13	4.26e-11	-0.38	-0.33	Longevity (90 years and older);	chr12:48313916	chr12:48054813~48055591:-
THCA	cis	rs12681366	0.761	rs2930963	ENSG00000253704.1	RP11-267M23.4	7.64	1.2e-13	4.26e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94434892	chr8:94553722~94569745:+
THCA	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-7.64	1.2e-13	4.28e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
THCA	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-7.64	1.2e-13	4.28e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
THCA	cis	rs2337406	0.866	rs7152038	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106778230	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs7152809	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106778385	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs7152832	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106778427	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.5	rs7152934	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106778702	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.789	rs12050392	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779073	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092505	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779163	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.789	rs74092507	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779174	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092511	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779234	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092512	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779306	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.789	rs74092514	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779385	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092520	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106779632	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs4583128	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106780669	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.929	rs12050200	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106780983	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.929	rs59263250	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781183	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs58083017	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781256	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.789	rs60390024	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781327	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092532	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781363	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092534	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781364	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74092537	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781883	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.81	rs74092538	ENSG00000274576.2	IGHV2-70	-7.64	1.2e-13	4.28e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781942	chr14:106770577~106771020:-
THCA	cis	rs9487094	0.813	rs34320275	ENSG00000260273.1	RP11-425D10.10	7.64	1.2e-13	4.28e-11	0.43	0.33	Height;	chr6:109436760	chr6:109382795~109383666:+
THCA	cis	rs853679	0.882	rs9380069	ENSG00000280107.1	AL022393.9	-7.64	1.2e-13	4.28e-11	-0.48	-0.33	Depression;	chr6:28235522	chr6:28170845~28172521:+
THCA	cis	rs7714584	1	rs10041072	ENSG00000197083.10	ZNF300P1	7.64	1.2e-13	4.28e-11	0.53	0.33	Crohn's disease;	chr5:150880080	chr5:150930645~150946289:-
THCA	cis	rs6504663	0.525	rs557	ENSG00000275897.1	RP11-94C24.13	7.64	1.2e-13	4.29e-11	0.32	0.33	Visceral fat;	chr17:50485873	chr17:50475819~50478391:+
THCA	cis	rs686320	1	rs3132770	ENSG00000245532.5	NEAT1	7.64	1.2e-13	4.29e-11	0.3	0.33	Hip circumference adjusted for BMI;	chr11:65483846	chr11:65422774~65445540:+
THCA	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	7.64	1.2e-13	4.29e-11	0.2	0.33	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
THCA	cis	rs150992	0.587	rs13179812	ENSG00000248489.1	CTD-2007H13.3	-7.64	1.2e-13	4.29e-11	-0.32	-0.33	Body mass index;	chr5:99021029	chr5:98929171~98995013:+
THCA	cis	rs737008	0.96	rs11640295	ENSG00000262636.1	CTD-3088G3.4	7.64	1.21e-13	4.3e-11	0.44	0.33	Obesity-related traits;	chr16:11296871	chr16:11380859~11381118:-
THCA	cis	rs67180937	0.778	rs3002126	ENSG00000272750.1	RP11-378J18.8	-7.64	1.21e-13	4.31e-11	-0.48	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222676939	chr1:222658867~222661512:-
THCA	cis	rs728616	0.867	rs76239460	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963471	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860400	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79963671	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860412	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79968730	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs12412257	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79969847	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs117139504	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974451	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs12412226	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79975532	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs4387301	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79976643	chr10:79663088~79826594:-
THCA	cis	rs728616	0.764	rs117833443	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978380	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs116994688	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79978381	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860420	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979623	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs75447386	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79979891	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs4520539	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79980773	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs61860421	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79983643	chr10:79663088~79826594:-
THCA	cis	rs728616	0.867	rs118134654	ENSG00000225484.5	NUTM2B-AS1	-7.64	1.21e-13	4.31e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79984625	chr10:79663088~79826594:-
THCA	cis	rs730566	0.64	rs6442112	ENSG00000229759.1	MRPS18AP1	7.64	1.21e-13	4.31e-11	0.42	0.33	Prion diseases;	chr3:48274544	chr3:48256350~48256938:-
THCA	cis	rs6142102	0.58	rs761233	ENSG00000275784.1	RP5-1125A11.6	-7.64	1.21e-13	4.31e-11	-0.33	-0.33	Skin pigmentation;	chr20:33981080	chr20:33989480~33991818:-
THCA	cis	rs853679	0.766	rs9368561	ENSG00000219392.1	RP1-265C24.5	-7.64	1.21e-13	4.32e-11	-0.58	-0.33	Depression;	chr6:28200565	chr6:28115628~28116551:+
THCA	cis	rs7849270	1	rs7855278	ENSG00000268707.1	RP11-247A12.7	7.64	1.21e-13	4.32e-11	0.41	0.33	Blood metabolite ratios;	chr9:129159086	chr9:129170434~129170940:+
THCA	cis	rs7160336	0.604	rs4903150	ENSG00000259065.1	RP5-1021I20.1	7.64	1.22e-13	4.33e-11	0.39	0.33	Blood protein levels;	chr14:73844725	chr14:73787360~73803270:+
THCA	cis	rs2581794	1	rs2581794	ENSG00000242142.1	SERBP1P3	7.64	1.22e-13	4.35e-11	0.39	0.33	Schizophrenia;	chr3:53002190	chr3:53064283~53065091:-
THCA	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	7.64	1.22e-13	4.35e-11	0.43	0.33	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
THCA	cis	rs516805	0.748	rs12189881	ENSG00000279453.1	RP3-425C14.4	7.64	1.22e-13	4.35e-11	0.34	0.33	Lymphocyte counts;	chr6:122375109	chr6:122436789~122439223:-
THCA	cis	rs2288884	0.945	rs78336183	ENSG00000275055.1	CTC-471J1.11	-7.64	1.22e-13	4.35e-11	-0.31	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52058230	chr19:52049007~52049754:+
THCA	cis	rs7945705	0.875	rs10769947	ENSG00000254860.4	TMEM9B-AS1	-7.64	1.22e-13	4.36e-11	-0.36	-0.33	Hemoglobin concentration;	chr11:8736567	chr11:8964675~8977527:+
THCA	cis	rs2787702	0.5	rs11591943	ENSG00000237233.2	TMEM26-AS1	7.64	1.23e-13	4.36e-11	0.54	0.33	Response to taxane treatment (placlitaxel);	chr10:61560817	chr10:61452639~61481956:+
THCA	cis	rs9341808	0.754	rs3805907	ENSG00000272129.1	RP11-250B2.6	-7.64	1.23e-13	4.37e-11	-0.42	-0.33	Sitting height ratio;	chr6:80263948	chr6:80355424~80356859:+
THCA	cis	rs7714584	1	rs1428555	ENSG00000197083.10	ZNF300P1	-7.64	1.23e-13	4.38e-11	-0.54	-0.33	Crohn's disease;	chr5:150877829	chr5:150930645~150946289:-
THCA	cis	rs2562456	0.755	rs2562421	ENSG00000268119.4	CTD-2561J22.5	-7.64	1.23e-13	4.38e-11	-0.42	-0.33	Pain;	chr19:21448502	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.793	rs2562420	ENSG00000268119.4	CTD-2561J22.5	-7.64	1.23e-13	4.38e-11	-0.42	-0.33	Pain;	chr19:21448503	chr19:21444241~21463908:-
THCA	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	7.64	1.23e-13	4.39e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
THCA	cis	rs11696845	1	rs11696845	ENSG00000276223.1	RP4-781B1.5	-7.64	1.24e-13	4.4e-11	-0.42	-0.33	Obesity-related traits;	chr20:44742679	chr20:44746642~44747201:+
THCA	cis	rs4819052	0.851	rs1999334	ENSG00000237664.1	LINC00316	-7.64	1.24e-13	4.4e-11	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250542	chr21:45338590~45341990:-
THCA	cis	rs7208859	0.623	rs8081299	ENSG00000264538.5	SUZ12P1	-7.64	1.24e-13	4.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8068645	ENSG00000264538.5	SUZ12P1	-7.64	1.24e-13	4.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30709299~30790908:+
THCA	cis	rs10510102	0.516	rs2420976	ENSG00000276742.1	RP11-500G22.4	-7.64	1.24e-13	4.41e-11	-0.51	-0.33	Breast cancer;	chr10:121986932	chr10:121956782~121957098:+
THCA	cis	rs1949733	1	rs1357481	ENSG00000205959.3	RP11-689P11.2	-7.64	1.24e-13	4.41e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8494494	chr4:8482270~8512610:+
THCA	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-7.64	1.24e-13	4.41e-11	-0.54	-0.33	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
THCA	cis	rs10971721	0.749	rs72725371	ENSG00000260947.1	RP11-384P7.7	7.64	1.24e-13	4.41e-11	0.81	0.33	Body mass index;	chr9:33825013	chr9:33697459~33700986:+
THCA	cis	rs9902453	1	rs28664971	ENSG00000264007.1	RP11-68I3.10	7.64	1.24e-13	4.42e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30110392	chr17:29621617~29622254:-
THCA	cis	rs12681366	0.761	rs2197003	ENSG00000253704.1	RP11-267M23.4	7.64	1.24e-13	4.42e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94444758	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.801	rs2921386	ENSG00000253704.1	RP11-267M23.4	7.64	1.24e-13	4.42e-11	0.35	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94446672	chr8:94553722~94569745:+
THCA	cis	rs832187	0.629	rs6798742	ENSG00000280620.1	SCAANT1	7.64	1.25e-13	4.43e-11	0.42	0.33	Schizophrenia;	chr3:63918083	chr3:63911518~63911772:-
THCA	cis	rs4927850	0.666	rs4927853	ENSG00000207650.1	MIR570	7.64	1.25e-13	4.43e-11	0.4	0.33	Pancreatic cancer;	chr3:196025182	chr3:195699401~195699497:+
THCA	cis	rs193541	0.632	rs30023	ENSG00000263432.2	RN7SL689P	7.64	1.25e-13	4.44e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122949604	chr5:123022487~123022783:-
THCA	cis	rs8072100	0.967	rs11656855	ENSG00000228782.6	CTD-2026D20.3	-7.64	1.25e-13	4.44e-11	-0.3	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47637289	chr17:47450568~47492492:-
THCA	cis	rs6840258	0.66	rs72667739	ENSG00000251411.1	RP11-397E7.4	-7.64	1.25e-13	4.44e-11	-0.41	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86956347	chr4:86913266~86914817:-
THCA	cis	rs1501911	0.611	rs56180458	ENSG00000248489.1	CTD-2007H13.3	7.64	1.25e-13	4.45e-11	0.32	0.33	Lung function (FEV1/FVC);	chr5:99043633	chr5:98929171~98995013:+
THCA	cis	rs9388451	0.874	rs3734634	ENSG00000237742.5	RP11-624M8.1	-7.64	1.25e-13	4.45e-11	-0.29	-0.33	Brugada syndrome;	chr6:125790654	chr6:125578558~125749190:-
THCA	cis	rs6603134	0.502	rs10405582	ENSG00000267939.1	CTD-2325M2.1	-7.64	1.25e-13	4.46e-11	-0.35	-0.33	Blood protein levels;	chr19:8038654	chr19:8008729~8016025:+
THCA	cis	rs9326248	1	rs7946257	ENSG00000280143.1	AP000892.6	7.64	1.26e-13	4.46e-11	0.42	0.33	Blood protein levels;	chr11:117182449	chr11:117204967~117210292:+
THCA	cis	rs77204473	0.744	rs17120293	ENSG00000254851.1	RP11-109L13.1	7.64	1.26e-13	4.47e-11	0.82	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117074130	chr11:117135528~117138582:+
THCA	cis	rs8114671	0.647	rs1124511	ENSG00000269202.1	RP4-614O4.12	-7.64	1.26e-13	4.5e-11	-0.28	-0.33	Height;	chr20:35148894	chr20:35201747~35203288:-
THCA	cis	rs9902453	0.967	rs55744550	ENSG00000264007.1	RP11-68I3.10	7.64	1.27e-13	4.5e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30148711	chr17:29621617~29622254:-
THCA	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	7.64	1.27e-13	4.51e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	7.64	1.27e-13	4.51e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
THCA	cis	rs7208859	0.524	rs77498725	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.5	rs57005940	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Body mass index;	chr17:30739311	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs73267872	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs57670615	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.5	rs2874724	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Body mass index;	chr17:30745415	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.568	rs9898097	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Body mass index;	chr17:30745654	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9911490	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7503542	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs11656278	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs6505207	ENSG00000264538.5	SUZ12P1	-7.64	1.27e-13	4.51e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30709299~30790908:+
THCA	cis	rs6603134	0.502	rs10406511	ENSG00000267939.1	CTD-2325M2.1	-7.64	1.27e-13	4.51e-11	-0.35	-0.33	Blood protein levels;	chr19:8039061	chr19:8008729~8016025:+
THCA	cis	rs1150668	0.83	rs213240	ENSG00000219392.1	RP1-265C24.5	-7.64	1.27e-13	4.52e-11	-0.37	-0.33	Pubertal anthropometrics;	chr6:28348098	chr6:28115628~28116551:+
THCA	cis	rs9902453	0.78	rs3115093	ENSG00000264007.1	RP11-68I3.10	7.64	1.27e-13	4.52e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:29712737	chr17:29621617~29622254:-
THCA	cis	rs6545883	0.524	rs17482440	ENSG00000271889.1	RP11-493E12.1	-7.63	1.27e-13	4.52e-11	-0.32	-0.33	Tuberculosis;	chr2:61321722	chr2:61151433~61162105:-
THCA	cis	rs9393777	0.92	rs13196692	ENSG00000280107.1	AL022393.9	-7.63	1.27e-13	4.52e-11	-0.65	-0.33	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28170845~28172521:+
THCA	cis	rs9393777	0.92	rs34150729	ENSG00000280107.1	AL022393.9	-7.63	1.27e-13	4.52e-11	-0.65	-0.33	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28170845~28172521:+
THCA	cis	rs9393777	0.92	rs13191227	ENSG00000280107.1	AL022393.9	-7.63	1.27e-13	4.52e-11	-0.65	-0.33	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28170845~28172521:+
THCA	cis	rs11673344	0.542	rs826325	ENSG00000226686.6	LINC01535	7.63	1.27e-13	4.53e-11	0.36	0.33	Obesity-related traits;	chr19:37003580	chr19:37251912~37265535:+
THCA	cis	rs8114671	0.967	rs6142322	ENSG00000269202.1	RP4-614O4.12	7.63	1.28e-13	4.53e-11	0.28	0.33	Height;	chr20:35200735	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.967	rs6142324	ENSG00000269202.1	RP4-614O4.12	7.63	1.28e-13	4.53e-11	0.28	0.33	Height;	chr20:35201240	chr20:35201747~35203288:-
THCA	cis	rs10971721	0.584	rs10971901	ENSG00000260947.1	RP11-384P7.7	7.63	1.28e-13	4.54e-11	0.77	0.33	Body mass index;	chr9:34085149	chr9:33697459~33700986:+
THCA	cis	rs7646881	0.812	rs73015665	ENSG00000240207.5	RP11-379F4.4	-7.63	1.28e-13	4.54e-11	-0.47	-0.33	Tetralogy of Fallot;	chr3:158736145	chr3:158732263~158784070:+
THCA	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	7.63	1.28e-13	4.54e-11	0.23	0.33	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
THCA	cis	rs801193	0.66	rs1962050	ENSG00000232559.3	GS1-124K5.12	-7.63	1.28e-13	4.54e-11	-0.31	-0.33	Aortic root size;	chr7:66775021	chr7:66554588~66576923:-
THCA	cis	rs2915864	0.8	rs13172358	ENSG00000280047.1	CTC-463A16.1	7.63	1.28e-13	4.56e-11	0.51	0.33	Facial morphology (factor 20);	chr5:142104560	chr5:142165767~142168387:+
THCA	cis	rs875971	0.929	rs4122249	ENSG00000232559.3	GS1-124K5.12	7.63	1.29e-13	4.57e-11	0.31	0.33	Aortic root size;	chr7:66455949	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.524	rs73988172	ENSG00000264538.5	SUZ12P1	-7.63	1.29e-13	4.57e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8067035	ENSG00000264538.5	SUZ12P1	-7.63	1.29e-13	4.57e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30709299~30790908:+
THCA	cis	rs2976388	0.647	rs2164307	ENSG00000253741.1	CTD-2292P10.4	-7.63	1.29e-13	4.59e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142707413	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.573	rs1529865	ENSG00000253741.1	CTD-2292P10.4	-7.63	1.29e-13	4.59e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142707753	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs1560986	ENSG00000253741.1	CTD-2292P10.4	-7.63	1.29e-13	4.59e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142708357	chr8:142702252~142726973:-
THCA	cis	rs9388451	0.869	rs7764016	ENSG00000237742.5	RP11-624M8.1	-7.63	1.29e-13	4.59e-11	-0.29	-0.33	Brugada syndrome;	chr6:125749643	chr6:125578558~125749190:-
THCA	cis	rs601999	1	rs601999	ENSG00000108785.7	HSD17B1P1	7.63	1.29e-13	4.59e-11	0.34	0.33	Parkinson's disease;	chr17:42546140	chr17:42546764~42548706:+
THCA	cis	rs737008	0.922	rs376374	ENSG00000262636.1	CTD-3088G3.4	-7.63	1.29e-13	4.59e-11	-0.43	-0.33	Obesity-related traits;	chr16:11276759	chr16:11380859~11381118:-
THCA	cis	rs737008	0.922	rs11074957	ENSG00000262636.1	CTD-3088G3.4	-7.63	1.29e-13	4.6e-11	-0.43	-0.33	Obesity-related traits;	chr16:11284294	chr16:11380859~11381118:-
THCA	cis	rs7208859	0.623	rs7220289	ENSG00000264538.5	SUZ12P1	-7.63	1.29e-13	4.6e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30709299~30790908:+
THCA	cis	rs2276314	0.857	rs28530656	ENSG00000278986.1	RP11-723J4.3	7.63	1.3e-13	4.6e-11	0.38	0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36008737	chr18:35972151~35973916:+
THCA	cis	rs7208859	0.623	rs122898	ENSG00000264538.5	SUZ12P1	7.63	1.3e-13	4.6e-11	0.34	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30709299~30790908:+
THCA	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	7.63	1.3e-13	4.6e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	7.63	1.3e-13	4.6e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	7.63	1.3e-13	4.6e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
THCA	cis	rs10181042	0.535	rs2441465	ENSG00000271889.1	RP11-493E12.1	7.63	1.3e-13	4.6e-11	0.3	0.33	Crohn's disease;	chr2:61084052	chr2:61151433~61162105:-
THCA	cis	rs9649213	0.574	rs34830366	ENSG00000272950.1	RP11-307C18.1	7.63	1.3e-13	4.61e-11	0.41	0.33	Prostate cancer (SNP x SNP interaction);	chr7:98270223	chr7:98322853~98323430:+
THCA	cis	rs9649213	0.593	rs34776142	ENSG00000272950.1	RP11-307C18.1	7.63	1.3e-13	4.61e-11	0.41	0.33	Prostate cancer (SNP x SNP interaction);	chr7:98270561	chr7:98322853~98323430:+
THCA	cis	rs4780355	0.877	rs243317	ENSG00000262636.1	CTD-3088G3.4	-7.63	1.3e-13	4.62e-11	-0.44	-0.33	Crohn's disease and psoriasis;	chr16:11263474	chr16:11380859~11381118:-
THCA	cis	rs42490	0.609	rs367640	ENSG00000251136.7	RP11-37B2.1	-7.63	1.3e-13	4.62e-11	-0.3	-0.33	Leprosy;	chr8:89852168	chr8:89609409~89757727:-
THCA	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-7.63	1.3e-13	4.62e-11	-0.36	-0.33	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
THCA	cis	rs4820539	1	rs5751589	ENSG00000221069.1	AC000029.1	7.63	1.3e-13	4.62e-11	0.4	0.33	Bone mineral density;	chr22:23133575	chr22:23136620~23136710:+
THCA	cis	rs9902453	0.716	rs3098949	ENSG00000264007.1	RP11-68I3.10	7.63	1.31e-13	4.64e-11	0.36	0.33	Coffee consumption (cups per day);	chr17:29651676	chr17:29621617~29622254:-
THCA	cis	rs11673344	0.523	rs2562599	ENSG00000226686.6	LINC01535	-7.63	1.31e-13	4.64e-11	-0.37	-0.33	Obesity-related traits;	chr19:37025472	chr19:37251912~37265535:+
THCA	cis	rs9640161	0.789	rs34728606	ENSG00000261305.1	RP4-584D14.7	7.63	1.31e-13	4.64e-11	0.42	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150357605	chr7:150341771~150342607:+
THCA	cis	rs9543976	0.623	rs6562914	ENSG00000261553.4	RP11-29G8.3	7.63	1.31e-13	4.64e-11	0.39	0.33	Diabetic retinopathy;	chr13:75593401	chr13:75549773~75807120:+
THCA	cis	rs1667284	0.967	rs1791221	ENSG00000266521.1	RP11-650P15.1	7.63	1.31e-13	4.65e-11	0.42	0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31639928	chr18:31496645~31497195:-
THCA	cis	rs1667284	0.967	rs1667281	ENSG00000266521.1	RP11-650P15.1	7.63	1.31e-13	4.65e-11	0.42	0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31640793	chr18:31496645~31497195:-
THCA	cis	rs1667284	1	rs1612691	ENSG00000266521.1	RP11-650P15.1	7.63	1.31e-13	4.65e-11	0.42	0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31640955	chr18:31496645~31497195:-
THCA	cis	rs9543976	0.623	rs6562913	ENSG00000261553.4	RP11-29G8.3	7.63	1.31e-13	4.65e-11	0.4	0.33	Diabetic retinopathy;	chr13:75593297	chr13:75549773~75807120:+
THCA	cis	rs10971721	0.822	rs12376145	ENSG00000260947.1	RP11-384P7.7	7.63	1.31e-13	4.67e-11	0.81	0.33	Body mass index;	chr9:34050408	chr9:33697459~33700986:+
THCA	cis	rs7674212	1	rs7674212	ENSG00000251288.2	RP11-10L12.2	-7.63	1.32e-13	4.67e-11	-0.45	-0.33	Type 2 diabetes;	chr4:103067742	chr4:102751401~102752641:+
THCA	cis	rs9640161	0.871	rs56156367	ENSG00000261305.1	RP4-584D14.7	7.63	1.32e-13	4.67e-11	0.4	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150350112	chr7:150341771~150342607:+
THCA	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-7.63	1.32e-13	4.68e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
THCA	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-7.63	1.32e-13	4.68e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
THCA	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-7.63	1.32e-13	4.68e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
THCA	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-7.63	1.32e-13	4.68e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
THCA	cis	rs9543976	0.557	rs6562916	ENSG00000261553.4	RP11-29G8.3	7.63	1.32e-13	4.68e-11	0.4	0.33	Diabetic retinopathy;	chr13:75597086	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.623	rs4885322	ENSG00000261553.4	RP11-29G8.3	7.63	1.32e-13	4.68e-11	0.4	0.33	Diabetic retinopathy;	chr13:75597195	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.623	rs7996884	ENSG00000261553.4	RP11-29G8.3	7.63	1.32e-13	4.68e-11	0.4	0.33	Diabetic retinopathy;	chr13:75598608	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.623	rs6562918	ENSG00000261553.4	RP11-29G8.3	7.63	1.32e-13	4.68e-11	0.4	0.33	Diabetic retinopathy;	chr13:75600441	chr13:75549773~75807120:+
THCA	cis	rs9543976	0.545	rs2328963	ENSG00000261553.4	RP11-29G8.3	7.63	1.32e-13	4.68e-11	0.4	0.33	Diabetic retinopathy;	chr13:75601390	chr13:75549773~75807120:+
THCA	cis	rs1075265	0.587	rs2949812	ENSG00000233266.1	HMGB1P31	7.63	1.32e-13	4.69e-11	0.42	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54051334~54051760:+
THCA	cis	rs7208859	0.623	rs7208441	ENSG00000264538.5	SUZ12P1	-7.63	1.32e-13	4.69e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30709299~30790908:+
THCA	cis	rs2032366	0.967	rs6650736	ENSG00000267279.1	RP11-879F14.2	-7.63	1.32e-13	4.69e-11	-0.34	-0.33	Obesity-related traits;	chr18:61601711	chr18:61585746~61606916:-
THCA	cis	rs2032366	0.967	rs9965804	ENSG00000267279.1	RP11-879F14.2	-7.63	1.32e-13	4.69e-11	-0.34	-0.33	Obesity-related traits;	chr18:61602021	chr18:61585746~61606916:-
THCA	cis	rs2032366	1	rs1894095	ENSG00000267279.1	RP11-879F14.2	-7.63	1.32e-13	4.69e-11	-0.34	-0.33	Obesity-related traits;	chr18:61605988	chr18:61585746~61606916:-
THCA	cis	rs10208649	1	rs78542544	ENSG00000272156.1	RP11-477N3.1	7.63	1.32e-13	4.69e-11	0.69	0.33	Body mass index;	chr2:53879589	chr2:54082554~54085066:+
THCA	cis	rs4780355	0.918	rs1646019	ENSG00000262636.1	CTD-3088G3.4	7.63	1.32e-13	4.69e-11	0.44	0.33	Crohn's disease and psoriasis;	chr16:11265823	chr16:11380859~11381118:-
THCA	cis	rs10483853	0.525	rs2302041	ENSG00000258695.2	RP3-414A15.2	-7.63	1.33e-13	4.7e-11	-0.51	-0.33	Coronary artery calcification;	chr14:73494166	chr14:73522878~73530610:+
THCA	cis	rs9640161	0.789	rs10248490	ENSG00000261305.1	RP4-584D14.7	7.63	1.33e-13	4.7e-11	0.4	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150354329	chr7:150341771~150342607:+
THCA	cis	rs950169	0.579	rs11633088	ENSG00000259728.4	LINC00933	-7.63	1.33e-13	4.7e-11	-0.47	-0.33	Schizophrenia;	chr15:84003429	chr15:84570649~84580175:+
THCA	cis	rs7942368	0.878	rs1866843	ENSG00000254632.1	RP11-21L23.4	7.63	1.33e-13	4.7e-11	0.48	0.33	Endometriosis;	chr11:76778292	chr11:76759916~76768223:-
THCA	cis	rs17684571	0.872	rs6926134	ENSG00000231441.1	RP11-472M19.2	7.63	1.33e-13	4.71e-11	0.42	0.33	Schizophrenia;	chr6:56723974	chr6:56844002~56864078:+
THCA	cis	rs12682352	0.602	rs4841044	ENSG00000253893.2	FAM85B	7.63	1.33e-13	4.72e-11	0.43	0.33	Neuroticism;	chr8:8807430	chr8:8167819~8226614:-
THCA	cis	rs3847687	1	rs34853396	ENSG00000279128.1	RP11-76C10.4	7.63	1.33e-13	4.72e-11	0.37	0.33	Longevity;	chr12:131034720	chr12:131022769~131024741:-
THCA	cis	rs1949733	1	rs6447875	ENSG00000205959.3	RP11-689P11.2	-7.63	1.33e-13	4.73e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8501479	chr4:8482270~8512610:+
THCA	cis	rs2115630	0.691	rs8040066	ENSG00000275120.1	RP11-182J1.17	-7.63	1.34e-13	4.74e-11	-0.34	-0.33	P wave terminal force;	chr15:84633234	chr15:84599434~84606463:-
THCA	cis	rs9902453	0.9	rs12451122	ENSG00000264007.1	RP11-68I3.10	7.63	1.34e-13	4.74e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30159358	chr17:29621617~29622254:-
THCA	cis	rs17772222	0.74	rs61975276	ENSG00000258789.1	RP11-507K2.3	-7.63	1.34e-13	4.75e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511193	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs61975277	ENSG00000258789.1	RP11-507K2.3	-7.63	1.34e-13	4.75e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511202	chr14:88551597~88552493:+
THCA	cis	rs6600671	1	rs10794671	ENSG00000223345.3	HIST2H2BA	7.63	1.34e-13	4.76e-11	0.36	0.33	Hip geometry;	chr1:121426382	chr1:121108210~121117257:-
THCA	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	7.63	1.34e-13	4.76e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
THCA	cis	rs9388451	0.903	rs9388446	ENSG00000237742.5	RP11-624M8.1	-7.63	1.35e-13	4.79e-11	-0.29	-0.33	Brugada syndrome;	chr6:125743774	chr6:125578558~125749190:-
THCA	cis	rs13113518	0.812	rs12648271	ENSG00000249700.7	SRD5A3-AS1	7.63	1.35e-13	4.79e-11	0.45	0.33	Height;	chr4:55501955	chr4:55363971~55395847:-
THCA	cis	rs8072100	0.967	rs8072644	ENSG00000228782.6	CTD-2026D20.3	-7.63	1.35e-13	4.79e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575998	chr17:47450568~47492492:-
THCA	cis	rs7615952	0.534	rs1503072	ENSG00000171084.14	FAM86JP	7.63	1.35e-13	4.8e-11	0.42	0.33	Blood pressure (smoking interaction);	chr3:126035848	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.599	rs7631268	ENSG00000171084.14	FAM86JP	7.63	1.35e-13	4.8e-11	0.42	0.33	Blood pressure (smoking interaction);	chr3:126036821	chr3:125916620~125930024:+
THCA	cis	rs2348418	0.864	rs7314984	ENSG00000247934.4	RP11-967K21.1	7.63	1.35e-13	4.8e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28557936	chr12:28163298~28190738:-
THCA	cis	rs2562456	0.793	rs2650819	ENSG00000268119.4	CTD-2561J22.5	-7.63	1.36e-13	4.8e-11	-0.42	-0.33	Pain;	chr19:21456071	chr19:21444241~21463908:-
THCA	cis	rs748404	0.56	rs570933	ENSG00000166763.7	STRCP1	7.63	1.36e-13	4.81e-11	0.36	0.33	Lung cancer;	chr15:43531832	chr15:43699488~43718184:-
THCA	cis	rs10129255	0.5	rs11627315	ENSG00000223648.3	IGHV3-64	7.63	1.36e-13	4.81e-11	0.2	0.33	Kawasaki disease;	chr14:106802182	chr14:106643132~106658258:-
THCA	cis	rs10208649	0.908	rs76073574	ENSG00000272156.1	RP11-477N3.1	7.63	1.36e-13	4.82e-11	0.71	0.33	Body mass index;	chr2:53980525	chr2:54082554~54085066:+
THCA	cis	rs2348418	0.864	rs11049716	ENSG00000247934.4	RP11-967K21.1	7.63	1.36e-13	4.82e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28564713	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7136843	ENSG00000247934.4	RP11-967K21.1	7.63	1.36e-13	4.82e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28564875	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7957495	ENSG00000247934.4	RP11-967K21.1	-7.63	1.36e-13	4.82e-11	-0.29	-0.33	Lung function (FEV1);Lung function (FVC);	chr12:28564522	chr12:28163298~28190738:-
THCA	cis	rs2337406	0.866	rs8003852	ENSG00000274576.2	IGHV2-70	-7.62	1.37e-13	4.85e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106776648	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs988131	ENSG00000274576.2	IGHV2-70	-7.62	1.37e-13	4.85e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106776833	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs8005518	ENSG00000274576.2	IGHV2-70	-7.62	1.37e-13	4.85e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106777009	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs57684263	ENSG00000274576.2	IGHV2-70	-7.62	1.37e-13	4.85e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106777263	chr14:106770577~106771020:-
THCA	cis	rs1949733	0.701	rs2631735	ENSG00000205959.3	RP11-689P11.2	-7.62	1.37e-13	4.86e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8474391	chr4:8482270~8512610:+
THCA	cis	rs2712184	0.66	rs10164732	ENSG00000229352.1	AC007563.3	7.62	1.37e-13	4.86e-11	0.39	0.33	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216780946	chr2:216799608~216805335:+
THCA	cis	rs4722166	0.695	rs35779989	ENSG00000179428.2	AC073072.5	-7.62	1.37e-13	4.87e-11	-0.41	-0.33	Lung cancer;	chr7:22760695	chr7:22725395~22727620:-
THCA	cis	rs10971721	0.822	rs7856487	ENSG00000260947.1	RP11-384P7.7	7.62	1.37e-13	4.87e-11	0.81	0.33	Body mass index;	chr9:33870942	chr9:33697459~33700986:+
THCA	cis	rs2380205	0.5	rs688388	ENSG00000232807.2	RP11-536K7.3	-7.62	1.38e-13	4.87e-11	-0.32	-0.33	Breast cancer;	chr10:5918667	chr10:5934270~5945900:-
THCA	cis	rs10875746	0.669	rs10875770	ENSG00000240399.1	RP1-228P16.1	-7.62	1.38e-13	4.87e-11	-0.36	-0.33	Longevity (90 years and older);	chr12:48206737	chr12:48054813~48055591:-
THCA	cis	rs2348418	0.831	rs7137119	ENSG00000247934.4	RP11-967K21.1	7.62	1.38e-13	4.87e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28565058	chr12:28163298~28190738:-
THCA	cis	rs2976388	0.609	rs2376491	ENSG00000253741.1	CTD-2292P10.4	-7.62	1.38e-13	4.88e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142709516	chr8:142702252~142726973:-
THCA	cis	rs5769707	0.568	rs2011097	ENSG00000235111.1	RP1-29C18.8	-7.62	1.38e-13	4.88e-11	-0.42	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49612657~49615716:-
THCA	cis	rs7727544	0.547	rs56083751	ENSG00000233006.5	AC034220.3	7.62	1.38e-13	4.9e-11	0.26	0.33	Blood metabolite levels;	chr5:132328945	chr5:132311285~132369916:-
THCA	cis	rs2337406	0.81	rs7161739	ENSG00000274576.2	IGHV2-70	-7.62	1.38e-13	4.9e-11	-0.29	-0.33	Alzheimer's disease (late onset);	chr14:106776118	chr14:106770577~106771020:-
THCA	cis	rs9813712	0.597	rs1453255	ENSG00000228252.7	COL6A4P2	-7.62	1.39e-13	4.9e-11	-0.33	-0.33	Response to amphetamines;	chr3:130258815	chr3:130212823~130273806:+
THCA	cis	rs6908034	0.66	rs74795718	ENSG00000228412.5	RP4-625H18.2	7.62	1.39e-13	4.93e-11	0.81	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19782068	chr6:19802164~19804752:-
THCA	cis	rs1150668	0.699	rs2394049	ENSG00000219392.1	RP1-265C24.5	-7.62	1.4e-13	4.94e-11	-0.36	-0.33	Pubertal anthropometrics;	chr6:28271903	chr6:28115628~28116551:+
THCA	cis	rs17695224	0.565	rs7248523	ENSG00000269483.1	AC006272.1	7.62	1.4e-13	4.94e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51833888	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.585	rs10406893	ENSG00000269483.1	AC006272.1	7.62	1.4e-13	4.94e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51833901	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.545	rs10406732	ENSG00000269483.1	AC006272.1	7.62	1.4e-13	4.94e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51833974	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.519	rs2159654	ENSG00000269483.1	AC006272.1	7.62	1.4e-13	4.94e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51834004	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.5	rs2159655	ENSG00000269483.1	AC006272.1	7.62	1.4e-13	4.94e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51834006	chr19:51839924~51843324:-
THCA	cis	rs17695224	0.527	rs2903546	ENSG00000269483.1	AC006272.1	7.62	1.4e-13	4.94e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51834082	chr19:51839924~51843324:-
THCA	cis	rs728616	0.867	rs34870056	ENSG00000225484.5	NUTM2B-AS1	-7.62	1.4e-13	4.95e-11	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:79663088~79826594:-
THCA	cis	rs13113518	0.595	rs13120635	ENSG00000249700.7	SRD5A3-AS1	7.62	1.4e-13	4.96e-11	0.44	0.33	Height;	chr4:55361200	chr4:55363971~55395847:-
THCA	cis	rs4845875	0.514	rs198406	ENSG00000242349.4	NPPA-AS1	-7.62	1.4e-13	4.97e-11	-0.31	-0.33	Midregional pro atrial natriuretic peptide levels;	chr1:11837535	chr1:11841017~11848079:+
THCA	cis	rs4845875	0.535	rs198408	ENSG00000242349.4	NPPA-AS1	-7.62	1.4e-13	4.97e-11	-0.31	-0.33	Midregional pro atrial natriuretic peptide levels;	chr1:11838073	chr1:11841017~11848079:+
THCA	cis	rs7430456	1	rs7430456	ENSG00000228221.4	LINC00578	-7.62	1.4e-13	4.97e-11	-0.42	-0.33	Breast cancer;	chr3:177768082	chr3:177441921~177752305:+
THCA	cis	rs496547	0.756	rs562059	ENSG00000255239.1	AP002954.6	7.62	1.41e-13	4.98e-11	0.43	0.33	Hip minimal joint space width;	chr11:118731349	chr11:118688039~118690600:-
THCA	cis	rs9400467	0.528	rs459403	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.41e-13	4.98e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111332674	chr6:111277932~111278742:+
THCA	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	7.62	1.41e-13	4.99e-11	0.39	0.33	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
THCA	cis	rs416603	0.967	rs11644184	ENSG00000262703.1	RP11-485G7.6	-7.62	1.41e-13	4.99e-11	-0.37	-0.33	Type 1 diabetes;	chr16:11271247	chr16:11348143~11349321:-
THCA	cis	rs11148252	0.538	rs2408611	ENSG00000235660.1	LINC00345	-7.62	1.41e-13	4.99e-11	-0.41	-0.33	Lewy body disease;	chr13:52135606	chr13:52484161~52484680:-
THCA	cis	rs9400467	0.528	rs462432	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.41e-13	4.99e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111338552	chr6:111277932~111278742:+
THCA	cis	rs7760535	0.931	rs466923	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.41e-13	4.99e-11	-0.26	-0.33	Metabolic traits;	chr6:111341774	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs1623806	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.41e-13	4.99e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111343868	chr6:111277932~111278742:+
THCA	cis	rs193541	0.632	rs7735618	ENSG00000263432.2	RN7SL689P	7.62	1.41e-13	5e-11	0.39	0.33	Glucose homeostasis traits;	chr5:122840550	chr5:123022487~123022783:-
THCA	cis	rs17695224	0.527	rs7250063	ENSG00000269483.1	AC006272.1	7.62	1.42e-13	5.01e-11	0.36	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51834447	chr19:51839924~51843324:-
THCA	cis	rs13068223	0.74	rs344028	ENSG00000243926.1	TIPARP-AS1	7.62	1.42e-13	5.01e-11	0.32	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:156671862~156674378:-
THCA	cis	rs9400467	0.528	rs455247	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111346596	chr6:111277932~111278742:+
THCA	cis	rs7760535	0.811	rs464401	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Metabolic traits;	chr6:111347804	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.509	rs463854	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111352004	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.509	rs463853	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111352008	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs456569	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111353598	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs455335	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111354313	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs465795	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111355240	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs110732	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111358666	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.592	rs462493	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111362537	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.508	rs456871	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111366447	chr6:111277932~111278742:+
THCA	cis	rs7760535	0.811	rs455732	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Metabolic traits;	chr6:111374065	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs458486	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111375649	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs455726	ENSG00000230177.1	RP5-1112D6.4	-7.62	1.42e-13	5.01e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111378165	chr6:111277932~111278742:+
THCA	cis	rs11148252	0.777	rs9535889	ENSG00000278238.1	RP11-245D16.4	-7.62	1.42e-13	5.02e-11	-0.38	-0.33	Lewy body disease;	chr13:52159499	chr13:52454775~52455331:-
THCA	cis	rs9902453	0.967	rs62070344	ENSG00000264007.1	RP11-68I3.10	7.62	1.42e-13	5.03e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30149979	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs4356528	ENSG00000264007.1	RP11-68I3.10	7.62	1.42e-13	5.03e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30162652	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.872	rs34698290	ENSG00000264007.1	RP11-68I3.10	7.62	1.42e-13	5.03e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30173447	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.866	rs4795529	ENSG00000264007.1	RP11-68I3.10	7.62	1.43e-13	5.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30116531	chr17:29621617~29622254:-
THCA	cis	rs5760092	0.755	rs915589	ENSG00000224205.1	AP000351.4	-7.62	1.43e-13	5.06e-11	-0.46	-0.33	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23987320~23991421:-
THCA	cis	rs732716	0.889	rs62129355	ENSG00000267980.1	AC007292.6	-7.62	1.43e-13	5.06e-11	-0.38	-0.33	Mean corpuscular volume;	chr19:4397037	chr19:4363789~4364640:+
THCA	cis	rs6603134	0.502	rs10406540	ENSG00000267939.1	CTD-2325M2.1	-7.62	1.43e-13	5.06e-11	-0.35	-0.33	Blood protein levels;	chr19:8039113	chr19:8008729~8016025:+
THCA	cis	rs4660456	0.572	rs1008204	ENSG00000237899.1	RP4-739H11.3	7.62	1.44e-13	5.08e-11	0.4	0.33	Platelet count;	chr1:40700189	chr1:40669089~40687588:-
THCA	cis	rs7646881	1	rs59217052	ENSG00000240207.5	RP11-379F4.4	-7.62	1.44e-13	5.08e-11	-0.45	-0.33	Tetralogy of Fallot;	chr3:158734667	chr3:158732263~158784070:+
THCA	cis	rs7646881	1	rs7646881	ENSG00000240207.5	RP11-379F4.4	-7.62	1.44e-13	5.08e-11	-0.45	-0.33	Tetralogy of Fallot;	chr3:158735490	chr3:158732263~158784070:+
THCA	cis	rs7615952	0.599	rs6438953	ENSG00000171084.14	FAM86JP	7.62	1.44e-13	5.09e-11	0.4	0.33	Blood pressure (smoking interaction);	chr3:126006108	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.599	rs1044215	ENSG00000171084.14	FAM86JP	7.62	1.44e-13	5.09e-11	0.4	0.33	Blood pressure (smoking interaction);	chr3:126006716	chr3:125916620~125930024:+
THCA	cis	rs172166	0.516	rs1225618	ENSG00000219392.1	RP1-265C24.5	-7.62	1.44e-13	5.09e-11	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:28161935	chr6:28115628~28116551:+
THCA	cis	rs172166	0.61	rs156737	ENSG00000219392.1	RP1-265C24.5	-7.62	1.44e-13	5.1e-11	-0.36	-0.33	Cardiac Troponin-T levels;	chr6:27927435	chr6:28115628~28116551:+
THCA	cis	rs7942368	1	rs12282785	ENSG00000254632.1	RP11-21L23.4	7.62	1.44e-13	5.1e-11	0.47	0.33	Endometriosis;	chr11:76764986	chr11:76759916~76768223:-
THCA	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	7.62	1.44e-13	5.1e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
THCA	cis	rs2337406	0.789	rs112027230	ENSG00000274576.2	IGHV2-70	-7.62	1.44e-13	5.1e-11	-0.29	-0.33	Alzheimer's disease (late onset);	chr14:106810329	chr14:106770577~106771020:-
THCA	cis	rs11148252	0.538	rs3368	ENSG00000235660.1	LINC00345	-7.62	1.45e-13	5.11e-11	-0.41	-0.33	Lewy body disease;	chr13:52133104	chr13:52484161~52484680:-
THCA	cis	rs17826219	0.568	rs2626985	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Body mass index;	chr17:30750419	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.636	rs7221463	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Body mass index;	chr17:30753533	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7219712	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs8078656	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs1061342	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs55938328	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs55961983	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs7222803	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.568	rs7213925	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Body mass index;	chr17:30794616	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11658945	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11657990	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11650982	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9915546	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9895815	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.706	rs73271850	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Body mass index;	chr17:30815122	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.636	rs79565452	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Body mass index;	chr17:30815823	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7208088	ENSG00000264538.5	SUZ12P1	-7.62	1.45e-13	5.12e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30709299~30790908:+
THCA	cis	rs7015263	0.581	rs1142528	ENSG00000254231.1	CTD-2284J15.1	7.62	1.45e-13	5.12e-11	0.33	0.33	Intelligence (multi-trait analysis);	chr8:86469071	chr8:86333274~86343314:-
THCA	cis	rs801193	0.613	rs2659900	ENSG00000232559.3	GS1-124K5.12	7.62	1.45e-13	5.12e-11	0.32	0.33	Aortic root size;	chr7:66719456	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.562	rs11650923	ENSG00000264538.5	SUZ12P1	-7.62	1.46e-13	5.14e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30681149	chr17:30709299~30790908:+
THCA	cis	rs7942368	0.941	rs737185	ENSG00000254632.1	RP11-21L23.4	7.62	1.46e-13	5.15e-11	0.48	0.33	Endometriosis;	chr11:76774314	chr11:76759916~76768223:-
THCA	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-7.62	1.46e-13	5.15e-11	-0.36	-0.33	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
THCA	cis	rs516805	0.706	rs9490427	ENSG00000279453.1	RP3-425C14.4	7.62	1.46e-13	5.15e-11	0.34	0.33	Lymphocyte counts;	chr6:122353084	chr6:122436789~122439223:-
THCA	cis	rs77204473	0.744	rs12273536	ENSG00000254851.1	RP11-109L13.1	7.62	1.46e-13	5.15e-11	0.83	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117040255	chr11:117135528~117138582:+
THCA	cis	rs9309473	0.528	rs7573275	ENSG00000163016.8	ALMS1P	7.61	1.46e-13	5.16e-11	0.45	0.33	Metabolite levels;	chr2:73325414	chr2:73644919~73685576:+
THCA	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	7.61	1.46e-13	5.16e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
THCA	cis	rs2839186	0.771	rs2280957	ENSG00000239415.1	AP001469.9	-7.61	1.46e-13	5.16e-11	-0.34	-0.33	Testicular germ cell tumor;	chr21:46222358	chr21:46251549~46254133:-
THCA	cis	rs2562456	0.793	rs627522	ENSG00000268555.1	RP11-678G14.3	7.61	1.46e-13	5.16e-11	0.45	0.33	Pain;	chr19:21313002	chr19:21570822~21587322:-
THCA	cis	rs7714584	1	rs11950957	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150874352	chr5:150930645~150946289:-
THCA	cis	rs7714584	0.793	rs11958146	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150874596	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11951694	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150874776	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs11955172	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150874816	chr5:150930645~150946289:-
THCA	cis	rs7714584	0.793	rs11955174	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150874829	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10061105	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150875623	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs6579803	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150875997	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs6579804	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150876369	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs7734928	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150877051	chr5:150930645~150946289:-
THCA	cis	rs7714584	1	rs10463240	ENSG00000197083.10	ZNF300P1	7.61	1.46e-13	5.17e-11	0.53	0.33	Crohn's disease;	chr5:150877291	chr5:150930645~150946289:-
THCA	cis	rs5769707	0.609	rs2071890	ENSG00000235111.1	RP1-29C18.8	-7.61	1.47e-13	5.17e-11	-0.41	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49612657~49615716:-
THCA	cis	rs17772222	0.696	rs28666030	ENSG00000258789.1	RP11-507K2.3	-7.61	1.47e-13	5.18e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511463	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs28493481	ENSG00000258789.1	RP11-507K2.3	-7.61	1.47e-13	5.18e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511491	chr14:88551597~88552493:+
THCA	cis	rs910316	0.967	rs4903292	ENSG00000279594.1	RP11-950C14.10	7.61	1.47e-13	5.19e-11	0.31	0.33	Height;	chr14:75189542	chr14:75011269~75012851:-
THCA	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	7.61	1.47e-13	5.2e-11	0.38	0.33	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
THCA	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-7.61	1.48e-13	5.21e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
THCA	cis	rs7829975	0.684	rs488904	ENSG00000253893.2	FAM85B	7.61	1.48e-13	5.22e-11	0.4	0.33	Mood instability;	chr8:8730061	chr8:8167819~8226614:-
THCA	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	7.61	1.48e-13	5.22e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
THCA	cis	rs7743045	0.548	rs2357023	ENSG00000253194.1	RP11-351A11.1	-7.61	1.48e-13	5.23e-11	-0.46	-0.33	Mean platelet volume;	chr6:119023364	chr6:118934785~119031541:+
THCA	cis	rs7208859	0.573	rs56031503	ENSG00000264538.5	SUZ12P1	-7.61	1.48e-13	5.23e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30709299~30790908:+
THCA	cis	rs11148252	0.538	rs9535879	ENSG00000235660.1	LINC00345	-7.61	1.48e-13	5.23e-11	-0.41	-0.33	Lewy body disease;	chr13:52130488	chr13:52484161~52484680:-
THCA	cis	rs42490	0.576	rs390536	ENSG00000251136.7	RP11-37B2.1	-7.61	1.48e-13	5.23e-11	-0.3	-0.33	Leprosy;	chr8:89857122	chr8:89609409~89757727:-
THCA	cis	rs3822625	0.541	rs112793966	ENSG00000271828.1	CTD-2310F14.1	7.61	1.49e-13	5.24e-11	0.76	0.33	Breast cancer (early onset);	chr5:56908291	chr5:56927874~56929573:+
THCA	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	7.61	1.49e-13	5.25e-11	0.2	0.33	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	7.61	1.49e-13	5.25e-11	0.2	0.33	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	7.61	1.49e-13	5.25e-11	0.2	0.33	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
THCA	cis	rs914615	0.508	rs7535292	ENSG00000160766.13	GBAP1	-7.61	1.49e-13	5.25e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155155273	chr1:155213821~155227422:-
THCA	cis	rs2562456	0.755	rs2562421	ENSG00000268555.1	RP11-678G14.3	-7.61	1.49e-13	5.25e-11	-0.47	-0.33	Pain;	chr19:21448502	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.793	rs2562420	ENSG00000268555.1	RP11-678G14.3	-7.61	1.49e-13	5.25e-11	-0.47	-0.33	Pain;	chr19:21448503	chr19:21570822~21587322:-
THCA	cis	rs10411161	0.808	rs892040	ENSG00000269483.1	AC006272.1	7.61	1.49e-13	5.25e-11	0.58	0.33	Breast cancer;	chr19:51893392	chr19:51839924~51843324:-
THCA	cis	rs7615952	0.599	rs6779141	ENSG00000171084.14	FAM86JP	7.61	1.49e-13	5.26e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125991152	chr3:125916620~125930024:+
THCA	cis	rs4660456	0.597	rs7518568	ENSG00000237899.1	RP4-739H11.3	7.61	1.5e-13	5.28e-11	0.4	0.33	Platelet count;	chr1:40708508	chr1:40669089~40687588:-
THCA	cis	rs4660456	0.596	rs1534956	ENSG00000237899.1	RP4-739H11.3	7.61	1.5e-13	5.28e-11	0.4	0.33	Platelet count;	chr1:40720771	chr1:40669089~40687588:-
THCA	cis	rs12908161	0.959	rs12906348	ENSG00000225151.9	GOLGA2P7	-7.61	1.5e-13	5.28e-11	-0.48	-0.33	Schizophrenia;	chr15:84786190	chr15:84199311~84230136:-
THCA	cis	rs12908161	0.959	rs34342559	ENSG00000225151.9	GOLGA2P7	-7.61	1.5e-13	5.28e-11	-0.48	-0.33	Schizophrenia;	chr15:84788040	chr15:84199311~84230136:-
THCA	cis	rs12908161	0.959	rs62019472	ENSG00000225151.9	GOLGA2P7	-7.61	1.5e-13	5.28e-11	-0.48	-0.33	Schizophrenia;	chr15:84788262	chr15:84199311~84230136:-
THCA	cis	rs12908161	0.959	rs35557864	ENSG00000225151.9	GOLGA2P7	-7.61	1.5e-13	5.28e-11	-0.48	-0.33	Schizophrenia;	chr15:84788398	chr15:84199311~84230136:-
THCA	cis	rs10971721	0.822	rs72725370	ENSG00000260947.1	RP11-384P7.7	7.61	1.5e-13	5.29e-11	0.81	0.33	Body mass index;	chr9:33818459	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.554	rs10971712	ENSG00000260947.1	RP11-384P7.7	7.61	1.5e-13	5.29e-11	0.81	0.33	Body mass index;	chr9:33820940	chr9:33697459~33700986:+
THCA	cis	rs950169	0.614	rs12903883	ENSG00000259728.4	LINC00933	7.61	1.5e-13	5.3e-11	0.47	0.33	Schizophrenia;	chr15:84011801	chr15:84570649~84580175:+
THCA	cis	rs6142102	0.602	rs68051854	ENSG00000275784.1	RP5-1125A11.6	-7.61	1.5e-13	5.3e-11	-0.33	-0.33	Skin pigmentation;	chr20:34114150	chr20:33989480~33991818:-
THCA	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	7.61	1.5e-13	5.3e-11	0.19	0.33	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
THCA	cis	rs7688540	0.8	rs10003142	ENSG00000211553.1	AC253576.2	-7.61	1.51e-13	5.33e-11	-0.45	-0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:297970	chr4:136461~136568:+
THCA	cis	rs7688540	0.771	rs11723803	ENSG00000211553.1	AC253576.2	-7.61	1.51e-13	5.33e-11	-0.45	-0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:298580	chr4:136461~136568:+
THCA	cis	rs17684571	0.872	rs4275049	ENSG00000231441.1	RP11-472M19.2	7.61	1.51e-13	5.33e-11	0.42	0.33	Schizophrenia;	chr6:56737530	chr6:56844002~56864078:+
THCA	cis	rs4934494	0.813	rs12775783	ENSG00000232936.4	RP11-80H5.2	7.61	1.51e-13	5.33e-11	0.45	0.33	Red blood cell count;	chr10:89646494	chr10:89645282~89650667:+
THCA	cis	rs11971779	0.68	rs4732379	ENSG00000273391.1	RP11-634H22.1	7.61	1.52e-13	5.35e-11	0.31	0.33	Diisocyanate-induced asthma;	chr7:139438068	chr7:139359032~139359566:-
THCA	cis	rs10208649	0.908	rs78244745	ENSG00000272156.1	RP11-477N3.1	7.61	1.53e-13	5.4e-11	0.7	0.33	Body mass index;	chr2:54056137	chr2:54082554~54085066:+
THCA	cis	rs2522056	1	rs6874639	ENSG00000233006.5	AC034220.3	7.61	1.53e-13	5.4e-11	0.29	0.33	Fibrinogen;Lymphocyte counts;	chr5:132443024	chr5:132311285~132369916:-
THCA	cis	rs853679	0.769	rs17720293	ENSG00000280107.1	AL022393.9	-7.61	1.53e-13	5.4e-11	-0.59	-0.33	Depression;	chr6:28246920	chr6:28170845~28172521:+
THCA	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	7.61	1.54e-13	5.41e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
THCA	cis	rs10208649	0.611	rs58851686	ENSG00000272156.1	RP11-477N3.1	7.61	1.54e-13	5.41e-11	0.48	0.33	Body mass index;	chr2:54057179	chr2:54082554~54085066:+
THCA	cis	rs10208649	0.611	rs1363060	ENSG00000272156.1	RP11-477N3.1	7.61	1.54e-13	5.41e-11	0.48	0.33	Body mass index;	chr2:54057447	chr2:54082554~54085066:+
THCA	cis	rs1426063	0.61	rs72862239	ENSG00000260265.1	RP11-44F21.5	7.61	1.54e-13	5.41e-11	0.8	0.33	QT interval;	chr4:75071967	chr4:75081702~75084717:-
THCA	cis	rs61041384	0.661	rs74917517	ENSG00000256092.2	RP13-942N8.1	-7.61	1.54e-13	5.42e-11	-0.49	-0.33	Schizophrenia;	chr12:123204258	chr12:123363868~123366113:+
THCA	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-7.61	1.54e-13	5.42e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	7.61	1.54e-13	5.42e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	7.61	1.54e-13	5.42e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	7.61	1.54e-13	5.42e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	7.61	1.54e-13	5.42e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	7.61	1.54e-13	5.42e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-7.61	1.54e-13	5.42e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	7.61	1.54e-13	5.42e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
THCA	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	7.61	1.54e-13	5.42e-11	0.33	0.33	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
THCA	cis	rs6723226	0.721	rs10172510	ENSG00000276334.1	AL133243.1	7.61	1.54e-13	5.44e-11	0.37	0.33	Intelligence (multi-trait analysis);	chr2:32395820	chr2:32521927~32523547:+
THCA	cis	rs1426063	0.614	rs6534447	ENSG00000260265.1	RP11-44F21.5	-7.61	1.54e-13	5.44e-11	-0.82	-0.33	QT interval;	chr4:75080682	chr4:75081702~75084717:-
THCA	cis	rs2439831	0.85	rs7169988	ENSG00000275601.1	AC011330.13	-7.61	1.55e-13	5.45e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43768237	chr15:43642389~43643023:-
THCA	cis	rs9487094	0.813	rs12524502	ENSG00000260273.1	RP11-425D10.10	7.61	1.55e-13	5.46e-11	0.43	0.33	Height;	chr6:109333018	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.813	rs61233650	ENSG00000260273.1	RP11-425D10.10	7.61	1.56e-13	5.48e-11	0.43	0.33	Height;	chr6:109365409	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.813	rs11753645	ENSG00000260273.1	RP11-425D10.10	7.61	1.56e-13	5.48e-11	0.43	0.33	Height;	chr6:109373851	chr6:109382795~109383666:+
THCA	cis	rs516805	0.748	rs72974455	ENSG00000279453.1	RP3-425C14.4	7.61	1.56e-13	5.49e-11	0.34	0.33	Lymphocyte counts;	chr6:122377134	chr6:122436789~122439223:-
THCA	cis	rs11214589	0.651	rs11214596	ENSG00000270179.1	RP11-159N11.4	-7.61	1.56e-13	5.49e-11	-0.36	-0.33	Neuroticism;	chr11:113393789	chr11:113368478~113369117:+
THCA	cis	rs17772222	0.74	rs10150986	ENSG00000258789.1	RP11-507K2.3	-7.61	1.56e-13	5.5e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88517326	chr14:88551597~88552493:+
THCA	cis	rs9487094	0.961	rs11153171	ENSG00000260273.1	RP11-425D10.10	7.61	1.56e-13	5.5e-11	0.41	0.33	Height;	chr6:109332622	chr6:109382795~109383666:+
THCA	cis	rs7208859	0.623	rs60890550	ENSG00000264538.5	SUZ12P1	-7.61	1.56e-13	5.5e-11	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30709299~30790908:+
THCA	cis	rs150992	0.587	rs6885458	ENSG00000248489.1	CTD-2007H13.3	7.61	1.56e-13	5.51e-11	0.32	0.33	Body mass index;	chr5:99046048	chr5:98929171~98995013:+
THCA	cis	rs7942368	0.941	rs10899279	ENSG00000254761.1	RP11-672A2.1	7.6	1.57e-13	5.54e-11	0.47	0.33	Endometriosis;	chr11:76766200	chr11:76712396~76719608:-
THCA	cis	rs17826219	0.636	rs4055314	ENSG00000264538.5	SUZ12P1	-7.6	1.57e-13	5.54e-11	-0.33	-0.33	Body mass index;	chr17:30752751	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs73263982	ENSG00000266490.1	CTD-2349P21.9	7.6	1.58e-13	5.54e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30792372~30792833:+
THCA	cis	rs7208859	0.623	rs216433	ENSG00000266490.1	CTD-2349P21.9	7.6	1.58e-13	5.54e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30792372~30792833:+
THCA	cis	rs516805	0.748	rs6930548	ENSG00000279453.1	RP3-425C14.4	-7.6	1.58e-13	5.54e-11	-0.34	-0.33	Lymphocyte counts;	chr6:122375807	chr6:122436789~122439223:-
THCA	cis	rs12681366	0.806	rs72672679	ENSG00000253704.1	RP11-267M23.4	7.6	1.58e-13	5.55e-11	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94368956	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.881	rs12675415	ENSG00000253704.1	RP11-267M23.4	7.6	1.58e-13	5.55e-11	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94371332	chr8:94553722~94569745:+
THCA	cis	rs10208649	0.611	rs7583626	ENSG00000272156.1	RP11-477N3.1	7.6	1.58e-13	5.55e-11	0.49	0.33	Body mass index;	chr2:54063635	chr2:54082554~54085066:+
THCA	cis	rs71636778	0.509	rs17162311	ENSG00000260063.1	RP5-968P14.2	7.6	1.58e-13	5.56e-11	0.61	0.33	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26848475	chr1:26692132~26694131:-
THCA	cis	rs2562456	0.92	rs2650784	ENSG00000268555.1	RP11-678G14.3	-7.6	1.58e-13	5.56e-11	-0.45	-0.33	Pain;	chr19:21483795	chr19:21570822~21587322:-
THCA	cis	rs7615952	0.576	rs2276726	ENSG00000171084.14	FAM86JP	7.6	1.58e-13	5.56e-11	0.4	0.33	Blood pressure (smoking interaction);	chr3:126107444	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.599	rs2279821	ENSG00000171084.14	FAM86JP	7.6	1.58e-13	5.57e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:126015465	chr3:125916620~125930024:+
THCA	cis	rs7247513	0.964	rs1007352	ENSG00000230310.1	CTD-2192J16.11	-7.6	1.59e-13	5.58e-11	-0.4	-0.33	Bipolar disorder;	chr19:12611731	chr19:12552597~12553644:+
THCA	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	7.6	1.59e-13	5.59e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	7.6	1.59e-13	5.59e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
THCA	cis	rs9487094	0.813	rs35969918	ENSG00000260273.1	RP11-425D10.10	7.6	1.59e-13	5.59e-11	0.43	0.33	Height;	chr6:109441837	chr6:109382795~109383666:+
THCA	cis	rs10916248	0.559	rs56023673	ENSG00000232628.4	RP11-365O16.3	7.6	1.59e-13	5.59e-11	0.52	0.33	QT interval (drug interaction);	chr1:224180821	chr1:224208747~224213279:-
THCA	cis	rs6723108	0.517	rs3739029	ENSG00000224043.6	CCNT2-AS1	-7.6	1.59e-13	5.6e-11	-0.34	-0.33	Type 2 diabetes;	chr2:134841837	chr2:134735464~134918710:-
THCA	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-7.6	1.59e-13	5.6e-11	-0.47	-0.33	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
THCA	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	7.6	1.59e-13	5.6e-11	0.43	0.33	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
THCA	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	7.6	1.59e-13	5.6e-11	0.43	0.33	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
THCA	cis	rs75422866	0.867	rs73102188	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47662993	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102195	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47666309	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102201	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47669269	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104103	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47669604	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104104	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47671986	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104111	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47673994	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104115	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47684843	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104116	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47685023	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104138	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47692302	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.717	rs73104143	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47693449	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104144	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47694390	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104148	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47696732	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104152	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47699091	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73104155	ENSG00000274902.1	RP1-197B17.4	7.6	1.59e-13	5.61e-11	0.72	0.33	Pneumonia;	chr12:47700790	chr12:47731908~47732351:+
THCA	cis	rs12681366	1	rs12681366	ENSG00000253704.1	RP11-267M23.4	7.6	1.6e-13	5.62e-11	0.33	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94389037	chr8:94553722~94569745:+
THCA	cis	rs2284219	1	rs2284219	ENSG00000244480.1	AC005154.7	-7.6	1.6e-13	5.63e-11	-0.26	-0.33	Type 2 diabetes;	chr7:30674820	chr7:30523143~30524535:-
THCA	cis	rs2284219	0.964	rs733453	ENSG00000244480.1	AC005154.7	-7.6	1.6e-13	5.63e-11	-0.26	-0.33	Type 2 diabetes;	chr7:30675157	chr7:30523143~30524535:-
THCA	cis	rs2284219	1	rs2267715	ENSG00000244480.1	AC005154.7	-7.6	1.6e-13	5.63e-11	-0.26	-0.33	Type 2 diabetes;	chr7:30676471	chr7:30523143~30524535:-
THCA	cis	rs7208859	0.623	rs55811708	ENSG00000264538.5	SUZ12P1	-7.6	1.6e-13	5.63e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30709299~30790908:+
THCA	cis	rs198389	0.589	rs198391	ENSG00000242349.4	NPPA-AS1	7.6	1.6e-13	5.63e-11	0.31	0.33	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;	chr1:11816360	chr1:11841017~11848079:+
THCA	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-7.6	1.61e-13	5.64e-11	-0.36	-0.33	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
THCA	cis	rs728616	0.867	rs61860417	ENSG00000225484.5	NUTM2B-AS1	-7.6	1.61e-13	5.64e-11	-0.64	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79974971	chr10:79663088~79826594:-
THCA	cis	rs75422866	0.867	rs73102125	ENSG00000274902.1	RP1-197B17.4	7.6	1.61e-13	5.64e-11	0.71	0.33	Pneumonia;	chr12:47637869	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs12426849	ENSG00000274902.1	RP1-197B17.4	7.6	1.61e-13	5.64e-11	0.71	0.33	Pneumonia;	chr12:47638975	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs117950951	ENSG00000274902.1	RP1-197B17.4	7.6	1.61e-13	5.64e-11	0.71	0.33	Pneumonia;	chr12:47639794	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs7954764	ENSG00000274902.1	RP1-197B17.4	7.6	1.61e-13	5.64e-11	0.71	0.33	Pneumonia;	chr12:47641136	chr12:47731908~47732351:+
THCA	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	7.6	1.61e-13	5.65e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
THCA	cis	rs3812049	0.826	rs34576922	ENSG00000245937.6	LINC01184	-7.6	1.61e-13	5.65e-11	-0.37	-0.33	Lymphocyte counts;Red cell distribution width;	chr5:128028411	chr5:127940426~128083172:-
THCA	cis	rs9902453	0.817	rs2628170	ENSG00000264007.1	RP11-68I3.10	-7.6	1.61e-13	5.66e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:29729594	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2874505	ENSG00000264007.1	RP11-68I3.10	7.6	1.61e-13	5.66e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:29710905	chr17:29621617~29622254:-
THCA	cis	rs9329221	0.527	rs4841352	ENSG00000261451.1	RP11-981G7.1	7.6	1.61e-13	5.66e-11	0.43	0.33	Neuroticism;	chr8:10470080	chr8:10433672~10438312:+
THCA	cis	rs240993	0.516	rs369594	ENSG00000230177.1	RP5-1112D6.4	-7.6	1.62e-13	5.67e-11	-0.36	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111303197	chr6:111277932~111278742:+
THCA	cis	rs4713118	0.911	rs9295746	ENSG00000280107.1	AL022393.9	-7.6	1.62e-13	5.67e-11	-0.4	-0.33	Parkinson's disease;	chr6:27762285	chr6:28170845~28172521:+
THCA	cis	rs42490	0.536	rs379015	ENSG00000251136.7	RP11-37B2.1	-7.6	1.62e-13	5.68e-11	-0.3	-0.33	Leprosy;	chr8:89856245	chr8:89609409~89757727:-
THCA	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-7.6	1.62e-13	5.68e-11	-0.32	-0.33	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
THCA	cis	rs11673344	0.542	rs826324	ENSG00000226686.6	LINC01535	7.6	1.62e-13	5.69e-11	0.36	0.33	Obesity-related traits;	chr19:37014343	chr19:37251912~37265535:+
THCA	cis	rs2243480	0.522	rs431168	ENSG00000226824.5	RP4-756H11.3	-7.6	1.62e-13	5.7e-11	-0.78	-0.33	Diabetic kidney disease;	chr7:66046617	chr7:66654538~66669855:+
THCA	cis	rs6496932	0.503	rs2086756	ENSG00000218052.5	ADAMTS7P4	-7.6	1.63e-13	5.71e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85424322	chr15:85255369~85330334:-
THCA	cis	rs1949733	1	rs2631740	ENSG00000205959.3	RP11-689P11.2	7.6	1.63e-13	5.72e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8482379	chr4:8482270~8512610:+
THCA	cis	rs17826219	0.636	rs12946563	ENSG00000264538.5	SUZ12P1	-7.6	1.63e-13	5.72e-11	-0.34	-0.33	Body mass index;	chr17:30776148	chr17:30709299~30790908:+
THCA	cis	rs4072705	0.967	rs4287038	ENSG00000224020.1	MIR181A2HG	7.6	1.63e-13	5.73e-11	0.3	0.33	Menarche (age at onset);	chr9:124607400	chr9:124658467~124698631:+
THCA	cis	rs494459	0.733	rs556437	ENSG00000255422.1	AP002954.4	-7.6	1.63e-13	5.74e-11	-0.35	-0.33	Height;	chr11:118835044	chr11:118704607~118750263:+
THCA	cis	rs12817211	0.502	rs7961065	ENSG00000272368.2	RP4-605O3.4	-7.6	1.64e-13	5.75e-11	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50119904	chr12:50112197~50165618:+
THCA	cis	rs9487094	0.813	rs6920962	ENSG00000260273.1	RP11-425D10.10	7.6	1.64e-13	5.75e-11	0.41	0.33	Height;	chr6:109403287	chr6:109382795~109383666:+
THCA	cis	rs1150668	0.699	rs13408	ENSG00000219392.1	RP1-265C24.5	-7.6	1.64e-13	5.75e-11	-0.36	-0.33	Pubertal anthropometrics;	chr6:28244970	chr6:28115628~28116551:+
THCA	cis	rs2115630	0.691	rs61322921	ENSG00000275120.1	RP11-182J1.17	-7.6	1.64e-13	5.75e-11	-0.34	-0.33	P wave terminal force;	chr15:84620407	chr15:84599434~84606463:-
THCA	cis	rs853679	0.517	rs6922063	ENSG00000220721.1	OR1F12	7.6	1.64e-13	5.77e-11	0.46	0.33	Depression;	chr6:28126588	chr6:28073316~28074233:+
THCA	cis	rs853679	0.517	rs2275508	ENSG00000220721.1	OR1F12	7.6	1.64e-13	5.77e-11	0.46	0.33	Depression;	chr6:28126953	chr6:28073316~28074233:+
THCA	cis	rs4604234	0.573	rs11961361	ENSG00000272129.1	RP11-250B2.6	-7.6	1.64e-13	5.77e-11	-0.72	-0.33	Cancer;	chr6:80294840	chr6:80355424~80356859:+
THCA	cis	rs4604234	0.541	rs11963917	ENSG00000272129.1	RP11-250B2.6	-7.6	1.64e-13	5.77e-11	-0.72	-0.33	Cancer;	chr6:80294843	chr6:80355424~80356859:+
THCA	cis	rs12681366	1	rs2930971	ENSG00000253704.1	RP11-267M23.4	7.6	1.65e-13	5.78e-11	0.33	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94420319	chr8:94553722~94569745:+
THCA	cis	rs3812049	0.826	rs6860245	ENSG00000245937.6	LINC01184	-7.6	1.65e-13	5.79e-11	-0.37	-0.33	Lymphocyte counts;Red cell distribution width;	chr5:128032306	chr5:127940426~128083172:-
THCA	cis	rs7267979	0.903	rs6115101	ENSG00000274414.1	RP5-965G21.4	-7.6	1.65e-13	5.79e-11	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.868	rs6107019	ENSG00000274414.1	RP5-965G21.4	-7.6	1.65e-13	5.79e-11	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:25239007~25245229:-
THCA	cis	rs2562456	0.833	rs8106025	ENSG00000268119.4	CTD-2561J22.5	-7.6	1.65e-13	5.8e-11	-0.41	-0.33	Pain;	chr19:21451922	chr19:21444241~21463908:-
THCA	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-7.6	1.66e-13	5.82e-11	-0.32	-0.33	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
THCA	cis	rs7208859	0.623	rs9915566	ENSG00000264538.5	SUZ12P1	-7.6	1.67e-13	5.84e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30709299~30790908:+
THCA	cis	rs10971721	0.584	rs12375716	ENSG00000260947.1	RP11-384P7.7	7.6	1.67e-13	5.86e-11	0.75	0.33	Body mass index;	chr9:34100034	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs12379730	ENSG00000260947.1	RP11-384P7.7	7.6	1.67e-13	5.86e-11	0.75	0.33	Body mass index;	chr9:34100072	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs55672700	ENSG00000260947.1	RP11-384P7.7	7.6	1.67e-13	5.86e-11	0.75	0.33	Body mass index;	chr9:34102723	chr9:33697459~33700986:+
THCA	cis	rs1949733	0.585	rs2631768	ENSG00000205959.3	RP11-689P11.2	7.6	1.67e-13	5.87e-11	0.26	0.33	Response to antineoplastic agents;	chr4:8471323	chr4:8482270~8512610:+
THCA	cis	rs950169	0.614	rs12911536	ENSG00000259728.4	LINC00933	7.6	1.68e-13	5.88e-11	0.47	0.33	Schizophrenia;	chr15:84004278	chr15:84570649~84580175:+
THCA	cis	rs9326248	1	rs4938344	ENSG00000280143.1	AP000892.6	7.6	1.68e-13	5.88e-11	0.43	0.33	Blood protein levels;	chr11:117133033	chr11:117204967~117210292:+
THCA	cis	rs6762	0.55	rs8672	ENSG00000279672.1	CMB9-55F22.1	7.6	1.68e-13	5.88e-11	0.37	0.33	Mean platelet volume;	chr11:838634	chr11:779617~780755:+
THCA	cis	rs950169	0.526	rs698620	ENSG00000275120.1	RP11-182J1.17	-7.59	1.68e-13	5.89e-11	-0.34	-0.33	Schizophrenia;	chr15:84633977	chr15:84599434~84606463:-
THCA	cis	rs11673344	0.503	rs703531	ENSG00000226686.6	LINC01535	7.59	1.68e-13	5.9e-11	0.36	0.33	Obesity-related traits;	chr19:37010050	chr19:37251912~37265535:+
THCA	cis	rs728616	0.558	rs116434658	ENSG00000225484.5	NUTM2B-AS1	-7.59	1.68e-13	5.9e-11	-0.48	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79994870	chr10:79663088~79826594:-
THCA	cis	rs73186030	0.764	rs4491840	ENSG00000272758.4	RP11-299J3.8	7.59	1.68e-13	5.9e-11	0.38	0.33	Serum parathyroid hormone levels;	chr3:122361900	chr3:122416207~122443180:+
THCA	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	7.59	1.68e-13	5.91e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
THCA	cis	rs9487094	0.813	rs12528566	ENSG00000260273.1	RP11-425D10.10	7.59	1.69e-13	5.91e-11	0.43	0.33	Height;	chr6:109416945	chr6:109382795~109383666:+
THCA	cis	rs9902453	0.791	rs6505141	ENSG00000264007.1	RP11-68I3.10	7.59	1.69e-13	5.92e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:29671169	chr17:29621617~29622254:-
THCA	cis	rs1949733	1	rs3103071	ENSG00000205959.3	RP11-689P11.2	7.59	1.69e-13	5.93e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8506852	chr4:8482270~8512610:+
THCA	cis	rs240993	0.812	rs459809	ENSG00000230177.1	RP5-1112D6.4	-7.59	1.69e-13	5.93e-11	-0.34	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111331964	chr6:111277932~111278742:+
THCA	cis	rs7208859	0.673	rs450585	ENSG00000266490.1	CTD-2349P21.9	7.59	1.69e-13	5.93e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624021	chr17:30792372~30792833:+
THCA	cis	rs9902453	0.904	rs4461132	ENSG00000264007.1	RP11-68I3.10	7.59	1.69e-13	5.94e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30096412	chr17:29621617~29622254:-
THCA	cis	rs34375054	0.558	rs12578774	ENSG00000279233.1	RP11-158L12.4	-7.59	1.7e-13	5.95e-11	-0.34	-0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125197215	chr12:125138245~125141711:+
THCA	cis	rs2688608	0.592	rs11814282	ENSG00000271816.1	BMS1P4	7.59	1.7e-13	5.95e-11	0.34	0.33	Inflammatory bowel disease;	chr10:73730459	chr10:73699151~73730487:-
THCA	cis	rs914615	0.507	rs4971085	ENSG00000160766.13	GBAP1	-7.59	1.7e-13	5.96e-11	-0.36	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155165746	chr1:155213821~155227422:-
THCA	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-7.59	1.7e-13	5.97e-11	-0.36	-0.33	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-7.59	1.7e-13	5.97e-11	-0.36	-0.33	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
THCA	cis	rs7945705	0.875	rs10769957	ENSG00000254860.4	TMEM9B-AS1	7.59	1.7e-13	5.97e-11	0.36	0.33	Hemoglobin concentration;	chr11:8787469	chr11:8964675~8977527:+
THCA	cis	rs10181042	0.565	rs3108630	ENSG00000271889.1	RP11-493E12.1	-7.59	1.71e-13	5.98e-11	-0.3	-0.33	Crohn's disease;	chr2:61041025	chr2:61151433~61162105:-
THCA	cis	rs1949733	1	rs1949733	ENSG00000205959.3	RP11-689P11.2	7.59	1.71e-13	5.98e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8501632	chr4:8482270~8512610:+
THCA	cis	rs74233809	1	rs74233809	ENSG00000213277.3	MARCKSL1P1	7.59	1.71e-13	5.98e-11	0.54	0.33	Birth weight;	chr10:103154183	chr10:103175554~103176094:+
THCA	cis	rs832187	0.594	rs832197	ENSG00000280620.1	SCAANT1	-7.59	1.71e-13	6.01e-11	-0.45	-0.33	Schizophrenia;	chr3:63898616	chr3:63911518~63911772:-
THCA	cis	rs947583	1	rs947583	ENSG00000231028.7	LINC00271	-7.59	1.71e-13	6.01e-11	-0.28	-0.33	Phosphorus levels;	chr6:135812521	chr6:135497801~135716055:+
THCA	cis	rs2253762	0.507	rs10159582	ENSG00000276742.1	RP11-500G22.4	7.59	1.72e-13	6.01e-11	0.48	0.33	Breast cancer;	chr10:121993110	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.507	rs10159583	ENSG00000276742.1	RP11-500G22.4	7.59	1.72e-13	6.01e-11	0.48	0.33	Breast cancer;	chr10:121993154	chr10:121956782~121957098:+
THCA	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	7.59	1.72e-13	6.03e-11	0.22	0.33	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
THCA	cis	rs7208859	0.673	rs73263981	ENSG00000266490.1	CTD-2349P21.9	7.59	1.72e-13	6.03e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30792372~30792833:+
THCA	cis	rs9388451	0.903	rs7758115	ENSG00000237742.5	RP11-624M8.1	-7.59	1.72e-13	6.04e-11	-0.29	-0.33	Brugada syndrome;	chr6:125740356	chr6:125578558~125749190:-
THCA	cis	rs8072100	0.967	rs62076549	ENSG00000228782.6	CTD-2026D20.3	-7.59	1.73e-13	6.06e-11	-0.3	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47502189	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.967	rs7221548	ENSG00000228782.6	CTD-2026D20.3	-7.59	1.73e-13	6.06e-11	-0.3	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47505586	chr17:47450568~47492492:-
THCA	cis	rs10129255	0.5	rs988132	ENSG00000223648.3	IGHV3-64	7.59	1.73e-13	6.06e-11	0.2	0.33	Kawasaki disease;	chr14:106776758	chr14:106643132~106658258:-
THCA	cis	rs4273100	0.79	rs60166680	ENSG00000228157.4	AC007952.5	7.59	1.73e-13	6.07e-11	0.52	0.33	Schizophrenia;	chr17:19374231	chr17:19092974~19096837:+
THCA	cis	rs4819052	0.851	rs4819041	ENSG00000237664.1	LINC00316	-7.59	1.73e-13	6.07e-11	-0.33	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45240040	chr21:45338590~45341990:-
THCA	cis	rs11148252	0.538	rs9535885	ENSG00000235660.1	LINC00345	-7.59	1.74e-13	6.08e-11	-0.4	-0.33	Lewy body disease;	chr13:52152389	chr13:52484161~52484680:-
THCA	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-7.59	1.74e-13	6.08e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
THCA	cis	rs914615	0.552	rs4276914	ENSG00000160766.13	GBAP1	-7.59	1.74e-13	6.09e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155169753	chr1:155213821~155227422:-
THCA	cis	rs914615	0.552	rs4971088	ENSG00000160766.13	GBAP1	-7.59	1.74e-13	6.09e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155170407	chr1:155213821~155227422:-
THCA	cis	rs914615	0.552	rs4971089	ENSG00000160766.13	GBAP1	-7.59	1.74e-13	6.09e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155170451	chr1:155213821~155227422:-
THCA	cis	rs2361718	0.521	rs2361724	ENSG00000279259.1	RP11-334C17.3	7.59	1.74e-13	6.1e-11	0.33	0.33	Yeast infection;	chr17:80125315	chr17:80147250~80148596:+
THCA	cis	rs7811142	1	rs7783550	ENSG00000078319.8	PMS2P1	7.59	1.74e-13	6.1e-11	0.46	0.33	Platelet count;	chr7:100390182	chr7:100320992~100341908:-
THCA	cis	rs6723226	0.598	rs2710629	ENSG00000276334.1	AL133243.1	7.59	1.74e-13	6.1e-11	0.36	0.33	Intelligence (multi-trait analysis);	chr2:32540777	chr2:32521927~32523547:+
THCA	cis	rs934734	0.563	rs11126035	ENSG00000281920.1	RP11-418H16.1	7.59	1.74e-13	6.1e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65369932	chr2:65623272~65628424:+
THCA	cis	rs61041384	0.661	rs74240768	ENSG00000256092.2	RP13-942N8.1	-7.59	1.75e-13	6.11e-11	-0.48	-0.33	Schizophrenia;	chr12:123199429	chr12:123363868~123366113:+
THCA	cis	rs61041384	0.661	rs74240769	ENSG00000256092.2	RP13-942N8.1	-7.59	1.75e-13	6.11e-11	-0.48	-0.33	Schizophrenia;	chr12:123203681	chr12:123363868~123366113:+
THCA	cis	rs61041384	0.661	rs4759407	ENSG00000256092.2	RP13-942N8.1	-7.59	1.75e-13	6.11e-11	-0.48	-0.33	Schizophrenia;	chr12:123205127	chr12:123363868~123366113:+
THCA	cis	rs453301	0.624	rs2288673	ENSG00000253893.2	FAM85B	-7.59	1.75e-13	6.12e-11	-0.41	-0.33	Joint mobility (Beighton score);	chr8:9002766	chr8:8167819~8226614:-
THCA	cis	rs7811142	0.779	rs111312383	ENSG00000078319.8	PMS2P1	-7.59	1.75e-13	6.12e-11	-0.46	-0.33	Platelet count;	chr7:100307702	chr7:100320992~100341908:-
THCA	cis	rs7811142	0.779	rs28680963	ENSG00000078319.8	PMS2P1	-7.59	1.75e-13	6.12e-11	-0.46	-0.33	Platelet count;	chr7:100307852	chr7:100320992~100341908:-
THCA	cis	rs17572109	0.666	rs11696005	ENSG00000261338.2	RP11-378A13.1	-7.59	1.75e-13	6.13e-11	-0.41	-0.33	Platelet count;Platelet distribution width;Mean platelet volume;	chr2:218364918	chr2:218255319~218257366:+
THCA	cis	rs1318937	1	rs2046725	ENSG00000224660.1	SH3BP5-AS1	7.59	1.75e-13	6.14e-11	0.24	0.33	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253651	chr3:15254184~15264493:+
THCA	cis	rs453301	0.658	rs12114954	ENSG00000253893.2	FAM85B	7.59	1.75e-13	6.14e-11	0.42	0.33	Joint mobility (Beighton score);	chr8:9047352	chr8:8167819~8226614:-
THCA	cis	rs10181042	0.565	rs1177234	ENSG00000271889.1	RP11-493E12.1	7.59	1.75e-13	6.14e-11	0.31	0.33	Crohn's disease;	chr2:61032928	chr2:61151433~61162105:-
THCA	cis	rs8072100	0.967	rs11079784	ENSG00000228782.6	CTD-2026D20.3	-7.59	1.75e-13	6.14e-11	-0.3	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47624914	chr17:47450568~47492492:-
THCA	cis	rs7208859	0.623	rs9898084	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30755316	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs28556733	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs28433704	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.706	rs55764512	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Body mass index;	chr17:30758740	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs12103508	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs11653605	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73269913	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7217984	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs60114476	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.636	rs2449770	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Body mass index;	chr17:30774046	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs59913838	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8067338	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs4055105	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.562	rs8078897	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9914499	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs12006	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs3752021	ENSG00000264538.5	SUZ12P1	-7.59	1.76e-13	6.15e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30709299~30790908:+
THCA	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	7.59	1.76e-13	6.15e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
THCA	cis	rs2284219	0.929	rs12533248	ENSG00000244480.1	AC005154.7	-7.59	1.76e-13	6.15e-11	-0.26	-0.33	Type 2 diabetes;	chr7:30678973	chr7:30523143~30524535:-
THCA	cis	rs11214589	0.905	rs12804573	ENSG00000270179.1	RP11-159N11.4	-7.59	1.76e-13	6.15e-11	-0.35	-0.33	Neuroticism;	chr11:113371004	chr11:113368478~113369117:+
THCA	cis	rs11214589	0.905	rs12805699	ENSG00000270179.1	RP11-159N11.4	-7.59	1.76e-13	6.15e-11	-0.35	-0.33	Neuroticism;	chr11:113371088	chr11:113368478~113369117:+
THCA	cis	rs5769707	0.681	rs4824068	ENSG00000235111.1	RP1-29C18.8	-7.59	1.76e-13	6.18e-11	-0.43	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49612657~49615716:-
THCA	cis	rs1850744	0.702	rs10805314	ENSG00000250942.1	ENPP7P11	7.59	1.77e-13	6.18e-11	0.46	0.33	Economic and political preferences;	chr4:9701557	chr4:9677308~9677934:+
THCA	cis	rs7208859	0.673	rs216409	ENSG00000266490.1	CTD-2349P21.9	-7.59	1.77e-13	6.19e-11	-0.42	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30579251	chr17:30792372~30792833:+
THCA	cis	rs12928939	0.815	rs7185575	ENSG00000260886.1	TAT-AS1	7.59	1.77e-13	6.2e-11	0.43	0.33	Post bronchodilator FEV1;	chr16:71638666	chr16:71565789~71578187:+
THCA	cis	rs41307935	0.908	rs111707709	ENSG00000260063.1	RP5-968P14.2	-7.59	1.77e-13	6.21e-11	-0.61	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr1:26848285	chr1:26692132~26694131:-
THCA	cis	rs10208649	0.656	rs60191560	ENSG00000272156.1	RP11-477N3.1	7.59	1.78e-13	6.21e-11	0.48	0.33	Body mass index;	chr2:54058661	chr2:54082554~54085066:+
THCA	cis	rs10129255	0.556	rs6576222	ENSG00000223648.3	IGHV3-64	7.59	1.78e-13	6.22e-11	0.19	0.33	Kawasaki disease;	chr14:106776442	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.536	rs6576223	ENSG00000223648.3	IGHV3-64	7.59	1.78e-13	6.22e-11	0.19	0.33	Kawasaki disease;	chr14:106776448	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs988134	ENSG00000223648.3	IGHV3-64	7.59	1.78e-13	6.22e-11	0.19	0.33	Kawasaki disease;	chr14:106776698	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs988133	ENSG00000223648.3	IGHV3-64	7.59	1.78e-13	6.22e-11	0.19	0.33	Kawasaki disease;	chr14:106776724	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.518	rs8009594	ENSG00000223648.3	IGHV3-64	7.59	1.78e-13	6.23e-11	0.19	0.33	Kawasaki disease;	chr14:106777494	chr14:106643132~106658258:-
THCA	cis	rs453301	0.592	rs4841084	ENSG00000253893.2	FAM85B	-7.59	1.78e-13	6.23e-11	-0.41	-0.33	Joint mobility (Beighton score);	chr8:9026395	chr8:8167819~8226614:-
THCA	cis	rs453301	0.653	rs2956244	ENSG00000253893.2	FAM85B	-7.59	1.78e-13	6.23e-11	-0.41	-0.33	Joint mobility (Beighton score);	chr8:9027656	chr8:8167819~8226614:-
THCA	cis	rs2337406	0.929	rs12050233	ENSG00000274576.2	IGHV2-70	-7.59	1.78e-13	6.23e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781123	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.852	rs12050466	ENSG00000274576.2	IGHV2-70	-7.59	1.78e-13	6.23e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106781131	chr14:106770577~106771020:-
THCA	cis	rs7208859	0.614	rs73265646	ENSG00000264538.5	SUZ12P1	-7.59	1.78e-13	6.23e-11	-0.36	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30709299~30790908:+
THCA	cis	rs10129255	0.5	rs7161740	ENSG00000223648.3	IGHV3-64	7.59	1.78e-13	6.23e-11	0.19	0.33	Kawasaki disease;	chr14:106776119	chr14:106643132~106658258:-
THCA	cis	rs9487094	0.567	rs11964864	ENSG00000260273.1	RP11-425D10.10	7.59	1.78e-13	6.23e-11	0.42	0.33	Height;	chr6:109773423	chr6:109382795~109383666:+
THCA	cis	rs72772090	0.539	rs11748328	ENSG00000248734.2	CTD-2260A17.1	-7.59	1.78e-13	6.24e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96834213	chr5:96784777~96785999:+
THCA	cis	rs516805	0.706	rs11752939	ENSG00000279453.1	RP3-425C14.4	7.59	1.79e-13	6.24e-11	0.34	0.33	Lymphocyte counts;	chr6:122350062	chr6:122436789~122439223:-
THCA	cis	rs2976388	0.609	rs2717605	ENSG00000253741.1	CTD-2292P10.4	-7.59	1.79e-13	6.25e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142719597	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs2572907	ENSG00000253741.1	CTD-2292P10.4	-7.59	1.79e-13	6.25e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142720520	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs2572908	ENSG00000253741.1	CTD-2292P10.4	-7.59	1.79e-13	6.25e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142721218	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.609	rs2717602	ENSG00000253741.1	CTD-2292P10.4	-7.59	1.79e-13	6.25e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142724265	chr8:142702252~142726973:-
THCA	cis	rs10129255	0.646	rs55995061	ENSG00000274576.2	IGHV2-70	-7.59	1.79e-13	6.25e-11	-0.28	-0.33	Kawasaki disease;	chr14:106799309	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs76871148	ENSG00000274576.2	IGHV2-70	-7.59	1.79e-13	6.25e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106799722	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs61521632	ENSG00000274576.2	IGHV2-70	-7.59	1.79e-13	6.25e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106801091	chr14:106770577~106771020:-
THCA	cis	rs7208859	0.573	rs73267829	ENSG00000264538.5	SUZ12P1	-7.59	1.79e-13	6.26e-11	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30676921	chr17:30709299~30790908:+
THCA	cis	rs9601248	0.874	rs9545158	ENSG00000227676.3	LINC01068	7.59	1.79e-13	6.26e-11	0.42	0.33	Major depressive disorder;	chr13:79618771	chr13:79566727~79571436:+
THCA	cis	rs12908161	0.959	rs3748376	ENSG00000225151.9	GOLGA2P7	-7.59	1.79e-13	6.27e-11	-0.48	-0.33	Schizophrenia;	chr15:84785121	chr15:84199311~84230136:-
THCA	cis	rs6762	0.692	rs5030778	ENSG00000279672.1	CMB9-55F22.1	7.58	1.8e-13	6.28e-11	0.37	0.33	Mean platelet volume;	chr11:836008	chr11:779617~780755:+
THCA	cis	rs10510102	0.516	rs12244921	ENSG00000276742.1	RP11-500G22.4	7.58	1.8e-13	6.28e-11	0.49	0.33	Breast cancer;	chr10:121990342	chr10:121956782~121957098:+
THCA	cis	rs7208859	0.573	rs73267865	ENSG00000264538.5	SUZ12P1	-7.58	1.8e-13	6.29e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30709299~30790908:+
THCA	cis	rs5769707	0.604	rs1018814	ENSG00000235111.1	RP1-29C18.8	-7.58	1.8e-13	6.29e-11	-0.43	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49643252	chr22:49612657~49615716:-
THCA	cis	rs1667284	1	rs1667283	ENSG00000266521.1	RP11-650P15.1	7.58	1.81e-13	6.32e-11	0.41	0.33	Problematic alcohol use in trauma-exposed individuals;	chr18:31643658	chr18:31496645~31497195:-
THCA	cis	rs728616	0.558	rs55803802	ENSG00000225484.5	NUTM2B-AS1	-7.58	1.81e-13	6.32e-11	-0.48	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79992908	chr10:79663088~79826594:-
THCA	cis	rs5769707	0.554	rs10854876	ENSG00000235111.1	RP1-29C18.8	-7.58	1.81e-13	6.32e-11	-0.43	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49612657~49615716:-
THCA	cis	rs3847687	0.966	rs3847689	ENSG00000279128.1	RP11-76C10.4	7.58	1.81e-13	6.33e-11	0.37	0.33	Longevity;	chr12:131040989	chr12:131022769~131024741:-
THCA	cis	rs79349575	0.716	rs595767	ENSG00000248278.1	SUMO2P17	7.58	1.81e-13	6.33e-11	0.39	0.33	Type 2 diabetes;	chr17:48880625	chr17:48874860~48908983:-
THCA	cis	rs9828933	0.752	rs12633353	ENSG00000280620.1	SCAANT1	7.58	1.82e-13	6.35e-11	0.66	0.33	Type 2 diabetes;	chr3:63984604	chr3:63911518~63911772:-
THCA	cis	rs1858037	0.867	rs871974	ENSG00000237979.1	AC007389.1	-7.58	1.82e-13	6.35e-11	-0.41	-0.33	Rheumatoid arthritis;	chr2:65330153	chr2:65500993~65502138:-
THCA	cis	rs28510890	0.658	rs12442454	ENSG00000260337.3	RP11-386M24.6	7.58	1.82e-13	6.35e-11	0.36	0.33	Lung cancer in ever smokers;	chr15:92615762	chr15:92592574~92596462:-
THCA	cis	rs13129231	0.924	rs2037675	ENSG00000206820.1	RNU1-138P	-7.58	1.82e-13	6.35e-11	-0.39	-0.33	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);	chr4:113422785	chr4:113420323~113420486:+
THCA	cis	rs4722166	0.695	rs4722177	ENSG00000179428.2	AC073072.5	-7.58	1.82e-13	6.36e-11	-0.41	-0.33	Lung cancer;	chr7:22758912	chr7:22725395~22727620:-
THCA	cis	rs11971779	0.793	rs9632774	ENSG00000273391.1	RP11-634H22.1	7.58	1.82e-13	6.36e-11	0.33	0.33	Diisocyanate-induced asthma;	chr7:139452816	chr7:139359032~139359566:-
THCA	cis	rs7247513	0.658	rs4804728	ENSG00000230310.1	CTD-2192J16.11	-7.58	1.82e-13	6.37e-11	-0.4	-0.33	Bipolar disorder;	chr19:12642114	chr19:12552597~12553644:+
THCA	cis	rs7208859	0.673	rs1347359	ENSG00000266490.1	CTD-2349P21.9	7.58	1.82e-13	6.37e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30587511	chr17:30792372~30792833:+
THCA	cis	rs944289	0.562	rs860200	ENSG00000257826.1	RP11-116N8.4	-7.58	1.82e-13	6.37e-11	-0.34	-0.33	Thyroid cancer;	chr14:36057079	chr14:36061026~36067190:-
THCA	cis	rs9902453	0.967	rs12450956	ENSG00000264007.1	RP11-68I3.10	7.58	1.83e-13	6.38e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30202007	chr17:29621617~29622254:-
THCA	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	7.58	1.83e-13	6.38e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
THCA	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	7.58	1.83e-13	6.38e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
THCA	cis	rs11118620	0.81	rs4587570	ENSG00000272823.1	RP11-295M18.6	7.58	1.83e-13	6.38e-11	0.44	0.33	Heart failure;	chr1:220860693	chr1:220828676~220829211:-
THCA	cis	rs801193	0.636	rs2659895	ENSG00000232559.3	GS1-124K5.12	7.58	1.83e-13	6.38e-11	0.31	0.33	Aortic root size;	chr7:66731484	chr7:66554588~66576923:-
THCA	cis	rs7829975	0.6	rs1719381	ENSG00000253893.2	FAM85B	7.58	1.83e-13	6.38e-11	0.42	0.33	Mood instability;	chr8:8744834	chr8:8167819~8226614:-
THCA	cis	rs4664293	0.737	rs1549579	ENSG00000226266.5	AC009961.3	-7.58	1.83e-13	6.38e-11	-0.4	-0.33	Monocyte percentage of white cells;	chr2:159812150	chr2:159670708~159712435:-
THCA	cis	rs9640161	0.83	rs17173702	ENSG00000261305.1	RP4-584D14.7	7.58	1.83e-13	6.39e-11	0.42	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150371516	chr7:150341771~150342607:+
THCA	cis	rs9640161	0.83	rs17173703	ENSG00000261305.1	RP4-584D14.7	7.58	1.83e-13	6.39e-11	0.42	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150371531	chr7:150341771~150342607:+
THCA	cis	rs2032366	1	rs2032366	ENSG00000267279.1	RP11-879F14.2	-7.58	1.83e-13	6.39e-11	-0.33	-0.33	Obesity-related traits;	chr18:61599138	chr18:61585746~61606916:-
THCA	cis	rs1949733	1	rs2688233	ENSG00000205959.3	RP11-689P11.2	-7.58	1.83e-13	6.39e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8490158	chr4:8482270~8512610:+
THCA	cis	rs1949733	1	rs2631758	ENSG00000205959.3	RP11-689P11.2	7.58	1.83e-13	6.39e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8493577	chr4:8482270~8512610:+
THCA	cis	rs77204473	0.744	rs17120523	ENSG00000254851.1	RP11-109L13.1	7.58	1.83e-13	6.4e-11	0.85	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117223875	chr11:117135528~117138582:+
THCA	cis	rs7208859	0.573	rs7223803	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.5	rs2449749	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Body mass index;	chr17:30751280	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9894709	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9896603	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8080882	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73269974	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs34756112	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs60724269	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs76633166	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs1061346	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs1061343	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73269988	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9899525	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs11653098	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9911784	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9911997	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9890862	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs78071511	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs2035494	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs8064686	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11657369	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8075341	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73271842	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs8077116	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs28760584	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7212991	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs28627615	ENSG00000264538.5	SUZ12P1	-7.58	1.84e-13	6.41e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30709299~30790908:+
THCA	cis	rs9487094	0.813	rs67857472	ENSG00000260273.1	RP11-425D10.10	7.58	1.84e-13	6.41e-11	0.43	0.33	Height;	chr6:109359125	chr6:109382795~109383666:+
THCA	cis	rs9487094	0.778	rs11757877	ENSG00000260273.1	RP11-425D10.10	7.58	1.84e-13	6.41e-11	0.43	0.33	Height;	chr6:109360679	chr6:109382795~109383666:+
THCA	cis	rs17772222	0.74	rs3783885	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88510714	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs11159857	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88510796	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs4390529	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88510853	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.771	rs4516145	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88510953	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs4594187	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511071	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs4514599	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511083	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs73317739	ENSG00000258789.1	RP11-507K2.3	-7.58	1.84e-13	6.41e-11	-0.32	-0.33	Coronary artery calcification;	chr14:88511400	chr14:88551597~88552493:+
THCA	cis	rs910316	0.967	rs4903293	ENSG00000279594.1	RP11-950C14.10	-7.58	1.84e-13	6.42e-11	-0.31	-0.33	Height;	chr14:75189865	chr14:75011269~75012851:-
THCA	cis	rs6142102	0.625	rs6142067	ENSG00000275784.1	RP5-1125A11.6	-7.58	1.84e-13	6.43e-11	-0.32	-0.33	Skin pigmentation;	chr20:33968766	chr20:33989480~33991818:-
THCA	cis	rs7208859	0.623	rs55814012	ENSG00000264538.5	SUZ12P1	-7.58	1.85e-13	6.45e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30709299~30790908:+
THCA	cis	rs2274273	0.686	rs66782529	ENSG00000258413.1	RP11-665C16.6	-7.58	1.85e-13	6.45e-11	-0.46	-0.33	Protein biomarker;	chr14:55121149	chr14:55262767~55272075:-
THCA	cis	rs690037	0.641	rs538525	ENSG00000272498.1	RP11-415F23.3	-7.58	1.85e-13	6.45e-11	-0.36	-0.33	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16334772	chr3:16339308~16339871:+
THCA	cis	rs7646881	1	rs59313096	ENSG00000240207.5	RP11-379F4.4	-7.58	1.85e-13	6.46e-11	-0.45	-0.33	Tetralogy of Fallot;	chr3:158734453	chr3:158732263~158784070:+
THCA	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	7.58	1.85e-13	6.46e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
THCA	cis	rs9847710	0.696	rs62253605	ENSG00000242142.1	SERBP1P3	7.58	1.85e-13	6.46e-11	0.4	0.33	Ulcerative colitis;	chr3:52944402	chr3:53064283~53065091:-
THCA	cis	rs1949733	1	rs1880023	ENSG00000205959.3	RP11-689P11.2	7.58	1.86e-13	6.47e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8479104	chr4:8482270~8512610:+
THCA	cis	rs2739330	0.828	rs2877178	ENSG00000206090.4	AP000350.7	7.58	1.86e-13	6.48e-11	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23939998~23942798:+
THCA	cis	rs780096	0.546	rs715326	ENSG00000234072.1	AC074117.10	7.58	1.86e-13	6.48e-11	0.26	0.33	Total body bone mineral density;	chr2:27502894	chr2:27356246~27367622:+
THCA	cis	rs7811142	0.666	rs28401739	ENSG00000078319.8	PMS2P1	-7.58	1.87e-13	6.51e-11	-0.46	-0.33	Platelet count;	chr7:100308061	chr7:100320992~100341908:-
THCA	cis	rs367615	0.918	rs13173339	ENSG00000249476.1	CTD-2587M2.1	7.58	1.87e-13	6.52e-11	0.36	0.33	Colorectal cancer (SNP x SNP interaction);	chr5:109535617	chr5:109237120~109326369:-
THCA	cis	rs6558530	0.698	rs7015858	ENSG00000253982.1	CTD-2336O2.1	7.58	1.87e-13	6.52e-11	0.29	0.33	Systolic blood pressure;	chr8:1776141	chr8:1761990~1764502:-
THCA	cis	rs1318937	1	rs1318937	ENSG00000224660.1	SH3BP5-AS1	-7.58	1.87e-13	6.53e-11	-0.21	-0.33	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15253857	chr3:15254184~15264493:+
THCA	cis	rs116175783	0.557	rs3731768	ENSG00000227403.1	AC009299.3	7.58	1.87e-13	6.53e-11	0.6	0.33	Intelligence (multi-trait analysis);	chr2:161250809	chr2:161244739~161249050:+
THCA	cis	rs1150668	0.699	rs12214383	ENSG00000219392.1	RP1-265C24.5	7.58	1.88e-13	6.54e-11	0.36	0.33	Pubertal anthropometrics;	chr6:28255953	chr6:28115628~28116551:+
THCA	cis	rs240993	0.809	rs11153277	ENSG00000271789.1	RP5-1112D6.7	-7.58	1.88e-13	6.56e-11	-0.36	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111259358	chr6:111297126~111298510:+
THCA	cis	rs914615	0.552	rs11264337	ENSG00000160766.13	GBAP1	-7.58	1.89e-13	6.57e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155165974	chr1:155213821~155227422:-
THCA	cis	rs6496932	0.503	rs7164354	ENSG00000218052.5	ADAMTS7P4	-7.58	1.89e-13	6.59e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85405217	chr15:85255369~85330334:-
THCA	cis	rs6603134	0.502	rs10405588	ENSG00000267939.1	CTD-2325M2.1	-7.58	1.89e-13	6.59e-11	-0.35	-0.33	Blood protein levels;	chr19:8038663	chr19:8008729~8016025:+
THCA	cis	rs7615952	0.599	rs2270986	ENSG00000171084.14	FAM86JP	7.58	1.89e-13	6.6e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125982256	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.599	rs12496921	ENSG00000171084.14	FAM86JP	7.58	1.89e-13	6.6e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125983105	chr3:125916620~125930024:+
THCA	cis	rs6597981	0.592	rs10902218	ENSG00000255142.1	AP006621.6	-7.58	1.89e-13	6.6e-11	-0.23	-0.33	Breast cancer;	chr11:743813	chr11:781645~782105:+
THCA	cis	rs2135507	0.501	rs10030631	ENSG00000270480.1	RP11-57B24.1	-7.58	1.9e-13	6.6e-11	-0.5	-0.33	Juvenile osteochondritis dissecans;	chr4:82675592	chr4:82691737~82692468:+
THCA	cis	rs9902453	0.904	rs7213076	ENSG00000264007.1	RP11-68I3.10	-7.58	1.9e-13	6.62e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:30092410	chr17:29621617~29622254:-
THCA	cis	rs7569084	0.522	rs906577	ENSG00000281920.1	RP11-418H16.1	7.58	1.9e-13	6.62e-11	0.43	0.33	Sum eosinophil basophil counts;	chr2:65369523	chr2:65623272~65628424:+
THCA	cis	rs934734	0.563	rs11673956	ENSG00000281920.1	RP11-418H16.1	7.58	1.9e-13	6.62e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65370523	chr2:65623272~65628424:+
THCA	cis	rs934734	0.563	rs11673987	ENSG00000281920.1	RP11-418H16.1	7.58	1.9e-13	6.62e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65370537	chr2:65623272~65628424:+
THCA	cis	rs7615952	0.576	rs4646748	ENSG00000171084.14	FAM86JP	7.58	1.9e-13	6.64e-11	0.4	0.33	Blood pressure (smoking interaction);	chr3:126107486	chr3:125916620~125930024:+
THCA	cis	rs5769707	0.681	rs2319346	ENSG00000235111.1	RP1-29C18.8	-7.58	1.91e-13	6.66e-11	-0.43	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49635992	chr22:49612657~49615716:-
THCA	cis	rs9902453	1	rs62070312	ENSG00000264007.1	RP11-68I3.10	7.58	1.91e-13	6.66e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30111859	chr17:29621617~29622254:-
THCA	cis	rs5769707	0.706	rs763128	ENSG00000235111.1	RP1-29C18.8	-7.58	1.92e-13	6.69e-11	-0.42	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49612657~49615716:-
THCA	cis	rs2688608	0.592	rs7908825	ENSG00000271816.1	BMS1P4	-7.57	1.93e-13	6.71e-11	-0.33	-0.33	Inflammatory bowel disease;	chr10:73794783	chr10:73699151~73730487:-
THCA	cis	rs8100891	0.665	rs7259259	ENSG00000267213.4	AC007773.2	-7.57	1.93e-13	6.72e-11	-0.29	-0.33	Neuroticism;	chr19:32328935	chr19:32390050~32405560:-
THCA	cis	rs11148252	0.583	rs9536048	ENSG00000278238.1	RP11-245D16.4	-7.57	1.93e-13	6.73e-11	-0.41	-0.33	Lewy body disease;	chr13:52384653	chr13:52454775~52455331:-
THCA	cis	rs8072100	0.875	rs9635762	ENSG00000228782.6	CTD-2026D20.3	-7.57	1.93e-13	6.73e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47571080	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.967	rs4793842	ENSG00000228782.6	CTD-2026D20.3	-7.57	1.93e-13	6.73e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47594140	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.967	rs8075411	ENSG00000228782.6	CTD-2026D20.3	-7.57	1.93e-13	6.73e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47599394	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.701	rs10163469	ENSG00000228782.6	CTD-2026D20.3	-7.57	1.93e-13	6.73e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47610401	chr17:47450568~47492492:-
THCA	cis	rs8072100	0.967	rs3760370	ENSG00000228782.6	CTD-2026D20.3	-7.57	1.93e-13	6.73e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47618466	chr17:47450568~47492492:-
THCA	cis	rs12681366	0.919	rs13248829	ENSG00000253704.1	RP11-267M23.4	7.57	1.93e-13	6.73e-11	0.32	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94476750	chr8:94553722~94569745:+
THCA	cis	rs13631	0.894	rs7856589	ENSG00000268996.3	MAN1B1-AS1	-7.57	1.93e-13	6.73e-11	-0.27	-0.33	Cerebrospinal fluid biomarker levels;	chr9:137109469	chr9:137084946~137086817:-
THCA	cis	rs116175783	0.557	rs1146024	ENSG00000227403.1	AC009299.3	7.57	1.93e-13	6.73e-11	0.58	0.33	Intelligence (multi-trait analysis);	chr2:161282740	chr2:161244739~161249050:+
THCA	cis	rs5769707	0.749	rs8137251	ENSG00000235111.1	RP1-29C18.8	-7.57	1.93e-13	6.73e-11	-0.4	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49643021	chr22:49612657~49615716:-
THCA	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-7.57	1.94e-13	6.75e-11	-0.36	-0.33	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
THCA	cis	rs875971	1	rs10244498	ENSG00000232559.3	GS1-124K5.12	7.57	1.94e-13	6.75e-11	0.31	0.33	Aortic root size;	chr7:66651069	chr7:66554588~66576923:-
THCA	cis	rs9890032	0.57	rs8068504	ENSG00000263531.1	RP13-753N3.1	7.57	1.95e-13	6.77e-11	0.45	0.33	Hip circumference adjusted for BMI;	chr17:30785052	chr17:30863921~30864940:-
THCA	cis	rs6142102	0.651	rs6059692	ENSG00000276073.1	RP5-1125A11.7	7.57	1.95e-13	6.77e-11	0.32	0.33	Skin pigmentation;	chr20:34158397	chr20:33985617~33988989:-
THCA	cis	rs73186030	0.92	rs2001548	ENSG00000272758.4	RP11-299J3.8	7.57	1.95e-13	6.8e-11	0.41	0.33	Serum parathyroid hormone levels;	chr3:122313942	chr3:122416207~122443180:+
THCA	cis	rs6840258	0.66	rs17012200	ENSG00000251411.1	RP11-397E7.4	7.57	1.96e-13	6.81e-11	0.4	0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86963494	chr4:86913266~86914817:-
THCA	cis	rs3812049	0.667	rs6888037	ENSG00000245937.6	LINC01184	7.57	1.96e-13	6.81e-11	0.37	0.33	Lymphocyte counts;Red cell distribution width;	chr5:128070567	chr5:127940426~128083172:-
THCA	cis	rs7208859	0.673	rs216435	ENSG00000266490.1	CTD-2349P21.9	7.57	1.96e-13	6.81e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30792372~30792833:+
THCA	cis	rs12655019	0.92	rs75167082	ENSG00000271828.1	CTD-2310F14.1	7.57	1.96e-13	6.82e-11	0.75	0.33	Breast cancer (early onset);	chr5:56915577	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs1466007	ENSG00000271828.1	CTD-2310F14.1	7.57	1.96e-13	6.82e-11	0.75	0.33	Breast cancer (early onset);	chr5:56917812	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs74865790	ENSG00000271828.1	CTD-2310F14.1	7.57	1.96e-13	6.82e-11	0.75	0.33	Breast cancer (early onset);	chr5:56923871	chr5:56927874~56929573:+
THCA	cis	rs12655019	0.92	rs12657064	ENSG00000271828.1	CTD-2310F14.1	7.57	1.96e-13	6.82e-11	0.75	0.33	Breast cancer (early onset);	chr5:56925172	chr5:56927874~56929573:+
THCA	cis	rs7267979	0.873	rs7453	ENSG00000274414.1	RP5-965G21.4	-7.57	1.96e-13	6.83e-11	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25239007~25245229:-
THCA	cis	rs17772222	0.71	rs1028455	ENSG00000258789.1	RP11-507K2.3	-7.57	1.96e-13	6.83e-11	-0.31	-0.33	Coronary artery calcification;	chr14:88363631	chr14:88551597~88552493:+
THCA	cis	rs10971721	0.643	rs10971699	ENSG00000281128.1	PTENP1-AS	7.57	1.97e-13	6.84e-11	0.84	0.33	Body mass index;	chr9:33777186	chr9:33677268~33688011:+
THCA	cis	rs6600671	1	rs1856572	ENSG00000223345.3	HIST2H2BA	7.57	1.97e-13	6.84e-11	0.36	0.33	Hip geometry;	chr1:121427719	chr1:121108210~121117257:-
THCA	cis	rs11673344	0.542	rs2562598	ENSG00000226686.6	LINC01535	7.57	1.97e-13	6.85e-11	0.36	0.33	Obesity-related traits;	chr19:37025318	chr19:37251912~37265535:+
THCA	cis	rs1949733	1	rs1916326	ENSG00000205959.3	RP11-689P11.2	7.57	1.98e-13	6.87e-11	0.28	0.33	Response to antineoplastic agents;	chr4:8498296	chr4:8482270~8512610:+
THCA	cis	rs1949733	1	rs2140337	ENSG00000205959.3	RP11-689P11.2	-7.57	1.98e-13	6.87e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8500385	chr4:8482270~8512610:+
THCA	cis	rs1949733	1	rs6837429	ENSG00000205959.3	RP11-689P11.2	-7.57	1.98e-13	6.87e-11	-0.28	-0.33	Response to antineoplastic agents;	chr4:8500647	chr4:8482270~8512610:+
THCA	cis	rs6745190	1	rs6745190	ENSG00000236153.1	AC104076.3	-7.57	1.98e-13	6.9e-11	-0.4	-0.33	White blood cell count;	chr2:181042998	chr2:180979427~180980090:-
THCA	cis	rs7208859	0.673	rs216420	ENSG00000266490.1	CTD-2349P21.9	7.57	1.99e-13	6.9e-11	0.42	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30611490	chr17:30792372~30792833:+
THCA	cis	rs9326248	1	rs3736120	ENSG00000280143.1	AP000892.6	7.57	1.99e-13	6.91e-11	0.42	0.33	Blood protein levels;	chr11:117161409	chr11:117204967~117210292:+
THCA	cis	rs3847687	0.966	rs3847689	ENSG00000279993.1	RP11-76C10.3	7.57	1.99e-13	6.91e-11	0.36	0.33	Longevity;	chr12:131040989	chr12:131025561~131028060:-
THCA	cis	rs853679	0.882	rs9468300	ENSG00000219392.1	RP1-265C24.5	-7.57	1.99e-13	6.91e-11	-0.56	-0.33	Depression;	chr6:28159062	chr6:28115628~28116551:+
THCA	cis	rs6745190	0.953	rs10171108	ENSG00000236153.1	AC104076.3	7.57	1.99e-13	6.92e-11	0.39	0.33	White blood cell count;	chr2:181046944	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.953	rs6744130	ENSG00000236153.1	AC104076.3	7.57	1.99e-13	6.92e-11	0.39	0.33	White blood cell count;	chr2:181048088	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.953	rs6731268	ENSG00000236153.1	AC104076.3	7.57	1.99e-13	6.92e-11	0.39	0.33	White blood cell count;	chr2:181048264	chr2:180979427~180980090:-
THCA	cis	rs6745190	0.953	rs10171998	ENSG00000236153.1	AC104076.3	7.57	1.99e-13	6.92e-11	0.39	0.33	White blood cell count;	chr2:181054763	chr2:180979427~180980090:-
THCA	cis	rs62355901	0.545	rs12657172	ENSG00000271828.1	CTD-2310F14.1	7.57	1.99e-13	6.92e-11	0.61	0.33	Breast cancer;	chr5:56768280	chr5:56927874~56929573:+
THCA	cis	rs516805	0.748	rs11154072	ENSG00000279453.1	RP3-425C14.4	7.57	1.99e-13	6.93e-11	0.34	0.33	Lymphocyte counts;	chr6:122374632	chr6:122436789~122439223:-
THCA	cis	rs7176527	0.784	rs62021162	ENSG00000188388.10	GOLGA6L3	7.57	2e-13	6.94e-11	0.48	0.33	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84565602	chr15:85240472~85247170:+
THCA	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	7.57	2e-13	6.94e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
THCA	cis	rs10055631	0.518	rs2662226	ENSG00000229666.1	MAST4-AS1	-7.57	2e-13	6.95e-11	-0.38	-0.33	Coronary artery disease;	chr5:67017390	chr5:67001383~67003953:-
THCA	cis	rs7015630	0.505	rs11989430	ENSG00000251136.7	RP11-37B2.1	-7.57	2.01e-13	6.97e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr8:89806387	chr8:89609409~89757727:-
THCA	cis	rs7208859	0.673	rs9895684	ENSG00000264538.5	SUZ12P1	-7.57	2.01e-13	6.98e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30709299~30790908:+
THCA	cis	rs957448	0.561	rs12679785	ENSG00000253704.1	RP11-267M23.4	7.57	2.02e-13	7e-11	0.34	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94553722~94569745:+
THCA	cis	rs957448	0.561	rs13258635	ENSG00000253704.1	RP11-267M23.4	7.57	2.02e-13	7e-11	0.34	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94553722~94569745:+
THCA	cis	rs12680842	0.842	rs34691145	ENSG00000253704.1	RP11-267M23.4	7.57	2.02e-13	7e-11	0.34	0.33	Body mass index;	chr8:94597715	chr8:94553722~94569745:+
THCA	cis	rs2688608	0.592	rs10824032	ENSG00000271816.1	BMS1P4	7.57	2.02e-13	7.02e-11	0.33	0.33	Inflammatory bowel disease;	chr10:73768372	chr10:73699151~73730487:-
THCA	cis	rs1009647	0.614	rs60726667	ENSG00000258413.1	RP11-665C16.6	-7.57	2.02e-13	7.03e-11	-0.59	-0.33	Testicular germ cell tumor;	chr14:55391205	chr14:55262767~55272075:-
THCA	cis	rs7942368	0.941	rs1465900	ENSG00000254632.1	RP11-21L23.4	7.57	2.03e-13	7.04e-11	0.47	0.33	Endometriosis;	chr11:76762094	chr11:76759916~76768223:-
THCA	cis	rs7942368	1	rs10160660	ENSG00000254632.1	RP11-21L23.4	7.57	2.03e-13	7.04e-11	0.47	0.33	Endometriosis;	chr11:76763493	chr11:76759916~76768223:-
THCA	cis	rs6496932	0.503	rs7170085	ENSG00000218052.5	ADAMTS7P4	-7.57	2.03e-13	7.05e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85403879	chr15:85255369~85330334:-
THCA	cis	rs10208649	0.731	rs6760038	ENSG00000272156.1	RP11-477N3.1	7.57	2.03e-13	7.06e-11	0.7	0.33	Body mass index;	chr2:53661017	chr2:54082554~54085066:+
THCA	cis	rs12935418	0.83	rs12448368	ENSG00000261061.1	RP11-303E16.2	7.57	2.04e-13	7.09e-11	0.41	0.33	Mean corpuscular volume;	chr16:81011342	chr16:81030770~81031485:+
THCA	cis	rs12928939	0.774	rs7192860	ENSG00000260886.1	TAT-AS1	7.57	2.05e-13	7.11e-11	0.43	0.33	Post bronchodilator FEV1;	chr16:71609719	chr16:71565789~71578187:+
THCA	cis	rs13068223	0.967	rs344035	ENSG00000243926.1	TIPARP-AS1	-7.57	2.05e-13	7.11e-11	-0.31	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743490	chr3:156671862~156674378:-
THCA	cis	rs7246657	0.943	rs7408563	ENSG00000226686.6	LINC01535	-7.57	2.05e-13	7.13e-11	-0.47	-0.33	Coronary artery calcification;	chr19:37317683	chr19:37251912~37265535:+
THCA	cis	rs4820539	1	rs4822357	ENSG00000221069.1	AC000029.1	-7.56	2.06e-13	7.16e-11	-0.4	-0.33	Bone mineral density;	chr22:23131044	chr22:23136620~23136710:+
THCA	cis	rs9549328	0.731	rs55804996	ENSG00000267868.1	RP11-120K24.3	7.56	2.07e-13	7.17e-11	0.34	0.33	Systolic blood pressure;	chr13:112971053	chr13:112964835~112966131:-
THCA	cis	rs4601821	0.522	rs754672	ENSG00000270179.1	RP11-159N11.4	-7.56	2.07e-13	7.17e-11	-0.35	-0.33	Alcoholic chronic pancreatitis;	chr11:113378414	chr11:113368478~113369117:+
THCA	cis	rs172166	0.516	rs1225710	ENSG00000219392.1	RP1-265C24.5	7.56	2.07e-13	7.17e-11	0.36	0.33	Cardiac Troponin-T levels;	chr6:28132862	chr6:28115628~28116551:+
THCA	cis	rs7942368	1	rs1440978	ENSG00000254761.1	RP11-672A2.1	7.56	2.07e-13	7.17e-11	0.46	0.33	Endometriosis;	chr11:76765236	chr11:76712396~76719608:-
THCA	cis	rs4819052	0.851	rs1006779	ENSG00000237664.1	LINC00316	-7.56	2.07e-13	7.18e-11	-0.32	-0.33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr21:45250837	chr21:45338590~45341990:-
THCA	cis	rs12908161	1	rs35960805	ENSG00000225151.9	GOLGA2P7	-7.56	2.07e-13	7.18e-11	-0.48	-0.33	Schizophrenia;	chr15:84800749	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs12912388	ENSG00000225151.9	GOLGA2P7	-7.56	2.07e-13	7.18e-11	-0.48	-0.33	Schizophrenia;	chr15:84801319	chr15:84199311~84230136:-
THCA	cis	rs11096990	0.593	rs35552004	ENSG00000249685.1	RP11-360F5.3	7.56	2.07e-13	7.19e-11	0.39	0.33	Cognitive function;	chr4:39170914	chr4:39133913~39135608:+
THCA	cis	rs11096990	0.552	rs7655170	ENSG00000249685.1	RP11-360F5.3	7.56	2.07e-13	7.19e-11	0.39	0.33	Cognitive function;	chr4:39171984	chr4:39133913~39135608:+
THCA	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	7.56	2.07e-13	7.19e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
THCA	cis	rs7727544	0.606	rs72795121	ENSG00000233006.5	AC034220.3	7.56	2.07e-13	7.19e-11	0.26	0.33	Blood metabolite levels;	chr5:132302631	chr5:132311285~132369916:-
THCA	cis	rs853679	1	rs1778508	ENSG00000219392.1	RP1-265C24.5	7.56	2.08e-13	7.2e-11	0.51	0.33	Depression;	chr6:28262103	chr6:28115628~28116551:+
THCA	cis	rs17826219	0.706	rs8075357	ENSG00000264538.5	SUZ12P1	-7.56	2.08e-13	7.21e-11	-0.33	-0.33	Body mass index;	chr17:30730179	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.706	rs61643715	ENSG00000264538.5	SUZ12P1	-7.56	2.08e-13	7.21e-11	-0.33	-0.33	Body mass index;	chr17:30730744	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.636	rs8080829	ENSG00000264538.5	SUZ12P1	-7.56	2.08e-13	7.21e-11	-0.33	-0.33	Body mass index;	chr17:30731712	chr17:30709299~30790908:+
THCA	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	7.56	2.08e-13	7.23e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	7.56	2.08e-13	7.23e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
THCA	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	7.56	2.08e-13	7.23e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
THCA	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	7.56	2.08e-13	7.23e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
THCA	cis	rs2739330	0.828	rs5751770	ENSG00000206090.4	AP000350.7	7.56	2.09e-13	7.24e-11	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23939998~23942798:+
THCA	cis	rs944289	0.536	rs1951375	ENSG00000257826.1	RP11-116N8.4	-7.56	2.09e-13	7.25e-11	-0.34	-0.33	Thyroid cancer;	chr14:36051569	chr14:36061026~36067190:-
THCA	cis	rs11118620	1	rs11118620	ENSG00000272823.1	RP11-295M18.6	7.56	2.09e-13	7.25e-11	0.44	0.33	Heart failure;	chr1:220855166	chr1:220828676~220829211:-
THCA	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	7.56	2.1e-13	7.29e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
THCA	cis	rs73607972	0.501	rs4784317	ENSG00000275191.1	RP11-36I17.2	-7.56	2.1e-13	7.29e-11	-0.48	-0.33	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;	chr16:53552273	chr16:53628256~53628816:-
THCA	cis	rs875971	1	rs2420820	ENSG00000232559.3	GS1-124K5.12	-7.56	2.1e-13	7.29e-11	-0.31	-0.33	Aortic root size;	chr7:66626920	chr7:66554588~66576923:-
THCA	cis	rs2839186	0.605	rs2839173	ENSG00000239415.1	AP001469.9	7.56	2.11e-13	7.3e-11	0.35	0.33	Testicular germ cell tumor;	chr21:46256797	chr21:46251549~46254133:-
THCA	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	7.56	2.11e-13	7.31e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
THCA	cis	rs7208859	0.573	rs79505916	ENSG00000264538.5	SUZ12P1	-7.56	2.11e-13	7.32e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30709299~30790908:+
THCA	cis	rs10971721	0.584	rs56145814	ENSG00000260947.1	RP11-384P7.7	7.56	2.11e-13	7.32e-11	0.75	0.33	Body mass index;	chr9:34088953	chr9:33697459~33700986:+
THCA	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-7.56	2.11e-13	7.33e-11	-0.47	-0.33	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
THCA	cis	rs116175783	0.557	rs1267058	ENSG00000227403.1	AC009299.3	-7.56	2.11e-13	7.33e-11	-0.58	-0.33	Intelligence (multi-trait analysis);	chr2:161264934	chr2:161244739~161249050:+
THCA	cis	rs4718428	1	rs12534637	ENSG00000273142.1	RP11-458F8.4	-7.56	2.12e-13	7.34e-11	-0.27	-0.33	Corneal structure;	chr7:66862667	chr7:66902857~66906297:+
THCA	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	7.56	2.12e-13	7.34e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
THCA	cis	rs1009647	0.633	rs11626485	ENSG00000258413.1	RP11-665C16.6	-7.56	2.12e-13	7.35e-11	-0.58	-0.33	Testicular germ cell tumor;	chr14:55360046	chr14:55262767~55272075:-
THCA	cis	rs10971721	0.584	rs72731212	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34109710	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs12376939	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34110139	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs72731214	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34113019	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs117997985	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34113176	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs72731216	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34115066	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs10971933	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34117073	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs10971935	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34118147	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs10971936	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34118988	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs72731217	ENSG00000260947.1	RP11-384P7.7	7.56	2.13e-13	7.37e-11	0.75	0.33	Body mass index;	chr9:34119555	chr9:33697459~33700986:+
THCA	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-7.56	2.13e-13	7.37e-11	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
THCA	cis	rs17826219	0.706	rs609472	ENSG00000266490.1	CTD-2349P21.9	7.56	2.13e-13	7.38e-11	0.41	0.33	Body mass index;	chr17:30624409	chr17:30792372~30792833:+
THCA	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-7.56	2.13e-13	7.38e-11	-0.3	-0.33	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
THCA	cis	rs9902453	0.817	rs880749	ENSG00000264007.1	RP11-68I3.10	-7.56	2.13e-13	7.39e-11	-0.38	-0.33	Coffee consumption (cups per day);	chr17:29732952	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs4473252	ENSG00000264007.1	RP11-68I3.10	7.56	2.13e-13	7.39e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30127405	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.836	rs62070337	ENSG00000264007.1	RP11-68I3.10	7.56	2.13e-13	7.39e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30139239	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.899	rs8067580	ENSG00000264007.1	RP11-68I3.10	7.56	2.13e-13	7.39e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30144230	chr17:29621617~29622254:-
THCA	cis	rs12817211	0.502	rs34167640	ENSG00000272368.2	RP4-605O3.4	-7.56	2.14e-13	7.41e-11	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50123208	chr12:50112197~50165618:+
THCA	cis	rs7182621	0.512	rs34151878	ENSG00000182397.13	DNM1P46	7.56	2.14e-13	7.43e-11	0.43	0.33	Colonoscopy-negative controls vs population controls;	chr15:99869179	chr15:99790156~99806927:-
THCA	cis	rs7182621	0.512	rs12903892	ENSG00000182397.13	DNM1P46	7.56	2.14e-13	7.43e-11	0.43	0.33	Colonoscopy-negative controls vs population controls;	chr15:99869662	chr15:99790156~99806927:-
THCA	cis	rs593531	0.614	rs596976	ENSG00000212961.4	HNRNPA1P40	-7.56	2.15e-13	7.45e-11	-0.42	-0.33	Neuroticism;	chr11:74332663	chr11:74354443~74355720:+
THCA	cis	rs4073416	0.712	rs11624104	ENSG00000276116.2	FUT8-AS1	-7.56	2.15e-13	7.46e-11	-0.33	-0.33	N-glycan levels;	chr14:65729419	chr14:65411170~65412690:-
THCA	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	7.56	2.15e-13	7.46e-11	0.35	0.33	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-7.56	2.15e-13	7.46e-11	-0.35	-0.33	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-7.56	2.15e-13	7.46e-11	-0.35	-0.33	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-7.56	2.15e-13	7.46e-11	-0.35	-0.33	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-7.56	2.15e-13	7.46e-11	-0.35	-0.33	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-7.56	2.15e-13	7.46e-11	-0.35	-0.33	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-7.56	2.15e-13	7.46e-11	-0.35	-0.33	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
THCA	cis	rs28510890	0.688	rs28438060	ENSG00000260337.3	RP11-386M24.6	7.56	2.16e-13	7.47e-11	0.36	0.33	Lung cancer in ever smokers;	chr15:92616176	chr15:92592574~92596462:-
THCA	cis	rs651907	0.557	rs11712748	ENSG00000256628.3	ZBTB11-AS1	7.56	2.16e-13	7.48e-11	0.39	0.33	Colorectal cancer;	chr3:101664718	chr3:101676475~101679217:+
THCA	cis	rs853679	1	rs2799077	ENSG00000219392.1	RP1-265C24.5	-7.56	2.17e-13	7.5e-11	-0.52	-0.33	Depression;	chr6:28266819	chr6:28115628~28116551:+
THCA	cis	rs13068223	0.792	rs344034	ENSG00000243926.1	TIPARP-AS1	-7.56	2.17e-13	7.51e-11	-0.32	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156745215	chr3:156671862~156674378:-
THCA	cis	rs6600671	1	rs2185281	ENSG00000223345.3	HIST2H2BA	7.56	2.17e-13	7.52e-11	0.36	0.33	Hip geometry;	chr1:121438132	chr1:121108210~121117257:-
THCA	cis	rs7849270	0.879	rs10988197	ENSG00000268707.1	RP11-247A12.7	-7.56	2.17e-13	7.52e-11	-0.4	-0.33	Blood metabolite ratios;	chr9:129078980	chr9:129170434~129170940:+
THCA	cis	rs9640161	0.789	rs66688634	ENSG00000261305.1	RP4-584D14.7	7.56	2.17e-13	7.52e-11	0.41	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150356717	chr7:150341771~150342607:+
THCA	cis	rs9902453	0.933	rs7224199	ENSG00000264007.1	RP11-68I3.10	7.56	2.17e-13	7.53e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30196708	chr17:29621617~29622254:-
THCA	cis	rs1318937	0.915	rs78365740	ENSG00000224660.1	SH3BP5-AS1	7.56	2.17e-13	7.53e-11	0.25	0.33	Alcohol dependence;Alcohol and nicotine co-dependence;	chr3:15258339	chr3:15254184~15264493:+
THCA	cis	rs6496932	0.503	rs7170370	ENSG00000218052.5	ADAMTS7P4	-7.56	2.18e-13	7.55e-11	-0.43	-0.33	Central corneal thickness;Corneal structure;	chr15:85414505	chr15:85255369~85330334:-
THCA	cis	rs7267979	0.903	rs6107015	ENSG00000274414.1	RP5-965G21.4	-7.56	2.18e-13	7.55e-11	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25239007~25245229:-
THCA	cis	rs2522056	1	rs2706383	ENSG00000233006.5	AC034220.3	-7.56	2.19e-13	7.57e-11	-0.28	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132456710	chr5:132311285~132369916:-
THCA	cis	rs7688540	0.771	rs11730202	ENSG00000275426.1	CH17-262A2.1	7.56	2.19e-13	7.58e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:149738~150317:+
THCA	cis	rs1015362	0.503	rs4911371	ENSG00000276073.1	RP5-1125A11.7	-7.56	2.19e-13	7.59e-11	-0.35	-0.33	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33904096	chr20:33985617~33988989:-
THCA	cis	rs9500256	0.515	rs12207710	ENSG00000215190.7	LINC00680	-7.56	2.2e-13	7.6e-11	-0.42	-0.33	Eosinophilic esophagitis (pediatric);	chr6:57943175	chr6:57946074~57961501:-
THCA	cis	rs193541	0.564	rs62377434	ENSG00000263432.2	RN7SL689P	-7.56	2.2e-13	7.6e-11	-0.4	-0.33	Glucose homeostasis traits;	chr5:123004874	chr5:123022487~123022783:-
THCA	cis	rs75422866	0.867	rs78912815	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47612065	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73113117	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47617299	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73113139	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47622826	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73113143	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47623060	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.717	rs73113159	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47631318	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.717	rs73113161	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47632361	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs117022227	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47633282	chr12:47731908~47732351:+
THCA	cis	rs75422866	1	rs73102120	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47637280	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs12422974	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47644559	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102127	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47645341	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102140	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47647497	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102148	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47648013	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102151	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47648023	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs75568526	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47649718	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs116302411	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47649788	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102166	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47653769	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102168	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47654010	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs73102171	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47656077	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.867	rs76100981	ENSG00000274902.1	RP1-197B17.4	7.56	2.2e-13	7.61e-11	0.71	0.33	Pneumonia;	chr12:47660092	chr12:47731908~47732351:+
THCA	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	7.56	2.2e-13	7.62e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
THCA	cis	rs11673344	0.523	rs2562594	ENSG00000226686.6	LINC01535	7.56	2.2e-13	7.62e-11	0.36	0.33	Obesity-related traits;	chr19:37023783	chr19:37251912~37265535:+
THCA	cis	rs9341808	0.727	rs9361599	ENSG00000272129.1	RP11-250B2.6	7.55	2.21e-13	7.63e-11	0.41	0.33	Sitting height ratio;	chr6:80315525	chr6:80355424~80356859:+
THCA	cis	rs9341808	0.754	rs9352817	ENSG00000272129.1	RP11-250B2.6	7.55	2.21e-13	7.63e-11	0.41	0.33	Sitting height ratio;	chr6:80316162	chr6:80355424~80356859:+
THCA	cis	rs1150668	0.745	rs213238	ENSG00000219392.1	RP1-265C24.5	-7.55	2.21e-13	7.64e-11	-0.37	-0.33	Pubertal anthropometrics;	chr6:28354216	chr6:28115628~28116551:+
THCA	cis	rs9326248	0.954	rs4938349	ENSG00000280143.1	AP000892.6	7.55	2.21e-13	7.64e-11	0.42	0.33	Blood protein levels;	chr11:117151207	chr11:117204967~117210292:+
THCA	cis	rs2439831	0.85	rs12441127	ENSG00000275601.1	AC011330.13	-7.55	2.21e-13	7.65e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43728977	chr15:43642389~43643023:-
THCA	cis	rs2337406	0.714	rs117798641	ENSG00000274576.2	IGHV2-70	-7.55	2.21e-13	7.65e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106777984	chr14:106770577~106771020:-
THCA	cis	rs5769707	0.632	rs135871	ENSG00000235111.1	RP1-29C18.8	-7.55	2.22e-13	7.67e-11	-0.42	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49612657~49615716:-
THCA	cis	rs2297363	0.841	rs13220323	ENSG00000213073.4	RP11-288H12.3	-7.55	2.22e-13	7.67e-11	-0.35	-0.33	Total cholesterol levels;Blood protein levels;	chr6:160085723	chr6:160093082~160096212:+
THCA	cis	rs17826219	0.5	rs28452421	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Body mass index;	chr17:30756962	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.573	rs28779471	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.5	rs61685770	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Body mass index;	chr17:30758695	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs57486336	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs12103440	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11657777	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.524	rs8065744	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.706	rs8071236	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Body mass index;	chr17:30772984	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs56163556	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8075163	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.706	rs8075107	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Body mass index;	chr17:30779631	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7223209	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs7223404	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9916725	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9916727	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73269945	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9897728	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs1054400	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9890558	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9912283	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs3752020	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9890855	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9893422	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9891166	ENSG00000264538.5	SUZ12P1	-7.55	2.22e-13	7.68e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.568	rs11658027	ENSG00000264538.5	SUZ12P1	7.55	2.22e-13	7.68e-11	0.33	0.33	Body mass index;	chr17:30767864	chr17:30709299~30790908:+
THCA	cis	rs42490	0.536	rs366867	ENSG00000251136.7	RP11-37B2.1	-7.55	2.22e-13	7.68e-11	-0.3	-0.33	Leprosy;	chr8:89851946	chr8:89609409~89757727:-
THCA	cis	rs42490	0.576	rs425140	ENSG00000251136.7	RP11-37B2.1	-7.55	2.22e-13	7.68e-11	-0.3	-0.33	Leprosy;	chr8:89852397	chr8:89609409~89757727:-
THCA	cis	rs42490	0.576	rs377897	ENSG00000251136.7	RP11-37B2.1	-7.55	2.22e-13	7.68e-11	-0.3	-0.33	Leprosy;	chr8:89852734	chr8:89609409~89757727:-
THCA	cis	rs10129255	0.5	rs2027902	ENSG00000223648.3	IGHV3-64	7.55	2.23e-13	7.7e-11	0.19	0.33	Kawasaki disease;	chr14:106807157	chr14:106643132~106658258:-
THCA	cis	rs11673344	0.542	rs2562585	ENSG00000226686.6	LINC01535	7.55	2.23e-13	7.7e-11	0.36	0.33	Obesity-related traits;	chr19:37018321	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs8101392	ENSG00000226686.6	LINC01535	7.55	2.23e-13	7.7e-11	0.36	0.33	Obesity-related traits;	chr19:37024416	chr19:37251912~37265535:+
THCA	cis	rs6504108	0.624	rs2305433	ENSG00000278765.1	RP5-890E16.5	7.55	2.23e-13	7.7e-11	0.37	0.33	Body mass index;	chr17:48188071	chr17:48066704~48067293:-
THCA	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	7.55	2.23e-13	7.71e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	7.55	2.23e-13	7.71e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	7.55	2.23e-13	7.71e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
THCA	cis	rs7942368	1	rs1440979	ENSG00000254632.1	RP11-21L23.4	7.55	2.23e-13	7.71e-11	0.47	0.33	Endometriosis;	chr11:76784085	chr11:76759916~76768223:-
THCA	cis	rs7208859	0.623	rs7214570	ENSG00000264538.5	SUZ12P1	-7.55	2.24e-13	7.72e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30820146	chr17:30709299~30790908:+
THCA	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	7.55	2.24e-13	7.72e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	7.55	2.24e-13	7.72e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
THCA	cis	rs910316	0.967	rs4384542	ENSG00000279594.1	RP11-950C14.10	-7.55	2.24e-13	7.73e-11	-0.31	-0.33	Height;	chr14:75191310	chr14:75011269~75012851:-
THCA	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	7.55	2.24e-13	7.73e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
THCA	cis	rs6745190	0.953	rs6433883	ENSG00000236153.1	AC104076.3	7.55	2.24e-13	7.73e-11	0.38	0.33	White blood cell count;	chr2:181046155	chr2:180979427~180980090:-
THCA	cis	rs910316	0.934	rs7141705	ENSG00000279594.1	RP11-950C14.10	-7.55	2.24e-13	7.73e-11	-0.31	-0.33	Height;	chr14:75188649	chr14:75011269~75012851:-
THCA	cis	rs9902453	0.904	rs12952179	ENSG00000264007.1	RP11-68I3.10	-7.55	2.24e-13	7.75e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:30085669	chr17:29621617~29622254:-
THCA	cis	rs2288884	0.541	rs8107827	ENSG00000275055.1	CTC-471J1.11	-7.55	2.25e-13	7.76e-11	-0.33	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51962228	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.505	rs4988334	ENSG00000275055.1	CTC-471J1.11	-7.55	2.25e-13	7.76e-11	-0.33	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51965745	chr19:52049007~52049754:+
THCA	cis	rs9640161	0.658	rs74348353	ENSG00000261305.1	RP4-584D14.7	7.55	2.25e-13	7.76e-11	0.41	0.33	Blood protein levels;Circulating chemerin levels;	chr7:150356566	chr7:150341771~150342607:+
THCA	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-7.55	2.25e-13	7.77e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs10163054	ENSG00000275601.1	AC011330.13	-7.55	2.25e-13	7.77e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43755440	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-7.55	2.25e-13	7.77e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-7.55	2.25e-13	7.77e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-7.55	2.25e-13	7.77e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
THCA	cis	rs240993	0.812	rs10214442	ENSG00000230177.1	RP5-1112D6.4	-7.55	2.25e-13	7.77e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111431857	chr6:111277932~111278742:+
THCA	cis	rs783540	0.874	rs10468217	ENSG00000278603.1	RP13-608F4.5	-7.55	2.25e-13	7.77e-11	-0.41	-0.33	Schizophrenia;	chr15:82579329	chr15:82472203~82472426:+
THCA	cis	rs193541	0.53	rs6595405	ENSG00000263432.2	RN7SL689P	7.55	2.25e-13	7.77e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122749050	chr5:123022487~123022783:-
THCA	cis	rs829883	0.738	rs249854	ENSG00000227825.4	SLC9A7P1	7.55	2.25e-13	7.78e-11	0.28	0.33	Colorectal adenoma (advanced);	chr12:98468994	chr12:98453835~98457145:-
THCA	cis	rs7208859	0.623	rs7219361	ENSG00000264538.5	SUZ12P1	-7.55	2.26e-13	7.79e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30709299~30790908:+
THCA	cis	rs2337406	0.866	rs7153964	ENSG00000274576.2	IGHV2-70	-7.55	2.26e-13	7.8e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106790480	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs2301536	ENSG00000274576.2	IGHV2-70	-7.55	2.26e-13	7.8e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106790636	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs7144369	ENSG00000274576.2	IGHV2-70	-7.55	2.26e-13	7.8e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106793065	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs78525520	ENSG00000274576.2	IGHV2-70	-7.55	2.26e-13	7.8e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106795643	chr14:106770577~106771020:-
THCA	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-7.55	2.26e-13	7.81e-11	-0.48	-0.33	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
THCA	cis	rs9813712	0.597	rs10934931	ENSG00000228252.7	COL6A4P2	-7.55	2.26e-13	7.81e-11	-0.32	-0.33	Response to amphetamines;	chr3:130261365	chr3:130212823~130273806:+
THCA	cis	rs9309473	0.632	rs11885217	ENSG00000163016.8	ALMS1P	7.55	2.27e-13	7.82e-11	0.44	0.33	Metabolite levels;	chr2:73326080	chr2:73644919~73685576:+
THCA	cis	rs4660456	0.572	rs7519348	ENSG00000237899.1	RP4-739H11.3	-7.55	2.27e-13	7.82e-11	-0.4	-0.33	Platelet count;	chr1:40694532	chr1:40669089~40687588:-
THCA	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	7.55	2.27e-13	7.83e-11	0.43	0.33	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
THCA	cis	rs6840258	0.66	rs55851914	ENSG00000251411.1	RP11-397E7.4	-7.55	2.27e-13	7.84e-11	-0.41	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955903	chr4:86913266~86914817:-
THCA	cis	rs17684571	0.748	rs13192478	ENSG00000231441.1	RP11-472M19.2	7.55	2.27e-13	7.84e-11	0.41	0.33	Schizophrenia;	chr6:56719979	chr6:56844002~56864078:+
THCA	cis	rs17684571	0.872	rs13213878	ENSG00000231441.1	RP11-472M19.2	7.55	2.27e-13	7.84e-11	0.41	0.33	Schizophrenia;	chr6:56725043	chr6:56844002~56864078:+
THCA	cis	rs42490	0.576	rs381456	ENSG00000251136.7	RP11-37B2.1	-7.55	2.27e-13	7.84e-11	-0.3	-0.33	Leprosy;	chr8:89865176	chr8:89609409~89757727:-
THCA	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	7.55	2.28e-13	7.85e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
THCA	cis	rs9388451	0.839	rs9321054	ENSG00000237742.5	RP11-624M8.1	7.55	2.28e-13	7.87e-11	0.28	0.33	Brugada syndrome;	chr6:125758822	chr6:125578558~125749190:-
THCA	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	7.55	2.28e-13	7.87e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
THCA	cis	rs240993	0.812	rs9487639	ENSG00000230177.1	RP5-1112D6.4	-7.55	2.29e-13	7.89e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111426791	chr6:111277932~111278742:+
THCA	cis	rs7302981	0.967	rs11831413	ENSG00000272368.2	RP4-605O3.4	7.55	2.29e-13	7.89e-11	0.2	0.33	Systolic blood pressure;	chr12:50156600	chr12:50112197~50165618:+
THCA	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	7.55	2.29e-13	7.91e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
THCA	cis	rs12928939	0.815	rs10500560	ENSG00000260886.1	TAT-AS1	7.55	2.29e-13	7.91e-11	0.43	0.33	Post bronchodilator FEV1;	chr16:71647250	chr16:71565789~71578187:+
THCA	cis	rs9329221	0.527	rs6989657	ENSG00000261451.1	RP11-981G7.1	7.55	2.3e-13	7.94e-11	0.43	0.33	Neuroticism;	chr8:10473363	chr8:10433672~10438312:+
THCA	cis	rs4308124	0.708	rs28871990	ENSG00000227992.1	AC108463.2	-7.55	2.3e-13	7.95e-11	-0.47	-0.33	Vitiligo;	chr2:111204864	chr2:111203964~111206215:-
THCA	cis	rs2562456	0.793	rs2650819	ENSG00000268555.1	RP11-678G14.3	-7.55	2.31e-13	7.95e-11	-0.47	-0.33	Pain;	chr19:21456071	chr19:21570822~21587322:-
THCA	cis	rs10208649	1	rs78887562	ENSG00000272156.1	RP11-477N3.1	7.55	2.31e-13	7.95e-11	0.68	0.33	Body mass index;	chr2:53904409	chr2:54082554~54085066:+
THCA	cis	rs9388451	0.874	rs7739566	ENSG00000237742.5	RP11-624M8.1	-7.55	2.31e-13	7.96e-11	-0.28	-0.33	Brugada syndrome;	chr6:125773611	chr6:125578558~125749190:-
THCA	cis	rs9388451	0.839	rs4897155	ENSG00000237742.5	RP11-624M8.1	-7.55	2.31e-13	7.96e-11	-0.28	-0.33	Brugada syndrome;	chr6:125773998	chr6:125578558~125749190:-
THCA	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	7.55	2.31e-13	7.96e-11	0.21	0.33	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
THCA	cis	rs8027521	0.54	rs2725582	ENSG00000280362.1	RP11-643A5.3	-7.55	2.31e-13	7.96e-11	-0.45	-0.33	Circulating chemerin levels;	chr15:53971770	chr15:53910769~53914712:+
THCA	cis	rs7247513	0.797	rs3815914	ENSG00000230310.1	CTD-2192J16.11	-7.55	2.31e-13	7.97e-11	-0.39	-0.33	Bipolar disorder;	chr19:12649850	chr19:12552597~12553644:+
THCA	cis	rs7657257	1	rs16892283	ENSG00000214846.4	RP11-115L11.1	7.55	2.31e-13	7.98e-11	0.7	0.33	Blood protein levels;	chr4:15729911	chr4:15730962~15731627:-
THCA	cis	rs6840258	0.66	rs74784659	ENSG00000251411.1	RP11-397E7.4	-7.55	2.32e-13	7.98e-11	-0.4	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86967777	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.66	rs17012213	ENSG00000251411.1	RP11-397E7.4	-7.55	2.32e-13	7.98e-11	-0.4	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968015	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.66	rs17012216	ENSG00000251411.1	RP11-397E7.4	-7.55	2.32e-13	7.98e-11	-0.4	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86968285	chr4:86913266~86914817:-
THCA	cis	rs6840258	0.66	rs72667741	ENSG00000251411.1	RP11-397E7.4	-7.55	2.32e-13	7.98e-11	-0.4	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86970923	chr4:86913266~86914817:-
THCA	cis	rs2243480	1	rs958550	ENSG00000273142.1	RP11-458F8.4	7.55	2.32e-13	7.98e-11	0.41	0.33	Diabetic kidney disease;	chr7:66170692	chr7:66902857~66906297:+
THCA	cis	rs957448	0.748	rs12680342	ENSG00000253704.1	RP11-267M23.4	7.55	2.32e-13	7.99e-11	0.38	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94347410	chr8:94553722~94569745:+
THCA	cis	rs748404	0.518	rs480108	ENSG00000166763.7	STRCP1	7.55	2.32e-13	7.99e-11	0.35	0.33	Lung cancer;	chr15:43525208	chr15:43699488~43718184:-
THCA	cis	rs748404	0.56	rs572837	ENSG00000166763.7	STRCP1	7.55	2.32e-13	7.99e-11	0.35	0.33	Lung cancer;	chr15:43531615	chr15:43699488~43718184:-
THCA	cis	rs116175783	0.557	rs3769968	ENSG00000227403.1	AC009299.3	7.55	2.32e-13	7.99e-11	0.57	0.33	Intelligence (multi-trait analysis);	chr2:161309640	chr2:161244739~161249050:+
THCA	cis	rs116175783	0.557	rs1733180	ENSG00000227403.1	AC009299.3	-7.55	2.32e-13	7.99e-11	-0.57	-0.33	Intelligence (multi-trait analysis);	chr2:161277119	chr2:161244739~161249050:+
THCA	cis	rs801193	0.548	rs2659904	ENSG00000232559.3	GS1-124K5.12	7.55	2.32e-13	8e-11	0.32	0.33	Aortic root size;	chr7:66713615	chr7:66554588~66576923:-
THCA	cis	rs7208859	0.623	rs73269916	ENSG00000264538.5	SUZ12P1	-7.55	2.32e-13	8e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30709299~30790908:+
THCA	cis	rs9902453	0.967	rs11080121	ENSG00000264007.1	RP11-68I3.10	7.55	2.32e-13	8e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30201824	chr17:29621617~29622254:-
THCA	cis	rs6539288	0.901	rs7974499	ENSG00000260329.1	RP11-412D9.4	-7.55	2.32e-13	8.01e-11	-0.3	-0.33	Total body bone mineral density;	chr12:106947607	chr12:106954029~106955497:-
THCA	cis	rs2297363	1	rs2282140	ENSG00000213073.4	RP11-288H12.3	-7.55	2.33e-13	8.02e-11	-0.35	-0.33	Total cholesterol levels;Blood protein levels;	chr6:160073489	chr6:160093082~160096212:+
THCA	cis	rs17772222	1	rs1955600	ENSG00000258983.2	RP11-507K2.2	7.55	2.33e-13	8.03e-11	0.42	0.33	Coronary artery calcification;	chr14:88359040	chr14:88499334~88515502:+
THCA	cis	rs950169	0.545	rs4354897	ENSG00000259728.4	LINC00933	7.55	2.33e-13	8.03e-11	0.47	0.33	Schizophrenia;	chr15:83976219	chr15:84570649~84580175:+
THCA	cis	rs2439831	0.867	rs12443102	ENSG00000249839.1	AC011330.5	-7.55	2.33e-13	8.04e-11	-0.51	-0.33	Lung cancer in ever smokers;	chr15:43639905	chr15:43663654~43684339:-
THCA	cis	rs875971	0.895	rs7788984	ENSG00000232559.3	GS1-124K5.12	7.55	2.33e-13	8.04e-11	0.31	0.33	Aortic root size;	chr7:66450629	chr7:66554588~66576923:-
THCA	cis	rs7674212	0.531	rs10006474	ENSG00000246560.2	RP11-10L12.4	7.55	2.34e-13	8.05e-11	0.41	0.33	Type 2 diabetes;	chr4:103006890	chr4:102828055~102844075:+
THCA	cis	rs9902453	0.967	rs12602065	ENSG00000264007.1	RP11-68I3.10	7.55	2.34e-13	8.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30155470	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.934	rs4343336	ENSG00000264007.1	RP11-68I3.10	7.55	2.34e-13	8.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30161218	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.934	rs7223645	ENSG00000264007.1	RP11-68I3.10	7.55	2.34e-13	8.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30164011	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs12450441	ENSG00000264007.1	RP11-68I3.10	7.55	2.34e-13	8.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30168003	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.967	rs7222685	ENSG00000264007.1	RP11-68I3.10	7.55	2.34e-13	8.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30169412	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.934	rs34433787	ENSG00000264007.1	RP11-68I3.10	7.55	2.34e-13	8.05e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30169762	chr17:29621617~29622254:-
THCA	cis	rs11214589	0.651	rs17600713	ENSG00000270179.1	RP11-159N11.4	-7.55	2.34e-13	8.05e-11	-0.36	-0.33	Neuroticism;	chr11:113389225	chr11:113368478~113369117:+
THCA	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-7.55	2.34e-13	8.05e-11	-0.39	-0.33	Migraine;	chr4:56881195	chr4:56960927~56961373:-
THCA	cis	rs42490	0.576	rs376962	ENSG00000251136.7	RP11-37B2.1	-7.55	2.34e-13	8.06e-11	-0.3	-0.33	Leprosy;	chr8:89862004	chr8:89609409~89757727:-
THCA	cis	rs42490	0.576	rs386587	ENSG00000251136.7	RP11-37B2.1	-7.55	2.34e-13	8.06e-11	-0.3	-0.33	Leprosy;	chr8:89862772	chr8:89609409~89757727:-
THCA	cis	rs2688608	0.592	rs11000757	ENSG00000271816.1	BMS1P4	7.55	2.34e-13	8.07e-11	0.33	0.33	Inflammatory bowel disease;	chr10:73727057	chr10:73699151~73730487:-
THCA	cis	rs4950322	0.542	rs4950384	ENSG00000237188.3	RP11-337C18.8	7.55	2.34e-13	8.07e-11	0.4	0.33	Protein quantitative trait loci;	chr1:147177310	chr1:147172771~147211568:+
THCA	cis	rs3847687	1	rs3847687	ENSG00000279128.1	RP11-76C10.4	7.55	2.35e-13	8.07e-11	0.36	0.33	Longevity;	chr12:131040508	chr12:131022769~131024741:-
THCA	cis	rs6908034	0.607	rs12526109	ENSG00000228412.5	RP4-625H18.2	7.55	2.35e-13	8.08e-11	0.82	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19819858	chr6:19802164~19804752:-
THCA	cis	rs9890032	0.618	rs1979507	ENSG00000263531.1	RP13-753N3.1	7.55	2.35e-13	8.08e-11	0.45	0.33	Hip circumference adjusted for BMI;	chr17:30811002	chr17:30863921~30864940:-
THCA	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-7.55	2.36e-13	8.11e-11	-0.38	-0.33	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
THCA	cis	rs6840258	0.66	rs72667737	ENSG00000251411.1	RP11-397E7.4	-7.55	2.36e-13	8.11e-11	-0.41	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86955264	chr4:86913266~86914817:-
THCA	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	7.54	2.36e-13	8.14e-11	0.22	0.33	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
THCA	cis	rs13113518	0.557	rs13142096	ENSG00000249700.7	SRD5A3-AS1	7.54	2.37e-13	8.14e-11	0.44	0.33	Height;	chr4:55566291	chr4:55363971~55395847:-
THCA	cis	rs9902453	0.935	rs9905950	ENSG00000264007.1	RP11-68I3.10	7.54	2.37e-13	8.14e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30104180	chr17:29621617~29622254:-
THCA	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	7.54	2.37e-13	8.14e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
THCA	cis	rs12908161	1	rs17601029	ENSG00000225151.9	GOLGA2P7	-7.54	2.37e-13	8.16e-11	-0.47	-0.33	Schizophrenia;	chr15:84804478	chr15:84199311~84230136:-
THCA	cis	rs914615	0.529	rs11264338	ENSG00000160766.13	GBAP1	-7.54	2.37e-13	8.16e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155166081	chr1:155213821~155227422:-
THCA	cis	rs7247513	0.701	rs8107642	ENSG00000230310.1	CTD-2192J16.11	-7.54	2.38e-13	8.19e-11	-0.38	-0.33	Bipolar disorder;	chr19:12655556	chr19:12552597~12553644:+
THCA	cis	rs2562456	0.876	rs7252585	ENSG00000268555.1	RP11-678G14.3	-7.54	2.38e-13	8.2e-11	-0.45	-0.33	Pain;	chr19:21475141	chr19:21570822~21587322:-
THCA	cis	rs1150668	0.835	rs203869	ENSG00000219392.1	RP1-265C24.5	-7.54	2.38e-13	8.2e-11	-0.36	-0.33	Pubertal anthropometrics;	chr6:28073041	chr6:28115628~28116551:+
THCA	cis	rs9902453	0.934	rs12453172	ENSG00000264007.1	RP11-68I3.10	7.54	2.39e-13	8.21e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30114572	chr17:29621617~29622254:-
THCA	cis	rs10129255	0.518	rs8009612	ENSG00000223648.3	IGHV3-64	7.54	2.39e-13	8.22e-11	0.19	0.33	Kawasaki disease;	chr14:106777510	chr14:106643132~106658258:-
THCA	cis	rs2337406	0.866	rs112089985	ENSG00000274576.2	IGHV2-70	-7.54	2.39e-13	8.22e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106780074	chr14:106770577~106771020:-
THCA	cis	rs9847710	0.545	rs2952830	ENSG00000242142.1	SERBP1P3	7.54	2.39e-13	8.23e-11	0.41	0.33	Ulcerative colitis;	chr3:52948280	chr3:53064283~53065091:-
THCA	cis	rs7674212	0.865	rs13149311	ENSG00000246560.2	RP11-10L12.4	7.54	2.39e-13	8.23e-11	0.42	0.33	Type 2 diabetes;	chr4:103056543	chr4:102828055~102844075:+
THCA	cis	rs934734	0.967	rs1866051	ENSG00000204929.10	AC074391.1	7.54	2.39e-13	8.23e-11	0.41	0.33	Rheumatoid arthritis;	chr2:65375015	chr2:65436711~66084639:+
THCA	cis	rs8072100	0.817	rs11869940	ENSG00000228782.6	CTD-2026D20.3	-7.54	2.4e-13	8.24e-11	-0.29	-0.33	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47501069	chr17:47450568~47492492:-
THCA	cis	rs42490	0.664	rs39516	ENSG00000251136.7	RP11-37B2.1	-7.54	2.41e-13	8.29e-11	-0.28	-0.33	Leprosy;	chr8:89822157	chr8:89609409~89757727:-
THCA	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-7.54	2.41e-13	8.29e-11	-0.36	-0.33	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
THCA	cis	rs6142102	0.602	rs11696338	ENSG00000275784.1	RP5-1125A11.6	-7.54	2.42e-13	8.3e-11	-0.32	-0.33	Skin pigmentation;	chr20:34099805	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.58	rs6142101	ENSG00000275784.1	RP5-1125A11.6	-7.54	2.42e-13	8.3e-11	-0.32	-0.33	Skin pigmentation;	chr20:34110039	chr20:33989480~33991818:-
THCA	cis	rs875971	1	rs1544549	ENSG00000232559.3	GS1-124K5.12	-7.54	2.42e-13	8.31e-11	-0.31	-0.33	Aortic root size;	chr7:66625676	chr7:66554588~66576923:-
THCA	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-7.54	2.42e-13	8.33e-11	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
THCA	cis	rs2562456	0.833	rs2968076	ENSG00000268555.1	RP11-678G14.3	-7.54	2.43e-13	8.34e-11	-0.47	-0.33	Pain;	chr19:21454299	chr19:21570822~21587322:-
THCA	cis	rs10129255	0.5	rs4774189	ENSG00000223648.3	IGHV3-64	7.54	2.43e-13	8.35e-11	0.19	0.33	Kawasaki disease;	chr14:106768275	chr14:106643132~106658258:-
THCA	cis	rs10411161	0.81	rs17778711	ENSG00000269483.1	AC006272.1	7.54	2.44e-13	8.37e-11	0.55	0.33	Breast cancer;	chr19:51882047	chr19:51839924~51843324:-
THCA	cis	rs853679	0.882	rs9393908	ENSG00000219392.1	RP1-265C24.5	-7.54	2.44e-13	8.37e-11	-0.58	-0.33	Depression;	chr6:28223052	chr6:28115628~28116551:+
THCA	cis	rs853679	0.882	rs9366717	ENSG00000219392.1	RP1-265C24.5	-7.54	2.44e-13	8.37e-11	-0.58	-0.33	Depression;	chr6:28223279	chr6:28115628~28116551:+
THCA	cis	rs7302981	0.934	rs7532	ENSG00000272368.2	RP4-605O3.4	-7.54	2.44e-13	8.38e-11	-0.2	-0.33	Systolic blood pressure;	chr12:50130181	chr12:50112197~50165618:+
THCA	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	7.54	2.44e-13	8.38e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	7.54	2.44e-13	8.38e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
THCA	cis	rs12817211	0.502	rs7135322	ENSG00000272368.2	RP4-605O3.4	-7.54	2.44e-13	8.39e-11	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50118065	chr12:50112197~50165618:+
THCA	cis	rs193541	0.53	rs2125857	ENSG00000263432.2	RN7SL689P	7.54	2.44e-13	8.4e-11	0.4	0.33	Glucose homeostasis traits;	chr5:122747461	chr5:123022487~123022783:-
THCA	cis	rs8114671	0.527	rs2253484	ENSG00000269202.1	RP4-614O4.12	7.54	2.44e-13	8.4e-11	0.27	0.33	Height;	chr20:34817460	chr20:35201747~35203288:-
THCA	cis	rs2439831	0.85	rs8042868	ENSG00000275601.1	AC011330.13	-7.54	2.45e-13	8.43e-11	-0.55	-0.33	Lung cancer in ever smokers;	chr15:43647444	chr15:43642389~43643023:-
THCA	cis	rs9902453	0.933	rs8080343	ENSG00000264007.1	RP11-68I3.10	7.54	2.46e-13	8.44e-11	0.36	0.33	Coffee consumption (cups per day);	chr17:30129740	chr17:29621617~29622254:-
THCA	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	7.54	2.46e-13	8.44e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
THCA	cis	rs9902453	0.933	rs1128156	ENSG00000264007.1	RP11-68I3.10	7.54	2.46e-13	8.45e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30186158	chr17:29621617~29622254:-
THCA	cis	rs7208859	0.623	rs1054397	ENSG00000264538.5	SUZ12P1	-7.54	2.46e-13	8.46e-11	-0.32	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30709299~30790908:+
THCA	cis	rs9902453	0.967	rs4325622	ENSG00000264007.1	RP11-68I3.10	7.54	2.46e-13	8.46e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30199457	chr17:29621617~29622254:-
THCA	cis	rs2412819	0.571	rs17727853	ENSG00000249839.1	AC011330.5	-7.54	2.46e-13	8.46e-11	-0.5	-0.33	Lung cancer;	chr15:43630299	chr15:43663654~43684339:-
THCA	cis	rs728616	0.85	rs3889823	ENSG00000225484.5	NUTM2B-AS1	-7.54	2.46e-13	8.47e-11	-0.66	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80158606	chr10:79663088~79826594:-
THCA	cis	rs10875746	0.551	rs3185921	ENSG00000240399.1	RP1-228P16.1	-7.54	2.47e-13	8.48e-11	-0.38	-0.33	Longevity (90 years and older);	chr12:48340948	chr12:48054813~48055591:-
THCA	cis	rs7208859	0.673	rs9895684	ENSG00000266490.1	CTD-2349P21.9	7.54	2.47e-13	8.5e-11	0.47	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30792372~30792833:+
THCA	cis	rs4820539	0.934	rs3788348	ENSG00000221069.1	AC000029.1	-7.54	2.48e-13	8.5e-11	-0.39	-0.33	Bone mineral density;	chr22:23125759	chr22:23136620~23136710:+
THCA	cis	rs4820539	0.932	rs3788349	ENSG00000221069.1	AC000029.1	-7.54	2.48e-13	8.5e-11	-0.39	-0.33	Bone mineral density;	chr22:23125763	chr22:23136620~23136710:+
THCA	cis	rs9902453	0.967	rs17825877	ENSG00000264007.1	RP11-68I3.10	7.54	2.48e-13	8.5e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:30188170	chr17:29621617~29622254:-
THCA	cis	rs2276314	1	rs4799835	ENSG00000278986.1	RP11-723J4.3	-7.54	2.48e-13	8.5e-11	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35991305	chr18:35972151~35973916:+
THCA	cis	rs6496932	0.503	rs11074205	ENSG00000218052.5	ADAMTS7P4	-7.54	2.48e-13	8.51e-11	-0.44	-0.33	Central corneal thickness;Corneal structure;	chr15:85401381	chr15:85255369~85330334:-
THCA	cis	rs11673344	0.504	rs2595555	ENSG00000226686.6	LINC01535	7.54	2.48e-13	8.52e-11	0.36	0.33	Obesity-related traits;	chr19:37000219	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.504	rs1667377	ENSG00000226686.6	LINC01535	7.54	2.48e-13	8.52e-11	0.36	0.33	Obesity-related traits;	chr19:37000966	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.523	rs1667379	ENSG00000226686.6	LINC01535	7.54	2.48e-13	8.52e-11	0.36	0.33	Obesity-related traits;	chr19:37001192	chr19:37251912~37265535:+
THCA	cis	rs2787702	0.5	rs72827301	ENSG00000237233.2	TMEM26-AS1	7.54	2.48e-13	8.52e-11	0.55	0.33	Response to taxane treatment (placlitaxel);	chr10:61550794	chr10:61452639~61481956:+
THCA	cis	rs10483853	0.525	rs10138789	ENSG00000258695.2	RP3-414A15.2	-7.54	2.49e-13	8.56e-11	-0.48	-0.33	Coronary artery calcification;	chr14:73497574	chr14:73522878~73530610:+
THCA	cis	rs2976388	0.647	rs2585154	ENSG00000253741.1	CTD-2292P10.4	-7.54	2.5e-13	8.58e-11	-0.41	-0.33	Urinary tract infection frequency;	chr8:142702067	chr8:142702252~142726973:-
THCA	cis	rs2839186	0.605	rs2839170	ENSG00000239415.1	AP001469.9	7.54	2.5e-13	8.59e-11	0.34	0.33	Testicular germ cell tumor;	chr21:46251391	chr21:46251549~46254133:-
THCA	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	7.54	2.51e-13	8.6e-11	0.49	0.33	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
THCA	cis	rs849141	0.925	rs520161	ENSG00000234336.5	JAZF1-AS1	-7.54	2.51e-13	8.6e-11	-0.36	-0.33	Height;Hip circumference adjusted for BMI;	chr7:28171041	chr7:28180322~28243917:+
THCA	cis	rs2033711	0.84	rs3764533	ENSG00000269473.1	CTD-2619J13.19	7.54	2.51e-13	8.6e-11	0.3	0.33	Uric acid clearance;	chr19:58417827	chr19:58440448~58445849:+
THCA	cis	rs2337406	0.789	rs60000589	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106782459	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs111881598	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106783113	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs61164979	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106783133	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs61419485	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106783374	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs8015361	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106783991	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74090151	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106785377	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs8012619	ENSG00000274576.2	IGHV2-70	-7.54	2.51e-13	8.61e-11	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106793907	chr14:106770577~106771020:-
THCA	cis	rs2361718	0.5	rs8068856	ENSG00000279259.1	RP11-334C17.3	7.54	2.51e-13	8.61e-11	0.33	0.33	Yeast infection;	chr17:80126932	chr17:80147250~80148596:+
THCA	cis	rs7615952	0.599	rs6766327	ENSG00000171084.14	FAM86JP	7.54	2.51e-13	8.61e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:126004834	chr3:125916620~125930024:+
THCA	cis	rs12554020	0.786	rs12349299	ENSG00000227603.1	RP11-165J3.6	7.54	2.51e-13	8.62e-11	0.5	0.33	Schizophrenia;	chr9:93412482	chr9:93435332~93437121:-
THCA	cis	rs1949733	0.656	rs2688243	ENSG00000205959.3	RP11-689P11.2	-7.54	2.51e-13	8.62e-11	-0.27	-0.33	Response to antineoplastic agents;	chr4:8434559	chr4:8482270~8512610:+
THCA	cis	rs1799949	0.628	rs4474733	ENSG00000267681.1	CTD-3199J23.6	-7.54	2.52e-13	8.63e-11	-0.41	-0.33	Menopause (age at onset);	chr17:43356292	chr17:43144956~43145255:+
THCA	cis	rs2412819	0.571	rs62018900	ENSG00000249839.1	AC011330.5	-7.54	2.52e-13	8.63e-11	-0.51	-0.33	Lung cancer;	chr15:43633252	chr15:43663654~43684339:-
THCA	cis	rs2412819	0.545	rs35333173	ENSG00000249839.1	AC011330.5	-7.54	2.52e-13	8.63e-11	-0.51	-0.33	Lung cancer;	chr15:43640818	chr15:43663654~43684339:-
THCA	cis	rs2412819	0.571	rs112667279	ENSG00000249839.1	AC011330.5	-7.54	2.52e-13	8.63e-11	-0.51	-0.33	Lung cancer;	chr15:43649258	chr15:43663654~43684339:-
THCA	cis	rs7208859	0.673	rs12103759	ENSG00000264538.5	SUZ12P1	-7.53	2.53e-13	8.68e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908669	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs59029591	ENSG00000264538.5	SUZ12P1	-7.53	2.53e-13	8.68e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30908728	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73265633	ENSG00000264538.5	SUZ12P1	-7.53	2.53e-13	8.68e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30909288	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9913782	ENSG00000264538.5	SUZ12P1	-7.53	2.53e-13	8.68e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910366	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9911989	ENSG00000264538.5	SUZ12P1	7.53	2.53e-13	8.68e-11	0.35	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30910684	chr17:30709299~30790908:+
THCA	cis	rs2033711	0.837	rs3764535	ENSG00000269473.1	CTD-2619J13.19	7.53	2.53e-13	8.68e-11	0.3	0.33	Uric acid clearance;	chr19:58417685	chr19:58440448~58445849:+
THCA	cis	rs2976388	0.647	rs2244163	ENSG00000253741.1	CTD-2292P10.4	-7.53	2.54e-13	8.69e-11	-0.4	-0.33	Urinary tract infection frequency;	chr8:142703082	chr8:142702252~142726973:-
THCA	cis	rs4073416	0.684	rs883081	ENSG00000276116.2	FUT8-AS1	7.53	2.54e-13	8.7e-11	0.34	0.33	N-glycan levels;	chr14:65413903	chr14:65411170~65412690:-
THCA	cis	rs2688608	0.62	rs12253408	ENSG00000271816.1	BMS1P4	7.53	2.54e-13	8.7e-11	0.33	0.33	Inflammatory bowel disease;	chr10:73736198	chr10:73699151~73730487:-
THCA	cis	rs875971	1	rs11974264	ENSG00000232559.3	GS1-124K5.12	-7.53	2.55e-13	8.73e-11	-0.31	-0.33	Aortic root size;	chr7:66182595	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs1540651	ENSG00000232559.3	GS1-124K5.12	-7.53	2.55e-13	8.73e-11	-0.31	-0.33	Aortic root size;	chr7:66185134	chr7:66554588~66576923:-
THCA	cis	rs2348418	0.864	rs6487687	ENSG00000247934.4	RP11-967K21.1	7.53	2.55e-13	8.75e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28558230	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs6487689	ENSG00000247934.4	RP11-967K21.1	7.53	2.55e-13	8.75e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28560101	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7304540	ENSG00000247934.4	RP11-967K21.1	7.53	2.55e-13	8.75e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28560489	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7304776	ENSG00000247934.4	RP11-967K21.1	7.53	2.55e-13	8.75e-11	0.29	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28560634	chr12:28163298~28190738:-
THCA	cis	rs11168351	1	rs11168351	ENSG00000258273.1	RP11-370I10.4	-7.53	2.56e-13	8.78e-11	-0.43	-0.33	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48333755~48333901:-
THCA	cis	rs934734	0.563	rs11684155	ENSG00000281920.1	RP11-418H16.1	7.53	2.57e-13	8.79e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65354166	chr2:65623272~65628424:+
THCA	cis	rs10181042	0.528	rs2564118	ENSG00000271889.1	RP11-493E12.1	7.53	2.57e-13	8.79e-11	0.31	0.33	Crohn's disease;	chr2:61006154	chr2:61151433~61162105:-
THCA	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-7.53	2.57e-13	8.8e-11	-0.41	-0.33	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
THCA	cis	rs7208859	0.673	rs79541516	ENSG00000264538.5	SUZ12P1	-7.53	2.58e-13	8.82e-11	-0.35	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30709299~30790908:+
THCA	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	7.53	2.58e-13	8.82e-11	0.42	0.33	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
THCA	cis	rs6723226	0.75	rs10182170	ENSG00000276334.1	AL133243.1	7.53	2.58e-13	8.84e-11	0.37	0.33	Intelligence (multi-trait analysis);	chr2:32479118	chr2:32521927~32523547:+
THCA	cis	rs2348418	0.864	rs11049714	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28561162	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7960369	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28561569	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7977817	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28562549	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.831	rs7977525	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28562584	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7977850	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28562715	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7978086	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28562761	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs11609924	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28563197	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs2137071	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28563797	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs7968563	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28563844	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs2137072	ENSG00000247934.4	RP11-967K21.1	7.53	2.58e-13	8.84e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28563872	chr12:28163298~28190738:-
THCA	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	7.53	2.58e-13	8.85e-11	0.29	0.33	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
THCA	cis	rs2439831	1	rs527921	ENSG00000275601.1	AC011330.13	7.53	2.58e-13	8.85e-11	0.5	0.33	Lung cancer in ever smokers;	chr15:43478218	chr15:43642389~43643023:-
THCA	cis	rs4927850	0.521	rs4927679	ENSG00000231464.1	AC024937.4	-7.53	2.58e-13	8.85e-11	-0.36	-0.33	Pancreatic cancer;	chr3:195931489	chr3:195996738~195998233:+
THCA	cis	rs801193	0.591	rs2707839	ENSG00000232559.3	GS1-124K5.12	7.53	2.59e-13	8.88e-11	0.31	0.33	Aortic root size;	chr7:66728097	chr7:66554588~66576923:-
THCA	cis	rs2276314	0.857	rs4799408	ENSG00000278986.1	RP11-723J4.3	7.53	2.59e-13	8.88e-11	0.37	0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36009019	chr18:35972151~35973916:+
THCA	cis	rs11146838	1	rs11146838	ENSG00000276805.1	RP11-291L22.6	7.53	2.59e-13	8.88e-11	0.35	0.33	Breast cancer;	chr10:38856846	chr10:38451030~38451785:+
THCA	cis	rs72772090	0.539	rs56319744	ENSG00000248734.2	CTD-2260A17.1	-7.53	2.6e-13	8.89e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96806235	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs10515250	ENSG00000248734.2	CTD-2260A17.1	-7.53	2.6e-13	8.89e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96814490	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs2042386	ENSG00000248734.2	CTD-2260A17.1	-7.53	2.6e-13	8.89e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96821080	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs72773989	ENSG00000248734.2	CTD-2260A17.1	-7.53	2.6e-13	8.89e-11	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96827910	chr5:96784777~96785999:+
THCA	cis	rs2675662	0.525	rs12264025	ENSG00000271816.1	BMS1P4	7.53	2.6e-13	8.9e-11	0.33	0.33	Psoriasis vulgaris;Psoriasis;	chr10:73734692	chr10:73699151~73730487:-
THCA	cis	rs2688608	0.592	rs12253429	ENSG00000271816.1	BMS1P4	7.53	2.6e-13	8.9e-11	0.33	0.33	Inflammatory bowel disease;	chr10:73736403	chr10:73699151~73730487:-
THCA	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	7.53	2.6e-13	8.9e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
THCA	cis	rs4927850	0.752	rs7618864	ENSG00000226155.1	AC124944.3	-7.53	2.61e-13	8.93e-11	-0.38	-0.33	Pancreatic cancer;	chr3:196022690	chr3:195912049~195913986:+
THCA	cis	rs6065	0.618	rs16954342	ENSG00000234203.1	RP5-1050D4.2	7.53	2.61e-13	8.94e-11	0.71	0.33	Platelet count;	chr17:5003808	chr17:4972851~4974681:+
THCA	cis	rs150992	0.548	rs12109067	ENSG00000248489.1	CTD-2007H13.3	7.53	2.61e-13	8.94e-11	0.32	0.33	Body mass index;	chr5:99038928	chr5:98929171~98995013:+
THCA	cis	rs1023500	0.551	rs133379	ENSG00000205702.9	CYP2D7	7.53	2.62e-13	8.95e-11	0.27	0.33	Schizophrenia;	chr22:42072531	chr22:42140203~42144577:-
THCA	cis	rs2688608	0.592	rs10762563	ENSG00000271816.1	BMS1P4	7.53	2.63e-13	9.01e-11	0.33	0.33	Inflammatory bowel disease;	chr10:73765044	chr10:73699151~73730487:-
THCA	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	7.53	2.64e-13	9.02e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	7.53	2.64e-13	9.02e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
THCA	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	7.53	2.64e-13	9.03e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
THCA	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	7.53	2.64e-13	9.03e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
THCA	cis	rs4820539	1	rs916584	ENSG00000221069.1	AC000029.1	-7.53	2.64e-13	9.04e-11	-0.39	-0.33	Bone mineral density;	chr22:23127246	chr22:23136620~23136710:+
THCA	cis	rs2276314	0.857	rs7237599	ENSG00000278986.1	RP11-723J4.3	-7.53	2.65e-13	9.05e-11	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36059433	chr18:35972151~35973916:+
THCA	cis	rs75422866	0.558	rs73104190	ENSG00000274902.1	RP1-197B17.4	7.53	2.65e-13	9.06e-11	0.68	0.33	Pneumonia;	chr12:47716040	chr12:47731908~47732351:+
THCA	cis	rs75422866	0.51	rs73104197	ENSG00000274902.1	RP1-197B17.4	7.53	2.65e-13	9.06e-11	0.68	0.33	Pneumonia;	chr12:47717273	chr12:47731908~47732351:+
THCA	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	7.53	2.65e-13	9.06e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
THCA	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	7.53	2.65e-13	9.06e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
THCA	cis	rs7208859	0.623	rs59447372	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs8079891	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73267858	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs56095789	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11656844	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11652533	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs11652631	ENSG00000264538.5	SUZ12P1	-7.53	2.65e-13	9.07e-11	-0.33	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30709299~30790908:+
THCA	cis	rs7615952	0.641	rs6438951	ENSG00000171084.14	FAM86JP	7.53	2.66e-13	9.08e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:125978156	chr3:125916620~125930024:+
THCA	cis	rs910316	0.737	rs175510	ENSG00000279594.1	RP11-950C14.10	-7.53	2.66e-13	9.09e-11	-0.3	-0.33	Height;	chr14:75058136	chr14:75011269~75012851:-
THCA	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-7.53	2.66e-13	9.1e-11	-0.47	-0.33	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
THCA	cis	rs9902453	0.967	rs56129908	ENSG00000264007.1	RP11-68I3.10	7.53	2.66e-13	9.1e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30094364	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs4350617	ENSG00000264007.1	RP11-68I3.10	7.53	2.66e-13	9.1e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30096070	chr17:29621617~29622254:-
THCA	cis	rs9902453	1	rs55971458	ENSG00000264007.1	RP11-68I3.10	7.53	2.66e-13	9.1e-11	0.38	0.33	Coffee consumption (cups per day);	chr17:30099998	chr17:29621617~29622254:-
THCA	cis	rs10208649	0.611	rs12620667	ENSG00000272156.1	RP11-477N3.1	7.53	2.66e-13	9.1e-11	0.48	0.33	Body mass index;	chr2:54063860	chr2:54082554~54085066:+
THCA	cis	rs7569084	0.566	rs7584295	ENSG00000281920.1	RP11-418H16.1	7.53	2.67e-13	9.12e-11	0.43	0.33	Sum eosinophil basophil counts;	chr2:65353940	chr2:65623272~65628424:+
THCA	cis	rs934734	0.563	rs11695373	ENSG00000281920.1	RP11-418H16.1	7.53	2.67e-13	9.12e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65354066	chr2:65623272~65628424:+
THCA	cis	rs2032366	1	rs8088329	ENSG00000267279.1	RP11-879F14.2	-7.53	2.67e-13	9.14e-11	-0.33	-0.33	Obesity-related traits;	chr18:61595758	chr18:61585746~61606916:-
THCA	cis	rs12817211	0.502	rs1554844	ENSG00000272368.2	RP4-605O3.4	-7.53	2.68e-13	9.16e-11	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50120582	chr12:50112197~50165618:+
THCA	cis	rs2688608	0.53	rs71507081	ENSG00000271816.1	BMS1P4	7.53	2.68e-13	9.16e-11	0.33	0.33	Inflammatory bowel disease;	chr10:73733378	chr10:73699151~73730487:-
THCA	cis	rs9388451	0.874	rs1159974	ENSG00000237742.5	RP11-624M8.1	7.53	2.68e-13	9.16e-11	0.28	0.33	Brugada syndrome;	chr6:125769131	chr6:125578558~125749190:-
THCA	cis	rs2032366	1	rs10439023	ENSG00000267279.1	RP11-879F14.2	-7.53	2.68e-13	9.16e-11	-0.33	-0.33	Obesity-related traits;	chr18:61597073	chr18:61585746~61606916:-
THCA	cis	rs9902453	0.791	rs3098950	ENSG00000264007.1	RP11-68I3.10	7.53	2.68e-13	9.17e-11	0.37	0.33	Coffee consumption (cups per day);	chr17:29671367	chr17:29621617~29622254:-
THCA	cis	rs7015263	0.727	rs4961194	ENSG00000254231.1	CTD-2284J15.1	-7.53	2.68e-13	9.17e-11	-0.32	-0.33	Intelligence (multi-trait analysis);	chr8:86482745	chr8:86333274~86343314:-
THCA	cis	rs9326248	0.861	rs4938343	ENSG00000280143.1	AP000892.6	7.53	2.69e-13	9.19e-11	0.46	0.33	Blood protein levels;	chr11:117132812	chr11:117204967~117210292:+
THCA	cis	rs914615	0.552	rs4421576	ENSG00000160766.13	GBAP1	-7.53	2.69e-13	9.19e-11	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155169734	chr1:155213821~155227422:-
THCA	cis	rs2253762	0.507	rs10159998	ENSG00000276742.1	RP11-500G22.4	7.53	2.69e-13	9.19e-11	0.48	0.33	Breast cancer;	chr10:121994550	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.54	rs11200311	ENSG00000276742.1	RP11-500G22.4	7.53	2.69e-13	9.19e-11	0.48	0.33	Breast cancer;	chr10:121995094	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.54	rs79069897	ENSG00000276742.1	RP11-500G22.4	7.53	2.69e-13	9.19e-11	0.48	0.33	Breast cancer;	chr10:121995680	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.54	rs77032313	ENSG00000276742.1	RP11-500G22.4	7.53	2.69e-13	9.19e-11	0.48	0.33	Breast cancer;	chr10:121995687	chr10:121956782~121957098:+
THCA	cis	rs3096299	0.606	rs2965946	ENSG00000274627.1	RP11-104N10.2	7.53	2.69e-13	9.2e-11	0.36	0.33	Multiple myeloma (IgH translocation);	chr16:89450204	chr16:89516797~89522217:+
THCA	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	7.53	2.69e-13	9.21e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
THCA	cis	rs10875746	0.903	rs11168370	ENSG00000240399.1	RP1-228P16.1	-7.53	2.7e-13	9.21e-11	-0.32	-0.33	Longevity (90 years and older);	chr12:48041497	chr12:48054813~48055591:-
THCA	cis	rs2712184	0.687	rs62180470	ENSG00000229352.1	AC007563.3	7.53	2.7e-13	9.23e-11	0.39	0.33	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);	chr2:216780728	chr2:216799608~216805335:+
THCA	cis	rs10932679	0.532	rs2024488	ENSG00000229352.1	AC007563.3	-7.52	2.71e-13	9.25e-11	-0.41	-0.33	Pulse pressure;	chr2:216798245	chr2:216799608~216805335:+
THCA	cis	rs11148252	0.564	rs2296350	ENSG00000235660.1	LINC00345	-7.52	2.71e-13	9.25e-11	-0.4	-0.33	Lewy body disease;	chr13:52135908	chr13:52484161~52484680:-
THCA	cis	rs11148252	0.538	rs2296348	ENSG00000235660.1	LINC00345	-7.52	2.71e-13	9.25e-11	-0.4	-0.33	Lewy body disease;	chr13:52136000	chr13:52484161~52484680:-
THCA	cis	rs2688482	0.557	rs2550236	ENSG00000224769.1	AC069213.1	7.52	2.71e-13	9.26e-11	0.48	0.33	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195614947~195620233:+
THCA	cis	rs2880765	0.835	rs7161880	ENSG00000259295.5	CSPG4P12	7.52	2.71e-13	9.27e-11	0.41	0.33	Coronary artery disease;	chr15:85475515	chr15:85191438~85213905:+
THCA	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	7.52	2.72e-13	9.28e-11	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
THCA	cis	rs1075265	0.62	rs2542584	ENSG00000233266.1	HMGB1P31	7.52	2.72e-13	9.28e-11	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54051334~54051760:+
THCA	cis	rs5769707	0.706	rs2071903	ENSG00000235111.1	RP1-29C18.8	-7.52	2.72e-13	9.29e-11	-0.43	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49612657~49615716:-
THCA	cis	rs2562456	0.833	rs516519	ENSG00000268119.4	CTD-2561J22.5	-7.52	2.73e-13	9.31e-11	-0.41	-0.33	Pain;	chr19:21298730	chr19:21444241~21463908:-
THCA	cis	rs2562456	0.833	rs552800	ENSG00000268119.4	CTD-2561J22.5	-7.52	2.73e-13	9.31e-11	-0.41	-0.33	Pain;	chr19:21301840	chr19:21444241~21463908:-
THCA	cis	rs3822625	0.541	rs12655019	ENSG00000271828.1	CTD-2310F14.1	7.52	2.73e-13	9.31e-11	0.76	0.33	Breast cancer (early onset);	chr5:56899963	chr5:56927874~56929573:+
THCA	cis	rs748404	0.518	rs2927085	ENSG00000166763.7	STRCP1	7.52	2.73e-13	9.32e-11	0.35	0.33	Lung cancer;	chr15:43697332	chr15:43699488~43718184:-
THCA	cis	rs7833787	0.502	rs6586783	ENSG00000278886.1	RP11-108A14.1	-7.52	2.74e-13	9.35e-11	-0.43	-0.33	Obesity-related traits;	chr8:18884042	chr8:18864681~18865247:-
THCA	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	7.52	2.74e-13	9.35e-11	0.44	0.33	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
THCA	cis	rs12681366	0.839	rs3019280	ENSG00000253704.1	RP11-267M23.4	7.52	2.74e-13	9.36e-11	0.34	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94437804	chr8:94553722~94569745:+
THCA	cis	rs12681366	0.839	rs3019281	ENSG00000253704.1	RP11-267M23.4	7.52	2.74e-13	9.36e-11	0.34	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94438061	chr8:94553722~94569745:+
THCA	cis	rs9500256	0.934	rs1343391	ENSG00000272541.1	XXbac-BPGBPG55C20.1	-7.52	2.74e-13	9.36e-11	-0.34	-0.33	Eosinophilic esophagitis (pediatric);	chr6:58017876	chr6:57855891~57856468:-
THCA	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	7.52	2.76e-13	9.42e-11	0.46	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
THCA	cis	rs11673344	0.598	rs826326	ENSG00000226686.6	LINC01535	7.52	2.76e-13	9.43e-11	0.36	0.33	Obesity-related traits;	chr19:37003863	chr19:37251912~37265535:+
THCA	cis	rs11673344	0.542	rs826328	ENSG00000226686.6	LINC01535	7.52	2.76e-13	9.43e-11	0.36	0.33	Obesity-related traits;	chr19:37004479	chr19:37251912~37265535:+
THCA	cis	rs2522056	1	rs2405528	ENSG00000233006.5	AC034220.3	-7.52	2.76e-13	9.43e-11	-0.28	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132458606	chr5:132311285~132369916:-
THCA	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-7.52	2.76e-13	9.44e-11	-0.36	-0.33	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
THCA	cis	rs10129255	0.5	rs6576225	ENSG00000223648.3	IGHV3-64	7.52	2.77e-13	9.44e-11	0.19	0.33	Kawasaki disease;	chr14:106778120	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs6576226	ENSG00000223648.3	IGHV3-64	7.52	2.77e-13	9.44e-11	0.19	0.33	Kawasaki disease;	chr14:106778135	chr14:106643132~106658258:-
THCA	cis	rs12681366	1	rs2960122	ENSG00000253704.1	RP11-267M23.4	7.52	2.78e-13	9.49e-11	0.32	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94419858	chr8:94553722~94569745:+
THCA	cis	rs6745190	0.953	rs7371639	ENSG00000236153.1	AC104076.3	7.52	2.79e-13	9.52e-11	0.38	0.33	White blood cell count;	chr2:181057272	chr2:180979427~180980090:-
THCA	cis	rs10971721	0.596	rs9650704	ENSG00000260947.1	RP11-384P7.7	7.52	2.79e-13	9.52e-11	0.74	0.33	Body mass index;	chr9:34141956	chr9:33697459~33700986:+
THCA	cis	rs17684571	0.872	rs2967960	ENSG00000231441.1	RP11-472M19.2	7.52	2.79e-13	9.52e-11	0.41	0.33	Schizophrenia;	chr6:56745971	chr6:56844002~56864078:+
THCA	cis	rs3847687	1	rs78233646	ENSG00000279128.1	RP11-76C10.4	7.52	2.79e-13	9.52e-11	0.37	0.33	Longevity;	chr12:131035625	chr12:131022769~131024741:-
THCA	cis	rs116175783	0.557	rs62197075	ENSG00000227403.1	AC009299.3	7.52	2.8e-13	9.55e-11	0.59	0.33	Intelligence (multi-trait analysis);	chr2:161312613	chr2:161244739~161249050:+
THCA	cis	rs11673344	0.542	rs826331	ENSG00000226686.6	LINC01535	7.52	2.8e-13	9.56e-11	0.36	0.33	Obesity-related traits;	chr19:37007360	chr19:37251912~37265535:+
THCA	cis	rs9400467	0.528	rs1989574	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.56e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111407330	chr6:111277932~111278742:+
THCA	cis	rs7760535	0.811	rs1002475	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Metabolic traits;	chr6:111388386	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs11153288	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111394035	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs11153290	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111396929	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs11153291	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111398927	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs11153292	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111401176	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs12190634	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111403957	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.508	rs11153294	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111409043	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs9487632	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111417970	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs11153295	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111420164	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs6915753	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111420476	chr6:111277932~111278742:+
THCA	cis	rs240993	0.812	rs4620159	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.8e-13	9.57e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111423532	chr6:111277932~111278742:+
THCA	cis	rs2337406	0.866	rs58850145	ENSG00000274576.2	IGHV2-70	-7.52	2.81e-13	9.58e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106806185	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs2027901	ENSG00000274576.2	IGHV2-70	-7.52	2.81e-13	9.58e-11	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106807164	chr14:106770577~106771020:-
THCA	cis	rs2348418	0.864	rs7312339	ENSG00000247934.4	RP11-967K21.1	7.52	2.81e-13	9.58e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28558751	chr12:28163298~28190738:-
THCA	cis	rs2348418	0.864	rs1343859	ENSG00000247934.4	RP11-967K21.1	7.52	2.81e-13	9.58e-11	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28559537	chr12:28163298~28190738:-
THCA	cis	rs1015362	0.581	rs4911373	ENSG00000276073.1	RP5-1125A11.7	-7.52	2.81e-13	9.6e-11	-0.35	-0.33	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33920952	chr20:33985617~33988989:-
THCA	cis	rs2562456	1	rs2562456	ENSG00000268555.1	RP11-678G14.3	7.52	2.82e-13	9.6e-11	0.44	0.33	Pain;	chr19:21483408	chr19:21570822~21587322:-
THCA	cis	rs1150668	0.699	rs1531681	ENSG00000219392.1	RP1-265C24.5	-7.52	2.82e-13	9.61e-11	-0.36	-0.33	Pubertal anthropometrics;	chr6:28259100	chr6:28115628~28116551:+
THCA	cis	rs7615952	0.599	rs6438955	ENSG00000171084.14	FAM86JP	7.52	2.83e-13	9.63e-11	0.39	0.33	Blood pressure (smoking interaction);	chr3:126011490	chr3:125916620~125930024:+
THCA	cis	rs10208649	0.706	rs75833613	ENSG00000272156.1	RP11-477N3.1	7.52	2.83e-13	9.64e-11	0.48	0.33	Body mass index;	chr2:54065224	chr2:54082554~54085066:+
THCA	cis	rs7847628	0.587	rs1060817	ENSG00000270917.1	RP11-27I1.6	-7.52	2.83e-13	9.64e-11	-0.45	-0.33	Birth weight;	chr9:120820914	chr9:120812475~120812845:-
THCA	cis	rs77204473	1	rs12275565	ENSG00000254851.1	RP11-109L13.1	7.52	2.83e-13	9.64e-11	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116882836	chr11:117135528~117138582:+
THCA	cis	rs7615952	0.599	rs60847438	ENSG00000171084.14	FAM86JP	7.52	2.83e-13	9.65e-11	0.41	0.33	Blood pressure (smoking interaction);	chr3:126027162	chr3:125916620~125930024:+
THCA	cis	rs875971	0.862	rs1860469	ENSG00000232559.3	GS1-124K5.12	-7.52	2.83e-13	9.66e-11	-0.32	-0.33	Aortic root size;	chr7:66641888	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs4718383	ENSG00000232559.3	GS1-124K5.12	-7.52	2.83e-13	9.66e-11	-0.32	-0.33	Aortic root size;	chr7:66643422	chr7:66554588~66576923:-
THCA	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	7.52	2.84e-13	9.68e-11	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
THCA	cis	rs853679	0.882	rs9461432	ENSG00000226314.6	ZNF192P1	-7.52	2.84e-13	9.69e-11	-0.54	-0.33	Depression;	chr6:28119105	chr6:28161781~28169594:+
THCA	cis	rs9506514	0.712	rs11838795	ENSG00000222726.1	RNU2-7P	7.52	2.85e-13	9.7e-11	0.4	0.33	Coronary artery calcification;	chr13:20684189	chr13:20612161~20612338:+
THCA	cis	rs910316	0.967	rs8013444	ENSG00000279594.1	RP11-950C14.10	-7.52	2.85e-13	9.71e-11	-0.31	-0.33	Height;	chr14:75195278	chr14:75011269~75012851:-
THCA	cis	rs1009647	0.583	rs72715746	ENSG00000258413.1	RP11-665C16.6	-7.52	2.85e-13	9.71e-11	-0.59	-0.33	Testicular germ cell tumor;	chr14:55274652	chr14:55262767~55272075:-
THCA	cis	rs9890032	0.618	rs55872374	ENSG00000263531.1	RP13-753N3.1	7.52	2.85e-13	9.71e-11	0.45	0.33	Hip circumference adjusted for BMI;	chr17:30822863	chr17:30863921~30864940:-
THCA	cis	rs11148252	0.84	rs3886077	ENSG00000278238.1	RP11-245D16.4	-7.52	2.85e-13	9.72e-11	-0.36	-0.33	Lewy body disease;	chr13:52374918	chr13:52454775~52455331:-
THCA	cis	rs7302981	0.934	rs7279	ENSG00000272368.2	RP4-605O3.4	-7.52	2.86e-13	9.73e-11	-0.2	-0.33	Systolic blood pressure;	chr12:50130164	chr12:50112197~50165618:+
THCA	cis	rs9400467	0.528	rs7451051	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.86e-13	9.74e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111423615	chr6:111277932~111278742:+
THCA	cis	rs9400467	0.528	rs6913769	ENSG00000230177.1	RP5-1112D6.4	-7.52	2.86e-13	9.74e-11	-0.26	-0.33	Amino acid levels;Blood metabolite levels;	chr6:111471694	chr6:111277932~111278742:+
THCA	cis	rs910316	0.737	rs108621	ENSG00000279594.1	RP11-950C14.10	-7.52	2.86e-13	9.75e-11	-0.3	-0.33	Height;	chr14:75013934	chr14:75011269~75012851:-
THCA	cis	rs7617773	0.817	rs9830016	ENSG00000228638.1	FCF1P2	-7.52	2.87e-13	9.77e-11	-0.32	-0.33	Coronary artery disease;	chr3:48241004	chr3:48290793~48291375:-
THCA	cis	rs17772222	0.74	rs11847417	ENSG00000258789.1	RP11-507K2.3	7.52	2.87e-13	9.77e-11	0.31	0.33	Coronary artery calcification;	chr14:88510606	chr14:88551597~88552493:+
THCA	cis	rs17772222	0.74	rs10138309	ENSG00000258789.1	RP11-507K2.3	-7.52	2.87e-13	9.77e-11	-0.31	-0.33	Coronary artery calcification;	chr14:88510352	chr14:88551597~88552493:+
THCA	cis	rs9326248	1	rs4938354	ENSG00000280143.1	AP000892.6	7.52	2.87e-13	9.77e-11	0.42	0.33	Blood protein levels;	chr11:117180449	chr11:117204967~117210292:+
THCA	cis	rs7945705	0.791	rs4579928	ENSG00000254860.4	TMEM9B-AS1	-7.52	2.88e-13	9.81e-11	-0.35	-0.33	Hemoglobin concentration;	chr11:8794157	chr11:8964675~8977527:+
THCA	cis	rs950169	0.545	rs4354897	ENSG00000225151.9	GOLGA2P7	-7.52	2.88e-13	9.81e-11	-0.51	-0.33	Schizophrenia;	chr15:83976219	chr15:84199311~84230136:-
THCA	cis	rs6565180	1	rs11863150	ENSG00000183604.13	SMG1P5	7.52	2.88e-13	9.82e-11	0.32	0.33	Tonsillectomy;	chr16:30374182	chr16:30267553~30335374:-
THCA	cis	rs7948661	1	rs2276045	ENSG00000278376.1	RP11-158I9.8	7.52	2.89e-13	9.84e-11	0.56	0.33	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr11:118494453	chr11:118791254~118793137:+
THCA	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	7.52	2.89e-13	9.85e-11	0.45	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
THCA	cis	rs875971	1	rs6979382	ENSG00000232559.3	GS1-124K5.12	7.52	2.89e-13	9.86e-11	0.31	0.33	Aortic root size;	chr7:66421388	chr7:66554588~66576923:-
THCA	cis	rs875971	1	rs6961990	ENSG00000232559.3	GS1-124K5.12	7.52	2.89e-13	9.86e-11	0.31	0.33	Aortic root size;	chr7:66423583	chr7:66554588~66576923:-
THCA	cis	rs9902453	0.753	rs3097118	ENSG00000264007.1	RP11-68I3.10	7.52	2.9e-13	9.87e-11	0.36	0.33	Coffee consumption (cups per day);	chr17:29651448	chr17:29621617~29622254:-
THCA	cis	rs270601	0.721	rs270621	ENSG00000233006.5	AC034220.3	7.51	2.91e-13	9.89e-11	0.26	0.33	Acylcarnitine levels;	chr5:132270128	chr5:132311285~132369916:-
THCA	cis	rs7247513	1	rs7247513	ENSG00000230310.1	CTD-2192J16.11	-7.51	2.91e-13	9.9e-11	-0.4	-0.33	Bipolar disorder;	chr19:12580371	chr19:12552597~12553644:+
THCA	cis	rs7942368	1	rs10899280	ENSG00000254761.1	RP11-672A2.1	7.51	2.92e-13	9.92e-11	0.46	0.33	Endometriosis;	chr11:76785693	chr11:76712396~76719608:-
THCA	cis	rs6142102	0.625	rs6142068	ENSG00000275784.1	RP5-1125A11.6	7.51	2.92e-13	9.94e-11	0.32	0.33	Skin pigmentation;	chr20:33969366	chr20:33989480~33991818:-
THCA	cis	rs527616	0.965	rs1667550	ENSG00000265369.3	PCAT18	7.51	2.92e-13	9.95e-11	0.4	0.33	Breast cancer;	chr18:26752512	chr18:26687621~26703638:-
THCA	cis	rs9902453	0.765	rs2264303	ENSG00000264007.1	RP11-68I3.10	-7.51	2.92e-13	9.95e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:29728330	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2264302	ENSG00000264007.1	RP11-68I3.10	-7.51	2.92e-13	9.95e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:29730077	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2447935	ENSG00000264007.1	RP11-68I3.10	-7.51	2.92e-13	9.95e-11	-0.37	-0.33	Coffee consumption (cups per day);	chr17:29730506	chr17:29621617~29622254:-
THCA	cis	rs12554020	0.892	rs10217595	ENSG00000227603.1	RP11-165J3.6	7.51	2.93e-13	9.97e-11	0.5	0.33	Schizophrenia;	chr9:93418609	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs10117236	ENSG00000227603.1	RP11-165J3.6	7.51	2.93e-13	9.97e-11	0.5	0.33	Schizophrenia;	chr9:93419731	chr9:93435332~93437121:-
THCA	cis	rs12554020	0.892	rs7863760	ENSG00000227603.1	RP11-165J3.6	7.51	2.93e-13	9.97e-11	0.5	0.33	Schizophrenia;	chr9:93420287	chr9:93435332~93437121:-
THCA	cis	rs240993	0.812	rs7766610	ENSG00000230177.1	RP5-1112D6.4	-7.51	2.93e-13	9.97e-11	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111386618	chr6:111277932~111278742:+
THCA	cis	rs934734	0.563	rs955903	ENSG00000281920.1	RP11-418H16.1	7.51	2.93e-13	9.98e-11	0.43	0.33	Rheumatoid arthritis;	chr2:65348419	chr2:65623272~65628424:+
THCA	cis	rs11696845	0.626	rs1111032	ENSG00000276223.1	RP4-781B1.5	-7.51	2.94e-13	1e-10	-0.39	-0.33	Obesity-related traits;	chr20:44750129	chr20:44746642~44747201:+
THCA	cis	rs7567389	0.677	rs11680949	ENSG00000236682.1	AC068282.3	-7.51	2.94e-13	1e-10	-0.5	-0.33	Self-rated health;	chr2:127365986	chr2:127389130~127400580:+
THCA	cis	rs12908161	0.92	rs35758837	ENSG00000225151.9	GOLGA2P7	-7.51	2.94e-13	1e-10	-0.48	-0.33	Schizophrenia;	chr15:84768151	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs17600551	ENSG00000225151.9	GOLGA2P7	-7.51	2.94e-13	1e-10	-0.48	-0.33	Schizophrenia;	chr15:84776027	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs36033486	ENSG00000225151.9	GOLGA2P7	-7.51	2.94e-13	1e-10	-0.48	-0.33	Schizophrenia;	chr15:84776461	chr15:84199311~84230136:-
THCA	cis	rs11214589	0.651	rs11214594	ENSG00000270179.1	RP11-159N11.4	-7.51	2.94e-13	1e-10	-0.36	-0.33	Neuroticism;	chr11:113388610	chr11:113368478~113369117:+
THCA	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-7.51	2.95e-13	1e-10	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	7.51	2.95e-13	1e-10	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	7.51	2.95e-13	1e-10	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
THCA	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	7.51	2.95e-13	1e-10	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
THCA	cis	rs2337406	0.866	rs7140974	ENSG00000274576.2	IGHV2-70	-7.51	2.95e-13	1e-10	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106795976	chr14:106770577~106771020:-
THCA	cis	rs12681366	0.881	rs16916760	ENSG00000253704.1	RP11-267M23.4	7.51	2.95e-13	1e-10	0.36	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94356881	chr8:94553722~94569745:+
THCA	cis	rs4073416	0.712	rs8010876	ENSG00000276116.2	FUT8-AS1	7.51	2.95e-13	1e-10	0.33	0.33	N-glycan levels;	chr14:65740258	chr14:65411170~65412690:-
THCA	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
THCA	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	7.51	2.95e-13	1e-10	0.4	0.33	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
THCA	cis	rs7727544	0.547	rs56083751	ENSG00000224431.1	AC063976.7	7.51	2.96e-13	1.01e-10	0.29	0.33	Blood metabolite levels;	chr5:132328945	chr5:132199456~132203487:+
THCA	cis	rs801193	0.66	rs2659897	ENSG00000232559.3	GS1-124K5.12	-7.51	2.96e-13	1.01e-10	-0.31	-0.33	Aortic root size;	chr7:66722728	chr7:66554588~66576923:-
THCA	cis	rs9393777	0.92	rs13207689	ENSG00000280107.1	AL022393.9	-7.51	2.96e-13	1.01e-10	-0.64	-0.33	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28170845~28172521:+
THCA	cis	rs11148252	0.875	rs9526913	ENSG00000278238.1	RP11-245D16.4	-7.51	2.96e-13	1.01e-10	-0.36	-0.33	Lewy body disease;	chr13:52401702	chr13:52454775~52455331:-
THCA	cis	rs2562456	0.793	rs627522	ENSG00000268119.4	CTD-2561J22.5	7.51	2.97e-13	1.01e-10	0.4	0.33	Pain;	chr19:21313002	chr19:21444241~21463908:-
THCA	cis	rs910316	0.763	rs175014	ENSG00000279594.1	RP11-950C14.10	-7.51	2.97e-13	1.01e-10	-0.3	-0.33	Height;	chr14:74990224	chr14:75011269~75012851:-
THCA	cis	rs2839186	0.605	rs2839174	ENSG00000239415.1	AP001469.9	7.51	2.98e-13	1.01e-10	0.34	0.33	Testicular germ cell tumor;	chr21:46257020	chr21:46251549~46254133:-
THCA	cis	rs7302981	0.967	rs2178173	ENSG00000272368.2	RP4-605O3.4	-7.51	2.98e-13	1.01e-10	-0.2	-0.33	Systolic blood pressure;	chr12:50124146	chr12:50112197~50165618:+
THCA	cis	rs7302981	0.967	rs7297421	ENSG00000272368.2	RP4-605O3.4	-7.51	2.98e-13	1.01e-10	-0.2	-0.33	Systolic blood pressure;	chr12:50125143	chr12:50112197~50165618:+
THCA	cis	rs2688608	0.587	rs2894040	ENSG00000271816.1	BMS1P4	7.51	2.98e-13	1.01e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73718401	chr10:73699151~73730487:-
THCA	cis	rs2688608	0.592	rs3849967	ENSG00000271816.1	BMS1P4	7.51	2.98e-13	1.01e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73723608	chr10:73699151~73730487:-
THCA	cis	rs2688608	0.592	rs7909802	ENSG00000271816.1	BMS1P4	7.51	2.98e-13	1.01e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73724428	chr10:73699151~73730487:-
THCA	cis	rs17711722	0.522	rs4642526	ENSG00000213640.3	EEF1DP4	-7.51	2.99e-13	1.01e-10	-0.38	-0.33	Calcium levels;	chr7:65751755	chr7:64862999~64864370:+
THCA	cis	rs914615	0.552	rs12752585	ENSG00000160766.13	GBAP1	-7.51	3e-13	1.02e-10	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155162930	chr1:155213821~155227422:-
THCA	cis	rs875971	1	rs1981798	ENSG00000232559.3	GS1-124K5.12	7.51	3e-13	1.02e-10	0.31	0.33	Aortic root size;	chr7:66489916	chr7:66554588~66576923:-
THCA	cis	rs10411161	0.552	rs2109657	ENSG00000269483.1	AC006272.1	7.51	3.01e-13	1.02e-10	0.47	0.33	Breast cancer;	chr19:51837473	chr19:51839924~51843324:-
THCA	cis	rs10411161	0.552	rs721891	ENSG00000269483.1	AC006272.1	7.51	3.01e-13	1.02e-10	0.47	0.33	Breast cancer;	chr19:51838218	chr19:51839924~51843324:-
THCA	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-7.51	3.01e-13	1.02e-10	-0.39	-0.33	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
THCA	cis	rs2408955	0.522	rs10875721	ENSG00000258273.1	RP11-370I10.4	7.51	3.01e-13	1.02e-10	0.44	0.33	Glycated hemoglobin levels;	chr12:48019810	chr12:48333755~48333901:-
THCA	cis	rs2288884	0.505	rs17835435	ENSG00000275055.1	CTC-471J1.11	-7.51	3.02e-13	1.03e-10	-0.34	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51931453	chr19:52049007~52049754:+
THCA	cis	rs72772090	0.539	rs17484359	ENSG00000248734.2	CTD-2260A17.1	-7.51	3.03e-13	1.03e-10	-0.56	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96861310	chr5:96784777~96785999:+
THCA	cis	rs4927850	0.752	rs7624460	ENSG00000226155.1	AC124944.3	-7.51	3.03e-13	1.03e-10	-0.38	-0.33	Pancreatic cancer;	chr3:196021659	chr3:195912049~195913986:+
THCA	cis	rs651907	0.557	rs7629753	ENSG00000256628.3	ZBTB11-AS1	-7.51	3.03e-13	1.03e-10	-0.38	-0.33	Colorectal cancer;	chr3:101653078	chr3:101676475~101679217:+
THCA	cis	rs17772222	1	rs7145588	ENSG00000258983.2	RP11-507K2.2	7.51	3.03e-13	1.03e-10	0.42	0.33	Coronary artery calcification;	chr14:88360452	chr14:88499334~88515502:+
THCA	cis	rs17772222	1	rs61977049	ENSG00000258983.2	RP11-507K2.2	7.51	3.03e-13	1.03e-10	0.42	0.33	Coronary artery calcification;	chr14:88360656	chr14:88499334~88515502:+
THCA	cis	rs17772222	1	rs12587386	ENSG00000258983.2	RP11-507K2.2	7.51	3.03e-13	1.03e-10	0.42	0.33	Coronary artery calcification;	chr14:88361420	chr14:88499334~88515502:+
THCA	cis	rs2253762	0.507	rs75383663	ENSG00000276742.1	RP11-500G22.4	7.51	3.04e-13	1.03e-10	0.48	0.33	Breast cancer;	chr10:121993340	chr10:121956782~121957098:+
THCA	cis	rs2276314	0.947	rs16967319	ENSG00000278986.1	RP11-723J4.3	-7.51	3.04e-13	1.03e-10	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35993562	chr18:35972151~35973916:+
THCA	cis	rs2439831	0.702	rs7171750	ENSG00000275601.1	AC011330.13	-7.51	3.04e-13	1.03e-10	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43733660	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs11070408	ENSG00000275601.1	AC011330.13	-7.51	3.04e-13	1.03e-10	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43742590	chr15:43642389~43643023:-
THCA	cis	rs748404	0.56	rs1060939	ENSG00000166763.7	STRCP1	7.51	3.04e-13	1.03e-10	0.35	0.33	Lung cancer;	chr15:43524719	chr15:43699488~43718184:-
THCA	cis	rs17684571	0.872	rs59247267	ENSG00000231441.1	RP11-472M19.2	7.51	3.05e-13	1.03e-10	0.41	0.33	Schizophrenia;	chr6:56733965	chr6:56844002~56864078:+
THCA	cis	rs8113308	0.81	rs10411484	ENSG00000269235.1	ZNF350-AS1	7.51	3.06e-13	1.04e-10	0.5	0.33	Survival in endocrine treated breast cancer (estrogen-receptor positive);	chr19:51940152	chr19:51949134~51981367:+
THCA	cis	rs11971779	0.68	rs7785903	ENSG00000273391.1	RP11-634H22.1	7.51	3.06e-13	1.04e-10	0.3	0.33	Diisocyanate-induced asthma;	chr7:139437897	chr7:139359032~139359566:-
THCA	cis	rs75422866	0.51	rs73105803	ENSG00000257433.4	RP1-197B17.3	7.51	3.06e-13	1.04e-10	0.48	0.33	Pneumonia;	chr12:47722135	chr12:47706085~47742294:+
THCA	cis	rs17772222	0.651	rs1950280	ENSG00000258789.1	RP11-507K2.3	7.51	3.07e-13	1.04e-10	0.31	0.33	Coronary artery calcification;	chr14:88366259	chr14:88551597~88552493:+
THCA	cis	rs7208859	0.673	rs75142521	ENSG00000266490.1	CTD-2349P21.9	7.51	3.07e-13	1.04e-10	0.46	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30792372~30792833:+
THCA	cis	rs7851660	0.654	rs2120264	ENSG00000236130.1	PTCSC2	-7.51	3.07e-13	1.04e-10	-0.26	-0.33	Strep throat;	chr9:97883446	chr9:97805935~97810008:-
THCA	cis	rs42490	0.664	rs368812	ENSG00000251136.7	RP11-37B2.1	-7.51	3.07e-13	1.04e-10	-0.28	-0.33	Leprosy;	chr8:89822269	chr8:89609409~89757727:-
THCA	cis	rs7646881	1	rs73015649	ENSG00000240207.5	RP11-379F4.4	-7.51	3.08e-13	1.04e-10	-0.44	-0.33	Tetralogy of Fallot;	chr3:158732509	chr3:158732263~158784070:+
THCA	cis	rs7646881	1	rs73015654	ENSG00000240207.5	RP11-379F4.4	-7.51	3.08e-13	1.04e-10	-0.44	-0.33	Tetralogy of Fallot;	chr3:158733865	chr3:158732263~158784070:+
THCA	cis	rs7646881	0.953	rs73015657	ENSG00000240207.5	RP11-379F4.4	-7.51	3.08e-13	1.04e-10	-0.44	-0.33	Tetralogy of Fallot;	chr3:158734143	chr3:158732263~158784070:+
THCA	cis	rs17772222	0.74	rs61975278	ENSG00000258789.1	RP11-507K2.3	-7.51	3.08e-13	1.05e-10	-0.32	-0.33	Coronary artery calcification;	chr14:88511223	chr14:88551597~88552493:+
THCA	cis	rs516805	0.667	rs7767993	ENSG00000279453.1	RP3-425C14.4	7.51	3.08e-13	1.05e-10	0.34	0.33	Lymphocyte counts;	chr6:122343192	chr6:122436789~122439223:-
THCA	cis	rs516805	0.667	rs10457432	ENSG00000279453.1	RP3-425C14.4	7.51	3.08e-13	1.05e-10	0.34	0.33	Lymphocyte counts;	chr6:122344699	chr6:122436789~122439223:-
THCA	cis	rs516805	0.673	rs12201010	ENSG00000279453.1	RP3-425C14.4	7.51	3.08e-13	1.05e-10	0.34	0.33	Lymphocyte counts;	chr6:122345675	chr6:122436789~122439223:-
THCA	cis	rs516805	0.64	rs12208084	ENSG00000279453.1	RP3-425C14.4	7.51	3.08e-13	1.05e-10	0.34	0.33	Lymphocyte counts;	chr6:122345745	chr6:122436789~122439223:-
THCA	cis	rs516805	0.706	rs17662514	ENSG00000279453.1	RP3-425C14.4	7.51	3.08e-13	1.05e-10	0.34	0.33	Lymphocyte counts;	chr6:122346013	chr6:122436789~122439223:-
THCA	cis	rs516805	0.706	rs9320863	ENSG00000279453.1	RP3-425C14.4	7.51	3.08e-13	1.05e-10	0.34	0.33	Lymphocyte counts;	chr6:122347086	chr6:122436789~122439223:-
THCA	cis	rs5769707	0.632	rs1476037	ENSG00000235111.1	RP1-29C18.8	-7.51	3.08e-13	1.05e-10	-0.42	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49612657~49615716:-
THCA	cis	rs5769707	0.681	rs8137111	ENSG00000235111.1	RP1-29C18.8	-7.51	3.08e-13	1.05e-10	-0.43	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49650102	chr22:49612657~49615716:-
THCA	cis	rs853679	1	rs2799079	ENSG00000219392.1	RP1-265C24.5	-7.51	3.08e-13	1.05e-10	-0.52	-0.33	Depression;	chr6:28267398	chr6:28115628~28116551:+
THCA	cis	rs7208859	0.623	rs609063	ENSG00000264538.5	SUZ12P1	-7.51	3.09e-13	1.05e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30624495	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs383436	ENSG00000264538.5	SUZ12P1	-7.51	3.09e-13	1.05e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30632161	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.714	rs11650821	ENSG00000264538.5	SUZ12P1	-7.51	3.09e-13	1.05e-10	-0.34	-0.33	Body mass index;	chr17:30641132	chr17:30709299~30790908:+
THCA	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	7.51	3.09e-13	1.05e-10	0.43	0.33	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
THCA	cis	rs10129255	0.556	rs8010005	ENSG00000223648.3	IGHV3-64	7.51	3.1e-13	1.05e-10	0.19	0.33	Kawasaki disease;	chr14:106777987	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.556	rs6576224	ENSG00000223648.3	IGHV3-64	7.51	3.1e-13	1.05e-10	0.19	0.33	Kawasaki disease;	chr14:106777997	chr14:106643132~106658258:-
THCA	cis	rs9506514	0.722	rs4769124	ENSG00000222726.1	RNU2-7P	7.5	3.11e-13	1.05e-10	0.4	0.33	Coronary artery calcification;	chr13:20652706	chr13:20612161~20612338:+
THCA	cis	rs11051970	0.625	rs2728709	ENSG00000274964.1	RP11-817I4.1	-7.5	3.11e-13	1.06e-10	-0.4	-0.33	Response to tocilizumab in rheumatoid arthritis;	chr12:32414782	chr12:32339368~32340724:+
THCA	cis	rs7208859	0.623	rs60890550	ENSG00000263603.1	CTD-2349P21.5	-7.5	3.11e-13	1.06e-10	-0.58	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30703843	chr17:30729469~30731202:+
THCA	cis	rs2253762	0.54	rs4752631	ENSG00000276742.1	RP11-500G22.4	7.5	3.11e-13	1.06e-10	0.48	0.33	Breast cancer;	chr10:121996442	chr10:121956782~121957098:+
THCA	cis	rs2253762	0.54	rs11200313	ENSG00000276742.1	RP11-500G22.4	7.5	3.11e-13	1.06e-10	0.48	0.33	Breast cancer;	chr10:121996523	chr10:121956782~121957098:+
THCA	cis	rs6142102	0.625	rs7263727	ENSG00000275784.1	RP5-1125A11.6	-7.5	3.11e-13	1.06e-10	-0.32	-0.33	Skin pigmentation;	chr20:33953133	chr20:33989480~33991818:-
THCA	cis	rs2839186	0.771	rs13046451	ENSG00000239415.1	AP001469.9	-7.5	3.12e-13	1.06e-10	-0.34	-0.33	Testicular germ cell tumor;	chr21:46221459	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.77	rs2280956	ENSG00000239415.1	AP001469.9	-7.5	3.12e-13	1.06e-10	-0.34	-0.33	Testicular germ cell tumor;	chr21:46222409	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.771	rs2839155	ENSG00000239415.1	AP001469.9	7.5	3.12e-13	1.06e-10	0.34	0.33	Testicular germ cell tumor;	chr21:46220078	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.771	rs2280959	ENSG00000239415.1	AP001469.9	7.5	3.12e-13	1.06e-10	0.34	0.33	Testicular germ cell tumor;	chr21:46222082	chr21:46251549~46254133:-
THCA	cis	rs2839186	0.739	rs2280958	ENSG00000239415.1	AP001469.9	7.5	3.12e-13	1.06e-10	0.34	0.33	Testicular germ cell tumor;	chr21:46222102	chr21:46251549~46254133:-
THCA	cis	rs9487094	0.778	rs61318425	ENSG00000260273.1	RP11-425D10.10	7.5	3.12e-13	1.06e-10	0.43	0.33	Height;	chr6:109427303	chr6:109382795~109383666:+
THCA	cis	rs910316	0.763	rs175450	ENSG00000279594.1	RP11-950C14.10	-7.5	3.14e-13	1.06e-10	-0.3	-0.33	Height;	chr14:75123637	chr14:75011269~75012851:-
THCA	cis	rs910316	0.789	rs175444	ENSG00000279594.1	RP11-950C14.10	-7.5	3.14e-13	1.06e-10	-0.3	-0.33	Height;	chr14:75135079	chr14:75011269~75012851:-
THCA	cis	rs651907	0.557	rs7651406	ENSG00000256628.3	ZBTB11-AS1	7.5	3.14e-13	1.06e-10	0.38	0.33	Colorectal cancer;	chr3:101674452	chr3:101676475~101679217:+
THCA	cis	rs651907	0.557	rs3864012	ENSG00000256628.3	ZBTB11-AS1	7.5	3.14e-13	1.06e-10	0.38	0.33	Colorectal cancer;	chr3:101678779	chr3:101676475~101679217:+
THCA	cis	rs4820539	0.966	rs5751587	ENSG00000221069.1	AC000029.1	-7.5	3.14e-13	1.07e-10	-0.38	-0.33	Bone mineral density;	chr22:23127903	chr22:23136620~23136710:+
THCA	cis	rs4820539	0.966	rs5759594	ENSG00000221069.1	AC000029.1	-7.5	3.14e-13	1.07e-10	-0.38	-0.33	Bone mineral density;	chr22:23128473	chr22:23136620~23136710:+
THCA	cis	rs4820539	1	rs5759595	ENSG00000221069.1	AC000029.1	-7.5	3.14e-13	1.07e-10	-0.38	-0.33	Bone mineral density;	chr22:23129437	chr22:23136620~23136710:+
THCA	cis	rs2288884	0.505	rs2278415	ENSG00000275055.1	CTC-471J1.11	-7.5	3.15e-13	1.07e-10	-0.36	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51964950	chr19:52049007~52049754:+
THCA	cis	rs2288884	0.505	rs3764538	ENSG00000275055.1	CTC-471J1.11	-7.5	3.15e-13	1.07e-10	-0.36	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51965334	chr19:52049007~52049754:+
THCA	cis	rs2946505	0.871	rs2466244	ENSG00000251468.2	RP11-369K16.1	7.5	3.15e-13	1.07e-10	0.44	0.33	Migraine;	chr8:12964370	chr8:12958387~12962200:+
THCA	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	7.5	3.16e-13	1.07e-10	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
THCA	cis	rs7942368	1	rs7107409	ENSG00000254761.1	RP11-672A2.1	7.5	3.16e-13	1.07e-10	0.46	0.33	Endometriosis;	chr11:76781151	chr11:76712396~76719608:-
THCA	cis	rs11148252	0.538	rs9535880	ENSG00000235660.1	LINC00345	-7.5	3.17e-13	1.07e-10	-0.4	-0.33	Lewy body disease;	chr13:52132007	chr13:52484161~52484680:-
THCA	cis	rs6142102	0.646	rs2223553	ENSG00000275784.1	RP5-1125A11.6	-7.5	3.17e-13	1.08e-10	-0.32	-0.33	Skin pigmentation;	chr20:34121638	chr20:33989480~33991818:-
THCA	cis	rs7208859	0.573	rs55661352	ENSG00000264538.5	SUZ12P1	-7.5	3.18e-13	1.08e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30709299~30790908:+
THCA	cis	rs11214589	0.651	rs11214595	ENSG00000270179.1	RP11-159N11.4	-7.5	3.19e-13	1.08e-10	-0.36	-0.33	Neuroticism;	chr11:113388936	chr11:113368478~113369117:+
THCA	cis	rs9902453	1	rs4581755	ENSG00000264007.1	RP11-68I3.10	7.5	3.19e-13	1.08e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:30100880	chr17:29621617~29622254:-
THCA	cis	rs957448	0.561	rs7459558	ENSG00000253704.1	RP11-267M23.4	7.5	3.19e-13	1.08e-10	0.33	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94553722~94569745:+
THCA	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	7.5	3.19e-13	1.08e-10	0.43	0.33	Height;	chr4:55413708	chr4:55363971~55395847:-
THCA	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	7.5	3.19e-13	1.08e-10	0.43	0.33	Height;	chr4:55415153	chr4:55363971~55395847:-
THCA	cis	rs8081395	0.741	rs180520	ENSG00000266992.1	DHX40P1	7.5	3.19e-13	1.08e-10	0.37	0.33	White blood cell count;	chr17:59937788	chr17:59976009~60002384:-
THCA	cis	rs7942368	1	rs1440979	ENSG00000254761.1	RP11-672A2.1	7.5	3.2e-13	1.08e-10	0.46	0.33	Endometriosis;	chr11:76784085	chr11:76712396~76719608:-
THCA	cis	rs2976388	0.647	rs2585136	ENSG00000253741.1	CTD-2292P10.4	-7.5	3.2e-13	1.08e-10	-0.41	-0.33	Urinary tract infection frequency;	chr8:142730723	chr8:142702252~142726973:-
THCA	cis	rs1198430	1	rs1198434	ENSG00000232482.2	RP4-654C18.1	-7.5	3.2e-13	1.09e-10	-0.58	-0.33	Total cholesterol levels;	chr1:23431641	chr1:23410832~23412146:+
THCA	cis	rs780096	1	rs780095	ENSG00000234072.1	AC074117.10	-7.5	3.2e-13	1.09e-10	-0.25	-0.33	Total body bone mineral density;	chr2:27518238	chr2:27356246~27367622:+
THCA	cis	rs6504108	0.624	rs3897986	ENSG00000278765.1	RP5-890E16.5	7.5	3.21e-13	1.09e-10	0.37	0.33	Body mass index;	chr17:48184177	chr17:48066704~48067293:-
THCA	cis	rs910316	0.763	rs175044	ENSG00000279594.1	RP11-950C14.10	-7.5	3.21e-13	1.09e-10	-0.3	-0.33	Height;	chr14:75005406	chr14:75011269~75012851:-
THCA	cis	rs4927850	0.723	rs7630825	ENSG00000226155.1	AC124944.3	-7.5	3.22e-13	1.09e-10	-0.38	-0.33	Pancreatic cancer;	chr3:196026869	chr3:195912049~195913986:+
THCA	cis	rs11971779	1	rs75919582	ENSG00000273391.1	RP11-634H22.1	7.5	3.22e-13	1.09e-10	0.36	0.33	Diisocyanate-induced asthma;	chr7:139370173	chr7:139359032~139359566:-
THCA	cis	rs7247513	0.79	rs17476839	ENSG00000230310.1	CTD-2192J16.11	7.5	3.22e-13	1.09e-10	0.39	0.33	Bipolar disorder;	chr19:12651969	chr19:12552597~12553644:+
THCA	cis	rs67340775	0.541	rs200965	ENSG00000219392.1	RP1-265C24.5	-7.5	3.22e-13	1.09e-10	-0.5	-0.33	Lung cancer in ever smokers;	chr6:27898606	chr6:28115628~28116551:+
THCA	cis	rs11672691	0.792	rs7248215	ENSG00000267107.5	PCAT19	7.5	3.23e-13	1.09e-10	0.34	0.33	Prostate cancer;	chr19:41493212	chr19:41454169~41500649:-
THCA	cis	rs2276314	0.857	rs62101379	ENSG00000278986.1	RP11-723J4.3	-7.5	3.24e-13	1.1e-10	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36004939	chr18:35972151~35973916:+
THCA	cis	rs748404	0.697	rs471122	ENSG00000205771.5	CATSPER2P1	7.5	3.24e-13	1.1e-10	0.33	0.33	Lung cancer;	chr15:43266376	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs473016	ENSG00000205771.5	CATSPER2P1	-7.5	3.24e-13	1.1e-10	-0.33	-0.33	Lung cancer;	chr15:43266625	chr15:43726918~43747094:-
THCA	cis	rs6762	0.748	rs1130719	ENSG00000279672.1	CMB9-55F22.1	7.5	3.24e-13	1.1e-10	0.36	0.33	Mean platelet volume;	chr11:838760	chr11:779617~780755:+
THCA	cis	rs10208649	1	rs13401719	ENSG00000272156.1	RP11-477N3.1	7.5	3.24e-13	1.1e-10	0.59	0.33	Body mass index;	chr2:53958510	chr2:54082554~54085066:+
THCA	cis	rs4820539	0.966	rs2301554	ENSG00000221069.1	AC000029.1	-7.5	3.25e-13	1.1e-10	-0.39	-0.33	Bone mineral density;	chr22:23142067	chr22:23136620~23136710:+
THCA	cis	rs944289	0.53	rs2755193	ENSG00000257826.1	RP11-116N8.4	7.5	3.25e-13	1.1e-10	0.35	0.33	Thyroid cancer;	chr14:36049416	chr14:36061026~36067190:-
THCA	cis	rs67340775	0.541	rs200964	ENSG00000219392.1	RP1-265C24.5	-7.5	3.25e-13	1.1e-10	-0.5	-0.33	Lung cancer in ever smokers;	chr6:27899165	chr6:28115628~28116551:+
THCA	cis	rs4072705	1	rs722477	ENSG00000224020.1	MIR181A2HG	-7.5	3.26e-13	1.1e-10	-0.29	-0.33	Menarche (age at onset);	chr9:124712315	chr9:124658467~124698631:+
THCA	cis	rs914615	0.552	rs4460629	ENSG00000160766.13	GBAP1	-7.5	3.26e-13	1.1e-10	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155162859	chr1:155213821~155227422:-
THCA	cis	rs748404	0.697	rs555001	ENSG00000205771.5	CATSPER2P1	-7.5	3.27e-13	1.11e-10	-0.34	-0.33	Lung cancer;	chr15:43253530	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs475261	ENSG00000205771.5	CATSPER2P1	-7.5	3.27e-13	1.11e-10	-0.34	-0.33	Lung cancer;	chr15:43254258	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-7.5	3.27e-13	1.11e-10	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs28595038	ENSG00000275601.1	AC011330.13	-7.5	3.27e-13	1.11e-10	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43752661	chr15:43642389~43643023:-
THCA	cis	rs2562456	0.833	rs2968076	ENSG00000268119.4	CTD-2561J22.5	-7.5	3.27e-13	1.11e-10	-0.41	-0.33	Pain;	chr19:21454299	chr19:21444241~21463908:-
THCA	cis	rs801193	0.636	rs10233806	ENSG00000232559.3	GS1-124K5.12	-7.5	3.27e-13	1.11e-10	-0.31	-0.33	Aortic root size;	chr7:66653261	chr7:66554588~66576923:-
THCA	cis	rs950169	0.512	rs4374136	ENSG00000259728.4	LINC00933	7.5	3.28e-13	1.11e-10	0.47	0.33	Schizophrenia;	chr15:83976255	chr15:84570649~84580175:+
THCA	cis	rs6504108	0.624	rs2060876	ENSG00000278765.1	RP5-890E16.5	-7.5	3.28e-13	1.11e-10	-0.37	-0.33	Body mass index;	chr17:48245604	chr17:48066704~48067293:-
THCA	cis	rs72772090	0.539	rs72773942	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96787663	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11743410	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96788750	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs11746534	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789104	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs55773007	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789215	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs111886458	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789344	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs10515249	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789556	chr5:96784777~96785999:+
THCA	cis	rs72772090	0.539	rs72773947	ENSG00000248734.2	CTD-2260A17.1	-7.5	3.28e-13	1.11e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96789830	chr5:96784777~96785999:+
THCA	cis	rs1023500	0.573	rs13057094	ENSG00000205702.9	CYP2D7	7.5	3.28e-13	1.11e-10	0.27	0.33	Schizophrenia;	chr22:42074313	chr22:42140203~42144577:-
THCA	cis	rs801193	0.66	rs10950049	ENSG00000232559.3	GS1-124K5.12	7.5	3.3e-13	1.12e-10	0.31	0.33	Aortic root size;	chr7:66765873	chr7:66554588~66576923:-
THCA	cis	rs3096299	0.606	rs2965960	ENSG00000274627.1	RP11-104N10.2	7.5	3.3e-13	1.12e-10	0.36	0.33	Multiple myeloma (IgH translocation);	chr16:89475387	chr16:89516797~89522217:+
THCA	cis	rs10129255	0.5	rs8006888	ENSG00000223648.3	IGHV3-64	7.5	3.3e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106782219	chr14:106643132~106658258:-
THCA	cis	rs651907	0.557	rs3806654	ENSG00000256628.3	ZBTB11-AS1	7.5	3.3e-13	1.12e-10	0.38	0.33	Colorectal cancer;	chr3:101677685	chr3:101676475~101679217:+
THCA	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	7.5	3.3e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	7.5	3.3e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	7.5	3.3e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	7.5	3.3e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
THCA	cis	rs7942368	0.793	rs12273016	ENSG00000254761.1	RP11-672A2.1	-7.5	3.31e-13	1.12e-10	-0.45	-0.33	Endometriosis;	chr11:76779672	chr11:76712396~76719608:-
THCA	cis	rs6600671	1	rs10903159	ENSG00000223345.3	HIST2H2BA	7.5	3.31e-13	1.12e-10	0.36	0.33	Hip geometry;	chr1:121440138	chr1:121108210~121117257:-
THCA	cis	rs10129255	0.5	rs8022547	ENSG00000223648.3	IGHV3-64	7.5	3.31e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106781985	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-7.5	3.31e-13	1.12e-10	-0.19	-0.33	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	7.5	3.31e-13	1.12e-10	0.19	0.33	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
THCA	cis	rs2284219	0.964	rs2284218	ENSG00000244480.1	AC005154.7	-7.5	3.31e-13	1.12e-10	-0.26	-0.33	Type 2 diabetes;	chr7:30674717	chr7:30523143~30524535:-
THCA	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	7.5	3.32e-13	1.12e-10	0.45	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
THCA	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-7.5	3.32e-13	1.12e-10	-0.35	-0.33	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
THCA	cis	rs2688608	0.592	rs10762560	ENSG00000271816.1	BMS1P4	7.49	3.33e-13	1.13e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73735647	chr10:73699151~73730487:-
THCA	cis	rs2337406	0.866	rs988130	ENSG00000274576.2	IGHV2-70	-7.49	3.33e-13	1.13e-10	-0.27	-0.33	Alzheimer's disease (late onset);	chr14:106777154	chr14:106770577~106771020:-
THCA	cis	rs11673344	0.504	rs1667378	ENSG00000226686.6	LINC01535	7.49	3.33e-13	1.13e-10	0.36	0.33	Obesity-related traits;	chr19:37001171	chr19:37251912~37265535:+
THCA	cis	rs7119038	0.609	rs11216998	ENSG00000255239.1	AP002954.6	-7.49	3.33e-13	1.13e-10	-0.46	-0.33	Sjögren's syndrome;	chr11:118734128	chr11:118688039~118690600:-
THCA	cis	rs77204473	1	rs12278117	ENSG00000254851.1	RP11-109L13.1	7.49	3.33e-13	1.13e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877453	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12292614	ENSG00000254851.1	RP11-109L13.1	7.49	3.33e-13	1.13e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116877799	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12286581	ENSG00000254851.1	RP11-109L13.1	7.49	3.33e-13	1.13e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878028	chr11:117135528~117138582:+
THCA	cis	rs10208649	1	rs11886024	ENSG00000272156.1	RP11-477N3.1	7.49	3.33e-13	1.13e-10	0.59	0.33	Body mass index;	chr2:53917682	chr2:54082554~54085066:+
THCA	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	7.49	3.34e-13	1.13e-10	0.19	0.33	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
THCA	cis	rs1198430	1	rs1198432	ENSG00000232482.2	RP4-654C18.1	7.49	3.34e-13	1.13e-10	0.58	0.33	Total cholesterol levels;	chr1:23429662	chr1:23410832~23412146:+
THCA	cis	rs7615952	0.599	rs1875683	ENSG00000171084.14	FAM86JP	7.49	3.34e-13	1.13e-10	0.41	0.33	Blood pressure (smoking interaction);	chr3:126013638	chr3:125916620~125930024:+
THCA	cis	rs2284378	0.515	rs6059579	ENSG00000275784.1	RP5-1125A11.6	-7.49	3.35e-13	1.13e-10	-0.32	-0.33	Breast cancer;	chr20:33940059	chr20:33989480~33991818:-
THCA	cis	rs193541	0.632	rs173481	ENSG00000263432.2	RN7SL689P	7.49	3.36e-13	1.13e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122918857	chr5:123022487~123022783:-
THCA	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-7.49	3.36e-13	1.13e-10	-0.38	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
THCA	cis	rs944289	0.53	rs2780308	ENSG00000257826.1	RP11-116N8.4	7.49	3.36e-13	1.14e-10	0.35	0.33	Thyroid cancer;	chr14:36050062	chr14:36061026~36067190:-
THCA	cis	rs9902453	0.967	rs12449783	ENSG00000264007.1	RP11-68I3.10	7.49	3.38e-13	1.14e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:30200635	chr17:29621617~29622254:-
THCA	cis	rs7674212	1	rs7674212	ENSG00000246560.2	RP11-10L12.4	7.49	3.38e-13	1.14e-10	0.41	0.33	Type 2 diabetes;	chr4:103067742	chr4:102828055~102844075:+
THCA	cis	rs12928939	0.815	rs8049163	ENSG00000260886.1	TAT-AS1	7.49	3.39e-13	1.14e-10	0.43	0.33	Post bronchodilator FEV1;	chr16:71685450	chr16:71565789~71578187:+
THCA	cis	rs690037	0.551	rs690522	ENSG00000272498.1	RP11-415F23.3	7.49	3.39e-13	1.14e-10	0.36	0.33	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16335560	chr3:16339308~16339871:+
THCA	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	7.49	3.39e-13	1.15e-10	0.19	0.33	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
THCA	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	7.49	3.39e-13	1.15e-10	0.38	0.33	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
THCA	cis	rs67340775	0.541	rs200975	ENSG00000219392.1	RP1-265C24.5	-7.49	3.4e-13	1.15e-10	-0.5	-0.33	Lung cancer in ever smokers;	chr6:27887847	chr6:28115628~28116551:+
THCA	cis	rs67340775	0.541	rs200974	ENSG00000219392.1	RP1-265C24.5	-7.49	3.4e-13	1.15e-10	-0.5	-0.33	Lung cancer in ever smokers;	chr6:27888067	chr6:28115628~28116551:+
THCA	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	7.49	3.4e-13	1.15e-10	0.19	0.33	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
THCA	cis	rs7945705	0.846	rs4929912	ENSG00000254860.4	TMEM9B-AS1	7.49	3.4e-13	1.15e-10	0.37	0.33	Hemoglobin concentration;	chr11:8795148	chr11:8964675~8977527:+
THCA	cis	rs11148252	0.87	rs11148246	ENSG00000278238.1	RP11-245D16.4	-7.49	3.41e-13	1.15e-10	-0.37	-0.33	Lewy body disease;	chr13:52223402	chr13:52454775~52455331:-
THCA	cis	rs875971	1	rs709597	ENSG00000232559.3	GS1-124K5.12	-7.49	3.41e-13	1.15e-10	-0.31	-0.33	Aortic root size;	chr7:66360996	chr7:66554588~66576923:-
THCA	cis	rs7726414	1	rs115808154	ENSG00000279469.1	RP11-215P8.2	7.49	3.41e-13	1.15e-10	0.67	0.33	Systemic lupus erythematosus;	chr5:134128584	chr5:134394360~134395008:-
THCA	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	7.49	3.41e-13	1.15e-10	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
THCA	cis	rs2688608	0.592	rs7080579	ENSG00000271816.1	BMS1P4	7.49	3.42e-13	1.15e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73744271	chr10:73699151~73730487:-
THCA	cis	rs853679	1	rs853676	ENSG00000219392.1	RP1-265C24.5	-7.49	3.42e-13	1.15e-10	-0.51	-0.33	Depression;	chr6:28331910	chr6:28115628~28116551:+
THCA	cis	rs17695224	0.545	rs4802875	ENSG00000269483.1	AC006272.1	7.49	3.42e-13	1.16e-10	0.35	0.33	HDL cholesterol;HDL cholesterol levels;	chr19:51827056	chr19:51839924~51843324:-
THCA	cis	rs2976388	0.565	rs2572905	ENSG00000253741.1	CTD-2292P10.4	-7.49	3.43e-13	1.16e-10	-0.4	-0.33	Urinary tract infection frequency;	chr8:142715686	chr8:142702252~142726973:-
THCA	cis	rs2976388	0.647	rs2572906	ENSG00000253741.1	CTD-2292P10.4	-7.49	3.43e-13	1.16e-10	-0.4	-0.33	Urinary tract infection frequency;	chr8:142716851	chr8:142702252~142726973:-
THCA	cis	rs2688608	0.592	rs11000758	ENSG00000271816.1	BMS1P4	7.49	3.43e-13	1.16e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73733852	chr10:73699151~73730487:-
THCA	cis	rs4820539	1	rs5759598	ENSG00000221069.1	AC000029.1	-7.49	3.43e-13	1.16e-10	-0.38	-0.33	Bone mineral density;	chr22:23138775	chr22:23136620~23136710:+
THCA	cis	rs728616	0.717	rs61860016	ENSG00000225484.5	NUTM2B-AS1	-7.49	3.43e-13	1.16e-10	-0.65	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80156133	chr10:79663088~79826594:-
THCA	cis	rs3096299	0.866	rs4238829	ENSG00000274627.1	RP11-104N10.2	7.49	3.44e-13	1.16e-10	0.32	0.33	Multiple myeloma (IgH translocation);	chr16:89395854	chr16:89516797~89522217:+
THCA	cis	rs224278	0.51	rs1888967	ENSG00000238280.1	RP11-436D10.3	-7.49	3.44e-13	1.16e-10	-0.41	-0.33	Ewing sarcoma;	chr10:62819700	chr10:62793562~62805887:-
THCA	cis	rs651907	0.557	rs3094297	ENSG00000256628.3	ZBTB11-AS1	7.49	3.45e-13	1.16e-10	0.38	0.33	Colorectal cancer;	chr3:101680416	chr3:101676475~101679217:+
THCA	cis	rs2348418	0.864	rs2175464	ENSG00000247934.4	RP11-967K21.1	-7.49	3.45e-13	1.16e-10	-0.28	-0.33	Lung function (FEV1);Lung function (FVC);	chr12:28564178	chr12:28163298~28190738:-
THCA	cis	rs12908161	1	rs62019469	ENSG00000225151.9	GOLGA2P7	-7.49	3.45e-13	1.16e-10	-0.48	-0.33	Schizophrenia;	chr15:84777989	chr15:84199311~84230136:-
THCA	cis	rs12908161	1	rs12908549	ENSG00000225151.9	GOLGA2P7	-7.49	3.45e-13	1.16e-10	-0.48	-0.33	Schizophrenia;	chr15:84779120	chr15:84199311~84230136:-
THCA	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	7.49	3.45e-13	1.16e-10	0.43	0.33	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
THCA	cis	rs2739330	0.734	rs2000467	ENSG00000228039.3	KB-1125A3.10	-7.49	3.45e-13	1.17e-10	-0.41	-0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23963780~23964374:+
THCA	cis	rs2337406	0.636	rs74090069	ENSG00000274576.2	IGHV2-70	-7.49	3.46e-13	1.17e-10	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106777532	chr14:106770577~106771020:-
THCA	cis	rs2337406	0.866	rs74090071	ENSG00000274576.2	IGHV2-70	-7.49	3.46e-13	1.17e-10	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106777533	chr14:106770577~106771020:-
THCA	cis	rs75422866	0.51	rs73105819	ENSG00000257433.4	RP1-197B17.3	7.49	3.46e-13	1.17e-10	0.49	0.33	Pneumonia;	chr12:47727190	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.51	rs73105818	ENSG00000257433.4	RP1-197B17.3	7.49	3.47e-13	1.17e-10	0.49	0.33	Pneumonia;	chr12:47726538	chr12:47706085~47742294:+
THCA	cis	rs801193	0.66	rs1016265	ENSG00000232559.3	GS1-124K5.12	7.49	3.47e-13	1.17e-10	0.31	0.33	Aortic root size;	chr7:66749580	chr7:66554588~66576923:-
THCA	cis	rs801193	0.66	rs4610622	ENSG00000232559.3	GS1-124K5.12	7.49	3.47e-13	1.17e-10	0.31	0.33	Aortic root size;	chr7:66759510	chr7:66554588~66576923:-
THCA	cis	rs17772222	0.74	rs61984675	ENSG00000258789.1	RP11-507K2.3	-7.49	3.48e-13	1.17e-10	-0.32	-0.33	Coronary artery calcification;	chr14:88511236	chr14:88551597~88552493:+
THCA	cis	rs1198430	0.714	rs946265	ENSG00000232482.2	RP4-654C18.1	-7.49	3.48e-13	1.17e-10	-0.51	-0.33	Total cholesterol levels;	chr1:23448803	chr1:23410832~23412146:+
THCA	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-7.49	3.48e-13	1.18e-10	-0.36	-0.33	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
THCA	cis	rs831571	1	rs831571	ENSG00000280620.1	SCAANT1	-7.49	3.48e-13	1.18e-10	-0.5	-0.33	Type 2 diabetes;	chr3:64062621	chr3:63911518~63911772:-
THCA	cis	rs7942368	1	rs1440980	ENSG00000254632.1	RP11-21L23.4	7.49	3.49e-13	1.18e-10	0.47	0.33	Endometriosis;	chr11:76784032	chr11:76759916~76768223:-
THCA	cis	rs2562456	0.833	rs2968078	ENSG00000268555.1	RP11-678G14.3	-7.49	3.49e-13	1.18e-10	-0.47	-0.33	Pain;	chr19:21458942	chr19:21570822~21587322:-
THCA	cis	rs2562456	0.755	rs2650773	ENSG00000268555.1	RP11-678G14.3	-7.49	3.49e-13	1.18e-10	-0.47	-0.33	Pain;	chr19:21461286	chr19:21570822~21587322:-
THCA	cis	rs6565180	0.962	rs6565183	ENSG00000183604.13	SMG1P5	-7.49	3.5e-13	1.18e-10	-0.32	-0.33	Tonsillectomy;	chr16:30371434	chr16:30267553~30335374:-
THCA	cis	rs875971	0.825	rs28480509	ENSG00000232559.3	GS1-124K5.12	-7.49	3.5e-13	1.18e-10	-0.32	-0.33	Aortic root size;	chr7:66634237	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs9791712	ENSG00000232559.3	GS1-124K5.12	-7.49	3.5e-13	1.18e-10	-0.32	-0.33	Aortic root size;	chr7:66640176	chr7:66554588~66576923:-
THCA	cis	rs875971	0.862	rs9791713	ENSG00000232559.3	GS1-124K5.12	-7.49	3.5e-13	1.18e-10	-0.32	-0.33	Aortic root size;	chr7:66640211	chr7:66554588~66576923:-
THCA	cis	rs1015362	0.54	rs2378026	ENSG00000276073.1	RP5-1125A11.7	-7.49	3.51e-13	1.18e-10	-0.35	-0.33	Freckles;Red vs. non-red hair color;Skin sensitivity to sun;Burning and freckling;	chr20:33921845	chr20:33985617~33988989:-
THCA	cis	rs77204473	0.744	rs80273401	ENSG00000254851.1	RP11-109L13.1	7.49	3.51e-13	1.18e-10	0.83	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117037990	chr11:117135528~117138582:+
THCA	cis	rs9828933	0.507	rs56030924	ENSG00000280620.1	SCAANT1	7.49	3.51e-13	1.18e-10	0.46	0.33	Type 2 diabetes;	chr3:64009887	chr3:63911518~63911772:-
THCA	cis	rs17772222	1	rs1955599	ENSG00000258983.2	RP11-507K2.2	7.49	3.53e-13	1.19e-10	0.42	0.33	Coronary artery calcification;	chr14:88358788	chr14:88499334~88515502:+
THCA	cis	rs2688608	0.592	rs11000760	ENSG00000271816.1	BMS1P4	7.49	3.54e-13	1.19e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73733976	chr10:73699151~73730487:-
THCA	cis	rs9388451	0.839	rs10457469	ENSG00000237742.5	RP11-624M8.1	-7.49	3.54e-13	1.19e-10	-0.28	-0.33	Brugada syndrome;	chr6:125762512	chr6:125578558~125749190:-
THCA	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	7.49	3.56e-13	1.2e-10	0.37	0.33	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
THCA	cis	rs193541	0.617	rs2045628	ENSG00000263432.2	RN7SL689P	7.48	3.56e-13	1.2e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122759459	chr5:123022487~123022783:-
THCA	cis	rs193541	0.632	rs6878609	ENSG00000263432.2	RN7SL689P	7.48	3.56e-13	1.2e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122759854	chr5:123022487~123022783:-
THCA	cis	rs7208859	0.673	rs9889755	ENSG00000266490.1	CTD-2349P21.9	-7.48	3.56e-13	1.2e-10	-0.43	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30907487	chr17:30792372~30792833:+
THCA	cis	rs9902453	0.933	rs2054846	ENSG00000264007.1	RP11-68I3.10	-7.48	3.57e-13	1.2e-10	-0.37	-0.33	Coffee consumption (cups per day);	chr17:30180675	chr17:29621617~29622254:-
THCA	cis	rs910316	0.967	rs7146523	ENSG00000279594.1	RP11-950C14.10	-7.48	3.57e-13	1.2e-10	-0.3	-0.33	Height;	chr14:75193177	chr14:75011269~75012851:-
THCA	cis	rs3812049	0.693	rs9327468	ENSG00000245937.6	LINC01184	7.48	3.58e-13	1.21e-10	0.37	0.33	Lymphocyte counts;Red cell distribution width;	chr5:128106169	chr5:127940426~128083172:-
THCA	cis	rs9902453	0.904	rs12951836	ENSG00000264007.1	RP11-68I3.10	-7.48	3.58e-13	1.21e-10	-0.36	-0.33	Coffee consumption (cups per day);	chr17:30083259	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.904	rs12948898	ENSG00000264007.1	RP11-68I3.10	-7.48	3.58e-13	1.21e-10	-0.36	-0.33	Coffee consumption (cups per day);	chr17:30083306	chr17:29621617~29622254:-
THCA	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	7.48	3.58e-13	1.21e-10	0.38	0.33	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
THCA	cis	rs11168351	0.927	rs7971880	ENSG00000258273.1	RP11-370I10.4	-7.48	3.59e-13	1.21e-10	-0.44	-0.33	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48333755~48333901:-
THCA	cis	rs947583	1	rs7742626	ENSG00000231028.7	LINC00271	7.48	3.59e-13	1.21e-10	0.27	0.33	Phosphorus levels;	chr6:135811358	chr6:135497801~135716055:+
THCA	cis	rs516805	0.64	rs55768410	ENSG00000279453.1	RP3-425C14.4	7.48	3.59e-13	1.21e-10	0.34	0.33	Lymphocyte counts;	chr6:122358588	chr6:122436789~122439223:-
THCA	cis	rs516805	0.706	rs9490431	ENSG00000279453.1	RP3-425C14.4	7.48	3.59e-13	1.21e-10	0.34	0.33	Lymphocyte counts;	chr6:122361132	chr6:122436789~122439223:-
THCA	cis	rs8027521	0.54	rs2725583	ENSG00000280362.1	RP11-643A5.3	-7.48	3.59e-13	1.21e-10	-0.45	-0.33	Circulating chemerin levels;	chr15:53972311	chr15:53910769~53914712:+
THCA	cis	rs7302981	0.51	rs860698	ENSG00000272368.2	RP4-605O3.4	7.48	3.61e-13	1.21e-10	0.2	0.33	Systolic blood pressure;	chr12:50092539	chr12:50112197~50165618:+
THCA	cis	rs9813712	0.574	rs11718032	ENSG00000228252.7	COL6A4P2	7.48	3.61e-13	1.21e-10	0.32	0.33	Response to amphetamines;	chr3:130257749	chr3:130212823~130273806:+
THCA	cis	rs4820539	1	rs916583	ENSG00000221069.1	AC000029.1	-7.48	3.61e-13	1.22e-10	-0.38	-0.33	Bone mineral density;	chr22:23127080	chr22:23136620~23136710:+
THCA	cis	rs2276314	0.857	rs62101376	ENSG00000278986.1	RP11-723J4.3	-7.48	3.61e-13	1.22e-10	-0.38	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:36002992	chr18:35972151~35973916:+
THCA	cis	rs9902453	0.967	rs34323226	ENSG00000264007.1	RP11-68I3.10	7.48	3.61e-13	1.22e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:30190436	chr17:29621617~29622254:-
THCA	cis	rs6539288	0.901	rs4964506	ENSG00000260329.1	RP11-412D9.4	-7.48	3.61e-13	1.22e-10	-0.3	-0.33	Total body bone mineral density;	chr12:106953307	chr12:106954029~106955497:-
THCA	cis	rs12460587	0.587	rs10415150	ENSG00000275055.1	CTC-471J1.11	-7.48	3.62e-13	1.22e-10	-0.26	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52101372	chr19:52049007~52049754:+
THCA	cis	rs7208859	0.623	rs3794796	ENSG00000263603.1	CTD-2349P21.5	-7.48	3.62e-13	1.22e-10	-0.57	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30729469~30731202:+
THCA	cis	rs4820539	0.902	rs9612237	ENSG00000221069.1	AC000029.1	-7.48	3.62e-13	1.22e-10	-0.38	-0.33	Bone mineral density;	chr22:23130767	chr22:23136620~23136710:+
THCA	cis	rs1962636	1	rs1962636	ENSG00000260306.1	RP11-645C24.5	-7.48	3.62e-13	1.22e-10	-0.29	-0.33	Schizophrenia;	chr16:22053074	chr16:21794095~21795759:-
THCA	cis	rs728616	0.717	rs12412999	ENSG00000225484.5	NUTM2B-AS1	-7.48	3.63e-13	1.22e-10	-0.64	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80248385	chr10:79663088~79826594:-
THCA	cis	rs9828933	0.577	rs832194	ENSG00000280620.1	SCAANT1	-7.48	3.63e-13	1.22e-10	-0.55	-0.33	Type 2 diabetes;	chr3:63871395	chr3:63911518~63911772:-
THCA	cis	rs9902453	0.765	rs3115087	ENSG00000264007.1	RP11-68I3.10	7.48	3.65e-13	1.23e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29703249	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.817	rs3115089	ENSG00000264007.1	RP11-68I3.10	7.48	3.65e-13	1.23e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29704863	chr17:29621617~29622254:-
THCA	cis	rs67340775	0.541	rs200979	ENSG00000219392.1	RP1-265C24.5	-7.48	3.65e-13	1.23e-10	-0.5	-0.33	Lung cancer in ever smokers;	chr6:27884579	chr6:28115628~28116551:+
THCA	cis	rs9326248	0.954	rs521171	ENSG00000280143.1	AP000892.6	7.48	3.65e-13	1.23e-10	0.41	0.33	Blood protein levels;	chr11:117193977	chr11:117204967~117210292:+
THCA	cis	rs7302981	0.746	rs836177	ENSG00000272368.2	RP4-605O3.4	7.48	3.65e-13	1.23e-10	0.2	0.33	Systolic blood pressure;	chr12:50098038	chr12:50112197~50165618:+
THCA	cis	rs17772222	0.917	rs4635267	ENSG00000258983.2	RP11-507K2.2	7.48	3.66e-13	1.23e-10	0.4	0.33	Coronary artery calcification;	chr14:88621922	chr14:88499334~88515502:+
THCA	cis	rs17772222	0.876	rs56144430	ENSG00000258983.2	RP11-507K2.2	7.48	3.66e-13	1.23e-10	0.4	0.33	Coronary artery calcification;	chr14:88622013	chr14:88499334~88515502:+
THCA	cis	rs914615	0.552	rs7556304	ENSG00000160766.13	GBAP1	-7.48	3.66e-13	1.23e-10	-0.35	-0.33	Urinary albumin-to-creatinine ratio;	chr1:155167033	chr1:155213821~155227422:-
THCA	cis	rs10129255	0.5	rs6576230	ENSG00000223648.3	IGHV3-64	7.48	3.66e-13	1.23e-10	0.19	0.33	Kawasaki disease;	chr14:106778539	chr14:106643132~106658258:-
THCA	cis	rs10129255	0.518	rs11847766	ENSG00000223648.3	IGHV3-64	7.48	3.66e-13	1.23e-10	0.19	0.33	Kawasaki disease;	chr14:106779186	chr14:106643132~106658258:-
THCA	cis	rs7208859	0.623	rs11657662	ENSG00000263603.1	CTD-2349P21.5	7.48	3.66e-13	1.23e-10	0.57	0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749329	chr17:30729469~30731202:+
THCA	cis	rs1075265	0.553	rs2692532	ENSG00000233266.1	HMGB1P31	7.48	3.66e-13	1.23e-10	0.41	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54051334~54051760:+
THCA	cis	rs77204473	1	rs75294699	ENSG00000254851.1	RP11-109L13.1	7.48	3.66e-13	1.23e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116878356	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs12416987	ENSG00000254851.1	RP11-109L13.1	7.48	3.66e-13	1.23e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116883549	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs10892040	ENSG00000254851.1	RP11-109L13.1	7.48	3.66e-13	1.23e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886270	chr11:117135528~117138582:+
THCA	cis	rs71636778	0.509	rs17162387	ENSG00000260063.1	RP5-968P14.2	-7.48	3.66e-13	1.23e-10	-0.59	-0.33	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26966865	chr1:26692132~26694131:-
THCA	cis	rs71636778	0.509	rs34976021	ENSG00000260063.1	RP5-968P14.2	-7.48	3.66e-13	1.23e-10	-0.59	-0.33	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:26972073	chr1:26692132~26694131:-
THCA	cis	rs2115630	0.691	rs2292462	ENSG00000275120.1	RP11-182J1.17	-7.48	3.67e-13	1.23e-10	-0.33	-0.33	P wave terminal force;	chr15:84657523	chr15:84599434~84606463:-
THCA	cis	rs453301	0.686	rs11787026	ENSG00000253893.2	FAM85B	-7.48	3.68e-13	1.24e-10	-0.41	-0.33	Joint mobility (Beighton score);	chr8:9044861	chr8:8167819~8226614:-
THCA	cis	rs67340775	0.541	rs169287	ENSG00000219392.1	RP1-265C24.5	-7.48	3.68e-13	1.24e-10	-0.5	-0.33	Lung cancer in ever smokers;	chr6:27886982	chr6:28115628~28116551:+
THCA	cis	rs4927850	0.723	rs7630825	ENSG00000273009.1	RP11-352G9.1	-7.48	3.69e-13	1.24e-10	-0.35	-0.33	Pancreatic cancer;	chr3:196026869	chr3:195913078~195913683:-
THCA	cis	rs12928939	0.723	rs71403864	ENSG00000260886.1	TAT-AS1	7.48	3.69e-13	1.24e-10	0.42	0.33	Post bronchodilator FEV1;	chr16:71661127	chr16:71565789~71578187:+
THCA	cis	rs6504108	0.624	rs954226	ENSG00000278765.1	RP5-890E16.5	-7.48	3.69e-13	1.24e-10	-0.37	-0.33	Body mass index;	chr17:48227450	chr17:48066704~48067293:-
THCA	cis	rs748404	0.697	rs530188	ENSG00000205771.5	CATSPER2P1	-7.48	3.7e-13	1.24e-10	-0.34	-0.33	Lung cancer;	chr15:43253116	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs475227	ENSG00000205771.5	CATSPER2P1	-7.48	3.7e-13	1.24e-10	-0.34	-0.33	Lung cancer;	chr15:43254248	chr15:43726918~43747094:-
THCA	cis	rs9649213	0.531	rs35216698	ENSG00000272950.1	RP11-307C18.1	7.48	3.7e-13	1.24e-10	0.4	0.33	Prostate cancer (SNP x SNP interaction);	chr7:98266863	chr7:98322853~98323430:+
THCA	cis	rs507080	0.922	rs525485	ENSG00000278376.1	RP11-158I9.8	-7.48	3.71e-13	1.25e-10	-0.26	-0.33	Serum metabolite levels;	chr11:118685045	chr11:118791254~118793137:+
THCA	cis	rs4664293	0.565	rs10165197	ENSG00000226266.5	AC009961.3	7.48	3.71e-13	1.25e-10	0.38	0.33	Monocyte percentage of white cells;	chr2:159537137	chr2:159670708~159712435:-
THCA	cis	rs2976388	0.609	rs2585148	ENSG00000253741.1	CTD-2292P10.4	-7.48	3.71e-13	1.25e-10	-0.4	-0.33	Urinary tract infection frequency;	chr8:142714775	chr8:142702252~142726973:-
THCA	cis	rs4604234	0.518	rs73463537	ENSG00000272129.1	RP11-250B2.6	-7.48	3.72e-13	1.25e-10	-0.69	-0.33	Cancer;	chr6:80275314	chr6:80355424~80356859:+
THCA	cis	rs77204473	1	rs11216174	ENSG00000254851.1	RP11-109L13.1	7.48	3.72e-13	1.25e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886532	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs11216175	ENSG00000254851.1	RP11-109L13.1	7.48	3.72e-13	1.25e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116886682	chr11:117135528~117138582:+
THCA	cis	rs7942368	1	rs7107409	ENSG00000254632.1	RP11-21L23.4	7.48	3.72e-13	1.25e-10	0.47	0.33	Endometriosis;	chr11:76781151	chr11:76759916~76768223:-
THCA	cis	rs193541	0.53	rs1466371	ENSG00000263432.2	RN7SL689P	7.48	3.72e-13	1.25e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122748093	chr5:123022487~123022783:-
THCA	cis	rs5769707	0.681	rs135879	ENSG00000235111.1	RP1-29C18.8	-7.48	3.73e-13	1.25e-10	-0.4	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49612657~49615716:-
THCA	cis	rs5769707	0.642	rs135880	ENSG00000235111.1	RP1-29C18.8	-7.48	3.73e-13	1.25e-10	-0.4	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49612657~49615716:-
THCA	cis	rs1275468	1	rs1795379	ENSG00000257497.2	RP11-585P4.5	-7.48	3.74e-13	1.26e-10	-0.48	-0.33	Polycystic ovary syndrome;	chr12:75547262	chr12:75483454~75489820:-
THCA	cis	rs11971779	0.68	rs73154134	ENSG00000273391.1	RP11-634H22.1	7.48	3.75e-13	1.26e-10	0.32	0.33	Diisocyanate-induced asthma;	chr7:139355205	chr7:139359032~139359566:-
THCA	cis	rs77204473	0.744	rs11216265	ENSG00000254851.1	RP11-109L13.1	7.48	3.75e-13	1.26e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117076464	chr11:117135528~117138582:+
THCA	cis	rs8027521	0.58	rs2725567	ENSG00000280362.1	RP11-643A5.3	-7.48	3.75e-13	1.26e-10	-0.41	-0.33	Circulating chemerin levels;	chr15:53944858	chr15:53910769~53914712:+
THCA	cis	rs2688608	0.592	rs3933085	ENSG00000271816.1	BMS1P4	7.48	3.76e-13	1.26e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73723573	chr10:73699151~73730487:-
THCA	cis	rs2688608	0.592	rs7909544	ENSG00000271816.1	BMS1P4	7.48	3.76e-13	1.26e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73724246	chr10:73699151~73730487:-
THCA	cis	rs13068223	0.584	rs344018	ENSG00000243926.1	TIPARP-AS1	-7.48	3.76e-13	1.26e-10	-0.32	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156698204	chr3:156671862~156674378:-
THCA	cis	rs6745190	0.953	rs4990275	ENSG00000236153.1	AC104076.3	7.48	3.76e-13	1.26e-10	0.38	0.33	White blood cell count;	chr2:181008934	chr2:180979427~180980090:-
THCA	cis	rs690037	0.528	rs568833	ENSG00000272498.1	RP11-415F23.3	7.48	3.76e-13	1.27e-10	0.35	0.33	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);	chr3:16326329	chr3:16339308~16339871:+
THCA	cis	rs732716	0.853	rs62129349	ENSG00000267980.1	AC007292.6	-7.48	3.77e-13	1.27e-10	-0.38	-0.33	Mean corpuscular volume;	chr19:4385662	chr19:4363789~4364640:+
THCA	cis	rs10971721	0.584	rs1378	ENSG00000260947.1	RP11-384P7.7	7.48	3.77e-13	1.27e-10	0.74	0.33	Body mass index;	chr9:34107506	chr9:33697459~33700986:+
THCA	cis	rs910316	0.737	rs175077	ENSG00000279594.1	RP11-950C14.10	-7.48	3.77e-13	1.27e-10	-0.3	-0.33	Height;	chr14:75040172	chr14:75011269~75012851:-
THCA	cis	rs9902453	0.967	rs4429345	ENSG00000264007.1	RP11-68I3.10	-7.48	3.77e-13	1.27e-10	-0.37	-0.33	Coffee consumption (cups per day);	chr17:30131087	chr17:29621617~29622254:-
THCA	cis	rs12928939	0.815	rs1345868	ENSG00000260886.1	TAT-AS1	7.48	3.77e-13	1.27e-10	0.42	0.33	Post bronchodilator FEV1;	chr16:71635721	chr16:71565789~71578187:+
THCA	cis	rs748404	0.723	rs573169	ENSG00000205771.5	CATSPER2P1	-7.48	3.78e-13	1.27e-10	-0.33	-0.33	Lung cancer;	chr15:43258383	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs524547	ENSG00000205771.5	CATSPER2P1	-7.48	3.78e-13	1.27e-10	-0.33	-0.33	Lung cancer;	chr15:43258825	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs564946	ENSG00000205771.5	CATSPER2P1	-7.48	3.78e-13	1.27e-10	-0.33	-0.33	Lung cancer;	chr15:43264074	chr15:43726918~43747094:-
THCA	cis	rs748404	0.723	rs565658	ENSG00000205771.5	CATSPER2P1	-7.48	3.78e-13	1.27e-10	-0.33	-0.33	Lung cancer;	chr15:43264109	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs579651	ENSG00000205771.5	CATSPER2P1	-7.48	3.78e-13	1.27e-10	-0.33	-0.33	Lung cancer;	chr15:43266178	chr15:43726918~43747094:-
THCA	cis	rs947583	0.588	rs12204523	ENSG00000231028.7	LINC00271	-7.48	3.78e-13	1.27e-10	-0.27	-0.33	Phosphorus levels;	chr6:135753856	chr6:135497801~135716055:+
THCA	cis	rs1962073	0.528	rs4582610	ENSG00000261451.1	RP11-981G7.1	-7.48	3.78e-13	1.27e-10	-0.41	-0.33	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr8:10460833	chr8:10433672~10438312:+
THCA	cis	rs853679	1	rs1679732	ENSG00000219392.1	RP1-265C24.5	7.48	3.79e-13	1.27e-10	0.52	0.33	Depression;	chr6:28253486	chr6:28115628~28116551:+
THCA	cis	rs516805	0.706	rs9490430	ENSG00000279453.1	RP3-425C14.4	7.48	3.79e-13	1.27e-10	0.34	0.33	Lymphocyte counts;	chr6:122360951	chr6:122436789~122439223:-
THCA	cis	rs193541	0.621	rs898391	ENSG00000263432.2	RN7SL689P	7.48	3.8e-13	1.28e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122746471	chr5:123022487~123022783:-
THCA	cis	rs4835473	0.838	rs6832094	ENSG00000251600.4	RP11-673E1.1	-7.48	3.8e-13	1.28e-10	-0.42	-0.33	Immature fraction of reticulocytes;	chr4:143795388	chr4:143912331~143982454:+
THCA	cis	rs9902453	0.765	rs3102555	ENSG00000264007.1	RP11-68I3.10	7.48	3.8e-13	1.28e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29717083	chr17:29621617~29622254:-
THCA	cis	rs934734	1	rs934734	ENSG00000204929.10	AC074391.1	-7.48	3.8e-13	1.28e-10	-0.4	-0.33	Rheumatoid arthritis;	chr2:65368452	chr2:65436711~66084639:+
THCA	cis	rs6430549	0.518	rs41521049	ENSG00000224043.6	CCNT2-AS1	-7.48	3.8e-13	1.28e-10	-0.35	-0.33	Hematocrit;	chr2:134935499	chr2:134735464~134918710:-
THCA	cis	rs9487605	1	rs9487605	ENSG00000271789.1	RP5-1112D6.7	-7.47	3.81e-13	1.28e-10	-0.35	-0.33	Inflammatory skin disease;	chr6:111261682	chr6:111297126~111298510:+
THCA	cis	rs2253762	0.54	rs10159634	ENSG00000276742.1	RP11-500G22.4	-7.47	3.82e-13	1.28e-10	-0.47	-0.33	Breast cancer;	chr10:121994520	chr10:121956782~121957098:+
THCA	cis	rs12817211	0.502	rs12369049	ENSG00000272368.2	RP4-605O3.4	-7.47	3.83e-13	1.29e-10	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50116679	chr12:50112197~50165618:+
THCA	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-7.47	3.83e-13	1.29e-10	-0.6	-0.33	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
THCA	cis	rs6539288	0.901	rs4964507	ENSG00000260329.1	RP11-412D9.4	-7.47	3.83e-13	1.29e-10	-0.3	-0.33	Total body bone mineral density;	chr12:106954979	chr12:106954029~106955497:-
THCA	cis	rs12701220	0.595	rs12532837	ENSG00000229043.2	AC091729.9	-7.47	3.84e-13	1.29e-10	-0.49	-0.33	Bronchopulmonary dysplasia;	chr7:1083215	chr7:1160374~1165267:+
THCA	cis	rs6142102	0.625	rs6142056	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.84e-13	1.29e-10	-0.32	-0.33	Skin pigmentation;	chr20:33953349	chr20:33989480~33991818:-
THCA	cis	rs11214589	0.806	rs4551806	ENSG00000270179.1	RP11-159N11.4	-7.47	3.85e-13	1.29e-10	-0.35	-0.33	Neuroticism;	chr11:113379818	chr11:113368478~113369117:+
THCA	cis	rs240993	0.516	rs240968	ENSG00000230177.1	RP5-1112D6.4	-7.47	3.85e-13	1.29e-10	-0.36	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111311517	chr6:111277932~111278742:+
THCA	cis	rs116175783	0.557	rs2042487	ENSG00000227403.1	AC009299.3	7.47	3.86e-13	1.3e-10	0.58	0.33	Intelligence (multi-trait analysis);	chr2:161293734	chr2:161244739~161249050:+
THCA	cis	rs2522056	0.808	rs2706373	ENSG00000233006.5	AC034220.3	-7.47	3.86e-13	1.3e-10	-0.28	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132468564	chr5:132311285~132369916:-
THCA	cis	rs2522056	1	rs2522062	ENSG00000233006.5	AC034220.3	-7.47	3.86e-13	1.3e-10	-0.28	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132469724	chr5:132311285~132369916:-
THCA	cis	rs2522056	1	rs2522063	ENSG00000233006.5	AC034220.3	-7.47	3.86e-13	1.3e-10	-0.28	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132469899	chr5:132311285~132369916:-
THCA	cis	rs2522056	1	rs2706379	ENSG00000233006.5	AC034220.3	-7.47	3.86e-13	1.3e-10	-0.28	-0.33	Fibrinogen;Lymphocyte counts;	chr5:132470043	chr5:132311285~132369916:-
THCA	cis	rs748404	0.56	rs529611	ENSG00000166763.7	STRCP1	7.47	3.87e-13	1.3e-10	0.35	0.33	Lung cancer;	chr15:43513790	chr15:43699488~43718184:-
THCA	cis	rs9388451	0.626	rs3799708	ENSG00000237742.5	RP11-624M8.1	-7.47	3.87e-13	1.3e-10	-0.29	-0.33	Brugada syndrome;	chr6:125757384	chr6:125578558~125749190:-
THCA	cis	rs748404	0.697	rs498227	ENSG00000205771.5	CATSPER2P1	-7.47	3.88e-13	1.3e-10	-0.34	-0.33	Lung cancer;	chr15:43280854	chr15:43726918~43747094:-
THCA	cis	rs2439831	0.85	rs10438303	ENSG00000275601.1	AC011330.13	-7.47	3.88e-13	1.3e-10	-0.54	-0.33	Lung cancer in ever smokers;	chr15:43724219	chr15:43642389~43643023:-
THCA	cis	rs9902453	0.933	rs9303628	ENSG00000264007.1	RP11-68I3.10	7.47	3.89e-13	1.31e-10	0.36	0.33	Coffee consumption (cups per day);	chr17:30200210	chr17:29621617~29622254:-
THCA	cis	rs7015630	0.648	rs62530862	ENSG00000251136.7	RP11-37B2.1	-7.47	3.89e-13	1.31e-10	-0.35	-0.33	Inflammatory bowel disease;Crohn's disease;	chr8:89822659	chr8:89609409~89757727:-
THCA	cis	rs7674212	0.581	rs10516496	ENSG00000251288.2	RP11-10L12.2	-7.47	3.9e-13	1.31e-10	-0.44	-0.33	Type 2 diabetes;	chr4:103021008	chr4:102751401~102752641:+
THCA	cis	rs12188164	0.582	rs80273890	ENSG00000221990.4	EXOC3-AS1	7.47	3.91e-13	1.31e-10	0.31	0.33	Cystic fibrosis severity;	chr5:482942	chr5:441498~443160:-
THCA	cis	rs5760842	0.933	rs5760837	ENSG00000279110.1	CTA-243E7.1	-7.47	3.91e-13	1.31e-10	-0.4	-0.33	Recurrent major depressive disorder;	chr22:25085119	chr22:25052122~25065241:-
THCA	cis	rs12817211	0.502	rs12819883	ENSG00000272368.2	RP4-605O3.4	-7.47	3.92e-13	1.31e-10	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50140005	chr12:50112197~50165618:+
THCA	cis	rs6545883	0.525	rs2049747	ENSG00000271889.1	RP11-493E12.1	-7.47	3.92e-13	1.32e-10	-0.31	-0.33	Tuberculosis;	chr2:61137019	chr2:61151433~61162105:-
THCA	cis	rs2739330	0.828	rs5760108	ENSG00000206090.4	AP000350.7	7.47	3.93e-13	1.32e-10	0.4	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23939998~23942798:+
THCA	cis	rs6504108	0.624	rs8069263	ENSG00000278765.1	RP5-890E16.5	-7.47	3.93e-13	1.32e-10	-0.36	-0.33	Body mass index;	chr17:48209416	chr17:48066704~48067293:-
THCA	cis	rs9487094	0.744	rs13204787	ENSG00000260273.1	RP11-425D10.10	7.47	3.93e-13	1.32e-10	0.43	0.33	Height;	chr6:109618283	chr6:109382795~109383666:+
THCA	cis	rs2276314	1	rs2298716	ENSG00000278986.1	RP11-723J4.3	-7.47	3.93e-13	1.32e-10	-0.37	-0.33	Endometriosis;Drug-induced torsades de pointes;	chr18:35972635	chr18:35972151~35973916:+
THCA	cis	rs2337406	0.866	rs4774019	ENSG00000274576.2	IGHV2-70	-7.47	3.93e-13	1.32e-10	-0.28	-0.33	Alzheimer's disease (late onset);	chr14:106805386	chr14:106770577~106771020:-
THCA	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-7.47	3.94e-13	1.32e-10	-0.35	-0.33	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
THCA	cis	rs3809863	0.602	rs11650072	ENSG00000228782.6	CTD-2026D20.3	7.47	3.94e-13	1.32e-10	0.31	0.33	Glaucoma (primary open-angle);	chr17:47316299	chr17:47450568~47492492:-
THCA	cis	rs9816784	0.696	rs6778081	ENSG00000242086.7	LINC00969	-7.47	3.95e-13	1.32e-10	-0.3	-0.33	Mean corpuscular hemoglobin;	chr3:196092334	chr3:195658062~195739964:+
THCA	cis	rs16886181	0.512	rs12652988	ENSG00000271828.1	CTD-2310F14.1	7.47	3.97e-13	1.33e-10	0.65	0.33	Breast cancer (early onset);	chr5:56739539	chr5:56927874~56929573:+
THCA	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	7.47	3.98e-13	1.33e-10	0.38	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
THCA	cis	rs12655019	0.92	rs2271202	ENSG00000271828.1	CTD-2310F14.1	7.47	3.98e-13	1.34e-10	0.75	0.33	Breast cancer (early onset);	chr5:56912714	chr5:56927874~56929573:+
THCA	cis	rs6142102	0.538	rs6142058	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33954995	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs2050208	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33955767	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.602	rs4911380	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33958418	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs4911138	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33959893	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs4243974	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33960062	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs6142061	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33960529	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs6142062	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33960706	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.625	rs6141432	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33960791	chr20:33989480~33991818:-
THCA	cis	rs6142102	0.602	rs6141433	ENSG00000275784.1	RP5-1125A11.6	-7.47	3.99e-13	1.34e-10	-0.32	-0.33	Skin pigmentation;	chr20:33961056	chr20:33989480~33991818:-
THCA	cis	rs2562456	1	rs2359155	ENSG00000268555.1	RP11-678G14.3	-7.47	4e-13	1.34e-10	-0.45	-0.33	Pain;	chr19:21489067	chr19:21570822~21587322:-
THCA	cis	rs9902453	0.74	rs2617867	ENSG00000264007.1	RP11-68I3.10	-7.47	4e-13	1.34e-10	-0.37	-0.33	Coffee consumption (cups per day);	chr17:29722381	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.765	rs2628191	ENSG00000264007.1	RP11-68I3.10	-7.47	4e-13	1.34e-10	-0.37	-0.33	Coffee consumption (cups per day);	chr17:29724122	chr17:29621617~29622254:-
THCA	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	7.47	4.01e-13	1.34e-10	0.37	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
THCA	cis	rs748404	0.697	rs1095389	ENSG00000205771.5	CATSPER2P1	-7.47	4.01e-13	1.35e-10	-0.34	-0.33	Lung cancer;	chr15:43274473	chr15:43726918~43747094:-
THCA	cis	rs77204473	0.744	rs78832854	ENSG00000254851.1	RP11-109L13.1	7.47	4.01e-13	1.35e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116903759	chr11:117135528~117138582:+
THCA	cis	rs728616	0.51	rs12416084	ENSG00000225484.5	NUTM2B-AS1	-7.47	4.02e-13	1.35e-10	-0.48	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989459	chr10:79663088~79826594:-
THCA	cis	rs728616	0.51	rs34817075	ENSG00000225484.5	NUTM2B-AS1	-7.47	4.02e-13	1.35e-10	-0.48	-0.33	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79989984	chr10:79663088~79826594:-
THCA	cis	rs1150668	0.799	rs1736891	ENSG00000219392.1	RP1-265C24.5	-7.47	4.02e-13	1.35e-10	-0.36	-0.33	Pubertal anthropometrics;	chr6:28219323	chr6:28115628~28116551:+
THCA	cis	rs6723108	0.603	rs4953938	ENSG00000224043.6	CCNT2-AS1	7.47	4.04e-13	1.35e-10	0.35	0.33	Type 2 diabetes;	chr2:134937278	chr2:134735464~134918710:-
THCA	cis	rs686320	1	rs616599	ENSG00000245532.5	NEAT1	7.47	4.04e-13	1.35e-10	0.29	0.33	Hip circumference adjusted for BMI;	chr11:65486554	chr11:65422774~65445540:+
THCA	cis	rs6840258	0.66	rs10516786	ENSG00000251411.1	RP11-397E7.4	-7.47	4.05e-13	1.36e-10	-0.39	-0.33	Mean corpuscular volume;Basophil percentage of granulocytes;	chr4:86971189	chr4:86913266~86914817:-
THCA	cis	rs9902453	0.791	rs3115100	ENSG00000264007.1	RP11-68I3.10	7.47	4.05e-13	1.36e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29718726	chr17:29621617~29622254:-
THCA	cis	rs6600671	1	rs7532615	ENSG00000223345.3	HIST2H2BA	-7.47	4.05e-13	1.36e-10	-0.36	-0.33	Hip geometry;	chr1:121430980	chr1:121108210~121117257:-
THCA	cis	rs6539288	0.835	rs2041893	ENSG00000260329.1	RP11-412D9.4	-7.47	4.06e-13	1.36e-10	-0.3	-0.33	Total body bone mineral density;	chr12:106956598	chr12:106954029~106955497:-
THCA	cis	rs75422866	0.51	rs73105812	ENSG00000257433.4	RP1-197B17.3	7.47	4.06e-13	1.36e-10	0.48	0.33	Pneumonia;	chr12:47724404	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.51	rs74733564	ENSG00000257433.4	RP1-197B17.3	7.47	4.06e-13	1.36e-10	0.48	0.33	Pneumonia;	chr12:47724644	chr12:47706085~47742294:+
THCA	cis	rs75422866	0.51	rs73105814	ENSG00000257433.4	RP1-197B17.3	7.47	4.06e-13	1.36e-10	0.48	0.33	Pneumonia;	chr12:47725817	chr12:47706085~47742294:+
THCA	cis	rs12817211	0.502	rs7294618	ENSG00000272368.2	RP4-605O3.4	-7.47	4.07e-13	1.36e-10	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50119192	chr12:50112197~50165618:+
THCA	cis	rs12817211	0.502	rs7961112	ENSG00000272368.2	RP4-605O3.4	-7.47	4.07e-13	1.36e-10	-0.19	-0.33	Colorectal or endometrial cancer;	chr12:50119736	chr12:50112197~50165618:+
THCA	cis	rs9341808	0.754	rs1015158	ENSG00000272129.1	RP11-250B2.6	7.47	4.07e-13	1.36e-10	0.42	0.33	Sitting height ratio;	chr6:80236028	chr6:80355424~80356859:+
THCA	cis	rs4950322	0.57	rs17356184	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147262943	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs80270233	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147263320	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs4950392	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147264889	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs17356219	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147265684	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs72691041	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147267084	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs17356233	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147268843	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs17356240	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147269877	chr1:147172771~147211568:+
THCA	cis	rs4950322	0.57	rs1999820	ENSG00000237188.3	RP11-337C18.8	7.46	4.08e-13	1.37e-10	0.41	0.33	Protein quantitative trait loci;	chr1:147270329	chr1:147172771~147211568:+
THCA	cis	rs1198430	0.929	rs1210852	ENSG00000232482.2	RP4-654C18.1	-7.46	4.09e-13	1.37e-10	-0.58	-0.33	Total cholesterol levels;	chr1:23427040	chr1:23410832~23412146:+
THCA	cis	rs453301	0.686	rs6601281	ENSG00000253893.2	FAM85B	7.46	4.09e-13	1.37e-10	0.41	0.33	Joint mobility (Beighton score);	chr8:9053494	chr8:8167819~8226614:-
THCA	cis	rs6142102	0.602	rs932388	ENSG00000275784.1	RP5-1125A11.6	-7.46	4.09e-13	1.37e-10	-0.32	-0.33	Skin pigmentation;	chr20:34069572	chr20:33989480~33991818:-
THCA	cis	rs9902453	0.868	rs8066602	ENSG00000264007.1	RP11-68I3.10	7.46	4.1e-13	1.37e-10	0.36	0.33	Coffee consumption (cups per day);	chr17:30196067	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.868	rs8066731	ENSG00000264007.1	RP11-68I3.10	7.46	4.1e-13	1.37e-10	0.36	0.33	Coffee consumption (cups per day);	chr17:30196103	chr17:29621617~29622254:-
THCA	cis	rs5769707	0.609	rs135861	ENSG00000235111.1	RP1-29C18.8	-7.46	4.1e-13	1.37e-10	-0.41	-0.33	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49612657~49615716:-
THCA	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-7.46	4.1e-13	1.37e-10	-0.35	-0.33	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
THCA	cis	rs77204473	0.744	rs11216270	ENSG00000254851.1	RP11-109L13.1	7.46	4.1e-13	1.37e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117082928	chr11:117135528~117138582:+
THCA	cis	rs77204473	0.744	rs2368149	ENSG00000254851.1	RP11-109L13.1	7.46	4.1e-13	1.37e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117085218	chr11:117135528~117138582:+
THCA	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	7.46	4.12e-13	1.38e-10	0.19	0.33	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
THCA	cis	rs3812049	0.737	rs1112956	ENSG00000245937.6	LINC01184	-7.46	4.12e-13	1.38e-10	-0.37	-0.33	Lymphocyte counts;Red cell distribution width;	chr5:128098106	chr5:127940426~128083172:-
THCA	cis	rs10181042	0.565	rs62150982	ENSG00000271889.1	RP11-493E12.1	-7.46	4.13e-13	1.38e-10	-0.3	-0.33	Crohn's disease;	chr2:61053540	chr2:61151433~61162105:-
THCA	cis	rs2439831	0.85	rs8023458	ENSG00000275601.1	AC011330.13	-7.46	4.13e-13	1.38e-10	-0.53	-0.33	Lung cancer in ever smokers;	chr15:43788741	chr15:43642389~43643023:-
THCA	cis	rs2439831	0.85	rs16963953	ENSG00000275601.1	AC011330.13	-7.46	4.13e-13	1.38e-10	-0.53	-0.33	Lung cancer in ever smokers;	chr15:43789521	chr15:43642389~43643023:-
THCA	cis	rs3812049	0.784	rs1560637	ENSG00000245937.6	LINC01184	7.46	4.13e-13	1.38e-10	0.37	0.33	Lymphocyte counts;Red cell distribution width;	chr5:128112374	chr5:127940426~128083172:-
THCA	cis	rs3812049	0.784	rs2617617	ENSG00000245937.6	LINC01184	7.46	4.13e-13	1.38e-10	0.37	0.33	Lymphocyte counts;Red cell distribution width;	chr5:128119316	chr5:127940426~128083172:-
THCA	cis	rs9876781	0.56	rs2362451	ENSG00000229759.1	MRPS18AP1	-7.46	4.13e-13	1.38e-10	-0.39	-0.33	Longevity;	chr3:48358338	chr3:48256350~48256938:-
THCA	cis	rs4835473	0.643	rs34680080	ENSG00000251600.4	RP11-673E1.1	-7.46	4.14e-13	1.39e-10	-0.42	-0.33	Immature fraction of reticulocytes;	chr4:143797290	chr4:143912331~143982454:+
THCA	cis	rs7646881	1	rs73015651	ENSG00000240207.5	RP11-379F4.4	-7.46	4.14e-13	1.39e-10	-0.45	-0.33	Tetralogy of Fallot;	chr3:158733133	chr3:158732263~158784070:+
THCA	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-7.46	4.15e-13	1.39e-10	-0.32	-0.33	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
THCA	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	7.46	4.15e-13	1.39e-10	0.19	0.33	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
THCA	cis	rs9388451	0.626	rs1935983	ENSG00000237742.5	RP11-624M8.1	-7.46	4.16e-13	1.39e-10	-0.29	-0.33	Brugada syndrome;	chr6:125747768	chr6:125578558~125749190:-
THCA	cis	rs9388451	0.626	rs1343116	ENSG00000237742.5	RP11-624M8.1	-7.46	4.16e-13	1.39e-10	-0.29	-0.33	Brugada syndrome;	chr6:125748556	chr6:125578558~125749190:-
THCA	cis	rs9388451	0.626	rs1343115	ENSG00000237742.5	RP11-624M8.1	-7.46	4.16e-13	1.39e-10	-0.29	-0.33	Brugada syndrome;	chr6:125748671	chr6:125578558~125749190:-
THCA	cis	rs9388451	0.626	rs2875881	ENSG00000237742.5	RP11-624M8.1	-7.46	4.16e-13	1.39e-10	-0.29	-0.33	Brugada syndrome;	chr6:125751707	chr6:125578558~125749190:-
THCA	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	7.46	4.16e-13	1.39e-10	0.19	0.33	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
THCA	cis	rs9902453	0.791	rs3115090	ENSG00000264007.1	RP11-68I3.10	7.46	4.16e-13	1.39e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29707996	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.726	rs3115092	ENSG00000264007.1	RP11-68I3.10	7.46	4.16e-13	1.39e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29709332	chr17:29621617~29622254:-
THCA	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-7.46	4.18e-13	1.4e-10	-0.38	-0.33	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
THCA	cis	rs4713118	0.581	rs200504	ENSG00000219392.1	RP1-265C24.5	-7.46	4.18e-13	1.4e-10	-0.45	-0.33	Parkinson's disease;	chr6:27818042	chr6:28115628~28116551:+
THCA	cis	rs193541	0.642	rs42538	ENSG00000263432.2	RN7SL689P	7.46	4.18e-13	1.4e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122956657	chr5:123022487~123022783:-
THCA	cis	rs193541	0.632	rs39821	ENSG00000263432.2	RN7SL689P	7.46	4.18e-13	1.4e-10	0.39	0.33	Glucose homeostasis traits;	chr5:122959777	chr5:123022487~123022783:-
THCA	cis	rs2288884	0.579	rs6509609	ENSG00000275055.1	CTC-471J1.11	-7.46	4.19e-13	1.4e-10	-0.32	-0.33	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51970353	chr19:52049007~52049754:+
THCA	cis	rs7208859	0.623	rs55724095	ENSG00000264538.5	SUZ12P1	-7.46	4.2e-13	1.41e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.568	rs9903854	ENSG00000264538.5	SUZ12P1	-7.46	4.2e-13	1.41e-10	-0.34	-0.33	Body mass index;	chr17:30826980	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs80355557	ENSG00000264538.5	SUZ12P1	-7.46	4.2e-13	1.41e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9911173	ENSG00000264538.5	SUZ12P1	-7.46	4.2e-13	1.41e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30709299~30790908:+
THCA	cis	rs9902453	0.765	rs3102560	ENSG00000264007.1	RP11-68I3.10	7.46	4.21e-13	1.41e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29702920	chr17:29621617~29622254:-
THCA	cis	rs9902453	0.726	rs3115088	ENSG00000264007.1	RP11-68I3.10	7.46	4.21e-13	1.41e-10	0.37	0.33	Coffee consumption (cups per day);	chr17:29704257	chr17:29621617~29622254:-
THCA	cis	rs9847710	0.901	rs2564964	ENSG00000242142.1	SERBP1P3	7.46	4.21e-13	1.41e-10	0.39	0.33	Ulcerative colitis;	chr3:53004102	chr3:53064283~53065091:-
THCA	cis	rs853679	1	rs9986596	ENSG00000280107.1	AL022393.9	-7.46	4.21e-13	1.41e-10	-0.47	-0.33	Depression;	chr6:28251883	chr6:28170845~28172521:+
THCA	cis	rs4835473	0.801	rs35839125	ENSG00000251600.4	RP11-673E1.1	-7.46	4.22e-13	1.41e-10	-0.42	-0.33	Immature fraction of reticulocytes;	chr4:143792351	chr4:143912331~143982454:+
THCA	cis	rs4835473	0.75	rs12498381	ENSG00000251600.4	RP11-673E1.1	-7.46	4.22e-13	1.41e-10	-0.42	-0.33	Immature fraction of reticulocytes;	chr4:143793928	chr4:143912331~143982454:+
THCA	cis	rs6487679	1	rs1017302	ENSG00000111788.10	RP11-22B23.1	7.46	4.22e-13	1.41e-10	0.39	0.33	Non-alcoholic fatty liver disease histology (AST);	chr12:9214806	chr12:9277235~9313241:+
THCA	cis	rs6487679	1	rs10734765	ENSG00000111788.10	RP11-22B23.1	7.46	4.22e-13	1.41e-10	0.39	0.33	Non-alcoholic fatty liver disease histology (AST);	chr12:9216789	chr12:9277235~9313241:+
THCA	cis	rs10129255	0.518	rs8010020	ENSG00000223648.3	IGHV3-64	7.46	4.24e-13	1.42e-10	0.19	0.33	Kawasaki disease;	chr14:106778016	chr14:106643132~106658258:-
THCA	cis	rs4072705	1	rs10818983	ENSG00000224020.1	MIR181A2HG	-7.46	4.25e-13	1.42e-10	-0.29	-0.33	Menarche (age at onset);	chr9:124649298	chr9:124658467~124698631:+
THCA	cis	rs9487094	0.71	rs10499052	ENSG00000260273.1	RP11-425D10.10	7.46	4.25e-13	1.42e-10	0.43	0.33	Height;	chr6:109564272	chr6:109382795~109383666:+
THCA	cis	rs8114671	0.562	rs959829	ENSG00000269202.1	RP4-614O4.12	7.46	4.25e-13	1.42e-10	0.28	0.33	Height;	chr20:34758244	chr20:35201747~35203288:-
THCA	cis	rs7267979	0.868	rs6138553	ENSG00000274414.1	RP5-965G21.4	-7.46	4.25e-13	1.42e-10	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25239007~25245229:-
THCA	cis	rs7267979	0.903	rs6115109	ENSG00000274414.1	RP5-965G21.4	-7.46	4.25e-13	1.42e-10	-0.39	-0.33	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25239007~25245229:-
THCA	cis	rs853679	0.517	rs1904841	ENSG00000220721.1	OR1F12	7.46	4.26e-13	1.42e-10	0.45	0.33	Depression;	chr6:28140307	chr6:28073316~28074233:+
THCA	cis	rs6745190	0.953	rs6433878	ENSG00000236153.1	AC104076.3	7.46	4.27e-13	1.43e-10	0.38	0.33	White blood cell count;	chr2:180973227	chr2:180979427~180980090:-
THCA	cis	rs17684571	0.872	rs3002003	ENSG00000231441.1	RP11-472M19.2	7.46	4.27e-13	1.43e-10	0.41	0.33	Schizophrenia;	chr6:56743274	chr6:56844002~56864078:+
THCA	cis	rs8012947	1	rs1951202	ENSG00000279636.2	LINC00216	7.46	4.27e-13	1.43e-10	0.34	0.33	Alcohol consumption in current drinkers;	chr14:58312699	chr14:58288033~58289158:+
THCA	cis	rs732716	0.889	rs11085074	ENSG00000267980.1	AC007292.6	-7.46	4.29e-13	1.43e-10	-0.38	-0.33	Mean corpuscular volume;	chr19:4386355	chr19:4363789~4364640:+
THCA	cis	rs732716	0.889	rs55637375	ENSG00000267980.1	AC007292.6	-7.46	4.29e-13	1.43e-10	-0.38	-0.33	Mean corpuscular volume;	chr19:4386848	chr19:4363789~4364640:+
THCA	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-7.46	4.3e-13	1.44e-10	-0.35	-0.33	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-7.46	4.3e-13	1.44e-10	-0.35	-0.33	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-7.46	4.3e-13	1.44e-10	-0.35	-0.33	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-7.46	4.3e-13	1.44e-10	-0.35	-0.33	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
THCA	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-7.46	4.3e-13	1.44e-10	-0.35	-0.33	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
THCA	cis	rs4950322	0.542	rs17159924	ENSG00000237188.3	RP11-337C18.8	7.46	4.3e-13	1.44e-10	0.4	0.33	Protein quantitative trait loci;	chr1:147199463	chr1:147172771~147211568:+
THCA	cis	rs2688608	0.592	rs7076585	ENSG00000271816.1	BMS1P4	7.46	4.31e-13	1.44e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73743934	chr10:73699151~73730487:-
THCA	cis	rs6142102	0.625	rs4911381	ENSG00000275784.1	RP5-1125A11.6	7.46	4.31e-13	1.44e-10	0.32	0.33	Skin pigmentation;	chr20:33962539	chr20:33989480~33991818:-
THCA	cis	rs2348418	0.864	rs2203088	ENSG00000247934.4	RP11-967K21.1	7.46	4.32e-13	1.44e-10	0.28	0.33	Lung function (FEV1);Lung function (FVC);	chr12:28556767	chr12:28163298~28190738:-
THCA	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-7.46	4.33e-13	1.44e-10	-0.5	-0.33	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
THCA	cis	rs10936632	0.728	rs10804840	ENSG00000242578.1	RP11-469J4.3	-7.46	4.33e-13	1.45e-10	-0.36	-0.33	Prostate cancer;	chr3:170354019	chr3:170410512~170418615:+
THCA	cis	rs2688608	0.592	rs10762559	ENSG00000271816.1	BMS1P4	7.46	4.33e-13	1.45e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73726695	chr10:73699151~73730487:-
THCA	cis	rs10971721	0.584	rs10971940	ENSG00000260947.1	RP11-384P7.7	7.46	4.34e-13	1.45e-10	0.73	0.33	Body mass index;	chr9:34127213	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs72731226	ENSG00000260947.1	RP11-384P7.7	7.46	4.34e-13	1.45e-10	0.73	0.33	Body mass index;	chr9:34128832	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.584	rs10971944	ENSG00000260947.1	RP11-384P7.7	7.46	4.34e-13	1.45e-10	0.73	0.33	Body mass index;	chr9:34129008	chr9:33697459~33700986:+
THCA	cis	rs10971721	0.631	rs74450404	ENSG00000260947.1	RP11-384P7.7	7.46	4.34e-13	1.45e-10	0.73	0.33	Body mass index;	chr9:34134666	chr9:33697459~33700986:+
THCA	cis	rs9326248	0.911	rs474339	ENSG00000280143.1	AP000892.6	7.46	4.34e-13	1.45e-10	0.41	0.33	Blood protein levels;	chr11:117188836	chr11:117204967~117210292:+
THCA	cis	rs10936632	0.755	rs10804839	ENSG00000242578.1	RP11-469J4.3	-7.46	4.35e-13	1.45e-10	-0.36	-0.33	Prostate cancer;	chr3:170353995	chr3:170410512~170418615:+
THCA	cis	rs7208859	0.623	rs73271869	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs73271872	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30709299~30790908:+
THCA	cis	rs17826219	0.568	rs9907834	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Body mass index;	chr17:30826995	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs73271887	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs9898858	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.673	rs55658077	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9899692	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30709299~30790908:+
THCA	cis	rs7208859	0.623	rs9906957	ENSG00000264538.5	SUZ12P1	-7.46	4.35e-13	1.45e-10	-0.34	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30709299~30790908:+
THCA	cis	rs13068223	0.74	rs237250	ENSG00000243926.1	TIPARP-AS1	7.46	4.35e-13	1.45e-10	0.31	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156726594	chr3:156671862~156674378:-
THCA	cis	rs4950322	0.547	rs6660507	ENSG00000237188.3	RP11-337C18.8	7.46	4.35e-13	1.45e-10	0.37	0.33	Protein quantitative trait loci;	chr1:147148574	chr1:147172771~147211568:+
THCA	cis	rs6907340	0.517	rs9465531	ENSG00000227116.1	RP3-471C18.1	-7.46	4.35e-13	1.45e-10	-0.35	-0.33	Endometriosis;	chr6:19798418	chr6:19730427~19734567:-
THCA	cis	rs8114671	0.647	rs6060267	ENSG00000269202.1	RP4-614O4.12	-7.46	4.35e-13	1.45e-10	-0.27	-0.33	Height;	chr20:35146209	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.647	rs6060268	ENSG00000269202.1	RP4-614O4.12	-7.46	4.35e-13	1.45e-10	-0.27	-0.33	Height;	chr20:35146490	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.647	rs1415771	ENSG00000269202.1	RP4-614O4.12	-7.46	4.35e-13	1.45e-10	-0.27	-0.33	Height;	chr20:35146690	chr20:35201747~35203288:-
THCA	cis	rs8114671	0.647	rs945959	ENSG00000269202.1	RP4-614O4.12	-7.46	4.35e-13	1.45e-10	-0.27	-0.33	Height;	chr20:35147102	chr20:35201747~35203288:-
THCA	cis	rs2439831	0.702	rs2467402	ENSG00000249839.1	AC011330.5	7.45	4.37e-13	1.46e-10	0.47	0.33	Lung cancer in ever smokers;	chr15:43732292	chr15:43663654~43684339:-
THCA	cis	rs11214589	0.62	rs34601878	ENSG00000270179.1	RP11-159N11.4	-7.45	4.37e-13	1.46e-10	-0.35	-0.33	Neuroticism;	chr11:113390176	chr11:113368478~113369117:+
THCA	cis	rs34375054	0.66	rs12303416	ENSG00000279233.1	RP11-158L12.4	7.45	4.37e-13	1.46e-10	0.32	0.33	Post bronchodilator FEV1/FVC ratio;	chr12:125108812	chr12:125138245~125141711:+
THCA	cis	rs944289	0.53	rs2780309	ENSG00000257826.1	RP11-116N8.4	7.45	4.38e-13	1.46e-10	0.34	0.33	Thyroid cancer;	chr14:36050646	chr14:36061026~36067190:-
THCA	cis	rs10971721	0.822	rs117703548	ENSG00000260947.1	RP11-384P7.7	7.45	4.38e-13	1.46e-10	0.8	0.33	Body mass index;	chr9:34041199	chr9:33697459~33700986:+
THCA	cis	rs467650	0.509	rs2591443	ENSG00000246763.5	RGMB-AS1	-7.45	4.38e-13	1.46e-10	-0.31	-0.33	Venous thromboembolism (SNP x SNP interaction);	chr5:98661785	chr5:98769618~98773469:-
THCA	cis	rs240993	0.812	rs7764543	ENSG00000230177.1	RP5-1112D6.4	-7.45	4.38e-13	1.46e-10	-0.33	-0.33	Inflammatory skin disease;Psoriasis;	chr6:111423116	chr6:111277932~111278742:+
THCA	cis	rs7746199	0.736	rs58616630	ENSG00000280107.1	AL022393.9	-7.45	4.39e-13	1.47e-10	-0.64	-0.33	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28170845~28172521:+
THCA	cis	rs7746199	0.736	rs34573979	ENSG00000280107.1	AL022393.9	-7.45	4.39e-13	1.47e-10	-0.64	-0.33	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28170845~28172521:+
THCA	cis	rs77204473	0.744	rs76942203	ENSG00000254851.1	RP11-109L13.1	7.45	4.39e-13	1.47e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:117102531	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs74881320	ENSG00000254851.1	RP11-109L13.1	7.45	4.4e-13	1.47e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116895209	chr11:117135528~117138582:+
THCA	cis	rs77204473	1	rs17120131	ENSG00000254851.1	RP11-109L13.1	7.45	4.4e-13	1.47e-10	0.8	0.33	Sum eosinophil basophil counts;Eosinophil counts;	chr11:116901770	chr11:117135528~117138582:+
THCA	cis	rs6142102	0.625	rs1883707	ENSG00000275784.1	RP5-1125A11.6	7.45	4.4e-13	1.47e-10	0.32	0.33	Skin pigmentation;	chr20:33964781	chr20:33989480~33991818:-
THCA	cis	rs6597981	0.675	rs4963120	ENSG00000255142.1	AP006621.6	-7.45	4.4e-13	1.47e-10	-0.22	-0.33	Breast cancer;	chr11:825777	chr11:781645~782105:+
THCA	cis	rs2361718	0.5	rs4889970	ENSG00000279259.1	RP11-334C17.3	-7.45	4.41e-13	1.47e-10	-0.33	-0.33	Yeast infection;	chr17:80122287	chr17:80147250~80148596:+
THCA	cis	rs72772090	0.539	rs72773969	ENSG00000248734.2	CTD-2260A17.1	-7.45	4.41e-13	1.47e-10	-0.53	-0.33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);	chr5:96809493	chr5:96784777~96785999:+
THCA	cis	rs9549328	0.8	rs9549620	ENSG00000267868.1	RP11-120K24.3	7.45	4.42e-13	1.47e-10	0.34	0.33	Systolic blood pressure;	chr13:112979107	chr13:112964835~112966131:-
THCA	cis	rs6908034	0.607	rs78774173	ENSG00000228412.5	RP4-625H18.2	7.45	4.42e-13	1.48e-10	0.81	0.33	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19820455	chr6:19802164~19804752:-
THCA	cis	rs4664293	0.899	rs7588710	ENSG00000226266.5	AC009961.3	-7.45	4.43e-13	1.48e-10	-0.38	-0.33	Monocyte percentage of white cells;	chr2:159673011	chr2:159670708~159712435:-
THCA	cis	rs6539288	0.901	rs4964193	ENSG00000260329.1	RP11-412D9.4	-7.45	4.44e-13	1.48e-10	-0.29	-0.33	Total body bone mineral density;	chr12:106927970	chr12:106954029~106955497:-
THCA	cis	rs6696239	0.531	rs2644150	ENSG00000227711.2	RP11-275O4.5	-7.45	4.44e-13	1.48e-10	-0.35	-0.33	Height;	chr1:227514120	chr1:227509028~227520477:-
THCA	cis	rs4266144	0.558	rs7623382	ENSG00000244515.1	KRT18P34	-7.45	4.44e-13	1.48e-10	-0.37	-0.33	Coronary artery disease;	chr3:157115105	chr3:157162663~157163932:-
THCA	cis	rs7430456	0.901	rs9824206	ENSG00000228221.4	LINC00578	7.45	4.45e-13	1.48e-10	0.42	0.33	Breast cancer;	chr3:177742093	chr3:177441921~177752305:+
THCA	cis	rs748404	0.697	rs572959	ENSG00000205771.5	CATSPER2P1	-7.45	4.45e-13	1.48e-10	-0.34	-0.33	Lung cancer;	chr15:43258304	chr15:43726918~43747094:-
THCA	cis	rs748404	0.697	rs554001	ENSG00000205771.5	CATSPER2P1	-7.45	4.45e-13	1.48e-10	-0.34	-0.33	Lung cancer;	chr15:43259721	chr15:43726918~43747094:-
THCA	cis	rs2688608	0.592	rs11000759	ENSG00000271816.1	BMS1P4	7.45	4.46e-13	1.49e-10	0.33	0.33	Inflammatory bowel disease;	chr10:73733968	chr10:73699151~73730487:-
THCA	cis	rs7674212	0.581	rs13150953	ENSG00000251288.2	RP11-10L12.2	-7.45	4.46e-13	1.49e-10	-0.43	-0.33	Type 2 diabetes;	chr4:103021341	chr4:102751401~102752641:+
THCA	cis	rs7674212	0.556	rs13151569	ENSG00000251288.2	RP11-10L12.2	-7.45	4.46e-13	1.49e-10	-0.43	-0.33	Type 2 diabetes;	chr4:103021633	chr4:102751401~102752641:+
THCA	cis	rs910316	0.967	rs4899551	ENSG00000279594.1	RP11-950C14.10	-7.45	4.46e-13	1.49e-10	-0.3	-0.33	Height;	chr14:75193543	chr14:75011269~75012851:-
THCA	cis	rs984222	0.775	rs2645294	ENSG00000231365.4	RP11-418J17.1	-7.45	4.49e-13	1.5e-10	-0.31	-0.33	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr1:119031964	chr1:119140396~119275973:+
THCA	cis	rs1949733	1	rs2631745	ENSG00000205959.3	RP11-689P11.2	7.45	4.5e-13	1.5e-10	0.27	0.33	Response to antineoplastic agents;	chr4:8488803	chr4:8482270~8512610:+
THCA	cis	rs2361718	0.5	rs4889818	ENSG00000279259.1	RP11-334C17.3	7.45	4.5e-13	1.5e-10	0.33	0.33	Yeast infection;	chr17:80111429	chr17:80147250~80148596:+
THCA	cis	rs2439831	0.702	rs8033995	ENSG00000275601.1	AC011330.13	-7.45	4.5e-13	1.5e-10	-0.53	-0.32	Lung cancer in ever smokers;	chr15:43721311	chr15:43642389~43643023:-
THCA	cis	rs7208859	0.573	rs55661352	ENSG00000263603.1	CTD-2349P21.5	-7.45	4.5e-13	1.5e-10	-0.58	-0.32	Mean corpuscular hemoglobin;Mean corpuscular